id|nct_id|pi_employee|agreement|restriction_type|other_details|restrictive_agreement
17150858|NCT06262191|f||||f
17195589|NCT01779141|f||GT60||t
17195590|NCT03752684|f||||f
17195591|NCT01596231|t||||f
17135902|NCT00747617|t||||f
17135903|NCT02279524|f||OTHER|"Consistent with scientific standards, publication of the results of the study shall be made only as part of a publication of the results obtained by all sites performing the protocol.~Investigators who wish to publish the results, must provide Galmed with a manuscript for review 60 (sixty) days prior to submission for publication.~Galmed retains the right to delete confidential and proprietary information and to object suggested publication and/or its timing (at the Company's sole discretion)."|t
17135904|NCT01746732|f||GT60||t
17135905|NCT03509207|t||||
17135906|NCT02817555|f||||f
17135907|NCT00137436|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150859|NCT03107026|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17150860|NCT02049450|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17150861|NCT00577395|f||OTHER|"The Study Site and Principal Investigator agree that all data, calculations, interpretations, opinions, and recommendations regarding the study will be the property of the Sponsor. The Study Site and Principal Investigator agree to consider the results as confidential information subject to use restrictions.~The names of the Investigator(s) will not be used by P\&GP for commercial purposes without appropriate written permission, unless required by law or government regulation."|t
17150862|NCT01404078|f||||f
17150863|NCT00554190|f||||f
17150864|NCT04820530|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17150865|NCT00569530|t||||f
17150866|NCT04709835|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150867|NCT04325204|t||||
17150868|NCT00820443|f||GT60||t
17150869|NCT04711902|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17150870|NCT04710979|t||||
17150871|NCT00026221|f||LTE60||t
17150872|NCT01289665|t||||
17150873|NCT01561430|f||GT60||t
17150874|NCT02570113|f||||f
17195592|NCT02722434|t||||
17150875|NCT02564211|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17150876|NCT01908816|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17150877|NCT05183217|t||||
17150878|NCT03201250|f||||f
17150879|NCT01297465|f||LTE60||t
17150880|NCT00969540|f||OTHER||t
17150881|NCT01646138|t||||
17150882|NCT01683838|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17150883|NCT04049617|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17150884|NCT03551496|f||OTHER||t
17150885|NCT01524679|f||||f
17150886|NCT00801099|t||||f
17150887|NCT01551888|f||OTHER|Publication of the results by the PI will be subject to mutual agreement between the PI and sponsor.|t
17150888|NCT00140426|t||||
17180709|NCT03055000|t||||
17180710|NCT00415909|t||||f
17180711|NCT03232281|f||||t
17180712|NCT01403246|f||OTHER|PIs of participating centres may disclose their centre's results only after the main study publication has been released, so that a single centre experience can be compared to the study overall results and give a more appropriate view of the study.|t
17195593|NCT02200705|f||||f
17195594|NCT00786864|f||||f
17195595|NCT01083732|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17195596|NCT03442777|f||||f
17165699|NCT03493451|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17135908|NCT01432262|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135909|NCT00165646|f||||f
17165700|NCT02709512|f||LTE60||t
17165701|NCT05327660|t||||
17165702|NCT00600106|f||||f
17165703|NCT00252512|t||||
17165704|NCT03015363|f||||f
17165705|NCT02200757|f||||t
17165706|NCT01206140|f||LTE60||t
17135910|NCT04657016|f||GT60||t
17165707|NCT00211172|f||||f
17165708|NCT02509936|f||||f
17165709|NCT01692496|f||LTE60||t
17165710|NCT01816776|f||||f
17180713|NCT02522286|f||||f
17195597|NCT01026805|f||LTE60||t
17195598|NCT00442104|f||||f
17195599|NCT04732000|t||||
17195600|NCT00610558|f||||f
17195601|NCT00463229|t||||
17135911|NCT00738543|t||||f
17135912|NCT03609658|t||||
17135913|NCT01755195|f||||f
17150532|NCT03535675|f||||f
17150533|NCT01196078|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150534|NCT00103311|f||LTE60||t
17150535|NCT01403064|f||||f
17150536|NCT00929331|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150537|NCT03537274|f||OTHER|The investigator agrees to provide the Sponsor thirty (30) days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication which report project results. The Sponsor shall have editorial rights with respect to Publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to (a) proprietary information and, (b) the accuracy of the information contained in the Publication.|t
17150538|NCT01969448|t||||
17150539|NCT04688931|f||||f
17150541|NCT00450619|t||||f
17150542|NCT02034058|f||||f
17150543|NCT02369900|f||||f
17150544|NCT03309007|f||||f
17150545|NCT02963311|f||||t
17150546|NCT03426566|t||||
17150547|NCT00333879|t||||
17150548|NCT02044796|t||||
17150549|NCT04408599|f||OTHER|PI cannot publish study results before the first multi-center publication. If a multi-center publication is not submitted within 12 months after the end of the study at all sites, or if Sponsor confirms there will be no multi-center publication, the PI may publish study results. However, PI will allow Sponsor at least 30 days to review any publication of study results and Sponsor may request an additional 60 days to review the publication.|t
17150550|NCT01968694|t||||
17150551|NCT02163486|f||||f
17150552|NCT00354341|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150553|NCT02836496|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150554|NCT01400919|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results without permission of the sponsor.~Trial is still ongoing"|t
17150555|NCT00251719|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17150556|NCT03822832|t||||
17150557|NCT01732874|t||||
17150558|NCT02737332|f||||f
17150559|NCT00846521|t||||
17150560|NCT01246011|t||||
17150561|NCT04392583|f||LTE60||t
17150562|NCT02303041|f||||f
17150563|NCT02623348|t||||
17150809|NCT04594707|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150810|NCT01155024|f||||f
17150811|NCT01593696|f||||f
17150812|NCT02633488|f||||f
17150813|NCT01936623|t||||
17135914|NCT00912015|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17135915|NCT01356602|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17135916|NCT01115569|f||GT60||t
17135917|NCT01931462|f||GT60||t
17135918|NCT02819310|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17135919|NCT02046265|f||||f
17135920|NCT00028002|f||LTE60||t
17135921|NCT01793051|t||||
17135922|NCT04067765|t||||
17135923|NCT05070429|f||||f
17150889|NCT02149108|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150890|NCT02981303|f||||f
17150891|NCT02393248|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17150892|NCT00987389|f||||f
17150893|NCT00507130|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17150894|NCT01772758|f||||f
17150895|NCT00080938|f||||f
17150896|NCT04561375|t||||
17150897|NCT01025271|t||||f
17150898|NCT00121472|f||||f
17150899|NCT00296231|t||||
17150900|NCT00338455|f||GT60||t
17150901|NCT02266134|t||||
17150902|NCT04740320|f||||f
17150903|NCT01437943|f||||f
17150904|NCT01119716|f||OTHER|The Scientific Committee for the study has the authority to make all decisions related to design, conduct, data interpretation and dissemination of study results.|t
17150905|NCT04647721|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17150906|NCT04771403|t||||
17150907|NCT05442866|f||||f
17150908|NCT01568320|f||GT60||t
17150909|NCT00546572|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195602|NCT01932970|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17195603|NCT01767467|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135924|NCT00943319|f||||f
17150910|NCT01394952|f||GT60||t
17150911|NCT01335997|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17135925|NCT02043301|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135926|NCT02653976|f||||f
17135927|NCT02023164|f||||f
17135928|NCT00883558|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17150814|NCT03167723|t||||f
17150815|NCT02122406|f||||f
17150816|NCT01175811|f||GT60||t
17150817|NCT03579966|f||||f
17150818|NCT02620150|f||||f
17150819|NCT01340768|f||OTHER|The Principal Investigator shall not publish any article or paper nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations, relating or referring to the following: (a) the study or any results, data or insight there from; (b) the services performed; or (c) any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of the sponsor.|t
17150820|NCT03052959|f||||f
17165711|NCT00770562|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17150912|NCT01763684|f||||f
17135929|NCT03703375|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150913|NCT00673244|f||||f
17150914|NCT01011179|f||||f
17165712|NCT01643408|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17165713|NCT00237666|f||||f
17165714|NCT00579553|t||||
17165715|NCT00253513|f||||f
17165716|NCT00318929|f||GT60||t
17165717|NCT01313910|t||||f
17165718|NCT01509846|f||||f
17165719|NCT01637584|f||||f
17165720|NCT02484443|f||LTE60||t
17165721|NCT02969915|t||||
17165722|NCT03799952|f||||f
17165723|NCT01393899|f||LTE60||t
17165724|NCT02503085|f||||f
17165725|NCT02595866|f||LTE60||t
17165726|NCT02520388|f||||f
17165727|NCT01232127|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165728|NCT03506412|t||||
17165729|NCT01176617|f||||f
17165730|NCT03035864|f||||f
17165731|NCT00480740|t||||f
17165732|NCT05110781|t||||
17165733|NCT02375373|f||||f
17165734|NCT01890265|f||OTHER||t
17165735|NCT01445613|f||GT60||t
17165736|NCT03674970|f||||f
17165737|NCT03299244|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165738|NCT02881775|t||||
17165739|NCT00809926|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17165740|NCT02530476|t||||
17165741|NCT00130039|f||||f
17165742|NCT00642707|f||OTHER|Because the study is a multicenter study, the PI(s) can only publish after the aggregate results of all investigators and institutions participating in the study have been published, and the proposed publication is reviewed by Progenics. In the event that Progenics does not publish the results of the study within eighteen months from availability of final study analysis, the PI can publish provided that the proposed publication is reviewed by Progenics.|t
17165743|NCT03321071|f||||f
17165744|NCT00100802|f||OTHER|Must obtain prior Sponsor approval.|t
17195604|NCT02785159|f||OTHER|Contact sponsor directly for details.|t
17195605|NCT03578965|t||||
17195606|NCT01787032|t||||
17195607|NCT00776009|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17150821|NCT00950963|f||||f
17150822|NCT00848107|f||OTHER|Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17150823|NCT00326963|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150824|NCT00859586|t||||
17150825|NCT02992418|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17150826|NCT01830205|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150827|NCT03246126|t||||
17150828|NCT01992523|t||||f
17150829|NCT01006135|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165745|NCT02709720|f||||f
17165746|NCT00648648|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17165747|NCT01198574|f||||f
17165748|NCT00325130|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165749|NCT00326001|f||||f
17165750|NCT01042158|f||||f
17165751|NCT02025634|t||||
17180714|NCT00174915|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17180715|NCT00183092|t||||
17180716|NCT03927612|t||||
17180717|NCT01870583|f||||f
17180718|NCT00937157|f||||f
17180719|NCT00469092|f||OTHER|Novo Nordisk maintains the right to be informed of any plans for publications and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17180720|NCT02024867|t||||
17180721|NCT04267133|t||||
17180722|NCT01998633|f||||f
17180723|NCT02350881|f||||f
17180724|NCT04344314|f||||f
17180725|NCT02140788|t||||
17180726|NCT02968563|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17180727|NCT03992781|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180728|NCT03287804|f||GT60||t
17180729|NCT00385996|f||||f
17180730|NCT00003644|f||LTE60||t
17180731|NCT01275833|f||||f
17180732|NCT02733991|f||GT60||t
17180733|NCT02049307|f||||f
17180734|NCT00857220|f||OTHER||t
17180735|NCT00680745|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17180736|NCT02612428|f||OTHER||t
17180737|NCT00137423|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17180738|NCT03611790|f||OTHER|The data resulting from this study is the proprietary information of the Sponsor. None of the data resulting from this study will be allowed to be presented or published in any form, by the investigator or any other person, without the prior written approval of the Sponsor.|t
17180739|NCT02141997|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180740|NCT00535990|t||||
17180741|NCT03063476|t||||
17180742|NCT04105998|t||||
17180743|NCT01510379|t||||
17180744|NCT00584558|f||||f
17180745|NCT00278109|t||||f
17180746|NCT02580357|f||||f
17180747|NCT02064166|t||||f
17195608|NCT01640951|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17150830|NCT01684436|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17150831|NCT00928707|f||||f
17150832|NCT00132028|f||LTE60||t
17180748|NCT03971188|t||||
17180749|NCT00619801|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17180750|NCT01551082|t||||
17180751|NCT01106898|t||||
17180752|NCT01698801|f||OTHER|Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17180753|NCT01991457|t||||
17165752|NCT03640325|f||||f
17165753|NCT03046927|f||||f
17165754|NCT02052661|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165755|NCT01133756|f||OTHER||t
17165756|NCT01566149|f||OTHER|The PI agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17195609|NCT02406092|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165757|NCT02234713|f||||f
17195610|NCT02195232|f||||f
17195611|NCT03041233|f||||f
17195612|NCT00942266|t||||
17195613|NCT02139436|f||||f
17195614|NCT00756574|f||||f
17195615|NCT04035447|t||||
17135930|NCT02969317|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135931|NCT01781429|f||||f
17135932|NCT02678741|t||||
17135933|NCT00903032|t||||
17165758|NCT03276728|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165759|NCT03501992|t||||
17165760|NCT03941873|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165761|NCT02982772|f||||f
17195616|NCT03660618|f||||f
17195617|NCT02816398|f||||f
17135934|NCT04510194|t||||
17135935|NCT06648161|f||||f
17135936|NCT02880319|f||||f
17135937|NCT05014776|t||||
17135938|NCT02983981|t||||
17135939|NCT01703286|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135940|NCT01984346|f||OTHER||t
17150915|NCT04453202|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150916|NCT01157897|f||||f
17150917|NCT03276221|f||||f
17150918|NCT02912650|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150919|NCT01795105|f||||t
17150920|NCT04700280|f||OTHER|Principal Investigators (PI) are NOT employed by organization sponsoring study. There IS an agreement between the PI and Sponsor (or its agents) that restricts PI's rights to discuss/publish trial results after trial is completed. Sponsor must review, approve any results of study or abstracts for professional meetings prepared by investigator(s). Published data must not compromise the objectives of study. Data from individual study centers in multicenter studies must not be published separately.|t
17165762|NCT01234480|f||||f
17165763|NCT00626782|f||||f
17195618|NCT01588951|t||||
17195619|NCT01595282|f||||f
17195620|NCT02130557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195621|NCT02408887|f||||f
17195622|NCT02517268|t||||
17195623|NCT05579730|f||||f
17195624|NCT03044158|t||||f
17195625|NCT03268421|f||||f
17195626|NCT04912856|f||GT60||t
17135941|NCT02440178|f||||f
17135942|NCT01532700|f||||f
17135943|NCT05058664|t||||
17150921|NCT02562482|f||||f
17150922|NCT00939120|f||||f
17150923|NCT00916136|f||||f
17150924|NCT00686582|f||||t
17150925|NCT02435836|f||||f
17150926|NCT02041091|f||GT60||t
17150927|NCT01855074|f||OTHER|"All the information generated through services from the Principal Investigator (PI), the Sponsor has the rights to publish the data without previous consent from the PI.~The PI must not publish completely or partially any results from the study, without previous authorization from the Sponsor."|t
17195627|NCT05613907|f||||f
17195628|NCT04728711|f||||t
17195629|NCT00748709|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17195630|NCT04660721|f||||f
17195631|NCT05483517|t||||f
17195632|NCT02751528|f||||t
17165764|NCT01238991|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165765|NCT03370419|t||||
17165766|NCT05875727|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180754|NCT01988857|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180755|NCT02062879|f||||f
17180756|NCT03251079|f||LTE60||t
17180757|NCT04219891|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to study.|t
17180758|NCT05636098|t||||
17195633|NCT05071430|f||||t
17195634|NCT01958021|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17195635|NCT04640974|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17195636|NCT04484623|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17135944|NCT00972244|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17195637|NCT04649047|t||||
17195638|NCT00719888|t||||
17195639|NCT05037513|t||||f
17195640|NCT05886777|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195641|NCT00872729|f||OTHER|Investigators may publish or disclose study data, with the restriction that sponsor may embargo such communications for a period up to 60 days from the time submitted to sponsor.|t
17195642|NCT03664804|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17195643|NCT04257994|t||||
17195644|NCT03002194|f||||f
17135945|NCT01597557|t||||f
17135946|NCT03480282|f||||f
17135947|NCT02424955|t||||
17135948|NCT02561000|f||LTE60||t
17165767|NCT01530178|f||||f
17165768|NCT01897727|t||||
17165769|NCT01308814|f||||f
17165770|NCT02013778|t||||
17195645|NCT00048932|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195646|NCT02232737|f||||f
17195647|NCT03971539|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195648|NCT04559698|t||||
17195649|NCT03987581|f||||f
17195650|NCT01641900|f||||f
17195651|NCT02330588|f||||f
17195652|NCT03220724|f||||f
17135949|NCT01234402|f||OTHER|The disclosure restriction on PI is for five years after the study conclusion/termination, after five years disclosure restriction on PI is that sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.|t
17135950|NCT02758717|f||||t
17195653|NCT00743574|t||||
17195654|NCT01664741|t||||f
17135951|NCT05761444|f||||t
17135952|NCT01005719|f||OTHER||t
17135953|NCT01594476|f||||f
17135954|NCT01106534|f||GT60||t
17135955|NCT02275026|t||||
17135956|NCT01585129|t||||
17135957|NCT01108809|t||||
17135958|NCT03230175|f||||f
17135959|NCT00001262|t||||f
17135960|NCT03844633|f||||f
17135961|NCT01618955|f||LTE60||t
17135962|NCT02588248|f||||f
17135963|NCT03403491|f||||f
17135964|NCT00576693|f||||f
17150928|NCT01150890|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150929|NCT00922987|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150930|NCT01822574|t||||
17150931|NCT02312063|f||||t
17150932|NCT05091307|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17150933|NCT03303625|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150934|NCT01167257|t||||
17150935|NCT02492880|f||LTE60||t
17150936|NCT02771795|f||OTHER|\- At least sixty (60) dayas prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow the Sponsor sixty (60) days to review and comment on them to ensure that the publication would not disclose any Confidential Information or impair the Sponsor's ability to obtain patent protection.|t
17150937|NCT02906930|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17150938|NCT01736241|f||GT60||t
17150939|NCT04796779|f||||f
17165771|NCT00293813|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17195655|NCT01478594|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or after 18 months after database lock, whichever comes first. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17165772|NCT01139411|f||||f
17195656|NCT02927249|f||||f
17195657|NCT02639637|t||||
17195658|NCT02463448|t||||
17135965|NCT00804193|f||OTHER||t
17135966|NCT01987986|f||OTHER||t
17135967|NCT03283163|f||||f
17135968|NCT00237796|t||||f
17150940|NCT01659866|f||||f
17135969|NCT04400318|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17150941|NCT00622466|f||||f
17150942|NCT03300544|f||LTE60||t
17150943|NCT04585789|f||||t
17135970|NCT01096446|t||||
17135971|NCT01043185|f||OTHER|There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed.The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ.|t
17135972|NCT01104558|f||OTHER||t
17135973|NCT05131880|f||||f
17135974|NCT03653507|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17135975|NCT00392171|f||OTHER|Study Chair agrees not to publish/present any interim results without prior Sponsor written consent. Investigators agree to provide 30 days to review prior to submission. Sponsor shall have proper representation/editorial rights/right to review/comment with regard to proprietary information. If the parties disagree concerning the appropriateness and/or confidentiality of information, Investigators agree to discuss and resolve any such issues prior to submission.|t
17135976|NCT01605071|f||||f
17135977|NCT03499808|f||LTE60||t
17150944|NCT00894738|f||||f
17150945|NCT01383135|t||||f
17150946|NCT00415194|f||GT60||t
17150947|NCT00369655|f||LTE60||t
17150948|NCT02397408|t||||
17150949|NCT01154816|f||OTHER|Must obtain prior Sponsor approval.|t
17150950|NCT03397771|f||LTE60||t
17150951|NCT03801265|t||||
17150952|NCT04078126|f||GT60||t
17165773|NCT01521923|f||GT60||t
17195659|NCT01359150|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195660|NCT03113409|f||||f
17150953|NCT03321630|t||||
17165774|NCT01683630|f||||f
17165775|NCT01179984|f||||f
17165776|NCT01465386|t||||
17165777|NCT01279044|f||||f
17165778|NCT01582009|t||||
17180759|NCT02960776|t||||
17195661|NCT01536093|f||||f
17195662|NCT02169869|t||||
17195663|NCT02275611|f||||f
17195664|NCT03911271|t||||
17195665|NCT01759862|t||||
17165779|NCT02248766|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17165780|NCT02440204|t||||
17180760|NCT00312494|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180761|NCT00413192|f||OTHER||t
17165781|NCT01947283|t||||f
17165782|NCT00460655|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165783|NCT03592771|t||||
17165784|NCT00735553|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17180762|NCT00159250|t||||
17180763|NCT01304966|t||||
17180764|NCT00870896|t||||
17180765|NCT00003901|f||LTE60||t
17165785|NCT01861704|t||||
17165786|NCT03654040|f||||f
17165787|NCT01709110|f||GT60||t
17165788|NCT02802293|t||||
17165789|NCT01484496|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165790|NCT01645735|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. The Sponsor will make all reasonable efforts to publish the results of the study in an appropriate peer-reviewed journal. Authorship on the primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results. Publication of results by the PI will be subject to mutual agreement between the PI and Sponsor.|t
17165791|NCT04830215|f||||f
17165792|NCT03782064|f||||f
17165793|NCT02446769|f||||f
17165794|NCT00645840|f||||f
17165795|NCT03994211|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165796|NCT00997984|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17180766|NCT05319795|t||||
17180767|NCT02268864|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17180768|NCT00527943|f||OTHER|All draft publications will be submitted to the Publication Committee for review. Full-length papers will be submitted at least 45 days prior to submission to a journal. Abstracts or public presentations (eg, poster) will be submitted at least 14 days in advance.|t
17180769|NCT00742001|f||OTHER|All publication of results and or design of this study are contingent upon approval from the sponsor.|t
17180770|NCT02617511|f||||f
17180771|NCT01050257|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180772|NCT00171223|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180773|NCT00006101|f||||f
17180774|NCT04949165|f||||f
17180775|NCT00612924|f||LTE60||t
17195666|NCT00731614|t||||
17195667|NCT03890289|f||||f
17195668|NCT02867059|f||GT60||t
17195669|NCT00274261|f||OTHER||t
17165797|NCT03232827|f||||f
17165798|NCT03205358|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17165799|NCT01653587|f||||f
17165800|NCT01736267|t||||
17195670|NCT03387189|t||||
17195671|NCT03292133|t||||
17195672|NCT00853606|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17180776|NCT03033511|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180777|NCT00730912|f||OTHER|"The investigator (sub-investigator) will disclose the results and knowledge obtained through this study after discussion with the Sponsor and approval is obtained from the Sponsor.~If the investigator (sub-investigator) is to present the results obtained from this study at a medical conference or medical journal, approval of the Sponsor must be obtained beforehand"|t
17150954|NCT02669758|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17165801|NCT00271856|f||||f
17150955|NCT02455050|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165802|NCT04599803|t||||
17180778|NCT02409459|f||||f
17180779|NCT04147455|t||||f
17180780|NCT03311659|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17180781|NCT04053023|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165803|NCT04677543|f||||t
17165804|NCT03087604|t||||
17180782|NCT00071760|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180783|NCT01994629|f||OTHER||t
17180784|NCT03424265|t||||
17180785|NCT01558752|f||||f
17180786|NCT02172742|t||||
17180787|NCT01471106|t||||
17180788|NCT01601782|t||||f
17180789|NCT00531817|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180790|NCT00894322|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180791|NCT01196923|f||||f
17180792|NCT03338855|f||||t
17180793|NCT00511667|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17150956|NCT02325518|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180794|NCT00056407|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180795|NCT02738450|f||OTHER|Institution may freely publish and disseminate the results of the Study. However Institution shall only make a Publication once the Study has been completed. Institution shall send Sponsor any Publication 60 days prior to submission and Sponsor may make editorial changes to the Publication. Institution shall delete information that Sponsor considers as Confidential and Institution shall delay Publication for an additional 60 days to protect the potential patentability of an invention.|t
17180796|NCT00706407|f||||f
17180797|NCT00951808|t||||
17150957|NCT00631449|t||||f
17180798|NCT02654483|f||||f
17180799|NCT00455429|f||GT60||t
17180800|NCT01165554|f||||f
17180801|NCT03439670|f||||f
17180802|NCT02951156|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180803|NCT04351087|f||||f
17180804|NCT02014844|f||||t
17180805|NCT03519347|t||||f
17180806|NCT05517382|t||||
17165805|NCT02110485|t||||
17165806|NCT00995436|t||||
17165807|NCT01740258|t||||
17165808|NCT01437111|f||OTHER|Investigators agreed to allow the Sponsor to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Investigators have also agreed that any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17165809|NCT00771927|f||GT60||t
17165810|NCT00577707|t||||
17165811|NCT01603043|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180807|NCT01641692|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180808|NCT01685996|f||||f
17180809|NCT00841087|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17180810|NCT02461225|f||||f
17180811|NCT00484939|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180812|NCT04948450|f||||f
17180813|NCT00735787|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17180814|NCT01566461|f||GT60||t
17180815|NCT00631566|f||||f
17180816|NCT03616899|f||OTHER|"The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:~(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial."|t
17180817|NCT03448185|f||||f
17180818|NCT04640519|t||||
17180819|NCT00862446|t||||
17195673|NCT02227706|f||OTHER|"Any publication based on the results obtained at the trial site (or group of sites) shall not be made before the first multi-centre publication.~During the review period of a proposed publication, the Sponsor is entitled to request that publication be delayed for a period of up to six months from the date of first submission to the Sponsor to enable the Sponsor to take steps to protect its proprietary information and/or Intellectual Property Rights and Know How."|t
17195674|NCT02628626|t||||
17195675|NCT04144868|f||||f
17195676|NCT01732120|t||||
17195677|NCT02972359|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17150958|NCT03393806|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165812|NCT01763333|t||||
17165813|NCT01618240|t||||
17165814|NCT02712996|t||||
17150959|NCT00886288|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165815|NCT01016132|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17165816|NCT01451749|f||LTE60||t
17165817|NCT02227810|f||||f
17165818|NCT02132572|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165819|NCT03063606|t||||
17165820|NCT01941927|f||||f
17165821|NCT03079531|t||||
17165822|NCT02454530|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180820|NCT00657241|f||||f
17180821|NCT01173718|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17180822|NCT01367158|f||OTHER|The terms and conditions of Novartis agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180823|NCT04595513|f||||f
17180824|NCT02226003|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17180825|NCT02467465|f||||f
17180826|NCT05986019|f||||f
17180827|NCT04262232|t||||f
17180828|NCT01975909|f||||f
17180829|NCT04709341|f||||f
17180830|NCT00296374|f||LTE60||t
17180831|NCT03730948|t||||
17180832|NCT00670800|t||||f
17180833|NCT01786629|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.|t
17180834|NCT02926924|t||||
17180835|NCT01024296|t||||
17180836|NCT05027438|f||||f
17180837|NCT01852942|t||||
17180838|NCT01921179|f||||f
17180839|NCT02315755|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180840|NCT04568590|t||||
17180841|NCT04693507|f||LTE60||t
17180842|NCT01002755|t||||
17180843|NCT00858442|t||||f
17180844|NCT02710890|f||GT60||t
17180845|NCT01829516|t||||
17180846|NCT00202644|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17180847|NCT00602576|f||||f
17180848|NCT00772772|t||||
17180849|NCT02750592|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17180850|NCT00861146|f||||f
17180851|NCT02981342|f||||t
17180852|NCT01372501|f||||f
17180853|NCT01466348|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180854|NCT03989440|f||OTHER|PIs are free to publish, present, or use institution specific study data and results arising out of their performance of the protocol. At least forty five (45) days prior to submission for publication, PIs must submit to sponsor for review and comment any proposed oral or written publication. The first publication of the results shall be a joint multi-center publication of the study results managed and coordinated by sponsor unless this is not completed within 18 months after completion date.|t
17180855|NCT02974296|f||||f
17180856|NCT03970733|f||||t
17195678|NCT02063659|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any Confidential Information, proprietary information or patentable subject matter.|t
17195679|NCT01532999|t||||f
17195680|NCT00914966|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.|t
17195681|NCT06571058|t||||
17195682|NCT01939288|t||||
17195683|NCT04724759|f||||f
17165823|NCT03265145|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195684|NCT03598907|f||||f
17195685|NCT04021862|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17195686|NCT05251363|f||OTHER|After publication of trial results, PIs have the right to publish and/or present the results of the study generated or collected at the institution. The sponsor requires 30 days to review the publication and has the right to obtain input from other investigators in the study. Additionally, the sponsor has the right to delete any confidential information or other proprietary information and may extend the review period if this type of information is included.|t
17195687|NCT01093612|t||||
17195688|NCT03835754|f||OTHER||t
17195689|NCT02830204|f||||f
17180857|NCT02341807|f||||t
17180858|NCT02189473|t||||
17195690|NCT02921555|f||||f
17195691|NCT01690624|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195692|NCT01341301|t||||
17195693|NCT04686266|f||||f
17180859|NCT01955161|f||||f
17180860|NCT01245270|t||||
17180861|NCT02784821|f||||f
17180862|NCT05333900|t||||
17180863|NCT00302042|f||||f
17180864|NCT03724812|f||||f
17180865|NCT01851720|t||||
17180866|NCT01394523|t||||
17180867|NCT00905554|f||||f
17180868|NCT04741074|t||||
17180869|NCT02432846|f||||f
17180870|NCT01770379|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17195694|NCT04306367|t||||
17180871|NCT03045887|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180872|NCT03839511|f||||f
17180873|NCT01912287|f||||f
17180874|NCT02929823|f||OTHER|The Principal Investigator will not disclose information regarding this clinical investigation, or publish results of the investigation without authorization from Senju Pharmaceuticals Co., Ltd.|t
17180875|NCT03226392|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17180876|NCT02357901|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17180877|NCT00491387|f||||f
17180878|NCT02621242|f||||f
17180879|NCT02631850|f||||f
17180880|NCT04098107|f||GT60||t
17180881|NCT01086540|f||||f
17180882|NCT02278263|f||||f
17180883|NCT03164928|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17180884|NCT01998737|f||||f
17180885|NCT01053819|t||||
17180886|NCT03251508|t||||
17180887|NCT00101907|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17180888|NCT01997515|t||||
17180889|NCT01474876|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180890|NCT01762631|t||||
17180891|NCT01523886|t||||f
17180892|NCT01721330|t||||
17180893|NCT04736199|f||LTE60||t
17180894|NCT04318080|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17195695|NCT02401815|f||GT60||t
17195696|NCT05080777|f||||f
17195697|NCT04705415|f||||f
17195698|NCT02473276|t||||
17195699|NCT03773107|f||||f
17195700|NCT00984815|f||OTHER|PI may disclose data resulting from the study upon the earliest of: a) publication of a multi-center publication coordinated by Sponsor, b) submission of the data by Sponsor to the FDA, and c) 18 months after the study is completed at all sites if a multi-center publication is not submitted by Sponsor for publication provided PI submits proposed publication at least 60 days in advance for review of any Sponsor Confidential Information.|t
17135978|NCT03470922|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165824|NCT03159468|f||||f
17180895|NCT00410761|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17180896|NCT06308822|f||LTE60||t
17180897|NCT03712904|t||||
17180898|NCT05608005|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180899|NCT04708886|f||||f
17180900|NCT05621252|f||OTHER|Per protocol, the data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Any publication of the results of this study must be authorized by the Sponsor.|t
17180901|NCT03525574|f||||t
17180902|NCT04155632|f||||f
17195701|NCT05001139|f||GT60||t
17195702|NCT05864209|t||||
17195703|NCT02303392|t||||
17195704|NCT00092534|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17195705|NCT05029284|t||||
17195706|NCT04001829|f||LTE60||t
17195707|NCT03678688|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17195708|NCT01427517|t||||
17135979|NCT02340819|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17135980|NCT02361762|f||||f
17135981|NCT04907539|f||||t
17135982|NCT01881620|t||||f
17135983|NCT03070730|t||||f
17135984|NCT04467164|t||||
17135985|NCT02369835|f||||f
17135986|NCT01701583|f||||f
17135987|NCT01441440|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135988|NCT00589888|f||||f
17150960|NCT01675661|f||OTHER|All publications/dissemination products must be reviewed and approved by the Center for Clinical Trials Network (CCTN) Publications Committee before publishing/disseminating.|t
17135989|NCT02750813|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135990|NCT03276936|f||LTE60||t
17135991|NCT01798134|f||LTE60||t
17135992|NCT00625365|f||||f
17150961|NCT04765384|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17150962|NCT01971970|f||||f
17195709|NCT02677766|f||||f
17195710|NCT00985088|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195711|NCT01727167|t||||
17135993|NCT02245568|f||||t
17150963|NCT02335983|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150964|NCT00655876|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17180903|NCT03914326|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17180904|NCT05855005|t||||
17180905|NCT04259762|f||||f
17135994|NCT00366548|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17135995|NCT01252134|f||OTHER||t
17180906|NCT01203046|t||||
17180907|NCT02769247|f||||f
17180908|NCT04788953|f||||f
17180909|NCT02293655|f||||f
17180910|NCT02150954|t||||
17180911|NCT04902924|t||||
17180912|NCT03814746|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17180913|NCT03642210|f||LTE60||t
17180914|NCT04473937|t||||
17180915|NCT01463644|f||||f
17180916|NCT03997383|f||OTHER|It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication (eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be provided and confirmed received at the Sponsor at least 30 days before its submission. The Clinical Trial Agreement will detail the procedures for publications.|t
17180917|NCT03880019|f||LTE60||t
17180918|NCT00326950|f||||f
17135996|NCT03463941|f||||f
17135997|NCT03650452|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17180919|NCT00519818|f||||f
17180920|NCT02972554|t||||
17180921|NCT01266460|f||LTE60||t
17180922|NCT03756688|t||||f
17180923|NCT01132547|t||||
17180924|NCT05811234|f||OTHER||t
17180925|NCT04499781|t||||
17180926|NCT03019107|f||||f
17180927|NCT00644280|t||||
17180928|NCT00227305|f||OTHER|AstraZeneca as sponsor will first publish results for the multicenter study|t
17180929|NCT02118012|t||||
17195712|NCT01278030|f||||f
17135998|NCT02273050|f||||f
17135999|NCT02297438|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195713|NCT02949297|f||OTHER|PI can publish institution's data/results 18 months after study conclusion at all sites or when multi-center results are published or notification that results will not be published. Institution is to submit drafts of manuscripts to Endologix 30 days prior to submission for publication or presentation.|t
17195714|NCT00458783|t||||
17195715|NCT01737398|f||||t
17195716|NCT06307457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136000|NCT02042404|f||||f
17195717|NCT02962284|f||OTHER||t
17195718|NCT03284359|f||||f
17195719|NCT00357994|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195720|NCT01354444|t||||
17136001|NCT01163162|t||||
17195721|NCT00982072|f||||f
17195722|NCT04162210|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17136002|NCT04126603|f||||f
17195723|NCT03244800|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17180930|NCT00483379|f||OTHER|In multi-site studies, PI will delay submission of a publication until the earlier of; (i) publication of the multi-center data by Genzyme (ii)12-24 months after study completion or termination of the Study at all sites, or (iii) Genzyme notification that a publication will not occur. PI will send Genzyme a draft 60 days before publication. Genzyme can defer publication 90-120 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17136003|NCT03952468|f||||f
17195724|NCT02803749|f||||f
17195725|NCT00371345|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136004|NCT04075266|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17195726|NCT00713596|t||||f
17195727|NCT04545619|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17195728|NCT03712371|t||||
17195729|NCT02788981|t||||
17195730|NCT00229658|f||LTE60||t
17195731|NCT00249769|f||||f
17195732|NCT01953224|f||||f
17195733|NCT01085513|f||||f
17136005|NCT04742907|f||||t
17136006|NCT02280291|t||||
17136007|NCT03508622|t||||
17136008|NCT05175261|t||||
17180931|NCT04318990|t||||
17195734|NCT03542305|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180932|NCT03698994|f||LTE60||t
17180933|NCT04969224|f||||t
17195735|NCT00857766|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180934|NCT03165110|f||||t
17136009|NCT00210158|t||||
17136010|NCT04716933|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17136011|NCT02534805|t||||
17136012|NCT03196505|t||||f
17150965|NCT01831765|f||OTHER|"At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk.~Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property."|t
17180935|NCT05533632|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17180936|NCT06273124|f||||f
17136013|NCT04430738|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136014|NCT05187013|t||||
17136015|NCT04488822|f||||f
17136016|NCT03838367|f||||f
17136017|NCT03406104|f||||t
17136018|NCT03277729|t||||
17136019|NCT02944071|f||LTE60||t
17136020|NCT03036592|t||||
17136021|NCT05407714|f||||f
17150966|NCT00977379|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136022|NCT02499146|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136023|NCT01879618|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136024|NCT02890329|f||LTE60||t
17136025|NCT00878072|f||||t
17136026|NCT01954121|f||GT60||t
17136027|NCT01413178|t||||
17136028|NCT01568905|f||||f
17136029|NCT04070378|f||||f
17136030|NCT03259334|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136031|NCT03860844|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17136032|NCT01678807|f||OTHER|The Sponsor has the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17136033|NCT00370149|f||||f
17136034|NCT05306873|f||||f
17136035|NCT01286272|f||LTE60||t
17136036|NCT03022032|t||||
17136037|NCT06018350|t||||
17150967|NCT01775852|f||||f
17150968|NCT00556400|t||||
17150969|NCT00706511|f||||f
17150970|NCT02605993|f||||t
17150971|NCT02603393|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17195736|NCT02040870|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17195737|NCT04971733|f||||f
17195738|NCT01273610|t||||
17195739|NCT02707198|f||||f
17195740|NCT01367236|t||||
17136038|NCT03625986|f||||f
17150972|NCT01342107|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17150973|NCT01974440|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17195741|NCT04960813|f||||f
17136039|NCT06787781|t||||
17136040|NCT00620321|f||GT60||t
17136041|NCT04191967|t||||
17136042|NCT01431144|f||||f
17136043|NCT01641835|f||LTE60||t
17136044|NCT03805932|f||||f
17150974|NCT00762437|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180937|NCT03706053|f||||f
17180938|NCT04232670|f||||f
17180939|NCT03632655|t||||
17195742|NCT01593020|t||||
17136045|NCT05141435|f||||f
17136046|NCT02410902|f||OTHER|Publications include input from PI and Curemark reflected in authorship. Institution's results may be submitted after results of the multicenter study are published, 18m after completion, or if multicenter publication isn't planned. Then PI may to publish, subject to confidentiality agreement. PI shall give to Curemark 45 days prior for review. Submission of such publication of results be can't delayed more than 105d after being received by Curemark. After 105 days, the PI may publish.|t
17136047|NCT00953043|t||||f
17136048|NCT03059810|f||GT60||t
17136049|NCT00701727|f||||f
17136050|NCT05291598|t||||f
17136051|NCT05113953|f||||f
17195743|NCT02350634|f||||t
17195744|NCT04205487|f||||f
17195745|NCT04241848|f||||f
17195746|NCT01400958|t||||
17150975|NCT02387983|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17150976|NCT05084963|f||||t
17150977|NCT03569228|t||||
17150978|NCT06354998|f||||t
17150979|NCT03819049|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150980|NCT00535587|t||||
17150981|NCT00816361|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17150982|NCT00436904|t||||
17150983|NCT01986010|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17150984|NCT04740814|f||GT60||t
17150985|NCT02440568|f||||f
17150986|NCT01948986|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17150987|NCT00548171|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150988|NCT01019928|f||GT60||t
17150989|NCT01103466|t||||
17150990|NCT04300010|t||||
17150991|NCT02331368|t||||
17150992|NCT03670264|f||||f
17150993|NCT02302859|t||||
17150994|NCT03003949|t||||
17150995|NCT03285308|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17150996|NCT02283983|f||||t
17150997|NCT02654860|f||||f
17150998|NCT00168311|f||||f
17150999|NCT00424775|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151000|NCT00681590|f||||f
17165825|NCT00802997|f||OTHER|The results communications must be provided to the Sponsor for review 30 days prior to public release. The Sponsor has the right to review materials for the purposes of preserving confidentiality of Sponsor's proprietary information, which may be removed at the Sponsor's request, and for identification of patentable inventions. The Investigator has no obligation to address any additional comments provided during the review and has final control and approval of publication content.|t
17165826|NCT03280303|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165827|NCT01848977|f||||f
17165828|NCT01541735|f||||f
17165829|NCT01664117|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165830|NCT02415244|t||||
17165831|NCT02974140|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17165832|NCT00617084|f||OTHER|"Prior to submission the Publication Committee (PC) and all co-authors will review and authorize the publication.\>~* Abstracts to be submitted to the PC at least 30 days before submission for publication or presentation.\>~* Manuscripts to be submitted to the PC at least 60 days before submission for publication or presentation. \> The Sponsor can review results communications, and can embargo communications regarding trial results prior to public release."|t
17165833|NCT03573206|f||GT60||t
17165834|NCT00416494|f||||f
17165835|NCT02222688|t||||
17165836|NCT06219967|t||||
17165837|NCT03844672|t||||
17165838|NCT04248712|t||||
17165839|NCT02522429|f||||f
17165840|NCT03440463|t||||
17165841|NCT00958360|t||||
17151001|NCT01898650|t||||
17151002|NCT01791153|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151003|NCT02876926|f||||f
17151004|NCT00975286|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17151005|NCT02357342|t||||
17165842|NCT00500357|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165843|NCT00078806|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165844|NCT01734785|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17165845|NCT00161616|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17165846|NCT00854724|t||||
17165847|NCT00879034|f||||f
17165848|NCT00861757|f||GT60||t
17165849|NCT00960401|t||||
17165850|NCT02140970|f||||f
17165851|NCT02705105|f||GT60||t
17165852|NCT03332173|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165853|NCT02168101|f||GT60||t
17165854|NCT00910910|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 12 months since study completion. Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17165855|NCT01973231|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17165856|NCT01485796|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxalta requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxalta may request an additional delay of ≤60 days eg, for intellectual property protection.|t
17180940|NCT04327388|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17180941|NCT05074693|f||||f
17180942|NCT01980355|f||||f
17195747|NCT02766517|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165857|NCT04381052|t||||f
17165858|NCT03697161|f||||f
17165859|NCT01775553|t||||
17165860|NCT00988052|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17165861|NCT01523743|f||GT60||t
17165862|NCT02569476|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165863|NCT01434654|f||||f
17165864|NCT04767061|t||||
17165865|NCT00604552|f||||f
17165866|NCT00703963|t||||f
17165867|NCT01103440|t||||
17165868|NCT00402324|f||GT60||t
17165869|NCT01277822|f||||f
17165870|NCT02625220|f||GT60||t
17180943|NCT03051607|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17180944|NCT03965533|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195748|NCT04445831|f||OTHER|Publication shall not be made by PIs before a first multi-site publication by Sponsor. If no multi-site publication is made within 18 months after study completion, PIs can publish under conditions: Prior any publication submission, PI shall send Sponsor any information to be disclosed and Sponsor have 60 days from receipt to review and comment. PI shall remove any Confidential Information and upon Sponsor request further delay publication for up to 120 days to protect Sponsor interests.|t
17136052|NCT03395197|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136053|NCT05137041|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17136054|NCT02856581|t||||
17136055|NCT02073435|f||||f
17195749|NCT05810285|f||||f
17136056|NCT00510224|t||||
17195750|NCT05470114|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17136057|NCT01808118|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136058|NCT00615290|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165871|NCT02923531|f||GT60||t
17165872|NCT01140867|f||||f
17195751|NCT05325294|f||GT60||t
17195752|NCT05961995|t||||
17195753|NCT01563185|f||LTE60||t
17195754|NCT04577651|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17195755|NCT04202133|f||||f
17195756|NCT03214081|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136059|NCT02044159|f||||f
17165873|NCT01119066|t||||
17165874|NCT04396795|t||||f
17180945|NCT01865539|f||||f
17165875|NCT02366923|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17180946|NCT01603459|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the Investigator will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17165876|NCT04855240|f||||f
17165877|NCT03902392|t||||
17165878|NCT00431444|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17165879|NCT00343564|f||OTHER|Sponsor intends to publish the results of the trial in collaboration with the Investigators.|t
17180947|NCT00196716|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17180948|NCT00399360|f||||f
17180949|NCT01412021|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180950|NCT01166178|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180951|NCT00471848|f||OTHER|Participating PIs can not publish on the patients they have included in this prospective trial before the results of the trial have been published in a peer-reviewed journal.|t
17180952|NCT01556581|f||||f
17180953|NCT00529542|t||||f
17136060|NCT01795898|f||||f
17136061|NCT01523808|f||||f
17136062|NCT06182631|f||||f
17136063|NCT03685019|t||||
17136064|NCT05374408|t||||
17165880|NCT04704713|f||||f
17165881|NCT02953561|t||||
17165882|NCT00556439|f||||f
17165883|NCT00848237|f||LTE60||t
17165884|NCT02100423|t||||
17180954|NCT05778786|f||GT60||t
17180955|NCT00099437|f||OTHER|The only disclosure restriction on the PI is that they cannot publish any information to do with the trial without written consent from Quintiles.|t
17136065|NCT05100316|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17136066|NCT00972478|f||LTE60||t
17136067|NCT01522976|f||LTE60||t
17136068|NCT04889144|t||||
17136069|NCT05132569|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17136070|NCT04102098|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136071|NCT03909763|f||||f
17136072|NCT01226420|f||||f
17136073|NCT05590793|f||||t
17136074|NCT04272216|f||||f
17195757|NCT03150875|f||||f
17195758|NCT01372085|t||||
17136075|NCT03015610|t||||
17136076|NCT05174039|f||||f
17136077|NCT05692154|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17195759|NCT00790569|f||||f
17136078|NCT00759473|f||||f
17195760|NCT04612868|f||||f
17136079|NCT00938327|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195761|NCT03376659|t||||
17136080|NCT01379534|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17136081|NCT02552355|t||||
17136082|NCT01519245|t||||f
17136083|NCT02345642|f||||f
17136084|NCT04072146|f||||t
17136085|NCT01193348|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17136086|NCT03141086|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17136087|NCT01064648|f||LTE60||t
17136088|NCT00977574|f||LTE60||t
17136089|NCT00719732|f||OTHER|No paper that incorporates Sponsor Condfidential information will be submitted for publication without Sponsor's prior written agreement.|t
17136090|NCT05345691|f||OTHER|"On Protocol signature page, investigator (PI) declares by signing that I will not disclose information regarding this clinical investigation or publish results of the investigation without authorization from Biocon Biologics UK Limited."|t
17136091|NCT05183867|t||||
17136092|NCT05299983|f||||f
17136093|NCT04491877|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17136094|NCT03538652|t||||
17136095|NCT04920084|t||||
17136096|NCT01109004|f||||f
17136097|NCT02891798|f||||f
17136098|NCT01953328|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136099|NCT00523341|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136100|NCT04710862|f||||f
17195762|NCT00512252|t||||
17195763|NCT00705406|f||||f
17195764|NCT01079806|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195765|NCT03732807|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195766|NCT01779700|t||||f
17136101|NCT02626819|f||||f
17180956|NCT05413369|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17180957|NCT02809677|f||||f
17195767|NCT00504023|t||||
17136102|NCT02491437|f||OTHER|"At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow sponsor sixty (60) days to review and comment on them.~If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials."|t
17136103|NCT00502307|f||||f
17136104|NCT00051558|f||GT60||t
17136105|NCT04936724|t||||f
17136106|NCT03902366|t||||
17180958|NCT04103892|f||OTHER|After the multicenter publication or 18 months after completion of the Study, whichever occurs first, Institution may itself publish the results of its data from the Study. Institution and Principal Investigator shall provide Sponsor with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor shall have 60 days to review the proposed publication.|t
17136107|NCT00751530|f||OTHER|Site Investigators (PIs) agree not to individually publish the results of the study. They may participate in a joint publication of the study results with the sponsor.|t
17136108|NCT02849990|t||LTE60||t
17136109|NCT01051986|f||||f
17136110|NCT02728258|f||LTE60||t
17136111|NCT01725152|f||||f
17151006|NCT01674647|t||OTHER|The Consultant agrees not to publish or cause to be published any works of authorship relating to the Project rendered pursuant to this Agreement without first notifying Bayer in writing and obtaining Bayer's written consent. Bayer will respond to such notification within sixty (60) days of receipt.Bayer reserves the right to insist on the removal of all or any of its Confidential Information from any such work prior to publication|t
17151007|NCT01490866|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17180959|NCT04340362|f||||t
17180960|NCT02422745|f||||f
17180961|NCT04170348|t||||
17180962|NCT05104567|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17180963|NCT05734443|t||||
17180964|NCT01602380|f||||f
17180965|NCT03658538|t||||
17180966|NCT03333044|t||||
17136112|NCT00750555|f||||f
17136113|NCT01111539|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17136114|NCT03628417|t||||
17136115|NCT03539458|f||OTHER|The investigators will not use study-related data without the written consent of the sponsor.|t
17136116|NCT00372190|t||||
17136117|NCT00718419|f||GT60||t
17136118|NCT00771407|f||LTE60||t
17136119|NCT00726323|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136120|NCT01487668|t||||f
17136121|NCT03000309|f||||f
17136122|NCT02145299|t||||
17136123|NCT01380106|f||||f
17136124|NCT00458406|t||||
17136125|NCT03521154|f||||f
17136126|NCT00376597|f||LTE60||t
17136127|NCT00365716|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136128|NCT06150573|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136129|NCT00069095|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136130|NCT02869854|t||||
17151008|NCT01181271|t||||
17151009|NCT04156620|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180967|NCT03188094|t||||
17180968|NCT06013176|t||||
17136131|NCT01071044|f||||f
17136132|NCT05114590|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17136133|NCT02439281|t||||f
17180969|NCT04537234|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180970|NCT03860584|f||||f
17195768|NCT01082575|f||||f
17136134|NCT00358917|f||OTHER|This study has varying agreements that have been negotiated individually; however, it appears that the most restrictive of the agreements states that following the first publication/presentation of the study by Abbott (or twelve \[12\] months after the completion of the study at all sites, whichever occurs first), the Principal Investigator (PI) shall, during a period of twelve (12) months, have the right to publish/present the results of the site.|t
17136135|NCT03347617|t||||
17165885|NCT02931838|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136136|NCT05309369|f||||f
17165886|NCT02701764|t||||
17136137|NCT05372575|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136138|NCT01544595|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17136139|NCT02200458|t||||
17136140|NCT00601523|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17136141|NCT03643432|t||||
17136142|NCT04415489|t||||
17136143|NCT03638947|f||||f
17151010|NCT02980874|f||OTHER|The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17136144|NCT05319535|t||||
17136145|NCT03566108|f||||f
17151011|NCT02722148|t||||f
17151012|NCT01753336|f||||f
17136146|NCT05281523|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data do not precede the primary publication of the entire clinical trial.|t
17151013|NCT02103270|t||||f
17136147|NCT05513391|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17136148|NCT05128162|t||||
17136149|NCT04038255|t||||
17136150|NCT01027910|f||||f
17136151|NCT00074412|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) \& company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review \& comment. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts \& five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17136152|NCT00924352|f||OTHER|The funder will be provided with a copy of the proposed publication at least 30 days prior to its submission or presentation. The funder may request the presentation/submission be delayed for an additional 90 days to allow the funder to seek patent protection. The funder can require the deletion of information deemed as confidential.|t
17136153|NCT00418834|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136154|NCT02775760|t||||
17165887|NCT02521974|f||||f
17136155|NCT01760941|t||||
17136156|NCT03300752|t||||f
17165888|NCT02949024|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical.|t
17165889|NCT01027650|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165890|NCT00912782|t||||
17165891|NCT03419897|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165892|NCT03759639|f||||f
17165893|NCT02719691|t||||f
17136157|NCT02364947|f||||f
17136158|NCT02163993|f||GT60||t
17136159|NCT00853489|f||||f
17151014|NCT00446199|f||OTHER|(A) PI will provide copy to Sponsor at least (30) days prior to date of planned submission or presentation. Sponsor will have thirty (30) days to review and provide feedback. If proposed publication presents material adverse effect on the confidentiality of Sponsor's information, then PI shall delay or prevent such publication. (B) In a multi-center trial, the investigative data will be pooled and published as a collaborative effort with consent from all parties including the Sponsor.|t
17151015|NCT03801382|t||||
17151016|NCT04188301|f||||f
17151017|NCT03548064|f||LTE60||t
17136160|NCT05525975|t||||
17136161|NCT00441441|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165894|NCT00336284|f||OTHER|The investigator agrees to provide copies of any abstracts, papers or manuscripts to the Sponsor for review within a reasonable period prior to submittal for publication. BIOTRONIK limits its review to a determination of whether Confidential Information (CI) is disclosed and may not attempt to censor or in any way interfere with the investigator's presentation or conclusions beyond the extent necessary to protect CI or to allow to protect its rights in patentable or copyrightable material.|t
17136162|NCT04009096|t||||
17165895|NCT02159898|f||||t
17165896|NCT01498744|t||||f
17165897|NCT03308968|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17136163|NCT05151471|f||OTHER||t
17165898|NCT04397939|t||||
17136164|NCT03010423|f||||t
17165899|NCT00776594|f||||f
17136165|NCT01856595|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165900|NCT01961297|f||||t
17165901|NCT02141633|f||||f
17165902|NCT02482298|f||OTHER|Public disclosure of trial results by Principle Investigators within two years of trial completion requires Sponsor's prior written consent.|t
17136166|NCT04426825|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165903|NCT00106119|t||||
17136167|NCT04346628|t||||
17136168|NCT03161938|t||||
17151018|NCT05011123|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17151019|NCT04221789|f||||f
17151020|NCT04732221|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17136169|NCT02528500|f||OTHER|Institution and Investigator agree not to submit any Publication until Study Completion and multi-center Publication has been published. If the multi-center Publication has not been submitted within 12 months of Study Completion, Institution and investigator may proceed with submission of the Publication; subject to the following: Investigator will provide all Publications to Sponsor for review that is more than 60 days but may extend an additional 120 days.|t
17136170|NCT01028651|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17136171|NCT00411788|t||||
17136172|NCT01554956|f||OTHER|Any results communication will be examined by the PIs and Sponsor 60 days before the submission. Sponsor should receive one copy of each publication proposed. The comments of Sponsor should be issued not beyond 60 days. PI cannot publish data which are considered to be common to such a study without the consent of the other PIs and previous review of Sponsor. In case of disagreement between the PIs, the the senior author and the Sponsor will discuss to find a common position.|t
17136173|NCT03993691|t||||
17136174|NCT01428063|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136175|NCT00913978|f||||f
17136176|NCT01327651|f||OTHER|All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts and five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17136177|NCT03484533|t||||f
17136178|NCT03249792|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17151021|NCT03747601|t||||
17165904|NCT02414607|t||||
17165905|NCT01188551|t||||
17165906|NCT02998684|f||||f
17165907|NCT03782259|t||||
17165908|NCT00603941|f||||f
17180971|NCT02070744|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17180972|NCT04199117|f||||f
17136179|NCT02284906|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136180|NCT04332640|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17151022|NCT05327816|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17136181|NCT00069576|f||||f
17136182|NCT04060667|t||||
17136183|NCT01750398|f||||f
17136184|NCT00525148|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17136185|NCT01734512|t||||
17136186|NCT05100199|f||||f
17136187|NCT00830037|f||||f
17136188|NCT00752609|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136189|NCT02154750|f||||f
17136190|NCT04111276|f||||f
17151023|NCT00112866|f||LTE60||t
17151024|NCT04305587|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151025|NCT01367665|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151026|NCT02752906|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17151027|NCT01539135|f||||f
17151028|NCT01480843|f||||f
17151029|NCT00673153|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor CAN require changes to the communication and CAN extend the embargo.|t
17136191|NCT01254396|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136192|NCT00923910|f||||f
17151030|NCT01345175|t||||
17151031|NCT00642694|f||||f
17151032|NCT03688282|f||LTE60||t
17136193|NCT01096550|f||||f
17136194|NCT03196297|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17136195|NCT00170157|t||||
17136196|NCT00829166|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136197|NCT00320385|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151033|NCT04112173|f||||f
17151034|NCT02109419|f||||f
17151035|NCT01259115|f||GT60||t
17180973|NCT05478252|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17136198|NCT02492750|t||||
17136199|NCT01280123|f||||f
17136200|NCT03288779|t||||
17136201|NCT00668434|f||||f
17136202|NCT02426658|t||||
17136203|NCT03017924|f||||f
17136204|NCT02928406|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136205|NCT02149836|t||||
17136206|NCT00436215|f||||f
17136207|NCT00309777|f||GT60||t
17151036|NCT03560986|f||OTHER|The sponsor reserves the right to review any proposed full publication or poster or presentation of the results of this study by the coordinating or other investigator before they are submitted for publication or public disclosure. Neither the sponsor nor the coordinating investigator has the right to prohibit publication or public disclosure. Publication or public disclosure can be postponed for patent purposes.|t
17151037|NCT02524730|f||GT60||t
17151038|NCT01383213|f||||f
17151039|NCT01868893|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151040|NCT01857271|f||||t
17151041|NCT01783548|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17151042|NCT03493386|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151043|NCT00988442|f||||f
17151044|NCT02468570|f||GT60||t
17151045|NCT04257552|f||||f
17151046|NCT05297578|f||OTHER|Sponsor shall review within the ninety (90) day period. Upon receiving any notification from Sponsor requesting deletion of Confidential Information, correction of inaccuracies, or a delay in publication to allow the filing of patent application, Institution or Investigator shall take the requested action of Sponsor.|t
17151047|NCT03456583|f||||f
17151048|NCT01265433|f||||f
17151049|NCT00759187|f||GT60||t
17151050|NCT01468818|f||||f
17151051|NCT01714232|t||||
17151052|NCT01212588|f||||f
17151053|NCT01735955|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151054|NCT05084716|f||||f
17151055|NCT02176408|f||||f
17151056|NCT01434186|f||||f
17151057|NCT00831766|t||||
17151058|NCT03893565|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151059|NCT02697240|t||||
17151060|NCT04795908|f||||f
17151061|NCT01520532|f||LTE60||t
17151062|NCT03734666|t||||
17151063|NCT00753220|f||||f
17151064|NCT00944749|t||||
17151065|NCT00914459|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151066|NCT01661179|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17151067|NCT01946191|f||||f
17151068|NCT03118570|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151069|NCT03970837|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17151070|NCT02811263|f||||f
17151071|NCT01425723|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17151072|NCT00186043|f||||f
17151073|NCT04874636|f||||t
17151074|NCT01362127|f||||f
17151075|NCT00228423|f||OTHER|The first publication will be a joint effort between all contributing parties. At least 30 days before submission for publication, the partnership will be provided the proposed publication and will be given 30 days to respond with approval or requests for holds. All contributing parties must be acknowledged in all publications.|t
17151076|NCT02642536|t||||
17151077|NCT00786994|f||OTHER|Agreement on publication prior to disclosure|t
17151078|NCT01104779|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17151079|NCT04018664|f||||f
17151080|NCT03845296|f||LTE60||t
17151081|NCT05104073|f||||f
17151082|NCT00671918|f||OTHER|The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.|t
17151083|NCT01200992|f||OTHER||t
17151084|NCT03402555|f||||f
17151085|NCT02155543|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151086|NCT02213510|f||||f
17151087|NCT03398070|f||||f
17151088|NCT04773301|t||||
17151089|NCT05958888|t||||
17151090|NCT03244644|f||GT60||t
17151091|NCT01997216|t||||
17151092|NCT04241315|f||LTE60||t
17151093|NCT00394524|f||||f
17151094|NCT01398514|f||OTHER|The sponsor shall require the PI to furnish the sponsor with a copy of any proposed publication at least 60 days prior to submission. The sponsor shall be entitled to review such proposed publications. The PI shall give due regard to the sponsor's comments on the proposed publication. If the sponsor reasonably believes a patent application claiming an invention should be filed prior to such publication, such submission shall not be submitted until applicable patent applications have been filed.|t
17151095|NCT01007942|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17151096|NCT02713386|f||LTE60||t
17151097|NCT05083585|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17151098|NCT04941521|t||||
17151099|NCT00114166|f||||f
17151100|NCT03614897|f||||f
17151101|NCT04040322|f||||f
17151102|NCT03056157|t||||
17151103|NCT00806286|f||||f
17151104|NCT03402750|t||||
17151105|NCT03469336|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151106|NCT02628743|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151107|NCT02534844|f||OTHER||t
17151108|NCT02958982|f||||t
17151109|NCT00593736|f||OTHER|The sponsor can review results communications prior to public release; such communications can be embargoed for a period up to 150 days to permit actions necessary to preserve sponsor's intellectual property. Sponsor can request changes to the results communication only for the purpose of removing non study related information that is proprietary and confidential to sponsor. Sponsor can require delay of a results communication until the study has been completed at all participating sites.|t
17151110|NCT04645966|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151111|NCT03825341|t||||
17151112|NCT04146116|f||||f
17151113|NCT00289536|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).|t
17151114|NCT04645264|t||||
17151115|NCT03272464|t||||
17151116|NCT02116608|t||||
17151117|NCT04283500|t||||
17151118|NCT03468075|t||||
17151119|NCT03599271|f||LTE60||t
17151120|NCT02006693|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151121|NCT03682224|f||||f
17151122|NCT01119508|t||||
17151123|NCT00265395|f||LTE60||t
17151124|NCT00271154|f||OTHER|"In most cases, contracts allow investigators to publish study results per the publication plan/protocol following Medtronic's review to determine whether confidential information (CI) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred."|t
17151125|NCT04053465|t||||
17151126|NCT01087489|f||||f
17151127|NCT00117325|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151128|NCT02338193|f||||f
17151129|NCT02971735|f||||f
17151130|NCT00997204|f||LTE60||t
17151131|NCT04380090|t||||
17151132|NCT05788289|t||||
17151133|NCT00762931|f||LTE60||t
17151134|NCT00115297|f||||f
17151135|NCT00085423|f||||f
17151136|NCT02800213|f||||f
17195769|NCT00683800|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151137|NCT00536263|f||OTHER|The principal investigator (PI) agrees not to publish/present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication/presentation to permit the sponsor to review copies of abstracts/manuscripts which report any study results. The sponsor shall have the right to review and comment. If the parties disagree the PI agrees to meet with the sponsor to discuss and resolve.|t
17151138|NCT02257541|t||||
17151139|NCT02642575|f||||f
17136208|NCT05513053|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17151140|NCT03055650|f||||t
17151141|NCT02829294|f||LTE60||t
17151142|NCT01140503|f||LTE60||t
17151143|NCT04154150|t||||f
17151144|NCT05161806|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151145|NCT00809159|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17151146|NCT03316378|t||||
17151147|NCT03201211|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17151148|NCT01083810|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17151149|NCT01629966|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the PI will be subject to mutual agreement between the PI and Forest Research Institute, Inc.|t
17151150|NCT01045174|f||||f
17151151|NCT00477295|f||||f
17151152|NCT04568031|f||||t
17151153|NCT04430855|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17151154|NCT00390221|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17151155|NCT01412372|f||||f
17151156|NCT02351544|f||||f
17151157|NCT02876575|f||OTHER|Medical Center /Investigator may publish the results of work performed under this Agreement, in accordance with the Publication Policy described in the Clinical Investigation Plan and publication guidelines from the Declaration of Helsinki; provided, however, that any such Publication shall be at a time determined by Medtronic and shall be provided to Medtronic for review at least sixty (60) days prior to submission or presentation.|t
17165909|NCT05069597|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17165910|NCT03379259|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17195770|NCT00229970|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195771|NCT01700205|f||||f
17195772|NCT02251652|t||||
17195773|NCT05783843|t||||
17136209|NCT01520324|f||OTHER|Publication to be reviewed by sponsor prior to submission.|t
17136210|NCT03488472|t||||
17136211|NCT02094872|f||||t
17136212|NCT00423085|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17136213|NCT00539253|f||||f
17136214|NCT02658994|f||||f
17136215|NCT00262080|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136216|NCT02273752|t||||
17165911|NCT05507567|f||||f
17165912|NCT00375427|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17165913|NCT03024112|f||||f
17165914|NCT03703232|f||||f
17165915|NCT01771991|t||||
17165916|NCT01399229|f||OTHER|PIs may publish or present results of the study after the expiration of 12 months from completion. Publications or presentations are subject to the protection of confidential information or patentable information.|t
17165917|NCT01204905|t||||
17165918|NCT03809078|t||||
17165919|NCT00606411|f||||f
17165920|NCT03726658|f||GT60||t
17165921|NCT00412958|f||GT60||t
17165922|NCT00090779|f||OTHER|"In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights."|t
17165923|NCT01318135|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17165924|NCT02179424|f||||f
17165925|NCT01794312|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17165926|NCT03012828|f||||f
17180974|NCT02928289|f||OTHER|After Sponsor's publication of trial results, the Institution and Principal Investigator may publish the results of the Study generated by the Institution, subject to the obligations of the CTA, and prior approval of Sponsor in writing. The Institution shall furnish Sponsor with a written copy of any proposed publication or disclosure at least 60 days prior to submission for publication or disclosure. Sponsor may request changes or other measures to ensure the information is fairly stated.|t
17180975|NCT03939897|f||LTE60||t
17180976|NCT07114198|f||||f
17180977|NCT02064907|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property|t
17180978|NCT00265473|t||||
17180979|NCT00708942|f||OTHER|"The PI may publish the results from his/her site, provided that the publication does not disclose confidential information or interfere with sponsor's efforts to obtain patent protection for inventions. The sponsor must receive material for review not less than sixty (60) days prior to their proposed submission.~In this multi center study, collective publications are anticipated. The PI must not independently publish the results of the Study before the first collective publication."|t
17151158|NCT00193427|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17151159|NCT04682730|f||||f
17151160|NCT02683265|f||||f
17151161|NCT03258853|t||||f
17151162|NCT03870477|f||||f
17151163|NCT00771745|f||||f
17151164|NCT03564444|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17151165|NCT04625426|f||||f
17151166|NCT01540773|f||||f
17151167|NCT03753763|f||||f
17151168|NCT00389831|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17165927|NCT02100930|t||||
17165928|NCT03115411|f||||f
17165929|NCT03751371|t||||
17165930|NCT03472495|t||||
17165931|NCT01107392|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165932|NCT02136004|f||||f
17165933|NCT01539070|t||||f
17165934|NCT02998671|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17165935|NCT04560686|t||||
17180980|NCT00939809|f||||f
17195774|NCT00983294|f||GT60||t
17151169|NCT03433755|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17151170|NCT04941729|f||LTE60||t
17151171|NCT03190330|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17151172|NCT02081209|f||||f
17165936|NCT02038946|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165937|NCT02623205|f||||f
17165938|NCT03162796|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17165939|NCT02473471|t||||f
17165940|NCT01928290|t||||
17165941|NCT02342288|f||||f
17180981|NCT01277523|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIs intellectual property rights.|t
17180982|NCT01030523|f||||f
17180983|NCT00426283|f||||f
17165942|NCT03082677|t||||
17165943|NCT01181804|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. The sponsor shall have the right to review and comment.|t
17165944|NCT01916824|t||||
17165945|NCT03163134|t||||
17165946|NCT02063984|f||||f
17165947|NCT01958580|t||||
17165948|NCT01169701|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165949|NCT02619591|t||||
17165950|NCT02455336|f||||f
17165951|NCT01158820|t||||
17165952|NCT02467192|t||||
17165953|NCT01955369|t||||
17165954|NCT01814046|f||||f
17165955|NCT03089047|t||||
17165956|NCT02517398|f||||t
17165957|NCT02008149|t||||
17165958|NCT00005947|f||OTHER|A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.|t
17165959|NCT00429182|t||||f
17165960|NCT01667250|f||LTE60||t
17165961|NCT00778167|f||LTE60||t
17165962|NCT04201639|f||||f
17180984|NCT02996864|f||||f
17165963|NCT02195700|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17180985|NCT02389998|f||||f
17165964|NCT03110029|f||||f
17180986|NCT05089682|t||||
17180987|NCT00706979|f||||f
17180988|NCT01996826|f||||f
17165965|NCT00921115|f||||f
17165966|NCT02524145|f||||f
17165967|NCT04357730|f||||f
17165968|NCT00283803|f||||f
17165969|NCT01127607|f||||f
17180989|NCT02734979|t||||
17180990|NCT02255981|f||||f
17180991|NCT00518323|f||GT60||t
17180992|NCT01514760|t||||
17180993|NCT02092662|f||||f
17180994|NCT03777007|t||||
17180995|NCT00391989|f||||f
17180996|NCT03329690|f||||f
17180997|NCT00151320|t||||
17180998|NCT02418468|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17180999|NCT02914769|t||||
17165970|NCT02220855|t||||
17165971|NCT03574610|f||||t
17165972|NCT01032954|f||||f
17165973|NCT04473950|t||||f
17165974|NCT03980743|f||||f
17165975|NCT00332579|f||||f
17165976|NCT01461499|f||||f
17181000|NCT02290106|f||||f
17181001|NCT02337907|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151173|NCT05205772|t||||
17151174|NCT06378749|t||||
17151175|NCT05538065|f||||f
17151176|NCT00191113|f||GT60||t
17165977|NCT01282242|t||||f
17165978|NCT03107052|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17165979|NCT02263326|f||||f
17181002|NCT02876900|f||||t
17181003|NCT01592344|f||LTE60||t
17195775|NCT03805672|f||||f
17195776|NCT03758742|f||||f
17195777|NCT03229408|f||||f
17195778|NCT04200664|t||||
17195779|NCT04233567|t||||
17181004|NCT00629499|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17181005|NCT01770483|f||||f
17181006|NCT02488681|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17181007|NCT00720057|f||LTE60||t
17181008|NCT03141242|t||||
17181009|NCT00545155|f||||f
17181010|NCT00525733|t||||
17181011|NCT00613015|t||||f
17181012|NCT01170091|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17181013|NCT01335581|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17181014|NCT01899300|f||GT60||t
17181015|NCT00391274|f||GT60||t
17181016|NCT03341533|t||||
17181017|NCT00112593|t||||
17181018|NCT03447990|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181019|NCT03559257|f||GT60||t
17181020|NCT03630120|t||||
17195780|NCT04541589|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195781|NCT02426138|f||||f
17195782|NCT00003459|f||||f
17195783|NCT03088800|t||||
17195784|NCT00291694|t||||
17195785|NCT03582475|f||||f
17195786|NCT02972424|f||||f
17195787|NCT01706159|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17195788|NCT03362190|f||OTHER|Institution/PI agrees not to individually publish the results of the Study without IVERIC bio's prior written consent. Institution/PI may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of IVERIC bio.|t
17195789|NCT00687219|f||||f
17195790|NCT04816955|t||||
17195791|NCT03775486|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years of completion of the Study shall require the Sponsor's prior written consent.|t
17181021|NCT01519960|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136217|NCT02808312|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17136218|NCT02713230|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17181022|NCT01387347|f||LTE60||t
17181023|NCT02658357|f||||f
17181024|NCT02153112|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17195792|NCT04041219|t||||
17195793|NCT01536366|t||||
17195794|NCT02940249|t||||
17195795|NCT00873782|f||||f
17195796|NCT02744066|t||||f
17195797|NCT02454959|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17195798|NCT04502472|t||||
17195799|NCT03024866|f||||f
17195800|NCT04104022|f||||f
17151177|NCT02087995|f||||f
17195801|NCT05256797|f||||f
17195802|NCT03496766|f||||f
17195803|NCT00647387|f||||f
17151178|NCT05339334|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195804|NCT02842749|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195805|NCT02969356|f||||t
17195806|NCT03187223|f||||f
17195807|NCT01850355|t||||
17195808|NCT02808468|f||||f
17195809|NCT04906057|t||||
17195810|NCT05395351|t||||
17195811|NCT04172675|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17195812|NCT03945773|f||||t
17195813|NCT05349721|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17195814|NCT03070392|f||||t
17195815|NCT02972034|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17195816|NCT03861052|f||||t
17195817|NCT03823703|f||OTHER|No individual publications will be allowed before publication of the multicenter results, except as agreed with the Sponsor. The Investigator agrees to submit all manuscripts or abstracts to the Sponsor for review before submission to the publisher.|t
17195818|NCT03137459|f||||f
17195819|NCT01550952|t||||
17195820|NCT01970878|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17195821|NCT00925548|f||OTHER||t
17195822|NCT04921358|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17195823|NCT02278796|f||||f
17195824|NCT04926857|f||||f
17195825|NCT05646719|f||LTE60||t
17195826|NCT02372799|f||OTHER|All data generated in this study are the property of the sponsor. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and the sponsor and will follow sponsor's standard operating procedures on publications.|t
17151179|NCT03786718|t||||
17151180|NCT00368979|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151181|NCT00945100|f||||f
17151182|NCT03190213|t||||
17151183|NCT01781481|f||||f
17151184|NCT01811316|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. PI shall delay publications for up to 90 days upon receipt of a written request from the sponsor in order to allow the sponsor to register intellectual property rights that are included in the proposed publication.|t
17151185|NCT00699283|f||GT60||t
17151186|NCT02684630|f||||f
17181025|NCT00561080|f||OTHER|Investigators must first obtain written consent from Sanofi Pasteur MSD. If consent is given, all abstracts manuscripts, texts, or presentation, etc... shall be sent to Sanofi Pasteur MSD for review and approval prior to their publication or presentation. Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17181026|NCT00827983|f||||f
17151187|NCT01531439|f||||f
17151188|NCT03796598|f||||f
17151189|NCT01916590|f||||f
17151190|NCT03537599|t||||
17195827|NCT03706261|t||||
17195828|NCT02637063|t||||
17195829|NCT00491400|f||||f
17195830|NCT00747006|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17195831|NCT03926026|f||||f
17195832|NCT00345046|f||||f
17195833|NCT02824198|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17195834|NCT00562094|f||||f
17195835|NCT01600482|f||||f
17181027|NCT01498458|f||||f
17181028|NCT01876485|t||||
17195836|NCT03689946|f||||f
17195837|NCT01555138|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17195838|NCT01613417|f||OTHER|Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement|t
17195839|NCT00790699|f||||f
17195840|NCT02357966|f||||f
17195841|NCT00019604|f||||f
17195842|NCT04608409|t||||
17195843|NCT00599196|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17195844|NCT02683174|f||||f
17195845|NCT03819543|f||||f
17195846|NCT01379651|t||||f
17195847|NCT00252382|f||GT60||t
17195848|NCT01545583|f||GT60||t
17151191|NCT03929757|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17151192|NCT01108406|f||GT60||t
17151193|NCT01136967|f||OTHER||t
17151194|NCT02885181|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17151195|NCT03317834|f||||f
17151196|NCT03327792|t||||
17151197|NCT00996775|t||||
17151198|NCT01234922|t||||
17151199|NCT00375830|t||||
17151200|NCT00123474|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151201|NCT01059344|t||||
17151202|NCT00742924|f||||f
17151203|NCT00660400|t||||
17151204|NCT03490760|t||||
17151205|NCT00528411|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.|t
17151206|NCT02643355|t||||
17151207|NCT01715571|f||||f
17151208|NCT01687972|t||||
17165980|NCT02397915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165981|NCT00933608|f||||f
17165982|NCT01685242|f||||t
17195849|NCT02522104|f||||f
17195850|NCT04497415|t||||
17195851|NCT01354145|f||LTE60||t
17195852|NCT00734578|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17195853|NCT01556594|f||||f
17195854|NCT02085941|t||||
17195855|NCT05462912|f||||f
17195856|NCT04566861|f||||f
17195857|NCT04652726|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151209|NCT04420273|f||||f
17151210|NCT04524364|f||OTHER|Authorship will be determined prior to development of any manuscript. All information concerning the study, investigational medical device, sponsor operations, patent application, manufacturing processes, and basic scientific data supplied by the sponsor to the investigator and not previously published, are considered confidential and remain the sole property of the sponsor.|t
17151211|NCT00826449|t||||
17151212|NCT03233230|f||OTHER||t
17151213|NCT02994940|t||||
17151214|NCT00475150|f||LTE60||t
17151215|NCT02327741|f||||f
17151216|NCT02987959|t||||
17195858|NCT02157116|t||||f
17195859|NCT00093496|f||LTE60||t
17195860|NCT03187678|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Actelion may provide comments and may also request alterations and/or deletions for the sole purpose of protecting its confidential information or patent rights.|t
17195861|NCT03274076|f||||f
17195862|NCT00975585|f||OTHER|Prior to submission for publication or presentation, the PI will provide SPONSOR with at least sixty (60) days for review of a manuscript. Notwithstanding the foregoing, no paper that incorporates SPONSOR Confidential Information will be submitted for publication without SPONSOR's prior written consent. If requested in writing, the PI will withhold such publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17195863|NCT00795184|f||||f
17195864|NCT04053270|f||||f
17195865|NCT00205179|f||||f
17195866|NCT00586313|t||||
17195867|NCT02079649|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17195868|NCT04941703|f||||f
17195869|NCT03760913|f||OTHER|The Principal Investigator shall not use the name, trademark or the name of any representative of the other, or the existence of their agreement with the sponsor for any promotional or advertising purposes, or any other publication, without the prior written consent of the sponsor, or state or imply that the sponsor endorses or approves any service, material, product or compound of the sponsor without the prior written consent of the sponsor.|t
17195870|NCT00853580|f||||f
17195871|NCT00748982|t||OTHER|The PI was employed at AstraZeneca and had therefore to follow AZ policy.|t
17195872|NCT01968967|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195873|NCT01170208|t||||
17195874|NCT01351376|f||||f
17195875|NCT04033315|f||||t
17195876|NCT03552276|f||||t
17195877|NCT00176202|t||||
17195878|NCT01160354|t||||
17136219|NCT03100942|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17136220|NCT04263142|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136221|NCT01623531|f||||f
17136222|NCT01429792|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136223|NCT04179968|t||||
17136224|NCT04184622|f||GT60||t
17136225|NCT00812916|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17136226|NCT00769704|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136227|NCT01351077|f||||f
17136228|NCT01617681|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17136229|NCT02599766|f||||f
17136230|NCT01883440|f||||f
17136231|NCT03696758|t||||
17151217|NCT04126213|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17151218|NCT00392236|t||||f
17151219|NCT02853370|f||||f
17151220|NCT02196701|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17151221|NCT02205983|t||||
17151222|NCT03275064|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151223|NCT04159935|f||||f
17151224|NCT01341782|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17151225|NCT00620555|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165983|NCT00391053|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17165984|NCT04908384|t||||
17165985|NCT05002985|t||||
17165986|NCT04077424|t||||
17165987|NCT01642901|f||||f
17165988|NCT00422448|t||||f
17165989|NCT02943070|f||||f
17195879|NCT03849066|f||||f
17195880|NCT03067948|f||||f
17195881|NCT02743819|f||||f
17195882|NCT04111510|t||||
17195883|NCT06193590|f||||f
17195884|NCT04205903|t||||
17195885|NCT03637296|t||||
17195886|NCT03683576|f||||t
17136232|NCT01835496|f||OTHER|"All unpublished information given to the PI by ApoPharma shall not be published or disclosed to a third party without the prior written consent of ApoPharma.~The data generated by this study are considered confidential information and the property of ApoPharma. This confidential information may be published only in collaboration with participating personnel from ApoPharma or upon ApoPharma written consent to publish the article."|t
17136233|NCT01763905|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136234|NCT03165721|f||||f
17136235|NCT02078882|f||||f
17136236|NCT01863849|f||OTHER|The disclosure restriction on the PI is that the sponsor in the frames of the general confidentiality agreement is that the PI cannot release any information concerning the study without the prior consent of the sponsor. To further specification is provided.|t
17136237|NCT01405313|f||||f
17136238|NCT01263691|f||OTHER|Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between National Institute of Allergy and Infectious Disease (NIAID) and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17136239|NCT02012608|t||||
17136240|NCT01533935|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17136241|NCT00316303|t||||
17136242|NCT00532948|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136243|NCT01753076|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136244|NCT02575079|t||||
17136245|NCT02918266|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17136246|NCT00300469|f||OTHER|Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.|t
17136247|NCT01259856|t||||
17136248|NCT00578864|t||||
17136249|NCT01087528|f||||f
17136250|NCT03450369|t||||
17136251|NCT00962000|f||GT60||t
17136252|NCT02702193|t||||
17136253|NCT01016106|t||||
17136254|NCT01201798|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17136255|NCT03609359|f||||f
17136256|NCT01035255|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17136257|NCT03007953|t||||
17136258|NCT02203838|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multicenter publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17136259|NCT04590937|t||||
17136260|NCT01635933|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17136261|NCT04525222|f||||f
17136262|NCT03208192|f||||f
17136263|NCT02615717|t||||
17136264|NCT04333433|f||||t
17136265|NCT02026271|f||OTHER|Disclosure shall not occur until (i) twenty-four (24) months have elapsed since Sponsor has notified Institution of the completion of the multi-center Study in order for Sponsor to comply with its obligations under 21 CFR 312.53(c)(4), or (ii) after the publication of the multi-center Study data, if the Study is a multi-center Study or Sponsor confirms in writing there will be no multi-center publication.|t
17136266|NCT04743635|f||OTHER||t
17136267|NCT01704781|f||OTHER|The Sponsor (or designee) will prepare a final report on the study. The Investigator may not publish or present any information on this study without the express written approval of the Sponsor. Additionally, the Sponsor, may, for any reason, withhold approval for publication or presentation.|t
17136268|NCT03382899|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165990|NCT03286829|f||||f
17165991|NCT04123093|t||||
17165992|NCT04556591|f||||f
17136269|NCT01355068|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136270|NCT00524745|t||||
17136271|NCT00872170|t||||
17136272|NCT00540449|f||OTHER||t
17136273|NCT01721408|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136274|NCT00524316|t||||
17136275|NCT01199263|f||LTE60||t
17136276|NCT01402284|f||||f
17136277|NCT04937816|t||||
17136278|NCT01113398|t||||
17136279|NCT00492856|f||||f
17136280|NCT01998581|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17136281|NCT01251276|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study sixty (60) days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17136282|NCT01345123|f||||f
17136283|NCT05936385|f||||f
17136284|NCT00335504|f||LTE60||t
17136285|NCT01457118|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17136286|NCT03540134|t||||
17136287|NCT03456713|f||GT60||t
17136288|NCT01202227|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136289|NCT00803010|t||||f
17136290|NCT04402008|f||||t
17136291|NCT03430245|f||||f
17136292|NCT00850759|f||||f
17136293|NCT00788775|f||||f
17136294|NCT00370695|f||||t
17136295|NCT01831934|f||||f
17136296|NCT00436969|f||GT60||t
17136297|NCT04490265|t||||
17136298|NCT01864018|t||||
17165993|NCT04551963|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165994|NCT00654836|f||||f
17181029|NCT02446990|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publication and/or communication related to the study results and can require changes. In case of a patent application, the sponsor can delay its authorization for publication or communication of the study results until the date of international registration of the patent.|t
17181030|NCT03158051|t||||
17195887|NCT01827839|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136299|NCT00114972|f||GT60||t
17136300|NCT01716468|f||||f
17136301|NCT01425190|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication.|t
17136302|NCT01912729|t||||
17136303|NCT00584220|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17136304|NCT01952834|f||||f
17136305|NCT04285346|f||||f
17136306|NCT02432287|f||||f
17136307|NCT00610935|f||||f
17136308|NCT00740779|f||LTE60||t
17136309|NCT00850460|t||||
17136310|NCT02773914|f||||f
17136311|NCT02399813|f||OTHER|The Investigator shall seek the Sponsor's written approval for study results publication which shall not be unreasonably withheld. Such publication by Institution and/or Investigator may be no earlier than after a cooperative publication has been published with Sponsor or 1 year from date of completion or termination of the Study \& only after review and comment by Sponsor. Institution agrees to provide Sponsor a copy of proposed publication at least 60 days prior to submission to a publisher.|t
17136312|NCT00988559|f||||f
17136313|NCT02224846|f||GT60||t
17136314|NCT03115801|t||||
17136315|NCT02188121|f||||f
17136316|NCT02538666|f||LTE60||t
17136317|NCT03510663|f||||f
17136318|NCT00843622|f||||f
17136319|NCT01555463|f||OTHER|The PI may publish study results of their own patients only after review/comment by the sponsor. At least 60 days prior to submitting a manuscript to a publisher, a copy of the manuscript will be provided to the sponsor for review. No publication of confidential information shall be made without the sponsor's prior written consent. The PI agrees to delete any confidential information which would prejudice the securing of adequate intellectual property protection from the proposed publication.|t
17136320|NCT04942483|t||||f
17136321|NCT01943864|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136322|NCT02965534|f||||f
17136323|NCT00540969|t||||
17136324|NCT00619684|f||GT60||t
17136325|NCT03552549|f||OTHER|The Principal Investigator agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of the Sponsor. The Principal Investigator further agrees to provide to the Sponsor thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the Protocol study.|t
17136326|NCT02739594|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136327|NCT01465178|f||||f
17136328|NCT01231633|t||||
17136329|NCT00527111|f||||f
17136330|NCT03827473|t||||
17136331|NCT01477892|f||||f
17136332|NCT01921257|f||OTHER|To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.|t
17136333|NCT00777491|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17136334|NCT00088634|f||||f
17136335|NCT03987620|f||||f
17136336|NCT03302416|t||||f
17136337|NCT01745393|f||||f
17136338|NCT00471445|f||||f
17136339|NCT03591146|f||OTHER|Unless Sponsor provides prior written consent, Institution may not use Confidential Information for any purpose other than that authorized in this Agreement, nor may Institution disclose Confidential Information to any third party except as authorized in this Agreement or as required by law. Required disclosure of Confidential Information to the Institutional Review Board (IRB) or to FDA representatives is specifically authorized.|t
17136340|NCT02330627|f||||f
17136341|NCT04737031|t||||f
17136342|NCT01468909|f||LTE60||t
17136343|NCT02592629|t||||
17136344|NCT01204658|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136345|NCT00905021|t||||
17136346|NCT01511419|f||||f
17136347|NCT00786838|f||GT60||t
17136348|NCT04594239|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17136349|NCT00091390|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17136350|NCT03229759|f||||f
17136351|NCT03484923|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17136352|NCT03439748|f||||f
17136353|NCT05131451|f||||f
17136354|NCT00782418|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136355|NCT04341675|t||||f
17136356|NCT00643487|t||||
17136357|NCT01706549|t||||
17136358|NCT00390416|t||||
17136359|NCT00681538|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17136360|NCT00630812|f||||f
17136361|NCT01728584|f||OTHER|Initial public presentation of the Investigator's results will occur only together with the other sites unless permission is obtained from Sponsor. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. In case of disagreement concerning appropriateness of materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues, prior to submission for publication/presentation.|t
17136362|NCT05628181|t||||f
17136363|NCT02649387|t||||
17136364|NCT03207022|f||||f
17136365|NCT00610727|f||LTE60||t
17136366|NCT03656926|f||||f
17136367|NCT05610176|f||LTE60||t
17136368|NCT00471536|f||LTE60||t
17136369|NCT03796091|f||||f
17136370|NCT01253044|f||||f
17136371|NCT03116399|t||||f
17136372|NCT00905307|f||||f
17136373|NCT00660504|f||GT60||t
17136374|NCT00837512|f||||f
17136375|NCT01401010|f||||f
17136376|NCT03860311|f||||f
17136377|NCT01975272|t||||
17136378|NCT03280550|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136379|NCT03345836|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136380|NCT04370028|f||||f
17136381|NCT01167595|f||||f
17136382|NCT02213198|f||||f
17136383|NCT05091060|f||||f
17136384|NCT01798706|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17136385|NCT00496873|t||||
17136386|NCT05896761|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136387|NCT00843310|t||||
17136388|NCT03403504|f||||t
17136389|NCT01257217|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17136390|NCT02796924|t||||
17136391|NCT02761993|f||||f
17136392|NCT01842620|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136393|NCT01442129|f||||f
17136394|NCT02916498|f||GT60||t
17136395|NCT00875017|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136396|NCT02689219|t||||
17136397|NCT03342469|f||||f
17136398|NCT00125658|t||||
17136399|NCT00363805|f||||f
17136400|NCT05515601|f||GT60||t
17136401|NCT00364845|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136402|NCT01912768|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17136403|NCT04160468|f||||t
17136404|NCT01187901|f||||f
17136405|NCT00540436|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136406|NCT03255291|t||||
17136407|NCT04019093|f||||f
17136408|NCT03929588|f||||t
17136409|NCT00962039|f||||f
17136410|NCT01067508|t||||
17136411|NCT00444626|f||OTHER|Principal investigators (PI) will give Genzyme a draft manuscript or draft publication 60 days before publication. Genzyme will make every reasonable attempt to review publication or manuscript and give feedback in such 60 day period. PI will not use Genzyme confidential information without prior written consent.|t
17136412|NCT00462020|t||||
17136413|NCT01686503|t||||f
17136414|NCT03050359|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136415|NCT01136668|f||||f
17136416|NCT02614287|f||||f
17136417|NCT01156597|f||LTE60||t
17136418|NCT01392989|f||||f
17136419|NCT00833248|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17136420|NCT00849121|t||||
17136421|NCT01848054|f||||f
17136422|NCT03580382|t||||
17136423|NCT03913221|t||||
17136424|NCT04281030|t||||
17165995|NCT00700622|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the study results subject to MNKD rights herein.|t
17165996|NCT00924001|f||||f
17165997|NCT03754556|f||OTHER|PI shall ensure that a written manuscript of any intended publication will be provided to BAYER at least 30 days prior to the intended submission or presentation in order to allow BAYER to review it. PI further agrees, upon written request from BAYER, not to submit such abstract or manuscript for publication or to make such presentation for the reasonably required time in order to allow for actions to be taken, which are necessary for BAYER to preserve rights to patents.|t
17165998|NCT04918381|f||LTE60||t
17136425|NCT01826422|t||||
17136426|NCT04549597|f||OTHER|Publications subject to the Sponsor's approval requirements.|t
17136427|NCT05619172|f||OTHER|The results will be published and/or presented at scientific meetings in their totality in a timely manner. Any formal publication of clinical trial results will be a collaborative effort between the sponsor and the investigator(s). All manuscripts or abstracts will be reviewed and approved in written by the sponsor before submission. The sponsor may request a delay in publication if there are important intellectual property concerns.|t
17136428|NCT00450372|t||||
17136429|NCT00401622|f||GT60||t
17136430|NCT02236546|t||||
17136431|NCT00520676|f||GT60||t
17136432|NCT03568539|f||||f
17136433|NCT02179515|f||||f
17136434|NCT01718509|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17165999|NCT00070109|f||OTHER|Must obtain prior Sponsor approval.|t
17136435|NCT05209932|f||||f
17136436|NCT03848221|f||||f
17136437|NCT02874404|f||||f
17136438|NCT00879814|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136439|NCT02251704|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17136440|NCT01219959|f||||t
17136441|NCT02935634|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136442|NCT05906732|f||||t
17136443|NCT00506077|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136444|NCT00818324|f||||f
17136445|NCT00138034|f||OTHER|"Freek W.A. Verheugt~has to following potential conflict of interest:~1. received educational and research grants from Bayer Healthcare, Roche, Eli Lilly and Boehringer Ingelheim~2. received honoraria for consultancies from Daiichi-Sankyo, Eli Lilly, Merck, The Medicines Company and Bayer Healthcare"|t
17136446|NCT01727713|f||||f
17166000|NCT02526212|f||||f
17166001|NCT01390298|t||||f
17166002|NCT03645096|f||||f
17166003|NCT00040742|f||||f
17166004|NCT00392834|f||||f
17166005|NCT03520920|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17166006|NCT00405392|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166007|NCT02032758|t||||
17166008|NCT01703091|f||GT60||t
17166009|NCT04904744|t||||
17166010|NCT02550288|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17166011|NCT00456625|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166012|NCT02819297|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17166013|NCT01569737|f||OTHER|In accordance with the Study protocol signed by the PI, (i) sponsor owns the study data (ii) HCP agrees that the results of the study may be used for the purposes of publications, and information for medical and pharmaceutical professionals (iii) if sponsor publishes the study results within 24-month, PI may elect to serve as co-authors, and following publication, will be permitted to present the results of such publications in symposia.|t
17166014|NCT01071252|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17166015|NCT01945996|f||||f
17166016|NCT03928418|f||||f
17166017|NCT00763256|f||LTE60||t
17166018|NCT02544750|f||OTHER||t
17166019|NCT00244725|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166020|NCT02131311|f||OTHER|"The STUDY SITE and PRINCIPAL INVESTIGATOR agree that all data, calculations, interpretations, opinions and recommendations regarding the STUDY (hereinafter referred to as RESULTS) shall be the property of P\&G. The STUDY SITE and PRINCIPAL INVESTIGATOR agree to consider the RESULTS as INFORMATION subject to confidentiality restrictions"|t
17166021|NCT00418093|f||||f
17166022|NCT03020004|f||OTHER|"After conclusion of the study and without prior written approval from Ascletis, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The study has been completed at all study sites for at least 3 years."|t
17166023|NCT00255723|t||||
17166024|NCT02749201|f||||f
17166025|NCT00581399|t||||
17166026|NCT03711370|f||||f
17166027|NCT00407602|f||||f
17166028|NCT00553436|f||GT60||t
17166029|NCT02368093|f||||f
17166030|NCT03146663|f||||f
17166031|NCT03599518|f||||f
17136447|NCT02651194|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136448|NCT01212172|f||||f
17136449|NCT03885726|f||||f
17136450|NCT01217190|t||||
17136451|NCT02868216|t||||
17136452|NCT02496585|t||||
17136453|NCT01507584|t||||
17136454|NCT03392753|t||||
17136455|NCT00515008|f||||f
17136456|NCT01915849|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17136457|NCT02775864|f||||f
17136458|NCT03238235|f||||f
17136459|NCT02028338|f||OTHER||t
17136460|NCT02094586|f||GT60||t
17136461|NCT00041717|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17136462|NCT01270581|t||||
17136463|NCT00722553|f||OTHER|Allos agreements with investigators (PIs) may vary. The PI may publish/make public data from the trial after the earlier of publication by Allos or 18 months after study completion. Allos can review results communications prior to public release and can embargo communications regarding trial results for a period less than or equal to 90 days from submission for review. Allos can request changes to the communication related to confidential or patent information, or to ensure accuracy.|t
17136464|NCT03047993|t||||
17136465|NCT03492463|t||||
17136466|NCT06704178|f||||f
17136467|NCT02417870|t||||
17136468|NCT00255684|t||||
17136469|NCT02006667|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136470|NCT02939937|t||||
17136471|NCT03007485|f||||f
17136472|NCT01361009|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17136473|NCT00115349|f||||f
17136474|NCT02116660|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17136475|NCT02750800|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136476|NCT03298412|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136477|NCT05631548|t||||
17136478|NCT00216099|f||||f
17136479|NCT02902172|t||||
17136480|NCT01434472|t||||
17136481|NCT00995345|f||OTHER|No explicit limitations on discussion by PI. PI may not publish results before a coordinated multicenter publication has been submitted for publication, marketing approval obtained, or until 7 years after the study has ended, whichever occurs first. Thereafter, the study site will have the opportunity to publish the results of the study, provided that the Sponsor has had the opportunity to review and comment on the study site's proposed publication prior to it being submitted for publication.|t
17136482|NCT02336594|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17136483|NCT01860534|f||||f
17136484|NCT01504854|f||||f
17136485|NCT04891770|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17166032|NCT01625416|f||||f
17166033|NCT02561481|t||||
17166034|NCT01574287|t||||
17166035|NCT02470585|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166036|NCT02591472|t||||
17166037|NCT02870985|f||OTHER||t
17166038|NCT03693144|t||||
17136486|NCT04026412|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17136487|NCT00904826|t||||f
17136488|NCT00195260|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136489|NCT01125176|t||||
17136490|NCT04058054|f||||f
17166039|NCT02311881|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136491|NCT04360187|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136492|NCT03220048|t||||
17136493|NCT00222729|f||||f
17136494|NCT01318083|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17136495|NCT00256867|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136496|NCT02993224|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166040|NCT04068948|f||||f
17166041|NCT00819156|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17166042|NCT00790582|f||||f
17166043|NCT05253755|f||OTHER||t
17166044|NCT01059357|t||||
17166045|NCT01575808|f||||f
17166046|NCT01527045|t||||
17166047|NCT05823974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166048|NCT00316706|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166049|NCT02346903|t||||
17166050|NCT03292874|f||||f
17166051|NCT02685566|f||||f
17166052|NCT00694577|t||||
17166053|NCT00760435|f||||f
17166054|NCT00485758|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166055|NCT00654745|f||OTHER|"Sponsor reflects the following restrictive language in the Clinical Study Agreements: If identified by Daiichi Sankyo Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted. Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site."|t
17166056|NCT01995526|f||GT60||t
17166057|NCT00383331|f||GT60||t
17166058|NCT00924612|f||||t
17166059|NCT04852055|f||||f
17166060|NCT02229825|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166061|NCT03415581|f||||f
17166062|NCT03226249|t||||
17166063|NCT01532921|f||LTE60||t
17166064|NCT01231334|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166065|NCT00436046|f||LTE60||t
17166066|NCT02096952|f||||f
17166067|NCT00624468|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17166068|NCT02544035|t||||
17166069|NCT03660865|f||||t
17166070|NCT01524224|f||GT60||t
17166071|NCT00803361|f||GT60||t
17166072|NCT02858440|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166073|NCT01670279|f||||f
17136497|NCT04286412|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136498|NCT01930799|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151226|NCT00724048|f||OTHER|Sponsor has the right 30 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 60 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17151227|NCT03923530|f||||f
17136499|NCT02915367|f||||f
17136500|NCT00952289|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17166074|NCT01901614|t||||
17166075|NCT01823198|t||||
17166076|NCT02674464|f||||f
17166077|NCT00783835|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo.|t
17166078|NCT01262638|f||||f
17166079|NCT00894699|f||OTHER||t
17151228|NCT04135196|t||||
17151229|NCT00911807|f||||f
17136501|NCT01515176|f||LTE60||t
17136502|NCT02932475|t||||
17136503|NCT02371759|t||||
17136504|NCT02322320|f||||f
17136505|NCT01452126|t||||
17136506|NCT01081223|f||||f
17136507|NCT03136185|f||OTHER|Sponsor will actively pursue publication of the results of the study in cooperation with the Lead Investigators subject to the terms and conditions of the clinical trial agreement between the Sponsor and Investigators. The Lead/Coordinating Investigator will have the right to submit for publication any results arising from the study subject to the terms and conditions of the Clinical Trial and Confidentiality Disclosure Agreements and the agreement of the Sponsor.|t
17136508|NCT02876055|t||||
17136509|NCT00488033|t||||
17136510|NCT01613014|f||||f
17136511|NCT04715230|f||OTHER|PI must provide Sponsor opportunity to review proposed publications/disclosures before submission/disclosure. The first publication is to be a joint publication involving all sites, with Sponsor in control of such publication. Afterward, and if such publication is not made within 12 months following finalization of the clinical study report or termination of the study at all sites, PI may publish separately.|t
17136512|NCT03453151|t||||
17151230|NCT01174082|t||||
17151231|NCT02991430|f||LTE60||t
17151232|NCT01672970|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151233|NCT01997229|f||OTHER|Publication rights are tied to the completion of the multi-center publication.|t
17151234|NCT02304991|t||||
17151235|NCT01770392|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17151236|NCT01531738|t||||
17151237|NCT02533375|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166080|NCT01122446|f||||f
17166081|NCT02243371|t||||
17166082|NCT01369199|f||OTHER|"From the Publications and Presentations policy Disagreements between the HBRN Steering Committee and the NIDDK on the merits of journal submission of a specific manuscript will be mediated through discussion on Steering Committee conference calls, ad hoc conference calls or during face to face Steering Committee meetings. The decision of the NIDDK is final and cannot be appealed."|t
17166083|NCT01066104|f||LTE60||t
17166084|NCT02771574|t||||
17166085|NCT02593903|t||||
17166086|NCT02091362|f||GT60||t
17166087|NCT00470262|t||||f
17136513|NCT00958308|f||LTE60||t
17136514|NCT02065622|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166088|NCT00690430|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17166089|NCT03900728|t||||
17151238|NCT01233921|t||||
17151239|NCT01709838|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17151240|NCT01193127|f||OTHER|The PI agreed not to publish or otherwise to disclose Study data without prior written consent from the sponsor for a period of 24 months following Study completion or until data are published in a combined publication (whichever occurs first). The sponsor can review communications containing results prior to public release and embargo those communications for a period that is no longer than 60 days from the date of receipt of the non-public communication. The sponsor cannot extend the embargo.|t
17151241|NCT03246646|f||||f
17151242|NCT02569112|f||||f
17151243|NCT02352779|f||||f
17151244|NCT01573169|f||||f
17151245|NCT01398943|f||||f
17151246|NCT01565850|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17151247|NCT05742347|f||GT60||t
17151248|NCT00006721|f||||f
17151249|NCT03611543|f||||f
17151250|NCT04395001|f||||f
17151251|NCT04347122|f||||f
17151252|NCT03186781|t||||
17151253|NCT00792935|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17166090|NCT00617097|f||||f
17166091|NCT05319899|f||||t
17166092|NCT01994746|f||||f
17166093|NCT00335738|f||OTHER|Must obtain prior Sponsor approval.|t
17166094|NCT02688270|f||||f
17166095|NCT05066750|f||||f
17166096|NCT03248167|t||||
17166097|NCT02122146|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166098|NCT01970241|f||||f
17166099|NCT03835481|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166100|NCT02727816|f||OTHER||t
17166101|NCT00191945|f||GT60||t
17166102|NCT02725476|f||||f
17166103|NCT01267864|t||||
17166104|NCT01356498|f||GT60||t
17166105|NCT02901249|f||||f
17166106|NCT04188834|f||||f
17166107|NCT01030952|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166108|NCT00391430|f||||f
17166109|NCT05007899|f||||f
17166110|NCT01576939|f||||f
17166111|NCT00958347|f||OTHER|"For 7 years from and after termination date of the agreement, prior to submission for publication of abstracts, manuscripts, presentations or other communications describing the results of any aspect of the Study (Manuscript), You and the Institution shall send Stryker Orthopaedics a copy of the Manuscript to be submitted, and allow Stryker Orthopaedics sixty (60) days from the date of receipt to review the Manuscript."|t
17151254|NCT04663295|f||OTHER||t
17151255|NCT03954834|f||GT60||t
17151256|NCT01812681|f||||f
17151257|NCT02903030|f||||f
17151258|NCT01502410|f||LTE60||t
17151259|NCT05984186|f||||f
17151260|NCT01404923|f||GT60||t
17151261|NCT04086407|f||||f
17166112|NCT01962428|f||GT60||t
17166113|NCT03497039|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166114|NCT00434993|f||||f
17166115|NCT00465972|t||||f
17166116|NCT03292640|f||||f
17166117|NCT02218697|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166118|NCT03306433|t||||
17166119|NCT00294671|f||||f
17166120|NCT01966354|f||||f
17166121|NCT01893411|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17166122|NCT02331589|f||OTHER||t
17166123|NCT02403817|t||||
17166124|NCT03053440|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17166125|NCT00430989|t||||
17166126|NCT01701362|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166127|NCT00570778|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166128|NCT01475643|f||||f
17166129|NCT02978157|t||||
17181031|NCT02738151|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17166130|NCT02120781|f||||f
17166131|NCT00984165|f||||f
17181032|NCT02047747|t||||
17181033|NCT03649711|t||||f
17181034|NCT01892371|t||||
17181035|NCT02410382|t||||
17151262|NCT01284361|f||OTHER|Variable restriction depends on site.|t
17151263|NCT00663026|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151264|NCT01570686|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17151265|NCT00754650|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151266|NCT00805675|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151267|NCT01911897|f||||f
17151268|NCT00325195|f||OTHER|Multicenter publication is to be generated before any individual PI publishes on the results. If multicenter publication is not completed within 18 months from the date of completion, then PI can publish individual results from the Study. Sponsor can review results prior to public release and embargo for no more than 90 days. Sponsor can request removal of Confidential Information only.|t
17151269|NCT01090921|f||||f
17181036|NCT00702403|t||||
17181037|NCT02016625|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17181038|NCT03303404|t||||f
17181039|NCT02356783|t||||
17181040|NCT00380978|t||||
17181041|NCT04146545|t||||
17181042|NCT01729754|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the Sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17181043|NCT00773292|t||||
17181044|NCT00824044|f||||f
17181045|NCT01291056|t||||
17181046|NCT00192504|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17181047|NCT01139450|f||OTHER||t
17181048|NCT04608500|f||GT60||t
17181049|NCT03928847|t||||
17181050|NCT01010906|f||OTHER|The Sponsor must have the opportunity to review all abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17181051|NCT00542919|f||GT60||t
17181052|NCT01881230|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 12 months since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for 90 more days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17181053|NCT00112502|t||||
17181054|NCT02385266|t||||
17181055|NCT02747420|t||||
17181056|NCT03662542|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17181057|NCT01217060|t||||
17181058|NCT03739112|f||OTHER|The Investigator understands that the information in the protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical review of the study, without prior written authorization from the Sponsor. It is, however, permissible to discuss information contained in the protocol with a participant in order to obtain consent once Institutional Review Board (IRB) approval is obtained.|t
17181059|NCT03492099|f||||f
17181060|NCT01854905|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181061|NCT01959542|f||||f
17181062|NCT03202264|f||||f
17181063|NCT03388138|f||GT60||t
17181064|NCT01528072|f||||f
17181065|NCT01268111|t||||
17181066|NCT01859494|f||GT60||t
17181067|NCT00862186|t||||
17181068|NCT02381418|f||OTHER||t
17181069|NCT01879228|f||||t
17181070|NCT02529137|f||LTE60||t
17181071|NCT02063854|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181072|NCT01462084|f||GT60||t
17166132|NCT00466947|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181073|NCT03538158|t||||
17166133|NCT03850093|f||||f
17166134|NCT04343534|f||||f
17181074|NCT00930579|t||||
17181075|NCT00695396|f||||f
17166135|NCT00066222|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17181076|NCT00772707|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17181077|NCT02735551|f||||f
17181078|NCT04120974|f||||f
17181079|NCT03338062|t||||
17181080|NCT04256785|f||||f
17181081|NCT01519414|f||LTE60||t
17181082|NCT03194321|f||||f
17181083|NCT03019939|t||||
17181084|NCT01288287|f||GT60||t
17181085|NCT03194555|t||||
17181086|NCT03831347|t||||f
17181087|NCT00238121|f||LTE60||t
17151270|NCT00686075|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17181088|NCT02155647|f||||f
17181089|NCT03706794|f||||f
17181090|NCT01675128|f||||f
17181091|NCT01724060|t||||
17181092|NCT00832585|f||||f
17181093|NCT00967993|f||||f
17181094|NCT04418999|f||||f
17151271|NCT04715932|t||||f
17181095|NCT01374087|f||OTHER|The Sponsor required reasonable opportunity to review any summary, presentation, or paper before the material was submitted for publication or communicated. This also applied to any amendments that were requested by evaluators or journal directors. The Sponsor committed to comment on the draft documents within a time period agreed in the contractual provisions between the Sponsor and authors or their institutions. Delays were also possible if publication would adversely affect patentability.|t
17181096|NCT03526458|t||||
17181097|NCT00271947|t||||
17181098|NCT01782664|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181099|NCT01786954|f||||f
17181100|NCT01522365|f||LTE60||t
17181101|NCT00673179|t||||f
17181102|NCT02404285|f||||f
17181103|NCT02466555|t||||
17181104|NCT01082965|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181105|NCT01467947|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181106|NCT02587065|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17181107|NCT03022292|t||||
17181108|NCT04035161|f||||f
17181109|NCT00445965|t||||
17181110|NCT03479307|f||||t
17181111|NCT03141281|f||||f
17181112|NCT02295995|f||||f
17181113|NCT02447081|f||||f
17181114|NCT01787175|t||||
17181115|NCT02124863|f||||f
17181116|NCT02113956|t||||
17181117|NCT02406651|f||||f
17181118|NCT00496756|f||||f
17181119|NCT02005250|t||||f
17181120|NCT02588833|f||||t
17181121|NCT02921776|f||||f
17181122|NCT02946047|t||||
17181123|NCT03084081|t||||
17181124|NCT04814433|t||||
17181125|NCT02496533|t||||
17181126|NCT02556333|f||||f
17136515|NCT04973228|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17166136|NCT02684617|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17136516|NCT04237207|f||OTHER|PI agrees to submit any publication to Sponsor at least 30 days before submission. Within 30 days of its receipt, Sponsor advises PI in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair availability of patent protection for Inventions. Sponsor has the right to require PI to remove specifically identified CI and/or to delay the publication for an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17136517|NCT04357379|f||||f
17136518|NCT02678780|f||LTE60||t
17166137|NCT02579421|t||||
17166138|NCT02767869|t||||f
17166139|NCT03125031|t||||
17166140|NCT04301934|t||||
17166141|NCT00615719|t||||f
17166142|NCT02318368|t||||f
17166143|NCT02201329|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166144|NCT03629223|f||||f
17166145|NCT01534351|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17166146|NCT02702609|f||OTHER|Institution will submit the manuscript of the proposed publication or presentation to Sponsor at least 30 days prior to publication or release, or submission for the publication of any manuscript, and Sponsor shall have the right to review and comment upon the publication in order to protect Sponsor's confidential information. Upon Sponsor's written request, publication will be delayed up to 60 additional days to enable Sponsor to secure adequate intellectual property protection.|t
17166147|NCT03786224|f||||f
17166148|NCT02125838|f||||f
17136519|NCT02100748|f||OTHER||t
17136520|NCT04614545|t||||
17136521|NCT00659724|f||||f
17136522|NCT05366413|f||||f
17136523|NCT03754933|f||OTHER|PI agrees that a MULTI CENTER PUBLICATION (MCP) coordinated by SPONSOR will be the first publication to present the pooled STUDY results. PI agrees not to independently publish, present or otherwise disclose any results of the STUDY until a MCP is published. Following the MCP, or if the MCP is not submitted for publication within18 months of database lock or any earlier termination of the STUDY, PI shall have the right to publish or present materials related to the STUDY.|t
17136524|NCT02349789|f||||f
17136525|NCT03522350|t||||
17136526|NCT00683475|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17136527|NCT02922634|f||||f
17136528|NCT02723604|t||||
17136529|NCT00304265|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17136530|NCT00352755|t||||
17136531|NCT01760993|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136532|NCT05138783|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study,|t
17136533|NCT00078559|f||||f
17136534|NCT01694420|f||||f
17136535|NCT03987919|f||GT60||t
17136536|NCT01194804|f||||t
17136537|NCT03621943|f||||f
17136538|NCT03813719|t||||
17136539|NCT00948818|f||OTHER|All data generated in this trial will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the trial. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17166149|NCT02565147|f||GT60||t
17166150|NCT00787839|t||||
17181127|NCT01816893|f||||f
17181128|NCT04729127|f||||f
17181129|NCT01365507|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17181130|NCT02794103|f||||f
17181131|NCT00525174|f||||f
17181132|NCT04782856|f||||f
17181133|NCT00870363|t||||
17181134|NCT01465022|f||||f
17181135|NCT01327300|t||||f
17181136|NCT02807350|f||||f
17181137|NCT03020823|f||||t
17166151|NCT02812238|t||||
17166152|NCT00745290|f||||f
17166153|NCT03578926|f||||f
17166154|NCT00992056|f||||f
17166155|NCT01001767|f||||f
17166156|NCT01104545|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17166157|NCT00626886|f||OTHER||t
17166158|NCT02846792|f||||f
17166159|NCT01116466|f||||f
17166160|NCT01271907|f||||f
17166161|NCT00564902|f||||f
17166162|NCT02723916|f||||f
17166163|NCT03583359|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17166164|NCT00375505|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17166165|NCT00508105|f||||f
17166166|NCT02146131|f||||f
17166167|NCT02567799|f||||f
17166168|NCT02781571|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166169|NCT00349349|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166170|NCT02991898|t||||
17166171|NCT00861692|f||OTHER||t
17166172|NCT02122666|t||||
17166173|NCT05111002|f||||f
17166174|NCT04380753|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166175|NCT03913013|f||||f
17166176|NCT00972517|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166177|NCT00851890|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166178|NCT03135431|t||||
17166179|NCT02709577|f||LTE60||t
17166180|NCT00375674|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166181|NCT03744910|f||||t
17166182|NCT00064259|f||LTE60||t
17166183|NCT02953093|t||||
17166184|NCT01132651|t||||
17166185|NCT00948857|t||||
17166186|NCT04105738|t||||
17136540|NCT01716533|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136541|NCT02330549|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17136542|NCT01575197|f||LTE60||t
17136543|NCT02405429|t||||f
17136544|NCT03303092|f||||f
17136545|NCT00050986|t||||
17136546|NCT01170117|f||||f
17136547|NCT01995136|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17136548|NCT02543398|f||||f
17136549|NCT01830543|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150564|NCT03979820|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166187|NCT03430843|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17166188|NCT03608371|f||LTE60||t
17166189|NCT05244603|t||||
17166190|NCT01658709|f||||t
17181138|NCT03050619|t||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17181139|NCT03340337|t||||
17150565|NCT00160641|f||GT60||t
17150566|NCT02519621|f||||f
17150567|NCT04764630|f||||f
17150568|NCT00899470|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166191|NCT00590122|f||||f
17166192|NCT03050450|f||||f
17166193|NCT00711594|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166194|NCT00443872|f||||f
17166195|NCT00135330|f||GT60||t
17166196|NCT01132846|f||||f
17166197|NCT02854436|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17166198|NCT00104416|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166199|NCT01309997|f||||f
17166200|NCT03462641|f||||f
17166201|NCT00372619|f||OTHER|Must obtain prior Sponsor approval.|t
17166202|NCT00338286|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17166203|NCT02888691|t||||
17166204|NCT05398159|f||||t
17166205|NCT02972606|t||||
17166206|NCT03748706|f||OTHER|Top enrolling PIs are included as authors on Cassava publications, but no individual PI has the right to publish alone without Cassava authorization.|t
17166207|NCT01959178|f||OTHER|Contact sponsor directly for details.|t
17166208|NCT03517371|f||||f
17166209|NCT05420961|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17166210|NCT04283656|t||||
17166211|NCT00394329|f||||f
17166212|NCT04482439|f||||f
17166213|NCT01555073|t||||
17166214|NCT04660552|f||||f
17166215|NCT03490292|t||||
17166216|NCT03177512|f||||f
17166217|NCT00286091|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166218|NCT02036580|f||||f
17166219|NCT00295334|f||||f
17166220|NCT03098433|t||||
17166221|NCT01667133|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17166222|NCT02371785|f||||f
17166223|NCT02548910|t||||
17166224|NCT02676895|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166225|NCT00289289|f||OTHER||t
17166226|NCT01642056|t||||
17166227|NCT04175340|f||||f
17150569|NCT01929031|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150570|NCT02150759|t||||
17166228|NCT01014936|f||||f
17166229|NCT03028129|t||||
17166230|NCT00940290|t||||
17166231|NCT00602225|f||||f
17166232|NCT03657134|t||||
17181140|NCT04307446|f||||f
17181141|NCT03001258|t||||f
17181142|NCT02430337|f||||f
17181143|NCT03257631|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181144|NCT00587483|t||||
17181145|NCT02829463|t||||
17151272|NCT03964649|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151273|NCT02740699|t||||
17151274|NCT03544424|t||||
17151275|NCT03783039|f||OTHER|Principal investigator and institution will not be able to publish single-center study data until combined results of the multicenter study are published. If multicenter publication is not performed within 12 months after the end or if sponsor notifies principal investigator and institution in writing that the multicenter study results will not be published, the principal investigator and institution may publish the results of their studies separately in accordance with contract.|t
17151276|NCT01682863|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17151277|NCT00918138|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151278|NCT01043653|t||||
17151279|NCT01955837|f||OTHER||t
17151280|NCT00552578|t||||f
17151281|NCT01716715|f||LTE60||t
17151282|NCT04228783|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17166233|NCT01831466|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.|t
17166234|NCT03148379|f||GT60||t
17166235|NCT04776720|t||||f
17166236|NCT05356910|f||||f
17166237|NCT00803595|f||OTHER|Principle investigator shall not publish the results of the study at any time without the prior written approval of Sponsor.|t
17166238|NCT00984594|f||GT60||t
17166239|NCT03122145|t||||f
17166240|NCT01597908|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17166241|NCT02384044|t||||
17166242|NCT00837161|f||LTE60||t
17166243|NCT04114071|f||||f
17166244|NCT01659996|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17166245|NCT00978419|t||||
17166246|NCT00475085|t||||
17166247|NCT01059864|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166248|NCT00451958|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17166249|NCT04912089|f||||f
17166250|NCT03108521|t||||
17166251|NCT05629312|t||||
17166252|NCT06899737|f||||f
17166253|NCT01308840|t||||
17166254|NCT03281629|t||||f
17166255|NCT01088295|t||||f
17166256|NCT02175277|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166257|NCT03974932|f||||f
17166258|NCT05455580|f||||f
17166259|NCT01905943|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166260|NCT02574078|f||LTE60||t
17166261|NCT02351063|f||||f
17166262|NCT05516797|f||||f
17166263|NCT00301262|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17166264|NCT00368745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166265|NCT03037476|f||||f
17166266|NCT01675297|f||||t
17181146|NCT02672423|f||GT60||t
17181147|NCT01312818|t||||f
17181148|NCT01046682|f||||f
17181149|NCT00912990|f||||f
17151283|NCT00626392|f||OTHER|Provide Abbott at least sixty (60) days prior to submission for review, Abbott shall return comments within sixty (60) days of receipt of draft. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period.|t
17151284|NCT03002571|f||OTHER|Contact sponsor for details.|t
17151285|NCT03151811|f||||f
17181150|NCT01454570|t||||
17181151|NCT00536107|f||||f
17181152|NCT01628601|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181153|NCT00371254|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181154|NCT00862810|f||||f
17151286|NCT01268501|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17151287|NCT05293639|f||||t
17151288|NCT01404832|f||||f
17151289|NCT00827632|t||||f
17151290|NCT01910389|t||||
17151291|NCT00511095|f||LTE60||t
17151292|NCT00407758|f||LTE60||t
17151293|NCT01158573|t||||
17151294|NCT05034276|f||||f
17151295|NCT00073021|f||LTE60||t
17151296|NCT01458106|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17151297|NCT00855803|t||||
17151298|NCT04048343|f||||t
17151299|NCT03050060|f||||f
17151300|NCT03276780|f||||f
17151301|NCT02304458|f||LTE60||t
17151302|NCT03835221|f||||f
17151303|NCT03375294|f||||f
17151304|NCT01580813|t||||
17151305|NCT04639713|f||OTHER||t
17151306|NCT03401450|t||||
17151307|NCT04271020|f||OTHER|PI agree not to make any Publications of Study results until completion of the Study and Publication of the results in a peer-reviewed journal by Sponsor. Thereafter, PI may publish their individual site experience. Should a manuscript not be submitted by Sponsor within 12 months of study closure, PI may publish study results. PI shall provide Sponsor 30 days prior notice of publication submission date and text of proposed Publication for review.|t
17151308|NCT00030992|f||||f
17151309|NCT02823652|f||LTE60||t
17151310|NCT01708629|f||OTHER||t
17151311|NCT02582866|f||GT60||t
17151312|NCT01666197|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17151313|NCT00578669|f||||f
17151314|NCT00871741|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151315|NCT04616430|f||||f
17151316|NCT00633243|f||||f
17151317|NCT02022748|f||OTHER|"The PIs shall be entitled to publish or make presentations related to the Study within 2 years of completion of the Study with Sponsor's prior written consent. PIs shall provide the Sponsor with copies of any materials at least thirty (30) days in advance of publication, submission or presentation.~All such publications or presentations shall be consistent with applicable standards, guidelines and laws, not be false or misleading, and not be made for any commercial purpose."|t
17151318|NCT02799095|f||OTHER||t
17151319|NCT04994483|f||OTHER|The Institution and PI must request review and comment of any proposed publication by the sponsor at least 90 days prior to submission of the publication. The sponsor will advise of any information which is confidential information or which may impair the sponsor's ability to obtain patent protection, and has the right to require confidential information or factual errors to be removed, or to delay the proposed publication by an additional 90 days to allow the sponsor to seek patent protection.|t
17151320|NCT03299088|f||||f
17151321|NCT03589768|f||LTE60||t
17151322|NCT03283319|f||||f
17151323|NCT00721630|t||||
17151324|NCT03665441|f||OTHER|"Sponsor has rights to the first publication for up to 18 months after study completion or termination, or until sponsor determines it does not plan to publish the study results.~Following this the Institution and/or Principal Investigator may publish data or results generated at Institution; provided, the proposed publication or presentation is submitted to the Sponsor at least 45 days prior to the date of the proposed publication or presentation for review and approval."|t
17151325|NCT04345601|t||||
17151326|NCT03700385|f||||f
17151327|NCT00658515|f||||f
17151328|NCT00372411|t||||f
17151329|NCT00631657|f||LTE60||t
17151330|NCT01749995|t||||
17151331|NCT00699374|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151332|NCT01853930|f||||f
17151333|NCT01996449|f||||f
17151334|NCT04540406|f||||f
17151335|NCT04091659|t||||f
17151336|NCT00054665|f||||f
17151337|NCT01243112|t||||
17151338|NCT01081834|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17151339|NCT01085734|f||||f
17166267|NCT01498692|f||OTHER|The Principal Investigator (PI) shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to the Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17151340|NCT01739348|f||OTHER|The investigator agrees to provide to the sponsor, 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17151341|NCT01963143|f||GT60||t
17166268|NCT01208324|t||||
17166269|NCT02707965|f||||f
17166270|NCT00249808|f||||f
17166271|NCT02789345|f||GT60||t
17166272|NCT03487588|f||LTE60||t
17166273|NCT00748618|t||||
17166274|NCT01977729|t||||
17166275|NCT01268046|f||||f
17166276|NCT00224120|f||LTE60||t
17166277|NCT00282087|f||||f
17166278|NCT01312805|f||||f
17166279|NCT01804049|t||||
17166280|NCT01260688|f||LTE60||t
17151342|NCT01447420|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151343|NCT04562155|f||LTE60||t
17151344|NCT02701270|f||OTHER|PI cannot release information without the sponsor's approval.|t
17151345|NCT01475097|f||||f
17151346|NCT03149445|f||||f
17151347|NCT05594264|t||||
17151348|NCT01085201|f||||f
17151349|NCT02699060|f||||f
17151350|NCT04916444|t||||f
17151351|NCT02955758|t||||
17151352|NCT00867503|f||||f
17151353|NCT01001988|f||||f
17151354|NCT03340207|f||||f
17151355|NCT01442688|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17166281|NCT03938103|t||||
17166282|NCT01147250|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17166283|NCT03588806|t||||f
17166284|NCT02346643|f||GT60||t
17166285|NCT05141708|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166286|NCT03985943|f||||t
17166287|NCT02029755|f||||f
17166288|NCT00022763|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166289|NCT00716482|f||||f
17151356|NCT00927394|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17151357|NCT01221363|f||||f
17151358|NCT02865460|t||||
17151359|NCT02238795|f||||f
17151360|NCT02737748|f||||t
17151361|NCT04480710|f||||f
17151362|NCT04480021|f||||f
17151363|NCT04823975|f||||f
17151364|NCT06154200|t||||
17151365|NCT03384654|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17151366|NCT00423319|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166290|NCT03248531|f||GT60||t
17166291|NCT04075513|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17181155|NCT02246673|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17181156|NCT01199744|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181157|NCT04356963|f||||f
17181158|NCT02285907|f||||f
17181159|NCT01335230|f||||f
17181160|NCT02726074|f||||t
17181161|NCT01679002|t||||
17181162|NCT01176266|f||LTE60||t
17181163|NCT01179477|f||||t
17181164|NCT00189228|f||||f
17181165|NCT01807897|t||||
17181166|NCT02014363|f||OTHER|There is an agreement between the Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17181167|NCT05075850|f||||f
17181168|NCT01265849|f||OTHER|See Clinical Protocol Section 13.0 Publication Plan|t
17181169|NCT01172184|t||||
17181170|NCT01547000|f||||f
17181171|NCT01895855|f||GT60||t
17181172|NCT02154581|f||||f
17181173|NCT01092182|f||||f
17181174|NCT02591147|f||||f
17181175|NCT02515045|f||||f
17181176|NCT02664909|f||||f
17181177|NCT03255382|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181178|NCT02221284|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181179|NCT03525210|f||||f
17181180|NCT03011307|f||||f
17181181|NCT00091273|t||||
17181182|NCT02677987|f||||f
17181183|NCT00651755|t||||f
17181184|NCT00624052|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17181185|NCT00281684|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181186|NCT04026048|f||||f
17181187|NCT00506155|t||||
17181188|NCT03760146|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181189|NCT03839212|t||||
17181190|NCT00679263|f||LTE60||t
17181191|NCT01464346|f||LTE60||t
17181192|NCT03245008|f||OTHER||t
17181193|NCT02075658|f||||f
17181194|NCT01286012|f||OTHER|No study results may be submitted for publication without Sponsor's prior written consent. Within 60 days from submission to Sponsor's review, Sponsor may withhold the consent. 1st publication of results is made in conjunction with the presentation of a joint, multicenter publication of results with certain PIs from all sites contributing data.|t
17181195|NCT00718328|t||||f
17181196|NCT01064401|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17181197|NCT04007094|t||||
17181198|NCT01581307|t||||
17166292|NCT01035463|t||||
17166293|NCT01250184|t||||
17166294|NCT04528017|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166295|NCT00158249|t||||
17166296|NCT01407952|f||||f
17166297|NCT00935493|t||||
17166298|NCT04153981|f||GT60||t
17166299|NCT01355679|f||||f
17166300|NCT01781806|f||||f
17166301|NCT00964002|t||||
17166302|NCT00904670|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166303|NCT03423238|t||||
17166304|NCT02584452|t||||f
17166305|NCT02057640|t||||
17166306|NCT03640507|t||||
17166307|NCT00923351|f||||f
17181199|NCT04994444|f||||f
17181200|NCT02117999|f||||f
17181201|NCT00378209|f||GT60||t
17181202|NCT01918761|t||||
17181203|NCT02145039|t||||
17181204|NCT01536379|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181205|NCT06063603|t||||
17181206|NCT04439253|f||GT60||t
17166308|NCT01536561|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166309|NCT04238481|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17166310|NCT04552288|t||||
17166311|NCT05285644|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166312|NCT04532294|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17166313|NCT04295759|f||||f
17166314|NCT01696981|f||LTE60||t
17166315|NCT02798315|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166316|NCT02299141|t||||
17166317|NCT03335150|t||||
17166318|NCT02097719|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166319|NCT03028415|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17166320|NCT02907216|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166321|NCT01854775|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166322|NCT02091531|t||||
17166323|NCT01433042|f||GT60||t
17166324|NCT04601532|t||||f
17166325|NCT02744612|t||||
17166326|NCT01945216|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17166327|NCT03054805|f||||f
17166328|NCT03062280|f||OTHER|Sponsor \& PI will prepare of manuscripts. Comments on publications will be considered by authors. Publications will not include company confidential details without Sponsor permission. Summary data may be announced to comply with Financial \& Regulatory Authorities, while ensuring this will not impact the investigator's ability to publish. Announcements made prior to publication will be reviewed \& approved by PI. Data from individual sites will only be published under exceptional circumstances.|t
17166329|NCT04299308|f||||f
17166330|NCT05258890|t||||
17166331|NCT04493424|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166332|NCT02482428|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17166333|NCT04309370|f||||f
17166334|NCT05959447|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166335|NCT01525862|f||LTE60||t
17166336|NCT00576628|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166337|NCT04027803|f||||f
17166338|NCT01092780|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17181207|NCT03971695|t||||
17181208|NCT04447417|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17181209|NCT01341600|t||||f
17181210|NCT01277354|f||||f
17181211|NCT01280552|f||LTE60||t
17181212|NCT02155738|t||||
17181213|NCT01190254|f||OTHER|It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.|t
17181214|NCT02603809|f||||t
17181215|NCT00156533|f||||f
17181216|NCT00887354|f||LTE60||t
17181217|NCT03265249|t||||
17151367|NCT01584843|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151368|NCT00311402|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17151369|NCT02640053|f||||f
17151370|NCT03283761|f||||f
17151371|NCT02036775|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151372|NCT00678886|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151373|NCT00206323|f||||f
17151374|NCT02329847|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17151375|NCT01943994|f||||f
17151376|NCT04314414|t||||
17151377|NCT00420459|f||||f
17151378|NCT00589329|t||||
17151379|NCT04669691|f||||f
17151380|NCT03039179|f||||f
17151381|NCT02288182|f||||f
17151382|NCT01088802|t||||f
17151383|NCT00620659|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151384|NCT00804713|t||||f
17151385|NCT01214915|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17151386|NCT02056392|f||LTE60||t
17151387|NCT00529282|f||GT60||t
17151388|NCT04555720|t||||
17181218|NCT00914810|t||||f
17181219|NCT02994732|t||||
17195888|NCT00491894|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17195889|NCT03427463|t||||
17195890|NCT03499964|f||||f
17195891|NCT02909959|t||||
17195892|NCT01979276|f||LTE60||t
17195893|NCT03739866|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17151389|NCT00968799|t||||
17151390|NCT00719849|t||||f
17151391|NCT03867097|f||||f
17151392|NCT01372774|f||||f
17151393|NCT02201290|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151394|NCT01177059|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17151395|NCT00459121|t||||f
17181220|NCT02312726|f||||f
17181221|NCT01516957|f||OTHER||t
17181222|NCT01290666|f||LTE60||t
17181223|NCT02063516|f||||f
17181224|NCT00507442|f||||f
17181225|NCT06002347|f||||f
17181226|NCT01192282|f||||f
17181227|NCT02449174|t||||
17181228|NCT02410954|t||||
17181229|NCT00271609|f||||f
17181230|NCT02188589|f||||f
17181231|NCT00867451|t||||
17195894|NCT01728324|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195895|NCT01335867|f||||f
17195896|NCT03057600|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17195897|NCT03489369|f||||f
17181232|NCT00975481|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181233|NCT00643682|t||||
17181234|NCT04311424|f||GT60||t
17181235|NCT02084147|t||||
17181236|NCT01826487|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17181237|NCT01408030|f||||f
17181238|NCT01169610|t||||
17181239|NCT03755414|t||||
17181240|NCT03168308|f||||f
17166339|NCT01864148|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17166340|NCT04181593|f||||f
17181241|NCT04039412|f||||f
17181242|NCT00944450|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181243|NCT00741039|t||||
17181244|NCT02081079|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181245|NCT01712854|f||||f
17181246|NCT01831154|f||||f
17181247|NCT02225743|f||||f
17181248|NCT01347541|f||||f
17181249|NCT03886220|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181250|NCT00768300|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181251|NCT02535845|f||||f
17195898|NCT02168309|f||||f
17181252|NCT05821842|f||||f
17195899|NCT02483468|f||||f
17150571|NCT02394730|f||OTHER|Investigators need to submit a proposal, abstract, manuscript or other form of communication of trial results to the Protocol Steering Committee for review and approval.|t
17150572|NCT03512262|f||||t
17150573|NCT03510182|t||||
17151396|NCT02315196|t||||
17151397|NCT00470067|t||||
17151398|NCT03839823|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151399|NCT00735306|t||||
17151400|NCT01517373|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151401|NCT03756506|f||||f
17151402|NCT02651259|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17151403|NCT03678285|f||||f
17151404|NCT00616629|f||LTE60||t
17151405|NCT01777620|f||||f
17151406|NCT01740726|t||||f
17151407|NCT00790335|t||||
17151408|NCT01045135|t||||f
17151409|NCT04516759|f||||f
17195900|NCT03335488|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17195901|NCT00388726|f||||f
17195902|NCT01953692|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17195903|NCT04638816|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17195904|NCT05313412|f||||f
17195905|NCT00109031|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17195906|NCT01822756|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17195907|NCT01006538|f||||f
17195908|NCT02233998|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17195909|NCT01328496|t||||
17195910|NCT01708278|t||||
17195911|NCT00853593|f||||f
17195912|NCT04230941|f||||f
17195913|NCT00600353|t||||f
17195914|NCT05966155|t||||
17195915|NCT00553332|f||LTE60||t
17195916|NCT04119063|f||||f
17195917|NCT02235298|t||||
17195918|NCT00485693|f||||f
17151410|NCT04005352|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151411|NCT06017479|t||||
17151412|NCT04058067|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151413|NCT02201212|f||||f
17151414|NCT00417170|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151415|NCT05005312|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151416|NCT01283035|f||LTE60||t
17166341|NCT03587428|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166342|NCT02936869|f||||f
17166343|NCT00506454|f||||f
17166344|NCT00851552|t||||
17195919|NCT02309294|f||OTHER|Master service agreement and confidentiality agreement in place|t
17195920|NCT03520036|f||OTHER||t
17195921|NCT00758550|f||||f
17195922|NCT06110546|t||||
17195923|NCT05426109|f||||f
17195924|NCT03102034|f||||f
17195925|NCT02222493|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195926|NCT03132298|f||||f
17195927|NCT03611075|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166345|NCT02689206|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166346|NCT00652314|f||LTE60||t
17166347|NCT01558596|t||||
17166348|NCT00595881|t||||
17166349|NCT01479764|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication and slides and texts of oral or other presentations that report any results of the trial.|t
17166350|NCT03800537|t||||
17166351|NCT00260832|f||||f
17166352|NCT00902850|t||||
17195928|NCT00676091|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151417|NCT02704403|f||OTHER|All materials, information (oral or written) and unpublished documentation provided to the Investigators (or any company/institution acting on their behalf) are the exclusive property of the Sponsor and may not be given or disclosed, either in part or in whole, by the Investigator or by any person under his/her authority to any third party without the prior express consent of the Sponsor.|t
17151418|NCT00851318|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication to seek patent protection.|t
17151419|NCT01839318|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17195929|NCT03160521|f||OTHER|The sponsor does not object to publication by the Institution of the results of the Trial based on information collected/generated by the Institution. The Institution will provide Sponsor an opportunity to review any proposed publication before it is submitted. If the Trial is part of a multi-center trial, the Institution agress that the first publication is to be a joint publication involving all Trials sites.|t
17195930|NCT01701401|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17195931|NCT00933270|f||LTE60||t
17195932|NCT01000805|f||GT60||t
17195933|NCT00989196|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17195934|NCT02409680|f||||f
17195935|NCT06211530|f||||f
17195936|NCT04162873|t||||
17195937|NCT03343704|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17195938|NCT05200416|f||||t
17195939|NCT05986617|f||||f
17195940|NCT03789656|f||OTHER|The only disclosure restriction on the PI is that PIs cannot publish until the multi-center publication is first published. If no multi-center publication is published within 18 months of the completion date, the PI may publish their results, provided that the Sponsor is given the opportunity to review the proposed publication in advance.|t
17195941|NCT04069247|f||||f
17195942|NCT06214052|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17195943|NCT01804166|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17195944|NCT02434328|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17195945|NCT00604890|f||||t
17195946|NCT04700904|f||||f
17195947|NCT00302211|f||OTHER|Written permission to publish results must be obtained in advance from Actelion (formerly CoTherix). Manuscript of any proposed publication must be sent to Actelion at least 30 days in advance of the submission date. Actelion will inform in writing of any objection of specific content in the proposed publication.In addition, the institution shall either delete disclosure of all potentially patentable inventions or delay submission of the proposed publication for up to 90 days.|t
17195948|NCT02294461|f||OTHER|Institution and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after study completion date at all sites, whichever is first. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. If requested Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17195949|NCT05432986|f||||f
17166353|NCT03745638|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17166354|NCT01032603|f||||f
17181253|NCT02068222|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195950|NCT03009344|f||||t
17151420|NCT01844856|f||OTHER|At least 60 days prior to submitting or presenting a manuscript, poster, presentation, abstract or other materials relating to the Trial, the PI shall provide to Sponsor all such manuscripts and materials, and Sponsor shall have 60 days to review and comment. If requested, the PI shall remove confidential information prior to submitting or presenting the materials, and shall delay publication or presentation for up to 90 days to allow Sponsor to protect its interests in any such materials.|t
17151421|NCT05502081|f||||f
17151422|NCT00176423|t||||
17151423|NCT00462124|f||||f
17195951|NCT00378898|t||||
17195952|NCT02794428|t||||
17195953|NCT02534233|f||||f
17195954|NCT00551421|f||LTE60||t
17195955|NCT02271906|t||||
17195956|NCT03136159|f||||f
17151424|NCT01329549|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151425|NCT02421224|f||||f
17151426|NCT02695537|f||||f
17151427|NCT03597529|t||||f
17151428|NCT03769714|f||||f
17195957|NCT03377049|t||||
17195958|NCT01732757|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17195959|NCT04456413|t||||
17195960|NCT03774849|t||||
17195961|NCT00089609|f||||f
17151429|NCT01755767|f||||f
17151430|NCT03464630|f||||f
17151431|NCT00191165|f||GT60||t
17195962|NCT03116464|f||||f
17195963|NCT00597376|f||||f
17151432|NCT03007238|t||||
17151433|NCT03196635|f||GT60||t
17151434|NCT01273896|t||||
17151435|NCT00670202|f||||f
17151436|NCT00998309|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151437|NCT01316315|f||OTHER|The investigator agrees with the use of results of the clinical study for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the competent authorities will be notified of the investigator's name, address, qualifications, and extent of involvement. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.|t
17166355|NCT04470050|f||||t
17166356|NCT03585764|t||||
17166357|NCT03604172|f||||f
17166358|NCT02168062|t||||f
17181254|NCT02448654|f||||f
17151438|NCT03769207|f||||f
17166359|NCT01270880|t||||
17181255|NCT01120756|f||||f
17181256|NCT03098173|f||||f
17181257|NCT02742987|f||||f
17181258|NCT00698581|f||GT60||t
17181259|NCT00449644|f||OTHER|It is the policy of the sponsor not to allow the investigators to publish their results or findings prior to the sponsor's publication of the overall trial results.The investigator agrees that before he/she publishes any results of this trial, he/she shall provide the sponsor with at least 45 days for full review of the prepublication manuscript prior to submission of the manuscript to the publisher.|t
17181260|NCT03642717|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17181261|NCT03930446|t||||
17181262|NCT01559012|t||||f
17181263|NCT00946712|f||LTE60||t
17195964|NCT03559205|t||||
17195965|NCT01703598|f||||f
17195966|NCT02489357|t||||
17195967|NCT04693637|f||||f
17195968|NCT04237792|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195969|NCT04091347|f||||f
17195970|NCT03205566|t||||
17195971|NCT02022670|f||||f
17195972|NCT02113449|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195973|NCT00087022|f||LTE60||t
17195974|NCT01957163|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195975|NCT03697603|f||||f
17195976|NCT02686658|f||OTHER|No individual site or investigator may publish or present any results from the trial until a joint, multi-center publication of the trial results is made by Sponsor in conjunction with various participating investigators and appropriate sites contributing data and comments. Subsequently, individual investigators may request to publish or present results from the trial; however approval will be at the sole discretion of the Sponsor.|t
17195977|NCT00467272|t||||
17195978|NCT00570505|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17195979|NCT01695291|f||||f
17195980|NCT00614614|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195981|NCT05212285|f||||t
17195982|NCT03975400|f||||f
17166360|NCT00976716|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166361|NCT04222699|t||||
17166362|NCT01606176|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17181264|NCT00302458|f||||f
17181265|NCT04665050|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17181266|NCT02291055|f||OTHER|The Investigator shall seek the Sponsor's written approval for study results publication which shall not be unreasonably withheld. Such publication by Institution and/or Investigator may be no earlier than after a cooperative publication has been published with Sponsor or 1 year from date of completion or termination of the Study \& only after review and comment by Sponsor. Institution agrees to provide Sponsor a copy of proposed publication at least 60 days prior to submission to a publisher.|t
17181267|NCT00853723|f||||f
17181268|NCT01531387|f||||f
17181269|NCT02517996|t||||f
17181270|NCT02642432|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181271|NCT00733746|f||LTE60||t
17181272|NCT03999892|f||||f
17181273|NCT01848756|f||LTE60||t
17181274|NCT01894581|f||||f
17181275|NCT01252940|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181276|NCT05230693|f||||f
17181277|NCT03759379|f||OTHER|It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication (eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be provided and confirmed/received at the Sponsor at least 30 days before its submission.|t
17181278|NCT05447156|t||||
17181279|NCT01254227|f||||t
17181280|NCT01263301|f||||f
17181281|NCT00834210|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17181282|NCT03684512|f||||f
17181283|NCT02535741|f||LTE60||t
17181284|NCT03873987|f||OTHER|No such presentation or publication will be initiated by PI until earliest to occur of the following (i) 12 months after the conclusion of the study (ii) publication by the Sponsor or the lead investigator or (iii) written approval is obtained by the Sponsor. PI will provide Sponsor with a draft of any proposed presentation or publication for review at least 45 days in advance of the submission, presentation or publication date.|t
17181285|NCT00798369|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181286|NCT04475588|f||||f
17181287|NCT00588822|t||||f
17181288|NCT01948739|f||||f
17166363|NCT01832493|f||LTE60||t
17166364|NCT02993822|f||GT60||t
17166365|NCT01732510|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17195983|NCT03924869|f||OTHER|The Sponsor will comply with the requirements for publication of study results, and will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17195984|NCT02542943|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195985|NCT02734355|t||||
17195986|NCT05250206|t||||f
17195987|NCT02581137|f||LTE60||t
17195988|NCT03476798|f||||f
17195989|NCT05824559|f||OTHER||t
17195990|NCT02823028|t||||
17195991|NCT06677203|f||OTHER|Agreement finally allows PI to publish independently.|t
17195992|NCT01836445|t||||
17151439|NCT00380744|f||GT60||t
17151440|NCT01497808|t||||
17151441|NCT00555152|f||LTE60||t
17151442|NCT02467478|f||||f
17151443|NCT03490344|t||||
17151444|NCT00276861|f||||f
17151445|NCT03065218|t||||f
17151446|NCT02348723|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151447|NCT02365558|f||||f
17151448|NCT01330420|f||||f
17151449|NCT02819050|f||||f
17151450|NCT02828241|f||||f
17151451|NCT03347006|t||||
17151452|NCT01222390|f||||f
17151453|NCT01822275|t||||
17151454|NCT02132754|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17151455|NCT03567382|t||||
17151456|NCT02175576|f||||f
17151457|NCT00499174|t||||f
17151458|NCT02269163|f||OTHER|Publication of data generated in the study is governed by the Investigator Clinical Trial Agreement|t
17151459|NCT01413516|f||||f
17151460|NCT02062294|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151461|NCT00638027|f||||f
17151462|NCT00371397|t||||
17151463|NCT01284621|t||||
17151464|NCT02802631|f||||f
17195993|NCT04602728|t||||
17195994|NCT05865392|t||||
17151465|NCT02968849|f||||f
17195995|NCT03365622|t||||f
17195996|NCT05366751|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17195997|NCT04937504|t||||
17195998|NCT04118894|f||||f
17151466|NCT02551666|f||||f
17151467|NCT03395405|f||LTE60||t
17151468|NCT00461253|t||||
17151469|NCT03510598|f||||f
17151470|NCT04036799|f||||f
17151471|NCT04240392|t||||
17151472|NCT05307510|t||||
17151473|NCT02358135|f||||f
17151474|NCT01555671|f||||f
17151475|NCT03047330|t||||
17151476|NCT03047629|f||||t
17151477|NCT04590040|t||||
17151478|NCT00000378|f||||f
17151479|NCT03376061|t||||
17151480|NCT04003896|t||||
17151481|NCT02026687|f||||f
17151482|NCT01957397|t||||
17151483|NCT00324649|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17151484|NCT00540293|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17151485|NCT04684238|f||||t
17151486|NCT01988129|f||||f
17151487|NCT02585934|f||OTHER|All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.|t
17195999|NCT03715946|t||||
17196000|NCT00686257|t||||
17196001|NCT02634307|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17151488|NCT04713553|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151489|NCT02448706|f||||f
17151490|NCT01359969|f||||t
17151491|NCT02067468|f||||f
17151492|NCT02174419|f||||f
17151493|NCT03972163|f||||f
17151494|NCT00110136|f||||f
17151495|NCT01059539|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17166366|NCT00313144|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. Baxter may require a review of results communications (e.g., for confidential information \& intellectual property) ≥45 days prior to submission or communication for review and comment. Baxter reserves the right to remove all confidential information from all publications.|t
17181289|NCT02082210|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release \& can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to sponsor for review. Sponsor can extend disclosure restriction for additional 60 days to protect intellectual property interests. If PI is unwilling to delay then PI shall remove the information that sponsor believes would jeopardize its IP interests|t
17166367|NCT01221753|t||||
17166368|NCT00617058|t||||f
17166369|NCT02959853|f||||f
17166370|NCT01262560|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17166371|NCT03213938|t||||
17166372|NCT00673231|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17166373|NCT03594747|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17151496|NCT00537303|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17151497|NCT02085135|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17151498|NCT05119348|f||||f
17166374|NCT01925040|f||GT60||t
17166375|NCT00295009|f||LTE60||t
17181290|NCT02520011|f||||f
17181291|NCT02436759|f||GT60||t
17181292|NCT03054857|f||||f
17181293|NCT01727141|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17181294|NCT04014075|f||||f
17181295|NCT02666183|f||||f
17181296|NCT03616912|f||GT60||t
17181297|NCT02584504|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17181298|NCT01716013|f||OTHER|Sponsor shall have been furnished copies of any proposed publication or presentation at least thirty (30) days in advance of the submission of such proposed publication or presentation to a journal, editor, or other third party. Sponsor reserves the right to object to the proposed presentation or publication.|t
17181299|NCT03430583|f||||f
17181300|NCT03446040|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181301|NCT01652664|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17181302|NCT05853250|f||||f
17181303|NCT03036098|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196002|NCT02698475|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17196003|NCT02132949|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196004|NCT01823224|f||||f
17196005|NCT01467934|f||||f
17196006|NCT05741450|f||||t
17196007|NCT00745875|f||OTHER|AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed for 90 days to allow for the filing of a patent application.|t
17196008|NCT01532648|f||OTHER|Please contact Sponsor directly for additional information.|t
17196009|NCT02310581|f||||f
17196010|NCT01737021|t||||
17196011|NCT04652869|t||||
17196012|NCT01583868|f||OTHER|Contact sponsor directly for details.|t
17151499|NCT00554606|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181304|NCT03453684|t||||
17181305|NCT01319812|f||||f
17181306|NCT00464568|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181307|NCT04335279|t||||
17181308|NCT00885755|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151500|NCT00952211|f||||f
17151501|NCT04505956|f||||f
17151502|NCT04314648|f||||f
17151503|NCT01392625|t||||
17151504|NCT00849186|t||||
17151505|NCT00492024|f||GT60||t
17151506|NCT03247816|f||OTHER||t
17151507|NCT01837524|f||||f
17181309|NCT04343521|t||||
17181310|NCT00107198|f||OTHER|Must obtain prior Sponsor approval.|t
17181311|NCT00751348|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181312|NCT04191382|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17181313|NCT05237206|f||||f
17181314|NCT04962009|f||OTHER|PI can not publish data without our permission. Sponsor can change communication and extend an embargo.|t
17181315|NCT02867709|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181316|NCT01395329|f||||f
17181317|NCT02865915|f||||t
17181318|NCT00663052|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181319|NCT05760300|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181320|NCT00877058|f||||f
17181321|NCT01722240|t||||
17181322|NCT02653560|f||||f
17196013|NCT01271244|f||||f
17196014|NCT04658784|t||||
17196015|NCT01083706|t||||
17196016|NCT02095145|f||LTE60||t
17196017|NCT02630186|f||||f
17196018|NCT01542255|t||||f
17196019|NCT03447912|f||||f
17196020|NCT04263714|f||||f
17151508|NCT02351271|f||LTE60||t
17151509|NCT00936897|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17151510|NCT02287818|f||||t
17151511|NCT03257865|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17196021|NCT01477177|t||||
17196022|NCT01505166|f||||t
17196023|NCT01034306|f||||f
17196024|NCT00836498|f||LTE60||t
17181323|NCT03628703|t||||
17181324|NCT01928524|f||||f
17181325|NCT04350788|t||||
17181326|NCT03615105|t||||
17181327|NCT03313804|t||||
17181328|NCT04383743|t||||
17181329|NCT04837131|t||||
17181330|NCT03482791|t||||
17181331|NCT01239368|f||||f
17181332|NCT02967692|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181333|NCT04916600|f||GT60||t
17181334|NCT06145542|t||||
17181335|NCT01541969|f||OTHER|The manufacturer acknowledges and accepts the right of the investigator to publish the results of the research, however, the Investigator shall send a draft manuscript of the publication or abstract of the study findings to the manufacturer 30 days in advance of submission to a scientific journal for approval. Adaptive Neuromodulation GmbH was the manufacturer at the start of the trial, subsequently passing to NeuroTherapies Reset (Brook Henderson Group) during open-label extension.|t
17181336|NCT01614990|t||||
17181337|NCT01012622|f||OTHER|Principal Investigator cannot provide any trial related information to external parties' without mutual agreement with the sponsor. This is valid even after the contract is cancelled.|t
17181338|NCT04762680|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17181339|NCT02094716|f||OTHER|In the event said right to publish is exercised, the Investigator shall submit to Sponsor for review 60 days prior to any publication. In the event that Sponsor desires to take patent action, Investigator agrees to delay the publication an additional 60 days. Sponsor shall have the right to review and comment upon such publication. Notwithstanding the foregoing, no paper that incorporates Sponsor Confidential Information shall be submitted for publication without Sponsor's prior written consent.|t
17181340|NCT01063764|f||GT60||t
17181341|NCT02310919|t||||f
17181342|NCT00697515|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17181343|NCT02603432|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181344|NCT01957462|t||||
17151512|NCT02677714|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151513|NCT02538965|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 30 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 60 additional days. Investigator must delete confidential data before submission or defer publication to permit patent applications.|t
17151514|NCT00875797|f||||f
17151515|NCT04558918|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151516|NCT00258128|t||||
17151517|NCT02871492|f||OTHER|The Institution and Investigator agree not to publish the results or other data of this Study without the prior written consent of Sponsor.|t
17151518|NCT04546724|f||||t
17151519|NCT02256436|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17151520|NCT04113785|f||||f
17181345|NCT05954052|t||||
17181346|NCT01856790|f||||f
17181347|NCT01124604|f||OTHER|The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17181348|NCT01686841|f||||f
17181349|NCT02596854|f||||f
17181350|NCT04345614|f||||f
17181351|NCT06027866|f||||f
17181352|NCT02631954|f||||f
17181353|NCT03425331|f||||f
17151521|NCT01441947|t||||
17151522|NCT02174432|f||||f
17181354|NCT00470574|t||||
17181355|NCT02864251|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181356|NCT05442554|f||||t
17181357|NCT04053101|t||||
17181358|NCT02438722|f||||f
17181359|NCT04583891|f||||f
17181360|NCT05172544|f||||f
17181361|NCT04829318|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17181362|NCT02951338|f||||f
17181363|NCT01737047|f||||f
17196025|NCT01619059|f||||f
17181364|NCT03965962|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17181365|NCT00003641|f||LTE60||t
17181366|NCT03659916|f||OTHER||t
17181367|NCT00878709|f||LTE60||t
17181368|NCT00322842|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17181369|NCT05214768|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181370|NCT05041322|f||||f
17151523|NCT00077857|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181371|NCT03795298|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17181372|NCT04303780|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17181373|NCT00483223|t||||
17181374|NCT01344161|t||||f
17181375|NCT04690751|f||||f
17181376|NCT04364620|f||||f
17181377|NCT04579380|f||||t
17181378|NCT00476021|t||||
17181379|NCT00066066|t||||
17181380|NCT02268409|f||OTHER|No publication or disclosure of study results will be permitted except as specified in a separate, written, agreement between the sponsor and the investigator(s).|t
17181381|NCT03752307|f||||f
17181382|NCT01230931|t||||
17196026|NCT03418545|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151524|NCT01292226|t||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181383|NCT00489853|f||OTHER|Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.|t
17181384|NCT02953990|f||||f
17181385|NCT03181828|f||||f
17181386|NCT05630274|f||GT60||t
17181387|NCT02255500|f||||f
17181388|NCT05129488|t||||
17181389|NCT02608268|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17181390|NCT01925404|f||||f
17181391|NCT04091646|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17181392|NCT03102918|f||||f
17181393|NCT01660893|f||||f
17181394|NCT04765358|f||||f
17181395|NCT02731729|f||OTHER|Trial Site and/or Co-Principal Investigators may publish or present Study Data and other results of the Study from the Trial Site individually upon the first to occur of: (i) twelve (12) months after conclusion, abandonment, or termination of the Study at all Affiliated Research Institutions, or (ii) after Parker Institute for Cancer Immunotherapy \[PICI\] confirms in writing there will not be a multi-site Study publication.|t
17181396|NCT00159588|t||||
17181397|NCT02066467|f||OTHER|The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.|t
17181398|NCT00456521|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17181399|NCT01316276|f||OTHER|Per the signed Investigator Agreement in the protocol and protocol amendments, the PI agreed that the information presented in the study protocol is confidential, and assured that no information based on the conduct of the study was released without prior Insmed Incorporated Consent, unless the requirement is superseded by the Food and Drug Administration or other regulatory authority.|t
17196027|NCT04273672|f||||f
17196028|NCT03672032|t||||
17196029|NCT00462072|f||||f
17181400|NCT00605475|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary, however, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data ( i.e., data from all sites ) in the clinical trial.|t
17181401|NCT00775931|f||||f
17181402|NCT00297037|f||||f
17181403|NCT00076011|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181404|NCT00581776|f||LTE60||t
17181405|NCT05469100|f||GT60||t
17181406|NCT03056755|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17181407|NCT05230082|t||||
17181408|NCT01633892|f||||f
17181409|NCT03615326|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17181410|NCT03240679|t||||
17181411|NCT00405587|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181412|NCT00390325|f||LTE60||t
17181413|NCT01701115|t||||
17181414|NCT03506373|t||||
17181415|NCT02211131|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17181416|NCT02120950|f||LTE60||t
17181417|NCT02424383|f||OTHER||t
17181418|NCT01852812|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17181419|NCT02250443|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17181420|NCT01549964|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181421|NCT02290821|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17181422|NCT00728130|f||||f
17181423|NCT01154218|t||||
17181424|NCT05365750|f||||f
17181425|NCT00362115|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17181426|NCT00335972|f||||f
17181427|NCT03803774|f||LTE60||t
17181428|NCT01340144|f||||f
17181429|NCT01057017|f||||f
17181430|NCT00699556|f||||f
17181431|NCT06002958|t||||
17181432|NCT05497284|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181433|NCT03878446|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17181434|NCT04365556|f||||f
17181435|NCT02485912|t||||
17181436|NCT03181399|f||||f
17181437|NCT05123222|f||||f
17181438|NCT00265343|f||OTHER|Publication/presentation of data may not be made without prior review and comment by the Sponsor; all reasonable comments of Sponsor will be incorporated as far as the scientific data content is not impaired. A complete copy shall be provided to the Sponsor at least 60 days prior to date of submission. Participation in the Study involves a commitment to publish data from the study in a cooperative publication prior to publication/presentation or on an individual basis.|t
17181439|NCT04865354|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17181440|NCT00706641|f||||f
17181441|NCT02229318|f||||f
17181442|NCT02515942|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17181443|NCT01810666|f||GT60||t
17181444|NCT00902564|f||OTHER|No results can be made public before appropriate steps by Lundbeck to secure patents and/or intellectual property rights. The Investigator shall send any manuscript and/or public presentation to Lundbeck at least 1 month before submission for publication. If Lundbeck finds matters requiring patents or the like, the Investigator shall delay publication and/or public presentation for an additional 3 months.|t
17181445|NCT00922766|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181446|NCT00843713|f||||f
17181447|NCT01649375|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17181448|NCT04939727|f||||f
17181449|NCT01762943|t||||
17181450|NCT00539838|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181451|NCT02658890|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181452|NCT02474199|f||||f
17181453|NCT03460587|f||||f
17181454|NCT00952341|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17181455|NCT02826681|f||||f
17181456|NCT02004028|f||||f
17181457|NCT02419742|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181458|NCT01232920|f||||f
17181459|NCT03340025|t||||
17181460|NCT00755131|t||||
17181461|NCT03897179|t||||
17181462|NCT00704535|f||OTHER|The prescribing physicians and investigators of this trial will not publish the results of any part of the study without previous written authorization from the sponsor.|t
17181463|NCT01480076|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17181464|NCT02503332|f||||t
17181465|NCT01413360|f||||f
17181466|NCT03559179|f||||f
17181467|NCT02916563|t||||
17181468|NCT02149173|t||||f
17181469|NCT01100242|t||||
17181470|NCT02418195|t||||
17181471|NCT00909779|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17181472|NCT00117559|f||||f
17181473|NCT02016482|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181474|NCT02653456|f||||f
17181475|NCT02738333|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181476|NCT00949325|f||||f
17181477|NCT00791518|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181478|NCT01520363|t||||
17181479|NCT01272830|f||OTHER|Published articles to be reviewed/approved by IC-MedTech prior to publication.|t
17181480|NCT02658136|f||||f
17181481|NCT01498952|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17181482|NCT00579826|f||||f
17181483|NCT00454987|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181484|NCT05102383|f||||f
17181485|NCT00620828|f||||f
17181486|NCT01096810|t||||
17181487|NCT02918851|t||||
17181488|NCT02073279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181489|NCT00304356|f||||f
17181490|NCT05265260|f||||f
17181491|NCT03082599|f||||f
17181492|NCT00729183|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17181493|NCT01519882|f||GT60||t
17181494|NCT00323115|t||||f
17181495|NCT02280941|t||||
17181496|NCT01502423|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181497|NCT00567892|t||||f
17181498|NCT00004888|f||LTE60||t
17181499|NCT02579265|f||OTHER||t
17181500|NCT03493828|t||||
17181501|NCT02174848|f||OTHER|Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.|t
17181502|NCT00644969|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181503|NCT00277212|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181504|NCT03336216|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181505|NCT06076694|f||||f
17181506|NCT01023581|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181507|NCT01231581|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181508|NCT02510794|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181509|NCT03090100|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17181510|NCT03253848|f||LTE60||t
17181511|NCT05352815|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17181512|NCT02759120|f||||t
17181513|NCT04133168|f||OTHER|Institution and Investigator shall have the right to publish the Results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. In addition, Sponsor may extend such review period for another ninety (90) days.|t
17181514|NCT04461015|f||||f
17181515|NCT04434131|f||||f
17181516|NCT04236804|t||||
17181517|NCT04452331|t||||f
17181518|NCT05071183|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181519|NCT02808130|f||||f
17181520|NCT01229423|f||||f
17196030|NCT02384382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196031|NCT00407888|t||||
17196032|NCT02941692|f||||f
17181521|NCT03970590|t||||
17196033|NCT01607320|t||||f
17196034|NCT03784898|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17196035|NCT01989793|t||||
17196036|NCT01074242|f||OTHER|In regard to surveillance results, any publication should be agreed by the sponsor in advance|t
17196037|NCT03567616|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196038|NCT03960957|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17196039|NCT03395080|f||||f
17196040|NCT04278833|t||||
17196041|NCT04447027|f||||f
17196042|NCT02831049|t||||
17196043|NCT04224272|f||||f
17196044|NCT02609048|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196045|NCT02485925|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17196046|NCT05995977|t||||
17196047|NCT04181788|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196048|NCT04535414|f||||f
17196049|NCT03662659|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196050|NCT06922643|f||||f
17181522|NCT04196140|f||||f
17181523|NCT03760796|f||||f
17181524|NCT02836600|f||GT60||t
17181525|NCT02532647|f||OTHER|At least 45 days prior to submission of communications, sponsor shall review and comment on the communications. Sponsor shall have the right to require institution and investigator to remove specifically identified confidential information and to delay the proposed publication an additional 45 days to enable sponsor to seek patent protection|t
17181526|NCT01820416|f||||f
17181527|NCT02492269|t||||
17181528|NCT04493060|t||||
17181529|NCT02420691|t||||
17181530|NCT04415281|f||||f
17181531|NCT00325754|f||||f
17181532|NCT01334723|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181533|NCT03836963|t||||
17181534|NCT00177970|f||||f
17181535|NCT00703885|f||||f
17181536|NCT02625090|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181537|NCT02439320|f||GT60||t
17181538|NCT02972632|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181539|NCT02245841|f||||f
17181540|NCT01451775|t||||
17181541|NCT01488097|f||||t
17181542|NCT03999411|t||||
17181543|NCT03441633|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181544|NCT00178841|f||||f
17181545|NCT01251380|f||OTHER|A plan for scientific publication and presentation of the results could be agreed and implemented by the study investigators or a steering committee. The sponsor required that reasonable opportunity be given to review the content and conclusions of any abstract, presentation, or paper before the material was submitted for publication or communicated. This condition also applied to any amendments that were subsequently requested by referees or journal editors.|t
17181546|NCT04383210|f||LTE60||t
17181547|NCT01748643|f||||f
17181548|NCT02701647|f||||f
17181549|NCT02205333|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17181550|NCT01476696|f||GT60||t
17181551|NCT03038815|f||||f
17181552|NCT02447133|t||||
17181553|NCT03054870|f||||f
17181554|NCT02009046|f||||f
17181555|NCT01324388|f||GT60||t
17181556|NCT02730299|f||OTHER|Sponsor can review/comment at least 30 days before publication submission. At Sponsor request, site will withhold publication another 60 days to allow for patent application or other measures Sponsor deems appropriate to establish \& preserve its proprietary rights. Results publication made as part of those obtained by all sites performing protocol. Site free to publish based on its study results after publication of multi-center results or one year after completion/termination of site study.|t
17181557|NCT00973479|f||LTE60||t
17181558|NCT03089606|t||||
17181559|NCT00922883|t||||
17181560|NCT01519453|f||||f
17181561|NCT02140567|f||||f
17181562|NCT02802592|t||||
17181563|NCT02136576|t||||
17181564|NCT00537381|f||LTE60||t
17181565|NCT00731770|f||||f
17181566|NCT00827255|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17181567|NCT00735878|t||||
17181568|NCT00352846|t||||f
17181569|NCT01527682|f||||f
17181570|NCT00600938|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17181571|NCT00549562|f||||f
17181572|NCT01698463|t||||f
17181573|NCT04709575|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17181574|NCT01074164|t||||
17181575|NCT04254978|f||OTHER|The Lead/Coordinating Investigator will have the right to submit for publication any results arising from the study subject to the terms and conditions of the Clinical Trial and Confidentiality Disclosure Agreements.|t
17181576|NCT05005390|t||||
17181577|NCT03239470|f||||f
17181578|NCT00666757|f||GT60||t
17181579|NCT01660711|t||||
17181580|NCT00076687|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181581|NCT00826800|t||||
17181582|NCT05664490|f||||f
17181583|NCT02939560|f||||f
17181584|NCT04773158|f||||f
17181585|NCT03002012|f||||f
17181586|NCT03167879|f||||f
17181587|NCT05694546|f||||f
17181588|NCT01589445|f||||f
17181589|NCT01835743|f||||f
17181590|NCT01505608|f||LTE60||t
17181591|NCT00914862|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17181592|NCT02319031|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181593|NCT02356692|f||OTHER|Recipient agress to maintain Confidential Information in strict confidence, not to disclose Confidential Information to any third parties and no to use Confidential Information for any purposes execpt for Business Purpose.|t
17181594|NCT00176592|f||||f
17181595|NCT03519971|f||||t
17181596|NCT00129129|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181597|NCT04017936|t||||
17181598|NCT00651573|t||||
17181599|NCT01524692|f||||f
17181600|NCT01209442|f||||f
17181601|NCT01709695|t||||f
17196051|NCT02678455|f||||f
17196052|NCT02556918|t||||
17181602|NCT02882854|t||||
17181603|NCT00788892|f||||f
17181604|NCT01278485|f||||f
17181605|NCT02039674|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17196053|NCT04837937|t||||
17196054|NCT03954106|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17196055|NCT06006455|f||||f
17196056|NCT01767688|f||OTHER|The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.|t
17196057|NCT01655563|t||||
17196058|NCT02148705|f||||f
17196059|NCT01583166|t||||f
17196060|NCT01833455|t||||
17196061|NCT00887224|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196062|NCT03883828|t||||
17196063|NCT01256359|t||||
17196064|NCT01429454|f||||f
17196065|NCT02000752|f||||f
17196066|NCT03903692|f||LTE60||t
17196067|NCT02431741|f||||f
17196068|NCT04938453|t||||
17196069|NCT00273052|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196070|NCT03783936|f||||f
17196071|NCT00454194|f||LTE60||t
17196072|NCT02827201|f||||f
17196073|NCT03345979|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17196074|NCT00999596|f||LTE60||t
17196075|NCT01263132|f||||f
17196076|NCT00439218|f||OTHER|Investigators must submit an application to the NPTUNE Publications Committee for the use of data. A Writing Committee, appointed by the Publications Committee, is responsible for initiating, coordinating, and approving publications and presentations.|t
17196077|NCT03176407|f||||f
17196078|NCT00670488|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17196079|NCT00546156|f||||f
17196080|NCT01124045|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17196081|NCT03298087|f||||f
17196082|NCT04228952|t||||
17196083|NCT05553366|f||||t
17196084|NCT02022657|f||||f
17196085|NCT01530334|f||OTHER||t
17151525|NCT01844505|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181606|NCT01358357|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17181607|NCT02590939|f||OTHER|"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 60 days from the time submitted to the sponsor for review. Sponsor may request:~* deletion of any trade secret, proprietary, or confidential information of Sponsor~* an additional 90 days to take measures to preserve its IP rights~Sponsor cannot require editorial changes. Sponsor's consent is required for results communication before trial completion"|t
17181608|NCT00368654|f||||f
17181609|NCT02347189|f||LTE60||t
17181610|NCT00994240|f||||f
17181611|NCT01308450|f||||f
17181612|NCT01457885|t||||
17181613|NCT03745092|f||||f
17181614|NCT03979638|f||OTHER|No data collected as part of this study will be utilized in any written work, including publications, without the written consent of sponsor.|t
17196086|NCT00797212|f||LTE60||t
17196087|NCT01485887|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196088|NCT02108171|f||||f
17196089|NCT01868230|f||||f
17181615|NCT04248933|f||||f
17181616|NCT00578942|t||||
17196090|NCT00659373|f||||f
17196091|NCT02382640|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17196092|NCT02356198|t||||
17196093|NCT03162614|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17196094|NCT00380250|f||||f
17196095|NCT02630966|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17196096|NCT00641537|f||OTHER||t
17196097|NCT01801007|f||OTHER|Investigators must inform and submit to sponsor all manuscripts or abstracts at least 30 days prior to submitting the proposed Publication to a publisher or other third party.|t
17196098|NCT00665392|f||||f
17196099|NCT00243867|f||||f
17196100|NCT02422524|f||LTE60||t
17196101|NCT01321073|f||LTE60||t
17196102|NCT00544115|t||||
17196103|NCT01638000|f||OTHER|"Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript 45 days prior to publication for review and comment.~Sponsor may delay the publication to seek patent protection."|t
17196104|NCT05352230|t||||
17196105|NCT01683409|f||GT60||t
17196106|NCT04218864|t||||f
17196107|NCT01227421|f||OTHER|Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.|t
17196108|NCT02499328|f||OTHER||t
17196109|NCT00145470|f||OTHER|Except for compelling legal reasons, neither the sponsor nor the investigator will communicate to third parties any result of the clinical trial before the clinical trial report (CTR) has been released by the sponsor.|t
17196110|NCT02628106|f||||f
17196111|NCT06269003|f||||f
17196112|NCT04186247|t||||
17196113|NCT03508700|f||OTHER|An industry standard NDA is in place with all investigators.|t
17196114|NCT04323800|f||||f
17151526|NCT00468650|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17151527|NCT04874155|f||||f
17181617|NCT00589316|f||||f
17181618|NCT01883427|f||||f
17181619|NCT04697693|t||||
17181620|NCT01063595|f||||f
17181621|NCT00747435|f||OTHER|The PI shall not publish until after the multi center publication, provided that the multi center publication is submitted within 12 months after conclusion of the study.|t
17181622|NCT04328207|t||||
17181623|NCT04439318|f||LTE60||t
17181624|NCT01331148|t||||f
17181625|NCT03509675|f||||f
17181626|NCT02622828|f||||f
17181627|NCT03483935|t||||
17181628|NCT00613028|f||||f
17181629|NCT04920123|f||||f
17181630|NCT02855437|f||||f
17181631|NCT00278954|f||OTHER|Publication of the Study results will be allowed only with prior written approval from Sponsor, said consent not to be unreasonably withheld. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor's Inventions from any proposed publications prior to submitting or presenting the materials. Any and all publications will give appropriate recognition of any support received from Sponsor.|t
17181632|NCT03406858|t||||
17181633|NCT02269280|f||||f
17181634|NCT02121483|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17181635|NCT01817725|t||||f
17181636|NCT03412084|t||||
17181637|NCT01420289|f||||f
17181638|NCT00481195|f||GT60||t
17181639|NCT02932904|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181640|NCT01142310|f||||f
17181641|NCT03342742|t||||
17181642|NCT03792672|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17181643|NCT03095456|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181644|NCT01907828|f||OTHER||t
17196115|NCT00489554|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196116|NCT06571695|t||||
17196117|NCT01380145|f||LTE60||t
17196118|NCT05139615|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151528|NCT03735316|t||||
17151529|NCT03541980|f||||f
17151530|NCT03477903|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17151531|NCT03201965|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17151532|NCT02373189|f||||f
17151533|NCT03344861|f||||f
17151534|NCT02151877|f||||f
17151535|NCT03918109|f||LTE60||t
17151536|NCT00861198|t||||
17151537|NCT01197755|f||||f
17151538|NCT03040323|t||||
17151539|NCT00761865|t||||
17151540|NCT01208220|f||||f
17151541|NCT00758680|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17151542|NCT03014180|f||LTE60||t
17151543|NCT02377427|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151544|NCT00704730|f||OTHER|PIs may publish trial results generated at his/ her site with sponsor's prior written consent and only after results of the trial from all participating sites have been released in a multi-center publication coordinated by the sponsor.|t
17151545|NCT06913153|t||||
17151546|NCT01523457|t||||
17151547|NCT01143766|f||||f
17151548|NCT03035929|t||||f
17151549|NCT02886624|f||||f
17151550|NCT00362466|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151551|NCT03875859|t||||
17151552|NCT03400943|f||OTHER||t
17151553|NCT02563106|f||OTHER|Investigators do not see trial results ahead of public disclosure unless it is under CDA. Investigators will not be allowed to publish or disclose any study results prior to sponsor communicating it to the public.|t
17151554|NCT04729309|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151555|NCT02784444|f||LTE60||t
17151556|NCT01110135|t||||
17151557|NCT04689867|t||||f
17151558|NCT01664130|t||||
17151559|NCT03634475|f||||f
17151560|NCT01161407|f||GT60||t
17181645|NCT00591942|f||||f
17181646|NCT04007523|t||||
17181647|NCT01821534|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181648|NCT02197806|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181649|NCT03352323|f||OTHER||t
17181650|NCT03774433|f||||f
17181651|NCT00108160|t||||f
17151561|NCT03781037|f||||f
17151562|NCT04746794|t||||
17151563|NCT04040192|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151564|NCT02792699|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17151565|NCT03200912|f||||t
17151566|NCT00735618|t||||f
17151567|NCT00961402|f||||f
17151568|NCT01338870|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151569|NCT01955083|f||||f
17151570|NCT02849938|f||||f
17151571|NCT03583086|t||||
17151572|NCT02143973|f||||f
17151573|NCT00128830|f||GT60||t
17151574|NCT04058249|t||||
17151575|NCT02927366|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151576|NCT02472223|f||||f
17181652|NCT01144442|t||||
17181653|NCT01150123|f||GT60||t
17196119|NCT02038049|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196120|NCT01808534|t||||
17196121|NCT02660086|f||||f
17196122|NCT01653509|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196123|NCT00667017|t||||
17196124|NCT01303796|f||||f
17196125|NCT00326196|f||||f
17196126|NCT02094534|f||OTHER|"Agreement is work for hire"|t
17196127|NCT01673594|f||||f
17196128|NCT00808834|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17196129|NCT01711294|f||GT60||t
17196130|NCT02605174|f||GT60||t
17196131|NCT02117310|t||||f
17196132|NCT03737110|f||OTHER|Sponsor has the first right to publish information obtained from the trial. After sponsor publishes, PI may publish its own trial results, provided that sponsor may embargo such publication for up to 60 days for purposes of identifying confidential information (other than trial data) that must be removed and up to an additional 120 days to prepare a patent application if there is patentable subject matter in the PI's proposed publication.|t
17196133|NCT01738698|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17196134|NCT02575365|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196135|NCT03392194|f||||f
17196136|NCT03865732|f||||f
17196137|NCT02125292|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17196138|NCT03068312|f||OTHER||t
17196139|NCT02551224|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e.,data from all sites)in the clinical trial.|t
17196140|NCT01509183|f||||f
17196141|NCT00343083|f||||f
17151577|NCT01943110|f||OTHER|The sponsor, funder, and PI of this study have jointly published the results.|t
17196142|NCT01951703|f||GT60||t
17196143|NCT01009645|t||||
17196144|NCT00620854|f||OTHER|The disclosure restriction is that the Principal Investigator (PI) cannot without the sponsor's prior written consent, transmit, publish, or otherwise disclose to any person or entity either clinical trial results information.|t
17196145|NCT01482325|f||||f
17196146|NCT05124210|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17196147|NCT05197452|t||||
17196148|NCT01428583|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196149|NCT01817491|f||||f
17196150|NCT00768755|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151578|NCT00369317|f||OTHER|Must obtain prior Sponsor approval.|t
17151579|NCT01687244|f||OTHER|Sponsor will complete its review within the review period and will have authority to require that the Institution and/or Investigator delete from the disclosure of any reference to Confidential Information, other than results.|t
17151580|NCT03322930|f||||f
17151581|NCT00426361|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151582|NCT01758588|f||||f
17151583|NCT02478320|t||||
17151584|NCT03185013|f||OTHER||t
17151585|NCT02575976|t||||
17151586|NCT01881113|f||||t
17181654|NCT01035944|f||LTE60||t
17181655|NCT02486042|f||||f
17181656|NCT01466387|f||||f
17181657|NCT00566150|f||||f
17181658|NCT02968979|f||OTHER|"The Study may not be published by the Health Institution or the Investigator without the prior written consent of the Promoter who has to respond as soon as possible.~If the Investigator wishes to proceed with a publication or communication relating to the Study, the Promoter may, in the event that a serious and valid reason appears to require it, request that certain modifications be made. The modifications cannot in any way affect the scientific value of the publication."|t
17181659|NCT04404855|t||||
17181660|NCT03320564|f||LTE60||t
17181661|NCT00788827|t||||
17181662|NCT01218555|t||||f
17181663|NCT03745144|f||OTHER||t
17181664|NCT01586819|t||||
17196151|NCT01786876|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17196152|NCT04278755|t||||
17196153|NCT00843050|f||||f
17196154|NCT03184987|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196155|NCT01220999|t||||
17196156|NCT01560429|t||||
17151587|NCT00673387|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151588|NCT01436799|f||||f
17151589|NCT00960115|f||OTHER||t
17181665|NCT00896337|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17181666|NCT01359254|t||||
17181667|NCT04668950|f||||f
17181668|NCT02586896|f||||f
17181669|NCT01124643|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information(excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17181670|NCT02910167|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17181671|NCT04220411|f||||t
17181672|NCT02028988|t||||
17181673|NCT02803307|f||||f
17181674|NCT02680639|f||||f
17181675|NCT02678676|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17181676|NCT04059146|f||||f
17181677|NCT00851799|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17181678|NCT01976442|f||||f
17181679|NCT05300295|t||||
17181680|NCT04056195|f||OTHER||t
17181681|NCT01951339|f||||f
17181682|NCT00302133|f||||f
17181683|NCT01001442|f||OTHER|Part of CTA:The Investigator or any Site employee, consultant or admitting physician to the Site or Study Team member is not allowed to make any publication of any Study Data, information, results, or similar information without the review and comment of SPONSOR. As the Study is part of a multi-center trial, and the Investigator/site agree that no publication by Site/Investigator of the results of the Study conducted at the Site shall be made before the first multi-centre publication.|t
17181684|NCT02753699|f||OTHER||t
17181685|NCT01342510|t||||
17181686|NCT01538862|t||||
17181687|NCT01400516|t||||
17181688|NCT01412866|f||||f
17181689|NCT02204748|t||||
17181690|NCT03007758|f||||f
17181691|NCT01633320|t||||
17181692|NCT01796197|f||||f
17181693|NCT01380184|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17181694|NCT04243538|t||||
17181695|NCT03532295|t||||
17181696|NCT02776917|t||||
17181697|NCT00983281|t||||f
17181698|NCT00864474|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181699|NCT00610532|t||||f
17181700|NCT02376946|t||||
17181701|NCT02558790|f||||f
17181702|NCT05477875|f||||f
17181703|NCT03961100|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181704|NCT03898349|t||||
17181705|NCT05620576|f||GT60||t
17181706|NCT02681549|t||||
17181707|NCT05394025|t||||
17181708|NCT01052207|f||||f
17181709|NCT01565330|f||GT60||t
17196157|NCT05353296|t||||
17196158|NCT02494336|t||||
17196159|NCT00556478|f||OTHER|Details of the Study and his/her results shall not be publicized or published in any form to cooperative publication without prior, written consent of Pharm-Olam or the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17196160|NCT03897699|t||||
17196161|NCT03026166|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196162|NCT03035942|f||||f
17196163|NCT05270460|f||||t
17196164|NCT02091752|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17196165|NCT01989104|t||||f
17196166|NCT00783952|t||||
17196167|NCT04029090|f||OTHER||t
17196168|NCT02397707|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196169|NCT01065779|f||||f
17196170|NCT02157948|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196171|NCT01604824|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17196172|NCT04899999|t||||
17196173|NCT03340415|t||||
17196174|NCT03775213|f||||f
17196175|NCT04821271|t||||
17196176|NCT05640167|t||||
17196177|NCT01567852|f||||f
17196178|NCT04809623|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17196179|NCT02202317|f||||f
17196180|NCT01005615|f||||f
17196181|NCT03510195|t||||f
17196182|NCT03263117|t||||
17196183|NCT01450007|t||||
17196184|NCT00639418|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17196185|NCT05005351|f||||f
17196186|NCT01852045|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17196187|NCT01487954|t||||
17196188|NCT00487240|f||GT60||t
17196189|NCT01698918|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196190|NCT01019135|f||||f
17196191|NCT02304757|f||||f
17196192|NCT02095678|t||||
17196193|NCT02203799|f||||f
17196194|NCT00681109|t||||
17196195|NCT04660799|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196196|NCT02764970|t||||
17196197|NCT04864834|f||OTHER|The terms and conditions of Sandoz agreements with its investigators may vary. However, Sandoz does not prohibit any investigators from publishing. Any publications from a single-site are postponed until the publication of the pooled date (i.e. data from all sites) in the clinical trial.|t
17196198|NCT02106884|f||||t
17196199|NCT01934452|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196200|NCT02037568|f||||f
17196201|NCT03861234|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196202|NCT00621842|f||LTE60||t
17196203|NCT02066636|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196204|NCT04806100|t||||
17196205|NCT00391170|t||||
17196206|NCT00849485|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17196207|NCT02831816|f||OTHER||t
17196208|NCT01218594|f||||f
17196209|NCT00452114|t||||
17196210|NCT04025125|t||||
17196211|NCT06943638|f||||f
17196212|NCT02421679|f||OTHER|An industry standard NDA is in place with all investigators.|t
17196213|NCT01458015|t||||
17196214|NCT01818063|t||||
17196215|NCT00949117|f||||f
17196216|NCT01214200|f||||f
17196217|NCT01719172|f||||f
17196218|NCT00770874|f||OTHER||t
17196219|NCT04250636|t||||
17196220|NCT03041090|f||||f
17196221|NCT01353274|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196222|NCT01409837|f||||f
17196223|NCT03960645|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196224|NCT03292406|f||||t
17196225|NCT00403494|f||GT60||t
17196226|NCT01335061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196227|NCT03851094|f||||f
17196228|NCT01536704|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196229|NCT00047385|f||LTE60||t
17196230|NCT03490032|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196231|NCT04689932|f||LTE60||t
17196232|NCT04220983|t||||
17196233|NCT00310037|f||LTE60||t
17196234|NCT02124044|t||||
17196235|NCT02822599|f||||f
17196236|NCT02128269|f||OTHER|Publication rights are tied to the completion of the multi-center publication|t
17196237|NCT00878189|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196238|NCT02007070|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17196239|NCT00703092|f||||f
17196240|NCT02708498|f||||f
17196241|NCT01218048|t||||
17196242|NCT01021748|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17196243|NCT03070548|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196244|NCT01260883|f||||f
17196245|NCT01890954|t||||
17196246|NCT03316170|f||||f
17196247|NCT03052517|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196248|NCT01640288|t||||
17196249|NCT04803734|f||||t
17196250|NCT02605876|t||||
17196251|NCT03775915|t||||
17196252|NCT03883724|t||||
17196253|NCT00195819|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17196254|NCT02124304|f||||f
17196255|NCT01629589|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17196256|NCT03781375|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196257|NCT02336958|t||||
17196258|NCT01303510|f||OTHER|The investigator to submit all manuscripts/abstracts to the sponsor for review at least 6 weeks before submission.|t
17196259|NCT02404441|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17196260|NCT00822900|f||||f
17196261|NCT04679675|f||||f
17196262|NCT02234141|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196263|NCT00701415|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17196264|NCT02161458|f||||f
17196265|NCT03042767|t||||
17196266|NCT00186446|f||||f
17181710|NCT01203072|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17181711|NCT02153944|t||||
17181712|NCT02286193|f||||f
17181713|NCT02023151|f||||f
17181714|NCT04064294|t||||
17181715|NCT03450707|f||||f
17181716|NCT03343483|f||||f
17181717|NCT00337103|f||||f
17181718|NCT01577758|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17181719|NCT03387813|f||||f
17181720|NCT01289847|f||OTHER|"There is an agreement between the PI and Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results.~Publication of Study results will be allowed only with prior written approval from Sponsor. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor's Inventions from any proposed publications prior to submitting or presenting the materials."|t
17181721|NCT05876273|f||||f
17181722|NCT00579111|t||||
17181723|NCT04327999|t||||
17181724|NCT03975647|f||||t
17181725|NCT02872116|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181726|NCT03735667|f||OTHER|A contractual agreement is in place between the PIs and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17181727|NCT03552575|t||||
17181728|NCT01271868|f||||f
17181729|NCT00006478|f||||f
17181730|NCT04534764|f||GT60||t
17181731|NCT03583996|f||||f
17181732|NCT03161483|f||LTE60||t
17181733|NCT02767427|t||||
17181734|NCT04128683|f||||f
17181735|NCT03608488|f||||t
17181736|NCT02127632|f||||f
17181737|NCT02404350|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181738|NCT04238728|t||||
17181739|NCT02901951|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181740|NCT05389657|t||||f
17181741|NCT00537446|t||||
17181742|NCT04414553|f||||f
17181743|NCT01085097|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17181744|NCT00369512|f||||f
17181745|NCT04652479|t||||
17181746|NCT00056563|f||OTHER||t
17181747|NCT00075582|f||OTHER|Must obtain prior Sponsor approval.|t
17181748|NCT02268812|f||LTE60||t
17181749|NCT05045144|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17181750|NCT02385084|f||GT60||t
17181751|NCT00768144|t||||f
17181752|NCT02268786|f||GT60||t
17196267|NCT00705159|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17196268|NCT00526994|t||||
17196269|NCT04604652|f||||f
17166376|NCT01063062|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166377|NCT03009162|f||OTHER|Details of the Study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17196270|NCT01469585|f||||f
17166378|NCT00136695|f||||f
17166379|NCT02015481|f||||t
17166380|NCT02485639|f||||f
17166381|NCT02597452|t||||f
17196271|NCT02170532|t||||
17166382|NCT00943098|f||LTE60||t
17196272|NCT03400579|t||||
17166383|NCT00625391|t||||f
17166384|NCT02566785|f||||f
17166385|NCT00281099|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication."|t
17196273|NCT02833948|f||||t
17196274|NCT02644122|t||||
17196275|NCT03182244|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17196276|NCT00257894|t||||f
17166386|NCT04621240|f||||f
17196277|NCT02852824|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196278|NCT00680771|t||||f
17166387|NCT02147197|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166388|NCT04956731|f||||f
17166389|NCT02712983|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166390|NCT02954406|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17196279|NCT02502461|t||||
17196280|NCT02790281|f||OTHER|Manuscripts or abstracts will be prepared in collaboration between Ferring and the Investigators.|t
17196281|NCT03787628|f||||f
17166391|NCT05360966|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166392|NCT03522246|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17196282|NCT04076059|f||OTHER|Principal Investigators (PI) are NOT employed by the organization sponsoring the study. There IS an agreement between PI's and the Sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed. Institute and/or PI may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17196283|NCT02521493|f||OTHER|Must obtain prior Sponsor approval|t
17196284|NCT04748341|f||||f
17166393|NCT04683029|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17166394|NCT01477710|t||||
17166395|NCT00814580|f||GT60||t
17166396|NCT03372434|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime|t
17166397|NCT06523010|t||||
17196285|NCT00684242|t||||f
17166398|NCT04812028|t||||
17196286|NCT00692185|f||||f
17166399|NCT05924165|t||||
17196287|NCT00768716|t||||
17196288|NCT03769090|f||OTHER|Data or results obtained from this study must not be published without prior approval from the Sponsor.|t
17196289|NCT00799409|f||LTE60||t
17196290|NCT03964974|t||||
17196291|NCT02068157|t||||
17196292|NCT01363128|t||||
17196293|NCT01779050|t||||
17196294|NCT04053699|f||||f
17196295|NCT02746107|f||||f
17151590|NCT02351960|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17166400|NCT04075292|f||||t
17196296|NCT00022672|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196297|NCT01332266|f||||t
17196298|NCT03302091|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166401|NCT04308239|f||||f
17196299|NCT02392507|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166402|NCT02643615|t||||
17166403|NCT00459875|t||||
17196300|NCT02224755|f||OTHER|MOMENTUM 3 has a study specific charter that governs the overall publication and presentation policy for all abstracts and manuscripts related to MOMENTUM 3 clinical data.|t
17166404|NCT00501592|f||OTHER|All proposed publications based on this study shall be approved by the Sponsor prior to submission for publication. Such approval will not be unreasonably witheld. Publications will reflect the contributions made by the Investigators, Sponsor personnel and other groups involved in the study.|t
17166405|NCT01432145|f||OTHER|PI Publication needs to be after the first study multip-centre publication and make reference to it.|t
17166406|NCT01436656|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166407|NCT04729972|f||||t
17166408|NCT00241176|t||||
17166409|NCT03206970|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17151591|NCT00319982|f||||f
17151592|NCT03480386|t||||
17151593|NCT01094886|f||GT60||t
17151594|NCT00574912|f||||f
17166410|NCT02516982|f||||f
17166411|NCT04136548|f||||f
17166412|NCT01129765|f||||f
17166413|NCT03093207|f||||f
17151595|NCT01282723|f||OTHER|PIs may publish or present results of the study after the expiration of 12 months from completion. Publications or presentations are subject to the protection of confidential information or patentable information.|t
17151596|NCT03866902|t||||
17166414|NCT00962741|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166415|NCT01814878|f||OTHER|Principal Investigator (PI) cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is cancelled.|t
17166416|NCT03645421|f||OTHER|PI needs to provide sponsor with the draft to review no later than 30 days prior to the date of publication of trial results.|t
17166417|NCT05096247|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17166418|NCT05445921|f||||f
17166419|NCT02253433|t||||
17196301|NCT01829711|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17166420|NCT01756573|f||||f
17196302|NCT01482091|f||||f
17196303|NCT01480258|f||OTHER|The Sponsor and Sponsor representative must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor or Sponsor representative as confidential must be deleted prior to submission.|t
17166421|NCT02008942|f||OTHER|Standard confidentiality agreement|t
17166422|NCT00807586|t||||f
17166423|NCT00759876|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the Sponsor for review. The Sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17166424|NCT02836717|t||||
17166425|NCT03636893|t||||
17196304|NCT02169414|f||OTHER||t
17196305|NCT03374254|f||OTHER|The sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17166426|NCT00438360|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17196306|NCT02309515|t||||
17196307|NCT04026256|f||||f
17166427|NCT02455804|f||||t
17166428|NCT04560816|f||||t
17196308|NCT00624377|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17196309|NCT05260437|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196310|NCT00910962|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196311|NCT00923078|t||||
17196312|NCT01858688|t||||
17196313|NCT01999335|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196314|NCT00787176|f||||f
17196315|NCT00884806|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17196316|NCT02486939|f||||f
17196317|NCT00825318|t||||
17196318|NCT02449902|f||OTHER|Investigators may publish their own data provided that the information is reviewed by the Sponsor. Otherwise, publication of the outcome and results of the study will be the sole domain of Sponsor, and publication of the study results by the Institution or Principal Investigator is not permitted, except with the Sponsor's prior written consent.|t
17196319|NCT02362789|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196320|NCT03326856|f||OTHER|Study Results are considered Confidential Information that may not be published or disclosed without Sponsor's written consent for a period of five (5) years after completion of the Study.|t
17196321|NCT03692871|f||OTHER|The investigators agree to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17196322|NCT04658888|t||||
17196323|NCT01316913|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196324|NCT02691702|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196325|NCT05169684|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151597|NCT02392351|f||||f
17151598|NCT00810576|t||||f
17151599|NCT00704847|f||GT60||t
17151600|NCT02013674|t||||
17151601|NCT01462773|t||||
17151602|NCT00416884|t||||f
17196326|NCT01668719|f||LTE60||t
17196327|NCT03539055|f||||f
17196328|NCT02060487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196329|NCT05484661|t||||
17196330|NCT01856569|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196331|NCT01860079|f||||f
17196332|NCT00718120|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196333|NCT03292692|f||||f
17196334|NCT02110381|t||||
17196335|NCT04063124|t||||
17196336|NCT02950961|t||||
17196337|NCT02241785|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17196338|NCT01640340|f||||f
17196339|NCT03055988|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196340|NCT00845520|f||||f
17196341|NCT01736475|f||OTHER|Baxalta's agreements with PIs may vary per individual PI, but contain common elements. For this study, PIs may be restricted from independently publishing results without prior approval.|t
17196342|NCT02807857|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196343|NCT03530631|f||||f
17196344|NCT00703391|f||||f
17196345|NCT03905642|f||OTHER|"Per the signed Investigator Agreement in the study protocol and protocol amendments, the PI agreed not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated."|t
17196346|NCT06164743|f||||f
17196347|NCT00443820|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17196348|NCT04633200|t||||
17196349|NCT02713594|f||||f
17196350|NCT00670449|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196351|NCT02771366|t||||f
17196352|NCT00671853|t||||
17196353|NCT00785798|f||||f
17196354|NCT00587171|f||||f
17196355|NCT01848483|t||||
17196356|NCT01148017|f||||f
17196357|NCT03928743|f||GT60||t
17196358|NCT01128959|f||||f
17196359|NCT02338999|t||||
17196360|NCT02958553|f||GT60||t
17151603|NCT06219278|t||||
17151604|NCT04051619|f||||f
17151605|NCT04308226|f||||f
17151606|NCT03610516|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151607|NCT01328379|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17196361|NCT00308308|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17196362|NCT01686152|f||OTHER|PIs may not publish results from this generic (ANDA) study unless reviewed and approved by sponsor.|t
17196363|NCT01802333|f||||f
17196364|NCT00724009|t||||f
17196365|NCT01947491|f||LTE60||t
17196366|NCT02067663|f||||f
17196367|NCT00704340|f||LTE60||t
17196368|NCT03137784|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17196369|NCT02736188|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17196370|NCT04070105|f||||f
17196371|NCT03054506|f||||f
17196372|NCT05228834|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196373|NCT00564447|f||OTHER||t
17196374|NCT03547154|f||OTHER|Principal Investigators have the right to publish or publicly present the results of the study. Principal Investigators further agree to provide to the Sponsor thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. No publication or manuscript shall contain any trade secret information of the Sponsor or any proprietary or confidential information of the Sponsor.|t
17196375|NCT00895245|t||||
17196376|NCT02706483|f||OTHER|Please contact Sponsor directly for additional information.|t
17196377|NCT01972776|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17196378|NCT01543204|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196379|NCT00603018|t||||
17196380|NCT02527694|f||||f
17196381|NCT02684136|f||||f
17196382|NCT00407485|f||LTE60||t
17196383|NCT00432445|t||||
17196384|NCT03938272|f||OTHER|The investigator may not publish the results of their cohort of subjects until the full study has been submitted for publication. They may not submit for publication or present the results of this study without allowing OxThera 30 days in which to review and comment on the pre-publication manuscript. The investigator may not submit the results of the study for publication without the prior consent of OxThera, unless the review period has passed and there has been no reaction from the sponsor.|t
17196385|NCT03936699|f||||f
17196386|NCT00068107|f||||f
17196387|NCT03288506|t||||
17196388|NCT00695188|f||LTE60||t
17196389|NCT01419184|f||OTHER||t
17196390|NCT00875706|t||||
17196391|NCT00786188|f||OTHER||t
17196392|NCT01990794|t||||
17196393|NCT02279732|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196394|NCT02970318|f||OTHER|Institution/Investigator will not publish or publicly present any study results without prior approval or prior to 12 months following completion of the study.|t
17196395|NCT00824408|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196396|NCT01880736|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17196397|NCT00046475|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17196398|NCT00266656|f||GT60||t
17196399|NCT02915783|f||||f
17151608|NCT00660907|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17196400|NCT02203032|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17196401|NCT01915914|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196402|NCT00116649|f||||f
17196403|NCT02114515|f||||f
17196404|NCT01213940|f||||f
17196405|NCT02659540|f||LTE60||t
17196406|NCT02725372|f||||f
17196407|NCT01075152|t||||f
17196408|NCT04820491|t||||
17196409|NCT02334215|t||||f
17196410|NCT06716632|f||||f
17196411|NCT03976323|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17196412|NCT00535626|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts \& abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to the submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17196413|NCT02710669|t||||
17196414|NCT01386632|t||||
17196415|NCT03062488|t||||f
17196416|NCT02014402|f||OTHER|Site may publish results from the study, after providing Sponsor 30 days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At Sponsor's request, site will remove any confidential information (other than study results) and site will, upon Sponsor's request, delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor interventions.|t
17196417|NCT02542202|f||||f
17196418|NCT01190124|f||||f
17196419|NCT03493282|f||||f
17196420|NCT00070707|f||OTHER|Manuscript(s) and abstract(s) were prepared through cooperation between the sponsor and the study investigator(s). The principal investigator (PI) had the right to publish or publicly present the Study results. The PI agreed to provide thirty (30) days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication. The sponsor had the right to review and comment on any publication.|t
17196421|NCT01523392|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of the submission for publication. The Investigators in the Multi-Center (MC) study agree to postpone MC publications until the earlier of the first AstraZeneca-authorized publication or up to eighteen months from study completion at all sites.|t
17196422|NCT03462966|f||||f
17196423|NCT02002689|f||OTHER|"The terms and conditions of Novartis' agreements with its investigators may vary.~However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."|t
17196424|NCT01377844|f||OTHER|The PI is not allowed to publish trial results.|t
17196425|NCT01212822|t||||
17196426|NCT02236611|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196427|NCT02132520|f||||f
17196428|NCT03403036|t||||
17196429|NCT00568087|f||||f
17196430|NCT02701296|f||||f
17196431|NCT00240994|f||||f
17196432|NCT01437540|f||OTHER|Publication of the results by the principal investigator (PI) will be subject to mutual agreement between the PI and sponsor|t
17196433|NCT03142932|f||||f
17196434|NCT02395692|f||LTE60||t
17196435|NCT00854594|t||||
17196436|NCT00749944|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196437|NCT02547974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196438|NCT01513902|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196439|NCT01393600|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17196440|NCT00603798|f||||f
17196441|NCT04766996|t||||f
17196442|NCT00508183|f||||f
17196443|NCT02988713|f||GT60||t
17196444|NCT02424968|t||||
17196445|NCT02065609|f||||f
17196446|NCT04347941|f||||f
17196447|NCT04248868|f||LTE60||t
17196448|NCT03131713|f||||f
17196449|NCT02208843|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196450|NCT01976507|t||||
17196451|NCT01676298|t||LTE60||t
17196452|NCT01762982|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196453|NCT01794299|f||||f
17196454|NCT01029704|f||OTHER|The Investigator does not have the right to publish trial results.|t
17196455|NCT02144597|t||||
17196456|NCT00089791|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196457|NCT00148122|f||||f
17196458|NCT01672242|f||||f
17196459|NCT05376397|t||||
17196460|NCT01137682|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17196461|NCT01365546|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17196462|NCT00721734|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196463|NCT00472082|t||||f
17196464|NCT04617847|f||||f
17196465|NCT01989689|t||||
17196466|NCT00761267|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196467|NCT04492475|f||LTE60||t
17196468|NCT03989232|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17196469|NCT00869609|f||||f
17196470|NCT02354144|t||||
17196471|NCT03212638|t||||
17196472|NCT01323790|f||GT60||t
17196473|NCT01263496|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17196474|NCT02432274|f||OTHER||t
17196475|NCT00779194|t||||
17196476|NCT00513071|f||LTE60||t
17196477|NCT01479010|t||||
17196478|NCT00286325|f||||f
17196479|NCT00667732|f||LTE60||t
17196480|NCT01240590|f||||f
17196481|NCT03890484|f||||f
17196482|NCT02106325|t||||
17196483|NCT00824850|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196484|NCT04669366|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196485|NCT01928732|f||OTHER|The presentation or publication of any data collected by investigators on participants entered into the VA cooperative study is under the control of the study's Executive Committee. No individual participating investigator is permitted to perform analyses or interpretations or to make public presentations or seek publication of any of the data other than under the auspices and approval of the Executive Committee.|t
17196486|NCT01185340|f||GT60||t
17196487|NCT00087516|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196488|NCT02065895|f||||f
17196489|NCT01093690|t||||
17196490|NCT01682928|f||||f
17196491|NCT00569166|t||||
17196492|NCT05005247|f||||f
17196493|NCT00484198|f||||f
17196494|NCT01299285|f||GT60||t
17196495|NCT00486954|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196496|NCT00929526|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196497|NCT01836523|f||OTHER|Novo Nordisk commits to communicating, and otherwise making available for public disclosure, results of trials regardless of outcome.At the end of the trial, one or more public disclosures may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17196498|NCT00321971|t||||
17196499|NCT00813709|f||OTHER|Sponsor has the right to publish any results communication in connection with the study. The PI shall submit any communications including study results to the sponsor for review 30 working days prior to communication submission. The sponsor can request the PI to modify or delete any sponsor's proprietary information. If the PI refuses the modification, the submission shall be postponed for 60 days from PI refusal, to provide the sponsor the opportunity to file a patent or seek legal remedies.|t
17196500|NCT02753075|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196501|NCT02245620|f||LTE60||t
17196502|NCT01102426|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17196503|NCT00889863|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17196504|NCT04361617|t||||
17196505|NCT00930644|f||OTHER|The terms and conditions of NPS Pharmaceuticals agreements with its investigators may vary. However, NPS does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial.|t
17196506|NCT03082313|t||||f
17196507|NCT01918033|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17196508|NCT01338506|f||||f
17196509|NCT00529204|f||||f
17196510|NCT01702259|f||||f
17196511|NCT05012462|f||||f
17196512|NCT03259568|f||||f
17196513|NCT03136861|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196514|NCT03150758|t||||
17196515|NCT02696200|f||||f
17196516|NCT01235936|f||||t
17196517|NCT02359916|f||||f
17196518|NCT03398798|t||||
17196519|NCT03200574|f||||t
17196520|NCT04183491|f||||f
17196521|NCT01262456|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17196522|NCT02538094|t||||f
17196523|NCT02074384|f||||f
17196524|NCT02773732|t||||
17196525|NCT03652610|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17136550|NCT03583372|f||OTHER|The Sponsor does not object to publication by Institution or Principal Investigator (PI) of results of the Trial based on information collected or generated by the Institution or PI. However, the Institution and PI are required to provide the Sponsor with an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed to ensure against any inadvertent disclosure of Sponsor Confidential Information or unprotected Sponsor Inventions.|t
17136551|NCT02324842|f||||f
17136552|NCT05142332|f||||f
17136553|NCT01409031|f||||f
17136554|NCT05122650|f||||f
17136555|NCT01429987|f||||t
17136556|NCT01689207|f||OTHER|Confidentiality clauses are in place through a Master Services agreement, which limits the discloser of confidential information to what's expressed in 33.2 and 33.3: disclosure to third party only after written consent, or disclosure of confidential information only to the extent necessary to comply with reporting obligations from AZ, CRO or applicable laws.|t
17136557|NCT03744780|t||||f
17196526|NCT00326183|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196527|NCT03241810|f||||t
17196528|NCT01706666|t||||
17196529|NCT05011292|t||||
17196530|NCT01528605|t||||
17196531|NCT01156675|f||||f
17196532|NCT02326220|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17196533|NCT02699099|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196534|NCT02656199|t||||
17196535|NCT05184062|f||||t
17196536|NCT04343716|f||||f
17196537|NCT04445337|t||||f
17196538|NCT03659136|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196539|NCT04173000|t||||
17136558|NCT03705962|t||||
17136559|NCT01423617|f||OTHER||t
17136560|NCT01515306|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17196540|NCT02830893|f||||f
17196541|NCT01277302|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196542|NCT00731692|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17196543|NCT03332589|f||||f
17136561|NCT00086957|t||||
17136562|NCT00634244|f||LTE60||t
17136563|NCT03201198|f||||f
17150574|NCT03502707|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17150575|NCT04551911|f||||t
17196544|NCT00279409|f||||f
17196545|NCT03627299|t||||
17196546|NCT00108355|f||||f
17196547|NCT00647699|f||OTHER|Site has the right to publish or communicate study results upon the earlier of: (a) publication of a multi-center publication of the Study results coordinated by Sponsor; or (b) submission of the Study data by Sponsor to the FDA; provided that the Sponsor reviews the proposed communication of results within ninety (90) days in advance of its release. Sponsor can request delay of publication or data release to allow for filing of patent application prior to the publication or release.|t
17196548|NCT00413283|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196549|NCT02354417|f||||t
17196550|NCT00246129|t||||f
17196551|NCT03469258|f||||f
17196552|NCT04205669|f||||f
17196553|NCT02005172|f||||f
17196554|NCT03340961|f||||f
17196555|NCT01853384|f||LTE60||t
17196556|NCT04311983|t||||
17196557|NCT01759459|f||||f
17196558|NCT01205126|f||LTE60||t
17196559|NCT03331978|f||||f
17196560|NCT00638456|t||||
17196561|NCT03236779|t||||f
17196562|NCT00667953|t||||
17196563|NCT00687297|f||LTE60||t
17196564|NCT03006393|t||||
17196565|NCT01584648|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196566|NCT01328756|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17196567|NCT02070276|f||||f
17196568|NCT00722865|t||||f
17196569|NCT00244751|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196570|NCT02206607|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196571|NCT00879710|f||||f
17181753|NCT00744627|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17181754|NCT04251221|f||||f
17181755|NCT00323492|f||OTHER|After conclusion of the study and without prior written approval from Gilead Sciences, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met: results of the study in their entirety have been publicly disclosed by or with the consent of Gilead Sciences in an abstract, manuscript, or presentation form; or study has been completed at all study sites for at least 2 years.|t
17196572|NCT04085614|f||LTE60||t
17196573|NCT02399449|t||||
17196574|NCT02516202|f||||f
17196575|NCT00337610|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196576|NCT03541369|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196577|NCT04012970|t||||
17196578|NCT03205488|f||||f
17196579|NCT04867382|t||||
17196580|NCT01888484|f||||f
17196581|NCT01326455|f||||f
17196582|NCT05445557|f||||f
17196583|NCT02008916|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196584|NCT03803475|t||||
17196585|NCT01971255|t||||f
17196586|NCT00392197|f||||f
17181756|NCT02530450|f||||f
17196587|NCT00145145|t||||f
17196588|NCT00428714|f||GT60||t
17196589|NCT01681511|f||||f
17196590|NCT02151994|f||OTHER||t
17196591|NCT00090519|f||GT60||t
17196592|NCT02161146|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17196593|NCT00309751|f||GT60||t
17196594|NCT02613403|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17196595|NCT02189759|f||||f
17150576|NCT01030341|f||||f
17150577|NCT01884311|f||GT60||t
17196596|NCT02067819|t||||f
17150578|NCT00915928|t||||f
17196597|NCT00800176|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196598|NCT04000399|f||||f
17196599|NCT02548585|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17136564|NCT03855137|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136565|NCT02467387|f||||f
17136566|NCT02427477|f||LTE60||t
17151609|NCT02813265|f||OTHER|"The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:~(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial."|t
17196600|NCT01782209|f||||f
17196601|NCT02033174|f||||f
17196602|NCT03242863|f||||f
17196603|NCT02739100|f||GT60||t
17196604|NCT01840722|f||||f
17196605|NCT01079949|f||OTHER||t
17196606|NCT02144285|f||GT60||t
17196607|NCT01529632|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17196608|NCT02759575|f||||f
17196609|NCT03377023|t||||
17196610|NCT01513447|t||||f
17196611|NCT01276509|f||OTHER||t
17196612|NCT04995601|f||||f
17196613|NCT01534052|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. The sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17196614|NCT03854734|f||||f
17196615|NCT02196259|t||||f
17196616|NCT01668355|t||||f
17196617|NCT00215943|t||||
17196618|NCT00996164|f||||f
17196619|NCT02556606|t||||
17196620|NCT00403845|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196621|NCT00805792|t||||
17196622|NCT02152384|f||GT60||t
17196623|NCT00823966|t||||
17196624|NCT04471805|f||||f
17196625|NCT01163214|t||||
17196626|NCT01393964|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196627|NCT04405180|f||||f
17196628|NCT03879538|t||||
17196629|NCT02132676|t||||
17196630|NCT03265132|f||||f
17196631|NCT00088166|f||LTE60||t
17196632|NCT02671266|f||||f
17136567|NCT02335216|f||GT60||t
17136568|NCT01672996|f||||f
17136569|NCT04369430|f||OTHER|"Institution and its employees and agents, and Principal Investigator shall not disclose to any third party or use for any purpose other than in the fulfillment of their respective obligations hereunder, any data, records or other information disclosed to Institution and Principal Investigator by Sponsor or Clinical Research Organization, or generated as a result of this Study, without the prior written consent of Sponsor (or PPD as the case may be) (hereinafter, collectively Information)."|t
17136570|NCT02435277|f||||t
17136571|NCT00654511|t||||
17136572|NCT02227329|t||||
17136573|NCT02635737|t||||
17196633|NCT00666705|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196634|NCT01109979|f||||f
17196635|NCT01228734|f||OTHER||t
17196636|NCT03500406|t||||
17196637|NCT02580799|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196638|NCT03128099|t||||
17196639|NCT03456856|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196640|NCT03711279|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17196641|NCT04534738|f||||f
17196642|NCT02542696|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17136574|NCT00937768|t||||f
17136575|NCT01687413|t||||
17136576|NCT01767194|f||LTE60||t
17136577|NCT00306917|f||LTE60||t
17136578|NCT01454401|f||||f
17136579|NCT04748783|t||||
17136580|NCT00488618|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17136581|NCT00992446|f||||f
17136582|NCT03675737|f||OTHER|In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17136583|NCT02669862|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor.|t
17136584|NCT00311181|f||||f
17136585|NCT02294318|f||||f
17136586|NCT02397694|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17136587|NCT03725202|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136588|NCT01247220|f||||f
17196643|NCT02410278|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17196644|NCT00201825|t||||f
17196645|NCT03695185|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196646|NCT05919732|t||||
17196647|NCT02137785|f||OTHER|The first publication of results from multi-center trial will be made by the Sponsor. If publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30-75 days before submission so that sponsor can review the publication for confidential information.|t
17196648|NCT02584257|f||||t
17196649|NCT01670877|t||||
17196650|NCT03390166|f||||f
17196651|NCT03125148|f||||f
17196652|NCT03693989|f||||t
17196653|NCT00113529|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196654|NCT04184271|f||||f
17196655|NCT02825550|t||||f
17196656|NCT00042939|f||||f
17196657|NCT00795639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196658|NCT02525744|t||||f
17196659|NCT01604122|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196660|NCT01138657|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196661|NCT03150589|f||OTHER||t
17196662|NCT02841449|t||||
17136589|NCT01328249|f||OTHER||t
17136590|NCT01215734|t||||
17136591|NCT00315705|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17136592|NCT00748553|f||||f
17136593|NCT01393171|f||||f
17136594|NCT02295735|f||||f
17136595|NCT00495495|f||||f
17136596|NCT00745368|f||LTE60||t
17136597|NCT02536170|t||||
17136598|NCT03331666|t||||f
17136599|NCT02326467|t||||
17136600|NCT00434512|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196663|NCT01000649|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17196664|NCT00346398|f||||f
17196665|NCT03979040|t||||
17196666|NCT02607956|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196667|NCT01005914|t||||
17196668|NCT04108858|f||LTE60||t
17196669|NCT01141075|f||OTHER|"The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review.~The sponsor may consult with the PI to require changes to the communication or extend the embargo."|t
17196670|NCT01240785|f||||f
17136601|NCT00797797|f||OTHER||t
17196671|NCT00696241|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17196672|NCT01742832|t||||
17196673|NCT03347396|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17196674|NCT03060525|f||||f
17196675|NCT01974102|t||||
17196676|NCT00747149|f||OTHER|AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed in order for AstraZeneca to file patent applications.|t
17196677|NCT05522777|f||OTHER|Not to disclose the data relating to or the results of the Study to any third party, except as otherwise agreed to in writing by Sponsor for a period of three (3) years from the date the last clinic visit is completed by a Research Subject.|t
17196678|NCT05006703|t||||
17196679|NCT01381549|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196680|NCT01416285|f||||f
17196681|NCT00578344|t||||
17196682|NCT02935673|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17136602|NCT04253834|t||||
17136603|NCT03137121|f||||f
17136604|NCT01290445|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196683|NCT04328467|t||||
17196684|NCT00990184|f||||f
17196685|NCT03835416|t||||
17151610|NCT05264129|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17151611|NCT00618332|f||||f
17196686|NCT01090739|f||OTHER|"After the primary or the combined data article has been published, an Investigator may publish the study experience from his/her site. However, the Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data.~All publications will be reviewed by the sponsor in order to assure that no confidential information is disclosed. Such confidential information is not allowed for publishing."|t
17196687|NCT00441168|f||GT60||t
17151612|NCT04208958|f||||t
17151613|NCT05773794|f||||f
17151614|NCT01027195|t||||
17151615|NCT00661895|t||||
17151616|NCT04247100|f||||f
17151617|NCT02198183|t||||
17151618|NCT02932306|f||OTHER|Please contact Sponsor directly for additional information.|t
17151619|NCT05776862|t||||
17151620|NCT01199471|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17151621|NCT02065700|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17151622|NCT00843479|f||||f
17151623|NCT01386983|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151624|NCT01305044|f||||f
17151625|NCT03303196|t||||f
17151626|NCT02315430|f||LTE60||t
17151627|NCT02278055|t||||
17151628|NCT03207243|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151629|NCT04015908|t||||
17151630|NCT00715624|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17151631|NCT00229723|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent applications.|t
17151632|NCT03150407|f||||f
17196688|NCT03909100|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17196689|NCT00807599|t||||
17196690|NCT00529529|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196691|NCT01020435|t||||
17196692|NCT00103857|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196693|NCT02978183|f||||f
17196694|NCT02132195|t||||
17196695|NCT01790659|f||||f
17196696|NCT03065400|f||||f
17196697|NCT02102724|f||||f
17151633|NCT03421730|f||OTHER|Publication can be delayed for 60 days for Sponsor review and revisions/deletions can be required. Furthermore, a 6-month delay to publication can be required by the Sponsor in order to take steps to protect its proprietary information and/or intellectual property rights.|t
17151634|NCT01054404|t||||f
17151635|NCT02876757|f||||f
17151636|NCT00118534|t||||
17151637|NCT03016975|f||||t
17136605|NCT00111475|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17151638|NCT01590797|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17151639|NCT01900561|t||||
17151640|NCT02901548|t||||
17151641|NCT01006018|f||||f
17151642|NCT01696279|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17151643|NCT01881984|t||||
17151644|NCT00873457|t||||
17151645|NCT02687217|t||||
17151646|NCT04106661|t||||
17151647|NCT03503864|f||||f
17151648|NCT03898908|f||||f
17151649|NCT02639052|t||||
17151650|NCT02730351|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151651|NCT00838435|f||||f
17151652|NCT01135186|f||||f
17151653|NCT03796039|f||||f
17151654|NCT00530218|t||||
17151655|NCT03750292|t||||
17151656|NCT02143648|f||||f
17151657|NCT04642365|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151658|NCT01144715|f||GT60||t
17136606|NCT01062568|f||||f
17136607|NCT01026389|f||LTE60||t
17136608|NCT00836277|t||||
17136609|NCT04410198|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17151659|NCT00510289|t||||
17151660|NCT04428333|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17151661|NCT03365011|f||||f
17151662|NCT03582826|t||||
17181757|NCT01319877|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181758|NCT03560531|f||OTHER|"In this study, investigators can share findings only after meeting these conditions:~* Study results disclosed publicly by Sponsor or completed at all sites for 2 years~* Investigator informs Sponsor of publication 30 days before submission~* Communication won't include Sponsor's confidential information~* Investigator removes sponsor's confidential information (other than the study results) and agrees to withhold for an additional 60 days in order to obtain patent protection"|t
17151663|NCT02519738|t||||
17151664|NCT04180163|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17151665|NCT04730349|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151666|NCT02629354|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151667|NCT03613727|t||||
17151668|NCT02099682|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17151669|NCT02342639|f||||f
17151670|NCT02212379|f||||f
17181759|NCT01751386|t||||
17151671|NCT02105974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151672|NCT03155945|f||||f
17151673|NCT02203331|f||OTHER|For a period of five (5) years from the date of last disclosure under this Agreement. Recipient shall (a) maintain all Confidential Information in confidence and not disclose the same to any third party unless required to do so by court order or by law, in which case Recipient shall notify Bayer in writing prior to making such a disclosure, and (b) not use any Confidential Information for its own benefit or for the benefit of any third party.|t
17151674|NCT02091466|f||||f
17151675|NCT03558061|f||LTE60||t
17151676|NCT05065567|t||||
17151677|NCT04975191|t||||
17151678|NCT01806571|t||||
17151679|NCT02618759|f||||t
17151680|NCT01823497|f||||f
17151681|NCT02856555|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17151682|NCT03333941|f||||f
17151683|NCT04176406|f||||f
17151684|NCT03323437|f||||f
17151685|NCT00605540|f||||f
17151686|NCT01025453|t||||
17151687|NCT00049530|f||||f
17151688|NCT02383810|f||||f
17151689|NCT02105558|t||||f
17151690|NCT01635283|t||||
17151691|NCT01433549|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17151692|NCT01631071|f||OTHER|Material for public dissemination will be submitted to the Sponsor for review at least ninety (90) days prior to submission for publication, public dissemination, or review by a publication committee.|t
17151693|NCT03511326|f||||t
17136610|NCT03222076|t||||
17136611|NCT00509496|f||||f
17181760|NCT01200797|f||LTE60||t
17151694|NCT04628793|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151695|NCT01696058|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151696|NCT01934335|t||||
17181761|NCT04681482|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181762|NCT00642668|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136612|NCT02059213|t||||
17136613|NCT00568958|t||||f
17136614|NCT01709136|t||||
17136615|NCT01354353|f||GT60||t
17136616|NCT01151046|f||OTHER|If no overall study publication has occurred by the Sponsor within 12 months of the completion of this Study, the Investigator shall have the right to publish or present independently the results of this Study subject to the review procedure set forth herein. The Investigator will provide the Sponsor with a copy of any such presentation or publication derived from the Study for review, and the Sponsor may delay publication for up to 90 days to preserve patent activities and proprietary rights.|t
17151697|NCT05384171|t||||f
17151698|NCT00106964|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by protocol team and AMLG.|t
17151699|NCT03196219|f||||t
17151700|NCT01422187|f||||f
17151701|NCT00168818|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17151702|NCT02227446|f||||t
17151703|NCT04623086|f||||f
17151704|NCT02309138|t||||f
17151705|NCT00242684|t||||
17151706|NCT03904264|t||||
17181763|NCT03608774|f||LTE60||t
17181764|NCT01177540|f||||f
17136617|NCT02935699|f||||f
17136618|NCT05439460|t||||
17136619|NCT03446651|t||||
17136620|NCT02420223|t||||
17136621|NCT00330863|t||||
17136622|NCT03226223|f||||f
17136623|NCT02780765|t||||
17136624|NCT01894477|f||||t
17136625|NCT02052778|f||||t
17136626|NCT04168593|f||||f
17136627|NCT03664193|t||||
17136628|NCT01773135|t||||
17136629|NCT01094730|f||OTHER|Publication requires the agreement and written authorization of the Sponsor.|t
17136630|NCT04171037|t||||
17151707|NCT00819637|t||||
17151708|NCT03369197|f||||f
17151709|NCT00735397|f||OTHER||t
17151710|NCT02763826|f||||f
17151711|NCT00901576|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17151712|NCT01559389|t||||
17151713|NCT01346293|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17151714|NCT00390559|f||||f
17151715|NCT01798316|t||||
17151716|NCT01147107|f||||f
17151717|NCT04693416|f||||f
17151718|NCT00474266|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151719|NCT02774642|f||||f
17151720|NCT01695863|t||||
17151721|NCT00813800|t||||f
17151722|NCT03456453|t||||f
17151723|NCT03095638|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151724|NCT03565679|f||OTHER||t
17151725|NCT00635232|f||||f
17151726|NCT05278650|t||||
17151727|NCT02369458|t||||
17151728|NCT00121134|f||||f
17151729|NCT04080544|f||||f
17151730|NCT04967508|f||||t
17151731|NCT00118131|t||||
17151732|NCT02803229|t||||
17151733|NCT01024686|f||||f
17151734|NCT00857584|f||||f
17151735|NCT02011386|t||||
17151736|NCT03255655|f||||f
17151737|NCT04853992|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17151738|NCT00259272|f||GT60||t
17151739|NCT03483363|t||||
17151740|NCT01908907|f||||f
17151741|NCT00761657|f||OTHER||t
17151742|NCT03593538|t||||
17151743|NCT00998868|f||||f
17151744|NCT02420912|t||||
17151745|NCT01056289|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151746|NCT01917916|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151747|NCT02487303|t||||
17151748|NCT00270855|f||||f
17151749|NCT05424679|f||||f
17151750|NCT02152605|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151751|NCT03151408|f||||t
17151752|NCT00837473|f||||f
17151753|NCT01724489|f||||f
17151754|NCT04576923|f||||t
17151755|NCT04732624|f||||f
17151756|NCT00923273|f||||f
17151757|NCT01235195|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151758|NCT01473524|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.|t
17151759|NCT01544179|f||LTE60||t
17151760|NCT01327508|f||OTHER|"* Sponsor shall have the sole right for 12 mo after completion of Study at all sites to arrange for the submission of the multi-center article or presentation~* After the 12 mo, upon Sponsor approval or after the multicenter publication occurs, Investigator may publish, present and use for instruction and research, Investigator's results arising out of its conduct of the Study at the Site. Investigator may not disclose Sponsor Confidential Information, and Sponsor protects its proprietary rights"|t
17151761|NCT00282919|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151762|NCT01438996|f||OTHER|In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results, provided that he furnishes NVGH with a copy of the proposed publication for NVGH's review and comment, at least 1 month prior to submission to a publisher or disclosure to any third party.|t
17151763|NCT02540850|f||OTHER|Agreement between the sponsor and the clinical hospitals was signed and will be valid if no parties propose to change the agreement, the detailed trial data will not be made public until the trial data is published by the sponsor and/or the hospitals.|t
17181765|NCT04993287|f||||f
17181766|NCT04662801|t||||
17181767|NCT02323854|f||||f
17151764|NCT02861014|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151765|NCT03551821|f||||f
17151766|NCT03857750|t||||
17151767|NCT01090752|t||||f
17151768|NCT01756079|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17151769|NCT02794246|t||||
17151770|NCT01994291|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151771|NCT02137486|t||||
17151772|NCT00856375|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17151773|NCT02794597|f||||f
17151774|NCT02922738|t||||f
17151775|NCT00385008|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151776|NCT03201445|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17151777|NCT01228019|f||OTHER|Any publication must be approved by the Sponsor.|t
17151778|NCT00717041|f||||f
17151779|NCT02087189|f||||f
17151780|NCT03203564|f||OTHER|Non-disclosure agreement that prohibits the PI to communicate results without a prior permission from the sponsor.|t
17151781|NCT01676415|f||||f
17151782|NCT01189487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151783|NCT00587990|t||||
17151784|NCT02754856|t||||
17151785|NCT04630158|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17196698|NCT03072862|f||OTHER|"It is planned to generate at least two joint publications by the clinical investigator(s), with support from the sponsor using collective data. Publications are requested to be reviewed by the sponsor at least 30 days in advance to submission for publication.~Investigators are able to publish their local data separately. The sponsor kindly requests a copy of manuscripts intended for submission for publication least 60 days in advance of submission."|t
17196699|NCT02203513|f||||f
17196700|NCT02513667|t||||
17196701|NCT02429115|f||||f
17196702|NCT02417376|f||||f
17196703|NCT01331408|f||OTHER|Any publication or presentation by PI shall be submitted to Q-Med for review no less than 60 days before submission for publication or presentation. Q-Med will provide any comments to PI within thirty (30) days following receipt of the proposed publication/presentation. PI agree to consider, discuss and give reasonable considerations to comments by Q-Med. Q-Med may also request that the Company name (or that of Q-Med employee) appear or not appear in such publication.|t
17196704|NCT01450397|f||||f
17196705|NCT01964547|f||OTHER|GW Pharma Ltd (GW) will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17196706|NCT00912964|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17136631|NCT00987623|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17136632|NCT03248947|f||||f
17136633|NCT02991937|t||||
17136634|NCT03135028|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17136635|NCT00748540|f||LTE60||t
17136636|NCT02065869|f||||f
17136637|NCT01814800|f||OTHER|Following the first publication (sponsor coordinated), the Institution/PI may publish data or results from the study, if the material is reviewed by the sponsor at least 60 days prior to the proposed deadline; sponsor may remove any information considered confidential other than study data and results. If a multi-center publication is not submitted within 24 months after conclusion of the study at all sites, the Institution/PI may publish the study results following review by the Sponsor.|t
17136638|NCT04436822|f||GT60||t
17151786|NCT05162014|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151787|NCT01860677|f||||f
17151788|NCT04762277|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17151789|NCT00642278|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17151790|NCT00090363|f||OTHER|AstraZeneca can review results communications prior to public release and may within 30 days of receipt require that submission or disclosure be delayed for up to 2 months in order to file patent applications. AstraZeneca can also, within 30 days of receipt, require amendments to be made in order to protect its patent and / or corporate interests.|t
17151791|NCT03713619|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151792|NCT06281171|t||||
17151793|NCT02552212|f||GT60||t
17151794|NCT03020589|t||||
17151795|NCT04572893|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151796|NCT00197496|f||||f
17151797|NCT00418821|f||OTHER||t
17151798|NCT00103610|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17151799|NCT00469911|t||||
17151800|NCT01246063|t||||
17151801|NCT04328961|f||||f
17151802|NCT01178528|t||||
17151803|NCT03739645|t||||f
17151804|NCT04042376|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will delay to allow for filing of a patent application.|t
17151805|NCT00805467|f||OTHER||t
17151806|NCT00213135|f||OTHER||t
17151807|NCT00359801|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151808|NCT03758716|f||LTE60||t
17151809|NCT01396512|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17151810|NCT00470392|t||||f
17151811|NCT02500043|f||||t
17151812|NCT02094417|f||||t
17151813|NCT00411411|f||LTE60||t
17151814|NCT03301649|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17151815|NCT01564537|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17151816|NCT01635218|t||||f
17151817|NCT03559400|t||||f
17151818|NCT03262038|t||||
17151819|NCT02679235|f||||f
17151820|NCT00094861|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17151821|NCT01551030|t||||
17151822|NCT02549027|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17151823|NCT01504958|f||||f
17151824|NCT00127218|f||||f
17151825|NCT01421511|f||OTHER|Sponsor intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between the Sponsor and Investigators. Sponsor approval in writing is required for publication of any data subsets. Final authorship will be determined in accordance with the International Committee of Medical Journal Editors definition of authorship.|t
17151826|NCT04581369|f||||f
17151827|NCT00780910|f||OTHER||t
17151828|NCT00089024|t||||
17151829|NCT01111825|f||LTE60||t
17151830|NCT05204082|t||||
17151831|NCT02691143|t||||
17151832|NCT04074616|t||||
17151833|NCT01377987|f||||f
17151834|NCT02552303|f||||f
17151835|NCT01775189|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151836|NCT04141930|f||||f
17151837|NCT02121392|t||||
17151838|NCT00741286|f||||f
17151839|NCT01352416|f||||f
17151840|NCT01831258|f||||f
17151841|NCT02597127|f||OTHER|The only disclosure restriction on the PI is that Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of more than 60 days but less than/equal to 180 days from the time submitted to Sponsor for review, allowing Sponsor to file a patent application or take such other measures as Sponsor deems appropriate to establish and preserve its proprietary rights. Sponsor may remove confidential or proprietary information.|t
17151842|NCT00811928|f||OTHER|"The Principal Investigator agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of the SPONSOR. The Principal Investigator further agrees to provide to the~SPONSOR thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the Protocol study."|t
17136639|NCT00430625|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17136640|NCT03375112|t||||
17136641|NCT00243230|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or for presentation, review copies of the publication or presentation for review and comment on the data analysis and presentation including proprietary information, the accuracy of the information, and to ensure compliance with FDA regulations.|t
17136642|NCT05118386|f||OTHER||t
17151843|NCT00171951|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151844|NCT00396812|f||||f
17136643|NCT02963714|f||||f
17136644|NCT00303108|f||||f
17136645|NCT04158908|t||||
17136646|NCT00894413|t||||
17136647|NCT00008138|f||||f
17136648|NCT00142519|t||||
17136649|NCT00500045|f||||f
17136650|NCT00755846|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17136651|NCT00786032|t||||f
17136652|NCT02429258|f||OTHER|Institution \& PI agree they will not use or disclose and confidential information to third parties for a period of 10 years from receipt|t
17136653|NCT02168933|t||||
17136654|NCT02616185|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136655|NCT01303380|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17136656|NCT01346371|f||||f
17136657|NCT02320695|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17136658|NCT00789958|f||||f
17136659|NCT00074724|f||||f
17136660|NCT01000727|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136661|NCT02207478|f||||f
17136662|NCT03544268|t||||
17136663|NCT02152670|t||||
17136664|NCT02607254|f||||f
17136665|NCT01206478|f||||f
17136666|NCT00377611|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136667|NCT04831515|f||||f
17151845|NCT02914210|t||||
17151846|NCT00912925|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17151847|NCT03485365|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17151848|NCT03136965|t||||
17151849|NCT04868968|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151850|NCT00767624|f||||f
17151851|NCT03661697|t||||
17151852|NCT00763061|f||||f
17151853|NCT02910063|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17151854|NCT02752087|t||||
17151855|NCT01547130|t||||f
17151856|NCT00843635|t||||
17151857|NCT03496610|t||||
17151858|NCT01727726|f||||t
17151859|NCT04435184|f||||f
17151860|NCT02714426|t||||f
17151861|NCT00048737|t||||f
17151862|NCT00896480|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17151863|NCT02012348|f||||f
17151864|NCT00205803|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151865|NCT00401986|f||LTE60||t
17151866|NCT05038800|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.|t
17136668|NCT01819311|f||||f
17136669|NCT01640925|t||||
17136670|NCT02343276|f||||f
17136671|NCT01319110|t||||
17136672|NCT03837353|f||||f
17136673|NCT00442013|f||||f
17136674|NCT01030458|f||||f
17136675|NCT01332019|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17136676|NCT00980785|f||||f
17136677|NCT01395368|t||||f
17136678|NCT03474406|t||||
17136679|NCT04131517|f||GT60||t
17136680|NCT00288860|f||||f
17136681|NCT05161351|t||||
17136682|NCT04149899|f||OTHER|The investigator shall agree to submit all manuscripts or abstracts to the sponsor for review before submission. Authorship and manuscript composition will reflect joint cooperation between the investigator(s) and sponsor personnel; authorship will be established by mutual agreement, and in line with ICMJE authorship requirements. No individual publications will be allowed prior to completion of the final report of the multicenter study, except as agreed with sponsor.|t
17136683|NCT00312884|f||||f
17136684|NCT02600325|t||||f
17136685|NCT02586233|f||||f
17136686|NCT01757405|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, results may not be published without prior written approval of Sponsor.|t
17136687|NCT01592409|t||||
17151867|NCT00612430|f||||f
17136688|NCT04322994|t||||
17136689|NCT01157416|f||||f
17136690|NCT02345252|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17136691|NCT00779324|f||||f
17136692|NCT00617409|t||||
17136693|NCT02913222|f||||f
17136694|NCT00809458|t||||
17136695|NCT01496430|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17151868|NCT01104792|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17151869|NCT01102374|f||||f
17181768|NCT01623596|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17181769|NCT00322335|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181770|NCT00699972|f||OTHER||t
17181771|NCT01545817|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17151870|NCT02071849|f||OTHER|Publication by the investigator was not allowed until completion of the trial. All proposed publications must be cleared by unanimous vote of a publication committee consisting of the sponsor and representatives of the study investigators. Publication materials must be submitted for review at least 60 day in advance of publication. The Sponsor may embargo publication for 60 additional days to allow for patent filing or may prevent publication if filling of such application would be premature.|t
17151871|NCT04619992|t||||
17151872|NCT01175031|f||LTE60||t
17151873|NCT00555360|t||||
17151874|NCT03301623|f||||f
17151875|NCT00658021|f||||f
17151876|NCT02067273|t||||
17151877|NCT02092467|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151878|NCT01595386|t||||
17151879|NCT01119794|f||||f
17151880|NCT02906566|t||||
17151881|NCT02297698|f||||f
17151882|NCT02952898|f||OTHER|The Institution and Investigator, including all employees and coworkers involved with this study, agree not to publish the results of this study without the prior written consent of Sponsor.|t
17151883|NCT00399880|f||||f
17151884|NCT04400682|f||OTHER||t
17151885|NCT02293863|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151886|NCT00261443|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17151887|NCT02755649|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17151888|NCT01286753|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151889|NCT02657928|t||||
17151890|NCT04933968|f||||f
17151891|NCT02119819|f||GT60||t
17151892|NCT02699684|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17151893|NCT04839692|t||||f
17151894|NCT03146962|t||||
17151895|NCT01917214|f||OTHER|"Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days.~Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."|t
17151896|NCT00926783|f||OTHER|The PI is allowed to publish but must submit draft pubs to Biosense Webster, Inc. at least 30 days prior to submission for publication or presentation.|t
17151897|NCT05177718|f||||f
17151898|NCT00613886|f||||f
17151899|NCT02186834|t||||
17151900|NCT00749892|t||||
17151901|NCT01053000|f||||f
17136696|NCT01100307|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17151902|NCT01191944|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17151903|NCT02814890|t||||
17151904|NCT01056315|f||OTHER|It is the Institution and Principal Investigator's obligation not to publish any information declaration, invention or whatsoever which is in connection with this Agreement without the prior written consent of the Sponsor.|t
17136697|NCT02509598|f||||t
17136698|NCT02196038|f||||f
17136699|NCT04056455|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17151905|NCT00469144|t||||
17151906|NCT04602546|f||||f
17151907|NCT02156167|f||LTE60||t
17151908|NCT03138590|f||||f
17151909|NCT00253448|t||||
17151910|NCT02564887|t||||f
17151911|NCT00000620|f||||f
17151912|NCT01199016|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136700|NCT02528097|t||||
17151913|NCT02318303|f||OTHER|Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the CRO/ Sponsor.|t
17151914|NCT01853332|f||||f
17151915|NCT00314951|f||LTE60||t
17151916|NCT03495921|f||||t
17151917|NCT05320887|f||||f
17151918|NCT00599053|t||||f
17151919|NCT03168334|f||OTHER|Please contact Sponsor directly for additional information.|t
17151920|NCT02015065|f||||f
17151921|NCT01120704|t||||
17151922|NCT00233402|f||||f
17151923|NCT04181723|f||||f
17151924|NCT03332979|t||||
17151925|NCT05147324|t||||
17151926|NCT03553576|f||||f
17151927|NCT01671332|t||LTE60||t
17151928|NCT02728843|f||LTE60||t
17151929|NCT01432379|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151930|NCT01806506|t||||f
17151931|NCT00088621|f||||f
17151932|NCT00373698|t||||
17151933|NCT03862755|t||||
17136701|NCT00590018|t||||
17136702|NCT04747808|f||||t
17136703|NCT00369668|f||||f
17136704|NCT03054077|f||||f
17136705|NCT00218036|f||||f
17136706|NCT03352414|f||||f
17136707|NCT03213626|t||||
17136708|NCT01249872|t||||
17136709|NCT03302793|t||||f
17136710|NCT04574297|t||||
17136711|NCT01079962|f||OTHER||t
17136712|NCT01331239|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17136713|NCT05818527|f||||f
17136714|NCT00946530|t||||
17136715|NCT01008995|f||LTE60||t
17151934|NCT04844762|f||||f
17151935|NCT00477633|f||LTE60||t
17151936|NCT00963560|f||OTHER|All data and discoveries arising out of the study, patentable or nonpatentable, shall be the sole property of Alcon Laboratories, Inc. Alcon reserves the right of prior review of any publication or presentation of information related to the study. Alcon may use these data now and in the future for presentation or publication at Alcon's discretion or for submission to government regulatory agencies.|t
17151937|NCT00815360|t||||f
17151938|NCT04123561|f||GT60||t
17151939|NCT02454127|t||||
17151940|NCT02777073|t||||
17151941|NCT01374269|f||||f
17151942|NCT00278889|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17181772|NCT02059928|t||||
17181773|NCT00571259|t||||
17181774|NCT01713868|f||||f
17181775|NCT03893799|f||||f
17136716|NCT00406640|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17136717|NCT02389712|t||||
17136718|NCT02457182|f||||f
17136719|NCT00734344|t||||
17136720|NCT00506948|t||||f
17136721|NCT00762372|f||||t
17136722|NCT02174861|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136723|NCT01670656|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including slides and texts of oral or other public presentations and texts of any transmission through any electronic media that report results of the trial. The Sponsor has the right to review and comment with respect to publications, abstracts, slides, and manuscripts, as wells as comment on the data analysis and presentation.|t
17151943|NCT01987479|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151944|NCT03462459|f||||f
17151945|NCT04998851|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151946|NCT02185690|f||||f
17151947|NCT00478244|t||||
17151948|NCT02929056|f||||f
17151949|NCT03132155|f||||t
17151950|NCT01650584|f||OTHER|Contact sponsor directly for detail.|t
17181776|NCT01742338|t||||
17181777|NCT03249779|t||||
17181778|NCT03314584|t||||
17181779|NCT04302389|f||||f
17181780|NCT04214288|f||OTHER||t
17181781|NCT01378221|t||||f
17181782|NCT01794806|t||||
17181783|NCT04896658|t||||
17181784|NCT01990495|t||||
17181785|NCT01928862|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17181786|NCT01478321|t||||
17181787|NCT03168464|t||||
17181788|NCT04649164|f||||f
17136724|NCT04863417|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136725|NCT01648452|t||||
17136726|NCT02860845|f||||f
17136727|NCT03196193|f||||f
17136728|NCT02709083|t||||
17136729|NCT01697267|f||||f
17136730|NCT00333619|t||||
17136731|NCT02681055|f||LTE60||t
17136732|NCT02695524|f||||f
17136733|NCT00831441|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136734|NCT00111917|f||||f
17136735|NCT00748085|f||||f
17136736|NCT02363270|f||||f
17136737|NCT02311309|t||||
17136738|NCT03623334|t||||
17136739|NCT02338492|f||OTHER|The PI shall submit copies of any material to sponsor for review at least 30 days in advance of submission to a publisher or other third party. The sponsor shall review the data provided for consistency and reserves the right to delete any confidential information or other proprietary information from the proposed material. Sponsor may extend such review period for another 60 days to allow for filing of patent applications or take other steps to protect the sponsor's IP interests.|t
17136740|NCT00871377|f||||f
17136741|NCT01590394|t||||
17136742|NCT00922194|f||||f
17136743|NCT03072719|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136744|NCT00882999|f||GT60||t
17136745|NCT01104584|f||||f
17136746|NCT04017442|t||||
17151951|NCT04320823|f||OTHER|Site and Investigator shall not publish, disclose, present or use for instruction any Results arising out of its conduct of the Study at the Site without the express prior written consent of Sponsor, except to the extent required by applicable law. Sponsor shall have final review and approval rights for any authorized publication by Investigator, including but not limited to publication strategy, publication decisions, publication content and authorship decisions.|t
17151952|NCT02925403|f||||f
17151953|NCT00459043|t||||
17151954|NCT01794455|t||||
17151955|NCT02899195|f||LTE60||t
17151956|NCT03156504|t||||
17151957|NCT00450801|t||||
17151958|NCT03452137|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17151959|NCT02089659|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17151960|NCT02928055|f||||f
17151961|NCT00509366|f||||f
17181789|NCT02053753|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17136747|NCT02082145|t||||
17136748|NCT00082758|f||OTHER|Must obtain prior Sponsor approval.|t
17136749|NCT00238303|f||LTE60||t
17136750|NCT01833741|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17151962|NCT02906358|t||||
17151963|NCT01171118|t||||
17181790|NCT01969812|t||||
17136751|NCT00208494|f||LTE60||t
17136752|NCT02561299|f||LTE60||t
17151964|NCT01145508|f||LTE60||t
17136753|NCT01358877|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136754|NCT04183179|f||||f
17136755|NCT03575884|f||||f
17136756|NCT01911845|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17136757|NCT01994226|f||||f
17136758|NCT03075176|t||||f
17136759|NCT00501046|f||OTHER||t
17136760|NCT00436566|t||||
17136761|NCT01980706|t||||
17151965|NCT02045147|t||||
17181791|NCT04916795|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136762|NCT02403830|t||||
17136763|NCT01515995|t||||
17136764|NCT01934894|f||GT60||t
17136765|NCT01842308|t||||
17136766|NCT00677690|f||||f
17136767|NCT01106625|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17136768|NCT03822871|f||OTHER|Sponsor can review results for a period that is less than or equal to 45 days prior to submission for publication or disclosure to a third party. If sponsor believes patentable subject matter is disclosed, it shall, within 30 days of receipt, notify university and publication or disclosure will be withheld for a period of up to 90 days from date of receipt or until university and sponsor agree that no patentable invention exists, whichever period is shorter.|t
17136769|NCT01088438|f||||f
17136770|NCT00511342|f||OTHER|The SPONSOR recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the SPONSOR. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the SPONSOR, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17136771|NCT00997321|f||||f
17136772|NCT00360243|f||||f
17136773|NCT02458690|f||||f
17136774|NCT03615469|t||||
17136775|NCT01153763|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136776|NCT02402218|t||||
17136777|NCT00321100|t||||
17136778|NCT02366663|f||||f
17136779|NCT03534063|t||||
17136780|NCT00789191|f||OTHER|Novo Nordisk reserves the right not to release data before passing specified milestones. This includes the right not to release interim results that may later be found to be incorrect. At the end of the trial, one or more manuscripts will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications but will reserve the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17136781|NCT03497429|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17136782|NCT01009983|t||||
17136783|NCT00554463|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17136784|NCT03364335|f||OTHER||t
17136785|NCT02670915|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17136786|NCT03736629|t||||
17136787|NCT00818207|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136788|NCT02494778|f||OTHER|Data and results are owned by the sponsor. Results can be used by the institution for internal noncommercial research, education and patient care, and as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.|t
17136789|NCT00967226|f||||f
17136790|NCT01915108|t||||
17136791|NCT03309787|f||||f
17136792|NCT00849251|f||GT60||t
17136793|NCT02702518|f||||f
17136794|NCT03496467|f||||t
17136795|NCT02796391|t||||
17136796|NCT02156492|f||||f
17136797|NCT05254613|f||||t
17136798|NCT01434641|f||||f
17136799|NCT04087343|t||||
17136800|NCT02106455|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136801|NCT00229203|f||OTHER||t
17136802|NCT03607838|f||OTHER|PI do not make any publication of trial results without the written permission of sponsor.|t
17136803|NCT01576016|f||||f
17136804|NCT00689819|f||||f
17136805|NCT02488551|t||||
17136806|NCT03709810|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136807|NCT04507867|f||||f
17136808|NCT04096326|f||||f
17136809|NCT04124536|t||||f
17136810|NCT01879176|t||||
17136811|NCT03741725|f||||f
17151966|NCT00264550|f||GT60||t
17151967|NCT02246114|t||||
17151968|NCT02740114|t||||
17151969|NCT03416829|f||||f
17151970|NCT01439009|f||||f
17151971|NCT01957761|f||||f
17151972|NCT00696787|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17151973|NCT01549405|f||||f
17151974|NCT00129389|f||LTE60||t
17151975|NCT02656069|f||||f
17151976|NCT01830790|t||||
17151977|NCT00603837|f||||f
17151978|NCT04611529|t||||
17151979|NCT03578549|f||||f
17151980|NCT04867174|f||||f
17151981|NCT00451048|f||LTE60||t
17151982|NCT04414345|t||||
17151983|NCT00425373|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17151984|NCT02052011|f||||f
17151985|NCT01851330|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17151986|NCT00561418|t||||
17151987|NCT02960490|f||||t
17166429|NCT02277691|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136812|NCT02512068|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17136813|NCT02569411|f||||f
17136814|NCT03521687|f||||f
17136815|NCT04365985|t||||
17136816|NCT01962714|t||||
17136817|NCT01151579|t||||
17136818|NCT01276457|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17136819|NCT01040208|f||||f
17136820|NCT01204255|t||||f
17136821|NCT01098461|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136822|NCT01474746|f||||f
17136823|NCT00400829|f||LTE60||t
17136824|NCT01766336|f||LTE60||t
17136825|NCT02605447|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor|t
17136826|NCT00039195|t||||
17136827|NCT02110121|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17136828|NCT04544709|t||||
17136829|NCT03628508|t||||
17136830|NCT02045212|f||LTE60||t
17136831|NCT00145249|f||LTE60||t
17136832|NCT03807739|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136833|NCT02742077|f||||f
17136834|NCT02774226|f||||f
17136835|NCT03992768|f||||f
17136836|NCT03126539|t||||
17136837|NCT02632110|f||OTHER|First publication of results will be made by the Sponsor. If publication is not submitted within 12 months after the date of study final report, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30 days before submission for publication so that sponsor can review the publication for confidential information|t
17136838|NCT03645408|f||||f
17136839|NCT00516269|t||||f
17166430|NCT03818607|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166431|NCT03560102|t||||
17196707|NCT02978716|f||OTHER|The investigator will submit results communications for review by the sponsor at least 60 days prior to expected submission to the intended publisher or meeting committee. This review period may be shortened upon mutual consent. The sponsor may request modification of any publication, presentation or use by the investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights.|t
17136840|NCT01005732|f||||f
17136841|NCT02596711|t||||
17136842|NCT01552928|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17151988|NCT02667067|f||OTHER|Publication results vary per investigator and per clinical trial agreement.|t
17151989|NCT02368314|f||||f
17151990|NCT02289456|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene sixty days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety day and must delete confidential information before submission or defer publication to permit patent applications.|t
17151991|NCT00920790|f||OTHER||t
17151992|NCT02279108|t||||f
17151993|NCT01661062|t||||
17151994|NCT04411914|t||||
17151995|NCT01778634|f||||f
17151996|NCT01504997|t||||
17151997|NCT00377832|f||||f
17151998|NCT00895414|t||||
17151999|NCT00252239|f||||f
17152000|NCT00478426|f||LTE60||t
17152001|NCT02288156|t||||
17152002|NCT02950818|f||||f
17152003|NCT03489109|t||||
17152004|NCT02181790|f||||f
17152005|NCT01178216|f||||f
17152006|NCT00025259|f||OTHER|Must obtain prior approval.|t
17152007|NCT00863772|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152008|NCT01449370|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17152009|NCT00908310|f||||f
17152010|NCT03423186|f||||t
17152011|NCT00534404|t||||
17152012|NCT01307748|f||||f
17152013|NCT02785952|f||||f
17152014|NCT00315731|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152015|NCT04614246|f||LTE60||t
17152016|NCT01680497|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152017|NCT00725205|f||OTHER|Investigators require the SPONSOR'S written permission to publish any information pertaining to the study during and five years after closure of the study.|t
17152018|NCT00602641|f||LTE60||t
17152019|NCT03722589|f||||f
17152020|NCT03408639|f||OTHER|The investigator (PI) may publish results provided a copy of the written publication is received by the sponsor at least 30 days in advance for review and comment. If the parties disagree, PI agrees to meet with the sponsor before submission to resolve any disagreement. It is also agreed that publishing any reports from data is under the condition of the subject's consent. Any reports are highly confidential, and the PI does not have the permission to reveal them without the sponsor's agreement.|t
17152021|NCT00070499|f||LTE60||t
17152022|NCT04648696|f||||f
17152023|NCT03120325|t||||
17152024|NCT01689779|f||||f
17152025|NCT00587860|t||||
17152026|NCT01371747|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17152027|NCT01403051|f||||f
17152028|NCT00573378|t||||
17152029|NCT03831711|t||||
17152030|NCT03760185|f||||f
17152031|NCT02473523|t||||
17152032|NCT00866879|f||||f
17152033|NCT00976911|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166432|NCT05059301|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166433|NCT01164891|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166434|NCT00441142|f||GT60||t
17152034|NCT02954991|f||||f
17152035|NCT00576316|f||LTE60||t
17152036|NCT01342757|f||LTE60||t
17152037|NCT01753557|f||OTHER||t
17152038|NCT01434810|f||||f
17152039|NCT04893018|f||||t
17152040|NCT00242632|f||||f
17152041|NCT01307111|f||||f
17152042|NCT00627861|t||||
17152043|NCT00682357|t||||
17152044|NCT03300843|f||||f
17152045|NCT04482387|t||||
17152046|NCT02252406|t||||
17152047|NCT02533180|f||||f
17152048|NCT00447876|f||||f
17152049|NCT01256944|f||||f
17152050|NCT01609023|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152051|NCT02047734|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one (1) year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene sixty (60) days prior to submission. Investigator must delete confidential information before submission.|t
17152052|NCT03904108|t||||
17152053|NCT01608061|f||||f
17152054|NCT01333397|f||||f
17152055|NCT01085357|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17152056|NCT00435812|f||LTE60||t
17152057|NCT03100123|t||||
17152058|NCT04082338|t||||
17152059|NCT04797221|t||||
17152060|NCT02029196|f||||f
17136843|NCT04030104|f||OTHER|The results of the study are the property of Seno Medical Instruments, Inc. All publications (manuscripts, abstracts or other modes of presentation) must be submitted and reviewed and approved in writing by Seno Medical Instruments, Inc., in advance of submission. The over all study results will first be submitted as a primary paper.|t
17136844|NCT04570657|f||||f
17136845|NCT01072539|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136846|NCT02856269|f||||f
17136847|NCT00115804|t||||
17136848|NCT01752842|t||||
17136849|NCT01683071|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17136850|NCT05092971|t||||
17136851|NCT01968187|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17136852|NCT02020031|t||||
17136853|NCT04047121|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136854|NCT02625324|f||OTHER|"Medtronic owns the data of this clinical study, a single investigation site may access and use the data provided by itself for scientific publications following prior approval by Medtronic.~Pooling data from several investigation sites for publication purposes, national projects and international projects all require prior approval from Medtronic."|t
17136855|NCT01116687|f||LTE60||t
17136856|NCT00424528|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17136857|NCT02395653|f||||f
17136858|NCT00605722|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136859|NCT01042613|t||||
17136860|NCT00165841|f||OTHER||t
17136861|NCT00487084|t||||f
17136862|NCT00254293|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136863|NCT02568345|f||||f
17136864|NCT04031404|t||||f
17136865|NCT01626352|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17136866|NCT05674344|f||GT60||t
17136867|NCT00798655|t||||
17136868|NCT00960934|f||OTHER|Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results of the study associated with their study site independently.|t
17136869|NCT02387372|f||||f
17136870|NCT00848549|f||||f
17152061|NCT01109147|f||OTHER|All results and publications are reviewed by the sponsor and the principle Investigator. None could be released without accordance from both parts.|t
17152062|NCT02952586|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152063|NCT00492778|f||LTE60||t
17152064|NCT00789035|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17152065|NCT01118975|f||LTE60||t
17152066|NCT01072617|f||||f
17152067|NCT00719615|t||||f
17152068|NCT00626808|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17152069|NCT00345943|f||||f
17152070|NCT00789737|f||OTHER|Until coordinated multicenter publication or one year after the study termination, whichever occurs first. After that, submit for Daiichi Sankyo, Inc. (DSI) review and comment at least 45 days before submission. DSI may ask up to 60 additional days, if patentable material is identified.|t
17152071|NCT00384930|f||GT60||t
17152072|NCT02686138|f||GT60||t
17152073|NCT04988087|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152074|NCT02613182|f||OTHER|The PI, institution and the sponsor have agreed that the PI and institution may publish or disclose study results from their site after the earlier of (a) publication of the complete multicenter study results or (b) 18 months after database lock for the multicenter study. The sponsor has at least 45 days to review a proposed publication and may request deletion of confidential information and up to 60 days additional delay to obtain patent protection.|t
17152075|NCT03968978|f||||t
17152076|NCT02064985|f||OTHER|Institution and Principal Investigator may use the Study results (data generated at the site) and shall not publish or present any such results until the earlier of (i) the date of the first Study results publication and (ii) the end of the eighteen (18) month period following the completion, or early termination, of the Study at all participating sites.|t
17152077|NCT02520297|f||OTHER||t
17152078|NCT01326923|t||||
17152079|NCT00351533|f||||f
17152080|NCT02125721|t||||
17152081|NCT00996892|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152082|NCT01653912|f||||f
17152083|NCT01200069|t||||
17152084|NCT02883049|f||LTE60||t
17152085|NCT01784055|f||||f
17152086|NCT01887171|f||||f
17152087|NCT01924754|f||||f
17152088|NCT00826007|f||||f
17196708|NCT00960206|f||OTHER|The disclosure restriction on the PI to publish results of this Clinical Study or the results of the activities hereunder, any abstract, manuscript, presentation or other communication shall be submitted to sponsor for review and approval at least 60 days prior to submission for publication. The sponsor retains the right to deny publication or, at its sole option, to revise the manuscript to delete proprietary or other confidential commercial information.|t
17152089|NCT02245412|f||OTHER|Publication rights are tied to the completion of the multi-center publication|t
17152090|NCT01392963|t||||
17152091|NCT00369486|f||||f
17152092|NCT00402116|f||GT60||t
17152093|NCT04778904|f||OTHER|There is an agreement restricting the right of the Participating Organisation and/or Principal Investigator to publish trial results, which may not be before the first multi-site publication. Following this, Participating Organisation and/or Principal Investigator may publish results, subject to Sponsor's prior review and comment (within 60 days). Sponsor can request a delay of publication up to six (6) months to enable protection of its proprietary information and/or IPR and know-how.|t
17152094|NCT02896712|t||||
17152095|NCT03772717|t||||
17196709|NCT02470806|f||||f
17196710|NCT01147471|f||||f
17152096|NCT04138043|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152097|NCT02856802|f||||t
17152098|NCT01810302|t||||
17152099|NCT03659929|f||||f
17152100|NCT02711878|f||||f
17152101|NCT03092219|f||GT60||t
17152102|NCT05289869|t||||f
17152103|NCT00580788|t||||f
17152104|NCT01443728|t||||
17196711|NCT02579915|f||||f
17196712|NCT01094106|t||||
17196713|NCT03020498|f||||f
17196714|NCT01294644|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17152105|NCT04971187|t||||f
17152106|NCT00547586|f||OTHER|Contact sponsor directly for details.|t
17152107|NCT03743415|f||||f
17152108|NCT01701011|t||||
17196715|NCT03075878|f||OTHER|Sponsor can review results communications at least 60 days prior to public release. Within 30 days of receipt, Sponsor shall advise of any information which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor can require removal of specifically identified Confidential Information (other than Study Data) and/or delay the communication an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17152109|NCT03112642|t||||
17152110|NCT04497948|f||OTHER|"PI shall provide copies of any materials relating to the Study, or the Developed Technologies that either intends to publish or make any presentations relating to, at least 30 days in advance of publication, submission or presentation.~PI shall not include in or shall remove from any proposed publication of any Confidential Information, errors or inaccuracies; and shall withhold publication, submission for publication or presentation for 90 days from the date the Company receives the material."|t
17152111|NCT01125371|t||||
17152112|NCT02242045|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152113|NCT02648932|t||||
17152114|NCT01266031|f||GT60||t
17152115|NCT04036838|f||||f
17152116|NCT00569855|f||||f
17152117|NCT01739699|f||||f
17136871|NCT01842841|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136872|NCT01902953|f||||f
17136873|NCT01248130|t||||
17136874|NCT00305643|t||||f
17136875|NCT02190747|f||||t
17136876|NCT04866303|f||OTHER|The Flathead Tribal Council expects prior approval for any secondary usage of Tribal data uploaded to RADx-UP central repository and coordinating center and maintains the authority to review all publications, conference presentations and other scholarly works prior to dissemination.|t
17136877|NCT01163253|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136878|NCT01188564|f||OTHER|To ensure against inadvertent disclosure of confidential information, the PI will provide Sponsor an opportunity to review any proposed publication/disclosure before it is submitted or otherwise disclosed. The PI will submit proposed manuscript, publication or disclosure to the Sponsor for comment at least 60 days prior to its submission/disclosure. If requested, the publishing party shall remove any Information (other than Study results) prior to submitting or disclosing the materials.|t
17136879|NCT02492997|f||||f
17136880|NCT00579501|f||OTHER|Before submitting the paper or abstract or disclose information to public concerning trabectedin (YONDELIS®), PharmaMar must be provided of 15 days in case of abstract and 30 days in case of full paper, to review and approve the publication to assure that confidential and proprietary data are protected. Primary authorship for publication is hold by the coordinating investigator of this project. Following authors will be named according to the number of patients treated under this protocol.|t
17136881|NCT03025217|t||||
17136882|NCT04069156|f||||f
17136883|NCT02208024|f||||t
17136884|NCT02207556|t||||
17136885|NCT03558555|t||||
17136886|NCT01958125|f||LTE60||t
17136887|NCT00194025|t||||
17136888|NCT00004418|t||||
17136889|NCT04804033|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136890|NCT02130427|t||||
17136891|NCT00258427|t||||
17136892|NCT00543569|f||OTHER|Standard Restriction Description: Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 12 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17136893|NCT04019275|f||||f
17136894|NCT02918409|f||||f
17136895|NCT00781599|t||||
17136896|NCT01202721|f||||f
17136897|NCT02740504|t||||
17136898|NCT00089479|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152118|NCT01708967|f||OTHER||t
17152119|NCT02842073|t||||
17136899|NCT01094717|t||||
17136900|NCT01124448|t||||f
17136901|NCT03198754|f||||f
17136902|NCT00503880|f||||f
17136903|NCT00986310|f||||f
17152120|NCT00195338|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152121|NCT03545893|f||||f
17152122|NCT00005957|t||||f
17152123|NCT03717012|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152124|NCT00900822|f||||f
17152125|NCT01721317|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152126|NCT00706485|t||||
17166435|NCT04952597|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17166436|NCT05730335|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166437|NCT00883168|f||OTHER|"Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.~Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)"|t
17136904|NCT00668200|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17166438|NCT05286658|t||||
17166439|NCT05411822|f||||f
17166440|NCT03352141|f||||f
17166441|NCT02027311|f||||f
17166442|NCT04004221|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17166443|NCT01153711|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17166444|NCT01814397|f||||f
17166445|NCT01178944|t||||
17166446|NCT01939977|f||||f
17166447|NCT01849692|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166448|NCT01253148|t||||
17196716|NCT02188459|t||||
17166449|NCT02952313|f||OTHER|Additional publications are restricted to after publication of the multicenter study results. The only other restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166450|NCT02095873|t||||
17136905|NCT02108951|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17136906|NCT00932152|t||||
17136907|NCT00421343|f||||f
17136908|NCT01580592|f||||f
17136909|NCT03471767|t||||f
17136910|NCT00564954|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary; however, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17136911|NCT00678587|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136912|NCT00116857|f||||f
17136913|NCT00305253|f||OTHER|Local PIs are required to review results with Dr. Miller before releasing.|t
17136914|NCT01785810|f||||f
17136915|NCT03599141|f||||f
17136916|NCT00807846|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136917|NCT01081873|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17136918|NCT00441558|f||||f
17166451|NCT00945529|t||||f
17166452|NCT00792740|f||||f
17166453|NCT04818216|t||||
17196717|NCT01986348|f||||t
17196718|NCT04520321|f||||f
17196719|NCT02935894|t||||
17196720|NCT00853957|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17196721|NCT02158806|f||||f
17196722|NCT02383043|f||||f
17196723|NCT01898299|f||||f
17196724|NCT04895085|t||||
17152127|NCT03366207|f||OTHER|Investigator may publish/present results provided the following are satisfied: (i) Sponsor consents to publication; (ii) Multi-Center Publication published; or at least 18 months since database lock; (iii) investigator must submit proposed publication to Sponsor for review, allowing at least 60 days to review. The Investigator shall delay publication/presentation for up to 45 days to permit the Sponsor time to obtain Intellectual Property protections and protect confidential information.|t
17152128|NCT01651793|t||||
17152129|NCT03907657|t||||
17152130|NCT02130622|f||||f
17152131|NCT03713632|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152132|NCT02806024|t||||
17152133|NCT02892149|f||||t
17152134|NCT01994850|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.|t
17152135|NCT00442962|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17152136|NCT03277066|f||||t
17152137|NCT02756208|t||||
17152138|NCT03774407|f||||f
17152139|NCT04841577|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17152140|NCT01992185|f||GT60||t
17152141|NCT03617783|t||||
17152142|NCT01420965|f||OTHER||t
17152143|NCT02895100|f||OTHER||t
17152144|NCT00339144|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17152145|NCT03280381|f||||f
17152146|NCT02257385|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152147|NCT03279692|t||||
17152148|NCT00575887|f||||f
17152149|NCT02458287|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152150|NCT03149757|t||||
17152151|NCT02800642|f||LTE60||t
17196725|NCT04919499|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152152|NCT02027428|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17152153|NCT00517556|t||||f
17152154|NCT03371459|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17152155|NCT01589497|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17152156|NCT02906241|t||||
17152157|NCT01191827|t||||
17152158|NCT02542605|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152159|NCT00676780|f||||f
17152160|NCT02682927|f||GT60||t
17152161|NCT01613313|f||OTHER||t
17152162|NCT02766283|f||OTHER||t
17196726|NCT04858295|f||||f
17196727|NCT03016091|f||||f
17196728|NCT04520256|f||||f
17196729|NCT03786471|f||||f
17196730|NCT05492786|f||||f
17196731|NCT03346200|f||||f
17196732|NCT02534129|f||||f
17196733|NCT04369664|t||||
17152163|NCT04007991|f||OTHER|PI must consult their clinical trial agreement. In summary, PI shall have the right to publish, present or otherwise use the results for their research publication objectives, provided that such Publication does not disclose Confidential Information. PI shall submit in writing to Sponsor any material at least 90 days for review and comment. Sponsor shall advise PI of any information which is Confidential Information or which may impair Sponsor's ability to obtain patent protection.|t
17152164|NCT05314816|f||||f
17152165|NCT03278626|t||||
17152166|NCT05013008|f||OTHER||t
17196734|NCT03840200|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196735|NCT01298219|f||||f
17196736|NCT05489770|t||||
17196737|NCT05487300|f||||f
17196738|NCT02713217|t||||
17196739|NCT02880293|t||||
17196740|NCT00264576|f||GT60||t
17136919|NCT02491073|f||OTHER|In the event the study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the study at all sites, institution and investigator shall be free to publish|t
17136920|NCT01165021|f||GT60||t
17136921|NCT01419665|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17136922|NCT01655823|f||LTE60||t
17136923|NCT02998554|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136924|NCT02357849|f||||f
17136925|NCT01536119|f||||f
17136926|NCT04095286|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17136927|NCT00810459|f||||f
17136928|NCT02604810|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17136929|NCT01586026|f||||f
17136930|NCT04092816|t||||
17136931|NCT02278640|f||OTHER|The PIs agreed that the first publication of results should be made in conjunction with the presentation of a joint, multicenter publication of the results with all PIs contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could have published the results from their individual sites.|t
17136932|NCT01313520|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor has the right to review and comment on publications, abstracts, slides and manuscripts and on the data analysis and presentation.|t
17136933|NCT03209440|f||||f
17136934|NCT02690207|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136935|NCT00127530|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17136936|NCT04348656|f||||f
17136937|NCT01453569|f||OTHER||t
17136938|NCT00418964|f||||f
17136939|NCT00937560|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17136940|NCT02373241|f||||f
17136941|NCT03364608|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17136942|NCT02239770|t||||
17136943|NCT02546674|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17136944|NCT02520518|t||||
17136945|NCT01397552|f||||f
17136946|NCT02665364|f||||f
17136947|NCT03888391|t||||
17136948|NCT00301028|t||||f
17136949|NCT00423735|f||LTE60||t
17136950|NCT00439673|f||OTHER|PIs of participating centers may disclose their centre's results only after the main study publication has been released, so that a single centre experience can be compared to the study overall results and give a more appropriate view of the study.|t
17136951|NCT00654784|f||||f
17196741|NCT01921166|f||||f
17196742|NCT02470312|f||||f
17136952|NCT01954251|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136953|NCT02864940|t||||
17136954|NCT02581111|f||||f
17136955|NCT02175771|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17136956|NCT01722487|f||||f
17136957|NCT03364673|t||||
17152167|NCT04981717|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17152168|NCT02207634|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152169|NCT00887289|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17152170|NCT00459355|t||||f
17152171|NCT00287586|t||||
17152172|NCT02462291|f||||f
17152173|NCT02495259|t||||
17152174|NCT03106987|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca.|t
17152175|NCT02114385|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17152176|NCT01275729|t||||
17152177|NCT02441660|t||||
17152178|NCT00799825|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152179|NCT00582010|f||GT60||t
17152180|NCT02439970|f||OTHER|Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 90 days to allow Sponsor to seek patent protection.|t
17152181|NCT02640690|t||||
17152182|NCT01520870|f||||f
17152183|NCT04520009|f||||f
17152184|NCT02910011|t||||f
17152185|NCT02463357|t||||
17196743|NCT03976102|f||LTE60||t
17196744|NCT04555694|f||||f
17136958|NCT02232087|f||OTHER|The sponsor reserves the right to the first publication of the results. Following the first publication, or if the sponsor confirms in writing no interest in publishing the results, Quotient Clinical Ltd or the Principal Investigator may proceed to publish results from the study, giving the sponsor 60 days to review the manuscript.|t
17136959|NCT01367301|t||||
17152186|NCT03509857|t||||
17152187|NCT01399658|t||||
17152188|NCT02460679|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17152189|NCT02620579|f||||f
17152190|NCT01277159|t||||
17196745|NCT02834624|t||||
17196746|NCT00092456|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196747|NCT04783389|f||LTE60||t
17196748|NCT00451906|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196749|NCT01250717|f||||f
17196750|NCT02121808|f||||f
17152191|NCT00796107|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196751|NCT01578278|f||OTHER|Contact sponsor directly for details.|t
17196752|NCT04820023|f||||f
17196753|NCT05066230|f||GT60||t
17196754|NCT02164578|f||||t
17196755|NCT02507297|t||||
17196756|NCT01018992|t||||
17196757|NCT03029585|f||||f
17196758|NCT02092285|f||OTHER|The Investigator agrees to provide to the Sponsor 45 days prior to submission, review copies of abstracts or manuscripts for publication that report any results of the trial. The Sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regards to proprietary information, data accuracy, fairness, and compliance with federal regulations.|t
17196759|NCT01825785|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17196760|NCT04721600|f||||t
17196761|NCT01304940|t||||
17196762|NCT00278395|f||LTE60||t
17196763|NCT02494076|f||||f
17196764|NCT03740737|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17196765|NCT00759798|t||||
17196766|NCT01286311|f||||f
17196767|NCT03034863|t||||
17196768|NCT00506025|t||||
17196769|NCT02981953|f||||t
17196770|NCT02889900|f||OTHER|The Institution and the PI are entitled to publish the results of or make presentations related to the study, provided that any publication or presentation to be made within 2 years of study completion require the Company's prior written consent. All publications or presentations shall be consistent with academic standards and International Committee of Medical Journal Editors guidelines, not be false or misleading, comply with all Applicable Laws and not be made for any commercial purpose.|t
17196771|NCT01735214|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17196772|NCT03146845|f||GT60||t
17196773|NCT03403153|t||||
17196774|NCT00185692|t||||
17196775|NCT03029156|f||||f
17196776|NCT00711022|f||LTE60||t
17196777|NCT01535261|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17196778|NCT04812977|f||||f
17196779|NCT03798756|t||||
17196780|NCT01757288|t||||
17196781|NCT01516710|t||||
17196782|NCT02791308|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17196783|NCT03349476|f||||f
17196784|NCT04417907|f||||f
17196785|NCT00674765|t||||
17196786|NCT04421456|f||||f
17196787|NCT00274287|f||LTE60||t
17152192|NCT02681510|f||||f
17152193|NCT04315506|f||||f
17196788|NCT01694199|f||||f
17196789|NCT01777932|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196790|NCT02466958|f||||f
17196791|NCT03400748|f||LTE60||t
17196792|NCT01414192|f||||f
17196793|NCT03031782|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196794|NCT01930188|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigators(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17196795|NCT02514824|f||||f
17196796|NCT03576118|f||||f
17196797|NCT02170207|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17196798|NCT00886834|f||||f
17196799|NCT03122860|f||||t
17196800|NCT03875729|f||OTHER|Sponsor has right to publish multi-center study results first, then PI may publish/present study results after Sponsor had at least 60 days and up to 105 days to review/comment/obtain intellectual property protection, PI has deleted all sponsor-requested references to confidential information, and PI has considered the Sponsor's proposed revisions in good faith and meets with the Sponsor to discuss/ resolve any disagreements regarding accuracy, data analyses or confidential information.|t
17196801|NCT02764320|t||||
17196802|NCT05303324|f||OTHER||t
17196803|NCT01405508|f||GT60||t
17196804|NCT00999336|t||||
17196805|NCT00476957|f||OTHER|For any publication or presentation of the Protected Materials or any portion thereof, a manuscript of the paper, abstract or other materials will be provided by Consultant to Sponsor for its approval at least sixty (60) days for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.|t
17196806|NCT02159352|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196807|NCT01214109|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17196808|NCT04620733|f||||t
17196809|NCT02221934|f||||f
17196810|NCT03565640|t||||
17196811|NCT06149416|f||||f
17196812|NCT02659059|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196813|NCT00230009|t||||
17196814|NCT03072238|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196815|NCT00112827|t||||
17196816|NCT03924193|f||||f
17196817|NCT02489799|f||||f
17196818|NCT04909593|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17196819|NCT01241448|f||GT60||t
17196820|NCT00630409|t||||
17196821|NCT01690000|t||||f
17196822|NCT02165202|f||||f
17196823|NCT04785794|f||OTHER|The first publication of the results of the Study will be made in conjunction with the presentation of a joint, multicenter publication of the Study results with the investigators and the institutions from all appropriate sites contributing data. If such a multicenter publication is not submitted within 24 months after conclusion of the Study at all sites, then Investigator may publish the results from their Site individually,|t
17196824|NCT01689740|f||LTE60||t
17196825|NCT04714359|f||GT60||t
17196826|NCT01773707|f||||f
17196827|NCT01420328|t||||
17196828|NCT00239642|f||LTE60||t
17196829|NCT01655498|f||GT60||t
17196830|NCT02958826|f||||f
17196831|NCT04540952|f||||f
17196832|NCT00950235|f||||f
17196833|NCT02291861|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data|t
17196834|NCT00963924|f||||f
17196835|NCT00237809|f||||f
17136960|NCT02504268|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17136961|NCT04732819|f||||f
17136962|NCT00209170|f||||f
17136963|NCT02108600|t||||f
17136964|NCT03150095|f||||f
17196836|NCT01297595|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196837|NCT01047709|t||||f
17196838|NCT00871715|f||||f
17196839|NCT03015220|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17196840|NCT01673256|f||LTE60||t
17196841|NCT01670526|f||||f
17196842|NCT02291549|f||||f
17196843|NCT04182217|t||||
17196844|NCT01970527|t||||
17196845|NCT01115309|f||LTE60||t
17196846|NCT04447287|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17196847|NCT05700851|t||||
17196848|NCT00613405|f||||f
17196849|NCT02147093|f||GT60||t
17196850|NCT03246724|t||||f
17196851|NCT00655824|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196852|NCT00589628|f||||f
17136965|NCT04032171|f||||t
17136966|NCT02124707|t||||
17136967|NCT00974051|t||||
17136968|NCT00555048|t||||
17136969|NCT01362686|f||||f
17136970|NCT00718666|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136971|NCT03806179|f||LTE60||t
17136972|NCT01952730|t||||
17196853|NCT01862159|f||||f
17196854|NCT00507767|f||LTE60||t
17196855|NCT00663819|f||LTE60||t
17196856|NCT01502813|t||||
17196857|NCT00725959|f||||f
17196858|NCT03032198|f||||t
17196859|NCT02934932|t||||
17196860|NCT01307800|f||GT60||t
17196861|NCT02892019|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196862|NCT00689351|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17136973|NCT02076321|t||||
17136974|NCT00790738|f||||f
17136975|NCT01357915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136976|NCT00757484|f||||f
17136977|NCT01479374|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17196863|NCT01766206|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17136978|NCT01606761|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17136979|NCT05086289|f||||f
17136980|NCT02237157|f||||f
17136981|NCT01062074|f||OTHER|With regard to surveillance results, any publication should be agreed by the sponsor in advance|t
17136982|NCT01996748|f||OTHER|Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.|t
17136983|NCT04533815|f||||f
17136984|NCT02130258|t||||
17136985|NCT03150108|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17136986|NCT01975935|f||||f
17136987|NCT02951988|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17136988|NCT05836818|f||||f
17136989|NCT03011840|t||||
17136990|NCT03738566|t||||
17136991|NCT04539249|f||||f
17136992|NCT05080179|f||||f
17196864|NCT01662505|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196865|NCT01313663|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196866|NCT02255474|f||||f
17196867|NCT02394912|f||OTHER|Principal Investigator shall have the right to publish or otherwise make public any data resulting from the study upon the earlier of (a) publication of a multi-center publication (or any publication, if the Study is not a multi-center study) coordinated by Sponsor with respect to the data resulting from the study, and (b) eighteen (18) months after the Study is completed at all participating sites if a multi-center publication.|t
17196868|NCT04588207|t||||
17196869|NCT01229176|f||OTHER|In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results.|t
17196870|NCT01127737|f||||f
17196871|NCT01082159|f||LTE60||t
17196872|NCT04348357|f||||f
17196873|NCT02736175|f||||f
17196874|NCT02367794|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196875|NCT00882050|f||||f
17196876|NCT02010684|f||||f
17196877|NCT02612285|f||||f
17196878|NCT00805441|f||GT60||t
17196879|NCT02399111|f||||f
17196880|NCT01884571|t||||
17196881|NCT00091572|f||OTHER||t
17196882|NCT01695044|f||||f
17196883|NCT02942771|t||||
17196884|NCT01078402|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17196885|NCT02340806|f||||f
17196886|NCT01186809|f||||t
17196887|NCT00452452|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17196888|NCT01303744|f||||f
17136993|NCT04799405|t||||
17136994|NCT00586924|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17136995|NCT03185455|f||||f
17136996|NCT00626912|f||||f
17196889|NCT02591056|f||||f
17196890|NCT01159600|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17196891|NCT04433091|f||||f
17196892|NCT04097535|t||||
17196893|NCT03070301|t||||
17136997|NCT03483506|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17136998|NCT00127062|t||||
17136999|NCT00621855|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17196894|NCT01975701|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196895|NCT01301183|f||||f
17196896|NCT01072149|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196897|NCT02784834|t||||
17196898|NCT02143713|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196899|NCT04264156|f||OTHER|The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement among Windtree and participating institutions. The publication or presentation of any study results shall comply with all applicable privacy laws, including but not limited to HIPAA.|t
17196900|NCT01768572|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17196901|NCT00080119|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17196902|NCT01062165|f||||f
17196903|NCT01919489|t||||
17196904|NCT01322386|t||||
17196905|NCT03800563|f||||t
17196906|NCT00949234|f||||f
17196907|NCT00871494|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196908|NCT03761849|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196909|NCT02637999|f||||t
17196910|NCT03344458|f||||f
17196911|NCT03840993|f||OTHER||t
17196912|NCT00988429|f||OTHER||t
17196913|NCT01074229|f||||f
17196914|NCT02662023|f||||f
17196915|NCT00825734|f||OTHER||t
17196916|NCT02823574|f||LTE60||t
17196917|NCT00590759|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites|t
17196918|NCT02802111|t||||
17196919|NCT04884191|f||||f
17196920|NCT00022490|t||||
17196921|NCT03845517|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196922|NCT01494467|f||OTHER|At least sixty (60) days prior to submission for publication, presentation or use, the Institution and the Investigator shall submit in writing to the Contract Research Organization and Sponsor for review and comment any proposed oral or written publication, which period may be extended for an additional thirty (30) days if requested in writing by Contract Research Organization and Sponsor.|t
17196923|NCT00417885|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196924|NCT01190436|f||OTHER|"PI shall make no press release, advertising or other promotional written or oral statements to public in connection with any reference to Sponsor's name of any member of Sponsor's staff, or PI, without prior approval of Sponsor or designated agent.~PI and/or Co-I shall not publish any information related to study data/results without first obtaining prior written consent of Sponsor and agrees to submit to Sponsor for review, a copy of any proposed publication resulting from completed study."|t
17196925|NCT02721147|t||||f
17196926|NCT01722097|t||||
17196927|NCT00257309|f||||f
17196928|NCT02009332|f||||f
17196929|NCT01912599|f||||f
17137000|NCT03731364|f||GT60||t
17166454|NCT03206918|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17166455|NCT03823287|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166456|NCT02453750|f||||f
17166457|NCT01170273|t||||
17166458|NCT01673854|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166459|NCT00334737|f||||f
17137001|NCT02953782|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166460|NCT00583752|f||||f
17166461|NCT02316353|f||||f
17166462|NCT04523454|t||||
17166463|NCT05396014|t||||f
17166464|NCT03179982|f||||f
17196930|NCT04739306|f||OTHER||t
17196931|NCT03386344|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17137002|NCT01328158|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196932|NCT03481725|f||||f
17196933|NCT00237718|t||||
17137003|NCT02487901|f||||f
17137004|NCT03260205|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17137005|NCT05301322|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17196934|NCT02991118|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17137006|NCT04211155|t||||
17137007|NCT00430521|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137008|NCT04552535|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137009|NCT05108805|t||||
17196935|NCT00595959|f||||f
17196936|NCT04144088|t||||
17137010|NCT02198651|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137011|NCT02115113|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137012|NCT02622724|f||||t
17196937|NCT02077374|f||LTE60||t
17196938|NCT00446095|f||||f
17137013|NCT00356863|t||||
17137014|NCT00343291|f||GT60||t
17137015|NCT05250830|t||||
17137016|NCT00884052|f||||f
17137017|NCT00839423|f||OTHER|The main publication has to be published before any sub publication. The investigators shall obtain Lundbeck's written approval before publishing any publication relating to Vortioxetine, the Study, the Protocol and/or the results recorded during the Study.|t
17137018|NCT01071096|f||||f
17137019|NCT03377244|t||||
17137020|NCT00756886|t||||
17137021|NCT00941889|f||||f
17137022|NCT01236742|f||||f
17137023|NCT03421964|t||||
17137024|NCT03457103|t||||
17137025|NCT00213980|f||||f
17166465|NCT04148482|f||||f
17166466|NCT05926544|t||||
17196939|NCT00409747|t||||
17196940|NCT03132571|t||||
17196941|NCT01916109|t||||
17196942|NCT03032965|t||||
17196943|NCT00636168|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17196944|NCT02951702|f||||f
17196945|NCT02707952|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196946|NCT02006641|f||||f
17196947|NCT01287832|t||||
17137026|NCT02411201|f||OTHER|"All written or oral papers and publications must have the joint agreement of the investigator and Guerbet.~The Investigator shall not use the sponsor's name in any publication without the prior permission of Guerbet.~Each investigator agrees not to publish/present the evaluation of the main criterion involving only the patients he/she has included.~Any abstract project will be first submitted to Guerbet at least 10 working days before submission to the congress scientific committee."|t
17137027|NCT01260467|f||||f
17137028|NCT00798694|f||||f
17137029|NCT05117229|t||||
17152194|NCT00958893|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17152195|NCT03593395|f||||f
17152196|NCT00741338|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17152197|NCT02995408|t||||
17152198|NCT01098474|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152199|NCT05560386|t||||
17152200|NCT01598194|t||||
17196948|NCT01894503|f||OTHER|There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17196949|NCT04749797|f||||f
17196950|NCT00632736|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196951|NCT01441596|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17196952|NCT01794689|t||||f
17137030|NCT01774344|f||LTE60||t
17137031|NCT03546413|f||||f
17137032|NCT02351258|t||||
17137033|NCT00611897|t||||
17137034|NCT01621672|t||||
17137035|NCT00734734|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137036|NCT01735617|f||||f
17137037|NCT02344407|f||||f
17137038|NCT00992784|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137039|NCT01363713|f||||f
17152201|NCT01654315|f||||f
17152202|NCT05084924|f||||f
17152203|NCT00704132|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17152204|NCT00182325|f||||f
17152205|NCT03417778|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152206|NCT03607487|f||OTHER|Clinical Study Agreement|t
17152207|NCT01141205|t||||
17152208|NCT04052334|t||||
17152209|NCT01898221|f||||f
17152210|NCT01822366|f||||f
17137040|NCT01658579|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17137041|NCT00576251|f||OTHER|Sponsor is allowed 30 days to review publication. With reasonable justification, sponsor may require the publication to be withheld an additional 60 days to obtain patent protection. Sponsor may request deletion of any trade secret, proprietary, or confidential information.|t
17137042|NCT00608530|t||||
17137043|NCT01514188|f||||t
17137044|NCT01019486|f||||f
17137045|NCT01277341|f||OTHER|Please contact sponsor directly for details.|t
17137046|NCT02932332|t||||
17137047|NCT03134313|f||LTE60||t
17137048|NCT05373706|f||||f
17137049|NCT02841787|t||||
17137050|NCT00853333|f||||f
17137051|NCT03029650|f||||f
17137052|NCT03976531|t||||
17137053|NCT01875367|f||LTE60||t
17137054|NCT02754830|f||GT60||t
17137055|NCT03977727|f||||f
17137056|NCT03448718|f||||f
17137057|NCT00603980|f||LTE60||t
17137058|NCT02683525|t||||
17137059|NCT00711269|f||||t
17137060|NCT01627067|t||||
17137061|NCT01700517|f||||f
17137062|NCT00926796|f||||f
17137063|NCT01341652|t||||
17137064|NCT01628016|f||||f
17137065|NCT02410707|t||||
17137066|NCT00632463|f||OTHER||t
17137067|NCT01269372|f||||f
17137068|NCT04146467|f||OTHER||t
17137069|NCT03689504|f||||f
17137070|NCT01934192|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137071|NCT01737840|f||||f
17137072|NCT01189435|t||||
17137073|NCT02118610|t||||
17137074|NCT03637699|f||||f
17137075|NCT03497026|f||OTHER|Study mutually terminated, no data analyzed|t
17137076|NCT03259490|t||||f
17137077|NCT03095521|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However Novartis does not prohibit any inversdtigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137078|NCT00434122|f||OTHER|The only disclosure restiction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17137079|NCT01963208|f||||f
17137080|NCT04191577|f||||f
17196953|NCT01697956|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17196954|NCT05957198|t||||
17196955|NCT03293238|f||||f
17196956|NCT02302157|f||||f
17196957|NCT00736502|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17181792|NCT00634088|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period of 60 days or less from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181793|NCT00499096|t||||
17181794|NCT00422032|f||||f
17196958|NCT00866619|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17196959|NCT00645411|f||GT60||t
17196960|NCT03987074|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17196961|NCT03100370|t||||
17196962|NCT01562275|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196963|NCT01863368|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17196964|NCT04371471|t||||
17196965|NCT01020487|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17196966|NCT04049578|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17196967|NCT01366976|f||||f
17196968|NCT02400749|f||OTHER|Investigator have an obligation to present or publish the results in accordance with GCP, ICH, and the declaration of Helsinki, provided that confidential information and/or proprietary information of the sponsor, not publicly known is not disclosed without prior, written permission from the sponsor.|t
17196969|NCT02240810|f||LTE60||t
17196970|NCT04425252|f||||f
17196971|NCT00307489|f||||f
17196972|NCT03473665|t||||
17196973|NCT02446015|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17196974|NCT04179799|f||||f
17196975|NCT02964234|t||||
17196976|NCT02163499|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17196977|NCT00857311|f||OTHER|"As this study is part of a multicenter trial, publications derived from this study should include input from the principal investigator, his/her colleagues, the other investigators in this trial, and SPONSOR personnel.~The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines."|t
17196978|NCT03512041|f||||f
17196979|NCT00828139|f||LTE60||t
17196980|NCT01714947|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17196981|NCT01922102|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17196982|NCT04343989|t||||
17196983|NCT01123356|t||||
17196984|NCT01074099|f||LTE60||t
17196985|NCT03262389|t||||
17196986|NCT01052272|f||||f
17196987|NCT02450747|f||GT60||t
17196988|NCT01077284|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17196989|NCT01280721|f||||f
17196990|NCT01180400|f||GT60||t
17196991|NCT05188248|t||||
17196992|NCT00096278|f||LTE60||t
17196993|NCT00248794|t||||
17196994|NCT03449979|t||||
17166467|NCT00516893|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17166468|NCT00284557|t||||
17137081|NCT00448916|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137082|NCT01185249|f||||f
17137083|NCT03521193|t||||
17137084|NCT04363437|f||||f
17137085|NCT01810042|f||||f
17166469|NCT05935878|f||||f
17166470|NCT01443364|f||GT60||t
17181795|NCT01256593|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181796|NCT00259090|f||OTHER|AZ shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time request that submission for publication or disclosure of the manuscript be delayed for no more than an additional 45 days in order for AZ to file patent applications.|t
17181797|NCT01841151|t||||
17181798|NCT02689258|f||||f
17181799|NCT00314236|f||OTHER|Disclosure restriction on the Institution/PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is \> 60 days but ≤ 90 days from time submitted to sponsor for review. Sponsor can require changes to communication. Control over publication/presentation shall be extended for maximum of 2 years after termination of Trial, after which Institution/PI shall be free to publish/present without restraint.|t
17181800|NCT00439556|t||||
17181801|NCT03615807|t||||
17181802|NCT01498640|f||OTHER||t
17181803|NCT05544786|t||||
17181804|NCT03065244|f||||f
17181805|NCT03717480|f||||f
17181806|NCT01894152|f||||t
17181807|NCT01708174|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137086|NCT03707158|f||||f
17137087|NCT02773238|f||||f
17137088|NCT01208038|f||||f
17137089|NCT02300077|t||||
17137090|NCT01743963|f||||f
17137091|NCT01877382|f||||f
17137092|NCT03637842|t||||
17137093|NCT03829332|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17137094|NCT04752189|f||||f
17166471|NCT00559845|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181808|NCT01774786|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181809|NCT04903249|t||||f
17181810|NCT03556579|f||GT60||t
17166472|NCT00335283|t||||f
17166473|NCT01406938|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17166474|NCT01576146|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166475|NCT03230890|f||||f
17166476|NCT00878254|t||||
17166477|NCT04995419|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17166478|NCT03086408|t||||
17181811|NCT02965703|f||LTE60||t
17181812|NCT02171260|f||||f
17181813|NCT05218018|t||||
17181814|NCT01062555|t||||
17181815|NCT04964128|f||LTE60||t
17181816|NCT01471379|f||||f
17181817|NCT02120794|f||GT60||t
17181818|NCT01162382|t||||f
17181819|NCT06021951|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17181820|NCT01886807|f||||f
17181821|NCT00026793|f||||f
17137095|NCT03422133|f||||f
17137096|NCT03003403|t||||
17196995|NCT02632747|f||OTHER|"Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17196996|NCT02069379|f||||f
17196997|NCT03195127|t||||
17196998|NCT00700999|t||||
17196999|NCT03651271|f||OTHER|Trial Site and/or Co-Principal Investigators may publish or present Study Data and other results of the Study from the Trial Site individually upon the first to occur of: (i) twelve (12) months after conclusion, abandonment, or termination of the Study at all Affiliated Research Institutions, or (ii) after Parker Institute for Cancer Immunotherapy (PICI) confirms in writing there will not be a multi-site Study publication.|t
17197000|NCT01125436|f||||f
17197001|NCT03444155|f||||t
17197002|NCT00821093|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197003|NCT02432183|t||||
17197004|NCT02877680|t||||
17197005|NCT01133678|t||||
17197006|NCT03424187|t||||
17197007|NCT05104242|t||||
17197008|NCT01864200|f||||f
17197009|NCT02428595|f||GT60||t
17197010|NCT00424476|f||OTHER|For multi-center trials, no investigator will be authorized to publish study results from an individual center until the earlier of the multi-center trial results are published or 12 months after the end or termination of the multi-center trial at all sites. All manuscripts and abstracts must be submitted to the sponsor for review at least 30 days prior to submission for publication or for presentation at a scientific meeting. The sponsor may delay publication for up to 3 months.|t
17197011|NCT02574286|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17197012|NCT01280656|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197013|NCT02138838|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197014|NCT00780741|f||||f
17197015|NCT02993926|f||OTHER|All publications and presentations must be prepared in accordance with this section and the Clinical Study Site Agreement.|t
17197016|NCT00860457|t||||f
17197017|NCT01084772|f||GT60||t
17197018|NCT01867307|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197019|NCT00518206|f||LTE60||t
17197020|NCT00623714|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197021|NCT01199302|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197022|NCT01892007|f||||f
17137097|NCT00296725|f||||f
17137098|NCT05283863|f||||f
17137099|NCT03712345|f||||t
17137100|NCT02943265|f||||f
17137101|NCT02585999|f||||f
17152211|NCT05199090|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197023|NCT03820024|t||||
17197024|NCT01448447|f||||f
17197025|NCT01945593|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17197026|NCT00234832|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17197027|NCT01540474|f||||f
17197028|NCT04454125|t||||f
17197029|NCT01587703|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197030|NCT01799993|f||OTHER|The PI will not make any publication of the results of the Study before the first multi-center publication, unless otherwise agreed upon by the Parties. In the event there is no multi-center publication within eighteen (18) months after a Study has been completed or terminated as all Study sites, Institution and/or Investigator shall have the right to publish the results from the Study at the Institution subject to the guideline laid out in the contacts.|t
17197031|NCT04271254|t||||
17197032|NCT04410445|f||OTHER||t
17197033|NCT01320683|t||||
17197034|NCT00759681|f||||f
17197035|NCT00476151|f||||f
17197036|NCT02962609|f||OTHER|"When the research is published, it has to describe that this research is funded by Istanbul University Scientific Research Project"|t
17197037|NCT01828476|t||||
17197038|NCT04332991|t||||
17197039|NCT02067000|f||||f
17197040|NCT02005484|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197041|NCT01129011|f||OTHER|PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.|t
17197042|NCT02416973|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated is not permitted without the prior written consent of sponsor. Such consent may be contingent on sponsor review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17197043|NCT01767376|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197044|NCT01113541|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197045|NCT03745651|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17197046|NCT00946088|f||||f
17197047|NCT04883541|f||||f
17197048|NCT01383616|f||||f
17197049|NCT01567150|f||LTE60||t
17197050|NCT02309892|f||||t
17197051|NCT01901302|f||OTHER||t
17197052|NCT01124916|f||||f
17197053|NCT05756647|t||||f
17197054|NCT03014726|f||||f
17197055|NCT01029925|f||||f
17197056|NCT05265247|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197057|NCT01368874|f||LTE60||t
17197058|NCT04791917|f||||f
17197059|NCT02790788|t||||f
17197060|NCT00134056|f||||f
17197061|NCT01852175|t||||f
17197062|NCT03816202|f||||f
17197063|NCT02555397|f||||f
17197064|NCT00872339|f||||f
17197065|NCT00537914|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197066|NCT02312258|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197067|NCT01180959|t||||
17197068|NCT01468597|t||||
17166479|NCT03367403|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 30 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166480|NCT00194077|t||||
17197069|NCT02260154|f||LTE60||t
17197070|NCT02684435|t||||
17197071|NCT02561195|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197072|NCT03905512|f||||t
17197073|NCT04990388|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17197074|NCT03560206|t||||f
17197075|NCT05062343|f||||f
17197076|NCT01138969|t||||
17166481|NCT04928885|f||||f
17166482|NCT03470194|t||||f
17166483|NCT03286543|f||||t
17166484|NCT01822899|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197077|NCT03138499|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197078|NCT01334606|f||LTE60||t
17197079|NCT02674399|f||||t
17197080|NCT01661972|t||||
17197081|NCT04313985|t||||
17197082|NCT00835328|t||||
17197083|NCT01175980|f||LTE60||t
17197084|NCT00267774|f||||f
17197085|NCT03444298|t||||
17197086|NCT01634165|t||||
17197087|NCT01857362|f||GT60||t
17197088|NCT02024477|f||||f
17197089|NCT00090064|t||||
17197090|NCT05379400|t||||
17197091|NCT05480410|t||||
17197092|NCT03978130|f||||f
17197093|NCT00515112|t||||f
17197094|NCT01458288|f||GT60||t
17197095|NCT02802176|t||||f
17197096|NCT00304278|t||||
17197097|NCT00409006|f||GT60||t
17197098|NCT00228813|t||||
17197099|NCT00507429|f||||f
17197100|NCT01053897|f||||f
17197101|NCT04025762|f||||f
17197102|NCT01574105|f||||f
17197103|NCT00608959|f||LTE60||t
17197104|NCT04351243|f||OTHER|PIs generally may not publish/present on study results before sponsor's first publication. If there is no sponsor publication within 12-18 months after study completion \[timeframe may vary among PIs\], PIs may publish/present results from only their site, provided the PI submits the publication to sponsor for review. Upon sponsor's request, PIs must delete references to sponsor's confidential information and delay publication to allow sponsor to obtain IP protection.|t
17197105|NCT01005602|t||||f
17197106|NCT01248715|t||||
17197107|NCT01330953|t||||
17197108|NCT03409276|f||||f
17197109|NCT03605745|f||LTE60||t
17197110|NCT01279447|t||||
17197111|NCT01215253|t||||
17197112|NCT00674609|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17197113|NCT03785756|f||||f
17197114|NCT01131325|f||||t
17197115|NCT03884478|t||||
17197116|NCT01272388|t||||
17197117|NCT02213094|t||||f
17197118|NCT01807234|f||||f
17197119|NCT00538629|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197120|NCT02301299|f||||f
17197121|NCT00555620|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197122|NCT05203822|f||||t
17197123|NCT00365599|t||||f
17197124|NCT01345253|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197125|NCT02043652|f||||f
17197126|NCT00547456|t||||
17197127|NCT00648895|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17197128|NCT02865083|f||||f
17197129|NCT00841321|t||||
17197130|NCT02379078|f||||f
17166485|NCT05332392|t||||
17166486|NCT02628405|t||||
17166487|NCT00758069|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166488|NCT00588237|t||||
17166489|NCT02342691|f||||f
17166490|NCT04908865|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166491|NCT01380197|f||||f
17166492|NCT02141399|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17166493|NCT01296711|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. The Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166494|NCT03915574|t||||
17166495|NCT03249909|f||||f
17166496|NCT00606034|f||||f
17166497|NCT02078180|t||||
17166498|NCT01500252|f||||f
17166499|NCT01825512|f||GT60||t
17166500|NCT02466425|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17166501|NCT00435227|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17166502|NCT03231917|f||||f
17166503|NCT01721486|t||||
17166504|NCT00582712|f||||f
17166505|NCT05141175|t||||
17166506|NCT02688829|f||||f
17166507|NCT01901289|f||OTHER|The sponsor can review results communications from PI prior to public release and can embargo communications of trial results between 60 and 180 days from the time submitted to the sponsor for review. The sponsor can embargo publications until the sponsor has published results or 180 days has elapsed after study closure at all participating sites. The sponsor cannot restrict publication but can require changes to protect sponsor's intellectual property rights or other confidential information.|t
17166508|NCT01813058|f||||f
17166509|NCT02777203|f||||f
17166510|NCT00182078|t||||
17166511|NCT00395486|f||LTE60||t
17197131|NCT04908488|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17197132|NCT00212888|t||||
17197133|NCT01894620|f||||f
17197134|NCT00657709|f||GT60||t
17197135|NCT00901459|t||||
17197136|NCT04765046|f||||f
17197137|NCT02741297|f||||t
17197138|NCT00963105|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17197139|NCT04930263|f||||f
17197140|NCT02314000|f||OTHER|Clinical study agreement that restricts PI until official study manuscript is available.|t
17197141|NCT00850993|f||GT60||t
17197142|NCT03839355|t||||
17197143|NCT05607147|t||||
17197144|NCT02499497|f||||f
17197145|NCT03547167|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17197146|NCT02502019|f||||f
17197147|NCT03266419|f||||f
17197148|NCT02009865|f||||f
17197149|NCT01760876|f||||f
17197150|NCT05777772|f||||f
17166512|NCT01076205|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17166513|NCT01145001|t||||
17166514|NCT00893152|t||||
17166515|NCT04731298|f||||t
17166516|NCT01591954|t||||
17166517|NCT06423456|t||||
17166518|NCT00744380|t||||
17166519|NCT02443116|f||||f
17166520|NCT01932372|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166521|NCT01917929|f||OTHER|Each study investigator has independent publication privileges for their own center's results after multi-center publications are submitted. Sponsor requires review of publications. Sponsor shall not edit or influence the publications except to ensure that confidential information is not disclosed, no off-label device use is promoted, and that data is accurately represented. Any publications must be submitted to Stryker for review at least 60 days prior to submission of publication.|t
17166522|NCT00810771|t||||
17166523|NCT05549232|f||OTHER|PI shall provide Sponsor with a copy of the papers, abstracts or presentations not less than thirty (30) days prior to submission to a scientific journal or presentation at scientific meetings. Sponsor shall have thirty (30) days to review the proposed publication. Sponsor may comment upon, but may not make any editorial changes to, the results and conclusions set forth in the papers unless Confidential Information is identified and must be deleted.|t
17166524|NCT03829969|f||||f
17166525|NCT02059499|f||||f
17166526|NCT00703846|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166527|NCT00258908|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17166528|NCT02374060|f||||f
17166529|NCT01700959|t||||
17166530|NCT00830375|f||||f
17137102|NCT00485589|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197151|NCT01517282|f||OTHER|All information supplied by MorphoSys is considered confidential until publication and shall not be disclosed without prior written consent from MorphoSys. No data can be published in any format without prior approval of MorphoSys, which has final decision on approving submissions for publication. In the event of disagreement in the content of a publication, both the Author's and MorphoSys' opinion will be fairly and sufficiently represented in the publication.|t
17197152|NCT00525915|t||||f
17197153|NCT00760877|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17197154|NCT01605435|f||||f
17197155|NCT00711555|t||||
17197156|NCT00946998|f||||f
17197157|NCT03020914|t||||
17197158|NCT02416102|t||||
17197159|NCT00668746|f||||f
17197160|NCT02109172|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17197161|NCT02011568|t||||
17197162|NCT02232009|f||||f
17197163|NCT01816165|t||||
17137103|NCT01369849|f||LTE60||t
17166531|NCT03304054|f||||f
17166532|NCT00782171|f||||f
17166533|NCT04500171|t||||
17166534|NCT02551094|f||GT60||t
17166535|NCT02582814|f||OTHER||t
17197164|NCT04694300|f||||f
17197165|NCT02740517|t||||
17197166|NCT01322347|f||LTE60||t
17197167|NCT00896389|f||||f
17197168|NCT01369147|t||||
17197169|NCT02755948|t||||
17197170|NCT00379210|t||||f
17197171|NCT01525875|t||||
17166536|NCT03530995|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17166537|NCT02058511|f||||f
17166538|NCT00801723|f||OTHER|Contact sponsor directly for details.|t
17166539|NCT01986231|t||||
17166540|NCT01558115|t||||
17166541|NCT01696994|f||LTE60||t
17166542|NCT04644276|f||||f
17166543|NCT00705250|t||||
17197172|NCT01762345|f||OTHER|"The STUDY SITE and PRINCIPAL INVESTIGATOR agree that all data, calculations, interpretations, opinions and recommendations regarding the STUDY (hereinafter referred to as RESULTS) shall be the property of P\&G. The STUDY SITE and PRINCIPAL INVESTIGATOR agree to consider the RESULTS as INFORMATION subject to confidentiality restrictions"|t
17197173|NCT01358175|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166544|NCT02926027|f||||f
17166545|NCT02377752|f||OTHER|Principal investigators are fully restricted to publish any results of the study without sponsor's permission.|t
17166546|NCT01951586|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166547|NCT01558492|t||||
17166548|NCT03454399|t||||
17166549|NCT01222091|f||||f
17166550|NCT06004895|t||||f
17166551|NCT02314156|f||OTHER||t
17166552|NCT02752633|f||||f
17166553|NCT02846389|t||||
17166554|NCT01295840|f||LTE60||t
17166555|NCT00853242|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17197174|NCT05072795|f||||f
17197175|NCT00138645|f||||f
17197176|NCT01107912|f||GT60||t
17197177|NCT01601821|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197178|NCT00834483|t||||f
17197179|NCT01958346|f||||f
17166556|NCT01265563|f||||f
17166557|NCT04998318|t||||
17166558|NCT01257230|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166559|NCT01126268|f||||f
17166560|NCT04026009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166561|NCT01113008|f||||f
17166562|NCT00842153|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166563|NCT00002540|f||LTE60||t
17166564|NCT01345929|f||OTHER|The investigator(s) must undertake not to submit any part of the data from this protocol for publication without the prior consent of Cubist Pharmaceuticals, Inc.|t
17166565|NCT02151903|f||LTE60||t
17166566|NCT04405999|t||||
17166567|NCT05319600|f||||f
17166568|NCT00323960|f||||f
17197180|NCT02562521|f||||f
17197181|NCT02627794|f||||f
17166569|NCT03768089|f||||t
17166570|NCT01780337|t||||f
17166571|NCT02120300|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166572|NCT00787241|t||||f
17166573|NCT00361231|f||||f
17166574|NCT03158740|f||||f
17197182|NCT00442559|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197183|NCT01318356|f||||f
17197184|NCT01508117|t||||
17197185|NCT01597856|f||||f
17197186|NCT01979211|f||||t
17152212|NCT03276078|f||OTHER|Publication and / or presentation whether complete or partial, of any part of the data or results of this study will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the Investigator and AstraZeneca|t
17152213|NCT02552732|f||||f
17152214|NCT02495623|f||OTHER|Investigators do not see trial results ahead of public disclosure unless it is under CDA. Investigators will not be allowed to publish or disclose any study results prior to sponsor communicating it to the public.|t
17152215|NCT02290223|f||||f
17152216|NCT01669603|f||||f
17152217|NCT01004003|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152218|NCT00563576|f||||f
17152219|NCT05819203|f||LTE60||t
17152220|NCT02185053|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152221|NCT01462812|f||OTHER|Found in PI contract.|t
17152222|NCT02521376|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152223|NCT03131544|f||||f
17152224|NCT03844386|t||||
17152225|NCT03597464|f||||f
17152226|NCT01621477|t||||
17152227|NCT02430038|t||||
17152228|NCT00143247|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17152229|NCT00340678|t||||
17152230|NCT05048329|f||||f
17152231|NCT03888066|f||OTHER||t
17152232|NCT01613768|f||||f
17152233|NCT00674739|f||OTHER|For few PIs, there were a restrict that the PI can not publish their trial results with 12 months from the completion of the trial.|t
17152234|NCT01368653|f||||f
17152235|NCT00591773|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17152236|NCT02135614|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152237|NCT03134248|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17152238|NCT01762800|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152239|NCT00478062|t||||
17197187|NCT00753896|f||GT60||t
17197188|NCT02959866|f||||f
17197189|NCT00952523|f||LTE60||t
17197190|NCT00848198|f||||f
17152240|NCT02111603|t||||
17152241|NCT00979199|f||||f
17152242|NCT04204057|f||||f
17152243|NCT01753297|f||||t
17152244|NCT02229474|f||||f
17152245|NCT01174043|t||||
17152246|NCT02646761|t||||f
17152247|NCT00486031|f||||t
17152248|NCT01931878|f||||f
17152249|NCT01645787|t||||
17152250|NCT01371539|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17152251|NCT04902014|t||||
17152252|NCT01783912|f||||f
17152253|NCT01545518|f||||f
17152254|NCT00919126|f||GT60||t
17152255|NCT02032680|t||||
17152256|NCT00687830|t||||
17152257|NCT02784795|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to public release and can embargo communications regarding trial results for a period that is more than 30 days but less than or equal to 90 days from the time the sponsor receives the publication for review. The sponsor can request that the PI hold publishing the communication in order to protect any intellectual property interest at stake.|t
17152258|NCT00295061|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17152259|NCT00595309|f||OTHER||t
17152260|NCT05445492|f||||f
17152261|NCT00191191|f||GT60||t
17152262|NCT03633825|f||||f
17152263|NCT03348163|t||||
17152264|NCT00652340|f||GT60||t
17152265|NCT03682107|f||LTE60||t
17152266|NCT00214383|t||||f
17152267|NCT01890434|f||LTE60||t
17152268|NCT03852537|t||||
17152269|NCT03203681|t||||t
17152270|NCT02655666|f||GT60||t
17152271|NCT01267994|f||||f
17152272|NCT03837743|f||OTHER|The disclosure agreement provides that if sponsor has not submitted a manuscript for publication within 12 months after the date of data lock and analysis at study completion at all sites, the PI can review results communications prior to public release and can embargo communications regarding trial results for a period up to 120 days from the time submitted to the sponsor for review. The PI cannot disclose SPONSOR Confidential Information without prior consent.|t
17152273|NCT01350583|t||||
17152274|NCT01275430|f||||f
17152275|NCT04759768|f||||f
17152276|NCT02996487|t||||
17152277|NCT01130597|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17152278|NCT01301729|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152279|NCT04873934|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152280|NCT05794503|f||||f
17152281|NCT01203020|t||||
17152282|NCT01464931|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152283|NCT00201409|f||||f
17152284|NCT00338728|t||||
17152285|NCT04102189|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17152286|NCT03020537|f||||f
17152287|NCT02933255|f||||f
17152288|NCT03532373|f||||f
17152289|NCT04803305|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152290|NCT03245827|t||||
17152291|NCT00708227|f||||f
17152292|NCT00553735|t||||f
17152293|NCT03654599|f||||f
17152294|NCT02017015|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally sixty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner|t
17152295|NCT03383523|f||OTHER|There is an agreement between the PI and the sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17152296|NCT02291510|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17152297|NCT03765788|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17152298|NCT03203850|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152299|NCT01659125|t||||f
17152300|NCT02126826|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17181822|NCT04151290|f||OTHER|Pub./disc. of the Study(30)days prior to submission for pub./disc. Sponsor to review/comment on the proposed pub./disc. identify any Confidential Information of Sponsor to be deleted from the proposed pub./disc.; protect proprietary rights to Inventions. Sponsor shall provide comments or identify any Confidential Information to be deleted from the proposed pub./disc.(30)day period.Upon Sponsor's reasonable request prior to expiration of the initial thirty (30) day review,Investigator shall delay|t
17152301|NCT02640482|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17152302|NCT01173120|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166575|NCT01208961|f||OTHER|Individual investigators may publish data arising from their own subjects. The PI will provide the Sponsor with copies of written publications (including abstracts and posters)at least 60 days in advance of submission. Data will be reviewed by all participating investigators prior to publication. The Sponsor will have 60 days to review all definitive publications, such as manuscripts and book chapters, and a minimum of 30 days to review all abstracts.|t
17166576|NCT01258790|f||||f
17166577|NCT02241733|t||||
17166578|NCT02285023|f||||f
17166579|NCT01866111|f||||f
17166580|NCT05079347|f||||f
17166581|NCT04576455|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166582|NCT03989349|f||OTHER||t
17166583|NCT01352221|f||||f
17166584|NCT02016716|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166585|NCT02248649|t||||
17166586|NCT01439971|f||OTHER|Catalyst Biosciences has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166587|NCT00722722|t||||
17166588|NCT02628600|f||OTHER|The PI agrees not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated.|t
17166589|NCT00147017|t||||
17166590|NCT02406573|t||||
17166591|NCT01221623|f||OTHER||t
17166592|NCT00875485|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166593|NCT01271010|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166594|NCT01631747|f||||f
17166595|NCT02908685|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166596|NCT03866538|t||||
17166597|NCT02370537|f||OTHER|Each Principal Investigator has signed a Confidential Disclosure Agreement which does not allow them to disclose any study related information for 10 years unless it is publically available.|t
17166598|NCT01691014|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166599|NCT03452033|f||||t
17166600|NCT03045406|f||LTE60||t
17166601|NCT03100539|t||||
17166602|NCT05897242|f||||f
17166603|NCT00809835|t||||
17166604|NCT00066703|f||||f
17166605|NCT01696968|f||LTE60||t
17166606|NCT05659719|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166607|NCT01681186|f||GT60||t
17181823|NCT01449526|f||OTHER||t
17181824|NCT00128921|t||||
17181825|NCT01132495|f||LTE60||t
17181826|NCT00082433|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197191|NCT03708744|f||LTE60||t
17197192|NCT03529942|f||||t
17152303|NCT00113763|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152304|NCT02013817|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152305|NCT03624920|f||GT60||t
17152306|NCT00451204|f||||f
17152307|NCT03055624|f||||f
17152308|NCT01582152|t||||
17152309|NCT02753920|f||||f
17152310|NCT00181714|t||||
17152311|NCT03437031|t||||
17152312|NCT02794870|f||||f
17152313|NCT05676814|t||||
17152314|NCT02237092|t||||
17152315|NCT02559180|f||LTE60||t
17152316|NCT00637494|f||OTHER||t
17152317|NCT01524978|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152318|NCT03066258|f||||t
17152319|NCT02165735|f||||f
17152320|NCT00626561|t||||f
17152321|NCT00101283|f||||f
17152322|NCT00185588|f||||f
17152323|NCT02604407|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17152324|NCT02010645|t||||
17152325|NCT00398866|f||||f
17152326|NCT03094637|f||||f
17152327|NCT00606632|f||LTE60||t
17152328|NCT02481869|f||||f
17152329|NCT00711880|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17152330|NCT02779166|f||||f
17152331|NCT03908437|f||||f
17152332|NCT02370238|f||||f
17166608|NCT05160415|f||||t
17166609|NCT04848220|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166610|NCT02923830|t||||
17166611|NCT01751906|f||LTE60||t
17152333|NCT02819284|f||OTHER|"The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:~(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial."|t
17152334|NCT04342819|t||||
17152335|NCT01569295|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152336|NCT03597295|f||OTHER|Clinical Study Agreement|t
17152337|NCT00879411|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17166612|NCT01110330|f||||f
17166613|NCT04925076|f||||f
17166614|NCT02557100|f||LTE60||t
17166615|NCT03289910|f||LTE60||t
17166616|NCT00510718|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166617|NCT01460875|t||||
17166618|NCT00611442|f||||f
17166619|NCT01511614|t||||
17152338|NCT01884337|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17152339|NCT00428116|f||||f
17152340|NCT02455518|t||||
17152341|NCT01038297|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152342|NCT02125877|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17152343|NCT01044264|f||OTHER||t
17152344|NCT02508935|f||OTHER|Investigators will be part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.|t
17152345|NCT01973595|f||||f
17152346|NCT04581330|t||||
17152347|NCT03901092|f||LTE60||t
17152348|NCT04791514|f||LTE60||t
17152349|NCT01316302|f||||f
17152350|NCT01210612|t||||
17152351|NCT03287843|f||||f
17152352|NCT00710866|f||||f
17152353|NCT00086281|f||OTHER||t
17152354|NCT02881840|f||||f
17152355|NCT03071276|t||||
17152356|NCT03390426|t||||
17152357|NCT02593682|t||||
17152358|NCT01325181|f||||f
17152359|NCT02516553|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152360|NCT01411527|f||||f
17152361|NCT02716727|t||||
17152362|NCT02924727|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152363|NCT03052127|f||OTHER|CSA states sites may publish or publicly disclose the results of the study after disclosure is given to the Sponsor for review at least 60 days prior to the date of submission for publication. Site agrees to discuss with Sponsor with respect to the presentation of study data and timing of the disclosure.|t
17181827|NCT04097821|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17152364|NCT02494180|f||||f
17152365|NCT03694327|t||||
17152366|NCT01982812|f||||f
17152367|NCT04784533|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17152368|NCT00307437|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152369|NCT03006302|t||||f
17152370|NCT00525798|f||GT60||t
17152371|NCT00754546|f||||f
17152372|NCT03316547|f||||f
17152373|NCT00721227|f||||f
17152374|NCT02759692|f||GT60||t
17152375|NCT00451178|f||GT60||t
17152376|NCT01243775|f||||f
17152377|NCT03207867|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152378|NCT02447744|f||||f
17152379|NCT05422625|t||||
17166620|NCT02150057|f||||f
17166621|NCT00489424|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166622|NCT00394251|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it has been more than 2 years since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decided publication would hinder patent applications, Investigator must delay submission for up to 1 year. Investigator must delete confidential information before submission.|t
17181828|NCT02818218|t||||
17181829|NCT04477304|f||||f
17181830|NCT05756790|f||||f
17181831|NCT00947297|f||GT60||t
17181832|NCT00502697|f||||f
17181833|NCT02327429|f||||f
17181834|NCT04076644|t||||
17181835|NCT00589108|t||||f
17181836|NCT03256552|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17181837|NCT02283814|f||OTHER||t
17181838|NCT03722017|t||||
17152380|NCT00916643|f||OTHER|Client may use the results of the study for its own teaching,research,education,clinical and publication purposes without the payment of royalties or other fees.Client shall submit to Sponsor for review, a copy of any proposed publication resulting from the Study at least thirty(30)days prior to the estimated date of publication, and if no response is received within thirty(30)days of the date submitted to Sponsor,it will be conclusively presumed that the publication may proceed without delay.|t
17152381|NCT00678210|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152382|NCT04825912|t||||
17152383|NCT02077140|f||LTE60||t
17152384|NCT01808547|f||OTHER||t
17152385|NCT01009814|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152386|NCT00618371|f||||f
17152387|NCT00836407|t||||f
17152388|NCT03022084|f||||f
17152389|NCT00517881|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152390|NCT01207583|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152391|NCT04933383|f||OTHER|Any publication and disclosure of results of this trial must be consistent with Aquilon Pharmaceuticals publication policy. The rights of the investigator and the sponsor with regard to publication or disclosure of the results of this trial are described in the investigator contract.|t
17152392|NCT00180661|t||||
17152393|NCT01383707|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152394|NCT02968602|t||||
17152395|NCT02129608|f||||f
17152396|NCT03336528|t||||f
17152397|NCT02437903|f||||f
17152398|NCT03834142|f||||f
17152399|NCT00230178|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17152400|NCT02652611|t||||
17152401|NCT03577301|f||||f
17152402|NCT04172597|f||||t
17152403|NCT00794339|f||||f
17152404|NCT01611857|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17152405|NCT02934191|f||||f
17152406|NCT03751007|f||OTHER|Confidentiality and consulting agreements restrict the dissemination of confidential information, but PIs are not restricted to act as a consultant for other companies.|t
17152407|NCT00658879|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152408|NCT00616421|f||||f
17152409|NCT02661217|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152410|NCT02075515|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152411|NCT00378573|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17166623|NCT05791565|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17166624|NCT02388165|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181839|NCT01398566|f||||f
17137104|NCT02924688|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152412|NCT03086486|f||OTHER|"Institution and Principal Investigator shall not publish, present or use the Study Data for its own instruction, research or publication without the prior express written consent of Sponsor. Because the Study is funded, in whole or in part, by the Bill and Melinda Gates Foundation (the Foundation), all peer-reviewed published research relating to the Study must comply with the Foundation's Open Access Policy."|t
17152413|NCT01372748|f||LTE60||t
17152414|NCT00134901|f||||f
17152415|NCT02268877|f||||f
17152416|NCT04238650|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17152417|NCT01807065|t||||
17152418|NCT02789137|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152419|NCT00462904|f||||f
17152420|NCT01685840|f||||f
17152421|NCT01406444|t||||
17152422|NCT01357148|f||||f
17152423|NCT00337181|f||||f
17152424|NCT04036110|t||||
17152425|NCT04252092|f||||t
17152426|NCT00537511|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation.|t
17152427|NCT01252277|t||||
17152428|NCT00246324|f||||f
17152429|NCT02006732|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152430|NCT03516513|f||||f
17152431|NCT01098487|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152432|NCT00345631|f||GT60||t
17152433|NCT00447993|f||||t
17152434|NCT01885195|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152435|NCT00548093|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152436|NCT04616547|f||||t
17152437|NCT02936180|f||||f
17181840|NCT03026257|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17181841|NCT04380857|t||||
17197193|NCT01989156|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17197194|NCT00349713|f||||f
17197195|NCT01721109|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17197196|NCT04362176|t||||
17181842|NCT00838201|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17181843|NCT01442363|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17181844|NCT04296006|f||||f
17181845|NCT06134817|t||||
17152438|NCT00509795|f||OTHER|After completion of the trial, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review; provided that the sponsor can remove confidential or proprietary information from such communications. The sponsor cannot require other changes to the communication and cannot extend the embargo.|t
17181846|NCT01193907|f||OTHER|In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results.|t
17181847|NCT02151448|t||||
17152439|NCT03764618|f||||t
17152440|NCT03023176|f||||f
17152441|NCT00912912|t||||
17152442|NCT00306995|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152443|NCT03102606|f||||f
17152444|NCT01277601|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152445|NCT00974922|f||||f
17152446|NCT00841828|f||||f
17152447|NCT04974749|f||||t
17152448|NCT00362336|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17152449|NCT04414618|f||OTHER|There are disclosure agreements between the Sponsor and each of the participating clinical sites and PI that slightly differ.|t
17152450|NCT01474200|f||OTHER||t
17152451|NCT01121562|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152452|NCT04152863|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17152453|NCT01297985|f||||f
17152454|NCT00196326|f||OTHER|The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.|t
17152455|NCT04237272|f||||f
17152456|NCT02797171|f||||f
17152457|NCT02540083|f||||f
17152458|NCT01427608|f||||f
17152459|NCT03993379|f||OTHER||t
17152460|NCT05044195|f||OTHER|"Seqirus will generally support publication of multicenter studies only in their entirety and not as individual center data.~Seqirus must be notified of any intent to publish data collected from the study and prior approval from Seqirus must be obtained prior to submission for publication."|t
17152461|NCT02292940|f||||f
17152462|NCT04289363|t||||
17152463|NCT02585778|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17152464|NCT00504751|t||||
17152465|NCT00445432|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17152466|NCT02054338|f||||f
17152467|NCT01482312|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17152468|NCT01699815|f||||f
17152469|NCT01085760|t||||
17152470|NCT03225001|f||||f
17152471|NCT02281422|f||OTHER||t
17152472|NCT00356525|f||GT60||t
17152473|NCT00799058|f||||f
17152474|NCT03639779|f||||f
17152475|NCT02088697|f||||f
17152476|NCT00810511|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17152477|NCT01295320|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152478|NCT02614924|t||||
17152479|NCT01012336|t||||
17181848|NCT01987427|f||||f
17152480|NCT00911300|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152481|NCT00794508|f||||f
17152482|NCT04642404|t||||
17181849|NCT01073865|f||OTHER|PIs cannot disclose trial results without prior approval in writing by the sponsor.|t
17181850|NCT00805766|f||OTHER||t
17181851|NCT00600756|f||||f
17181852|NCT04503564|f||||f
17152483|NCT01128543|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152484|NCT01941498|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17152485|NCT00396565|f||OTHER|Without prior notification to the sponsor, the PI cannnot dislose trial results and related documents of trials to a third party.|t
17152486|NCT04324021|f||LTE60||t
17152487|NCT03097991|t||||
17152488|NCT00299130|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152489|NCT02211417|f||||t
17152490|NCT01198132|f||OTHER|The first publication will be publication of results of the analysis of primary endpoint(s) that will include data from all trial centers. Any publications and presentations of results, either in whole or in part, by investigators or their representatives will require pre-submission review by the sponsor/CRO. Sponsor will not suppress or veto publications, but maintains right to delay publication in order to protect intellectual property rights.|t
17152491|NCT01755091|f||||f
17152492|NCT02252354|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17152493|NCT02350816|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17152494|NCT04700137|t||||
17152495|NCT00839254|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152496|NCT04460560|f||||f
17152497|NCT00789997|f||||f
17152498|NCT03859765|f||||f
17152499|NCT02374138|t||||
17152500|NCT00464438|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152501|NCT00489827|f||||f
17152502|NCT02296931|f||||f
17152503|NCT01590277|t||||
17152504|NCT04386616|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152505|NCT01377012|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17152506|NCT02159079|f||||f
17152507|NCT04380961|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17166625|NCT00880269|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197197|NCT00742560|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17197198|NCT02438410|t||||f
17197199|NCT01426217|t||||
17197200|NCT01536795|f||||f
17197201|NCT01812837|f||||f
17197202|NCT05866887|f||||f
17197203|NCT05008224|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors requirements.|t
17197204|NCT05234632|f||LTE60||t
17197205|NCT00658632|f||||f
17197206|NCT03800602|f||||f
17197207|NCT02991456|t||||
17197208|NCT01699178|f||GT60||t
17197209|NCT01664806|t||||
17197210|NCT00738400|f||LTE60||t
17197211|NCT02312245|t||||
17197212|NCT00508144|t||||
17197213|NCT00442507|t||||
17197214|NCT02070640|t||||
17197215|NCT01045057|f||||f
17152508|NCT00805961|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17152509|NCT01862484|f||||f
17152510|NCT01632280|f||||f
17152511|NCT00993421|f||GT60||t
17152512|NCT05410964|t||||
17152513|NCT03736031|t||||
17152514|NCT02215967|f||||f
17152515|NCT02254265|f||||t
17152516|NCT01954745|f||||f
17152517|NCT00352417|f||OTHER|The PIs agreed to allow the sponsor 30 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable.|t
17152518|NCT01496976|t||||
17152519|NCT05938621|f||||f
17152520|NCT03598790|f||GT60||t
17166626|NCT03462927|f||LTE60||t
17152522|NCT02555254|f||||f
17152523|NCT02638090|t||||
17152524|NCT03686488|t||||
17152525|NCT06075277|f||OTHER|Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152526|NCT05292183|f||||f
17152527|NCT03325101|t||||
17152528|NCT05573763|f||||f
17152529|NCT04324073|t||||
17152530|NCT03975491|t||||
17152531|NCT05833139|t||||
17152532|NCT00371033|f||||f
17152533|NCT03922529|f||||f
17152534|NCT02506153|f||LTE60||t
17152535|NCT03128060|f||||f
17152536|NCT06400238|f||LTE60||t
17152537|NCT06419907|t||||
17152538|NCT02311933|f||LTE60||t
17152539|NCT05929651|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17152540|NCT02260570|f||||f
17152541|NCT05026177|f||OTHER|The Institution and PI must request review and comment of any proposed publication by the sponsor at least 90 days prior to submission of the publication. The sponsor will advise of any information which is confidential information or which may impair the sponsor's ability to obtain patent protection, and has the right to require confidential information or factual errors to be removed, or to delay the proposed publication by an additional 90 days to allow the sponsor to seek patent protection.|t
17152542|NCT04856917|f||OTHER||t
17152543|NCT01169337|f||LTE60||t
17152544|NCT04008030|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17152545|NCT03560037|t||||
17152546|NCT04034927|f||LTE60||t
17152547|NCT06831760|t||||
17152548|NCT03996447|f||OTHER||t
17152549|NCT03816878|f||||f
17152550|NCT03355469|t||||f
17152551|NCT01708941|f||LTE60||t
17152552|NCT01575548|f||LTE60||t
17152553|NCT04175912|f||LTE60||t
17152554|NCT03952585|f||LTE60||t
17152555|NCT02048813|f||LTE60||t
17152556|NCT01708954|f||LTE60||t
17152557|NCT06400251|f||LTE60||t
17152558|NCT04158245|t||||
17152559|NCT03631199|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152560|NCT03785600|t||||
17152561|NCT03842228|f||LTE60||t
17152562|NCT02567435|f||LTE60||t
17152563|NCT06390826|f||LTE60||t
17152564|NCT05612685|f||||f
17152565|NCT06390839|f||LTE60||t
17152566|NCT04458922|f||LTE60||t
17152567|NCT05849454|t||||
17152568|NCT06351371|f||LTE60||t
17152569|NCT03651700|t||||
17152570|NCT05064384|f||||f
17166627|NCT01289275|t||||f
17152572|NCT01272037|f||LTE60||t
17152573|NCT04856930|f||OTHER||t
17152574|NCT03965689|f||LTE60||t
17152575|NCT03104400|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17152576|NCT04948333|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152577|NCT01625988|f||OTHER|Arteaus Therapeutics executed the contracts and trial, and the Principal Investigators are restricted by any original contractual disclosure restrictions or agreements with Arteaus Therapeutics.|t
17152578|NCT01495702|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166628|NCT01667224|f||||f
17166629|NCT00316225|f||GT60||t
17166630|NCT02710981|f||||f
17152579|NCT01644617|f||OTHER|The investigator agrees not to publish or publicly present any interim results without the prior written consent of the sponsor. The Sponsor has the opportunity to review all proposed abstracts, manuscripts, presentations, or data analyses regarding this trial 45 days prior to submission for publication/presentation. The sponsor has the right to review and comment with regard to proprietary information, accuracy, and compliance with FDA regulations.|t
17152580|NCT05246670|f||||f
17152581|NCT05879991|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152582|NCT04152291|t||||
17152583|NCT05124691|f||LTE60||t
17152584|NCT05831774|t||||
17152585|NCT04223752|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17152586|NCT04759703|t||||
17152587|NCT03985852|f||||f
17152588|NCT04345913|f||LTE60||t
17152589|NCT04877457|t||||t
17152590|NCT00490841|f||GT60||t
17152591|NCT02503787|f||OTHER|The disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 90 days.|t
17152592|NCT03648853|f||||f
17152593|NCT00174954|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17152594|NCT01320150|f||||f
17152595|NCT00919854|f||GT60||t
17152596|NCT04842292|t||||
17197216|NCT03122548|f||OTHER|The only disclosure restriction is that study results will first be published in a joint multi-center paper unless (a) written confirmation is provided to the site or PI indicating that there will be no multi-center publication, or (b) at least 12 months have passed after the completion of data analysis at all study sites. Publications will be submitted for sponsor review ≥ 30 days prior to the publication date. Sponsor cannot require changes to the communication or extend the embargo.|t
17197217|NCT03677986|f||||f
17197218|NCT02332889|f||||f
17197219|NCT00424502|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197220|NCT04448561|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17197221|NCT05356130|t||||
17197222|NCT03141177|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197223|NCT02680314|f||||f
17197224|NCT03523897|f||||f
17197225|NCT05349123|f||||f
17197226|NCT01107717|t||||
17197227|NCT03696342|f||||t
17197228|NCT04077437|f||||f
17197229|NCT05361304|f||GT60||t
17152597|NCT02687529|f||||f
17152598|NCT03698019|f||LTE60||t
17152599|NCT00588770|f||LTE60||t
17152600|NCT01856192|f||LTE60||t
17152601|NCT02642042|f||LTE60||t
17152602|NCT04976621|t||||
17152603|NCT05992623|t||||
17152604|NCT03348631|f||LTE60||t
17152605|NCT06184399|t||||
17152606|NCT06376682|f||OTHER|"As mentionned in the protocol: Prior to submitting the results of this study for publication or presentation, the investigator will have to receive the formal validation by the sponsor on the publication manuscript or presentation. In accordance with generally recognized principles of scientific collaboration, co-authorship with any sponsor personnel will be discussed and mutually agreed upon before submission of a manuscript to a publisher."|t
17152607|NCT05223920|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors (ICMJE) authorship requirements.|t
17152608|NCT03790657|t||||
17152609|NCT03509467|t||||
17152610|NCT02829918|t||||
17152611|NCT04151667|t||||
17152612|NCT05320406|t||||
17152613|NCT06132763|f||||f
17152614|NCT06101264|t||||
17152615|NCT03071406|f||||f
17152616|NCT03617458|f||||f
17152617|NCT04186845|f||||f
17152618|NCT03431493|t||||
17152619|NCT03290079|t||||
17166631|NCT01280058|f||LTE60||t
17166632|NCT01942668|f||GT60||t
17166633|NCT02363972|f||||f
17166634|NCT01334216|f||||f
17166635|NCT01491789|f||||f
17166636|NCT03497975|f||||f
17166637|NCT02209545|t||||f
17166638|NCT01205061|f||OTHER||t
17166639|NCT00765037|f||LTE60||t
17166640|NCT01320553|f||OTHER||t
17152620|NCT04487067|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152621|NCT06385483|f||LTE60||t
17152622|NCT04697069|f||||t
17152623|NCT05180227|t||||
17152624|NCT04739800|f||LTE60||t
17152625|NCT02779855|t||||
17152626|NCT01546454|f||||f
17152627|NCT01906515|t||||
17152628|NCT04787627|f||||f
17152629|NCT00985491|f||||f
17152630|NCT03514017|t||||
17152631|NCT06360081|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152632|NCT07112885|f||||f
17152633|NCT05192889|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17152634|NCT01290302|f||||t
17152635|NCT04140032|f||||f
17152636|NCT02905240|f||||f
17152637|NCT01769456|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications, and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17152638|NCT02923232|f||GT60||t
17152639|NCT05490771|f||LTE60||t
17152640|NCT01221207|f||||f
17152641|NCT00661193|f||||f
17152642|NCT03001453|f||||f
17152643|NCT02862730|t||||
17152644|NCT03685344|f||||f
17152645|NCT03474874|f||||f
17152646|NCT03126435|f||LTE60||t
17152647|NCT02969421|t||||
17152648|NCT03971474|f||LTE60||t
17152649|NCT00261950|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152650|NCT01375946|f||OTHER|Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL16 study is required prior to publication submission.|t
17197230|NCT02409732|f||||f
17197231|NCT03015961|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17152651|NCT01937871|f||GT60||t
17152652|NCT05273411|t||||
17152653|NCT00577863|f||GT60||t
17181853|NCT03261947|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17181854|NCT03969992|f||||t
17181855|NCT02063737|f||||f
17152654|NCT03154125|t||||
17152655|NCT01412086|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152656|NCT05061420|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17152657|NCT02859142|t||||f
17181856|NCT02319005|f||LTE60||t
17181857|NCT03373383|f||GT60||t
17181858|NCT03317431|t||||
17181859|NCT04649775|t||||
17152658|NCT02466685|f||||f
17152659|NCT01255137|f||||f
17152660|NCT03010683|t||||
17152661|NCT05299528|t||||
17152662|NCT03307226|t||||
17152663|NCT01070953|f||||f
17152664|NCT02445963|f||||f
17152665|NCT01957176|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152666|NCT02359994|f||OTHER|Investigators will postpone single-site publications until after publication or disclosure of data representative of the entire study (i.e., from all study sites).|t
17152667|NCT00207883|t||||
17152668|NCT04597632|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152669|NCT01823835|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152670|NCT03017612|f||OTHER|The investigator agreed to hold this information in confidence and not to disclose it to any third parties for a period of three years from the date of this agreement, or until this information becomes a matter of public knowledge or until a formal agreement for that purpose has been entered into by the parties.|t
17152671|NCT04895982|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152672|NCT01893346|f||OTHER||t
17152673|NCT02213289|t||||
17152674|NCT01449812|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152675|NCT01866098|t||||
17152676|NCT04239027|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152677|NCT03449446|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17152678|NCT01319500|t||||f
17152679|NCT01579747|f||||f
17152680|NCT04182334|f||||f
17152681|NCT02839707|f||LTE60||t
17152682|NCT01950390|f||LTE60||t
17152683|NCT01059786|f||||f
17152684|NCT04021238|t||||
17152685|NCT02586688|f||||f
17166641|NCT01988662|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166642|NCT03503591|f||||f
17197232|NCT00376259|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197233|NCT03734588|f||||t
17197234|NCT01877720|f||||f
17197235|NCT00447499|f||||f
17197236|NCT02068352|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17197237|NCT01286870|f||||f
17197238|NCT03960437|t||||
17197239|NCT01732419|f||||f
17197240|NCT00473512|f||LTE60||t
17197241|NCT00267956|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17197242|NCT01263223|f||GT60||t
17197243|NCT02246647|f||LTE60||t
17197244|NCT04387773|f||||f
17152686|NCT02454608|f||||f
17197245|NCT01012999|t||||
17197246|NCT03557307|t||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17197247|NCT04175834|t||||
17152687|NCT04721808|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152688|NCT00573261|f||||f
17152689|NCT02185339|t||||
17152690|NCT01602068|f||OTHER||t
17166643|NCT03070171|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166644|NCT03374683|f||||f
17152691|NCT00599248|f||GT60||t
17166645|NCT01471028|f||||t
17152692|NCT02969382|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17152693|NCT01250210|f||OTHER|All publications must be reviewed and approved by sponsor|t
17152694|NCT02847260|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17152695|NCT02871011|f||||f
17152696|NCT00886015|t||||f
17152697|NCT01692626|t||||
17152698|NCT00855894|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152699|NCT03395288|t||||
17152700|NCT01983566|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152701|NCT00743717|f||||f
17152702|NCT00444587|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152703|NCT00582660|f||||f
17152704|NCT02229461|f||OTHER||t
17152705|NCT01720225|f||||f
17152706|NCT01473407|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152707|NCT04071405|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152708|NCT02422797|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152709|NCT00369941|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17152710|NCT01027702|f||||f
17152711|NCT00403585|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152712|NCT03514966|t||||
17152713|NCT04019626|f||||f
17152714|NCT02964312|f||GT60||t
17152715|NCT02276807|t||||
17152716|NCT01103492|f||||f
17152717|NCT01023035|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts.|t
17152718|NCT00524420|f||||f
17152719|NCT01090414|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17152720|NCT00897910|t||||
17166646|NCT01812213|f||||f
17166647|NCT00610857|t||||
17137105|NCT00174785|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such publication for comment at least 45 days before any submission for publication. If requested by the Sponsor, any submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17137106|NCT00274768|t||||f
17137107|NCT00120289|f||||f
17166648|NCT04826094|f||||f
17166649|NCT05312697|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166650|NCT04445519|f||||t
17166651|NCT00832598|t||||
17166652|NCT00586716|t||||
17166653|NCT02241655|t||||f
17137108|NCT01754922|t||||
17137109|NCT00882102|t||||
17152721|NCT03127514|f||||f
17152722|NCT04080739|t||||
17152723|NCT02665221|f||||f
17152724|NCT03408171|f||||f
17152725|NCT02413229|f||||t
17152726|NCT02932462|f||||t
17152727|NCT02652949|f||OTHER|"Medtronic owns the data of this clinical study, a single investigation site may access and use the data provided by itself for scientific publications following prior approval by Medtronic.~Pooling data from several investigation sites for publication purposes, national projects and international projects all require prior approval from Medtronic."|t
17152728|NCT05219448|f||||f
17152729|NCT02287922|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki and will require prior review and written agreement of the Sponsor.|t
17152730|NCT00668317|t||||
17152731|NCT01565356|f||GT60||t
17152732|NCT01894087|f||||f
17152733|NCT02411916|f||||f
17152734|NCT05534061|t||||
17152735|NCT01027598|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17152736|NCT01814553|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152737|NCT04138823|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152738|NCT04868500|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17152739|NCT02676765|t||||
17152740|NCT03340974|f||OTHER|A copy of the proposed study manuscript for publication, presentation or other disclosure must first be forwarded to Sponsor not less than 30 days prior to submission for review and comment. PI agrees to delete or revise references to confidential information upon Sponsor's request and PI agrees to to consider all other comments of Sponsor in good faith.|t
17152741|NCT02391987|t||||
17152742|NCT03473015|t||||
17152743|NCT01199146|f||||f
17152744|NCT01330303|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152745|NCT01107197|f||||f
17152746|NCT03548337|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152747|NCT01911273|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Pfizer at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17152748|NCT01855828|t||||t
17166654|NCT04590404|f||||f
17166655|NCT00177294|f||||f
17166656|NCT04154605|f||||t
17166657|NCT05352412|f||||f
17166658|NCT06359028|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166659|NCT04382586|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17166660|NCT02425956|f||||f
17166661|NCT03236909|f||GT60||t
17166662|NCT03479541|f||||f
17166663|NCT00661726|f||||f
17166664|NCT03088930|t||||
17166665|NCT02109432|t||||
17166666|NCT02920528|f||||f
17166667|NCT01375127|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197248|NCT03184519|f||||f
17197249|NCT04239911|t||||
17137110|NCT01944969|f||||f
17152749|NCT03649347|f||||f
17152750|NCT03629080|f||||f
17152751|NCT00224289|t||||
17152752|NCT02517463|f||||f
17152753|NCT00727597|f||||f
17152754|NCT02890355|f||LTE60||t
17152755|NCT01128179|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17152756|NCT00134004|f||||f
17152757|NCT00289120|f||||f
17152758|NCT00720382|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. Authorship will be determined by mutual agreement.|t
17152759|NCT04514679|f||||f
17152760|NCT03956355|f||||t
17152761|NCT03999996|f||||t
17152762|NCT01433055|f||||f
17152763|NCT02717455|f||||t
17152764|NCT00486525|t||||
17152765|NCT00233948|t||||
17152766|NCT01728844|f||OTHER|Institution will submit the manuscript of the proposed publication to Sponsor at least 30 days prior to publication, and Sponsor shall have the right to review and comment upon the publication in order to protect Sponsor's confidential information. Upon Sponsor's written request, publication will be delayed up to 60 additional days to enable Sponsor to secure adequate intellectual property protection on Sponsor's intellectual property that would be affected by said publication.|t
17152767|NCT03573830|t||||
17152768|NCT00733005|f||GT60||t
17152769|NCT01068548|t||||
17152770|NCT02465398|f||GT60||t
17152771|NCT05244122|t||||
17152772|NCT03410056|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17152773|NCT00266630|f||GT60||t
17152774|NCT03525886|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17152775|NCT03284723|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152776|NCT00615199|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152777|NCT01216735|t||||
17152778|NCT05239611|f||||f
17152779|NCT00764881|f||OTHER|Institution must ensure Discloser gives 40 days notice of proposed Publication to Sponsor who may within 40-day period: provide comments, Institution must consider such comments but is not bound to follow them; request delay of Publication for 120 days to allow Sponsor to file patent applications or take other measures to preserve its proprietary rights, Institution must abide by request; request Discloser remove specified Confidential Information, Institution must remove such Information.|t
17152780|NCT03450473|f||||f
17152781|NCT01153425|f||||f
17152782|NCT01232452|f||GT60||t
17152783|NCT05024747|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152784|NCT03022370|f||||f
17152785|NCT00699816|f||||f
17152786|NCT00371436|t||||
17152787|NCT02454933|f||OTHER|The PI shall provide AstraZeneca with an opportunity to review/comment on drafts of any publication, review article or presentation (Publication) and shall afford AstraZeneca the opportunity to review the final draft of the Publication before its submission. The PI shall give AstraZeneca up to 45 days to respond with any proposed corrections and shall delete any confidential information before submission. If requested the PI shall delay submission for an additional period, not more than 60 days.|t
17152788|NCT01311687|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to submission; Celgene shall complete its review within 60 days after receipt. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of patentable material.|t
17152789|NCT01526655|f||||f
17137111|NCT00310388|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137112|NCT00868959|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17152790|NCT04753216|t||||
17152791|NCT02142608|f||||f
17152792|NCT00955929|t||||
17152793|NCT05211726|t||||
17152794|NCT02040077|f||||f
17152795|NCT02683421|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and make modifications to the publication.|t
17152796|NCT00344448|t||||
17137113|NCT00848250|f||||f
17152797|NCT02565511|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152798|NCT04807400|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17152799|NCT04805515|f||||f
17152800|NCT00706589|f||OTHER||t
17152801|NCT03076775|t||||
17152802|NCT01696760|t||||
17152803|NCT01332292|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152804|NCT03295630|t||||
17152805|NCT02324582|f||||f
17152806|NCT03541317|t||||
17152807|NCT01487525|f||||f
17152808|NCT04650204|t||||
17152809|NCT01061476|f||LTE60||t
17152810|NCT04388553|f||||f
17152811|NCT02123446|f||GT60||t
17152812|NCT02864355|f||||f
17152813|NCT04502212|f||GT60||t
17152814|NCT00125515|t||||f
17152815|NCT03048552|f||||f
17152816|NCT02448368|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17152817|NCT01958073|f||||f
17152818|NCT01734161|t||||
17152819|NCT01182376|f||||f
17152820|NCT02487225|t||||
17152821|NCT04208750|f||||f
17152822|NCT04977479|t||||
17152823|NCT05680740|f||||t
17152824|NCT04460885|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17152825|NCT04559347|t||||
17152826|NCT05377749|t||||
17152827|NCT00064987|f||||f
17152828|NCT01214655|f||GT60||t
17152829|NCT05256134|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152830|NCT03870880|f||OTHER|The sponsor does not object to publication by the Institution of the results of the Trial based on information collected/generated by the Institution. The Institution will provide Sponsor an opportunity to review any proposed publication before it is submitted. If the Trial is part of a multi-center trial, the Institution agress that the first publication is to be a joint publication involving all Trials sites.|t
17152831|NCT01567462|t||||
17152832|NCT01977417|f||||f
17152833|NCT03182933|f||||f
17152834|NCT03397589|f||||f
17152835|NCT03242408|f||OTHER||t
17152836|NCT02548156|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181860|NCT04753164|f||OTHER|Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17152837|NCT01068262|f||OTHER|The SPONSOR has the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17152838|NCT01439581|f||||f
17152839|NCT02301390|f||||f
17152840|NCT02121652|f||||t
17152841|NCT05584189|f||||f
17152842|NCT01037452|f||LTE60||t
17152843|NCT04108299|t||||
17152844|NCT04123405|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17152845|NCT00247676|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17181861|NCT00694369|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181862|NCT01015586|f||||f
17152846|NCT00662649|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."|t
17152847|NCT03594071|f||GT60||t
17152848|NCT01026194|f||OTHER||t
17152849|NCT01750190|f||OTHER|"The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.~The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).~FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total)."|t
17152850|NCT04584684|t||||
17152851|NCT02955212|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17152852|NCT02009722|t||||
17152853|NCT00545714|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/ or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152854|NCT02664181|t||||
17152855|NCT01113723|f||||f
17152856|NCT04428034|f||||f
17152857|NCT02319317|f||||f
17152858|NCT00560391|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17152859|NCT02556801|f||||f
17152860|NCT03668808|f||||f
17152861|NCT04362670|f||||f
17152862|NCT05274178|t||||
17152863|NCT02839772|f||||f
17152864|NCT02001987|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152865|NCT01965860|t||||
17152866|NCT02526667|f||OTHER|Confidential information based on contract.|t
17152867|NCT00972374|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152868|NCT02288325|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152869|NCT00717288|f||||f
17152870|NCT04020887|t||||
17152871|NCT04347993|t||||
17152872|NCT03519087|f||||f
17152873|NCT00548470|f||||f
17152874|NCT02374346|f||||f
17152875|NCT01137071|f||LTE60||t
17152876|NCT04194645|t||||
17152877|NCT03656744|f||||f
17181863|NCT00907374|f||||f
17181864|NCT02457403|t||||
17181865|NCT02871739|t||||
17181866|NCT03818516|t||||
17181867|NCT01642238|t||||
17181868|NCT04372602|t||||
17181869|NCT00594464|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17181870|NCT03458130|f||OTHER|Publication of the results by the PI will be subject to mutual agreement between the PI and the Sponsor.|t
17181871|NCT00775437|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181872|NCT01183975|f||LTE60||t
17181873|NCT02907359|f||OTHER||t
17152878|NCT03104855|f||||f
17152879|NCT03910673|f||LTE60||t
17152880|NCT00098774|f||LTE60||t
17152881|NCT02290405|f||||f
17152882|NCT03142191|f||LTE60||t
17152883|NCT01277211|f||OTHER|The sponsor must have the opportunity to review and comment on data analysis and presentation for all abstracts, manuscripts, and slide presentations that report any results of this trial 45 days prior to the submission for publication or presentation.|t
17152884|NCT02536846|f||||f
17152885|NCT02593110|f||||f
17152886|NCT04604795|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17152887|NCT00611624|t||||
17152888|NCT00719186|f||||f
17152889|NCT03022916|f||||f
17152890|NCT00111241|t||||
17152891|NCT02096744|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17152892|NCT04912232|t||||
17152893|NCT01994785|t||||
17152894|NCT00952731|t||||
17152895|NCT01450683|f||||f
17152896|NCT02108912|f||||f
17152897|NCT00625872|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152898|NCT00852202|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17152899|NCT02972892|f||LTE60||t
17152900|NCT05022212|f||||t
17152901|NCT01682811|f||||f
17152902|NCT02694328|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17152903|NCT05789576|f||||t
17152904|NCT04100018|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17152905|NCT05736861|t||||
17152906|NCT00879255|f||||f
17152907|NCT03860974|t||||
17152908|NCT02653625|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152909|NCT02090725|t||||
17152910|NCT01499095|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17152911|NCT02037425|t||||
17166668|NCT01716039|f||OTHER|The PI of this Investigator-Initiated study had right to prior publication. If PI did not commence publication within 12months after the close of trial at all sites or after PI's manuscript was accepted for publication, whichever occurs first, the Sub-I and Sub-Institution were free to publish or present, provided that the Sub-I provided to the PI any doc. to be submitted for publication at least 30days prior to the planned date of submission for publication to permit a review of the Manuscript.|t
17152912|NCT00221338|t||||f
17152913|NCT04358081|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17152914|NCT01130532|f||GT60||t
17152915|NCT02762929|f||||f
17152916|NCT02656303|f||||f
17152917|NCT05021900|f||||f
17152918|NCT01842438|t||||
17152919|NCT01622257|t||||
17152920|NCT00782626|f||||f
17152921|NCT04909853|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152922|NCT04054765|f||||f
17152923|NCT01198769|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17152924|NCT00077207|f||||f
17166669|NCT03713398|t||||
17166670|NCT00623233|f||GT60||t
17152925|NCT00853099|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17152926|NCT01811472|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17152927|NCT03280264|f||||f
17152928|NCT02574832|f||||f
17152929|NCT02738138|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17152930|NCT00645970|f||||f
17152931|NCT01995513|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152932|NCT03105518|t||||
17152933|NCT05387889|t||||
17152934|NCT03345771|t||||
17152935|NCT02045446|t||||
17152936|NCT02071225|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152937|NCT00567008|t||||f
17152938|NCT01769248|f||||f
17152939|NCT00280735|f||GT60||t
17152940|NCT01895777|f||||f
17152941|NCT02064296|t||||
17152942|NCT03606343|f||||f
17152943|NCT03044028|f||||f
17152944|NCT04149821|t||||
17152945|NCT00218387|t||||
17152946|NCT00918866|f||||f
17152947|NCT03885661|t||||
17152948|NCT02607046|t||||
17152949|NCT01472692|t||||
17152950|NCT03735121|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152951|NCT03138655|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17152952|NCT03151304|f||||t
17152953|NCT01783886|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17152954|NCT04542057|f||||t
17152955|NCT00104572|t||||
17152956|NCT00940316|t||||
17152957|NCT03897634|f||||f
17152958|NCT00796757|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17152959|NCT04309617|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152960|NCT01924559|f||||f
17152961|NCT02016183|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17152962|NCT00996489|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17152963|NCT00825786|f||||f
17152964|NCT00770328|t||||
17152965|NCT01130493|f||||f
17181874|NCT01405963|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17181875|NCT01805024|f||OTHER|Cooperative Research and Development Agreement|t
17152966|NCT03452943|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17152967|NCT03730207|f||OTHER||t
17152968|NCT00879086|f||OTHER||t
17152969|NCT02286843|t||||
17152970|NCT03172494|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17152971|NCT02764151|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152972|NCT03086551|f||||f
17152973|NCT02614274|f||||f
17152974|NCT02201277|f||||f
17152975|NCT00489255|f||||f
17152976|NCT03485352|f||||f
17152977|NCT01512160|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152978|NCT02084160|t||||
17152979|NCT01260701|f||LTE60||t
17152980|NCT04536376|f||||f
17152988|NCT05355532|t||||f
17152989|NCT04205812|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17152991|NCT05221320|f||||f
17152992|NCT06473519|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17152994|NCT03184571|f||||t
17152996|NCT04582149|t||||
17152997|NCT02514447|f||||t
17153002|NCT04903288|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17153003|NCT03713593|f||OTHER|"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."|t
17153004|NCT04776148|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17153005|NCT03130777|f||||t
17153007|NCT03367572|t||||f
17153008|NCT05849259|f||||f
17166671|NCT01811485|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17166672|NCT01545934|f||||f
17181876|NCT03023085|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17181877|NCT04371380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17197250|NCT01580306|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197251|NCT03823794|f||||f
17197252|NCT00584909|t||||
17197253|NCT03345407|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197254|NCT00065611|t||||
17197255|NCT02256553|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation.|t
17197256|NCT02092909|f||OTHER|The Idera staff in collaboration with the Investigator will be responsible for writing presentations and manuscripts for publication. Investigators will not be allowed to publish or present the data from this study without prior agreement with Idera.|t
17197257|NCT03436797|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17197258|NCT02955225|f||||f
17197259|NCT04626128|f||OTHER|All information concerning CLS1002-101 and the operations of Clearside Biomedical, Inc. are considered CONFIDENTIAL and shall remain the sole property of Clearside Biomedical Inc. The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17197260|NCT01182285|f||||f
17197261|NCT02137603|t||||
17197262|NCT01951105|f||||f
17197263|NCT03209492|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197264|NCT04463004|f||||f
17197265|NCT02604199|f||||f
17197266|NCT02812706|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17197267|NCT01532830|f||LTE60||t
17197268|NCT02465632|f||OTHER|Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the Sponsor.|t
17197269|NCT01648491|f||||f
17166673|NCT03654404|f||||f
17166674|NCT03215758|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166675|NCT02003638|t||||f
17166676|NCT04115748|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166677|NCT00713349|f||LTE60||t
17166678|NCT03764631|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197270|NCT03166215|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17197271|NCT02632045|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.|t
17153015|NCT02498613|f||LTE60||t
17153016|NCT05168202|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17153017|NCT05109611|t||||
17153021|NCT02731638|t||||
17153023|NCT05626231|t||||
17153025|NCT06195930|f||OTHER|CONSULTANT agrees that it will nit use the Confidential Information, which consultant is required hereunder to keep confidential, for any purposes other than the provision of services, without first entering into a written agreement signed by the consultant and Bayer covering the use thereof.|t
17153033|NCT05878093|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17153034|NCT04995029|f||OTHER|The Investigator will not disseminate, present or publish any of the study data without the prior written approval from Indivior to do so.|t
17153036|NCT06227052|f||||f
17153037|NCT03690388|f||OTHER|Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤ 60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.|t
17153039|NCT02487966|f||||f
17153042|NCT04589247|f||||f
17153043|NCT03915652|t||||
17181878|NCT01113632|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17181879|NCT00738972|f||||f
17137114|NCT02938585|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17153045|NCT03041311|f||OTHER||t
17153053|NCT01295112|f||||f
17153054|NCT04182490|f||||f
17153056|NCT03071692|f||||t
17153057|NCT00295893|t||||
17153059|NCT03934541|f||||f
17153061|NCT02673775|t||||f
17153063|NCT02441686|f||||f
17181880|NCT00680901|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17181881|NCT04544293|f||||f
17181882|NCT01951157|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review|t
17181883|NCT04809220|f||GT60||t
17181884|NCT01429272|f||||f
17181885|NCT03035955|t||||
17181886|NCT00329407|t||||
17181887|NCT00978068|f||||f
17181888|NCT01048723|t||||
17153071|NCT03282916|f||||f
17153072|NCT03164616|f||||t
17153077|NCT04768686|f||OTHER||t
17153078|NCT05934396|t||||
17153087|NCT06018129|f||||t
17153088|NCT04917861|f||||t
17153089|NCT06389487|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153092|NCT04004403|f||||f
17166679|NCT01200407|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single enter publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166680|NCT03299881|t||||
17166681|NCT01505673|f||||f
17166682|NCT01549886|f||||f
17166683|NCT00473668|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166684|NCT03195660|f||||f
17166685|NCT03713294|t||||
17166686|NCT05260073|f||||t
17166687|NCT03458910|f||||f
17166688|NCT04484649|t||||
17166689|NCT02731820|t||||
17181889|NCT04258605|f||LTE60||t
17181890|NCT04222712|f||OTHER||t
17181891|NCT04052542|t||||f
17166690|NCT01450696|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166691|NCT00967694|f||||f
17166692|NCT05742646|f||||f
17166693|NCT02321319|f||||t
17166694|NCT02249091|f||||f
17166695|NCT00433966|f||||f
17181892|NCT01070316|f||||f
17181893|NCT01712256|f||OTHER|The Sponsor (or designee) will prepare a final report on the study. The Investigator may not publish or present any information on this study without the express written approval of the Sponsor. Additionally, the Sponsor, may, for any reason, withhold approval for publication or presentation.|t
17166696|NCT02570152|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166697|NCT02957747|f||||f
17166698|NCT00960011|t||||
17166699|NCT00632827|f||||f
17166700|NCT01177553|f||||f
17166701|NCT03560752|t||||
17166702|NCT03931382|t||||
17166703|NCT05623475|f||||f
17166704|NCT00542490|t||||
17166705|NCT03316118|f||||f
17166706|NCT03115827|f||||f
17166707|NCT00778375|t||||
17166708|NCT01671293|f||||f
17166709|NCT02445014|f||||f
17166710|NCT01002235|f||||t
17166711|NCT00675441|t||||f
17166712|NCT01581021|f||||f
17166713|NCT01006655|f||||f
17166714|NCT01232504|f||||f
17166715|NCT00054327|t||||
17166716|NCT00700882|f||LTE60||t
17166717|NCT00683930|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166718|NCT02591537|f||||f
17166719|NCT01454505|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166720|NCT04154293|f||||f
17166721|NCT02487654|f||||f
17166722|NCT03814382|f||||f
17166723|NCT02152371|f||GT60||t
17166724|NCT04084366|f||||f
17166725|NCT05596734|f||OTHER|Sponsor (or its agents) has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166726|NCT04113018|t||||
17166727|NCT00079391|t||||
17181894|NCT00543764|t||||f
17181895|NCT00748215|t||||
17181896|NCT04944901|f||LTE60||t
17181897|NCT02138461|f||||f
17181898|NCT03200899|f||||f
17181899|NCT04646499|t||||
17181900|NCT04866771|t||||
17181901|NCT05083442|t||||
17181902|NCT03878316|f||||f
17153093|NCT06389396|f||||t
17153094|NCT04479852|f||OTHER||t
17153095|NCT00001521|t||||
17153096|NCT01917682|f||||f
17153097|NCT00970593|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153098|NCT04176250|f||OTHER||t
17153099|NCT04090125|t||||
17153100|NCT01121250|f||||f
17153101|NCT01342081|f||||f
17153102|NCT02790437|f||OTHER|"At the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Hansa Medical AB.~Any confidential information relating to the IMP or the study, including any data and results from the study will be the exclusive property of Hansa Medical AB. The investigator and any other persons involved in the trial will protect the confidentiality of the proprietary information belonging to Hansa Medical AB."|t
17153103|NCT01608100|f||GT60||t
17153104|NCT01202175|t||||
17153105|NCT03440840|t||||
17153106|NCT04720053|t||||
17153107|NCT01942993|f||||f
17153108|NCT02143128|f||||f
17153109|NCT01350271|f||OTHER|Release after two years after completing trial|t
17153110|NCT02906670|f||LTE60||t
17153111|NCT01349192|f||||f
17153112|NCT03749330|f||||f
17153113|NCT01973439|f||LTE60||t
17153114|NCT05027308|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153115|NCT02038010|t||||
17153116|NCT02144714|f||||t
17153117|NCT01275846|f||||f
17153118|NCT03908125|f||LTE60||t
17153119|NCT02262325|t||||
17153120|NCT02815995|t||||
17153121|NCT01071915|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17153122|NCT00114140|t||||
17153123|NCT00387335|f||LTE60||t
17153124|NCT00666328|f||OTHER|The site agrees that it will not publish until the earlier of presentation and publication of results or until 12 months after study conclusion. The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted to the sponsor for review in order to allow sponsor time to file any patent applications. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153125|NCT05064397|f||||f
17153126|NCT02232984|f||||f
17153127|NCT03164538|f||||f
17153128|NCT00535405|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153129|NCT03404674|f||||f
17153130|NCT03091179|t||||
17153131|NCT00129545|f||LTE60||t
17153132|NCT00523939|t||||
17153133|NCT02765256|t||||
17153134|NCT02969044|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153135|NCT02263963|t||||
17153136|NCT04728802|t||||
17153137|NCT00262028|f||GT60||t
17153138|NCT01176513|f||||f
17153139|NCT03714919|t||||
17153140|NCT02308124|f||||f
17153141|NCT01329900|t||||
17153142|NCT05275920|t||||
17153143|NCT04233073|f||||t
17153144|NCT00143390|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153145|NCT00041132|f||||f
17153146|NCT03417687|f||OTHER|Independent analyses and/or publication of trial results by the PI is not permitted without prior written consent of the sponsor. Written permission to investigators to publish results is contingent on review by the sponsor of the methodology and statistical analyses used. The PI must submit all manuscripts to the sponsor at least 60 days prior to submission for review.|t
17153147|NCT03997851|t||||
17181903|NCT03711162|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17181904|NCT01554891|f||||f
17181905|NCT03034954|f||||f
17153148|NCT00681031|f||OTHER|The investigator shall send to Sanofi Pasteur MSD for approval any of the publication and/or communication draft, in whatever forms (abstracts, manuscripts, texts). Sanofi Pasteur MSD shall have 60 (sixty) days to review the draft, have reserves if any, and formulate its refusal to the draft in whole or in part if the draft contains confidential data, may prejudice to Sanofi Pasteur MSD patent/intellectual property rights and/or is not compliant with the study results.|t
17153149|NCT00995774|t||||
17153150|NCT03420521|t||||
17153151|NCT03953612|t||||
17153152|NCT04277962|t||||
17153153|NCT02028676|f||||f
17153154|NCT00773474|f||||f
17153155|NCT03008174|t||||f
17153156|NCT04359797|t||||
17153157|NCT03691727|f||||f
17153158|NCT03200717|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17153159|NCT03051672|f||||f
17153160|NCT03126448|t||||
17153161|NCT04211831|f||OTHER|The Sponsor does not object to publication by Institution or Principal Investigator (PI) of results of the Trial based on information collected or generated by the Institution or PI. However, the Institution and PI are required to provide the Sponsor with an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed to ensure against any inadvertent disclosure of Sponsor Confidential Information or unprotected Sponsor Inventions.|t
17153162|NCT00397514|f||||f
17153163|NCT02833337|t||||
17153164|NCT01256879|t||||
17153165|NCT01328184|t||||
17153166|NCT01959295|f||||t
17153167|NCT02698033|t||||
17153168|NCT01611779|f||||f
17153169|NCT03475992|f||||t
17153170|NCT01191450|f||||f
17153171|NCT03493685|f||OTHER||t
17153172|NCT03300817|f||LTE60||t
17153173|NCT00265759|t||||
17153174|NCT03122730|f||||t
17153175|NCT01581437|f||||f
17153176|NCT03729596|f||LTE60||t
17153177|NCT04467840|f||GT60||t
17153178|NCT04408183|f||||f
17153179|NCT05126693|t||||
17153180|NCT04483583|t||||
17153181|NCT04761926|f||||f
17153182|NCT04011722|f||OTHER|Principal Investigators are bound by the Abbott Investigator Agreement, which includes confidentiality clauses and limits what study details and data they are permitted to share and/or publish without prior authorization from Abbott.|t
17153183|NCT05061134|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB.|t
17153184|NCT01013077|t||GT60||t
17153185|NCT04848480|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17153186|NCT01368497|f||OTHER|"From the Publications and Presentations policy Disagreements between the HBRN Steering Committee and the NIDDK on the merits of journal submission of a specific manuscript will be mediated through discussion on Steering Committee conference calls, ad hoc conference calls or during face to face Steering Committee meetings. The decision of the NIDDK is final and cannot be appealed."|t
17153187|NCT01383720|f||OTHER|The Principal Investigator (PI) shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to the Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17153188|NCT02366689|f||GT60||t
17153189|NCT03283566|t||||
17153190|NCT03718832|f||||f
17153191|NCT01231646|f||||f
17153192|NCT00128401|t||||
17153193|NCT03288714|f||||f
17153194|NCT04882241|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17153195|NCT00074308|f||LTE60||t
17153196|NCT02521415|t||||
17153197|NCT02543944|t||||f
17153198|NCT02203357|t||||f
17153199|NCT01648530|f||||f
17153200|NCT01561716|t||||f
17153201|NCT00629018|t||||
17153202|NCT00200902|f||||f
17153203|NCT00470535|t||||
17153204|NCT05262387|f||GT60||t
17153205|NCT02070965|f||GT60||t
17153206|NCT02515331|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153207|NCT00124748|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153208|NCT00322712|t||||
17153209|NCT03889886|f||OTHER|All information concerning SDP-4 and the operations of Silk Technologies, such as patent applications, formulas, manufacturing processes, basic scientific data or formulation information not previously published, are considered CONFIDENTIAL and shall remain the sole property of Silk Technologies. The Investigator agrees to use this information only in accomplishing this study and will not use it for other purposes without the written consent of Silk Technologies|t
17153210|NCT04004481|t||||f
17153211|NCT00758524|f||OTHER|Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17181906|NCT02340299|t||||
17166728|NCT02791516|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153212|NCT01339403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166729|NCT02620878|f||||f
17166730|NCT02664311|f||||f
17166731|NCT01101958|f||LTE60||t
17166732|NCT00107900|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site's proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.|t
17166733|NCT02644096|t||||
17166734|NCT02461290|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166735|NCT00526656|t||||
17166736|NCT03224403|f||LTE60||t
17166737|NCT00569309|t||||
17166738|NCT01456195|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17166739|NCT02547038|t||||
17153213|NCT03983980|f||||t
17137115|NCT01850745|f||||f
17153214|NCT00354913|t||||
17153215|NCT03901313|f||||f
17153216|NCT04747470|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17153217|NCT02481206|f||||f
17153218|NCT00769379|f||LTE60||t
17153219|NCT01928472|f||GT60||t
17153220|NCT01308424|f||GT60||t
17153221|NCT01253902|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153222|NCT01841593|t||||
17153223|NCT00307086|t||||f
17153224|NCT00312338|f||LTE60||t
17153225|NCT02553772|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153226|NCT02216097|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153227|NCT03785327|f||||f
17153228|NCT02198963|f||OTHER|Disclosure Agreement|t
17153229|NCT00736632|f||||f
17153230|NCT00281957|f||LTE60||t
17153231|NCT01876446|t||||
17153232|NCT05329259|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153233|NCT03180645|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153234|NCT01808573|f||||f
17153235|NCT02208089|t||||
17153236|NCT01244503|f||GT60||t
17166740|NCT01340625|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17166741|NCT01668628|f||||f
17166742|NCT05081167|f||||t
17166743|NCT01842035|f||||f
17153237|NCT00972595|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153238|NCT03629184|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153239|NCT01461538|f||GT60||t
17153240|NCT00141778|f||||f
17153241|NCT02729909|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153242|NCT02730663|f||||t
17153243|NCT02046603|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153244|NCT05101343|f||||f
17153245|NCT02461160|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17153246|NCT00061932|f||LTE60||t
17153247|NCT02899962|f||OTHER|LEO Pharma acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO Pharma retains the right to have any publication submitted to LEO Pharma for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO Pharma.|t
17153248|NCT01245283|t||||f
17153249|NCT02153983|t||||
17153250|NCT01610492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153251|NCT01982955|f||OTHER||t
17197272|NCT01613599|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197273|NCT02091102|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17153252|NCT04599075|f||||f
17153253|NCT00768248|t||||
17153254|NCT01547390|f||||f
17153255|NCT01459783|f||||f
17153256|NCT00640315|f||OTHER|The Investigator may prepare the data derived from the Trial for publication. Such data will be submitted to the Sponsor for review at least 60 days prior to submission for publication. The Sponsor should respond within 50 days after receipt of the manuscript. The Investigator agrees that all reasonable comments made by the Sponsor in relation to a proposed publication will be incorporated. Confidential data provided by the Sponsor may not be published without written approval of the Sponsor.|t
17153257|NCT04927845|f||||f
17153258|NCT01004744|t||||f
17153259|NCT05201794|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17153260|NCT06082843|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153261|NCT05473182|f||||t
17166744|NCT00734604|f||GT60||t
17166745|NCT02589665|f||GT60||t
17197274|NCT01075815|f||OTHER||t
17197275|NCT00617708|f||LTE60||t
17197276|NCT02058992|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153262|NCT02732730|f||||f
17153263|NCT00118157|f||LTE60||t
17166746|NCT00978380|f||OTHER|At the end of the trial, one or more scientific publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17166747|NCT00327015|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166748|NCT01519791|f||GT60||t
17153264|NCT05989672|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153265|NCT00696423|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153266|NCT00443729|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153267|NCT03989102|t||||
17153268|NCT03642262|f||||f
17153269|NCT01365819|t||||
17153270|NCT01582490|f||||f
17153271|NCT01783990|f||||f
17153272|NCT03503669|f||||f
17153273|NCT04793711|f||||f
17153274|NCT01050530|f||||f
17153275|NCT02288312|f||OTHER||t
17153276|NCT01276041|t||||
17153277|NCT00485264|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17153278|NCT00276484|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153279|NCT02440464|f||||f
17153280|NCT01626690|t||||
17153281|NCT04688671|f||OTHER|The only disclosure restriction on the PI is that the PI will provide the sponsor with a copy of any proposed communication at least 90 days in advance of the proposed submission or presentation date. Within this 90 day period, the sponsor will review the communication to determine whether it contains any sponsor Confidential Information, or whether the sponsor desires to file patent applications on subject matter contained therein, and to ensure the accuracy of the information.|t
17153282|NCT01525329|f||||f
17153283|NCT02414958|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153284|NCT01269918|f||||f
17197277|NCT03503188|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153285|NCT03571828|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153286|NCT04442464|t||||
17153287|NCT05767905|t||||
17153288|NCT03762239|t||||
17153289|NCT04471428|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153290|NCT03645863|f||OTHER||t
17153291|NCT06372210|f||||f
17197278|NCT03867396|f||LTE60||t
17153292|NCT02171195|f||OTHER||t
17153293|NCT04660331|f||||f
17153294|NCT03112473|f||||f
17153295|NCT03624192|f||||f
17153296|NCT02635984|t||||
17153297|NCT01640249|f||GT60||t
17166749|NCT00837265|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17166750|NCT01289353|t||||
17166751|NCT02226562|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166752|NCT03257202|t||||
17153298|NCT00291317|t||||
17153299|NCT00890617|t||||
17153300|NCT01776632|f||||f
17153301|NCT01870778|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17197279|NCT03747575|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197280|NCT00321555|f||||f
17153302|NCT00708110|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153303|NCT00613171|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17153304|NCT00951496|f||LTE60||t
17153305|NCT04201197|f||||f
17153306|NCT03123068|t||||
17153307|NCT00786409|t||||
17153308|NCT00610129|t||||
17153309|NCT04851873|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153310|NCT00950365|t||||
17153311|NCT01184079|f||||f
17153312|NCT01263938|f||||f
17153313|NCT02905032|t||||
17153314|NCT03220854|t||||
17153315|NCT02085447|f||||f
17153316|NCT01500473|t||||
17153317|NCT00193050|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17166753|NCT01474772|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166754|NCT00223808|t||||
17166755|NCT00152477|f||GT60||t
17197281|NCT01107795|t||||
17197282|NCT04407442|t||||
17197283|NCT02907489|f||||f
17197284|NCT02066389|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153318|NCT03672227|t||||
17153319|NCT00866359|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 45 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential data before submission or defer publication to permit patent applications.|t
17153320|NCT00550459|f||||f
17153321|NCT01625091|t||||f
17197285|NCT00762853|f||LTE60||t
17153322|NCT02163057|f||OTHER||t
17153323|NCT00445146|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17153324|NCT00625820|f||||f
17153325|NCT01243957|f||GT60||t
17153326|NCT03759392|f||||f
17166756|NCT00614445|f||OTHER|No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. No publications or communications involving the results of the trial are authorized without prior review and written consent from the sponsor. The investigator must agree to send the sponsor for review prior to their submission. The sponsor reserves the right to delete from such materials any part or parts deemed to be confidential or proprietary.|t
17153327|NCT02623725|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17153328|NCT02548143|f||||f
17153329|NCT05954988|f||||f
17153330|NCT02360215|f||OTHER|Must obtain prior Sponsor approval.|t
17153331|NCT02603146|f||||f
17153332|NCT05351164|t||||
17153333|NCT04452669|f||||f
17166757|NCT01467037|f||||f
17166758|NCT01194089|t||||
17166759|NCT01626118|f||||f
17166760|NCT00888329|t||||
17166761|NCT00939029|t||||
17166762|NCT00142168|f||||f
17166763|NCT01421303|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166764|NCT06003777|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166765|NCT01106651|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17166766|NCT03397394|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17166767|NCT00613327|f||||f
17166768|NCT00118248|f||LTE60||t
17166769|NCT00869791|f||||f
17166770|NCT00932438|f||||f
17166771|NCT00290771|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166772|NCT00005901|t||||f
17166773|NCT02661737|f||OTHER||t
17166774|NCT03403361|t||||
17166775|NCT03641716|t||||f
17166776|NCT02247011|t||||
17166777|NCT00656058|f||||f
17166778|NCT03718884|f||GT60||t
17166779|NCT04700540|f||||f
17166780|NCT03515551|f||||t
17166781|NCT05818956|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17166782|NCT02265536|f||GT60||t
17166783|NCT03268954|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17166784|NCT03802630|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166785|NCT05005013|t||||
17166786|NCT06099223|f||||f
17166787|NCT02488135|f||||f
17166788|NCT01802580|t||||f
17166789|NCT00211757|t||||f
17153334|NCT06418529|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153335|NCT04653454|t||||
17153336|NCT03620708|t||||
17153337|NCT05525520|f||LTE60||t
17153338|NCT03176134|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17166790|NCT04091581|f||||f
17166791|NCT02889289|t||||
17153339|NCT03657797|f||||t
17153340|NCT02760004|t||||f
17153341|NCT01094704|f||LTE60||t
17153342|NCT00245518|t||||
17166792|NCT03724981|f||GT60||t
17166793|NCT03804021|f||OTHER|Disclosure restrictions on the PIs are that Sponsor can review communications by the PI prior to public release and can embargo communications regarding trial results for varying time periods from the time submitted to the sponsor for review. The Sponsor may require changes to the communication after review and may delay publication upon request by the Sponsor to allow the Sponsor to seek/obtain patent protection.|t
17153343|NCT01332487|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153344|NCT00654095|f||OTHER|"Principal Investigator (PI) agrees, for a period of 5 years following the Effective Date, to retain the Disclosure made to it by or on behalf of Sponsor (SPKK), in confidence and not to disclose it to any third party.~PI further agrees that during such time period it will not, either directly or indirectly, use the Disclosure for any purpose(s) other than that indicated herein without the prior written consent of SPKK."|t
17153345|NCT01431079|f||LTE60||t
17153346|NCT03565900|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17153347|NCT02423200|f||OTHER|"Clinical study was conducted at at clinical pharmacology unit owned by a contract research organization (CRO; Parexel) that was contracted by the sponsor to conduct the study. Site principal investigator is an employee of a contract research organization. As per the contract, the sponsor has all rights, title and interest in the results."|t
17153348|NCT01999920|f||||f
17153349|NCT03805386|t||||
17153350|NCT04937881|f||||f
17153351|NCT04055740|f||||f
17153352|NCT00100828|t||||
17153353|NCT01215136|f||||f
17153354|NCT01197911|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153355|NCT02020278|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17153356|NCT01526057|f||LTE60||t
17153357|NCT00571324|t||||
17153358|NCT01555697|f||||f
17166794|NCT04439539|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17166795|NCT03116828|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming withing twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17166796|NCT05422365|f||||t
17166797|NCT03596047|t||||
17197286|NCT01755598|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197287|NCT02423447|t||||
17197288|NCT02924051|f||||f
17197289|NCT00828178|f||||f
17197290|NCT03005106|f||||t
17197291|NCT00321672|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The PI shall comply with the sponsor's requests to delete references to trade secrets, intellectual properties or other proprietary information.|t
17197292|NCT03163472|f||||f
17197293|NCT00512902|t||||f
17197294|NCT00635609|f||LTE60||t
17197295|NCT01754389|t||||
17197296|NCT01730118|f||||f
17197297|NCT03154827|f||||t
17197298|NCT00489489|f||OTHER|"The investigator can publish only the results of the work performed pursuant to this protocol. Prior to publication, the investigator provides the sponsor with the manuscript for review and comment at least 45 days in advance of its submission for publication.~The sponsor can require the investigator to withhold publication an additional 90 days to allow for filing a patent application or taking such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17197299|NCT06091982|f||||f
17197300|NCT04851587|f||||f
17197301|NCT04588246|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17197302|NCT04483791|f||||t
17197303|NCT02101554|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197304|NCT01350102|t||||
17197305|NCT03624023|f||||t
17197306|NCT00612716|t||||
17197307|NCT02136797|t||||
17197308|NCT04523571|f||OTHER|PIs respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17197309|NCT03782545|f||||f
17153359|NCT02289729|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153360|NCT01875978|f||LTE60||t
17153361|NCT03354598|f||OTHER|The PI will provide Iterum opportunity to review proposed publication/other type of disclosure before submitted/disclosed. PI will provide full text of intended disclosure to Iterum at least 30 days before submitted/disclosed. If any patent action is required to protect intellectual property rights, PI agrees to delay disclosure for a period not to exceed an additional 60 days. PI will, on request, remove previously undisclosed Confidential Information before disclosure.|t
17153362|NCT04870710|f||||f
17153363|NCT05724589|t||||f
17153364|NCT02329015|f||||f
17153365|NCT02577991|f||||f
17153366|NCT01042093|t||||
17153367|NCT02435524|f||||f
17153368|NCT02273388|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153369|NCT04589663|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153370|NCT02513212|t||||
17153371|NCT01256502|f||OTHER|As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with Allergan.|t
17153372|NCT01523002|f||||f
17153373|NCT03281876|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153374|NCT01478373|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153375|NCT03098082|t||||
17153376|NCT01074944|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17153377|NCT02103855|f||||f
17153378|NCT02348112|f||||f
17153379|NCT03741400|f||OTHER||t
17153380|NCT03423940|f||||f
17153381|NCT01998841|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153382|NCT02552121|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153383|NCT02854527|t||||
17153384|NCT00580502|f||||f
17153385|NCT02575833|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153386|NCT01821807|f||||f
17153387|NCT04446247|f||||f
17153388|NCT02633787|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17153389|NCT01742897|f||OTHER|Company shall have right to publish data or information generated in trial without approval of Principal Investigator (PI). PI shall have right to publish results and information provided by Company if necessary. Prior to submission, PI will provide company 60 days for review. No paper with confidential Information will be submitted without company consent. If requested, PI will withhold it for 60 days to allow patent application filing. PI warrants compliance of all personnel involved in Study.|t
17153390|NCT02404805|f||||f
17153391|NCT02601014|t||||
17153392|NCT01168427|f||||f
17137116|NCT01089582|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166798|NCT03727646|f||GT60||t
17166799|NCT05280158|f||||f
17197310|NCT03694210|f||OTHER|At least sixty days before publication submission PI shall submit to Sponsor for review and comment. PI will consider comments, but is not obligated to incorporate suggestions. Publication shall acknowledge Sponsor contributions as appropriate. Investigator agrees that first publication of results shall be a joint, multicenter publication, with the investigators and the institutions from all appropriate sites contributing data, analyses and comments.|t
17166800|NCT02290691|f||OTHER|Sponsor may invite Study's Investigators to participate in the preparation of a multicenter article for a professional journal; terms will be at the discretion of the sponsor. Investigators may also wish to publish, present, or use for instruction and research the results of the Study collected at their individual research sites only after publication of pooled, multicenter results and under the following conditions. Materials will be provided to Sponsor for approval prior to submission.|t
17166801|NCT04324541|t||||
17166802|NCT01858545|f||||t
17166803|NCT01707654|t||||
17166804|NCT00923975|f||LTE60||t
17166805|NCT01328535|t||||
17166806|NCT01005316|f||||f
17166807|NCT04417218|f||||f
17166808|NCT02925078|f||||f
17166809|NCT02516098|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property right.|t
17166810|NCT00873041|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166811|NCT01074463|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17166812|NCT01734395|f||GT60||t
17166813|NCT01032291|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication~* Multicenter publication has priority over subset (single center) publication, for duration of 1 year after study completion~* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 90 days"|t
17166814|NCT00313313|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166815|NCT02652208|t||||
17166816|NCT00758264|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181907|NCT05228470|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197311|NCT03050372|f||||f
17197312|NCT04385849|f||||t
17197313|NCT01375777|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197314|NCT02169089|t||||
17197315|NCT01838499|f||||f
17153393|NCT02456740|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17166817|NCT03425006|t||||
17166818|NCT02141867|f||||f
17166820|NCT02126553|t||||
17166821|NCT02084706|f||||f
17166822|NCT03831191|f||GT60||t
17197316|NCT02368691|f||||f
17197317|NCT03863184|t||||
17197318|NCT03314233|t||||
17197319|NCT01114217|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17197320|NCT01183013|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17166823|NCT02300558|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17181908|NCT00136084|t||||
17181909|NCT02449239|f||OTHER|Any and all data resulting from the Study will not be presented or published in any form or media by the Institution, Investigator or Research Staff without the prior written consent of Sponsor which consent maybe as directed within the Protocol.|t
17181910|NCT03244865|f||||f
17181911|NCT00394212|f||OTHER|First publication of study results will be the multicenter results. In the event no multicenter publication has been made within one to two years of the completion of the study at all centers, Investigators will be free to publish their own single-center results. Investigators seeking publication must submit a draft for sponsor review at least 60 days prior to submission of the draft for publication. Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17181912|NCT00588445|t||||
17181913|NCT03240133|f||||f
17181914|NCT01176292|f||OTHER|Any paper drafted by authors regarding project results should be sent to sponsor at least 30 days before being submitted for publication. An abstract should be sent to the sponsor at least 10 days before being submitted. The sponsor will inform the authors of any changes deemed necessary to preserve the confidentiality of proprietary information or to insure scientific accuracy.|t
17181915|NCT00997503|f||OTHER|During the term of the agreement and for a period of one year thereafter, the PI must submit to Boston Scientific each paper, summary, abstract or outline that he intends to present or publish relating to the study, and will not submit or present any proposed publication to a publisher or other party prior to the expiration of 45 days from the date such Proposed Publication is submitted to Boston Scientific.|t
17181916|NCT00116831|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181917|NCT01933048|t||||f
17181918|NCT00110812|t||||
17181919|NCT00380393|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181920|NCT02130063|f||||f
17181921|NCT02780804|f||LTE60||t
17181922|NCT02476968|f||||t
17181923|NCT01723163|t||||f
17181924|NCT04855643|t||||
17181925|NCT01859507|t||||
17181926|NCT01921829|f||||f
17197321|NCT02074709|t||||
17197322|NCT02722278|f||GT60||t
17197323|NCT04175392|t||||
17197324|NCT02727998|t||||
17197325|NCT02105688|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17197326|NCT00329771|t||||f
17197327|NCT02010021|t||||f
17166824|NCT00695955|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17166825|NCT01059682|f||||f
17166826|NCT03888235|f||||f
17181927|NCT04476030|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17181928|NCT02404311|f||||f
17181929|NCT02752191|t||||
17181930|NCT01536496|f||||f
17181931|NCT02256891|f||||f
17181932|NCT01344447|f||OTHER||t
17181933|NCT00218296|t||||f
17181934|NCT01067768|t||||
17181935|NCT00151814|f||||f
17181936|NCT01293240|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17181937|NCT03394768|t||||
17181938|NCT00980395|t||||
17181939|NCT01094548|f||OTHER|Any publications of the results, either in part or in total (abstracts in journals or newspapers, oral presentations, etc.) by Investigators or their representatives will require pre-submission review by the Sponsor. The Sponsor is entitled to delay publication in order to obtain patent protection.|t
17181940|NCT00983216|f||GT60||t
17181941|NCT01971853|t||||
17197328|NCT01757171|t||||
17197329|NCT00103116|t||||f
17197330|NCT00887471|f||||f
17197331|NCT05878522|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197332|NCT02252172|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17197333|NCT05740371|f||OTHER||t
17197334|NCT02051972|f||||f
17197335|NCT03010878|t||||
17166827|NCT01054560|f||OTHER|Physician shall not make any publication without providing Sponsor 30 days notice.If Sponsor determines that the proposed publication contains confidential information, Sponsor may require the delay of publication for a period of time not to exceed 90 days and may require that any confidential information be removed from the publication. Sponsor may also require Physician to delay publication until any factual errors or inaccuracies in the publication are corrected.|t
17166828|NCT00712725|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166829|NCT03466099|f||LTE60||t
17166830|NCT03709277|t||||
17166831|NCT00344318|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166832|NCT03832322|t||||
17166833|NCT01923363|f||||f
17166834|NCT00616018|f||||f
17153394|NCT00967330|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197336|NCT03019289|f||OTHER|Data and results are owned by the sponsor. Results can be used by the institution for internal noncommercial research, education and patient care, and as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.|t
17197337|NCT02389894|f||||f
17197338|NCT02228889|t||||
17153395|NCT05493501|f||||f
17153396|NCT00619723|f||||f
17153397|NCT05620082|f||||f
17153398|NCT01277783|f||||f
17153399|NCT03207776|t||||
17153400|NCT00942357|f||LTE60||t
17153401|NCT00780338|t||||
17153402|NCT01960257|f||||f
17153403|NCT02002221|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153404|NCT03347110|f||GT60||t
17153405|NCT01518322|f||LTE60||t
17153406|NCT03104192|t||||f
17153407|NCT00110396|f||OTHER|SPONSOR shall have the right to publish or present any results or information, including the Study Results, arising in connection with the STUDY for any purposes. The INSTITUTION, its officers, agents, employees and affiliated entities shall not publish or use any results or information arising in connection with the STUDY, including the Study Results, for professional, research, training or other purposes without SPONSOR's prior written consent.|t
17166835|NCT02609841|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication|t
17197339|NCT00145496|f||OTHER|Except for compelling legal reasons, neither the sponsor nor the investigator will communicate to third parties any result of the clinical trial before the clinical trial report has been released by the sponsor.|t
17197340|NCT00927849|t||||
17197341|NCT01549951|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17153408|NCT00882518|f||OTHER||t
17153409|NCT00815880|f||||f
17153410|NCT02137252|t||||
17166836|NCT00404755|f||||f
17166837|NCT00350870|t||||
17166838|NCT03194568|t||||
17166839|NCT05248997|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197342|NCT01123200|f||||f
17197343|NCT02168855|f||||f
17197344|NCT04604899|f||||f
17197345|NCT03689452|f||OTHER||t
17153411|NCT00245466|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17153412|NCT01958437|t||||
17197346|NCT02676778|f||||t
17197347|NCT00732498|t||||
17197348|NCT03000829|t||||f
17197349|NCT04992494|t||||
17153413|NCT04408729|f||||f
17153414|NCT04886596|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153415|NCT00981812|f||||f
17153416|NCT00948155|t||||f
17153417|NCT04620746|f||||f
17153418|NCT03473925|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17153419|NCT03411863|f||||f
17153420|NCT04584502|t||||
17197350|NCT01430299|f||GT60||t
17197351|NCT03394508|f||||f
17197352|NCT01288729|f||||f
17153421|NCT02777372|f||||f
17153422|NCT04661150|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153423|NCT03535740|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153424|NCT04481035|f||||f
17153425|NCT05807828|t||||f
17153426|NCT05198518|t||||
17153427|NCT03168022|f||GT60||t
17153428|NCT02756611|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153429|NCT01651078|f||||f
17153430|NCT03125798|t||||
17153431|NCT02463773|t||||
17153432|NCT03135015|f||||t
17153433|NCT00065156|f||OTHER|Unless approved by Celgene, single center data will not be published before multicenter data, unless more than 1 year has elapsed since completion of the Study. Thereafter, Investigator may publish single center data provided that Investigator shall: i) provide a copy of the publication to Celgene at least 60 days in advance of submission for publication; ii) delete Celgene Confidential Information and; iii) delay submission up to 90 additional days to permit intellectual property filings.|t
17153434|NCT04583735|f||OTHER||t
17153435|NCT00124917|f||||f
17153436|NCT03518008|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17166840|NCT01453205|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17166841|NCT02835313|f||||f
17166842|NCT05747209|t||||
17166843|NCT05021133|f||||f
17166844|NCT03869385|t||||f
17166845|NCT02602275|f||||t
17166846|NCT04262882|f||||f
17166847|NCT01301066|f||OTHER|Sponsor shall have the right to the first publication of the results of the Study. PI may publish, however PI must submit publication to sponsor for review at least 60 days prior to proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary.|t
17166848|NCT00868140|f||||f
17166849|NCT02187887|f||||f
17166850|NCT02333396|t||||
17166851|NCT01108731|t||||
17166852|NCT04210245|f||||f
17197353|NCT03214198|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197354|NCT04295499|f||||t
17197355|NCT02135445|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197356|NCT02132598|t||||
17153437|NCT01169350|f||LTE60||t
17153438|NCT00931411|f||LTE60||t
17166853|NCT01892722|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17166854|NCT01252186|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17153439|NCT02280200|f||||f
17153440|NCT04429945|t||||
17153441|NCT00476190|t||||
17166855|NCT00772915|t||||
17166856|NCT04420598|f||||t
17166857|NCT04283994|f||||f
17181942|NCT01364428|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17153442|NCT02466321|f||GT60||t
17153443|NCT00115076|t||||
17181943|NCT00228917|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181944|NCT00706836|f||||f
17181945|NCT03131440|f||||f
17153444|NCT06071754|f||||f
17153445|NCT04331808|t||||
17181946|NCT03892460|f||||f
17153446|NCT02189837|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153447|NCT02421055|t||||
17153448|NCT00619060|t||||
17153449|NCT00822692|f||||f
17153450|NCT02443740|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153451|NCT00456300|t||||f
17153452|NCT01199380|f||||f
17153453|NCT02473926|f||||f
17153454|NCT00683657|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17153455|NCT02757326|f||||f
17153456|NCT00194779|t||||
17197357|NCT03451292|f||OTHER|Site may publish results from the Study, after providing Sponsor 30 days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17197358|NCT05030467|f||||f
17197359|NCT05878990|t||||
17197360|NCT01933776|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17197361|NCT02543294|t||||
17197362|NCT03672188|f||OTHER|"Investigators may discuss or publish results after:~* the study results in their entirety have been publicly disclosed by or with the consent of the Sponsor OR study has been completed at all investigative sites for at least 2 years~* provision of publication up to 60 days before planned submission to allow Sponsor to remove confidential information or identify Sponsor intellectual property~Publication may be delayed as applicable, up to 120 days for Sponsor to file patent application(s)"|t
17197363|NCT00984334|f||LTE60||t
17197364|NCT00396409|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197365|NCT01309802|t||||
17197366|NCT04203199|t||||
17197367|NCT03320941|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17153457|NCT01408043|t||||
17153458|NCT03560128|f||||f
17153459|NCT03714828|t||||
17153460|NCT00739063|t||||f
17153461|NCT03447743|t||||f
17153462|NCT03567980|f||||f
17153463|NCT03093259|f||GT60||t
17153464|NCT00254592|f||||f
17153465|NCT02409927|t||||
17153466|NCT04871776|t||||
17153467|NCT00692692|t||||f
17153468|NCT05287230|f||||f
17153469|NCT06146361|t||||
17153470|NCT04075487|f||||f
17153471|NCT05579782|t||||
17153472|NCT02848001|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17153473|NCT01410097|t||||f
17153474|NCT00725283|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153475|NCT02115269|f||LTE60||t
17153476|NCT01402570|t||||f
17153477|NCT03514459|f||||f
17153478|NCT02892955|f||OTHER|MOMENTUM 3 studies have a study specific charter that governs the overall publication and presentation policy for all abstracts and manuscripts related to MOMENTUM 3 clinical data.|t
17153479|NCT03825939|t||||
17153480|NCT04179838|t||||
17153481|NCT03456102|t||||
17153482|NCT01290068|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17153483|NCT00513695|t||||
17153484|NCT01907490|f||OTHER|For any publication or presentation the materials will be provided to the sponsor for approval. Sponsor will be permitted of 90-120 days for a review and shall have right to request modification if the material to be published will jeopardize the intellectual property of the sponsor .|t
17153485|NCT02099786|f||||f
17153486|NCT00080912|t||||f
17153487|NCT01417156|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153488|NCT00818766|f||||f
17153489|NCT00086684|f||||f
17153490|NCT01996241|f||||f
17153491|NCT02400996|f||||f
17153492|NCT04515147|f||||t
17153493|NCT01111318|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17153494|NCT02094300|f||GT60||t
17153495|NCT02091856|f||||f
17153496|NCT04505969|f||||f
17153497|NCT00725491|f||OTHER|The sponsor can review any scientific paper, presentation, or other communication concerning the clinical trial at least 6 weeks ahead of estimated publication or presentation. In order to protect its proprietary interests, the sponsor shall have the right to make its consent, which shall not be withheld unreasonably, conditional upon proper representation of the interpretation of both the sponsor and the investigator(s) in the discussion of the data in such communications.|t
17153498|NCT01495000|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153499|NCT01514461|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153500|NCT03499067|f||||f
17197368|NCT03614923|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is 18 months since study completion. Then, Investigator can publish if manuscript is submitted to Sponsor 90 days prior to submission. Sponsor may require the Investigator to remove specifically identified Confidential Information (other than Trial Data) and/or to delay the proposed publication for an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17197369|NCT01107353|f||GT60||t
17197370|NCT01136733|f||||f
17197371|NCT00113334|t||||f
17197372|NCT03360071|f||OTHER|Publication must be approved by sponsor within first 10 years after completion.|t
17197373|NCT03490942|f||||f
17153501|NCT02548832|t||||f
17153502|NCT03345420|t||||
17153503|NCT02058069|f||GT60||t
17153504|NCT01299103|f||||f
17153505|NCT01280643|f||||f
17153506|NCT01629511|t||||
17153507|NCT03290378|f||||t
17153508|NCT02015611|f||||f
17153509|NCT01320293|f||GT60||t
17153510|NCT00470470|f||LTE60||t
17153511|NCT00793455|t||||
17153512|NCT04338022|f||||t
17153513|NCT02749617|f||||f
17153514|NCT04782076|f||GT60||t
17153515|NCT00462917|t||||
17153516|NCT02574598|f||||f
17153517|NCT02860546|f||||t
17153518|NCT04910100|f||||f
17153519|NCT01949662|t||||
17153520|NCT07034820|t||||
17153521|NCT00729937|f||LTE60||t
17153522|NCT03207386|f||||f
17153523|NCT00243412|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153524|NCT03787134|t||||
17197374|NCT01585597|f||||f
17197375|NCT02504502|t||||
17197376|NCT01014013|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197377|NCT00316121|f||OTHER|The PI cannot publish the results without consent of Sponsor. The results must be given to Sponsor 60 days prior to use. This review is not meant to curtail distribution of data, but to identify confidential material and/or to review the content for conformance to regulations. The Sponsor has the right to edit materials to preserve confidentiality of proprietary information. If requested, the Institution and PI will withhold publication for 60 days to allow for filing of a patent application.|t
17197378|NCT02305797|f||||f
17153525|NCT00202930|t||||f
17153526|NCT02586155|f||||f
17153527|NCT04779879|f||||t
17153528|NCT02072980|t||||
17153529|NCT02624180|f||||f
17153530|NCT00266279|f||||f
17153531|NCT01333592|f||||f
17153532|NCT00955617|f||LTE60||t
17153533|NCT04952922|t||||
17153534|NCT00070564|f||LTE60||t
17153535|NCT02059512|t||||
17153536|NCT04576507|f||||f
17153537|NCT04470518|f||OTHER|Investigator may only publish the Results provided that Sponsor has duly published the main Study publication. Once the main Study publication has been duly published by the Sponsor, Investigator are entitled to publish the Results provided that Sponsor has granted its prior written approval with Principal Investigator's proposed publication.|t
17153538|NCT03848715|f||||f
17153539|NCT00931528|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17153540|NCT06379048|f||||f
17153541|NCT00711243|t||||
17153542|NCT04074941|t||||f
17153543|NCT01557504|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17153544|NCT01962103|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days. Investigator must delete confidential information before submission or defer publication to permit patent applications|t
17153545|NCT01321749|t||||f
17153546|NCT02750618|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153547|NCT02826486|f||OTHER|The restrictions are as per the signed agreement with each PI and institution.|t
17153548|NCT01067105|f||OTHER||t
17153549|NCT01634048|t||||
17166858|NCT03763656|f||OTHER|Any publication or sub-set analysis of data based on the results obtained shall not be made before the first publication by the Sponsor, in which the Investigators may be named as authors. After initial publication material for public dissemination will be submitted to the Sponsor for review at least 60 days prior to submission, where all reasonable comments by the Sponsor will be incorporated. Sponsor may request additional delay for up to 6 months to protect proprietary information/IP.|t
17166859|NCT00487942|f||GT60||t
17197379|NCT03075449|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197380|NCT02100189|f||||f
17197381|NCT00460577|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197382|NCT02213458|f||||f
17153550|NCT02302833|t||||
17153551|NCT04878432|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153552|NCT05017246|t||||
17153553|NCT00934024|t||||
17153554|NCT02719184|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17153555|NCT02439216|f||||f
17153556|NCT03359850|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153557|NCT02023983|t||||
17153558|NCT01087918|t||||
17153559|NCT01690117|f||||f
17153560|NCT01004354|t||||f
17153561|NCT00397462|t||||f
17153562|NCT01288807|f||||f
17153563|NCT03472014|f||||t
17153564|NCT02792517|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197383|NCT00910871|f||OTHER|It is the policy of the sponsor not to allow the investigators to publish their results or findings prior to the sponsor's publication of the overall trial results.The investigator agrees that before he/she publishes any results of this trial, he/she shall provide the sponsor with at least 45 days for full review of the prepublication manuscript prior to submission of the manuscript to the publisher.|t
17197384|NCT01878253|f||OTHER|The Investigator must provide the Sponsor at least 30 days to review publications for legal and regulatory compliance and will include in publications a statement that the study was supported by the Sponsor. Sponsor confidential information will not be submitted for publication without Sponsor consent. Sponsor may request delay of publication for 60 days to allow for patent application filing.|t
17197385|NCT04043806|f||||t
17153565|NCT00711087|f||||f
17153566|NCT01422200|t||||
17153567|NCT00856193|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197386|NCT01622088|f||OTHER|Sponsor must be consulted|t
17197387|NCT02035345|t||||
17197388|NCT04799587|f||||f
17197389|NCT04598776|t||||
17197390|NCT00515281|f||||f
17197391|NCT04374435|t||||
17197392|NCT03613363|f||||f
17197393|NCT06312566|f||GT60||t
17197394|NCT04736472|f||||f
17197395|NCT02116582|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17197396|NCT03861078|t||||f
17197397|NCT02971683|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197398|NCT04206501|t||||f
17197399|NCT02268526|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197400|NCT00596960|t||||
17197401|NCT01158716|f||||f
17197402|NCT03941769|t||||
17153568|NCT00428246|f||||f
17153569|NCT02569801|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153570|NCT00501995|f||||f
17153571|NCT02396511|f||LTE60||t
17153572|NCT01223378|f||||f
17153573|NCT01015534|t||||f
17153574|NCT01125917|f||GT60||t
17153575|NCT02501928|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153577|NCT03737357|f||||f
17153578|NCT04941131|f||||f
17153579|NCT00838526|f||||f
17197403|NCT01292005|t||||f
17197404|NCT02130401|f||||f
17197405|NCT00936065|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197406|NCT00070317|f||LTE60||t
17153580|NCT03483012|t||||
17153581|NCT02845700|f||||f
17166860|NCT03284333|f||||f
17166861|NCT00197145|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166862|NCT03040011|t||||f
17197407|NCT01429285|t||||
17197408|NCT01885559|f||||f
17197409|NCT02680145|t||||
17197410|NCT01542502|t||||
17197411|NCT01052714|t||||
17197412|NCT02168153|f||||f
17197413|NCT04623996|f||LTE60||t
17197414|NCT03584282|t||||
17197415|NCT01184755|f||||f
17197416|NCT00318591|f||LTE60||t
17197417|NCT01613807|f||LTE60||t
17197418|NCT01612221|t||||
17197419|NCT00644332|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17197420|NCT01654445|f||||f
17197421|NCT01896921|f||||f
17197422|NCT00627523|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153582|NCT02452476|f||OTHER|Chiesi Farmaceutici S.p.A. (Sponsor) can publish or present results of this study at scientific meetings and submit the data to national and international Regulatory Authorities. The Sponsor reserves the right to use the data for industry purposes. Investigators will inform the Sponsor before using the results of the study for publication or presentation, and will provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17153583|NCT02201784|f||||f
17153584|NCT01757275|f||||f
17153585|NCT02139137|f||||f
17153586|NCT01941615|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153587|NCT02290444|f||||f
17153588|NCT01618344|t||||
17197423|NCT00702338|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to the Sponsor, at least 6 weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17197424|NCT00355784|t||||
17197425|NCT02794441|f||||f
17197426|NCT00406276|t||||
17197427|NCT03602053|t||||
17197428|NCT01038128|t||||f
17197429|NCT01769352|t||||
17197430|NCT04203225|f||||f
17197431|NCT01193283|t||||
17197432|NCT00830284|t||||
17197433|NCT01537900|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17197434|NCT01838447|f||||f
17197435|NCT00168805|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17197436|NCT04117711|f||||f
17197437|NCT00472199|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17197438|NCT01540071|f||||f
17197439|NCT02446912|f||||f
17197440|NCT01268488|f||GT60||t
17197441|NCT00828542|t||||f
17197442|NCT00147745|f||OTHER|If identified by Daiichi Sankyo, Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted…Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by Study Site.|t
17197443|NCT01509040|t||||
17197444|NCT05274906|f||||f
17153589|NCT01749826|t||||f
17153590|NCT02721732|t||||
17153591|NCT01051310|f||||f
17153592|NCT01038336|t||||
17153593|NCT03077737|f||||f
17153594|NCT02572570|t||||
17153595|NCT02763046|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17153596|NCT04544241|t||||
17153597|NCT03411031|t||||
17153598|NCT03052751|f||GT60||t
17153599|NCT01103180|f||||f
17153600|NCT01173523|f||||f
17153601|NCT06192589|f||||f
17153602|NCT01439802|t||||f
17153603|NCT01927575|f||||f
17153604|NCT01866826|t||||
17153605|NCT02493660|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 45 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and can only extend the embargo with patent protection review.|t
17153606|NCT03073876|f||||f
17153607|NCT04552795|f||||f
17153608|NCT02502149|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17197445|NCT03508830|f||||f
17153609|NCT02968576|f||||f
17166863|NCT01321216|f||||f
17166864|NCT01301521|f||||f
17197446|NCT02522299|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197447|NCT02342275|t||||
17197448|NCT04908800|f||OTHER|Each party agrees that all confidential information of the disclosing part is and shall we the sole property of the disclosing party. Without prejudice to any Labcorp Property, all test information, results, data and records developed by Labcorp specifically as a result of performing the study and related to the test materials or sponsor information shall be the confidential information of the sponsor.|t
17197449|NCT02267746|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed|t
17197450|NCT03720717|t||||f
17153610|NCT02222922|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153611|NCT06160609|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153612|NCT02090088|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153613|NCT00116779|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of ublication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17153614|NCT02714218|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17153615|NCT00663793|t||||
17153616|NCT04784091|f||OTHER|It is specified in the protocol that the data generated in this clinical trial, all related information and any materials containing such data and information are the exclusive property of Tarsus Pharmaceuticals, Inc. and are confidential to Tarsus Pharmaceuticals. Also, the investigator or other study-related personnel may not disclose to anyone or use any data, information or materials related to this clinical trial without the express written consent of Tarsus Pharmaceuticals.|t
17153617|NCT03743051|f||OTHER|The Sponsor has the sole right to first publication of the study data, which would be a multi-center publication. Investigators may publish the Study Data they obtained if they follow the conditions provided in the protocol. These include, but are not limited to: the multi-center publication has occurred; the Sponsor is given 60 days to review the document and possibly 60 more days to obtain Intellectual Property protections; and all Confidential Information is deleted, as requested by Sponsor.|t
17153618|NCT00811733|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197451|NCT00728884|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17197452|NCT00348283|f||OTHER|Provide ABBOTT at least sixty (60) days prior to submission for review, ABBOTT shall return within sixty (60) days. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period|t
17197453|NCT04453709|f||||f
17197454|NCT03590847|f||||f
17197455|NCT04372186|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197456|NCT00763919|f||||f
17197457|NCT02374476|f||LTE60||t
17197458|NCT03305458|f||||f
17153619|NCT04460911|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153620|NCT00793871|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153621|NCT02500589|f||||f
17153622|NCT03652051|f||||f
17153623|NCT01936844|f||||f
17153624|NCT02200055|t||||
17153625|NCT03442751|f||||t
17153626|NCT02603887|t||||
17153627|NCT05966506|t||||
17153628|NCT02766335|f||LTE60||t
17153629|NCT01903798|f||OTHER||t
17153630|NCT03618017|t||||
17153631|NCT00423878|f||||f
17153632|NCT00235755|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153633|NCT03164551|f||||t
17197459|NCT05431543|f||||t
17197460|NCT00440037|f||||t
17137117|NCT00862849|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17137118|NCT03943953|t||||
17153634|NCT01515423|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17153635|NCT02314026|f||LTE60||t
17197461|NCT00498797|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17197462|NCT00914732|f||LTE60||t
17153636|NCT05824754|f||||f
17197463|NCT04964297|t||||
17197464|NCT01855399|t||||
17197465|NCT03953079|f||OTHER|Any investigator wishing to publish or present any study finding must present a manuscript or abstract to Graybug Vision 120 days prior to submission for publication or presentation to provide Graybug Vision an opportunity for review and comment.|t
17197466|NCT04394624|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17197467|NCT04617574|f||||f
17197468|NCT00998517|t||||
17197469|NCT00448344|t||||
17197470|NCT00410150|t||||f
17197471|NCT00141271|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17197472|NCT00990314|f||GT60||t
17197473|NCT01195584|t||||
17197474|NCT02704156|f||||f
17197475|NCT00604461|t||||f
17197476|NCT00267865|f||||f
17197477|NCT03686176|f||||f
17197478|NCT00515879|t||||f
17197479|NCT01636778|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153637|NCT04421131|t||||
17153638|NCT00858494|f||LTE60||t
17153639|NCT01401452|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153640|NCT00584454|f||||f
17153641|NCT01133067|t||||
17153642|NCT02483676|f||||f
17153643|NCT03717155|t||||
17153644|NCT04135937|t||||
17153645|NCT01710787|f||||f
17153646|NCT02654054|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153647|NCT00420420|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197480|NCT03458416|f||LTE60||t
17197481|NCT01154699|f||||f
17166865|NCT03372551|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17166866|NCT00678535|f||OTHER||t
17166867|NCT04178993|f||||f
17166868|NCT03285958|t||||
17166869|NCT02578680|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17166870|NCT00218634|f||||f
17166871|NCT00176488|t||||
17197482|NCT00083122|f||LTE60||t
17197483|NCT01846988|t||||
17197484|NCT03530345|f||OTHER|The sponsor reserves the right to review any proposed full publication or poster or presentation of the results of this study by the coordinating or other investigator before they are submitted for publication or public disclosure. Neither the sponsor nor the coordinating investigator has the right to prohibit publication or public disclosure. Publication or public disclosure can be postponed for patent purposes.|t
17197485|NCT03282071|f||||f
17197486|NCT04853394|f||||f
17197487|NCT04212299|f||||f
17153648|NCT00273182|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred."|t
17153649|NCT00856492|f||LTE60||t
17153650|NCT05411991|t||||f
17153651|NCT05842967|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153652|NCT02157935|f||||f
17153653|NCT02764762|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153654|NCT01662778|t||||
17153655|NCT00742209|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153656|NCT02562066|f||||f
17153657|NCT02003209|f||LTE60||t
17197488|NCT03537014|f||||f
17197489|NCT00705614|f||OTHER|The sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17197490|NCT01044901|f||||f
17197491|NCT00676195|f||||f
17197492|NCT02878590|f||||f
17197493|NCT02661490|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197494|NCT02706834|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17197495|NCT01862614|f||||f
17197496|NCT03149887|t||||f
17197497|NCT01634620|f||||f
17197498|NCT03416335|f||||f
17197499|NCT03034772|f||||f
17197500|NCT00411463|t||||f
17197501|NCT00116584|f||||f
17197502|NCT01745380|f||||f
17197503|NCT01882088|t||||f
17197504|NCT00125619|t||||f
17197505|NCT02333071|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17197506|NCT01797705|f||||f
17197507|NCT01493947|f||||f
17197508|NCT01533181|f||LTE60||t
17197509|NCT01837719|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197510|NCT01703988|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17197511|NCT02995733|f||||f
17197512|NCT02186587|f||||f
17197513|NCT01189370|t||||
17197514|NCT03785210|f||||f
17197515|NCT04879823|t||||
17197516|NCT03897075|f||||t
17197517|NCT04468633|t||||
17153658|NCT00638508|f||||f
17166872|NCT04388319|f||||f
17166873|NCT02918396|f||||f
17197518|NCT01843920|t||||
17197519|NCT00460434|f||||f
17197520|NCT02465866|f||||f
17197521|NCT00203502|t||||
17197522|NCT01403805|t||||
17197523|NCT03082196|t||||
17197524|NCT01103141|f||GT60||t
17197525|NCT01695993|t||||f
17197526|NCT04057937|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17153659|NCT03500198|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime|t
17153660|NCT00324987|f||LTE60||t
17197527|NCT02103816|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17197528|NCT00427297|f||||f
17197529|NCT05319756|f||OTHER||t
17197530|NCT00422162|f||GT60||t
17197531|NCT03287947|t||||
17197532|NCT00166361|t||||f
17197533|NCT01047306|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17197534|NCT00538616|f||||f
17197535|NCT00274846|t||||
17197536|NCT01357564|t||||
17197537|NCT01648699|f||||f
17197538|NCT02038803|f||||f
17197539|NCT02588027|t||||f
17197540|NCT03219216|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17197541|NCT02332824|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197542|NCT03840148|f||OTHER|Certain PIs are not allowed to present or publish data from the Study without Sponsor's prior written consent.|t
17197543|NCT03615404|f||||f
17197544|NCT01774929|f||OTHER|If an Investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication. If requested by the Sponsor, the Investigator will withhold it up to an additional 60 days to allow for filing of a patent application. The Sponsor will not change or suppress the scientific content. For multicenter study, results may not be published before the primary endpoints of a study have been published.|t
17197545|NCT00939211|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.|t
17197546|NCT02577315|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197547|NCT01945086|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17197548|NCT05022472|f||||f
17197549|NCT04413149|t||||
17197550|NCT01178281|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then Investigator can publish if the manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides a publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17197551|NCT05335005|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17197552|NCT04050722|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197553|NCT01828593|f||OTHER|If no multi-site publication is made within 18 months, Site may publish Site's results, subject to the following. At least 30 days prior to submitting a manuscript the Site shall provide to Entera a copy, and Entera shall have 30 days to review. Site shall remove any Confidential Information, upon Entera's request, prior to submitting the materials, and the Site shall delay publication for an additional period of up to 60 days to allow Entera to protect its interests in any Inventions.|t
17197554|NCT00443755|t||||f
17197555|NCT00678899|f||||f
17197556|NCT01093976|f||||f
17153661|NCT00268450|t||||
17153662|NCT01254643|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines|t
17153663|NCT03817125|f||||t
17153664|NCT02105467|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17153665|NCT01037218|f||LTE60||t
17153666|NCT02676882|f||||f
17153667|NCT02568072|t||||
17153668|NCT01302743|t||||
17153669|NCT01321879|t||||
17153670|NCT00897715|t||||
17197557|NCT00376935|f||OTHER|Restriction Description:In accordance with the Clinical Trial Agreement between NIAID (DAIDS)and company collaborators,NIAID provides companies with a copy of any abstract,press release,or manuscript prior to submission for publication with sufficient time for company review and comment.The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and 5 business days for abstracts,to preserve U.S. or foreign patent or other intellectual property rights.|t
17197558|NCT00084409|t||||
17197559|NCT05129592|f||||f
17197560|NCT02339506|f||||f
17197561|NCT01572493|f||||f
17197562|NCT00609245|f||||f
17197563|NCT01234675|f||||f
17197564|NCT00331799|f||||f
17197565|NCT02889809|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17197566|NCT05065918|f||||f
17153671|NCT00958828|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17153672|NCT01268553|f||||f
17197567|NCT01090076|t||||
17197568|NCT00553800|t||||
17197569|NCT00113880|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17197570|NCT01116440|f||OTHER|All PIs must seek written permission from the sponsor prior to publication of any trial results.|t
17197571|NCT02630147|t||||
17153673|NCT02321111|f||||f
17153674|NCT02687451|f||||f
17153675|NCT01125189|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17166874|NCT01018134|f||||f
17153676|NCT00927589|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197572|NCT01870999|f||||f
17153677|NCT00707239|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153678|NCT02961595|f||||f
17153679|NCT02386319|f||||f
17153680|NCT01651117|t||||
17197573|NCT01636258|t||||f
17153681|NCT01656460|f||||f
17197574|NCT01763346|f||||f
17197575|NCT02798861|f||||f
17197576|NCT02186015|t||||
17197577|NCT00907517|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17153682|NCT01113892|f||OTHER|The publication or presentation of the results from a single site was not allowed until the preparation and publication of the multi-center results. Individual sites could publish or present information, provided that a draft was given to the sponsor for review and comment for a period that is at least 60 days prior to the first date of submission to allow the sponsor to review its content for accuracy, confidential information or patentable inventions.|t
17153683|NCT00656656|t||||
17153684|NCT03490110|t||||
17153685|NCT03757819|t||||
17153686|NCT06811155|f||||f
17153687|NCT03447639|t||||
17153688|NCT01532934|t||||
17153689|NCT01147068|f||||f
17153690|NCT02291237|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17153691|NCT01149863|t||||
17153692|NCT01306305|f||OTHER|The investigator to submit all manuscripts/abstracts to the sponsor for review at least 6 weeks before submission.|t
17153693|NCT03326193|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153694|NCT00978874|t||||
17153695|NCT00699998|f||GT60||t
17153696|NCT04052620|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153697|NCT01406574|f||||f
17197578|NCT02660034|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17197579|NCT02030847|t||||
17197580|NCT01074437|t||||
17197581|NCT06247488|f||||f
17197582|NCT02720198|f||||f
17197583|NCT00641797|t||||
17197584|NCT02023099|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17197585|NCT02592434|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197586|NCT01469819|f||||f
17197587|NCT02029521|f||||f
17197588|NCT02389725|t||||
17197589|NCT00428441|f||||f
17197590|NCT03912298|f||||f
17197591|NCT00724750|t||||
17197592|NCT03410953|f||||f
17197593|NCT00510783|f||||f
17197594|NCT02744898|t||||
17197595|NCT02391714|f||||f
17197596|NCT01348763|t||||
17197597|NCT01078571|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17197598|NCT01132378|f||||f
17197599|NCT03647709|f||||f
17197600|NCT05045638|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197601|NCT03802513|t||||
17153698|NCT03552380|f||||f
17153699|NCT03093701|f||||f
17153700|NCT02431364|f||||t
17153701|NCT00916383|f||OTHER|An Institution Publication may be published provided that it does not disclose Confidential Information other than the study results from the Institution's study data. The proposed Institution Publication shall be submitted to sponsor for review and comment at least 30 days prior to submitting it to a third party. If sponsor requests a delay in order to file patent applications, the Institution Publication may be delayed for submission to a third party for up to 120 days after sponsor request.|t
17153702|NCT00258960|f||LTE60||t
17153703|NCT00473590|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153704|NCT04778475|f||||f
17153705|NCT01112059|f||||f
17153706|NCT00395161|f||||f
17153707|NCT03367819|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17153708|NCT00725920|t||||
17153709|NCT03918629|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153710|NCT01891864|f||OTHER|At least sixty days prior to submitting/presenting manuscript or other materials relating to the study a copy should be provided to Sandoz and Sandoz has sixty days to review and comment. Sandoz has the right to require amendments to any such proposed presentation or publication on reasonable grounds. Sandoz may require any proposed publication or presentation to be delayed for up to four months to enable a patent application to be prepared and filed.|t
17153711|NCT04720105|f||||f
17153712|NCT02771977|t||||
17153713|NCT02698163|t||||
17153714|NCT05373108|t||||
17153715|NCT02892331|f||||f
17153716|NCT00610428|f||LTE60||t
17153717|NCT00349973|f||||f
17153718|NCT04314037|f||||f
17153719|NCT02490631|t||||
17153720|NCT00868530|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153721|NCT00858273|t||||
17153722|NCT04199104|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17153723|NCT05120193|f||GT60||t
17153725|NCT04748510|t||||f
17153726|NCT02325973|f||OTHER|Since it is a multicenter study,no results presentation or publication shall be made prior to the communication,presentation or publication to congresses and/or scientific journals without Sponsor consent.Investigator has to provide copy of any proposed Publication\&all related materials to Sponsor for consideration at least 30 days prior to the proposed submission date.Sponsor can ask Investigator to refrain from making the Publication for 60 days in order to verify the accuracy of information|t
17153727|NCT05655546|f||||f
17153728|NCT04510090|f||LTE60||t
17153729|NCT05825404|f||||f
17153730|NCT01415518|f||OTHER|PI shall not publish any results until the earlier of (i) the date of the first Study results publication authorized by AZ and (ii) the end of the 18 month period following the completion of the Study. PI shall provide AZ with such material for review, at least 60 days prior to submission for publication. If requested in writing by AZ, PI shall withhold material from submission for publication for an additional 90 days from the date of AZ's request.|t
17153731|NCT00679211|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153732|NCT01730053|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17153733|NCT01470248|t||||
17153734|NCT05085834|f||||f
17153735|NCT02243605|f||LTE60||t
17197602|NCT02382913|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197603|NCT02032420|t||||f
17153736|NCT01823328|f||||f
17153737|NCT04173507|f||LTE60||t
17153738|NCT02739789|t||||
17153739|NCT02717507|f||OTHER|Must obtain prior Sponsor approval|t
17153740|NCT00595621|t||||
17166875|NCT02450383|t||||
17166876|NCT03990415|t||||
17166877|NCT03258281|f||LTE60||t
17166878|NCT00731653|f||||f
17166879|NCT04051710|f||OTHER|Sponsor has the ownership of all the data generated from the study and PI has no rights to publish the results or any information derived from the study.|t
17166880|NCT00664560|f||||f
17197604|NCT03869541|t||||
17197605|NCT03045302|f||GT60||t
17197606|NCT05287178|t||||
17153741|NCT02392481|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153742|NCT01998919|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153743|NCT01342471|t||||
17153744|NCT02088177|t||||
17153745|NCT01774760|f||||f
17153746|NCT01778530|f||||f
17153747|NCT01199939|f||GT60||t
17153748|NCT01894919|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153749|NCT03711188|f||||f
17153750|NCT01823861|f||||f
17153751|NCT01433471|f||||f
17166881|NCT03350035|f||||f
17166882|NCT03576066|f||OTHER|Assembly Biosciences agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Assembly Biosciences supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166883|NCT00006164|f||||f
17166884|NCT02642393|f||||f
17166885|NCT00633074|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166886|NCT00365105|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17166887|NCT06422364|t||||
17166888|NCT01681069|f||OTHER||t
17166889|NCT01463696|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17166890|NCT04726137|f||||f
17166891|NCT03883165|t||||
17166892|NCT04478071|t||||
17166893|NCT06053541|t||||
17197607|NCT00603278|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197608|NCT02406859|t||||
17197609|NCT04374253|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197610|NCT01207453|f||||f
17197611|NCT00990821|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197612|NCT00308113|t||||f
17197613|NCT01123642|f||||f
17137119|NCT01102218|f||OTHER|After Sponsor's (S) publication (pub) of multi-center pub,Institution (I) and/or Principal Investigator (PI) may publish data/results from Study based solely upon Study conducted by I/PI,provided that I/PI submits pub to S for review/comment \> 60 days before date of proposed pub.S may review in advance contents of pub.If pub is not submitted within 12 months after termination of Study at all sites,or if S confirms there will be no pub,the I/PI may publish Study results.|t
17137120|NCT00803543|f||||f
17166894|NCT00245050|t||||f
17197614|NCT00925288|f||||f
17197615|NCT03322514|t||||
17197616|NCT01184859|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17153752|NCT03238651|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17166895|NCT01843673|t||||
17166896|NCT00425698|t||||
17166897|NCT02704702|f||OTHER|Obligation of disclosure restriction continue for 3 years from the date of termination or expiration of Agreement effected on November 16th, 2015.|t
17166898|NCT00123162|f||||f
17166899|NCT03275246|f||LTE60||t
17166900|NCT02292082|t||||
17166901|NCT03905265|f||OTHER|"Institution agrees that no Publication of the Study results may be made until Publication of the results of the Study or 2 years after Study Completion, whichever is the sooner.~The Institution must ensure that the Discloser gives a copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the Study to the Sponsor at least 40 days before forwarding it to any person that is not bound by the confidentiality obligations"|t
17166902|NCT01973387|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17153753|NCT03875508|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17153754|NCT01400477|t||||
17153755|NCT04341363|f||||f
17153756|NCT00063934|f||LTE60||t
17153757|NCT01837901|f||GT60||t
17153758|NCT00840749|f||||f
17153759|NCT02550561|t||||
17153760|NCT00395629|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17153761|NCT01051960|t||||
17153762|NCT03534687|f||||f
17153763|NCT02394600|f||||f
17197617|NCT00961298|t||||f
17197618|NCT01100268|f||||f
17197619|NCT01904019|f||||t
17153764|NCT01686373|f||||f
17153765|NCT00754130|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17153766|NCT00661557|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153767|NCT00774163|f||||f
17153768|NCT01960413|f||||f
17153769|NCT03957200|f||||f
17153770|NCT00776035|t||||
17153771|NCT01082328|f||OTHER||t
17153772|NCT00791778|f||LTE60||t
17153773|NCT02285361|t||||
17153774|NCT00381862|f||||f
17153775|NCT02411656|t||||
17153776|NCT06481709|f||||t
17153777|NCT05365451|f||||f
17153778|NCT03933904|f||LTE60||t
17153779|NCT04578535|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17153780|NCT05317312|f||OTHER|Subject to a multi-site coordination for publication, Institution and Investigator may publish its results by providing a copy of any presentation/publication derived from the Study for review and comment at least 30 days in advance of any disclosure, presentation, or submission for publication in order for the removal of anything that Sponsor identifies as trade secrets, proprietary information or Confidential Information.|t
17153781|NCT00837148|t||||
17166903|NCT01562314|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17166904|NCT03655054|f||||f
17166905|NCT02808052|f||||f
17197620|NCT01537120|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17197621|NCT00392704|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17197622|NCT00282828|f||||f
17197623|NCT01503515|f||OTHER|Must obtain prior sponsor approval.|t
17197624|NCT00515697|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17197625|NCT03087851|t||||
17153782|NCT03839628|f||||f
17153783|NCT00380874|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17153784|NCT01964976|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153785|NCT04306211|f||||f
17153786|NCT01451463|f||||f
17153787|NCT01565889|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17166906|NCT02512874|t||||
17166907|NCT02330653|t||||
17166908|NCT02256384|t||||f
17166909|NCT01404559|f||||f
17166910|NCT02970006|f||||f
17166911|NCT02357472|f||||f
17166912|NCT00244933|t||||
17166913|NCT00349921|f||||f
17197626|NCT01742949|f||||f
17166914|NCT00920387|f||||f
17197627|NCT02123797|f||||f
17197628|NCT04441996|t||||
17197629|NCT03997409|t||||
17197630|NCT01753323|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153788|NCT03793608|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17153789|NCT01326845|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17153790|NCT00982657|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153791|NCT01615367|t||||
17197631|NCT02115542|t||||
17197632|NCT01498445|t||||
17197633|NCT00605384|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197634|NCT00730925|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17197635|NCT00561678|t||||
17197636|NCT01732627|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17197637|NCT01072396|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17197638|NCT00005908|f||||f
17197639|NCT00475787|t||||
17197640|NCT01106586|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17137121|NCT00289185|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153792|NCT00752128|f||OTHER||t
17153793|NCT02286713|t||||
17153794|NCT02235454|t||||
17153795|NCT03323398|f||OTHER||t
17153796|NCT02546986|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year from study completion. Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17153797|NCT01168232|f||LTE60||t
17153798|NCT01279317|f||||f
17153799|NCT05012098|f||||f
17153800|NCT05258773|f||OTHER|The PI must in advance inform and provide to the sponsor a copy of the proposed publication. The sponsor may request that the PI remove confidential information from the publication.|t
17153801|NCT05277922|f||||f
17153802|NCT03018288|f||||f
17153803|NCT03593473|t||||
17153804|NCT06700512|f||LTE60||t
17153805|NCT01490086|f||LTE60||t
17153806|NCT06025721|f||||f
17153807|NCT01127256|f||||f
17153808|NCT03944668|t||||
17153809|NCT02068508|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17153810|NCT05857488|f||||f
17166915|NCT00157196|f||OTHER|The study as a whole will be published prior to any individual investigator publications. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17166916|NCT02524275|t||||
17166917|NCT00778258|f||||f
17166918|NCT05470842|t||||
17166919|NCT01926041|f||||f
17166920|NCT03111550|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17166921|NCT04696276|f||||f
17153811|NCT00413699|f||OTHER|The only disclosure restriction on the investigator is that the sponsor can review results communications at least 30 days prior to public release and can embargo communications regarding trial results for a period that is no more than an additional 60 days. Investigators will, on request, remove any previously undisclosed confidential information (other than the study results themselves) before disclosure.|t
17153812|NCT03511105|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153813|NCT02810457|f||OTHER|Any publications/presentations made within 2 years of study completion require the Sponsor or CRO's prior written consent. The Sponsor shall be provided with copies of any materials relating to the study that they intend to publish/present at least 30 days in advance of publication, submission or presentation and the Institution shall withhold publication, submission or presentation for 90 days from the date on which the Sponsor receives the material (total time-frame of 120 days).|t
17153814|NCT02832687|f||||f
17153815|NCT04231825|t||||f
17153816|NCT02019472|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17153817|NCT03192488|t||||
17153818|NCT01401361|f||OTHER||t
17153819|NCT00867529|t||||
17153820|NCT04144413|f||||f
17153821|NCT00572936|f||||f
17153822|NCT02547428|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17153823|NCT01479465|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17153824|NCT02806908|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17153825|NCT01760304|f||||f
17197641|NCT01379521|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17197642|NCT00938041|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197643|NCT01026103|f||||f
17197644|NCT00105521|f||||f
17153826|NCT04429503|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17153827|NCT05516108|f||||f
17153828|NCT00709995|f||GT60||t
17153829|NCT01641640|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17153830|NCT01234350|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17166922|NCT00780143|f||GT60||t
17153831|NCT01839708|f||||f
17153832|NCT01836471|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166923|NCT01098253|f||||f
17166924|NCT00082368|f||||f
17166925|NCT00322452|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent applications.|t
17166926|NCT00882583|f||||f
17197645|NCT02475733|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197646|NCT00404547|f||GT60||t
17197647|NCT00094497|t||||f
17137122|NCT01199055|f||||f
17137123|NCT02432040|f||||f
17137124|NCT03633227|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.|t
17153833|NCT02059135|f||OTHER|"The site may publish the results of the study after the multi-center publication or 18 months after the sponsor's final evaluation of all study data from all sites, whichever occurs first.~Up to 90 days prior to submitting a manuscript or prior to any public presentation, a copy of the abstract, manuscript, or presentation will be provided to Sponsor by the Site for review and comment. Sponsor shall have said 90 day period to respond to the Site with comments."|t
17153834|NCT03335475|f||||f
17153835|NCT02755103|f||||f
17153836|NCT01285362|t||||f
17153837|NCT00658723|f||GT60||t
17153838|NCT05921903|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153839|NCT03305848|t||||
17153840|NCT00789854|f||LTE60||t
17153841|NCT05366010|f||OTHER|The sponsor reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17153842|NCT02224157|f||||f
17153843|NCT01639157|f||||f
17153844|NCT05906628|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17153845|NCT01060072|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17153846|NCT01707290|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17153847|NCT04837196|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17153848|NCT01522456|f||LTE60||t
17153849|NCT03641469|f||OTHER|Agreements are not uniform across the sites. The most restrictive agreement states that the site PI and sponsor agree present results only together with the other clinical study sites unless specific written permission is obtained in advance from Sponsor up to 1 year post-completion. After that, the PI can publish/present independently if Sponsor is given the opportunity to review and comment prior to dissemination.|t
17153850|NCT05479435|f||||f
17153851|NCT02562235|f||OTHER|Most restricted agreement: CTA Japan; Embargo time mentioned. Hospital shall obtain prior written consent of Sponsor if PI intends to publish the information obtained from study externally such as in a professional society or association.|t
17153852|NCT05016960|f||||f
17153853|NCT04796961|f||||f
17153854|NCT02218463|f||||f
17153855|NCT03700125|f||||f
17153856|NCT02513160|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17153857|NCT02844543|t||||
17153858|NCT03241862|t||||
17153859|NCT03220204|f||||f
17153860|NCT00728260|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17153861|NCT04710576|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17153862|NCT04581824|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17153863|NCT04796909|f||||f
17153864|NCT03879135|f||||t
17153865|NCT04162847|f||||f
17153866|NCT03428958|f||||f
17153867|NCT03874117|f||||f
17153868|NCT01922037|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137125|NCT01069523|f||||f
17137126|NCT02724774|t||||
17137127|NCT04836455|f||||f
17197648|NCT02131155|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17153869|NCT00637312|f||OTHER|Within the first 12 months following completion of the study, any publication must be initiated as a multi-center publication in conjunction with other PIs in the study. After 12 months, each PI is able to publish their data, but must first submit the publication to the sponsor within 60 days prior to publication. The sponsor has the right to make reasonable requests to protect the rights and interests of the sponsor.|t
17153870|NCT00813150|f||GT60||t
17153871|NCT03851406|t||||
17153872|NCT03861390|t||||
17153873|NCT01217112|f||OTHER|GW Pharmaceuticals Ltd (GW) will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17153874|NCT02512302|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17153875|NCT01002989|f||||f
17153876|NCT03664232|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17153877|NCT00370552|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period of 60 days or less from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17153878|NCT04650217|f||||f
17153879|NCT03334435|f||GT60||t
17153880|NCT01607450|f||||f
17197649|NCT01887418|f||LTE60||t
17197650|NCT01614899|f||||t
17197651|NCT02350127|f||||f
17166927|NCT04753658|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166928|NCT05243745|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197652|NCT01446042|f||||t
17197653|NCT03906240|t||||
17197654|NCT00720629|t||||
17197655|NCT02724423|f||||t
17153881|NCT04067050|f||||f
17153882|NCT00659711|t||||
17153883|NCT02677753|f||OTHER|There were no sponsors for this study|t
17197656|NCT03152409|t||||
17197657|NCT00296504|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197658|NCT02815709|f||OTHER||t
17197659|NCT00310050|t||||
17153884|NCT01644240|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17153885|NCT03036657|f||||f
17153886|NCT00942084|t||||f
17153887|NCT01366417|f||||f
17153888|NCT02342678|t||||
17153889|NCT01545648|t||||
17153890|NCT01313897|t||||
17153891|NCT01930162|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17153892|NCT00031590|t||||
17153893|NCT05506046|f||||f
17153894|NCT03124368|f||||t
17153895|NCT01120808|f||||f
17153896|NCT03051100|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17153897|NCT03776357|t||||
17153898|NCT00489866|t||||
17153899|NCT01198470|f||OTHER|To prevent premature disclosure of trade secrets or other confidential information, PI agrees not to present, publish, or disclose study results or information about the investigational device without the express written consent of the sponsor.|t
17153900|NCT02949973|f||||f
17153901|NCT01422213|f||OTHER|The results of this study will be published. Authors of the primary publication based on this study must fulfil the criteria defined by the International Committee of Medical Journal Editors (ICMJE). The primary publication must be published before any secondary publications are submitted for publication.|t
17153902|NCT03197389|t||||
17153903|NCT04129125|f||||f
17153904|NCT04484142|f||||f
17153905|NCT03181633|f||||t
17153906|NCT05303194|f||||f
17153907|NCT01210560|f||||f
17153908|NCT05271175|f||||f
17153909|NCT00991887|f||||f
17153910|NCT02723344|t||||
17153911|NCT00524940|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17153912|NCT03473184|f||||f
17153913|NCT02964247|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17153914|NCT00607321|f||LTE60||t
17153915|NCT02044380|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17166929|NCT05160168|f||OTHER|Agreements between Theseus Pharmaceuticals and individual investigators may vary. Theseus has the right to review results disclosures prior to public release and can embargo results disclosures for \>60 days but ≤180 days from the date of submission for review. Theseus supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197660|NCT02162771|f||OTHER|Confidentiality and non-disclosure agreement (CDA) was executed between Celltrion, Inc. and some PIs who have participated in publications funded by the sponsor for academic purposes for a period that is more than 180 days from the time submitted to the sponsor for review.|t
17153916|NCT00740636|t||||
17153917|NCT03832686|t||||
17153918|NCT01609790|f||LTE60||t
17153919|NCT00739882|f||OTHER||t
17153920|NCT05022667|f||||f
17153921|NCT02024607|f||LTE60||t
17153922|NCT04514692|t||||
17197661|NCT04422210|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197662|NCT02732899|t||||
17153923|NCT01741311|f||||f
17153924|NCT03593525|f||||f
17153925|NCT03103087|f||LTE60||t
17153926|NCT00075816|f||||f
17153927|NCT01662635|t||||
17153928|NCT02445248|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17153929|NCT00351468|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17153930|NCT00683618|f||||f
17153931|NCT04570670|f||OTHER||t
17153932|NCT01892501|t||||
17153933|NCT02549859|f||||f
17153934|NCT03070236|f||||f
17153935|NCT03922321|f||||f
17153936|NCT02383017|t||||f
17153937|NCT01068860|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197663|NCT03317288|f||||f
17197664|NCT03594266|f||||f
17197665|NCT00449033|f||OTHER|The investigator, whilst free to use data from the study for scientific purposes, must not publish any document relating to the Trial without first notifying Bayer in writing and obtaining written consent. Bayer recognizes the right of the investigator to publish the results upon completion of the study. The investigator must send a draft manuscript of the publication or abstract to Bayer 60 days ahead of submission to obtain approval prior to submission of the final version for publication.|t
17197666|NCT04393779|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation to ensure proprietary information shall not be divulged. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17197667|NCT01190228|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17197668|NCT02488070|t||||
17197669|NCT01770509|f||||f
17197670|NCT01370564|f||||f
17197671|NCT02181400|t||||
17197672|NCT00905255|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17197673|NCT01245699|t||||
17197674|NCT00390806|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197675|NCT02135419|f||||f
17197676|NCT04150250|f||||f
17197677|NCT01786551|t||||f
17197678|NCT01391234|t||||
17197679|NCT00170950|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197680|NCT00748098|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197681|NCT02442622|t||||
17197682|NCT04890158|t||||
17197683|NCT01819233|t||||
17197684|NCT01232569|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197685|NCT04044352|f||LTE60||t
17197686|NCT00651937|t||||
17197687|NCT00511147|f||OTHER|Site may publish results from the study, after providing sponsor 30 days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At sponsor's request, site will remove any confidential information (other than study results), and site will upon sponsor's request delay publication or presentation for a period of up to 120 days to allow sponsor to protect its interests in any sponsor inventions|t
17197688|NCT01956071|t||||
17197689|NCT00396097|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197690|NCT03461211|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17197691|NCT04086576|f||||f
17197692|NCT00578929|f||OTHER|The sponsor reserves the right of review 60 days prior to any publication or presentation of information related to the study. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than study data and results. The Institution and the Primary Investigator agree not to publish any study related material other than above.|t
17197693|NCT04736602|f||OTHER||t
17197694|NCT00957671|f||||f
17197695|NCT00475735|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197696|NCT03132753|f||||f
17197697|NCT00125853|t||||
17153938|NCT00460603|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153939|NCT00513240|t||||
17197698|NCT02713698|f||||f
17197699|NCT03575572|t||||
17197700|NCT04405089|t||||
17197701|NCT00179478|f||||f
17153940|NCT05263908|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153941|NCT00289848|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197702|NCT00157209|f||OTHER|By signing this protocol, the investigator affirms to the Sponsor that information furnished by the Sponsor will be maintained in confidence, and such information will be divulged to the IRB/IEC under an appropriate understanding of confidentiality with such a committee. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17197703|NCT03751280|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197704|NCT00685659|t||||f
17197705|NCT02943109|f||||f
17197706|NCT01818245|f||GT60||t
17197707|NCT01257698|t||||
17197708|NCT01109602|f||||f
17197709|NCT00024102|t||||
17197710|NCT01078376|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17197711|NCT03023878|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197712|NCT01247922|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for an additional to 60 days to seek patent protection.|t
17197713|NCT04281875|f||||f
17197714|NCT01876823|f||||f
17197715|NCT00577096|f||LTE60||t
17197716|NCT04593641|f||||f
17197717|NCT00794573|f||||f
17197718|NCT03928821|f||||f
17197719|NCT02784535|f||||t
17197720|NCT02916745|f||||f
17197721|NCT00985621|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197722|NCT01911819|f||||f
17197723|NCT01732406|f||||f
17197724|NCT03849300|t||||
17197725|NCT03479502|f||||t
17197726|NCT00464737|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17197727|NCT02814279|f||||f
17197728|NCT00676663|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17197729|NCT00580047|t||||f
17197730|NCT02363933|t||||
17197731|NCT01114334|f||||f
17197732|NCT00546884|f||||f
17197733|NCT04382053|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197734|NCT00924833|f||||f
17197735|NCT03247985|t||||
17197736|NCT00417989|f||GT60||t
17197737|NCT01879735|t||||
17197738|NCT00672100|t||||
17197739|NCT01436045|t||||
17153942|NCT00860795|f||||f
17153943|NCT03871543|f||GT60||t
17153944|NCT01967862|t||||
17153945|NCT01169064|t||||
17153946|NCT01833481|t||||
17197740|NCT00497198|f||OTHER||t
17197741|NCT02799745|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17197742|NCT00814632|t||||
17197743|NCT02004132|f||GT60||t
17197744|NCT00635570|t||||
17197745|NCT02652390|t||||
17197746|NCT01064882|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17197747|NCT00729053|f||OTHER||t
17197748|NCT02514577|f||OTHER|Please contact Sponsor directly for additional information.|t
17153947|NCT00923013|f||||f
17197749|NCT02552810|f||||f
17197750|NCT04816708|t||||
17197751|NCT02388932|t||||
17197752|NCT01103271|f||||f
17197753|NCT03568708|f||||f
17153948|NCT01108718|f||||f
17153949|NCT01416636|f||||f
17153950|NCT02301169|f||OTHER|Specific agreement as part of Eureka project|t
17153951|NCT00218023|t||||
17153952|NCT01805089|f||||f
17153953|NCT02857816|f||||f
17153954|NCT04383327|t||||
17153955|NCT01289678|t||||
17153956|NCT04740918|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153957|NCT02524847|f||||t
17153958|NCT04352101|t||||
17153959|NCT01709500|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17153960|NCT00908544|f||||f
17153961|NCT03170544|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17153962|NCT02387840|t||||
17153963|NCT00226577|f||||f
17153964|NCT04143373|f||||f
17153965|NCT03888469|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17153966|NCT03539302|f||||f
17153967|NCT03477006|t||||f
17153968|NCT00071110|f||||f
17153969|NCT04707573|f||OTHER||t
17153970|NCT02389829|t||||
17153971|NCT05207865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153972|NCT03150329|t||||
17153973|NCT05423093|f||||f
17153974|NCT05364931|f||||f
17153975|NCT03504397|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17153976|NCT02596971|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17153977|NCT03190993|t||||
17153978|NCT00595920|f||GT60||t
17153979|NCT00611923|t||||
17153980|NCT03588910|f||||f
17153981|NCT00838903|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17153982|NCT04565145|f||||f
17153983|NCT03096314|f||OTHER||t
17153984|NCT00471822|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153985|NCT01062425|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17153986|NCT03003962|f||OTHER||t
17153987|NCT02695446|f||||f
17153988|NCT03103438|f||||f
17197754|NCT00809783|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17153989|NCT01468337|t||||
17153990|NCT02069015|f||||f
17153991|NCT02179892|t||||
17153992|NCT04535141|t||||
17153993|NCT00586703|t||||
17153994|NCT03762265|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17153995|NCT02452944|f||||f
17153996|NCT00806403|f||||f
17153997|NCT01882985|f||||f
17153998|NCT00765102|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation|t
17153999|NCT02547012|t||||
17154000|NCT01787292|t||||
17154001|NCT01827111|t||||
17154002|NCT02641093|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication but has the right to delay or extend publication or presentation timeframes for a period not to exceed 60 days after the initial review period when this would impact sponsor's ability to obtain patent protection.|t
17154003|NCT02962648|f||OTHER|Institution may publish the study results. Before submission for publication or presentation, Institution shall allow Sponsor not less than 90 days to review any manuscript and not less than 30 days to review any poster presentation, abstract, or any other written or oral material which describes or discloses the study results. If sponsor so requests in writing, Institution shall withhold any publication or presentation for an additional 90 days.|t
17154004|NCT01924689|f||OTHER|This document contains confidential information of BioMed Valley Discoveries, Inc. Do not copy or distribute without written permission from the Sponsor.|t
17154005|NCT02755285|f||||f
17154006|NCT01597778|f||||f
17154007|NCT03267212|f||||f
17154008|NCT01560975|f||||f
17154009|NCT04132973|t||||
17154010|NCT05691712|f||GT60||t
17154011|NCT00468819|f||LTE60||t
17154012|NCT04030299|f||||f
17154013|NCT02174627|f||||t
17154014|NCT04564092|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17154015|NCT03830333|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17154016|NCT02816346|f||||f
17154017|NCT02362360|f||LTE60||t
17154018|NCT05081063|f||||f
17154019|NCT02996227|t||||
17154020|NCT03578367|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17154021|NCT01267019|t||||
17154022|NCT02729025|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154023|NCT06954493|f||||f
17154024|NCT05966584|t||||
17154025|NCT04692103|t||||
17154026|NCT04665765|t||||
17154027|NCT04563754|t||||
17154028|NCT04023396|f||||f
17154029|NCT04021914|t||||
17154030|NCT03349060|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154031|NCT00955409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154032|NCT00485732|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154033|NCT00803790|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17197755|NCT00126555|f||LTE60||t
17197756|NCT02133066|t||||
17197757|NCT03327051|t||||
17197758|NCT03229356|t||||
17197759|NCT01939405|f||||f
17197760|NCT00694564|f||||f
17197761|NCT01284634|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17154034|NCT01880554|f||||f
17154035|NCT05161481|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17154036|NCT05537233|f||||f
17154037|NCT03802825|f||||f
17197762|NCT01059526|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154038|NCT03428152|f||||f
17154039|NCT01564693|t||||
17154040|NCT03396653|f||||f
17154041|NCT02570308|f||||t
17154042|NCT01283464|f||||f
17154043|NCT01286467|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154044|NCT01058642|f||OTHER||t
17154045|NCT01256450|f||OTHER|The oral or written use of study results by the Investigator is not permitted without the express written consent from the Sponsor.|t
17154046|NCT03866512|t||||
17154047|NCT05188261|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17154048|NCT05697809|f||||f
17154049|NCT04242498|f||GT60||t
17154050|NCT04426006|t||||
17154051|NCT06180122|f||||f
17154052|NCT03380429|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154053|NCT04760626|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17154054|NCT02946463|f||||t
17154055|NCT01753310|f||||f
17154056|NCT02169271|f||LTE60||t
17154057|NCT04846400|t||||
17154058|NCT00226499|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154059|NCT03482973|f||||f
17154060|NCT00946920|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17154061|NCT04616612|t||||
17154062|NCT01597973|f||||f
17154063|NCT02692859|f||||f
17154064|NCT01268527|f||OTHER||t
17154065|NCT02794727|t||||
17154066|NCT01288079|f||GT60||t
17154067|NCT01530464|f||||f
17154068|NCT05192239|t||||
17154069|NCT03223350|f||||f
17154070|NCT01927120|t||||
17154071|NCT01759602|f||||f
17154072|NCT04507464|f||||f
17154073|NCT00503698|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17154074|NCT02696291|f||||t
17154075|NCT02107131|t||||
17154076|NCT02259010|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17154077|NCT02817763|f||||f
17154078|NCT01546025|f||||f
17154079|NCT01276860|t||||f
17154080|NCT03796988|t||||
17154081|NCT04242446|f||GT60||t
17154082|NCT04075825|f||||t
17154083|NCT02861586|f||GT60||t
17154084|NCT03985800|t||||f
17154085|NCT04815083|f||||t
17154086|NCT06497699|f||||t
17154087|NCT04281485|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154088|NCT04673149|f||||f
17154089|NCT00127231|f||||f
17154090|NCT00957801|f||||f
17154091|NCT01778855|t||||f
17154092|NCT02182492|t||||
17154093|NCT03922308|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17154094|NCT01118741|t||||f
17154095|NCT00777296|f||OTHER||t
17154096|NCT03437863|f||||f
17154097|NCT01139125|f||||f
17154098|NCT01841047|t||||
17154099|NCT02022202|t||||
17154100|NCT05581641|f||OTHER|Principal Investigators respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17154101|NCT01383174|f||||f
17154102|NCT00204490|t||||
17154103|NCT02166333|f||||f
17154104|NCT01853215|t||||
17154105|NCT03523520|f||||f
17154106|NCT00682786|t||||
17166930|NCT03842969|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166931|NCT01044745|f||||f
17166932|NCT02890303|f||||t
17166933|NCT04086693|t||||
17154107|NCT00359424|f||OTHER|No publication will be authored prior to 12 mos after publication of the primary results without consent of the Publications Subcommittee. 12 mos after this time an Investigator may publish the results at the Collaborating Institution. No institution involved may be restricted from publishing independently 12 mos from publication of the primary paper. After 12 mo all manuscripts from the study must be submitted to the PI/Publications Subcommittee 45 days prior to any submission.|t
17154108|NCT00762710|f||||f
17154109|NCT02462603|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17154110|NCT01370629|f||OTHER||t
17154111|NCT02716714|f||||t
17154112|NCT01991743|t||||f
17154113|NCT01167140|f||OTHER||t
17154114|NCT03805412|f||||f
17154115|NCT04390113|f||||f
17154116|NCT01769573|t||||
17154117|NCT01806051|f||||f
17154118|NCT02208362|t||||
17154119|NCT03817190|f||||t
17154120|NCT03525678|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154121|NCT00887575|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17154122|NCT05251337|f||||f
17154123|NCT00917852|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17154124|NCT00471081|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154125|NCT02844933|f||LTE60||t
17166934|NCT01461928|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166935|NCT01159171|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166936|NCT01892436|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166937|NCT00583414|f||||f
17166938|NCT00733291|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study.|t
17166939|NCT02222909|t||||
17166940|NCT01981863|t||||
17166941|NCT02242435|f||LTE60||t
17166942|NCT00814697|f||||f
17166943|NCT03895086|f||||f
17166944|NCT00117715|t||||f
17154126|NCT00083382|t||||
17166945|NCT02390414|f||||f
17166946|NCT01089413|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154127|NCT02393950|f||||f
17154128|NCT04335123|t||||
17154129|NCT02506868|f||||f
17154130|NCT04537078|t||||
17154131|NCT01293695|f||||f
17154132|NCT02626026|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17154133|NCT02479451|t||||f
17154134|NCT00191477|f||GT60||t
17154135|NCT02962492|t||||
17166947|NCT02383420|f||||f
17166948|NCT02513485|t||||
17166949|NCT03811847|t||||
17166950|NCT02034175|f||OTHER|The Sponsor is responsible for publishing the study results and the PIs are not allowed to publish the study data without an approval from the sponsor|t
17166951|NCT01971463|f||||f
17154136|NCT01697748|f||OTHER|The application was initiated in 12/12. A sponsor subsequently was identified with the addition of objectives to the study. After completion of the University Clinical Trials agreement by both parties and IRB notification, the clinical trials registration was completed with receipt in 8/13. Patients were then consented and the first randomized patient occurred 9/13.|t
17154137|NCT01704495|f||GT60||t
17154138|NCT03328507|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17154139|NCT00997373|f||||f
17154140|NCT05209867|f||||f
17197763|NCT02720081|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17197764|NCT01732588|f||LTE60||t
17197765|NCT03690921|t||||
17197766|NCT02754310|f||||f
17197767|NCT05012397|f||||f
17197768|NCT03334747|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17197769|NCT02567227|t||||
17197770|NCT04362111|f||||f
17197771|NCT00935649|t||||
17197772|NCT02498418|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17197773|NCT00762502|f||OTHER|Publication requires agreement and written consent from the Sponsor.|t
17197774|NCT03042559|t||||
17197775|NCT01485991|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17154141|NCT00323453|f||||f
17154142|NCT03376789|f||LTE60||t
17154143|NCT04177095|f||||f
17197776|NCT01475370|f||||f
17197777|NCT04864236|t||||
17197778|NCT01675050|t||||
17197779|NCT04474691|f||||f
17197780|NCT02625922|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e.,data from all sites)in the clinical trial.|t
17197781|NCT01209936|f||||f
17197782|NCT01591655|f||OTHER|Contact sponsor directly for details.|t
17197783|NCT00739024|f||||f
17197784|NCT01261793|f||GT60||t
17197785|NCT01518517|f||||f
17197786|NCT00832650|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197787|NCT01229527|t||||f
17197788|NCT02335242|t||||
17197789|NCT02214017|f||||f
17197790|NCT00257556|f||OTHER|The only disclosure restiction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17197791|NCT04839289|t||||
17197792|NCT00991185|f||||f
17197793|NCT02418819|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197794|NCT04743999|t||||
17197795|NCT01721759|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197796|NCT01399905|t||||f
17197797|NCT00513292|f||LTE60||t
17197798|NCT02319304|t||||
17197799|NCT00966641|f||OTHER|Standard Confidentiality Agreement|t
17197800|NCT01804140|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197801|NCT02785900|f||GT60||t
17197802|NCT01808144|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17197803|NCT00383500|f||||f
17154144|NCT04973267|t||||f
17154145|NCT03876743|t||||f
17154146|NCT03889418|f||||f
17154147|NCT00092118|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154148|NCT03751098|f||||f
17154149|NCT03440229|f||||f
17154150|NCT01213966|f||LTE60||t
17154151|NCT03644342|t||||
17154152|NCT01845441|f||||f
17154153|NCT02976129|f||LTE60||t
17154154|NCT01591096|f||||f
17197804|NCT02648282|t||||
17197805|NCT04387201|t||||
17197806|NCT04341584|t||||
17197807|NCT04320602|f||||t
17197808|NCT04853238|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17154155|NCT01831635|f||||f
17154156|NCT03655405|t||||
17154157|NCT02045264|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17154158|NCT03218995|f||OTHER||t
17197809|NCT02956122|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonmentor termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17197810|NCT02176356|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17197811|NCT00792259|f||||f
17197812|NCT00332488|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17197813|NCT00371462|t||||
17197814|NCT02983877|f||||f
17197815|NCT03721978|f||||t
17197816|NCT05244226|t||||
17197817|NCT00733226|t||||f
17197818|NCT03722485|f||||f
17197819|NCT00349622|f||||f
17197820|NCT01902381|t||||
17197821|NCT00755716|t||||
17197822|NCT02762500|f||OTHER|Center results cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then Investigator can publish if manuscript is submitted to Lycera ≥ 60 days prior to submission (or per Investigator contract). If Lycera decides publication would hinder development, Investigator must delay submission. Investigator must delete confidential information before submission and defer publication to allow patent applications.|t
17197823|NCT02229396|f||OTHER|At least 30 days prior to submission for publication or presentation, Authors shall provide Sponsor with such material for its review. Sponsor shall have 30 days to comment. If requested by Sponsor, Authors shall withhold material for an additional 90 days to allow for the taking of measures to establish its proprietary rights. No publication or presentation shall be made unless and until any information determined at Sponsor's sole discretion to be Confidential has been removed.|t
17197824|NCT01514630|f||||f
17197825|NCT03275402|f||||f
17197826|NCT00253019|t||||
17197827|NCT05135156|f||||f
17197828|NCT00926952|t||||
17197829|NCT00647998|f||||f
17197830|NCT01259440|t||||
17197831|NCT02402465|t||||
17197832|NCT03807700|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197833|NCT03209050|f||GT60||t
17197834|NCT02005029|t||||
17197835|NCT02316847|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17197836|NCT01370018|t||||f
17197837|NCT01525641|t||||
17197838|NCT03772041|f||||f
17197839|NCT02795819|t||||
17197840|NCT03643705|f||||f
17197841|NCT04748445|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197842|NCT01994538|t||||
17197843|NCT01855997|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197844|NCT01536535|f||||f
17197845|NCT03866434|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17197846|NCT05216952|t||||
17197847|NCT00385697|f||LTE60||t
17197848|NCT00815347|f||||f
17197849|NCT02538471|t||||f
17197850|NCT00084747|f||||f
17154159|NCT02859337|f||||f
17154160|NCT01445730|t||||
17154161|NCT01465412|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with regard to proprietary information; the accuracy of the information; and to ensure that the presentation is fairly balanced and in compliance with Food and Drug Administration (FDA) regulations.|t
17154162|NCT00030901|f||||f
17154163|NCT03126968|f||||f
17154164|NCT02576847|f||||f
17154165|NCT01205776|f||OTHER||t
17154166|NCT00734994|t||||f
17154167|NCT02021929|f||||f
17154168|NCT04146012|f||||f
17154169|NCT01622673|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17154170|NCT05514873|f||GT60||t
17154171|NCT05425927|f||||f
17154172|NCT02747108|t||||
17154173|NCT03896503|f||LTE60||t
17154174|NCT00437021|f||LTE60||t
17154175|NCT05573464|f||OTHER|"PI may not independently publish results until one of the following occurs: 1. multicentre primary publication is published; 2. no multicentre primary publication is submitted within 2 years after conclusion; 3. Sponsor confirms in writing there will be no multicentre primary publication.~PI shall provide the Sponsor with copies of any materials relating to the study that they intend to publish or make presentations relating to, at least 30 days in advance."|t
17154176|NCT05734157|f||LTE60||t
17154177|NCT05338489|f||GT60||t
17154178|NCT02979587|f||LTE60||t
17154179|NCT00210210|t||||
17154180|NCT03096418|t||||
17154181|NCT04225715|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154182|NCT03318861|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17154183|NCT02004366|f||||f
17154184|NCT03158038|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17154185|NCT02527746|f||||t
17154186|NCT02275546|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17154187|NCT02955355|f||||t
17154188|NCT02612623|f||OTHER|The results obtained during the course of this study will be kept confidential and will not be disclosed in whole or in part to others or used for any purpose other than reviewing or performing the study without the written consent of the Sponsor. No data collected as part of this study will be utilized in any written work, including publications, without the written consent of the Sponsor.|t
17154189|NCT05177484|t||||
17154190|NCT03426124|f||||t
17154191|NCT01129440|t||||f
17154192|NCT05486091|f||||f
17154193|NCT01568892|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154194|NCT01275365|t||||f
17154195|NCT00553839|f||||f
17154196|NCT01965756|f||||f
17154197|NCT01592786|f||OTHER|"All data generated in this study are the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17154198|NCT02199964|f||||f
17154199|NCT02172664|f||||f
17154200|NCT03810092|f||||f
17154201|NCT02816736|f||LTE60||t
17154202|NCT01139775|f||GT60||t
17154203|NCT02774941|f||||f
17154204|NCT03193853|t||||
17154205|NCT01956773|f||||f
17154206|NCT00126750|t||||
17154207|NCT00450437|f||||f
17154208|NCT02492867|t||||
17154209|NCT03296527|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17154210|NCT00122382|f||OTHER||t
17154211|NCT01008605|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154212|NCT02040805|f||||f
17154213|NCT03591874|f||||f
17154214|NCT02269098|f||||f
17154215|NCT01766076|t||||f
17154216|NCT02245516|f||OTHER|No submission for publication or public disclosure will be made by the PI until after the publication of the results of the multi-center clinical trial by the Sponsor. Thereafter, PI shall provide KALA with an advance copy of any proposed publication or public disclosure at least sixty (60) days prior to the planned date of submission or disclosure and KALA shall have forty-five (45) days from the date of its receipt to recommend changes.|t
17166952|NCT03018418|f||||f
17166953|NCT00309140|f||GT60||t
17166954|NCT00420004|f||GT60||t
17166955|NCT00591149|t||||
17166956|NCT00470093|t||||f
17166957|NCT02456636|f||||f
17166958|NCT00866034|t||||f
17166959|NCT05312632|f||||t
17166960|NCT02379221|f||||f
17166961|NCT01610557|f||OTHER|No outcome data should be presented until after a manuscript is accepted for publication.|t
17166962|NCT00484393|f||||f
17154217|NCT03194542|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154218|NCT04762160|f||OTHER||t
17154219|NCT07091916|f||||f
17154220|NCT03576326|f||||f
17154221|NCT03375918|t||||f
17154222|NCT03971071|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154223|NCT05267236|t||||
17154224|NCT03210714|f||LTE60||t
17154225|NCT01909934|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154226|NCT06684951|f||||f
17154227|NCT03872427|f||LTE60||t
17154228|NCT03831932|f||LTE60||t
17154229|NCT04577807|f||LTE60||t
17154230|NCT03907488|f||LTE60||t
17154231|NCT01662492|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17154232|NCT00673439|t||||f
17154233|NCT03175536|f||||f
17154234|NCT05286450|t||||
17154235|NCT03134144|f||||f
17197851|NCT03327571|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17197852|NCT01136798|f||||f
17197853|NCT02382406|f||||f
17197854|NCT01093183|f||||f
17154236|NCT01611883|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17154237|NCT03757312|t||||
17154238|NCT05009602|t||||
17154239|NCT05142722|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17154240|NCT05731700|f||LTE60||t
17154241|NCT04495946|f||||f
17154242|NCT05468164|f||GT60||t
17154243|NCT04846569|t||||f
17154244|NCT01467713|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154245|NCT00382200|t||||
17154246|NCT00536939|f||GT60||t
17154247|NCT01100086|f||GT60||t
17154248|NCT03532425|t||||
17154249|NCT01174823|f||OTHER|Contact sponsor directly for details.|t
17154250|NCT02767011|f||||f
17154251|NCT02954601|f||||t
17154252|NCT01611935|f||||f
17154253|NCT00333983|t||||
17154254|NCT00833105|f||||f
17154255|NCT01739231|f||GT60||t
17154256|NCT03204786|t||||
17154257|NCT06188715|t||||f
17154258|NCT03817853|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154259|NCT00314340|f||||f
17154260|NCT00607620|f||||f
17154261|NCT01620138|f||||f
17154262|NCT03252535|f||||f
17154263|NCT06509438|f||||t
17154264|NCT05600283|t||||
17154265|NCT02867592|f||LTE60||t
17154266|NCT03581292|f||LTE60||t
17154267|NCT02565628|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166963|NCT00519376|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197855|NCT03794609|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197856|NCT04543942|f||||f
17197857|NCT03840278|f||||f
17197858|NCT03805698|t||||
17197859|NCT02097056|f||OTHER||t
17166964|NCT02039219|t||||
17166965|NCT02974855|f||LTE60||t
17166966|NCT00129701|t||||
17154268|NCT04286269|t||||
17154269|NCT01220466|f||OTHER||t
17154270|NCT00570141|f||||f
17154271|NCT04547985|t||||
17154272|NCT02992236|f||||f
17154273|NCT03446027|f||||f
17154274|NCT03097341|f||OTHER|Aronora shall retain title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with this study. Such publications shall not be made by the PI or Celerion without the prior written consent of Aronora.|t
17154275|NCT01209949|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17154276|NCT01067781|f||OTHER||t
17154277|NCT00729612|t||||
17154278|NCT04556305|f||||f
17154279|NCT03808948|t||||
17166967|NCT02750345|f||||f
17166968|NCT02650128|f||||f
17166969|NCT00635739|f||||f
17166970|NCT00608023|f||LTE60||t
17197860|NCT01323309|t||||
17197861|NCT00472056|t||||
17197862|NCT02133131|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17197863|NCT01544153|f||||f
17197864|NCT02127892|t||||
17197865|NCT00884793|t||||
17197866|NCT03169530|f||||f
17197867|NCT01032200|t||LTE60||t
17197868|NCT00067808|t||||f
17197869|NCT00714688|f||GT60||t
17154280|NCT02075203|f||||f
17154281|NCT03214224|t||||
17154282|NCT02712320|f||OTHER|All information from the trial is property of the Sponsor and the PI has no right on it except the prior writing authorization of the sponsor.|t
17154283|NCT00568451|t||||
17154284|NCT03982511|f||||f
17154285|NCT05266053|f||||f
17154286|NCT05344560|f||GT60||t
17154287|NCT01593670|f||||f
17154288|NCT02535026|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154289|NCT01343043|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154290|NCT00360282|f||||f
17154291|NCT00925704|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17154292|NCT02996968|t||||
17154293|NCT00216125|f||||f
17154294|NCT02044302|t||||
17154295|NCT04029584|t||||
17154296|NCT04268771|f||LTE60||t
17154297|NCT00449865|f||||f
17154298|NCT00444535|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17154299|NCT00406367|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 weeks before submission. Sponsor to give written opinion within 30 days. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17154300|NCT00171210|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17154301|NCT00253435|f||OTHER||t
17154302|NCT03187301|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17154303|NCT01808963|f||||f
17154304|NCT00304096|t||||
17154305|NCT02158585|f||||f
17154306|NCT05005507|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17154307|NCT00942578|f||||f
17154308|NCT01072773|t||||
17154309|NCT04381728|f||||f
17154310|NCT00442897|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154311|NCT04498182|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17154312|NCT02667704|t||OTHER||
17154313|NCT02275819|f||||f
17154314|NCT01346059|t||||f
17154315|NCT02556775|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17154316|NCT01011816|f||OTHER|"Disclosure restrictions:~* Sponsor can review results communication prior to public release and can embargo communications regarding trial results for up to 30 days from the time submitted for review.~* If the communication contains patentable invention information, disclosure may be delayed up to 6 months for patent application filing.~* If the communication contains confidential information, Sponsor will notify the PI to remove the confidential information prior to release."|t
17154317|NCT01354652|f||||f
17154318|NCT00558467|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17154319|NCT02344238|f||||f
17166971|NCT02975999|t||||
17166972|NCT04924530|t||||
17166973|NCT01591837|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17166974|NCT04022226|f||||f
17166975|NCT03130439|t||||
17154320|NCT05028790|f||||f
17154321|NCT05002790|t||||
17154322|NCT01549587|f||OTHER|Joint agreement with PIs.|t
17154323|NCT02025725|f||LTE60||t
17154324|NCT03331796|f||||f
17154325|NCT00594165|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17154326|NCT02757053|f||||f
17154327|NCT00571727|f||OTHER||t
17154328|NCT03914612|f||LTE60||t
17154329|NCT01047527|t||||
17154330|NCT02573597|t||||
17154331|NCT01735916|f||||f
17154332|NCT04227197|f||||f
17166976|NCT03544476|f||||f
17166977|NCT04838054|f||||f
17197870|NCT00500539|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17197871|NCT02316171|f||||t
17197872|NCT03859622|f||||f
17197873|NCT01524887|f||OTHER|For this study, PIs are restricted from independently publishing results before completion of a single multicenter publication or one year after study completion, whichever occurs first. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (eg, for intellectual property protection).|t
17197874|NCT00547300|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17197875|NCT01596699|t||||
17197876|NCT04380688|f||OTHER|"PI shall provide copies of any materials relating to the Study, or the Developed Technologies that either intends to publish or make any presentations relating to, at least 30 days in advance of publication, submission or presentation.~PI shall not include in or shall remove from any proposed publication of any Confidential Information, errors or inaccuracies; and shall withhold publication, submission for publication or presentation for 90 days from the date the Company receives the material."|t
17197877|NCT03993054|t||||
17197878|NCT04990973|t||||
17154333|NCT03656068|t||||
17154334|NCT00162981|f||OTHER|Principal Investigator agrees to delete, at Sponsor's request, from any proposed Public Presentation any information or material that Sponsor deems confidential or proprietary.|t
17154335|NCT01323517|t||||
17166978|NCT00729677|f||||f
17154336|NCT00300235|f||||f
17154337|NCT00455403|t||||
17154338|NCT00350207|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17154339|NCT00495391|f||OTHER|Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.|t
17154340|NCT03566199|t||||
17154341|NCT01953302|t||||
17154342|NCT05340764|t||||
17166979|NCT01801436|f||LTE60||t
17166980|NCT02899650|t||||
17166981|NCT01126437|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17166982|NCT01418703|t||||
17166983|NCT00615589|t||||
17166984|NCT01220973|t||||
17166985|NCT01846663|f||OTHER|Contact sponsor for details.|t
17154343|NCT00502242|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154344|NCT03207815|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17154345|NCT01671007|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17154346|NCT00391768|f||||f
17154347|NCT04630002|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154348|NCT02182843|f||||f
17154349|NCT05541003|f||||f
17154350|NCT02375971|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17166986|NCT01215110|f||OTHER|The investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting, for review and removal of confidential information.|t
17166987|NCT00813865|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17166988|NCT03525600|f||||t
17166989|NCT01191736|t||||
17166990|NCT03703817|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17166991|NCT03927482|f||||f
17166992|NCT03255967|t||||
17166993|NCT01202188|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17166994|NCT01311115|f||||f
17166995|NCT03319953|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17166996|NCT02438384|t||||f
17166997|NCT03315793|f||GT60||t
17166998|NCT01331837|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17166999|NCT03345160|t||||
17167000|NCT01521871|f||||f
17167001|NCT03407053|t||||
17167002|NCT02640625|t||||
17167003|NCT00511433|f||OTHER|The Sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17197879|NCT04267393|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17197880|NCT03273283|t||||
17137128|NCT02010216|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137129|NCT04167306|f||||f
17137130|NCT00403559|f||||f
17167004|NCT01740089|f||||f
17167005|NCT00790868|t||||f
17167006|NCT01380535|f||LTE60||t
17167007|NCT02013206|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167008|NCT02791191|f||GT60||t
17197881|NCT00710814|t||||
17154351|NCT00891020|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154352|NCT01932060|f||||f
17154353|NCT03137160|t||||
17154354|NCT03291080|f||||f
17154355|NCT01339260|f||OTHER|Sponsor and investigator(s) agree that no publications discussing trials' results will occur until release of final report. Sponsor has no objections if the investigators publish study results, however the investigator is requested to contact the sponsor before publishing, to prevent premature disclosure of data and is not intended as a restrictive measure concerning results or opinions of investigators.|t
17154356|NCT00320710|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17154357|NCT03448419|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17154358|NCT00832455|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154359|NCT00343044|f||||f
17197882|NCT02548754|t||||
17197883|NCT02093897|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197884|NCT00088452|f||||f
17197885|NCT02629419|f||||f
17197886|NCT02081196|f||||f
17197887|NCT02055053|t||||
17197888|NCT03098797|f||GT60||t
17197889|NCT01101464|f||OTHER|All publications must be based on data validated by Organon. Any such communication will first be submitted to Organon, at least 6 weeks ahead of time for written consent. Organon shall have the right to make its consent conditional upon proper representation of the interpretation of both Organon and the investigator. In any communication concerning this trial, the authors of this protocol will be included in the list of authors.|t
17197890|NCT00381888|t||||f
17197891|NCT01231464|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197892|NCT01410084|t||||f
17197893|NCT00993798|f||||t
17197894|NCT00383630|t||||
17197895|NCT01589523|t||||
17197896|NCT00961896|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17197897|NCT02503982|t||||
17197898|NCT01997437|t||||f
17197899|NCT04397614|f||||f
17197900|NCT00555997|f||||f
17197901|NCT02507687|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17197902|NCT02675998|f||GT60||t
17197903|NCT02916706|f||OTHER||t
17197904|NCT04357964|t||||
17197905|NCT00575367|f||OTHER|PI cannot publish or discuss trial results until written communication is received from Inspire Pharmaceuticals, Inc.|t
17197906|NCT01194271|t||||
17154360|NCT05047211|f||||f
17167009|NCT01952665|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor.|t
17167010|NCT01760473|f||||f
17167011|NCT01537081|f||LTE60||t
17197907|NCT01750086|f||||f
17197908|NCT00381797|f||LTE60||t
17197909|NCT02288364|t||||
17197910|NCT00443898|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17197911|NCT00043186|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17197912|NCT00958711|f||GT60||t
17197913|NCT03065205|f||||f
17197914|NCT01341444|f||||f
17197915|NCT05012280|f||OTHER||t
17197916|NCT01701271|f||||f
17197917|NCT00550771|f||OTHER|The principal investigators (PIs) agree not to publish/publicly present any interim study results without prior sponsor written consent. The PIs further agree to provide 45 days written notice to the sponsor, prior to submission for publication or presentation, to permit the sponsor to review abstracts/manuscripts, which report any study results. The sponsor has the right to review/comment. If the parties disagree, the PIs agree to meet with the sponsor, prior to submission, to discuss/resolve.|t
17154361|NCT00561392|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17154362|NCT01575834|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154363|NCT01548040|f||||f
17154364|NCT01069510|f||||f
17154365|NCT03858998|t||||
17154366|NCT02220764|f||||f
17154367|NCT05000164|f||GT60||t
17154368|NCT03493854|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154369|NCT02422446|f||||f
17154370|NCT02198664|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17154371|NCT00999609|f||||t
17154372|NCT05343364|f||OTHER|Principal investigators (PIs) are not permitted to publish the data. Data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the PIs to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority over all such issues.|t
17154373|NCT02251821|t||||f
17154374|NCT01262872|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154375|NCT01753570|f||OTHER||t
17154376|NCT04709562|f||||f
17197918|NCT00730847|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197919|NCT03022578|t||||
17197920|NCT04517877|t||||
17197921|NCT01223963|f||LTE60||t
17197922|NCT03245762|f||||f
17197923|NCT03681353|f||||f
17197924|NCT01189617|f||OTHER|Study is considered a work made for hire and the Sponsor retains all rights to publish results.|t
17197925|NCT02640807|f||||f
17197926|NCT00726388|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197927|NCT00111839|f||||f
17197928|NCT01502787|t||||
17197929|NCT00377312|f||||f
17197930|NCT02775214|f||||f
17197931|NCT00762723|f||||f
17197932|NCT00382408|f||OTHER|The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.|t
17197933|NCT01145417|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197934|NCT02435381|f||OTHER|Investigator shall have the right to publish or otherwise publicly disclose information gained in the course of this Agreement. Investigator agrees to submit to Company copies of manuscripts, posters, slides, or abstracts that are intended for presentation or publication and that contain the results of the performance of this Agreement not less than 30 days before submission of manuscripts for publications or presentations of slides and posters, or 10 days prior to abstract submission.|t
17197935|NCT01191697|t||||
17197936|NCT03939793|f||||f
17197937|NCT01066897|f||||f
17197938|NCT03861429|f||||f
17197939|NCT00529555|f||OTHER||t
17197940|NCT05372913|f||||f
17197941|NCT02986659|t||||
17154377|NCT01000155|f||||f
17154378|NCT03193684|t||||
17154379|NCT00720213|f||GT60||t
17154380|NCT00097448|f||||f
17181947|NCT00746941|f||OTHER|The PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 45 to 60 days as agreed within their clinical trial agreement to review any manuscript for a proposed publication and must delay publication for up to an additional 60 to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17181948|NCT01820754|t||||f
17181949|NCT02180412|f||||t
17181950|NCT04654117|f||||f
17154381|NCT02092298|t||||
17154382|NCT00620945|t||||f
17154383|NCT01808066|f||||f
17154384|NCT01252095|f||OTHER|No data may be published or presented from the study except with the prior written consent of Progen. Progen reserves the right to a 30-day review and approval of all manuscripts related to the study prior to publication.|t
17154385|NCT00365794|f||||f
17154386|NCT00745901|f||LTE60||t
17154387|NCT00884117|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154388|NCT01786993|f||LTE60||t
17154389|NCT02555228|f||||f
17154390|NCT02505217|f||||f
17154391|NCT00153179|f||||f
17154392|NCT04495829|f||||f
17154393|NCT02712554|f||||f
17154394|NCT03859427|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154395|NCT02503540|f||||f
17154396|NCT01804946|f||OTHER||t
17154397|NCT00722137|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154398|NCT01129557|f||||f
17154399|NCT00669669|t||||
17154400|NCT00848718|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17154401|NCT02689154|f||||f
17154402|NCT02418182|f||||f
17154403|NCT03334344|f||||f
17154404|NCT02431676|t||||f
17197942|NCT01955720|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197943|NCT00191984|f||GT60||t
17197944|NCT02137239|f||LTE60||t
17197945|NCT00139659|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17197946|NCT03048058|t||||f
17197947|NCT00924209|f||||f
17197948|NCT02359552|f||||f
17197949|NCT02391116|f||LTE60||t
17197950|NCT02520414|f||||f
17197951|NCT02282917|f||||f
17197952|NCT01747629|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17197953|NCT01395914|f||OTHER|The Sponsor intends to publish the complete study results in a timely manner that is appropriate to the project. Separate publication of a portion of the study results by any PI is discouraged.|t
17197954|NCT04414397|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17197955|NCT02502487|f||||f
17197956|NCT01150500|t||||f
17197957|NCT01920178|t||||
17197958|NCT02391545|f||||t
17197959|NCT03868735|f||||f
17197960|NCT01557699|f||||f
17197961|NCT01002547|f||||f
17197962|NCT02515656|f||||t
17197963|NCT00434577|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137131|NCT03105700|t||||
17137132|NCT01253421|f||||f
17137133|NCT00121992|f||LTE60||t
17154405|NCT00570687|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17154406|NCT01624740|f||||f
17154407|NCT02999269|f||||f
17154408|NCT01102257|t||||
17167012|NCT01022359|t||||
17167013|NCT01463111|t||||
17181951|NCT03190889|f||||f
17181952|NCT00405548|t||||
17181953|NCT02741700|t||||
17181954|NCT00923559|f||||f
17154409|NCT01120184|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154410|NCT04003636|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17154411|NCT01904526|f||||f
17154412|NCT03270657|t||||
17154413|NCT04509076|t||||
17154414|NCT00459862|f||LTE60||t
17197964|NCT01967719|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17197965|NCT02329223|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17154415|NCT01812109|t||||f
17154416|NCT03313180|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17154417|NCT00461630|t||||f
17154418|NCT02546375|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154419|NCT02104219|f||OTHER|Participation in a multicenter study involves a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis. Therefore, PIs are subject to certain disclosure and publication limitations.|t
17154420|NCT01788631|f||||f
17154421|NCT02588612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154422|NCT00717912|f||GT60||t
17154423|NCT02841995|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17154424|NCT01051596|t||||
17154425|NCT03809663|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154426|NCT01703260|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154427|NCT05333601|f||||f
17154428|NCT02215369|f||||f
17154429|NCT02531308|t||||
17154430|NCT04548193|t||||
17154431|NCT02721277|t||||
17154432|NCT00630825|f||GT60||t
17154433|NCT02042014|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154434|NCT03892642|t||||
17154435|NCT02211209|f||||t
17154436|NCT01719367|t||||
17154437|NCT02792062|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17154438|NCT01216241|f||||f
17154439|NCT03309943|f||||f
17154440|NCT00931255|f||||f
17154441|NCT01372995|t||||
17154442|NCT01483963|f||||t
17154443|NCT05245526|f||||f
17154444|NCT00558701|t||||
17154445|NCT00427648|f||||f
17154446|NCT01297517|t||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17154447|NCT01155180|f||||f
17154448|NCT00775229|f||||f
17154449|NCT00628212|f||OTHER||t
17154450|NCT01681212|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17181955|NCT00811577|f||LTE60||t
17181956|NCT01625455|t||||
17154451|NCT01464424|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17154452|NCT01464333|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17154453|NCT00789373|f||GT60||t
17154454|NCT00470717|t||||
17154455|NCT01741688|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154456|NCT02282813|f||LTE60||t
17154457|NCT01514292|f||||f
17154458|NCT00739661|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154459|NCT04316104|f||||f
17154460|NCT02105987|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154461|NCT00920439|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154462|NCT01420068|f||OTHER|"Contract with new study sponsor Noden Pharma."|t
17154463|NCT00758290|f||GT60||t
17154464|NCT01699373|t||||
17154465|NCT02170220|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17154466|NCT01153815|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154467|NCT02147834|t||||f
17154468|NCT01890122|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154469|NCT02062450|f||LTE60||t
17154470|NCT02907177|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17154471|NCT00867659|f||||f
17154472|NCT01334229|f||||f
17154473|NCT02003404|f||||f
17154474|NCT01486446|f||GT60||t
17154475|NCT04031846|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17154476|NCT03048747|f||||f
17154477|NCT00824772|t||||f
17154478|NCT00866281|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17154479|NCT02235064|t||||
17154480|NCT01894841|t||||
17154481|NCT00730483|t||||
17154482|NCT00529087|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17154483|NCT00318474|f||||f
17154484|NCT01775813|f||||f
17154485|NCT00457002|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154486|NCT02918565|f||||f
17181957|NCT02641379|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181958|NCT01165138|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181959|NCT04982250|f||||f
17154487|NCT02283268|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until completion of the multicenter publication or one year after the conclusion of the study at all sites. Baxalta requires a review of results communication (e.g. for confidential information) \>= 30 days prior to submission. Baxalta may request an additional delay of \<= 6 months (e.g. for intellectual property protection).|t
17154488|NCT00454246|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17154489|NCT05326529|f||||t
17154490|NCT01379768|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17154491|NCT01135329|t||||
17154492|NCT03417557|f||||t
17154493|NCT01944878|f||||f
17154494|NCT00708552|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154495|NCT00616343|t||||
17154496|NCT01317095|t||||
17154497|NCT03168711|f||||f
17154498|NCT01609010|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154499|NCT01017874|f||GT60||t
17154500|NCT01966120|f||OTHER|The only disclosure restriction on the PI is that the sponsor will review results communications prior to public release and has to approve in order to ensure the adequate reporting of study results. The sponsor can't refuse publication for unfair reasons.|t
17154501|NCT04557215|t||||f
17154502|NCT03123393|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154503|NCT03197038|f||||f
17154504|NCT02069041|f||GT60||t
17154505|NCT03321968|f||OTHER|The Investigator understands that the information in the protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical review of the study, without prior written authorization from the Sponsor. It is, however, permissible to discuss information contained in the protocol with a participant in order to obtain consent once Institutional Review Board (IRB) approval is obtained.|t
17154506|NCT02249728|f||LTE60||t
17154507|NCT02155283|f||||f
17154508|NCT00232739|f||GT60||t
17154509|NCT02744430|f||||f
17154510|NCT00463047|f||GT60||t
17154511|NCT03283787|f||||f
17154512|NCT00426166|t||||
17154513|NCT03020992|f||GT60||t
17154514|NCT02560922|t||||f
17197966|NCT02924350|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197967|NCT00097708|f||OTHER||t
17197968|NCT00506922|t||||f
17154515|NCT01006122|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154516|NCT02094352|t||||
17154517|NCT00529308|t||||
17154518|NCT00660517|f||OTHER|"Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.~Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)"|t
17154519|NCT02554682|t||||
17154520|NCT02705365|f||||f
17154521|NCT04526288|f||||f
17154522|NCT04830969|t||||f
17154523|NCT00086138|f||||f
17154524|NCT02798380|f||||f
17154525|NCT00952068|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17154526|NCT01873846|f||||f
17154527|NCT03147690|f||||f
17154528|NCT00708461|t||||f
17154529|NCT01786161|t||||
17154530|NCT00580151|t||||
17197969|NCT01502306|f||||f
17197970|NCT02137499|t||||
17197971|NCT00848393|t||||
17197972|NCT01011049|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17197973|NCT02312622|t||||
17197974|NCT00871143|t||||
17154531|NCT01934582|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17167014|NCT03817463|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167015|NCT04140695|f||OTHER||t
17167016|NCT02964559|f||||f
17167017|NCT01215643|f||OTHER||t
17167018|NCT02596958|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167019|NCT01559259|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167020|NCT01995669|t||||
17167021|NCT05425732|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17167022|NCT02150551|f||||f
17167023|NCT00306293|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167024|NCT00185380|f||OTHER|The sponsor is interested in the publication of the results of every study. As some of the information concerning the study drug and the sponsor's development activities may be strictly confidential, any publication manuscript (including conference contributions, etc.) must first be reviewed by the sponsor before its submission or presentation.|t
17167025|NCT02998203|f||||f
17197975|NCT00352053|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17197976|NCT00520403|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197977|NCT01490359|t||||
17197978|NCT00405912|f||||f
17197979|NCT03730662|f||GT60||t
17197980|NCT01797562|f||||f
17197981|NCT01309243|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17197982|NCT03930238|t||||
17197983|NCT00632931|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17197984|NCT03009019|f||||f
17197985|NCT01441583|f||OTHER|Consultant (PI) acknowledges and agrees that (i) Consultant shall not publish any data, report, white papers or other materials arising out of the Services performed pursuant to this Agreement without the prior written consent of Boston Scientific, and (ii) any such publication shall not include Boston Scientific Confidential Information except prior written consent of Boston Scientific.|t
17197986|NCT03341312|f||GT60||t
17197987|NCT00839306|f||||f
17197988|NCT01812707|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17197989|NCT05060237|f||OTHER|Details of the Study and results shall not be published in any form without prior consent of Sponsor. All decisions on the timing and content of publications/ presentations will be coordinated by Sponsor. A draft of any manuscript, talks, abstracts, and all similar material shall be submitted to sponsor at least sixty (60) days before submission of the final form to any journal, scientific conference, symposium, or program review committee prior to publication or other release.|t
17154532|NCT02630251|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154533|NCT02174510|f||OTHER||t
17154534|NCT01225250|t||||
17154535|NCT03111940|t||||
17154536|NCT02188147|f||||f
17167026|NCT01120236|f||LTE60||t
17167027|NCT02199314|t||||
17154537|NCT01537042|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17154538|NCT00979654|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17154539|NCT01779440|f||||f
17154540|NCT01205269|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.|t
17154541|NCT01408303|f||OTHER|Individual investigators may publish data arising from their own subjects. The PI will provide the Sponsor with copies of written publications (including abstracts and posters)at least 60 days in advance of submission. Data will be reviewed by all participating investigators prior to publication. The Sponsor will have 60 days to review all definitive publications, such as manuscripts and book chapters, and a minimum of 30 days to review all abstracts.|t
17154542|NCT01207687|f||LTE60||t
17154543|NCT01801865|t||||f
17154544|NCT00523848|t||||
17154545|NCT01938092|t||||
17154546|NCT01367886|t||||
17154547|NCT00985504|f||GT60||t
17154548|NCT00574704|f||GT60||t
17154549|NCT03711786|f||||f
17154550|NCT00715273|t||||
17154551|NCT03379727|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17154552|NCT06868654|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17154553|NCT04138498|f||OTHER|Institution/PI shall not have the right to use the results pertaining to Institution's/PI's activities for their own instructional or research publication objectives, unless provided written permission by Sponsor. Publication must not disclose Confidential Information. Institution and PI shall submit in writing to Sponsor review of any Publication. Sponsor shall advise Institution of information which is Confidential Information or which may impair Sponsor's ability to obtain patent protection.|t
17154554|NCT00764660|f||OTHER|In case the proposed publication contains reference to an invention owned by Organon or to which Organon otherwise has rights, Organon may request a reasonable suspension of the publication in order to be able to file a patent application protecting such invention.|t
17154555|NCT01131455|f||||f
17154556|NCT03103152|f||OTHER|The NHS Organisation shall not publish/disseminate the conclusions of the Study, including all or any part of the Results of the Study without the prior written consent of the Sponsor. Any publication/dissemination of the conclusions of the Study by the NHS Organisation shall not occur until the Sponsor has published the conclusions of the Study in accordance with clause 7.2 and shall refer to publication by the Sponsor in such form as the Sponsor may reasonably direct.|t
17167028|NCT04187144|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167029|NCT02650804|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release regarding trial results.|t
17167030|NCT02759107|f||GT60||t
17167031|NCT02526524|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17167032|NCT02913430|t||||
17167033|NCT02019108|f||||f
17167034|NCT01084278|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17167035|NCT04569136|f||||f
17167036|NCT00611468|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.|t
17181960|NCT01148511|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154557|NCT03208166|f||||f
17154558|NCT03668119|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154559|NCT04170738|t||||
17154560|NCT03055338|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17154561|NCT03058705|t||||
17154562|NCT02151851|f||GT60||t
17154563|NCT02159053|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154564|NCT01135381|f||||f
17154565|NCT01540487|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17154566|NCT01256164|f||OTHER|Investigators were part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.|t
17154567|NCT01754350|t||||
17154568|NCT03773172|t||||
17154569|NCT02974686|f||||f
17154570|NCT02525783|f||OTHER|If a manuscript for the multi-center Publication has not been submitted within twelve (12) months of the conclusion (as defined in the Protocol), abandonment or termination of the Study, then the Researchers may Publish a subset of multi-center results of the Study. Sponsor personnel shall be acknowledged in accordance with customary scientific practice.|t
17154571|NCT01295671|f||||f
17154572|NCT01202578|f||GT60||t
17154573|NCT00808210|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17154574|NCT02017210|t||||
17154575|NCT02356588|f||OTHER||t
17154576|NCT01987089|t||||
17154577|NCT03150719|f||OTHER||t
17154578|NCT01790984|t||||
17154579|NCT00383760|f||LTE60||t
17154580|NCT01346696|f||LTE60||t
17154581|NCT01450306|t||||
17154582|NCT00375973|f||||f
17154583|NCT01691560|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154584|NCT01051791|t||||
17154585|NCT04545008|t||||
17154586|NCT00506415|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17154587|NCT04578457|t||||
17154588|NCT00245128|t||||f
17154589|NCT02019264|f||||f
17154590|NCT00105079|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17197990|NCT01697592|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17197991|NCT02396758|f||||t
17154591|NCT02053766|t||||
17154592|NCT02414243|f||||f
17154593|NCT01609296|f||LTE60||t
17154594|NCT00386360|t||LTE60||t
17154595|NCT02230904|f||GT60||t
17154596|NCT01532518|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A.~has reviewed/commented and agreed to any publication."|t
17154597|NCT04332081|t||||
17197992|NCT00265096|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17154598|NCT02677922|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154599|NCT03365635|f||||f
17181961|NCT00446147|f||||f
17197993|NCT00774306|f||||f
17197994|NCT03897049|f||||f
17154600|NCT03004638|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17154601|NCT03926117|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17154602|NCT02748356|f||||f
17167037|NCT01466660|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17197995|NCT00666835|f||||t
17197996|NCT01126879|t||||
17197997|NCT03319719|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17197998|NCT01212952|t||||
17197999|NCT03193216|t||||
17198000|NCT00735462|f||OTHER|a term restricts that PI can publish their trial results within 12 months of completion of the trial.|t
17198001|NCT02236598|f||||f
17198002|NCT01484314|f||||f
17198003|NCT01264887|f||OTHER|The Sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17198004|NCT02959177|f||GT60||t
17198005|NCT01947153|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198006|NCT01061775|t||||
17198007|NCT04349124|t||||
17198008|NCT00360971|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17198009|NCT01313299|f||||f
17198010|NCT05021757|f||||f
17198011|NCT03799289|f||||f
17198012|NCT04089332|t||||
17198013|NCT00050167|t||||f
17198014|NCT03418701|f||||f
17198015|NCT04754594|f||OTHER|The sponsor (or its agents) has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198016|NCT04896502|t||||
17198017|NCT03340766|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198018|NCT00581009|f||||f
17198019|NCT02849509|t||||
17198020|NCT02256488|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site was postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17198021|NCT03847389|f||||f
17198022|NCT02864147|t||||
17198023|NCT00975130|f||OTHER|Investigator is granted the right to use the results of all work under this study including but not limited to, the results of tests and any raw data and statistical data generated for investigator's own teaching, research, and publication purposes only. Investigator/Institution agrees, on behalf of itself and its employees, officers, trustees, and agents, not to cause said results to be knowingly used for any commercial purpose whatsoever except as authorized by the sponsor in writing.|t
17198024|NCT00240097|f||||f
17198025|NCT02383927|f||OTHER|There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.|t
17198026|NCT00734851|t||||
17198027|NCT03427177|f||||f
17198028|NCT03562117|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198029|NCT01294358|f||||f
17198030|NCT03356145|t||||
17154603|NCT00996125|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154604|NCT03515811|f||||f
17198031|NCT03613454|t||||
17198032|NCT02963922|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17167038|NCT00191724|f||GT60||t
17167039|NCT02301546|f||||f
17167040|NCT01636063|f||||f
17167041|NCT02447250|f||||f
17154605|NCT00237458|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17154606|NCT03308097|f||||f
17154607|NCT01453088|t||||
17154608|NCT01796392|f||||f
17198033|NCT00702234|f||OTHER|Publications must be based on data validated and released by the Sponsor. Any scientific paper, presentation, or other communication concerning the study must first be submitted to the Sponsor, at least 6 weeks prior to estimated publication or presentation, for written consent. Sponsor has the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the Investigator in the discussion of the data in such communications.|t
17198034|NCT02684942|f||||f
17154609|NCT00953654|t||||
17154610|NCT03807544|t||||
17154611|NCT03517540|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154612|NCT01777282|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154613|NCT05336227|f||||f
17154614|NCT04850989|f||||f
17154615|NCT01068678|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17198035|NCT04374019|f||||f
17198036|NCT00655668|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17198037|NCT04763863|f||||f
17198038|NCT03873038|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17198039|NCT01074034|f||OTHER||t
17198040|NCT04222088|t||||
17198041|NCT00595764|t||||f
17198042|NCT01071317|t||||
17198043|NCT00585910|f||||f
17198044|NCT01332318|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198045|NCT02040532|f||||f
17198046|NCT01350388|f||||f
17198047|NCT00789399|f||||f
17198048|NCT02820298|f||OTHER|The investigator has no right to publish the results.|t
17198049|NCT01894256|f||OTHER||t
17198050|NCT01780584|f||||f
17198051|NCT01772147|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198052|NCT02025647|f||||f
17154616|NCT00347958|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17154617|NCT00754234|t||||f
17154618|NCT00975611|t||||
17154619|NCT01682226|t||||
17154620|NCT03503370|f||||f
17154621|NCT00298272|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17154622|NCT04168112|t||||
17154623|NCT01598064|f||||f
17154624|NCT01344824|f||||f
17154625|NCT04506463|f||||f
17154626|NCT02273063|f||||f
17154627|NCT05125848|f||||f
17154628|NCT01436370|f||LTE60||t
17154629|NCT02395848|t||||
17167042|NCT01885208|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property."|t
17154630|NCT01754129|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17154631|NCT02058537|f||||f
17154632|NCT02126579|t||||
17167043|NCT01709422|t||||f
17167044|NCT01498575|f||||f
17198053|NCT04588519|f||||f
17198054|NCT01921114|f||LTE60||t
17137134|NCT04863014|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17154633|NCT00981214|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17154634|NCT04229095|f||||f
17154635|NCT01780038|t||||f
17198055|NCT00796614|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198056|NCT00509821|f||GT60||t
17198057|NCT01816685|t||||
17198058|NCT03449134|f||OTHER|In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission to allow the Sponsor to protect proprietary information and comment.|t
17198059|NCT00957996|f||||f
17198060|NCT02542410|f||||f
17198061|NCT00275301|f||||f
17198062|NCT02097849|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17198063|NCT02561078|f||GT60||t
17198064|NCT01983462|f||||f
17198065|NCT00684203|f||OTHER|Prior approval by the Sponsor is required before the results obtained in the clinical study can be made public by the investigator (sub-investigator) in a publication or at a medical meeting.|t
17198066|NCT00719212|f||||f
17198067|NCT00508274|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17198068|NCT03296566|f||||f
17198069|NCT00821119|t||||f
17198070|NCT03935932|t||||
17198071|NCT03924947|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198072|NCT01631825|f||||f
17198073|NCT02499835|t||||
17198074|NCT03226353|f||||f
17198075|NCT01797822|t||||
17198076|NCT00498433|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198077|NCT04491006|f||OTHER||t
17198078|NCT04318587|t||||f
17198079|NCT00744796|t||||
17198080|NCT03192202|t||||
17198081|NCT02581189|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198082|NCT01514864|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17198083|NCT02253147|f||GT60||t
17198084|NCT02223871|f||OTHER|Publication of the data is under the responsibility of Actelion Pharmaceuticals Ltd. The PI has the opportunity to review the analysis of the data and to discuss with the sponsor the interpretation of the study results prior to publication.|t
17198085|NCT02254681|t||||
17198086|NCT00797511|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17198087|NCT00843115|f||OTHER||t
17198088|NCT02621047|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198089|NCT01951261|f||||f
17154636|NCT01085630|t||||
17154637|NCT01237041|f||||f
17154638|NCT02609607|t||||
17154639|NCT00651261|f||LTE60||t
17154640|NCT00687271|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines|t
17154641|NCT01134107|f||GT60||t
17154642|NCT03656692|f||||t
17154643|NCT02314260|t||||
17154644|NCT01644292|t||||
17154645|NCT02362672|f||OTHER|If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of the study, the PI is free to publish separately, upon provision of any proposed publication or manuscript to the Sponsor at least sixty (60) days before it is submitted or otherwise disclosed.|t
17154646|NCT00695292|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17154647|NCT05483686|t||||
17154648|NCT00184717|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17154649|NCT01543178|f||GT60||t
17154650|NCT03351608|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data.|t
17154651|NCT02877004|t||||
17154652|NCT02727478|t||||f
17154653|NCT02633293|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17154654|NCT03877068|t||||
17154655|NCT00778817|f||LTE60||t
17154656|NCT01418378|f||LTE60||t
17154657|NCT02829320|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154658|NCT00288626|f||||f
17154659|NCT02348918|f||OTHER|Investigator will submit to Sponsor a copy of the proposed publication or presentation and the name of the scientific journal or forum to which it will be submitted- at least ninety (90) days prior to the submission.Investigator shall comply with Sponsor's request to delete references to Confidential Information,in any such paper or presentation and agrees to withhold publication or presentation of same for an additional ninety (90) days in order to permit Sponsor to obtain patent protection.|t
17154660|NCT00749073|f||LTE60||t
17154661|NCT01511978|f||OTHER|"The first publication shall be a multicenter publication submitted after conclusion of the Study at all sites. If a multicenter publication is not submitted within 12 months, PIs may use results.~The only other disclosure restriction on the PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 30 days for confidential review. This period may be extended by 60 days at Sponsor's request."|t
17154662|NCT02187198|t||||
17154663|NCT00546377|t||||
17154664|NCT01921322|f||||f
17154665|NCT01964222|f||||f
17154666|NCT03325816|f||||t
17154667|NCT04994691|t||||
17154668|NCT01737710|f||||f
17154669|NCT03363776|f||LTE60||t
17154670|NCT00942890|t||||f
17154671|NCT03451591|f||||f
17154672|NCT02097238|f||LTE60||t
17154673|NCT01106911|f||||f
17154674|NCT01814696|f||||f
17154675|NCT00410813|f||LTE60||t
17154676|NCT05027451|f||OTHER|PI may prepare and submit manuscripts or slide shows based on Study Data. Such manuscripts or slide shows shall be submitted to Sponsor for review, at which time these may be approved or rejected. PI will not release those that are rejected by Sponsor. One investigator may be identified as an author or co-author of Sponsor-sponsored publications resulting from this study.|t
17181962|NCT01644175|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17181963|NCT00265512|t||||f
17181964|NCT00868712|t||||
17154677|NCT00954941|t||||
17154678|NCT00812981|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154679|NCT02199795|t||||
17154680|NCT02818946|t||||
17154681|NCT04922255|f||||f
17154682|NCT01935934|f||LTE60||t
17154683|NCT01791894|f||||f
17154684|NCT02268916|f||||f
17154685|NCT02418949|f||||f
17154686|NCT03146806|t||||
17181965|NCT02818777|t||||
17198090|NCT00495612|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198091|NCT02189122|t||||
17198092|NCT00818519|f||LTE60||t
17198093|NCT01239056|t||||
17198094|NCT03740919|f||GT60||t
17154687|NCT03337087|t||||
17154688|NCT02684097|t||||
17154689|NCT00460811|f||OTHER|The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.|t
17154690|NCT02097745|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154691|NCT00425750|t||||
17154692|NCT01757184|f||OTHER|"Institution and/or Principal Investigator may publish or make an individual oral or written presentation of publication of study results either 1) after Alexion publishes the study data or 2) 18 months after the completion of the study, whichever comes first.~Alexion reserves the right to review and comment on a communication at least 30 days prior to submission with a provision to extend the review for an additional 60 days where information is relevant to a patent application."|t
17154693|NCT03546491|t||||
17154694|NCT04331067|t||||
17154695|NCT04339062|f||||f
17154696|NCT05870371|f||||f
17154697|NCT00735969|t||||
17154698|NCT02801617|f||OTHER||t
17154699|NCT01372618|t||||
17154700|NCT01954056|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies|t
17154701|NCT01081769|f||OTHER|"A copy of the manuscript must be provided to the Sponsor for review at least 60 days prior to submission for publication or presentation.~No paper that incorporates Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, such publication will be withheld for up to an additional 60 calendar days. A publication from the individual Study site data will not be published until the combined results have been published."|t
17154702|NCT00507455|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site only after Sponsor's prior written consent.|t
17154703|NCT00746889|f||||f
17154704|NCT06110494|t||||
17154705|NCT02182115|f||||f
17154706|NCT03915587|f||||f
17154707|NCT02914613|f||||t
17154708|NCT02461966|f||||f
17198095|NCT03640754|f||||f
17198096|NCT05329402|f||||t
17198097|NCT03249272|f||||f
17198098|NCT01679613|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17198099|NCT04783519|f||||f
17198100|NCT00727259|f||OTHER|Any publication or communication (written or oral) could be performed by the Principal Investigator only after written approval from Schering-Plough.|t
17198101|NCT01021683|f||OTHER|PI cannot provide any trial related information to external parties without mutual agreement with the Sponsor. This is valid even after the contract is cancelled.|t
17198102|NCT00645099|f||GT60||t
17198103|NCT01201915|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154709|NCT03612596|f||||f
17154710|NCT02573181|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17154711|NCT03421210|t||||
17154712|NCT03850496|t||||
17154713|NCT03728348|f||OTHER|Principal Investigator agreed that they shall not, without the Sponsor's prior written consent, independently publish, publicly disclose, present or discuss any results of or information pertaining to the activities conducted under their agreement for a period of one (1) year following completion of the Study.|t
17154714|NCT02861807|f||||f
17167045|NCT00396006|f||OTHER|The data from the study shall be published (if applicable) by the sponsor. The investigators and the steering committee may be involved if agreed to by the sponsor. Neither the investigator nor any other person within his/her institution has the right to publish separately or individually without permission by the sponsor.|t
17198104|NCT02154516|f||LTE60||t
17198105|NCT03406507|f||||t
17198106|NCT00663923|t||||f
17198107|NCT02965599|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154715|NCT05310071|f||OTHER|Our agreement is subject to confidentiality but generally, the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor's Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of the Sponsor's intellectual property contained in the proposed publication.|t
17198108|NCT00230971|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17154716|NCT01391858|t||||
17154717|NCT04205643|f||||f
17154718|NCT05653479|f||||t
17154719|NCT00504712|t||||
17154720|NCT01303172|f||||f
17154721|NCT02359955|t||||
17154722|NCT02293512|t||||
17154723|NCT00554515|f||||f
17154724|NCT00488644|t||||f
17154725|NCT02977572|t||||
17154726|NCT05107492|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154727|NCT01197534|f||LTE60||t
17154728|NCT05630287|f||GT60||t
17154729|NCT03527589|f||||f
17154730|NCT02683928|f||OTHER||t
17154731|NCT03723850|t||||f
17154732|NCT01014169|f||||f
17154733|NCT02589639|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17154734|NCT02203721|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17154735|NCT01276756|t||||
17154736|NCT01877642|f||LTE60||t
17154737|NCT02593097|t||||
17154738|NCT00703157|f||LTE60||t
17154739|NCT02968173|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17154740|NCT02670525|f||||f
17154741|NCT00591565|f||||f
17154742|NCT01099618|t||||
17154743|NCT03564119|f||OTHER|Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.|t
17154744|NCT00634036|t||||
17154745|NCT04573322|f||||f
17154746|NCT02811965|f||LTE60||t
17154747|NCT03896022|t||||
17154748|NCT02438423|f||||f
17154749|NCT01554527|f||||f
17154750|NCT01052480|f||||f
17154751|NCT01094574|t||||
17154752|NCT00529373|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17154753|NCT01863667|f||OTHER|"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."|t
17154754|NCT03627546|t||||f
17154755|NCT01115244|t||||
17154756|NCT02965573|f||||t
17154757|NCT00315458|f||GT60||t
17154758|NCT00987337|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154759|NCT01669863|t||||
17154760|NCT00086619|f||||f
17154761|NCT00489918|f||||f
17154762|NCT00913263|f||||f
17154763|NCT03225105|f||||t
17154764|NCT01209520|t||||
17154765|NCT00961350|f||OTHER|PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.|t
17154766|NCT02134015|f||||t
17154767|NCT01022307|t||||
17154768|NCT00617890|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the Sponsor. The Investigator further agrees to provide to the Sponsor 45 days prior to submission any publication, presentation, abstracts, manuscripts, or electronic media that report any results of the study. The Sponsor shall have the right to review and comment.|t
17154769|NCT06045325|t||||
17154770|NCT00915018|f||LTE60||t
17167046|NCT01972308|f||||f
17198109|NCT01879085|t||||
17167047|NCT03691844|f||||t
17167048|NCT02851797|f||||f
17198110|NCT01960348|f||LTE60||t
17198111|NCT01580995|f||||f
17198112|NCT05109117|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198113|NCT00397020|t||||
17154771|NCT00326716|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154772|NCT00684411|f||||f
17154773|NCT05253573|f||||f
17154774|NCT06098339|f||||t
17154775|NCT02276560|t||||
17154776|NCT04134767|f||||f
17154777|NCT02582242|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17154778|NCT00300885|f||LTE60||t
17154779|NCT00603902|f||OTHER|Publication of study results are only allowed with prior written consent from Arena Pharmaceuticals, Inc.|t
17154780|NCT00459290|f||||f
17154781|NCT02366637|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154782|NCT02309411|f||||f
17154783|NCT02027545|t||||
17154784|NCT00693498|t||||f
17154785|NCT02693106|t||||
17154786|NCT02509507|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154787|NCT00302848|t||||
17154788|NCT04742400|t||||
17154789|NCT00839800|f||OTHER||t
17154790|NCT04687137|f||OTHER|"If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.~."|t
17154791|NCT02510664|t||||
17154792|NCT03337113|f||||f
17154793|NCT02215200|f||||f
17154794|NCT02176655|f||||f
17154795|NCT02464163|f||||f
17154796|NCT03782012|f||||f
17154797|NCT04938180|f||OTHER||t
17154798|NCT04747886|t||||
17154799|NCT01417741|f||||f
17154800|NCT05209464|f||||f
17154801|NCT03777436|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154802|NCT01342770|f||LTE60||t
17154803|NCT03821259|f||||f
17167049|NCT00543803|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198114|NCT02406495|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17154804|NCT00869999|f||||f
17154805|NCT04478695|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154806|NCT00644917|f||LTE60||t
17154807|NCT00758485|f||||f
17154808|NCT02347774|f||OTHER|In the event the Study is part of a multi-center study , the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17154809|NCT00921557|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17154810|NCT00656292|t||||
17154811|NCT03259425|t||||
17167050|NCT03570918|f||LTE60||t
17167051|NCT04295681|f||||t
17167052|NCT00803400|t||||
17198115|NCT05110014|t||||
17198116|NCT03371485|f||||f
17198117|NCT02204319|t||||f
17198118|NCT00383747|f||||f
17154812|NCT04157296|t||||
17154813|NCT02892110|f||||f
17154814|NCT00744965|t||||f
17154815|NCT05393869|t||||f
17154816|NCT01431716|f||LTE60||t
17154817|NCT02730403|f||||f
17154818|NCT02266797|t||||
17154819|NCT00694473|f||||f
17154820|NCT00014495|t||||
17154821|NCT00984542|t||||f
17154822|NCT01045187|f||||f
17154823|NCT00608777|t||||
17154824|NCT01342523|t||||f
17167053|NCT00210353|f||||f
17198119|NCT04970381|f||||f
17154825|NCT00556946|f||||f
17154826|NCT02091089|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17154827|NCT02755467|f||||f
17154828|NCT02929589|f||||f
17154829|NCT01422889|f||LTE60||t
17154830|NCT02343939|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17154831|NCT04668248|f||||f
17154832|NCT03187730|t||||
17154833|NCT01580670|f||OTHER||t
17154834|NCT00462709|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to sponsor for pre-review. If sponsor requests, PI must delete sponsor confidential information before publication and/or delay publication for 90 days so sponsor can file for patents or take other action to protect its patent rights.|t
17154835|NCT04468347|f||LTE60||t
17154836|NCT03957473|f||||f
17154837|NCT02522884|f||OTHER|PI acknowledges that Clinical Trial is part of multi-center clinical study. Publication of multi-center data requires prior review and consent of both Sponsor and all participating sites. PI agrees that the first publication of the results of the Clinical Trial shall be made in conjunction with results from other participating sites. Provided, however, that if no multi-center publication is made within one year from database lock, then PI may publish individually.|t
17198120|NCT03389451|t||||
17198121|NCT01860807|f||LTE60||t
17198122|NCT02171130|f||GT60||t
17198123|NCT04531813|f||OTHER|No information based on the conduct of the study (incl. protocol, data resulting from the study, or the fact that the study was being conducted) will be released without prior written consent of the sponsor unless the requirement is superseded by State or Federal law.|t
17198124|NCT02853305|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17198125|NCT00858507|t||||
17198126|NCT00349388|t||||
17198127|NCT02381652|f||||f
17198128|NCT01340300|t||||
17198129|NCT03544229|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198130|NCT04772313|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17198131|NCT02143310|f||||f
17198132|NCT01836198|f||GT60||t
17137135|NCT00264849|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137136|NCT05291949|f||||f
17154838|NCT01992172|f||GT60||t
17154839|NCT00615550|f||||f
17154840|NCT00564850|f||GT60||t
17154841|NCT02640664|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154842|NCT00413582|t||||
17154843|NCT00314327|t||||
17154844|NCT02741076|t||||
17154845|NCT01294241|f||||f
17154846|NCT02571673|t||||
17154847|NCT02748213|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137137|NCT04387136|t||||
17137138|NCT01788306|f||||f
17154848|NCT04200651|f||||f
17154849|NCT01500382|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17154850|NCT02640950|f||||f
17154851|NCT00154284|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17154852|NCT00566020|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154853|NCT02101736|f||||f
17167054|NCT02494518|t||||f
17198133|NCT03187353|f||||f
17198134|NCT02215954|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17198135|NCT01656486|f||||f
17154854|NCT01033032|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from the date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish results until 18 mos. after the trial has been completed at all sites.|t
17154855|NCT02498444|t||||
17154856|NCT02453334|f||LTE60||t
17154857|NCT03097757|f||||f
17198136|NCT02460562|f||||f
17198137|NCT03303521|f||||f
17154858|NCT00725153|f||LTE60||t
17154859|NCT02476578|t||||
17154860|NCT03018080|t||||
17154861|NCT01831076|t||||
17154862|NCT04244084|f||||t
17154863|NCT00026494|t||||
17154864|NCT01684423|f||GT60||t
17154865|NCT01455597|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17154866|NCT00441129|f||GT60||t
17154867|NCT04042623|f||OTHER|Per protocol, data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld. However, since the study was terminated, there are no results to be published.|t
17154868|NCT03412734|t||||
17154869|NCT00423332|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17154870|NCT00676364|t||||
17154871|NCT01136356|f||||f
17154872|NCT00402688|f||LTE60||t
17154873|NCT00927862|t||||
17154874|NCT04306965|f||||f
17154875|NCT00820248|t||||f
17154876|NCT04112043|f||||f
17154877|NCT02237196|f||||f
17154878|NCT02049905|f||||t
17154879|NCT01750697|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154880|NCT03980145|f||||f
17154881|NCT02653144|t||||
17154882|NCT03674112|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154883|NCT00862823|f||||f
17154884|NCT04724538|t||||
17154885|NCT00832572|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17154886|NCT00863343|f||LTE60||t
17154887|NCT01421225|t||||
17198138|NCT01654289|f||||f
17198139|NCT02642159|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17154888|NCT02527434|f||OTHER|Publication of any or all of the results of the Research by the PI requires prior written consent of the Sponsor.|t
17154889|NCT01322490|f||||t
17154890|NCT00568061|f||||f
17154891|NCT01896128|f||||f
17154892|NCT00356148|f||||f
17154893|NCT02484456|f||||f
17154894|NCT04594070|t||||
17154895|NCT02693002|f||||f
17154896|NCT01537926|f||||f
17154897|NCT02064816|f||OTHER||t
17154898|NCT01732458|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17154899|NCT04571645|f||OTHER|Within 18 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17154900|NCT03759587|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154901|NCT04615403|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of data from this study.|t
17154902|NCT00665431|f||||f
17154903|NCT02060838|t||||
17198140|NCT04194541|t||||
17198141|NCT03746483|f||||f
17198142|NCT00187135|t||||
17198143|NCT01924806|f||||t
17198144|NCT01954771|f||LTE60||t
17198145|NCT02886234|f||||f
17198146|NCT03635775|t||||
17198147|NCT05562583|f||||f
17198148|NCT04098497|t||||
17154904|NCT01329380|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17154905|NCT04471194|f||||f
17154906|NCT00757042|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17154907|NCT02508077|t||||
17154908|NCT02915705|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17154909|NCT01870973|f||||f
17154910|NCT00150488|f||||f
17154911|NCT01266291|f||||f
17154912|NCT03291431|f||||f
17154913|NCT00481351|f||||f
17154914|NCT00550745|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154915|NCT02835625|t||||
17154916|NCT03850483|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154917|NCT04432831|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154918|NCT01623310|f||OTHER|Disclosure agreement is described in the CTA between sponsor and PI|t
17154919|NCT02898597|t||||
17154920|NCT02530125|t||||
17154921|NCT00356603|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154922|NCT01234870|f||||f
17154923|NCT01568034|f||OTHER||t
17154924|NCT00728468|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154925|NCT01262287|f||||f
17154926|NCT00932373|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17154927|NCT01637922|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights..|t
17154928|NCT00638404|t||||
17154929|NCT02492984|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from completion/termination at all participating sties. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154930|NCT02110758|t||||
17154931|NCT04090060|t||||
17154932|NCT02074358|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17154933|NCT01164579|f||||f
17154934|NCT03070600|f||||f
17154935|NCT04005404|t||||
17154936|NCT03038867|t||||
17181966|NCT01418937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17181967|NCT03483675|f||||f
17181968|NCT00656630|f||||f
17181969|NCT00181961|f||||f
17181970|NCT01667978|f||||f
17181971|NCT01324349|f||||f
17181972|NCT02531321|f||||f
17198149|NCT00297778|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198150|NCT00679549|f||||f
17137139|NCT02278289|t||||
17137140|NCT01982773|f||||f
17137141|NCT01029886|f||GT60||t
17154937|NCT01464593|f||||f
17198151|NCT03280108|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17154938|NCT00302328|t||||f
17154939|NCT00435708|t||||
17154940|NCT01288937|t||||
17154941|NCT02490371|f||||t
17154942|NCT02403479|f||||f
17154943|NCT03491462|f||GT60||t
17154944|NCT00740792|f||OTHER|"Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.~Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)"|t
17154945|NCT01019694|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17154946|NCT00795002|f||LTE60||t
17167055|NCT02135029|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167056|NCT01558362|f||||f
17198152|NCT02996097|t||||f
17198153|NCT02201771|f||||f
17198154|NCT01820637|f||OTHER|Institution and Investigator shall have the right to publish the Results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17198155|NCT00264498|f||GT60||t
17198156|NCT00583115|f||||f
17198157|NCT02205476|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198158|NCT02109107|f||||f
17198159|NCT01643902|f||||f
17198160|NCT04289714|t||||
17198161|NCT02694198|f||||f
17198162|NCT00607789|f||OTHER|All trial data will be posted \& published by the Lindner Center of HOPE (PI: Dr. Susan McElroy)|t
17198163|NCT01919398|f||GT60||t
17198164|NCT03106337|t||||
17198165|NCT02016690|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198166|NCT05401149|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198167|NCT02264353|f||||f
17137142|NCT03294681|f||OTHER|Investigators can publish and/or present their own data and process their data with their own algorithms. At study end 2 joint publications by the clinical investigators/sponsor are planned with the Coordinating Investigator writing the publication. All abstract/publication must be reviewed by the sponsor at least 30 days in advance. If a publication contains information that the sponsor finds worth protecting the sponsor has the right to delay the publication/presentation for 90 days.|t
17137143|NCT01553916|t||||
17137144|NCT01948388|f||||f
17137145|NCT03089216|f||||f
17154947|NCT04632069|f||||f
17154948|NCT00885664|f||LTE60||t
17154949|NCT00685399|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154950|NCT01562782|t||||
17154951|NCT01371110|f||||f
17154952|NCT00911612|t||||f
17154953|NCT00945035|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17154954|NCT02049814|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17154955|NCT00835224|f||||f
17198168|NCT02865135|t||||
17198169|NCT03927742|t||||
17198170|NCT01196741|f||OTHER|Participating sites may not publish trial results without prior written consent from the Trial Management Group|t
17198171|NCT02273180|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17154956|NCT01282372|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17154957|NCT00214786|f||||f
17154958|NCT02993250|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17154959|NCT02307279|f||||f
17154960|NCT02023411|f||||f
17154961|NCT01996254|f||OTHER||t
17154962|NCT03348930|f||||f
17154963|NCT00708214|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17154964|NCT02411396|t||||
17154965|NCT02865499|t||||
17154966|NCT01339923|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17154967|NCT01931995|f||||f
17154968|NCT00403481|f||OTHER|If identified by Daiichi Sankyo Inc., any of DSI's confidential information, as defined to the author, shall be deleted. Nothing in our site agreement shall be taken as giving Daiichi Sankyo, Inc. any right of editorial control over any publication prepared by the study site.|t
17154969|NCT03635515|t||||
17154970|NCT02099110|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17154971|NCT01435304|f||||f
17154972|NCT04002115|t||||
17154973|NCT02145260|t||||
17154974|NCT03340454|t||||
17154975|NCT03682848|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17154976|NCT01464164|t||||f
17154977|NCT00454363|f||LTE60||t
17154978|NCT00570063|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17154979|NCT00697463|t||||f
17154980|NCT03307252|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17154981|NCT03482453|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17154982|NCT02568189|t||||
17154983|NCT02157376|f||||f
17154984|NCT01074268|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17198172|NCT00509925|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17198173|NCT02207322|f||||f
17198174|NCT03302559|t||||
17198175|NCT01540162|t||||f
17198176|NCT00598871|f||OTHER|RegeneRx (the Sponsor) agreements may vary with individual investigators, but will not prohibit any investigator from publishing. RegeneRx supports the publication of results from all centers of a multi-center trial but requests that reports based on a single-site data not precede the primary publication of the entire clinical trial.|t
17198177|NCT01699698|f||OTHER|Sponsor can ask PI to consider that PI delete Sponsor's confidential information from any publication or extend the publication for a certain time to seek patent protection, provided, however that, PI can publish or registry any other information in accordance with FDAAA.|t
17198178|NCT00197119|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198179|NCT02151643|f||||t
17198180|NCT03619889|f||||f
17198181|NCT00791102|f||||f
17198182|NCT01084239|f||||f
17154985|NCT00966992|t||||
17198183|NCT02396953|f||||f
17154986|NCT01578239|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17154987|NCT03000010|t||||
17154988|NCT01731119|f||||f
17154989|NCT01017536|f||||f
17154990|NCT01031680|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17154991|NCT03649932|f||||f
17154992|NCT02934698|t||||
17154993|NCT02654977|t||||f
17154994|NCT01921101|f||||f
17154995|NCT01483027|f||||f
17154996|NCT03456804|t||||f
17154997|NCT03548779|t||||
17154998|NCT04973176|t||||f
17154999|NCT00652626|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17155000|NCT01605552|t||||
17155001|NCT01050582|f||||f
17155002|NCT00912743|f||LTE60||t
17155003|NCT02973503|f||||f
17155004|NCT03431831|f||||f
17155005|NCT00179660|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17155006|NCT03935425|t||||
17155007|NCT03090958|t||||f
17155008|NCT01998932|f||||f
17155009|NCT00178685|f||||f
17155010|NCT00181285|f||||f
17155011|NCT03219840|t||||
17155012|NCT00443079|f||||f
17155013|NCT02714595|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17155014|NCT00713258|f||OTHER|After publication of the results or 24 months after Clinical Trial Report has been finalised, whichever comes first, Nycomed acknowledge the Investigator's rights to publish results from this trial. Any such scientific paper, presentation, communication or other information concerning the trial described in this protocol must be submitted to Nycomed for review prior to submission for publication/presentation. Review comments will be given within a month from receipt of the manuscript.|t
17155015|NCT01053663|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155016|NCT03533114|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17155017|NCT01028014|t||||f
17155018|NCT02423343|f||GT60||t
17155019|NCT00090493|t||||f
17155020|NCT02071706|f||LTE60||t
17155021|NCT00179777|f||||f
17167057|NCT05898672|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155022|NCT01214083|f||||f
17155023|NCT01908829|f||OTHER|The PI shall provide sponsor with a copy of proposed publication/presentation for review and comment at least 30 days prior to submission for publication/presentation. The sponsor can delay communications regarding trial results for an additional 90 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the delay.|t
17155024|NCT02792192|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155025|NCT02320058|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17155026|NCT01430403|f||||f
17155027|NCT02887248|f||||f
17155028|NCT01166438|f||||f
17155029|NCT04321356|t||||
17155030|NCT01377922|f||LTE60||t
17155031|NCT03170362|f||||f
17155032|NCT02948751|t||||
17155033|NCT02347813|t||||
17155034|NCT01385137|f||||f
17167058|NCT01024972|f||||f
17155035|NCT02837731|f||OTHER|Specifics of the publication policy will be outlined to the Investigator in the Clinical Trial Research Agreement.|t
17155036|NCT01119859|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155037|NCT00603473|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155038|NCT00691444|f||||f
17155039|NCT02644668|f||||f
17155040|NCT01134939|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17155041|NCT00733421|t||||
17155042|NCT00251238|f||||f
17155043|NCT02461433|t||||
17155044|NCT01523782|f||LTE60||t
17155045|NCT02547220|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17155046|NCT00550043|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17155047|NCT03771560|f||||f
17155048|NCT02887183|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155049|NCT02434146|t||||
17155050|NCT00789698|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17167059|NCT05129449|f||||f
17167060|NCT01777217|f||||f
17167061|NCT02839720|f||LTE60||t
17167062|NCT00516906|f||||f
17167063|NCT01974206|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17198184|NCT02679079|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17198185|NCT04150341|f||||f
17198186|NCT03713073|t||||
17198187|NCT01907113|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198188|NCT00833898|f||||f
17198189|NCT00805285|f||||f
17198190|NCT00917462|t||||
17198191|NCT01402063|f||||f
17198192|NCT01057888|f||||f
17198193|NCT02110225|f||||f
17198194|NCT02176018|f||GT60||t
17198195|NCT03022045|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198196|NCT03436433|t||||
17198197|NCT01751451|t||||
17198198|NCT03972137|t||||f
17198199|NCT00899379|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198200|NCT01906658|f||OTHER|Institution/Investigator shall not, without Sponsor's prior written consent, independently publish or otherwise disclose any results of the study until a Multi-Center Publication is published. If a Multi-Center Publication is not submitted for publication within the specified timeframe, Institution and Principal Investigator shall have the right to publish and present the results of Institution's and Principal Investigator's activities solely in accordance with the Sponsor's written provisions.|t
17198201|NCT03220776|f||||f
17198202|NCT03441789|f||||f
17198203|NCT01780545|f||||f
17198204|NCT03168425|t||||
17198205|NCT02747121|f||||f
17137146|NCT00242385|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. Baxter requires a review of results communications (e.g., for confidential information) ≥60 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).|t
17155051|NCT00596817|f||OTHER|The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.|t
17155052|NCT04722315|f||||f
17155053|NCT06047366|t||||
17155054|NCT04556084|f||||f
17155055|NCT04797611|f||||f
17155056|NCT03867409|f||||f
17155057|NCT03300505|f||||f
17155058|NCT05119595|f||OTHER|The clinic will ensure that a manuscript intended for publication that is related to this study is made available to the sponsor for review before submission in order to give the sponsor the opportunity to comment. Furthermore, the clinic ensures that an abstract intended for presentation, as well as a manuscript intended for this purpose and the presentation slides themselves, are sent to the sponsor before submission to a congress.|t
17155059|NCT00679029|t||||
17155060|NCT03483961|f||OTHER|PI may publish or release study data after the earlier of (a) the date of publication of a multi-center publication coordinated by Sponsor on the study data, or (b) the date of submission of the study data by Sponsor to regulatory authorities for regulatory approval; provided that PI furnishes Sponsor with a copy of any proposed publication or release at least ninety days in advance of the proposed submission or presentation date for review. PI must acknowledge Sponsor on any publication.|t
17155061|NCT03100968|t||||f
17155062|NCT01108341|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17155063|NCT04402138|f||||t
17155064|NCT03508726|t||||
17155065|NCT04411810|t||||
17155066|NCT03981926|f||||f
17155067|NCT01920958|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155068|NCT01560234|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17155069|NCT01620190|f||||f
17155070|NCT02035202|f||||f
17155071|NCT00083759|f||OTHER|Sponsor will have at least 30 days to request revisions to a proposed Publication. Institution will delete any Confidential Information provided by Sponsor, will delay Publication submission for a further 90 days for the filing of patent applications, and will not issue a press release about the Study without the Sponsor's prior written consent.|t
17155072|NCT02875613|t||||
17155073|NCT01566539|t||||
17155074|NCT03645395|f||OTHER||t
17155075|NCT01057810|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17155076|NCT00267969|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155077|NCT00291876|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155078|NCT01309360|f||||f
17155079|NCT02308540|f||||f
17167064|NCT05235971|f||||f
17167065|NCT03645941|t||||
17167066|NCT04432064|t||||
17167067|NCT04448392|f||||f
17155080|NCT02285166|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155081|NCT00384839|f||||f
17155082|NCT02649439|f||||f
17167068|NCT05463744|f||GT60||t
17167069|NCT01795495|t||||
17167070|NCT03703310|f||||f
17167071|NCT01579565|f||OTHER|The PI agreed not to publish or otherwise to disclose Study data without prior written consent from the sponsor for a period of 24 months following Study completion or until data are published in a combined publication (whichever occurs first). The sponsor can review communications containing results prior to public release and embargo those communications for a period that is no longer than 60 days from the date of receipt of the non-public communication. The sponsor cannot extend the embargo.|t
17167072|NCT02867813|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17167073|NCT01448824|f||LTE60||t
17167074|NCT00932620|f||||f
17167075|NCT03389555|t||||f
17167076|NCT03806556|t||||f
17137147|NCT04348591|f||||f
17137148|NCT00417976|f||||f
17137149|NCT01003080|f||||f
17137150|NCT01778127|t||||
17137151|NCT01348425|f||GT60||t
17155083|NCT00776295|t||||f
17155084|NCT01862250|t||||
17155085|NCT05478135|t||||
17155086|NCT00693238|t||||
17155087|NCT02016105|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17155088|NCT02247440|f||||t
17155089|NCT02073448|f||||f
17155090|NCT02751450|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155091|NCT00562302|f||||f
17155092|NCT01290679|f||GT60||t
17155093|NCT01413750|f||LTE60||t
17155094|NCT02905981|f||LTE60||t
17155095|NCT03124407|f||OTHER|No disclosure of any of the data and results of this STUDY by way of publication or otherwise, shall be made by RESEARCH CENTER, or any third party, without the prior written consent of VIZURI.|t
17155096|NCT03660189|t||||
17155097|NCT01860040|t||||
17155098|NCT02821754|f||||f
17155099|NCT00514215|t||||f
17155100|NCT03480542|t||||
17155101|NCT03278223|f||OTHER|"The Investigator shall not disclose to others any information relating to the study without written authorisation from the Sponsor.~All data and discoveries arising out of the Study, patentable or non-patentable, shall be the sole property of the Sponsor or its designated affiliate.~The Investigator shall agree to obtain the Sponsor's written consent before discussing, presenting or publicising any pre-clinical and/or clinical data or impressions."|t
17155102|NCT02324504|f||||f
17155103|NCT01959464|f||||f
17155104|NCT00994461|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155105|NCT03478644|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155106|NCT01029782|f||||f
17155107|NCT00687544|f||OTHER|The Principal Investigator agrees not to publish/present any interim results without sponsor's prior written consent and agrees to provide sponsor 45 days written notice prior to submission for publication/presentation to permit the sponsor to review copies. The sponsor shall have the right to review and comment, including editing.|t
17155108|NCT02195869|f||OTHER|Institution/Investigator will not publish without Sponsor prior review and approval.|t
17155109|NCT00869622|f||||f
17155110|NCT03960008|f||||f
17155111|NCT03056638|t||||
17155112|NCT04392375|t||||
17155113|NCT02669901|f||||t
17155114|NCT00610155|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155115|NCT01718535|t||LTE60||t
17155116|NCT00648115|t||||
17155117|NCT01073605|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155118|NCT01284348|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication.|t
17155119|NCT02417142|f||||f
17155120|NCT01517763|f||||f
17155121|NCT02088905|f||||f
17155122|NCT02317276|f||||f
17155123|NCT00379080|f||LTE60||t
17155124|NCT02901067|t||||
17155125|NCT00288366|t||||
17155126|NCT00857896|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155127|NCT02907918|t||||
17155128|NCT01091662|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17155129|NCT01222520|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17155130|NCT04109391|f||OTHER||t
17155131|NCT02156908|t||||
17155132|NCT01089608|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17155133|NCT04606394|f||||f
17167077|NCT00920218|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167078|NCT02130687|f||||f
17167079|NCT03224507|f||||f
17155134|NCT00955955|f||||f
17155135|NCT03423173|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155136|NCT02920008|f||||t
17155137|NCT02737930|t||||
17155138|NCT03852264|f||||f
17155139|NCT03169881|f||||f
17155140|NCT01631149|f||||f
17155141|NCT01665950|f||||f
17155142|NCT03522714|f||||f
17155143|NCT00839527|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155144|NCT04481789|f||OTHER||t
17155145|NCT00943150|f||LTE60||t
17181973|NCT02013167|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17181974|NCT01113879|f||||f
17137152|NCT02104804|f||OTHER|Without limitation to any other right of AstraZeneca hereunder, Institution and Principal Investigator acknowledge and agree that only AZ as Sponsor will register the Study and post the Study results in accordance with AZ internal policy on one or more publicly-accessible trial registries and websites (including the publicly-funded website http://www.clinicaltrials.gov/ and on its own website http://www.astrazenecaclinicaltrials.com) to avoid duplication.|t
17155146|NCT01704651|t||||
17155147|NCT03761030|f||||f
17155148|NCT03315286|t||||f
17155149|NCT00766636|t||||
17155150|NCT03139578|f||GT60||t
17155151|NCT00461773|t||||
17155152|NCT02477332|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155153|NCT03793842|t||||
17155154|NCT04657198|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17155155|NCT02549287|f||||f
17155156|NCT02880475|f||||t
17155157|NCT00638222|t||||
17155158|NCT00427921|f||OTHER|Responsibility of preparation and maintenance of the single database, first publication, and, presentation of Study shall reside with Abbott. No independent manuscript may be submitted for publication until first manuscript has been accepted for publication or twelve (12) months after completion of the Study at all sites, which ever occurs first.|t
17155159|NCT00900159|f||LTE60||t
17181975|NCT04327986|f||||f
17155160|NCT01075256|f||||f
17155161|NCT02115581|f||||f
17155162|NCT02858583|f||||f
17155163|NCT00347009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155164|NCT00006178|t||||
17155165|NCT01972438|t||||
17155166|NCT00511914|f||GT60||t
17155167|NCT01030289|f||||f
17155168|NCT03063437|f||||f
17155169|NCT00602836|t||||
17155170|NCT00468481|f||LTE60||t
17155171|NCT03831113|f||||f
17155172|NCT01068730|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17155173|NCT04134429|t||||
17155174|NCT01515865|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17155175|NCT03691207|f||||f
17155176|NCT01113385|t||||
17167080|NCT01007435|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167081|NCT02613117|f||OTHER|PI should disclose plans to sponsor prior to public release.|t
17167082|NCT01345591|t||||
17167083|NCT02163967|t||||
17167084|NCT00847665|f||||f
17137153|NCT03722784|f||||f
17155177|NCT01736397|f||GT60||t
17155178|NCT03396315|f||||f
17155179|NCT02448537|t||||
17155180|NCT03611777|t||||
17155181|NCT04696055|f||LTE60||t
17155182|NCT05406479|f||||t
17155183|NCT03567005|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17155184|NCT02799667|t||||
17155185|NCT04075682|f||||f
17155186|NCT00887315|f||||f
17155187|NCT00619892|f||||f
17155188|NCT00280397|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.|t
17155189|NCT00497289|f||LTE60||t
17155190|NCT02257489|f||OTHER||t
17155191|NCT00863356|f||||f
17155192|NCT03200704|f||LTE60||t
17167085|NCT00624585|t||||
17167086|NCT04392141|t||||
17167087|NCT03549572|f||||f
17167088|NCT00676520|f||GT60||t
17155193|NCT00832871|f||||f
17155194|NCT00729157|f||LTE60||t
17155195|NCT02217410|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155196|NCT03055897|f||OTHER||t
17181976|NCT02131402|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17155197|NCT00661609|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.|t
17155198|NCT00637000|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17155199|NCT03457116|t||||
17155200|NCT01855243|f||||f
17155201|NCT04431908|f||||f
17155202|NCT03075891|f||||t
17155203|NCT01131169|t||||
17155204|NCT02223546|t||||
17155205|NCT00828568|f||GT60||t
17155206|NCT00634803|f||||f
17155207|NCT00396656|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155208|NCT00778869|f||OTHER|Principal investigator (PI) agrees not to publish or publicly present any interim results of study without prior written consent of sponsor. PI further agrees to provide 30 days written notice to sponsor prior to submission for publication or presentation to permit sponsor to review copies of abstracts or manuscripts for publication including without limitation slides and texts of oral or other public presentations and text of any transmission through any electronic media which report results.|t
17155209|NCT00364923|f||OTHER|Allos agreements with investigators (PIs) may vary. The PI may publish/make public data from the trial after the earlier of publication by Allos or 18 months after study completion. Allos can review results communications prior to public release and can embargo communications regarding trial results for a period less than or equal to 90 days from submission for review. Allos can request changes to the communication related to confidential or patent information, or to ensure accuracy.|t
17198206|NCT03029234|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198207|NCT01443546|t||||f
17181977|NCT03865329|t||||
17198208|NCT02166047|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198209|NCT01960114|f||LTE60||t
17198210|NCT02469077|t||||f
17198211|NCT00991029|f||||f
17198212|NCT01318538|t||||f
17198213|NCT00053352|f||OTHER|Must obtain prior Sponsor approval.|t
17198214|NCT00439647|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17198215|NCT02845375|t||||
17198216|NCT05215418|f||||t
17198217|NCT01177137|f||||f
17155210|NCT03474731|t||||
17155211|NCT03706430|f||||f
17155212|NCT00765336|f||OTHER|Specific restrictions and agreements are specified in each investigator's contract.|t
17155213|NCT00478777|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.~* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 90 days."|t
17155214|NCT01218087|t||||
17181978|NCT01746784|f||GT60||t
17198218|NCT01287416|t||||
17198219|NCT05127018|t||||
17198220|NCT02506881|f||||f
17198221|NCT00741468|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17198222|NCT03722836|f||||f
17155215|NCT00552396|f||GT60||t
17155216|NCT01323387|f||LTE60||t
17155217|NCT04185220|f||||f
17155218|NCT00604591|t||||
17155219|NCT01186692|f||OTHER|A publication committee is in place for this study.|t
17155220|NCT00767455|f||LTE60||t
17155221|NCT04463251|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17198223|NCT05756348|t||||
17198224|NCT01363297|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.|t
17198225|NCT02515097|f||OTHER|Please contact Sponsor directly for additional information.|t
17198226|NCT00006099|f||||f
17198227|NCT06016127|t||||
17155222|NCT00022698|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155223|NCT03297645|t||||f
17155224|NCT00725361|f||||f
17155225|NCT02118727|f||||f
17155226|NCT02863445|f||||f
17155227|NCT04520997|f||OTHER||t
17155228|NCT02981082|f||||f
17155229|NCT05367973|f||OTHER|PI are not allowed to publish without prior approval from Sponsor.|t
17155230|NCT04138953|t||||
17155231|NCT01314872|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17155232|NCT03232931|t||||
17155233|NCT04925557|f||LTE60||t
17155234|NCT05488470|f||||f
17155235|NCT01941745|f||||f
17155236|NCT00068393|f||||f
17155237|NCT00893997|t||||f
17155238|NCT02986282|f||||f
17155239|NCT05127330|t||||f
17155240|NCT04981470|f||||f
17155241|NCT04325568|f||||f
17155242|NCT04390503|f||||f
17155243|NCT03187418|t||||
17155244|NCT00593684|t||||
17155245|NCT00734162|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17155246|NCT00653133|f||||f
17198228|NCT03915951|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198229|NCT02656745|f||||f
17198230|NCT02269917|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17198231|NCT02033499|f||||f
17198232|NCT01393314|f||||f
17198233|NCT00574171|f||||f
17198234|NCT01121185|f||LTE60||t
17198235|NCT03015181|t||||
17198236|NCT02150109|f||GT60||t
17198237|NCT02825849|t||||f
17198238|NCT01189136|f||||f
17198239|NCT01064856|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198240|NCT01478256|f||||f
17198241|NCT01204775|f||||f
17198242|NCT01374971|t||||
17198243|NCT02946788|f||||f
17198244|NCT03749616|f||||f
17198245|NCT04435522|f||||f
17198246|NCT00951171|t||||
17198247|NCT00919061|t||||
17198248|NCT02868788|t||||
17198249|NCT02270463|f||||f
17198250|NCT03579680|t||||
17198251|NCT05294328|f||OTHER||t
17198252|NCT02056873|t||||
17198253|NCT02972242|f||||f
17198254|NCT04572997|f||||f
17198255|NCT02956278|t||||f
17198256|NCT03067610|t||||
17198257|NCT01226485|f||GT60||t
17198258|NCT00740597|t||||
17198259|NCT00932659|f||||f
17198260|NCT03443063|f||||f
17198261|NCT00552513|f||OTHER|PHRI agreements may vary with individual investigators, but will not prohibit any investigator from publishing. PHRI supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155247|NCT00596687|f||||f
17155248|NCT01828983|f||||f
17198262|NCT02720185|t||||
17198263|NCT01157351|f||GT60||t
17198264|NCT03418493|f||GT60||t
17198265|NCT02028247|f||||f
17198266|NCT05446714|t||||
17198267|NCT02742532|t||||f
17198268|NCT00197106|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198269|NCT01709123|t||||
17198270|NCT00329550|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17155249|NCT01270464|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17155250|NCT01369030|f||||f
17155251|NCT04725812|f||||f
17155252|NCT00527644|f||||f
17155253|NCT00742963|f||||f
17198271|NCT02179853|f||||f
17198272|NCT01530477|f||LTE60||t
17198273|NCT01649557|f||||f
17198274|NCT01763645|f||||f
17198275|NCT00666198|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198276|NCT00922441|f||||f
17198277|NCT00543101|f||OTHER|Site Investigators (PIs) agree not to individually publish the results of the study. They may participate in a joint publication of the study results with the sponsor.|t
17198278|NCT01040403|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198279|NCT02973477|t||||
17198280|NCT01885936|t||||
17198281|NCT03036150|f||||t
17198282|NCT00317603|t||||
17198283|NCT00523549|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17198284|NCT02487251|f||||f
17198285|NCT00427778|f||||f
17198286|NCT01388478|t||||
17198287|NCT01990664|f||GT60||t
17137154|NCT01968954|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155254|NCT03969901|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors (ICMJE) authorship requirements.|t
17155255|NCT04511520|t||||
17155256|NCT00638716|f||||t
17155257|NCT02589626|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property right|t
17155258|NCT02564900|f||||f
17198288|NCT01037413|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198289|NCT00619983|f||||f
17198290|NCT00931918|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17198291|NCT00570921|f||||f
17155259|NCT00892151|f||LTE60||t
17155260|NCT00821964|t||||
17155261|NCT04347564|t||||
17155262|NCT00555464|f||||f
17155263|NCT00930774|t||||
17155264|NCT01680861|f||||f
17155265|NCT03921840|t||||
17155266|NCT01940887|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publications of the Study results with the other investigators and/or institutions only, upon prior written consent of Ophthotech.|t
17155267|NCT04807205|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17155268|NCT01663285|t||||
17155269|NCT02475265|f||||f
17155270|NCT01598090|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17155271|NCT02449798|f||||f
17155272|NCT00799474|f||LTE60||t
17155273|NCT02209519|f||||f
17155274|NCT02401048|f||||f
17155275|NCT01826513|f||OTHER|"The Sponsor has the right to~* review~* provide comments (site is not bound to follow them)~* request delay of publication for no more than 120 days to allow for securing of IP~* request the removal of specified confidential information~within 40 days of the proposed publication being released to those not bound by confidentiality obligations."|t
17155276|NCT04087720|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17155277|NCT02743936|f||||f
17155278|NCT00520533|t||||f
17155279|NCT02438826|f||GT60||t
17155280|NCT02397122|f||||f
17155281|NCT04201574|f||GT60||t
17155282|NCT02703467|t||||
17155283|NCT02754427|f||||f
17155284|NCT00389532|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17155285|NCT03425396|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17155286|NCT02428309|f||||f
17198292|NCT02832284|f||||f
17198293|NCT00784277|f||LTE60||t
17198294|NCT02222337|f||||f
17137155|NCT03655717|t||||
17155287|NCT03689374|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17198295|NCT00999141|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17155288|NCT00078767|t||||
17155289|NCT02919423|t||||
17137156|NCT05149040|f||||f
17155290|NCT04082572|t||||
17155291|NCT01058993|f||||f
17155292|NCT00831311|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17155293|NCT05088603|t||||
17155294|NCT01868438|f||||f
17155295|NCT02207803|f||||f
17155296|NCT00594100|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17155297|NCT03981900|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155298|NCT02162719|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155299|NCT00160706|f||GT60||t
17155300|NCT03214380|f||GT60||t
17155301|NCT02593526|t||||
17155302|NCT00977704|f||OTHER|Researcher agree to submit to Medicis for Medicis' prior review and written approval, which approval shall not be unreasonably withheld, any written publication utilizing results or other data generated from this study at least ninety days, or, for abstracts, at least thirty days before such publication is presented or submitted for publication.|t
17155303|NCT04181606|f||||f
17155304|NCT03192306|f||OTHER|Any manuscript, abstract, or other publication or presentation of results or information arising in connection with the study must be prepared in conjunction with Topical Remedy, LLC.|t
17155305|NCT04932655|f||OTHER|The PI is an employee of the CRO who conducted the study and is restricted by CDA.|t
17155306|NCT01289639|t||||f
17155307|NCT02780713|f||OTHER|All of the study information and data collected during the study are confidential and the property of AstraZeneca. After completion of the study, the investigator may prepare a joint publication with AstraZeneca. The investigator must undertake not to submit any part of the individual data from this clinical study protocol for publication without prior consent of AstraZeneca at a mutually agreed time.|t
17155308|NCT01931475|f||GT60||t
17155309|NCT03461952|t||||
17155310|NCT04292912|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17155311|NCT06175026|t||||f
17155312|NCT04081610|f||OTHER|Only the sponsor has the decision to disseminate or publish the information obtained from the investigation and the PIs involved must submit a formal request to the sponsor if they are willing to disseminate or publish such information, they may only publish them if they have the written authorization of the sponsor (Laboratoios Sophia S.A. de C.V.).|t
17155313|NCT02225860|f||||f
17155314|NCT05338502|f||OTHER||t
17155315|NCT00436475|f||||f
17155316|NCT03575793|f||||f
17155317|NCT01250873|f||GT60||t
17198296|NCT00413634|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17198297|NCT01262118|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198298|NCT02046941|t||||
17155318|NCT02278939|f||||f
17155319|NCT02669836|f||||f
17155320|NCT04826965|t||||
17155321|NCT01127451|f||||f
17155322|NCT02111577|f||OTHER|Any formal publication of clinical trial results will be a collaborative effort between the sponsor and the investigator(s). All manuscripts or abstracts will be reviewed and approved in written by the sponsor before submission. The sponsor may request a delay in publication if there are important intellectual property concerns but does not have the right to suppress the publication of the clinical trial results indefinitely.|t
17155323|NCT04791319|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17155324|NCT02353442|t||||
17155325|NCT02798289|f||OTHER|The data provided by this clinical trial, and all related information and any materials containing such data and information, are the exclusive property of Oculeve and are confidential to Oculeve. The investigator or other study-related personnel may not disclose to anyone or use any data, information, or materials related to this clinical trial without the express written consent of Oculeve.|t
17155326|NCT00679289|f||LTE60||t
17198299|NCT02025985|f||||t
17198300|NCT03041701|f||||f
17198301|NCT00745121|f||LTE60||t
17155327|NCT01985932|t||||
17155328|NCT01355575|t||||
17155329|NCT01707108|f||||f
17155330|NCT01088672|f||GT60||t
17198302|NCT01713998|f||||f
17155331|NCT05831644|f||||f
17155332|NCT02553499|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17155333|NCT00842023|t||||
17155334|NCT01726270|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17155335|NCT02171234|f||OTHER||t
17155336|NCT02819973|t||||
17155337|NCT03767153|f||||f
17155338|NCT01965366|t||||f
17155339|NCT02073929|f||||f
17155340|NCT03319732|f||||t
17155341|NCT03887442|f||||f
17155342|NCT00430573|t||||
17155343|NCT05020665|f||||t
17155344|NCT00072280|f||OTHER|Must obtain prior Sponsor approval.|t
17155345|NCT02504827|f||||f
17155346|NCT02965729|t||||
17155347|NCT00322231|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155348|NCT01732640|f||||f
17155349|NCT04574908|t||||f
17155350|NCT00877487|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17155351|NCT03070002|t||||
17155352|NCT00712543|f||||f
17155353|NCT02702388|f||||f
17137157|NCT00808249|f||OTHER||t
17155354|NCT02729051|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155355|NCT03687684|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17155356|NCT04740827|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17155357|NCT03033602|f||||f
17155358|NCT01441765|f||||f
17155359|NCT02060058|f||||f
17155360|NCT01190410|f||GT60||t
17155361|NCT01399047|t||||
17155362|NCT02046005|f||||f
17155363|NCT00251303|t||||
17155364|NCT04532619|f||||t
17155365|NCT01976650|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155366|NCT01435018|f||OTHER||t
17155367|NCT03806933|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17155368|NCT03625466|f||||t
17155369|NCT02282631|f||||f
17155370|NCT00730730|f||OTHER|"Investigator/Institution agree to submit to Sponsor copies of any proposed publication/public presentation (Proposed Publication) at least sixty (60) calendar days in advance of dissemination. Sponsor will review/comment within thirty (30) calendar days after receipt thereof. If Sponsor objects to dissemination of any part of the Proposed Publication, Investigator, and Institution shall refrain from disseminating or presenting such Proposed Publication until Sponsor is satisfied."|t
17155371|NCT01841762|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17155372|NCT03260244|f||OTHER|The data and results from the clinical investigation are the sole property of the Sponsor. The Investigators will not use this clinical investigation-related data without the written consent of the Sponsor for any purpose other than for clinical investigation completion or for generation of publication materials, as referenced in the Clinical Trial Agreement. Single-center results are not allowed to be published or presented before the multi-center results.|t
17155373|NCT00956592|t||||f
17155374|NCT00287872|t||||
17155375|NCT04286581|t||||
17198303|NCT02101268|f||OTHER|Agreements varied with individual investigators, but did not prohibit any investigator from publishing. Investigators were not to publish results of the study until a period of time (eg. 2 years) following completion of the trial at all participating institutions but could do so earlier with consent of the Sponsor.|t
17155376|NCT03528369|f||OTHER|Sponsor can review results and communications prior to public release, and Sponsor can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the Sponsor for review. At all times, PIs retain editorial control of all publications and have a right to publish the study data, subject only to Sponsor's time-limited right to protect its intellectual property rights and prevent disclosure of Sponsor's confidential information.|t
17155377|NCT03555565|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155378|NCT00394836|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155379|NCT01163851|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155380|NCT02028767|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17155381|NCT00140244|f||||f
17155382|NCT01665157|f||||f
17155383|NCT02042950|t||||
17155384|NCT02935179|f||||f
17155385|NCT02429778|f||||f
17155386|NCT00784303|f||OTHER||t
17155387|NCT04501640|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17155388|NCT01981954|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript sixty (60) days prior to publication for review and comment.|t
17155389|NCT03655470|t||||f
17155390|NCT00887783|f||||f
17155391|NCT04590586|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198304|NCT00740870|f||GT60||t
17198305|NCT02831998|f||OTHER||t
17198306|NCT00839332|f||GT60||t
17198307|NCT01200485|t||||
17198308|NCT06080438|t||||
17198309|NCT03569475|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198310|NCT03638258|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17198311|NCT01564953|t||||
17198312|NCT02630706|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17198313|NCT01678898|f||||t
17198314|NCT00549042|f||||f
17198315|NCT01527500|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17198316|NCT03039088|f||||f
17198317|NCT03790878|t||||
17198318|NCT00655083|f||LTE60||t
17155392|NCT03063086|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17155393|NCT00489086|t||||
17155394|NCT02218736|t||||
17155395|NCT03879525|t||||
17198319|NCT03078751|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17198320|NCT01209286|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198321|NCT00981578|f||||f
17198322|NCT03030599|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17198323|NCT01180790|f||OTHER|Prior to submitting/presenting a manuscript or materials relating to a Study to a publisher, reviewer, or outside person, the Institution shall provide to Sponsor a copy of all such manuscripts or materials, and Sponsor shall have sixty (60) days to review and comment. The Institution shall, upon Sponsor's request, further delay publication or presentation for a period of up to one hundred twenty (120) days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17198324|NCT04582864|t||||
17198325|NCT00316589|f||||t
17198326|NCT01482819|f||LTE60||t
17198327|NCT00562484|f||LTE60||t
17198328|NCT02811302|f||||f
17198329|NCT00702520|f||OTHER|The sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17198330|NCT02481934|f||||f
17198331|NCT03735147|t||||
17198332|NCT00749671|f||||f
17198333|NCT00068718|t||||
17198334|NCT00960505|f||||f
17198335|NCT04130061|f||||f
17198336|NCT01568112|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17198337|NCT03390933|f||||f
17198338|NCT03371706|t||||
17198339|NCT00560313|f||LTE60||t
17198340|NCT00746785|f||||f
17198341|NCT00356993|f||||f
17198342|NCT00966979|f||OTHER|There is an agreement between Principal Investigators and the Sponsor (or its agents) that requires Investigators to allow Sponsor at least 60 days to review material intended for publications to ensure that confidential information is not disclosed and that the data is accurately represented. The investigators can submit publication proposals prior to the study completion date for Sponsor consideration and for up to 7 years after study completion.|t
17198343|NCT04140266|f||||f
17198344|NCT01990313|f||||f
17198345|NCT03511378|f||||f
17198346|NCT00837096|f||GT60||t
17198347|NCT05006417|t||||
17198348|NCT00280683|f||||f
17198349|NCT01243411|f||OTHER||t
17198350|NCT00082641|t||||
17198351|NCT00510198|f||||f
17198352|NCT03018223|t||||
17198353|NCT02176382|f||||f
17155396|NCT05481125|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17198354|NCT02209610|f||||f
17198355|NCT00387959|t||||
17198356|NCT03712449|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198357|NCT01592396|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The Principal Investigator (PIs) also agree for data to be presented first as a joint, multi-center publication.|t
17198358|NCT05376787|f||||f
17198359|NCT05153499|f||OTHER|The disclosure restrictions on the PI are: (i) the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to twenty-four months from the lock-down of all study data and (ii) the sponsor can require the removal of its confidential information from results communications and may delay release for a period of up to 60 days for the purpose of filing patent applications.|t
17198360|NCT01369706|t||||
17198361|NCT01649297|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198362|NCT01685047|f||LTE60||t
17198363|NCT01176435|f||||f
17198364|NCT01940523|t||||
17198365|NCT02541942|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17198366|NCT02490878|f||||t
17198367|NCT02544113|t||||f
17155397|NCT02244463|t||||
17198368|NCT00451555|f||GT60||t
17198369|NCT02847637|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198370|NCT03430050|t||||
17198371|NCT02685007|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198372|NCT01887990|t||||
17198373|NCT02741713|t||||
17198374|NCT01093222|f||LTE60||t
17198375|NCT00588341|t||||
17198376|NCT01670188|t||||
17198377|NCT01372202|t||||
17198378|NCT01961921|f||LTE60||t
17198379|NCT03416621|f||||f
17155398|NCT01769508|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17155399|NCT03615144|t||||
17155400|NCT00422695|f||||f
17155401|NCT02587598|f||OTHER|Clinical Study Agreement|t
17155402|NCT04709692|f||OTHER|"1. All data or results arising out of the performance of this Study shall be considered Information as defined above and shall not be used for the commercial benefit of Institution, Investigator, or Research Staff.~2. Any and all data resulting from the Study will not be presented or published in any form or media by the Institution, Investigator or Research Staff without the prior written consent of Sponsor which consent maybe as directed within the protocol."|t
17155403|NCT02828124|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17155404|NCT01590121|t||||
17155405|NCT03613909|t||||
17155406|NCT06586788|f||||f
17155407|NCT03514485|f||GT60||t
17198380|NCT01281917|t||||
17155408|NCT00791661|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17198381|NCT00096109|f||LTE60||t
17198382|NCT01187407|f||GT60||t
17198383|NCT04491084|t||||
17198384|NCT00776984|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198385|NCT03083093|f||||f
17198386|NCT01212484|f||||f
17198387|NCT03697083|f||||f
17198388|NCT02573883|f||||f
17198389|NCT01544309|f||||f
17198390|NCT00118703|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198391|NCT00953212|t||||
17198392|NCT03796208|f||||f
17198393|NCT01560585|t||||
17198394|NCT02175745|f||||f
17198395|NCT04688086|f||||f
17198396|NCT04206384|f||||f
17198397|NCT00006436|f||||f
17198398|NCT03594045|t||||
17198399|NCT00942188|f||GT60||t
17155409|NCT00492648|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155410|NCT01721096|f||GT60||t
17167089|NCT01425359|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167090|NCT03172325|f||OTHER|The investigator (PI) may publish results provided a copy of the written publication is received by the sponsor at least 30 days in advance for review and comment. If the parties disagree, PI agrees to meet with the sponsor before submission to resolve any disagreement. It is also agreed that publishing any reports from data is under the condition of the subject's consent. Any reports are highly confidential, and the PI does not have the permission to reveal them without the sponsor's agreement.|t
17198400|NCT00276016|f||LTE60||t
17198401|NCT05041439|t||||f
17198402|NCT01431105|f||||f
17198403|NCT02628964|t||||
17198404|NCT00113269|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17198405|NCT00467298|t||||
17198406|NCT01318317|t||||
17198407|NCT03119688|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198408|NCT03226106|t||||f
17198409|NCT00721214|f||||f
17155411|NCT01167881|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17155412|NCT01435460|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17155413|NCT01706939|t||||
17155414|NCT00482677|t||||f
17155415|NCT01094301|f||LTE60||t
17155416|NCT02235077|f||OTHER|To minimize the probability of inaccurate data in published materials, it is the policy of the Heart Failure Network that all data and text considered for all papers, and all abstracts for presentation at scientific meetings be submitted to the Publication and Presentation Subcommittee, the NHLBI Project Officer, and the Coordinating Center for review and approval prior to presentation or publication.|t
17155417|NCT00582608|t||||
17155418|NCT04013672|t||||
17155419|NCT03010800|f||||f
17155420|NCT03763929|f||LTE60||t
17155421|NCT01868022|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155422|NCT03386994|t||||
17155423|NCT04679311|t||||
17155424|NCT01217476|f||OTHER|PI have no implicit or explicit rights to publish study data and results of their services.|t
17155425|NCT02147158|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155426|NCT04445714|f||OTHER|The Investigator shall be entitled to publish the results of or make presentations related to the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17155427|NCT02805660|f||OTHER|PI can not disclose, discuss, or publish study results until final manuscript has been published.|t
17155428|NCT01684943|t||||
17155429|NCT04223635|f||||f
17155430|NCT02122887|t||||
17155431|NCT04383938|f||LTE60||t
17155432|NCT00836888|f||||t
17155433|NCT03652636|t||||
17155434|NCT00504725|f||||f
17155435|NCT04019613|t||||
17155436|NCT00769067|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155437|NCT00809471|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17167091|NCT03520348|f||OTHER|Researchers can not disseminate research results unless they obtain written authorization from the sponsor.|t
17167092|NCT02292758|f||||t
17198410|NCT00637247|f||OTHER|The manuscript or abstract shall be submitted at least (45) days prior to submission for publication to permit Sponsor to request removal of any Confidential Information and to protect its rights to any patentable inventions set forth therein. Upon Sponsor's reasonable request, the investigator shall redact Sponsor's Confidential Information from any such proposed publication or shall delay publication for up to 90 days to permit Sponsor to protect its proprietary Information.|t
17198411|NCT00488319|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17198412|NCT02158247|f||||f
17198413|NCT02041221|f||OTHER||t
17198414|NCT00875615|t||||f
17198415|NCT01772823|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications, and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17198416|NCT02601105|f||||f
17198417|NCT01732926|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198418|NCT00583050|f||||f
17198419|NCT00676897|f||||f
17198420|NCT02262364|f||OTHER|The Investigator must provide the Sponsor at least 90 days to review publications for legal and regulatory compliance and will include in publications a statement that the study was supported by the Sponsor. Sponsor confidential information will not be submitted for publication without Sponsor consent. Sponsor may request delay of publication for 60 days to allow for patent application filing.|t
17198421|NCT00902226|f||OTHER|No results can be made public before appropriate steps by Lundbeck to secure patents / intellectual property rights. The Investigator shall send any manuscript / public presentation to Lundbeck at least 1 month before submission for publication. If Lundbeck finds matters requiring patents or the like, the Investigator shall delay publication / public presentation for an additional 3 months.|t
17155438|NCT02497040|f||||f
17198422|NCT01049984|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. Sponsor may remove information that is considered confidential and/or proprietary other than Study data and results.|t
17198423|NCT04765553|f||||f
17155439|NCT01942486|f||||f
17155440|NCT03728426|t||||
17155441|NCT02064270|f||||f
17155442|NCT04470544|t||||
17155443|NCT02173522|t||||
17155444|NCT04967885|f||||f
17155445|NCT00654875|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17155446|NCT01011465|f||||f
17155448|NCT00068367|f||LTE60||t
17155449|NCT00723008|t||||
17155450|NCT02879617|f||||f
17155451|NCT00882778|f||||f
17155452|NCT01014988|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155453|NCT01683266|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17155454|NCT00886743|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198424|NCT00321321|t||||
17198425|NCT02154477|t||||
17198426|NCT03503162|f||||t
17198427|NCT01182103|t||||f
17198428|NCT03891641|t||||f
17198429|NCT03628456|f||||f
17198430|NCT00920699|f||||t
17198431|NCT01880697|f||GT60||t
17198432|NCT00953862|f||||f
17198433|NCT03723915|t||||
17198434|NCT01547247|t||||f
17198435|NCT01978236|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198436|NCT02906696|f||||f
17198437|NCT00634920|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198438|NCT00819013|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17198439|NCT00363649|t||||
17198440|NCT00979745|f||||f
17198441|NCT00607997|f||GT60||t
17198442|NCT00576823|f||OTHER|"If no publication has occurred within 12 months after trial completion, the investigators can publish the results. Prior to the publication, the sponsor can review and request changes to the manuscript, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not to exceed 90 days.~To protect by a property right any information the sponsor can postpone the publication, for a period not to exceed 18 months."|t
17198443|NCT05324007|t||||
17198444|NCT03360110|f||OTHER||t
17198445|NCT00510146|f||GT60||t
17198446|NCT03041298|f||||f
17198447|NCT01930214|f||OTHER|Any previously unpublished information provided to the Investigators by the Sponsor is confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study not use it for other purposes without the Sponsor's written consent. An Investigator can generate additional publication ideas based on the trial data. The Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data|t
17198448|NCT02132117|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198449|NCT03589300|f||||t
17198450|NCT01376297|f||OTHER|Sponsor and investigator(s) agree that no publications discussing trials' results will occur until release of final report. Sponsor has no objections if the investigators publish study results, however the investigator is requested to contact the sponsor before publishing, to prevent premature disclosure of data and is not intended as a restrictive measure concerning results or opinions of investigators.|t
17198451|NCT02569632|t||||f
17198452|NCT03352882|f||||f
17198453|NCT03029611|t||||
17198454|NCT02864342|f||OTHER|The only disclosure restriction on the PI is that within 2 years of study completion, the sponsor must review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.|t
17198455|NCT00661466|f||||f
17198456|NCT02301364|t||||
17198457|NCT01612767|f||||f
17198458|NCT02725008|t||||
17198459|NCT01149876|f||||f
17198460|NCT00513461|f||LTE60||t
17198461|NCT00853021|t||||
17155455|NCT04903496|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167093|NCT03305419|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167094|NCT00075946|f||||f
17155456|NCT05217641|f||||f
17155457|NCT00756236|f||||f
17155458|NCT02632409|f||LTE60||t
17167095|NCT00380029|t||||
17198462|NCT01329419|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198463|NCT02920021|f||||t
17198464|NCT05400226|f||LTE60||t
17198465|NCT01145547|t||||
17198466|NCT02212197|f||LTE60||t
17155459|NCT00537316|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17155460|NCT01867710|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17167096|NCT03639623|f||||f
17167097|NCT00889603|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167098|NCT01229254|f||OTHER|Due to multiple studies, centers and countries this may vary.|t
17198467|NCT01688895|f||LTE60||t
17198468|NCT02551692|t||||
17198469|NCT01091519|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198470|NCT00621946|f||||f
17198471|NCT01177228|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155461|NCT01062113|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155462|NCT03521115|t||||
17155463|NCT01471340|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor, and to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication which report any trial results. The sponsor has the right to review and comment on publications, abstracts, slides, and manuscripts, and to review and comment on data analysis and presentation.|t
17198472|NCT01592383|f||||f
17198473|NCT04159805|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17198474|NCT04167085|t||||
17198475|NCT01314014|f||||f
17155464|NCT00526669|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155465|NCT04259424|t||||
17155466|NCT03499899|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155467|NCT01893281|f||GT60||t
17198476|NCT03480919|t||||
17198477|NCT01171183|t||||f
17198478|NCT00835510|f||GT60||t
17198479|NCT01904136|t||||
17198480|NCT00853372|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198481|NCT01821729|t||||
17198482|NCT02517528|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198483|NCT01542398|f||||f
17198484|NCT03713281|f||GT60||t
17198485|NCT00320398|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198486|NCT01355978|f||||f
17198487|NCT04150913|t||||f
17198488|NCT02815735|f||OTHER||t
17198489|NCT05786521|t||||f
17198490|NCT01746108|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198491|NCT00997932|f||||f
17198492|NCT00468858|f||||f
17155468|NCT03933618|t||||
17155469|NCT00910208|t||||f
17155470|NCT04016779|f||||t
17155471|NCT02295020|f||||f
17155472|NCT02726906|f||||f
17155473|NCT00355147|t||||
17155474|NCT00256854|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155475|NCT05239494|f||||f
17155476|NCT00937040|f||OTHER|PI has the right to publish results of research and background information provided by SPONSOR necessary to include in publication of research results or for others to verify results. PI shall include a statement that creation of data was supported by SPONSOR. Prior to submission for publication/presentation, the INSTITUTION shall provide SPONSOR at least sixty (60) days for review.|t
17155477|NCT02294396|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi center data. Sponsor must receive a site's manuscript prior to publication for review and comment.|t
17155478|NCT02120833|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17167099|NCT02231892|f||||f
17167100|NCT00799227|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155479|NCT03502070|f||LTE60||t
17155480|NCT02805179|t||||
17155481|NCT00595517|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17155482|NCT00305084|f||||t
17155483|NCT04105218|t||||
17167101|NCT04463693|t||||
17167102|NCT01694121|f||||f
17198493|NCT04458181|t||||
17198494|NCT00809341|t||||
17198495|NCT01219777|t||||
17198496|NCT01743521|f||||f
17198497|NCT02975297|t||||
17155484|NCT00926848|f||||f
17155485|NCT00853645|f||||f
17155486|NCT04678232|f||||f
17155487|NCT03831360|f||||f
17155488|NCT03388645|t||||
17155489|NCT01894100|f||||f
17155490|NCT04192071|f||||f
17155491|NCT00586820|t||||f
17155492|NCT00684320|t||||
17155493|NCT00101166|t||||
17155494|NCT00686829|f||OTHER|The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to (1) proprietary information that is protected by the provisions contained in paragraph B below, (2) the accuracy of the information contained in the publication, and (3) to ensure that the presentation is fairly balanced and in compliance with FDA regulations.|t
17155495|NCT01672710|t||||f
17155496|NCT01729338|t||||f
17155497|NCT01694069|t||||
17155498|NCT00981669|t||||
17137158|NCT00479557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137159|NCT01594294|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17137160|NCT00847938|t||||
17137161|NCT03508661|t||||
17137162|NCT04124692|f||OTHER||t
17137163|NCT02370498|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17137164|NCT01122030|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17137165|NCT02275767|t||||
17155499|NCT01905553|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17155500|NCT00655707|t||||
17155501|NCT03138252|t||||
17155502|NCT03854370|t||||
17155503|NCT00076752|f||||f
17155504|NCT01767506|f||||f
17155505|NCT00452673|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17155506|NCT02656290|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review. Manuscripts will be submitted to EW for review 30 days prior to submission of manuscript for publication/presentation. EW may ask for a 60 day delay to protect proprietary information/filing of related patent applications. Site-specific results of devices which haven't been market released shall not include claims of device safety/effectiveness and require EW review/approval.|t
17155507|NCT04638881|t||||
17155508|NCT01608087|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17155509|NCT01949844|t||||f
17155510|NCT04429555|f||||f
17155511|NCT00231114|f||LTE60||t
17155512|NCT02048826|f||||f
17198498|NCT00225277|f||OTHER|The sponsor can review results communications prior to public release and can embargo trial results communications up to 150 days to permit actions necessary to preserve sponsor's intellectual property. Sponsor can request changes to the results communication only for the purpose of removing non study related information that is proprietary and confidential to sponsor. Sponsor can require delay of a results communication until the study has been completed at all participating sites.|t
17198499|NCT03432650|t||||
17198500|NCT00711997|f||||f
17198501|NCT04731675|f||OTHER||t
17198502|NCT04582669|t||||
17198503|NCT00591409|f||OTHER|Any scientific paper, presentation, or other communication concerning this clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17198504|NCT00677092|f||||f
17198505|NCT02716298|f||OTHER||t
17198506|NCT00550446|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198507|NCT02246218|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17198508|NCT04952701|f||||f
17198509|NCT02212301|f||LTE60||t
17198510|NCT03927222|t||||
17198511|NCT03690284|t||||
17198512|NCT03455218|f||||f
17198513|NCT00578318|f||||f
17155513|NCT00712881|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17155514|NCT00823069|f||GT60||t
17137166|NCT01453998|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155515|NCT03436693|f||OTHER||t
17155516|NCT03766165|t||||
17155517|NCT00626821|f||LTE60||t
17155518|NCT02261948|t||||
17155519|NCT01913535|t||||
17155520|NCT03341143|t||||
17155521|NCT01082211|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17155522|NCT01316211|f||||f
17155523|NCT03834766|f||LTE60||t
17155524|NCT03702010|f||||f
17155525|NCT01080118|t||||f
17155526|NCT02196688|f||||f
17155527|NCT01137110|f||||f
17155528|NCT02793674|t||||
17155529|NCT01146379|f||||f
17155530|NCT02394340|f||OTHER|Please contact Sponsor directly for additional information.|t
17155531|NCT02004886|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17155532|NCT01813214|t||||
17155533|NCT01876784|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17155534|NCT03605862|f||||f
17198514|NCT00866918|f||OTHER|Must obtain prior Sponsor approval.|t
17137167|NCT01486784|t||||
17137168|NCT03491553|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17137169|NCT00473837|t||||
17137170|NCT00973921|f||||f
17137171|NCT00488592|t||||
17137172|NCT04593940|f||GT60||t
17137173|NCT01096849|f||OTHER|The Investigator may publish/present the study results provided all of the following: (i) the primary publication has been published; or, if no such publication has occurred, at least 18m have passed since the completion of the study; (ii) Achaogen is allowed at least 60d to review; (iii) confidential information is deleted as requested; (iv) comments and proposed revisions are considered; and (v) during the 60d review, if requested, the Investigator shall delay the publication or presentation.|t
17137174|NCT04460690|f||||f
17137175|NCT00242580|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137176|NCT01232894|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137177|NCT03970395|f||||f
17137178|NCT00125190|f||OTHER||t
17137179|NCT03927508|f||||f
17155535|NCT03891862|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17155536|NCT01194531|f||OTHER|"Each PI signed an agreement that all data, analyses, information and materials prepared or derived as a direct result of the Study are required to be provided to the sponsor and in accordance with the Protocol, whether preliminary or final (the Study Results) shall be property of the sponsor. Site may utilize the Study Results for patient care and for it's own internal education purposes."|t
17155537|NCT01053962|f||OTHER|Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, oral presentations, abstracts) by the Investigator(s) or their representative(s), shall require prior notification, review, within a reasonable time frame, and written approval by the Sponsor. Additionally such publications cannot be made in violation of the Sponsor's confidentiality restrictions or to the detriment of the Sponsor's intellectual property rights.|t
17155538|NCT04143594|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198515|NCT00096681|t||||
17198516|NCT00527514|f||OTHER|"If identified by Daiichi Sankyo, Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted…Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by Study Site."|t
17198517|NCT00812838|f||||f
17137180|NCT00929734|f||||f
17155539|NCT02410798|f||||f
17155540|NCT00834639|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17155541|NCT04603482|f||||f
17155542|NCT05229952|t||||f
17155543|NCT01054196|t||||
17155544|NCT00282113|t||||
17198518|NCT04148521|f||||f
17198519|NCT01530659|f||||t
17137181|NCT03172520|t||||
17137182|NCT00980980|f||||f
17137183|NCT01449682|f||||f
17137184|NCT00414960|f||GT60||t
17137185|NCT02223455|f||||f
17155545|NCT00474201|t||||
17155546|NCT02380261|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17155547|NCT02253316|t||||
17155548|NCT02521051|t||||
17155549|NCT02784613|t||||
17198520|NCT01723514|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198521|NCT01329185|t||||
17198522|NCT00001941|f||||f
17198523|NCT00014222|f||||f
17198524|NCT00640042|f||OTHER|Results may only be published through Sponsor.|t
17198525|NCT00519285|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission to a journal, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17198526|NCT01020747|t||||f
17198527|NCT01222078|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198528|NCT02970305|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's Prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment|t
17198529|NCT00983892|t||||
17198530|NCT01729923|f||||f
17198531|NCT00808899|t||||
17198532|NCT06135675|f||||f
17198533|NCT03120949|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17198534|NCT00988117|f||||f
17198535|NCT00702273|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably. The Sponsor shall have the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the investigator(s) in the discussion of the data in such communications.|t
17198536|NCT04522778|t||||
17198537|NCT01225159|t||||
17198538|NCT00312845|f||||f
17198539|NCT01220856|f||||f
17137186|NCT00975195|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137187|NCT04633473|t||||
17137188|NCT01608724|f||LTE60||t
17137189|NCT02720016|f||||f
17137190|NCT02049749|f||||f
17137191|NCT02038218|f||||t
17137192|NCT04501679|f||OTHER||t
17155550|NCT02258373|f||||f
17155551|NCT01046903|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155552|NCT02107859|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17155553|NCT01303406|f||||f
17155554|NCT00135512|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155555|NCT04439214|f||LTE60||t
17155556|NCT05476250|t||||
17155557|NCT04152837|f||GT60||t
17155558|NCT00602459|f||LTE60||t
17155559|NCT06343467|t||||f
17155560|NCT01668173|t||||
17155561|NCT00688662|f||||f
17155562|NCT01295827|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17155563|NCT00746564|f||LTE60||t
17155564|NCT01628198|t||||
17155565|NCT03318497|t||||
17155566|NCT02842580|f||||f
17155567|NCT02551770|f||GT60||t
17137193|NCT00186056|f||||f
17137194|NCT04846348|t||||
17137195|NCT03615911|t||||
17137196|NCT04511026|t||||
17137197|NCT05319080|t||||
17155568|NCT04089904|t||||
17155569|NCT00321698|f||||f
17137198|NCT00751114|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17137199|NCT01423773|f||||f
17137200|NCT02648724|f||||f
17137201|NCT03076190|t||||
17137202|NCT05027516|t||||
17137203|NCT00379197|t||||
17155570|NCT04999163|f||||f
17155571|NCT05270395|t||||
17155572|NCT03725761|t||||f
17155573|NCT02260869|t||||
17155574|NCT00378508|t||||
17155575|NCT01283334|t||||
17167103|NCT02680041|f||OTHER|Neither Institution nor Investigator will submit for publication or public disclosure any publication or disclosure based on the results of the Study until after the first to occur of (a) publication of the Multi-Center Clinical Trial results; (b) notification by Sponsor that the Multi-Center Clinical Trial submission is no longer planned; or (c) the eighteen (18) month anniversary of the completion or early termination of the Multi-Center Clinical Trial.|t
17167104|NCT00521599|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of sponsor. The investigator further agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. The sponsor has the right to review and comment. If the parties disagree, the investigator agrees to meet with the sponsor's representative in order to resolve such issues.|t
17167105|NCT02186652|t||||
17198540|NCT04088500|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17198541|NCT03821064|t||||
17198542|NCT02617667|f||GT60||t
17198543|NCT03777553|t||||
17198544|NCT01554371|t||||
17198545|NCT03325608|t||||
17198546|NCT02188784|f||OTHER|To minimize the probability of inaccurate data in published materials, it is the policy of The Heart Failure Network (HFN) that all data and text considered for all papers, and all abstracts for presentation at scientific meetings, be submitted to the Publication \& Presentation Subcommittee, the NHLBI Project Officer and the Coordinating Center for review and approval prior to presentation or publication.|t
17198547|NCT01190449|t||||
17198548|NCT04298099|f||||f
17198549|NCT01268098|f||OTHER||t
17198550|NCT00665132|f||LTE60||t
17198551|NCT00970320|t||||
17198552|NCT01093599|f||||f
17198553|NCT01703845|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198554|NCT01644188|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17198555|NCT03756168|f||||f
17198556|NCT01929876|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137204|NCT00406783|f||OTHER|PI must provide sponsor w/ review copies of abstracts or manuscripts for publication that report any results of the study, 45 days before submission for publication or presentation. The sponsor shall have the right to review/comment on the material. If the parties disagree about the appropriateness of the material, PI must meet with sponsor's representatives before submission for publication, for the purpose of making good faith efforts to discuss and resolve any issues of disagreement.|t
17137205|NCT05294211|f||||t
17137206|NCT00064350|f||||f
17155576|NCT03467217|f||||f
17155577|NCT01770366|t||||
17155578|NCT02989246|t||||
17155579|NCT03233529|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198557|NCT01845649|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198558|NCT03991988|t||||
17198559|NCT00248534|f||||f
17198560|NCT01222533|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17198561|NCT01947517|f||||f
17198562|NCT02276638|f||||f
17155580|NCT01177293|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155581|NCT00348595|t||||
17155582|NCT01323153|f||||f
17155583|NCT03991299|f||||f
17155584|NCT04304235|f||||f
17155585|NCT01916681|t||||f
17155586|NCT02821338|f||LTE60||t
17155587|NCT00860535|f||||f
17155588|NCT01194999|f||||f
17155589|NCT05835011|f||||f
17155590|NCT03834974|f||||f
17155591|NCT00187681|t||||
17155592|NCT04720911|f||||f
17155593|NCT00090220|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication or presentation|t
17155594|NCT00941863|f||OTHER|Sponsor recognizes right of principle investigator (PI) to publish results on completion of study, however, PI must provide draft of the communication to sponsor for approval 30 days prior to submission for publication. In case of difference of opinion between sponsor and PI, the parties will seek a solution satisfactory to both.|t
17155595|NCT00823043|f||OTHER|Prior to submission for publication or presentation, the PI will provide the Sponsor with at least 60 days for review of a manuscript. If requested in writing, the PI will withhold publication for up to an additional 60 days.|t
17155596|NCT05113979|f||||f
17155597|NCT00565643|f||||f
17155598|NCT00281632|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155599|NCT03990571|t||||
17155600|NCT01369108|f||||f
17155601|NCT04748458|f||||f
17155602|NCT00638443|f||||f
17155603|NCT00179673|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17155604|NCT02949843|t||||
17167106|NCT01218958|f||OTHER|Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.|t
17167107|NCT00744978|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167108|NCT00866047|f||LTE60||t
17167109|NCT02928029|f||LTE60||t
17167110|NCT00515294|t||||f
17167111|NCT02778555|t||||
17198563|NCT02418845|f||OTHER|PI submits complete copy of publication material to sponsor at least 60 days prior to submission implementing all reasonable sponsor comments. If sponsor determines that proposed publication contains disclosure of intellectual property for which sponsor is seeking patent protection, PI shall delay submission 60 days from sponsor notice so sponsor may file patent application covering intellectual property. PI shall have no further rights to publish sponsor confidential information.|t
17198564|NCT00526097|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198565|NCT00460564|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198566|NCT00511836|f||OTHER|The PI/Institution may publish study results for noncommercial purposes. Sponsor will have 30 days to review a proposed publication. PI/Institution will delete any Sponsor Confidential Information other than study results, will revise a publication based on regulatory requirements of Sponsor as manufacture of the study drug, and will delay publication for no more than 60 days to allow for filing of patent applications to protect Sponsor's intellectual property contained in such publication.|t
17167112|NCT01179217|f||OTHER|PI agrees that any INFORMATION submitted to it by EMMAUS shall be maintained in secrecy for a period of seven (7) years from each disclosure of INFORMATION. PI will use the up most due diligence to prevent disclosure by it except to its employees, agents, and contractors necessary for evaluation, all of whom shall be bound by similar written obligations of confidentiality, and who agree not to use the INFORMATION for any purpose other than for evaluation purposes.|t
17198567|NCT01936324|f||||t
17198568|NCT00943618|t||||
17137207|NCT00838916|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137208|NCT04398199|t||||
17155605|NCT00671528|f||OTHER|The principal investigators agree not to publish or publicly present any interim results of the study without prior written consent of the SPONSOR. The principal investigator further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the SPONSOR to review copies of abstracts or manuscripts for publication which report any results of the study. The SPONSOR shall have the right to review and comment on any presentation.|t
17167113|NCT01849575|f||||f
17198569|NCT06142578|f||OTHER||t
17198570|NCT06178718|f||||f
17198571|NCT05566886|f||||f
17155606|NCT03226769|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155607|NCT01827267|f||LTE60||t
17155608|NCT02119455|f||||f
17198572|NCT00487552|f||OTHER|Each PI/site is restricted from making any publication until the multi-center publication has been presented (published) or 12 months after conclusion/abandonment/or termination of the Study (in the case where the multi-center publication has not been submitted within the 12 months) or Cook confirms there will be no multi-center publication.|t
17155609|NCT02640677|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17155610|NCT00537576|f||||f
17155611|NCT01516008|f||GT60||t
17155612|NCT04553471|t||||
17155613|NCT03641326|f||||f
17155614|NCT03129945|f||||f
17155615|NCT02036840|t||||
17155616|NCT00813813|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication at least 60 days prior to the intended submission, presentation, or publication date.|t
17155617|NCT00986921|f||||f
17155618|NCT00833482|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17155619|NCT02778074|f||||f
17155620|NCT03699280|f||||f
17155621|NCT06137131|f||||f
17155622|NCT03489707|t||||
17137209|NCT01842607|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155623|NCT01817582|f||OTHER|Please contact Sponsor directly for additional information.|t
17155624|NCT00170625|f||GT60||t
17155625|NCT00356135|f||GT60||t
17155626|NCT03617770|f||||f
17155627|NCT03963232|f||GT60||t
17155628|NCT04965311|f||||f
17155629|NCT03512210|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17155630|NCT04432090|t||||
17155631|NCT04250350|f||GT60||t
17155632|NCT03190668|t||||
17155633|NCT02836236|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198573|NCT02412111|f||OTHER|PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or(3)18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17198574|NCT00630552|f||||t
17155634|NCT01806961|f||OTHER|"There is an agreement between the PI and the Sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.~Investigator is granted a right to publish and present Trial Results together with other investigators of Trial and to be referred to in publications containing such results. However, PI shall not publish or present Results unless Investigator has submitted to Spirig a draft of the intented publication or presentation for review and approval."|t
17155635|NCT03653351|f||||f
17198575|NCT04349644|f||||f
17137210|NCT00012012|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17137211|NCT02034474|f||||f
17155636|NCT03681990|f||||t
17155637|NCT04420585|t||||
17155638|NCT00972816|f||||f
17155639|NCT04114357|f||||f
17155640|NCT03558152|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198576|NCT00983905|f||GT60||t
17155641|NCT03693612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17155642|NCT02991729|t||||f
17155643|NCT02230696|f||OTHER||t
17155644|NCT05537441|f||||f
17155645|NCT04310397|t||||
17155646|NCT05225298|t||||
17155647|NCT01450826|t||||f
17155648|NCT02877095|f||||f
17155649|NCT03309657|t||||
17137212|NCT01391819|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137213|NCT03600714|t||||
17137214|NCT04597619|f||||f
17137215|NCT01628250|t||||
17137216|NCT02509494|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17155650|NCT01470651|f||||f
17155651|NCT01936181|f||OTHER|At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them. If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.|t
17155652|NCT00970632|f||GT60||t
17155653|NCT02817516|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17155654|NCT00748189|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17155655|NCT01424514|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155656|NCT02653170|f||||f
17155657|NCT02147522|f||||f
17198577|NCT01114139|f||OTHER|If no multi-site publication within 18 months after Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, Site, and Site Management Organization (SMO) shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17198578|NCT01169636|t||||
17198579|NCT02705625|f||||t
17198580|NCT00494026|f||GT60||t
17198581|NCT02190552|f||||f
17198582|NCT01057251|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17198583|NCT02637856|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198584|NCT00784147|f||LTE60||t
17198585|NCT03677245|t||||
17198586|NCT01982786|t||||f
17198587|NCT04544865|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17198588|NCT02287883|f||||f
17198589|NCT00802438|t||||
17198590|NCT04016805|f||||f
17198591|NCT03175198|t||||
17198592|NCT03367910|f||||f
17198593|NCT01193218|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198594|NCT03811834|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17137217|NCT02871401|t||||
17137218|NCT01120379|f||GT60||t
17137219|NCT03162055|f||LTE60||t
17137220|NCT02586077|f||||f
17155658|NCT03557931|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17155659|NCT00737204|t||||f
17155660|NCT02829723|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155661|NCT02989649|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155662|NCT00330343|f||||f
17155663|NCT03614078|f||OTHER||t
17155664|NCT02691936|t||||
17155665|NCT06191393|f||||f
17155666|NCT03382834|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17155667|NCT02387957|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.|t
17155668|NCT02685358|f||||f
17155669|NCT05819086|f||||f
17155670|NCT01551264|f||||f
17155671|NCT01992653|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155672|NCT00977314|f||GT60||t
17155673|NCT00153543|f||||f
17155674|NCT01343277|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17155675|NCT02344251|f||||f
17155676|NCT00288600|f||||f
17155677|NCT03600194|f||||f
17155678|NCT01582178|f||||f
17155679|NCT03852628|f||LTE60||t
17155680|NCT02964208|f||||f
17155681|NCT00556933|f||||f
17155682|NCT01743560|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155683|NCT02439814|t||||
17198595|NCT01242371|f||||f
17198596|NCT03188536|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198597|NCT01748045|f||||f
17198598|NCT04947436|f||||t
17198599|NCT00673127|f||||f
17155684|NCT00940823|f||||f
17155685|NCT02572076|f||LTE60||t
17155686|NCT02255305|f||||f
17198600|NCT03719378|f||||f
17198601|NCT02161185|f||OTHER|A manuscript or abstract should not be submitted by investigator(s) for publication or presentation until a New Drug Application is approved by the US FDA or permission is granted in writing by the sponsor.|t
17155687|NCT01640379|f||||f
17155688|NCT03395184|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155689|NCT00199797|f||||f
17155690|NCT01351480|t||||
17155691|NCT00811317|f||||f
17155692|NCT01106677|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17155693|NCT03937908|f||||f
17155694|NCT03205761|f||GT60||t
17155695|NCT02163226|t||||
17155696|NCT00477750|t||||
17155697|NCT01585324|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155698|NCT03448575|f||||f
17155699|NCT00601172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155700|NCT05318092|f||OTHER|The publication of the results from any single site experience within the study is not allowed until the preparation and publication of the multi-center results. Exceptions to this rule require the prior written approval of the Sponsor. If after 180 days from the conclusion of the study, the Sponsor has not published the results, the investigators may publish without prior approval from the Sponsor.|t
17155701|NCT02219581|f||||f
17155702|NCT03030989|t||||
17155703|NCT02706886|f||LTE60||t
17155704|NCT03917472|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17155705|NCT04364802|t||||
17155706|NCT04434469|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155707|NCT01669174|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17155708|NCT03788434|f||||t
17167114|NCT04659174|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167115|NCT04077996|t||||f
17198602|NCT00372255|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198603|NCT02341599|f||||f
17198604|NCT01215032|t||||
17198605|NCT01424189|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17198606|NCT05288504|f||||f
17198607|NCT01078584|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17198608|NCT01208870|f||||f
17198609|NCT01077622|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198610|NCT00424177|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198611|NCT01123512|f||||f
17198612|NCT03822377|f||||f
17198613|NCT02356484|t||||
17198614|NCT00496834|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198615|NCT05399082|t||||
17198616|NCT04944784|f||||f
17198617|NCT02210208|f||GT60||t
17155709|NCT01953601|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17155710|NCT01154296|f||||f
17155711|NCT02223650|f||||f
17155712|NCT05167370|t||||f
17155713|NCT00840307|f||||f
17155714|NCT03966924|f||LTE60||t
17155715|NCT01934517|f||||f
17155716|NCT01070095|f||||f
17155717|NCT02153671|f||||f
17155718|NCT02796352|t||||
17155719|NCT01322594|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17198618|NCT01066936|f||LTE60||t
17198619|NCT04333732|f||OTHER||t
17198620|NCT04984239|f||||f
17198621|NCT04190225|f||||f
17198622|NCT02994784|t||||
17198623|NCT02363998|f||||t
17198624|NCT02466243|f||||f
17155720|NCT04184362|f||||f
17155721|NCT00664859|f||OTHER|The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PI's.|t
17167116|NCT01818739|t||||
17167117|NCT01382303|f||||f
17198625|NCT00477464|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198626|NCT00639769|t||||
17198627|NCT00863798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198628|NCT04238520|f||||f
17198629|NCT01470599|f||LTE60||t
17137221|NCT01617655|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17155722|NCT01943851|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17155723|NCT00900757|f||OTHER|The Institution will provide Eisai with a copy of any manuscript, paper, or poster connected with the study at least 30 days prior to submission to journal/presentation in order for Eisai to review for Eisai's Confidential Information (CI). Should Eisai notify Institution with such 30 day period that materials contain CI, Institution agrees to delay submission/publication/presentation for an additional 60 days to allow Eisai to seek patent or other protection.|t
17198630|NCT00195442|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198631|NCT01917006|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198632|NCT00624013|f||||f
17198633|NCT00847132|f||||f
17198634|NCT04912700|t||||
17198635|NCT01508832|f||||f
17198636|NCT03357471|f||GT60||t
17198637|NCT02973802|f||||t
17198638|NCT00706914|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and sponsor.|t
17198639|NCT02122549|f||GT60||t
17198640|NCT03954223|f||||f
17198641|NCT03927690|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17198642|NCT01850823|f||OTHER||t
17198643|NCT01751165|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198644|NCT04026399|t||||
17198645|NCT02431455|t||||
17198646|NCT00988533|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17198647|NCT03248141|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198648|NCT00661544|t||||f
17198649|NCT00675792|f||OTHER|In case a proposed publication contains reference to an invention owned by the sponsor or to which the sponsor otherwise has rights, the sponsor may request a reasonable suspension of the publication.|t
17198650|NCT00943722|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17198651|NCT01036165|f||OTHER|Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.|t
17198652|NCT03468179|t||||
17155724|NCT03320850|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198653|NCT01387815|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17198654|NCT03082898|f||||f
17198655|NCT00913523|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written consent. The Institution will provide Sponsor with at least sixty (60) days for review of a manuscript, and if requested in writing, the Institution and Principal Investigators will withhold such publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17198656|NCT02895360|f||GT60||t
17198657|NCT00916305|f||||f
17198658|NCT01844726|f||||f
17198659|NCT02149524|f||OTHER|At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them.|t
17198660|NCT00307164|f||||f
17155725|NCT00546117|f||||f
17155726|NCT06207149|f||||f
17155727|NCT01968356|f||||t
17155728|NCT02274870|f||||f
17155729|NCT01975571|t||||
17155730|NCT01609543|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155731|NCT00507819|t||||f
17155732|NCT03452488|f||||f
17155733|NCT01254318|f||OTHER|The Principal Investigator and Institution agree to provide 45 days written notice to Sponsor prior to submission for publication or presentation to permit Sponsor to review drafts of abstracts and manuscripts for publication which report any results arising out of the Study.|t
17155734|NCT01945970|f||||f
17155735|NCT00782184|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17155736|NCT02050919|t||||
17155737|NCT00749684|f||||f
17155738|NCT01878084|t||||
17155739|NCT02643849|f||||f
17155740|NCT02892422|f||||f
17155741|NCT01023256|f||OTHER|All information supplied by MorphoSys is considered confidential until publication and shall not be disclosed without prior written consent from MorphoSys. No data can be published in any format without prior approval of the MSC-1001 Publication Committee, which has final decision on approving submissions for publication. In the event of disagreement in the content of a publication, both the Author's and MorphoSys' opinion will be fairly and sufficiently represented in the publication.|t
17155742|NCT03155178|f||||t
17155743|NCT03089697|f||||t
17155744|NCT03613649|f||LTE60||t
17155745|NCT00675428|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17155746|NCT00319592|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17155747|NCT01512446|t||||
17155748|NCT01500187|f||||f
17155749|NCT02537431|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155750|NCT02727777|t||||
17155751|NCT05152966|f||||f
17155752|NCT01758731|f||||f
17155753|NCT01340027|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 90 days prior to publication for review and comment.|t
17167118|NCT01639339|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167119|NCT03022097|f||||f
17167120|NCT03306979|t||||
17167121|NCT01451931|f||||f
17167122|NCT00503581|f||LTE60||t
17198661|NCT04067843|f||||f
17198662|NCT04151706|t||||
17198663|NCT02434523|f||||f
17198664|NCT01167192|t||||
17198665|NCT02560389|t||||
17198666|NCT00498615|f||||f
17198667|NCT04074343|t||||
17198668|NCT00241969|f||||f
17198669|NCT01664897|t||||
17137222|NCT02093234|f||OTHER|The sponsor will conduct a peer review of the research report before it may be published.|t
17137223|NCT01844830|f||||f
17137224|NCT02170649|f||OTHER||t
17155754|NCT04687072|f||||t
17155755|NCT00915876|f||||f
17155756|NCT01662791|t||||
17155757|NCT01923298|t||||
17155758|NCT01397786|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17155759|NCT00784550|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155760|NCT00688701|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17155761|NCT02195622|f||||f
17155762|NCT00743730|f||||f
17155763|NCT03875092|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17155764|NCT00784238|f||LTE60||t
17155765|NCT02759055|t||||
17155766|NCT00723255|f||LTE60||t
17155767|NCT00614523|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial resul|t
17155768|NCT03692325|t||||
17155769|NCT02461524|f||||t
17155770|NCT01470781|f||||f
17155771|NCT00765895|f||||f
17155772|NCT02062710|f||||f
17155773|NCT04481191|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17155774|NCT02487771|t||||
17155775|NCT02002533|t||||
17155776|NCT00101036|f||LTE60||t
17155777|NCT00722566|f||||f
17155778|NCT04984278|f||||f
17155779|NCT01482065|t||||f
17155780|NCT00425061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155781|NCT02161484|t||||
17155782|NCT02137850|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17198670|NCT01203956|f||||f
17198671|NCT00069277|f||||f
17198672|NCT02230306|t||||
17198673|NCT02657954|t||||
17198674|NCT00953199|f||||f
17198675|NCT01770314|t||||
17198676|NCT00361842|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17198677|NCT03512288|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198678|NCT04814992|f||||f
17198679|NCT01355471|f||GT60||t
17198680|NCT01260142|f||OTHER||t
17198681|NCT00691678|t||||
17155783|NCT02651155|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155784|NCT02655510|t||||
17155785|NCT04533412|f||||f
17167123|NCT04470908|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17167124|NCT03354546|f||||f
17198682|NCT01227928|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198683|NCT01042145|t||||
17198684|NCT00934700|t||||
17198685|NCT01494298|f||LTE60||t
17198686|NCT02930837|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198687|NCT00566345|f||LTE60||t
17198688|NCT01393613|f||||f
17198689|NCT01831726|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198690|NCT01618227|f||||f
17198691|NCT00654615|f||||f
17198692|NCT02592486|f||||f
17198693|NCT01283971|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198694|NCT01502371|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17198695|NCT02598934|f||OTHER|The study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the Overall Study. The sponsor may request that the confidential information be deleted and/or the publication to be postponed inorder to present the Sponsor's intellectual property rights.|t
17198696|NCT02672514|f||||f
17198697|NCT03049306|f||||f
17198698|NCT02154347|f||||f
17198699|NCT01568021|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198700|NCT02473913|f||||f
17198701|NCT00605566|f||||t
17198702|NCT04156399|t||||
17198703|NCT03440047|t||||
17198704|NCT01181609|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198705|NCT01333111|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17198706|NCT04732871|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17198707|NCT00384865|f||||f
17137225|NCT00502320|t||||
17155786|NCT02355821|t||||
17155787|NCT00968981|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155788|NCT05875025|f||OTHER|Results of this study may be published or presented at scientific meetings. If a publication is presented by the Investigator, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17167125|NCT02713997|t||||
17167126|NCT06107803|f||||f
17167127|NCT05129072|t||||
17167128|NCT02378298|f||||f
17167129|NCT04730635|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17198708|NCT03294941|f||||t
17198709|NCT00702650|f||GT60||t
17137226|NCT02173392|f||OTHER||t
17198710|NCT03993457|t||||
17198711|NCT03752242|t||||
17155789|NCT01489254|f||OTHER|The terms and conditions of Synthon's agreements with its investigators may vary. However, Synthon BV does not prohibit any investigator from publishing. Any publication from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17155790|NCT01098500|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155791|NCT01187771|t||||f
17155792|NCT02833844|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17155793|NCT01154088|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155794|NCT01475851|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155795|NCT01576276|f||||f
17155796|NCT02017912|f||||f
17155797|NCT03845491|f||||t
17155798|NCT01508130|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155799|NCT01680159|f||OTHER||t
17155800|NCT02200536|f||||f
17155801|NCT02388815|f||GT60||t
17155802|NCT03429244|f||||f
17155803|NCT03403751|f||||f
17198712|NCT01475461|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198713|NCT01271036|f||OTHER|Study is considered a work made for hire and the Sponsor retains all rights to publish results.|t
17198714|NCT02512861|t||||
17198715|NCT01774019|f||||f
17198716|NCT03206476|f||||f
17198717|NCT03214250|f||OTHER|Trial Site and/or Co-Principal Investigators may publish or present Study Data and other results of the Study from the Trial Site individually upon the first to occur of: (i) twelve (12) months after conclusion, abandonment, or termination of the Study at all Affiliated Research Institutions, or (ii) after Parker Institute for Cancer Immunotherapy \[PICI\] confirms in writing there will not be a multi-site Study publication.|t
17198718|NCT00616577|t||||
17198719|NCT01376050|f||||f
17198720|NCT03463577|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17198721|NCT05694533|f||OTHER||t
17198722|NCT00292981|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.|t
17198723|NCT00594178|f||||f
17198724|NCT02172950|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198725|NCT00496626|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198726|NCT00611715|t||||
17198727|NCT00107978|f||LTE60||t
17198728|NCT00727415|f||||f
17198729|NCT02005393|f||LTE60||t
17198730|NCT04191148|f||||f
17198731|NCT02090998|t||||
17198732|NCT00374088|t||||
17198733|NCT01274559|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17198734|NCT02971228|f||||f
17137227|NCT05137730|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17137228|NCT02394808|f||GT60||t
17137229|NCT04724733|f||||f
17137230|NCT03341923|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17137231|NCT01742078|f||GT60||t
17155804|NCT00750139|f||OTHER|Institution and Principal Investigator agree not to individually publish the results of the Study. Institution and Principal Investigator may, however, upon written notice to Merz participate in a joint, multicenter publication of the Study results with other investigators and/or institutions, provided that the manuscript or abstract is first reviewed by Merz.|t
17155805|NCT00351741|t||||f
17155806|NCT00658775|f||||f
17155807|NCT05033262|f||||f
17155808|NCT03518619|t||||
17155809|NCT04413552|f||OTHER|The PI will not disseminate, present or publish any of the study data without the prior written approval from Indivior to do so.|t
17155810|NCT01188876|t||||
17155811|NCT03717051|t||||
17155812|NCT00029536|f||||f
17155813|NCT01168908|f||||f
17155814|NCT01300338|t||||f
17155815|NCT01895270|f||||f
17155816|NCT00976820|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155817|NCT02233296|f||LTE60||t
17155818|NCT03261674|t||||
17155819|NCT01883817|f||||f
17155820|NCT00623935|t||||
17155821|NCT03628339|f||OTHER||t
17155822|NCT03961061|f||||f
17155823|NCT00747474|f||GT60||t
17155824|NCT04507256|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17155825|NCT00631410|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155826|NCT00890084|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17155827|NCT02233101|t||||
17155828|NCT03330262|t||||
17155829|NCT01647516|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17155830|NCT02980341|f||||f
17155831|NCT01323595|t||||f
17155832|NCT03886519|t||||
17155833|NCT03193801|f||||t
17155834|NCT04964544|f||OTHER|The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17155835|NCT03875274|t||||
17198735|NCT01664923|f||OTHER|PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.|t
17198736|NCT02856490|f||OTHER||t
17198737|NCT03700372|f||||f
17198738|NCT03409731|f||LTE60||t
17198739|NCT01537185|f||LTE60||t
17198740|NCT00827775|f||||f
17155836|NCT01613222|f||OTHER|The sponsor cannot require changes to the PI's disclosure, with the exception of requesting the removal of sponsor's confidential information. The study results themselves are not considered confidential information. Sponsor cannot extend the embargo beyond 60 days unless the PI's disclosure contains patentable subject matter, in which an embargo beyond 60 days may be necessary to allow for the filing of a patent application|t
17155837|NCT03696108|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17155838|NCT02319174|f||||f
17155839|NCT04798989|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17155840|NCT01899742|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155841|NCT02662764|f||OTHER|Investigator must obtain approval from AcelRx in order to discuss or publish trial results|t
17155842|NCT04323306|f||GT60||t
17155843|NCT00089778|f||||f
17155844|NCT02195310|f||||t
17167130|NCT04934800|f||||t
17198741|NCT02427958|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17155845|NCT05129137|f||OTHER|The CRO (ACCUTEST) shall not make any publication or communication, written or oral, in connection with the Study and the results of the Study, whether partial or final, without the prior written consent of the sponsor (UNITHER PHARMACEUTICALS) during, and following termination or expiration of this Clinical study Service Agreement|t
17155846|NCT01104246|f||LTE60||t
17155847|NCT05093530|f||||f
17198742|NCT03410108|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198743|NCT01009138|f||||f
17198744|NCT01013740|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198745|NCT00338949|f||||f
17198746|NCT00025662|t||||
17155848|NCT05178641|f||LTE60||t
17155849|NCT01869699|f||||f
17155850|NCT01867294|f||||f
17155851|NCT02658734|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155852|NCT00459706|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155853|NCT04676451|f||||f
17155854|NCT01252563|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155855|NCT01880086|t||||
17155856|NCT02458768|f||||f
17155857|NCT03843632|f||OTHER|The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17155858|NCT01820572|f||LTE60||t
17155859|NCT00896181|t||||
17155860|NCT00387010|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17155861|NCT00520481|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17155862|NCT04586634|f||||f
17155863|NCT00789256|f||||f
17198747|NCT00582114|f||||f
17198748|NCT02604342|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198749|NCT00130728|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.|t
17198750|NCT02196168|f||LTE60||t
17155864|NCT01931956|f||GT60||t
17155865|NCT02847494|t||||
17155866|NCT02841280|f||||f
17155867|NCT01738503|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17155868|NCT03005327|f||||t
17155869|NCT01490073|f||||f
17155870|NCT02782065|t||||
17198751|NCT02881047|t||||
17198752|NCT03028012|t||||
17198753|NCT03181282|f||||f
17198754|NCT02624375|f||LTE60||t
17155871|NCT02496091|f||LTE60||t
17155872|NCT02272842|f||||f
17155873|NCT00569673|f||||f
17155874|NCT01493284|f||||t
17155875|NCT02663102|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17155876|NCT03626363|f||||f
17155877|NCT00533702|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17155878|NCT05685264|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155879|NCT02341495|t||||
17155880|NCT02100670|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155881|NCT04852679|f||||t
17155882|NCT01294696|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17155883|NCT01953874|f||||f
17155884|NCT03339726|f||LTE60||t
17155885|NCT01275755|f||OTHER||t
17155886|NCT02210247|f||||f
17155887|NCT00636194|f||OTHER|"The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.~Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment."|t
17155888|NCT03470012|f||||f
17155889|NCT01246349|f||||f
17155890|NCT01579045|f||LTE60||t
17155891|NCT04934189|f||||f
17155892|NCT03962790|f||GT60||t
17155893|NCT00880581|f||||f
17155894|NCT01286168|t||||f
17155895|NCT04630249|f||||f
17155896|NCT04598451|f||||t
17155897|NCT02893553|t||||f
17155898|NCT00061373|t||||
17155899|NCT04594941|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17155900|NCT02091960|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17155901|NCT00382590|t||||f
17155902|NCT01579084|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167131|NCT04603495|f||OTHER|If publication or presentation at scientific meetings is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Requirements for publication of study results are defined in the clinical trial agreement. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data.|t
17167132|NCT02118766|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17167133|NCT05413512|t||||
17167134|NCT03760016|f||||f
17198755|NCT00569010|t||||
17198756|NCT04525456|f||LTE60||t
17155903|NCT02424630|t||||f
17155904|NCT02703272|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17155905|NCT00384748|f||||f
17155906|NCT02637895|t||||f
17155907|NCT02005692|f||LTE60||t
17155908|NCT01892709|t||||
17155909|NCT02091375|f||GT60||t
17155910|NCT02682823|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/ or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155911|NCT01741792|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17155912|NCT02222545|f||||t
17155913|NCT00761280|f||OTHER|Investigator and Sponsor both have publication / presentation privileges. Investigator abstracts or publications had to be reviewed and approved by the Sponsor prior to submission or presentation. The Clinic/Investigator agrees to delete information or defer publication or presentation, if (i) publication would hinder or delay the development of the investigational product or (ii) necessary to permit the filing of any desired patent applications by the Sponsor.|t
17155914|NCT01938430|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17155915|NCT03875482|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17155916|NCT00949403|t||||
17155917|NCT02111785|t||||
17155918|NCT00979875|f||GT60||t
17155919|NCT02738879|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17167135|NCT03941964|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17155920|NCT01438294|f||GT60||t
17155921|NCT01302444|f||||f
17155922|NCT01346189|t||||
17155923|NCT02360631|f||||f
17155924|NCT00205868|f||||t
17155925|NCT01730534|f||||t
17155926|NCT01520558|f||OTHER|Agreement is specific to clinical trial agreement|t
17155927|NCT01676896|f||||f
17155928|NCT02256982|t||||
17155929|NCT03369067|t||||
17155930|NCT01783639|f||LTE60||t
17198757|NCT02484547|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information.PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17198758|NCT01813305|f||||f
17155931|NCT00655733|f||LTE60||t
17155932|NCT02447497|f||||f
17155933|NCT01322035|f||||f
17155934|NCT00732758|f||||f
17155935|NCT01844206|f||||f
17155936|NCT04240457|t||||
17155937|NCT02773212|f||||f
17155938|NCT00271011|f||||f
17155939|NCT02105246|f||||f
17155940|NCT05036668|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167136|NCT03219034|f||||f
17198759|NCT02736955|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17198760|NCT01665599|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17198761|NCT01837797|f||||f
17155941|NCT01190267|f||OTHER|It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.|t
17155942|NCT02468154|t||||
17155943|NCT00325156|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155944|NCT00519428|f||||f
17155945|NCT03053063|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167137|NCT03478254|f||||f
17167138|NCT02438683|t||||
17155946|NCT02600845|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17155947|NCT05250102|f||LTE60||t
17155948|NCT03192995|t||||f
17155949|NCT03506568|f||||f
17155950|NCT02579343|t||||
17155951|NCT00381238|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17155952|NCT02806544|t||||f
17155953|NCT02086448|f||||f
17155954|NCT05027048|f||||f
17198762|NCT01705145|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17155955|NCT00843037|f||||f
17155956|NCT04112160|t||||
17155957|NCT03535194|f||||t
17155958|NCT01279070|t||||f
17155959|NCT03781583|t||||
17155960|NCT02045862|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17155961|NCT03164564|f||||f
17155962|NCT02691013|t||||
17155963|NCT06017752|f||||f
17155964|NCT02357706|f||||f
17155965|NCT02327403|f||||f
17155966|NCT01075646|t||||
17155967|NCT01895608|t||||
17155968|NCT03829618|t||||f
17198763|NCT02083679|f||||f
17198764|NCT02176837|f||||f
17198765|NCT00618917|t||||
17198766|NCT01503164|t||||
17198767|NCT04088136|f||||f
17198768|NCT01669720|f||||f
17155969|NCT03505593|f||OTHER|Twelve months following the completion of the study, Investigator may publish the results of the study. Investigator shall provide sponsor advanced copies of any proposed publication sixty days prior to planned publication Sponsor will have sixty days to review the proposed publication.|t
17155970|NCT02275780|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17155971|NCT03960866|t||||
17155972|NCT00405522|t||||
17155973|NCT02855359|f||||t
17155974|NCT05129475|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155975|NCT00348790|t||||
17155976|NCT01044290|t||||
17155977|NCT02319967|f||||f
17155978|NCT05010512|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17155979|NCT02737631|f||OTHER|Confidentiality agreement in place with PIs.|t
17155980|NCT01084668|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17198769|NCT04013932|f||||f
17198770|NCT03972397|t||||
17198771|NCT00731588|t||||
17198772|NCT00143598|f||||f
17155981|NCT01118624|f||||f
17155982|NCT01083186|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17155983|NCT00828074|t||||
17155984|NCT02122770|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17155985|NCT00688935|f||||f
17155986|NCT00189306|f||||f
17198773|NCT00420147|t||||f
17155987|NCT03640481|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17155988|NCT00535847|f||GT60||t
17155989|NCT04569968|t||||
17155990|NCT00727844|t||||
17155991|NCT00373958|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17155992|NCT05007041|f||||f
17155993|NCT01552915|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17155994|NCT01902758|f||||f
17155995|NCT02850016|f||||f
17155996|NCT02457832|t||||
17155997|NCT00423189|t||||
17155998|NCT03421145|f||||f
17155999|NCT03973918|f||||f
17156000|NCT03826628|f||GT60||t
17156001|NCT02951533|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17156002|NCT03338803|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156003|NCT05870956|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156004|NCT03724877|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167139|NCT02302092|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198774|NCT03900715|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17198775|NCT00771238|f||||f
17198776|NCT01878383|f||||f
17198777|NCT03464383|t||||
17198778|NCT04260464|t||||
17198779|NCT00695136|t||||
17198780|NCT03469492|f||||f
17198781|NCT01726049|t||||
17198782|NCT01811498|t||||
17198783|NCT02806505|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198784|NCT04334668|t||||
17198785|NCT02416713|f||||f
17198786|NCT01722045|f||OTHER|After completion of the trial, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review; provided that the sponsor can remove confidential or proprietary information from such communications. The sponsor cannot require other changes to the communication and cannot extend the embargo.|t
17198787|NCT01339299|t||||
17198788|NCT03339271|f||||f
17198789|NCT00263211|t||||f
17198790|NCT00760513|t||||
17198791|NCT01572298|t||||
17198792|NCT00908349|f||OTHER||t
17198793|NCT01343251|f||||f
17198794|NCT01937195|f||||f
17137232|NCT04580394|f||OTHER|PIs agreed that because the Study is part of a Multi-center Study, individual publication could not be made until the publication of the Multi-center study results, notification that that a Multi-center publication was not planned, or after 18 months had passed|t
17137233|NCT00084929|f||||f
17137234|NCT00913133|f||LTE60||t
17156005|NCT01446237|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198795|NCT03834623|t||||
17137235|NCT00642746|t||||
17156006|NCT04535531|f||OTHER|The PI must wait 18 months after the closeout of the trial at all Study sites or until the publication of the multi-site Sponsor results. The only restriction on PI publication after that time is that the sponsor can review results communications prior to public release and can request confidential or proprietary information be removed or can embargo communications regarding trial results for a period that is more than 90 days but less than 120 days.|t
17156007|NCT00742508|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156008|NCT04017832|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17156009|NCT02046395|t||||f
17156010|NCT04257032|t||||
17156011|NCT01901653|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17156012|NCT02091986|f||||f
17156013|NCT04616573|f||GT60||t
17156014|NCT00957268|f||OTHER|Research Organization shall not publish any articles or papers, nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data, or insights therefrom or any data, information, or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17156015|NCT00794040|f||||f
17156016|NCT02396420|t||||
17198796|NCT00478647|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17198797|NCT01522703|f||||f
17198798|NCT01755546|f||||f
17198799|NCT00362375|f||||f
17198800|NCT04606199|t||||
17198801|NCT02948569|f||||f
17198802|NCT05145439|f||OTHER|Institution and Investigator shall have the right to publish data obtained from the Study provided that the Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for written approval, for which approval shall not be unreasonably denied. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.|t
17198803|NCT01009762|f||||f
17198804|NCT02624869|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17198805|NCT03376555|f||||f
17198806|NCT04867707|f||||f
17198807|NCT03596242|t||||
17198808|NCT02509312|t||||
17198809|NCT04184349|t||||
17198810|NCT04051242|f||||f
17198811|NCT00704171|f||OTHER|Institution and Investigator agree to submit the draft of any proposed publication to Sponsor at least 30 dyas prior to submission for publication, presentation, or use, and agrees, at the request of the Sponsor, to withhold any such submission for an additional period, not to exceed 90 days to allow Sponsor to file patent applications. The first publication of the results shall be made in conjunction with the presentation of a joint, multi-center publication.|t
17198812|NCT01874665|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for up to 1 year (to first generate a multicenter publication) and a period that is 60 to 120 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to delete confidential information, excluding the results of the Study.|t
17198813|NCT00078728|t||||f
17198814|NCT04269434|f||OTHER||t
17198815|NCT04962698|f||||f
17198816|NCT00853229|f||||f
17198817|NCT02208037|f||||f
17198818|NCT03201900|f||||f
17198819|NCT04752033|t||||
17198820|NCT03634306|f||||f
17198821|NCT00776659|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198822|NCT03247738|t||||
17198823|NCT02314104|t||||
17198824|NCT02835092|f||OTHER||t
17156017|NCT01273623|f||LTE60||t
17198825|NCT02767609|f||||f
17198826|NCT00025506|f||LTE60||t
17198827|NCT01321723|f||||f
17198828|NCT00713206|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17198829|NCT02561806|f||GT60||t
17198830|NCT02547441|f||||f
17137236|NCT01811355|f||||f
17137237|NCT03337152|f||||f
17198831|NCT01859611|f||||f
17198832|NCT01322009|t||||
17156018|NCT04064411|f||||t
17156019|NCT01290978|f||OTHER|Restriction for PI to publish trial results without review and approval by sponsor|t
17156020|NCT02342197|t||||
17156021|NCT01746420|f||||t
17156022|NCT01970475|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156023|NCT05129293|f||||f
17156024|NCT00860249|t||||
17156025|NCT00908791|f||||f
17156026|NCT01871402|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17156027|NCT05356533|f||||f
17156028|NCT05896527|f||GT60||t
17156029|NCT05139303|t||||f
17156030|NCT00981045|f||LTE60||t
17156031|NCT00738881|f||LTE60||t
17156032|NCT04874233|f||||f
17198833|NCT01657877|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156033|NCT02809859|f||||t
17156034|NCT00759785|f||OTHER|The sponsor must review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation and can delete information identified as confidential prior to submission.|t
17156035|NCT01646021|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17156036|NCT04712019|f||LTE60||t
17156037|NCT04521621|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17198834|NCT00992719|f||LTE60||t
17198835|NCT02872311|f||||f
17198836|NCT00511797|f||OTHER|Sponsor will confirm the contents before disclosure.|t
17198837|NCT03974100|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17198838|NCT02019641|t||||
17198839|NCT03398421|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156038|NCT04525079|f||||f
17156039|NCT01282164|f||||f
17198840|NCT00545571|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17198841|NCT03269695|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156040|NCT00438100|t||||
17156041|NCT01460654|f||||f
17156042|NCT01663779|f||||f
17156043|NCT01967706|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17156044|NCT02581475|f||||f
17156045|NCT02777970|f||||t
17156046|NCT05845567|f||||f
17156047|NCT02347891|f||||f
17156048|NCT02541669|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17156049|NCT00725608|f||OTHER|Study results belong to the Sponsor only, all investigators are not allowed to publish study results without permission of the Sponsor.|t
17156050|NCT03409107|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17156051|NCT00343785|t||||
17156052|NCT03783130|t||||
17156053|NCT00258349|f||LTE60||t
17156054|NCT01223469|f||||f
17156055|NCT01890226|t||||
17156056|NCT05028413|t||||
17156057|NCT03912818|t||||
17156058|NCT00715728|f||||f
17156059|NCT01258075|f||||f
17198842|NCT02024750|f||||f
17198843|NCT01349036|f||||f
17198844|NCT00746356|f||LTE60||t
17198845|NCT01449747|f||||f
17156060|NCT01500213|f||||f
17156061|NCT03488849|f||||f
17156062|NCT00669552|t||||f
17167140|NCT04669262|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17167141|NCT01638013|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17167142|NCT01585779|f||GT60||t
17167143|NCT01846299|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198846|NCT03605368|f||||f
17198847|NCT01125566|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.\>|t
17198848|NCT03151551|f||GT60||t
17198849|NCT00514813|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17198850|NCT02979613|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198851|NCT01138098|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198852|NCT01075100|f||||f
17198853|NCT02250183|t||||
17198854|NCT03282799|f||||f
17198855|NCT00092521|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198856|NCT03475056|f||||f
17156063|NCT03197870|f||OTHER|Principal Investigators are not employed by the organization sponsoring the study|t
17156064|NCT01570634|f||GT60||t
17156065|NCT01618019|t||||
17156066|NCT05174949|t||||
17156067|NCT02880865|f||||f
17156068|NCT00756561|t||||
17156069|NCT02224820|f||||f
17156070|NCT01597375|f||||f
17156071|NCT04696354|f||||f
17156072|NCT05238025|f||||t
17156073|NCT03040804|f||||f
17156074|NCT03814720|t||||
17156075|NCT03197324|f||OTHER|PI does not have the right to publish trial results.|t
17156076|NCT00965341|f||||f
17156077|NCT02807506|f||||f
17156078|NCT03057054|f||OTHER|Must obtain prior Sponsor approval|t
17156079|NCT00960986|f||GT60||t
17156080|NCT01077739|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156081|NCT00877071|f||||f
17156082|NCT01984892|t||||
17156083|NCT04464720|f||||f
17156084|NCT00342563|t||||
17156085|NCT02156895|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156086|NCT05723328|t||||
17156087|NCT03476174|f||||f
17156088|NCT05537792|f||||f
17156089|NCT00954512|f||OTHER|The Investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17156090|NCT03955081|f||||f
17156091|NCT01794793|f||||t
17156092|NCT03495154|f||||f
17156093|NCT05685732|f||OTHER|"Institution/PI shall have the right to publish results pertaining to Institution's or PI's Study activities (individually, a Publication) for their own publication objectives, provided that such Publication does not disclose Confidential Information (CI) as described in the Agreement. At least ninety (90) days prior to submission for publication, presentation or use, Institution and PI shall submit in writing to Sponsor for review and comment of any proposed oral or written Publication."|t
17156094|NCT02640404|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17156095|NCT05397171|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca. Access to this document must be restricted to relevant parties. This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17156096|NCT02234596|t||||
17156097|NCT05633992|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17156098|NCT06366087|f||||f
17156099|NCT01515462|f||OTHER|The Principal Investigator shall send any manuscript to the Sponsor/FT prior to its submission for publication. The Sponsor/FT shall have 45 days (silence=consent), from receipt of the manuscript, during which time any manuscript amendments may be suggested. The Principal Investigator shall accept the incorporation into the publication of any comments that do not affect the reliability of data, as well as the rights, safety and well-being of the patients.|t
17156100|NCT01944670|f||||f
17156101|NCT00743288|f||||f
17156102|NCT05903924|f||||t
17156103|NCT04338269|f||OTHER|Collaborators are Exelixis and Chugai. The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156104|NCT00174967|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17156105|NCT02031640|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17156106|NCT00635453|f||||f
17156107|NCT03085238|f||||f
17156108|NCT00535782|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156109|NCT00880230|f||OTHER|Medtronic has a legitimate interest in ensuring that a multi-center publication is the first publication to be released regarding the completed Study. The Institution agrees that it will not publish or disclose any results of or information pertaining to the study until a multi-center publication is released. If a publication is not released within one year after completion of the study, the Institution will have the right to publish information pertaining to their activities conducted.|t
17167144|NCT03559517|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17167145|NCT02251561|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167146|NCT00496483|f||OTHER|The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PI's.|t
17167147|NCT00230802|t||||f
17167148|NCT03095027|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167149|NCT04021524|f||||f
17167150|NCT05275010|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17181979|NCT00526058|f||OTHER|The Site may publish its own results of the FUTURA Trial after a cooperative publication or 12 months after Sponsor's final evaluation of all the FUTURA Trial data from all sites, whichever occurs first. At least 90 days prior to submitting a manuscript to a publisher or other outside persons or prior to any public presentation, a copy of the abstract, manuscript, or presentation will be provided to Sponsor for review and comment. Sponsor shall have said 90 day period to respond w/ comment.|t
17181980|NCT01714310|t||||f
17181981|NCT02822508|f||OTHER||t
17137238|NCT00077610|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137239|NCT04895605|f||||f
17137240|NCT02662985|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137241|NCT02493426|t||||
17137242|NCT02408796|f||OTHER|Publication subject to Sponsor consent.|t
17137243|NCT02242994|t||||
17156110|NCT02729038|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156111|NCT02822573|f||||f
17156112|NCT01054300|f||OTHER|Institution will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Pfizer at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Institution agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17156113|NCT00308087|f||OTHER|Investigator agrees to provide sponsor with an advance copy of any proposed publication or presentation at least 60 days prior to the planned submission or presentation. Genzyme shall have 30 days in which to recommend changes and to inform investigator if confidential information is contained. In the event of the latter, investigator will delay or prevent publication for no more that 90 days to permit sponsor to file a patent application.|t
17156114|NCT00135798|f||||f
17156115|NCT04186806|f||||f
17156116|NCT00387751|f||LTE60||t
17137244|NCT01025817|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety.|t
17137245|NCT03482141|t||||
17137246|NCT01599754|f||LTE60||t
17137247|NCT01029002|t||||
17137248|NCT00702052|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial.|t
17137249|NCT01577160|f||LTE60||t
17137250|NCT01551758|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137251|NCT00101192|f||||f
17137252|NCT00906074|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156117|NCT02416193|t||||
17156118|NCT00177307|t||||
17156119|NCT01878812|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156120|NCT02523924|t||||
17156121|NCT02677038|t||||
17156122|NCT03671564|f||||f
17156123|NCT02609100|t||||
17156124|NCT04739722|f||||f
17156125|NCT01917812|f||||f
17156126|NCT01185509|f||||f
17156127|NCT03687372|f||||f
17156128|NCT03991013|f||||f
17156129|NCT05028075|f||||f
17156130|NCT00878969|t||||
17156131|NCT01152359|t||||
17156132|NCT00380081|f||OTHER|Sponsor agrees to review manuscripts within a reasonable period of time. If sponsor determines the publication included patentable subject matter, sponsor will be granted no less than 120 days to prepare patent applications.|t
17156133|NCT01546168|t||||
17156134|NCT03787303|t||||
17156135|NCT01459718|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17156136|NCT01023841|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17156137|NCT01542034|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17156138|NCT02612610|f||OTHER|In order to ensure that the Sponsor will be able to make comments and suggestions where pertinent, material for public dissemination will be submitted to the Sponsor for review at least sixty (60) days prior to submission for publication, public dissemination, or review by a publication committee. All reasonable comments made by the Sponsor in relation to a proposed publication by the Trust, University and/or the Investigator will be incorporated into the publication.|t
17156139|NCT00176644|t||||
17156140|NCT01801280|t||||
17156141|NCT02783729|f||||t
17156142|NCT02693171|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17156143|NCT05127304|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156144|NCT01866657|t||||
17156145|NCT01421186|f||||t
17156146|NCT05600270|f||||f
17156147|NCT04360174|f||LTE60||t
17156148|NCT00901017|f||GT60||t
17156149|NCT04021121|t||||
17156150|NCT02288091|t||||
17156151|NCT00214149|f||||f
17156152|NCT00978250|f||||f
17156153|NCT01323010|f||||f
17156154|NCT01330394|f||||f
17156155|NCT02029989|f||||f
17156156|NCT04351373|t||||
17156157|NCT04537910|f||OTHER|Neither Lilly or Supplier shall publish, discuss, or release data emanating from a study without the other party's express written permission which shall not be unreasonably withheld. Nothing herein shall limit supplier's right to respond to legal inquiries.|t
17156158|NCT02071810|f||OTHER||t
17156159|NCT02751879|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156160|NCT00471718|t||||
17156161|NCT03098498|f||||f
17156162|NCT04713592|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17156163|NCT01056198|f||||f
17156164|NCT03951064|t||||
17156165|NCT03376256|t||||
17156166|NCT02294175|f||||f
17156167|NCT00792688|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days. The sponsor can require changes to the communication to remove any confidential information.|t
17156168|NCT01664949|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167151|NCT00730041|f||OTHER|Investigators agree to submit copies of proposed manuscripts or abstracts to sponsor at least 45 days in advance of public release. If sponsor requests or requires changes, an additional 90 days are allowed for this. Upon completion of the last subject follow-up for the Evaluation, a period of one year shall be reserved for publication of the entire trial results. No individual investigator may publish their individual site results prior to the publication of the group data.|t
17156169|NCT03003494|t||||
17167152|NCT05526781|t||||
17156170|NCT03634033|f||||f
17156171|NCT01296542|t||||
17156172|NCT02142361|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17156173|NCT02715700|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17156174|NCT04166591|f||||f
17156175|NCT02730377|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17167153|NCT04085458|f||GT60||t
17167154|NCT03632993|f||||f
17198857|NCT01932762|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17198858|NCT00837590|f||||f
17198859|NCT01101334|f||||f
17198860|NCT01004029|f||||f
17198861|NCT03864341|t||||
17198862|NCT04831047|t||||f
17198863|NCT00612352|t||||
17198864|NCT02161406|t||||
17198865|NCT02034162|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17198866|NCT03379545|t||||
17198867|NCT03458728|f||OTHER||t
17198868|NCT02367430|t||||f
17198869|NCT00858247|t||||f
17198870|NCT00337285|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17198871|NCT00553605|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198872|NCT03481556|f||||f
17198873|NCT01085812|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17198874|NCT01101997|f||||f
17198875|NCT01035047|t||||
17198876|NCT02669407|t||||
17198877|NCT03634839|t||||f
17198878|NCT00350298|f||LTE60||t
17198879|NCT02447432|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198880|NCT02647788|t||||
17156176|NCT02111746|t||||
17167155|NCT02743949|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17198881|NCT04198948|t||||
17198882|NCT00233389|f||||f
17198883|NCT00913068|t||||
17198884|NCT00302159|f||||f
17198885|NCT00726713|f||OTHER|Investigators agreed to delay publication of study results until after multi-center results were published or, a period of up to 20 months had elapsed after termination of the study, whichever shall occur first.|t
17198886|NCT01233999|t||||f
17198887|NCT02367105|f||||f
17198888|NCT03231969|f||||t
17198889|NCT00129649|t||||
17156177|NCT02203851|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17156178|NCT00697541|f||GT60||t
17156179|NCT04045132|f||||f
17156180|NCT05210101|f||LTE60||t
17156181|NCT03796442|f||||f
17156182|NCT01632150|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17156183|NCT02143791|f||||f
17156184|NCT03051516|t||||f
17156185|NCT00401544|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156186|NCT01429064|f||OTHER||t
17156187|NCT01272141|t||||
17156188|NCT01131884|f||||f
17156189|NCT02339155|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156190|NCT01214252|f||||f
17198890|NCT01532635|t||||
17198891|NCT00905034|t||||
17198892|NCT00394589|f||||f
17198893|NCT04081389|t||||
17198894|NCT01114672|f||||f
17198895|NCT01163955|t||||
17198896|NCT01710800|t||||f
17198897|NCT02586415|f||||f
17198898|NCT01585298|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17198899|NCT04545476|f||||f
17198900|NCT01980524|t||||
17198901|NCT03318783|t||||t
17198902|NCT01246050|f||||f
17198903|NCT04035577|f||||f
17198904|NCT02591862|f||OTHER|The PI of the clinical units has independent rights of publication but will agree to discuss any intended publications or presentations with the Sponsor and to allow the Sponsor reasonable time to make comments, file or add to patent applications or request changes to the manuscript|t
17156191|NCT02176083|f||||f
17156192|NCT04327661|f||OTHER||t
17156193|NCT04516343|f||||f
17156194|NCT01877551|f||||f
17156195|NCT02697890|f||||f
17156196|NCT00742872|f||||f
17156197|NCT03719287|f||LTE60||t
17156198|NCT01968707|f||||t
17156199|NCT00916344|f||||f
17156200|NCT02614222|f||||f
17167156|NCT03327220|f||||f
17167157|NCT00201448|f||||f
17198905|NCT01313624|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198906|NCT00104637|f||LTE60||t
17198907|NCT00505414|f||OTHER|The Sponsor and the Sponsor's designee reserves the right to review any publication pertaining to the trial at least 30 days before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17198908|NCT01560871|t||||
17198909|NCT00644878|f||||t
17198910|NCT00948610|f||||f
17198911|NCT00591591|t||||f
17198912|NCT03121612|f||||f
17198913|NCT01419977|t||||
17198914|NCT05674292|f||||f
17198915|NCT01841112|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198916|NCT00878553|f||OTHER|"PROTOCOL CONFIDENTIALITY/COMPLIANCE STATEMENT:~Investigators ...agree not to originate or use the name of Somnus Therapeutics, Inc and/or Zaleplon or SKP-1041, or any of its employees, in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment hereto, or to the performance hereunder, without the prior written consent of Somnus Therapeutics, Inc.~SKP refers to SkyePharma PLC"|t
17198917|NCT00461123|f||||f
17167158|NCT00523705|f||||f
17167159|NCT00368836|f||||f
17167160|NCT01345513|t||||
17167161|NCT00090142|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167162|NCT02442310|f||OTHER|Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.|t
17167163|NCT04154345|f||||f
17167164|NCT03848208|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17167165|NCT03106844|t||||
17167166|NCT00668382|t||||
17167167|NCT03622112|f||||f
17167168|NCT03773133|f||||t
17198918|NCT00702546|f||OTHER|The Sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17198919|NCT03180008|f||||f
17156201|NCT00984139|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156202|NCT00108485|f||||f
17156203|NCT01097421|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17156204|NCT02634268|f||||f
17156205|NCT00805870|t||||
17156206|NCT01701193|f||||f
17156207|NCT02062944|f||||f
17156208|NCT00278148|t||||f
17156209|NCT02035748|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17156210|NCT03998163|f||||t
17156211|NCT01088243|f||||f
17167169|NCT01610713|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17167170|NCT02959827|f||OTHER||t
17167171|NCT00503776|t||||
17167172|NCT00178919|t||||
17167173|NCT03943550|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167174|NCT03359785|f||||t
17167175|NCT03539211|t||||
17167176|NCT03276026|f||OTHER|Physician shall submit each publication to the Virtua Clinical Trials Office for review and approval prior to publication or presentation, which approval shall not be unreasonably withheld.|t
17167177|NCT01083979|t||||
17167178|NCT03650803|t||||
17167179|NCT04011826|f||||f
17137253|NCT02618928|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137254|NCT03670641|f||||f
17137255|NCT00118482|f||||f
17156212|NCT02083185|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17156213|NCT03419598|f||||f
17156214|NCT01740128|t||||
17156215|NCT02474589|f||LTE60||t
17156216|NCT01041976|t||||
17167180|NCT00350363|f||||f
17167181|NCT04049266|f||OTHER||t
17167182|NCT02901054|f||||f
17167183|NCT01534260|t||||
17167184|NCT04674111|f||OTHER||t
17167185|NCT00642434|t||||
17167186|NCT01818258|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17167187|NCT02708849|f||||f
17167188|NCT03655301|f||||f
17137256|NCT00753935|f||||f
17137257|NCT02128763|f||||f
17137258|NCT00665288|f||||f
17156217|NCT02231879|t||||
17156218|NCT04889157|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156219|NCT02370667|f||||f
17156220|NCT02954653|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156221|NCT03054064|f||||f
17156222|NCT00711828|t||||
17198920|NCT05896696|f||OTHER|Institution may not publish the results of the Study, based on information collected or generated by Institution and Principal Investigator without the Sponsor's prior written consent. No publication, presentation in any forum or any other form of disclosure with respect to the Study or the results thereof will be made without Sponsor's prior written consent. The provisions shall apply during the term of the Agreement and for an additional period of 15 years following Study Completion.|t
17198921|NCT04510948|f||||f
17198922|NCT02080403|f||||f
17198923|NCT01999972|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156223|NCT01210495|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156224|NCT01695330|f||||f
17156225|NCT02619396|t||||
17156226|NCT00570349|f||OTHER||t
17156227|NCT00985959|f||GT60||t
17156228|NCT00976209|f||||f
17137259|NCT02921919|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156229|NCT00979420|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17156230|NCT00574249|f||OTHER|Investigator shall provide Abbott at least (60) days prior to publication or presentation, for Abbott's review and comment, to ascertain whether any patent subject matter or Abbott confidential information are disclosed. During the review, Abbott may request a delay for up to six (6) months from the date of first submission to Abbott in order to protect proprietary information.|t
17156231|NCT01259375|f||||f
17156232|NCT03124121|f||||f
17156233|NCT04060199|f||OTHER|The most restrictive relevant agreement on the PI provides that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is not less than 30 days from the time submitted to the sponsor for review.|t
17156234|NCT00478699|f||||f
17156235|NCT01629290|f||||f
17156236|NCT00656851|f||||f
17156237|NCT01123941|f||OTHER||t
17181982|NCT00654381|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17181983|NCT01797328|f||||f
17156238|NCT04601103|t||||
17156239|NCT01203826|f||LTE60||t
17156240|NCT06011161|t||||
17156241|NCT04065451|f||||f
17156242|NCT02513498|f||||f
17156243|NCT02548351|f||||t
17156244|NCT00125242|t||||
17156245|NCT00326781|f||||f
17181984|NCT04883632|f||||t
17156246|NCT02659514|f||||t
17181985|NCT04164901|f||OTHER||t
17181986|NCT02638298|t||||f
17181987|NCT01978314|f||LTE60||t
17181988|NCT00097721|f||||f
17181989|NCT03869450|f||||t
17198924|NCT02668198|t||||
17198925|NCT02826798|f||||f
17198926|NCT02330276|f||||f
17198927|NCT01986114|f||||t
17198928|NCT00664105|t||||
17198929|NCT04702893|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17198930|NCT04469465|f||||t
17198931|NCT01951378|f||||f
17198932|NCT01660256|f||||f
17198933|NCT03491215|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17198934|NCT04585737|f||||f
17198935|NCT01848067|t||||t
17198936|NCT00541671|t||||
17198937|NCT00551135|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17198938|NCT01202409|t||||
17198939|NCT01004185|f||LTE60||t
17198940|NCT01649505|t||||
17198941|NCT01983553|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17198942|NCT01172639|f||||f
17198943|NCT00720369|f||||f
17156247|NCT03502018|f||||f
17156248|NCT00454818|f||GT60||t
17156249|NCT01384019|t||||f
17156250|NCT00767039|t||LTE60||t
17156251|NCT01826370|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156252|NCT01575275|f||||f
17156253|NCT04416737|t||||
17156254|NCT03332628|f||||f
17156255|NCT01472757|f||OTHER|Publication can be delayed for 60 days for Sponsor review and revisions/deletions can be required. Furthermore, a 6-month delay to publication can be required by the Sponsor in order to take steps to protect its proprietary information and/or intellectual property rights.|t
17156256|NCT04489381|f||||f
17156257|NCT02833935|f||||f
17156258|NCT00070018|f||||f
17198944|NCT00469456|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17198945|NCT04731142|t||||
17198946|NCT01624298|t||||
17198947|NCT02840916|t||||
17198948|NCT00345800|f||GT60||t
17198949|NCT01127321|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17198950|NCT00719043|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17198951|NCT01588366|t||||
17198952|NCT03245619|t||||
17198953|NCT01704547|t||||
17198954|NCT03671239|f||LTE60||t
17198955|NCT00690378|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17198956|NCT03100864|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17198957|NCT00846768|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17198958|NCT03849768|f||||f
17198959|NCT03467698|t||||
17198960|NCT00912223|f||||f
17198961|NCT01099579|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17198962|NCT00909532|f||GT60||t
17198963|NCT00859976|f||||f
17198964|NCT01157377|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17198965|NCT00927901|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17198966|NCT02383407|f||||f
17198967|NCT00984698|t||||
17156259|NCT02961062|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17156260|NCT03861871|t||||
17156261|NCT02939716|t||||
17156262|NCT00371644|t||||
17156263|NCT02543892|f||||f
17156264|NCT00785213|f||GT60||t
17156265|NCT00525902|t||||
17156266|NCT04756128|t||||
17156267|NCT01777568|f||||f
17156268|NCT02858180|t||||
17156269|NCT00844480|f||||f
17156270|NCT00526331|t||||f
17167189|NCT00835198|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17167190|NCT03651856|t||||
17167191|NCT02493257|t||||
17156271|NCT01005888|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to sponsor for pre-review. If sponsor requests, PI must delete sponsor confidential information before publication and/or delay publication for 90 days so sponsor can file for patents or take other action to protect its patent rights.|t
17156272|NCT01043705|f||||f
17156273|NCT00669019|f||LTE60||t
17156274|NCT00581542|f||||f
17198968|NCT01263925|f||GT60||t
17198969|NCT03029819|f||||f
17198970|NCT03536702|f||||f
17198971|NCT03559829|t||||
17198972|NCT01536197|f||||f
17198973|NCT04522206|t||||
17198974|NCT02650466|f||||f
17198975|NCT01726517|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17198976|NCT00573651|f||||f
17198977|NCT03765164|f||||f
17198978|NCT01351337|f||||f
17198979|NCT05275023|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17198980|NCT04562896|t||||
17198981|NCT03797989|t||||
17198982|NCT04052997|f||GT60||t
17198983|NCT01024036|f||GT60||t
17198984|NCT03459612|f||GT60||t
17198985|NCT00604188|f||OTHER|The disclosure restriction on the PI cannot publish an individual study until a publication disclosing results from multicenter studies is published. The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review.|t
17198986|NCT01817712|t||||
17198987|NCT00097669|f||||f
17198988|NCT00356759|t||||
17198989|NCT04236245|f||LTE60||t
17198990|NCT00474383|f||LTE60||t
17198991|NCT02998918|f||||f
17198992|NCT03500835|f||||f
17198993|NCT02364609|f||||f
17198994|NCT00443599|f||||f
17198995|NCT03110692|f||||f
17198996|NCT04396847|f||||f
17198997|NCT02202109|t||||
17198998|NCT00803777|f||LTE60||t
17198999|NCT01256671|f||OTHER|Investigators shall provide to the SPONSOR 30 days prior to submission all documents for publication, presentation, etc that report any trial results. The SPONSOR shall have editorial rights on documents and the right to review/comment with regard to (1) proprietary information, (2) accuracy of the information, (3) correctness of the scientific evaluation/conclusions and (4) to ensure that the information is fairly balanced and in compliance with regulations.|t
17199000|NCT01788475|f||GT60||t
17156275|NCT01623037|f||||f
17156276|NCT03099694|t||||
17156277|NCT02291601|f||OTHER|Confidential information based on contract|t
17156278|NCT00381043|f||LTE60||t
17156279|NCT03045276|f||||f
17199001|NCT03006185|t||||
17199002|NCT03984513|f||||f
17199003|NCT01468077|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156280|NCT03379753|t||||
17156281|NCT00347919|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156282|NCT01032239|f||GT60||t
17156283|NCT00624195|f||||f
17156284|NCT02738255|t||||f
17156285|NCT01508052|t||||
17156286|NCT01940900|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.|t
17156287|NCT00654992|t||||
17156288|NCT02225366|t||||
17156289|NCT03782298|f||LTE60||t
17156290|NCT03492398|f||||f
17156291|NCT01382225|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199004|NCT00761956|f||||f
17199005|NCT03024996|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199006|NCT02263040|f||||f
17199007|NCT01479270|t||||
17199008|NCT00030823|t||||
17199009|NCT01083199|f||||f
17156292|NCT01797081|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17156293|NCT02426749|f||||f
17156294|NCT01852201|t||||
17156295|NCT01177709|f||||f
17156296|NCT02767492|f||||f
17156297|NCT00819780|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156298|NCT01793688|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156299|NCT03596723|f||||t
17156300|NCT02484651|t||||
17156301|NCT04972968|f||||f
17156302|NCT00150800|f||GT60||t
17156303|NCT01698879|f||GT60||t
17156304|NCT00796705|f||||f
17156305|NCT02251106|f||||f
17156306|NCT02375555|f||||f
17156307|NCT02267772|t||||
17156308|NCT01565369|f||GT60||t
17156309|NCT01996410|f||||f
17156310|NCT01744184|t||||
17156311|NCT00606554|f||||f
17156312|NCT04654754|t||||
17199010|NCT04333147|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17199011|NCT02106195|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17199012|NCT00408928|t||||
17199013|NCT03194867|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17199014|NCT00464945|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17199015|NCT03831854|t||||
17199016|NCT03305809|f||GT60||t
17199017|NCT00816556|t||||f
17199018|NCT02438371|t||||
17199019|NCT03546816|f||GT60||t
17199020|NCT01161446|t||||
17199021|NCT03065933|t||||
17199022|NCT02330562|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199023|NCT00258362|t||||f
17199024|NCT00568698|t||||
17199025|NCT01184885|t||||
17199026|NCT01162135|t||||
17199027|NCT01379703|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17199028|NCT01316887|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199029|NCT00813098|f||OTHER|The sponsor requires that written permission be given before the PI can release any data publicly.|t
17156313|NCT04542421|f||||f
17156314|NCT01638312|t||||
17156315|NCT01263782|t||||
17156316|NCT02336360|f||LTE60||t
17156317|NCT04545567|t||||
17156318|NCT03979807|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156319|NCT04060277|t||||
17156320|NCT02754674|f||||f
17156321|NCT00129727|f||GT60||t
17156322|NCT01312233|t||||
17156323|NCT03026530|f||||f
17156324|NCT03721835|f||LTE60||t
17156325|NCT04010747|t||||
17156326|NCT05079750|t||||
17156327|NCT05897827|t||||
17156328|NCT02017717|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17156329|NCT04161079|f||LTE60||t
17156330|NCT02407132|f||||f
17156331|NCT03617861|t||||
17156332|NCT00623597|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156333|NCT02515994|f||GT60||t
17156334|NCT03790618|t||||
17156335|NCT03384784|t||||
17156336|NCT01849068|f||||f
17156337|NCT02210286|f||||f
17156338|NCT01668966|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156339|NCT00842075|f||||f
17156340|NCT02817698|f||||f
17156341|NCT01813734|t||||
17156342|NCT00345878|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156343|NCT00552032|f||OTHER|The Principal Investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the SPONSOR. The Principal Investigator further agrees to provide thirty (30) days written notice to the SPONSOR prior to submission for publication or presentation to permit the SPONSOR to review copies of abstracts or manuscripts for publication which report any results of the Study.|t
17199030|NCT01809899|t||||
17199031|NCT03470545|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199032|NCT02312206|f||OTHER|The PI, institution and the sponsor have agreed that the PI and institution may publish or disclose study results from their site after the earlier of (a) publication of the complete multicenter study results or (b) 18 months after database lock for the multicenter study. The sponsor has at least 45 days to review a proposed publication and may request deletion of confidential information and up to 60 days additional delay to obtain patent protection.|t
17156344|NCT01643798|t||||
17156345|NCT04178824|t||||
17156346|NCT04810247|t||||f
17156347|NCT03794661|f||OTHER||t
17156348|NCT00984061|f||GT60||t
17156349|NCT05363072|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167192|NCT02649218|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17156350|NCT00614120|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication and other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17156351|NCT03047720|f||||f
17156352|NCT02946073|f||OTHER||t
17156353|NCT05803096|f||||f
17156354|NCT03602391|f||||f
17156355|NCT01588457|f||||f
17156356|NCT04789291|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156357|NCT01013844|f||||f
17156358|NCT00108342|t||||f
17156359|NCT01527487|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17156360|NCT02865590|f||||f
17199033|NCT00585975|f||OTHER|The PI will provide to the sponsor a copy of the proposed publication information for review, comment and approval following completion of the study and at least sixty (60) days prior to submission for publication of any manuscript, or at least thirty (30) days prior to submission for publication of any abstract. If sponsor requests in writing, the PI will withhold publication for an additional sixty (60) days.|t
17156361|NCT00667186|f||||f
17199034|NCT03082612|t||||
17199035|NCT01336205|f||GT60||t
17199036|NCT01006616|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, e.g., any computer access system such as the Internet, World Wide Web, etc.) that report any results of the study.|t
17199037|NCT00336817|f||||f
17199038|NCT03672175|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17199039|NCT02482935|f||GT60||t
17199040|NCT03414047|f||GT60||t
17199041|NCT04974723|f||||f
17199042|NCT04672798|f||||f
17199043|NCT03854019|t||||
17199044|NCT03197025|f||||f
17199045|NCT00217022|t||||
17199046|NCT00156923|f||OTHER|Should a PI wish to disclose results, the sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days but less than or equal to 90 days from the time submitted to the sponsor for review. Revisions will be negotiated in good faith. For a multicenter study the institution/PI agree to publish/publicly present the results together with the other sites unless the sponsor grants written permission in advance.|t
17199047|NCT02625571|f||||f
17199048|NCT02777242|f||OTHER||t
17199049|NCT01898442|t||||
17199050|NCT05178979|f||||f
17199051|NCT03035318|f||||f
17199052|NCT03990298|t||||
17156362|NCT02258542|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17156363|NCT00986986|t||||
17156364|NCT04009668|t||||
17156365|NCT02419612|f||||f
17156366|NCT03083561|f||GT60||t
17156367|NCT01095978|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection|t
17156368|NCT02135107|f||OTHER||t
17167193|NCT00895752|f||||f
17167194|NCT05145322|t||||
17167195|NCT01349322|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17167196|NCT02063867|t||||
17199053|NCT02980705|f||OTHER||t
17199054|NCT01721746|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199055|NCT04358068|f||||f
17199056|NCT00239681|f||||f
17199057|NCT02447718|f||||f
17199058|NCT03599622|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17156369|NCT00474045|f||OTHER|Novo Nordisk (NN) reserves the right not to release data until specified milestones, e.g. Clinical Trial Report is available. This includes the right not to release interim results, because the release of such information can invalidate the results of the trial. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between authors and NN. NN reserves the right to postpone publication and communication for a short time to protect intellectual property.|t
17156370|NCT00581347|f||||f
17199059|NCT03579433|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199060|NCT00468130|f||||t
17199061|NCT00436956|f||||f
17199062|NCT01006889|f||||f
17199063|NCT01130168|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines|t
17199064|NCT01702519|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199065|NCT01795859|f||LTE60||t
17156371|NCT02009397|t||||
17156372|NCT05523011|f||||f
17156373|NCT02987374|f||||f
17156374|NCT02278120|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17156375|NCT00287989|f||||f
17156376|NCT02266472|t||||
17156377|NCT01966068|t||||
17156378|NCT00808639|t||||
17156379|NCT01187498|t||||f
17156380|NCT01717482|t||||
17156381|NCT00191282|f||GT60||t
17156382|NCT00102531|f||||f
17156383|NCT00288067|f||LTE60||t
17156384|NCT04756154|f||||t
17156385|NCT02345460|t||||
17156386|NCT01790828|f||||f
17199066|NCT03738397|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199067|NCT00904722|t||||
17199068|NCT01891890|t||||
17199069|NCT01143883|f||||f
17156387|NCT04198584|t||||
17156388|NCT01834716|t||||
17156389|NCT05072964|f||||f
17156390|NCT01726036|t||||
17156391|NCT01047332|t||||
17156392|NCT00291161|t||||f
17156393|NCT03521817|f||||f
17156394|NCT03153982|t||||
17156395|NCT00082017|f||||f
17156396|NCT03055494|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17156397|NCT00197002|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156398|NCT03527264|f||||f
17156399|NCT04488419|f||OTHER||t
17156400|NCT01089933|f||||f
17156401|NCT02276053|f||GT60||t
17156402|NCT05573672|f||||f
17156403|NCT04542499|f||||f
17156404|NCT05711381|f||||f
17156405|NCT03427268|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17156406|NCT03391232|f||||f
17156407|NCT01995175|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156408|NCT01021761|t||||
17156409|NCT03729570|t||||f
17199070|NCT00806598|t||||
17156410|NCT01608815|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17199071|NCT01729845|t||||
17199072|NCT03448536|f||||f
17199073|NCT03783546|f||||f
17199074|NCT00557349|t||||
17156411|NCT01482962|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17156412|NCT02407457|f||OTHER|PI shall be free to publish Institution's data/results from the Clinical Study at time of multicenter results published, notification that publication is not planned, or 18 months after the study conclusion at all centers, whichever occurs first.|t
17156413|NCT04495816|f||||f
17156414|NCT00558896|t||||
17156415|NCT02160847|t||||
17156416|NCT04329091|t||||
17156417|NCT01801358|f||OTHER|The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in the clinical trial.|t
17156418|NCT00723190|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17156419|NCT03181503|f||||t
17156420|NCT00001656|t||||
17156421|NCT03141983|f||||f
17156422|NCT01573325|t||||f
17156423|NCT00640653|t||||f
17156424|NCT04450407|f||GT60||t
17156425|NCT02814227|t||||
17156426|NCT02776644|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156427|NCT03589976|t||||
17156428|NCT02089334|f||LTE60||t
17156429|NCT02832375|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156430|NCT06350461|f||||f
17156431|NCT00514904|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156433|NCT03430895|t||||
17156434|NCT00754208|f||||f
17156435|NCT00084318|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17156436|NCT03597009|t||||
17156437|NCT01317797|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17156438|NCT01378377|f||||f
17156439|NCT01550705|f||||f
17199075|NCT04811339|f||||f
17199076|NCT02536742|f||||f
17199077|NCT04629443|f||OTHER||t
17199078|NCT01547117|t||||
17199079|NCT03021551|f||GT60||t
17199080|NCT01777126|t||||
17199081|NCT00565266|f||||f
17199082|NCT02088554|f||OTHER|Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) \& won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) \& its rights in patentable or copyrightable materials, \& check technical accuracy of MDT data. If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested.|t
17199083|NCT04205955|f||LTE60||t
17199084|NCT03898960|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17199085|NCT00548847|t||||
17199086|NCT01086384|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156440|NCT00754520|f||||f
17156441|NCT01645891|f||||f
17156442|NCT00138073|t||||
17156443|NCT03301740|t||||
17156444|NCT01239212|f||||f
17156445|NCT00334633|t||||f
17156446|NCT01173055|f||LTE60||t
17167197|NCT01335724|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17199087|NCT01196819|f||||f
17199088|NCT02250534|f||||f
17199089|NCT03045809|f||||f
17199090|NCT02725567|f||||t
17199091|NCT00255944|f||||f
17199092|NCT03124550|f||||f
17199093|NCT01129115|f||||f
17199094|NCT04626271|f||||f
17199095|NCT01747837|f||||f
17167198|NCT04376684|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167199|NCT02244840|t||||
17167200|NCT02950155|f||||f
17199096|NCT00751634|f||GT60||t
17199097|NCT01435798|f||||f
17199098|NCT01253447|f||LTE60||t
17199099|NCT00817336|t||||
17199100|NCT02299427|f||||f
17199101|NCT02108652|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199102|NCT03311269|f||||f
17199103|NCT01182181|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17199104|NCT01121913|f||OTHER|The scientific results from this study are the property of the Sponsors, ie, Labopharm Inc., Canada and A.C.R.A.F. S.p.A., Italy. No data reported in the final integrated clinical trial report of this study will be used for publication in scientific journals and/or for presentation at scientific meetings without a previous agreed written consent between the Sponsors.|t
17156447|NCT00456508|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199105|NCT03101033|f||||f
17199106|NCT02564718|f||OTHER|Bayer shall own the exclusive rights to all results, data, findings, radiological \& diagnostic images, discoveries, inventions \& specifications, whether patentable or not, that are originated, conceived, derived, produced, discovered, invented or otherwise made by Center, PI and/or Study Team Physicians and/or Members in connection with the performance of the Study (i.e. Results). Contract Partners hereby assign their rights to the Results to Bayer in advance and Bayer accepts such assignment.|t
17156448|NCT04325698|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156449|NCT00962091|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17156450|NCT04253782|t||||
17156451|NCT04216589|f||||f
17156452|NCT04530591|t||||
17156453|NCT00003910|f||||f
17156454|NCT01690910|f||||f
17156455|NCT01768845|t||||
17156456|NCT03191864|f||LTE60||t
17156457|NCT02086682|f||||f
17156458|NCT02342548|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156459|NCT04231396|t||||
17156460|NCT00073983|f||LTE60||t
17156461|NCT03800836|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199107|NCT00937521|f||GT60||t
17199108|NCT04353817|f||OTHER||t
17156462|NCT01390428|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17199109|NCT00770588|f||OTHER|PI agrees to collaborate in good faith with AZ regard to contents and formation of any publication and to pay due consideration to the comments, views and opinions offered by AZ. AZ shall have a period of 30 days from receipt of the proposed final manuscript to review and may require submission be delayed in order for AZ to file patent application|t
17199110|NCT00002597|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17199111|NCT01494545|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199112|NCT02485899|f||OTHER|The only disclosure restrictions on the PI are that (i) they cannot publish results communications until after the multicenter dataset is published, (ii) the sponsor has an opportunity to review results communications prior to public release, and (iii) the sponsor can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days.|t
17199113|NCT01918371|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199114|NCT02143063|f||||f
17199115|NCT03245463|t||||
17199116|NCT00623363|f||||f
17199117|NCT02669615|f||||f
17199118|NCT01880437|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199119|NCT00823836|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199120|NCT03713320|f||OTHER|"Investigators in this study may present or publish study results in scientific journals or other scholarly media without prior written approval after the following conditions have been met:~* Results of study have been publicly disclosed by or with the consent of the sponsor~* Investigator has complied with the Clinical Trial Agreement and requests from the sponsor to delete confidential information (other than study results)~* Study has been completed at all study sites for at least 2 years"|t
17199121|NCT02271230|f||||f
17199122|NCT04354168|t||||
17199123|NCT03042299|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17156463|NCT03050541|t||||
17156464|NCT05103176|f||||f
17156465|NCT04281784|f||||f
17156466|NCT04322539|f||||t
17156467|NCT01702532|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156468|NCT01451164|f||||f
17156469|NCT01846221|t||||
17156470|NCT04599933|f||||t
17156471|NCT05098067|t||||
17156472|NCT02872857|t||||
17167201|NCT03099174|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167202|NCT04173260|f||||f
17167203|NCT02308163|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17167204|NCT02684058|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17199124|NCT01438840|f||OTHER||t
17167205|NCT00443053|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167206|NCT04319380|t||||
17167207|NCT02136680|f||||f
17167208|NCT05151445|t||||
17167209|NCT02298179|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167210|NCT01457014|f||||f
17167211|NCT01357161|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17167212|NCT02320812|f||||f
17167213|NCT02825420|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17167214|NCT04027049|t||||
17167215|NCT04910074|t||||
17167216|NCT01730339|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199125|NCT03004586|t||||
17199126|NCT02062645|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17199127|NCT02804399|t||||f
17199128|NCT01774305|f||||f
17199129|NCT04211389|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17199130|NCT02357264|t||||
17156473|NCT02663752|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data form all sites) in the clinical trial.|t
17156474|NCT04392167|t||||
17156475|NCT02879994|t||||
17156476|NCT04063657|t||||
17156477|NCT03408444|f||GT60||t
17156478|NCT04984681|f||||f
17156479|NCT01447446|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156480|NCT01230424|f||||f
17156481|NCT01128218|f||||f
17167217|NCT01145352|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156482|NCT02052596|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156483|NCT03536949|f||GT60||t
17167218|NCT04143217|f||||t
17199131|NCT03623373|t||||
17199132|NCT00087555|f||OTHER||t
17199133|NCT00193596|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17199134|NCT01062971|f||OTHER|only the sponsor can publish the results of the authorization, if the IP wishes to report or discuss the results, it must request the sponsor a signed agreement.|t
17199135|NCT05523219|f||||f
17199136|NCT02261285|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this tiral prior to submission for publication/presentation.|t
17199137|NCT02760485|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17199138|NCT01182207|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17199139|NCT01087814|f||||f
17199140|NCT01161628|f||LTE60||t
17199141|NCT00715117|f||OTHER|No restrictions by the sponsor. The PI may disclose results after the manuscript has been published.|t
17199142|NCT01482429|t||||f
17199143|NCT04680637|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199144|NCT02037256|t||||
17156484|NCT00705718|f||OTHER|Publication of single site experience is not allowed until the Multicenter results are published. The Multicenter manuscript will be made available to all authors \& Medtronic prior to submission. Final analysis and review on the multicenter manuscript will require Medtronic approval.|t
17156485|NCT02901275|t||||
17156486|NCT02063178|f||||f
17156487|NCT00182728|t||||
17156488|NCT02657577|f||||f
17156489|NCT00250458|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156490|NCT06137703|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199145|NCT05250960|t||||
17156491|NCT04106089|f||||f
17156492|NCT00741091|f||OTHER|The disclosure restriction on the PI is that the Sponsor can review results communications prior to public release and can embargo communication regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the Sponsor for review. The Sponsor can require changes to the communication to remove any confidential information or other proprietary information of Sponsor.|t
17156493|NCT00595114|f||||f
17156494|NCT01967641|t||||f
17156495|NCT01892085|f||||f
17156496|NCT02505334|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17156497|NCT01549041|t||||f
17156498|NCT00597506|t||||
17156499|NCT03199612|f||||f
17156500|NCT02747849|f||||f
17156501|NCT02938949|f||||f
17199146|NCT02917421|t||||
17199147|NCT00497874|t||||f
17199148|NCT02185105|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17199149|NCT01789840|f||||f
17199150|NCT04843579|t||||
17199151|NCT04009629|f||||f
17199152|NCT04398368|t||||
17156502|NCT00201240|f||||f
17156503|NCT00081731|f||||f
17156504|NCT01135069|f||OTHER||t
17156505|NCT02386345|f||OTHER|All manuscripts should be submitted to the sponsor for review and comment prior to submission to the publisher.|t
17156506|NCT04050124|t||||
17156507|NCT04281901|f||||f
17156508|NCT03584464|f||OTHER||t
17156509|NCT05168878|f||||f
17156510|NCT01914159|t||||
17156511|NCT03336268|f||||f
17156512|NCT01537068|f||||f
17156513|NCT00483704|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17156514|NCT04442269|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17156515|NCT02326298|f||GT60||t
17199153|NCT00004146|f||LTE60||t
17156516|NCT00787917|f||OTHER|The terms and conditions of Novartis's agreements with it's investigators vary. However, Novartis does not prohibit any investigator from publishing. Any publication from a single-center site are postponed until the publication of the pooled data ( i.e. data from all sites) in the clinical trial.|t
17156517|NCT00778102|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199154|NCT02808975|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199155|NCT03602586|f||LTE60||t
17199156|NCT03305887|f||OTHER|The disclosure restriction on the principal investigator(PI) is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199157|NCT00848510|f||OTHER||t
17199158|NCT00891046|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17199159|NCT02166476|f||||f
17156518|NCT01328548|f||||f
17156519|NCT00538512|f||||f
17156520|NCT02417961|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17199160|NCT01076244|t||||f
17199161|NCT02034019|f||OTHER||t
17156521|NCT00642603|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156522|NCT03197467|f||||f
17156523|NCT06229132|f||||f
17156524|NCT03666533|t||||
17156525|NCT00626236|f||||t
17156526|NCT04240886|f||OTHER|The Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156527|NCT04743804|f||||t
17156528|NCT01632904|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17156529|NCT00715104|f||OTHER|The results of the study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the study will be coordinated by Dendreon in communication with institutions contributing patients to the study.|t
17156530|NCT01473394|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17156531|NCT03117881|f||||f
17156532|NCT00546455|t||||
17156533|NCT01027897|t||||f
17156534|NCT03870529|t||||
17156535|NCT00473824|f||LTE60||t
17156536|NCT02560623|t||||
17156537|NCT04527003|t||||
17156538|NCT01661933|f||||f
17156539|NCT02720744|f||||f
17156540|NCT02262000|t||||
17156541|NCT02174913|t||||
17156542|NCT02609724|t||||t
17156543|NCT03077659|f||||f
17156544|NCT02844907|t||||
17156545|NCT00426660|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156546|NCT00738062|f||LTE60||t
17156547|NCT00550862|f||OTHER|All publications or lectures involving study material or data will be submitted for approval to Intercept Pharmaceuticals prior to submission to any journal/publication/lecture according to the clinical trial agreement.|t
17156548|NCT03207074|t||||
17156549|NCT00980174|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156550|NCT02335749|f||||f
17156551|NCT01683422|t||||
17156552|NCT01393132|f||||f
17156553|NCT04631107|f||||f
17156554|NCT02003963|t||||f
17156555|NCT01797159|t||||
17156556|NCT01935128|f||||f
17199162|NCT04523207|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application..|t
17156557|NCT01440569|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17156558|NCT02787057|t||||
17156559|NCT01260272|t||||
17156560|NCT03589326|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17156561|NCT05087966|f||||f
17156562|NCT00501059|f||GT60||t
17156563|NCT03559868|t||||
17156564|NCT00430352|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156565|NCT04326439|t||||
17156566|NCT00565669|f||||f
17156567|NCT05805085|f||||t
17156568|NCT03653091|f||GT60||t
17156569|NCT01785849|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156570|NCT00204477|t||||f
17156571|NCT00359736|t||||f
17156572|NCT04272606|f||||f
17156573|NCT01037127|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199163|NCT03113383|t||||
17156574|NCT02584998|t||||
17156575|NCT02637713|f||||f
17156576|NCT02847182|t||||
17156577|NCT02345889|f||||f
17156578|NCT02059434|f||OTHER|Publication and / or presentation whether complete or partial, of any part of the data or results of this study will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the Investigator and AstraZemeca|t
17199164|NCT02122172|t||||
17199165|NCT03062449|t||||
17199166|NCT03765398|f||||f
17156579|NCT02956447|t||||
17156580|NCT00771264|f||||f
17156581|NCT01004406|t||||
17156582|NCT02928770|f||||f
17156583|NCT00929474|f||||f
17156584|NCT03201874|f||||f
17156585|NCT02907593|f||||f
17156586|NCT04618471|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17156587|NCT01752634|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17199167|NCT02053610|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156588|NCT01250171|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17199168|NCT03568812|f||||f
17199169|NCT01296763|t||||
17199170|NCT00543062|f||LTE60||t
17156589|NCT01196936|t||||f
17156590|NCT06474078|t||||
17156591|NCT04216784|f||||f
17156592|NCT00962949|t||||
17156593|NCT04557124|t||||
17156594|NCT05409131|f||||f
17156595|NCT03596671|f||||f
17156596|NCT02672332|f||||t
17156597|NCT01779167|t||||
17156598|NCT03226678|f||||t
17156599|NCT01279564|f||LTE60||t
17156600|NCT01911780|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156601|NCT02045732|f||OTHER|"Pfizer has the right to review disclosures, requesting a delay of less than 60 days.~Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."|t
17156602|NCT05014815|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17156603|NCT04247880|t||||
17156604|NCT06303167|f||LTE60||t
17156605|NCT02453282|f||||t
17156606|NCT03902522|f||||f
17156607|NCT03385304|f||||f
17156608|NCT01120249|f||LTE60||t
17156609|NCT01007136|f||||f
17156610|NCT01629823|f||||f
17156611|NCT00480493|t||||f
17199171|NCT01439854|t||||
17199172|NCT00328562|t||||
17199173|NCT04014790|f||||t
17199174|NCT02720211|f||||f
17199175|NCT01010204|f||||f
17199176|NCT01513330|f||||f
17156612|NCT01032070|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17156613|NCT00894790|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199177|NCT01519778|f||OTHER|Trius intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between Trius and Investigators. Trius written approval is required for publication of any data subsets. Final authorship will be determined in accordance with the International Conference of Medical Journal Editors definition of authorship.|t
17199178|NCT01657799|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199179|NCT00412880|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17199180|NCT03297398|f||OTHER|The obligations of non-disclosure and non-use set forth in the confidentiality is 10 years after expiration of the agreement|t
17199181|NCT02988349|f||||f
17199182|NCT01772563|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156614|NCT04093492|f||||f
17199183|NCT04068051|f||||t
17199184|NCT01192776|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17199185|NCT00736125|f||||f
17199186|NCT02877732|t||||
17199187|NCT04919070|f||||f
17199188|NCT02632812|f||||f
17199189|NCT03732820|f||GT60||t
17156615|NCT00551161|f||||f
17199190|NCT00992992|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199191|NCT00832000|f||||f
17199192|NCT03845075|f||||f
17199193|NCT00935259|f||OTHER|Publications should include input from the investigator(s), and Sponsor personnel. Such input should be reflected in publication authorship. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17199194|NCT03856047|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17199195|NCT02023905|t||||
17199196|NCT00874497|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199197|NCT01017263|t||||
17199198|NCT01818427|f||||f
17199199|NCT02420041|t||||
17199200|NCT00665223|f||OTHER|Sponsor has the right 30 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17156616|NCT00096993|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156617|NCT00231283|f||LTE60||t
17156618|NCT00772005|f||GT60||t
17156619|NCT03280225|f||||f
17156620|NCT01828216|f||||f
17156621|NCT01606202|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17156622|NCT05020366|t||||f
17156623|NCT00392496|f||LTE60||t
17156624|NCT01044758|f||||f
17156625|NCT04150705|t||||
17156626|NCT01065714|t||||
17156627|NCT03442699|t||||
17156628|NCT00435487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156629|NCT03301844|f||||t
17156630|NCT01267201|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156631|NCT02978859|t||||
17156632|NCT02719938|t||||
17156633|NCT00955968|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17156634|NCT01455181|f||OTHER||t
17199201|NCT01278615|f||LTE60||t
17199202|NCT00905359|f||LTE60||t
17199203|NCT02654132|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199204|NCT00621192|f||||f
17156635|NCT05020899|t||||
17156636|NCT05619536|f||OTHER||t
17156637|NCT02923245|t||||
17156638|NCT00793624|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17156639|NCT00710684|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156640|NCT00656487|f||||f
17167219|NCT02264665|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167220|NCT01962987|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17167221|NCT03711929|f||OTHER||t
17181990|NCT01752855|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17181991|NCT02882321|t||||
17181992|NCT02852265|f||||f
17181993|NCT03137693|t||||
17199205|NCT04706793|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199206|NCT01283022|f||OTHER|Any abstract,presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days prior to submission for any meeting or journal.If deemed necessary by the Sponsor for protection of proprietary information prior to patent filing,the Investigator agrees to a further delay of 60 days before any presentation or publication is submitted.Publications must be in a form that does not reveal technical information that is considered confidential or proprietary.|t
17199207|NCT02601209|f||LTE60||t
17199208|NCT03636373|t||||
17199209|NCT00572533|t||||f
17199210|NCT03382769|f||||t
17199211|NCT00835185|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17199212|NCT01530087|f||OTHER||t
17199213|NCT01324700|f||||f
17199214|NCT02344173|f||||t
17199215|NCT00661713|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17199216|NCT00416598|f||LTE60||t
17199217|NCT05155566|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199218|NCT00429143|t||||f
17199219|NCT03427060|f||||f
17199220|NCT00810342|f||||f
17199221|NCT04504630|f||||f
17199222|NCT04486313|f||||f
17199223|NCT01496365|f||||f
17199224|NCT03017937|f||||f
17199225|NCT02706951|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199226|NCT01843777|t||||
17199227|NCT01821105|t||||
17199228|NCT04883060|t||||f
17199229|NCT03539068|t||||
17199230|NCT01777334|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199231|NCT01181492|f||||f
17199232|NCT04070768|f||||f
17199233|NCT04599855|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17199234|NCT02165397|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination."|t
17199235|NCT00424554|f||OTHER|The principal investigator (PI) agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review, without limitation, including editorial rights. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues or disagreement.|t
17199236|NCT00236184|f||OTHER||t
17181994|NCT03144180|f||||f
17150579|NCT02031458|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150580|NCT03062228|f||||f
17150581|NCT00609518|f||GT60||t
17150582|NCT02381626|t||||
17167222|NCT03086707|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17167223|NCT03015649|t||||
17167224|NCT02200328|t||||
17156641|NCT04676412|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17167225|NCT02688088|f||GT60||t
17181995|NCT00743652|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17181996|NCT02547129|t||||
17199237|NCT02599688|f||OTHER|If multi-center study publication not published within two (2) years after the completion of the Study at all sites, Investigator may publish the results of the Study obtained by Investigator with 60 days notice to Sponsor|t
17199238|NCT01841697|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17199239|NCT00756457|f||||f
17199240|NCT01973062|t||||
17199241|NCT02113410|f||||f
17199242|NCT01777490|t||||
17199243|NCT04915131|f||||f
17199244|NCT00364377|t||||f
17199245|NCT00822770|t||||f
17199246|NCT02818998|f||||f
17156642|NCT04697056|f||||t
17156643|NCT04550832|f||||f
17156644|NCT04823130|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17156645|NCT03312595|f||LTE60||t
17156646|NCT03315455|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156647|NCT03711058|t||||
17156648|NCT04439357|f||LTE60||t
17156649|NCT04765722|t||||
17156650|NCT05175131|f||GT60||t
17156651|NCT05906836|f||GT60||t
17156652|NCT02542293|f||||t
17167226|NCT00366028|t||||
17181997|NCT03925324|f||||f
17156653|NCT03030118|t||||t
17156654|NCT01541839|f||||f
17156655|NCT03488225|t||||
17156656|NCT02303990|t||||
17156657|NCT02669914|t||||
17156658|NCT00503997|t||||
17167227|NCT01921218|t||||
17181998|NCT04227236|f||||f
17181999|NCT00409617|f||OTHER|Provide ABBOTT at least thirty (30) days prior to submission for review, ABBOTT shall return comments promptly. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period.|t
17182000|NCT02159521|f||GT60||t
17182001|NCT03712410|f||||f
17199247|NCT00926380|f||||f
17199248|NCT00632021|f||||f
17199249|NCT00458393|f||||f
17199250|NCT01690923|t||||f
17199251|NCT01101061|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199252|NCT00857233|f||OTHER|The main publication has to be published before any sub-publications. Order of authors has to be established. Publication of the results by the investigator will be subject to mutual agreement between the investigator and H. Lundbeck A/S. Manuscripts and abstracts must be sent to H. Lundbeck A/S at least one month prior to submission for publication or presentation.|t
17199253|NCT05043883|f||||f
17199254|NCT01587118|f||||f
17199255|NCT00263575|f||OTHER|Publication statement in clinical trial agreement|t
17156659|NCT01195844|f||OTHER|"The initial publication of this study will be multicenter, comprising data from all sites involved. After the multicenter publication, or 24 months after the end of the study, each site involved may publish its own results in an independent fashion.~The sponsor will also have the opportunity to review all the proposed abstracts,~manuscripts or lectures related to this study 60 days before submission for~publication/presentation."|t
17199256|NCT01586975|f||||f
17199257|NCT01728623|f||OTHER||t
17199258|NCT00243022|t||||
17199259|NCT01390441|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17199260|NCT03517111|f||||f
17199261|NCT04438382|f||LTE60||t
17199262|NCT01781832|t||||
17199263|NCT01163474|t||||
17199264|NCT01280604|f||||f
17199265|NCT03432390|f||||f
17199266|NCT05702541|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199267|NCT00798304|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199268|NCT00980590|f||||f
17199269|NCT03850275|f||||f
17199270|NCT00672451|t||||
17199271|NCT02689453|f||||f
17199272|NCT04206085|f||||f
17199273|NCT00763451|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17199274|NCT01473992|f||||f
17199275|NCT00725543|f||||f
17199276|NCT05594589|f||||f
17199277|NCT03200444|t||||
17199278|NCT02168478|t||||f
17199279|NCT05479747|f||||f
17199280|NCT03845023|f||OTHER|PIs agreed that because the Study is part of a Multi-center Study, individual publication could not be made until the publication of the Multi-center study results, notification that that a Multi-center publication was not planned, or after 18 months had passed.|t
17199281|NCT01743976|f||||f
17199282|NCT02072421|f||||f
17199283|NCT02554383|f||||f
17199284|NCT02918292|f||||f
17199285|NCT01801982|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199286|NCT01966978|f||||f
17199287|NCT01185171|t||||
17199288|NCT00727506|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17156660|NCT05385224|f||||f
17156661|NCT01935700|f||||f
17156662|NCT01225289|f||||f
17156663|NCT01294371|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17182002|NCT03316885|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199289|NCT03561597|f||||f
17199290|NCT03545412|f||||f
17199291|NCT03783689|f||||t
17199292|NCT04996940|t||||
17199293|NCT01255761|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17199294|NCT01437488|t||||t
17199295|NCT03947918|t||||
17199296|NCT06124131|t||||
17199297|NCT03783871|f||||f
17199298|NCT06638840|t||||
17199299|NCT04594733|f||||f
17199300|NCT00796627|t||||
17199301|NCT02647645|f||||f
17199302|NCT00356811|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199303|NCT02386839|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17199304|NCT02101983|t||||
17199305|NCT00826228|f||||f
17199306|NCT00903760|t||||
17199307|NCT01197612|f||||f
17199308|NCT01845805|t||||
17199309|NCT01226732|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17199310|NCT00589303|t||||f
17199311|NCT04367480|t||||
17167228|NCT02449889|f||OTHER|The only disclosure restriction on the Principal Investigator (PI) is that Sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the Sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Sponsor to seek patent protection of the invention.|t
17167229|NCT00688324|f||||f
17167230|NCT00006046|f||||f
17167231|NCT03176472|f||LTE60||t
17167232|NCT00596154|t||||
17167233|NCT00746239|t||||
17167234|NCT00642369|f||||f
17167235|NCT03582553|f||||f
17167236|NCT00585546|t||||
17167237|NCT03077438|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17167238|NCT04243577|f||||f
17167239|NCT01190475|f||OTHER|All PIs must seek written permission from the sponsor prior to publication of any trial results.|t
17167240|NCT01679600|t||||
17167241|NCT01535599|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167242|NCT04452435|f||||f
17167243|NCT04043234|f||||f
17199312|NCT01780454|f||||f
17167244|NCT01165320|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to publication or presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17199313|NCT00730015|f||OTHER|The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.|t
17167245|NCT03826173|t||||f
17167246|NCT00385944|f||GT60||t
17167247|NCT00590824|t||||
17167248|NCT00834990|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17167249|NCT01114971|f||||f
17167250|NCT00791479|f||GT60||t
17167251|NCT01778049|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167252|NCT03119181|f||OTHER|PI must submit communications to Sponsor for review and comment to verify accurate content at least 30 days prior to submitting to any third party. A delay up to 90 days may be requested by Sponsor in order to file patent applications relating to an Invention if applicable. Sponsor and PI agree that any Institution Publication shall only be made after the Multicenter Publication, provided that the Multicenter Publication is submitted within 18 months after conclusion of the study at all sites.|t
17167253|NCT01025076|f||||f
17167254|NCT03770728|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17167255|NCT01364558|t||||
17167256|NCT02379988|t||||
17199314|NCT04120376|f||||f
17199315|NCT00634842|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17150583|NCT00292188|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150584|NCT00824616|f||OTHER|After multicenter publication or 24 months after study completion, whichever comes first, an investigator may publish the results for their study site only. Sponsor can review publications 60 days prior to submission.|t
17150585|NCT01796912|t||||
17150586|NCT03275766|t||||
17150587|NCT00971841|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150588|NCT02920918|f||||f
17150589|NCT00974974|f||OTHER|Publication of the results of the Study conducted at the Site shall not be made before the first multi-site publication by Sponsor.|t
17150590|NCT01959035|f||||f
17150591|NCT03254602|f||||f
17150592|NCT00334061|f||LTE60||t
17150593|NCT04539886|f||LTE60||t
17150594|NCT00688376|f||||f
17150595|NCT00858962|f||LTE60||t
17150596|NCT02181426|f||||f
17150597|NCT04492020|f||||f
17150598|NCT00063635|f||||f
17150599|NCT01663935|f||||f
17150600|NCT02792959|t||||
17150601|NCT02075671|f||||f
17150602|NCT03914950|t||||
17150603|NCT00119067|f||OTHER|PIs must have the approval of all 5 PIs to conduct and publish additional research using clinical trial data or specimens|t
17150604|NCT00242619|f||||f
17150605|NCT00003875|t||||f
17156664|NCT02520427|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156665|NCT00655473|f||||f
17156666|NCT04778059|f||||f
17156667|NCT01553240|t||||
17167257|NCT00107315|t||||
17156668|NCT00157248|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17156669|NCT02681757|f||||f
17156670|NCT01254851|t||||
17156671|NCT01306045|f||||f
17167258|NCT00945061|t||||
17167259|NCT02509039|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167260|NCT01794741|f||OTHER|Meda Pharmaceuticals requests that it receive copies of any intended communication at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript). This is to allow Meda Pharmaceuticals to review the communications for accuracy , to verify that confidential information is not being inadvertently divulged, to provide any relevant supplementary information, and to allow establishment of co-authorship.|t
17167261|NCT05427539|t||||
17167262|NCT02089464|f||||f
17199316|NCT02007200|f||LTE60||t
17199317|NCT02643225|f||||f
17199318|NCT04182113|f||||f
17199319|NCT01667406|t||||
17199320|NCT02768597|t||||
17199321|NCT00943787|t||||
17199322|NCT03792347|f||||f
17199323|NCT01288209|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17199324|NCT01015677|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17199325|NCT02232399|f||||f
17199326|NCT03064152|f||||f
17199327|NCT01646385|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199328|NCT01216072|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17199329|NCT02440334|t||||
17199330|NCT04294667|f||GT60||t
17199331|NCT04799418|f||||f
17199332|NCT03563313|f||||f
17199333|NCT00952848|t||||
17199334|NCT00537329|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199335|NCT02049515|f||||f
17199336|NCT01640171|f||||f
17199337|NCT02138253|f||OTHER|Sponsor has the right to publish the results before the PI.|t
17150606|NCT01780987|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150607|NCT04168190|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17150608|NCT00629265|f||||f
17150609|NCT04465630|f||OTHER|Depending on certain terms described in the agreement, the Institution and Principal Investigator may publish the results of the Study generated by the Institution, subject to...the prior approval of Sponsor in writing. The Institution shall furnish Sponsor with a written copy of any proposed publication or disclosure,...at least sixty (60) days prior to submission for publication or disclosure.|t
17150610|NCT01775865|t||||
17150611|NCT01169532|t||||
17150612|NCT02660528|f||||f
17150613|NCT04355663|f||||f
17150614|NCT02931045|t||||
17150615|NCT00876018|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150616|NCT01230892|t||||f
17150617|NCT00679913|t||LTE60||
17150618|NCT00725621|f||||f
17137260|NCT03666858|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17137261|NCT03282357|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the investigator will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17137262|NCT01586156|t||||
17137263|NCT00547378|f||||f
17137264|NCT04105244|f||||f
17156672|NCT02987972|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17137265|NCT02112994|f||||f
17137266|NCT01525927|t||||
17137267|NCT02768194|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137268|NCT00426517|t||||f
17137269|NCT00363246|t||||
17156673|NCT04149574|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17156674|NCT04506905|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17156675|NCT00602290|f||||f
17156676|NCT02345265|f||LTE60||t
17156677|NCT05072106|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17156678|NCT03839459|t||||
17156679|NCT02567422|f||LTE60||t
17156680|NCT04569240|f||||f
17156681|NCT05773781|t||||
17156682|NCT05128773|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17156683|NCT05365958|f||||f
17156684|NCT04250714|f||||f
17156685|NCT04529850|f||OTHER|PI has publication and presentation privileges provided that manuscript/presentation is submitted to the sponsor 60 days prior to submission of the publication or 60 days prior to presentation. PI agrees to remove confidential information of sponsor prior to submission of publication or presentation or defer submission until confidential information can be protected by filing of a patent application. PI cannot publish the results from their site until the sponsor has published multi-site data.|t
17137270|NCT00099359|f||||f
17137271|NCT02756650|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17137272|NCT01822691|t||||
17137273|NCT01022567|f||||f
17156686|NCT00310466|f||OTHER|ALK must receive copies of any intended communication in advance of publication (at least 15 working days for an abstract or oral presentation and 45 working days for a journal submission). ALK will review the communications for accuracy (thus avoiding potential discrepancies with submissions to health authorities), verify that confidential information is not being inadvertently divulged and provide any relevant supplementary information.|t
17167263|NCT01895543|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17167264|NCT00543296|t||||
17167265|NCT00934947|f||||f
17167266|NCT01907321|t||||
17167267|NCT00735826|t||||f
17167268|NCT01703208|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17167269|NCT02099344|f||||f
17167270|NCT03858335|t||||
17167271|NCT04699032|f||||t
17167272|NCT05593913|f||||f
17167273|NCT04570605|t||||
17167274|NCT02979093|f||||f
17167275|NCT01096368|f||OTHER|Must obtain prior Sponsor approval.|t
17167276|NCT03070223|f||||f
17167277|NCT03609385|t||||
17167278|NCT00053677|f||||f
17167279|NCT00118846|t||||
17167280|NCT00726037|f||||f
17167281|NCT01394692|t||||
17167282|NCT00350272|f||OTHER|Prior to submitting/presenting a manuscript or materials relating to a Study to a publisher, reviewer, or outside person, the Institution shall provide to Sponsor a copy of all such manuscripts or materials, and Sponsor shall have thirty (30) days to review and comment. The Institution shall, upon Sponsor's request, further delay publication or presentation for a period of up to sixty (60) days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17182003|NCT01102413|f||OTHER|If Pharmacosmos or its agents has not prepared a draft for submission to a peer reviewed journal prior to 1 year following completion of the study report, the investigators have the right to publish the results. Such publications are to be submitted to Pharmacosmos for comment 30 days prior to submision for publication.|t
17156687|NCT01458951|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156688|NCT00585013|f||||f
17156689|NCT02963558|t||||
17156690|NCT03309696|t||||
17156691|NCT01573767|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156692|NCT00850096|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor.|t
17156693|NCT01371877|t||||
17156694|NCT00869557|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17156695|NCT05940077|f||||f
17156696|NCT02304380|t||||
17156697|NCT02368210|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review thirty days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17156698|NCT00078949|t||||f
17156699|NCT01143064|f||||f
17156700|NCT00323037|f||OTHER|The publishing party will submit any proposed manuscript or publication to the sponsor for comment at least 60 days prior to its release. The publishing party will make every reasonable attempt to incorporate comments received from the sponsor, and will upon request remove any previously undisclosed confidential information, prior to publication or disclosure. There will be no publication or publicizing of individual site data or results prior to the multicenter publication.|t
17156701|NCT00230022|f||||f
17156702|NCT03258008|t||||
17156703|NCT01199822|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17156704|NCT03747302|f||||f
17156705|NCT03769675|t||||
17167283|NCT02226198|f||OTHER|Upon completion of the Clinical Trial (CT), the Principal Investigator (PI) may prepare the data derived from the CT for publication or presentation. Material should be submitted to the Sponsor for review prior to review or submission for publication, or public dissemination. Publications from individual sites must not precede the primary manuscript, but if not published within twelve months after completion of the CT, the PI has the right to publish or present the methods and results of the CT.|t
17167284|NCT00859339|f||||f
17167285|NCT01288612|t||||
17167286|NCT00871923|t||||
17137274|NCT03371160|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Twelve months following the completion of the study, Investigator may publish the results of the study. Investigator shall provide sponsor advanced copies of any proposed publication sixty days prior to planned publication Sponsor will have sixty days to review the proposed publication.|t
17137275|NCT01317667|t||||
17137276|NCT00910429|f||OTHER||t
17137277|NCT01322646|f||||f
17137278|NCT02358369|f||OTHER|"No presentation or publication of Institution's data relating to the Trial may occur until after the Trial has been completed at all sites. If Investigator desires to present or publish, investigator must submit any and all manuscripts, posters, abstracts, or other intended publications (hereinafter collectively referred to as manuscripts) to Sponsor at least sixty (60) days prior to the actual submission of such manuscript(s) for publication."|t
17137279|NCT04465396|f||||f
17137280|NCT00547638|f||LTE60||t
17137281|NCT02821455|f||||f
17137282|NCT00622544|f||||f
17137283|NCT02365584|f||OTHER|Results are owned by the Sponsor and data communication collected in a center by the investigator is allowed only after publication of aggregate results of the study by the Sponsor. If an investigator intends to communicate data, the Sponsor must be informed and should review the manuscript/publication before its submission. The investigator should accept any Sponsor comments provided they are not in contrast to the reliability of data, with rights, with the safety and well-being of patients.|t
17137284|NCT03052842|f||||t
17137285|NCT01973452|t||||
17137286|NCT00349752|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17137287|NCT02193815|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137288|NCT00675103|f||LTE60||t
17137289|NCT02006264|t||||
17156706|NCT00583375|f||||t
17156707|NCT04027075|t||||
17156708|NCT01472965|t||||
17156709|NCT01928797|t||||f
17156710|NCT02635542|t||||
17156711|NCT01432275|f||GT60||t
17156712|NCT02565706|f||||f
17156713|NCT02584959|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17156714|NCT03526055|f||||f
17199338|NCT01426113|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167287|NCT05599451|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17167288|NCT00395291|f||||f
17167289|NCT00789581|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17167290|NCT01468207|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17182004|NCT03216850|t||||
17199339|NCT00224029|f||LTE60||t
17156715|NCT03008278|f||LTE60||t
17156717|NCT03019003|f||||f
17156718|NCT03802565|f||||t
17156719|NCT02124759|t||||
17156720|NCT01068626|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications during 3 months prior to public release and can embargo communications regarding trial results for an additional period of 3 months from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17156721|NCT04340843|f||LTE60||t
17156722|NCT04249622|t||||
17156723|NCT04250298|t||||
17156724|NCT03604705|f||||t
17199340|NCT02872012|f||||f
17199341|NCT00020722|t||||f
17199342|NCT01305473|f||GT60||t
17199343|NCT02725528|f||||f
17199344|NCT02569957|t||||
17199345|NCT02635386|t||||
17199346|NCT01209598|t||||
17199347|NCT02719743|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199348|NCT02287233|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199349|NCT03772613|t||||
17199350|NCT01427738|f||||f
17199351|NCT05314374|t||||f
17199352|NCT02658175|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199353|NCT01214421|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17199354|NCT03928392|t||||
17199355|NCT04115189|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199356|NCT02581059|f||||f
17199357|NCT02392104|t||||f
17199358|NCT04887506|f||||f
17199359|NCT01999777|f||OTHER|A manuscript or abstract should not be submitted by investigator(s) for publication or presentation until a New Drug Application is approved by the US FDA or permission is granted in writing by the sponsor.|t
17199360|NCT02394665|t||||
17156725|NCT05708703|t||||
17156726|NCT03689543|t||||
17156727|NCT01634659|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17156728|NCT03627416|t||||
17156729|NCT05497960|f||||f
17156730|NCT03619902|f||OTHER|The PI may not publish trial results until after the first multi-center publication unless such publication is not published within a period that is at least 18 months but less than or equal to 24 months after trial completion. In addition, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17156731|NCT05670314|t||||
17156732|NCT05625477|f||||t
17156733|NCT02502266|f||LTE60||t
17156734|NCT02327013|f||||f
17156735|NCT04829331|f||||f
17156736|NCT03435224|t||||
17156737|NCT02523235|f||||f
17156738|NCT00367484|f||OTHER||t
17156739|NCT01404208|f||||f
17156740|NCT02570139|f||||f
17156741|NCT04007107|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17156742|NCT04068688|t||||
17156743|NCT04679051|f||||f
17167291|NCT01559922|f||OTHER|Suneva, as the Sponsor, has a proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation among multiple investigators and sites and Suneva personnel. Authorship will be established prior to the writing of the manuscript. As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multi-center study except as agreed with Suneva.|t
17167292|NCT01328041|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167293|NCT00908115|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167294|NCT01728077|f||GT60||t
17199361|NCT02636608|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199362|NCT03506347|t||||
17199363|NCT05613088|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199364|NCT03912532|f||||f
17199365|NCT04461158|f||||f
17199366|NCT04199052|f||||f
17199367|NCT03569891|f||||t
17199368|NCT00815919|t||||
17199369|NCT03614676|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17199370|NCT01641653|t||||
17199371|NCT02825251|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17199372|NCT00487825|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17199373|NCT01473745|f||OTHER|no financial PI disclosure|t
17199374|NCT01639742|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199375|NCT02531867|f||OTHER|The Investigators are subject to certain disclosure and publication limitations. In cases of publication of the study results at conferences or on academic journals, the post-approval clinical study coordinating investigator and the study sponsor should discuss about details of publication, publication methods and presenters before decision-making|t
17199376|NCT01190644|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication.|t
17156744|NCT00956631|f||LTE60||t
17156745|NCT02772276|f||OTHER|MediBeacon requests that no presentation/publication occur until after the first publication of study results or until 1 yr after a study is completed/terminated early, whichever occurs first. Proposed results publication/disclosure must be given to Sponsor for review at least 45 days prior to the date of submission. If a patent application is to be filed, both the Institution and the Sponsor will defer publication or other disclosure for a period of time, not to exceed an additional 60 days.|t
17156746|NCT00455520|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication. The sponsor can embargo for an additional 60 days to allow for the filing of a patent application.|t
17156747|NCT00109876|f||LTE60||t
17156748|NCT02248974|t||||
17156749|NCT02332239|f||||f
17156750|NCT03448939|f||OTHER|Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.|t
17167295|NCT01366612|t||||
17167296|NCT03879044|t||||
17137290|NCT02164513|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137291|NCT02560493|t||||
17137292|NCT03073213|f||GT60||t
17137293|NCT00961662|f||||f
17137294|NCT00280150|f||GT60||t
17137295|NCT03303040|t||||f
17156751|NCT00628095|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156752|NCT01576003|t||||
17156753|NCT03235115|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any use of data for results communication.|t
17156754|NCT00006305|f||||f
17156755|NCT00662558|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156756|NCT00329641|f||LTE60||t
17156757|NCT00115037|f||||f
17156758|NCT00396877|f||OTHER|If no publication has occurred within 12 months after trial completion, the Investigator can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not exceeding 90 days.|t
17156759|NCT05765253|f||||f
17156760|NCT00783224|f||OTHER|The only restriction on the PI is that the PI needs to get approval from the sponsor for publication of the trial results prior to public release.|t
17156761|NCT01711619|f||OTHER|The Study Publication Committee manages and oversees publications generated from the study. The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication related to patentable and copyrightable material and can extend the embargo.|t
17156762|NCT03422159|t||||
17156763|NCT02631070|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17156764|NCT01118988|f||||f
17156765|NCT00087126|f||LTE60||t
17156766|NCT01839799|t||||
17156767|NCT00934856|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156768|NCT01836809|t||||
17156769|NCT03646149|t||||
17156770|NCT00475878|f||||f
17156771|NCT01273155|f||||f
17156772|NCT00401960|f||||f
17156773|NCT02649426|f||||f
17156774|NCT00195494|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17156775|NCT00513357|t||||
17167297|NCT01106859|f||OTHER|Sponsor agrees to review manuscripts within a reasonable period of time. If sponsor determines the publication included patentable subject matter, sponsor will be granted no less than 120 days to prepare patent applications.|t
17156776|NCT00878605|t||||
17167298|NCT00347438|t||||
17167299|NCT00322023|f||||f
17167300|NCT00693017|f||||f
17167301|NCT01082874|f||||f
17156777|NCT01217385|f||||f
17156778|NCT00090987|f||||f
17156779|NCT02292186|f||LTE60||t
17156780|NCT00835679|f||LTE60||t
17167302|NCT01952444|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Written approval from the Sponsor is required prior to disclosing any information related to this clinical study.|t
17167303|NCT01477463|f||||f
17167304|NCT00986401|f||||f
17199377|NCT02366143|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199378|NCT04411186|t||||
17199379|NCT00575042|f||||f
17199380|NCT01053247|f||OTHER||t
17199381|NCT04795336|t||||
17199382|NCT03898700|f||||f
17199383|NCT03023722|t||||
17156781|NCT01443494|t||||
17156782|NCT04769739|t||||
17156783|NCT01451632|f||LTE60||t
17156784|NCT04891406|f||||f
17156785|NCT00585715|f||||f
17156786|NCT02431806|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17156787|NCT02968433|f||||f
17156788|NCT02079636|f||LTE60||t
17199384|NCT03616964|f||GT60||t
17199385|NCT00656201|t||||f
17199386|NCT01928693|t||||
17137296|NCT03379506|f||OTHER|The results of this study may be published or presented at scientific meetings. The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17156789|NCT00875433|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17167305|NCT00354107|f||LTE60||t
17167306|NCT00369226|t||||
17199387|NCT03752177|f||OTHER|PI must delay publications until a multi-center publication is disclosed, (or for a time period if no multi-center publication is disclosed).|t
17199388|NCT02641587|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17137297|NCT03006471|t||||
17199389|NCT01165177|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199390|NCT01663506|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199391|NCT01642147|t||||
17199392|NCT01852032|f||||f
17199393|NCT03210519|f||||f
17150619|NCT01189500|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150620|NCT00062751|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150621|NCT03345394|f||||f
17150622|NCT01635062|f||||f
17150623|NCT00851643|f||OTHER|As this study is part of a multicenter trial, the SPONSOR does not recommend separate publication of individual study site results due to scientific concerns. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17150624|NCT01019707|t||||
17150625|NCT01940497|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150626|NCT02707861|f||LTE60||t
17150627|NCT01641133|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150628|NCT05816200|f||||f
17150629|NCT01366443|f||||f
17150630|NCT00369382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150631|NCT03554603|f||||f
17150632|NCT00507546|t||||f
17150633|NCT01673698|f||OTHER|After 12 months after the clinical study report is available, the PI may publish clinical study results, subject to confidentiality agreements and sponsor approval. The PI shall provide sponsor a copy of proposed publication at least 60 days prior to submission so that sponsor may have the opportunity to protect its proprietary rights to information, inventions, or products developed under the clinical study. PI agrees to remove confidential information upon sponsor request.|t
17150634|NCT03322384|t||||
17150635|NCT00448136|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150636|NCT00609466|f||OTHER|Grünenthal GmbH reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither Grünenthal nor the investigator has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17150637|NCT03407430|f||||f
17150638|NCT02518919|t||||f
17150639|NCT03882528|f||||f
17150640|NCT02227147|f||||f
17150641|NCT02923674|t||||
17150642|NCT03709823|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17150643|NCT01055132|f||OTHER|Publications require agreement and written approval from Sponsor.|t
17167307|NCT01180036|f||||f
17167308|NCT01685801|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17167309|NCT00113399|f||||f
17167310|NCT00396136|f||OTHER||t
17167311|NCT03368053|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167312|NCT04686084|t||||
17167313|NCT02576041|f||OTHER|The PI can disclose the results after sending to the Sponsor, for appropriate knowledge and / or possible review, copy of the document, at least 90 days prior to publication and / or presentation. If requested in writing by the Sponsor, the PI will agree to make changes to the manuscript and / or deferred publication of the manuscript further 90 days to allow the patent application.|t
17167314|NCT01779856|f||||f
17167315|NCT03350256|f||||f
17167316|NCT03960580|f||GT60||t
17167317|NCT01528891|f||||f
17167318|NCT01155466|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy, fair balance, and compliance.|t
17167319|NCT02210689|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17167320|NCT00223977|f||LTE60||t
17167321|NCT03136497|t||||
17167322|NCT00410826|f||||f
17167323|NCT00557310|f||GT60||t
17167324|NCT01180894|f||||f
17167325|NCT00367744|f||||f
17167326|NCT00793572|t||||
17167327|NCT05082428|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167328|NCT01271712|f||GT60||t
17167329|NCT00607269|t||||f
17167330|NCT00096226|f||||f
17167331|NCT01666119|f||||f
17167332|NCT05487040|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclosure previously undisclosed confidential information other than study results.|t
17167333|NCT04270682|f||||f
17167334|NCT05479097|t||||
17167335|NCT03269968|f||||f
17167336|NCT04003207|f||GT60||t
17167337|NCT01790178|t||||f
17167338|NCT00589056|t||||
17167339|NCT03894969|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167340|NCT03569748|t||||
17167341|NCT00468676|f||||f
17167342|NCT01893372|t||||
17167343|NCT02388490|f||||f
17167344|NCT01327053|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17167345|NCT01574157|t||||
17199394|NCT04351269|f||||f
17167346|NCT00721578|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167347|NCT01352442|f||||f
17167348|NCT01330628|f||LTE60||t
17167349|NCT02910401|f||||f
17167350|NCT01182805|f||GT60||t
17167351|NCT01660672|f||||f
17167352|NCT03955250|f||||f
17167353|NCT03802344|t||||
17167354|NCT01010568|f||||f
17167355|NCT02793817|f||OTHER|No submission for publication or public disclosure will be made by the PI until after the publication of the results of the multi-center clinical trial by the Sponsor. Thereafter, PI shall provide KALA with an advance copy of any proposed publication or public disclosure at least sixty (60) days prior to the planned date of submission or disclosure and KALA shall have forty-five (45) days from the date of its receipt to recommend changes.|t
17167356|NCT03222973|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17167357|NCT02080481|t||||
17167358|NCT02345772|t||||
17167359|NCT03895632|f||||f
17167360|NCT01440517|f||||f
17167361|NCT02263911|f||GT60||t
17199395|NCT00535938|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 4 weeks from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17156790|NCT00622336|f||OTHER|Investigator has the right to publish and/or present study data after multicentric publication or one year has elapsed until completion this multicentric study provided that he/she (i) furnishes the sponsor a copy of any proposed publication or presentation before its submission, (ii) deletes any sponsor's confidential data as pointed out by sponsor, and (iii) delays any submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications.|t
17156791|NCT04148287|f||OTHER|The Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156792|NCT03164265|t||||
17156793|NCT03912428|t||||
17156794|NCT03233204|f||LTE60||t
17156795|NCT01777139|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156796|NCT02921750|f||||f
17156797|NCT03605849|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17156798|NCT02102100|f||||f
17156799|NCT00328094|t||||
17156800|NCT00590538|f||||f
17156801|NCT02309723|f||||f
17156802|NCT01125813|f||LTE60||t
17156803|NCT00985426|f||LTE60||t
17156804|NCT01565668|f||||f
17156805|NCT04258254|f||||f
17156806|NCT02255552|f||OTHER||t
17156807|NCT04566133|f||||f
17156808|NCT03570554|f||LTE60||t
17156809|NCT00176436|t||||
17167362|NCT02723006|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17167363|NCT00983515|f||GT60||t
17167364|NCT04385238|f||GT60||t
17167365|NCT01967823|f||||f
17199396|NCT03598699|f||OTHER|"1. Master Clinical Development Agreement (MCDA) between AxeroVision and ORA stipulating written confidentiality agreement with third parties containing substantially similar restrictions on disclosure, use and other obligations contained in this MCDA.~2. Publication section in the Clinical Trial Protocol prohibiting individual publications without the company's consent."|t
17199397|NCT02229578|t||||
17199398|NCT04611347|f||||f
17156810|NCT00355706|f||||f
17156811|NCT01642485|t||||
17156812|NCT03180515|f||||f
17156813|NCT02718248|f||||f
17156814|NCT02223819|f||||f
17156815|NCT04339179|f||||f
17156816|NCT02956057|f||||f
17156817|NCT00565916|t||||
17156818|NCT01420679|f||||f
17156819|NCT01313494|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17156820|NCT02604550|t||||
17156821|NCT04472026|f||||f
17156822|NCT02525536|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17156823|NCT00231309|t||||f
17156824|NCT01153620|f||LTE60||t
17156825|NCT03769194|f||||t
17156826|NCT01985958|t||||
17156827|NCT01832818|f||||f
17156828|NCT01256385|f||LTE60||t
17156829|NCT01080391|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17156830|NCT01904903|f||||f
17156831|NCT00672841|f||||f
17156832|NCT03578146|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization.|t
17156833|NCT03677934|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167366|NCT00539513|t||||
17156834|NCT01260584|f||OTHER|"Sponsor reflects the following restrictive language in the Clinical Study Agreements: If Daiichi Sankyo Inc. (DSI) identifies any of its confidential information as defined herein, it shall be deleted … Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site."|t
17167367|NCT00316693|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167368|NCT03002818|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17156835|NCT00932451|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156836|NCT02624388|t||||
17167369|NCT00966849|t||||
17167370|NCT00711113|f||LTE60||t
17167371|NCT00100230|f||||f
17167372|NCT01332188|f||||t
17156837|NCT01605032|t||||
17156838|NCT00637806|f||OTHER||t
17156839|NCT00561470|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17156840|NCT03434249|f||||t
17156841|NCT00725101|f||GT60||t
17156842|NCT03325894|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17167373|NCT01606787|t||||
17167374|NCT00413894|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167375|NCT04225676|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167376|NCT03245736|f||OTHER|All proposed publications and presentations shall be submitted to the sponsor for its review at least 30 days before such presentation or publication is submitted to any third party.|t
17167377|NCT01942161|f||||f
17167378|NCT01783574|f||||f
17167379|NCT05289271|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17167380|NCT01116024|f||||f
17167381|NCT01257568|f||OTHER|Each investigator shall have privileges for their own center's results. These manuscripts and abstracts will be delayed until after the 5-year multi-center publication is submitted. All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication. The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17167382|NCT02074345|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167383|NCT03392883|f||||f
17167384|NCT00132691|f||||f
17167385|NCT02994953|f||||t
17167386|NCT01792817|f||GT60||t
17167387|NCT01739933|f||||f
17167388|NCT04098367|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167389|NCT01245738|f||OTHER|The scientific information generated from this study will be publically disclosed in forms of peer reviewed publication and scientific presentations and may even be actively disseminated amongst the practicing medical community in appropriate scientific platforms.|t
17167390|NCT03824405|f||OTHER|As Study is a Multi-centre Study, no Publication of the Study results may be made until Publication of the results of the Multi-centre study or 2 years after Study Completion, whichever is sooner.|t
17167391|NCT01846195|f||||f
17137298|NCT02581865|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17137299|NCT01993615|t||||f
17156843|NCT01592292|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156844|NCT02722837|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17156845|NCT03660475|f||||f
17156846|NCT00948506|f||||f
17156847|NCT01294007|f||||f
17156848|NCT00824382|t||||
17156849|NCT00721279|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17156850|NCT02680834|f||OTHER|After the multi-center publication, or if no multi-center publication is submitted for publication within 12 months after the conclusion or termination of the study at all sites, site may publish on your own site's data only. A draft of the manuscript must be submitted to Sponsor for review at least 45 days prior to submission for publication and 15 days for oral presentation. Sponsor shall respond to institution within 45 days of the receipt of draft.|t
17156851|NCT01732471|f||OTHER|All written or oral publications and/or information related to Study and/or results of Study should be submitted at first in writing to Sponsor at least 30 working days for publication and 15 working days for brief review, abstract before planned date of submission. If Sponsor is filing a patent application on Study results, Sponsor can delay its authorization for publication/communication of Study results to Investigator and/or Research Centre until date of international registration of patent.|t
17156852|NCT00232596|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156853|NCT01253174|f||OTHER|PI (principal investigator) of CRO (contract research organization) will refrain from publishing any data or information generated or derived as a result of the performance of the Services.|t
17156854|NCT03467763|t||||f
17156855|NCT02889835|f||||f
17156856|NCT04438499|f||||f
17156857|NCT04918355|t||||
17156858|NCT03200847|t||||
17156859|NCT00224406|f||||f
17156860|NCT01556997|f||||f
17156861|NCT01172808|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17156862|NCT03529799|t||||f
17156863|NCT03315962|f||||f
17156864|NCT01010009|t||||
17156865|NCT01092637|t||||f
17156866|NCT00577005|t||||
17156867|NCT01004432|f||GT60||t
17156868|NCT02667626|f||||f
17156869|NCT03933020|t||||
17156870|NCT02696434|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17156871|NCT01253668|f||||f
17156872|NCT01149421|f||GT60||t
17156873|NCT00616603|t||||
17156874|NCT04108988|t||||
17156875|NCT03738800|f||||f
17156876|NCT00943670|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156877|NCT03956615|f||||f
17167392|NCT01231321|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17167393|NCT01247363|f||GT60||t
17167394|NCT03777709|f||||f
17167395|NCT03575065|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17150644|NCT00158600|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17150645|NCT02252718|t||||
17150646|NCT02618408|f||OTHER||t
17150647|NCT03365752|t||||
17150648|NCT02575911|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17150649|NCT01249365|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150650|NCT01070771|f||GT60||t
17150651|NCT01460901|f||||f
17199399|NCT02085473|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17156878|NCT01777295|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156879|NCT02554318|f||||f
17156880|NCT00033657|f||||f
17156881|NCT02945254|t||||
17156882|NCT02348359|f||||f
17156883|NCT03436199|f||||f
17156884|NCT00085098|f||||f
17156885|NCT03515629|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17167396|NCT02359045|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17199400|NCT01407276|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17199401|NCT02446613|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167397|NCT00541866|f||GT60||t
17167398|NCT00957944|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17167399|NCT03172884|f||OTHER|Center will refrain from making any publications and shall not publish any press releases or other public announcements or statements about this Agreement, the Study, the Results of the Study and/or the Study Drug without Bayer's prior written consent.|t
17167400|NCT01482169|t||||
17156886|NCT01886781|f||||f
17156887|NCT00980018|f||||f
17156888|NCT01522235|f||||f
17156889|NCT01523704|f||GT60||t
17156890|NCT01672294|t||||
17156891|NCT00336323|f||||f
17156892|NCT01438814|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17167401|NCT00522418|f||OTHER|Investigator and Site agree not to publish or otherwise publicaly disclose clinical data generated in connection with the Study, unless approved in advance in writing by Cyberonics. Investigators and Site agree to provide Cyberonics with a copy of any proposed publication, abstract, or presentation relating to the research conducted under this Agreement at least 30 days prior to submission for publication or presentation.|t
17167402|NCT01944098|f||||f
17182005|NCT02074995|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17199402|NCT01062269|t||||
17199403|NCT00085566|t||||
17199404|NCT00745498|f||||f
17199405|NCT03174782|t||||
17199406|NCT00778921|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17199407|NCT04805073|t||||
17156893|NCT01666210|f||OTHER|The PIs agree that the first publication of the data and results of the Study shall be made in conjunction with the presentation of a joint, multi-center publication of the Study results, with the investigators from all appropriate sites contributing data, analyses, and comments.|t
17156894|NCT01440387|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156895|NCT01870297|f||GT60||t
17156896|NCT00337779|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17156897|NCT01162122|f||GT60||t
17156898|NCT02020512|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17156899|NCT01001806|t||||
17167403|NCT00951080|f||||f
17167404|NCT00759356|f||||f
17167405|NCT02124018|f||||f
17167406|NCT00359944|f||||f
17167407|NCT01686750|t||||f
17199408|NCT03178045|t||||
17199409|NCT00133575|f||LTE60||t
17199410|NCT01078922|f||||f
17156900|NCT00422422|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17156901|NCT03313310|f||||f
17156902|NCT00926536|f||LTE60||t
17156903|NCT00990665|f||||f
17156904|NCT02560324|t||||
17156905|NCT01717391|t||||
17156906|NCT03290547|f||||f
17199411|NCT02706847|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17156907|NCT02918552|t||||f
17199412|NCT00675584|f||||f
17156908|NCT01731470|f||||f
17156909|NCT04395274|f||||f
17156910|NCT02315872|f||||f
17156911|NCT00335959|f||||f
17156912|NCT05727306|f||||f
17156913|NCT03482167|t||||
17156914|NCT00737893|t||||
17156915|NCT01319851|t||||
17199413|NCT01174264|f||LTE60||t
17199414|NCT00358007|t||||
17199415|NCT02058836|t||||
17199416|NCT00267098|f||||f
17199417|NCT00547534|t||||
17156916|NCT02450552|t||||
17156917|NCT04877535|t||||
17156918|NCT02167815|f||LTE60||t
17156919|NCT01343667|f||||f
17156920|NCT00810446|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156921|NCT05079230|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17156922|NCT02920177|t||||
17156923|NCT01876979|t||||
17199418|NCT02111863|f||||f
17156924|NCT02202044|t||||
17156925|NCT05153148|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17156926|NCT01953432|t||||
17156927|NCT01712334|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156928|NCT02892513|f||||f
17156929|NCT03426436|f||LTE60||t
17156930|NCT02044874|f||LTE60||t
17156931|NCT01043562|t||||
17156932|NCT04284930|f||||f
17156933|NCT02278367|f||LTE60||t
17156934|NCT00810017|t||||f
17156935|NCT05932225|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17156936|NCT02638129|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 24 months after conclusion, abandonment or termination of the study or notification that there will be no such multi-center publication, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17156937|NCT02397291|t||||
17156938|NCT02949908|f||OTHER||t
17156939|NCT04946552|t||||
17156940|NCT05070468|t||||
17156941|NCT02607280|f||||f
17199419|NCT02688530|t||||
17199420|NCT01658020|t||LTE60||t
17199421|NCT02353871|f||OTHER|A plan for scientific publication and presentation of the results could be agreed and implemented by the study investigators or a steering committee. The sponsor required that reasonable opportunity be given to review the content and conclusions of any abstract, presentation, or paper before the material was submitted for publication or communicated. This condition also applied to any amendments that were subsequently requested by referees or journal editors.|t
17199422|NCT00115336|f||||f
17199423|NCT02526186|t||||f
17156942|NCT02539134|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17199424|NCT01527162|f||||f
17199425|NCT02121912|f||||f
17199426|NCT04599907|f||||f
17199427|NCT03780010|f||||f
17199428|NCT01466790|f||LTE60||t
17199429|NCT00311246|f||||f
17199430|NCT02242643|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199431|NCT01251887|t||||
17199432|NCT02633397|f||||f
17199433|NCT03595878|f||OTHER|Investigators' joint publication is required.|t
17199434|NCT03668223|f||||f
17156943|NCT04395391|t||OTHER|Principal Investigator agreed that they shall not, without the Sponsor's prior written consent, independently publish, publicly disclose, present or discuss any results of or information pertaining to the activities conducted under their agreement for a period of one (1) year following completion of the Study.|t
17199435|NCT01103232|f||||f
17156944|NCT00766467|f||LTE60||t
17156945|NCT00676572|t||||
17156946|NCT01966419|f||||t
17199436|NCT03036124|f||||t
17199437|NCT02660112|t||||
17199438|NCT04650698|t||||
17156947|NCT00259285|f||GT60||t
17156948|NCT00985517|f||||f
17156949|NCT01069419|f||GT60||t
17156950|NCT00908076|f||||f
17156951|NCT02382796|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17156952|NCT02570321|f||||f
17156953|NCT00334802|f||GT60||t
17156954|NCT03887117|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17156955|NCT01739764|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17156956|NCT01389258|f||LTE60||t
17156957|NCT01534208|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17156958|NCT00045734|f||LTE60||t
17156959|NCT00885742|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned, before seeking publication review.|t
17156960|NCT01001598|f||||f
17156961|NCT00925652|f||||f
17156962|NCT04612777|f||||f
17156963|NCT01524783|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in the clinical trial|t
17156964|NCT00100841|f||LTE60||t
17156965|NCT02054910|t||||
17156966|NCT01131065|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsor's request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsor's request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17156967|NCT01782352|f||||f
17156968|NCT01096589|f||LTE60||t
17156969|NCT03673345|f||||f
17156970|NCT01362244|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17156971|NCT02267135|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17156972|NCT03806231|f||||f
17156973|NCT00900731|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17156974|NCT02919267|f||||f
17199439|NCT01090011|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17199440|NCT00307047|f||OTHER|Investigators will not use Trial related data without written consent of sponsor for any purpose other than Trial completion or generation of publication material. Publication or presentation of results from a trial site are not allowed until publication and/or presentation of multi-center results. Sponsor must receive materials at least 60 days prior to the proposed date of the presentation or the initial submission of proposed publication in order to be reviewed by the sponsor.|t
17156975|NCT02407054|f||GT60||t
17156976|NCT00932698|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17199441|NCT00379769|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199442|NCT03778294|t||||
17137300|NCT01175213|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxalta requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxalta may request an additional delay of ≤60 days eg, for intellectual property protection.|t
17137301|NCT03224585|f||||f
17137302|NCT01921634|t||||
17156977|NCT04608344|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17156978|NCT00131365|f||||f
17156979|NCT00655681|f||||f
17156980|NCT00415597|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the Sponsor for review. Sponsor may request a delay in publication to allow the filing of patent applications before publication or release. The sponsor can require deletion of Confidential Information or request correction of inaccuracies.|t
17156981|NCT01447927|f||LTE60||t
17156982|NCT04102865|f||OTHER|Upon completion of the Clinical Investigation the PI may prepare the data derived from the Clinical Investigation for publication. Such data will be submitted to the Sponsor for review and comment prior to publication. In order to ensure that Sponsor will be able to make comment and suggestions where pertinent, the material for public dissemination will be submitted for review at least 60 days prior to submission for publication, public dissemination or review by a publication committee.|t
17156983|NCT02429310|t||||
17156984|NCT00394433|f||||f
17156985|NCT01764997|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17156986|NCT01554176|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17167408|NCT01939002|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17167409|NCT01165112|t||||
17167410|NCT03300024|t||||
17199443|NCT02388347|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17199444|NCT01177956|f||OTHER|All submissions by the PI for publication require the written permission from the sponsor. The PI commits to forward to the sponsor all documents intended for publication which contains data or results generated in connection with the study. Documents must be available at least 60 days before the planned submission date to allow for review. Any publication should follow the policy in the protocol. The PI shall not publish results derived from the study until the study has been reported in full.|t
17199445|NCT02820597|f||||t
17199446|NCT00566813|t||||f
17199447|NCT00701909|t||||
17199448|NCT00158197|f||||f
17199449|NCT04012619|f||||f
17199450|NCT02666664|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17199451|NCT00971997|f||GT60||t
17199452|NCT01385748|f||LTE60||t
17199453|NCT02022111|t||||
17199454|NCT01266018|f||LTE60||t
17199455|NCT03167151|f||||t
17199456|NCT01458522|f||||f
17199457|NCT02684123|t||||
17199458|NCT00516139|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199459|NCT03382561|f||LTE60||t
17199460|NCT01131104|f||GT60||t
17199461|NCT03121820|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from GEROPHARM will be obtained and a draft manuscript will be submitted to GEROPHARM for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and GEROPHARM.|t
17199462|NCT02370251|t||||
17199463|NCT02270671|f||||f
17199464|NCT00476242|f||||f
17199465|NCT02693704|f||||f
17199466|NCT00399841|f||||t
17199467|NCT01585441|t||||
17156987|NCT01085136|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17156988|NCT00083720|f||OTHER|Investigators may not independently publish/disclose any study data, findings or conclusions except as part of an overall multi-center publication. After final publication, or if a draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to review for sponsor confidential information which may be redacted at sponsor request. Publication may be delayed up to 90 days to seek patent protection.|t
17156989|NCT02678000|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17156990|NCT01650545|f||||f
17156991|NCT01463267|f||||f
17156992|NCT00684749|f||||f
17156993|NCT02539654|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17156994|NCT01210352|f||||f
17156995|NCT01298141|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17156996|NCT02093390|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17156997|NCT01854879|f||||f
17199468|NCT02367352|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17199469|NCT00174447|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199470|NCT01437423|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17199471|NCT05878873|t||||
17199472|NCT01383447|f||LTE60||t
17199473|NCT00633945|f||||f
17199474|NCT03865953|f||OTHER|Except for legal reasons, the investigator will not reveal the result of the study to a third party without a mutual agreement about the analysis and interpretation of the data with the sponsor.|t
17199475|NCT00882115|f||||f
17199476|NCT01271504|f||||t
17199477|NCT02552147|f||||f
17199478|NCT02375347|f||||f
17199479|NCT00696488|t||||
17199480|NCT02031536|f||||f
17199481|NCT04530604|t||||
17199482|NCT00762645|f||||f
17199483|NCT03272711|f||||f
17199484|NCT03434028|f||||f
17199485|NCT02037776|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17199486|NCT00873327|t||||
17199487|NCT04147858|f||||t
17137303|NCT03235817|t||||
17137304|NCT01245764|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17137305|NCT00003476|f||||f
17156998|NCT02301039|f||||f
17199488|NCT01191008|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199489|NCT03786744|t||||
17199490|NCT04905849|t||||f
17199491|NCT05010850|f||||f
17199492|NCT02810873|t||||
17199493|NCT00838929|t||||
17199494|NCT04683510|f||||f
17199495|NCT03522389|f||||f
17199496|NCT02257918|f||LTE60||t
17199497|NCT00589836|t||||
17199498|NCT02923193|f||GT60||t
17199499|NCT02634814|t||||
17199500|NCT03766373|f||LTE60||t
17199501|NCT03494985|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199502|NCT02282059|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199503|NCT05093504|f||||f
17199504|NCT02394925|f||GT60||t
17199505|NCT02272244|t||||
17199506|NCT03670277|f||GT60||t
17199507|NCT00212992|f||||f
17199508|NCT02774668|f||||f
17156999|NCT04683939|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~Principal Investigators respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor."|t
17157000|NCT02000882|f||GT60||t
17157001|NCT00549601|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157002|NCT02389374|f||||f
17157003|NCT00908596|f||LTE60||t
17157004|NCT01842906|f||||f
17157005|NCT02437188|f||||f
17167411|NCT00845039|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17167412|NCT00433160|f||GT60||t
17167413|NCT00570037|f||||f
17199509|NCT05347485|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17167414|NCT03372460|t||||f
17167415|NCT02499900|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17167416|NCT01097642|t||||
17167417|NCT02439450|f||GT60||t
17199510|NCT04886518|f||||f
17167418|NCT03998670|f||||f
17157006|NCT02517021|f||LTE60||t
17157007|NCT02661061|t||||
17157008|NCT03246061|f||||f
17157009|NCT00401401|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17157010|NCT01937715|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199511|NCT03733899|f||GT60||t
17167419|NCT01170065|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167420|NCT04258995|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167421|NCT04580277|f||||f
17199512|NCT02852356|f||||f
17199513|NCT01689363|f||OTHER||t
17137306|NCT02500368|f||OTHER||t
17157011|NCT05459558|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157012|NCT02020837|t||||
17157013|NCT01361113|f||GT60||t
17157014|NCT03292458|f||||f
17157015|NCT00593606|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17157016|NCT04643964|t||||f
17157017|NCT01472939|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17157018|NCT00114738|f||||f
17157019|NCT00308750|f||GT60||t
17157020|NCT01358578|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17167422|NCT05858450|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167423|NCT01746511|t||||
17167424|NCT00642174|f||GT60||t
17199514|NCT02104505|t||||f
17199515|NCT02859064|f||GT60||t
17137307|NCT02621619|t||||
17137308|NCT00781963|t||||f
17157021|NCT00388297|f||||t
17157022|NCT01048905|t||||
17157023|NCT01492101|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17157024|NCT01675154|t||||
17157025|NCT01810705|f||||f
17157026|NCT02971800|f||||f
17157027|NCT00460265|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157028|NCT05323994|f||||t
17157029|NCT02454075|f||||f
17157030|NCT02719353|f||||f
17157031|NCT02651415|t||||f
17157032|NCT02777944|t||||
17157033|NCT01917344|t||||
17157034|NCT00624559|t||||f
17157035|NCT04526574|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157036|NCT01678885|f||||f
17157037|NCT01099774|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17199516|NCT00321685|f||LTE60||t
17199517|NCT00127842|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199518|NCT01589926|t||||
17199519|NCT01638390|f||LTE60||t
17199520|NCT01377389|t||||
17199521|NCT01439867|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199522|NCT00334542|t||||f
17199523|NCT00013611|t||||
17199524|NCT02431052|f||||t
17199525|NCT02094898|t||||
17199526|NCT03520075|f||OTHER||t
17199527|NCT05382039|t||||
17199528|NCT01432626|f||||f
17199529|NCT01234883|f||OTHER||t
17199530|NCT01535001|f||||f
17199531|NCT03182998|f||||f
17199532|NCT00126659|f||LTE60||t
17199533|NCT01013961|f||LTE60||t
17199534|NCT02866669|f||||f
17199535|NCT01375751|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199536|NCT02980523|f||OTHER|PI (s) can not make use of the partial or total information of this investigation, due to the clauses contained in the agreement of confidentiality of the study.|t
17199537|NCT02743897|f||||f
17199538|NCT00590226|f||||f
17199539|NCT01547598|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199540|NCT00371176|f||||f
17157038|NCT00717275|t||||
17157039|NCT00424021|f||||f
17157040|NCT03000530|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17157041|NCT00312572|f||GT60||t
17167425|NCT00896363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167426|NCT02982018|f||GT60||t
17167427|NCT03638908|f||||f
17167428|NCT00780481|f||||f
17167429|NCT03334851|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199541|NCT01573949|t||||
17199542|NCT00777634|f||||f
17199543|NCT02229227|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199544|NCT04071301|f||||f
17199545|NCT05186311|f||LTE60||t
17199546|NCT02125279|f||||t
17199547|NCT03178344|t||||f
17199548|NCT00567840|f||OTHER|The investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting, for review and removal of confidential information.|t
17157042|NCT01285492|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17157043|NCT00310076|t||||
17157044|NCT00719914|f||||f
17157045|NCT02046772|f||||f
17157046|NCT00634049|f||OTHER|Publication. At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials , and allow Sponsor sixty (60) days to review and comment on them.|t
17157047|NCT00314132|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17157048|NCT00428922|t||||
17157049|NCT01380691|f||GT60||t
17157050|NCT05972941|f||||f
17157051|NCT01987232|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17167430|NCT01691885|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199549|NCT01850589|t||||f
17199550|NCT01392703|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199551|NCT03714659|f||||f
17199552|NCT04468230|t||||
17199553|NCT04560374|f||||f
17199554|NCT03721705|f||||f
17199555|NCT03721172|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199556|NCT00148668|f||||f
17199557|NCT02417441|f||OTHER||t
17199558|NCT01951768|t||||
17199559|NCT03080142|t||||
17199560|NCT00983853|f||GT60||t
17199561|NCT00485953|t||||
17199562|NCT05034939|f||||f
17199563|NCT02947100|t||||f
17199564|NCT02402322|f||||f
17199565|NCT05400837|f||||f
17157052|NCT03564795|f||||f
17157053|NCT02906033|t||||
17167431|NCT03555981|t||||
17167432|NCT03989427|f||||f
17167433|NCT02563860|f||||f
17167434|NCT02754141|f||LTE60||t
17167435|NCT03361189|t||||
17167436|NCT03617536|f||||t
17167437|NCT03344549|t||||
17167438|NCT02323126|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17199566|NCT02472145|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17199567|NCT01080326|t||||
17199568|NCT01318876|f||||f
17199569|NCT01296555|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199570|NCT00409409|f||||f
17199571|NCT01200498|t||||
17199572|NCT00820664|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199573|NCT03635086|f||LTE60||t
17157054|NCT00770133|f||OTHER|Contact sponsor directly for details.|t
17157055|NCT00889187|f||||f
17157056|NCT01333956|t||||
17167439|NCT03333252|t||||
17167440|NCT00108303|t||||
17167441|NCT00666588|f||LTE60||t
17199574|NCT03000348|f||||f
17199575|NCT04042077|f||GT60||t
17199576|NCT01367444|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17199577|NCT00521976|f||LTE60||t
17199578|NCT00513747|f||||t
17199579|NCT00884897|f||||f
17199580|NCT01236352|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157057|NCT00432276|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17157058|NCT05530980|f||||f
17157059|NCT01801241|f||||f
17157060|NCT00756600|f||||f
17157061|NCT03240406|t||||
17157062|NCT02360475|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157063|NCT00316862|f||LTE60||t
17157064|NCT02978885|t||||
17157065|NCT01764659|t||||
17157066|NCT00628927|f||||f
17157067|NCT02440854|t||||
17157068|NCT02669082|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17157069|NCT04852276|t||||
17157070|NCT01463358|f||||f
17157071|NCT04103034|f||||f
17157072|NCT00316914|t||||
17157073|NCT04105010|f||GT60||t
17157074|NCT05873335|f||||f
17157075|NCT01075399|f||||f
17157076|NCT01179737|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17157077|NCT01881087|f||||f
17157078|NCT03329248|f||||t
17157079|NCT00987402|f||||f
17157080|NCT01254721|f||LTE60||t
17157081|NCT01996657|t||||
17157082|NCT03597022|f||OTHER||t
17157083|NCT03878875|t||||
17157084|NCT02614131|f||GT60||t
17199581|NCT01545557|f||OTHER|Any intent of Institution and Investigator/Researcher to publish or disclose in any way Information requires Sponsor's prior written approval. Investigator/Researcher shall provide his draft of such publication to Sponsor for review and approval at least two months prior to the date of intended publication. Sponsor hereby agrees he shall endeavour to preserve accuracy of results in authorized publications and negative as well as positive results shall be published or made publicly available.|t
17199582|NCT01963169|f||||f
17199583|NCT04101565|f||||f
17199584|NCT04913948|t||||
17199585|NCT02353312|f||||f
17199586|NCT01068210|t||||
17199587|NCT05990387|f||||f
17199588|NCT04750577|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17199589|NCT04980378|f||OTHER|Publication results vary per investigator and per clinical trial agreement.|t
17199590|NCT03371823|t||||
17199591|NCT02145169|t||||
17157085|NCT03209518|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17157086|NCT00236899|f||GT60||t
17157087|NCT00798018|t||||
17157088|NCT03014622|f||OTHER|With respect to any proposed publication or disclosure of the results of the Study, the Study Center and Investigator shall submit to Revance a copy of the proposed publication or disclosure at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i) to provide Revance with the opportunity to review and comment on the contents thereof, and (ii) to identify any Confidential Information to be deleted from the proposed publication or disclosure.|t
17182006|NCT00500292|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17182007|NCT01025427|f||||f
17182008|NCT01017237|t||||
17199592|NCT01263054|f||||f
17199593|NCT00668785|f||||f
17199594|NCT04243512|f||||f
17199595|NCT02035696|f||LTE60||t
17199596|NCT00966264|t||||
17199597|NCT01246999|f||||f
17199598|NCT01867047|t||||
17199599|NCT00349466|f||||f
17199600|NCT01536587|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199601|NCT02354651|f||||f
17199602|NCT01515943|f||||f
17199603|NCT05224843|f||||f
17199604|NCT03415243|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157089|NCT00568334|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157090|NCT01897571|f||GT60||t
17157091|NCT00939471|f||OTHER|Scientific Publications Reporting results initiated only by SPONSOR. Sites may not publish single center results before aggregate results. Drafts of abstracts, etc. must be submitted to SPONSOR for review at least sixty (60) days prior to submission for publication. Investigator(s) shall delay submission for up to 90 days to permit patent application filing or shall redact paper to remove language detrimental to SPONSOR's intellectual property interests.|t
17157092|NCT01797094|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157093|NCT02203162|t||||
17157094|NCT00625404|t||||
17157095|NCT03217968|f||OTHER|"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted to the sponsor for review. Sponsor may request:~* deletion of any trade secret, proprietary, or confidential information of Sponsor~* an additional 90 days to take measures to preserve its Intellectual Property rights"|t
17157096|NCT02447575|f||||f
17157097|NCT00306787|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157098|NCT03913104|f||||f
17157099|NCT01897792|t||||
17157100|NCT01361867|f||||f
17157101|NCT05656885|f||||t
17157102|NCT01593254|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157103|NCT02366403|t||||f
17157104|NCT03013985|t||||
17157105|NCT01887678|f||OTHER|Investigator agreements in place restricting the PI from independently publishing the study results.|t
17157106|NCT01044589|f||||f
17157107|NCT00791492|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157108|NCT02410213|f||||f
17157109|NCT02322333|f||||t
17182009|NCT00828191|f||||f
17182010|NCT00799578|f||||f
17167442|NCT02075047|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167443|NCT03552536|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17167444|NCT01235923|t||||
17167445|NCT00457977|f||||f
17167446|NCT00773786|t||||
17167447|NCT04195438|t||||
17167448|NCT00585494|t||||
17167449|NCT03061721|f||||f
17167450|NCT03447314|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167451|NCT02309645|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17167452|NCT00405509|t||||
17167453|NCT04600076|t||||
17167454|NCT03006458|f||||f
17167455|NCT01468233|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17167456|NCT00457821|f||GT60||t
17167457|NCT00842946|f||||f
17167458|NCT00578877|f||OTHER|"Data obtained from a clinical trial in which 2 or more research centers participate cannot be published or presented by any of the individual investigators before the end of the clinical trial. Only after publication of the pooled results can data from individual centers be published.~When the Principal Investigator wishes to write a paper using data collected from his or her own center, the Recipient Institution agrees to allow CONRAD and USAID the opportunity to review \& provide comments."|t
17167459|NCT02139878|f||||f
17167460|NCT02305017|f||OTHER||t
17167461|NCT02437409|f||OTHER|"Data must only be published after completion of the study. Publication of e.g. single center experience within the study is not allowed until the aggregate data have been submitted.~All information and data generated in association with this study will be held in strict confidence and remain in the sole property of phenox GmbH. The investigator agrees to use this information for the sole purpose of completing this study and for no other purpose without written consent from phenox GmbH."|t
17167462|NCT01632241|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167463|NCT03296137|t||||
17167464|NCT05131971|t||||f
17167465|NCT05032690|t||||f
17167466|NCT04926831|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167467|NCT01687088|f||||f
17167468|NCT00737568|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167469|NCT00855933|f||GT60||t
17167470|NCT01960998|f||||f
17199605|NCT01245140|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199606|NCT04836559|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17199607|NCT02635360|f||||f
17199608|NCT04978350|t||||
17199609|NCT02078726|t||||
17199610|NCT05765435|t||||
17199611|NCT01597843|t||||
17199612|NCT02701062|f||OTHER|Before publishing or presenting, PI shall submit copies to Sponsor at least 60 days in advance. If Sponsor makes a good faith determination within such period that this release would be detrimental to its or its affiliates' intellectual property interests, PI shall refrain from publishing for another 90 days to allow Sponsor to file patent applications or take other steps to protect interests. Alternatively, these sections and/or inaccurately reported results may be redacted or modified.|t
17199613|NCT05252845|t||||
17199614|NCT00781937|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, e.g. a clinical trial report is available, including right to not release interim trial results, because this may lead to conclusions later shown to be incorrect. At trial end, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17199615|NCT04698915|f||LTE60||t
17199616|NCT01150045|f||GT60||t
17199617|NCT03124693|f||LTE60||t
17199618|NCT01790295|f||||f
17199619|NCT01908751|t||||f
17199620|NCT02489734|t||||
17199621|NCT00420784|f||GT60||t
17199622|NCT03603639|f||||t
17199623|NCT00607672|f||||f
17199624|NCT03016598|t||||
17157110|NCT00076999|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17157111|NCT05821296|f||OTHER|There is an agreement between Dermosciences France and the Clinical Research Organization who contracted the PI. Clinical Research Organization expressly agreed that any results communication must be submitted in advanced to Dermosciences France for approval.|t
17157112|NCT01115556|t||||
17157113|NCT02648477|t||||
17167471|NCT01713283|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167472|NCT02403635|f||||f
17167473|NCT03088748|f||||f
17157114|NCT00713661|f||OTHER|After publication of the results or 24 months after Clinical Trial Report has been finalised, whichever comes first, Nycomed acknowledge the Investigator's rights to publish results from this trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted to Nycomed prior to submission for publication/presentation for review. Review comments will be given within a month from receipt of the manuscript.|t
17157115|NCT03083769|t||||
17157116|NCT02603562|f||||t
17157117|NCT00438802|t||||
17157118|NCT05749068|f||||f
17157119|NCT04493151|f||||f
17157120|NCT02117713|f||||t
17157121|NCT00574795|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17157122|NCT00678470|t||||
17167474|NCT01904149|f||OTHER|Prior to submitting the results of this study for publication or presentation, the PI will allow the Sponsor at least 60 days to review and comment upon the publication manuscript. The Sponsor will provide any manuscript of the results of this study at least 60 days before publishing to the authors for a complete review.|t
17167475|NCT00835640|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17167476|NCT00812006|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167477|NCT00068250|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17182011|NCT00856908|f||OTHER|CONTRACT RESEARCH ORGANIZATION AGREEMENT by and between ASTRAZENECA AB and the CRO. CRO agrees that AstraZeneca shall have the exclusive right to publish the results of the Study, including all Work Product, and that such results may not be published or otherwise disseminated by CRO without the prior written approval of AstraZeneca.|t
17157123|NCT00586508|f||GT60||t
17157124|NCT05822648|t||||
17157125|NCT01863498|t||||
17157126|NCT05249127|f||OTHER|Study results may only be published by the principal investigator / institution following the first multi-site publication. The proposed publication will be submitted to Sponsor at least 90 days prior to submission to the publication to allow the Sponsor to delete Sponsor Confidential Information (other than Study results), correct any inaccuracies or delay the publication to allow for filing of patent applications.|t
17167478|NCT00235391|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167479|NCT03349645|f||||t
17167480|NCT02956044|f||||f
17167481|NCT00580034|t||||f
17167482|NCT00750191|f||LTE60||t
17167483|NCT00098748|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167484|NCT02023801|f||||f
17167485|NCT02538419|t||||
17167486|NCT01081301|t||||
17157127|NCT02073565|f||||t
17157128|NCT03646305|f||||f
17157129|NCT03417024|f||||f
17157130|NCT03168919|t||||
17157131|NCT04015518|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157132|NCT02195427|f||GT60||t
17157133|NCT00386425|f||GT60||t
17157134|NCT02604173|t||||
17157135|NCT01324570|f||GT60||t
17157136|NCT00207727|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167487|NCT00101816|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167488|NCT03551665|f||||f
17167489|NCT05538312|t||||
17167490|NCT03614416|f||||f
17150652|NCT02566993|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17167491|NCT00428220|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182012|NCT00962104|f||GT60||t
17199625|NCT00996502|f||||f
17199626|NCT04593823|f||||f
17199627|NCT00742326|t||LTE60||t
17199628|NCT03218566|f||LTE60||t
17199629|NCT00443209|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17199630|NCT01628692|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199631|NCT01653210|t||||
17199632|NCT02196077|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17199633|NCT03316807|f||||f
17199634|NCT02046512|f||||f
17199635|NCT02781311|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199636|NCT01056263|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199637|NCT01262092|t||||
17199638|NCT03771638|f||||f
17199639|NCT00699842|t||||
17199640|NCT03023423|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150653|NCT02356003|f||||f
17150654|NCT01912274|f||||f
17150655|NCT01708590|f||OTHER||t
17150656|NCT03127644|f||||f
17150657|NCT02032706|t||||f
17150658|NCT04972123|t||||
17150659|NCT00893737|f||OTHER|Publication of Results is specifically authorized, subject to the provisions of STUDY AGREEMENT. INVESTIGATOR is free to publish Results of its part of study in collaboration with other investigators, but in compliance with confidentiality agreement and subsequent to full study publication issued by CLINVEST. INVESTIGATOR agrees to submit a copy of any results communication to CLINVEST for review and comment 60 days prior to submission for publication.|t
17150660|NCT01156142|t||||
17137309|NCT03057951|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137310|NCT02064205|f||||f
17137311|NCT00680953|f||OTHER|Principal Investigator shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17137312|NCT00696436|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17137313|NCT02282982|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137314|NCT02062463|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17137315|NCT00707655|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17157137|NCT05362695|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17157138|NCT00539032|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17157139|NCT00435019|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17157140|NCT01669785|f||LTE60||t
17157141|NCT00422292|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17157142|NCT04607980|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157143|NCT00727090|f||LTE60||t
17157144|NCT01833936|f||||f
17157145|NCT02824562|f||||f
17157146|NCT01709864|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157147|NCT01520519|t||||
17157148|NCT00525876|t||||
17137316|NCT03353753|f||OTHER|Neither Institution nor Investigator will submit for publication or public disclosure any publication or disclosure based on the results of the Study until after the first to occur of (a) publication of the Multi-Center Clinical Trial results; (b) notification by Sponsor that the Multi-Center Clinical Trial submission is no longer planned; or (c) the 12 month anniversary of the completion or early termination of the Multi-Center Clinical Trial.|t
17137317|NCT02979301|f||||f
17137318|NCT00363051|f||OTHER|The terms and conditions of Novartis's agreements with it's investigators vary. However, Novartis does not prohibit any investigator from publishing. Any publication from a single-center site is postponed until the publication of the pooled data ( i.e. data from all sites) in the clinical trial.|t
17157149|NCT01313221|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157150|NCT00994214|f||||f
17157151|NCT02217800|f||||f
17157152|NCT00632632|t||||
17157153|NCT01698268|f||||f
17157154|NCT00298363|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157155|NCT00153816|f||||f
17157156|NCT03278847|f||||f
17157157|NCT05916131|t||||
17157158|NCT02289105|t||||f
17157159|NCT01586871|t||||f
17157160|NCT00935064|f||||f
17157161|NCT03943823|t||||
17157162|NCT01211483|f||||f
17157163|NCT00427999|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157164|NCT02380859|t||||
17157165|NCT02284568|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17157166|NCT00412217|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157167|NCT00365209|f||LTE60||t
17157168|NCT03114657|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157169|NCT01546038|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157170|NCT01398410|f||OTHER||t
17157171|NCT04245202|f||||f
17157172|NCT04742309|f||||f
17157173|NCT04344535|t||||
17157174|NCT01069315|f||||f
17157175|NCT01362517|f||OTHER|The investigator to submit all manuscripts/abstracts to the sponsor for review at least 60 days prior to any intended submission.|t
17157176|NCT00416793|f||LTE60||t
17199641|NCT03512197|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17199642|NCT03842436|f||||f
17199643|NCT01806389|f||||f
17199644|NCT01688310|f||||f
17199645|NCT01310699|f||||f
17199646|NCT00936598|t||||f
17199647|NCT00926575|f||OTHER||t
17199648|NCT01939301|f||||t
17199649|NCT00490698|t||||f
17199650|NCT02201901|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17199651|NCT01907269|f||||f
17199652|NCT01654068|f||||f
17157177|NCT03379792|f||||f
17157178|NCT01121536|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17157179|NCT03924505|t||||f
17199653|NCT03358238|t||||
17157180|NCT02854605|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157181|NCT01010399|t||||
17157182|NCT05268016|f||OTHER||t
17157183|NCT02273908|f||||f
17157184|NCT04908475|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157185|NCT00404924|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17157186|NCT03303391|f||||f
17157187|NCT00089635|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157188|NCT02477709|f||OTHER|60 days prior to the submission of any results, the PI shall submit to SPONSOR any proposed PUBLICATION, which period may be extended for an additional 30 days if requested by SPONSOR. If any Confidential Information should be redacted or patent applications relating to an Invention should be filed prior to PUBLICATION, then PUBLICATION will be delayed until patent application has been filed. Delay of a PUBLICATION shall not exceed 24 months from the date of such notice to the PI.|t
17157189|NCT00821015|t||||
17157190|NCT00456261|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17157191|NCT04482036|f||||f
17157192|NCT04964986|f||||t
17157193|NCT01857102|f||GT60||t
17157194|NCT01490697|t||||
17157195|NCT05604794|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17157196|NCT00090584|f||||f
17157197|NCT00270231|f||||f
17157198|NCT00497770|f||GT60||t
17157199|NCT03409120|f||||f
17157200|NCT00796744|f||OTHER|The sponsor prepared an integrated clinical/statistical report. As this was a multicenter study, any publication/presentation of data was to include the entire study population. Publication/presentation of data from individual study centers is not allowed without explicit permission from US Biotest.|t
17157201|NCT04208321|f||||t
17157202|NCT01889355|f||||f
17157203|NCT00467961|t||||f
17157204|NCT03759366|f||||t
17167492|NCT01065051|f||OTHER|The Investigative Site, Institution and/or Principal Investigator shall furnish the Sponsor with a copy of any proposed publication of material described in Clinical Trial Agreement at least sixty (60) days in advance of the date of submission for publication or presentation. Within sixty (60) day period, the Sponsor shall: review such proposed publication for any patentable subject matter or designated Confidential Information, which the Sponsor may have furnished to facilitate the study.|t
17167493|NCT02068846|t||||
17157205|NCT00597012|f||||f
17157206|NCT04226495|t||||
17157207|NCT03403621|t||||
17157208|NCT00583102|t||||
17157209|NCT03557684|t||||
17157210|NCT02168777|f||OTHER|Written consent must be obtained from Bayer prior to any information being submitted for publication. Material proposed for publication or presentation must be provided to Bayer at least 60 days prior to submission.|t
17167494|NCT03283098|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17167495|NCT03440723|f||||f
17167496|NCT03356977|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167497|NCT01545232|f||||f
17167498|NCT02043197|f||||f
17167499|NCT01246479|f||GT60||t
17167500|NCT00445939|f||OTHER|Disclosure agreements vary; most restrictive agreement states Medical Institution shall not disclose materials/information disclosed by Abbott Japan in connection with the Clinical Research, or information obtained by conducting the Clinical Research, to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting the Clinical Research, Medical Institution shall obtain Abbott Japan's prior written approval.|t
17167501|NCT02154048|t||||f
17167502|NCT00798317|f||OTHER|Varying agreements. The most restrictive is as follows: The Centre and Investigator agree to neither publish nor make public any of the results of the Study without the prior written consent from Sponsor, which consent shall not be unreasonably withheld.|t
17167503|NCT00378599|f||OTHER|Lead investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. Lead investigator further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication, which report any results of the Study. Sponsor shall have the right to review and comment on any presentation, including editorial rights.|t
17167504|NCT00416715|t||||
17167505|NCT03333317|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17167506|NCT00489736|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such publication for comment at least 45 days before any submission for publication. If requested by the Sponsor, any submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17167507|NCT03812185|f||||f
17167508|NCT01294306|f||LTE60||t
17167509|NCT04028765|f||||f
17167510|NCT04857437|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167511|NCT03515226|t||||f
17167512|NCT02576535|t||||
17167513|NCT02545517|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167514|NCT03010137|t||||
17167515|NCT01529515|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. if requested in writing, such publication will be withheld for up to an additional 60 days.|t
17167516|NCT01706497|t||||
17167517|NCT03920293|f||||t
17167518|NCT01069861|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167519|NCT00504504|t||||f
17167520|NCT03272828|f||||f
17167521|NCT02002936|f||||f
17157211|NCT05243563|t||||
17157212|NCT02697916|f||||f
17157213|NCT03774394|t||||
17157214|NCT03334422|f||GT60||t
17157215|NCT02864316|f||||f
17157216|NCT04710368|t||||
17157217|NCT00135356|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157218|NCT01887288|t||||
17157219|NCT01692002|t||||
17157220|NCT00253370|f||LTE60||t
17157221|NCT02470403|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157222|NCT04812795|t||||
17157223|NCT00904839|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17157224|NCT01430624|f||||f
17157225|NCT01688141|f||||f
17157226|NCT01167634|f||||f
17157227|NCT00553358|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17157228|NCT03887429|f||||t
17157229|NCT02147067|t||||
17157230|NCT01074255|f||OTHER|If an investigator intends to publish trial results in an academic journal, prior consent of the sponsor must be obtained.|t
17157231|NCT02943785|f||||f
17137319|NCT00131677|f||OTHER|All presentations and publications of data from CDC funded studies are subject to CDC clearance prior to publication or presentation.|t
17137320|NCT00205699|f||||f
17137321|NCT02574858|f||||f
17157232|NCT02603107|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157233|NCT04103515|f||||f
17157234|NCT03170609|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157235|NCT01281956|t||||
17157236|NCT02572856|f||||f
17167522|NCT00996281|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167523|NCT03505788|f||||f
17167524|NCT01920568|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199654|NCT01227616|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17199655|NCT04277507|f||LTE60||t
17199656|NCT01431950|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199657|NCT02884492|t||||
17199658|NCT04577573|t||||
17199659|NCT06719986|f||LTE60||t
17199660|NCT06915285|t||||
17199661|NCT05992922|f||||f
17199662|NCT04596995|f||GT60||t
17199663|NCT03445793|f||||f
17199664|NCT00590564|t||||
17199665|NCT01434680|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17199666|NCT02833805|f||||f
17199667|NCT00983749|f||||f
17199668|NCT01952847|t||||
17199669|NCT01907906|f||LTE60||t
17199670|NCT00708851|f||||f
17199671|NCT00121667|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199672|NCT01453023|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199673|NCT02879383|f||GT60||t
17199674|NCT02018653|t||||
17157237|NCT00419159|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157238|NCT02051335|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17157239|NCT00187278|f||LTE60||t
17157240|NCT02735096|f||||f
17199675|NCT02677870|f||||f
17199676|NCT03343093|t||||
17199677|NCT00325598|t||||
17137322|NCT03225716|f||||f
17157241|NCT04779606|f||||f
17157242|NCT02638259|f||OTHER|Terms related to publication are part of the contract templates between Sponsor and sites/investigators. In general, these terms outlined that authorship of any publications relating to the clinical study shall be determined by agreement with the Sponsor. Sponsor reserves the right to request amendments or deletions to proposed publications, or request that any publication or presentation be delayed up to four months. A very limited number of exceptions can be granted to modify these terms.|t
17157243|NCT02569086|t||||
17167525|NCT04599959|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17167526|NCT01933230|f||||f
17167527|NCT02891681|t||||
17167528|NCT06276881|t||||
17167529|NCT00856206|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17167530|NCT04584346|t||||
17167531|NCT00358332|f||LTE60||t
17167532|NCT00534118|t||||
17167533|NCT02780856|f||GT60||t
17167534|NCT03640052|f||||f
17167535|NCT04422561|t||||
17167536|NCT05039671|t||||f
17167537|NCT04239222|f||LTE60||t
17167538|NCT05494736|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17167539|NCT04762043|t||||
17167540|NCT00090233|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199678|NCT05288829|f||||t
17199679|NCT02413593|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17199680|NCT00723125|f||||f
17199681|NCT01512797|f||||f
17137323|NCT01114373|t||||
17137324|NCT01827930|f||||f
17137325|NCT01653158|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137326|NCT00421603|t||||f
17167541|NCT04863248|f||||f
17167542|NCT01691105|f||||f
17167543|NCT03232645|f||||f
17167544|NCT02480166|f||||f
17167545|NCT00803517|f||||f
17167546|NCT04420572|f||||f
17167547|NCT00790647|t||||
17199682|NCT01895036|f||||f
17199683|NCT03482752|f||||f
17199684|NCT04947514|t||||
17199685|NCT01080300|f||OTHER|"The PI agrees that sponsor shall have the right to first publication of study results which is intended to be a joint, multi-center publication. Following first publication, the PI may publish study data or results, provided however PI submits proposed publication to sponsor for review at least 60 days prior to the date of proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary other than study data.~ACCEPTED FOR PUBLICATION IN MENOPAUSE."|t
17199686|NCT01807182|t||||
17199687|NCT01776008|f||LTE60||t
17199688|NCT00813982|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.|t
17199689|NCT04458818|f||||f
17199690|NCT03513068|f||||f
17137327|NCT00765128|t||||
17167548|NCT02701777|t||||
17167549|NCT00445211|f||||f
17167550|NCT03549871|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17167551|NCT01644695|t||||f
17199691|NCT00478205|f||||f
17157244|NCT04299048|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157245|NCT01706575|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157246|NCT02952872|f||||f
17199692|NCT00405938|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17199693|NCT00003477|f||||f
17199694|NCT01575873|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17199695|NCT01850030|f||OTHER|"At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow sponsor sixty (60) days to review and comment on them.~If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials."|t
17199696|NCT00762476|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period 1 year after study completion.|t
17199697|NCT02266342|f||||f
17199698|NCT00965497|f||||f
17199699|NCT01267240|f||LTE60||t
17199700|NCT02638103|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17199701|NCT02037620|f||||f
17199702|NCT01031498|t||||
17199703|NCT01827046|f||||f
17157247|NCT02536781|f||||f
17157248|NCT03423147|t||||
17157249|NCT02069093|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17199704|NCT02734004|f||||t
17199705|NCT01294436|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17199706|NCT02482610|f||||f
17199707|NCT02296892|f||OTHER|At least 30 days prior to submission of communications, sponsor shall review and comment on the communications. Sponsor shall have the right to require institution and investigator to remove specifically identified confidential information and to delay the proposed publication an additional 45 days to enable sponsor to seek patent protection.|t
17199708|NCT00585078|f||||f
17199709|NCT01018732|f||GT60||t
17157250|NCT02028169|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157251|NCT02258334|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17157252|NCT01969084|f||||f
17199710|NCT01536171|f||||f
17199711|NCT04198571|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199712|NCT04253119|f||OTHER||t
17199713|NCT02165826|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17199714|NCT02562898|t||||
17199715|NCT01936467|f||||f
17199716|NCT01774045|f||||f
17199717|NCT04547023|t||||
17199718|NCT00250432|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199719|NCT01011868|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17199720|NCT03784820|t||||
17199721|NCT00794170|f||||f
17199722|NCT00658606|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17199723|NCT06314438|t||||
17199724|NCT00365547|t||||
17199725|NCT03170518|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17199726|NCT04428476|f||||f
17199727|NCT00546078|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199728|NCT02325830|f||LTE60||t
17199729|NCT02314689|t||||
17199730|NCT01261247|t||||
17199731|NCT02559310|f||OTHER|All data from the study is confidential information. Sponsor has the right to publish first. Thereafter, PI may publish data from the study, but PI must submit the publication to Sponsor for review at least 60 days prior to publication. Sponsor may remove any confidential and/or proprietary information. If Sponsor's publication is not submitted within 12 months after the study, or if Sponsor decides not to publish, PI may publish the data, subject to Sponsor's rights in the agreement.|t
17199732|NCT01740154|t||||
17199733|NCT00551746|t||||f
17199734|NCT03267810|f||||f
17199735|NCT00624910|f||||f
17157253|NCT00862459|f||OTHER|Publication of results will be a group publication. Sites with recruitment of \>= 6 valid patients will contribute. There will be one author from each site having contributed \>= 6 valid patients. Authorship listed according to recruitment. Sponsor will appoint up to 3 persons as co-authors. Main author of publication may be announced by site with most valid patients enrolled. In case more than 1 center reaches maximum patient No., main author will be from the center with fastest recruitment|t
17157254|NCT01236326|t||||
17157255|NCT04776018|f||||t
17157256|NCT00326170|t||||
17157257|NCT02908074|f||||f
17157258|NCT00093847|f||||f
17157259|NCT02436031|t||||
17157260|NCT02655419|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17199736|NCT02737826|f||||f
17199737|NCT00129935|f||LTE60||t
17199738|NCT02783573|f||OTHER|The sponsor shall review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17199739|NCT00159263|t||||
17199740|NCT01012245|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199741|NCT02797522|f||||f
17199742|NCT00725712|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199743|NCT03020069|t||||
17199744|NCT01475305|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17199745|NCT00132678|f||GT60||t
17199746|NCT00953147|f||OTHER||t
17199747|NCT01367847|t||||f
17199748|NCT02056626|t||||
17199749|NCT00863512|f||LTE60||t
17199750|NCT00078338|f||OTHER||t
17199751|NCT02037477|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17199752|NCT01673022|f||||f
17199753|NCT01454739|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17199754|NCT01784523|f||||f
17199755|NCT05146206|t||||
17199756|NCT02577003|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17199757|NCT02786004|f||||f
17199758|NCT01677299|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17199759|NCT04312256|t||||
17199760|NCT00559377|f||LTE60||t
17199761|NCT00940875|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199762|NCT00490945|f||||f
17199763|NCT03334253|f||||f
17199764|NCT00203047|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17199765|NCT01580904|t||||
17199766|NCT00872001|f||OTHER|"The investigator agrees not to publish or publicly present any interim results~of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media that report any study results)."|t
17157261|NCT03053427|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17157262|NCT03816644|f||||f
17157263|NCT02172040|f||GT60||t
17157264|NCT02607306|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17157265|NCT00505661|t||||f
17157266|NCT01093651|f||||f
17157267|NCT03611582|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17199767|NCT00340704|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17199768|NCT00980642|t||||
17199769|NCT05020145|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199770|NCT02239744|t||||
17199771|NCT00246090|f||||f
17199772|NCT02595372|t||||
17199773|NCT00953615|t||||f
17199774|NCT01299480|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199775|NCT02389764|t||||
17199776|NCT00583947|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17199777|NCT00738283|t||||
17199778|NCT00869947|t||||
17199779|NCT00486252|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17199780|NCT01210651|f||||f
17199781|NCT01976572|f||OTHER||t
17199782|NCT02592707|f||OTHER||t
17199783|NCT00469859|f||OTHER|Must obtain prior Sponsor approval.|t
17199784|NCT04855734|t||||f
17199785|NCT02520310|f||||t
17199786|NCT01340014|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17199787|NCT03790306|t||||
17199788|NCT01769430|t||||
17199789|NCT04535544|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17199790|NCT01754987|t||||
17199791|NCT05131477|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17199792|NCT02194829|f||LTE60||t
17199793|NCT01124838|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199794|NCT04297618|f||||f
17199795|NCT04581343|f||GT60||t
17199796|NCT02726945|f||||f
17199797|NCT03728985|f||OTHER|Institution and Investigator must wait until after the multi-center manuscript is published. Investigator will provide all Publications to allow the sponsor to review at least 60 days in advance of submission for publication or other public disclosure to suggest any modifications to protect proprietary information, and extend (as applicable) if filing a patent application.|t
17199798|NCT01882413|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199799|NCT00554996|t||||
17199800|NCT02560753|f||||f
17199801|NCT02172911|f||OTHER||t
17199802|NCT00580489|t||||
17199803|NCT01606319|f||||f
17199804|NCT04646369|t||||
17199805|NCT01124097|f||OTHER||t
17157268|NCT04459598|f||||f
17157269|NCT01078298|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157270|NCT00463840|t||||
17157271|NCT00866333|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17157272|NCT01653327|t||||
17157273|NCT01738191|t||||
17157274|NCT02243046|f||GT60||t
17157275|NCT03338569|t||||
17157276|NCT01051440|f||||f
17157277|NCT02109445|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157278|NCT00441363|t||||
17157279|NCT01043094|f||OTHER|PI not to publish.|t
17157280|NCT02474355|f||OTHER||t
17157281|NCT01066793|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157282|NCT01911793|f||||f
17199806|NCT01821937|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17199807|NCT02153905|f||||f
17199808|NCT00193479|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17199809|NCT01304498|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17199810|NCT00894504|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17199811|NCT01834586|t||||
17199812|NCT01667549|f||||f
17199813|NCT04210843|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17199814|NCT02844777|f||||f
17199815|NCT00150618|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17199816|NCT01012947|f||||f
17199817|NCT01791413|t||||
17157283|NCT01533688|f||||f
17157284|NCT04591015|f||||f
17157285|NCT02509078|f||OTHER|In addition to the restriction on the PI for sponsor to review results prior to public release within 60 days, there is a network provision: The Publications Committee of the PETAL Network must review and approve all pre-submission PETAL Network studies before publication or presentation. Manuscripts comparing outcomes of PETAL study endpoints from one center to the reminder of the group are not permitted.|t
17157286|NCT02686814|f||||t
17157287|NCT00290693|t||||
17157288|NCT02907619|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157289|NCT04400656|t||||
17157290|NCT01450072|f||||f
17157291|NCT02370056|f||||f
17157292|NCT04942210|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17157293|NCT03749499|f||||f
17157294|NCT03688802|f||||t
17157295|NCT05697627|f||||f
17157296|NCT02570750|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157297|NCT01410240|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤60 days(e.g., for intellectual property protection)|t
17157298|NCT00791037|t||||f
17157299|NCT00998205|t||||
17157300|NCT02553798|f||||t
17157301|NCT00983541|t||||
17157302|NCT02722746|t||||
17199818|NCT00855413|t||||
17199819|NCT00825305|f||LTE60||t
17199820|NCT04016272|f||||f
17199821|NCT03617289|f||||f
17199822|NCT02493946|f||||t
17199823|NCT03355209|f||GT60||t
17199824|NCT05000047|t||||
17157303|NCT03706469|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17157304|NCT02635009|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17157305|NCT02636699|f||||t
17157306|NCT05869864|f||||f
17157307|NCT01134263|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17157308|NCT01973335|f||||f
17157309|NCT00506714|f||||f
17157310|NCT02305446|f||GT60||t
17157311|NCT01636947|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17157312|NCT00957424|f||||f
17157313|NCT01004718|t||||
17157314|NCT02343380|f||||f
17199825|NCT01727505|f||||f
17199826|NCT02878603|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17199827|NCT00358644|f||||f
17199828|NCT03327831|t||||
17199829|NCT02838134|f||||f
17199830|NCT04674189|f||||t
17199831|NCT03981939|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17199832|NCT01564277|t||||
17199833|NCT01637077|f||||f
17199834|NCT00794924|f||||f
17199835|NCT01594970|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199836|NCT03053453|t||||
17157315|NCT00369161|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or publication of the trial results in their entirety.|t
17157316|NCT00750919|f||LTE60||t
17157317|NCT02612688|f||||f
17157318|NCT03763058|f||||f
17157319|NCT02445859|t||||
17157320|NCT01404949|t||||
17157321|NCT00032630|t||||
17157322|NCT03411902|t||||
17157323|NCT01017601|f||LTE60||t
17157324|NCT00803205|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17157325|NCT00379808|f||||f
17157326|NCT01432561|f||||f
17157327|NCT03092934|f||GT60||t
17157328|NCT04907227|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17157329|NCT02240069|f||||f
17157330|NCT03723070|f||||f
17157331|NCT01810783|f||||f
17157332|NCT02770768|t||||
17157333|NCT02208050|t||||
17157334|NCT02134353|f||||f
17157335|NCT00824434|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 40 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17157336|NCT00477607|t||||f
17157337|NCT00474786|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157338|NCT00358956|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17157339|NCT01238341|t||||
17157340|NCT00499343|t||||
17157341|NCT02578940|f||||f
17157342|NCT04513899|f||||f
17157343|NCT00445744|f||||f
17157344|NCT03724084|f||LTE60||t
17199837|NCT03332784|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17199838|NCT03306420|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17199839|NCT02498236|f||||f
17199840|NCT00383123|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199841|NCT01814072|f||||f
17199842|NCT02336425|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17199843|NCT00978562|t||||f
17199844|NCT01782690|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199845|NCT04121897|t||||
17199846|NCT04946942|t||||
17199847|NCT04907357|f||||f
17199848|NCT01948076|t||||
17199849|NCT03995225|t||||
17157345|NCT03319810|f||||f
17157346|NCT05182606|t||||
17157347|NCT01294748|f||LTE60||t
17157348|NCT01955109|f||||t
17157349|NCT02600767|f||||f
17157350|NCT01618916|f||GT60||t
17157351|NCT04521114|t||||
17157352|NCT02867202|t||||
17157353|NCT00438256|t||||
17157354|NCT01133288|f||||f
17157355|NCT01918072|t||||
17157356|NCT03292471|t||||
17157357|NCT02865811|t||||
17157358|NCT00911586|f||||t
17157359|NCT02555930|t||||
17157360|NCT00380718|f||GT60||t
17157361|NCT01094782|t||||f
17157362|NCT02912455|t||||
17157363|NCT01712308|t||||
17157364|NCT03725033|f||||t
17157365|NCT02230540|f||OTHER|Investigators who want to publish/present results based on own data from a Coloplast-sponsored investigation, must send the publication/presentation to sponsor for review 60 days prior to submission. Sponsor reserves the right to delay publications to avoid compromising intellectual property. Publications of sub-analyses may be delayed by sponsor until main results of investigation have been published.|t
17157366|NCT00957905|f||LTE60||t
17157367|NCT02073656|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157368|NCT01938989|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157369|NCT02638051|f||||f
17157370|NCT04292639|f||||f
17157371|NCT01048099|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17157372|NCT00508157|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157373|NCT04164004|f||||f
17157374|NCT01625689|f||LTE60||t
17157375|NCT00106639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157376|NCT05011890|t||||
17157377|NCT00594386|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17167552|NCT01133626|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17167553|NCT00561002|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17199850|NCT00569192|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17199851|NCT00691600|f||||f
17199852|NCT04124471|f||||f
17157378|NCT03260426|f||||f
17157379|NCT01210144|f||OTHER||t
17157380|NCT02664922|t||||
17157381|NCT00094536|f||||f
17199853|NCT05226130|t||||
17157382|NCT00494221|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17157383|NCT00732680|t||||f
17157384|NCT03040427|f||||f
17157385|NCT01900431|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17199854|NCT03358472|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17167554|NCT03298984|f||||f
17199855|NCT03732677|f||||t
17157386|NCT03755518|f||LTE60||t
17199856|NCT04013971|t||||
17157387|NCT03172364|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157388|NCT01714609|t||||
17167555|NCT02851407|f||||f
17199857|NCT05853900|t||||f
17199858|NCT03429166|t||||
17199859|NCT00344032|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199860|NCT03746509|f||||f
17199861|NCT02706249|f||||f
17157389|NCT00630747|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤ 180 days from the time submitted to Shire for review. Shire does not prohibit publication but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17157390|NCT03858894|f||OTHER|Site/Investigator is not permitted to publish results communications without Santen's consent until after a period of sixty (60 days) for Santen review/comment. Santen may request removal of any Confidential Information (other than Study results) from manuscripts or materials prior to submission or presentation. At Santen's request Site/Investigator has to withhold any publication if there is a patentable invention until such time as Santen is able to secure adequate patent protection.|t
17157391|NCT02306694|t||||
17157392|NCT00603382|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157393|NCT00395642|f||OTHER|The investigator agrees to submit copies of any proposed publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may delete any Confidential Information or other proprietary information. In addition, Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests.|t
17157394|NCT02012959|f||OTHER|Sponsor reserves the right to review, edit, and authorize publications.|t
17157395|NCT02993354|f||||f
17157396|NCT00714753|t||||
17157397|NCT02333383|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157398|NCT01665677|f||||f
17157399|NCT00986947|t||||
17157400|NCT03704948|f||||f
17167556|NCT00294645|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PIs may not publish single-site data until the main multi-site publication has occurred."|t
17157401|NCT03489941|f||OTHER|Please contact sponsor directly for details.|t
17157402|NCT01726621|f||OTHER||t
17157403|NCT00182000|t||||
17167557|NCT00075725|f||OTHER|Must obtain prior Sponsor approval|t
17167558|NCT02387801|f||GT60||t
17167559|NCT01444027|f||||f
17167560|NCT01485380|t||||
17167561|NCT00737711|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167562|NCT00840060|t||||
17199862|NCT05101993|f||||f
17199863|NCT02065882|f||OTHER||t
17199864|NCT02600897|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199865|NCT06840769|f||||f
17199866|NCT05304117|f||||f
17199867|NCT03258723|t||||
17199868|NCT03991741|t||||
17199869|NCT00592293|t||||
17199870|NCT00944229|f||||f
17199871|NCT04292470|f||||f
17199872|NCT02906020|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17199873|NCT05330988|f||||f
17199874|NCT04340947|f||||f
17199875|NCT05890027|t||||f
17199876|NCT00884650|t||||f
17199877|NCT00880022|t||||f
17157404|NCT01905592|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157405|NCT03089853|f||||f
17157406|NCT04114656|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167563|NCT01263015|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167564|NCT03571672|f||||f
17167565|NCT00303446|t||||f
17199878|NCT02154906|t||||
17199879|NCT01594827|f||||f
17199880|NCT02484664|f||||f
17199881|NCT02030002|t||||
17199882|NCT01592045|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17157407|NCT03282591|f||||t
17157408|NCT00940576|t||||f
17157409|NCT04987931|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199883|NCT03994731|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17199884|NCT00609947|f||||f
17199885|NCT01528319|f||||f
17199886|NCT04148989|t||||f
17199887|NCT03812029|f||OTHER|The data may be considered for publication in a scientific journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data pertaining to the study confidential. The Investigator must consult with the Sponsor before any study data are submitted for publication. The Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.|t
17199888|NCT03149042|f||||f
17199889|NCT00790205|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study at least 30 days prior to submission for publication/presentation or at least 14 calendar days prior to submission for abstracts.|t
17199890|NCT04937920|f||OTHER||t
17199891|NCT03632083|f||||f
17199892|NCT04092452|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17199893|NCT02127125|t||||
17157410|NCT03326518|f||||f
17150661|NCT02140411|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17150662|NCT03584724|f||||f
17150663|NCT03981419|f||OTHER|The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI.|t
17150664|NCT01330459|f||||f
17150665|NCT03562559|t||||
17157411|NCT02030886|f||||f
17150666|NCT02337959|f||||f
17157412|NCT01375374|f||GT60||t
17157413|NCT01908582|f||GT60||t
17157414|NCT00888290|t||||
17157415|NCT01108237|f||LTE60||t
17157416|NCT01829997|f||||f
17157417|NCT02065518|t||||
17157418|NCT00858468|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17157419|NCT03484403|f||||f
17157420|NCT02131636|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157421|NCT02173379|f||LTE60||t
17157422|NCT02263014|f||||t
17157423|NCT00674479|t||||
17157424|NCT06226649|f||||f
17157425|NCT04703270|t||||
17157426|NCT04767529|f||OTHER|Following the first publication of the Study results by Sponsor, or if a publication is not submitted within 18 months after conclusion, the Investigator may publish or present the results of Institution's and Investigator's activities conducted under this Agreement. Investigator agrees to submit any proposed publication or presentation to Sponsor for review at least 90 days prior to submitting.|t
17157427|NCT02598778|t||||
17157428|NCT04122625|f||OTHER|Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.|t
17157429|NCT04348500|f||||f
17157430|NCT02776670|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157431|NCT01937884|f||||f
17157432|NCT00004088|t||||
17199894|NCT02353468|t||||
17199895|NCT02344342|t||||f
17199896|NCT00848484|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199897|NCT02526498|t||||
17199898|NCT03151746|f||||f
17199899|NCT01059305|t||||
17199900|NCT00153985|f||||f
17199901|NCT02097303|f||||f
17199902|NCT01715883|t||||
17199903|NCT03017742|f||GT60||t
17199904|NCT02975102|f||OTHER|Sponsor have at least 60 days to review any publication or presentation. The first release of results will involve all sites in this multicenter study.|t
17199905|NCT04069585|f||GT60||t
17199906|NCT02614690|f||||f
17199907|NCT01441635|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17199908|NCT01825577|f||||f
17199909|NCT01358331|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication, presentation, or any media that report any results of the trial.|t
17199910|NCT01055704|t||||f
17199911|NCT01969851|f||GT60||t
17199912|NCT02694445|t||||
17199913|NCT01661764|f||||f
17199914|NCT00763490|f||||f
17199915|NCT01430468|t||||
17199916|NCT04176731|f||||f
17199917|NCT03518567|t||||f
17199918|NCT00617929|t||||
17199919|NCT01426347|t||||
17199920|NCT01292304|f||||f
17199921|NCT01151423|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.|t
17199922|NCT03192462|t||||
17199923|NCT02419417|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17199924|NCT00078377|f||GT60||t
17199925|NCT00233480|t||||
17199926|NCT00581893|t||||
17199927|NCT02120001|t||||
17199928|NCT00790400|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17199929|NCT03941600|t||||
17199930|NCT02356705|t||||
17199931|NCT01107899|f||GT60||t
17199932|NCT00974259|f||||f
17199933|NCT06024278|t||||f
17199934|NCT00283283|f||||f
17199935|NCT00867100|f||OTHER||t
17199936|NCT01810939|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17199937|NCT02963090|f||||f
17199938|NCT01375673|t||||
17199939|NCT02349152|f||||f
17150667|NCT01231399|t||||
17150668|NCT00895947|f||||f
17150669|NCT02005887|f||||f
17150670|NCT01550744|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150671|NCT01660334|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150672|NCT01610453|t||||
17150673|NCT00311311|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150674|NCT01229735|f||GT60||t
17150675|NCT00520286|f||||f
17150676|NCT01715064|t||||
17150677|NCT00725751|f||||f
17150678|NCT02787408|f||||t
17182013|NCT00842348|f||OTHER|The Sponsor required reasonable opportunity to review any abstract, presentation, or paper before the material is submitted for publication or communicated. This also applied to any amendments that are requested by referees or journal editors. The Sponsor committed to comment on the draft documents within a time period agreed in the contractual arrangements between the Sponsor and authors or their institution. Delays were also possible if publication would adversely affect patentability.|t
17182014|NCT03274986|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17182015|NCT03200925|t||||
17182016|NCT00603746|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199940|NCT00979953|f||OTHER||t
17199941|NCT01634269|f||||f
17199942|NCT00577135|f||||f
17199943|NCT01607879|f||||f
17199944|NCT01100606|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17199945|NCT02406248|f||||f
17199946|NCT02643628|f||||f
17199947|NCT00706654|f||||f
17199948|NCT03937141|f||OTHER|Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Chinook ≥ 45 days in advance of submission for publication; (ii) deletes Chinook Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings.|t
17199949|NCT00594022|f||||f
17199950|NCT01001390|t||||
17199951|NCT03690427|t||||
17199952|NCT02251236|t||||
17199953|NCT01151215|f||GT60||t
17199954|NCT01721954|f||||f
17199955|NCT00727740|t||||
17199956|NCT04591171|t||||
17199957|NCT02956837|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17199958|NCT02597712|f||||f
17199959|NCT02637323|f||||t
17199960|NCT00513708|t||||
17199961|NCT01162486|f||||f
17199962|NCT02588872|f||||f
17199963|NCT01093469|f||LTE60||t
17199964|NCT03274895|f||||f
17199965|NCT03037203|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17199966|NCT01584518|t||||
17199967|NCT03229486|f||||f
17199968|NCT01461005|f||GT60||t
17199969|NCT05672771|t||||
17199970|NCT00760747|f||GT60||t
17199971|NCT01443923|t||||
17199972|NCT01426230|f||OTHER|Restriction Description: The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary other than study data.|t
17199973|NCT03566979|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150679|NCT00001586|f||||f
17150680|NCT00985712|f||GT60||t
17150681|NCT02581007|t||||
17157433|NCT00981058|f||GT60||t
17157434|NCT02667587|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157435|NCT04165135|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157436|NCT02893423|f||||f
17157437|NCT01243294|t||||
17157438|NCT02886884|t||||
17157439|NCT00497055|f||||f
17157440|NCT00575510|f||||f
17157441|NCT01267422|f||||f
17157442|NCT02104167|f||||f
17157443|NCT01693185|f||||f
17157444|NCT01084538|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17157445|NCT02279745|f||LTE60||t
17157446|NCT00595101|f||OTHER|Contact sponsor directly for details|t
17157447|NCT01606748|f||GT60||t
17157448|NCT02603926|f||||f
17157449|NCT03084315|t||||
17157450|NCT01952080|f||||f
17157451|NCT02732327|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157452|NCT04503668|t||||
17157453|NCT03782974|f||||t
17157454|NCT01687283|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157455|NCT00642954|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17157456|NCT01663857|f||GT60||t
17157457|NCT03041467|f||||t
17157458|NCT02732015|t||||
17157459|NCT03052920|t||||
17157460|NCT01980628|f||OTHER|"Agreement restrictions can vary and typically include (but are not limited to):~Required submission of all material for sponsor review at least thirty days prior to the proposed date of any presentation or submission. Materials must remove Proprietary Information, excluding Data /Study results. All Sponsor's comments are required to be included. Sponsor may delay the presentation/submission upon Sponsor review of materials that are being proposed for presentation/submission."|t
17157461|NCT00564278|f||||f
17157462|NCT06439095|t||||
17157463|NCT03341936|t||||
17157464|NCT02368886|f||||f
17157465|NCT02339974|f||||f
17157466|NCT04849416|f||LTE60||t
17157467|NCT02485418|t||||f
17157468|NCT06046209|f||||t
17157469|NCT04525131|f||OTHER|The Sponsor and the PI plan to publish the data.|t
17157470|NCT04997265|t||||
17157471|NCT04847232|f||||t
17157472|NCT03798327|t||||
17157473|NCT01056913|f||||f
17182017|NCT05516082|f||||t
17157474|NCT02290925|f||||f
17157475|NCT01716520|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157476|NCT03699540|t||||
17157477|NCT02066727|t||||
17157478|NCT05460078|t||||f
17157479|NCT02697591|f||OTHER|Clinical Study Agreement|t
17157480|NCT00624832|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157481|NCT04379700|t||||
17157482|NCT00592592|t||||
17157483|NCT00894244|t||||
17157484|NCT01038752|f||||f
17157485|NCT00530790|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of the multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157486|NCT00423358|f||||f
17157487|NCT01656187|f||||f
17157488|NCT02005627|t||||
17157489|NCT04000360|f||||f
17157490|NCT01912352|f||||f
17157491|NCT03003000|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157492|NCT01178814|t||||
17157493|NCT04933617|f||||f
17199974|NCT03321253|f||||f
17199975|NCT02781649|f||||f
17199976|NCT01889069|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17199977|NCT01228175|f||||f
17199978|NCT00108745|f||LTE60||t
17167566|NCT02251717|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167567|NCT04035564|t||||
17167568|NCT00297102|f||OTHER|The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.|t
17167569|NCT02324205|f||||f
17167570|NCT01774097|t||||
17167571|NCT03664674|f||LTE60||t
17167572|NCT01101971|t||||
17167573|NCT02174523|f||OTHER||t
17167574|NCT00794365|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167575|NCT00937404|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157494|NCT03743402|f||||f
17167576|NCT04854031|t||||
17167577|NCT00230282|f||||f
17167578|NCT03263923|f||||f
17167579|NCT03362931|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17167580|NCT02061397|f||||f
17167581|NCT02802241|f||||f
17167582|NCT01655043|f||||f
17167583|NCT01924442|t||||
17157495|NCT02191046|t||||
17157496|NCT03760458|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17199979|NCT00723749|f||OTHER|Trial results belong to the Sponsor only, all investigators are not allowed to publish trial results without permission of the Sponsor.|t
17199980|NCT00455741|f||||f
17199981|NCT02332902|t||||
17157497|NCT04006509|t||||
17157498|NCT01660802|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for at least 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167584|NCT02229214|f||GT60||t
17167585|NCT01057225|t||||
17167586|NCT00969761|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157499|NCT00048997|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17199982|NCT02138097|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157500|NCT02819440|t||||
17157501|NCT01701505|f||||f
17157502|NCT02759835|f||||f
17157503|NCT00459368|f||||f
17157504|NCT03970200|t||||
17157505|NCT03742258|t||||
17157506|NCT01428115|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157507|NCT00687882|f||||f
17157508|NCT02101359|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17157509|NCT01783821|t||||
17157510|NCT01907217|t||||
17157511|NCT00659776|f||||f
17157512|NCT01180049|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157513|NCT04504175|f||||f
17157514|NCT00350779|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157515|NCT02946489|t||||
17157516|NCT02919007|f||||f
17157517|NCT03015194|t||||
17157518|NCT02707172|f||||f
17157519|NCT04757805|t||||
17157520|NCT02469168|f||||f
17157521|NCT00433017|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157522|NCT01741350|t||||
17157523|NCT01709409|f||||f
17157524|NCT03594955|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17157525|NCT01602679|f||||f
17157526|NCT00255840|t||||
17167587|NCT02927925|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17167588|NCT00559468|f||OTHER|The Sponsor recognizes the right of the investigators to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17167589|NCT03305081|t||||
17167590|NCT04600505|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca AB.|t
17167591|NCT01571284|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17167592|NCT04065074|f||GT60||t
17167593|NCT00871117|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167594|NCT03385265|f||||f
17167595|NCT03416920|f||||f
17167596|NCT01648296|t||||
17167597|NCT01560637|f||LTE60||t
17167598|NCT02323204|f||||f
17167599|NCT00395135|f||OTHER|Publication of study results are only allowed with prior written consent from Arena Pharmaceuticals, Inc.|t
17182018|NCT01524627|t||||
17182019|NCT03323658|f||LTE60||t
17182020|NCT03913091|t||||
17157527|NCT03141034|t||||
17157528|NCT00715520|t||||
17157529|NCT01006590|f||LTE60||t
17157530|NCT03332095|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17157531|NCT00329745|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157532|NCT00178646|t||||
17157533|NCT00895934|f||LTE60||t
17157534|NCT02700698|t||||
17157535|NCT00703118|f||GT60||t
17157536|NCT05053035|f||||t
17157537|NCT05835063|t||||
17157538|NCT02007278|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157539|NCT04475718|f||||f
17157540|NCT00435188|f||||f
17157541|NCT00521885|t||||
17157542|NCT00055497|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17157543|NCT00048165|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157544|NCT00731731|f||LTE60||t
17157545|NCT02112877|f||||f
17157546|NCT02503254|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17157547|NCT02083653|f||OTHER|The investigator will inform the sponsor in advance about any plans to publish or present data from the trial. Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by investigators or their representatives will require pre-submission review by the sponsor. The sponsor will not suppress or veto publications, but maintains the right to delay publication in order to protect intellectual property rights.|t
17157548|NCT00621517|t||||f
17157549|NCT02949141|f||||f
17157550|NCT02155322|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17157551|NCT00073008|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157552|NCT00913770|t||||
17157553|NCT03337048|t||LTE60||t
17157554|NCT03260790|t||||
17157555|NCT02791438|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17157556|NCT02910726|t||||
17157557|NCT02669667|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17182021|NCT00969553|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157558|NCT01945294|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17167600|NCT03831880|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167601|NCT01852825|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17182022|NCT01726738|t||||
17157559|NCT02839876|f||||f
17157560|NCT02721017|t||||
17157561|NCT01156051|t||||f
17157562|NCT01313351|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17157563|NCT01218971|f||OTHER|Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.|t
17157564|NCT01926197|f||||f
17157565|NCT03884985|f||||f
17199983|NCT01245374|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, including the right to not release interim results of clinical trials. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17157566|NCT00564395|f||||f
17157567|NCT02620384|f||||f
17157568|NCT02071082|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157569|NCT00624650|f||||f
17157570|NCT02183909|f||||f
17157571|NCT02320227|f||OTHER|Master service agreement and confidentiality agreement in place|t
17157572|NCT02494401|f||||f
17157573|NCT00958412|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17157574|NCT00966355|f||||f
17157575|NCT03646487|f||||f
17199984|NCT02623998|f||||f
17199985|NCT00935532|f||GT60||t
17199986|NCT02227992|f||OTHER|Any publication or other public presentation of results from this study requires prior review by ETHICON. Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 days prior to submission for publication, public dissemination, or review by a publication committee.|t
17199987|NCT04954326|f||OTHER||t
17199988|NCT04982575|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17199989|NCT00475228|t||||f
17199990|NCT00338988|t||||f
17199991|NCT03931746|f||||f
17157576|NCT03850691|t||||
17157577|NCT02227368|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require Confidential Information to be removed and the sponsor can extend the embargo for an additional 90 days.|t
17157578|NCT03765229|t||||
17157579|NCT04494425|f||||t
17199992|NCT05454813|f||OTHER||t
17199993|NCT04949802|f||||f
17199994|NCT02473965|f||OTHER||t
17199995|NCT01183390|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17199996|NCT03816761|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17199997|NCT01240551|f||||f
17199998|NCT04403542|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157580|NCT01291264|f||||f
17157581|NCT01744483|t||||
17157582|NCT01190189|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167602|NCT01327274|f||LTE60||t
17167603|NCT00724854|f||OTHER|Whenever a Principal Investigator wishes to use the results of the study, he/she should contact the sponsor to obtain the authorization.|t
17167604|NCT01095653|f||||f
17182023|NCT02276612|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17182024|NCT02196324|f||GT60||t
17157583|NCT02287688|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157584|NCT03214679|f||||f
17157585|NCT05251064|f||||f
17157586|NCT01754766|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157587|NCT02412878|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157588|NCT02190721|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17157589|NCT04571385|f||||f
17157590|NCT04046263|t||||
17157591|NCT05025332|f||||f
17157592|NCT01212159|f||||f
17157593|NCT01306214|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17157594|NCT01888653|t||||
17157595|NCT01928199|f||||f
17157596|NCT00755261|f||GT60||t
17157597|NCT02081014|f||||f
17157598|NCT01502956|f||||f
17157599|NCT03959488|f||||f
17157600|NCT01026818|f||GT60||t
17157601|NCT02830074|t||||
17157602|NCT01760447|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17167605|NCT00171925|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167606|NCT02692040|t||||
17167607|NCT02752958|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167608|NCT00853125|t||||
17167609|NCT02599649|t||||
17199999|NCT03325790|f||OTHER|The PI will not, during or subsequent to the term of the Clinical Trial Agreement, use Confidential Information for any purpose whatsoever other than the performance of the Services, and will not disclose Confidential Information to any third party. Confidential Information will remain the sole property of Sponsor, as applicable.|t
17200000|NCT01730950|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17200001|NCT00667459|f||LTE60||t
17200002|NCT02568397|f||GT60||t
17200003|NCT01200342|t||||
17200004|NCT02748889|t||||
17200005|NCT04546217|t||||
17200006|NCT02550938|f||GT60||t
17200007|NCT01484431|f||GT60||t
17200008|NCT03085836|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17200009|NCT01888874|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17200010|NCT02763215|f||||f
17200011|NCT05302440|f||||f
17200012|NCT00475644|f||GT60||t
17200013|NCT01411241|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17200014|NCT01976273|t||||
17200015|NCT00725270|f||||f
17200016|NCT02980042|f||||f
17200017|NCT02301377|t||||
17200018|NCT00769600|f||||f
17200019|NCT01483144|f||GT60||t
17200020|NCT02460575|t||||
17200021|NCT00425607|f||||f
17200022|NCT00079339|f||LTE60||t
17200023|NCT02563548|f||GT60||t
17200024|NCT00520845|t||||
17200025|NCT01189110|t||||f
17200026|NCT03274453|t||||
17200027|NCT00583466|t||||
17200028|NCT01732549|f||||f
17200029|NCT01516749|t||||
17200030|NCT00351377|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17200031|NCT00584077|t||||
17157603|NCT01641471|f||||f
17157604|NCT04575584|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17157605|NCT03488563|f||OTHER|Sponsor shall have 45 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional one hundred twenty (120) days to enable Sponsor to seek patent protections.|t
17157606|NCT02788188|t||||f
17137328|NCT03444870|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137329|NCT01583985|t||||
17157607|NCT02815267|f||GT60||t
17157608|NCT01681095|f||||f
17157609|NCT04278924|f||||t
17157610|NCT05600036|f||OTHER|"Investigator may publish after the earlier of: publication of the final multicenter publication or 24 months after completion of the Study.~Investigator will provide to Sponsor a copy of any publication at least 60 days prior to submission. Sponsor may delete any confidential or proprietary information of Sponsor from the publication. Investigator will delay any publication an additional 90 days if requested to enable Sponsor to secure patent protection."|t
17157611|NCT00591019|t||||
17157612|NCT01522131|t||||f
17157613|NCT01204918|t||||
17157614|NCT03714776|f||OTHER||t
17157615|NCT01853696|f||||f
17157616|NCT02798120|f||||t
17157617|NCT00431067|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17157618|NCT00938587|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157619|NCT00849290|f||OTHER|A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.|t
17157620|NCT00548249|f||||f
17157621|NCT01687387|f||||f
17200032|NCT00168389|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17200033|NCT02493062|f||||f
17200034|NCT02106962|f||||f
17200035|NCT03845140|f||OTHER||t
17200036|NCT03054337|f||OTHER||t
17200037|NCT01150461|f||||f
17200038|NCT01681992|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200039|NCT01327612|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17200040|NCT02838979|f||||f
17200041|NCT01415934|f||||f
17200042|NCT01762904|t||||f
17200043|NCT01967069|f||GT60||t
17200044|NCT01028677|f||||f
17200045|NCT01661205|f||||f
17200046|NCT00775411|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17200047|NCT00346905|f||||f
17200048|NCT04191421|t||||
17200049|NCT05569421|f||OTHER|This confidential document is the property of AstraZeneca AB. No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17200050|NCT03111095|t||||
17137330|NCT01170702|t||||
17137331|NCT01677507|t||||
17137332|NCT00571688|f||||f
17137333|NCT00190983|f||GT60||t
17157622|NCT00466206|t||||f
17157623|NCT00002525|f||LTE60||t
17157624|NCT03230838|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17200051|NCT00504075|f||OTHER|Publication of the Study results will be allowed only with prior written approval from Sponsor, said consent not to be unreasonably withheld. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor's Inventions from any proposed publications prior to submitting or presenting the materials. Any and all publications will give appropriate recognition of any support received from Sponsor.|t
17200052|NCT01186705|t||||
17200053|NCT04079634|f||||f
17200054|NCT03106753|t||||
17200055|NCT01434745|f||||f
17157625|NCT03304184|t||||
17157626|NCT01505179|f||||f
17157627|NCT01915771|f||OTHER|Described in contract|t
17157628|NCT01096680|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17157629|NCT03420222|f||LTE60||t
17157630|NCT02697734|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157631|NCT00284154|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17157632|NCT02334384|f||||f
17157633|NCT02651688|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157634|NCT04527978|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157635|NCT01429441|f||OTHER|Sponsor shall have the right to the 1st publication of the Study results (joint, multi-center publication in conjunction with PI). Following the 1st publication, PI may publish data/results from the Study; provided that PI submits the proposed publication to Sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may request that Confidential/Proprietary Information be deleted and/or publication be postponed to protect Sponsor's intellectual property rights.|t
17157636|NCT03780972|f||||f
17157637|NCT01349933|f||LTE60||t
17157638|NCT01578499|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17157639|NCT00830518|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17200056|NCT04245345|f||OTHER|PIs will not publish/present results until a multi-center pub. is released. If a multi-center pub. is not released within 1 year of completion PI may publish the results pertaining to their activities. Pubs will be provided to MDT at least 60 days prior to submission or presentation for review. Within 60 days of receipt, MDT will verify presence of CI or technical errors. PI will make requested changes prior to publication/presentation. PI will delay publication up to 90 more days if requested.|t
17137334|NCT02287402|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17137335|NCT04247815|f||||f
17137336|NCT00838006|f||||f
17137337|NCT03495453|f||||t
17137338|NCT02769351|f||LTE60||t
17137339|NCT00844649|f||OTHER|Authorship/contents of any publication is determined by site and provides sponsor a publication prior to submission. Sponsor has 60 days to review and avoid editorial changes but may request site delete confidential data. If publication contains patentable matter, site agrees to delay publication for 60 days. If study is part of multicenter protocol, site agrees not to independently publish. If multicenter publication is not forthcoming in 18 months after study end, site may proceed accordingly.|t
17200057|NCT00780455|f||||f
17200058|NCT02609672|f||||f
17200059|NCT03392168|f||||t
17200060|NCT00401258|f||||f
17200061|NCT00844597|f||OTHER|The PI required written permission to publish any information relating to the trial and if given permission to acknowledge the sponsor's contribution and ownership of the materials.|t
17200062|NCT04160988|f||||f
17200063|NCT02670122|t||||f
17200064|NCT01262547|f||||f
17200065|NCT02762903|t||||
17200066|NCT00243074|f||LTE60||t
17200067|NCT00664534|f||GT60||t
17200068|NCT03041792|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200069|NCT04978090|t||||
17200070|NCT04263987|t||||
17200071|NCT03075527|t||||f
17157640|NCT03439462|f||||f
17157641|NCT00808470|t||||f
17167610|NCT00711490|t||||
17167611|NCT03746600|f||||f
17167612|NCT03023826|f||GT60||t
17167613|NCT00977938|f||||f
17167614|NCT02142283|f||OTHER|Physician shall not make any publication without providing Sponsor 60 days notice. If Sponsor determines that the proposed publication contains confidential information, Sponsor may require the delay of publication for a period of time not to exceed 90 days and may require that any confidential information be removed from the publication. Sponsor may also require Physician to delay publication until any factual errors or inaccuracies in the publication are corrected.|t
17200072|NCT06926673|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167615|NCT03373890|f||||f
17200073|NCT02358668|f||||f
17157642|NCT00523809|t||||f
17200074|NCT04057573|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17167616|NCT00717522|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation.|t
17167617|NCT00937118|f||||f
17167618|NCT01660737|f||||f
17167619|NCT04092907|f||||t
17167620|NCT02981407|t||||
17167621|NCT02466074|t||||
17167622|NCT00355342|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167623|NCT01416441|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17167624|NCT04627675|t||||
17167625|NCT02653495|t||||f
17200075|NCT05609604|t||||
17167626|NCT00953680|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200076|NCT01317875|f||OTHER|Clinical Study Agreement|t
17167627|NCT01360398|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167628|NCT01258153|f||OTHER|The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17167629|NCT00624780|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167630|NCT01514240|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17200077|NCT03466047|t||||
17200078|NCT03211234|f||LTE60||t
17200079|NCT02271984|f||OTHER||t
17157643|NCT00394771|f||OTHER|Details of the study and its results shall not be publicized or published in any form to cooperative publication without prior, written consent of sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17157644|NCT00520767|t||||f
17157645|NCT01342172|t||||
17167631|NCT00450294|f||||f
17167632|NCT00549900|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167633|NCT01430325|t||||
17167634|NCT01007123|f||LTE60||t
17167635|NCT00149994|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157646|NCT03597139|f||||f
17157647|NCT00382109|f||OTHER|Must obtain prior sponsor approval.|t
17157648|NCT00248833|f||||f
17167636|NCT00613925|f||||f
17167637|NCT03828422|f||||f
17167638|NCT00252694|f||||f
17182025|NCT00692770|f||GT60||t
17182026|NCT04248816|f||||f
17200080|NCT01020877|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17200081|NCT02277054|t||||
17200082|NCT04307940|f||||f
17200083|NCT04624243|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17200084|NCT05543174|f||OTHER||t
17200085|NCT00953771|t||||
17157649|NCT01900899|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157650|NCT02006056|f||||f
17200086|NCT04896008|f||OTHER|No publication or disclosure of study results will be permitted except as specified in a separate, written agreement between the Sponsor and the investigator. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication.|t
17200087|NCT04595682|t||||
17200088|NCT01933243|t||||f
17200089|NCT01270828|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200090|NCT06456385|f||||f
17200091|NCT06490302|f||||f
17200092|NCT00015847|t||||
17157651|NCT00723697|f||OTHER|No publication (abstract, poster, communication...) can be made without the agreement of SCHERING-PLOUGH.|t
17157652|NCT02770846|t||||
17157653|NCT01483599|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17157654|NCT01160380|f||||f
17157655|NCT02510820|f||OTHER||t
17157656|NCT03046056|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157657|NCT02913105|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200093|NCT01877148|f||||f
17200094|NCT00709228|f||OTHER|Lead investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. Lead investigator further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication, which report any results of the Study. Sponsor shall have the right to review and comment on any presentation, including editorial rights.|t
17200095|NCT01007110|t||||
17200096|NCT02870972|f||||f
17200097|NCT04497389|t||||
17200098|NCT02179177|t||||
17200099|NCT03322540|f||OTHER|Clinical Study Agreement|t
17200100|NCT04052425|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17200101|NCT04334278|t||||f
17200102|NCT03023553|f||||f
17200103|NCT04829747|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17200104|NCT02330094|t||||
17200105|NCT03445533|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17200106|NCT02615509|f||||f
17200107|NCT00703339|f||LTE60||t
17200108|NCT00945672|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200109|NCT00968526|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200110|NCT00566540|t||||
17200111|NCT03926195|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17200112|NCT01236378|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200113|NCT03724253|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200114|NCT00447590|f||||f
17200115|NCT01689857|t||||f
17200116|NCT05105087|t||||
17157658|NCT01317004|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157659|NCT02092649|f||||f
17157660|NCT01533948|t||||
17157661|NCT01344759|t||||
17157662|NCT01153009|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17157663|NCT03151083|t||||
17157664|NCT04003623|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17157665|NCT02918097|f||||f
17157666|NCT00703326|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17157667|NCT04640038|t||||
17157668|NCT02242019|f||||f
17157669|NCT04316260|t||||
17157670|NCT01393106|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17157671|NCT03307837|f||GT60||t
17157672|NCT01601067|t||||f
17157673|NCT00693485|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157674|NCT03083353|f||||f
17157675|NCT02771860|t||||
17157676|NCT03972501|f||||f
17157677|NCT02263729|t||||f
17182027|NCT00262067|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182028|NCT00655564|f||||f
17137340|NCT00424294|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137341|NCT00304915|t||||
17157678|NCT04676152|f||GT60||t
17182029|NCT04536727|f||||f
17167639|NCT01342965|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200117|NCT01736540|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157679|NCT02135016|t||||
17157680|NCT01088711|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17157681|NCT01240902|f||LTE60||t
17157682|NCT03678675|t||||
17157683|NCT01441245|f||||f
17157684|NCT03543176|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157685|NCT02626000|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157686|NCT02164318|t||||f
17157687|NCT02508103|t||||
17157688|NCT04392219|f||OTHER|PI is required to obtain written consent from the Sponsor before anything relating to the study can be published.|t
17157689|NCT02335346|f||GT60||t
17157690|NCT03738163|f||||f
17157691|NCT01515566|t||||
17157692|NCT03300050|f||||f
17157693|NCT02085070|t||||
17157694|NCT02476916|f||OTHER|The information obtained from the clinical study will be used towards the development of AG-348 and may be disclosed to regulatory authority(ies), other Investigators, corporate partners, or consultants as required.|t
17157695|NCT06010732|f||||f
17157696|NCT04401202|f||||f
17157697|NCT03491397|t||||
17157698|NCT00631163|f||||t
17157699|NCT01263717|f||||f
17157700|NCT02714036|f||||f
17157701|NCT01597492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157702|NCT03624569|f||||f
17157703|NCT02826577|t||||
17157704|NCT02053259|t||||
17157705|NCT00004500|f||GT60||t
17157706|NCT03517449|f||||f
17157707|NCT01119846|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157708|NCT01557868|f||||f
17157709|NCT00795769|t||||
17157710|NCT00602446|t||||f
17167640|NCT01175434|f||||f
17137342|NCT04124042|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17137343|NCT03442829|f||||f
17157711|NCT01370616|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17157712|NCT02324699|t||||
17157713|NCT00212264|f||||f
17157714|NCT03292614|t||||
17157715|NCT01605825|f||OTHER|Sponsor (Acorda) has the right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17157716|NCT02740335|f||||f
17157717|NCT03973697|t||||
17157718|NCT02033200|f||GT60||t
17157719|NCT00006110|f||GT60||t
17157720|NCT03469999|t||||
17157721|NCT01863732|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17157722|NCT01249833|f||OTHER|If Sponsor has not submitted a manuscript for publication for this multi-center study within 12 months of study completion/termination, the PI will be free to publish separately. Sponsor can review results communications prior to public release and can embargo communications for up to 90 days if the proposed publication contains information relating to patentable items. If Sponsor believes proposed communications contain any confidential information, Sponsor has the right to remove it.|t
17157723|NCT03796676|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167641|NCT02868034|f||||f
17167642|NCT01170598|t||||
17167643|NCT03538444|f||||f
17167644|NCT01509677|f||||f
17200118|NCT00479882|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17157724|NCT00535392|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17157725|NCT02724410|t||||f
17157726|NCT02432144|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157727|NCT00448812|f||LTE60||t
17157728|NCT00385827|f||LTE60||t
17157729|NCT00410072|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17157730|NCT01080976|f||||f
17157731|NCT00810498|f||||f
17157732|NCT01421147|f||GT60||t
17157733|NCT01270321|f||||f
17157734|NCT03364036|f||||t
17157735|NCT03536663|f||||t
17157736|NCT05437640|f||||f
17157737|NCT00904917|t||||f
17157738|NCT05206734|f||||f
17157739|NCT04228965|f||||f
17157740|NCT02330172|f||||f
17157741|NCT00734656|t||||
17157742|NCT01471444|t||||
17157743|NCT03915626|f||||t
17157744|NCT02769312|f||||f
17157745|NCT02178358|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of less than 90 days from the time submitted to the sponsor for review.The PI will remove from publication the information which the sponsor reasonably thinks would jeopardize its intellectual property interests or delay the publication until the publication no longer jeopardizes its intellectual property interests.|t
17157746|NCT01110967|f||OTHER|Confidential Information shall not be disclosed and shall be sole property of sponsor during the term of the agreement and for 3 years after agreement termination. Results might be published or presented, however sponsor should receive publication for review at least 7 days prior to submittal. Sponsor shall limit its review to a determination of whether Confidential Information is disclosed, to allow sponsor to protect its rights in copyrightable material, and to check for technical correctness.|t
17157747|NCT01066663|t||||
17157748|NCT02985021|f||||f
17157749|NCT02756819|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167645|NCT02119156|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137344|NCT00156910|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137345|NCT00712322|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157750|NCT01090050|f||LTE60||t
17157751|NCT03539484|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167646|NCT02124512|t||||
17167647|NCT01431014|t||||
17167648|NCT03660228|f||||f
17167649|NCT04283942|f||||f
17200119|NCT03738475|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167650|NCT04685707|f||||f
17200120|NCT03836859|f||||f
17200121|NCT02159040|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17167651|NCT01638052|t||||
17167652|NCT04644237|f||||f
17200122|NCT02676843|t||||
17200123|NCT00759642|f||||f
17200124|NCT02803593|t||||
17200125|NCT01993849|f||||f
17200126|NCT03443414|f||OTHER|The Principal Investigator and Institution may only publish their center study activities and/or study data with prior written approval of the Sponsor.|t
17157752|NCT02232061|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167653|NCT01779869|f||||f
17200127|NCT00732992|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167654|NCT01459653|f||OTHER|The Sponsor is the sole owner of all data, results and any work summarizing the Study to which this agreement refers, and it should be noted that the Investigator agrees to their publication by Sponsor in any scientific or medical journal chosen by Sponsor. It should be noted that the Investigator may not make any communications or publications relating to the Study which forms the basis of this agreement, without the prior written agreement of the Sponsor.|t
17200128|NCT02103114|t||||
17167655|NCT02233738|f||||f
17200129|NCT03933462|f||||f
17167656|NCT00096174|f||||f
17167657|NCT03315104|f||OTHER|The result of the study may not be published until prior publication of the global results by the Sponsor, in the case of multi-center studies.|t
17200130|NCT04692467|t||||f
17200131|NCT01160237|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200132|NCT00422734|f||GT60||t
17200133|NCT01445327|f||||f
17200134|NCT01824589|f||||f
17200135|NCT00368875|f||LTE60||t
17157753|NCT00264290|t||||
17157754|NCT03108066|f||OTHER|The Sponsor reserves the right to review all planned communications and manuscripts based on the results of this study. This reservation of right is not intended to restrict or hinder publication of any dissemination of study results, but to allow the Sponsor to confirm the accuracy of the data, to protect proprietary information, and to provide comments based on information that may not yet be available to the study Investigators.|t
17157755|NCT00560703|f||||f
17157756|NCT02693717|t||||
17157757|NCT01679028|f||OTHER|PI can be co-authored with sponsor for the publication but cannot publish the result solely.|t
17157758|NCT03247322|f||||f
17157759|NCT00339833|t||||
17157760|NCT03077607|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17157761|NCT03004924|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17157762|NCT00269477|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17157763|NCT02670382|f||||f
17157764|NCT03244618|f||LTE60||t
17157765|NCT01836185|f||GT60||t
17157766|NCT01603394|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167658|NCT00027378|f||||f
17167659|NCT05605691|f||||f
17200136|NCT02078492|t||||
17200137|NCT02080546|t||||
17200138|NCT01715207|t||||
17200139|NCT00996606|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200140|NCT00167206|t||||
17200141|NCT00305344|f||||f
17200142|NCT00632502|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17200143|NCT00921947|f||LTE60||t
17200144|NCT00681668|f||OTHER|Site has to inform sponsor about a publication at least 60 day in advance and 10 days before submission of an abstract or presenation. Change requests by the sponsor are recognized unless the scientific character or the objectivity is on risk. If the sponsor plans a patent applicaion the publication has to be postponed up to 120 days.|t
17200145|NCT02209181|f||LTE60||t
17137346|NCT01981967|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17157767|NCT01819844|f||||f
17157768|NCT01215435|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol.|t
17157769|NCT00840034|f||GT60||t
17157770|NCT05811026|f||||f
17157771|NCT02870205|f||OTHER|Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the CRO/Sponsor.|t
17157772|NCT03557476|t||||
17157773|NCT00586898|t||||
17157774|NCT03816007|f||||f
17157775|NCT02179749|f||||f
17157776|NCT01897766|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157777|NCT00793546|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157778|NCT01416155|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17157779|NCT02634710|t||||
17157780|NCT02772809|f||||f
17157781|NCT02828137|f||||f
17157782|NCT02860507|f||||f
17157783|NCT02774005|f||OTHER|The below agreement was included in the Clinical Trial Agreement : Study Team Member agrees not to publish or refer to the study, in whole or in part, without the prior expressed written consent of the sponsor. Study team member will not use the name of the sponsor or \[name of the study co-ordinating Contract Research Organization (CRO)\] in connection with any publication or promotion without sponsor's or \[name co-ordinating CRO\]'s prior, written consent.|t
17157784|NCT00534105|t||||
17157785|NCT02379273|f||||f
17157786|NCT03402230|f||LTE60||t
17157787|NCT03275389|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17157788|NCT00978341|f||OTHER||t
17157789|NCT03035916|t||||
17157790|NCT03885999|f||||t
17157791|NCT02452554|f||OTHER|Must obtain prior sponsor approval.|t
17157792|NCT03634813|f||||f
17157793|NCT05188729|f||OTHER|The Institution is restricted from disclosing all data or results which are the sole property of the sponsor and considered confidential information. The Institution may not present data or results without prior Sponsor review and written consent|t
17157794|NCT02552888|f||||f
17157795|NCT02014051|f||||f
17157796|NCT01732445|t||||
17157797|NCT04542278|t||||
17157798|NCT01859949|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157799|NCT01890759|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17167660|NCT04706273|f||OTHER|The PI is required to obtain written permission from the Sponsor prior to publishing trial results.|t
17157800|NCT00171158|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17157801|NCT01305772|t||||f
17157802|NCT01084148|f||OTHER|Mutual agreement|t
17167661|NCT00899717|f||||f
17157803|NCT01268189|t||||
17157804|NCT03525808|f||||f
17157805|NCT01031004|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17167662|NCT03199053|f||||f
17167663|NCT02769338|t||||
17167664|NCT01824823|f||LTE60||t
17167665|NCT02098369|t||||
17167666|NCT00246025|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17167667|NCT00909545|f||||f
17200146|NCT02548078|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167668|NCT03995680|f||||f
17200147|NCT00920647|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information(excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17167669|NCT03958656|f||||f
17200148|NCT03128671|t||||
17200149|NCT04072445|t||||
17200150|NCT04641962|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17200151|NCT02281500|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17200152|NCT00862836|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17200153|NCT04463680|t||||
17200154|NCT02171247|t||||
17200155|NCT05239598|t||||f
17157806|NCT02634801|f||GT60||t
17167670|NCT01672658|f||||f
17167671|NCT03444766|f||LTE60||t
17167672|NCT02836873|f||OTHER|The PI has no right to publish the trial results.|t
17167673|NCT03190265|t||||
17167674|NCT01310179|f||||f
17167675|NCT02540330|f||||f
17167676|NCT00832130|f||||f
17167677|NCT02460783|t||||
17167678|NCT01646645|t||||
17167679|NCT02030080|f||||f
17167680|NCT02881112|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated or arising from the performance of this Agreement is not permitted without the prior written consent of Regenesis. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17167681|NCT02374814|t||||
17167682|NCT00712530|f||GT60||t
17167683|NCT00884039|f||||f
17167684|NCT02214225|f||OTHER|"bioCSL agreements and restrictions on publishing may vary with individual investigators; however, bioCSL will not prohibit any investigator from publishing. bioCSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.~(Note: bioCSL was previously known as CSL Biotherapies; bioCSL QIV \& TIV were called CSL QIV \& TIV in the original protocol)"|t
17167685|NCT02648022|t||||
17167686|NCT00072293|f||||f
17167687|NCT01166958|t||||
17167688|NCT04209114|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167689|NCT00901511|f||||f
17157807|NCT00582426|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial.|t
17167690|NCT00624819|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157808|NCT00662311|t||||
17157809|NCT01649362|f||||f
17167691|NCT02880514|f||||f
17167692|NCT02436668|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination."|t
17167693|NCT02826421|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167694|NCT04899440|f||OTHER||t
17167695|NCT02210221|f||LTE60||t
17167696|NCT02141490|f||||f
17150682|NCT03323723|f||OTHER|Research results and associated data will be considered confidential until the earlier of: (i) the first publication or presentation thereof data according to the terms of this agreement; (ii) one (1) year after conclusion, abandonment, or termination of the Research at all sites.|t
17182030|NCT01077804|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission, it being understood that the results of this study are not to be considered confidential. The sponsor review can be expedited to meet publication guidelines.|t
17167697|NCT00434759|t||||
17167698|NCT00997425|t||||
17167699|NCT02436408|t||||
17200156|NCT02222870|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17167700|NCT02649855|f||||f
17200157|NCT05823012|f||OTHER|The publication policy allows the Sponsor to submit a multi-center publication within 18-month period after the study is completed at all institutions. If it is not submitted within such 18-month period, an individual PI may furnish the Sponsor with a copy of any proposed publication or release at least 90 days in advance of the proposed submission or presentation. The Sponsor may review such proposed publication or release and may request a delay in publication of up to an additional 90 days.|t
17167701|NCT01300819|f||GT60||t
17167702|NCT05434013|t||||
17167703|NCT01319721|f||GT60||t
17167704|NCT00461305|f||OTHER|Sponsor will confirm the contents before disclosure.|t
17150683|NCT01144364|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167705|NCT04545047|t||||
17167706|NCT03020017|t||||
17167707|NCT01103063|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167708|NCT03115853|t||||
17167709|NCT01437098|f||OTHER|It is not required per Japan GCP. There is an agreement with the site, but not the individual investigator at the site.|t
17167710|NCT01187446|f||||f
17167711|NCT00496197|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167712|NCT01344538|f||||f
17182031|NCT00256698|f||OTHER|The only disclosure restriction on the PI is that they cannot disclose or publish any information to do with the trial without consent from AstraZeneca|t
17182032|NCT04399928|f||||f
17200158|NCT01381575|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200159|NCT01920477|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200160|NCT01443403|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17157810|NCT01467271|f||OTHER||t
17157811|NCT01548768|t||||f
17157812|NCT03441685|t||||
17157813|NCT04948827|f||||f
17182033|NCT02620046|f||||t
17200161|NCT01681277|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167713|NCT01655381|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167714|NCT00320255|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167715|NCT00043108|t||||f
17167716|NCT03405935|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167717|NCT04979897|t||||
17167718|NCT00868218|t||||
17167719|NCT00929773|f||||f
17167720|NCT02781792|t||||
17167721|NCT01703117|f||||f
17200162|NCT00474526|f||GT60||t
17167722|NCT02583230|t||||
17167723|NCT00683917|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17167724|NCT02725879|t||||f
17167725|NCT02685748|t||||f
17167726|NCT00328653|f||||t
17167727|NCT02536300|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17167728|NCT02637427|t||||
17167729|NCT01080768|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182034|NCT03962543|f||LTE60||t
17182035|NCT03252522|t||||f
17200163|NCT03222505|f||||f
17200164|NCT02224404|f||LTE60||t
17200165|NCT01251770|t||||f
17182036|NCT02181556|f||||f
17200166|NCT02113124|t||||
17200167|NCT02514239|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200168|NCT03104075|f||||f
17150684|NCT01301508|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150685|NCT03123861|t||||f
17150686|NCT02206620|f||||f
17150687|NCT01346774|f||||f
17150688|NCT00502801|f||GT60||t
17150689|NCT01565616|t||||
17150690|NCT01733147|t||||
17150691|NCT03212521|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150692|NCT03736213|f||||f
17150693|NCT00444457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150694|NCT01401049|f||||f
17150695|NCT03082664|f||||f
17150696|NCT01602965|f||||f
17150697|NCT02283294|f||||f
17157814|NCT04126317|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17157815|NCT01796301|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17157816|NCT00667563|f||||f
17157817|NCT01939223|f||OTHER||t
17157818|NCT01557517|f||||f
17200169|NCT04024462|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157819|NCT00162097|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17167730|NCT03832114|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17167731|NCT02115750|f||||f
17167732|NCT00931723|f||OTHER||t
17157820|NCT01963091|t||||f
17157821|NCT00915603|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from the date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish results until 18 mos. after the trial has been completed at all sites.|t
17157822|NCT03585712|f||||f
17157823|NCT03360214|t||||
17157824|NCT01280682|t||||
17157825|NCT04677387|t||||
17157826|NCT03611101|f||||f
17157827|NCT03838510|f||||f
17157828|NCT01964716|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157829|NCT02540161|f||||f
17167733|NCT03054350|f||OTHER||t
17167734|NCT01133405|f||GT60||t
17167735|NCT02737553|f||||f
17167736|NCT01238835|f||||t
17167737|NCT00772369|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17167738|NCT01774253|f||||f
17200170|NCT03065075|t||||
17200171|NCT00789360|f||LTE60||t
17200172|NCT04400487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200173|NCT00022659|f||LTE60||t
17157830|NCT01464619|f||||f
17167739|NCT00554619|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167740|NCT02250807|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17157831|NCT01658904|f||||f
17167741|NCT00908648|f||||f
17167742|NCT02240368|f||||f
17167743|NCT03352557|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17167744|NCT00907803|f||OTHER|The PI must obtain the sponsor's written consent to publish any study results and must notify the sponsor within 30 working days prior to publishing.|t
17167745|NCT03510468|t||||
17200174|NCT03559062|f||OTHER||t
17200175|NCT00426127|t||||
17167746|NCT04612842|f||||f
17167747|NCT02419131|f||||f
17200176|NCT00458952|f||LTE60||t
17200177|NCT05048238|f||||f
17157832|NCT00080483|f||||f
17157833|NCT01808222|t||||
17157834|NCT00462449|f||||f
17157835|NCT04333225|f||||f
17157836|NCT04100590|t||||
17157837|NCT02820181|f||||f
17157838|NCT00460746|f||OTHER|If TTCA does not publish within 12 months after study conclusion or after TTCA confirms there will be no multicenter publication, Institution may publish their results from their site individually, provided TTCA has 60 day review for confidentiality and additional 60 day delay for patent application.|t
17157839|NCT02356107|f||||f
17157840|NCT00822328|t||||f
17157841|NCT00789685|f||OTHER|Review by sponsor of related publication \& communications|t
17157842|NCT04399538|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157843|NCT01420016|f||||f
17157844|NCT01454414|f||||f
17157845|NCT00636961|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157846|NCT00410059|t||||
17157847|NCT02756364|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17157848|NCT02655016|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157849|NCT02223364|t||||
17157850|NCT01841567|f||OTHER||t
17157851|NCT01327313|f||||f
17157852|NCT01573754|t||||
17157853|NCT02061683|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of at least 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17157854|NCT00829829|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17157855|NCT02984267|f||||f
17157856|NCT02685072|t||||
17157857|NCT00742027|f||OTHER|Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17157858|NCT00681265|f||||f
17157859|NCT00477204|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review.|t
17157860|NCT02717442|f||LTE60||t
17157861|NCT02798354|f||||f
17157862|NCT00528372|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157863|NCT00762034|f||GT60||t
17157864|NCT02442206|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17167748|NCT05426031|t||||
17200178|NCT01730378|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200179|NCT00955708|f||||f
17150698|NCT01769339|f||||f
17150699|NCT04062448|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150700|NCT05101486|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17150701|NCT02788045|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150702|NCT03188666|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17167749|NCT04677660|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17167750|NCT00089986|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167751|NCT02334683|f||GT60||t
17167752|NCT00916058|t||||
17167753|NCT02437305|t||||f
17167754|NCT03964246|f||||f
17167755|NCT03403231|t||||
17167756|NCT01071200|f||OTHER||t
17167757|NCT03410797|t||||
17167758|NCT04895293|t||||
17167759|NCT01527513|f||OTHER||t
17167760|NCT04465877|f||OTHER|The sponsor can review results communications at least 60 days prior to public release. The sponsor will have a review period of 60 days and can embargo communications regarding trial results for an additional period of 60 days from the end of sponsor review period. The sponsor may require removal of any and all confidential information (other than study results) in the communication.|t
17167761|NCT03762616|f||||f
17167762|NCT02794844|t||||
17167763|NCT05894538|t||||
17200180|NCT01016262|f||OTHER|Restrictions may vary in accordance with each agreement that is negotiated with individual investigators. Sponsor will allow publication after multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and defer publication for period of time to allow Sponsor to obtain patent or other intellectual property right protection.|t
17200181|NCT00737477|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167764|NCT03576755|t||||f
17167765|NCT04962230|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200182|NCT01370655|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17200183|NCT00581477|t||||
17167766|NCT01767493|t||||
17200184|NCT02069366|f||||f
17200185|NCT03119233|f||OTHER||t
17200186|NCT02057575|f||||f
17167767|NCT04346108|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167768|NCT01598753|f||||f
17200187|NCT00332462|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17200188|NCT01643044|f||||f
17200189|NCT02451176|f||||f
17200190|NCT01735175|f||||t
17150703|NCT03696953|f||||f
17150704|NCT05104476|f||||f
17150705|NCT04908683|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17150706|NCT05392907|t||||
17150707|NCT03047473|f||||f
17150708|NCT06204887|t||||f
17150709|NCT02935686|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17167769|NCT03158012|f||||f
17167770|NCT02788201|f||||f
17167771|NCT02159118|f||||f
17167772|NCT00386477|f||||f
17167773|NCT02446418|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167774|NCT04508751|t||||
17167775|NCT03114124|f||||f
17200191|NCT01853475|f||OTHER|After completion of the study, the Investigator may prepare a joint publication with the Sponsor. The Investigator must undertake not to submit any part of the individual data from this protocol for publication without prior consent of the Sponsor at a mutually agreed time.|t
17200192|NCT02470780|t||||
17157865|NCT00497146|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157866|NCT01225926|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157867|NCT02155309|f||||f
17157868|NCT01299896|f||||f
17157869|NCT02107313|f||LTE60||t
17157870|NCT00950729|t||||
17157871|NCT03084302|t||||f
17157872|NCT00929994|f||||f
17157873|NCT01867515|t||||
17157874|NCT01411319|t||||
17157875|NCT01214668|f||GT60||t
17157876|NCT01964989|f||LTE60||t
17157877|NCT00424593|f||GT60||t
17137347|NCT00916370|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication except to delay any proposed publication or presentation to enable the Sponsor to secure patent or other protection of proprietary rights.|t
17200193|NCT01023958|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200194|NCT03080493|f||||f
17157878|NCT01449864|t||||
17157879|NCT01247675|f||OTHER||t
17157880|NCT03042910|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157881|NCT02082769|f||||f
17157882|NCT01491841|t||||
17157883|NCT02933528|f||||t
17157884|NCT01301079|f||||f
17157885|NCT00479115|t||||
17157886|NCT00948922|t||||
17157887|NCT02784288|t||||
17157888|NCT02734862|f||OTHER||t
17157889|NCT02757625|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157890|NCT04854057|t||||
17157891|NCT02131233|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17157892|NCT03519919|f||||f
17157893|NCT00645671|f||OTHER|"The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with, the Sponsor and such that confidential or proprietary information is not disclosed.~Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee for comment."|t
17157894|NCT00790556|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157895|NCT00177866|f||||f
17157896|NCT01951573|t||||
17157897|NCT00217581|t||||f
17157898|NCT04399889|t||||
17157899|NCT01537835|f||||f
17157900|NCT02829047|f||OTHER|Permission to use study data is required|t
17157901|NCT02020135|f||||f
17157902|NCT01909973|t||||
17157903|NCT00460239|f||||f
17157904|NCT01462305|f||||f
17157905|NCT02455453|t||||
17157906|NCT00649792|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17157907|NCT00368459|f||||f
17157908|NCT03610334|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17157909|NCT02020889|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157910|NCT01005901|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17157911|NCT00760487|f||OTHER|No paper that incorporates Sponsor Condfidential information will be submitted for publication without Sponsor's prior written agreement.|t
17157912|NCT02813473|f||||f
17157913|NCT05347966|f||||f
17157914|NCT06360588|f||LTE60||t
17157915|NCT06363292|f||||t
17167776|NCT02014480|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167777|NCT01338610|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157916|NCT02087943|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 12 months since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17157917|NCT02716506|f||||f
17200195|NCT00755417|f||OTHER|The PI agree that the sponsor shall have the right to the first publication of the results of the study which is intended to be joint, multi-center publication. Following the first publication, the PI may publish data or results from the study, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the data of the proposed publication.Sponsor may remove any information that is considered confidential and or proprietary other than study data.|t
17157918|NCT01690299|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 12 months since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17157919|NCT03836209|f||||f
17167778|NCT01865812|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.|t
17167779|NCT01854632|f||LTE60||t
17167780|NCT01414205|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167781|NCT02046226|f||OTHER|An agreement between Sponsor and Investigator(s) in the final form of abstracts and articles shall be obtained within an appropriate time frame of 60 days. Any and all information supplied or obtained during this study by or on behalf of any party involved in the study (in whatever form) shall be treated as confidential, shall not be disclosed to any third party unless with the prior written consent of the Sponsor in each case.|t
17167782|NCT02470754|t||||f
17200196|NCT02362503|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200197|NCT05143138|f||||f
17200198|NCT02977286|t||||
17200199|NCT03325777|f||||f
17200200|NCT00786643|f||OTHER|If the Investigator wishes to make a submission for a presentation or publication, the Investigator shall submit all such materials to InterMune at least 60 days prior to the date on which such submission is proposed to be made, and InterMune shall provide timely review of such materials. InterMune may cause the presentation or submission to be delayed for up to 60 additional days if patentable material or proprietary information is identified.|t
17200201|NCT01099917|t||||
17200202|NCT00980746|f||OTHER||t
17200203|NCT02990468|f||||f
17200204|NCT02335905|f||||f
17200205|NCT01485120|f||||f
17200206|NCT02567708|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200207|NCT03993210|t||||
17200208|NCT01193010|f||||f
17200209|NCT01154140|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200210|NCT00478192|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17200211|NCT01818531|t||||
17200212|NCT00477490|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention|t
17200213|NCT01646177|f||GT60||t
17200214|NCT02204657|f||||f
17200215|NCT03697122|t||||
17200216|NCT01305239|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200217|NCT00561145|f||||f
17200218|NCT00402051|f||GT60||t
17200219|NCT02142153|f||||f
17200220|NCT04529005|f||||f
17200221|NCT01791972|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17200222|NCT00570908|t||||
17200223|NCT01213524|t||||
17157920|NCT03739710|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17157921|NCT01753115|f||OTHER|Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between the Biomedical Advanced Research \& Development Authority (BARDA) and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17157922|NCT03642067|t||||
17157923|NCT01424241|t||||
17157924|NCT05259917|f||||f
17157925|NCT00482170|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157926|NCT04595279|t||||
17157927|NCT05537428|t||||
17157928|NCT01994902|f||LTE60||t
17157929|NCT00467558|f||||f
17157930|NCT02636439|f||||f
17157931|NCT04679948|t||||
17157932|NCT02371668|t||||
17157933|NCT00376532|t||||f
17157934|NCT03372382|f||||f
17157935|NCT04656301|f||LTE60||t
17157936|NCT02213380|f||||f
17157937|NCT03063619|t||||
17157938|NCT02090283|f||GT60||t
17157939|NCT03132415|t||||f
17157940|NCT03498313|f||||f
17157941|NCT00184002|t||||
17157942|NCT02499263|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17157943|NCT01579669|f||||f
17157944|NCT00527124|f||LTE60||t
17157945|NCT01041274|f||||f
17167783|NCT01166373|f||||f
17200224|NCT00630734|f||OTHER|Prior to publication or presentation, the PI will provide the sponsor with at least 60 days for review of a manuscript|t
17157946|NCT02075008|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17157947|NCT00660595|f||LTE60||t
17157948|NCT02028780|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17157949|NCT00777335|f||||f
17157950|NCT05205005|f||||f
17157951|NCT00909220|f||||f
17167784|NCT01819129|f||OTHER|At the end of the trial, one or more public disclosures may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17167785|NCT02914548|f||||f
17167786|NCT02182440|f||||f
17200225|NCT05985538|f||||f
17200226|NCT06152224|t||||
17167787|NCT02230761|f||LTE60||t
17200227|NCT00281320|f||OTHER|Institution will provide manuscripts, abstracts, or the full text of any other intended disclosure to the sponsor at least 30 days prior to submission for publication or other disclosure. If any patent action is required to protect intellectual property rights, Institution agrees to delay the disclosure for a period not to exceed and additional 60 days. Institution will, on request, remove any previously undisclosed Confidential Information (other than study results) before disclosure.|t
17200228|NCT01647945|t||||
17200229|NCT02902770|f||||f
17200230|NCT02755129|f||||t
17200231|NCT01447576|f||||f
17200232|NCT00975676|f||||f
17200233|NCT02579772|f||||f
17200234|NCT04991753|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17200235|NCT03388268|f||||f
17200236|NCT03299049|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200237|NCT01901419|t||||
17200238|NCT02296502|f||||f
17200239|NCT01667926|f||||f
17200240|NCT04486625|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200241|NCT04227145|f||||f
17200242|NCT01088984|f||OTHER|Investigator/Institution must submit proposed publication to Sponsor for review within a prespecified number of days before submission for publication. If Sponsor's review shows that potentially patentable subject matter would be disclosed, publication/public disclosure shall be delayed to enable Sponsor, or Sponsor's designees, to file necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17200243|NCT04707664|f||LTE60||t
17200244|NCT00699153|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with, the Sponsor and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee for comment.|t
17200245|NCT03054051|t||||
17200246|NCT02412735|f||OTHER|Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection.|t
17200247|NCT02521363|t||||
17167788|NCT00405964|f||LTE60||t
17167789|NCT01001546|t||||
17167790|NCT00167180|f||||f
17200248|NCT03374488|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17167791|NCT01253265|f||GT60||t
17167792|NCT02342379|t||||
17167793|NCT02863523|f||||f
17167794|NCT00066469|f||OTHER|Must obtain prior Sponsor approval.|t
17200249|NCT01757197|f||||f
17200250|NCT05530577|f||||f
17157952|NCT01148459|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17157953|NCT02187029|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157954|NCT00694356|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17157955|NCT05886907|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17157956|NCT03083808|f||||f
17137348|NCT01318512|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157957|NCT02700425|f||||f
17157958|NCT02496039|f||OTHER||t
17157959|NCT04472494|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17157960|NCT00571103|f||||f
17157961|NCT03735407|f||OTHER|All proposed publications and presentations by the Investigator, the Institution or their personnel and associates, resulting from or relating to the Study, must be submitted to the Company for review and approval at least forty five (45) days prior to submission for publication or presentation.|t
17200251|NCT01077128|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17200252|NCT01706705|t||||
17200253|NCT04703192|f||||f
17200254|NCT02088957|f||GT60||t
17200255|NCT01939353|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17200256|NCT02413645|t||||f
17200257|NCT00874731|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17200258|NCT00186017|f||||f
17200259|NCT02132832|t||||
17200260|NCT02931253|f||||f
17200261|NCT01132820|f||LTE60||t
17200262|NCT03470740|f||||f
17200263|NCT01048697|f||||f
17200264|NCT00667394|f||||f
17200265|NCT05000216|f||||f
17200266|NCT02874014|t||||
17200267|NCT06381986|f||||t
17200268|NCT05138289|f||||f
17200269|NCT02195479|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17200270|NCT03329300|f||||f
17200271|NCT03004404|t||||f
17200272|NCT01937975|f||OTHER|The sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.|t
17200273|NCT02522728|f||LTE60||t
17200274|NCT02028325|t||||f
17200275|NCT01266161|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200276|NCT01436305|f||||f
17200277|NCT03563066|f||||f
17200278|NCT05071053|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17200279|NCT01081886|f||LTE60||t
17200280|NCT04148651|f||||f
17200281|NCT01602510|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200282|NCT05262751|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137349|NCT00230100|t||||
17137350|NCT01032993|f||||f
17157962|NCT01308463|f||OTHER|"A publication which uses data in addition to the authors will be reviewed by all who have contributed data, and all of the contributors will be recognized.~All publications will be reviewed by BIOMET at least 30 days prior to publication."|t
17157963|NCT03297021|t||||
17157964|NCT04096001|f||||f
17157965|NCT02095197|t||||
17157966|NCT05114564|f||||f
17157967|NCT04217317|t||||
17200283|NCT03519204|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17200284|NCT02627118|f||||f
17200285|NCT01572740|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk Trial Manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17200286|NCT01289210|f||||f
17200287|NCT00137969|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200288|NCT01110408|f||GT60||t
17200289|NCT02269423|f||OTHER|All data may be published in the open medical or military literature with the identity of the subjects protected. Anyone desiring to publish or present data obtained during the conduct of the study will conform to WRAIR, USAMRIID, and the sponsor's policies and then forward the publication for review to the sponsor and usarmy.detrick.medcom-usamrmc.list.clearances@mail.mil prior to submission.|t
17200290|NCT00839956|f||||f
17200291|NCT01509547|t||||
17200292|NCT00277095|f||||f
17157968|NCT04313400|f||OTHER|The Investigator will refer to the Investigator agreement and clinical trial agreement for the publication and disclosure policy.|t
17157969|NCT01461473|t||||
17157970|NCT01784926|t||||
17157971|NCT00496587|t||||
17157972|NCT02383355|t||||
17157973|NCT01183416|t||||
17157974|NCT01146561|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17157975|NCT02036541|f||OTHER|The disclosure restriction on the PI is that the results of the multi-center trial must be published first, prior to any of the individual data being published|t
17157976|NCT01778751|t||||
17157977|NCT00868751|t||||
17157978|NCT03628716|f||OTHER|The Agreement entitles Bavarian Nordic to request the Institution(s) to delay their publication for a period of up to three (3) months from the date of the first submission to Bavarian Nordic.|t
17157979|NCT00856843|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.|t
17157980|NCT03078127|t||||f
17157981|NCT01366638|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17157982|NCT01451554|t||||
17157983|NCT01402986|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17157984|NCT01085084|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17157985|NCT02427802|f||OTHER|Results of the multicenter study had to be published prior to the publication of any site specific data.|t
17157986|NCT02749799|f||||f
17157987|NCT02634983|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17157988|NCT03749109|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17157989|NCT02070978|f||||t
17157990|NCT03951753|f||||t
17157991|NCT03178851|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or present ation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17157992|NCT04633291|f||LTE60||t
17157993|NCT02226120|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17157994|NCT00076258|f||||f
17157995|NCT02669043|f||||f
17157996|NCT03884270|t||||
17200293|NCT04147195|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17200294|NCT05899413|t||||f
17200295|NCT01555489|t||||
17200296|NCT01006980|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200297|NCT03312023|t||||
17200298|NCT02706405|t||||
17200299|NCT01228318|t||||
17200300|NCT03011567|f||||f
17200301|NCT01182441|f||||f
17200302|NCT02124811|t||||
17200303|NCT04043143|t||||
17200304|NCT03480932|f||||f
17200305|NCT05504954|f||||f
17200306|NCT02138786|f||||t
17200307|NCT01923662|t||||
17200308|NCT00659880|f||OTHER|PI may present/publish in meetings, journals, theses, dissertations the results of Investigation provided that RTI will have been furnished copies of any proposed publication/presentation at least 40 days in advance of the submission. RTI will have 30 days after receipt to object \& withhold consent to the proposed presentation/publication either because there is patentable subject matter which needs protection and or there is Confidential or inaccurate information contained in the publication|t
17200309|NCT04076787|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200310|NCT04646291|f||LTE60||t
17200311|NCT00669877|t||||
17157997|NCT00661453|t||||f
17157998|NCT01037816|f||||f
17157999|NCT02699190|t||||
17158000|NCT00401193|f||OTHER||t
17158001|NCT00398216|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site's proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.|t
17158002|NCT00570960|f||||f
17158003|NCT01048944|f||||f
17158004|NCT01844817|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17158005|NCT04227405|f||||f
17158006|NCT02207400|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158007|NCT03396822|f||||f
17158008|NCT02757352|f||GT60||t
17167795|NCT03271047|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200312|NCT01465763|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200313|NCT02920970|f||||t
17200314|NCT02378038|f||GT60||t
17200315|NCT01711853|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17200316|NCT01016847|t||||f
17200317|NCT02079025|f||||f
17200318|NCT02992691|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200319|NCT01427725|f||||f
17200320|NCT05071586|t||||
17200321|NCT04276051|t||||
17200322|NCT00392925|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17200323|NCT02221557|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. Sponsor reserves the right to require the PI to remove sponsor's confidential information. Upon sponsor's written request, publication will be delayed up to 60 days to enable sponsor to secure adequate intellectual property protection.|t
17200324|NCT01281839|f||GT60||t
17200325|NCT01277887|t||||
17200326|NCT00415051|f||||f
17200327|NCT00780559|t||||
17200328|NCT01495572|f||||f
17200329|NCT04462289|f||||f
17200330|NCT01518153|t||||
17200331|NCT00856245|t||||
17158009|NCT03638466|f||||t
17158010|NCT03251482|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17200332|NCT03168542|f||GT60||t
17200333|NCT02514551|f||GT60||t
17200334|NCT00672737|t||||
17200335|NCT01460225|f||||f
17200336|NCT01956097|f||||f
17200337|NCT04430439|f||||f
17200338|NCT03564353|t||||
17200339|NCT02645123|f||||f
17200340|NCT00388804|t||||f
17200341|NCT00777764|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200342|NCT05472740|t||||
17200343|NCT02998476|f||OTHER|Clinical Study Agreement|t
17200344|NCT03832595|f||||f
17200345|NCT03277352|f||OTHER|Clinical Study Agreement|t
17200346|NCT02397447|f||||f
17200347|NCT01435772|t||||
17200348|NCT03238963|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17200349|NCT02506933|t||||
17158011|NCT02447328|f||OTHER|14.1 The Institution and the Principal Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years of completion of the Study shall require the Company's prior written consent.|t
17158012|NCT02362425|t||||
17158013|NCT00596453|t||||
17158014|NCT00802672|f||OTHER||t
17158015|NCT01220726|f||||f
17158016|NCT02579382|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158017|NCT04474054|f||||f
17158018|NCT03026283|f||||f
17158019|NCT03782571|f||GT60||t
17158020|NCT00576524|t||||
17158021|NCT00493311|f||OTHER|Investigator may publish only after cooperative publication or 18 months after sponsor's final evaluation of study data, whichever occurs first. At least 60 days prior to submission for publication, investigator must submit manuscript to sponsor for review and comment. Sponsor has 60 day period thereafter to respond with comment. Investigator will remove confidential information at the request of sponsor.|t
17158022|NCT02779075|f||||f
17158023|NCT03959527|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo for a further 90 days in order to enable the sponsor to take steps to protect its proprietary information and/or Intellectual Property Rights.|t
17158024|NCT00707980|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17158025|NCT01152996|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17158026|NCT02163681|f||||f
17158027|NCT02072941|f||||f
17158028|NCT03146741|f||||f
17158029|NCT03224624|t||||f
17158030|NCT01884545|f||||f
17158031|NCT00519584|f||||f
17158032|NCT01648920|f||LTE60||t
17158033|NCT02521792|f||||t
17158034|NCT00398047|f||||f
17158035|NCT00902746|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17158036|NCT00351936|t||||
17158037|NCT02937636|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158038|NCT00889915|t||||f
17158039|NCT00770913|f||||f
17158040|NCT00596102|f||OTHER||t
17158041|NCT00359294|f||OTHER||t
17158042|NCT00583011|t||||
17200350|NCT01424813|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17200351|NCT02614183|f||||f
17200352|NCT03838731|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17200353|NCT01997905|f||||f
17200354|NCT05817383|f||||f
17200355|NCT02354820|t||||
17158043|NCT02946021|f||LTE60||t
17158044|NCT00290654|t||||
17158045|NCT02548949|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158046|NCT01398358|t||||
17158047|NCT01961167|f||||f
17158048|NCT03148067|f||||f
17158049|NCT02559570|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158050|NCT01396551|f||LTE60||t
17158051|NCT02934555|f||||f
17158052|NCT02446847|f||||f
17158053|NCT00524680|t||||
17158054|NCT01607346|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158055|NCT01098162|f||GT60||t
17158056|NCT00625183|t||||
17158057|NCT04424914|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158058|NCT04485637|f||||f
17158059|NCT02787681|f||||f
17158060|NCT00334295|f||||f
17158061|NCT01446250|f||OTHER||t
17158062|NCT03383692|f||||f
17158063|NCT00492232|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 150 days to permit actions necessary to preserve sponsor's intellectual property; can request changes to the results communication only for the purpose of removing non study related information that is proprietary and confidential to sponsor; can require delay of a results communication until the study has been completed at all participating sites.|t
17158064|NCT02453256|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158065|NCT01216332|f||||f
17158066|NCT00636636|f||OTHER|The PI agree that the sponsor shall have the right to the first publication of the results of the study which is intended to be joint, multi-center publication. Following the first publication, the PI may publish data or results from the study, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the data of the proposed publication.Sponsor may remove any information that is considered confidential and or proprietary other than study data.|t
17158067|NCT00524173|t||||
17158068|NCT01237327|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158069|NCT04233671|f||||f
17158070|NCT02483572|f||||f
17158071|NCT04811664|f||||f
17158072|NCT05052697|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158073|NCT01289574|f||||f
17158074|NCT00262002|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single site are postponed until the publication of the pool data (i.e., data from all sites) in the clinical trial.|t
17158075|NCT01790516|t||||f
17158076|NCT01554163|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17158077|NCT03034135|f||||f
17158078|NCT01972464|f||||f
17158079|NCT01133704|f||OTHER|A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.|t
17158080|NCT00136214|f||||f
17158081|NCT04985942|f||||t
17158082|NCT02232477|f||||f
17158083|NCT02849704|f||||f
17158084|NCT01290952|f||||f
17158085|NCT02576977|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17158086|NCT04508647|t||||
17158087|NCT01128400|t||||f
17158088|NCT03417752|t||||
17158089|NCT00699400|f||OTHER|Institution and Principal Investigator may disclose confidential information to the extent required by law or court order, provided that they promptly provide to EMD Serono prior notice of such disclosure and provide assistance in obtaining an order protecting Confidential Information from public disclosure.|t
17158090|NCT00885378|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤ 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17158091|NCT00006244|f||||f
17200356|NCT00603525|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200357|NCT02304705|f||||f
17200358|NCT01195948|t||||
17200359|NCT00770029|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 wks before submission. Sponsor to give written opinion within 30 d. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17158092|NCT04750278|f||||f
17158093|NCT01523834|f||||f
17158094|NCT01616758|f||||f
17158095|NCT03231397|t||||f
17158096|NCT04076319|f||||f
17158097|NCT01054222|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158098|NCT00824655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158099|NCT03504189|f||||t
17158100|NCT04336475|f||||f
17158101|NCT02511132|f||LTE60||t
17158102|NCT03188523|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17158103|NCT02665741|f||||f
17158104|NCT01983826|f||||f
17158105|NCT01466075|t||||f
17158106|NCT02096276|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17158107|NCT03746405|f||||f
17158108|NCT01703169|t||||
17158109|NCT01465230|t||||
17158110|NCT02014519|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158111|NCT04026750|t||||t
17158112|NCT02372383|t||||
17158113|NCT05076604|f||||f
17158114|NCT03258645|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17158115|NCT02171429|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158116|NCT01704755|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17158117|NCT01763203|f||||f
17200360|NCT02734498|t||||
17200361|NCT04210427|f||||f
17158118|NCT02187861|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158119|NCT04105842|f||||f
17158120|NCT01639703|f||OTHER|"All written or oral papers and publications must have the joint agreement of the investigator and the sponsor.~Each investigator agrees not to publish/submit/present the results of the study main criterion involving only the patients he/she has included.~Any abstract project will be first submitted to Guerbet at least 10 working days before submission to the congress scientific committee."|t
17158121|NCT00893074|f||||f
17158122|NCT04957212|t||||
17158123|NCT03476642|t||||
17158124|NCT02768792|t||||
17158125|NCT05980013|f||||f
17158126|NCT03124160|f||||f
17158127|NCT01768559|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17158128|NCT02782377|t||||
17158129|NCT01515696|t||||f
17158130|NCT00657657|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158131|NCT01188668|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158132|NCT00303472|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158133|NCT02081001|f||||f
17158134|NCT00090870|t||||
17158135|NCT05816070|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17158136|NCT02347072|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17158137|NCT02022735|t||||
17158138|NCT04388176|f||||f
17158139|NCT03124537|f||||f
17158140|NCT02801370|f||OTHER|Publication subject to Sponsor consent.|t
17158141|NCT03681184|f||LTE60||t
17158142|NCT02308371|f||||f
17158143|NCT00396383|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17158144|NCT03338244|f||||f
17158145|NCT04318132|f||||t
17158146|NCT00585325|t||||
17158147|NCT00893971|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17158148|NCT02526160|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158149|NCT00314808|t||||f
17200362|NCT01174446|f||OTHER|Agreements may vary with individual PIs, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or up to 3 years after study completion. Baxter requires a review of results communications (eg for confidential information) ≥60 days prior to submission/communication. Baxter may request additional delay of ≤180 days(e.g., for intellectual property protection). Prior authorization may be required.|t
17200363|NCT00929253|f||||f
17158150|NCT04304508|f||OTHER|PI prohibited from publishing results for 18 months following completion of the study at all sites. Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17158151|NCT02688764|f||OTHER|No results of the Services or other information on the Clinical Study may be disclosed or submitted for publication or presentation without the Sponsor's prior written agreement.|t
17158152|NCT02113007|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17158153|NCT01775787|t||||
17158154|NCT05725824|t||||
17158155|NCT03252145|t||||
17158156|NCT03091738|t||||
17158157|NCT03304106|f||OTHER|The disclosure restriction on the PIs, restricts sites from publishing site data or study data without sponsor review and approval.|t
17158158|NCT01267929|t||||f
17158159|NCT00199849|f||||f
17158160|NCT01662856|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17158161|NCT01944644|t||||
17158162|NCT00759655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158163|NCT01393522|f||||f
17158164|NCT02090777|f||||f
17158165|NCT03479008|t||||
17158166|NCT01490840|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17158167|NCT00389467|f||||f
17158168|NCT02362191|t||||
17158169|NCT01738919|f||||f
17158170|NCT00947310|f||GT60||t
17158171|NCT00741598|t||||
17158172|NCT02087670|t||||
17158173|NCT01042392|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158174|NCT05753735|f||||f
17158175|NCT02869893|f||||f
17158176|NCT01534416|t||||
17158177|NCT00435461|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158178|NCT00837967|f||||f
17158179|NCT02589847|f||GT60||t
17158180|NCT00551525|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17158181|NCT04676724|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17158182|NCT00287729|f||OTHER||t
17158183|NCT01150903|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158184|NCT01309451|f||||f
17158185|NCT04274075|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158186|NCT04156906|f||||f
17158187|NCT02588092|f||||f
17158188|NCT01090141|f||||f
17158189|NCT01030718|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17158190|NCT00099632|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17158191|NCT00423813|f||OTHER||t
17158192|NCT01386944|f||GT60||t
17158193|NCT03883477|t||||
17158194|NCT03853291|t||||f
17158195|NCT00777062|f||||f
17158196|NCT03658642|t||||
17158197|NCT00098670|f||LTE60||t
17158198|NCT02432209|f||||f
17158199|NCT02611765|f||||f
17158200|NCT02137226|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158201|NCT03290391|t||||
17158202|NCT03762681|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158203|NCT04270695|f||||f
17167796|NCT00915655|f||OTHER|The Sponsor will not unreasonably withhold consent to publish the data generated in this trial. However, it is the policy of the Sponsor not to allow the investigators to publish their results or findings prior to the Sponsor's publication of the overall trial results. The investigator agrees that before he/she publishes any results of this trial, he/she shall allow at least 45 days for the Sponsor to review the prepublication manuscript prior to submission of the manuscript to the publisher.|t
17167797|NCT01241344|f||OTHER|Within 18 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publication may be delayed up to an additional 3 months to allow Sponsor to seek patent protection.|t
17200364|NCT00847626|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17200365|NCT03057847|t||||f
17200366|NCT02769442|f||||f
17158204|NCT00882661|f||OTHER|To prevent premature disclosure of information, Investigators agree not to present, publish, or disclose study results or information about the Investigational Device without the express written consent of Sponsor.|t
17158205|NCT00003896|f||||f
17158206|NCT02373137|f||||f
17158207|NCT00985686|f||||f
17158208|NCT03134911|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158209|NCT01087203|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158210|NCT01670045|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200367|NCT05627258|t||||
17200368|NCT02658877|t||||
17200369|NCT01294397|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17200370|NCT01199068|f||||f
17200371|NCT01250925|f||LTE60||t
17200372|NCT00678301|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200373|NCT03338296|f||||t
17200374|NCT04421950|f||||f
17200375|NCT00387244|f||||t
17200376|NCT01725126|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200377|NCT01128270|f||||f
17200378|NCT03296800|f||OTHER|The Investigator has no right to publish the trial results.|t
17200379|NCT00677534|t||||
17200380|NCT02687035|f||||f
17200381|NCT01102764|f||||f
17200382|NCT02160730|t||||
17200383|NCT05214378|f||||f
17200384|NCT04028921|f||||f
17200385|NCT04076943|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17200386|NCT01031628|f||||f
17200387|NCT01238536|f||GT60||t
17200388|NCT00967005|f||||f
17200389|NCT00758342|t||OTHER|Confidentiality agreement|
17200390|NCT01371825|f||||f
17200391|NCT00895895|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200392|NCT01261000|t||||
17200393|NCT00504777|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158211|NCT00537290|f||||f
17158212|NCT04283253|t||||
17158213|NCT01064362|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200394|NCT03514277|f||||t
17200395|NCT01621776|f||||f
17200396|NCT03552523|t||||
17200397|NCT03285555|t||||
17200398|NCT00755105|t||||
17200399|NCT03995316|t||||
17200400|NCT03697551|f||||t
17200401|NCT02985840|t||||
17200402|NCT01250509|t||||
17200403|NCT01766713|f||||f
17200404|NCT02205034|t||||
17200405|NCT00203268|t||||f
17200406|NCT00600613|t||||
17200407|NCT00847522|t||||
17200408|NCT02807883|t||||
17200409|NCT01691950|t||||
17200410|NCT02523690|t||||f
17200411|NCT04041037|f||||f
17200412|NCT01399918|t||||
17200413|NCT05380362|f||||f
17200414|NCT05415748|t||||
17200415|NCT04520659|f||||f
17200416|NCT03852719|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17200417|NCT02819024|t||||
17200418|NCT00792948|f||LTE60||t
17200419|NCT04944290|f||GT60||t
17200420|NCT03809039|f||OTHER||t
17200421|NCT01252355|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17200422|NCT01734239|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17200423|NCT03882177|f||||f
17200424|NCT00509249|f||LTE60||t
17200425|NCT02224703|f||GT60||t
17200426|NCT02922023|t||||
17200427|NCT00863681|f||OTHER||t
17200428|NCT03031496|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200429|NCT01254552|f||OTHER||t
17200430|NCT02579135|f||||f
17200431|NCT01146600|t||||
17200432|NCT02766777|f||||t
17200433|NCT01886287|t||||
17200434|NCT03596762|f||OTHER|The PI is required to postpone communication of results until a joint, multicenter publication of the multicenter study has occurred, or the sponsor confirms that no joint publication will be prepared, or 18 months since completion of the data analysis have passed. The sponsor can review planned publications for up to 60 days and request reasonable amendments. The review period can be extended by up to 6 months in case a patent application is planned.|t
17200435|NCT01263509|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17158214|NCT02787083|f||LTE60||t
17158215|NCT02710084|t||||
17167798|NCT00495521|f||||f
17167799|NCT00392808|t||||
17200436|NCT02593123|t||||
17200437|NCT02440425|f||OTHER|The study may be presented at scientific meetings by any of the study investigators with the approval of the Sponsor and also allowing time for prior review by Merck. Intent to submit should be made no later than 4 weeks before a submission is due, and a copy of an abstract or presentation should be submitted no later than 3 weeks prior to finalization or submission to allow time to review.|t
17200438|NCT02807272|f||OTHER|There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.|t
17200439|NCT01038427|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200440|NCT01162863|t||||f
17200441|NCT00588692|t||||f
17200442|NCT01374568|f||||f
17200443|NCT01912404|f||LTE60||t
17200444|NCT04910139|f||||f
17200445|NCT00820170|t||||
17200446|NCT03538938|f||||f
17200447|NCT00604708|f||OTHER||t
17200448|NCT01361594|t||||
17200449|NCT01754753|f||||f
17200450|NCT02775071|f||||f
17200451|NCT04526730|t||||
17200452|NCT03745898|f||||f
17200453|NCT03197766|f||OTHER||t
17200454|NCT00671177|f||||f
17200455|NCT04485611|t||||
17158216|NCT05305989|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17158217|NCT03162328|f||||f
17158218|NCT00282152|t||||
17200456|NCT03361865|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17200457|NCT05543187|f||||t
17200458|NCT05619575|t||||
17200459|NCT01647542|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17200460|NCT03086655|f||||f
17200461|NCT03008005|f||||f
17200462|NCT01744704|f||||f
17200463|NCT04522921|t||||f
17200464|NCT01040169|f||GT60||t
17200465|NCT00558792|f||OTHER|The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.|t
17200466|NCT05371665|t||||
17200467|NCT03633799|f||||t
17200468|NCT03551691|f||||f
17200469|NCT05855967|f||GT60||t
17158219|NCT03301831|f||||f
17158220|NCT01124370|f||||f
17158221|NCT02182830|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158222|NCT00154375|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158223|NCT03268005|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17158224|NCT03715452|f||||f
17158225|NCT00357890|t||||
17158226|NCT00845676|t||||
17158227|NCT01680653|f||||f
17158228|NCT00481767|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158229|NCT01142947|f||||f
17200470|NCT02446821|f||||f
17200471|NCT02638883|f||||t
17158230|NCT04378569|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17158231|NCT01962948|t||||
17167800|NCT03911752|f||||f
17200472|NCT02284009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200473|NCT04897841|t||||
17200474|NCT02603328|f||||f
17200475|NCT03898778|f||||f
17200476|NCT05430815|t||||
17200477|NCT06532357|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200478|NCT04092530|f||||f
17200479|NCT04942366|f||||f
17200480|NCT03301155|f||||t
17200481|NCT00448201|t||||
17200482|NCT00384189|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17200483|NCT00608868|f||LTE60||t
17200484|NCT03289351|t||||f
17200485|NCT00335140|f||||f
17200486|NCT04546425|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200487|NCT03165747|t||||
17200488|NCT02979249|f||||f
17200489|NCT01125046|t||||
17200490|NCT02339545|f||LTE60||t
17200491|NCT03868787|f||||f
17200492|NCT01685229|f||GT60||t
17200493|NCT00558844|f||OTHER|"Per the signed Investigator Agreement in the study protocol and protocol amendments, the PI agreed not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated."|t
17200494|NCT01012362|f||||f
17200495|NCT01720277|f||||f
17200496|NCT01399697|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200497|NCT04313608|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200498|NCT03079284|f||||f
17200499|NCT03019640|t||||
17200500|NCT00668265|t||||
17200501|NCT01229878|t||||
17200502|NCT03617835|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200503|NCT02817906|f||||t
17200504|NCT03686423|t||||
17200505|NCT02833077|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17200506|NCT00972322|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17200507|NCT01077518|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17200508|NCT01495598|t||||f
17200509|NCT03599687|t||||
17200510|NCT01807000|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17200511|NCT05511038|f||GT60||t
17200512|NCT05140915|f||||f
17200513|NCT04879849|f||||t
17200514|NCT03746392|t||||
17200515|NCT03810235|t||||
17200516|NCT04777864|f||||f
17200517|NCT05576662|t||||
17200518|NCT01217437|f||LTE60||t
17200519|NCT00871286|t||||
17200520|NCT03682185|f||||f
17200521|NCT00350727|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200522|NCT04908631|t||||
17200523|NCT03520712|f||LTE60||t
17200524|NCT03841526|f||||f
17158232|NCT03630705|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17200525|NCT04047862|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17200526|NCT04746846|t||||
17200527|NCT04996004|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158233|NCT04560868|f||||f
17158234|NCT04727528|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years of completion of the Study shall require the Sponsor's prior written consent.|t
17158235|NCT01763827|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158236|NCT01826981|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158237|NCT02906579|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17158238|NCT05381454|f||||f
17158239|NCT00168428|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158240|NCT02030119|f||||f
17158241|NCT02793947|t||||
17158242|NCT03457818|f||||f
17158243|NCT02179047|f||||t
17158244|NCT01310127|t||||f
17158245|NCT00412932|f||OTHER|"If identified by Daiichi Sankyo, Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted. Nothing in this Publication section shall be taken as giving DSI the right of editorial control over any publication prepared by the study site."|t
17158246|NCT03331263|f||OTHER|Written consent must be obtained|t
17158247|NCT02749227|t||||
17158248|NCT03639857|t||||f
17158249|NCT01025284|f||GT60||t
17158250|NCT02753816|t||||
17158251|NCT00905567|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17158252|NCT02542397|t||||f
17158253|NCT01473940|t||||
17158254|NCT00547248|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158255|NCT00534248|f||LTE60||t
17158256|NCT02020369|f||LTE60||t
17158257|NCT02532257|t||||
17158258|NCT02849171|t||||
17158259|NCT04727736|t||||
17158260|NCT00459810|f||GT60||t
17158261|NCT02259400|f||||f
17158262|NCT00315614|t||||
17158263|NCT00697593|f||OTHER||t
17158264|NCT00112918|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158265|NCT02964338|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17158266|NCT00587795|t||||
17158267|NCT02826161|f||OTHER|Before submission for publication or presentation, Institution and/or Investigator shall allow Sponsor not less than sixty ( 60) days to review any manuscript and not less than thirty ( 30) days to review any poster presentation, abstract or any other written or oral material which describes or discloses the study results. If Sponsor requests in writing, institution and/or Investigator shall withhold any publication or presentation for an additional sixty ( 60) days.|t
17158268|NCT05593770|f||||f
17158269|NCT00123682|t||||
17158270|NCT05446142|t||||
17158271|NCT02098395|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17158272|NCT01310582|f||||f
17158273|NCT00547157|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158274|NCT00110357|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17158275|NCT03382418|f||||f
17158276|NCT04633226|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17158277|NCT02536105|f||||f
17158278|NCT01151345|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158279|NCT04585243|f||||f
17158280|NCT04208412|f||||f
17158281|NCT03828214|f||OTHER||t
17158282|NCT00305565|f||LTE60||t
17158283|NCT00420628|f||OTHER|"The results of the study may be published or presented by the investigator(s) after the review by, and in consultation and agreement with Bausch \& Lomb, and such that confidential or proprietary information is not disclosed.~Prior to publication or presentation, a copy of the final text should be forwarded by the investigator(s) to Bausch \& Lomb or its designee, for comment."|t
17158284|NCT01830933|f||||f
17158285|NCT02984644|f||||f
17200528|NCT02942277|f||OTHER|"Before either Party submits a paper or abstract for publication or otherwise intends to publicly disclose information about a CRADA Subject Invention, CRADA Data, or CRADA Materials, the other Party will have thirty (30) days to review proposed manuscripts and fifteen (15) days to review proposed abstracts to assure that Confidential Information is protected.~Dr. Patrick Duffy is employed by the clinical sponsor, NIAID (clinical sponsor). Dr. Sagara is not employed by either sponsor."|t
17200529|NCT05577715|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17200530|NCT04087811|f||||t
17200531|NCT03317990|f||||f
17200532|NCT01656252|f||||f
17200533|NCT04833127|f||||f
17200534|NCT04440839|f||||f
17200535|NCT04552899|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167801|NCT00823212|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17167802|NCT01975519|f||||f
17167803|NCT02585830|f||||f
17167804|NCT02509052|t||||
17167805|NCT00620425|f||||f
17167806|NCT00760461|t||||
17167807|NCT01044212|t||||
17167808|NCT01690546|f||||f
17167809|NCT01323270|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167810|NCT03404804|f||||f
17167811|NCT00711347|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17167812|NCT03761394|t||||f
17167813|NCT05357664|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17167814|NCT01657344|f||||f
17167815|NCT04274153|f||||f
17200536|NCT05282121|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200537|NCT01736189|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17200538|NCT00561431|f||||f
17200539|NCT03512964|f||||f
17200540|NCT05467293|f||||f
17200541|NCT00731133|t||||
17200542|NCT03510455|f||||f
17200543|NCT02190903|t||||
17200544|NCT03098563|f||||f
17200545|NCT01476449|t||||
17200546|NCT02964325|f||LTE60||t
17200547|NCT02510040|f||||f
17200548|NCT00643617|f||||f
17200549|NCT03085225|f||||f
17200550|NCT04606901|f||||f
17200551|NCT02551653|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200552|NCT01373580|f||OTHER|The investigator agreed to hold this information in confidence and not to disclose it to any third parties for a period of three years from the date of this agreement, or until this information becomes a matter of public knowledge or until a formal agreement for that purpose has been entered into by the parties.|t
17200553|NCT02202785|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17200554|NCT02180243|t||||f
17158286|NCT00360009|f||||f
17158287|NCT03620383|t||||
17158288|NCT05095311|f||||f
17158289|NCT01540513|t||||
17158290|NCT00502853|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158291|NCT02588664|f||||f
17158292|NCT01429298|t||||
17158293|NCT04229771|t||||
17158294|NCT00227019|f||||f
17158295|NCT03092791|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17158296|NCT02348008|f||||f
17158297|NCT01909141|t||||
17158298|NCT04672044|t||||
17158299|NCT01181947|f||OTHER|Medical Center or Investigator may, at his/her discretion, publish and/or present publicly the results of the work of Medical Center and/or Investigator performed under this Agreement. However, should Medical Center or Investigator contemplate publishing and/or presenting publicly such results, the Investigator shall provide copies of any abstracts, papers, or manuscripts to Medtronic for review at least 90 (ninety) days prior to submittal for publication or presentation.|t
17158300|NCT00792116|t||||
17200555|NCT01137578|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17200556|NCT00968071|t||||
17200557|NCT04145700|f||GT60||t
17200558|NCT00818779|t||||
17200559|NCT04978493|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200560|NCT01327846|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200561|NCT04343976|t||||
17200562|NCT00594880|f||||f
17200563|NCT01371708|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200564|NCT00694109|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17200565|NCT01254747|t||||
17137351|NCT01317615|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17167816|NCT01643850|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17167817|NCT03242772|f||||f
17200566|NCT00846807|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17200567|NCT00245960|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200568|NCT00737698|t||||
17200569|NCT01067846|f||||f
17200570|NCT02654652|f||||f
17200571|NCT00201877|t||||f
17200572|NCT04608773|t||||f
17200573|NCT02387970|t||||
17200574|NCT01310231|f||||f
17200575|NCT04662060|t||||
17200576|NCT01436253|f||OTHER|No Investigator may publish or disclose any study information without permission from the Sponsor.|t
17200577|NCT01390870|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200578|NCT00316017|f||||f
17200579|NCT01198067|t||||
17200580|NCT04531982|f||||f
17200581|NCT04839185|t||||
17200582|NCT03468478|t||||
17200583|NCT04266795|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17200584|NCT03570892|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17200585|NCT01876082|t||||
17200586|NCT04854850|t||||f
17200587|NCT04427280|t||||
17200588|NCT04683627|f||||t
17200589|NCT03829501|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17200590|NCT01123070|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17200591|NCT03284229|f||||f
17200592|NCT00954187|t||||
17200593|NCT02988050|t||||
17200594|NCT01977677|f||LTE60||t
17200595|NCT00974818|t||||
17167818|NCT00529126|f||||f
17167819|NCT01118520|t||||
17167820|NCT01187004|f||||f
17167821|NCT00145418|t||||
17167822|NCT01070693|f||||f
17167823|NCT01089023|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200596|NCT00626197|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158301|NCT04541329|t||||f
17158302|NCT03335813|t||||
17158303|NCT01724177|f||OTHER|Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17158304|NCT00856791|f||OTHER|The Investigators agree to inform the Sponsor of any publication or presentations on the study. All manuscripts, abstracts or presentations (in outline form with copies of slides if available) will be submitted to the Sponsor at least 30 days prior to the submission of the data for publication in order for the Sponsor to protect proprietary information. The Sponsor will review the submitted material within a reasonable period of time and will not unreasonably withhold publication permission.|t
17158305|NCT01400906|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158306|NCT01457417|f||OTHER|Publication of the results shall not be made before the publication by Sponsor. If there is no multi-site publication within 18 months after the Study completion/termination at all sites, the Site shall have the right to publish its results. Prior to submitting to public release the Sponsor has 60 days from receipt to review and comment. The Site shall, upon Sponsor's request, further delay publication/presentation for up to 120 days to allow Sponsor to protect its interests.|t
17158307|NCT02762071|t||||
17200597|NCT00461981|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17200598|NCT02383940|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17200599|NCT02308787|f||OTHER|Study Site reserves the right to publish the results of its work on the Study. Study Site and the PI agree to submit copies of any manuscript/abstract proposed for publication to Sponsor at least 30 days in advance of the presentation. Sponsor may require the delay of publication for no longer than 90 days for the purpose of filing patent applications.|t
17200600|NCT02672852|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17200601|NCT04958642|f||||t
17200602|NCT04308590|f||OTHER|No individual publications will be allowed before publication of the multicenter results, except as agreed with Corcept. The Investigator agrees to submit all manuscripts or abstracts to Corcept for review before submission to the publisher.|t
17200603|NCT01541384|f||||f
17200604|NCT05487586|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200605|NCT04798781|t||||
17200606|NCT03853551|f||OTHER|The institution and/or investigator/Physician or Sponsor will provide a copy of any proposed publication or presentation for review and comment at least sixty (60) days prior to submission for publication.|t
17200607|NCT02476175|f||||f
17200608|NCT03417544|f||||f
17200609|NCT02175641|f||||f
17200610|NCT00821951|t||||
17200611|NCT03921723|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200612|NCT01876901|f||||f
17200613|NCT02683785|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200614|NCT00534495|f||||f
17200615|NCT00441259|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17200616|NCT01346072|f||LTE60||t
17158308|NCT00141518|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17158309|NCT01101750|f||||t
17200617|NCT02233803|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137352|NCT02121756|f||||f
17137353|NCT00255086|f||||f
17137354|NCT00632541|f||||f
17137355|NCT03629041|f||||f
17137356|NCT03041909|f||OTHER|The sponsor and the PI will have to agree on any publications regarding the study.|t
17200618|NCT03635099|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158310|NCT01806168|f||||f
17158311|NCT02693262|f||||f
17158312|NCT01753713|t||||
17200619|NCT01068665|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17200620|NCT00858689|f||||f
17200621|NCT04191616|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17200622|NCT04230122|f||OTHER||t
17200623|NCT03398902|f||||f
17200624|NCT01840410|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17200625|NCT01868425|t||||
17200626|NCT01800890|t||||
17200627|NCT01012297|f||LTE60||t
17200628|NCT02671500|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17200629|NCT02870049|f||||f
17200630|NCT05686122|t||||f
17200631|NCT05235269|f||OTHER|All study data will be regarded as confidential until analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented at scientific meetings by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor. Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment.|t
17158313|NCT02438280|f||||f
17137357|NCT00592553|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17137358|NCT02379390|f||||f
17137359|NCT01179347|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17158314|NCT01100723|f||||f
17158315|NCT02134795|f||||f
17158316|NCT03066778|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17158317|NCT02328937|f||GT60||t
17167824|NCT04644796|f||||f
17167825|NCT00904618|t||||
17167826|NCT03220581|f||||f
17200632|NCT00798434|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200633|NCT05292586|f||OTHER|Results of this study may be published or presented at scientific meetings. If a publication is presented by the Investigator, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor to Chiesi before submission.|t
17200634|NCT06122870|f||||f
17200635|NCT05511467|f||||f
17200636|NCT01099215|f||OTHER|Company-specific confidentiality agreement|t
17200637|NCT02896075|t||||f
17200638|NCT00747227|f||OTHER|PIs may not publish or disclose study data without Sponsor's prior written approval.|t
17200639|NCT03554629|f||||f
17200640|NCT03149809|t||||
17200641|NCT01692951|t||||
17200642|NCT01174576|f||||f
17200643|NCT03789175|t||||f
17200644|NCT00515671|f||||f
17200645|NCT00814177|f||||f
17200646|NCT00288639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17200647|NCT02952534|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17200648|NCT02385240|f||OTHER||t
17200649|NCT01014208|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200650|NCT04165031|f||GT60||t
17200651|NCT00225017|f||||f
17200652|NCT01332630|t||||
17200653|NCT03140280|t||||
17200654|NCT02981108|f||||f
17137360|NCT03342937|f||||f
17137361|NCT00369967|t||||f
17137362|NCT01677624|f||OTHER||t
17167827|NCT00413920|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167828|NCT02434354|f||||f
17167829|NCT03730961|f||LTE60||t
17167830|NCT02071420|f||||f
17167831|NCT01185964|f||GT60||t
17167832|NCT01920893|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17167833|NCT02257177|f||OTHER|The Investigators must agree to maintain the confidentiality of the study at all times and must not reveal any information relating to the study without express permission from the study Sponsor.|t
17167834|NCT03440918|f||||f
17167835|NCT02081638|t||||
17167836|NCT00391469|f||||f
17200655|NCT00663702|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17200656|NCT01498887|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17200657|NCT03079297|t||||
17200658|NCT00667225|f||||f
17200659|NCT02993406|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17200660|NCT02248818|f||GT60||t
17200661|NCT05262517|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200662|NCT04325282|t||||
17158318|NCT02091414|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200663|NCT00465998|t||||
17200664|NCT00527787|f||OTHER|PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential results following Sponsor review and comment.|t
17200665|NCT03330405|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200666|NCT02643303|f||||f
17158319|NCT02237989|f||||f
17158320|NCT03665077|t||||
17158321|NCT02959918|f||||t
17158322|NCT03231306|f||||f
17158323|NCT02306850|f||||f
17158324|NCT00237692|t||||f
17158325|NCT01456143|f||||f
17158326|NCT05391555|t||||
17158327|NCT00685360|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158328|NCT02488018|f||||f
17158329|NCT01850394|t||||f
17158330|NCT03571607|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158331|NCT00074815|f||||f
17158332|NCT04865419|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17158333|NCT02733341|t||||
17158334|NCT05415462|f||||t
17200667|NCT02783027|t||||f
17200668|NCT01598662|t||||
17200669|NCT03898167|f||||f
17137363|NCT03713957|f||OTHER|The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI.|t
17137364|NCT02757092|f||||f
17200670|NCT05177354|f||OTHER|"The Institution must ensure the Discloser gives a copy of any proposed Publication drafted by them and/or Personnel involved in the conduct of the Study to the Sponsor at least 40 days The Sponsor may do one of the following~1. provide optional comments~2. request delay for no more than 120 days to file patent applications or take other measures to preserve or secure its IP, Institution must abide by request~3. request removal of Confidential Information from the Publication"|t
17137365|NCT00255034|f||LTE60||t
17200671|NCT00462605|f||LTE60||t
17200672|NCT03548220|f||OTHER|The information obtained from the clinical study will be used towards the development of AG-348 and may be disclosed to regulatory authority(ies), other Investigators, corporate partners, or consultants as required|t
17137366|NCT01743872|f||||f
17137367|NCT02858154|f||||f
17200673|NCT02906007|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17137368|NCT00218426|f||||f
17167837|NCT03754582|f||||t
17167838|NCT02680574|f||||t
17167839|NCT02847858|f||||f
17200674|NCT05486416|f||GT60||t
17200675|NCT01946529|t||||
17200676|NCT03960047|f||||f
17200677|NCT06655558|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 365 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17200678|NCT00542542|t||||f
17200679|NCT03446001|f||||t
17158335|NCT01348100|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17158336|NCT01129804|f||||f
17158337|NCT03882957|t||||f
17158338|NCT02974803|f||||f
17158339|NCT01608672|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158340|NCT02259699|f||||f
17158341|NCT04186221|f||OTHER|Sites shall have right to publish results. To balance this right with TransMedics' (TM) proprietary interests, site will submit manuscripts intended for publication for TM review at least 30 days prior to submission date. TM will complete its review within 30 days of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request.|t
17200680|NCT03987295|f||OTHER|Alector's agreements with principal investigators may vary but will not prohibit any investigator from publishing. Alector supports the publication of the results from all centers in a multi-center trial, and its agreements include provisions to enable the multi-center publication to occur before publication of data from a single site.|t
17200681|NCT06748729|t||||
17200682|NCT00282672|f||LTE60||t
17200683|NCT02525718|t||||
17200684|NCT01253135|f||LTE60||t
17200685|NCT01802151|f||||f
17200686|NCT01901432|f||||f
17200687|NCT00129480|t||||
17200688|NCT00379288|f||OTHER|The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.|t
17200689|NCT00918879|f||||f
17200690|NCT00685139|f||GT60||t
17200691|NCT00833261|t||||
17200692|NCT00357110|f||OTHER|The PI will provide ASTRAZENECA as soon as possible with preliminary data and drafts of proposed results communications and with the proposed final draft at least 14 days prior to submission of an abstract and 30 days prior to submission of a manuscript. ASTRAZENECA can, upon written request, embargo communications regarding trial results for no more than 45 days from the date of the written request. ASTRAZENECA cannot require changes to the communication and cannot extend the embargo.|t
17200693|NCT04045964|t||||
17200694|NCT05602727|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17200695|NCT05520775|t||||
17200696|NCT01283152|f||||f
17200697|NCT02441985|f||||f
17200698|NCT05241314|t||||
17200699|NCT04020185|f||||f
17200700|NCT04414202|t||||
17200701|NCT03433677|f||GT60||t
17200702|NCT04339959|f||||f
17200703|NCT01499303|f||||f
17200704|NCT06264128|t||||
17200705|NCT04939701|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17200706|NCT00565773|f||||f
17200707|NCT00702962|f||||f
17200708|NCT00919191|f||LTE60||t
17200709|NCT01923467|f||||f
17200710|NCT03015129|t||||
17200711|NCT02242097|t||||
17200712|NCT01075958|f||||f
17200713|NCT01562041|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17200714|NCT03733314|f||||t
17200715|NCT01240915|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200716|NCT04297631|f||||f
17200717|NCT02574845|t||||
17200718|NCT04246021|t||||
17200719|NCT03435692|t||||f
17200720|NCT04091061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200721|NCT00821587|t||||f
17200722|NCT01693900|f||||f
17200723|NCT01712061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200724|NCT04481568|t||||
17200725|NCT00879775|f||||f
17200726|NCT01195623|t||||
17158342|NCT01134393|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17158343|NCT00531947|f||OTHER|The Investigator is free to publish for their own research or publication objectives, provided that such does not disclose Confidential Information. At least 45 days prior the Investigator shall submit for Sponsor review. Sponsor will advise of revisions necessary to preserve confidential and proprietary information. The first publication of the results shall be a joint Multi-Center publication of results with the investigators from all study sites contributing data.|t
17158344|NCT02364076|t||||
17200727|NCT01677767|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200728|NCT03846453|f||||t
17200729|NCT00468143|f||||f
17200730|NCT00472849|t||||f
17200731|NCT01606670|f||GT60||t
17200732|NCT04664075|t||||
17200733|NCT02636725|t||||
17200734|NCT02145468|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158345|NCT02903420|f||OTHER|Without the Sponsor's prior written consent, the Principal Investigator shall not publish the clinical study results or any documents containing any Study information at any academic conferences or in any publications of any nature.|t
17158346|NCT03852498|f||||t
17158347|NCT00980655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158348|NCT03939533|f||||f
17158349|NCT01124292|f||||f
17158350|NCT03373461|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158351|NCT03300180|f||||f
17158352|NCT00461097|f||||f
17158353|NCT01941537|t||||
17158354|NCT00857961|f||GT60||t
17158355|NCT02557516|f||||f
17158356|NCT03020550|f||||f
17158357|NCT02957357|f||||f
17158358|NCT00588146|t||||f
17158359|NCT02823470|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17158360|NCT03442725|f||||f
17158361|NCT00463801|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158362|NCT02315664|f||||f
17158363|NCT02501161|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17158364|NCT03159299|f||||f
17158365|NCT01990573|t||||
17158366|NCT01957579|f||||f
17158367|NCT00652145|f||||f
17158368|NCT01639144|t||||
17158369|NCT00983645|t||||
17158370|NCT02224612|t||||f
17158371|NCT01520207|t||||
17158372|NCT04812184|f||||f
17158373|NCT02630563|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158374|NCT02239640|f||OTHER|Researchers may Publish their individual site experience, but Sponsor reserves the exclusive right to Publish (or coordinate the Publication of) the complete accumulated results of the Registry, and to establish authorship criteria for such Publications for the Registry group based on Registry conduct and compliance, contribution to the Registry's design, management or enrollment and willingness to accept the rights and responsibilities of an author.|t
17200735|NCT00623805|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158375|NCT02485483|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158376|NCT02061813|f||||f
17158377|NCT00558012|f||||f
17158378|NCT01965002|f||||f
17158379|NCT00700375|t||||
17158380|NCT01705080|f||||f
17158381|NCT04846270|f||||f
17158382|NCT00206427|t||||
17158383|NCT01999985|t||||
17158384|NCT00281697|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158385|NCT00828061|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158386|NCT03130959|f||LTE60||t
17158387|NCT02384538|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17158388|NCT04446429|f||||f
17158389|NCT02256917|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17158390|NCT00313586|f||LTE60||t
17200736|NCT00635128|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200737|NCT01949389|t||||
17158391|NCT03076996|t||||
17158392|NCT03117361|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17158393|NCT01027468|t||||
17158394|NCT00988000|t||||
17158395|NCT03280056|f||||f
17158396|NCT02144077|f||OTHER|The only disclosure restriction on the PI is that the sponsor will review results communications prior to public release and has to approve in order to ensure the adequate reporting of study results. The sponsor can't refuse publication for unfair reasons.|t
17158397|NCT00610168|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158398|NCT00943592|f||||f
17158399|NCT01247350|f||GT60||t
17200738|NCT04655027|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17200739|NCT02245022|f||||f
17200740|NCT03519997|f||||f
17200741|NCT03820947|f||OTHER||t
17200742|NCT03578887|f||||f
17158400|NCT00169104|f||OTHER|The sponsor will be provided 30 days to review a manuscript and 15 days to review a poster. The sponsor may request an additional 60 days to review study results prior to their release, if the request is submitted in writing.|t
17158401|NCT01540981|f||||f
17158402|NCT00397189|f||LTE60||t
17158403|NCT02620683|f||||f
17158404|NCT01535443|f||OTHER|"All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.~All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor."|t
17158405|NCT02457195|f||||f
17200743|NCT06118957|f||||f
17200744|NCT01736943|t||||
17200745|NCT00387426|f||LTE60||t
17200746|NCT02218606|t||||
17200747|NCT00890695|t||||
17200748|NCT01531673|f||OTHER|Restriction Description: PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or(3)18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17200749|NCT02187159|f||||f
17200750|NCT00567567|f||OTHER|Must obtain prior Sponsor approval.|t
17200751|NCT03889704|t||||
17200752|NCT03482466|f||||f
17200753|NCT02060370|t||||
17200754|NCT01493427|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17200755|NCT01461811|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17200756|NCT02781090|f||||f
17200757|NCT02278484|f||LTE60||t
17200758|NCT01401153|t||||
17200759|NCT00757627|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200760|NCT00403767|f||LTE60||t
17200761|NCT05330676|t||||
17200762|NCT00436605|f||LTE60||t
17200763|NCT03878277|f||||f
17200764|NCT03417570|t||||
17200765|NCT01559129|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17200766|NCT00368927|f||LTE60||t
17200767|NCT03525392|f||||t
17200768|NCT03750786|f||||f
17200769|NCT03284203|t||||
17200770|NCT02229851|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17200771|NCT01111240|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17200772|NCT02206061|f||||f
17200773|NCT04187326|f||||f
17200774|NCT01607476|t||||
17200775|NCT01675453|t||||
17200776|NCT02193490|t||||
17158406|NCT02028507|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 30 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication.|t
17158407|NCT00551174|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158408|NCT02420262|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17158409|NCT05050448|f||||f
17158410|NCT00436826|f||OTHER||t
17158411|NCT00784719|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158412|NCT06597084|f||OTHER||t
17200777|NCT02299414|t||||
17200778|NCT04958200|f||||f
17200779|NCT02539459|t||||
17200780|NCT00749957|f||||f
17200781|NCT01533753|t||||
17200782|NCT04531098|f||||t
17200783|NCT02628028|f||GT60||t
17200784|NCT04157400|t||||
17200785|NCT01809834|f||LTE60||t
17200786|NCT00186888|t||||
17200787|NCT02108964|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200788|NCT04711837|f||GT60||t
17200789|NCT05570630|f||||f
17200790|NCT05820295|t||||f
17200791|NCT02344290|f||LTE60||t
17200792|NCT04998812|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200793|NCT03826030|t||||
17200794|NCT02745353|f||||f
17200795|NCT05014568|f||||t
17200796|NCT04893460|f||||f
17200797|NCT04015869|t||||
17200798|NCT04193826|f||||f
17200799|NCT05718466|t||||
17200800|NCT03203473|f||||f
17200801|NCT04420949|t||||
17200802|NCT01325311|f||LTE60||t
17200803|NCT00568178|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200804|NCT01008553|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17200805|NCT04138576|f||||f
17200806|NCT03733990|f||||f
17200807|NCT03563157|f||||t
17200808|NCT04335591|f||||f
17200809|NCT03268603|t||||
17200810|NCT00356408|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17200811|NCT02863289|t||||
17200812|NCT05775991|f||||f
17200813|NCT04514510|t||||
17200814|NCT00406692|t||||
17200815|NCT03174431|t||||
17200816|NCT01867333|f||||f
17200817|NCT01145898|t||||f
17200818|NCT02638597|t||||
17200819|NCT00951015|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200820|NCT01167452|f||||f
17200821|NCT03819634|f||||f
17200822|NCT01208103|t||||
17200823|NCT00299494|f||||f
17200824|NCT00416195|f||||f
17200825|NCT01882764|f||||f
17200826|NCT00414167|f||||f
17200827|NCT01417104|f||||f
17200828|NCT03101462|t||||
17200829|NCT00795275|f||||f
17200830|NCT00214019|t||||f
17200831|NCT00842244|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200832|NCT00827099|f||||f
17200833|NCT01701102|t||||
17200834|NCT00635661|f||||f
17200835|NCT01353118|t||||
17200836|NCT01696955|f||LTE60||t
17200837|NCT03192475|t||||f
17200838|NCT01681121|f||OTHER||t
17158413|NCT01588405|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17158414|NCT03479944|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17158415|NCT00729300|f||||f
17182037|NCT01572038|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182038|NCT03662100|f||GT60||t
17182039|NCT01275066|f||LTE60||t
17182040|NCT02281851|t||||
17182041|NCT01661712|f||||f
17182042|NCT01200875|f||||f
17158416|NCT02029274|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17158417|NCT02735473|t||||
17158418|NCT05346237|t||||
17158419|NCT03654729|f||||t
17158420|NCT00308516|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17158421|NCT01563198|f||||f
17158422|NCT01000974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158423|NCT02750332|f||||f
17158424|NCT00621257|t||||
17182043|NCT02623803|t||||
17182044|NCT00850200|t||||
17182045|NCT02981381|f||||f
17182046|NCT02098161|t||||
17200839|NCT01696045|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17200840|NCT00573859|f||||f
17200841|NCT05319912|f||||t
17200842|NCT03541200|f||OTHER||t
17200843|NCT02297100|t||||
17158425|NCT01255904|t||||
17158426|NCT00581061|f||LTE60||t
17158427|NCT00632125|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17158428|NCT02872909|t||||
17158429|NCT00540644|t||||
17158430|NCT00809094|f||||f
17158431|NCT02094326|f||||f
17158432|NCT00232557|t||||
17158433|NCT01059773|f||OTHER|A copy of the manuscript must be provided to the Sponsor for review at least 60 days prior to submission for publication or presentation. No paper that incorporates Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, such publication will be withheld for up to an additional 60 calendar days. A publication from the individual Study site data will not be published until the combined results have been published.|t
17158434|NCT00235573|t||||
17158435|NCT01029262|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 12 months since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17158436|NCT03410992|f||GT60||t
17158437|NCT02260817|f||||f
17158438|NCT04435808|f||||f
17158439|NCT03299101|t||||
17158440|NCT02104427|f||GT60||t
17158441|NCT01896193|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158442|NCT00807612|f||||t
17158443|NCT01300247|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158444|NCT04819438|f||||f
17158445|NCT03465709|f||||t
17158446|NCT05359952|t||||
17158447|NCT02258659|t||||
17158448|NCT04892446|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158449|NCT00272844|t||||
17158450|NCT03060291|t||||
17158451|NCT00718094|t||||
17158452|NCT05171270|f||||f
17158453|NCT01556932|t||||
17158454|NCT01882803|f||||t
17158455|NCT01563913|t||||
17158456|NCT01549340|f||OTHER|The Sponsor shall be notified and have a right to timely and prior review of public disclosures of the results, including without limitation, disclosures at research seminars, lectures and professional meetings and submission of papers for publication.|t
17158457|NCT02585713|f||||f
17158458|NCT02264210|f||||f
17158459|NCT03956030|t||||
17158460|NCT03173456|t||||
17137369|NCT01830816|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17137370|NCT00830115|f||||f
17137371|NCT05340322|f||||f
17158461|NCT01733121|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17158462|NCT04736069|t||||
17158463|NCT02247739|f||LTE60||t
17158464|NCT04501952|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158465|NCT03061188|t||||
17158466|NCT00573872|t||||f
17158467|NCT00613379|f||OTHER|Because the study is a multicenter study, the PI(s) can only publish after the aggregate results of all investigators and institutions participating in the study have been published, and the proposed publication is reviewed by Progenics. In the event that Progenics does not publish the results of the study within eighteen months from availability of final study analysis, the PI can publish provided that the proposed publication is reviewed by Progenics.|t
17158468|NCT02080364|f||OTHER|Where PI requires the use of the Study Results for publication, the PI shall seek the Sponsor's written approval which shall not be unreasonably withheld; provided, however, that (i) Sponsor may require removal of any Confidential Information of Sponsor or may delay publication for a reasonable period of time in order to secure protection any IP Rights; and, (ii) as the Study is designed as a multi-center Study, no publication shall be made until after the first multi-center publication.|t
17158469|NCT02609984|f||OTHER|Manuscripts reporting the results of this clinical trial, abstracts, press releases, and other media presentations must be provided to the Sponsor for review and comment 30 days prior to submission for publication and may be delayed for up to an additional 30 days in order to ensure that confidential and proprietary data, and intellectual property rights, are protected. Co-authorship of publications will be discussed and mutually agreed upon before submission of a manuscript to a publisher.|t
17158470|NCT02504320|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17158471|NCT01210222|f||LTE60||t
17158472|NCT02497404|t||||
17158473|NCT01408901|f||||f
17158474|NCT04978337|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17158475|NCT03509181|f||||f
17200844|NCT01333813|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200845|NCT01276379|f||OTHER|"Complying with the R.D. 223/2004, the results of this trial will be published, both positive and negative results in recognized scientific journals or congress.~The Sponsor and the Investigators are fully committed to publishing the results of the study.~All publications (i.e., manuscripts, abstracts, oral / slide presentations, book chapters) based on this study must be submitted to the sponsor for review prior to publication."|t
17200846|NCT00864253|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to submission; Celgene shall complete its review within 60 days. Institution shall review comments from Celgene. Upon Celgene's request, proposed publication will be delayed up to 60 additional days to allow Celgene to secure adequate intellectual property protection of patentable material.|t
17200847|NCT01896726|f||GT60||t
17200848|NCT01128114|f||||f
17137372|NCT03050216|t||||
17137373|NCT01207388|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17137374|NCT01885078|f||GT60||t
17137375|NCT01546285|f||OTHER|The sponsor cannot require changes to the PI's disclosure, with the exception of requesting the removal of sponsor's confidential information. The study results themselves are not considered confidential information. Sponsor cannot extend the embargo beyond 60 days unless the PI's disclosure contains patentable subject matter, in which an embargo beyond 60 days may be necessary to allow for the filing of a patent application|t
17137376|NCT01610076|f||||f
17200849|NCT00208325|f||OTHER|DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but the PI will retain final editorial control.In case of disagreement,DePuy and the PI will make every effort to meet in order to discuss and resolve any issues.|t
17158476|NCT04686422|f||LTE60||t
17158477|NCT04060797|t||||
17158478|NCT00544908|t||||
17158479|NCT03131687|f||GT60||t
17158480|NCT00826150|f||||f
17158481|NCT01654263|f||LTE60||t
17158482|NCT01904032|t||||
17158483|NCT00768287|f||||f
17158484|NCT01616160|t||||
17158485|NCT04074330|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17158486|NCT01903993|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158487|NCT00184093|t||||
17158488|NCT00972283|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17158489|NCT00401518|f||OTHER|To prevent premature disclosure of trade secrets or other confidential information, Investigator agrees not to present, publish, or disclose study results or information about the investigational device without the express written consent of the sponsor.|t
17158490|NCT01242241|t||||
17158491|NCT02600611|f||||t
17158492|NCT01868165|t||||
17158493|NCT03167255|f||OTHER|The most restrictive relevant agreement on the PI provides that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is not less than 30 days from the time submitted to the sponsor for review.|t
17158494|NCT02282163|f||||f
17158495|NCT01603407|f||OTHER|The PI cannot publish any manuscript without review and written consent of the FOR-DMD study steering committee.|t
17158496|NCT02500719|t||||f
17158497|NCT01990768|f||GT60||t
17158498|NCT03538691|f||||f
17158499|NCT01440634|f||||f
17158500|NCT01243177|f||GT60||t
17158501|NCT05251233|t||||
17158502|NCT02271217|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17158503|NCT00707967|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158504|NCT03117634|f||OTHER|"Contract Partners shall provide to Sponsor any proposed publication or oral presentation relating to the Study or Study Drug and Results (Publications), at least thirty days prior to the intended submission or presentation in order to allow SPONSOR to review it.~If Sponsor does not notify Contract Partner within thirty (30) days of receipt of intended Publication, Contract Partner shall be free to publish."|t
17158505|NCT02245815|t||||
17158506|NCT01919164|f||||f
17182047|NCT02046148|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158507|NCT01398852|f||OTHER|All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.|t
17158508|NCT01543568|t||||
17158509|NCT00667992|f||||f
17158510|NCT01431313|t||||f
17158511|NCT02748057|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17158512|NCT03834025|t||||
17158513|NCT02588586|t||||
17158514|NCT00391872|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.|t
17158515|NCT02484092|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158516|NCT05554640|f||GT60||t
17158517|NCT00215644|f||||f
17158518|NCT05122624|t||||
17158519|NCT02861664|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158520|NCT01239394|t||||f
17158521|NCT01476267|f||||f
17182048|NCT00181207|f||||f
17182049|NCT01110421|f||GT60||t
17158522|NCT00905632|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIs intellectual property rights.|t
17158523|NCT01666912|t||||
17158524|NCT03782987|t||||
17158525|NCT02781818|t||||f
17158526|NCT00524771|t||||f
17158527|NCT01223404|f||||f
17158528|NCT00707057|f||LTE60||t
17158529|NCT02492165|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17158530|NCT04611542|t||||
17158531|NCT02915159|f||LTE60||t
17158532|NCT01761643|t||||
17158533|NCT02821416|f||GT60||t
17158534|NCT01065571|f||||f
17158535|NCT00716807|t||||
17158536|NCT01001520|t||||
17158537|NCT02541422|t||||
17158538|NCT01351090|f||||f
17158539|NCT04254081|f||||f
17158540|NCT00613821|f||||f
17158541|NCT01266824|t||||
17158542|NCT02302846|t||||
17158543|NCT03868839|t||||
17158544|NCT00872521|f||GT60||t
17158545|NCT01468454|t||||
17158546|NCT02620787|f||||f
17158547|NCT02982863|t||||
17158548|NCT03929263|t||||
17158549|NCT03549598|t||||
17158550|NCT05612217|f||||f
17158551|NCT00705341|f||||f
17158552|NCT00791700|f||OTHER|Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study participating sites. Investigator may not disclose previously undisclosed confidential other than study results.|t
17158553|NCT01472822|t||||f
17158554|NCT00205660|f||||f
17158555|NCT03672344|f||OTHER|Research sites that employed the PIs agreed not to disclose the trial results without the sponsor's prior written consent.|t
17158556|NCT01720524|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200850|NCT04445987|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17200851|NCT01803282|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17200852|NCT01743989|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200853|NCT03568643|f||||f
17200854|NCT02235311|f||||f
17200855|NCT05543707|f||||f
17200856|NCT03006848|t||||
17158557|NCT00996034|f||OTHER|The sponsor has 30 days to approve anything that PI would like to publish and/or present|t
17158558|NCT02493452|f||||t
17158559|NCT00527826|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158560|NCT00158262|f||||f
17158561|NCT03628378|t||||
17158562|NCT02105285|f||||f
17158563|NCT01421641|f||||f
17158564|NCT00883415|f||||f
17158565|NCT00086450|t||||
17158566|NCT01504672|f||||f
17158567|NCT04550364|f||||f
17158568|NCT01436227|t||||
17158569|NCT03774888|f||||f
17137377|NCT01396239|f||OTHER|"The Non Disclosure Agreement provides that the PI, Dr. Jerry Mendell, cannot disclose any results of the discussions or evaluation without our consent, and that the proprietary information shall not be evaluated by any laboratory or clinical testing or experimentation conducted without our consent."|t
17158570|NCT05464420|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17158571|NCT01383018|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158572|NCT00438204|t||||f
17158573|NCT03021317|t||||
17158574|NCT03414229|t||||
17158575|NCT03576924|f||||f
17158576|NCT04533438|f||||f
17158577|NCT05279131|f||OTHER||t
17158578|NCT02497937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158579|NCT03790865|f||||t
17158580|NCT02273362|f||LTE60||t
17158581|NCT03866278|f||||f
17158582|NCT00990509|f||||f
17158583|NCT01888952|t||||
17158584|NCT01066871|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can with reasonable grounds require changes to the communication which do not change the scientific statement or neutrality of the communication.|t
17158585|NCT04162795|f||LTE60||t
17158586|NCT01065558|f||LTE60||t
17158587|NCT01449734|t||||
17158588|NCT04530838|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158589|NCT00803712|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158590|NCT00052078|f||||f
17158591|NCT02672176|t||||f
17158592|NCT04780815|f||||f
17158593|NCT03565874|t||||
17158594|NCT03440619|t||||
17158595|NCT00669318|t||||
17158596|NCT01073163|f||OTHER|Investigator/Institution must submit proposed publication to Sponsor for review within a prespecified number of days before submission for publication. If Sponsor's review shows that potentially patentable subject matter would be disclosed, publication/public disclosure shall be delayed to enable Sponsor, or Sponsor's designees, to file necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17158597|NCT03272347|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17158598|NCT00703677|f||OTHER|The Publication Policy for the National Institute of Neurological Disorders and Stroke (NINDS) Pilot Therapeutic Trials Network (NPTUNE) outlines procedures for the development and review of concept sheets, abstracts, publications, presentations. Investigators must submit an application to the NPTUNE Publications Committee for the use of data. A Writing Committee, appointed by the Publications Committee, is responsible for initiating, coordinating, and approving publications and presentations.|t
17158599|NCT00578279|t||||f
17158600|NCT04441788|f||OTHER||t
17158601|NCT00753298|f||OTHER|Astra Tech shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed in order for Astra Tech to file patent applications.|t
17158602|NCT01196377|f||||f
17158603|NCT03859648|f||||f
17158604|NCT01677182|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17158605|NCT00995722|f||||f
17158606|NCT00762762|f||LTE60||t
17158607|NCT02489448|t||||
17158608|NCT01971567|t||||
17158609|NCT02603211|t||||
17158610|NCT03939923|f||||f
17200857|NCT01187381|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17200858|NCT00384397|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17200859|NCT02336451|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17200860|NCT01214642|f||GT60||t
17200861|NCT00994175|t||||
17200862|NCT02954198|f||||f
17200863|NCT04372121|f||||f
17200864|NCT03345576|f||||f
17200865|NCT01732822|f||||f
17200866|NCT02314780|t||||
17200867|NCT02083107|t||||
17200868|NCT00215137|f||||f
17200869|NCT00336700|t||||
17200870|NCT01183260|f||||f
17200871|NCT01255631|t||||f
17200872|NCT00384774|f||OTHER|Details of the Study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17200873|NCT02420951|f||||f
17200874|NCT00264303|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17200875|NCT02815579|f||||f
17158611|NCT00758498|f||GT60||t
17158612|NCT01516736|f||||t
17158613|NCT00320242|f||||f
17158614|NCT00472732|f||||f
17158615|NCT01369745|f||LTE60||t
17158616|NCT00878800|f||LTE60||t
17158617|NCT00715299|f||||f
17158618|NCT00411450|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158619|NCT00614874|f||||f
17158620|NCT01502033|f||||f
17158621|NCT01808261|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158622|NCT00941304|f||OTHER||t
17158623|NCT03293394|f||||f
17158624|NCT01861002|f||GT60||t
17158625|NCT04004260|f||||f
17158626|NCT01765569|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158627|NCT00271219|t||||
17158628|NCT06329687|f||||t
17158629|NCT05568797|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17158630|NCT02651337|f||||f
17158631|NCT02401035|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158632|NCT00869128|f||||f
17158633|NCT05137002|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo for up to 90 days.|t
17158634|NCT02998996|f||||t
17158635|NCT04693078|f||||f
17158636|NCT01118663|f||||f
17158637|NCT03046953|f||||f
17158638|NCT04039204|t||||
17158639|NCT01189461|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158640|NCT02716584|t||||
17158641|NCT04457362|t||||
17158642|NCT00656175|t||||
17158643|NCT00594230|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17158644|NCT02149264|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17158645|NCT03472521|t||||
17158646|NCT02284386|f||||f
17158647|NCT03705286|f||||f
17200876|NCT02389452|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17200877|NCT02311673|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17200878|NCT02566044|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17200879|NCT00769652|t||||
17200880|NCT00414908|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment.|t
17158648|NCT01401543|f||GT60||t
17158649|NCT02308228|f||||f
17158650|NCT03999749|f||OTHER|The Sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the Investigator. Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17158651|NCT05259163|f||||f
17158652|NCT00913081|t||||
17158653|NCT01381926|f||||f
17158654|NCT05787860|t||||
17158655|NCT02100839|f||||f
17158656|NCT00940888|f||||f
17158657|NCT01952418|t||||
17158658|NCT00678015|t||||
17158659|NCT01409915|f||||f
17158660|NCT00511173|t||||
17158661|NCT04826484|f||||f
17158662|NCT02250300|t||||
17200881|NCT00818168|f||OTHER|Trial results belong to the SPONSOR only, all investigators are not allowed to publish trial results without permission of the SPONSOR.|t
17200882|NCT02040259|f||OTHER|Physician shall not make any publication without providing Sponsor 60 days notice. If Sponsor determines that the proposed publication contains confidential information, Sponsor may require the delay of publication for a period of time not to exceed 90 days and may require that any confidential information be removed from the publication. Sponsor may also require Physician to delay publication until any factual errors or inaccuracies in the publication are corrected.|t
17200883|NCT04476251|f||||f
17158663|NCT03782181|f||||f
17158664|NCT01587105|t||||
17158665|NCT02726789|f||||f
17158666|NCT01307891|f||||f
17158667|NCT03365934|f||OTHER||t
17158668|NCT01781208|f||||f
17158669|NCT02937740|f||||t
17158670|NCT04194489|f||||f
17158671|NCT01289548|t||||
17158672|NCT01851655|f||||f
17158673|NCT03397121|f||||t
17158674|NCT00305227|f||||f
17158675|NCT04085601|f||OTHER||t
17158676|NCT03492437|f||OTHER||t
17158677|NCT02418234|f||||f
17158678|NCT04534517|f||GT60||t
17158679|NCT03872843|t||||
17158680|NCT00823264|t||||
17158681|NCT05133323|f||||f
17158682|NCT00113295|f||||f
17158683|NCT01714544|f||OTHER|No report, abstract, oral presentation, or publication proposed by the Investigator/Institution in regard to Study shall be presented or published without the prior written consent of the Sponsor. Sponsor reserves the right to comment on and delay the proposed report, abstract, oral presentation, or publication and to revise as necessary to protect confidential information or intellectual property.|t
17158684|NCT02697214|t||||
17158685|NCT02459197|f||LTE60||t
17158686|NCT00577772|t||||
17158687|NCT00572455|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158688|NCT02824224|t||||
17158689|NCT03846544|f||||f
17158690|NCT03180957|f||||f
17158691|NCT04152083|f||||f
17158692|NCT00856999|f||||f
17158693|NCT03557918|f||||f
17158694|NCT04575090|t||||
17158695|NCT02465437|f||||t
17158696|NCT00003483|f||||f
17158697|NCT04131712|t||||f
17158698|NCT02363387|f||||f
17158699|NCT00873730|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17158700|NCT02299388|f||||f
17158701|NCT00103662|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17158702|NCT04391179|t||||
17158703|NCT04218279|t||||f
17158704|NCT01869777|t||||
17158705|NCT00613366|f||||f
17158706|NCT02820870|t||||
17158707|NCT02051790|f||||f
17158708|NCT01716663|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present, or publish trial results after the trial is completed. Please contact Biosense Webster for additional information.|t
17200884|NCT02334982|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17200885|NCT00921687|t||||
17200886|NCT00316602|f||||t
17200887|NCT00626990|f||||f
17200888|NCT01507987|f||OTHER|The sponsor can review results communications prior to public release and embargo communications regarding trial results for 12 months from study completion date to allow time for multi-center study publication. After this period, the PI shall submit to sponsor for review a copy of any proposed manuscript at least 30 days prior to the estimated date of submission for publication. Sponsor may require delay of publication not to exceed 60 days for the purpose of filing patent applications.|t
17200889|NCT01534143|t||||
17200890|NCT01008410|f||OTHER|Please contact Sponsor directly for additional information.|t
17200891|NCT01151852|f||||f
17200892|NCT00297427|f||||f
17158709|NCT01936363|f||OTHER||t
17158710|NCT02644278|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17158711|NCT03478371|f||OTHER||t
17167840|NCT03785587|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied .|t
17167841|NCT00711802|f||GT60||t
17200893|NCT01951352|f||||f
17200894|NCT03056300|f||LTE60||t
17200895|NCT03248882|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200896|NCT01656200|f||||f
17200897|NCT02734576|t||||f
17200898|NCT01156376|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17200899|NCT04073446|f||||t
17200900|NCT02797080|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights.|t
17200901|NCT01305408|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17200902|NCT02530970|f||GT60||t
17200903|NCT02119442|f||||f
17200904|NCT04678505|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17200905|NCT01365481|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200906|NCT00047697|f||||f
17200907|NCT05254080|t||||
17200908|NCT00799981|f||||f
17200909|NCT01641159|f||||f
17200910|NCT00632489|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17200911|NCT03653208|f||||t
17158712|NCT00905424|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17158713|NCT01156805|f||||f
17158714|NCT03311841|f||OTHER|The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.|t
17158715|NCT03360019|f||||f
17167842|NCT02305849|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17167843|NCT02410824|f||OTHER||t
17167844|NCT02782325|t||||f
17167845|NCT02818036|t||||f
17167846|NCT01038713|t||||
17200912|NCT01249027|f||LTE60||t
17200913|NCT03752970|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17200914|NCT03478904|f||||f
17200915|NCT01152814|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17167847|NCT03058666|f||||f
17200916|NCT04368364|t||||
17200917|NCT01669577|f||||f
17158716|NCT01462110|f||OTHER|PI must provide Sponsor 60 days to review any publication (unless expedited review requested); if includes Sponsor's confidential info, written Sponsor approval is required. Sponsor may require another 60 days' delay to file patent app. If multicenter, PI agrees 1st publication is joint publication. If join publication not submitted within 24 months of study end or Sponsor confirms there will be no joint publication, PI may publish the results individually following previous guidelines.|t
17158717|NCT00964028|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158718|NCT02385110|t||||
17158719|NCT02371876|f||GT60||t
17200918|NCT01283516|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17200919|NCT05833100|f||||f
17158720|NCT00534638|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158721|NCT04776928|t||||
17158722|NCT00103285|f||OTHER|Must obtain prior Sponsor approval.|t
17158723|NCT03031340|t||||
17158724|NCT02624947|f||||t
17158725|NCT06785090|f||||f
17158726|NCT02675764|f||||f
17158727|NCT00335517|f||||f
17158728|NCT03569098|f||||t
17158729|NCT01697800|f||||f
17158730|NCT00954122|f||OTHER||t
17158731|NCT01000987|f||||f
17158732|NCT00522548|f||||f
17158733|NCT02121795|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158734|NCT00994110|t||||
17158735|NCT00666211|t||||
17158736|NCT02683239|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17158737|NCT02609386|f||OTHER|Sponsor shall have the right to first publication. Following first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to Sponsor for review at least 60 days prior to the date of the proposed publication. Sixty days shall be extended to 120 days if Sponsor determines that the publication contains patentable matter.|t
17158738|NCT00815997|t||||
17158739|NCT01354197|t||||f
17158740|NCT03334188|f||||f
17158741|NCT03373760|f||||f
17158742|NCT01093586|t||||
17158743|NCT03442088|t||||
17158744|NCT00105989|f||GT60||t
17158745|NCT00357877|f||||f
17158746|NCT04668209|f||||f
17158747|NCT03570047|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200920|NCT00132873|f||LTE60||t
17200921|NCT02045875|t||||
17158748|NCT00028262|t||||
17158749|NCT01588158|t||||f
17158750|NCT00766597|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17158751|NCT02754518|t||||
17158752|NCT01135524|f||GT60||t
17158753|NCT03318003|f||||f
17158754|NCT02907463|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17158755|NCT02427841|t||||
17158756|NCT00511810|t||||
17167848|NCT01154283|f||||f
17158757|NCT02896569|f||||f
17158758|NCT03861780|f||||t
17158759|NCT00618826|t||||f
17167849|NCT03777917|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17200922|NCT00444275|f||||f
17200923|NCT03030859|f||||f
17200924|NCT01204710|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. Sponsor may request publication delay up to 90 days to seek patent protection.|t
17158760|NCT04167189|f||LTE60||t
17158761|NCT01509664|t||||f
17158762|NCT02855567|t||||
17158763|NCT03626701|f||||f
17158764|NCT00426764|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation.|t
17158765|NCT05225389|f||OTHER|The Institution will not publish or present any Study Data, results, Study Inventions, or Sponsor Confidential Information without prior written approval from the Sponsor. Institution will keep confidential and not disclose any information provided by or on behalf of Sponsor or CRO or that is generated, discovered, or obtained by any Party as a result of the Study (other than patient medical records), including the Study results, Study Inventions and information related thereto.|t
17158766|NCT03804268|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158767|NCT01737879|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158768|NCT01843803|t||||
17158769|NCT05285787|f||||f
17158770|NCT01509612|f||||f
17158771|NCT02360280|t||||
17200925|NCT00586612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158772|NCT02472886|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17158773|NCT00320788|f||OTHER|After completion of the trial, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review; provided that the sponsor can remove confidential or proprietary information from such communications. The sponsor cannot require other changes to the communication and cannot extend the embargo.|t
17158774|NCT00627926|f||GT60||t
17158775|NCT02017093|f||||f
17158776|NCT05216835|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca.|t
17158777|NCT01678664|f||||f
17158778|NCT01408719|t||||
17158779|NCT02797678|f||||f
17158780|NCT02981914|t||||
17158781|NCT01852513|f||||f
17158782|NCT00753675|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17158783|NCT00333710|t||||
17158784|NCT03283930|t||||
17158785|NCT02686164|f||||f
17158786|NCT02465164|t||||
17158787|NCT01074177|t||||
17158788|NCT02106351|f||||t
17167850|NCT00042432|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17167851|NCT01853072|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167852|NCT01816906|t||||
17167853|NCT01527383|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17200926|NCT02839889|f||LTE60||t
17200927|NCT02001064|f||||f
17200928|NCT01609062|f||OTHER|PI cannot publish any data prior to multi-centre publication. If publication related to sub-sets of data it shall make reference to the relevant multi-centre publication. PI agrees to submit material to Sponsor for review up to 60 days prior to publication and incorporate all reasonable comments. During review, Sponsor may request that publication be delayed for up to 6 months from date of first submission to Sponsor in order for Sponsor to take steps to protect its proprietary information.|t
17200929|NCT02738853|f||||f
17158789|NCT01931397|f||||f
17158790|NCT00520039|t||||f
17158791|NCT00223665|f||||f
17200930|NCT00515723|f||||f
17200931|NCT02626455|f||LTE60||t
17200932|NCT01937026|f||GT60||t
17200933|NCT01882543|f||OTHER|1st publication to be a joint publication within 18 months of completion or termination of the trial at all sites. If not done the PI can publish separately, pending sponsor review 60 days prior to publication. PI agrees to remove sponsor confidential info. If sponsor identifies info it wishes to obtain IP protection for, PI agrees to remove sponsor identified info, or delay publication until the sponsor obtains IP protection and 120 calendar days from 1st submission for review to sponsor.|t
17200934|NCT00979550|f||||f
17200935|NCT03002220|f||||f
17200936|NCT01015560|f||||f
17200937|NCT00926497|t||||
17200938|NCT00640133|f||||f
17200939|NCT00128102|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17200940|NCT02225132|t||||
17158792|NCT05176717|f||OTHER|Institution shall be free to publish, present, or use any Data and results arising out of its performance of the protocol. At least 30 days prior to submission for publication, institution shall submit to Sponsor for review and comment any proposed oral or written publication. Institution will consider any such comments in good faith but is under no obligation to incorporate Sponsor's suggestions. The review period for abstracts or poster presentations shall be 30 days.|t
17158793|NCT03284853|f||||f
17158794|NCT00534417|f||OTHER|The Investigator shall submit a copy of any manuscript or material proposed for publication or the text of any presentation relating to the results of the Study to AstraZeneca and Roche for review and comment at least 30 days prior to its submission for publication or presentation.|t
17158795|NCT00765817|f||GT60||t
17200941|NCT01202903|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200942|NCT01302080|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200943|NCT03425097|t||||
17200944|NCT01006252|f||GT60||t
17200945|NCT02654691|f||||f
17200946|NCT02683772|f||LTE60||t
17200947|NCT01076153|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17200948|NCT01318018|t||||
17200949|NCT02124603|f||||f
17200950|NCT01142232|t||||
17200951|NCT01663922|t||||f
17200952|NCT00574873|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200953|NCT00597246|t||||
17200954|NCT00201643|f||LTE60||t
17158796|NCT01043133|t||||
17158797|NCT00255164|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17158798|NCT05219968|f||OTHER|Except as approved by Sponsor, single center data will not be published before multicenter data, unless \>1 year has elapsed since completion of the Study. PI may publish single center data provided that PI shall: i) provide a copy of the publication to Sponsor at least 60 days in advance of submission for publication; ii) delete Sponsor Confidential Information and make other reasonable changes; and iii) delay submission by up to 90 additional days to permit intellectual property filings.|t
17158799|NCT04587336|t||||
17158800|NCT00452439|t||||
17200955|NCT03866798|f||||f
17200956|NCT04142359|f||||t
17200957|NCT05263388|f||||f
17200958|NCT02787044|f||||f
17158801|NCT03974802|f||||f
17158802|NCT01550510|t||||
17158803|NCT03107182|f||||f
17158804|NCT04147247|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158805|NCT00130689|t||||f
17158806|NCT00943397|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158807|NCT04878055|f||||f
17158808|NCT01968811|f||||f
17158809|NCT01254656|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158810|NCT00814138|f||||f
17158811|NCT02372344|f||LTE60||t
17158812|NCT01116037|f||||f
17158813|NCT02258217|f||||f
17158814|NCT02532374|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17158815|NCT02254772|f||||f
17158816|NCT05225558|f||||f
17158817|NCT03006562|t||||
17158818|NCT03904420|f||OTHER|The disclosure restriction on the PIs, no data was to be published prior to sponsor publishing. However, an agreement was in place with one site to provide presentation at upcoming conference for a poster presentation.|t
17158819|NCT00716456|t||||
17158820|NCT00447772|f||LTE60||t
17158821|NCT00572260|f||||f
17158822|NCT00875563|f||GT60||t
17158823|NCT05417412|f||||f
17158824|NCT05438277|f||||f
17158825|NCT02592447|t||||
17158826|NCT01841970|f||||f
17158827|NCT05926648|t||||
17158828|NCT02849743|t||||f
17158829|NCT02050334|f||||f
17158830|NCT01048541|f||LTE60||t
17158831|NCT00627497|f||OTHER|The PI must provide the sponsor a copy of the results communication ninety (90) days prior to submission or disclosure. The sponsor shall not censor the results communication beyond the protection of confidential information. Investigator agrees to delete confidential information prior to any submission, publication, presentation or other disclosure. The sponsor can embargo results communications up to sixty (60) days.|t
17158832|NCT00922116|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158833|NCT04607135|t||||
17158834|NCT00807885|f||OTHER|For this study, Baxter requires a review of any planned PI results communications (eg, for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).|t
17158835|NCT02364388|f||OTHER|Any publication based on the results obtained at the trial site (or a group of sites), including subsets of data, shall not be made before the first multi-center publication.|t
17158836|NCT00327717|f||||f
17158837|NCT00805129|t||||
17158838|NCT02487797|f||||f
17158839|NCT02499120|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158840|NCT03571724|f||||t
17158841|NCT03471832|f||||f
17167854|NCT00746733|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17167855|NCT03412604|f||||f
17167856|NCT02989844|t||||
17167857|NCT01287221|f||||f
17200959|NCT00794144|f||OTHER|The sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17200960|NCT00490490|f||||f
17200961|NCT02324608|t||||
17200962|NCT03207451|f||||f
17200963|NCT02040584|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17200964|NCT05540717|f||OTHER||t
17158842|NCT00870467|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17158843|NCT00181883|f||||f
17158844|NCT00101868|f||||f
17158845|NCT00069823|f||||f
17158846|NCT02329327|f||||t
17158847|NCT03560869|f||||f
17167858|NCT00930969|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication."|t
17167859|NCT00657150|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17200965|NCT01940939|f||||f
17200966|NCT01470001|f||||f
17200967|NCT04786964|f||OTHER|The sponsor owns and publishes clinical trial results. The PI cannot publish results unless and until requested in writing by the sponsor.|t
17200968|NCT02591953|t||||
17200969|NCT00673959|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party onther than Contractors, the data arising out of the study.|t
17200970|NCT03167359|t||||
17200971|NCT01896557|f||||f
17200972|NCT01517295|f||||f
17200973|NCT02182947|f||||f
17200974|NCT02440659|f||||f
17158848|NCT01801111|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158849|NCT01210482|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158850|NCT01223937|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17158851|NCT00765947|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158852|NCT02058589|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158853|NCT02532283|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17158854|NCT00490971|f||GT60||t
17158855|NCT00816777|f||GT60||t
17158856|NCT04376515|f||||f
17158857|NCT01683604|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158858|NCT04369833|t||||
17158859|NCT03430856|f||||f
17158860|NCT01900847|f||||f
17158861|NCT00962078|t||||
17158862|NCT01949142|f||OTHER|"From the Protocol:~14.11. Use of Information and Publication. All information concerning OTO-201...remains the sole property of Otonomy. Any publication or other public presentation of results from this study requires prior review and written approval of Otonomy. Draft abstracts, manuscripts, and materials for presentation at scientific meetings should be provided to the sponsor at least 30 working days prior to abstract or other relevant submission deadlines."|t
17158863|NCT02002871|f||||f
17158864|NCT00565604|f||LTE60||t
17158865|NCT00674206|t||||
17158866|NCT03512353|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158867|NCT01845597|f||||f
17158868|NCT04403113|t||||f
17158869|NCT02581488|f||OTHER|PI to submit results for proposed publication/presentation to the sponsor no later than 90 days prior to the submission. Sponsor to reply within 60 days. Submission of publication/presentation may be delayed an additional 6 months to permit filing of appropriate patent applications. If a multicenter publication is not submitted within 24 months of the conclusion of the study, the Investigator may publish individual site results after review by sponsor.|t
17158870|NCT01877668|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158871|NCT01302418|f||LTE60||t
17158872|NCT04754646|f||GT60||t
17158873|NCT00377637|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158874|NCT03045653|f||||f
17167860|NCT02966795|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17167861|NCT02649192|t||||
17167862|NCT03561701|f||OTHER|Neither institution nor investigator can disclose information pertaining to study until sponsor issues multi-center publication. If multi-center publication is not issued within 18 months of study completion and database lock at all sites, sponsor has 30 days from receipt to review institution's and/or investigator's communication and can require removal of confidential information other than study data and/or delay release of institution's and/or investigator's communication for 60 days.|t
17167863|NCT00438854|t||||
17167864|NCT01243567|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167865|NCT04432493|f||||f
17200975|NCT02236988|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17200976|NCT00730275|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17200977|NCT04032613|f||||f
17158875|NCT01111565|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17158876|NCT00368108|f||||f
17158877|NCT00583908|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17158878|NCT05270980|t||||
17158879|NCT03870334|f||OTHER||t
17158880|NCT00848757|f||||f
17158881|NCT04553666|f||||f
17158882|NCT01089127|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17158883|NCT03200548|t||||
17158884|NCT00059228|t||||
17158885|NCT03257436|f||||t
17158886|NCT01305811|f||||f
17158887|NCT03064113|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158888|NCT03407417|f||||f
17158889|NCT03874013|f||||t
17158890|NCT01204203|f||||f
17158891|NCT01096160|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17158892|NCT01460732|f||||f
17158893|NCT01610037|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17158894|NCT00705757|f||||f
17158895|NCT06060496|t||||f
17158896|NCT03990051|f||OTHER|Sponsor has prior review rights before publications or presentations.|t
17158897|NCT01411852|f||OTHER|Research activities of the Resuscitation Outcomes Consortium (ROC) are intended to contribute applicable knowledge to the field of Resuscitative Medicine. Definitive contributions are made through publications in peer-reviewed literature. No participating institution may present or publish individual findings from work performed on study protocols without approval of the Publications Subcommittee (PS).|t
17158898|NCT03193047|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17158899|NCT03861091|t||||
17158900|NCT03743025|t||||
17158901|NCT01960465|t||||
17158902|NCT02420119|f||||f
17158903|NCT00149396|f||||f
17200978|NCT00626626|f||LTE60||t
17200979|NCT01652495|f||||f
17158904|NCT02681458|t||||
17158905|NCT00186485|t||||
17158906|NCT03126786|f||OTHER|The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17158907|NCT00991289|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17158908|NCT02533934|t||||f
17158909|NCT00227539|t||||
17158910|NCT00379899|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17158911|NCT02404610|f||||f
17158912|NCT01922258|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17158913|NCT00673257|f||OTHER|Must obtain prior Sponsor approval.|t
17158914|NCT04552132|f||||f
17200980|NCT03053518|t||||
17200981|NCT02071290|t||||f
17200982|NCT05435482|t||||f
17158915|NCT02716779|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158916|NCT00121719|f||||f
17158917|NCT01951417|f||LTE60||t
17158918|NCT03138577|t||||
17158919|NCT01472445|t||||
17158920|NCT01051817|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17158921|NCT01026948|t||||
17158922|NCT01951118|t||||
17158923|NCT02288819|f||||f
17158924|NCT00096538|t||||
17158925|NCT02824627|f||||f
17158926|NCT00672633|f||||f
17158927|NCT01938846|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158928|NCT00929344|f||||f
17158929|NCT01689441|t||||f
17158930|NCT02477358|f||||f
17158931|NCT02324361|f||||f
17158932|NCT01481558|f||||f
17158933|NCT00571662|f||||f
17158934|NCT01377636|t||||f
17158935|NCT01839916|f||||f
17158936|NCT01815502|f||||f
17158937|NCT04235504|f||||f
17158938|NCT02541409|f||||f
17158939|NCT02143024|t||||
17158940|NCT01945944|f||||f
17158941|NCT01545141|f||||f
17158942|NCT06236113|t||||
17158943|NCT01395810|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17158944|NCT03574038|f||||f
17158945|NCT04265261|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17158946|NCT04570709|t||||
17158947|NCT00493012|t||||
17158948|NCT02962427|f||||f
17158949|NCT03407313|f||LTE60||t
17158950|NCT03234036|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17158951|NCT00552695|f||||f
17158952|NCT04547140|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17158953|NCT04613739|f||||f
17158954|NCT00003537|f||||f
17158955|NCT02196857|f||||f
17158956|NCT00270296|f||||f
17158957|NCT00580957|f||||f
17158958|NCT00735943|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158959|NCT04033146|t||||
17158960|NCT00500578|t||||f
17158961|NCT01719380|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17158962|NCT01064414|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17167866|NCT00787137|f||OTHER|An investigator shall not publish any data (poster, abstract, paper etc) without having consulted with the Sponsor in advance.|t
17167867|NCT01628614|f||||f
17158963|NCT00249873|f||OTHER|Publication of the study will be made jointly in the name of all wholehearted collaborators. Other papers will be authored based on the contributions of the individuals to the overall study. Substudies with scientific merit which have received prior approval from the Steering Committee (SC) may be published in the names of the contributing investigators. A copy of all manuscripts will be provided to the sponsors for their review. The final decision to publish articles will be made by the SC.|t
17158964|NCT03286218|f||GT60||t
17158965|NCT01348139|f||LTE60||t
17158966|NCT01015326|t||||
17158967|NCT02762084|f||||f
17158968|NCT01164202|f||||f
17158969|NCT00165503|t||||
17167868|NCT02652416|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17167869|NCT02395055|f||||f
17167870|NCT00787930|f||||f
17167871|NCT01896271|t||||
17158970|NCT00643201|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17158971|NCT02976519|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17158972|NCT02346708|t||||
17158973|NCT03416270|f||||f
17158974|NCT00928434|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17167872|NCT01357135|f||OTHER|Investigators cannot disclose any results without sponsor's agreement, only on request of French Health Authorities as per French law.|t
17200983|NCT04488770|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200984|NCT02075073|f||OTHER|Project results may not be published or referred to, in whole or in part, by the Service Provider or any of its Affiliates without the prior expressed written consent of Sponsor, which will not be unreasonably withheld or delayed. Neither Party shall use the other Party's name in connection with any publication or promotion without the other Party's prior written consent.|t
17200985|NCT05731999|f||LTE60||t
17200986|NCT01538966|t||||
17200987|NCT03361605|t||||
17200988|NCT02770612|t||||
17167873|NCT01049802|f||||f
17167874|NCT01367704|f||||f
17200989|NCT02369068|f||||f
17200990|NCT00958841|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17200991|NCT02402153|f||OTHER|Data is the property of UNEEG medical A/S. The PI is offered co-authorship for publications related to the investigation. If the PI does not agree on the interpretation of the results, then the PI have the right to publish and present the results.|t
17200992|NCT03014011|t||||
17200993|NCT02416453|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17200994|NCT01143181|f||OTHER|Within 18 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17158975|NCT01781962|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17158976|NCT01001910|t||||
17158977|NCT01687114|f||||f
17158978|NCT06331507|t||||
17158979|NCT01278342|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17158980|NCT05439421|f||||f
17158981|NCT02654639|t||||
17158982|NCT02862080|t||||
17158983|NCT00313846|f||GT60||t
17158984|NCT02276963|f||||f
17158985|NCT01462630|t||||
17158986|NCT01765296|f||OTHER|Principal Investigator (PI) cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is canceled.|t
17158987|NCT01619852|t||||f
17158988|NCT01464190|f||OTHER|Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.|t
17158989|NCT00970489|f||||f
17200995|NCT00359983|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17200996|NCT00831129|t||||
17137378|NCT01895452|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17137379|NCT01709786|f||||f
17158990|NCT03933449|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17158991|NCT02659943|f||||f
17158992|NCT01576575|t||||
17158993|NCT01723072|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single-site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety.|t
17158994|NCT03428100|f||GT60||t
17158995|NCT04556760|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca.|t
17158996|NCT02168491|f||||f
17158997|NCT00844090|t||||
17200997|NCT01877239|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17200998|NCT01098318|f||||f
17200999|NCT00743431|f||||f
17201000|NCT03291288|f||||f
17201001|NCT04276415|f||||f
17201002|NCT04561778|t||||
17201003|NCT01989169|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17201004|NCT02406677|f||OTHER|Registry Site shall submit to the Committee for its review a copy of any proposed publication resulting from the Registry at least thirty (30) days prior to the date of submission for publication or at least fifteen (15) days prior to submission for an abstract, and if no response is received within sixty (60) days of the date submitted to Sponsor, it will be conclusively presumed that the publication may proceed without delay.|t
17201005|NCT01114880|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17201006|NCT04531904|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17201007|NCT00283244|t||||
17201008|NCT04500769|f||||f
17158998|NCT00394888|t||||
17158999|NCT01246895|f||LTE60||t
17159000|NCT03380377|f||||f
17167875|NCT00526110|t||||
17201009|NCT01967147|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17201010|NCT00550589|f||||f
17201011|NCT00166712|t||||f
17201012|NCT03986944|f||||f
17201013|NCT02548845|f||OTHER|"As a multicentre study, the first publication shall be based on consolidated analysed data from all centres, i.e. the publication of results from individual institution/Investigator is not allowed before the publication of the full study results.~The PI agrees to give the sponsor 60 days to review the communications. If case of propietary information inadvertenly divulged, intellectual property rights at risk or inaccurate information presented, changes can be required by the sponsor."|t
17201014|NCT03795753|t||||
17201015|NCT03339245|t||||
17201016|NCT00837694|t||||
17159001|NCT02600923|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159002|NCT02256839|f||||f
17159003|NCT03758157|f||||f
17159004|NCT00382785|f||||f
17159005|NCT02925858|f||||f
17159006|NCT01705977|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159007|NCT03030625|f||||f
17159008|NCT00808067|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17159009|NCT01514383|f||||f
17137380|NCT01204697|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159010|NCT01575756|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17159011|NCT02049983|f||||f
17201017|NCT04143945|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17201018|NCT04370548|f||||t
17201019|NCT00306670|f||||f
17201020|NCT00503139|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201021|NCT02735577|t||||
17201022|NCT02731690|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17201023|NCT00833833|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, and has priority over subset (single center) publication, for 1 year after study completion.~* Investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. Celgene has 45 days to review and comment on draft manuscript/presentation, and may ask for an additional delay (not to exceed 90 days total) to address intellectual property issues."|t
17201024|NCT01994837|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17201025|NCT01127893|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201026|NCT01262677|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137381|NCT01205451|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137382|NCT01194869|t||||
17137383|NCT03874754|f||||f
17159012|NCT00691652|f||||f
17159013|NCT06450457|t||||
17159014|NCT04940156|t||||
17159015|NCT05027815|f||||f
17159016|NCT03677869|f||||f
17159017|NCT03877224|t||||f
17159018|NCT00447902|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17159019|NCT04754542|f||||f
17159020|NCT00395993|f||LTE60||t
17159021|NCT01212094|f||||f
17159022|NCT01490892|t||||
17159023|NCT02772666|f||||f
17159024|NCT02019550|f||OTHER|PI shall not publish or present any results from the Study to any third parties until i- EMD Serono publishes results from all sites participating in such Study;ii- Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned;or iii- twenty-four months following completion of the multi-site study at all sites, whichever comes first. Prior to publishing or presenting results from the study, PI must provide proposed publication to EMD Serono.|t
17159025|NCT00675987|f||||f
17201027|NCT04512703|f||OTHER|Any proposed publication relating to the research conducted under this protocol will be submitted to the sponsor for review at least 45 days prior to submission for publication. The publication may be delayed for an additional period of up to 90 days for intellectual property considerations or until all confidential information has been eliminated from the publication(s) and sponsor has approved the publication. It may be determined by the sponsor that no data from this study will be published.|t
17201028|NCT02055781|f||OTHER||t
17137384|NCT04321252|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137385|NCT03004469|f||OTHER||t
17159026|NCT02359110|f||||f
17159027|NCT04771013|f||||f
17159028|NCT01450319|f||OTHER||t
17159029|NCT00078403|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve US or foreign patent or other intellectual property rights.|t
17159030|NCT02291029|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159031|NCT00193414|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at the site.|t
17159032|NCT01519817|t||||
17159033|NCT02881658|f||||f
17159034|NCT02999789|t||||
17159035|NCT02537951|t||||
17159036|NCT00521365|f||OTHER||t
17159037|NCT03627832|t||||
17159038|NCT03150082|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159039|NCT01051557|f||LTE60||t
17159040|NCT02958787|t||||
17159041|NCT01099358|f||GT60||t
17159042|NCT02946892|f||||f
17159043|NCT01178125|f||OTHER|Investigator/Institution must submit proposed publication to Sponsor for review within a prespecified number of days before submission for publication. If Sponsor's review shows that potentially patentable subject matter would be disclosed, publication/public disclosure shall be delayed to enable Sponsor, or Sponsor's designees, to file necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17159044|NCT02948829|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17159045|NCT00369915|t||||
17159046|NCT01711983|f||||t
17201029|NCT03446781|f||||f
17159047|NCT02381678|f||||f
17159048|NCT01050946|t||||
17167876|NCT02193087|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167877|NCT04096820|t||||
17167878|NCT04030247|t||||
17167879|NCT00509093|t||||
17201030|NCT02093949|f||||f
17201031|NCT02551718|t||||
17201032|NCT02796300|f||||f
17201033|NCT05141500|f||||f
17201034|NCT01638429|f||||f
17167880|NCT04431713|t||||
17167881|NCT04114604|t||||
17167882|NCT03287674|t||||
17167883|NCT03383783|f||||f
17201035|NCT02885324|t||||
17201036|NCT00996476|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17201037|NCT00473265|f||||f
17201038|NCT01802567|f||LTE60||t
17159049|NCT01749410|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159050|NCT00737100|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17159051|NCT01447407|t||||
17159052|NCT01265394|f||||f
17159053|NCT03131167|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17159054|NCT03760224|t||||f
17159055|NCT00954681|f||||f
17159056|NCT03335800|f||||f
17159057|NCT02038179|f||||f
17159058|NCT02221648|t||||f
17159059|NCT01168921|f||||f
17159060|NCT02937623|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159061|NCT03489343|f||||f
17159062|NCT01166750|t||||
17159063|NCT01585246|f||||f
17167884|NCT02838420|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167885|NCT00118352|t||||
17201039|NCT04513652|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17201040|NCT00692276|f||||t
17201041|NCT01895101|t||||
17201042|NCT03339583|f||||f
17201043|NCT00734591|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201044|NCT01659853|f||GT60||t
17201045|NCT01085968|t||||
17201046|NCT05187364|f||||f
17201047|NCT05560243|f||||f
17201048|NCT02757872|f||||f
17201049|NCT00939822|t||||
17201050|NCT01021618|t||||
17201051|NCT01072630|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17201052|NCT01232738|f||||f
17201053|NCT00338962|t||||
17201054|NCT03046121|f||||f
17201055|NCT03214640|t||||f
17201056|NCT00910039|t||||
17201057|NCT03151993|f||||f
17201058|NCT02147899|f||||f
17201059|NCT04155047|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17201060|NCT01143870|f||||f
17201061|NCT01911390|f||||f
17201062|NCT01280357|f||LTE60||t
17201063|NCT00886795|f||LTE60||t
17201064|NCT02818244|t||||
17201065|NCT01259089|f||||f
17201066|NCT02310100|f||||f
17201067|NCT00688870|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201068|NCT00477659|f||||f
17201069|NCT02571153|f||||f
17201070|NCT01140295|f||||f
17201071|NCT01821352|f||||f
17201072|NCT02917603|f||||f
17201073|NCT01253018|t||||
17201074|NCT03449901|t||||
17201075|NCT03466073|f||||f
17201076|NCT00744757|f||LTE60||t
17201077|NCT03682302|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17201078|NCT00860847|f||||f
17201079|NCT03309813|f||||f
17201080|NCT00658788|f||GT60||t
17201081|NCT00653523|f||OTHER|"Principal Investigator (PI) agrees, for a period of 5 years following the Effective Date, to retain the Disclosure made to it by or on behalf of Sponsor (SPKK), in confidence and not to disclose it to any third party.~PI further agrees that during such time period it will not, either directly or indirectly, use the Disclosure for any purpose(s) other than that indicated herein without the prior written consent of SPKK."|t
17201082|NCT05384938|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17201083|NCT00848588|f||||f
17201084|NCT02079740|f||LTE60||t
17167886|NCT01224821|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167887|NCT01340937|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17167888|NCT02638207|f||||f
17167889|NCT02469415|t||||
17159064|NCT04396626|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167890|NCT00499655|t||||
17167891|NCT00350623|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167892|NCT00623545|f||||f
17167893|NCT04126564|t||||
17167894|NCT03500172|f||||f
17167895|NCT04081961|t||||
17167896|NCT01752400|t||||
17167897|NCT01035346|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167898|NCT01974752|f||||f
17167899|NCT04754230|t||||
17167900|NCT01318278|t||||
17167901|NCT03837665|t||||
17201085|NCT02328014|f||||f
17201086|NCT01274338|f||LTE60||t
17159065|NCT00289094|f||LTE60||t
17159066|NCT02111174|t||||
17159067|NCT00838097|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159068|NCT00871234|t||||f
17159069|NCT00687908|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor for review and approval at least 2 months prior to the date of the intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17159070|NCT00910845|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167902|NCT02435680|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17167903|NCT00330928|f||GT60||t
17167904|NCT00445848|f||LTE60||t
17167905|NCT01309906|f||OTHER|Contact sponsor directly for details.|t
17167906|NCT03028480|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167907|NCT05074888|f||||t
17167908|NCT02270255|f||||f
17201087|NCT03493945|f||||f
17201088|NCT05422339|t||||f
17201089|NCT04319198|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17201090|NCT03843554|f||||f
17201091|NCT04396366|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17201092|NCT06056310|f||||t
17201093|NCT04803370|t||||
17167909|NCT02279719|f||OTHER|A copy of any proposed publication or disclosure of the results of the Study will be given to Sponsor for review at least thirty (30) days prior to the date of submission for publication ( including abstracts) or of public disclosure ( the review period).|t
17167910|NCT03541187|f||||f
17167911|NCT06239441|f||||f
17167912|NCT00869050|t||||
17167913|NCT01369680|f||||f
17167914|NCT00383643|f||||f
17167915|NCT01310400|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release. A time period for this review is not specified in the study protocol.|t
17167916|NCT01062841|f||||f
17201094|NCT02843165|t||||
17201095|NCT03283254|t||||
17201096|NCT06072170|t||||
17201097|NCT06039579|f||OTHER|ViiV Healthcare agreements may vary with individual investigators, but will not prohibit any investigator from publishing. ViiV Healthcare supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17201098|NCT03786042|t||||
17201099|NCT02443077|f||LTE60||t
17201100|NCT03560323|t||||
17201101|NCT02356159|f||||f
17201102|NCT00861705|f||LTE60||t
17159071|NCT00792909|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159072|NCT04865029|t||||
17159073|NCT00128661|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159074|NCT01261390|f||||f
17159075|NCT00977613|t||||
17159076|NCT02864732|f||||f
17159077|NCT02223351|f||||f
17159078|NCT04001803|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159079|NCT05404711|t||||f
17159080|NCT00418028|f||GT60||t
17159081|NCT02346877|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159082|NCT04789382|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159083|NCT00823134|f||||f
17159084|NCT00419757|f||||f
17159085|NCT02922153|f||||t
17159086|NCT00327340|f||OTHER|All investigators had an agreement with the Canadian Urological Oncology Group (CUOG). The investigators were to provide CUOG with text to be presented or published 45 days prior to the release for review. Results from one institution were not to be presented before the multi-center publication. If there is no multi-center publication within 12 months after the Study completion the Investigator had the right to publish the results.|t
17159087|NCT03429348|f||||f
17159088|NCT02692586|f||||f
17159089|NCT04421040|t||||
17159090|NCT03506438|f||||f
17159091|NCT01128296|t||||
17159092|NCT03316586|t||||
17159093|NCT01396083|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17159094|NCT02806713|t||||
17159095|NCT00735709|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17159096|NCT01165307|t||||
17159097|NCT02492802|t||||
17159098|NCT01126099|f||||f
17159099|NCT01718483|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17159100|NCT03049501|t||||
17201103|NCT06418152|t||||
17201104|NCT05250115|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159101|NCT01831427|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17201105|NCT04401267|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17201106|NCT03568318|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17201107|NCT03360682|f||||f
17159102|NCT00536510|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159103|NCT02169505|t||||
17159104|NCT04110314|f||||f
17159105|NCT04658797|f||||f
17159106|NCT01004978|f||LTE60||t
17159107|NCT02326272|f||GT60||t
17159108|NCT00268983|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159109|NCT02147613|t||||
17159110|NCT00433550|f||LTE60||t
17159111|NCT00809445|f||||f
17137386|NCT00259740|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159112|NCT00676403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159113|NCT03506048|t||||
17159114|NCT00972959|t||||f
17159115|NCT02048722|t||||
17159116|NCT01039467|f||||f
17159117|NCT05209880|f||||f
17159118|NCT05017272|f||||f
17137387|NCT03654755|f||||t
17159119|NCT00321906|t||||
17159120|NCT01272908|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137388|NCT02835677|f||||f
17137389|NCT03934710|t||||
17159121|NCT01158261|f||||f
17159122|NCT03143101|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17159123|NCT01912950|f||||f
17159124|NCT01630135|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159125|NCT02541864|t||||
17159126|NCT03243305|f||LTE60||t
17159127|NCT01655719|f||||f
17201108|NCT05256901|t||||
17201109|NCT05815342|f||||f
17201110|NCT05767021|f||GT60||t
17201111|NCT03822897|t||||
17201112|NCT03535506|t||||
17201113|NCT05126563|t||||
17159128|NCT01715948|f||||f
17159129|NCT01005576|f||||f
17159130|NCT01129245|f||||f
17201114|NCT06612255|f||||f
17201115|NCT04885998|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17201116|NCT05230433|t||||f
17201117|NCT02723929|f||GT60||t
17201118|NCT00876200|t||||
17201119|NCT04154943|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17159131|NCT01497067|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159132|NCT03742986|t||||
17159133|NCT01598610|f||GT60||t
17159134|NCT04346199|f||||t
17159135|NCT00485069|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159136|NCT02989402|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137390|NCT00947752|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17159137|NCT03066830|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17159138|NCT02039778|t||||
17159139|NCT00765856|f||||f
17159140|NCT01715233|t||||f
17159141|NCT03505372|f||||f
17159142|NCT03065647|t||||
17159143|NCT04786691|t||||
17201120|NCT03431584|t||||
17137391|NCT01360762|f||||t
17159144|NCT01871077|f||OTHER|by contract only the sponsor has the rights to the results of the study, if the principal researcher wishes the publication or discuss for dissemination of the same can only perform them prior written authorization with the sponsor and its legal department.|t
17159145|NCT03801642|f||||f
17159146|NCT04878120|t||||
17159147|NCT00992017|f||||f
17159148|NCT02864407|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159149|NCT02992119|t||||
17159150|NCT01720316|f||||f
17159151|NCT01877161|f||||f
17167917|NCT01218100|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17167918|NCT01909180|f||||f
17167919|NCT01396265|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17201121|NCT02362035|f||||f
17201122|NCT04497727|t||||
17201123|NCT04250194|f||||f
17201124|NCT01239381|t||||
17201125|NCT06237049|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201126|NCT05870228|t||||
17201127|NCT05014412|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201128|NCT03547739|f||||f
17201129|NCT02101775|f||LTE60||t
17201130|NCT04928287|t||||
17201131|NCT03502447|f||||f
17201132|NCT04035499|f||||f
17201133|NCT02003222|f||LTE60||t
17137392|NCT04511819|f||OTHER||t
17137393|NCT01940510|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137394|NCT03930641|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137395|NCT03247413|f||||f
17137396|NCT04397718|t||||
17137397|NCT01797965|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17201134|NCT03262662|f||||f
17201135|NCT01886872|f||LTE60||t
17201136|NCT04908397|f||||f
17201137|NCT04264442|f||OTHER||t
17201138|NCT04941482|t||||
17201139|NCT04662931|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17201140|NCT03691909|f||OTHER|"In the protocol signature page, the investigator agreed to the following: I further agree to treat the results of this Study as confidential information and will not submit the results of the Study for publication without prior written authorization from Hope Biosciences. "|t
17159152|NCT01827592|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17159153|NCT02849080|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17159154|NCT02493517|f||OTHER||t
17159155|NCT02249104|f||OTHER|Investigator may publish, present, or use any results that do not disclose any confidential information furnished by Galderma. The investigator shall provide their draft of such publication to sponsor for review and approval at least 45 days prior to the date of the intended publication. Upon written request from Galderma, within the forty-five (45) day review period, the investigator will delay the publication or presentation for a maximum of an additional one-hundred eighty (180) days.|t
17159156|NCT03718429|t||||
17159157|NCT05254340|f||||f
17159158|NCT04632225|f||||t
17159159|NCT00325819|t||||f
17159160|NCT01817075|f||OTHER|Must obtain prior sponsor approval|t
17159161|NCT01466361|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159162|NCT00611806|f||||f
17159163|NCT02317991|f||GT60||t
17159164|NCT01921517|f||||f
17159165|NCT01116921|f||||f
17159166|NCT01325350|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159167|NCT01460303|t||||
17159168|NCT04155463|f||||f
17159169|NCT01491022|f||||f
17159170|NCT01095497|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.|t
17159171|NCT01914393|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17159172|NCT01063855|f||GT60||t
17159173|NCT02472730|t||||
17159174|NCT02163395|f||||f
17159175|NCT01195779|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159176|NCT01401595|f||||f
17159177|NCT03713684|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17159178|NCT02185417|t||||
17159179|NCT02595502|f||GT60||t
17159180|NCT00974311|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159181|NCT00412841|t||||f
17159182|NCT05556148|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159183|NCT00458003|f||||f
17159184|NCT01139996|t||||
17159185|NCT00468585|t||||
17159186|NCT02154139|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17159187|NCT00496340|t||||
17201141|NCT04168203|f||||f
17201142|NCT05051462|f||||f
17201143|NCT02425904|f||||t
17201144|NCT05452278|f||||f
17201145|NCT06451965|f||||f
17159188|NCT04073303|f||||f
17159189|NCT01898403|f||||f
17159190|NCT03107208|t||||
17201146|NCT05260021|f||GT60||t
17159191|NCT02899065|f||||f
17159192|NCT02554760|f||||f
17159193|NCT05227118|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17159194|NCT02689804|t||||f
17159195|NCT02417753|f||||f
17201147|NCT03663257|f||||f
17201148|NCT02586857|f||||f
17201149|NCT03842358|t||||
17201150|NCT03745313|f||||t
17159196|NCT03113968|f||||f
17159197|NCT00936455|f||||f
17201151|NCT04879628|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17201152|NCT03516812|f||||t
17201153|NCT05675046|f||||f
17201154|NCT04875195|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17201155|NCT03389802|f||||t
17201156|NCT05190120|t||||f
17201157|NCT03069352|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17201158|NCT02621424|t||||
17201159|NCT05626673|f||||f
17201160|NCT05350501|f||||t
17201161|NCT06665919|t||||
17201162|NCT05148234|f||||f
17201163|NCT03061201|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201164|NCT03062358|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17201165|NCT04745676|f||||f
17201166|NCT04150068|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17201167|NCT05316701|f||||f
17201168|NCT04696653|f||||f
17201169|NCT03861273|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17201170|NCT04625413|f||||f
17201171|NCT03799341|t||||
17201172|NCT04679935|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17201173|NCT01116648|f||LTE60||t
17201174|NCT04539938|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159198|NCT04805671|f||||t
17159199|NCT01387178|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17201175|NCT02993146|f||LTE60||t
17137398|NCT00976950|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17137399|NCT01021852|f||LTE60||t
17159200|NCT02550743|f||||f
17159201|NCT01657162|f||||t
17159202|NCT00901342|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17201176|NCT04362189|f||||f
17201177|NCT02111681|t||||
17201178|NCT02962102|f||||f
17137400|NCT01887587|t||||
17137401|NCT01016691|f||OTHER|Publication requires written consent of the sponsor.|t
17137402|NCT02802878|f||||f
17137403|NCT00536978|t||||f
17137404|NCT03550131|f||||f
17159203|NCT00614172|t||||
17159204|NCT03421379|f||GT60||t
17167920|NCT02275117|f||||f
17201179|NCT03100149|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17201180|NCT01697397|f||||f
17201181|NCT05116540|t||||
17182050|NCT00235872|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17182051|NCT01446965|t||||
17201182|NCT04827732|t||||
17201183|NCT04348435|t||||
17201184|NCT05807074|t||||
17201185|NCT05785832|f||||f
17201186|NCT03414684|t||||
17159205|NCT02782741|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17159206|NCT04157088|f||OTHER||t
17159207|NCT02421419|t||||
17159208|NCT00726180|t||||
17159209|NCT04195061|f||||f
17159210|NCT03377270|t||||
17159211|NCT00196105|f||GT60||t
17159212|NCT04863872|t||||
17159213|NCT04058028|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159214|NCT01121939|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17159215|NCT01211756|t||||
17159216|NCT01691378|f||||f
17159217|NCT01819727|f||GT60||t
17159218|NCT02998151|f||||f
17159219|NCT02155985|f||LTE60||t
17159220|NCT03110133|f||OTHER|The disclosure restrictions on the PI are: (i) the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to eighteen months from the lock-down of all study data and (ii) the sponsor can require the removal of its confidential information from results communications and may delay release for a period of up to 60 days for the purpose of filing patent applications.|t
17159221|NCT02573259|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159222|NCT00751140|t||||
17159223|NCT02472262|f||||f
17159224|NCT05212168|f||OTHER||t
17159225|NCT03811821|t||||
17159226|NCT03574974|t||||
17159227|NCT04888494|f||||f
17159228|NCT01298700|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159229|NCT00129441|f||||f
17159230|NCT01716806|f||||t
17159231|NCT00956839|t||||
17159232|NCT01053156|f||||f
17159233|NCT03527277|f||||f
17159234|NCT00643760|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159235|NCT03934216|f||LTE60||t
17201187|NCT04038580|t||||
17201188|NCT02954432|f||LTE60||t
17201189|NCT04972162|f||||f
17201190|NCT00336024|f||OTHER|Must obtain prior Sponsor approval.|t
17201191|NCT00310180|f||LTE60||t
17201192|NCT04349631|f||||f
17201193|NCT03147287|f||||f
17201194|NCT01982448|f||||f
17159236|NCT01950299|f||||f
17159237|NCT01959113|t||||
17159238|NCT02787499|f||||f
17159239|NCT00048035|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17167921|NCT03089879|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17167922|NCT03421743|f||||f
17167923|NCT02825966|f||||t
17167924|NCT00681564|f||||f
17167925|NCT04151628|f||GT60||t
17167926|NCT03468816|f||||f
17167927|NCT01009346|t||LTE60||t
17167928|NCT02330523|f||||f
17167929|NCT01688843|f||||f
17167930|NCT00541099|t||||f
17167931|NCT00432744|f||||f
17167932|NCT01256281|t||||
17167933|NCT00892606|t||||
17167934|NCT02759315|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17167935|NCT03840525|f||||f
17167936|NCT02761694|f||OTHER|The Investigator agrees not to independently publish the findings except as part of an overall multi-center publication, unless specifically approved in writing by the Sponsor or unless more than 12 months have elapsed since the last participant in the study has completed study treatment.|t
17167937|NCT01370837|t||||
17167938|NCT03464422|t||||
17167939|NCT04240093|t||||
17167940|NCT01628367|t||||f
17167941|NCT02839902|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17167942|NCT02513823|t||||f
17167943|NCT03353922|f||LTE60||t
17167944|NCT00740714|f||||f
17167945|NCT03688555|f||OTHER|Any study-related publication written independently by investigators must be submitted to Idorsia for review at least 30 days prior to submission for publication or presentation. Upon review, Idorsia may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17167946|NCT00183963|t||||
17167947|NCT01955434|t||||
17167948|NCT00886119|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.|t
17167949|NCT01294462|f||||f
17167950|NCT02743780|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17167951|NCT01140568|t||||
17167952|NCT01400243|f||||f
17167953|NCT01216943|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17167954|NCT02279498|f||OTHER||t
17167955|NCT01048866|f||LTE60||t
17167956|NCT00758589|f||LTE60||t
17167957|NCT05320393|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the Study Sponsor. Any Investigator involved with this study is obligated to provide the Sponsor with complete test results and all data derived from the study.|t
17167958|NCT05693922|t||||
17167959|NCT03383757|f||||t
17167960|NCT03187834|t||||
17167961|NCT03559699|f||OTHER|The information obtained from the clinical study will be used towards the development of AG-348 and may be disclosed to regulatory authority(ies), other Investigators, corporate partners, or consultants as required.|t
17167962|NCT04790812|t||||
17167963|NCT04699812|f||||f
17167964|NCT05438602|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17167965|NCT01930890|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17167966|NCT02091284|f||||f
17167967|NCT01278407|f||OTHER||t
17167968|NCT02534935|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159240|NCT02035553|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17159241|NCT05137717|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17159242|NCT02619617|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159243|NCT00509899|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17159244|NCT02735980|f||GT60||t
17159245|NCT01854697|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17159246|NCT05081388|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17159247|NCT03677635|t||||
17159248|NCT00597818|f||OTHER||t
17159249|NCT04176939|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17159250|NCT03250689|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159251|NCT02157519|f||||f
17159252|NCT01656395|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17159253|NCT03075267|f||OTHER|The study site will have the opportunity to publish the results of the study, provided that the sponsor has had the opportunity to review and comment on the study site's proposed publication prior to its being submitted for publication with the prior advice of legal (intellectual property counsel) and with proper regard to the protection of subjects' identities.|t
17159254|NCT02895035|f||||f
17159255|NCT00274742|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159256|NCT01575080|t||||
17159257|NCT02697071|f||||f
17159258|NCT02256696|f||||f
17159259|NCT01529606|f||||f
17159260|NCT01285843|f||OTHER|Both the investigator and Medacta have the right to publish or allow to be published the results of the trial. The investigator recognizes that Medacta has a special interest in the results of the trial and will submit manuscripts to Medacta prior to publication. If Medacta desires changes to be made, these are communicated to the investigator within 60 days.|t
17167969|NCT01460719|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17167970|NCT03093636|f||||f
17159261|NCT01746862|f||||f
17159262|NCT04742673|f||||f
17159263|NCT01900444|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17159264|NCT02233530|f||||f
17167971|NCT00076336|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17159265|NCT04074265|t||||f
17167972|NCT02838901|f||||f
17167973|NCT02285114|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17159266|NCT00072384|f||OTHER|Must obtain prior Sponsor approval.|t
17159267|NCT01825200|f||LTE60||t
17159268|NCT00490035|f||GT60||t
17159269|NCT03519009|f||||f
17159270|NCT06058390|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17167974|NCT03397134|f||||t
17167975|NCT01156389|f||||f
17167976|NCT02089113|f||||f
17167977|NCT00585221|t||||f
17167978|NCT03846531|f||GT60||t
17137405|NCT00717366|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159271|NCT03877744|f||||f
17159272|NCT03361306|t||||
17159273|NCT03437694|f||||f
17159274|NCT04817332|f||LTE60||t
17159275|NCT01368263|t||||
17159276|NCT01982695|t||||
17167979|NCT03276052|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17167980|NCT01994863|f||GT60||t
17167981|NCT01145053|t||||
17182052|NCT01232296|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17159277|NCT04795466|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17159278|NCT05635045|t||||
17159279|NCT02778152|t||||
17159280|NCT01218542|t||||
17159281|NCT05044429|t||||
17159282|NCT02131064|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159283|NCT01062893|t||||
17159284|NCT00810069|f||GT60||t
17159285|NCT03675360|f||||f
17159286|NCT03242941|f||||f
17159287|NCT00971867|f||LTE60||t
17159288|NCT04767373|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17159289|NCT00367003|t||||
17159290|NCT02983045|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17159291|NCT00593918|f||||f
17159292|NCT02658669|f||||f
17159293|NCT03727841|f||||f
17159294|NCT01601496|f||||f
17159295|NCT02078193|f||||f
17159296|NCT01569126|f||GT60||t
17159297|NCT03771963|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17159298|NCT03014206|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159299|NCT05502302|t||||
17159300|NCT00791219|f||LTE60||t
17159301|NCT00952315|f||||f
17159302|NCT01628848|f||||f
17159303|NCT00003471|f||||f
17159304|NCT02104895|f||||f
17159305|NCT01733745|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159306|NCT02895295|f||||f
17159307|NCT01367249|f||OTHER||t
17159308|NCT00060606|f||LTE60||t
17159309|NCT00960804|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159310|NCT00490919|f||GT60||t
17159311|NCT02358031|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17159312|NCT05664581|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patentor proprietary protection.|t
17159313|NCT05541939|f||GT60||t
17159314|NCT03101150|t||||
17159315|NCT03163446|f||OTHER|After multi-center publication has been published by sponsor, or if it hasn't been published in 24 months following completion of Clinical Study Report, PI may publish results independently. PI must allow sponsor at least 90 days to review submission, to request deletion of sponsor confidential information (not study results) and in that initial 90 day period, allow delay of up to 60 additional days to allow sponsor to protect its rights to any confidential information.|t
17159316|NCT01317641|f||OTHER||t
17159317|NCT00563290|f||LTE60||t
17159318|NCT01228591|f||GT60||t
17159319|NCT02787304|f||||t
17159320|NCT01051921|f||LTE60||t
17159321|NCT00379834|t||||
17159322|NCT01204736|f||||f
17159323|NCT01640548|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159324|NCT02864069|f||||f
17159325|NCT01775670|t||||
17159326|NCT01001429|t||||
17159327|NCT02880254|f||||f
17159328|NCT03979066|t||||f
17159329|NCT02189668|t||||
17159330|NCT02063672|f||GT60||t
17159331|NCT01053741|f||||f
17159332|NCT03143257|f||LTE60||t
17159333|NCT00619827|f||||f
17159334|NCT00104052|f||LTE60||t
17159335|NCT02498678|f||||f
17159336|NCT04789304|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159337|NCT00710931|f||OTHER|When a clinical study report or manuscript, in lieu of a final report, is completed, Alcon will provide the summary findings of the study to the investigator.|t
17159338|NCT01484951|f||OTHER|Alcon reserves the right to review the results communication prior to its public release.|t
17159339|NCT04685993|f||OTHER|After the multicenter publication or twelve months after the completion of the study, whichever occurs first, the PI may itself publish the results of its data from the study. The PI shall provide Sponsor with an advance copy of any proposed publication or oral presentation at least sixty days prior to the planned date of submission.|t
17159340|NCT02539992|f||LTE60||t
17159341|NCT00917124|t||||f
17159342|NCT00115778|t||LTE60||t
17159343|NCT04428385|t||||
17159344|NCT00528424|f||OTHER|Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17159345|NCT01167569|f||||f
17159346|NCT02130999|f||GT60||t
17159347|NCT02087774|t||||
17159348|NCT00661089|f||||f
17159349|NCT02572453|f||LTE60||t
17159350|NCT04144322|f||||f
17159351|NCT01431339|f||OTHER|The PI will provide Durata an opportunity to review any proposed publication or other type of disclosure at least 30 days before they are submitted. If any patent action is required to protect intellectual property rights, the Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. If the study is part of a multi-center study, the Investigator agrees that the first publication is to be a joint publication covering all centers.|t
17159352|NCT00385918|f||||f
17159353|NCT01676701|f||GT60||t
17159354|NCT04406714|t||||
17159355|NCT05918406|f||||t
17159356|NCT05117112|f||||f
17159357|NCT02227784|f||GT60||t
17159358|NCT02155699|f||||f
17159359|NCT02108977|t||||
17159360|NCT00909064|t||||
17159361|NCT03834506|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17159362|NCT04577794|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17159363|NCT05770713|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159364|NCT03311945|f||||f
17159365|NCT01107925|f||GT60||t
17159366|NCT04877990|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159367|NCT03839394|t||||
17159368|NCT01619878|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17159369|NCT04821830|f||||f
17159370|NCT04853043|f||OTHER|"Each party shall have the right to publish and disseminate information derived from the performance of the Statement of Work.~Qualification for authorship shall be in keeping with generally accepted criteria. Intermountain Health Services shall provide the University of Utah with a copy of any proposed publication for review and comment at least thirty (30) days prior to submission."|t
17159371|NCT00593450|f||OTHER|Dr. Grunwald reports receiving consulting fees from GlaxoSmithKline; and Dr. Jaffe, consulting fees from Neurotech and SurModics. No other potential conflict of interest relevant to this article was reported.|t
17159372|NCT00991081|t||||f
17159373|NCT02100280|f||||f
17159374|NCT03110354|f||||f
17159375|NCT03041441|t||||
17159376|NCT00239720|f||||f
17159377|NCT02515630|f||OTHER|Most restrictive: Site may not present or publish results of Trial without advance written notice of Sponsor or two years after completion of Trial at all participating sites. Site must submit all proposed publications or presentations to Sponsor for review. Sponsor can review communications prior to public release and embargo trial results communications for a period between 75 and 180 days from submission to Sponsor for review. Sponsor has right to request Site remove Confidential Information.|t
17159378|NCT00483652|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17159379|NCT01477762|t||||
17159380|NCT00473655|f||OTHER|PI has the right to publish Study results in scientific journals. PI may use the Study results but not publish any results until: the date of the first Study results publication or the end of the 18-month period following the completion of the Study. PI shall provide AZ with the material for review. AZ has the right to publish the Study results|t
17159381|NCT02219685|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17159382|NCT02869789|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159383|NCT02389959|t||||
17159384|NCT01566604|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17159385|NCT03225170|t||||
17159386|NCT02634073|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159387|NCT01668836|f||||f
17159388|NCT02577640|f||||f
17159389|NCT00731822|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159390|NCT04585919|t||||
17159391|NCT06290089|f||||f
17159392|NCT02127658|f||||f
17159393|NCT01534273|f||GT60||t
17159394|NCT00719160|t||||
17159395|NCT02638974|t||||
17159396|NCT04663685|f||||f
17159397|NCT01435759|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17159398|NCT01579513|f||||f
17159399|NCT00570401|t||||
17159400|NCT02849587|t||||f
17159401|NCT03976752|t||||
17159402|NCT04907214|f||||f
17159403|NCT01342354|t||||
17159404|NCT04536701|f||GT60||t
17159405|NCT02201342|f||OTHER||t
17159406|NCT00549549|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159407|NCT01787006|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications (presentation of results obtained at a participating center at scientific meetings or publication of these results) prior to public release and can embargo communications regarding trial results prior to submission of the results of the entire study for publication.|t
17182053|NCT02871375|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17182054|NCT03592121|f||||f
17182055|NCT00534235|f||||f
17137406|NCT01906866|f||||f
17182056|NCT02667483|f||||f
17182057|NCT00802412|f||||f
17182058|NCT00606892|f||||f
17159408|NCT02688933|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17159409|NCT00248651|f||||f
17159410|NCT00828113|f||LTE60||t
17167982|NCT03060512|f||OTHER|"The Institution and PIs shall be entitled to publish or make presentations related to the Study within 2 years of completion of the Study with Sponsor's prior written consent. PIs shall provide the Sponsor with copies of any materials at least thirty (30) days in advance of publication, submission or presentation.~All such publications or presentations shall be consistent with applicable standards, guidelines and laws, not be false or misleading, and not be made for any commercial purpose."|t
17167983|NCT03946124|f||||f
17167984|NCT02370004|f||||f
17167985|NCT00919867|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17167986|NCT00182767|f||LTE60||t
17167987|NCT02498067|t||||
17167988|NCT01484834|f||||f
17167989|NCT00747344|f||LTE60||t
17167990|NCT00765882|f||OTHER|All data generated in this study will be the property of Forest Research Institute. An integrated clinical and statistical report will be prepared at the completion of the trial. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute|t
17137407|NCT02235987|f||||f
17137408|NCT01364233|f||||f
17167991|NCT02337530|f||||f
17159411|NCT01275144|f||GT60||t
17159412|NCT01365130|f||||f
17159413|NCT00535652|f||||f
17159414|NCT05547386|t||||
17159415|NCT04622969|t||||
17159416|NCT05607576|f||||f
17159417|NCT04467515|f||GT60||t
17159418|NCT04252625|t||||
17182059|NCT03007394|f||LTE60||t
17182060|NCT04590547|f||||f
17182061|NCT03799484|t||||
17182062|NCT00794196|f||||f
17182063|NCT02129803|t||||
17182064|NCT03917420|t||||
17159419|NCT04391842|f||||f
17159420|NCT00810199|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159421|NCT02287038|t||||
17159422|NCT02731300|f||||f
17159423|NCT01298167|t||||
17159424|NCT01217827|t||||
17159425|NCT01105312|f||LTE60||t
17159426|NCT01533116|f||OTHER||t
17159427|NCT02283658|t||||
17159428|NCT00689338|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159429|NCT00715403|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159430|NCT02700048|t||||
17159431|NCT02175225|f||||f
17159432|NCT00078286|f||||f
17159433|NCT02340000|t||||f
17159434|NCT01883895|t||||
17159435|NCT01190813|f||||f
17137409|NCT00438399|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor to review and approval at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17137410|NCT00878215|t||||f
17159436|NCT00807365|t||||
17159437|NCT05163392|f||||f
17159438|NCT03810456|t||||f
17159439|NCT00738426|f||||f
17182065|NCT00149747|t||||
17182066|NCT02508636|t||||
17137411|NCT00723073|f||||f
17137412|NCT05522673|t||||
17137413|NCT00302718|t||||
17137414|NCT00819585|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137415|NCT00738374|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137416|NCT03334396|f||GT60||t
17137417|NCT01969799|f||||f
17137418|NCT04914377|f||OTHER|The sponsor will be responsible for developing publication procedures and resolving authorship issues. Please refer to your specific contract, grant, and/or Clinical Trials Agreements.|t
17137419|NCT01244191|f||||f
17137420|NCT04390568|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137421|NCT01255306|t||||f
17137422|NCT01283997|t||||
17137423|NCT02017899|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~Trial results may not be published or disclosed in any other way by the Institution, without the prior written consent by the Sponsor."|t
17159440|NCT00464685|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159441|NCT03621956|f||||f
17159442|NCT00587067|t||||
17159443|NCT01094288|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17159444|NCT02611882|t||||
17159445|NCT01317940|f||||f
17167992|NCT02231762|f||OTHER|No publication of the Study Results shall be made without the Sponsor's prior written approval which shall not be unreasonably withheld. Sponsor must be provided with the final version of any abstract, presentation or paper before submission, and the Sponsor shall provide scientific comments within 2 weeks for an abstract or presentation or 6 weeks for an article. If no comments are received within these periods, this silence of Sponsor can be considered as approval to proceed to publication.|t
17167993|NCT01757561|t||||
17167994|NCT01799239|f||LTE60||t
17167995|NCT02594098|t||||
17167996|NCT00033540|f||||f
17167997|NCT03366103|f||LTE60||t
17167998|NCT01036529|f||||f
17167999|NCT01945775|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168000|NCT02876328|f||||f
17159446|NCT04152200|f||OTHER|"1. Copy of disclosure is provided to Sponsor at least 60 days before submission for publication or date of disclosure~2. Confidential information is deleted if requested by Sponsor~3. If a Discovery is disclosed, defer publication or disclosure for 60 days from time Sponsor notifies them of its wish to file a patent application on such Discovery~4. Site/Investigator will not disclose or publish results until results from all sites have been received and analyzed by Sponsor"|t
17159447|NCT04980014|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17159448|NCT00593814|f||||f
17159449|NCT00715559|t||||
17159450|NCT02699996|t||||
17168001|NCT03849690|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17168002|NCT03515941|t||||f
17168003|NCT01152515|f||||f
17168004|NCT00468845|f||OTHER||t
17159451|NCT00500448|f||||f
17159452|NCT01095835|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159453|NCT01198002|f||GT60||t
17159454|NCT00001322|t||||
17159455|NCT00116688|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159456|NCT03593200|f||||t
17159457|NCT04006145|f||OTHER|Albireo will retain the ownership of all data. All proposed publications based on this study must be subject to the sponsor's approval requirements.|t
17159458|NCT00010257|f||||f
17159459|NCT03799614|f||GT60||t
17159460|NCT01996371|t||||
17159461|NCT01249417|f||||f
17182067|NCT01874262|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.|t
17182068|NCT01845792|f||||f
17159462|NCT01607593|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159463|NCT00723827|f||OTHER|The institution has the right to publish/present the study results. The institution agrees not to publish/present any interim results of the Study without the Sponsor's prior written consent. The institution further agrees to provide the Sponsor 30 days written notice prior to submission. The Sponsor has the right to review and comment. If the parties disagree, the institution agrees to meet with the Sponsor, prior to submission, to discuss and resolve any such issues or disagreement.|t
17168005|NCT00334282|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168006|NCT01689350|f||LTE60||t
17168007|NCT00985907|f||||f
17168008|NCT02076399|f||||f
17168009|NCT00085254|f||LTE60||t
17168010|NCT01540409|f||OTHER|There is an agreement between the Principal Investigators and the Sponsor (or its agents) that restricts the PIs' rights to discuss or publish trial results after the trial is completed.|t
17168011|NCT03503292|t||||
17168012|NCT04342689|t||||
17168013|NCT01460407|f||GT60||t
17168014|NCT03035773|f||||f
17168015|NCT00462735|t||||
17159464|NCT00126594|f||LTE60||t
17159465|NCT03769649|f||||f
17159466|NCT01421498|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17159467|NCT01290718|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159468|NCT00243919|f||||f
17159469|NCT01805895|f||||f
17159470|NCT02059239|t||||
17159471|NCT01268267|f||GT60||t
17159472|NCT00685815|f||||f
17159473|NCT03871153|f||||f
17159474|NCT02318849|t||||
17159475|NCT03669549|f||||t
17159476|NCT04919317|t||||
17159477|NCT02974868|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159478|NCT00230048|f||||f
17159479|NCT03817606|f||||f
17159480|NCT00297648|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17159481|NCT01443858|t||||
17159482|NCT03589807|f||LTE60||t
17159483|NCT03586050|f||LTE60||t
17159484|NCT01211145|f||OTHER||t
17159485|NCT04202497|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17182069|NCT00850395|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182070|NCT06049043|t||||
17159486|NCT02115607|t||||
17182071|NCT00262509|t||||f
17182072|NCT01425879|f||LTE60||t
17159487|NCT00102596|t||LTE60||t
17159488|NCT00069264|f||||f
17159489|NCT05067972|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159490|NCT01091246|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17159491|NCT02713178|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17159492|NCT01676012|f||||f
17159493|NCT00596271|f||OTHER||t
17159494|NCT02667301|f||||f
17159495|NCT02421354|t||||
17182073|NCT02739269|t||||f
17182074|NCT01354496|t||||
17182075|NCT03554291|f||||f
17182076|NCT01228747|f||GT60||t
17137424|NCT00168324|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137425|NCT01747811|t||||
17137426|NCT01337167|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17137427|NCT03833817|t||LTE60||
17137428|NCT00884221|f||OTHER|The only disclosure restriction on the principle investigator (PI) is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17137429|NCT03363919|t||||
17137430|NCT01646398|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137431|NCT02499575|f||||f
17137432|NCT00574119|t||||
17159496|NCT03528551|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17159497|NCT00846586|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159498|NCT00735007|f||LTE60||t
17159499|NCT01061606|f||LTE60||t
17159500|NCT01789047|f||||f
17159501|NCT03644017|f||GT60||t
17159502|NCT02668640|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137433|NCT03794752|f||||f
17137434|NCT01206452|t||||
17137435|NCT03292952|f||||f
17159503|NCT03669588|f||||t
17159504|NCT01721447|f||||f
17182077|NCT02036502|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17137436|NCT01362946|f||||f
17137437|NCT02700919|f||LTE60||t
17182078|NCT01068509|f||OTHER|For study centers in Australia, no publication of the study results may be made until publication of the results of the study from all centers or until 2 years after study completion, whichever is sooner. For study centers in the USA, no submission for publication or public disclosure of the results by will be made until the results from all centers have been received and analyzed by the sponsor, or the multi-center study has been terminated or abandoned at all centers.|t
17182079|NCT02442778|f||||f
17182080|NCT02482025|t||||
17182081|NCT05233566|t||||
17182082|NCT02603835|f||OTHER|"Per the clinical trial agreement executed between the Sponsor and one or more Primary Investigators:~The PRIMARY INVESTIGATOR and/or other INSTITUTION clinical research personnel cannot publicly report the single-center results until an all-inclusive multicenter manuscript is in press or one (1) year following the completion of this STUDY."|t
17159505|NCT00369343|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17159506|NCT01100502|f||LTE60||t
17159507|NCT02322749|f||OTHER|Neither Party (PI or Sponsor) will use the other Party's name in connection with any publication or promotion without the other Party's prior, written consent.|t
17159508|NCT02121860|f||LTE60||t
17159509|NCT00073918|t||||
17159510|NCT01409239|f||||f
17159511|NCT04344028|f||||f
17159512|NCT04000438|f||||t
17159513|NCT04414787|f||||f
17159514|NCT00919633|f||OTHER||t
17137438|NCT01842646|t||||
17137439|NCT03434418|t||||
17137440|NCT05343585|t||||
17159515|NCT01121263|f||OTHER|MSSM and sites shall cooperate in the submission of manuscript(s) for publication of the study results and sites shall not submit manuscripts for publication without express written permission of the Operations Committee. After dissolution of the Operations committee or one year after the completion of the agreement, whichever occurs first, no such permission shall be required.|t
17159516|NCT01778413|f||||f
17159517|NCT02481050|f||||t
17159518|NCT01386606|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights.|t
17182083|NCT00615056|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159519|NCT04159714|t||||
17159520|NCT03246347|t||||
17159521|NCT01022203|t||||
17137441|NCT01509872|f||||f
17137442|NCT01956240|f||||f
17159522|NCT00903201|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159523|NCT01334086|t||||f
17159524|NCT04069715|f||||f
17159525|NCT03205150|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159526|NCT02723188|f||||f
17159527|NCT00871624|f||||f
17159528|NCT00729521|t||||
17159529|NCT04735705|f||||f
17159530|NCT03652818|f||||t
17159531|NCT01929889|t||||
17159532|NCT02863666|f||||f
17159533|NCT01930539|f||||f
17182084|NCT04425746|f||||f
17182085|NCT04010266|t||||
17182086|NCT02679911|f||||t
17182087|NCT02849548|f||||f
17182088|NCT00638885|t||||
17182089|NCT02357147|f||||t
17182090|NCT04476537|t||||
17182091|NCT00560950|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159534|NCT01241279|f||OTHER|Study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17159535|NCT05252858|f||||t
17159536|NCT00301834|t||||
17159537|NCT01811732|f||OTHER|Melinta has the right to first publication of results, which would be made in conjunction with the PIs from all appropriate sites. Thereafter, PIs may publish results provided the PI submits the proposed publication to Melinta for review at least 60 days prior to the date of the proposed publication. Melinta may remove any information that is considered confidential and/or proprietary. If a publication is not submitted within 12 months of study conclusion, the PI may publish results.|t
17159538|NCT01405560|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17159539|NCT01783743|t||||
17159540|NCT02771275|f||OTHER|PI must submit publication 60 days prior to its submission for presentation/publication to Sponsor. The Sponsor may, at its sole discretion, (a) approve the publication, (b) reject the publication, or (c) suggest changes to the publication to ensure protection of confidential commercial information in compliance with regulatory requirements. Until the content of any publication is approved by the Sponsor and the PI, the PI shall not disclose such publication.|t
17159541|NCT03191799|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159542|NCT04821063|f||||f
17159543|NCT01240382|f||||f
17159544|NCT02076100|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17159545|NCT02456727|t||||f
17159546|NCT02643693|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17159547|NCT00492297|f||OTHER|Publication will be discussed with the sponsor prior to release and written consent of the sponsor will be obtained. A draft manuscript of the publication or abstract must be sent to sponsor thirty days in advance of submission.|t
17159548|NCT01408706|t||||f
17159549|NCT01307956|f||||f
17159550|NCT00698815|f||LTE60||t
17159551|NCT03903172|t||||
17159552|NCT01545388|f||OTHER|"The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.~Any information identified by the sponsor as confidential must be deleted prior to submission."|t
17159553|NCT01701245|f||||f
17159554|NCT01255163|t||||
17159555|NCT02265965|t||||
17159556|NCT04683640|t||||
17159557|NCT05796791|f||||f
17159558|NCT03041636|t||||
17159559|NCT01867008|f||||f
17159560|NCT05518539|t||||
17159561|NCT03077893|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated or arising from the performance of this Agreement is not permitted without the prior written consent of Regenesis. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17182092|NCT05535777|f||||f
17182093|NCT03264404|t||||
17182094|NCT03036566|f||||f
17137443|NCT02092441|t||||
17137444|NCT00600028|t||||f
17159562|NCT02053493|f||LTE60||t
17159563|NCT03569397|t||||
17182095|NCT04625803|t||||
17182096|NCT04320940|f||||f
17182097|NCT01914666|f||GT60||t
17159564|NCT04613518|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159565|NCT04002791|t||||
17182098|NCT01940120|f||GT60||t
17182099|NCT00427635|f||LTE60||t
17182100|NCT03277846|f||||f
17182101|NCT01088646|f||||f
17182102|NCT01888497|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159566|NCT01619865|t||||
17159567|NCT00791999|f||||f
17159568|NCT05616013|f||GT60||t
17159569|NCT05116202|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâ€™s intellectual property rights.|t
17159570|NCT02408198|t||||f
17159571|NCT00953290|f||OTHER|Prepare the study results for publication and presentation in cooperation with Cutera. The Doctor will not publish or present the results of the Study, or speak publicly about it, unless Cutera has first had a reasonable opportunity to review and comment on the contents of the proposed presentation or publication.|t
17159572|NCT00441285|t||||
17159573|NCT02951312|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17159574|NCT05158140|f||OTHER|Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. A coordinating investigator will be designated by mutual agreement. If publication activity is not directed by Sponsor, investigator agrees to submit all manuscripts or abstracts to Sponsor before submission, allowing Sponsor to protect proprietary information and provide comments. Authorship will be determined by mutual agreement in line with ICMJE authorship requirements.|t
17159575|NCT01526785|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17159576|NCT02007720|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However Novartis does not prohibit any inverstigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159577|NCT01461733|t||||
17159578|NCT04194814|t||||
17159579|NCT04113694|f||GT60||t
17159580|NCT02674503|t||||f
17159581|NCT04350593|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication with the exception of requiring the removal of confidential information. The embargo can be extended to 90 days if there would be any patent applications to be filed by the sponsor related to the proposed publication.|t
17159582|NCT03638128|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159583|NCT00329108|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159584|NCT01389232|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137445|NCT03172481|f||||t
17137446|NCT01957709|t||||
17137447|NCT03746808|f||||f
17159585|NCT04678284|f||||f
17159586|NCT00945243|f||LTE60||t
17159587|NCT02990000|t||||
17159588|NCT04969289|t||||
17159589|NCT00557466|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17159590|NCT03268343|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17159591|NCT00857506|f||LTE60||t
17159592|NCT00313729|f||||f
17159593|NCT01307787|t||||
17159594|NCT01547715|f||LTE60||t
17159595|NCT00789321|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159596|NCT01125098|f||||f
17159597|NCT01965327|t||||
17159598|NCT03342001|t||||
17159599|NCT03477162|t||||
17159600|NCT04161391|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159601|NCT01507181|t||||
17159602|NCT01162343|f||||f
17159603|NCT03964207|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159604|NCT02860988|f||||f
17159605|NCT01962675|t||||
17159606|NCT04773223|f||||f
17159607|NCT02067858|t||||
17159608|NCT01699750|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159609|NCT02737358|t||||
17159610|NCT02119299|f||GT60||t
17159611|NCT00744939|f||||f
17159612|NCT02452047|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17159613|NCT00288912|t||||
17159614|NCT03657069|t||||
17159615|NCT01878799|t||||
17159616|NCT02026141|f||||f
17159617|NCT00565461|f||OTHER||t
17159618|NCT00728494|f||OTHER|All the information obtained in the course of conducting the study, including all data concerning the study and its results, are confidential and cannot be disclosed to any third parties without the consent of Schering-Plough.|t
17159619|NCT03439137|f||OTHER||t
17159620|NCT00748241|f||GT60||t
17159621|NCT00685516|f||||f
17159622|NCT00888654|t||||
17159623|NCT01639352|t||||
17159624|NCT00379145|f||LTE60||t
17159625|NCT01663402|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17159626|NCT00514618|f||||f
17159627|NCT03575702|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17159628|NCT02495389|t||||
17159629|NCT01297283|f||||f
17159630|NCT01802385|f||||f
17159631|NCT03834493|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17159632|NCT05559905|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.|t
17168016|NCT00844805|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media. The sponsor shall have the right to review and comment with respect to data analysis and presentation with regard to protected proprietary information, data accuracy, and fair balance.|t
17168017|NCT01287377|f||||f
17168018|NCT03618628|t||||
17168019|NCT03094286|f||||f
17168020|NCT01741532|f||OTHER|Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.|t
17168021|NCT00475865|f||OTHER|"The investigator can publish only the results of the work performed pursuant to this protocol. Prior to publication, the investigator provides the sponsor with the manuscript for review and comment at least 45 days in advance of its submission for publication.~The sponsor can require the investigator to withhold publication an additional 90 days to allow for filing a patent application or taking such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17168022|NCT05044104|t||||f
17168023|NCT02032641|f||||f
17168024|NCT01453946|f||||f
17168025|NCT00846040|t||||
17168026|NCT00858897|t||||
17168027|NCT03158272|f||LTE60||t
17168028|NCT02725593|f||||f
17168029|NCT01822535|t||||
17159633|NCT04003103|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17159634|NCT02756910|f||||f
17159635|NCT03829462|f||||f
17168030|NCT01071356|t||||
17182103|NCT04152447|f||||t
17182104|NCT04013191|f||GT60||t
17182105|NCT02159547|f||||f
17159636|NCT02240667|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159637|NCT01494818|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159638|NCT01077323|f||LTE60||t
17159639|NCT01710020|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159640|NCT00427908|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159641|NCT02984982|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17159642|NCT02153918|f||||f
17159643|NCT02616783|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17159644|NCT04344301|f||||f
17159645|NCT01747499|t||||
17159646|NCT02903446|t||||
17159647|NCT05214118|t||||
17159648|NCT04010461|t||||
17159649|NCT03797898|f||||f
17159650|NCT00086190|f||||f
17159651|NCT00004547|f||||f
17159652|NCT03902613|t||||
17159653|NCT02027025|f||||t
17159654|NCT02360488|f||||f
17159655|NCT01939314|f||||f
17159656|NCT02530437|t||||
17159657|NCT02370511|t||||
17159658|NCT01190085|f||||f
17159659|NCT03882918|f||||t
17159660|NCT02357459|f||OTHER||t
17159661|NCT01251952|t||||
17159662|NCT02486692|f||||f
17159663|NCT00496769|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159664|NCT03028142|f||OTHER|The employees of the Medicines Evaluation shall not be permitted to present at symposia, national or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial subject to the publication policy described in the Protocol without prior written approval of the Sponsor.|t
17168031|NCT02278614|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA."|t
17168032|NCT03190694|f||||f
17168033|NCT03582813|f||||f
17168034|NCT04765644|t||||
17137448|NCT02928380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137449|NCT00671723|t||||
17137450|NCT01093755|t||||f
17159665|NCT00607243|f||||f
17159666|NCT02810418|f||||f
17159667|NCT02224625|f||OTHER|Confidential information based on contract|t
17159668|NCT02812186|t||||
17159669|NCT02169440|t||||
17159670|NCT05088772|t||||
17159671|NCT01669434|t||||f
17159672|NCT01003106|f||||f
17159673|NCT02420639|f||||f
17159674|NCT02579629|t||||
17159675|NCT01968421|f||||f
17159676|NCT00830219|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17168035|NCT02366767|f||||f
17168036|NCT00579995|t||||f
17168037|NCT02558400|f||||f
17168038|NCT02230683|f||LTE60||t
17168039|NCT00260065|f||||f
17182106|NCT02904057|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17159677|NCT01294423|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17159678|NCT01145482|t||||f
17168040|NCT04068519|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17168041|NCT04559022|t||||
17168042|NCT05275582|t||||f
17168043|NCT00628589|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."|t
17168044|NCT05740332|t||||
17168045|NCT04599166|t||||f
17168046|NCT01777542|f||||f
17168047|NCT00953524|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17168048|NCT02867618|t||||
17168049|NCT02299570|f||||f
17168050|NCT04942665|f||||f
17168051|NCT03554772|f||||t
17168052|NCT05136898|f||||f
17168053|NCT03784846|t||||
17168054|NCT00867087|f||LTE60||t
17168055|NCT03597178|f||GT60||t
17168056|NCT02088073|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17168057|NCT00241631|t||||
17168058|NCT03883113|f||LTE60||t
17168059|NCT00902018|t||||
17168060|NCT00273754|t||||
17168061|NCT03523273|t||||
17137451|NCT03115112|f||OTHER|The investigator has no right to publish trial results.|t
17137452|NCT04019795|f||OTHER|General Corporate Non-disclosure Agreement|t
17137453|NCT02168803|f||GT60||t
17159679|NCT04635839|t||||
17159680|NCT00896493|t||||
17159681|NCT02870868|f||||f
17168062|NCT01457950|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168063|NCT00435162|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168064|NCT02963987|f||||f
17168065|NCT01765426|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor is permitted to protect any proprietary information and to provide comments based on information from other studies that may not be available to the Investigator.|t
17168066|NCT01510184|f||||f
17168067|NCT01863134|t||||
17168068|NCT02266277|f||||f
17168069|NCT00694096|t||||
17168070|NCT03900923|t||||
17159682|NCT01739335|t||||
17159683|NCT02105324|t||||f
17159684|NCT01868646|f||||t
17168071|NCT03351114|f||||f
17159685|NCT00896064|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159686|NCT03843372|f||||f
17159687|NCT02337062|f||GT60||t
17159688|NCT00785356|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17159689|NCT02280252|t||||
17159690|NCT01232790|t||||
17159691|NCT03238417|t||||
17159692|NCT00083915|t||||
17159693|NCT01239797|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17159694|NCT00458237|f||||f
17159695|NCT03059914|f||||f
17159696|NCT00853762|f||OTHER|The study as a whole will be published prior to any individual investigator publications. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17159697|NCT00956085|f||||f
17159698|NCT02461693|t||||
17159699|NCT02000921|f||||f
17159700|NCT03108482|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17159701|NCT02051296|t||||f
17159702|NCT00915590|t||||f
17159703|NCT02631941|f||||f
17159704|NCT00848016|f||LTE60||t
17159705|NCT01225549|f||OTHER|PI shall not publish any results until (i) the date of the first Study results publication, or in case of a Multi-Centre Study the first Multi-Centre Results publication, agreed by the participating sites, and (ii) the end of the eighteen (18) month period following the completion or early termination of the Study at all participating sites.|t
17159706|NCT02858401|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17159707|NCT03722576|t||||
17159708|NCT04474483|t||||
17159709|NCT02513550|f||GT60||t
17159710|NCT00192114|f||GT60||t
17159711|NCT00193453|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17159712|NCT02204917|t||||
17159713|NCT00749398|f||OTHER|Prior to publication or presentation (abstract, poster, oral communication and any other support existing or future), a copy of the final text should be forwarded by the Investigator(s) to the sponsor, for comment and authorization. Such comments and authorization shall aim to ensure the scientific content of the proposed publication and/or presentations and shall ensure that data and the material referring to the sponsor activities receive fair, accurate, and reasonable presentation.|t
17137454|NCT01107405|f||OTHER|Prior to any presentation of results, draft versions of manuscripts will be made available to co-authors and to the Sponsor for review and comment. At least 30 days in the case of abstracts or 60 days in the case of full papers should be allowed for comments prior to submission for consideration of acceptance of presentation or publication.|t
17137455|NCT00980343|f||LTE60||t
17137456|NCT03060083|t||||f
17137457|NCT01608490|f||||f
17137458|NCT02310906|f||OTHER|The most restrictive relevant agreement provides that the PI can only publish the study results with the approval of Sponsor.|t
17137459|NCT01010854|t||||
17137460|NCT00664755|f||||f
17137461|NCT02500602|f||||f
17137462|NCT00098020|f||||t
17137463|NCT02823600|t||||f
17137464|NCT01309867|f||OTHER|Contact sponsor directly for details.|t
17137465|NCT01840228|f||||f
17137466|NCT01148563|f||||f
17137467|NCT01879319|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17137468|NCT01647464|f||||f
17137469|NCT03886701|t||||
17159714|NCT00678418|f||OTHER|No individual investigator may publish results until after the publication of the overall study without receiving Alkermes' written approval. After that time, a PI/Institution may publish results for noncommercial purposes. Should an investigator wish to do so, the Sponsor will have 30 days to review the proposed publication. The PI/Institution will delete any Sponsor Confidential Information other than study results and will revise a publication based on regulatory requirements of the Sponsor.|t
17159715|NCT03924323|f||||f
17159716|NCT04710004|f||||f
17159717|NCT02277028|f||||f
17159718|NCT02718911|f||GT60||t
17159719|NCT05002972|t||||
17159720|NCT04195594|f||OTHER|The PI is an employee of the CRO that conducted the study. The research agreement indicates that the data is the property of the sponsor and therefore they control the option for disclosing results.|t
17159721|NCT01447888|f||||f
17159722|NCT01172873|t||||f
17159723|NCT00983372|f||GT60||t
17159724|NCT00372424|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159725|NCT00072410|f||||f
17159726|NCT03724357|t||||
17159727|NCT01419314|f||||f
17159728|NCT00732069|f||||f
17159729|NCT00974363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159730|NCT01754519|t||||
17159731|NCT03459625|t||||
17159732|NCT02743364|f||LTE60||t
17159733|NCT00969228|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159734|NCT02563899|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159735|NCT02344316|t||||f
17159736|NCT00545623|f||||f
17159737|NCT02100124|f||||f
17159738|NCT04350827|f||||f
17159739|NCT02188160|f||OTHER|The institution and Investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of the sponsor.|t
17159740|NCT00641563|f||||f
17159741|NCT01655901|f||||f
17159742|NCT00934375|f||||f
17159743|NCT03256578|f||LTE60||t
17159744|NCT02371616|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159745|NCT00754741|f||||f
17159746|NCT00922636|t||GT60||t
17159747|NCT01573000|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159748|NCT03353792|t||||
17159749|NCT00194129|f||||f
17159750|NCT00452374|t||||
17159751|NCT01433159|f||LTE60||t
17159752|NCT01100853|f||||f
17159753|NCT01190891|t||||
17159754|NCT00266708|t||||
17159755|NCT01926028|f||LTE60||t
17159756|NCT01130272|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17159757|NCT01548404|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17159758|NCT00737048|f||OTHER|The only disclosure restriction on the Principal Investigator is that the Sponsor can review results communications prior to public release.|t
17159759|NCT00641056|f||GT60||t
17159760|NCT02351934|t||||
17159761|NCT01115452|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159762|NCT05310877|f||||f
17159763|NCT01657617|f||||f
17159764|NCT02659501|f||||f
17159765|NCT01309386|f||OTHER|The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17159766|NCT02062437|f||LTE60||t
17159767|NCT01674725|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17159768|NCT00960193|f||GT60||t
17159769|NCT03362944|t||||f
17159770|NCT01235065|t||||
17159771|NCT04753034|f||OTHER|After database lock, Institution/Investigator may publish trial data generated by Investigator at Institution upon the earlier of: (i) publication of primary Multicenter Publication; or (ii) 18 months after the Trial is completed, if a Multicenter Publication is not submitted by Sponsor for publication within such 18 month period; provided Sponsor has opportunity to review proposed publication or disclosure at least 60 days in advance of its submission to a journal, congress, panel, etc.|t
17159772|NCT00501631|f||OTHER|No individual Investigator may publish results without written agreement from Alkermes. Should an Investigator wish to publish or present the data at a meeting, a copy of the manuscript or abstract must be provided to the Sponsor at least 30 days prior to the submission for review and approval. Any revisions will be negotiated in good faith by the Investigator and Sponsor.|t
17159773|NCT01249131|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159774|NCT00578903|t||||
17182107|NCT00913744|f||OTHER|Institution and the Principal Investigator (PI) reserve the right to publish only the results of the work performed by the Principal Investigator pursuant to this Agreement; provided, however, that Institution provides Sponsor a copy of any proposed publication, for review and comment at least sixty (60) days in advance of its submission for publication.|t
17159775|NCT00891813|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17159776|NCT01329198|t||||f
17159777|NCT00113607|f||GT60||t
17159778|NCT01222104|f||GT60||t
17159779|NCT01418339|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17159780|NCT03885908|t||||
17159781|NCT00909844|f||GT60||t
17159782|NCT00706004|t||||
17159783|NCT01064479|t||||
17159784|NCT02965924|t||||
17159785|NCT04219189|t||||
17159786|NCT03101020|f||LTE60||t
17159787|NCT03918811|f||||f
17159788|NCT03585270|f||OTHER|Any study-related publication written independently by the investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17159789|NCT03292016|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17182108|NCT00805935|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17159790|NCT02115984|f||||f
17159791|NCT00359203|f||||f
17159792|NCT01038687|t||||
17159793|NCT05057221|f||GT60||t
17159794|NCT01076543|f||LTE60||t
17159795|NCT00338741|f||OTHER||t
17182109|NCT02945410|f||||f
17182110|NCT01344369|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17182111|NCT03848845|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17159796|NCT05222880|f||GT60||t
17159797|NCT04458675|f||OTHER|Permission to use study data is required|t
17159798|NCT00904007|f||||f
17159799|NCT00617357|f||||f
17182112|NCT01454726|f||||f
17182113|NCT04200248|f||LTE60||t
17159800|NCT01764841|f||OTHER|Bayer acknowledges and accepts the interest in the noncommercial scientific publication of Results. In a multicenter study the PIs will not make any publication of the results before the first multi-center publication. Proposed publication/presentation shall be provided to Bayer at least 60 days prior to the intended submission or presentation of the publication in order to allow Bayer to review it. Any difference of opinion shall be discussed.|t
17159801|NCT00866905|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from the date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish results until 18 mos. after the trial has been completed at all sites.|t
17182114|NCT02155335|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17159802|NCT01791985|f||||f
17159803|NCT01103323|f||OTHER|The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17159804|NCT02956382|f||||f
17159805|NCT02314728|f||||f
17159806|NCT01791595|f||||f
17159807|NCT03118934|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17159808|NCT02895347|f||||f
17159809|NCT02589145|t||||
17159810|NCT03177148|f||||f
17159811|NCT02456194|f||||f
17159812|NCT01439035|f||||f
17159813|NCT00965237|f||OTHER|No distribution of trial-specific information without express written permission of director.|t
17137470|NCT02670330|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137471|NCT01868776|f||||f
17159814|NCT00577317|f||LTE60||t
17159815|NCT04460326|t||||
17159816|NCT03160716|f||||t
17159817|NCT01831895|f||LTE60||t
17159818|NCT04794751|f||GT60||t
17159819|NCT00875810|f||OTHER|The sponsor can review results communications prior to public release. The sponsor will limit its review to the determination of whether Confidential Information is disclosed and to check for technical correctness.|t
17159820|NCT00780975|f||GT60||t
17159821|NCT04054544|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17159822|NCT03044314|t||||
17182115|NCT00934544|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182116|NCT00302003|f||OTHER|Must obtain prior Sponsor approval.|t
17182117|NCT01218516|f||||t
17182118|NCT02042924|f||||f
17182119|NCT00283439|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17182120|NCT00935428|t||||f
17159823|NCT01035749|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159824|NCT03781726|f||||f
17182121|NCT04033003|f||||f
17159825|NCT00794664|f||OTHER|In multi-site studies, PI can publish site data after a multi-centered publication or 12 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 6 months (contracts have variable timeframes) upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17182122|NCT00430092|f||GT60||t
17182123|NCT00706966|t||||
17159826|NCT01062308|t||||f
17159827|NCT00457730|t||||f
17182124|NCT02995915|f||||f
17182125|NCT00265616|f||||f
17182126|NCT02607514|f||||f
17159828|NCT01305564|f||||f
17182127|NCT03100825|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17182128|NCT04693585|f||||f
17182129|NCT03221595|f||||f
17182130|NCT02146482|f||||f
17182131|NCT02212587|f||||f
17182132|NCT01675882|f||||t
17182133|NCT02984384|f||||f
17159829|NCT01702909|t||||
17182134|NCT00542750|f||||f
17159830|NCT01419535|t||||
17182135|NCT00735371|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17182136|NCT00994448|f||||f
17159831|NCT00929838|t||||
17159832|NCT01814007|f||||f
17159833|NCT02374320|t||||
17159834|NCT01548599|f||||f
17159835|NCT05630196|f||GT60||t
17159836|NCT00916578|t||||
17182137|NCT01604343|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17182138|NCT03405142|f||||f
17182139|NCT00820612|f||||f
17159837|NCT03438266|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159838|NCT00352118|t||||
17168072|NCT01665430|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168073|NCT02310230|f||||f
17159839|NCT02576899|f||||f
17159840|NCT02308046|f||OTHER|Investigators have the right to disclose and publish results of the Study conducted by them; provided that, in order to protect any Sponsor confidential information, Investigator shall submit to Sponsor manuscripts at least 30 days before submission for publication or 10 days before public presentation. After that time, Investigator is free to submit the manuscript for publication or deliver the presentation, provided Investigator removes any confidential information as directed by Sponsor.|t
17159841|NCT02124824|f||||f
17159842|NCT04040439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159843|NCT03102762|f||||f
17159844|NCT00958074|f||LTE60||t
17159845|NCT02779491|f||||f
17159846|NCT00752089|f||||f
17168074|NCT01371643|t||||
17168075|NCT03249935|f||||f
17168076|NCT02170363|f||GT60||t
17168077|NCT00320749|t||||
17168078|NCT01669421|f||||f
17168079|NCT03630198|t||||
17168080|NCT00167102|f||||f
17137472|NCT04404010|t||||f
17137473|NCT02120157|t||||
17137474|NCT04368455|f||||f
17159847|NCT02900352|t||||
17159848|NCT03074695|t||||
17159849|NCT01774981|f||GT60||t
17159850|NCT01324102|t||||
17159851|NCT00386334|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17159852|NCT00902577|f||||f
17159853|NCT00001566|f||||f
17159854|NCT02914834|t||||
17159855|NCT03060473|t||||
17159856|NCT00106002|f||GT60||t
17159857|NCT04896216|t||||
17159858|NCT01245101|t||||
17159859|NCT04456686|f||||t
17159860|NCT03836586|f||||f
17159861|NCT02532036|f||||f
17159862|NCT00473083|f||||f
17159863|NCT02915835|f||||f
17159864|NCT00466817|f||GT60||t
17168081|NCT01561755|t||||
17168082|NCT02740543|t||||
17168083|NCT01286987|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168084|NCT04662073|t||||
17168085|NCT01007071|f||||f
17168086|NCT02042534|f||||f
17168087|NCT00353431|t||||
17168088|NCT03040414|f||||f
17168089|NCT04066686|t||||
17168090|NCT01550341|f||||f
17168091|NCT01479595|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137475|NCT00441103|f||OTHER||t
17137476|NCT00400439|f||||f
17137477|NCT00239837|f||||f
17137478|NCT01153893|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137479|NCT01838590|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168092|NCT05268744|t||||f
17168093|NCT02255565|f||||f
17168094|NCT03109262|t||||
17168095|NCT03398265|f||||f
17168096|NCT02133664|t||||
17168097|NCT03906656|f||||f
17168098|NCT00300482|f||OTHER|Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.|t
17168099|NCT00343915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168100|NCT00882908|f||GT60||t
17168101|NCT05291936|f||GT60||t
17168102|NCT02370095|t||||
17168103|NCT00048815|f||||f
17168104|NCT01667562|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168105|NCT01129882|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17168106|NCT02130986|t||||f
17168107|NCT01312389|t||||
17159865|NCT03093181|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159866|NCT04210986|t||||
17159867|NCT02378662|f||OTHER|Should the investigator wish to publish the results of this study, the investigator agrees to provide Medgenics with a manuscript for review 60 days prior to submission for publication. Medgenics retains the right to delete from the manuscript information that is confidential and proprietary and to object to suggested publication and/or its timing (at the Company's sole discretion).|t
17159868|NCT01159574|f||LTE60||t
17159869|NCT02666222|f||LTE60||t
17159870|NCT02443623|f||LTE60||t
17159871|NCT01474486|t||||
17159872|NCT03504917|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159873|NCT04233879|f||OTHER|The sponsor will comply with the requirements for publication of study results. The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17159874|NCT02414698|t||||
17159875|NCT02368132|t||||
17159876|NCT04232839|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159877|NCT01673178|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159878|NCT00767572|t||||f
17159879|NCT01405898|t||||
17168108|NCT00993499|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159880|NCT01835912|t||||f
17159881|NCT01328964|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159882|NCT03106077|t||||
17159883|NCT00449163|t||||
17159884|NCT00541242|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17159885|NCT00606307|f||||f
17159886|NCT00597272|t||||
17159887|NCT02008526|t||||
17182140|NCT00436748|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159888|NCT00193375|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17159889|NCT00492726|f||OTHER|The agreed point of publication is 12/18 months after database lock at the earliest. Bayer will have up to 30/45 days to review publications and may request an additional publication delay of up to 60 days to allow for filing a patent application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17159890|NCT04386902|f||||f
17159891|NCT00828711|f||OTHER|Any abstract,presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days prior to submission for any meeting or journal.If deemed necessary by the Sponsor for protection of proprietary information prior to patent filing,the Investigator agrees to a further delay of 60 days before any presentation or publication is submitted.Publications must be in a form that does not reveal technical information that is considered confidential or proprietary.|t
17159892|NCT02230891|t||||
17159893|NCT00942786|t||||
17159894|NCT02033759|f||||f
17159895|NCT05994963|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159896|NCT02764801|f||||f
17159897|NCT03141359|t||||
17159898|NCT01081626|f||OTHER||t
17159899|NCT05619471|f||OTHER|Consultant (PI) shall not, either during or subsequent to the Term of the Agreement, directly or indirectly publish any such information (Proprietary Information) without the prior written authorization from Company (Sponsor).|t
17159900|NCT03813108|t||||
17159901|NCT00870727|f||||f
17159902|NCT00720278|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.|t
17159903|NCT01712516|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17159904|NCT00869414|t||||
17159905|NCT01181167|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17159906|NCT00161213|t||||
17159907|NCT03103503|f||||t
17159908|NCT01384877|f||||f
17168109|NCT01352741|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17168110|NCT04070326|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17168111|NCT00645528|t||||
17168112|NCT02953665|t||||
17168113|NCT01498185|f||||f
17168114|NCT00946322|t||||
17168115|NCT02153346|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168116|NCT00957333|f||||f
17168117|NCT03959982|t||||
17168118|NCT01798641|t||||
17168119|NCT04411420|f||||f
17168120|NCT00340379|f||||f
17168121|NCT01151761|t||||
17168122|NCT00524589|t||||
17168123|NCT03037541|t||||
17168124|NCT01030874|t||||
17168125|NCT05257148|f||LTE60||t
17168126|NCT04639219|f||||t
17168127|NCT00970814|f||||f
17159909|NCT01586195|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159910|NCT00702780|t||||f
17159911|NCT02683109|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17159912|NCT00183430|f||||f
17159913|NCT01587885|f||OTHER|"MERCK retains the title to and exclusive right to publish all documentation, research data, records, raw data, other work product, data, and/or results generated with respect to the Services and/or the Study (Work Product). Such Work Product will be retained in the CRO archive in compliance with regulatory requirements."|t
17159914|NCT03073486|f||||t
17159915|NCT00975416|t||||f
17159916|NCT01690663|t||||
17159917|NCT03555149|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17159918|NCT00898937|t||||
17159919|NCT03863353|f||||f
17159920|NCT05817669|f||OTHER||t
17159921|NCT03810183|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159922|NCT00072449|f||||f
17159923|NCT00323063|t||||
17159924|NCT03786380|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17159925|NCT01664091|t||||f
17159926|NCT02783898|f||||f
17159927|NCT00726609|f||||f
17168128|NCT01998893|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168129|NCT02046174|f||OTHER|Sponsor retains the first right for scientific disclosure of study results. PI may draft a study results disclosure for scientific publication following the earlier of sponsor's disclosure or 12 months after study completion at all sites. Sponsor has 60 days to review PI's draft for patentable subject matter or confidential information. PI will delete any confidential information and delay any disclosure for another 60 days for sponsor to secure proprietary protection.|t
17159928|NCT01067586|f||||f
17168130|NCT02118597|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168131|NCT01891344|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17168132|NCT02969590|t||||
17168133|NCT00186537|t||||
17159929|NCT00549393|f||||f
17159930|NCT01048424|t||||
17159931|NCT01307813|t||||f
17159932|NCT03327324|t||||
17159933|NCT04264208|t||||
17159934|NCT03080935|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17182141|NCT01610791|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182142|NCT01241903|f||||f
17182143|NCT05040152|t||||
17182144|NCT01295515|f||||f
17159935|NCT01614470|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17182145|NCT04998136|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17182146|NCT04938232|f||||f
17137480|NCT01354431|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17137481|NCT01662297|f||||f
17137482|NCT00538980|f||||f
17137483|NCT02055430|t||||
17137484|NCT02927873|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17137485|NCT01519284|t||||
17137486|NCT01262755|f||||f
17137487|NCT01927419|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17137488|NCT00393913|t||||f
17159936|NCT02175121|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159937|NCT02557399|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159938|NCT02848664|f||||f
17159939|NCT00402727|f||OTHER|If Bayer informs coordinating investigator's hospital that such publication could be expected to have an adverse effect on the confidentiality of any confidential information, then the coordinatin investigator's hospital shall prevent the publication, unless the confidential information can be deleted from the publication without having adetrimental effect on the scientific correctness of the publication.|t
17159940|NCT03372798|t||||
17159941|NCT01687218|f||||f
17159942|NCT03301636|f||LTE60||t
17159943|NCT01645059|f||LTE60||t
17159944|NCT02084511|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17159945|NCT01733277|f||||f
17159946|NCT03139552|f||||f
17137489|NCT03488251|f||OTHER||t
17137490|NCT03019744|t||||
17137491|NCT00810719|f||||f
17137492|NCT01511107|f||||f
17137493|NCT01146951|f||OTHER||t
17159947|NCT03204643|t||||
17159948|NCT01768325|f||||f
17159949|NCT00944710|f||||f
17159950|NCT00887484|f||OTHER|If the Investigator wishes to make any such publication or presentation, the Investigator must first submit such publication or presentation to Stiefel for review at least thirty (30) days prior to the date on which such publication or presentation is proposed to be made.|t
17159951|NCT01204671|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17159952|NCT00264147|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137494|NCT01299610|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137495|NCT00804843|f||OTHER|Publications derived from the study should include input from the investigator(s) and SPONSOR. After to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator may publish the results for the study site independently. The SPONSOR must have the opportunity to review all proposed publications 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17137496|NCT02223429|t||||
17137497|NCT02097485|f||||f
17159953|NCT01316224|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17159954|NCT03234465|f||||t
17159955|NCT01274533|f||||f
17159956|NCT00628407|f||||f
17159957|NCT01118052|f||LTE60||t
17159958|NCT02949947|t||||
17159959|NCT02247466|t||||
17159960|NCT01618968|f||LTE60||t
17159961|NCT02404545|t||||
17159962|NCT00721799|t||||
17159963|NCT04347408|f||||f
17159964|NCT01162733|t||||f
17159965|NCT00733278|f||||f
17159966|NCT05965752|t||||
17159967|NCT03630393|t||||
17159968|NCT00408499|t||||
17159969|NCT01042795|t||||
17159970|NCT00997334|f||||f
17159971|NCT01507350|t||||
17159972|NCT03312738|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17159973|NCT01130844|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17159974|NCT03895801|f||||t
17159975|NCT02466399|f||OTHER|If multi-center study publication not published within two (2) years after the completion of the Study at all sites, Investigator may publish the results of the Study obtained by Investigator with 60 days notice to Sponsor|t
17159976|NCT03408899|f||||f
17159977|NCT00606008|t||||
17159978|NCT02014272|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17159979|NCT01863771|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17159980|NCT00883181|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17159981|NCT01218308|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137498|NCT04172701|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137499|NCT02126670|f||||f
17137500|NCT01975246|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137501|NCT01263093|f||GT60||t
17159982|NCT00547339|t||||
17159983|NCT00526474|f||OTHER|The investigators agreed not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor review copies of abstracts or manuscripts for publication 45 days prior to submission.|t
17159984|NCT03845894|t||||
17159985|NCT01248455|f||||f
17159986|NCT00426270|f||||f
17159987|NCT01450813|f||||f
17159988|NCT04236284|t||||
17159989|NCT02271451|f||||f
17159990|NCT02709746|f||||f
17159991|NCT02025075|t||||
17159992|NCT00095979|f||LTE60||t
17159993|NCT01483118|t||||f
17159994|NCT01206465|f||||f
17159995|NCT03322293|f||||f
17159996|NCT02089347|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17159997|NCT02783066|f||||f
17159998|NCT05052580|t||||f
17159999|NCT03712280|f||||t
17160000|NCT00551369|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17160001|NCT03248297|f||||f
17160002|NCT05379920|f||||f
17160003|NCT01997125|t||||
17160004|NCT00719901|f||LTE60||t
17160005|NCT01122173|f||||f
17160006|NCT01184872|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17160007|NCT03426345|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160008|NCT00116142|t||||
17160009|NCT00644059|f||GT60||t
17160010|NCT02133508|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160011|NCT02431598|f||||f
17160012|NCT02497469|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17160013|NCT04023578|t||||
17160014|NCT04076917|f||||t
17160015|NCT00305162|f||OTHER|"PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.~PI must submit results communications to sponsor for review at least 40 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 135 days solely to seek appropriate patent protection."|t
17160016|NCT01774591|f||||f
17160017|NCT01787552|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie. data from all sites) in the clinical trial.|t
17160018|NCT00000575|f||||f
17160019|NCT02184208|t||||
17160020|NCT02679976|f||GT60||t
17160021|NCT03055936|f||||f
17160022|NCT03167242|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160023|NCT01909804|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17160024|NCT04182958|f||||f
17160025|NCT02144701|t||||
17160026|NCT03217591|f||||t
17137502|NCT00424346|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137503|NCT01827319|f||OTHER|Additionally, Sponsor has the right to request removal of any confidential information prior to publication.|t
17160027|NCT00249834|f||OTHER||t
17160028|NCT05324306|t||||
17160029|NCT01251042|f||GT60||t
17160030|NCT00269152|f||GT60||t
17160031|NCT04249427|t||||
17160032|NCT03886272|t||||
17168134|NCT03294135|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17137504|NCT00571519|f||||f
17160033|NCT00931632|f||OTHER|Site shall use Confidential Information solely for the purposes of preforming its obligations under the Clinical Study Agreement and shall not, without Sponsor's prior written consent, publish, disseminate or otherwise disclose to any third party (including any of its affiliates) any Confidential Information. These obligations shall survive and continue for ten years after the termination or expiration of the Agreement or such longer period as required by Applicable Law.|t
17160034|NCT02569892|t||||
17160035|NCT03188055|f||||f
17160036|NCT01257347|t||||f
17160037|NCT04865588|f||OTHER|Since study is being conducted at two sites, PIs agree that study results must be published in an integrated manner reflecting results from both sites. Written consent from ISMMS is required for publication. If there is no multi-site publication within 18 months after the study has been completed or terminated at all Study locations, Pl shall have the right to publish and/or present the results of the study generated at their site.|t
17160038|NCT04356937|f||||f
17160039|NCT03533751|f||||t
17160040|NCT05117060|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17160041|NCT05079321|f||||f
17160042|NCT02003144|f||||t
17160043|NCT04158219|f||||f
17160044|NCT02074514|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17160045|NCT01274351|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160046|NCT00535613|t||||
17160047|NCT00032591|t||||
17160048|NCT02873689|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17160049|NCT00350545|t||||
17160050|NCT01794702|f||||f
17160051|NCT03150043|f||||f
17160052|NCT04166214|t||||
17160053|NCT02997163|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160054|NCT02337764|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17160055|NCT02470741|t||||
17160056|NCT00485836|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160057|NCT01446705|t||||
17160058|NCT03653741|t||||
17160059|NCT03631641|t||||
17160060|NCT01677286|f||||f
17160061|NCT01258374|t||||
17160062|NCT01855958|t||||f
17160063|NCT03946059|t||||
17160064|NCT00368251|f||GT60||t
17160065|NCT03159143|f||||f
17160066|NCT00607893|t||||
17160067|NCT02543840|t||||f
17160068|NCT02669849|f||||t
17160069|NCT01248416|f||||f
17160070|NCT04745351|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17160071|NCT01244477|t||||
17160072|NCT03499795|f||||t
17160073|NCT02741284|f||||f
17160074|NCT03636256|f||||f
17160075|NCT00183339|f||||f
17160076|NCT01516216|t||||f
17160077|NCT01117870|t||||
17160078|NCT01065818|t||||
17160079|NCT03785028|t||||
17160080|NCT01079780|f||LTE60||t
17160081|NCT03435055|t||||
17160082|NCT01178294|f||OTHER|For this study, PIs are restricted from independently publishing results before completion of a single multicenter publication or one year after study completion, whichever occurs first. Baxter requires a review of results communications (eg, for confidential information) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (eg, if a patentable invention is disclosed).|t
17160083|NCT01267279|f||||f
17160084|NCT03176771|f||OTHER||t
17160085|NCT02732639|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17160086|NCT04081688|t||||
17160087|NCT02662569|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160088|NCT00289211|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to sponsor for pre-review. If sponsor requests, PI must delete sponsor confidential information before publication and/or delay publication for 90 days so sponsor can file for patents or take other action to protect its patent rights.|t
17160089|NCT00630916|f||GT60||t
17160090|NCT00243243|t||||
17160091|NCT02425306|f||||f
17160092|NCT01299584|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160093|NCT04079790|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160094|NCT00390689|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17160095|NCT01253161|f||||f
17160096|NCT03871556|f||||f
17160097|NCT01924533|f||OTHER|At least 60 days prior to submission of any material for publication or presentation, Institution and Principal Investigator (PI) shall jointly provide AstraZeneca with such material for review. If requested in writing by AstraZeneca, Institution and PI shall withhold material from submission for publication or presentation for an additional 90 days from the date of AstraZeneca's request to allow for the filing patent application or preserve its proprietary rights in the information.|t
17160098|NCT02747927|f||OTHER|Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|t
17160099|NCT05412134|t||||
17160100|NCT03072186|f||||f
17160101|NCT04275336|t||||
17160102|NCT04664205|t||||
17160103|NCT02709317|t||||
17160104|NCT01578772|f||||f
17160105|NCT00423046|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160106|NCT00830128|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160107|NCT05401565|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160108|NCT02886923|f||GT60||t
17160109|NCT00808340|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17160110|NCT01218802|f||||f
17160111|NCT03329885|f||LTE60||t
17160112|NCT02037893|f||||f
17160113|NCT03368807|f||OTHER|Some investigators wait until a multi-site publication is published (or 2 years if not published sooner) plus a 90 day review period.|t
17160114|NCT00843492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160115|NCT01339416|t||||
17160116|NCT01677741|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160117|NCT01973218|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160118|NCT02941640|f||||f
17160119|NCT01441973|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160120|NCT01149655|f||||f
17160121|NCT04030598|f||||t
17160122|NCT01324947|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to submission; Celgene shall complete its review within 60 days after receipt. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of patentable material.|t
17160123|NCT00879190|f||||f
17160124|NCT01603602|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160125|NCT02209064|f||||f
17160126|NCT01040819|f||||f
17160127|NCT04748718|t||||f
17160128|NCT01935089|t||||
17160129|NCT00723229|f||||f
17160130|NCT02337491|f||||f
17160131|NCT01607658|f||||t
17160132|NCT03530293|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17160133|NCT01668797|f||||f
17160134|NCT02530385|f||||f
17160135|NCT03044418|f||||f
17160136|NCT01569022|t||||
17160137|NCT03613493|t||||
17160138|NCT00433836|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160139|NCT02446691|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160140|NCT00472420|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160141|NCT00686972|t||||
17168135|NCT02590562|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168136|NCT02763254|f||GT60||t
17160142|NCT03144232|t||||
17160143|NCT01026493|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17160144|NCT02674516|f||||f
17160145|NCT01535118|t||||f
17160146|NCT02295644|f||||f
17160147|NCT01380366|t||||
17160148|NCT02182804|f||||f
17160149|NCT00572832|f||LTE60||t
17160150|NCT00966433|t||||f
17160151|NCT01258049|f||||f
17168137|NCT03684304|t||||
17168138|NCT00054691|t||||f
17160152|NCT00324155|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160153|NCT03307174|t||||
17160154|NCT03444584|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17160155|NCT01090180|f||||f
17160156|NCT00846053|f||||f
17160157|NCT00111761|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160158|NCT00746551|f||||f
17160159|NCT00747214|f||LTE60||t
17160160|NCT00171249|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160161|NCT04386785|f||||f
17160162|NCT03608826|f||||f
17160163|NCT00461734|f||||f
17160164|NCT02236000|f||LTE60||t
17160165|NCT01085643|f||GT60||t
17160166|NCT00381628|f||||f
17160167|NCT03122171|f||||f
17160168|NCT00465530|t||||
17160169|NCT00948090|f||||f
17160170|NCT02845674|f||||t
17160171|NCT02139540|t||||
17160172|NCT02139397|f||LTE60||t
17168139|NCT03593681|f||LTE60||t
17168140|NCT01229943|f||LTE60||t
17168141|NCT03987932|f||||f
17160173|NCT00349336|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160174|NCT00720499|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160175|NCT04541355|t||||
17160176|NCT01414244|f||||f
17160177|NCT03638323|t||||
17160178|NCT01326871|f||||t
17160179|NCT01004939|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160180|NCT01621009|t||||
17160181|NCT01200329|t||||
17160182|NCT00677898|t||||
17160183|NCT03400449|f||||f
17160184|NCT03641508|t||||
17160185|NCT03642990|f||||f
17160186|NCT00525837|f||||f
17160187|NCT02717195|f||||f
17160188|NCT00855218|f||OTHER|The investigator must discuss and obtain written consent of the sponsor on the intended publication. The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of the submission inorder to obtain approval.|t
17160189|NCT00764790|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160190|NCT03191552|f||||f
17160191|NCT01265498|f||||f
17160192|NCT00545025|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160193|NCT00617279|f||LTE60||t
17160194|NCT03880474|f||LTE60||t
17160195|NCT00921024|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Authorship on any primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results.|t
17160196|NCT03225287|f||GT60||t
17160197|NCT03036267|f||||f
17160198|NCT01749956|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17160199|NCT02394769|t||||
17160200|NCT01296412|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17160201|NCT04176224|f||OTHER||t
17160202|NCT02160626|f||OTHER|The Institution and investigators agree to not publish the results of this study without the permission of the sponsor.|t
17160203|NCT04239924|t||||
17160204|NCT04059250|t||||f
17160205|NCT02097732|t||||
17160206|NCT02349438|f||GT60||t
17160207|NCT01949545|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160208|NCT01050153|f||||f
17160209|NCT01831219|t||||f
17160210|NCT00623181|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160211|NCT00499122|t||||
17160212|NCT00903968|f||||f
17160213|NCT04539275|f||||f
17160214|NCT00612235|f||||f
17160215|NCT01373164|f||GT60||t
17160216|NCT00843349|f||||f
17160217|NCT01799941|f||OTHER||t
17160218|NCT00420745|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160219|NCT04596319|f||OTHER|The publications policy is also provided in the Clinical Trial Agreement. The data from this study will be available to the Investigators for publication upon the completion of the study. The Sponsor agrees to have the results published, whether positive or negative. The Sponsor will review any manuscripts to ensure that proprietary information has the appropriate patent protection prior to journal submission.|t
17160220|NCT01125930|f||LTE60||t
17160221|NCT01715831|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160222|NCT02426684|f||||f
17160223|NCT02419807|t||||
17160224|NCT00250484|f||||f
17160225|NCT04018066|f||||f
17160226|NCT03817528|t||||
17160227|NCT03181308|f||||f
17160228|NCT03177395|f||||f
17160229|NCT01663623|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160230|NCT02251275|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17160231|NCT00667511|f||GT60||t
17160232|NCT01381120|f||||f
17160233|NCT02730962|t||||
17160234|NCT00856180|f||||f
17160235|NCT02265510|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160236|NCT01004614|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160237|NCT02111083|t||||
17160238|NCT02423408|f||OTHER|An industry standard NDA in place with all study investigators.|t
17160239|NCT01462942|f||OTHER|Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will not be allowed until global publication and study results disclosure by the sponsor as per EUDRACT/FDA regulatory compliance obligations, and only after mutual agreement between the investigator and sponsor|t
17160240|NCT01027845|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160241|NCT00368550|f||||f
17160242|NCT00486044|f||||f
17160243|NCT03072550|f||||f
17160244|NCT02449434|t||||
17160245|NCT03306199|f||||f
17160246|NCT01670292|t||||
17160247|NCT03194334|t||||
17160248|NCT01308619|f||GT60||t
17160249|NCT03154086|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160250|NCT01603277|f||||f
17160251|NCT03148262|t||||
17160252|NCT01183923|f||||f
17160253|NCT04494646|t||||
17160254|NCT00286182|t||||
17160255|NCT02785939|f||||f
17160256|NCT04465422|t||||
17160257|NCT02668003|t||||
17160258|NCT01692119|f||||f
17160259|NCT02147626|f||||f
17160260|NCT00997893|f||||f
17160261|NCT01142336|f||||f
17160262|NCT01704261|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17160263|NCT02722967|f||OTHER|Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.|t
17160264|NCT02391337|t||||
17160265|NCT03704064|f||||f
17160266|NCT00773357|f||||f
17160267|NCT00706563|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160268|NCT01092767|f||OTHER|The Principal Investigator (PI) and institution agree not to publish the results of the study until after the earliest of the following: a)conclusion of the study, b)the early termination of the study, c)at discretion and approval of the sponsor, or d)after sponsor confirms there will be no multicenter study publication, whichever occurs first. PI and institution further agree to submit to sponsor copies of any proposed publication or public presentation at least sixty days before dissemination.|t
17160269|NCT00071981|f||||f
17160270|NCT00467519|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17160271|NCT01123655|t||||
17160272|NCT00062166|f||||f
17160273|NCT00833755|f||||f
17160274|NCT02439164|f||||f
17160275|NCT02475369|f||||f
17160276|NCT00595361|f||||f
17160277|NCT02908347|f||||t
17160278|NCT01036802|f||||f
17160279|NCT03974282|t||||f
17160280|NCT03054428|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17160281|NCT01093846|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160282|NCT01416571|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160283|NCT00753519|t||||f
17160284|NCT00737178|t||||
17160285|NCT01477567|t||||
17160286|NCT00296244|t||||
17160287|NCT00427934|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160288|NCT02305316|f||OTHER||t
17160289|NCT01605903|f||||f
17160290|NCT03563222|f||LTE60||t
17160291|NCT03098979|f||OTHER|Material for public dissemination will be submitted to the Sponsor for review at least thirty (30) days prior to submission for publication, public dissemination, or review by a publication committee. If Sponsor does not respond within this period Institution and/or the Principal Investigator is/are free to proceed with the intended publication or presentation without further delay|t
17160292|NCT03736967|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17160293|NCT02369653|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160294|NCT01458587|f||OTHER|The first publication of results from multi-center trial will be made by the Sponsor. If publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 60 days before publication so that sponsor can review the publication for confidential information.|t
17160295|NCT01006629|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17160296|NCT01118299|f||||f
17137505|NCT01109069|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of the study are submitted for publication (ii) notification that submission of the multicenter results is no longer planned (iii) 18 months after study termination."|t
17137506|NCT00562640|t||||
17137507|NCT05263921|t||||
17160297|NCT02090881|t||||
17160298|NCT04459338|f||||f
17160299|NCT03157089|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160300|NCT02932943|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160301|NCT01454284|f||GT60||t
17160302|NCT02665117|t||||
17160303|NCT03248037|t||||
17160304|NCT02300610|f||||f
17160305|NCT01829347|f||||t
17137508|NCT02658968|f||LTE60||t
17137509|NCT01353144|t||||
17160306|NCT01289522|f||LTE60||t
17160307|NCT03113955|f||||t
17160308|NCT05998967|f||||f
17160309|NCT04418947|f||||f
17160310|NCT01259245|f||||f
17160311|NCT02152007|f||||f
17160312|NCT03316105|t||||
17160313|NCT00447083|t||||
17160314|NCT01302899|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137510|NCT02267226|f||||f
17137511|NCT02475850|f||||f
17137512|NCT02667457|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137513|NCT03330041|t||||
17137514|NCT01746940|f||OTHER|Sponsor right of review of publication, right to remove confidential or proprietary information, and all multi-center data publication done before any additional publications.|t
17137515|NCT03297216|t||||
17160315|NCT00217490|t||||
17160316|NCT03363906|f||GT60||t
17137516|NCT00603733|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17137517|NCT00605696|f||||f
17137518|NCT01057134|f||||f
17137519|NCT00944216|f||||f
17137520|NCT00397878|f||LTE60||t
17137521|NCT00912340|t||||
17137522|NCT04241146|t||||
17137523|NCT00915538|f||||f
17137524|NCT01517412|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17137525|NCT01253187|f||OTHER|PI (principal investigator) of CRO (contract research organization) will refrain from publishing any data or information generated or derived as a result of the performance of the Services.|t
17137526|NCT03027388|f||||f
17160317|NCT03261999|f||OTHER|All information from the trial is property of the Sponsor and the PI has no right on it except the prior writing authorization of the sponsor.|t
17160318|NCT02714153|t||||
17160319|NCT01658839|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17160320|NCT00485303|f||LTE60||t
17160321|NCT01391611|t||||
17160322|NCT00087178|f||LTE60||t
17160323|NCT02783911|f||||f
17160324|NCT00843466|f||||f
17160325|NCT02343224|t||||
17160326|NCT01776554|f||||f
17160327|NCT01041859|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17160328|NCT02075125|t||||
17160329|NCT00982345|f||||f
17137527|NCT01149343|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160330|NCT00885118|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17160331|NCT02816723|f||||f
17160332|NCT02643875|t||||
17160333|NCT02147301|f||||f
17160334|NCT01589315|f||||f
17160335|NCT03087058|f||||t
17160336|NCT02577029|f||||f
17160337|NCT02078817|t||||f
17160338|NCT01420536|f||||f
17160339|NCT01502085|t||||
17160340|NCT01652690|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160341|NCT03415178|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17160342|NCT01884597|f||||f
17160343|NCT02097823|t||||
17160344|NCT00747916|f||||f
17160345|NCT03082729|t||||
17160346|NCT02936999|t||||
17160347|NCT00959751|f||OTHER|Sponsor may request Investigator or Institution not to publish or disclose information related to the clinical study.|t
17160348|NCT00434252|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160349|NCT02807259|f||||f
17160350|NCT03861039|f||LTE60||t
17160351|NCT01673386|f||||f
17160352|NCT02934178|f||||f
17160353|NCT04323592|t||||
17160354|NCT01898078|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17160355|NCT00542308|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17160356|NCT01075048|f||||f
17160357|NCT04596293|f||||t
17137528|NCT01061736|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17137529|NCT02476357|f||||f
17137530|NCT01222572|t||||f
17137531|NCT00432094|t||||
17137532|NCT01429077|f||||f
17137533|NCT00280241|t||||
17137534|NCT01103778|t||||f
17137535|NCT03084718|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17137536|NCT04929613|t||||
17160358|NCT01287936|f||||f
17160359|NCT01140906|f||OTHER|"The results of this study will be published at the discretion of H. Lundbeck A/S. H. Lundbeck A/S will ensure that the authorship of all publications based on this study is in accordance with the criteria defined by the International Committee of Medical Journal Editors (ICMJE).~The primary publication must be published before any secondary publications."|t
17160360|NCT00703534|f||OTHER|AZ shall have 30 days from the proposed final manuscript for any disclosure to review it and may within such time require that submission for publication/disclosure be delayed in order for AZ to file patent applications. If study site/investigator requests permission to publish data(incl oral presentations) it is to be agreed with AZ prior to publ.|t
17160361|NCT00900562|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17160362|NCT03587636|t||||
17160363|NCT02058095|t||||
17160364|NCT00316004|f||||f
17160365|NCT02202252|f||||f
17160366|NCT00470548|t||||
17160367|NCT03720119|f||||f
17160368|NCT03743194|t||||
17160369|NCT01944423|f||||f
17160370|NCT02897349|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160371|NCT01708603|f||GT60||t
17160372|NCT00906243|f||OTHER|This was a Phase 1 and Phase 2 study. The study was terminated after completion of Phase 1 under terms of a settlement agreement that restricts disclosure to limited Phase 1 results only.|t
17160373|NCT01027949|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17160374|NCT03315949|f||||f
17160375|NCT00671749|f||GT60||t
17160376|NCT02515227|f||||f
17160377|NCT03451071|f||||f
17160378|NCT02834975|t||||
17160379|NCT01856933|f||||f
17160380|NCT03558516|f||||f
17160381|NCT00676143|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160382|NCT00929669|t||||
17160383|NCT02318264|f||||f
17160384|NCT02065557|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160385|NCT00250588|f||||f
17160386|NCT02330341|t||||
17182147|NCT03754959|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160387|NCT00706797|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160388|NCT02879032|t||||
17160389|NCT02465450|f||OTHER||t
17160390|NCT00112957|f||LTE60||t
17160391|NCT02366871|f||||f
17160392|NCT02309359|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, and will require prior review and written agreement of the Sponsor.|t
17160393|NCT00701363|f||||f
17160394|NCT01641042|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160395|NCT00863707|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17160396|NCT00289276|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred."|t
17160397|NCT00869960|f||||f
17160398|NCT02029417|t||||
17160399|NCT03040726|t||||
17160400|NCT01451372|f||GT60||t
17160401|NCT00465179|t||||
17160402|NCT01894906|f||LTE60||t
17160403|NCT00976339|t||||f
17160404|NCT01434511|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤30 days(e.g., for intellectual property protection)|t
17160405|NCT00262925|f||LTE60||t
17160406|NCT04062227|t||||
17160407|NCT04682301|f||||f
17160408|NCT04066374|t||||
17160409|NCT02781324|f||||f
17160410|NCT00834041|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160411|NCT05471505|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160412|NCT03415152|f||||f
17160413|NCT03321721|f||||f
17160414|NCT00666237|t||||
17168142|NCT01861925|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require an extension of the embargo for 90 days. If the communication contains confidential information of the sponsor, the sponsor can require to replace this information by scientifically meaningful equivalent information.|t
17168143|NCT02403895|f||OTHER||t
17168144|NCT02129478|f||||f
17168145|NCT02813668|t||||
17160415|NCT01533259|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17160416|NCT00315341|f||||f
17160417|NCT04240314|t||||
17160418|NCT02987868|f||||f
17160419|NCT01750502|f||LTE60||t
17160420|NCT01950663|f||||f
17160421|NCT00498550|f||||f
17160422|NCT00750269|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17137537|NCT00865189|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137538|NCT02484898|f||LTE60||t
17137539|NCT03641547|f||||f
17137540|NCT02767856|t||||
17137541|NCT01392053|t||||f
17137542|NCT01464788|t||||
17137543|NCT00091026|f||LTE60||t
17137544|NCT02513784|t||||f
17137545|NCT00418379|f||||f
17137546|NCT00843843|f||||f
17137547|NCT00589979|f||OTHER|Delay of 12-18 months from Completion Date to publish results from all sites, embargo of 60 to 180 days from the time communication is submitted to sponsor, and ability to redact confidential information (excluding results).|t
17160423|NCT02791269|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160424|NCT00336544|f||OTHER||t
17168146|NCT02961790|t||||
17168147|NCT02078102|t||||
17137548|NCT00565058|f||LTE60||t
17168148|NCT00885638|t||||f
17168149|NCT00598078|f||OTHER||t
17168150|NCT02185014|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168151|NCT03093974|f||||f
17168152|NCT02387164|t||||
17160425|NCT01649765|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137549|NCT00510068|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137550|NCT01397448|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.|t
17137551|NCT00570531|t||||
17137552|NCT02938052|f||||f
17137553|NCT00669916|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137554|NCT02159469|f||OTHER||t
17137555|NCT02475395|f||||f
17137556|NCT00995670|t||||
17160426|NCT01648764|f||GT60||t
17160427|NCT00715208|f||||f
17160428|NCT01316614|t||||
17160429|NCT00076570|t||||
17160430|NCT03427411|f||||f
17168153|NCT02370641|f||||f
17160431|NCT04889040|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160432|NCT00998946|f||||f
17160433|NCT00148798|f||OTHER||t
17160434|NCT00977197|t||||
17160435|NCT00784875|f||GT60||t
17168154|NCT02120365|f||||f
17168155|NCT01726673|f||||f
17160436|NCT02842866|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160437|NCT03703895|t||||
17160438|NCT01901185|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160439|NCT03502798|t||||
17160440|NCT00296335|f||||f
17160441|NCT01401322|t||||f
17160442|NCT02737722|f||||f
17182148|NCT00314574|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17160443|NCT02219256|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17160444|NCT02667639|f||||f
17160445|NCT00284856|f||OTHER|"The SPONSOR must have the opportunity to review all proposed abstracts,~manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as~confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines."|t
17160446|NCT03207399|f||||f
17182149|NCT00449956|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182150|NCT02086110|t||||
17160447|NCT01192815|t||||
17182151|NCT02462967|f||||f
17160448|NCT00477685|f||||f
17160449|NCT03451045|f||||t
17160450|NCT03350919|f||||f
17160451|NCT04142242|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160452|NCT05219162|f||||f
17160453|NCT03506061|t||||
17160454|NCT04609514|t||||
17160455|NCT00909870|f||OTHER|Company-specific confidentiality agreement|t
17160456|NCT00943436|f||||f
17160457|NCT02792504|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160458|NCT00848497|t||||f
17160459|NCT01114724|f||OTHER|The Principal Investigator (PI) and institution agree not to publish the results of the study until after the earliest of the following: a)conclusion of the study, b)the early termination of the study, c)at discretion and approval of the sponsor, or d)after sponsor confirms there will be no multicenter study publication, whichever occurs first. PI and institution further agree to submit to sponsor copies of any proposed publication or public presentation at least sixty days before dissemination.|t
17160460|NCT02873975|t||||
17160461|NCT02966834|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160462|NCT03699748|f||||f
17160463|NCT01712711|t||||
17160464|NCT01387269|f||OTHER|The Sponsor intends to publish the complete study results in a timely manner that is appropriate to the project. Separate publication of a portion of the study results by any PI is discouraged.|t
17160465|NCT01471626|f||||f
17160466|NCT01222299|f||OTHER|Contact sponsor directly for details.|t
17160467|NCT01981616|f||OTHER||t
17160468|NCT01132508|f||LTE60||t
17182152|NCT02432716|t||||
17182153|NCT01828034|t||||
17182154|NCT01988571|f||||f
17182155|NCT00004412|f||||f
17182156|NCT02308735|t||||
17182157|NCT00453999|f||||f
17182158|NCT01632202|t||||
17182159|NCT00594061|f||||f
17160469|NCT01020123|f||LTE60||t
17160470|NCT04711005|f||||f
17150833|NCT02240030|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17160471|NCT03824561|f||||t
17160472|NCT01773928|f||OTHER|Agreements may vary with individual PIs, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or up to 18 months after study completion. Baxter requires a review of results communications (eg for confidential information) ≥60 days prior to submission/communication. Baxter may request additional delay of ≤60 days(e.g. for intellectual property protection). Prior authorization may be required.|t
17150834|NCT00328016|t||||
17150835|NCT02731326|t||||f
17150836|NCT03362112|t||||
17150837|NCT02272634|f||||f
17160473|NCT03092752|t||||f
17160474|NCT03684408|f||||f
17160475|NCT02431299|f||||f
17160476|NCT01526408|t||||
17160477|NCT01899911|f||LTE60||t
17160478|NCT01499810|t||||f
17160479|NCT03658980|f||||f
17160480|NCT03308669|f||GT60||t
17160481|NCT03456245|f||||f
17160482|NCT02273167|f||||f
17160483|NCT00763360|f||||f
17160484|NCT03353220|t||||
17160485|NCT06649409|f||||t
17160486|NCT05539131|f||||f
17160487|NCT03370172|f||||t
17160488|NCT03694171|t||||
17160489|NCT00863122|f||LTE60||t
17160490|NCT00849056|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160491|NCT02711137|f||OTHER|Clinical Study Agreement|t
17160492|NCT03427892|t||||
17160493|NCT00548327|t||||f
17160494|NCT00274456|f||OTHER|Publications of this multicenter trial should include input from INVESTIGATORS, his/her colleagues, and SPONSOR personnel. Such input should be reflected in publication authorship, and agreement regarding order of authors should be established before writing a manuscript. Subsequent to the multicenter publication or one year after completion of the study, whichever occurs first, an investigator and/or his/her colleagues may publish the results of INVESTIGATOR's part of the study independently.|t
17160495|NCT02314546|t||||
17160496|NCT03255187|f||||f
17160497|NCT00375752|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e.,data from all sites)in the clinical trial.|t
17160498|NCT02034006|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17160499|NCT03042546|t||||
17160500|NCT00109343|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160501|NCT01799889|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17160502|NCT03944616|f||||f
17160503|NCT01721798|f||||f
17168156|NCT01719003|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17168157|NCT00581828|f||||f
17168158|NCT01735708|f||||f
17168159|NCT04883528|t||||
17168160|NCT03558074|f||LTE60||t
17168161|NCT05242354|f||||f
17168162|NCT01996592|t||||
17168163|NCT01406015|t||||
17168164|NCT00394901|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17168165|NCT00376805|t||||f
17150838|NCT05070546|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17150839|NCT00302081|f||LTE60||t
17150840|NCT01616953|t||||
17150841|NCT01359644|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150842|NCT01222286|f||||f
17150843|NCT02500641|f||OTHER|All data, information, inventions, discoveries, works, results, reports, presentations, intellectual property rights and whatever else arising out of the performance of the activities by PI, shall be of exclusive property of Sponsor or its designee(s). Sponsor shall be free to use the Results for publication or any other purpose, without any further obligations towards PI, and that, unless agreed in writing by Sponsor, PI shall have no right to publish, use or make presentations of the Results.|t
17150844|NCT01031953|f||||f
17150845|NCT00643565|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150846|NCT02317614|f||||f
17150847|NCT01355159|t||||
17150848|NCT00741936|f||||f
17160504|NCT01294046|t||||
17168166|NCT01886690|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137557|NCT00383721|f||OTHER|"The investigator has the right to publish or publicly present results. The investigator agrees not to publish or publicly present any interim results without prior written consent of the sponsor. The investigator agrees to provide to the sponsor 45 days before submission for publication that~report results of the study. The sponsor shall have the right to review \& comment with respect to publications, abstracts, slides, \& manuscripts \& the right to review \& comment on the data \& presentation."|t
17160505|NCT04319224|f||||f
17160506|NCT01499511|t||||
17160507|NCT00091819|f||LTE60||t
17160508|NCT01151436|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor to review and approval at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17160509|NCT03692949|t||||
17160510|NCT02592824|f||||f
17160511|NCT01286129|f||||f
17160512|NCT01604785|f||||f
17160513|NCT03084237|f||LTE60||t
17160514|NCT01394276|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160515|NCT05049122|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17137558|NCT03828149|f||GT60||t
17160516|NCT02187783|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17168167|NCT03757130|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168168|NCT02360293|t||||
17137559|NCT03784027|f||||f
17137560|NCT00937794|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17137561|NCT04777214|f||||f
17137562|NCT00597935|f||||f
17137563|NCT01738737|f||||f
17137564|NCT06076148|f||||f
17137565|NCT00646113|f||LTE60||t
17137566|NCT02109744|t||||
17137567|NCT04656418|f||OTHER||t
17160517|NCT00471497|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17160518|NCT01654276|t||||
17160519|NCT01991795|f||GT60||t
17160520|NCT03344757|t||||
17160521|NCT02121210|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17160522|NCT01316575|t||||
17160523|NCT01232283|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17160524|NCT00402831|f||OTHER|Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17160525|NCT04773028|t||||
17160526|NCT03043053|t||||
17160527|NCT01535924|t||||
17160528|NCT03883386|t||||
17160529|NCT02814526|f||||f
17137568|NCT03287245|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137569|NCT02701192|f||||f
17137570|NCT00989612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137571|NCT01383109|f||||f
17137572|NCT02150213|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137573|NCT00751179|f||OTHER|If a proposed publication contains reference to an invention owned by the Sponsor or to which the Sponsor otherwise has rights, the Sponsor may request a reasonable suspension of the publication in order to be able to file a patent application protecting such invention.|t
17137574|NCT01666145|t||||f
17160530|NCT00251758|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17160531|NCT01141608|f||||f
17160532|NCT02866643|f||||f
17160533|NCT02753881|t||||
17160534|NCT00506675|f||||f
17160535|NCT02858908|f||OTHER|The investigator has the right to publish study results from his/her specific site. However, any publication that includes AMO Pharma confidential information cannot be submitted for publication without AMO Pharma's prior written approval.|t
17160536|NCT03573297|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160537|NCT06996301|f||||f
17160538|NCT00505635|t||||f
17137575|NCT01297309|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17137576|NCT03039738|f||||f
17160539|NCT02634177|f||||f
17160540|NCT00661388|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160541|NCT01171534|f||LTE60||t
17160542|NCT00362232|f||||f
17160543|NCT03588624|f||||f
17160544|NCT02340676|t||||
17160545|NCT02472405|t||||
17182160|NCT04964453|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160546|NCT01715298|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17160547|NCT03424304|f||||f
17160548|NCT00726453|f||OTHER||t
17160549|NCT00941928|t||||f
17160550|NCT00577408|f||||f
17160551|NCT00656617|t||||
17160552|NCT01107015|f||||f
17160553|NCT02081807|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160554|NCT02765035|f||LTE60||t
17160555|NCT01604772|f||LTE60||t
17160556|NCT02349386|f||||f
17160557|NCT01712178|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17182161|NCT00696137|f||GT60||t
17182162|NCT03621878|f||||f
17182163|NCT02508571|f||||f
17182164|NCT03742141|t||||
17182165|NCT02376166|t||||
17160558|NCT02765165|f||OTHER|The Sponsor has first right to first publication which is intended to be a joint, multi-center publication in conjunction with the Investigators. Following first publication, the Investigator may publish results provided the proposed publication is submitted for review to the Sponsor at least 60 days in advance; the Sponsor has the right to remove confidential/proprietary information. If publication may affect patentability of an invention, an additional delay of 90 days may be requested.|t
17160559|NCT02411643|f||||f
17160560|NCT00321763|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168169|NCT02226549|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168170|NCT02726880|f||||f
17168171|NCT04316741|f||||f
17168172|NCT01510145|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17168173|NCT02312219|t||||
17168174|NCT01269385|t||||
17168175|NCT01842594|t||||
17168176|NCT04941807|t||||
17168177|NCT01827332|f||||f
17182166|NCT04180020|t||||
17182167|NCT00363779|f||||f
17182168|NCT03639766|f||||f
17182169|NCT02769702|f||||f
17182170|NCT00816101|f||||f
17137577|NCT02678312|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137578|NCT02527187|f||||f
17137579|NCT02716194|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication. The sponsor requires a review of results communication (e .g. for confidential information) \>= 45 days prior to submission and may request an additional delay of \<=210 days (e .g. for intellectual property protection).|t
17137580|NCT00971425|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137581|NCT05197140|f||||f
17137582|NCT01753830|f||||t
17137583|NCT03587584|t||||
17137584|NCT00225147|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to its submission or disclosure. The sponsor may request to delete information identified by sponsor as confidential information prior to submitting such manuscript and/or abstract for publication. For a multi-center study, the investigator must wait (i) at least 24 months after the study is completed at all sites or (ii) until after the multi-center publication.|t
17137585|NCT04169113|t||||
17137586|NCT02685995|t||||f
17160561|NCT00410163|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160562|NCT00961415|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160563|NCT02841046|f||||t
17160564|NCT04759131|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17168178|NCT00546260|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo. Additionally, individual publication may occur after coordinated multi-center publication.|t
17168179|NCT01213823|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168180|NCT00316524|f||||t
17168181|NCT02246608|f||||f
17168182|NCT03654885|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168183|NCT02418312|t||||
17168184|NCT00803413|t||||
17168185|NCT02209948|f||||f
17168186|NCT04562597|f||||f
17168187|NCT02630017|t||||f
17168188|NCT00289198|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182171|NCT02917031|f||||f
17182172|NCT00403273|f||||f
17182173|NCT04041869|f||||f
17182174|NCT05087875|t||||f
17182175|NCT01852292|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17182176|NCT02586012|t||||
17137587|NCT03625141|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137588|NCT00193219|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17137589|NCT00868166|f||LTE60||t
17182177|NCT01195467|t||||f
17160565|NCT05144945|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160566|NCT03692312|f||OTHER|The investigator has the right to publish study results from his/her specific site. However, any publication that includes AMO Pharma confidential information cannot be submitted for publication without AMO Pharma's prior written approval.|t
17160567|NCT01032928|t||||
17160568|NCT03426878|f||||f
17160569|NCT00465517|f||LTE60||t
17160570|NCT02111200|f||||f
17160571|NCT05033041|t||||f
17160572|NCT05233761|t||||
17160573|NCT00914069|f||OTHER|The Principal Investigators may publish or present the study results with prior consent of the Sponsor, but will not disclose confidential information. Prior to submission by a Principal Investigator for publication or presentation, the Sponsor will be provided with the opportunity to review the submission for confidential information and accuracy.|t
17160574|NCT00560404|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160575|NCT06015490|t||||
17160576|NCT04513366|f||||t
17160577|NCT00392223|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160578|NCT01426581|t||||f
17160579|NCT02657551|t||||
17160580|NCT01498549|t||||
17168189|NCT01176565|f||OTHER|The overall Principal Investigator IS, but the Data Coordination Unit (statistical) Principal Investigator IS NOT employed by the sponsor. Prior to release of a public-use data set, any study PIs/other collaborators may submit a proposal requesting data access, assistance with statistical analyses, and publication of additional results. All proposals are reviewed by a Publications Committee that includes the primary study PI, the statistical PI, the NINDS project scientist, and appointed others.|t
17168190|NCT02406443|f||||f
17168191|NCT01062061|f||||f
17168192|NCT03435562|t||||f
17168193|NCT04214639|f||OTHER|Please contact sponsor for details.|t
17168194|NCT03573700|t||||
17168195|NCT01143051|f||OTHER|The PI is to maintain all information, data, inventions and discoveries disclosed by the Sponsor in confidence unless that information was in public domain at time of disclosure or becomes part of the public domain or is published through no fault of the PI or Institution, or was in the possession of the PI or Institution at time of disclosure and was not acquired from Sponsor under any obligation of confidentiality or is produced pursuant to a validly issued subpoena.|t
17160581|NCT04478266|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17160582|NCT06119854|f||||f
17160583|NCT05190770|t||||
17160584|NCT04798027|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160585|NCT03104374|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160586|NCT04622345|f||||t
17160587|NCT00094445|t||||f
17160588|NCT05203185|t||||
17160589|NCT00769561|t||||
17160590|NCT04585893|t||||
17160591|NCT03729362|f||GT60||t
17160592|NCT01113749|f||||f
17160593|NCT00961064|t||||
17168196|NCT03180398|t||||
17160594|NCT00576758|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160595|NCT00761319|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17160596|NCT00795340|t||||t
17160597|NCT01432951|f||GT60||t
17160598|NCT00853385|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160599|NCT01951950|t||||
17160600|NCT00915525|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160601|NCT03104413|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160602|NCT00984867|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17160603|NCT00513799|f||||f
17160604|NCT03482024|f||GT60||t
17160605|NCT03937778|t||||
17160606|NCT00819039|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17160607|NCT01240694|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17160608|NCT01881425|f||OTHER||t
17160609|NCT00397579|t||||
17160610|NCT02524119|t||||
17160611|NCT01928849|f||||f
17160612|NCT01200355|t||||
17160613|NCT03185208|t||||f
17160614|NCT03834350|f||||f
17160615|NCT02410629|f||||f
17160616|NCT01206764|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17160617|NCT01186770|f||OTHER|Please contact Sponsor directly for additional information.|t
17160618|NCT02567188|f||OTHER|The study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the Overall Study. The sponsor may request that the confidential information be deleted and/or the publication to be postponed inorder to present the Sponsor's intellectual property rights.|t
17160619|NCT01033136|t||||
17160620|NCT05824026|f||||t
17160621|NCT00797563|f||LTE60||t
17160622|NCT00688597|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17160623|NCT05853120|t||||
17160624|NCT04431206|t||||
17160625|NCT02763566|f||GT60||t
17160626|NCT02855268|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17160627|NCT00639509|f||LTE60||t
17160628|NCT03869268|t||||
17160629|NCT05722015|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17160630|NCT04058717|t||||f
17160631|NCT00671788|f||||f
17160632|NCT01832766|f||||f
17160633|NCT02525523|f||||f
17160634|NCT01925417|f||||f
17160635|NCT03479905|t||||
17160636|NCT00720759|t||||
17160637|NCT04376567|f||||f
17160638|NCT02598661|f||OTHER|Consistent with Good Publication Practices and ICMJE guidelines, the sponsor shall have right to publish such primary (multicenter) data and information without approval from investigator. Investigator has right to publish study site-specific data after primary data published. If an investigator wishes to publish information from study, a copy of manuscript must be provided to sponsor for review at least 60 days before submission for publication or presentation.|t
17160639|NCT01366092|f||||f
17160640|NCT03074500|f||||f
17160641|NCT03608163|t||||f
17160642|NCT03857256|f||OTHER|The disclosure restriction on the PI is that the sponsor can review material for publication or presentation before public release and can embargo the release for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can request removal of sponsor's confidential information and the sponsor can request removal of information for which sponsor wishes to obtain intellectual protection.|t
17160643|NCT03114150|f||||f
17160644|NCT02659865|f||GT60||t
17160645|NCT05335161|f||||f
17160646|NCT02100631|f||||t
17160647|NCT03979313|f||||f
17160648|NCT00089648|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160649|NCT00300053|f||OTHER|For this study, PIs are restricted from independently publishing results before completion of a single multicenter publication or one year after study completion, whichever occurs first. Baxter requires a review of the intended publication at least 60 days prior to submission. Baxter may request an additional delay of 45 days to secure patent and/or other proprietary protection.|t
17160650|NCT00423605|f||OTHER||t
17160651|NCT00396292|f||LTE60||t
17160652|NCT02631057|t||||f
17160653|NCT03261401|f||||f
17160654|NCT03837847|t||||
17160655|NCT03860753|t||||
17160656|NCT01653418|t||||
17160657|NCT01983930|t||||f
17160658|NCT01104285|t||||
17160659|NCT02730130|t||||
17160660|NCT00141921|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160661|NCT02805998|t||||
17160662|NCT02471339|f||||f
17160663|NCT00626639|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17160664|NCT00634504|f||||f
17160665|NCT00204737|t||||
17160666|NCT05001620|t||||
17160667|NCT04383132|f||||f
17160668|NCT00481676|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. any publications from a single-site are postponed until the publication of the pooled date (ie, data from all sites) in the clinical trial.|t
17160669|NCT01513590|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17160670|NCT01056276|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17160671|NCT02054156|f||||f
17160672|NCT04424901|f||||f
17160673|NCT00147238|t||||f
17160674|NCT00297167|f||OTHER|Restrictions may vary in accordance with each agreement that is negotiated with individual investigators. Sponsor will allow publication after multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and defer publication for period of time to allow Sponsor to obtain patent or other intellectual property right protection.|t
17160675|NCT04232137|f||||f
17160676|NCT00754923|f||LTE60||t
17160677|NCT02701634|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17160678|NCT02511717|f||||f
17160679|NCT04342169|f||||f
17160680|NCT02456896|t||||
17160681|NCT04009837|f||||f
17160682|NCT02674659|f||||f
17160683|NCT01572792|f||OTHER|Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor|t
17160684|NCT03530696|t||||
17160685|NCT02472353|t||||
17160686|NCT01129128|f||||f
17160687|NCT04497883|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17160688|NCT06309394|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17160689|NCT03609177|t||||f
17160690|NCT01047319|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17160691|NCT01288430|f||||f
17160692|NCT03166709|f||||f
17160693|NCT03836053|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160694|NCT04006457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160695|NCT04486716|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160696|NCT03643848|t||||f
17160697|NCT02700841|t||||
17160698|NCT05423743|f||||f
17160699|NCT00090103|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160700|NCT04476043|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17160701|NCT00320086|t||||f
17160702|NCT02194465|f||GT60||t
17160703|NCT01408641|f||||f
17160704|NCT02156258|f||||f
17160705|NCT03183908|f||||f
17160706|NCT01240746|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17160707|NCT03738696|f||||f
17160708|NCT02566005|t||||
17160709|NCT03617588|f||||f
17160710|NCT01294514|t||||
17160711|NCT02690727|f||OTHER||t
17160712|NCT06094647|t||||
17160713|NCT01675778|t||||
17160714|NCT01461551|t||||
17160715|NCT01155141|f||||f
17160716|NCT00303186|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160717|NCT03473197|f||||f
17160718|NCT00785629|f||LTE60||t
17160719|NCT00267670|t||||
17160720|NCT00851591|t||||
17160721|NCT01114555|t||||
17160722|NCT02326883|f||||f
17160723|NCT02736617|t||||
17160724|NCT01718691|f||||f
17160725|NCT02911116|t||||
17160726|NCT04796415|f||||f
17160727|NCT02469857|f||||f
17160728|NCT02110693|f||||f
17160729|NCT00937950|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160730|NCT00630292|t||||
17160731|NCT00142415|f||LTE60||t
17160732|NCT00537277|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17168197|NCT01605227|f||OTHER|Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.|t
17168198|NCT00402714|f||||f
17160733|NCT03620162|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17160734|NCT02767531|f||||f
17160735|NCT01838876|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160736|NCT02101294|t||||f
17160737|NCT03416179|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160738|NCT00475332|f||||f
17168199|NCT05418153|f||||f
17168200|NCT01813721|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168201|NCT01866423|t||||
17168202|NCT00810901|f||||f
17168203|NCT01133275|t||||
17168204|NCT00900146|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160739|NCT03134768|f||LTE60||t
17160740|NCT01545336|f||||f
17160741|NCT01138735|f||OTHER||t
17160742|NCT01056536|f||||f
17160743|NCT03136198|f||||f
17160744|NCT01052948|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160745|NCT01933594|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17160746|NCT00315445|f||GT60||t
17160747|NCT01035138|f||GT60||t
17160748|NCT01811238|f||||f
17160749|NCT01579214|f||||f
17160750|NCT02164916|f||||f
17160751|NCT03229499|f||||f
17160752|NCT02916927|t||||
17160753|NCT00944554|f||||f
17160754|NCT02587936|f||||f
17160755|NCT00655889|f||OTHER|Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval prior to publication or presentation in any form.|t
17160756|NCT02318940|f||||f
17160757|NCT01191749|t||||
17160758|NCT03454555|t||||
17160759|NCT05399680|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication, provided that those comments do not jeopardize the scientific integrity of the publication.|t
17160760|NCT04530630|t||||
17160761|NCT00850642|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160762|NCT03675308|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160763|NCT06128954|f||OTHER|Full study agreement in place with Richmond Pharmacology.|t
17160764|NCT01386385|f||LTE60||t
17160765|NCT05032183|t||||
17160766|NCT03737994|f||OTHER|Must obtain prior approval from the sponsor. In addition, PI's are required to abide by Collaborator's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17160767|NCT02332707|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17137590|NCT00240539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137591|NCT00284739|t||||
17137592|NCT03819218|f||LTE60||t
17137593|NCT02680587|t||||
17137594|NCT02899377|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137595|NCT00469209|t||||f
17137596|NCT00943488|f||LTE60||t
17160768|NCT01473134|f||OTHER|Each participating PI has signed a Clinical Trial Agreement and results are not publicly available until FDA provides approval/closure of the study.|t
17137597|NCT00712933|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137598|NCT00085917|t||||
17137599|NCT01295580|f||||f
17137600|NCT02022033|f||||f
17160769|NCT04761822|f||||f
17160770|NCT04734652|f||||t
17160771|NCT02233413|f||||f
17160772|NCT03265964|t||||
17160773|NCT00890162|t||||
17160774|NCT02385318|f||OTHER||t
17168205|NCT00700102|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160775|NCT00248560|t||||f
17160776|NCT02471183|f||OTHER|"Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation.~Upon review, Actelion may provide comments, and may also request changes for the sole purpose of protecting its confidential information and/or patent rights.~Neither the institution nor the investigator should permit publication during such a review period."|t
17160777|NCT02721069|f||||t
17160778|NCT00827567|t||||
17160779|NCT04810962|f||OTHER|The Institutions and Investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of the Sponsor.|t
17168206|NCT01811303|f||||f
17168207|NCT02525939|f||||f
17168208|NCT01028716|t||||
17160780|NCT05169905|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17160781|NCT02412657|f||||f
17160782|NCT00460798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160783|NCT01898130|t||||
17160784|NCT01189266|f||LTE60||t
17160785|NCT01682031|t||||
17160786|NCT01101100|f||OTHER||t
17160787|NCT05653843|f||||f
17160788|NCT00924898|t||||
17160789|NCT01285518|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160790|NCT00294658|f||GT60||t
17160791|NCT03805841|f||LTE60||t
17160792|NCT01719653|t||||
17160793|NCT01910441|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17160794|NCT02340949|f||||f
17160795|NCT01192178|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160796|NCT02460289|f||||t
17160797|NCT01155570|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160798|NCT00296517|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the Publication of results from all centers of a multi-center trial but requests that reports based on Single-site data not precede the primary publication of the entire clinical trial.|t
17160799|NCT02517658|t||||t
17160800|NCT00964782|t||||
17160801|NCT03513952|f||LTE60||t
17160802|NCT01484340|f||||f
17160803|NCT02630030|f||||f
17160804|NCT01143324|f||OTHER|Confidential Disclosure Agreements were signed by all investigators. The information had to be kept confidential and investigators agreed not to disclose information to any third party.|t
17160805|NCT00596635|t||||
17160806|NCT01010763|f||||f
17160807|NCT01101178|f||GT60||t
17160808|NCT01850641|f||||f
17160809|NCT00141817|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160810|NCT01643213|f||||f
17168209|NCT05590000|f||OTHER|The PI may not publish the study results until publication of the results of the multi-center study or 2 years after study completion, whichever is sooner and allows the Sponsor to review any proposed publication at least 40 days before forwarding it to any person that is not bound by the confidentiality agreement between Sponsor and PI.|t
17168210|NCT00536874|t||||
17160811|NCT02530541|f||OTHER|Data considered confidential|t
17168211|NCT00762996|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17168212|NCT04610489|t||||
17168213|NCT02689076|t||||f
17168214|NCT02944565|t||||
17168215|NCT01143896|t||||
17168216|NCT02084238|t||||
17168217|NCT00320372|f||||f
17160812|NCT00127803|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17160813|NCT02353780|t||||f
17160814|NCT02774889|t||||
17160815|NCT00858988|t||||
17160816|NCT00846365|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17160817|NCT03133676|f||||t
17168218|NCT00849875|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168219|NCT00086502|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168220|NCT01304329|t||||
17182178|NCT02388737|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182179|NCT03018392|f||LTE60||t
17182180|NCT03299842|f||GT60||t
17182181|NCT01816139|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17182182|NCT03661814|f||||f
17182183|NCT03240575|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160818|NCT04901624|t||||f
17160819|NCT03654417|t||||
17160820|NCT00862992|f||OTHER||t
17160821|NCT03100747|t||||
17168221|NCT00525629|f||||f
17168222|NCT00283816|f||||f
17182184|NCT02431754|f||GT60||t
17182185|NCT03856437|t||||
17182186|NCT00554671|f||||f
17160822|NCT02072200|f||OTHER|PI/ Institution shall provide to Mundipharma any proposed presentation at least 15 working days prior to being disclosed and any other proposed publication at least 45 working days prior to being disclosed. Mundipharma may in its sole discretion permit such publications and presentations and shall have the right to require amendments to any such proposed presentation or publication on reasonable grounds.|t
17160823|NCT00658619|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160824|NCT03261193|f||||f
17168223|NCT02575118|t||||
17168224|NCT01643876|t||||
17168225|NCT00885768|t||||
17168226|NCT02068118|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release, can require changes to the communication and can embargo communications regarding trial results for a period that is less than or equal to 180 days from the time submitted to the sponsor for review. The modifications made by the sponsor cannot in any way affect the scientific value of the publication.|t
17168227|NCT00283868|f||||f
17168228|NCT01515475|f||||f
17168229|NCT01420627|f||GT60||t
17168230|NCT00837876|t||||
17168231|NCT00453973|f||OTHER|Publications may not contain Sponsor confidential information, and will be subject to Sponsor review prior to submission for publication.|t
17168232|NCT00276094|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17168233|NCT01511809|f||||f
17168234|NCT00130923|f||||f
17168235|NCT02075632|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168236|NCT05028517|f||||f
17168237|NCT02256267|f||OTHER|The Clinical Research Organization (CRO) and its third party contractors shall not publish, discuss or release data emanating from a Study without Lilly's express written permission.|t
17168238|NCT04557787|f||LTE60||t
17168239|NCT00259298|f||GT60||t
17168240|NCT05182580|f||||f
17168241|NCT05445206|f||||f
17168242|NCT02916407|f||||f
17168243|NCT01969500|f||||f
17168244|NCT00613080|f||||f
17182187|NCT02061969|f||||f
17182188|NCT02342704|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17182189|NCT00614913|t||||
17182190|NCT02347527|f||||f
17160825|NCT04084015|f||||f
17160826|NCT01277861|f||||f
17160827|NCT02696798|f||LTE60||t
17160828|NCT00857389|t||||
17160829|NCT01157845|f||LTE60||t
17168245|NCT03553498|t||||
17168246|NCT01100567|f||||f
17168247|NCT02741570|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168248|NCT01005212|f||||f
17168249|NCT00160199|f||OTHER|Independent analysis and/or publication of these data by the investigator or any member of his/her staff are not permitted without prior written consent of Solvay Pharmaceuticals,Inc. Written permission will be contingent on the review by Solvay Pharmaceuticals, Inc. of the statistical analysis and manuscript and providing for non-disclosure of Solvay Pharmaceuticals, Inc. confidential or proprietary information.|t
17168250|NCT03352453|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160830|NCT03311555|t||||
17160831|NCT01120197|f||||f
17160832|NCT00788671|t||||
17160833|NCT03405870|f||||f
17160834|NCT05172609|f||||f
17160835|NCT00549055|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160836|NCT03846479|f||LTE60||t
17160837|NCT05020015|f||||t
17160838|NCT02515253|t||||
17160839|NCT06217380|f||||f
17160840|NCT06633965|f||||f
17160841|NCT04213261|f||LTE60||t
17160842|NCT00947544|f||GT60||t
17160843|NCT01080261|f||OTHER|In Japan, the study agreement was executed between the head of hospital (not PI) and Boston Scientific Japan. The site must get written approval before they publish any study data/information to an outside community such as a scientific society.|t
17160844|NCT00409825|f||||f
17160845|NCT02594111|f||||f
17160846|NCT01963611|f||OTHER||t
17160847|NCT01126424|f||OTHER|Institute and/or Principal Investigator may not publish trial data generated at their specific study site without prior written approval of the Sponsor.|t
17160848|NCT03801252|t||||
17160849|NCT01134042|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160850|NCT02478671|f||OTHER|PI shall be permitted to publish the results of the Study in a manner that fairly and accurately sets forth the conclusions reached. The party seeking publication shall submit to SPONSOR for review a draft of the proposed publication at least thirty (30) days prior to submission of the draft for publication.|t
17160851|NCT00393367|f||||f
17160852|NCT03286504|t||||f
17160853|NCT05350423|f||||f
17160854|NCT01432327|t||||f
17160855|NCT04706221|f||||f
17160856|NCT03320369|f||||f
17160857|NCT01732692|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17160858|NCT01951066|f||OTHER||t
17160859|NCT02030600|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17160860|NCT01155323|f||OTHER|The results of the study may not be published or publicly presented without prior written approval of the sponsor. If the investigator wishes to publish or present any study findings, investigator shall contact sponsor to discuss publication plan.|t
17160861|NCT02052635|f||OTHER|The PI shall provide the Sponsor with copies of any materials at least thirty days in advance of publication, submission or presentation. At the request of the Sponsor, the PI shall withhold publication, submission for publication or presentation for a period of ninety days from the date on which the Sponsor receives the material to allow the Sponsor to take such measures as the Sponsor considers necessary to preserve its proprietary rights and/or protect its Confidential Information.|t
17160862|NCT03340883|f||OTHER|Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Aduro ≥ 60 days in advance of submission for publication; (ii) deletes Aduro Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings.|t
17168251|NCT01241760|f||OTHER|If the PI (Investigator) wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17168252|NCT01667146|f||||f
17168253|NCT03689244|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 30 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filling of a patent application.|t
17168254|NCT02700165|f||||f
17150849|NCT02450526|f||OTHER|The disclosure restriction on the PI is that the sponsor must review all results communications prior to public release. The sponsor has the right to delay a publication by 60 days from the time submitted to the sponsor for review. Any factual amendments proposed by sponsor will be incorporated, provided that they do not alter the scientific value of the material.|t
17150850|NCT01970865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150851|NCT01576874|t||||
17160863|NCT02240329|f||||f
17160864|NCT04154956|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17160865|NCT00805532|t||||
17160866|NCT01859741|f||||f
17160867|NCT03988647|t||||
17160868|NCT00154466|t||||f
17160869|NCT03823131|t||||
17160870|NCT01281306|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17160871|NCT04491994|f||||f
17160872|NCT03589703|f||||f
17160873|NCT01953237|f||||f
17160874|NCT02320396|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17160875|NCT02606253|f||||f
17160876|NCT00890721|f||||f
17160877|NCT03331562|f||LTE60||t
17160878|NCT03718000|f||||f
17160879|NCT02234180|f||||f
17160880|NCT02441283|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160881|NCT05383209|f||||t
17160882|NCT01582451|f||GT60||t
17160883|NCT00487188|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17160884|NCT01654887|t||||
17160885|NCT04882800|t||||f
17160886|NCT03822416|t||||
17160887|NCT04666298|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17160888|NCT00226655|f||LTE60||t
17160889|NCT03149770|t||||
17160890|NCT01311661|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17160891|NCT00207740|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17160892|NCT00390013|t||||
17160893|NCT00722020|f||||f
17160894|NCT03188822|t||||
17160895|NCT01998360|f||||f
17160896|NCT01977846|f||||f
17182191|NCT01632891|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17182192|NCT02919670|t||||
17182193|NCT01466270|t||||
17182194|NCT04070833|f||||f
17160897|NCT01093417|t||||
17160898|NCT01349595|t||||
17160899|NCT00001305|t||||
17160900|NCT04584788|f||||f
17160901|NCT03726476|f||||f
17160902|NCT02019069|t||||
17160903|NCT02328105|t||||
17160904|NCT00614393|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17160905|NCT01588509|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17160906|NCT02612857|f||||f
17160907|NCT00855582|f||GT60||t
17160908|NCT03345004|f||LTE60||t
17160909|NCT01013753|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17182195|NCT02118428|f||LTE60||t
17182196|NCT04171414|f||OTHER||t
17182197|NCT02299050|t||||
17182198|NCT02619409|f||||f
17182199|NCT02884089|f||GT60||t
17160910|NCT04757636|f||OTHER|The principles for publication of results of this study will be addressed in clinical trial agreements between Opthea (Sponsor) and the study site, and Opthea and the subcontractors performing the study. Results means any and all information and know-how (whether patentable or not) which is discovered, invented or developed or which arises in the course of or as a result of the conduct of the Study, including any and all improvements to the products being studied.|t
17160911|NCT01733953|f||||f
17160912|NCT02018107|f||||f
17160913|NCT00674297|f||||f
17160914|NCT01433913|f||LTE60||t
17160915|NCT02097277|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160916|NCT01091259|t||||
17160917|NCT03813654|f||||f
17160918|NCT01208051|f||LTE60||t
17160919|NCT00255177|f||||f
17160920|NCT00973973|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17160921|NCT01541748|f||OTHER||t
17160922|NCT06057064|t||||
17160923|NCT02832037|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17160924|NCT04773795|f||||f
17160925|NCT01137786|f||GT60||t
17160926|NCT01531153|t||||
17160927|NCT00770367|f||||f
17160928|NCT00435942|f||OTHER|Investigator must provide Bolton Medical with the proposed publication for review. Bolton Medical had 30 days to review and had discretion to make changes.|t
17160929|NCT00920816|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160930|NCT01180777|f||OTHER|Publication requires agreement and written authorization from the Sponsor|t
17160931|NCT00350220|f||||f
17160932|NCT03755076|t||||
17160933|NCT04167462|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160934|NCT05522751|f||||f
17160935|NCT02475213|f||LTE60||t
17160936|NCT00505921|t||||f
17160937|NCT01325441|f||LTE60||t
17160938|NCT02382939|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17160939|NCT02026297|f||||f
17160940|NCT03318341|f||||f
17160941|NCT00717886|t||||
17160942|NCT00716417|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17160943|NCT01369433|f||||f
17160944|NCT01553851|f||||f
17160945|NCT01807455|f||OTHER||t
17160946|NCT02321527|t||||
17160947|NCT00149643|f||||f
17160948|NCT02196831|f||||f
17160949|NCT01932606|t||||
17160950|NCT06525727|t||||
17160951|NCT02508389|f||OTHER||t
17160952|NCT01869374|t||||
17160953|NCT00844519|f||||f
17160954|NCT06438601|f||||f
17160955|NCT03329001|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160956|NCT02178956|f||GT60||t
17182200|NCT01631474|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17160957|NCT01138046|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160958|NCT03769493|f||||f
17160959|NCT02709369|t||||
17160960|NCT01900314|f||LTE60||t
17160961|NCT00585182|f||||f
17160962|NCT01104766|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17160963|NCT01341470|f||GT60||t
17182201|NCT02624284|t||||
17160964|NCT04057235|f||||f
17160965|NCT04225832|f||||f
17160966|NCT00311168|f||||f
17160967|NCT05658887|t||||
17160968|NCT03965923|f||||f
17160969|NCT01732211|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17160970|NCT02755090|f||||f
17160971|NCT04940221|f||||f
17160972|NCT03839641|f||||f
17160973|NCT03481049|f||||f
17160974|NCT00770809|f||LTE60||t
17160975|NCT01566370|f||||f
17160976|NCT06023563|f||||f
17182202|NCT02487394|f||||f
17182203|NCT01010282|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17137601|NCT03067129|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137602|NCT03986190|t||||f
17150852|NCT03071094|f||OTHER||t
17150853|NCT01079832|t||||
17150854|NCT03982199|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17150855|NCT00594646|t||||f
17150856|NCT03544879|t||||
17150857|NCT03907462|f||||f
17160977|NCT02469233|t||||
17160978|NCT03474107|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17160979|NCT03095287|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17160980|NCT01431976|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17160981|NCT00055237|f||||f
17160982|NCT04601506|t||||
17160983|NCT00867932|f||||t
17160984|NCT02127671|f||||f
17182204|NCT01641367|f||||f
17160985|NCT01136954|f||||f
17160986|NCT02394275|t||||
17160987|NCT03834168|t||||
17168255|NCT02011490|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17168256|NCT01244633|f||||f
17168257|NCT03697993|f||LTE60||t
17168258|NCT03759041|f||OTHER||t
17160988|NCT00782067|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17160989|NCT03556683|t||||
17160990|NCT00764517|f||||f
17160991|NCT00520468|t||||f
17160992|NCT01890577|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168259|NCT04384107|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17168260|NCT00276614|f||||f
17168261|NCT00552448|f||||f
17168262|NCT01522404|t||||
17168263|NCT02698371|t||||
17168264|NCT03734029|f||||f
17168265|NCT03081858|f||OTHER|At least 90 days before the proposed submission for publication/presentation of Study data or findings, the PI will provide the Sponsor with a manuscript for review. No release of confidential information without the Sponsor's written approval. Multi-center results to be published conjointly under Sponsor's direction, but if this final manuscript has not been published within 12 months after study end at all sites, the PI may publish results, subject to contract confidentiality.|t
17168266|NCT01800318|t||||
17160993|NCT00835926|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17160994|NCT00621530|f||||f
17160995|NCT04398966|t||||
17160996|NCT00671060|t||OTHER||t
17160997|NCT02239328|f||||f
17160998|NCT03483103|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17160999|NCT03881371|f||OTHER||t
17161000|NCT00933933|f||OTHER|The principal investigator (PI) must provide copy of any proposed publication/presentation at least 30 days prior to submission for sponsor review/approval. PI must incorporate changes as the sponosr requires in order to protect the sponsor's proprietary rights and interests. Sponsor may require the PI to include acknowledgement of sponosr's role in the study. PI may be requested to delay publication/presentation an extra 60 days to enable sponor to secure patent or other proprietary protection.|t
17161001|NCT03282097|t||||
17161002|NCT02226159|t||||
17161003|NCT06001021|t||||f
17161004|NCT04797169|f||||f
17161005|NCT05473039|f||||f
17161006|NCT02236364|t||||
17161007|NCT02535312|f||LTE60||t
17161008|NCT04221490|f||||t
17161009|NCT03034967|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161010|NCT04279483|f||||f
17161011|NCT01670006|f||OTHER||t
17161012|NCT04926233|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17161013|NCT04800627|t||||
17161014|NCT02550795|f||||f
17161015|NCT02084797|f||||f
17161016|NCT02373865|t||||
17161017|NCT00879658|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17161018|NCT00314145|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17161019|NCT00580840|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17161020|NCT01551173|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17161021|NCT04530344|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161022|NCT01402700|f||OTHER|"There is an agreement between the Principal Investigator and Sponsor \[or its agents\] that restricts PI's rights to discuss or publish trial results without permission of the Sponsor.~Trial is still ongoing."|t
17161023|NCT03279952|t||||f
17161024|NCT02489539|f||OTHER|PI(s) are restricted publishing multi-site aggregate trial results until the multi-center manuscript is published (Gore reserves the right to extend (as applicable) if filing a patent application). Prior to publication, Gore is allowed 60 day review period and the right to remove proprietary information.|t
17161025|NCT05277207|t||||
17161026|NCT05523297|f||||f
17161027|NCT03462680|t||||
17161028|NCT02246777|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161029|NCT02401230|t||||
17161030|NCT04133909|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17161031|NCT00830765|f||||f
17161032|NCT01299909|f||||f
17161033|NCT04262219|t||||
17161034|NCT02546570|f||||f
17161035|NCT03069989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161036|NCT01740206|t||||
17161037|NCT04356833|t||||f
17161038|NCT01509105|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161039|NCT03595748|f||||f
17161040|NCT05352763|f||GT60||t
17161041|NCT04809974|f||||f
17161042|NCT05019430|f||||f
17161043|NCT05493111|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161044|NCT05399485|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161045|NCT06125964|f||||f
17161046|NCT01787838|f||||f
17161047|NCT02020941|t||||
17161048|NCT01038765|t||||
17161049|NCT02107898|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17161050|NCT03329989|f||||f
17161051|NCT00620542|f||LTE60||t
17161052|NCT01401166|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161053|NCT03901300|f||||f
17161054|NCT01283386|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161055|NCT02210195|f||||f
17161056|NCT01989975|f||GT60||t
17161057|NCT04115059|f||||f
17161058|NCT06420232|t||||
17168267|NCT00131456|t||||
17161059|NCT00963235|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161060|NCT01136915|f||GT60||t
17161061|NCT01756235|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161062|NCT03225482|t||||
17161063|NCT02213926|f||||f
17161064|NCT01234116|t||||
17161065|NCT01697579|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17161066|NCT04635345|f||||f
17161067|NCT01044498|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161068|NCT06001866|f||||f
17161069|NCT02903914|f||OTHER|Clinical Trial Agreement|t
17161070|NCT04341636|f||||f
17161071|NCT04725188|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17161072|NCT02337829|f||||f
17161073|NCT03765073|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161074|NCT05850494|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17161075|NCT04325386|t||||
17161076|NCT00957359|t||||
17161077|NCT00392041|f||||f
17161078|NCT04297917|f||LTE60||t
17161079|NCT02802228|f||LTE60||t
17161080|NCT00695019|f||||f
17137603|NCT00830804|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17137604|NCT02180217|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17161081|NCT01014091|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161082|NCT03197129|f||||f
17161083|NCT06026813|t||||
17161084|NCT02879695|f||LTE60||t
17161085|NCT02442349|f||GT60||t
17161086|NCT03507790|f||OTHER||t
17161087|NCT06181799|t||||
17161088|NCT01160614|f||GT60||t
17161089|NCT05845619|t||||
17161090|NCT03636477|f||OTHER|Disclosure shall not occur until (i) twenty-four (24) months have elapsed since Sponsor has notified Institution of the completion of the multi-center Study in order for Sponsor to comply with its obligations under 21 CFR 312.53(c)(4), or (ii) after the publication of the multi-center Study data, if the Study is a multi-center Study or Sponsor confirms in writing there will be no multi-center publication.|t
17161091|NCT03621592|t||||
17161092|NCT02382380|t||||
17161093|NCT01149083|f||LTE60||t
17161094|NCT04153864|t||||
17161095|NCT00569127|f||LTE60||t
17161096|NCT06442800|t||||
17137605|NCT00645567|t||||
17137606|NCT04664855|f||||f
17137607|NCT02219087|t||||
17161097|NCT04279522|f||OTHER|PI shall have the right to publish the results and information about the results. PI agree to submit any proposed publication to Sponsor for review and approval at least 60 days prior to submitting to a publisher. Sponsor shall respond in writing within 45 days of its receipt and have the right to require PI to (a) remove Confidential Information; (b) delay the proposed Publication for an additional ninety (90) days to enable Sponsor to seek patent application or other proprietary protection.|t
17161098|NCT00724945|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17161099|NCT04817410|f||||f
17161100|NCT01970371|f||OTHER|The Investigator may publish/present the study results provided all of the following: (i) the primary publication has been published; or, if no such publication has occurred, at least 18m have passed since the completion of the study; (ii) Achaogen is allowed at least 60d to review; (iii) confidential information is deleted as requested; (iv) comments and proposed revisions are considered; and (v) during the 60d review, if requested, the Investigator shall delay the publication or presentation.|t
17161101|NCT01348269|f||||f
17161102|NCT04727749|t||||
17161103|NCT01481779|f||GT60||t
17161104|NCT02378181|t||||f
17161105|NCT02145676|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17161106|NCT01088789|t||||
17161107|NCT03517137|f||||f
17161108|NCT01866592|t||||
17161109|NCT02313155|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161110|NCT00689936|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days; Investigator must delete confidential information before submission or defer publication to permit patent applications|t
17161111|NCT01532089|f||||t
17168268|NCT00664326|f||OTHER|"The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~No publication of single center data should be done prior of publication if multi-center data."|t
17168269|NCT00262847|f||LTE60||t
17168270|NCT03966885|t||||f
17168271|NCT03880838|t||||
17168272|NCT03899064|t||||
17168273|NCT00607113|t||||f
17168274|NCT00031460|f||||f
17137608|NCT01632735|f||||f
17137609|NCT01912716|f||||f
17137610|NCT00601796|t||||f
17137611|NCT03730194|f||||f
17161112|NCT01303419|f||||f
17161113|NCT01995201|f||GT60||t
17161114|NCT00622518|f||||f
17168275|NCT02210832|f||||f
17168276|NCT01401699|f||||f
17161115|NCT02013414|t||||
17161116|NCT05376358|t||||f
17161117|NCT02452190|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17161118|NCT00743093|t||||f
17161119|NCT00820534|f||||f
17161120|NCT02327078|f||OTHER|Clinical Study Agreement|t
17161121|NCT05513950|f||OTHER|Results of this study may be published or presented at scientific meetings. If a publication is presented by the Investigator, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor to Chiesi before submission.|t
17161122|NCT05142774|f||||t
17161123|NCT03112603|f||OTHER|Clinical Study Agreement|t
17161124|NCT04225039|t||||
17161125|NCT02320175|t||||
17161126|NCT02242630|t||||
17161127|NCT05984030|t||||f
17161128|NCT02225587|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17161129|NCT03116230|t||||f
17161130|NCT01933932|f||||f
17161131|NCT04896385|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161132|NCT05258721|f||||f
17161133|NCT04512924|t||||
17161134|NCT01931098|f||||f
17161135|NCT03073759|f||||f
17161136|NCT01564407|f||||f
17161137|NCT03126110|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161138|NCT04235374|f||||f
17161139|NCT02572167|f||||t
17161140|NCT05495997|t||||
17161141|NCT00005047|f||||f
17161142|NCT00088153|f||||f
17161143|NCT00208975|t||||
17161144|NCT00976027|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17161145|NCT00261040|f||||f
17161146|NCT04612400|t||||
17161147|NCT04426656|t||||
17161148|NCT01771107|f||LTE60||t
17161149|NCT00619528|f||||f
17161150|NCT02296125|f||OTHER||t
17161151|NCT00157755|f||LTE60||t
17161152|NCT02141555|t||||
17161153|NCT03314935|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161154|NCT00168298|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17161155|NCT05807477|f||||f
17161156|NCT04967222|t||||
17161157|NCT03785366|f||||f
17161158|NCT03093844|t||||
17161159|NCT05219552|t||||
17161160|NCT03916926|f||||f
17161161|NCT03330197|f||||t
17161162|NCT04537299|t||||
17161163|NCT03806296|t||||f
17161164|NCT00876343|f||||f
17161165|NCT00230737|f||||f
17161166|NCT00848185|f||||f
17137612|NCT04427917|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|
17161167|NCT01925794|f||LTE60||t
17161168|NCT00790036|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161169|NCT04357795|f||||f
17161170|NCT05248386|f||OTHER|The results (or parts thereof) of this trial may be published as a publication (e.g., journal publication) or at a congress (e.g., as a poster or presentation). The sponsor reserves the right to review any proposed full publication, poster, or presentation of the results of this trial by the coordinating investigator before they are submitted for publication or public disclosure.|t
17182205|NCT02586493|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182206|NCT01117727|f||||f
17182207|NCT02711800|t||||
17182208|NCT01869192|t||||
17137613|NCT00870818|f||||t
17161171|NCT01139879|f||||f
17161172|NCT02864992|f||||t
17161173|NCT01295944|f||||f
17161174|NCT05168800|f||||f
17161175|NCT03240874|t||||f
17161176|NCT05252702|f||||f
17161177|NCT04958707|f||||f
17161178|NCT03834688|f||||f
17168277|NCT02968381|f||||f
17168278|NCT01722292|f||GT60||t
17168279|NCT02080260|t||||
17168280|NCT00471887|f||||f
17168281|NCT03602885|f||||f
17168282|NCT00098722|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168283|NCT02351349|f||||f
17168284|NCT00440310|f||GT60||t
17168285|NCT01987219|t||||
17168286|NCT01610596|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17168287|NCT01519674|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17137614|NCT00178464|f||||f
17161179|NCT05457855|f||OTHER||t
17161180|NCT02629159|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161181|NCT04383223|t||||
17161182|NCT03036254|f||OTHER|There is an agreement between the sponsor (or its agent) and any non-employee PI(s) that restricts the PI's rights to discuss or publish trial results after the Primary Completion Date.|t
17161183|NCT03331341|t||||
17161184|NCT00278408|f||OTHER|Regarding publications the PIs and the sponsor will be in understanding between considering the publication arrangement of the trial protocol. This only serves the optimization of the research activity and the security of the results for the community.|t
17161185|NCT03033355|t||||f
17161186|NCT02783274|f||GT60||t
17161187|NCT03954535|t||||f
17161188|NCT00373672|t||||
17161189|NCT04717557|t||||
17161190|NCT04871074|t||||
17161191|NCT06011798|f||||t
17168288|NCT00799591|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168289|NCT02317809|f||||f
17168290|NCT04424225|f||||f
17168291|NCT03106415|t||||
17161192|NCT00098475|f||LTE60||t
17161193|NCT02213003|t||||
17161194|NCT05352399|t||||
17161195|NCT05484778|t||||
17161196|NCT01802281|f||||f
17161197|NCT02685735|f||||f
17161198|NCT05965427|f||GT60||t
17161199|NCT02101788|f||LTE60||t
17161200|NCT01470170|f||||f
17161201|NCT00927472|f||||f
17168292|NCT00293709|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168293|NCT02785458|f||||f
17168294|NCT01804582|f||||f
17168295|NCT00520013|t||||f
17168296|NCT02677844|f||GT60||t
17137615|NCT04900038|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17137616|NCT02227108|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17161202|NCT04556097|t||||
17161203|NCT04812015|f||||f
17161204|NCT02516241|f||||t
17161205|NCT03370276|f||OTHER|The rights to publish the results of the study are vested in Moffitt. Subsite is free to publish any academic article, presentation or abstracts of the study results (including supporting data) twelve months after the conclusion or termination of the study provided that any such manuscript is first submitted to Moffitt sixty days prior to the proposed publication date.|t
17161206|NCT04057365|t||||
17161207|NCT03976375|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17161208|NCT04635423|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17182209|NCT00423891|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182210|NCT00414661|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182211|NCT00357370|f||||f
17182212|NCT02108821|t||||
17182213|NCT00937547|f||||f
17182214|NCT02963493|f||||f
17182215|NCT00404352|f||OTHER|Sponsor has the right to publish any results communication in connection with the study. The PI shall submit any communications including study results to the sponsor for review 30 working days prior to communication submission. The sponsor can request the PI to modify or delete any sponsor's proprietary information. If the PI refuses the modification, the submission shall be postponed for 60 days from PI refusal, to provide the sponsor the opportunity to file a patent or seek legal remedies.|t
17182216|NCT03663283|t||||
17182217|NCT02346136|f||||f
17182218|NCT01052545|t||||
17137617|NCT02486952|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137618|NCT01928485|t||||
17137619|NCT04111107|t||||
17137620|NCT03011450|f||||t
17137621|NCT03814590|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17137622|NCT01568424|f||OTHER||t
17161209|NCT03228537|f||LTE60||t
17161210|NCT00385840|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161211|NCT01017250|f||||f
17161212|NCT00832975|f||||f
17161213|NCT02112916|f||LTE60||t
17137623|NCT01825655|t||||
17137624|NCT00567541|f||LTE60||t
17161214|NCT05032196|f||||t
17182219|NCT00582933|t||||
17182220|NCT04120610|f||||f
17182221|NCT03837899|f||OTHER||t
17182222|NCT01465464|f||OTHER||t
17182223|NCT00785486|f||GT60||t
17182224|NCT00544076|t||||
17137625|NCT03519516|f||OTHER|only the sponsor has the decision to disseminate or publish the information obtained from the investigation and the PIs involved must submit a formal request to the sponsor if they are willing to disseminate or publish such information, they may only publish them if they have the written authorization of the sponsor (Laboratoios Sophia S.A. de C.V.).|t
17137626|NCT01890512|f||||f
17137627|NCT01935336|t||||
17182225|NCT01554618|f||||t
17137628|NCT01529385|f||||f
17137629|NCT00321269|f||||f
17137630|NCT00964158|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161215|NCT05260008|f||OTHER|Material for public dissemination will be submitted to the Sponsor for review at least sixty (60) days (or the time specified in the Protocol if longer) prior to submission for publication, public dissemination, or review by a publication committee. Principal Investigator agrees that all reasonable comments made by the Sponsor in relation to a proposed publication by the Trial Site, any Other Trial Site, and/or the Principal Investigator will be incorporated into the publication.|t
17161216|NCT04070703|f||||f
17161217|NCT05977868|t||||f
17161218|NCT04385888|f||||f
17161219|NCT03841513|f||||f
17161220|NCT03575364|f||||f
17161221|NCT06540170|f||||f
17161222|NCT04803279|f||||f
17137631|NCT00413335|t||||
17161223|NCT05696847|f||GT60||t
17161224|NCT03323502|f||||f
17161225|NCT04092777|f||||f
17161226|NCT02306161|f||LTE60||t
17161227|NCT01081951|f||LTE60||t
17161228|NCT04443452|t||||
17161229|NCT04291131|t||||
17161230|NCT01963234|t||||
17161231|NCT00975923|t||||f
17161232|NCT04613453|t||||
17182226|NCT01566448|t||||
17182227|NCT01116232|t||||f
17161233|NCT05291689|f||OTHER|"Per the study protocol: The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission."|t
17161234|NCT02278354|f||LTE60||t
17161235|NCT00562328|t||||
17161236|NCT01901562|t||||
17161237|NCT02612155|f||||f
17182228|NCT02357940|f||OTHER|Principal investigators agreed not to publish the study results without prior sponsor approval.|t
17137632|NCT04009213|f||||f
17137633|NCT03450915|f||||f
17137634|NCT01709981|t||||
17137635|NCT01763866|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161238|NCT01601977|t||||
17161239|NCT05007925|f||GT60||t
17161240|NCT04435626|f||GT60||t
17161241|NCT03837704|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17161242|NCT02595892|f||LTE60||t
17161243|NCT06354257|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17161244|NCT00433537|f||LTE60||t
17161245|NCT01757847|f||||f
17161246|NCT02512419|f||||f
17161247|NCT00831844|f||LTE60||t
17161248|NCT03771716|f||||f
17161249|NCT03133156|f||||f
17161250|NCT05748626|t||||f
17161251|NCT04046471|f||||f
17161252|NCT04336943|t||||
17161253|NCT05119569|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161254|NCT03683030|f||OTHER|All information concerning the study, investigational medical device, sponsor operations, patent application, manufacturing processes, and basic scientific data supplied by the sponsor to the investigator and not previously published, are considered confidential and remain the sole property of the sponsor.|t
17161255|NCT03980223|f||||f
17161256|NCT06239610|f||||f
17137636|NCT05055570|t||||
17137637|NCT01559064|f||||f
17161257|NCT00434434|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161258|NCT01922934|f||LTE60||t
17161259|NCT02290184|f||||f
17161260|NCT02354118|t||||
17161261|NCT01069939|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17161262|NCT05166876|f||||f
17161263|NCT00658528|f||||f
17161264|NCT02402062|f||OTHER|The sponsor commits to the timely dissemination of the results through scientific conferences and publications which will be responsible for the scientific coordinator and the translational study coordinator. The study coordinator reserves the option to choose your position in the different publications and reports that could be carried out of the study. The coordinator of the study will have a secure position within the authors. The rest of IPs will be assigned according to order of recruitment|t
17161265|NCT01937299|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161266|NCT04017962|t||||
17161267|NCT01260948|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17137638|NCT03245723|t||||
17137639|NCT03337139|f||||f
17137640|NCT02554253|t||||
17137641|NCT03288493|f||||f
17137642|NCT01998269|f||LTE60||t
17137643|NCT01736254|f||GT60||t
17137644|NCT02559206|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17137645|NCT01561560|f||OTHER|Study data should not be disclosed to any third party for a period of three years after the termination of the study without prior written consent.|t
17137646|NCT01064076|f||||f
17137647|NCT05294341|t||||
17137648|NCT02267278|t||||
17161268|NCT01163617|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137649|NCT00650091|f||||f
17161269|NCT02394756|f||GT60||t
17161270|NCT02335944|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17161271|NCT01706328|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161272|NCT01525589|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review|t
17161273|NCT03424148|f||||f
17161274|NCT01235377|t||||
17161275|NCT02101853|f||LTE60||t
17161276|NCT04409002|t||||
17161277|NCT04835441|f||||t
17161278|NCT04132050|f||||f
17161279|NCT03168672|f||LTE60||t
17161280|NCT03506477|f||||f
17161281|NCT05436613|t||||
17161282|NCT00843882|f||LTE60||t
17161283|NCT05317546|f||||f
17161284|NCT03331250|t||||
17161285|NCT04590963|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17161286|NCT04738487|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17161287|NCT05350202|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17161288|NCT01063114|t||||f
17161289|NCT04115098|t||||
17161290|NCT02717611|f||LTE60||t
17161291|NCT05556057|t||||
17161292|NCT04431960|f||||f
17161293|NCT02466971|f||LTE60||t
17161294|NCT03409367|t||||f
17168297|NCT01697462|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168298|NCT03630302|f||||f
17168299|NCT01135914|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e. data from all sites) in the clinical trial or dislcosure of trial results in their entirety.|t
17168300|NCT01053013|f||OTHER|Sponsor retains the first right for scientific disclosure of study results. PI may draft a study results disclosure for scientific publication following the earlier of sponsor's disclosure or 12 months after study completion at all sites. Sponsor has 60 days to review PI's draft for patentable subject matter or confidential information. PI will delete any confidential information and delay any disclosure for another 60 days for sponsor to secure proprietary protection.|t
17168301|NCT03532932|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17168302|NCT02699450|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168303|NCT01344629|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17168304|NCT00837824|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17161295|NCT04164979|t||||
17161296|NCT06480032|t||||
17161297|NCT04818112|t||||
17161298|NCT03824158|f||||f
17161299|NCT05184842|t||||
17161300|NCT02390284|t||||
17161301|NCT01683526|t||||
17161302|NCT01034553|t||||
17161303|NCT01428245|t||||
17161304|NCT00462462|f||GT60||t
17161305|NCT04685811|t||||f
17161306|NCT01270659|t||||
17161307|NCT03160170|t||||
17161308|NCT03018938|f||GT60||t
17161309|NCT01769586|t||||
17161310|NCT00191100|f||GT60||t
17161311|NCT02811159|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17161312|NCT02406612|f||||f
17161313|NCT01744821|f||||f
17161314|NCT02916771|f||||f
17161315|NCT02924376|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161316|NCT01471639|f||||f
17161317|NCT04253626|t||||
17161318|NCT06904404|f||||f
17161319|NCT05763875|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17161320|NCT00217737|f||LTE60||t
17161321|NCT04589650|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17161322|NCT03290768|t||||
17161323|NCT04937387|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17161324|NCT04134845|f||||f
17161325|NCT01371981|f||LTE60||t
17161326|NCT05759338|f||||f
17161327|NCT03244189|t||||
17161328|NCT06481579|f||||t
17137650|NCT01784588|f||OTHER|Before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Boston Scientific Corporation (BSC) for review at least 60 days in advance of submission for publication or presentation to a publisher or other third party. BSC reserves the right to delete any Confidential Information or other proprietary information of BSC (including trade secrets but not including Results) from the proposed publication or presentation.|t
17137651|NCT02307838|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137652|NCT01413542|f||||f
17137653|NCT02505542|f||GT60||t
17137654|NCT03372603|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137655|NCT02806947|f||||f
17137656|NCT00289744|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137657|NCT01978509|t||||
17137658|NCT00664209|f||||f
17137659|NCT00082329|t||||f
17137660|NCT00065442|f||OTHER|A provision provides for sponsor review up to 45 days with the right to request modification based on disclosure of confidential information; extendable by 60 days to file a patent application.|t
17137661|NCT01594333|t||||
17137662|NCT01764256|f||||f
17137663|NCT02029638|f||||f
17137664|NCT01153841|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137665|NCT02666508|f||||f
17137666|NCT02792049|f||||f
17137667|NCT00779311|f||OTHER|Prior to publication or presentation of Sponsored Research results, Researcher agrees to provide Bayer with such presentation, abstract, or manuscript at least 30 days prior to its presentation or submission for the sole purpose of allowing Bayer to redact Confidential Information and protect any existing or future patents.|t
17137668|NCT03428997|f||OTHER|The Principal Investigator (PI) will provide Sponsor with at least sixty (60) days to review any Publication. No Publication that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, the PI withholds such Publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17137669|NCT05506969|f||||f
17137670|NCT02563925|t||||
17137671|NCT00400712|f||||f
17137672|NCT02466412|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17137673|NCT00425477|t||||
17137674|NCT02553317|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.|t
17137675|NCT03176277|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation.|t
17161329|NCT06170827|f||||t
17161330|NCT05253807|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161331|NCT04611126|t||||
17161332|NCT03884374|f||||f
17161333|NCT03459846|f||||f
17161334|NCT05423756|f||||f
17168305|NCT02227836|t||||
17168306|NCT02312765|f||||f
17137676|NCT00634114|f||OTHER|All PIs were prohibited to disclose all information related to this study withiout AZ approval before this study was completed.|t
17161335|NCT03579771|f||||f
17161336|NCT05708924|t||||
17137677|NCT03691610|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17137678|NCT03699631|t||||
17137679|NCT02940626|f||||f
17137680|NCT01996904|t||||f
17137681|NCT00756496|f||||f
17137682|NCT00585923|f||||f
17137683|NCT00622869|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137684|NCT01324622|f||LTE60||t
17137685|NCT00138424|f||LTE60||t
17137686|NCT01802554|f||||f
17137687|NCT02176291|f||||f
17161337|NCT06455111|t||||
17161338|NCT02141113|f||||f
17161339|NCT00357565|t||||
17161340|NCT02266576|f||OTHER|Upon approval of community advisory board.|t
17161341|NCT05578872|f||OTHER|PI must obtain Sponsor's written approval before any disclosure. Sponsor may delete confidential info, require edits, and delay release: 60-day review plus one-time patent embargo ≤ 90 additional days (total ≤ 150). Publication otherwise allowed after multicenter paper or 12 months post-study.|t
17137688|NCT03454412|t||||
17137689|NCT01167582|t||||
17137690|NCT00115765|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17137691|NCT01518244|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17137692|NCT03543358|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17137693|NCT02902913|f||||f
17137694|NCT03956225|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17137695|NCT02260648|f||GT60||t
17137696|NCT04093258|f||GT60||t
17161342|NCT03421561|f||OTHER|Research Institution and PI shall have the right to publish, present or otherwise publicly disclose the results to their own activity conducted in the trial. Proposals must be submitted to the sponsor for review 30 days prior to publishing submission. Sponsor has the right to require confidentially sensitive information be removed (not including results) and/or delay publication for an additional 60 days.|t
17161343|NCT00884065|f||||f
17161344|NCT01732783|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161345|NCT04615507|f||GT60||t
17168307|NCT00693472|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the Sponsor. The investigator further agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17168308|NCT01556061|f||||f
17161346|NCT04598828|t||||
17168309|NCT04063787|f||||f
17168310|NCT04375397|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168311|NCT02568449|f||||f
17168312|NCT05545644|t||||
17168313|NCT01797380|t||||f
17168314|NCT01873729|f||||f
17168315|NCT02463032|f||||f
17168316|NCT02945553|f||||f
17168317|NCT00624416|t||||
17168318|NCT03343080|t||||
17168319|NCT01565564|f||||f
17161347|NCT06187909|t||||
17161348|NCT02676973|f||||f
17161349|NCT02580604|t||||
17161350|NCT05020743|f||||f
17161351|NCT03488524|f||||f
17161352|NCT01078662|f||LTE60||t
17161353|NCT00325416|t||||
17161354|NCT02324153|f||||f
17168320|NCT02138240|t||||f
17168321|NCT01591863|f||OTHER|Publication or other public presentation of results from this study requires prior review and written approval of the Sponsor. Draft abstracts, manuscripts, and materials for presentation at scientific meetings should be provided to the Sponsor at least 30 working days prior to submission deadlines. Authorship of publications resulting from this study will be based on generally accepted criteria for major medical journals.|t
17168322|NCT00969436|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161355|NCT01563081|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161356|NCT03122106|t||||
17161357|NCT03279458|t||||f
17161358|NCT01913353|f||||t
17161359|NCT01147458|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161360|NCT03550209|t||||
17161361|NCT02555878|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17161362|NCT00765076|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161363|NCT02875080|f||||f
17161364|NCT00768053|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161365|NCT01164475|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17161366|NCT01859091|f||||f
17161367|NCT04603066|f||||f
17161368|NCT07021443|t||||
17161369|NCT05666245|t||||
17161370|NCT00632359|t||||
17161371|NCT02872714|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161372|NCT02145390|t||||
17161373|NCT02880176|f||||f
17161374|NCT00000142|f||LTE60||t
17161375|NCT01858948|f||||f
17161376|NCT02737618|f||OTHER|Confidentiality agreement in place with PI|t
17161377|NCT03014362|f||||f
17161378|NCT00817063|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161379|NCT00584285|f||||f
17161380|NCT02362451|f||||f
17168323|NCT00167661|t||||
17161381|NCT00700635|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17137697|NCT00594204|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137698|NCT00986427|t||||f
17161382|NCT05172570|t||||
17161383|NCT00942851|t||||
17161384|NCT04950686|t||||
17161385|NCT03421808|f||||f
17137699|NCT01401465|f||OTHER||t
17161386|NCT06717399|t||||
17161387|NCT05061888|t||||f
17161388|NCT02180867|f||LTE60||t
17161389|NCT02337686|t||||
17161390|NCT02259621|f||||f
17161391|NCT00639093|t||||
17168324|NCT03306641|f||||f
17168325|NCT02789410|t||||
17168326|NCT01605942|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17168327|NCT00737594|f||||f
17168328|NCT00459537|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168329|NCT03159104|f||OTHER||t
17168330|NCT00456599|t||||f
17168331|NCT01999218|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17168332|NCT00387647|t||||
17168333|NCT02032407|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17168334|NCT02191605|f||||f
17168335|NCT03809910|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161392|NCT01089595|t||||f
17161393|NCT01692015|t||||
17161394|NCT01680172|t||||
17161395|NCT00177671|f||||f
17161396|NCT02293499|t||||
17161397|NCT00690898|f||||f
17161398|NCT05370326|t||||
17161399|NCT01847209|f||||f
17161400|NCT02606305|f||||t
17161401|NCT02008370|t||||
17161402|NCT00601627|f||LTE60||t
17161403|NCT03317496|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161404|NCT01879852|f||||f
17161405|NCT02111980|f||||f
17161406|NCT02696616|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17161407|NCT01500083|f||OTHER|The results of this study will be published. Authors of the primary publication based on this study must fulfil the criteria defined by the International Committee of Medical Journal Editors (ICMJE). The primary publication must be published before any secondary publications are submitted for publication.|t
17161408|NCT01555931|f||||f
17161409|NCT01922011|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. The Sponsor will make all reasonable efforts to publish the results of the study in an appropriate peer-reviewed journal. Authorship on the primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results.|t
17161410|NCT01063907|f||LTE60||t
17161411|NCT02299167|t||||
17161412|NCT01695746|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161413|NCT02239289|f||||f
17161414|NCT03010501|f||||f
17161415|NCT00640289|f||||f
17161416|NCT01202591|f||LTE60||t
17161417|NCT04882709|t||||
17161418|NCT05635370|f||OTHER||t
17161419|NCT03496129|f||||f
17161420|NCT02207608|f||||f
17161421|NCT00980460|f||LTE60||t
17161422|NCT03580928|f||||f
17161423|NCT01035788|t||||
17161424|NCT00704353|f||LTE60||t
17161425|NCT01001104|f||GT60||t
17161426|NCT03235414|t||||
17161427|NCT02397837|t||||
17161428|NCT00599313|f||||f
17161429|NCT02536794|t||||
17161430|NCT00458835|f||||f
17161431|NCT01201863|t||||f
17161432|NCT00448357|t||||
17161433|NCT01496456|t||||
17161434|NCT04919161|t||||
17161435|NCT00712920|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.|t
17161436|NCT02199496|t||||f
17161437|NCT02887586|f||||f
17161438|NCT03086343|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161439|NCT00306488|t||||f
17161440|NCT04298853|t||||
17161441|NCT04050605|f||||f
17161442|NCT02830087|t||||f
17161443|NCT02583269|t||||
17161444|NCT03611946|f||||f
17161445|NCT03043573|t||||f
17161446|NCT05291975|f||||f
17161447|NCT01251861|f||LTE60||t
17161448|NCT06231511|f||||f
17161449|NCT06937346|t||||
17161450|NCT05800145|f||||f
17161451|NCT02850406|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161452|NCT04167670|f||OTHER||t
17161453|NCT00962598|t||||
17161454|NCT01092923|t||||
17137700|NCT01115738|f||GT60||t
17161455|NCT00587457|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17161456|NCT00876395|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17161457|NCT03807843|f||OTHER|After completion of the study, the Investigator may prepare a joint publication with the Sponsor and Project Oversight Agency. The Investigator must not submit any part of the data from this protocol for publication without the prior consent of the Sponsor and Project Oversight Agency.|t
17161458|NCT01312129|f||||f
17161459|NCT00104234|f||OTHER|The first publication of the results shall be made by Sponsor in a joint publication. If such a multicenter publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from their site individually, subject however to comply with the other terms of the agreement.|t
17161460|NCT00924651|f||||f
17161461|NCT00729586|f||LTE60||t
17161462|NCT00879359|f||||f
17161463|NCT00970944|f||LTE60||t
17161464|NCT00662259|t||||
17161465|NCT00972738|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161466|NCT03915067|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161467|NCT02693418|f||LTE60||t
17161468|NCT01750346|t||||
17161469|NCT01143792|f||||f
17161470|NCT02260986|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17161471|NCT04764604|t||||
17161472|NCT02034591|f||LTE60||t
17161473|NCT00597675|t||||f
17161474|NCT04772547|f||||f
17161475|NCT01771913|f||||f
17161476|NCT04307394|f||||f
17161477|NCT01121926|f||OTHER|If a publication based on the results of this study is envisaged, approval from the Sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment. The choice of scientific journal will be mutually agreed on by the principal investigator and the sponsor.|t
17161478|NCT01111370|f||OTHER||t
17161479|NCT00416949|f||||f
17161480|NCT02782468|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161481|NCT00313170|f||LTE60||t
17137701|NCT01606735|f||OTHER|All information related to this study is considered confidential information belonging to Icon Bioscience, Inc. Data on the use of the study drug and results of all clinical and laboratory studies are considered private and confidential. None of the details, results, or other information for this study shall be published or made known to a third party without written consent from Icon Bioscience, Inc., except for disclosure to regulatory agencies if required by law.|t
17161482|NCT00607594|f||LTE60||t
17161483|NCT01410604|t||||
17161484|NCT00356590|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161485|NCT01149785|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161486|NCT02199574|f||||f
17161487|NCT00898807|f||||f
17161488|NCT02489773|f||OTHER|After (a) the date multicenter publication is made, (b) Sponsor notifies Institution that there will be no multicenter publication, or (c) 12 months after the date the Study has been closed at all participating sites, whichever date comes first, Institution may itself publish the results of its data from the Study.|t
17161489|NCT02115386|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17161490|NCT02493855|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161491|NCT02453048|f||OTHER|Publications will be co-authored by the PI and the Sponsor (Inserm).|t
17161492|NCT01482221|f||LTE60||t
17161493|NCT01047501|f||OTHER|PIs are restricted in sharing data until an abstract presentation or publication of the manuscript.|t
17161494|NCT00741611|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release at least 60 days prior to publication and that the multi-center results should be published prior to any individual site results unless the multi-center results are not published 2 years after the trial is complete. The only embargo that the sponsor can impose is on the release of confidential information.|t
17161495|NCT00731198|f||||f
17161496|NCT04757584|t||||
17161497|NCT00429299|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182229|NCT02275481|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming with twenty-four (24) months following completion of the study at all sites, institution and investigator shall be free to publish.|t
17137702|NCT01669811|f||OTHER|All PIs were prohibited to disclose all information related to this study withiout AZ approval before this study was completed.|t
17137703|NCT03558191|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17161498|NCT01510756|t||||
17161499|NCT04871113|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17161500|NCT00315822|t||||
17182230|NCT01495585|t||||
17182231|NCT00704028|f||LTE60||t
17161501|NCT01257542|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161502|NCT01566162|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17161503|NCT03562507|t||||
17161504|NCT02132468|f||GT60||t
17161505|NCT00693303|t||||f
17161506|NCT03600428|f||GT60||t
17161507|NCT04398134|f||OTHER|Assembly Biosciences agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Assembly Biosciences supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161508|NCT03802110|f||LTE60||t
17161509|NCT00153920|t||||f
17161510|NCT00063622|f||||f
17161511|NCT04502524|f||||f
17161512|NCT01666652|f||||f
17161513|NCT01018979|f||OTHER|PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.|t
17161514|NCT03301714|f||||f
17161515|NCT02317549|f||||t
17161516|NCT04055519|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161517|NCT01403584|f||||f
17161518|NCT02635035|t||||
17161519|NCT04913636|f||OTHER|PI should disclose plans to sponsor prior to public release.|t
17161520|NCT02013427|f||||f
17161521|NCT00544882|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17161522|NCT01127061|f||||f
17161523|NCT00003456|f||||f
17161524|NCT00479232|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17161525|NCT01373229|t||||
17161526|NCT02787291|f||LTE60||t
17161527|NCT00143507|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publication and/or communication related to the study results and can require changes. In case of a patent application, the sponsor can delay its authorization for publication or communication of the study results until the date of international registration of the patent.|t
17161528|NCT01991314|t||||
17161529|NCT01033942|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17161530|NCT03071744|f||||f
17161531|NCT01199614|t||||
17161532|NCT01793935|t||||
17161533|NCT04900272|t||||
17161534|NCT01716195|t||||
17161535|NCT05059080|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161536|NCT05607043|t||||
17161537|NCT00478036|f||||f
17161538|NCT00800540|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161539|NCT01385644|t||||
17161540|NCT02447029|f||||f
17161541|NCT00549328|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161542|NCT00770484|f||||f
17161543|NCT02162433|f||||f
17161544|NCT03097315|f||OTHER|The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17161545|NCT01946802|t||||
17161546|NCT04327271|f||||f
17161547|NCT03637374|t||||
17161548|NCT03759184|f||||f
17161549|NCT01479530|f||OTHER|"The results of this study will be published. Authors of the primary publication based on this study must fulfil the criteria defined by the International Committee of Medical Journal Editors (ICMJE).~The primary publication must be published before any secondary publications are submitted for publication."|t
17161550|NCT00303628|f||LTE60||t
17161551|NCT00376506|t||||
17161552|NCT03780387|t||||
17161553|NCT00776997|f||LTE60||t
17161554|NCT02948400|f||||f
17161555|NCT02403271|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination"|t
17182232|NCT01251588|f||GT60||t
17182233|NCT03350503|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17182234|NCT04492891|t||||
17182235|NCT00344773|f||LTE60||t
17161556|NCT03487445|f||||t
17161557|NCT00221104|f||||f
17161558|NCT02989389|f||GT60||t
17161559|NCT00374868|f||GT60||t
17161560|NCT04470427|f||||t
17161561|NCT01179516|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17161562|NCT03349515|f||||f
17161563|NCT03412890|f||LTE60||t
17161564|NCT02315625|f||||f
17168336|NCT01309269|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168337|NCT04787055|t||||
17168338|NCT04129411|t||||
17168339|NCT03647267|f||||f
17168340|NCT01350115|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17168341|NCT05079477|t||||
17168342|NCT04948307|f||||f
17168343|NCT05013424|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168344|NCT00240110|f||||f
17168345|NCT04872998|f||||f
17168346|NCT04638127|f||||f
17168347|NCT02654236|f||||f
17168348|NCT03204890|t||||
17168349|NCT01549873|t||||
17168350|NCT03769311|t||||
17161565|NCT00021255|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17161566|NCT01163656|t||||f
17161567|NCT02337946|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17161568|NCT00728923|f||||f
17161569|NCT05324371|f||||f
17161570|NCT03599713|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17161571|NCT01440920|f||||f
17161572|NCT04827446|t||||
17161573|NCT02955394|t||||
17161574|NCT05399771|f||||f
17168351|NCT01596335|f||OTHER||t
17168352|NCT03627065|f||OTHER|Clinical Study Agreement|t
17168353|NCT01838785|f||||f
17168354|NCT04524455|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168355|NCT02262078|t||||
17168356|NCT00996801|f||LTE60||t
17168357|NCT01688739|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161575|NCT02906618|f||GT60||t
17161576|NCT00484159|f||||f
17161577|NCT03234881|t||||
17161578|NCT03720847|t||||
17161579|NCT01239680|t||||f
17182236|NCT02766244|f||||f
17182237|NCT02141074|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17182238|NCT05965349|t||||
17161580|NCT03033901|f||||f
17161581|NCT03096353|t||||
17161582|NCT02734667|f||||f
17161583|NCT01870596|f||LTE60||t
17161584|NCT05177094|f||GT60||t
17161585|NCT00410488|t||||
17161586|NCT02513199|t||||
17161587|NCT01115231|t||||
17182239|NCT06023394|t||||
17137704|NCT00800865|f||OTHER|This is an exploratory study to develop data for possible future studies. It is not intended to be published, unless important new information or data concerning the safety of a marketed product is obtained. The Sponsor must have the opportunity to review all abstracts, manuscripts, or presentations 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. Sponsor review can be expedited.|t
17137705|NCT05691829|t||||
17161588|NCT01988415|f||OTHER|The sponsor shall have the first right of publication of study data for the first 12 months. The institution or principal investigator may not disclose any of the Sponsor's proprietary information.|t
17161589|NCT00580398|f||||f
17161590|NCT04119336|t||||
17161591|NCT01733888|f||||f
17137706|NCT04095442|f||||f
17137707|NCT02762799|f||||f
17137708|NCT00453180|f||||f
17137709|NCT03722472|f||||f
17137710|NCT00547898|f||||t
17137711|NCT01002742|f||||f
17137712|NCT00369746|t||||
17137713|NCT03947255|f||||t
17137714|NCT02862548|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17137715|NCT00880763|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17137716|NCT00949910|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137717|NCT03097614|f||OTHER|All data generated in this study is the property of Allergan. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Allergan|t
17137718|NCT02670928|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137719|NCT05158179|t||||
17137720|NCT01804257|f||||f
17161592|NCT03928327|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17161593|NCT00407511|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161594|NCT00529035|t||||
17182240|NCT04036500|f||||f
17182241|NCT02283788|f||OTHER||t
17182242|NCT02565381|t||||
17161595|NCT03439514|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161596|NCT01521364|t||||f
17161597|NCT02175758|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17161598|NCT02636283|f||||f
17161599|NCT02409901|t||||
17161600|NCT03927157|f||||t
17161601|NCT00726557|f||OTHER|Trial results belong to the Sponsor only, all investigators are not allowed to publish trial results without permission of the Sponsor.|t
17137721|NCT00609804|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17137722|NCT04807101|t||||
17161602|NCT01239745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161603|NCT00081458|f||LTE60||t
17161604|NCT02541903|t||||
17161605|NCT03384966|f||||t
17161606|NCT02202616|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161607|NCT01334515|f||OTHER|Must obtain prior Sponsor approval.|t
17161608|NCT00363168|f||||f
17161609|NCT01365611|f||||f
17161610|NCT02836769|t||||
17161611|NCT01119222|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161612|NCT00585650|f||||f
17182243|NCT03369717|t||||
17182244|NCT01696435|f||||f
17182245|NCT02554656|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161613|NCT01197898|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17161614|NCT03144635|f||||f
17161615|NCT04285411|f||LTE60||t
17161616|NCT01786109|t||||f
17161617|NCT00781950|t||||
17161618|NCT02641834|f||||f
17161619|NCT02991521|f||||f
17161620|NCT02949934|f||||f
17161621|NCT01684592|t||||
17182246|NCT02400723|t||||
17137723|NCT02254551|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17137724|NCT02215616|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17137725|NCT01598207|f||||f
17137726|NCT02325687|t||||
17137727|NCT01705964|f||||f
17161622|NCT00657605|t||||
17161623|NCT00118287|t||||
17161624|NCT00627978|f||||f
17161625|NCT03442569|t||||
17161626|NCT01590875|f||||f
17161627|NCT01214720|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161628|NCT02347787|f||||f
17161629|NCT01565551|t||||f
17161630|NCT00924482|f||||f
17161631|NCT00243061|f||LTE60||t
17161632|NCT00875667|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17161633|NCT00894647|f||||f
17161634|NCT00412451|f||LTE60||t
17161635|NCT04285684|t||||
17161636|NCT00195429|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17161637|NCT04795323|t||||
17161638|NCT01186406|t||||
17182247|NCT02674412|t||||f
17182248|NCT00749463|f||LTE60||t
17161639|NCT02691663|t||||
17161640|NCT03142750|f||||f
17161641|NCT04925934|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17182249|NCT03641378|f||||f
17182250|NCT01433107|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17182251|NCT03643562|f||||t
17182252|NCT01982253|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182253|NCT02809430|f||||f
17161642|NCT03158688|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161643|NCT00565864|f||||f
17161644|NCT04837521|f||||f
17161645|NCT05955378|f||||f
17161646|NCT01944774|f||OTHER|PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.|t
17161647|NCT03325439|f||GT60||t
17161648|NCT03188185|f||||t
17161649|NCT00634972|t||||
17161650|NCT02522845|t||||
17161651|NCT00774748|f||||f
17161652|NCT02503865|t||||
17161653|NCT00303953|f||LTE60||t
17161654|NCT00464464|t||||
17161655|NCT01132755|t||||
17161656|NCT02232698|f||GT60||t
17161657|NCT00387127|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161658|NCT02393755|t||||
17161659|NCT03491917|f||||f
17161660|NCT04069520|t||||
17161661|NCT01068912|f||GT60||t
17161662|NCT04822194|f||||f
17161663|NCT04057768|f||||f
17161664|NCT01947933|f||GT60||t
17161665|NCT00248547|f||||f
17161666|NCT00294398|t||||
17161667|NCT02965833|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17161668|NCT01769365|t||||
17161669|NCT03407482|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161670|NCT02943213|f||||f
17182254|NCT01364090|t||||f
17182255|NCT01886833|f||||f
17161671|NCT04507321|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161672|NCT01685437|f||OTHER||t
17161673|NCT01059851|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17161674|NCT03770455|t||||f
17161675|NCT01039675|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161676|NCT00153842|t||||
17161677|NCT06400914|f||||f
17161678|NCT03651609|t||||
17161679|NCT02626611|f||||f
17161680|NCT05643794|f||GT60||t
17161681|NCT02813447|t||||
17161682|NCT01192698|f||||f
17161683|NCT01363076|f||||f
17161684|NCT04706403|t||||f
17161685|NCT00182637|f||||f
17161686|NCT05463055|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release. Sponsor have the right to require Principal Investigator, as applicable, to remove specifically identified Confidential Information (other than Trial Data) and/or to delay the proposed publication, presentation or other public disclosure for an additional sixty (60) days to enable Sponsor to seek patent protection.|t
17161687|NCT04766333|t||||
17161688|NCT05124184|f||||f
17161689|NCT00639379|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17161690|NCT00723944|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17161691|NCT02400736|t||||
17161692|NCT03712852|f||||f
17161693|NCT02582632|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17161694|NCT03298061|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17137728|NCT02759562|f||OTHER|"* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17161695|NCT01956942|f||||t
17161696|NCT00138294|f||||f
17161697|NCT00992836|f||||f
17161698|NCT01724190|t||||
17168358|NCT02804750|f||OTHER|Corcept Therapeutics as the Sponsor, has a proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between multiple Investigators and sites and Corcept Therapeutics personnel. Authorship will be established before writing of the manuscript. Because this study involves multiple centers, no individual publications will be allowed before completion of the final report of the multicenter study except as agreed with Corcept Therapeutics.|t
17168359|NCT02559414|f||||f
17168360|NCT03369431|t||||
17168361|NCT01973608|f||||f
17168362|NCT00046930|f||||f
17137729|NCT00387348|t||||f
17137730|NCT00278863|f||||f
17137731|NCT00505752|f||OTHER||t
17161699|NCT01617967|f||LTE60||t
17161700|NCT04764539|t||||
17137732|NCT00232505|t||||
17161701|NCT03228914|t||||
17161702|NCT00977184|t||||
17161703|NCT01137812|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17161704|NCT00753142|f||||f
17161705|NCT02383173|t||||
17137733|NCT01925612|f||GT60||t
17137734|NCT01009918|f||||f
17137735|NCT01271413|t||||
17161706|NCT04621760|f||||f
17161707|NCT01297244|f||||f
17161708|NCT03677401|f||LTE60||t
17161709|NCT02421211|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17168363|NCT01113580|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168364|NCT01352637|f||||f
17182256|NCT01127503|f||||t
17161710|NCT01177410|f||OTHER|INVESTIGATOR shall not publish the results of the Study conducted at the INSTITUTION, unless they (i) obtain the prior written consent of SALIX for the publication; or (ii) withhold any publication for a period of two (2) years following the Completion of the Study by all participating institutions and investigators|t
17168365|NCT06504524|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168366|NCT04912895|t||||
17168367|NCT03458702|f||||f
17168368|NCT01390779|f||||f
17168369|NCT00545532|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168370|NCT01394614|f||||f
17168371|NCT01149486|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17168372|NCT01789138|t||||f
17168373|NCT00706329|t||||f
17168374|NCT00852527|t||||
17161711|NCT01846871|t||||
17161712|NCT00357162|f||LTE60||t
17161713|NCT02143778|t||||
17161714|NCT00875329|t||||
17168375|NCT00921310|t||||
17168376|NCT00931801|t||||
17168377|NCT01275092|f||GT60||t
17168378|NCT01635764|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168379|NCT03236168|t||||
17168380|NCT01174004|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17168381|NCT00933244|f||||f
17168382|NCT00539617|f||||f
17168383|NCT00610441|f||LTE60||t
17168384|NCT01173029|t||||f
17168385|NCT02469714|f||||f
17182257|NCT00254995|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17182258|NCT01489969|f||GT60||t
17161715|NCT00625378|f||OTHER|The PI will not present or publish data until the full multi-center Trial has been reported in full. If a publication is not published within 24 \[OR: 12-THIS IS MINIMUM\] months after completion of the Trial, the PI may present or publish data.|t
17161716|NCT03270241|f||||f
17161717|NCT02639559|t||||
17161718|NCT03880565|t||||
17161719|NCT01692756|f||||f
17161720|NCT02969018|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161721|NCT00367458|f||||f
17161722|NCT02556788|f||LTE60||t
17168386|NCT03002623|f||||f
17182259|NCT02223767|t||||
17182260|NCT02129075|f||LTE60||t
17137736|NCT04624672|f||||f
17161723|NCT04018001|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161724|NCT01017497|t||||
17161725|NCT05762679|t||||
17161726|NCT03670628|f||||f
17161727|NCT02942407|f||||f
17161728|NCT06069609|t||||f
17161729|NCT01716156|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17161730|NCT03925220|f||||f
17161731|NCT05221866|t||||f
17161732|NCT05561140|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161733|NCT06377488|f||||f
17161734|NCT00866320|t||||
17161735|NCT05073315|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17161736|NCT01529268|f||||f
17161737|NCT02691572|t||||
17161738|NCT00699751|f||OTHER|No PI may disclose or publish information from the trial before publication of the principal and first communication arising from the trial, unless 12 months has elapsed after completion of the trial. There is restriction on the PI that the sponsor can review results communication prior to public release and can embargo regarding trial results for a period that is less/or equal to 60 days from the time submitted to the sponsor for review. Sponsor cannot require changes or extend the embargo.|t
17137737|NCT03472040|f||||f
17137738|NCT02769832|t||||
17137739|NCT03064568|f||||f
17161739|NCT02475837|f||OTHER||t
17161740|NCT05089357|f||||t
17161741|NCT05537571|f||||f
17161742|NCT05494632|f||||f
17161743|NCT05752487|f||||t
17161744|NCT03091439|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.|t
17161745|NCT01860989|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161746|NCT00223821|t||||
17161747|NCT03128086|f||||f
17161748|NCT00134719|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161749|NCT03439839|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17137740|NCT00834886|t||||f
17137741|NCT03874351|f||||f
17137742|NCT00074802|f||||f
17137743|NCT03007719|t||||
17161750|NCT00990288|t||||
17161751|NCT04529980|t||||
17161752|NCT05276804|f||||f
17161753|NCT02827708|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17161754|NCT04602000|f||OTHER||t
17161755|NCT00471354|f||GT60||t
17161756|NCT01875237|t||||
17161757|NCT03050489|t||||
17161758|NCT01913470|t||||
17161759|NCT02573467|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161760|NCT00923702|f||||f
17161761|NCT02153827|f||||f
17161762|NCT00299221|f||||f
17161763|NCT00505362|f||||f
17161764|NCT01004393|f||||f
17161765|NCT02448043|t||||
17161766|NCT04790201|t||||f
17161767|NCT02320292|t||||
17161768|NCT01431846|f||||f
17161769|NCT04339972|f||||f
17161770|NCT02120079|f||||f
17161771|NCT03683901|f||||f
17161772|NCT03034928|t||||
17161773|NCT01188447|f||||f
17161774|NCT01835756|f||||f
17161775|NCT02112552|t||||f
17161776|NCT01131585|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161777|NCT00812097|f||OTHER|Investigator and his/her collaborators are free to publish the background, methods, and results of their own research without restraint. Prior review of any proposed manuscript or abstract will be provided to the sponsor to prevent premature disclosure of trade secrets or proprietary information. The review will occur 30 days prior to submission of manuscript or abstract for consideration of publication or to a conference. Sponsor reserves right to publish or present the overall study results.|t
17161778|NCT00317369|f||||f
17182261|NCT00333229|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17182262|NCT00348556|t||||f
17182263|NCT00240071|f||||f
17182264|NCT01944059|t||||
17182265|NCT02633956|f||OTHER|Principal Investigators must wait 18 months after the study end to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.|t
17182266|NCT01166594|f||||f
17137744|NCT04547998|f||||f
17161779|NCT00849472|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161780|NCT03838874|t||||
17161781|NCT01767415|t||||
17161782|NCT05893823|f||||f
17161783|NCT01257438|f||OTHER||t
17161784|NCT02085551|f||||f
17161785|NCT03370302|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161786|NCT00985790|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161787|NCT01648959|t||||
17161788|NCT04180696|f||||t
17161789|NCT02759458|f||||f
17161790|NCT02593864|t||||f
17161791|NCT04739709|f||OTHER|The Institutions and Investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of the Sponsor.|t
17161792|NCT04124965|f||GT60||t
17161793|NCT02184156|f||||t
17161794|NCT00002874|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17161795|NCT03837938|f||||f
17161796|NCT01397747|f||||f
17161797|NCT01789775|f||||f
17161798|NCT03828383|f||||f
17161799|NCT00504309|t||||f
17161800|NCT03694652|f||||f
17182267|NCT04118010|t||||
17137745|NCT01147406|f||OTHER|The investigator agrees with the use of results of the clinical study for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the competent authorities will be notified of the investigator's name, address, qualifications, and extent of involvement. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.|t
17137746|NCT01280266|f||||f
17137747|NCT04655703|t||||f
17137748|NCT00881361|t||||
17137749|NCT00365768|t||||
17137750|NCT02988219|t||||
17137751|NCT01522443|f||OTHER|Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.|t
17137752|NCT01256983|t||||
17137753|NCT05590767|t||||f
17137754|NCT03452891|f||||f
17137755|NCT00776555|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17137756|NCT00936117|t||||
17137757|NCT04685499|t||||
17137758|NCT00618449|f||||f
17161801|NCT03158311|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17161802|NCT01018953|f||||f
17161803|NCT03927716|f||OTHER|The PI must wait 18 months after the closeout of the trial at all Study sites or until the publication of the multi-site Sponsor results. The only restriction on PI publication after that time is that the sponsor can review results communications prior to public release and can request confidential or proprietary information be removed or can embargo communications regarding trial results for a period that is more than 90 days but less than 120 days.|t
17161804|NCT04115228|f||OTHER|For this clinical feasibility study, the investigator agrees to maintain confidentiality and refrain from publication without the sponsor's prior written approval.|t
17161805|NCT03812328|f||GT60||t
17161806|NCT01928771|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17161807|NCT03932331|f||||t
17161808|NCT01455519|f||||f
17161809|NCT01271855|f||||f
17161810|NCT01407367|f||||f
17161811|NCT01452347|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17161812|NCT02642679|f||||f
17161813|NCT00371631|t||||
17161814|NCT01112267|f||OTHER|PI cannot provide the any trial related information to external parties' without mutual agreement with the sponsor. This is valid even after the contract is canceled.|t
17161815|NCT04928339|t||||
17161816|NCT05638737|f||GT60||t
17161817|NCT00142597|f||||f
17161818|NCT04633447|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17182268|NCT04206293|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17182269|NCT04587934|f||||f
17161819|NCT03641924|f||||f
17161820|NCT04333498|t||||
17182270|NCT01454934|f||||f
17182271|NCT02227485|t||||
17182272|NCT02378844|f||LTE60||t
17182273|NCT04322396|f||||f
17182274|NCT04061694|t||||
17182275|NCT01993108|t||||
17137759|NCT05127421|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17137760|NCT01441115|f||||f
17137761|NCT00574496|t||||
17137762|NCT01766817|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17137763|NCT00094887|f||OTHER||t
17137764|NCT00258206|t||||
17137765|NCT02721251|f||||f
17137766|NCT04142216|f||||f
17137767|NCT02007954|t||||
17137768|NCT03095053|t||||
17137769|NCT02659605|t||||
17137770|NCT01054976|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release (time limit not indicated).|t
17137771|NCT01929473|f||OTHER||t
17137772|NCT01195363|f||||f
17137773|NCT01589510|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137774|NCT00750165|f||||f
17137775|NCT00538824|f||LTE60||t
17137776|NCT00077376|f||LTE60||t
17161821|NCT01565694|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor at least 1 month prior to the submission of any such information to an editorial board or scientific review committee. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.|t
17137777|NCT02664532|t||||
17137778|NCT02024204|t||||
17161822|NCT03690544|t||||
17161823|NCT05416203|t||||
17137779|NCT01871896|t||||
17137780|NCT02415439|f||GT60||t
17137781|NCT06422377|f||||t
17161824|NCT06059066|f||||f
17137782|NCT02843178|f||||f
17137783|NCT02420795|t||||
17137784|NCT01874119|f||||f
17137785|NCT04306900|f||||f
17137786|NCT04327518|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17137787|NCT01293006|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17161825|NCT02724644|f||OTHER||t
17161826|NCT05417113|f||GT60||t
17161827|NCT01022580|t||||f
17161828|NCT00541229|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137788|NCT01494987|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17161829|NCT01807520|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161830|NCT01500096|f||||f
17161831|NCT01797185|f||OTHER||t
17161832|NCT03520569|t||||f
17161833|NCT01952678|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17161834|NCT03418675|f||||f
17161835|NCT03422718|f||||f
17137789|NCT01184456|f||||f
17137790|NCT00436982|f||LTE60||t
17137791|NCT01052831|f||||f
17137792|NCT00520299|f||LTE60||t
17137793|NCT01807091|t||||
17161836|NCT01178411|f||OTHER|The Investigator shall have the right to publish the results of research performed under this protocol, provided that such publication does not disclose any confidential information or trade secrets of ArQule (other than the data).|t
17161837|NCT01129284|t||||
17161838|NCT00771602|t||||
17161839|NCT01629862|f||||f
17161840|NCT02985710|f||LTE60||t
17161841|NCT01625182|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17161842|NCT03380572|t||||
17161843|NCT00447278|f||GT60||t
17161844|NCT00886236|t||||
17161845|NCT05427916|t||||
17161846|NCT03558672|f||LTE60||t
17161847|NCT00421733|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17161848|NCT02265744|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168387|NCT02639338|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168388|NCT00493636|f||OTHER|"Onyx has the right to require the deletion of any Confidential Information in a publication. If Onyx believes that information contained in the publication is patentable and communicates that in writing, the submission/delivery of the publication may be delayed for up to 60 additional days to allow for the filing of a United States (and any other appropriate) patent application(s)."|t
17161849|NCT05161936|f||||f
17161850|NCT01086475|f||||f
17161851|NCT01279187|f||||f
17161852|NCT04999020|f||||t
17161853|NCT00933166|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17161854|NCT03914703|f||||f
17161855|NCT00837447|f||||f
17161856|NCT04465955|f||||f
17161857|NCT05399355|f||||f
17161858|NCT03501277|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161859|NCT01327703|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17161860|NCT00927082|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161861|NCT00825175|t||||
17161862|NCT01428128|t||||
17161863|NCT00424008|f||OTHER|The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.|t
17137794|NCT01352845|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161864|NCT00963508|f||||f
17161865|NCT01181479|f||OTHER|Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL12 study is required prior to publication submission.|t
17161866|NCT00759096|f||||f
17161867|NCT01276652|f||||f
17161868|NCT04249778|t||||
17161869|NCT03233217|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17161870|NCT02530242|t||||
17161871|NCT00283959|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17161872|NCT05591755|f||||f
17161873|NCT00433290|f||GT60||t
17161874|NCT01483651|t||||
17161875|NCT00500890|t||||
17161876|NCT01917773|f||||f
17161877|NCT02260622|f||||f
17161878|NCT02643199|f||||f
17161879|NCT00308685|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17161880|NCT03345095|f||||f
17161881|NCT01121575|f||OTHER|"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites.~Investigator may not disclose previously undisclosed confidential information other than study results."|t
17161882|NCT01799278|t||||
17161883|NCT02665455|f||GT60||t
17161884|NCT00724503|f||||f
17161885|NCT01186419|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17161886|NCT01937117|f||||f
17161887|NCT01671059|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161888|NCT01560416|t||||
17161889|NCT01179399|f||||f
17161890|NCT03018730|f||OTHER|The clinical trial agreement that is generally provided to the sites and Investigators contains a Publication paragraph that indicates the following: shall not, without the Sponsor's prior written consent, independently publish, present or otherwise disclose any results of or information pertaining to the trial until a multi-center publication is published, subject to certain limitations regarding timing and the confidentiality of unpublished data.|t
17161891|NCT04073407|f||||f
17161892|NCT03921541|f||GT60||t
17161893|NCT01653262|f||GT60||t
17161894|NCT02798952|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161895|NCT00420407|t||||f
17161896|NCT01734928|f||LTE60||t
17161897|NCT01778985|t||||f
17161898|NCT03761914|f||||t
17161899|NCT01631188|t||||
17161900|NCT03600350|t||||
17161901|NCT00835978|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161902|NCT03684057|t||||f
17161903|NCT01105130|t||||
17161904|NCT03404167|f||LTE60||t
17161905|NCT00943904|f||||f
17161906|NCT00327171|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study, for review and comment at least 45 days in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17168389|NCT01893359|f||OTHER|Site has the right to publish or communicate study results upon the earlier of: (a) publication of a multi-center publication of the Study results coordinated by Sponsor; or (b) submission of the Study data by Sponsor to the FDA; provided that the Sponsor reviews the proposed communication of results within ninety (90) days in advance of its release. Sponsor can request delay of publication or data release to allow for filing of patent application prior to the publication or release.|t
17168390|NCT00201123|t||||f
17137795|NCT02427750|f||||f
17137796|NCT00873288|f||||f
17137797|NCT05905601|f||||f
17161907|NCT01363440|f||OTHER|Not less than 45 days prior to submission of any (M)anuscript, (I)nstitution shall, or cause PI to, provide (S)ponsor a copy of (M). (I) to consider comments submitted by (S), \& to delete confidential information upon (S) request. At (S)'s request, (I) to delay publication for an additional 60 days to allow filing of patent applications. (I) \& PI agree to delay publication, prior to (M) summarizing data from all sites, unless no (M) is published prior to first anniversary of final study report.|t
17161908|NCT02323334|f||GT60||t
17161909|NCT00530075|f||||f
17161910|NCT01263379|f||||f
17161911|NCT00845182|f||||f
17161912|NCT00743262|f||||f
17161913|NCT02810327|f||||f
17161914|NCT04368910|f||||f
17161915|NCT04565288|f||||f
17161916|NCT01158404|f||GT60||t
17161917|NCT02249793|f||||f
17161918|NCT02384460|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17161919|NCT01060111|f||OTHER|PI cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is cancelled.|t
17161920|NCT03281538|f||||t
17161921|NCT00583804|t||||
17161922|NCT00997126|f||||f
17161923|NCT04402957|f||||f
17161924|NCT04246476|f||||f
17161925|NCT02122952|f||OTHER|PI will provide proposed publication or presentation for review 60 days prior; Sponsor informs PI in writing of revisions required to protect Sponsor's confidential and proprietary technical information and to address inaccurate data or inappropriate interpretations. At expiration of such 60 days, PI may proceed unless Sponsor has notified in writing that such proposed publication or presentation discloses the Sponsor's confidential and proprietary technical information.|t
17161926|NCT00896233|f||OTHER|Publications derived from this study should include input from the investigators and SPONSOR personnel.Such input should be reflected in publication authorship.The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17161927|NCT04280562|f||||f
17161928|NCT02965456|f||OTHER|Please contact Sponsor directly for additional information.|t
17161929|NCT02583477|f||||t
17161930|NCT00729807|f||||f
17161931|NCT04056468|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161932|NCT01860404|t||||
17161933|NCT02762604|t||||
17161934|NCT06038643|t||||
17161935|NCT00762177|f||LTE60||t
17161936|NCT04136366|f||||t
17161937|NCT04514458|t||||
17161938|NCT03159195|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17161939|NCT05259033|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17161940|NCT04210375|f||LTE60||t
17161941|NCT01405911|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17161942|NCT02213575|t||||
17161943|NCT01980888|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17161944|NCT02193152|t||||
17161945|NCT02015104|f||||f
17161946|NCT05762744|t||||
17161947|NCT03630354|f||||f
17161948|NCT01537367|f||||f
17161949|NCT01030900|f||||f
17161950|NCT00441896|f||||f
17161951|NCT01301092|f||GT60||t
17161952|NCT03334175|t||||f
17161953|NCT02507284|f||||f
17161954|NCT01350973|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17168391|NCT01066780|f||OTHER|At least 60 days before submission for publication, presentation or use, Institution or Principal Investigator will submit to Sponsor for review and comment any proposed oral or written Publication. Sponsor will have the right to request any modification of any Publication if in Sponsor's reasonable opinion that Publication would jeopardize a patent application or patent.|t
17161955|NCT03738215|f||||f
17168392|NCT04983797|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17161956|NCT01033071|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17161957|NCT00254072|f||||f
17161958|NCT01695772|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161959|NCT03277274|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17161960|NCT04941898|f||||t
17161961|NCT03022630|t||||
17161962|NCT03150797|f||||f
17161963|NCT04290676|f||OTHER|During the Study and for a period of ten (10) years after completion or early termination of the Multi-Center Retrospective Trial, without Sponsor's and/or its representative prior written consent, Institution and Investigator will not publish, disseminate or otherwise disclose, deliver or make available any Confidential Information to any third party other than Study Personnel or Sponsor's representative, and then only for the purpose of conducting the Study.|t
17161964|NCT00088881|f||LTE60||t
17161965|NCT01309880|f||OTHER||t
17161966|NCT02927145|t||||
17161967|NCT01002105|f||||f
17161968|NCT03017261|f||OTHER|"PI must submit proposed publications to Sponsor for review per contract timelines.~Hospital \& PI shall:~* not publish the Hospital's and PI's results until a multi-center publication is released; however, if a multi-center publication is not released within 1 year after the study, Hospital \& PI may publish the results of their activities.~* keep all unpublished data \& results confidential and not disclose such in greater detail than disclosed in any publications, presentations or disclosures."|t
17161969|NCT00266812|f||OTHER||t
17161970|NCT00818272|f||OTHER|Trial results belong to the SPONSOR only, all investigators are not allowed to publish trial results without permission of the SPONSOR.|t
17161971|NCT03695094|f||GT60||t
17161972|NCT01834261|f||||f
17161973|NCT02506036|f||||f
17161974|NCT02316613|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17161975|NCT01166945|f||||f
17161976|NCT00442689|f||||f
17161977|NCT00758043|f||GT60||t
17161978|NCT02313597|f||||f
17161979|NCT00552058|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17182276|NCT01802775|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The site may publish the results with proper regard to the protection of subjects' identities, provided that sponsor (including legal and intellectual property) has had the opportunity to review and comment on the proposed publication prior to its being submitted for publication.|t
17182277|NCT00386256|t||||
17161980|NCT01348698|f||||f
17182278|NCT01691027|t||||
17182279|NCT03341052|t||||f
17161981|NCT02595749|t||||
17161982|NCT00263562|f||||f
17161983|NCT01286324|t||||
17182280|NCT00782210|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17182281|NCT01018420|f||GT60||t
17161984|NCT00986232|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161985|NCT05558410|f||||t
17161986|NCT02400580|t||||
17161987|NCT00965094|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17161988|NCT01336972|f||||f
17161989|NCT02313272|t||||
17161990|NCT03446573|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17161991|NCT01793909|f||||f
17161992|NCT05987540|f||||f
17161993|NCT00471107|t||||
17161994|NCT04996264|f||GT60||t
17161995|NCT04433975|t||||
17161996|NCT04606771|f||||f
17161997|NCT03896217|t||||
17161998|NCT04392635|t||||f
17161999|NCT02030418|f||||f
17162000|NCT00888849|f||OTHER||t
17162001|NCT02508207|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17162002|NCT02723331|f||||f
17162003|NCT03296345|t||||
17162004|NCT04149353|f||||f
17162005|NCT02068599|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data|t
17162006|NCT00632970|f||||f
17162007|NCT01106950|t||||
17137798|NCT03024255|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied .|t
17137799|NCT03532776|f||OTHER|Any use of information, data or results related to, associated with and directly resulting from the Study shall only be published or presented only after providing a copy of the manuscript or presentation, at least 60 days in advance of such publication or presentation, to the Sponsor for its review and approval in writing. No Confidential Information may be published without the express written consent of Sponsor.|t
17162008|NCT00356421|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17162009|NCT00887588|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17162010|NCT00106535|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162011|NCT02958527|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162012|NCT03587857|t||||
17162013|NCT00371449|t||||f
17162014|NCT03753542|f||||f
17162015|NCT06100250|f||||f
17162016|NCT02021318|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study after Sponsor publication of multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17162017|NCT03585543|t||||
17162018|NCT00421993|f||OTHER|Following the expiration of twenty-four (24) months after the completion of the Study, Investigator shall have the right to publish the results of the Study; provided, however that Sponsor shall have the right to review any proposed publication generated from the Study prior to publication or presentation. The Sponsor shall have the absolute right to refuse the publication altogether, to delay it or to amend its contents as it deems fit.|t
17162019|NCT03969420|f||LTE60||t
17162020|NCT02638493|t||||
17162021|NCT00004859|f||LTE60||t
17162022|NCT00126737|t||||
17162023|NCT02860000|t||||
17162024|NCT01729091|t||||
17162025|NCT00884949|f||OTHER|PI cannot publish any data prior to multi-centre publication. If publication related to sub-sets of data shall make reference to the relevant multi-centre publication. PI agrees to submit data to Sponsor for review and comment 60 days prior to publication. During review period, Sponsor may request that publication be delayed for up to 6 months from date of first submission to Sponsor in order for Sponsor to take steps to protect its proprietary information.|t
17162026|NCT01258855|f||LTE60||t
17162027|NCT01567085|f||||f
17162028|NCT00504231|f||||f
17162029|NCT03928704|f||GT60||t
17162030|NCT03083379|t||||
17162031|NCT04575324|f||||f
17162032|NCT03403517|t||||
17162033|NCT05027282|f||OTHER|Contact sponsor for details.|t
17162034|NCT00456612|f||||f
17162035|NCT03202550|f||||f
17162036|NCT03309605|f||||f
17162037|NCT00784927|t||||
17162038|NCT01779362|f||||f
17162039|NCT00714272|f||||f
17162040|NCT01795937|t||||
17162041|NCT04027946|f||||f
17162042|NCT01028053|f||||f
17162043|NCT00983957|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17162044|NCT00790933|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17162045|NCT03395990|t||||f
17162046|NCT00245570|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162047|NCT01829165|t||||
17162048|NCT01033227|t||||
17182282|NCT00826267|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17162049|NCT01901588|t||||
17137800|NCT03583606|f||LTE60||t
17137801|NCT04131933|f||||f
17162050|NCT02002208|f||||f
17162051|NCT03676725|f||LTE60||t
17162052|NCT05696158|f||LTE60||t
17162053|NCT00489268|f||||f
17162054|NCT01579305|f||OTHER|Allergan, as the Sponsor, has proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between multiple Investigators and sites and Allergan personnel. Authorship will be established prior to the writing of the manuscript. As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with Allergan.|t
17162055|NCT04233580|f||||f
17162056|NCT00593645|t||||
17162057|NCT02441114|f||||f
17162058|NCT01371565|f||GT60||t
17162059|NCT02070991|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17162060|NCT00827242|f||GT60||t
17162061|NCT00899847|f||||f
17162062|NCT01769443|f||||f
17162063|NCT01279200|t||||
17162064|NCT01968317|f||LTE60||t
17162065|NCT02216851|f||||t
17162066|NCT01149538|f||||f
17162067|NCT01254877|f||||f
17162068|NCT05507450|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17162069|NCT02904356|f||||f
17162070|NCT01118091|f||||f
17162071|NCT00514917|f||OTHER|The investigator shall provide the Steering Committee a copy of any manuscript, abstract or oral communication derived from the study for review and comment at least 30 days in advance of any submission. The Sponsor's representatives shall have the right to review and/or delay any publication or presentation to prevent disclosure of Sponsor's confidential information and preserve intellectual property rights.|t
17162072|NCT02697422|t||||
17162073|NCT01708525|f||||f
17162074|NCT01659541|f||||f
17162075|NCT01222351|t||||
17168393|NCT00787202|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168394|NCT02008357|f||GT60||t
17168395|NCT00966719|t||||
17168396|NCT03089944|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168397|NCT00884910|f||||f
17168398|NCT00831701|f||||f
17168399|NCT03131596|t||||
17182283|NCT00134381|f||||f
17182284|NCT04066426|f||||f
17137802|NCT01754207|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17137803|NCT03728140|f||||f
17137804|NCT00698035|t||||
17137805|NCT00433446|f||||f
17137806|NCT01188538|f||OTHER||t
17182285|NCT01105247|f||||f
17137807|NCT00654953|f||||f
17162076|NCT01873833|t||||
17162077|NCT03055507|f||||f
17162078|NCT03983109|f||||f
17162079|NCT01871727|f||||f
17162080|NCT00309244|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multi-center Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17162081|NCT01263028|t||||
17162082|NCT03019588|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17162083|NCT00501085|f||||f
17162084|NCT00366535|t||||
17162085|NCT02821793|t||||
17162086|NCT00250718|f||||f
17162087|NCT01666314|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17162088|NCT04230304|t||||
17162089|NCT03003468|f||||f
17162090|NCT02114684|f||||f
17162091|NCT00990769|t||||f
17162092|NCT01346683|f||LTE60||t
17162093|NCT02641353|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17182286|NCT00651482|f||||f
17162094|NCT00003474|f||||f
17162095|NCT00809146|f||||f
17162096|NCT00908687|f||OTHER||t
17162097|NCT02487199|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17162098|NCT00853047|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17162099|NCT00727064|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17137808|NCT01231607|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168400|NCT00434356|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.|t
17162100|NCT00422461|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162101|NCT01471574|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17162102|NCT03593629|t||||
17162103|NCT02346916|t||||
17162104|NCT00864513|t||||
17162105|NCT00762788|f||GT60||t
17162106|NCT03073109|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182287|NCT00048542|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17162107|NCT02083263|t||||
17162108|NCT00069329|t||||
17162109|NCT02331407|t||||f
17182288|NCT00578175|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182289|NCT00577512|t||||
17182290|NCT02272413|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17182291|NCT02126969|f||||f
17182292|NCT01533246|f||LTE60||t
17162110|NCT01562444|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162111|NCT00546273|f||OTHER|The disclosure of the results has to be previously arranged if mutually agreeable to both investigators and the company manufacturer of the vaccine RUTI: Archivel Farma S.L.|t
17162112|NCT00038610|t||||
17162113|NCT02930941|t||||
17162114|NCT00574951|f||LTE60||t
17162115|NCT00585585|f||||f
17162116|NCT00710970|f||||f
17162117|NCT01567020|t||||
17162118|NCT01960842|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17162119|NCT00397930|f||||f
17162120|NCT02391584|f||LTE60||t
17162121|NCT01030575|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17162122|NCT02296801|f||LTE60||t
17162123|NCT01160744|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17162124|NCT02056288|t||||
17162125|NCT02301429|f||GT60||t
17162126|NCT01502072|t||||
17162127|NCT00500110|t||||
17162128|NCT03954938|t||||
17162129|NCT04676646|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17162130|NCT02217982|t||||
17162131|NCT04270760|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17162132|NCT02421510|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17162133|NCT04022694|t||||
17162134|NCT02609633|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162135|NCT03611062|f||||f
17162136|NCT02287025|f||GT60||t
17137809|NCT02501902|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137810|NCT02513771|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17162137|NCT01096186|f||OTHER|Publication of the results of the Study conducted at the Site shall not be made before the first multi-site publication by Sponsor.|t
17162138|NCT04053452|t||||
17162139|NCT02203786|f||||f
17162140|NCT00122187|t||||
17182293|NCT01143090|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17182294|NCT00548860|f||LTE60||t
17162141|NCT02061592|f||OTHER|"Prior to submission for publication or presentation the Institution will provide sponsor with at least sixty (60) days for review of a manuscript.~If needed, the Institution and Principal Investigator will withhold publication for up to an additional sixty days to allow for filing of a patent application."|t
17162142|NCT03338023|f||GT60||t
17162143|NCT00799864|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182295|NCT02719158|f||OTHER|Publication subject to Sponsor consent.|t
17162144|NCT02346370|f||OTHER||t
17162145|NCT02734147|t||||
17137811|NCT01797445|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17137812|NCT01595438|f||OTHER|Principal investigator submits the proposed publication and /or presentation to AZAB for review at least 60 days prior to proposed publication and/or presentation. If AZAB, requests in writing, then PI shall withhold publication and/or presentation for an additional 90 days to allow AZAB to protect its intellectual rights.|t
17137813|NCT02084069|f||||f
17137814|NCT04116073|t||||
17137815|NCT05814471|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is 1 year from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17137816|NCT03646760|f||||f
17137817|NCT04904614|f||||f
17137818|NCT04190186|t||||
17137819|NCT04015440|t||||
17137820|NCT01668030|f||||f
17137821|NCT00618995|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137822|NCT02451202|f||||f
17137823|NCT03373110|f||||f
17137824|NCT03329599|f||||f
17137825|NCT01804036|f||||f
17137826|NCT02677220|f||||f
17137827|NCT00965146|f||OTHER|The disclosure restriction on the PI to publish results of this Clinical Study or the results of the activities hereunder, any abstract, manuscript, presentation or other communication shall be submitted to sponsor for review and approval at least 60 days prior to submission for publication. The sponsor retains the right to deny publication or, at its sole option, to revise the manuscript to delete proprietary or other confidential commercial information.|t
17137828|NCT01181102|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17137829|NCT01315002|t||||
17137830|NCT05053126|f||OTHER||t
17137831|NCT01309841|f||GT60||t
17137832|NCT00050960|f||||f
17137833|NCT03488914|f||||f
17137834|NCT04311177|t||||
17137835|NCT02391350|f||||f
17162146|NCT00685698|f||OTHER|PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.|t
17162147|NCT03528577|f||OTHER||t
17162148|NCT04882215|f||||f
17162149|NCT02213107|t||||
17162150|NCT04098302|t||||
17162151|NCT05061706|f||||t
17162152|NCT01584388|f||||f
17162153|NCT00724893|f||||f
17162154|NCT01290731|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17162155|NCT05064800|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162156|NCT04477486|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17162157|NCT03335267|t||||
17168401|NCT00734071|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17168402|NCT00151372|t||||
17168403|NCT02384434|t||||
17168404|NCT00541346|t||LTE60||t
17168405|NCT04732949|f||OTHER|This document is the property of Synairgen Research Ltd and may not be used, divulged, published, or otherwise disclosed with.|t
17168406|NCT05264116|f||||f
17168407|NCT06034652|f||||f
17168408|NCT00583791|f||||f
17168409|NCT03323736|f||OTHER|PI must submit communications to Sponsor for review and comment to verify accurate content at least 30 days prior to submitting to any third party. A delay up to 90 days may be requested by Sponsor in order to file patent applications relating to an Invention if applicable. Sponsor and PI agree that any Institution Publication shall only be made after the Multicenter Publication, provided that the Multicenter Publication is submitted within 18 months after conclusion of the study at all sites.|t
17168410|NCT03710876|f||||t
17168411|NCT02853435|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162158|NCT01853085|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17162159|NCT01078545|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection|t
17168412|NCT04973696|f||||f
17168413|NCT03747120|t||||
17168414|NCT04172467|f||||f
17168415|NCT04332614|t||||
17168416|NCT04144959|f||LTE60||t
17162160|NCT02864914|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17182296|NCT01461096|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17182297|NCT01112293|t||||
17182298|NCT00112242|f||||f
17182299|NCT01734551|f||||f
17182300|NCT04225923|f||OTHER||t
17182301|NCT01417481|t||||f
17182302|NCT00855309|t||||
17182303|NCT00829296|t||||f
17182304|NCT00577083|f||||f
17182305|NCT04630093|f||||f
17182306|NCT04116710|f||GT60||t
17182307|NCT04296396|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17182308|NCT01077960|f||OTHER||t
17182309|NCT01371656|f||OTHER|Must obtain prior Sponsor approval.|t
17182310|NCT01537783|t||||
17182311|NCT00847288|f||OTHER||t
17182312|NCT04448210|t||||
17182313|NCT00291668|f||GT60||t
17182314|NCT00313612|f||LTE60||t
17182315|NCT00451035|f||||f
17182316|NCT01965288|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor.|t
17182317|NCT01393405|f||||f
17182318|NCT03664752|f||OTHER|Contact sponsor for details.|t
17182319|NCT00717769|f||||f
17162161|NCT01774370|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162162|NCT05436288|f||||f
17162163|NCT03948386|f||||f
17182320|NCT01153581|t||OTHER||
17182321|NCT01399593|f||||f
17182322|NCT02214277|f||||f
17182323|NCT00244712|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182324|NCT02777125|f||||f
17182325|NCT00574405|f||LTE60||t
17182326|NCT01336738|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182327|NCT02383667|t||||
17182328|NCT02970968|f||||t
17182329|NCT03003520|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182330|NCT01332149|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182331|NCT01558700|f||||f
17182332|NCT04615949|f||||f
17182333|NCT05458856|f||||t
17182334|NCT01920932|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17162164|NCT01436500|f||OTHER|PI can publish data generated at their study site after multi=center study data have already been published, or after 18 months have elapsed following database lock. The sponsor may review manuscripts before submission and delay publication by an additional 60 days, if necessary.|t
17182335|NCT01140477|f||OTHER|For a period of ten years, the PI agrees to keep confidential and not disclose, without the prior written consent of Sponsor, to any third party or use any technology, data, reports, results of clinical studies conducted under this Study or other information received by Sponsor, or any technology, data, reports, study materials, or other information developed by Sponsor unless disclosure by PI is required by law.|t
17182336|NCT03285373|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162165|NCT01109381|f||LTE60||t
17162166|NCT02487485|f||||f
17162167|NCT01487161|f||||t
17162168|NCT02945046|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17162169|NCT03113136|f||||f
17162170|NCT02675452|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17162171|NCT02939781|t||||
17162172|NCT04267328|t||||
17162173|NCT00689052|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17162174|NCT02569242|f||||f
17162175|NCT04625972|t||GT60||t
17162176|NCT03259308|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17162177|NCT00694122|f||||f
17162178|NCT01767285|t||||
17182337|NCT01945489|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17162179|NCT01727154|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17182338|NCT00697346|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17182339|NCT01381861|f||LTE60||t
17182340|NCT03569371|f||OTHER|Clinical Study Agreement|t
17182341|NCT01236755|f||||f
17182342|NCT03567850|t||||
17162180|NCT03020888|f||||f
17182343|NCT01539226|f||||f
17182344|NCT02643251|f||GT60||t
17182345|NCT03863210|f||||f
17162181|NCT01198548|t||||
17182346|NCT02365636|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17182347|NCT02111252|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182348|NCT03427658|f||||f
17162182|NCT02269488|f||||f
17182349|NCT01163604|t||||
17182350|NCT00463060|t||||
17162183|NCT01245062|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182351|NCT01782313|t||||
17182352|NCT02506816|t||||
17162184|NCT06025695|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17182353|NCT01369875|f||||f
17182354|NCT01236196|f||||f
17162185|NCT03834883|f||||f
17182355|NCT00699010|f||||f
17162186|NCT00314106|f||||f
17162187|NCT04971837|t||||f
17162188|NCT00160615|f||GT60||t
17182356|NCT04370691|f||OTHER|Inst. may publish data/results individually from its site after any of (1) a multi-center publication is published, (2) no multicenter publication is submitted within 18months after closure of the Study, or (3) Abbott confirms there will be no multi-center publication. Inst. shall provide Sponsor with draft at least 60 days prior to submission for Sponsor review/comment. Upon request, Publication shall be delayed an additional 60 days. Due consideration will be given to Sponsor comments.|t
17182357|NCT04152226|f||OTHER||t
17182358|NCT03013543|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17182359|NCT04960228|f||||f
17182360|NCT02471521|f||||f
17182361|NCT02281552|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182362|NCT03900299|f||||f
17182363|NCT04365699|t||||f
17182364|NCT02540954|f||LTE60||t
17182365|NCT01393743|f||OTHER||t
17182366|NCT02581384|t||||
17182367|NCT01076504|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17182368|NCT02321462|f||OTHER|No publication of the Study Results shall be made without Sponsor's prior written approval. If a multi-centre publication is not submitted to a journal within 24 months after study conclusion at all sites the PI may individually publish results from the Institution Site subject to Sponsor's prior approval. Sponsor to be provided with final version of any abstract/presentation/paper prior to disclosure to provide scientific comments within 2 weeks for abstract/presentation or 6 weeks for article.|t
17182369|NCT02469116|t||||
17182370|NCT01183169|f||OTHER||t
17182371|NCT01514396|f||||f
17182372|NCT03044197|t||||
17182373|NCT05409235|f||||f
17182374|NCT00834912|f||OTHER|Publication of the study results may only be allowed with written permission from the sponsor.|t
17182375|NCT00749931|f||||f
17182376|NCT03829046|t||||
17182377|NCT00989833|f||LTE60||t
17182378|NCT01431703|f||||f
17182379|NCT00249470|f||||f
17182380|NCT04859868|t||||
17182381|NCT00624806|t||||f
17182382|NCT00500370|f||GT60||t
17182383|NCT01282424|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17182384|NCT00714259|t||||f
17182385|NCT04804813|f||||t
17168417|NCT04191499|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168418|NCT01266317|t||||
17168419|NCT00490776|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168420|NCT02937766|f||||f
17168421|NCT01670565|t||||
17182386|NCT05627518|f||LTE60||t
17182387|NCT04976530|f||||f
17182388|NCT03750903|t||||
17182389|NCT00705107|f||||f
17182390|NCT01168024|f||||f
17182391|NCT05677425|t||||
17182392|NCT05084053|f||||t
17182393|NCT00071812|f||OTHER|For multi-center trials, no investigator will be authorized to publish study results from an individual center until the multi-center trial results are published. All manuscripts and abstracts must be submitted to the sponsor for review at least 30 days prior to submission for publication or for presentation at a scientific meeting. Proposed abstracts and publications will be reviewed promptly.|t
17182394|NCT01589822|f||GT60||t
17137836|NCT00413062|f||OTHER|The SPONSOR recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the SPONSOR. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the SPONSOR, at least six weeks ahead of estimated publication or presentation, for consent, which shall not be withheld unreasonably.|t
17137837|NCT01848899|f||||f
17137838|NCT02815293|f||OTHER|As this study was terminated, no data will be published.|t
17137839|NCT00006604|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17137840|NCT03180489|f||||f
17137841|NCT01056341|f||OTHER|"The investigators can reserve the right to publish or present study data; provided that the sponsor reviews the abstract or manuscript at least 60 days prior to the expected date of submission to the intended publisher or planned presentation.~Publication of study results by each site shall be made only after completion and finalisation of the study by all sites and first publication by the Sponsor."|t
17137842|NCT01086150|f||||f
17168422|NCT00308165|t||||
17168423|NCT02151331|f||||f
17168424|NCT04271475|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17168425|NCT00733135|f||OTHER|PI can not make any publication concerning the study without providing the sponsor 30 days to review it and provide comments. The Sponsor may require PI to delay publication until any factual errors are corrected. If the sponsor determines the proposed publication contains confidential information, or patentable subject matter that requires protection, the sponsor may require delay of the publication less than or equal to 90 days.|t
17162189|NCT03166631|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17182395|NCT05168475|f||OTHER|"Any publication or other dissemination of the Results (or any part of them) by any of the Parties shall not occur until the Lead has published the Results of the Project in the primary publication (the Primary Publication)."|t
17182396|NCT05543928|f||||f
17162190|NCT02740582|t||||f
17182397|NCT03568942|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137843|NCT01681576|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17137844|NCT00736580|f||||f
17162191|NCT00567580|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17162192|NCT00358579|f||||f
17162193|NCT01245751|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17162194|NCT05788328|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162195|NCT03197935|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162196|NCT02082483|f||||f
17162197|NCT02357485|f||||f
17162198|NCT00145327|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162199|NCT05938010|t||||
17162200|NCT02197104|f||||f
17162201|NCT01454063|f||OTHER|The PI agreed not to publish or otherwise to disclose Study data without prior written consent from the sponsor for a period of 24 months following Study completion or until data are published in a combined publication (whichever occurs first). The sponsor can review communications containing results prior to public release and embargo those communications for a period that is no longer than 60 days from the date of receipt of the non-public communication. The sponsor cannot extend the embargo.|t
17162202|NCT01161121|f||LTE60||t
17162203|NCT00509600|t||||f
17162204|NCT00666978|t||||
17162205|NCT03055195|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162206|NCT01908842|f||||f
17162207|NCT02568423|f||||t
17162208|NCT01027416|t||||
17162209|NCT01045265|f||GT60||t
17162210|NCT00676052|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162211|NCT00289978|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162212|NCT02979054|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17162213|NCT04017910|f||||f
17162214|NCT01967277|f||OTHER|PI may not disclose the results of the trial.|t
17162215|NCT00727337|f||||f
17162216|NCT01676350|f||||f
17162217|NCT00103506|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17162218|NCT00585169|f||||f
17162219|NCT01028560|t||||f
17162220|NCT03055221|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17162221|NCT01243424|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162222|NCT02011464|f||||f
17162223|NCT01215240|f||||f
17162224|NCT04366583|f||||f
17162225|NCT01441414|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162226|NCT03737032|t||||f
17162227|NCT01773889|f||||f
17162228|NCT03646188|f||LTE60||t
17162229|NCT00976391|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162230|NCT00617903|f||OTHER|A) Investigator shall provide Sponsor with intended publication 60 days upfront publication date, Sponsor has 30 d to comment, recommended changes shall not be unreasonably refused B) Sponsor has the right to ask Investigator to delay publication for a maximum of 90 days C) Investigative data will be pooled and published by Sponsor - no other publication without the consent of all parties prior to publication of the pooled data, or within 12 months after LPLV, whatever comes first|t
17162231|NCT05156125|f||GT60||t
17162232|NCT04863807|t||||
17162233|NCT05075772|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162234|NCT03123588|f||OTHER|Clinical Study Agreement|t
17162235|NCT02993302|t||||
17162236|NCT01698008|t||||
17168426|NCT00159913|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162237|NCT00508300|t||||
17162238|NCT00668564|t||||
17162239|NCT01755637|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162240|NCT01814332|t||||
17168427|NCT00824005|t||||
17168428|NCT01874275|f||||f
17168429|NCT04709484|f||||f
17168430|NCT00168103|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.|t
17162241|NCT02959892|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17162242|NCT03099863|f||||f
17162243|NCT04263532|f||||f
17162244|NCT03911687|f||||f
17162245|NCT01810952|t||||f
17162246|NCT03362957|t||||
17162247|NCT01399099|f||||f
17162248|NCT01668537|f||||t
17162249|NCT02497755|f||||f
17162250|NCT02555098|f||||f
17162251|NCT04097223|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162252|NCT02280499|f||||f
17162253|NCT05254210|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17162254|NCT03677180|t||||
17162255|NCT04786600|t||||
17162256|NCT02547935|f||||f
17162257|NCT03461861|t||OTHER|There is an agreement between Dr. Li and AgeneBio since AgeneBio supplies AGB101 drug to Dr. Li's for conducting the trial. The only restriction on the PI is that the sponsor can review results communications prior to public release.|t
17162258|NCT05136430|f||||f
17162259|NCT03554473|f||||f
17162260|NCT01501513|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17162261|NCT00382070|f||LTE60||t
17162262|NCT01552889|f||||f
17162263|NCT05715346|f||OTHER|PI to collegially coordinate presentations and papers with Sponsor's scientists.|t
17162264|NCT00284934|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162265|NCT04132466|f||||f
17162266|NCT03989570|t||||
17162267|NCT00520572|f||LTE60||t
17162268|NCT02802865|t||||
17162269|NCT03315689|f||||f
17162270|NCT00985192|f||||f
17162271|NCT02707744|t||||
17162272|NCT00720083|f||||f
17162273|NCT03926598|t||||
17162274|NCT02018887|t||||
17162275|NCT01058005|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17162276|NCT01145222|f||OTHER|At least 60 days prior to submission for publication, presentation or use, sponsor shall review and comment any proposed oral or written publication, which period may be extended for an additional 30 days. To seek patent protection, sponsor shall have the right to delay the proposed publication for an additional 60 days.|t
17162277|NCT00927186|f||GT60||t
17162278|NCT01421134|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17162279|NCT00580294|t||||
17162280|NCT01851369|f||||f
17162281|NCT02453191|t||||
17162282|NCT03364686|t||||
17162283|NCT02636322|t||||f
17162284|NCT02502071|f||||f
17162285|NCT02336503|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied .|t
17162286|NCT01543503|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162287|NCT03712618|t||||
17162288|NCT01936974|t||||
17162289|NCT00986583|t||||
17162290|NCT04584554|t||||
17162291|NCT00063999|f||LTE60||t
17162292|NCT03767894|t||||f
17162293|NCT04243837|f||||f
17162294|NCT02826551|t||||
17162295|NCT00977561|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162296|NCT01482286|f||||f
17162297|NCT05610267|f||||t
17162298|NCT02540434|t||||
17182398|NCT01076985|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17182399|NCT02547662|t||||
17182400|NCT00640510|f||GT60||t
17162299|NCT01968785|t||||
17162300|NCT01457430|f||||f
17182401|NCT05028374|t||||
17182402|NCT01467076|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17182403|NCT02744846|f||||f
17182404|NCT00418691|t||||f
17162301|NCT00400205|t||||
17162302|NCT00137280|t||||
17162303|NCT05001165|t||||
17162304|NCT04000724|f||||f
17162305|NCT00455455|f||||f
17162306|NCT01827943|t||||
17162307|NCT04689009|f||OTHER|The PI will not disclose information about the Trial without the consent of the Sponsor. These confidentiality obligations will remain in force until the information is made public by the Promoter. The PI must submit the manuscript to the Promoter, at least 60 days before publication. The Sponsor will then have 45 days to suggest changes to the Investigator.|t
17162308|NCT01266083|f||||t
17162309|NCT00545948|f||||f
17162310|NCT03467945|f||||f
17162311|NCT01509807|f||||f
17162312|NCT02187055|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Investigators will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.|t
17162313|NCT04159480|f||||f
17162314|NCT03520387|t||||
17182405|NCT01067352|f||OTHER||t
17162315|NCT03336866|f||OTHER|Sponsor agrees that the Investigator may present and publish methods and results of the study, but only after Sponsor has first published the results and with Sponsor's written permission. PRA shall provide to Sponsor any proposed presentation or publication for review 30 days prior to submission so that Sponsor may review for accuracy and provide comments and/or remove its proprietary or confidential information. PRA agrees that all reasonable comments will be incorporated.|t
17162316|NCT00541775|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162317|NCT00032487|t||||
17162318|NCT02975700|f||||f
17162319|NCT04501445|t||||
17162320|NCT01541254|f||OTHER|As part of a multi-center study the results of the national Trial shall be published by a National Principal Investigator within 12 months of completion of last study site. If no publication within that time frame, Principal Investigator is free to publish. Copies of proposed publication must be submitted to Sponsor at least 30 days in advance to ensure removal of proprietary or confidential information.|t
17162321|NCT05660538|f||||t
17162322|NCT02082288|t||||
17162323|NCT04518410|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17162324|NCT05737745|f||||f
17162325|NCT05103332|f||||t
17162326|NCT00362609|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17162327|NCT01807104|f||||f
17162328|NCT02278237|t||||
17162329|NCT05067270|f||GT60||t
17162330|NCT01800058|f||LTE60||t
17182406|NCT01096784|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17182407|NCT03761628|f||||f
17162331|NCT02186171|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17162332|NCT02169401|f||GT60||t
17162333|NCT04289298|t||||
17162334|NCT00620035|f||OTHER|SPONSOR recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by SPONSOR. Any such scientific paper, presentation, or other communication concerning the clinical trial described in protocol will first be submitted to SPONSOR, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17162335|NCT01292265|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17162336|NCT04193176|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17162337|NCT01629563|f||OTHER|PI shall submit to sponsor results communication for review 60 days prior to publication submission. If in the sponsor judgement, publication at a given time would hinder the sponsor's IP development, PI shall consider modifying the publication schedule. PI agrees to delete information identified by sponsor as confidential or defer publication to permit filing of patent application by the sponsor. Publication based on 1 site results shall not be made before the first muti-centre publication.|t
17162338|NCT04229381|t||||
17162339|NCT02370394|t||||
17168431|NCT00989235|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168432|NCT02266875|t||||
17168433|NCT02459275|f||||f
17182408|NCT03064126|f||||t
17182409|NCT04508725|t||||
17162340|NCT01108796|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17162341|NCT00454142|f||LTE60||t
17162342|NCT01902303|f||GT60||t
17162343|NCT02821000|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17162344|NCT04634903|f||||f
17162345|NCT05890586|t||||
17162346|NCT02545127|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17162347|NCT01389284|f||||f
17162348|NCT00476788|f||||f
17162349|NCT00908388|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17162350|NCT00960856|f||GT60||t
17162351|NCT01783015|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162352|NCT00669331|f||LTE60||t
17162353|NCT03387046|f||||t
17162354|NCT03794544|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17162355|NCT02550210|t||||
17162356|NCT02320825|t||||
17162357|NCT00120250|f||||f
17162358|NCT03300336|f||||f
17162359|NCT01404260|f||LTE60||t
17168434|NCT00875056|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17168435|NCT01318070|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17162360|NCT01034527|t||||
17162361|NCT01964560|f||GT60||t
17162362|NCT00710554|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17162363|NCT01433978|f||OTHER||t
17162364|NCT00378560|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162365|NCT02852434|f||||f
17162366|NCT03203512|f||||f
17162367|NCT02053584|f||||f
17162368|NCT01011283|f||||f
17162369|NCT02822287|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162370|NCT01623752|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162371|NCT02933476|f||||f
17162372|NCT01556100|f||||f
17162373|NCT03994120|t||||
17137845|NCT01714817|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17162374|NCT04865978|t||||
17162375|NCT03835117|f||||f
17162376|NCT00428077|f||||f
17162377|NCT00609973|f||||f
17162378|NCT04308694|f||||f
17162379|NCT00191152|f||GT60||t
17162380|NCT04219774|t||||
17162381|NCT00114777|f||LTE60||t
17162382|NCT00629239|f||OTHER|The PI agrees to collaborate with AZ in regard to the contents and formation of any publication or disclosure and to considerate the comments,views and opinions offered by AZ. Prior to any publication or disclosure the PI will provide AZ with preliminary data and drafts of proposed publication or disclosure and the proposed final manuscript. AZ will have a period of 30 days from receipt of the proposed final manuscript to review and may require submission for publication or disclosure be delayed|t
17162383|NCT02460380|f||||f
17162384|NCT00682838|t||||
17162385|NCT02957123|t||||
17162386|NCT03095976|f||||f
17162387|NCT03566550|f||||f
17162388|NCT02618187|f||OTHER|Proposed publications must be submitted to Sponsor for review at least 30 days prior to publication. Sponsor can require removal of confidential information other than study data and Site/Investigator agree to consider Sponsor's suggestions with respect to the presentation of study data. Sponsor can force publication to be deferred for a period of up to 60 days in order to file any patents.|t
17162389|NCT02614768|t||||
17162390|NCT00052715|f||||f
17182410|NCT02465528|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17182411|NCT00645333|f||||f
17137846|NCT02921763|t||||
17137847|NCT01582971|f||||f
17162391|NCT01210443|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162392|NCT02807181|f||OTHER|PI must provide a proposed publication to Sponsor \>=30 days prior to publication submission for review and comment on the appropriateness of the data analysis and presentation, confidential Information, and rights regarding inventions or other intellectual property. The Sponsor may extend the review period by +30 days. Publication can be delayed by Sponsor to file patent applications but such delay shall not exceed 24 months from the date of such notice to the Investigator.|t
17162393|NCT01063881|f||GT60||t
17162394|NCT01309100|f||OTHER||t
17162395|NCT01895647|f||||f
17162396|NCT03343886|f||||f
17162397|NCT01270867|f||GT60||t
17162398|NCT04146909|t||||
17162399|NCT03808909|f||||f
17162400|NCT03335566|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17162401|NCT01084135|f||||f
17162402|NCT00663351|f||||f
17182412|NCT03907683|f||||f
17162403|NCT02362412|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment.|t
17162404|NCT03462563|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17162405|NCT02218268|f||||f
17162406|NCT03651336|f||||f
17162407|NCT01740427|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182413|NCT02975934|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17162408|NCT04906421|f||||f
17162409|NCT04796207|f||||f
17162410|NCT06173648|f||||f
17162411|NCT06765889|t||||
17162412|NCT05206604|t||||
17162413|NCT03735498|f||||f
17162414|NCT05675020|f||||f
17162415|NCT03787212|f||GT60||t
17162416|NCT02014103|f||||f
17162417|NCT01148420|f||||f
17162418|NCT00394472|f||OTHER|AZ shall have 30 days from the proposed final manuscript for any disclosure to review it and may within such time require that submission for publication/disclosure be delayed in order for AZ to file patent applications. If study site/investigator requests permission to publish data(incl oral presentations) it is to be agreed with AZ before publ.|t
17162419|NCT02181621|f||||f
17137848|NCT02396342|f||||t
17137849|NCT03700970|f||||f
17137850|NCT04860752|f||||t
17137851|NCT06025396|f||OTHER|Investigator/site may not disclose, present, disseminate or produce any publication that contains information regarding the Services, Deliverables, or Study Data without Sponsor's prior written consent.|t
17162420|NCT03794323|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17162421|NCT01301001|t||||
17137852|NCT06382064|f||||f
17137853|NCT02373371|t||||
17137854|NCT01539811|f||||f
17162422|NCT01560988|t||||
17162423|NCT01346709|f||||f
17162424|NCT02194088|f||||f
17162425|NCT04334681|t||||f
17162426|NCT00458705|t||||
17162427|NCT02565186|f||GT60||t
17162428|NCT00337194|f||LTE60||t
17162429|NCT03188705|t||||
17162430|NCT01174459|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17162431|NCT03511066|f||OTHER||t
17162432|NCT04203056|f||||f
17162433|NCT00165698|f||||f
17162434|NCT01026038|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162435|NCT01107457|f||GT60||t
17162436|NCT03679884|f||OTHER|Any study-related publication written independently by investigators must be submitted to Idorsia for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Idorsia may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17162437|NCT03601052|f||OTHER|"Investigators in this study may present or publish study results in scientific journals or other scholarly media without prior written approval after the following conditions have been met:~* Results of study have been publicly disclosed by or with the consent of the sponsor~* Investigator has complied with the Clinical Trial Agreement and requests from the sponsor to delete confidential information (other than study results)~* Study has been completed at all study sites for at least 2 years"|t
17162438|NCT00837330|t||||
17162439|NCT01227395|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162440|NCT01398475|t||||
17162441|NCT00086307|f||||f
17162442|NCT00105508|f||OTHER||t
17162443|NCT00683384|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162444|NCT03888274|f||||f
17162445|NCT00120874|t||||
17162446|NCT00845000|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17162447|NCT00300495|f||||f
17137855|NCT01985971|t||||
17137856|NCT00591240|f||||f
17162448|NCT03632720|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17162449|NCT01300065|f||OTHER|Contact sponsor directly for details.|t
17137857|NCT04578015|t||||
17162450|NCT00682435|t||||
17162451|NCT04902144|f||||f
17162452|NCT02129556|f||||f
17162453|NCT01049828|t||||f
17162454|NCT00290238|f||OTHER|If the PI expects to participate in the publication or presentation of data generated in the performance of the study, any reports, abstracts, manuscripts, or other presentation materials shall be submitted to the sponsor for review prior to submission for publication or presentation. The sponsor shall have 30 calendar days to respond with any requested revisions in order to protect the sponsor's confidential information.|t
17162455|NCT03772340|f||OTHER||t
17162456|NCT06868667|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17162457|NCT05330429|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17162458|NCT03572218|f||||f
17162459|NCT00286455|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17162460|NCT04826731|f||||f
17162461|NCT03404375|f||||f
17162462|NCT06097273|f||||t
17162463|NCT03181009|f||||f
17162464|NCT05894564|t||||
17162465|NCT03882801|f||OTHER|In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17162466|NCT03076164|t||||
17162467|NCT03532490|f||||f
17162468|NCT03548415|f||||t
17162469|NCT01803737|t||||
17162470|NCT01748552|t||||
17162471|NCT04630626|f||OTHER|Publication results vary per investigator and per clinical trial agreement.|t
17162472|NCT01260324|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162473|NCT03052257|t||||
17162474|NCT00004228|f||OTHER|Must obtain prior Sponsor approval.|t
17162475|NCT02255279|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162476|NCT03607695|f||||f
17162477|NCT02741193|t||||
17162478|NCT00527748|t||||
17162479|NCT02533674|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17162480|NCT02799290|t||||
17162481|NCT01292473|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162482|NCT00548691|f||LTE60||t
17162483|NCT00393380|f||||f
17162484|NCT05688657|f||||f
17162485|NCT01717859|f||||f
17162486|NCT04389671|f||OTHER|"The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement among Windtree and participating institutions.~The publication or presentation of any study results shall comply with all applicable privacy laws, including but not limited to HIPAA. Every attempt will be made to publish results in peer-reviewed journals."|t
17162487|NCT00474968|f||||f
17162488|NCT01111292|f||LTE60||t
17162489|NCT01750281|f||||f
17162490|NCT00673114|t||||
17162491|NCT00271570|f||||f
17162492|NCT00201773|t||||
17162493|NCT05463705|t||||
17162494|NCT05529173|t||||
17162495|NCT05574764|t||||
17162496|NCT04072432|f||||f
17162497|NCT01530997|f||GT60||t
17162498|NCT00965991|t||||
17162499|NCT02181738|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17162500|NCT02298491|f||||f
17162501|NCT02046200|f||||f
17162502|NCT01691482|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162503|NCT00183391|f||||f
17162504|NCT01986751|f||||f
17162505|NCT01478087|f||OTHER|The PI shall provide the sponsor with a copy of any proposed publication for review at least 60 days prior to submission to a publisher. The sponsor may request that any confidential information or intellectual property contained be removed, redacted, or modified. If the PI do not agree to such deletion or modification, they shall notify the sponsor and agree to postpone such submission for an additional 60 days to allow sponsor to file the appropriate applications or seek protective remedies.|t
17162506|NCT04576949|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17162507|NCT00407030|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 weeks before submission. Sponsor to give written opinion within 30 days. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17162508|NCT01489358|t||||
17162509|NCT00736476|f||GT60||t
17162510|NCT03193307|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162511|NCT02018809|f||||f
17162512|NCT03518203|f||||t
17162513|NCT02829957|t||||
17162514|NCT00625729|t||||f
17162515|NCT04560309|f||||f
17162516|NCT05085405|t||||
17162517|NCT01783236|f||||f
17162518|NCT01370538|f||GT60||t
17162519|NCT04193527|f||||f
17162520|NCT02366130|f||||f
17162521|NCT00567112|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17168436|NCT02956850|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168437|NCT00391391|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17168438|NCT02481713|t||||
17168439|NCT01920152|t||||
17168440|NCT01777945|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168441|NCT02165462|f||||f
17168442|NCT01995552|f||||t
17168443|NCT00353873|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168444|NCT01968057|f||GT60||t
17168445|NCT00506597|t||||f
17168446|NCT00870194|f||GT60||t
17168447|NCT02717130|f||||f
17162522|NCT06171399|f||||f
17162523|NCT04595370|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca AB.|t
17162524|NCT01945242|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17168448|NCT00554099|f||LTE60||t
17168449|NCT01443130|f||LTE60||t
17168450|NCT02818114|t||||
17168451|NCT02228343|t||||
17168452|NCT03461406|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17162525|NCT02512445|f||||f
17162526|NCT05661734|f||||t
17162527|NCT01125748|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162528|NCT02405962|f||||f
17168453|NCT00180297|f||||f
17168454|NCT01011933|f||LTE60||t
17168455|NCT01439074|f||||f
17168456|NCT00612508|f||||f
17168457|NCT02012686|f||||f
17168458|NCT01442064|f||||f
17168459|NCT01703065|f||||f
17168460|NCT02635347|t||||
17168461|NCT02144155|t||||
17168462|NCT00514020|t||||
17168463|NCT01688921|f||LTE60||t
17162529|NCT01028391|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162530|NCT01184118|f||||f
17162531|NCT00574353|t||||
17162532|NCT02946996|f||||f
17162533|NCT04967417|f||||f
17162534|NCT03020082|f||OTHER|After conclusion of the study and without prior written approval from Ascletis, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: The study has been completed at all study sites for at least 3 years.|t
17162535|NCT04359680|f||||f
17162536|NCT03254147|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162537|NCT03931785|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17162538|NCT02504775|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162539|NCT01723839|t||||
17162540|NCT04605588|t||||
17162541|NCT01230814|f||||f
17162542|NCT02527265|f||||t
17162543|NCT02596893|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17162544|NCT03280615|f||||f
17162545|NCT01529112|f||OTHER||t
17162546|NCT02683954|f||||f
17162547|NCT02502383|t||||
17162548|NCT00363467|t||||
17162549|NCT00903344|t||||
17162550|NCT01524705|t||||
17162551|NCT00090402|f||||f
17162552|NCT04250675|f||||f
17162553|NCT01530256|f||||f
17162554|NCT02164721|f||||f
17162555|NCT02004275|f||||f
17162556|NCT03912805|f||OTHER|Study Results are considered Confidential Information that may not be published or disclosed without Sponsor's written consent for a period of five (5) years after completion of the Study.|t
17162557|NCT04621786|f||||f
17162558|NCT01093885|f||||f
17162559|NCT00292370|f||||f
17162560|NCT02123511|t||||
17162561|NCT04821245|f||||f
17162562|NCT01133977|f||OTHER||t
17162563|NCT01291160|f||||f
17162564|NCT01975285|f||||f
17162565|NCT03074643|f||||f
17162566|NCT03615534|f||||f
17168464|NCT03780959|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to1 review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168465|NCT04064346|f||GT60||t
17162567|NCT00604383|f||GT60||t
17162568|NCT00281580|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17162569|NCT01122680|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17162570|NCT01550965|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17162571|NCT03760640|f||GT60||t
17162572|NCT03016403|f||||f
17162573|NCT00225758|f||||f
17162574|NCT00576407|t||||
17162575|NCT00621322|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162576|NCT00756444|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17162577|NCT00564070|f||||f
17162578|NCT01018056|f||||f
17162579|NCT01391299|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17162580|NCT03142334|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17162581|NCT03071965|f||||t
17162582|NCT01217047|t||||
17162583|NCT06399471|f||||f
17168466|NCT01636713|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168467|NCT02525094|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17168468|NCT00699218|t||||
17168469|NCT02242981|f||GT60||t
17168470|NCT01831817|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162584|NCT05587998|f||OTHER|AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17162585|NCT02043847|f||||f
17162586|NCT03892915|f||||f
17168471|NCT01858753|f||||f
17168472|NCT00940485|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168473|NCT05621239|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168474|NCT06687824|f||||f
17168475|NCT03921554|t||||
17168476|NCT03446053|f||||t
17168477|NCT03283150|t||||
17162587|NCT01181128|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17162588|NCT02371252|f||||f
17162589|NCT01362270|f||||f
17162590|NCT02318277|f||OTHER|Clinical Study Agreement|t
17168478|NCT02674425|f||OTHER|The sponsor must agree with the company partner involved in this study prior to public release. The company partner involved in this study can require changes to the communication and can extend the embargo for a period that is more than 180 days from the time submitted to the sponsor for review.|t
17168479|NCT01299571|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168480|NCT00864851|f||OTHER||t
17168481|NCT05810714|t||||
17168482|NCT03028987|f||||f
17168483|NCT01842581|f||OTHER|Please contact Sponsor directly for additional information.|t
17168484|NCT01287195|t||||
17168485|NCT03562793|t||||
17168486|NCT02006069|f||GT60||t
17168487|NCT00106691|f||OTHER|Disclosure restriction: PIs may publish/present trial results at med. conferences after 1st of 1 of following occurs: complete Multicenter Study publication presented/Sponsor confirms there won't be Multicenter Study publication/18 mos. elapsed after Study ends. PI:submits advance copy w/in 60 days. Sponsor:60 days to review. Sponsor:tells PI w/in 60 days the pres./pub. might have adverse effect to obtain patents on inventions or confidentiality of info, PI can't make pres/pub w/o changes|t
17168488|NCT00530920|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17168489|NCT01483209|t||||
17168490|NCT04957758|f||||t
17168491|NCT00707746|f||OTHER|Institution will submit for review a proposed publication or presentation at least 90 days prior to submission date. Sponsor has the right to delay publication or presentation for not more than 6 months to address patent applications. Sponsor also has the right to demand in writing the deletion of confidential information. Investigator will not make public raw study data, detailed subject cases, or information identifying any subject.|t
17168492|NCT02322190|f||||f
17168493|NCT01656629|t||||
17168494|NCT04904809|f||||f
17162591|NCT01520714|f||||f
17162592|NCT00395512|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17162593|NCT00185900|t||||f
17162594|NCT00754559|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17162595|NCT01663987|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17162596|NCT01829503|t||||
17162597|NCT03721965|f||OTHER|Clinical Study Agreement|t
17162598|NCT04913675|f||||t
17162599|NCT01341990|t||||
17162600|NCT02489045|f||||f
17162601|NCT03378336|f||||f
17162602|NCT01751685|t||||
17162603|NCT01940146|f||OTHER||t
17162604|NCT05181657|f||||f
17162605|NCT01348490|f||OTHER|Clinical Study Agreement|t
17162606|NCT04002557|f||||f
17162607|NCT01117350|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any abstract/manuscript for comment at least 20/45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17162608|NCT03389750|f||||f
17162609|NCT00800384|f||LTE60||t
17162610|NCT03361072|f||OTHER|Investigators will postpone single-site publications until after publication.|t
17162611|NCT03885206|f||||f
17162612|NCT01027754|t||||f
17162613|NCT00326495|f||||f
17162614|NCT00432991|t||||
17162615|NCT01489826|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or is agents) that restricts the PIs rights to discuss or publish trial results after the trial is completed.|t
17162616|NCT01755156|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17162617|NCT03142451|f||GT60||t
17162618|NCT00382928|f||||f
17162619|NCT01084759|f||||f
17162620|NCT03048019|f||LTE60||t
17162621|NCT02016885|f||||t
17162622|NCT00949078|t||||
17162623|NCT01716559|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17162624|NCT00782379|f||LTE60||t
17162625|NCT02284854|f||OTHER||t
17162626|NCT00662038|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162627|NCT03606213|t||||
17162628|NCT00397046|f||LTE60||t
17162629|NCT01749293|f||||f
17162630|NCT04189588|f||||f
17162631|NCT01655069|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 90 days prior to publication for review and comment. Sponsor may delay the publication temporarily to seek patent protection or permanently withhold the publication.|t
17162632|NCT04034056|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162633|NCT03225989|f||||t
17162634|NCT00601107|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17162635|NCT04130425|t||||f
17162636|NCT03722030|f||||f
17162637|NCT00147537|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162638|NCT02523040|f||||f
17162639|NCT02006654|f||||f
17162640|NCT00478140|f||LTE60||t
17162641|NCT01933425|t||||
17162642|NCT00676689|f||OTHER|Investigator will submit to Edwards all manuscripts or presentations authored by investigator and his/her collaborators which result from the Clinical Study at least thirty days prior to submission of the manuscript for publication or presentation.|t
17162643|NCT03438656|f||||f
17162644|NCT00684554|t||||f
17162645|NCT00563316|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17162646|NCT04217057|t||||
17162647|NCT02468700|f||||f
17162648|NCT01217411|f||LTE60||t
17162649|NCT03375164|f||OTHER||t
17162650|NCT02970812|f||||f
17162651|NCT04401293|t||||
17162652|NCT00291226|t||||
17182414|NCT02075840|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182415|NCT00846742|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17182416|NCT02775344|f||||f
17162653|NCT00694161|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162654|NCT03111732|f||||f
17162655|NCT01108055|f||||f
17162656|NCT00964444|t||||
17162657|NCT03339453|f||GT60||t
17162658|NCT00063232|t||||f
17162659|NCT03377127|f||||f
17162660|NCT00450749|f||LTE60||t
17162661|NCT01245049|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162662|NCT02151604|t||||
17162663|NCT04495478|f||OTHER|Neither Lilly or Supplier shall publish, discuss, or release data emanating from a study without the other party's express written permission which shall not be unreasonably withheld. Nothing herein shall limit supplier's right to respond to legal inquiries.|t
17162664|NCT00594308|t||||f
17162665|NCT00295503|f||||f
17162666|NCT03312114|t||||
17162667|NCT00944645|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162668|NCT03537729|t||||f
17162669|NCT04668599|t||||
17162670|NCT02562040|f||||f
17162671|NCT01654250|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162672|NCT01862029|t||||
17162673|NCT00504556|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site's proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.|t
17162674|NCT01013870|f||||f
17162675|NCT01386645|f||||f
17162676|NCT01052428|f||||f
17182417|NCT02650986|t||||
17182418|NCT03817320|f||GT60||t
17162677|NCT00871000|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162678|NCT03408808|t||||
17162679|NCT01990352|t||||
17162680|NCT04432298|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17162681|NCT02365064|f||||f
17162682|NCT00678574|t||||
17162683|NCT02451007|f||LTE60||t
17162684|NCT00348374|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162685|NCT01644331|f||GT60||t
17162686|NCT02062008|t||||f
17162687|NCT01631929|f||||f
17162688|NCT02327143|f||GT60||t
17162689|NCT01585207|f||||f
17162690|NCT02595437|f||GT60||t
17162691|NCT01531803|f||||f
17162692|NCT03777176|f||||t
17162693|NCT02551809|f||OTHER|Site PIs must jointly publish results, unless permission is granted by Sponsor. If a joint publication is not done within 12 months after trial completion and database lock, then the site may publish its own results; provided that, a) Sponsor has 45 business days to review the proposed publication; b) the PI must delete any confidential information identified by Sponsor; and c) the PI must delay disclosure for 1 year if a patent application is filed by Sponsor.|t
17162694|NCT03023683|f||||f
17162695|NCT02773537|t||||
17162696|NCT01840163|f||||f
17162697|NCT00383565|f||LTE60||t
17162698|NCT03992482|t||||
17162699|NCT03636269|f||||t
17162700|NCT01368185|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162701|NCT03008213|t||||
17162702|NCT03774810|f||||f
17162703|NCT02212977|t||||
17162704|NCT00290758|f||LTE60||t
17162705|NCT03436420|t||||
17162706|NCT04914000|t||||
17162707|NCT01429623|f||||f
17162708|NCT01834651|t||||f
17162709|NCT01896986|f||||f
17162710|NCT02728726|f||||f
17162711|NCT00793611|t||||
17162712|NCT00948935|t||||
17162713|NCT01061710|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168495|NCT01685983|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17162714|NCT03156621|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17182419|NCT03909165|f||OTHER|In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17182420|NCT04609020|f||||f
17182421|NCT02018458|t||||
17137858|NCT02528253|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137859|NCT01357980|f||||f
17162715|NCT03757715|f||||f
17162716|NCT03302936|t||||
17162717|NCT04299425|f||||f
17162718|NCT02350998|f||OTHER|Publication subject to Sponsor consent.|t
17162719|NCT01259024|t||||
17162720|NCT01657500|t||||
17162721|NCT00063362|t||||
17162722|NCT00619242|t||||
17182422|NCT00354172|t||||f
17182423|NCT01800916|f||LTE60||t
17182424|NCT00727714|t||||
17162723|NCT00986102|f||GT60||t
17182425|NCT00325234|f||GT60||t
17182426|NCT01234467|f||GT60||t
17162724|NCT06083493|t||||
17168496|NCT00685373|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162725|NCT03093870|f||||f
17168497|NCT02642965|f||OTHER|Must obtain prior sponsor approval|t
17168498|NCT01167907|t||||
17168499|NCT00857948|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17168500|NCT00701636|f||||f
17168501|NCT03077698|f||||t
17168502|NCT03123614|f||||f
17168503|NCT00973102|t||||
17168504|NCT00853840|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17168505|NCT03099148|f||GT60||t
17168506|NCT01439126|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17168507|NCT01710527|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168508|NCT03923582|t||||
17168509|NCT02124772|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17168510|NCT01617447|f||||f
17168511|NCT01075971|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17168512|NCT02713529|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168513|NCT02367391|f||||f
17168514|NCT00780273|f||||f
17168515|NCT02827500|f||||f
17168516|NCT02358044|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17168517|NCT04498377|f||||f
17168518|NCT02308488|t||||
17168519|NCT01739803|f||||f
17168520|NCT01428336|f||||f
17168521|NCT02423122|f||LTE60||t
17168522|NCT02248740|t||||
17168523|NCT02645617|f||||f
17168524|NCT02210091|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, results may not be published without prior written approval of Sponsor.|t
17168525|NCT02739321|f||||f
17168526|NCT02290938|t||||
17168527|NCT01294163|f||OTHER||t
17162726|NCT04008069|f||||f
17162727|NCT02134028|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17162728|NCT00449007|f||||f
17162729|NCT00819832|t||||f
17162730|NCT00930787|f||||f
17162731|NCT04957082|f||||f
17162732|NCT02719366|f||||f
17168528|NCT05065190|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168529|NCT04938037|f||||f
17162733|NCT01260311|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162734|NCT01452789|f||||f
17162735|NCT00066170|f||OTHER||t
17162736|NCT00098293|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162737|NCT01370642|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17162738|NCT01928576|f||||t
17162739|NCT01796470|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17162740|NCT01927861|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17162741|NCT00987935|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17162742|NCT01089543|f||||f
17162743|NCT02222181|f||||f
17162744|NCT01248468|f||OTHER|Data of \&/or resulting from the performance of the Clinical Trial (CT) shall be pooled with the data from other centers \& analyzed as stipulated in the Protocol.Without the consent of the steering committee of the multi-center CT, no presentation/publication of the results obtained from datasets other than the final pooled dataset shall be made prior to the presentation/ publication based on the final pooled dataset.|t
17162745|NCT00345592|f||||f
17162746|NCT03124602|t||||
17162747|NCT02176525|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168530|NCT03350906|t||||
17168531|NCT03320330|f||OTHER|Must obtain prior sponsor approval|t
17168532|NCT00203021|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17168533|NCT01410812|t||||
17168534|NCT02936284|f||||f
17168535|NCT04284813|f||||f
17162748|NCT00468546|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17162749|NCT00472641|f||||f
17162750|NCT03721107|f||||t
17162751|NCT01189227|f||LTE60||t
17162752|NCT03000751|f||||f
17162753|NCT01213251|f||LTE60||t
17137860|NCT00393068|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17137861|NCT02293993|f||||f
17162754|NCT02529488|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17162755|NCT00324857|t||||
17162756|NCT01557244|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162757|NCT01428713|t||||f
17162758|NCT00862277|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17162759|NCT03400787|f||GT60||t
17162760|NCT01889563|f||||f
17162761|NCT01282138|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17162762|NCT02070380|f||OTHER|Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement|t
17162763|NCT01507103|f||OTHER|"The Investigator will inform the Sponsor in advance about any plans to publish or present data from the trial. Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their representatives will require pre-submission review by the Sponsor.~The Sponsor will not suppress or veto publications, but maintains the right to delay publication in order to protect intellectual property rights."|t
17162764|NCT02242903|f||GT60||t
17162765|NCT03939494|f||||f
17162766|NCT02105012|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17162767|NCT00493285|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17162768|NCT04535362|t||||
17162769|NCT03791060|f||||f
17162770|NCT00943202|f||LTE60||t
17162771|NCT02619812|t||||
17162772|NCT00981175|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17162773|NCT04032327|t||||
17162774|NCT01658735|f||||f
17162775|NCT01379937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168536|NCT03859739|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17162776|NCT01104870|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17162777|NCT01694186|f||||t
17162778|NCT00501943|t||||
17162779|NCT02134808|f||||f
17162780|NCT02317042|f||OTHER|"The Sponsor has the right to~* review~* provide comments (site is not bound to follow them)~* request delay of publication for no more than 120 days to allow for securing of IP~* request the removal of specified confidential information~within 40 days of the proposed publication being released to those not bound by confidentiality obligations."|t
17162781|NCT03093246|f||||f
17162782|NCT00079781|f||OTHER|Each Investigator, Coordinator, and Institution agree to submit publications to the RNS® System Study Publication Committee for review prior to submission for publication (at least 30 days for manuscripts and at least 7 days for abstracts) to assure that publication does not compromise the scientific integrity of the study or contain confidential NeuroPace information. NeuroPace may require that presentation/publication be withheld for up to 60 days to allow for filing of a patent application.|t
17162783|NCT04641975|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17162784|NCT01431573|t||||
17162785|NCT00087672|t||||f
17162786|NCT02067156|f||LTE60||t
17162787|NCT03596983|t||||
17162788|NCT05287685|t||||f
17162789|NCT02201628|t||||
17168537|NCT01146652|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17168538|NCT02499692|f||LTE60||t
17168539|NCT03476876|f||LTE60||t
17168540|NCT01300351|f||||f
17168541|NCT00431951|f||OTHER|The PI must obtain the sponsor's written consent to publish any study results and must notify the sponsor within 30 working days prior to publishing.|t
17168542|NCT00343863|t||||
17168543|NCT00673881|t||||
17168544|NCT00096018|f||||f
17168545|NCT00689793|f||||f
17162790|NCT02261532|f||||f
17162791|NCT02777190|f||||f
17162792|NCT03063164|t||||
17162793|NCT01340170|f||||f
17162794|NCT03733483|f||||f
17168546|NCT01100528|t||||
17168547|NCT03968159|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's Prior written consent. At least 60 days prior to submitting a manuscript or Prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17168548|NCT01342549|t||||
17168549|NCT05260333|f||||f
17168550|NCT00686842|f||||f
17168551|NCT01335750|f||||f
17168552|NCT01541917|f||||f
17168553|NCT00047619|f||||f
17168554|NCT01014455|t||||
17168555|NCT00094107|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168556|NCT00525824|f||||f
17168557|NCT04728594|t||||
17168558|NCT01497613|f||||f
17168559|NCT00128713|f||||f
17168560|NCT01378429|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17168561|NCT01018095|f||||f
17168562|NCT02356887|t||||
17168563|NCT01490294|f||LTE60||t
17168564|NCT00199888|f||||f
17168565|NCT02030288|t||||
17168566|NCT01751776|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168567|NCT05714943|t||||
17168568|NCT05219669|f||||f
17162795|NCT00452530|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17162796|NCT01378273|f||||f
17162797|NCT01608308|f||||f
17162798|NCT04648241|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162799|NCT02057666|f||OTHER|The Sponsor required reasonable opportunity to review any abstract, presentation, or paper before the material was submitted for publication or communicated. This also applied to any amendments that were requested by referees or journal editors. The Sponsor committed to comment on the draft documents within a time period agreed in the contractual arrangements between the Sponsor and authors or their institution. Delays were also possible if publication would adversely affect patentability.|t
17162800|NCT05259722|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17162801|NCT00962650|f||||f
17162802|NCT02402036|t||||
17162803|NCT00308282|f||GT60||t
17162804|NCT00498485|f||||f
17162805|NCT01539525|f||||f
17162806|NCT01712074|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162807|NCT02268851|t||||
17162808|NCT02474901|f||||f
17162809|NCT02539394|f||||f
17162810|NCT01472835|f||||f
17162811|NCT02903381|t||||f
17162812|NCT02205359|f||||t
17162813|NCT00236197|f||OTHER||t
17162814|NCT00667589|t||||
17162815|NCT02792257|f||||f
17162816|NCT00553475|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17162817|NCT04921800|t||||
17162818|NCT04028960|t||||
17162819|NCT02043860|f||||f
17162820|NCT00992394|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162821|NCT01905683|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17162822|NCT01395537|t||||
17162823|NCT00537082|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17162824|NCT02568254|f||GT60||t
17162825|NCT00655746|t||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17162826|NCT03645681|f||||f
17162827|NCT01793129|f||||f
17162828|NCT04128215|f||||f
17168569|NCT01902459|f||LTE60||t
17168570|NCT01122108|t||||
17168571|NCT02404649|f||LTE60||t
17168572|NCT04075409|f||GT60||t
17168573|NCT02382848|t||||f
17168574|NCT00330668|f||OTHER|Each investigator may publish or report data from their own subjects. The trial data in aggregate are the property of Tercica, Inc. and may not be published without permission of Tercica, Inc. Tercica, Inc. will be the final arbitrator of issues relating to the publication or presentation of the aggregate data.|t
17168575|NCT01839656|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17168576|NCT01595581|t||||
17168577|NCT00408590|t||||
17137862|NCT00094835|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17137863|NCT00126581|f||LTE60||t
17137864|NCT00793182|f||||f
17137865|NCT02384395|t||||
17162829|NCT01926509|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17162830|NCT03004183|t||||
17162831|NCT03681093|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17162832|NCT02698787|f||||t
17162833|NCT05033561|f||OTHER|The PI and/or the Institution are not entitled to publish or present any study information, either partial or complete, without written approval by FIDEC.|t
17162834|NCT01882829|t||||
17162835|NCT03453515|f||||f
17168578|NCT02621073|f||||f
17168579|NCT01440881|f||||f
17168580|NCT03474081|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168581|NCT00693654|f||||f
17168582|NCT01176955|f||||f
17168583|NCT01058941|f||||f
17168584|NCT02920957|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17168585|NCT01274611|t||||
17168586|NCT02644356|f||||f
17168587|NCT03449433|f||GT60||t
17168588|NCT01557881|t||||
17168589|NCT01711866|f||GT60||t
17137866|NCT00550277|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17137867|NCT04295356|f||||t
17162836|NCT01313676|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162837|NCT00800345|f||LTE60||t
17162838|NCT02469961|f||||f
17162839|NCT02935036|f||||t
17162840|NCT03435107|f||||f
17162841|NCT05130281|t||||
17162842|NCT06844812|f||||f
17162843|NCT04566510|t||||
17162844|NCT00368849|t||||
17162845|NCT02006836|t||||
17162846|NCT01699685|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17162847|NCT03635996|f||OTHER||t
17162848|NCT05058456|f||||t
17162849|NCT02933151|f||||f
17162850|NCT04392362|f||||f
17162851|NCT02925143|f||||f
17162852|NCT03850431|t||||
17162853|NCT01034657|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17162854|NCT01791205|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17162855|NCT01433081|f||||f
17162856|NCT04985682|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17162857|NCT03374956|t||||
17162858|NCT01546987|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17162859|NCT02197065|f||||f
17162860|NCT05938816|t||||
17162861|NCT03878602|f||||f
17162862|NCT02191397|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162863|NCT04629521|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17162864|NCT01618708|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17162865|NCT04792970|t||||
17162866|NCT02554474|f||||f
17162867|NCT03211832|f||||f
17162868|NCT02770365|f||OTHER|PI's cannot disclose trial results under any circumstances.|t
17162869|NCT02991859|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17162870|NCT01065766|f||OTHER|In regard to surveillance result, any publication should be agreed by sponsor in advance.|t
17162871|NCT00712075|t||||
17162872|NCT02268305|f||||f
17162873|NCT00908908|f||||f
17162874|NCT04223687|t||||f
17162875|NCT00425854|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17168590|NCT01345682|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137868|NCT04268004|t||||
17162876|NCT02882178|t||||
17162877|NCT03189433|f||OTHER|The Pi is not permitted to discuss or publish trial results.|t
17162878|NCT01064284|f||||f
17162879|NCT05652140|f||||f
17162880|NCT06048705|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17162881|NCT01016015|f||LTE60||t
17168591|NCT00795288|f||||f
17162882|NCT01602666|f||OTHER|Must obtain prior approval|t
17162883|NCT03000166|f||||f
17162884|NCT01331330|f||||f
17162885|NCT03069937|f||||f
17162886|NCT03624036|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17162887|NCT02774278|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162888|NCT01312675|f||OTHER|"Study sites are able to publish on their own data if Sponsor does not publish a multi-center study paper within 18 months after trial completion.~Sites agree to submit any proposed publication, presentation or other public disclosure to Sponsor for review at least 30 days prior to submitting to a publisher or other 3rd party. Within 30 days of receipt, Sponsor shall advise removal of any confidential information or which may impair Sponsor's ability to obtain patent protection."|t
17162889|NCT00127933|f||||f
17162890|NCT01339013|t||||
17162891|NCT01783938|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17162892|NCT03478787|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168592|NCT00897390|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168593|NCT00958217|f||||f
17168594|NCT04350307|f||||f
17168595|NCT01075984|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts.|t
17168596|NCT01685021|f||OTHER|As specified in the respective clinical trial agreements with the PI.|t
17168597|NCT02198235|t||||
17168598|NCT01742065|f||||f
17168599|NCT03052530|f||||t
17168600|NCT02440789|f||||f
17168601|NCT02410577|t||||
17168602|NCT04573881|f||OTHER||t
17168603|NCT02564978|t||||
17168604|NCT03684694|f||OTHER|PI can publish after first multi-site publication or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on PI is sponsor can review results comms. prior to public release and can embargo comms. Regarding trial results for a period \>60 but ≤180 days from time submitted to sponsor review. Sponsor can't require changes to the comms, extend embargo or require changes to comms, except removing confidential info that are not results.|t
17168605|NCT00474617|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17168606|NCT01825941|t||||
17137869|NCT03783442|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17137870|NCT01381718|f||||f
17162893|NCT00089583|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162894|NCT00954538|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17168607|NCT00528996|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17168608|NCT01307462|f||||f
17168609|NCT02349685|f||OTHER||t
17168610|NCT03875664|f||||f
17168611|NCT05565937|f||||t
17168612|NCT01022424|f||||f
17168613|NCT02706197|t||||
17168614|NCT04253587|t||||f
17168615|NCT01806064|f||||f
17168616|NCT01330966|f||||t
17137871|NCT04150562|f||||f
17162895|NCT03338686|f||||f
17168617|NCT01885910|t||||
17168618|NCT03046225|t||||
17168619|NCT05160766|f||||f
17162896|NCT03178942|f||OTHER|In the Clinical Trials Agreements between the sites and the Contract Research Organization, sites are instructed that the Investigator shall not publish, or seek to publish, either in whole or in part any results of the Study without the written consent.|t
17162897|NCT01657942|f||OTHER|PI needs to consult Sponsor for accuracy of trial results and approval before being published|t
17162898|NCT06896734|f||||f
17162899|NCT03061214|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17162900|NCT01832038|f||GT60||t
17162901|NCT01267136|t||||f
17162902|NCT02722330|f||GT60||t
17162903|NCT01934231|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162904|NCT00101400|f||GT60||t
17162905|NCT04565353|t||||
17162906|NCT05333965|f||||f
17162907|NCT00382863|f||||f
17162908|NCT02168439|f||||f
17162909|NCT02685436|t||||
17162910|NCT00605657|t||||
17162911|NCT02180672|f||||f
17162912|NCT02837952|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162913|NCT01362530|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17162914|NCT04315961|f||||f
17168620|NCT01282294|f||OTHER|"A single comprehensive publication may be authored on the procedure and outcomes of the trial. Sites that enroll less than five patients will not be included in the publication. Synthes GmbH will have the right to review prior to submission.~Each clinical site that enrolls ten patients will have the option to submit an abstract for publication or presentation at a regional, national, or international conference on their work. Synthes GmbH will have the right to review prior to submission."|t
17168621|NCT05970120|f||OTHER|Publications and/or presentation of clinical investigation results will be coordinated and governed between Biosense Webster, Inc., the clinical investigation author(s) and if applicable local law. Authorship will be determined prior to development of any manuscript.|t
17162915|NCT01772693|f||||f
17162916|NCT04250363|f||||f
17162917|NCT03021005|f||||f
17162918|NCT00276380|f||||f
17162919|NCT03473301|t||||
17162920|NCT04829214|f||LTE60||t
17162921|NCT05071027|t||||
17168622|NCT00004445|f||||f
17168623|NCT04692077|f||||f
17168624|NCT04243330|t||||
17168625|NCT02753127|f||||f
17162922|NCT04635280|f||OTHER|The only disclosure restriction on the PI is that the Sponsor can review results communications prior to public release. According to Article R. 5121-13 of the French Public Health Code, the results of the Research may not be published or the subject of written or oral communications by the PI without prior written consent of the Sponsor.The disclosure restriction applies to the Parties during the entire duration of the agreement and as long as the confidential data are not in the public domain.|t
17162923|NCT04135352|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17162924|NCT00511199|f||OTHER|The SPONSOR recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the SPONSOR. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the SPONSOR, at least six weeks ahead of estimated publication or presentation, for consent, which shall not be withheld unreasonably.|t
17162925|NCT04601493|t||||
17162926|NCT03255200|f||||f
17168626|NCT03826342|t||||
17168627|NCT01694108|f||||f
17168628|NCT01657760|t||||
17168629|NCT02506660|t||||
17168630|NCT02961946|t||||
17168631|NCT04555837|t||||
17168632|NCT06250738|t||||
17162927|NCT02739828|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17162928|NCT02314247|f||||t
17162929|NCT01953354|f||||f
17162930|NCT01392495|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17162931|NCT02571244|f||||f
17162932|NCT00483509|f||||t
17162933|NCT01696214|f||||f
17162934|NCT01570192|f||GT60||t
17162935|NCT02965976|t||||
17162936|NCT00806026|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17162937|NCT01687595|f||||t
17162938|NCT01307618|f||LTE60||t
17162939|NCT03180138|f||||f
17162940|NCT01775410|f||LTE60||t
17162941|NCT01905267|f||||f
17162942|NCT03888482|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17162943|NCT03907579|t||||
17162944|NCT00567229|t||||
17162945|NCT00979615|f||||f
17162946|NCT01630811|f||||f
17162947|NCT04818086|t||||
17162948|NCT03319654|f||||f
17162949|NCT01725308|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment.|t
17162950|NCT05094102|t||||
17162951|NCT02364271|f||||f
17162952|NCT04128228|t||||f
17162953|NCT03511209|t||||
17162954|NCT03163264|t||||f
17162955|NCT01444924|t||||f
17162956|NCT00215657|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17162957|NCT03769467|f||||t
17162958|NCT02614066|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17162959|NCT04565756|f||||f
17162960|NCT04274218|t||||
17162961|NCT05226884|t||||f
17162962|NCT00968968|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17162963|NCT01185366|t||||f
17162964|NCT01691313|f||OTHER||t
17162965|NCT00025233|f||LTE60||t
17162966|NCT00066937|f||||f
17162967|NCT03072875|f||||f
17162968|NCT01720602|t||||f
17162969|NCT04679818|t||||f
17162970|NCT02413346|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17162971|NCT02403778|f||||f
17162972|NCT01044693|f||||f
17162973|NCT01316900|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17162974|NCT02427672|f||||f
17162975|NCT01684033|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17162976|NCT02687165|f||||f
17162977|NCT00507507|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17162978|NCT02916433|t||||f
17162979|NCT01623154|f||OTHER|Central/Principal Investigator may publish the results of the study. However, at least 60 days prior to submitting to a publisher or a public presentation, a copy of the manuscript will be provided to the Sponsor for review. PI understands and agrees that as such, participation in the study involves a commitment to publish the data from the study in a cooperative publication prior to publication or oral presentation of efficacy/safety results on an individual basis.|t
17162980|NCT01412983|f||OTHER||t
17162981|NCT00890097|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17162982|NCT00684138|f||OTHER||t
17162983|NCT02290574|t||||
17162984|NCT00600704|t||||
17162985|NCT01509404|f||||f
17162986|NCT00185614|f||||f
17162987|NCT00107614|t||||
17162988|NCT02918630|t||||
17162989|NCT02389738|t||||
17162990|NCT02715856|t||||
17162991|NCT02462057|f||||f
17162992|NCT02336555|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17162993|NCT01633112|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17162994|NCT01908699|f||GT60||t
17162995|NCT01697501|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17162996|NCT05084885|t||||f
17162997|NCT02094885|f||LTE60||t
17162998|NCT03917901|f||||f
17162999|NCT00889005|f||||f
17163000|NCT04498273|t||||
17163001|NCT04046952|f||||f
17168633|NCT03493607|f||OTHER|The Investigators agree not to publish reports, abstracts, or other data compilations concerning the Study before the first multi-site publication by Sponsor. If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study locations, Principal Investigator shall have the right to publish and or present the results of the Study generated or collected at Study Site(s) (but not the results of any other Study location).|t
17168634|NCT00419315|f||||f
17137872|NCT00992186|f||OTHER|If Investigator wishes to publish information from study, a copy of manuscript must be provided to Sponsor for review at least 60 days before publication. Expedited reviews will be arranged for abstracts, poster presentations. If requested by Sponsor in writing, Investigator will withhold such publication for up to additional 60 days to allow for patent filing. If the issues arise regarding scientific integrity or regulatory compliance, Sponsor will review them with Investigator.|t
17137873|NCT00830960|f||GT60||t
17137874|NCT01504971|f||||f
17163002|NCT00215553|f||GT60||t
17163003|NCT00756314|t||||
17163004|NCT02944461|f||||f
17163005|NCT02605967|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17163006|NCT02193347|t||||
17168635|NCT01818284|t||||
17163007|NCT01079390|f||||f
17168636|NCT03681678|t||||
17163008|NCT00159874|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163009|NCT01234714|t||||
17163010|NCT04019704|f||||t
17163011|NCT01475825|f||GT60||t
17163012|NCT02570425|t||||
17163013|NCT00309946|f||LTE60||t
17163014|NCT04045145|f||||t
17163015|NCT02579057|f||||f
17163016|NCT01347086|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163017|NCT03232892|t||||
17163018|NCT00395447|f||OTHER|All information obtained from BIOTRONIK or PharmaLink concerning the research ideas used in this study and all information obtained under or concerning this study is considered BIOTRONIK property. Investigator will maintain such information in confidence and not release it to anyone without written consent from BIOTRONIK or prior public disclosure, with the exception of information required by law or regulations to be disclosed to the reviewing IRB, the patient, or the FDA.|t
17163019|NCT02090894|t||||f
17163020|NCT02264821|f||||f
17163021|NCT00489359|f||GT60||t
17163022|NCT03719300|f||||f
17163023|NCT02100644|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163024|NCT00728182|f||OTHER|The Investigator shall have the right to publish any information after prior submittal to NoNO, where NoNO can request a hold for up to 60 days, provided that no publication shall disclose Proprietary Information other than Data containing the results of the Study. Investigators may not publish in the first 18 months after the close of the trial except within a publication representing all participating clinical sites.|t
17163025|NCT02236767|t||||f
17163026|NCT01898091|f||||f
17163027|NCT04754399|t||||
17163028|NCT00231465|t||||
17163029|NCT03782103|f||||f
17163030|NCT00930176|f||GT60||t
17163031|NCT03406975|t||||
17163032|NCT00401830|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17168637|NCT01068249|t||||
17168638|NCT04979910|f||||f
17163033|NCT01943825|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17163034|NCT00452400|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17163035|NCT03315559|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163036|NCT03378635|f||||f
17163037|NCT01098578|t||||
17163038|NCT03425188|f||OTHER|Without prior written agreement of the Sponsor, Research Institution and site Principal Investigator agree not to publish results for at least 1 year from finalization of the study database, after which time site Principal Investigator may publish or submit for publication a Manuscript without further delay subject to the sponsor having 60 days to review the proposed publication and additional 90 day provision if intellectual property is at risk to allow time for submitting patent applications.|t
17163039|NCT02978508|f||||f
17163040|NCT00562861|f||||f
17163041|NCT01694771|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163042|NCT03721367|f||||f
17163043|NCT01941628|f||||f
17163044|NCT00289900|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17163045|NCT01152385|f||||f
17163046|NCT02656173|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163047|NCT01064622|f||LTE60||t
17163048|NCT04132427|f||||f
17163049|NCT01426555|f||||f
17163050|NCT05177328|f||||f
17163051|NCT03927846|t||||
17163052|NCT03289741|t||||
17163053|NCT02318979|f||||f
17163054|NCT01157429|f||||f
17163055|NCT02037984|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17163056|NCT00974233|f||||f
17163057|NCT01691092|f||||f
17163058|NCT04857281|f||||f
17163059|NCT01569763|f||OTHER|Investigator has the right to publish their research for non-profit and academic purposes, provided the 1st publication of results shall be in conjunction with results from all centers in this Study. If Investigator desires to publish/present data obtained by Investigator, following completion of the Study at all sites, Investigator may do so, provided a copy of proposed publication/presentation is received by Company for review/comment at least 15 days in advance of submission for publication.|t
17163060|NCT03211858|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17163061|NCT01866150|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163062|NCT03810365|t||||
17168639|NCT04030962|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168640|NCT05288166|f||LTE60||t
17168641|NCT01114360|t||||
17168642|NCT03007745|f||||f
17168643|NCT02811913|f||||f
17168644|NCT01146288|t||||
17168645|NCT00385723|t||||
17168646|NCT03455829|f||||t
17168647|NCT01305655|t||||
17168648|NCT05824936|f||||f
17168649|NCT03689712|f||OTHER|A copy of the proposed manuscript (or other document) for publication, presentation or other disclosure must be forwarded to the sponsor not less than 30 days prior to submission or presentation and the Principal Investigator shall comply with Sponsor's requests to delete or revise references to Confidential Information and consider all other comments of Sponsor in good faith.|t
17168650|NCT01221194|f||||f
17168651|NCT03842683|t||||f
17163063|NCT03137407|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17163064|NCT03160573|f||||f
17163065|NCT01620047|f||||f
17163066|NCT02402907|t||||f
17163067|NCT00594997|f||||f
17163068|NCT01423084|f||GT60||t
17163069|NCT00661687|f||LTE60||t
17163070|NCT01682603|t||||
17168652|NCT01533922|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168653|NCT02634606|f||||f
17168654|NCT00286221|t||||
17168655|NCT00889200|f||||f
17168656|NCT02276547|f||LTE60||t
17168657|NCT01754194|f||||f
17168658|NCT00907296|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168659|NCT03208530|f||||f
17168660|NCT03344640|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17168661|NCT01403376|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The Investigator provides the Sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.~The Sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as the Sponsor deems appropriate to establish and preserve its proprietary rights."|t
17163071|NCT01959919|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/ termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163072|NCT03992872|t||||
17163073|NCT03707821|f||GT60||t
17168662|NCT00815191|t||||
17168663|NCT02576860|f||||f
17163074|NCT00128492|f||OTHER|Institution and investigator may publish or present the results of the trial generated there with prior written consent of Gilead; or 2 years after the trial has ended at all institutions. Proposed publications/target venue must go to Gilead 30 days (manuscripts) or 15 days (abstracts/presentations) prior. Any Gilead confidential information in the document(s) must be deleted or, if requested publication, delayed for up to 45 days to permit Gilead to obtain intellectual property protection.|t
17163075|NCT00612768|f||||f
17163076|NCT04629157|f||||f
17163077|NCT03956082|f||||f
17163078|NCT00692237|t||||
17163079|NCT03111108|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17163080|NCT02771145|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17163081|NCT02662582|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163082|NCT05463952|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168664|NCT01985763|t||||f
17168665|NCT03335254|f||OTHER|"Sponsor will review and provide prior written consent, which shall not be unreasonably withheld.~PI will be permitted to publish in journals, theses, dissertations, or other formats of their own choosing."|t
17168666|NCT01355796|f||||f
17168667|NCT00860015|t||||
17168668|NCT02621398|t||||
17168669|NCT00424268|f||OTHER|The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.|t
17168670|NCT00160654|f||GT60||t
17168671|NCT05216627|t||||f
17168672|NCT02544373|f||||f
17168673|NCT03172130|f||||f
17168674|NCT03295396|f||OTHER|Within 12 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given the opportunity to review and comment. Institution publications may be delayed up to an additional 90 days to allow the Sponsor to seek patent protection.|t
17168675|NCT02218593|t||||
17163083|NCT01903733|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163084|NCT02395627|t||||
17163085|NCT00318136|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163086|NCT02852005|f||||f
17163087|NCT05370209|f||||f
17163088|NCT02294019|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163089|NCT02369159|f||||f
17163090|NCT03769116|f||OTHER||t
17163091|NCT04743206|f||||f
17163092|NCT02844075|f||||f
17163093|NCT04409418|t||||
17163094|NCT01217515|f||LTE60||t
17163095|NCT01887600|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163096|NCT03688139|t||||f
17163097|NCT00420056|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163098|NCT02069184|f||||f
17163099|NCT02470377|f||||f
17163100|NCT03274661|t||||
17163101|NCT01083472|f||OTHER||t
17163102|NCT01390584|f||LTE60||t
17163103|NCT00907088|t||||
17163104|NCT01292538|f||||f
17163105|NCT01835431|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication|t
17163106|NCT02301793|t||||
17163107|NCT00655356|f||OTHER|Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval.|t
17163108|NCT00480025|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163109|NCT04634331|f||||f
17163110|NCT02189629|f||OTHER|All data or results arising out of the study will not be presented or published in any form or media by the PI/Institution without the prior written consent of sponsor.|t
17163111|NCT02766478|t||||
17163112|NCT02496156|f||||f
17163113|NCT03760666|f||||f
17163114|NCT03708770|f||||f
17163115|NCT04349098|f||||t
17163116|NCT01703221|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17137875|NCT03483116|f||OTHER|The Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the Sponsor such approval will not to be unreasonably withheld|t
17163117|NCT05486065|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17163118|NCT03878069|f||LTE60||t
17163119|NCT00834587|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163120|NCT00176254|f||||f
17163121|NCT03810495|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17163122|NCT00879619|t||||
17163123|NCT02536339|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163124|NCT03449147|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17163125|NCT00527878|t||||f
17168676|NCT01882868|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17168677|NCT02783170|f||||f
17168678|NCT02943915|f||||f
17163126|NCT02931539|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17168679|NCT05601102|t||||
17168680|NCT04908280|t||||
17168681|NCT02981524|t||||
17163127|NCT02059642|f||OTHER|"Publication of the Study results in scientific literature is encouraged, but any publication should require gaining prior approval from the Company and the Company reserves the right to review any paper written utilizing data generated from the Study before such paper is presented or submitted for publication."|t
17163128|NCT03508440|t||||
17163129|NCT02730169|f||||f
17163130|NCT06358144|f||||f
17163131|NCT04804709|t||||f
17163132|NCT02144337|t||||
17163133|NCT01730729|f||||f
17163134|NCT00449787|t||||f
17163135|NCT03701074|t||||
17163136|NCT02695771|t||||
17163137|NCT03574389|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163138|NCT00993473|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17163139|NCT05122143|f||||f
17163140|NCT03766906|t||||f
17163141|NCT02624687|f||||f
17163142|NCT00552279|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163143|NCT00983801|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17163144|NCT01651208|f||||f
17163145|NCT00836901|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163146|NCT00830336|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163147|NCT02772302|f||||f
17163148|NCT01853280|f||||f
17163149|NCT03032484|t||||
17163150|NCT01229111|f||LTE60||t
17163151|NCT01689649|f||||f
17163152|NCT04526158|f||||f
17163153|NCT03760081|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163154|NCT03533491|t||||
17163155|NCT02517918|t||||
17163156|NCT05702047|t||||
17137876|NCT02703987|f||OTHER|"Results communication be submitted to Nutricia Research for review and comment prior to publication at least sixty (60) days prior to submission for publication, public dissemination, or review by a publication committee.~All reasonable comments made by Nutricia Research in relation to a proposed publication by Contractor will be incorporated into the publication."|t
17137877|NCT00426556|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17163157|NCT05263791|f||||f
17137878|NCT00225212|t||||
17137879|NCT03438578|t||||
17137880|NCT01519063|t||||f
17137881|NCT01583452|f||||f
17163158|NCT04576481|f||||f
17163159|NCT05261490|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163160|NCT02732145|f||||f
17163161|NCT01244412|f||LTE60||t
17163162|NCT01722734|t||||
17163163|NCT01837550|f||||f
17163164|NCT01971593|f||||f
17163165|NCT01682720|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17163166|NCT04204902|f||OTHER||t
17163167|NCT03876808|t||||
17163168|NCT04191733|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17163169|NCT00928720|t||||f
17163170|NCT02349477|f||||f
17163171|NCT01714063|f||||f
17163172|NCT01646216|f||||f
17137882|NCT01182337|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication at least 60 days prior to the intended submission, presentation, or publication date.|t
17137883|NCT03448224|t||||
17163173|NCT02633527|f||OTHER||t
17163174|NCT04717479|f||||f
17163175|NCT01681849|t||||
17163176|NCT04135443|f||||f
17163177|NCT00979407|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168682|NCT00483041|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17168683|NCT03119389|f||||f
17168684|NCT00413010|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17168685|NCT01189292|t||||
17168686|NCT00708734|f||||f
17168687|NCT02688868|f||||t
17168688|NCT00895661|t||||f
17168689|NCT02066129|f||||f
17168690|NCT00357656|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication. Baxalta requires a review of results communication (e.g. for confidential information) \>= 30 days prior to submission. Baxalta may request an additional delay of \<=120 days (e.g. for intellectual property protection).|t
17168691|NCT02573246|f||||f
17168692|NCT01219933|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168693|NCT01902888|f||||f
17168694|NCT00316888|f||LTE60||t
17163178|NCT01166646|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public dissemination. The PI may not disclose previously undisclosed confidential information other than study results.|t
17163179|NCT02420314|f||||f
17163180|NCT03760068|f||LTE60||t
17163181|NCT03856177|f||||f
17163182|NCT00846482|f||||f
17163183|NCT03777020|f||||f
17163184|NCT00489476|f||LTE60||t
17163185|NCT03460704|f||||f
17163186|NCT03888287|t||||
17163187|NCT02913326|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163188|NCT01767857|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17163189|NCT04126174|t||||
17163190|NCT03138382|f||||f
17163191|NCT01514422|t||||
17163192|NCT00214526|f||LTE60||t
17163193|NCT03784300|f||LTE60||t
17163194|NCT03657407|f||||f
17163195|NCT02628145|t||||f
17163196|NCT01044459|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17163197|NCT04105725|f||||f
17163198|NCT00966446|t||||
17163199|NCT03726879|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163200|NCT01093573|t||||
17163201|NCT05626686|f||GT60||t
17163202|NCT04681885|f||LTE60||t
17163203|NCT00581100|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17163204|NCT04744831|f||||f
17163205|NCT05170061|f||||f
17168695|NCT03149003|f||OTHER|Institution shall submit to Sponsor for its review a copy of any proposed publication resulting from the study at least thirty days prior to the date of submission for publication. Sponsor shall complete its review within thirty days of its receipt of the proposed publication.|t
17168696|NCT04135859|f||||f
17168697|NCT01291836|f||OTHER||t
17163206|NCT00385515|f||OTHER|Individual investigators are restricted from disclosure of results until 24 months after the completion of the Study at all participating research centers. Sponsor can review results communication prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days.|t
17163207|NCT03676270|t||||
17163208|NCT04616196|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results after the trial is completed.|t
17163209|NCT05401409|t||||
17163210|NCT02371889|t||||
17163211|NCT05520333|t||||f
17163212|NCT02579759|f||||t
17163213|NCT02735642|f||||f
17163214|NCT02410200|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17163215|NCT02457546|f||GT60||t
17163216|NCT05069415|t||||
17163217|NCT02743312|f||||f
17163218|NCT00203242|t||||
17163219|NCT00866775|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17163220|NCT01661595|f||||f
17168698|NCT01814670|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17168699|NCT01565941|f||||f
17168700|NCT04047420|f||||f
17168701|NCT03242018|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17168702|NCT02365285|t||||
17168703|NCT03262116|t||||
17163221|NCT01500135|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17163222|NCT00912509|f||||f
17163223|NCT03439072|f||OTHER|Neither the Institution nor the principal investigator may submit for publication or presentation, the results of this trial without prior written consent of the sponsor.|t
17163224|NCT02923167|t||||
17168704|NCT02968914|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17168705|NCT02636946|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17163225|NCT01537432|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17163226|NCT05166902|f||||f
17163227|NCT01998477|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17163228|NCT00779909|t||||
17163229|NCT03523585|f||||f
17163230|NCT05345405|f||||f
17163231|NCT01132690|f||||f
17163232|NCT03704922|t||||
17163233|NCT00944021|f||OTHER||t
17163234|NCT02872142|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17163235|NCT01903720|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163236|NCT02244957|t||||
17163237|NCT02150863|t||||
17163238|NCT00601731|f||GT60||t
17163239|NCT00104884|f||LTE60||t
17163240|NCT05965323|f||||f
17137884|NCT03103906|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137885|NCT03571256|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17163241|NCT04893811|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163242|NCT03268499|f||||f
17163243|NCT01725282|f||OTHER|PI needs to get prior approval from Sponsor in writing for publication of trial data.|t
17163244|NCT04064567|f||||f
17163245|NCT00595075|f||LTE60||t
17163246|NCT01946880|f||||f
17163247|NCT02360085|t||||
17163248|NCT04543786|f||||f
17163249|NCT02034565|f||LTE60||t
17163250|NCT00113373|f||LTE60||t
17163251|NCT01548885|t||||
17163252|NCT06091956|t||||
17163253|NCT01586897|f||||f
17163254|NCT04710303|f||||t
17163255|NCT03813121|t||||
17163256|NCT04525183|f||||f
17163257|NCT00967486|t||||f
17163258|NCT01813227|t||||
17163259|NCT01335685|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property|t
17163260|NCT02542280|f||||f
17163261|NCT02214628|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.|t
17163262|NCT02801578|f||||f
17163263|NCT00668642|f||||f
17163264|NCT02003898|f||GT60||t
17163265|NCT03412591|t||||
17163266|NCT02272985|t||||f
17163267|NCT00770679|t||||
17163268|NCT00814983|t||||
17163269|NCT03627468|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied .|t
17163270|NCT04157738|t||||
17163271|NCT00160563|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17163272|NCT03177798|f||||f
17163273|NCT01514279|f||||f
17163274|NCT00347269|f||||f
17163275|NCT04889950|f||||t
17163276|NCT05201495|f||OTHER||t
17163277|NCT03689179|f||||f
17163278|NCT03168529|f||||f
17163279|NCT04581629|f||||f
17163280|NCT04463914|f||||f
17163281|NCT00456365|f||||f
17163282|NCT05451329|f||OTHER|All investigators will work collaboratively with the Sponsor on presentations and publications.|t
17163283|NCT02202577|f||||f
17163284|NCT00069953|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17163285|NCT00829868|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163286|NCT02799043|f||OTHER||t
17163287|NCT01950039|f||||f
17163288|NCT00855166|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17163289|NCT02702999|t||||
17163290|NCT01848457|f||||f
17163291|NCT00803049|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17182427|NCT01639040|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17163292|NCT01421459|f||GT60||t
17163293|NCT05181085|f||OTHER||t
17163294|NCT01272219|f||OTHER|When the primary results are available, Novo Nordisk plans to discuss the interpretation of these with the principal Investigator, but reserves the right to release results that may impact Novo Nordisk financial expectations (e.g. a press release directly to the public or similar) without prior consultation with the remaining participating Investigators. Novo Nordisk reserves the right not to release data until specified milestones, e.g. a clinical trial report is available.|t
17163295|NCT03131479|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17163296|NCT04379271|f||||f
17163297|NCT04439903|f||||f
17163298|NCT02899754|t||||f
17163299|NCT03186378|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17163300|NCT02181413|f||||t
17163301|NCT01512251|t||||
17163302|NCT02514746|f||||f
17163303|NCT02365688|f||||f
17163304|NCT00050011|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17163305|NCT02598973|f||||f
17163306|NCT04003142|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163307|NCT04042311|t||||
17163308|NCT03382873|t||||
17163309|NCT02592655|f||||f
17163310|NCT00890656|t||||
17163311|NCT03996395|t||||
17163312|NCT01924065|f||||f
17163313|NCT02061085|f||||f
17163314|NCT03247673|f||OTHER||t
17163315|NCT02097225|f||LTE60||t
17163316|NCT05135754|f||OTHER||t
17163317|NCT01027351|f||GT60||t
17163318|NCT02971137|t||||
17163319|NCT02757963|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163320|NCT00911157|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137886|NCT00868452|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17163321|NCT04755231|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17163322|NCT04650893|t||||
17163323|NCT00298155|f||||f
17163324|NCT00057577|f||||f
17163325|NCT03109769|f||||f
17163326|NCT05346640|t||||
17163327|NCT00761137|f||LTE60||t
17163328|NCT04548219|f||GT60||t
17163329|NCT04778709|f||||f
17163330|NCT03549507|f||||f
17163331|NCT02613507|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17163332|NCT03941093|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17163333|NCT05339659|f||||f
17163334|NCT01258985|f||||f
17163335|NCT01197300|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17163336|NCT02113878|t||||
17163337|NCT00834574|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17163338|NCT04129398|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17163339|NCT03058952|t||||
17163340|NCT01428635|t||||
17163341|NCT03837509|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17163342|NCT01251965|t||||
17163343|NCT02363283|f||LTE60||t
17163344|NCT02257138|t||||
17163345|NCT00530257|f||||f
17163346|NCT01897896|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17163347|NCT04622267|f||||f
17163348|NCT03829514|f||||f
17163349|NCT01339091|f||OTHER|The PI will provide Durata an opportunity to review any proposed publication or other type of disclosure at least 30 days before they are submitted. If any patent action is required to protect intellectual property rights, the Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. If the study is part of a multi-center study, the Investigator agrees that the first publication is to be a joint publication covering all centers.|t
17163350|NCT02593630|f||||f
17163351|NCT00003907|f||||f
17163352|NCT01517178|f||LTE60||t
17163353|NCT02553473|t||||f
17163354|NCT03895476|f||||f
17163355|NCT01050218|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17163356|NCT01149460|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163357|NCT00781898|f||||f
17168706|NCT00121641|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168707|NCT01365624|f||||f
17168708|NCT01792518|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168709|NCT04468074|f||||f
17168710|NCT00915148|t||||f
17168711|NCT00249613|t||||f
17168712|NCT02378207|f||||f
17168713|NCT01184417|t||||
17168714|NCT00906958|t||||
17163358|NCT00353119|t||LTE60||
17163359|NCT01879826|t||||
17163360|NCT01630109|f||||f
17163361|NCT00839930|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163362|NCT02500836|f||OTHER|Sponsor right of review of publication, right to remove confidential or proprietary information, and all multi-center data publication done before any additional publications.|t
17163363|NCT02267447|f||||f
17163364|NCT02790736|f||||f
17163365|NCT03446690|f||LTE60||t
17163366|NCT03682367|t||||
17163367|NCT00129974|t||||
17168715|NCT00806442|t||||f
17168716|NCT00654004|f||||f
17168717|NCT01264770|f||OTHER|The disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to publication. Sponsor will be allowed a review period of at least 60 days from submission but can request that publication be delayed for a period up to 6 months. Any reasonable comments made by the sponsor will be incorporated by the PI into the publication.|t
17137887|NCT00575094|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17163368|NCT00414609|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17163369|NCT03318393|t||||
17163370|NCT03680521|f||||f
17163371|NCT01047540|f||||t
17163372|NCT04250207|f||OTHER|Sponsor must review proposed publication 60 days before submission. Sponsor can request revisions and delay publication for up to 60 days to file patents. Sponsor may also require removal of specific information (other than study results).|t
17163373|NCT01437189|f||||f
17137888|NCT00772382|f||OTHER||t
17137889|NCT01673191|f||||f
17137890|NCT05128682|t||||
17137891|NCT02763072|f||||f
17137892|NCT03141372|f||||f
17163374|NCT03654326|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17163375|NCT04102514|f||||f
17163376|NCT00835549|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17163377|NCT00835042|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17163378|NCT00619918|f||||f
17163379|NCT04169009|f||||f
17163380|NCT03492385|f||||f
17163381|NCT00677040|t||||
17163382|NCT04989218|t||||
17163383|NCT05524948|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163384|NCT05155085|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17163385|NCT00607477|t||||f
17163386|NCT04661839|f||OTHER||t
17163387|NCT03329131|t||||
17163388|NCT02758626|t||||
17163389|NCT04818229|f||LTE60||t
17163390|NCT02214212|f||||f
17163391|NCT03538808|f||||f
17163392|NCT04903093|t||||
17163393|NCT03555994|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is more than 60 days but less than or equal to 180 days from the date that the communication is submitted to the sponsor for review. The sponsor can make comments and suggestions where pertinent to the communication and the Sponsor can request for an exceptional additional delay.|t
17163394|NCT03973489|f||||f
17163395|NCT00392288|f||GT60||t
17163396|NCT02544763|f||GT60||t
17163397|NCT02376010|f||||f
17163398|NCT00590317|f||||f
17163399|NCT00266032|f||OTHER|Bayer Schering Pharma (BSP AG) coordinates publishing of study results. Principal investigators (PIs) provide BSP AG with a draft at least 90 days prior to date of planned submission or presentation. BSP AG shall have 60 days to recommend any changes. BSP AG can prevent or delay publication by informing PIs within 60 days of BSP AG´s receipt of the document about to be published. PIs shall not publish press releases/other public statements about study/study drug without BSP AG´s written consent.|t
17163400|NCT02118831|t||||
17163401|NCT01514357|t||||
17168718|NCT04039867|t||||
17168719|NCT00424190|f||||f
17168720|NCT00351273|f||||f
17182428|NCT01479621|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17163402|NCT00752219|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163403|NCT02811419|t||||f
17163404|NCT04691115|f||||f
17163405|NCT05898178|t||||
17163406|NCT01220687|f||||f
17163407|NCT02096354|f||||f
17163408|NCT03715829|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163409|NCT03579719|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163410|NCT02800785|f||||f
17163411|NCT03253627|f||||f
17163412|NCT00742157|t||||
17163413|NCT05807945|f||||f
17163414|NCT01922895|t||||
17163415|NCT01916226|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163416|NCT03163667|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17163417|NCT01257750|t||||
17163418|NCT04104477|f||||f
17163419|NCT04910165|t||||f
17163420|NCT02940223|t||||
17163421|NCT00143845|t||||
17163422|NCT00521352|t||||
17163423|NCT01422382|f||OTHER|May not publish.|t
17163424|NCT01813357|f||||f
17163425|NCT03773562|t||||
17163426|NCT01854762|f||||f
17163427|NCT04082364|f||GT60||t
17163428|NCT01375140|t||||
17163429|NCT04806373|f||||f
17163430|NCT03630679|f||||f
17163431|NCT03301415|f||LTE60||t
17163432|NCT02412436|f||||f
17163433|NCT00622843|f||||f
17163434|NCT04090749|f||||f
17163435|NCT02528305|t||||
17163436|NCT02184442|f||OTHER||t
17163437|NCT01852214|t||||f
17163438|NCT04091438|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17163439|NCT00421408|t||||f
17163440|NCT02370693|f||||f
17163441|NCT00373360|f||GT60||t
17163442|NCT00787800|t||||f
17163443|NCT02481141|f||||f
17163444|NCT04309500|t||||
17163445|NCT00913835|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17163446|NCT01308788|f||||f
17163447|NCT02414841|f||||f
17163448|NCT02842242|f||OTHER|PI's have the right to publish data after the primary publication is released.|t
17137893|NCT00643604|f||OTHER|"There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the Principal Investigator's rights to discuss or publish trial results after the trial is completed.~Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the Investigator contract."|t
17137894|NCT03539861|t||||
17163449|NCT03249558|f||||f
17163450|NCT00964678|f||||f
17163451|NCT03164356|f||||f
17163452|NCT05943990|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17163453|NCT02657356|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17163454|NCT03379870|t||||f
17163455|NCT01394185|t||||
17163456|NCT02904265|t||||
17163457|NCT04255381|f||||f
17163458|NCT01254214|f||||f
17163459|NCT06151418|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163460|NCT01557569|t||||
17163461|NCT00267488|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163462|NCT02254460|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163463|NCT02943499|t||||
17163464|NCT01817777|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137895|NCT02702011|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137896|NCT02407041|f||||f
17137897|NCT01374217|f||||f
17137898|NCT01740388|f||LTE60||t
17137899|NCT01369212|f||OTHER|"From the Publications and Presentations policy Disagreements between the HBRN Steering Committee and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on the merits of journal submission of a specific manuscript will be mediated through discussion on Steering Committee conference calls, ad hoc conference calls or during face to face Steering Committee meetings. The decision of the NIDDK is final and cannot be appealed."|t
17137900|NCT00862121|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17137901|NCT01641991|f||LTE60||t
17137902|NCT00895193|t||||
17168721|NCT01672866|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168722|NCT02241187|t||||
17168723|NCT01020903|t||||
17168724|NCT02033213|f||||f
17168725|NCT02383433|t||||
17168726|NCT02535416|f||||f
17168727|NCT02831933|t||||
17163465|NCT00557440|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17163466|NCT03524157|f||OTHER|only the sponsor can publish the information held by the research centers, if the principal investigator of a center wishes to publish the information, it must have the written consent of the sponsor.|t
17163467|NCT01592747|f||OTHER|All data generated in this study are the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17137903|NCT01578785|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17163468|NCT02853136|t||||
17163469|NCT00867334|f||||f
17163470|NCT01847014|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information an/or patient rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17168728|NCT04544683|f||||f
17137904|NCT03371732|t||||
17137905|NCT00171314|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17163471|NCT05418426|f||OTHER|PI unable to publish trial results after the trial is completed without prior approval from Sponsor.|t
17163472|NCT04620668|t||||f
17163473|NCT01397591|f||||f
17163474|NCT04103814|f||||f
17163475|NCT06301815|t||||
17168729|NCT01073930|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17168730|NCT02081599|f||OTHER||t
17168731|NCT01266590|f||GT60||t
17182429|NCT00486265|f||OTHER|The PI agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.|t
17182430|NCT01452412|f||||f
17182431|NCT03029624|f||||f
17182432|NCT01640366|f||GT60||t
17182433|NCT02045511|t||||
17137906|NCT00475540|f||||f
17168732|NCT04558359|t||||f
17168733|NCT00720343|f||||f
17168735|NCT02008773|t||||f
17182434|NCT02722928|t||||f
17137907|NCT00377429|f||OTHER|"The 1st publication of study results shall be a multicenter publication or disclosure coordinated by sponsor.~Prior to submitting for publication, the Investigator shall allow sponsor at least 60 days to review the proposed Publication. Proposed Publications shall not include either Fresenius Biotech confidential information other than the study results or personal data on any patient. If parties disagree, parties will meet to discuss and resolve any disagreements."|t
17137908|NCT00904995|t||||
17137909|NCT00675558|t||||f
17137910|NCT01033487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17137911|NCT02939599|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17137912|NCT02148211|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137913|NCT02726113|f||||f
17163476|NCT02951819|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17163477|NCT05273437|f||||f
17163478|NCT03566732|f||||f
17163479|NCT05810597|f||GT60||t
17163480|NCT05021224|f||||f
17163481|NCT03213405|t||||
17163482|NCT01111552|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163483|NCT03926247|f||||f
17163484|NCT00912873|f||||f
17163485|NCT04691492|f||||f
17163486|NCT02691494|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17163487|NCT01827306|f||||f
17163488|NCT00637156|f||LTE60||t
17163489|NCT00461812|t||||
17163490|NCT03193437|t||||
17163491|NCT05487378|f||OTHER|"The material for public dissemination will be submitted to the Sponsor for review at least sixty (60) days (or the time specified in the Protocol if longer) prior to submission for publication, public dissemination, or review by a publication committee.~All reasonable comments made by the Sponsor in relation to a proposed publication will be incorporated by the Participating Organisation and/or the Principal Investigator into the publication."|t
17163492|NCT05472870|f||||f
17163493|NCT01385995|t||||
17163494|NCT00112385|f||||f
17163495|NCT04136288|f||||f
17163496|NCT03053362|f||||f
17163497|NCT06003829|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163498|NCT05251805|t||||
17163499|NCT03918031|f||||f
17163500|NCT05572567|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163501|NCT02620865|t||||
17163502|NCT00821821|f||OTHER||t
17163503|NCT04632030|f||||f
17163504|NCT02605616|f||||f
17163505|NCT03359395|t||||
17163506|NCT00561821|f||LTE60||t
17163507|NCT01415453|t||||f
17163508|NCT02520154|t||||
17163509|NCT05964166|t||||
17163510|NCT05670756|t||||
17163511|NCT04526925|t||||
17163512|NCT00088699|t||||
17163513|NCT03443401|f||||f
17163514|NCT00137449|f||OTHER|Pfizer has the right to review disclosure, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17163515|NCT01356940|f||||f
17163516|NCT00685295|t||||
17163517|NCT00505687|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17163518|NCT00586157|f||||f
17163519|NCT04556006|f||||f
17182435|NCT00838565|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163520|NCT02014467|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163521|NCT04642976|f||||f
17163522|NCT00831389|f||LTE60||t
17163523|NCT01377402|t||||
17163524|NCT00278161|t||||
17163525|NCT00443456|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17163526|NCT02157610|t||||
17163527|NCT00124657|t||||
17163528|NCT01935947|f||||f
17163529|NCT04507763|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163530|NCT03427619|f||||f
17163531|NCT00425555|f||||t
17163532|NCT05763381|f||||f
17137914|NCT01305213|f||LTE60||t
17137915|NCT01376362|t||||f
17137916|NCT00638924|t||||
17137917|NCT01987349|f||||f
17137918|NCT01512108|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17163533|NCT01674062|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17137919|NCT01824693|f||OTHER|Must obtain sponsor approval|t
17137920|NCT01966263|t||||
17137921|NCT03287869|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17137922|NCT03488238|f||GT60||t
17137923|NCT00656084|f||||f
17137924|NCT02591238|t||||
17137925|NCT00953225|f||||f
17137926|NCT03864536|f||||f
17163534|NCT01881932|t||||
17163535|NCT01443026|f||||f
17163536|NCT00581919|f||||f
17163537|NCT02655601|f||||f
17163538|NCT00802503|t||||f
17163539|NCT01603368|t||||f
17163540|NCT03829683|t||||
17163541|NCT01251757|f||||f
17163542|NCT02796651|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17163543|NCT04248153|f||||t
17163544|NCT05142306|f||||t
17137927|NCT00640146|f||OTHER|Please contact Sponsor directly for additional information.|t
17137928|NCT04058158|f||||t
17137929|NCT01634113|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137930|NCT00324740|f||LTE60||t
17137931|NCT03628599|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17137932|NCT02514772|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17137933|NCT03250377|f||GT60||t
17137934|NCT00817206|f||OTHER||t
17163545|NCT05430919|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17163546|NCT05014919|f||||f
17163547|NCT01469156|t||||
17163548|NCT02971163|f||||f
17163549|NCT01287208|t||||
17163550|NCT01299961|f||||f
17163551|NCT02904096|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17163552|NCT01491919|f||||f
17163553|NCT02871219|t||||
17163554|NCT03975660|t||||
17163555|NCT00257933|f||||f
17163556|NCT02298946|f||||f
17163557|NCT03285893|t||||
17163558|NCT03792737|f||OTHER|The disclosure restriction on the principal investigator(PI) is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163559|NCT01450631|f||GT60||t
17137936|NCT02197897|f||||f
17137937|NCT01106391|f||GT60||t
17137938|NCT04426890|f||||t
17137939|NCT02759861|f||||f
17163560|NCT00835354|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17182436|NCT03571516|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17137940|NCT01707368|f||||f
17137941|NCT00282867|t||||f
17137942|NCT02855450|f||||f
17137943|NCT00769808|f||OTHER||t
17182437|NCT06259331|f||||f
17182438|NCT04011410|t||||
17182439|NCT02940327|f||||f
17182440|NCT01838642|f||||f
17137944|NCT02494440|f||||f
17163561|NCT04551053|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17163562|NCT05375929|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163563|NCT03204812|t||||
17163564|NCT01270555|f||||f
17163565|NCT00773461|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163566|NCT00322218|f||||f
17163567|NCT05700422|f||||f
17163568|NCT03048682|t||||
17163569|NCT05528445|f||||f
17163570|NCT00908141|t||||
17163571|NCT03648372|f||||t
17163572|NCT04494971|t||||
17163573|NCT00499447|t||||
17163574|NCT00980044|f||||f
17163575|NCT02254291|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property."|t
17163576|NCT02078869|t||||
17163577|NCT04717258|f||||f
17163578|NCT05787782|f||GT60||t
17137945|NCT01376245|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163579|NCT03026777|f||||f
17163580|NCT00833703|f||OTHER|If no publication has occurred within 12 months after trial completion, the Investigator can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not exceeding 90 days.|t
17163581|NCT05538728|f||||t
17163582|NCT01904279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163583|NCT03562156|f||OTHER|Neither institution nor investigator can disclose information pertaining to study until sponsor issues multi-center publication. If multi-center publication is not issued within 18 months of study completion and database lock at all sites, sponsor has 30 days from receipt to review institution's and/or investigator's communication and can require removal of confidential information other than study data and/or delay release of institution's and/or investigator's communication for 60 days.|t
17182441|NCT01557400|f||OTHER|"The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review.~The sponsor may consult with the PI to require changes to the communication or extend the embargo."|t
17137946|NCT05159362|f||||f
17168736|NCT02198794|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17137947|NCT01357889|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163584|NCT02489279|t||||
17163585|NCT02263547|f||LTE60||t
17163586|NCT01344356|f||||f
17163587|NCT00095576|f||OTHER|"As this study is part of a multicenter trial, publications derived from this study should include input from the principal investigator, his/her colleagues, the other investigators in this trial, and SPONSOR personnel.~The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines."|t
17163588|NCT03663582|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17163589|NCT02069847|t||||
17163590|NCT04189484|f||||f
17163591|NCT03242434|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163592|NCT02367885|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17163593|NCT01602484|t||||f
17163594|NCT01378195|t||||
17163595|NCT03574363|f||OTHER|Results are only unblinded after full study is completed. Therefore, PI would be unable to disclose results until after the full database lock and unblinding.|t
17163596|NCT04023045|t||||
17163597|NCT00841815|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163598|NCT04805593|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to study.|t
17163599|NCT01148771|f||LTE60||t
17163600|NCT03787615|f||||f
17163601|NCT03464461|t||||
17163602|NCT03658304|t||||
17163603|NCT03685149|f||||f
17163604|NCT02609503|t||||
17163605|NCT03647137|t||||f
17163606|NCT02226653|f||GT60||t
17163607|NCT05007639|t||||
17163608|NCT04876391|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163609|NCT05781685|f||||f
17163610|NCT02871440|t||||
17163611|NCT00209131|t||||f
17163612|NCT05360784|f||OTHER|Contact Sponsor directly for details|t
17163613|NCT00437073|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163614|NCT02251041|t||||
17163615|NCT04079920|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163616|NCT04918771|f||||t
17163617|NCT01046669|f||OTHER|The only disclosure restriction on the PI is that the sponsor will be given a copy of the disclosure for review at least 60 days prior to the date of submission for publication or public disclosure. Sponsor may request to delete confidential information, other than study data. PI agrees to discuss with sponsor any of sponsor's suggestions with respect to the presentation of study data and the timing of the disclosure.|t
17163618|NCT02915601|f||||f
17163619|NCT00680914|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163620|NCT00539500|t||||f
17163621|NCT05305651|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17163622|NCT00526799|f||||f
17163623|NCT04003389|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163624|NCT04629196|t||||
17163625|NCT04280783|f||||f
17163626|NCT05654181|t||||
17163627|NCT04101331|f||OTHER|The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication|t
17163628|NCT04110145|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163629|NCT00963638|f||||f
17163630|NCT04378153|f||||f
17163631|NCT00488293|t||||
17163632|NCT00500331|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163633|NCT03436732|f||||f
17163634|NCT03345550|t||||
17163635|NCT00959049|f||LTE60||t
17163636|NCT00567502|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17163637|NCT00337168|f||||f
17163638|NCT01382108|t||||
17163639|NCT00666263|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 18 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤120 days(e.g., for intellectual property protection)|t
17182442|NCT01434290|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17168737|NCT00701805|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17168738|NCT00418977|t||||
17168739|NCT00877370|f||||f
17168740|NCT02252965|f||||f
17168741|NCT01733771|t||||
17168742|NCT00167388|t||||
17182443|NCT01224639|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17182444|NCT03465878|f||GT60||t
17182445|NCT04656132|t||||
17163640|NCT02439957|f||OTHER|Within 18 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17163641|NCT00062764|t||||
17163642|NCT01225952|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor.|t
17163643|NCT01189760|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163644|NCT01230060|f||OTHER||t
17163645|NCT03226691|f||||f
17163646|NCT01052779|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data has been received by Sponsor, the Site and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17163647|NCT03802916|f||LTE60||t
17163648|NCT00480532|f||||f
17168743|NCT04435600|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168744|NCT05501795|t||||
17163649|NCT03729609|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17163650|NCT02997085|f||||f
17163651|NCT00492544|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163652|NCT01704157|f||OTHER||t
17163653|NCT01683812|t||||f
17163654|NCT00605189|f||GT60||t
17163655|NCT02697448|t||||
17163656|NCT05473715|f||||f
17163657|NCT05498870|f||||f
17163658|NCT06045273|f||||f
17163659|NCT02919618|t||||
17163660|NCT02592863|t||||
17163661|NCT02743221|f||||t
17163662|NCT04503616|t||||
17163663|NCT04770285|f||||t
17163664|NCT03766399|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca AB.|t
17163665|NCT03411044|f||||f
17163666|NCT01969409|f||||f
17163667|NCT01840072|t||||
17168745|NCT03133221|t||||
17168746|NCT02797184|t||||
17168747|NCT05149313|f||OTHER||t
17168748|NCT04831424|t||||
17168749|NCT03199391|f||||f
17168750|NCT04736628|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168751|NCT04927663|t||||
17168752|NCT01727011|t||||
17168753|NCT02733653|f||OTHER|The restriction depends on the conditions on the Clinical Study Agreement at each site. The PI must notify the sponsor about the publication and receive the approval from the sponsor prior to any results/data relavant to the J-SUPREME trial to be in public.|t
17168754|NCT05251753|f||||f
17168755|NCT00890682|f||||f
17168756|NCT02046070|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17168757|NCT04619004|f||||f
17168758|NCT00306475|f||||f
17168759|NCT05991934|f||||f
17168760|NCT02258529|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168761|NCT02942654|t||||t
17168762|NCT01557959|t||||
17168763|NCT01012921|f||||f
17163668|NCT01051661|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168764|NCT05432167|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca.|t
17168765|NCT01267175|f||GT60||t
17168766|NCT00140842|t||||f
17168767|NCT00875342|t||||
17168768|NCT02553538|t||||f
17168769|NCT04094584|t||||f
17168770|NCT02690649|f||||f
17168771|NCT00791557|t||||
17168772|NCT00660985|f||||f
17168773|NCT00110461|f||OTHER|PIs may not publish trial results for 18 months - 2 years after trial is completed.|t
17168774|NCT02616393|f||||f
17168775|NCT02314364|t||||
17168776|NCT03412097|f||||f
17168777|NCT02657564|f||||f
17168778|NCT02900170|t||||
17168779|NCT01600053|t||||
17168780|NCT02855944|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17168781|NCT01581008|f||||f
17168782|NCT03619135|f||||f
17168783|NCT01722435|f||||f
17168784|NCT02282904|t||||f
17168785|NCT01475162|t||||
17168786|NCT00490022|t||||f
17168787|NCT02608450|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17168788|NCT01283542|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17168789|NCT03443427|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17168790|NCT04285489|f||GT60||t
17168791|NCT00477269|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17168792|NCT03263780|t||||
17168793|NCT03781791|f||||t
17168794|NCT02449018|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17168795|NCT03831945|t||||
17168796|NCT03426631|f||||f
17168797|NCT00447122|f||||f
17168798|NCT02540291|f||||t
17168799|NCT03907033|t||||
17168800|NCT00007644|t||||
17182446|NCT00677807|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182447|NCT04019041|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17182448|NCT00314366|t||||
17168801|NCT01174173|f||||f
17168802|NCT00168454|f||LTE60||t
17168803|NCT03938324|t||||
17168804|NCT02769962|f||||f
17168805|NCT00837759|t||||
17168806|NCT05063539|f||GT60||t
17168807|NCT04256512|t||||
17168808|NCT03298841|f||||f
17168809|NCT01646203|f||GT60||t
17168810|NCT04495868|t||||
17168811|NCT00300677|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168812|NCT00680368|t||||
17168813|NCT00450073|t||||f
17168814|NCT01224444|t||||f
17182449|NCT01831232|f||||f
17137948|NCT01335698|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17137949|NCT03970824|f||||t
17137950|NCT00416312|f||||f
17137951|NCT03005041|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163669|NCT04642079|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163670|NCT02412982|f||||f
17163671|NCT03078868|f||||f
17163672|NCT03038620|f||LTE60||t
17163673|NCT04011241|t||||
17163674|NCT01648322|f||GT60||t
17163675|NCT01435356|f||OTHER|PI submits the proposed publication to Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor shall have the right to remove from the proposed publication any information that is considered confidential and/or proprietary. Sponsor shall have the right to request an additional delay to the proposed disclosure of no more than ninety (90) days so as to allow Sponsor to preserve its intellectual property.|t
17163676|NCT01275300|f||||f
17163677|NCT04221438|f||LTE60||t
17163678|NCT01441492|f||||f
17163679|NCT03633058|f||||f
17163680|NCT03034044|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163681|NCT03312543|f||OTHER|PI must provide Sponsor 60 days to review any publication (unless expedited review requested); if it includes Sponsor's confidential info, written Sponsor approval is required. Sponsor may require another 60 days' delay to file a patent application.|t
17163682|NCT05535972|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17163683|NCT02614248|t||||
17163684|NCT04197583|f||LTE60||t
17163685|NCT04732468|f||||t
17163686|NCT00690339|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163687|NCT01992757|t||||
17163688|NCT04992273|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17163689|NCT00856557|t||||
17163690|NCT01432444|f||||f
17163691|NCT02301897|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163692|NCT03673176|t||||
17163693|NCT03283241|f||LTE60||t
17163694|NCT02378480|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17163695|NCT01217892|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17163696|NCT01285102|f||||f
17163697|NCT01905540|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17163698|NCT00498628|f||||f
17163699|NCT02743962|f||||f
17163700|NCT06034340|t||||
17163701|NCT01661283|f||||f
17163702|NCT02327169|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17163703|NCT00478257|t||||
17163704|NCT00952692|t||||
17163705|NCT04330859|t||||
17163706|NCT04897568|f||||f
17163707|NCT01381679|f||LTE60||t
17163708|NCT04023487|f||||f
17163709|NCT00361712|f||||f
17163710|NCT02014376|f||GT60||t
17163711|NCT01531335|f||||f
17163712|NCT01833078|f||||f
17163713|NCT02951481|f||||f
17163714|NCT00759395|f||||f
17163715|NCT04875533|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163716|NCT03648892|t||||
17163717|NCT03338920|f||||f
17163718|NCT02657343|t||||
17168815|NCT00443781|f||OTHER|No publication, abstract, or presentation shall be submitted unless the multi-center report has been published. If report is not submitted within 24 months after completion, PI can present outcomes from their site. Proposed publications or presentations to be submitted to sponsor for review at least 60 days in advance. If proposed publication or presentation contains subject matter which is deemed to warrant intellectual property protection, sponsor may delay up to an additional 90 days.|t
17168816|NCT00537407|f||OTHER||t
17182450|NCT01806896|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182451|NCT01083433|f||||f
17182452|NCT01581593|f||||f
17182453|NCT04982029|f||||f
17182454|NCT05308901|t||||
17182455|NCT01896895|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17163719|NCT00811850|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17163720|NCT02011542|f||||f
17163721|NCT03988205|t||||
17163722|NCT00330733|t||||f
17163723|NCT02678377|t||||
17163724|NCT00982280|f||OTHER|Grünenthal reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17163725|NCT01979185|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17163726|NCT00980798|f||GT60||t
17163727|NCT04724837|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17163728|NCT00522379|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17163729|NCT03135067|f||||f
17163730|NCT02100826|f||GT60||t
17163731|NCT00967499|f||||t
17163732|NCT05070819|t||||
17163733|NCT02607722|t||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163734|NCT04562090|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163735|NCT02402647|f||||f
17163736|NCT03637348|t||||f
17163737|NCT05852470|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17168817|NCT00582738|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168818|NCT02758301|f||GT60||t
17168819|NCT00364533|f||OTHER|A provision provides for 60 day prior review by sponsor extendable by 60 days to file a patent application and prior written consent of sponsor for disclosure of confidential information, if any.|t
17168820|NCT00652899|t||||f
17182456|NCT04127786|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17182457|NCT01904604|f||||f
17182458|NCT05124665|f||||f
17182459|NCT04147442|t||||
17182460|NCT02871128|f||||f
17182461|NCT00358527|f||OTHER|The PI is not allowed to release any interim results of the Study without prior consent of the sponsor, and must provide 45 days written notice to the sponsor prior to public release to permit the sponsor's review. The PI can use the study results for his/her own teaching, research, and publication purposes only, not for commercial purposes, except as authorized by the sponsor. No publication shall contain any trade secret or proprietary/confidential information of the sponsor.|t
17182462|NCT04144166|f||LTE60||t
17163738|NCT04134936|f||OTHER|No investigator or institution may publish any results of the trial conducted at their site, before a first multicentre publication is made which covers the data from all sites. The author must coordinate the publication with the sponsor, who has the right to review it at least 60 days before their submission. If publication would affect the patentability of any invention to which the sponsor has rights, the sponsor can request to delay the proposed publication for no more than 90 days.|t
17163739|NCT02170519|t||||
17182463|NCT00145509|f||OTHER|Institution will provide manuscripts, abstracts, or the full text of any other intended disclosure to the sponsor at least 30 days prior to submission for publication or other disclosure. If any patent action is required to protect intellectual property rights, Institution agrees to delay the disclosure for a period not to exceed and additional 60 days. Institution will, on request, remove any previously undisclosed Confidential Information (other than study results) before disclosure.|t
17182464|NCT02881996|f||||f
17182465|NCT04145895|t||||
17163740|NCT00323622|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163741|NCT02420717|t||||
17163742|NCT00543127|f||||f
17163743|NCT02513641|f||||f
17163744|NCT00131885|f||||f
17163745|NCT02953457|t||||
17163746|NCT04191135|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17163747|NCT03514134|f||||f
17163748|NCT02471144|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17163749|NCT00003645|t||||
17163750|NCT00107575|f||||f
17163751|NCT03768336|f||||f
17163752|NCT03977155|f||GT60||t
17163753|NCT00936936|t||||
17163754|NCT01373281|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17163755|NCT00775658|f||||f
17163756|NCT03502681|f||||f
17163757|NCT01444781|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17163758|NCT06790303|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17163759|NCT03413995|f||||f
17163760|NCT05796245|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163761|NCT04999267|f||||f
17163762|NCT00889330|f||OTHER||t
17163763|NCT02956473|t||||
17163764|NCT02085980|f||||f
17163765|NCT02374255|f||||f
17163766|NCT02093520|f||||f
17163767|NCT03014089|f||||t
17163768|NCT00321932|t||||
17163769|NCT02310269|f||OTHER|Physician or Institution must submit to Sponsor at least 45 days before any publication, the material that they would publish, for Sponsor review and approval of this publication.|t
17163770|NCT03257657|f||||f
17163771|NCT01085903|t||||
17163772|NCT02296099|t||||
17163773|NCT02971839|f||OTHER||t
17163774|NCT00688740|f||OTHER|No publication of the study will be made without approval of the advisory board of the Breast Cancer International Research Group and Rhone- Poulenc Rorer.|t
17163775|NCT01943227|t||||
17163776|NCT03931330|f||||f
17163777|NCT03412929|f||||t
17163778|NCT04547556|t||||
17163779|NCT00645658|t||||
17163780|NCT01722643|f||||f
17163781|NCT00023595|f||OTHER|The agreement is that all publications need to be reviewed and approved by the Policy and Publication Committee and the Sponsor prior to publication.|t
17163782|NCT01472185|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17163783|NCT05889468|t||||
17163784|NCT05468918|t||||
17163785|NCT03900650|f||||f
17163786|NCT00823797|f||||f
17163787|NCT01554904|f||||f
17163788|NCT04486677|t||||
17163789|NCT00635050|f||||f
17163790|NCT00086515|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163791|NCT00049543|f||LTE60||t
17163792|NCT02106832|f||OTHER|Bayer acknowledges and accepts the interest in the non-commercial scientific publication of Results. In a multi-center study the Principal Investigators will not make any publication of the results before the first multi-center publication. Proposed publication/presentation shall be provided to Bayer at least 60 days prior to the intended submission or presentation of the publication in order to allow Bayer to review it. Any difference of opinion shall be discussed.|t
17163793|NCT03485157|f||GT60||t
17168821|NCT00551291|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17168822|NCT01943552|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168823|NCT02641522|t||||
17168824|NCT01304407|f||||f
17168825|NCT05059977|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17168826|NCT00576472|t||||
17168827|NCT03833713|f||||f
17168828|NCT00574548|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168829|NCT02478580|f||||f
17168830|NCT02768753|t||||
17168831|NCT03984487|f||||f
17168832|NCT04807387|t||||
17168833|NCT01504204|f||||f
17168834|NCT00903331|f||LTE60||t
17168835|NCT02723175|f||||f
17168836|NCT03283436|t||||
17168837|NCT00257660|f||OTHER|A publication of results from all sites in this multicenter study is expected. If the sponsor no longer plans this or 6 months after study completion at all sites, the PI may publish the results. He will supply any proposed publication to the sponsor for review and comment at least 30 days before submission for publication. If the sponsor believes a patent application should be filed, the publication will be delayed for another 60 days or until patent filing; with a maximum delay of 90 days.|t
17168838|NCT04109976|f||GT60||t
17168839|NCT01965899|f||LTE60||t
17168840|NCT04971941|f||||f
17168841|NCT03691779|f||OTHER||t
17168842|NCT00267150|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168843|NCT02718040|f||||f
17168844|NCT00521222|f||||f
17168845|NCT00475215|f||OTHER|Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17168846|NCT03332160|f||||t
17168847|NCT01561963|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168848|NCT01008969|t||||f
17168849|NCT01175395|f||||f
17168850|NCT04208087|f||OTHER||t
17168851|NCT01977690|t||||
17168852|NCT00952614|t||||
17168853|NCT04023682|t||||
17168854|NCT00569868|f||||f
17168855|NCT00637572|f||OTHER|All manuscripts, abstracts or other modes of presentation arising from the results of this study must be reviewed and approved in writing by Par, in advance of submission.|t
17168856|NCT00428207|f||||f
17168857|NCT01181674|t||||
17168858|NCT02530996|t||||
17168859|NCT04268745|t||||f
17168860|NCT01086852|f||GT60||t
17168861|NCT01286077|f||OTHER|A copy of the manuscript must be provided to the Sponsor for review at least 60 days prior to submission for publication or presentation. No paper that incorporates Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, such publication will be withheld for up to an additional 60 calendar days. A publication from the individual Study site data will not be published until the combined results have been published|t
17168862|NCT01918332|f||OTHER||t
17168863|NCT02408523|f||GT60||t
17168864|NCT01751139|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168865|NCT01867086|f||||t
17168866|NCT04279613|f||||f
17168867|NCT04428151|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17168868|NCT02704689|f||||f
17168869|NCT00759525|f||||f
17168870|NCT02212678|f||||f
17168871|NCT02337634|f||||f
17168872|NCT04068610|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17182466|NCT01481116|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17168873|NCT02428205|f||||f
17168874|NCT00527319|f||LTE60||t
17168875|NCT02066415|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17168876|NCT00430937|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17168877|NCT03826199|f||||f
17182467|NCT04904185|t||||
17182468|NCT02789176|t||||
17163794|NCT00265122|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163795|NCT00608062|f||||f
17163796|NCT05205616|t||||f
17163797|NCT04992065|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17163798|NCT00663260|f||||f
17163799|NCT01799135|t||||
17163800|NCT01890031|f||||f
17163801|NCT02231580|f||OTHER|PI shall not proceed to publication or communication in connection with the subject matter of this Agreement or Results, without the prior written consent of Ipsen.|t
17163802|NCT03620981|f||||f
17163803|NCT04554836|f||GT60||t
17163804|NCT03238196|t||||
17163805|NCT04938427|f||||t
17163806|NCT01903863|t||||f
17163807|NCT04261985|f||||f
17163808|NCT04906512|f||||t
17163809|NCT02397720|t||||
17163810|NCT03033784|f||||f
17163811|NCT03332056|f||||f
17163812|NCT00851084|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission to a journal, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17163813|NCT00734032|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163814|NCT03809000|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17163815|NCT01798225|f||||f
17163816|NCT03360344|t||||
17163817|NCT01145183|t||||
17163818|NCT00133705|f||||f
17182469|NCT02433834|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17163819|NCT03840967|f||||f
17163820|NCT04881058|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17163821|NCT01342666|t||||f
17163822|NCT05012579|f||||f
17163823|NCT04033640|f||||f
17163824|NCT01892189|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property|t
17163825|NCT03440411|f||||f
17163826|NCT01139515|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163827|NCT02323048|t||||
17163828|NCT04484857|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17163829|NCT03359161|t||||
17163830|NCT01358734|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications|t
17163831|NCT01195597|f||||f
17163832|NCT03322566|f||OTHER|Clinical Study Agreement|t
17168878|NCT03242252|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17168879|NCT01659255|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17168880|NCT00958932|t||||f
17168881|NCT01116427|f||||f
17168882|NCT02989805|t||||
17168883|NCT02211313|t||||
17168884|NCT03973905|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17168885|NCT02648217|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17168886|NCT03316950|f||||f
17182470|NCT00596011|t||||
17182471|NCT02821962|f||||f
17182472|NCT03097653|f||||f
17182473|NCT01956110|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17182474|NCT01857258|f||||f
17163833|NCT03641287|f||||f
17163834|NCT00600340|t||||
17163835|NCT03847519|f||||f
17163836|NCT00376558|t||||
17182475|NCT00742313|t||||f
17182476|NCT01962558|f||||f
17182477|NCT01436279|t||||
17182478|NCT00910715|t||||
17182479|NCT05923229|t||||f
17182480|NCT05288556|t||||
17182481|NCT03307759|t||||
17137952|NCT02727660|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17137953|NCT00305604|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137954|NCT00105560|t||||
17137955|NCT02171819|f||||f
17137956|NCT01248364|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17137957|NCT01200160|f||OTHER|An agreement is in place that includes a clause of keeping Abbott´s information confidential and that any publication would be performed under agreement with Abbott.|t
17182482|NCT03400332|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17182483|NCT01188577|f||OTHER||t
17182484|NCT04476017|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182485|NCT02704364|f||||f
17182486|NCT04063761|f||||f
17163837|NCT02314923|f||OTHER|All data may be published in the open medical literature with the identity of the subjects protected. Anyone desiring to publish or present data obtained during the conduct of the study will conform to the Sponsor's policies and then forward the publication for review to the Sponsor prior to submission.|t
17163838|NCT00725985|f||OTHER||t
17163839|NCT04476784|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17163840|NCT00863304|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163841|NCT06582732|f||||f
17163842|NCT02507934|f||||f
17182487|NCT04664998|t||||
17182488|NCT04627064|f||||f
17182489|NCT02107599|t||||
17137958|NCT01567891|f||GT60||t
17137959|NCT00764946|f||OTHER|Twenty-four months after completion of this study or after publication of the multicenter results, an investigator may publish the results for their study site independently. The sponsor must have the opportunity to review all proposed publications or presentations regarding the study 60 days before submission.|t
17137960|NCT04569799|t||||
17137961|NCT03086317|t||||f
17137962|NCT02431468|f||GT60||t
17137963|NCT01361919|f||||f
17137964|NCT03001843|t||||
17163843|NCT03528902|f||||f
17163844|NCT05030766|t||||
17182490|NCT00779103|f||||f
17182491|NCT04033159|f||LTE60||t
17182492|NCT02845752|f||LTE60||t
17182493|NCT00006489|f||||f
17163845|NCT02947048|f||||f
17163846|NCT03605693|t||||f
17163847|NCT04258631|t||||
17163848|NCT03895372|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163849|NCT03093415|t||||f
17163850|NCT00304161|f||||f
17163851|NCT03331354|t||||f
17163852|NCT04618276|t||||
17163853|NCT03896633|f||OTHER|Contact sponsor directly for details.|t
17163854|NCT04047355|f||||f
17163855|NCT01309230|f||||t
17163856|NCT04481685|f||||f
17163857|NCT00427700|f||||f
17163858|NCT04581395|t||||
17163859|NCT00356187|f||||f
17163860|NCT00815633|t||||
17163861|NCT00721110|t||||
17163862|NCT01605097|f||||f
17163863|NCT02038647|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17163864|NCT02757430|f||LTE60||t
17163865|NCT02082977|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17163866|NCT05852340|t||||
17163867|NCT01397253|f||||f
17163868|NCT01599286|f||||f
17163869|NCT02300545|t||||
17163870|NCT01731782|f||||f
17137965|NCT01770691|t||||
17137966|NCT00039741|f||||f
17163871|NCT05870345|t||||
17163872|NCT02546323|f||||f
17163873|NCT01055028|f||||f
17163874|NCT03559530|f||||f
17163875|NCT01362790|f||||f
17163876|NCT02457065|f||||f
17163877|NCT01969214|f||||f
17163878|NCT05805150|f||||t
17163879|NCT04116684|t||||f
17163880|NCT03817580|f||||t
17163881|NCT01506726|f||||f
17163882|NCT03863574|f||||f
17163883|NCT04347538|t||||
17163884|NCT02135133|t||||
17163885|NCT02259231|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17163886|NCT05081843|t||||
17182494|NCT05583903|t||||
17182495|NCT00654069|f||||f
17163887|NCT02303821|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17163888|NCT04341012|t||||
17163889|NCT03408262|t||||
17168887|NCT02392403|f||OTHER|The investigator agrees to send any Conference presentations/publications to the Sponsor for review at least 30 days prior to publication/presentation and after the first publication has been submitted. The Sponsor has the right to require any confidential information to be removed. If there is intellectual property disclosed, which the Sponsor intends to protect by registration such as by patent application, the Sponsor may require the release of the publication to be delayed by up to 120 days.|t
17168888|NCT00678834|f||||f
17168889|NCT02335424|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17168890|NCT01264614|t||||
17168891|NCT02776033|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168892|NCT02712424|f||||f
17168893|NCT00657371|f||||f
17137967|NCT01767519|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17163890|NCT00553969|f||||f
17163891|NCT04116489|t||||f
17163892|NCT03734536|f||OTHER|Sponsor has the right to modify any proposed publication within 30 days after receipt if it discloses potentially patentable items, patent, trade secret, or other proprietary or confidential information of Sponsor. If patentable items are involved, proposed, disclosure to third party may be delayed up to 90 days. If not submitted within 18 months after the Study's conclusion, the Site/Investigator may publish results after Sponsor's review.|t
17163893|NCT04727151|f||OTHER|The PIs have the right to publish or discuss the results of the Study provided such disclosure is submitted to the SPONSOR for review and comment 45 days prior to submission for publication or 60 days prior to presentation. The PIs have agreed to defer disclosure at the request of the SPONSOR, to permit the filing of any desired patent applications. Any disclosure based on the results obtained at PI's Site shall not be made before the first multi-centre publication.|t
17163894|NCT00723632|f||||f
17163895|NCT01346592|f||GT60||t
17163896|NCT02679274|f||||f
17163897|NCT03207347|t||||
17163898|NCT02085720|f||||f
17163899|NCT00689884|t||||f
17163900|NCT02038036|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17163901|NCT02476448|f||||f
17163902|NCT04262479|f||||f
17163903|NCT00937105|f||LTE60||t
17163904|NCT03537508|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17163905|NCT02516813|f||||f
17163906|NCT01972659|t||||f
17163907|NCT02399228|f||LTE60||t
17163908|NCT04983979|f||||f
17163909|NCT04144517|f||OTHER||t
17163910|NCT03664544|f||OTHER||t
17163911|NCT05697380|t||||
17163912|NCT05293314|t||||
17168894|NCT02713867|f||LTE60||t
17168895|NCT00628147|f||||f
17182496|NCT03491150|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17163913|NCT02757768|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17163914|NCT05218434|f||||f
17163915|NCT00835367|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17163916|NCT02495883|t||||
17163917|NCT02185183|f||||f
17163918|NCT00791648|t||||
17163919|NCT00462826|f||LTE60||t
17163920|NCT04976777|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17163921|NCT02278003|t||||
17163922|NCT02947984|t||||
17163923|NCT03369158|f||||f
17163924|NCT03744637|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17163925|NCT04123704|t||||
17163926|NCT03440385|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17163927|NCT00939185|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17163928|NCT00363298|f||||f
17163929|NCT03134209|t||||
17163930|NCT03552029|f||||f
17168896|NCT02411929|f||OTHER|The investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. An additional 60 days will be requested if any patent action is required to protect intellectual property rights. The investigator will, on request, remove any previously undisclosed confidential information before disclosure.|t
17168897|NCT02715726|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17168898|NCT01177969|f||||f
17168899|NCT02445573|f||||f
17168900|NCT03230292|f||GT60||t
17168901|NCT01639755|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17168902|NCT00996346|f||||f
17168903|NCT04897607|f||||f
17168904|NCT03995355|t||GT60||t
17168905|NCT03945019|f||||f
17137968|NCT00946881|f||LTE60||t
17168906|NCT01462877|f||OTHER||t
17168907|NCT01407523|f||GT60||t
17168908|NCT00535821|f||||f
17168909|NCT00710385|f||||f
17163931|NCT01198691|t||||
17163932|NCT03468998|f||||f
17163933|NCT01765400|f||||f
17163934|NCT00836706|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17163935|NCT01467557|f||GT60||t
17163936|NCT00633126|f||||f
17163937|NCT00793520|f||||f
17163938|NCT02541591|t||||
17137969|NCT00293423|t||||
17137970|NCT00805545|t||||
17163939|NCT02390076|f||||f
17163940|NCT01383005|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17163941|NCT00030264|t||||
17163942|NCT01822925|f||||f
17163943|NCT04617860|f||||f
17163944|NCT00833690|f||||f
17163945|NCT01182350|f||||f
17163946|NCT03898180|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17163947|NCT01646827|f||OTHER|There is no agreement between PI and sponsor that restricts the PI's right to discuss or publish trial results after the trial is completed.|t
17163948|NCT00928668|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17163949|NCT01838226|t||||
17163950|NCT05078437|f||||f
17163951|NCT01767987|t||||
17163952|NCT03232567|f||||f
17163953|NCT05837481|f||||f
17163954|NCT00103844|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17163955|NCT03038087|f||||f
17163956|NCT01202162|f||||f
17163957|NCT05022719|f||||f
17163958|NCT05006495|f||||f
17163959|NCT03139721|f||OTHER|The PI is restricted to publish results until the Sponsor has published the results.|t
17168910|NCT01325714|t||||
17168911|NCT02914561|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17168912|NCT00721175|t||||f
17168913|NCT03294629|f||||f
17163960|NCT02284893|f||OTHER|PI to provide AstraZeneca (AZ) with an opportunity to review/comment on drafts of publication and review final draft at least 30 days in advance of submission for publication or public presentation (15 days for an abstract or poster). If requested agree to delay submission or presentation for an additional period, not more than additional 90 days, to allow AZ to file a patent or application to preserve our rights in any intellectual property disclosed in the publication.|t
17163961|NCT00105066|t||||f
17163962|NCT05036343|t||||
17163963|NCT02733757|f||||f
17163964|NCT03815344|f||||f
17163965|NCT02421094|f||||f
17163966|NCT01483560|f||||f
17163967|NCT02878785|f||||f
17163968|NCT01957384|t||||
17163969|NCT03126630|f||LTE60||t
17163970|NCT00847730|f||||f
17163971|NCT03607500|t||||
17163972|NCT04507269|f||OTHER|"Investigator will submit the proposed publication to sponsor at least 60 days prior to submission to a publisher.~Sponsor shall advise investigator any information that are confidential or may impair the availability of patent protection for study inventions.~Sponsor may require to remove confidential information and/or to delay the proposed publication or presentation for an additional 60 days to seek patent protection for study inventions."|t
17163973|NCT02120261|t||||
17163974|NCT00071032|t||||
17163975|NCT01889251|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17163976|NCT02784587|f||||f
17163977|NCT03584490|f||||f
17163978|NCT06071104|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17163979|NCT03518060|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17163980|NCT05078112|t||||
17163981|NCT00085839|f||LTE60||t
17163982|NCT04312022|t||||f
17137971|NCT00507416|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17163983|NCT03211416|t||||
17163984|NCT01877278|f||||f
17163985|NCT04890509|f||OTHER|PI's will not discuss or publish trial results after the trial is completed without seeking prior permission of sponsor.|t
17163986|NCT02371187|t||||
17163987|NCT00618787|f||||f
17163988|NCT01107886|f||OTHER|AstraZeneca's Publication Policy, data disclosure and transparency are available at the website: http://www.astrazeneca.com/responsibility/code-and-policies/policies?itemId=4861823\&nav=yes. All papers or abstracts must be submitted to the Steering Committee and the SPONSOR, through BRIGHAM, for review of its appropriateness and scientific merit at least six weeks prior to submission to any publication.|t
17163989|NCT02445911|f||OTHER|Written consent|t
17137972|NCT04428359|f||||f
17163990|NCT01649869|f||||f
17163991|NCT02776735|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17163992|NCT05395338|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17163993|NCT03556891|f||||f
17163994|NCT01168596|f||||f
17163995|NCT00123630|f||LTE60||t
17163996|NCT03978598|f||||f
17163997|NCT02297516|f||||t
17163998|NCT03835078|f||||f
17163999|NCT02332928|t||||
17164000|NCT01425814|f||OTHER|Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subjected to revision and written agreement between the investigator and Sponsor|t
17164001|NCT01999530|f||||f
17164002|NCT02243358|t||||
17164003|NCT00573768|f||||f
17164004|NCT03243084|t||||f
17164005|NCT01137890|f||||f
17164006|NCT02090764|f||OTHER|Any and all data resulting from the Study will not be presented or published in any form or media by the Institution, Investigator or Research Staff without the prior written consent of Sponsor which consent maybe as directed within the Protocol.|t
17164007|NCT02384421|t||||
17164008|NCT02300233|f||||t
17164009|NCT04752566|f||||t
17164010|NCT02661815|f||LTE60||t
17164011|NCT01153516|f||||f
17164012|NCT00189475|f||||f
17164013|NCT02474498|f||||f
17164014|NCT00654355|f||||f
17164015|NCT01728246|f||||f
17137973|NCT02157506|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17164016|NCT01983111|f||||f
17164017|NCT03502200|f||||f
17164018|NCT00855335|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17137974|NCT03101514|f||||f
17164019|NCT00731484|f||||f
17164020|NCT05126303|f||GT60||t
17168914|NCT03897036|f||OTHER|No submission for publication or public disclosure by Institution or Investigator will be made until after publication of the multicenter results. After the first to occur of (i) publication of the multicenter results, (ii) notification by Sponsor that such a multicenter submission is no longer planned, or (iii) eighteen months after the Completion Date of the Study as defined in 42 CFR 11.10, Institution and Investigator may publish or publicly present the Study Data.|t
17168915|NCT01459913|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17164021|NCT00509288|f||||f
17164022|NCT04380142|f||||f
17164023|NCT00737360|f||LTE60||t
17164024|NCT02908178|f||||f
17164025|NCT02706392|t||||
17164026|NCT03290027|f||||f
17164027|NCT04716894|t||||
17164028|NCT01772654|t||||
17164029|NCT00787150|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164030|NCT04537650|t||||
17164031|NCT02268656|f||||f
17164032|NCT01262105|t||||
17164033|NCT00879398|f||GT60||t
17164034|NCT03773484|f||||f
17164035|NCT05216380|f||||f
17137975|NCT01021813|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17137976|NCT00764478|f||OTHER|The investigator agrees to provide to the sponsor 45 days to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17137977|NCT02270684|f||||f
17137978|NCT01555905|f||||f
17137979|NCT02682030|t||||
17137980|NCT02029495|f||OTHER||t
17137981|NCT03498287|f||OTHER|"Authorship will reflect joint cooperation between PPS and participating PI(s). Authorship responsibilities should be established prior to the writing of any manuscript.~No individual publications are allowed unless agreed upon, reviewed, and approved by the Sponsor before submission and/or publication. No individual publications are allowed prior to the completion of a final report for the study."|t
17137982|NCT05515952|f||||f
17137983|NCT00493974|f||||f
17137984|NCT02555657|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17137985|NCT02188719|f||||f
17137986|NCT00966693|t||||
17137987|NCT00599027|f||OTHER|The PI agrees not to publish or publicly present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication.|t
17137988|NCT02581982|t||||
17137989|NCT00676793|f||||f
17137990|NCT03479216|f||||f
17137991|NCT00798577|f||OTHER|All presentations/publications of study results are subject to Alcon approval.|t
17137992|NCT02259127|f||||f
17137993|NCT03326869|t||||
17164036|NCT01344226|f||||f
17164037|NCT04118764|t||||
17164038|NCT02302222|f||GT60||t
17164039|NCT01950520|t||||
17164040|NCT04212442|f||||f
17164041|NCT03781570|f||||f
17164042|NCT01107496|f||||t
17164043|NCT03709472|t||||
17164044|NCT01350479|t||||
17164045|NCT02496000|f||GT60||t
17164046|NCT02255656|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17164047|NCT01969058|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17164048|NCT04976855|f||||t
17164049|NCT05318287|t||||
17164050|NCT05185453|t||||f
17164051|NCT04652765|t||||
17164052|NCT00391716|t||||
17164053|NCT05715827|f||OTHER|The PI cannot publish or disclose study results until a multicenter publication is released. If not published within one year after study completion at all sites, the PI may then publish, subject to review. The PI must submit publications to Medtronic 60 days before submission for review. Medtronic can request removal of Confidential Information, corrections, and may delay publication by up to 90 days to protect intellectual property.|t
17164054|NCT02457793|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164055|NCT04316143|f||OTHER||t
17164056|NCT03814044|f||LTE60||t
17164057|NCT00934180|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17164058|NCT05929326|t||||f
17164059|NCT00835172|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17164060|NCT02625428|t||||
17164061|NCT04093453|t||||
17164062|NCT03274466|f||||t
17164063|NCT00730327|f||||f
17164064|NCT02552225|t||||
17164065|NCT02989857|f||OTHER|The information obtained from the clinical study will be used towards the development of ivosidenib and may be disclosed to regulatory authority(ies), other Investigators, corporate partners, or consultants as required.|t
17164066|NCT02682056|t||||
17164067|NCT01882816|t||||
17164068|NCT01212900|t||||
17164069|NCT05157360|f||||f
17164070|NCT00876447|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164071|NCT02965781|f||||f
17164072|NCT00366457|t||||
17164073|NCT02538614|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164074|NCT01098747|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164075|NCT00189423|f||GT60||t
17164076|NCT03302767|t||||
17164077|NCT01638507|f||OTHER|For any publication or presentation of the Protected Materials or any portion thereof, a manuscript of the paper, abstract or any materials will be provided by Consultant to Sponsor for its approval at least sixty (60days) for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.|t
17164078|NCT04622592|f||OTHER|The Investigator understands that the information in the protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical review of the study, without prior written authorization from the Sponsor. It is, however, permissible to discuss information contained in the protocol with a participant in order to obtain consent once Institutional Review Board (IRB) approval is obtained.|t
17164079|NCT01497197|f||LTE60||t
17164080|NCT01332981|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164081|NCT03901430|f||||f
17168916|NCT01915823|f||OTHER|Meda Pharmaceuticals requests that it receive copies of any intended communication at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript). This is to allow Meda Pharmaceuticals to review the communications for accuracy , to verify that confidential information is not being inadvertently divulged, to provide any relevant supplementary information, and to allow establishment of co-authorship.|t
17168917|NCT01064687|f||GT60||t
17168918|NCT02299076|t||||
17168919|NCT01969721|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168920|NCT00495755|t||||
17168921|NCT02117349|f||||t
17168922|NCT01012323|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17168923|NCT02265796|f||||f
17168924|NCT02477553|f||||f
17168925|NCT02963701|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17168926|NCT01548742|t||||f
17168927|NCT00896649|f||||f
17168928|NCT03652675|f||||f
17168929|NCT03442296|t||||
17168930|NCT00707954|f||OTHER||t
17168931|NCT01306656|t||||f
17168932|NCT01571232|f||||f
17168933|NCT01854268|t||||
17168934|NCT03517969|f||LTE60||t
17168935|NCT00687102|t||||f
17168936|NCT02227394|f||||f
17168937|NCT05138549|f||||f
17168938|NCT03344172|t||||
17168939|NCT03779503|f||||f
17168940|NCT03629912|t||||
17168941|NCT00687609|f||GT60||t
17168942|NCT00908037|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168943|NCT01727791|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168944|NCT00869401|t||||
17168945|NCT01147900|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168946|NCT01848847|t||||
17168947|NCT00581360|f||||f
17168948|NCT04405245|f||OTHER|Product acquired from Aerpio with limited transfer of documents. Site CTAs not provided.|t
17168949|NCT02391961|t||||
17168950|NCT04596085|f||OTHER|Confidential information during the course of the study and clinical development plan, except the information already existing in the public domain, and all results and reports obtained, collected, conceived, processed and developed pursuant to this Agreement, The INSTITUTION shall use confidential information for the sole purpose of providing services under this Agreement and shall not use confidential information for the INSTITUTION's own benefit at any time.|t
17164082|NCT01681147|f||||f
17182497|NCT01054703|f||OTHER|Principal investigator shall not issue or disseminate any press release or statement, nor initiate or cause to be initiated any communication of information regarding the clinical trial (written or oral) to the communications media or third parties without the prior written consent of Sponsor.|t
17182498|NCT00117143|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17182499|NCT01103934|t||||
17182500|NCT01265446|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17182501|NCT02402452|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17182502|NCT02287896|f||||t
17182503|NCT00559962|f||OTHER|PI can publish after sponsor reviews the proposed publication. PI must give sponsor at least 60 days to review before publication. PI needs to obtain sponsor's prior written consent to publish confidential information, which shall not be unreasonably withheld or delayed. The PI shall, upon request of sponsor, delete any confidential information which would prejudice the securing of adequate intellectual property protection from the publication.|t
17182504|NCT05052190|f||||f
17182505|NCT05422053|f||||f
17182506|NCT00323414|t||||
17182507|NCT02552316|f||||f
17182508|NCT04382911|t||||
17182509|NCT02385799|f||||f
17182510|NCT02016963|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182511|NCT04688164|f||||t
17182512|NCT00376168|f||||f
17182513|NCT02350309|f||||t
17182514|NCT00058825|t||||
17182515|NCT04399161|t||||
17164083|NCT00565747|f||OTHER|Confidentiality until publication of the main results of the study|t
17164084|NCT00183248|f||||f
17164085|NCT03309202|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164086|NCT01697709|t||||
17164087|NCT00415636|f||GT60||t
17164088|NCT04734210|f||||t
17164089|NCT02684461|f||GT60||t
17164090|NCT02138825|f||OTHER|Written consent must be obtained from Bayer prior to any information being submitted for publication. Material proposed for publication or presentation must be provided to Bayer prior to submission. All reasonable comments made by the Sponsor in relation to a proposed publication by the Investigator will be incorporated by the Investigator into the publication.|t
17164091|NCT01690273|t||||f
17164092|NCT05201807|f||GT60||t
17164093|NCT01209767|t||||
17164094|NCT01702298|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17164095|NCT00400686|f||||f
17164096|NCT01752049|f||||f
17182517|NCT00477672|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17182518|NCT03078946|t||||f
17182519|NCT02800148|f||OTHER|PI's cannot disclose trial results under any circumstances.|t
17182520|NCT01467999|f||||f
17182521|NCT01398956|f||GT60||t
17182522|NCT04155008|t||||
17182523|NCT00739752|f||||f
17182524|NCT03761732|t||||
17182525|NCT03925727|f||OTHER|Sponsor, or its designee, shall have the right to coordinate one or more publications of the aggregate multi-site Study results. Accordingly, Investigator agrees not to publish or present the results of the Study until such time as the aggregate multi-site Study results are published.|t
17182526|NCT00558103|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182527|NCT02215070|f||||f
17182528|NCT02381392|f||||f
17182529|NCT00978731|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182530|NCT02488785|f||||f
17182531|NCT00293384|t||||f
17182532|NCT00773175|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17182533|NCT01302964|f||||f
17182534|NCT04718870|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17182535|NCT00192075|f||GT60||t
17182536|NCT00779675|f||OTHER|The investigator agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data.|t
17182537|NCT03237234|f||||f
17182538|NCT01818804|t||||
17182539|NCT01569529|f||||f
17182540|NCT02224872|f||||f
17182541|NCT00355238|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182542|NCT04300296|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182543|NCT03325166|t||||
17182544|NCT01633944|f||OTHER|PI and Institution reserve the right to publish and present the results of the work performed provided that Institution and/or PI submits a copy of any proposed publication to Sponsor's agent for review and comment at least 90 days in advance of its presentation or submission for publication. In addition, if Sponsor's agent requests, Institution and/or PI will withhold publication or presentation for an additional 60 days to allow for establishing and preserving its proprietary rights.|t
17182545|NCT02096458|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17182546|NCT03913078|f||||f
17182547|NCT02412631|t||||
17182548|NCT00958776|f||||f
17182549|NCT06138756|f||||f
17182550|NCT03795610|t||||
17182551|NCT02509065|t||||
17182552|NCT04098458|t||||
17182553|NCT03762083|f||||f
17182554|NCT00116558|t||||
17182555|NCT02027844|f||||f
17164097|NCT01206517|f||OTHER|Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.|t
17164098|NCT03493958|t||||
17164099|NCT01029535|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164100|NCT04047446|t||||
17164101|NCT02367456|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164102|NCT02458235|t||||f
17164103|NCT00895921|t||||
17164104|NCT00845702|f||GT60||t
17164105|NCT00548886|t||||
17164106|NCT00687076|f||||f
17137994|NCT03788967|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 45 days to preserve intellectual property|t
17182556|NCT00378014|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17182557|NCT02662387|f||||f
17182558|NCT04889625|f||GT60||t
17164107|NCT04987372|t||||
17164108|NCT01198587|t||||
17164109|NCT00904371|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17164110|NCT04252014|t||||f
17182559|NCT03746522|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17182560|NCT02439775|f||||f
17182561|NCT03047135|f||||f
17182562|NCT04087122|f||||f
17182563|NCT02659020|f||GT60||t
17137995|NCT03927911|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17137996|NCT04432376|f||OTHER|Proprietary Information will need prior written consent of the sponsor. PI will hold in confidence and not disclose any Proprietary Information unless disclosure has its prior written consent from sponsor, or that the information is disclosed to personnel who need to know. Sponsor will not prohibit PI to comply with applicable laws and regulations, provided PI gives prior written notice to Sponsor. Disclosure allowed if legally required and accorded confidential treatment.|t
17164111|NCT00553254|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164112|NCT00189137|t||||
17164113|NCT02008617|t||||
17164114|NCT02134184|f||||f
17164115|NCT00583219|t||||f
17182564|NCT01585766|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17164116|NCT00754572|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164117|NCT01864434|t||||
17164118|NCT00998010|t||||
17164119|NCT05448950|f||OTHER|"Agreement states the following:~Research results and associated data generated by this Study conducted under this Agreement will be considered confidential until the first publication or presentation thereof of data according to the terms of this Agreement or one (1) year after conclusion, abandonment or termination of the Study."|t
17164120|NCT02836249|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17182565|NCT01120210|f||OTHER|If an Investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the Sponsor in writing, the Investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17164121|NCT00619866|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17164122|NCT00963872|t||||
17164123|NCT01098422|t||||
17164124|NCT01968980|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164125|NCT01474109|f||OTHER||t
17164126|NCT02589938|f||||f
17164127|NCT02521285|f||LTE60||t
17164128|NCT01849276|t||||
17164129|NCT00375713|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17182566|NCT02043015|t||||
17164130|NCT01722669|f||||f
17164131|NCT04716725|t||||
17164132|NCT03559556|t||||
17164133|NCT03506360|t||||
17164134|NCT02927964|t||||
17164135|NCT03140969|f||OTHER|Institution shall be free to publish, present, or use any Data and results arising out of its performance of the protocol. At least 30 days prior to submission for publication, institution shall submit to Sponsor for review and comment any proposed oral or written publication. Institution will consider any such comments in good faith but is under no obligation to incorporate Sponsor's suggestions. The review period for abstracts or poster presentations shall be 30 days.|t
17164136|NCT03012880|t||||
17164137|NCT01587196|t||||
17164138|NCT02769481|f||OTHER|Investigator has no publication right.|t
17168951|NCT02219503|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17168952|NCT00491608|f||OTHER|ZymoGenetics (ZG) agreements vary by trial, but each states that presentation/publication (p/p) cannot disclose Confidential Information (CI), excluding trial results; p/p may not begin until the earlier of 18 months after study end, ZG/lead investigator publishes, or ZG notification that multicenter publication is not planned; ZG has specified time for draft review before submission/presentation and may delay or modify content, require CI removal, and delay p/p for patent application filing.|t
17168953|NCT00025155|f||LTE60||t
17168954|NCT00413374|f||||f
17168955|NCT00552760|t||||
17168956|NCT01944345|f||GT60||t
17168957|NCT04079881|t||||
17168958|NCT00924404|t||||
17168959|NCT02613169|f||||f
17168960|NCT00343382|t||||
17168961|NCT01985360|t||||
17168962|NCT02976103|t||||
17168963|NCT01455220|f||||f
17168964|NCT04881747|f||GT60||t
17168965|NCT04598269|f||||t
17168966|NCT00721539|f||||f
17168967|NCT00225784|f||||f
17168968|NCT04054999|t||||
17168969|NCT03869333|f||||f
17168970|NCT02598128|f||LTE60||t
17168971|NCT03134183|t||||
17168972|NCT02504931|f||||f
17168973|NCT00845065|f||OTHER|Investigator agrees not to present any interim results of study without prior written consent of sponsor. Investigator agrees to provide sponsor 45 days prior to submission publication, review copies of abstracts/manuscripts that report any results of the study. Sponsor shall have the right to review/comment on data analysis. If parties disagree investigator agrees to meet with sponsor's representatives at clinical study site for purpose of making good faith efforts to resolve any such issues.|t
17168974|NCT00162266|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17168975|NCT01198509|t||||f
17168976|NCT00499746|f||||f
17168977|NCT03028636|f||GT60||t
17168978|NCT01102894|f||||f
17168979|NCT01291277|f||||f
17168980|NCT03480009|t||||
17168981|NCT01563172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168982|NCT02495454|f||OTHER|The Sponsor, in accordance with art.5 of DM, minist. decree (Feb8,2013), guarantees the publication of the results of the study without any constraints and ensuring all the participating centres a proportional visibility to the actual participation. The single centre will be able to publish partial data of patients treated at the centre after the publication of the global results, or 24 months after the last patient's enrolment date, regardless of which centre the last patient was recruited at.|t
17168983|NCT01120990|t||||
17168984|NCT01638559|f||||f
17168985|NCT02539511|t||||
17168986|NCT00483002|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17168987|NCT00772109|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17168988|NCT01624090|f||||f
17168989|NCT00752726|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17168990|NCT01403116|f||GT60||t
17168991|NCT01895309|f||OTHER|At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them. If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.|t
17168992|NCT00042666|f||GT60||t
17168993|NCT04232215|t||||
17168994|NCT02454153|f||||f
17168995|NCT02048371|f||||f
17168996|NCT01879072|f||||f
17168997|NCT02108691|t||||
17168998|NCT00626405|t||||
17168999|NCT00370838|f||||f
17169000|NCT04046250|f||OTHER|"Each of the three clinical sites has a PI. Each PI is bound by a CDA covering the clinical data.~Tosk intends to prepare a manuscript reporting results from this trial combined with the results from the Phase 1b clinical trial. All the PIs will have a chance to review and approve the findings reported in the manuscript. Tosk expects to submit the manuscript for publication in early 2022."|t
17169001|NCT00709878|f||||f
17169002|NCT04576897|f||||t
17169003|NCT00527332|f||||f
17169004|NCT02666105|f||||f
17169005|NCT01078168|t||||
17169006|NCT02147769|f||||f
17169007|NCT01264419|f||OTHER|Standard Non-Disclosure agreement and clinical trial agreement publishing policy in addition.|t
17169008|NCT01962870|f||||f
17169009|NCT00358436|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17169010|NCT05101798|t||||
17169011|NCT02905006|f||GT60||t
17169012|NCT01387464|f||OTHER||t
17169013|NCT04091048|f||||f
17182567|NCT00974571|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17137997|NCT04847141|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17137998|NCT04507776|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182568|NCT01990677|t||||f
17182569|NCT00966238|f||LTE60||t
17182570|NCT02927457|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182571|NCT00868621|f||||f
17164139|NCT03510715|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17164140|NCT03826472|f||||f
17164141|NCT04604431|f||||f
17164142|NCT00643279|f||||f
17164143|NCT04603560|t||||
17164144|NCT02096107|f||||f
17164145|NCT03612570|f||GT60||t
17164146|NCT03557502|f||||f
17164147|NCT02333799|f||||t
17164148|NCT00710944|f||LTE60||t
17164149|NCT01657370|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164150|NCT03021486|t||||
17164151|NCT04795531|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17164152|NCT04887831|f||OTHER|Investigator agrees to submit any disclosure to Sponsor for review at least thirty (30) days prior to submission. Within sixty (60) days of its receipt, Sponsor can provide feedback on any disclosure Sponsor may require Investigator to remove, Confidential Information (other than study data), and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for inventions.|t
17164153|NCT03014635|f||OTHER|With respect to any proposed publication or disclosure of the results of the Study, the Study Center and Investigator shall submit to Revance a copy of the proposed publication or disclosure at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i) to provide Revance with the opportunity to review and comment on the contents thereof, and (ii) to identify any Confidential Information to be deleted from the proposed publication or disclosure.|t
17164154|NCT04507204|f||||t
17164155|NCT03580044|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164156|NCT05093621|t||||
17164157|NCT02095106|f||||f
17164158|NCT03373435|f||||f
17164159|NCT05134649|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17164160|NCT01559935|t||||f
17182572|NCT01494610|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182573|NCT03395314|t||||
17182574|NCT00915798|f||||f
17182575|NCT02130765|f||||f
17137999|NCT01624506|f||OTHER||t
17138000|NCT00962754|t||||
17138001|NCT01711541|f||LTE60||t
17164161|NCT02958865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164162|NCT04198012|f||||t
17164163|NCT05112640|f||||f
17164164|NCT02527512|f||||f
17164165|NCT03057704|t||||
17164166|NCT01014871|f||OTHER|Disclosure agreement in full force and effect for a period of 10 years.|t
17164167|NCT00244985|t||||
17164168|NCT02329587|t||||
17164169|NCT00455702|f||||f
17164170|NCT01038323|f||||f
17164171|NCT01143402|f||LTE60||t
17164172|NCT04462471|t||||
17164173|NCT01734525|f||||f
17164174|NCT02526290|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164175|NCT00538850|f||||f
17164176|NCT03949517|t||||
17164177|NCT03078452|t||||
17164178|NCT02347410|f||||f
17182576|NCT04514991|t||||
17182577|NCT00283933|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17182578|NCT02244580|f||||f
17164179|NCT01380080|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17164180|NCT05634538|f||GT60||t
17164181|NCT06378008|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164182|NCT00210132|t||||
17164183|NCT00432965|f||GT60||t
17138002|NCT00132314|t||||f
17164184|NCT05677347|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17164185|NCT03636022|t||||
17164186|NCT04532749|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will delay to allow for filing of a patent application.|t
17164187|NCT00642759|t||||
17164188|NCT01230411|t||||
17164189|NCT01346176|t||||f
17164190|NCT02255435|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17164191|NCT01227785|f||OTHER|Sponsor shall be provided with copy of all Trial-related manuscripts and reports for review and comment|t
17182579|NCT01736696|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182580|NCT02114879|f||||f
17182581|NCT01455012|f||GT60||t
17138003|NCT00700063|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor. As used herein, the term 'publish' shall include oral presentations, written abstracts, written manuscripts, etc.|t
17164192|NCT00442702|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164193|NCT01664624|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17164194|NCT00127439|t||||f
17164195|NCT01500317|t||||f
17164196|NCT00335829|f||||f
17164197|NCT04373369|t||||
17164198|NCT04067011|f||||t
17164199|NCT03746015|f||OTHER||t
17164200|NCT05209386|t||||f
17164201|NCT05200845|t||||
17164202|NCT02303262|f||||f
17164203|NCT01121757|t||||
17164204|NCT04251533|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164205|NCT05901636|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17164206|NCT04583618|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17164207|NCT02711202|t||||
17182582|NCT00613509|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17138004|NCT00749268|f||LTE60||t
17138005|NCT00877006|f||OTHER|Investigator/Institution must submit proposed publication to Sponsor for review within a prespecified number of days before submission for publication. If Sponsor's review shows that potentially patentable subject matter would be disclosed, publication/public disclosure shall be delayed to enable Sponsor, or Sponsor's designees, to file necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17138006|NCT01415908|f||LTE60||t
17138007|NCT02034552|f||GT60||t
17138008|NCT00546429|f||LTE60||t
17138009|NCT03728504|f||||f
17164208|NCT01561469|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164209|NCT02274675|t||||f
17164210|NCT03189719|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17164211|NCT03448393|f||||f
17164212|NCT03330847|f||OTHER|Disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17164213|NCT01355627|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17164214|NCT03532256|f||||f
17164215|NCT02293551|t||||f
17164216|NCT03546439|t||||
17164217|NCT02106429|t||||
17164218|NCT04756531|t||||
17164219|NCT05643495|f||||t
17164220|NCT02257528|f||LTE60||t
17164221|NCT06272383|t||||
17138010|NCT02062398|f||OTHER|"Participating Institution and /or investigator may publish/present the results of the clinical investigation (publication) only upon prior written consent provided by BlueWind Medical Ltd."|t
17138011|NCT03485222|t||||f
17138012|NCT01618422|f||||f
17138013|NCT03657810|f||||f
17164222|NCT00253422|f||OTHER|There is an agreement between principal investigators and the Sponsor (or its agents) that restricts the PIs rights to discuss or publish trial results after the trial is completed.|t
17164223|NCT02918942|f||||f
17164224|NCT04569084|f||OTHER||t
17164225|NCT01994876|t||||
17164226|NCT01400412|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17164227|NCT05395936|t||||
17164228|NCT04043286|f||||f
17164229|NCT01323192|f||GT60||t
17164230|NCT02296476|f||OTHER|The Sponsor has the opportunity to review proposed publications regarding this trial 45 days prior to submission for publication. Publication can be withheld an additional 90 days to allow for filing a patent or taking other measures to establish and preserve proprietary rights. Publication of the results of the study shall be made only as part of a publication of the results obtained by all sites performing the study.|t
17164231|NCT00313560|t||||f
17164232|NCT04073056|t||||
17164233|NCT02964377|t||||
17138014|NCT03554850|f||OTHER||t
17138015|NCT03325556|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17138016|NCT02487277|t||||
17138017|NCT02119026|f||||f
17138018|NCT01373918|f||||f
17138019|NCT05859971|t||||
17164234|NCT03122184|f||||f
17164235|NCT02835690|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17164236|NCT03674281|t||||
17164237|NCT00710593|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17164238|NCT04490278|t||||
17164239|NCT00525421|t||||
17164240|NCT02829996|f||||f
17164241|NCT01441960|f||||f
17164242|NCT02004158|t||||
17164243|NCT02986074|f||||f
17164244|NCT02481414|t||||
17164245|NCT01444911|t||||f
17164246|NCT00069641|f||GT60||t
17164247|NCT03186638|f||||f
17164248|NCT01263119|f||GT60||t
17164249|NCT02369536|f||||f
17164250|NCT04573972|f||||f
17164251|NCT05067335|f||GT60||t
17164252|NCT01645176|f||||f
17164253|NCT00560417|f||GT60||t
17164254|NCT00261833|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164255|NCT00622726|t||||f
17164256|NCT01948427|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17164257|NCT00402987|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17164258|NCT05528770|f||||f
17164259|NCT03130569|f||||f
17164260|NCT01874392|t||||
17164261|NCT01394159|t||||f
17164262|NCT02006927|t||||
17164263|NCT03229538|t||||
17164264|NCT02735200|t||||
17164265|NCT00673920|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164266|NCT01416025|f||||f
17164267|NCT01164007|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164268|NCT04165824|f||OTHER||t
17164269|NCT04138056|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17164270|NCT01215851|f||OTHER|All unpublished information given to the Investigator by the Sponsor shall not be published/disclosed to a third party, other than to IEC/IRB, within the understanding of the confidentiality, without the prior written consent of the Sponsor. Results of this research will be submitted for publication as soon as feasible upon completion of the study in the form of a joint publication(s) between the Sponsor and Investigator(s), including site clinical and laboratory investigators, as appropriate.|t
17164271|NCT01606150|f||||f
17164272|NCT01082939|t||||
17182583|NCT01215227|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17182584|NCT02253810|t||||
17182585|NCT01686646|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182586|NCT02549508|f||||f
17182587|NCT00213148|f||OTHER||t
17182588|NCT00556842|f||||f
17164273|NCT00862940|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and H. Lundbeck A/S. Manuscripts and abstracts must be sent to H. Lundbeck A/S at least one month prior to submission for publication or presentation.|t
17164274|NCT05552859|f||OTHER||t
17164275|NCT02876172|t||||
17164276|NCT04533646|t||||
17164277|NCT04630769|t||||
17164278|NCT03423979|f||||f
17164279|NCT05239221|f||||f
17164280|NCT02581930|f||LTE60||t
17164281|NCT01270529|f||||f
17164282|NCT01385579|t||||f
17164283|NCT03386773|f||||f
17164284|NCT03983421|f||||f
17164285|NCT03639610|f||||f
17164286|NCT03136055|t||||
17164287|NCT02410772|f||||f
17164288|NCT01517984|f||||f
17164289|NCT02234362|f||||f
17164290|NCT02164864|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164291|NCT03807089|f||||f
17164292|NCT02569853|f||||t
17164293|NCT04358406|f||||f
17164294|NCT02434081|f||||f
17182589|NCT03400033|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182590|NCT01458327|t||||
17182591|NCT03993938|f||||f
17182592|NCT02469610|t||||
17182593|NCT02434770|f||||f
17182594|NCT01574352|f||||f
17182595|NCT00245765|f||GT60||t
17138020|NCT00340834|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."|t
17138021|NCT02892201|t||||
17138022|NCT01803854|f||||f
17164295|NCT01668004|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy of information, and regulatory compliance.|t
17164296|NCT00419744|f||OTHER|The PI may use the Multi-Center Study Results and the Site Data for the limited purpose of his or her own research and academic analysis until the earlier of the publication of the first Multi-center Publication and the second anniversary of the completion of the Multi-center Study at all participating sites.|t
17164297|NCT03462745|t||||
17164298|NCT02196922|f||||f
17182596|NCT00660348|t||||
17182597|NCT01617603|f||OTHER||t
17164299|NCT02448381|f||||f
17164300|NCT04856527|f||||f
17164301|NCT01816295|f||GT60||t
17164302|NCT01823289|f||LTE60||t
17164303|NCT02814656|f||OTHER|Publication and / or presentation whether complete or partial, of any part of the data or results of this study will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the Investigator and AstraZeneca|t
17164304|NCT01259011|f||||f
17164305|NCT02135484|t||||
17164306|NCT01656161|f||OTHER|Agreement restricts the PI from discussing or publishing trial results after the trial is completed.|t
17164307|NCT03510273|t||||
17164308|NCT01276106|f||LTE60||t
17164309|NCT03199079|t||||
17164310|NCT04079738|f||||f
17164311|NCT05196776|t||||f
17164312|NCT00867035|t||||
17164313|NCT00404248|f||||f
17164314|NCT00789555|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17164315|NCT04646005|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17164316|NCT04398706|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17164317|NCT02611037|t||||
17182598|NCT03316872|t||||
17182599|NCT01966926|t||||
17182600|NCT04074317|f||||t
17182601|NCT01507493|t||||
17182602|NCT00653224|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17182603|NCT04482179|t||||
17182604|NCT04709237|f||OTHER||t
17138023|NCT03939637|f||||f
17138024|NCT05224076|f||||f
17164318|NCT04577404|f||OTHER||t
17164319|NCT04066829|t||||
17164320|NCT00775671|t||||
17164321|NCT04237584|f||||t
17164322|NCT03586973|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182605|NCT04048460|f||||f
17164323|NCT01005290|f||OTHER|Communications and publication must be agreed between sponsor and PI|t
17164324|NCT02661672|f||||f
17164325|NCT04696146|f||||f
17164326|NCT00285779|f||LTE60||t
17164327|NCT04164277|f||||f
17164328|NCT01334918|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17164329|NCT00529633|f||||f
17164330|NCT01576783|f||||f
17164331|NCT04096417|t||||
17164332|NCT01897493|f||GT60||t
17164333|NCT05489328|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164334|NCT01083602|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17182606|NCT02489318|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17182607|NCT05723770|f||||f
17164335|NCT03698279|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17164336|NCT02180828|f||||f
17164337|NCT01276704|t||||
17164338|NCT02276040|f||||f
17169014|NCT04201093|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169015|NCT00881504|t||||
17164339|NCT02239926|t||||
17164340|NCT02704208|f||||f
17164341|NCT03801525|f||||f
17169016|NCT00007020|f||||f
17164342|NCT02673944|f||||f
17164343|NCT05077969|f||||f
17164344|NCT04388826|f||||t
17164345|NCT00329420|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17164346|NCT02862574|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164347|NCT00284180|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17164348|NCT00822094|f||||f
17164349|NCT02724839|t||||f
17164350|NCT05878067|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169017|NCT01276223|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17169018|NCT03950492|t||||
17169019|NCT02455076|t||||
17182608|NCT01171898|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17182609|NCT00419562|f||||f
17182610|NCT03854916|f||||f
17138025|NCT01082367|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17138026|NCT02016898|t||||
17138027|NCT01665768|f||||f
17138028|NCT01329341|t||||
17138029|NCT03017846|f||||f
17138030|NCT04603391|t||||
17138031|NCT02151682|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17138032|NCT01306032|f||||f
17138033|NCT02375984|t||||
17138034|NCT03260894|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17138035|NCT00707343|t||||
17138036|NCT00168064|f||||f
17138037|NCT00290589|t||||
17138038|NCT05014542|t||||
17138039|NCT06000501|t||||
17138040|NCT00318565|f||||f
17164351|NCT00949533|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164352|NCT01440764|f||||f
17164353|NCT00320606|f||||f
17182611|NCT05194020|t||||
17182612|NCT01276314|t||||
17182613|NCT02267629|f||||f
17164354|NCT03984825|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164355|NCT01190527|t||||
17164356|NCT01117779|f||OTHER|"Per the Boston Scientific (BSCI) Clinical Trial Agreement, BSCI needs to publish first.~PIs may publish their own data one year after the study has completed. If the PI wishes to publish after BSCI, then BSCI needs to be acknowledged in the publication."|t
17164357|NCT00399035|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17164358|NCT01959685|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17164359|NCT02621892|f||GT60||t
17164360|NCT03781479|f||||f
17164361|NCT02921256|f||LTE60||t
17164362|NCT02943473|t||||
17164363|NCT03261830|f||||f
17138041|NCT01896856|f||OTHER|The Principal Investigators (PIs) from participating sites must provide the Johns Hopkins PI with a copy of any proposed publication for review and comment at least 30 days prior to submission.|t
17164364|NCT04211363|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17138042|NCT00979017|t||||
17138043|NCT03589885|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17138044|NCT02486211|f||||f
17138045|NCT02807363|f||||t
17138046|NCT00476996|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138047|NCT05202223|t||||
17138048|NCT02443571|f||||f
17138049|NCT01214317|t||||
17138050|NCT00505895|t||||f
17138051|NCT05351710|t||||
17138052|NCT01181778|f||OTHER|"Investigators have accepted and committed not to disclose~information herein contained. Investigators will not to publish or disclose any results pertaining to the study without written authorization by the Sponsor.~Investigators accept that the Sponsor will review any manuscript or abstract 30 days before submission for a publication or presentation (including oral~presentations) containing data derived from the present study."|t
17138053|NCT01265420|f||||f
17164365|NCT03097289|f||OTHER|Sponsor retains the right to review and comment on any public disclosure of study results. If no response is received within 60 days, the Principal Investigator may presume that the submission for publication may proceed without delay. If the Sponsor asks to defer publication, Study Site shall not publish, or otherwise disclose to any third party, any of the information contained in the publication or presentation until expiration of the 60 day period.|t
17164366|NCT01736917|f||||f
17138054|NCT04884945|f||||f
17138055|NCT02332798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164367|NCT01911260|f||||f
17164368|NCT00654732|t||||
17164369|NCT01951391|f||||f
17164370|NCT02481557|t||||
17164371|NCT01734902|t||||
17164372|NCT01959932|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17164373|NCT00758563|f||GT60||t
17164374|NCT00060944|f||GT60||t
17164375|NCT01138514|f||LTE60||t
17164376|NCT00776230|f||OTHER||t
17164377|NCT03381989|f||||f
17164378|NCT01242514|f||OTHER|The disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to publication. Sponsor will be allowed a review period of at least 60 days from submission but can request that publication be delayed for a period up to 6 months. Any reasonable comments made by the sponsor will be incorporated by the PI into the publication.|t
17138056|NCT05406440|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17138057|NCT00525785|t||||
17138058|NCT02455388|t||||
17164379|NCT03112902|f||||f
17164380|NCT03861338|t||||
17164381|NCT02274571|f||||f
17164382|NCT04951193|f||||f
17164383|NCT03110562|f||OTHER||t
17164384|NCT02936323|f||OTHER|"Institute and/or Principal Investigator may submit for publication or public disclosure based on the results of the study only after one of the following occurs as specified in the Clinical Trial Agreement:~1. Sponsor publication of the multi-center clinical trial results;~2. Sponsor notification that the multi-center clinical trial results submission is no longer planned; or~3. The eighteenth (18) month anniversary of the completion or early termination of the multi-center clinical trial."|t
17164385|NCT05788991|f||||f
17164386|NCT05270863|f||||f
17164387|NCT04464473|f||||f
17164388|NCT01585025|t||||
17164389|NCT00805389|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164390|NCT01409096|f||||f
17164391|NCT00557193|f||OTHER|Must obtain sponsor approval.|t
17164392|NCT00976456|f||||f
17164393|NCT02037529|t||||
17164394|NCT02131766|f||||f
17164395|NCT00718315|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164396|NCT01170663|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17169020|NCT04051827|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17164397|NCT00427037|t||||
17164398|NCT02746809|f||||f
17164399|NCT01650402|f||||f
17169021|NCT04394715|t||||
17169022|NCT03675516|f||||f
17169023|NCT03743064|f||OTHER|The Sponsor has the sole right to first publication of the study data, which would be a multi-center publication. Investigators may publish the Study Data they obtained if they follow the conditions provided in the protocol. These include, but are not limited to: the multi-center publication has occurred; the Sponsor is given 60 days to review the document and possibly 60 more days to obtain Intellectual Property protections; and all Confidential Information is deleted, as requested by Sponsor.|t
17169024|NCT02387294|f||OTHER|The disclosure restriction on the PI is that the sponsor in the frames of the general confidentiality agreement is that the PI cannot release any information concenning the study without the prior consent of the sponsor. To further specification is provided.|t
17169025|NCT02771626|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17169026|NCT01852383|t||||
17169027|NCT00635089|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17169028|NCT00444067|f||OTHER|"* The sponsor can review results at least 30 days prior to public release, and at the request of Sponsor, the PI will withhold submission for an additional period, not to exceed 30 days.~* The first publication of the study results shall be made in conjunction with a joint, multi-center publication of the results. If a multi-center publication is not submitted within 12 months after the conclusion of the study, the PI may publish the results from their individual site."|t
17169029|NCT01300455|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17169030|NCT02528357|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169031|NCT00412074|f||||f
17169032|NCT01399268|t||||
17169033|NCT02438813|f||OTHER|Institution and/or Investigator shall allow Sponsor not less than 45 days to review any manuscript and not less than 30 days to review any poster presentation, abstract or any other written or oral material which describes or discloses the Study results. Institution and Investigator agree that because the Study is part of a multi-center Study, any publication by Institution or Investigator of the Study Results shall not be made before the first multi-center publication of participating sites.|t
17169034|NCT01927055|f||||f
17169035|NCT00499408|t||||
17169036|NCT03002454|t||||
17169037|NCT00619489|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169038|NCT02966015|f||LTE60||t
17169039|NCT03445390|t||||
17169040|NCT00552409|t||||
17169041|NCT00509171|f||GT60||t
17164400|NCT00894387|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17164401|NCT01128569|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164402|NCT02519842|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17164403|NCT02468830|f||||f
17164404|NCT02319486|f||||f
17164405|NCT01295710|f||||f
17164406|NCT02115321|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17164407|NCT00859833|f||LTE60||t
17164408|NCT02610634|f||||f
17164409|NCT01493414|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17164410|NCT03443635|t||||
17169042|NCT00054028|f||LTE60||t
17169043|NCT03274804|t||||
17169044|NCT01183468|f||||f
17169045|NCT00181610|t||||
17169046|NCT01994993|f||||f
17169047|NCT02228096|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169048|NCT00558272|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17169049|NCT00454649|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169050|NCT02745535|t||||
17169051|NCT01789606|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169052|NCT00849108|f||GT60||t
17169053|NCT00716742|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169054|NCT01105377|f||LTE60||t
17169055|NCT00712582|t||||
17138059|NCT01316939|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138060|NCT00801892|t||||
17164411|NCT01072526|t||OTHER|This study had no external sponsors. It was supported by the University of Missouri, my employer. The University of Missouri can review the data at anytime.|t
17164412|NCT01119287|f||OTHER||t
17164413|NCT01977222|t||||
17164414|NCT00680628|t||GT60||t
17164415|NCT02976181|f||||f
17164416|NCT04773665|f||||f
17164417|NCT01605669|f||||f
17164418|NCT00945659|f||||f
17164419|NCT04562116|f||OTHER||t
17138061|NCT01016678|f||||f
17138062|NCT01766219|t||||
17138063|NCT00728936|f||||t
17164420|NCT00534001|f||||f
17164421|NCT02412670|f||LTE60||t
17164422|NCT00934921|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17164423|NCT03342560|f||||f
17164424|NCT03213509|f||||f
17164425|NCT01370551|f||||t
17164426|NCT00833521|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17164427|NCT01280942|t||||
17164428|NCT04549454|t||||
17164429|NCT02371356|f||||f
17164430|NCT04336826|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17164431|NCT03801993|f||||f
17164432|NCT00016354|t||||
17164433|NCT02160808|f||||f
17164434|NCT02993263|t||||
17164435|NCT01405196|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164436|NCT01729039|t||||
17169056|NCT00491374|f||OTHER||t
17169057|NCT02014584|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138064|NCT02966353|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17138065|NCT00093470|f||LTE60||t
17138066|NCT01188096|t||||
17138067|NCT00851253|f||||f
17164437|NCT00698841|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17164438|NCT00829998|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17164439|NCT02114177|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17164440|NCT03326245|t||||
17164441|NCT00140140|f||OTHER|Celgene shall complete its review within 30 days after receipt of a proposed publication or presentation submitted by the investigator. Upon request, the publication/presentation might be delayed up to 60 additional days for Celgene to secure intellectual property protection. Subsequent to the multicenter publication or one year after study completion, whichever occurs first, an investigator and/or his/her colleagues may publish the results of INVESTIGATOR's part of the study independently.|t
17164442|NCT03376516|f||||f
17164443|NCT01359956|f||||f
17164444|NCT01784029|t||||f
17164445|NCT00582907|f||||f
17164446|NCT01453166|t||||
17164447|NCT01161771|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17164448|NCT03564886|f||||f
17169058|NCT01555125|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17169059|NCT02651220|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17169060|NCT02039856|t||||
17169061|NCT00896441|f||||f
17169062|NCT01304589|f||||f
17169063|NCT01447121|f||GT60||t
17138068|NCT01779648|t||||
17138069|NCT00415519|f||OTHER||t
17138070|NCT03154307|f||||f
17138071|NCT01705587|f||||f
17138072|NCT03004976|t||||
17138073|NCT00291499|f||||f
17138074|NCT03807245|f||||f
17138075|NCT01532570|f||OTHER||t
17138076|NCT05034614|t||||
17138077|NCT03892707|f||LTE60||t
17138078|NCT04263363|f||||f
17138079|NCT01807949|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17138080|NCT03819764|f||||f
17138081|NCT04325906|f||OTHER|The study funder (Rice foundation) had no role in study design, data analysis, the preparation or approval of the manuscript, or the decision to submit the manuscript for publication|t
17138082|NCT02141217|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138083|NCT03515213|f||||f
17138084|NCT01978600|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138085|NCT01181141|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17138086|NCT00448760|t||||
17138087|NCT01226706|t||||
17138088|NCT01789346|f||||f
17138089|NCT01899677|f||||f
17138090|NCT01213264|f||OTHER|Results from Investigator's site will initially only be published/presented with results from the other sites, unless permission is obtained to publish separate results. Investigator will not publish interim results. Sponsor must be able to review all proposed study results communications 45 days prior to submission for publication/presentation. If parties disagree concerning appropriateness of proposed content, Investigator will meet with Sponsor's representatives to discuss/resolve any issues.|t
17138091|NCT01229891|t||||
17138092|NCT00118911|f||||f
17138093|NCT05507580|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138094|NCT01438307|f||||f
17138095|NCT04702984|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138096|NCT03496662|t||||
17138097|NCT02378883|f||||f
17138098|NCT03037307|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138099|NCT00691093|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164449|NCT03610048|f||||t
17164450|NCT01155050|f||||f
17164451|NCT01636284|f||||f
17164452|NCT01146613|f||OTHER|"The NIAAA Project Officer is responsible for overseeing the preparation of the main paper summarizing the main findings of the completed Study (the Main Paper). No single site data will be published or otherwise disseminated without first consulting and coordinating any such publication or dissemination with the investigators from all stakeholders. Additional manuscripts published after the publication of the Main Paper may be initiated and primarily authored by NIAAA."|t
17164453|NCT01959529|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property"|t
17164454|NCT00652834|f||||f
17164455|NCT02668666|f||||f
17164456|NCT01987414|f||||f
17164457|NCT01999192|f||GT60||t
17164458|NCT00854360|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17164459|NCT02441218|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publication and/or communication related to the study results and can require changes. In case of a patent application, the sponsor can delay its authorization for publication or communication of the study results until the date of international registration of the patent.|t
17164460|NCT01541371|f||OTHER||t
17164461|NCT01131052|t||||
17164462|NCT01528592|f||||f
17164463|NCT02271880|f||||f
17164464|NCT00806585|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17138100|NCT01588353|f||OTHER|Asahi Kasei Pharma Corporation agreements may vary with individual facilities but will not prohibit any investigator from publishing. Asahikasei supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17138101|NCT03123055|f||||f
17138102|NCT06444165|f||GT60||t
17164465|NCT00474903|f||LTE60||t
17164466|NCT00399529|f||||f
17164467|NCT03435380|t||||
17164468|NCT01103414|f||LTE60||t
17164469|NCT01936831|f||||f
17164470|NCT02133573|t||||
17164471|NCT01093014|t||||
17138103|NCT03814005|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17164472|NCT02493764|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17164473|NCT01307449|t||||
17164474|NCT03218917|f||LTE60||t
17164475|NCT01561976|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164476|NCT02468583|f||||t
17164477|NCT00427193|t||||f
17164478|NCT01463527|t||||f
17164479|NCT05136170|f||||f
17164480|NCT01788943|t||||
17164481|NCT00383071|t||||
17164482|NCT04403919|t||||
17138104|NCT05489081|t||||
17164483|NCT01612676|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17164484|NCT04319809|t||||
17164485|NCT01156844|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17164486|NCT01204788|t||||
17164487|NCT03892317|t||||
17164488|NCT00107276|f||||f
17164489|NCT04846231|f||||f
17164490|NCT02980107|f||OTHER|The sponsor had no role in the research planning, its execution nor publication.|t
17138105|NCT00810810|f||||f
17164491|NCT00476645|t||||f
17164492|NCT01448616|f||||f
17164493|NCT01991860|f||GT60||t
17164494|NCT00397540|t||||f
17164495|NCT01129206|t||||
17164496|NCT01800786|t||||
17138106|NCT01409993|t||||
17164497|NCT00485173|f||LTE60||t
17164498|NCT00746811|f||||f
17182614|NCT00701129|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17182615|NCT04027218|f||||f
17182616|NCT03004534|f||OTHER|No publication, abstract or presentation of the study will be made without the approval of the Study Steering Committee (SSC).|t
17182617|NCT03963518|t||||
17182618|NCT00976898|t||||
17164499|NCT00545779|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164500|NCT01356147|f||||f
17164501|NCT00834197|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17164502|NCT04712669|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17169064|NCT02409342|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17126875|NCT01827475|t||||f
17169065|NCT03908970|f||||f
17169066|NCT00279812|f||||f
17169067|NCT01274429|t||||f
17169068|NCT02423980|f||||f
17169069|NCT01729494|f||||f
17164503|NCT01819272|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17164504|NCT00503984|t||||
17164505|NCT03430349|f||||f
17164506|NCT01246960|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17164507|NCT00716820|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164508|NCT00639457|f||||f
17164509|NCT00370292|f||GT60||t
17164510|NCT00276419|t||||f
17164511|NCT00508521|t||||
17164512|NCT01622296|t||||
17169070|NCT01399008|f||OTHER|Publication requires the prior written consent of the Sponsor. The Principal Investigator must provide the Sponsor the opportunity to review any proposed abstracts, manuscripts or presentations that relate to any research or clinical results at least 30 days prior to its intended submission for publication.|t
17169071|NCT05327361|t||||f
17169072|NCT01776723|t||||
17169073|NCT02986802|f||||f
17164513|NCT00372957|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182619|NCT05107128|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182620|NCT01470469|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17182621|NCT04988295|f||OTHER|Study site and investigator shall not publish study results except as required by law or as specified in a separate, written agreement between the sponsor and the study site or the investigator.|t
17182622|NCT04649151|f||||t
17182623|NCT03752619|f||||f
17182624|NCT05847153|t||||
17164514|NCT04778592|f||OTHER|The only disclosure restriction on the PI is that the PI will provide the sponsor with a copy of any proposed communication at least 90 days in advance of the proposed submission or presentation date. Within this 90 day period, the sponsor will review the communication to determine whether it contains any sponsor Confidential Information, or whether the sponsor desires to file patent applications on subject matter contained therein, and to ensure the accuracy of the information.|t
17164515|NCT01192126|f||OTHER||t
17164516|NCT02660229|f||||f
17164517|NCT03085680|f||||f
17169074|NCT01439373|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169075|NCT03281304|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169076|NCT03834220|f||OTHER|Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.|t
17169077|NCT02593318|t||||
17126888|NCT02898077|f||GT60||t
17169078|NCT02020408|t||||f
17169079|NCT05498467|t||||
17126889|NCT04410523|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17126890|NCT00621777|f||||f
17164518|NCT02431325|f||LTE60||t
17164519|NCT00744861|f||||f
17164520|NCT02304159|t||||f
17164521|NCT03398330|f||||t
17164522|NCT02347605|f||LTE60||t
17169080|NCT02720692|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17169081|NCT05011513|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169082|NCT03878758|f||||f
17169083|NCT02315560|t||||
17169084|NCT01969435|t||||
17164523|NCT01567722|f||LTE60||t
17164524|NCT00431964|f||||f
17164525|NCT01918189|f||||f
17164526|NCT00382174|f||OTHER|RegeneRx (RGN) agreements may vary with individual PIs, but will not prohibit any PI from publishing. RGN supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169085|NCT02100969|t||||
17169086|NCT01629953|t||||f
17164527|NCT02108288|f||||f
17164528|NCT02160288|f||||f
17164529|NCT02170064|f||OTHER||t
17164530|NCT03323164|f||||f
17164531|NCT03434834|t||||
17164532|NCT04103450|f||OTHER|The Sponsor does not object to publication by Institution or Principal Investigator (PI) of results of the Trial based on information collected or generated by the Institution or PI. However, the Institution and PI are required to provide the Sponsor with an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed to ensure against any inadvertent disclosure of Sponsor Confidential Information or unprotected Sponsor Inventions.|t
17164533|NCT01126957|t||||
17164534|NCT02092181|t||||
17164535|NCT00790673|f||||f
17164536|NCT03508050|f||||f
17164537|NCT03368066|t||||
17164538|NCT02625181|t||||
17164539|NCT03961308|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17164540|NCT03710889|f||OTHER|Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/\> 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/\> 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.|t
17164541|NCT00570713|f||LTE60||t
17164542|NCT04881760|f||GT60||t
17164543|NCT00867139|t||||
17164544|NCT01538199|f||||f
17164545|NCT02081586|f||||f
17164546|NCT03722810|t||||
17164547|NCT01677988|t||||
17164548|NCT00928772|f||||f
17164549|NCT00659425|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17164550|NCT00271544|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Medtronic reviews publications to determine if confidential information (CI) is included. Any such CI is deleted before publication. Medtronic may not censor/interfere with the publication. Investigators may publish single-site publications after a decision by Medtronic that no multi-site study publication will be done or 12 months after the study is closed, whichever is earlier."|t
17126892|NCT01239043|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17164551|NCT03358030|f||||t
17164552|NCT00829244|f||OTHER|The PI shall submit any results communication to the sponsor for review and comment at least 30 business days prior to submission. The sponsor shall have the right to request the PI to delete or modify any of sponsor's proprietary information contained therein. If the PI does not agree to the deletion or appropriate modification of such information, it shall postpone submission for publication or presentation for 60 days from the date the PI notifies the sponsor.|t
17164553|NCT02604511|t||||
17164554|NCT03770286|t||||
17164555|NCT02505425|f||||f
17164556|NCT02297412|f||||f
17169087|NCT06359080|f||||f
17169088|NCT01840527|f||||f
17126901|NCT01519089|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17126902|NCT00127205|f||LTE60||t
17126903|NCT03784001|f||||f
17126904|NCT00224887|t||||
17126905|NCT03199118|t||||
17126906|NCT04343287|f||||t
17126907|NCT03582943|t||||
17126908|NCT05032872|f||||f
17126909|NCT00488475|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17126910|NCT00267085|t||||f
17126911|NCT00461513|t||||
17126912|NCT03894618|f||OTHER|Site agrees not to publish any Study Results or data before the publication of results from the Overall Study. After Sponsor has published the results of the Overall Study, Site may publish or present results generated at Site. If Sponsor has not published results of the Overall Study within 18 months of data base lock, Site may publish the results of the Study that were generated at Site. Site agrees to first submit to Sponsor the proposed publication at least 30 days prior to the submission.|t
17126913|NCT02946853|f||||f
17126914|NCT00798590|t||||
17126915|NCT01404429|t||||f
17126916|NCT03794700|f||||f
17126917|NCT02120287|t||||
17169089|NCT00306527|f||GT60||t
17126918|NCT01163292|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17126919|NCT01546675|t||||
17126920|NCT00680992|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17126921|NCT01585155|f||OTHER||t
17126922|NCT01397422|f||||f
17126923|NCT00513305|f||GT60||t
17126924|NCT00636805|f||OTHER|Research site shall provide MGI copies of publication at least 30 days prior to submission to allow MGI to protect its copyrights, to determine any Confidential Information (CI) and to check for technical correctness. Site shall consider any MGI comments and delete any CI requested by MGI, unless CI removal changes accuracy or interpretation of results, in which case site and MGI will discuss timing of submission. MGI may request delay of up to 60 days to protect its copyright or patent rights.|t
17126925|NCT03491891|f||LTE60||t
17126926|NCT00710905|f||OTHER|When a clinical study report or manuscript, in lieu of a final report, is completed, Alcon will provide the summary findings of the study to the investigator.|t
17126927|NCT03776539|f||||f
17164557|NCT02031302|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor|t
17164558|NCT03050710|f||||t
17164559|NCT03374306|f||||f
17164560|NCT03950856|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17164561|NCT05899829|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164562|NCT05175014|t||||
17126928|NCT02297139|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17126929|NCT05907707|t||||
17138107|NCT01700985|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17138108|NCT05067452|t||||f
17126930|NCT04688320|f||||f
17126931|NCT03798691|t||||
17138109|NCT03859960|f||||f
17138110|NCT03074149|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138111|NCT00067470|f||OTHER|The first publication of the results shall be made by Sponsor in a joint publication. If such a multi-center publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from their site individually, subject however to comply with the other terms of the agreement.|t
17138112|NCT00050622|t||||
17138113|NCT01192204|f||||f
17138114|NCT02146248|f||||f
17138115|NCT01315847|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17138116|NCT02247401|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138117|NCT02995330|t||||
17138118|NCT01117012|f||GT60||t
17138119|NCT03695393|f||||f
17182625|NCT03362502|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138120|NCT00673894|t||||
17126932|NCT05148962|f||OTHER||t
17126933|NCT02368457|t||||
17138121|NCT01164865|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17138122|NCT01861054|f||||f
17138123|NCT03796182|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138124|NCT00405821|t||||
17138125|NCT04962503|f||||f
17138126|NCT01586806|t||||
17164563|NCT02781558|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164564|NCT00713193|f||||f
17182626|NCT00433654|f||||f
17182627|NCT01428193|t||||
17182628|NCT02315768|f||||f
17182629|NCT04135703|f||||f
17182630|NCT06219915|f||||f
17182631|NCT05320029|f||||t
17182632|NCT06105528|f||||f
17182633|NCT01246791|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17126934|NCT03670004|t||||
17138127|NCT04218799|t||||
17164565|NCT03802396|t||||
17164566|NCT00163293|f||GT60||t
17169090|NCT04037254|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17169091|NCT01023672|t||||f
17169092|NCT02504580|f||||f
17182634|NCT04049760|f||||f
17126935|NCT01525238|f||||f
17138128|NCT01769469|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17169093|NCT00448747|f||OTHER|"Study Protocol Section 10.7 Draft versions of abstracts or manuscripts must be made available to the co-authors and to the sponsor before any presentation of results or submission for publication. At least 2 weeks should be allowed for review and comment of an abstract and 4 weeks in the case of a full paper, respectively.~Multiple review cycles are usual for full papers and respective planning must account for this."|t
17138129|NCT02031432|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17138130|NCT00888615|f||LTE60||t
17138131|NCT01617187|f||OTHER|It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.|t
17138132|NCT04430283|f||OTHER|Faraday agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Faraday supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial through a multi-center publication.|t
17164567|NCT02561962|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17164568|NCT01150357|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164569|NCT03366454|f||||f
17164570|NCT03508674|f||||f
17164571|NCT01658059|t||||
17164572|NCT03198871|f||||f
17164573|NCT01732536|f||||f
17164574|NCT02359006|f||||f
17164575|NCT01581684|t||||
17164576|NCT03728933|f||GT60||t
17169094|NCT00387725|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164577|NCT03235050|f||OTHER|The Principal Investigator shall provide AstraZeneca with copies of any materials relating to the Study, the Study Documentation, or the Developed Technologies that either Party intends to publish (or submit for publication) or make any presentations relating to, at least 60 days in advance of publication, submission or presentation.|t
17164578|NCT03545672|f||||f
17126936|NCT00607724|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17126937|NCT03738423|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17164579|NCT01628913|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164580|NCT02415556|f||||f
17164581|NCT01621178|f||GT60||t
17164582|NCT00105534|f||OTHER|Institution and Principal Investigator shall not publish, present or use any data or results arising out of the performance of this study for their own instruction, research or publication without the prior express written consent of Sponsor.|t
17164583|NCT02935192|f||||f
17126938|NCT01241604|f||||f
17126939|NCT01593787|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17126940|NCT00151281|t||||
17126941|NCT01865747|f||OTHER|Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.|t
17126942|NCT02592876|f||||t
17126943|NCT01464775|f||||f
17126944|NCT01133418|f||||f
17126945|NCT00611975|t||||
17126946|NCT03621787|f||||f
17164584|NCT01561833|f||||f
17164585|NCT02896257|t||||
17164586|NCT02465931|t||||
17126947|NCT01077271|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17169095|NCT01085435|f||OTHER|Consultant (PI) acknowledges and agrees that (i) Consultant shall not publish any data, report, white papers or other materials arising out of the Services performed pursuant to this Agreement without the prior written consent of Boston Scientific, and (ii) any such publication shall not include Boston Scientific Confidential Information except prior written consent of Boston Scientific.|t
17126948|NCT03333876|t||||
17126949|NCT00095498|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17126950|NCT05020327|t||||
17126951|NCT04684394|f||||t
17126952|NCT00482690|f||||f
17126953|NCT00591370|t||||
17126954|NCT03439254|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45-day review period with the option to extend to an additional 90 days.|t
17126955|NCT03232580|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17126956|NCT02075476|f||||f
17126957|NCT00095056|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17126958|NCT04019990|t||||
17126959|NCT03918499|t||||
17126960|NCT00682851|f||||f
17126961|NCT00923260|t||||
17126962|NCT03829475|f||||f
17126963|NCT02060539|f||OTHER|All information gathered during this study is proprietary and should be made available only to those directly involved in the study. Information and reports arising from this project are the property of the sponsor.|t
17126964|NCT00353522|f||||f
17164587|NCT00492557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164588|NCT01574144|f||||f
17164589|NCT04102007|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17164590|NCT05130593|t||||
17164591|NCT00892008|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164592|NCT00329030|f||||f
17169096|NCT04724967|t||||
17169097|NCT02429791|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169098|NCT02166463|f||LTE60||t
17169099|NCT05856227|f||GT60||t
17169100|NCT01272869|t||||
17126965|NCT03377699|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17126966|NCT02580305|f||GT60||t
17126967|NCT01244529|f||OTHER|Publication requires agreement and written authorization from Sponsor.|t
17126968|NCT00941070|f||LTE60||t
17126969|NCT01247285|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17126970|NCT01416389|f||GT60||t
17126971|NCT01125514|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17126972|NCT02033083|t||||f
17126973|NCT02755818|f||||f
17126974|NCT02535091|f||||f
17126975|NCT03223662|f||||f
17126976|NCT02217475|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17126977|NCT02643472|f||||f
17164593|NCT01627691|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17164594|NCT00181844|t||||
17126978|NCT01215188|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17126979|NCT01012414|t||||f
17126980|NCT00506441|f||OTHER||t
17126981|NCT02601300|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17126982|NCT00673400|t||||
17126983|NCT01127763|f||||f
17126984|NCT01680640|t||||
17126985|NCT00528931|f||OTHER|Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not preceed the primary publication of the entire clinical trial.|t
17126986|NCT00992225|f||GT60||t
17164595|NCT04661033|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17164596|NCT03767881|f||||f
17164597|NCT02622191|f||||f
17126987|NCT03835351|t||||
17126988|NCT00291642|f||GT60||t
17126989|NCT00684723|f||GT60||t
17126990|NCT00924118|t||||
17126991|NCT02576587|f||||f
17126992|NCT00532493|f||OTHER||t
17126993|NCT00707759|t||||
17126994|NCT01769326|f||||f
17126995|NCT01036438|f||LTE60||t
17126996|NCT02153073|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17126997|NCT03702231|t||||
17126998|NCT01278173|f||||f
17126999|NCT00738894|f||OTHER|Publication of results requires review and approval by REDUCE Publication and Presentation Committee|t
17127000|NCT05745701|t||||
17127001|NCT00719329|f||||f
17127002|NCT03211117|t||||
17127003|NCT02546921|f||||f
17127004|NCT01504477|f||||f
17127005|NCT00422812|f||LTE60||t
17127006|NCT03772587|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17127007|NCT03367429|t||||f
17127008|NCT01942785|f||||f
17127009|NCT02227199|t||||
17127010|NCT05597787|f||||f
17127011|NCT04512430|f||||f
17127012|NCT01934790|f||OTHER|The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17127013|NCT05061472|t||||
17127014|NCT00552929|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17127015|NCT01200290|f||GT60||t
17127016|NCT00728910|f||||f
17127017|NCT04155203|f||OTHER||t
17164598|NCT00565409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164599|NCT01484652|f||||f
17164600|NCT03134326|f||LTE60||t
17164601|NCT04207320|t||||
17127018|NCT01144377|f||GT60||t
17127019|NCT02489968|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127020|NCT01728337|f||||f
17127021|NCT00660543|f||||f
17164602|NCT03440008|t||||
17127022|NCT00836745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127023|NCT02121301|f||OTHER|Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor will have the final decision regarding the manuscript and publication.|t
17127024|NCT01066520|f||LTE60||t
17127025|NCT00436852|f||||f
17127026|NCT00370682|f||||f
17127027|NCT00943852|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127028|NCT02141620|f||||f
17127029|NCT03651622|t||||f
17127030|NCT00307684|f||GT60||t
17127031|NCT01744392|f||||f
17164603|NCT04700423|f||||f
17164604|NCT02958345|f||||f
17164605|NCT02287779|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17164606|NCT03498716|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164607|NCT04849897|f||||f
17164608|NCT04064905|f||||t
17164609|NCT02257684|f||||f
17164610|NCT00265850|f||LTE60||t
17164611|NCT01570387|t||||
17164612|NCT01987557|t||||
17164613|NCT00760552|t||||
17164614|NCT01657305|f||OTHER|Publication requires approval of the sponsor without specification of an embargo time period.|t
17164615|NCT04442893|f||||f
17164616|NCT00814255|f||||f
17164617|NCT01180127|t||||f
17164618|NCT01696643|f||OTHER||t
17164619|NCT00518180|f||||f
17164620|NCT03060902|f||||f
17164621|NCT01465841|f||||f
17164622|NCT00956293|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17164623|NCT03383666|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17164624|NCT02536664|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164625|NCT02972996|t||||
17164626|NCT04655157|t||||
17164627|NCT01143636|f||||f
17164628|NCT01174563|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164629|NCT03402841|f||||t
17164630|NCT01347060|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164631|NCT02666560|f||||f
17164632|NCT01542788|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164633|NCT01280968|t||||f
17164634|NCT04704193|f||||f
17164635|NCT00542178|f||||f
17127032|NCT03992131|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17127033|NCT00858364|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127034|NCT01655693|f||||f
17127035|NCT00357331|f||||f
17127036|NCT00929110|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127037|NCT02935660|f||||f
17127038|NCT00939159|t||||
17127039|NCT01472549|t||||
17127040|NCT03001076|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17127041|NCT00948766|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127042|NCT00841555|t||||
17127043|NCT00287690|t||||
17127044|NCT03592745|f||||f
17127045|NCT03590366|f||OTHER|Sponsor shall have 60 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional 90 days to enable Sponsor to seek patent protections.|t
17127046|NCT05017103|t||||
17127047|NCT01081665|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17127048|NCT03796962|f||OTHER||t
17138133|NCT02293902|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17138134|NCT01770145|f||OTHER|The Sponsor shall have the first right, within nine months following the Sponsor having in its possession all data related to the Study, to publish the Study lead paper. Following the foregoing, the Institution shall have the right, consistent with academic standards, to publish the results of Study provided the Institution provides a publications committee, comprised of at least the Sponsor, with a draft at least thirty (30) days prior to planned submission.|t
17138135|NCT00595868|f||||f
17138136|NCT03380026|t||||
17138137|NCT04268303|f||||t
17138138|NCT02979444|f||||f
17138139|NCT04055467|f||||f
17138140|NCT05742841|t||||f
17138141|NCT02911818|f||||f
17138142|NCT01175590|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment.|t
17138143|NCT00223652|f||||f
17138144|NCT00081328|f||OTHER|This work was conducted by a collaborative group. All investigators in the study group adhere to the Publications \& Presentations Policy. The policy spells out procedures for proposing, developing, and submitting publications and presentations using study data. Once results have been published or presented, all members of the study group are free to discuss them.|t
17138145|NCT04671342|f||||f
17138146|NCT03911869|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164636|NCT03449576|t||||
17164637|NCT04133415|t||||
17164638|NCT02051426|t||||
17164639|NCT03984188|t||||f
17164640|NCT01173679|t||||f
17138147|NCT00688545|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164641|NCT01250054|t||||
17164642|NCT02777086|f||||f
17164643|NCT03372161|f||OTHER|The Sponsor has the right to first publication of the results of the study. Following the first publication, PIs may publish study data or results; however, the proposed publication must be submitted to the Sponsor for review and approval in writing at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study Data.|t
17164644|NCT01312519|f||LTE60||t
17164645|NCT01133665|t||||
17164646|NCT02122380|f||||f
17138148|NCT01878097|f||||f
17138149|NCT00367341|f||||f
17138150|NCT00109005|f||||f
17138151|NCT02533401|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138152|NCT00129740|t||||
17138153|NCT02451488|t||||
17138154|NCT02786836|f||||f
17138155|NCT03617913|t||||
17138156|NCT01143714|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17138157|NCT01387074|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17138158|NCT02373163|f||||f
17138159|NCT02137837|f||||f
17138160|NCT02307318|f||||f
17164647|NCT00272792|f||OTHER|The first publication of the results shall be made by Sponsor in a joint publication. If such a multi-center publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from their site individually, subject however to comply with the other terms of the agreement.|t
17164648|NCT02921789|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17164649|NCT04099277|f||GT60||t
17164650|NCT01766102|t||||
17164651|NCT00598650|f||OTHER||t
17164652|NCT03423602|f||||f
17164653|NCT03423121|f||||f
17164654|NCT00560508|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17127049|NCT03916458|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127050|NCT03406078|f||||t
17127051|NCT01413503|t||||
17138161|NCT00555568|t||||
17138162|NCT03167541|f||||f
17138163|NCT01118715|t||||f
17138164|NCT03819478|f||||f
17138165|NCT01135017|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish trial results. A copy is submitted to the Sponsor for review and comment at least 45 days in advance of the submission to journal (20 days for abstracts).~The Sponsor can require to delay the communication for a period not exceeding 90 days to allow for filing a patent application or such other measures as Sponsor deems appropriate to establish and preserve its proprietary rights."|t
17138166|NCT03688685|f||OTHER|The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release and can embargo communications regarding trial results. At least sixty (60) days prior to submission for publication or presentation, Institution or Investigator shall submit in writing to sponsor for review or comment of any proposed oral or written publication. The sponsor can require changes to the communication and can delay the publication an additional sixty (60) days.|t
17164655|NCT01354223|f||OTHER|Release of this data (through presentation, publication or other written or oral communication) to other than listed personnel (listed in protocol) requires the prior written permission from the study Sponsor. Study investigators and all office personnel are prohibited from acknowledging participation in the study to individuals and organizations except those listed.|t
17164656|NCT04790786|t||||
17164657|NCT03246087|t||||
17164658|NCT00948688|t||||
17164659|NCT01493089|f||||f
17164660|NCT03012334|f||OTHER|Details of the Study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17164661|NCT00325143|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164662|NCT01870869|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127052|NCT01373151|f||||f
17127053|NCT02186600|f||||f
17127054|NCT03026075|f||||f
17127055|NCT02387268|f||||f
17127056|NCT03117998|f||LTE60||t
17127057|NCT00293059|f||LTE60||t
17127058|NCT03970538|f||GT60||t
17127059|NCT00350103|f||GT60||t
17164663|NCT02286895|f||||f
17127060|NCT00438672|f||||f
17127061|NCT00878826|t||||f
17127062|NCT01468181|f||GT60||t
17127063|NCT02712905|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17164664|NCT03036852|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164665|NCT01073293|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17164666|NCT00991809|f||||f
17164667|NCT01451411|f||OTHER|PI can publish data generated at their study site after multi-center study data have already been published, or after 18 months have elapsed following database lock, whichever comes first. The sponsor may review manuscripts before submission and delay publication by an additional 60 days, if necessary.|t
17164668|NCT00002766|t||||
17164669|NCT00077974|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164670|NCT00256126|f||OTHER||t
17164671|NCT02652221|f||||f
17164672|NCT00003816|t||||
17164673|NCT02250417|f||||f
17164674|NCT02949011|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17169101|NCT00771615|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169102|NCT00859937|f||LTE60||t
17169103|NCT02478164|f||||f
17169104|NCT04588389|f||||f
17169105|NCT03445559|f||||f
17169106|NCT02484950|f||||f
17127064|NCT04828837|f||||f
17127065|NCT00320528|f||GT60||t
17164675|NCT00163189|f||OTHER|Pfizer has the right to review disclosures, requesting delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164676|NCT02154061|t||||f
17164677|NCT00506142|f||||f
17164678|NCT00454116|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17164679|NCT02213250|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164680|NCT01917318|f||||f
17164681|NCT01008618|f||OTHER||t
17164682|NCT00742625|f||LTE60||t
17164683|NCT03338400|t||||
17164684|NCT02941614|f||||f
17164685|NCT01865487|f||||f
17164686|NCT00129285|f||||f
17164687|NCT01213082|f||||f
17164688|NCT03758261|f||||f
17164689|NCT03848416|f||GT60||t
17164690|NCT02639390|t||||
17164691|NCT01908140|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of AstraZeneca. This information will not be given to a third party without the written consent of AstraZeneca. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and AstraZeneca.|t
17164692|NCT01436110|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169107|NCT05147662|f||OTHER|The sponsor can review results communications before submission for publication and embargo such communications for 45 days. If confidential information is present, the sponsor can embargo proposed publications for an additional 75 days to seek protection of intellectual property. For multi-center studies, publication of results specific to the PI's institution can be embargoed for as long as a multi-center publication is not published, up to a maximum of 18 months.|t
17169108|NCT04676867|f||||f
17127066|NCT00545753|f||||f
17127067|NCT05453201|t||||
17127068|NCT00669279|f||||f
17127069|NCT04577001|t||||
17127070|NCT00588900|f||LTE60||t
17127071|NCT01717742|t||||f
17164693|NCT01175343|f||LTE60||t
17164694|NCT01088503|f||GT60||t
17164695|NCT01531998|t||||
17164696|NCT02604459|f||||f
17164697|NCT00186628|f||||f
17169109|NCT00549770|f||OTHER||t
17169110|NCT01079936|t||||
17169111|NCT00548717|t||||
17127072|NCT03465904|f||OTHER|"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted to the sponsor for review. Sponsor may request:~* deletion of any trade secret, proprietary, or confidential information of Sponsor~* an additional 90 days to take measures to preserve its Intellectual Property rights~Sponsor's written consent is required for results communication before trial completion."|t
17127073|NCT01305200|f||OTHER||t
17164698|NCT02927795|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164699|NCT01076010|f||||f
17164700|NCT03259295|f||||f
17164701|NCT01306292|f||GT60||t
17164702|NCT02797821|f||||f
17164703|NCT02271529|f||GT60||t
17164704|NCT03507127|f||||f
17164705|NCT01497756|t||||
17127074|NCT05618912|f||||f
17127075|NCT05110690|t||||
17127076|NCT01209234|t||||
17127077|NCT01022112|f||OTHER||t
17127078|NCT00925353|f||||f
17127079|NCT02081443|t||||
17127080|NCT01302067|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127081|NCT00834626|f||||f
17164706|NCT01685684|f||OTHER|If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of the study, the PI is free to publish separately, upon provision of any proposed publication or manuscript to the Sponsor at least sixty (60) days before it is submitted or otherwise disclosed.|t
17164707|NCT00907621|t||||f
17164708|NCT04290624|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164709|NCT02579811|t||||
17164710|NCT00656370|f||OTHER|The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless prior written permission from the Sponsor (Halozyme) is obtained.|t
17164711|NCT02121509|t||||
17164712|NCT03111030|f||||f
17164713|NCT03069716|f||||f
17164714|NCT03391882|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17164715|NCT03913130|f||OTHER|Institution shall be free to publish, present, or use any Data and results arising out of its performance of the protocol. At least 30 days prior to submission for publication, institution shall submit to Sponsor for review and comment any proposed oral or written publication. Institution will consider any such comments in good faith but is under no obligation to incorporate Sponsor's suggestions. The review period for abstracts or poster presentations shall be 30 days.|t
17164716|NCT02006108|f||||f
17169112|NCT01302054|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127082|NCT03241927|t||||
17127083|NCT01198756|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127084|NCT01290315|f||GT60||t
17127085|NCT00591721|f||||f
17127086|NCT00423943|t||||
17127087|NCT02699086|f||||f
17127088|NCT01597141|f||||f
17127089|NCT02383056|t||||
17127090|NCT03828747|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127091|NCT05816330|f||||f
17127092|NCT03245151|f||||t
17127093|NCT03900416|f||||f
17127094|NCT00359216|f||LTE60||t
17127095|NCT00703937|f||LTE60||t
17127096|NCT01033422|f||||f
17169113|NCT00847015|t||||
17169114|NCT02809053|f||||f
17169115|NCT00084149|f||||f
17169116|NCT02565810|f||||t
17169117|NCT02981966|f||||f
17169118|NCT03544307|t||||
17127097|NCT02663518|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127098|NCT03896152|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127099|NCT00772330|f||||t
17127100|NCT01353859|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127101|NCT01153321|f||OTHER|The Institutions or Investigators were permitted to publish or present the study results from their site (or the overall results), providing the article or presentation was submitted to and approved by AstraZeneca beforehand.|t
17127102|NCT00911937|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127103|NCT03398213|f||||f
17127104|NCT00424385|t||||
17127105|NCT02683876|f||||f
17127106|NCT00355199|f||||f
17127107|NCT02503852|f||||f
17127108|NCT03231800|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17127109|NCT00859222|f||||f
17127110|NCT00942305|f||OTHER|Within 18 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publication may be delayed up to an additional 45 days to allow Sponsor to seek patent protection.|t
17127111|NCT00400725|f||OTHER||t
17127112|NCT04075994|t||||
17127113|NCT01141647|t||||
17127114|NCT04850794|t||||
17127115|NCT01941719|t||||
17127116|NCT01480219|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127117|NCT01670760|f||||f
17127118|NCT03980808|f||||f
17127119|NCT02741323|f||||f
17127120|NCT04718779|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17127121|NCT00741390|f||LTE60||t
17127122|NCT02703259|t||||
17127123|NCT02615002|f||||f
17164717|NCT01492426|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17164718|NCT00322049|f||||f
17164719|NCT01978145|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127124|NCT04738292|t||||
17127125|NCT02285153|t||||
17127126|NCT02544451|f||OTHER||t
17127127|NCT01489891|f||||f
17127128|NCT00998790|f||||f
17138167|NCT01170221|f||OTHER|Sponsor intends to pursue publication of results in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between the Sponsor and Investigators. Sponsor approval is required for publication of any data subsets. Final authorship will be determined in accordance with the International Committee of Medical Journal Editors definition of authorship.|t
17138168|NCT00432562|f||OTHER|Any publication of data related to the Study, including publication in special medical magazines, or the disclosure at medical congresses shall be previously authorized in writing by the Sponsor, whereby the Principal Investigator should present the material with an anticipation of not less than 60 days as from the publication or medical congress. The Sponsor decides upon the authorship of any publication related to the Study.|t
17164720|NCT02026011|f||||f
17127129|NCT00888927|f||GT60||t
17127130|NCT03459443|f||||t
17127131|NCT01080716|f||||f
17127132|NCT01056718|t||||f
17127133|NCT05086276|f||OTHER|PIs must obtain sponsor's written consent before publishing or presenting the trial results|t
17127134|NCT00777088|f||||f
17127135|NCT00421954|t||||
17127136|NCT00760474|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127137|NCT00515853|t||||
17127138|NCT02101385|f||||f
17138169|NCT02693691|f||||f
17138170|NCT04169061|f||||t
17138171|NCT01948141|t||||
17138172|NCT00844285|f||GT60||t
17138173|NCT03219892|f||||f
17138174|NCT00192036|f||GT60||t
17138175|NCT05425719|f||OTHER|MediBeacon requests that no presentation/publication occur until after the first publication of study results or until 1 yr after a study is completed/terminated early, whichever occurs first. Proposed results publication/disclosure must be given to Sponsor for review at least 45 days prior to the date of submission. If a patent application is to be filed, both the Institution and the Sponsor will defer publication or other disclosure for a period of time, not to exceed an additional 60 days.|t
17138176|NCT04682353|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17138177|NCT01476748|t||||
17138178|NCT02750267|t||||
17138179|NCT02394795|f||OTHER|"The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication.~Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."|t
17138180|NCT02392494|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17164721|NCT01770743|f||OTHER|Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between the Division of Microbiology and Infectious Diseases (DMID) and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17164722|NCT00755807|f||GT60||t
17164723|NCT03531814|f||||f
17164724|NCT00529243|t||||
17164725|NCT01053507|f||||f
17164726|NCT03233828|f||||f
17127139|NCT02432196|f||OTHER|PI must submit publication 60 days prior to its submission for presentation/publication to Sponsor. The Sponsor may, at its sole discretion, (a) approve the publication, (b) reject the publication, or (c) suggest changes to the publication to ensure protection of confidential commercial information in compliance with regulatory requirements. Until the content of any publication is approved by the Sponsor and the PI, the PI shall not disclose such publication.|t
17127140|NCT05038163|f||||f
17127141|NCT01147536|f||||t
17127142|NCT00383110|t||||
17127143|NCT03762200|f||OTHER|"Publication based on results shall not be made before the first multi-centre publication.~Trust and/or Investigator may prepare data derived from the Clinical Investigation for publication. Sponsor to be given at least 60 days for review. During review period, Sponsor is entitled to request publication be delayed for up to 6 months from date of first submission to Sponsor to enable Sponsor to take steps to protect its proprietary information and/or Intellectual Property Rights and Know How."|t
17127144|NCT02631577|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127145|NCT02299089|f||LTE60||t
17127146|NCT04949243|t||||
17127147|NCT03973931|f||||f
17127148|NCT00905515|f||||f
17127149|NCT02738203|f||||f
17127150|NCT00670631|f||||f
17127151|NCT02716818|f||OTHER|"Specified in the contractual agreements between the Sponsor and investigators: Neither the CRO, nor the Heath Board, nor the Investigator shall register the Clinical Trial, or the results, on any publicly accessible clinical trial registry."|t
17127152|NCT00901186|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127153|NCT00581555|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127154|NCT03507777|f||LTE60||t
17127155|NCT01552603|t||||
17127156|NCT01587027|f||||f
17127157|NCT01164644|t||||
17127158|NCT04797650|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17127159|NCT00657020|t||||
17127160|NCT01144052|t||||f
17127161|NCT03178643|f||||f
17127162|NCT02015455|f||||f
17127163|NCT00774930|f||OTHER|With permission from the Sponsor, each investigator may have published or reported data from their own subjects. The study data in aggregate are the property of the Sponsor and may not be published without permission of the Sponsor. The Sponsor is the final arbitrator of issues relating to the publication or presentation of the aggregate data.|t
17127164|NCT01181323|f||LTE60||t
17127165|NCT01631227|f||LTE60||t
17127166|NCT00766363|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted for review. At the sponsor's request, the PI will delete confidential information other than trial data and will delay publication or disclosure for up to 90 days to allow patent filings. The PI agrees that the first publication shall be a joint publication.|t
17127167|NCT03020576|f||||f
17127168|NCT03385343|f||||f
17127169|NCT01177800|f||LTE60||t
17164727|NCT01466491|f||||f
17164728|NCT02727322|f||||f
17164729|NCT02852967|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17164730|NCT01123148|f||||f
17127170|NCT03527550|f||||f
17127171|NCT01097707|f||GT60||t
17127172|NCT01841931|t||||
17164731|NCT00355030|f||GT60||t
17164732|NCT02499887|f||||f
17127173|NCT01498679|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127174|NCT00700427|f||GT60||t
17127175|NCT01767701|t||||
17127176|NCT03212989|t||||
17127177|NCT02111187|t||||
17127178|NCT01801735|f||OTHER|Investigator is required to submit any materials describing the results of the study at the site to sponsor for review not less than 30 days prior to publication and agrees to remove any of the Sponsor's confidential information. Sponsor also retains right to delay publication for an additional 60 day period to allow time for filing of patent applications.|t
17127179|NCT00620282|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones (e.g. when clinical trial report is available), including right to not release interim results because such action can invalidate results of the entire trial. At trial end, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17127180|NCT01258595|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17127181|NCT01820585|f||OTHER||t
17127182|NCT00548262|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127183|NCT01712659|f||||f
17127184|NCT01390077|t||||
17127185|NCT02338973|t||||
17127186|NCT01302860|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127187|NCT00844532|f||GT60||t
17127188|NCT03189745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127189|NCT00895154|t||||
17169119|NCT01732913|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169120|NCT02925741|f||||f
17169121|NCT05086510|t||||
17169122|NCT03022981|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years."|t
17169123|NCT00295932|t||||
17169124|NCT04891107|f||||f
17169125|NCT01571453|f||||f
17169126|NCT03098745|f||||f
17127190|NCT02729831|f||||f
17127191|NCT03381339|f||||f
17127192|NCT03230877|t||||
17127193|NCT01170390|t||||
17127194|NCT04664400|t||||
17127195|NCT04041453|f||||f
17127196|NCT01011153|f||GT60||t
17127197|NCT03014479|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127198|NCT02688218|t||||
17127199|NCT01781078|f||OTHER|The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.|t
17127200|NCT04887064|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127201|NCT02217501|t||||
17127202|NCT01394978|f||||f
17127203|NCT01081132|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17127204|NCT02019667|t||||
17127205|NCT02577822|t||||
17127206|NCT05121246|f||||t
17127207|NCT01905150|t||||
17127208|NCT03981861|f||||f
17127209|NCT00432666|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 wks before submission. Sponsor to give written opinion within 30 d. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17127210|NCT00978627|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17127211|NCT02516332|t||||
17127212|NCT03037931|f||||f
17127213|NCT00605215|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17127214|NCT02914275|f||OTHER|Seqirus agreements and restrictions on publishing may vary with individual investigators; however, Seqirus will not prohibit any investigator from publishing. Seqirus supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127215|NCT00661479|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127216|NCT02704754|f||||f
17127217|NCT04464954|t||||
17127218|NCT03809429|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17127219|NCT00538915|f||LTE60||t
17127220|NCT04214600|t||||
17127221|NCT02366468|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127222|NCT00446043|f||||t
17127223|NCT04772898|f||||f
17127224|NCT02947087|t||||
17127225|NCT00105001|t||||
17127226|NCT01879722|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17127227|NCT00697697|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127228|NCT01253304|f||GT60||t
17127229|NCT01327495|t||||
17127230|NCT01534689|f||||f
17127231|NCT00006011|f||||f
17127232|NCT00831753|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17127233|NCT00795366|f||||f
17164733|NCT01693367|f||||f
17164734|NCT02136914|f||||f
17164735|NCT04136145|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164736|NCT02831660|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164737|NCT01247064|t||||
17164738|NCT02918669|f||||f
17127234|NCT02207569|f||||f
17127235|NCT01833845|f||OTHER|The publication of the results of the Research in their entirety or in part, will be at the sole initiative of BIOLINERX Ltd. Reference to the results of the search cannot be made without the prior written agreement of BioLineRx Ltd..|t
17127236|NCT01844687|f||||f
17127237|NCT04245228|t||||
17127238|NCT05383508|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17127239|NCT03047395|f||||f
17127240|NCT01145209|t||||
17127241|NCT04560010|t||||
17127242|NCT00635427|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information(excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication|t
17127243|NCT03307005|f||||f
17127244|NCT03484273|f||||f
17127245|NCT02081417|f||||f
17127246|NCT01157676|t||||f
17127247|NCT01426867|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127248|NCT01263665|f||OTHER|Before the single-center publication is submitted or presented, the\> Investigator will provide a copy to the Sponsor and allow the Sponsor 30 days to review and\> comment. The Sponsor will review the publication for data accuracy only and not the\> conclusions or interpretations. If the Sponsor requests, the publication will be delayed an\> additional ninety (90) days, to allow Sponsor to ensure the protection of inventions or other\> property of Sponsor.|t
17127249|NCT00294515|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127250|NCT00324675|t||||f
17127251|NCT00252577|t||||
17127252|NCT02335710|t||||
17127253|NCT00560066|f||||f
17127254|NCT04535310|f||||f
17127255|NCT02442336|f||||f
17127256|NCT01993927|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127257|NCT02478710|f||||f
17127258|NCT03699826|t||||
17127259|NCT01630694|t||||
17127260|NCT01747551|f||||f
17127261|NCT01142115|f||OTHER||t
17127262|NCT00633880|f||LTE60||t
17127263|NCT02734953|f||||f
17127264|NCT03208036|f||||f
17127265|NCT02091206|f||GT60||t
17127266|NCT00700778|f||||f
17127267|NCT04927247|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127268|NCT00591851|t||||
17127269|NCT01099475|f||||f
17127270|NCT03419832|t||||
17127271|NCT03748992|t||||
17127272|NCT00847808|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127273|NCT03924765|t||||
17127274|NCT03417895|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17127275|NCT04548544|t||||f
17127276|NCT02158052|f||||f
17127277|NCT00969709|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17164739|NCT05518461|t||||
17164740|NCT03179761|f||||f
17164741|NCT00584857|t||||
17164742|NCT00448448|f||||f
17164743|NCT02284191|f||||f
17164744|NCT01188967|f||LTE60||t
17164745|NCT01859013|t||||
17164746|NCT04031729|f||||f
17164747|NCT01832727|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17164748|NCT02216526|t||||f
17164749|NCT02478489|t||||
17164750|NCT00696878|f||OTHER|Publications must be based on data validated and released by the Sponsor. Any scientific paper, presentation, or other communication concerning the study must first be submitted to the Sponsor, at least 6 weeks prior to estimated publication or presentation, for written consent. Sponsor has the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the Investigator in the discussion of the data in such communications.|t
17164751|NCT02455167|t||||
17127278|NCT02980731|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127279|NCT01342341|t||||f
17127280|NCT01238900|t||||
17127281|NCT00616902|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17127282|NCT03725085|f||||f
17127283|NCT01119105|f||OTHER|All data from the study is confidential information. Sponsor has the right to publish first. Thereafter, PI may publish data from the study, but PI must submit the publication to Sponsor for review at least 60 days prior to publication. Sponsor may remove any confidential and/or proprietary information. If Sponsor's publication is not submitted within 12 months after the study, or if Sponsor decides not to publish, PI may publish the data, subject to Sponsor's rights in the agreement.|t
17127284|NCT01775475|f||||f
17127285|NCT00435591|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17164752|NCT04436744|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127286|NCT00210470|f||LTE60||t
17164753|NCT02411461|f||||f
17164754|NCT02712788|t||||
17164755|NCT01133847|f||||f
17164756|NCT00940602|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164757|NCT01880957|f||||f
17164758|NCT01463033|f||||f
17164759|NCT00967616|f||||f
17164760|NCT01368614|f||||f
17164761|NCT02951780|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169127|NCT00084487|f||LTE60||t
17169128|NCT01848366|t||||f
17169129|NCT03040986|f||LTE60||t
17169130|NCT02273960|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169131|NCT04033068|f||OTHER|The investigators may not submit the results for publication or presentation without prior written permission of the sponsor. Authorship for any publication will be determined in mutual agreement.|t
17169132|NCT01735981|f||||f
17127287|NCT02245737|f||OTHER|The sponsor shall review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60days but less than or equal to 180days from the time submitted to the sponsor.Authors agree not to publish results until data is compiled. No publication/presentation with respect to the research activities shall be made unless \& until any information determined at sponsors sole discretion to be confidential information has been removed.|t
17127288|NCT00936741|f||GT60||t
17127289|NCT00618618|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17127290|NCT01008319|t||||
17138181|NCT01313208|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17138182|NCT04152642|t||||
17138183|NCT01829217|f||||f
17138184|NCT00587769|t||||f
17164762|NCT01374425|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138185|NCT04377672|t||||f
17138186|NCT02486367|t||||
17138187|NCT03954444|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17138188|NCT03096444|t||||
17138189|NCT03505749|f||||f
17138190|NCT03846219|f||LTE60||t
17138191|NCT01688635|t||||
17164763|NCT02359903|f||||f
17164764|NCT00546481|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164765|NCT01227057|t||||
17164766|NCT01240863|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17164767|NCT01419119|t||||
17164768|NCT03783780|t||||
17164769|NCT03768427|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17164770|NCT00776789|t||||f
17164771|NCT02742129|f||LTE60||t
17164772|NCT02874092|t||||
17164773|NCT01974284|t||||
17164774|NCT02629861|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17164775|NCT00606489|f||||f
17164776|NCT00902330|f||||f
17164777|NCT00165789|f||||f
17164778|NCT01816048|t||||f
17164779|NCT00956384|f||||f
17164780|NCT00601367|f||||f
17169133|NCT01280695|f||LTE60||t
17169134|NCT02893917|f||LTE60||t
17169135|NCT01778426|f||OTHER|It is stated in the CIP and Agreement signed by the investigators that the French SCS Registry data are the sole property of Medtronic.|t
17164781|NCT01816984|t||||
17164782|NCT01147302|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17164783|NCT01342094|f||||f
17164784|NCT01600287|t||||f
17164785|NCT01061528|f||||f
17164786|NCT04021290|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17164787|NCT00636181|f||||f
17164788|NCT03820011|t||||
17164789|NCT05437419|f||||t
17164790|NCT05076045|f||||f
17164791|NCT02878382|f||||f
17164792|NCT01085214|f||LTE60||t
17164793|NCT01482715|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17169136|NCT01364740|f||||f
17169137|NCT03603106|f||OTHER||t
17169138|NCT05532891|f||||f
17169139|NCT00417963|f||GT60||t
17169140|NCT04274556|f||||f
17164794|NCT01634152|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127291|NCT02929329|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127292|NCT03840915|f||||t
17127293|NCT03250234|t||||
17127294|NCT00309959|f||LTE60||t
17127295|NCT01983254|f||||f
17127296|NCT00434213|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after SPONSOR confirms there shall be no multicenter Study publication, the INSTITUTION and/or such PRINCIPAL INVESTIGATOR may publish the results from the INSTITUTION site individually.|t
17127297|NCT00768079|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17127298|NCT02796625|f||||f
17127299|NCT02235831|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127300|NCT01859988|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17127301|NCT03097484|f||||f
17127302|NCT01721460|t||||
17127303|NCT01227382|t||||
17127304|NCT02706899|f||GT60||t
17127305|NCT01435616|f||GT60||t
17127306|NCT00371683|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17127307|NCT03122223|f||||f
17127308|NCT03181789|f||||f
17127309|NCT01151410|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127310|NCT02624791|t||||
17164795|NCT02751814|f||||f
17164796|NCT01349114|f||||f
17164797|NCT01985022|t||||
17164798|NCT01152437|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17164799|NCT00279214|f||GT60||t
17164800|NCT01214837|f||||f
17164801|NCT00457626|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127311|NCT00735475|f||LTE60||t
17127312|NCT00662818|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17182635|NCT02457598|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17164802|NCT03549338|f||OTHER|No publication before the completion of the trial without written approval from the Sponsor. Publications shall not disclose any Sponsor confidential information and property (not including the trial results). The Sponsor reserves the right to review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164803|NCT00269113|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164804|NCT00652743|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164805|NCT01714323|t||||
17164806|NCT02495285|f||OTHER||t
17164807|NCT05111145|f||||t
17164808|NCT02336815|f||||t
17127313|NCT02327351|t||||
17127314|NCT04602221|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17127315|NCT03988920|f||OTHER||t
17127316|NCT01237587|f||GT60||t
17127317|NCT02656329|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17127318|NCT01139580|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127319|NCT01118013|f||LTE60||t
17127320|NCT00911768|f||||f
17127321|NCT01758900|f||||f
17127322|NCT03122691|f||||f
17127323|NCT00935818|t||||
17127324|NCT01370590|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17127325|NCT05172050|f||||f
17164809|NCT00952705|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17164810|NCT03702179|f||||f
17127326|NCT04617275|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127327|NCT03387137|f||||f
17127328|NCT02437253|f||||f
17127329|NCT04927884|f||||t
17127330|NCT01533597|f||||f
17164811|NCT03759600|f||||t
17164812|NCT05173974|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164813|NCT02098304|f||OTHER|The Sponsor will not suppress or veto publications however the Sponsor reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17164814|NCT03257358|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164815|NCT03289143|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164816|NCT00730756|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164817|NCT00305877|f||LTE60||t
17164818|NCT01152307|f||||f
17164819|NCT01126190|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17164820|NCT00524121|t||||
17164821|NCT01114737|f||LTE60||t
17164822|NCT01446874|t||||
17182636|NCT01403974|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164823|NCT00457392|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164824|NCT01135992|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17164825|NCT01977898|f||||f
17164826|NCT04563767|t||||
17164827|NCT03886948|f||GT60||t
17164828|NCT01049373|f||LTE60||t
17164829|NCT00339040|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and Merck \& Co., Inc., NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17164830|NCT00988156|t||OTHER||t
17164831|NCT00812955|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17164832|NCT02391311|f||||f
17164833|NCT02649920|f||||f
17164834|NCT01815424|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164835|NCT01309204|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17164836|NCT03046446|f||||t
17164837|NCT02808897|f||||f
17169141|NCT00477152|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (eg, for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).|t
17169142|NCT01329848|t||||
17169143|NCT00568126|f||||f
17169144|NCT02911142|f||||f
17169145|NCT02883062|f||||f
17169146|NCT02888743|f||LTE60||t
17164838|NCT00925002|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164839|NCT01496287|f||GT60||t
17164840|NCT00305448|f||LTE60||t
17164841|NCT00328172|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17164842|NCT00030147|t||||
17164843|NCT00558636|f||LTE60||t
17164844|NCT01990742|f||||f
17169147|NCT05779007|t||||
17169148|NCT01424566|f||GT60||t
17169149|NCT04816721|f||||t
17138192|NCT05064332|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138193|NCT03862131|t||||
17138194|NCT02947022|t||||
17138195|NCT04021706|t||||
17138196|NCT02354092|f||||f
17164845|NCT03443687|f||||f
17164846|NCT04108273|t||||
17169150|NCT00026312|f||LTE60||t
17169151|NCT01638546|f||LTE60||t
17169152|NCT06328660|f||||t
17169153|NCT03194438|f||||t
17169154|NCT02294734|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169155|NCT03157583|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169156|NCT01395277|f||||f
17169157|NCT05375214|f||||f
17169158|NCT01141478|f||||f
17169159|NCT03096873|t||||
17169160|NCT05236712|f||||f
17164847|NCT03715790|f||OTHER|"In most cases, the contract allows the principal investigator to publish their data after release of a multi-center publication per the publication strategy following Medtronic's review for disclosure of confidential information (CI), technical correctness, disclosure of patentable or copyrightable material, and selection and order of publications by the publications committee. Any such CI and/or item identified as not technically correct is deleted prior to publication/presentation."|t
17127331|NCT05593445|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17127332|NCT00727311|f||OTHER|All rights according to the results belong to Essex, Germany. Publications or transmission of data need a previous written agreement of the company.|t
17127333|NCT02199743|f||||f
17127334|NCT00266227|f||OTHER||t
17127335|NCT02295553|t||||
17127336|NCT02470910|t||||
17127337|NCT00560560|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127338|NCT03836716|f||GT60||t
17127339|NCT01954966|f||||f
17127340|NCT04988867|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17127341|NCT00037830|f||||f
17127342|NCT01854138|f||||f
17127343|NCT01699503|f||||f
17127344|NCT01879059|f||||f
17127345|NCT01004848|t||||
17127346|NCT01160289|f||GT60||t
17127347|NCT01090479|f||||f
17127348|NCT03292432|f||||f
17127349|NCT04193436|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127350|NCT01236534|f||LTE60||t
17127351|NCT01014143|f||GT60||t
17127352|NCT02029872|f||||f
17127353|NCT01963923|f||||f
17127354|NCT03699085|f||||f
17127355|NCT02038543|t||||
17127356|NCT04638920|f||||f
17127357|NCT03775434|f||OTHER|Sponsor shall have 60 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional 90 days to enable Sponsor to seek patent protections.|t
17127358|NCT02334423|f||||f
17127359|NCT02930226|f||||f
17127360|NCT02065687|f||LTE60||t
17127361|NCT00652327|f||LTE60||t
17127362|NCT01076647|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17127363|NCT00920075|t||OTHER|Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation.|t
17127364|NCT02926898|f||||t
17127365|NCT01871805|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127366|NCT02006251|t||||
17164848|NCT02261961|t||||
17164849|NCT02897115|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17164850|NCT00487981|f||LTE60||t
17164851|NCT01365793|f||||f
17164852|NCT02808429|f||||t
17127367|NCT03412747|f||GT60||t
17127368|NCT01039792|f||||f
17127369|NCT00468104|f||||f
17127370|NCT00141219|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17127371|NCT02224690|f||GT60||t
17164853|NCT01469039|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17138197|NCT00355134|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138198|NCT01412151|f||||f
17138199|NCT00713284|f||||f
17138200|NCT03127852|f||||f
17138201|NCT00741104|f||OTHER|PI agrees not to publish/publicly present any interim results of the Study. PI further agrees to provide 45 days written notice to Sponsor prior to submission for publication/presentation to permit Sponsor to review drafts of any material before publication which report any results arising out of the Study. Sponsor shall have the right to review and comment.|t
17138202|NCT00859573|t||||
17138203|NCT04134728|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17138204|NCT03382262|f||OTHER||t
17138205|NCT03300258|t||||
17127372|NCT00297596|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17127373|NCT00122460|f||OTHER||t
17127374|NCT01506609|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127375|NCT01710891|f||||f
17127376|NCT00381615|f||GT60||t
17138206|NCT03537092|t||||f
17138207|NCT01759160|t||||f
17138208|NCT02905825|f||OTHER|The Investigator shall be entitled to publish the Proprietary Data in scientific journals and other scientific and professional publications and oral dissertations and the like, provided that a draft of the intended publication or dissertation shall be submitted to the Company at least sixty (60) days before the date of intended publication or dissertation so as to enable the Company to make comments to the Center regarding the contents of such intended publication or dissertation.|t
17138209|NCT01136746|f||GT60||t
17138210|NCT01019252|f||||f
17138211|NCT02273037|f||||f
17138212|NCT00806078|f||GT60||t
17138213|NCT03351478|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17138214|NCT00510484|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment.|t
17164854|NCT00698828|f||||f
17164855|NCT02013609|f||||f
17164856|NCT00856609|t||||f
17164857|NCT00783432|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the Sponsor. Authorship will be determined by mutual agreement.|t
17164858|NCT03273907|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138215|NCT00762268|f||||f
17164859|NCT03019887|t||||
17164860|NCT02581891|f||OTHER||t
17164861|NCT04828707|f||||f
17164862|NCT03139448|f||||f
17164863|NCT00523978|f||LTE60||t
17127377|NCT02595073|f||||t
17127378|NCT02962960|f||GT60||t
17164864|NCT02750514|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169161|NCT02636712|f||||t
17169162|NCT04122170|f||||f
17169163|NCT03222414|t||||
17138216|NCT00961441|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17164865|NCT02259114|f||OTHER|Subject to obligations of confidentiality, the investigator reserves the right to publish only the results of the work performed pursuant to this protocol, provided, however, that the investigator provides an authorized representative of the Sponsor with a copy of any proposed publication for review and comment at least 45 days in advance of its submission for publication.|t
17164866|NCT03937479|f||||t
17164867|NCT02578901|f||||f
17164868|NCT01378117|f||||f
17164869|NCT00740181|f||||f
17164870|NCT01120405|f||OTHER|Air Liquide Sante International may delay publication or disclosure for a term not exceeding eighteen (18) months with effect from the request in the event that Air Liquide Sante International wishes to seek protection of the results of the Trial by industrial property rights.|t
17164871|NCT02961244|t||||f
17164872|NCT01854528|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17164873|NCT03789292|f||||t
17164874|NCT00575666|t||||
17169164|NCT02250664|f||||f
17169165|NCT03847909|f||OTHER|SPONSOR agrees that the Principal Investigator shall have the right to publish or permit the publication of any information or material relating to or arising out of the work after prior submittal to SPONSOR provided that if SPONSOR shall so request, the investigator will delay publication for a maximum of ninety (90) days after submittal to SPONSOR to enable SPONSOR to protect its rights. SPONSOR will comment on such documents within thirty (30) days.|t
17169166|NCT00117793|t||||
17169167|NCT04268173|t||||
17127379|NCT02261597|f||||f
17127380|NCT04860297|f||||t
17127381|NCT01464840|f||||f
17127382|NCT00396019|f||||f
17127383|NCT00468559|f||LTE60||t
17127384|NCT04811131|f||||t
17164875|NCT00508482|t||||
17164876|NCT02289469|t||||
17164877|NCT00587041|t||||
17164878|NCT00956761|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17164879|NCT01904721|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169168|NCT00975143|f||LTE60||t
17169169|NCT01375608|t||||f
17169170|NCT00545103|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17169171|NCT01953913|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169172|NCT00082381|f||GT60||t
17182637|NCT01526889|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17182638|NCT01589302|t||||
17182639|NCT02703636|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127385|NCT00003453|f||||f
17127386|NCT01528345|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17127387|NCT02601976|f||||t
17127388|NCT01131182|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17127389|NCT01146782|f||||f
17127390|NCT02270515|f||||f
17127391|NCT03358251|f||||f
17127392|NCT01892540|t||||
17138217|NCT00973622|f||||f
17138218|NCT00493467|t||||f
17138219|NCT00835003|t||||
17138220|NCT03395223|f||GT60||t
17138221|NCT04446299|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17138222|NCT01855945|f||OTHER||t
17164880|NCT00950651|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information|t
17164881|NCT01944020|f||||f
17164882|NCT03793621|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164883|NCT00110214|f||LTE60||t
17164884|NCT03623698|f||||f
17127393|NCT00604825|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127394|NCT00133809|t||||
17127395|NCT02317432|t||||
17127396|NCT04807582|t||||
17127397|NCT05559476|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17127398|NCT03992846|f||||f
17127399|NCT03647488|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127400|NCT00565851|f||LTE60||t
17127401|NCT00775463|f||OTHER||t
17127402|NCT00452426|f||OTHER||t
17127403|NCT01789567|f||LTE60||t
17138223|NCT01148693|f||||f
17127404|NCT00091169|f||LTE60||t
17127405|NCT00872989|f||LTE60||t
17138224|NCT03228394|f||||f
17138225|NCT04024072|f||||t
17138226|NCT02584868|t||||
17138227|NCT00091962|f||||f
17138228|NCT01488409|f||||f
17138229|NCT00587834|f||OTHER|The sponsor can review communications prior to public release and can embargo communications regarding trial results for at least 30 days in advance of public release. The sponsor can request removal of any confidential or proprietary information provided by sponsor and extend such review period for another 90 days to file patent applications or take other steps to protect the sponsor's intellectual property interests.|t
17138230|NCT01162304|t||||
17138231|NCT00125372|f||||f
17138232|NCT00983359|t||||
17138233|NCT02293096|t||||
17138234|NCT00326417|f||||f
17138235|NCT02618343|f||||f
17138236|NCT00862654|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor to review and approval at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17138237|NCT03219567|t||||
17138238|NCT01654523|t||||
17138239|NCT02447458|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17138240|NCT02133742|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138241|NCT00405652|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138242|NCT01637870|f||||f
17138243|NCT00435994|f||||f
17138244|NCT03288324|f||||f
17138245|NCT02790463|f||||f
17138246|NCT02472795|f||||t
17138247|NCT05109702|f||||f
17138248|NCT03812588|t||||
17138249|NCT02679807|f||||f
17138250|NCT00180271|f||||f
17138251|NCT01392378|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138252|NCT02322411|t||||
17138253|NCT04350905|t||||
17138254|NCT02261883|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17138255|NCT00629525|t||||
17138256|NCT04491240|t||||f
17138257|NCT03549117|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138258|NCT00367432|f||GT60||t
17138259|NCT00903370|f||||f
17138260|NCT00014911|f||||f
17138261|NCT01924299|f||GT60||t
17138262|NCT00605072|f||||f
17138263|NCT01999946|t||||
17138264|NCT00523614|t||||
17138265|NCT04482244|f||||f
17138266|NCT01379924|f||||f
17127406|NCT02407990|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17127407|NCT00734097|f||LTE60||t
17127408|NCT05130047|t||||
17127409|NCT01764685|f||||f
17127410|NCT01546636|t||||
17138267|NCT03801356|f||||f
17138268|NCT00642018|f||GT60||t
17138269|NCT01544478|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17138270|NCT02574481|f||GT60||t
17138271|NCT01461824|t||||f
17138272|NCT03404219|f||||f
17138273|NCT02038790|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17138274|NCT01089751|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17138275|NCT01818986|t||||
17138276|NCT00438464|f||LTE60||t
17138277|NCT03943446|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138278|NCT00905268|f||||f
17138279|NCT01281189|f||OTHER|Sponsor must be consulted|t
17127411|NCT02233543|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127412|NCT03573583|f||||f
17182640|NCT00393939|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182641|NCT00748956|t||||
17182642|NCT02561130|f||||f
17127413|NCT04004936|t||||
17127414|NCT02062593|t||||
17127415|NCT03730480|f||||f
17182643|NCT04334460|f||||f
17182644|NCT00547703|t||||
17182645|NCT00358462|f||||f
17182646|NCT03995953|f||||f
17182647|NCT00384813|t||||
17182648|NCT01764607|f||||f
17182649|NCT00167934|t||||
17182650|NCT04707534|t||||
17182651|NCT04951622|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17138280|NCT05355818|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17138281|NCT01589263|f||||f
17138282|NCT03955055|f||||f
17138283|NCT00756093|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17138284|NCT00092677|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138285|NCT01601704|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 24 months after conclusion, abandonment or termination of the study or notification that there will be no such multi-center publication, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 90 days to review and comment on the proposed publication. Sponsor may delay publication for up to an additional 6-month period to file for patent protection.|t
17138286|NCT01090102|t||||
17138287|NCT03518034|f||||f
17138288|NCT02814448|t||||
17138289|NCT00010803|f||||f
17164885|NCT00811954|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17138290|NCT04209530|f||||f
17138291|NCT00756678|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17138292|NCT01660230|f||LTE60||t
17138293|NCT00985738|f||||f
17138294|NCT01619488|t||||
17138295|NCT02227849|f||OTHER||t
17138296|NCT01590212|t||||
17164886|NCT01016067|f||LTE60||t
17164887|NCT02103127|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17164888|NCT03421886|f||||f
17164889|NCT01138475|f||||f
17182652|NCT04108208|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182653|NCT03463889|t||||
17182654|NCT02948842|t||||
17182655|NCT00409292|f||||f
17182656|NCT04865432|t||||
17182657|NCT05124873|t||||
17138297|NCT04897594|f||||f
17138298|NCT02849184|f||LTE60||t
17138299|NCT01324128|f||OTHER|Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.|t
17164890|NCT01534481|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication Policies|t
17164891|NCT01130337|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164892|NCT05525910|t||||
17164893|NCT03886493|t||||
17164894|NCT03326063|f||||f
17164895|NCT02553629|f||||f
17164896|NCT01812057|t||||
17164897|NCT02348203|f||LTE60||t
17164898|NCT01882465|f||GT60||t
17127416|NCT01227577|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127417|NCT00852540|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164899|NCT02148588|f||||f
17164900|NCT03763747|f||||t
17164901|NCT02633735|f||||f
17164902|NCT01957865|f||||f
17164903|NCT01082614|t||||
17164904|NCT02524561|f||||f
17164905|NCT00811720|f||OTHER|The main publication has to be published before any sub publication. The investigators shall obtain Lundbeck's written approval before publishing any publication relating to nalmefene, the Study, the Protocol and/or the results recorded during the Study.|t
17164906|NCT01077063|t||||
17164907|NCT02750930|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164908|NCT03894891|t||||
17164909|NCT01585402|t||||
17164910|NCT01730872|f||||f
17164911|NCT00553631|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17127418|NCT01639495|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17127419|NCT01183234|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17127420|NCT00704379|f||||f
17127421|NCT01639560|f||||f
17127422|NCT03909529|f||||f
17127423|NCT01467882|f||OTHER|Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.|t
17164912|NCT02761642|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164913|NCT01044030|f||||f
17164914|NCT01937520|t||||
17127424|NCT01156792|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164915|NCT01644643|f||OTHER|The investigator agrees not to use such Confidential study information and not to disclose them to any other third parties, except that the undersigned shall not be prevented from using or disclosing information: (a) which by written records was previously known; (b) which is now public knowledge, (c) which is lawfully obtained by the undersigned from sources who have a lawful right to disclose such information.|t
17164916|NCT02756403|f||||f
17164917|NCT02099084|t||||
17164918|NCT01205503|f||||f
17164919|NCT02471313|f||||f
17164920|NCT02850978|t||||
17164921|NCT02404168|t||||
17164922|NCT01197547|f||||f
17127425|NCT01474434|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127426|NCT02483000|f||||f
17127427|NCT02876159|t||||
17127428|NCT02971761|t||||
17164923|NCT01953211|f||||f
17164924|NCT03188263|f||||f
17164925|NCT01030822|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127429|NCT01605916|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17127430|NCT02073747|t||||f
17127431|NCT01588431|t||||
17127432|NCT02632526|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17127433|NCT02549196|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127434|NCT03954392|f||||f
17127435|NCT01103362|f||||f
17127436|NCT00669682|f||||f
17127437|NCT03265938|f||||f
17127438|NCT02679508|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127439|NCT03143166|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164926|NCT00539240|t||||f
17164927|NCT01628523|f||||f
17164928|NCT01055613|f||GT60||t
17164929|NCT02765399|f||||f
17164930|NCT02393339|f||||f
17164931|NCT00768261|f||||f
17164932|NCT02651545|f||||f
17164933|NCT01182298|t||||f
17164934|NCT01832610|f||OTHER|In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor's ability to obtain patent protection.|t
17127440|NCT00467350|f||||f
17127441|NCT03538301|f||OTHER|Nitto Denko Corporation agreements with investigators vary; constant is Nitto's right to embargo communications regarding trial results prior to public release for a period \<30 days from submittal for review. Nitto will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17127442|NCT00453193|t||||
17127443|NCT03661762|t||||
17182658|NCT04181827|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182659|NCT01256710|f||||f
17182660|NCT02681302|t||||
17127444|NCT02842151|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127445|NCT01879553|f||LTE60||t
17127446|NCT01253070|f||LTE60||t
17127447|NCT02559895|f||||f
17127448|NCT01030406|f||||f
17127449|NCT04540887|t||||
17164935|NCT02525679|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164936|NCT04540367|t||||
17164937|NCT01563055|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164938|NCT03958331|f||||f
17164939|NCT01911351|t||||
17164940|NCT04422431|f||||t
17164941|NCT02199041|t||||
17164942|NCT03210701|f||||f
17164943|NCT02317627|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17164944|NCT00806260|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17164945|NCT01903005|f||||f
17164946|NCT01088906|f||||f
17164947|NCT00027560|t||||
17164948|NCT03384875|f||LTE60||t
17164949|NCT05547412|f||||f
17164950|NCT03181971|t||||
17164951|NCT01772550|f||LTE60||t
17164952|NCT02291133|f||||f
17164953|NCT02554799|f||OTHER|"Richmond Pharmacology Limited (RPL) shall not issue or submit any press release for publication without MMV's prior written approval.~In recognition that RPL and the Site Principal Investigator have a responsibility to ensure that results of scientific interest arising from a Clinical Trial are appropriately published and disseminated, RPL may, upon MMV's written consent which will not be unreasonably withheld, publish Results of a clinical trial carried out under a Project Agreement."|t
17164954|NCT03374358|f||||f
17127450|NCT01262027|t||||
17127451|NCT00610740|t||||
17127452|NCT02819557|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the Sponsor for review. The Sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17127453|NCT00531453|f||||f
17127454|NCT02665338|t||||
17127455|NCT00589121|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17164955|NCT03183063|t||||
17164956|NCT01127633|f||GT60||t
17164957|NCT00688467|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17164958|NCT01805687|f||LTE60||t
17164959|NCT02163577|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17164960|NCT00690794|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17164961|NCT01823107|f||||f
17164962|NCT01343888|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17164963|NCT02217618|f||GT60||t
17164964|NCT02764996|t||||
17164965|NCT00800735|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164966|NCT02805790|f||OTHER|The Investigator may not submit for publication or presentation the results of this study without first receiving written authorization from Stealth BioTherapeutics Inc. Stealth BioTherapeutics Inc., agrees that before it publishes any results of the study, it shall provide the Investigator with at least 30 days for review of the pre-publication manuscript prior to the submission of the manuscript to the publisher.|t
17164967|NCT04460183|f||||t
17164968|NCT00856323|f||||f
17164969|NCT01847092|f||GT60||t
17164970|NCT00825994|f||||f
17169173|NCT02049138|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169174|NCT00884832|t||||f
17169175|NCT03322423|f||GT60||t
17169176|NCT02096263|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164971|NCT01331681|f||OTHER|CONTRACT PARTNERS shall provide to BSP (Bayer Schering Pharma) any proposed publication or oral at least sixty (60) days prior to the intended submission or presentation. If BSP does not notify CONTRACT PARTNERS within sixty (60) days of BSP's receipt of the intended PUBLICATION, CONTRACT PARTNERS shall be free to publish. CONTRACT PARTNERS acknowledge that in case of multi-centre studies the RESULTS of the STUDY are to be published only through coordination by Bayer.|t
17164972|NCT01976871|f||LTE60||t
17164973|NCT00658541|f||GT60||t
17164974|NCT01063348|f||||f
17164975|NCT01876381|f||||f
17164976|NCT00461708|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17164977|NCT02394561|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17164978|NCT00501644|f||||f
17164979|NCT02803203|t||||
17164980|NCT04577781|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17164981|NCT00114127|f||||f
17164982|NCT00699413|f||||f
17164983|NCT00881894|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17164984|NCT00421148|f||OTHER|Organon recognizes the right of the investigator(s) to publish, but all publications must be based on data validated by Organon. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Organon, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17164985|NCT04005586|f||||t
17164986|NCT00469833|f||||f
17164987|NCT01253369|f||||f
17164988|NCT03289533|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17164989|NCT04016714|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17164990|NCT02358993|t||||
17164991|NCT02246010|t||||
17164992|NCT03708367|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17164993|NCT01822665|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17164994|NCT04089020|t||||
17164995|NCT00959907|f||||f
17164996|NCT02665260|f||||f
17164997|NCT01722929|t||||
17164998|NCT01932788|t||||
17164999|NCT01171677|t||||
17165000|NCT01847443|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165001|NCT03571971|f||||f
17165002|NCT06158867|f||||f
17165003|NCT01939145|t||||
17165004|NCT02421757|f||||f
17165005|NCT02806414|f||||f
17165006|NCT02382588|f||||f
17165007|NCT03848455|f||||f
17169177|NCT02337725|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165008|NCT04046939|f||OTHER|The terms and conditions of Knopp's agreements with its investigators may vary. However, Knopp does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial, and are subject to a minimum 60 day review period by Knopp.|t
17165009|NCT00403130|f||||f
17165010|NCT03559270|f||GT60||t
17165011|NCT04743011|f||||f
17165012|NCT00896012|t||||f
17165013|NCT02735421|f||OTHER||t
17165014|NCT00939107|t||||
17165015|NCT05010070|f||||f
17165016|NCT00628498|f||||f
17165017|NCT02094118|f||||f
17165018|NCT01861665|t||||
17165019|NCT03247829|f||||t
17165020|NCT01783444|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17165021|NCT02722408|f||||t
17165022|NCT01058239|t||||
17165023|NCT01900067|f||OTHER|The agreement state that sponsor is the owner of all results. The Investigator may perform a secondary publication from an individual investigation site without disclosing confidential information received from sponsor after the multi-center publication or within 12 months after termination of the investigation if no such multi-centre publication takes place.|t
17165024|NCT03557125|t||||
17165025|NCT04011592|t||||
17165026|NCT00441272|t||||
17165027|NCT01856322|f||||f
17165028|NCT00427011|f||||f
17165029|NCT01047007|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17165030|NCT04776161|t||||
17169178|NCT02453555|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169179|NCT00500760|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169180|NCT00141115|f||||f
17165031|NCT01334554|f||OTHER||t
17169181|NCT00129961|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17169182|NCT03178669|f||LTE60||t
17169183|NCT01600092|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17169184|NCT00079677|f||GT60||t
17169185|NCT00565136|f||LTE60||t
17169186|NCT01008462|t||||
17169187|NCT04284774|f||LTE60||t
17169188|NCT01270256|t||||
17169189|NCT02879578|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17169190|NCT00790478|f||||f
17169191|NCT02641067|f||OTHER|Sponsor's policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript.|t
17169192|NCT02851823|t||||f
17169193|NCT02925728|t||||
17169194|NCT05098509|f||||t
17169195|NCT01154751|f||GT60||t
17169196|NCT02986854|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165032|NCT02071901|t||||
17165033|NCT02393859|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165034|NCT00954447|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165035|NCT04592341|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165036|NCT00692003|f||||f
17165037|NCT01248793|f||GT60||t
17169197|NCT00534833|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17169198|NCT00324233|f||LTE60||t
17169199|NCT03385330|f||||f
17127456|NCT01028027|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17127457|NCT01116102|f||OTHER|For this study, Baxter requires a review of any planned PI results communications (eg, for confidential information) up to 30 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).|t
17127458|NCT05000931|f||OTHER|Sponsor has first rights to publish the multi-site data. During the study and the 12-months following the conclusion of the study, the PI may not publish or present on its own data obtained under the study. The PI may publish on their own study data (without permission from the Sponsor) or the consolidated data (with written consent from the Sponsor) by providing notice and a copy of the publication to the Sponsor at least 30 days prior to submission and allowing the Sponsor 30 days to review.|t
17127459|NCT03562975|t||||
17127460|NCT00979134|f||OTHER||t
17127461|NCT05180500|t||||
17127462|NCT05917470|f||||f
17127463|NCT03694275|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127464|NCT03695237|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138300|NCT01628393|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17138301|NCT00706394|f||LTE60||t
17138302|NCT00792701|f||||f
17138303|NCT03943888|f||||t
17165038|NCT00517699|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165039|NCT03951610|f||||f
17165040|NCT02332187|t||||f
17165041|NCT01840943|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17165042|NCT04606927|f||||f
17165043|NCT02580877|f||||f
17165044|NCT00980148|f||||f
17165045|NCT00551031|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17165046|NCT02903823|f||||f
17165047|NCT01747915|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165048|NCT03341637|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165049|NCT00887159|f||LTE60||t
17165050|NCT00441766|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165051|NCT03500211|t||||
17169200|NCT01972789|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169201|NCT00971295|t||||
17169202|NCT01707381|f||||f
17169203|NCT00955513|f||||f
17169204|NCT00086411|t||||
17169205|NCT00375167|f||||f
17169206|NCT01441466|f||||f
17138304|NCT02135900|t||||
17138305|NCT01998438|f||||f
17138306|NCT03862495|t||||
17138307|NCT01467661|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17138308|NCT03673956|t||||
17138309|NCT00425113|t||||
17165052|NCT03420742|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17165053|NCT00099021|f||LTE60||t
17165054|NCT02189889|t||||
17165055|NCT00290810|f||LTE60||t
17165056|NCT01639469|t||||
17165057|NCT01119443|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165058|NCT00420381|f||GT60||t
17165059|NCT03500289|f||||f
17165060|NCT00775268|f||||f
17165061|NCT03604497|f||||f
17165062|NCT02921295|f||||f
17138310|NCT01074658|f||OTHER|PI will provide results to sponsor for review and approval at least 60 days prior to submittal for publication or presentation. Review will be limited to determination whether Confidential Information is disclosed and not to censor or interfere with presentation or conclusions beyond the extent necessary to protect Confidential Information, to allow the sponsor to protect its rights in patentable or copyrightable material, and to check for technical correctness of sponsor information.|t
17169207|NCT02885246|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138311|NCT01342952|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138312|NCT02156804|f||LTE60||t
17169208|NCT02069119|f||||f
17138313|NCT00879437|f||||f
17169209|NCT02566590|f||||f
17169210|NCT03667690|f||OTHER||t
17138314|NCT04581863|f||||f
17138315|NCT01803711|t||||
17138316|NCT00636441|t||||
17138317|NCT02157168|t||||f
17138318|NCT03495817|f||||f
17138319|NCT02781454|f||||f
17138320|NCT04585451|f||||f
17138321|NCT02372097|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17138322|NCT02608229|t||||
17138323|NCT02714504|f||||t
17169211|NCT04802187|t||||
17127465|NCT03541174|f||OTHER|Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17127466|NCT02002650|f||||f
17127467|NCT02217332|f||OTHER||t
17138324|NCT02849626|f||||t
17138325|NCT01957787|f||OTHER|Galil Medical can require Investigator to postpone publications/presentations for up to 12 months so data from all sites can be published. Galil Medical will limit review of Investigator's draft to confirm Confidential Information is not being disclosed. If Galil Medical notes publishing Study results may affect obtaining a patent, Investigator may not publish for up to 60 days until patent application is filed. Investigator will acknowledge Galil Medical in any publication/presentation.|t
17138326|NCT04176445|f||||f
17138327|NCT02248857|f||||f
17138328|NCT01412060|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17138329|NCT00004732|f||||f
17138330|NCT00442767|f||||f
17138331|NCT01183312|t||||
17165063|NCT03068897|t||||
17165064|NCT00589797|f||GT60||t
17165065|NCT01881009|f||||f
17165066|NCT01194245|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17165067|NCT00269087|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165068|NCT05069649|f||||t
17165069|NCT01886235|t||||
17165070|NCT00041470|f||||f
17165071|NCT03800030|t||||
17165072|NCT02230189|t||||
17165073|NCT01074125|f||||f
17165074|NCT00746187|f||LTE60||t
17165075|NCT01193101|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165076|NCT02347085|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17165077|NCT02834819|t||||f
17169212|NCT00520910|t||||
17169213|NCT00321464|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169214|NCT04327024|f||LTE60||t
17169215|NCT00668811|t||||
17169216|NCT00582998|f||||f
17169217|NCT01192568|f||||f
17127468|NCT04058366|f||||t
17127469|NCT00603304|t||||
17127470|NCT02480153|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127471|NCT00512317|f||||f
17127472|NCT04433585|f||GT60||t
17138332|NCT02674685|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138333|NCT02713789|f||||f
17138334|NCT02091921|t||||
17138335|NCT03307629|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165078|NCT01313507|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17165079|NCT02694601|t||||
17165080|NCT00527618|t||||f
17165081|NCT02706925|t||||f
17165082|NCT01111162|f||||f
17165083|NCT00363311|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165084|NCT03175731|t||||
17165085|NCT00120627|t||||f
17165086|NCT01595529|f||||f
17165087|NCT01508910|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, results may not be published without prior written approval of Sponsor.|t
17165088|NCT00730886|f||||f
17165089|NCT01991483|f||GT60||t
17165090|NCT04344184|t||||
17165091|NCT04819113|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165092|NCT00833027|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165093|NCT05119582|f||||f
17165094|NCT03096886|f||||f
17165095|NCT00553410|f||||f
17165096|NCT03092479|t||||
17165097|NCT04683913|f||||f
17165098|NCT01364480|t||||
17165099|NCT00288886|t||||
17165100|NCT03663855|t||||
17165101|NCT01475721|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165102|NCT04343092|f||||f
17165103|NCT00803738|f||OTHER||t
17165104|NCT02364037|f||||f
17165105|NCT04567524|f||||t
17165106|NCT00901303|t||||f
17165107|NCT02848092|f||||f
17165108|NCT01244711|f||||f
17169218|NCT00652951|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169219|NCT02593825|f||||f
17169220|NCT01206582|t||||
17169221|NCT02522325|f||||f
17169222|NCT01209078|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169223|NCT00924508|t||||
17169224|NCT00495625|t||||f
17127473|NCT02778932|t||||
17127474|NCT03606668|t||||
17127475|NCT00495586|t||||
17127476|NCT02057523|f||||f
17127477|NCT00158860|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169225|NCT01912339|f||LTE60||t
17169226|NCT01754493|f||||f
17169227|NCT01543776|f||LTE60||t
17127478|NCT03098420|t||||
17127479|NCT01029652|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127480|NCT02313233|f||OTHER||t
17127481|NCT02095951|f||||f
17127482|NCT03618823|t||||f
17127483|NCT00944073|f||LTE60||t
17127484|NCT00964886|t||||
17127485|NCT02758847|f||||f
17127486|NCT00523640|t||||
17127487|NCT03139669|t||||
17127488|NCT04587752|t||||
17127489|NCT01621568|f||||f
17127490|NCT02399254|t||||
17127491|NCT02765802|f||||f
17127492|NCT00564889|t||||
17127493|NCT03500159|f||OTHER|Restrictions are specific to applicable clinical trial agreements with PI(s)|t
17127494|NCT04595318|f||||f
17127495|NCT03535597|f||||f
17127496|NCT02292927|t||||
17127497|NCT00568802|t||||
17127498|NCT03545503|t||||
17127499|NCT03028220|t||||
17127500|NCT02684851|t||||
17127501|NCT00862719|t||||
17127502|NCT00470366|t||||
17127503|NCT04493502|f||GT60||t
17127504|NCT02751320|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127505|NCT01021215|f||LTE60||t
17127506|NCT00296400|f||LTE60||t
17127507|NCT01014533|t||||
17127508|NCT00578461|t||||
17127509|NCT00412061|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127510|NCT01942590|t||||
17127511|NCT05332145|f||||f
17127512|NCT00312923|f||||f
17127513|NCT01011387|f||OTHER|The Coordinating Investigator will be the lead author for the mail (primary) publication from this Investigation. For any abstract and/or manuscript the Investigators will be given at least 14 days review time before the intended submission of the document.|t
17169228|NCT01356628|t||||
17169229|NCT03055013|f||LTE60||t
17169230|NCT02207491|f||||f
17169231|NCT00126776|t||||
17169232|NCT00599755|f||OTHER|Subsequent to multicenter publication, or 24 months after study completion, whichever comes first, an investigator and/or colleague(s) may publish the results for their study site independently. The SPONSOR recommends against this practice due to scientific concerns. The SPONSOR must have the opportunity to review all publications or presentations regarding this study 60 days prior to submission, and any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17169233|NCT03267888|f||||f
17169234|NCT03626545|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169235|NCT01939366|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17169236|NCT03909152|t||||
17169237|NCT02615691|f||||t
17169238|NCT02017522|t||||f
17169239|NCT00597493|f||||f
17169240|NCT00615030|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17169241|NCT00151476|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127514|NCT02433340|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127515|NCT01178385|f||||f
17127516|NCT01226095|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection|t
17127517|NCT00857272|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.|t
17127518|NCT01688830|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17127519|NCT01285609|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17127520|NCT04822597|t||||
17127521|NCT03283072|f||||f
17127522|NCT03797677|f||||f
17127523|NCT02552368|f||||f
17127524|NCT03002753|f||||f
17127525|NCT05652647|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127526|NCT05326815|t||||
17169242|NCT03446456|f||||f
17169243|NCT04532931|t||||
17169244|NCT02917733|f||LTE60||t
17169245|NCT04099511|f||||f
17169246|NCT00065806|f||OTHER|PIs agree to follow the CARRA Publication Guidelines. https://www.carragroup.org/about-carra/carra-policies/carra-endorsed-studies-policies|t
17169247|NCT00581867|t||||
17169248|NCT03002311|t||||
17169249|NCT03908476|f||||t
17169250|NCT05194267|f||||f
17169251|NCT00802893|t||||
17169252|NCT02868229|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17127527|NCT00925132|t||||
17127528|NCT02545933|t||||f
17127529|NCT03149549|f||||f
17127530|NCT00835900|f||||f
17127531|NCT01846494|t||||
17127532|NCT00867308|t||||
17127533|NCT00452023|t||||
17127534|NCT00715754|t||||
17127535|NCT03029351|t||||
17127536|NCT01034176|f||||f
17127537|NCT00715962|f||||f
17127538|NCT03207009|f||||t
17127539|NCT04343872|f||||f
17127540|NCT03241225|t||||f
17127541|NCT04390022|t||||
17127542|NCT02618915|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127543|NCT01635920|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127544|NCT00007345|f||||f
17127545|NCT00194987|f||||f
17127546|NCT01664598|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165109|NCT00913510|f||GT60||t
17165110|NCT02329743|f||||f
17165111|NCT02462187|f||||t
17165112|NCT02656836|t||||
17165113|NCT02078752|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165114|NCT00439335|f||LTE60||t
17165115|NCT00753948|t||||
17165116|NCT00616642|f||||f
17165117|NCT03856359|f||||f
17165118|NCT03391986|t||||
17165119|NCT01553292|t||||f
17165120|NCT01102738|t||||
17165121|NCT02141672|f||||f
17165122|NCT00705874|f||||f
17165123|NCT00332696|f||OTHER|Disclosure Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or of the trial results in their entirety.|t
17165124|NCT03091361|f||||f
17165125|NCT01061385|f||OTHER|The PI shall furnish a copy of any proposed publication or disclosure at least 60 days prior to submission so that Sponsor may have the opportunity to protect its proprietary rights to information, inventions, or products developed under the Clinical Study. If such publication or disclosure contains Confidential Information, the PI agrees to remove such Confidential Information upon the Sponsor's request.|t
17165126|NCT00533429|f||GT60||t
17165127|NCT01464879|f||OTHER|There is a restriction on joint publications prepared in collaboration between investigator and sponsor as Ferring reserves the right to be involved in this decision. In the event of any disagreement in the content of any publication both investigator's and Ferring´s opinion will be fairly and sufficiently represented in the publication.|t
17165128|NCT00244621|f||GT60||t
17127547|NCT04187989|f||||f
17127548|NCT02454179|f||||f
17127549|NCT03356626|f||||f
17165129|NCT00800982|f||||f
17165130|NCT01824290|f||GT60||t
17165131|NCT02537730|f||OTHER||t
17165132|NCT00648037|t||||
17165133|NCT01545765|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor to review and approval at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17165134|NCT02967679|f||||f
17165135|NCT02379195|t||||
17165136|NCT00003631|t||||
17138336|NCT03296787|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17138337|NCT00719953|f||||f
17138338|NCT01626989|f||||f
17138339|NCT02437487|f||OTHER|Proposed publications must be submitted to Sponsor for review at least 30 days prior to publication. Sponsor can require removal of confidential information other than study data and Site/Investigator agree to consider Sponsor's suggestions with respect to the presentation of study data. Sponsor can force publication to be deferred for a period of up to 60 days in order to file any patents.|t
17138340|NCT01230749|f||GT60||t
17138341|NCT01060098|t||||
17138342|NCT02480998|f||||t
17127550|NCT04279392|t||||f
17127551|NCT01488877|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127552|NCT01035073|t||||
17127553|NCT04289051|f||LTE60||t
17127554|NCT01901341|f||OTHER||t
17127555|NCT02561754|f||||f
17127556|NCT01981473|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127557|NCT01336803|t||||
17127558|NCT02937454|f||||t
17127559|NCT01147601|t||||
17127560|NCT02630693|t||||
17127561|NCT02192879|t||||
17127562|NCT00993668|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17127563|NCT04955444|t||||
17127564|NCT00952120|t||||
17127565|NCT01288521|f||||f
17127566|NCT00580645|f||||f
17127567|NCT00682890|f||||f
17127568|NCT02884908|f||||f
17127569|NCT04080908|t||||
17138343|NCT02687711|f||GT60||t
17138344|NCT03621189|t||||f
17138345|NCT03077243|f||OTHER|LCCC1612 is a multi-site study. Three of the four site investigators are not employees of the Sponsor. Restrictions to disclosure do not apply due to circumstances of non-compliance. Study data was sequestered, data is not accessible for further analysis or publication.|t
17138346|NCT02848313|f||GT60||t
17138347|NCT01432457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138348|NCT03154294|t||||
17138349|NCT00247273|f||LTE60||t
17127570|NCT01605019|f||LTE60||t
17127571|NCT00324116|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127572|NCT01806623|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138350|NCT01419015|f||||f
17138351|NCT02580240|f||||f
17138352|NCT00607919|f||GT60||t
17138353|NCT00646581|t||||f
17138354|NCT01527110|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165137|NCT00600067|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17165138|NCT00869167|f||||f
17165139|NCT04339413|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17165140|NCT01684839|t||||
17165141|NCT01224236|t||||
17165142|NCT00401843|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17165143|NCT02103062|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally sixty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17165144|NCT00761345|t||||
17165145|NCT02030821|t||||
17165146|NCT03192137|f||OTHER|The investigator agrees to submit the manuscript of any journal article, abstract or other presentation arising from an InSite Vision-sponsored clinical investigation to InSite Vision for editorial review prior to submission for publication or presentation. At the sponsor's request, if proprietary information is to be disclosed, proposed publications or presentations will be delayed until appropriate patent applications and/or legal documents of a similar nature have been filed.|t
17165147|NCT02153489|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the investigator and sponsor.|t
17165148|NCT00657267|f||GT60||t
17165149|NCT04373421|f||||f
17165150|NCT02737501|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17165151|NCT01261975|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17165152|NCT00716274|f||LTE60||t
17165153|NCT00405288|t||||
17165154|NCT04067492|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17165155|NCT00786422|f||OTHER|The investigator, whilst free to utilize data derived from the study for scientific purposes, must discuss any publication with Bayer prior to release and obtain written consent of Bayer on the intended publication. The investigator must send a draft manuscript of the publication or abstract to Bayer thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication.|t
17165156|NCT01646814|f||GT60||t
17165157|NCT00543985|t||||f
17165158|NCT02015039|t||||
17165159|NCT04570384|f||||f
17165160|NCT01673126|f||||f
17165161|NCT00237042|f||||f
17165162|NCT01876212|t||||f
17165163|NCT03111316|f||OTHER|Ferring shall have the right to review all clinical data arising from the research project. Sponsor/investigator shall provide any manuscript to Ferring prior to submission to permit at least 30 days for comment. Sponsor/investigator may incorporate the written suggestions or comments from Ferring in his/her own discretion. Ferring reserves the right to delay publication of clinical data arising from the research project, not to exceed 90 days to permit any intellectual property to be protected.|t
17165164|NCT01897532|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17165165|NCT03132467|t||||
17165166|NCT00038948|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17165167|NCT03682965|t||||
17165168|NCT01404234|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165169|NCT02670473|f||OTHER||t
17165170|NCT05223673|f||||t
17165171|NCT00937495|f||LTE60||t
17165172|NCT00443703|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165173|NCT04552041|f||||t
17165174|NCT00661830|t||||
17165175|NCT00488514|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165176|NCT01669902|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165177|NCT01535287|f||||f
17165178|NCT01047189|f||||f
17165179|NCT00052910|t||||
17165180|NCT01187095|t||||
17165181|NCT00387088|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165182|NCT02178800|f||||f
17165183|NCT05160363|f||OTHER|If the Sponsor and RPL agree that it will be desirable to publish the results of this trial; both parties will liaise in good faith to publish the results. RPL agree to obtain the Sponsor's prior written approval of such publications.|t
17165184|NCT01428219|t||||
17165185|NCT00512278|f||||f
17165186|NCT00592631|f||||f
17165187|NCT00410189|t||||f
17165188|NCT03745768|f||||f
17165189|NCT00443118|f||||f
17165190|NCT01100112|f||||f
17165191|NCT01718522|f||||f
17165192|NCT01023217|f||||f
17165193|NCT01106157|t||||f
17165194|NCT01154335|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17165195|NCT01673646|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165196|NCT03064074|f||||f
17165197|NCT03368196|f||||f
17165198|NCT02651116|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165199|NCT02457247|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165200|NCT01492088|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17165201|NCT02379052|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17165202|NCT03824392|f||||t
17165203|NCT00127855|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165204|NCT02343302|f||||f
17165205|NCT01887717|f||OTHER|BTG can require Investigator to postpone publications/presentations for up to 12 months so data from all sites can be published. BTG will limit review of Investigator's draft to confirm Confidential Information is not being disclosed. If BTG notes publishing Study results may affect obtaining a patent, Investigator will not publish for up to 60 days until patent application is filed. Investigator will acknowledge BTG in any publication/presentation.|t
17165206|NCT02655887|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17165207|NCT00532844|f||GT60||t
17165208|NCT03637491|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165209|NCT03988426|f||||f
17165210|NCT02020590|f||||t
17165211|NCT00598819|f||LTE60||t
17165212|NCT04389866|f||||f
17165213|NCT01339936|f||OTHER|"Publication policy~The investigation data is wholly owned by the Sponsor. The results of the investigation may not be used in publications or presentations without the written permission of the Sponsor."|t
17165214|NCT01186250|f||||f
17165215|NCT03465722|f||||t
17165216|NCT01490918|f||||f
17165217|NCT03046836|f||||f
17165218|NCT03542019|f||||f
17165219|NCT03141255|f||||f
17165220|NCT04940130|f||||f
17165221|NCT02240121|f||OTHER|Please contact Sponsor directly for additional information.|t
17165222|NCT04581785|f||||t
17127573|NCT01737827|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127574|NCT01451827|f||OTHER|Center may publish study results but ≥ 60 days prior to any public presentation, a copy is sent to Sponsor for review and Center can delay publication for 60 days to permit Sponsor to protect its intellectual property rights or confidential information contained within the publication. The first publication is a joint publication, if Center is part of a multi-center study. Center is free to publish, if there is no multi-center publication within 18 months of completion/ termination of study.|t
17127575|NCT02413333|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127576|NCT02996474|t||||
17127577|NCT00540046|f||||f
17127578|NCT02891837|f||GT60||t
17127579|NCT00185965|f||||f
17127580|NCT02533531|f||||f
17127581|NCT02047903|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127582|NCT03901482|f||OTHER||t
17127583|NCT03616977|t||||
17169253|NCT00320424|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165223|NCT01925768|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications|t
17165224|NCT03511001|f||||f
17165225|NCT05501639|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17165226|NCT00251693|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17165227|NCT02779777|f||OTHER|There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.|t
17165228|NCT04571060|f||LTE60||t
17165229|NCT04410159|f||||f
17165230|NCT01361217|f||||f
17165231|NCT00087698|f||GT60||t
17165232|NCT03139032|f||OTHER||t
17165233|NCT02073162|f||||t
17165234|NCT04970069|t||||f
17165235|NCT00585637|f||LTE60||t
17165236|NCT01070979|f||LTE60||t
17127584|NCT03456427|f||||f
17127585|NCT01323972|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127586|NCT02008877|f||||f
17127587|NCT03539887|t||||
17127588|NCT01049217|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127589|NCT02412371|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127590|NCT00903682|f||OTHER|A copy of the manuscript must be provided to the Sponsor for review at least 60 days prior to submission for publication or presentation. No paper that incorporates Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, such publication will be withheld for up to an additional 60 calendar days. A publication from the individual Study site data will not be published until the combined results have been published.|t
17127591|NCT02495792|f||||f
17127592|NCT02053792|f||||t
17127593|NCT02909764|f||||f
17127594|NCT03141905|f||||f
17127595|NCT02502799|f||||f
17127596|NCT01304238|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127597|NCT01621737|t||||
17127598|NCT01076192|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127599|NCT05087979|t||||
17127600|NCT02924428|f||||f
17127601|NCT01850446|f||||t
17127602|NCT00759915|f||||f
17127603|NCT02074553|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127604|NCT01658150|t||||
17138355|NCT02007252|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165237|NCT01846702|t||||f
17165238|NCT01328743|t||||
17165239|NCT01900665|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165240|NCT02481258|t||||
17165241|NCT05599100|f||||f
17165242|NCT04749745|f||||f
17165243|NCT04541667|t||||
17165244|NCT04050384|f||||f
17165245|NCT03816176|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17165246|NCT04472650|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information and may request a further delay to protect its IP rights.|t
17165247|NCT03121144|f||GT60||t
17165248|NCT00298389|t||||
17165249|NCT00288015|t||||
17165250|NCT01333722|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17165251|NCT01104402|f||||f
17165252|NCT02477527|f||||f
17165253|NCT01291108|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165254|NCT01144143|t||||
17165255|NCT03432494|t||||f
17138356|NCT02236273|f||||f
17169254|NCT06151288|f||OTHER|Sponsor shall review within the ninety (90) day period. Upon receiving any notification from Sponsor requesting deletion of Confidential Information, correction of inaccuracies, or a delay in publication to allow the filing of patent application, Institution or Investigator shall take the requested action of Sponsor.|t
17169255|NCT00658814|f||LTE60||t
17169256|NCT06225466|f||||f
17169257|NCT04909229|f||||f
17169258|NCT02219659|t||||f
17169259|NCT00231413|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17165256|NCT00856635|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17165257|NCT00437398|t||||f
17165258|NCT01244035|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17165259|NCT01162551|t||||
17165260|NCT02383862|t||||
17165261|NCT01696773|f||||f
17165262|NCT01833494|f||||f
17165263|NCT01694433|f||||f
17165264|NCT03071861|t||||
17165265|NCT00374595|t||||
17165266|NCT01773954|f||||f
17165267|NCT01664247|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17165268|NCT02607124|t||||f
17165269|NCT01212471|f||OTHER|Contact sponsor directly for details.|t
17165270|NCT01580410|t||||
17165271|NCT03417466|f||OTHER|Investigators are required to submit any proposed publications to the study sponsor for review and approval at least 60 days prior to submitting the materials for external publication.|t
17165272|NCT01118780|f||GT60||t
17165273|NCT01531582|f||||f
17165274|NCT03885154|t||||
17165275|NCT03889028|f||||f
17165276|NCT05018689|f||||f
17165277|NCT03962855|t||||
17165278|NCT03119168|t||||
17165279|NCT04419467|f||||t
17165280|NCT00442416|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165281|NCT03301779|f||||f
17165282|NCT01284959|f||||f
17138357|NCT00812604|t||||
17138358|NCT00081939|f||||f
17165283|NCT04342091|f||||f
17165284|NCT00003869|f||LTE60||t
17165285|NCT03364231|f||||f
17165286|NCT04068922|f||||f
17165287|NCT02272946|t||||
17165288|NCT01333436|f||OTHER|Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results for their study site independently. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17165289|NCT00444106|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17165290|NCT04749914|t||||
17165291|NCT02965989|t||||
17165292|NCT01913327|f||||f
17165293|NCT01352286|f||GT60||t
17165294|NCT00000134|f||GT60||t
17169260|NCT02708485|f||||f
17165295|NCT01074931|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17165296|NCT00953706|f||GT60||t
17165297|NCT03081689|f||||f
17165298|NCT02137070|f||||f
17165299|NCT02112656|f||OTHER|PI shall seek the Sponsor's prior review of publications, not before the multi-center publication has been published with Sponsor or 1 year from the date of Study completion/termination and only after review and comment by Sponsor. Proposed publication must be provided to Sponsor at least 60 days prior to submission to publisher. On Sponsor request, PI shall withhold a Publication from submission an additional 60 days to allow for the filing of a patent or any other protective actions available.|t
17165300|NCT03761056|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165301|NCT04028648|f||||f
17165302|NCT03670160|t||||
17165303|NCT00577278|t||||
17165304|NCT03965403|t||||f
17165305|NCT02292537|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17165306|NCT01979614|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17165307|NCT00756275|f||||f
17165308|NCT04103112|f||||f
17165309|NCT00938912|f||GT60||t
17165310|NCT00456755|t||||f
17165311|NCT06164691|t||||
17165312|NCT02970136|t||||
17165313|NCT02126319|t||||f
17127605|NCT02342743|f||OTHER|"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 60 days from the time submitted to the sponsor for review. Sponsor may request:~* deletion of any trade secret, proprietary, or confidential information of Sponsor~* an additional 60 days to take measures to preserve its Intellectual Property rights"|t
17127606|NCT04875676|f||||f
17127607|NCT03646656|t||||
17127608|NCT03602066|t||||
17127609|NCT00092495|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127610|NCT03182725|f||||f
17165314|NCT02609425|f||||f
17165315|NCT01424943|f||||f
17165316|NCT01435174|f||||f
17165317|NCT01482195|f||||f
17165318|NCT00641108|t||||
17165319|NCT02370368|f||||f
17165320|NCT03723980|f||||f
17165321|NCT00347932|f||OTHER|Sponsor has 45 days to review materials and provide comments back to the investigator.|t
17165322|NCT04512001|f||||t
17165323|NCT01029912|t||||f
17165324|NCT03389308|f||LTE60||t
17165325|NCT03198767|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17165326|NCT00570323|t||||
17165327|NCT04232943|f||||f
17169261|NCT03266172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17169262|NCT00997620|f||||f
17169263|NCT01554514|f||||f
17165328|NCT02639247|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165329|NCT02820844|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165330|NCT02266147|f||LTE60||t
17165331|NCT00382265|f||||f
17165332|NCT03896477|f||||t
17165333|NCT01791517|f||GT60||t
17165334|NCT04011735|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review Prior to any Submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI´s intellectual property rights.|t
17165335|NCT02298868|t||||
17165336|NCT01000506|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165337|NCT00739310|f||||f
17165338|NCT01071954|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165339|NCT00590967|t||||
17165340|NCT01847755|t||||
17165341|NCT00920556|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165342|NCT04245709|f||||f
17165343|NCT03734822|t||||
17165344|NCT02185534|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17165345|NCT02213068|f||||f
17165346|NCT02041299|f||LTE60||t
17165347|NCT02389465|f||||f
17165348|NCT00846846|f||OTHER|For any publication or presentation of the Protected Materials or any portion thereof, a maunscript of the paper, abstract or any materials will be provided by Consultant to Sponsor for its approval at least sixty (60days) for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.|t
17165349|NCT00243191|f||LTE60||t
17165350|NCT00943631|f||LTE60||t
17165351|NCT00530634|t||||
17165352|NCT01791491|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165353|NCT04179305|t||||f
17165354|NCT00361972|f||||f
17169264|NCT05222555|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17169265|NCT02903394|t||||
17169266|NCT00300365|f||||f
17127611|NCT00938470|f||LTE60||t
17127612|NCT01171807|f||||f
17127613|NCT04101318|f||LTE60||t
17165355|NCT00503425|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165356|NCT00326599|f||LTE60||t
17165357|NCT00142792|f||||f
17165358|NCT00437268|f||GT60||t
17165359|NCT00444925|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165360|NCT03129464|t||||
17165361|NCT03870048|t||||
17165362|NCT03484429|f||||f
17127614|NCT00822172|t||||
17127615|NCT01874431|f||OTHER||t
17127616|NCT00757588|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17127617|NCT04601870|f||||f
17127618|NCT00691327|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127619|NCT01888900|t||||
17127620|NCT03932812|f||||f
17127621|NCT02234687|t||||
17165363|NCT00943761|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17165364|NCT00714948|t||||
17165365|NCT04581811|t||||
17165366|NCT01342926|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165367|NCT03382912|f||GT60||t
17165368|NCT05653700|f||||f
17165369|NCT02317692|f||||f
17165370|NCT02573948|f||||f
17165371|NCT04421404|t||||
17165372|NCT00707993|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17165373|NCT04500457|t||||
17165374|NCT05414175|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165375|NCT00678288|f||OTHER|Protocol and PI clinical trial agreements.|t
17165376|NCT01415583|f||||f
17165377|NCT03611881|f||||f
17165378|NCT00552071|f||||f
17165379|NCT00532129|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165380|NCT02224508|t||||
17165381|NCT00784368|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17165382|NCT02079909|f||||f
17165383|NCT02277249|f||||f
17165384|NCT01784367|t||||
17165385|NCT00720356|t||||f
17165386|NCT01869634|t||||
17165387|NCT02237001|f||GT60||t
17165388|NCT04254692|t||||
17165389|NCT00342628|t||||
17165390|NCT04551898|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165391|NCT03427814|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165392|NCT03145064|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17169267|NCT01422824|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169268|NCT01581619|t||||
17169269|NCT01818492|f||||f
17169270|NCT03077204|f||||f
17169271|NCT00109577|f||||f
17169272|NCT00587847|t||||f
17165393|NCT03846427|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17165394|NCT01693250|f||||f
17169273|NCT03729245|f||||t
17169274|NCT00695864|t||||
17165395|NCT00628446|t||||f
17165396|NCT01396187|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165397|NCT03394781|f||OTHER|If a joint publication is not submitted within 18-24 months after study completion, PI shall have the right to submit to sponsor a proposed results communication based on results at their institution. Sponsor can review proposed results communications prior to public release, can request removal of confidential information, and can embargo communications regarding trial results for up to 105-120 days after submission to sponsor.|t
17165398|NCT03460652|f||||f
17165399|NCT04971967|t||||f
17165400|NCT00535769|f||||f
17165401|NCT00682929|t||||
17165402|NCT01462929|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17165403|NCT04723355|f||OTHER|It was agreed with the funding source that the trial results will be published in the Clinicaltrials.gov only.|t
17165404|NCT04072835|f||||t
17165405|NCT01109108|t||||
17165406|NCT00841776|f||GT60||t
17165407|NCT00672594|t||||
17165408|NCT01306643|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165409|NCT02071771|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17165410|NCT02746406|f||OTHER|Sponsor can review results communications prior to public release regarding trial results for a period that is less than 60 days. The sponsor can request changes to the communication.|t
17165411|NCT01516632|t||||f
17165412|NCT02479880|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169275|NCT00718770|t||||
17165413|NCT00355368|t||||
17165414|NCT01349673|f||OTHER|Please contact Sponsor directly for additional information.|t
17165415|NCT00348946|f||||f
17165416|NCT03688919|f||||f
17165417|NCT03975153|f||||f
17165418|NCT01285024|f||||f
17165419|NCT00506779|t||||
17165420|NCT03462758|f||||f
17165421|NCT01896687|t||||f
17169276|NCT01704456|f||||f
17169277|NCT00498355|f||||f
17169278|NCT00988364|f||||f
17169279|NCT02107157|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17169280|NCT00575965|t||||f
17169281|NCT03268941|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169282|NCT01216683|f||LTE60||t
17169283|NCT01237613|f||LTE60||t
17169284|NCT02503501|t||||
17169285|NCT01740401|t||||
17169286|NCT02806960|f||GT60||t
17169287|NCT03495102|f||GT60||t
17169288|NCT01706588|f||LTE60||t
17169289|NCT01161537|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17169290|NCT01755455|f||||f
17127622|NCT01383499|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17127623|NCT04275089|f||||f
17127624|NCT02585232|f||||f
17127625|NCT02257567|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127626|NCT03038438|f||LTE60||t
17138359|NCT00150345|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165422|NCT00413660|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165423|NCT02831855|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165424|NCT01722994|t||||
17165425|NCT03012191|f||||f
17165426|NCT01803880|f||OTHER|Authorship and contents of publications shall be discussed between each Principal Investigator and Sponsor. Sponsor shall serve as coordinator of multi-center study disclosures and, in event of a disagreement among investigators, Sponsor shall determine resolution of any such dispute. Sponsor shall be furnished copies of any proposed multi-center publication or disclosure at least 90 days prior to the proposed date for submission for publication or disclosure.|t
17165427|NCT02954887|f||GT60||t
17165428|NCT02388880|f||LTE60||t
17165429|NCT01459666|f||GT60||t
17169291|NCT00856726|f||||f
17169292|NCT03464019|f||||t
17127627|NCT03215810|f||LTE60||t
17127628|NCT00992433|f||LTE60||t
17127629|NCT03814031|f||||f
17127630|NCT01656733|f||||f
17127631|NCT03625895|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165430|NCT01404650|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17165431|NCT01152788|t||||t
17165432|NCT02251496|f||||f
17165433|NCT00889707|f||OTHER|Principal Investigators will take all steps reasonably necessary to hold Protox's Proprietary Information in trust and confidence, will not use Proprietary Information in any manner or for any purpose not expressly set forth in their Agreement, and will not disclose any such Proprietary Information to any third party without first obtaining Protox's express written consent.|t
17165434|NCT03198156|t||||
17169293|NCT00511134|f||LTE60||t
17169294|NCT01949090|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169295|NCT03459365|f||||f
17169296|NCT02146001|f||||f
17169297|NCT00567359|t||||
17169298|NCT00785980|f||GT60||t
17169299|NCT00528801|f||||f
17138360|NCT04526067|t||||f
17169300|NCT00344500|t||||
17169301|NCT00793169|f||||f
17127632|NCT01065844|t||||
17127633|NCT02679573|f||LTE60||t
17169302|NCT00680797|f||||f
17169303|NCT04680975|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17127634|NCT02476279|f||||f
17127635|NCT01096823|f||||f
17127636|NCT00577473|f||LTE60||t
17127637|NCT01580423|t||||f
17127638|NCT01502631|f||||f
17127639|NCT02084056|t||||
17127640|NCT01293487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127641|NCT00395460|f||OTHER|PIs shall provide sponsor with an advance copy of any proposed publication or oral presentation at least ninety (90) days prior to the date of the planned submission or presentation. Sponsor shall have sixty (60) days to recommend any changes it reasonably believes are necessary for scientific purposes or to preserve the confidentiality of sponsor's confidential information. PIs agree that the adoption of such recommended changes shall not be unreasonably refused.|t
17127642|NCT01975974|t||||f
17127643|NCT02489123|t||||
17127644|NCT04299438|f||||f
17127645|NCT04771611|t||||
17127646|NCT04223830|f||GT60||t
17127647|NCT01964924|f||LTE60||t
17127648|NCT01808326|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165435|NCT02157909|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17165436|NCT02268383|f||OTHER|No publication or disclosure of study results will be permitted except as specified in a separate, written, agreement between the sponsor and the investigator(s).|t
17165437|NCT02708680|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17165438|NCT04162470|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17165439|NCT02568722|f||GT60||t
17165440|NCT05588440|f||||f
17165441|NCT00962871|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165442|NCT01544348|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17165443|NCT01445847|t||||
17165444|NCT00125788|f||OTHER|PI agrees that any INFORMATION submitted to it by EMMAUS shall be maintained in secrecy for a period of seven (7) years from each disclosure of INFORMATION. PI will use the up most due diligence to prevent disclosure by it except to its employees, agents, and contractors necessary for evaluation, all of whom shall be bound by similar written obligations of confidentiality, and who agree not to use the INFORMATION for any purpose other than for evaluation purposes.|t
17165445|NCT04790279|f||||f
17165446|NCT03930771|t||||
17165447|NCT01222117|f||OTHER|Site may publish results from the study, after providing sponsor 30 days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At sponsor's request, site will remove any confidential information (other than study results), and site will upon sponsor's request delay publication or presentation for a period of up to 60 days to allow sponsor to protect its interests in any sponsor inventions|t
17165448|NCT00810277|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165449|NCT02836470|f||||f
17165450|NCT03402932|f||||f
17165451|NCT02549989|t||||
17165452|NCT00972023|t||||f
17165453|NCT02628444|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17169304|NCT02702414|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17169305|NCT02596230|t||||
17169306|NCT02271945|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17169307|NCT00290498|t||||
17127649|NCT00577577|f||||f
17127650|NCT01153958|f||OTHER||t
17127651|NCT03572387|f||||f
17127652|NCT01856868|t||||
17127653|NCT00968227|f||||f
17127654|NCT01034163|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127655|NCT02424734|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127656|NCT00528645|f||LTE60||t
17127657|NCT00116753|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17127658|NCT01642251|f||LTE60||t
17169308|NCT03957876|t||||
17127659|NCT01445301|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127660|NCT00752557|f||OTHER|Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study participating sites. Investigator may not disclose previously undisclosed confidential other than study results.|t
17127661|NCT02141451|t||||f
17127662|NCT02150343|f||OTHER|Wording included in the clinical protocol - The Investigator and Circassia will normally prepare a manuscript together. To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.|t
17127663|NCT01986075|t||||
17127664|NCT03683823|f||||f
17127665|NCT03103490|t||||
17127666|NCT03965351|f||||f
17127667|NCT00490724|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17127668|NCT00994682|f||||f
17165454|NCT01713582|f||OTHER|The Sponsor has the opportunity to review all proposed publications regarding this trial 60 days prior to submission for publication. In addition, if requested, the investigator will withhold publication an additional 90 days to allow for filing a patent application or taking such other measures to establish and preserve its proprietary rights. Publication of the results of the study shall be made only as part of a publication of the results obtained by all sites performing the protocol.|t
17165455|NCT02155101|f||LTE60||t
17165456|NCT01898286|f||OTHER|Investigator shall submit any paper or presentation to the Sponsor for review and comments at least 60 days prior to submitting the same to a third party. Upon receiving any request from the Sponsor to delete any Confidential Information or request to delay in publication up to 90 days to allow the filing of any Sponsor application, the Investigator shall take the request action. Investigator shall not be restricted after 18 months from completion of their site's performance in the study.|t
17165457|NCT02257242|f||||f
17165458|NCT02433496|t||||
17165459|NCT00548197|f||||f
17165460|NCT01650831|t||||f
17165461|NCT02259725|f||||f
17165462|NCT04005391|t||||
17165463|NCT01048242|f||||f
17165464|NCT02964273|f||OTHER|The sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17165465|NCT03358355|t||||
17165466|NCT03333928|f||GT60||t
17127669|NCT02677428|t||||
17127670|NCT02859324|f||LTE60||t
17127671|NCT01710332|f||||f
17127672|NCT02680002|f||OTHER|Data and results owned by Sponsor. Results can be used by Institution for (a) internal non-commercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of Sponsor.|t
17127673|NCT04259645|t||||f
17165467|NCT01453036|t||||
17165468|NCT00559104|f||||f
17165469|NCT01336712|t||||f
17165470|NCT02469701|f||||f
17165471|NCT00620373|t||||f
17165472|NCT00399568|f||OTHER|Investigator may publish only after cooperative publication or 18 months after sponsor's final evaluation of study data, whichever occurs first. At least 60 days prior to submission for publication, investigator must submit manuscript to sponsor for review and comment. Sponsor has 60 day period thereafter to respond with comment. Investigator will remove confidential information at the request of sponsor.|t
17165473|NCT03073525|f||||f
17165474|NCT03692403|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17169309|NCT01716104|f||||t
17169310|NCT03129360|t||||
17169311|NCT05026853|f||||f
17169312|NCT03006887|f||||f
17169313|NCT03836677|f||GT60||t
17169314|NCT01729208|f||||f
17169315|NCT03249103|f||||t
17169316|NCT02428413|f||LTE60||t
17169317|NCT02025439|f||||f
17169318|NCT03688100|t||||f
17169319|NCT01786252|f||||f
17127674|NCT03527173|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17127675|NCT02856828|t||||
17127676|NCT00504660|t||||f
17127677|NCT01248780|f||GT60||t
17127678|NCT04097301|f||OTHER|The Company will keep the information related to the trial in the strictest confidence and won't disclose such confidential information to third parties without the written consent of the Sponsor. It warrants that the obligation of confidentiality will be extended to the PI, his collaborators and to any other person who may become aware of confidential data. These obligations will remain in effect until the information is released into the public domain by the by the Sponsor.|t
17127679|NCT00203476|f||||f
17127680|NCT01190514|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127681|NCT01813929|t||||
17127682|NCT03103763|f||||f
17127683|NCT01970345|t||||
17127684|NCT03346161|t||||
17127685|NCT01346475|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review and comment on any proposed publication, and all Study results and data reasonably necessary for a meaningful review of the proposed publication are submitted to the sponsor for a period of at least thirty (30) days prior to submitting the publication to any third party.|t
17127686|NCT00955253|t||||
17127687|NCT00558259|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17127688|NCT02874924|t||||f
17127689|NCT02190045|t||||
17127690|NCT02029846|t||||f
17127691|NCT02966301|f||||f
17127692|NCT00700258|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127693|NCT00832637|t||||
17165475|NCT02776683|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17165476|NCT03350451|f||OTHER||t
17165477|NCT01891396|f||||f
17165478|NCT04231097|f||||f
17165479|NCT00540592|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165480|NCT01456130|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165481|NCT00400517|f||||f
17165482|NCT01692743|f||||f
17127694|NCT00370331|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165483|NCT00353301|t||||
17127695|NCT02367820|f||OTHER|If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of the study, the PI is free to publish separately, upon provision of any proposed publication or manuscript to the Sponsor at least sixty (60) days before it is submitted or otherwise disclosed.|t
17127696|NCT03834051|f||||f
17127697|NCT00738582|f||OTHER||t
17127698|NCT00642772|t||||f
17127699|NCT01052103|f||GT60||t
17127700|NCT04800432|f||||f
17127701|NCT00888628|t||||
17165484|NCT01821326|t||||f
17165485|NCT02688192|t||||
17165486|NCT05384834|t||||
17165487|NCT00515528|f||||f
17169320|NCT02345330|f||LTE60||t
17169321|NCT00494507|t||||
17169322|NCT02437084|f||||f
17169323|NCT00614484|t||||
17169324|NCT01218399|f||OTHER|Please contact the sponsor Astra Zeneca for the agreement|t
17169325|NCT00989781|f||||f
17169326|NCT00694304|f||OTHER|The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.|t
17169327|NCT04566692|f||OTHER|Site may publish results from the Study after 12 months of study completion date or after Grifols confirms there will be no joint, multi-center publication, then institution and/or investigator shall have the right, at their discretion, to publish, either in writing or orally, the results of the study performed under the protocol under certain conditions. At Sponsors' request, Site will remove any Confidential Information (other than Study results).|t
17169328|NCT00671437|t||||f
17169329|NCT02208349|f||||f
17169330|NCT03203291|t||||f
17169331|NCT00440830|t||||
17169332|NCT00377364|f||||f
17169333|NCT04042727|t||||
17169334|NCT02540265|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17169335|NCT00908466|f||||f
17169336|NCT01919216|f||||f
17169337|NCT03157037|f||||t
17169338|NCT02102399|t||||f
17169339|NCT03101085|f||||f
17169340|NCT03596450|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17169341|NCT04583956|f||||t
17169342|NCT02332291|f||||f
17169343|NCT04407234|f||GT60||t
17169344|NCT02518191|f||||f
17169345|NCT02280317|f||OTHER|"There is an agreement in place with the PI and the sponsor that restricts the PI's rights to discuss and publish the trial results after the trial is completed."|t
17169346|NCT00727558|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17169347|NCT02100475|f||OTHER|At the end of trial, one or more scientific publications may be prepared collaboratively by the investigators and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17169348|NCT04599465|f||||t
17169349|NCT00757822|t||||f
17169350|NCT02814175|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169351|NCT03416127|t||||f
17169352|NCT02702180|f||||f
17169353|NCT02397057|f||LTE60||t
17169354|NCT04473664|f||||f
17169355|NCT03392649|t||||
17169356|NCT00753454|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17169357|NCT03927144|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169358|NCT05346653|t||||
17169359|NCT01452919|f||GT60||t
17169360|NCT02421588|f||GT60||t
17169361|NCT01359943|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169362|NCT03781505|t||||
17169363|NCT00652080|f||||t
17169364|NCT02408263|t||||
17169365|NCT00612560|t||||
17169366|NCT00759408|f||||f
17169367|NCT02446600|f||LTE60||t
17169368|NCT02540668|f||GT60||t
17169369|NCT03270891|t||||
17169370|NCT02251938|f||||t
17127702|NCT00545051|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127703|NCT05398237|t||||
17127704|NCT00903006|f||||f
17127705|NCT03271021|f||GT60||t
17127706|NCT02469389|f||||f
17127707|NCT01079663|f||||f
17127708|NCT01847469|t||||
17127709|NCT00297232|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17127710|NCT00180323|f||||f
17127711|NCT02350777|t||||
17127712|NCT00190749|f||GT60||t
17165488|NCT01881789|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17165489|NCT05089292|t||||
17165490|NCT04229888|t||||
17165491|NCT02592421|t||||
17165492|NCT01282866|f||||f
17165493|NCT03502915|t||||
17165494|NCT01964378|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17165495|NCT03386435|f||||f
17165496|NCT03542266|t||||
17165497|NCT01183429|t||||
17165498|NCT00149799|f||||f
17165499|NCT01162473|t||||f
17165500|NCT01072136|f||||f
17165501|NCT03503396|f||||f
17165502|NCT01591408|f||||f
17165503|NCT03662282|f||||f
17165504|NCT01176877|t||||
17165505|NCT01392573|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17165506|NCT03008070|f||||f
17165507|NCT00841412|t||||
17165508|NCT04409834|f||||f
17165509|NCT01365455|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17165510|NCT00928187|f||||f
17165511|NCT01682356|f||||f
17165512|NCT05393245|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17165513|NCT01747343|t||||
17165514|NCT04245449|t||||
17165515|NCT01273038|t||||
17165516|NCT01976299|f||||f
17165517|NCT01537315|f||||f
17165518|NCT01947335|f||||f
17165519|NCT01299389|f||||f
17165520|NCT01151020|f||GT60||t
17165521|NCT01635998|f||||f
17165522|NCT00958477|f||||f
17165523|NCT04615624|f||||f
17165524|NCT01107964|t||||
17165525|NCT01220401|f||||f
17165526|NCT00362882|f||LTE60||t
17165527|NCT00625586|f||||f
17165528|NCT00906178|t||||f
17165529|NCT00124072|t||||
17165530|NCT02534883|f||||f
17127713|NCT02729753|f||||f
17165531|NCT03328832|f||||f
17165532|NCT00886769|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial or publication of trial results in their entirety.|t
17165533|NCT00414076|t||||
17165534|NCT00778336|f||GT60||t
17165535|NCT00873821|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17165536|NCT00049257|f||OTHER|The obligations of confidentiality shall apply for a period of 5 yrs beyond termination of Agreement between Sponsor and Investigator,but do not apply to the extent information:is or later becomes known to public;is obtained from a third party without restriction who had a legal right to disclose;is possessed by Investigators,as demonstrated by recipient's written records predating receipt from Sponsor;is required to be disclosed pursuant to a subpoena, law, regulation or other legal proceeding.|t
17165537|NCT04721158|f||||f
17165538|NCT00132301|t||||
17165539|NCT02720523|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17165540|NCT04872569|f||||f
17165541|NCT02340169|f||||t
17165542|NCT00742170|f||||f
17165543|NCT02382991|f||||f
17165544|NCT04466384|f||||f
17169371|NCT02516592|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169372|NCT01286740|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169373|NCT00510744|t||||
17169374|NCT01110382|f||GT60||t
17169375|NCT04921332|f||||f
17169376|NCT01641822|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169377|NCT00454584|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169378|NCT02421601|f||OTHER||t
17165545|NCT03666988|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165546|NCT01166347|f||OTHER|In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor's ability to obtain patent protection.|t
17165547|NCT03554018|t||||
17165548|NCT04792190|t||||
17165549|NCT02891226|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 5 years from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165550|NCT01928433|f||||f
17165551|NCT00145626|t||||
17165552|NCT00436436|f||||f
17165553|NCT00947219|f||||f
17169379|NCT02522442|f||||f
17169380|NCT01753401|f||||t
17169381|NCT00470418|f||||f
17169382|NCT00599638|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127714|NCT01200589|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165554|NCT00766116|t||||
17165555|NCT03654274|f||||t
17165556|NCT02752490|t||||
17165557|NCT02847169|f||OTHER||t
17165558|NCT01837680|t||||
17165559|NCT05005273|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165560|NCT02151786|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17165561|NCT03533660|t||||f
17165562|NCT00996658|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165563|NCT04685213|f||LTE60||t
17165564|NCT02161536|f||||f
17169383|NCT01463202|t||||
17127715|NCT01090427|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127716|NCT01154010|f||||f
17127717|NCT00439231|t||||
17127718|NCT03294148|f||||f
17127719|NCT00986973|t||||f
17127720|NCT00598273|f||OTHER|The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.|t
17127721|NCT01465347|f||||f
17127722|NCT01590082|t||||
17127723|NCT02414932|t||||
17127724|NCT00906945|t||||
17127725|NCT02434497|f||OTHER|Upon completion of the Clinical Trial (CT), the Principal Investigator (PI) may prepare the data derived from the CT for publication or presentation. Material should be submitted to the Sponsor for review prior to review or submission for publication. Publications from individual sites must not precede the primary manuscript, but if published within twelve months after completion of the CT, the PI has the right to publish or present the methods and results of the CT.|t
17127726|NCT01210664|f||||f
17127727|NCT01853644|t||||
17127728|NCT02891408|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165565|NCT00971282|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor for review and approval at least 2 months prior to the date of the intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17127729|NCT01054170|f||||f
17138361|NCT01457924|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138362|NCT02001688|f||||t
17165566|NCT04446312|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17165567|NCT02685826|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17165568|NCT03154476|t||||
17165569|NCT02610972|t||||f
17165570|NCT00200967|f||||f
17165571|NCT00936663|f||||f
17165572|NCT01444430|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17165573|NCT01144624|f||LTE60||t
17165574|NCT00276406|t||||f
17165575|NCT02297815|t||||
17165576|NCT00662831|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169384|NCT01353911|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17169385|NCT04003987|t||||
17169386|NCT01946126|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169387|NCT00462748|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169388|NCT03233438|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169389|NCT03429543|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169390|NCT03615066|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169391|NCT01054625|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17169392|NCT03074682|t||||
17169393|NCT00651625|t||||f
17169394|NCT02953886|t||||
17127730|NCT00709852|f||OTHER|The sponsor is interested in the publication of the results of every study it performs. All relevant aspects regarding publication will be part of the contract between the sponsor and the investigator/institution. The sponsor has committed to the global industry position on disclosure of information about clinical trials. The information regarding the study protocol is made publicly available on the internet at www.clinicaltrials.gov.|t
17127731|NCT02951767|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127732|NCT00196976|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127733|NCT02689518|t||||
17127734|NCT00825825|f||||f
17127735|NCT01920854|f||LTE60||t
17138363|NCT01089569|f||||f
17138364|NCT05441540|t||||f
17165577|NCT01061723|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17165578|NCT02476032|f||||f
17165579|NCT01147393|t||||
17165580|NCT02975804|t||||
17165581|NCT00901225|f||||f
17165582|NCT01408277|f||||f
17165583|NCT02840253|t||||
17165584|NCT00473889|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165585|NCT02956746|f||||f
17165586|NCT03346083|f||||t
17165587|NCT03801928|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165588|NCT04263766|f||||f
17165589|NCT00581048|t||||
17165590|NCT03369665|f||||t
17165591|NCT02553928|f||||f
17165592|NCT03230318|f||GT60||t
17165593|NCT03569878|f||||f
17165594|NCT02440139|f||||f
17165595|NCT02933879|f||||t
17165596|NCT00075764|t||||
17165597|NCT02817594|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17165598|NCT02010593|f||||t
17165599|NCT01773967|f||||f
17165600|NCT01135459|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17165601|NCT01766037|f||||f
17165602|NCT02413996|f||||f
17165603|NCT02443337|f||GT60||t
17165604|NCT04169529|f||||f
17165605|NCT00635349|f||OTHER|Principal Investigator (PI) cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is canceled.|t
17165606|NCT01017042|f||GT60||t
17165607|NCT04345900|f||||f
17165608|NCT01672879|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17165609|NCT04860869|f||||f
17165610|NCT01871545|f||||f
17165611|NCT04828135|t||||
17165612|NCT00598507|t||||
17165613|NCT04834726|f||||f
17165614|NCT00833443|f||||f
17165615|NCT02948582|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17165616|NCT02137447|f||||f
17165617|NCT03810014|t||||
17165618|NCT04684576|f||||f
17165619|NCT01853462|f||||f
17165620|NCT02148263|f||||f
17165621|NCT02012218|f||||f
17165622|NCT02880228|t||||
17165623|NCT01569815|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17165624|NCT03929913|t||OTHER|A Publications Committee comprised of the NIH Principal Investigator (PI) and Investigators participating in the study, as appropriate, will be formed to oversee the publication and presentation of the study results, which will reflect the experience of all investigational sites. No publication or disclosure of study results will be permitted except under the terms and conditions of a separate written agreement between NIH PI and the non-NIH Investigator and/or the Investigator's institution.|
17165625|NCT01154452|f||LTE60||t
17165626|NCT03381287|f||GT60||t
17169395|NCT02163421|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169396|NCT00576576|f||||f
17169397|NCT04018313|f||OTHER|A confidentiality and non-disclosure agreement (CDA) was executed between Celltrion, Inc. and some PIs who have participated in publications funded by the sponsor for academic purposes for a period that is more than 180 days from the time submitted to the sponsor for review.|t
17169398|NCT01805037|t||||
17169399|NCT03040115|t||||
17169400|NCT02964585|f||||f
17169401|NCT02177838|t||||
17169402|NCT00881465|t||||
17169403|NCT03517566|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169404|NCT04040621|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169405|NCT00303511|t||||
17169406|NCT03927404|f||||f
17169407|NCT04311463|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17169408|NCT00803062|f||LTE60||t
17169409|NCT01599741|f||LTE60||t
17169410|NCT00737633|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17169411|NCT01300260|f||GT60||t
17169412|NCT02145351|t||||
17169413|NCT02128074|f||GT60||t
17169414|NCT00439374|f||||f
17169415|NCT02533726|t||||f
17169416|NCT00293020|f||LTE60||t
17169417|NCT01147848|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169418|NCT03180307|f||||f
17169419|NCT01181258|f||||f
17169420|NCT04349033|f||||f
17169421|NCT01990859|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169422|NCT00771056|t||||
17169423|NCT02262754|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169424|NCT02577016|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17169425|NCT02126839|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17169426|NCT00812565|f||||f
17169427|NCT00765063|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169428|NCT03614325|t||||
17169429|NCT01041287|t||||
17169430|NCT00119366|f||||f
17169431|NCT01673620|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17169432|NCT00610311|f||||f
17169433|NCT01597635|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165627|NCT01265992|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17165628|NCT01102491|t||||f
17169434|NCT01363661|f||LTE60||t
17169435|NCT01971008|t||||
17165629|NCT03300206|f||OTHER|If a publication by the collaborative participants is not being conceived or submitted within 10 months following the conclusion of enrollment at the last enrolling site, an individual site may petition to publish his or her site data independently of the group. Hologic will advise on the status of publications in process and determine when individual results may be released.|t
17165630|NCT00566982|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17165631|NCT03323853|t||||
17165632|NCT02197572|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17165633|NCT03783962|f||||f
17165634|NCT03458325|f||||f
17165635|NCT00833469|f||||f
17165636|NCT01665911|t||||f
17165637|NCT00118274|t||||
17165638|NCT01724216|f||||f
17165639|NCT00175916|f||GT60||t
17165640|NCT03650413|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17165641|NCT00564733|f||||f
17165642|NCT01014767|t||||
17165643|NCT02621476|f||||f
17165644|NCT00344175|f||GT60||t
17165645|NCT00310375|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165646|NCT00573391|t||||
17165647|NCT00131352|f||OTHER|In multi-site studies, principal investigator (PI) can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17165648|NCT01194219|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17165649|NCT03377816|f||||f
17165650|NCT00292045|f||LTE60||t
17165651|NCT04474197|f||||t
17165652|NCT02236572|t||||
17165653|NCT01057693|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17165654|NCT00709319|f||||f
17165655|NCT03951766|t||||
17165656|NCT00363142|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165657|NCT01541865|f||||f
17165658|NCT01757301|t||||
17165659|NCT03606486|f||||f
17165660|NCT00049322|f||||f
17165661|NCT00730353|f||||f
17165662|NCT03072043|f||||t
17165663|NCT01340664|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17127736|NCT00757783|f||OTHER|If TTCA does not publish within 12 months after study conclusion or after TTCA confirms there will be no multicenter publication, Institution may publish their results from their site individually, provided TTCA has 60 day review for confidentiality and additional 60 day delay for patent application.|t
17127737|NCT02054520|f||GT60||t
17127738|NCT03032393|t||||
17127739|NCT01043393|f||||f
17127740|NCT02372136|f||||f
17127741|NCT00985946|f||||f
17127742|NCT02471833|t||||
17165664|NCT00415870|f||||f
17165665|NCT00633087|t||||
17165666|NCT02997865|f||||f
17165667|NCT01926444|f||OTHER|this was stipulated in the contract|t
17165668|NCT03943290|f||LTE60||t
17165669|NCT00295646|f||||f
17165670|NCT03579693|f||||f
17165671|NCT02626156|t||||f
17165672|NCT02441101|t||||
17165673|NCT00955474|f||||f
17165674|NCT02691416|f||||f
17165675|NCT02528942|f||||f
17127743|NCT03422198|t||||f
17127744|NCT00112047|f||OTHER|The PI may publish study results 2 years after the completion of the study or earlier with the advance written permission of Gilead. The PI will submit any proposed publication or presentation of study results together with the name of the proposed scientific journal, forum or confeence to Gilead prior to submission or presentation (30 days prior for manuscripts and 15 days for abstracts and oral presentations).|t
17138365|NCT00813917|t||||f
17165676|NCT01737762|f||LTE60||t
17169436|NCT03775512|f||OTHER|Publications and presentation of clinical investigation results will be coordinated between sponsor and the clinical investigation authors. Authorship to be determined prior to development of any manuscript. All information concerning the study, investigational medical device, sponsor operations, patent application, manufacturing processes and basic scientific data supplied by the sponsor to the investigator and not previously published, are confidential and remain sole property of the sponsor.|t
17169437|NCT01378325|f||||f
17169438|NCT01963845|f||||f
17169439|NCT00767806|f||GT60||t
17169440|NCT02489942|t||||
17165677|NCT00881530|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17165678|NCT00517010|f||||f
17165679|NCT03083665|f||GT60||t
17165680|NCT01467466|f||OTHER|"Cooperative Studies Program (CSP) retains ownership rights to all data collected in a CSP study…policies for data analysis and dissemination of results apply to all members of the Study Group (Study Chair (SC), Site Investigators (SIs), Study Biostatistician or Epidemiologist, etc.). If a SC or SI misuses study data, submits unauthorized manuscripts for publication, or releases results prior to the lifting of any embargoes or agreed upon time...administrative actions may be taken…"|t
17165681|NCT02622295|f||||f
17165682|NCT01027559|f||||f
17165683|NCT01841021|t||||
17165684|NCT01144416|f||OTHER|The investigator agreed not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report(s) any results of the trial.|t
17165685|NCT03541499|f||LTE60||t
17165686|NCT02131662|f||LTE60||t
17165687|NCT01402869|t||||
17165688|NCT01740687|f||GT60||t
17165689|NCT01562886|t||||f
17165690|NCT00104728|t||||
17165691|NCT01963767|t||||f
17165692|NCT03960684|f||||f
17165693|NCT02043145|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17165694|NCT03941483|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17169441|NCT00858208|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169442|NCT01393639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169443|NCT00679172|f||OTHER|Any proposed publication was subject to review conditions and timelines agreed between Emergent Product Development UK Ltd and the site Principal Investigator and detailed in the agreements with these parties prior to the start of the study.|t
17169444|NCT00793325|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127745|NCT01307579|f||OTHER|Must obtain prior sponsor approval.|t
17127746|NCT00812331|f||GT60||t
17127747|NCT01506453|t||||
17127748|NCT01783847|t||||
17127749|NCT01007643|t||||
17165695|NCT01082081|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17165696|NCT00932035|t||||
17165697|NCT00670930|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17165698|NCT03368781|f||OTHER|Restriction of individual site publication until the multi-center data is published|t
17169445|NCT01815840|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169446|NCT00901199|t||||f
17127750|NCT03706313|f||||f
17127751|NCT00055601|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17169447|NCT03221842|f||||t
17169448|NCT00704288|f||||t
17169449|NCT04395690|f||||f
17169450|NCT02692755|t||||
17169451|NCT03387020|f||OTHER|Investigator Initiated Interventional Trial Agreement between Novartis and PBTC and Cincinnati Children's Hospital Medical Center.|t
17169452|NCT00434642|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169453|NCT04120363|t||||
17169454|NCT05979922|t||||
17169455|NCT04512976|f||||f
17169456|NCT00527982|t||||
17169457|NCT00789672|f||||f
17169458|NCT03400163|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169459|NCT02241343|t||||
17169460|NCT03858530|t||||
17169461|NCT01463072|t||||
17169462|NCT04541628|f||GT60||t
17169463|NCT02781480|f||OTHER||t
17169464|NCT05011058|f||GT60||t
17169465|NCT01192412|f||||f
17169466|NCT00383942|t||||f
17169467|NCT03433417|f||||f
17169468|NCT00308074|f||||f
17169469|NCT02092311|f||||f
17169470|NCT01329939|f||OTHER|"You shall have the right to publish the results derived from your performance of the Study. You agree to submit a copy of...Study results (Publication) to Merck for comment sixty (60) days prior to its submission for publication. Merck shall have the applicable sixty (60) day period to respond to you with any requested revisions. You agree to delete any confidential information (excluding results) identified by Merck as confidential prior to submitting/presenting the Publication....."|t
17169471|NCT02942485|f||||f
17169472|NCT00687674|t||||
17169473|NCT04369950|t||||
17169474|NCT00989963|f||GT60||t
17169475|NCT01240200|f||||f
17169476|NCT01529034|f||OTHER|A manuscript or abstract should not be submitted by investigator(s) for publication or presentation until a New Drug Application is approved by the US FDA or permission is granted in writing by sponsor.|t
17169477|NCT01991522|f||||f
17169478|NCT03123328|f||||f
17169479|NCT03194646|f||LTE60||t
17169480|NCT02649894|f||||t
17169481|NCT00719680|f||OTHER|CSL agreements may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169482|NCT02141360|f||||f
17169483|NCT04071158|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169484|NCT01178099|f||GT60||t
17169485|NCT05198843|f||LTE60||t
17169486|NCT01436266|t||||
17169487|NCT03514433|t||||
17169488|NCT04484207|t||||
17169489|NCT03037983|t||||
17169490|NCT04058886|t||||
17169491|NCT04016077|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169492|NCT02474407|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17169493|NCT04118595|t||||
17169494|NCT02220712|f||||f
17169495|NCT00609739|t||||
17169496|NCT00760838|t||||
17169497|NCT03624127|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169498|NCT02999633|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17169499|NCT02607228|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years."|t
17169500|NCT00788710|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17169501|NCT00006400|f||||f
17169502|NCT02933502|f||||t
17169503|NCT04365452|f||||f
17169504|NCT00605345|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169505|NCT01369732|t||||f
17127752|NCT00117845|f||||f
17127753|NCT00910689|t||||f
17127754|NCT00850603|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17127755|NCT00484289|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169506|NCT02596945|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169507|NCT00422383|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169508|NCT01853605|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17182661|NCT02942017|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182662|NCT00457197|f||||f
17182663|NCT05059600|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182664|NCT02152995|f||LTE60||t
17182665|NCT06561217|t||||f
17182666|NCT04552587|f||||f
17182667|NCT00480779|f||||f
17182668|NCT03072134|f||||f
17182669|NCT04907032|f||||f
17182670|NCT06017089|f||||f
17182671|NCT00712296|f||||f
17182672|NCT02084628|f||||f
17182673|NCT02741115|f||||f
17182674|NCT03548584|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17182675|NCT01101841|f||OTHER||t
17182676|NCT02616250|f||||f
17182677|NCT03940508|t||||f
17182678|NCT03633396|f||OTHER|The PI may not publish trial results until after the first multi-center publication unless such publication is not published within a period that is at least 18 months but less than or equal to 24 months after trial completion. In addition, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17182679|NCT01012817|f||LTE60||t
17127756|NCT02349425|f||OTHER|No data collected as part of this study will be utilized in any written work, including publications, without the written consent of sponsor.|t
17138366|NCT01349972|f||LTE60||t
17138367|NCT03043807|t||||
17138368|NCT02143141|f||||f
17182680|NCT02143414|f||LTE60||t
17182681|NCT03366077|f||||t
17182682|NCT05478174|f||GT60||t
17169509|NCT05066165|f||||t
17169510|NCT00742417|f||OTHER|Investigators are free to publish the results after signing the final report. When several papers are published, each one will be mainly prepared by the more experienced investigator who will appear as first author. The rest of co-authors will appear in the order considered opportune by the principal investigator. Sponsor will receive a copy of the manuscript for review at least 30 days prior to submission for publication or presentation of the abstract at some scientific meeting.|t
17169511|NCT00627367|t||||
17169512|NCT00680459|t||||f
17169513|NCT04566601|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169514|NCT04996251|t||||
17169515|NCT00372697|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169516|NCT01055314|f||LTE60||t
17169517|NCT01279616|f||OTHER|No Outcome data are available for this study as the study was terminated. The PI has left the institution and cannot be contacted.|t
17169518|NCT02462720|f||||t
17169519|NCT00972530|t||||f
17169520|NCT00183625|f||||f
17169521|NCT00414518|t||||f
17169522|NCT05249569|t||||
17169523|NCT03722524|f||||f
17169524|NCT00765570|t||||f
17169525|NCT00663403|f||||f
17169526|NCT00646399|f||OTHER||t
17169527|NCT02703480|f||||f
17169528|NCT02473367|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17169529|NCT02678923|f||||f
17169530|NCT00455143|t||||
17169531|NCT02004977|f||||f
17169532|NCT01423916|f||||f
17169533|NCT01274520|t||||
17169534|NCT02435706|t||||f
17169535|NCT01966445|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169536|NCT01374178|t||||
17169537|NCT00524017|f||||f
17169538|NCT04856904|f||OTHER||t
17169539|NCT00902174|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169540|NCT00077649|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169541|NCT02825212|t||||
17169542|NCT02895945|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17169543|NCT03286283|f||||f
17169544|NCT04882787|t||||
17169545|NCT00454181|f||LTE60||t
17169546|NCT04032080|t||||
17169547|NCT03045341|t||||
17169548|NCT03689855|t||||
17169549|NCT00764673|f||LTE60||t
17169550|NCT01438177|t||||
17169551|NCT01727336|f||||f
17169552|NCT00849862|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17169553|NCT00619099|f||||f
17169554|NCT00885482|t||||
17169555|NCT00084656|f||LTE60||t
17169556|NCT02772978|t||||f
17169557|NCT00129467|t||||
17169558|NCT01532869|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169559|NCT01331291|f||||f
17169560|NCT01026220|f||OTHER|Must obtain prior Sponsor approval.|t
17169561|NCT04684992|t||||
17169562|NCT00409344|t||||
17182683|NCT00679341|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169563|NCT01389323|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169564|NCT01424228|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17169565|NCT00844558|f||||f
17169566|NCT02837042|t||||
17169567|NCT01894022|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169568|NCT03256253|t||||
17169569|NCT04496453|f||||f
17169570|NCT00410605|f||LTE60||t
17169571|NCT03001778|f||||f
17169572|NCT01323140|f||LTE60||t
17169573|NCT01623739|f||||f
17169574|NCT02013245|f||LTE60||t
17169575|NCT03235089|f||||f
17169576|NCT03238924|f||||f
17169577|NCT03576716|f||||f
17169578|NCT04356040|f||OTHER|The data and results from the clinical investigation are the sole property of the Sponsor. The Investigators will not use this clinical investigation-related data without the written consent of the Sponsor for any purpose other than for clinical investigation completion or for generation of publication materials, as referenced in the Clinical Trial Agreement. Single-center results are not allowed to be published or presented before the multi-center results.|t
17169579|NCT03688620|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169580|NCT01008904|t||||f
17169581|NCT00781859|f||LTE60||t
17169582|NCT01717326|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17169583|NCT01338857|f||||f
17169584|NCT03738618|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17169585|NCT00649428|f||OTHER|Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval.|t
17169586|NCT01450098|f||GT60||t
17169587|NCT02277925|t||||f
17169588|NCT01272635|f||||f
17169589|NCT01832155|t||||
17169590|NCT04783077|f||OTHER|The C-CAD pilot study was part of the BLOODSAFE initiative. The Publications and Presentations (P\&P) Committee reviews and approves all abstracts, presentations, and manuscripts that utilize data generated from BLOODSAFE. The BLOODSAFE P\&P Committee has voting members from the sponsor (NHLBI), the data coordinating center and each of the country-specific research teams (Ghana, Kenya, Malawi).|t
17169591|NCT01141491|f||OTHER|Site shall withhold publication of Site's individual Study results for a period of 18 months following completion of the Study at all sites, or until after Sponsor's written confirmation that Sponsor will not publish a joint, multicenter publication, whichever occurs first.|t
17169592|NCT02409719|t||||f
17169593|NCT02479139|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169594|NCT00778895|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169595|NCT02540993|f||OTHER||t
17169596|NCT03550404|f||||f
17169597|NCT03776461|f||||f
17169598|NCT01009086|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17169599|NCT05096312|f||||f
17169600|NCT03135210|t||||
17169601|NCT02647346|f||||f
17169602|NCT01192828|f||||f
17169603|NCT00820222|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169604|NCT00590577|f||GT60||t
17169605|NCT01229449|f||OTHER|The Investigator must submit any proposed manuscript to RB for approval prior to submission for publication. No timelines are stated. However, note that the results of this study have already been published.|t
17169606|NCT01417455|f||||f
17169607|NCT00418574|f||OTHER|The only disclosure restriction on the PI is that result communications shall be exchanged and discussed with the sponsor 60 days prior to submission for publication or presentation.|t
17138369|NCT00615914|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17169608|NCT04836247|f||||f
17169609|NCT05392803|f||||f
17169610|NCT00604045|t||||
17127757|NCT02134977|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17127758|NCT01773291|t||||
17169611|NCT00699335|f||||f
17169612|NCT01887353|t||||
17169613|NCT03262441|t||||f
17169614|NCT01545050|f||||f
17169615|NCT01204216|t||||f
17169616|NCT03665688|f||||f
17169617|NCT04775264|f||||f
17169618|NCT00559988|f||||f
17169619|NCT01455194|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169620|NCT02249182|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169621|NCT03274518|t||||
17169622|NCT02516228|f||||f
17169623|NCT03916484|t||||
17169624|NCT03050320|f||||f
17169625|NCT01092663|t||||
17169626|NCT01183065|t||||
17169627|NCT02456857|t||||
17169628|NCT05546229|f||||f
17169629|NCT01983774|t||||
17169630|NCT01008449|f||||f
17169631|NCT01220180|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169632|NCT00761202|f||LTE60||t
17169633|NCT02713659|t||||f
17169634|NCT01078844|t||||
17169635|NCT01067469|t||||
17169636|NCT04943432|t||||
17169637|NCT01299116|t||||
17127759|NCT02080312|f||||f
17127760|NCT00107120|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17127761|NCT03296033|t||||
17169638|NCT01123707|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169639|NCT01727414|f||||f
17169640|NCT04378114|f||GT60||t
17169641|NCT04079114|f||||f
17169642|NCT00629798|t||||
17169643|NCT01227005|f||||f
17169644|NCT01959243|f||OTHER|Please contact Sponsor directly for additional information.|t
17169645|NCT02684188|t||||
17169646|NCT00428844|f||OTHER|The first publication is initiated by Cubist. If first publication not published within 1 year of study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17169647|NCT00488826|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17169648|NCT00671606|t||||f
17169649|NCT02292706|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169650|NCT01229722|t||||f
17169651|NCT02725866|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169652|NCT03595527|f||||f
17169653|NCT02413047|f||||f
17169654|NCT01549977|f||OTHER|Insufficient data to publish.|t
17169655|NCT01705106|f||||f
17182684|NCT04015219|f||||f
17169656|NCT04667104|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17169657|NCT03043651|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the study without the prior written consent of the Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17169658|NCT01630889|f||OTHER|"The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.~The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).~FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total)."|t
17169659|NCT01854281|t||||
17169660|NCT03208088|f||GT60||t
17169661|NCT00566254|f||||f
17169662|NCT01424033|f||||f
17169663|NCT00238238|f||LTE60||t
17169664|NCT01345669|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169665|NCT01793883|f||||t
17169666|NCT02478255|f||||f
17169667|NCT00761527|f||OTHER|SPONSOR is the owner of all the data in the record forms including subsequent reports relating to this study. The prescribing physicians \& investigators agree only to use such information to conduct the study \& will not be able to publish the results of any part of this study without previous written authorization from SPONSOR. By signing the protocol, the investigator accepts that the results may be used in written publications \& for the purpose of providing information to health professionals.|t
17169668|NCT01730586|t||||
17169669|NCT01431963|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169670|NCT00619307|f||OTHER||t
17169671|NCT00547521|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \<= 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169672|NCT01769196|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17169673|NCT03499314|t||||
17169674|NCT00258817|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17127762|NCT03076333|t||||
17127763|NCT00896051|f||OTHER|It is the policy of the sponsor not to allow investigators to publish their results or findings from the study prior to the sponsor's publication of the overall trial results. The investigator agrees that before he/she publishes any results of this trial, he/she shall allow at least 45 days for the sponsor to review the prepublication manuscript prior to submission of the manuscript to the publisher.|t
17127764|NCT02935452|t||||f
17127765|NCT00876928|f||||f
17127766|NCT03719170|t||||
17127767|NCT01143038|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127768|NCT01248065|f||||f
17127769|NCT01762501|f||OTHER|The only disclosure restriction on the PIs is that PIs must get approval about publish by study director(Kazuo Kario).|t
17127770|NCT01749904|f||||f
17138370|NCT00270998|f||||f
17169675|NCT00655629|f||OTHER|In the protocol it is specified that all results are the property of the sponsor. The investigator must discuss any publication with the sponsor prior to release and obtain written consent of the sponsor. The investigator must send a draft publication to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication.|t
17169676|NCT05126836|t||||
17169677|NCT00705367|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169678|NCT01468350|f||OTHER|Sponsor (Acorda) has the right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17169679|NCT03149055|t||||
17169680|NCT04440813|f||||f
17169681|NCT02629822|f||OTHER|Subsequent to the multicenter publication (or after public disclosure of the results at www.clinicaltrials.gov if multicenter manuscript is not planned), an investigator and colleagues may publish their data independently. Sponsor must have opportunity to review proposed abstracts, manuscripts or presentations 45 days prior to submission for publication/presentation. Confidential information must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17127771|NCT03010176|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17138371|NCT00563368|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17127772|NCT00321373|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127773|NCT01774487|f||||f
17127774|NCT00461032|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138372|NCT00134017|t||||
17138373|NCT00739960|f||||f
17138374|NCT00763243|t||||
17138375|NCT01082588|f||||f
17138376|NCT03379376|t||||
17138377|NCT01611298|t||||
17138378|NCT00753623|f||||f
17138379|NCT03332303|f||||t
17138380|NCT03383614|f||||t
17138381|NCT01170949|f||||f
17169682|NCT00741013|f||||f
17169683|NCT02133781|f||||f
17169684|NCT00193180|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17169685|NCT00539305|f||||f
17169686|NCT00921843|t||||
17169687|NCT02870101|f||OTHER|Following completion of the study, the Investigator may publish the results of this research under the oversight of the Antibiotic Resistance Leadership Group (ARLG) Publication Committee. All public presentations by participating Investigators, participating institutions, SDMC, and ARLG, that use ARLG data and are intended to represent the ARLG, or are supported by the ARLG, will be reviewed by the ARLG Publication Committee per the ARLG Publication Committee Charter.|t
17127775|NCT04447846|f||||f
17127776|NCT01878214|f||||f
17138382|NCT03639987|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17138383|NCT00425100|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17138384|NCT02559713|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138385|NCT03418051|t||||f
17169688|NCT01317901|f||||f
17169689|NCT01059994|t||||
17182685|NCT01433263|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17169690|NCT01331109|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17169691|NCT04047979|t||||
17169692|NCT00661622|t||||
17169693|NCT02466009|t||||
17169694|NCT02176161|t||||
17169695|NCT00098306|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169696|NCT00932165|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17169697|NCT00588094|t||||
17169698|NCT01336023|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17169699|NCT04373746|t||||
17169700|NCT01122849|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169701|NCT02202538|f||||f
17169702|NCT01853878|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169703|NCT02161757|f||LTE60||t
17169704|NCT03997825|f||||f
17169705|NCT01361178|t||||
17169706|NCT00391625|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17169707|NCT00383162|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169708|NCT01399866|f||||f
17169709|NCT01069705|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17169710|NCT02726022|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169711|NCT00915551|f||OTHER|"For US sites: The institution and investigator agree not to publish the results of this study without prior written consent of the Sponsor. As used herein, the term publish shall include oral presentations,written abstracts, written manuscripts, etc."|t
17169712|NCT00235716|f||||f
17169713|NCT04390841|f||OTHER|The sponsor has exclusive ownership of the trial data and results. During the clinical trial, the sponsor has the right to access and use all data and results of the trial. Individual clinical trial centers are not allowed to publish and/or report their results until the results of all center are published and/or reported. The sponsor agrees that the leading investigators of the trial will publish the results of the clinical trial.|t
17169714|NCT03036189|f||||f
17169715|NCT01860950|f||||f
17169716|NCT02188849|f||||f
17169717|NCT00692419|t||||
17169718|NCT04450329|f||||t
17169719|NCT03937960|f||||f
17169720|NCT05090852|t||||
17169721|NCT00504894|t||||f
17169722|NCT02561221|f||||f
17169723|NCT01196416|f||LTE60||t
17182686|NCT03107988|f||||f
17182687|NCT01359592|f||LTE60||t
17182688|NCT00326612|t||||f
17182689|NCT00548808|f||GT60||t
17169724|NCT00148941|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169725|NCT02841241|t||||
17169726|NCT03244826|f||||f
17169727|NCT02673684|f||||f
17169728|NCT02387008|f||||t
17169729|NCT03368235|f||||t
17169730|NCT01515046|t||||
17169731|NCT00416455|f||LTE60||t
17169732|NCT02355210|f||||f
17169733|NCT04699461|f||||f
17127777|NCT00946101|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17127778|NCT03568331|f||OTHER|PI is restricted from presenting or publishing independently until the expiration of eighteen (18) months from the completion of the Clinical Trial or as otherwise noted in the Investigator's clinical trial agreement.|t
17127779|NCT02318992|t||||
17127780|NCT01944371|f||||f
17127781|NCT00552240|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17127782|NCT02783768|t||||
17127783|NCT01323647|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127784|NCT01935180|f||||f
17169734|NCT00516165|t||||f
17169735|NCT03068767|f||||f
17169736|NCT00061633|f||LTE60||t
17169737|NCT00554372|f||GT60||t
17169738|NCT02921087|f||||f
17169739|NCT00687531|f||OTHER|30 days written notice is required prior to submission of study results for publication/presentation so that Sponsor can review the material to be submitted. Sponsor has the right to review/comment on the material \& if the parties have any disagreement concerning the appropriateness of the material, the PI and Sponsor must meet to discuss/resolve any issues/disagreement prior to submission. Interim results of the Study may not be published/presented without prior written consent of Sponsor.|t
17169740|NCT03848949|f||||f
17169741|NCT02353728|t||||
17169742|NCT03253328|t||||
17169743|NCT02301624|f||OTHER|Sponsor can review results communications at least 60 days prior to public release. Within 30 days of receipt, Sponsor shall advise of any information which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor can require removal of specifically identified Confidential Information (other than Study Data) and/or delay the communication an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17169744|NCT00895310|t||||
17169745|NCT02964767|f||||f
17169746|NCT03109184|f||||f
17169747|NCT00602420|f||||f
17169748|NCT01178268|f||||f
17169749|NCT00592124|f||||f
17169750|NCT00703924|f||||f
17169751|NCT03077919|t||||
17169752|NCT05388617|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17169753|NCT01031979|t||||
17169754|NCT00301418|t||||
17169755|NCT03592368|f||||f
17169756|NCT03831100|t||||
17169757|NCT02175979|f||||f
17169758|NCT01107665|t||||
17169759|NCT02008227|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169760|NCT01332253|f||||f
17138386|NCT00555906|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138387|NCT00889681|f||||f
17138388|NCT02026206|f||||f
17138389|NCT03258632|t||||
17169761|NCT02625844|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169762|NCT01618695|f||||t
17169763|NCT02376179|t||||
17169764|NCT02454478|f||||t
17169765|NCT01128192|f||||f
17169766|NCT01271725|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169767|NCT03354273|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17169768|NCT01721226|f||||f
17169769|NCT05148806|t||||
17169770|NCT02950480|t||||
17169771|NCT03121365|t||||
17169772|NCT00746863|f||||f
17169773|NCT03229109|f||||f
17169774|NCT01835223|t||||
17169775|NCT01504841|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17169776|NCT01610336|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169777|NCT03679624|t||||
17169778|NCT01193114|f||||f
17169779|NCT01559675|f||||f
17169780|NCT01496469|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169781|NCT00291018|f||LTE60||t
17169782|NCT00630344|f||||f
17169783|NCT01357551|t||||
17169784|NCT00774800|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless prior written permission from the Sponsor (Halozyme) is obtained.|t
17169785|NCT01578577|f||||f
17169786|NCT00773773|t||||
17169787|NCT04016259|t||||
17169788|NCT03068754|f||||t
17169789|NCT00666965|f||||f
17169790|NCT04569357|f||||t
17169791|NCT02697188|f||||t
17169792|NCT00767819|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169793|NCT03029091|f||OTHER||t
17138390|NCT01686958|f||OTHER|Sponsor will review the publication text within twenty days of receipt, however, Sponsor can request changes if text contains Sponsor's Confidential Information, or text contains information for which the Sponsor wishes to obtain patent protection, whereupon such information will be removed or there will be a delay to the presentation or publication to enable the Sponsor to proceed with patent application for an additional 60 days or until patent application has been filed, whichever is earlier.|t
17138391|NCT00187889|f||||f
17138392|NCT04046341|f||||f
17169794|NCT00881647|t||||
17169795|NCT03916081|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17169796|NCT00465647|f||GT60||t
17169797|NCT01339897|f||OTHER|The investigator agrees with the use of results of the clinical study for the purposes of national and international registration, publication, and information for medical and pharmaceutical professionals. If necessary, the competent authorities will be notified of the investigator's name, address, qualifications, and extent of involvement. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.|t
17169798|NCT04534881|t||||
17169799|NCT00847197|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169800|NCT00622388|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169801|NCT00348309|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169802|NCT01894243|f||GT60||t
17169803|NCT00223704|f||||f
17169804|NCT01620944|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17169805|NCT04016844|t||||
17169806|NCT01364389|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169807|NCT02687581|t||||
17169808|NCT01431391|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17169809|NCT02554981|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169810|NCT01114438|f||LTE60||t
17169811|NCT00753363|t||||
17169812|NCT02508324|t||||
17169813|NCT00991406|t||||
17169814|NCT03597061|t||||
17169815|NCT02160145|f||||t
17169816|NCT00375518|t||||
17169817|NCT01108523|f||LTE60||t
17169818|NCT04978818|t||||
17169819|NCT01211340|f||||f
17169820|NCT03755661|f||||f
17169821|NCT02277119|f||GT60||t
17169822|NCT05399290|f||||f
17169823|NCT00852241|t||||
17169824|NCT02524418|f||||f
17169825|NCT02069392|f||||f
17169826|NCT01248741|f||||f
17169827|NCT02227667|t||||
17169828|NCT00791089|t||||
17169829|NCT03521141|f||||f
17169830|NCT03335774|f||||f
17169831|NCT01702025|f||||f
17169832|NCT03653988|t||||
17169833|NCT04207749|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17169834|NCT05362058|f||GT60||t
17169835|NCT00904488|t||||
17169836|NCT00930553|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17182690|NCT00749775|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138393|NCT03162458|f||OTHER||t
17169837|NCT00413036|f||OTHER|Investigator can publish/present study data after multicenter publication is submitted or 1 yr after study completion. Investigator shall (i) furnish the sponsor a copy of any proposed publication/presentation at least 60 days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for up to 90 days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17169838|NCT04042909|f||||f
17169839|NCT01369641|t||||
17169840|NCT00842543|t||||f
17169841|NCT03738891|f||||f
17169842|NCT01483183|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169843|NCT00239928|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days.Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites.Investigator may not disclose previously undisclosed confidential info other than study results.|t
17169844|NCT00286494|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17169845|NCT04776317|f||||t
17169846|NCT00896025|f||||f
17169847|NCT02524158|f||||f
17169848|NCT03100058|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17169849|NCT03276546|t||||
17169850|NCT03671304|t||||
17169851|NCT00626444|t||||
17169852|NCT00479856|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169853|NCT02760810|f||GT60||t
17169854|NCT02690714|f||OTHER|Publication of data generated in the study is governed by the Investigator Clinical Trial Agreement|t
17169855|NCT04294147|f||GT60||t
17169856|NCT01240135|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17169857|NCT01371305|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17169858|NCT01124955|f||||f
17169859|NCT02891382|f||||f
17169860|NCT01628965|f||||f
17169861|NCT02828020|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17169862|NCT00966550|t||||
17169863|NCT00379912|f||||f
17169864|NCT01128946|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182691|NCT01400841|f||OTHER|Publication by the investigator was not allowed until completion of the trial. All proposed publications must be cleared by unanimous vote of a publication committee consisting of the sponsor and representatives of the study investigators. Publication materials must be submitted for review at least 60 day in advance of publication. The Sponsor may embargo publication for 60 additional days to allow for patent filing or may prevent publication if filling of such application would be premature.|t
17182692|NCT00770120|f||||f
17182693|NCT00480636|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182694|NCT00933491|f||||f
17127785|NCT00732225|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17127786|NCT01236339|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17182695|NCT02583256|f||LTE60||t
17182696|NCT04537806|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17169865|NCT00621140|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17169866|NCT01138501|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol.|t
17169867|NCT00365274|f||LTE60||t
17169868|NCT00360568|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17127787|NCT02450799|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127788|NCT02054741|t||||
17127789|NCT01945060|t||||
17127790|NCT02777385|t||||
17127791|NCT00402597|f||LTE60||t
17127792|NCT01442779|t||||f
17169869|NCT03696589|t||||
17169870|NCT02467842|f||||t
17169871|NCT02873338|f||OTHER|Details of the Study and its results shall not be publicized or published in any form without prior consent of the Sponsor.|t
17169872|NCT03657095|f||GT60||t
17169873|NCT00830180|f||LTE60||t
17169874|NCT01990612|f||OTHER||t
17169875|NCT03968848|f||||f
17127793|NCT03426605|f||OTHER||t
17127794|NCT01048671|f||||f
17127795|NCT03814187|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127796|NCT00513604|f||||f
17127797|NCT02009761|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127798|NCT02740374|f||||f
17127799|NCT02697292|t||||
17127800|NCT04555031|t||||
17127801|NCT00491829|f||||f
17127802|NCT01047293|t||||
17127803|NCT01272804|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127804|NCT02318797|f||||f
17127805|NCT00001984|f||||f
17127806|NCT02673515|t||||
17127807|NCT02112708|f||||f
17127808|NCT01796548|f||OTHER|Sponsor shall have first to present the data of Clinical Trial (CT) without approval from the Institution or PI. If the Institution and PI wish to publish data from CT, a copy of the same must be provided to Sponsor for review at least 60 days prior to submission. No paper with Confidential Information will be submitted with Sponsor's prior written consent. If requested in writing, Institution and PI will withhold publication for up to an additional 60 days to allow filing of patent application.|t
17127809|NCT03801473|t||||
17127810|NCT01134952|f||||f
17127811|NCT04227704|t||||
17127812|NCT02760277|f||||t
17127813|NCT02390050|f||OTHER|Investigator has no publication right.|t
17127814|NCT01522469|f||||f
17127815|NCT03432260|f||OTHER|If a joint publication is not submitted within 18-24 months after study completion, PI shall have the right to submit to sponsor a proposed results communication based on results at their institution. Sponsor can review proposed results communications prior to public release, can request removal of confidential information, and can embargo communications regarding trial results for up to 120-180 days after submission to sponsor.|t
17127816|NCT04763421|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17127817|NCT01775124|f||OTHER|"The terms and conditions of Novartis' agreements with its investigators may vary.~However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety"|t
17169876|NCT01000324|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169877|NCT00360724|f||LTE60||t
17169878|NCT00123604|f||||f
17169879|NCT01068158|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17169880|NCT03824587|f||GT60||t
17169881|NCT01300572|t||||
17169882|NCT00986362|f||LTE60||t
17169883|NCT03845738|f||LTE60||t
17169884|NCT00384332|f||||f
17169885|NCT03170193|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169886|NCT00411632|t||||
17169887|NCT02560012|t||||
17169888|NCT06037408|f||||f
17169889|NCT01007838|t||||
17169890|NCT04517643|t||||
17169891|NCT00767767|t||||
17169892|NCT05261009|t||||
17169893|NCT02762331|t||||
17169894|NCT01549925|t||||f
17169895|NCT01748825|f||||f
17169896|NCT01849419|t||||
17169897|NCT00118430|f||||f
17169898|NCT00659230|f||||f
17169899|NCT02147288|t||||
17169900|NCT00669383|f||||f
17169901|NCT00269633|f||||f
17169902|NCT04412707|f||||f
17169903|NCT02476006|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17169904|NCT03210961|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169905|NCT01487265|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17169906|NCT02291419|f||||f
17169907|NCT01115673|f||OTHER|The results may not be published or referred to at research seminars, lectures or professional meetings, in whole or in part, without the prior written consent of McNeil Consumer Healthcare, to be given or withheld at McNeil Consumer Healthcare's sole and absolute discretion|t
17169908|NCT00965575|f||||f
17169909|NCT03043391|f||GT60||t
17169910|NCT01593592|t||||f
17169911|NCT00389493|t||||
17127818|NCT01589237|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17127819|NCT02594163|f||||t
17127820|NCT04497142|f||||f
17127821|NCT01022268|t||||
17127822|NCT00189488|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17127823|NCT02831387|f||OTHER|Principal Investigator may publish or present the results based on data generated at their Institution, provided that: (a) Sponsor publishes the results from all sites participating in the Study; (b) Institution receives notification from Sponsor that publication of the multi-site results is no longer planned; or (c) eighteen (18) months following the close of study, whichever occurs first.|t
17127824|NCT00192647|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127825|NCT01828073|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17127826|NCT02915302|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17138394|NCT03094832|f||OTHER|The investigator shall have the right to publish the results performed under this protocol, provided that such publication does not disclose any Confidential Information or trade secrets of the Sponsor (other than the data). The investigator agrees not to independently publish the findings except as part of an overall multicenter publication, unless approved in writing by the Sponsor or unless more than 12 months have elapsed since the last participant in the study has completed study treatment.|t
17138395|NCT01285791|t||||
17138396|NCT01419080|f||||f
17169912|NCT01732770|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169913|NCT03047031|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169914|NCT01959841|f||||t
17169915|NCT00780416|f||OTHER||t
17169916|NCT03304119|t||||f
17169917|NCT00666224|f||OTHER|"Should the investigator wish to publish the results of this study, he/she agrees to provide Teva with a manuscript for review 60 days prior to submission for publication. Teva retains the right to delete confidential information and to object to suggest publication and/or its timing (at the Company's sole discretion).~If Teva chooses to publish this study a copy will be provided to the investigator at least 30 days prior to the expected date of submission to the intended publisher."|t
17169918|NCT05443256|t||||
17169919|NCT00482625|f||LTE60||t
17169920|NCT00871338|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17169921|NCT01078363|f||||f
17169922|NCT03251937|f||||t
17169923|NCT03828331|t||||
17169924|NCT00244101|f||||f
17169925|NCT01959139|f||LTE60||t
17169926|NCT04756804|f||||t
17169927|NCT02445326|f||||f
17169928|NCT01964963|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169929|NCT01235234|f||||f
17169930|NCT02352753|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17169931|NCT00607867|t||||
17169932|NCT01363908|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17169933|NCT00711971|t||||
17169934|NCT02644343|f||||t
17169935|NCT02967510|f||||t
17169936|NCT03437577|t||||
17169937|NCT00536471|f||GT60||t
17169938|NCT02551822|f||||f
17169939|NCT00328614|t||||
17169940|NCT04774926|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17169941|NCT01336413|t||||
17169942|NCT01440816|f||LTE60||t
17169943|NCT01687101|t||||
17169944|NCT03397342|t||||
17169945|NCT03250182|f||OTHER|Drafts of any and all publications or presentations that may arise from this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review and approval and to ensure consistency with the policy in this protocol. Pearl Therapeutics will have the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17169946|NCT01858740|t||||
17169947|NCT01458418|f||||f
17169948|NCT00734968|f||||f
17169949|NCT00894361|f||||f
17169950|NCT02920749|f||||f
17169951|NCT04207060|f||||f
17169952|NCT01871441|t||||
17169953|NCT02718716|f||GT60||t
17169954|NCT01683825|f||||f
17169955|NCT00296140|t||||
17127827|NCT00690443|f||OTHER|Information is unavailable.|t
17127828|NCT01877837|t||||
17127829|NCT01135537|t||||
17127830|NCT00645801|t||||f
17169956|NCT01856582|t||||
17169957|NCT03041896|f||GT60||t
17169958|NCT03245398|t||||
17169959|NCT02638168|f||||f
17169960|NCT00596830|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169961|NCT00887926|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17169962|NCT00880191|t||||
17169963|NCT02097030|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor.|t
17169964|NCT01919801|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17169965|NCT01843062|f||OTHER|If the Study is part of a multi-centre clinical trial, the Institution or Investigator agree not to independently publish results of, or make presentations related to, the Study until first occurrence of one of the following: multi-centre primary Publication is published; no multi-centre primary Publication is submitted within 2 years after conclusion, abandonment or termination of the Study at all sites; or Sponsor confirms in writing there will be no multi-centre primary Publication.|t
17169966|NCT01677858|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127831|NCT00705679|f||||f
17127832|NCT00932113|f||||f
17127833|NCT01403610|f||||f
17169967|NCT00773747|f||OTHER|"An investigator may not independently publish the results for their study site until after the multicenter publication, or 24 months after completion of study.~Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines."|t
17169968|NCT04260347|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17169969|NCT02669212|t||||
17169970|NCT03549104|f||||f
17169971|NCT04869358|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17169972|NCT04164732|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17169973|NCT03197922|t||||
17169974|NCT01987583|f||||f
17169975|NCT01844778|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17169976|NCT01623869|f||LTE60||t
17169977|NCT01868334|f||||f
17169978|NCT02951429|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169979|NCT01620528|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17169980|NCT01457846|f||LTE60||t
17169981|NCT01743040|f||GT60||t
17127834|NCT00118755|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127835|NCT00686725|f||OTHER|The Institution and Principal Investigator (PI) have the right to publish/present study results. PI and Institution agree not to publish/present any interim study results. PI and Institution further agree to provide 30 days written notice to Sponsor prior to submission for publication or presentation to permit Sponsor to review drafts of abstracts and manuscripts for publication which report any study results. Sponsor shall have the right to review and comment on any Public Presentation.|t
17127836|NCT00292162|f||||f
17127837|NCT03064035|t||||
17127838|NCT04609306|t||||
17169982|NCT02974842|f||||f
17169983|NCT02006979|f||||f
17169984|NCT04167137|f||LTE60||t
17169985|NCT00997594|t||||
17169986|NCT02467582|f||OTHER|SAKK GENERAL TERMS AND CONDITIONS (SAKK GTC) FOR TRIAL SPECIFIC AGREEMENTS|t
17169987|NCT01370265|t||||f
17169988|NCT02611817|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17169989|NCT00265317|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169990|NCT02510001|f||||f
17169991|NCT04042324|f||LTE60||t
17169992|NCT00303485|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17169993|NCT00385138|f||OTHER|"PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.~PI must submit results communications to sponsor for review at least 40 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 135 days solely to seek appropriate patent protection."|t
17127839|NCT02090959|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17127840|NCT03480217|t||||
17127841|NCT02349646|f||GT60||t
17127842|NCT01529203|f||LTE60||t
17127843|NCT00893984|f||||f
17127844|NCT02725801|f||||f
17127845|NCT04256629|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca AB.|t
17127846|NCT02647866|f||GT60||t
17127847|NCT00069108|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127848|NCT00801931|t||||
17127849|NCT01415531|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc|t
17127850|NCT00250926|f||||f
17127851|NCT02319525|f||||f
17127852|NCT00938860|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17127853|NCT00232544|t||||
17169994|NCT04120402|f||OTHER|"Investigators may not present or publish partial or complete study results individually without the Sponsor's agreement.~Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by the Sponsor before submission for publication. Names of all Investigators participating in the study will be included in the publication."|t
17169995|NCT01362894|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17169996|NCT03078855|f||||f
17127854|NCT00336895|f||||f
17127855|NCT02481947|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17127856|NCT05249829|f||||t
17127857|NCT02666846|t||||f
17127858|NCT00060424|t||||
17127859|NCT01535560|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17127860|NCT01853774|f||||f
17127861|NCT03386110|f||||f
17127862|NCT01815138|f||||f
17127863|NCT01981772|t||||
17127864|NCT03426267|f||OTHER||t
17127865|NCT00609765|t||||f
17127866|NCT00577356|f||||f
17169997|NCT01938833|t||||
17169998|NCT00391027|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17169999|NCT02186665|f||||f
17170000|NCT04124705|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170001|NCT01973998|f||||f
17170002|NCT01763606|t||||
17170003|NCT04302545|f||||f
17170004|NCT04865237|f||||f
17170005|NCT01636986|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170006|NCT04867733|t||||
17170007|NCT03929640|t||||
17170008|NCT01130896|t||||
17170009|NCT02106403|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170010|NCT04146935|f||||f
17170011|NCT04038567|f||||f
17170012|NCT03533244|f||||f
17170013|NCT01496846|t||||
17170014|NCT02024724|t||||
17170015|NCT01817959|f||||f
17170016|NCT01772576|f||||t
17170017|NCT00923845|f||||f
17170018|NCT00961714|f||||f
17170019|NCT02019875|f||||f
17170020|NCT04356352|f||||f
17170021|NCT03202134|t||||
17170022|NCT01371734|f||LTE60||t
17170023|NCT02578186|f||LTE60||t
17170024|NCT03565237|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170025|NCT01140061|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17170026|NCT00828750|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170027|NCT04006392|f||||f
17170028|NCT01832532|f||||f
17170029|NCT01534195|f||||f
17170030|NCT01368081|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170031|NCT00714311|t||||
17170032|NCT01736618|f||OTHER|PI shall submit publication to Sponsor for review at least 60 days prior to submission. Sponsor reserves the right to delete any confidential info or other proprietary info of Sponsor (not incl. Results). Sponsor may extend 90 days to protect its intellectual property (IP) interests. PI shall be free to publish the results of the study after: Initial Publication is published; notification by Sponsor that Initial Publication is no longer planned; or 12 mo. after the expiration date at all sites|t
17170033|NCT02634827|t||||
17170034|NCT03637517|f||LTE60||t
17170035|NCT00400569|t||||
17170036|NCT02714283|f||||f
17170037|NCT00620113|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17170038|NCT02973516|f||||t
17170039|NCT02461745|f||GT60||t
17170040|NCT02268994|f||GT60||t
17170041|NCT00211887|t||||
17170042|NCT01979133|f||||f
17170043|NCT00486824|t||||
17170044|NCT00965419|f||GT60||t
17170045|NCT02927938|t||||
17170046|NCT01704404|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170047|NCT00082407|f||GT60||t
17170048|NCT01626092|t||||
17170049|NCT00891228|f||||f
17170050|NCT00118742|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170051|NCT02688985|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170052|NCT01726582|t||||
17170053|NCT01177189|t||||
17170054|NCT03606187|f||||t
17170055|NCT03704688|t||||
17170056|NCT01566500|f||||f
17170057|NCT04878211|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170058|NCT02783599|f||GT60||t
17170059|NCT00856544|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170060|NCT00787189|f||||f
17170061|NCT00847886|f||OTHER|The sponsor requires that written permission be given before the investigator can release any data publicly.|t
17170062|NCT01401517|f||LTE60||t
17170063|NCT02546492|f||||f
17170064|NCT03920254|f||||t
17170065|NCT05274269|f||||t
17170066|NCT02206035|t||||
17170067|NCT04240574|f||||t
17170068|NCT05173012|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17170069|NCT03668613|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170070|NCT02106494|f||OTHER|A period of 60 working days for presentational material and abstracts and 90 days for manuscripts is permitted for the sponsor's review. The sponsor can request modifications of any manuscript or other materials to be published or presented. The sponsor can also request additional time to obtain additional patent protection or take such other measures to establish and preserve its intellectual property and proprietary rights before publishing information from this trial.|t
17170071|NCT01068769|f||||f
17170072|NCT00709618|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170073|NCT04428619|f||||f
17170074|NCT01948063|f||||f
17170075|NCT00887510|f||||f
17170076|NCT03781414|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170077|NCT04752358|f||LTE60||t
17170078|NCT00719355|t||||
17182697|NCT05459129|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182698|NCT04182100|f||||f
17182699|NCT06285981|f||||t
17127867|NCT02094755|t||||
17138397|NCT01998880|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138398|NCT01575899|t||||f
17170079|NCT04054375|f||||f
17170080|NCT03364738|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170081|NCT02932748|f||||f
17170082|NCT00066963|f||||f
17170083|NCT00988091|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17170084|NCT00994422|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17170085|NCT00820872|t||||
17170086|NCT01846741|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted for sponsor's review if such publication contains Confidential Information or will adversely affect any intellectual property or proprietary right of the sponsor. The sponsor can require changes to the communication, but cannot extend the embargo set forth in the study agreement.|t
17170087|NCT03664765|f||||f
17170088|NCT01153698|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170089|NCT01090063|f||||f
17170090|NCT02326233|f||||t
17170091|NCT02484222|t||||
17170092|NCT00177255|t||||
17170093|NCT00330681|f||OTHER||t
17170094|NCT00428389|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170095|NCT04384523|f||||f
17170096|NCT03216746|t||||f
17170097|NCT04405076|f||||t
17170098|NCT00392990|t||||
17170099|NCT02980133|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17170100|NCT00172042|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170101|NCT03052816|f||||f
17170102|NCT00408434|f||||f
17170103|NCT01278797|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170104|NCT00895453|t||||
17170105|NCT01931163|t||||
17170106|NCT03188510|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170107|NCT04182672|t||||
17170108|NCT03052049|f||||f
17170109|NCT00999518|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170110|NCT03319212|f||GT60||t
17170111|NCT02248636|t||||
17170112|NCT04254666|f||||f
17138399|NCT02671461|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170113|NCT03343626|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17170114|NCT02798978|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170115|NCT02475278|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170116|NCT00826618|f||||f
17170117|NCT03712787|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170118|NCT00952081|f||||f
17182700|NCT04083976|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17170119|NCT00931606|f||OTHER|All information concerning Sotatercept is considered confidential and shall remain the sole property of the Sponsor. No publication or disclosure of study results will be permitted except as specified in a separate, written, agreement between the Sponsor and the Investigator.|t
17170120|NCT00860171|t||||
17170121|NCT02170870|t||||
17170122|NCT03412812|t||||
17170123|NCT00491491|f||||f
17170124|NCT01350232|t||||
17170125|NCT00125957|f||||f
17170126|NCT02391363|t||||f
17170127|NCT03828617|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170128|NCT00941915|t||||
17170129|NCT04794270|f||GT60||t
17170130|NCT01937260|f||OTHER||t
17170131|NCT00704938|f||||f
17170132|NCT00732875|f||OTHER|All proposed publications/presentations by the investigators or their personnel/associates resulting from/relating to this study must be submitted to SP Korea for review and approval before submission for publication/presentation. If the proposed publication/presentation contains patentable subject matter, which, at SP Korea's sole discretion, warrants intellectual property protection, SP Korea may delay any publication or presentation for the purpose of pursuing such protection.|t
17170133|NCT03826186|t||||
17170134|NCT06831513|t||||f
17170135|NCT03688074|f||||t
17170136|NCT00724984|f||||f
17170137|NCT00721188|f||LTE60||t
17170138|NCT03928717|f||||f
17170139|NCT04648683|t||||
17170140|NCT00581581|f||||f
17170141|NCT03056339|t||||
17170142|NCT00635167|t||||
17170143|NCT01048658|t||||
17170144|NCT05224453|t||||
17170145|NCT01128244|f||||f
17170146|NCT02219334|t||||
17170147|NCT00939536|f||OTHER||t
17170148|NCT04171219|t||||
17170149|NCT04838626|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170150|NCT02381015|f||||f
17170151|NCT01934010|f||OTHER|"The Investigator agrees to submit a copy of any intended communication, presentation or publication (abstract, poster, article, etc.) (all together Communication) at least 2 month in advance of the submission of proposed Communication. The Sponsor shall have 60 days, after receipt of said copies, to object to such proposed Communication. In case of such objection, the Investigator shall refrain from making such Communication for 6 months from date of receipt of such objection."|t
17170152|NCT01393821|t||||
17170153|NCT03386487|t||||
17170154|NCT03422536|t||||f
17170155|NCT04929249|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170156|NCT01561053|f||OTHER|A 18-month post-study period is reserved for a joint, multi-center publication of study results. After this period, individual sites may publish results provided that the Sponsor is allowed 60 days to review any proposed publication for removal of confidential, protected, and trademarked material prior to submission with an option to delay publication up to 120 days if needed to protect its interests. The Sponsor shall retain the option to receive acknowledgment for its sponsorship of the study.|t
17170157|NCT01716455|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170158|NCT00395850|t||||
17170159|NCT02652468|t||||
17170160|NCT01620762|f||OTHER|To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.|t
17170161|NCT03521479|f||||f
17170162|NCT00705146|f||||f
17170163|NCT02910102|f||OTHER|All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.|t
17170164|NCT02669121|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170165|NCT00492336|t||||f
17170166|NCT00241904|f||||f
17170167|NCT04331002|t||||
17170168|NCT00825812|f||OTHER|The PI must not publish/publicly present any interim results without prior written consent of sponsor. The PI must provide copies of material for sponsor to review, 45 days prior to submission for publication/presentation. The sponsor may review/comment. If the parties disagree on the appropriateness of the data analysis and presentation, the PI must agree to meet prior to submission for publication/presentation to make good faith efforts to discuss and resolve any issues or disagreement.|t
17170169|NCT00483938|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182701|NCT05358821|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17127868|NCT02649946|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17170170|NCT02218008|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17170171|NCT00106353|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170172|NCT02038075|f||||f
17170173|NCT00588354|t||||f
17170174|NCT04000581|t||||
17170175|NCT03477838|t||||
17170176|NCT02519595|f||||f
17170177|NCT00850538|f||||f
17170178|NCT00387036|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170179|NCT03139344|f||||f
17170180|NCT02328027|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170181|NCT00122369|f||||f
17170182|NCT00250276|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170183|NCT01088399|f||GT60||t
17170184|NCT00782483|f||||f
17170185|NCT00349778|f||||f
17170186|NCT01811186|f||||f
17170187|NCT02022436|f||||f
17170188|NCT03369236|f||||t
17170189|NCT03334812|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170190|NCT02566317|f||||f
17170191|NCT01865448|t||||
17182702|NCT02504372|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 30 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17170192|NCT00872599|f||||f
17170193|NCT00801229|f||||f
17170194|NCT02255461|f||OTHER||t
17170195|NCT02380443|f||||f
17170196|NCT04809285|f||GT60||t
17170197|NCT06292130|f||||f
17170198|NCT03350815|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170199|NCT02630472|t||||
17170200|NCT01015781|t||||
17170201|NCT03040674|f||||f
17170202|NCT02936843|t||||
17170203|NCT02703324|f||GT60||t
17170204|NCT04303572|f||||f
17170205|NCT06312592|f||||f
17170206|NCT01858766|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17170207|NCT03517228|t||||
17170208|NCT01340053|f||OTHER|Publications must be reviewed and approved by sponsor|t
17170209|NCT00156390|t||||
17170210|NCT01439594|f||||f
17170211|NCT00475709|f||OTHER||t
17170212|NCT04491539|f||||f
17170213|NCT01835158|f||LTE60||t
17170214|NCT01415401|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170215|NCT00475904|f||||f
17170216|NCT00939562|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182703|NCT03901963|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182704|NCT02102256|f||||f
17182705|NCT03032796|t||||f
17170217|NCT02465372|t||||
17170218|NCT01806675|t||||
17170219|NCT00532298|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170220|NCT02023996|t||||
17170221|NCT05758402|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170222|NCT02211456|t||||
17170223|NCT00095173|f||LTE60||t
17170224|NCT00639626|t||||
17170225|NCT00145574|f||OTHER|"Sponsor reflects the following restrictive language in the Clinical Study Agreements: If identified by Daiichi Sankyo,Inc. (DSI), any of DSI's confidential information as defined herein shall be deleted…Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site."|t
17170226|NCT00527904|f||OTHER|PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.|t
17170227|NCT03323801|f||||f
17170228|NCT02708355|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170229|NCT01320202|f||LTE60||t
17170230|NCT01340573|f||OTHER||t
17170231|NCT01019369|f||||f
17170232|NCT01380834|f||||f
17170233|NCT04310566|f||GT60||t
17170234|NCT01711645|f||LTE60||t
17138400|NCT02807844|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138401|NCT00709124|t||||f
17138402|NCT04294095|f||||f
17138403|NCT00992602|f||||f
17170235|NCT02109809|t||||
17170236|NCT01041521|f||||f
17170237|NCT03691662|f||||t
17182706|NCT05429203|t||||
17182707|NCT00462696|t||||
17182708|NCT01351896|f||LTE60||t
17182709|NCT05944250|t||||f
17182710|NCT02365597|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17170238|NCT01746173|f||||f
17138404|NCT02629614|f||||f
17138405|NCT01425229|t||||f
17138406|NCT00744848|f||||f
17138407|NCT00976248|f||||f
17170239|NCT00147316|f||OTHER||t
17170240|NCT01771250|f||||f
17170241|NCT02110264|f||||f
17170242|NCT03543137|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170243|NCT03294850|t||||
17170244|NCT01153724|t||||
17170245|NCT03850535|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170246|NCT00870545|f||||f
17170247|NCT04230213|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170248|NCT00524472|f||||f
17170249|NCT02178696|t||||
17170250|NCT02508428|f||OTHER|Materials should be submitted to the sponsor for review at least thirty days before they are due to be submitted for publication. The sponsor will inform the authors of any changes deemed necessary to preserve confidentiality, protect intellectual property or ensure scientific accuracy and the authors agree to make these changes before submission.|t
17170251|NCT02748070|t||||
17170252|NCT02859441|t||||
17170253|NCT00928694|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170254|NCT00534976|f||OTHER|Subsequent to a multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator may publish the results for their study site independently. However, the SPONSOR does not recommend separate publication of individual study site results. The SPONSOR must have the opportunity to review all proposed communications regarding this study 60 days prior to submission. Any information identified by the SPONSOR as confidential must be deleted.|t
17170255|NCT00861471|t||||
17170256|NCT02834247|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17170257|NCT00439296|f||GT60||t
17170258|NCT05111249|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170259|NCT05128578|t||||f
17170260|NCT03004911|f||||f
17170261|NCT01016600|t||||
17170262|NCT02679755|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170263|NCT00725049|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17170264|NCT02451917|f||||f
17170265|NCT01724866|f||||t
17170266|NCT02324283|f||||f
17170267|NCT03032263|t||||
17170268|NCT02300259|f||GT60||t
17170269|NCT01424501|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170270|NCT01980095|f||OTHER|The PI agree that the Sponsor shall have the right to the first publication of the results of the Study. Following the first publication, the PI may publish data or results from the Study; subject to Sponsor for review and approval in writing at least sixty (60) days prior to the date of the publication. Sponsor may require changes and may extend the embargo to protect its intellectual property or other proprietary interests and to allow for the taking actions for this purpose.|t
17170271|NCT04737278|f||OTHER|The study PI (Dale Wilson) retired soon after the study was completed. KGK Synergize has undergone reorganization as KGK Science. The original intent was to publish the study results in a peer review journal.|t
17170272|NCT02737475|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170273|NCT00546000|f||OTHER||t
17170274|NCT00889824|t||||f
17170275|NCT00660179|f||LTE60||t
17170276|NCT01504412|f||||f
17170277|NCT01449006|f||LTE60||t
17170278|NCT01703507|t||||
17170279|NCT02096549|f||||f
17170280|NCT02221674|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17170281|NCT05292131|f||GT60||t
17170282|NCT03829449|f||||f
17170283|NCT04390880|f||||f
17170284|NCT02557542|t||||
17170285|NCT06136897|f||LTE60||t
17170286|NCT03705559|t||||f
17170287|NCT01077401|f||||f
17170288|NCT01979952|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17170289|NCT05438576|t||||
17170290|NCT01028846|t||||
17170291|NCT01511068|f||||f
17170292|NCT00465088|f||OTHER|Prior to release; Sponsor shall receive up to 180 days for review. Differences shall be resolved in good faith through appropriate scientific debate.|t
17170293|NCT01067144|t||||
17170294|NCT01821859|t||||
17170295|NCT00203424|f||OTHER|The obligations of confidentiality shall apply for a period of 5 years beyond termination of Agreement between Sponsor and PI,but do not apply to the extent information:is or later becomes generally known to the public;is obtained from third party without restriction who had legal right to disclose;is already possessed by PI,as demonstrated by recipient's written records predating receipt from Sponsor;or is required to be disclosed pursuant to a subpoena,law,regulation,or other legal proceeding.|t
17170296|NCT00555672|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170297|NCT01053988|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170298|NCT04759157|f||||f
17170299|NCT01824355|f||GT60||t
17170300|NCT01635881|f||OTHER|Institution and Investigator shall have the right to publish the results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17170301|NCT04427072|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170302|NCT03375489|f||||f
17170303|NCT01350245|t||||
17170304|NCT02104947|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17170305|NCT03777319|f||||f
17170306|NCT00328861|f||||f
17170307|NCT04698993|f||||f
17170308|NCT02021955|t||||
17170309|NCT01366885|f||||f
17170310|NCT00635882|f||OTHER|"The investigator agrees not to publish/present any interim results without prior~sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement."|t
17182711|NCT05132127|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17182712|NCT05619692|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17170311|NCT00858637|f||OTHER||t
17170312|NCT00835341|f||||f
17170313|NCT02305238|f||||f
17170314|NCT02513472|f||||f
17170315|NCT02748928|f||||f
17170316|NCT04560075|t||||
17170317|NCT01100775|f||||f
17170318|NCT04565951|t||||
17170319|NCT04677504|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170320|NCT03301298|f||||f
17170321|NCT03771274|f||||f
17170322|NCT00112125|f||||f
17170323|NCT00167310|f||||f
17170324|NCT04371666|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17170325|NCT00445770|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170326|NCT03857542|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170327|NCT02123576|f||||f
17170328|NCT00934128|t||||f
17170329|NCT04649177|t||||
17170330|NCT01985425|t||||
17170331|NCT01946152|t||||
17170332|NCT01698814|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170333|NCT04255862|f||GT60||t
17170334|NCT01061359|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170335|NCT04014062|f||||t
17170336|NCT03038126|f||||f
17170337|NCT02610777|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170338|NCT03974945|t||||
17170339|NCT06476548|t||||
17170340|NCT03274414|t||||
17170341|NCT00398567|f||LTE60||t
17170342|NCT02837029|t||||
17170343|NCT02034877|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170344|NCT03782701|t||||f
17170345|NCT04421482|t||||
17170346|NCT00526591|t||||
17170347|NCT04426318|t||||
17170348|NCT03906071|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170349|NCT02700386|t||||
17170350|NCT05613257|f||||f
17170351|NCT05380505|t||||
17170352|NCT00783614|t||||
17170353|NCT00694018|t||||
17170354|NCT01564732|f||||f
17170355|NCT01159015|f||OTHER|Please contact sponsor directly for details.|t
17170356|NCT01036321|t||||
17170357|NCT01957202|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170358|NCT04808141|f||||f
17170359|NCT00381693|t||||
17170360|NCT00345865|t||||
17170361|NCT02553395|f||||f
17170362|NCT02159976|f||||f
17170363|NCT00972725|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170364|NCT02506192|f||||f
17170365|NCT01854034|t||||
17170366|NCT01922271|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17170367|NCT00632619|f||||f
17170368|NCT00836186|f||||f
17170369|NCT04406649|f||OTHER||t
17170370|NCT04531241|f||GT60||t
17170371|NCT02576795|f||LTE60||t
17170372|NCT04210622|f||GT60||t
17170373|NCT05232864|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170374|NCT05723263|t||||
17170375|NCT01870505|t||||
17170376|NCT04067609|t||||
17170377|NCT04765202|f||||t
17170378|NCT00465452|t||||
17170379|NCT02687139|t||||f
17170380|NCT01635855|f||OTHER|No manuscripts may be submitted for publication without prior review by the Sponsor. Investigator agrees to accommodate requests by Sponsor to protect proprietary rights/interests. Sponsor will be given full credit/acknowledgment for support provided for any publication resulting from this research. Investigator shall grant to the Sponsor an irrevocable royalty free, non-exclusive right to reproduce, translate, use all such copyrighted material arising from publications from study.|t
17170381|NCT03828019|f||||f
17170382|NCT03400176|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170383|NCT00206440|t||||
17170384|NCT01298765|f||||f
17170385|NCT03401671|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170386|NCT03302247|t||||
17170387|NCT04090242|f||OTHER||t
17170388|NCT03214406|f||OTHER|Confidentiality agreement in place with Investigator.|t
17170389|NCT01898013|t||||
17170390|NCT01957410|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17170391|NCT01098305|t||||
17170392|NCT03182907|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts and manuscripts regarding this study prior to submission for publication. This will allow the SPONSOR to protect the proprietary information prior to submission.|t
17170393|NCT00429169|f||||f
17170394|NCT03747640|t||||
17170395|NCT02815644|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17170396|NCT01180296|f||||f
17170397|NCT01718444|f||||f
17170398|NCT01511081|t||||
17170399|NCT01371552|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17170400|NCT03364309|f||GT60||t
17170401|NCT03304873|t||||
17170402|NCT01546688|f||||f
17170403|NCT00667849|f||LTE60||t
17170404|NCT01895959|t||||
17170405|NCT01052077|f||||f
17170406|NCT02465203|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety.|t
17170407|NCT00042991|f||LTE60||t
17170408|NCT04072887|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182713|NCT01946204|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17170409|NCT03193736|f||OTHER|"* first publication to be made by Sponsor as part of publication of results obtained from all sites participating in the study~* intended manuscript to be submitted to Sponsor for review min 60 days in advance, proposals for changes submitted by Sponsor to be taken into consideration by Principal Investigator, unless they interfere with scientific nature or neutrality of the publication~* Sponsor may demand postponement of publication by max 90 days to protect intellectual property rights"|t
17170410|NCT00423449|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17170411|NCT02697435|t||||
17170412|NCT00240500|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170413|NCT01445080|f||LTE60||t
17170414|NCT02363621|t||||
17170415|NCT05690555|t||||
17170416|NCT04784143|f||||f
17170417|NCT02974257|f||||f
17170418|NCT03571555|t||||
17170419|NCT02828436|t||||
17170420|NCT01136408|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17170421|NCT04220554|f||||f
17170422|NCT01013194|t||||
17170423|NCT02128724|t||||
17170424|NCT03329092|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170425|NCT05786508|f||||f
17170426|NCT04273893|t||||
17170427|NCT01761019|f||||f
17170428|NCT00225498|t||||
17170429|NCT01456169|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170430|NCT02598297|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17170431|NCT05651867|f||||f
17170432|NCT00412243|f||||f
17170433|NCT00935311|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170434|NCT00394706|t||||
17170435|NCT04846322|f||||f
17170436|NCT03369249|f||||f
17170437|NCT02003534|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170438|NCT02652156|t||||
17170439|NCT01073449|f||||f
17170440|NCT02342223|f||||f
17170441|NCT02223338|t||||
17170442|NCT00496080|f||LTE60||t
17170443|NCT03101254|t||||
17170444|NCT01200368|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170445|NCT00570310|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182714|NCT03466411|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182715|NCT03778931|f||||f
17182716|NCT02115282|f||LTE60||t
17170446|NCT00108862|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17170447|NCT03534141|t||||
17170448|NCT01664182|f||LTE60||t
17170449|NCT03785405|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170450|NCT05234957|t||||
17170451|NCT02881762|t||||
17170452|NCT00795236|t||||
17170453|NCT04137731|f||LTE60||t
17170454|NCT01151371|f||OTHER|The sponsor must provide written approval for any publication.|t
17170455|NCT03983304|f||||f
17170456|NCT00310817|t||GT60||t
17170457|NCT01702246|f||||f
17170458|NCT01587040|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17170459|NCT00432341|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release for a period that is not less than 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication.|t
17170460|NCT01518374|f||GT60||t
17170461|NCT04300309|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170462|NCT03035331|t||||
17170463|NCT03724890|f||||t
17170464|NCT02314221|t||||
17170465|NCT04607837|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170466|NCT02362464|f||||f
17170467|NCT04346654|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17170468|NCT02093962|f||||f
17170469|NCT05715242|f||||f
17170470|NCT02915978|f||||f
17170471|NCT03605914|t||||
17170472|NCT02275156|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17170473|NCT02343406|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170474|NCT02451124|f||||f
17170475|NCT00766051|f||||f
17170476|NCT00801398|f||||f
17170477|NCT03274856|f||OTHER||t
17170478|NCT03058692|f||LTE60||t
17170479|NCT01392547|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17170480|NCT00571974|t||||
17170481|NCT02346461|t||||
17170482|NCT00799266|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170483|NCT00954993|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17170484|NCT02477124|f||||f
17170485|NCT01340586|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182717|NCT03431350|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17182718|NCT04325828|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17182719|NCT02026115|f||||f
17182720|NCT02219815|f||||f
17170486|NCT03671213|f||OTHER|Institution agrees study is multi-center study conducted by Sponsor and agrees not to publish until study completion and not before publication of multi-center results in peer-reviewed journal. Thereafter, Institution may publish its site experience. Sponsor reserves exclusive right to publish results and establish authorship based on compliance, contribution and acceptance of responsibilities. If no publication submitted by Sponsor within 12 months of study closure, Institution may publish.|t
17170487|NCT00681889|t||||
17170488|NCT03223337|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170489|NCT01362608|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170490|NCT00726414|f||GT60||t
17170491|NCT01336140|t||||
17170492|NCT04506502|f||||f
17170493|NCT00699608|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170494|NCT00566462|f||OTHER||t
17170495|NCT03010319|f||OTHER|Investigators are barred from publishing or disclosing results until a multicenter publication is published or until a period of 24 months after study completion passes, whichever comes first.|t
17170496|NCT04720417|t||||
17170497|NCT04587050|t||||
17170498|NCT02588261|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the muli-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17170499|NCT03781778|t||||
17170500|NCT02287467|f||||f
17170501|NCT00900666|f||||f
17170502|NCT01137032|f||OTHER||t
17170503|NCT03472950|t||||
17170504|NCT02608463|t||||f
17170505|NCT00517361|f||||f
17170506|NCT01076036|f||||f
17170507|NCT00195091|t||||
17170508|NCT00945256|f||||f
17170509|NCT00245037|t||||
17170510|NCT00684775|f||||f
17170511|NCT04181762|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170512|NCT00666406|f||OTHER|Baxter requires a review of results communications (e.g., for confidential information and/or manuscript amendment proposals which do not negatively influence the scientific character of impartiality) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17170513|NCT06964165|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17182721|NCT04602624|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182722|NCT04084769|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17170514|NCT04211441|f||GT60||t
17170515|NCT02440685|f||||f
17170516|NCT04289311|f||||f
17170517|NCT01514201|f||LTE60||t
17170518|NCT02352844|t||||
17170519|NCT00590863|f||||f
17170520|NCT05888181|t||||
17170521|NCT03124836|f||LTE60||t
17170522|NCT03054649|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170523|NCT02735343|f||||f
17170524|NCT00637416|t||||
17170525|NCT01070173|f||||f
17170526|NCT02534909|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170527|NCT01804881|f||||f
17170528|NCT01625000|f||OTHER||t
17170529|NCT00566852|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17170530|NCT03165916|t||||
17170531|NCT00577824|f||GT60||t
17170532|NCT04079816|t||||
17170533|NCT00362648|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170534|NCT04493203|t||||
17127869|NCT00950950|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127870|NCT01809002|f||OTHER|The Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of at least sixty days prior to submission for publication for sponsor to review and comment. The Sponsor may extend the embargo for an additional 60 days to allow for the filing of a patent application or taking such measures Sponsor deems appropriate to establish and preserve its proprietary rights.|t
17127871|NCT02464033|t||||
17170535|NCT02123823|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17170536|NCT03453489|t||||
17170537|NCT03190460|f||||f
17170538|NCT05870865|f||||f
17170539|NCT04752332|f||GT60||t
17170540|NCT00952393|t||||
17170541|NCT01868477|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170542|NCT02528786|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17170543|NCT02387554|f||||f
17170544|NCT00856297|f||OTHER|The terms and conditions of Novartis agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170545|NCT03526146|t||||
17170546|NCT01717872|f||||f
17170547|NCT02214290|f||||f
17170548|NCT02517541|f||LTE60||t
17170549|NCT01510158|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17170550|NCT03078556|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170551|NCT03314987|f||||t
17170552|NCT03574779|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17170553|NCT02751580|t||||
17170554|NCT03106636|t||||
17170555|NCT01915173|f||||f
17170556|NCT02152761|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e.; data from all sites) in the clinical trial.|t
17170557|NCT03755882|f||GT60||t
17127872|NCT03102645|f||||f
17127873|NCT01413087|f||GT60||t
17127874|NCT02232243|f||||f
17170558|NCT02292446|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170559|NCT01822457|t||||
17170560|NCT00352001|t||||
17170561|NCT03329846|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170562|NCT03066193|f||||f
17170563|NCT02631551|f||OTHER|Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the CRO/Sponsor.|t
17170564|NCT05419232|f||||f
17170565|NCT01318408|f||||f
17170566|NCT05636852|f||||t
17170567|NCT00377858|f||GT60||t
17170568|NCT01685697|f||||f
17170569|NCT01543074|t||||
17170570|NCT04034004|f||||f
17170571|NCT01345188|f||||f
17170572|NCT01397461|f||OTHER|Any and all data resulting from the Study will not be presented or published in any form or media by the Institution, Investigator or Research Staff without the prior written consent of Sponsor which consent maybe as directed within the Protocol.|t
17170573|NCT05139927|f||||f
17170574|NCT05729568|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17170575|NCT04526145|t||||
17170576|NCT01502228|t||||
17182723|NCT03492177|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17182724|NCT06425458|t||||
17182725|NCT03945981|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170577|NCT04477759|t||||
17170578|NCT05747027|f||||f
17170579|NCT00048347|t||||
17170580|NCT00958165|f||||f
17170581|NCT00195663|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170582|NCT00604695|f||OTHER|Principal Investigator shall furnish Sponsor with copy of any proposed publication for review/comment prior to submission for publication, at least thirty (30) days prior to submission for manuscripts and at least fifteen (15) days prior to submission for abstracts. Institution agrees to delete information identified by Sponsor as Confidential Information prior to submission for publication.|t
17170583|NCT04551950|f||||f
17182726|NCT03665038|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182727|NCT04466891|f||||f
17182728|NCT00445328|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182729|NCT05114005|t||||
17182730|NCT00316199|f||GT60||t
17182731|NCT00590954|t||||
17170584|NCT02058563|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170585|NCT00166439|f||||t
17170586|NCT04039217|t||||
17170587|NCT00615992|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170588|NCT04522141|f||||f
17170589|NCT03508609|f||||f
17170590|NCT00555217|f||||f
17170591|NCT01135095|f||||f
17170592|NCT00367835|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17170593|NCT04338971|f||||f
17170594|NCT01025830|f||||f
17170595|NCT03761810|f||OTHER|Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.|t
17170596|NCT01574651|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17170597|NCT03887221|f||OTHER|This document contains confidential information of Zambon S.p.A., Italy. Do not copy or distribute without written permission from the sponsor.|t
17170598|NCT02487030|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17170599|NCT02092025|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170600|NCT00264537|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170601|NCT02395614|f||||f
17170602|NCT03228212|f||GT60||t
17170603|NCT01807299|t||||
17170604|NCT00811174|f||||f
17170605|NCT01938040|t||||
17170606|NCT03621657|t||||f
17170607|NCT00999544|f||||f
17170608|NCT04683835|f||||f
17170609|NCT02407223|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17170610|NCT04864639|t||||
17170611|NCT00615017|f||LTE60||t
17170612|NCT00806988|t||||f
17170613|NCT01478971|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182732|NCT02285504|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17127875|NCT00704405|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17127876|NCT00928018|t||||
17127877|NCT03218397|t||||
17127878|NCT00943111|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17170614|NCT00584012|f||||f
17170615|NCT01525615|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170616|NCT04050618|f||||f
17170617|NCT04404556|f||||f
17170618|NCT04775953|f||||t
17170619|NCT00855959|f||LTE60||t
17170620|NCT02451943|f||||t
17170621|NCT00368641|f||||f
17170622|NCT02029911|f||||f
17170623|NCT00763386|f||||f
17170624|NCT00555880|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170625|NCT01290757|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170626|NCT00887549|f||GT60||t
17170627|NCT00759161|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170628|NCT00479336|f||||f
17170629|NCT02021643|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17170630|NCT02947646|f||||f
17170631|NCT04854551|f||||f
17170632|NCT04112303|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17170633|NCT00726232|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17170634|NCT03088917|t||||
17127879|NCT01946438|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17170635|NCT01022138|t||||
17127880|NCT02775695|t||||
17127881|NCT01078454|f||LTE60||t
17170636|NCT05447663|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17170637|NCT06041919|f||||t
17170638|NCT01588444|t||||
17170639|NCT01221350|t||||f
17170640|NCT00799435|f||||f
17170641|NCT03319134|t||||
17170642|NCT04030520|t||||
17170643|NCT04209205|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170644|NCT03254940|f||||f
17170645|NCT05236257|f||OTHER|The disclosure agreement is that the publication is restricted for external partners.|t
17170646|NCT03427749|t||||
17170647|NCT03071393|t||||
17170648|NCT00924443|f||OTHER|There IS an agreement between the Principal Investigator (PI) and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. In multi-site studies, PI can publish after sponsor publishes or 18 months after study completion. PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application.|t
17170649|NCT03559933|f||||f
17170650|NCT01746225|f||||f
17170651|NCT03405818|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127882|NCT06298669|t||||
17127883|NCT00409773|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170652|NCT02451514|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170653|NCT03197376|f||||t
17170654|NCT00003199|f||||f
17170655|NCT02137096|t||||
17170656|NCT01223183|t||||
17170657|NCT02309944|t||||
17170658|NCT03049917|f||||f
17170659|NCT02232022|f||||f
17170660|NCT03777059|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170661|NCT02813889|f||||f
17170662|NCT01026012|f||||f
17170663|NCT05589610|f||GT60||t
17170664|NCT02607618|f||OTHER||t
17170665|NCT00655538|f||||f
17170666|NCT01101035|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17170667|NCT00681629|f||OTHER|Site has to inform sponsor about a publication at least 60 day in advance and 10 days before submission of an abstract or presentation. Change requests by the sponsor are recognized unless the scientific character or the objectivity is on risk. If the sponsor plans a patent application the publication has to be postponed up to 120 days.|t
17170668|NCT00411671|t||||
17170669|NCT01764711|f||||f
17170670|NCT03796637|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17170671|NCT01173601|f||GT60||t
17170672|NCT03951077|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170673|NCT00889512|f||||f
17170674|NCT01395901|f||OTHER|If Sponsor does not submit a publication regarding the study to a journal within 12 months from study data analysis completion, the Investigator may publish an analysis of the study data collected as a result of the conduct of the study by the Investigator. The Investigator shall ensure that at least 60 days prior to submitting/presenting a manuscript/material relating to study to publishers a copy of all manuscripts/materials is provided to the Sponsor to allow the Sponsor sixty days to review.|t
17170675|NCT03923790|t||||
17170676|NCT02279667|t||||
17170677|NCT00713544|f||LTE60||t
17170678|NCT02380287|f||||f
17170679|NCT01641601|t||||
17170680|NCT01908530|t||||
17170681|NCT00950846|t||||
17170682|NCT02178995|t||||
17170683|NCT00587158|t||LTE60||t
17170684|NCT05258149|f||GT60||t
17170685|NCT00832416|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17170686|NCT02114606|t||||f
17170687|NCT00981461|f||||f
17170688|NCT03187119|f||||f
17170689|NCT01999400|f||||f
17170690|NCT01466127|t||||
17170691|NCT01910402|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170692|NCT00483405|t||||
17170693|NCT00571038|t||||
17170694|NCT01442714|t||||
17170695|NCT04306510|f||GT60||t
17170696|NCT01023711|f||||f
17170697|NCT06068426|f||||f
17170698|NCT01898429|t||||
17170699|NCT04829916|f||||f
17170700|NCT04343755|t||||
17170701|NCT00193206|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17170702|NCT02940496|t||||
17170703|NCT03318016|t||||
17170704|NCT01717001|f||||f
17170705|NCT01147055|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170706|NCT00132808|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170707|NCT05919888|t||||
17170708|NCT02403999|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170709|NCT02204072|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127884|NCT00153062|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17127885|NCT02359877|f||||f
17127886|NCT04461483|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17127887|NCT01919814|f||||f
17127888|NCT00275262|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17127889|NCT02164383|f||||f
17127890|NCT00690040|t||||
17127891|NCT02110147|f||||f
17127892|NCT02340767|f||||f
17127893|NCT01290029|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17170710|NCT05725746|f||||f
17170711|NCT01895946|f||||f
17170712|NCT03657849|t||||
17170713|NCT00874848|f||||f
17170714|NCT03089541|f||||f
17170715|NCT02324816|f||||f
17170716|NCT05169424|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17170717|NCT01870726|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170718|NCT00286429|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17170719|NCT00942825|f||||f
17170720|NCT00595478|f||||f
17170721|NCT01092910|f||||f
17170722|NCT01123395|f||GT60||t
17170723|NCT03691571|f||||f
17170724|NCT00746694|f||OTHER|"Study data may be used in general publications or at conferences. Authorship will be attributed to those responsible for preparing the report and/or those who had a relevant part in designing the study. Whenever publication rules allow, all investigators will be listed individually.~Investigators may publish their data individually. In this case investigators will notify the study sponsor, including the communication/manuscript to be published, at least 30 days before submission."|t
17170725|NCT00186901|t||||
17170726|NCT02921490|f||||f
17170727|NCT02682992|t||||
17170728|NCT03274063|f||||f
17170729|NCT02363959|t||||
17170730|NCT01511016|f||||f
17170731|NCT00950248|f||||f
17170732|NCT02578199|t||||
17170733|NCT02267538|t||||
17170734|NCT00869518|t||||
17170735|NCT00947115|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170736|NCT00662545|f||||f
17170737|NCT00511238|f||OTHER|After the study is completed and all case report forms have been sent to Sponsor, Institution shall have the right to publish or otherwise make public any data resulting from the study under this agreement after publication of a multi-center publication coordinated by Sponsor with respect to the data resulting from the study, or 12 months after the Study is completed at all participating sites if a multi-center publication is not submitted by Sponsor for publication within such 12 month period.|t
17170738|NCT02587819|f||||f
17170739|NCT03772665|f||||f
17170740|NCT02986711|f||||f
17170741|NCT05561582|f||||f
17170742|NCT00988013|f||||f
17170743|NCT02871635|f||||f
17170744|NCT02420379|f||OTHER|The most restrictive relevant agreement provides that the PI can only publish the study results with the approval of Sponsor.|t
17127894|NCT02336178|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127895|NCT00618982|f||OTHER|The Principal Investigator (PI) can publish results following completion of study. The PI must discuss a publication with Bayer prior to release\&obtain written consent to proceed. The Investigator must send a draft to Bayer at least 30d in advance of submission to obtain approval. Any submission to Bayer will be reviewed w/o unreasonable delay\&approval not be withheld unreasonably. In difference of opinion publication will be discussed.|t
17127896|NCT02394951|f||||f
17127897|NCT01197833|f||||f
17127898|NCT01776541|f||||f
17127899|NCT00156819|f||||f
17127900|NCT00522873|f||LTE60||t
17127901|NCT00624923|f||||f
17127902|NCT00799513|f||||f
17127903|NCT00666679|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127904|NCT02370810|f||||f
17127905|NCT05062759|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17127906|NCT02781844|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17127907|NCT02518490|f||||f
17127908|NCT00346632|f||OTHER||t
17127909|NCT00918580|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127910|NCT04882995|t||||
17127911|NCT01028937|f||||f
17127912|NCT02700945|f||||f
17127913|NCT03476707|f||||f
17127914|NCT00116337|t||||
17127915|NCT00262951|t||||
17170745|NCT00502671|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170746|NCT03633344|t||||
17170747|NCT03795116|f||||f
17170748|NCT00412893|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17170749|NCT00853151|f||GT60||t
17170750|NCT00269919|f||LTE60||t
17170751|NCT00797277|t||||f
17170752|NCT04473963|f||||f
17170753|NCT02123849|f||LTE60||t
17170754|NCT01799226|f||||f
17170755|NCT02274792|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17170756|NCT00476827|f||||f
17170757|NCT03370042|t||||
17170758|NCT01388907|f||LTE60||t
17170759|NCT03361293|t||||
17170760|NCT02461927|t||||
17170761|NCT03187132|f||||f
17170762|NCT03594773|f||||f
17170763|NCT01550757|t||||
17170764|NCT02134717|f||||f
17170765|NCT04098809|t||||
17170766|NCT03618420|f||||f
17170767|NCT02741596|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17170768|NCT01426958|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17170769|NCT02968368|f||||t
17170770|NCT02859246|t||||
17170771|NCT00100789|f||||f
17170772|NCT01746368|f||||f
17127916|NCT01577745|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17127917|NCT04196101|f||OTHER||t
17127918|NCT00394082|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it has been more than 2 years since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decided publication would hinder patent applications, Investigator must delay submission for up to 1 year. Investigator must delete confidential information before submission.|t
17127919|NCT03430531|t||||
17127920|NCT02344004|f||OTHER|"Per the signed Investigator Agreement in the study protocol and protocol amendments, the PI agreed not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated."|t
17127921|NCT02842827|f||OTHER|The Lead/Coordinating Investigator will have the right to submit for publication any results arising from the study subject to the terms and conditions of the Clinical Trial and Confidentiality Disclosure Agreements.|t
17127922|NCT00882687|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17127923|NCT00527592|f||OTHER|Sponsor does not guarantee the Investigator's right to publish study results since this is a pilot trial with results intended primarily for internal use. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17170773|NCT05280717|f||LTE60||t
17170774|NCT00080301|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170775|NCT00740584|f||OTHER|No disclosure without SPL consent.|t
17170776|NCT00123123|f||||f
17170777|NCT02794766|f||||f
17170778|NCT03071887|f||||f
17170779|NCT02073682|f||GT60||t
17170780|NCT03461146|f||OTHER||t
17170781|NCT00181766|f||||f
17170782|NCT00855816|f||||f
17170783|NCT03393494|f||OTHER||t
17170784|NCT01965704|f||||f
17170785|NCT00061893|f||||f
17170786|NCT01526213|f||||f
17170787|NCT00687804|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127924|NCT03801915|f||||f
17170788|NCT04390243|t||||
17170789|NCT03869008|f||||f
17170790|NCT00413218|f||OTHER|The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the Sponsor at least 1 month prior to the submission of any such information to an editorial board or scientific review committee. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.|t
17170791|NCT00206336|f||||f
17170792|NCT01196026|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170793|NCT01687296|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170794|NCT04912583|t||||
17170795|NCT02486016|f||||t
17170796|NCT03672292|f||||f
17170797|NCT00799903|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170798|NCT02518971|t||||
17170799|NCT02336230|f||OTHER|Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection.|t
17170800|NCT02524171|t||||
17170801|NCT00940901|f||||f
17170802|NCT00757237|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~The study has been completed at all study sites for at least 2 years."|t
17170803|NCT05150990|f||||f
17170804|NCT00466921|f||||f
17170805|NCT02864901|t||||
17170806|NCT01219985|t||||
17170807|NCT04797780|f||OTHER|Note that the agreements are between the clinical sites and the Sponsor (or its agents), which restrict the clinical trial sites' rights to discuss or publish trial results after the trial is completed.|t
17170808|NCT04669301|f||||f
17170809|NCT02863328|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17170810|NCT00398320|f||||f
17170811|NCT00121186|f||||f
17170812|NCT03152591|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17127925|NCT01736865|f||||f
17127926|NCT02308020|f||GT60||t
17170813|NCT00163020|t||||
17170814|NCT03553758|t||||
17170815|NCT00597402|t||||
17170816|NCT00447226|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127927|NCT01211288|t||||f
17127928|NCT04217590|f||||f
17170817|NCT03868254|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17170818|NCT01860287|t||||
17170819|NCT02848222|f||||f
17170820|NCT01606709|f||||f
17170821|NCT00977171|f||LTE60||t
17170822|NCT03315572|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170823|NCT00991939|f||||f
17170824|NCT01631994|t||||f
17170825|NCT00714415|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170826|NCT03315039|f||||f
17170827|NCT01461707|f||||f
17170828|NCT00535002|t||||
17170829|NCT01582139|t||||
17170830|NCT01327677|t||||
17170831|NCT01220739|f||||f
17170832|NCT06260670|f||||f
17170833|NCT01592071|f||||f
17170834|NCT01100320|f||GT60||t
17170835|NCT03797586|t||||
17170836|NCT04980612|t||||f
17170837|NCT05730387|f||||f
17170838|NCT01951651|t||||
17170839|NCT01369784|f||||f
17170840|NCT02680665|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170841|NCT02905266|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170842|NCT04871425|t||||
17170843|NCT03149172|f||||f
17170844|NCT00596752|f||GT60||t
17170845|NCT05973006|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."|t
17170846|NCT03884790|f||||f
17170847|NCT04378270|f||||f
17170848|NCT01327599|f||OTHER|France: All results obtained during this study are the property of the Sponsor. All information given to the investigators must remain confidential and cannot be used outside the framework of this study. Germany: Investigators can publish results 12 months after the Sponsor's final evaluation of the data. The Sponsor is entitled to request a delay of such publication due to business or operational reasons.|t
17170849|NCT03838978|f||OTHER|Institution agrees study is multi-center study conducted by Sponsor and agrees not to publish until study completion and not before publication of multicenter results in peer-reviewed journal. Thereafter, Institution may publish its site experience. Sponsor reserves exclusive right to publish results and establish authorship based on compliance, contribution and acceptance of responsibilities. If no publication submitted by Sponsor within 12 months of study closure, Institution may publish.|t
17170850|NCT04544956|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17170851|NCT03402035|f||||f
17170852|NCT00548145|f||OTHER||t
17170853|NCT02119663|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17170854|NCT00892775|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170855|NCT00699660|t||||f
17182733|NCT03890367|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17170856|NCT00064792|t||||
17170857|NCT03301350|t||||
17170858|NCT03137225|t||||
17170859|NCT01248949|f||OTHER|"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome in the agreement description."|t
17170860|NCT01973413|f||||f
17170861|NCT03915470|f||OTHER|Protocol limits Investigators to not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.|t
17170862|NCT02601833|f||||f
17170863|NCT03245775|f||||f
17170864|NCT02713828|f||||f
17170865|NCT00434109|t||||
17170866|NCT01773187|f||OTHER||t
17127929|NCT04619251|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17127930|NCT01242800|f||LTE60||t
17127931|NCT00953745|t||||
17127932|NCT03527238|f||||f
17170867|NCT02978833|t||||
17170868|NCT00103740|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17170869|NCT02771197|t||||
17170870|NCT02155920|f||||f
17170871|NCT01802710|t||||
17170872|NCT00291486|t||||
17170873|NCT01099397|t||||
17170874|NCT03421106|f||||f
17170875|NCT01900652|f||GT60||t
17170876|NCT02774148|t||||
17170877|NCT02663622|f||||f
17170878|NCT01792115|t||||
17170879|NCT00900029|f||LTE60||t
17170880|NCT01594931|f||||f
17170881|NCT03678311|f||||f
17170882|NCT02222610|t||||
17170883|NCT02744092|f||OTHER|Complete study results are available in JAMA.|t
17170884|NCT02936635|f||||f
17170885|NCT01633788|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17127933|NCT01395888|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127934|NCT00982995|t||||
17127935|NCT03063125|t||||
17138408|NCT05567393|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138409|NCT04199793|t||||
17138410|NCT02758119|f||||f
17138411|NCT02677623|t||||f
17138412|NCT04186663|f||||f
17138413|NCT01569087|t||||
17138414|NCT01602549|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170886|NCT01929226|f||||t
17170887|NCT03652181|f||||f
17170888|NCT01473732|t||||f
17170889|NCT03271424|t||||
17170890|NCT01798966|f||||f
17170891|NCT01165983|f||LTE60||t
17170892|NCT03579940|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17138415|NCT00771173|t||||f
17138416|NCT05200455|t||||
17170893|NCT01217944|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17170894|NCT00671034|f||OTHER|Must obtain sponsor approval.|t
17170895|NCT01751984|f||||f
17170896|NCT01797263|t||||f
17170897|NCT02045095|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17127936|NCT01679405|t||||
17127937|NCT00126503|f||LTE60||t
17127938|NCT01427595|f||||f
17138417|NCT00719862|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.|t
17138418|NCT03328624|f||||f
17182734|NCT02533921|f||||f
17182735|NCT01707004|f||||f
17127939|NCT02457559|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17127940|NCT00974376|f||||f
17127941|NCT04819776|f||||t
17127942|NCT00998335|f||||f
17127943|NCT00979810|t||||
17127944|NCT03169101|t||||
17127945|NCT02250092|t||||f
17127946|NCT02641496|t||||
17127947|NCT03075410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127948|NCT01321151|t||||
17127949|NCT00790751|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17127950|NCT02549014|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17127951|NCT00346268|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170898|NCT01450761|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17170899|NCT00337207|t||||
17170900|NCT03573323|f||GT60||t
17170901|NCT04498143|f||||f
17170902|NCT04502290|t||||
17170903|NCT00837213|f||GT60||t
17170904|NCT02293798|f||||f
17170905|NCT02545608|f||OTHER||t
17170906|NCT02698826|f||||f
17170907|NCT00452868|t||||
17170908|NCT02326064|f||OTHER||t
17170909|NCT00216671|f||GT60||t
17170910|NCT04961541|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."|t
17170911|NCT01684202|f||||f
17170912|NCT00191308|f||GT60||t
17170913|NCT00851279|f||GT60||t
17170914|NCT01843023|t||||
17170915|NCT00779025|f||||f
17170916|NCT03305770|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170917|NCT03539601|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170918|NCT03710642|f||||f
17170919|NCT01970306|t||||
17170920|NCT00226811|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17170921|NCT02741635|f||||f
17170922|NCT01427933|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17170923|NCT01643382|t||||
17170924|NCT01633541|t||||
17127952|NCT00031551|t||||
17127953|NCT00743275|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17127954|NCT01966380|f||OTHER||t
17127955|NCT00619762|f||||f
17127956|NCT00575029|t||||
17127957|NCT01592500|f||||t
17127958|NCT02204176|t||||f
17170925|NCT01010971|f||OTHER||t
17170926|NCT03472326|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17170927|NCT03386721|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17170928|NCT03081884|t||||
17170929|NCT03676972|f||||t
17170930|NCT03948334|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17170931|NCT05114473|f||||f
17170932|NCT00700713|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17138419|NCT01184846|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170933|NCT01128426|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170934|NCT00550953|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17170935|NCT02446717|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170936|NCT02777827|f||OTHER|Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor.|t
17170937|NCT03160898|f||||f
17170938|NCT04441255|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17170939|NCT01023724|t||||
17170940|NCT02696759|t||||
17170941|NCT02424175|f||||f
17170942|NCT04178720|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17170943|NCT03145259|f||||t
17170944|NCT04177212|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17170945|NCT04725500|f||||f
17182736|NCT04368429|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17182737|NCT01167712|f||LTE60||t
17182738|NCT03756558|f||LTE60||t
17138420|NCT02483078|f||||f
17138421|NCT02853032|t||||
17138422|NCT03366844|t||||
17138423|NCT02688153|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17170946|NCT00857857|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170947|NCT00930930|f||GT60||t
17170948|NCT04618744|f||GT60||t
17170949|NCT02709330|t||||
17170950|NCT01172535|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and seven (7) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17170951|NCT00988598|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170952|NCT01588561|t||||
17170953|NCT01740414|f||||f
17170954|NCT02501590|f||||f
17170955|NCT04317040|f||OTHER|The Sponsor will support writing and publication of scientific reports, journal papers and oral presentations by the study principal investigator and others making scientific contribution to the research effort. Any reports, papers, and/or presentations must be reviewed and approved prior to submitting for publication.|t
17170956|NCT00004092|t||||
17170957|NCT01177007|t||||
17170958|NCT01961271|f||OTHER|Data emerging from the study cannot be released without the permission of the sponsor.|t
17170959|NCT03782233|t||||
17170960|NCT03259087|f||OTHER|The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.|t
17170961|NCT04308941|t||||
17170962|NCT03740659|f||OTHER||t
17170963|NCT02366195|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17170964|NCT01338818|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17170965|NCT00740207|f||OTHER|The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.|t
17170966|NCT02507388|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138424|NCT00107172|t||||
17138425|NCT00789724|t||||f
17170967|NCT00556998|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170968|NCT00947271|f||||f
17170969|NCT00490269|f||||f
17170970|NCT04400058|f||||f
17170971|NCT03030417|f||||f
17170972|NCT00782717|f||OTHER|Sponsor reserves the right to review study related information prior to presentation or publication|t
17170973|NCT02292719|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17170974|NCT02538042|f||||f
17170975|NCT04936061|f||||f
17170976|NCT02586727|f||||f
17170977|NCT02481297|t||||
17170978|NCT03967054|f||||f
17170979|NCT04628780|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170980|NCT05315479|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17170981|NCT03622814|f||||f
17170982|NCT01862536|t||||
17170983|NCT01288989|f||GT60||t
17170984|NCT01132313|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17170985|NCT01156714|t||||
17170986|NCT02052752|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17170987|NCT03946748|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17170988|NCT00165672|f||||f
17170989|NCT03830359|f||||f
17170990|NCT02715609|t||||
17170991|NCT03201419|f||OTHER||t
17170992|NCT04854694|f||||f
17170993|NCT05907395|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17170994|NCT04896593|f||OTHER|The principal investigator was designated by the sponsor to be the party responsible for conducting the trial and has the right to publish the results of the trial with approval from the sponsor.|t
17170995|NCT01406990|t||||
17170996|NCT00369577|f||LTE60||t
17170997|NCT05551611|f||||f
17170998|NCT00543777|t||||
17170999|NCT00848783|f||||f
17171000|NCT02937558|f||||f
17171001|NCT02360228|t||||f
17171002|NCT04266925|f||||f
17171003|NCT01059318|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17171004|NCT03790917|t||||
17171005|NCT04186871|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17171006|NCT02464410|t||||
17171007|NCT01971385|f||||f
17171008|NCT00176462|t||||
17171009|NCT01408459|t||||
17171010|NCT01604291|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171011|NCT01657292|f||OTHER|Publication requires approval of the sponsor without specification of an embargo time period.|t
17171012|NCT00650845|f||OTHER|"No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. The data are the exclusive property of Guerbet.~The investigator undertakes to submit to Guerbet any draft articles or papers related to this study within 30 days of their submission to the scientific review or the congress scientific committee.~All written or oral papers and publications must have the joint agreement of the investigator and the sponsor."|t
17171013|NCT03932760|f||||f
17171014|NCT01301833|f||OTHER||t
17171015|NCT03566082|f||LTE60||t
17171016|NCT03922620|t||||
17171017|NCT02373774|t||||
17171018|NCT00983385|f||OTHER|Grünenthal reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17171019|NCT00513435|f||LTE60||t
17171020|NCT01279681|f||LTE60||t
17171021|NCT01454791|t||||f
17171022|NCT01467505|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17171023|NCT02807623|t||||
17171024|NCT02098746|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17171025|NCT00217425|f||||f
17171026|NCT03273673|f||||f
17171027|NCT00086047|f||||f
17171028|NCT02471014|t||||
17171029|NCT04640311|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171030|NCT00592904|f||||f
17171031|NCT03191630|f||||f
17171032|NCT02707146|f||||f
17171033|NCT02459119|t||||
17171034|NCT02148523|f||||f
17171035|NCT01367834|f||LTE60||t
17171036|NCT01284517|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17171037|NCT00040443|f||||f
17171038|NCT01020786|f||GT60||t
17171039|NCT01165541|t||||f
17171040|NCT05413668|f||||t
17171041|NCT01818596|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17171042|NCT03801174|t||||
17182739|NCT00326911|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. Sponsor may request publication delay up to 90 days to seek patent protection.|t
17171043|NCT01337336|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171044|NCT05350163|t||||
17171045|NCT02915263|f||||f
17171046|NCT01879683|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17182740|NCT02530294|f||||t
17171047|NCT01618669|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17171048|NCT01698502|f||||f
17127959|NCT00477334|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17127960|NCT02572882|f||||f
17127961|NCT02418676|f||||f
17127962|NCT02354508|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17127963|NCT03587974|f||||f
17127964|NCT04371198|t||||
17127965|NCT00760006|t||||
17127966|NCT03486457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171049|NCT01702558|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171050|NCT01680666|t||||f
17171051|NCT04950465|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171052|NCT01788566|f||GT60||t
17171053|NCT01379183|t||||
17171054|NCT01620086|t||||
17171055|NCT01695135|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17171056|NCT02562716|f||||t
17171057|NCT00684996|f||LTE60||t
17171058|NCT01775371|f||||f
17171059|NCT01076959|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17171060|NCT01078441|f||LTE60||t
17171061|NCT01425801|f||OTHER|Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and sponsor|t
17171062|NCT02868554|t||||
17171063|NCT02175017|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this tiral prior to submission for publication/presentation.|t
17171064|NCT04915729|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17171065|NCT02451995|f||||f
17171066|NCT05282927|t||||
17171067|NCT02727907|f||||f
17171068|NCT02294058|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one (1) year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene sixty (60) days prior to submission. Celgene may remove confidential and/or proprietary information before publication|t
17127967|NCT00372229|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17127968|NCT03536143|f||||f
17127969|NCT01590017|f||||f
17127970|NCT00093808|t||||
17127971|NCT00871780|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17171069|NCT05006261|f||||f
17171070|NCT03575403|t||||f
17171071|NCT02330055|f||||f
17171072|NCT04544358|f||||f
17182741|NCT01948375|t||||
17127972|NCT02527343|f||||f
17127973|NCT00701220|t||||f
17127974|NCT03235284|f||||f
17127975|NCT03575754|f||||f
17127976|NCT00440999|f||||f
17171073|NCT03359174|t||||
17138426|NCT01102140|f||||f
17138427|NCT03682055|f||||f
17182742|NCT03019627|f||||f
17182743|NCT03364049|f||OTHER|Authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. Merck funding of a trial will be acknowledged in publications.|t
17182744|NCT02953821|f||||t
17182745|NCT02103478|f||||f
17171074|NCT00239733|f||||f
17171075|NCT03715803|f||||f
17171076|NCT01332994|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138428|NCT01135394|f||||f
17138429|NCT00462488|f||GT60||t
17171077|NCT02800863|f||OTHER|Sponsor Review. Principal investigator and Institution shall provide a copy of any abstract, presentation, journal, manuscript (written by Principal Investigator or Study Staff) and all related materials relating to the Study to Sponsor at least sixty (60) days prior to the proposed submission date.|t
17171078|NCT00279916|t||||f
17171079|NCT01807598|t||||
17171080|NCT01451385|f||||t
17171081|NCT02717494|f||||f
17171082|NCT01887184|f||||f
17171083|NCT01598922|t||||f
17171084|NCT00731679|f||GT60||t
17171085|NCT02488005|f||OTHER|There is an agreement between Principal Investigator and the Sponsor (and its agents) that allows study results to be posted to clinicaltrials.gov, and has limitations regarding PI's rights to publications and presentations.|t
17171086|NCT05431478|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17171087|NCT02326597|f||||f
17171088|NCT02286921|t||||
17171089|NCT04089761|f||||f
17171090|NCT04485546|f||OTHER|The agreement is between the Sponsor and the sites, and restricts all use of trial related content and results for the duration of the trial until contractual obligations are superseded. The Sponsor has sole rights to all trial related content and results, and all PIs must gain permission to utilize the results.|t
17171091|NCT04739436|f||||f
17171092|NCT00676013|f||||f
17171093|NCT00428948|f||||f
17171094|NCT03449758|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17171095|NCT00948753|f||||f
17171096|NCT00922623|f||OTHER|Any proposed press release, announcement, disclosure for publication, whether or not in writing, prepared by or on behalf of Consultant as part of services under this Agreement or that relates to the work performed hereunder must be reviewed and approved in writing by Merz prior to dissemination.|t
17171097|NCT01402817|t||||
17171098|NCT00181363|t||||
17171099|NCT03310723|f||||f
17171100|NCT01410890|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17171101|NCT01121146|f||OTHER|The sponsor requires at least 30 days to review and comment on manuscripts before submission. For abstracts, the time frame for review is at least 10 days before submission. The sponsor will inform the investigator of any changes deemed necessary to preserve the confidentiality of proprietary information or to ensure scientific accuracy.|t
17171102|NCT01227980|t||||f
17171103|NCT00997035|f||||f
17171104|NCT01380769|f||OTHER|The Investigator interested in participating in writing the manuscript should contact the Sponsor. The Investigsator shall not make any Study-related publication or other disclosure without the Sponsor's prior written approval, which may be withheld or granted by the Sponsor, in its sole discretion.|t
17171105|NCT02640547|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17171106|NCT01314001|f||||f
17171107|NCT02485561|f||||f
17171108|NCT02526277|f||||f
17171109|NCT02753946|f||GT60||t
17171110|NCT02519439|f||||f
17171111|NCT02412228|f||||f
17171112|NCT01126723|f||||f
17171113|NCT00837200|t||||
17171114|NCT01539759|f||||f
17171115|NCT03901144|f||OTHER|"Clause 10 of the Clinical Trial Agreement:~The Sponsor agrees that the Principal Investigator shall be permitted to present at symposia, national and regional professional meetings and to publish in journals, theses or dissertations, or otherwise of their own choosing, the methods and Results of the Clinical Trial, subject to this Clause 10 and any publication policy described in the Protocol, provided any such policy is consistent with the Joint Position."|t
17171116|NCT02491983|f||||f
17171117|NCT02714569|f||GT60||t
17171118|NCT00587678|f||||f
17182746|NCT03219333|f||||t
17182747|NCT03912753|f||||f
17182748|NCT04530552|f||LTE60||t
17171119|NCT00104650|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17171120|NCT00773513|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171121|NCT02946034|f||||f
17171122|NCT02728089|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17171123|NCT01550809|f||||f
17171124|NCT03384940|f||||f
17171125|NCT04184297|t||||t
17171126|NCT02412098|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17171127|NCT03089580|t||||
17171128|NCT03087513|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17171129|NCT00770601|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171130|NCT02506634|f||||f
17182749|NCT03748641|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17127977|NCT02483585|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17127978|NCT01485055|f||||f
17127979|NCT00912301|t||||f
17127980|NCT01324440|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127981|NCT00903630|f||||f
17127982|NCT04025580|f||||f
17171131|NCT04417361|t||||f
17171132|NCT02784171|t||||
17171133|NCT04965688|t||||
17171134|NCT05864586|f||||f
17171135|NCT00801216|t||||
17171136|NCT03213834|t||||
17171137|NCT00791908|f||||f
17171138|NCT00319254|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171139|NCT01505374|t||||
17171140|NCT02315534|f||GT60||t
17171141|NCT02452424|f||||f
17171142|NCT01463306|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171143|NCT02679287|t||||
17171144|NCT01840345|t||||
17171145|NCT04408040|f||||f
17171146|NCT02679170|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171147|NCT00992459|f||GT60||t
17182750|NCT06034496|f||OTHER|This research is funded by the U.S. Special Operations Command (SOCOM). Disclosure of research findings is subject to government operational security (OPSEC) and Public Affairs Office (PAO) review processes, in accordance with DoD Directives 5205.02E and 5230.29. As such, the Principal Investigator's ability to publicly disseminate or discuss trial results following study completion is restricted until appropriate clearances are obtained.|t
17171148|NCT00543387|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17171149|NCT00940498|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171150|NCT01943591|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than 12 months after the conclusion of the study at all sites.|t
17171151|NCT02302365|f||OTHER|Study Site reserves the right to publish the results of its work on the Study. The timing of publication however shall not exceed the 6 months after completion of the Study. Study Site and the PI agree to submit copies of any manuscript/abstract proposed for publication to Sponsor at least 30 days in advance of the presentation. Sponsor may require the delay of publication for no longer than 90 days for the purpose of filing patent applications.|t
17171152|NCT00227721|t||||f
17171153|NCT01083849|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17171154|NCT05298202|f||||f
17171155|NCT01875159|f||||f
17171156|NCT01253642|t||||
17171157|NCT01412164|f||||f
17171158|NCT01389882|f||||f
17171159|NCT03074409|f||||f
17171160|NCT04367831|t||||
17171161|NCT00381004|t||||
17171162|NCT01116401|t||||
17171163|NCT01560286|f||GT60||t
17171164|NCT01521026|f||||f
17171165|NCT00859547|f||OTHER|ZymoGenetics (ZG) agreements vary by trial, but each states that presentation/publication (p/p) cannot disclose Confidential Information (CI), excluding trial results; p/p may not begin until the earlier of 18 months after study end, ZG/lead investigator publishes, or ZG notification that multicenter publication is not planned; ZG has specified time for draft review before submission/presentation and may delay or modify content, require CI removal, and delay p/p for patent application filing.|t
17171166|NCT01302483|f||||f
17171167|NCT01364584|f||||f
17171168|NCT00669214|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171169|NCT00754377|t||||f
17171170|NCT02362321|f||||f
17171171|NCT01276639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171172|NCT01982123|t||||
17171173|NCT04363879|f||||f
17171174|NCT01822197|f||||f
17171175|NCT03999515|t||||
17171176|NCT00330759|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17171177|NCT03110471|f||||f
17171178|NCT03726489|f||||f
17171179|NCT03654690|t||||f
17171180|NCT00203229|t||||
17171181|NCT00742183|f||OTHER|The Coordinating Investigator will be the lead author for the mail (primary) publication from this Investigation. For any abstract and/or manuscript the Investigators will be given at least 14 days review time before the intended submission of the document.|t
17171182|NCT04057807|t||||
17182751|NCT04397263|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182752|NCT02377089|t||||
17171183|NCT00972335|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17171184|NCT00786799|f||||f
17171185|NCT02544503|t||||
17171186|NCT00068341|f||||f
17171187|NCT01080807|f||GT60||t
17171188|NCT02430090|f||||f
17171189|NCT01072188|f||GT60||t
17171190|NCT03922581|t||||
17171191|NCT04472611|f||||f
17171192|NCT04685798|t||||
17171193|NCT02223715|f||||f
17171194|NCT03956550|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17171195|NCT00984308|t||||
17171196|NCT01745367|f||||f
17171197|NCT00896298|f||GT60||t
17171198|NCT00287222|t||||f
17171199|NCT00824473|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.|t
17171200|NCT01359904|t||||f
17171201|NCT02660853|t||||
17171202|NCT02525588|f||LTE60||t
17171203|NCT01837277|f||||f
17182753|NCT03277261|f||||f
17182754|NCT00499603|t||||f
17182755|NCT05179421|f||||f
17182756|NCT00792610|f||||f
17182757|NCT03473743|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182758|NCT04521166|t||||
17182759|NCT06431061|f||||f
17182760|NCT02614547|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182761|NCT02052739|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182762|NCT05267054|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17182763|NCT01552226|f||||f
17182764|NCT04697628|f||||t
17182765|NCT03604692|f||||t
17182766|NCT00006184|f||||f
17182767|NCT00087633|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171204|NCT03018691|f||||f
17171205|NCT01433016|f||LTE60||t
17171206|NCT03369418|t||||
17171207|NCT01495286|t||||
17171208|NCT00796666|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171209|NCT03174366|f||||f
17171210|NCT00057863|f||LTE60||t
17171211|NCT01521507|f||OTHER|Sponsor can review communications for at least 30 days prior to public release with an extension for up to 45 additional days, if the Sponsor notifies the Investigator that the publication contains patentable material or Proprietary Information other than the study results. Upon Sponsor's written request, Investigator agrees to delete any Proprietary Information.|t
17171212|NCT01479868|f||LTE60||t
17171213|NCT01292187|f||||f
17171214|NCT00195039|t||||
17171215|NCT00113841|t||||f
17171216|NCT00488488|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171217|NCT02721875|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17171218|NCT00430716|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171219|NCT01433172|t||||
17171220|NCT03890588|t||||f
17171221|NCT00214539|f||LTE60||t
17171222|NCT03116685|f||OTHER|The investigator may not publish the results of their cohort of subjects until the full study has been submitted for publication. They may not submit for publication or present the results of this study without allowing OxThera 30 days in which to review and comment on the pre-publication manuscript. The investigator may not submit the results of the study for publication without the prior consent of OxThera, unless the review period has passed and there has been no reaction from the sponsor.|t
17171223|NCT01045694|t||||
17171224|NCT01150097|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17171225|NCT02919072|f||||f
17171226|NCT02719171|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17171227|NCT02796677|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17171228|NCT00961181|f||LTE60||t
17171229|NCT03811340|t||||
17171230|NCT01045967|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17171231|NCT00769886|f||OTHER|Contact sponsor directly for details.|t
17171232|NCT04662359|f||||f
17171233|NCT02960516|f||||f
17171234|NCT03477396|t||||
17171235|NCT01485094|f||OTHER|Joint publications are only possible if both parties agree. All editorial decisions will be jointly taken by the sponsor and the international coordinating investigator. The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17171236|NCT02576639|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17171237|NCT02079038|f||GT60||t
17171238|NCT02478463|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171239|NCT01290614|f||||f
17171240|NCT01358825|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171241|NCT01825187|f||||f
17171242|NCT01508169|f||||f
17171243|NCT03600740|t||||
17182768|NCT01110915|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17182769|NCT03985813|t||||
17182770|NCT02161718|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance|t
17182771|NCT02151526|f||LTE60||t
17171244|NCT01814527|t||||
17171245|NCT04524858|f||||f
17171246|NCT03571204|t||||
17171247|NCT02396212|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17171248|NCT01363700|f||||f
17171249|NCT01155336|t||||f
17171250|NCT02119871|t||||
17171251|NCT05065905|f||||f
17171252|NCT05202418|t||||
17171253|NCT00675909|t||||
17171254|NCT01329978|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17171255|NCT02952365|t||||
17171256|NCT03324802|t||||
17171257|NCT01887132|t||||
17171258|NCT00287716|f||OTHER||t
17171259|NCT02021669|t||||f
17171260|NCT04170543|f||||f
17171261|NCT04303559|f||||f
17171262|NCT01987102|f||OTHER|At least 30 d prior to submission the PI shall provide the Sponsor with results communication for review. The Sponsor shall notify the PI in writing about the review outcome within 30 d from receipt. No public release shall be made unless the Sponsor has consented in writing. The Sponsor may notify the PI that the material shall be withhold from submission for 90 days more to allow filing of applications to secure IPR or to take such measures to establish and preserve its proprietary rights.|t
17171263|NCT00592488|f||||f
17171264|NCT04037891|f||GT60||t
17171265|NCT03446313|t||||
17171266|NCT05274958|f||||f
17171267|NCT05481359|f||||f
17171268|NCT03066063|t||||
17171269|NCT04491136|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17171270|NCT01611194|f||||f
17171271|NCT01857297|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171272|NCT00452790|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171273|NCT02918357|t||||f
17171274|NCT00348673|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182772|NCT00207142|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17171275|NCT01712204|f||LTE60||t
17182773|NCT01857063|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17171276|NCT02110095|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17171277|NCT00386243|t||||f
17171278|NCT02781610|f||||f
17171279|NCT01114828|f||||f
17171280|NCT00549445|t||||f
17171281|NCT04437485|f||||f
17171282|NCT04456634|f||||f
17171283|NCT01848158|f||||f
17171284|NCT03790111|f||||f
17171285|NCT01432405|t||||
17171286|NCT02467179|f||||f
17171287|NCT03798717|t||||
17171288|NCT00942903|f||||f
17171289|NCT02752880|t||||
17171290|NCT01777308|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171291|NCT03410628|f||LTE60||t
17171292|NCT03212326|f||LTE60||t
17171293|NCT03430791|f||||f
17171294|NCT02918617|f||||f
17171295|NCT00985673|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171296|NCT05736874|f||||f
17171297|NCT00984256|t||||
17171298|NCT03057496|f||||f
17171299|NCT00280917|f||||f
17171300|NCT01307319|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17171301|NCT03689582|t||||
17171302|NCT02372877|f||||t
17171303|NCT01731912|t||||
17171304|NCT02222558|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment and provide written permission prior to publication.|t
17171305|NCT03400852|f||||t
17171306|NCT00936702|f||LTE60||t
17171307|NCT02532465|t||||
17171308|NCT00622505|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171309|NCT00411749|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171310|NCT00965081|f||LTE60||t
17171311|NCT00964496|t||||
17171312|NCT02541812|t||||f
17171313|NCT01147666|f||||t
17171314|NCT02159066|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171315|NCT00474955|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171316|NCT01135134|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The Sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17171317|NCT00631358|f||OTHER|The sponsor shall be furnished with copies of any proposed disclosure as follows: Published abstracts will be submitted to the sponsor one month prior to submission allowing the sponsor three weeks to respond. Presentations will be submitted to the sponsor one moth prior to submission allowing the sponsor three weeks to respond. Publications will be submitted to the sponsor two months prior to submission allowing the sponsor two months to respond.|t
17171318|NCT02254473|t||||
17171319|NCT00256724|f||||f
17171320|NCT02197702|f||||f
17182774|NCT00531843|t||||
17171321|NCT01569841|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17171322|NCT00706446|t||||f
17182775|NCT04115358|f||||f
17171323|NCT01859923|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17171324|NCT00429949|t||||
17171325|NCT03148613|t||||
17171326|NCT02878317|t||||
17171327|NCT00764361|f||LTE60||t
17171328|NCT02090426|f||||f
17171329|NCT02462148|t||||
17171330|NCT01141712|f||||f
17171331|NCT01308736|f||||f
17171332|NCT03634085|f||OTHER|The PI shall have no right to publish the Research Output, without the Customer's prior written consent. The Parties make their best efforts to reach an agreement on the issue of conditions of the publication of the Reseach Output. In case of repeated disagreement, Customer shall be the sole Party to decide in its capacity of Sponsor under what conditions and release period the Research Output should be published.|t
17171333|NCT04458909|f||LTE60||t
17171334|NCT03246789|t||||f
17171335|NCT00296816|f||OTHER|"The sponsor encourages the publication of the results of their studies, using only clean, checked and validated data in order to ensure the accuracy of the results.~At least 45 days in advance of proposed submission, the Investigator should forward a copy of the manuscript or abstract for review by the sponsor, and, if necessary, delay publication or communication for a limited time in order to protect the confidentiality or proprietary nature of any information contained therein."|t
17171336|NCT01556451|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17171337|NCT00945282|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171338|NCT00985465|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171339|NCT03101566|t||||
17171340|NCT04701333|t||||
17171341|NCT01012258|f||OTHER|All submissions by the PI for publication require the written permission from the sponsor. The PI commits to forward to the sponsor all documents intended for publication which contains data or results generated in connection with the study. Documents must be available at least 60 days before the planned submission date to allow for review. Any publication should follow the policy in the protocol. The PI shall not publish results derived from the study until the study has been reported in full.|t
17171342|NCT03742973|f||GT60||t
17171343|NCT02109640|t||||
17171344|NCT02230566|f||GT60||t
17171345|NCT03507036|f||||f
17171346|NCT00580723|f||||f
17171347|NCT00148759|t||||
17171348|NCT01454596|f||||f
17171349|NCT00857285|f||||f
17171350|NCT00895284|t||||f
17171351|NCT04532034|f||||f
17171352|NCT01236521|t||||
17171353|NCT03492125|f||||f
17171354|NCT02756572|t||||
17171355|NCT03628976|f||||f
17171356|NCT01137370|t||||
17171357|NCT00350844|t||||
17171358|NCT01420926|f||LTE60||t
17171359|NCT00932321|f||LTE60||t
17171360|NCT02775916|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17171361|NCT02252146|f||||t
17171362|NCT00531284|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17171363|NCT00291135|t||||
17171364|NCT02219464|t||||
17171365|NCT02040623|f||||f
17171366|NCT03270943|t||||
17171367|NCT02981368|f||OTHER|Study results cannot be published before the earlier of a multi-site publication; or 18 months after the end of the Study at all sites; or confirmation by Sponsor that there will be no multi-site publication. The proposed publication must be submitted to Sponsor at least 60 days prior to publication so that Sponsor can delete Sponsor Confidential Information (other than Study results) and obtain a further 60 days to file on any invention disclosed in the proposed publication.|t
17171368|NCT01459588|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171369|NCT02544321|t||||
17171370|NCT01584232|f||GT60||t
17171371|NCT03347123|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17171372|NCT01132807|f||LTE60||t
17171373|NCT00763412|f||||f
17171374|NCT00178477|t||||f
17171375|NCT02043938|f||GT60||t
17171376|NCT00248495|t||||
17171377|NCT03812380|t||||
17171378|NCT01285401|f||OTHER||t
17171379|NCT00659802|f||||f
17171380|NCT00494585|t||||
17127983|NCT02325557|f||OTHER|The Investigator shall seek the Sponsor's written approval for study results publication which shall not be unreasonably withheld. Such publication by Institution and/or Investigator may be no earlier than after a cooperative publication has been published with Sponsor or 1 year from date of completion or termination of the Study \& only after review and comment by Sponsor. Institution agrees to provide Sponsor a copy of proposed publication at least 60 days prior to submission to a publisher.|t
17171381|NCT01507688|t||||
17171382|NCT02163824|f||OTHER|"The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:~(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial."|t
17171383|NCT02366312|f||||f
17171384|NCT00790192|f||||f
17171385|NCT04115384|t||||
17182776|NCT01205165|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171386|NCT00354679|t||||
17171387|NCT03719131|t||||
17171388|NCT01544920|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17171389|NCT00466440|f||GT60||t
17171390|NCT01839058|f||||f
17171391|NCT03294590|t||||
17171392|NCT01844388|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171393|NCT00255190|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17171394|NCT02513121|f||||f
17171395|NCT02609308|f||||f
17171396|NCT03367858|t||||
17182777|NCT04352140|t||||
17182778|NCT03306264|f||||f
17182779|NCT00458484|t||||
17171397|NCT01303939|f||||f
17171398|NCT01217463|f||OTHER|PI have no implicit or explicit rights to publish study data and results of their services.|t
17171399|NCT01623115|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17171400|NCT03827655|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17171401|NCT00961311|f||OTHER|Investigator and or Participating lnstitution may publish the results of work performed in accordance with the Publication Strategy described in the Clinical Investigational Plan; provided, however, that any such publication or presentation shall be at a time determined by Medtronic and shall be provided to Medtronic for review at least 60 days prior to submission or presentation, for a determination by Medtronic of whether Confidential lnformation is disclosed.|t
17127984|NCT00138671|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17127985|NCT01488487|t||||
17127986|NCT02534038|f||OTHER||t
17138430|NCT00927758|f||OTHER|The terms and conditions of Sandoz's agreements with its investigators may vary. However, Sandoz does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17138431|NCT03125018|t||||
17138432|NCT03030183|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's right to discuss or publish trial results after the trial is completed. Disclosure agreements are negotiated separately with each PI|t
17138433|NCT03788616|t||||
17171402|NCT01721161|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17171403|NCT00434226|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.|t
17182780|NCT04538664|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182781|NCT04136912|t||||
17182782|NCT02448875|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17182783|NCT05093426|f||||f
17182784|NCT03390504|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17182785|NCT03508219|f||||f
17182786|NCT05711927|t||||
17182787|NCT02782949|f||LTE60||t
17182788|NCT05645432|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17182789|NCT03370341|f||||f
17182790|NCT02307552|f||||f
17182791|NCT00634647|f||||f
17182792|NCT02984020|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclosure previously undisclosed confidential information other than study results.|t
17182793|NCT02610868|t||||
17182794|NCT01700179|f||OTHER|Prior to submitting/presenting a manuscript or materials relating to a Study to a publisher, reviewer, or outside person, the Institution shall provide to Sponsor a copy of all such manuscripts or materials, and Sponsor shall have thirty (30) days to review and comment. The Institution shall, upon Sponsor's request, further delay publication or presentation for a period of up to sixty (60) days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17182795|NCT00667342|t||||
17182796|NCT05220397|t||||
17138434|NCT00212758|f||LTE60||t
17182797|NCT05091528|f||||t
17127987|NCT01136772|f||||f
17127988|NCT02943226|t||||
17127989|NCT02354443|f||||t
17127990|NCT02996565|f||||f
17127991|NCT01602562|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17127992|NCT03881553|f||||f
17127993|NCT01849822|f||||t
17138435|NCT01673490|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182798|NCT04958109|f||||f
17182799|NCT00835497|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17127994|NCT01959516|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17182800|NCT01573624|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182801|NCT05435885|f||||f
17182802|NCT02353247|f||||f
17182803|NCT02445027|f||||f
17182804|NCT03037528|f||||f
17171404|NCT02052544|f||OTHER|Any proposed publication, lecture, manuscript, poster presentation or other disclosure or dissemination of the data or Results of this study by PI shall be submitted to DSM at least forty-five (45) days prior to its submission for publication or use for DSM's review, comment and approval. DSM reserves the right to have deleted from the proposed text all of DSM's Confidential Information which may be contained therein. DSM's comments shall be provided without undue delay.|t
17171405|NCT02888106|f||LTE60||t
17171406|NCT01894607|t||||
17171407|NCT00431626|f||||f
17171408|NCT02673918|f||||f
17171409|NCT02927392|f||||f
17171410|NCT00512876|f||OTHER|"All materials that reflects the WRAMC affiliation must be approved and properly cleared before the material is submitted for public dissemination and publication. All publications whereby WRAMC is cited in the bylines will state on the cover page the following sample disclaimer: The views expressed in this \[article, book chapter, speech, presentation, etc.\] are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or U.S. Government."|t
17171411|NCT01708317|f||||f
17171412|NCT02401347|f||||f
17171413|NCT02354534|f||||f
17171414|NCT03259555|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17171415|NCT04393493|f||||f
17171416|NCT01125800|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single--site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171417|NCT00055692|f||LTE60||t
17171418|NCT01168726|f||||f
17171419|NCT04332107|f||||f
17171420|NCT02348593|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17171421|NCT01670721|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17171422|NCT00271102|f||||f
17171423|NCT04970654|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17171424|NCT05524220|t||||
17171425|NCT06319898|t||||
17171426|NCT04894669|f||||f
17171427|NCT05579977|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171428|NCT00866814|f||GT60||t
17171429|NCT01063153|f||OTHER|Brain Network Analysis \[the primary analysis of EEG data related to BAFPA (Brain Activity Flow Patterns Analysis) and functional connectivity networks\] is still in progress by the Sponsor, and there is an agreement between the Sponsor and the Principal Investigator preventing the PI from disclosing EEG results from this trial until the data has been published. We are, however, at liberty to report adverse events from the open-label clinical trial and have done so here.|t
17171430|NCT02614729|f||||f
17171431|NCT01232868|f||||f
17171432|NCT02539797|f||||f
17171433|NCT01139814|f||LTE60||t
17171434|NCT04002960|t||||
17171435|NCT01609348|t||||
17171436|NCT00865345|f||GT60||t
17171437|NCT00383786|f||||f
17171438|NCT00246519|f||||f
17171439|NCT01517750|f||||f
17171440|NCT02723773|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17171441|NCT03629886|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17182805|NCT01188603|f||OTHER|Any publication of the result of this trial must be consistent with the Sprout Pharmaceuticals publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17171442|NCT00404651|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17171443|NCT00666666|f||LTE60||t
17171444|NCT00346216|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171445|NCT05098028|f||OTHER|Please contact sponsor for details.|t
17171446|NCT01220167|t||||
17171447|NCT02341235|f||||f
17171448|NCT05200143|t||||
17171449|NCT00619515|t||||
17171450|NCT02493036|f||OTHER|Investigators do not see trial results ahead of public disclosure unless it is under CDA. Investigators will not be allowed to publish or disclose any study results prior to sponsor communicating it to the public.|t
17171451|NCT02420093|f||||f
17171452|NCT04862065|f||OTHER|The PI must provide a copy of any proposed publication/presentation at least 60 days prior to submission for sponsor's review/approval. The PI must incorporate changes as the sponsor requires in order to protect the sponsor's proprietary rights and interests. The sponsor may require the PI to include acknowledgement of the sponsor's role in the study. The PI may be requested to delay publication/presentation an extra 60 days to enable sponsor to secure patent or other proprietary protection.|t
17171453|NCT02525653|t||||
17171454|NCT03170661|t||||
17171455|NCT03244917|f||||f
17171456|NCT03001557|f||||f
17171457|NCT01272232|f||OTHER|Novo Nordisk reserves the right not to release data until specified milestones are available. This includes the right not to release interim results from clinical trials, as such results may lead to conclusions that are later proven incorrect. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to briefly postpone publication or communication to protect intellectual property.|t
17171458|NCT02531217|f||||t
17171459|NCT04140396|t||||
17171460|NCT01960140|f||GT60||t
17171461|NCT00628030|t||||f
17171462|NCT03392935|t||||
17171463|NCT01156480|t||||
17171464|NCT01176058|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171465|NCT04276233|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17171466|NCT01946139|f||||f
17171467|NCT01191723|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171468|NCT02525471|t||||f
17171469|NCT00890825|f||LTE60||t
17171470|NCT02336607|f||||f
17171471|NCT02643459|f||||f
17171472|NCT01216202|t||||
17171473|NCT00230126|f||LTE60||t
17171474|NCT01775774|f||||f
17171475|NCT00271375|t||||
17171476|NCT02365649|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17171477|NCT03483896|f||||f
17171478|NCT02314936|t||||
17171479|NCT03476135|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17171480|NCT01188772|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17182806|NCT02257736|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17171481|NCT04388254|f||||t
17171482|NCT00066677|t||||f
17171483|NCT03370718|t||||
17171484|NCT04106609|t||||
17171485|NCT03863509|f||||f
17171486|NCT03095248|t||||
17171487|NCT01572480|f||||f
17182807|NCT00308711|f||||f
17182808|NCT02167256|f||||f
17182809|NCT04590495|f||||f
17182810|NCT00414388|t||||
17182811|NCT03591575|f||LTE60||t
17182812|NCT01723228|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17171488|NCT06172348|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171489|NCT00191334|f||GT60||t
17171490|NCT02647723|f||||f
17171491|NCT02831764|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171492|NCT04564846|f||GT60||t
17171493|NCT02735239|f||||f
17171494|NCT02041325|f||||f
17171495|NCT02038153|t||||
17171496|NCT03016312|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171497|NCT01050634|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171498|NCT00496015|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171499|NCT00527735|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17171500|NCT01535807|f||||f
17171501|NCT01590979|t||||
17171502|NCT02730728|t||||
17171503|NCT01855412|f||LTE60||t
17171504|NCT01293825|f||||f
17171505|NCT02785185|f||OTHER|Contact sponsor directly for details.|t
17171506|NCT00934635|f||OTHER|"Publication of study data will be coordinated by the Sponsor, but written by the Investigator.~The Medical Institution will not be entitled to publish any data unless the Sponsor has received the manuscript within 3 months after the Clinical Study Report for review (within 30 days) to ensure that the publication does not reveal secret information. If the Sponsor suggests changes, these changes must be incorporated unless they compromise the scientific nature of the publication."|t
17171507|NCT01702844|t||||
17171508|NCT02123134|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171509|NCT03431441|f||GT60||t
17171510|NCT00904813|t||||
17171511|NCT00914186|f||GT60||t
17171512|NCT02271698|t||||
17171513|NCT00764699|t||||
17171514|NCT03788057|f||||f
17171515|NCT03985761|f||||f
17171516|NCT01755234|t||||
17171517|NCT00303823|f||LTE60||t
17171518|NCT02322281|f||OTHER|All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.|t
17171519|NCT05757648|t||||
17171520|NCT03518294|t||||
17171521|NCT05789745|f||||f
17171522|NCT03232346|f||||f
17171523|NCT03650088|t||||f
17171524|NCT05470387|f||||f
17171525|NCT03275740|f||GT60||t
17171526|NCT03880058|f||||f
17171527|NCT00687401|f||OTHER|No specific time period restrictions. If the parties disagree concerning the accuracy and appropriateness of the data analysis and presentation, and/or confidentiality of information, the Sponsor and the Investigator will make good faith efforts to resolve any issues or disagreement.|t
17171528|NCT02920892|f||LTE60||t
17171529|NCT04486235|f||||f
17171530|NCT03935126|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17171531|NCT03649217|f||||f
17171532|NCT02520726|t||||
17171533|NCT01092728|t||||
17171534|NCT02552966|f||||f
17171535|NCT00721396|f||GT60||t
17171536|NCT00226590|f||||f
17171537|NCT01091675|f||OTHER||t
17171538|NCT00614380|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17171539|NCT03435185|t||||
17171540|NCT04142034|f||||f
17171541|NCT03865446|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182813|NCT00218543|t||||
17182814|NCT01864291|t||||f
17171542|NCT04875806|f||OTHER|PI cannot publish study results before the first multi-center publication. If a multi-center publication is not submitted within 12 months after the end of the study at all sites, or if Sponsor confirms there will be no multi-center publication, the PI may publish study results. However, PI will allow Sponsor at least 30 days to review any publication of study results and Sponsor may request an additional 60 days to review the publication.|t
17171543|NCT02021565|t||||
17171544|NCT03318549|t||||f
17171545|NCT02303093|f||||f
17171546|NCT02021942|t||||
17171547|NCT00510835|f||||f
17171548|NCT02870283|f||||f
17171549|NCT00607087|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17171550|NCT00700440|f||LTE60||t
17171551|NCT00650767|f||OTHER|The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in the clinical trial.|t
17171552|NCT01774799|f||||f
17171553|NCT02586623|f||||f
17171554|NCT02910466|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17171555|NCT04037865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171556|NCT00965250|f||||f
17171557|NCT02221869|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17171558|NCT01808196|t||||
17171559|NCT00479713|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171560|NCT00141102|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171561|NCT00410956|t||||
17171562|NCT03400475|t||||
17171563|NCT01871519|f||LTE60||t
17171564|NCT00794950|t||||
17171565|NCT02485704|f||OTHER|Site may not publish or publicly present Study results. If Sponsor has given its prior written consent to the Site to publish or present Study results, Site will provide Sponsor with a copy of any proposed oral or written publication to at least sixty (60) days in advance of submission for publication or presentation for review and comment on the appropriateness of the data analysis and presentation. The terms of this paragraph shall survive expiration or termination of this Agreement.|t
17171566|NCT02649556|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17171567|NCT04481243|t||||
17171568|NCT02413918|f||||f
17171569|NCT02173769|t||||
17171570|NCT04388111|f||||f
17171571|NCT00928486|f||OTHER|Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17171572|NCT01342913|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171573|NCT05295849|f||||f
17171574|NCT02682381|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonmentor termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17171575|NCT00387881|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the Publication of results from all centers of a multi-center trial but requests that reports based on Single-site data not precede the primary publication of the entire clinical trial.|t
17171576|NCT00453154|f||LTE60||t
17171577|NCT02719535|f||||f
17171578|NCT01790594|f||||f
17171579|NCT03052101|f||||f
17171580|NCT03291067|f||OTHER||t
17171581|NCT02152631|f||GT60||t
17171582|NCT05473026|t||||f
17171583|NCT03776747|f||||f
17171584|NCT00905450|f||OTHER|Contact sponsor directly for details.|t
17171585|NCT03683173|t||||
17138436|NCT00379236|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17171586|NCT02210000|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171587|NCT01378988|f||||f
17171588|NCT01329263|t||||f
17171589|NCT01366872|f||||f
17171590|NCT00308139|f||LTE60||t
17138437|NCT02940860|f||OTHER|Institution may publish the study results. Before submission for publication or presentation, Institution shall allow Sponsor not less than 90 days to review any manuscript and not less than 30 days to review any poster presentation, abstract, or any other written or oral material which describes or discloses the study results. If sponsor so requests in writing, Institution shall withhold any publication or presentation for an additional 90 days.|t
17171591|NCT02152826|f||OTHER|Written consent from Sponsor|t
17171592|NCT00833040|f||OTHER|No publication without prior written consent|t
17171593|NCT02313766|t||||
17171594|NCT01893801|f||||f
17171595|NCT02193776|f||OTHER|The Investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting for review and removal of confidential information.|t
17171596|NCT01169103|f||||f
17171597|NCT01458639|f||||f
17171598|NCT01884077|f||||f
17171599|NCT00981149|f||||f
17171600|NCT02648204|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17171601|NCT02634333|f||||f
17171602|NCT01794000|f||GT60||t
17171603|NCT02748863|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17171604|NCT04537793|f||||t
17171605|NCT01255423|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17171606|NCT03831477|f||||f
17171607|NCT00657046|f||GT60||t
17171608|NCT01858363|f||||t
17138438|NCT04914819|t||||
17171609|NCT03004365|f||||t
17171610|NCT01619839|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17171611|NCT03480152|f||||f
17171612|NCT00101686|f||OTHER||t
17171613|NCT00867165|f||OTHER|The investigator agreed not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17171614|NCT02738008|f||||f
17171615|NCT02972931|f||LTE60||t
17171616|NCT03550378|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17171617|NCT00468299|f||||f
17171618|NCT03546621|f||LTE60||t
17171619|NCT00646646|t||||
17171620|NCT00377520|f||GT60||t
17171621|NCT02111447|f||||f
17171622|NCT02570503|t||||
17171623|NCT00462306|t||||
17171624|NCT01623479|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171625|NCT00154297|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17171626|NCT06098937|t||||
17171627|NCT05051579|f||GT60||t
17171628|NCT00990106|f||||f
17171629|NCT01650194|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17171630|NCT04388683|f||||f
17171631|NCT00880698|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17171632|NCT01663012|f||||f
17171633|NCT01855360|f||||t
17171634|NCT04158583|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171635|NCT00320515|f||GT60||t
17127995|NCT01477333|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed, except as provided below. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17171636|NCT01777776|f||OTHER|The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in the clinical trial.|t
17171637|NCT00851786|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17171638|NCT03737123|f||||f
17171639|NCT04290039|f||||f
17171640|NCT04046328|f||OTHER|Publication of the study results by the Investigator, the Center and by any member of the Investigational Team shall require a prior express approval of Pharmascience in writing.|t
17171641|NCT04104256|t||||
17171642|NCT01650298|f||||f
17127996|NCT02501538|f||||f
17127997|NCT02316366|t||||
17127998|NCT01765465|f||||f
17127999|NCT00928746|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128000|NCT01804062|f||||f
17128001|NCT02955147|f||||f
17128002|NCT04129216|f||||f
17128003|NCT02004353|f||||f
17128004|NCT01691768|f||||f
17128005|NCT02581631|f||LTE60||t
17128006|NCT00819390|f||||f
17128007|NCT01759368|f||||f
17128008|NCT01651442|f||||f
17128009|NCT01191268|f||GT60||t
17128010|NCT00700973|t||||
17128011|NCT01270971|f||OTHER|Institution or Principal Investigator may only publish Study results after: (i) the results of the multicenter Study in its entirety have been publicly disclosed by the Sponsor in an abstract, manuscript or presentation form, or (ii) two (2) years after conclusion of the Study at all sites, whichever is first to occur.|t
17128012|NCT02411357|f||||f
17128013|NCT01588496|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128014|NCT02791945|t||||f
17128015|NCT03333837|f||||f
17128016|NCT00705523|t||||f
17128017|NCT01911065|f||||f
17128018|NCT01013285|f||||f
17128019|NCT02003573|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128020|NCT03324451|f||||f
17138439|NCT03961295|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17138440|NCT00233324|f||||f
17128021|NCT00803751|f||||f
17128022|NCT02640157|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17128023|NCT04677179|f||GT60||t
17138441|NCT02683707|f||||f
17138442|NCT00662389|f||LTE60||t
17182815|NCT01451424|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17182816|NCT00689481|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182817|NCT02254278|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17182818|NCT04413929|f||||t
17182819|NCT04745689|f||||t
17182820|NCT03091192|f||||f
17182821|NCT04953442|f||||f
17182822|NCT01038778|f||LTE60||t
17182823|NCT04487080|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17171643|NCT04233801|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17182824|NCT03195478|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17182825|NCT05648565|t||||
17182826|NCT05346406|f||||f
17182827|NCT01677195|f||||f
17182828|NCT01706952|t||||f
17182829|NCT02472756|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182830|NCT01532362|f||||f
17182831|NCT02453113|f||||f
17182832|NCT00110266|f||||t
17171644|NCT04755816|f||||f
17171645|NCT02792231|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171646|NCT05196828|f||||f
17171647|NCT02469623|f||||f
17171648|NCT04073186|f||GT60||t
17171649|NCT01096316|t||||
17171650|NCT02763644|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17171651|NCT02836652|f||||f
17171652|NCT00473434|f||LTE60||t
17182833|NCT02896400|t||||
17182834|NCT01207778|f||||f
17171653|NCT02349633|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171654|NCT00558246|f||LTE60||t
17171655|NCT01008943|f||GT60||t
17171656|NCT05552027|f||||f
17182835|NCT00646204|f||LTE60||t
17182836|NCT02582840|f||OTHER||t
17182837|NCT02492451|t||||
17182838|NCT00298896|f||GT60||t
17182839|NCT01221441|f||||f
17182840|NCT02649972|t||||
17182841|NCT01845155|t||||
17182842|NCT02665481|f||||f
17182843|NCT03285646|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17182844|NCT04016324|f||||f
17182845|NCT00503841|t||||f
17128024|NCT02374671|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~The Sponsor encourages publication and presentation of the safety and effectiveness results upon completion of the study. Per the established agreement, the Principal Investigators will work with the Sponsor, in good faith, to ensure all confidential and proprietary information is redacted."|t
17128025|NCT00462332|f||||f
17128026|NCT03866473|f||||f
17128027|NCT03110185|f||||f
17128028|NCT00600886|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17128029|NCT02523599|f||OTHER||t
17128030|NCT01427751|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171657|NCT01453140|t||||
17171658|NCT02611479|f||||f
17171659|NCT00743249|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17171660|NCT03936608|f||||f
17171661|NCT01332123|t||||
17171662|NCT00423657|f||||f
17171663|NCT02795117|f||OTHER||t
17171664|NCT02653326|f||||f
17171665|NCT02422498|t||||
17171666|NCT03206216|f||||f
17171667|NCT01582061|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171668|NCT04177706|t||||
17171669|NCT04698343|f||||f
17171670|NCT01054456|f||OTHER||t
17171671|NCT04621448|t||||f
17138443|NCT01783470|f||||f
17138444|NCT01510834|f||||f
17138445|NCT03276572|t||||
17138446|NCT01709708|f||||f
17138447|NCT00527072|f||GT60||t
17138448|NCT00810043|f||LTE60||t
17138449|NCT01989754|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17138450|NCT01659268|f||||f
17171672|NCT02519023|t||||
17171673|NCT04590014|f||||f
17171674|NCT01506271|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17171675|NCT03040141|f||OTHER|"The institution may not publish study results until publication of the results of the full study or 2 years after study completion.~The institution must provide a copy of any proposed publication to the Sponsor at least 40 days in advance~The Sponsor may:~1. provide comments on the proposed publication;~2. request delay of the publication for 120 days;~3. request that specified confidential information be removed"|t
17171676|NCT01391663|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17171677|NCT03515824|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17171678|NCT01384734|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171679|NCT00920855|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17171680|NCT01290523|f||||f
17171681|NCT00539994|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171682|NCT03071263|f||OTHER|"1. No Confidential Information will be disclosed, excluding CT results from Institution~2. No publication shall be initiated by PI until:~   * 18 months after the conclusion of the Study, defined as the locking of the clinical database~  * the publication of a Multicenter Publication (publication of results from all participating sites)~  * written notice from Sponsor that no Multicenter Publication shall ensue~3. PI shall provide a draft of proposed publication for review at least 60 days in advance"|t
17171683|NCT03084796|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17171684|NCT05470985|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17171685|NCT01917747|f||||f
17171686|NCT02741245|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17171687|NCT01685567|f||||f
17171688|NCT02997501|f||||f
17171689|NCT01787461|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171690|NCT00152503|f||GT60||t
17171691|NCT02922725|f||||f
17171692|NCT01300234|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171693|NCT03253679|f||LTE60||t
17171694|NCT04816214|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138451|NCT01498588|t||||
17138452|NCT03364491|f||||t
17171695|NCT00550407|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171696|NCT00584415|t||||
17171697|NCT04487106|t||||
17171698|NCT00717249|f||GT60||t
17171699|NCT00360412|f||||f
17171700|NCT00871871|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17171701|NCT02093793|f||||t
17171702|NCT02511379|f||||t
17171703|NCT03741088|f||OTHER|The results or conclusions of this study will be reported at scientific congresses and published in scientific journals. The investigator agrees to maintain this information in strict confidence, and will not use it for any other purpose without the written authorization of the sponsor.|t
17171704|NCT03064490|f||||f
17171705|NCT01928927|f||||f
17171706|NCT03043885|f||||f
17171707|NCT03439280|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17171708|NCT01147042|t||||
17171709|NCT01419795|t||||
17171710|NCT01391364|f||OTHER|Contact sponsor directly for details.|t
17171711|NCT02421172|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17171712|NCT00915954|t||||
17171713|NCT00683878|f||||f
17171714|NCT03112681|f||||f
17171715|NCT02869633|t||||
17171716|NCT04024891|f||||f
17171717|NCT01421017|t||||
17171718|NCT03489863|f||||f
17171719|NCT02754570|f||||f
17171720|NCT00962208|t||||
17171721|NCT00791388|f||OTHER|Data, calculations, interpretations, opinions, and recommendations are the property of P\&GP. In the event study results are published in the scientific literature by P\&GP, acknowledgment will be made to the Investigator(s) in the accepted style, as appropriate.|t
17171722|NCT02995980|f||||f
17171723|NCT01173016|t||||f
17171724|NCT00657540|f||||f
17171725|NCT03714178|f||||f
17171726|NCT03010527|f||GT60||t
17171727|NCT02656017|f||||f
17171728|NCT02681809|f||OTHER|Sponsor has the right to the 1st publication of the Study results (multi-center publication). Following the 1st publication, PI may publish Study Results. Before submission for publication, Sponsor will be allowed 60 days for review. Sponsor may request to withhold the publication for an additional 60 days. Sponsor reserves the right to remove Confidential Information from the publication and withhold publication if this is not sufficient to protect Intellectual Property Rights.|t
17171729|NCT04245111|f||||f
17171730|NCT04392739|f||OTHER||t
17171731|NCT04175730|f||||f
17171732|NCT03309878|f||LTE60||t
17171733|NCT03679975|f||GT60||t
17171734|NCT03192176|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17171735|NCT00667628|f||||t
17171736|NCT04244253|f||||f
17171737|NCT04663321|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17171738|NCT05108246|t||||
17171739|NCT03532542|f||OTHER||t
17171740|NCT01962441|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17171741|NCT02055898|t||||
17171742|NCT01441843|t||||
17171743|NCT01500772|f||OTHER||t
17171744|NCT02314052|f||OTHER|SPONSOR agrees that the Principal Investigator shall have the right to publish or permit the publication of any information or material relating to or arising out of the work after prior submittal to SPONSOR provided that if SPONSOR shall so request, the investigator will delay publication for a maximum of ninety (90) days after submittal to SPONSOR to enable SPONSOR to protect its rights. SPONSOR will comment on such documents within thirty (30) days.|t
17171745|NCT00117637|f||OTHER|Publication will be discussed with the sponsor prior to release and written consent of the sponsor will be obtained. A draft manuscript of the publication or abstract must be sent to sponsor thirty days in advance of submission.|t
17171746|NCT01620060|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17171747|NCT00231777|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171748|NCT00702468|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17171749|NCT04551989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17171750|NCT02756338|f||OTHER|Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period another 90 days to file patent applications to take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.|t
17171751|NCT04309110|f||||f
17171752|NCT00088530|f||LTE60||t
17171753|NCT04864249|t||||f
17171754|NCT00300755|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17171755|NCT03192826|f||||f
17171756|NCT02694744|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17171757|NCT00686777|f||||f
17171758|NCT01945021|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171759|NCT03582215|f||||f
17171760|NCT02163902|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171761|NCT03119259|f||||f
17171762|NCT00983346|t||||
17171763|NCT00003468|f||||f
17171764|NCT02903160|f||LTE60||t
17171765|NCT01838317|t||||
17171766|NCT01664910|t||||
17171767|NCT02374164|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17171768|NCT00730158|t||||
17171769|NCT04678115|f||||f
17171770|NCT01168349|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171771|NCT04059549|t||||
17171772|NCT02639494|f||||f
17171773|NCT00988884|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17171774|NCT01632020|t||||
17171775|NCT04368260|t||||
17128031|NCT05330312|f||OTHER|"The primary publication should be published by the sponsor prior to any other investigator-initiated publications, manuscripts, abstracts, or presentations.~The results of this clinical investigation may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission."|t
17138453|NCT01369225|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138454|NCT02980692|f||OTHER||t
17138455|NCT01788150|f||||f
17138456|NCT00064077|f||LTE60||t
17138457|NCT02291445|f||||f
17138458|NCT05097157|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17171776|NCT01362348|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171777|NCT02851303|f||||f
17171778|NCT00647296|f||OTHER||t
17171779|NCT02537717|f||||f
17171780|NCT01673828|t||||
17171781|NCT01519323|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171782|NCT01572207|f||||f
17171783|NCT00383552|f||OTHER|"The investigator agrees not to publish/present any interim results without prior~sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement."|t
17171784|NCT03096834|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17171785|NCT00966654|t||||
17171786|NCT00575185|f||||f
17171787|NCT04416204|f||||f
17171788|NCT03858049|f||||f
17171789|NCT04456504|t||||
17171790|NCT04617782|f||||t
17171791|NCT01405768|t||||
17171792|NCT03692208|f||||f
17171793|NCT01690052|f||||f
17171794|NCT02777021|f||||f
17171795|NCT03397264|f||OTHER|The Principal Investigator may publish data or results from the Study; provided the Principal Investigator submits the proposed publication to Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary and/or commercially sensitive to the Sponsor.|t
17171796|NCT00599872|f||||f
17171797|NCT01474317|f||GT60||t
17138459|NCT01112982|f||||f
17171798|NCT01914003|f||OTHER|As outlined in each Clinical Trial Agreement between Sponsor and PI.|t
17171799|NCT01381016|f||||f
17171800|NCT01693029|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17138460|NCT00049504|t||||
17138461|NCT00334204|f||||f
17138462|NCT00660075|f||||f
17171801|NCT02647281|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171802|NCT05801991|f||||f
17171803|NCT00467077|f||LTE60||t
17171804|NCT01451723|t||||f
17171805|NCT01631435|f||||f
17171806|NCT02780401|f||||f
17171807|NCT02542046|f||||f
17171808|NCT04233008|t||||
17171809|NCT01005251|f||OTHER|There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed.The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ.|t
17171810|NCT02660788|t||||
17171811|NCT00443040|f||OTHER|Investigator understands and agrees that the first publication of the results of the Research Study, if any, shall be a multicenter publication of the results from all sites. Institution shall not publish, present, or use any results of the Research Study for any purpose until such Research Study has been completed in its entirety at all sites and until such multi-center study publication has been published or for a period of one year following such completion, whichever occurs first.|t
17171812|NCT00435409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171813|NCT03316196|t||||
17171814|NCT03661723|t||||
17171815|NCT00883779|f||OTHER|Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171816|NCT00499681|t||||
17171817|NCT02174731|f||||t
17171818|NCT00079040|f||LTE60||t
17171819|NCT00099372|f||||f
17171820|NCT00739401|f||||f
17171821|NCT04575155|f||||f
17171822|NCT05748275|t||||
17171823|NCT00467740|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17171824|NCT03535974|f||||f
17171825|NCT02678351|f||||f
17128032|NCT03319849|f||OTHER|Site agrees not to make any publication prior to Sponsor's initial publication. Site agrees that proposed manuscripts, abstracts, or oral presentations relating to the Study Drug will be submitted directly to Sponsor at least sixty (60) days prior to submission for publication or presentation to ensure that Confidential Information (including Clinical Data or Study results not disclosed in Sponsor's prior publication), Sponsor Technology or Sponsor-Owned Inventions are protected.|t
17128033|NCT03938545|f||||f
17128034|NCT02186223|f||GT60||t
17128035|NCT02550470|f||||f
17171826|NCT01919229|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17171827|NCT03022396|f||||f
17171828|NCT00803283|f||LTE60||t
17171829|NCT04999839|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17171830|NCT00399516|f||LTE60||t
17128036|NCT02079610|t||||
17128037|NCT01111474|f||||f
17171831|NCT00982735|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17171832|NCT02794207|f||||f
17171833|NCT00526292|t||||
17171834|NCT00756106|t||||
17171835|NCT00837902|f||||f
17171836|NCT03180385|t||||
17171837|NCT03324776|f||||f
17171838|NCT02675907|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17171839|NCT00539981|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17171840|NCT01611792|f||||f
17171841|NCT04326920|t||||
17171842|NCT02898454|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17171843|NCT01601535|f||||t
17171844|NCT03649074|f||||f
17171845|NCT00795704|f||||f
17171846|NCT03980730|f||OTHER|Where PI requires the use of the Study Results for publication, the PI shall seek the Sponsor's written approval which shall not be unreasonably withheld; provided, however, that (i) Sponsor may require removal of any Confidential Information of Sponsor or may delay publication for a reasonable period of time in order to secure protection any IP Rights; and, (ii) as the Study is designed as a multi-center Study, no publication shall be made until after the first multi-center publication.|t
17171847|NCT00556894|f||||f
17171848|NCT00880620|f||OTHER|Publication of the results of the Study conducted at the Site shall not be made before the first multi-site publication by Sponsor.|t
17171849|NCT03125226|t||||f
17171850|NCT03883581|f||||f
17128038|NCT01016977|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128039|NCT01236365|t||||
17128040|NCT00717067|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171851|NCT04612725|f||||t
17171852|NCT02354235|f||OTHER||t
17171853|NCT05790460|t||||
17171854|NCT04750642|f||||f
17171855|NCT02926638|f||||f
17171856|NCT00644423|t||||
17171857|NCT02426580|f||||t
17171858|NCT00445549|f||||f
17171859|NCT00768989|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17171860|NCT02690181|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171861|NCT00718510|f||||f
17171862|NCT03255902|t||||
17171863|NCT00590187|f||||f
17171864|NCT02527681|f||GT60||t
17171865|NCT00844376|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171866|NCT01011673|t||||f
17171867|NCT00549640|f||||f
17171868|NCT00660192|f||||f
17171869|NCT02734693|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17171870|NCT03207126|t||||
17171871|NCT03740048|f||||f
17171872|NCT01476722|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17171873|NCT03261336|f||||f
17171874|NCT03174353|t||||f
17171875|NCT01069484|f||||f
17171876|NCT02296164|f||||f
17171877|NCT00292942|f||||f
17171878|NCT00644358|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171879|NCT00079326|f||LTE60||t
17171880|NCT02151487|t||||f
17171881|NCT00651924|f||||f
17171882|NCT00758771|f||||f
17171883|NCT00960063|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17171884|NCT00771914|f||||f
17171885|NCT01636765|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17171886|NCT02654782|t||||
17171887|NCT02978417|t||||
17171888|NCT03111875|t||||
17171889|NCT03273426|f||||f
17171890|NCT05083351|t||||
17171891|NCT03485924|f||||f
17171892|NCT03360903|t||||
17171893|NCT04097431|f||||f
17171894|NCT01759420|t||||
17171895|NCT01422161|t||||
17182846|NCT01344057|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17182847|NCT00306592|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17182848|NCT02488629|f||||t
17171896|NCT01129622|t||||f
17171897|NCT02970799|f||OTHER|Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor and Ora will have the final decision regarding the manuscript and publication.|t
17171898|NCT00960375|f||||f
17171899|NCT00591006|f||||f
17182849|NCT02940691|f||||f
17128041|NCT01689337|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can with reasonable grounds require changes to the communication which do not change the scientific statement or neutrality of the communication.|t
17128042|NCT00824161|f||||f
17128043|NCT04754477|f||||t
17128044|NCT01347762|t||||
17128045|NCT03406260|f||OTHER|Details of the Study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17128046|NCT04745026|f||||f
17128047|NCT01205152|f||LTE60||t
17128048|NCT00249002|f||OTHER|"* Study data will not be published in part before the complete multicenter data has been reported in full, unless more than 1 year has elapsed since completion of the Study.~* Investigator/institution must supply copy of presentation or publication to Celgene within 30 days of submission for publication. Celgene may request in writing within that 30 days that Celgene Confidential Information be deleted or be granted a 60 day delay prior to publication to permit intellectual property filings."|t
17128049|NCT03256851|f||||f
17128050|NCT02208999|f||||f
17128051|NCT00319839|t||||
17128052|NCT00986674|f||LTE60||t
17128053|NCT02128542|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128054|NCT01853137|t||||
17128055|NCT00825916|f||LTE60||t
17128056|NCT01778023|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, e.g. when the clinical trial report is available. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17128057|NCT01098097|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts. Investigator agrees to meet with sponsor's representatives prior to submission for publication to discuss and resolve any disagreements.|t
17128058|NCT01411215|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171900|NCT00689390|f||OTHER|Principal Investigator (PI) agrees to provide to the sponsor 30 days prior to submission for publication or presentation, review results communications. Sponsor shall have editorial rights with respect to results communications and the right to review and comment on the data analysis and presentation with regard to proprietary information, the accuracy of the information contained in the publication, and to ensure that the presentation is fairly balanced and in compliance with FDA regulations.|t
17171901|NCT02343263|t||||
17171902|NCT03174184|f||||f
17182850|NCT03912233|f||OTHER||t
17182851|NCT00654628|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182852|NCT02177266|t||||
17128059|NCT00848926|f||LTE60||t
17128060|NCT03086213|t||||
17171903|NCT00973752|t||||
17182853|NCT01288534|t||||
17182854|NCT00494494|t||||
17182855|NCT00546715|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128061|NCT02924064|f||OTHER||t
17128062|NCT04507126|f||||f
17128063|NCT02832154|t||||
17128064|NCT00966277|t||||
17128065|NCT01100034|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128066|NCT00455325|t||||
17128067|NCT04620811|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17128068|NCT02294227|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128069|NCT01768637|f||||f
17128070|NCT00887432|t||||
17128071|NCT01636960|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the trial without prior written consent of the Sponsor. The Investigator further agrees to provide review copies of abstracts or manuscripts (both oral and textual including transmission through any electronic medium). No publication or manuscript shall contain any trade secret information of the Sponsor or any proprietary or confidential information of the Sponsor.|t
17128072|NCT01001559|f||||f
17128073|NCT01580969|t||||
17128074|NCT01209780|f||GT60||t
17128075|NCT03463161|t||||f
17128076|NCT00645047|f||GT60||t
17171904|NCT00392392|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17128077|NCT02709096|f||||f
17128078|NCT00511472|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17128079|NCT00505284|f||||f
17128080|NCT01575028|t||||
17128081|NCT00529958|t||||f
17128082|NCT04308395|f||||f
17128083|NCT03534284|f||||f
17128084|NCT03316300|f||OTHER|Site agrees not to make any publication prior to Sponsor's initial publication. Site agrees that proposed manuscripts, abstracts, or oral presentations relating to the Study Drug will be submitted directly to Sponsor at least sixty (60) days prior to submission for publication or presentation to ensure that Confidential Information (including Clinical Data or Study results not disclosed in Sponsor's prior publication), Sponsor Technology or Sponsor-Owned Inventions are protected.|t
17128085|NCT04737187|f||OTHER||t
17128086|NCT03756129|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128087|NCT03035201|f||||f
17128088|NCT01050790|t||||
17128089|NCT03705832|t||||
17128090|NCT01880528|t||||
17128091|NCT01439360|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128092|NCT05203068|t||||
17128093|NCT03045068|t||||
17128094|NCT02871258|f||||f
17128095|NCT01122160|t||||
17128096|NCT05406752|f||OTHER|The PI shall not make any publication or communication, written or oral, in connection with the Study and the results of the Study, whether partial or final, without the prior written consent of the sponsor (UNITHER PHARMACEUTICALS) during, and following termination or expiration of this Clinical Study Services Agreement.|t
17128097|NCT01912456|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128098|NCT01201343|f||OTHER||t
17128099|NCT00185679|f||||f
17128100|NCT00709696|f||||f
17128101|NCT00001962|t||||
17128102|NCT01036763|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128103|NCT01672723|f||||f
17128104|NCT01845220|t||||
17128105|NCT01177722|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17128106|NCT01060540|t||||
17128107|NCT02049151|f||OTHER|The first publication will be publication of results of the analysis of primary endpoint(s) that will include data from all trial centers. Any publications and presentations of results, either in whole or in part, by investigators or their representatives will require pre-submission review by the sponsor/CRO. Sponsor will not suppress or veto publications, but maintains right to delay publication in order to protect intellectual property rights.|t
17128108|NCT03572478|t||||
17128109|NCT00596427|t||||
17128110|NCT00320541|f||GT60||t
17128111|NCT01605292|f||||f
17171905|NCT00409539|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17171906|NCT00525512|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17171907|NCT01239511|f||||f
17171908|NCT04258423|f||||f
17171909|NCT03289208|f||OTHER||t
17171910|NCT01784991|t||||
17171911|NCT00662207|t||||
17171912|NCT03353675|f||||t
17171913|NCT01938079|t||||
17171914|NCT02362724|f||||f
17171915|NCT02025179|f||||f
17171916|NCT00402168|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17171917|NCT01854359|t||||
17171918|NCT01128049|f||OTHER|Sponsor review required before publishing results.|t
17171919|NCT00395746|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17171920|NCT02747186|t||||
17171921|NCT00582361|f||||f
17171922|NCT03137992|f||||f
17128112|NCT03057977|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128113|NCT02401867|f||GT60||t
17128114|NCT02502097|f||OTHER|No data collected as part of this study will be utilized in any written work, including publications, without the written consent of Sponsor.|t
17171923|NCT02370420|f||||f
17171924|NCT03077542|t||||
17171925|NCT01300728|f||||f
17171926|NCT02392806|t||||
17171927|NCT00301808|t||||f
17171928|NCT03332459|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17171929|NCT05893862|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17171930|NCT02429830|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the Sponsor for the purposes of performing the study, will be published or passed on to any third party without the written consent of Sponsor. Any Investigator involved with this study is obligated to provide the Sponsor with complete test results and all data derived from the study.|t
17171931|NCT01908426|f||OTHER|Our agreements with investigators vary; constant is our right to review results communications prior to public release, and embargo communications for a period of ≤ 60 days from submittal for review. We do not prohibit investigators from publishing, but we may require previously undisclosed confidential information, other than study results, to be removed from publications, and single-center publications are postponed until after publication of the trial's primary multicenter publication.|t
17171932|NCT03346434|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17171933|NCT03240601|t||||
17171934|NCT01782898|f||||f
17171935|NCT01414634|f||||f
17171936|NCT01183689|f||||f
17171937|NCT01419236|f||GT60||t
17171938|NCT02849418|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171939|NCT00762359|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17171940|NCT01453049|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171941|NCT00882440|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17171942|NCT03287791|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of Multicenter data.|t
17171943|NCT03441477|f||||f
17171944|NCT01048879|f||||f
17171945|NCT05482308|t||||
17171946|NCT03893396|t||||
17171947|NCT02250326|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17171948|NCT00416624|t||||
17171949|NCT03924622|f||||f
17171950|NCT04673214|f||||f
17171951|NCT00141453|f||OTHER|Results of Study shall not be published without prior express written consent and approval of Sponsor. Sponsor has right to change proposed publication and/or prohibit publication and Contractor must comply with requirements of Sponsor.|t
17171952|NCT04375150|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171953|NCT03793751|f||||f
17171954|NCT00866177|f||LTE60||t
17171955|NCT03585660|f||LTE60||t
17171956|NCT05120713|t||||
17171957|NCT02039115|t||||
17171958|NCT05635461|f||||f
17171959|NCT02498925|t||||
17171960|NCT03760029|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17171961|NCT03137654|t||||
17171962|NCT04890652|t||||f
17171963|NCT00524485|t||||
17171964|NCT00474123|t||||
17171965|NCT02767271|f||OTHER|Please contact Sponsor directly for additional information.|t
17171966|NCT00286442|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17171967|NCT04055675|f||||f
17171968|NCT01339689|f||||f
17171969|NCT04571944|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17171970|NCT00667888|t||||
17171971|NCT02140047|f||OTHER||t
17171972|NCT00659061|f||||f
17171973|NCT01277744|t||||
17171974|NCT00325897|f||||f
17128115|NCT01201317|f||OTHER|No such publication or presentation may include any of AstraZeneca's Confidential Information without AstraZeneca's prior written approval. AZ should have 60 days for review and can extend time until submission up to 90 days.|t
17128116|NCT00252733|f||||f
17128117|NCT01350336|f||||f
17171975|NCT03915717|f||||f
17171976|NCT03808090|t||||f
17171977|NCT03748823|f||||t
17171978|NCT00626275|f||OTHER||t
17171979|NCT01046565|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17171980|NCT01650558|f||||f
17171981|NCT02732600|t||||
17171982|NCT00528957|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17171983|NCT03624881|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17171984|NCT01969708|f||OTHER|Trial results can not be discussed until they have been made available to the public.|t
17171985|NCT05086705|t||||
17171986|NCT03284710|f||||f
17171987|NCT04992312|f||GT60||t
17171988|NCT05941702|t||||f
17171989|NCT02412306|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17171990|NCT04709068|t||||
17171991|NCT04019379|f||||f
17171992|NCT01706458|t||||
17171993|NCT03359629|f||||f
17171994|NCT05875532|t||||
17171995|NCT00072462|f||OTHER|Individual sites have statements of agreement that outline disclosure restrictions.|t
17171996|NCT04349891|f||||f
17171997|NCT03679247|f||||f
17171998|NCT02927301|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17171999|NCT05796557|t||||f
17172000|NCT04851691|t||||
17172001|NCT04247347|f||||f
17172002|NCT03562195|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17172004|NCT02529852|t||||
17172005|NCT02646826|f||||f
17172006|NCT01752426|t||||
17172007|NCT02269124|f||||f
17172008|NCT00614575|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17172009|NCT03776864|t||||
17172010|NCT03452540|f||||t
17172011|NCT05075746|f||OTHER|Please contact Sponsor for details.|t
17172012|NCT04664153|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172013|NCT01045460|t||||
17172014|NCT00097500|f||GT60||t
17172015|NCT03388346|t||||
17172016|NCT00189098|f||||f
17172017|NCT01600885|f||||f
17172018|NCT00436332|f||||f
17172019|NCT00472108|f||||t
17172020|NCT00716963|f||GT60||t
17172021|NCT00642356|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17172022|NCT01009060|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172023|NCT00005906|t||||f
17172024|NCT03043534|t||||
17172025|NCT00119847|t||||f
17172026|NCT02726620|t||||
17172027|NCT02542865|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172028|NCT00966186|t||||f
17172029|NCT04913610|f||OTHER|A multisite publication of the results is made prior to any publication based on results obtained by a specific site. Written publications or oral presentations that include all or part of the results must be sent to DNDi for review and comment at least 28 days prior to the planned date of publication/presentation. In addition, publication/presentation of results will be delayed for a further 90 days in the event that DNDi wishes to protect the results by patent application or other means.|t
17172030|NCT01210716|f||OTHER|Publication of data and/or information derived from the study requires prior review and approval by Sponsor.|t
17172031|NCT04657679|f||||f
17172032|NCT02358473|f||||f
17172033|NCT02051764|f||OTHER|Data confidentiality for a period of 5 years following study termination|t
17172034|NCT03557970|t||||
17172035|NCT03155724|f||||t
17172036|NCT00732212|t||||
17172037|NCT01991808|t||||
17172038|NCT00321789|t||||
17172039|NCT02588599|f||||f
17172040|NCT03309020|t||||f
17172041|NCT01319981|t||||
17172042|NCT02919761|f||||t
17172043|NCT05550779|f||||f
17172044|NCT03349723|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172045|NCT00399308|f||||f
17172046|NCT03409796|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17128118|NCT01491672|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17172047|NCT00740220|t||||f
17172048|NCT01602224|f||GT60||t
17172049|NCT01352117|f||LTE60||t
17172050|NCT00633477|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17172051|NCT02539823|f||||f
17172052|NCT00770653|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 14 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172053|NCT01962792|f||||f
17172054|NCT04906499|t||||
17172055|NCT05622734|f||||f
17172056|NCT02722564|t||||
17172057|NCT01273766|t||||
17172058|NCT03525444|f||||t
17172059|NCT00262860|t||||
17172060|NCT02741128|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17172061|NCT01419769|f||OTHER|"PI must wait 9 months after close of study for Sponsor to present collaborative publication. If Sponsor does not publish within 9 months after close of study, PI is free to publish institution's results at that time.~Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 6 months from the date the PI receives the objection. The Sponsor cannot require changes to the communication and cannot extend the embargo."|t
17172062|NCT00878501|f||OTHER||t
17172063|NCT00812708|t||||f
17172064|NCT01959503|f||OTHER|INSTITUTION and INVESTIGATOR agree if the Study is part of a multi-center study, the first publication of the results of the Study shall be made in coajunction with the results from the investigators at the other Study centers. In the event no publication of the multi-center study has been made within two years after the completion of the Study at all Study centers, then INSTITUTION and INVESTIGATOR shall be free to publish the Study results generated.|t
17172065|NCT01600326|t||||
17172066|NCT03965130|f||LTE60||t
17172067|NCT01131507|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17172068|NCT01393158|f||||f
17172069|NCT03224130|f||||f
17172070|NCT02985827|f||||f
17172071|NCT03095651|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17172072|NCT00851357|f||||f
17172073|NCT02714400|t||||
17172074|NCT02587520|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17172075|NCT01751061|f||||f
17172076|NCT00503750|t||||
17172077|NCT01194830|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17172078|NCT04861597|f||||f
17172079|NCT01815918|t||||
17172080|NCT04682197|f||||f
17172081|NCT02814916|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17172082|NCT03804840|t||||
17172083|NCT05626738|f||||f
17172084|NCT04951115|t||||
17182856|NCT00723606|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172085|NCT00910104|t||||f
17172086|NCT04364386|f||||f
17172087|NCT03960541|f||OTHER|Any reports, papers, and/or presentations must be reviewed and approved by the sponsor prior to submitting for publication. All publications relating to the study will comply with the guidelines set forth by the Uniform Requirements for Manuscripts Submitted to Biomedical Journals drawn up by the International Committee of Medical Journal Editors.|t
17172088|NCT04739982|f||||f
17172089|NCT00702702|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17172090|NCT02240485|t||||f
17172091|NCT00953667|t||||
17172092|NCT04819945|f||||f
17172093|NCT00475670|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138463|NCT01001234|f||OTHER|Investigator agrees to delay publication of study results until Food and Drug Administration (FDA) grants pediatric exclusivity on the study drug. Investigator may publish results for his/her study site after primary publication of results of entire multicenter trial. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17128119|NCT02795429|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17172094|NCT04949191|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17172095|NCT02913482|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172096|NCT01983228|t||||
17172097|NCT00918385|t||||
17172098|NCT02005016|t||||
17172099|NCT00317473|f||||f
17172100|NCT05288816|f||||t
17172101|NCT01323582|t||||f
17172102|NCT03416868|f||||f
17128120|NCT00362453|f||OTHER|The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Complementary and Alternative Medicine or the National Institutes of Health. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript.|t
17128121|NCT01640054|f||GT60||t
17128122|NCT02080221|f||||f
17128123|NCT01386788|t||||f
17128124|NCT03310268|f||OTHER||t
17128125|NCT02564354|f||OTHER|Investigators are restricted from disclosure or results until after multi-center publication or 12 months after the completion of the Study at all participating research centers. Sponsor can review results communication prior to public release and can embargo communications regarding trial results for a period that is more than 60 days (varying per site). Sponsor may request redaction of confidential information.|t
17128126|NCT00706433|f||OTHER|A multi-center publication will be prepared at the end of the Study under the direction of the Sponsor. In the event that such manuscript has not been submitted for publication within twelve (12) months after the date of the final study report, the INVESTIGATOR shall have the right to individually publish the results of his/her Study. Sponsor can review and comment on results communications prior to public release and can delete confidential information contained in results communication.|t
17128127|NCT04187053|t||||
17128128|NCT00120406|f||GT60||t
17128129|NCT02808143|t||||
17128130|NCT04964388|f||||f
17128131|NCT00250679|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17128132|NCT01093521|f||||f
17128133|NCT03718533|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128134|NCT05041101|t||||
17172103|NCT00083889|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172104|NCT00388349|t||||
17172105|NCT00112736|f||LTE60||t
17172106|NCT05435339|f||||t
17172107|NCT01283555|f||OTHER|Investigators have agreed to provide drug sponsor with a copy of any draft manuscript or abstract for its review and comment at least thirty days prior to submission for publication and provide a copy of any draft presentation at least seven days in advance of any scientific meeting or conference.|t
17172108|NCT00537394|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17182857|NCT01830140|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17182858|NCT01502644|t||||
17138464|NCT00928512|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17138465|NCT04153929|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128135|NCT04426851|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128136|NCT01990560|t||||
17128137|NCT01616056|f||||f
17172109|NCT04267380|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172110|NCT04731636|f||||t
17172111|NCT03473236|f||||t
17172112|NCT00685165|f||GT60||t
17172113|NCT05135871|f||||t
17172114|NCT02855281|t||||
17172115|NCT00534365|f||||f
17172116|NCT02856412|t||||
17128138|NCT01831856|f||||f
17172117|NCT04886154|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17182859|NCT00637195|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182860|NCT02388997|f||||f
17182861|NCT03025828|t||||
17182862|NCT01020019|t||||f
17182863|NCT02375672|f||||f
17182864|NCT01559311|f||LTE60||t
17182865|NCT03023488|f||||f
17128139|NCT01498653|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128140|NCT02070588|f||||f
17172118|NCT02099864|t||||f
17172119|NCT01400698|f||||f
17172120|NCT01740713|f||||f
17172121|NCT04084171|f||||f
17172122|NCT00948064|t||||
17172123|NCT00289653|t||||f
17172124|NCT00179621|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.~* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 90 days."|t
17172125|NCT00837252|t||||f
17172126|NCT02973100|f||GT60||t
17172127|NCT00960622|f||||f
17172128|NCT00414635|f||OTHER|Site investigators agree not to individually publish the results of the study. They may participate in a joint publication of the study results with the sponsor.|t
17172129|NCT01841281|f||||f
17172130|NCT00350025|t||||
17172131|NCT04516746|f||||t
17172132|NCT00322777|f||||f
17172133|NCT03115359|f||||f
17182866|NCT02346240|f||GT60||t
17182867|NCT00554749|t||||
17182868|NCT03417141|t||||
17182869|NCT02165111|f||||f
17182870|NCT03706690|f||||t
17182871|NCT02098109|t||||
17128141|NCT00298090|t||||
17128142|NCT00972205|f||||f
17128143|NCT04409886|f||||f
17128144|NCT01718353|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17128145|NCT01078675|f||||f
17128146|NCT01366495|t||||
17172134|NCT03285724|f||OTHER|PI must submit publication 60 days prior to its submission for presentation/publication to Sponsor. The Sponsor may, at its sole discretion, (a) approve the publication, (b) reject the publication, or (c) suggest changes to the publication to ensure protection of confidential commercial information in compliance with regulatory requirements. Until the content of any publication is approved by the Sponsor and the PI, the PI shall not disclose such publication.|t
17172135|NCT02994238|f||||f
17172136|NCT04231669|t||||
17172137|NCT05543265|f||||f
17172138|NCT05316597|f||||f
17172139|NCT05526716|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17172140|NCT04750824|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172141|NCT04204447|f||||f
17172142|NCT03859024|f||||f
17172143|NCT00907426|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17172144|NCT03547518|t||||f
17172145|NCT04854135|f||||f
17172146|NCT02384551|t||||
17172147|NCT04742556|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172148|NCT03035032|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17172149|NCT02201524|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172150|NCT02855203|t||||
17172151|NCT02914639|f||||t
17172152|NCT01814774|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172153|NCT01018030|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172154|NCT00524511|t||||
17172155|NCT03617172|t||||
17182872|NCT02143843|f||OTHER|"No presentation or publication of Institution's data relating to the Trial may occur until after the Trial has been completed at all sites. If Investigator desires to present or publish, investigator must submit any and all manuscripts, posters, abstracts, or other intended publications (hereinafter collectively referred to as manuscripts) to Sponsor at least sixty (60) days prior to the actual submission of such manuscript(s) for publication."|t
17182873|NCT01822132|f||||f
17128147|NCT00509587|f||LTE60||t
17172156|NCT01089504|t||||
17172157|NCT01924845|t||||
17172158|NCT00062439|f||||f
17172159|NCT01889667|f||GT60||t
17172160|NCT00001832|f||||f
17182874|NCT00005669|t||||f
17182875|NCT02519712|t||||
17182876|NCT03029689|f||||f
17182877|NCT00006916|f||||f
17182878|NCT01922024|f||||f
17182879|NCT02967367|f||||f
17182880|NCT01524770|f||GT60||t
17172161|NCT05139680|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172162|NCT01546857|t||||
17172163|NCT01469221|f||||f
17172164|NCT05005260|t||||
17172165|NCT03164668|f||||f
17172166|NCT00790803|t||||
17172167|NCT01149096|f||OTHER|Must obtain prior approval.|t
17172168|NCT02004236|t||LTE60||t
17172169|NCT02987231|f||||f
17172170|NCT00918281|f||||f
17182881|NCT02751983|t||||
17128148|NCT01959334|f||OTHER|This study was conducted by a Contract Research Organization. The Sponsor is and shall remain owner of all data pertaining to and/or resulting from the Study as well as all rights on intellectual property and patents arising from the said Study. Confidential Information may not be disclosed to any third party without the other party's prior written consent (except to the relevant authorities, providing the confidentiality is maintained).|t
17128149|NCT05007808|f||||f
17128150|NCT00731120|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17128151|NCT01551212|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128152|NCT00710021|f||||f
17128153|NCT02112838|f||||f
17128154|NCT01822301|t||||
17128155|NCT00557947|f||LTE60||t
17128156|NCT00423930|t||||
17128157|NCT04002401|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128158|NCT00822523|t||||
17128159|NCT01315353|f||||f
17128160|NCT03567434|f||||f
17128161|NCT02513719|f||LTE60||t
17172171|NCT00168844|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128162|NCT01009580|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17172172|NCT00988832|f||OTHER|The Sponsor recognises the right of the investigator to publish the study results. The investigator is asked to send a draft of the publication/abstract to the Sponsor 30 days in advance of submission in order to obtain approval prior to submission. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion, the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17172173|NCT00995761|f||||f
17172174|NCT01377584|f||||f
17172175|NCT00849940|t||||
17172176|NCT00601835|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17172177|NCT01927497|t||||
17172178|NCT03914417|t||||
17172179|NCT03361137|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172180|NCT03009058|f||||f
17172181|NCT02103309|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17172182|NCT01486966|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, for example, when the clinical trial report is available. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17172183|NCT00506350|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172184|NCT01691794|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172185|NCT04972786|f||||f
17172186|NCT00844844|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17172187|NCT01943344|f||||f
17172188|NCT02891447|t||||
17172189|NCT05472090|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17172190|NCT03641937|t||||
17172191|NCT01350999|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17172192|NCT03593044|t||||
17172193|NCT01195701|t||||f
17172194|NCT00281463|f||||f
17172195|NCT02891174|t||||
17172196|NCT04124939|f||||f
17172197|NCT04235140|f||||t
17172198|NCT00945958|f||OTHER||t
17172199|NCT02177695|f||LTE60||t
17172200|NCT00419393|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17172201|NCT00979901|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172202|NCT00681044|t||||
17172203|NCT01317472|f||||f
17128163|NCT04485858|f||||t
17128164|NCT02390245|f||||f
17172204|NCT03583099|f||||f
17128165|NCT03727438|f||||f
17172206|NCT02182895|f||||f
17172207|NCT05164120|t||||
17172208|NCT03631940|f||||f
17172209|NCT03789669|f||OTHER||t
17172210|NCT00836589|f||OTHER|Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests|t
17172211|NCT00442169|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17172212|NCT02595983|f||LTE60||t
17172213|NCT01890343|f||GT60||t
17172214|NCT02918370|f||||f
17172215|NCT03550118|f||||f
17172216|NCT01187017|t||||f
17172217|NCT02399215|t||||
17172218|NCT00772538|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17172219|NCT00189540|f||OTHER|Multi-center all inclusive initial publication planned. Any proposed publications must be submitted to the steering committee and sponsor thirty (30) days prior to publication submission.|t
17138466|NCT01963780|f||OTHER|Site shall have right to publish results. To balance this right with TransMedics' (TM) proprietary interests, site will submit manuscripts intended for publication for TM's review at least 60d prior to submission date. TM will complete its review within 60d of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request. After 60d period, site will have right to publish manuscript, as amended by TM.|t
17138467|NCT01614912|f||||t
17138468|NCT04406389|t||||
17138469|NCT02971293|f||OTHER|Publication and / or presentation whether complete or partial, of any part of the data or results of this study will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the Investigator and AstraZeneca|t
17138470|NCT00729326|f||GT60||t
17172220|NCT01903356|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172221|NCT00713609|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172222|NCT04529083|t||||
17172223|NCT03305666|f||||f
17172224|NCT02005549|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172225|NCT04196686|t||||
17172226|NCT01166139|t||||
17128166|NCT00029172|f||||f
17128167|NCT05220254|t||||
17128168|NCT01557283|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172227|NCT02051452|f||||f
17172228|NCT02587221|f||OTHER|Any formal publication of the study in which contribution of Seqirus personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Seqirus personnel. Seqirus must be notified of any intent to publish data collected from the study and prior approval from Seqirus must be obtained prior to submission for publication.|t
17172229|NCT02546609|f||||f
17172230|NCT00914849|t||||
17172231|NCT01001221|f||OTHER|At least 45 days in advance of proposed submission, the Investigator should forward a copy of the manuscript or abstract for review by the sponsor, and, if necessary, delay publication or communication for a limited time in order to protect the confidentiality or proprietary nature of any information contained therein.|t
17172232|NCT05106959|f||||f
17172233|NCT01292486|f||LTE60||t
17128169|NCT02047643|t||||
17128170|NCT00448279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128171|NCT03907410|f||||f
17128172|NCT01295034|f||||f
17128173|NCT00549783|f||LTE60||t
17138471|NCT01235728|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17138472|NCT02193828|f||OTHER||t
17172234|NCT04369404|f||||f
17172235|NCT01995708|t||||
17138473|NCT01185704|f||OTHER||t
17172236|NCT04602390|f||||t
17172237|NCT00265564|t||||
17172238|NCT01553084|f||||f
17172239|NCT03988400|t||||
17172240|NCT04201431|t||||
17172241|NCT01176032|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17172242|NCT00375999|f||||f
17172243|NCT04205240|t||||
17172244|NCT01791244|f||||f
17172245|NCT04079296|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement|t
17172246|NCT06133816|t||||f
17172247|NCT01346358|f||GT60||t
17172248|NCT02839096|f||||f
17172249|NCT05058365|f||||f
17172250|NCT04038359|f||||f
17172251|NCT00703014|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial will first be presented to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent. The Sponsor shall have the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the investigator(s) in the discussion of the data in such communications.|t
17172252|NCT05121766|t||||
17172253|NCT02893293|t||||
17172254|NCT02970981|t||||
17172255|NCT01033240|f||||f
17172256|NCT05468814|t||||
17172257|NCT02955589|f||OTHER|"Huya has agreements with PIs and the agreements restricts the right of the PI to discuss or publish trial results after the trial is completed.~The content of disclosure restriction stated in the agreement is PI shall obtain sponsor's prior written consent before disclosing the information obtained from this clinical trial to a professional society or other external party."|t
17128174|NCT01174160|f||OTHER|The PI agrees to submit a copy of a 'Publication' to CRO/Sponsor for review and comment 60 days prior to submission for publication and / or disclosure. Sponsor has the applicable 60 day period to respond to PI with any requested revisions. PI agrees to delete any confidential information (excluding results) identified by Sponsor as confidential prior to submitting/presenting the publication.|t
17128175|NCT04218084|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128176|NCT05580588|f||||f
17128177|NCT05093699|t||||
17128178|NCT00211185|f||OTHER||t
17128179|NCT00712673|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17128180|NCT03603028|f||||f
17128181|NCT01990209|f||GT60||t
17128182|NCT01468831|t||||
17128183|NCT00842985|f||||f
17128184|NCT01037244|f||LTE60||t
17128185|NCT00690820|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the study to a publisher, reviewer or outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment.|t
17128186|NCT00585377|t||||
17138474|NCT01151540|f||OTHER||t
17138475|NCT03380624|f||||f
17172258|NCT04716426|f||||f
17172259|NCT00551759|f||||f
17172260|NCT02960217|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172261|NCT00214045|t||||
17172262|NCT00625131|t||||
17172263|NCT01003301|f||||f
17172264|NCT01404039|t||||
17172265|NCT00668148|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17172266|NCT01766050|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172267|NCT03577275|f||||f
17172268|NCT01941485|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17172269|NCT00089297|f||||f
17172270|NCT03270436|t||||
17172271|NCT03406377|f||||t
17172272|NCT01910298|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172273|NCT01364896|f||||f
17172274|NCT00717574|f||||f
17172275|NCT03037385|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172276|NCT01977547|f||||f
17172277|NCT02535481|f||||f
17172278|NCT01838694|f||LTE60||t
17172279|NCT00672555|t||||
17172280|NCT03623243|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17172281|NCT03904017|f||||f
17172282|NCT02153086|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17172283|NCT00446849|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17182882|NCT01420081|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182883|NCT03467425|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182884|NCT00411619|t||||
17182885|NCT02318693|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential may be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17182886|NCT00025883|t||||
17182887|NCT00862784|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17182888|NCT04174313|t||||
17182889|NCT00352612|t||||
17182890|NCT00528528|f||OTHER|As per revised Protocol dated 21 Dec 2007, Investigator may not submit for publication or presentation, the results of trial without prior written consent of Sponsor. The Investigator agrees to allow at least 45 days for Sponsor to review prepublication manuscript prior to submission to Publisher. In accordance with generally recognized principles of scientific collaboration, co-authorship with any company personnel will be discussed and mutually agreed upon before submission to Publisher.|t
17182891|NCT04973488|f||||f
17182892|NCT04197713|f||LTE60||t
17182893|NCT05569954|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17182894|NCT01660412|t||||
17182895|NCT04579679|f||||t
17172284|NCT00904943|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17172285|NCT05546476|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172286|NCT03480048|f||||f
17172287|NCT00807911|f||||f
17172288|NCT02953652|f||OTHER|"HUYABIO International, LLC has agreements with PIs and the agreements restricts the right of the PI to discuss or publish trial results after the trial is completed.~The content of disclosure restriction stated in the agreement is PI shall obtain sponsor's prior written consent before disclosing the information obtained from this clinical trial to a professional society or other external party."|t
17172289|NCT02135861|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172290|NCT03780452|t||||f
17172291|NCT03130738|f||OTHER|Proprietary Information will need prior written consent of the sponsor. PI will hold in confidence and not disclose any Proprietary Information unless disclosure has its prior written consent from sponsor, or that the information is disclosed to personnel who need to know. Sponsor will not prohibit PI to comply with applicable laws and regulations, provided PI gives prior written notice to Sponsor. Disclosure allowed if legally required and accorded confidential treatment.|t
17172292|NCT03098641|f||||f
17172293|NCT01440959|f||||f
17172294|NCT03796728|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172295|NCT00333775|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172296|NCT03926208|f||||f
17172297|NCT02968134|f||LTE60||t
17172298|NCT01383928|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17172299|NCT01490151|f||||f
17172300|NCT01350947|t||||
17172301|NCT03853473|f||||f
17172302|NCT03651765|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17172303|NCT01349543|t||||
17172304|NCT01856270|f||||f
17172305|NCT06047210|f||||t
17172306|NCT05444855|t||||
17172307|NCT05379179|f||||f
17172308|NCT04842747|f||||t
17172309|NCT01743469|f||OTHER|The Sponsor required reasonable opportunity to review any abstract, presentation, or paper before the material was submitted for publication or communicated. This also applied to any amendments that were requested by referees or journal editors. The Sponsor committed to comment on the draft documents within a time period agreed in the contractual arrangements between the Sponsor and authors or their institution. Delays were also possible if publication would adversely affect patentability.|t
17172310|NCT01451606|f||||f
17172311|NCT01590264|t||||
17172312|NCT00564681|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17172313|NCT04011540|f||||f
17172314|NCT01026844|t||||f
17172315|NCT01260649|f||||f
17172316|NCT02138890|f||LTE60||t
17172317|NCT01446159|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17172318|NCT03668873|f||||f
17172319|NCT02183675|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138476|NCT00788697|f||OTHER|Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement|t
17138477|NCT01078558|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138478|NCT03199638|t||||
17138479|NCT00373490|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138480|NCT00358501|f||||f
17138481|NCT00141037|f||||f
17138482|NCT00260429|t||||
17138483|NCT00628758|f||||f
17138484|NCT04179786|f||||t
17138485|NCT01938001|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17138486|NCT03310580|f||||f
17138487|NCT01576120|f||||f
17138488|NCT01495923|t||||
17138489|NCT02762708|t||||
17138490|NCT01062009|f||||f
17138491|NCT01468701|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138492|NCT01068717|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17138493|NCT01822223|t||||
17138494|NCT04366713|f||||f
17138495|NCT00631540|f||GT60||t
17138496|NCT03984838|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138497|NCT03136367|t||||
17138498|NCT00892957|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17138499|NCT04034043|f||||f
17138500|NCT01760187|f||OTHER|Described in the contract.|t
17138501|NCT01549223|t||||
17138502|NCT03175562|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138503|NCT02823080|t||||
17138504|NCT00676208|t||||
17172320|NCT01521117|t||||
17172321|NCT02228681|f||LTE60||t
17138505|NCT03700736|f||||f
17138506|NCT04532918|f||OTHER||t
17138507|NCT01410799|t||||
17138508|NCT00191386|f||GT60||t
17138509|NCT05711862|t||||
17138510|NCT02061748|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138511|NCT01742091|f||GT60||t
17138512|NCT03750240|t||||
17172322|NCT01336933|f||||f
17172323|NCT04875013|t||||
17172324|NCT00795535|f||||f
17138513|NCT03706040|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138514|NCT00439725|f||LTE60||t
17138515|NCT03510910|t||||
17138516|NCT00110591|f||OTHER||t
17172325|NCT04576988|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication.|t
17172326|NCT01844765|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17172327|NCT00617734|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17172328|NCT04897711|f||||f
17172329|NCT00556075|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17172330|NCT02485691|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17172331|NCT00604565|t||||
17172332|NCT04292535|t||||f
17172333|NCT01897025|t||||
17172334|NCT03836625|f||||f
17172335|NCT00310765|f||||f
17172336|NCT01420861|f||||f
17172337|NCT01247324|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172338|NCT01253291|f||GT60||t
17172339|NCT03905096|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172340|NCT02016781|f||||f
17172341|NCT03563209|t||||f
17172342|NCT03724942|f||||f
17172343|NCT00278343|f||LTE60||t
17172344|NCT01021020|f||GT60||t
17172345|NCT02764385|f||||f
17172346|NCT03598036|f||||t
17172347|NCT04494841|f||||t
17172348|NCT04607668|f||OTHER|The investigator will submit results communications for review by the sponsor at least 60 days prior to expected submission to the intended publisher or meeting committee. This review period may be shortened upon mutual consent. The sponsor may request modification of any publication, presentation or use by the investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights.|t
17172349|NCT01488045|t||||
17172350|NCT05043363|t||||
17172351|NCT00989911|f||||f
17172352|NCT00060528|f||||f
17172353|NCT02230410|t||||
17172354|NCT02212015|t||||
17172355|NCT01048593|f||||f
17138517|NCT02715804|f||GT60||t
17138518|NCT04038385|f||||f
17138519|NCT00948194|t||||
17138520|NCT01333098|t||||
17138521|NCT00601146|f||||f
17172356|NCT04701814|t||||
17172357|NCT02388269|f||LTE60||t
17172358|NCT03448406|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17172359|NCT03405792|f||||f
17172360|NCT03962491|t||||
17172361|NCT03882021|f||OTHER|First publication of study results will be made as a joint multi-center publication with investigators from all sites contributing data. Institutions may publish data and results individually from its site after any of the following (1) a multi-center publication is published, (2) no multicenter publication is submitted within eighteen months after closures of the Study at all sites or (3) sponsor confirms in writing there will be no multi-center publication.|t
17172362|NCT03186209|f||OTHER|The Institution and/or the Principal Investigator shall not include in or shall remove from any proposed publication any Confidential Information, errors or inaccuracies; and shall withhold publication, submission for publication or presentation for a period of ninety (90) days from the date on which the Company receives the material to allow the Company to take such measures as the Company considers necessary to preserve its proprietary rights and/or protect its Confidential Information.|t
17172363|NCT01260493|f||||f
17172364|NCT02989493|t||||
17172365|NCT02559622|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17172366|NCT02163538|t||||
17172367|NCT04643808|f||||f
17172368|NCT01339832|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172369|NCT01126749|f||||t
17172370|NCT01318577|f||OTHER|Contact sponsor directly for details.|t
17182896|NCT04740034|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172371|NCT00627393|f||OTHER|All publications and presentations resulting from studies from the TMH Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P\&P Committee along with Network Investigators. Members of the P\&P Committee can recommend changes to publications.|t
17182897|NCT04346615|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172372|NCT01056822|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety.|t
17172373|NCT05498649|t||||
17172374|NCT00568022|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172375|NCT03896438|t||||
17172376|NCT03025282|f||||t
17172377|NCT02761330|t||||
17172378|NCT03638453|t||||
17172379|NCT03043313|f||||t
17172380|NCT00980954|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17172381|NCT02657889|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172382|NCT00374140|t||||
17172383|NCT01576341|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17172384|NCT03371836|f||||f
17172385|NCT03218384|t||||
17172386|NCT00517296|t||||
17172387|NCT04366349|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172388|NCT01235897|t||||
17172389|NCT00829738|f||||f
17182898|NCT02851108|f||||f
17182899|NCT04524403|f||OTHER|No individual publications will be allowed before publication of the multicenter results, except as agreed with the Sponsor. The Investigator agrees to submit all manuscripts or abstracts to the Sponsor for review before submission to the publisher.|t
17182900|NCT02449356|t||||
17182901|NCT00533949|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17172390|NCT05421624|t||||
17172391|NCT03413891|f||||f
17172392|NCT05358366|t||||
17172393|NCT03755206|f||||f
17182902|NCT00727194|f||||f
17182903|NCT05063734|f||||t
17182904|NCT03853707|t||||
17182905|NCT04269161|f||||f
17182906|NCT01513317|f||GT60||t
17182907|NCT04108130|f||||f
17182908|NCT04031885|f||GT60||t
17182909|NCT01663272|t||||
17172394|NCT04905134|t||||
17172395|NCT03642873|f||||f
17182910|NCT02610192|f||LTE60||t
17182911|NCT00279708|f||||f
17182912|NCT03354429|f||GT60||t
17182913|NCT01873989|t||||
17182914|NCT00953329|f||||f
17182915|NCT01465802|f||LTE60||t
17182916|NCT01340976|f||GT60||t
17182917|NCT02331446|f||||f
17182918|NCT02566759|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17182919|NCT00226941|f||||f
17172396|NCT05556265|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17172397|NCT04359810|f||||f
17172398|NCT03221556|t||||
17172399|NCT04760782|t||||
17172400|NCT02234843|f||LTE60||t
17172401|NCT02336282|t||||
17172402|NCT04875975|f||GT60||t
17172403|NCT03253393|f||||f
17172404|NCT00558142|t||||
17172405|NCT04515771|t||||
17172406|NCT00948246|f||OTHER|At least one month prior to any proposed submission for publication or presentation of trial data, the PI will provide the Sponsor the manuscript for review, comment, and approval. No confidential information may be disclosed without Sponsor's written approval. If it is a multi-center trial, the first publication of the results shall be made in conjunction with the results from other Investigators at other centers.|t
17172407|NCT04346745|f||||f
17172408|NCT04199351|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172409|NCT03365102|f||||f
17172410|NCT00474487|f||||f
17172411|NCT02464540|f||||f
17172412|NCT02443688|f||OTHER|"PI is free to publish results of the study after (1) the first multi-center publication or (2) 24 months after close of the study, whichever occurs first.~Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 90 days (which may be extended under certain circumstances related to protection of intellectual property as well as for deletion of any Confidential Information)."|t
17172413|NCT03182374|f||LTE60||t
17172414|NCT01691534|f||OTHER|The investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting, for review and removal of confidential information.|t
17172415|NCT03198715|f||||f
17172416|NCT00616759|f||||f
17172417|NCT02007096|t||||
17172418|NCT02437344|f||||f
17172419|NCT03324607|f||||f
17172420|NCT05365217|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17138522|NCT01155193|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138523|NCT01858597|t||||
17172421|NCT01809938|t||||
17172422|NCT03402217|f||||f
17172423|NCT01680341|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17172424|NCT04614363|t||||f
17172425|NCT02558894|f||||f
17172426|NCT02689427|t||||
17172427|NCT03581279|f||||f
17172428|NCT02967991|f||||f
17172429|NCT02476617|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17172430|NCT03486912|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172431|NCT02491684|f||OTHER||t
17172432|NCT02199184|t||||
17172433|NCT01263769|t||||
17172434|NCT01500733|t||||
17172435|NCT02242942|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172436|NCT03259230|f||||t
17172437|NCT00561652|f||||f
17172438|NCT01063049|t||||f
17172439|NCT03019406|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17172440|NCT03710187|t||||
17172441|NCT00468169|t||||
17172442|NCT00231816|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172443|NCT04372017|t||||
17128187|NCT01768117|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128188|NCT02939170|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17128189|NCT03305731|f||||f
17128190|NCT03658668|t||||
17128191|NCT01952054|t||||
17128192|NCT01127139|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17172444|NCT00599014|t||||
17172445|NCT01283139|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17172446|NCT01075243|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172447|NCT00976274|f||||f
17172448|NCT03593902|t||||
17172449|NCT05328102|f||||t
17172450|NCT00784563|f||||f
17172451|NCT01614249|t||||
17172452|NCT02954536|t||||
17172453|NCT02946580|f||||f
17172454|NCT04764162|f||||f
17172455|NCT00791934|f||GT60||t
17172456|NCT02018562|t||||
17172457|NCT05194124|f||||f
17172458|NCT04609319|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172459|NCT04076540|f||||f
17172460|NCT00453895|t||||
17172461|NCT02787564|t||||
17172462|NCT03474588|t||||
17172463|NCT03902418|f||||f
17172464|NCT03804528|t||||
17172465|NCT01607957|f||OTHER|Taiho agreements vary with individual investigators, but do not prohibit any from publishing. Taiho is provided time to review material discussing trial results (generally 30 to 120 days with possible extension), and can remove undisclosed confidential, proprietary and intellectual property rights-related information. Authors have final control and approval of publication content of final study results. The investigator agrees not to publish any results before the first multicenter publication.|t
17172466|NCT04570930|f||||f
17172467|NCT00584948|f||||f
17128193|NCT05208866|f||GT60||t
17128194|NCT02216357|f||||f
17128195|NCT00836095|t||||f
17128196|NCT03609853|f||||f
17128197|NCT04964414|t||||
17128198|NCT02673203|t||||
17128199|NCT05116046|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128200|NCT03311334|f||GT60||t
17128201|NCT02745392|f||LTE60||t
17128202|NCT02145247|t||||
17128203|NCT00899548|t||||f
17172468|NCT00498940|t||||f
17172469|NCT05460754|f||||f
17172470|NCT03589859|f||||f
17172471|NCT02331134|t||||
17172472|NCT04966013|f||OTHER|All study data and reports of study data are the property of the study sponsor. The sponsor may grant the PI the right to publish the results of this research in a scientific journal, conditional upon the review and concurrence of the sponsor|t
17172473|NCT05010707|f||||f
17172474|NCT03518086|f||GT60||t
17172475|NCT05967260|f||||f
17172476|NCT00626106|f||||t
17172477|NCT03735875|t||||
17172478|NCT05856422|f||||f
17172479|NCT00874510|f||||f
17172480|NCT03007966|t||||
17172481|NCT01428258|f||||f
17172482|NCT00248625|f||||f
17172483|NCT03085095|f||||t
17172484|NCT00408317|f||OTHER|Restrictions may vary in accordance with each agreement that is negotiated with individual investigators. Sponsor will allow publication after multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and defer publication for period of time to allow Sponsor to obtain patent or other intellectual property right protection.|t
17172485|NCT00286468|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17172486|NCT02923726|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Sponsor may extend the review period for another 90 days to take steps to protect its intellectual property interests, or to remove any language detrimental to Sponsor's intellectual property interests.|t
17172487|NCT00074711|t||||f
17172488|NCT03466658|t||||
17172489|NCT00129402|f||LTE60||t
17172490|NCT01527149|t||||
17172491|NCT00481832|f||||f
17172492|NCT02992288|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 30 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172493|NCT03416985|t||||
17172494|NCT02006472|f||OTHER|Data and results are owned by the sponsor. Results can be used by the institution for (a) internal noncommercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.|t
17172495|NCT00499486|t||||
17172496|NCT00656513|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17172497|NCT00087152|f||LTE60||t
17172498|NCT03913455|f||||f
17172499|NCT05467007|f||||f
17172500|NCT01436149|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17172501|NCT05261386|f||||t
17172502|NCT01643668|t||||
17172503|NCT00322881|t||||f
17172504|NCT00573508|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17128204|NCT02269332|t||||
17128205|NCT02684253|t||||
17128206|NCT00610467|t||||
17172505|NCT03253796|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17172506|NCT02285855|t||||
17172507|NCT00528112|f||OTHER|Principal investigators (PIs) have to send the publication to sponsor 90 days prior to planned publishing. The sponsor has maximum 60 days for review and for recommending changes or mark parts that have to be deleted from the publication due to harming sponsor's confidentiality rights. Sponsor can request a delay in publication release up to 6 months.|t
17172508|NCT02718898|f||OTHER|Disclosures are prohibited until after the sponsor discloses the primary and secondary publications of clinical trial data.|t
17172509|NCT00894803|t||||
17172510|NCT04484961|t||||
17172511|NCT01667900|f||GT60||t
17172512|NCT01468558|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172513|NCT01259063|t||||
17172514|NCT00347022|f||OTHER|"* Draft of publication to be submitted by the coordinating investigator (no more than 6 months after getting study results) to sponsor and other investigators for review at least 1 month before the submission to the scientific review. Comments to be reviewed and approved by the coordinating investigator and sponsor.~* Each investigator agrees not to publish the comparison of the renal tolerance involving only the patients he/she has included."|t
17172515|NCT00004563|f||||f
17172516|NCT03337308|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17172517|NCT01569191|f||||f
17172518|NCT00762164|t||||f
17172519|NCT03138369|f||||t
17172520|NCT03094416|f||LTE60||t
17172521|NCT04756427|t||||
17172522|NCT04528641|f||OTHER|Publication of the results will be agreed between ReiThera SRL and Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani. If one of the parties is interested in proceeding with a scientific publication, it must give written and electronic communication to the other party. Any impediments to publication must be communicated electronically within 30 days. If a party deems it inappropriate to publish, it will try to provide written changes to the text that could allow its publication.|t
17172523|NCT03341299|f||GT60||t
17172524|NCT01001975|f||OTHER|The only disclosure restriction on the PI is that no information based on the conduct (including the protocol, the data resulting from this study or the fact that this study is being conducted) will be released without prior written consent of the sponsor, unless this requirement is superceded by the State or Federal law.|t
17172525|NCT00945009|f||||f
17172526|NCT04607005|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17172527|NCT05305443|f||||f
17172528|NCT03919773|f||||f
17172529|NCT02977403|t||||
17172530|NCT04659044|f||||f
17172531|NCT04671901|t||||
17172532|NCT05417438|f||||f
17172533|NCT02845297|f||||f
17172534|NCT04053036|t||||
17172535|NCT04051996|t||||
17172536|NCT02677493|f||||f
17172537|NCT03863795|t||||
17172538|NCT02994108|f||||f
17172539|NCT01395797|f||||f
17172540|NCT00781768|t||||
17172541|NCT04567628|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17172542|NCT00079417|f||OTHER|Must obtain prior Sponsor approval.|t
17172543|NCT02458313|f||||f
17172544|NCT02081677|f||GT60||t
17172545|NCT00904969|f||||f
17182920|NCT01513291|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17172546|NCT01097668|f||OTHER|If the Investigator drafts a publication, he/she agrees to send it to Apitope for review and comment before its submission to the journal. If Apitope considers that the proposed publication contains patentable material or information which should be protected as valuable confidential information, Apitope reserves the right to delay submission to the journal until patent applications have been filed and/or require the deletion of the confidential information from the proposed publication.|t
17172547|NCT04396756|f||OTHER|Per protocol, the data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Any publication of the results of this study must be authorized by the Sponsor.|t
17172548|NCT00199381|f||||f
17172549|NCT00603408|t||||
17172550|NCT00385671|f||GT60||t
17172551|NCT04944992|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.|t
17172552|NCT01295814|t||OTHER||t
17172553|NCT03414983|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172554|NCT00181168|f||||f
17172555|NCT01775501|t||||
17172556|NCT02170376|f||OTHER||t
17172557|NCT02166346|f||||f
17172558|NCT03780244|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites|t
17172559|NCT03629535|t||||
17172560|NCT02364700|f||||f
17172561|NCT00804908|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17172562|NCT01280903|f||||f
17172563|NCT03453164|f||||f
17172564|NCT02770014|f||||f
17172565|NCT03822117|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17172566|NCT01074502|t||||
17172567|NCT03459079|f||||f
17172568|NCT00976183|f||||f
17172569|NCT00834977|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17182921|NCT03732638|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is less than or equal to 60 days from the date that the communication is submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17172570|NCT00726063|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17182922|NCT01358981|t||||f
17182923|NCT03728582|t||||f
17172571|NCT05719311|f||OTHER||t
17172572|NCT05176314|f||GT60||t
17172573|NCT01231984|f||OTHER|The PI and Clinical Center will not publish the results pursuant to the Protocol without sponsor review and opportunity to comment on the publication or oral presentation. Abstracts and synopsis of oral presentations must be received by sponsor 30 days, and journal submissions 60 days, prior to submission. The data generated pursuant to the Protocol will be the property of the sponsor and may be used in any manner by the sponsor as it may determine in its sole discretion.|t
17172574|NCT01968447|f||||f
17172575|NCT02766023|f||LTE60||t
17172576|NCT06271993|f||||f
17172577|NCT01827137|f||||t
17172578|NCT03557294|f||||f
17172579|NCT04026113|f||||f
17172580|NCT02887820|t||||
17172581|NCT04613362|t||||
17172582|NCT02218372|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17172583|NCT02753283|t||||f
17172584|NCT04386291|f||||f
17172585|NCT05172128|f||||f
17172586|NCT00671658|t||||
17172587|NCT01921205|f||GT60||t
17172588|NCT00322855|f||||f
17172589|NCT00456846|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to their submission; Celgene shall complete its review within 60 days after receipt. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of patentable material.|t
17172590|NCT00771277|t||||f
17172591|NCT03125395|f||||t
17172592|NCT01668784|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172593|NCT00311766|f||LTE60||t
17172594|NCT01436526|f||OTHER|Any disclosure of study results by the Principal Investigator or investigators has to be in agreement with the sponsor.|t
17172595|NCT02560038|t||||
17172596|NCT03542812|f||||f
17172597|NCT02783690|t||||
17172598|NCT05178173|t||||
17172599|NCT03157830|t||||
17172600|NCT01723384|f||||f
17172601|NCT05138653|f||LTE60||t
17172602|NCT04272242|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17172603|NCT02702492|f||||t
17172604|NCT01824836|f||LTE60||t
17172605|NCT01243190|t||||
17172606|NCT02711891|f||||f
17172607|NCT00751296|f||LTE60||t
17172608|NCT01972217|f||||t
17172609|NCT00578539|t||||
17172610|NCT04106557|f||||f
17172611|NCT03175367|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17172612|NCT02151058|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17172613|NCT00809185|t||||
17172614|NCT00674817|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172615|NCT03379818|t||||
17172616|NCT03199976|t||||
17172617|NCT03020667|f||||t
17172618|NCT01780506|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17172619|NCT05236270|t||||f
17172620|NCT04030143|f||||f
17172621|NCT01499940|t||||
17172622|NCT00412984|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172623|NCT04218240|f||||f
17172624|NCT04914364|f||||f
17172625|NCT04097678|t||||
17172626|NCT03694678|f||||f
17172627|NCT02435212|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17172628|NCT05131308|f||||f
17172629|NCT05179785|t||||
17172630|NCT05966142|t||||
17172631|NCT03292926|t||||
17172632|NCT02453737|t||||
17172633|NCT04852302|f||||f
17172634|NCT03267277|t||||
17172635|NCT04849364|f||||f
17172636|NCT00965354|f||||f
17172637|NCT03521570|t||||
17172638|NCT04076696|t||||
17172639|NCT03496844|f||||f
17172640|NCT04531176|t||||
17172641|NCT02516696|t||||f
17172642|NCT02958995|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17172643|NCT04006288|t||||
17172644|NCT03656939|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172645|NCT01766440|f||||f
17172646|NCT01345240|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172647|NCT04298697|t||||
17172648|NCT00449696|f||OTHER|SKK has the right to review the disclosures. Investigator shall not make any publication of study data, information, results or similar information without the express of permission of SKK.|t
17172649|NCT02673372|f||||f
17172650|NCT00593346|t||||
17172651|NCT00464698|f||||f
17172652|NCT01903460|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17172653|NCT02246530|f||||f
17172654|NCT00888173|f||||f
17172655|NCT01488890|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17172656|NCT05712460|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172657|NCT02735863|f||GT60||t
17172658|NCT00829426|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17172659|NCT05452486|f||||f
17172660|NCT05560425|t||||
17172661|NCT05135767|t||||f
17172662|NCT03475004|t||||
17172663|NCT02260934|f||||f
17172664|NCT03605667|f||LTE60||t
17172665|NCT00537134|t||||
17172666|NCT03597347|f||||f
17172667|NCT00107653|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172668|NCT02867436|f||||f
17172669|NCT02920632|f||||f
17172670|NCT01838395|f||OTHER||t
17172671|NCT02532517|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results that is more than 60 days but less than or equal to 180 days from the time submitted to sponsor for review. No results that contain sponsor confidential information may be released without sponsor prior written consent.|t
17172672|NCT03312231|f||LTE60||t
17172673|NCT05720897|t||||
17172674|NCT00400179|f||OTHER|Taiho agreements vary with individual investigators, but do not prohibit any from publishing. Taiho is provided time to review material discussing trial results (generally 30 to 120 days with possible extension), and can remove undisclosed confidential, proprietary and intellectual property rights-related information. Authors have final control and approval of publication content of final study results. The investigator agrees not to publish any results before the first multicenter publication.|t
17172675|NCT04780061|t||||f
17172676|NCT04825574|f||OTHER||t
17172677|NCT00303069|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172678|NCT00092417|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172679|NCT00574197|f||||f
17172680|NCT02958917|f||||f
17172681|NCT02318706|f||||f
17182924|NCT01034397|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182925|NCT01018264|t||||f
17182926|NCT01785524|t||||
17182927|NCT00672438|f||||f
17182928|NCT03915548|f||||f
17182929|NCT03217136|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17182930|NCT01740596|f||||f
17182931|NCT03670810|f||GT60||t
17172682|NCT01456039|f||OTHER|Disclosure agreements vary; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17172683|NCT04936945|t||||
17172684|NCT04273737|t||||
17172685|NCT00335777|t||||
17172686|NCT02798627|f||||f
17172687|NCT00992108|t||||
17172688|NCT03821402|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17172689|NCT04639245|t||||
17172690|NCT01702311|f||||f
17172691|NCT01314313|f||||t
17172692|NCT01209689|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172693|NCT03337477|f||GT60||t
17172694|NCT03181932|f||||f
17172695|NCT02220920|f||OTHER||t
17172696|NCT00853307|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17172697|NCT00473564|t||||f
17172698|NCT01112917|f||GT60||t
17128207|NCT04781387|f||OTHER|Any publication or other public disclosure, written or oral, relating to or derived from the Confidential Information, or relating to the Consultant's work with Crestone, shall be provided by the Consultant to Crestone at least 90 days prior to submission for publication or other disclosure. Crestone shall review the publication or other disclosure within a reasonable period of time and inform the Consultant as to whether or not Crestone consents to publication or other disclosure.|t
17172699|NCT02177123|f||||t
17172700|NCT04723056|t||||
17172701|NCT04441138|f||||f
17172702|NCT02118584|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172703|NCT03431285|t||||
17172704|NCT03103542|f||GT60||t
17172705|NCT03406780|f||||f
17172706|NCT00837434|f||||f
17172707|NCT01122238|t||||
17172708|NCT03041038|f||||f
17172709|NCT00360230|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172710|NCT00581308|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17172711|NCT00886379|t||||
17172712|NCT04558125|t||||
17172713|NCT01614886|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17172714|NCT03848325|t||||f
17172715|NCT01207414|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17172716|NCT02191111|f||||f
17172717|NCT01527370|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17172718|NCT01748292|f||||f
17172719|NCT02224560|f||GT60||t
17172720|NCT03165617|f||||t
17172721|NCT02383576|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172722|NCT02340026|f||||f
17172723|NCT03844997|t||||
17128208|NCT01745848|f||||f
17172724|NCT00135226|t||||
17172725|NCT04552301|f||||f
17172726|NCT01184898|t||||
17172727|NCT00074165|f||||f
17172728|NCT04797585|t||||
17172729|NCT02738801|f||OTHER|The investigator must agree that before publishing or communicating any results of the trial, the sponsor has at least 60 days for full review of the information prior to submission.|t
17172730|NCT03279081|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17172731|NCT04771455|t||||f
17172732|NCT01210313|f||||f
17172733|NCT01710345|f||OTHER|Sponsor must be able to review and approve all published|t
17172734|NCT04475081|f||||f
17172735|NCT01808755|f||||f
17172736|NCT01502293|f||LTE60||t
17172737|NCT02105740|f||||f
17172738|NCT05810740|f||||f
17172739|NCT01539824|f||||f
17172740|NCT00723736|f||OTHER|Any trial related information may be released by the PI to third party only after written consent is obtained from the sponsor. This restriction is valid until 5 years after study closure.|t
17172741|NCT03694353|f||GT60||t
17172742|NCT00651742|f||||t
17172743|NCT01535040|t||||
17172744|NCT05430854|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172745|NCT04314284|t||||
17172746|NCT01652235|f||LTE60||t
17172747|NCT02023086|f||||f
17172748|NCT02608684|t||||
17172749|NCT04295720|t||||
17172750|NCT00755183|t||||
17172751|NCT00148317|f||LTE60||t
17172752|NCT00124943|f||OTHER|"* Study data will not be published in part before the complete multicenter data has been reported in full, unless more than 1 year has elapsed since completion of the Study.~* Investigator/institution must supply copy of presentation or publication to Celgene within 30 days of publication. Celgene may request in writing within that 30 days that Celgene Confidential Information be deleted or be granted a 60 day delay prior to publication to permit intellectual property filings."|t
17172753|NCT04196777|f||||f
17172754|NCT02939287|f||||f
17172755|NCT02903771|f||||f
17172756|NCT04033926|f||OTHER|"PI shall have the right to publish or present their own data resulting from the Study (Publication) upon the earlier of: (a) the date following a multicenter publication coordinated by Sponsor regarding the Protocol; (b) 12 months after completion of the Protocol by all sites; or (c) the date after submission of the Study Data by Sponsor to the FDA.~The PI must furnish Sponsor with a copy of any Publication at least 30 days in advance of the proposed submission or presentation date."|t
17172757|NCT03299556|f||||f
17172758|NCT03520998|f||LTE60||t
17172759|NCT01435382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172760|NCT00910650|t||||
17172761|NCT03367793|f||||f
17172762|NCT02435992|f||LTE60||t
17172763|NCT00260533|t||||f
17172764|NCT01761877|f||||f
17172765|NCT03542877|t||||
17172766|NCT01310777|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17172767|NCT03697252|f||GT60||t
17172768|NCT04711850|f||OTHER|"At the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Hansa Biopharma.~Any confidential information relating to imlifidase or the study, including any data and results from the study will be the exclusive property of Hansa Biopharma AB. The investigators and any other persons involved in the trial will protect the confidentiality of the proprietary information belonging to Hansa Biopharma AB"|t
17172769|NCT00774046|t||||
17172770|NCT02731469|f||||f
17172771|NCT01353898|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17172772|NCT03558737|t||||
17172773|NCT03183869|f||||f
17172774|NCT03041181|f||||f
17172775|NCT03536572|t||||
17172776|NCT00286728|t||||
17172777|NCT01292135|f||||f
17172778|NCT03050801|t||||
17172779|NCT03600909|t||||
17172780|NCT04973449|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17172781|NCT00521079|f||LTE60||t
17172782|NCT02651675|f||||f
17172783|NCT03674411|t||||
17128209|NCT00679627|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17128210|NCT01886378|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17128211|NCT00815685|t||||f
17172784|NCT03816696|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172785|NCT01506596|f||OTHER|Institution/PI may use Institution/PI derived Study results in a Publication provided Publication does not disclose Vector Confidential Information unnecessary to publish Study results. Institution/PI will submit to Vector for review/comment proposed Publication and data necessary for meaningful review at least 30 days prior to submission. Vector may request delay of submission up to 60 days in order to file patent applications relating to an Invention.|t
17172786|NCT03645122|t||||
17172787|NCT04606134|f||||f
17172788|NCT01099267|f||OTHER|Unless approved by Celgene, single center data will not be published before multicenter data, unless more than 1 year has elapsed since completion of the Study. Thereafter, Investigator may publish single center data provided that Investigator shall: i) provide a copy of the publication to Celgene at least 60 days in advance of submission for publication; ii) delete Celgene Confidential Information and; iii) delay submission up to 90 additional days to permit intellectual property filings.|t
17172789|NCT03373240|f||||f
17172790|NCT03327948|f||||f
17172791|NCT05737069|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172792|NCT04309396|t||||
17172793|NCT04050553|f||GT60||t
17128212|NCT03143816|f||||f
17172794|NCT00938704|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17172795|NCT03472885|f||||t
17172796|NCT02201953|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128213|NCT02656160|t||||
17172797|NCT01350258|t||||
17172798|NCT02153632|f||OTHER|"Investigator shall allow SPONSOR 60 days to review any manuscript and 30 days to review any poster presentation, abstract or any other written or oral material which discloses the Study Results. SPONSOR may request in writing an additional 60 days for review.~SPONSOR may remove all Confidential Information from any publications or presentations, or if deemed not sufficient to protect its Intellectual Property Rights, then SPONSOR may embargo the publication or presentation."|t
17172799|NCT01615939|t||||
17172800|NCT04671017|f||||t
17172801|NCT02892344|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17172802|NCT01520506|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results without permission of the sponsor.|t
17182932|NCT03192150|f||OTHER|The investigator agrees to submit the manuscript of any journal article, abstract or other presentation arising from an InSite Vision-sponsored clinical investigation to InSite Vision for editorial review prior to submission for publication or presentation. At the sponsor's request, if proprietary information is to be disclosed, proposed publications or presentations will be delayed until appropriate patent applications and/or legal documents of a similar nature have been filed.|t
17182933|NCT02579616|f||||f
17182934|NCT00482391|t||||
17172803|NCT00425269|t||||
17128214|NCT00446992|f||||f
17128215|NCT01275131|f||OTHER||t
17128216|NCT02076178|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128217|NCT03430206|t||||
17172804|NCT00758667|f||||f
17172805|NCT03531112|t||||
17128218|NCT04877730|f||||f
17182935|NCT03226652|t||||
17182936|NCT03758040|f||||f
17182937|NCT04875520|f||||f
17182938|NCT05371054|f||||f
17182939|NCT02713321|t||||
17182940|NCT05773287|t||||
17182941|NCT01350128|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17128219|NCT04633551|f||||f
17128220|NCT01992393|f||||f
17128221|NCT01907360|f||||f
17128222|NCT02953860|f||||f
17128223|NCT00585195|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128224|NCT02796560|f||||f
17128225|NCT00345293|t||||
17128226|NCT02788903|f||||f
17172806|NCT01084655|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17172807|NCT02189317|t||||
17172808|NCT02419001|f||OTHER|Investigators do not see trial results ahead of public disclosure unless it is under CDA. Investigators will not be allowed to publish or disclose any study results prior to sponsor communicating it to the public.|t
17172809|NCT00535496|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial will first be submitted at least six weeks ahead of publication or presentation, for written consent. The Sponsor shall have the right to make its consent conditional upon proper representation of the interpretation and discussion of the data.|t
17172810|NCT01074814|f||LTE60||t
17172811|NCT02326155|f||||t
17172812|NCT05024032|f||GT60||t
17172813|NCT02231086|f||||f
17172814|NCT03591406|f||||t
17172815|NCT02066181|f||LTE60||t
17172816|NCT01083771|f||||f
17172817|NCT02393378|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17172818|NCT00939393|f||GT60||t
17172819|NCT02851615|f||||f
17172820|NCT00354978|t||||
17172821|NCT05764785|f||||f
17172822|NCT01843621|f||||f
17172823|NCT02670811|t||||
17172824|NCT03937570|f||||f
17172825|NCT03714672|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17172826|NCT00371150|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17182942|NCT03523117|f||||f
17182943|NCT03909009|t||||f
17128227|NCT01440374|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128228|NCT02673151|t||||
17128229|NCT01709747|f||||f
17128230|NCT00231153|f||GT60||t
17128231|NCT04487834|f||||f
17128232|NCT01222507|t||||f
17172827|NCT00732030|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17172828|NCT02345070|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17172829|NCT03081117|t||||
17172830|NCT01533207|f||LTE60||t
17172831|NCT05887388|t||||
17172832|NCT00321620|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172833|NCT03829228|f||||t
17172834|NCT02844569|t||||f
17172835|NCT03304626|f||||f
17172836|NCT01887327|f||||f
17182944|NCT01495481|f||||f
17182945|NCT02644967|f||||t
17182946|NCT02867605|t||||
17182947|NCT03323099|t||||f
17182948|NCT02082717|t||||
17182949|NCT01409291|t||||
17182950|NCT03254134|t||||
17172837|NCT03027609|f||||f
17172838|NCT03649646|f||||t
17172839|NCT01462370|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. The sponsor review can be expedited to meet publication timelines.|t
17172840|NCT05106894|f||||f
17172841|NCT04385277|f||OTHER|Must obtain prior Sponsor approval|t
17172842|NCT03566511|t||||
17172843|NCT04538989|f||LTE60||t
17172844|NCT02988466|t||||
17172845|NCT00981656|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17172846|NCT00687596|f||OTHER||t
17172847|NCT01537666|f||OTHER|The PI cannot at any time during or after the Study make any announcement, oral presentation or publication relating to the Study, or any of the methods, results of, or conclusions from, the Study without the prior written consent of the Sponsor.|t
17172848|NCT03331315|f||||f
17172849|NCT02121158|t||||
17172850|NCT00643864|t||||
17172851|NCT02461758|t||||
17172852|NCT04689139|t||||
17172853|NCT02380573|t||||f
17172854|NCT02226367|f||||f
17172855|NCT03773978|f||GT60||t
17172856|NCT04659863|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17172857|NCT01033019|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17172858|NCT00888134|f||LTE60||t
17172859|NCT03094325|t||||
17172860|NCT03224819|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172861|NCT03104868|f||||f
17172862|NCT00005780|f||||f
17172863|NCT04408989|f||||t
17172864|NCT05082857|t||||
17172865|NCT04672239|t||||
17172866|NCT02961894|f||||f
17172867|NCT04876521|f||||f
17172868|NCT05494385|f||||t
17172869|NCT05408429|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17172870|NCT03108131|t||||
17172871|NCT01074970|f||||f
17172872|NCT03205709|f||||f
17172873|NCT04760613|t||||
17172874|NCT05565742|f||GT60||t
17172875|NCT02855125|f||||t
17172876|NCT04467905|f||OTHER||t
17172877|NCT06904586|f||||f
17172878|NCT03894124|f||||f
17172879|NCT00744497|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17172880|NCT03298035|t||||
17172881|NCT03819114|f||||f
17172882|NCT02379728|f||||f
17172883|NCT02135432|f||||f
17172884|NCT00242502|t||||f
17172885|NCT05101122|f||OTHER|"Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.~The Sponsor retains the right to disapprove any submission for publication, including any publication using trial data, including abstracts, presentations or manuscripts.~A summary of the study results will also be posted in a publicly accessible database (e.g., www.ClinTrials.gov)."|t
17172886|NCT03131219|f||||f
17172887|NCT01528332|f||||f
17172888|NCT04945733|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17172889|NCT02584686|t||||
17172890|NCT01709721|f||||f
17172891|NCT00763035|f||||f
17172892|NCT02131259|t||||
17172893|NCT03219723|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17172894|NCT03137381|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17172895|NCT01684917|t||||
17172896|NCT00459316|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17172897|NCT01980017|f||||f
17172898|NCT03044106|t||||f
17172899|NCT02057250|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17172900|NCT04843007|f||||f
17172901|NCT01271946|f||OTHER|Prior to submission for publication or presentation, the Institution will provide the Sponsor with at least sixty (60) days for review of a manuscript. If requested in writing,The Institution and Principal Investigator will withhold such publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17172902|NCT00423579|f||OTHER|The investigator shall not publish or publicly present the study results without prior written authorization from the sponsor, except for dispositions in the Ministerial Circular n. 6 dated 02 SEP 2002. The investigator shall notify the sponsor in writing of any publication submission or presentation reporting results of the study 30 days prior to submission or presentation to permit sponsor review.|t
17172903|NCT02392637|t||||
17172904|NCT02161016|f||LTE60||t
17172905|NCT00003475|f||||f
17172906|NCT03288103|t||||
17172907|NCT03675126|f||OTHER||t
17172908|NCT00001959|t||||
17172909|NCT02698215|f||||t
17172910|NCT04393935|t||||
17172911|NCT04757766|f||||t
17172912|NCT04189952|t||||
17172913|NCT01052493|t||||f
17172914|NCT01498068|f||GT60||t
17172915|NCT03931941|f||GT60||t
17172916|NCT02252666|t||||
17172917|NCT01318915|f||||f
17172918|NCT01032538|f||||f
17172919|NCT00453206|t||||
17172920|NCT01664975|t||||
17172921|NCT00664443|f||||f
17172922|NCT05523089|f||OTHER||t
17172923|NCT02681523|t||||
17172924|NCT01899040|f||||f
17172925|NCT03712358|f||GT60||t
17172926|NCT02638220|f||||t
17172927|NCT03204188|t||||
17172928|NCT04743778|f||||f
17172929|NCT01181349|f||OTHER|Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.|t
17172930|NCT01198795|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17172931|NCT01116986|t||||
17172932|NCT00936715|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17172933|NCT02492763|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17128233|NCT02647320|f||GT60||t
17128234|NCT03836989|t||||
17172934|NCT01337960|t||||
17172935|NCT01772316|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17172936|NCT01213316|f||OTHER|The results of this study will be published by the sponsor according to the current guidelines for publication. The Contract Research Organization will assist the sponsor with initial publication. Further details will be laid down in the financial agreement between the sponsor and the Contract Research Organization.|t
17172937|NCT01747876|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17172938|NCT02092610|f||GT60||t
17172939|NCT00914316|t||||
17172940|NCT04135417|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo.|t
17172941|NCT03163303|t||||f
17172942|NCT00600080|f||OTHER|Publication requires agreement and written authorization from Sponsor.|t
17172943|NCT04163952|t||||
17172944|NCT02047032|t||||
17172945|NCT05660577|f||||f
17172946|NCT05753449|t||||f
17172947|NCT03363841|f||||f
17172948|NCT01744977|f||||f
17172949|NCT00821795|f||||f
17172950|NCT02878343|f||||f
17172951|NCT04090203|t||||
17172952|NCT03418714|f||||f
17172953|NCT03879772|f||OTHER|The Principal Investigator agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of the Sponsor. The Principal Investigator further agrees to provide thirty (30) days prior to submission for publication or presentation to the Sponsor to review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the Protocol study.|t
17172954|NCT03856788|t||||
17172955|NCT00106704|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172956|NCT03818321|t||||
17172957|NCT03415685|f||||f
17172958|NCT03216226|f||||f
17172959|NCT00497081|f||||f
17172960|NCT00871975|f||||f
17172961|NCT05249582|f||||f
17172962|NCT00283296|f||||f
17172963|NCT02668653|f||||f
17172964|NCT00979940|f||||f
17172965|NCT02158442|f||||f
17172966|NCT01294553|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17172967|NCT01151189|f||||f
17172968|NCT00926237|t||||
17172969|NCT02054689|t||||
17172970|NCT00632229|f||||f
17172971|NCT02323217|t||||
17172972|NCT05386329|t||||f
17172973|NCT00577889|f||LTE60||t
17172974|NCT03146585|t||||
17172975|NCT02667119|f||||f
17172976|NCT03783078|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17172977|NCT02758210|t||||
17172978|NCT02059278|f||||t
17172979|NCT02180100|f||LTE60||t
17172980|NCT00737672|f||||f
17172981|NCT02694185|t||||
17172982|NCT01551186|t||||f
17172983|NCT04029883|f||||f
17172984|NCT04080505|t||||
17172985|NCT03175679|t||||
17172986|NCT05972993|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17172987|NCT04792645|f||||f
17172988|NCT03866577|f||OTHER|The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17172989|NCT04825678|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17172990|NCT03818256|f||OTHER|No individual publications will be allowed before publication of the multicenter results except as agreed with Corcept. The Investigator agrees to submit all manuscripts or abstracts to Corcept for review before submission to the publisher.|t
17172991|NCT02344108|f||GT60||t
17172992|NCT02086175|f||||f
17172993|NCT00734149|t||||
17172994|NCT03353688|t||||
17172995|NCT03043794|f||||f
17172996|NCT00595088|f||||f
17172997|NCT00735436|t||||f
17172998|NCT04323124|t||||
17182951|NCT00806546|f||OTHER|Per the study agreement, Investigators shall have the right to publish or present information and/or data arising from the study, provided the text of any such publication or presentation is submitted for review at least thirty days prior to submission for publication or other disclosure and NuPathe shall have the right to request the removal of any confidential information|t
17182952|NCT01247090|t||||f
17172999|NCT00489307|t||||
17173000|NCT04586205|f||||f
17173001|NCT04684836|t||||f
17173002|NCT01586364|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17173003|NCT02121535|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17173004|NCT00091949|f||||f
17173005|NCT01256788|f||||f
17173006|NCT02083354|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17173007|NCT03312634|f||OTHER||t
17173008|NCT00906204|f||||f
17173009|NCT04328077|f||||f
17173010|NCT05291520|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17182953|NCT01226719|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17182954|NCT02367599|f||||f
17182955|NCT03385239|f||LTE60||t
17128235|NCT01650246|f||OTHER|Principal Investigator (PI) shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17128236|NCT00953407|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17128237|NCT02268474|f||||f
17128238|NCT03435497|f||||f
17128239|NCT04234425|f||||f
17128240|NCT01824160|f||||f
17128241|NCT04281004|t||||
17128242|NCT00701779|f||||f
17128243|NCT03628898|t||||
17173011|NCT01347112|t||||
17173012|NCT01679314|f||||f
17173013|NCT01615120|f||||f
17173014|NCT00696072|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128244|NCT01217957|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17128245|NCT02482870|t||||
17128246|NCT01873495|t||||
17128247|NCT01206777|t||||
17128248|NCT02986334|f||||f
17128249|NCT01115660|f||||f
17128250|NCT00816348|t||||
17128251|NCT00846391|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128252|NCT03339570|f||||f
17128253|NCT01249274|f||||f
17128254|NCT01000636|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide his draft of such publication to sponsor to review and approve at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17128255|NCT03451162|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128256|NCT04634825|f||LTE60||t
17128257|NCT00286078|f||||f
17128258|NCT04756960|f||OTHER|Investigator should inform Chiesi Farmaceutici S.p.A. before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation.|t
17128259|NCT02388646|f||||f
17128260|NCT01708213|f||||f
17128261|NCT03128008|t||||
17128262|NCT01079741|t||||
17128263|NCT02292654|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17128264|NCT02169453|f||OTHER||t
17128265|NCT02434939|f||||f
17128266|NCT01426763|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.|t
17128267|NCT01001832|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128268|NCT02594826|f||||f
17128269|NCT01536015|f||GT60||t
17128270|NCT03598088|f||OTHER|The PIs are restricted from publishing results without prior approval from the Sponsor.|t
17128271|NCT00511901|t||||
17128272|NCT00178126|f||||f
17128273|NCT02447172|f||OTHER|results of the multicenter study had to be published prior to the publication of any site specific data.|t
17128274|NCT03562247|t||||
17128275|NCT01013597|t||||
17128276|NCT00603720|t||||
17128277|NCT00960531|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128278|NCT02533570|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor may extend the embargo for a period up to 60 days to allow for the filing of a one or more patent applications. The sponsor cannot require changes to the communication and cannot otherwise extend the embargo.|t
17128279|NCT03995667|f||||f
17128280|NCT00637923|f||OTHER|Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.|t
17128281|NCT03373201|f||||t
17128282|NCT02656823|f||||f
17128283|NCT01000285|t||||
17128284|NCT02880540|t||||
17128285|NCT01607112|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128286|NCT02881957|t||||
17128287|NCT05269355|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the Sponsor for review. The Sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17128288|NCT00081497|f||OTHER|In multi-site studies, Principal Investigator (PI) can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17173015|NCT01597596|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17173016|NCT01601236|f||OTHER|"A sole participant institution shall not, without Sponsor's prior written consent, independently publish or otherwise disclose any results of this multicenter study prior to a multicenter publication, or 12 months after completion of the study, whichever occurs first. Institution and Principal Investigator shall have the right to publish and present the results of Institution's and Principal Investigator's activities solely in accordance with the Sponsor's written provisions."|t
17173017|NCT02937116|f||||f
17173018|NCT02208310|f||||f
17182956|NCT01574703|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17182957|NCT02915744|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17182958|NCT00813358|f||GT60||t
17182959|NCT01282216|t||||
17128289|NCT00959647|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128290|NCT01786174|t||||
17128291|NCT02315352|f||||f
17128292|NCT03442985|f||||t
17128293|NCT03077360|t||||
17128294|NCT01716117|f||OTHER|Research parties agree not to make any publication of study results, including without limitation the study data, until completion of the study and publication of the multi-center results in a peer-reviewed journal. Thereafter, the research parties may publish their individual site experience.|t
17128295|NCT03645057|t||||
17128296|NCT00288509|f||OTHER|A publication of results from all sites in this multicenter study is expected. If the sponsor no longer plans this or 6 months after study completion at all sites, the PI may publish the results. He will supply any proposed publication to the sponsor for review and comment at least 30 days before submission for publication. If the sponsor believes a patent application should be filed, the publication will be delayed for another 60 days or until patent filing; with a maximum delay of 90 days.|t
17128297|NCT04005053|t||||
17128298|NCT00388453|t||||f
17173019|NCT00313014|f||GT60||t
17182960|NCT03851016|f||||f
17182961|NCT03080961|f||||f
17128299|NCT00762970|t||||
17128300|NCT01480674|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128301|NCT03818204|f||||f
17128302|NCT03864146|t||||
17128303|NCT02440451|t||||
17128304|NCT01749605|t||||
17128305|NCT01313637|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128306|NCT01009203|f||||f
17128307|NCT00892723|f||LTE60||t
17128308|NCT00615836|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17128309|NCT01313689|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17128310|NCT03362879|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17128311|NCT01007448|f||OTHER|Please contact Sponsor directly for additional information.|t
17128312|NCT01105754|f||||f
17128313|NCT00406653|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128314|NCT00818649|t||||
17128315|NCT03513588|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128316|NCT00940108|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138524|NCT00724815|f||OTHER|Per the study agreement, Investigators have the right to publish or present information and/or data arising from the study, provided the text of any such publication or presentation is submitted for review at least thirty days prior to submission for publication or other disclosure and NuPathe shall have the right to request the removal of any confidential information.|t
17138525|NCT02516150|f||||f
17138526|NCT02186457|f||||f
17138527|NCT03168841|f||||f
17138528|NCT00105183|f||OTHER|"Protocol: The 1st publication of study results shall be a complete, joint multicenter publication or disclosure coordinated by sponsor. Later publications will reference 1st publication.~Prior to submitting for publication, the Investigator shall allow sponsor at least 30 days to review the proposed Publication. Proposed Publications shall not include either Fresenius Biotech confidential information other than the study results or personal data on any patient, such as name or initials."|t
17138529|NCT01819506|t||||
17128317|NCT02075541|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128318|NCT04388774|t||||
17128319|NCT01142596|f||OTHER|It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.|t
17128320|NCT01054846|t||||
17128321|NCT02446886|t||||f
17128322|NCT00928447|f||OTHER|The PI must submit a copy of the proposed publication to the Sponsor 30 days prior to date of submission for publication. They can request a delay of up to 90 days if it is determined there is any patentable subject matter or confidential Information. Sponsor can make changes to the communication to remove sponsor's confidential information from it prior to publication.|t
17128323|NCT01259284|t||||f
17128324|NCT03021954|f||||f
17128325|NCT00069238|f||||f
17128326|NCT02453360|t||||
17128327|NCT06172881|f||||f
17128328|NCT00807235|f||GT60||t
17128329|NCT01765179|f||GT60||t
17128330|NCT03581825|f||GT60||t
17128331|NCT01668667|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128332|NCT00421707|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128333|NCT06020118|f||||f
17138530|NCT03000686|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138531|NCT00294684|f||OTHER||t
17138532|NCT00968708|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138533|NCT00389441|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138534|NCT01981109|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17173020|NCT01054885|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173021|NCT03881852|f||||t
17173022|NCT01421719|f||||f
17173023|NCT01942837|f||||t
17182962|NCT03878134|t||||
17128334|NCT03261700|t||||
17128335|NCT01204398|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128336|NCT00983931|f||GT60||t
17128337|NCT04009850|f||||f
17128338|NCT01281969|t||||f
17128339|NCT01723254|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128340|NCT01564628|f||LTE60||t
17128341|NCT01201265|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128342|NCT04640077|f||GT60||t
17128343|NCT01257425|f||||f
17128344|NCT04262817|t||||
17128345|NCT01182194|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17128346|NCT03343301|f||OTHER|The CTA generally does not restrict an investigator's discussion of trial results after completion. Amgen has limited time to review material discussing trial results (up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control/approval of content. For multicenter studies, PI agrees not to publish results before first multi-center publication for at least 18 mo after study completion at all sites \& all analyses of data resulting from Study.|t
17128347|NCT00368992|f||LTE60||t
17128348|NCT02668185|t||||
17128349|NCT03087019|f||||f
17128350|NCT00427895|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128351|NCT02279394|f||||f
17128352|NCT00723021|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128353|NCT00770341|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17182963|NCT00586469|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128354|NCT01163916|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17128355|NCT00883051|f||GT60||t
17128356|NCT02337751|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17128357|NCT01078220|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17128358|NCT03824639|t||||
17128359|NCT03224351|f||OTHER||t
17128360|NCT01328717|t||||
17128361|NCT03440320|t||||f
17128362|NCT01980654|f||LTE60||t
17128363|NCT01620255|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128364|NCT05779397|t||||
17128365|NCT03794908|t||||
17128366|NCT03607539|f||||f
17128367|NCT04256603|t||||
17128368|NCT01155375|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 120 days to allow Sponsor to protect its interests.|t
17128369|NCT01933113|t||||
17128370|NCT04981366|f||||f
17128371|NCT00795951|f||||f
17128372|NCT00427336|t||||f
17128373|NCT02136420|f||||f
17128374|NCT01122862|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128375|NCT01222273|t||||
17128376|NCT04316182|f||||f
17128377|NCT02699983|f||||f
17128378|NCT01790126|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128379|NCT01211197|t||||
17128380|NCT00261846|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128381|NCT00150969|t||||
17128382|NCT03554954|f||||f
17128383|NCT02121834|f||OTHER||t
17128384|NCT01337115|t||||
17128385|NCT00551460|f||GT60||t
17128386|NCT00448123|t||||
17128387|NCT00419666|f||OTHER||t
17128388|NCT02027623|f||||f
17128389|NCT04465760|t||||
17128390|NCT01768520|f||||t
17128391|NCT01971203|t||||
17128392|NCT03353350|f||||f
17128393|NCT01285050|f||||f
17128394|NCT01519466|f||GT60||t
17128395|NCT01210079|f||||f
17128396|NCT00147823|f||||f
17128397|NCT01012713|f||||f
17128398|NCT02571049|f||||f
17128399|NCT01055262|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128400|NCT03370471|t||||
17128401|NCT00561951|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128402|NCT01581541|t||||f
17138535|NCT01522768|t||||
17138536|NCT00126672|t||||
17138537|NCT01851863|f||||f
17138538|NCT03238352|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138539|NCT04083794|t||||
17138540|NCT01296698|f||OTHER|Principal Investigators agreed not to discuss or publish the details/results of this study.|t
17138541|NCT00224003|f||LTE60||t
17138542|NCT03104985|f||||f
17128403|NCT00392327|f||OTHER|Must obtain prior sponsor approval|t
17138543|NCT01202760|f||GT60||t
17138544|NCT04197986|f||||f
17182964|NCT03090256|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17128404|NCT04508023|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17128405|NCT04845633|t||||
17128406|NCT02341859|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17128407|NCT02988622|f||||f
17128408|NCT03525431|t||||
17128409|NCT01074216|t||||
17128410|NCT01323634|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128411|NCT05056987|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17128412|NCT03717129|f||||f
17128413|NCT00753272|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128414|NCT03604523|t||||
17128415|NCT01162317|t||||
17128416|NCT05462886|t||||
17128417|NCT02618642|f||||f
17128418|NCT01675479|f||OTHER|The sponsor must review results communications prior to public release and can embargo communications regarding trial results at any time.|t
17128419|NCT01910181|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128420|NCT01104116|f||||f
17128421|NCT03622619|t||||f
17128422|NCT00235547|f||||f
17128423|NCT00861263|t||||f
17128424|NCT01274585|t||||
17128425|NCT00676065|t||||
17128426|NCT02579174|f||||f
17128427|NCT00655486|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17128428|NCT03840486|t||||
17138545|NCT03920865|t||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17138546|NCT03097029|f||||f
17138547|NCT00411086|t||||
17138548|NCT01669642|t||||
17138549|NCT00108953|f||OTHER|The institution of the Coordinating Investigator (CI) has the right, consistent with academic standards, to publish any proposed publication written by the consultant as part of their services under this agreement. If the sponsor believes that any proposed publication contained any confidential information, the sponsor shall notify the CI, and the CI shall remove such confidential information.|t
17138550|NCT02661464|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17138551|NCT01125293|f||||t
17182965|NCT02908529|f||||f
17182966|NCT02056171|f||||f
17138552|NCT03148756|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.|t
17138553|NCT01270958|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138554|NCT00927264|f||||f
17138555|NCT00936299|f||||f
17138556|NCT02177175|t||||
17138557|NCT03820726|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138558|NCT01011218|f||||f
17138559|NCT00345540|f||||f
17138560|NCT01406652|t||||
17138561|NCT00861380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138562|NCT02481596|f||||f
17138563|NCT00637377|f||OTHER|Confidentiality agreement with sponsor, contract with the sponsor via the CRO (Clinical research organization), set up based on local legal requirements, changes addressed+confirmed with local responsible persons; PIs interested in presenting the study on meetings, contacted the sponsor and received slides and approval to do so either by the Clinical Lead or the Medical Affairs department|t
17138564|NCT03001310|f||||t
17138565|NCT04876599|t||||
17138566|NCT02146833|f||||t
17138567|NCT02564029|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138568|NCT04126031|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138569|NCT00617656|f||||f
17138570|NCT00131664|f||||f
17138571|NCT02088541|f||OTHER||t
17138572|NCT00612339|t||||f
17138573|NCT01105936|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138574|NCT03062267|f||||f
17138575|NCT02431793|f||||f
17138576|NCT02286726|t||||
17138577|NCT03170258|t||||
17138578|NCT01563107|t||||
17138579|NCT03907969|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17138580|NCT00666536|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138581|NCT01391468|f||||f
17138582|NCT02657434|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138583|NCT00608881|f||||f
17138584|NCT04866823|f||||f
17138585|NCT01392742|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138586|NCT01998958|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17138587|NCT03210220|f||||f
17138588|NCT02911519|f||||f
17138589|NCT01707095|f||||f
17138590|NCT00839436|t||||
17138591|NCT00364819|f||||f
17138592|NCT01444898|f||||f
17138593|NCT02238782|f||||f
17128429|NCT02768870|f||OTHER|PI shall not publish site data until first multi-center publication. Publications will be submitted to Sponsor for review 60 days prior to publication/dissemination. Sponsor may ask for a 6-month delay of publication to protect proprietary information.|t
17128430|NCT01774110|f||||f
17128431|NCT00640016|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The Principal Investigator (PIs) also agree for data to be presented first as a joint, multi-center publication.|t
17128432|NCT01287065|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128433|NCT02875977|t||||
17138594|NCT02580591|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138595|NCT03304262|f||||f
17138596|NCT00445341|f||||f
17138597|NCT02021071|f||||f
17138598|NCT01661946|f||||f
17138599|NCT01902004|f||||f
17138600|NCT01831804|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138601|NCT00268463|f||LTE60||t
17128434|NCT01259726|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17128435|NCT01978262|f||||f
17128436|NCT04040400|t||||
17128437|NCT02959450|f||||f
17128438|NCT04578574|f||||f
17128439|NCT03421431|f||||t
17128440|NCT00828841|f||OTHER|The study funder will be provided with a copy of any results communication at least 30 days prior to its submission to a scientific journal or presentation at a scientific meeting to allow review of the publication for confidential information. If confidential information is being disclosed, it may be required to be redacted. Upon request by the study funder, the PI may be asked to withhold disclosure for an additional 90 days to allow the study funder to seek patent protection.|t
17128441|NCT00141726|f||||f
17128442|NCT04147650|f||||t
17138602|NCT02920450|f||||f
17138603|NCT04206670|f||||f
17182967|NCT03337724|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182968|NCT03551210|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17128443|NCT00235326|f||LTE60||t
17182969|NCT05445128|f||||f
17128444|NCT01128738|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128445|NCT01178671|f||||f
17128446|NCT00490009|f||||f
17128447|NCT01917513|f||||f
17128448|NCT02349451|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138604|NCT01732107|f||||f
17138605|NCT03407170|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17128449|NCT02683941|f||||t
17128450|NCT03136328|t||||
17128451|NCT02168842|f||||f
17128452|NCT00325039|f||||f
17128453|NCT02974088|f||||f
17128454|NCT00426153|t||||f
17128455|NCT02891603|f||GT60||t
17128456|NCT00687973|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However,Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128457|NCT00343252|f||GT60||t
17128458|NCT01740323|t||||
17128459|NCT03975595|f||||f
17128460|NCT02618031|f||||f
17128461|NCT03945825|f||LTE60||t
17128462|NCT01610011|f||||f
17128463|NCT00927160|t||||
17128464|NCT00710996|f||OTHER|No paper that incorporates Sponsor Condfidential information will be submitted for publication without Sponsor's prior written agreement.|t
17128465|NCT01423253|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17128466|NCT00307125|f||||f
17128467|NCT00051363|f||||f
17128468|NCT00985153|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128469|NCT00865969|f||||f
17138606|NCT01153672|t||||
17138607|NCT00615459|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138608|NCT01150760|f||||f
17138609|NCT02076334|f||||f
17182970|NCT02239536|f||||f
17182971|NCT05559320|f||||f
17182972|NCT02373124|t||||
17182973|NCT00368940|f||||f
17128470|NCT01596621|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17128471|NCT04329832|f||||f
17128472|NCT01280110|f||||f
17128473|NCT02678247|f||||f
17138610|NCT01975675|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17138611|NCT00871572|f||GT60||t
17138612|NCT00735670|t||||
17182974|NCT05226104|t||||
17182975|NCT02564198|t||||
17182976|NCT01440322|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17182977|NCT00348205|f||OTHER|Contact sponsor directly for details.|t
17182978|NCT03394391|f||||f
17182979|NCT05044234|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17182980|NCT02896127|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128474|NCT00352911|f||LTE60||t
17128475|NCT00971243|f||OTHER||t
17128476|NCT02730598|f||||f
17128477|NCT02910739|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17182981|NCT00739336|f||||f
17182982|NCT01434823|t||||f
17182983|NCT00622427|t||||f
17182984|NCT02477020|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17182985|NCT01299077|f||||f
17182986|NCT00519649|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17182987|NCT04879745|t||||
17182988|NCT00120042|t||||
17182989|NCT02099721|f||||f
17182990|NCT01126541|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17182991|NCT02476565|t||||
17182992|NCT01263873|t||||
17128478|NCT02181387|t||||
17128479|NCT01696942|f||||f
17128480|NCT03413735|f||||f
17128481|NCT01313117|t||||
17182993|NCT01420302|t||||
17128482|NCT01350453|f||||f
17128483|NCT04223856|f||||t
17128484|NCT03226275|f||||f
17182994|NCT05446909|f||||f
17128486|NCT03442114|f||||f
17128487|NCT02903368|f||||f
17128488|NCT01340196|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128489|NCT01422226|f||||f
17128490|NCT00081770|f||LTE60||t
17128491|NCT02245672|f||||t
17128492|NCT00971932|f||OTHER||t
17182995|NCT03738826|t||||
17182996|NCT05560932|t||||
17182997|NCT06640829|f||||f
17182998|NCT01859715|t||||
17182999|NCT01252290|t||||
17128493|NCT01765192|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17128494|NCT01322048|f||||f
17128495|NCT04344600|f||||f
17128496|NCT00876694|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138613|NCT03803202|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17138614|NCT01367860|t||||f
17138615|NCT02540772|f||||f
17138616|NCT00659126|t||||
17138617|NCT02633046|f||||t
17138618|NCT02925312|t||||
17138619|NCT00089102|t||||
17138620|NCT03644108|f||||f
17138621|NCT02766907|f||||f
17138622|NCT02281344|f||||f
17138623|NCT01360229|f||||f
17138624|NCT03205982|t||||f
17138625|NCT00994162|f||GT60||t
17138626|NCT01425749|f||||f
17138627|NCT01293084|t||||
17138628|NCT02096042|t||||
17138629|NCT02983799|f||OTHER|Institution and PI shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within two (2) years of completion of the Study shall require the Sponsor's prior written consent. Sponsor to be consulted prior to presentation or publication.|t
17138630|NCT03406715|t||||
17138631|NCT00845507|f||||f
17138632|NCT00537680|f||||f
17138633|NCT01225172|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17138634|NCT00156013|f||LTE60||t
17138635|NCT00795509|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138636|NCT01601470|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17138637|NCT02079519|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128497|NCT01535014|f||OTHER||t
17128498|NCT01215422|f||||f
17128499|NCT01708122|f||||f
17128500|NCT00294554|t||||
17128501|NCT00462865|f||||f
17128502|NCT02864381|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128503|NCT02544217|f||||f
17128504|NCT05398016|f||||f
17128505|NCT01146054|f||||f
17128506|NCT04335812|f||||f
17128507|NCT02113241|t||||
17128508|NCT02090374|t||||
17128509|NCT02901041|t||||
17128510|NCT00975507|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128511|NCT00887250|t||||
17128512|NCT00605644|f||OTHER|Contact sponsor directly for details.|t
17128513|NCT00879762|f||LTE60||t
17128514|NCT00881608|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17128515|NCT03214094|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17128516|NCT03401229|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17128517|NCT03575143|f||||f
17128518|NCT02566265|t||||
17128519|NCT02027701|f||OTHER|CSL agreements may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128520|NCT02435966|f||||f
17128521|NCT01110876|t||||
17128522|NCT02893930|f||LTE60||t
17128523|NCT02349360|t||||f
17138638|NCT04821960|f||||f
17138639|NCT01041404|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128524|NCT02019927|t||||
17128525|NCT00394953|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128526|NCT04250987|f||||t
17128527|NCT00390182|f||||f
17128528|NCT02917278|f||||f
17128529|NCT02271425|f||GT60||t
17138640|NCT01607073|f||||f
17138641|NCT03726333|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183000|NCT00086580|f||OTHER|In multi-site studies, PI can publish after an independent multi-investigator publication (in which the PI can participate) or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17183001|NCT00261716|t||||
17183002|NCT02075437|f||||f
17183003|NCT04439240|f||LTE60||t
17183004|NCT00673452|f||GT60||t
17183005|NCT00813124|t||||
17183006|NCT00767676|f||LTE60||t
17183007|NCT00079274|f||LTE60||t
17183008|NCT00617240|f||||f
17183009|NCT01611259|f||OTHER||t
17183010|NCT04936685|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17183011|NCT00811564|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17183012|NCT03969212|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183013|NCT02075320|t||||
17183014|NCT00075335|t||||f
17183015|NCT01147653|t||||f
17183016|NCT00353366|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183017|NCT00259857|t||OTHER|Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation.|t
17183018|NCT00203203|t||||f
17183019|NCT00858390|f||OTHER|"This work was supported by the Department of Health and Human Services Health Resources and Services Administration Award Number 1R38OT10585-01-00 and, in part, by Public Health Service Grant DK56338.~Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the PHS or HHS."|t
17183020|NCT02144675|t||||f
17128530|NCT04079803|f||LTE60||t
17128531|NCT04318951|f||||f
17128532|NCT01294683|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17128533|NCT01134016|f||OTHER|All the PI should grand sponcer's agree to discuss or publish trial results after the trial is completed.|t
17128534|NCT01032382|f||OTHER|Parties agree to keep Referenced Information in strict confidence and not to disclose it to any other party or use Referenced Information for any purpose, other than for the performance of the clinical studies herein described, without prior written consent of the providing party. Parties may disclose the Referenced Information to their employees and consultants, and employees and consultants of their affiliates, who have a need to know such Referenced Information.|t
17128535|NCT00412971|f||GT60||t
17128536|NCT02409368|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128537|NCT01296347|f||||f
17128538|NCT01585987|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128539|NCT02041520|f||||f
17128540|NCT01759407|t||||
17128541|NCT03737474|f||||f
17128542|NCT02513745|t||||
17173024|NCT00632814|f||OTHER|The Institute shall supply a draft of any intended publication to the Customer not less than 60 (sixty) days before submission it for the publication in question and will supply a draft of any abstract or detailed paper or oral statement intended for public presentation not less than 60 (sixty) days before the earliest of the date of submission of the abstract or delivery of the public presentation. The Institute agrees that in any such publication only such data as is contained in an analysis.|t
17173025|NCT01424215|f||||f
17128543|NCT01209143|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173026|NCT02993107|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17173027|NCT03250273|t||||
17173028|NCT04226742|f||||f
17173029|NCT01047358|f||GT60||t
17173030|NCT01759446|f||||f
17173031|NCT01357525|t||||
17173032|NCT04646044|f||||t
17173033|NCT01391546|f||OTHER|Investigators must first obtain written consent from Sponsor. If consent is given, all abstracts manuscripts, texts, or presentation, etc. will be sent to Sponsor for review and approval prior to their publication or presentation. Sponsor shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17173034|NCT03961672|t||||
17173035|NCT02156076|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173036|NCT01213472|f||OTHER||t
17173037|NCT01101867|f||||f
17173038|NCT04225897|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173039|NCT02085460|f||||f
17138642|NCT01946412|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17173040|NCT01285323|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17173041|NCT02703597|f||||f
17173042|NCT02606643|f||||f
17173043|NCT02376998|f||||f
17173044|NCT02796170|t||||
17173045|NCT03216512|f||||f
17173046|NCT01011894|t||||
17173047|NCT04313244|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173048|NCT00089752|f||||f
17173049|NCT01472289|f||LTE60||t
17173050|NCT00907335|f||LTE60||t
17128544|NCT01145755|f||OTHER|"No publication or presentation of results until the earlier of 1) the date of the first study results publication or 2) 18 months after completion or termination of the study.~AZ review 60 days prior submission and AZ has the possibility to further delay publication for an additional 90 days"|t
17128545|NCT01783041|f||||f
17173051|NCT03873116|f||||f
17128546|NCT03796260|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128547|NCT00742053|f||||f
17128548|NCT02265367|t||||
17128549|NCT02092220|t||||f
17128550|NCT02739360|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128551|NCT01193920|f||OTHER|Other disclosure agreement: the terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128552|NCT02097641|f||||f
17128553|NCT01231516|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128554|NCT00026208|f||||f
17128555|NCT03170154|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17173052|NCT00912808|t||||
17173053|NCT01096875|t||||
17173054|NCT03941288|t||||
17173055|NCT03994081|t||||
17173056|NCT00474812|f||LTE60||t
17173057|NCT02620774|f||||f
17173058|NCT03542487|f||||f
17173059|NCT03529669|f||OTHER|NHS Organisations shall not publish or otherwise disseminate the conclusions of the Study, including all or any part of the Results of the Study without prior written consent of the Sponsor, such consent not to be unreasonably withheld. Any publication or other dissemination of the conclusions of the Study by NHS Organisations shall not occur until the Sponsor has published the conclusions of the Study \& shall refer to publication by the Sponsor in such form as the Sponsor may reasonably direct.|t
17173060|NCT03955146|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17173061|NCT04798183|t||||
17173062|NCT04363320|t||||
17173063|NCT02002598|t||||
17173064|NCT05632211|f||OTHER||t
17173065|NCT02628873|f||||f
17173066|NCT00541658|f||OTHER|The findings of the study may be published in a scientific journal or presented at a scientific meeting. Before submitting the results of the study for publication or presentation, the Investigator will allow the sponsor 30 days in which to review and comment on the manuscript.|t
17173067|NCT04123470|f||||t
17173068|NCT05530252|f||||f
17173069|NCT02195518|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173070|NCT04370873|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17173071|NCT00911170|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17173072|NCT02594124|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173073|NCT05370495|f||OTHER|Collaborative and collegial interaction on presentations and publications.|t
17173074|NCT02514083|t||||
17173075|NCT02230995|t||||
17173076|NCT02141295|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173077|NCT01710501|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17173078|NCT02536976|t||||
17173079|NCT00071890|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results with no delay specified|t
17173080|NCT01671319|t||||f
17173081|NCT01709084|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17173082|NCT02144610|f||||f
17173083|NCT02169427|f||OTHER||t
17173084|NCT00214201|t||||
17173085|NCT01399372|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17173086|NCT01432730|f||OTHER|The data generated in this clinical trial are the property of Sponsor and are confidential. Authorship on any publication or presentation of the results from this study will be govern by the executed Clinical Trial Agreement as well as being consistent with the Uniform Requirements of the International Committee of Medical Journal Editors.|t
17173087|NCT02505919|f||GT60||t
17173088|NCT01712399|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17173089|NCT01298648|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173090|NCT02201394|t||||
17173091|NCT02648919|t||||
17173092|NCT03252431|f||||f
17138643|NCT01625611|f||||f
17138644|NCT05091918|f||||f
17138645|NCT00994760|f||||f
17173093|NCT02038933|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173094|NCT04154904|t||||
17173095|NCT01635439|t||||f
17173096|NCT03877510|f||||f
17173097|NCT02113982|f||||f
17173098|NCT00267059|t||||f
17173099|NCT02085161|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173100|NCT04591353|t||||
17173101|NCT01647217|t||||
17128556|NCT05266586|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17128557|NCT02225353|f||OTHER||t
17128558|NCT01117857|f||||f
17128559|NCT03282240|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable partcipant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17128560|NCT02146326|t||||
17128561|NCT01340651|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least thirty (30) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17128562|NCT03253926|t||||
17128563|NCT03660553|f||||f
17128564|NCT00171704|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in clinical trial.|t
17128565|NCT01101477|t||||f
17128566|NCT02141984|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17128567|NCT04262947|t||||
17128568|NCT00816400|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17128569|NCT00601419|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128570|NCT01614197|f||||f
17128571|NCT01097785|f||||f
17128572|NCT01729156|f||||f
17128573|NCT04142450|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17173102|NCT01936870|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173103|NCT03651479|t||||
17128574|NCT03249714|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128575|NCT01112306|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128576|NCT03008707|f||||f
17173104|NCT01635504|f||||f
17173105|NCT02399163|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173106|NCT03910244|f||LTE60||t
17128577|NCT01942720|f||||f
17128578|NCT01607554|f||||f
17173107|NCT03734692|t||||
17173108|NCT00217399|f||LTE60||t
17173109|NCT00803569|f||LTE60||t
17173110|NCT03345784|f||LTE60||t
17173111|NCT04798196|f||||f
17173112|NCT01834911|f||||f
17173113|NCT02512783|t||||
17173114|NCT03611829|f||||f
17128579|NCT03952806|f||LTE60||t
17173115|NCT00728689|f||OTHER|PI must have sponsor's written consent to publish and must provide information to the sponsor at least 30 working days prior to publication submission deadline.|t
17128580|NCT00655863|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17128581|NCT01138007|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128582|NCT04661878|t||||
17128583|NCT03867175|t||||
17128584|NCT01806129|f||LTE60||t
17128585|NCT04442737|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17128586|NCT00744523|f||GT60||t
17128587|NCT05195814|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128588|NCT01139021|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128589|NCT04823221|f||||t
17128590|NCT02963610|t||||
17173116|NCT00929695|t||||
17173117|NCT00425802|t||||
17173118|NCT00887809|t||||
17173119|NCT01615484|t||||
17173120|NCT05465317|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173121|NCT01690143|t||||
17173122|NCT03777982|t||||
17173123|NCT00870740|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173124|NCT03755934|f||OTHER|AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17173125|NCT00817843|f||||f
17173126|NCT00307801|f||OTHER|Schering AG is interested in the publication of the results of every study. As some of the information concerning the study drug and development activities at Schering AG may be of strictly confidential nature, any publication manuscript must first be reviewed by the sponsor before its submission or presentation.|t
17173127|NCT01069003|f||OTHER||t
17173128|NCT03431259|t||||
17173129|NCT00551642|f||OTHER||t
17173130|NCT02596867|f||||f
17173131|NCT00361296|t||||
17173132|NCT00198822|f||||f
17173133|NCT03011099|t||||
17173134|NCT00963859|t||||f
17173135|NCT00129246|t||||f
17173136|NCT02072668|f||||f
17173137|NCT04482647|t||||
17173138|NCT04223479|f||||f
17173139|NCT01231906|f||OTHER|Must obtain prior sponsor approval|t
17128591|NCT05333224|f||||f
17128592|NCT00063154|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128593|NCT03588728|t||||f
17173140|NCT04163341|f||||f
17173141|NCT05030129|t||||
17173142|NCT02484391|t||||
17173143|NCT06714682|t||||f
17173144|NCT00905164|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17173145|NCT02633059|t||||
17173146|NCT04730804|f||||t
17173147|NCT05366738|f||OTHER|Principal investigators (PIs) are not permitted to publish the data. Data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the PIs to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority over all such issues.|t
17173148|NCT01389596|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17173149|NCT04082819|f||||f
17173150|NCT01124006|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication at least 60 days prior to the intended submission, presentation, or publication date.|t
17128594|NCT03285178|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17128595|NCT01388790|f||LTE60||t
17128596|NCT01128894|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128597|NCT00195507|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17128598|NCT00973362|f||LTE60||t
17128599|NCT00887679|t||||f
17128600|NCT00959166|t||||
17128601|NCT02311998|t||||
17128602|NCT01630434|f||OTHER|Site shall have right to publish results. To balance this right with TransMedics' (TM) proprietary interests, site will submit manuscripts intended for publication for TM's review at least 60d prior to submission date. TM will complete its review within 60d of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request. After 60d period, site will have right to publish manuscript, as amended by TM.|t
17128603|NCT02578862|t||||
17128604|NCT01026454|f||||f
17128605|NCT01176773|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17128606|NCT03586687|t||||
17128607|NCT02196714|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17173151|NCT00565084|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173152|NCT03124342|f||||f
17183021|NCT01813019|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17183022|NCT03075644|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17183023|NCT02164396|f||GT60||t
17183024|NCT01458171|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183025|NCT02270060|t||||
17183026|NCT02214121|f||OTHER|No publication can be made in advance of the first multicenter publication by the sponsor. Any publication will be submitted to the sponsor for review prior to the being published. The sponsor has the right to defer this publication for a period between 60 days to 6 months. The sponsor has the right to restrict the use of confidential information in any of the publications submitted.|t
17183027|NCT00715793|t||||
17183028|NCT04942938|t||||
17183029|NCT01849588|t||||f
17128608|NCT00690833|t||||
17128609|NCT01592864|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128610|NCT02858349|f||||f
17128611|NCT02120716|f||||f
17128612|NCT01862133|f||||f
17128613|NCT04668586|t||||
17128614|NCT02804178|f||||t
17128615|NCT01106404|f||GT60||t
17128616|NCT01290601|f||||f
17128617|NCT00775450|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17128618|NCT04071795|t||||
17128619|NCT03552822|f||||f
17128620|NCT01749540|f||OTHER|No publication or disclosure of study results will be permitted except as specified in a separate, written, agreement between the sponsor and the investigator(s).|t
17128621|NCT00954421|t||||
17128622|NCT00633061|f||||f
17128623|NCT05245097|f||LTE60||t
17128624|NCT04770493|f||||f
17128625|NCT02791737|t||||
17128626|NCT01005459|t||||
17128627|NCT04675151|f||||f
17173153|NCT04441892|t||||
17173154|NCT03841604|f||||f
17128628|NCT00777946|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17173155|NCT01417377|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173156|NCT01774721|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173157|NCT03594110|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173158|NCT02351817|t||||
17173159|NCT01194856|t||||
17128629|NCT00763867|f||||f
17128630|NCT01658826|f||||t
17128631|NCT05677893|f||||t
17128632|NCT01485354|f||||f
17128633|NCT02101034|t||||
17128634|NCT03081052|t||||
17128635|NCT04109196|f||||f
17128636|NCT00733993|f||||f
17128637|NCT02730988|t||||f
17128638|NCT02382016|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17128639|NCT00084266|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128640|NCT00730171|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published|t
17128641|NCT01614743|t||||
17128642|NCT02919657|f||OTHER||t
17128643|NCT00604812|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128644|NCT02335125|t||||
17128645|NCT01326533|t||||f
17138646|NCT00239356|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128646|NCT01881750|f||||f
17128647|NCT00926211|f||||f
17128648|NCT00078754|f||||f
17128649|NCT00894686|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128650|NCT00564018|t||||
17128651|NCT00287339|f||||f
17128652|NCT03267940|f||GT60||t
17128653|NCT01869075|t||||f
17173160|NCT02488915|f||||f
17173161|NCT00417417|t||||f
17173162|NCT00684021|t||||
17173163|NCT00927953|f||GT60||t
17183030|NCT00094653|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128654|NCT00388154|t||||
17128655|NCT01401907|f||||f
17128656|NCT02240693|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128657|NCT01948908|f||||f
17183031|NCT03921411|f||||t
17128658|NCT03291587|f||||f
17128659|NCT00796120|f||OTHER|Before Investigators of this study publicly disclose information, PharmaMar must be provided with at least 60 days to review and approve disclosure in order to ensure that confidential and proprietary data are protected. If PharmaMar determines that patentable patient matter is disclosed in the proposed disclosure, the latter shall be withheld for period of time considered convenient.|t
17128660|NCT02197767|t||||
17128661|NCT03482583|f||||f
17128662|NCT00413972|t||||
17173164|NCT02976038|f||GT60||t
17183032|NCT00330551|t||||f
17183033|NCT03120013|f||||f
17128663|NCT01898923|f||GT60||t
17128664|NCT01477320|f||||f
17128665|NCT00381303|f||OTHER|If TTCA does not publish within 12 months after study conclusion or after TTCA confirms there will be no multicenter publication, Institution may publish their results from their site individually, provided TTCA has 60 day review for confidentiality and additional 60 day delay for patent application.|t
17128666|NCT03933774|f||||f
17128667|NCT01966471|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128668|NCT00494481|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17128669|NCT01030198|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17128670|NCT00332189|f||OTHER|The first publication of the results shall be made in a joint publication. If such a multi-center publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from their site individually, subject however, to compliance with the other terms of the agreement.|t
17128671|NCT02370043|f||OTHER||t
17128672|NCT02279862|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128673|NCT01163721|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128674|NCT00688181|f||||f
17138647|NCT00511108|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138648|NCT02698566|f||OTHER|Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173165|NCT01046396|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17173166|NCT01208207|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17173167|NCT04041414|f||||f
17173168|NCT04004988|t||||
17173169|NCT00930046|f||||f
17173170|NCT01598532|t||||
17173171|NCT04682366|f||||f
17173172|NCT00702221|f||||f
17173173|NCT02989597|t||||
17173174|NCT01028820|t||||f
17128675|NCT01050205|f||||f
17128676|NCT01119001|f||||f
17128677|NCT04931836|f||||f
17128678|NCT00692978|t||||
17128679|NCT00607022|f||||f
17128680|NCT00810394|t||||
17128681|NCT03254485|f||||t
17128682|NCT00467285|t||||
17128683|NCT03221192|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128684|NCT01491893|f||||f
17173175|NCT01867671|f||||f
17128685|NCT01377753|f||||f
17128686|NCT05312151|f||||t
17128687|NCT01598311|f||||f
17128688|NCT00658684|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173176|NCT01523366|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of the submission for publication. The Investigators in the Multi-Center (MC) study agree to postpone MC publications until the earlier of the first AZ-authorized publication or up to 18 months from study completion at all sites.|t
17173177|NCT04543279|t||||
17173178|NCT01352715|f||||f
17173179|NCT04596267|f||||f
17173180|NCT00071058|f||||f
17173181|NCT02000440|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173182|NCT04109547|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17173183|NCT01550003|f||GT60||t
17183034|NCT03697811|f||||t
17128689|NCT00688103|f||||f
17173184|NCT01656408|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17173185|NCT03995368|f||||f
17173186|NCT03592186|t||||f
17173187|NCT02968758|f||||f
17173188|NCT01409707|f||||f
17173189|NCT01658436|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17173190|NCT01217229|f||GT60||t
17173191|NCT03987503|f||||f
17173192|NCT03678493|t||||
17173193|NCT02784548|f||||f
17173194|NCT00656448|t||||
17173195|NCT01808456|f||||f
17173196|NCT01929317|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173197|NCT04322526|t||||f
17128690|NCT00724308|t||||f
17128691|NCT03602261|f||||t
17128692|NCT06515483|f||||f
17128693|NCT03722407|t||||
17128694|NCT00604279|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to publication and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The paper that incorporates confidential information requires Sponsor's written consent. PI will withhold publication for up to an additional 60 days to allow for filing of a patent application.|t
17128695|NCT02884427|f||||f
17128696|NCT00995020|t||||f
17128697|NCT04878731|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128698|NCT03330457|f||||t
17128699|NCT00719563|t||||
17128700|NCT00567268|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128701|NCT00420017|f||||f
17128702|NCT01717989|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128703|NCT00792805|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128704|NCT03224325|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17128705|NCT02952001|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical.|t
17128706|NCT03599557|f||||f
17128707|NCT04533451|t||||
17128708|NCT03890419|f||||f
17173198|NCT01523756|t||||
17173199|NCT00993967|f||||f
17173200|NCT02760498|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17173201|NCT02529072|f||||f
17173202|NCT00935584|t||||f
17128709|NCT01996813|t||||
17128710|NCT03278106|t||||
17128711|NCT02982187|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173203|NCT00687193|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173204|NCT03534804|f||OTHER|"Agreement with UNIVERSITY OF UTAH and MOFFITT CANCER CENTER:~University and PI shall have first right to publish and disseminate the results of their investigative findings under the Study unless 18 months have elapsed following completion of the Study without such publication by University or PI.~Agreement with UNIVERSITY OF UTAH and EMORY UNIVERSITY:~University and PI shall have first right to publish and disseminate the results of their investigative findings under the Study."|t
17173205|NCT04986904|t||||
17173206|NCT00174187|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173207|NCT03435211|t||||
17173208|NCT00759941|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17173209|NCT03863080|f||||f
17183035|NCT01541826|f||||f
17183036|NCT02600637|f||||f
17128712|NCT02604433|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128713|NCT03437278|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128714|NCT02202551|f||||f
17128715|NCT02147353|t||||
17128716|NCT02796001|f||||f
17128717|NCT00186069|f||||f
17128718|NCT00759291|f||||f
17128719|NCT04744285|t||||
17128720|NCT00934141|f||||f
17128721|NCT03057808|f||||f
17173210|NCT01342211|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173211|NCT06482125|f||||f
17173212|NCT05353777|f||||f
17128722|NCT00752622|f||OTHER|Prior to submission for publication of results obtained in this study, written permission is required. Draft manuscripts, abstracts \& presentations should be submitted for review \& approval. Schering-Plough Canada will retain the ownership of the data obtained in this study. Authorship of publications resulting from this study should accurately reflect the academic contribution of individuals to the design and implementation of the study, analysis of the data and preparation of the manuscript.|t
17173213|NCT02582775|t||||
17128723|NCT00576836|t||||f
17128724|NCT02520284|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17128725|NCT00267631|f||||f
17128726|NCT02441062|t||||
17128727|NCT01211522|f||||f
17128728|NCT02740972|f||OTHER|The most restrictive relevant agreement on the PI provides that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is not less than 30 days from the time submitted to the sponsor for review.|t
17128729|NCT01116882|f||||f
17128730|NCT00547365|f||||f
17128731|NCT01139658|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128732|NCT00504881|f||GT60||t
17128733|NCT01777269|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128734|NCT00282282|t||||f
17128735|NCT00803270|f||OTHER||t
17128736|NCT02737917|t||||
17128737|NCT03349892|t||||
17138649|NCT02044822|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17138650|NCT02147691|t||||
17138651|NCT02967172|f||||f
17173214|NCT01588522|f||OTHER||t
17138652|NCT03417505|f||OTHER|The PI has the right to publish results from the study. The Sponsor has 30 days to review communications prior to publication with respect to the disclosure of confidential information (study results would not qualify as confidential information).|t
17128738|NCT00593957|t||||f
17128739|NCT03481023|t||||
17128740|NCT03707925|t||||
17128741|NCT01786239|t||||
17128742|NCT02511678|f||OTHER|Galil Medical can require Investigator to postpone publications/presentations for up to 12 months so data from all sites can be published. Galil Medical will limit review of Investigator's draft to confirm Confidential Information is not being disclosed. If Galil Medical notes publishing Study results may affect obtaining a patent, Investigator may not publish for up to 60 days until patent application is filed. Investigator will acknowledge Galil Medical in any publication/presentation.|t
17128743|NCT01295281|f||GT60||t
17128744|NCT05101707|f||||f
17128745|NCT01411839|f||||f
17128746|NCT06389838|f||||f
17128747|NCT05461794|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17138653|NCT02954952|f||OTHER|The PI can initiate publication after 12 months of study completion or early termination (whichever is applicable). The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.|t
17173215|NCT04504253|t||||
17173216|NCT03205423|f||||f
17173217|NCT04364867|f||||f
17173218|NCT05786651|t||||
17173219|NCT04390763|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173220|NCT03666663|t||||
17128748|NCT02684357|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17128749|NCT01079130|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17173221|NCT00420771|t||||f
17173222|NCT02696967|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173223|NCT01803607|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17173224|NCT03077412|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173225|NCT03824769|f||||f
17173226|NCT02266888|f||||f
17173227|NCT02351856|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173228|NCT01550224|f||||f
17173229|NCT01281124|f||LTE60||t
17173230|NCT03038100|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183037|NCT01365273|f||OTHER|Sponsor is the owner of the results.|t
17183038|NCT04043312|f||||f
17183039|NCT01339390|f||||f
17128750|NCT03714425|f||||f
17128751|NCT03019796|f||||f
17128752|NCT00508352|f||||f
17128753|NCT04821869|f||||f
17128754|NCT03444324|f||||t
17128755|NCT01390181|t||||
17128756|NCT01103245|f||||f
17128757|NCT00720941|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17128758|NCT00355056|f||OTHER||t
17128759|NCT02805725|t||||
17128760|NCT01195545|t||||
17128761|NCT02425644|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128762|NCT01072877|f||||f
17128763|NCT02720536|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128764|NCT00909792|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.|t
17128765|NCT03290196|f||||f
17128766|NCT02120625|f||OTHER|"Sponsor has final say on publication of data, after their review.~Abstract of data from first 6 cases published:~Bainbridge JS, et al; Pain Medicine 2015, Volume 16, Number 8, p.1650"|t
17128767|NCT01177787|f||||f
17128768|NCT02158520|f||||f
17128769|NCT00402363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128770|NCT00293722|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128771|NCT00819260|f||||f
17128772|NCT02634346|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17128773|NCT01346488|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17128774|NCT02824263|f||||f
17128775|NCT01008696|f||||f
17173231|NCT00918255|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17173232|NCT02392624|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173233|NCT00706238|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173234|NCT00874094|f||||f
17173235|NCT01698333|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public dissemination. The PI may not disclose previously undisclosed confidential information other than study results.|t
17173236|NCT01193244|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17173237|NCT00384670|f||||f
17173238|NCT03763877|f||||f
17173239|NCT03040336|t||||
17173240|NCT03537404|f||OTHER|Any study related information could be made public availiable only after Sponsors written permission.|t
17173241|NCT03906448|f||||f
17173242|NCT00068692|f||LTE60||t
17173243|NCT01222689|f||LTE60||t
17173244|NCT04790916|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173245|NCT00248040|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo.|t
17173246|NCT00842335|f||||f
17128776|NCT00568321|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173247|NCT03481595|f||||f
17173248|NCT00832299|t||||
17173249|NCT02930824|f||||f
17173250|NCT02540629|f||||f
17173251|NCT00628108|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17173252|NCT03848832|f||OTHER||t
17173253|NCT01760733|t||||
17173254|NCT02404025|f||OTHER|The terms and conditions of Novartis'agreements with its investigators may vary. However Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128777|NCT00937833|f||GT60||t
17128778|NCT01676909|f||||f
17128779|NCT01707225|f||LTE60||t
17128780|NCT03260595|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128781|NCT00221195|f||LTE60||t
17128782|NCT05057923|t||||
17128783|NCT00162032|f||GT60||t
17128784|NCT00833911|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17128785|NCT00718640|f||||f
17128786|NCT02431650|f||LTE60||t
17128787|NCT00818389|f||||f
17173255|NCT01524796|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173256|NCT00080535|f||||f
17173257|NCT01374438|f||LTE60||t
17173258|NCT03938259|t||||
17173259|NCT01002339|f||||f
17128788|NCT01207596|t||||f
17128789|NCT03548987|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17128790|NCT05103228|f||||f
17173260|NCT01907854|f||OTHER|At the end of the trial, one or more public disclosures may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property. The results of this trial will be subject to public disclosure on external web sites according to international regulations, as reflected in the Novo Nordisk Code of Conduct for Clinical Trial Disclosure.|t
17173261|NCT02004041|f||OTHER||t
17173262|NCT02215252|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173263|NCT03774576|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173264|NCT01716234|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy, fair balance, and compliance.|t
17173265|NCT00702299|f||GT60||t
17173266|NCT00515619|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17173267|NCT03815929|t||||f
17173268|NCT01467960|f||||f
17173269|NCT00771758|f||GT60||t
17173270|NCT03067077|t||||
17173271|NCT03801408|t||||f
17173272|NCT01394016|f||GT60||t
17173273|NCT01899521|t||||
17128791|NCT01106014|f||LTE60||t
17128792|NCT00784693|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128793|NCT03673865|t||||
17128794|NCT00756470|t||||
17128795|NCT00820027|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17128796|NCT00908232|f||GT60||t
17173274|NCT03397966|t||||
17173275|NCT04983680|f||||f
17173276|NCT04949490|f||OTHER|Principal Investigators respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17173277|NCT02017405|f||OTHER|45 days|t
17173278|NCT00811590|t||||
17173279|NCT02864394|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17173280|NCT04988477|f||||f
17183040|NCT04847674|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17183041|NCT02281136|f||OTHER|First publication of results will be made by the Sponsor. If publication is not submitted within 12 months after the date of study final report, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30 days before submission for publication so that sponsor can review the publication for confidential information|t
17183042|NCT02563028|f||||f
17183043|NCT01228968|f||||f
17183044|NCT01462357|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183045|NCT00096044|t||||
17183046|NCT00004031|f||||f
17183047|NCT01387607|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183048|NCT00501891|t||||f
17183049|NCT03013491|f||||f
17183050|NCT03265119|f||OTHER|The information generated by this study is the property of Aevi Genomic Medicine, Inc. Publication or other public presentation of AEVI-001 data resulting from this study requires prior review and written approval of Aevi Genomic Medicine, Inc. Abstracts, manuscripts, and presentation materials should be provided to Aevi Genomic Medicine, Inc. for review at least 30 days prior to the relevant submission deadline.|t
17173281|NCT00777153|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17173282|NCT01833247|f||||f
17173283|NCT00554216|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17173284|NCT02079246|f||||f
17173285|NCT00463567|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17173286|NCT02633306|t||||
17173287|NCT00956007|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17173288|NCT01746901|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173289|NCT02683577|f||OTHER|The PI will provide the sponsor with any results communications for public release at least 90 days prior to the planned submission for their review.|t
17173290|NCT02968004|f||||t
17173291|NCT05029362|t||||
17173292|NCT05571605|t||||
17173293|NCT00419952|f||OTHER|The PI may use the Multi-Center Study Results and the Site Data for the limited purpose of his or her own research and academic analysis until the earlier of the publication of the first Multi-Center Study at all participating sites|t
17173294|NCT03126591|f||GT60||t
17173295|NCT02158546|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17173296|NCT02900378|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173297|NCT01807624|f||||f
17173298|NCT02531802|f||||f
17173299|NCT03769519|t||||
17128797|NCT02260882|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17128798|NCT02119325|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173300|NCT00767364|f||||f
17128799|NCT00954174|f||LTE60||t
17173301|NCT03429270|f||LTE60||t
17173302|NCT01249261|f||LTE60||t
17173303|NCT02819804|t||||
17173304|NCT03060096|f||||f
17173305|NCT00482053|f||||f
17173306|NCT01441076|t||||f
17173307|NCT03114683|f||||f
17173308|NCT00346697|f||||f
17128800|NCT02287376|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.|t
17128801|NCT01776424|f||OTHER|Global principal investigator (PI) to provide to Bayer for review any proposed Publication/oral presentation relating to Study/Study Drug/Results at least 45 days prior to submission or presentation of the Publication. Abstracts to be provided to Bayer 5 working days before Publication. Bayer may provide comments within the applicable period. Under certain circumstances Bayer may request a further delay of publications to avoid adverse effects on a Bayer patent application.|t
17173309|NCT04454918|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17173310|NCT01055197|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17173311|NCT03739203|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173312|NCT03131570|f||||f
17173313|NCT01782378|t||||
17173314|NCT00830440|f||||f
17173315|NCT04266717|f||||f
17173316|NCT00391586|f||||f
17173317|NCT00904982|f||||f
17183051|NCT03238911|f||OTHER|Before 1 year after completion of the Study report the Investigator must not publish details regarding the Protocol and the conduct or results of the Trial. However, if a joint publication is submitted for publication the individual Investigator has no right to publish results from his/her centre until such the joint publication is actually issued.|t
17173318|NCT04355169|f||OTHER|The sponsor can embargo results from a PIs center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication.Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 45 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17128802|NCT00146757|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17128803|NCT02019888|t||||
17128804|NCT02064855|f||OTHER|The Institution/PI shall not disclose/use any confidential/proprietary information (CI) disclosed to/developed by the Institution during the study. Institution/PI agree to hold the results of the Study in confidence, and shall not disclose them except with prior written consent of K2M. Institution agrees to submit any Articles to K2M for review prior to publication and agrees to edit out any confidential information identified by K2M.|t
17128805|NCT00550368|f||||f
17128806|NCT03181451|f||||t
17128807|NCT04384848|f||||f
17128808|NCT00256451|f||||f
17128809|NCT03478163|t||||
17128810|NCT01762722|f||||f
17128811|NCT03037619|t||||
17128812|NCT03294109|f||||f
17128813|NCT01794923|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128814|NCT00759330|f||OTHER|An Institution Publication may be published provided that it does not disclose Confidential Information other than the study results from Institution's study data. The proposed Institution Publication shall be submitted to sponsor for review and comment at least 30 days prior to submitting it to a third party. If sponsor requests a delay in order to file patent applications, the Institution Publication may be delayed for submission to a third party for up to 120 days after sponsor request.|t
17128815|NCT03318809|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128816|NCT03270332|t||||f
17128817|NCT03681886|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17128818|NCT02198430|f||LTE60||t
17128819|NCT01050907|f||||f
17128820|NCT02030405|f||||f
17128821|NCT00986440|f||||f
17128822|NCT02973048|t||||
17128823|NCT03099005|t||||f
17128824|NCT00651157|f||LTE60||t
17128825|NCT01721603|t||||
17128826|NCT00364156|t||||f
17128827|NCT00292461|f||||f
17128828|NCT00680823|t||||f
17128829|NCT00846651|t||||f
17128830|NCT04356183|t||||
17128831|NCT01570036|f||OTHER|In the event a Study is a multi-center clinical study, Institution and Principal Investigator will refrain from any disclosure or publication of Study data until the earlier of: (i) the publication of a multi-center publication or (ii) eighteen months following the conclusion of the Study. Nothing in this Article 6 is intended to limit or restrict in any way Sponsor's right to publish independently any Study results.|t
17128832|NCT00667355|f||OTHER|Disclosure agreements vary; the Medical Institution shall not disclose any material/information disclosed by Abbott Japan in connection with the Clinical Research or information obtained by conducting the Clinical Research to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting Clinical Research, Institution shall obtain Abbott Japan's prior written approval.|t
17128833|NCT00823901|f||||f
17128834|NCT01247571|f||LTE60||t
17128835|NCT01369511|f||GT60||t
17128836|NCT01180998|f||OTHER|Publication required agreement and written authorization from the Sponsor.|t
17128837|NCT01376349|f||LTE60||t
17128838|NCT01137955|t||||f
17128839|NCT00068588|f||LTE60||t
17128840|NCT05193500|f||||f
17128841|NCT04098068|t||||
17128842|NCT03871829|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128843|NCT04092101|f||||f
17128844|NCT01720173|f||LTE60||t
17128845|NCT05458479|f||||f
17128846|NCT01324323|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation|t
17128847|NCT01821378|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17128848|NCT02888665|f||||f
17173319|NCT02420821|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173320|NCT00686712|t||||
17183052|NCT03655236|f||||t
17173321|NCT03058146|f||||f
17183053|NCT00991302|f||||f
17183054|NCT01709318|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17173322|NCT00999102|f||||f
17183055|NCT03042312|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173323|NCT01352793|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173324|NCT03000608|f||LTE60||t
17173325|NCT02839200|f||||f
17183056|NCT02383758|t||||
17173326|NCT00411684|f||||f
17173327|NCT00646048|f||OTHER||t
17183057|NCT00273364|t||||
17183058|NCT02805647|f||||f
17183059|NCT00646958|f||OTHER|The sponsor retains control of all publication rights.|t
17128849|NCT00993915|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128850|NCT01386658|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17128851|NCT02267356|f||OTHER|Neither Institution nor Principal Investigator shall publish the results of the Trial without the prior written consent of Sponsor, which it may withhold in its sole discretion.|t
17128852|NCT00592761|t||||
17128853|NCT02465463|f||||f
17128854|NCT00821431|f||||f
17128855|NCT00372385|f||GT60||t
17128856|NCT01699789|f||||f
17128857|NCT01222260|t||||
17128858|NCT05062083|t||||
17128859|NCT02411578|f||||f
17128860|NCT02340091|f||OTHER||t
17128861|NCT01244451|f||OTHER|PIs of participating centres may disclose their centre's results only after the main study publication has been released, so that a single centre experience can be compared to the study overall results and give a more appropriate view of the study.|t
17173328|NCT01094119|f||||f
17173329|NCT03352609|f||||f
17173330|NCT02205736|t||||
17173331|NCT03326713|t||||
17173332|NCT01624350|f||||f
17173333|NCT03529695|f||||f
17173334|NCT06078124|f||||f
17173335|NCT01198977|t||||f
17183060|NCT04318210|t||||
17128862|NCT02460666|f||||f
17183061|NCT03085927|t||||f
17183062|NCT02349711|f||OTHER|The PI shall provide the sponsor copies of any proposed publication or presentation at least 30 days in advance of submission to a journal, editor, or other third party to allow sponsor to determine whether patentable subject matter or sponsor's confidential information would be disclosed.|t
17183063|NCT00194012|t||||
17183064|NCT01516268|t||||f
17183065|NCT01595516|f||||f
17183066|NCT02200042|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17183067|NCT02097134|f||||f
17183068|NCT00218062|t||||
17183069|NCT02939404|t||||
17183070|NCT02942979|t||||
17183071|NCT02665728|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17128863|NCT03431857|f||||t
17173336|NCT01285557|f||||t
17173337|NCT01781728|f||||f
17173338|NCT05615922|t||||
17173339|NCT05378672|f||||t
17173340|NCT04410367|f||OTHER|Neither the INSTITUTION nor the INVESTIGATOR will submit for publication or public disclosure any publication or disclosure based on the results of the Study until after the first to occur of (a) publication of the multi-center clinical trial results; (b) notification by BED that the multi-center clinical trial submission is no longer planned; or (c) the eighteen (18) month anniversary of the completion or early termination of the multi-center clinical trial.|t
17173341|NCT03173248|f||LTE60||t
17173342|NCT05174416|f||||f
17173343|NCT01648751|t||||
17173344|NCT02833233|t||||
17173345|NCT03111121|t||||
17173346|NCT02991768|f||||f
17173347|NCT03467750|t||||
17183072|NCT02047110|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183073|NCT02247349|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183074|NCT00821626|f||||f
17183075|NCT01271543|t||||f
17183076|NCT01959581|f||||f
17183077|NCT02003625|t||||
17183078|NCT03773757|f||||f
17183079|NCT01109316|f||GT60||t
17173348|NCT05673876|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173349|NCT03052829|t||||
17173350|NCT04500158|t||||
17173351|NCT04701762|t||||
17173352|NCT02110069|t||||
17173353|NCT02749422|t||||
17173354|NCT04377659|t||||
17173355|NCT02538510|t||||f
17173356|NCT04098237|t||||f
17173357|NCT04610281|t||||
17173358|NCT02812342|t||||
17173359|NCT01458392|f||||f
17173360|NCT03762993|f||||f
17173361|NCT00753506|f||||f
17173362|NCT01394003|f||GT60||t
17173363|NCT03557034|t||||
17173364|NCT02494323|f||GT60||t
17173365|NCT03809104|f||GT60||t
17173366|NCT00790842|f||||f
17173367|NCT02115048|f||OTHER|No publication, abstract or presentation of the Study will be made without the approval of the Study Steering Committee (SCC). The SSC will be solely responsible for the analysis, interpretation and public disclosure of the results of the trial in accordance with the statistical plan.|t
17173368|NCT00093041|f||||f
17173369|NCT03408392|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173370|NCT00885170|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17173371|NCT00561925|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17173372|NCT00724698|f||OTHER|The PI agree only to use such information to conduct the study and will not be able to publish the results of any part of the study without previous writeen authorization from Schering-Plough.|t
17173373|NCT05021978|f||||t
17173374|NCT03122509|t||||
17173375|NCT02177032|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17173376|NCT00665652|f||||t
17173377|NCT04592887|f||||t
17173378|NCT01749215|t||||f
17173379|NCT02556177|f||||t
17173380|NCT01526577|f||||f
17128864|NCT04195958|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128865|NCT01323621|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128866|NCT01472380|f||GT60||t
17128867|NCT01891721|f||||f
17128868|NCT02075411|t||||
17128869|NCT02208297|f||OTHER|Contact sponsor directly for details.|t
17128870|NCT05125679|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. If requested by the Sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17173381|NCT02415608|f||||f
17173382|NCT02871934|t||||
17173383|NCT00734539|t||||
17173384|NCT01187355|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17173385|NCT02504151|f||||f
17173386|NCT01942694|f||||f
17173387|NCT00389610|t||||
17173388|NCT00538902|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17173389|NCT00472576|f||||f
17173390|NCT04170608|f||||f
17173391|NCT02557139|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17173392|NCT01454102|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173393|NCT01378871|t||||
17173394|NCT04355143|t||||
17173395|NCT02148874|f||||f
17183080|NCT01936259|f||OTHER|The Investigator must provide the Sponsor with at least 30 days to review publications for legal and regulatory compliance and will include in publications a statement that the study was supported by the Sponsor. Sponsor confidential information will not be submitted for publication without Sponsor consent. Sponsor may request delay of publication for 60 days to allow for patent application filing.|t
17128871|NCT05629962|f||OTHER|Publication or presentation of data from individual study centers is subject to prior review by the Sponsor. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128872|NCT05640648|t||||
17128873|NCT04908189|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128874|NCT04683731|f||||f
17128875|NCT03454308|f||||f
17128876|NCT02083705|t||||
17128877|NCT01210118|f||||f
17128878|NCT02958267|t||||
17128879|NCT04225221|t||||
17128880|NCT01853982|f||OTHER||t
17128881|NCT01839487|f||GT60||t
17128882|NCT05066724|f||||f
17173396|NCT02592798|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173397|NCT00705016|f||LTE60||t
17173398|NCT02233517|t||||
17173399|NCT00765206|f||OTHER|"Schering-Plough HealthCare Products, Inc. reserves all publication and~presentation rights."|t
17173400|NCT02416206|t||||
17173401|NCT01967940|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173402|NCT00942604|f||OTHER|"For US sites: The institution and investigator agree not to publish the results of this study without prior written consent of the Sponsor. As used herein, the term publish shall include oral presentations,written abstracts, written manuscripts, etc."|t
17173403|NCT01188343|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17173404|NCT01143246|f||OTHER|Disclosure of individual investigator/site results is restricted for 18 months after final evaluation of study results or after release of a cooperative publication including all study from all sites, whichever occurs first. The sponsor has 60 days to review and comment on the publication and can request removal of any confidential information prior to public disclosure or publication.|t
17173405|NCT01663103|f||||f
17173406|NCT05375760|f||||f
17173407|NCT00363480|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173408|NCT04008745|f||||f
17173409|NCT05567783|f||OTHER||t
17173410|NCT05005182|t||||
17173411|NCT03982355|t||||
17173412|NCT03113487|t||||
17173413|NCT04916587|f||||f
17183081|NCT01302392|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128883|NCT00475033|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128884|NCT02069353|t||||f
17128885|NCT03645954|t||||f
17128886|NCT01422850|f||LTE60||t
17128887|NCT04484831|f||||f
17128888|NCT02244996|f||||f
17128889|NCT01335009|f||||f
17128890|NCT04596384|f||||f
17128891|NCT04751656|f||||f
17128892|NCT00955487|f||||f
17128893|NCT03874325|t||||
17128894|NCT00146328|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17128895|NCT00300781|f||LTE60||t
17128896|NCT01256658|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17128897|NCT01213589|f||LTE60||t
17128898|NCT02072434|f||GT60||t
17128899|NCT00619190|f||||f
17128900|NCT02525861|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17128901|NCT00389857|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17128902|NCT01117454|t||||
17128903|NCT00888433|f||OTHER|The institution agrees that no Publication of the Study Results may be made until Publication of the results of the multi-centre study or 2 years after Study Completion, whichever is sooner.|t
17128904|NCT01681628|f||||f
17128905|NCT01794520|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173414|NCT03944577|t||||f
17173415|NCT00940771|f||||f
17173416|NCT04351334|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173417|NCT02593006|f||||f
17173418|NCT02048670|t||||
17173419|NCT00722072|f||||f
17128906|NCT01566682|f||||f
17128907|NCT03312348|t||||
17173420|NCT03129568|f||||f
17173421|NCT00949702|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173422|NCT01654302|f||||f
17173423|NCT04119414|t||||f
17173424|NCT02431637|f||LTE60||t
17173425|NCT01167504|t||||
17173426|NCT05720312|t||||
17173427|NCT00630838|f||||f
17173428|NCT00670748|f||||f
17173429|NCT01424072|t||OTHER|The copyright of the search results are the exclusive property of Latin American Journal of Nursing, barring any reproduction, in whole or in part in any form or means of printed or electronic, without the prior and necessary authorization is requested.|t
17173430|NCT02807402|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173431|NCT03123731|f||||f
17173432|NCT04922216|t||||
17173433|NCT04721977|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173434|NCT03278249|f||||t
17173435|NCT02786394|f||||f
17173436|NCT04828343|f||GT60||t
17173437|NCT00775190|t||||
17128908|NCT00281021|t||||
17128909|NCT04796896|f||||t
17173438|NCT00959985|t||||
17173439|NCT00904033|f||||f
17128910|NCT00538304|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17128911|NCT00969878|f||||f
17128912|NCT02170389|t||||
17128913|NCT01859078|f||GT60||t
17128914|NCT02175004|f||||t
17128915|NCT02960854|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17128916|NCT01176968|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173440|NCT01357850|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173441|NCT04939714|t||||
17173442|NCT01600716|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17173443|NCT00779155|t||||
17173444|NCT03349034|t||LTE60||t
17173445|NCT01177397|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173446|NCT00865566|f||||f
17173447|NCT03403283|t||||
17128917|NCT01383161|f||||f
17128918|NCT01736085|f||||f
17128919|NCT03942406|f||OTHER|"Protocol Section 10.9: After study completion, data may be considered for reporting at scientific meeting/publication in scientific journal. In these cases, sponsor will be responsible for these activities to determine how the manuscript is written/edited, number/order of authors, publication for submission, etc. Sponsor has final approval over all issues.~Data are property of sponsor and cannot be published without prior authorization, but data/publication thereof will not be unduly withheld."|t
17128920|NCT00819286|f||OTHER|Principal investigator may publish his/her own results from the study provided such publication does not include or disclose any confidential information. Principal investigator may also participate in joint publications. All proposed publications shall be submitted to Biomet for review. Biomet will have 30 days to review the proposed publication.|t
17173448|NCT00719472|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173449|NCT02395471|f||||f
17173450|NCT01244893|f||||f
17173451|NCT00357552|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17173452|NCT00976404|f||||f
17173453|NCT02086500|f||||f
17173454|NCT00711191|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173455|NCT03584789|f||||f
17173456|NCT02035267|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17173457|NCT04827680|f||||f
17173458|NCT02803580|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173459|NCT00955916|t||||
17173460|NCT03134703|f||||f
17173461|NCT03543878|t||||
17173462|NCT00836693|f||GT60||t
17173463|NCT02612779|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173464|NCT02118961|f||OTHER||t
17173465|NCT01750229|f||OTHER|"The Trust and/or the PI may prepare the data derived from the study for publication. Data will be submitted to the Sponsor for review and comment prior to publication and at least sixty (60) days prior to submission for publication, public dissemination, or review by a publication committee.~All reasonable comments made by the Sponsor in relation to a proposed publication will be incorporated by the Trust and/or the Investigator into the publication."|t
17173466|NCT03722238|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173467|NCT03771664|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173468|NCT00891904|t||||
17128921|NCT00216203|f||||f
17128922|NCT04263909|f||||f
17128923|NCT02310672|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128924|NCT04288778|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128925|NCT02691260|f||||f
17128926|NCT03118674|t||||
17128927|NCT03153137|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17128928|NCT04209621|t||||
17128929|NCT02249767|f||OTHER|With OK from Sponsor|t
17128930|NCT01372410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128931|NCT04585646|f||||f
17128932|NCT01368809|f||||f
17173469|NCT04069702|f||||f
17173470|NCT03096288|t||||
17173471|NCT02690948|t||||
17173472|NCT02551887|f||||f
17173473|NCT02004093|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173474|NCT01411891|t||||
17173475|NCT04639258|f||OTHER|Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) \& won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) \& its rights in patentable or copyrightable materials, \& check technical accuracy of MDT data. If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested.|t
17173476|NCT00414596|f||||f
17128933|NCT00642382|f||OTHER||t
17173477|NCT04320316|f||||f
17173478|NCT02558296|f||||t
17173479|NCT00297258|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173480|NCT00571493|f||||f
17173481|NCT01385293|t||||
17173482|NCT05038982|f||||f
17173483|NCT03133793|f||||f
17173484|NCT04476797|f||LTE60||t
17173485|NCT03614156|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17173486|NCT02535806|f||||f
17173487|NCT04287517|t||||
17173488|NCT03070964|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17173489|NCT02708186|f||||t
17173490|NCT00834093|t||||f
17173491|NCT02425943|f||||f
17173492|NCT02379091|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173493|NCT01662765|f||||f
17173494|NCT02129699|f||OTHER|"The SPLENDOUR Steering Committee will be responsible for review and approval of any publication of results from this trial.~The SPLENDOUR Steering Committee will decide the appropriate journal and corresponding author(s).~The SPLENDOUR Steering Committee will decide on authorship of the manuscript. No other participating group or institution should publish its own data on therapy results prior to the major publication."|t
17173495|NCT01607255|f||||f
17173496|NCT01076361|f||LTE60||t
17173497|NCT02530515|t||||
17173498|NCT04400643|f||GT60||t
17173499|NCT04801420|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173500|NCT04774094|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173501|NCT00815659|f||OTHER||t
17173502|NCT03847896|f||OTHER|Data or results obtained from this study must not be published without prior approval from the Sponsor.|t
17173503|NCT00118417|f||||f
17173504|NCT02978781|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173505|NCT00785785|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17173506|NCT02453321|t||||
17173507|NCT00521404|f||||f
17173508|NCT00842296|f||LTE60||t
17173509|NCT02282605|f||OTHER||t
17128934|NCT01087931|t||||
17128935|NCT01067326|t||||f
17128936|NCT00696761|t||||
17128937|NCT01207726|f||LTE60||t
17128938|NCT01230788|f||||f
17128939|NCT00769860|f||||f
17173510|NCT04287036|f||GT60||t
17173511|NCT04396639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173512|NCT02350296|f||||f
17173513|NCT01544335|f||||f
17173514|NCT05050227|t||||
17173515|NCT01532986|t||||
17173516|NCT04614974|t||||
17173517|NCT01635153|f||||f
17173518|NCT00658359|f||LTE60||t
17128940|NCT01603082|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of the submission for publication. The Investigators in the Multi-Center (MC) study agree to postpone MC publications until the earlier of the first AZ-authorized publication or up to 18 months from study completion at all sites.|t
17128941|NCT00852592|t||||
17138654|NCT04179032|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17128942|NCT05467774|f||||f
17128943|NCT01019317|t||||
17128944|NCT00695253|f||||f
17128945|NCT01498289|f||LTE60||t
17128946|NCT01774084|t||||
17173519|NCT02754440|f||OTHER|Sponsor retains the right to review and comment on any public disclosure of study results. If no response is received within 30 days, the Principal Investigator may presume that the submission for publication may proceed without delay. If the Sponsor asks to defer publication, Study Site shall not publish, or otherwise disclose to any third party, any of the information contained in the publication or presentation until such time as permission is granted from the Sponsor.|t
17128947|NCT01629784|t||||
17128948|NCT04526197|f||OTHER||t
17128949|NCT01557348|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128950|NCT02000427|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128951|NCT04343248|f||||f
17173520|NCT02560558|t||||
17173521|NCT00176917|t||||
17173522|NCT00533117|f||||f
17128952|NCT04484259|t||||
17128953|NCT03140423|f||||f
17128954|NCT03566810|f||||f
17128955|NCT02087748|t||||f
17128956|NCT05640466|t||||
17128957|NCT00509665|t||||
17128958|NCT03078907|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Actelion may provide comments and may also request alterations and/or deletions for the sole purpose of protecting its confidential information or patent rights.|t
17128959|NCT01955122|f||GT60||t
17128960|NCT00826111|f||||f
17128961|NCT01672788|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128962|NCT02445196|f||||f
17128963|NCT01837069|t||||
17128964|NCT04968197|t||||
17128965|NCT03511053|f||||f
17128966|NCT01128361|f||||f
17128967|NCT01929980|t||||
17128968|NCT01028222|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17128969|NCT04697264|f||||f
17128970|NCT03236246|f||OTHER||t
17128971|NCT02598557|f||LTE60||t
17128972|NCT01810692|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17128973|NCT01637623|f||||f
17128974|NCT04615247|t||||
17138655|NCT02432703|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17138656|NCT00653328|t||||
17173523|NCT02245217|t||||
17173524|NCT01263197|f||GT60||t
17173525|NCT01134055|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128975|NCT00247377|f||||f
17128976|NCT02743377|t||||
17128977|NCT02076113|f||||f
17128978|NCT04682977|f||||f
17128979|NCT01621230|t||||
17128980|NCT02596620|t||||
17128981|NCT01054144|t||||
17128982|NCT05628285|f||||f
17128983|NCT05664763|t||||
17138657|NCT00561340|f||||f
17138658|NCT03437044|f||||f
17138659|NCT01359046|t||||
17173526|NCT04587661|f||||f
17173527|NCT00847210|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of it's obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17173528|NCT03023397|t||||
17173529|NCT02387502|t||||
17173530|NCT01146795|t||||
17128984|NCT01284062|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173531|NCT03853109|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17128985|NCT00559585|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173532|NCT00385216|t||||
17173533|NCT01721044|f||GT60||t
17183082|NCT00670228|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17183083|NCT01702233|f||LTE60||t
17183084|NCT05035017|f||||t
17183085|NCT04646616|t||||f
17128986|NCT01633814|f||||f
17128987|NCT01717768|f||OTHER|Restriction Description: At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment and provide written permission prior to publication.|t
17128988|NCT00809523|f||||f
17128989|NCT04195581|f||||f
17128990|NCT04721821|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17128991|NCT01237340|f||OTHER||t
17128992|NCT01906346|f||||f
17128993|NCT04226833|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17128994|NCT02088788|t||||
17128995|NCT02876835|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17128996|NCT02540538|f||||f
17128997|NCT00403754|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17128998|NCT02979925|t||||
17128999|NCT02708095|f||GT60||t
17129000|NCT01313650|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173534|NCT04032093|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183086|NCT03049813|f||||f
17183087|NCT00550836|f||LTE60||t
17183088|NCT00179413|f||||f
17183089|NCT01072682|f||||f
17183090|NCT00627679|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17183091|NCT01696032|f||||t
17183092|NCT02188576|t||||
17183093|NCT01192152|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183094|NCT05013905|f||||f
17183095|NCT02978690|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17183096|NCT04666259|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183097|NCT00854581|t||||
17183098|NCT01446731|t||||
17183099|NCT00378703|f||LTE60||t
17183100|NCT02705820|t||||
17173535|NCT04987333|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17173536|NCT01457703|f||||f
17173537|NCT02952820|f||||f
17173538|NCT04139018|t||||
17173539|NCT03486834|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17173540|NCT02364570|f||||f
17173541|NCT00638014|f||||f
17183101|NCT05402995|f||||f
17183102|NCT01009099|t||||
17129001|NCT05393037|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.|t
17129002|NCT01012739|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17129003|NCT00458341|f||OTHER|The only disclosure restriction on the Principal Investigator is that the Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication embargo.|t
17129004|NCT04540133|t||||f
17129005|NCT05090995|t||||
17129006|NCT02271477|t||||
17129007|NCT03049735|f||LTE60||t
17129008|NCT03153111|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129009|NCT03891524|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129010|NCT00390910|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129011|NCT04585776|f||GT60||t
17129012|NCT01389765|f||GT60||t
17129013|NCT03877432|t||||
17129014|NCT00174265|f||OTHER|Except for compelling legal reasons, neither the sponsor nor the investigator will communicate to third parties any result of the clinical trial before the clinical trial report has been released by the sponsor.|t
17129015|NCT01473160|f||||f
17129016|NCT03471871|f||||f
17129017|NCT02577601|f||||f
17129018|NCT01572922|t||||
17129019|NCT03040622|f||||f
17129020|NCT00445068|f||||t
17129021|NCT00447382|f||OTHER|One or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17129022|NCT04600336|f||||f
17129023|NCT03834038|f||||f
17129024|NCT03144804|t||||f
17129025|NCT01786187|f||||f
17129026|NCT04091451|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17129027|NCT04124614|f||||f
17129028|NCT05772156|t||||
17129029|NCT06060717|f||||f
17129030|NCT03769181|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17129031|NCT03971422|f||GT60||t
17129032|NCT03217266|f||LTE60||t
17129033|NCT00985166|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129034|NCT00530868|f||||f
17129035|NCT01831544|f||GT60||t
17129036|NCT04175808|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129037|NCT06078579|t||||
17129038|NCT05050682|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129039|NCT03801902|f||LTE60||t
17129040|NCT03258554|f||OTHER|Must obtain prior approval from the sponsor. In addition, PI's are required to abide by Collaborator's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17129041|NCT00528866|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17173542|NCT02745119|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173543|NCT01587924|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173544|NCT00432172|f||LTE60||t
17173545|NCT03810105|t||||
17173546|NCT01106248|f||||f
17173547|NCT00357903|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17173548|NCT00606593|f||OTHER||t
17173549|NCT03714880|f||||f
17173550|NCT03181529|f||||f
17173551|NCT02139007|t||||
17173552|NCT03507569|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173553|NCT06042855|t||||
17173554|NCT03313037|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173555|NCT02546388|f||||f
17173556|NCT04546672|f||||f
17173557|NCT03710577|t||||
17173558|NCT00525161|f||||f
17173559|NCT02447003|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17173560|NCT03848728|f||||f
17173561|NCT04161157|t||||
17129042|NCT01601847|f||||f
17129043|NCT02234323|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17129044|NCT02644941|f||||f
17129045|NCT04614662|f||||f
17129046|NCT04325308|f||||f
17129047|NCT01136811|f||||f
17129048|NCT01009554|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17129049|NCT01605253|f||||t
17129050|NCT01405937|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17173562|NCT01108185|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17173563|NCT02581410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173564|NCT01393392|f||||f
17173565|NCT00658385|t||||
17173566|NCT03752567|f||||f
17173567|NCT05069948|t||||
17173568|NCT06083506|t||||
17129051|NCT00822588|f||GT60||t
17129052|NCT03510988|t||||
17129053|NCT00408603|f||GT60||t
17129054|NCT00324701|t||||
17129055|NCT01474863|f||||f
17129056|NCT03231943|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129057|NCT05564299|f||||f
17129058|NCT04824521|t||||f
17129059|NCT06605391|t||||
17129060|NCT01843218|t||||
17129061|NCT03829319|f||OTHER|"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."|t
17129062|NCT04498832|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17173569|NCT02000115|f||||f
17173570|NCT04815824|t||||
17173571|NCT05522153|t||||
17173572|NCT03493464|f||||t
17129063|NCT05183360|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129064|NCT05579990|f||||f
17129065|NCT05560763|f||||f
17129066|NCT00805038|f||||f
17129067|NCT02408861|f||LTE60||t
17129068|NCT03660826|f||LTE60||t
17129069|NCT03620890|t||||
17129070|NCT06018844|f||||f
17129071|NCT03338192|f||||f
17129072|NCT03808688|f||||f
17129073|NCT03329196|f||OTHER||t
17183103|NCT02702401|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17129074|NCT04612036|t||||
17129075|NCT03157232|t||||
17129076|NCT01096342|f||LTE60||t
17129077|NCT00234494|f||||f
17183104|NCT00247728|f||||f
17183105|NCT01106456|f||||f
17183106|NCT01930058|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17173573|NCT02374450|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinic.|t
17173574|NCT01582477|f||||f
17173575|NCT04145349|f||GT60||t
17173576|NCT01148979|f||||f
17173577|NCT01376804|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173578|NCT00882557|f||OTHER|The first publication is initiated by Cubist. If First Publication not published within 1 year of Study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17173579|NCT04816552|f||||f
17173580|NCT01908062|f||||f
17173581|NCT01383356|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17173582|NCT04803396|f||||f
17173583|NCT03038880|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129078|NCT01774851|f||||f
17129079|NCT00257686|f||GT60||t
17129080|NCT04229472|t||||
17129081|NCT02021292|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17183107|NCT01924169|f||||f
17183108|NCT04292730|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183109|NCT02694315|f||||f
17183110|NCT01527292|t||||
17129082|NCT04147234|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129083|NCT02022085|f||GT60||t
17129084|NCT05972733|f||||t
17129085|NCT03865940|t||||
17129086|NCT04982588|f||OTHER|"Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) \& won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) \& its rights in patentable or copyrightable materials, \& check technical accuracy of MDT data.~If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested."|t
17129087|NCT02366728|t||||
17129088|NCT00980681|f||GT60||t
17129089|NCT00992511|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129090|NCT04498169|f||||f
17138660|NCT01484561|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138661|NCT00047853|t||||
17129091|NCT02993523|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17129092|NCT03694418|f||||f
17129093|NCT00867113|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17129094|NCT01387230|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173584|NCT00602472|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17129095|NCT02257957|t||||
17173585|NCT02885025|t||||
17173586|NCT00194532|t||||
17173587|NCT02054104|f||||f
17173588|NCT00823615|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.|t
17173589|NCT03926611|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173590|NCT00084136|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17129096|NCT02066051|t||||
17129097|NCT04561765|t||||
17129098|NCT03027557|t||||
17129099|NCT01610687|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17129100|NCT03836807|f||||f
17129101|NCT02430051|f||||f
17129102|NCT03272763|f||||t
17129103|NCT02019420|f||OTHER|Cubist intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between Cubist and Investigators. Cubist approval in writing is required for publication of any data subsets.|t
17129104|NCT04722250|f||||f
17129105|NCT02554903|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129106|NCT02742766|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129107|NCT00999713|f||||f
17129108|NCT04974515|t||||f
17129109|NCT01444209|t||||
17129110|NCT03739437|f||||f
17129111|NCT00690235|f||||f
17129112|NCT01395316|t||||
17129113|NCT01868139|f||||f
17129114|NCT03359590|t||||
17129115|NCT02846532|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129116|NCT03951220|f||||f
17129117|NCT06132425|f||||f
17129118|NCT05649657|f||||f
17129119|NCT04598477|f||||t
17129120|NCT02876302|t||||f
17129121|NCT06263582|t||||
17129122|NCT02673619|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129123|NCT04225806|f||||f
17129124|NCT07052682|f||||t
17129125|NCT05868811|f||||f
17129126|NCT01940354|f||||f
17129127|NCT03872453|f||LTE60||t
17129128|NCT00352885|t||||f
17129129|NCT03873493|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17129130|NCT02960113|t||||
17129131|NCT00863109|f||OTHER|The study data/results may not be published or disseminated without prior consent from the study sponsor. All publications arising from the study will cite all the participating researchers.|t
17129132|NCT03756350|f||||f
17129133|NCT04283981|t||||
17129134|NCT00440700|f||||f
17138662|NCT02443805|f||||t
17173591|NCT02230670|f||LTE60||t
17173592|NCT05488535|t||||
17173593|NCT00892099|f||||f
17183111|NCT01482767|f||LTE60||t
17173594|NCT01657019|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17173595|NCT00998296|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173596|NCT02346721|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173597|NCT00124514|t||||
17173598|NCT03219528|t||||
17173599|NCT02120898|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17173600|NCT00831181|t||||
17173601|NCT04048356|t||||
17173602|NCT00196313|f||OTHER|The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.|t
17173603|NCT00043979|f||||f
17173604|NCT04085289|f||GT60||t
17173605|NCT01219881|f||||f
17173606|NCT02382705|f||||f
17173607|NCT02919995|f||OTHER|The Investigator shall not be permitted to present at symposia, national or regional professional meetings, nor publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial without the prior written approval of the Sponsor. Any such approved presentation or publication shall acknowledge the Sponsor as the sponsor of the Clinical Trial and owner of the results of the Clinical Trial.|t
17173608|NCT03196349|f||||f
17173609|NCT01963078|t||||
17173610|NCT02369796|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173611|NCT02892448|f||||f
17173612|NCT01012440|t||||
17173613|NCT00594815|t||||
17173614|NCT02691507|f||OTHER|Principal investigators agreed not to publish the study results without prior sponsor approval.|t
17173615|NCT01812252|t||||f
17173616|NCT05126953|t||||f
17173617|NCT04634253|f||GT60||t
17173618|NCT03155841|f||||f
17173619|NCT01569607|t||||
17173620|NCT01356277|f||||f
17173621|NCT03529422|f||OTHER|Subcontractor agrees that the first publication of the Study results will be made by Institution as a multi-site publication. Subcontractor can publish its site-specific results after Institution's publication, 12 months post-study completion, or upon Institution's notice of completion. Subcontractor must provide Institution 30 days for manuscript review and may delay publication for 45 days for institution's patent filing. Institution will register the Study and post results as required by law.|t
17173622|NCT05006573|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17173623|NCT01967238|f||||f
17173624|NCT05232682|t||||
17173625|NCT03387085|f||||t
17173626|NCT01442103|f||||f
17138663|NCT04362813|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single-site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety|t
17173627|NCT02202759|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17173628|NCT01987453|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173629|NCT02064582|f||||t
17173630|NCT01590888|f||LTE60||t
17183112|NCT01856543|t||||
17183113|NCT02353091|f||||f
17138664|NCT00961116|f||GT60||t
17138665|NCT00466661|f||||f
17183114|NCT01541930|f||||f
17183115|NCT02501096|f||||t
17183116|NCT04187196|t||||
17183117|NCT01556204|t||||
17183118|NCT03139916|t||||
17183119|NCT01957475|t||||
17183120|NCT04587193|t||||
17183121|NCT01552772|f||||f
17183122|NCT02920983|f||||t
17183123|NCT02682420|f||||f
17129135|NCT03434353|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173631|NCT01646125|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17129136|NCT04906616|f||||f
17129137|NCT02464228|f||OTHER|There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.|t
17173632|NCT02118441|f||||f
17129138|NCT01990534|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173633|NCT05462756|f||GT60||t
17173634|NCT02042274|f||||f
17173635|NCT04040933|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17173636|NCT02653417|f||||f
17173637|NCT01705509|t||||
17173638|NCT02301416|f||||f
17173639|NCT01528969|t||||
17173640|NCT01662102|f||||f
17173641|NCT02832115|t||||
17173642|NCT00275509|t||||
17173643|NCT03388164|t||||
17173644|NCT03967444|f||||f
17173645|NCT02210039|f||||f
17173646|NCT01821118|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173647|NCT01605799|f||||f
17173648|NCT00345358|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173649|NCT00499083|f||||f
17173650|NCT00686686|f||OTHER|"All proposed publications/presentations by the investigators or their personnel resulting from or relating to this study must be submitted to Sponsor for review 60 days before submission for publication or presentation. If the proposed publication/presentation contains patentable subject matter which, at~Sponsor's sole discretion, warrants intellectual property protection, the Sponsor may delay any publication or presentation for up to 60 days for the purpose of pursuing such protection."|t
17173651|NCT01278212|t||||
17173652|NCT01559857|f||||f
17173653|NCT00131248|t||||
17173654|NCT00477386|t||||
17173655|NCT01254422|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17129139|NCT00390611|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17129140|NCT00148954|f||||f
17129141|NCT01521897|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129142|NCT03308942|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129143|NCT02194062|f||||f
17138666|NCT02801006|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17138667|NCT04354155|f||||f
17173656|NCT02207088|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173657|NCT00643162|t||||
17173658|NCT02284243|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17173659|NCT04539795|f||||t
17173660|NCT00454324|f||GT60||t
17173661|NCT02699749|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17129144|NCT02276872|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17173662|NCT00734500|f||||f
17173663|NCT02721966|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single-site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety|t
17173664|NCT03857867|t||||
17173665|NCT02157883|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17129145|NCT00140231|f||||f
17173666|NCT00888940|f||OTHER|The first publication is initiated by Cubist. If the First Publication is not published within 1 year of Study conclusion or termination, Investigator shall have the right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17173667|NCT00607373|f||OTHER|The first publication for a multi-centre trial must address all centers. Institution will submit for review a proposed publication or presentation at least 60 days prior to submission date. Sponsor has the right to delay publication or presentation for not more than 6 months (contracts have variable timeframes) to address patent applications. Sponsor also has the right to demand in writing the deletion of confidential information, as long as such removal will not preclude publication.|t
17173668|NCT01918306|t||||
17173669|NCT02170077|f||OTHER||t
17173670|NCT01780974|f||||f
17173671|NCT01724346|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173672|NCT02876601|t||||
17173673|NCT00256997|f||LTE60||t
17173674|NCT00354432|t||||
17173675|NCT02736578|t||||
17173676|NCT02827877|t||||
17173677|NCT02819011|f||GT60||t
17173678|NCT04953728|t||||
17173679|NCT01136980|f||||f
17173680|NCT02105662|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17173681|NCT02331277|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173682|NCT03978117|t||||
17173683|NCT04375085|f||||f
17183124|NCT00895180|f||OTHER|In accordance with the ABTC publication, JHU will submit the draft of any proposed publication to ImClone at least thirty (30) days prior to submission for publication and agrees to withhold any such submission for an additional period, not to exceed ninety (90) days to allow ImClone to file patent applications. If Confidential Information is in the publication, it will notify JHU, which will insure such Confidential Information is redacted.|t
17183125|NCT03212963|f||||t
17129146|NCT01423812|f||||f
17183126|NCT02553421|f||LTE60||t
17183127|NCT06893809|f||||f
17183128|NCT02453594|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17183129|NCT02506114|t||||
17183130|NCT04101526|t||||
17129147|NCT01179672|f||GT60||t
17129148|NCT01660607|t||||
17183131|NCT02932891|f||||t
17129149|NCT00578786|f||||f
17129150|NCT05105789|t||||
17129151|NCT02797067|t||||
17129152|NCT00323297|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129153|NCT01003990|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129154|NCT04086433|f||LTE60||t
17129155|NCT01343485|f||||f
17129156|NCT00634010|t||||
17129157|NCT01452854|f||||f
17173684|NCT00990704|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17173685|NCT02409277|f||||f
17129158|NCT02616523|f||||f
17129159|NCT00448435|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit an investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not preceed the primary publication of the entire clinical trial.|t
17129160|NCT01463384|t||||f
17129161|NCT01822522|f||LTE60||t
17129162|NCT00890929|t||||f
17129163|NCT03712189|f||||f
17173686|NCT01354899|f||||f
17173687|NCT00641667|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17173688|NCT01235741|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173689|NCT01106690|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17173690|NCT02863419|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17173691|NCT01924949|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173692|NCT00831480|f||||f
17173693|NCT03066947|f||||f
17173694|NCT01059435|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17173695|NCT02454517|f||||f
17173696|NCT01189032|f||||f
17173697|NCT00473382|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173698|NCT01470326|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173699|NCT01166282|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173700|NCT02577718|f||||f
17173701|NCT01995838|f||||f
17173702|NCT01967576|f||||f
17173703|NCT03449667|f||||f
17173704|NCT00380367|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173705|NCT03281200|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173706|NCT00225732|f||||f
17129164|NCT01006265|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129165|NCT01272947|f||OTHER|Preliminary agreement between Novartis Consumer Health and the Principal Investigator|t
17129166|NCT03531788|t||||f
17129167|NCT02510560|f||||t
17129168|NCT00132496|f||OTHER||t
17129169|NCT02374398|t||||
17173707|NCT00392769|f||||f
17173708|NCT01155518|t||||
17173709|NCT03511937|t||||
17173710|NCT00060840|f||OTHER||t
17173711|NCT01227993|t||||f
17173712|NCT03710161|f||||f
17173713|NCT03702283|f||||f
17129170|NCT01093625|f||OTHER|Publication required agreement and written authorization from the Sponsor|t
17129171|NCT02014740|t||||f
17129172|NCT01431534|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17129173|NCT06154213|f||||f
17129174|NCT04427501|f||GT60||t
17129175|NCT00639223|f||||f
17129176|NCT04936841|t||||
17129177|NCT04145544|f||GT60||t
17129178|NCT02767128|f||GT60||t
17129179|NCT01080677|f||||f
17129180|NCT01544023|t||||
17183132|NCT02652624|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17129181|NCT02499770|f||OTHER|The investigator will submit results communications for review by the sponsor at least 60 days prior to expected submission to the intended publisher or meeting committee. This review period may be shortened upon mutual consent. The sponsor may request modification of any publication, presentation or use by the investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary rights.|t
17183133|NCT01023659|t||||
17183134|NCT01560624|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17183135|NCT00501540|f||||f
17173714|NCT00541385|f||||f
17173715|NCT02981446|f||||f
17173716|NCT01499355|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173717|NCT01526733|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless prior written permission from the Sponsor (Halozyme) is obtained.|t
17173718|NCT01599637|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17173719|NCT02565108|f||GT60||t
17173720|NCT01310075|t||||
17173721|NCT02395081|t||||
17173722|NCT02991040|f||||t
17173723|NCT00467753|f||||f
17173724|NCT01869764|t||||
17173725|NCT01286480|t||||
17173726|NCT02536963|f||||f
17173727|NCT05503823|f||||f
17173728|NCT02668393|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173729|NCT02141204|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17173730|NCT02053376|t||||
17173731|NCT02963506|f||GT60||t
17173732|NCT00750438|t||||
17173733|NCT02284035|f||||f
17173734|NCT04845568|f||||f
17173735|NCT00928408|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17173736|NCT00536744|f||||f
17173737|NCT00787644|f||||f
17173738|NCT02908672|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173739|NCT04163016|f||GT60||t
17173740|NCT01071798|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173741|NCT01732718|t||||
17173742|NCT00145158|t||||f
17173743|NCT00847509|f||OTHER|The restriction on the PI is that the sponsor can review results communication prior to public release and can embargo communications regarding trial results.|t
17173744|NCT02223702|t||||
17173745|NCT01227018|t||||
17173746|NCT00753649|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173747|NCT00499616|f||OTHER|Must obtain prior Sponsor approval.|t
17129182|NCT00617188|t||||f
17129183|NCT02564926|f||OTHER|"* The Institution and PI shall provide the Company with copies of any materials relating to the Study that either intends to publish (or submit for publication) or make any presentations relating to, at least 30 days in advance of publication~* At the request of the Company, the Institution and PI shall withhold publication for a period of 90 days from the date on which the Company receives the material."|t
17129184|NCT01298518|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183136|NCT01797536|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17129185|NCT01019980|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17183137|NCT00098839|f||OTHER|Must obtain prior Sponsor approval.|t
17183138|NCT00323739|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17183139|NCT02514252|t||||
17173748|NCT03108469|f||||f
17173749|NCT00826462|t||||
17173750|NCT01189409|f||||f
17173751|NCT01938716|t||||
17173752|NCT00098813|f||LTE60||t
17173753|NCT01614392|f||||f
17173754|NCT00433004|f||||f
17173755|NCT00220636|f||||f
17173756|NCT00330967|f||||f
17173757|NCT00539942|f||LTE60||t
17129186|NCT01351753|f||||f
17183140|NCT03228680|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17129187|NCT00012298|f||LTE60||t
17183141|NCT01268644|f||||f
17183142|NCT01416194|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173758|NCT00790088|f||LTE60||t
17173759|NCT04329806|t||||f
17173760|NCT05814367|f||GT60||t
17173761|NCT02636595|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173762|NCT00880919|f||||f
17173763|NCT02578706|t||||
17173764|NCT00408200|t||||
17173765|NCT01576809|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17173766|NCT02015637|f||OTHER|Melinta has the right to first publication of results, which would be made in conjunction with the PIs from all appropriate sites. Thereafter, PIs may publish results provided the PI submits the proposed publication to Melinta for review at least 60 days prior to the date of the proposed publication. Melinta may remove any information that is considered confidential and/or proprietary. If a publication is not submitted within 12 months of study conclusion, the PI may publish results.|t
17173767|NCT01695304|t||||
17173768|NCT04211909|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173769|NCT04455815|f||||f
17173770|NCT02106390|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173771|NCT03198507|f||LTE60||t
17173772|NCT03977818|t||||
17183143|NCT01222494|f||||f
17129188|NCT02038920|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17129189|NCT02204566|f||||f
17129190|NCT00047320|f||OTHER|Must obtain prior Sponsor approval.|t
17138668|NCT02565615|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138669|NCT00158223|t||||
17173773|NCT00921518|t||||
17173774|NCT02297373|f||||f
17173775|NCT00241839|f||||f
17173776|NCT00439517|f||OTHER||t
17173777|NCT02304367|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129191|NCT02383589|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183144|NCT02167035|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor may request but cannot require changes to the communication and cannot extend the embargo.|t
17129192|NCT00866697|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17129193|NCT04376060|f||||f
17173778|NCT00526071|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17173779|NCT01626872|f||OTHER||t
17173780|NCT01696188|t||||
17173781|NCT00960999|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17173782|NCT01578486|f||||f
17173783|NCT01958164|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173784|NCT01397968|f||||f
17173785|NCT00828204|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17173786|NCT02970162|f||LTE60||t
17173787|NCT02302339|f||||f
17173788|NCT02264249|t||||
17173789|NCT01642589|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17173790|NCT00298558|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17173791|NCT01185080|f||OTHER|There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed. The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ|t
17173792|NCT03959176|t||||
17173793|NCT01322945|f||||f
17173794|NCT01104311|f||||f
17173795|NCT03760718|f||||f
17173796|NCT02433366|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17173797|NCT01255436|t||||
17173798|NCT00372593|f||OTHER|Must obtain prior Sponsor approval.|t
17173799|NCT03534180|t||||
17173800|NCT04439136|f||LTE60||t
17173801|NCT02223858|t||||
17173802|NCT04288661|t||||
17173803|NCT03682770|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17173804|NCT02362282|t||||
17173805|NCT03588884|f||OTHER|Some institution and PI have the right to publish info 12 months after the study ended. For one PI that all Confidential Information must be held secret for a period of 5 years after end of the relevant Work Order.|t
17173806|NCT02058303|t||||
17183145|NCT02148003|t||||
17129194|NCT04275297|f||||f
17129195|NCT02818920|t||||
17129196|NCT05460273|f||OTHER||t
17129197|NCT04890054|t||||
17129198|NCT01292447|t||||
17129199|NCT02748018|f||OTHER|PI agrees not to publish until 12 months from trial completion or until sponsor publishes multi-center results, whichever occurs first. In either case, sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period more than 60 days but less than or equal to 180 days from the date that the communication is submitted to sponsor for review. Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129200|NCT05178134|f||||f
17173807|NCT03599089|f||||f
17173808|NCT03214666|f||LTE60||t
17129201|NCT02315898|t||||
17183146|NCT02489981|t||||
17129202|NCT05352048|t||||
17129203|NCT01214187|f||||f
17129204|NCT00998426|f||||f
17173809|NCT00470275|f||OTHER|Must obtain prior Sponsor approval.|t
17129205|NCT01233869|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129206|NCT03678103|t||||
17129207|NCT01158651|f||||f
17129208|NCT01296035|f||||f
17173810|NCT00272311|t||||f
17173811|NCT00318643|f||OTHER|The PI must submit a copy of the proposed publication to the Sponsor 40 days prior to date of submission for publication. They can request a delay of up to 45 days if it is determined there is any patentable subject matter or confidential Information. Sponsor can make changes to the communication to remove sponsor's confidential information from it prior to publication.|t
17173812|NCT03417154|t||||
17173813|NCT01519921|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173814|NCT02500797|f||LTE60||t
17173815|NCT02289157|f||OTHER|"8\. PUBLICATION AND REPORTS ON DATA; COPYRIGHTS~A. Prior to public presentation or submission to a journal, Investigator will submit for review to Company...content of any manuscript for publication, abstract, or presentation containing data and results of the Study, ...such review is for the limited purposes of ensuring that the manuscript accurately describes the Product and does not contain any Confidential lnformation...Investigator will have the unfettered right to publish."|t
17173816|NCT01415882|t||||
17173817|NCT02983552|f||||f
17173818|NCT00357006|f||||f
17173819|NCT00976560|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173820|NCT01216189|t||||
17173821|NCT03210337|f||GT60||t
17173822|NCT00125164|f||OTHER|Each investigator may publish or report data from their own subjects. The trial data in aggregate are the property of Tercica, Inc. and may not be published without permission of Tercica, Inc. Tercica, Inc. will be the final arbitrator of issues relating to the publication or presentation of the aggregate data.|t
17173823|NCT01339052|f||GT60||t
17173824|NCT02637037|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17173825|NCT03339219|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173826|NCT01497496|t||||
17173827|NCT01469377|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17173828|NCT01733680|t||||
17173829|NCT03937999|f||||f
17173830|NCT06404021|f||||f
17173831|NCT04139798|f||||f
17173832|NCT04269889|t||||
17173833|NCT03102437|f||OTHER|The Publication Committee shall consist of the National PIs and Impulse Dynamics representatives. All abstracts and papers of the multi-center publications will be reviewed by members of the publication committee and all authors. When appropriate, the publication committee will collect comments and resolve final draft issues. If a paper is rejected, the publication committee and its authors will decide the next course of action.|t
17173834|NCT04308291|f||||f
17173835|NCT00003469|f||||f
17173836|NCT03610269|t||||
17173837|NCT00523302|f||||f
17173838|NCT04411667|f||||f
17129209|NCT05073679|t||||f
17173839|NCT00067002|t||||
17173840|NCT02481219|f||OTHER|Prior written consent is required for PI to independently publish any study results before a multi-center publication is released. If a multi-center manuscript is not submitted for publication within 1 year after completion of the Trial, PI shall have the right to Publish results. Sponsor shall respond within 45 days and shall have the right to delay the Publication for an additional 90.|t
17173841|NCT04379011|t||||
17173842|NCT01354314|t||||
17173843|NCT02911844|f||||f
17173844|NCT00478023|f||OTHER|Grünenthal GmbH reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither Grünenthal nor the coordinating Investigator/Investigator has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17173845|NCT01004991|t||||
17173846|NCT00714870|t||||
17173847|NCT02357368|t||||
17173848|NCT02377817|f||||f
17173849|NCT03895840|f||||f
17129210|NCT00533468|f||||f
17129211|NCT05696236|t||||
17129212|NCT05341700|t||||
17129213|NCT01829360|f||||f
17129214|NCT00201838|t||||
17129215|NCT01145495|f||LTE60||t
17129216|NCT02378220|f||||f
17129217|NCT00312221|f||GT60||t
17129218|NCT00866723|t||||f
17129219|NCT04884763|f||||f
17129220|NCT02178553|f||||f
17129221|NCT01975428|t||||f
17129222|NCT02187809|f||||f
17129223|NCT01641809|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129224|NCT03690141|f||OTHER|Any publication or presentation of the results of this study may only be made in compliance with the provisions outlined in the executed Clinical Trial Agreement. Publication of scientific and clinical data will follow the recommendations of the International Committee of Medical Journal Editors, the Consolidated Standards of Reporting Trials group, and Good Publication Practice.|t
17129225|NCT00778622|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129226|NCT01505010|f||||f
17129227|NCT03837379|f||||f
17129228|NCT02403622|f||||f
17129229|NCT02558231|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17129230|NCT03367715|t||||
17129231|NCT02536755|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17129232|NCT02301936|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17129233|NCT01416987|f||||f
17129234|NCT03065023|f||OTHER|The Sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the Investigator(s). Published data must not compromise the objectives of the study. Data from individual study sites in multicenter studies must not be published separately.|t
17129235|NCT04029961|f||||f
17129236|NCT03427125|f||OTHER|The sponsor must approve all proposed publications.|t
17129237|NCT00824824|f||||f
17129238|NCT05975840|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17129239|NCT05180279|f||||f
17129240|NCT04014361|f||GT60||t
17129241|NCT05225103|t||||
17129242|NCT01130051|f||GT60||t
17129243|NCT05315947|f||GT60||t
17129244|NCT04252287|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17129245|NCT02715466|f||LTE60||t
17129246|NCT02273726|f||OTHER|"The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.~The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).~FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total)."|t
17129247|NCT03610165|f||||f
17129248|NCT02129205|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129249|NCT01554488|t||||
17129250|NCT02877927|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17173850|NCT00659789|f||OTHER|The Sponsor (or designee) will prepare a final report on the study. The Investigator may not publish or present any information on this study without the express written approval of the Sponsor. Additionally, the Sponsor, may, for any reason, withhold approval for publication or presentation.|t
17183147|NCT05022810|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183148|NCT01860417|f||||f
17129251|NCT00708175|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17129252|NCT03196232|t||||
17129253|NCT01829399|t||||
17129254|NCT02906787|f||||f
17129255|NCT04115878|t||||f
17129256|NCT04435782|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17129257|NCT03672461|t||||
17129258|NCT06615544|t||||
17129259|NCT04667247|f||||f
17173851|NCT01147874|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173852|NCT02109497|f||LTE60||t
17173853|NCT02175030|f||||f
17173854|NCT02817464|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17173855|NCT00885534|t||||
17173856|NCT02453711|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17173857|NCT03008369|t||||
17173858|NCT01292629|f||||f
17173859|NCT01273519|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17173860|NCT04292899|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17173861|NCT03695367|f||||f
17173862|NCT01600170|f||||f
17173863|NCT01974635|t||||
17173864|NCT01209325|f||||f
17173865|NCT00396253|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173866|NCT02282514|t||||
17173867|NCT01594216|t||||
17173868|NCT05340478|t||||
17173869|NCT00092443|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173870|NCT01319552|f||||f
17173871|NCT01951963|t||||
17173872|NCT04798768|f||OTHER|PI shall submit publication to Sponsor for review at least 60 days prior to submission. Sponsor reserves the right to delete any confidential info or other proprietary info of Sponsor (not incl. Results). Sponsor may extend 90 days to protect its intellectual property (IP) interests. PI shall be free to publish the results of the study after: Initial Publication is published; notification by Sponsor that Initial Publication is no longer planned; or 12 mo. after the expiration date at all sites|t
17173873|NCT03207763|t||||
17173874|NCT02605122|f||OTHER|Study Site will not submit its results for independent publication until after a coordinated, multicenter Study publication has been submitted or one (1) year after the conclusion of the Study, whichever occurs first. Study Site and/or Investigator shall submit any proposed publication or presentation resulting from Study Site's performance of the Protocol to the Prime Recipient for review and comment at least forty-five (45) days prior to the date of submission.|t
17173875|NCT02248246|f||OTHER|The PIs agreed that the first publication of results should be made in conjunction with the presentation of a joint, multicenter publication of the results with all PIs contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could have published the results from their individual sites.|t
17183149|NCT03852316|f||LTE60||t
17129260|NCT06950879|t||||
17129261|NCT01310803|f||OTHER|Institution and/or Principal Investigator shall not publish or present information related to the Study without prior written permission of Sponsor. Sponsor may withhold permission if a publication or presentation is in violation of other agreements, is not consistent with academic standards, is false or misleading, or is for commercial purposes.|t
17129262|NCT01306890|f||||f
17129263|NCT03219320|f||||t
17129264|NCT03739762|f||||f
17129265|NCT01681810|t||||
17173876|NCT00807001|f||OTHER|Disclosure restriction on the PI that permits the sponsor to review results communications prior to public release and embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor may request the PI to remove the sponsor's confidential information prior to such publication.|t
17173877|NCT00854113|t||||
17129266|NCT01131351|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17173878|NCT03284307|t||||f
17173879|NCT04683887|t||||
17173880|NCT02273596|f||||t
17173881|NCT02604160|f||GT60||t
17173882|NCT01596062|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129267|NCT02294682|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183150|NCT03592641|f||LTE60||t
17183151|NCT00436280|f||GT60||t
17183152|NCT04904510|f||||f
17173883|NCT02139592|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173884|NCT03180840|f||OTHER|The clinical trial agreement provided to the sites and Investigators contains a Publication paragraph that indicates the following: shall not, without the Sponsor's prior written consent, independently publish, present or otherwise disclose any results of or information pertaining to the trial until a multi-center publication is published, subject to certain limitations regarding timing and the confidentiality of unpublished data.|t
17173885|NCT00214890|f||||f
17173886|NCT03249116|f||||f
17173887|NCT00221117|f||||f
17173888|NCT03007225|f||||f
17173889|NCT01413204|f||OTHER||t
17173890|NCT00123422|t||||
17173891|NCT03089281|t||||
17173892|NCT04555616|t||||f
17173893|NCT04816669|f||OTHER|BioNTech SE has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173894|NCT01229267|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17173895|NCT00659737|f||||f
17129268|NCT01281007|f||||f
17173896|NCT01358721|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17173897|NCT01908803|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17173898|NCT00867815|f||OTHER|"The agreed point of publication is 12-18 months after database lock at the earliest.~* Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~* No publication of single center data should be done prior of publication if multi -center data)。"|t
17173899|NCT01864603|t||||
17173900|NCT02446899|f||||f
17173901|NCT04050202|t||||f
17173902|NCT00001213|t||||f
17173903|NCT05801341|t||||
17173904|NCT01554241|f||||f
17173905|NCT01943903|f||LTE60||t
17183153|NCT01403090|f||LTE60||t
17129269|NCT03422172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129270|NCT01002456|t||||
17129271|NCT00059839|f||||f
17129272|NCT00129623|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129273|NCT03155373|t||||
17129274|NCT04504357|t||||
17129275|NCT01662115|t||||
17129276|NCT01178333|f||OTHER|All publications and presentations resulting from studies from the TMH Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P\&P Committee along with Network Investigators. Members of the P\&P Committee can recommend changes to publications.|t
17173906|NCT02974543|t||||
17173907|NCT00742235|t||||f
17173908|NCT01237899|f||GT60||t
17173909|NCT01051518|f||LTE60||t
17173910|NCT02141438|f||OTHER|The PI shall not publish results of the study before the first multi-center publication, unless agreed otherwise. If no multi-center publication occurs within 18 months after study completion, the PI may publish results at their site, provided they submit the publication to the sponsor at least 60 days prior for review and delay publication for up to 60 days if advised by the sponsor regarding patentable subject matter or Confidential Information (CI) to allow for patent filing or CI removal|t
17173911|NCT05661409|t||||
17173912|NCT05782179|f||||f
17173913|NCT03675321|f||||f
17183154|NCT01049919|f||||f
17183155|NCT01663259|t||||
17183156|NCT00754247|t||||
17183157|NCT01540370|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17183158|NCT01532687|f||||f
17183159|NCT03160703|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183160|NCT02984995|f||||f
17183161|NCT00047463|f||||f
17183162|NCT04589559|t||||
17173914|NCT00343460|f||OTHER|A period of 60 working days for presentational material and abstracts and 90 days for manuscripts is permitted for the sponsor's review. The sponsor can request modifications of any manuscript or other materials to be published or presented. The sponsor can also request additional time to obtain additional patent protection or take such other measures to establish and preserve its intellectual property and proprietary rights before publishing information from this trial.|t
17173915|NCT02549365|t||||
17173916|NCT02999672|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17173917|NCT03565497|f||||f
17173918|NCT00531661|f||||f
17173919|NCT02194985|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17173920|NCT02561832|f||||f
17173921|NCT04103749|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the right to discuss or publish trial results without prior review by the Sponsor|t
17173922|NCT03048578|t||||
17173923|NCT01052701|f||||f
17173924|NCT03021343|f||||f
17173925|NCT00996333|t||||
17183163|NCT01401530|f||OTHER||t
17173926|NCT02902237|t||||
17173927|NCT01301027|f||||f
17173928|NCT00074490|f||||f
17173929|NCT02722499|f||||f
17173930|NCT03111628|f||||f
17173931|NCT03566485|t||||
17173932|NCT04999852|f||||f
17173933|NCT02506244|f||||f
17173934|NCT03523988|f||||f
17173935|NCT01369888|f||||f
17173936|NCT05220436|t||||
17173937|NCT02840461|f||||t
17173938|NCT01737502|t||||
17173939|NCT05307965|t||||
17173940|NCT04672655|t||||
17173941|NCT00494676|t||||
17173942|NCT05358353|f||||f
17173943|NCT04603027|f||OTHER|After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. The sponsor has final approval authority over publication of the study data.|t
17173944|NCT02688777|t||||
17129277|NCT00537485|f||||f
17129278|NCT02967354|f||||f
17129279|NCT01241552|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17129280|NCT00859950|t||||
17129281|NCT01886313|f||||f
17129282|NCT03838198|t||||
17173945|NCT01932437|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor. Written approval from the Sponsor is required prior to disclosing any information related to this clinical study.|t
17173946|NCT01009619|t||||
17173947|NCT01620216|t||||
17129283|NCT02060721|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation.|t
17129284|NCT00117507|f||||f
17138670|NCT00753688|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138671|NCT01854593|t||||
17173948|NCT04638660|f||GT60||t
17173949|NCT04939415|t||||
17173950|NCT03239106|f||LTE60||t
17173951|NCT03399552|t||||
17173952|NCT01931566|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17173953|NCT02622178|f||||f
17173954|NCT00611026|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17173955|NCT05019521|f||||t
17173956|NCT00760617|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17173957|NCT04625101|f||||t
17173958|NCT01436435|f||||f
17173959|NCT04150861|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17173960|NCT03613519|t||||
17183164|NCT02104557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183165|NCT02832674|f||GT60||t
17129285|NCT01271803|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129286|NCT01236105|f||GT60||t
17129287|NCT00846885|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17173961|NCT02533453|f||OTHER|"* The Institution and PI shall provide the Company with copies of any materials relating to the Study that either intends to publish (or submit for publication) or make any presentations relating to, at least 30 days in advance of publication~* At the request of the Company, the Institution and PI shall withhold publication for a period of 90 days from the date on which the Company receives the material."|t
17173962|NCT02037230|t||||
17173963|NCT01072643|t||||
17173964|NCT03519711|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17173965|NCT02469870|f||||f
17173966|NCT02039843|t||||
17173967|NCT03962062|f||||f
17173968|NCT00806819|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17173969|NCT02373683|t||||
17173970|NCT03564678|f||||f
17173971|NCT04420325|f||||f
17173972|NCT04016623|f||||f
17173973|NCT02752165|f||||f
17173974|NCT01704599|f||||f
17173975|NCT06139887|f||||f
17173976|NCT04901715|t||||
17173977|NCT04022499|f||||f
17173978|NCT03843541|f||OTHER|This document contains confidential information of Zambon S.p.A. Do not copy or distribute without written permission from the sponsor.|t
17173979|NCT05070416|f||LTE60||t
17129288|NCT01862640|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17173980|NCT04858035|t||||
17173981|NCT03217071|t||||
17173982|NCT00487461|f||||f
17173983|NCT05767749|t||||f
17173984|NCT05603312|f||||t
17173985|NCT01077050|f||LTE60||t
17173986|NCT03894813|t||||
17173987|NCT01213199|f||||f
17173988|NCT03083873|f||OTHER|Sponsor's agreements with sites ensure the site/investigator may publish study results following the earlier of a multicenter publication or 18 months after end of the multicenter trial consistent with academic standards for non-commercial purposes. Sponsor may review the publication for 30-60 days to remove confidential information and up to 60-90 more days to protect its intellectual property. Sponsor may not prohibit disclosure of site's results.|t
17173989|NCT01677377|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multicenter publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17173990|NCT01284335|f||GT60||t
17173991|NCT02656693|f||||f
17173992|NCT00842751|t||||
17173993|NCT02269267|f||||f
17173994|NCT03773796|t||||
17173995|NCT00590772|f||||f
17129289|NCT05211739|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17129290|NCT05085665|f||||f
17129291|NCT00728481|t||||f
17138672|NCT01787799|f||LTE60||t
17173996|NCT03805659|f||||f
17173997|NCT00796419|t||||
17173998|NCT01250145|f||GT60||t
17173999|NCT01404936|t||||f
17174000|NCT01069900|f||OTHER|"The agreed point of publication is 12/18 months after database lock at the earliest.~* Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~* No publication of single center data should be done prior of publication if multi-center data."|t
17174001|NCT02642315|f||||f
17174002|NCT02687191|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174003|NCT00662675|f||LTE60||t
17174004|NCT01089517|f||OTHER|No individual site or investigator may publish or present any results from the trial until a joint, multi center publication of the trial results is made by Sponsor in conjunction with various participating investigators and appropriate sites contributing data and comments. Subsequently, individual investigators may request to publish or present results from the trial; however, approval will be at the sole discretion of the Sponsor.|t
17174005|NCT01788358|f||LTE60||t
17174006|NCT01168219|f||LTE60||t
17174007|NCT06131476|f||GT60||t
17174008|NCT02736890|f||OTHER|Recipient will have all rights to data resulting from the Study; provided, however, at least 30 calendar days prior to any submission...Recipient shall provide Allergan a copy of the proposed publication for review. Recipient agrees to delay submission for an additional 30 calendar days to allow Allergan the right to a) address any factual inaccuracies with the publisher as it relates to any Allergan materials or b) request redaction of information that Allergan deems confidential or proprietary|t
17174009|NCT02873702|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17174010|NCT03762317|f||||f
17129292|NCT03030235|f||OTHER|Sponsor will have 18 months after the study closure to arrange for the submission of multicenter publications. If multicenter publications are not submitted within 24 months after conclusion of the study, PI may publish the results from their site's data, pursuant to approval by the Sponsor and Executive Committee at least 60 days prior to submission. The Sponsor cannot require changes to the communication with the exception of requiring the removal of confidential information.|t
17183166|NCT01448850|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17183167|NCT02214147|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17174011|NCT01039376|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17174012|NCT03252925|t||||
17174013|NCT01765972|f||GT60||t
17174014|NCT01742117|t||||
17174015|NCT00673738|t||||
17174016|NCT03830892|t||||
17174017|NCT01499277|f||OTHER|The investigator agrees not to use such Confidential study information and not to disclose them to any other third parties, except that the undersigned shall not be prevented from using or disclosing information: (a) which by written records was previously known; (b) which is now public knowledge, (c) which is lawfully obtained by the undersigned from sources who have a lawful right to disclose such information.|t
17174018|NCT04661579|f||||f
17174019|NCT01743859|f||||f
17174020|NCT04730271|f||LTE60||t
17174021|NCT04954833|f||GT60||t
17174022|NCT00614432|f||||f
17174023|NCT02023697|f||OTHER|The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17174024|NCT00845897|f||||f
17174025|NCT03904693|f||OTHER|Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17174026|NCT00068419|f||OTHER|Must obtain prior Sponsor approval.|t
17183168|NCT00280566|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17183169|NCT00799812|f||||t
17183170|NCT04542070|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17183171|NCT02709395|f||||t
17183172|NCT02188485|t||||
17183173|NCT03367312|f||||f
17183174|NCT01868633|t||||
17129293|NCT00626210|t||||
17129294|NCT01251120|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129295|NCT04553068|f||||f
17129296|NCT02080455|f||OTHER|Described in site contract.|t
17129297|NCT01807923|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17129298|NCT00108069|f||||f
17129299|NCT00995007|f||||f
17129300|NCT01910116|f||||f
17129301|NCT03606980|t||||f
17129302|NCT02469896|f||LTE60||t
17129303|NCT02218190|f||||f
17174027|NCT04674761|f||OTHER|Albireo will retain the ownership of all data. All proposed publications based on this study must be subject to the sponsor's approval requirements.|t
17174028|NCT02773576|f||||f
17174029|NCT01237197|f||||f
17174030|NCT01160822|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174031|NCT04772560|f||||f
17174032|NCT04717336|t||||
17183175|NCT02457325|t||||
17183176|NCT02489227|f||||f
17183177|NCT04099524|f||||t
17183178|NCT00773097|t||||
17174033|NCT01500720|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17174034|NCT02624986|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174035|NCT02527421|f||OTHER|No report, abstract, oral presentation, or publication of the results of the Study proposed by Institution shall be presented or published without the prior written consent of the Sponsor or as otherwise permitted for regulatory agency inspections.|t
17174036|NCT02116205|f||||f
17174037|NCT02541604|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129304|NCT01294150|f||OTHER|"Investigator agreements restricted data disclosure until written agreement by or publication by Sponsor. The first publication appeared in the Journal of Urology, June 2013. The Prostatic Urethral Lift for the Treatment of Lower Urinary Tract Symptoms Associated with Prostate Enlargement Due to Benign Prostatic Hyperplasia: The L.I.F.T. Study  Claus G. Roehrborn, Steven N. Gange, Neal D. Shore, Jonathan L. Giddens, et al. The Vol. 190, Issue 6, Pages 2161-2167."|t
17129305|NCT03675776|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129306|NCT01464229|f||||f
17129307|NCT04233164|t||||
17129308|NCT01840605|f||OTHER||t
17174038|NCT00427765|t||||f
17174039|NCT04301193|f||||f
17174040|NCT00560352|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174041|NCT04434937|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17174042|NCT00924027|f||||f
17174043|NCT04695977|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17174044|NCT03474965|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174045|NCT03229941|t||||
17174046|NCT03751657|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17174047|NCT02600819|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17174048|NCT01027273|t||||
17174049|NCT02631590|t||||
17174050|NCT02904954|t||||
17174051|NCT05097963|t||||
17183179|NCT02707640|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129309|NCT01959048|t||||
17129310|NCT01351623|t||||
17129311|NCT01130974|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor,and such that confidential or proprietary information is not disclosed.|t
17129312|NCT00387764|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129313|NCT04399122|t||||
17129314|NCT01083628|f||||f
17174052|NCT00337675|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174053|NCT00859456|t||||
17174054|NCT04141839|f||||f
17174055|NCT01491607|f||OTHER|Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between Biomedical Advanced Research and Development Authority (BARDA)and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17174056|NCT01317277|f||||f
17174057|NCT00774566|f||OTHER|This is an investigator initiated study. The study was supported with 20.000 EUR to acquire Holter monitor devices by CryoCath/Medtronic.|t
17174058|NCT00912795|t||||f
17174059|NCT01075685|t||||
17174060|NCT02858362|f||||t
17174061|NCT01262989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174062|NCT02813577|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17129315|NCT01102803|f||||f
17129316|NCT02684279|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17129317|NCT02733185|f||||f
17129318|NCT00782288|t||||f
17174063|NCT02921841|f||||f
17174064|NCT01470118|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17174065|NCT00775593|f||OTHER|Results are analyzed together with the sponsor, being the present study a fully independent not-for-profit trial.|t
17174066|NCT02067676|f||||f
17174067|NCT01243580|f||OTHER|Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL14 study is required prior to publication submission.|t
17174068|NCT04853017|f||||f
17174069|NCT02164461|f||OTHER|The Investigator shall seek the Sponsor's written approval for study results publication which shall not be unreasonably withheld. Such publication by Institution and/or Investigator may be no earlier than after a cooperative publication has been published with Sponsor or 1 year from date of completion or termination of the Study \& only after review and comment by Sponsor. Institution agrees to provide Sponsor a copy of proposed publication at least 60 days prior to submission to a publisher.|t
17174070|NCT01814241|t||||f
17174071|NCT02100696|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174072|NCT00078897|t||||
17129319|NCT00671554|f||||f
17129320|NCT00601250|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17129321|NCT01810016|f||LTE60||t
17129322|NCT01703663|f||||f
17138673|NCT02999100|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138674|NCT01664858|f||||f
17138675|NCT03595384|t||||
17174073|NCT03865381|t||||
17174074|NCT05626322|f||OTHER|The sponsor (or its agents) has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129323|NCT03828292|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17129324|NCT00315939|t||||f
17129325|NCT05591274|t||||f
17129326|NCT01444651|f||||f
17129327|NCT03498131|f||||f
17129328|NCT03383289|f||||f
17129329|NCT00832117|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129330|NCT00404066|f||||f
17129331|NCT01426516|t||||
17129332|NCT01524133|f||||f
17129333|NCT00786825|f||||f
17129334|NCT03632109|f||||f
17129335|NCT00966823|t||||
17174075|NCT00369265|f||||f
17174076|NCT01847027|f||||f
17138676|NCT00293241|f||GT60||t
17138677|NCT02224638|f||||f
17129336|NCT03842163|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174077|NCT00048074|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17129337|NCT03829241|f||LTE60||t
17129338|NCT00698451|f||GT60||t
17174078|NCT02873377|t||||
17129339|NCT02224599|f||LTE60||t
17174079|NCT04473469|t||||
17129340|NCT01187550|f||OTHER||t
17174080|NCT01627288|t||||
17129341|NCT00733304|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129342|NCT01627002|f||OTHER|After completion of the study, the Investigator may prepare a joint publication with the Sponsor. The Investigator must undertake not to submit any part of the individual data from this protocol for publication without prior consent of the Sponsor at a mutually agreed time.|t
17174081|NCT00314795|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17174082|NCT01493167|f||||f
17174083|NCT02015910|f||||f
17174084|NCT03830307|t||||f
17174085|NCT00740857|f||OTHER|The PI agreed to allow the sponsor 30 days to review and approve abstracts and 60 days to review and approve manuscripts prior to submission to protect against disclosure of confidential information.|t
17174086|NCT03433040|f||||f
17174087|NCT03532451|f||||f
17174088|NCT01519167|f||OTHER|The Investigator may not submit the results of the study for publication without the prior written consent of Hospira.|t
17129343|NCT02616614|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17129344|NCT00596934|t||||f
17129345|NCT02445755|f||||f
17174089|NCT02654769|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17174090|NCT00556504|f||LTE60||t
17174091|NCT02561338|f||||t
17174092|NCT04200352|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17174093|NCT00233064|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17174094|NCT03508908|f||||f
17174095|NCT01881828|f||||f
17174096|NCT01120964|f||GT60||t
17174097|NCT01003769|t||||
17129346|NCT03239483|f||||f
17129347|NCT02308007|f||OTHER|Investigators have the right to disclose and publish results of the Study conducted by them; provided that, in order to protect any Curatek confidential information, Investigator shall submit to Curatek manuscripts at least 30 days before submission for publication or 10 days before public presentation. After that time, Investigator is free to submit the manuscript for publication or deliver the presentation, provided Investigator removes any confidential information as directed by Curatek.|t
17174098|NCT00826202|f||||f
17174099|NCT04237116|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174100|NCT00829504|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17129348|NCT02563093|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17129349|NCT00528567|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174101|NCT03212144|t||||
17174102|NCT00599339|f||GT60||t
17174103|NCT05978713|f||GT60||t
17174104|NCT05307692|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17129350|NCT03352011|f||||f
17129351|NCT03085758|f||||t
17129352|NCT01191541|t||||
17129353|NCT04004429|f||GT60||t
17174105|NCT05407064|f||OTHER|"1. Sponsor has at least 60 days to review a proposed publication before submission for purposes of requesting the removal of Sponsor's confidential information.~2. Institutions and PI's will not publish or disclosure their single-site data prior to a multi-center publication of the aggregate study data, unless Sponsor does not publish a multi-center publication within 12 months following conclusion of the overall study."|t
17174106|NCT04194437|f||OTHER|Site shall have right to publish results. To balance this right with TransMedics' (TM proprietary interests, site will submit manuscripts intended for publication for TM's review at least 30d prior to submission date. TM will complete its review within 30d of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request. After 60d period, site will have right to publish manuscript, as amended by TM.|t
17129354|NCT00631189|f||OTHER|If the PI wants to discuss or publish results after the trial is completed he must obtain writing authorization from AstraZeneca|t
17174107|NCT06019611|t||||
17174108|NCT02003924|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129355|NCT04464265|t||||
17129356|NCT01063829|f||OTHER|Every Publication, disclosure or other use of Information conveyed to the Institution and the Investigator in relation to the Trial and of data and results derived from the Performance of the Trial requires the express written consent of Sponsor.|t
17129357|NCT00974090|f||OTHER||t
17129358|NCT00056862|t||||
17129359|NCT01122576|f||OTHER||t
17129360|NCT02024165|f||||f
17129361|NCT03574441|t||||
17129362|NCT00381563|f||||f
17174109|NCT05186805|f||||t
17174110|NCT04693767|f||||t
17174111|NCT04917757|t||||
17174112|NCT00114517|t||||f
17174113|NCT02587637|f||GT60||t
17129363|NCT03326895|f||LTE60||t
17129364|NCT00931944|f||||t
17129365|NCT01132612|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129366|NCT02252536|f||OTHER|Restricts disclosure until the main study paper is published.|t
17129367|NCT04044183|f||||f
17129368|NCT01438151|f||GT60||t
17129369|NCT02340728|t||||
17129370|NCT01836042|f||GT60||t
17129371|NCT02822950|f||||f
17129372|NCT00006392|f||||f
17129373|NCT01049243|f||||f
17129374|NCT02545322|t||||
17129375|NCT02401412|f||GT60||t
17174114|NCT00684060|t||||
17129376|NCT01184053|t||||
17129377|NCT01174238|t||||
17129378|NCT02593786|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129379|NCT01479829|t||||
17129380|NCT01578967|f||GT60||t
17129381|NCT01791803|t||||
17174115|NCT02641561|t||||
17129382|NCT03823768|f||||f
17129383|NCT00846547|f||OTHER|Seaside Therapeutics agreements with investigators vary; constant is our right to restrict communications regarding trial results prior to public release for ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129384|NCT01093326|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17174116|NCT00702715|f||OTHER|All published results will be based on validated data released by the sponsor and must include one sponsor author. There may be one author from each investigational site, provided that the criteria for authorship are met. In case the proposed publication contains reference to an invention owned by sponsor or to which sponsor otherwise has rights, the sponsor may request a reasonable suspension of the publication in order to be able to file a patent application protecting such invention.|t
17174117|NCT02082119|t||||
17174118|NCT01350401|f||LTE60||t
17174119|NCT02840799|t||||f
17174120|NCT04990804|f||||f
17129385|NCT01444456|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129386|NCT04263896|t||||
17129387|NCT01744353|f||||f
17129388|NCT04532372|t||||
17129389|NCT03435003|f||||f
17129390|NCT01436071|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129391|NCT00789867|t||||
17129392|NCT03047551|t||||
17129393|NCT00726622|t||||
17129394|NCT02462928|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129395|NCT01493557|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129396|NCT03998176|f||||f
17174121|NCT01014351|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17174122|NCT01760785|f||||f
17174123|NCT01193257|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17174124|NCT00921895|f||OTHER|Results to be published or presented shall be submitted to RPS for review and comment at least 30 days prior to submission for publication or presentation. Institution and/or PI may publish or present the results and data from the Institution's site individually (i) 12 months after conclusion, abandonment or termination of study at all sites, or (ii) after RPS confirms there will be no multicenter study publication, whichever occurs first.|t
17174125|NCT00662298|t||||
17174126|NCT04657094|t||||
17174127|NCT01621802|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174128|NCT02948634|f||||f
17174129|NCT03062540|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17174130|NCT03052400|t||||
17174131|NCT00555061|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174132|NCT03291964|t||||
17174133|NCT00485134|f||||f
17174134|NCT00970684|t||||
17174135|NCT00481091|f||||f
17174136|NCT04294680|f||||f
17174137|NCT01296672|f||LTE60||t
17174138|NCT04027608|f||||f
17183180|NCT02517905|f||OTHER|Site shall reasonably cooperate with the sponsor to prepare an abstract and/or manuscript reporting trial results within 90 and 120 days, respectively, after final CSR is available and should not otherwise publish any results within 120 days. Scientific meeting and journal are to be determined by the sponsor. Site shall give sponsor ≥60 days before submitting materials and upon sponsor request shall withhold publication for an additional 90 days.|t
17174139|NCT02453347|f||||f
17183181|NCT00466960|t||||
17129397|NCT02656420|f||||f
17129398|NCT01088464|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study completion or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17129399|NCT01611948|f||||f
17129400|NCT03018587|f||||f
17129401|NCT03662139|f||||f
17129402|NCT00749879|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17129403|NCT01890148|f||LTE60||t
17129404|NCT01215175|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17129405|NCT01678209|f||OTHER|Dr. Newcorn has FCOI reporting obligations as stipulated by the Mount Sinai FCOI committee|t
17174140|NCT01386970|f||||f
17174141|NCT04881942|f||||f
17174142|NCT01349959|f||LTE60||t
17174143|NCT02675634|f||LTE60||t
17174144|NCT01652534|f||||f
17174145|NCT03860259|t||||f
17174146|NCT00811018|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174147|NCT01976091|f||OTHER||t
17174148|NCT00934362|f||LTE60||t
17174149|NCT03527732|t||||
17174150|NCT02280408|f||||f
17174151|NCT01092117|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or itsagents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. PI can publish institution's data/results 18 months after study conclusion at all sites or when multi-center results are published or notification that results will not be published. Institution is to submit drafts of manuscripts to Endologix 30 days prior to submission for publication or presentation.|t
17174152|NCT01594528|t||||
17174153|NCT04625517|t||||
17174154|NCT00441064|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17174155|NCT00953056|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. SPONSOR review can be expedited to meet publication guidelines.|t
17174156|NCT03962504|t||||t
17174157|NCT01077076|f||OTHER|Schering-Plough HealthCare Products, Inc. reserves all publication and presentation rights.|t
17174158|NCT01976741|f||LTE60||t
17129406|NCT00702845|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17174159|NCT00889720|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174160|NCT00670306|f||LTE60||t
17174161|NCT01327482|f||||f
17174162|NCT00476229|t||||f
17174163|NCT01032889|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17174164|NCT01721837|t||||
17174165|NCT00993148|f||||f
17174166|NCT00472030|f||LTE60||t
17174167|NCT00912197|t||||
17174168|NCT02267837|f||||f
17174169|NCT00756613|t||||
17174170|NCT02538354|f||||f
17129407|NCT00682565|f||OTHER|Sponsor intends to publish the results of the trial in collaboration with the Investigators.|t
17129408|NCT02973425|f||||f
17129409|NCT03876171|t||||f
17129410|NCT00454532|f||||f
17129411|NCT03503513|f||||f
17129412|NCT00929656|t||||
17174171|NCT03801044|f||||f
17174172|NCT01615029|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129413|NCT00607880|t||||f
17129414|NCT04321980|f||||t
17129415|NCT01170039|t||||
17129416|NCT00908583|f||||f
17129417|NCT00993954|f||||f
17129418|NCT00860951|f||||f
17129419|NCT00727649|t||||
17129420|NCT03627767|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174173|NCT01326104|f||||f
17174174|NCT01287741|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174175|NCT00802945|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17174176|NCT04421027|f||GT60||t
17174177|NCT05036733|f||||t
17174178|NCT02930018|f||||f
17174179|NCT05283031|t||||
17174180|NCT04193189|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17174181|NCT02042872|f||||f
17174182|NCT00539864|f||||f
17174183|NCT02565784|f||||t
17174184|NCT00578734|f||OTHER|First publication must be joint, multicenter publication in conjunction with a presentation. Following multicenter publication, proposed publications or presentations must be submitted to sponsor 30 days in advance. In the event of an objection by sponsor, PI agrees to delay the publication or presentation until modifications or revisions have been made to protect Sponsor's patent rights, copyrights, or proprietary rights.|t
17129421|NCT01873417|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17129422|NCT00785044|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17129423|NCT00385203|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17129424|NCT01798992|t||||f
17129425|NCT03823404|f||OTHER|Individual investigators and/or their associates may publish findings of this study in scientific journals or present them at scientific meetings, provided the Sponsor is given ample opportunity to review any proposed abstract, manuscript, or slide presentation before its submission.|t
17129426|NCT03189862|t||||
17129427|NCT00024167|t||||
17174185|NCT01745822|f||||f
17129428|NCT03610399|f||||f
17129429|NCT00729781|f||GT60||t
17129430|NCT02764164|t||||
17129431|NCT00706550|t||||
17129432|NCT00806676|f||||f
17129433|NCT00072358|t||||
17129434|NCT01534013|t||||
17129435|NCT02459769|t||||
17129436|NCT01186796|t||||
17129437|NCT01287364|f||OTHER||t
17129438|NCT01936909|f||||f
17129439|NCT01958788|f||||f
17129440|NCT01379573|t||||
17129441|NCT00962390|f||LTE60||t
17129442|NCT00744211|t||||
17129443|NCT00000125|f||||f
17129444|NCT00113230|t||||f
17174186|NCT04202419|f||LTE60||t
17174187|NCT00943072|f||OTHER|The only disclosure restriction on the PI, after completion of the trial and multi-center publication, is that the sponsor can review results communications prior to public release \& may have the right to embargo communications regarding results for a period between 60 \& 180 days from the time submitted to the sponsor for review; provided that the sponsor can remove confidential/proprietary information. The sponsor cannot require other changes to the communication and cannot extend the embargo.|t
17174188|NCT00552188|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented as a joint, multi-center publication prior to publishing individual site results.|t
17174189|NCT03887702|f||LTE60||t
17174190|NCT04432727|f||LTE60||t
17174191|NCT01675544|t||||
17174192|NCT00689260|f||OTHER|The institution or Principal Investigator can publish or present any results to a third party until (i) EMD Serono publishes the results (ii) Institution receives notification from EMD Serono that publication is no longer planned (iii) 18 months following the completion of the study whichever occurs first. Prior to publishing or presenting results, the Principal Investigator needs to provide EMD Serono with a copy of the presentation for review and approval.|t
17174193|NCT05780424|f||||f
17174194|NCT00476008|t||||
17174195|NCT01170247|t||||f
17174196|NCT01934647|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17174197|NCT00792571|f||GT60||t
17174198|NCT04857320|f||||f
17174199|NCT03790696|f||||f
17129445|NCT01673568|f||||f
17129446|NCT03740997|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17129447|NCT01026142|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129448|NCT01829425|f||||f
17129449|NCT04178967|f||GT60||t
17129450|NCT00628251|f||OTHER|No publication of the study results may be made until publication of the results of the multi-centre study or 2 years after study completion, whichever is the sooner|t
17129451|NCT00041067|f||||f
17129452|NCT02354781|t||||
17129453|NCT01078207|f||LTE60||t
17174200|NCT01149148|t||||
17174201|NCT03436082|f||||f
17183182|NCT04114058|t||||
17183183|NCT01578044|t||||
17183184|NCT05419947|f||||f
17129454|NCT00882310|t||||
17129455|NCT02756351|f||OTHER|"As stated in the Clinical Investigation Plan (CIP):~The Principal Investigator may publish results from this investigation; however as some of the information regarding the investigational medical device and development activities may be of a strictly confidential nature, the Sponsor must first be given the opportunity to review any publication manuscript prior to submission to journals, meetings or conferences."|t
17129456|NCT04246801|f||OTHER|Any publication shall be expressly authorized in written by the Sponsor|t
17129457|NCT03684642|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17129458|NCT02743351|f||GT60||t
17129459|NCT00717054|f||||f
17129460|NCT04556396|f||||f
17129461|NCT01643525|f||||f
17129462|NCT01883986|f||||f
17129463|NCT00835120|t||||
17129464|NCT00232141|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17129465|NCT04572854|f||||t
17129466|NCT04752475|t||||
17129467|NCT03746951|t||||
17129468|NCT01194453|f||||f
17129469|NCT00594516|f||GT60||t
17129470|NCT00088907|f||LTE60||t
17129471|NCT04946825|f||||f
17129472|NCT03426787|f||||f
17129473|NCT02217436|f||||f
17129474|NCT04641299|f||LTE60||t
17129475|NCT04650282|t||||
17129476|NCT01016964|f||||f
17129477|NCT02039726|f||||f
17129478|NCT02393677|t||||
17129479|NCT00813319|f||||f
17129480|NCT01330914|f||||f
17129481|NCT01817907|f||||f
17129482|NCT01650285|f||||f
17174202|NCT01079299|f||||f
17183185|NCT02742103|f||||t
17129483|NCT00659529|t||||f
17129484|NCT02053909|f||||f
17174203|NCT00950859|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129485|NCT00907257|f||LTE60||t
17129486|NCT00283049|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17129487|NCT00295633|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129488|NCT00763971|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17174204|NCT04896086|t||||
17129489|NCT01655329|f||GT60||t
17129490|NCT02496897|f||||f
17129491|NCT00931242|f||||f
17129492|NCT03631667|t||||
17129493|NCT04439071|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17129494|NCT02645760|t||||
17129495|NCT01446016|t||||
17129496|NCT02267603|f||LTE60||t
17174205|NCT02917642|f||||f
17129497|NCT01087957|f||OTHER|(b) Publication- Investigator and Institution agree not to publish the results of the Trial until after the conclusion of the Trial. Investigator agrees to submit to Sponsor copies of any proposed publication at least sixty (60) calendar days in advance of dissemination. Sponsor agrees to review and comment in a timely manner after receipt . All proprietary and/or confidential information of Sponsor must be removed from the Proposed Publication.|t
17129498|NCT01754857|t||||
17129499|NCT03938038|t||||
17129500|NCT01399190|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129501|NCT00436618|t||||
17129502|NCT00698204|f||||f
17129503|NCT00314249|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17129504|NCT00210184|t||||
17129505|NCT01690897|f||||f
17129506|NCT01118325|f||LTE60||t
17129507|NCT03334409|t||||
17129508|NCT00975715|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129509|NCT00418951|t||||
17129510|NCT04214301|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17129511|NCT01674712|f||OTHER|At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the PI shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them. If the Sponsor requests, the PI shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.|t
17129512|NCT00874770|f||OTHER|Bristol Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single center publications until after disclosure of the clinical trial's primary publication.|t
17129513|NCT05395104|f||OTHER||t
17174206|NCT02249832|f||||f
17183186|NCT00600821|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129514|NCT03974334|t||||
17129515|NCT01109173|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17129516|NCT01892306|f||||f
17129517|NCT00770770|f||GT60||t
17129518|NCT03568045|t||||f
17129519|NCT01761279|t||||
17174207|NCT02516969|t||||
17174208|NCT04216264|f||||f
17174209|NCT02563067|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174210|NCT00839319|t||||
17174211|NCT00774267|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174212|NCT03544333|t||||
17174213|NCT01039519|f||OTHER|Sponsor has the right, 60 days before submission for publication, to review disclosures and require deletion of its confidential information, excluding the study results. Public disclosure shall be delayed for up to 60 additional days in order for the Sponsor to file a patent application, if needed. Single center publications will be postponed until after disclosure of pooled data (all sites), or, for a period of 18 months from study completion/termination at all participating sites.|t
17174214|NCT05844007|f||||f
17174215|NCT00808080|f||||f
17174216|NCT02810509|f||||f
17174217|NCT00423917|t||||
17174218|NCT00093379|t||||f
17174219|NCT03565328|t||||
17174220|NCT01396447|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17174221|NCT00578292|t||||
17129520|NCT05372653|f||||f
17138678|NCT01216397|t||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17129521|NCT04808622|f||||f
17129522|NCT00711529|f||||f
17174222|NCT04726969|t||||
17174223|NCT00856518|t||||
17129523|NCT00038727|f||||f
17129524|NCT00928174|t||||
17129525|NCT03681951|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17129526|NCT01020448|f||||f
17129527|NCT01230554|f||||f
17129528|NCT01968070|f||GT60||t
17129529|NCT03078595|t||||
17138679|NCT02352103|f||||f
17174224|NCT00947193|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17174225|NCT04849559|f||OTHER||t
17174226|NCT02105961|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174227|NCT00459186|t||||f
17174228|NCT03710083|f||OTHER||t
17174229|NCT05300763|f||GT60||t
17174230|NCT01485172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174231|NCT00974480|f||||f
17174232|NCT02920242|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129530|NCT04201821|t||||
17174233|NCT01587014|f||||f
17129531|NCT01326728|f||||f
17129532|NCT02939989|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17129533|NCT03785678|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129534|NCT01660451|f||OTHER|"Contract Partners (PI) shall provide to Bayer any proposed publication or oral presentation relating to the Study or the Results (Publication) at least sixty (60) days prior to the intended submission or presentation of the Publication in order to allow Bayer to review it. If Bayer does not notify PI within forty-five (45) days of Bayer's receipt of the intended Publication, PI shall remind Bayer. If Bayer does not provide any comments within the sixty day period, PI shall be free to publish."|t
17174234|NCT02948088|f||||f
17174235|NCT01409811|t||||
17129535|NCT03620019|t||||
17129536|NCT02374021|f||||f
17129537|NCT01667107|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17129538|NCT01162239|t||||
17174236|NCT01942733|f||||f
17174237|NCT00634101|f||GT60||t
17174238|NCT01543633|t||||
17174239|NCT00838513|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17174240|NCT02416622|f||LTE60||t
17174241|NCT00139477|t||||
17174242|NCT01491984|f||||f
17174243|NCT00573144|t||||f
17129539|NCT00228566|f||GT60||t
17129540|NCT01499953|f||||t
17174244|NCT02625909|f||||f
17174245|NCT02367833|f||||f
17174246|NCT03001817|f||||t
17174247|NCT00035932|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174248|NCT01459497|t||||
17174249|NCT01192191|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174250|NCT03179319|f||||f
17174251|NCT00356304|f||||f
17174252|NCT04393454|t||||
17129541|NCT04448756|f||||f
17129542|NCT01624259|f||GT60||t
17129543|NCT04313153|f||||t
17129544|NCT05586269|f||||f
17129545|NCT00523718|t||||
17129546|NCT02113579|f||OTHER|Principal Investigators agreed not to publish the study results without prior sponsor approval.|t
17129547|NCT02060383|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17129548|NCT00332839|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129549|NCT01999569|f||||f
17129550|NCT01974089|t||||
17174253|NCT01224145|f||||f
17174254|NCT02685267|f||||f
17174255|NCT01027806|f||||f
17174256|NCT01264705|t||||
17174257|NCT01812668|t||||
17174258|NCT03059355|t||||
17174259|NCT03860818|f||||f
17174260|NCT03126344|t||||
17174261|NCT05367492|t||||
17174262|NCT01088048|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17174263|NCT01588418|f||||f
17174264|NCT00333762|t||||
17174265|NCT01330108|f||||f
17174266|NCT00243269|f||||f
17174267|NCT00857714|t||||
17174268|NCT03085797|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174269|NCT00545272|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174270|NCT01837823|t||||
17174271|NCT03848182|t||||
17174272|NCT02936648|t||||
17174273|NCT02914301|f||||f
17174274|NCT00436345|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174275|NCT01175083|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174276|NCT00475306|t||||
17174277|NCT01716052|t||||f
17174278|NCT02405442|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17174279|NCT02950467|f||||f
17174280|NCT03275350|t||||
17129551|NCT02020863|t||||f
17129552|NCT01920594|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174281|NCT00926029|f||GT60||t
17174282|NCT02566369|f||LTE60||t
17174283|NCT04154189|f||||f
17174284|NCT02283827|f||OTHER||t
17174285|NCT02147561|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174286|NCT01191762|f||||f
17174287|NCT03898557|f||||f
17174288|NCT02283762|f||OTHER|Any proposed publications should be sent to Bayer for review at least 40 days before forwarding to any person that is not bound by the confidentially obligations. Bayer may request delay of publication for no more than 120 days to allow for filing Patent Applications (if applicable). No publication of single center data should be done prior to publication of multicenter data.|t
17174289|NCT00202878|f||OTHER|All draft publications (eg, original manuscripts and abstracts of data and information relating to the IMPROVE-IT clinical study) shall be submitted to the Publication Committee at least 45 days prior to submission to a journal or public presentation.|t
17174290|NCT02028208|f||||f
17174291|NCT03563183|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17174292|NCT03801031|f||||f
17174293|NCT01209702|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174294|NCT00486291|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17174295|NCT00528450|t||||
17174296|NCT00126490|f||LTE60||t
17174297|NCT00975780|t||||
17174298|NCT01056016|f||||f
17174299|NCT03051178|f||||f
17174300|NCT01598506|t||||
17174301|NCT03855059|f||||f
17174302|NCT02268175|f||||t
17174303|NCT04080167|f||||f
17174304|NCT04518358|f||||f
17174305|NCT03530124|f||||f
17174306|NCT01583296|f||||f
17174307|NCT01047553|f||OTHER||t
17174308|NCT01063283|f||||f
17174309|NCT01120717|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174310|NCT05343624|t||||
17174311|NCT03117140|f||||f
17174312|NCT02504216|f||OTHER||t
17174313|NCT00862082|f||OTHER|Single site data may be published/presented prior to the publication of multi-center data from overall study if agreed to by the sponsor in writing, or 12 months have elapsed following termination or completion of the study, whichever comes first.|t
17174314|NCT02598583|f||||t
17174315|NCT02093819|t||||
17174316|NCT05334212|t||||
17174317|NCT02152956|f||LTE60||t
17129553|NCT04085341|f||OTHER|Any investigator wishing to publish or present any study finding must present a manuscript or abstract to Graybug Vision 120 days prior to submission for publication or presentation to provide Graybug Vision an opportunity for review and comment.|t
17129554|NCT00928564|f||||f
17129555|NCT01244243|f||||f
17129556|NCT02460497|f||OTHER||t
17174318|NCT02445794|f||||f
17174319|NCT01668589|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174320|NCT02758184|t||||
17174321|NCT00661427|t||||
17174322|NCT00488683|f||OTHER|the terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174323|NCT02260180|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of the Sponsor.|t
17174324|NCT00611403|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17174325|NCT02741518|f||||f
17174326|NCT01139008|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17174327|NCT01715857|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17174328|NCT02785770|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174329|NCT03968939|t||||f
17174330|NCT00505778|f||LTE60||t
17174331|NCT01056302|t||||
17129557|NCT02012296|t||||
17129558|NCT01448213|f||||f
17129559|NCT02615470|f||||f
17129560|NCT01025492|f||||f
17129561|NCT00916539|f||||f
17129562|NCT01826851|t||||
17129563|NCT04163900|f||||f
17129564|NCT01830855|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129565|NCT01667081|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17129566|NCT00930722|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129567|NCT03034460|f||||t
17129568|NCT00419120|f||OTHER|The investigator is free to individually communicate, orally present or publish in scientific journals or other scholarly media the study information at the conclusion of the study without the prior approval of the sponsor provided that 1)the results of the study in its entirely have been publically disclosed by or with the consent of the sponsor 2)18 months after the conclusion of the study at all sites whichever is first to occur.|t
17129569|NCT02525055|t||||
17129570|NCT04621734|t||||
17129571|NCT01186939|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17129572|NCT01509079|f||||f
17129573|NCT01636414|f||||f
17129574|NCT01949155|f||OTHER|"From the Protocol; 14.11. Use of Information and Publication. All information concerning OTO-201...remains the sole property of Otonomy.~Any publication or other public presentation of results from this study requires prior review and written approval of Otonomy. Draft abstracts, manuscripts, and materials for presentation at scientific meetings should be provided to the sponsor at least 30 working days prior to abstract or other relevant submission deadlines."|t
17129575|NCT00685685|f||GT60||t
17129576|NCT02941926|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129577|NCT02729740|f||||f
17129578|NCT00307333|f||||f
17129579|NCT00531882|t||||
17129580|NCT00601705|t||||
17129581|NCT04513665|t||||
17129582|NCT01653964|f||||f
17129583|NCT02232282|t||||
17129584|NCT03422679|f||OTHER|Partners shall provide to Cellestia any proposed publication or oral pesentation relating to the study or the study drug or the results at least 60 days prior to the intended submission or presentation of the publication to allow Cellestia to review it. If Cellestia doesn't provide any comments within the sixty day period, Partner are free to publish.|t
17129585|NCT02608879|t||||
17129586|NCT00760669|f||OTHER|Principal Investigator (PI) cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is canceled.|t
17129587|NCT01572675|f||||f
17129588|NCT01692691|t||||
17129589|NCT02966223|f||||f
17129590|NCT05426759|f||||f
17129591|NCT02456662|t||||
17129592|NCT02499081|t||||f
17129593|NCT00805025|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17129594|NCT00375219|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17129595|NCT01353079|f||LTE60||t
17129596|NCT05314712|f||||f
17129597|NCT03007979|t||||
17129598|NCT00482703|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17129599|NCT01428661|f||||f
17129600|NCT00972777|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17129601|NCT04968041|t||||
17129602|NCT03523728|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17129603|NCT00621751|f||||f
17129604|NCT01667536|f||LTE60||t
17129605|NCT01950247|f||||t
17129606|NCT01831921|t||||f
17129607|NCT00710879|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17129608|NCT01809132|f||||f
17129609|NCT00434421|f||||f
17129610|NCT01688466|f||||f
17129611|NCT01205438|f||GT60||t
17129612|NCT02334787|f||||f
17129613|NCT01540825|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129614|NCT00884325|f||||f
17174332|NCT02136069|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174333|NCT01092546|f||||f
17174334|NCT01667419|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174335|NCT03364270|f||||f
17174336|NCT04364984|t||||
17129615|NCT02247765|f||||f
17129616|NCT00623974|t||||f
17129617|NCT00892177|t||||
17129618|NCT00393796|t||||
17129619|NCT04130633|f||||f
17129620|NCT00616434|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17129621|NCT03945591|t||||
17129622|NCT03083847|f||||f
17129623|NCT04216251|t||||
17129624|NCT00058552|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129625|NCT02319668|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129626|NCT02783443|t||||
17129627|NCT02316340|t||||
17129628|NCT01986920|f||OTHER|The Institution and the investigator agree not to publish the results of this study without the written approval of the Sponsor.|t
17129629|NCT03781323|t||||
17129630|NCT01338415|f||OTHER|Any study-related article or abstract written independently by investigators must be submitted to Actelion for review at least 60 days prior to submission for publication or presentation.|t
17129631|NCT02150499|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17129632|NCT00467389|t||||
17129633|NCT00866749|f||||f
17129634|NCT04880447|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129635|NCT01970488|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129636|NCT04060563|f||||f
17129637|NCT02137122|t||||
17129638|NCT01033552|t||||
17129639|NCT01478360|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17129640|NCT04029116|f||||f
17129641|NCT01688856|t||||
17174337|NCT01941186|t||||
17174338|NCT04380519|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17174339|NCT04173494|f||OTHER|GlaxoSmithKline (GSK) agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17183187|NCT01379963|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigators is free to publish in reputed journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129642|NCT01514136|t||||
17129643|NCT00223678|f||LTE60||t
17129644|NCT03346057|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17129645|NCT02003014|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17129646|NCT01159912|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129647|NCT02281357|f||LTE60||t
17129648|NCT00823303|f||||f
17129649|NCT00591825|t||||
17174340|NCT02474069|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17174341|NCT03656380|t||||
17174342|NCT01623050|f||LTE60||t
17129650|NCT04631796|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17129651|NCT04223791|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17129652|NCT06291831|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129653|NCT00729378|t||||
17129654|NCT01330134|f||||f
17129655|NCT02246582|f||GT60||t
17174343|NCT00393861|t||||
17174344|NCT02577445|f||OTHER|The legal manufacturer of the medical device, Respicardia, shall be the owner of the Clinical study data including any results, and Respicardia shall have the right to control the publication timing, content and method for any public disclosure of the clinical study data. Respicardia's prior written approval must be obtained prior to any publication or disclosure of Clinical study data or results by Sponsor or Institution.|t
17183188|NCT02448303|f||||f
17129656|NCT02899078|t||||
17129657|NCT03441334|f||||f
17129658|NCT00395863|f||OTHER|The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.|t
17129659|NCT00316355|f||||f
17129660|NCT02592551|t||||
17129661|NCT01876251|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174345|NCT01388335|f||GT60||t
17174346|NCT01805791|f||||f
17174347|NCT00518089|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174348|NCT04413617|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183189|NCT02277626|t||||
17129662|NCT00268437|t||||
17129663|NCT01355484|f||OTHER|"Provide Sponsor with an advance copy of any proposed results communication at least 60 days prior to the date of the planned submission or presentation and Sponsor shall have 60 days from receipt to request any changes. Sponsor may request a delay of up to 60 additional days.~The PI shall not present data until the earlier of Sponsor's publication of the results of all investigators participating in the Study or 18 months after completion of the Study at all participating sites."|t
17129664|NCT02137512|f||||f
17129665|NCT01628107|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single centre publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129666|NCT01086410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129667|NCT02953639|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129668|NCT04196803|f||||f
17129669|NCT01022996|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129670|NCT03349775|f||||f
17129671|NCT01516970|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17129672|NCT01756040|f||||f
17183190|NCT00659646|f||OTHER||t
17183191|NCT00023673|f||||f
17183192|NCT02033005|t||||
17183193|NCT01326780|f||||f
17183194|NCT02684591|f||||f
17129673|NCT00789750|f||OTHER|PI agrees to wait until after coordinated multicenter publication or one year after the trial is over, whichever occurs first. After such time, Study Site will submit any publication to DSI for CCI review and comment at least forty-five (45) days prior to submission. Site agrees to delay publication for an additional sixty (60) days for legal (e.g., patent) concerns. Nothing shall be taken as giving DSI any right of editorial control over any publication prepared by Study Site.|t
17174349|NCT02657408|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174350|NCT02471326|t||||
17174351|NCT00324961|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174352|NCT01719744|t||||
17174353|NCT05854784|f||||f
17174354|NCT04059159|t||||
17174355|NCT03350672|f||||f
17174356|NCT01247272|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17174357|NCT00223080|f||||f
17174358|NCT03237286|t||||
17174359|NCT03193593|f||||f
17129674|NCT02613884|t||||
17129675|NCT00619970|f||||f
17129676|NCT00433914|f||||f
17129677|NCT02486653|t||||
17129678|NCT02518997|f||||f
17129679|NCT02945150|f||||f
17129680|NCT03530917|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129681|NCT01286454|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129682|NCT02367066|f||||f
17129683|NCT02678416|f||OTHER|Investigators will be part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.|t
17129684|NCT04556136|f||||f
17129685|NCT01848353|f||||f
17129686|NCT03933397|f||||f
17129687|NCT00953719|f||LTE60||t
17129688|NCT00935272|f||GT60||t
17129689|NCT01170546|f||||f
17129690|NCT02017379|t||||
17129691|NCT01727765|t||||
17129692|NCT02289352|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17129693|NCT04340557|f||||f
17129694|NCT01177384|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17129695|NCT01849497|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129696|NCT04458103|f||||f
17129697|NCT01772004|f||||f
17129698|NCT00911625|f||||f
17129699|NCT00529451|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129700|NCT02101515|t||||
17129701|NCT01289821|f||OTHER|PI has to submit a draft manuscript of the publication or abstract to Bayer for review and approval at least 60 days before submission. Possible discrepancies will be discussed to find solution which satifies both parties. Bayer may delay publication for up to three months after analyzing the results.|t
17129702|NCT03591354|f||||f
17129703|NCT02901574|t||||
17129704|NCT00773136|t||||
17129705|NCT03945357|t||||
17129706|NCT01010633|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17129707|NCT04666350|f||||f
17129708|NCT00097773|f||||f
17174360|NCT00948441|f||||f
17129709|NCT00003702|f||LTE60||t
17129710|NCT01009034|f||GT60||t
17129711|NCT01494350|f||||f
17138680|NCT00971633|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174361|NCT02797613|f||||f
17174362|NCT00947882|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17129712|NCT00698932|f||OTHER|The Principal Investigator undertakes to provide AstraZeneca as soon as possible with preliminary data and drafts of proposed publications and disclosures, whether oral or in writing, and as soon as available, with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed|t
17129713|NCT01245387|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129714|NCT04267770|t||||
17129715|NCT03061175|f||||f
17129716|NCT02243865|f||||f
17129717|NCT02101021|f||OTHER|"After conclusion of the study and without prior written approval from Sierra Oncology, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Sierra Oncology in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17129718|NCT01621542|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17129719|NCT02632721|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17129720|NCT04207801|f||LTE60||t
17129721|NCT01500525|t||||
17129722|NCT00460551|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17129723|NCT02921269|f||LTE60||t
17129724|NCT02054325|t||||
17129725|NCT04411953|f||||f
17129726|NCT02322229|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17129727|NCT03250832|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17129728|NCT04411628|f||GT60||t
17129729|NCT01252810|f||||f
17129730|NCT02347488|t||||
17129731|NCT01932242|f||OTHER|The data generated in this clinical study are the exclusive property of the sponsor and are confidential. Written approval from the sponsor is required prior to disclosing any information related to this clinical study.|t
17129732|NCT05162027|t||||
17129733|NCT04296877|f||||f
17129734|NCT00886704|f||||f
17129735|NCT02767323|f||||f
17174363|NCT01396057|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17174364|NCT04449263|f||||f
17174365|NCT03037580|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17174366|NCT02087423|f||||f
17129736|NCT01847430|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129737|NCT01069120|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17129738|NCT00388505|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129739|NCT04311697|f||||f
17129740|NCT01480284|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129741|NCT01641237|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129742|NCT02716675|f||||f
17138681|NCT03124901|f||LTE60||t
17174367|NCT03500224|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17174368|NCT00268853|f||||f
17174369|NCT01324401|f||||f
17174370|NCT03574181|f||||f
17174371|NCT01708902|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174372|NCT00442364|t||||f
17174373|NCT00530816|f||OTHER|After the study is completed and all case report forms have been sent to Sponsor, Institution shall have the right to publish or otherwise make public any data resulting from the study under this agreement after publication of a multi-center publication coordinated by Sponsor with respect to the data resulting from the study, or 12 months after the Study is completed at all participating sites if a multi-center publication is not submitted by Sponsor for publication within such 12 month period.|t
17174374|NCT00800254|t||||
17174375|NCT01388985|t||||
17174376|NCT01057589|f||GT60||t
17174377|NCT03761368|f||||f
17129743|NCT00709111|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17129744|NCT01301456|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174378|NCT00899431|t||||
17174379|NCT00238355|f||||f
17129745|NCT00915772|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17129746|NCT03583450|t||||
17174380|NCT02902146|f||||f
17174381|NCT03304249|f||||f
17174382|NCT01253577|f||LTE60||t
17174383|NCT00334113|t||||
17174384|NCT04189224|f||GT60||t
17174385|NCT02509026|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174386|NCT00721968|f||||f
17174387|NCT04198714|f||||f
17129747|NCT03374995|t||||
17129748|NCT01383096|f||LTE60||t
17129749|NCT01211535|f||OTHER||t
17129750|NCT04747834|f||||f
17129751|NCT05368961|f||||f
17129752|NCT03593850|t||||
17129753|NCT01735279|f||||f
17129754|NCT01817855|f||GT60||t
17129755|NCT05097716|t||||
17129756|NCT00119041|t||||f
17129757|NCT05686928|f||||t
17129758|NCT04872348|f||OTHER|After Sponsor's publication of trial results, the Institution and Principal Investigator may publish the results of the Study generated by the Institution, subject to the obligations of the CTA, and prior approval of Sponsor in writing. The Institution shall furnish Sponsor with a written copy of any proposed publication or disclosure at least 60 days prior to submission for publication or disclosure. Sponsor may request changes or other measures to ensure the information is fairly stated.|t
17129759|NCT04748653|f||||f
17129760|NCT00922480|f||||f
17129761|NCT01011439|f||LTE60||t
17129762|NCT01372150|f||LTE60||t
17129763|NCT00536809|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129764|NCT01364623|f||||f
17129765|NCT03496324|f||||f
17174388|NCT01064947|f||||f
17174389|NCT02970942|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17174390|NCT00508196|t||||
17174391|NCT02529553|f||GT60||t
17174392|NCT04549545|f||||f
17174393|NCT05475483|f||GT60||t
17174394|NCT01006291|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17183195|NCT00424372|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183196|NCT04622254|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17183197|NCT00912405|f||||f
17183198|NCT00796861|f||LTE60||t
17183199|NCT02370888|f||||f
17129766|NCT02092350|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17129767|NCT00729482|f||||f
17129768|NCT01303965|t||||
17129769|NCT02448225|t||||
17129770|NCT00851682|t||||
17129771|NCT00240981|t||||
17129772|NCT00766090|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129773|NCT00800436|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129774|NCT05417607|t||||
17129775|NCT01106027|t||||
17129776|NCT02653300|f||GT60||t
17129777|NCT00369785|t||||
17129778|NCT01898689|f||||f
17129779|NCT01983839|t||||
17129780|NCT02937194|f||||f
17129781|NCT00888381|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129782|NCT00757003|f||||f
17129783|NCT05144113|f||||f
17129784|NCT02146599|f||OTHER||t
17129785|NCT02705807|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129786|NCT00995475|t||||
17129787|NCT02431897|f||||f
17129788|NCT03044249|f||GT60||t
17129789|NCT00955279|f||GT60||t
17129790|NCT01368042|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17129791|NCT03694613|f||||f
17129792|NCT02221349|t||||
17129793|NCT00544648|t||||
17129794|NCT02663271|f||||f
17129795|NCT01235793|t||||
17129796|NCT00053703|f||||f
17129797|NCT04166383|f||||f
17129798|NCT03044886|t||||
17129799|NCT01995578|t||||
17129800|NCT00703053|f||LTE60||t
17129801|NCT00822354|t||||
17129802|NCT00982007|f||LTE60||t
17129803|NCT00504153|f||LTE60||t
17129804|NCT00407654|f||LTE60||t
17129805|NCT00074581|f||OTHER|All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts and five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17129806|NCT03613662|f||OTHER|The Sponsor has the right to first publication of the results of the study. Following the first publication, PIs may publish study data or results; however, the proposed publication must be submitted to the Sponsor for review and approval in writing at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study Data.|t
17129807|NCT00617604|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 12 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication temporarily to seek patent protection.|t
17129808|NCT02303704|t||||f
17129809|NCT03407651|f||||f
17129810|NCT03142438|f||||f
17129811|NCT00705432|f||OTHER|"In this multicenter trial, initially, the investigator may only publish study results together with the other sites, unless specific written permission is obtained in advance from the sponsor.~The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a 45 day period from the time submitted to the sponsor for review."|t
17129812|NCT00732251|t||||
17129813|NCT00521053|f||LTE60||t
17129814|NCT01034540|f||||f
17129815|NCT00351416|f||||f
17129816|NCT03519867|f||OTHER|Organon recognizes the right of the investigator(s) to publish, but all publications must be based on data validated by Organon. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Organon, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17129817|NCT00667823|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17129818|NCT04376827|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17129819|NCT00761306|f||OTHER|The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.|t
17174395|NCT02102204|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174396|NCT01865552|f||||t
17174397|NCT03079102|f||||f
17174398|NCT02923921|f||LTE60||t
17174399|NCT00479687|f||||f
17174400|NCT01474239|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174401|NCT04458090|f||||f
17183200|NCT02178475|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129820|NCT04042740|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17129821|NCT00880555|t||||
17129822|NCT01651104|f||||f
17129823|NCT00338039|f||||f
17129824|NCT04479436|f||||f
17129825|NCT02357134|t||||
17129826|NCT01380730|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129827|NCT00467779|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129828|NCT01701999|t||||
17129829|NCT05111041|t||||
17129830|NCT01205230|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129831|NCT01701674|t||||
17129832|NCT00791258|f||OTHER|"As stated in the clinical study agreement, If identified by DSI, any of DSI's confidential information as defined herein shall be deleted...Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publicartion prepared by the Study Site."|t
17129833|NCT00041080|f||LTE60||t
17129834|NCT02066311|f||||f
17129835|NCT01312038|f||||f
17129836|NCT03198520|f||||t
17129837|NCT01670539|f||||f
17129838|NCT04353596|t||||
17129839|NCT02665052|t||||
17129840|NCT00823823|f||||f
17129841|NCT03923556|f||||f
17129842|NCT00550654|f||||f
17129843|NCT01526551|f||||f
17129844|NCT05215262|f||||f
17129845|NCT00718549|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129846|NCT01353508|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129847|NCT02606461|f||OTHER||t
17174402|NCT02175199|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17174403|NCT00459732|f||||f
17174404|NCT01322841|f||||f
17174405|NCT03983317|f||||f
17174406|NCT01349049|f||||f
17174407|NCT01170533|t||||f
17174408|NCT02933450|f||||f
17174409|NCT02810444|f||OTHER||t
17174410|NCT02506985|f||||f
17174411|NCT01373671|f||LTE60||t
17174412|NCT01320137|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174413|NCT02881567|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17174414|NCT03010488|t||||
17174415|NCT01290913|f||||f
17174416|NCT02078960|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17174417|NCT01737593|f||||f
17129848|NCT00239226|f||OTHER|INVESTIGATOR may publish/present the results of the work. However, INVESTIGATOR shall provide copies of any abstracts, or manuscripts to the sponsor for review at least 30 (thirty) days prior to submittal for publication or presentation. The sponsor shall limit its review to a determination of whether Confidential Information is disclosed and to check for technical correctness. Sponsor shall not attempt to censor or in any way interfere with INVESTIGATOR's presentation or conclusions.|t
17129849|NCT01614821|f||||f
17129850|NCT00646906|t||||
17129851|NCT00956657|t||||f
17129852|NCT00713479|t||||
17129853|NCT02844920|f||LTE60||t
17129854|NCT02224313|f||||f
17129855|NCT03331861|t||||
17129856|NCT00528580|t||||
17129857|NCT02871778|f||||t
17129858|NCT02170779|t||||
17129859|NCT00800683|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17129860|NCT03492554|f||||t
17129861|NCT01196533|f||||f
17129862|NCT01561495|f||||f
17129863|NCT02463071|f||||f
17129864|NCT03986866|t||||
17129865|NCT01560923|t||||
17129866|NCT05093322|f||||t
17129867|NCT01380639|t||||
17129868|NCT00932425|f||||f
17129869|NCT02774616|f||||f
17129870|NCT00397033|f||GT60||t
17129871|NCT01984164|t||||
17129872|NCT05293743|t||||
17129873|NCT02546765|f||||f
17129874|NCT02064920|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17129875|NCT05834348|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129876|NCT01129921|f||||f
17174418|NCT02173509|t||||
17174419|NCT00975689|t||||
17129877|NCT00583024|t||||
17129878|NCT04890314|t||||f
17174420|NCT04335136|f||||t
17174421|NCT00787618|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17129879|NCT02229539|f||LTE60||t
17129880|NCT00574145|t||||
17129881|NCT02737852|f||OTHER|Master service agreement and confidentiality agreement in place|t
17129882|NCT04050670|f||OTHER||t
17129883|NCT02348775|f||||f
17129884|NCT02553265|t||||
17129885|NCT01653288|f||||f
17129886|NCT02982239|f||||f
17129887|NCT03042780|t||||
17129888|NCT02000596|t||||
17129889|NCT02982590|f||||f
17129890|NCT01168973|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17129891|NCT00699803|f||OTHER|Contact sponsor directly for details.|t
17129892|NCT00625989|t||||
17129893|NCT01195090|t||||f
17129894|NCT04784897|f||OTHER|The terms and conditions of the disclosure agreement with investigators may vary. However, an investigator/institution may publish results, with any single center publication to be deferred until after a publication of results covering all centers in the clinical trial.|t
17129895|NCT04667377|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129896|NCT02428855|t||||
17129897|NCT00006151|f||||f
17129898|NCT00702364|t||||
17129899|NCT05418673|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17129900|NCT02475070|t||||
17129901|NCT02902081|t||||
17138682|NCT01455415|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138683|NCT00587301|t||||
17129902|NCT00303979|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred."|t
17129903|NCT04366050|f||||f
17129904|NCT04422990|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17129905|NCT01490814|f||LTE60||t
17129906|NCT01127659|t||||
17129907|NCT01750931|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129908|NCT03024970|f||||f
17129909|NCT00814671|f||||f
17129910|NCT01221727|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17129911|NCT00590044|f||||f
17129912|NCT02790138|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17129913|NCT03199040|t||||
17129914|NCT01786603|f||||f
17129915|NCT01226459|f||OTHER|Multi-Center Publication will be the first publication to present the results of the Study. Upon such Multi-Center Publication, or the earlier of (a) Sponsor's confirmation that there will be no Multi-Center Publication or presentation, or (b) 12 months after the completion of the entire multi-center study, Institution and Investigator may publish or present Study data and results generated in their performance of the Study in accordance with the terms of this Article.|t
17129916|NCT00474708|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17129917|NCT03700320|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129918|NCT03770091|t||||f
17129919|NCT00175877|f||GT60||t
17129920|NCT01978535|t||||
17129921|NCT01092143|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17129922|NCT01937598|f||||f
17129923|NCT00199836|f||||f
17129924|NCT01708291|t||||
17129925|NCT01843972|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17129926|NCT02232126|f||||f
17129927|NCT02336763|t||||
17129928|NCT03982342|t||||f
17129929|NCT01854645|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17129930|NCT03086265|t||||
17129931|NCT01202279|f||LTE60||t
17129932|NCT01908972|f||||f
17129933|NCT00475722|f||||f
17129934|NCT00916279|f||OTHER||t
17129935|NCT02109562|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multicenter publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17129936|NCT00310804|f||GT60||t
17129937|NCT03598647|f||||f
17129938|NCT00688155|f||||f
17129939|NCT04310085|f||OTHER|No announcement, oral presentation or publication relating to the Services shall be made by SGS without the prior written approval of Sponsor, except as may be otherwise required by law.|t
17129940|NCT00068575|t||||f
17129941|NCT04887155|f||||f
17129942|NCT03318978|t||||
17129943|NCT01292798|t||||
17129944|NCT01200238|f||||f
17129945|NCT01005745|t||||
17129946|NCT03548285|t||||
17129947|NCT01944293|f||||f
17129948|NCT00121836|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129949|NCT03227471|f||||t
17174422|NCT01305577|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17174423|NCT00796978|t||||
17174424|NCT02364336|t||||
17174425|NCT05246514|f||||f
17174426|NCT02910986|t||||
17174427|NCT01068600|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174428|NCT01727024|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17174429|NCT02167139|f||OTHER|At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor sixty (60) days to review and comment on them.|t
17174430|NCT00329797|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17174431|NCT00104520|f||OTHER|Institution and investigator may publish or present the results of the trial generated there with prior written consent of Gilead; or 2 years after the trial has ended at all institutions. Proposed publications/target venue must go to Gilead 30 days (manuscripts) or 15 days (abstracts/presentations) prior. Any Gilead confidential information in the document(s) must be deleted, or if requested publication delayed for up to 45 days to permit Gilead to obtain intellectual property protection.|t
17174432|NCT01151904|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174433|NCT01026324|f||LTE60||t
17174434|NCT05188053|t||||
17174435|NCT00794313|t||||
17174436|NCT02447302|f||OTHER||t
17129950|NCT00382720|f||OTHER|If no publication has occurred within 12 months after trial completion, the Investigator can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not exceeding 90 days.|t
17129951|NCT00682448|f||||f
17129952|NCT00311376|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17129953|NCT00257166|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17129954|NCT00829049|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17129955|NCT00521924|f||OTHER|Principal Investigator (PI) has the right to publish/publicly present the results of the Study, but may not to publish/publicly present any interim results. PI must provide 45 days written notice to Sponsor prior to submission for publication/presentation to permit Sponsor to review drafts for publication which report any results arising out of the Study. Sponsor shall have the right to review and comment on any Public Presentation.|t
17129956|NCT00982865|f||OTHER||t
17129957|NCT03335163|t||||
17129958|NCT00525044|t||||f
17129959|NCT00483561|f||||f
17129960|NCT03713034|t||||
17129961|NCT00713817|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17129962|NCT04415658|f||||f
17129963|NCT00415506|t||||
17129964|NCT02023242|f||OTHER|"If the Clinical Investigation is multi-centered, any publication based on the results obtained at the Investigation Site (or a group of sites) shall not be made before the first multi-center publication."|t
17129965|NCT02528370|t||||
17129966|NCT02650999|t||||f
17129967|NCT02251379|t||||f
17129968|NCT00618436|f||||f
17129969|NCT04854434|f||||t
17129970|NCT02709694|t||||
17129971|NCT00514514|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17129972|NCT02667275|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of the Sponsor.|t
17129973|NCT01274715|t||||
17129974|NCT03947983|f||||f
17129975|NCT02285920|f||||f
17129976|NCT01101438|f||||f
17129977|NCT02713542|f||OTHER|"In the Clinical Trial Agreement between sponsor and PI it states, Institution and clinical Investigator may not publish or publicly present the results of the study without the prior written approval of sponsor."|t
17174437|NCT01901250|t||||
17174438|NCT03686007|t||||
17174439|NCT01456897|f||||f
17174440|NCT06057727|f||||f
17174441|NCT01400880|f||||f
17174442|NCT01396070|f||||f
17129978|NCT00066742|f||LTE60||t
17129979|NCT00791336|t||||
17138684|NCT04128527|f||LTE60||t
17174443|NCT01561313|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17174444|NCT04254913|f||OTHER||t
17174445|NCT02695420|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174446|NCT04535453|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17174447|NCT00916929|f||LTE60||t
17174448|NCT02929407|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17174449|NCT02413151|f||||f
17174450|NCT00850421|t||||
17174451|NCT02442804|f||||f
17174452|NCT02036853|t||||
17174453|NCT01742286|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17174454|NCT02633020|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174455|NCT01136785|t||||
17174456|NCT03435783|f||||f
17174457|NCT02954172|f||||f
17183201|NCT01430585|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174458|NCT00853567|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17174459|NCT03818035|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17174460|NCT00982423|t||||
17174461|NCT03374202|t||||
17174462|NCT02712047|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17129980|NCT03794583|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17174463|NCT05286749|t||||
17174464|NCT01395524|f||GT60||t
17174465|NCT01657461|f||OTHER|Physician shall not make any publication without providing Sponsor 30 days notice.If Sponsor determines that the proposed publication contains confidential information, Sponsor may require the delay of publication for a period of time not to exceed 90 days and may require that any confidential information be removed from the publication. Sponsor may also require Physician to delay publication until any factual errors or inaccuracies in the publication are corrected.|t
17174466|NCT01303224|f||OTHER|Prior to submitting the results of this study for publication or presentation, the PI will allow Sponsor at least 60 days time to review and comment upon the publication manuscript. No publication of PI is permitted before the overall publication of the multicentre study made by the Sponsor (or its designee), unless said overall publication is not made within 18 months from the completion of the Final Study Report.|t
17174467|NCT01574183|f||||f
17174468|NCT02609113|t||||f
17174469|NCT00295880|t||||f
17174470|NCT00843284|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17129981|NCT01488279|f||LTE60||t
17129982|NCT01172197|t||||
17129983|NCT00415857|t||||
17129984|NCT00233363|f||||f
17129985|NCT03000088|f||||f
17129986|NCT01495858|f||||f
17129987|NCT00873366|t||||
17129988|NCT01576172|f||LTE60||t
17129989|NCT00324753|f||||f
17174471|NCT00147069|t||||
17174472|NCT05480111|t||||
17129990|NCT04234672|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17174473|NCT01761162|f||OTHER|Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.|t
17174474|NCT01856218|f||GT60||t
17174475|NCT03718091|f||||f
17174476|NCT02490670|f||GT60||t
17174477|NCT01717053|t||||
17174478|NCT02160899|f||||t
17174479|NCT00798759|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17174480|NCT01754727|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17174481|NCT04540510|t||||
17174482|NCT04518995|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17174483|NCT01971086|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174484|NCT02891070|f||||t
17174485|NCT04491604|f||||f
17174486|NCT02934503|t||||
17174487|NCT04248491|f||||f
17174488|NCT02597478|t||||
17174489|NCT01536067|t||||
17174490|NCT01652469|f||||f
17174491|NCT01402102|t||||f
17174492|NCT05043142|t||||
17174493|NCT00905645|f||||f
17174494|NCT01731938|f||OTHER|Site may publish results from the study, after providing Sponsor at least thirty days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At Sponsor's request, the site will remove any confidential information (other than study results), and incorporate all reasonable comments by Sponsor, or delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17174495|NCT04931888|t||||
17174496|NCT04538144|f||||f
17174497|NCT02350478|f||||t
17174498|NCT00771953|t||||
17174499|NCT03328208|t||||
17174500|NCT01179113|f||||f
17174501|NCT02722304|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17174502|NCT02644109|f||OTHER|Prior authorization of the text by the Sponsor|t
17174503|NCT06026124|f||||f
17129991|NCT04792567|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17129992|NCT01537198|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17129993|NCT01231659|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174504|NCT01519869|t||||
17174505|NCT03023813|f||||f
17174506|NCT00577798|t||||
17174507|NCT02433080|t||||
17174508|NCT04530136|f||||t
17174509|NCT01309282|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174510|NCT01387542|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to publication and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The paper that incorporates confidential information requires Sponsor's written consent. PI will withhold publication for up to an additional 60 days to allow for filing of a patent application.|t
17174511|NCT03601117|t||||f
17174512|NCT01010867|t||||
17174513|NCT00884741|f||LTE60||t
17174514|NCT01233232|f||LTE60||t
17174515|NCT02762370|f||||t
17174516|NCT02917122|f||||f
17174517|NCT00125528|f||||f
17174518|NCT00101452|f||||f
17174519|NCT00499590|f||||f
17174520|NCT05661851|f||GT60||t
17174521|NCT01014910|f||||f
17174522|NCT00612807|f||||f
17174523|NCT02252939|t||||
17174524|NCT00580671|f||||f
17174525|NCT00870584|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174526|NCT01497366|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17174527|NCT03800420|f||OTHER|"The Institution and Investigator shall not publish the results of this study without the prior written consent of sponsor. As used herein, the term publish shall include oral presentations, written abstracts, written manuscripts, etc."|t
17174528|NCT03911102|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17174529|NCT00746512|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174530|NCT00419445|f||GT60||t
17174531|NCT02745080|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174532|NCT01821560|t||||
17174533|NCT01254760|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17174534|NCT01338298|f||||f
17174535|NCT05601544|f||GT60||t
17174536|NCT02491632|t||||
17174537|NCT06221826|f||||f
17174538|NCT03390114|t||||
17174539|NCT03036215|f||||f
17174540|NCT01505764|f||||f
17129994|NCT02887404|t||||
17174541|NCT01256294|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174542|NCT04681352|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17174543|NCT02603666|f||||f
17174544|NCT01643772|f||GT60||t
17174545|NCT02338882|f||||f
17174546|NCT01328405|t||||
17174547|NCT04838977|f||||f
17174548|NCT04780919|f||||f
17174549|NCT02314637|f||OTHER||t
17174550|NCT04126278|t||||
17174551|NCT00724867|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174552|NCT00373113|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174553|NCT00856232|t||||f
17174554|NCT03241030|t||||f
17174555|NCT00621348|t||||f
17174556|NCT03120351|t||||
17174557|NCT01256190|f||OTHER|Investigators will be part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.|t
17129995|NCT00545402|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17129996|NCT03520959|f||LTE60||t
17138685|NCT01496274|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138686|NCT02758613|f||GT60||t
17138687|NCT00721617|t||||
17138688|NCT00351819|f||||f
17138689|NCT01804114|f||||f
17138690|NCT00719537|t||||f
17138691|NCT01459068|t||||f
17138692|NCT00841269|f||||f
17138693|NCT00196196|f||LTE60||t
17138694|NCT02910219|t||||
17174558|NCT02834793|f||||f
17174559|NCT01049009|t||||f
17174560|NCT02423902|f||LTE60||t
17174561|NCT02197078|f||||f
17174562|NCT00622440|t||||
17174563|NCT04915950|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174564|NCT00536913|f||OTHER||t
17174565|NCT04195893|f||||f
17174566|NCT01999517|f||||f
17174567|NCT01802073|t||||
17174568|NCT00332722|f||||f
17174569|NCT01421355|f||||f
17174570|NCT02123472|f||GT60||t
17174571|NCT00918736|t||||
17174572|NCT01474018|f||||f
17174573|NCT01137604|f||OTHER||t
17129997|NCT03734016|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17129998|NCT01979835|f||||f
17129999|NCT01777412|f||||f
17130000|NCT04633174|f||||f
17130001|NCT02592018|t||||f
17130002|NCT00314353|f||LTE60||t
17130003|NCT02710136|f||||f
17130004|NCT00418665|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17130005|NCT00891319|t||||
17130006|NCT01133379|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17130007|NCT00591214|f||OTHER||t
17130008|NCT00841204|f||LTE60||t
17130009|NCT02072928|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174574|NCT01297491|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17174575|NCT02511106|f||OTHER||t
17174576|NCT00947167|f||||f
17174577|NCT05099263|f||||f
17174578|NCT01838980|f||GT60||t
17174579|NCT00344487|t||||
17174580|NCT03764293|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17174581|NCT03679754|f||OTHER|Disclosure shall not occur until (i) twenty-four (24) months have elapsed since Sponsor has notified Institution of the completion of the multi-center Study in order for Sponsor to comply with its obligations under 21 CFR 312.53(c)(4), or (ii) after the publication of the multi-center Study data, if the Study is a multi-center Study or Sponsor confirms in writing there will be no multi-center publication.|t
17174582|NCT01262820|t||||
17174583|NCT00711477|f||OTHER|Upon completion or termination of the CRADA, a final report including a list of inventions must be prepared and delivered to the Dept. of Energy Office of Scientific and Technical Information. Each party must provide the other with up to 45 days to review any proposed publication associated with the CRADA results. Approval of the planned publication will not be unreasonably withheld.|t
17174584|NCT03043105|f||||f
17174585|NCT01640834|f||GT60||t
17174586|NCT01430169|f||OTHER||t
17174587|NCT00145977|t||||
17174588|NCT01567839|t||||
17174589|NCT02645019|t||||
17174590|NCT00782834|f||||f
17174591|NCT02055118|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonmentor termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17174592|NCT02281383|t||||
17174593|NCT01215097|t||||
17174594|NCT01221311|f||||f
17130010|NCT02786134|f||||f
17130011|NCT05470465|f||||f
17130012|NCT03706417|t||||
17130013|NCT05938998|f||||f
17174595|NCT02560025|t||||
17174596|NCT02703337|f||GT60||t
17130014|NCT03022318|t||||
17130015|NCT05050318|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130016|NCT05907213|t||||
17130017|NCT02142738|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17130018|NCT03688880|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17138695|NCT01015820|t||||f
17138696|NCT00701441|f||||f
17138697|NCT02025829|f||||f
17174597|NCT00282308|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174598|NCT00329524|f||||f
17174599|NCT05073432|t||||
17174600|NCT01001325|f||LTE60||t
17174601|NCT01584440|f||OTHER||t
17174602|NCT00531427|f||GT60||t
17174603|NCT00773604|f||||f
17174604|NCT00273793|t||||
17174605|NCT03524729|t||||
17174606|NCT01548833|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17174607|NCT02626624|f||||f
17174608|NCT04075812|t||||
17174609|NCT00122980|f||||f
17130019|NCT01704287|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17130020|NCT04490395|t||||f
17130021|NCT02230254|f||||t
17130022|NCT01861028|f||||f
17130023|NCT01462435|f||||f
17130024|NCT01942148|f||||f
17130025|NCT00857532|f||LTE60||t
17130026|NCT00257725|t||||
17130027|NCT02573870|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130028|NCT01858532|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17130029|NCT00366275|t||||
17130030|NCT03785925|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17130031|NCT03370536|t||||
17130032|NCT00806195|f||GT60||t
17130033|NCT02490475|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130034|NCT00139776|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130035|NCT00674583|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130036|NCT00357214|f||||f
17130037|NCT01519934|f||||f
17130038|NCT01994382|f||||t
17130039|NCT01687179|f||||f
17130040|NCT01368536|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17174610|NCT01124864|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174611|NCT01243242|f||LTE60||t
17174612|NCT00724711|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17174613|NCT01945710|f||OTHER||t
17174614|NCT00375609|f||OTHER|Due to multiple studies, centers and countries this will vary.|t
17174615|NCT01368562|f||OTHER|Please contact Sponsor directly for additional information.|t
17130041|NCT03861936|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130042|NCT00359021|f||OTHER|The investigator agrees that before he/she publishes any results of this trial, he/she shall provide the sponsor with at least 45 days for full review of the pre-publication manuscript prior to submission of the manuscript to the publisher.|t
17130043|NCT03496220|f||||f
17130044|NCT02234284|f||||f
17130045|NCT01835015|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17130046|NCT04569032|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130047|NCT00588536|t||||
17130048|NCT00701090|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130049|NCT02201420|f||OTHER|The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.|t
17130050|NCT01314963|f||||f
17130051|NCT00131469|f||||f
17130052|NCT00574288|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17138698|NCT00607126|f||||f
17138699|NCT02690168|f||||f
17138700|NCT01313078|f||||f
17174616|NCT05111301|f||||f
17130053|NCT00702325|f||OTHER|If Sponsor does not publish within 2 years after study completion, PI is permitted to publish, with confidential information removed from manuscript. Sponsor will have opportunity to review and approve publication at least 60 days pior to being submitted/disclosed. Sponsor can request, in writing, an additional 90 day embargo.|t
17130054|NCT01022502|t||||
17130055|NCT03123250|f||GT60||t
17130056|NCT01390272|t||||
17130057|NCT00861913|f||LTE60||t
17130058|NCT02566577|t||||
17130059|NCT01210170|t||||
17130060|NCT01751399|f||GT60||t
17130061|NCT02032550|f||||f
17130062|NCT00073528|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174617|NCT00669409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174618|NCT04978454|f||LTE60||t
17174619|NCT03583385|f||||f
17174620|NCT00095940|f||LTE60||t
17174621|NCT03029988|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and make modifications to the publication.|t
17174622|NCT03539549|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174623|NCT02864862|t||||
17174624|NCT02191865|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17130063|NCT03086057|f||||f
17130064|NCT02179671|f||||f
17130065|NCT01770912|f||||f
17174625|NCT04693234|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17174626|NCT04643158|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17174627|NCT04540198|f||||f
17174628|NCT02888119|t||||
17174629|NCT05573386|f||||f
17174630|NCT03646123|f||||t
17174631|NCT02209532|f||||f
17174632|NCT04036292|f||||t
17174633|NCT03462511|f||||f
17174634|NCT02925416|f||OTHER||t
17174635|NCT03595228|f||LTE60||t
17174636|NCT00200356|f||OTHER||t
17174637|NCT03495856|t||||f
17174638|NCT00435045|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174639|NCT00312195|f||GT60||t
17174640|NCT03152929|t||||
17174641|NCT01015638|f||||f
17174642|NCT04296448|t||||
17174643|NCT05051631|t||||
17174644|NCT01703754|f||LTE60||t
17174645|NCT04950816|t||||
17174646|NCT00964171|t||||
17174647|NCT05871450|t||||
17174648|NCT05487196|t||||
17174649|NCT02872935|t||||
17174650|NCT02792829|f||OTHER||t
17174651|NCT02873429|t||||
17174652|NCT04270370|f||GT60||t
17174653|NCT03009396|f||||t
17174654|NCT00530504|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results without permission of the sponsor.|t
17174655|NCT00610480|t||||
17174656|NCT02872285|f||OTHER|Center results cannot be submitted for publication before results of multicenter study are published unless it is ≥18 months since study completion. Then Investigator can publish if manuscript is submitted to Lycera ≥ 60 days prior to submission (or per Investigator contract). If Lycera decides publication would hinder development, Investigator must delay submission. Investigator must delete confidential information before submission and defer publication to allow patent applications.|t
17130066|NCT01536951|f||GT60||t
17130067|NCT00615472|f||||f
17130068|NCT04261504|f||||f
17130069|NCT00430482|t||||
17130070|NCT00555477|f||||f
17130071|NCT01817751|t||||
17130072|NCT01721876|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130073|NCT00382018|f||LTE60||t
17174657|NCT05477108|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB.|t
17174658|NCT02660983|f||||f
17174659|NCT02083861|f||||f
17183202|NCT01412424|f||OTHER|The results of the study cannot be published for a period of up to 150 days, 60 days for sponsor review and 90 days for patent protection. In addition, the first publication may only occur after the first multi-center publication or, if no such multi-center publication is made, 12-18 months after completion of the study at all study sites.|t
17183203|NCT03161314|f||||f
17130074|NCT01721057|f||GT60||t
17130075|NCT03805750|f||||f
17130076|NCT00789880|f||||f
17130077|NCT01177683|f||||f
17130078|NCT02219321|t||||
17130079|NCT00617539|t||||
17130080|NCT03057613|t||||
17130081|NCT01977820|f||OTHER|All written or oral publications and/or information related to Study and/or results of Study should be submitted at first in writing to Sponsor at least 30 working days for publication and 15 working days for brief review, abstract before planned date of submission. If Sponsor is filing a patent application on Study results, Sponsor can delay its authorization for publication/communication of Study results to Investigator and/or Research Centre until date of international registration of patent.|t
17130082|NCT02568475|f||||f
17130083|NCT02426476|t||||
17130084|NCT01889238|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130085|NCT04136184|f||||t
17130086|NCT02844816|f||LTE60||t
17130087|NCT06557122|f||OTHER|Investigators shall not independently publish, publicly disclose, present or discuss any results or information pertaining to study conducted under the mutual agreement until such a multi-center publication is released under Sponsor's direction.|t
17130088|NCT02717754|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130089|NCT00938717|f||OTHER|The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.|t
17174660|NCT03376295|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174661|NCT04303195|f||||f
17174662|NCT01065454|f||OTHER|The Investigative Site, Institution and/or Principal Investigator shall furnish the Sponsor with a copy of any proposed publication of material at least sixty (60) days in advance of the date of submission for publication or presentation.|t
17174663|NCT01601652|t||||
17174664|NCT05688670|t||||
17174665|NCT03425253|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174666|NCT05009979|f||||f
17174667|NCT03093662|f||||f
17130090|NCT00998049|t||||
17130091|NCT05092919|f||||f
17174668|NCT03844945|f||OTHER|Prior to publishing any trial results, site shall provide the to be published information to the Sponsor for review and obtain written approval at least thirty (30) days in advance of publication.|t
17174669|NCT03159260|t||||
17174670|NCT01043939|t||||
17174671|NCT01077921|t||||
17130092|NCT01490684|f||||f
17130093|NCT02248259|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130094|NCT01575106|t||||f
17130095|NCT01206062|f||||f
17130096|NCT01848288|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17130097|NCT02091778|f||||f
17130098|NCT00677820|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restricion is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17130099|NCT01673919|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130100|NCT05335356|f||OTHER|Data are the property of the Sponsor and cannot be published without prior authorization from the Sponsor, but data and publication thereof will not be unduly withheld.|t
17130101|NCT00986544|t||||f
17174672|NCT04129151|f||||f
17130102|NCT04814342|f||||f
17130103|NCT01871220|f||||f
17130104|NCT05102344|t||||
17130105|NCT01825057|f||||f
17174673|NCT02051933|t||||
17174674|NCT00407381|f||||f
17174675|NCT00588861|f||OTHER|The only disclosure restriction on the PI is that the sponsor can conduct a pre-publication review of articles, papers, or presentations which the PI desires to publish. Any such review must be completed by sponsor within thirty (30)days of the submission of the request. The PI must include whatever credits the sponsor deems necessary or appropriate to disclose its proprietary interest to the material disclosed in the article, paper or presentation.|t
17174676|NCT02730195|t||||
17183204|NCT04304001|f||||f
17183205|NCT02722668|t||||
17130106|NCT01688596|f||||f
17130107|NCT04746833|t||||
17130108|NCT02865018|t||||
17138701|NCT01961089|f||||f
17174677|NCT00265148|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174678|NCT03101111|f||||f
17174679|NCT05525078|t||||
17174680|NCT00942994|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174681|NCT00296296|t||||
17174682|NCT01874340|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis doesn not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of the trial results in their entirety.|t
17174683|NCT01421472|f||LTE60||t
17174684|NCT00641641|t||||f
17174685|NCT01068964|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17174686|NCT01311024|t||||f
17174687|NCT03630770|f||||f
17174688|NCT01523275|f||||f
17174689|NCT01206322|f||||f
17174690|NCT00689117|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174691|NCT00802113|t||||
17174692|NCT01086358|f||||f
17130109|NCT00290290|f||||f
17130110|NCT02015442|t||||
17130111|NCT02809131|t||||
17130112|NCT04013789|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17130113|NCT03319407|t||||
17130114|NCT00549939|f||OTHER|"If no publication has occurred within 12 months after trial completion, the investigators can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not to exceed 90 days.~To protect by a property right any information the sponsor can postpone the publication, for a period not to exceed 18 months."|t
17130115|NCT03677596|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130116|NCT00003895|f||LTE60||t
17130117|NCT04912245|f||||f
17130118|NCT01134614|f||LTE60||t
17130119|NCT00702754|f||OTHER|No individual PI can disclose results until after a group manuscript is published.|t
17130120|NCT01353196|f||||f
17130121|NCT03633526|f||||t
17130122|NCT01085786|t||||
17130123|NCT04534491|f||GT60||t
17130124|NCT00496730|t||||
17130125|NCT00113074|f||||f
17174693|NCT04975230|f||||f
17174694|NCT03206788|f||||f
17174695|NCT02471612|t||||
17174696|NCT03899805|f||||f
17174697|NCT03317405|f||LTE60||t
17174698|NCT02291016|f||||f
17174699|NCT01018810|f||GT60||t
17174700|NCT01640314|f||||f
17174701|NCT04450381|f||GT60||t
17174702|NCT01989208|f||||f
17174703|NCT04973436|f||||f
17174704|NCT00566696|t||||
17174705|NCT06338462|t||||
17130126|NCT02114268|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17130127|NCT03962738|f||GT60||t
17130128|NCT00509067|t||||
17130129|NCT01365585|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130130|NCT02247960|t||||
17130131|NCT00356889|f||LTE60||t
17130132|NCT01507779|f||||f
17130133|NCT00736034|f||||f
17130134|NCT01591317|f||GT60||t
17138702|NCT02679781|t||||f
17138703|NCT04209400|f||||f
17138704|NCT04644484|f||||f
17138705|NCT00677560|t||||
17138706|NCT01203787|f||||f
17174706|NCT03048006|f||||f
17174707|NCT01534897|f||||f
17174708|NCT00452361|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17174709|NCT01472718|f||||f
17174710|NCT03116152|f||||f
17174711|NCT03179605|f||||t
17174712|NCT00910299|f||GT60||t
17174713|NCT00635999|t||||
17174714|NCT03849118|f||OTHER|If the Study is a Multi-center Study, then the Institution agrees that no publication of the study results may be made until publication of the results of the multi-center study or 2 years after study completion, whichever is the sooner.|t
17174715|NCT02448641|f||||t
17174716|NCT00228553|f||GT60||t
17174717|NCT01536392|t||||
17174718|NCT01012089|f||||f
17183206|NCT03204942|f||||f
17130135|NCT03716050|t||||
17130136|NCT02361944|f||||f
17130137|NCT04305275|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17130138|NCT00749476|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17130139|NCT01022242|f||LTE60||t
17130140|NCT03654976|f||OTHER|Sponsor shall be able to review any proposed publication or presentation at least 60 days in advance of submission. Sponsor cannot require changes. Upon sponsor's request, the investigator shall delay a publication or presentation for 6 months to permit the sponsor to take necessary steps to protect confidential information. For this multi-site trial it is mandatory that the primary publication is based on data from all trial sites analyzed as stipulated in the protocol and in the SAP.|t
17130141|NCT00117598|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130142|NCT01775735|f||GT60||t
17130143|NCT04688775|f||||f
17130144|NCT00493220|f||OTHER|For this study, Baxter requires a review of any planned PI results communications (eg, for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (eg, to allow for intellectual property protection).|t
17130145|NCT02625233|f||GT60||t
17130146|NCT01379469|t||||f
17130147|NCT01877915|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17130148|NCT01449461|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130149|NCT00943579|t||||f
17130150|NCT01357577|f||||f
17130151|NCT02414399|f||||f
17138707|NCT00970268|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17138708|NCT03404518|t||||
17138709|NCT01079195|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17138710|NCT01745913|t||||
17138711|NCT04454138|f||||f
17138712|NCT03693404|t||||
17138713|NCT00201760|t||||
17138714|NCT01999348|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130152|NCT01502709|f||||f
17130153|NCT05745675|f||||f
17130154|NCT00937937|f||LTE60||t
17130155|NCT00984490|t||||
17130156|NCT02932410|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. If requested by the Sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17130157|NCT00760019|f||||f
17130158|NCT05506956|f||||f
17138715|NCT01240304|t||||
17138716|NCT01685203|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138717|NCT02320214|f||OTHER|Master service agreement and confidentiality agreement in place|t
17138718|NCT01576406|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138719|NCT05151367|f||||f
17138720|NCT01962688|t||||
17138721|NCT00669032|f||OTHER|The only disclosure restriction on the PIs is that the study results will be presented during scientific meetings or published in scientific journals with prior agreement with the sponsor.|t
17138722|NCT01375647|f||||f
17138723|NCT03140722|f||OTHER||t
17183207|NCT02664038|t||||
17130159|NCT01007032|f||GT60||t
17130160|NCT01841749|t||||
17130161|NCT04774250|f||||f
17130162|NCT05714982|f||||f
17130163|NCT03634397|f||||f
17130164|NCT02752035|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17130165|NCT03442036|f||||f
17130166|NCT01161043|f||GT60||t
17130167|NCT01236573|f||||f
17174719|NCT02259088|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130168|NCT00330876|f||GT60||t
17130169|NCT02164929|t||||
17130170|NCT00971178|f||||f
17130171|NCT01846728|f||||f
17130172|NCT02161575|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130173|NCT01925573|t||||
17130174|NCT00424749|t||||f
17130175|NCT02446314|f||||f
17130176|NCT04109222|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130177|NCT02577406|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130178|NCT03023059|t||||
17130179|NCT02138617|f||OTHER|Subcontractor agrees that the first publication of the Study results will be made by Institution as a multi-site publication. Subcontractor can publish its site-specific results after Institution's publication, 12 months post-study completion, or upon Institution's notice. Subcontractor must provide Institution 30 days for manuscript review and may delay publication for 45 days for patent filing. Institution will register the Study and post results as required by law.|t
17130180|NCT05500274|f||||f
17130181|NCT04252859|t||||
17130182|NCT04451161|f||||f
17130183|NCT00125762|f||||f
17130184|NCT01555151|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17130185|NCT03596866|f||||t
17130186|NCT00596947|f||||f
17130187|NCT03098836|t||||
17130188|NCT00898443|t||||
17130189|NCT04695392|f||||f
17130190|NCT00580372|f||||f
17130191|NCT03472924|t||||
17130192|NCT04743921|f||||f
17130193|NCT00427349|f||LTE60||t
17130194|NCT01660321|f||||f
17130195|NCT00698997|f||||f
17130196|NCT03491007|t||||
17130197|NCT05082376|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130198|NCT01436084|t||||f
17130199|NCT03023930|t||||
17130200|NCT04425720|f||||f
17174720|NCT00932828|t||||f
17174721|NCT01033448|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174722|NCT01818752|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174723|NCT01324141|f||||f
17130201|NCT00290186|t||||
17130202|NCT00445224|t||||
17130203|NCT01771055|f||||f
17130204|NCT04391036|t||||f
17130205|NCT00912002|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17130206|NCT01675635|f||||f
17130207|NCT02904915|t||||
17130208|NCT00262522|f||OTHER|Provide ABBOTT at least thirty (30) days prior to submission for review, ABBOTT shall return comments within thirty (30) days of receipt of draft. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period|t
17130209|NCT03159091|f||||t
17130210|NCT04814823|f||||f
17130211|NCT04085523|f||||f
17130212|NCT00232583|f||||f
17130213|NCT03977974|f||GT60||t
17130214|NCT05338515|f||GT60||t
17130215|NCT04024228|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130216|NCT05197049|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17130217|NCT00309465|f||||f
17174724|NCT04784065|f||||f
17174725|NCT00893815|f||||f
17174726|NCT01165216|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174727|NCT00167219|t||||
17174729|NCT06457204|t||||
17174730|NCT01808092|f||||f
17174731|NCT01097005|f||OTHER|The investigators will be granted by sponsor.|t
17174732|NCT01909011|f||||f
17174733|NCT00695097|f||||f
17174734|NCT05289037|f||LTE60||t
17174735|NCT05141448|f||GT60||t
17174736|NCT01217307|t||||
17174737|NCT01868542|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17174738|NCT02248675|f||||f
17174739|NCT00395057|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17174740|NCT01816711|t||||
17130218|NCT04033445|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17174741|NCT05011279|f||||f
17174742|NCT00813943|f||OTHER|All manuscripts and materials relating to Study shall be submitted to Sponsor at least 60 days prior to submitting/presenting and allow Sponsor 60 days for review. If Sponsor requests, any confidential information shall be removed. In multi-center study, any publication shall not be made before the first multi-center publication; provided, however, that if no multi-center publication is made within 1 year from database lock, then Site may publish individually in accordance with this provision.|t
17174743|NCT02551991|f||||t
17174744|NCT00984620|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174745|NCT01632267|f||||f
17174746|NCT02424578|f||LTE60||t
17174747|NCT03899467|f||||f
17174748|NCT00470834|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130219|NCT04630171|f||||f
17174749|NCT00244140|f||LTE60||t
17174750|NCT05408637|f||||f
17174751|NCT04975438|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17174752|NCT02693132|t||||
17130220|NCT05807464|f||||f
17130221|NCT04754802|f||||f
17130222|NCT05525689|t||||
17130223|NCT01671111|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17130224|NCT03680911|t||||
17130225|NCT00889226|f||||f
17130226|NCT02504554|t||||f
17130227|NCT01806857|t||||
17130228|NCT01020591|f||||f
17130229|NCT04702737|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174753|NCT04615832|t||||
17174754|NCT01276054|f||||f
17174755|NCT02640508|t||||
17174756|NCT01168986|f||||f
17174757|NCT05405257|f||||f
17174758|NCT00776919|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174759|NCT00275340|f||||f
17174760|NCT01469715|t||||
17174761|NCT01966718|f||||f
17174762|NCT01454258|f||||f
17174763|NCT02379637|f||OTHER|Sponsor shall review results communications prior to public release to evaluate the manuscript for accuracy, ascertain whether information (other than the results of the Clinical Trial) is being improperly disclosed, provided information which may have not have yet been made available by the Sponsor, provide input for consideration regarding the content and/or conclusion(s) of the manuscript and determine whether the manuscript discloses any potentially patentable invention(s).|t
17183208|NCT05421078|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17183209|NCT02606136|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17183210|NCT03296696|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17183211|NCT02409615|f||||f
17183212|NCT04694131|t||||
17183213|NCT04456699|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17183214|NCT04112810|t||||
17183215|NCT01333488|f||OTHER|PI must obtain permission from sponsor to publish any data related to this trial.|t
17183216|NCT01468896|f||LTE60||t
17183217|NCT02915029|f||||f
17183218|NCT04452188|t||||f
17183219|NCT02357576|t||||
17183220|NCT00128180|t||||
17174764|NCT00862641|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17183221|NCT00699699|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17183222|NCT03296163|f||||t
17183223|NCT01000051|t||||
17183224|NCT00414050|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130230|NCT02811549|f||OTHER|"PI agrees to submit any publication to Sponsor at least 30 days before submission. Within 30 days, Sponsor advises PI in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair availability of patent protection for Inventions.~Sponsor has the right to require PI to remove specifically identified CI and/or to delay the publication for an additional 60 days to enable Sponsor to seek patent protection for Inventions."|t
17130231|NCT04272892|t||||
17130232|NCT05318937|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17130233|NCT02454140|t||||
17130234|NCT05359679|t||||
17130235|NCT05678257|f||||f
17130236|NCT05314517|f||||t
17174765|NCT02365480|f||LTE60||t
17174766|NCT03091348|f||||f
17130237|NCT04969276|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130238|NCT04551677|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130239|NCT04655144|t||||f
17174767|NCT02791763|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174768|NCT04534686|f||||f
17174769|NCT00706342|f||LTE60||t
17174770|NCT01034670|t||||
17174771|NCT04762719|t||||
17174772|NCT01419197|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17174773|NCT02410343|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17183225|NCT03495908|f||||f
17183226|NCT02097992|f||||f
17183227|NCT05468398|f||||f
17183228|NCT01397695|t||||
17183229|NCT02660918|t||||
17183230|NCT00780572|t||||
17130240|NCT04490018|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17130241|NCT04714073|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review Prior to any Submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI´s intellectual property rights|t
17130242|NCT01401842|f||||f
17130243|NCT03337542|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17130244|NCT00282295|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130245|NCT01181076|t||||
17130246|NCT00121108|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17130247|NCT01380379|f||||f
17130248|NCT02971631|t||||
17130249|NCT03372928|f||||f
17130250|NCT03996980|f||||f
17130251|NCT03697720|t||||
17130252|NCT04456764|t||||
17130253|NCT03116997|t||||
17130254|NCT02322125|t||||
17130255|NCT01463670|t||||
17130256|NCT00095875|t||||
17130257|NCT00766038|f||||f
17130258|NCT00449670|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130259|NCT04701138|t||||
17130260|NCT03743311|f||||f
17130261|NCT04183790|f||||t
17130262|NCT01251653|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130263|NCT00847145|f||GT60||t
17130264|NCT01798589|f||||f
17130265|NCT02833974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130266|NCT01524198|t||||f
17130267|NCT04419610|t||||
17130268|NCT01439282|f||||f
17130269|NCT02232802|f||||f
17130270|NCT00751777|f||OTHER||t
17130271|NCT00634634|t||||
17130272|NCT01973777|f||||f
17130273|NCT00885703|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17130274|NCT01183143|t||OTHER||t
17130275|NCT00675922|f||||f
17130276|NCT05745662|f||||f
17130277|NCT03197493|t||||
17130278|NCT01180478|f||||f
17130279|NCT02163187|t||||
17130280|NCT01979159|f||||f
17130281|NCT03281668|t||||
17130282|NCT01785160|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130283|NCT01901575|f||||f
17174774|NCT02428478|t||||
17130284|NCT00957528|f||||f
17130285|NCT01021956|f||LTE60||t
17130286|NCT02234479|t||||f
17130287|NCT02318667|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17130288|NCT02289742|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17174775|NCT02663934|t||||
17174776|NCT02878798|t||||
17174777|NCT00246740|t||||
17174778|NCT01510769|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17174779|NCT00335764|f||LTE60||t
17174780|NCT01442844|f||||f
17174781|NCT02466659|t||||
17174782|NCT00929643|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174783|NCT01980485|f||||f
17174784|NCT00934440|t||||
17174785|NCT00744042|f||LTE60||t
17174786|NCT00750152|f||OTHER|Institution and Principal Investigator agree not to individually publish the results of the Study. Institution and Principal Investigator may, however, upon written notice to Merz participate in a joint, multicenter publication of the Study results with other investigators and/or institutions, provided that the manuscript or abstract is first reviewed by Merz.|t
17174787|NCT02057081|t||||f
17174788|NCT04629066|f||||f
17174789|NCT01028300|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication prior to the intended submission, presentation, or publication date|t
17174790|NCT02140593|t||||
17174791|NCT01214395|f||||f
17174792|NCT04166240|t||||
17174793|NCT00715910|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174794|NCT02034409|t||||
17174795|NCT05092360|f||||t
17174796|NCT04180540|t||||
17174797|NCT03952039|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174798|NCT04219085|t||||
17174799|NCT04469998|f||OTHER|Clinical Study Agreement defined what qualifies as Confidential Information and restrictions on publication of study results.|t
17174800|NCT04614324|f||||f
17174801|NCT04627285|f||GT60||t
17174802|NCT04473235|f||||f
17174803|NCT01754402|t||||
17174804|NCT01282463|f||GT60||t
17174805|NCT02726542|t||||f
17174806|NCT01221285|f||||f
17174807|NCT02491944|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17174808|NCT01239992|t||||
17174809|NCT02165839|t||||
17130289|NCT01489670|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130290|NCT01365039|f||OTHER||t
17130291|NCT04396860|f||LTE60||t
17130292|NCT04223843|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130293|NCT06243198|f||GT60||t
17130294|NCT01961349|f||LTE60||t
17130295|NCT00896779|f||||f
17130296|NCT00829179|f||||f
17174810|NCT03861988|t||||
17174811|NCT00220779|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17174812|NCT03390101|f||||f
17130297|NCT01075412|t||||
17130298|NCT00916149|f||||f
17130299|NCT02132884|t||||
17130300|NCT00589420|t||||
17174813|NCT00281658|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174814|NCT01343693|f||||f
17174815|NCT02704143|f||||f
17174816|NCT01235598|f||GT60||t
17174817|NCT02151773|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17174818|NCT00395343|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174819|NCT02507960|t||||
17174820|NCT01463007|f||||f
17174821|NCT00387790|f||LTE60||t
17174822|NCT00444678|t||||
17174823|NCT01558128|t||||f
17174824|NCT04693052|t||||
17174825|NCT02779556|t||||f
17174826|NCT02223377|f||||f
17174827|NCT03236662|t||||
17174828|NCT03110770|f||||f
17174829|NCT00260962|f||||f
17174830|NCT01996839|f||OTHER|Contact sponsor directly for details.|t
17174831|NCT04586387|f||||f
17130301|NCT01940471|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130302|NCT01846624|f||||f
17130303|NCT03574753|f||||f
17130304|NCT00832520|f||||f
17130305|NCT02218242|f||||f
17130306|NCT03462719|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17130307|NCT03740165|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17130308|NCT02044133|t||||
17174832|NCT02082340|t||||
17174833|NCT01625260|f||||t
17174834|NCT02937584|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17174835|NCT00635219|f||OTHER|The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.|t
17174836|NCT00280384|f||||f
17174837|NCT01598129|f||GT60||t
17130310|NCT00683163|f||||f
17130311|NCT03496012|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17130312|NCT03029715|t||||
17130313|NCT02722863|f||||t
17130314|NCT04096274|f||||f
17174838|NCT00591318|t||||f
17174839|NCT02420015|t||||
17174840|NCT04074161|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17174841|NCT02317744|f||||f
17174842|NCT03236155|t||||
17130315|NCT05030454|t||||
17130316|NCT03600142|f||||f
17130317|NCT00516048|f||GT60||t
17174843|NCT03890666|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17130318|NCT02807480|t||||f
17174844|NCT01639729|f||OTHER|requires prior approval|t
17174845|NCT03052426|t||||
17174846|NCT05387434|f||||f
17130319|NCT00054704|f||||f
17130320|NCT00362414|t||||f
17130321|NCT02369848|f||||f
17130322|NCT01543152|f||OTHER|All proposed written materials related to the study or an outline of any proposed oral presentations, shall be submitted to Sangamo for approval at least 45 days prior to submission of materials for publication or any oral disclosure to a third party. If Sangamo determines that a description of patentable subject matter is contained in such written material or outline, it shall notify the clinical site within 1 month after receipt and Sangamo will have an additional 90 days for review.|t
17130323|NCT02053168|f||||f
17174847|NCT03083990|f||||f
17174848|NCT03672097|f||||f
17174849|NCT01781299|t||||
17174850|NCT00146848|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review.|t
17174851|NCT01798849|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17174852|NCT02636361|t||GT60||t
17130324|NCT00636675|f||||f
17130325|NCT00096785|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130326|NCT04053868|t||||f
17130327|NCT02877693|f||||f
17174853|NCT02032238|f||LTE60||t
17183231|NCT01469065|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130328|NCT02829307|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130329|NCT00833053|f||LTE60||t
17130330|NCT01408992|f||LTE60||t
17130331|NCT02187471|f||||f
17130332|NCT02236520|t||||
17130333|NCT02081534|f||GT60||t
17174854|NCT03098615|f||||t
17174855|NCT01573052|f||||f
17174856|NCT01955629|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17174857|NCT03158285|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17174858|NCT02228980|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17174859|NCT01642615|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17174860|NCT01699867|f||||f
17174861|NCT00796926|f||||f
17174862|NCT04002908|f||||f
17174863|NCT01085006|t||||
17174864|NCT00006289|t||||
17174865|NCT02973438|t||||
17174866|NCT02043808|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174867|NCT02465099|f||OTHER|The PIs agreed that the first publication of results should be made in conjunction with the presentation of a joint, multicenter publication of the results with all sites contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could have published the results from their individual sites.|t
17174868|NCT00582075|t||||
17174869|NCT04359901|t||||
17174870|NCT00575146|f||||f
17174871|NCT04410133|f||||f
17174872|NCT03703297|f||||t
17174873|NCT01888432|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17174874|NCT03054129|f||||f
17174875|NCT00130247|f||||f
17174876|NCT02848729|f||||f
17130334|NCT00762892|f||||f
17130335|NCT00383084|t||LTE60||
17130336|NCT02159729|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130337|NCT02636582|f||LTE60||t
17130338|NCT01263483|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17130339|NCT00326209|f||OTHER|Please contact Sponsor directly for additional information.|t
17130340|NCT00714285|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130341|NCT01372384|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130342|NCT01621633|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17174877|NCT01904773|f||GT60||t
17174878|NCT00791076|t||||
17174879|NCT04565327|t||||
17138724|NCT03984812|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174880|NCT00606905|f||||f
17174881|NCT03700684|f||||f
17174882|NCT03319745|t||||
17174883|NCT00870103|f||||f
17174884|NCT03255629|f||||f
17174885|NCT00859638|f||||f
17174886|NCT02910505|f||||f
17174887|NCT02969408|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17174888|NCT01767142|f||||f
17174889|NCT01331213|t||||f
17174890|NCT04075734|f||||f
17174891|NCT02250703|t||||
17130343|NCT01131676|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17130344|NCT03000179|t||||
17130345|NCT00258011|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17130346|NCT03959332|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130347|NCT00865904|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17130348|NCT03625687|f||||f
17130349|NCT01431274|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174892|NCT01776307|f||OTHER|The sponsor can review results communications prior to public release and embargo communications of results up to 60 days.|t
17174893|NCT03615040|t||||
17174894|NCT00945295|f||||f
17174895|NCT02737891|f||||f
17130350|NCT00941668|f||GT60||t
17130351|NCT01396226|f||GT60||t
17130352|NCT00711425|f||LTE60||t
17130353|NCT01748942|t||||
17130354|NCT04607148|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130355|NCT00353834|f||||f
17130356|NCT02973087|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17130357|NCT04311216|f||||f
17130358|NCT00932360|t||||
17130359|NCT01924182|f||OTHER|The disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 90 days.|t
17130360|NCT00993265|t||||
17174896|NCT05194579|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174897|NCT04145219|f||OTHER|No publication can be made before the primary publication. PI shall provide Sponsor (S) with a copy of any publication or presentation 60 days before submission/public disclosure. S can require changes or non-publication of the article, if appropriate. Upon S request, the PI must delay the publication, presentation or public disclosure for an additional 120 days to permit S to apply for a patent application. Any other public statements regarding the trial requires prior written consent from S.|t
17174898|NCT01518270|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17174899|NCT02246413|f||||f
17174900|NCT02371941|f||||f
17174901|NCT01788215|t||||
17174902|NCT01950013|f||||f
17174903|NCT02751385|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17174904|NCT02299791|t||||
17174905|NCT03163017|t||||
17174906|NCT01099449|t||||
17174907|NCT00612105|f||OTHER|Agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Valeant supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17174908|NCT00824733|t||||
17174909|NCT00271505|t||||
17174910|NCT04556383|f||||t
17183232|NCT00578565|t||||
17183233|NCT01752933|f||||f
17183234|NCT02203591|f||||t
17183235|NCT03022617|f||||f
17130361|NCT01744665|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130362|NCT01357655|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174911|NCT00119678|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174912|NCT01146457|f||||f
17174913|NCT02692391|f||||f
17174914|NCT02720042|f||LTE60||t
17174915|NCT01761240|f||||t
17174916|NCT02356900|t||||f
17174917|NCT00509145|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17174918|NCT01994889|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17174919|NCT03632954|f||||f
17174920|NCT02969655|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174921|NCT02674204|t||||
17174922|NCT01748240|f||LTE60||t
17174923|NCT03753113|t||||
17174924|NCT01516034|f||GT60||t
17174925|NCT03060551|f||||f
17174926|NCT03562988|f||OTHER|Confidentiality and Master Service Agreement|t
17174927|NCT01809639|f||||f
17174928|NCT01525225|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17174929|NCT00363545|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17174930|NCT01379508|f||||f
17174931|NCT01457352|f||OTHER||t
17174932|NCT02537015|f||OTHER|"No presentation or publication of Institution's data relating to the Trial may occur until after the Trial has been completed at all sites. If Investigator desires to present or publish, investigator must submit any and all manuscripts, posters, abstracts, or other intended publications (hereinafter collectively referred to as manuscripts) to Sponsor at least sixty (60) days prior to the actual submission of such manuscript(s) for publication."|t
17174933|NCT04174365|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17174934|NCT02957968|f||OTHER|All study data and results will be owned by the institution. Subject to the terms and conditions of this agreement, institution and principal investigator have the right to publish or publicly present the results of the study. Merck shall have the right to review and comment on any public presentation. No public presentation shall contain any confidential information of Merck.|t
17183236|NCT01706250|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130363|NCT01590550|t||||
17130364|NCT03184077|t||||
17174935|NCT02156271|t||||
17174936|NCT00109590|f||OTHER|"In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights."|t
17174937|NCT00353470|t||||f
17174938|NCT00409331|t||||f
17174939|NCT02793856|t||||
17174940|NCT01511055|t||||
17174941|NCT00480987|t||||
17174942|NCT04590248|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17174943|NCT01109056|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17183237|NCT03678181|f||||f
17174944|NCT02052414|f||||f
17174945|NCT01303003|t||||
17174946|NCT03619811|f||||f
17174947|NCT03263702|f||||f
17174948|NCT02527200|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17174949|NCT01734889|f||OTHER|The results are intended to be published as a whole. If no comprehensive publication appears within 12 months of the trial termination, Investigators have the right to publish their results. Such data to be submitted to the Sponsor for review at least 60 days prior to submission for publication, public dissemination, or review by a publication committee. The Sponsor shall be entitled to make a reasoned request that publication be delayed for a period of up to 6 months.|t
17174950|NCT00966875|f||GT60||t
17174951|NCT02747433|f||||f
17174952|NCT04657666|f||||f
17174953|NCT02386189|t||||
17174954|NCT01651806|f||||f
17174955|NCT01659554|f||||f
17174956|NCT01790243|f||GT60||t
17174957|NCT01022398|t||||
17174958|NCT01317550|t||||
17174959|NCT03179202|f||||t
17174960|NCT01120782|f||OTHER|Publication requires agreement and written authorization from Sponsor.|t
17174961|NCT01147627|f||||f
17174962|NCT00640224|f||||f
17174963|NCT00583713|f||OTHER||t
17174964|NCT04224688|f||GT60||t
17174965|NCT01584544|f||||f
17174966|NCT01024309|f||||f
17174967|NCT01988584|t||||
17174968|NCT03816709|t||||
17174969|NCT03232333|f||||f
17174970|NCT01980589|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17174971|NCT00653432|f||||f
17174972|NCT00567255|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17174973|NCT05037578|t||||
17174974|NCT03194737|f||OTHER|Investigator agreements restrict data disclosure until written agreement by or publication by Sponsor|t
17174975|NCT01290796|f||||f
17174976|NCT02343549|t||||
17174977|NCT03087617|f||||f
17174978|NCT01896206|t||||
17174979|NCT01090323|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17174980|NCT01864005|f||GT60||t
17174981|NCT00763698|f||LTE60||t
17174982|NCT02059291|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17174983|NCT01433289|t||||
17174984|NCT03241368|f||||f
17174985|NCT00324259|t||||
17174986|NCT00080899|f||LTE60||t
17174987|NCT01462253|f||||f
17174988|NCT00787267|t||||
17174989|NCT04343235|t||||f
17174990|NCT00865280|f||LTE60||t
17130365|NCT01045798|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17130366|NCT05599672|f||||f
17174991|NCT01616693|f||||f
17174992|NCT00653939|f||||f
17174993|NCT01105767|f||||f
17174994|NCT00743106|t||||f
17174995|NCT00817596|f||GT60||t
17174996|NCT02646371|f||OTHER||t
17174997|NCT00574236|t||||f
17174998|NCT02874144|f||||f
17174999|NCT00486811|f||OTHER|The Sponsor and the Sponsor's designee reserves the right to review any publication pertaining to the trial at least 30 days before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17175000|NCT02369744|t||||
17175001|NCT03753789|f||LTE60||t
17175002|NCT02975557|f||||f
17175003|NCT00597597|f||||f
17175004|NCT00601952|t||||
17175005|NCT01711216|f||OTHER|Investigator shall not publish/present the results without Abbott's prior written consent. In the event that applicable law permits Investigator to publish or present results without Abbott's prior written consent, Investigator shall provide Abbott with a complete copy of such publication or presentation at least 60 days prior to submission for publication or presentation and Investigator shall reasonably consider all comments which Abbott may provide regarding such publication or presentation|t
17175006|NCT02878057|f||||f
17175007|NCT00946153|f||||t
17175008|NCT01030666|f||||f
17175009|NCT00985829|t||||
17175010|NCT03698591|t||||f
17175011|NCT05225805|f||LTE60||t
17175012|NCT02369172|f||||f
17175013|NCT00831493|t||||f
17175014|NCT00620503|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17183238|NCT01565291|f||GT60||t
17183239|NCT01346267|f||||f
17183240|NCT03149237|f||||f
17183241|NCT04568122|t||||
17183242|NCT01227512|f||||f
17130367|NCT05321069|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175015|NCT00557856|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175016|NCT01675167|f||OTHER|PI and Institution reserve the right to publish and present the results of the work performed provided that Institution and/or PI submits a copy of any proposed publication to Sponsor's agent for review and comment at least 90 days in advance of its presentation or submission for publication. In addition, if Sponsor's agent requests, Institution and/or PI will withhold publication or presentation for an additional 60 days to allow for establishing and preserving its proprietary rights.|t
17175017|NCT01925131|f||LTE60||t
17175018|NCT03278067|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175019|NCT01696929|f||||f
17175020|NCT01794338|t||||
17175021|NCT02522624|f||||f
17175022|NCT02123251|f||GT60||t
17175023|NCT04313647|f||||f
17175024|NCT04672954|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175025|NCT03381742|t||||
17175026|NCT02617485|f||||t
17175027|NCT04434846|t||||
17175028|NCT00617669|f||OTHER|"3\. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed to allow for"|t
17175029|NCT03680742|f||||f
17175030|NCT01248104|t||||
17175031|NCT02894502|f||||f
17175032|NCT04605991|f||GT60||t
17175033|NCT01410357|f||||f
17175034|NCT00615901|t||||
17175035|NCT03598114|t||||
17175036|NCT01589653|f||OTHER|Individual reports by the investigator should not precede the primary manuscript and should always reference the primary manuscript of the trial. Novo Nordisk reserves the right to prior review of such publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.|t
17175037|NCT03124927|f||LTE60||t
17175038|NCT00361634|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial resul|t
17175039|NCT00833417|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175040|NCT03330002|f||OTHER|Research Institution and Principal Investigator agree that they shall not, without the Sponsor's prior written consent, independently Publish any results of or information about the activities conducted until the multicenter publication is released. If a multi-center manuscript is not submitted for publication within one (1) year after completion of the multi-center Study, Research Institution and Principal Investigator shall have the right to Publish results.|t
17175041|NCT01883453|f||||f
17175042|NCT00505076|f||||f
17175043|NCT00647270|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17175044|NCT03337490|f||||f
17130368|NCT04702451|f||LTE60||t
17130369|NCT06156215|t||||f
17130370|NCT03451851|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17130371|NCT05885737|f||||t
17175045|NCT02745145|f||||f
17175046|NCT00388583|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17175047|NCT04233918|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17175048|NCT02709538|f||OTHER||t
17175049|NCT00835211|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17175050|NCT02160041|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130372|NCT00307151|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscript and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17130373|NCT02966509|f||||f
17130374|NCT01717287|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17130375|NCT01490450|f||||f
17130376|NCT00404820|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130377|NCT03887533|t||||
17130378|NCT02329964|f||||f
17130379|NCT01469182|f||OTHER|The investigator agrees to provide to the sponsor for review 45 days prior to submission for publication or presentation copies of abstracts or manuscripts that report any results of the trial. If the parties disagree concerning the sponsor's confidential information the investigator agrees to meet with the sponsor's representative, prior to submission for publication, to discuss and resolve any issues or disagreement.|t
17130380|NCT02687542|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130381|NCT02114164|f||||f
17130382|NCT00003535|f||||f
17130383|NCT02181816|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130384|NCT03807349|f||||f
17175051|NCT01403948|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175052|NCT05498701|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175053|NCT02495038|f||||f
17175054|NCT00006409|f||||f
17175055|NCT00638183|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17175056|NCT02902484|t||||
17175057|NCT01763996|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17175058|NCT00993226|f||||t
17175059|NCT03704636|t||||
17175060|NCT00791817|f||OTHER|Data, calculations, interpretations, opinions, and recommendations are the property of P\&GP. In the event study results are published in the scientific literature by P\&GP, acknowledgment will be made to the Investigator(s) in the accepted style, as appropriate.|t
17130385|NCT00294060|f||OTHER|"In most cases, contracts allow investigators to publish study results per the publication plan/protocol following Medtronic's review to determine whether confidential information (CI) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred."|t
17138725|NCT03565991|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138726|NCT02225925|t||||f
17175061|NCT00539188|t||||
17175062|NCT01546623|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17175063|NCT01134705|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17175064|NCT04784442|f||||f
17130386|NCT01360554|f||||f
17130387|NCT02210065|t||||
17138727|NCT03424044|t||||
17183243|NCT04497987|f||GT60||t
17183244|NCT00512096|t||||f
17183245|NCT00298038|f||OTHER|Please contact Sponsor directly for additional information.|t
17183246|NCT02696096|f||||f
17130388|NCT00187096|t||||
17130389|NCT00111800|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130390|NCT00253643|t||||
17130391|NCT01549275|f||||f
17130392|NCT03448068|t||||
17130393|NCT03329911|t||||
17130394|NCT01486927|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130395|NCT03668600|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130396|NCT01476475|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17130397|NCT01278745|f||||f
17130398|NCT01111851|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17175065|NCT02037555|f||OTHER|A 12-month post-study period is reserved for a joint, multi-center publication of study results. After this period, individual sites may publish results provided that the Sponsor is allowed 30 days to review any proposed publication for removal of confidential, protected, and trademarked material prior to submission with an option to delay publication up to 60 days if needed to protect its interests. The Sponsor shall retain the option to receive acknowledgment for its sponsorship of the study.|t
17175066|NCT01590758|f||OTHER|If no multi-site publication within 18 months of study completion, Site shall have right to publish subject to: 1) Prior to submitting/presenting, Site shall provide Sponsor a copy; Sponsor shall have 60 days to review/comment. 2) Site shall remove any Confidential Information prior to submitting/presenting the materials. 3) Site shall further delay publication/presentation for up to 120 days to allow Sponsor to protect its interests in any Sponsor Inventions described in any such materials.|t
17175067|NCT01578850|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175068|NCT02756806|f||||f
17175069|NCT02717832|f||||f
17175070|NCT02929498|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175071|NCT02744040|t||||f
17175072|NCT00096356|t||||f
17175073|NCT01008423|f||OTHER|Please contact Sponsor directly for additional information.|t
17175074|NCT01522937|t||||
17175075|NCT03288142|f||||f
17175076|NCT00934843|t||||
17175077|NCT03456882|f||||f
17175078|NCT01144299|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175079|NCT03353233|t||||
17175080|NCT00183729|f||LTE60||t
17175081|NCT03512457|f||||f
17183247|NCT04733157|f||||f
17183248|NCT01755416|f||||f
17183249|NCT02573324|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183250|NCT01105533|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130399|NCT01471015|t||||f
17130400|NCT02576444|t||||
17130401|NCT00988143|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17130402|NCT00842231|f||OTHER|No paper that incorporates Sponsor confidential information will be submitted for publication without Sponsor's prior written agreement.|t
17130403|NCT01843842|f||OTHER||t
17130404|NCT02953340|f||||t
17130405|NCT00112671|f||LTE60||t
17130406|NCT00928889|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130407|NCT03078075|t||||
17175082|NCT04947085|f||||f
17183251|NCT02096835|t||||
17175083|NCT03976648|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17175084|NCT00243841|t||||
17175085|NCT00881868|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17175086|NCT01981551|f||||f
17175087|NCT03255083|f||||f
17175088|NCT01182844|t||||
17175089|NCT00960570|f||GT60||t
17175090|NCT01451437|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the Sponsor. The Investigator further agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17175091|NCT03254108|f||||f
17175092|NCT00923949|t||||f
17175093|NCT00490529|t||||
17175094|NCT03254459|f||||f
17175095|NCT00727441|t||||
17175096|NCT00535288|f||LTE60||t
17175097|NCT00745849|t||||
17175098|NCT01129583|f||||f
17175099|NCT02600871|f||||f
17175100|NCT04507373|t||||
17175101|NCT00830869|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17175102|NCT03745820|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17175103|NCT01324518|f||||f
17175104|NCT00668733|f||||f
17175105|NCT01561703|t||||
17175106|NCT04583709|f||||f
17175107|NCT00945906|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175108|NCT00797966|f||||f
17175109|NCT03859973|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175110|NCT01478048|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175111|NCT03897439|f||||f
17175112|NCT02047344|f||||f
17175113|NCT00955201|t||||
17175114|NCT03032380|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17183252|NCT03892889|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17183253|NCT04260191|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17183254|NCT01643473|f||||f
17183255|NCT01519518|f||||f
17183256|NCT02517580|f||||f
17183257|NCT01312909|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183258|NCT01151553|f||||f
17183259|NCT03738904|f||||f
17183260|NCT01383681|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175115|NCT01561898|f||OTHER|The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17175116|NCT00294762|f||LTE60||t
17175117|NCT02238080|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175118|NCT01738646|t||||
17175119|NCT01707238|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor.|t
17175120|NCT04093024|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175121|NCT01566084|f||||f
17175122|NCT00233454|f||||f
17175123|NCT00796445|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175124|NCT02366091|f||||f
17175125|NCT00322621|f||GT60||t
17175126|NCT01743001|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 60 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17175127|NCT01565343|f||GT60||t
17175128|NCT01012674|f||LTE60||t
17175129|NCT01853839|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175130|NCT02350764|t||||
17175131|NCT03531632|f||OTHER|Institution shall allow SPONSOR at least 45 days to review manuscript and at least 21 days to review poster, abstract or other material. SPONSOR can review publications solely for identifying Proprietary Information, which shall be removed upon SPONSOR's request to the extent deletion does not preclude complete/accurate presentation and interpretation of Study results; to identify patentable Inventions, and provide other comments, provided that Investigator isn't obligated to address comments.|t
17175132|NCT00600119|f||GT60||t
17175133|NCT00729469|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17175134|NCT00514852|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175135|NCT01270802|t||||f
17175136|NCT02535572|f||||f
17175137|NCT04620798|f||||f
17175138|NCT00568633|f||||f
17175139|NCT01960907|f||||f
17175140|NCT02080819|f||||f
17175141|NCT00684541|t||||f
17175142|NCT00439738|f||OTHER||t
17175143|NCT01094522|f||||f
17175144|NCT03774719|f||||f
17175145|NCT00402740|f||OTHER|Principal Investigator (PI), Institute, and Research Site (RS) acknowledge this is a multi-center study. An independent, joint publication is anticipated from investigators in the study, including the PI. Therefore, the PI, Institute, and RS agree not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall PI, Institute, and/or RS be so restricted after the expiration of twelve months from completion of the Study at all sites.|t
17175146|NCT01295879|t||||
17175147|NCT01185353|f||GT60||t
17183261|NCT00938431|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17183262|NCT02086591|t||||
17183263|NCT01774903|f||OTHER|Company has the right to publish the data which generated here under by Principal Investigator (PI), without PIs approval. The PI has the right to publish the results, but prior to submission, PI will provide at least 60 days to company for review. No paper that incorporates Company Confidential Information will be submitted for publication without Company prior written consent. If requested, the PI will withhold such publication for up to an additional 60 days to allow for filing of a patent.|t
17183264|NCT00593372|t||||
17175148|NCT02270944|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175149|NCT00095147|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175150|NCT02390791|t||||
17175151|NCT01375075|f||GT60||t
17175152|NCT01011309|f||OTHER|IDRI encourages publication in peer-reviewed medical journals and will not unduly withhold permission to publish. However, all proposed publications, papers, abstracts or written materials related to the study or an outline of any oral presentation, shall be submitted to and coordinated by IDRI to assure that no proprietary information is presented and that authorship is fairly represented.|t
17175153|NCT03207035|f||||f
17175154|NCT03708393|f||||t
17175155|NCT01252732|f||||t
17175156|NCT03048383|f||||f
17175157|NCT03472547|f||||f
17175158|NCT02635425|t||||
17175159|NCT04236141|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17175160|NCT01948193|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17175161|NCT02695160|f||OTHER|All proposed written materials related to the study or an outline of proposed oral presentations, shall be submitted to Sangamo for approval at least 30 days prior to submission of materials for publication or oral disclosure to a third party. If Sangamo determines that a description of patentable subject matter is contained in written material or outline, it shall notify the clinical site within 1 month after receipt and Sangamo will have an additional 60 days for further review and action.|t
17175162|NCT02720107|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17175163|NCT01049945|t||||
17175164|NCT00507728|t||||
17175165|NCT01964755|t||||
17175166|NCT01710137|f||||f
17175167|NCT03035487|f||||f
17175168|NCT01332799|f||||f
17175169|NCT01909791|f||||f
17175170|NCT02908490|t||||f
17175171|NCT02168387|t||||
17175172|NCT03467152|f||||f
17175173|NCT01236547|f||LTE60||t
17175174|NCT04250077|t||||
17175175|NCT00910624|f||OTHER|Investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor, and further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17175176|NCT04140227|f||||t
17175177|NCT01713933|f||LTE60||t
17175178|NCT00412373|f||GT60||t
17175179|NCT02871882|t||||f
17175180|NCT02248688|f||||f
17175181|NCT04022733|f||||f
17175182|NCT00576680|t||||
17175183|NCT02855541|f||||f
17175184|NCT00422513|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights"|t
17175185|NCT03135119|f||||f
17175186|NCT01541397|t||||
17175187|NCT02267317|f||||f
17175188|NCT00807560|t||||
17175189|NCT01689532|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17175190|NCT01363349|f||||f
17175191|NCT02208063|f||||f
17175192|NCT00913458|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175193|NCT02279407|f||||f
17175194|NCT00766753|t||||
17175195|NCT01816945|t||||
17175196|NCT01155011|f||||f
17175197|NCT00422084|f||||f
17175198|NCT00915499|f||LTE60||t
17175199|NCT03774823|f||||f
17175200|NCT00958438|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17175201|NCT00759564|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175202|NCT01410344|f||||f
17175203|NCT02788279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175204|NCT00329849|f||GT60||t
17175205|NCT03996369|f||||f
17175206|NCT02238067|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175207|NCT00700141|f||||f
17175208|NCT01566214|t||||f
17175209|NCT04821362|f||||f
17175210|NCT00832624|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175211|NCT02395172|f||||f
17175212|NCT00717236|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17175213|NCT00475982|f||||f
17175214|NCT02778113|f||GT60||t
17175215|NCT00783198|f||OTHER|The Investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17175216|NCT00946985|f||||f
17175217|NCT04345367|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175218|NCT00852371|f||||f
17175219|NCT00796523|f||||f
17175220|NCT04525885|f||OTHER|Authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in publications.|t
17175221|NCT02252744|f||||f
17175222|NCT01876329|t||||
17175223|NCT03208985|f||||f
17175224|NCT02453672|f||||t
17175225|NCT00978757|t||||
17175226|NCT01700387|f||||f
17175227|NCT01031836|f||||f
17175228|NCT03137069|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175229|NCT03225859|f||||f
17175230|NCT02043899|f||||f
17175231|NCT01954927|t||||
17175232|NCT03320824|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17175233|NCT00955305|f||LTE60||t
17175234|NCT03387111|f||||t
17175235|NCT00594945|f||OTHER||t
17175236|NCT00588159|t||||
17175237|NCT02438358|f||||f
17175238|NCT01325337|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175239|NCT00362180|f||OTHER|PI gives Sponsor a draft 90 days before publication. Sponsor has the right to demand that confidential information be removed, and can defer publication another 180 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17175240|NCT03483922|f||||f
17175241|NCT03930264|f||||t
17175242|NCT02434471|t||||
17175243|NCT00369629|t||||
17175244|NCT00874939|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17175245|NCT02204124|t||||
17175246|NCT01250496|t||||f
17175247|NCT04620213|f||GT60||t
17175248|NCT00883688|f||||f
17175249|NCT00918931|t||||
17175250|NCT00918125|f||||f
17175251|NCT00791973|t||||
17175252|NCT01104376|f||||f
17175253|NCT04240678|t||||
17175254|NCT00541190|f||||f
17175255|NCT00732901|f||||f
17175256|NCT01486043|f||||f
17175257|NCT03085914|f||OTHER|Clinical Study Agreement|t
17175258|NCT04644315|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175259|NCT05315908|f||||f
17175260|NCT01445548|t||||f
17175261|NCT04497038|f||||f
17175262|NCT03642132|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175263|NCT03145818|t||||
17175264|NCT00856414|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17175265|NCT01839604|f||LTE60||t
17175266|NCT04493892|t||||f
17175267|NCT01128621|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175268|NCT03595618|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17175269|NCT01253811|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17175270|NCT00740376|f||GT60||t
17175271|NCT01782469|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175272|NCT01214057|t||||
17175273|NCT04987788|t||||f
17175274|NCT02614469|f||OTHER|All data and results and all intellectual-property rights in the data and results derived from the study will be the property of the sponsor. No publication or disclosure of study results will be permitted except as specified in a separate, written agreement between the Sponsor and the Investigator. If results of this study are reported in medical journals or at meetings, all subjects' identities will remain confidential.|t
17175275|NCT00357760|f||LTE60||t
17175276|NCT04136444|f||GT60||t
17175277|NCT02010151|f||||f
17175278|NCT01962961|f||||f
17175279|NCT02184572|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175280|NCT03726996|f||||f
17175281|NCT01328444|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175282|NCT03180619|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17175283|NCT02743611|f||||f
17175284|NCT00561977|f||||f
17175285|NCT00781885|f||GT60||t
17175286|NCT01755026|t||||
17175287|NCT00392379|f||||f
17175288|NCT03041129|f||||f
17175289|NCT03678870|t||||
17175290|NCT03104816|f||||f
17175291|NCT01055067|f||||f
17175292|NCT01159431|f||||f
17175293|NCT00645450|t||||f
17175294|NCT03645434|f||||f
17175295|NCT00833664|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17175296|NCT00678743|f||||f
17175297|NCT03658876|t||||f
17175298|NCT01330017|t||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission or publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17175299|NCT01106092|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175300|NCT00843778|f||GT60||t
17175301|NCT01473368|t||||
17175302|NCT03338959|t||LTE60||t
17175303|NCT02933671|t||||
17175304|NCT03328182|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 18 months from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130408|NCT01299376|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17175305|NCT04601454|f||||f
17175306|NCT00762424|f||||f
17175307|NCT01347580|f||LTE60||t
17175308|NCT02870933|t||||
17175309|NCT00003590|f||||f
17175310|NCT01425463|f||GT60||t
17175311|NCT01009840|f||||f
17175312|NCT04144127|t||||
17175313|NCT02528721|f||LTE60||t
17175314|NCT00052442|f||||f
17175315|NCT00947791|t||||
17175316|NCT01958489|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17175317|NCT00917644|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175318|NCT02338232|t||||
17175319|NCT02500056|f||||f
17175320|NCT00864916|t||||f
17175321|NCT02331095|t||||f
17175322|NCT01087736|t||||
17175323|NCT01568528|t||||
17175324|NCT01323855|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17130409|NCT02343159|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17130410|NCT04712110|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17175325|NCT02122783|f||||f
17130411|NCT00635479|t||||f
17175326|NCT00924040|f||||f
17175327|NCT00362128|f||||f
17175328|NCT01579812|t||||
17130412|NCT02285777|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175329|NCT01101308|f||GT60||t
17175330|NCT05168501|f||||f
17175331|NCT00253708|t||||
17175332|NCT04905498|t||||
17175333|NCT02599051|f||||f
17130413|NCT03269435|f||||f
17175334|NCT00869778|f||OTHER|Investigators can't publish articles relevant to the study unless the sponsor permits.|t
17175335|NCT03339297|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17175336|NCT03051620|t||||
17175337|NCT00393510|t||||f
17175338|NCT03077087|t||||
17175339|NCT01054183|t||||
17175340|NCT02112045|t||||
17130414|NCT04490863|f||GT60||t
17130415|NCT03962101|f||||f
17130416|NCT01496131|f||||f
17130417|NCT00271596|t||||f
17130418|NCT04315181|t||||
17130419|NCT00585611|t||||
17130420|NCT05879107|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the full clinical trial.|t
17130421|NCT03901079|f||||f
17130422|NCT00843518|f||GT60||t
17130423|NCT00445484|t||||
17130424|NCT00912028|f||GT60||t
17130425|NCT04143009|t||||
17130426|NCT05003622|f||OTHER|Except for the release of SAE of study drug/product defects of the institution, institution and/or investigator shall promptly notify sponsor of the content to be released before releasing other research information and obtain sponsor's consent. If there is no response from sponsor within 60 working days after issuance or specific reason for disagreement and modification suggestions are not listed in the response, it shall be deemed that sponsor agrees.|t
17130427|NCT00609986|f||||f
17130428|NCT02012621|f||||f
17175341|NCT02775240|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17175342|NCT00977080|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17130429|NCT01031550|t||||f
17130430|NCT03497806|f||OTHER|The disclosure restrictions on the PI are: (i) the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to eighteen months from the lock-down of all study data and (ii) the sponsor can require the removal of its confidential information from results communications and may delay release for a period of up to 60 days for the purpose of filing patent applications.|t
17130431|NCT02247245|t||||
17130432|NCT02046096|f||GT60||t
17130433|NCT02090413|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17130434|NCT00487396|f||||f
17130435|NCT04347226|t||||
17130436|NCT04090580|f||||f
17175343|NCT02992197|f||||f
17175344|NCT00441116|f||OTHER|GSK agreements may vary with individual investigators, but will no prohibit any investigator form publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175345|NCT03192358|t||||
17175346|NCT00637780|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175347|NCT01251536|f||||t
17175348|NCT00597896|t||||
17175349|NCT05396599|f||OTHER||t
17130437|NCT00597753|f||OTHER|The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.|t
17175350|NCT00796991|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130438|NCT00736255|f||||f
17175351|NCT01765218|f||||f
17175352|NCT03148691|f||||f
17130439|NCT03427047|f||GT60||t
17175353|NCT00171834|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17175354|NCT02184624|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130440|NCT03650842|t||||
17130441|NCT00586261|f||||f
17130442|NCT01838616|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17130443|NCT00840086|f||OTHER|The information obtained during the conduct of this trial is considered confidential and can be used by Novo Nordisk for regulatory purposes and for the general development of the trial product. The information obtained during this trial may be made available to other physicians who are conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk.|t
17130444|NCT03332498|t||||
17130445|NCT01566773|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17130446|NCT04036708|f||||f
17130447|NCT01033734|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130448|NCT02538016|f||||f
17130449|NCT04203745|t||||
17130450|NCT01444742|f||||f
17130451|NCT02535715|t||||
17130452|NCT00909181|f||LTE60||t
17130453|NCT00867789|f||||f
17175355|NCT03417713|f||||f
17175356|NCT01294098|f||||f
17175357|NCT02365233|t||||f
17175358|NCT01978938|f||OTHER|Publications should include input from the PI, his/her colleagues, other PIs in this trial and the Sponsor's personnel; such input should be reflected in the authorship. Agreement of order of authors should be established before writing a manuscript. The PI interested in participating in writing the manuscript should contact the Sponsor. The PI shall not make any publication without the Sponsor's prior written approval, which may be withheld or granted by the Sponsor, in its sole discretion.|t
17175359|NCT02342418|f||||f
17175360|NCT04255394|f||||f
17175361|NCT00428584|f||OTHER|Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.|t
17130454|NCT02933034|t||||
17130455|NCT02349048|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17130456|NCT02219282|f||||f
17130457|NCT00094770|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130458|NCT00914927|f||OTHER||t
17130459|NCT02113436|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130460|NCT01648790|f||GT60||t
17130461|NCT00527475|f||||f
17130462|NCT02969187|f||||f
17130463|NCT00365456|f||OTHER|After publication of the results or 24 months after Clinical Trial Report has been finalised, whichever comes first, Nycomed acknowledge the Investigator's rights to publish results from this trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted to Nycomed prior to submission for publication/presentation for review. Review comments will be given within a month from receipt of the manuscript.|t
17130464|NCT03451786|f||||f
17130465|NCT05143489|f||||f
17130466|NCT01816061|t||||
17130467|NCT01265615|t||||f
17130468|NCT00731055|t||||
17130469|NCT03370120|f||GT60||t
17130470|NCT01376778|f||||t
17175362|NCT00200343|f||OTHER||t
17130471|NCT00454857|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17130472|NCT03672370|f||GT60||t
17175363|NCT02285062|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175364|NCT00821509|t||||
17175365|NCT03127098|f||||t
17175366|NCT01227629|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17175367|NCT03602560|f||||t
17175368|NCT00222131|t||||
17175369|NCT00534599|f||OTHER|If Sponsor does not publish within 2 years after study completion, PI is permitted to publish, with confidential information removed from manuscript. Sponsor will have opportunity to review and approve publication at least 60 days prior to being submitted/disclosed. Sponsor can request, in writing, an additional 90 day embargo.|t
17175370|NCT01588470|f||||f
17175371|NCT03865316|f||GT60||t
17175372|NCT02616146|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17175373|NCT00336856|t||||
17130473|NCT01977599|f||||f
17130474|NCT04206020|f||OTHER|Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor will have the final decision regarding the manuscript and publication.|t
17130475|NCT03769246|t||||f
17130476|NCT02375724|f||OTHER|Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the investigator and the sponsor|t
17130477|NCT02684604|f||||f
17130478|NCT01517893|t||||
17130479|NCT01309659|f||||f
17130480|NCT03462576|f||||f
17130481|NCT01921751|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17130482|NCT00761007|f||LTE60||t
17130483|NCT01329679|f||||f
17130484|NCT01409213|f||||f
17130485|NCT02512809|t||||
17130486|NCT01069172|f||OTHER|There is an agreement between the PI and the sponsor (or its agents) that restricts the PI's rights to publish trial results, but does not prohibit publication provided that prior written permission from the sponsor has been granted.|t
17130487|NCT04206605|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130488|NCT01651351|f||OTHER|PI may not publish without the prior written consent of Sponsor|t
17130489|NCT00827606|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130490|NCT03437564|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130491|NCT04037748|f||||f
17130492|NCT00573989|t||||
17130493|NCT04544475|t||||
17130494|NCT01378858|t||||
17130495|NCT00942175|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of it's obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17130496|NCT02664272|f||OTHER|Investigator must submit results for any proposed publication to the sponsor at least 60 days before the submission. All publications will include any comments by the sponsor to modify publication for any potentially patentable item, trade secret, proprietary right, or confidential information of the sponsor. Any publication based on the results obtained from the site (or group of sites) shall not be made before the first multicenter publication.|t
17130497|NCT01071538|f||||f
17175374|NCT01604278|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17175375|NCT02184455|f||||f
17175376|NCT01012219|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17130498|NCT01784770|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130499|NCT03073980|f||||f
17183265|NCT02212730|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17183266|NCT02880371|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183267|NCT00854087|f||LTE60||t
17183268|NCT01777997|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17183269|NCT02660359|f||||f
17183270|NCT00127790|t||||f
17183271|NCT00721526|f||||f
17183272|NCT02944578|t||||
17183273|NCT02691455|t||||
17183274|NCT01257204|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183275|NCT01878604|f||||f
17183276|NCT03511521|f||||f
17183277|NCT00451282|f||||f
17183278|NCT00577122|t||||
17183279|NCT01174030|f||GT60||t
17183280|NCT00529386|f||||f
17183281|NCT04532112|f||||f
17183282|NCT03348904|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17183283|NCT01241734|t||||
17183284|NCT02039427|f||||f
17183285|NCT04354831|t||||
17183286|NCT02732847|f||||f
17183287|NCT04027686|f||||f
17183288|NCT00111228|f||GT60||t
17183289|NCT00779766|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183290|NCT03054909|t||||
17183291|NCT01274637|f||||f
17183292|NCT02100007|f||OTHER|Each PI has a CDA in place that restricts them from discussing the results of the clinical study at a scientific meeting or any other public or private forum or to publish in a scientific or academic journal the results of the clinical study without the approval of the Sponsor Company (MEI Pharma Inc.).|t
17183293|NCT01194297|t||||
17175377|NCT01491113|f||GT60||t
17183294|NCT02170727|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17183295|NCT00720876|t||||
17183296|NCT00286949|f||||f
17183297|NCT03304379|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17183298|NCT02873104|t||||
17183299|NCT03097068|f||||f
17175378|NCT00522925|f||||f
17175379|NCT02396160|f||||f
17183300|NCT01298063|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17183301|NCT00395044|f||||f
17175380|NCT01444092|f||||f
17175381|NCT01328366|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175382|NCT00594425|f||OTHER|All data from the study are free for publication. However if publication of the results may endanger adequate patent protection for new principles,compounds,or formulations,Photocure has the right to decide when the results are free to be published. Before this agreed time, no data from the trial will be published, presented, or communicated, except to regulatory authorities and ethics committees. Both the investigators and Photocure will be given 30 days to review and comment.|t
17175383|NCT01122264|f||GT60||t
17175384|NCT03005873|f||||f
17183302|NCT03511560|t||||
17183303|NCT03487913|f||||f
17183304|NCT02985736|t||||
17183305|NCT00382733|f||LTE60||t
17130500|NCT00545064|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130501|NCT00501007|t||||
17130502|NCT03113656|t||||
17130503|NCT00258674|f||||f
17130504|NCT00075088|t||||
17175385|NCT04585009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17175386|NCT02558829|f||OTHER|INSTITUTIONS / INVESTIGATORS are allowed to publish data pursuant to the Sponsor's publication policies per individual agreements. Any material prepared for publication shall be submitted to the Sponsor for review and comment within an individually agreed period (30 up to 180 days). INSTITUTION / INVESTIGATOR shall modify the publication / presentation according to the comments by the Sponsor, provided that the scientific neutrality of the publication is not impaired hereby.|t
17175387|NCT00097981|f||GT60||t
17175388|NCT01031420|t||||f
17175389|NCT00895011|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17130505|NCT03880032|f||||f
17175390|NCT02713256|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17130506|NCT01358760|f||OTHER|Investigators shall provide to the SPONSOR 30 days prior to submission all documents for publication, presentation, etc that report any trial results. The SPONSOR shall have editorial rights on documents and the right to review/comment with regard to (1) proprietary information, (2) accuracy of the information, (3) correctness of the scientific evaluation/conclusions and (4) to ensure that the information is fairly balanced and in compliance with regulations.|t
17175391|NCT02230527|f||||f
17175392|NCT04941443|t||||
17175393|NCT04461600|f||||f
17175394|NCT01242813|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17175395|NCT02766582|f||||f
17175396|NCT01910311|f||GT60||t
17175397|NCT01369329|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17175398|NCT01252667|t||||
17175399|NCT01836276|f||||f
17175400|NCT01847131|f||||f
17175401|NCT00331552|t||||
17175402|NCT02204761|t||||
17175403|NCT02577887|f||||f
17175404|NCT03560518|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175405|NCT03708562|f||||t
17175406|NCT02984943|t||||
17175407|NCT01133990|f||OTHER||t
17175408|NCT05277337|f||OTHER|Investigators agree not to present/publish any data or reports collected individually or by subgroup of trial sites prior to first publication based on data obtained from all sites. Investigators can publish results 18 months after the completion of the trial, but Sponsor shall have the right to review any proposed publication before publication/presentation to prevent the disclosure of confidential information. Sponsor can refuse the publication, delay it or request amendment of its contents|t
17175409|NCT03271983|f||OTHER||t
17175410|NCT02282345|t||||
17183306|NCT05580575|f||||f
17130507|NCT01506960|t||||
17130508|NCT01439672|t||||
17130509|NCT00219284|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17130510|NCT04473690|f||||t
17130511|NCT02321930|t||||
17130512|NCT01293968|t||||
17130513|NCT00853749|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130514|NCT01392677|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17130515|NCT01054742|f||OTHER|The PI agrees to provide forty-five (45) days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication (including, without limitation, slides and text of oral or other public presentations and text of any transmission through any electronic media), which report any results of the Study. The sponsor shall have the right to review and comment on any presentation including editorial rights.|t
17130516|NCT03366298|t||||
17130517|NCT02481921|t||||
17138728|NCT02971007|f||OTHER|Data may be considered for publication in a scientific journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data pertaining to the study confidential and must consult with the Sponsor before any study data are submitted for publication. Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.|t
17138729|NCT05302804|f||||f
17138730|NCT01807611|t||||
17138731|NCT02935595|t||||
17175411|NCT01185301|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175412|NCT02683746|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130518|NCT04360551|t||||
17130519|NCT00520884|t||||
17130520|NCT00388973|f||OTHER|The PI agrees to collaborate in good faith with AstraZeneca with regard to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca.|t
17130521|NCT03138538|t||OTHER||t
17130522|NCT02530528|f||OTHER|Data remains confidential|t
17130523|NCT02700412|f||||f
17130524|NCT04416555|f||||f
17130525|NCT02006342|t||||
17130526|NCT01118273|f||||f
17130527|NCT03374189|f||||f
17130528|NCT04512040|f||||f
17130529|NCT01197521|f||||f
17175413|NCT04987944|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130530|NCT00552175|f||GT60||t
17130531|NCT00884273|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17130532|NCT03715153|f||||f
17130533|NCT02512224|f||||f
17130534|NCT01412554|f||||f
17130535|NCT00450723|t||||
17130536|NCT00078325|f||GT60||t
17130537|NCT00578136|t||||
17130538|NCT02047253|t||||
17130539|NCT01034592|f||||f
17130540|NCT03710486|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130541|NCT01987960|f||||f
17130542|NCT00445705|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17130543|NCT04118270|f||||f
17130544|NCT01892163|t||||
17130545|NCT01058070|f||OTHER||t
17130546|NCT03302975|f||||f
17130547|NCT04018794|t||||
17130548|NCT03497585|t||||
17130549|NCT02258451|f||OTHER|Where done for the purpose of filing a patent application, and where deemed necessary, the Sponsor/Bayer may request the PI of the Trial to postpone by 90 days the publication or presentation of a paper. The PI of the Trial may not publish the data yielded by its Site until all the results of the trial (in the case of a multi-center trial) have been published in their entirety or until at least 12 months have passed following completion, discontinuation or early termination of the Trial.|t
17130550|NCT04722042|t||||f
17130551|NCT03067571|t||||
17130552|NCT00517751|f||LTE60||t
17130553|NCT01839396|f||OTHER|Clinical Study Agreement that restricts the PIs until official study manuscript is published.|t
17130554|NCT02958007|t||||
17130555|NCT05097144|f||||t
17138732|NCT00402285|t||||f
17138733|NCT00784459|f||GT60||t
17175414|NCT00345332|f||||f
17175415|NCT04121078|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17175416|NCT02353143|f||OTHER|Prior to submitting the results of this study for publication or presentation, the Investigator will allow Menarini Ricerche S.p.A. at least 30-day time to review and comment upon the publication manuscript. Menarini Ricerche S.p.A.|t
17175417|NCT01981057|t||||
17138734|NCT02707601|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17138735|NCT02009930|t||||
17175418|NCT02946931|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17183307|NCT03282955|f||OTHER|"In order to ensure that the Sponsor will be able to make comments and suggestions where pertinent, material for public dissemination will be submitted to the Sponsor for review at least sixty (60) days (or longer if specified elsewhere) prior to submission for publication, public dissemination, or review by a publication committee.~The PI agrees that all reasonable comments made by the Sponsor in relation to a proposed publication will be incorporated into the publication."|t
17175419|NCT02213133|f||||t
17175420|NCT02012582|f||||f
17175421|NCT01883856|f||||f
17175422|NCT02673541|f||||f
17183308|NCT02185768|f||||f
17183309|NCT00832429|t||||
17130556|NCT01484977|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17175423|NCT04740905|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175424|NCT02700334|t||||
17175425|NCT01023477|t||||
17130557|NCT00450242|t||||
17175426|NCT02412488|f||||t
17175427|NCT01989468|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17175428|NCT01640327|f||||f
17175429|NCT03222492|f||||f
17130558|NCT02269787|t||||
17175430|NCT01229462|f||||f
17175431|NCT01476202|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130559|NCT00687440|f||||f
17130560|NCT02228720|f||||f
17130561|NCT00290199|t||||
17175432|NCT01224782|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175433|NCT02189954|f||||f
17175434|NCT00065429|f||||f
17130562|NCT00255970|f||LTE60||t
17130563|NCT03996876|t||||f
17130564|NCT02726971|t||||
17175435|NCT00528541|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release for a period that is not less than 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication.|t
17130565|NCT02324075|f||||f
17130566|NCT05264740|f||||f
17130567|NCT01538628|f||||f
17130568|NCT01423851|f||OTHER|This confidential document is the property of NS Pharma, Inc. No unpublished information contained herein may be disclosed without prior written approval from NS Pharma, Inc. Access to this document must be restricted to relevant parties.|t
17130569|NCT03080883|t||||
17130570|NCT00346073|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175436|NCT02015221|f||LTE60||t
17130571|NCT02013180|f||||f
17130572|NCT00075023|f||||f
17130573|NCT04342871|f||||f
17175437|NCT00995566|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175438|NCT01576159|t||||
17130574|NCT04179734|f||||f
17130575|NCT00290615|f||||f
17138736|NCT01769612|f||||f
17175439|NCT00223236|f||||f
17175440|NCT01181986|f||||f
17175441|NCT03720652|t||||f
17175442|NCT03073733|f||||f
17175443|NCT01454778|t||||
17175444|NCT00835731|f||||f
17130576|NCT01429584|f||||f
17130577|NCT02263079|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130578|NCT02603120|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130579|NCT04467424|f||||f
17130580|NCT04639973|t||||
17130581|NCT00176605|t||||
17130582|NCT01423162|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 18 months from the time submitted to the sponsor for review.|t
17130583|NCT01321710|f||||f
17130584|NCT01227187|f||||f
17130585|NCT01761292|f||||f
17130586|NCT02554019|f||OTHER|The Investigator shall not publish, present, or use any Study data or results arising out of the performance of the Study for their own instruction, research, or publication purposes without the prior express written consent of Sponsor, which consent may be withheld at Sponsor's discretion.|t
17130587|NCT02463409|t||||
17130588|NCT00772954|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17130589|NCT02495844|f||GT60||t
17130590|NCT02325219|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17130591|NCT03303950|t||||
17130592|NCT03901105|f||LTE60||t
17130593|NCT01911442|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17130594|NCT00871845|f||||f
17130595|NCT00825500|f||LTE60||t
17130596|NCT04773106|f||||f
17130597|NCT00330382|f||LTE60||t
17130598|NCT03200366|f||||f
17130599|NCT03201458|f||LTE60||t
17130600|NCT01785459|f||||f
17130601|NCT00750737|t||||f
17130602|NCT05112536|f||OTHER|Investigator agrees to submit any disclosure to Sponsor for review at least thirty (30) days prior to submission. Within sixty (60) days of its receipt, Sponsor can provide feedback on any disclosure Sponsor may require Investigator to remove, Confidential Information (other than study data), and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for inventions.|t
17130603|NCT04707157|f||||t
17130604|NCT01543828|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17130605|NCT03975920|f||||f
17130606|NCT03054922|t||||
17130607|NCT01279850|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130608|NCT01131520|t||||
17130609|NCT01147744|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130610|NCT01555567|f||||f
17130611|NCT02536313|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130612|NCT02941705|f||||f
17130613|NCT01252745|f||GT60||t
17130614|NCT02437864|t||||
17130615|NCT01080248|t||||
17130616|NCT00807742|f||||f
17130617|NCT00492752|f||OTHER|The Investigator must send a draft manuscript to be submitted for publication or to be presented or abstract to Bayer at least 60 days in advance of submission in order to obtain approval prior to submission of the final version for publication or presentation. In case of a difference of opinion between Bayer and the Investigator(s), the contents of the publication will be discussed in order to find a solution, which satisfies both parties.|t
17130618|NCT05419128|f||||f
17175445|NCT00348881|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17175446|NCT04084561|t||||
17175447|NCT01221272|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17175448|NCT04839562|f||||f
17175449|NCT01246466|f||||t
17175450|NCT00877773|t||||
17175451|NCT01145638|f||OTHER|If Pharmacosmos or its agents has not prepared a draft for submission to a peer reviewed journal prior to 1 year following completion of the study report, the investigators have the right to publish the results. Such publications are to be submitted to Pharmacosmos for comment 30 days prior to submission for publication.|t
17175452|NCT00456807|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175453|NCT00003472|f||||f
17175454|NCT01350544|f||||f
17130619|NCT03834519|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17130620|NCT04066491|f||||f
17175455|NCT00538785|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17175456|NCT01002820|f||||f
17175457|NCT01673347|f||||f
17175458|NCT03086967|t||||
17175459|NCT00813176|t||||
17175460|NCT02617901|t||||f
17175461|NCT00177047|t||||
17175462|NCT02661178|f||OTHER|The Institution (HMR) could not make any public communication related to the Results or Trial Subjects, notably, without DNDi's prior written approval. The Institution shall inform DNDi in advance of any media visits to the Clinical Trial site and comply with the guidance provided by DNDi.|t
17175463|NCT01733212|t||||
17175464|NCT00775203|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 60 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified/delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17175465|NCT00704522|f||||f
17175466|NCT01213576|t||||
17175467|NCT01525901|t||||
17175468|NCT00641316|f||||f
17175469|NCT02486627|f||OTHER|The Investigator may publish/present the study results provided all of the following: (i) the primary publication has been published; or, if no such publication has occurred, at least 18m have passed since the completion of the study; (ii) Achaogen is allowed at least 60d to review; (iii) confidential information is deleted as requested; (iv) comments and proposed revisions are considered; and (v) during the 60d review, if requested, the Investigator shall delay the publication or presentation.|t
17175470|NCT01073462|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175471|NCT01126671|t||||
17175472|NCT00445588|f||LTE60||t
17175473|NCT03554486|t||||
17175474|NCT01509053|f||||f
17175475|NCT04114617|t||||
17175476|NCT01738477|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175477|NCT01915303|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17175478|NCT02925338|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175479|NCT02509117|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175480|NCT00568386|t||||f
17175481|NCT00548184|t||||
17175482|NCT00636363|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17175483|NCT01764919|f||GT60||t
17175484|NCT00280748|t||||
17175485|NCT00029146|f||||f
17175486|NCT02199717|f||||f
17175487|NCT03567343|f||||f
17175488|NCT00875589|t||||
17175489|NCT01138917|f||||f
17175490|NCT03007888|f||||f
17175491|NCT01806662|f||||f
17175492|NCT01479426|t||||f
17175493|NCT00043550|f||||f
17175494|NCT03471624|f||||f
17175495|NCT03259620|f||||f
17175496|NCT00827931|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175497|NCT00300430|f||OTHER|Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.|t
17175498|NCT01917656|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17175499|NCT02081859|f||||f
17175500|NCT01870076|t||||
17175501|NCT00492063|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17175502|NCT04160975|f||||f
17175503|NCT00368290|f||||f
17175504|NCT01143701|f||||f
17130621|NCT04506086|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17130622|NCT01671423|t||||
17130623|NCT00495820|t||||
17130624|NCT04857996|f||||f
17130625|NCT00820950|f||OTHER|Clinical Study Agreement|t
17130626|NCT00798135|t||||
17130627|NCT00199914|t||||
17130628|NCT05472012|f||||f
17130629|NCT03670953|f||||f
17130630|NCT01199042|f||||f
17130631|NCT00880399|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130632|NCT04353284|t||||
17130633|NCT00122681|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130634|NCT01422356|f||LTE60||t
17130635|NCT02819635|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17130636|NCT01035099|t||||
17138737|NCT02959970|f||OTHER|Authorship and manuscript composition will reflect joint cooperation between multiple investigators and sites and the Sponsor's personnel. Authorship will be established prior to the writing of the manuscript. As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with the Sponsor.|t
17175505|NCT00510653|t||||f
17175506|NCT04157673|f||||f
17175507|NCT02312687|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175508|NCT00878436|f||||f
17175509|NCT00217464|t||||
17175510|NCT00169442|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175511|NCT01426789|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17175512|NCT00123643|f||||f
17175513|NCT00311584|f||OTHER|Must obtain prior Sponsor approval.|t
17175514|NCT00548652|t||||
17175515|NCT02103153|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17175516|NCT00167778|t||||
17175517|NCT02654717|f||||f
17175518|NCT03521102|t||||
17175519|NCT01371032|f||||f
17175520|NCT01280201|f||||f
17175521|NCT00430183|f||||t
17175522|NCT02126748|f||||f
17175523|NCT01844479|f||||f
17175524|NCT01976988|f||||f
17175525|NCT05395091|f||OTHER||t
17175526|NCT01332461|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175527|NCT00313781|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175528|NCT01433250|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17175529|NCT00834080|f||OTHER|A copy of such disclosure must be given to Alkermes for review at least sixty (60) days prior to submission for publication, presentation or delivery to any other party. Revisions to such disclosure will be negotiated in good faith by the Institution, Principal Investigator and Alkermes. Expedited reviews for abstracts or poster presentations may be arranged if mutually agreeable to Alkermes and the Institution.|t
17130637|NCT02833922|f||||f
17130638|NCT03179891|f||OTHER|Trial results were included as confidential information and required written sponsor approval.|t
17175530|NCT02431260|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17130639|NCT01349465|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17130640|NCT00632099|t||||
17130641|NCT00754832|t||||
17130642|NCT02004262|f||LTE60||t
17130643|NCT01923285|f||||f
17130644|NCT04331795|t||||
17130645|NCT00804570|f||GT60||t
17130646|NCT00290342|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130647|NCT03341975|f||||f
17130648|NCT01056510|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130649|NCT00243386|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or ≤2 years after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥60 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., intellectual property protection)|t
17130650|NCT02285998|f||||f
17130651|NCT00545298|f||OTHER|The PI is only allowed to publish the results of the trial with the permission of the Sponsor|t
17130652|NCT01953575|t||||
17130653|NCT01793142|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175531|NCT00321646|f||||f
17175532|NCT01037192|t||||f
17175533|NCT02576145|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175534|NCT02660138|f||||f
17175535|NCT00308581|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17130654|NCT02242578|f||||f
17130655|NCT00685880|t||||f
17130656|NCT01820364|f||OTHER|The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in the clinical trial.|t
17130657|NCT03339206|f||||f
17130658|NCT03451084|f||||f
17130659|NCT04995055|f||GT60||t
17130660|NCT02662036|t||||
17130661|NCT02668874|f||||f
17130662|NCT03418129|t||||
17130663|NCT01017003|f||GT60||t
17130664|NCT03300674|t||||
17130665|NCT01553188|f||||f
17130666|NCT02445625|t||||
17130667|NCT02087956|f||||f
17130668|NCT04744207|f||||f
17130669|NCT00891982|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130670|NCT03096730|t||||
17130671|NCT00974246|f||||f
17130672|NCT01617070|t||||
17130673|NCT05289570|t||||
17130674|NCT02777268|f||OTHER|The investigator must obtain written consent from the Sponsor prior to any publication of results.|t
17130675|NCT02230384|t||||
17130676|NCT00808236|f||LTE60||t
17130677|NCT00777101|f||LTE60||t
17130678|NCT00961220|f||LTE60||t
17175536|NCT01247298|t||||
17175537|NCT01087788|f||GT60||t
17175538|NCT03235180|t||||
17175539|NCT01779219|f||||f
17175540|NCT00534313|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175541|NCT01905423|f||||f
17175542|NCT03709576|f||||f
17175543|NCT01947855|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175544|NCT01233518|f||||f
17175545|NCT00436501|f||LTE60||t
17175546|NCT00714571|t||||
17175547|NCT03011892|f||OTHER|Clinical Study Agreement|t
17175548|NCT02282293|f||||f
17130679|NCT05376215|f||OTHER|Prior to any publication or presentation, Sonova reserves the right to review, oppose, or restrict the publication or presentation of protected intellectual property and/or confidential information. If an objection is raised by Sonova, discussion shall be held without delay to determine acceptable modifications to resolve the issue and allow dissemination within sixty days.|t
17130680|NCT02031770|t||||
17130681|NCT01947816|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17130682|NCT00471705|f||||f
17130683|NCT01301950|f||LTE60||t
17130684|NCT02651584|f||||f
17130685|NCT01066585|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17130686|NCT03455491|t||||t
17130687|NCT01391286|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130688|NCT01732809|f||||f
17130689|NCT04247061|t||||
17130690|NCT03610724|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17130691|NCT01519765|f||||f
17130692|NCT01473563|f||GT60||t
17130693|NCT04126083|t||||
17130694|NCT00786565|f||LTE60||t
17130695|NCT01699542|f||GT60||t
17130696|NCT04402970|f||||f
17130697|NCT03499509|f||||f
17130698|NCT01475175|f||OTHER|In most cases, contracts allow investigators to publish study results per the protocol and publication plan following Medtronic's review to determine whether confidential information (CI) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred.|t
17130699|NCT05248295|f||||f
17130700|NCT03021499|f||||f
17130701|NCT01210690|f||GT60||t
17130702|NCT00470054|f||LTE60||t
17130703|NCT04093843|t||||
17130704|NCT01878526|f||||f
17130705|NCT03310450|f||||f
17130706|NCT04869345|t||||f
17130707|NCT00359138|f||LTE60||t
17130708|NCT00528021|f||LTE60||t
17130709|NCT04050982|t||||
17130710|NCT05054114|f||||f
17130711|NCT02186847|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17130712|NCT00733954|f||OTHER|The principal investigator has the right to publish or present the data results from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17175549|NCT03381729|f||OTHER|Depending on local requirements, Sponsor's consent necessary before publication of study, or Sponsor can review results communications before public release with a right to request changes to communications regarding trial results between 40 to 60 and up to 90 or 120 days, as applicable, from the time submitted to Sponsor for review to remove references to Sponsor's Confidential Information or delay results communications to permit Sponsor to obtain appropriate Intellectual Property protection.|t
17175550|NCT03758755|t||||
17175551|NCT01264601|t||||
17175552|NCT02000908|f||||f
17130713|NCT02663453|t||||f
17130714|NCT03416153|f||||f
17130715|NCT02204150|f||||f
17130716|NCT03703882|f||||f
17130717|NCT01617460|f||||f
17130718|NCT01140360|t||||
17130719|NCT01535573|t||||
17130720|NCT03382665|f||LTE60||t
17130721|NCT00666458|f||||f
17130722|NCT02222207|f||OTHER|In mulit centre studies result of study are to be published only through coordination by Bayer in order to combine the results of all centres. Center free to publish its results provided the overall results have not been published within 18 months from study completion (data base lock), subject to the compliance to remaining terms set forth in the PI contract.|t
17130723|NCT02982954|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130724|NCT04002037|f||||f
17130725|NCT00747643|t||||f
17130726|NCT00750698|f||||t
17130727|NCT01417195|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17130728|NCT03357731|f||LTE60||t
17130729|NCT01239342|f||LTE60||t
17130730|NCT03118232|f||||f
17130731|NCT02918864|f||||f
17130732|NCT03289650|f||||f
17130733|NCT03577730|t||||
17130734|NCT02634151|f||||t
17130735|NCT04640272|f||GT60||t
17130736|NCT01523496|f||||f
17130737|NCT00751400|f||LTE60||t
17130738|NCT00676676|t||||
17130739|NCT03129321|f||OTHER|Investigator shall not publish, or seek to publish, either in whole or in part any results of the study without the written consent of CRO.|t
17130740|NCT00441974|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130741|NCT02770547|f||||f
17130742|NCT01148537|f||GT60||t
17130743|NCT00060346|f||||f
17130744|NCT03134599|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17130745|NCT00393887|f||GT60||t
17130746|NCT03503877|t||||
17130747|NCT01517529|t||||
17130748|NCT02018822|t||||
17130749|NCT00715026|f||||f
17130750|NCT04784182|f||||f
17130751|NCT01389752|f||GT60||t
17130752|NCT01063075|f||GT60||t
17130753|NCT01157364|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130754|NCT02225080|f||LTE60||t
17130755|NCT01713621|f||LTE60||t
17130756|NCT04251910|f||||t
17175553|NCT01924429|f||||f
17130757|NCT01722604|f||OTHER|Please contact sponsor directly for details.|t
17175554|NCT00384111|f||||f
17130758|NCT00841568|f||||f
17175555|NCT00807573|t||||
17130759|NCT01087775|f||||f
17175556|NCT01089361|t||||
17175557|NCT03612856|f||OTHER|Aronora, Inc. shall retain title to and the right to publish all documentation, records, raw data, specimens, or other work product generated in connection with this study. Such publications shall not be made by the PI or Celerion without the prior written consent of Aronora, Inc.|t
17175558|NCT04463069|f||||f
17130760|NCT02153528|f||||t
17130761|NCT00841789|f||||f
17130762|NCT01024010|t||||
17130763|NCT00825162|f||LTE60||t
17130764|NCT00781911|f||GT60||t
17130765|NCT02086786|f||OTHER|The sponsor intends to publish clinical data from all centers participating in the investigation. A draft manuscripts will submit to all participating investigators for their comments. Individual investigators subsequently may publish additional findings of this study in scientific journals/scientific meetings, provided that the sponsor is given ample opportunity to review any proposed abstract, manuscript, or slide presentation prior to its submission.|t
17130766|NCT03317795|t||||
17175559|NCT01634191|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17130767|NCT00939783|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130768|NCT02189161|f||LTE60||t
17130769|NCT00713427|f||GT60||t
17130770|NCT00455689|t||||
17130771|NCT01549002|t||||
17130772|NCT01664559|t||||
17130773|NCT06290206|f||||f
17130774|NCT02255409|f||LTE60||t
17175560|NCT01155167|f||||f
17175561|NCT02076425|t||||
17175562|NCT00156936|f||OTHER|Should a PI wish to disclose results, the sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days but less than or equal to 90 days from the time submitted to the sponsor for review. Revisions will be negotiated in good faith. For a multicenter study, the institution/PI agree to publish/publicly present the results together with the other sites unless the sponsor grants written permission in advance.|t
17175563|NCT02491359|f||||f
17130775|NCT01251367|f||||f
17130776|NCT02189213|t||||
17130777|NCT02016820|t||||
17130778|NCT02424253|f||OTHER|The terms and conditions of the agreements with investigators may vary. However, the investigator is not prohibited from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17130779|NCT03998046|f||||f
17130780|NCT01136655|f||GT60||t
17130781|NCT02431572|t||||
17130782|NCT01733628|f||LTE60||t
17130783|NCT02901925|f||||f
17130784|NCT02701868|f||||f
17130785|NCT03557281|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130786|NCT00402649|f||LTE60||t
17130787|NCT01999465|f||||f
17130788|NCT05030012|f||||f
17130789|NCT01114503|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130790|NCT02628236|f||OTHER|First publication of results will be made by the Sponsor. If publication is not submitted within 12 months after the date of study final report, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30 days before submission for publication so that sponsor can review the publication for confidential information|t
17130791|NCT01584479|f||||f
17175564|NCT02880956|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17130792|NCT01611974|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17175565|NCT00853970|f||OTHER|The disclosure restriction on the PI is that the PI will provide to the sponsor a copy of proposed publication information for review, comment and approval following completion of the study and at least sixty (60) days prior to submission of the publication. If sponsor requests in writing, the PI will withhold publication until written permission is given by Sponsor.|t
17175566|NCT04096482|t||||
17130793|NCT00916357|f||GT60||t
17130794|NCT01308008|f||||f
17130795|NCT04766021|f||||f
17130796|NCT01656031|t||||
17130797|NCT00789529|f||LTE60||t
17130798|NCT01875783|f||||f
17130799|NCT04172714|t||||
17130800|NCT01761084|f||||f
17130801|NCT00940589|f||GT60||t
17130802|NCT00429403|t||||f
17130803|NCT00573430|f||LTE60||t
17130804|NCT01261507|f||LTE60||t
17130805|NCT04962022|t||||
17130806|NCT02841397|f||GT60||t
17130807|NCT00354770|f||||f
17130808|NCT03782402|t||||
17130809|NCT01146873|f||OTHER||t
17130810|NCT01967628|f||||f
17130811|NCT01356407|f||LTE60||t
17130812|NCT02055820|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130813|NCT01594515|t||||f
17175567|NCT00576420|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17175568|NCT02000154|f||||f
17175569|NCT01502332|f||||f
17175570|NCT04133064|t||||
17175571|NCT01771809|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17130814|NCT02184195|f||OTHER|This submission /document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17175572|NCT02656680|f||||f
17130815|NCT00133991|t||||
17130816|NCT03002155|f||||f
17130817|NCT00978029|f||OTHER|The investigator agrees to provide to the sponsor for review 45 days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication that report any results of the trial. If the parties disagree concerning the sponsor's confidential information, the investigator agrees to meet with the sponsor's representative, prior to submission for publication, in order to make good faith efforts to discuss and resolve any issues or disagreements.|t
17130818|NCT00964743|t||||
17130819|NCT01298752|f||OTHER|Contact sponsor directly for details.|t
17130820|NCT01227044|t||||
17130821|NCT00583362|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130822|NCT00473343|f||||t
17130823|NCT00345176|f||||f
17130824|NCT02290873|f||OTHER|At least 60 days prior to submission of communications, sponsor shall review and comment on the communications. Sponsor shall have the right to require institution and investigator to remove specifically identified confidential information and to delay the proposed publication an additional 60 days to enable sponsor to seek patent protection.|t
17130825|NCT02370615|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17130826|NCT01378104|f||||f
17175573|NCT00911443|f||LTE60||t
17175574|NCT01142089|f||OTHER|Principal Investigator will provide Sponsor an opportunity of at least 30 days to review and comment on any proposed publication before it is disclosed and Sponsor shall have the right to require the removal of any Confidential Information. Sponsor shall have the right to require the publication be delayed for an additional period not to exceed 60 days to permit the filing of patent applications or to seek intellectual property protection related to information contained in such publication.|t
17175575|NCT00789074|t||||
17175576|NCT02907892|t||||
17130827|NCT02287623|t||||
17130828|NCT02700997|t||||
17130829|NCT02354222|f||OTHER||t
17130830|NCT03471975|f||||f
17130831|NCT01342484|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175577|NCT01974765|t||||
17130832|NCT01840579|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17130833|NCT00432042|f||OTHER|Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17130834|NCT02822885|t||||
17130835|NCT01585272|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17130836|NCT00645593|t||||
17130837|NCT03704142|f||||f
17130838|NCT02577146|t||||
17130839|NCT03765138|t||||
17130840|NCT01970501|f||||f
17130841|NCT03924752|t||||
17130842|NCT03803059|f||||f
17130843|NCT01027819|f||||f
17130844|NCT04013529|f||||f
17130845|NCT03116698|f||||f
17130846|NCT00788372|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17130847|NCT05815719|t||||
17130848|NCT02116777|f||LTE60||t
17130849|NCT02589496|f||||f
17138738|NCT03300427|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17175578|NCT00528970|f||OTHER|Please contact Sponsor directly for additional information.|t
17175579|NCT03860935|f||LTE60||t
17175580|NCT01430754|f||||f
17175581|NCT01020006|f||||f
17175582|NCT00701662|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175583|NCT00635024|t||||f
17175584|NCT01105065|f||||f
17175585|NCT00880464|t||||
17175586|NCT00606047|t||||
17175587|NCT01038869|t||||
17175588|NCT04575597|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17175589|NCT03207438|f||LTE60||t
17175590|NCT03316911|t||||
17175591|NCT01119937|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17175592|NCT01512667|f||LTE60||t
17183310|NCT02550652|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130850|NCT00980200|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130851|NCT00457015|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130852|NCT01773109|t||||
17130853|NCT01500109|t||||
17130854|NCT02257372|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130855|NCT04325542|f||||f
17175593|NCT04132804|t||||
17175594|NCT00853996|t||||
17175595|NCT02536404|f||||f
17175596|NCT00770146|f||OTHER|After the multicenter publication or 12 months after completion of the study the PI may publish the results of his/her data from the study. The PI shall provide the sponsor with an advance copy at least 60 days prior to planned submission and the Sponsor shall have 60 days to review (contracts have variable timeframes; maximum times are stated here). The sponsor may request the deletion of any confidential information, or a delay in submission for an additional period not to exceed 90 days.|t
17175597|NCT01967784|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17183311|NCT03286140|t||||
17183312|NCT00515827|f||||f
17183313|NCT03181542|t||||
17183314|NCT01833403|f||||f
17183315|NCT04138615|f||||f
17183316|NCT02553746|f||||f
17183317|NCT04055116|t||||
17183318|NCT04150224|f||OTHER||t
17183319|NCT02774681|t||||
17130856|NCT02387359|f||||t
17130857|NCT01230242|t||||
17183320|NCT01069289|f||OTHER||t
17183321|NCT02047604|f||||t
17175598|NCT00816023|f||OTHER|The first publication is initiated by Cubist. If the First Publication is not published within 1 year of Study conclusion or termination, Investigator shall have the right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17175599|NCT05027971|f||LTE60||t
17130858|NCT04075721|f||||f
17175600|NCT00968032|f||||f
17175601|NCT02181517|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175602|NCT01238588|t||||
17175603|NCT01544088|t||||
17175604|NCT02055638|f||||f
17175605|NCT01903252|f||||f
17130859|NCT04329702|f||||f
17130860|NCT01438489|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17175606|NCT02437110|t||||
17175607|NCT03467685|t||||
17175608|NCT03836001|t||||
17130861|NCT00766532|f||||f
17175609|NCT01381562|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130862|NCT02037295|t||||
17130863|NCT01140451|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17175610|NCT04876690|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130864|NCT00556452|t||||f
17175611|NCT02971033|t||||
17130865|NCT00960661|f||||f
17138739|NCT00693420|f||OTHER|At least ninety (90) days prior to any proposed submission for publication or presentation of Study data or other findings related to the Study, the Institution will provide the Sponsor with a manuscript of such submission(s) for review and comment.|t
17138740|NCT02568852|f||||f
17138741|NCT01894555|f||||f
17138742|NCT01810289|f||||f
17138743|NCT00063986|f||||f
17175612|NCT01642732|t||||
17175613|NCT02438475|t||||
17175614|NCT00899353|t||||
17175615|NCT04475198|f||||t
17175616|NCT02730793|t||||
17175617|NCT01284491|f||LTE60||t
17175618|NCT02489422|t||||
17175619|NCT02694757|f||||f
17175620|NCT02650921|f||||f
17175621|NCT00783302|f||||f
17175622|NCT04604132|f||GT60||t
17175623|NCT00952380|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175624|NCT03400956|f||LTE60||t
17175625|NCT00160667|f||GT60||t
17175626|NCT00927940|f||||f
17175627|NCT00270842|f||||f
17175628|NCT03044574|t||||
17175629|NCT00890045|f||||f
17175630|NCT01402427|t||||
17175631|NCT04355728|t||||f
17175632|NCT00483756|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175633|NCT00906971|f||||f
17175634|NCT04054947|t||||f
17175635|NCT01606878|f||OTHER|Must obtain prior sponsor approval|t
17175636|NCT03473548|t||||
17175637|NCT00129311|f||||f
17175638|NCT01543581|t||||
17175639|NCT00721253|f||OTHER|No paper that incorporates Sponsor Condfidential information will be submitted for publication without Sponsor's prior written agreement.|t
17175640|NCT01340872|f||||f
17175641|NCT03603509|t||||
17175642|NCT02248558|f||||f
17175643|NCT01258998|f||LTE60||t
17175644|NCT01215929|t||||
17175645|NCT01143389|f||||f
17175646|NCT04966910|f||||f
17175647|NCT02930980|f||LTE60||t
17175648|NCT02276027|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17175649|NCT03224598|f||||f
17175650|NCT02361476|f||||f
17183322|NCT04035486|f||OTHER|The Investigator agrees to submit all manuscripts or abstracts to the sponsor before submission for publication or presentation at scientific meetings to allow the sponsor to protect proprietary information and to provide comments.|t
17183323|NCT03995758|t||||
17183324|NCT02556710|f||||t
17130866|NCT02699892|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130867|NCT01981590|f||||f
17130868|NCT02152085|f||||f
17130869|NCT00067028|t||||
17130870|NCT01324232|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130871|NCT00661531|f||||f
17130872|NCT02310776|f||||f
17130873|NCT02888093|f||||f
17130874|NCT00530270|f||||f
17130875|NCT02324920|f||LTE60||t
17130876|NCT01468584|f||OTHER||t
17130877|NCT02614859|t||||
17130878|NCT01628588|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130879|NCT01399788|t||||f
17130880|NCT02919436|t||||
17138744|NCT01235338|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17138745|NCT03669146|t||||
17175651|NCT01845103|f||OTHER|Site and Investigator agree not to publish or present results prior to Sponsor's final report, but in no event shall Site or Investigator be restricted after the expiration of 12m from Project completion. Publication or disclosure made by Site or Investigator shall not contain Sponsor Confidential Information (CI) and text shall be submitted for Sponsor CI review and comment 30d prior to submission or disclosure and can be deferred, not exceeding 90d for the Sponsor to protect its rights in CI.|t
17130881|NCT01441037|t||||
17130882|NCT03699007|t||||f
17130883|NCT04718974|f||||f
17130884|NCT03259074|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17130885|NCT01780662|f||LTE60||t
17130886|NCT05032612|t||||
17130887|NCT00183274|f||||f
17130888|NCT02370875|f||||f
17130889|NCT04081363|f||||f
17130890|NCT02409290|f||||f
17130891|NCT00708500|f||OTHER|Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.|t
17130892|NCT01242267|t||||
17130893|NCT00618410|t||||
17130894|NCT00705783|f||||f
17130895|NCT02327052|f||||f
17130896|NCT02788097|t||||
17130897|NCT02997735|t||||
17175652|NCT00830791|f||GT60||t
17175653|NCT01527357|f||||f
17175654|NCT02446171|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17175655|NCT04531462|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175656|NCT00504582|t||||
17175657|NCT04175509|t||||f
17175658|NCT02292784|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175659|NCT00348933|f||||f
17175660|NCT01264081|f||||f
17175661|NCT01489111|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17175662|NCT00134784|t||||
17175663|NCT01546402|f||||f
17175664|NCT02641483|t||||
17175665|NCT02564432|t||||f
17175666|NCT00730028|f||LTE60||t
17175667|NCT03811093|f||||f
17175668|NCT00464490|t||||
17175669|NCT03188042|t||||
17175670|NCT00925938|f||OTHER|All publications resulting from the clinical trial must be in a form that does not reveal technical information that the Sponsor considers confidential or proprietary. A copy of any abstract, presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days before its submission. If deemed necessary for protection of proprietary information prior to patent filing, a further delay of 60 days is required before any publication is submitted.|t
17175671|NCT03565367|t||||
17175672|NCT03396952|t||||
17175673|NCT00400803|t||||
17175674|NCT01227824|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175675|NCT02805504|t||||
17130898|NCT03029143|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17130899|NCT00619255|f||||f
17130900|NCT00974675|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17130901|NCT02121262|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17130902|NCT01991990|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130903|NCT03292809|f||GT60||t
17175676|NCT02395302|f||LTE60||t
17175677|NCT01306929|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Data and results owned by Sponsor. Results can be used by institution for (a) internal non-commercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of Sponsor.|t
17175678|NCT02589600|t||||f
17175679|NCT00710762|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175680|NCT00495040|t||||
17175681|NCT01816451|t||||f
17175682|NCT01892384|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175683|NCT00592774|f||||f
17175684|NCT01700439|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17175685|NCT01872325|t||||f
17175686|NCT01390064|t||||
17175687|NCT00621621|f||LTE60||t
17175688|NCT00481507|f||||f
17175689|NCT04850781|t||||f
17130904|NCT02025907|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17130905|NCT03681119|t||||
17130906|NCT01923129|t||||f
17130907|NCT00879645|f||OTHER||t
17130908|NCT03631732|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130909|NCT04288154|t||||
17130910|NCT01624662|f||||t
17130911|NCT04048616|f||||f
17130912|NCT01848184|f||||t
17130913|NCT02813551|t||||
17130914|NCT00102960|f||||f
17130915|NCT01849874|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130916|NCT02104583|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130917|NCT02347098|t||||
17130918|NCT02187172|t||||
17130919|NCT04673292|f||||f
17130920|NCT02830880|t||||
17130921|NCT03045861|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130922|NCT02646982|f||||f
17130923|NCT05400213|t||||
17130924|NCT03551509|f||||f
17130925|NCT01040351|t||||
17130926|NCT01230307|f||||f
17130927|NCT00291447|t||||f
17130928|NCT00530894|f||OTHER|"Site cannot publish or present on overall study results not yet published. PI may publish his own clinical study data subject to EW review prior submission or presentation, but data analyses of site-specific results can occur only in intervals as specified in the CSA.~Publication of site-specific results cannot include claims of device safety and effectiveness and requires EW review."|t
17130929|NCT02256540|f||||f
17175690|NCT02452931|f||OTHER|Protocol Section 11.3 Publication, the Investigator shall not make any publication related to this study without the express written permission of the Sponsor. The Investigator agrees to provide abstract, manuscript, and/or documentation for Sponsor review 90 days prior to submission for publication/presentation. The Sponsor retains the right to delete from the manuscript confidential information and to object to suggested publication and/or its timing (at the Sponsor's sole discretion).|t
17175691|NCT00608569|f||OTHER|"In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights."|t
17175692|NCT00562315|f||||f
17175693|NCT01059929|f||||f
17175694|NCT03445156|t||||
17175695|NCT00053898|f||GT60||t
17175696|NCT01254942|f||||f
17175697|NCT00545129|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175698|NCT01894568|f||||f
17130930|NCT02605187|t||||
17130931|NCT05433571|t||||
17130932|NCT02340585|f||OTHER||t
17130933|NCT03923426|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130934|NCT00769002|t||||
17130935|NCT01918007|f||||f
17130936|NCT03070470|f||||f
17175699|NCT04545944|f||OTHER|PPD cannot publish data from a Phathom trial (or assist a third party with a publication) that includes any vonoprazan data without consent.|t
17175700|NCT01514370|f||GT60||t
17175701|NCT01551420|f||||f
17130937|NCT01732796|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130938|NCT05626270|t||||
17130939|NCT03972969|t||||
17130940|NCT02459795|f||OTHER||t
17130941|NCT00734799|f||||f
17130942|NCT00595556|t||||f
17130943|NCT00371293|f||||f
17130944|NCT02182687|t||||
17130945|NCT01707043|f||GT60||t
17130946|NCT02829138|f||||f
17138746|NCT00948428|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17175702|NCT03068091|f||||f
17175703|NCT03353740|t||||
17175704|NCT02232880|f||||f
17130947|NCT02588976|f||||f
17130948|NCT01394627|t||||
17130949|NCT01765920|f||||t
17130950|NCT01081249|f||||f
17130951|NCT02411539|f||||f
17130952|NCT00282334|t||||
17130953|NCT01236300|t||||
17130954|NCT01347554|f||||f
17130955|NCT01439204|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130956|NCT02223260|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17130957|NCT00047060|t||||f
17130958|NCT00336973|f||OTHER||t
17130959|NCT03917823|f||||f
17130960|NCT03775421|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 30 days before submission for publication or presentation.|t
17130961|NCT00135668|f||||f
17130962|NCT02445807|f||||f
17130963|NCT02008682|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17138747|NCT00509028|f||LTE60||t
17138748|NCT02918721|f||||t
17138749|NCT02933372|t||||
17175705|NCT02545543|f||OTHER|Seqirus agreements and restrictions on publishing may vary with individual investigators; however, Seqirus will not prohibit any investigator from publishing. Seqirus supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175706|NCT01395784|f||||f
17130964|NCT00768521|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17130965|NCT04377711|f||||f
17130966|NCT02870309|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17130967|NCT00455013|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17130968|NCT04901481|f||||f
17130969|NCT02739620|f||||f
17130970|NCT02873936|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17130971|NCT05513625|f||||t
17130972|NCT00754793|t||||
17175707|NCT04268823|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17175708|NCT02055365|t||||
17175709|NCT02882152|t||||
17175710|NCT02531971|f||||t
17175711|NCT01343823|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175712|NCT00923364|f||||f
17175713|NCT01752036|t||||
17175714|NCT04352127|t||||
17175715|NCT01437995|f||||f
17175716|NCT05338671|f||||f
17175717|NCT04456673|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17175718|NCT04391049|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17175719|NCT03874429|f||||t
17175720|NCT02160002|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17175721|NCT00246571|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175722|NCT04896229|t||||
17175723|NCT01203644|f||||f
17175724|NCT00159822|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175725|NCT00713310|f||LTE60||t
17175726|NCT02307253|f||||f
17130973|NCT02461550|t||||
17175727|NCT00275821|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17130974|NCT01225731|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the Sponsor. The investigator further agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication in any media that report any results of the trial. The Sponsor shall have the right to review and comment on the data analysis and presentation.|t
17130975|NCT04341441|t||||
17130976|NCT00917150|f||||f
17130977|NCT03891264|t||||
17130978|NCT01692275|f||||f
17175728|NCT00329901|f||GT60||t
17175729|NCT00992589|f||LTE60||t
17175730|NCT01215916|f||GT60||t
17175731|NCT02142387|f||||f
17175732|NCT05028361|f||||f
17175733|NCT01848782|f||||f
17175734|NCT00618098|f||||f
17175735|NCT00779259|f||GT60||t
17175736|NCT02280122|f||||f
17175737|NCT02047318|f||OTHER||t
17175738|NCT02296138|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175739|NCT00711516|f||OTHER||t
17175740|NCT02921061|t||||
17175741|NCT01431209|t||||
17175742|NCT01029405|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175743|NCT00409175|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175744|NCT02596750|f||||f
17175745|NCT02108262|f||||t
17183325|NCT02258152|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17130979|NCT03099187|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130980|NCT01100437|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130981|NCT00868348|t||||
17130982|NCT03077685|f||||f
17130983|NCT02159703|t||||
17130984|NCT01246583|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17130985|NCT01076049|f||||f
17130986|NCT01806779|t||||
17130987|NCT01779024|t||||
17130988|NCT02284126|t||||f
17175746|NCT00761150|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175747|NCT05463198|f||||f
17175748|NCT01860846|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175749|NCT01856764|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17175750|NCT00466687|t||||
17175751|NCT01925989|f||GT60||t
17175752|NCT01535976|f||||f
17175753|NCT04964193|f||||f
17175754|NCT00868517|t||||f
17175755|NCT01982968|t||||f
17175756|NCT00420641|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175757|NCT03723603|f||||t
17175758|NCT03459690|t||||f
17175759|NCT02586506|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175760|NCT00684047|f||OTHER|Site may publish results from the Study, after providing Sponsor at least thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsor's request, Site will remove any Confidential Information (other than Study results), and incorporate all reasonable comments by Sponsor, or delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17175761|NCT01367080|f||||f
17175762|NCT02815280|f||LTE60||t
17183326|NCT04258839|f||||f
17183327|NCT01607905|f||||t
17130989|NCT04218201|t||||
17130990|NCT00218491|t||||
17130991|NCT02562924|t||||
17130992|NCT01183559|f||||f
17130993|NCT03723707|t||||
17130994|NCT05121480|f||OTHER|After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. The sponsor has final approval authority over publication of the study data.|t
17130995|NCT02366611|t||||
17130996|NCT01733472|t||||
17130997|NCT01135498|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17130998|NCT03239574|t||||
17175763|NCT00603642|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17175764|NCT01514162|f||OTHER||t
17175765|NCT00040846|t||||
17175766|NCT00654147|f||||f
17175767|NCT01230177|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175768|NCT02538783|f||||f
17175769|NCT01534182|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17175770|NCT01944839|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.|t
17130999|NCT00713700|f||OTHER||t
17131000|NCT03077347|t||||
17131001|NCT05396742|f||OTHER||t
17131002|NCT00847912|t||||
17131003|NCT01757678|f||LTE60||t
17131004|NCT00838331|t||||
17131005|NCT01074190|f||||f
17131006|NCT00264875|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17131007|NCT00397813|t||||
17131008|NCT00732303|f||||f
17131009|NCT01500278|f||GT60||t
17131010|NCT01709435|f||LTE60||t
17131011|NCT00053417|f||OTHER|The INSTITUTION shall submit any such manuscript or release to the SPONSOR for comment prior to publication or release at least forty-five (45) days in advance of submission for publication. If the parties disagree concerning appropriateness of the data analysis and presentation, INSTITUTION agrees to meet with SPONSOR's representatives for the purpose of making good faith efforts to discuss and resolve any issues or disagreement.|t
17131012|NCT02798536|f||||f
17131013|NCT01297270|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131014|NCT02863809|t||||
17131015|NCT02830776|f||||f
17175771|NCT01178827|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175772|NCT05093790|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175773|NCT00924170|f||||f
17175774|NCT00579436|t||||
17175775|NCT04449029|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17175776|NCT02312882|t||||
17175777|NCT02025556|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17175778|NCT03681288|t||||
17175779|NCT00627445|f||OTHER|Manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17175780|NCT04098224|f||||t
17175781|NCT02217527|t||||f
17175782|NCT01203852|f||||f
17175783|NCT00787904|f||||f
17175784|NCT00081861|t||||f
17175785|NCT00247611|f||||f
17175786|NCT01587898|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175787|NCT00502203|f||||f
17175788|NCT03608150|f||LTE60||t
17175789|NCT01829243|t||||
17175790|NCT01439815|f||||t
17175791|NCT01484288|f||||f
17175792|NCT02829944|f||||f
17175793|NCT00336583|t||||
17175794|NCT03039621|f||||t
17175795|NCT00636701|t||||
17175796|NCT00814333|t||||
17131016|NCT00607386|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17131017|NCT00440947|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131018|NCT00524342|t||||
17131019|NCT00549172|f||||f
17131020|NCT01265797|f||||f
17131021|NCT02813694|f||OTHER|All data from the study is confidential information. Sponsor has the right to publish first. Thereafter, PI may publish data from the study, but PI must submit the publication to Sponsor for review at least 60 days prior to publication. Sponsor may remove any confidential and/or proprietary information. If Sponsor's publication is not submitted within 12 months after the study, or if Sponsor decides not to publish, PI may publish the data, subject to Sponsor's rights in the agreement.|t
17131022|NCT04474795|f||||f
17131023|NCT04041284|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17131024|NCT02980224|f||OTHER||t
17131025|NCT00606320|f||||f
17131026|NCT00563186|t||||
17131027|NCT04839380|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17131028|NCT01087905|f||||f
17131029|NCT00886600|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131030|NCT01179009|t||||
17131031|NCT02937818|f||OTHER|Study results are Sponsor's intellectual property and PIs cannot present or publish results without prior Sponsor approval.|t
17131032|NCT00205855|f||LTE60||t
17131033|NCT01632995|f||||f
17175797|NCT02927067|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17175798|NCT02716896|t||||
17175799|NCT01727700|f||||f
17175800|NCT02519855|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17175801|NCT02415842|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175802|NCT00003830|f||LTE60||t
17175803|NCT04179409|t||||
17175804|NCT00603590|f||||f
17131034|NCT00361270|t||||
17131035|NCT00677014|f||LTE60||t
17131036|NCT01033825|f||OTHER||t
17131037|NCT00081159|t||||
17131038|NCT01548339|t||||
17131039|NCT03449095|f||||f
17131040|NCT03921021|t||||
17131041|NCT01553136|t||||
17131042|NCT02899689|f||||f
17131043|NCT00894556|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131044|NCT01439555|t||||
17131045|NCT00396201|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17131046|NCT00616122|f||||f
17131047|NCT03921424|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17131048|NCT00867321|f||LTE60||t
17175805|NCT01634256|t||||f
17131049|NCT02122198|f||||f
17131050|NCT01143727|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17131051|NCT02581202|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131052|NCT02587650|t||||
17175806|NCT02057042|t||||
17175807|NCT00874614|f||LTE60||t
17175808|NCT03699475|f||||f
17175809|NCT00137839|f||||f
17175810|NCT01440543|t||||f
17175811|NCT01514786|f||||f
17175812|NCT03739242|f||LTE60||t
17175813|NCT02446743|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175814|NCT03718299|f||OTHER||t
17131053|NCT02595450|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131054|NCT02330978|t||||
17131055|NCT04294901|t||||
17131056|NCT01934556|f||||f
17131057|NCT03471065|f||||t
17131058|NCT05038020|f||LTE60||t
17131059|NCT02831673|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131060|NCT00919035|f||||f
17175815|NCT01556347|f||||f
17175816|NCT02013141|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 90 days. The sponsor can require changes to the communication but cannot extend the embargo beyond the 90 days.|t
17175817|NCT01475071|f||OTHER|Disclosure agreement covered by contract.|t
17175818|NCT01011478|f||LTE60||t
17175819|NCT02642744|f||||f
17175820|NCT00636220|f||||f
17175821|NCT05072470|f||LTE60||t
17175822|NCT02158364|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17175823|NCT02514473|f||OTHER|Restriction Description: PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or (3)18 months after close of the study, whichever occurs first.Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17175824|NCT01607203|f||||f
17175825|NCT00674154|t||||
17175826|NCT01107379|f||GT60||t
17175827|NCT04559529|t||||
17131061|NCT02356562|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131062|NCT03615183|f||||f
17131063|NCT01977781|t||||f
17131064|NCT02611154|f||||f
17131065|NCT01351389|f||||f
17131066|NCT03719690|f||OTHER|There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.|t
17131067|NCT04091087|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131068|NCT01224626|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131069|NCT01577186|f||LTE60||t
17131070|NCT05074251|f||||f
17131071|NCT01897285|f||OTHER|Confidentiality Agreement|t
17131072|NCT00631020|f||||f
17131073|NCT03221751|f||||f
17131074|NCT03571646|f||||f
17131075|NCT02214238|t||||
17131076|NCT01604265|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17131077|NCT02706873|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131078|NCT05051904|t||||
17131079|NCT03824808|t||||f
17131080|NCT00586495|f||LTE60||t
17131081|NCT03882970|f||GT60||t
17131082|NCT03831971|f||||f
17175828|NCT00609362|t||||
17175829|NCT01009281|f||||f
17175830|NCT00548405|f||OTHER|PI can publish after sponsor published, after a defined period of time after study completion, and/or with written Sponsor approval. Generally PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information can be removed, and can further defer publication upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17175831|NCT02582684|f||||f
17175832|NCT02548728|t||||
17175833|NCT01431300|f||||f
17175834|NCT06054269|f||||f
17175835|NCT01911910|t||||
17175836|NCT00899392|t||||f
17175837|NCT02067975|t||||
17175838|NCT01261780|t||||
17131083|NCT05284760|f||OTHER|No publication related to study results was made without Sponsor's prior written approval. Any proposed publication or presentation was submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17175839|NCT01239732|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175840|NCT00732940|f||OTHER|For multi-center trials,no investigator will be authorized to publish study results from an individual center until the earlier of the multi-center trial results are published or 12 months after the end or termination of the multi-center trial at all sites. All manuscripts and abstracts must be submitted to the sponsor for review least 30 days prior to submission for publication or for presentation at a scientific meeting. The sponsor may delay publication for up to 3 months if indicated.|t
17131084|NCT02716987|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17131085|NCT01850485|t||||
17175841|NCT02241889|t||||
17131086|NCT02681172|f||||f
17175842|NCT02004288|f||||f
17175843|NCT00266877|f||LTE60||t
17131087|NCT03223428|f||||f
17131088|NCT01834274|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17175844|NCT02387476|f||||f
17175845|NCT03705273|f||||f
17175846|NCT00830076|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17175847|NCT01077375|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17175848|NCT03720392|t||||
17175849|NCT00002975|t||||
17175850|NCT01453387|f||OTHER|The study as a whole will be published prior to any individual investigator publications. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17175851|NCT03985878|f||OTHER|There are agreements between the Principal Investigators and the Sponsor (or its agents) that restrict the PIs rights to discuss or publish trial results after the trial is completed.|t
17175852|NCT00729846|t||||
17175853|NCT00599131|f||||f
17175854|NCT00278915|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17175855|NCT02520089|t||||
17131089|NCT01142401|f||LTE60||t
17175856|NCT02081248|f||||f
17175857|NCT00002931|t||||
17175858|NCT02197455|f||||f
17175859|NCT00910247|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17175860|NCT01879579|t||||
17175861|NCT01695668|f||||f
17175862|NCT02404532|t||||
17175863|NCT01757691|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis doesn not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of the trial results in their entirety.|t
17175864|NCT02484859|t||||
17175865|NCT03386253|t||||
17175866|NCT01949337|f||||t
17175867|NCT02919969|t||||f
17175868|NCT01842633|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17175869|NCT05347147|f||OTHER|If the Investigator wishes to publish anything related to the trial, then they must provide the Sponsor with the draft publication and allow them no less than 30 days to review the document. The Investigator cannot publish without written authorisation from the Sponsor.|t
17175870|NCT01555957|t||||
17175871|NCT00718081|f||OTHER|requires prior consent|t
17175872|NCT01397825|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17175873|NCT00357032|f||LTE60||t
17175874|NCT01931670|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17175875|NCT00244842|f||||f
17175876|NCT03042702|f||GT60||t
17175877|NCT00976508|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17175878|NCT01661088|t||||
17175879|NCT01205581|t||||
17175880|NCT01063712|f||||f
17175881|NCT00978432|t||||
17175882|NCT04418661|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17131090|NCT02017327|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17131091|NCT03362970|f||||f
17131092|NCT02595723|f||||f
17131093|NCT00004259|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17138750|NCT04839393|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138751|NCT00671970|t||||
17138752|NCT00633893|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17138753|NCT02741310|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17138754|NCT03051217|f||GT60||t
17138755|NCT00109772|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17138756|NCT04539262|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17138757|NCT02351739|f||||f
17138758|NCT00602771|f||LTE60||t
17138759|NCT03725293|t||||
17138760|NCT02665468|t||||
17138761|NCT04397796|f||||t
17138762|NCT00802867|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17138763|NCT01061567|t||OTHER|There was no PI assigned for the overall study|
17138764|NCT00444080|f||||f
17138765|NCT03979872|t||||
17138766|NCT01156532|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138767|NCT03371251|f||GT60||t
17138768|NCT00114218|f||LTE60||t
17138769|NCT00291187|f||||f
17138770|NCT01927887|t||||
17138771|NCT03168555|f||||f
17138772|NCT01040845|f||GT60||t
17138773|NCT04965116|t||||
17138774|NCT02708966|f||||f
17138775|NCT02165072|t||||f
17138776|NCT01515488|f||||f
17138777|NCT02959190|f||OTHER|The sponsor can review the study result with PIs prior to public release and can embargo a communication about it until the public release by the contract with Investigator sites.|t
17175883|NCT03702244|f||OTHER|Confidentiality embargo was in place until primary results were published.|t
17175884|NCT00045942|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17175885|NCT02095132|f||LTE60||t
17175886|NCT03492840|f||||f
17131094|NCT00996944|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131095|NCT00769184|f||||f
17131096|NCT00730964|f||||f
17131097|NCT01015768|t||||
17175887|NCT01895361|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17175888|NCT01887743|t||||
17175889|NCT00761748|f||LTE60||t
17131098|NCT02943564|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17131099|NCT00063570|f||GT60||t
17131100|NCT01073267|t||||
17131101|NCT00577642|t||||f
17131102|NCT01556425|f||||f
17131103|NCT01505634|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17131104|NCT02054897|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17131105|NCT02076997|t||||
17131106|NCT00794157|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17131107|NCT00531752|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131108|NCT01811875|f||||f
17131109|NCT00401375|f||OTHER|Please contact Sponsor directly for additional information.|t
17131110|NCT02351505|t||||
17131111|NCT00950664|f||||f
17175890|NCT01209832|f||GT60||t
17175891|NCT01268579|t||||
17175892|NCT02692651|f||||f
17175893|NCT02480712|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17175894|NCT02239120|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175895|NCT01698710|t||||
17175896|NCT02830438|t||||
17175897|NCT03102190|t||||
17131112|NCT02821715|f||GT60||t
17131113|NCT00640328|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131114|NCT02374099|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17131115|NCT01326546|f||OTHER|Investigators can't publish articles relevant to the study unless the sponsor permits.|t
17131116|NCT03152019|t||||
17131117|NCT04294719|t||||
17131118|NCT01714687|f||GT60||t
17131119|NCT01979536|f||LTE60||t
17131120|NCT02909985|t||||
17131121|NCT03770260|f||LTE60||t
17175898|NCT00625703|t||||
17175899|NCT01878149|f||LTE60||t
17175900|NCT02048241|t||||
17175901|NCT00402233|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17175902|NCT02819908|t||||f
17175903|NCT03493932|f||||f
17131122|NCT04138017|f||||f
17131123|NCT01292642|t||||f
17131124|NCT04649255|f||||f
17131125|NCT01040052|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17131126|NCT00605423|f||GT60||t
17131127|NCT01652885|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131128|NCT00075400|f||LTE60||t
17131129|NCT00490568|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131130|NCT01395394|f||||f
17131131|NCT01066364|f||||f
17131132|NCT03451773|f||||f
17131133|NCT01964352|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131134|NCT03468855|f||||f
17175904|NCT04658940|f||||f
17175905|NCT03579602|f||LTE60||t
17131135|NCT01908101|t||||f
17175906|NCT02518464|t||||f
17175907|NCT04456153|t||||
17131136|NCT00166205|f||OTHER|The PI shall have the right to publish the results of research to include in any publication. The PI will provide the Sponsor with at least sixty (60) days for review of a manuscript. No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17131137|NCT03787472|f||GT60||t
17131138|NCT00412750|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131139|NCT00477165|t||||
17131140|NCT00105443|f||LTE60||t
17131141|NCT02135692|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131142|NCT03187769|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17131143|NCT04429061|f||||f
17131144|NCT03186677|f||||f
17131145|NCT00879229|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131146|NCT01097746|t||||
17131147|NCT04762537|f||||f
17131148|NCT00631371|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131149|NCT00390546|t||||
17131150|NCT01093027|t||||
17131151|NCT03962439|t||||
17131152|NCT00665457|f||||f
17131153|NCT01526902|f||GT60||t
17131154|NCT00812214|t||||
17131155|NCT02289222|t||||
17131156|NCT02145741|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131157|NCT01192022|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17131158|NCT01692964|f||OTHER|Publications shall be submitted to the Sponsor for review/comment 45 days prior to publication. Sponsor may remove confidential information. First publication shall be a multicenter study publication. Institution and/or PI may publish or present the results and data from the Institution's site individually (i) 12 months after conclusion, abandonment or termination of study at all sites, or (ii) after the Sponsor confirms there will be no multicenter study publication, whichever occurs first.|t
17131159|NCT00129766|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17131160|NCT02181829|t||||
17131161|NCT03865706|t||||
17131162|NCT01594853|f||||f
17131163|NCT03709654|t||||
17131164|NCT01515787|t||||
17131165|NCT02631200|t||||
17131166|NCT03174132|f||||t
17131167|NCT01081912|f||GT60||t
17131168|NCT02868242|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131169|NCT03776175|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131170|NCT03124823|t||||
17131171|NCT04677712|f||||t
17131172|NCT00711100|t||||f
17131173|NCT00517595|f||OTHER|A copy of the proposed publication or presentation must be submitted to the funders for review and comment two months prior to the presentation or submission for publication. An additional 60 day delay of presentation or publication may be requested by the funder.|t
17175908|NCT01120067|t||||f
17175909|NCT00819793|f||||f
17175910|NCT03848871|f||||f
17175911|NCT02162576|f||||f
17175912|NCT04721067|t||||
17175913|NCT02233478|f||||f
17175914|NCT00873873|t||||f
17175915|NCT01947907|f||||f
17131174|NCT05440539|f||||f
17131175|NCT03808077|t||||
17131176|NCT04152161|f||OTHER||t
17131177|NCT00001379|f||||f
17131178|NCT03246958|t||||
17131179|NCT03703102|f||GT60||t
17131180|NCT02311153|t||||
17131181|NCT01379274|f||||f
17131182|NCT04086823|f||||t
17131183|NCT00405067|f||OTHER|PI can publish after sponsor has 60 days to review the proposed publication. PI is committed to publish the results of the study in a cooperative publication with other investigators prior to individual publication. PI needs sponsor's prior consent to publish confidential information, not to be unreasonably withheld. The PI shall, upon sponsor's request, delete from the publication any confidential information which would prejudice the securing of adequate intellectual property protection.|t
17131184|NCT01650636|t||||
17131185|NCT01560780|t||||
17131186|NCT03363321|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131187|NCT02915523|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17131188|NCT00930761|t||||
17131189|NCT00957008|t||||
17131190|NCT00811135|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131191|NCT01685463|t||||
17131192|NCT00518154|f||||f
17131193|NCT03548935|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17175916|NCT00604214|f||OTHER|The only disclosure restriction on the site PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo. An independent Steering Committee responsible for data analyses and publications did not have an embargo.|t
17175917|NCT00686998|f||GT60||t
17175918|NCT03666676|t||||f
17175919|NCT00130442|f||||f
17175920|NCT02233946|f||||f
17175921|NCT02054481|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17175922|NCT02320903|f||||f
17175923|NCT00773383|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175924|NCT03384693|t||||
17175925|NCT03493815|t||||
17175926|NCT03621475|f||||f
17175927|NCT00178503|f||||f
17175928|NCT01095094|t||||
17175929|NCT02093351|f||||f
17175930|NCT01099709|f||GT60||t
17175931|NCT00266851|f||||f
17175932|NCT03616223|f||OTHER|PIs must obtain sponsor's written consent before publishing or presenting the trial results.|t
17175933|NCT01122394|t||||
17131194|NCT00763815|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17131195|NCT00283595|f||||f
17131196|NCT01263639|t||||f
17131197|NCT01576549|f||GT60||t
17131198|NCT04951037|t||||
17131199|NCT05630937|f||GT60||t
17131200|NCT03341962|f||LTE60||t
17131201|NCT01422915|t||||f
17131202|NCT03761615|f||||f
17131203|NCT01152021|t||||
17131204|NCT01916928|f||||f
17131205|NCT03817775|f||||f
17131206|NCT00755274|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17131207|NCT00350142|t||||
17131208|NCT00609791|t||||
17131209|NCT02484911|t||||
17175934|NCT00039871|f||LTE60||t
17175935|NCT02153476|f||||f
17175936|NCT00815516|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17131210|NCT04129528|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131211|NCT01258504|t||||f
17131212|NCT01682135|f||GT60||t
17131213|NCT01157078|f||GT60||t
17131214|NCT02586675|t||||
17131215|NCT00513409|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131216|NCT03189446|t||||
17131217|NCT04839978|t||||
17131218|NCT00781456|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17131219|NCT02513329|f||||f
17131220|NCT01294670|t||||
17131221|NCT04852848|f||||f
17131222|NCT02083380|f||||f
17131223|NCT02412787|f||||t
17131224|NCT05525533|f||||f
17131225|NCT03405259|f||OTHER||t
17175937|NCT01736657|f||OTHER|If Study Site is performing services in a multi-center Study, it agrees not to independently publish, publicly disclose, present or discuss any results of or information pertaining to the Study until a multi-center manuscript is published; provided however, that if a multi-center manuscript is not published within one year after completion of the Study at all Study sites, Study Site may publish the Study data generated by Study Site|t
17175938|NCT02415855|f||||f
17175939|NCT04198818|t||||t
17175940|NCT01285947|t||||
17175941|NCT01992159|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17175942|NCT01198158|t||||
17175943|NCT03023046|t||||f
17175944|NCT02278471|f||||f
17175945|NCT00640835|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17175946|NCT01741012|f||||f
17131226|NCT00876187|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131227|NCT01032915|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17131228|NCT00915681|f||OTHER|Mylan is allowed to require modifications.|t
17131229|NCT01118351|t||||
17131230|NCT00919100|f||||f
17131231|NCT03345108|f||||f
17131232|NCT01437852|f||||f
17131233|NCT01598779|f||||f
17131234|NCT00919503|t||||
17131235|NCT04677959|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17131236|NCT01970995|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17131237|NCT00845728|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17131238|NCT01717209|f||||f
17131239|NCT04442230|f||OTHER|All information provided regarding the study, as well as all information collected/documented during the course of the study, will be regarded as confidential. The Investigator agrees not to disclose such information in any way without prior written permission from the Sponsor.|t
17131240|NCT02599961|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175947|NCT03468543|f||OTHER||t
17175948|NCT00586729|f||||f
17175949|NCT04618770|f||LTE60||t
17175950|NCT04393298|f||GT60||t
17175951|NCT05033002|f||||f
17175952|NCT02311582|f||||f
17175953|NCT05822531|f||||f
17175954|NCT04972630|t||||
17175955|NCT04111939|f||||f
17175956|NCT02339376|f||||f
17131241|NCT00464334|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17131242|NCT02432235|f||OTHER|PI can publish after first multi-site publication or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on PI is sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period \>60 but ≤180 days from time submitted to sponsor review. Sponsor can't require changes to the comms, extend embargo or require changes to comms, except removing confidential info that are not results|t
17131243|NCT03196076|t||||
17131244|NCT02631525|f||||f
17131245|NCT02424526|f||||f
17131246|NCT02461992|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131247|NCT00794677|t||||f
17131248|NCT05515250|f||||f
17131249|NCT03015259|f||||t
17131250|NCT01965262|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor that restricts the PI's right to discuss or publish trial results after the trial is completed without prior approval of Sponsor.~The investigator will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17131251|NCT04400474|f||||f
17183328|NCT01602315|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data all sites) in the clinical trial.|t
17175957|NCT03390842|f||||t
17183329|NCT01733368|f||||f
17183330|NCT00440271|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17175958|NCT01129024|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17183331|NCT00723801|f||||f
17175959|NCT03442868|t||||
17175960|NCT04656899|f||||f
17183332|NCT03358576|f||OTHER|The PI will provide manuscripts, abstracts, or full text of any other intended disclosure (poster, invited speaker or guest lecturer, etc) to Iterum at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, the PI agrees to delay disclosure for a period not to exceed an additional 60 days. The PI will, on request, remove any previously undisclosed Confidential Information before disclosure.|t
17183333|NCT01565993|t||||f
17175961|NCT03513848|f||||f
17175962|NCT00686634|t||||
17175963|NCT00799773|f||||f
17183334|NCT01824303|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17183335|NCT04086472|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17183336|NCT00844545|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17183337|NCT01743092|t||||f
17183338|NCT05165121|f||||f
17131252|NCT00143312|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17131253|NCT01029366|t||||
17183339|NCT03058796|t||||
17183340|NCT03586869|f||||t
17183341|NCT00403455|t||||
17183342|NCT04805983|t||||
17183343|NCT02809976|f||||f
17131254|NCT01479543|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17131255|NCT00906087|f||OTHER|Sponsor wants an opportunity to review the data. I will send a PDF of this record on 3/17/2017.|t
17131256|NCT00517829|f||||f
17131257|NCT00385255|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131258|NCT02443883|f||LTE60||t
17131259|NCT01297335|f||||f
17131260|NCT01997411|f||||f
17131261|NCT02079987|f||||f
17131262|NCT00506883|f||GT60||t
17131263|NCT01445951|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17138778|NCT02023268|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever from without prior written agreement of THEA|t
17138779|NCT04445688|f||||f
17131264|NCT00796315|f||OTHER|The Investigator and Sub-Investigators agree that all data, calculations, interpretations, opinions, and recommendations regarding the study will be the property of the Sponsor. The Investigator agrees to consider the results as information subject to confidentiality and use restrictions.|t
17131265|NCT05182554|f||||f
17131266|NCT00889265|f||||f
17131267|NCT00610987|f||||f
17131268|NCT00254501|t||||f
17131269|NCT00923130|f||||f
17175964|NCT00924781|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17131270|NCT00250835|t||||
17131271|NCT03221738|f||||f
17131272|NCT03885089|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131273|NCT00802204|t||||
17131274|NCT04489888|f||OTHER|If publication activity was not directed by the Sponsor, the investigator agreed to submit all manuscripts or abstracts to the Sponsor before submission. This allowed the Sponsor to protect proprietary information and to provide comments.|t
17131275|NCT06080451|f||||f
17131276|NCT00278993|f||||f
17131277|NCT01003275|f||LTE60||t
17131278|NCT02701387|t||||
17175965|NCT01653132|f||||f
17175966|NCT03828370|f||||f
17175967|NCT02677324|t||||
17175968|NCT00461331|f||||f
17175969|NCT03312751|f||||t
17175970|NCT00475423|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175971|NCT00046891|t||||
17175972|NCT02496676|f||||f
17175973|NCT01624870|f||LTE60||t
17175974|NCT03734705|f||||f
17175975|NCT01334827|f||||f
17175976|NCT04672252|t||||
17175977|NCT04391569|f||OTHER||t
17175978|NCT01431638|f||||f
17175979|NCT00773838|f||OTHER|The Sponsor have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17131279|NCT02043548|f||||f
17131280|NCT01500759|f||||f
17131281|NCT01430455|f||||f
17131282|NCT02408471|f||||t
17131283|NCT01014689|f||OTHER|Disclosure agreement in full force and effect for a period of 10 years.|t
17131284|NCT06706245|f||||f
17131285|NCT05634577|t||||
17131286|NCT01902966|t||||
17131287|NCT00783094|f||GT60||t
17131288|NCT03287219|f||||t
17131289|NCT00003460|f||||f
17131290|NCT02429414|t||||
17131291|NCT03245450|f||||f
17131292|NCT01784861|t||||
17131293|NCT05098041|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17131294|NCT03948178|f||||f
17131295|NCT00382993|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131296|NCT01046877|f||GT60||t
17131297|NCT03350217|f||||f
17131298|NCT00513500|t||||
17138780|NCT00299416|t||||
17138781|NCT01262599|f||||f
17138782|NCT01998399|f||||f
17175980|NCT03351101|f||OTHER|Contact sponsor directly for details.|t
17175981|NCT04445792|t||||
17175982|NCT04085367|f||||t
17175983|NCT03274999|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17175984|NCT01752712|f||||f
17175985|NCT01631656|t||||
17175986|NCT01545843|f||||f
17175987|NCT04243421|f||||f
17175988|NCT00470158|f||||f
17175989|NCT01249118|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17175990|NCT00880685|f||||f
17175991|NCT00997438|t||||
17175992|NCT01236118|f||GT60||t
17175993|NCT00095238|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17175994|NCT03505671|t||||
17175995|NCT01408329|f||||f
17175996|NCT04535167|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131299|NCT02248727|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17131300|NCT04639583|f||||f
17175997|NCT02038829|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17175998|NCT00075270|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131301|NCT00749996|f||LTE60||t
17131302|NCT00109707|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17131303|NCT03339921|f||||f
17131304|NCT00606086|f||OTHER|PI will not publish or present in any forum any writing or discussion that involves Sponsor intellectual property or clinical trial information until the study has been finalized and all completed case report forms have been delivered to Sponsor. The confidentiality obligations will remain in effect for 5 years from the date of termination or expiration of study agreement.|t
17175999|NCT03469570|f||||f
17176000|NCT04656275|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176001|NCT00300742|f||||f
17176002|NCT02361580|t||||
17176003|NCT03490981|f||||f
17176004|NCT02324543|t||||
17176005|NCT01995045|t||||
17176006|NCT00723203|t||||
17176007|NCT00740051|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17176008|NCT00274924|f||||f
17176009|NCT04739865|f||LTE60||t
17176010|NCT01903525|t||||
17176011|NCT04381988|t||||
17176012|NCT03025035|t||||
17176013|NCT05780268|f||||f
17176014|NCT02502006|t||||f
17176015|NCT00573287|f||||f
17176016|NCT03562767|t||||f
17176017|NCT01230125|f||OTHER|Contact sponsor directly for details.|t
17176018|NCT01589770|f||||f
17176019|NCT00725842|f||OTHER|Study data disclosure is prohibited; data and study results are the exclusive property of the Sponsor.|t
17176020|NCT00997113|t||||f
17176021|NCT01853618|f||||f
17131305|NCT02500628|t||||
17176022|NCT01658813|t||||f
17131306|NCT01441570|f||||f
17131307|NCT01627860|f||GT60||t
17176023|NCT05615935|f||||f
17176024|NCT00938886|t||||
17176025|NCT01075191|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17131308|NCT03215771|f||||f
17131309|NCT02039375|t||||
17138783|NCT01269047|f||||f
17176026|NCT02674854|f||||f
17138784|NCT00617591|t||||
17176027|NCT00913692|f||||f
17176028|NCT04738318|f||||f
17176029|NCT01226121|f||||f
17176030|NCT04231981|f||||f
17176031|NCT02889562|f||LTE60||t
17176032|NCT01943474|f||LTE60||t
17176033|NCT01470989|f||||f
17176034|NCT00969280|f||||f
17176035|NCT02119676|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17176036|NCT00570232|f||||f
17176037|NCT04148872|t||||
17176038|NCT01037088|t||||
17176039|NCT02216812|t||||
17176040|NCT01585584|f||||f
17176041|NCT00527488|f||OTHER|After the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Ferring Pharmaceuticals A/S (Ferring). Ferring reserves the right to be last author(s) in all publications related to this study. In the event of any disagreement in the content of any publication, both the Investigator's and Ferring's opinion will be fairly and sufficiently represented in the publication.|t
17183344|NCT00087568|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17176042|NCT01958827|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176043|NCT00266864|f||||f
17183345|NCT04394351|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17131310|NCT04770389|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17131311|NCT02613936|t||||
17131312|NCT02249143|f||||f
17131313|NCT00689871|f||OTHER|The timing of separate presentation or publication of the study by the PI is subject to mutual agreement in advance between the Sponsor and PI.|t
17131314|NCT01783080|f||||f
17131315|NCT02185404|f||||f
17131316|NCT02533063|f||||f
17131317|NCT04514523|t||||
17131318|NCT00708123|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131319|NCT01445821|t||||
17131320|NCT00814892|t||||
17131321|NCT04486950|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17131322|NCT00550680|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131323|NCT00562354|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131324|NCT03124771|t||||
17131325|NCT03693625|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131326|NCT00684255|f||||f
17176044|NCT03036800|f||||t
17131327|NCT01187953|f||OTHER||t
17131328|NCT01464307|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the Investigator will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17131329|NCT02997904|f||OTHER|Not without sponsor permission|t
17131330|NCT00761514|f||OTHER|Investigator shall provide Abbott at least sixty (60) days prior to publication or presentation, with a draft of the same for Abbott's review and comment, to ascertain whether any patentable subject matter or Abbott confidential infromariont are disclosed therin. Abbott shall return comment within sixty (60) days after receipt of the draft.|t
17131331|NCT02457637|f||||f
17131332|NCT04011280|f||||f
17131333|NCT01836783|f||||f
17131334|NCT01273883|t||||
17131335|NCT00159861|f||OTHER||t
17131336|NCT03349099|f||||f
17131337|NCT00456989|f||||f
17131338|NCT01290874|f||||f
17131339|NCT04194528|f||LTE60||t
17131340|NCT03829657|f||||t
17131341|NCT04867473|f||||f
17131342|NCT02549209|f||||f
17131343|NCT00333359|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131344|NCT02380716|f||||f
17131345|NCT02867995|t||||
17131346|NCT00938314|f||GT60||t
17131347|NCT01394939|f||||f
17131348|NCT03379662|f||||f
17131349|NCT03955133|f||||f
17131350|NCT01339559|f||GT60||t
17131351|NCT00623480|f||OTHER|The Investigator must send a draft manuscript of the publication or abstract to the Sponsor sixty days in advance of submission in order to obtain written approval prior to submission of the final version for publication. In case of a difference of opinion between the Sponsor and the Investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17131352|NCT03548558|f||||f
17131353|NCT03716869|t||||
17131354|NCT03273166|t||||
17138785|NCT04114539|f||OTHER|PI must consult their clinical trial agreement. In summary, PI shall have the right to publish, present or otherwise use the results for their research publication objectives, provided that such Publication does not disclose Confidential Information. PI shall submit in writing to Sponsor any material at least 90 days for review and comment. Sponsor shall advise PI of any information which is Confidential Information or which may impair Sponsor's ability to obtain patent protection.|t
17138786|NCT00376246|t||||
17138787|NCT01875510|t||||
17138788|NCT01711658|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17138789|NCT02918656|f||OTHER|The sponsor had no role in planning of research, its execution nor publication.|t
17138790|NCT04671615|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138791|NCT01072448|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17138792|NCT00877604|f||||f
17138793|NCT00418717|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17138794|NCT01400139|f||GT60||t
17138795|NCT02867163|t||||
17138796|NCT00249795|f||OTHER|Publication of the study will be made jointly in the name of all wholehearted collaborators. Other papers will be authored based on the contributions of the individuals to the overall study. Substudies with scientific merit which have received prior approval from the Steering Committee (SC) may be published in the names of the contributing investigators. A copy of all manuscripts will be provided to the sponsors for their review. The final decision to publish articles will be made by the SC.|t
17138797|NCT03179410|t||||
17138798|NCT02460978|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17138799|NCT01142193|f||||f
17138800|NCT03380000|f||||f
17138801|NCT03549429|t||||
17138802|NCT02562989|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17138803|NCT00588523|t||||
17138804|NCT03032510|f||||t
17138805|NCT03032250|t||||
17138806|NCT00383708|f||||f
17176045|NCT01077154|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176046|NCT05985980|f||||f
17131355|NCT02669017|f||OTHER|PI can publish after first multi-site publication, or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on the PI is the sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period that is more than 60 but less than or equal to 180 days from the time submitted to sponsor for review. The sponsor can't require changes to the communication and can't extend the embargo.|t
17131356|NCT00428974|f||||f
17131357|NCT02797808|f||||f
17131358|NCT03509350|t||||
17131359|NCT04338815|f||||f
17131360|NCT01425203|f||OTHER|Investigator agrees not to publish or publicly present any interim results of trial without prior written consent of Sponsor. Investigator further agrees to provide to Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. Sponsor has right to review and comment with respect to publications, abstracts, slides, data analysis and presentation|t
17131361|NCT00535132|f||LTE60||t
17131362|NCT02590588|t||||
17131363|NCT00414453|f||||f
17138807|NCT00318370|f||LTE60||t
17138808|NCT01750840|f||||f
17138809|NCT03627494|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138810|NCT03906136|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17138811|NCT00323310|f||OTHER|The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.|t
17138812|NCT00446641|f||||f
17138813|NCT01689324|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17138814|NCT01826448|f||||f
17138815|NCT00442611|f||||f
17183346|NCT00058240|f||LTE60||t
17183347|NCT02738775|f||||f
17131364|NCT01751308|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17131365|NCT00290433|t||||
17131366|NCT00822757|f||||f
17131367|NCT04749459|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131368|NCT03031301|f||OTHER|Permission to use study data is required|t
17176047|NCT02207946|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17131369|NCT03504410|f||||f
17131370|NCT02898259|t||||
17131371|NCT03016325|f||LTE60||t
17131372|NCT02970292|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's Prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17131373|NCT00814775|f||||f
17131374|NCT02671136|t||||
17131375|NCT00446511|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131376|NCT01471457|f||||f
17131377|NCT02692495|t||||
17131378|NCT00542269|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131379|NCT00652366|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131380|NCT01890642|f||||f
17131381|NCT03873714|f||||f
17131382|NCT03028870|f||LTE60||t
17131383|NCT01618942|t||||f
17131384|NCT00845650|f||||t
17131385|NCT00533442|f||||f
17131386|NCT03115567|f||||f
17131387|NCT00137111|t||||
17131388|NCT04703075|t||||
17131389|NCT01119248|t||||
17131390|NCT00317109|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131391|NCT01508702|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17131392|NCT01883635|f||||f
17131393|NCT02572752|t||||
17131394|NCT02911922|t||||
17131395|NCT04942925|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17131396|NCT02124564|f||GT60||t
17131397|NCT00254462|f||||f
17131398|NCT00631748|f||||f
17131399|NCT03315871|f||||f
17131400|NCT05032157|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131401|NCT00150592|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17131402|NCT03047980|f||||f
17131403|NCT02227693|f||OTHER||t
17131404|NCT00874120|f||OTHER|The sponsor reserves all publication and presentation rights.|t
17131405|NCT01823679|f||||f
17183348|NCT02992899|t||||
17131406|NCT02164981|f||||f
17131407|NCT02404103|t||||
17131408|NCT00328627|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17131409|NCT04682405|t||||
17131410|NCT03378076|f||||t
17131411|NCT01049035|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17131412|NCT01137773|t||||
17131413|NCT03927105|f||||f
17131414|NCT03470493|f||||f
17138816|NCT02431702|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17138817|NCT02108223|f||||f
17138818|NCT02252068|f||||f
17138819|NCT03250624|f||||t
17138820|NCT02809118|f||||t
17138821|NCT01597440|f||||f
17138822|NCT04241120|f||||f
17138823|NCT02408484|f||||f
17138824|NCT01488188|f||||f
17138825|NCT06103591|f||||f
17138826|NCT04083404|f||||f
17138827|NCT03008187|f||OTHER|The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17138828|NCT03805971|t||||
17138829|NCT03613818|f||||f
17138830|NCT03012594|f||||t
17138831|NCT03962634|t||||
17138832|NCT01510028|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17138833|NCT01355497|f||OTHER|"Provide Sponsor with an advance copy of any proposed results communication at least 60 days prior to the date of the planned submission or presentation and Sponsor shall have 60 days from receipt to request any changes. Sponsor may request a delay of up to 60 additional days.~The PI shall not present data until the earlier of Sponsor's publication of the results of all investigators participating in the Study or 18 months after completion of the Study at all participating sites."|t
17138834|NCT03235726|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138835|NCT00443846|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138836|NCT03744598|f||||f
17138837|NCT00810095|f||||f
17138838|NCT05301803|f||||f
17138839|NCT04521920|t||||
17138840|NCT01263314|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17138841|NCT03436147|t||||
17138842|NCT00282568|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or until 18 months have elapsed following study completion. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document.|t
17138843|NCT03006926|f||||t
17131415|NCT02684981|t||||f
17131416|NCT00820898|f||LTE60||t
17131417|NCT01000662|t||||f
17131418|NCT01652287|t||||
17131419|NCT00763139|f||||f
17131420|NCT02095535|f||||f
17138844|NCT03689972|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17131421|NCT01877187|t||||f
17131422|NCT03756038|t||||
17131423|NCT01789814|f||||f
17131424|NCT05526833|t||||
17131425|NCT01289015|f||OTHER|Institution and Principal Investigator agreed not to individually publish or assist other person or entity with any articles, papers, and/or make presentations, speeches referring to the protocol, clinical trial data, the study, or the study drug or any data, results, materials, or information generated or obtained by the Institution or the Principal Investigator without the prior written consent of Merz, which consent may be withheld in the sole discretion of Merz.|t
17131426|NCT03799458|f||||f
17131427|NCT03621280|f||OTHER|The disclosure restrictions aligned with local requirements, allow Sponsor time to submit a multi-center publication after study completion prior to individual site publication. The Sponsor could review results communications before release, request changes and/or removal of confidential information and prohibit communication about trial results for more than 60 days but less than or equal to 6 months from the time submitted for Sponsor review. The Sponsor cannot extend the embargo.|t
17131428|NCT01709149|f||||f
17131429|NCT02192827|f||||f
17131430|NCT02918773|t||||
17131431|NCT03001674|f||||f
17131432|NCT02559687|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17138845|NCT01838213|t||||
17138846|NCT00324272|t||||
17138847|NCT02417064|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17138848|NCT00990249|t||||
17138849|NCT00371540|f||||f
17138850|NCT01548417|f||||f
17138851|NCT04583969|f||||t
17138852|NCT01057862|f||||f
17138853|NCT00415584|t||||
17138854|NCT02640755|f||OTHER||t
17183349|NCT04574362|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176048|NCT00811642|f||OTHER|Principal Investigator (PI) agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of the Sponsor. PI further agrees to provide to the Sponsor thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the Protocol study. The sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts.|t
17176049|NCT05419999|f||||f
17131433|NCT01968135|f||||f
17131434|NCT00793650|t||||
17183350|NCT01060384|f||||f
17131435|NCT00983983|f||||f
17131436|NCT03759665|f||||f
17131437|NCT01515657|f||OTHER|Standard confidentiality agreement|t
17176050|NCT05744258|t||||
17183351|NCT02002767|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17176051|NCT01848041|f||||t
17131438|NCT00714792|t||||f
17131439|NCT01857869|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131440|NCT03988335|f||||t
17131441|NCT02482675|f||||f
17131442|NCT00689572|f||||f
17131443|NCT00283075|t||||
17131444|NCT03711500|f||||f
17131445|NCT01902290|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17131446|NCT03389854|t||||
17131447|NCT00907101|f||GT60||t
17176052|NCT01163318|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176053|NCT06432088|f||||f
17176054|NCT01006603|f||OTHER|No publication or presentation may include any of AZ's confidential information without AZ's prior written approval.|t
17176055|NCT01481129|f||LTE60||t
17131448|NCT03042715|f||||f
17131449|NCT00586209|f||||f
17131450|NCT02199080|f||||f
17131451|NCT02250274|f||||f
17131452|NCT01277549|f||LTE60||t
17131453|NCT02018627|f||||f
17131454|NCT01618214|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17131455|NCT00391222|f||GT60||t
17131456|NCT00574275|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17131457|NCT00558870|t||||
17131458|NCT01181011|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17131459|NCT02788747|f||LTE60||t
17131460|NCT01967550|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17176056|NCT03050775|t||||
17176057|NCT01206387|f||||f
17131461|NCT00844753|f||||f
17131462|NCT02425826|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17176058|NCT02155946|t||||
17176059|NCT00706849|f||OTHER|After the multicenter publication or 12 months after completion of the study the PI may publish the results of his/her data from the study. The PI shall provide the sponsor with an advance copy at least 60 days prior to planned submission and the Sponsor shall have 60 days to review (contracts have variable timeframes; maximum times are stated here). The sponsor may request the deletion of any confidential information, or a delay in submission for an additional period not to exceed 90 days.|t
17131463|NCT00853671|f||LTE60||t
17176060|NCT01611454|f||||f
17131464|NCT03441178|f||LTE60||t
17138855|NCT04075396|f||OTHER|All draft publications, including abstracts or detailed summaries of any proposed presentations, must be submitted to the Sponsor at the earliest practicable time for review, but in any event not less than 30 days before submission or presentation unless otherwise set forth in the clinical trial agreement (CTA).|t
17176061|NCT02873585|t||||
17176062|NCT03269552|f||||f
17131465|NCT03649061|f||OTHER|Institution/PI may only publish the Results provided that Sponsor has duly published the main Study publication. Once the main Study publication has been duly published by the Sponsor, Institution/PI are entitled to publish the Results provided that Sponsor has granted its prior written approval with Institution's/PI's proposed publication. If SPONSOR did not respond within 90 days, the institution/PI may proceed with the publication.|t
17183352|NCT00812929|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131466|NCT00507559|f||||f
17131467|NCT00400881|t||||f
17183353|NCT00883389|f||||f
17183354|NCT00211081|f||||f
17183355|NCT01332305|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176063|NCT00920907|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17176064|NCT02616601|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17131468|NCT00858858|t||||
17131469|NCT01471782|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17131470|NCT01425008|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17131471|NCT00939900|f||||f
17183356|NCT01600040|t||||
17131472|NCT01314716|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131473|NCT00562588|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17131474|NCT01452152|f||||f
17131475|NCT00313209|f||OTHER|The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.|t
17131476|NCT03784079|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131477|NCT04099251|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17131478|NCT01995071|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131479|NCT01783678|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131480|NCT02049944|f||||f
17131481|NCT00522431|f||OTHER|Publication statement in clinical trial agreement|t
17131482|NCT03548051|f||LTE60||t
17131483|NCT03402607|f||||f
17131484|NCT03874377|f||||f
17131485|NCT01745146|f||||f
17176065|NCT01490723|t||||
17176066|NCT04389970|f||||f
17176067|NCT04179890|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176068|NCT02579928|f||||f
17176069|NCT02352922|f||||f
17183357|NCT04713748|t||||
17131486|NCT04623242|f||OTHER|PI's may publish data and study results individually after the earlier of: 1) multi-center Publication is published; 2) no multi-center publication is submitted within 18 months after conclusion, abandonment, or termination of the Protocol at all sites; or 3) sponsor confirms in writing there will be no multi-center Publication. PI must submit results communications to the sponsor at least 75 days prior to submission or presentation. Sponsor can require changes to the communication.|t
17131487|NCT00647556|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17131488|NCT01480297|t||||
17183358|NCT00113516|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131489|NCT00179309|t||||f
17183359|NCT00642304|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131490|NCT00488982|t||||
17131491|NCT02363686|t||||
17131492|NCT01780831|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17131493|NCT02128230|t||||f
17131494|NCT01849172|t||||
17131495|NCT02041377|f||GT60||t
17131496|NCT01857713|f||||f
17131497|NCT01662895|f||||f
17131498|NCT00797732|f||||f
17176070|NCT03754972|f||||f
17176071|NCT03422627|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176072|NCT05293392|f||||f
17176073|NCT00934648|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176074|NCT01993836|t||||
17176075|NCT02409914|f||||f
17176076|NCT02195687|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176077|NCT04369924|t||||f
17176078|NCT00708201|f||||f
17176079|NCT00282464|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17176080|NCT00812487|f||||f
17176081|NCT02360605|f||||f
17131499|NCT03958552|t||||
17131500|NCT00401752|f||LTE60||t
17131501|NCT04607733|f||GT60||t
17131502|NCT00967551|f||||f
17131503|NCT01797575|f||||f
17131504|NCT02941627|f||OTHER|No independent manuscript is submitted for publication until the multicentre manuscript is accepted for publication. PI can publish results from his/her own site after multicentre manuscript is accepted for publication or 18 months after study completion. Independent manuscript must be submitted to Sponsor for review at least 30 days prior to publication. Sponsor can request within the 30-day review period, PI shall delay proposed communication up to 60 days from the date of Sponsor's request.|t
17131505|NCT03099486|t||||
17131506|NCT03594227|f||||f
17131507|NCT00790907|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131508|NCT01888640|f||||f
17131509|NCT00684788|f||||f
17176082|NCT00290407|t||||f
17176083|NCT01499862|f||||f
17176084|NCT01117792|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."|t
17176085|NCT01721577|f||OTHER|I am not privvy to all the agreements that exist. But the original PI left the institution where this study was conducted, and he left with a separation agreement in place. I (Crista Brawley) am named in that agreement. Please direct questions to Dr. Robert Aiken.|t
17131510|NCT01265550|t||||
17131511|NCT00623428|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131512|NCT03436862|f||GT60||t
17131513|NCT01212302|f||||f
17131514|NCT02342015|f||||f
17131515|NCT04336995|f||||f
17131516|NCT01692301|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17131517|NCT04352439|t||||
17131518|NCT01929408|f||||f
17131519|NCT02228590|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a mult-center publication; provided however, if a mult-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, institution and Investigator shall be free to publish.|t
17176086|NCT01277081|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176087|NCT01653028|f||LTE60||t
17176088|NCT01055496|f||GT60||t
17176089|NCT02524977|f||||f
17176090|NCT00181623|t||||
17176091|NCT00963677|t||||
17176092|NCT01361854|t||||
17176093|NCT01673282|f||GT60||t
17176094|NCT03935399|t||||
17176095|NCT01112683|f||||f
17131520|NCT02109484|f||||f
17131521|NCT00265538|t||||f
17131522|NCT01097863|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussion, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17131523|NCT00293579|t||||
17131524|NCT03127384|f||||t
17131525|NCT00763750|f||||f
17131526|NCT00960843|f||LTE60||t
17131527|NCT00490451|f||GT60||t
17131528|NCT01223703|f||||f
17131529|NCT00784654|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17131530|NCT01026831|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131531|NCT04249687|f||GT60||t
17176096|NCT01931709|f||||f
17176097|NCT02106923|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176098|NCT03485495|f||||t
17131532|NCT01180660|f||||f
17131533|NCT01550562|f||||t
17131534|NCT04036968|t||||
17131535|NCT02500121|f||||f
17131536|NCT03730116|f||||t
17131537|NCT00852995|f||LTE60||t
17131538|NCT00498173|t||||
17131539|NCT01110200|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131540|NCT03627403|t||||
17131541|NCT04518462|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication \</= 18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for \</=120 days to allow Sponsor to protect its interests in Inventions.|t
17131542|NCT02866279|f||||f
17131543|NCT04418076|f||||f
17131544|NCT00805480|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17131545|NCT04311502|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17131546|NCT03040999|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17131547|NCT03368170|f||||f
17131548|NCT02068547|t||||
17131549|NCT03657043|f||||t
17176099|NCT01323920|t||||
17176100|NCT02915874|f||||f
17176101|NCT03103061|f||||f
17176102|NCT01056380|f||OTHER|Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.|t
17176103|NCT03901456|t||||
17176104|NCT03964337|t||||
17176105|NCT00947505|f||||f
17176106|NCT01715129|f||||f
17176107|NCT00133978|f||||f
17176108|NCT02068768|f||||f
17176109|NCT00555425|f||||f
17176110|NCT02128100|t||||
17176111|NCT02995369|t||||f
17131550|NCT01736579|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxalta requires a review of results communications (eg, for confidential information) ≥30 days prior to submission or communication. Baxalta may request an additional delay of ≤60 days eg, for intellectual property protection.|t
17131551|NCT02240654|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131552|NCT02543528|f||GT60||t
17131553|NCT01408147|f||||f
17131554|NCT01765673|f||||f
17131555|NCT01042600|f||||f
17183360|NCT01646671|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17183361|NCT00982189|f||||f
17183362|NCT02074735|f||||f
17183363|NCT00812812|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183364|NCT03755765|f||||f
17131556|NCT01975922|f||||f
17131557|NCT02643004|f||OTHER||t
17131558|NCT05048719|f||GT60||t
17131559|NCT04541004|f||LTE60||t
17131560|NCT00141765|t||||
17131561|NCT00605085|f||OTHER||t
17131562|NCT00621504|f||||f
17131563|NCT00731874|t||||f
17131564|NCT03257267|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17176112|NCT03769376|t||||
17176113|NCT00400153|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17176114|NCT01423604|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17176115|NCT00424255|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176116|NCT02186301|f||OTHER|All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.|t
17176117|NCT00371761|f||OTHER|Principal Investigator and Institution agree not to publish or publicly present any interim results of the study. Principal Investigator and Institution further agree to provide 45 days written notice to Sponsor prior to submission for publication or presentation to permit Sponsor to review drafts of abstracts and manuscripts for publication.|t
17176118|NCT03560739|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17176119|NCT03361176|f||||f
17176120|NCT03123185|t||||f
17176121|NCT05386823|f||||f
17183365|NCT03091751|f||OTHER|Site may publish results from the study, after providing Sponsor 30 days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At Sponsor's request, site will remove any confidential information (other than study results) and site will, upon Sponsor's request, delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor interventions.|t
17131565|NCT01979523|f||LTE60||t
17183366|NCT04455893|f||||f
17183367|NCT01161329|f||||f
17183368|NCT00678691|f||||f
17183369|NCT01150838|t||||
17183370|NCT00354224|t||||
17131566|NCT03311711|t||||
17131567|NCT02229552|f||||f
17131568|NCT03657368|t||||
17131569|NCT01623271|t||||
17131570|NCT00706134|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17131571|NCT01982292|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17131572|NCT02730884|t||||
17131573|NCT00746252|f||||f
17131574|NCT00082888|f||LTE60||t
17131575|NCT02239939|f||||f
17131576|NCT01514682|f||||f
17131577|NCT01870401|f||||t
17131578|NCT01602692|t||||
17183371|NCT01599650|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17183372|NCT03402243|f||||f
17183373|NCT00684424|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183374|NCT02410811|t||||
17183375|NCT00057746|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17183376|NCT00427804|f||||f
17183377|NCT00439140|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17183378|NCT04154631|t||||
17183379|NCT03012386|f||||f
17183380|NCT01032135|f||||f
17183381|NCT01466192|f||OTHER||t
17183382|NCT01613339|t||||f
17183383|NCT00700011|f||||f
17183384|NCT00678561|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183385|NCT00437034|f||LTE60||t
17131579|NCT02105454|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17131580|NCT01667471|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176122|NCT01083173|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176123|NCT02519387|f||OTHER|Data emerging from the study cannot be released by the PI without permission from the sponsor.|t
17176124|NCT02288377|f||||f
17176125|NCT02554279|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17176126|NCT01933789|f||||f
17176127|NCT01966432|f||||f
17176128|NCT00930982|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor 30 days in advance of submission in order to obtain written approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion, the contents of the publication will be discussed in order to find a solution that satisfies both parties.|t
17176129|NCT01609478|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176130|NCT04966741|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17176131|NCT02783469|t||||
17176132|NCT00957593|t||||
17176133|NCT03160859|t||||
17176134|NCT02953509|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183386|NCT01910064|f||||f
17183387|NCT00853658|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17183388|NCT01976845|f||||f
17183389|NCT01157533|t||||f
17131581|NCT00272038|t||||
17131582|NCT00493870|f||GT60||t
17131583|NCT02721355|f||||f
17131584|NCT03605680|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17131585|NCT00356278|f||||f
17131586|NCT05594173|t||||
17131587|NCT03126760|f||||t
17183390|NCT03246529|f||OTHER|The restrictions are as per the signed agreement with each PI and institution.|t
17183391|NCT01209624|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183392|NCT03117387|t||||
17183393|NCT00441337|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183394|NCT06748040|t||||
17183395|NCT00320281|f||||f
17183396|NCT01856140|f||||f
17183397|NCT00827372|t||||
17183398|NCT02293005|t||||
17183399|NCT04011475|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17183400|NCT02595567|f||||f
17183401|NCT00941733|f||GT60||t
17183402|NCT05036642|t||||
17183403|NCT00612066|f||||f
17183404|NCT00630877|f||OTHER|Provide ABBOTT at least sixty (60) days prior to submission for review, ABBOTT shall return comments within sixty (60) days of receipt of draft. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period.|t
17131588|NCT01592760|f||||f
17131589|NCT04312009|t||||
17131590|NCT01008280|f||||f
17131591|NCT01968460|f||||f
17131592|NCT01678144|f||LTE60||t
17176135|NCT00484185|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176136|NCT00459056|f||||f
17176137|NCT02522871|f||||t
17176138|NCT00509262|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17176139|NCT00558571|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17176140|NCT02793622|t||||
17176141|NCT01146860|f||||f
17176142|NCT01092832|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. PI will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. PI may not disclose previously undisclosed confidential information other than study results.|t
17176143|NCT00495079|f||LTE60||t
17176144|NCT00393042|f||||f
17176145|NCT00330161|f||LTE60||t
17183405|NCT01529645|f||GT60||t
17183406|NCT00048724|f||OTHER|The investigator agrees to provide review copies to the sponsor 30 days prior to submission for publication or presentation. The sponsor shall have editorial rights and the right to review and comment on the data analysis and presentation. If the parties disagree, investigator agrees to meet with the sponsor's representatives for the purpose of making good faith efforts to discuss and resolve any such issues.|t
17183407|NCT02595684|t||||
17131593|NCT00539695|t||||
17131594|NCT02264990|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176146|NCT01150474|t||||
17176147|NCT02290431|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17176148|NCT00432601|t||||
17176149|NCT00821327|f||||f
17176150|NCT03122301|t||||
17176151|NCT00459979|t||||
17176152|NCT00453388|t||||
17176153|NCT00056498|f||||f
17176154|NCT01007253|t||||
17176155|NCT00814801|f||OTHER|The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17176156|NCT04856865|f||||t
17176157|NCT01163032|f||||f
17176158|NCT02751931|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study after Sponsor publication of multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17176159|NCT02380690|t||||
17176160|NCT04647890|f||LTE60||t
17176161|NCT00817479|t||||
17183408|NCT02863354|t||||
17183409|NCT03235024|f||OTHER|Sponsor shall have 45 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional one hundred twenty (120) days to enable Sponsor to seek patent protections.|t
17183410|NCT01632800|t||||
17131595|NCT00267748|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131596|NCT01294800|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17131597|NCT01895322|f||||f
17131598|NCT02275338|f||||f
17131599|NCT02154386|f||||f
17131600|NCT02465073|t||||
17131601|NCT02501265|f||||f
17131602|NCT01827670|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131603|NCT03303794|t||||
17131604|NCT02365714|t||||f
17131605|NCT03603496|f||||f
17131606|NCT00774345|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17131607|NCT00835237|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131608|NCT00075504|f||LTE60||t
17131609|NCT02685709|f||||t
17131610|NCT02171611|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131611|NCT00264238|t||||
17131612|NCT01411085|f||||f
17131613|NCT01332357|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131614|NCT01197326|f||LTE60||t
17131615|NCT02627495|t||||
17131616|NCT00880893|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17131617|NCT00479154|t||||f
17131618|NCT01662440|f||LTE60||t
17131619|NCT00112905|f||LTE60||t
17131620|NCT02600507|f||||t
17131621|NCT00600015|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17131622|NCT00616109|f||||f
17131623|NCT04872101|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-center publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17131624|NCT00971945|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17131625|NCT03354663|f||LTE60||t
17131626|NCT03691974|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights|t
17131627|NCT03354754|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17131628|NCT01661140|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176162|NCT04808999|t||||
17176163|NCT04030026|f||||f
17176164|NCT00523367|t||||f
17176165|NCT01278927|f||||f
17131629|NCT00691483|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131630|NCT00439946|f||OTHER|Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17131631|NCT01391000|f||||f
17131632|NCT00049673|f||||f
17131633|NCT00817531|t||||
17131634|NCT02896595|t||||
17131635|NCT02475681|f||OTHER|Institution/Investigator will not publish or publicly present any study results without prior approval or prior to 12 months following completion of the study.|t
17131636|NCT03678402|f||||f
17131637|NCT02323698|f||||f
17131638|NCT01069562|t||||
17131639|NCT03325673|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17131640|NCT01659320|t||||f
17131641|NCT00590590|f||OTHER|Investigator shall not publish, or seek to publish, either in whole or in part, any results of the Clinical Investigation without the written consent of the Sponsor.|t
17131642|NCT02025426|t||||
17131643|NCT00132132|t||||
17131644|NCT00494091|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131645|NCT03300466|f||||t
17131646|NCT00452699|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131647|NCT00326898|f||LTE60||t
17131648|NCT03847987|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131649|NCT01265459|f||LTE60||t
17131650|NCT03733392|f||||t
17131651|NCT01166230|f||GT60||t
17131652|NCT00883337|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The investigator provides the sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.~The sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17131653|NCT00527605|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131654|NCT01363986|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131655|NCT01637142|f||GT60||t
17131656|NCT02111564|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17131657|NCT00687362|f||OTHER|"The PI agrees not to publish/publicly present any interim results of the Study without prior written consent of Sponsor. The PI further agrees to~provide 30 days written notice to Sponsor prior to submission for publication/presentation to allow Sponsor to review materials which report any results of the Study. Sponsor shall have the right to review/comment on~any presentation, which include editorial rights to ensure protection of confidential information, accuracy, and fair balance."|t
17131658|NCT02354703|f||||f
17131659|NCT04415073|f||||f
17131660|NCT03468309|f||||f
17131661|NCT01707472|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131662|NCT03790683|f||||f
17131663|NCT01485627|f||||f
17131664|NCT02246062|f||||f
17131665|NCT02112370|f||||f
17131666|NCT02728830|t||||
17131667|NCT01142726|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17131668|NCT01568593|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever from without prior written agreement of THEA|t
17131669|NCT00143455|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131670|NCT01325428|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131671|NCT03713944|f||||f
17131672|NCT02111993|f||||f
17183411|NCT01243944|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17131673|NCT00419380|f||||f
17131674|NCT00440505|t||||
17131675|NCT04074928|f||||f
17131676|NCT00758745|f||OTHER|All study data is held confidential and not be disclosed to a 3rd party without written consent from Alcon Laboratories for a period of 3 years.|t
17131677|NCT02703311|f||||t
17131678|NCT01294579|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17131679|NCT02069899|f||OTHER|The sponsor can review results communication prior to public release. The PI shall consider the comments received from the sponsor and shall delete any confidential information. The sponsor may require the delay of publication submission if it contains any patentable subject matter which requires protection.|t
17131680|NCT02511730|f||||f
17131681|NCT04417894|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17131682|NCT00262873|t||||f
17131683|NCT03440814|f||OTHER|To avoid disclosures that could jeopardize proprietary rights, ensure accuracy of the study data, and ensure integrity is maintained, PI must submit all manuscripts, abstracts, and presentations related to this study to the Soleno for review at least 45 days before their release or as specified in separate written agreements.|t
17131684|NCT02751502|t||||
17131685|NCT02678390|t||||f
17183412|NCT01166984|f||||f
17183413|NCT01416805|f||||f
17183414|NCT02802345|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17183415|NCT04632940|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17183416|NCT02661828|t||||
17183417|NCT05857527|f||||f
17131686|NCT01437397|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the investigator and sponsor.|t
17131687|NCT00371865|f||||f
17183418|NCT02737566|f||||f
17183419|NCT02799082|f||OTHER|A publication or presentation of the study results may be planned and initiated by everybody of the scientific personnel involved in this clinical trial but not before the integrated report has been issued. Each party generating the manuscript for publication should allow the other parties a sufficient time in which to review and comment upon the prepublication manuscript.|t
17183420|NCT05038137|t||||f
17183421|NCT00245557|f||||f
17183422|NCT01748994|f||||f
17183423|NCT04378933|t||||
17131688|NCT04817111|f||LTE60||t
17131689|NCT01632566|f||GT60||t
17183424|NCT00727857|f||OTHER|The sponsor can review results communications prior to public release and can embargo trial results communications up to 150 days to permit actions necessary to preserve sponsor's intellectual property. Sponsor can request changes to the results communication only for the purpose of removing non study related information that is proprietary and confidential to sponsor. Sponsor can require delay of a results communication until the study has been completed at all participating sites.|t
17183425|NCT02181231|f||||f
17131690|NCT01318109|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17131691|NCT01328951|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183426|NCT02520531|f||LTE60||t
17183427|NCT01159067|t||||
17183428|NCT03074734|f||||f
17183429|NCT01723904|f||GT60||t
17131692|NCT04042103|f||||t
17131693|NCT03711578|f||||f
17131694|NCT02193074|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17183430|NCT03251924|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183431|NCT01193556|f||LTE60||t
17183432|NCT02617589|f||LTE60||t
17183433|NCT02678039|f||||f
17183434|NCT01121211|t||||
17183435|NCT00835406|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17183436|NCT00733343|f||||f
17183437|NCT02138214|t||||
17183438|NCT01362907|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17183439|NCT02158039|t||||
17183440|NCT01196871|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17183441|NCT01744730|f||||f
17183442|NCT03509948|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17183443|NCT01334866|f||LTE60||t
17183444|NCT00495716|t||||
17131695|NCT01534533|t||||
17131696|NCT05110300|t||||
17131697|NCT05159648|t||||
17131698|NCT03036293|f||||t
17131699|NCT00648375|t||||
17131700|NCT00679952|f||||f
17131701|NCT01578980|t||||
17131702|NCT01535365|t||||
17131703|NCT02615990|f||||f
17131704|NCT03522324|f||||f
17131705|NCT00925015|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17131706|NCT02396732|t||||
17183445|NCT04519658|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo for up to 90 days.|t
17183446|NCT01071512|t||||
17183447|NCT01427296|f||||t
17183448|NCT05267171|f||||t
17131707|NCT01368835|f||LTE60||t
17131708|NCT02754726|t||||
17131709|NCT01777152|f||||t
17131710|NCT02792842|f||||f
17131711|NCT02952222|t||||
17131712|NCT00586573|f||||f
17131713|NCT01496885|f||||f
17131714|NCT03446885|f||||f
17131715|NCT05726318|t||||f
17131716|NCT04589988|f||||f
17131717|NCT03524339|t||||
17131718|NCT01084265|f||OTHER||t
17131719|NCT01098071|f||OTHER|The principal investigator and his co-workers agree not to publish or publicly present any results of the study without the prior written consent and approval of the sponsor.|t
17183449|NCT02076412|f||||f
17131720|NCT03326843|f||OTHER|Following a multicenter publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Institution shall remove from the proposed publication any information that is considered confidential other than Study data and results.|t
17131721|NCT01081795|f||OTHER|The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17131722|NCT00661271|f||||f
17131723|NCT01707693|t||||
17183450|NCT02665975|f||||f
17183451|NCT00799617|f||||f
17183452|NCT04545515|f||||t
17183453|NCT00958880|f||||f
17131724|NCT03557892|f||||f
17131725|NCT03847610|t||||
17131726|NCT03298022|f||||f
17131727|NCT01787916|f||OTHER||t
17131728|NCT03099707|t||||
17131729|NCT01445769|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17131730|NCT04906980|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17131731|NCT02340338|f||||f
17131732|NCT03496428|f||||f
17183454|NCT01848990|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17183455|NCT01712984|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17183456|NCT00955266|t||||
17183457|NCT02755831|f||||f
17183458|NCT01720069|f||OTHER|The terms and conditions of Vectura's agreements with its investigators may vary. Publication may be delayed for Sponsor review and revisions/deletions can be required. Furthermore, a delay to publication may be required by the Sponsor in order to take steps to protect its proprietary information and/or intellectual property rights.|t
17183459|NCT00508742|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183460|NCT01228929|t||||
17183461|NCT02002494|t||||
17183462|NCT02460224|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17183463|NCT01394926|f||||f
17183464|NCT03146650|t||||
17183465|NCT01312766|f||||f
17183466|NCT03333486|t||||
17183467|NCT00774995|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183468|NCT02143518|f||||f
17131733|NCT00343889|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17131734|NCT01951820|f||||f
17131735|NCT01967537|f||||f
17131736|NCT05130463|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17183469|NCT00452335|f||GT60||t
17183470|NCT01818336|f||||f
17183471|NCT02139644|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17183472|NCT01010984|t||||f
17131737|NCT02864368|f||||f
17131738|NCT03652662|f||||f
17131739|NCT03861559|f||OTHER|The principal investigator and his co-workers agree not to publish or publicly present any results of the study without the prior written consent and approval of the sponsor.|t
17131740|NCT00487539|f||OTHER|12 months after study ends, Sponsor will be provided with a copy of the materials at least 45 days prior to submission, with details of proposed date, journal or conference name of publication \& it will have 30 days post receipt to send a written request that the publication be delayed on the basis it exposes intellectual property that requires propriety protection but it will be only for 60 days after which Investigator will be free to publish. The participation of Sponsor will be acknowledged.|t
17131741|NCT00879697|t||||f
17131742|NCT00088374|f||||f
17131743|NCT03499028|f||||f
17183473|NCT02192684|t||||
17183474|NCT00608829|f||OTHER|Gore has the right to review disclosures, requesting a delay of more than 60 days but less than or equal to 180 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17183475|NCT02602288|t||||f
17183476|NCT01310413|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131744|NCT03595553|f||GT60||t
17131745|NCT00903175|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17131746|NCT00106171|f||||f
17183477|NCT02564471|t||||
17183478|NCT02805257|t||||
17183479|NCT01621373|f||||f
17183480|NCT01965067|f||||f
17183481|NCT02033889|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the Sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17183482|NCT02080091|f||LTE60||t
17183483|NCT03143829|f||||f
17183484|NCT02717949|t||||
17183485|NCT02391948|f||||f
17183486|NCT03843502|f||||f
17183487|NCT02886572|t||||
17183488|NCT01176591|f||||f
17183489|NCT00982319|f||||f
17183490|NCT01923181|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17183491|NCT01863446|f||||f
17183492|NCT02312310|f||||f
17183493|NCT03603964|f||||t
17131747|NCT01687712|f||OTHER|Contract agreement. Results may not be published or referred to, in whole or in part, without the prior express written consent of the Sponsor.|t
17131748|NCT01785134|f||||f
17183494|NCT00563797|t||||
17183495|NCT04317586|f||LTE60||t
17131749|NCT03074474|f||||f
17131750|NCT02987621|t||||
17131751|NCT01627899|f||||f
17138856|NCT03434041|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17138857|NCT03363165|f||||f
17138858|NCT02255760|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17138859|NCT00618813|f||OTHER|Must obtain prior Sponsor approval.|t
17138860|NCT00003838|t||||
17138861|NCT01809197|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138862|NCT02052141|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17138863|NCT02420990|t||||
17138864|NCT03326583|f||||f
17138865|NCT01592006|t||||
17138866|NCT02157103|t||||
17138867|NCT00228943|f||||f
17138868|NCT04685538|f||||f
17138869|NCT01921452|f||OTHER|The disclosure restriction on the PI is that the sponsor can review the results communications prior to public release, and the sponsor can embargo communications regarding trial results if the PI does not get approval from the sponsor.|t
17138870|NCT01525667|f||||f
17138871|NCT01784614|f||GT60||t
17138872|NCT01235507|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138873|NCT02475629|f||||f
17138874|NCT02242760|f||||t
17138875|NCT00643097|f||||f
17138876|NCT02754661|f||||f
17138877|NCT04423757|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138878|NCT02709109|f||OTHER||t
17138879|NCT05563714|f||||f
17138880|NCT01815580|t||||f
17138881|NCT02228564|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17138882|NCT03061812|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17138883|NCT01802515|f||||f
17138884|NCT00517413|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138885|NCT01502761|f||||f
17138886|NCT02668952|t||||
17138887|NCT00441727|f||OTHER||t
17138888|NCT02100410|t||||f
17138889|NCT01237223|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17131752|NCT04685876|f||||f
17131753|NCT01003210|f||||f
17138890|NCT04586673|t||||
17138891|NCT05686044|f||OTHER|The terms and conditions of Annovis Bio's agreements with its investigators may vary. However, Annovis Bio does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data for a clinical trial or for 12 months.|t
17138892|NCT00407550|t||||
17138893|NCT00641706|f||LTE60||t
17138894|NCT02057276|t||||
17138895|NCT01599806|f||OTHER|Principal investigator submits the proposed publication and /or presentation to AZAB for review at least 60 days prior to proposed publication and/or presentation. If AZAB, requests in writing, then PI shall withhold publication and/or presentation for an additional 90 days to allow AZAB to protect its intellectual rights.|t
17138896|NCT02023918|f||||f
17138897|NCT00391807|f||LTE60||t
17131754|NCT00271817|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131755|NCT00931359|f||GT60||t
17131756|NCT04153188|f||||f
17131757|NCT00700271|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or publication of the trial results in their entirety.|t
17138898|NCT01266070|t||||
17131758|NCT00861744|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131759|NCT05107765|t||||
17176166|NCT00282347|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176167|NCT02361346|f||OTHER||t
17176168|NCT00782795|t||||
17176169|NCT04480424|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17176170|NCT02782923|t||||
17176171|NCT03368118|f||||f
17176172|NCT00993044|f||||f
17176173|NCT00734747|f||LTE60||t
17176174|NCT01275339|f||||f
17176175|NCT02469038|f||||f
17176176|NCT03028350|f||LTE60||t
17176177|NCT02777749|f||||f
17176178|NCT01850602|f||||f
17176179|NCT01857310|f||||f
17176180|NCT02497976|f||||f
17176181|NCT00584740|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17176182|NCT00121173|t||||f
17176183|NCT03915860|f||OTHER||t
17183496|NCT00807092|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones. This includes the right to not release interim results of clinical trials. At the end of the trial, manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17183497|NCT04116229|t||||f
17183498|NCT01794949|t||||
17183499|NCT03003676|f||||t
17183500|NCT05209191|f||||f
17183501|NCT01229228|f||||f
17183502|NCT02443298|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183503|NCT04627727|f||||f
17183504|NCT03759223|f||||f
17131760|NCT01295216|f||||f
17131761|NCT03124563|f||||f
17131762|NCT04365465|f||||f
17131763|NCT00264004|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17131764|NCT01535729|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131765|NCT01262365|f||GT60||t
17131766|NCT02322710|f||||f
17131767|NCT04161131|t||||f
17131768|NCT03905863|f||||f
17131769|NCT00532480|f||||f
17176184|NCT02195011|f||GT60||t
17176185|NCT01325792|f||OTHER|Proposed publications/public disclosures within 60 days prior to submission will be provided to sponsor for review by Investigator. Sponsor may make modifications to the proposals only as reasonably necessary to ensure the proper use of any references to itself, its trademarks, and trade names. Sponsor may correct inaccuracies in any technical specifications or descriptions of the biosynthetic material.|t
17176186|NCT04831788|t||||
17176187|NCT00768469|f||LTE60||t
17183505|NCT03698773|t||||
17131770|NCT02392013|f||||f
17131771|NCT05499559|f||||f
17131772|NCT04681170|f||OTHER|The investigators may use the study data only after prior written consent of Amryt Pharmaceuticals DAC. Amryt will review the proposed publication/disclosure prior to submission for publication, presenting, using for instructional purposes or otherwise disclosing the study results. If Amryt supposes the publication/disclosure to risk its ability to patent any invention related to the study, the publication/disclosure will be modified or delayed to allow Amryt to file a patent application.|t
17131773|NCT04986202|f||||f
17131774|NCT02468648|t||||
17138899|NCT04080752|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17138900|NCT01585168|f||||f
17176188|NCT03835728|f||||f
17176189|NCT00722371|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17176190|NCT02635646|f||||f
17176191|NCT03189381|t||||
17183506|NCT00908960|t||||f
17183507|NCT05074433|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17176192|NCT03761797|t||||
17176193|NCT00251004|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176194|NCT00645788|f||OTHER|The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17176195|NCT03149848|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176196|NCT01244490|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176197|NCT01486810|t||||
17176198|NCT00971620|f||||f
17176199|NCT00824070|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17183508|NCT02821104|f||||f
17183509|NCT01158924|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication at least 60 days prior to the intended submission, presentation, or publication date.|t
17183510|NCT03795922|f||OTHER|General research agreement between the sponsor and PI's that includes a confidentiality section that includes a statement that the sponsor is and shall remain the exclusive owner of 'Information'. 'Information' shall include, but shall not be limited to, protocols, trade secrets, know-how, formulations, inventions, techniques, equipment, data and results.|t
17183511|NCT00705575|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183512|NCT02248922|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17131775|NCT02118792|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131776|NCT05131204|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17131777|NCT04656652|f||||f
17131778|NCT02787863|f||||f
17131779|NCT01978093|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131780|NCT01885000|f||OTHER|Disclosure agreement covered by contract.|t
17131781|NCT03124784|t||||
17131782|NCT01676714|t||||
17131783|NCT01272999|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131784|NCT01695473|t||||
17131785|NCT01484626|t||||
17176200|NCT03020446|t||||
17176201|NCT00256282|f||||f
17176202|NCT06165627|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17131786|NCT04852120|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17176203|NCT00327470|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176204|NCT01723696|f||||f
17176205|NCT02581943|t||||
17176206|NCT03021564|t||||
17176207|NCT00219544|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17176208|NCT01629771|t||||
17131787|NCT02163434|f||||f
17131788|NCT04283123|f||||f
17131789|NCT03494881|t||||
17131790|NCT01415752|f||LTE60||t
17131791|NCT06117319|f||LTE60||t
17131792|NCT03066102|f||||f
17138901|NCT01194414|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176209|NCT00745615|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17183513|NCT02822794|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183514|NCT03056690|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17183515|NCT02442700|f||||f
17183516|NCT00059475|f||||f
17183517|NCT02015234|f||OTHER|An industry standard NDA in place with all study investigators.|t
17183518|NCT01591681|f||||f
17183519|NCT00179647|f||OTHER|The investigator shall have the right to publish and/or present the clinical data generated from the study provided that such Investigator shall furnish sponsor with a copy of the proposed publication or presentation at least 60 days in advance of submission, delete any confidential information, and delay submission for up to 90 days to permit the preparation and filing of appropriate intellectual property applications.|t
17183520|NCT03027466|t||||
17183521|NCT01440946|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17131793|NCT00876993|f||||f
17131794|NCT00825565|t||||f
17131795|NCT00705939|f||||f
17176210|NCT00586664|f||OTHER|Agreement is between contract research organization and third parties on behalf of ISTA Pharmaceuticals, Inc.|t
17176211|NCT01464723|f||||f
17176212|NCT00727532|t||||
17176213|NCT00829933|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17176214|NCT02338336|f||||f
17176215|NCT01986933|f||OTHER||t
17176216|NCT03119701|f||OTHER||t
17176217|NCT00596362|t||||
17176218|NCT02043379|t||||
17131796|NCT02164422|f||||f
17131797|NCT01558661|t||||
17131798|NCT03345472|f||OTHER|Per the Clinical Investigation Plan, all proposed publications must be reviewed and approved by Medtronic prior to publication.|t
17131799|NCT01926782|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17131800|NCT02615743|f||||f
17131801|NCT04372927|f||||f
17131802|NCT01665807|f||||f
17131803|NCT01243320|f||||f
17131804|NCT01459705|f||||f
17131805|NCT03461757|f||LTE60||t
17131806|NCT00720109|f||LTE60||t
17131807|NCT04397094|t||||
17131808|NCT01035905|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17131809|NCT01227551|f||OTHER||t
17131810|NCT03977467|f||||t
17131811|NCT05913232|f||||f
17131812|NCT00970853|f||||f
17131813|NCT06142643|f||OTHER||t
17131814|NCT03485820|f||||f
17131815|NCT02177201|t||||
17131816|NCT04158648|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17131817|NCT03809611|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176219|NCT00356122|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 60 days in advance of any submission for publication. The Sponsor may request for the publication to be delayed for a limited time, not to exceed 90 days to preserve its proprietary rights.|t
17176220|NCT00491556|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17131818|NCT02926950|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17131819|NCT04622046|f||||t
17131820|NCT04647253|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17131821|NCT02787850|f||||f
17131822|NCT03598166|f||||f
17138902|NCT02256345|t||||f
17138903|NCT00770224|f||LTE60||t
17138904|NCT04737759|f||||f
17138905|NCT01505114|f||OTHER|All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts \& five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17138906|NCT02260388|f||||f
17138907|NCT00442260|t||||
17138908|NCT01363258|f||||f
17138909|NCT01587274|t||||
17176221|NCT02418156|f||GT60||t
17176222|NCT01445626|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176223|NCT04461509|f||||f
17176224|NCT01094561|t||||
17176225|NCT02104739|t||||
17176226|NCT05772702|f||LTE60||t
17176227|NCT01909453|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176228|NCT00884377|f||||f
17176229|NCT02003365|f||||t
17176230|NCT00622739|f||||f
17176231|NCT00902161|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17176232|NCT02670343|f||||t
17176233|NCT00306202|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17176234|NCT02097537|f||||f
17176235|NCT03387150|f||||f
17176236|NCT04617795|f||||f
17176237|NCT03442764|f||||f
17176238|NCT04850313|t||||f
17176239|NCT02395016|f||||f
17176240|NCT01547780|t||||
17176241|NCT02195414|f||||f
17176242|NCT01288976|f||GT60||t
17176243|NCT01276197|t||||
17176244|NCT01966692|t||||
17176245|NCT01823510|t||||
17176246|NCT02478398|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17176247|NCT00334074|f||LTE60||t
17176248|NCT01362595|t||||f
17176249|NCT00959374|f||||f
17176250|NCT02448680|f||||f
17176251|NCT00636987|f||OTHER||t
17131823|NCT02921971|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17131824|NCT04316585|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17138910|NCT01421069|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138911|NCT01641081|f||OTHER|Publication of the results by the PI will be subject to mutual agreement between the PI and sponsor.|t
17138912|NCT03011775|t||||
17138913|NCT00588380|t||||f
17138914|NCT01749800|f||||f
17138915|NCT01511640|f||||f
17138916|NCT03297944|t||||
17176252|NCT01251146|f||OTHER||t
17176253|NCT01689909|f||||f
17176254|NCT02876640|f||LTE60||t
17176255|NCT04534465|f||GT60||t
17176256|NCT00737464|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176257|NCT00872027|f||||f
17176258|NCT03220438|f||||f
17176259|NCT00634270|f||||f
17131825|NCT00130832|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131826|NCT02944448|f||||t
17131827|NCT03660878|f||||t
17176260|NCT01634178|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176261|NCT01076296|f||LTE60||t
17176262|NCT02757950|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176263|NCT03398278|f||||t
17176264|NCT01778179|f||||f
17176265|NCT00991952|f||LTE60||t
17176266|NCT03742440|f||||f
17176267|NCT02483533|f||||f
17176268|NCT03452527|f||||f
17176269|NCT00582816|f||||f
17131828|NCT01282073|f||||f
17138917|NCT01451398|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17138918|NCT00661570|f||||f
17176270|NCT00055224|t||||
17176271|NCT01677312|t||||
17176272|NCT02301611|f||||t
17176273|NCT04291001|f||||f
17176274|NCT00174291|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176275|NCT02313454|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176276|NCT03116347|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176277|NCT03170232|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176278|NCT00586326|f||GT60||t
17176279|NCT01439347|f||||f
17176280|NCT05361031|f||||t
17176281|NCT04068896|f||||f
17176282|NCT01101191|f||GT60||t
17176283|NCT02009384|t||||
17176284|NCT03442400|f||||f
17176285|NCT00718237|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176286|NCT02694718|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176287|NCT02925793|f||||t
17176288|NCT00879879|f||||f
17176289|NCT02581839|t||||
17176290|NCT00667446|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176291|NCT01343901|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176292|NCT01412918|t||||
17176293|NCT00769483|t||||
17176294|NCT03455764|t||||
17176295|NCT05080660|f||GT60||t
17176296|NCT04533685|f||||f
17176297|NCT04221230|f||OTHER||t
17176298|NCT03615508|f||||f
17176299|NCT02750215|t||||
17131829|NCT03704194|f||||f
17131830|NCT03491384|f||||f
17131831|NCT03118297|f||||f
17131832|NCT02479802|f||||f
17131833|NCT03340610|f||||f
17131834|NCT04580290|f||||f
17131835|NCT02469090|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites,Institution and Investigator shall be free to publish.|t
17183522|NCT02486406|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183523|NCT00627406|f||||f
17183524|NCT01826825|t||||
17183525|NCT01858194|f||||f
17183526|NCT03062891|f||||f
17183527|NCT02127307|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17183528|NCT03221257|t||||
17183529|NCT02149342|f||||f
17183530|NCT01129141|t||||
17183531|NCT00075829|f||||f
17183532|NCT01122511|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17131836|NCT01833130|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17138919|NCT01000025|t||||f
17138920|NCT00422669|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication."|t
17138921|NCT00996593|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176300|NCT01307020|f||OTHER|Prior to submitting the results of this study for publication or presentation, the investigator will allow the Sponsor at least 60 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until the Sponsor has reviewed/commented and agreed to any publication.|t
17176301|NCT02021656|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17176302|NCT02300727|t||||
17176303|NCT01952470|t||||
17176304|NCT03150485|f||GT60||t
17176305|NCT01394718|t||||
17176306|NCT00814879|t||||
17176307|NCT01461057|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176308|NCT01739400|f||OTHER|Any study-related article or abstract written independently by investigators must be submitted to Actelion for review at least 60 days prior to submission for publication or presentation. The list of authors of any formal publication or presentation of study results may include, as appropriate, representatives of Actelion, and will be determined by mutual agreement.|t
17176309|NCT03350984|t||||
17176310|NCT00642473|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176311|NCT01680549|t||||f
17183533|NCT00685932|f||||f
17183534|NCT01687166|f||OTHER||t
17183535|NCT02296112|t||||
17183536|NCT02442830|t||||
17183537|NCT01516879|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17183538|NCT00183872|t||||
17183539|NCT02797262|f||||f
17183540|NCT01600586|t||||f
17183541|NCT01898793|t||||
17183542|NCT00931307|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17183543|NCT00983814|f||||f
17183544|NCT00829621|f||||f
17183545|NCT04356716|t||||
17183546|NCT02160873|f||||f
17183547|NCT02766608|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17183548|NCT02066298|f||||f
17131837|NCT01391507|f||OTHER|If Sponsor should have justified objections, then Hospital will respond to these objections as the scientific nature of publication are not negatively affected. If no agreement can be reached, they will appeal to an independent body of experts to resolve the points in dispute. It is not permissible to publish study data before overall study results are published without the written consent of Sponsor. However, this applies to a maximum period of 12 months after study has ended or been cancelled.|t
17131838|NCT01202656|t||||f
17131839|NCT02507011|t||||
17131840|NCT01562548|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131841|NCT00252057|f||||f
17131842|NCT01496066|f||||f
17131843|NCT02926209|f||LTE60||t
17131844|NCT01022190|f||||f
17131845|NCT01903837|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17131846|NCT05048342|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17138922|NCT02738580|t||||
17176312|NCT00478881|f||OTHER|Publishing incl confidential information only after Bayer written approval. Manuscript to Bayer 60 days before submission. Confidential Information to be deleted. Other Bayer comments to be considered, if they do not alter the scientific character. If no Bayer comment within 45 days, consider approval given. If multisite study Principal Investigator (PI) not to independently publish results before publication of multisite paper, but PI not restricted from 24 months from study completion onwards.|t
17176313|NCT03410823|f||||f
17176314|NCT04911426|t||||
17176315|NCT05128929|t||||
17176316|NCT02742246|t||||
17176317|NCT02397564|f||||f
17176318|NCT03584373|t||||
17176319|NCT01487577|t||||
17176320|NCT05765227|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17176321|NCT00662532|f||||f
17176322|NCT00367770|f||LTE60||t
17176323|NCT01155479|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The Investigator further agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment.|t
17176324|NCT00998764|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176325|NCT04761627|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176326|NCT01214174|f||OTHER|All information related to this study is considered confidential information belonging to Icon Bioscience, Inc. Data on the use of the study drug and results of all clinical and laboratory studies are considered private and confidential. None of the details, results, or other information for this study shall be published or made known to a third party without written consent from Icon Bioscience, Inc., except for disclosure to regulatory agencies if required by law.|t
17176327|NCT00689091|f||||f
17176328|NCT03823378|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176329|NCT02093026|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176330|NCT02376829|f||||f
17176331|NCT01255787|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176332|NCT00476047|f||||f
17176333|NCT05153473|f||||f
17176334|NCT02283177|f||||f
17176335|NCT02398227|f||||f
17176336|NCT01185834|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17176337|NCT01975831|f||LTE60||t
17183549|NCT02284828|f||OTHER||t
17183550|NCT02261818|f||||f
17183551|NCT00598689|f||||f
17176338|NCT00887744|f||OTHER|Institution and Investigator acknowledge that all information affecting or relating to Sponsor's products that is developed, discovered, or transmitted in connection with the study, including the multi-center data resulting from the study and any inventions or moral rights, shall belong to Sponsor, and nothing shall be construed to confer upon or grant to Institution or Investigator any right, title, or interest therein.|t
17176339|NCT00829985|f||||f
17176340|NCT01115582|f||||f
17176341|NCT03324581|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17176342|NCT02274038|t||||
17176343|NCT03783702|f||||f
17176344|NCT04473482|t||||
17176345|NCT01120834|t||||
17176346|NCT00321893|f||LTE60||t
17176347|NCT01306877|f||||f
17176348|NCT01958112|f||LTE60||t
17176349|NCT01781169|t||||
17176350|NCT00939952|f||LTE60||t
17176351|NCT00999921|t||||
17176352|NCT02376283|t||||
17176353|NCT00989573|f||||f
17176354|NCT05074173|t||||
17176355|NCT01076075|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17176356|NCT01860573|t||||
17176357|NCT00995865|f||||f
17176358|NCT00439465|t||||
17176359|NCT03687970|f||||f
17176360|NCT01604109|f||||f
17176361|NCT02359851|t||||
17176362|NCT01888003|t||||
17176363|NCT00055471|f||GT60||t
17176364|NCT01854944|f||LTE60||t
17176365|NCT02101112|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17176366|NCT04340063|t||||
17176367|NCT01857583|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17176368|NCT01510457|f||||f
17176369|NCT00458536|f||||f
17176370|NCT04894916|t||||
17176371|NCT00562627|t||||
17176372|NCT00625742|t||||
17176373|NCT01709578|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17176374|NCT04050371|t||||f
17176375|NCT02935543|t||||
17176376|NCT01314911|f||||f
17176377|NCT00255801|t||||
17176378|NCT00588952|t||||
17176379|NCT01277042|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176380|NCT02284178|f||||f
17176381|NCT02547714|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17176382|NCT04396496|f||||f
17176383|NCT01483690|f||GT60||t
17176384|NCT04633460|t||||
17176385|NCT03569293|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176386|NCT05803603|t||||
17176387|NCT03553836|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17176388|NCT04062123|t||||
17176389|NCT01041495|f||||f
17176390|NCT02882074|t||||
17176391|NCT05048082|f||||f
17176392|NCT03780400|t||||f
17176393|NCT01479985|f||||f
17176394|NCT01653782|f||||f
17176395|NCT01142128|f||||f
17176396|NCT00442468|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176397|NCT00926588|t||||
17176398|NCT05867342|t||||
17176399|NCT00470184|t||||
17176400|NCT05442775|f||||f
17176401|NCT01410552|f||||f
17176402|NCT00058539|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183552|NCT02343458|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17183553|NCT01913041|f||GT60||t
17183554|NCT02873923|t||||
17183555|NCT01265953|f||||f
17131847|NCT02462473|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17131848|NCT03138876|t||||
17131849|NCT01400451|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17131850|NCT03850912|t||||
17131851|NCT00619073|f||||f
17131852|NCT01539590|f||GT60||t
17131853|NCT01079182|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131854|NCT00903929|t||||
17131855|NCT03208231|f||||f
17131856|NCT03321097|f||||f
17176403|NCT03190369|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17176404|NCT02963831|f||||f
17176405|NCT04543409|f||OTHER|The Institution and/or the Principal Investigator shall not include in or shall remove from any proposed publication any Confidential Information, errors or inaccuracies; and shall withhold publication, submission for publication or presentation for a period of ninety (90) days from the date on which the Company receives the material to allow the Company to take such measures as the Company considers necessary to preserve its proprietary rights and/or protect its Confidential Information.|t
17176406|NCT01923168|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17176407|NCT03418571|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.|t
17176408|NCT03882008|f||||f
17176409|NCT04341662|t||||f
17176410|NCT03101267|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17176411|NCT01222403|f||GT60||t
17176412|NCT00618839|f||||f
17176413|NCT01262352|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17176414|NCT02045303|t||||
17176415|NCT01642407|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176416|NCT03533686|t||||
17183556|NCT01610700|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17183557|NCT02648698|f||||f
17183558|NCT01640301|t||||
17131857|NCT03861143|f||||f
17131858|NCT02158091|t||||f
17131859|NCT01358864|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131860|NCT02656485|f||||f
17131861|NCT03194373|t||||
17131862|NCT04209855|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131863|NCT02289950|f||||f
17131864|NCT04338009|f||GT60||t
17183559|NCT02842060|f||||f
17183560|NCT00672477|f||LTE60||t
17183561|NCT02348489|f||||t
17131865|NCT01250379|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176417|NCT00755911|t||||
17176418|NCT00245583|f||||f
17176419|NCT00829283|f||||f
17176420|NCT03004248|f||OTHER|With respect to any proposed publication or disclosure of the results of the Study, the Study Center and Investigator shall submit to Revance a copy of the proposed publication or disclosure at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i) to provide Revance with the opportunity to review and comment on the contents thereof, and (ii) to identify any Confidential Information to be deleted from the proposed publication or disclosure.|t
17176421|NCT01879540|f||LTE60||t
17176422|NCT00591578|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17176423|NCT03945175|t||||
17176424|NCT00870233|t||||
17176425|NCT00378079|f||||f
17176426|NCT00006389|f||LTE60||t
17176427|NCT03114059|t||||f
17176428|NCT04466228|t||||f
17176429|NCT05038904|t||||
17176430|NCT04867434|f||||t
17176431|NCT01445886|t||||
17176432|NCT03500679|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17176433|NCT01962922|f||OTHER|Sponsor has no objection to publication of the results of the Study by Site based on information collected or generated by Site; provided, however, that such publication must not precede the primary manuscript (unless no such multi-site publication is completed within twelve (12) months following the completion of the Study or unless Sponsor notifies Site in writing that no such multi- center publication shall be made).|t
17176434|NCT03224546|t||||f
17176435|NCT02730208|f||OTHER||t
17176436|NCT00245219|f||||f
17176437|NCT01827358|f||LTE60||t
17176438|NCT00510952|f||GT60||t
17183562|NCT01639001|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183563|NCT02866682|f||||f
17183564|NCT00201006|t||||f
17183565|NCT02837744|f||||f
17131866|NCT05902364|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17131867|NCT02270242|f||OTHER|Investigator remains responsible \& has final approval for any publication and can publish/present results but shall submit manuscript/material proposed for publication/presentation relating to results to AZ for review ≤45 days prior to submission. AZ has 45 days to respond with comments. If requested by AZ, Investigator shall delay submission for further period ≤45 days, for deemed appropriate measures to establish/preserve parties' proprietary rights in intellectual property disclosed.|t
17131868|NCT03963011|t||||
17131869|NCT02321436|f||OTHER|The only disclosure restriction on the PI is that the first communication or publication regarding the study must be a joint publication between the PI and Sponsor.|t
17131870|NCT00644787|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17131871|NCT03355300|f||LTE60||t
17131872|NCT02553512|f||||f
17176439|NCT00048893|f||||f
17176440|NCT02691962|f||OTHER|The publication of the principal results from any single-center experience within the study is not allowed until the preparation and publication of the multi-center results.|t
17176441|NCT02325856|t||||
17176442|NCT02793128|f||||f
17176443|NCT02355977|t||||
17176444|NCT03287635|f||||f
17176445|NCT03670836|f||||f
17176446|NCT00396032|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176447|NCT03070444|f||||f
17176448|NCT01373489|f||||f
17176449|NCT04088656|t||||
17176450|NCT04285580|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176451|NCT02582255|f||OTHER|The PI and/or the institution does not have the right to publish or perform presentations, which contain partial or complete summaries, data, results or any other information obtained as a result of this investigation, without prior written authorization by FIDEC.|t
17176452|NCT04854642|f||||f
17176453|NCT00847171|t||||
17176454|NCT01107418|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183566|NCT00423436|t||||f
17131873|NCT01489527|t||||
17131874|NCT03048422|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17131875|NCT01984268|f||||f
17131876|NCT04899232|t||||f
17131877|NCT00936208|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17131878|NCT00898560|t||||f
17131879|NCT01327157|f||||f
17131880|NCT01344876|f||||f
17176455|NCT00597701|f||||f
17176456|NCT02417844|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176457|NCT00076024|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176458|NCT00988325|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176459|NCT01155219|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17176460|NCT01785095|f||||f
17176461|NCT00301821|t||||
17176462|NCT01981759|f||||f
17176463|NCT00403403|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176464|NCT04078178|f||||f
17176465|NCT04006119|f||OTHER||t
17176466|NCT00472459|f||OTHER||t
17176467|NCT05283928|t||||
17176468|NCT03544775|f||||f
17176469|NCT03981822|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17176470|NCT06460493|f||LTE60||t
17176471|NCT02651714|f||OTHER||t
17176472|NCT03489551|t||||
17176473|NCT01515540|f||||f
17176474|NCT02987660|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17176475|NCT00054717|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17176476|NCT03707184|t||||
17176477|NCT04704154|f||GT60||t
17176478|NCT04251156|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17176479|NCT04209426|f||||f
17176480|NCT04423939|t||||
17176481|NCT02285283|t||||
17176482|NCT04626310|f||||f
17176483|NCT02278341|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17176484|NCT02604017|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176485|NCT00740246|f||LTE60||t
17176486|NCT03682809|f||||f
17176487|NCT01606254|f||||f
17176488|NCT02011893|f||OTHER||t
17176489|NCT03977454|t||||
17176490|NCT01289782|f||GT60||t
17176491|NCT01241240|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release. No documents containing confidential information from the sponsor or information developed will be submitted for publication without prior written authorization from the sponsor.|t
17176492|NCT04499599|t||||
17176493|NCT04365257|t||||
17176494|NCT00518973|t||||
17176495|NCT03239665|f||||f
17176496|NCT01001299|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176497|NCT01754909|f||||f
17176498|NCT04081233|t||||
17176499|NCT01565499|f||LTE60||t
17176500|NCT00781508|f||||f
17131881|NCT04428424|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131882|NCT03376477|f||||f
17131883|NCT03110224|f||||f
17131884|NCT04818593|t||||
17131885|NCT01564862|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17131886|NCT04526665|f||OTHER||t
17131887|NCT01844986|f||GT60||t
17131888|NCT05429073|f||||t
17131889|NCT02396589|t||||f
17131890|NCT04341948|f||||t
17131891|NCT01761266|f||||f
17131892|NCT01284114|t||||f
17131893|NCT03936387|t||||
17131894|NCT03445000|f||||f
17131895|NCT03409744|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17131896|NCT02532231|t||||
17131897|NCT00748579|f||OTHER|Sponsor's intention was to publish the results of the trial in collaboration with the Investigators.|t
17131898|NCT03591380|t||||
17131899|NCT01869647|f||||f
17131900|NCT03269344|t||||
17131901|NCT02597855|f||||f
17131902|NCT00559507|f||LTE60||t
17131903|NCT02889796|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17131904|NCT01629797|t||||
17131905|NCT06414512|t||||
17131906|NCT01394081|f||||f
17131907|NCT01407926|t||||
17131908|NCT02814565|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17131909|NCT01411345|t||||
17131910|NCT01414257|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131911|NCT04631029|f||LTE60||t
17131912|NCT01882907|f||GT60||t
17131913|NCT05215600|f||LTE60||t
17131914|NCT03286842|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17138923|NCT01000818|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17176501|NCT03519386|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of data from this study.|t
17176502|NCT02340715|t||||
17176503|NCT01582854|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176504|NCT06138145|f||||f
17176505|NCT02652767|f||||t
17176506|NCT01028378|f||||f
17131915|NCT02261727|f||OTHER|"All papers will be authored by all or a subgroup of members of the TASCS Publications Committee. Publications prior to the primary and major secondary papers may only be initiated by the Publications Committee. Publications subsequent to the primary and major secondary papers may be authored by individually named authors, and may at the request of the Publication Committee be required to include the annotation On behalf of the Theophylline and Steroids in COPD (TASCS) trial investigators."|t
17131916|NCT01453855|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17131917|NCT00857727|t||||
17131918|NCT01445028|t||||
17138924|NCT00741260|f||LTE60||t
17138925|NCT02810951|f||GT60||t
17138926|NCT01250756|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17138927|NCT01928082|t||||
17131919|NCT01441063|f||||f
17131920|NCT00119158|f||||f
17131921|NCT02574637|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17131922|NCT01568606|t||||
17176507|NCT00645710|t||||
17176508|NCT00107952|f||LTE60||t
17131923|NCT00070941|f||OTHER|"According to the NIH -grant that supported this clinical trial all publications must be reported to the grant office prior to the release of publications.~Statement from NIH award letter:~This includes manuscripts submitted or accepted for publication to the awarding component. Report only those publications resulting directly from this grant and those publications. If there have been no publications, so state."|t
17131924|NCT01232829|f||LTE60||t
17131925|NCT00703664|f||LTE60||t
17131926|NCT00953758|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131927|NCT01675960|t||||
17131928|NCT01703858|t||||
17131929|NCT04600895|t||||
17131930|NCT03987854|f||||f
17131931|NCT00706030|f||LTE60||t
17131932|NCT01276236|t||||
17131933|NCT00044512|f||OTHER|Agreement between Sponsor and PI should be reached before publication|t
17131934|NCT01097304|f||LTE60||t
17138928|NCT00583661|f||OTHER|PI has agreed to discuss or publish trial results only after review by the Publication Committee and the sponsor.|t
17138929|NCT04010370|t||||f
17138930|NCT01324687|f||||f
17138931|NCT03383627|t||||
17138932|NCT02142504|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138933|NCT01351064|f||||f
17138934|NCT02120352|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176509|NCT01401959|f||GT60||t
17176510|NCT02051816|f||||f
17176511|NCT03794882|t||||
17176512|NCT03614975|t||||f
17176513|NCT00450385|t||||
17176514|NCT01569464|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17176515|NCT01376557|f||OTHER|Institutions cannot publish any data generated from the clinical trial until Sponsor publishes such data or until 18 months have elapsed since completion of the clinical trial. Proposed publication must be provided to Sponsor at least 60 days prior to submission for publication and Sponsor has 30 days from receipt to review. Sponsor can delete any info to which it objects, Confidential Information, proprietary information or patentable subject matter from the final version of the publication.|t
17176516|NCT01390220|f||OTHER|A manuscript or abstract should not be submitted by investigator(s) for publication or presentation until a New Drug Application is approved by the US FDA or permission is granted in writing by sponsor.|t
17176517|NCT03063203|t||||
17176518|NCT04718103|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17176519|NCT00136604|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131935|NCT00470600|f||||f
17131936|NCT02695628|t||||
17131937|NCT02189850|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17131938|NCT01141595|f||||f
17131939|NCT00516737|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131940|NCT01844895|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17138935|NCT01610206|f||LTE60||t
17138936|NCT00444964|t||||
17176520|NCT03631355|t||||f
17176521|NCT00633867|t||||f
17176522|NCT03640559|f||||f
17176523|NCT02125604|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17176524|NCT05176093|f||LTE60||t
17176525|NCT01876810|t||||
17176526|NCT01030783|f||||f
17176527|NCT05824741|f||||f
17131941|NCT00512798|t||||
17131942|NCT06245551|t||||
17131943|NCT02508194|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17131944|NCT00511355|f||OTHER|The SPONSOR recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the SPONSOR. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the SPONSOR, at least six weeks ahead of estimated publication or presentation, for consent, which shall not be withheld unreasonably.|t
17131945|NCT00393874|f||||f
17131946|NCT00713583|t||||
17131947|NCT01031914|t||||
17131948|NCT00454805|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17131949|NCT03742037|f||OTHER|"Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation.~Upon review, the sponsor may provide comments and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period."|t
17131950|NCT00802685|t||||
17131951|NCT02772432|f||||f
17131952|NCT01545700|t||||
17131953|NCT00281879|f||||f
17131954|NCT04347239|f||||f
17131955|NCT03430921|f||||f
17131956|NCT02028455|f||||f
17138937|NCT00166517|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17138938|NCT02186561|f||||f
17138939|NCT03094611|t||||
17138940|NCT04285853|t||||
17138941|NCT02573233|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17138942|NCT02119468|t||||f
17138943|NCT01042938|f||||f
17138944|NCT05041062|t||||
17138945|NCT04018612|f||||t
17138946|NCT01915095|t||||
17138947|NCT01983878|f||GT60||t
17138948|NCT02671760|f||||f
17138949|NCT02999191|t||||
17138950|NCT00136838|t||||
17176528|NCT00719264|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17176529|NCT03034200|t||||
17176530|NCT05523323|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17176531|NCT03435640|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17176532|NCT00792077|t||||
17176533|NCT01948310|f||||f
17176534|NCT00775944|t||||f
17176535|NCT00920829|f||||f
17176536|NCT04533880|t||||
17176537|NCT05654441|t||||
17176538|NCT01955980|f||||f
17176539|NCT01711879|t||||
17176540|NCT02464917|t||||
17176541|NCT02239224|f||||t
17176542|NCT03718871|t||||f
17176543|NCT03183778|t||||
17176544|NCT00073073|f||||f
17176545|NCT01466179|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176546|NCT00749580|f||||f
17176547|NCT02266914|t||||
17183567|NCT00274716|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17138951|NCT03418064|f||OTHER|Investigator cannot publish / present data without prior consent from CooperVision.|t
17138952|NCT00410904|f||LTE60||t
17138953|NCT00878644|f||||f
17138954|NCT01389076|t||||
17176548|NCT02090075|t||||
17176549|NCT03868124|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of data from this study.|t
17176550|NCT04565236|f||OTHER|"The PI shall ensure that any manuscripts of publications related to the study or the results of the study are provided to Bayer for review at least 60 working days before publication, during which time the PI shall maintain confidentiality. If Bayer does not make any comments within the 60 working days, the PI is free to publish. Within 60 working days, Bayer may propose amendments to the publication and reach a consensus with the PI."|t
17176551|NCT01117051|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176552|NCT03535571|f||OTHER|The study was conducted by a contract research organization (CRO) of which the PI is a contract employee. The agreement between the CRO and sponsor indicates that all rights to discuss and publish the trial results belong to the sponsor.|t
17176553|NCT00206076|f||||f
17176554|NCT02661711|t||||
17176555|NCT01060345|t||||
17183568|NCT01162005|t||||
17183569|NCT00975975|t||||
17183570|NCT00961259|f||GT60||t
17183571|NCT00843791|f||||f
17183572|NCT01252251|t||||
17131957|NCT01790503|f||||f
17131958|NCT02326805|f||LTE60||t
17131959|NCT02740478|t||||
17131960|NCT02803164|t||||f
17138955|NCT02371980|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17138956|NCT01731990|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17138957|NCT01280812|t||||f
17138958|NCT04483544|t||||
17176556|NCT00366340|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176557|NCT03355664|t||||
17176558|NCT01337687|t||||f
17131961|NCT01449708|f||||f
17131962|NCT05022641|t||||f
17131963|NCT00223496|t||||f
17131964|NCT05702515|f||||f
17131965|NCT02698735|f||||f
17131966|NCT02653768|t||||
17131967|NCT01784965|f||||f
17131968|NCT01491178|t||||f
17131969|NCT04175626|f||||f
17131970|NCT03178487|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131971|NCT01262846|t||||f
17131972|NCT03655756|f||OTHER|Moffitt shall be free to publish any academic articles, presentations, or abstracts of the Study results (including supporting data); provided that any such manuscript is first submitted to Company thirty (30) days prior to the proposed publication date so that Company may take any action necessary to protect its confidential information and intellectual property rights prior to said publication.|t
17131973|NCT00253630|f||LTE60||t
17131974|NCT03237065|f||OTHER|Before 1 year after completion of the Study report the Investigator must not publish details regarding the Protocol and the conduct or results of the Trial. However, if a joint publication is submitted for publication the individual Investigator has no right to publish results from his/her centre until such the joint publication is actually issued.|t
17131975|NCT00209339|f||GT60||t
17131976|NCT00429858|t||||
17138959|NCT05569850|f||||f
17138960|NCT01131078|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138961|NCT01636453|f||||f
17176559|NCT00057681|f||||f
17176560|NCT01315236|f||OTHER|Per the signed Investigator Agreement in the protocol and protocol amendments, the PI agreed that the information presented in the study protocol is confidential, and assured that no information based on the conduct of the study was released without prior Insmed Incorporated Consent, unless the requirement is superseded by the Food and Drug Administration or other regulatory authority.|t
17176561|NCT01751802|f||||f
17176562|NCT03115580|f||||f
17176563|NCT00589784|t||||
17176564|NCT00521001|t||||
17131977|NCT01587079|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17131978|NCT02268058|f||||f
17138962|NCT00790218|f||||f
17131979|NCT00493038|f||OTHER|"The results of the trial as well as any discoveries and inventions, are exclusive property of the Promoter.~Publications on scientific review, comments or presentations about the study in scientific environment must be agreed between the Sponsor and the investigator who engages to submit to Bayer, any publication by sending one text or presentations at least 60 days before the expected publication for comments and corrections."|t
17176565|NCT01960387|t||||
17176566|NCT02821910|t||||f
17176567|NCT00287079|f||OTHER||t
17176568|NCT04218123|f||||f
17176569|NCT01082640|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17131980|NCT04781816|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17131981|NCT01121393|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17131982|NCT01100944|f||||f
17131983|NCT00577993|t||||
17131984|NCT02679469|f||||f
17131985|NCT01847885|f||LTE60||t
17131986|NCT04311086|f||||f
17131987|NCT00355394|t||||f
17131988|NCT02064387|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131989|NCT02706730|f||LTE60||t
17131990|NCT02499029|f||||f
17131991|NCT00094055|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17131992|NCT01175902|f||||f
17131993|NCT00411554|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17131994|NCT00699907|t||||
17131995|NCT02161211|f||||f
17131996|NCT00430508|f||OTHER|Results of Study shall not be published without prior express written consent and approval of Sponsor. If Contractor wishes to use data generated at Sites by Investigator, such data includes but not limited to data used in collection of metrics, copy of any intended publication, details of use must be sent in writing to Quintiles and Sponsor for review. Sponsor has right to change proposed publication and/or prohibit publication and Contractor must comply with requirements of Sponsor|t
17176570|NCT00413478|t||||
17176571|NCT03577171|f||OTHER|Assembly Biosciences agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Assembly Biosciences supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176572|NCT01278303|f||||f
17176573|NCT01282203|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17176574|NCT04163822|f||||f
17183573|NCT01324024|t||||
17131997|NCT03728309|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17131998|NCT01164722|f||||f
17131999|NCT00999908|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132000|NCT01158521|f||||f
17132001|NCT01662583|t||||
17132002|NCT02556255|f||||f
17132003|NCT01290692|f||||f
17132004|NCT01849770|t||||
17132005|NCT00993031|f||||f
17132006|NCT03115151|t||||
17132007|NCT00465595|f||||f
17132008|NCT01543087|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17132009|NCT04673786|f||||t
17132010|NCT04438174|t||||
17132011|NCT02682901|f||||f
17132012|NCT03870555|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17132013|NCT02340663|f||||f
17132014|NCT01337076|f||||f
17132015|NCT03694925|f||||f
17132016|NCT03104725|t||||
17132017|NCT01422239|t||||
17132018|NCT06488157|t||||
17138963|NCT00880100|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17138964|NCT02279160|f||LTE60||t
17132019|NCT03167073|t||||
17132020|NCT00357500|f||LTE60||t
17132021|NCT03033875|t||||
17132022|NCT02065154|t||||f
17132023|NCT02573155|f||OTHER|Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor.|t
17132024|NCT01681433|f||||f
17132025|NCT02301403|f||||f
17132026|NCT00730639|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trials primary publication.|t
17132027|NCT02665286|t||||
17132028|NCT00361595|t||||f
17132029|NCT03528512|t||||
17132030|NCT03790280|f||||f
17132031|NCT00425386|t||||
17176575|NCT01082380|t||||
17132032|NCT03434977|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17132033|NCT03064841|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132034|NCT00217087|t||||f
17132035|NCT03920670|t||||
17132036|NCT03436615|f||OTHER|The PI must wait 18 months after the closeout of the trial at all Study sites or until the publication of the multi-site Sponsor results. The only restriction on PI publication after that time is that the sponsor can review results communications prior to public release and can request confidential or proprietary information be removed or can embargo communications regarding trial results for a period that is more than 90 days but less than 120 days.|t
17132037|NCT05574062|f||||f
17132038|NCT03505021|f||||f
17176576|NCT02129777|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176577|NCT03436810|f||||f
17176578|NCT00977808|t||||
17176579|NCT00542451|t||||
17176580|NCT03367247|t||||
17176581|NCT00064298|t||||
17176582|NCT01856023|f||||f
17176583|NCT02829983|t||||
17132039|NCT03087955|f||OTHER|The sponsor authorizes publications by a single site provided that multicentric results are published beforehand and any communication is submitted to the sponsor for review at least 28 days before the expected publication date. The sponsor can comment for 28 days. Upon sponsor request, any confidential information will have to be removed before publishing. Publishing can be postponed by 90 additional days, should the sponsor want to protect data through a patent application or any other mean.|t
17132040|NCT04705051|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132041|NCT00482014|f||GT60||t
17132042|NCT01178138|t||||
17132043|NCT03718143|t||||
17132044|NCT05064059|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17132045|NCT00741156|t||||
17132046|NCT02762513|t||||
17132047|NCT02165384|f||||f
17132048|NCT01390909|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132049|NCT03438045|f||||f
17132050|NCT00984204|f||||f
17132051|NCT01294384|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132052|NCT02848079|t||||
17132053|NCT02168686|f||OTHER|Disclosure restrictions on the PIs are that Sponsor can review communications by the PI prior to public release and can embargo communications regarding trial results for varying time periods from the time submitted to the sponsor for review. The Sponsor may require changes to the communication after review and may delay publication upon request by the Sponsor to allow the Sponsor to seek/obtain patent protection.|t
17132054|NCT00699348|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132055|NCT01268293|f||OTHER||t
17132056|NCT00618748|f||GT60||t
17132057|NCT01099202|f||||f
17132058|NCT04288570|f||||f
17132059|NCT01396005|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17132060|NCT00424827|f||||f
17176584|NCT00322153|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17176585|NCT01309893|f||OTHER||t
17176586|NCT02414139|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17176587|NCT02632838|t||||f
17132061|NCT01467492|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17132062|NCT01583894|f||||f
17132063|NCT00159432|t||||
17132064|NCT05218499|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132065|NCT05689047|f||||t
17132066|NCT01604512|t||||
17132067|NCT04161495|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132068|NCT03005054|f||||t
17132069|NCT01239160|f||LTE60||t
17132070|NCT01789970|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17132071|NCT02123485|f||||f
17132072|NCT04668352|f||||t
17132073|NCT02296242|f||||f
17132074|NCT02217566|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17132075|NCT01077973|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132076|NCT00883246|f||LTE60||t
17132077|NCT01639833|f||||f
17138965|NCT02853123|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17138966|NCT05283499|f||||f
17138967|NCT05516134|t||||
17176588|NCT02810340|f||||f
17176589|NCT02797054|t||||f
17176590|NCT04644783|t||||
17176591|NCT03221764|f||||f
17176592|NCT01233687|t||||
17176593|NCT01484938|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17132078|NCT02450578|f||||f
17132079|NCT04016311|f||||f
17132080|NCT04029519|f||||f
17132081|NCT00794560|f||||f
17132082|NCT01999582|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132083|NCT03326141|t||||
17132084|NCT02436876|f||||f
17132085|NCT03950973|f||||f
17176594|NCT02211638|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176595|NCT03173534|f||||f
17176596|NCT04571515|f||GT60||t
17132086|NCT01536860|t||||
17132087|NCT02809833|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132088|NCT03889639|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132089|NCT00927095|f||||f
17132090|NCT03506295|t||||
17132091|NCT03285243|f||||f
17132092|NCT01269710|t||||f
17176597|NCT05140382|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17176598|NCT03642327|f||||f
17176599|NCT01711372|t||||
17176600|NCT00323869|f||||f
17176601|NCT00905827|t||||
17176602|NCT00509392|f||OTHER|The data/info related to Study are legal property of VNUS \& can be used by PI for publication, communication or scientific presentation only after duly informing VNUS of proposed dissemination, providing to VNUS for review/comment a copy of said proposed publication, communication or scientific presentation \& allowing at least 30 days from the time of receipt by VNUS for VNUS to provide comment on said proposed publication, communication or scientific presentation prior to said dissemination.|t
17132093|NCT02387580|f||OTHER|Quotient shall have the right to publish the results of the research, subject to the sponsor's prior written consent, which shall not be unreasonably withheld or delayed. Following the receipt of such consent, Quotient shall submit a copy of the proposed publication to the sponsor who shall have 30 days in which to request amendments thereto which, to the extent that such proposed amendments are reasonable, Quotient shall be obliged to incorporate prior to such publication.|t
17132094|NCT00725075|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the sponsor at least six weeks ahead of estimated publication or presentation, for written consent. The sponsor shall have the right to make its consent of information conditional upon proper representation of the interpretation of both the sponsor and the investigator(s) in the discussion of the data in such communications.|t
17132095|NCT02979431|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, and will require prior review and written agreement of the Sponsor.|t
17132096|NCT01656434|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including slides and texts of oral or other public presentations that report any results of the trial). The Sponsor has the right to review and comment on publications, abstracts, slides, and manuscripts, as well as the data analysis and presentation.|t
17132097|NCT01639872|f||||f
17132098|NCT02799069|f||OTHER|The publication of study results requires Biofrontera's acceptance. Investigators can claim an authorship if they have completely treated and documented at least 35 patients. Planned publications and presentations of investigations which are within the scope of the clinical study should be previously presented to Biofrontera for a statement.|t
17132099|NCT01614093|f||||f
17132100|NCT00848354|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132101|NCT02067039|t||||
17132102|NCT01972074|t||||f
17132103|NCT05721482|t||||
17132104|NCT04770779|f||||t
17132105|NCT04820309|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132106|NCT03692052|f||OTHER|The information obtained from the clinical study will be used towards the development of AG-348 and may be disclosed to regulatory authority(ies), other Investigators, corporate partners, or consultants as required.|t
17132107|NCT06232317|f||||f
17132108|NCT05600309|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17132109|NCT06033079|t||||
17132110|NCT03512418|t||||
17132111|NCT03864653|t||||
17176603|NCT06053463|f||||f
17176604|NCT04902326|f||||f
17176605|NCT00427960|f||OTHER||t
17176606|NCT01617148|f||||f
17176607|NCT03127956|f||||t
17176608|NCT00423670|f||OTHER|The Principal Investigator agrees to provide to the sponsor thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including slides and texts of oral or other public presentations and texts of any transmission through any electronic media) that report any results of the study.|t
17176609|NCT04163718|t||||
17176610|NCT01025154|t||||
17176611|NCT03696927|f||||f
17176612|NCT02942576|f||||f
17176613|NCT00938964|t||||f
17138968|NCT01838655|t||||
17138969|NCT01094808|t||||f
17138970|NCT00369278|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176614|NCT01858636|f||||f
17176615|NCT02139800|f||||f
17176616|NCT01765803|t||||
17176617|NCT03523000|t||||
17176618|NCT01085500|t||||f
17176619|NCT01227564|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176620|NCT04697381|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176621|NCT04812080|t||||
17176622|NCT06309407|f||||f
17176623|NCT01057901|f||||f
17176624|NCT02096575|f||||f
17176625|NCT02862600|f||||f
17176626|NCT01987401|f||||f
17176627|NCT04859114|f||||f
17176628|NCT02378025|f||||f
17176629|NCT02495103|f||||f
17176630|NCT01654796|f||||f
17176631|NCT00772070|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17176632|NCT01309308|t||||
17183574|NCT05711069|f||||f
17132112|NCT00546052|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132113|NCT02482129|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17132114|NCT01928381|f||GT60||t
17132115|NCT05036083|t||||
17132116|NCT01355705|f||||f
17132117|NCT04441905|f||LTE60||t
17132118|NCT02392429|f||LTE60||t
17132119|NCT06523491|f||||f
17132120|NCT03266016|t||||
17132121|NCT03656562|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132122|NCT03686397|f||OTHER|Any publication shall be expressly authorized in written by the Sponsor.|t
17132123|NCT02257580|t||||f
17132124|NCT05036681|t||||
17132125|NCT01241708|t||||
17132126|NCT05159557|f||||f
17132127|NCT02968810|f||LTE60||t
17176633|NCT01017575|f||OTHER|Bristol Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single center publications until after disclosure of the clinical trial's primary publication.|t
17176634|NCT01476644|f||||f
17176635|NCT00095628|f||LTE60||t
17176636|NCT04271280|f||||f
17176637|NCT00495131|f||||f
17176638|NCT00744471|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176639|NCT02034422|f||||f
17176640|NCT01525173|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176641|NCT04706416|t||||
17176642|NCT00970736|f||||f
17176643|NCT03014492|f||||f
17176644|NCT01539317|t||||
17176645|NCT04705363|f||||f
17176646|NCT01616082|t||||
17176647|NCT00976573|t||||
17176648|NCT02117427|f||OTHER|Should the investigator wish to publish the results of this study, the investigator agrees to provide Medgenics with a manuscript for review 60 days prior to submission for publication. Medgenics retains the right to delete from the manuscript information that is confidential and proprietary and to object to suggested publication and/or its timing (at the Company's sole discretion).|t
17176649|NCT04616027|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176650|NCT03737851|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176651|NCT00937391|f||LTE60||t
17176652|NCT01753739|f||OTHER|Contact sponsor directly for details.|t
17183575|NCT00856024|f||OTHER|The text of the article that will be submitted to the journal shall be defined in common accord between the Investigators and the Sponsor. The principal investigators also agree to not publish and/or present interim results of the study without due written authorization of the Sponsor.|t
17183576|NCT01531959|f||||f
17132128|NCT04137887|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132129|NCT02040298|t||||
17132130|NCT00898222|f||||f
17132131|NCT04183335|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132132|NCT02605642|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176653|NCT01232205|f||||f
17176654|NCT02945787|t||||
17132133|NCT01934140|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176655|NCT04192370|f||||f
17176656|NCT01436162|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17183577|NCT02057757|f||||f
17183578|NCT03614793|f||||f
17183579|NCT02082522|f||LTE60||t
17132134|NCT00805740|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132135|NCT00200850|t||||
17132136|NCT02595879|f||LTE60||t
17176657|NCT05032859|f||||t
17176658|NCT01535664|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17176659|NCT01931202|f||||f
17176660|NCT02153710|f||||f
17176661|NCT04597918|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176662|NCT00395538|t||||
17176663|NCT01074047|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation 60 days in advance of the submission and (ii) delete any confidential information of the sponsor and (iii) delay submission for up to 90 days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17176664|NCT01069185|t||||
17132137|NCT04669678|f||GT60||t
17132138|NCT05227690|f||||t
17132139|NCT04294459|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132140|NCT03757988|t||||
17132141|NCT03806127|f||OTHER|The Sponsor does not object to publication by Institution or Principal Investigator (PI) of results of the Trial based on information collected or generated by the Institution or PI. However, the Institution and PI are required to provide the Sponsor with an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed to ensure against any inadvertent disclosure of Sponsor Confidential Information or unprotected Sponsor Inventions.|t
17132142|NCT01390259|t||||
17132143|NCT00522795|f||||f
17132144|NCT03823391|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132145|NCT02450487|f||||f
17132146|NCT05159596|f||||f
17132147|NCT03946670|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17132148|NCT03132636|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17132149|NCT03461445|f||LTE60||t
17132150|NCT03470129|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132151|NCT04537208|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132152|NCT03142321|f||||f
17132153|NCT03042468|t||||
17132154|NCT03083886|t||||f
17132155|NCT01764633|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132156|NCT02263833|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132157|NCT00704964|f||||f
17132158|NCT02062658|f||||f
17132159|NCT04418765|f||||f
17176665|NCT00859027|t||||
17176666|NCT04041700|f||OTHER|The institutions agree that no publication of the study results may be made until publication of the results of the multi-centre study or 2 years after study completion, whichever is the sooner.|t
17176667|NCT02775903|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132160|NCT02161562|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132161|NCT03423342|f||||f
17132162|NCT03033745|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132163|NCT00323557|t||||f
17132164|NCT00662792|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132165|NCT00090545|f||||f
17132166|NCT02347176|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17132167|NCT01014741|f||||f
17132168|NCT00236977|f||LTE60||t
17132169|NCT01665118|f||||f
17132170|NCT05779072|f||||f
17132171|NCT02194439|t||||
17132172|NCT03984305|f||OTHER|A participating institution/PI may publish its individual site results; however, the sponsor has the exclusive right to publish the complete accumulated results of the multi-center trial. If a manuscript for the multi-center publication has not been submitted within 12 months of the conclusion or termination of the trial, then the institution/PI may publish a subset of the trial results. The sponsor shall be acknowledged in accordance with scientific practice.|t
17132173|NCT02004873|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17132174|NCT00630955|f||||f
17132175|NCT04925752|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17132176|NCT00866307|f||OTHER|Must obtain prior Sponsor approval.|t
17132177|NCT03726164|f||||f
17132178|NCT01060059|f||||f
17132179|NCT05165654|f||||f
17132180|NCT00980538|f||OTHER|The investigator agrees that before he/she publishes any results of this trial, he/she shall allow at least 45 days for the Sponsor to review the pre-publication manuscript prior to submission of the manuscript to the publisher, as specified in the Clinical Trial Agreement between Institution/Investigator and Sponsor.|t
17132181|NCT05556525|t||||
17132182|NCT04770753|f||OTHER||t
17132183|NCT02775851|f||LTE60||t
17132184|NCT00598975|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17176668|NCT00911742|f||OTHER|The investigator must agree to maintain the confidentiality of the study at all times, and he cannot reveal any information coming from the protocol, the study results or any documentation related to the study, without permission of the sponsor. Any publication of the results, in whole or in part will require the permission of the sponsor.|t
17176669|NCT01683019|f||||f
17176670|NCT00543855|f||||f
17176671|NCT04509739|f||||f
17176672|NCT04444895|f||OTHER||t
17176673|NCT05959200|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study|t
17176674|NCT03954041|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17176675|NCT04177355|f||||f
17176676|NCT00397943|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176677|NCT05007717|f||||f
17176678|NCT03436563|t||||
17176679|NCT02806973|f||GT60||t
17176680|NCT02840240|t||||
17176681|NCT02477423|t||||
17176682|NCT00842764|f||||t
17183580|NCT00456092|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17176683|NCT03282565|f||||f
17176684|NCT02131532|f||||f
17176685|NCT01466595|f||||f
17176686|NCT00450112|f||OTHER|SKK has the right to review the disclosures. Investigator shall not make any publication of study data, results or similar information without the express of permission of SKK.|t
17176687|NCT01264016|f||GT60||t
17176688|NCT02147184|f||||f
17183581|NCT02840877|f||||f
17183582|NCT01168999|t||||
17183583|NCT01276327|t||OTHER||t
17132185|NCT04033367|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17183584|NCT01047683|f||OTHER|PIs are restricted in sharing data until an abstract presentation or publication of the manuscript.|t
17183585|NCT03732248|t||||
17183586|NCT00733824|t||||
17183587|NCT02708745|f||||f
17183588|NCT02480621|t||||f
17183589|NCT01825408|t||||f
17132186|NCT02908880|f||OTHER|Typical language included: Research Institution and Principal Investigator agree that they shall not, without the Sponsor's prior written consent, independently Publish any results of or information about the activities conducted until the multi-center publication is released. If a multi-center manuscript is not submitted for publication within one (1) year after completion of the multi-center Study, Research Institution and Principal Investigator shall have the right to Publish results.|t
17132187|NCT03521505|t||||
17132188|NCT03193398|f||||f
17132189|NCT02170662|t||||
17132190|NCT00491179|f||||f
17132191|NCT01790048|t||||
17132192|NCT04269395|f||||f
17132193|NCT00584233|t||||f
17132194|NCT02222714|f||||f
17176689|NCT02117414|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17176690|NCT00417482|f||||f
17176691|NCT05402020|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176692|NCT06400979|f||||f
17176693|NCT03739840|f||GT60||t
17176694|NCT01828515|f||LTE60||t
17176695|NCT01058265|t||||
17176696|NCT02962765|f||||f
17176697|NCT02343081|t||||
17176698|NCT06207435|f||||f
17176699|NCT00750880|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176700|NCT00984568|f||OTHER|The investigator agrees to provide the sponsor 45 days prior to publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor has the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis with respect to: proprietary information, accuracy, and fair balance.|t
17176701|NCT02964507|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17176702|NCT05014490|f||||t
17176703|NCT05078138|t||||
17176704|NCT03880461|f||||f
17176705|NCT04847622|f||||f
17176706|NCT03862040|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17176707|NCT04025710|f||||f
17176708|NCT02431247|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17176709|NCT01562873|f||||f
17183590|NCT00235989|f||||f
17183591|NCT00178191|f||||f
17183592|NCT00983580|f||LTE60||t
17183593|NCT00433992|f||||f
17183594|NCT01971346|f||||f
17132195|NCT05030311|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176710|NCT01369485|f||||f
17176711|NCT04811573|t||||
17176712|NCT00194675|t||||f
17176713|NCT01285960|f||||f
17176714|NCT00586196|t||||
17183595|NCT01652716|f||LTE60||t
17183596|NCT03735862|f||||f
17183597|NCT01514318|f||LTE60||t
17183598|NCT00360334|f||GT60||t
17183599|NCT00594256|t||||f
17183600|NCT04160260|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17183601|NCT01978184|t||||f
17183602|NCT03837496|f||||f
17183603|NCT00236938|f||LTE60||t
17183604|NCT01218997|f||OTHER|Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.|t
17132196|NCT03529773|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132197|NCT01415427|t||||
17132198|NCT01537211|f||||f
17176715|NCT02280473|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176716|NCT01484054|f||OTHER||t
17176717|NCT01610271|f||||f
17176718|NCT00364130|f||||f
17176719|NCT00410202|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17176720|NCT01482351|f||||f
17176721|NCT00144027|t||||
17176722|NCT05223335|t||||
17176723|NCT01520454|t||||f
17176724|NCT00392821|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17176725|NCT03304639|f||LTE60||t
17176726|NCT03194490|t||||
17176727|NCT01758289|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176728|NCT01574079|t||||
17176729|NCT02865343|f||||f
17176730|NCT00285207|f||||f
17176731|NCT02294773|t||||
17176732|NCT03052764|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17176733|NCT05828095|f||||f
17176734|NCT03206073|f||||f
17176735|NCT03332771|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17183605|NCT01815671|t||||f
17183606|NCT03390907|f||||f
17183607|NCT01222585|t||||f
17183608|NCT01767792|f||GT60||t
17183609|NCT02584309|t||||
17132199|NCT00328770|f||||f
17183610|NCT02287415|t||||
17183611|NCT04551105|t||||
17183612|NCT02447991|f||||f
17183613|NCT00459134|t||||
17132200|NCT00653861|f||OTHER|At least ninety (90) days prior to any proposed submission for publication or presentation of Study data or other findings related to the Study, the Investigator will provide the Sponsor with a manuscript of such submission(s) for review and comment.|t
17132201|NCT01877564|t||||
17132202|NCT01573273|t||||
17132203|NCT03545906|f||||f
17132204|NCT01347034|t||||
17132205|NCT00257010|f||GT60||t
17132206|NCT00608985|f||OTHER||t
17132207|NCT00584480|f||||f
17132208|NCT01699087|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study|t
17132209|NCT02582957|f||||f
17132210|NCT00744874|f||LTE60||t
17132211|NCT03403205|f||||t
17132212|NCT01834729|t||||
17132213|NCT02971670|f||||f
17132214|NCT00288080|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17132215|NCT01017952|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132216|NCT01235962|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17132217|NCT00087646|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132218|NCT01331304|t||||f
17132219|NCT01580397|f||||t
17132220|NCT02902120|f||||f
17132221|NCT04926779|f||||f
17132222|NCT03522441|f||||f
17132223|NCT00693160|t||||
17132224|NCT04063371|t||||f
17132225|NCT05787847|t||||
17132226|NCT06468059|f||||f
17132227|NCT02199197|t||||
17132228|NCT06098729|t||||
17132229|NCT02129660|f||||t
17132230|NCT03650192|t||||
17183614|NCT04523129|f||GT60||t
17183615|NCT01612546|t||||
17183616|NCT00234884|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17183617|NCT01016834|f||GT60||t
17183618|NCT02969928|f||||f
17183619|NCT03568461|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17138971|NCT01224106|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138972|NCT00446797|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17138973|NCT02133001|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17138974|NCT05935982|f||||f
17138975|NCT03967847|t||||
17138976|NCT02498392|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17138977|NCT02864706|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17138978|NCT03135262|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17138979|NCT01675141|f||||f
17138980|NCT03097133|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17176736|NCT00096954|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176737|NCT04176497|t||||
17176738|NCT04478123|t||||
17176739|NCT04999982|f||||f
17176740|NCT03581786|f||||f
17176741|NCT00572897|f||||f
17176742|NCT01347307|f||||f
17176743|NCT00606944|f||||f
17176744|NCT01557894|t||||f
17176745|NCT04123665|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176746|NCT02237911|f||||f
17176747|NCT00053365|f||LTE60||t
17176748|NCT01583543|f||||f
17176749|NCT02260531|f||||f
17176750|NCT00958789|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts \& abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to the submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17183620|NCT03964454|f||||f
17183621|NCT03328897|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17183622|NCT00158379|f||||f
17183623|NCT01750268|t||||f
17183624|NCT00509197|f||||f
17183625|NCT04175262|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183626|NCT01969838|f||OTHER|Agreements varied with individual investigators, but did not prohibit any investigator from publishing. Investigators were not to publish results of the study until a period of time (eg. 2 years) following completion of the trial at all participating institutions but could do so earlier with consent of the Sponsor.|t
17183627|NCT03087591|t||||
17183628|NCT00408993|f||GT60||t
17183629|NCT03738865|f||OTHER|Neither the Institution nor the principal investigator may submit for publication or presentation, the results of this trial without prior written consent of the sponsor.|t
17183630|NCT02621606|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17132231|NCT04116112|f||||f
17132232|NCT02692209|f||||f
17176751|NCT00721123|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176752|NCT01885871|t||||
17176753|NCT03007407|f||LTE60||t
17176754|NCT00090051|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176755|NCT01896479|f||||t
17176756|NCT00433511|f||LTE60||t
17176757|NCT03139604|f||OTHER|Clinical Study Agreement|t
17176758|NCT04950608|f||||f
17176759|NCT00585559|t||||
17176760|NCT02007512|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176761|NCT02145507|f||LTE60||t
17176762|NCT00608543|f||||f
17176763|NCT01654861|t||||
17176764|NCT03026088|f||||f
17176765|NCT03727373|t||||
17176766|NCT01869725|t||||
17176767|NCT01143207|t||||f
17176768|NCT04457973|f||||f
17176769|NCT01056328|f||OTHER||t
17176770|NCT02960997|t||||
17176771|NCT04824365|f||||f
17176772|NCT01770652|f||LTE60||t
17176773|NCT03416374|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176774|NCT01052844|f||||f
17176775|NCT03463031|f||||t
17176776|NCT00920231|f||||f
17176777|NCT01684020|f||||f
17176778|NCT02537574|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17176779|NCT00048061|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17183631|NCT01694706|t||||
17183632|NCT03779997|f||||f
17183633|NCT02252081|t||||
17183634|NCT00491244|f||||f
17183635|NCT03766646|f||||f
17132233|NCT03467958|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132234|NCT02925156|t||||
17132235|NCT03434379|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132236|NCT03564626|t||||
17132237|NCT01658657|f||||f
17132238|NCT03502993|f||||f
17132239|NCT04202679|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17132240|NCT01680900|f||||f
17132241|NCT03406897|t||||f
17132242|NCT02066792|f||||f
17132243|NCT00975156|f||||f
17176780|NCT02675231|f||||f
17176781|NCT02495233|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17176782|NCT00672204|t||||
17183636|NCT00759967|t||||f
17183637|NCT03264157|f||OTHER||t
17183638|NCT01037309|f||LTE60||t
17183639|NCT00786916|t||||
17183640|NCT01734746|f||||f
17183641|NCT04279925|t||||
17183642|NCT00659269|t||||
17183643|NCT01158222|t||||
17183644|NCT01132144|f||||f
17183645|NCT00962429|t||||
17183646|NCT01490060|t||||
17183647|NCT01877421|f||||f
17183648|NCT01611571|f||||f
17183649|NCT00724451|f||OTHER|The principal investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. The principal investigator further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication.|t
17183650|NCT03835260|t||||
17183651|NCT01260922|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17183652|NCT04165291|f||||f
17183653|NCT02658851|f||||f
17183654|NCT03653429|f||||f
17183655|NCT01525082|t||||
17183656|NCT01385059|t||||
17183657|NCT01767116|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183658|NCT02141516|f||OTHER|"The terms and conditions of Novartis' agreement with its investigators may vary.~However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial."|t
17183659|NCT00752908|t||||
17183660|NCT00153101|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17183661|NCT02610140|f||OTHER|The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.|t
17183662|NCT03169153|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17183663|NCT04524962|f||||f
17183664|NCT01975389|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183665|NCT00333606|t||||f
17183666|NCT03333746|t||||
17183667|NCT01485601|f||LTE60||t
17183668|NCT04278417|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183669|NCT00850031|f||OTHER||t
17183670|NCT01603875|t||||f
17183671|NCT00298831|f||OTHER|Sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17138981|NCT02873208|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17138982|NCT01192100|f||||f
17138983|NCT03882723|t||||
17138984|NCT02074904|t||||
17138985|NCT02017704|t||||
17138986|NCT00918346|f||OTHER|The sponsor respects the investigators' wish to publish results of the study, and will not unnecessarily restrict the spreading of information of scientific interest. However, the study may involve confidential information affecting the company's business, such as aspects related to patent application. Therefore, the investigators agree to allow the sponsor to review any manuscripts and to negotiate timing and forum of publication.|t
17138987|NCT01095666|f||||f
17138988|NCT00744692|t||||
17138989|NCT01577628|f||||f
17138990|NCT00841672|f||OTHER||t
17138991|NCT00356057|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17138992|NCT02219997|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17138993|NCT02427100|f||||f
17138994|NCT00842361|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17138995|NCT01877941|f||||f
17138996|NCT00924729|t||||
17183672|NCT01306617|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183673|NCT04028388|f||||f
17183674|NCT01114516|f||||f
17183675|NCT00129259|f||||f
17183676|NCT02758236|f||||f
17183677|NCT05789875|t||||
17183678|NCT01994395|f||||f
17183679|NCT01940705|t||||f
17183680|NCT00139997|f||||f
17183681|NCT01632579|f||GT60||t
17132244|NCT02723201|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17132245|NCT03472560|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132246|NCT01946178|f||GT60||t
17132247|NCT01534676|t||||
17132248|NCT00540579|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17132249|NCT02421887|f||||f
17132250|NCT01970176|t||||
17132251|NCT01285908|t||||f
17132252|NCT01340209|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17132253|NCT06219577|t||||
17132254|NCT02475655|f||||f
17132255|NCT03382847|f||||f
17132256|NCT00353418|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132257|NCT01895127|f||||f
17138997|NCT00214487|f||OTHER|The Investigator acknowledges that the data to be collected is proprietary. The Investigator agrees not to publish, divulge, reveal, disclose or otherwise make available, the data to others without the permission of sponsor unless the data have already been, or are subsequently published or disclosed by order of a court of law. The Investigator will not be free to publish papers dealing with the results of any Research performed under this Agreement without the consent of sponsor.|t
17138998|NCT00981747|f||||f
17138999|NCT01814826|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17139000|NCT02917629|f||LTE60||t
17176783|NCT02220998|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17176784|NCT02314143|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176785|NCT02354482|t||||
17176786|NCT00873860|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17176787|NCT00708071|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17176788|NCT02140775|f||||f
17176789|NCT00945854|f||||f
17176790|NCT04650854|f||GT60||t
17176791|NCT00704808|f||OTHER|Publishing or dissemination of study results requires a written approval of the sponsor.|t
17176792|NCT01388920|f||||f
17176793|NCT01280955|f||||f
17176794|NCT04223232|f||||f
17176795|NCT05281601|f||OTHER|No unpublished information may be disclosed without prior written approval from AstraZeneca.|t
17176796|NCT03172910|f||||f
17176797|NCT01659658|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176798|NCT03402659|f||||f
17132258|NCT03244033|f||||f
17139001|NCT03339401|f||OTHER|Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publication may be delayed up to an additional 3 months to allow Sponsor to seek patent protection.|t
17139002|NCT00718523|f||||f
17139003|NCT03271307|f||||f
17183682|NCT00818441|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183683|NCT00612313|f||||f
17183684|NCT04176796|f||||f
17183685|NCT01736566|f||||f
17183686|NCT05955560|f||||f
17183687|NCT04621500|f||||f
17183688|NCT01343160|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Sponsor can require changes to the communication as necessary to ensure the proper use of any references to itself, its trademarks, and trade names and to correct inaccuracies in any technical specifications or descriptions of the device, including its component materials.|t
17183689|NCT01337089|f||GT60||t
17183690|NCT03574129|f||||f
17183691|NCT02710630|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17183692|NCT02461589|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17183693|NCT01978119|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183694|NCT03295201|f||||f
17183695|NCT01465334|f||||f
17183696|NCT00572572|f||||f
17183697|NCT01831089|f||LTE60||t
17183698|NCT01958918|f||OTHER|The terms and condition of Novartis'agreements with its investigator may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17183699|NCT01925183|t||||
17183700|NCT02114892|f||||f
17183701|NCT02061345|t||||
17183702|NCT04327934|t||||
17183703|NCT03525834|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183704|NCT03095417|f||||f
17183705|NCT01410110|f||||f
17183706|NCT00539526|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17183707|NCT04689737|f||||f
17183708|NCT03895853|t||||
17183709|NCT03783923|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17183710|NCT02543346|f||||f
17183711|NCT01242527|f||OTHER|Individual investigators may publish data arising from their own subjects. The PI will provide the Sponsor with copies of written publications (including abstracts and posters)at least 60 days in advance of submission. Data will be reviewed by all participating investigators prior to publication. The Sponsor will have 60 days to review all definitive publications, such as manuscripts and book chapters, and a minimum of 30 days to review all abstracts.|t
17132259|NCT03021642|f||OTHER|Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their representatives will require review by the Sponsor before submission. The Sponsor will not suppress publication, but maintains the right to delay publication in order to protect intellectual property rights.|t
17132260|NCT00441545|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17132261|NCT02474082|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132262|NCT03452371|f||||f
17132263|NCT04317274|f||||f
17132264|NCT03534427|t||||
17132265|NCT03439033|t||||f
17132266|NCT00566930|f||||f
17132267|NCT01064167|t||||
17132268|NCT02435914|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132269|NCT01353703|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132270|NCT00868101|f||LTE60||t
17132271|NCT02642094|t||||
17132272|NCT02882633|t||||
17132273|NCT02286947|f||OTHER|The most restrictive relevant agreement provides that the PI can only publish the study results with the approval of Sponsor.|t
17132274|NCT02175680|f||||f
17132275|NCT03979274|f||||f
17183712|NCT00887341|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183713|NCT01649856|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183714|NCT00622635|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17183715|NCT00281840|t||||
17183716|NCT00006411|f||||f
17183717|NCT03383588|t||||
17183718|NCT01079234|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17183719|NCT01037790|f||||f
17183720|NCT01312961|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17183721|NCT03291613|f||||f
17183722|NCT00205712|f||||f
17132276|NCT01665144|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132277|NCT01128829|t||||f
17132278|NCT04520113|f||||f
17176799|NCT01442038|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17176800|NCT00089284|t||||
17176801|NCT02428608|f||||f
17176802|NCT03646643|f||||f
17176803|NCT04521777|t||||
17176804|NCT00900601|f||||f
17176805|NCT01669096|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176806|NCT00214500|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17176807|NCT00147251|f||||f
17176808|NCT01629706|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17176809|NCT00701376|t||||f
17176810|NCT02663687|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonmentor termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176811|NCT03595774|f||||f
17176812|NCT01151098|f||GT60||t
17176813|NCT01880047|t||||
17176814|NCT01593722|f||||f
17176815|NCT00116168|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17176816|NCT02788474|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132279|NCT01913483|f||||f
17132280|NCT02302963|t||||
17132281|NCT01816243|f||OTHER|"Timing and publication of the results will be subject to mutual agreement in the project between all Investigators participating in the project and Janssen-Cilag., Thailand.~All manuscripts and abstracts utilizing the data from this study are subjected to the approval of Janssen. All manuscripts and abstract must be sent to Janssen at least one month prior to the submission for publication or presentation."|t
17176817|NCT01272284|f||LTE60||t
17176818|NCT00117286|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17176819|NCT03555435|f||||f
17176820|NCT00992927|t||||
17176821|NCT04489732|t||||
17176822|NCT01272661|t||||f
17132282|NCT00915343|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176823|NCT02869438|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17176824|NCT04115644|t||||
17176825|NCT01601431|t||||
17176826|NCT02169284|f||LTE60||t
17176827|NCT04505540|f||||f
17176828|NCT03583073|f||||f
17176829|NCT01367119|t||||f
17176830|NCT05342532|f||||f
17176831|NCT01257802|t||||
17176832|NCT02057393|t||||
17176833|NCT03180684|f||||t
17132283|NCT01920711|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132284|NCT02319044|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publications prior to public release for a period up to 120 days to confirm accuracy, prevent disclosure of confidential information, and ensure that information is handled appropriately.|t
17132285|NCT01145066|t||||
17132286|NCT00723788|f||||f
17132287|NCT03687502|t||||
17132288|NCT01724528|f||LTE60||t
17132289|NCT00466310|t||||
17132290|NCT04949841|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17132291|NCT01777581|t||||f
17132292|NCT01211600|f||||f
17132293|NCT01634555|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17132294|NCT04247425|t||||
17132295|NCT06228586|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132296|NCT02527707|f||||f
17132297|NCT00930059|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132298|NCT01636466|t||||
17132299|NCT01966770|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior consent from the sponsor.|t
17132300|NCT01299766|f||||f
17132301|NCT03075085|t||||f
17132302|NCT03064763|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132303|NCT00403260|f||||f
17132304|NCT01354028|t||||
17132305|NCT02109159|f||||f
17132306|NCT00935883|f||||f
17132307|NCT03195517|f||||f
17132308|NCT03312517|f||||f
17132309|NCT00808444|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132310|NCT01846455|f||GT60||t
17176834|NCT01115803|f||GT60||t
17132311|NCT00305578|f||||f
17132312|NCT03881007|t||||
17132313|NCT02770326|t||||
17132314|NCT01622569|f||OTHER|Disclosure agreement is described in CTA between sponsor and PI|t
17176835|NCT03475875|f||GT60||t
17176836|NCT02017171|f||||f
17176837|NCT02721979|t||||
17176838|NCT03091777|f||GT60||t
17176839|NCT02536833|f||||t
17176840|NCT00922701|f||||f
17176841|NCT02764190|f||||f
17176842|NCT01172275|f||||f
17176843|NCT01810588|t||||
17176844|NCT05308290|f||||f
17176845|NCT04437368|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17176846|NCT01982331|f||||f
17176847|NCT01490788|f||GT60||t
17176848|NCT04186481|f||GT60||t
17176849|NCT01231230|t||||
17176850|NCT04105543|t||||
17176851|NCT02393690|f||GT60||t
17176852|NCT00586846|t||||
17176853|NCT01674634|f||OTHER||t
17176854|NCT02059005|f||||f
17176855|NCT02142803|f||LTE60||t
17132315|NCT01505894|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132316|NCT01001702|f||||f
17132317|NCT00997516|t||||
17132318|NCT03222427|f||GT60||t
17132319|NCT01940484|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132320|NCT03106779|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17132321|NCT02288247|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17132322|NCT04142983|t||||
17132323|NCT01394705|t||||f
17132324|NCT00643994|f||||f
17132325|NCT00197054|f||||f
17132326|NCT02272686|t||||
17132327|NCT04823949|f||||f
17176856|NCT01298544|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176857|NCT02900560|f||OTHER|No publication, abstract or presentation of the study will be made without the approval of the Study Steering Committee (SSC).|t
17176858|NCT02718300|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17176859|NCT03120624|t||||
17132328|NCT01307930|f||||f
17132329|NCT00797823|f||||f
17132330|NCT02568046|f||OTHER|Publications shall not disclose any Sponsor confidential information and property (not including the trial results). The Sponsor reserves the right to review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132331|NCT00523991|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17132332|NCT00193063|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17132333|NCT04173429|t||||
17132334|NCT00379795|f||||f
17132335|NCT02435849|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17132336|NCT04849780|f||GT60||t
17132337|NCT00352105|t||||
17132338|NCT01405053|f||||f
17132339|NCT02551159|f||||f
17176860|NCT05063318|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17176861|NCT00729924|f||||f
17176862|NCT04070144|f||||f
17176863|NCT01847001|t||||
17132340|NCT00268242|f||||f
17176864|NCT01927341|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176865|NCT04233034|f||||f
17132341|NCT00993928|f||LTE60||t
17132342|NCT04871711|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-center publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17132343|NCT02420873|t||||
17132344|NCT01493180|f||||f
17132345|NCT04556617|f||||f
17132346|NCT03179436|f||OTHER|If publication activity was not directed by the Sponsor, the investigator agreed to submit all manuscripts or abstracts to the Sponsor before submission. This allowed the Sponsor to protect proprietary information and to provide comments.|t
17132347|NCT03382574|f||||f
17132348|NCT02247193|t||||
17176866|NCT02791399|f||||f
17132349|NCT01877083|f||OTHER||t
17132350|NCT00429585|t||||
17132351|NCT02017574|t||||
17139004|NCT03365947|f||OTHER|The only disclosure restriction on the PI is that the sponsor retains first right to publish results for this multi-center study, and thereafter can review results communications prior to release and can embargo communications regarding trial results for a period that is 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication of results but can require removal of its confidential information (excluding results).|t
17139005|NCT03136484|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17139006|NCT00360685|t||||
17139007|NCT04399980|f||||f
17139008|NCT03997760|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17139009|NCT00856986|f||OTHER|"Novo Nordisk reserves the right not to release data until specified milestones, e.g. a clinical trial report is available. This includes the right not to release interim results from clinical trials.~At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications. Novo Nordisk reserves the right to postpone publication for a short time to protect intellectual property."|t
17139010|NCT00044655|f||||f
17139011|NCT01347632|t||||f
17139012|NCT01883804|f||||f
17139013|NCT01906476|f||||f
17139014|NCT01115517|f||||f
17139015|NCT01176240|f||LTE60||t
17139016|NCT01931150|t||||
17176867|NCT00451451|f||OTHER|The provisions of our agreement are subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication|t
17176868|NCT00084838|f||LTE60||t
17176869|NCT00122278|t||||
17176870|NCT01865084|f||GT60||t
17176871|NCT01994590|t||||
17176872|NCT03607422|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176873|NCT03693170|f||LTE60||t
17176874|NCT03875118|t||||
17176875|NCT01043146|f||OTHER|The PI can discuss and publish trial results upon review of results communication by the sponsor. The sponsor can require changes to the communication.|t
17176876|NCT03092024|t||||
17176877|NCT02128828|f||||f
17183723|NCT01331694|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183724|NCT04796831|f||||f
17183725|NCT01337297|f||||f
17183726|NCT02316717|f||||t
17132352|NCT02192931|f||||f
17132353|NCT01227902|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132354|NCT04002310|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132355|NCT00542997|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.|t
17132356|NCT03303911|f||OTHER|Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.|t
17132357|NCT02949128|f||||f
17132358|NCT02388568|f||||f
17132359|NCT01641120|t||||f
17132360|NCT02594644|f||||f
17132361|NCT03160560|f||||t
17132362|NCT01664793|f||||f
17132363|NCT03179085|f||||f
17132364|NCT02002975|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17132365|NCT04391959|f||LTE60||t
17132366|NCT01430442|f||LTE60||t
17139017|NCT02896192|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17139018|NCT03561246|t||||f
17139019|NCT00464711|f||||f
17132367|NCT01641939|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176878|NCT03228420|f||OTHER|Initial publication of the results will be a joint, multicenter publication with all PIs and sites contributing data, analyses, and critical review of the manuscript. If no such publication occurs within 12 months of study completion, individual PIs may publish results from their center. PIs will allow sponsor 30 days to review any potential publications or presentations and sponsor can request an additional 60 days if needed.|t
17132368|NCT02088385|t||||
17132369|NCT00847587|f||||f
17132370|NCT02971202|t||||
17132371|NCT02634580|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132372|NCT01418001|t||||
17176879|NCT01298531|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176880|NCT01841736|f||LTE60||t
17176881|NCT01933217|f||||f
17176882|NCT02861131|f||||f
17176883|NCT03923738|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176884|NCT02751788|f||||f
17176885|NCT03583164|f||OTHER|F2G retains the right to review all articles referring to olorofim and generated from sponsored studies. All articles should be submitted to F2G for review at least 8 weeks prior to submission to the target journal. F2G reserves the right to delay publication or presentation if there is an issue relating to protecting intellectual property rights.|t
17176886|NCT00735254|t||||
17176887|NCT01952600|f||||f
17176888|NCT00057954|f||||f
17176889|NCT00559754|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132373|NCT05425563|f||||f
17132374|NCT01087541|t||||f
17132375|NCT05210504|f||||f
17132376|NCT04652804|t||||
17132377|NCT00584194|f||||f
17132378|NCT04093531|t||||
17132379|NCT02918019|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132380|NCT01212185|f||||f
17132381|NCT03222349|f||GT60||t
17132382|NCT00510809|t||||
17132383|NCT00094757|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132384|NCT01808612|f||GT60||t
17132385|NCT00756938|f||OTHER|Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results for their study site independently. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17132386|NCT01700192|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17132387|NCT01727895|t||||
17132388|NCT03403192|t||||
17132389|NCT01127165|f||||f
17132390|NCT03175549|f||||f
17132391|NCT00763321|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132392|NCT02486757|f||||f
17132393|NCT02793232|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139020|NCT01308294|t||||
17139021|NCT00479167|t||||
17139022|NCT01311895|t||||
17139023|NCT01390038|f||OTHER|PIs are restricted from publishing study results until either 18 months after the study is completed or the primary manuscript has been accepted, whichever comes first.|t
17139024|NCT01044056|f||||f
17132394|NCT01298492|f||OTHER|Sponsor has the right to review disclosures, requesting a delay of up to 60 days. The first publication must be a joint publication covering all centers. However, if a joint manuscript has not been submitted for publication within 12 months of completion or termination of study at all participating sites, Investigator may publish individual site results separately. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132395|NCT03543410|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17176890|NCT01251744|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176891|NCT00315146|t||||
17176892|NCT01068652|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17176893|NCT00751621|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132396|NCT02883244|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. PI shall delay publications for up to 60 days to allow sufficient time to resolve any questions or seek patent protection.|t
17176894|NCT03343067|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132397|NCT00820755|f||OTHER||t
17132398|NCT00535925|t||||
17132399|NCT02180893|t||||
17132400|NCT02838407|t||||
17176895|NCT01323946|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176896|NCT01243671|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17176897|NCT00573248|t||||f
17176898|NCT05619523|t||||
17176899|NCT01013649|f||LTE60||t
17176900|NCT02808871|f||||f
17132401|NCT03551743|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization.|t
17132402|NCT00911989|f||LTE60||t
17176901|NCT05323656|f||||t
17176902|NCT02398409|f||||f
17176903|NCT03370289|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176904|NCT03309046|f||||f
17176905|NCT00236951|f||LTE60||t
17176906|NCT03963401|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176907|NCT00979069|f||||f
17176908|NCT01721070|f||OTHER|Requires prior approval from AcelRx Pharmaceuticals, Inc.|t
17176909|NCT02204007|f||||f
17176910|NCT00910988|f||||f
17176911|NCT03004443|t||||
17176912|NCT00828854|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication|t
17176913|NCT03911843|f||||f
17132403|NCT01407094|f||||f
17132404|NCT01116544|f||||f
17132405|NCT02183519|t||||
17132406|NCT02542072|f||OTHER||t
17132407|NCT00289107|f||LTE60||t
17132408|NCT01172652|f||||f
17132409|NCT00695565|f||OTHER|The Investigator may not publish or present any study information without the express written approval of the Sponsor. The Sponsor may withhold approval for publication or presentation.|t
17132410|NCT02937350|f||||f
17139025|NCT03619837|f||||f
17139026|NCT00118404|f||||f
17139027|NCT02650895|f||||f
17176914|NCT01907100|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17176915|NCT03635788|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17176916|NCT04382755|t||||
17176917|NCT03811002|f||LTE60||t
17176918|NCT04191187|t||||
17183727|NCT02778204|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17176919|NCT01397201|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17176920|NCT00215683|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17176921|NCT01083485|f||||f
17183728|NCT04122443|t||||
17132411|NCT01119456|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17183729|NCT01072201|f||GT60||t
17132412|NCT02288273|f||OTHER|Institution \& PI agree they will not use or disclose and confidential information to third parties for a period of 10 years from receipt.|t
17183730|NCT02052466|f||||f
17183731|NCT00595582|t||||
17132413|NCT02419508|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17183732|NCT04409041|t||||
17132414|NCT03110900|t||||
17132415|NCT02447848|f||OTHER||t
17176922|NCT04493333|f||||f
17176923|NCT02247531|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176924|NCT03468985|f||LTE60||t
17183733|NCT00965848|f||OTHER|If the Institution \& Principal Investigator wish to publish information from Clinical Trial, a copy of manuscript must be provided to Sponsor at least 60 days prior to submission for publication/presentation \& will arrange expedited reviews for the same. No paper with confidential Information will be submitted without Sponsor's prior consent. If requested, Institution \& Principal Investigator will hold such publication for up to additional 60 days to allow filing of patent application.|t
17183734|NCT01130740|t||||
17183735|NCT03077165|f||LTE60||t
17183736|NCT00555438|t||||f
17183737|NCT00061048|f||||f
17183738|NCT01431508|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183739|NCT02755935|f||||f
17183740|NCT01092195|t||||
17183741|NCT01609556|f||OTHER||t
17183742|NCT04452344|f||||f
17183743|NCT00023452|t||||f
17183744|NCT02939105|f||||f
17183745|NCT03779841|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183746|NCT00162136|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132416|NCT00762515|f||LTE60||t
17132417|NCT00500682|f||OTHER||t
17132418|NCT02851173|f||||f
17183747|NCT02788175|t||||
17183748|NCT03930745|f||||t
17183749|NCT01693601|t||||
17183750|NCT04095858|f||||f
17183751|NCT04292301|f||||f
17183752|NCT03483623|t||||
17183753|NCT02770391|t||||
17176925|NCT04131556|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17176926|NCT04882501|t||||
17176927|NCT04060862|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17176928|NCT04629508|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17176929|NCT03288454|f||||f
17176930|NCT03051646|t||||
17176931|NCT00504985|t||||f
17176932|NCT00760214|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17176933|NCT03126370|t||||
17176934|NCT04157621|t||||
17176935|NCT03960554|f||||f
17176936|NCT02545075|f||LTE60||t
17176937|NCT01810432|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17176938|NCT00736879|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17176939|NCT03090412|t||||
17176940|NCT02360111|t||||
17176941|NCT00718302|f||||f
17176943|NCT02310321|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17176944|NCT01698905|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17176945|NCT03207555|f||||f
17176946|NCT01729247|f||||f
17176947|NCT02325791|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17176948|NCT03953183|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17176949|NCT01465191|t||||f
17132419|NCT01582308|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17132420|NCT02320487|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132421|NCT01182428|f||GT60||t
17132422|NCT01841333|f||||f
17132423|NCT05442853|t||||
17132424|NCT05280756|f||||f
17132425|NCT00836355|t||||
17132426|NCT01461044|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132427|NCT00716976|f||OTHER|Must obtain prior Sponsor approval.|t
17132428|NCT00122135|t||||
17132429|NCT03068325|t||||
17132430|NCT00374803|t||||f
17132431|NCT02298933|t||||
17132432|NCT00168831|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17132433|NCT02009878|f||OTHER|Center may publish study results but ≥ 60 days prior to any public presentation, a copy is sent to Sponsor for review and Center can delay publication for 60 days to permit Sponsor to protect its intellectual property rights or confidential information contained within the publication. The first publication is a joint publication, if Center is part of a multi-center study. Center is free to publish, if there is no multi-center publication within 18 months of completion/ termination of study.|t
17132434|NCT01044966|f||||f
17176950|NCT02273739|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17176951|NCT04795622|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17183754|NCT02199691|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132435|NCT03634800|t||||
17132436|NCT03118596|t||||
17132437|NCT01757717|t||||
17132438|NCT00927368|f||||f
17132439|NCT00883675|f||GT60||t
17132440|NCT05325775|f||||f
17132441|NCT00343512|t||||
17132442|NCT02876887|f||||f
17132443|NCT03887299|f||||f
17132444|NCT00191451|f||GT60||t
17132445|NCT00684515|f||OTHER|Prior approval by the Sponsor is required before the results obtained in the clinical study can be made public by the investigator (sub-investigator) in a publication or at a medical meeting.|t
17132446|NCT00592475|f||OTHER|Institute and/or Principal Investigator may publish trial data generated from the Study. Sponsor must receive the manuscript 60 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17132447|NCT01114529|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132448|NCT04428411|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132449|NCT00331409|f||||f
17132450|NCT00272987|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132451|NCT00356031|t||||f
17132452|NCT01163786|f||||f
17132453|NCT00634569|f||||f
17132454|NCT01076348|f||||f
17132455|NCT04137783|f||||f
17132456|NCT02167945|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132457|NCT01192347|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17132458|NCT04409873|t||||f
17132459|NCT03433781|t||||
17132460|NCT00408694|f||LTE60||t
17132461|NCT00492973|t||||
17132462|NCT03261531|t||||
17132463|NCT00363038|f||||f
17132464|NCT01983787|t||||
17132465|NCT02063035|t||||f
17132466|NCT01916629|f||GT60||t
17132467|NCT02082678|f||||f
17132468|NCT03543085|f||||f
17132469|NCT01099969|t||||
17132470|NCT00956254|f||||f
17183755|NCT02276495|f||||f
17183756|NCT03154710|f||||t
17132471|NCT00091832|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132472|NCT00946309|f||||f
17132473|NCT01478854|t||||f
17132474|NCT00874250|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17132475|NCT02317562|f||||t
17132476|NCT00626093|f||||f
17132477|NCT00603915|t||||f
17132478|NCT03891901|f||||f
17132479|NCT02105415|t||||
17132480|NCT00742469|f||||t
17132481|NCT04033419|t||||
17132482|NCT03122431|f||||f
17132483|NCT02558374|f||||f
17132484|NCT00573794|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132485|NCT02026063|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17132486|NCT02154087|f||LTE60||t
17132487|NCT00604968|f||OTHER|If an investigator wishes to publish data from the study, a copy must be provided to the sponsor for review at least 60 days before submission for publication. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days. If issues arise regarding scientific integrity or regulatory compliance, the sponsor will review these issues with the investigator. The sponsor will not change scientific content or suppress information.|t
17132488|NCT00486278|f||OTHER|The information obtained during the conduct of this trial is considered confidential and can be used by Novo Nordisk for regulatory purposes and for the general development of the trial product. The information obtained during this trial may be made available to other physicians who are conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk.|t
17139028|NCT01628042|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17139029|NCT02988401|f||||f
17139030|NCT04772469|f||||f
17139031|NCT03038672|f||LTE60||t
17139032|NCT01696396|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139033|NCT00983242|f||GT60||t
17139034|NCT03140488|t||||
17139035|NCT00959894|t||||
17139036|NCT00653068|f||OTHER|Must obtain prior Sponsor approval.|t
17139037|NCT01305941|f||GT60||t
17139038|NCT03950440|t||||
17139039|NCT02892734|t||||
17139040|NCT02043509|t||||
17176952|NCT00089674|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17176953|NCT02961218|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17176954|NCT00591266|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17176955|NCT03488927|f||||f
17176956|NCT00901927|t||||
17176957|NCT02239627|t||||
17132489|NCT05501119|f||||f
17132490|NCT01831960|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17132491|NCT03042936|t||||
17132492|NCT05168267|t||||
17132493|NCT05702736|f||||f
17139041|NCT04724291|f||||f
17139042|NCT03189563|f||LTE60||t
17139043|NCT00608244|f||OTHER|This study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PIs.|t
17139044|NCT02748785|f||||f
17139045|NCT01957215|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139046|NCT01670825|t||||
17139047|NCT04697888|t||||
17139048|NCT02613338|t||||f
17139049|NCT00698139|t||||f
17139050|NCT01685060|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17139051|NCT03597503|f||||t
17139052|NCT02944513|f||||f
17139053|NCT02314598|f||||t
17139054|NCT03690674|f||||f
17139055|NCT00937326|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17176958|NCT02676466|t||||
17176959|NCT01016561|t||||
17132494|NCT01356589|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132495|NCT01462266|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17183757|NCT00836875|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183758|NCT02927691|f||||f
17183759|NCT03403634|t||||
17176960|NCT01178073|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183760|NCT00428610|f||GT60||t
17183761|NCT01043874|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17183762|NCT03894449|f||OTHER|The research is the property of the University and we have signed an Intellectual Property Rights agreement whereby we will not disclose the study results.|t
17183763|NCT00182689|f||LTE60||t
17183764|NCT03422003|t||||
17183765|NCT03151265|t||||
17183766|NCT01040871|f||||f
17183767|NCT02451748|f||||f
17183768|NCT01353339|f||||f
17183769|NCT00673049|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183770|NCT01175824|f||GT60||t
17183771|NCT00924950|f||||f
17183772|NCT02979535|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17183773|NCT01519713|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17183774|NCT02530619|t||||
17132496|NCT01106846|t||||
17132497|NCT00803179|t||||
17132498|NCT04811716|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17132499|NCT00494143|t||||
17176961|NCT01352468|f||||f
17132500|NCT02542761|t||||
17132501|NCT03219866|t||||
17139056|NCT02578992|f||||f
17176962|NCT03497676|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17176963|NCT03496571|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17176964|NCT00484718|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183775|NCT01282710|f||OTHER|PIs may publish or present results of the study after the expiration of 12 months from completion. Publications or presentations are subject to the protection of confidential information or patentable information.|t
17183776|NCT00009737|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183777|NCT01807585|f||||f
17183778|NCT01163682|t||||
17183779|NCT03021759|t||||
17183780|NCT02504645|f||LTE60||t
17183781|NCT00530023|f||LTE60||t
17183782|NCT00359762|f||GT60||t
17183783|NCT02829034|f||||f
17183784|NCT02652780|f||||t
17183785|NCT01172938|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17183786|NCT00003498|f||||f
17183787|NCT04188041|f||||f
17132502|NCT00578305|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132503|NCT00684957|t||||
17132504|NCT03196180|f||LTE60||t
17132505|NCT04439175|f||LTE60||t
17176965|NCT01226043|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17176966|NCT03425019|t||||
17176967|NCT00191646|f||GT60||t
17183788|NCT05282004|f||OTHER|The terms and conditions of Sandoz' agreements with its investigators may vary. However, Sandoz does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183789|NCT04808609|f||||f
17183790|NCT02202135|f||OTHER|The investigator agrees not to use such Confidential study information and not to disclose them to any other third parties, except that the undersigned shall not be prevented from using or disclosing information: (a) which by written records was previously known; (b) which is now public knowledge, (c) which is lawfully obtained by the undersigned from sources who have a lawful right to disclose such information.|t
17183791|NCT02256111|t||||
17183792|NCT01993719|f||||f
17183793|NCT04177693|f||||f
17183794|NCT04382326|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183795|NCT00365859|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183796|NCT03224468|f||||f
17183797|NCT04067141|f||||f
17183798|NCT01038921|t||||
17183799|NCT02352493|f||LTE60||t
17183800|NCT00889421|t||||
17132506|NCT00939198|f||||f
17132507|NCT02363478|t||||
17176968|NCT00322101|t||||
17132508|NCT00768898|t||||
17132509|NCT02554929|t||||
17132510|NCT00546364|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132511|NCT00667576|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17132512|NCT03968419|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132513|NCT01390389|f||||f
17132514|NCT00772629|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132515|NCT02894840|f||||f
17176969|NCT00723931|f||||f
17132516|NCT04866290|f||LTE60||t
17132517|NCT05162066|f||||f
17132518|NCT01072344|f||||f
17132519|NCT02307916|f||||f
17132520|NCT03065179|t||||
17176970|NCT04350606|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17176971|NCT05211284|f||||f
17176972|NCT00739596|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183801|NCT00652457|t||||
17183802|NCT03586999|t||||
17132521|NCT05499520|f||||f
17132522|NCT03720899|t||||
17132523|NCT01613326|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17132524|NCT03980938|f||||f
17132525|NCT00840827|t||||f
17132526|NCT01445535|f||||f
17132527|NCT02408692|t||||
17132528|NCT03569202|f||OTHER|The disclosure restrictions on the PI are that the sponsor can review results communications 30 days prior to planned date of public release. If public release of information in communications may jeopardize protecting sponsor's immaterial rights, the sponsor can additionally embargo the communications for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132529|NCT00420511|f||||f
17132530|NCT02415712|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17132531|NCT01668654|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132532|NCT04557384|f||||f
17132533|NCT00454779|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132534|NCT02397473|f||OTHER|All information provided to Investigator \&/or Institution by Lilly or Lilly-designated representatives, or generated by Investigator \&/or institution in connection with Study, will be kept in confidence and not used for any purpose not expressly provided in the Agreement for at least 5 years after termination or conclusion of Study, except to the extent that Lilly gives Investigator \&/or Institution written permission or particular information is required by laws or regulations to be disclosed.|t
17176973|NCT02103218|f||||f
17139057|NCT00681291|f||OTHER|Should Institution/PI/coPI/other staff want to publish information, data, or orally communicate,a complete copy of information/data will be provided to the Sponsor for review and comment at least 30 days prior to 1st submission. If Sponsor determines proposed publication/oral communication contains patentable or proprietary subject matter (requiring protection),Institution will delay for at least 90 days following the Sponsor's receipt of such copy for the purpose of filing patent applications.|t
17132535|NCT03256045|f||||f
17132536|NCT00929071|t||||f
17132537|NCT03856255|t||||
17139058|NCT00086385|f||||f
17139059|NCT00899600|t||||
17139060|NCT00505518|t||||
17139061|NCT00405275|f||OTHER|"Dr. O'Dell is an employee of the Sponsor. Dr. Edward Keystone is not.~Per the signed Investigator Agreement, PIs agreed to maintaining the confidentiality of study data and not publishing study data without prior approval of the study's Executive Committee."|t
17139062|NCT00731666|f||||f
17139063|NCT02468804|t||||
17139064|NCT02471586|f||||f
17139065|NCT04830839|f||||f
17139066|NCT00488059|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139067|NCT00179998|f||||f
17139068|NCT02037204|f||||f
17139069|NCT01495689|f||||f
17139070|NCT00254163|f||||f
17139071|NCT01952288|f||||f
17139072|NCT00606177|f||||f
17139073|NCT00136357|t||||
17139074|NCT04480749|t||||
17139075|NCT00927576|t||||
17139076|NCT00216086|f||||f
17139077|NCT01766986|t||||
17139078|NCT01784211|f||GT60||t
17139079|NCT01001572|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139080|NCT02019758|t||||f
17139081|NCT02025530|t||||
17139082|NCT00711412|t||||
17139083|NCT05364437|t||||
17139084|NCT03551626|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139085|NCT04211961|t||||
17139086|NCT01620658|f||||f
17139087|NCT00429572|t||||f
17139088|NCT04882072|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139089|NCT02918318|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139090|NCT03345342|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the Sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139091|NCT01268943|f||||f
17139092|NCT02782104|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17176974|NCT00908011|f||||f
17132538|NCT02624492|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139093|NCT03185819|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139094|NCT03375203|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17139095|NCT03321526|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17132539|NCT00364689|t||||
17132540|NCT03473561|f||||f
17132541|NCT03555266|f||||f
17139096|NCT00732641|f||OTHER|The principal investigator (PI) agrees not to publish/publicly present any interim study results without the sponsor's prior written consent. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication/presentation to permit the sponsor to review copies of abstracts or manuscripts for publication which report any results of the Study. The sponsor shall have the right to review and comment on any presentation, which shall include editorial rights.|t
17139097|NCT02910089|f||||f
17139098|NCT04254796|t||||
17139099|NCT00954824|t||||
17139100|NCT05103475|t||||
17139101|NCT00045630|f||||f
17139102|NCT00088972|f||||f
17139103|NCT04401904|f||||f
17139104|NCT02023112|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17139105|NCT03536923|f||||f
17139106|NCT02228824|t||||f
17139107|NCT00807014|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139108|NCT00394277|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139109|NCT00547729|f||||f
17139110|NCT02712008|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17139111|NCT00430027|t||||
17176975|NCT02567552|t||||
17176976|NCT03763318|f||LTE60||t
17176977|NCT04669535|f||||f
17176978|NCT02452697|t||||
17176979|NCT02658097|t||||
17176980|NCT03552965|t||||
17176981|NCT02477696|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17176982|NCT06120777|t||||
17176983|NCT05419908|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17139112|NCT01149772|t||||
17176984|NCT00085709|f||||f
17176985|NCT00293215|f||LTE60||t
17176986|NCT00841971|f||||f
17176987|NCT01229371|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period between 30 to 90 days (depending on the complexitiy of the work) from the time submitted to the sponsor for review.|t
17183803|NCT04096560|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17176988|NCT04622735|f||GT60||t
17176989|NCT05314478|t||||
17176990|NCT02923427|f||||f
17176991|NCT01325623|f||GT60||t
17176992|NCT01229397|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. The sponsor reserves the right to remove any proprietary or confidential information and to require that publication be delayed for up to 60 additional days to enable the sponsor to prepare and file patent applications.|t
17132542|NCT00132730|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17183804|NCT02464969|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183805|NCT00534352|f||OTHER|If TTCA does not publish within 12 months after study conclusion or after TTCA confirms there will be no multicenter publication, Institution may publish their results from their site individually, provided TTCA has 60 day review for confidentiality and additional 60 day delay for patent application.|t
17183806|NCT01591746|t||||
17183807|NCT03735420|f||||f
17183808|NCT02399085|f||||t
17183809|NCT01645709|f||||f
17183810|NCT02673697|f||||f
17183811|NCT01814722|t||||
17132543|NCT01554579|f||OTHER|60 days prior to the submission of any results, the PI shall submit to SPONSOR any proposed PUBLICATION, which period may be extended for an additional 30 days if requested by SPONSOR. If any Confidential Information should be redacted or patent applications relating to an Invention should be filed prior to PUBLICATION, then PUBLICATION will be delayed until patent application has been filed. Delay of a PUBLICATION shall not exceed 24 months from the date of such notice to the PI.|t
17176993|NCT02694523|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17183812|NCT01070810|f||||f
17183813|NCT03373591|t||||
17183814|NCT02749903|f||||t
17132544|NCT03419078|t||||
17132545|NCT03683394|f||||f
17132546|NCT01420146|t||||
17132547|NCT03072160|f||||f
17132548|NCT01046695|t||||
17132549|NCT02239263|f||||f
17132550|NCT00822107|f||||f
17132551|NCT01058096|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17132552|NCT04276207|f||GT60||t
17132553|NCT01463098|f||OTHER||t
17132554|NCT01891331|f||OTHER|Neither institution nor principal investigator shall publish the results of the trial without prior written consent of the sponsor, which it may withhold in its sole discretion.|t
17132555|NCT00939692|f||OTHER||t
17132556|NCT04451330|f||OTHER||t
17132557|NCT02769624|f||||f
17132558|NCT05099640|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17132559|NCT00179959|f||||f
17132560|NCT00448708|f||||f
17132561|NCT00928421|f||||f
17132562|NCT00236080|f||GT60||t
17132563|NCT02400255|f||||f
17183815|NCT02041429|t||||
17183816|NCT00861341|f||LTE60||t
17183817|NCT03299192|f||||f
17183818|NCT01418209|f||||f
17183819|NCT00658112|t||||
17183820|NCT04737538|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132564|NCT00602355|f||||f
17132565|NCT00480857|t||||
17132566|NCT00931489|f||||f
17132567|NCT01725750|t||||
17132568|NCT03961360|t||||
17132569|NCT00654498|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17132570|NCT05243628|f||OTHER|Neither the Institution nor the Principal Investigator will disclose any of the results arising out of or in connection with the Clinical Trial or information provided by the Sponsor to the Institution without the prior express written consent of the Sponsor.|t
17132571|NCT00502216|t||||f
17132572|NCT02549755|t||||
17132573|NCT01332071|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132574|NCT01738971|f||||f
17132575|NCT01031446|t||||
17132576|NCT00692211|t||||f
17132577|NCT04320407|f||OTHER|The PI can't publish or discuss the results without the permission of the sponsor.|t
17132578|NCT02531646|f||||f
17132579|NCT02490293|f||||f
17132580|NCT01879345|t||||
17132581|NCT04484285|f||||f
17132582|NCT05888103|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132583|NCT01815229|f||||f
17132584|NCT00167245|t||||
17132585|NCT01871090|f||||f
17132586|NCT03562663|f||||f
17132587|NCT00804687|f||GT60||t
17132588|NCT03037281|t||||
17132589|NCT00688909|f||||f
17132590|NCT01936389|f||||f
17132591|NCT01220414|f||||f
17132592|NCT00445302|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 12 months after study completion. PI gives Genzyme a draft 30 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 90 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17132593|NCT01029730|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17132594|NCT00445887|f||||f
17132595|NCT00860158|f||||f
17132596|NCT00669617|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132597|NCT03216382|f||||f
17176994|NCT05896748|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17176995|NCT00764504|f||LTE60||t
17176996|NCT01298193|f||||f
17176997|NCT04010539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17176998|NCT00249288|f||||f
17176999|NCT03059446|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17177000|NCT04231318|f||OTHER|PI shall not publish Index or the WOMAC® User Guide in any publication, on the Internet or any other public access medium. NICHOLAS BELLAMY, MD, MSc, DSc, MBA, FRACP shall be acknowledged as the source of the Index. Results at the Institution shall not be made before the first multi-site publication by Sponsor. If no multi-site publication within18 months after the Trial completion, PI has right to publish and or present its results (but not the results of any other site) from the Trial.|t
17139113|NCT02443155|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17139114|NCT02000219|f||OTHER|The investigator may not publish the results of their cohort of subjects until the full study has been submitted for publication. They may not submit for publication or present the results of this study without allowing OxThera 30 days in which to review and comment on the pre-publication manuscript. The investigator may not submit the results of the study for publication without the prior consent of OxThera, unless the review period has passed and there has been no reaction from the sponsor.|t
17139115|NCT01605890|f||||f
17177001|NCT01234207|f||||f
17177002|NCT04490239|t||||
17177003|NCT05298306|f||OTHER|Every participating investigator agrees to keep all information and results concerning the study and the investigational product confidential for as long as the data remain unpublished.|t
17177004|NCT00413166|t||||
17177005|NCT03538431|f||||f
17177006|NCT00620464|f||OTHER|All investigator publications must be based on data validated and released by sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to sponsor, at least six weeks ahead of estimated publication or presentation, for consent. In the event that no response is received within six weeks after submission, the investigator may use the submitted data.|t
17177007|NCT01267656|f||OTHER|Contact sponsor directly for details.|t
17177008|NCT00986479|f||||f
17177009|NCT04638673|t||||
17177010|NCT01782833|f||||t
17177011|NCT01842815|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17132598|NCT01175005|t||||
17132599|NCT01337973|t||||
17177012|NCT00771316|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177013|NCT02027376|f||LTE60||t
17177014|NCT05466448|f||||f
17177015|NCT00252629|t||||
17177016|NCT03171051|f||||f
17177017|NCT00972088|t||||
17177018|NCT02595996|t||||
17177019|NCT00880165|t||||
17139116|NCT00302055|f||||f
17139117|NCT00634751|t||||f
17139118|NCT00088595|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139119|NCT03870893|t||||
17177020|NCT00667602|f||GT60||t
17177021|NCT01594385|f||||f
17177022|NCT00285467|f||||f
17177023|NCT00644228|f||LTE60||t
17177024|NCT00760084|f||||f
17177025|NCT00973349|f||||f
17177026|NCT03187756|t||||
17177027|NCT02301988|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183821|NCT01916304|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17183822|NCT01974050|t||||
17183823|NCT02460198|f||OTHER|"The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."|t
17183824|NCT04382612|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation to ensure proprietary information shall not be divulged. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17139120|NCT03689699|f||||f
17139121|NCT03542149|f||||f
17139122|NCT00053014|f||||f
17139123|NCT01473355|f||LTE60||t
17139124|NCT00106249|t||||
17139125|NCT00524043|f||GT60||t
17139126|NCT01843205|f||||f
17139127|NCT00728728|t||||
17139128|NCT02062827|f||||t
17139129|NCT05784129|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139130|NCT01156363|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139131|NCT01801124|f||||f
17139132|NCT02728206|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17139133|NCT04989504|t||||
17139134|NCT02773368|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."|t
17139135|NCT01665872|f||||f
17139136|NCT03960658|t||||
17139137|NCT01929018|f||||f
17139138|NCT01366534|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139139|NCT00748865|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17139140|NCT00987727|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo|t
17139141|NCT05784103|t||||
17177028|NCT04755283|f||OTHER|No publication by Institution or Investigator until after publication of the results by Sponsor. If there is no multicenter publication within 18 months after the end of the Study, Institution and Investigator may publish if Sponsor is given the opportunity to review at least 45 days prior to submission for publication. Sponsor may remove any Information other than Study Data from a proposed publication. Sponsor may defer publication or other disclosure for a period of 60 additional days.|t
17177029|NCT02750943|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177030|NCT00171054|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177031|NCT02981940|t||||
17177032|NCT05098938|f||OTHER|Per Master Service Agreement between Bayer and Science 37 dated 08-Apr-2019, Science 37 shall have no rights of publication whatsoever in connection with the Study nor will Science 37 assist any other Party in the preparation of a publication. Publication of results in whole or in part, shall be within the sole and absolute discretion of Bayer, and such shall not be unreasonably withheld.|t
17139142|NCT01789255|f||LTE60||t
17177033|NCT01828320|t||||
17139143|NCT02635867|f||||f
17139144|NCT02565576|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139145|NCT03377452|t||||
17139146|NCT02438787|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139147|NCT01620593|t||||
17132600|NCT02494596|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132601|NCT00254566|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17139148|NCT03034057|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139149|NCT00655057|t||||
17183825|NCT04666441|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17183826|NCT03149328|f||||f
17183827|NCT01328002|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17183828|NCT00813761|f||OTHER|Written consent of the sponsor is required for publication.|t
17183829|NCT00691210|t||||
17183830|NCT01208233|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183831|NCT00132769|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17183832|NCT02710526|f||GT60||t
17183833|NCT01343706|t||||
17183834|NCT00560833|f||LTE60||t
17183835|NCT05350449|t||||
17183836|NCT01076400|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17183837|NCT01032694|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183838|NCT02696850|t||||
17183839|NCT03455855|f||||f
17183840|NCT04193202|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17183841|NCT03971617|t||||
17132602|NCT00059202|f||||f
17132603|NCT03378479|t||||
17132604|NCT00358657|t||||f
17177034|NCT02160782|f||||t
17177035|NCT00309738|f||GT60||t
17177036|NCT01956435|f||||f
17177037|NCT00401531|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17177038|NCT01801072|t||||f
17177039|NCT03906461|f||OTHER|First publication of study results will be made as a joint multi-center publication with investigators from all sites contributing data. Institutions may publish data and results individually from its site after any of the following (1) a multi-center publication is published, (2) no multicenter publication is submitted within eighteen months after closures of the Study at all sites or (3) sponsor confirms in writing there will be no multi-center publication.|t
17177040|NCT00510874|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183842|NCT00581945|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183843|NCT04820673|f||||t
17132605|NCT02658448|f||||f
17132606|NCT00648167|f||||f
17183844|NCT02621983|t||||f
17183845|NCT00587587|f||GT60||t
17132607|NCT01688050|f||GT60||t
17132608|NCT01872338|f||||f
17132609|NCT02614079|t||||
17132610|NCT02623335|f||||f
17132611|NCT03739528|f||||f
17183846|NCT01138124|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183847|NCT03226067|f||||t
17183848|NCT01075321|t||||
17132612|NCT01261819|t||||
17132613|NCT00536172|f||||f
17132614|NCT01961544|f||OTHER||t
17139150|NCT00701103|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17139151|NCT01929707|f||GT60||t
17139152|NCT00179517|f||||f
17139153|NCT00437203|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139154|NCT01449955|t||||
17139155|NCT01332097|f||OTHER|All PIs must seek written permission from the sponsor before publication of any trial results.|t
17139156|NCT02067533|f||||f
17139157|NCT02566109|t||||f
17139158|NCT01993667|f||||f
17139159|NCT02650440|t||||
17139160|NCT02448914|f||OTHER||t
17139161|NCT01997281|t||||
17177041|NCT00695578|t||||
17177042|NCT02423109|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17177043|NCT03956056|t||||
17177044|NCT03403374|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17177045|NCT00950911|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17177046|NCT01742936|t||||
17177047|NCT02476422|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132615|NCT03665285|f||OTHER|PI cannot publish study results before the first multi-center publication. If a multi-center publication is not submitted within 12 months after the end of the study at all sites, or if Sponsor confirms there will be no multi-center publication, the PI may publish study results. However, PI will allow Sponsor at least 30 days to review any publication of study results and Sponsor may request an additional 60 days to review the publication.|t
17132616|NCT03076983|f||LTE60||t
17132617|NCT03450083|f||||f
17132618|NCT03213366|f||||f
17132619|NCT00820573|f||||f
17132620|NCT02471716|f||||f
17132621|NCT00130286|f||||f
17132622|NCT01815645|f||||f
17132623|NCT03604445|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132624|NCT01154933|t||||
17132625|NCT01558063|t||||
17132626|NCT03365778|f||||f
17132627|NCT00713219|t||||
17132628|NCT00880256|f||||f
17132629|NCT00165958|f||||f
17132630|NCT01481896|f||OTHER|Any paper drafted regarding the results of the study shall be sent to Depuy Clinical Research for review and comment at least thirty (30) days before being submitted for publication; the same shall apply to abstracts, except the time for review by DePuy shall be ten (10) days. DePuy will promptly inform the authors of any changes deemed necessary to preserve the confidentiality of proprietary information or to ensure scientific accuracy.|t
17132631|NCT03336502|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17132632|NCT01054079|t||||
17132633|NCT00565617|f||||f
17132634|NCT01890421|f||OTHER|The sponsor is interested in the publication of the results of every study it performs. All relevant aspects regarding the publication will be part of the contract between the sponsor and the investigator/institution. The sponsor has made the information regarding the study protocol publicly available on the internet at www.clinicaltrials.gov.|t
17132635|NCT00464178|t||||
17132636|NCT01228903|f||||f
17139162|NCT01570309|f||||f
17139163|NCT00560794|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139164|NCT04857892|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139165|NCT00655811|t||||
17139166|NCT01237301|t||||
17139167|NCT03304912|f||||f
17139168|NCT00368472|f||OTHER||t
17139169|NCT00981682|f||||f
17183849|NCT00875394|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183850|NCT01933334|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183851|NCT00767000|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17183852|NCT03103282|f||GT60||t
17183853|NCT02039505|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17183854|NCT01800877|t||||
17139170|NCT04095793|f||||t
17139171|NCT02384993|t||||
17139172|NCT00651313|f||GT60||t
17139173|NCT01199198|t||||
17139174|NCT00922974|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor|t
17139175|NCT00608894|f||OTHER|The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PI's.|t
17139176|NCT01376388|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139177|NCT01119963|f||||f
17139178|NCT01480232|f||||f
17139179|NCT03938636|f||||t
17139180|NCT02603172|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139181|NCT03285490|f||||t
17139182|NCT03745989|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17139183|NCT01047436|f||OTHER|The PI was restricted from publishing results for 6 months from the end of the trial. This has now passed and the PI is free to publish the results without restriction|t
17139184|NCT00939341|f||||f
17177048|NCT01288027|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17177049|NCT00994318|f||OTHER|Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.|t
17177050|NCT01134315|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17177051|NCT00739999|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177052|NCT02180165|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17177053|NCT03875768|t||||
17177054|NCT00737438|t||||
17177055|NCT02791594|f||||f
17177056|NCT04926077|f||||f
17177057|NCT02234986|f||||f
17177058|NCT04950166|f||||f
17139185|NCT00424099|t||||
17139186|NCT02280096|t||||
17139187|NCT02939976|f||||f
17177059|NCT00857415|f||GT60||t
17177060|NCT03660488|t||||
17177061|NCT04508140|f||||f
17177062|NCT01130103|t||||f
17177063|NCT01199731|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139188|NCT01872897|f||||f
17139189|NCT02418585|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17139190|NCT02040857|f||||f
17139191|NCT04159701|f||GT60||t
17183855|NCT00633984|f||||f
17183856|NCT00097591|f||GT60||t
17183857|NCT03017508|f||||f
17183858|NCT01557946|f||||f
17183859|NCT02639884|f||LTE60||t
17183860|NCT01597687|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183861|NCT01114646|f||||f
17183862|NCT01381172|f||||f
17132637|NCT01557166|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in the protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.|t
17132638|NCT02986230|t||||
17132639|NCT01465659|t||||
17132640|NCT00374244|t||||f
17177064|NCT02992132|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17177065|NCT01289457|f||||f
17177066|NCT03194503|f||||f
17177067|NCT00381381|f||||f
17177068|NCT00337350|t||||
17177069|NCT00846287|f||LTE60||t
17177070|NCT01437878|f||OTHER||t
17177071|NCT01070043|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177072|NCT01194427|t||||f
17177073|NCT00473746|f||GT60||t
17177074|NCT00832390|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177075|NCT00667420|f||||f
17177076|NCT01528215|f||LTE60||t
17177077|NCT01462227|t||||
17177078|NCT01158703|f||||f
17177079|NCT00586066|f||||f
17183863|NCT01243450|f||OTHER||t
17132641|NCT02445586|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132642|NCT01698528|t||||
17132643|NCT03550066|f||||f
17132644|NCT00428597|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132645|NCT01469000|f||GT60||t
17132646|NCT03618056|f||||f
17132647|NCT00686647|f||OTHER|Prior to submission, the Sponsor, Institution, and Site Investigators will review and authorize the publication. A review period of 15 days for Presentational materials and abstracts; and 30 days for manuscripts is required for the Sponsor's review. Sponsor review does not include editorial privileges but can protect proprietary information and correct errors in data reporting or analysis if the Investigator agrees that there is an error.|t
17177080|NCT00467610|f||||f
17177081|NCT01369615|f||GT60||t
17177082|NCT04263454|f||||f
17177083|NCT03911154|f||||f
17177084|NCT02035475|f||||f
17177085|NCT01231347|f||||t
17177086|NCT02322021|f||||t
17177087|NCT02047227|f||||f
17177088|NCT01209923|t||||
17177089|NCT01483807|t||||
17177090|NCT04468321|t||||f
17183864|NCT00718042|f||OTHER|The PI must provide a copy of any proposed publication/presentation at least 30 days prior to submission for sponsor's review/approval. The PI must incorporate changes as the sponsor requires in order to protect the sponsor's proprietary rights and interests. The sponsor may require the PI to include acknowledgement of the sponsor's role in the study. The PI may be requested to delay publication/presentation an extra 60 days to enable sponsor to secure patent or other proprietary protection.|t
17132648|NCT02385279|f||||t
17132649|NCT00632853|f||||f
17177091|NCT00492050|t||||
17177092|NCT01104701|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17177093|NCT03437512|t||||
17177094|NCT00674973|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17177095|NCT00763048|f||LTE60||t
17177096|NCT01002482|f||||f
17177097|NCT03861611|t||||
17177098|NCT05108922|f||GT60||t
17177099|NCT05036369|f||OTHER|Permission to use study data is required|t
17177100|NCT04925271|t||||
17183865|NCT00575588|f||||f
17183866|NCT00614939|f||||f
17183867|NCT00840970|f||||f
17132650|NCT01990261|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132651|NCT00954109|t||||f
17132652|NCT02153099|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17132653|NCT04663945|t||||
17132654|NCT00772668|t||||
17132655|NCT03344003|f||||f
17177101|NCT00426231|f||||f
17177102|NCT01795638|t||||f
17177103|NCT03061097|t||||
17177104|NCT03911713|f||||t
17177105|NCT02437513|f||||f
17177106|NCT01845818|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17177107|NCT00422097|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \<or=60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17177108|NCT02360995|f||GT60||t
17177109|NCT02395666|f||LTE60||t
17177110|NCT02611960|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17177111|NCT00994929|f||||f
17177112|NCT04839146|t||||
17177113|NCT01409434|f||||f
17177114|NCT05061966|t||||f
17177115|NCT02213042|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17177116|NCT04644003|f||||f
17177117|NCT01146275|f||LTE60||t
17177118|NCT04396665|t||||
17177119|NCT00777205|t||||
17177120|NCT01287078|t||||
17177121|NCT03053271|f||||t
17177122|NCT00559936|t||||
17177123|NCT04137224|f||OTHER||t
17177124|NCT01225887|f||||f
17177125|NCT01669928|f||||f
17177126|NCT02439879|f||||f
17177127|NCT01417936|f||OTHER||t
17177128|NCT00925990|f||LTE60||t
17177129|NCT00679055|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17132656|NCT02065453|t||||f
17132657|NCT03631706|f||||f
17132658|NCT05027932|t||||
17177130|NCT00835159|f||||f
17177131|NCT01270542|f||||f
17177132|NCT03839082|f||||f
17177133|NCT01822678|f||OTHER||t
17177134|NCT01200862|f||OTHER|All PIs must seek written permission from the sponsor prior to publication of any trial results.|t
17177135|NCT00943124|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177136|NCT00179127|f||||f
17177137|NCT01916967|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17177138|NCT01912963|f||||f
17177139|NCT03616171|t||||
17177140|NCT01702571|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177141|NCT01721473|f||||f
17177142|NCT01977937|t||||
17177143|NCT00915356|f||GT60||t
17177144|NCT01302379|f||||f
17177145|NCT00725504|t||||f
17132659|NCT02152345|t||||f
17132660|NCT01916980|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17132661|NCT04439279|f||LTE60||t
17132662|NCT02324270|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17132663|NCT03521791|f||OTHER|The principal investigator can not publish any information about the investigation without prior written authorization from the atrocifier|t
17132664|NCT04024501|f||OTHER|This confidential document is the property of AstraZeneca AB. No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17132665|NCT00680836|t||||f
17183868|NCT00504829|f||OTHER|Individual investigators may publish data arising from their own subjects. The Principal Investigator will provide the Sponsor with copies of written publications (including abstracts and posters) at least 60 days in advance of submission.|t
17183869|NCT01854827|f||||f
17183870|NCT02571452|t||||
17183871|NCT01984398|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17183872|NCT03834194|f||||f
17183873|NCT02660944|f||||t
17183874|NCT00088218|t||||f
17183875|NCT01701375|t||||
17183876|NCT00833924|f||GT60||t
17183877|NCT01485861|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183878|NCT00466323|t||||
17183879|NCT01144338|f||||f
17183880|NCT04796610|f||||f
17183881|NCT02059148|f||GT60||t
17183882|NCT01714024|t||||f
17183883|NCT00403546|t||||
17132666|NCT03786432|f||||f
17132667|NCT04793399|f||||t
17132668|NCT03054363|t||||
17132669|NCT00925600|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132670|NCT01974817|f||||f
17177146|NCT02001181|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177147|NCT00292318|t||||
17177148|NCT01278160|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, e.g. when the clinical trial report is available. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17177149|NCT02819518|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17177150|NCT01505647|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17177151|NCT03112590|t||||
17177152|NCT00843726|t||||
17177153|NCT00406718|f||||f
17177154|NCT06352060|f||||f
17177155|NCT02176343|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17177156|NCT02780609|t||||
17177157|NCT02898116|f||LTE60||t
17177158|NCT02745210|f||||f
17177159|NCT05597020|f||OTHER|Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 60 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator is permitted to write a publication during such a review period.|t
17177160|NCT05169567|f||LTE60||t
17177161|NCT01015131|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17177162|NCT05430022|f||||f
17177163|NCT03029702|t||||f
17132671|NCT05512949|f||LTE60||t
17132672|NCT03593915|f||LTE60||t
17132673|NCT04660643|f||GT60||t
17132674|NCT03988907|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132675|NCT02810964|f||||f
17132676|NCT01276171|t||||
17132677|NCT00325078|t||||
17132678|NCT03932799|f||||f
17132679|NCT03760484|t||||
17132680|NCT00568555|f||||f
17177164|NCT02037607|t||||
17177165|NCT03237871|t||||
17177166|NCT05595382|t||||
17177167|NCT02422940|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17177168|NCT02445391|f||LTE60||t
17183884|NCT00437489|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17183885|NCT02388321|f||||f
17132681|NCT01307033|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17132682|NCT01231555|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132683|NCT00947531|f||||f
17132684|NCT03856944|t||||
17132685|NCT01773421|f||||f
17132686|NCT02804763|f||GT60||t
17132687|NCT03657459|f||||f
17132688|NCT00282243|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or until 18 months have elapsed following study completion. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document.|t
17132689|NCT02863848|f||||f
17132690|NCT00395967|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17132691|NCT03118947|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17177169|NCT03722173|t||||f
17177170|NCT06624449|f||||f
17177171|NCT00413400|f||||f
17177172|NCT00891462|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute."|t
17177173|NCT00970073|t||||
17177174|NCT00423722|t||||
17177175|NCT00414271|f||||f
17177176|NCT00518687|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17177177|NCT01846104|f||||f
17177178|NCT02095223|f||||f
17177179|NCT01397162|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17177180|NCT02339285|t||||
17177181|NCT00931879|f||||f
17177182|NCT00282412|t||||
17177183|NCT00697073|f||||f
17177184|NCT03538678|t||||
17177185|NCT00145704|f||||f
17177186|NCT00736957|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17132692|NCT01528787|f||||f
17132693|NCT03882424|f||||f
17132694|NCT00666926|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132695|NCT01727258|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17132696|NCT01360645|f||||f
17132697|NCT02981069|f||||f
17177187|NCT02841189|t||||
17177188|NCT02231918|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177189|NCT00331864|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177190|NCT01092507|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17177191|NCT04735536|f||||f
17177192|NCT04073368|f||||t
17177193|NCT00145600|t||||
17177194|NCT01420653|f||||f
17183886|NCT03893448|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17177195|NCT04465162|t||||
17177196|NCT01539642|f||GT60||t
17177197|NCT00761579|f||LTE60||t
17177198|NCT03611010|f||||f
17183887|NCT04408963|t||||
17183888|NCT02418546|f||||f
17132698|NCT01014585|f||OTHER|All data generated in this study is the property of Forest Research Institute, Inc. An integrated clinical and statistical report was prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17132699|NCT04178772|f||GT60||t
17132700|NCT00773279|f||OTHER|Novo Nordisk reserves the right not to release data until specified milestones, eg a clinical trial report is available. This includes the right not to release interim results from clinical trials, because such results may lead to conclusions that are later shown to be incorrect. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17132701|NCT02808390|f||||f
17132702|NCT02817087|f||||f
17132703|NCT00508391|f||||f
17132704|NCT00802360|f||OTHER|"The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor.~Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention."|t
17132705|NCT02041962|f||||f
17132706|NCT02908516|t||||
17132707|NCT01225562|f||||f
17132708|NCT01818726|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17132709|NCT01162421|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132710|NCT00611247|f||||f
17132711|NCT00836433|f||||f
17132712|NCT02604940|t||||
17132713|NCT03357393|f||||f
17132714|NCT02349178|f||||f
17132715|NCT01446419|f||OTHER|Individual PIs will not publish any study results until completion of study and publication of the multi-center results in a peer-reviewed journal, which shall occur within one year after study completion. Thereafter, PIs may publish individual site experience. Sponsor can review results communications prior to public release and can embargo communications regarding results for a period that is less than or equal to 60 days from the time submitted to sponsor for review.|t
17132716|NCT02052557|f||||f
17132717|NCT02867761|t||||
17132718|NCT04506294|f||||f
17132719|NCT00282841|t||||
17132720|NCT01931059|f||||f
17132721|NCT01445678|f||OTHER|The Investigator(s) must undertake not to submit any part of the data from this protocol for publication without the prior consent of Cubist Pharmaceuticals, Inc.|t
17132722|NCT02307370|f||||f
17132723|NCT04698629|f||||f
17132724|NCT03641560|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17132725|NCT05847686|f||||f
17132726|NCT06272370|f||||f
17177199|NCT00598702|f||OTHER|The Investigator may publish 18 months after Cadence's final evaluation of all study data from all sites, whichever occurs first.Manuscripts/abstracts will be provided to Cadence for review and comment at least 30 days prior to submission.Cadence shall have 30 days to respond with comments.|t
17177200|NCT02600351|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177201|NCT01813110|f||||f
17177202|NCT04087213|f||OTHER||t
17177203|NCT01859143|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17177204|NCT00438451|f||OTHER|This study was supported (as investigator-initated trial) by an educational grant from UCB GmbH, Germany. A disclosure restriction applies on the PI in that UCB can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted. As of Jan-01-2012 the study chair is an employee to UCB Biosciences GmbH working as Medical Director in the Therapeutic Area CNS within Global Projects and Development.|t
17177205|NCT02413372|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17177206|NCT01550471|f||||f
17177207|NCT02556203|f||GT60||t
17177208|NCT04587271|t||||
17177209|NCT02563990|t||||f
17177210|NCT00093782|f||LTE60||t
17177211|NCT02943460|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17132727|NCT05523973|f||||f
17132728|NCT00352534|f||OTHER||t
17183889|NCT03321981|f||OTHER|No publication of results by PI before the first multi-center publication by Sponsor. If there is no multi-center publication within 18 months after the study has been completed, PI may publish subject to 45 days' notice to Sponsor to review, comment, identify confidential information to be deleted, and request delay of publishing for a maximum of 120 days to permit filing of patent applications. PI agrees to accept Sponsor's reasonable comments and suggestions with respect to such publications.|t
17183890|NCT05061446|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183891|NCT03880578|f||||f
17183892|NCT04934670|f||||f
17183893|NCT03259035|f||||f
17183894|NCT00817089|f||||f
17132729|NCT01602341|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183895|NCT03067441|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld."|t
17183896|NCT01785602|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17183897|NCT04177108|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17183898|NCT02100072|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17183899|NCT03127228|t||||
17183900|NCT01827904|f||||f
17183901|NCT00101101|t||||
17183902|NCT01800903|f||||f
17183903|NCT01891734|f||||f
17183904|NCT02780349|f||||f
17183905|NCT01181895|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183906|NCT03362515|f||||f
17183907|NCT00766415|f||LTE60||t
17183908|NCT01312467|f||LTE60||t
17183909|NCT02430077|t||||
17183910|NCT02752048|f||OTHER||t
17132730|NCT02090855|f||||f
17132731|NCT00388947|f||OTHER|AMS (sponsor) is the sole owner of the conglomerate data inputted into the POWER database and has the right to publish such data at its sole discretion. Registry Physician will provide AMS with a copy of any data, finding, result, article, abstract, manuscripts, presentation, or other information intended for publication, at least thirty (30) days prior to submission of same for publication.|t
17132732|NCT03038308|t||||
17132733|NCT04187092|f||||f
17132734|NCT00278876|f||||f
17132735|NCT03695913|t||||
17132736|NCT00544869|f||||f
17132737|NCT01903265|f||OTHER|An industry standard NDA in place with all study investigators.|t
17132738|NCT02303431|f||||f
17132739|NCT01777763|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17132740|NCT03242954|f||||f
17132741|NCT04690699|f||GT60||t
17132742|NCT03969875|f||||f
17132743|NCT02327260|t||||
17132744|NCT03502330|t||||
17132745|NCT04656990|t||||f
17132746|NCT01070329|f||GT60||t
17132747|NCT06062264|f||||f
17132748|NCT00700180|f||OTHER|The study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132749|NCT01072409|f||||f
17132750|NCT03588741|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17183911|NCT01003418|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183912|NCT00898677|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183913|NCT00019682|f||LTE60||t
17183914|NCT02116322|t||||
17183915|NCT05932290|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17132751|NCT00793793|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132752|NCT00950170|f||OTHER|The investigator may publish or otherwise publicly communicate the results, subject to the provisions of the Clinical Study Agreement.|t
17132753|NCT02661594|f||GT60||t
17132754|NCT02522767|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17132755|NCT01705691|f||LTE60||t
17132756|NCT00214461|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17132757|NCT02913313|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17132758|NCT03289416|f||||f
17132759|NCT04233229|f||OTHER|The only disclosure restriction on the PI is that the Sponsor can review results communications prior to public release. According to Article R.5121-13 of the French Public Health Code, the results of the Research may not be published or the subject of written or oral communications by the PI without prior written consent of the Sponsor. The disclosure restriction applies to the Parties during the entire duration of the agreement and as long as the confidential data are not in the public domain.|t
17132760|NCT00841763|f||LTE60||t
17132761|NCT02631538|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132762|NCT00964431|f||||f
17132763|NCT01482910|f||LTE60||t
17132764|NCT00305942|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17132765|NCT00440726|f||GT60||t
17132766|NCT03370770|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17132767|NCT00234039|f||||f
17132768|NCT01284504|f||||f
17132769|NCT00110019|f||LTE60||t
17132770|NCT03897751|f||OTHER|Please contact sponsor for details.|t
17132771|NCT04426695|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177212|NCT01925274|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177213|NCT01967433|f||||f
17177214|NCT01031381|t||||
17177215|NCT00723398|t||||
17132772|NCT04303000|f||||f
17132773|NCT00559273|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132774|NCT00506857|t||||f
17132775|NCT01016873|f||OTHER|Institution and the Principal Investigator agree not to publish or issue a press release or authorize the publication or presentation of any Study Results without obtaining Oraya's prior written approval.|t
17132776|NCT03653390|f||||f
17132777|NCT01109940|f||||f
17132778|NCT01262976|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132779|NCT02516670|t||||
17132780|NCT02690194|t||||
17132781|NCT02769728|t||||
17132782|NCT01552681|f||||f
17177216|NCT04865640|f||||f
17177217|NCT00580970|t||||f
17177218|NCT01008150|f||LTE60||t
17177219|NCT01400815|f||OTHER|The PI's have a general obligation of confidentiality, which extends to the study results and data procured under the study. There are exceptions to this obligation of confidentiality, which include the disclosure of study information and results in connection with publication and is necessary for the medical care of a study subject.|t
17177220|NCT00805948|f||||t
17132783|NCT01987908|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, results may not be published without prior written approval of Sponsor.|t
17132784|NCT03715426|t||||
17132785|NCT00354601|f||||f
17132786|NCT03603652|f||LTE60||t
17132787|NCT02532855|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17132788|NCT01960855|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132789|NCT02058147|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17132790|NCT03640832|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132791|NCT02154425|f||GT60||t
17132792|NCT02251912|t||||f
17132793|NCT01107444|f||GT60||t
17132794|NCT01750255|t||||f
17132795|NCT02526550|t||||
17132796|NCT03875950|f||||f
17132797|NCT03969888|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132798|NCT01260454|t||||
17132799|NCT02238847|f||GT60||t
17132800|NCT03094195|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132801|NCT01961115|f||LTE60||t
17132802|NCT00360399|t||||
17132803|NCT00578643|t||||
17132804|NCT02440581|f||||f
17132805|NCT02474329|t||||
17132806|NCT03186989|f||||t
17132807|NCT05900115|t||||
17177221|NCT04429243|f||OTHER|The PI is required to obtain written permission from the Sponsor prior to publish trial results.|t
17177222|NCT04007198|f||LTE60||t
17177223|NCT02759354|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations based on these study results 60 calendar days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential will be deleted prior to submission. Whenever needed, Sponsor review may be shorter upon agreement between the Sponsor and the authors.|t
17177224|NCT00568685|f||GT60||t
17177225|NCT01147172|f||LTE60||t
17177226|NCT02787551|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17177227|NCT01638819|t||||
17177228|NCT00237185|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17177229|NCT05069259|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177230|NCT03148275|f||LTE60||t
17177231|NCT03803683|f||||f
17177232|NCT01897714|f||||t
17177233|NCT00683085|f||||f
17177234|NCT00704912|t||||f
17177235|NCT01262131|t||||
17177236|NCT00851630|t||||f
17177237|NCT02349061|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication o r presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17177238|NCT00398411|t||||
17132808|NCT00619502|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17132809|NCT00771472|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17132810|NCT00845195|f||||f
17132811|NCT00880750|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17132812|NCT00483327|t||||
17132813|NCT00670007|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132814|NCT00618722|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17132815|NCT00624221|f||||f
17132816|NCT00200057|f||||f
17132817|NCT00778830|f||OTHER||t
17132818|NCT01891643|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17132819|NCT02863068|f||||f
17132820|NCT01734655|f||||f
17132821|NCT03363633|f||||f
17132822|NCT01322022|f||||f
17132823|NCT01097629|f||OTHER|Investigator may publish results for his/her study site after publication of results of entire multicenter trial, or after public disclosure of the results online if a multicenter manuscript is not planned. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17132824|NCT03057366|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17132825|NCT02707770|t||||
17132826|NCT02720757|t||||f
17132827|NCT00463476|f||||f
17177239|NCT00537238|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177240|NCT03347188|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17132828|NCT00988247|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17132829|NCT04173741|t||||
17132830|NCT01989130|f||||f
17132831|NCT01169779|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17132832|NCT00548548|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132833|NCT00542620|f||OTHER|The Steering Committee has the right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation must be approved by the Steering Committee, and copies submitted in writing to Novo Nordisk prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17132834|NCT00956930|f||||f
17132835|NCT03617705|f||||f
17132836|NCT03502187|f||||f
17132837|NCT01061008|t||||
17132838|NCT01492673|t||||
17132839|NCT02908100|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132840|NCT04088409|f||GT60||t
17177241|NCT01193660|t||||
17177242|NCT02572388|f||||f
17177243|NCT00161473|f||||f
17177244|NCT00810108|f||||f
17177245|NCT01051466|f||GT60||t
17177246|NCT03326726|f||OTHER|Data remains confidential|t
17177247|NCT00547196|t||||
17177248|NCT01676727|f||LTE60||t
17177249|NCT01578330|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17177250|NCT01086423|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177251|NCT03114488|f||||f
17177252|NCT00566501|f||||f
17177253|NCT04558281|f||||f
17183916|NCT01850004|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183917|NCT01946711|f||||f
17183918|NCT01787604|t||||
17183919|NCT04331366|t||||
17183920|NCT03019536|f||GT60||t
17183921|NCT03223298|t||||
17183922|NCT01782131|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media) that report any results of the trial.|t
17183923|NCT01627249|f||OTHER|Trial results can not be discussed until they have been made available to the public.|t
17183924|NCT00796718|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183925|NCT03266588|f||LTE60||t
17183926|NCT00736242|f||OTHER||t
17177254|NCT00749515|f||||f
17183927|NCT02627677|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17183928|NCT00966940|f||LTE60||t
17183929|NCT01073618|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183930|NCT03041415|t||||
17183931|NCT02044510|f||||f
17183932|NCT02032901|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17183933|NCT00982020|f||GT60||t
17132841|NCT00400400|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177255|NCT01368432|f||||f
17177256|NCT02409810|f||||f
17177257|NCT00437320|f||||t
17177258|NCT01938573|f||||f
17177259|NCT01649609|t||||t
17177260|NCT02617888|f||||f
17183934|NCT01722331|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17183935|NCT00262834|f||LTE60||t
17132842|NCT04139122|f||OTHER||t
17132843|NCT00189462|f||||f
17132844|NCT00849667|f||OTHER||t
17132845|NCT03501966|f||||f
17132846|NCT00553163|t||||
17132847|NCT01262625|f||||f
17132848|NCT02789657|f||||f
17132849|NCT01214044|f||||f
17132850|NCT01589484|f||||f
17132851|NCT02772757|t||||f
17132852|NCT00464204|f||OTHER|All investigators agreed that there will be one or more publications describing the study and the results. No center or combination of centers will submit their results for publication separately. Highest recruiting centers and Fresenius Kabi will contribute authors. The writing of the manuscript will be a collaborative effort.|t
17132853|NCT00384241|t||||f
17132854|NCT04698525|f||||f
17132855|NCT05384041|t||||
17132856|NCT02086331|t||||
17132857|NCT00510276|f||GT60||t
17177261|NCT00762216|f||||f
17177262|NCT00277446|t||||
17177263|NCT03845543|f||OTHER|Investigator agrees not to make announcements or oral presentations in any context without the Sponsor's prior written consent, except as required by law or by court administrative order. The relevant manuscripts shall be thus submitted to the Sponsor for approval to ensure that no confidential matters are made public. Once clinical research and/or results have been approved for publication by the Sponsor, they are no longer subjected to this provision in regards to any form of disclosure.|t
17177264|NCT02456103|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the Sponsor for review. The Sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17132858|NCT03329378|f||||f
17132859|NCT03176316|t||||
17132860|NCT01349140|f||||f
17132861|NCT03486392|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17132862|NCT00923117|f||||f
17132863|NCT01731678|f||||f
17132864|NCT01225341|t||||
17132865|NCT01175798|t||||
17132866|NCT00888355|t||||
17132867|NCT00880360|t||||f
17132868|NCT01551693|f||||f
17132869|NCT01893567|f||||f
17132870|NCT04897867|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17132871|NCT01948830|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17132872|NCT01133171|t||||
17132873|NCT01859247|f||||f
17132874|NCT01282229|f||||f
17132875|NCT01144598|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17132876|NCT00769119|f||||f
17132877|NCT02525549|f||OTHER||t
17132878|NCT01578031|f||||f
17132879|NCT03828487|f||GT60||t
17132880|NCT03430986|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17132881|NCT02022826|f||||f
17132882|NCT01078805|f||GT60||t
17132883|NCT01609842|t||||
17132884|NCT01811147|f||||f
17132885|NCT01821300|f||||f
17132886|NCT03694392|f||||f
17132887|NCT00865020|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132888|NCT04785612|t||||
17132889|NCT01583179|t||||f
17132890|NCT01246206|t||||
17132891|NCT02965716|f||LTE60||t
17132892|NCT04047797|t||||
17132893|NCT03523351|t||||
17132894|NCT04051957|t||||
17132895|NCT01929057|f||||f
17132896|NCT05197803|t||||
17132897|NCT00132041|f||||f
17132898|NCT03609619|f||OTHER|The information generated by this study is the property of Aevi Genomic Medicine, Inc. Publication or other public presentation of AEVI-001 data resulting from this study requires prior review and written approval of Aevi Genomic Medicine, Inc. Abstracts, manuscripts, and presentation materials should be provided to Aevi Genomic Medicine, Inc. for review at least 30 days prior to the relevant submission deadline.|t
17177265|NCT03649867|t||||
17177266|NCT02448810|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17177267|NCT05708586|t||||
17177268|NCT02907268|f||||f
17177269|NCT00470847|f||||f
17132899|NCT01171820|f||LTE60||t
17132900|NCT00956943|t||||
17132901|NCT02613208|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132902|NCT02663895|f||||t
17183936|NCT00003457|f||||f
17132903|NCT01496157|f||||f
17132904|NCT02472847|f||||f
17132905|NCT03793439|f||||f
17132906|NCT00623831|f||LTE60||t
17132907|NCT00270894|f||OTHER|Sponsor shall submit to Aventis for review of confidential information and patent protection purposes, any manuscript or abstract prepared for publication at least 30 days prior to submission to publisher. Upon written request by Aventis to Sponsor within such 30 days, Sponsor agrees to delay such publication until Aventis determines that the publication will not compromise any patent rights. However, such delay shall not exceed 90 additional days.|t
17132908|NCT01748071|t||||
17132909|NCT00605267|f||LTE60||t
17132910|NCT02939131|f||||f
17132911|NCT00883493|f||OTHER||t
17132912|NCT01084551|f||||f
17132913|NCT00289913|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.|t
17132914|NCT02024971|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17132915|NCT00947284|t||||
17177270|NCT00590460|t||||
17177271|NCT01687036|f||OTHER|Following approval of the Sponsor and before publishing or presenting data related to the Trial or the Device, Research lnstitution, Principal lnvestigator, and Co-lnvestigator agree to submit copies of any and all proposed manuscripts or abstracts to Sponsor at least 30 days in advance of the date that the applicable party proposes to submit such proposed manuscripts or abstracts to a publisher or other third party.|t
17177272|NCT00457366|f||||f
17132916|NCT00944034|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17132917|NCT00531960|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17132918|NCT01500057|t||||
17132919|NCT00701714|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17132920|NCT01510327|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17132921|NCT01318122|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17132922|NCT01486199|t||||
17132923|NCT01539980|f||||f
17132924|NCT00481845|f||||f
17132925|NCT02849639|f||||f
17132926|NCT01958645|f||||f
17132927|NCT03773302|f||||f
17132928|NCT01647737|f||||f
17132929|NCT01900002|t||||
17132930|NCT00754156|f||OTHER||t
17132931|NCT01751971|t||||
17139192|NCT03605836|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17139193|NCT02463227|f||||f
17177273|NCT04856891|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17177274|NCT00390234|f||LTE60||t
17177275|NCT03139279|f||||f
17177276|NCT01090973|t||||
17177277|NCT03648827|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17177278|NCT00706810|f||||f
17177279|NCT01626495|f||||t
17177280|NCT01934972|t||||
17177281|NCT03131453|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177282|NCT01945112|f||||f
17132932|NCT04591054|f||||f
17132933|NCT01261559|t||||f
17132934|NCT02601573|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17177283|NCT03438383|t||||
17177284|NCT02766465|f||||f
17177285|NCT02435069|f||||f
17177286|NCT01528033|t||||
17132935|NCT02921425|t||||
17177287|NCT02520661|t||||
17183937|NCT04564833|f||OTHER|Study Center and Investigator shall not publish or present the Study results until after the first publication or presentation regarding the overall study is completed, such publication or presentation to be at the sole discretion of Sponsor, or eighteen (18) months from the completion date of the Study (as defined in 42 U.S.C. 282(j)(1)(A)(v)), whichever occurs first.|t
17132936|NCT03403400|t||||
17132937|NCT00989989|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132938|NCT01384292|f||GT60||t
17132939|NCT01171612|t||||
17132940|NCT00243659|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17132941|NCT03310970|f||||f
17132942|NCT01273064|f||LTE60||t
17132943|NCT04062214|f||||f
17132944|NCT00291551|f||||f
17132945|NCT04666038|f||GT60||t
17132946|NCT03400800|f||||f
17132947|NCT03219073|t||||
17177288|NCT03170856|t||||f
17177289|NCT05156073|f||||f
17177290|NCT01532973|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17177291|NCT02891161|f||||f
17177292|NCT03309150|f||||t
17177293|NCT04266769|t||||
17177294|NCT02734433|f||||f
17177295|NCT02628769|t||||
17177296|NCT00990938|f||||t
17177297|NCT05521906|f||||f
17132948|NCT03887130|f||||f
17132949|NCT04082663|f||||f
17132950|NCT01752023|t||||
17132951|NCT02899156|t||||f
17132952|NCT00909155|f||||f
17132953|NCT00787787|t||||
17132954|NCT01412957|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17132955|NCT04722991|f||LTE60||t
17132956|NCT01370460|f||||f
17132957|NCT01400932|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132958|NCT04646148|f||||f
17132959|NCT03244059|f||||f
17132960|NCT01276821|t||||
17132961|NCT03580616|t||||
17132962|NCT03706365|f||LTE60||t
17132963|NCT02162862|f||||f
17132964|NCT03116113|f||OTHER|Our agreement is subject to confidentiality but generally, the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor's Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of the Sponsor's intellectual property contained in the proposed publication.|t
17132965|NCT00006227|f||LTE60||t
17132966|NCT05195528|f||OTHER||t
17132967|NCT01552902|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17132968|NCT02487108|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17132969|NCT01254669|t||||f
17132970|NCT00600171|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132971|NCT00469612|t||||
17132972|NCT00430755|t||||
17132973|NCT02932787|t||||
17132974|NCT02633371|f||||f
17132975|NCT02620904|f||||f
17132976|NCT03990870|f||LTE60||t
17132977|NCT02557178|t||||
17132978|NCT01989221|t||||f
17132979|NCT01279057|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132980|NCT01196442|t||||f
17132981|NCT01427309|f||||f
17177298|NCT00560885|f||OTHER|The Sponsor can review communications prior to public release and can embargo communication regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the tim submitted to the sponsor for review. The sponsor can redact or modify the proposed publication to remove any language the sponsor believes would be detrimental to intellectual property or inaccurately reflect the results of the study.|t
17132982|NCT00849017|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17132983|NCT00544830|t||||
17132984|NCT04933123|t||||
17132985|NCT05254418|f||||f
17132986|NCT01111305|f||||f
17132987|NCT03624946|f||OTHER|CRO agrees that Emergent shall have the exclusive right to publish the results of each Study under a Task Order, including all Work Product relating thereto, and that such results may not be published or otherwise disseminated by CRO.|t
17132988|NCT01869348|t||||
17132989|NCT03711604|f||||f
17132990|NCT00624520|t||||
17132991|NCT01925209|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17132992|NCT03075163|f||||f
17132993|NCT02796755|t||||
17132994|NCT00110994|f||LTE60||t
17132995|NCT00675025|f||OTHER||t
17132996|NCT02002702|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single--site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17132997|NCT00556426|f||GT60||t
17132998|NCT00486447|f||||f
17132999|NCT02055404|t||||
17133000|NCT01299727|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133001|NCT02737163|f||||f
17133002|NCT00441792|t||||
17133003|NCT00638937|f||LTE60||t
17133004|NCT03062657|f||||f
17133005|NCT04354428|f||||f
17133006|NCT00579813|t||||f
17133007|NCT01879410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133008|NCT02649634|f||||f
17133009|NCT01012492|t||||f
17133010|NCT00626743|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release|t
17133011|NCT02211261|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133012|NCT03002974|f||||f
17133013|NCT01737931|f||||f
17133014|NCT01814787|f||||f
17133015|NCT03183128|f||||t
17133016|NCT00330187|t||||
17133017|NCT03258814|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17133018|NCT01413958|f||OTHER|"The Sponsor must have the opportunity to review all proposed abstracts,~manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines."|t
17133019|NCT03382509|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133020|NCT00364182|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133021|NCT01286493|t||||
17133022|NCT00705263|f||LTE60||t
17133023|NCT02246621|f||GT60||t
17133024|NCT01583374|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally sixty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17133025|NCT01265524|f||OTHER|A standard confidentiality agreement is in place.|t
17133026|NCT02281591|f||OTHER||t
17133027|NCT03267004|f||||f
17133028|NCT01542645|f||||f
17133029|NCT03652909|t||||
17133030|NCT02591615|f||||f
17133031|NCT04188197|f||||f
17133032|NCT02107703|f||GT60||t
17133033|NCT04574999|f||||f
17133034|NCT03631927|f||||f
17133035|NCT00008385|f||LTE60||t
17133036|NCT00398112|f||LTE60||t
17133037|NCT00595231|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17133038|NCT00365989|f||||f
17177299|NCT02887859|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo.|t
17177300|NCT02260440|t||||
17177301|NCT02793921|f||||f
17177302|NCT01507298|t||||
17177303|NCT01920555|f||||f
17177304|NCT03265665|f||||f
17177305|NCT01614600|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17177306|NCT01680965|f||||t
17177307|NCT00195273|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17177308|NCT02186873|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17177309|NCT00595465|f||OTHER||t
17177310|NCT02595970|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133039|NCT02318095|t||||
17133040|NCT00686127|t||||
17177311|NCT00107783|t||||
17177312|NCT01886716|f||||f
17177313|NCT02910362|f||LTE60||t
17177314|NCT04879225|f||||f
17177315|NCT03257696|t||||
17177316|NCT03894046|f||||f
17133041|NCT06441877|f||LTE60||t
17133042|NCT00066690|f||LTE60||t
17133043|NCT05256888|f||||f
17133044|NCT02159807|t||||
17133045|NCT05130008|f||||f
17177317|NCT02367131|t||||f
17133046|NCT06415305|f||GT60||t
17133047|NCT02367521|t||||
17133048|NCT02104414|t||||
17183938|NCT02246998|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183939|NCT02855060|f||||f
17183940|NCT02525133|f||OTHER||t
17183941|NCT01343082|f||||f
17183942|NCT01075074|t||||
17183943|NCT04265755|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17183944|NCT01575561|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17183945|NCT02496884|f||||f
17183946|NCT02956629|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17183947|NCT00618657|t||||
17183948|NCT01762761|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17133049|NCT00542191|t||||
17133050|NCT00970606|f||||f
17133051|NCT00103012|t||||
17133052|NCT01790490|f||||f
17133053|NCT04684420|f||||f
17133054|NCT00254410|f||||f
17133055|NCT03480802|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17133056|NCT03822884|f||OTHER|The PI is not allowed to disclose any confidential information of the clinical trial.|t
17133057|NCT01841619|f||||f
17133058|NCT02326337|f||||t
17133059|NCT02411448|f||GT60||t
17133060|NCT01551979|f||||f
17133061|NCT04067518|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17133062|NCT02771522|f||||f
17133063|NCT01577238|f||OTHER|For multicenter trials, PIs can publish only after the data from all sites are published collectively.|t
17183949|NCT00995449|f||OTHER|The sponsor has right of first publication of trial results, which will be a joint, multi-center publication of the study results from all appropriate sites contributing data, analysis and comments.|t
17183950|NCT01219738|t||||
17183951|NCT04695691|f||||f
17183952|NCT00795600|f||OTHER||t
17183953|NCT03936244|t||||
17133064|NCT05655377|f||||f
17133065|NCT01256177|f||OTHER|Institution and Principal Investigator shall not publish or present any such results until the earlier of (i) the date of the first Study results publication, or in case of a Multi-Centre Study the first Multi-Centre Results publication, authorized by AstraZeneca and (ii) the end of the eighteen (18) month period following the completion, or early termination, of the Study at all participating sites.|t
17133066|NCT01110395|t||||
17133067|NCT01728779|f||||f
17133068|NCT05617521|f||||f
17133069|NCT02673333|t||||
17133070|NCT01509625|f||||f
17133071|NCT00792298|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17133072|NCT04258579|t||||f
17133073|NCT02388295|f||LTE60||t
17133074|NCT02076165|t||||
17133075|NCT01756456|f||||f
17133076|NCT04244370|f||OTHER|Investigator seeking publication shall submit to Sponsor for review a draft of the proposed publication at least 60 days prior to submission of the draft for publication. Sponsor shall have the right to: (i) review and make editorial comments on any such proposed publication; and (ii) make any results from the Study known to its customers and governmental agencies prior to publication.|t
17133077|NCT00974220|f||||f
17133078|NCT01850615|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17133079|NCT01375764|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17133080|NCT02658812|t||||
17133081|NCT01512264|f||||f
17133082|NCT01194440|t||||
17133083|NCT02675075|t||||
17133084|NCT04957290|f||LTE60||t
17133085|NCT02411747|t||||
17177318|NCT01973569|f||||f
17133086|NCT02149810|t||||
17177319|NCT03714620|t||||
17133087|NCT00675597|t||||
17133088|NCT01176916|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177320|NCT00137631|f||LTE60||t
17177321|NCT00351000|t||||
17177322|NCT02486302|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177323|NCT01871142|f||||f
17177324|NCT02754557|t||||
17177325|NCT01237821|f||||f
17177326|NCT05015530|f||LTE60||t
17177327|NCT02063880|f||||f
17177328|NCT00567593|f||||f
17177329|NCT02106910|t||||
17177330|NCT02521766|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17177331|NCT01675427|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177332|NCT00700570|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177333|NCT00611533|f||||f
17177334|NCT01431131|f||||f
17177335|NCT05246397|f||||f
17177336|NCT01924988|f||||f
17177337|NCT01359007|t||||
17177338|NCT01892267|t||||
17177339|NCT00922233|t||||f
17177340|NCT04327674|f||||f
17177341|NCT01461980|f||OTHER||t
17177342|NCT00122109|t||||
17177343|NCT03584100|t||||
17177344|NCT03153956|t||||
17177345|NCT02540226|t||||
17177346|NCT00809354|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177347|NCT00267189|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177348|NCT00100178|f||||f
17177349|NCT03257371|f||||f
17177350|NCT00783965|t||||
17177351|NCT02477839|f||GT60||t
17177352|NCT02781779|t||||
17177353|NCT00745940|f||||f
17177354|NCT02268955|t||||
17133089|NCT01014403|t||||
17133090|NCT03158220|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17133091|NCT01015833|f||LTE60||t
17133092|NCT01671280|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177355|NCT01439568|f||GT60||t
17177356|NCT01784848|f||||t
17177357|NCT02607930|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177358|NCT03198078|f||||f
17177359|NCT03711266|t||||
17177360|NCT01646073|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17177361|NCT00057876|f||||f
17177362|NCT04040244|t||||
17177363|NCT00975637|f||||f
17177364|NCT03799211|t||||
17177365|NCT00764491|f||||f
17177366|NCT00542971|f||||f
17177367|NCT02484287|t||||f
17177368|NCT02396251|f||||t
17177369|NCT02927262|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17177370|NCT00923936|f||||f
17177371|NCT01697358|f||||f
17177372|NCT02038452|t||||f
17133093|NCT00996203|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17133094|NCT00622895|f||||f
17133095|NCT01959165|f||LTE60||t
17133096|NCT03686969|f||||f
17133097|NCT00560755|f||OTHER|Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17133098|NCT00848120|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133099|NCT02344225|f||||f
17133100|NCT01988090|t||||
17133101|NCT04870671|t||||
17133102|NCT01734317|f||OTHER||t
17133103|NCT01083667|f||||f
17133104|NCT03497845|f||||f
17133105|NCT00927563|f||||f
17133106|NCT03135249|f||||f
17133107|NCT01784796|t||||
17133108|NCT03120832|f||||t
17133109|NCT00413959|t||||f
17133110|NCT03057795|t||||
17133111|NCT04343651|f||||f
17133112|NCT04152824|f||||f
17133113|NCT01943565|t||||
17133114|NCT01292057|f||||f
17133115|NCT01459614|t||||
17133116|NCT04451707|f||||f
17133117|NCT02587338|t||||
17133118|NCT01506882|f||GT60||t
17133119|NCT01302808|t||||
17133120|NCT00821678|t||||
17133121|NCT02265913|f||OTHER||t
17133122|NCT01059448|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17133123|NCT00809328|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133124|NCT00806221|f||||f
17133125|NCT00832819|f||OTHER||t
17133126|NCT00851903|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17139194|NCT02845440|f||||f
17139195|NCT02057068|f||||f
17139196|NCT01782885|t||||
17139197|NCT03447821|f||OTHER|No disclosure was to take place without written authorisation from Cosmo Technologies Ltd, except to the extent necessary to obtain informed consent from potential volunteers.|t
17139198|NCT01704976|t||||f
17139199|NCT00329784|f||||f
17139200|NCT01098032|t||||
17177373|NCT02617784|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133127|NCT05742984|f||||f
17133128|NCT00379340|f||OTHER|Must obtain prior Sponsor approval.|t
17133129|NCT04801758|f||||f
17133130|NCT02064764|f||||f
17133131|NCT05019131|f||||f
17139201|NCT00481988|f||||f
17177374|NCT01460368|f||GT60||t
17177375|NCT00273910|f||||f
17177376|NCT05055453|f||||f
17177377|NCT01224665|f||LTE60||t
17177378|NCT00299182|t||||f
17177379|NCT01631812|f||||f
17177380|NCT00590889|f||||f
17177381|NCT00072176|f||LTE60||t
17177382|NCT03318900|t||||
17177383|NCT02024555|t||||
17177384|NCT03861702|f||||f
17177385|NCT03805646|f||||f
17177386|NCT03806491|t||||
17177387|NCT03350620|f||||f
17177388|NCT00814788|t||||
17177389|NCT04382391|f||||f
17177390|NCT00257608|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177391|NCT02171065|f||||f
17177392|NCT02053051|t||||
17177393|NCT01854658|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17177394|NCT01858376|f||||f
17177395|NCT03150160|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17177396|NCT02203071|t||||
17177397|NCT01012167|f||||f
17177398|NCT01006369|t||||
17177399|NCT02436304|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17177400|NCT03793556|f||||f
17177401|NCT04416633|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17177402|NCT04612790|f||||t
17177403|NCT00785928|f||GT60||t
17177404|NCT03764007|t||||
17177405|NCT03572244|f||||f
17177406|NCT00365144|t||||
17177407|NCT00570765|f||OTHER|Per protocol, Intercept retains ownership of the study data. Proposed publications based on the study shall be approved prior to submission for publications and will not be unreasonably withheld.|t
17177408|NCT03387683|f||LTE60||t
17177409|NCT02148107|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177410|NCT00875979|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177411|NCT01649804|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177412|NCT03686514|t||||
17177413|NCT05012657|t||||
17177414|NCT04242173|t||||
17177415|NCT00739050|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177416|NCT01123850|f||||f
17177417|NCT02083081|f||||f
17177418|NCT01336296|f||||f
17177419|NCT02028871|t||||
17177420|NCT01691898|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177421|NCT01104155|f||OTHER||t
17177422|NCT01484132|f||||f
17177423|NCT03139318|t||||
17177424|NCT02808650|f||OTHER|Must obtain prior sponsor approval|t
17177425|NCT02939079|t||||
17177426|NCT04093414|t||||
17177427|NCT04209348|f||||f
17177428|NCT00240227|t||||
17177429|NCT04102956|f||||f
17177430|NCT04398316|f||||f
17183954|NCT01046110|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17183955|NCT00905580|f||||f
17133132|NCT01703000|f||OTHER|Institution and Investigator shall have the right to publish the results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17133133|NCT02348099|t||||
17133134|NCT06118385|f||OTHER||t
17177431|NCT02080637|t||||
17177432|NCT02770170|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177433|NCT00445978|f||GT60||t
17177434|NCT02497300|t||||
17177435|NCT01822496|f||OTHER|Must obtain prior Sponsor approval.|t
17177436|NCT00304239|f||||t
17177437|NCT02979197|f||GT60||t
17177438|NCT03643159|f||OTHER|Sponsor reserves the right to review, edit, and authorize publications.|t
17177439|NCT03467048|t||||
17177440|NCT01898208|t||||
17177441|NCT02436681|f||||f
17177442|NCT01498601|t||||
17177443|NCT02030938|f||||f
17177444|NCT01599832|t||||
17177445|NCT03954132|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177446|NCT00834678|t||||f
17177447|NCT01739361|f||||f
17177448|NCT02443519|f||||f
17183956|NCT02753751|t||||
17133135|NCT01323478|f||OTHER|The primary publication must be published before any secondary publications. H. Lundbeck A/S will ensure that the authorship of all publications based on this study is in accordance with the criteria defined by the International Committee of Medical Journal Editors (ICMJE).|t
17133136|NCT00553462|f||LTE60||t
17183957|NCT02013765|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17183958|NCT04023695|t||||
17183959|NCT04171700|f||||f
17183960|NCT01134900|f||||f
17183961|NCT02334800|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183962|NCT01430130|f||||f
17183963|NCT00801684|f||OTHER|No individual Investigator may publish results without written agreement from Alkermes. Should an Investigator wish to publish or present the data at a meeting, a copy of the manuscript or abstract must be provided to the Sponsor at least 30 days prior to the submission for review and approval. Any revisions will be negotiated in good faith by the Investigator and Sponsor.|t
17183964|NCT01751568|f||OTHER|"In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights."|t
17183965|NCT04079933|f||||f
17183966|NCT01229436|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17183967|NCT05101252|f||GT60||t
17183968|NCT01459796|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17183969|NCT02073968|t||||
17183970|NCT01384539|f||||f
17133137|NCT04398732|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133138|NCT02395991|t||||
17133139|NCT01596257|t||||
17133140|NCT01570244|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133141|NCT02266108|t||||
17133142|NCT00934102|f||OTHER|No distribution of trial-specific information without express written permission of director.|t
17133143|NCT02318784|f||GT60||t
17133144|NCT01564706|f||GT60||t
17177449|NCT00932737|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177450|NCT04399837|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177451|NCT00894127|t||||
17177452|NCT01554397|f||||f
17177453|NCT06350474|f||||f
17177454|NCT02219438|f||||f
17177455|NCT00809848|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17177456|NCT02160990|t||||
17177457|NCT00320931|t||||f
17177458|NCT00369122|f||LTE60||t
17177459|NCT00004635|f||||f
17133145|NCT04007159|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133146|NCT01963481|t||||
17133147|NCT01242644|t||||
17133148|NCT04340050|t||||
17133149|NCT04134494|f||||f
17177460|NCT00408629|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17177461|NCT00191906|f||GT60||t
17177462|NCT00333801|t||||
17183971|NCT00345579|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183972|NCT01731171|t||||f
17183973|NCT00413413|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17183974|NCT01736852|f||OTHER|The sponsor can review results communications from PI prior to public release and can embargo communications of trial results between 60 and 180 days from the time submitted to the sponsor for review. The sponsor can embargo publications until the sponsor has published results or 180 days has elapsed after study closure at all participating sites. The sponsor cannot restrict publication but can require changes to protect sponsor's intellectual property rights or other confidential information.|t
17183975|NCT03054844|t||||
17183976|NCT03009110|f||||f
17183977|NCT02604589|t||||
17183978|NCT01286818|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17183979|NCT01168934|t||||
17183980|NCT01504438|t||||f
17183981|NCT00877448|f||LTE60||t
17183982|NCT00723177|f||||f
17183983|NCT01592708|t||||
17183984|NCT02921412|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any results communications and has ability to review.|t
17183985|NCT02283528|t||||
17183986|NCT03136068|f||||f
17183987|NCT03189914|f||||f
17183988|NCT03047447|f||||f
17183989|NCT00432380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17183990|NCT00734305|f||LTE60||t
17183991|NCT01071395|f||||f
17183992|NCT01539291|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183993|NCT02239510|f||||f
17183994|NCT00466193|f||OTHER|Sponsor agrees to review manuscripts within sixty (60) days prior to submission for publication. If sponsor determines the publication includes patentable subject matter, sponsor may take an additional sixty (60) days to permit the filing of any patent applications.|t
17183995|NCT01054729|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177463|NCT03633617|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177464|NCT01890746|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17177465|NCT02642029|f||||f
17177466|NCT02059902|t||||
17177467|NCT03028103|f||||t
17177468|NCT01050543|f||OTHER|"The sponsor shall have the right to review and comment with respect to publications with regard to the following concerns: proprietary information; accuracy of the information; and to ensure that the presentation is fairly balanced and in compliance with FDA regulations.~The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial."|t
17177469|NCT00676338|f||GT60||t
17183996|NCT01375049|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17183997|NCT02066857|f||||f
17183998|NCT01175382|f||||f
17177470|NCT00149734|f||||f
17177471|NCT00412542|t||||
17183999|NCT00774787|f||OTHER|PIs must agree on communication of complete results, but may discuss individual site results. Collaborator can review complete results communications prior to public release and can embargo communications regarding trial results, if patents are to be pursued, for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the collaborator for review. The collaborator cannot require changes to the communication and cannot extend the embargo.|t
17184000|NCT02554773|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17184001|NCT02203019|t||||
17177472|NCT02654314|t||||
17184002|NCT02031276|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17184003|NCT01148810|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184004|NCT01854554|t||||
17184005|NCT02509624|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184006|NCT02613481|f||||f
17184007|NCT01033747|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17133150|NCT01950819|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133151|NCT00781365|f||||f
17133152|NCT01474590|f||OTHER||t
17177473|NCT02124161|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177474|NCT02517866|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17177475|NCT01147640|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Authorship on any primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results. All investigators who enroll at least one subject will be acknowledged in any journal publication.|t
17177476|NCT01436006|f||||f
17177477|NCT01797731|t||||
17177478|NCT01954342|f||||f
17177479|NCT01631110|f||OTHER|Material for public dissemination will be submitted to the sponsor for review at least ninety (90) days prior to submission for publication, public dissemination, or review by a publication committee.|t
17177480|NCT02175628|t||||
17177481|NCT00629772|f||LTE60||t
17177482|NCT01497275|t||||
17177483|NCT01950169|f||||f
17177484|NCT03420625|t||||
17177485|NCT01680887|t||||f
17177486|NCT01955564|f||||f
17177487|NCT00285818|f||||f
17177488|NCT01986946|f||||f
17177489|NCT02263131|f||||f
17177490|NCT01230710|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177491|NCT05394350|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17177492|NCT01336569|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17133153|NCT00756548|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extent the embargo.|t
17133154|NCT01573910|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17133155|NCT01649947|t||||
17133156|NCT01920802|f||||f
17133157|NCT01227967|f||||f
17177493|NCT03530800|f||||f
17177494|NCT02963935|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17177495|NCT00464269|f||GT60||t
17177496|NCT02337738|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17177497|NCT00406354|f||GT60||t
17177498|NCT00747461|f||||f
17177499|NCT01212107|f||GT60||t
17177500|NCT04181320|f||||f
17177501|NCT01565642|t||||f
17177502|NCT01498978|t||||
17177503|NCT00961649|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17139202|NCT00654420|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17139203|NCT01525420|f||||f
17139204|NCT00471276|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139205|NCT01594411|f||OTHER|CardioDx will provide a copy of the proposed publication to Collaborator for prior review for a thirty (30)-day period, during which period any Collaborator personnel listed as authors may either (a) elect to opt out from being listed as an author, or (b) suggest modifications to the proposed publication, and if they do not elect either (a) or (b) within that period, they will be deemed to have consented to publication as an author.|t
17139206|NCT00838383|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139207|NCT00910728|f||OTHER||t
17139208|NCT00431496|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139209|NCT00361218|f||||f
17139210|NCT01248585|t||||f
17139211|NCT02820038|t||||f
17139212|NCT01372813|f||||f
17139213|NCT00044213|f||OTHER|Enrolling Centers must abide by all TACT and NIH conflict of interest policies. Decisions about authorship on all multi-center publications resulting from research under this agreement will be made by the TACT Publica¬tions Committee prior to publication. No publications or other public disclosure shall be made until the TACT results are unblinded and results from all sites have been received and analyzed or TACT has been abandoned at all sites.|t
17139214|NCT03148795|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139215|NCT01927068|f||||t
17177504|NCT02711345|f||OTHER||t
17177505|NCT04043728|t||||f
17133158|NCT01763164|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139216|NCT00880607|t||||
17139217|NCT02104141|f||||f
17139218|NCT02963766|f||GT60||t
17139219|NCT00499460|f||||f
17139220|NCT00814307|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139221|NCT01256918|t||||
17177506|NCT01033851|f||||f
17177507|NCT02349542|f||||f
17177508|NCT01011738|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177509|NCT00200161|t||||
17184008|NCT00844194|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17133159|NCT03384329|f||||f
17133160|NCT01167608|t||||
17184009|NCT02647658|f||||f
17184010|NCT00803023|f||||f
17133161|NCT03670030|f||||f
17133162|NCT03709602|f||||f
17133163|NCT02678429|f||||f
17133164|NCT02602223|f||||f
17133165|NCT03595280|t||||
17133166|NCT00584870|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133167|NCT00854828|f||||f
17133168|NCT01239355|f||LTE60||t
17133169|NCT02292212|f||LTE60||t
17133170|NCT00896532|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17133171|NCT00631137|t||||
17133172|NCT01791855|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133173|NCT00772447|f||OTHER||t
17133174|NCT01439945|f||LTE60||t
17139222|NCT02290340|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17139223|NCT04129086|t||||
17139224|NCT00045487|f||||f
17139225|NCT03209362|f||OTHER||t
17139226|NCT01186003|f||||f
17139227|NCT00251589|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139228|NCT00323427|t||||
17139229|NCT03039192|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139230|NCT03074318|f||||f
17139231|NCT00093756|f||LTE60||t
17139232|NCT00360672|t||||
17139233|NCT00643448|f||LTE60||t
17139234|NCT02177812|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139235|NCT01167153|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17139236|NCT05166603|t||||
17139237|NCT01594749|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17139238|NCT02177786|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17139239|NCT00439309|f||LTE60||t
17139240|NCT01977040|t||||
17139241|NCT02027272|t||||
17139242|NCT01780324|t||||
17177510|NCT01163266|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17139243|NCT04037462|t||||
17139244|NCT00189436|f||||f
17139245|NCT04402385|t||||
17139246|NCT03180294|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17139247|NCT02058706|t||||f
17139248|NCT02650193|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139249|NCT01308853|f||OTHER|Individual publications shall not be made prior to the first, multi-center publication of the results of the multicenter study. The Investigator shall have the right to publish the results of his work. Any publication or presentation by Institution and/or Principal Investigator shall be submitted to Q Med for review and comment no less than 60 days before submission to allow Q Med to determine whether any patentable invention or Confidential Information would be disclosed.|t
17139250|NCT01951326|f||||t
17139251|NCT04984876|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139252|NCT02204410|f||||f
17139253|NCT02444936|f||||f
17139254|NCT03654560|f||||f
17139255|NCT00209092|t||||
17139256|NCT01193049|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17139257|NCT01462045|f||||f
17139258|NCT02462122|f||OTHER|Contact sponsor directly for details.|t
17139259|NCT01726504|t||||
17139260|NCT00864539|t||||
17139261|NCT01117181|f||||f
17139262|NCT01100658|t||||
17139263|NCT02658149|f||||f
17139264|NCT04358991|f||GT60||t
17139265|NCT02527564|f||OTHER||t
17139266|NCT00420342|f||OTHER|(A). PI will provide copy to Sponsor sixty (60) days. Sponsor will have thirty (30) days to review and provide feedback. (B). If proposed publication presents material adverse effect on Sponsor's confidentiality information, then PI shall delay or prevent such publication. (C) In multi-center trial, the investigative data will be pooled and published as a collaborative effort with consent from all parties including the Sponsor.|t
17139267|NCT03053401|f||||f
17139268|NCT01017549|f||OTHER|The results are published; therefore the disclosure agreement is no longer in effect. The site investigators were to ask permission to publish single center results if they chose to publish prior to the entire study results were published.|t
17177511|NCT02586064|t||||
17177512|NCT02919696|f||GT60||t
17177513|NCT04308304|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17177514|NCT00945555|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177515|NCT03374631|f||||f
17133175|NCT00777179|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17133176|NCT01497262|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133177|NCT02730260|f||||f
17133178|NCT00054132|f||LTE60||t
17133179|NCT01290887|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17133180|NCT01468987|f||GT60||t
17133181|NCT01795547|f||||f
17133182|NCT01285427|f||||f
17133183|NCT05032950|t||||f
17133184|NCT03257189|f||||f
17133185|NCT00299988|t||||
17133186|NCT00961961|f||||f
17133187|NCT02764541|t||||
17177516|NCT01706822|f||||f
17177517|NCT04502979|t||||
17177518|NCT02856698|f||GT60||t
17177519|NCT00772304|f||||f
17177520|NCT02046902|f||||f
17177521|NCT01892865|t||||f
17177522|NCT01558739|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17177523|NCT03950791|f||||f
17177524|NCT04294277|f||||f
17177525|NCT02719327|f||||f
17177526|NCT01470859|f||||f
17177527|NCT01066000|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177528|NCT00566111|t||||
17133188|NCT00749190|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17133189|NCT01245673|f||||f
17133190|NCT03404648|t||||
17133191|NCT00355121|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17133192|NCT00630331|f||||f
17133193|NCT00524537|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17133194|NCT04640766|t||||
17133195|NCT01565980|f||||f
17133196|NCT06120530|t||||
17133197|NCT01629615|f||||f
17133198|NCT00895830|f||||f
17133199|NCT02425098|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17133200|NCT01929135|t||||f
17133201|NCT02078219|f||||f
17133202|NCT03036527|f||||f
17133203|NCT02761967|f||||f
17133204|NCT03136107|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177529|NCT02497612|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17177530|NCT05203289|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177531|NCT05021081|f||GT60||t
17133205|NCT03283085|f||||t
17133206|NCT05070338|f||||f
17133207|NCT02292771|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133208|NCT01475734|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133209|NCT00376961|f||LTE60||t
17133210|NCT02911688|t||||f
17133211|NCT04201717|f||||f
17133212|NCT01678976|t||||
17133213|NCT01922921|f||||f
17133214|NCT00709826|f||||f
17133215|NCT05148884|f||||t
17133216|NCT01993888|f||LTE60||t
17133217|NCT00317044|f||GT60||t
17133218|NCT02357420|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17133219|NCT00582517|f||||f
17139269|NCT01804842|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17139270|NCT03933215|f||OTHER|Sponsor must be notified of plans to present or publish data. Presentations and/or publications require pre-submission review and approval by sponsor. Sponsor maintains right to delay publication to protect IP rights.|t
17139271|NCT04222673|f||||f
17139272|NCT04097028|t||||
17139273|NCT04072575|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139274|NCT02473289|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139275|NCT02244619|t||||
17139276|NCT00383266|t||||
17139277|NCT01291511|f||OTHER|Pooled site data analysis is restricted to publication by consent of steering committee. PI is restricted from presenting or publishing independently on their own site data until the expiration of eighteen (18) months from the completion of the Clinical Trial or as otherwise noted in the Investigator's clinical trial agreement.|t
17139278|NCT02367859|t||||
17139279|NCT00047008|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17139280|NCT02748525|t||||
17139281|NCT01408732|f||||f
17139282|NCT04904640|f||||f
17139283|NCT00796003|f||GT60||t
17139284|NCT05179057|f||||f
17139285|NCT02437162|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139286|NCT04338321|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139287|NCT03107793|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17139288|NCT02808507|f||||f
17139289|NCT01989572|f||LTE60||t
17139290|NCT00865046|t||||
17139291|NCT04146038|t||||
17139292|NCT00176878|t||||
17133220|NCT00928070|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133221|NCT02371850|f||OTHER|Restricted until the manuscript is published in a peer-reviewed journal.|t
17133222|NCT00891995|f||||f
17133223|NCT02054702|f||||f
17133224|NCT00887458|t||||
17133225|NCT00501228|t||||f
17133226|NCT02304926|f||||f
17133227|NCT00848744|f||||f
17133228|NCT03157531|f||||f
17139293|NCT01024920|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17133229|NCT00331006|f||OTHER|Baxter donated Factor VIII and Genentech donated rituximab for the study. Both Baxter and Genentech can review results communications prior to public release for a period of time less than or equal to 60 days from the time submitted to them for review. These companies cannot require changes to the communication.|t
17133230|NCT03804684|f||||f
17133231|NCT00109473|f||||f
17133232|NCT00238264|f||OTHER|Must obtain prior Sponsor approval.|t
17133233|NCT02706938|f||||f
17139294|NCT02977507|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17133234|NCT01838044|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139295|NCT00633360|t||||f
17139296|NCT01188460|t||||
17139297|NCT01673425|t||||
17139298|NCT01987752|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17139299|NCT00621244|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single-site are postponed until the publication of the polled data (ie, data from all sites) in the clinical trial.|t
17139300|NCT04238689|t||||f
17139301|NCT04449276|f||OTHER||t
17139302|NCT01614795|f||LTE60||t
17139303|NCT00565812|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139304|NCT04968353|f||||f
17139305|NCT00845845|t||||
17139306|NCT04266158|f||||f
17139307|NCT03595449|t||||
17139308|NCT03242590|f||OTHER||t
17139309|NCT02033850|t||||
17139310|NCT00260195|f||||f
17133235|NCT00495157|f||||f
17133236|NCT00860470|t||||f
17133237|NCT03689192|t||||
17133238|NCT01662648|f||||f
17133239|NCT02928952|t||||
17133240|NCT00723957|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17133241|NCT03751111|t||||
17133242|NCT01007526|t||||
17133243|NCT00706628|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133244|NCT01264939|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133245|NCT03251326|t||||
17133246|NCT02266433|t||||f
17133247|NCT04525703|t||||
17133248|NCT01285349|t||||
17139311|NCT02590640|f||||f
17139312|NCT00550290|f||||f
17139313|NCT02571972|f||||f
17139314|NCT02493868|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139315|NCT02407236|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17139316|NCT00089999|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139317|NCT03186261|f||||f
17139318|NCT02828644|f||LTE60||t
17177532|NCT02651467|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133249|NCT01145560|f||LTE60||t
17133250|NCT00712348|f||||f
17133251|NCT02278783|f||||f
17133252|NCT02452762|f||||f
17133253|NCT03682120|f||LTE60||t
17133254|NCT03308188|f||||f
17133255|NCT01957137|f||||f
17133256|NCT01656772|f||GT60||t
17133257|NCT02497001|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17133258|NCT03898063|t||||f
17139319|NCT02436915|f||||f
17139320|NCT02158728|f||||f
17139321|NCT00863317|t||||
17139322|NCT03878160|t||||f
17139323|NCT03531762|f||||f
17177533|NCT01072669|t||||f
17177534|NCT02024529|f||||t
17177535|NCT00573937|t||||
17139324|NCT00809614|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17139325|NCT01080625|t||||f
17139326|NCT01092364|t||||f
17177536|NCT04171765|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177537|NCT01480089|t||||
17177538|NCT00631696|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177539|NCT04046055|f||||f
17177540|NCT01426438|f||||f
17177541|NCT01134731|f||LTE60||t
17177542|NCT02122458|t||||
17177543|NCT03161093|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177544|NCT00091442|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission. Expedited reviews will be arranged if needed. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application. The sponsor will not mandate modifications to scientific content and does not have the right to suppress information.|t
17177545|NCT02480920|f||||f
17177546|NCT01332331|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177547|NCT01076231|t||||
17177548|NCT04810481|f||||f
17177549|NCT02664610|t||||f
17177550|NCT06448078|t||||
17177551|NCT04981392|f||||f
17177552|NCT01833546|f||OTHER||t
17177553|NCT05055128|f||OTHER|This document contains confidential information about Cinclus Pharma Holding AB. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor use it for unauthorized purposes. In the event of an actual or suspected breach of this obligation, Cinclus Pharma Holding AB should be promptly notified.|t
17177554|NCT01385371|f||OTHER|The investigator agrees to provide to the SPONSOR 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17177555|NCT00936611|t||||
17177556|NCT01346969|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177557|NCT01881373|f||||f
17177558|NCT02906332|t||||
17177559|NCT02949700|t||||
17177560|NCT03945266|f||||f
17177561|NCT01686828|f||||f
17177562|NCT03750461|t||||f
17177563|NCT04176705|f||||f
17177564|NCT02423772|f||||f
17177565|NCT03882788|t||||
17177566|NCT03727425|f||||f
17177567|NCT02484690|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177568|NCT03360747|f||LTE60||t
17177569|NCT04432272|t||||
17177570|NCT01759511|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177571|NCT02127723|f||LTE60||t
17177572|NCT04916769|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177573|NCT03772678|f||OTHER||t
17177574|NCT04526509|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17177575|NCT03448653|f||||f
17139327|NCT00364832|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139328|NCT00054756|t||||
17139329|NCT00762528|f||LTE60||t
17139330|NCT01973972|t||||
17139331|NCT01440972|f||||f
17177576|NCT04340193|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17177577|NCT00589290|f||||f
17177578|NCT01067976|f||||f
17177579|NCT04449861|f||||f
17139332|NCT00068822|t||||f
17177580|NCT05268055|t||||
17177581|NCT03507400|f||||f
17177582|NCT01555983|f||||f
17177583|NCT02353754|f||||f
17177584|NCT02475031|f||||f
17177585|NCT00289718|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177586|NCT04128579|f||GT60||t
17177587|NCT02875132|f||||f
17177588|NCT02598960|f||LTE60||t
17177589|NCT00108433|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177590|NCT04195906|f||LTE60||t
17177591|NCT02006888|f||||t
17177592|NCT03485391|f||||f
17177593|NCT00371826|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17177594|NCT01137396|f||||f
17177595|NCT00734474|f||GT60||t
17177596|NCT01601860|f||||f
17177597|NCT00942448|f||LTE60||t
17177598|NCT03089320|t||||
17177599|NCT00385762|t||||
17177600|NCT00573183|t||||
17177601|NCT01126801|t||||f
17177602|NCT00428792|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177603|NCT02570074|t||||
17177604|NCT05027464|t||||t
17177605|NCT04075279|f||||f
17177606|NCT00608972|t||||
17177607|NCT03270644|f||GT60||t
17177608|NCT04066647|t||||
17177609|NCT00354614|f||||f
17177610|NCT01500031|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17177611|NCT02657538|t||||
17177612|NCT01856907|f||||f
17177613|NCT02927327|f||||f
17177614|NCT01604408|f||GT60||t
17177615|NCT03711318|f||||f
17177616|NCT00917501|f||||f
17177617|NCT05095454|t||||f
17177618|NCT01999114|f||GT60||t
17177619|NCT02437383|t||||f
17177620|NCT00722423|t||||
17177621|NCT01954160|f||||f
17177622|NCT05085730|f||||f
17177623|NCT01453725|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including slides and texts of oral or other public presentations and texts of any transmission through any electronic media) that report any results of the trial.|t
17177624|NCT03605212|f||OTHER|Prior to submitting the results of this study for publication or presentation, the Investigator will allow the sponsor at least 60 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until the sponsor has reviewed/commented and agreed to any publication.|t
17177625|NCT01756053|t||||
17177626|NCT01986140|f||||f
17177627|NCT04048122|f||||f
17177628|NCT01069627|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139333|NCT04944758|f||||f
17139334|NCT00617162|f||||f
17139335|NCT00735072|t||||f
17177629|NCT00471146|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177630|NCT02149875|t||||
17177631|NCT02478372|t||||f
17177632|NCT04836312|f||||f
17177633|NCT03860597|f||||f
17177634|NCT03800173|f||||f
17177635|NCT02507973|t||||f
17177636|NCT00910273|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177637|NCT03841448|f||||f
17133259|NCT02949830|f||OTHER|It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A copy of any proposed manuscript must be provided and confirmed received at the Sponsor at least 30 days before its submission, and according to any additional publication details in the Investigator Agreement.|t
17177638|NCT00543543|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17177639|NCT01361568|f||GT60||t
17177640|NCT02959983|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17177641|NCT00484094|f||GT60||t
17177642|NCT00586625|f||OTHER|Agreement is between contract research organization and third parties on behalf of ISTA Pharmaceuticals, Inc.|t
17177643|NCT00165984|t||||f
17177644|NCT01736124|t||||
17177645|NCT03553927|t||||
17177646|NCT03242824|t||||
17177647|NCT01193842|f||LTE60||t
17177648|NCT03698331|f||||t
17177649|NCT06033521|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177650|NCT02130024|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17177651|NCT01467583|f||||f
17177652|NCT02717273|t||||
17177653|NCT05274165|t||||
17177654|NCT01386008|f||OTHER|The principal investigators are not permitted to publish or make public any of the results without prior written approval from the Sponsor.|t
17177655|NCT03001882|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17177656|NCT00976677|f||LTE60||t
17177657|NCT00485433|f||||f
17177658|NCT01182610|f||OTHER|Prior to publication or presentation of Sponsored Research results, Researcher agrees to provide Amgen 60 days to review a manuscript and 15 days to review any poster presentation, abstract or other written or oral materials derived from a Study. If Amgen requests in writing, the Researcher shall withhold material an additional 60 days. Amgen reserves the right to remove confidential information from any publications. The Researcher shall reference Amgen's support of the Study in any material.|t
17177659|NCT00546104|f||||f
17177660|NCT00615108|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17177661|NCT01393301|f||||f
17177662|NCT02758171|t||||f
17177663|NCT00853073|f||||f
17177664|NCT03643575|f||||f
17177665|NCT01309165|f||||f
17177666|NCT05143541|f||||f
17177667|NCT02410551|t||||
17177668|NCT02315989|f||||f
17177669|NCT01739309|f||GT60||t
17177670|NCT04137627|t||||
17177671|NCT00986830|f||GT60||t
17177672|NCT01495975|f||||f
17177673|NCT05447897|f||||f
17177674|NCT04553679|f||||f
17177675|NCT00333840|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177676|NCT00392860|f||||f
17177677|NCT00074984|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17177678|NCT01360593|t||||
17177679|NCT03719586|t||||f
17177680|NCT03441269|f||||f
17177681|NCT00369707|t||||
17177682|NCT02046733|f||||f
17177683|NCT01296360|f||OTHER||t
17177684|NCT02394548|t||||
17177685|NCT04562792|f||||f
17177686|NCT01254292|f||LTE60||t
17177687|NCT04041375|t||||
17177688|NCT00515177|t||||
17177689|NCT01967342|t||||
17177690|NCT04674644|t||||
17177691|NCT00199875|f||LTE60||t
17177692|NCT03789214|f||||f
17133260|NCT02959814|t||||
17133261|NCT02116621|f||||f
17133262|NCT03437447|f||||f
17133263|NCT04492566|f||||f
17133264|NCT02040142|t||||
17133265|NCT00888511|f||||f
17133266|NCT02330419|t||||f
17133267|NCT01438008|f||||f
17133268|NCT01813890|f||GT60||t
17177693|NCT03277690|f||LTE60||t
17177694|NCT00747812|f||||f
17177695|NCT01013350|f||||f
17177696|NCT01708161|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133269|NCT03952559|f||GT60||t
17133270|NCT01997463|f||||f
17133271|NCT01870739|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17133272|NCT01986062|f||LTE60||t
17133273|NCT03538743|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177697|NCT02019277|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177698|NCT01349231|t||||
17177699|NCT02633501|f||OTHER||t
17177700|NCT00395733|f||OTHER|PIs shall provide sponsor with an advance copy of any proposed publication or oral presentation at least ninety (90) days prior to the date of the planned submission or presentation. Sponsor shall have sixty (60) days to recommend any changes it reasonably believes are necessary for scientific purposes or to preserve the confidentiality of sponsor's confidential information. PIs agree that the adoption of such recommended changes shall not be unreasonably refused.|t
17177701|NCT05835323|f||OTHER|The Principal Investigator(s) may publish or present the Study results with prior consent of the Sponsor but will not disclose confidential information. Prior to submission by a Principal Investigator for publication or presentation, the Sponsor will be provided with the opportunity to review the submission for confidential information and accuracy.|t
17177702|NCT01672736|f||LTE60||t
17177703|NCT01044706|f||OTHER|This document contains trade secrets and commercial information that is confidential and may not be disclosed to third parties. Persons to whom this study protocol is disclosed must be informed that all the information herein is confidential and may not be further divulged. These restrictions will apply as well to all future communications if deemed privileged or confidential. Publication of the study results may only be allowed with written permission from the Sponsor.|t
17177704|NCT01485393|t||||
17177705|NCT02853344|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17177706|NCT02913612|f||||f
17177707|NCT03452228|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177708|NCT01262573|t||||
17177709|NCT02955797|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17177710|NCT01783054|t||||
17177711|NCT02081183|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177712|NCT01021306|f||||f
17177713|NCT04128371|t||||
17177714|NCT00968864|f||||f
17177715|NCT02308189|t||||
17177716|NCT03022435|f||||f
17177717|NCT00644189|t||||
17177718|NCT00397215|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177719|NCT02128932|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator (s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for upto 60 days to protect intellectual property.|t
17177720|NCT01433731|f||||f
17177721|NCT00657358|t||GT60||
17177722|NCT02728596|f||LTE60||t
17177723|NCT03221270|t||||
17133274|NCT00667615|t||||
17133275|NCT01827384|f||LTE60||t
17133276|NCT01110252|t||||
17133277|NCT00288574|f||||f
17177724|NCT03353246|t||||
17177725|NCT01414608|f||LTE60||t
17133278|NCT00382031|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17133279|NCT03639948|f||||f
17133280|NCT03636906|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17133281|NCT01291017|f||||f
17133282|NCT04596891|t||||
17133283|NCT03690869|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17133284|NCT02274688|f||||f
17133285|NCT01524991|f||||f
17133286|NCT00951821|f||||f
17133287|NCT01805180|f||LTE60||t
17133288|NCT03455673|t||||
17133289|NCT00582556|t||||
17133290|NCT03124459|f||LTE60||t
17133291|NCT04647110|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133292|NCT01717638|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133293|NCT01099111|f||||f
17133294|NCT02300129|f||OTHER||t
17133295|NCT06131294|f||LTE60||t
17133296|NCT00522392|f||LTE60||t
17133297|NCT01910792|f||||f
17133298|NCT02472457|t||||
17133299|NCT03051633|f||||f
17133300|NCT05211336|f||||f
17133301|NCT01834235|f||||f
17133302|NCT04271761|f||||f
17133303|NCT00332709|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety.|t
17133304|NCT03575104|f||OTHER|Any study-related publication written independently by investigators must be submitted to Idorsia for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Idorsia may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17133305|NCT04226469|f||||f
17133306|NCT01409928|f||||f
17133307|NCT00893516|f||||f
17133308|NCT00432237|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133309|NCT01354132|f||||f
17133310|NCT00603239|f||GT60||t
17133311|NCT00191854|f||GT60||t
17139336|NCT00911144|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139337|NCT03981744|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17133312|NCT04355013|f||||f
17133313|NCT00862251|f||OTHER|An investigator and/or his/her colleagues may publish the results for their study site independently after the multicenter publication, or 24 months after completion of the study, whichever comes first. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17133314|NCT01727089|f||LTE60||t
17133315|NCT02673229|f||||f
17133316|NCT00499109|t||||
17133317|NCT01756274|f||GT60||t
17133318|NCT01147926|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133319|NCT03417440|f||||f
17133320|NCT01290627|t||||f
17133321|NCT00670709|f||||f
17133322|NCT03304522|f||||t
17133323|NCT00486603|f||GT60||t
17133324|NCT01670994|f||||t
17133325|NCT02013544|f||OTHER|Investigators shall provide to the SPONSOR 30 days prior to submission all documents for publication, presentation, etc that report any trial results. The SPONSOR shall have editorial rights on documents and the right to review/comment with regard to (1) proprietary information, (2) accuracy of the information, (3) correctness of the scientific evaluation/conclusions and (4) to ensure that the information is fairly balanced and in compliance with regulations.|t
17133326|NCT01295125|f||||f
17133327|NCT02036320|f||GT60||t
17133328|NCT00885365|f||OTHER|Upon PI submission of publication to Sponsor, Sponsor will complete its review within 90 days after receipt. At Sponsor's request, publication may be delayed up to 120 additional days for Sponsor to file necessary patent applications. In multicenter trials, PIs will postpone single center publications until after multicenter data publication. If no multicenter publication occurs within 12 months of trial completion, PI may publish single center results, subject to review timelines listed above.|t
17133329|NCT01824979|f||||f
17133330|NCT01221857|f||||f
17133331|NCT02507349|f||||f
17133332|NCT00888238|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133333|NCT01748799|f||||f
17133334|NCT00516919|f||||f
17139338|NCT00732238|t||||
17139339|NCT06181708|t||||
17139340|NCT00246376|f||||f
17139341|NCT00077922|f||||f
17139342|NCT05241288|t||||
17139343|NCT04246489|f||||f
17139344|NCT00610207|f||LTE60||t
17177726|NCT03672643|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177727|NCT05736224|t||||
17177728|NCT02557295|f||||t
17177729|NCT01484041|f||||f
17177730|NCT01805440|f||||f
17177731|NCT04806503|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177732|NCT03589469|f||OTHER|PI can publish after first multi-site publication or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on PI is sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period \>60 but ≤180 days from time submitted to sponsor review. Sponsor can't require changes to the comms, extend embargo or require changes to comms, except removing confidential info that are not results|t
17177733|NCT00617851|f||LTE60||t
17177734|NCT02239354|f||OTHER|If a multi-center publication is not published within 14 to 18 months (depends on the individual PI's contract) after completion of the study, the PI will have the right to publish and present results. The PI will submit any proposed publication or presentation to the Sponsor for review at least 30 to 60 days (depending on the individual PI's contract) prior to submitting any such proposed publication to a publisher, proceeding with such proposed presentation or making any other disclosure.|t
17177735|NCT02056639|f||||f
17177736|NCT04172623|f||||f
17177737|NCT00902668|t||||f
17177738|NCT01914757|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17177739|NCT03509883|f||LTE60||t
17177740|NCT00333177|t||||f
17177741|NCT02833350|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177742|NCT03342963|f||||f
17177743|NCT04517500|t||||
17177744|NCT04269707|f||||f
17177745|NCT01189604|f||OTHER|If the PI wants to publish the results, the PI must send the English documents to AZ beforehand. And AZ can review and revise the documents, after that, AZ will give the approval to the PI about the publication of the results.|t
17177746|NCT03626168|f||||f
17177747|NCT02248701|t||||
17177748|NCT00808483|f||||f
17177749|NCT02038881|f||||t
17177750|NCT02357979|t||||f
17177751|NCT03945214|t||||f
17177752|NCT00880542|f||GT60||t
17177753|NCT00850070|t||||f
17177754|NCT05047770|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17177755|NCT02391701|f||||f
17177756|NCT04289623|t||||
17177757|NCT03758443|f||||t
17177758|NCT01436396|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17177759|NCT01102270|f||||f
17177760|NCT00843531|t||||
17177761|NCT01772160|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177762|NCT01522248|t||||
17177763|NCT00303901|t||||f
17177764|NCT00178633|t||||
17177765|NCT00538291|t||||
17177766|NCT00591344|f||||f
17177767|NCT00694707|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17177768|NCT02640716|f||||t
17177769|NCT04081324|f||GT60||t
17177770|NCT01464996|f||||f
17177771|NCT01904058|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17177772|NCT03417804|f||||f
17139345|NCT03241589|t||||
17177773|NCT03096483|f||OTHER|The results of this study may not be used in future publications.|t
17177774|NCT01318642|f||||t
17139346|NCT02465489|f||OTHER|Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.|t
17139347|NCT00693693|f||||f
17133335|NCT03371355|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17133336|NCT02633540|f||||f
17133337|NCT01508455|f||||f
17133338|NCT00977470|t||||
17133339|NCT02284165|f||||f
17133340|NCT00620061|f||GT60||t
17133341|NCT03757039|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17133342|NCT00125034|f||GT60||t
17133343|NCT01818297|f||OTHER|Disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 90 days.|t
17133344|NCT00650858|f||OTHER|The PI shall provide the sponsor with a copy of any proposed publication for review and comment thirty (30) days prior to submission. JHU may request a delay in publication, not to exceed 90 days if it is necessary to protect any intellectual property.|t
17133345|NCT03529409|t||||f
17133346|NCT01412229|f||OTHER||t
17133347|NCT01889602|t||||
17133348|NCT03303989|t||OTHER||
17133349|NCT00591734|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17133350|NCT04752384|t||||
17133351|NCT02921386|f||GT60||t
17133352|NCT01955707|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17133353|NCT01905956|f||||f
17133354|NCT01817790|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133355|NCT01671345|t||||
17139348|NCT02972593|f||||f
17139349|NCT04599972|f||||t
17177775|NCT02556736|f||OTHER|Allergan as the sponsor, has proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between multiple investigators and sites and Allergan personnel. Authorship will be established prior to the writing of the manuscript. As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with Allergan.|t
17177776|NCT03594435|f||||f
17177777|NCT01024231|f||LTE60||t
17177778|NCT01419639|t||||
17177779|NCT01561378|t||||
17177780|NCT00973674|t||||
17177781|NCT02713204|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177782|NCT02350569|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177783|NCT01710046|f||||f
17177784|NCT03896165|t||||
17177785|NCT03181893|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133356|NCT04980391|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17133357|NCT04981223|t||||
17133358|NCT04280081|f||GT60||t
17133359|NCT01468311|f||||f
17133360|NCT04714372|t||||
17133361|NCT03219164|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133362|NCT02689492|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133363|NCT02029976|f||||f
17133364|NCT04025632|f||||t
17133365|NCT01750918|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17177786|NCT03000569|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17177787|NCT04815031|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177788|NCT04122534|f||||f
17177789|NCT00579878|f||||f
17177790|NCT01254630|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17177791|NCT02020577|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177792|NCT00761631|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177793|NCT03319173|t||||
17177794|NCT03673046|f||||f
17177795|NCT03817879|f||||f
17177796|NCT03428932|f||||f
17177797|NCT01896050|f||||f
17177798|NCT00392015|f||||f
17177799|NCT02180724|f||OTHER||t
17177800|NCT03693300|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17177801|NCT02206048|t||||
17177802|NCT00089414|t||||
17177803|NCT02925923|f||||f
17177804|NCT00866788|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17177805|NCT02742441|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17177806|NCT01564914|f||LTE60||t
17177807|NCT01517074|t||||f
17177808|NCT00509041|t||||
17177809|NCT01854242|f||||f
17177810|NCT00082342|t||||
17177811|NCT01824342|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17177812|NCT02495831|f||LTE60||t
17177813|NCT03789396|t||||f
17177814|NCT00928395|f||||f
17177815|NCT02008318|f||GT60||t
17177816|NCT02281773|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177817|NCT02104752|f||||f
17133366|NCT00460993|f||||f
17177818|NCT05439941|f||OTHER|After completion of the study, the data may be considered for reporting at a scientific meeting or for publication in a scientific journal. The sponsor has final approved authority over publication of the study data.|t
17177819|NCT00231842|t||||f
17177820|NCT02422303|t||||
17177821|NCT03481907|f||||f
17177822|NCT02899299|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17184011|NCT00701389|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17133367|NCT02561897|f||||f
17133368|NCT00127127|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17133369|NCT00371267|t||||
17184012|NCT01542528|f||||f
17184013|NCT00659165|t||||f
17184014|NCT01931839|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17184015|NCT01790750|t||||
17184016|NCT01992536|f||||f
17184017|NCT03907501|t||||f
17184018|NCT01709227|f||||f
17184019|NCT03669081|f||||f
17184020|NCT00559897|t||||
17184021|NCT00389324|f||OTHER|Institution or Principal investigator (PI) furnishes Talecris a copy of any proposed publication (either in writing or oral) of results of the study performed under the protocol, at least 30 days before the date of submission for publication or presentation. Talecris can ask the Principal Investigator to remove Confidential Information before publication or Talecris shall have an additional time, not to exceed 60 days, to file a patent application for such Confidential Information.|t
17184022|NCT02317575|t||GT60||t
17184023|NCT01921348|f||||f
17184024|NCT03326999|t||||
17184025|NCT02187016|f||||f
17184026|NCT04788147|f||||f
17184027|NCT00781326|f||||f
17184028|NCT02266381|f||||f
17184029|NCT02401672|t||||
17184030|NCT00701051|t||||
17184031|NCT05051241|f||OTHER|After the completion of the research, researchers can collaborate with the sponsoring party for publication. Researchers must commit not to submit any part of the data from this study for publication without prior approval from the sponsoring party.|t
17184032|NCT03207750|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17184033|NCT00793910|f||OTHER|"All materials that reflects the WRAMC affiliation must be approved and properly cleared before the material is submitted for public dissemination and publication. All publications whereby WRAMC is cited in the bylines will state on the cover page the following sample disclaimer: The views expressed in this \[article, book chapter, speech, presentation, etc.\] are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or U.S. Government."|t
17184034|NCT01700946|t||||
17184035|NCT00583492|t||||f
17184036|NCT03634579|t||||
17184037|NCT04111497|f||||f
17184038|NCT03321019|f||||f
17184039|NCT02255110|f||OTHER||t
17184040|NCT04289753|t||||
17184041|NCT03433456|f||||t
17184042|NCT03694548|t||||
17184043|NCT04496258|f||||f
17184044|NCT04102501|f||||f
17184045|NCT01427712|f||||f
17184046|NCT03329352|f||||f
17184047|NCT00968617|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17184048|NCT00819182|f||||f
17133370|NCT02338843|f||OTHER|All investigators were restricted from publishing individual papers until the study-wide publication was published. After this time, investigator restrictions varied by institution.|t
17133371|NCT00023322|t||||
17133372|NCT02828267|f||||f
17133373|NCT01793792|f||||f
17133374|NCT00391599|f||||f
17133375|NCT02185521|f||||f
17133376|NCT01341457|f||GT60||t
17133377|NCT01676831|t||||
17133378|NCT00999830|f||||f
17133379|NCT00496366|t||||
17177823|NCT00313300|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17177824|NCT02336373|t||||
17177825|NCT00726375|t||||
17177826|NCT00850343|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication to seek patent protection.|t
17177827|NCT02022020|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17184049|NCT01390246|t||||f
17184050|NCT01024387|f||||f
17184051|NCT03864900|f||||f
17184052|NCT03191903|f||||f
17184053|NCT01443442|f||LTE60||t
17184054|NCT01578551|t||||
17184055|NCT01127438|f||||f
17184056|NCT04369469|f||||t
17184057|NCT02841644|t||||
17184058|NCT01344460|f||OTHER||t
17184059|NCT03283670|t||||
17184060|NCT01085318|f||OTHER|Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.|t
17184061|NCT01751022|f||LTE60||t
17184062|NCT04286594|f||||f
17184063|NCT03823651|t||||
17139350|NCT01236768|f||OTHER|Review and approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL13 study is required prior to publication submission.|t
17184064|NCT03864614|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17184065|NCT03859323|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17184066|NCT00822510|f||||f
17184067|NCT01404312|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17133380|NCT03804671|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133381|NCT00687453|t||||
17133382|NCT03902080|f||||t
17133383|NCT00434967|f||OTHER|AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed in order for AstraZeneca to file patent applications.|t
17133384|NCT01479348|f||||f
17133385|NCT00412529|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17133386|NCT00408005|f||LTE60||t
17133387|NCT04130646|f||||f
17133388|NCT01701258|f||||f
17133389|NCT03155997|f||GT60||t
17133390|NCT01848145|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17133391|NCT03093402|f||||f
17133392|NCT02886702|f||OTHER|The terms and conditions of Fougera' agreements with its investigators may vary. However, Fougera does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133393|NCT01276184|f||||f
17133394|NCT02347631|t||||
17133395|NCT02429856|f||||f
17133396|NCT03700047|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17133397|NCT00863551|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17133398|NCT03837184|f||OTHER|Depending on local requirements, Sponsor's consent necessary before publication of study, or Sponsor can review results communications before public release with a right to request changes to communications regarding trial results between 40 to 60 and up to 90 or 120 days, as applicable, from the time submitted to Sponsor for review to remove references to Sponsor's Confidential Information or delay results communications to permit Sponsor to obtain appropriate Intellectual Property protection.|t
17133399|NCT00758784|f||OTHER|Please contact sponsor directly for details.|t
17133400|NCT02494570|f||||f
17133401|NCT03514914|f||||f
17133402|NCT01841632|t||||
17133403|NCT01355289|f||OTHER||t
17133404|NCT04336163|t||||
17133405|NCT01085682|f||||f
17133406|NCT01451645|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17177828|NCT01926015|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17177829|NCT00639678|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184068|NCT04419493|t||||
17133407|NCT01365156|t||||
17133408|NCT02198833|f||||f
17133409|NCT01379625|f||||f
17133410|NCT00813995|f||OTHER|Following the multicenter publication or 24 months after study completion, whichever comes first, an investigator may publish the results for their study site independently. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17133411|NCT01614964|f||||f
17133412|NCT03424161|f||||f
17133413|NCT03618030|f||OTHER||t
17133414|NCT01053312|f||||f
17133415|NCT02700984|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17133416|NCT03705481|f||||f
17133417|NCT00473876|t||||
17133418|NCT00348140|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133419|NCT01032629|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17133420|NCT03545282|t||||
17133421|NCT00755079|t||||
17133422|NCT01231412|t||||
17133423|NCT03377634|t||||
17133424|NCT00737529|f||OTHER|Single center publications may not be submitted until after multicenter publication is submitted (or 1 year after study completion), whichever comes first. The investigator may then publish results provided that Celgene receive a copy of any proposed publication/presentation at least 30 days in advance of submission, delete any confidential information \& delay the submission for up to 60 additional days for patent filing. Multicenter publications must include input from investigators \& Celgene.|t
17133425|NCT00096161|t||||
17133426|NCT03056443|t||||
17177830|NCT01364649|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17177831|NCT01134276|f||||f
17177832|NCT02468232|f||OTHER|Other disclosure agreement that restricts the right of the Pl to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17177833|NCT00246753|f||GT60||t
17177834|NCT00545766|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17177835|NCT03423641|f||||f
17177836|NCT03643796|t||||
17177837|NCT02710396|f||||f
17177838|NCT02764333|t||||
17177839|NCT01348607|f||||f
17177840|NCT00752102|f||||f
17177841|NCT02234570|f||LTE60||t
17177842|NCT01303861|f||||f
17177843|NCT00659360|f||LTE60||t
17177844|NCT01788046|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17177845|NCT00567307|f||||f
17177846|NCT01031706|t||||
17177847|NCT03840174|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17177848|NCT03656107|f||||f
17177849|NCT00131508|t||||
17177850|NCT01479127|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17184069|NCT00524134|f||||f
17184070|NCT00129987|t||||
17184071|NCT01577706|f||||f
17133427|NCT02630953|f||||f
17133428|NCT00151892|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133429|NCT02901431|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133430|NCT00404092|f||||f
17133431|NCT04223609|t||||
17133432|NCT02549716|f||||f
17133433|NCT02797470|f||||f
17133434|NCT06119191|f||||t
17133435|NCT04533711|t||||
17133436|NCT03220412|t||||
17133437|NCT02612909|f||||f
17133438|NCT04486560|f||||f
17133439|NCT00450580|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133440|NCT04938648|f||||f
17133441|NCT03293654|f||||f
17133442|NCT03742427|f||||f
17133443|NCT00004054|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17133444|NCT02639351|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133445|NCT00158184|t||||f
17133446|NCT05340504|f||||f
17133447|NCT00661583|f||||f
17139351|NCT03949621|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17139352|NCT02069704|f||||f
17177851|NCT03569033|f||OTHER|The sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17177852|NCT01268150|f||||f
17177853|NCT03557853|f||||t
17184072|NCT01760954|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17184073|NCT03320070|f||||t
17184074|NCT00996996|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184075|NCT02819726|f||||f
17184076|NCT00406029|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17184077|NCT02162810|t||||f
17184078|NCT02223390|t||||
17184079|NCT01994486|f||||f
17184080|NCT03963895|f||OTHER|Aronora, Inc. shall retain title to and the right to publish all documentation, records, raw data, specimens, or other work product generated in connection with this study. Such publications shall not be made by the PI or Celerion without the prior written consent of Aronora, Inc.|t
17184081|NCT02843568|t||||
17184082|NCT01255358|f||LTE60||t
17184083|NCT04847050|f||||f
17133448|NCT00619957|f||LTE60||t
17133449|NCT03401749|f||||f
17133450|NCT00190775|f||GT60||t
17133451|NCT01526148|f||||f
17133452|NCT01173653|t||||
17133453|NCT00481065|f||GT60||t
17133454|NCT00885079|f||||f
17177854|NCT04738734|f||LTE60||t
17177855|NCT03072732|f||||f
17177856|NCT02435147|f||||f
17177857|NCT04402060|f||||t
17177858|NCT02256072|f||||f
17177859|NCT03998566|f||||f
17177860|NCT06238362|t||||
17177861|NCT05136690|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17177862|NCT02637622|f||||f
17177863|NCT04638400|t||||
17177864|NCT03366012|t||||
17177865|NCT02675114|f||||f
17177866|NCT01863953|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17177867|NCT02202837|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177868|NCT01313858|f||||f
17177869|NCT01935791|t||||
17177870|NCT01191333|t||||
17177871|NCT01626456|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/ publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17177872|NCT00506662|f||OTHER|The Steering Committee has the right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be approved by the Steering Committee, and copies submitted in writing to Novo Nordisk prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17177873|NCT04015336|f||||f
17177874|NCT03792191|t||||
17177875|NCT03423082|t||||f
17177876|NCT03921073|t||||
17177877|NCT01816074|f||||f
17177878|NCT00270790|t||||f
17177879|NCT01200524|f||OTHER|The agreement restricts the PI's rights to discuss or publish trial results after the trial is completed. No publication or presentation may include any of AZ's Confidential Information without AZ's prior written approval. AZ should have 60 days for review and can extend time until submission up to 90 days.|t
17177880|NCT02758132|t||||
17177881|NCT02476201|f||||f
17177882|NCT02585843|t||||f
17177883|NCT00398918|t||||
17184084|NCT00096941|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184085|NCT00022516|f||||f
17184086|NCT01528228|t||||
17184087|NCT02056301|t||||
17184088|NCT02209324|f||||t
17184089|NCT01198600|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17184090|NCT04798586|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184091|NCT01669343|f||||f
17184092|NCT04433767|f||||f
17133455|NCT01709331|f||OTHER|The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, e.g., any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17177884|NCT00723580|t||||
17177885|NCT00491764|f||OTHER|PI must provide to sponsor 45 days prior to submission for publication/presentation, review copies of content to be presented that contains any results of the study. The sponsor has the right to review/comment with regard to proprietary information, accuracy, and fair balance. If disagreements arise concerning appropriateness of content to be presented, investigator must meet with sponsor prior to submission for publication to make good faith efforts to discuss/resolve any issues/disagreement.|t
17184093|NCT00298233|f||||f
17184094|NCT00439777|f||LTE60||t
17184095|NCT00661492|f||||f
17184096|NCT03855189|f||OTHER|Sponsor has 30 days prior to submission for publication or presentation to review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the Protocol study. Sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information and the accuracy of the information contained in the publication.|t
17184097|NCT01143259|f||||f
17184098|NCT00099983|t||||
17184099|NCT02641080|f||||f
17184100|NCT00803634|f||OTHER|After initial multicenter results communications are published, or after 12 months from study closure (whichever occurs first), sponsor can review results communications prior to submission and can embargo submissions for a period of 45 days from the time submitted to the sponsor for review, agreeing to resolve differences of opinion or interpretation through scientific debate. Sponsor can request further delay for an additional 90 days to file any patent applications if deemed necessary.|t
17184101|NCT03424681|f||||f
17184102|NCT04307186|f||OTHER|A written manuscript of any oral/written publication relating to the trial, the investigational medicinal products or the results shall be submitted to Bayer for review at least 60 days before the planned filing or presentation of the publication. If Bayer does not confirm receipt of the intended publication within 45 days, Bayer must be informed again of the intended publication date. If Bayer does not comment on the publication within the 60-day period, the publication is free to be published.|t
17184103|NCT01175226|f||||t
17184104|NCT02854540|t||||
17133456|NCT02844998|f||||f
17133457|NCT02914509|f||OTHER||t
17133458|NCT01651780|f||||f
17177886|NCT01479478|f||||f
17177887|NCT00689078|t||||
17177888|NCT01188421|f||||t
17177889|NCT03225573|f||||f
17177890|NCT03725852|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17177891|NCT00116428|f||OTHER|The PI is allowed to publish but must submit draft publication(s) to Biosense Webster, Inc. at least 30 days prior to submission for publication or presentation.|t
17177892|NCT00669396|f||||f
17177893|NCT01297920|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17177894|NCT00474760|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177895|NCT02572609|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17177896|NCT01848704|f||||f
17177897|NCT02503410|f||||f
17177898|NCT04206800|t||||
17184105|NCT03238001|f||OTHER||t
17184106|NCT03165045|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133459|NCT01628926|f||||f
17184107|NCT00759109|f||OTHER|The disclosure restriction on the principal investigator (PI) is that the PI agrees not to publish or publicly present any results of the study without the prior written permission of the sponsor. The PI further agrees to allow the sponsor to review, 30 days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the study.|t
17184108|NCT02582905|f||||f
17184109|NCT01866709|f||OTHER|The PI cannot publish any results related to the study without prior written approval of the Sponsor.|t
17184110|NCT03791398|f||||f
17133460|NCT03029832|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133461|NCT03359902|f||||f
17133462|NCT00323284|f||GT60||t
17133463|NCT02930174|t||||
17133464|NCT01272583|f||LTE60||t
17133465|NCT01275222|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133466|NCT03440944|f||||f
17133467|NCT00484315|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17133468|NCT00943683|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133469|NCT04672083|f||||t
17133470|NCT02500537|f||GT60||t
17177899|NCT02155881|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17177900|NCT00066729|f||||f
17133471|NCT01551745|f||||t
17177901|NCT01811225|f||||f
17177902|NCT02158975|t||||
17133472|NCT01661790|t||||
17139353|NCT00638690|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 60 days from the time submitted to the sponsor for review. After 1) publication of multi-center results, 2) notification by sponsor that a multi-center submission is no longer planned, or 3) the 18 month anniversary of the termination of the study at all sites, the institution and investigator may publish or publicly present study data.|t
17139354|NCT00605358|f||||f
17177903|NCT02000180|f||||f
17177904|NCT02840721|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177905|NCT01967173|f||||f
17177906|NCT00423514|t||||
17177907|NCT03685123|f||||f
17177908|NCT00400764|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177909|NCT02628938|f||||f
17177910|NCT03113916|f||||f
17177911|NCT00241358|t||||
17177912|NCT01758523|f||||f
17177913|NCT00621959|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17177914|NCT00590135|t||||
17177915|NCT03439657|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17177916|NCT02401022|f||LTE60||t
17177917|NCT04032652|t||||
17177918|NCT00502944|t||||
17177919|NCT00289016|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17177920|NCT02764697|f||||f
17177921|NCT00302107|t||||
17177922|NCT01790932|f||||f
17133473|NCT00382148|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.|t
17177923|NCT04223973|f||||f
17184111|NCT02207829|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133474|NCT02536248|f||||f
17133475|NCT02048904|f||||f
17133476|NCT03035760|f||LTE60||t
17133477|NCT01552343|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17133478|NCT00784758|f||OTHER|The University (the PI) must furnish the Sponsor with a copy of any proposed written or oral publication (including manuscripts, abstracts, and oral presentations) at least 30 days prior to submission for publication. The Sponsor can direct the PI to delete their confidential information. The information contained in this results section was provided to the Sponsor 30 days ago and they have not asked for any deletions.|t
17133479|NCT04439123|f||LTE60||t
17133480|NCT02875223|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17133481|NCT00046228|f||GT60||t
17133482|NCT03866200|t||||
17133483|NCT02382133|f||||f
17133484|NCT00655928|t||||
17133485|NCT04906707|t||||
17133486|NCT01707992|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17133487|NCT01976806|f||||f
17133488|NCT04188730|f||||t
17133489|NCT04551014|t||||
17133490|NCT01041248|f||||f
17133491|NCT02654002|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133492|NCT01523873|f||||f
17184112|NCT00766376|f||||f
17133493|NCT00891202|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17133494|NCT01946516|f||LTE60||t
17133495|NCT04108429|f||||f
17133496|NCT01587950|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133497|NCT03313050|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133498|NCT04211337|f||GT60||t
17133499|NCT04977037|t||||
17133500|NCT02963376|f||||f
17133501|NCT04167345|f||OTHER||t
17133502|NCT04068103|f||LTE60||t
17133503|NCT02732951|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133504|NCT03263806|t||||
17133505|NCT01412879|f||||f
17177924|NCT03630042|f||||f
17177925|NCT02612129|f||OTHER||t
17177926|NCT05764408|f||||f
17177927|NCT00531934|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177928|NCT00721500|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17177929|NCT01543698|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177930|NCT00150709|f||GT60||t
17177931|NCT02975336|f||OTHER||t
17177932|NCT03650556|f||||t
17177933|NCT00691301|f||||f
17177934|NCT01823146|f||||f
17177935|NCT00463580|t||||f
17177936|NCT03917459|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133506|NCT04840667|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133507|NCT04544566|f||||f
17133508|NCT01445171|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 60 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 90 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17133509|NCT03195894|f||||f
17133510|NCT00162773|t||||
17133511|NCT00654927|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17133512|NCT03783195|t||||
17133513|NCT01903876|f||||f
17133514|NCT04317690|f||||f
17133515|NCT00393718|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17133516|NCT02988856|f||||f
17133517|NCT00391976|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133518|NCT01919307|t||||
17133519|NCT02724033|f||||f
17133520|NCT02601950|f||OTHER||t
17133521|NCT02991599|f||||f
17133522|NCT02731742|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17133523|NCT02786901|f||OTHER|Please contact Sponsor directly for additional information.|t
17133524|NCT03367871|t||||
17133525|NCT00680225|f||||f
17133526|NCT00763009|f||||f
17133527|NCT01157117|f||||f
17133528|NCT00891735|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133529|NCT02547623|f||||f
17133530|NCT00673595|t||||
17133531|NCT03663166|f||||f
17133532|NCT01686568|t||||
17133533|NCT02978222|f||LTE60||t
17133534|NCT01110187|f||||f
17133535|NCT03954626|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133536|NCT03838484|t||||
17133537|NCT03862027|t||||
17133538|NCT04579549|f||||f
17133539|NCT01071070|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17133540|NCT02207907|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133541|NCT03624816|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17133542|NCT02868892|t||||
17133543|NCT02393209|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17133544|NCT00868790|f||OTHER|The SPONSOR has the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17133545|NCT02582671|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17133546|NCT03068715|t||||
17133547|NCT01276288|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17133548|NCT03496701|f||||f
17133549|NCT03168867|f||||f
17133550|NCT04348851|t||||
17133551|NCT05003115|f||||f
17133552|NCT03040024|t||||
17133553|NCT00519077|t||||
17133554|NCT01967225|f||GT60||t
17133555|NCT01984515|t||||
17133556|NCT04696861|f||||f
17133557|NCT02093702|f||||f
17133558|NCT02848833|t||||
17133559|NCT02847598|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17133560|NCT01575912|t||||
17133561|NCT01542307|f||||f
17133562|NCT03338556|f||||t
17133563|NCT00937235|t||||
17133564|NCT00961532|t||||f
17133565|NCT02010203|f||||f
17133566|NCT05047523|f||||t
17133567|NCT03658889|f||||f
17133568|NCT02216695|t||||
17133569|NCT02923271|f||||f
17133570|NCT01495819|f||||f
17133571|NCT04246554|t||||
17133572|NCT00224016|f||LTE60||t
17133573|NCT01609933|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17133574|NCT01252966|t||||
17133575|NCT03340350|f||||f
17133576|NCT03275870|f||||f
17133577|NCT01133639|f||||f
17133578|NCT01871506|f||||f
17133579|NCT02811744|t||||
17133580|NCT03576144|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133581|NCT00278629|t||||
17133582|NCT03323749|f||GT60||t
17133583|NCT01444716|f||||f
17184113|NCT02358889|f||||f
17184114|NCT01027793|t||||
17184115|NCT00927927|f||OTHER|Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for short period to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.|t
17184116|NCT02379585|t||||
17133584|NCT03263091|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17133585|NCT02468193|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17133586|NCT00742781|t||||f
17133587|NCT01719757|f||||f
17133588|NCT02626338|f||||f
17133589|NCT00826748|t||||
17133590|NCT04214080|t||||
17133591|NCT03312218|t||||f
17184117|NCT01976416|t||||
17133592|NCT01901224|t||||
17133593|NCT03802721|t||||
17133594|NCT04125680|t||||
17133595|NCT01562028|f||||f
17133596|NCT02360098|t||||
17133597|NCT03193866|f||||f
17133598|NCT04439266|f||LTE60||t
17133599|NCT05040971|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17133600|NCT06161012|f||GT60||t
17133601|NCT03878147|f||||f
17133602|NCT05817045|f||OTHER|All study data and reports of study data are the property of the study sponsor. The sponsor may grant the PI the right to publish the results of this research in a scientific journal, conditional upon the review and concurrence of the sponsor.|t
17133603|NCT04889209|f||LTE60||t
17133604|NCT02148029|t||||
17133605|NCT05113940|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133606|NCT04122196|f||||f
17133607|NCT02688647|f||||f
17133608|NCT00382967|f||||f
17133609|NCT00378326|t||||
17133610|NCT02073487|t||||
17133611|NCT03049449|f||||f
17133612|NCT00474240|f||OTHER|Information is unavailable.|t
17133613|NCT01808560|f||OTHER|Within 18 months of Sponsor's receipt of data from all sites, Investigators may publish or present the Investigator's individual results. Investigator must submit materials to Sponsor for review and comment at least 30 days prior to presentation or submission for publication. Investigator will consider all reasonable comments from Sponsor. Upon Sponsor's written request, Investigator agrees to delete any Proprietary Information other than Investigator's individual Study results.|t
17133614|NCT00054847|t||||
17133615|NCT01147497|t||||f
17133616|NCT00331760|f||||f
17133617|NCT02514044|t||||f
17133618|NCT03093155|t||||
17133619|NCT00619229|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17184118|NCT01110239|t||||
17184119|NCT02897141|t||||
17184120|NCT00080223|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184121|NCT02936076|f||||f
17184122|NCT05204134|f||||f
17184123|NCT03135522|f||||f
17184124|NCT03099382|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17184125|NCT00499369|f||LTE60||t
17184126|NCT01802411|f||OTHER|Any proposed publication/presentation of study-related information is subject to advance review by the Sponsor ≥60 days before intended submission/presentation. Investigator/institution shall amend publication/presentation as needed to address errors or confidential information identified by the Sponsor. If requested in writing by the Sponsor, investigator/institution shall withhold publication for an additional 90 days.|t
17184127|NCT02670629|f||||f
17184128|NCT03285477|f||OTHER||t
17184129|NCT02756624|f||||t
17184130|NCT00852397|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184131|NCT02345512|f||||f
17184132|NCT02663817|t||||
17184133|NCT01438541|f||||f
17184134|NCT03861000|t||||
17184135|NCT01968434|f||||f
17184136|NCT01688336|t||||
17184137|NCT02091167|f||||f
17184138|NCT05872035|f||||t
17184139|NCT00489970|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184140|NCT00116805|f||OTHER|Institution and investigator may publish or present the results of the trial generated there with prior written consent of Gilead; or 2 years after the trial has ended at all institutions. Proposed publications/target venue must go to Gilead 30 days (manuscripts) or 15 days (abstracts/presentations) prior. Any Gilead confidential information in the document(s) must be deleted, or if requested publication delayed for up to 45 days to permit Gilead to obtain intellectual property protection.|t
17184141|NCT01093794|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.|t
17184142|NCT02740127|t||||
17184143|NCT02707055|t||||
17184144|NCT03564496|t||||
17184145|NCT01159938|f||GT60||t
17184146|NCT02487563|t||||
17184147|NCT00317772|t||||
17184148|NCT01126593|f||GT60||t
17139355|NCT02861118|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17184149|NCT04088097|t||||
17184150|NCT03556761|t||||
17184151|NCT03057119|t||||f
17184152|NCT00693992|f||LTE60||t
17184153|NCT00353704|t||||
17184154|NCT04495374|f||||f
17139356|NCT01452191|f||||f
17139357|NCT01347073|f||||f
17139358|NCT01478581|f||||f
17184155|NCT02473614|f||||f
17184156|NCT01303627|f||||f
17184157|NCT00111657|t||||f
17184158|NCT02416791|t||||
17184159|NCT01054820|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139359|NCT01690988|f||||f
17139360|NCT02705352|t||||
17139361|NCT00638274|t||||
17184160|NCT01576536|t||||
17184161|NCT01154166|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184162|NCT03774186|f||||f
17184163|NCT04121962|f||||f
17184164|NCT02019719|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184165|NCT04535037|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17184166|NCT02880852|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184167|NCT02165722|f||||f
17184168|NCT01235910|f||||f
17184169|NCT05423509|f||||f
17133620|NCT02620020|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17133621|NCT03456115|f||||f
17133622|NCT02209506|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17133623|NCT01287104|f||||f
17133624|NCT01755169|f||||f
17133625|NCT02537678|f||||f
17139362|NCT00372489|f||OTHER|Publications may not contain Sponsor confidential information, and may be subject to Sponsor review 30 days prior to submission for publication.|t
17139363|NCT03634228|t||||
17139364|NCT00552344|f||GT60||t
17177937|NCT00075218|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177938|NCT03534362|t||||
17177939|NCT00845858|f||LTE60||t
17177940|NCT02191137|f||LTE60||t
17177941|NCT02956070|f||||f
17177942|NCT01191411|f||||f
17177943|NCT02737397|f||||f
17177944|NCT02404220|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177945|NCT01259596|f||||f
17177946|NCT03469934|f||||t
17177947|NCT02329080|f||||f
17177948|NCT04208997|f||||f
17177949|NCT02387710|t||||
17177950|NCT02100579|t||||
17177951|NCT00071396|t||||f
17177952|NCT03082261|f||OTHER||t
17177953|NCT02639546|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177954|NCT02068027|f||GT60||t
17177955|NCT01032174|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177956|NCT03783975|f||||f
17177957|NCT00113087|f||||f
17177958|NCT01281137|f||||f
17177959|NCT01581710|f||||f
17177960|NCT00386607|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17177961|NCT01222884|f||OTHER|If Pharmacosmos or its agents has not prepared a draft for submission to a peer reviewed journal prior to 1 year following completion of the study report, the investigators have the right to publish the results. Such publications are to be submitted to Pharmacosmos for comment 30 days prior to submission for publication.|t
17177962|NCT04251273|t||||f
17177963|NCT01986907|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17133626|NCT02965378|f||||f
17133627|NCT04552470|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133628|NCT00629083|f||LTE60||t
17133629|NCT02909153|f||GT60||t
17133630|NCT01193686|t||||
17133631|NCT01147809|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139365|NCT00023712|f||LTE60||t
17177964|NCT00810693|f||OTHER|The embargo can be up to 6 months (equal to the 180 days), moreover if it is necessary the embargo period can be prolonged to expiry of priority year.|t
17177965|NCT03212690|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177966|NCT02149719|t||||
17139366|NCT01378299|t||||
17139367|NCT02046382|t||||
17139368|NCT01448707|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days. The sponsor will not mandate modifications to scientific content and does not have the right to suppress information.|t
17139369|NCT02667392|t||||f
17139370|NCT03215667|f||LTE60||t
17139371|NCT00946023|t||||
17139372|NCT01810380|f||||f
17139373|NCT00614991|f||||f
17177967|NCT00331422|t||||
17133632|NCT01307423|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17133633|NCT03075839|f||||f
17133634|NCT01499290|f||OTHER|The PI shall not publish results until the earliest of (i) date of the 1st study publication (joint between PI, sponsor and study sites) (ii) 18 months after study completion, or (iii) sponsor notification that no multi-center publication is to be made. The PI submits the publication for review 60 days before submission. Sponsor may embargo for a further 90 days to protect IP rights. Sponsor may request removal of confidential and/or proprietry information.|t
17133635|NCT04052139|f||||f
17133636|NCT03896295|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17133637|NCT00700804|t||||
17133638|NCT01511445|f||||f
17133639|NCT00518349|t||||f
17133640|NCT00998738|t||||
17133641|NCT03946449|f||OTHER|The only disclosure restriction on the PI is that the sponsor retains first right to publish results for this multi-center study, and thereafter can review results communications prior to release and can embargo communications regarding trial results for a period that is 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication of results but can require removal of its confidential information (excluding results).|t
17133642|NCT04375761|f||||f
17133643|NCT05630846|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17133644|NCT05105243|f||||t
17133645|NCT00500266|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17177968|NCT02345226|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17177969|NCT04141046|t||||
17177970|NCT02127710|f||||f
17177971|NCT00989157|f||||f
17177972|NCT03386474|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17177974|NCT02282358|t||||
17177975|NCT04203797|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17177976|NCT04357782|f||||f
17177977|NCT01786148|t||||
17177978|NCT00675259|t||||
17177979|NCT03780543|f||GT60||t
17177980|NCT03505190|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17177981|NCT03488355|f||||f
17177982|NCT00098956|f||LTE60||t
17177983|NCT00516074|f||GT60||t
17177984|NCT02215096|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177985|NCT00287365|f||||f
17177986|NCT03021304|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133646|NCT01431287|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133647|NCT04585763|f||GT60||t
17133648|NCT00075881|f||LTE60||t
17133649|NCT02109029|f||GT60||t
17133650|NCT00110305|f||GT60||t
17133651|NCT00142506|t||||
17133652|NCT00539071|f||||f
17133653|NCT03890679|f||||f
17133654|NCT00215150|f||||f
17133655|NCT02251743|f||||f
17133656|NCT02240134|f||||f
17133657|NCT03021577|t||||
17133658|NCT00206726|f||||f
17133659|NCT01028352|t||||f
17133660|NCT02718820|t||||
17133661|NCT02091440|f||OTHER|The PI cannot disclose the trial results without the sponsor's permission. The disclosure restriction is not limited by a set period.|t
17133662|NCT00768222|f||OTHER||t
17133663|NCT01887912|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17133664|NCT02924896|t||||
17133665|NCT04053387|f||||t
17133666|NCT05067127|f||||t
17133667|NCT04462536|f||||f
17133668|NCT01499173|f||||f
17133669|NCT03198221|t||||
17133670|NCT01154101|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17177987|NCT02663908|f||OTHER|A Publications Committee, including the signatory investigators, other Steering Committee members, and Sponsor representatives was established to function as an independent body of scientific and medical experts acting to facilitate, encourage, and coordinate the complete and accurate presentation and publication of the trial results. Members of the Publication Committee are responsible for review and approval of all abstracts and manuscripts based on the trial results.|t
17133672|NCT02354833|t||||
17177988|NCT00193258|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17177989|NCT03308786|f||||f
17177990|NCT03698409|f||||f
17177991|NCT00370071|f||LTE60||t
17177992|NCT01441180|t||||
17177993|NCT01267045|t||||
17177994|NCT01771952|f||||f
17177995|NCT01402011|f||||f
17177996|NCT04508335|f||||f
17177997|NCT03948698|f||||t
17177998|NCT00418015|t||||f
17177999|NCT00825682|f||||f
17133673|NCT02623972|t||||
17133674|NCT03905928|t||||f
17133675|NCT01725165|t||||
17133676|NCT05039086|f||||t
17133677|NCT03619213|f||||t
17133678|NCT02542267|f||OTHER|Institution and Investigator agree not to submit any Publication until Study Completion and the multi-center Publication has been published. If the multi-center Publication has not been submitted within 12 months of Study Completion, Institution and Investigator may be able to proceed with submission of the Publication.|t
17133679|NCT01316042|f||||f
17133680|NCT01974323|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178000|NCT00316719|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178001|NCT02903355|f||||f
17178002|NCT01644565|f||||f
17178003|NCT01550289|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17178004|NCT04667481|f||||f
17178005|NCT03689114|t||||
17178006|NCT00094172|f||||f
17178007|NCT00713323|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17178008|NCT02478632|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178009|NCT04622306|f||||f
17178010|NCT00864721|f||||f
17178011|NCT01868503|f||||f
17178012|NCT00736944|f||||f
17178013|NCT05350410|f||||f
17178014|NCT01601132|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17178015|NCT02110238|f||||f
17178016|NCT00697788|t||||
17178017|NCT02432742|f||||t
17178018|NCT02509481|f||||f
17178019|NCT01419626|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17178020|NCT01365052|f||GT60||t
17178021|NCT01145625|f||OTHER|Multi-Center Publication will be the first publication to present the results of the Study. Upon such Multi-Center Publication, or the earlier of (a) Sponsor's confirmation that there will be no Multi-Center Publication or presentation, or (b) 12 months after the completion of the entire multi-center study, Institution and Investigator may publish or present Study data and results generated in their performance of the Study in accordance with the terms of this Article.|t
17178022|NCT03080454|f||||f
17178023|NCT00216476|f||GT60||t
17178024|NCT02202980|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17178025|NCT01573260|f||||f
17178026|NCT00696800|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any scientific paper, presentation or other communication concerning this clinical trial will first be submitted to the Sponsor at least six weeks before publication or presentation. The Sponsor shall have the right to make its consent conditional upon proper representation of the interpretation of both the Sponsor and the investigator(s) in the discussion of the data in such communications.|t
17178027|NCT05294640|t||||f
17178028|NCT03779711|f||||f
17178029|NCT05224141|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17178030|NCT04460937|f||LTE60||t
17178031|NCT00624234|f||||f
17178032|NCT01609231|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17178033|NCT04873700|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17178034|NCT01961362|f||||f
17178035|NCT04569253|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17178036|NCT01927627|t||||
17178037|NCT00467857|f||OTHER|All publications and presentations resulting from this multi-center trial sponsored by Kimberly-Clark must be approved by all investigators and the sponsor.|t
17178038|NCT00338104|f||||f
17178039|NCT00968890|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178040|NCT02298023|f||||f
17178041|NCT02096679|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent applications|t
17178042|NCT02002832|f||||f
17178043|NCT03307785|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178044|NCT01811680|f||||f
17178045|NCT00492531|f||||f
17178046|NCT01749631|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178047|NCT00843856|t||||
17178048|NCT04729621|f||OTHER|The PI must receive sponsor approval for all publications of study results.|t
17178049|NCT03943160|f||LTE60||t
17178050|NCT03104543|f||||f
17178051|NCT03175978|f||||f
17178052|NCT00319501|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178053|NCT02556554|f||||f
17178054|NCT01696071|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific and statistical accuracy, within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17178055|NCT03572972|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178056|NCT02569671|f||||t
17178057|NCT03487549|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17178058|NCT01259128|f||||t
17178059|NCT01977794|f||||f
17178060|NCT01895062|f||||f
17133681|NCT01075178|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17184170|NCT01319318|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184171|NCT02731131|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184172|NCT02348216|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133682|NCT02983604|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133683|NCT01111604|f||GT60||t
17133684|NCT01687790|f||||f
17133685|NCT00316264|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17178061|NCT00827502|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178062|NCT03273543|t||||
17178063|NCT01024335|f||||f
17178064|NCT01705730|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178065|NCT03228433|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion .|t
17178066|NCT01773733|f||||f
17178067|NCT01030536|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17178068|NCT02765269|t||||
17178069|NCT03289858|t||||f
17178070|NCT01330030|t||||
17178071|NCT01101880|f||||f
17178072|NCT04424888|t||||
17178073|NCT04891978|f||OTHER|Receiving party will keep Confidential Information in confidence and will not, at any time during or for ten years after the expiration of this Agreement, without the disclosing party's prior written consent, disclose, publish, disseminate or otherwise make available, any item of Confidential Information to any third party. Receiving party will use the Confidential Information only in connection with performance or receipt of Services, or in the exercise of a right granted under this Agreement.|t
17178074|NCT02390908|f||||f
17178075|NCT01781975|f||LTE60||t
17178076|NCT01622231|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178077|NCT02264639|f||||t
17178078|NCT03881670|f||LTE60||t
17178079|NCT00914485|t||||
17178080|NCT04889222|t||||
17178081|NCT01180647|f||||f
17178082|NCT01704521|f||||f
17178083|NCT00702689|f||||f
17133686|NCT00607048|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133687|NCT00355264|f||||f
17133688|NCT00826514|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133689|NCT04485455|t||||f
17178084|NCT01833988|f||||f
17178085|NCT01761175|f||||f
17178086|NCT00784641|f||OTHER|Contact sponsor directly for details.|t
17184173|NCT00765245|t||||
17184174|NCT02377986|t||||
17184175|NCT04450823|f||||f
17184176|NCT01614210|t||||
17178087|NCT02716805|f||LTE60||t
17178088|NCT04288752|f||||f
17178089|NCT04718961|f||LTE60||t
17178090|NCT02121522|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17178091|NCT03476278|f||||f
17178092|NCT00633750|t||||
17178093|NCT01903031|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17178094|NCT03540030|f||||f
17178095|NCT03329508|f||||f
17178096|NCT03666624|t||||f
17178097|NCT03225599|t||||
17178098|NCT00569270|f||||f
17178099|NCT00447005|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178100|NCT03822182|t||||
17178101|NCT01469234|f||||f
17178102|NCT00810355|t||||
17178103|NCT01484275|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17178104|NCT03407625|t||||
17178105|NCT04154930|f||OTHER||t
17178106|NCT02130297|t||||
17178107|NCT00347360|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the Publication of results from all centers of a multi-center trial but requests that reports based on Single-site data not precede the primary publication of the entire clinical trial.|t
17178108|NCT05004077|f||||f
17178109|NCT03763175|f||||f
17178110|NCT00913380|t||||
17178111|NCT00806351|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178112|NCT02187744|f||LTE60||t
17178113|NCT00134030|f||||f
17178114|NCT00601198|t||||f
17178115|NCT00508755|t||||
17178116|NCT03351933|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17133690|NCT03926143|f||OTHER||t
17133691|NCT02561156|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17133692|NCT00967941|t||||f
17133693|NCT03723447|f||||f
17133694|NCT00691665|f||||f
17133695|NCT00098787|f||||f
17133696|NCT01834404|t||||
17178117|NCT01435603|f||||f
17178118|NCT01468675|f||||f
17178119|NCT02004522|f||||f
17178120|NCT01787331|f||||f
17178121|NCT01999868|f||||f
17178122|NCT00310401|f||||f
17178123|NCT01682954|f||||f
17178124|NCT00561457|f||LTE60||t
17178125|NCT00450255|f||LTE60||t
17178126|NCT01757535|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178127|NCT03730012|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17178128|NCT05147428|f||||f
17178129|NCT04680052|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17178130|NCT03320057|f||||f
17133697|NCT02203149|f||OTHER|The investigator or sub-investigators may publicly present the academic accomplishment acquired from the Study at a specialized academic meeting or research conference. The Sponsor may freely use the information acquired from the Study for the purpose of marketing authorization application of the test drug.|t
17133698|NCT01360996|t||||
17133699|NCT01454076|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17178131|NCT02027883|f||OTHER||t
17178132|NCT01367002|t||||
17178133|NCT02614092|t||||
17133700|NCT04964258|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17178134|NCT00717093|f||OTHER||t
17178135|NCT01516437|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178136|NCT00217620|f||LTE60||t
17178137|NCT01650844|f||||f
17178138|NCT01925534|f||||f
17178139|NCT02468674|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178140|NCT01897454|f||||f
17178141|NCT03642457|f||LTE60||t
17178142|NCT03095885|f||OTHER||t
17178143|NCT02609204|f||||f
17178144|NCT03689530|f||||f
17178145|NCT01392443|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17178146|NCT02160535|f||||f
17178147|NCT03019575|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17178148|NCT00533897|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178149|NCT02555683|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178150|NCT05074667|t||||
17178151|NCT01925677|t||||
17178152|NCT01826604|t||||
17178153|NCT00491075|f||||f
17178154|NCT02911857|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17178155|NCT02061774|f||||f
17178156|NCT02614586|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17178157|NCT03019185|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17178158|NCT05049616|t||||
17178159|NCT00705289|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and the sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17178160|NCT02601027|t||||
17178161|NCT01146912|t||||f
17178162|NCT02577549|f||||f
17178163|NCT02609828|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184177|NCT01181921|f||OTHER|Study results as well as all reports or publications related to the study, belong to the sponsor exclusively. If the investigator would like to public results in journals or scientific magazines, it has to be in agreement with the sponsor and according to the protocol.|t
17133701|NCT01478958|f||||f
17133702|NCT03406962|f||||t
17133703|NCT00327444|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days) in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17133704|NCT04439344|f||LTE60||t
17133705|NCT00552110|f||LTE60||t
17133706|NCT02305563|f||LTE60||t
17133707|NCT00454207|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17184178|NCT04408469|t||||
17178164|NCT02980783|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178165|NCT01696695|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178166|NCT02000583|f||||f
17178167|NCT03173313|f||||f
17178168|NCT03863197|t||||
17178169|NCT05981391|f||||f
17178170|NCT02498132|f||||f
17178171|NCT01065597|f||||f
17178172|NCT01869439|f||LTE60||t
17178173|NCT05280782|t||||
17178174|NCT02589405|f||LTE60||t
17178175|NCT01457573|t||LTE60||t
17178176|NCT02905149|f||||f
17178177|NCT03285984|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178178|NCT00839852|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.|t
17178179|NCT02761733|t||||
17178180|NCT00120523|f||||f
17178181|NCT04295772|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17178182|NCT02846324|f||||t
17178183|NCT03993132|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17178184|NCT00147212|f||||f
17178185|NCT02640573|t||||
17178186|NCT02805972|f||||f
17178187|NCT01206166|f||||f
17178188|NCT00932126|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178189|NCT02727842|f||OTHER||t
17178190|NCT02605304|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17178191|NCT03576495|t||||
17178192|NCT02867150|f||||f
17178193|NCT02635776|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17178194|NCT00788073|f||OTHER|Seaside Therapeutics agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178195|NCT03608254|f||||f
17178196|NCT01216748|t||||f
17178197|NCT00660673|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178198|NCT03208127|f||||f
17178199|NCT00579098|t||||f
17178200|NCT01713608|f||||f
17178201|NCT00003487|f||||f
17178202|NCT02197273|t||||f
17178203|NCT03451578|t||||
17178204|NCT03558087|f||||f
17178205|NCT04584970|t||||
17178206|NCT03855228|f||OTHER|The Principal Investigator agrees not to publish or publicly present any interim results of the Protocol study without the prior written consent of Sponsor. The Principal Investigator further agrees to provide thirty (30) days prior to submission for publication or presentation to Sponsor to review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the Protocol study.|t
17178207|NCT00737243|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17178208|NCT01893203|f||||f
17184179|NCT00910481|f||||f
17133708|NCT04214652|f||OTHER|Please contact sponsor for details.|t
17133709|NCT02272790|f||||f
17133710|NCT00332202|f||GT60||t
17133711|NCT03658954|t||||
17178209|NCT02564497|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178210|NCT01219673|t||||
17178211|NCT00678080|t||||f
17178212|NCT02515825|f||GT60||t
17178213|NCT01546207|t||||
17178214|NCT03260881|t||||f
17178215|NCT03355365|t||||
17133712|NCT00818259|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17178216|NCT01952145|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17178217|NCT03019783|f||||f
17133713|NCT05391438|f||||f
17178218|NCT00493025|t||||
17178219|NCT05338216|f||||f
17178220|NCT00413244|t||||
17178221|NCT00446251|f||GT60||t
17178222|NCT01440452|f||||f
17178223|NCT00753766|f||||f
17178224|NCT04545554|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17178225|NCT00494299|f||LTE60||t
17178226|NCT00066365|f||OTHER|Must obtain prior Sponsor approval.|t
17178227|NCT02713373|t||||
17178228|NCT00787761|f||LTE60||t
17178229|NCT00239590|t||||
17178230|NCT01202565|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178231|NCT03638622|f||||f
17178232|NCT01589978|f||LTE60||t
17178233|NCT02362269|t||||
17178234|NCT05213481|f||||t
17178235|NCT01216631|t||||
17178236|NCT00415168|f||GT60||t
17178237|NCT03273270|t||||
17178238|NCT00515411|t||||
17178239|NCT02058693|t||||
17178240|NCT00722800|f||||f
17178241|NCT02850601|f||||f
17178242|NCT02925117|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178243|NCT01533077|f||OTHER||t
17178244|NCT01449539|t||||f
17178245|NCT01972568|f||OTHER||t
17133714|NCT01926626|t||||
17133715|NCT02863198|t||||
17133716|NCT01237951|t||||
17133717|NCT00825370|t||||
17178246|NCT00306189|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17133718|NCT00924703|f||GT60||t
17133719|NCT00666562|f||LTE60||t
17133720|NCT01106040|f||OTHER|The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.|t
17133721|NCT03971721|f||||f
17133722|NCT04429022|f||||f
17133723|NCT00407355|f||||f
17178247|NCT02572401|t||||
17133725|NCT02237235|f||||f
17133726|NCT03896581|f||GT60||t
17133727|NCT03797001|f||||f
17133728|NCT05404776|t||||
17133729|NCT06369779|t||||
17178248|NCT02059408|f||||f
17178249|NCT00945893|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17178250|NCT00775346|f||OTHER||t
17178251|NCT01681472|f||OTHER||t
17178252|NCT00667875|f||||f
17178253|NCT00795145|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178254|NCT01187433|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17178255|NCT01234831|t||||f
17178256|NCT00074269|f||||f
17178257|NCT00437983|f||||f
17178258|NCT00144391|t||||
17178259|NCT00672646|f||OTHER|AstraZeneca has the exclusive right to publish the results of the study.|t
17178260|NCT04721171|t||||f
17139374|NCT02623699|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17139375|NCT00899678|f||GT60||t
17139376|NCT00033371|f||LTE60||t
17139377|NCT02150460|f||||f
17139378|NCT02699125|t||||f
17139379|NCT03796195|t||||
17139380|NCT03799627|f||||t
17139381|NCT01451983|f||||f
17139382|NCT00570362|f||||f
17139383|NCT02092324|f||||f
17139384|NCT02512276|f||||f
17139385|NCT02637804|f||OTHER||t
17139386|NCT03150199|f||||f
17139387|NCT01190020|f||||f
17139388|NCT00695500|t||||
17139389|NCT02481440|t||||
17139390|NCT04374149|t||||
17139391|NCT01116661|t||||
17139392|NCT00777257|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17139393|NCT01183104|f||||f
17139394|NCT03267511|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139395|NCT00364351|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17139396|NCT00464620|f||||f
17139397|NCT01518309|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17139398|NCT02855086|f||||f
17139399|NCT02579863|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17139400|NCT02209259|t||||
17139401|NCT02253394|f||||f
17139402|NCT00038142|t||||t
17139403|NCT00589602|f||||f
17139404|NCT02734849|f||||f
17139405|NCT04210232|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17139406|NCT01525745|f||||f
17139407|NCT04323098|f||LTE60||t
17139408|NCT02352090|t||||f
17178261|NCT00142298|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17139409|NCT01678313|t||||
17178262|NCT00300274|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139410|NCT00981292|t||||f
17139411|NCT01131130|f||OTHER||t
17139412|NCT03464136|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17139413|NCT03412565|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17139414|NCT03277105|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139415|NCT00262639|f||||f
17139416|NCT01976975|t||||
17139418|NCT01849562|f||OTHER|Prior to submitting/presenting a manuscript or materials relating to a Study to a publisher, reviewer, or outside person, the Institution shall provide to Sponsor a copy of all such manuscripts or materials, and Sponsor shall have thirty (30) days to review and comment. The Institution shall, upon Sponsor's request, further delay publication or presentation for a period of up to sixty (60) days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17139419|NCT03146403|f||||t
17139420|NCT03136913|f||||f
17178263|NCT00242216|f||||f
17178264|NCT04439201|f||LTE60||t
17178265|NCT06956170|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17139421|NCT00250497|t||||
17139422|NCT02182999|t||||
17139423|NCT02252588|t||||
17178266|NCT01385566|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication or presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17178267|NCT01539694|f||OTHER|Contact sponsor directly for details.|t
17178268|NCT00403234|f||GT60||t
17178269|NCT02280304|t||||
17133730|NCT00960076|f||||f
17133731|NCT02224664|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178270|NCT00539656|t||||
17178271|NCT01431170|f||||f
17178272|NCT04218695|f||||f
17178273|NCT03166735|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133732|NCT03019549|f||GT60||t
17133733|NCT00659295|f||OTHER|Novo Nordisk acknowledges the physician's right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17178274|NCT00003473|f||||f
17178275|NCT01292746|f||||f
17178276|NCT04021771|f||||f
17133734|NCT00260208|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139424|NCT03039790|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17139425|NCT00058188|f||||f
17178277|NCT00814970|f||GT60||t
17178278|NCT03372096|t||||
17178279|NCT03513328|t||||
17178280|NCT01947582|f||||f
17178281|NCT01603355|t||||
17178282|NCT05154578|f||||f
17178283|NCT03930680|t||||
17178284|NCT02924571|t||||
17178285|NCT00434954|f||GT60||t
17178286|NCT00894166|f||||f
17178287|NCT00354887|t||||f
17178288|NCT00944671|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178289|NCT03750955|f||||f
17178290|NCT00815698|t||||
17178291|NCT00142935|f||||f
17178292|NCT01180985|f||OTHER|Publication requires agreement and written consent from the Sponsor.|t
17178293|NCT03055156|t||||
17178294|NCT01315665|f||||f
17133735|NCT03739619|t||||
17133736|NCT06331884|f||OTHER||t
17133737|NCT03539432|t||||
17133738|NCT00318292|t||||
17139426|NCT01520688|f||||f
17139427|NCT02266004|t||||
17139428|NCT01791465|f||||f
17178295|NCT01431989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178296|NCT04755790|t||||
17178297|NCT00129272|f||||f
17178298|NCT03345914|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17178299|NCT02569658|f||||f
17178300|NCT03758066|f||||f
17178301|NCT01216761|f||||f
17178302|NCT04138810|t||||
17178303|NCT01786668|f||LTE60||t
17178304|NCT00762385|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17178305|NCT01540838|f||||f
17133739|NCT02443402|t||||
17133740|NCT02241486|t||||
17139429|NCT03289052|f||||t
17139430|NCT00537771|f||LTE60||t
17139431|NCT04246541|t||||
17139432|NCT02575300|t||||
17139433|NCT02736929|f||||f
17178306|NCT02130570|f||||f
17178307|NCT01849783|t||||
17178308|NCT01776840|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17178309|NCT01152697|f||||f
17178310|NCT03641339|t||||
17178311|NCT01042678|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178312|NCT00408460|t||||
17178313|NCT02653872|f||OTHER|All of the study information and data collected during the study were considered confidential and the property of AstraZeneca. After completion of the study, the investigator should prepare a joint publication with AstraZeneca. The investigator must undertake not to submit any part of the individual data from this clinical study protocol for publication without prior consent of AstraZeneca at a mutually agreed time.|t
17178314|NCT02506465|f||||f
17178315|NCT01058655|f||||f
17178316|NCT01117948|f||LTE60||t
17178317|NCT04545060|f||||t
17178318|NCT02509767|t||||f
17178319|NCT00619177|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184180|NCT04321460|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184181|NCT04495712|f||||f
17184182|NCT00706121|f||LTE60||t
17133741|NCT02770521|f||GT60||t
17133742|NCT00824564|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133743|NCT04504318|f||||f
17133744|NCT02935738|t||||
17178320|NCT02319837|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178321|NCT00892047|f||||f
17178322|NCT05306977|f||||f
17133745|NCT00469508|t||||
17178323|NCT00578383|f||||f
17178324|NCT02050841|f||||f
17178325|NCT01387789|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178326|NCT00181155|f||||f
17178327|NCT01788228|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178328|NCT02358681|t||||
17178329|NCT01548287|f||GT60||t
17178330|NCT02012283|f||||f
17178331|NCT00579137|t||||
17178332|NCT00289783|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178333|NCT02403986|f||OTHER||t
17178334|NCT00566995|f||||f
17178335|NCT03128047|t||||
17178336|NCT01995825|t||||f
17178337|NCT03811028|f||||f
17178338|NCT00560105|f||||f
17178339|NCT01542125|f||||f
17178340|NCT02400333|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17178341|NCT00956020|f||||f
17178342|NCT01332500|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178343|NCT02958293|t||||
17178344|NCT01034631|f||||f
17178345|NCT01560403|f||||f
17178346|NCT00983437|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17184183|NCT01308749|f||||f
17184184|NCT02519504|t||||
17184185|NCT04726709|f||||f
17184186|NCT02546544|t||||
17184187|NCT02548962|f||||f
17184188|NCT01197950|f||||f
17184189|NCT04831736|t||||
17184190|NCT05734846|f||||t
17184191|NCT01666002|f||||f
17184192|NCT02159482|t||||
17184193|NCT02703844|f||||f
17184194|NCT02828111|f||||f
17184195|NCT01184014|t||||
17133746|NCT01552057|f||GT60||t
17133747|NCT01389245|f||LTE60||t
17133748|NCT05127486|f||GT60||t
17133749|NCT00870688|f||||f
17139434|NCT00926185|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17139435|NCT01855425|f||||f
17139436|NCT02108522|f||||t
17133750|NCT01287754|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178347|NCT01890473|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17133751|NCT04971226|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17139437|NCT03378973|t||||
17139438|NCT00373880|t||||
17139439|NCT01634100|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17139440|NCT03645811|f||||f
17139441|NCT01662986|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139442|NCT02809846|f||||f
17139443|NCT01512693|f||GT60||t
17139444|NCT01975376|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139445|NCT04731922|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion|t
17139446|NCT02564068|f||||f
17139447|NCT01819194|f||LTE60||t
17178348|NCT04019288|t||||
17178349|NCT00934089|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178350|NCT02767843|f||||f
17178351|NCT01270516|t||||
17178352|NCT00541931|f||||f
17178353|NCT00040365|f||||f
17178354|NCT00680017|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17178355|NCT00612040|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17178356|NCT00899574|t||||
17133752|NCT02516657|f||||f
17133753|NCT03464045|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133754|NCT00001337|f||||f
17133755|NCT05590377|f||GT60||t
17133756|NCT00442598|f||||f
17133757|NCT01262898|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133758|NCT04026568|t||||
17133759|NCT02197377|f||||f
17133760|NCT00502840|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133761|NCT00461175|t||||
17133762|NCT01700829|f||||f
17133763|NCT02589977|f||||f
17139448|NCT03054740|t||||
17139449|NCT03489850|f||||f
17139450|NCT02343952|f||||f
17139451|NCT00456885|f||||f
17139452|NCT01922739|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17178357|NCT01086033|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178358|NCT04572633|f||OTHER||t
17133764|NCT01025635|f||OTHER|Investigator may publish the results of Study only after review, comment and approval by Intendis. At least sixty (60) days prior to submitting a manuscript to a publisher or other outside persons (i.e., reviewer(s)) or prior to any public presentation), a copy of the manuscript or presentation will be provided to Intendis by the Investigator for review and comment. No publication of confidential information shall be made without Intendis' prior written consent.|t
17178359|NCT03783949|f||||f
17178360|NCT03473171|t||||
17133765|NCT00727402|f||||f
17133766|NCT05292755|f||||f
17178361|NCT03992014|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133767|NCT03102411|t||||
17178362|NCT03478657|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178363|NCT02590003|t||||
17133768|NCT00432809|t||||
17178364|NCT03570697|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17133769|NCT04433117|t||||
17178365|NCT03948581|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17178366|NCT03068455|f||LTE60||t
17178367|NCT02989545|f||||f
17133770|NCT01051739|t||||
17178368|NCT01876420|f||||f
17184196|NCT03465540|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184197|NCT02844946|f||||f
17184198|NCT00736996|f||||f
17184199|NCT02806986|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17133771|NCT00707577|f||||f
17133772|NCT03853694|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17133773|NCT03770403|f||||t
17133774|NCT03633084|f||OTHER||t
17133775|NCT01557790|t||||
17133776|NCT00642642|f||OTHER|Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval prior to publication or presentation in any form.|t
17133777|NCT02337387|f||GT60||t
17133778|NCT03871491|f||||f
17133779|NCT04439331|f||LTE60||t
17133780|NCT02901314|f||||f
17133781|NCT01444300|f||LTE60||t
17133782|NCT00490542|f||||f
17133783|NCT01587989|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133784|NCT03128957|t||||
17133785|NCT00684177|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133786|NCT05198713|t||||
17133787|NCT02582658|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178369|NCT04472429|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17178370|NCT01172522|t||||
17178371|NCT01416272|t||||
17178372|NCT01719783|f||||f
17178373|NCT01313312|f||||f
17178374|NCT01252147|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17133788|NCT03274687|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17178375|NCT01612858|f||||f
17178376|NCT03988088|f||OTHER||t
17178377|NCT03113071|t||||
17178378|NCT01540266|f||||f
17178379|NCT00868608|f||LTE60||t
17178380|NCT03344796|f||||f
17178381|NCT01999179|f||||f
17178382|NCT00880997|f||||f
17178383|NCT02564796|f||||f
17178384|NCT04547712|f||||f
17178385|NCT00594659|f||||f
17178386|NCT00660699|t||||
17178387|NCT03432897|f||||f
17178388|NCT03105479|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17178389|NCT02963649|f||OTHER||t
17178390|NCT05358444|f||||f
17178391|NCT03802227|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17178392|NCT02900976|f||OTHER|Must obtain prior sponsor approval|t
17178394|NCT04997304|t||||
17178395|NCT01752985|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178396|NCT06934993|t||||
17178397|NCT04092582|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178398|NCT00690274|f||||f
17178399|NCT01696084|f||||f
17178400|NCT03663816|t||||f
17178401|NCT00300391|f||||f
17178402|NCT03243071|t||||
17178403|NCT01871532|f||OTHER||t
17184200|NCT00462384|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184201|NCT02667912|t||||
17184202|NCT04443218|f||OTHER|Publication or presentation of the overall registry results and/or site-specific results requires prior written approval of Edwards.|t
17184203|NCT00346034|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results|t
17133789|NCT05556616|f||||t
17133790|NCT00608465|f||||f
17133791|NCT02863263|f||OTHER|Mundipharma Pte Ltd is owner of the data. No Investigator may publish the results of this study without prior approval from Mundipharma Pte Ltd.|t
17133792|NCT03026803|t||||
17133793|NCT03095703|f||||f
17184204|NCT04000165|t||||
17133794|NCT01381094|f||||f
17133795|NCT04092257|t||||
17133796|NCT01934504|f||||f
17133797|NCT02665689|t||||
17178404|NCT00283400|f||||f
17178405|NCT04401423|f||||f
17178406|NCT01020981|t||||
17178407|NCT01337700|f||||f
17178408|NCT00064337|f||LTE60||t
17178409|NCT02279420|f||||f
17178410|NCT01948947|t||||
17178411|NCT05096221|f||||t
17178412|NCT01896102|f||OTHER||t
17178413|NCT03719612|f||||f
17178414|NCT05091047|t||||
17178415|NCT00727636|f||LTE60||t
17178416|NCT00900237|f||OTHER||t
17178417|NCT04461210|f||||f
17178418|NCT01554683|t||||
17178419|NCT04515394|f||OTHER||t
17178420|NCT03330288|f||LTE60||t
17178421|NCT02581787|t||||
17178422|NCT00381550|f||LTE60||t
17178423|NCT02284516|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133798|NCT00541307|f||OTHER|The investigator will provide the materials to the sponsor at least 30 days in advance of submission for publication or public disclosure. The sponsor has the right to make modifications as necessary to protect proprietary information or correct inaccuracies in technical specifications or device descriptions.|t
17178424|NCT01254331|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178425|NCT01443078|t||||
17133799|NCT02455557|t||||
17178426|NCT01809106|f||||f
17178427|NCT01706978|t||||
17178428|NCT02467075|f||||f
17178429|NCT01323959|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178430|NCT02993757|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17184205|NCT05799495|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184206|NCT03105362|f||||f
17184207|NCT03330834|f||||f
17184208|NCT02371369|f||||f
17184209|NCT01573702|t||||
17184210|NCT03115424|t||||
17184211|NCT00503685|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17184212|NCT00389818|f||||f
17184213|NCT02838017|f||||f
17178431|NCT02762578|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17184214|NCT02120924|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17184215|NCT01884350|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17184216|NCT01059617|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184217|NCT02669329|f||||f
17184218|NCT01543256|f||||f
17184219|NCT03704376|t||||
17184220|NCT00074282|f||LTE60||t
17184221|NCT00464542|t||||
17184222|NCT01319396|t||||
17184223|NCT01773226|f||LTE60||t
17184224|NCT01429259|f||||f
17184225|NCT01203189|f||||f
17184226|NCT02055352|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17184227|NCT02180646|f||||f
17184228|NCT03809182|t||||
17178432|NCT00828412|f||||f
17178433|NCT00259610|f||LTE60||t
17184229|NCT02062502|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17184230|NCT03794089|f||||f
17184231|NCT03985423|f||LTE60||t
17184232|NCT03119766|f||||t
17184233|NCT02562755|f||||f
17184234|NCT02034578|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trials primary publication.|t
17184235|NCT01045447|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17133800|NCT03615222|t||||f
17133801|NCT00476086|f||||f
17133802|NCT02900092|t||||
17133803|NCT04178590|t||||
17133804|NCT03895203|f||GT60||t
17133805|NCT04630301|f||||f
17178434|NCT02028754|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178435|NCT00957580|f||OTHER||t
17178436|NCT01090492|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178437|NCT01768286|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17178438|NCT01602120|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178439|NCT01611155|t||||
17178440|NCT00929383|f||||f
17178441|NCT02699593|f||GT60||t
17178442|NCT00911547|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178443|NCT00915278|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178444|NCT02168361|f||||f
17178445|NCT01199965|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178446|NCT00453063|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17178447|NCT00228384|f||OTHER|The investigator will provide the materials to the sponsor at least 30 days in advance of submission for publication or public disclosure. The sponsor has the right to make modifications as necessary to protect proprietary information or correct inaccuracies in technical specifications or device descriptions.|t
17178448|NCT03100500|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17178449|NCT02352974|t||||f
17178450|NCT02151383|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17178451|NCT01785069|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178452|NCT03569618|t||||f
17178453|NCT01453361|f||||t
17178454|NCT04560998|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17178455|NCT04659928|t||||
17178456|NCT01661621|t||||
17178457|NCT02025621|f||||f
17178458|NCT00739674|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178459|NCT01594281|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178460|NCT02373852|f||||f
17178461|NCT04805541|f||||f
17133806|NCT00996840|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133807|NCT03424109|t||||
17133808|NCT02292849|f||||f
17133809|NCT01485614|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17133810|NCT02210780|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17133811|NCT00886938|t||||
17184236|NCT02181530|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184237|NCT03821376|f||||f
17184238|NCT02391402|t||||
17184239|NCT02318329|f||||f
17184240|NCT00086346|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17184241|NCT03268811|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17184242|NCT01055639|f||||f
17184243|NCT00562159|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17184244|NCT02417246|t||||
17133812|NCT00364793|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178462|NCT03695250|t||||
17178463|NCT00289471|t||||
17178464|NCT01543958|f||||f
17178465|NCT01945281|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17178466|NCT04538430|f||||f
17178467|NCT01112358|f||||f
17178468|NCT01519271|f||||f
17178469|NCT00799383|f||||f
17178470|NCT00726986|t||||
17178471|NCT03119831|t||||
17178472|NCT02840097|f||||f
17178473|NCT02165215|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178474|NCT04678661|t||||
17178475|NCT01397890|f||OTHER|The PI Disclosure Restriction is indicated in the Clinical Study Agreement, please refer to this document of each PI and country.|t
17178476|NCT03094169|f||||t
17178477|NCT04645953|f||OTHER|Alexza Pharmaceuticals has full ownership of the data collected as part of the study. The results of this study may be published in a medical publication, journal, or another public dissemination, presented at a medical conference or used for teaching purposes. This study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations.|t
17178478|NCT00002651|f||||f
17184245|NCT04729803|f||||f
17184246|NCT01233817|t||||
17184247|NCT01248884|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133813|NCT00310310|t||||
17133814|NCT00363415|f||GT60||t
17133815|NCT04802837|f||||f
17178479|NCT03741062|f||||f
17178480|NCT00304746|f||||f
17178481|NCT00541593|t||||
17184248|NCT02511431|t||||
17133816|NCT05027802|f||||t
17133817|NCT03826875|t||||
17133818|NCT03872180|t||||
17133819|NCT01506141|f||||t
17133820|NCT04607408|f||||f
17178482|NCT02763462|f||||f
17178483|NCT03417219|t||||
17178484|NCT00261807|f||||f
17178485|NCT01550731|t||||
17178486|NCT00675948|f||OTHER|"Publication Policy:~GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release."|t
17178487|NCT02527161|f||OTHER|Discloser must give at least 40 days notice to Sponsor including a copy of the proposed publication. The Sponsor can then provide comments (which Discloser is not bound to follow), request delay of publication by no more than 120 days to allow for Sponsor to protect its intellectual property, or request that the Discloser remove certain proprietary or confidential information from the study (other than the results of the study).|t
17178488|NCT05209360|t||||
17178489|NCT02100514|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17184249|NCT04479618|f||||f
17184250|NCT01202773|f||GT60||t
17184251|NCT05053087|t||||
17184252|NCT01452269|f||||f
17184253|NCT01243333|t||||
17184254|NCT04827212|f||||f
17184255|NCT01173848|t||||
17184256|NCT04360824|f||||f
17133821|NCT04586504|t||||
17133822|NCT02725788|f||||f
17178490|NCT00724932|f||||f
17178491|NCT02021331|f||||f
17178492|NCT00762229|t||||f
17178493|NCT02218320|t||||f
17133823|NCT00828464|f||GT60||t
17133824|NCT00809133|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133825|NCT02499952|f||||f
17133826|NCT05089708|f||||t
17133827|NCT03333577|f||||f
17133828|NCT02209766|f||LTE60||t
17133829|NCT00064701|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or until 18 months have elapsed following study completion. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document.|t
17178494|NCT02096731|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17178495|NCT00319553|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17178496|NCT02673138|t||||
17178497|NCT00885846|t||||
17178498|NCT01439633|f||||f
17178499|NCT01081678|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17178500|NCT00695409|t||||
17178501|NCT01496248|f||||f
17178502|NCT00444912|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17178503|NCT01281865|f||LTE60||t
17178504|NCT02747875|f||||f
17178505|NCT02983825|t||||
17178506|NCT01702805|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication Policies|t
17178507|NCT02499783|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178508|NCT01866293|t||||
17178509|NCT04457336|f||||f
17178510|NCT00244010|t||||
17178511|NCT00000371|f||||f
17178512|NCT02571075|f||||f
17178513|NCT02693119|f||GT60||t
17178514|NCT04203498|f||||f
17178515|NCT02106975|f||||f
17178516|NCT02718157|f||||f
17178517|NCT02935842|t||||
17178518|NCT01201785|t||||f
17178519|NCT04545385|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17178520|NCT00939770|f||OTHER|Must obtain prior sponsor approval|t
17178521|NCT00191139|f||GT60||t
17178522|NCT00758836|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17178523|NCT01289080|f||||f
17178524|NCT03128411|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178525|NCT00394147|t||||
17178526|NCT01798004|f||OTHER|Must obtain prior Sponsor approval.|t
17178527|NCT00666029|t||||
17178528|NCT01633853|f||||f
17178529|NCT02785432|t||||
17178530|NCT00871260|f||||f
17178531|NCT03539081|f||||f
17178532|NCT03542474|f||||f
17178533|NCT00990236|f||||f
17178534|NCT01673867|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178535|NCT02048891|t||||
17178536|NCT02550106|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17139453|NCT02725268|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17178537|NCT02195583|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178538|NCT01709513|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17184257|NCT00320216|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184258|NCT02265705|f||GT60||t
17184259|NCT04030416|f||||f
17184260|NCT00377676|f||OTHER|After FDA filing, Principal Liaison shall be free to publish the results of the Study subject only to the provisions of Section 7 regarding Veroscience Proprietary Information. The Principal Liaison shall furnish Veroscience with a copy of any proposed publication for review and comment prior to submission for publication, at least thirty (30) days prior to submission for manuscripts and at least fifteen (15) days prior to submission for abstracts.|t
17184261|NCT03421197|f||||f
17184262|NCT00779246|f||||f
17184263|NCT04153409|f||OTHER|Except for legal reasons, the investigator will not reveal the result of the study to a third party without a mutual agreement about the analysis and interpretation of the data with the sponsor.|t
17184264|NCT04844281|f||||f
17184265|NCT01592435|f||||f
17184266|NCT03660683|f||||f
17139454|NCT04498468|f||||f
17139455|NCT01154322|f||LTE60||t
17139456|NCT02224274|f||||f
17178539|NCT00926328|f||GT60||t
17178540|NCT00289133|f||||f
17178541|NCT01227434|f||||f
17178542|NCT00779701|t||||
17178543|NCT04613375|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178544|NCT00187200|f||OTHER|Publications and presentation should be presented to sponsor 30 days (manuscripts) or 7 days (abstracts) prior to submission for publication. The sponsor reserves the right to deny submission of study results if based on data owned by sponsor.|t
17178545|NCT01921387|f||||f
17178546|NCT00510497|f||GT60||t
17178547|NCT00469274|f||||f
17178548|NCT03095612|t||||
17178549|NCT04447794|t||||
17178550|NCT00621582|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17178551|NCT01387932|f||LTE60||t
17178552|NCT00963937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178553|NCT03463512|f||||f
17184267|NCT00941603|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17184268|NCT02014116|f||GT60||t
17184269|NCT01753193|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17184270|NCT00383435|f||OTHER|The investigator has the right to publish or publicly present results. The investigator agrees not to publish or publicly present any interim results without prior written consent of the sponsor. The investigator agrees to provide to the sponsor 45 days before submission for publication that report results of the study. The sponsor shall have the right to review \& comment with respect to publications, abstracts, slides, \& manuscripts \& the right to review \& comment on the data \& presentation.|t
17184271|NCT00583557|f||OTHER|For multi-center trials, no investigator will be authorized to publish study results from an individual center until the earlier of the multi-center trial results are published or 12 months after the end or termination of the multi-center trial at all sites. All manuscripts and abstracts must be submitted to the sponsor for review least 30 days prior to submission for publication or for presentation at a scientific meeting. The sponsor may delay publication for up to 3 months.|t
17184272|NCT01131312|f||||f
17184273|NCT02682264|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17184274|NCT02942160|f||||f
17184275|NCT04040985|f||GT60||t
17178554|NCT00939640|f||||f
17178555|NCT02169479|f||OTHER||t
17178556|NCT04010695|f||||f
17178557|NCT01235689|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178558|NCT00389597|f||OTHER|The clinical site must submit to the Company, for review, any manuscripts, papers, summaries, abstracts, outlines or other media for publication at least 60 days before disclosure for the Company to review. The company has 30 days to review the proposed publication for any patentable subject matter or designated confidential information or confidential health information and by written notice to the site/PI identify such text so that the Company has time to file a patent application.|t
17178559|NCT00005044|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17178560|NCT04431453|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17178561|NCT03546062|f||||f
17178562|NCT00353795|t||||
17178563|NCT02083965|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17178564|NCT04502433|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17178565|NCT02774954|f||||f
17178566|NCT01702961|t||||
17178567|NCT02229383|f||OTHER|At least 30 days prior to submission for publication or presentation, Authors shall provide Sponsor with such material for its review. Sponsor shall have 30 days to comment. If requested by Sponsor, Authors shall withhold material for an additional 90 days to allow for the taking of measures to establish its proprietary rights. No publication or presentation shall be made unless and until any information determined at Sponsor's sole discretion to be Confidential has been removed.|t
17178568|NCT02653183|f||OTHER||t
17178569|NCT00674362|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17178570|NCT01899261|t||||
17178571|NCT00084383|t||||
17178572|NCT03137537|f||||f
17178573|NCT03386448|t||||
17178574|NCT01146665|f||||f
17178575|NCT00981370|f||||f
17178576|NCT01817530|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178577|NCT03846804|f||||f
17178578|NCT00404235|t||||
17178579|NCT00345839|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184276|NCT04071951|f||||f
17184277|NCT03264989|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17184278|NCT00797667|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17184279|NCT01986829|t||||
17184280|NCT01775137|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17184281|NCT03029208|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184282|NCT01732835|f||OTHER|Publication by the investigator was not allowed until completion of the trial. All proposed publications must be cleared by unanimous vote of a publication committee consisting of the sponsor and representatives of the study investigators. Publication materials must be submitted for review at least 60 day in advance of publication. The Sponsor may embargo publication for 60 additional days to allow for patent filing or may prevent publication if filling of such application would be premature.|t
17178580|NCT01960400|t||||
17178581|NCT03298867|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights.|t
17184283|NCT02334748|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184284|NCT00305058|t||||
17139457|NCT01976624|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178582|NCT00743483|f||OTHER||t
17139458|NCT04350372|f||||f
17139459|NCT00514592|t||||
17139460|NCT00412113|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17139461|NCT02058251|f||||f
17139462|NCT01627782|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17178583|NCT01466153|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17184285|NCT04575428|t||||f
17184286|NCT02944877|f||||f
17184287|NCT03965052|f||OTHER|The Principal Investigator undertakes not to publish or communicate data collected from the study, unless there is prior written agreement of Laboratorios Sophia, S.A. from C.V.|t
17184288|NCT02545907|f||||f
17184289|NCT01910519|t||||
17178584|NCT01213329|t||||
17178585|NCT03483740|f||||f
17178586|NCT02383498|f||||t
17178587|NCT05263895|t||||
17178588|NCT03835780|f||||f
17178589|NCT02823431|f||||f
17178590|NCT00544466|t||||
17178591|NCT03281577|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17178592|NCT02323113|f||OTHER|In general, investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17178593|NCT01663532|f||||f
17178594|NCT00354744|f||||f
17178595|NCT01513343|f||||f
17178596|NCT01749137|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17178597|NCT02587234|f||||f
17178598|NCT01153347|f||GT60||t
17178599|NCT01706146|f||||f
17178600|NCT02582983|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178601|NCT01751178|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184290|NCT04266028|f||||t
17184291|NCT02863991|f||OTHER|Within 12 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given the opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17184292|NCT00724347|t||||
17184293|NCT01629329|t||||
17184294|NCT03096782|t||||
17184295|NCT03843788|t||||f
17184296|NCT01177098|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184297|NCT00993447|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17184298|NCT00970502|t||||
17184299|NCT03811912|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17184300|NCT00566228|t||||
17184301|NCT03521635|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17184302|NCT02244944|t||||
17184303|NCT00414700|f||LTE60||t
17184304|NCT00512135|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17184305|NCT01659021|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184306|NCT01205685|t||||
17184307|NCT04320069|f||||f
17184308|NCT01169467|f||||f
17184309|NCT03058679|f||||f
17184310|NCT03108924|f||||f
17184311|NCT01098006|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184312|NCT00599326|t||||
17184313|NCT00924885|f||||f
17178602|NCT00289991|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139463|NCT03573401|f||OTHER|Details of the Study and results shall not be published in any form without prior consent of Sponsor. All decisions on the timing and content of publications/ presentations will be coordinated by Sponsor. A draft of any manuscript, talks, abstracts, and all similar material shall be submitted to sponsor at least sixty (60) days before submission of the final form to any journal, scientific conference, symposium, or program review committee prior to publication or other release.|t
17184314|NCT00784810|f||||f
17184315|NCT02862106|f||OTHER|Investigators can't publish articles relevant to the study unless the sponsor permits.|t
17139464|NCT00616772|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178603|NCT02249585|f||||f
17178604|NCT01158157|t||||
17184316|NCT02508480|f||||f
17184317|NCT02995967|t||||f
17133830|NCT02249052|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17133831|NCT01491945|f||||f
17133832|NCT05681715|f||GT60||t
17178605|NCT01606007|f||LTE60||t
17178606|NCT01517711|t||||
17178607|NCT01007812|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17178608|NCT01091974|t||||
17178609|NCT00555971|f||||f
17178610|NCT00518284|f||OTHER|"* Study data will not be published in part before complete multicenter data have been reported in full, unless more than 18 months have elapsed since completion of the Study.~* Investigator/institution must supply copy of presentation or publication to Celgene 30 days of prior to submission for publication. Celgene may request in writing within that 30 days that Celgene Confidential Information be deleted or be granted a 60 day delay prior to publication for intellectual property filings."|t
17184318|NCT04137380|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184319|NCT00563784|t||||
17184320|NCT04634604|f||||f
17184321|NCT02127164|t||||
17133833|NCT04898166|t||||
17133834|NCT01894672|t||||
17133835|NCT00582894|t||||
17133836|NCT01207466|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17133837|NCT02700451|f||||f
17133838|NCT04373460|f||||f
17133839|NCT01672957|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133840|NCT01852084|f||OTHER|Contact sponsor directly for details.|t
17133841|NCT01578902|f||||f
17178611|NCT02571777|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178612|NCT00801632|f||||f
17178613|NCT04600375|t||||f
17178614|NCT04672993|t||||
17178615|NCT04092439|f||||f
17178616|NCT01350492|t||||
17178617|NCT00205881|f||OTHER|Investigators were not permitted to disclose study results until the Sponsor had completed data analyses and report generation for regulatory purposes, and/or received regulatory approval. The Sponsor agreed to notify the Investigators when they were free to publish, present or use any results arising out of this study for their own instructional, research, or publication objectives, provided that such publication did not disclose any of the Sponsor's proprietary information.|t
17178618|NCT04789499|f||||f
17178619|NCT00644657|t||||f
17178620|NCT01146834|t||||
17178621|NCT00781274|f||OTHER||t
17178622|NCT01534962|f||LTE60||t
17178623|NCT00282984|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months (mo) from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17178624|NCT00191269|f||GT60||t
17133842|NCT02115308|f||||f
17133843|NCT03322358|f||||f
17133844|NCT02344576|f||||f
17133845|NCT04325503|t||||
17133846|NCT02413203|f||||f
17133847|NCT03832387|t||||
17133848|NCT05202808|f||||t
17133849|NCT02495948|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17133850|NCT02747004|f||||t
17133851|NCT06218251|f||||f
17133852|NCT05087030|f||OTHER|No unpublished information may be disclosed without prior written approval from sponsor.|t
17133853|NCT01053429|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133854|NCT00963807|f||LTE60||t
17133855|NCT04840836|t||||
17133856|NCT03697564|t||||
17133857|NCT02031679|f||||f
17133858|NCT04030195|f||||f
17133859|NCT01024244|f||GT60||t
17133860|NCT01232946|f||||f
17133861|NCT02511522|f||||f
17133862|NCT02660580|f||OTHER||t
17133863|NCT00377962|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133864|NCT01035151|f||||f
17133865|NCT04645797|f||OTHER|After the multicenter publication or 12 months after completion of the Study, whichever occurs first, Institution may itself publish the results of its data from the Study. Institution/Principal Investigator shall provide Sponsor/CRO with advance copy of any proposed publication/oral presentation sixty (60) days prior to the planned date of submission/presentation; Sponsor shall have 60 days to review the proposed publication/presentation.|t
17133866|NCT00049127|f||LTE60||t
17133867|NCT02582515|f||||f
17133868|NCT00775021|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17133869|NCT02599402|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17133870|NCT00833092|t||||f
17133871|NCT01773473|f||GT60||t
17133872|NCT03431012|f||||f
17133873|NCT00929240|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133874|NCT02371629|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17133875|NCT00805207|f||||f
17133876|NCT00201851|f||||f
17133877|NCT02469246|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133878|NCT00046566|t||||
17133879|NCT05564052|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17178625|NCT00941005|t||||
17178626|NCT01745133|t||||
17178627|NCT02151110|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17178628|NCT02015754|t||||f
17178629|NCT01128842|f||LTE60||t
17178630|NCT04528732|f||||f
17178631|NCT01086761|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178632|NCT01300650|f||||f
17178633|NCT02369016|f||OTHER||t
17178634|NCT00668707|f||||f
17133880|NCT03185546|f||||f
17178635|NCT00923156|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17133881|NCT01658514|f||OTHER|The results of the Study may be published by INSTITUTE, however the publication shall not disclose any SPONSOR Confidential Information, the INSTITUTE shall send the SPONSOR a copy of any such proposed publication 90 days prior to submission for publication, the INSTITUTE, on request of the SPONSOR, shall delete any SPONSOR Confidential Information in the proposed publication, and the INSTITUTE shall, on the SPONSOR's request, delay submission while the SPONSOR files applications for patents.|t
17139465|NCT00863434|f||||f
17178636|NCT01201850|f||||f
17178637|NCT03338010|f||GT60||t
17139466|NCT04058990|f||OTHER|The restriction depends on the conditions on the Clinical Study Agreement at each site. The PI must notify the sponsor about the publication and receive the approval from the sponsor prior to any results/data relavant to the AGENT Japan trial to be in public.|t
17178638|NCT01211730|f||||f
17178639|NCT02465515|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178640|NCT00816595|t||||
17178641|NCT00293033|f||OTHER|The oral or written use of study results by the investigator are not permitted without the express written consent from BDSI. All data resulting from this study remain property of BDSI.|t
17178642|NCT03583697|f||GT60||t
17178643|NCT01586065|t||||
17178644|NCT00114530|f||||f
17178645|NCT01577108|t||||f
17178646|NCT00365508|f||||f
17178647|NCT02450591|t||||
17178648|NCT01064310|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17178649|NCT00679432|f||||f
17178650|NCT03704467|f||OTHER||t
17178651|NCT00873015|f||||f
17178652|NCT02339584|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17178653|NCT01382212|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17133882|NCT02658461|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133883|NCT02319369|f||||f
17133884|NCT01856114|t||||
17178654|NCT02914119|f||||f
17178655|NCT00873912|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17178656|NCT03261973|t||||
17178657|NCT01980940|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17178658|NCT03000283|t||||
17178659|NCT04096963|f||||f
17178660|NCT01637935|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 45 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17178661|NCT00259649|f||||f
17178662|NCT00709761|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17178663|NCT00443261|f||||f
17178664|NCT03311724|f||GT60||t
17178665|NCT02432729|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17178666|NCT01433991|f||||f
17178667|NCT00844831|f||||f
17178668|NCT02957305|t||||
17178669|NCT01193530|t||||
17178670|NCT00993200|t||||
17178671|NCT00842608|f||||f
17178672|NCT00903396|t||||
17178673|NCT03305575|t||||
17133885|NCT00144170|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17133886|NCT00981526|f||||f
17133887|NCT01243268|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17133888|NCT01564784|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Investigators will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.|t
17133889|NCT00957853|t||||
17133890|NCT00702143|f||GT60||t
17133891|NCT04174599|f||||t
17139467|NCT04315298|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17178674|NCT01691339|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17178675|NCT02577978|f||||f
17178676|NCT01335191|f||||f
17178677|NCT03486223|f||||f
17178678|NCT01819831|t||||
17139468|NCT00736385|t||||
17178679|NCT01758432|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization|t
17178680|NCT05166824|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17139469|NCT00098865|f||LTE60||t
17178681|NCT02647203|f||||f
17178682|NCT02417831|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139470|NCT02145754|t||||
17178683|NCT01144286|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publications and/or presentations (results communications) prior to public release and communications regarding trial results for a period that is 60 days from the time submitted to the sponsor for review. The sponsor may require changes to the publication and /or presentation regarding its content or the time of release.|t
17178684|NCT03068130|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17178685|NCT03130257|t||||
17178686|NCT00297830|f||||f
17178687|NCT01548651|t||||
17178688|NCT04377620|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17178689|NCT00288054|f||||f
17178690|NCT01610570|f||||f
17178691|NCT04159571|f||||f
17178692|NCT00332163|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17178693|NCT02621060|f||||f
17178694|NCT03733470|f||||f
17178695|NCT01010061|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178696|NCT03050554|f||||f
17178697|NCT01004705|f||OTHER|Publication must be agreed upon with the sponsor.|t
17178698|NCT00864383|f||||f
17178699|NCT02197520|f||GT60||t
17178700|NCT01306942|f||LTE60||t
17178701|NCT01957930|t||||
17178702|NCT02021773|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17178703|NCT02243696|f||||t
17184322|NCT03434119|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17178704|NCT00087607|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17178705|NCT00190671|f||GT60||t
17178706|NCT02094677|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17178707|NCT03408483|t||||
17133892|NCT01701622|t||||
17139471|NCT00688623|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139472|NCT02667236|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor.|t
17139473|NCT00794469|f||||f
17139474|NCT02458352|t||||
17184323|NCT00304070|f||OTHER|Must obtain prior Sponsor approval.|t
17139475|NCT03887052|f||OTHER|No less than one month prior to public disclosure of any results of the Project, Investigator will provide Kestra a manuscript or other draft of the proposed public disclosure. Within one month following receipt thereof, Kestra will notify Investigator in writing if the proposed disclosure contains any Kestra Confidential Information or substantial duplications of the written reports provided and specify the portions of the proposed disclosure requiring redactions or other modifications.|t
17133893|NCT00741819|f||OTHER|Any publication of the result of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17139476|NCT00257322|f||||f
17139477|NCT00628134|f||||f
17139478|NCT03687827|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17139479|NCT02128958|f||||f
17139480|NCT00498368|f||||f
17139481|NCT01744041|f||||f
17139482|NCT00285649|f||||f
17139483|NCT03342404|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139484|NCT01957085|t||||f
17139485|NCT03748420|t||||
17139486|NCT01137006|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17139487|NCT00312728|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139488|NCT01215786|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17139489|NCT00423592|f||OTHER||t
17178708|NCT05399641|f||||f
17178709|NCT00478231|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178710|NCT00672932|f||||f
17184324|NCT03579459|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184325|NCT00148343|f||||f
17184326|NCT01754714|f||||f
17133894|NCT00609622|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133895|NCT01696461|f||||f
17133896|NCT00752986|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17133897|NCT02226965|f||||t
17133898|NCT03481270|f||||f
17178711|NCT02516046|f||LTE60||t
17178712|NCT00255125|t||||f
17178713|NCT04066023|f||LTE60||t
17178714|NCT00751933|t||||
17178715|NCT00072566|f||LTE60||t
17178716|NCT05248867|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17178717|NCT05544734|t||||f
17178718|NCT01084083|f||LTE60||t
17178719|NCT01273597|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17178720|NCT01088997|t||||
17178721|NCT04543838|t||||
17178722|NCT05695209|f||||f
17178723|NCT04731363|t||||
17178724|NCT02513394|f||||f
17178725|NCT05766423|t||||
17178726|NCT00688753|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178727|NCT03749447|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17178728|NCT05996718|f||||f
17178729|NCT01218113|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178730|NCT01713686|f||||f
17178731|NCT04840615|f||||f
17178732|NCT00967668|t||||
17178733|NCT00115739|t||||f
17178734|NCT01055171|t||||f
17178735|NCT02200211|f||||f
17178736|NCT01918774|t||||f
17178737|NCT01606800|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17178738|NCT00042289|f||||f
17178739|NCT00745823|f||OTHER|Twenty-four months after completion of this study or after publication of the multicenter results, an investigator may publish the results for their study site independently. The sponsor must have the opportunity to review all proposed publications or presentations regarding the study 60 days before submission.|t
17178740|NCT01687998|f||GT60||t
17178741|NCT01337739|f||||f
17178742|NCT01182675|f||||f
17178743|NCT01135420|t||||
17178744|NCT00717197|t||||
17178745|NCT00982137|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17178746|NCT01811654|t||||
17178747|NCT02519036|f||||t
17178748|NCT00612690|f||||f
17178749|NCT04869644|t||||
17178750|NCT00787891|f||LTE60||t
17178751|NCT02955602|f||||t
17178752|NCT01258582|t||||
17178753|NCT02980601|t||||
17178754|NCT01575769|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178755|NCT01619982|t||||
17178756|NCT03156543|t||||
17178757|NCT00674700|f||||f
17178758|NCT00395304|f||||f
17178759|NCT02543437|f||||f
17178760|NCT03797014|t||||
17178761|NCT01970397|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17178762|NCT00681083|f||OTHER||t
17178763|NCT01389817|t||||
17178764|NCT01023620|t||||
17178765|NCT01509950|t||||
17178766|NCT01434667|f||||f
17178767|NCT04115839|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17178768|NCT02966028|f||||f
17178769|NCT02577510|f||||f
17133899|NCT02970929|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17133900|NCT00291343|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133901|NCT01245647|f||||f
17133902|NCT02370121|f||||f
17133903|NCT03072602|t||||
17133904|NCT03912584|f||LTE60||t
17133905|NCT02570672|t||||
17133906|NCT00275561|t||||
17133907|NCT01769105|t||||
17133908|NCT01530243|f||||f
17133909|NCT04321343|f||||f
17133910|NCT04194944|f||GT60||t
17133911|NCT04238819|f||GT60||t
17133912|NCT00000479|t||||
17133913|NCT06238999|t||||
17133914|NCT04984889|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133915|NCT00045032|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17133916|NCT05818124|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.|t
17133917|NCT01075347|f||||f
17133918|NCT02581995|f||OTHER|Center provides publication/presentation related to the Study Drug/Results 60 days prior to due date submission/presentation allowing Bayer review. Center receives notification within 45 days, Center reminds Bayer of Publication´s due date. Expected comments are within 60 days, if not Center to publish. Multi-center´s Results publication coordinates through Bayer Center publishes their Results provided overall results haven't been published within 18 months from Study completion for compliance.|t
17133919|NCT04907045|t||||
17133920|NCT02364778|t||||
17133921|NCT02357992|f||||f
17133922|NCT05224258|f||GT60||t
17133923|NCT00486902|t||||
17133924|NCT00733902|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133925|NCT00699192|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139490|NCT03446612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139491|NCT01437267|f||OTHER|In the event that no publication of the Study results has been made by NVGH within twelve (12) months of Study database lock and no proposed publication is under discussion by the publication committee, Principal Investigator may publish its own Study results.|t
17139492|NCT00838695|f||||f
17139493|NCT03934203|t||||
17139494|NCT04925947|t||||
17139495|NCT04319445|t||||
17139496|NCT00608842|f||OTHER|The clinical study agreement requires that the investigator or institution obtain written consent from Kythera Biopharmaceuticals, Inc. prior to presenting and/or publishing results of this study.|t
17178770|NCT01738321|t||||
17178771|NCT03644212|t||||
17178772|NCT03535844|f||||f
17178773|NCT01803204|f||||f
17178774|NCT02835820|f||||f
17178775|NCT00905151|f||||f
17178776|NCT03554746|f||||f
17178777|NCT00160693|f||GT60||t
17178778|NCT01966159|f||LTE60||t
17178779|NCT03039283|f||OTHER|Investigators will be able to publish and/or present their own data. The publishing investigator will provide the sponsor with a manuscript copy of the abstract and paper at least 30 days in advance of publication or presentation. If the publication contains information that the sponsor at his discretion finds worth protecting in the form of a patent or trademark etc., the sponsor has the right to delay the publication or presentation for 90 days.|t
17178780|NCT01867424|f||||f
17178781|NCT01056653|f||||f
17178782|NCT05386680|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17178783|NCT01847274|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178784|NCT03727230|f||||f
17178785|NCT01373242|t||||f
17178786|NCT02114216|f||||f
17178787|NCT03470441|f||OTHER|We have multiple agreements (through our CRO) with multiple PIs in various countries. The most restrictive of those agreements prohibits the PI from publicly disclosing any study results without our (or our CRO's) prior written permission to do so.|t
17178788|NCT03768414|f||LTE60||t
17178789|NCT01804465|t||||
17178790|NCT02538029|t||||
17178791|NCT00895232|f||LTE60||t
17178792|NCT04292743|t||||
17178793|NCT00809276|f||||f
17178794|NCT03187197|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17178795|NCT02385045|t||||
17178796|NCT02871297|f||||f
17178797|NCT02034110|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178798|NCT00621985|t||||
17178799|NCT01244724|f||||f
17178800|NCT01877265|f||GT60||t
17178801|NCT00691015|t||||f
17178802|NCT04160195|f||||f
17178803|NCT00706823|f||||f
17178804|NCT03719885|f||||f
17178805|NCT00684593|f||OTHER|The Sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to (1) proprietary information that is protected, (2) the accuracy of the information contained in the publication, and (3) to ensure that the presentation is fairly balanced and in compliance with FDA regulations.|t
17178806|NCT01223001|f||GT60||t
17178807|NCT00590720|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17184327|NCT02528214|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17184328|NCT00347308|f||||f
17184329|NCT03447769|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184330|NCT01343407|f||OTHER|This study is intended for publication, even if terminated prematurely. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17184331|NCT03950739|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17184332|NCT03526900|f||||f
17184333|NCT02504866|t||||
17184334|NCT00293540|t||||
17184335|NCT01343056|t||||
17184336|NCT03231371|t||||
17184337|NCT02745626|f||||f
17184338|NCT01863017|f||||f
17184339|NCT02493361|f||LTE60||t
17184340|NCT01046643|f||||f
17184341|NCT00289341|f||||f
17184342|NCT02785406|t||||
17184343|NCT01776645|t||||
17184344|NCT01351740|t||||
17184345|NCT00412087|f||||f
17139497|NCT03787095|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17139498|NCT01039428|f||LTE60||t
17139499|NCT01562678|f||||f
17139500|NCT00422240|f||||t
17184346|NCT00553267|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184347|NCT01310036|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184348|NCT01175668|t||||f
17184349|NCT02078284|f||||f
17184350|NCT00096135|f||OTHER|Must obtain prior sponsor approval.|t
17184351|NCT03473886|f||||f
17184352|NCT01568047|f||OTHER||t
17184353|NCT00874029|f||LTE60||t
17184354|NCT03359096|f||||f
17184355|NCT00856583|f||OTHER|Publication of the results by the investigator will be subject to mutual agreement between the investigator and H. Lundbeck A/S.|t
17184356|NCT02291718|f||||f
17184357|NCT01944046|t||||
17184358|NCT03023891|t||||
17184359|NCT00823082|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsor's request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsor's request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17184360|NCT02328326|t||||
17139501|NCT04489940|f||||f
17139502|NCT01624467|f||GT60||t
17139503|NCT01838304|f||||f
17139504|NCT03964493|f||||t
17139505|NCT02470429|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17178808|NCT01001377|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17178809|NCT02643381|t||||
17178810|NCT02193867|f||||f
17178811|NCT03616600|f||||f
17178812|NCT03600818|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17178813|NCT02124083|t||||f
17178814|NCT03416946|f||||t
17178815|NCT01488370|t||||
17178816|NCT01471171|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17178817|NCT03355820|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178818|NCT03478930|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178819|NCT04189081|f||OTHER|PI agreed to not publish results without prior written consent of Sponsor.|t
17178820|NCT01112865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178821|NCT00705484|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.|t
17178822|NCT00740831|f||||f
17178823|NCT01979445|f||||t
17178824|NCT03982368|f||||f
17178825|NCT03706079|f||||t
17178826|NCT00329238|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17178827|NCT03652012|f||||f
17178828|NCT05393895|f||||t
17178829|NCT04124757|f||||f
17178830|NCT00968513|f||||f
17178831|NCT05537883|f||||f
17178832|NCT01302834|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17178833|NCT01328431|f||||f
17178834|NCT05379231|f||||f
17178835|NCT00769392|t||||
17178836|NCT00018031|t||||
17178837|NCT01521546|f||||f
17178838|NCT02158273|f||||f
17184361|NCT03452917|f||||f
17133926|NCT00422279|f||OTHER|I understand that I retain the right to publish the data from the clinical work that I perform. I agree that Nobel Biocare USA, LLC will be allowed to review and comment on such a document prior to its publication to ensure that the document does not disclose any trade secrets or other confidential information which may be known to me by virtue of my participation in the clinical study. I will not disclose any information regarding the study without permission from Nobel Biocare USA, LLC.|t
17133927|NCT04927312|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133928|NCT00605826|f||OTHER|Contact sponsor directly for details.|t
17139506|NCT00398138|t||||
17139507|NCT01947647|t||||
17139508|NCT01188811|t||||f
17139509|NCT01602744|t||||f
17139510|NCT03418376|f||||f
17139511|NCT03028467|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17133929|NCT04919564|f||||f
17133930|NCT01241786|t||||
17133931|NCT00215930|f||||f
17139512|NCT01387594|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139513|NCT03054298|t||||
17139514|NCT03144089|t||||
17139515|NCT00802880|t||||
17139516|NCT00864123|f||||f
17178839|NCT02296320|f||OTHER|Medimmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17178840|NCT03292562|t||||
17178841|NCT00764738|f||||f
17178842|NCT01203098|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17178843|NCT00730405|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178844|NCT02650856|t||||
17178845|NCT03851705|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17178846|NCT02478775|f||||f
17178847|NCT01496807|t||||
17178848|NCT00959764|f||||f
17178849|NCT00692341|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178850|NCT02591290|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17178851|NCT00913497|t||||
17178852|NCT03676010|f||||f
17178853|NCT01390649|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178854|NCT02217878|f||||f
17178855|NCT00334958|f||||f
17178856|NCT01194466|f||||f
17178857|NCT02933606|f||OTHER||t
17178858|NCT03087643|f||||f
17178859|NCT00113022|t||||f
17178860|NCT02083783|f||||f
17178861|NCT01546883|f||GT60||t
17178862|NCT02256631|f||||f
17178863|NCT01427972|f||GT60||t
17178864|NCT01919606|f||||f
17178865|NCT00824720|f||OTHER|Prior to submission for publication or presentation, the PI will provide the Sponsor 60 days for review of the manuscript. The Sponsor may request that the PI withhold the publication for an additional 60 days.|t
17178866|NCT03928353|f||||t
17178867|NCT02777333|t||||
17178868|NCT00837811|f||GT60||t
17178869|NCT01700725|t||||
17178870|NCT01340885|t||||
17178871|NCT02849678|f||||f
17178872|NCT01667029|t||||
17178873|NCT02899793|t||||
17178874|NCT03310021|f||||t
17178875|NCT01874054|f||OTHER|The first study related publication will be a multi-center publication submitted within 18 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to the Sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17178876|NCT00702923|t||||
17178877|NCT02334358|f||OTHER||t
17178878|NCT02423993|t||||
17178879|NCT02002091|t||||
17178880|NCT00369824|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178881|NCT03953820|f||||t
17178882|NCT02846714|t||||
17178883|NCT03385564|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17178884|NCT00622401|f||||f
17178885|NCT00183677|f||||f
17178886|NCT00223262|f||||f
17178887|NCT04746963|f||||f
17178888|NCT00799422|t||||
17178889|NCT01481376|f||LTE60||t
17178890|NCT00530946|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17178891|NCT00622284|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17178892|NCT03965039|f||OTHER|PI should disclose plans to sponsor prior to public release.|t
17178893|NCT00880009|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178894|NCT00457301|f||||f
17178895|NCT03322631|f||GT60||t
17178896|NCT02412618|f||||f
17178897|NCT01646762|t||||
17133932|NCT01122927|f||||f
17133933|NCT00278525|t||||
17133935|NCT00768560|f||LTE60||t
17133936|NCT00195650|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17133937|NCT03375320|f||LTE60||t
17133938|NCT01535235|f||||f
17133939|NCT00389207|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17133940|NCT01794780|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17133941|NCT02286102|t||||
17133942|NCT01440101|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17133943|NCT02362373|t||||
17133944|NCT01985321|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 40 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and but can extend the embargo for up to 120 day to file patents or take other measures to preserve or secure its Intellectual Property.|t
17133945|NCT00636818|f||GT60||t
17133946|NCT00074958|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17133947|NCT03352245|t||||
17133948|NCT02643095|f||||f
17133949|NCT02690701|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17133950|NCT02553135|t||||
17139517|NCT00796224|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139518|NCT02569398|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17139519|NCT02116361|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17139520|NCT03227224|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17178898|NCT02378961|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17178899|NCT01253408|t||||f
17178900|NCT01217801|t||||
17178901|NCT04456959|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17133951|NCT02107755|t||||
17133952|NCT02853760|f||||f
17133953|NCT00004980|f||||f
17133954|NCT01299025|f||||f
17133955|NCT03577990|f||||f
17133956|NCT02793544|t||||f
17133957|NCT00682630|f||||f
17133958|NCT05369806|t||||
17178902|NCT04338074|f||||f
17178903|NCT03035409|t||||
17178904|NCT00727220|t||||
17133959|NCT01236391|f||||f
17178905|NCT00291577|f||OTHER||t
17178906|NCT04967443|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178907|NCT02494297|t||||
17178908|NCT04502693|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17178909|NCT01552694|f||||f
17133960|NCT01097044|f||||f
17178910|NCT00672243|t||||
17133961|NCT03972488|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17133962|NCT02730546|t||||
17133963|NCT04865731|t||||
17133964|NCT03277196|f||||t
17133965|NCT02017444|t||||f
17133966|NCT01225263|f||||f
17133967|NCT01380899|f||||f
17133968|NCT02351115|f||||f
17133969|NCT03494647|t||||
17133970|NCT00651040|t||||
17133971|NCT00684814|f||GT60||t
17133972|NCT00503399|f||GT60||t
17133973|NCT01676961|f||||f
17133974|NCT00117312|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17133975|NCT01128387|t||||
17133976|NCT02635204|f||||f
17133977|NCT00858832|t||||
17133978|NCT01021111|t||||
17133979|NCT01588821|t||||
17133980|NCT02216136|t||||
17133981|NCT01159262|f||||f
17133982|NCT02696083|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated or arising from the performance of this Agreement is not permitted without the prior written consent of Regenesis. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17139521|NCT02406027|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17178911|NCT03943147|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17178912|NCT02756013|t||||
17178913|NCT00629707|f||||f
17178914|NCT00418457|t||||
17178915|NCT03724032|f||||f
17133983|NCT02704104|f||||f
17133984|NCT03830281|f||||f
17133985|NCT03293680|f||||f
17133986|NCT02201940|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17133987|NCT03192904|f||||f
17133988|NCT02335502|f||GT60||t
17133989|NCT01442181|f||||f
17133990|NCT00749203|t||||
17133991|NCT00709202|f||||f
17133992|NCT02823457|f||||f
17133993|NCT01271686|f||||f
17178916|NCT02267083|f||||f
17133994|NCT00931164|t||||
17178917|NCT02929667|f||||f
17178918|NCT00001880|t||||
17178919|NCT02657369|f||||t
17178920|NCT02639065|f||||f
17178921|NCT00481078|f||LTE60||t
17178922|NCT01845831|t||||
17184362|NCT03198000|f||OTHER|Prior to submission for publication, PI was to provide sponsor with ≥ 60 days for publication review. No publication that included sponsor confidential information was to be submitted without sponsor's prior written consent. If requested, the PI was to withhold publication for up to 60 additional days to allow for patent application filing.|t
17184363|NCT01194674|t||||
17133995|NCT01642212|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17133996|NCT04454411|f||||f
17133997|NCT01397851|f||||f
17133998|NCT00463437|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139522|NCT02497287|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17139523|NCT03559192|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139524|NCT03517722|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17139525|NCT01990703|t||||
17139526|NCT05849441|t||||
17139527|NCT03277794|t||||
17139528|NCT02168660|t||||
17178923|NCT02610725|f||||f
17178924|NCT04094883|t||||
17178925|NCT00826943|f||||f
17178926|NCT01348165|t||||
17178927|NCT00382252|t||||
17178928|NCT01703039|f||||f
17178929|NCT05570500|f||||f
17178930|NCT04706091|f||||f
17178931|NCT02612727|f||||f
17178932|NCT01063868|f||LTE60||t
17178933|NCT00147446|t||||
17178934|NCT01446289|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17178935|NCT02302807|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178936|NCT03329573|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178937|NCT00650260|f||||f
17178938|NCT03307967|f||||f
17178939|NCT02578316|f||||f
17178940|NCT02166905|t||||
17178941|NCT02617628|t||||
17178942|NCT02065375|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17178943|NCT03278873|f||||t
17178944|NCT05243641|t||||
17178945|NCT04518306|f||||f
17178946|NCT05372419|f||GT60||t
17178947|NCT02801331|t||||f
17178948|NCT01352546|t||||
17178949|NCT03253744|f||||f
17178950|NCT00946478|t||||
17178951|NCT00887653|f||||f
17178952|NCT05438888|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178953|NCT02761252|t||||
17178954|NCT04698187|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17178955|NCT03904043|t||||
17178956|NCT04362072|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178957|NCT01133522|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17178958|NCT00607815|t||||
17178959|NCT00381485|f||LTE60||t
17178960|NCT01206660|f||||f
17178961|NCT00126191|t||||f
17184364|NCT02096055|t||||f
17184365|NCT06281548|t||||
17133999|NCT03934684|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134000|NCT04996797|f||OTHER|All information concerning the product subsequently generated from this study (such as patent applications, formulae, manufacturing processes, basic scientific data, or formulation information supplied to the Investigator by the Sponsor and not previously published) is considered confidential by and shall remain the sole property of the Sponsor. The Investigator agrees not to use it for other purposes without the Sponsor's written consent.|t
17134001|NCT04091217|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134002|NCT05662332|f||GT60||t
17134003|NCT00100048|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134004|NCT03878485|t||||
17134005|NCT01624142|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134006|NCT01822561|t||||
17134007|NCT01696357|f||||f
17134008|NCT04826900|f||||f
17134009|NCT02597062|f||||f
17134010|NCT03372941|f||||f
17134011|NCT01126580|f||GT60||t
17139529|NCT03991468|f||||f
17139530|NCT01226472|f||GT60||t
17139531|NCT01425307|f||LTE60||t
17139532|NCT03573804|f||||f
17178962|NCT01898806|f||||f
17178963|NCT01648101|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178964|NCT00940225|f||||t
17178965|NCT02140372|t||||
17134012|NCT00686543|f||OTHER|The sponsor and investigator will publish/present study results together with other study sites, unless written permission is obtained. The investigator provides to the sponsor 45 days prior to submission for publication/presentation, copies of abstracts or manuscripts reporting any study results. The sponsor has the right to review/comment on the data analysis and presentation regarding proprietary information, accuracy and fair blance of the information, and compliance with FDA regulations.|t
17134013|NCT00803114|f||||f
17134014|NCT01708057|f||GT60||t
17134015|NCT00947349|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134016|NCT00538681|f||GT60||t
17134017|NCT01697345|f||||f
17134018|NCT00140855|f||||f
17134019|NCT01815957|f||||f
17134020|NCT00342355|f||||f
17134021|NCT03929250|f||||f
17134022|NCT05262764|t||||
17134023|NCT01392183|t||||
17134024|NCT03430310|f||||f
17134025|NCT02770807|f||||f
17134026|NCT01826214|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17134027|NCT02101437|f||||f
17134028|NCT02108457|t||||
17178966|NCT02469298|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17178967|NCT04249583|f||GT60||t
17178968|NCT03000439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17178969|NCT01308060|f||||t
17178970|NCT02954237|f||OTHER||t
17178971|NCT03292588|f||||f
17178972|NCT02151591|f||||f
17178973|NCT00869349|f||||f
17178974|NCT03633695|f||OTHER|The only disclosure restriction on the PI is that the PI must provide sponsor a manuscript of such submission(s) for review, comment and approval at least 90 days prior to a planned submission for publication or presentation and that sponsor is permitted to delay any publication or presentation in specific circumstances.|t
17178975|NCT02728050|t||||
17178976|NCT01354990|f||||f
17178977|NCT02853604|f||OTHER|The Investigator shall seek the Sponsor's written approval for study results publication which shall not be unreasonably withheld. Such publication by Institution and/or Investigator may be no earlier than after a cooperative publication has been published with Sponsor or 1 year from date of completion or termination of the Study \& only after review and comment by Sponsor. Institution agrees to provide Sponsor a copy of proposed publication at least 60 days prior to submission to a publisher.|t
17178978|NCT05275400|f||GT60||t
17178979|NCT06333613|f||||f
17178980|NCT04538261|f||||f
17134029|NCT00745030|f||||f
17134030|NCT00469079|t||||
17134031|NCT00942162|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134032|NCT02833311|f||||f
17134033|NCT03874234|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134034|NCT01623466|f||OTHER|All publications must be reviewed and approved by sponsor|t
17178981|NCT04251169|f||||f
17178982|NCT01903187|f||||f
17178983|NCT03648541|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17178984|NCT04623216|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17178985|NCT01651039|t||||
17178986|NCT02837328|f||||f
17178987|NCT04930965|t||||
17178988|NCT00134082|t||||
17178989|NCT02713347|t||||
17178990|NCT02197247|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17178991|NCT00961233|f||||f
17178992|NCT01529502|t||||
17178993|NCT02019693|f||||f
17178994|NCT05673889|t||||
17178995|NCT04353271|t||||
17178996|NCT02228460|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17184366|NCT01618838|f||||f
17184367|NCT00288587|f||||f
17184368|NCT00754845|t||||f
17184369|NCT00127673|f||||f
17184370|NCT00358735|f||||f
17178997|NCT01243892|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17178998|NCT00119106|f||||f
17178999|NCT03066804|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17179000|NCT02099708|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179001|NCT03282682|f||||f
17179002|NCT05466682|t||||
17179003|NCT01930123|f||||f
17179004|NCT04171050|t||||
17179005|NCT01447433|t||||
17179006|NCT00036270|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179007|NCT01578187|f||||f
17179008|NCT01964430|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179009|NCT02516163|f||OTHER|Discloser must give at least 40 days notice to Sponsor including a copy of the proposed publication. The Sponsor can then provide comments (which Discloser is not bound to follow), request delay of publication by no more than 120 days to allow for Sponsor to protect its intellectual property, or request that the Discloser remove certain proprietary or confidential information from the study (other than the results of the study).|t
17179010|NCT02801396|f||GT60||t
17179011|NCT02446483|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179012|NCT01658072|t||||
17179013|NCT03208244|f||||f
17179014|NCT03834441|f||||f
17179015|NCT02771093|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179016|NCT02051686|t||||
17179017|NCT00335478|f||||f
17179018|NCT00602797|t||||f
17179019|NCT03473977|t||||
17179020|NCT01996852|t||||
17179021|NCT00834171|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17179022|NCT01318993|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179023|NCT00361569|f||OTHER|The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.|t
17179024|NCT01558271|f||GT60||t
17179025|NCT01594762|f||OTHER|If no multi-site publication within 18 months of study completion, Site shall have right to publish subject to: 1) Prior to submitting/presenting, Site shall provide Sponsor a copy; Sponsor shall have 60 days to review/comment. 2) Site shall remove any Confidential Information prior to submitting/presenting the materials. 3) Site shall further delay publication/presentation for up to 120 days to allow Sponsor to protect its interests in any Sponsor Inventions described in any such materials.|t
17179026|NCT03547583|f||OTHER||t
17179027|NCT02657915|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17179028|NCT04147221|f||||f
17179029|NCT00595530|t||||f
17179030|NCT01235351|t||||
17179031|NCT01511315|f||||f
17179032|NCT01354977|t||||
17179033|NCT03003390|f||||f
17179034|NCT00307294|f||||f
17179035|NCT03576976|f||||f
17179036|NCT01664533|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179037|NCT00680862|t||||
17184371|NCT03176693|t||||
17184372|NCT02279641|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17184373|NCT00746954|t||||
17184374|NCT01763567|f||||f
17184375|NCT03082963|t||||
17184376|NCT04401579|f||LTE60||t
17184377|NCT01438411|f||||f
17184378|NCT01863680|f||OTHER|The study as a whole will be published prior to any individual investigator publications. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17184379|NCT00618514|f||LTE60||t
17184380|NCT02053350|f||||f
17134035|NCT02799381|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179038|NCT00290888|t||||
17179039|NCT00634166|f||OTHER|The Principal Investigator shall provide Sponsor with (i) a copy of the papers prepared for publication by him or her as soon as possible, but in any event not less than sixty (60) days prior to their submission to a scientific journal or other publication; or (ii) a reasonably detailed summary or abstract of any oral presentation not less than forty-five (45) days prior to their submission or presentation. Sponsor may comment and remove any confidential information as needed.|t
17179040|NCT02370160|t||||
17179041|NCT04487730|t||||
17179042|NCT01581931|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17179043|NCT02551757|f||||f
17179044|NCT02734940|t||||
17179045|NCT03291808|f||||f
17179046|NCT03875885|t||||
17179047|NCT04666051|t||||
17179048|NCT01651195|f||||f
17179049|NCT02417974|t||||
17179050|NCT01892293|f||LTE60||t
17179051|NCT04988646|f||||f
17179052|NCT03602482|f||||f
17179053|NCT02397278|f||||f
17179054|NCT02161731|f||GT60||t
17179055|NCT02381288|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179056|NCT01397084|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17179057|NCT02139228|f||OTHER|Other disclosure agreement: The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179058|NCT00618072|f||||f
17179059|NCT00592384|f||LTE60||t
17179060|NCT01468012|t||||f
17179061|NCT02380677|f||GT60||t
17179062|NCT04932096|t||||
17179063|NCT01089062|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179064|NCT00461045|f||||f
17179065|NCT00133952|f||GT60||t
17179066|NCT00314093|t||||
17179067|NCT01976338|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17179068|NCT00777608|f||||f
17179069|NCT04213079|t||||
17179070|NCT00528788|f||||f
17179071|NCT00844714|t||||
17179072|NCT03766581|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179073|NCT02732119|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184381|NCT00492349|t||||
17184382|NCT00272168|f||||f
17184383|NCT02367911|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review thirty days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17184384|NCT00902304|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184385|NCT01153633|f||||f
17134036|NCT00783289|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17134037|NCT03952130|f||GT60||t
17134038|NCT00506389|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the Sponsor, at least 6 weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17139533|NCT03399786|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17139534|NCT04852666|t||||
17179074|NCT00520936|f||GT60||t
17179075|NCT00964860|f||LTE60||t
17179076|NCT03716024|f||LTE60||t
17179077|NCT00867568|f||LTE60||t
17179078|NCT04343261|t||||
17179079|NCT02123121|f||||f
17179080|NCT00975650|f||||f
17179081|NCT02585960|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17179082|NCT03639935|t||||
17179083|NCT02683161|t||||f
17179084|NCT00003479|f||||f
17179085|NCT01061177|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179086|NCT00299104|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179087|NCT00587054|t||||f
17179088|NCT03680105|f||||f
17179089|NCT05873257|f||OTHER||t
17179090|NCT02059395|f||||f
17179091|NCT00044083|t||||
17179092|NCT01619423|f||||f
17179093|NCT02340975|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17179094|NCT04003012|t||||
17179095|NCT03675477|f||||f
17179096|NCT00790985|f||GT60||t
17179097|NCT00601458|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179098|NCT01288235|t||||
17179099|NCT01697566|t||||
17179100|NCT01709162|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179101|NCT01805154|f||LTE60||t
17179102|NCT02856035|t||||
17179103|NCT02405780|f||OTHER|Investigator and Sponsor will discuss the preparation of a manuscript for publication in a peer reviewed journal or an abstract for presentation. Either party may undertake the task but both must agree to the strategy before work is started. Each party will allow the other 30 days to comment before any results are submitted for publication or presentation. Authorship should reflect work done by the Investigator an Sponsor, in accordance with recognized principles of scientific collaboration.|t
17179104|NCT01654536|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17179105|NCT01587001|f||||f
17179106|NCT00074152|f||||f
17184386|NCT00384085|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17134039|NCT01217749|f||||f
17184387|NCT03846024|f||||f
17184388|NCT00352365|f||LTE60||t
17134040|NCT02523586|f||||f
17184389|NCT01230593|f||||f
17184390|NCT00987467|f||||f
17184391|NCT02646423|t||||
17134041|NCT03033108|f||||f
17134042|NCT00810797|t||||
17134043|NCT01503021|f||LTE60||t
17134044|NCT01591005|t||||
17139535|NCT03050307|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17134045|NCT01075087|t||||
17134046|NCT01602731|t||||f
17134047|NCT00283387|t||||f
17134048|NCT01931865|t||||f
17134049|NCT02176486|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17179107|NCT02197130|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139536|NCT01998906|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139537|NCT02996110|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139538|NCT01077193|f||OTHER|The PIs agreed that the first publication should be made in conjunction with the presentation of a joint, multicenter publication with the PIs from all sites contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, termination of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could publish the results from their individual sites.|t
17139539|NCT00911326|f||OTHER|The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.|t
17139540|NCT04283773|t||||
17139541|NCT06048809|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139542|NCT04193605|f||||f
17139543|NCT01250899|f||||f
17139544|NCT01847560|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139545|NCT00673816|t||||f
17139546|NCT05129124|f||||t
17139547|NCT02869451|t||||
17139548|NCT00554853|f||LTE60||t
17139549|NCT02128919|f||||f
17139550|NCT02148952|f||||f
17139551|NCT01600105|t||||
17139552|NCT04007367|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17139553|NCT01764022|f||||f
17139554|NCT00626340|f||||f
17139555|NCT01899768|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139556|NCT04098016|t||||
17139557|NCT04043416|f||||f
17139558|NCT02203916|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17139559|NCT00414973|f||GT60||t
17139560|NCT00865202|f||OTHER|The manuscript has been accepted by the Journal of the American Geriatrics Society for publication.|t
17139561|NCT03531710|f||OTHER|Site PIs must jointly publish results, unless permission is granted by Sponsor. If a joint publication is not done within 12 months after trial completion and database lock, then the site may publish its own results; provided that, a) Sponsor has 45 business days to review the proposed publication; b) the PI must delete any confidential information identified by Sponsor; and c) the PI must delay disclosure for 1 year if a patent application is filed by Sponsor.|t
17139562|NCT01925014|f||||f
17139563|NCT03813199|f||||f
17179108|NCT01473836|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179109|NCT03364023|f||||f
17179110|NCT02356575|t||||
17184392|NCT02807948|f||LTE60||t
17184393|NCT02624804|t||||
17134050|NCT03584009|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134051|NCT00446030|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 60 days in advance of any submission for publication. The Sponsor may request for the publication to be delayed for a limited time, not to exceed 90 days to preserve its proprietary rights.|t
17134052|NCT02886715|f||OTHER|The terms and conditions of Fougera' agreements with its investigators may vary. However, Fougera does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17134053|NCT00222105|t||||
17179111|NCT00105469|f||OTHER|Institution and Principal Investigator shall not publish, present or use any data or results arising out of the performance of this study for their own instruction, research or publication without the prior express written consent of Sponsor.|t
17134054|NCT00608140|f||||f
17134055|NCT03812510|f||||f
17139564|NCT03696576|t||||
17139565|NCT01922986|f||||f
17179112|NCT03444961|t||||
17179113|NCT00599924|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179114|NCT02601469|f||||t
17179115|NCT01806298|f||||f
17179116|NCT03808545|t||||f
17179117|NCT03229278|t||||
17179118|NCT00980057|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17179119|NCT04980040|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179120|NCT02820753|f||||f
17179121|NCT02471430|f||||f
17179122|NCT00062374|f||LTE60||t
17179123|NCT03555591|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179124|NCT00840450|t||||
17179125|NCT00617123|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17179126|NCT02170298|t||||
17179127|NCT02128113|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17179128|NCT03739593|f||||f
17179129|NCT00003499|f||||f
17179130|NCT03822078|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17179131|NCT01854710|f||LTE60||t
17184394|NCT01206738|f||||f
17184395|NCT01227889|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184396|NCT01301963|t||||
17184397|NCT03073603|f||||f
17184398|NCT02312739|f||||f
17184399|NCT02553330|f||OTHER|Clinical Study Agreement|t
17184400|NCT03750487|f||||f
17184401|NCT03551938|f||||f
17184402|NCT00353275|f||||f
17184403|NCT02079805|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17134056|NCT01172067|f||||t
17134057|NCT01120626|f||||f
17134058|NCT03348514|f||||t
17139566|NCT00850135|f||||f
17139567|NCT00338806|f||||f
17139568|NCT00438490|t||||
17134059|NCT02700529|f||||t
17134060|NCT00551707|f||LTE60||t
17134061|NCT03502746|f||||f
17139569|NCT00744991|f||GT60||t
17139570|NCT01501162|f||||f
17139571|NCT02515851|t||||
17139572|NCT01487863|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17139573|NCT03198728|f||||t
17134062|NCT01073943|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17179132|NCT00370032|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179133|NCT00823095|f||||f
17179134|NCT01525563|f||OTHER||t
17179135|NCT03685968|f||||f
17179136|NCT01844518|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179137|NCT02557555|t||||
17179138|NCT04584645|f||||f
17179139|NCT00390468|f||LTE60||t
17179140|NCT00830362|t||||
17179141|NCT03129100|f||GT60||t
17179142|NCT03845985|t||||f
17179143|NCT02701400|f||||f
17179144|NCT03334539|f||||f
17179145|NCT00363883|f||LTE60||t
17179146|NCT03736447|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17179147|NCT00968201|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179148|NCT02619175|t||||
17179149|NCT04974697|f||GT60||t
17179150|NCT01434030|t||||
17179151|NCT03706456|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179152|NCT02784431|f||||f
17179153|NCT02644135|f||||f
17179154|NCT03302234|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17179155|NCT02795832|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17179156|NCT04523220|f||OTHER|It's typically 30 days to review, and only if there is some need to file a patent application based on that review would there be an additional 60 days.|t
17179157|NCT00571948|f||||f
17179158|NCT04112784|t||||
17179159|NCT00221403|f||||f
17179160|NCT02010775|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179161|NCT02389361|f||||f
17179162|NCT00256750|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179163|NCT02030041|t||||
17179164|NCT02989714|t||||
17179165|NCT01197560|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17179166|NCT02006719|f||||t
17179167|NCT04659161|f||GT60||t
17179168|NCT01929343|f||||f
17179169|NCT00901316|f||||f
17179170|NCT02320669|f||||f
17179171|NCT00565045|f||||f
17179172|NCT01600638|f||||f
17179173|NCT01737697|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17179174|NCT00858130|t||||
17134063|NCT00824421|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134064|NCT03527043|t||||
17134065|NCT04871815|f||||f
17134066|NCT00927485|f||||f
17184404|NCT02347761|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17184405|NCT03879798|t||||
17184406|NCT03625570|f||||f
17184407|NCT03370887|f||LTE60||t
17184408|NCT02807597|t||||
17184409|NCT01040130|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17184410|NCT00283504|f||||f
17184411|NCT01761747|f||||f
17184412|NCT02937545|f||||f
17184413|NCT02007577|t||||
17184414|NCT02504294|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134067|NCT01309737|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134068|NCT00256295|t||||
17134069|NCT04109599|f||||f
17134070|NCT01731002|f||||f
17134071|NCT03040154|f||||f
17179175|NCT03338998|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179176|NCT03288129|f||||f
17179177|NCT03129178|t||||
17179178|NCT02579239|f||OTHER|"Institutions and investigators agreed that no submission for publication or public disclosure will be made until after publication of the multi-center trial results by the sponsor, except in the following conditions:~* notification by sponsor that such multi-center trial submission is no longer planned;~* after the eighteen (18) month anniversary of the completion, abandonment or termination of such multi-center trial."|t
17179179|NCT04404361|f||||f
17179180|NCT00558558|t||||f
17179181|NCT02144012|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179182|NCT02915016|f||||f
17179183|NCT02885012|t||||
17179184|NCT00651794|t||||
17179185|NCT01874132|t||||f
17184415|NCT02252211|f||LTE60||t
17184416|NCT01985126|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17184417|NCT00968669|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17184418|NCT02255175|t||||f
17184419|NCT00144339|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184420|NCT01109992|f||||f
17184421|NCT02338362|f||||f
17184422|NCT00690755|t||||f
17184423|NCT00784043|f||LTE60||t
17184424|NCT03538626|t||||
17184425|NCT01156701|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184426|NCT01434602|f||||f
17184427|NCT01835626|t||||f
17184428|NCT01108081|t||||
17184429|NCT00648908|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17184430|NCT00690521|t||||
17184431|NCT03819660|f||||f
17134072|NCT00628355|f||||f
17134073|NCT03542682|t||||
17134074|NCT00765765|t||||
17179186|NCT01408485|f||OTHER||t
17179187|NCT01315678|f||OTHER|"Per the signed Investigator Agreement in the study protocol and protocol amendments, the PI agreed not to originate or use the name of Insmed Incorporated, or study drug code in any publicity, news release, or other public announcement, written or oral, whether to the public, press, or otherwise, relating to this protocol, to any amendment to the protocol, or to the performance of this protocol, without the prior written consent of Insmed Incorporated."|t
17184432|NCT03421691|f||||f
17184433|NCT01286259|f||||f
17184434|NCT00780962|f||||f
17184435|NCT00499889|t||||f
17184436|NCT02908269|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17184437|NCT00345397|t||||f
17184438|NCT01422070|f||||f
17184439|NCT03351049|f||||f
17184440|NCT02877485|t||||
17184441|NCT01700816|t||||f
17184442|NCT03832192|t||||
17134075|NCT03476239|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134076|NCT02871479|f||LTE60||t
17134077|NCT01446809|t||||
17134078|NCT00785577|f||GT60||t
17134079|NCT01331161|f||||f
17134080|NCT01212445|f||OTHER|Schering-Plough HealthCare Products, Inc. reserves all publication and presentation rights.|t
17134081|NCT01682044|t||||
17134082|NCT01659151|t||||
17134083|NCT03665155|t||||
17134084|NCT00934895|t||||
17134085|NCT01695369|f||LTE60||t
17134086|NCT01056107|t||||f
17134087|NCT01614457|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17134088|NCT00886821|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134089|NCT00914628|f||||t
17179188|NCT01532414|f||OTHER|Investigator shall submit a copy of proposed publication. Sponsor shall have sixty (60) days (or such longer period as Sponsor shall determine is necessary) to review the proposed publication and, upon request, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication.|t
17134090|NCT03404960|t||||
17134091|NCT03311126|t||||
17134092|NCT00374556|t||||
17134093|NCT00473694|f||OTHER|All publications including scientific papers, presentations, or other communication concerning the clinical trial must first be submitted to the Sponsor at least six weeks ahead of estimated publication or presentation, for written consent. In order to protect proprietary interests, the Sponsor shall have the right to make consent conditional upon proper representation of the interpretation of both the Sponsor and the investigator(s) in the discussion of the data in such communications.|t
17134094|NCT03062917|t||||
17139574|NCT01836029|f||OTHER|PI should not publish the site's results prior to the sponsor's 1st multi-site publication. PI can publish if no multi-site publication within 18 months after the study has been completed or terminated, provided that the site's results are statistically significant and consistent with the multi-site publication. Prior to submitting or presenting, PI should provide sponsor to review and comment. If requested by sponsor, PI should delay publication/presentation for up to 120 days.|t
17139575|NCT04051944|f||GT60||t
17139576|NCT02139280|f||||f
17139577|NCT02044367|t||||
17139578|NCT00491751|t||||f
17139579|NCT00427791|t||||
17179189|NCT00187486|t||||
17179190|NCT05426902|t||||
17184443|NCT03738150|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication.|t
17134095|NCT00673855|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study.|t
17134096|NCT03285529|t||||
17134097|NCT01670201|f||LTE60||t
17134098|NCT01587963|t||||f
17184444|NCT03762135|t||||
17184445|NCT01915563|t||||f
17184446|NCT01898195|f||||f
17184447|NCT02259608|t||||
17134099|NCT04101890|f||||f
17134100|NCT02189382|f||OTHER|Written consent from sponsor.|t
17134101|NCT01821963|t||||
17134102|NCT03368859|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17134103|NCT02698410|f||OTHER|Results are owned by the Sponsor and data communication collected in a center by the investigator is allowed only after publication of aggregate results of the study by the Sponsor. If an investigator intends to communicate data, the Sponsor must be informed and should review the manuscript/publication before its submission. The investigator should accept any Sponsor comments provided they are not in contrast to the reliability of data, with rights, with the safety and well-being of patients.|t
17134104|NCT01713348|f||GT60||t
17139580|NCT01395966|f||OTHER|Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.|t
17139581|NCT01425853|f||||f
17139582|NCT00422903|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139583|NCT00801138|t||||
17139584|NCT01302691|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17139585|NCT00441480|f||||f
17184448|NCT02720484|t||||
17184449|NCT01812044|t||||
17184450|NCT05070897|t||||
17184451|NCT05039268|t||||
17134105|NCT01896232|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134106|NCT04425850|f||||f
17134107|NCT00852644|t||||
17134108|NCT00686205|f||OTHER|The PI must provide a copy of any proposed publication or presentation at least 30 days prior to submission for sponsor's review/approval. The PI must incorporate changes as the sponsor requires in order to protect the sponsor's proprietary rights and interests. The sponsor may require the PI to include acknowledgement of the sponsor's role in the study. The PI may be requested to delay publication/presentation an extra 60 days to enable sponsor to secure patent or other proprietary protection.|t
17134109|NCT00265941|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17134110|NCT01583647|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17134111|NCT03816995|t||||
17134112|NCT03109951|f||||f
17134113|NCT05882890|t||||
17134114|NCT03370757|f||||f
17134115|NCT00613314|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17134116|NCT00719810|f||OTHER|The sponsor retains control of all publication rights.|t
17134117|NCT03090191|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134118|NCT02432807|f||||f
17134119|NCT01845025|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17134120|NCT03976401|f||||f
17134121|NCT00089128|t||||
17134122|NCT01324830|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17134123|NCT00942409|t||||
17134124|NCT03617926|f||||f
17134125|NCT00817414|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134126|NCT02966314|t||||
17134127|NCT01012661|f||OTHER|Sponsor reserves right to review/comment on any manuscript for publication/presentation presenting data from the trial. No manuscript may be submitted for publication without prior review. Investigator agrees to accommodate reasonable requests to protect propriety rights/interests. Investigator must ensure accuracy of results. Investigator shall grant Sponsor right to reproduce/translate/use all copyrighted material from study publications.|t
17134128|NCT01242111|f||OTHER|PI cannot publish any data prior to multi-centre publication. If publication related to sub-sets of data it shall make reference to the relevant multi-centre publication. PI agrees to submit material to Sponsor for review at least 60 days prior to publication and incorporate all reasonable comments. During review, Sponsor may request that publication be delayed for up to 6 months from date of first submission to Sponsor in order for Sponsor to take steps to protect its proprietary information.|t
17134129|NCT04586712|t||||
17134130|NCT01021007|f||GT60||t
17134131|NCT02945657|f||OTHER|Since the study is part of a multi-center study and an independent publication that will incorporate multi-center trial data is anticipated, Institution agrees not to independently publish its results of the study if such publication is published within 12 months from completion of the study. The Institution and Investigator agree not to publish the results of the study without prior written consent of the Sponsor, which consent may be withheld by Sponsor for any or no reason.|t
17134132|NCT00087438|f||||f
17134133|NCT00466505|t||||
17134134|NCT00327392|f||||f
17179191|NCT00578812|f||OTHER|Investigators and Institutions will allow NuVasive to review and comment on any presentation or publication of any study information prior to its release to ensure such documents are accurate and do not disclose any trade secret or other confidential information. No information may be disclosed regarding the study without NuVasive's written permission.|t
17134135|NCT02120417|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17134136|NCT02604264|f||||f
17134137|NCT02533089|f||||f
17134138|NCT00855439|f||LTE60||t
17134139|NCT00477087|t||||
17134140|NCT00613626|f||||f
17134141|NCT03212261|f||||f
17179192|NCT00617773|f||LTE60||t
17179193|NCT02113592|f||||f
17179194|NCT03217175|t||||
17179195|NCT01896544|t||||f
17179196|NCT00036738|t||||
17179197|NCT02552199|t||||
17179198|NCT03487276|f||||f
17179199|NCT05035550|t||||
17179200|NCT01751867|f||GT60||t
17134142|NCT01076179|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17134143|NCT00457639|t||||
17134144|NCT04885257|t||||
17134145|NCT01200433|t||||
17134146|NCT04067661|f||||f
17134147|NCT00853632|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 30 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 60-day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17134148|NCT01672892|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17134149|NCT01385696|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17134150|NCT00597558|t||||f
17134151|NCT01756976|f||LTE60||t
17134152|NCT00918723|f||||f
17134153|NCT02579603|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17134154|NCT01006356|f||||f
17134155|NCT00430040|t||||
17134156|NCT02981472|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17134157|NCT01756157|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17134158|NCT04191668|f||||f
17134159|NCT01498991|t||||
17134160|NCT02907944|t||||
17134161|NCT02559505|t||||
17134162|NCT03715465|t||||
17139586|NCT00441012|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139587|NCT02201472|t||||
17139588|NCT03674541|t||||
17139589|NCT00262314|f||OTHER||t
17139590|NCT05104749|t||||
17139591|NCT01300767|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17139592|NCT00117572|t||||
17139593|NCT03256136|f||||f
17139594|NCT04973085|f||||f
17139595|NCT00887068|t||||
17139596|NCT03190967|f||||f
17139597|NCT04195750|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17139598|NCT03782376|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17139599|NCT00952419|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17139600|NCT04507360|f||||f
17134163|NCT01495988|f||||f
17134164|NCT01584024|t||||f
17139601|NCT00636155|t||||f
17139602|NCT05643170|f||GT60||t
17139603|NCT01432756|t||||
17139604|NCT01357720|f||OTHER|Any material for public dissemination will be submitted to the Sponsor for review at least ninety (90) days prior to submission for publication, public dissemination, or review by a publication committee|t
17139605|NCT00438191|t||||
17139606|NCT00365872|t||||
17139607|NCT01004159|t||||
17139608|NCT02973997|f||||f
17139609|NCT01431521|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17139610|NCT00444951|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17139611|NCT03637959|t||||
17139612|NCT00366444|f||OTHER||t
17134165|NCT01217606|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17134166|NCT02677779|f||||f
17134167|NCT00753636|f||||f
17134168|NCT00702624|f||OTHER|The Sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17134169|NCT01568944|f||||f
17134170|NCT00893789|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17134171|NCT04723537|f||OTHER|There are disclosure agreements between the Sponsor and each of the participating clinical sites and PI that slightly differ.|t
17134172|NCT05408858|f||||f
17134173|NCT04419506|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134174|NCT02513940|f||||f
17134175|NCT01973283|t||||
17134176|NCT03537664|f||||f
17134177|NCT00097539|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134178|NCT01552876|f||GT60||t
17134179|NCT03941548|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17134180|NCT02081963|t||||
17134181|NCT03717922|t||||
17134182|NCT02015819|t||||
17134183|NCT01049776|t||||
17134184|NCT00811252|f||OTHER|The main publication has to be published before any sub-publications. H. Lundbeck A/S follows the Vancouver declaration with respect to authorship.|t
17134185|NCT01486264|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17139613|NCT05724069|f||LTE60||t
17139614|NCT04829734|f||||f
17139615|NCT03552289|f||||f
17139616|NCT01320033|f||||t
17139617|NCT00963469|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139618|NCT00782756|t||||
17139619|NCT03979495|f||||f
17179201|NCT01806545|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17179202|NCT01396148|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179203|NCT02536040|f||||f
17139620|NCT04403802|t||||
17139621|NCT01938391|f||LTE60||t
17139622|NCT00533780|t||||
17179204|NCT00884312|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17179205|NCT00224042|f||LTE60||t
17179206|NCT03052725|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17179207|NCT03809117|f||||f
17179208|NCT01448486|f||||f
17179209|NCT04028700|t||||
17179210|NCT02548650|t||||
17179211|NCT01539538|f||OTHER|prior review and approval required|t
17179212|NCT01909674|t||||
17179213|NCT00847379|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17134186|NCT00813748|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134187|NCT00504257|t||||
17134188|NCT00716443|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17134189|NCT00759577|f||||f
17134190|NCT04249882|f||||f
17134191|NCT02317510|f||||f
17134192|NCT01667848|f||||f
17134193|NCT03932240|t||||
17134194|NCT00594399|f||||f
17134195|NCT03953118|t||||f
17134196|NCT01119040|f||||f
17134197|NCT03124069|f||||f
17134198|NCT00424398|f||OTHER|Agreement is between contract research organization and third parties on behalf of ISTA Pharmaceuticals, Inc.|t
17134199|NCT05480514|f||GT60||t
17134200|NCT00213239|t||||f
17134201|NCT00986349|f||||f
17134202|NCT02299934|t||||
17179214|NCT02969369|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17179215|NCT00521014|t||||
17179216|NCT02794883|t||||
17179217|NCT01744574|f||||f
17179218|NCT05201703|f||LTE60||t
17134203|NCT02722044|f||||f
17134204|NCT02117687|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17134205|NCT02656472|t||||
17134206|NCT01491958|t||||f
17134207|NCT03551028|t||||
17134208|NCT03528681|f||||f
17134209|NCT01195025|t||||
17134210|NCT00621023|t||||f
17134211|NCT01712360|f||||f
17134212|NCT02123329|f||||f
17134213|NCT04430348|f||OTHER|Other disclosure agreement, Non-disclosure and Clinical Trial Agreement|t
17134214|NCT04902885|f||||f
17179219|NCT00393029|f||||f
17179220|NCT03715530|t||||
17179221|NCT01072331|f||OTHER||t
17179222|NCT00211510|f||LTE60||t
17179223|NCT01362205|f||||f
17179224|NCT01372462|f||||f
17179225|NCT03648983|t||||
17179226|NCT01269463|f||OTHER|PI is restricted from using, disclosing, presenting, or publishing trial information without the prior written consent from the Sponsor|t
17179227|NCT02288897|f||||f
17179228|NCT02862171|f||||f
17179229|NCT01125605|t||||
17179230|NCT02549937|f||||t
17179231|NCT00662012|f||||f
17179232|NCT05853185|f||||f
17179233|NCT01893632|t||||
17179234|NCT01949506|t||||
17179235|NCT04936256|t||||
17134215|NCT04331899|t||||
17134216|NCT00101361|t||||
17134217|NCT02424539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134218|NCT01479725|f||||f
17134219|NCT03102736|t||||
17134220|NCT00290472|f||LTE60||t
17134221|NCT00987415|f||||f
17134222|NCT01697215|t||||
17134223|NCT01829048|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134224|NCT02904226|f||OTHER|"Any publication (pub.) can be restricted until the 1st to occur of (a) pub. of the clinical trial results, or (b) 18 mo's after the Primary Completion Date. Pub. rights depend on PI conducting the study in compliance with the Protocol, that the pub. is made in a recognized journal or conference, and makes use of all study data. The Sponsor can require removal of Sponsor's confidential information from any pub. and can defer pub. for up to an add'l 60 days to file a related patent application."|t
17134225|NCT00728416|f||GT60||t
17134226|NCT02389881|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17134227|NCT01244737|f||||f
17134228|NCT01748227|t||||
17134229|NCT01660815|f||LTE60||t
17179236|NCT05475236|f||||f
17179237|NCT02136810|f||||f
17179238|NCT05425745|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17179239|NCT02342327|f||||f
17179240|NCT05255068|f||||f
17179241|NCT00872534|f||OTHER|Standard Confidentiality Agreement|t
17179242|NCT00907777|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134230|NCT00356915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134231|NCT01225354|f||||f
17134232|NCT00509106|f||||f
17134233|NCT02318602|f||||f
17134234|NCT00693706|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134235|NCT00488631|f||OTHER|12 months after study ends, sponsor will be provided with a copy of the materials at least 45 days prior to submission, with details of proposed date, journal or conference name of publication \& it will have 30 days post receipt to send a written request that the publication be delayed on the basis it exposes intellectual property that requires propriety protection but it will be only for 60 days after which investigator will be free to publish. The participation of sponsor will be acknowledged.|t
17134236|NCT01873950|f||||f
17139623|NCT01536418|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139624|NCT02234050|f||||f
17139625|NCT02365506|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17139626|NCT00592176|f||||f
17179243|NCT02674529|t||||t
17179244|NCT02891850|f||LTE60||t
17179245|NCT02129725|t||||
17179246|NCT00331682|f||LTE60||t
17179247|NCT00573469|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17179248|NCT03761277|f||OTHER|No manuscripts, abstracts, or case reports that jeopardize the primary publication will be submitted prior to the submission of the primary publication. It is required that all publications undergo review at Medtronic for confidential information and technical accuracy prior to publication.|t
17179249|NCT00004978|f||||f
17179250|NCT01508650|t||||
17179251|NCT02064894|f||||f
17179252|NCT02864498|f||||t
17179253|NCT01812174|f||OTHER|All information which I hereafter obtain from ON-X LIFE TECHNOLOGIES … about or relating to the prosthesis … which is the subject of this study and all information which I have … concerning this study is considered by ON-X to be proprietary and confidential to ON-X .I … will not use such confidential information, or release, reveal or disclose such confidential information to anyone without the written consent of ON-X or prior public disclosure by ON-X.|t
17179254|NCT04950998|f||||f
17179255|NCT00977860|t||||
17179256|NCT00851747|t||||
17179257|NCT01051323|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179258|NCT01537393|f||||f
17179259|NCT04518293|f||||f
17179260|NCT01369758|t||||f
17179261|NCT05451225|t||||f
17179262|NCT01233258|f||GT60||t
17179263|NCT01637272|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17179264|NCT01496612|t||||
17179265|NCT01146418|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.|t
17179266|NCT03789474|t||||
17179267|NCT02457260|t||||f
17179268|NCT03889444|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179269|NCT03708328|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179270|NCT02605824|f||||f
17179271|NCT00496808|t||||
17184452|NCT01617629|f||OTHER|For study centers in Australia, no publication of the study results may be made until publication of the results of the study from all centers or until 2 years after study completion, whichever is sooner. For study centers in the USA, no submission for publication or public disclosure of the results by will be made until the results from all centers have been received and analyzed by the sponsor, or the multi-center study has been terminated or abandoned at all centers.|t
17134237|NCT01697332|t||||f
17134238|NCT01193335|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134239|NCT01733329|t||||f
17134240|NCT05614011|f||||f
17184453|NCT01337245|t||||
17134241|NCT00730236|f||OTHER|The CTAs generally envision a multisite publication, with the PI's right to publish individually if the pooled publication does not occur within 12 months of study completion. Sponsor has a 45 to 60 day review/approval period to request deletion of confidential information or to request limited deferral to protect its proprietary technology. In one case, the publication provision is more general, specifying that the Sponsor and clinical site will agree on the manner/terms of publication.|t
17134242|NCT02039947|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17134243|NCT01078753|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention|t
17134244|NCT00462423|f||LTE60||t
17134245|NCT01772134|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134246|NCT02500550|f||||f
17134247|NCT01740362|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134248|NCT03655444|t||||
17134249|NCT01023789|f||LTE60||t
17134250|NCT00095563|f||LTE60||t
17134251|NCT02814721|f||||f
17134252|NCT02034123|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134253|NCT00246259|f||LTE60||t
17134254|NCT06105138|t||||
17134255|NCT04233424|f||||f
17134256|NCT03133767|t||||
17134257|NCT03517436|f||||f
17134258|NCT01175369|f||||f
17179272|NCT00779285|f||OTHER|"Principal investigator agrees not to publish/publicly present any~interim results without prior Sponsor written consent and agrees to provide 30 days written notice prior to submission to permit review of abstracts/manuscripts which report any results. Sponsor has the right to review/comment/edit to ensure confidentiality, information accuracy, and that the presentation is fairly balanced. If the parties disagree, the investigator agrees to meet with Sponsor to discuss/resolve any disagreement."|t
17179273|NCT02695329|f||||f
17179274|NCT03936985|f||||f
17179275|NCT01032837|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179276|NCT00843024|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179277|NCT03123913|t||||f
17179278|NCT02439138|f||||f
17179279|NCT02517567|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17179280|NCT00006237|f||||f
17179281|NCT00585247|t||||f
17179282|NCT01846416|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179283|NCT01487200|f||OTHER||t
17179284|NCT02837783|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17179285|NCT01962896|t||||
17179286|NCT02216591|t||||f
17179287|NCT02207244|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17179288|NCT00039130|f||OTHER|Must obtain prior Sponsor approval|t
17179289|NCT01866930|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179290|NCT00750815|t||||
17179291|NCT00279305|f||||f
17184454|NCT01663636|f||||f
17184455|NCT03832946|f||OTHER|The Investigators must agree to maintain the confidentiality of the study at all times and must not reveal any information relating to the study without express permission from the study Sponsor.|t
17179292|NCT00456014|f||||f
17179293|NCT03930797|t||||
17179294|NCT00701675|t||||
17179295|NCT00317356|f||||f
17179296|NCT02154243|t||||
17179297|NCT00176228|t||||f
17179298|NCT04212650|f||||f
17179299|NCT03919799|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17179300|NCT05405309|t||||
17179301|NCT05284656|t||||
17179302|NCT03734055|f||||f
17179303|NCT02255604|f||||f
17179304|NCT00630396|f||||f
17179305|NCT00279591|t||||
17179306|NCT04617509|f||OTHER|Any confidential information relating to the IMP or the study, including any data and results from the study, will be the exclusive property of the Sponsor. The Investigator and any other persons involved in the study are responsible for protecting the confidentiality of this proprietary information belonging to the Sponsor. The results from this study may be submitted for publication at the discretion of the Sponsor.|t
17179307|NCT00790023|f||OTHER||t
17179308|NCT01338792|t||||
17179309|NCT01044862|f||||f
17179310|NCT01652703|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17179311|NCT02155608|t||||
17179312|NCT04532164|f||OTHER|No information based on the conduct of the study (incl. protocol, data resulting from the study, or the fact that the study was being conducted) will be released without prior written consent of the sponsor unless the requirement is superseded by State or Federal law.|t
17179313|NCT02599129|t||||
17179314|NCT02515058|f||||f
17179315|NCT03808493|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17179316|NCT00846430|t||||
17179317|NCT01029795|f||LTE60||t
17179318|NCT03684811|f||OTHER|Principle investigators are required to ensure Forma has at least 60 days time for review and to provide input or request modifications where pertinent.|t
17179319|NCT00429273|f||||f
17179320|NCT01438957|f||OTHER|If an investigator publishes any results of this study, a pre-publication manuscript shall be provided the sponsor for review at least 60 days prior to the submission of the manuscript to the publisher.|t
17179321|NCT00144963|f||LTE60||t
17179322|NCT02495168|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17179323|NCT00727025|f||||f
17179324|NCT02269241|f||||f
17179325|NCT02270957|f||||f
17179326|NCT00859053|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179327|NCT00489541|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17179328|NCT01898611|f||||f
17179329|NCT02221947|f||OTHER|PI cannot disclose trial results without permission from sponsor.|t
17179330|NCT04390191|f||||f
17179331|NCT01774604|t||||
17179332|NCT01312272|t||||
17179333|NCT03978832|f||OTHER|The Principal Investigator and Institution may have access to the Case Report Forms resulting solely from their participation in the study for purely scientific or educational purposes, but unless previously explicitly permitted in writing by the Sponsor, Principal Investigator and Institution may not use it for any publication, presentation, disclosure, or commercial purposes.|t
17179334|NCT01727297|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and participating institutions will provide any publication of study data generated by the Investigator and/or participating institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17179335|NCT02042183|f||OTHER||t
17179336|NCT01192516|t||||
17179337|NCT01256008|t||||
17179338|NCT02244606|f||||f
17179339|NCT02256189|t||||
17179340|NCT02248103|f||||f
17179341|NCT00378378|f||LTE60||t
17179342|NCT00407797|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179343|NCT00553644|f||LTE60||t
17184456|NCT00136955|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17184457|NCT02744534|t||||
17134259|NCT02698189|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17134260|NCT02240706|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134261|NCT03301857|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134262|NCT00816036|t||||
17134263|NCT00843986|t||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17134264|NCT01909492|t||||
17134265|NCT01901328|f||OTHER||t
17134266|NCT03232073|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17134267|NCT00955110|f||OTHER|Any analysis and/or publication of any data generated or arising from the study is not permitted without the prior written consent of Endo Pharmaceuticals Inc.|t
17134268|NCT00450463|f||||f
17134269|NCT04893265|t||||
17134270|NCT00573131|f||GT60||t
17134271|NCT01251575|t||||
17134272|NCT02024464|f||OTHER|PI agrees that they shall not, without the Sponsor's prior written consent, independently publish, publicly disclose, present or discuss any results of or information pertaining to PI's activities conducted under this Agreement; unless the multi-center manuscript is not submitted for publication within one (1) year after completion of the trial.|t
17134273|NCT03818815|f||||f
17134274|NCT03618641|t||||
17134275|NCT02158533|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17134276|NCT02037919|f||||f
17179344|NCT03782792|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179345|NCT04866225|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179346|NCT00814164|t||||
17179347|NCT02321800|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17179348|NCT00982878|t||||
17179349|NCT03722966|t||||f
17179350|NCT01746745|f||GT60||t
17179351|NCT03132220|t||||
17179352|NCT01169493|f||||f
17179353|NCT05228132|f||||f
17179354|NCT01336764|f||||f
17179355|NCT05374434|t||||
17179356|NCT03284398|f||||t
17179357|NCT05883449|f||OTHER|The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication|t
17184458|NCT00773968|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184459|NCT04579757|f||||t
17184460|NCT00071487|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179358|NCT01044771|f||||f
17179359|NCT01906008|t||||
17184461|NCT03725982|f||||f
17184462|NCT01262651|f||GT60||t
17184463|NCT03165526|f||OTHER||t
17184464|NCT04743908|f||||f
17184465|NCT04969783|t||||
17134277|NCT01475955|f||OTHER|The first publication of results from multi-center trial will be made by the Sponsor. If publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 60 days before publication so that sponsor can review the publication for confidential information.|t
17134278|NCT02872103|f||||f
17134279|NCT00756002|f||OTHER|The sponsor can review results communications prior to public release; such communications can be embargoed for a period up to 150 days to permit actions necessary to preserve sponsor's intellectual property. Sponsor can request changes to the results communication only for the purpose of removing non study related information that is proprietary and confidential to sponsor. Sponsor can require delay of a results communication until the study has been completed at all participating sites.|t
17134280|NCT03767738|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17134281|NCT02417415|t||||
17134282|NCT03047005|t||||f
17134283|NCT04899271|f||||f
17134284|NCT01929083|t||||
17179360|NCT00730132|f||OTHER|A disclosure agreement restricts the rights on publications within 5 years after the document is signed off. The Clinical Trial Agreement restricts the rights on publication within 5 years after the trial completion.|t
17179361|NCT01626391|f||GT60||t
17179362|NCT02220205|f||||f
17179363|NCT02227758|f||LTE60||t
17179364|NCT00518986|f||GT60||t
17179365|NCT02088047|t||||
17179366|NCT03647033|f||||f
17179367|NCT04171531|f||||f
17179368|NCT04862585|t||||
17179369|NCT03366337|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17179370|NCT05229406|t||||
17179371|NCT00459953|f||||f
17179372|NCT00496470|f||OTHER|Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.|t
17179373|NCT01257087|t||||
17179374|NCT03844646|t||||
17179375|NCT00621153|f||LTE60||t
17179376|NCT00753415|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17179377|NCT04419714|f||||f
17179378|NCT05231954|f||||f
17179379|NCT05947643|t||||
17179380|NCT04023526|f||GT60||t
17179381|NCT03631472|f||||f
17134285|NCT01315574|f||||f
17134286|NCT02233842|f||||f
17134287|NCT01057277|f||||f
17134288|NCT03981029|t||||f
17134289|NCT02586805|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17134290|NCT03014648|t||||
17134291|NCT00749606|f||||f
17179382|NCT02470234|f||||f
17179383|NCT00540514|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to their submission; Celgene shall complete its review within 60 days after receipt. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of patentable material.|t
17179384|NCT02501473|f||OTHER|The Sponsor will have 30 days for review/ comment on any manuscripts from results of this clinical trial, and can request an additional 30 days in order to protect the Sponsor's confidential, proprietary data, and intellectual property rights. Abstracts, press releases, and other media presentations must also be forwarded to the Sponsor prior to release. No publication, manuscript, or other form of public disclosure shall contain any of the Sponsor's confidential/ proprietary information.|t
17179385|NCT02324569|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179386|NCT00911820|f||||f
17179387|NCT05519540|f||||t
17179388|NCT00218465|f||||f
17179389|NCT02114814|t||||f
17179390|NCT03098550|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179391|NCT02804932|f||||f
17179392|NCT03825315|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17184466|NCT04837482|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17184467|NCT00328510|t||||
17184468|NCT02061384|f||||f
17184469|NCT00317239|f||LTE60||t
17184470|NCT00803647|f||GT60||t
17184471|NCT02824913|f||OTHER|Principal Investigator may publish or present the results based on data generated at their Institution, provided that: (a) Sponsor publishes the results from all sites participating in the Study; (b) Institution receives notification from Sponsor that publication of the multi-site results is no longer planned; or (c) twelve (12) months following the close of study, whichever occurs first.|t
17184472|NCT03701555|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17184473|NCT04757649|f||||f
17184474|NCT01286779|f||OTHER|Agreements may vary with individual PIs, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or up to 2 years after study completion. The sponsor requires a review of results communication (e .g. for confidential information) ≥ 60 days prior to submission and may request an additional delay up to 6 months (e .g. for intellectual property protection). Prior authorization may be required.|t
17184475|NCT02896855|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184476|NCT02370602|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17184477|NCT01296568|f||GT60||t
17184478|NCT00237744|t||||
17184479|NCT00574080|t||||
17184480|NCT00407537|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184481|NCT01519206|f||||f
17184482|NCT04139317|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184483|NCT05857163|f||OTHER||t
17184484|NCT06027216|f||||f
17184485|NCT05348681|f||||t
17184486|NCT01470027|f||||f
17134292|NCT00892437|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17134293|NCT01961531|f||||f
17179393|NCT01693653|f||||f
17179394|NCT01204853|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184487|NCT03646513|f||||f
17184488|NCT00782340|f||LTE60||t
17184489|NCT04174521|f||||f
17184490|NCT01972061|t||||t
17184491|NCT02219932|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17184492|NCT01866410|f||LTE60||t
17134294|NCT02504541|f||OTHER||t
17134295|NCT01860170|f||||t
17134296|NCT01531725|f||LTE60||t
17134297|NCT00500071|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17134298|NCT00472303|f||OTHER|The Sponsor reserves the right to review any publication pertaining to the trial at least 30 days before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17134299|NCT01238120|f||||f
17134300|NCT03182738|t||||f
17134301|NCT01043640|f||||f
17179395|NCT01304316|f||||f
17179396|NCT05276401|f||||t
17179397|NCT01411774|f||||f
17179398|NCT00056316|f||||f
17179399|NCT02038023|t||||
17179400|NCT02990910|t||||
17179401|NCT02893514|t||||
17179402|NCT00583778|f||||f
17134302|NCT00296322|f||||f
17134303|NCT02888626|f||||f
17134304|NCT03596164|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17134305|NCT04112914|f||||f
17134306|NCT03427073|f||||t
17134307|NCT02955329|t||||f
17134308|NCT01486238|f||||f
17134309|NCT00759603|t||||
17134310|NCT02835495|f||||f
17134311|NCT05421754|f||||f
17134312|NCT01330290|f||GT60||t
17134313|NCT02095561|f||||f
17134314|NCT01576471|f||OTHER|As specified in each clinical trial agreement|t
17134315|NCT03486314|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17134316|NCT00659438|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17134317|NCT00410891|f||||f
17134318|NCT03826914|f||||f
17134319|NCT02379858|f||||f
17134320|NCT04334148|f||||f
17134321|NCT03228186|t||||
17134322|NCT04003610|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17134323|NCT01523821|f||||f
17134324|NCT02502864|t||||
17134325|NCT03772327|t||||f
17179403|NCT02468414|f||OTHER|Should the Primary Investigator (PI) wish to publish the results of this study, the PI agrees to provide the Sponsor with a manuscript for review 60 days prior to submission for publication. The Sponsor retains the right to delete from the manuscript information that is confidential and proprietary and to object to suggested publication and/or its timing (at the Sponsor's sole discretion).|t
17179404|NCT00903695|t||||f
17179405|NCT04882540|f||GT60||t
17134326|NCT03643692|t||||
17134327|NCT03664726|f||||f
17134328|NCT04378426|t||||
17134329|NCT05502289|f||GT60||t
17134330|NCT03119649|f||OTHER|The investigator must agree that before publishing or communicating any results of the trial, the sponsor has at least 90 days for full review of the information prior to submission.|t
17134331|NCT02333227|t||||
17134332|NCT01254344|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17134333|NCT01416129|f||||f
17134334|NCT03022461|f||||f
17134335|NCT01624194|f||||f
17134336|NCT03459040|f||||f
17134337|NCT00561353|f||LTE60||t
17134338|NCT01273818|f||||f
17134339|NCT03815175|f||LTE60||t
17179406|NCT00543140|f||OTHER|The PIs agreed that the first publication of results should be made in conjunction with the presentation of a joint, multicenter publication of the results with the PIs from all sites contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could have published the results from their individual sites.|t
17179407|NCT02584673|f||||f
17179408|NCT03902574|f||||f
17179409|NCT01603056|f||OTHER|Sponsor has the right to review and comment any manuscript within 30 days of receipt, but cannot prevent publications of findings. Sponsor will review the communications for accuracy (thus avoiding potential discrepancies with submissions to health authorities), verify that the confidential information is not being inadvertently divulged and provide any relevant supplementary information.|t
17179410|NCT05147350|f||||f
17179411|NCT03012165|f||||t
17134340|NCT02493751|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134341|NCT03822468|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17134342|NCT02985801|t||||
17134343|NCT05768789|f||||f
17134344|NCT01084252|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17134345|NCT04909463|t||||f
17134346|NCT05635838|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17134347|NCT04933812|t||||
17134348|NCT00468715|t||||
17134349|NCT02062177|f||||f
17184493|NCT00093145|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Sponsor a copy of the manuscript at least 30 days prior to submission; if no response is received within 30 days the publication or presentation may proceed without delay. Sponsor may request that Confidential Information be deleted. Publication may be delayed for an additional 60 days if patentable matter is included.|t
17134350|NCT03518840|t||||
17134351|NCT00920309|f||||f
17134352|NCT05652660|t||||
17134353|NCT04745832|f||OTHER||t
17134354|NCT02983058|t||||
17134355|NCT03199911|t||||
17134356|NCT00698516|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134357|NCT03549520|f||||f
17134358|NCT04260607|t||||
17134359|NCT03215914|f||||f
17134360|NCT02586207|f||||f
17134361|NCT03453060|f||OTHER|Aronora, Inc. shall retain title to and the right to publish all documentation, records, raw data, specimens, or other work product generated in connection with this study. Such publications shall not be made by the PI or Celerion without the prior written consent of Aronora, Inc.|t
17134362|NCT01142323|f||||f
17134363|NCT01959204|f||||f
17139627|NCT01680991|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139628|NCT01852591|t||||
17179412|NCT02627144|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179413|NCT05820685|t||||
17179414|NCT00420927|f||OTHER|Any investigator or institution that plans on presenting/publishing results disclosure, should provide written notification to Abbott within 60 days of their presentation/publication. Abbott requests that no presentation/publication will be allowed until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay of any proposed presentation/publication maybe requested if Abbott needs to secure patent or other proprietary protection.|t
17179415|NCT01115101|t||||
17179416|NCT04605484|f||||f
17134364|NCT03019055|t||||
17134365|NCT02494141|t||||
17134366|NCT00345605|f||||f
17134367|NCT01335971|f||||f
17134368|NCT00384956|t||||
17134369|NCT00917384|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study completion or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17134370|NCT00149214|f||GT60||t
17134371|NCT01538615|t||||
17134372|NCT00644592|t||||f
17134373|NCT00900796|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134374|NCT01859403|f||||f
17134375|NCT01120639|t||||
17134376|NCT03185130|f||||f
17134377|NCT02750410|f||GT60||t
17134378|NCT00058370|t||||
17134379|NCT03215277|f||GT60||t
17134380|NCT02580058|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134381|NCT04207710|f||||f
17134382|NCT02388776|t||||
17134383|NCT00542828|f||LTE60||t
17134384|NCT01773395|t||||
17134385|NCT04312997|f||OTHER||t
17134386|NCT04246047|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17134387|NCT02481505|f||||f
17134388|NCT05139030|f||OTHER|"Disclosure restrictions include:~* PIs or any other party are not allowed to publish any publication for a period of twelve months following completion of the clinical study report for the trial.~* PIs or any other party shall submit a proposal to the Sponsor for approval to obtain trial results that have not been previously made public and any publication, abstract or paper or other written materials to the trial shall be submitted to the Sponsor at least 60 days prior to submission."|t
17139629|NCT06073054|f||||f
17139630|NCT04574570|f||||f
17139631|NCT03630185|t||||
17139632|NCT00413777|f||||f
17179417|NCT02454296|f||||f
17179418|NCT01370356|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134389|NCT01982630|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17184494|NCT04389840|f||OTHER|Within 18 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17134390|NCT00820040|f||||f
17134391|NCT03195140|f||||f
17134392|NCT01259466|f||||f
17134393|NCT03322657|t||||f
17134394|NCT01824602|f||OTHER||t
17134395|NCT02513446|t||||f
17134396|NCT02485717|f||OTHER|Site may not publish or publicly present Study results. If Sponsor has given its prior written consent to the Site to publish or present Study results, Site will provide Sponsor with a copy of any proposed oral or written publication to at least sixty (60) days in advance of submission for publication or presentation for review and comment on the appropriateness of the data analysis and presentation. The terms of this paragraph shall survive expiration or termination of this Agreement.|t
17134397|NCT05036785|t||||
17134398|NCT05300087|f||||t
17134399|NCT05121103|f||||t
17134400|NCT03248128|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17134401|NCT01914679|f||||f
17179419|NCT00040664|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179420|NCT02925494|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179421|NCT03636061|f||||t
17179422|NCT06149247|f||||f
17179423|NCT05182125|f||||f
17179424|NCT01218243|t||||
17179425|NCT01003288|t||||
17179426|NCT02615145|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179427|NCT03727347|f||OTHER|First publication of study results shall be made in conjunction with the results from all clinical study centers participating in the multicenter study. If results of the multi-center study have not been published in full within 18 months after completion of the study, investigator shall be free to publish results. Investigator agrees to submit all proposed publications to the sponsor at least 60 days prior submission; the company has the right to comment.|t
17179428|NCT03200860|t||||
17179429|NCT00217594|t||||
17179430|NCT01744197|f||||f
17179431|NCT04342897|f||GT60||t
17179432|NCT02970422|f||||f
17179433|NCT03779724|f||||f
17179434|NCT02959307|f||||f
17179435|NCT03159624|f||||f
17179436|NCT01325584|t||||
17179437|NCT00887978|f||OTHER|Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17179438|NCT00534430|t||||
17179439|NCT01011634|f||||f
17179440|NCT00309387|f||||f
17179441|NCT00616200|t||||
17179442|NCT02483520|f||||f
17179443|NCT00786682|t||||
17179444|NCT04492618|t||||
17179445|NCT01401283|f||||f
17179446|NCT03991715|t||||
17179447|NCT02111772|f||||f
17179448|NCT02376361|f||||f
17179449|NCT02101060|t||||f
17179450|NCT03291054|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.|t
17179451|NCT01246401|t||||
17179452|NCT03462082|t||||
17179453|NCT00919724|t||||f
17179454|NCT00166114|f||||f
17179455|NCT02335294|f||OTHER||t
17179456|NCT00545168|f||||f
17179457|NCT01218204|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179458|NCT00799604|f||OTHER|The site agrees that publication of Study results at the site is not permitted until after the presentation and publication of the multi-center results or an affirmative decision is made by Sponsor not to proceed with such publication. In such a case, Sponsor shall provide access to all Study site data to the academic Study Coordination Center, or upon request Sponsor will provide access to all Study site data to Institution. The site will adhere to terms for Sponsor review prior to submission.|t
17179459|NCT00960778|t||||
17179460|NCT00127660|f||||f
17184495|NCT00366626|t||||
17184496|NCT01953926|f||||f
17184497|NCT01276587|t||||
17184498|NCT04644328|f||||f
17134402|NCT01363050|f||||f
17134403|NCT03885284|t||||
17134404|NCT00484354|t||||f
17134405|NCT00002850|f||||f
17134406|NCT00590161|f||||f
17134407|NCT02234622|t||||
17134408|NCT01294228|f||GT60||t
17134409|NCT05175170|f||||f
17134410|NCT04090164|f||||f
17134411|NCT01650805|f||||f
17134412|NCT02452359|f||||f
17134413|NCT01877655|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17134414|NCT03439345|t||||f
17134415|NCT04974307|t||||
17134416|NCT03590457|f||||f
17134417|NCT02128490|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17139633|NCT01994109|f||OTHER|Sponsor has the first right, within 9 months following the later to occur 1) close out meeting or 2) Sponsor possessing all data, to publish the lead paper. Following the foregoing, Institution has the right to publish the results provided the Institution provides a Publications Committee, which includes the Sponsor, with a draft at least 30 days before submission. At Sponsor's request, Institution shall withhold publication for 45 days to allow filing of a patent application.|t
17139634|NCT05505734|f||OTHER|Data or results obtained from this study must not be published without prior approval from the Sponsor.|t
17139635|NCT00764322|f||||f
17139636|NCT03008889|t||||
17179461|NCT01987505|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179462|NCT05131646|f||OTHER|All information concerning CLS1002-102 and the operations of Clearside Biomedical, Inc. are considered CONFIDENTIAL and shall remain the sole property of Clearside Biomedical Inc. The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17179463|NCT03266107|f||||f
17179464|NCT03454997|f||||f
17179465|NCT03784729|t||||
17179466|NCT01191801|f||GT60||t
17179467|NCT03348956|t||||
17179468|NCT00114101|f||LTE60||t
17179469|NCT03210376|t||||
17179470|NCT04394286|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17179471|NCT00484874|f||||f
17179472|NCT00811798|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179473|NCT00299975|f||||f
17179474|NCT01193868|f||LTE60||t
17179475|NCT01815515|t||||
17179476|NCT00171730|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17179477|NCT05025241|f||LTE60||t
17179478|NCT01053221|t||||f
17179479|NCT02266225|t||||
17179480|NCT01465997|f||GT60||t
17179481|NCT02246660|f||||f
17179482|NCT03018704|f||||f
17179483|NCT02397785|f||||f
17179484|NCT00642460|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179485|NCT00320411|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179486|NCT01110434|f||||f
17179487|NCT02557646|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179488|NCT04448171|t||||
17179489|NCT00660309|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184499|NCT01272934|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17184500|NCT00214136|t||||
17134418|NCT02243176|f||GT60||t
17134419|NCT04442581|t||||
17134420|NCT00875420|f||OTHER|Results may not be published prior to Study Report completion. Subsequent to formation of a Publications Committee, Investigators may publish results, providing a manuscript to Sponsor =/\> 30 days prior to its submission. Sponsor will provide manuscript to Investigators =/\> 30 days prior to its submission. Investigator will comply with Sponsor's policy, withholding publication for another 60 days to permit Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.|t
17134421|NCT00001259|t||||
17134422|NCT03705494|f||||f
17134423|NCT03704051|f||||f
17134424|NCT02629393|f||OTHER|Institution/Investigator shall have the right to publish or present the results of Institution's and Investigator's activities including that Study Data which was obtained or derived at Institution. Institution/Investigator agree to submit any proposed publication/presentation to Sponsor for review at least 60 days prior to submitting any such proposed publication. Within 30 days of its receipt, Sponsor shall advise if any changes are needed to protect confidentiality.|t
17134425|NCT04573777|f||||f
17134426|NCT03716726|t||||
17134427|NCT01416181|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17134428|NCT03638011|t||||
17134429|NCT01981187|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134430|NCT03440112|f||||f
17134431|NCT01943539|f||||f
17139637|NCT00435929|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139638|NCT00564265|t||||f
17139639|NCT00976963|t||||f
17139640|NCT01775800|t||||
17139641|NCT01328769|f||||f
17179490|NCT02573311|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179491|NCT00603889|f||||f
17179492|NCT05683249|f||OTHER|This agreement establishes that all protocol information, data, and materials related to Neurocentria's study are confidential and Neurocentria's property. Institution retains ownership of subject medical records but must maintain strict confidentiality, sharing information only with necessary parties bound by the same confidentiality terms. Exceptions include publicly available information, third-party disclosures, previously known information, or independently developed information.|t
17179493|NCT00265798|f||LTE60||t
17179494|NCT01401582|f||||f
17179495|NCT05860647|t||||
17179496|NCT05288062|t||||
17179497|NCT01217814|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17179499|NCT03725098|f||||f
17179500|NCT03926169|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179501|NCT00844896|t||||f
17179502|NCT02233647|f||||f
17179503|NCT04774328|f||OTHER|"Disclosure restriction on the PI and/or institution:~1. Sponsor can embargo communications or publications regarding trial results for more than 60 days but less than 181 days from the time submitted to the sponsor. The sponsor cannot extend the embargo.~2. The Institution and Investigator agree that any Institutional Publication shall be made after the Multicenter Publication, provided that the Multicenter Publication is submitted within eighteen (18) months after conclusion of the Study."|t
17179504|NCT01835587|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission up to 90 additional days. Investigator must delete confidential data before submission or defer publication to permit patent applications.|t
17184501|NCT04287920|t||||
17184502|NCT04313634|t||||
17184503|NCT05219877|t||||
17184504|NCT00167544|f||||f
17134432|NCT02333331|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17134433|NCT05309668|f||||f
17134434|NCT03815292|f||||t
17134435|NCT01092442|f||OTHER|The PI can not publish any results or data arising from the study except with the institution's approval and sponsor's written consent.|t
17134436|NCT03180736|f||||f
17134437|NCT01518530|f||||f
17134438|NCT00467844|f||LTE60||t
17134439|NCT01451515|t||||
17139642|NCT02768103|t||||
17139643|NCT03369704|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139644|NCT02283840|f||OTHER||t
17139645|NCT02348840|t||||
17134440|NCT00174941|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17134441|NCT03126227|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17134442|NCT03669133|f||||f
17134443|NCT01464697|t||||
17134444|NCT01121406|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17134445|NCT01925703|f||||f
17134446|NCT03794986|f||||f
17134447|NCT01882725|f||||f
17134448|NCT01854177|t||||
17134449|NCT01415960|f||OTHER|All information from the trial is property of the Sponsor and the PI has no right on it except the prior writing authorization of the sponsor|t
17134450|NCT02498652|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17134451|NCT00465569|f||||f
17134452|NCT00922935|f||||f
17134453|NCT00849212|f||||f
17134454|NCT00095303|f||||f
17134455|NCT01499576|f||||f
17134456|NCT04283461|f||LTE60||t
17134457|NCT02228499|f||||f
17134458|NCT02495779|t||||
17134459|NCT00748657|f||LTE60||t
17134460|NCT00397150|f||||f
17134461|NCT04375878|f||||f
17134462|NCT00195351|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17134463|NCT02111369|f||||f
17134464|NCT00971321|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134465|NCT00519623|f||OTHER|"PI is restricted from using, disclosing, presenting or publishing trial information without the prior written consent from the Sponsor.~PI is not an employee of the Sponsor but was paid to conduct the study at the Sponsor's Phase 1 Clinical Resarch Unit."|t
17134466|NCT03679494|t||||
17134467|NCT02527304|f||||f
17134468|NCT02296840|t||||
17179505|NCT03501069|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17179506|NCT03199274|t||||
17179508|NCT02846779|f||||f
17179509|NCT00040937|f||||f
17134469|NCT00843180|t||||f
17134470|NCT00104871|f||LTE60||t
17134471|NCT00761215|f||OTHER|Sponsor intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical trial agreement between Sponsor and Investigators. Sponsor approval is required for publication of any data subsets. Final authorship will be determined by contributions to study design, enrollment, data analysis, and/or interpretation of the results.|t
17134472|NCT00667277|t||||
17134473|NCT04333966|f||||f
17134474|NCT01926886|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134475|NCT03368898|t||||
17134476|NCT04429932|f||||f
17179510|NCT00806390|t||||f
17179511|NCT02267811|f||||f
17134477|NCT01662999|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17134478|NCT04002167|t||||f
17134479|NCT01322815|f||||f
17134480|NCT02932267|f||||t
17134481|NCT02049502|t||||
17134482|NCT01586091|t||||
17134483|NCT01687673|t||||
17134484|NCT02453841|t||||
17139646|NCT01263444|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17179512|NCT02239978|t||||
17179513|NCT00602953|f||||f
17179514|NCT04567225|t||||
17134485|NCT00618956|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17134486|NCT02006576|f||||f
17134487|NCT02625402|t||||f
17134488|NCT05847881|t||||
17134489|NCT06046560|f||||f
17134490|NCT04513158|t||||
17134491|NCT04493619|f||OTHER||t
17134492|NCT01419171|f||OTHER|Institution and Investigator shall have the right to publish the results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17134493|NCT01612793|f||LTE60||t
17134494|NCT02413255|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17134495|NCT04243369|f||GT60||t
17134496|NCT04329949|f||OTHER|No individual publications will be allowed before publication of the multicenter results except as agreed with the Sponsor. The Investigator agrees to submit all manuscripts or abstracts to the Sponsor for review before submission to the publisher. The Sponsor will comply with the requirements for publication of study results and determination of authorship in accordance with standard editorial and ethical practice and with the International Committee of Medical Journal Editors requirements.|t
17134497|NCT03851744|t||||
17134498|NCT00427661|f||||f
17134499|NCT04281537|f||||f
17134500|NCT03230097|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134501|NCT01241539|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17134502|NCT00779038|f||||f
17134503|NCT04786210|t||||
17134504|NCT05370157|t||||
17134505|NCT03700892|t||||
17134506|NCT03652454|f||||f
17179515|NCT00345345|t||||
17134507|NCT03583424|t||||
17134508|NCT01144637|f||||t
17134509|NCT01364467|t||||
17134510|NCT01634243|f||||f
17134511|NCT03842137|f||||f
17134512|NCT01472276|t||||
17134513|NCT00780403|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17179516|NCT02016560|f||LTE60||t
17179517|NCT01943292|f||OTHER|The site is not able to publish any clinical trial results without first seeking permission from Verastem.|t
17179518|NCT00638378|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17179519|NCT01852110|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17179520|NCT00759031|f||GT60||t
17179521|NCT02430311|f||OTHER|Institution and Principal Investigator may use the Study results (data generated at the site) and shall not publish or present any such results until the earlier of (i) the date of the first Study results publication and (ii) the end of the eighteen (18) month period following the completion, or early termination, of the Study at all participating sites.|t
17179522|NCT04180488|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17179523|NCT00471068|f||||f
17179524|NCT04113304|f||||f
17179525|NCT01393704|t||||
17179526|NCT01804296|t||||
17179527|NCT04159025|t||||
17179528|NCT00381095|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179529|NCT01104493|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17179530|NCT00208091|f||||f
17139647|NCT01611662|f||||f
17139648|NCT03236506|t||||
17179531|NCT01342796|f||GT60||t
17134514|NCT04322708|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17134515|NCT01161225|f||||f
17134516|NCT00587223|f||OTHER|Before publishing PI shall submit copies of any proposed publication/presentation to Sponsor for review at least 30 days in advance of submission. Sponsor shall review the data provided in proposed publication against the Study database for consistency. Sponsor reserves right to delete any Confidential Information/proprietary information of Sponsor from the proposed publication/presentation. Sponsor may extend such review period for another 90 days.|t
17134517|NCT01233726|t||||
17134518|NCT03240081|f||||f
17134519|NCT00883753|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134520|NCT02256358|f||||f
17134521|NCT03959189|f||OTHER|Expansion Therapeutics reserves the right to embargo communications regarding trial results prior to public release for a period ≤ 60 days in order to protect patentable information. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed company confidential information other than study results.|t
17134522|NCT01480180|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17134523|NCT01341912|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period|t
17134524|NCT02436239|f||OTHER|All data generated in this study are the property of the sponsor. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and the sponsor and will follow sponsor's standard operating procedures on publications.|t
17134525|NCT04925570|f||||f
17134526|NCT00828451|f||||f
17134527|NCT03721328|f||||f
17134528|NCT03429075|t||||
17179532|NCT01599234|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17179533|NCT02433483|t||||
17179534|NCT03489720|t||||f
17179535|NCT03342690|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179536|NCT03219294|t||||
17179537|NCT04626297|f||GT60||t
17179538|NCT03167411|f||||f
17179539|NCT02602496|t||||
17179540|NCT02651922|f||||f
17179541|NCT00729651|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179542|NCT00545662|f||||f
17179543|NCT00592943|f||||f
17179544|NCT02984709|f||||f
17179545|NCT00680706|t||||
17179546|NCT00080470|f||||f
17179547|NCT01950741|f||||f
17179548|NCT02521870|f||LTE60||t
17179549|NCT00519831|f||GT60||t
17179550|NCT02854631|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17179551|NCT01064713|t||||
17179552|NCT01900704|f||||t
17179553|NCT04656691|t||||
17179554|NCT00600483|f||||f
17179555|NCT04208698|f||LTE60||t
17179556|NCT01482884|f||LTE60||t
17179557|NCT04102020|f||||f
17179558|NCT03898362|f||||f
17179559|NCT04216329|f||||f
17179560|NCT03857321|t||||
17179561|NCT05542576|f||||f
17179562|NCT05980182|t||||
17179563|NCT04600921|f||||f
17179564|NCT01113983|f||||f
17179565|NCT00410046|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17179566|NCT01384760|f||||f
17179567|NCT00963547|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17179568|NCT01479517|f||||f
17179569|NCT01206608|f||||f
17179570|NCT00719134|f||||f
17179571|NCT00482612|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial will first be submitted to the Sponsor, at least 6 weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17134529|NCT00814710|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134530|NCT02280811|f||||f
17134531|NCT01476787|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17134532|NCT01591330|f||GT60||t
17134533|NCT01450137|t||||
17134534|NCT01450540|f||||f
17179572|NCT01366521|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134535|NCT01477450|t||||
17134536|NCT03875235|f||||f
17134537|NCT02514070|t||||
17134538|NCT03851510|f||||f
17134539|NCT01151137|f||OTHER|"If no publication has occurred within 12 months after trial completion, the investigator can present or publish trial results. A copy is submitted to the sponsor for review and comment at least 30 days in advance of any presentation or submission for publication.~The sponsor can require to delay the communication for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17134540|NCT03478683|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134541|NCT01887210|f||||f
17134542|NCT02043574|t||||
17179573|NCT00660023|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179574|NCT00684307|f||LTE60||t
17179575|NCT03506815|f||||f
17179576|NCT04160091|f||GT60||t
17179577|NCT02033694|f||||t
17179578|NCT02899988|f||GT60||t
17179579|NCT02056782|f||||f
17179580|NCT01059825|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the Sponsor at least 30-days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17179581|NCT00549302|f||GT60||t
17179582|NCT03585504|f||||f
17179583|NCT01414114|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17179584|NCT00105482|t||||
17179585|NCT05620563|f||GT60||t
17179586|NCT00869206|f||GT60||t
17179587|NCT00411645|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17179588|NCT03143894|t||||
17179589|NCT04118166|f||||f
17179590|NCT03521934|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17179591|NCT03434275|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17179592|NCT03020160|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179593|NCT01513473|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17179594|NCT04488068|t||||
17179595|NCT00211809|t||||
17179596|NCT04294472|f||GT60||t
17179597|NCT01191398|f||||f
17179598|NCT01619774|t||||
17179599|NCT00589563|t||||
17179600|NCT02603419|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179601|NCT02988843|t||||
17179602|NCT01049308|t||||
17134543|NCT00770861|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17134544|NCT00662155|f||||f
17139649|NCT01466062|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17134545|NCT01287117|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134546|NCT00630032|f||||f
17134547|NCT02332915|f||||f
17134548|NCT02862912|t||||f
17134549|NCT02677740|t||||f
17134550|NCT03063385|t||||
17134551|NCT02342171|f||||t
17134552|NCT05165394|f||||t
17134553|NCT00492622|t||||
17134554|NCT01332435|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134555|NCT02517515|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17134556|NCT02786537|t||||t
17134557|NCT02638012|t||||
17134558|NCT00443560|t||||
17134559|NCT01494038|f||||f
17134560|NCT05299892|f||||f
17134561|NCT01458340|f||||f
17139650|NCT02865928|t||||f
17139651|NCT03152110|t||||
17184505|NCT00680316|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184506|NCT03585244|t||||
17134562|NCT03806452|f||||f
17134563|NCT01126619|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17134564|NCT03351244|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17134565|NCT00091793|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134566|NCT03002506|f||LTE60||t
17134567|NCT05309083|t||||
17134568|NCT01165229|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134569|NCT01720251|f||OTHER|The PI of the trial owns options in the sponsor company and is member of the Board of Anergis SA|t
17139652|NCT02213081|f||||f
17179603|NCT02289417|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17179604|NCT04786990|f||||t
17179605|NCT00923247|f||||f
17179606|NCT01782222|f||GT60||t
17179607|NCT02071914|f||OTHER||t
17179608|NCT01756898|f||||f
17184507|NCT02388633|t||||
17184508|NCT02830594|t||||
17179609|NCT01500694|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17134570|NCT00881205|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17134571|NCT00550238|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17134572|NCT00537745|f||||f
17184509|NCT01764945|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17184510|NCT05077267|f||OTHER|Institution/Investigator agree to submit any proposed publication or presentation to Sponsor for review at least 60 days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Sponsor shall have the right to require Institution/Investigator to remove specifically identified Confidential Information and/or to delay the proposed publication or presentation for an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17184511|NCT02911948|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17184512|NCT02679690|f||||f
17184513|NCT03970109|f||OTHER|PIs may only publish on study results after the main results are published.|t
17184514|NCT00142909|t||||
17184515|NCT01307501|f||OTHER|BTG can require Investigator to postpone publications/presentations for up to 12 months so data from all sites can be published. BTG will limit review of Investigator's draft to confirm Confidential Information is not being disclosed. If BTG notes publishing Study results may affect obtaining a patent, Investigator will not publish for up to 60 days until patent application is filed. Investigator will acknowledge BTG in any publication/presentation.|t
17184516|NCT02005471|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184517|NCT03478891|t||||
17184518|NCT03662750|t||||
17184519|NCT00932893|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184520|NCT00443547|f||LTE60||t
17184521|NCT04450264|f||||f
17184522|NCT04295564|f||||f
17184523|NCT01682460|t||||
17184524|NCT00639717|t||||
17184525|NCT05349617|f||OTHER|This is a multi-center study and agreement with investigators depends on the individual site contact.|t
17184526|NCT00724282|t||||
17184527|NCT01159691|f||GT60||t
17184528|NCT01928719|t||||
17184529|NCT02250612|f||||f
17184530|NCT05732454|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184531|NCT02692248|f||GT60||t
17184532|NCT03812146|f||||f
17134573|NCT04276558|f||||t
17134574|NCT00845429|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17134575|NCT01856673|f||||f
17134576|NCT04332419|t||||
17134577|NCT00184054|f||||f
17134578|NCT04045912|t||||f
17134579|NCT00519532|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17134580|NCT03138564|t||||
17134581|NCT02830165|t||||
17134582|NCT02772783|t||||
17134583|NCT03443024|f||GT60||t
17134584|NCT00513344|t||||
17134585|NCT01548638|t||||
17134586|NCT05593432|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17134587|NCT02964078|t||||
17134588|NCT04037085|t||||
17134589|NCT02609399|f||||f
17134590|NCT02986373|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17134591|NCT04800315|f||LTE60||t
17134592|NCT00753922|f||OTHER|Sponsor acknowledges that the Investigator and his/her collaborators shall be free to publish the background, methods and results of their own research without restraint. Prior review of any proposed manuscript or abstract will be provided to Sponsor to prevent premature disclosure of trade secrets or proprietary information. The Investigator acknowledges that the Sponsor reserves the right to publish and present the overall study results, including assigning authorship.|t
17184533|NCT00377819|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184534|NCT02091726|f||||f
17184535|NCT03727750|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184536|NCT03523533|t||||
17134593|NCT03598777|f||||t
17134594|NCT01919411|t||||f
17134595|NCT00072189|f||LTE60||t
17184537|NCT03388619|f||||f
17134596|NCT01933672|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184538|NCT00823719|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184539|NCT02357836|t||||
17184540|NCT00344682|f||||f
17184541|NCT01380327|f||||f
17134597|NCT01031095|f||||f
17134598|NCT04125745|t||||
17134599|NCT02426086|f||OTHER|Consistent with Good Publication Practices and ICMJE guidelines, the sponsor shall have right to publish such primary (multicenter) data and information without approval from investigator. Investigator has right to publish study site-specific data after primary data published. If an investigator wishes to publish information from study, a copy of manuscript must be provided to sponsor for review at least 60 days before submission for publication or presentation.|t
17134600|NCT00524303|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134601|NCT00499915|f||||f
17134602|NCT00833859|t||||f
17139653|NCT00085644|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17184542|NCT00586105|f||LTE60||t
17184543|NCT03835533|f||OTHER|Trial Site and/or Co-Principal Investigators may publish or present Study Data and other results of the Study from the Trial Site individually upon the first to occur of: (i) twelve (12) months after conclusion, abandonment, or termination of the Study at all Affiliated Research Institutions, or (ii) after Parker Institute for Cancer Immunotherapy \[PICI\] confirms in writing there will not be a multi-site Study publication.|t
17184544|NCT03867734|f||||f
17184545|NCT01136291|t||||f
17184546|NCT00884585|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184547|NCT02308033|f||OTHER|Investigators have the right to disclose and publish results of the Study conducted by them; provided that, in order to protect any Sponsor confidential information, Investigator shall submit to Sponsor manuscripts at least 30 days before submission for publication or 10 days before public presentation. After that time, Investigator is free to submit the manuscript for publication or deliver the presentation, provided Investigator removes any confidential information as directed by Sponsor|t
17184548|NCT04773015|f||||f
17184549|NCT01870843|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17184550|NCT03021187|f||OTHER||t
17184551|NCT01664078|f||||f
17184552|NCT00718718|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17134603|NCT00840463|f||||f
17134604|NCT02312986|f||||f
17134605|NCT01739595|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17134606|NCT02515669|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134607|NCT04278573|t||||
17134608|NCT01903148|f||LTE60||t
17139654|NCT04259346|f||GT60||t
17134609|NCT01676116|f||OTHER|At the end of the trial, one or more public disclosures may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17134610|NCT00778999|f||OTHER|Sponsor recognizes the right of the investigator(s) to publish, but all communication concerning the clinical trial must be based on data validated and released and will first be submitted to the Sponsor for written consent, which shall not be withheld unreasonably. Sponsor is free to use the data for publication. The investigator(s) may be invited to be co-author(s). In any communication concerning this clinical trial, the author(s) of this protocol will be included in the list of authors.|t
17134611|NCT02032524|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17134612|NCT00538642|f||LTE60||t
17134613|NCT02975349|f||||f
17134614|NCT01497171|f||||f
17134615|NCT02258412|f||LTE60||t
17134616|NCT03497689|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17134617|NCT04358458|f||LTE60||t
17134618|NCT03191786|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134619|NCT01382186|t||||
17134620|NCT01266148|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17134621|NCT03348683|f||||f
17134622|NCT03937986|f||||f
17134623|NCT00345371|f||||f
17134624|NCT01853228|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17134625|NCT03167619|f||||f
17134626|NCT00678496|f||||f
17134627|NCT01348919|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17134628|NCT01518699|f||||f
17134629|NCT02110108|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17139655|NCT03330106|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17139656|NCT03441594|t||||f
17139657|NCT00623766|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17184553|NCT01548690|f||||f
17134630|NCT03846947|t||||
17134631|NCT00812110|t||||
17134632|NCT02082184|f||GT60||t
17134633|NCT04352660|f||||f
17134634|NCT01197573|t||||
17139658|NCT04555811|t||||
17139659|NCT00486889|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17139660|NCT00893763|f||||f
17139661|NCT02324049|f||||f
17139662|NCT00285246|t||||
17139663|NCT00736450|t||||
17139664|NCT04157751|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139665|NCT02901080|f||||f
17139666|NCT02829775|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139667|NCT01249157|t||||
17139668|NCT00062647|f||LTE60||t
17184554|NCT01117311|f||||f
17184555|NCT01253343|t||||
17184556|NCT04558346|f||||f
17184557|NCT01462344|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184558|NCT00724971|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184559|NCT01003249|t||||
17184560|NCT05244525|t||||
17184561|NCT01962974|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17184562|NCT01692197|t||||
17184563|NCT00147966|f||||f
17184564|NCT02467777|f||||f
17184565|NCT03510481|f||OTHER|"NIAID cannot contact the FDA regarding the trial independent of the IND Sponsor (Sanaria, Inc.).~Dr. Patrick Duffy is employed by the clinical sponsor, NIAID (clinical sponsor). Dr. Diawara is not employed by either sponsor."|t
17184566|NCT02276482|f||OTHER|Sponsor intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between Sponsor and Investigators. Sponsor approval in writing is required for publication of any data subsets.|t
17184567|NCT02267382|f||OTHER|Neither Institution nor Principal Investigator shall publish the results of the Trial without the prior written consent of Sponsor, which it may withhold in its sole discretion.|t
17184568|NCT01165281|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17184569|NCT01154634|f||GT60||t
17184570|NCT00363766|f||GT60||t
17184571|NCT00558285|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184572|NCT02730819|t||||
17184573|NCT02331992|f||OTHER|The PI agrees to supply the sponsor with any proposed publications or presentation. Any information that affect the sponsor IP, or information that is commercially sensitive, may be delayed, deleted or amended.|t
17179610|NCT00663169|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134635|NCT01362322|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134636|NCT03187379|t||||
17134637|NCT01009463|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134638|NCT00634543|f||OTHER|Principal Investigator (PI) cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is cancelled.|t
17134639|NCT02836886|t||||f
17134640|NCT02401256|f||||f
17134641|NCT03279237|t||||
17139669|NCT04445051|f||LTE60||t
17139670|NCT02939651|t||||
17139671|NCT02996994|t||||
17179611|NCT00787852|f||||f
17179612|NCT00496054|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179613|NCT00508716|f||||f
17179614|NCT01858389|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179615|NCT03572062|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179616|NCT00471328|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179617|NCT04051008|f||||f
17179618|NCT01605877|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17179619|NCT00458211|f||||f
17179620|NCT02818569|t||||
17179621|NCT03158116|t||||
17179622|NCT01897402|f||OTHER|All abstracts, presentations or manuscripts, and any data analyses conducted independently by the Investigator must be submitted in advance to the sponsor for review and approval. The sponsor will not unreasonably withhold publication of study findings. The objective of this policy is to ensure consistency between data filed with a regulatory authority and those appearing in the publication.|t
17179623|NCT01307007|f||GT60||t
17139672|NCT03296280|t||||
17139673|NCT00390429|t||||
17134642|NCT00430781|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134643|NCT05099991|t||||
17134644|NCT01059812|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17134645|NCT01389128|f||||f
17134646|NCT01521845|t||||
17134647|NCT01532453|f||OTHER|Investigator is granted a right to publish and present Trial Results together with other investigators of Trial and to be referred to in publications containing such results. However, investigator shall not publish or present Trial Results unless Investigator has submitted to Spirig a draft of the intended publication or presentation for review and approval.|t
17134648|NCT03056287|f||||f
17134649|NCT00981435|f||||f
17134650|NCT00947154|f||||f
17134651|NCT00609271|t||||
17134652|NCT01588197|f||||f
17134653|NCT03968965|f||||f
17134654|NCT01844076|t||||
17134655|NCT05483127|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17134656|NCT00315302|f||||f
17134657|NCT00217438|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication. In the event the sponsor decides a patent application should be filed, the embargo may extend up to an additional 60 days or until a patent application is filed.|t
17134658|NCT02437669|t||||f
17134659|NCT02286960|t||||
17134660|NCT00440401|f||LTE60||t
17134661|NCT01937312|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17134662|NCT00474253|f||OTHER|The Sponsor recognizes the right of the investigator(s) to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning this clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17134663|NCT02273115|t||||
17134664|NCT02102230|f||||f
17134665|NCT00736229|f||||f
17134666|NCT00593112|f||||f
17134667|NCT00482001|f||||f
17134668|NCT00258154|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134669|NCT00754390|t||||
17134670|NCT00847613|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134671|NCT03633331|t||||
17134672|NCT01009294|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17134673|NCT00658333|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134674|NCT04687917|t||||
17134675|NCT00624338|f||OTHER||t
17134676|NCT03476850|f||||f
17139674|NCT02392468|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179624|NCT02634320|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17134677|NCT02912364|t||||
17134678|NCT05439928|t||||
17134679|NCT01526356|t||||
17134680|NCT00995371|f||||f
17134681|NCT04725682|f||||f
17134682|NCT02190591|t||||
17134683|NCT00857246|t||||
17134684|NCT00144300|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17134685|NCT03750838|f||||f
17134686|NCT00538733|t||LTE60||t
17179625|NCT00687323|f||OTHER|The Study Chair agrees not to publish/present any interim results without the Sponsor's prior written consent. The Principal Investigators (PIs) agree to provide 30 days prior to submission to the Sponsor to review copies of abstracts/manuscripts. The Sponsor shall have proper representation on publications and editorial rights with regard to data analysis, presentation, proprietary information, and accuracy. If the parties disagree, the PIs agree to meet with the Sponsor to discuss/resolve.|t
17139675|NCT01313039|t||||
17179626|NCT00387023|t||||f
17134687|NCT02032875|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17134688|NCT02858193|f||||f
17134689|NCT03412630|f||LTE60||t
17134690|NCT02031146|f||||f
17134691|NCT02420652|t||||
17134692|NCT04957498|f||||f
17134693|NCT02927223|t||||
17134694|NCT02114203|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134695|NCT02839746|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134696|NCT00744055|t||||
17134697|NCT02767570|t||||f
17134698|NCT00151411|f||||f
17134699|NCT01712438|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17134700|NCT01819935|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134701|NCT01157169|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17134702|NCT01123889|t||||
17134703|NCT00117962|t||||
17134704|NCT02396147|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17134705|NCT00728507|f||||f
17134706|NCT02413398|f||||f
17134707|NCT02874794|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17134708|NCT00537940|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134709|NCT05665335|f||||f
17139676|NCT05083949|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139677|NCT03338036|f||||f
17139678|NCT00997555|t||||
17134710|NCT00623012|f||||f
17134711|NCT02465034|t||||
17139679|NCT00901394|t||||f
17139680|NCT02422186|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will be withheld such publication for up to an additional 60 days.|t
17139681|NCT03039569|t||||
17139682|NCT02254304|f||OTHER||t
17179627|NCT01209260|t||||
17179628|NCT02132130|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17179629|NCT01580618|t||||
17179630|NCT01179568|f||||f
17179631|NCT03310775|f||||f
17179632|NCT00838578|f||OTHER||t
17179633|NCT00357968|f||GT60||t
17179634|NCT02812160|f||||t
17179635|NCT01730833|t||||
17179636|NCT04847557|f||GT60||t
17179637|NCT00996216|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179638|NCT03758274|f||||f
17179639|NCT00793403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179640|NCT00842712|f||GT60||t
17179641|NCT00875212|t||||
17179642|NCT00760578|f||LTE60||t
17179643|NCT01549860|f||||f
17179644|NCT04677374|t||||
17179645|NCT01148940|f||||f
17184574|NCT02121847|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184575|NCT01660906|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17184576|NCT01538745|t||||
17184577|NCT02099006|t||||
17184578|NCT03431168|f||||f
17184579|NCT00809757|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17184580|NCT00253864|t||||
17184581|NCT00659334|f||||f
17184582|NCT04697758|f||||f
17184583|NCT01174342|t||||
17184584|NCT01410448|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17184585|NCT01308580|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17184586|NCT00360529|f||OTHER|Any publication of the result of this trial must be consistent with the Sprout Pharmaceuticals publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17184587|NCT03712917|f||||f
17184588|NCT01218438|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or ≤15 months after study completion. Baxalta requires a review of results communications (eg, for confidential information) ≥30 days prior to submission or communication. Baxalta may request an additional delay of ≤60 days eg, for intellectual property protection.|t
17184589|NCT01932164|t||||
17184590|NCT01218646|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17184591|NCT04198662|f||||f
17184592|NCT05437510|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17134712|NCT00320671|f||||f
17134713|NCT00073333|f||||f
17134714|NCT02397655|f||LTE60||t
17134715|NCT01736683|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17134716|NCT03334214|f||||t
17134717|NCT01330446|t||||
17134718|NCT05780281|f||||f
17134719|NCT00308620|f||||f
17134720|NCT00546351|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17134721|NCT00592683|f||||f
17134722|NCT02162979|t||||
17134723|NCT00479466|f||LTE60||t
17134724|NCT01325493|f||||f
17134725|NCT05372315|f||||f
17134726|NCT01015443|f||OTHER||t
17134727|NCT00650585|f||OTHER|All reports and products must be submitted for review prior to publication.|t
17134728|NCT00467649|f||LTE60||t
17134729|NCT00807664|f||||f
17134730|NCT03233048|t||||
17134731|NCT01852344|t||||
17134732|NCT01950078|t||||
17134733|NCT04901507|f||||f
17134734|NCT00729430|f||||f
17134735|NCT05897853|f||||f
17134736|NCT03246074|t||||
17134737|NCT01039207|f||LTE60||t
17134738|NCT02782715|t||||
17184593|NCT05706506|f||GT60||t
17184594|NCT00838110|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184595|NCT05356221|t||||
17184596|NCT03240588|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17184597|NCT01914926|t||||
17184598|NCT00467870|f||OTHER||t
17184599|NCT00321919|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184600|NCT02261363|f||||f
17184601|NCT01517802|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17184602|NCT02590354|f||||t
17184603|NCT00760929|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184604|NCT02099838|t||||
17184605|NCT02301143|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17184606|NCT03740490|f||||f
17184607|NCT02536508|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17184608|NCT04483479|f||||t
17184609|NCT01889420|t||||
17184610|NCT03535649|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17184611|NCT02460991|f||||f
17184612|NCT00434057|f||GT60||t
17184613|NCT02473952|f||OTHER|Site may publish results from the study, after providing Sponsor at least thirty days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At Sponsor's request, the site will remove any confidential information (other than study results), and incorporate all reasonable comments by Sponsor, or delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17134739|NCT04458857|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17134740|NCT00968344|f||||f
17134741|NCT03368404|f||OTHER|Sponsor have at least 60 days to review any publication or presentation. The first release of results will involve all sites in this multicenter study.|t
17139683|NCT04888507|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17139684|NCT00400946|f||||f
17139685|NCT03765736|t||||
17139686|NCT01673373|f||||f
17139687|NCT05426460|f||||f
17139688|NCT02996305|f||OTHER|"Publication~1. Institution/Investigator will submit to Sponsor any paper relating to the Study 60 days prior to disclosure. If Sponsor wants a patent to be filed on Inventions, then the period shall be extended by 90 days~2. Multi-center Studies.Institution/Investigator may publish a paper in its performance of Study after the later of (a) publication of the multi-center publication; (b) confirmation there will be no multi-center publication; or(c) 36 months after the completion of the Study"|t
17139689|NCT01712776|t||||
17139690|NCT02531633|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139691|NCT01572844|t||||
17139692|NCT05171816|f||||f
17139693|NCT04667949|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139694|NCT02000622|f||GT60||t
17139695|NCT01405027|f||LTE60||t
17139696|NCT00424840|f||||f
17134742|NCT03949673|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17134743|NCT01328873|f||OTHER|Publications will need prior written consent from sponsor.|t
17134744|NCT00586690|t||||
17134745|NCT00098059|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134746|NCT01684826|f||LTE60||t
17134747|NCT01607892|f||||t
17134748|NCT04884243|f||||t
17134749|NCT03414359|t||||
17134750|NCT02273973|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134751|NCT03294304|t||||
17134752|NCT02403206|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17134753|NCT02798523|t||||
17134754|NCT02628223|t||||
17134755|NCT01769404|f||GT60||t
17134756|NCT02768129|t||||
17134757|NCT02680301|t||||f
17134758|NCT00095121|f||OTHER|Publication must include results in their entirety and not as individual center data. Results may be published/presented at scientific meetings. All manuscripts/abstracts must be submitted to Gilead prior to submission. Any formal publication of the study in which input of Gilead personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Gilead personnel.|t
17179646|NCT03975790|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179647|NCT04271605|t||||
17179648|NCT02485301|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179649|NCT04493281|f||OTHER||t
17179650|NCT01781403|f||OTHER||t
17179651|NCT00085631|f||||f
17179652|NCT01349790|f||||f
17179653|NCT00597545|f||||f
17179654|NCT02085785|t||||
17134759|NCT02209597|t||||
17134760|NCT00003270|t||||
17134761|NCT02378753|f||||f
17134762|NCT03572634|f||||f
17134763|NCT03551522|f||||t
17134764|NCT03567187|f||||f
17134765|NCT01225068|f||||f
17134766|NCT00907738|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17134767|NCT00266110|t||||
17134768|NCT02742649|f||OTHER|"No presentation or publication of Institution's data relating to the Trial may occur until after the Trial has been completed at all sites. If Investigator desires to present or publish, investigator must submit any and all manuscripts, posters, abstracts, or other intended publications (hereinafter collectively referred to as manuscripts) to Sponsor at least sixty (60) days prior to the actual submission of such manuscript(s) for publication."|t
17134769|NCT01709799|f||||f
17134770|NCT00435539|f||LTE60||t
17134771|NCT02089737|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179655|NCT00779467|t||||
17134773|NCT04426630|f||||f
17134774|NCT01466751|f||||f
17134775|NCT03847337|t||||
17134776|NCT03451825|f||||f
17134777|NCT00849693|f||GT60||t
17134778|NCT01062399|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17134779|NCT00249379|t||||
17134780|NCT03323307|t||||
17134781|NCT03163342|f||||f
17134782|NCT04021472|t||||
17134783|NCT00003820|f||||f
17134784|NCT01260181|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179656|NCT02692703|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179657|NCT02442869|f||||f
17134785|NCT00984659|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134786|NCT02951273|f||||f
17134787|NCT00121225|f||LTE60||t
17134788|NCT00635102|t||||
17184614|NCT00455195|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17184615|NCT02117570|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184616|NCT00546728|f||||f
17184617|NCT02508311|f||||f
17184618|NCT02169674|f||||f
17184619|NCT03349710|f||LTE60||t
17184620|NCT02727894|f||OTHER|Results can be published exclusively by the main investigator or after main investigator approval.|t
17184621|NCT02585895|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184622|NCT04258020|t||||
17184623|NCT00659633|f||||f
17184624|NCT00986999|t||||
17184625|NCT03836287|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied.|t
17184626|NCT00833989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134789|NCT01938625|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17134790|NCT02088034|f||||f
17134791|NCT02424149|t||||
17134792|NCT03063255|t||||
17134793|NCT01025336|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134794|NCT00545818|f||LTE60||t
17134795|NCT02723630|f||OTHER||t
17134796|NCT03811951|t||||
17134797|NCT02255838|f||||f
17134798|NCT01184989|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17134799|NCT01570491|f||||f
17134800|NCT03047213|f||LTE60||t
17134801|NCT01515072|f||||f
17134802|NCT00609128|f||||f
17134803|NCT04407507|f||||f
17134804|NCT00923091|f||OTHER|A site may not publish results until after a coordinated multicentre publication has been submitted for publication or until one year after the study has ended, whichever occurs first. Then, the site will have the opportunity to publish the results, provided that DSE has had the opportunity to review and comment on the site's proposed publication prior to its being submitted for publication with the advice of company patent council and in accord with needs for subject protection.|t
17134805|NCT01633060|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139697|NCT05085327|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17184627|NCT04159688|f||||f
17134806|NCT04460027|f||||f
17134807|NCT00949650|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17134808|NCT03529214|t||||f
17134809|NCT00938548|f||||f
17134810|NCT00069121|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139698|NCT00585104|f||||f
17139699|NCT01145833|f||||f
17139700|NCT05241470|f||GT60||t
17184628|NCT01805297|f||||f
17184629|NCT00836641|t||||f
17134811|NCT01832961|t||||
17134812|NCT02983292|f||||f
17139701|NCT02334813|t||||
17139702|NCT03624478|t||||
17139703|NCT02784496|t||||
17139704|NCT04924114|f||OTHER|The investigator will submit the proposed publication to the sponsor at least 30 days prior to the date of submission for publication. The sponsor can request to remove any confidential information other than study data from a proposed publication during the review period. The sponsor may also suggest changes to the presentation of study data and timing of the proposed publication.|t
17139705|NCT04960202|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139706|NCT00354484|f||LTE60||t
17139707|NCT03558828|f||||f
17139708|NCT00378534|t||||f
17139709|NCT00732654|t||||f
17139710|NCT03657576|f||||t
17139711|NCT05618808|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17139712|NCT04284787|f||LTE60||t
17139713|NCT01874353|f||GT60||t
17139714|NCT04392154|f||GT60||t
17139715|NCT04992507|f||||f
17139716|NCT03728881|f||LTE60||t
17139717|NCT04088331|f||LTE60||t
17139718|NCT00576147|f||||f
17139719|NCT03137888|t||||
17139720|NCT02155712|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts \& abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to the submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17139721|NCT01933399|t||||
17139722|NCT02756845|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139723|NCT01688999|f||||f
17139724|NCT02951455|f||||f
17139725|NCT01025232|t||||
17139726|NCT02618512|f||OTHER||t
17139727|NCT00815776|f||||f
17139728|NCT00559013|f||||f
17139729|NCT04228445|f||GT60||t
17184630|NCT01757964|f||||f
17184631|NCT02105948|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184632|NCT03447782|f||||f
17139730|NCT02583360|f||||f
17139731|NCT00835276|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17139732|NCT01316380|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17139733|NCT02253160|f||LTE60||t
17139734|NCT01894776|f||||f
17139735|NCT03512275|f||OTHER|The results of this study will be published and/or presented at scientific meetings in a timely manner. The publication policy is described in the contract between the Sponsor and Investigator.|t
17139736|NCT01307046|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. The sponsor review can be expedited to meet publication timelines.|t
17139737|NCT00609167|t||||
17139738|NCT02574520|f||||t
17139739|NCT02550093|t||||
17139740|NCT01365091|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139741|NCT05116683|t||||
17139742|NCT00392951|t||||
17139743|NCT01474889|f||||f
17184633|NCT04747977|f||||f
17139744|NCT03298048|t||||
17139745|NCT03935594|f||||f
17139746|NCT01435122|t||||
17139747|NCT04412668|f||||t
17139748|NCT02482389|t||||
17139749|NCT03864627|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17139750|NCT01388491|f||OTHER|Investigator/Institution must submit proposed publication to Sponsor for review within a prespecified number of days before submission for publication. If Sponsor's review shows that potentially patentable subject matter would be disclosed, publication/public disclosure shall be delayed to enable Sponsor, or Sponsor's designees, to file necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17139751|NCT00397891|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139752|NCT04964557|f||||t
17134813|NCT00964795|f||OTHER|The investigator (PI) may publish results provided a copy of oral/ written publication is received by sponsor at least 45 days in advance for review \& comment. If the parties disagree, PI agrees to meet with sponsor prior to submission to resolve any disagreement. Sponsor reserves the right to remove confidential information from such submission. It is also agreed that publication of results shall be made only as part of a publication of the results obtained by all sites performing the study.|t
17134814|NCT03661541|f||||f
17184634|NCT01587651|f||OTHER|Consultants may not publish in any way without the prior written consent of Daiichi Sankyo Inc., which consent may be witheld by DSI in its sole discretion, any material or manuscript relating to Consultant's work hereunder and/or any information or materials that Consultant received in connection with or pursuant to this Agreement or Consultant's relationship established with DSI.|t
17184635|NCT00355082|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184636|NCT04323436|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184637|NCT03971643|f||OTHER|Publication of the results of the Study conducted at the Study Site shall not be made before the first multi-site publication by Sponsor occured within 18 months|t
17184638|NCT01660763|f||GT60||t
17184639|NCT03325712|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17184640|NCT00952653|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184641|NCT02265237|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17184642|NCT00650546|f||||f
17184643|NCT01178853|f||OTHER|May not publish|t
17184644|NCT03550313|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184645|NCT00839072|f||OTHER|Approval from the sponsor will be required prior to publication of the results of this study and a draft manuscript will be submitted to the sponsor for scrutiny and comment. The choice of scientific journal will be mutually agreed on by the investigator and the sponsor.|t
17184646|NCT05003791|t||||f
17134815|NCT00231478|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17134816|NCT04095416|t||||
17134817|NCT01134510|f||||f
17134818|NCT03983941|t||||
17134819|NCT03022422|f||||f
17134820|NCT00393458|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17134821|NCT00603044|t||||
17134822|NCT01282814|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17134823|NCT02509546|t||||
17134824|NCT00957372|f||OTHER||t
17134825|NCT01524289|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17134826|NCT02104180|f||||f
17134827|NCT01444391|f||GT60||t
17134828|NCT01535937|t||||
17134829|NCT02704429|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17134830|NCT00104104|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety.|t
17134831|NCT01274897|f||GT60||t
17134832|NCT01821677|f||||t
17134833|NCT01855789|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134834|NCT03067311|t||||
17184647|NCT00380068|f||OTHER|PIs have right disclose data upon publication of a multi-center publication coordinated by Sponsor or 18 months after Study is completed at all sites if multi-center publication is not submitted by Sponsor within 12 mos. PI to furnish Sponsor with copy of proposed disclosure at least 90 days prior to proposed disclosure. Sponsor has right to ensure accuracy of disclosure and request deletion of confidential information. Sponsor may not make editorial changes to the results or conclusions.|t
17184648|NCT01297062|f||LTE60||t
17184649|NCT01458574|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184650|NCT02125786|t||||
17184651|NCT04964089|f||OTHER|Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184652|NCT01682837|t||||
17184653|NCT01196975|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184654|NCT01365494|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial|t
17134835|NCT01089725|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134836|NCT01777438|t||||
17134837|NCT02495077|f||||f
17134838|NCT03726671|t||||
17134839|NCT01978912|f||LTE60||t
17134840|NCT04220866|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17134841|NCT02138110|f||||f
17134842|NCT00844298|f||||f
17134843|NCT05134974|f||GT60||t
17134844|NCT01408537|f||||f
17134845|NCT01878006|t||||
17134846|NCT00052429|t||||
17184655|NCT01494051|f||||f
17184656|NCT03006328|t||||
17184657|NCT03086447|f||GT60||t
17184658|NCT00955877|f||||f
17184659|NCT03394924|f||||t
17184660|NCT01842789|f||||f
17184661|NCT03588572|f||||t
17184662|NCT00450424|f||||f
17184663|NCT00364858|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17184664|NCT00627705|f||||f
17134847|NCT03140254|f||||f
17134848|NCT03842709|t||||
17134849|NCT00791128|f||||f
17134850|NCT03897712|f||OTHER|Please contact sponsor for details.|t
17134851|NCT03952650|t||||
17134852|NCT02757547|f||LTE60||t
17134853|NCT04901897|f||OTHER|Please contact sponsor directly for details.|t
17134854|NCT01357239|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17134855|NCT01542372|f||||f
17134856|NCT03133481|t||||
17134857|NCT00577590|t||||
17134858|NCT00609609|t||||
17134859|NCT00637728|f||OTHER||t
17134860|NCT00325572|t||||
17134861|NCT01050062|t||||
17134862|NCT04084392|t||||
17134863|NCT00670111|f||OTHER||t
17134864|NCT03988751|t||||
17134865|NCT02623361|f||||f
17134866|NCT01673061|t||||
17134867|NCT00844883|t||||
17134868|NCT03894540|f||||t
17134869|NCT01938170|f||||f
17134870|NCT01625169|t||||
17134871|NCT03000452|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17134872|NCT03043365|t||||
17134873|NCT03455543|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated or arising from the performance of this Agreement is not permitted without the prior written consent of Regenesis. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17134874|NCT02873221|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17134875|NCT01508676|f||||f
17134876|NCT02532543|t||||
17134877|NCT02048878|f||||f
17134878|NCT02614794|f||||t
17139753|NCT04511338|f||OTHER||t
17139754|NCT02369211|f||||f
17139755|NCT03649815|t||||
17139756|NCT03695471|t||||
17184665|NCT03151434|f||||f
17184666|NCT02142049|f||||f
17184667|NCT02535065|f||OTHER|The sponsor can review results communications from PI prior to public release and can embargo communications of trial results between 60 and 180 days from the time submitted to the sponsor for review. The sponsor can embargo publications until the sponsor has published results or 180 days has elapsed after study closure at all participating sites. The sponsor cannot restrict publication but can require changes to protect sponsor's intellectual property rights or other confidential information.|t
17184668|NCT00110617|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184669|NCT01781572|f||OTHER|The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in the clinical trials.|t
17184670|NCT00045110|f||LTE60||t
17184671|NCT00660010|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17184672|NCT01489579|f||||f
17184673|NCT04827576|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184674|NCT03069482|f||||f
17184675|NCT04537923|f||GT60||t
17184676|NCT01261611|f||||f
17184677|NCT02527798|t||||
17184678|NCT02498483|t||||
17184679|NCT00920426|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184680|NCT03282981|f||||f
17134879|NCT00906789|f||OTHER|Sponsor can review results communications prior to public release; review by sponsor must be completed within 60 days. Public release of results cannot occur prior to the completion of the FDA review of submitted results.|t
17134880|NCT02334267|f||LTE60||t
17134881|NCT02984878|f||OTHER|There are restrictions within the site contracts, sites cannot publish any results and also have confidentiality agreements in place separately that restrict any publications by sites regarding results, findings, etc.|t
17134882|NCT02796144|t||||f
17134883|NCT03291197|f||||f
17134884|NCT02460822|f||||f
17134885|NCT00691574|f||||f
17134886|NCT01396525|f||LTE60||t
17134887|NCT03114969|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139757|NCT02859558|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17139758|NCT05665595|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17139759|NCT02358863|t||||
17179658|NCT05048784|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139760|NCT00142818|f||LTE60||t
17139761|NCT04021628|t||||
17179659|NCT00885105|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17179660|NCT03519932|f||||f
17179661|NCT00284050|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179662|NCT00038857|f||||f
17179663|NCT03729960|f||||f
17179664|NCT02573350|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17134888|NCT04601272|f||||f
17139762|NCT04969900|f||||f
17139763|NCT03691649|f||||t
17139764|NCT03537937|f||||f
17184681|NCT01432366|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184682|NCT02345031|f||LTE60||t
17184683|NCT01997398|t||||
17184684|NCT01787617|t||||
17184685|NCT01275625|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184686|NCT01349569|t||||
17184687|NCT02105116|t||||
17184688|NCT00263666|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184689|NCT00896168|f||GT60||t
17184690|NCT02492100|f||||f
17184691|NCT03319277|f||||f
17184692|NCT02346383|f||||f
17184693|NCT01003899|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184694|NCT04389762|t||||
17184695|NCT01512225|f||||f
17184696|NCT02489500|t||||
17184697|NCT02863926|f||||f
17184698|NCT01259713|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184699|NCT03422250|t||||f
17184700|NCT00440050|f||||f
17184701|NCT01780922|f||||f
17184702|NCT06111742|t||||
17184703|NCT01917526|t||||
17184704|NCT04717596|f||||f
17184705|NCT00085410|f||LTE60||t
17184706|NCT02864082|f||||f
17184707|NCT01127178|f||OTHER||t
17184708|NCT03621696|t||||
17184709|NCT04349553|f||||f
17184710|NCT02063724|t||||
17184711|NCT01715805|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184712|NCT04936230|f||LTE60||t
17184713|NCT05177770|f||||f
17184714|NCT02365467|f||OTHER|Medtronic owns the data of this clinical study, a single investigation site may access and use the data provided by itself for scientific publications following prior approval by Medtronic.|t
17184715|NCT02043782|t||||
17184716|NCT00709722|f||||f
17184717|NCT04667117|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17184718|NCT01306162|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184719|NCT02626715|t||||
17184720|NCT01947946|f||||f
17184721|NCT02959437|f||OTHER|Clinical Study Agreement|t
17184722|NCT00864032|f||LTE60||t
17184723|NCT01059760|t||||
17184724|NCT01949480|t||||
17184725|NCT02372396|f||||f
17184726|NCT02890381|f||||f
17184727|NCT00958035|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17184728|NCT02952924|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184729|NCT03085563|t||||
17184730|NCT03825380|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17184731|NCT02232893|f||||f
17184732|NCT01358526|f||GT60||t
17184733|NCT04690855|f||||f
17184734|NCT00527566|f||||f
17184735|NCT00156065|f||OTHER|Except for compelling legal reasons, neither the sponsor nor the investigator will communicate to third parties any result of the clinical trial before the CTR has been released by the sponsor.|t
17184736|NCT04745169|f||||f
17184737|NCT01292603|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184738|NCT01808690|f||||f
17134889|NCT00414440|f||OTHER|"Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety."|t
17134890|NCT02168946|f||||f
17134891|NCT04634162|t||||
17134892|NCT04222725|f||OTHER|There is an agreement between Principal Investigators (and their Institutions) and the Sponsor that restricts the PI's rights to discuss or publish results of this study without the prior written consent of the study Sponsor.|t
17134893|NCT02457897|t||||
17134894|NCT03134963|t||||
17134895|NCT01743027|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17184739|NCT03870763|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17184740|NCT02891187|t||||f
17134896|NCT02498821|f||||f
17134897|NCT01363843|f||||f
17134898|NCT02708212|f||||f
17134899|NCT05341466|f||||f
17134900|NCT03037905|f||||f
17134901|NCT01333189|t||||
17184741|NCT01615731|f||||f
17184742|NCT03586648|f||GT60||t
17184743|NCT02041195|f||||f
17184744|NCT02395120|f||||f
17184745|NCT01641978|t||||
17184746|NCT00674986|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134902|NCT01928030|f||||f
17134903|NCT03557372|t||||
17134904|NCT02042131|f||||f
17134905|NCT01787591|f||||f
17134906|NCT04435769|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17134907|NCT02725177|t||||
17134908|NCT00793585|t||||
17134909|NCT00377299|t||||
17134910|NCT01894516|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17134911|NCT01582282|f||OTHER|Data, calculations, interpretations, opinions, and recommendations are the property of P\&GP|t
17134912|NCT01486316|f||||f
17184747|NCT02526693|f||||f
17184748|NCT03009045|f||||f
17184749|NCT01585103|t||||
17184750|NCT02434692|f||||f
17184751|NCT03581305|t||||
17184752|NCT00778648|f||||f
17184753|NCT01798927|f||||f
17184754|NCT03750552|f||||t
17184755|NCT00626522|f||OTHER|Publication and/or presentation whether complete or partial, of any part of the data or results of this trial, will be subject to revision and written agreement between the investigator and sponsor.|t
17184756|NCT02156674|t||||
17134913|NCT00112151|f||||f
17134914|NCT01792986|t||||
17134915|NCT03191396|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17134916|NCT02770287|f||||f
17134917|NCT03635190|f||||f
17134918|NCT00970203|t||||
17134919|NCT03692910|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17134920|NCT01322607|t||||
17134921|NCT03774745|f||||f
17134922|NCT01981122|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17184757|NCT01562756|t||||
17184758|NCT01490632|f||GT60||t
17184759|NCT03822533|t||||
17184760|NCT00780208|t||||
17184761|NCT02349295|f||GT60||t
17184762|NCT01449305|f||||f
17184763|NCT06390098|f||OTHER|Agreement finally allows PI to publish independently.|t
17184764|NCT02148250|f||||f
17184765|NCT00958919|f||||f
17184766|NCT01552213|f||||f
17184767|NCT00695903|f||OTHER|The first publication is initiated by Cubist. If first publication not published within 1 year of study conclusion or termination, Investigator has right to publish and disclose the data. Prior to any submission for publication, presentation, or communication of results or information arising from the study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17184768|NCT04723576|f||||f
17184769|NCT02097472|f||||f
17184770|NCT03966157|f||||f
17184771|NCT03305016|f||||f
17184772|NCT01362140|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184773|NCT01673802|t||||
17184774|NCT06476366|f||||f
17184775|NCT01546194|t||||
17184776|NCT01201629|t||||
17184777|NCT02310750|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184778|NCT01226745|f||OTHER||t
17184779|NCT00395876|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184780|NCT01435577|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17184781|NCT01934218|f||OTHER||t
17134923|NCT03060577|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134924|NCT02435173|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17134925|NCT02392208|f||||f
17134926|NCT00092547|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184782|NCT00875836|f||||f
17184783|NCT01939028|t||||
17184784|NCT01140191|f||||f
17184785|NCT02955511|f||||f
17184786|NCT00700401|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184787|NCT01220557|t||||
17184788|NCT01650259|t||||f
17184789|NCT04782323|f||||f
17184790|NCT05893992|t||||
17184791|NCT01359735|f||LTE60||t
17134927|NCT04328623|f||OTHER||t
17134928|NCT01539837|t||||
17134929|NCT02988986|t||||
17134930|NCT00685178|f||||f
17184792|NCT02663128|f||GT60||t
17184793|NCT00105027|f||||f
17184794|NCT01778465|f||||f
17184795|NCT02715765|f||||f
17134931|NCT00077623|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134932|NCT02412644|f||||f
17134933|NCT00882713|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134934|NCT02760602|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17184796|NCT02060890|f||||f
17184797|NCT00581529|t||||
17184798|NCT00801827|t||||
17184799|NCT03387852|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17184800|NCT02596451|f||OTHER|Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the Sponsor.|t
17184801|NCT04631666|f||OTHER|Publications by PIs are to be submitted to the sponsor for review at least 30 days prior to planned disclosure. Modifications suggested by the sponsor should be considered unless they affect the scientific character or neutrality of the publication. A maximum embargo period of 90 days is applicable only if disclosure would affect (potential) intellectual property rights.|t
17184802|NCT02194621|f||GT60||t
17184803|NCT02763384|t||||
17184804|NCT02493127|f||||f
17184805|NCT02037347|t||||
17184806|NCT03034577|f||||f
17184807|NCT04177758|t||||
17184808|NCT03708198|t||||
17184809|NCT02587351|f||||f
17134935|NCT00708877|t||||
17134936|NCT03159754|t||||
17134937|NCT01954628|f||OTHER|Investigators shall not publish any articles or make any presentations or communications (including any written, oral or electronic manuscript, abstract, presentation or other publication) relating to the Services, Sponsor Information, Study Drug or other Material, Deliverables or other Developments, in whole or part, without the prior written consent of the Sponsor.|t
17134938|NCT02740153|f||||f
17134939|NCT00283712|f||||f
17134940|NCT03321617|t||||
17134941|NCT01272180|f||GT60||t
17134942|NCT00098345|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17134943|NCT01183858|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134944|NCT02747043|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134945|NCT02046564|f||||f
17134946|NCT01419249|f||OTHER|Sponsor does not object to trial results publication by Investigator. Investigator will provide sponsor proposed publication/disclosure for review before submission. In multi-center trial, Investigator agree on first publication to be joint involving all sites. Investigator can decline to be part of joint publication. If joint manuscript has not submitted for publication within 12 months of trial completion/termination at all sites, Investigator can publish separately, subject to this agreement.|t
17134947|NCT01295905|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17134948|NCT01958606|f||||f
17134949|NCT03707977|f||||f
17134950|NCT02564120|f||||f
17134951|NCT01629667|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17134952|NCT02441803|t||||
17134953|NCT02267577|f||||f
17134954|NCT01857986|f||LTE60||t
17134955|NCT00537823|t||||
17134956|NCT03065530|t||||f
17134957|NCT00852930|f||||f
17134958|NCT01505062|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17134959|NCT01512368|t||||f
17134960|NCT00066781|t||||
17134961|NCT02648230|t||||
17134962|NCT01823653|f||OTHER|Investigator shall notify Sponsor of the intent to publish or present independent Study Data, and agrees not to publish or publicly present and/or discuss such data, Investigator's current findings and/or the results of the Study independently without the express written consent of Sponsor, which consent may be withheld. Sponsor reserves the right to require Investigator to remove any/all confidential information from any/all publications.|t
17134963|NCT02717546|f||||f
17134964|NCT01754688|f||||f
17134965|NCT05207436|t||||
17134966|NCT03756012|t||||f
17134967|NCT01731691|t||||f
17134968|NCT03396471|f||||f
17134969|NCT02282332|f||||f
17134970|NCT01716169|f||||f
17134971|NCT01088412|f||GT60||t
17134972|NCT02111811|f||||f
17134973|NCT02101008|t||||
17134974|NCT03291379|f||LTE60||t
17134975|NCT01065428|f||||f
17134976|NCT03489291|f||||t
17134977|NCT00153166|f||||f
17134978|NCT02333045|t||||
17134979|NCT01145391|f||OTHER|The study funder, Novartis Pharmaceuticals Corporation, had no role in the data analysis or manuscript preparation; however, as part of the study agreement Novartis approved the investigators' study design and final manuscript.|t
17134980|NCT05258058|f||||f
17134981|NCT05610969|t||||
17134982|NCT04579393|t||||
17134983|NCT01326962|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17134984|NCT01596595|f||GT60||t
17134985|NCT00035815|f||||f
17134986|NCT03165981|f||||f
17134987|NCT05243550|f||||f
17134988|NCT03729869|t||||
17134989|NCT01438710|f||OTHER||t
17134990|NCT01383200|f||||f
17134991|NCT00128206|t||||
17134992|NCT03270085|t||||
17134993|NCT01300286|t||||f
17134994|NCT00417612|f||||f
17134995|NCT01330381|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17134996|NCT00663858|f||GT60||t
17184810|NCT03156023|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17134997|NCT03216265|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17134998|NCT01277289|f||||f
17134999|NCT00224107|f||LTE60||t
17135000|NCT00401973|f||GT60||t
17135001|NCT05523362|t||||
17135002|NCT03515538|f||||f
17135003|NCT04075604|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17135004|NCT00950352|f||||f
17135005|NCT01650779|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17135006|NCT03666143|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17135007|NCT00471380|f||OTHER|Any formal presentation of data publication from this study has to be a joint presentation from both the Investigators and the Sponsor. Being the study multicentric, it is mandatory that the first publication is based on data from all the centres, analysed according to the protocol. Data from a single Centre can not be presented, unless there Is a formal agreement from the other Investigators and Alcon.|t
17135008|NCT04329923|t||||
17135009|NCT01048125|t||||
17135010|NCT04146272|t||||
17135011|NCT00641147|f||LTE60||t
17135012|NCT01966731|t||||
17135013|NCT00353977|t||||
17135014|NCT01380093|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135015|NCT04734873|f||OTHER|Investigators are free to publish/present study results from their site upon occurrence of one of either: a multi-center publication, no publication is submitted within 18 months after end of study, or sponsor confirms there will be no publication. Investigators must provide the sponsor all draft publications for review at least 30 days prior to submission. Sponsor may request to defer publication and/or delete sponsor's confidential information to allow the sponsor to preserve its IP rights.|t
17135016|NCT00318708|f||||f
17135017|NCT00824538|f||||f
17135018|NCT00328198|f||OTHER|In multi-site studies, PI can publish after an independent multi-investigator publication (in which the PI can participate) or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17135019|NCT00718861|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17135020|NCT03237845|f||LTE60||t
17135021|NCT04355117|f||||f
17135022|NCT01889810|t||||
17135023|NCT03865407|t||||
17135024|NCT02117050|f||OTHER|The study as a whole will be published prior to any individual investigator publications. It is required that copies of all papers, abstracts, articles, etc. that contain study data are to be forward to the Sponsor for review 30 days prior to submission for publication.|t
17135025|NCT01645280|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17135026|NCT02723162|t||||
17135027|NCT00234104|f||||f
17135028|NCT01819922|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139765|NCT03671148|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17139766|NCT04423718|f||LTE60||t
17139767|NCT00425945|f||||f
17139768|NCT03315702|t||||
17184811|NCT02010060|f||||f
17135029|NCT00546819|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.|t
17135030|NCT00175006|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17135031|NCT02052960|f||OTHER|Publication, presentation or use of the methods and/or results of the clinical trial are not permitted without prior written sponsor´s consent.|t
17135032|NCT03849560|f||||t
17135033|NCT04045613|f||GT60||t
17184812|NCT00726752|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184813|NCT00976599|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184814|NCT00791765|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17184815|NCT04575896|t||||
17184816|NCT04704375|f||||f
17184817|NCT01429532|t||LTE60||t
17184818|NCT03576547|t||||
17184819|NCT01461668|t||||f
17184820|NCT01024569|t||||
17184821|NCT00907153|t||||
17184822|NCT04546581|t||||
17184823|NCT03147248|f||||t
17184824|NCT02062632|t||||
17184825|NCT02212028|t||||
17184826|NCT02280044|t||||
17184827|NCT00581230|f||||f
17184828|NCT02241967|t||||
17184829|NCT04517396|f||||f
17184830|NCT02332720|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17184831|NCT03832010|f||GT60||t
17184832|NCT01412944|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17184833|NCT01990950|f||GT60||t
17184834|NCT00922428|f||||f
17184835|NCT01343368|f||||f
17184836|NCT00321854|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184837|NCT03204279|f||||f
17184838|NCT02119416|f||||f
17135034|NCT04983901|t||||
17135035|NCT01243593|f||||f
17135036|NCT01057121|f||LTE60||t
17135037|NCT02859415|f||||f
17135038|NCT01174784|f||LTE60||t
17135039|NCT01678846|t||||
17135040|NCT02046135|t||||
17135041|NCT00450866|t||||
17135042|NCT00754767|t||||
17139769|NCT05032755|t||||
17184839|NCT04323852|t||||
17184840|NCT01617421|t||||
17184841|NCT02384759|f||||f
17184842|NCT03043664|f||||f
17184843|NCT02297308|f||OTHER|PI shall be permitted to publish the results of the study in a manner that fairly and accurately sets forth the conclusions reached. The party seeking publication shall submit to the sponsor for review a draft of the proposed publication at least thirty (30) days prior to submission of the draft for publication.|t
17184844|NCT03593655|f||||f
17184845|NCT01631630|t||||
17184846|NCT01981564|t||||
17184847|NCT03732209|f||||f
17184848|NCT05046795|f||OTHER|"Any publication by an Institution/Investigator of the study results shall not be made before the first multi-center publication by the Sponsor.~Thereafter, before submission for publication or presentation, the Investigator shall allow the Sponsor at least 60 days to review any manuscript and at least 30 days to review any poster presentation, abstract or other written or oral material. The Sponsor may request in writing that any publication or presentation be withheld for a further 60 days."|t
17184849|NCT04738643|f||||f
17184850|NCT03759873|f||||f
17184851|NCT03579563|f||||f
17184852|NCT02647359|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17139770|NCT06085443|f||||f
17184853|NCT02513563|t||||
17184854|NCT00233493|f||||f
17184855|NCT04618718|f||||f
17184856|NCT04818346|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17184857|NCT03150056|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184858|NCT00965523|f||||f
17135043|NCT01478347|f||OTHER|Other disclosure agreement: the terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial|t
17135044|NCT03461965|t||||
17135045|NCT01399827|f||||f
17139771|NCT03774875|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139772|NCT05706623|f||||t
17139773|NCT03149029|t||||
17139774|NCT03233308|f||||f
17139775|NCT03287830|f||||f
17139776|NCT02974621|f||LTE60||t
17139777|NCT01856855|t||||
17139778|NCT00557323|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17139779|NCT03003130|f||||t
17139780|NCT01863901|f||LTE60||t
17139781|NCT04099836|t||||
17139782|NCT01196091|f||GT60||t
17139783|NCT03797144|f||GT60||t
17139784|NCT03077711|f||||f
17139785|NCT00376675|t||||
17139786|NCT00995215|t||||
17139787|NCT02943668|t||||
17139788|NCT02201251|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139789|NCT01332851|f||||f
17139790|NCT01937624|f||||f
17139791|NCT01947894|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139792|NCT00333970|t||||
17139793|NCT02005510|f||||f
17139794|NCT01300949|f||||f
17179665|NCT00743340|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17179666|NCT01929460|t||||
17179667|NCT02708121|f||||f
17179668|NCT03508921|f||||f
17179669|NCT01425281|f||LTE60||t
17179670|NCT01833520|t||||
17179671|NCT02743520|t||||
17179672|NCT01749514|f||OTHER|The publication or disclosure of study results will be permitted as per the agreement between the sponsor and the investigator(s).|t
17179673|NCT01979016|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17179674|NCT04648631|t||||
17179675|NCT04983264|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179676|NCT00938639|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179677|NCT02606604|t||||f
17179678|NCT02509156|t||||
17179679|NCT02547649|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17179680|NCT04326231|t||||
17179681|NCT00571987|f||||f
17179682|NCT00426855|t||||f
17179683|NCT02551731|f||||f
17179684|NCT05259696|f||OTHER||t
17179685|NCT06185374|f||||f
17179686|NCT01750242|f||LTE60||t
17179687|NCT03857243|f||||f
17179688|NCT03765918|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17179689|NCT04202965|f||||t
17179690|NCT00006903|f||||f
17179691|NCT00187369|f||||f
17179692|NCT02254252|f||||f
17179693|NCT02348606|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17184859|NCT01762046|t||||
17184860|NCT01581281|f||||f
17184861|NCT02187991|f||GT60||t
17184862|NCT01404572|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17184863|NCT03282890|f||||f
17184864|NCT03273946|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184865|NCT01308918|f||||f
17184866|NCT00092131|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184867|NCT02522715|t||||
17184868|NCT01808313|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17184869|NCT03980470|t||||
17184870|NCT03858803|f||||f
17184871|NCT01954017|f||GT60||t
17184872|NCT04598152|f||||f
17135046|NCT01863758|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17184873|NCT01748916|f||||f
17184874|NCT02271386|t||||f
17184875|NCT03346759|t||||
17184876|NCT03277313|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17184877|NCT00746603|t||||
17184878|NCT01311102|f||||f
17184879|NCT02132611|f||OTHER|Any previously unpublished information provided to the Investigators by the Sponsor is confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study not use it for other purposes without the Sponsor's written consent. An Investigator can generate additional publication ideas based on the trial data. The Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data.|t
17184880|NCT02096900|t||||
17184881|NCT03919422|t||||
17184882|NCT01592643|t||||
17184883|NCT01995123|f||||f
17184884|NCT02657226|f||||f
17184885|NCT03680755|f||||f
17184886|NCT05819749|f||||f
17184887|NCT01877408|f||||f
17184888|NCT00377234|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184889|NCT01880424|f||OTHER|All data generated in this trial will be the property of AstraZeneca and Ironwood Pharmaceuticals, Inc. An integrated clinical and statistical report will be prepared at the completion of the trial. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator, AstraZeneca, and Ironwood Pharmaceuticals, Inc.|t
17184890|NCT04396834|f||||f
17184891|NCT01983293|f||||f
17184892|NCT01747772|t||||
17184893|NCT03929029|t||||
17184894|NCT00381966|f||||f
17184895|NCT01944631|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17184896|NCT01578993|f||||f
17184897|NCT02388724|f||OTHER|The first study-related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17184898|NCT02716974|t||||
17135047|NCT02369510|t||||
17135048|NCT02088216|t||||
17135049|NCT04661813|f||||f
17135050|NCT04285723|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17139795|NCT01678560|t||||
17184899|NCT02605954|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184900|NCT00511862|f||||f
17184901|NCT00856856|f||LTE60||t
17184902|NCT03814889|f||||f
17135051|NCT03118843|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17135052|NCT01507246|f||||f
17135053|NCT04224987|f||||f
17135054|NCT02903511|t||||
17135055|NCT00969618|f||GT60||t
17135056|NCT05136885|t||||
17135057|NCT05363293|f||LTE60||t
17135058|NCT01318902|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17135059|NCT02747628|f||||f
17135060|NCT06384989|f||||f
17135061|NCT05287893|f||OTHER|The PI's organisation will prepare the manuscript once the Clinical Study Report finalisation (within 12 months of trial completion). The Sponsor organisation will have 45 days to review prior to submission for for publication.|t
17135062|NCT01783522|t||||
17135063|NCT00375934|f||OTHER||t
17135064|NCT02452970|f||||f
17139796|NCT00533351|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 40 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17139797|NCT00056550|f||||f
17139798|NCT00322387|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17139799|NCT02092168|f||OTHER||t
17184903|NCT02696317|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17184904|NCT00413153|f||LTE60||t
17184905|NCT02277106|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17184906|NCT00485485|t||||f
17184907|NCT01669629|f||GT60||t
17184908|NCT01221597|f||OTHER||t
17184909|NCT02504073|t||||
17184910|NCT01877538|f||||f
17184911|NCT00487162|t||||f
17184912|NCT02278328|f||||f
17184913|NCT01347333|f||||f
17184914|NCT02366338|f||||f
17184915|NCT03834779|f||||f
17184916|NCT01059565|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17135065|NCT00893113|t||||
17135066|NCT04192448|f||||f
17135067|NCT02400346|f||||f
17139800|NCT01828567|t||||
17139801|NCT00195624|t||||
17139802|NCT00090766|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184917|NCT02162420|t||||
17184918|NCT03638141|t||||
17135068|NCT01269125|t||||
17135069|NCT02340104|f||GT60||t
17135070|NCT04510922|f||||f
17135071|NCT01283581|f||GT60||t
17135072|NCT00486226|f||||f
17135073|NCT01259492|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17135074|NCT02773758|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135075|NCT02778880|t||||
17135076|NCT04315363|f||||f
17139803|NCT00707486|f||||f
17184919|NCT05725005|f||||f
17184920|NCT03526250|f||LTE60||t
17184921|NCT00388414|f||||f
17184922|NCT00522275|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17184923|NCT02576067|f||LTE60||t
17184924|NCT04773587|f||OTHER|The Sponsor is generally supportive of publication of trial results.|t
17184925|NCT02372409|t||||
17184926|NCT00477191|f||||f
17184927|NCT00622167|t||||
17184928|NCT02073331|f||GT60||t
17184929|NCT00158743|f||||f
17135077|NCT00641043|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135078|NCT03088605|f||||f
17135079|NCT04635735|t||||
17135080|NCT01936649|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17135081|NCT03136705|f||||f
17135082|NCT01215318|t||||f
17135083|NCT04655586|f||||f
17135084|NCT02345369|t||||
17135085|NCT00201201|t||||f
17135086|NCT02296346|f||||f
17135087|NCT00631319|f||||f
17135088|NCT00621933|f||LTE60||t
17135089|NCT01342640|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135090|NCT00891657|f||||f
17135091|NCT01745055|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139804|NCT03296072|f||OTHER||t
17139805|NCT00654368|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17139806|NCT00804986|f||GT60||t
17139807|NCT00959699|f||OTHER|The Investigator must provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc.) that report any results of the trial. The sponsor shall have the right to review and comment.|t
17139808|NCT00606294|t||||
17139809|NCT02421146|f||||f
17135092|NCT02739698|f||||f
17135093|NCT02927171|t||||
17135094|NCT01065480|f||||f
17135095|NCT04530825|t||||
17135096|NCT03870022|t||||
17135097|NCT04101422|t||||
17135098|NCT02640612|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135099|NCT01720667|f||||f
17135100|NCT03472534|f||||f
17135101|NCT00552305|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17135102|NCT01319929|f||GT60||t
17135103|NCT01507545|f||||t
17135104|NCT00553787|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17135105|NCT02285010|t||||
17179694|NCT01678911|f||||f
17179695|NCT03250845|t||||
17179696|NCT02706691|t||||
17179697|NCT01402492|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results. The sponsor can require changes to the communication and can extend the embargo.|t
17179698|NCT01980992|t||||
17179699|NCT04380116|t||||
17179700|NCT02408315|f||||f
17179701|NCT01366209|f||||f
17179702|NCT01985867|f||||f
17179703|NCT02670837|t||||
17179704|NCT03546192|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17179705|NCT00553514|f||OTHER||t
17179706|NCT03483051|t||||
17179707|NCT01442675|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17179708|NCT01919723|f||||f
17179709|NCT00752232|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179710|NCT04502589|t||||
17184930|NCT03674177|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17135106|NCT04170621|f||||f
17135107|NCT01426386|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17135108|NCT01457339|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17135109|NCT03694522|f||OTHER|The CTA generally does not restrict an investigator's discussion of trial results after completion. Amgen has limited time to review material discussing trial results (up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control/approval of content. For multicenter studies, PI agrees not to publish results before first multi-center publication for at least 18 mo after study completion at all sites \& all analyses of data resulting from Study.|t
17135110|NCT00196937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135111|NCT01748760|f||||f
17135112|NCT01164501|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135113|NCT01096667|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17184931|NCT00714168|f||||f
17184932|NCT01428765|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184933|NCT03969654|f||LTE60||t
17184934|NCT03230916|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17184935|NCT00383448|f||||f
17184936|NCT01128413|f||||f
17184937|NCT00765193|f||||f
17184938|NCT03077724|f||||f
17184939|NCT05023304|t||||
17184940|NCT04370054|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184941|NCT00722761|f||||f
17184942|NCT05054816|t||||
17184943|NCT02075593|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135114|NCT02522377|t||||
17135115|NCT00306891|f||OTHER|If a Study Site or an Investigator requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17135116|NCT02263365|f||||f
17135117|NCT00673673|t||||
17135118|NCT01462292|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135119|NCT01751646|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications, and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17135120|NCT00945191|f||||f
17135121|NCT02335450|f||||f
17135122|NCT01004107|f||||f
17135123|NCT02973815|f||||f
17135124|NCT02613572|f||||f
17135125|NCT00953121|t||||
17135126|NCT02342561|f||||f
17135127|NCT04538950|t||||
17135128|NCT00853905|f||||f
17135129|NCT04940598|f||||f
17135130|NCT01004146|f||||f
17135131|NCT00649961|f||LTE60||t
17135132|NCT02218203|f||||f
17135133|NCT00465738|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 weeks before submission. Sponsor to give written opinion within 30 days. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17135134|NCT02234011|f||||f
17135135|NCT02489630|f||||f
17135136|NCT01056523|f||||f
17135137|NCT03425656|f||||f
17184944|NCT05672628|t||||
17184945|NCT02522494|t||||
17184946|NCT02239679|f||OTHER|First publication of results will be made by the Sponsor. If publication is not submitted within 12 months after the date of study final report, the PI may publish the results from the site individually, subject to compliance with the other terms of the clinical trial agreement, including a requirement that the PI provide a draft of the publication for the sponsor's review 30 days before submission for publication so that sponsor can review the publication for confidential information|t
17135138|NCT03429556|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135139|NCT04952389|t||||
17135140|NCT02050048|t||||
17135141|NCT04902950|t||||
17135142|NCT02653092|f||||f
17135143|NCT02699515|f||||t
17135144|NCT01842061|f||||f
17135145|NCT02123017|f||||f
17135146|NCT01592851|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135147|NCT03454048|t||||
17135148|NCT01166659|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135149|NCT02024711|f||OTHER|Contact sponsor directly for details.|t
17135150|NCT02889510|f||||f
17135151|NCT02901262|t||||
17135152|NCT03463265|f||||f
17135153|NCT03952546|t||||f
17135154|NCT00416351|t||||
17135155|NCT01371838|f||OTHER||t
17135156|NCT01334125|f||||f
17135157|NCT01509586|f||||f
17135158|NCT04901026|f||||f
17135159|NCT04013737|t||||
17135160|NCT02584634|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135161|NCT04275310|t||||
17135162|NCT02225223|f||||f
17179711|NCT00555321|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179712|NCT00160251|f||OTHER|The principal investigator (PI) agrees to provide review copies to the sponsor 30 days prior to submission. The sponsor shall have editorial rights and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy of information, and to ensure that the presentation is fairly balanced and in compliance with regulations. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues or disagreement.|t
17179713|NCT03782272|t||||
17179714|NCT00582166|t||||
17179715|NCT00126568|f||LTE60||t
17135163|NCT02004990|t||||
17135164|NCT01749735|f||||f
17135165|NCT01221233|t||||
17135166|NCT03099369|t||||
17135167|NCT00611455|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179716|NCT02343627|f||||f
17179717|NCT00705653|f||OTHER|Any formal presentation or publication of data collected from this trial will be considered as a joint publication by the investigator(s) and the appropriate personnel of Progen. Authorship will be determined by mutual agreement.|t
17135168|NCT01241513|f||||f
17135169|NCT00858702|f||||f
17135170|NCT00491530|f||OTHER|Provide ABBOTT at least sixty (60) days prior to submission for review, ABBOTT shall return comments within sixty (60) days of receipt of draft. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period.|t
17135171|NCT02278146|f||||f
17135172|NCT03671369|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17135173|NCT02732912|f||||f
17179718|NCT00580606|f||||f
17179719|NCT01684007|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135174|NCT04382651|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17135175|NCT01873742|f||||f
17135176|NCT03739983|t||||
17135177|NCT00790296|t||||
17184947|NCT01227681|t||||
17184948|NCT02047045|t||||
17135178|NCT01671488|f||||f
17135179|NCT02612077|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135180|NCT01022853|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135181|NCT01753518|t||||
17135182|NCT01971476|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135183|NCT01985685|f||||f
17135184|NCT02075255|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17135185|NCT03792750|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135186|NCT00138151|t||||
17135187|NCT03503773|f||||f
17135188|NCT00607828|t||||
17135189|NCT02624700|t||||
17135190|NCT02675517|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135191|NCT00425438|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135192|NCT02619253|t||||
17135193|NCT02694029|t||||
17184949|NCT03214367|f||GT60||t
17184950|NCT03508843|f||||f
17184951|NCT00765843|f||||f
17184952|NCT03555396|f||||f
17184953|NCT04829344|f||OTHER|Investigative site, the Principal Investigator, and any other investigators understand and agree that the Study is a multi-center clinical study and that a multi-center publication may be prepared and published by the Sponsor. The investigative site and its investigators will not, individually or together, present or publish any findings, data or results of the Study.|t
17184954|NCT00448539|f||||f
17184955|NCT02103439|f||||f
17184956|NCT02606838|t||||
17184957|NCT04955639|t||||
17184958|NCT04447404|f||OTHER|The disclosure restriction on the PI is that if sponsor has not submitted a multi-site publication within 18 months of study completion, the PI can submit the sponsor results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI will remove confidential information from results communications prior to publication upon request.|t
17135194|NCT01417286|t||||
17135195|NCT00301067|f||||f
17135196|NCT01359982|f||||f
17135197|NCT01208181|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17135198|NCT00943878|f||LTE60||t
17135199|NCT02730247|t||||
17135200|NCT00206518|t||||
17135201|NCT04542291|t||||
17135202|NCT01269034|t||||
17135203|NCT01748695|f||||f
17135204|NCT00970294|f||||f
17135205|NCT00847561|t||||
17135206|NCT00408681|t||||f
17135207|NCT03004846|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135208|NCT01050660|t||||f
17184959|NCT01369342|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17184960|NCT01816594|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17184961|NCT03905655|f||||f
17184962|NCT01064739|t||||
17135209|NCT00447421|f||GT60||t
17184963|NCT05762835|f||||f
17184964|NCT03667053|f||||f
17135210|NCT01707147|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135211|NCT02792777|f||||f
17135212|NCT02053246|t||||
17135213|NCT03863496|f||||f
17135214|NCT02795156|f||LTE60||t
17135215|NCT02707757|t||||
17135216|NCT03320512|t||||
17184965|NCT01292928|f||OTHER|Institution and Investigator shall have the right to publish the Results, provided that before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17135217|NCT00638846|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17135218|NCT01171521|f||LTE60||t
17135219|NCT01589094|t||||
17135220|NCT03575468|f||||f
17135221|NCT03123939|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17135222|NCT02112448|f||||f
17179720|NCT03918447|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17135223|NCT02605863|t||||
17135224|NCT01040832|f||LTE60||t
17135225|NCT01058369|f||||t
17135226|NCT02940886|f||OTHER|Institution may publish the study results. Before submission for publication or presentation, Institution shall allow Sponsor not less than 90 days to review any manuscript and not less than 30 days to review any poster presentation, abstract, or any other written or oral material which describes or discloses the study results. If sponsor so requests in writing, Institution shall withhold any publication or presentation for an additional 90 days.|t
17135227|NCT00502905|t||||f
17135228|NCT01306058|f||||f
17135229|NCT01666444|f||||f
17135230|NCT00935857|t||||
17179721|NCT03278613|f||||f
17179722|NCT01405456|f||||f
17179723|NCT05353985|f||||t
17179724|NCT02298803|f||||f
17179725|NCT02989194|f||||f
17179726|NCT01327885|f||||f
17179727|NCT03824912|f||OTHER|In the Clinical Trials Agreements between the sites and the Contract Research Organization, sites are instructed that the Investigator shall not publish, or seek to publish, either in whole or in part any results of the Study without the written consent.|t
17179728|NCT01577329|t||||
17179729|NCT02950025|t||||
17179730|NCT03836612|f||||f
17179731|NCT02254486|f||||f
17179732|NCT01427504|f||||f
17179733|NCT01350414|f||LTE60||t
17179734|NCT04166435|t||||
17179735|NCT01484197|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179736|NCT00586001|t||||
17179737|NCT03033394|t||||
17179738|NCT02036294|t||||
17179739|NCT00356369|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179740|NCT03545165|t||||
17179741|NCT02117648|f||GT60||t
17179742|NCT03530098|f||||f
17135231|NCT00592358|t||||
17135232|NCT00084682|f||LTE60||t
17135233|NCT04011436|f||||f
17135234|NCT03152136|f||LTE60||t
17135235|NCT02657252|t||||
17135236|NCT03238248|t||||
17179743|NCT02695498|t||||
17179744|NCT02532972|t||||f
17179745|NCT01606436|f||GT60||t
17179746|NCT02859454|f||||f
17179747|NCT01025752|t||||f
17179748|NCT04026308|t||||
17179749|NCT01417234|f||||f
17179750|NCT00023764|f||LTE60||t
17179751|NCT02245308|t||||
17179752|NCT02407704|f||||f
17179753|NCT03944954|f||||f
17179754|NCT05564429|t||||
17135237|NCT01013883|t||||
17135238|NCT02241512|f||||f
17135239|NCT00474630|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17135240|NCT00352781|t||||
17135241|NCT00958568|f||GT60||t
17135242|NCT04978376|f||||f
17135243|NCT00915967|f||||f
17135244|NCT01591018|t||||
17135245|NCT01733069|f||LTE60||t
17135246|NCT03268746|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135247|NCT02677701|f||||f
17135248|NCT00850499|f||||f
17135249|NCT01834326|t||||
17135250|NCT03881163|f||GT60||t
17135251|NCT04109443|t||||
17135252|NCT00909090|f||||f
17135253|NCT02057237|t||||
17135254|NCT02345434|f||||f
17135255|NCT00062738|f||||f
17135256|NCT02221739|f||||f
17135257|NCT01214434|f||LTE60||t
17135258|NCT03100435|t||||
17135259|NCT02902809|f||LTE60||t
17135260|NCT00532259|f||||f
17135261|NCT00793104|f||LTE60||t
17179755|NCT02480439|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17179756|NCT02268084|f||||f
17179757|NCT05227027|f||||f
17179758|NCT03170401|f||||f
17179759|NCT02911753|t||||
17179760|NCT03334448|f||GT60||t
17179761|NCT01683383|f||||f
17184966|NCT00130533|f||LTE60||t
17184967|NCT03263429|t||||
17184968|NCT01605617|t||||f
17184969|NCT03806270|f||||f
17135262|NCT03494725|f||OTHER|Overall Non-disclosure and Confidentiality Agreement|t
17135263|NCT04983940|t||||f
17135264|NCT00514449|f||||f
17135265|NCT00149825|f||||f
17135266|NCT00942708|t||||f
17135267|NCT02760407|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17135268|NCT01645930|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application|t
17135269|NCT03245814|f||||f
17135270|NCT01158950|t||||f
17135271|NCT01811030|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17135272|NCT00510692|f||LTE60||t
17135273|NCT01765712|f||||f
17179762|NCT00855920|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17135274|NCT04337138|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135275|NCT04286867|f||||f
17179763|NCT00996307|f||||f
17179764|NCT04891874|f||||f
17179765|NCT02496611|t||||
17179766|NCT02850965|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179767|NCT01767155|f||OTHER|"According to the study protocol, draft versions of abstracts or manuscripts must be made available to the co-authors and to the sponsor before any presentation of results or submission for publication. At least 3 weeks should be allowed for review and comment of an abstract and 4 weeks in case of a full paper, respectively. Multiple review cycles are usual for full papers and respective planning must account for this. In addition, the definitions per individual trial site agreement did apply."|t
17179768|NCT02788357|f||||f
17179769|NCT00371137|f||OTHER||t
17179770|NCT00536198|f||||f
17179771|NCT02013791|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179772|NCT03798483|f||||f
17179773|NCT02784275|f||LTE60||t
17179774|NCT00640601|f||OTHER|AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed for an additional period of ninety (90) days in order for AstraZeneca to file patent applications.|t
17179775|NCT02007109|t||||
17179776|NCT01918085|f||||f
17179777|NCT01118221|t||||
17179778|NCT00646776|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17179779|NCT00439244|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179780|NCT03655691|f||OTHER|Study Results are considered Confidential Information that may not be published or disclosed without Sponsor's written consent for a period of five (5) years after completion of the Study.|t
17179781|NCT01753856|f||GT60||t
17179782|NCT05109442|f||OTHER|The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication|t
17179783|NCT04853225|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17179784|NCT01804075|t||||f
17179785|NCT00793598|f||OTHER|Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment.|t
17179786|NCT02154490|f||LTE60||t
17179787|NCT02961751|f||LTE60||t
17135276|NCT01001494|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17135277|NCT03896425|t||||
17135278|NCT02519231|f||OTHER|The PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. If requested in writing, Institution and Investigator will withhold such Public Presentation for up to an additional ninety (90) days to allow for filing of a patent application.|t
17179788|NCT02373202|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17179789|NCT02299479|t||||
17179790|NCT02785354|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179791|NCT02566083|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at any time.|t
17179792|NCT02310568|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179793|NCT00441883|f||OTHER|Contact sponsor directly for details.|t
17179794|NCT01129609|f||||f
17179795|NCT00088985|t||||
17179796|NCT01224431|f||||f
17179797|NCT01635101|f||OTHER|Disclosure of individual investigator/site results is restricted for 18 months after final evaluation of study results or after release of a cooperative publication including all study from all sites, whichever occurs first. The sponsor has 60 days to review and comment on the publication and can request removal of any confidential information prior to public disclosure or publication.|t
17179798|NCT02569723|t||||
17179799|NCT03232801|t||||f
17179800|NCT02511184|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179801|NCT03828357|f||GT60||t
17179802|NCT02041286|f||GT60||t
17179803|NCT01824901|f||LTE60||t
17179804|NCT00844051|f||||f
17179805|NCT01963403|f||||f
17179806|NCT02289690|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179807|NCT01170754|t||||f
17179808|NCT04016285|f||||f
17179809|NCT01391559|f||||f
17179810|NCT00460408|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179811|NCT01442493|t||||
17179812|NCT02461563|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17179813|NCT01111149|t||||f
17179814|NCT00759954|f||||f
17179815|NCT02368431|t||||
17179816|NCT03124875|f||||f
17179817|NCT01313936|f||||f
17179818|NCT01238471|t||OTHER||t
17179819|NCT01200602|t||||
17179820|NCT03856164|f||||f
17179821|NCT00911053|f||||f
17179822|NCT02518750|t||||
17179823|NCT01365910|t||||
17135279|NCT03958201|f||||f
17135280|NCT01435512|f||||f
17135281|NCT01797432|t||||
17135282|NCT00815308|f||||f
17135283|NCT02428140|f||||f
17135284|NCT03534271|t||||
17135285|NCT03809546|t||||
17135286|NCT02262130|f||||f
17135287|NCT00542815|f||OTHER||t
17135288|NCT00734929|f||||f
17135289|NCT01422304|f||OTHER|Initial public presentation of the Investigator's results will occur only together with the other sites unless permission is obtained from Sponsor. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. In case of disagreement concerning appropriateness of materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues, prior to submission for publication/presentation.|t
17179824|NCT01294267|t||||
17179825|NCT03681405|t||||
17179826|NCT00833794|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information.|t
17179827|NCT03791489|f||LTE60||t
17179828|NCT01927367|f||||f
17179829|NCT01161862|f||||f
17179830|NCT00598832|f||OTHER|disclosure restriction varies per institutional request/agreement|t
17179831|NCT02760069|f||||f
17179832|NCT02465216|f||||f
17179833|NCT01648205|f||||f
17179834|NCT01414010|t||||
17135290|NCT00866294|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135291|NCT04799782|f||||f
17135292|NCT00515463|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135293|NCT01558089|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135294|NCT02190435|t||||f
17135295|NCT02269319|f||||t
17135296|NCT02211495|t||||
17135297|NCT05270694|t||||
17135298|NCT03624101|t||||
17135299|NCT01991977|t||||
17135300|NCT00945750|f||OTHER|Merck must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by Merck as confidential must be deleted prior to submission.|t
17135301|NCT02531035|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17135302|NCT02898207|f||LTE60||t
17135303|NCT00912158|t||||
17135304|NCT03032068|t||||f
17135305|NCT01597622|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135306|NCT01976819|f||||f
17135307|NCT01856491|f||LTE60||t
17135308|NCT01289392|f||||f
17135309|NCT05085392|f||||f
17135310|NCT03042611|f||||t
17135311|NCT03567291|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17135312|NCT01103349|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135313|NCT00090285|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17135314|NCT00907478|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135315|NCT03864237|f||||f
17135316|NCT03069690|f||||f
17135317|NCT01372878|f||||f
17135318|NCT02240628|t||||
17135319|NCT02385123|f||||f
17135320|NCT04498910|f||GT60||t
17135321|NCT01070303|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17135322|NCT01849848|f||||f
17135323|NCT03121352|t||||
17135324|NCT02926573|t||||
17179835|NCT04748120|t||||
17179836|NCT00790855|t||||f
17179837|NCT02142959|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17179838|NCT03547687|t||||f
17179839|NCT00679302|t||||
17179840|NCT03305653|f||||f
17179841|NCT03031678|f||||f
17184970|NCT00845663|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17179842|NCT00434330|f||OTHER|Publications may not contain Sponsor confidential information, and will be subject to Sponsor review prior to submission for publication.|t
17179843|NCT01317030|t||||
17179844|NCT06092710|f||||f
17179845|NCT00850564|f||LTE60||t
17135325|NCT01933984|t||||
17135326|NCT02487745|f||||f
17135327|NCT02844582|t||||
17135328|NCT04083144|f||||f
17135329|NCT00946270|t||||
17135330|NCT02092415|f||||f
17135331|NCT00392444|f||LTE60||t
17135332|NCT00387660|t||||
17135333|NCT01183546|f||||f
17135334|NCT00044044|f||||f
17135335|NCT00787332|f||||f
17135336|NCT02179398|f||||f
17135337|NCT02124798|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135338|NCT03531957|f||||t
17139810|NCT03924427|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139811|NCT04922710|f||||f
17139812|NCT02858713|t||||
17139813|NCT02774291|t||||
17139814|NCT00126425|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17139815|NCT00149890|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17139816|NCT02332876|f||||f
17139817|NCT01895634|f||||f
17139818|NCT02415595|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139819|NCT02614261|f||||f
17139820|NCT00471315|f||||f
17139821|NCT00926263|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139822|NCT01611311|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17139823|NCT02875366|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17139824|NCT01744340|f||||f
17139825|NCT02141854|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17139826|NCT02659098|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139827|NCT04363944|f||||f
17139828|NCT03219476|t||||
17139829|NCT00766142|t||||
17139830|NCT01670487|f||||f
17139831|NCT06436300|t||||
17139832|NCT03793010|f||GT60||t
17139833|NCT05016037|t||||
17139834|NCT02219516|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17139835|NCT00129376|f||LTE60||t
17139836|NCT04209634|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17135339|NCT02746679|t||||
17135340|NCT00487279|f||OTHER|All publications must be reviewed by the Sponsor, Executive Sterring Committe and the Publications Committee at least 30 days prior to submittal. In the event that no multi-center study publication occurs within 12 months of study completion, investigators may publish the restuls of the study data from those subjects enrolled in a study at the Institution provided the Sponsor, Executive Steering Committee and Publicaiton Committee review at least 30 days prior to submittal.|t
17135341|NCT00501852|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17135342|NCT01221298|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17135343|NCT04441931|f||GT60||t
17135344|NCT00642616|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17135345|NCT00399802|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17135346|NCT00492921|t||||f
17135347|NCT00652093|f||||f
17135348|NCT02955186|f||||f
17135349|NCT04036136|t||||
17135350|NCT01618656|t||||
17135351|NCT02961764|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135352|NCT00469014|t||||f
17135353|NCT03321929|f||LTE60||t
17135354|NCT01632878|f||||f
17135355|NCT02606877|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135356|NCT00756977|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extent the embargo.|t
17135357|NCT02989727|f||||f
17135358|NCT01319760|f||||f
17135359|NCT02029430|f||||t
17135360|NCT02222129|f||||f
17135361|NCT03465735|t||||
17179846|NCT05355805|f||OTHER|"Per Clinical Trial Agreements, sites may not publish study results without sponsor's written consent:~* sponsor has right to first publication~* after first publication, site may publish if sponsor is given 60 days to review for confidential/proprietary information~* if publication may impact sponsor rights (eg, a patent), sponsor may request 90-day delay~* if sponsor does not publish within 12 months after study end or confirms they will not, site may publish, subject to sponsor's rights above"|t
17179847|NCT02167893|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17179848|NCT04818840|f||||f
17179849|NCT02152696|f||||f
17179850|NCT02422511|f||||f
17179851|NCT02345850|f||||f
17179852|NCT01430091|f||GT60||t
17179853|NCT01991067|t||||
17179854|NCT01075204|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17179855|NCT03909295|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17179856|NCT01411228|f||||f
17179857|NCT01752907|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17179858|NCT00333814|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179859|NCT00187876|f||||f
17179860|NCT02670083|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179861|NCT02014597|f||||f
17135362|NCT01903434|f||GT60||t
17135363|NCT01781026|t||||
17135364|NCT01118143|f||||f
17135365|NCT02026908|t||||
17135366|NCT05094154|t||||
17135367|NCT01937130|f||LTE60||t
17135368|NCT02133235|f||||f
17135369|NCT03990766|f||||f
17135370|NCT01543490|f||||t
17135371|NCT00403117|f||||f
17135372|NCT03026504|t||||f
17135373|NCT04168645|f||||f
17135374|NCT03918642|t||||f
17135375|NCT03825042|f||OTHER||t
17135376|NCT02601001|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135377|NCT02316470|f||OTHER|Not less than 60 days prior to the earlier of Publication or submission for Publication of any Manuscript Sponsor has to be provided with a copy of the Manuscript (unless the Manuscript is an abstract, presentation, or poster: not less than 30 days prior to the earlier of Publication or submission for Publication). Site shall delay Publication/ submission for Publication of the Manuscript, as the case may be, for an additional 120 days to allow patent applications to be filed.|t
17135378|NCT01988012|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135379|NCT00089843|t||||f
17135380|NCT02115815|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17135381|NCT01228071|f||LTE60||t
17135382|NCT03314519|f||||f
17135383|NCT04003155|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17135384|NCT01912872|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17135385|NCT01741272|f||||f
17135386|NCT01713036|t||OTHER||t
17135387|NCT01096771|f||||f
17135388|NCT04410783|f||||f
17135389|NCT01148056|f||||f
17135390|NCT00915005|t||||
17135391|NCT03090620|f||||f
17135392|NCT00631488|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17135393|NCT03648476|f||||f
17135394|NCT02639182|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17135395|NCT01391312|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135396|NCT02546856|f||||f
17135397|NCT01097616|f||OTHER|Investigator may publish results for his/her study site after publication of results of entire multicenter trial, or after public disclosure of the results online if a multicenter manuscript is not planned. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17135398|NCT04504032|f||OTHER||t
17135399|NCT00771030|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135400|NCT01839188|f||OTHER|Subsequent to public disclosure of study results, an investigator and colleagues participating in a multicenter study may publish data collected in their center independently. In such case the Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations based on these study results 60 calendar days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential will be deleted prior to submission.|t
17135401|NCT02235285|t||||
17135402|NCT01842464|f||||f
17135403|NCT02544984|t||||
17139837|NCT03218826|f||LTE60||t
17139838|NCT01426009|f||OTHER|In the event the study is part of a multi-center study. The first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17139839|NCT02283333|f||||f
17179862|NCT01780636|f||||f
17179863|NCT00603993|f||OTHER|Disclosure agreements vary; most restrictive agreement states Medical Institution shall not disclose materials/information disclosed by Abbott Japan in connection with the Clinical Research, or information obtained by conducting the Clinical Research, to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting the Clinical Research, Medical Institution shall obtain Abbott Japan's prior written approval.|t
17179864|NCT00464087|f||||f
17179865|NCT02425046|f||||f
17179866|NCT00931762|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17135404|NCT00114114|f||||f
17135405|NCT01302769|t||OTHER|Study takes place at military hospital with DoD active duty, veterans, and beneficiaries. Publishing of aggregate or simply deidentified data is prohibited.|t
17135406|NCT01845077|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135407|NCT00394914|f||OTHER|"The investigator agrees not to publish or publicly present any interim results~of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts."|t
17135408|NCT00312377|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17135409|NCT00872898|f||OTHER|"All data generated in this study are the property of Forest Research Institute. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute."|t
17135410|NCT01137435|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17135411|NCT01416610|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179867|NCT01432886|f||OTHER||t
17179868|NCT02692716|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17179869|NCT03709771|f||||f
17179870|NCT02782780|t||||
17179871|NCT03562481|t||||
17179872|NCT02664441|f||||f
17179873|NCT01413191|f||LTE60||t
17179874|NCT03654651|f||||f
17179875|NCT01702454|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179876|NCT02000973|t||||
17179877|NCT03510884|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17179878|NCT00856284|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17179879|NCT02560584|f||LTE60||t
17179880|NCT03848650|t||||
17179881|NCT02904512|f||||f
17179882|NCT02634684|f||||f
17179883|NCT02557698|f||||f
17179884|NCT00267046|t||||f
17179885|NCT01077856|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17179886|NCT03950167|f||||f
17179887|NCT00936585|t||||
17179888|NCT01124422|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179889|NCT02775162|f||LTE60||t
17179890|NCT00137046|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179891|NCT03223246|f||||f
17179892|NCT02730455|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17184971|NCT01314118|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days. The sponsor will not mandate modifications to scientific content and does not have the right to suppress information.|t
17184972|NCT05545072|t||||
17135412|NCT01927562|f||OTHER|"All information received by PRINCIPAL INVESTIGATOR from SPONSOR, including, but not limited to, the Protocol, and all information developed during the Study is confidential information (Confidential Information), which is the sole and exclusive property of SPONSOR during the period of this Agreement and subsequent thereto."|t
17135413|NCT03176966|t||||
17135414|NCT02351037|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until after the completion of the study or until 12 months after results are received"|t
17135415|NCT01520922|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17135416|NCT01696877|t||||
17135417|NCT04076072|f||||f
17135418|NCT01566838|f||||f
17135419|NCT04770155|t||||
17135420|NCT04331730|f||GT60||t
17135421|NCT03595215|f||||f
17135422|NCT04064684|t||||
17135423|NCT03028025|f||||f
17135424|NCT02644525|t||||
17135425|NCT00336492|f||GT60||t
17135426|NCT00227877|f||||f
17135427|NCT02517047|f||||f
17139840|NCT01866306|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17139841|NCT00796549|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135428|NCT01452425|t||||
17135429|NCT01240811|f||||f
17135430|NCT03459131|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135431|NCT03132805|f||||f
17135432|NCT00500149|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after SPONSOR confirms there shall be no multicenter Study publication, the INSTITUTION and/or such PRINCIPAL INVESTIGATOR may publish the results from the INSTITUTION site individually.|t
17135433|NCT03123354|f||LTE60||t
17139842|NCT02661256|t||||
17139843|NCT01878175|t||||
17139844|NCT03083470|f||||f
17139845|NCT00606229|f||||f
17139846|NCT01526928|f||OTHER|All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.|t
17135434|NCT02778867|f||OTHER||t
17139847|NCT01108068|f||||f
17139848|NCT00836953|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17139849|NCT01833026|f||||f
17135435|NCT03504774|t||||
17135436|NCT02344628|f||||f
17135437|NCT00719576|f||GT60||t
17135438|NCT00305006|t||||f
17135439|NCT02383719|f||||f
17135440|NCT01084499|f||OTHER|The results of the study shall be owned by the Sponsor. The results of this study can be published in journals with the consent of the Sponsor, and the Sponsor can also request the presentation of the results to the investigator(s).|t
17135441|NCT03626415|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135442|NCT01703819|f||OTHER|Investigator agreements are in place restricting the PI from independently publishing the study results. Currently working with both PIs on several publications of the NEUPRO studies.|t
17135443|NCT00859898|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139850|NCT05393570|f||||f
17135444|NCT02145156|t||||
17135445|NCT01302041|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data.Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17135446|NCT02367170|f||||f
17139851|NCT02877134|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139852|NCT00778310|f||||f
17139853|NCT01197794|f||LTE60||t
17139854|NCT01055457|f||GT60||t
17135447|NCT02416908|t||||
17135448|NCT01797783|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135449|NCT00940342|f||||f
17135450|NCT05232097|f||||f
17135451|NCT01327339|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135452|NCT00466752|t||||
17135453|NCT01847547|f||||f
17135454|NCT00700752|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17135455|NCT03662334|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17135456|NCT00691197|f||OTHER|"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review.~The sponsor cannot require changes to the communication and cannot extend the embargo."|t
17135457|NCT00298610|f||||f
17135458|NCT00717418|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17135459|NCT01097330|f||||f
17135460|NCT05848245|f||||f
17135461|NCT02853331|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17135462|NCT03511638|f||OTHER|Please contact sponsor directly for details.|t
17135463|NCT03425799|f||||t
17135464|NCT01858428|f||GT60||t
17135465|NCT03290300|f||OTHER|First publication of study results shall be made in conjunction with the results from all clinical study centers participating in the multicenter study. If results of the multi-center study have not been published in full within 18 months after completion of the study, investigator shall be free to publish results. Investigator agrees to submit all proposed publications to the sponsor at least 60 days prior submission; the company has the right to comment.|t
17135466|NCT02679066|t||||
17135467|NCT01088815|t||||f
17135468|NCT02234115|f||OTHER|All information from the trial is property of the Sponsor and the PI has no right on it except the prior writing authorization of the sponsor.|t
17135469|NCT01732263|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17135470|NCT01276847|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17135471|NCT01899144|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17135472|NCT02213757|f||||f
17135473|NCT00751881|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The investigator provides the sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.~The sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17135474|NCT00864227|f||||f
17135475|NCT02722577|f||||f
17135476|NCT03461289|f||OTHER|Sponsor can review results communications prior to public release \& has the right to request changes to communications regarding trial results for a period of 30 to 60 days with an additional 6 months, if needed, from the time submitted to the Sponsor for review in order to either remove references to Sponsor's Confidential Information or delay such results communications to permit Sponsor to obtain appropriate Intellectual Property protection as set forth in each of the agreements.|t
17135477|NCT03418662|f||||f
17135478|NCT00081289|f||||f
17135479|NCT00916721|f||||f
17135480|NCT01797029|f||LTE60||t
17135481|NCT01202110|t||||
17139855|NCT04055844|t||||
17139856|NCT04716010|t||||
17139857|NCT00679380|f||||f
17139858|NCT03630016|f||||f
17139859|NCT00255008|f||LTE60||t
17139860|NCT01833806|f||||f
17139861|NCT02724111|f||||f
17139862|NCT02996500|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17139863|NCT02485860|t||||
17139864|NCT02402881|f||||f
17139865|NCT03325010|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17139866|NCT00108277|f||||f
17139867|NCT00460525|f||LTE60||t
17139868|NCT02460172|f||||f
17139869|NCT03073200|f||||t
17139870|NCT04757376|f||OTHER||t
17139871|NCT04474366|t||||f
17139872|NCT04063865|f||||f
17139873|NCT03898323|t||||
17179893|NCT03235154|t||||
17179894|NCT02423876|t||||
17179895|NCT02725710|t||||
17179896|NCT01462097|f||||f
17184973|NCT05585307|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17184974|NCT01360606|t||||
17184975|NCT04597190|f||||f
17184976|NCT04420221|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17184977|NCT01618864|f||OTHER|Sponsor reserves the right to remove all Confidential Information from any publications or presentations to protect its intellectual property rights.|t
17184978|NCT03074630|f||||f
17184979|NCT02879812|t||||
17184980|NCT02085408|f||LTE60||t
17184981|NCT01391962|f||||f
17184982|NCT02388386|f||||f
17184983|NCT01672801|t||||
17184984|NCT01518868|f||OTHER|Contact sponsor directly for details.|t
17184985|NCT02273141|f||||f
17184986|NCT00492284|f||OTHER|Publication materials will be reviewed and commented on by the Sponsor prior to submission for publication; Names of all Investigators and Sponsor representatives responsible for study design and analysis of results will be disclosed in the publication.|t
17184987|NCT01556438|f||GT60||t
17184988|NCT00529399|f||||f
17184989|NCT03726346|f||||t
17184990|NCT02734212|t||||
17184991|NCT04313881|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17184992|NCT02935062|f||||f
17184993|NCT04732286|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigators are free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17184994|NCT01733056|t||||f
17184995|NCT01910129|f||LTE60||t
17184996|NCT03543826|f||||f
17135482|NCT01469052|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17184997|NCT03595904|f||||f
17184998|NCT01392560|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17184999|NCT00572234|f||||f
17185000|NCT03143218|t||||
17185001|NCT00374842|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185002|NCT01681589|t||||
17185003|NCT01913600|f||||f
17185004|NCT04764396|t||||
17185005|NCT02653482|f||LTE60||t
17185006|NCT04657211|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17185007|NCT03776136|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17185008|NCT00613951|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17185009|NCT03016871|t||||
17185010|NCT06675500|t||||
17185011|NCT01329029|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17135483|NCT02167204|t||||f
17135484|NCT04073823|f||OTHER||t
17135485|NCT02749370|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135486|NCT02101411|f||||f
17135487|NCT01519427|f||LTE60||t
17135488|NCT03894904|t||||
17135489|NCT03242759|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17185012|NCT06854601|f||GT60||t
17185013|NCT00680407|f||||f
17185014|NCT06167031|f||||f
17185015|NCT01266642|t||||
17185016|NCT03854461|t||||
17185017|NCT00924287|t||||f
17185018|NCT02621931|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17185019|NCT01912612|t||||
17185020|NCT01588184|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185021|NCT04953390|t||||
17185022|NCT05912400|f||||f
17185023|NCT01092338|f||||f
17185024|NCT03248739|t||||
17185025|NCT03461003|t||||
17185026|NCT03489304|f||||f
17135490|NCT00328263|f||OTHER|Any proposed publication or formal presentation of the data directly derived from the study shall be submitted to Bio-K+. Bio-K+ will have 15 business days to give comments to the Investigator.This review is no way intended to restrict publication of facts or opinions formulated by the Investigator through this research.|t
17135491|NCT01810991|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17135492|NCT04430582|t||||
17135493|NCT02522481|f||||f
17135494|NCT03340805|f||||f
17135495|NCT00404768|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135496|NCT04773041|t||||
17135497|NCT02100657|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review|t
17135498|NCT04359823|f||||f
17135499|NCT01850563|f||||f
17135500|NCT05047640|t||||
17135501|NCT02322892|f||||f
17135502|NCT03478878|t||||
17135503|NCT02125331|f||OTHER|All proposed publications using study data, in full or in part, will be subject to approval by the Sponsor prior to submission. The Investigator and Sponsor agree to act in good faith to consider the interests of each party in publication.|t
17135504|NCT00710034|t||||
17135505|NCT01158534|t||||
17135506|NCT00521339|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17135507|NCT00950690|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17135508|NCT06001372|t||||
17135509|NCT00103194|f||LTE60||t
17135510|NCT03735095|t||||
17135511|NCT01996319|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17135512|NCT00591227|f||||f
17135513|NCT00130208|f||||f
17135514|NCT03132246|t||||
17185027|NCT04256733|t||||
17185028|NCT04542343|f||||f
17185029|NCT02539342|f||||f
17185030|NCT02566031|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17185031|NCT02962687|t||||
17185032|NCT02479412|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed.|t
17185033|NCT04969250|f||||f
17185034|NCT00574587|f||||f
17185035|NCT02040116|f||||f
17185036|NCT04642638|f||||t
17185037|NCT00511004|f||||f
17185038|NCT00990652|t||||
17185039|NCT03695172|t||||
17185040|NCT02486328|f||||f
17185041|NCT06242444|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185042|NCT00054353|t||||
17185043|NCT03317977|f||||f
17185044|NCT02076152|t||||
17185045|NCT02635880|f||||f
17185046|NCT00727272|f||GT60||t
17185047|NCT00651664|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17185048|NCT01988246|f||LTE60||t
17185049|NCT00688636|f||||f
17185050|NCT01572727|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17185051|NCT04053764|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17185052|NCT02384954|f||||t
17185053|NCT01692340|t||||
17185054|NCT01474681|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17185055|NCT03998618|t||||
17185056|NCT00319098|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185057|NCT01968213|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17185058|NCT02558010|f||||f
17185059|NCT00295750|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17185060|NCT02439710|f||||f
17135515|NCT00589472|f||LTE60||t
17135516|NCT00553059|f||||f
17179897|NCT01666782|f||OTHER|All research data and results generated during the course of or as a result of the Research Project shall be the property of Investigator and/or institution. Sanofi Pasteur will have access to the full set of data collected during the Research Project. The text of any manuscript, abstract or oral presentation based on this Research Project will be provided to Sanofi Pasteur at least 30 days prior to submission to a journal, a congress, or prior to an oral presentation.|t
17179898|NCT03809052|f||||f
17179899|NCT01691781|f||||f
17185061|NCT00936858|t||||
17185062|NCT01289912|f||||f
17185063|NCT01953081|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135517|NCT00117338|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135518|NCT02805907|f||||f
17135519|NCT01264965|f||||f
17135520|NCT02202031|t||||
17135521|NCT01596842|t||||
17135522|NCT01776268|t||||
17135523|NCT00871858|t||||
17135524|NCT01188798|t||||
17135525|NCT00611130|f||GT60||t
17135526|NCT03078608|f||||f
17135527|NCT00723840|f||OTHER|The disclosure restriction on the principal investigator (PI) is that the PI agrees not to publish or publicly present any results of the study without the prior written permission of the sponsor. The PI further agrees to allow the sponsor to review, 30 days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the study.|t
17135528|NCT01729598|f||||f
17135529|NCT00844428|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17135530|NCT04172831|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17135531|NCT02138578|t||||
17135532|NCT00668525|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 90 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential info. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in pub. On sponsor's request, PI shall delay submission for any pub while sponsor files patent apps. If trial is multi-center, PI agrees that first publication shall be a multi-center pub.|t
17135533|NCT02119104|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135534|NCT01765764|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135535|NCT01597193|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135536|NCT02508701|f||||f
17135537|NCT03184701|f||||f
17179900|NCT03978520|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17179901|NCT00230607|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17179902|NCT02032810|t||||
17179903|NCT01112241|f||||f
17179904|NCT01550302|t||||f
17179905|NCT02547454|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179906|NCT00590005|f||||f
17179907|NCT04557371|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179908|NCT03694821|f||||f
17179909|NCT00203996|t||||
17179910|NCT03064451|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17179911|NCT01154764|f||OTHER||t
17179912|NCT00064844|t||||
17179913|NCT02700815|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17179914|NCT00524368|f||OTHER|The Sponsor will not unreasonably withhold consent to publish the data generated in this trial. However, it is the policy of the Sponsor not to allow the investigators to publish their results or findings prior to the Sponsor's publication of the overall trial results. The investigator agrees that before he/she publishes any results of this trial, he/she shall allow at least 45 days for the Sponsor to review the prepublication manuscript prior to submission of the manuscript to the publisher.|t
17179915|NCT00531232|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17179916|NCT01850550|t||||
17179917|NCT02066740|f||OTHER|"There is an agreement between the Principal Investigator and Sponsor \[or its agents\] that restricts PI's rights to discuss or publish trial results without permission of the Sponsor.~Trial is still ongoing."|t
17179918|NCT00113217|t||||f
17179919|NCT00609492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179920|NCT00720434|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17179921|NCT02057406|t||||
17179922|NCT01571427|f||||f
17179923|NCT03138889|f||||t
17179924|NCT03395886|t||||
17179925|NCT00865124|t||||
17179926|NCT03247530|f||OTHER||t
17179927|NCT02533427|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17179928|NCT03454893|f||||f
17179929|NCT01830699|t||||
17179930|NCT02309489|f||||f
17179931|NCT01986985|f||GT60||t
17179932|NCT03042533|t||||
17179933|NCT01354951|t||||
17135538|NCT01863563|t||||
17135539|NCT01553539|t||||
17135540|NCT00530712|f||LTE60||t
17135541|NCT03415464|f||||f
17135542|NCT03020524|t||||
17135543|NCT02273323|f||GT60||t
17135544|NCT03117049|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this tiral prior to submission for publication/presentation.|t
17179934|NCT02288559|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179935|NCT03303079|f||||f
17179936|NCT02005445|t||||
17179937|NCT01980914|f||||f
17179938|NCT00449540|f||LTE60||t
17179939|NCT02709785|f||||f
17179940|NCT01961323|f||||f
17179941|NCT03472469|t||||
17179942|NCT02746874|f||||f
17179943|NCT03179995|t||||
17135545|NCT00651118|f||OTHER|"Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.~Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)"|t
17135546|NCT00839098|f||||f
17135547|NCT00121810|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135548|NCT00365976|f||LTE60||t
17135549|NCT02260193|f||||f
17135550|NCT02389946|f||||f
17135551|NCT01377467|t||||
17135552|NCT01354691|f||||f
17135553|NCT00633139|f||||f
17135554|NCT00410280|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135555|NCT01522651|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17135556|NCT02658656|t||||
17135557|NCT04220489|f||LTE60||t
17135558|NCT02338076|f||||f
17135559|NCT00408421|f||GT60||t
17135560|NCT02772965|t||||
17135561|NCT01997567|t||||
17135562|NCT01790438|f||GT60||t
17179944|NCT02320149|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179945|NCT00473642|f||LTE60||t
17179946|NCT01156311|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17179947|NCT01741701|t||||
17179948|NCT00487747|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17179949|NCT01669915|f||||f
17179950|NCT00372112|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179951|NCT01025791|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17179952|NCT04649060|f||||f
17179953|NCT01830972|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17179954|NCT01660698|t||||f
17179955|NCT01907815|f||LTE60||t
17179956|NCT02205814|f||OTHER|Prior to submitting the results of this study for publication or presentation, the Investigator will allow the sponsor at least 30 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until the sponsor has reviewed/commented and agreed to any publication.|t
17179957|NCT01426373|f||OTHER|The clinical study agreement requires that the investigator or institution obtain written consent from Kythera Biopharmaceuticals, Inc. prior to presenting and/or publishing results of this study.|t
17179958|NCT04952402|f||||f
17135563|NCT01847638|f||||f
17135564|NCT00950612|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135565|NCT00733512|f||OTHER|No paper that incorporates Sponsor Confidential information will be submitted for publication without Sponsor's prior written agreement.|t
17139874|NCT00320190|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17135566|NCT04760314|f||GT60||t
17135567|NCT01290484|f||||f
17135568|NCT00960440|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135569|NCT02421120|f||||f
17135570|NCT02207530|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review publications prior to public release for a period up to 120 days to confirm accuracy, prevent disclosure of confidential information, and ensure that information is handled appropriately.|t
17135571|NCT02345161|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135572|NCT02869867|t||||
17135573|NCT03554005|f||OTHER|The investigator agrees to provide the Sponsor, thirty (30) days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication which report project results. The Sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts, and the right to review and comment on the data analysis and presentation with regard to (a) proprietary information and, (b) the accuracy of the information contained in the publication.|t
17179959|NCT02756689|f||||f
17135574|NCT02606045|f||LTE60||t
17135575|NCT00907881|f||OTHER|The study sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the study sponsor as confidential must be deleted prior to submission.|t
17135576|NCT01671085|f||GT60||t
17135577|NCT00637273|f||LTE60||t
17135578|NCT00986258|f||OTHER|Grünenthal reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17135579|NCT04465370|f||||f
17135580|NCT05057988|t||||
17135581|NCT02616029|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17135582|NCT02191917|f||GT60||t
17135583|NCT01530399|f||OTHER|After initial multicenter results communications are published, or after 12 months from study closure (whichever occurs first), sponsor can review results communications prior to submission and can embargo submissions for a period of 45 days from the time submitted to the sponsor for review, agreeing to resolve differences of opinion or interpretation through scientific debate. Sponsor can request further delay for an additional 90 days to file any patent applications if deemed necessary|t
17135584|NCT04230486|t||||
17135585|NCT03215264|f||LTE60||t
17135586|NCT00205504|t||||
17135587|NCT02234583|f||||f
17135588|NCT01740440|f||OTHER||t
17135589|NCT00532883|f||||f
17135590|NCT00076219|f||||f
17135591|NCT01172288|f||||f
17135592|NCT02134314|f||||f
17135593|NCT02795767|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135594|NCT02553915|f||||f
17135595|NCT01016483|f||OTHER||t
17135596|NCT01564654|f||GT60||t
17179960|NCT01214811|f||||f
17179961|NCT01018186|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179962|NCT03049280|f||||t
17179963|NCT03552198|f||||f
17179964|NCT02845453|t||||
17179965|NCT02326025|f||GT60||t
17179966|NCT00001723|t||||
17135597|NCT04156646|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135598|NCT00751101|t||||
17135599|NCT00784784|f||||f
17179967|NCT02643082|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17179968|NCT01324999|t||||
17179969|NCT01966900|t||||
17179970|NCT02505867|f||||f
17179971|NCT01862874|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17179972|NCT03178903|t||||
17135600|NCT01905397|f||||f
17135601|NCT02099799|t||||
17135602|NCT00863928|t||||
17139875|NCT01547806|f||||f
17139876|NCT00712270|f||||f
17139877|NCT00886691|f||LTE60||t
17139878|NCT00721357|t||||
17139879|NCT03017040|t||||
17139880|NCT00985140|t||||
17135603|NCT00772967|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135604|NCT00693719|t||||
17179973|NCT01714635|f||OTHER|After the trial is completed, investigators must obtain approval from AMO in writing prior to disclosing trial results.|t
17179974|NCT02860169|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17179975|NCT03667924|f||||f
17179976|NCT01593215|f||||f
17179977|NCT03482440|f||||f
17179978|NCT01937559|t||||
17179979|NCT04203238|f||||f
17179980|NCT00733408|f||LTE60||t
17179981|NCT04346537|f||OTHER|Restriction on the PI that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is equal to 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. Sponsor reserves the right to require deletion of any Confidential Information or other proprietary information of Sponsor.|t
17179982|NCT01134783|t||||f
17179983|NCT04221009|t||||
17179984|NCT04232124|t||||
17179985|NCT02423577|f||||t
17179986|NCT02392247|f||||f
17179987|NCT02715076|f||||f
17179988|NCT00106392|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document.|t
17179989|NCT01500629|f||OTHER|Sponsor has the right to publish results without PI approval. PI has right to present and/or publish research results and related background information, but must provide publication to Sponsor in advance with at least 30 days for review. Sponsor confidential information cannot be submitted for publication without Sponsor's written consent. Sponsor cannot require changes or extend the embargo. If requested, the PI will withhold the publication for ≤60 days to allow for patent application.|t
17179990|NCT00588848|f||||f
17179991|NCT00589914|f||GT60||t
17179992|NCT00531050|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17179993|NCT01067456|f||||f
17179994|NCT02781051|f||||f
17179995|NCT02233309|t||||
17179996|NCT01737944|f||LTE60||t
17179997|NCT00799487|f||||f
17179998|NCT01402544|t||||
17179999|NCT01828281|f||||f
17180000|NCT02959944|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination."|t
17180001|NCT04876274|f||||f
17180002|NCT02051608|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180003|NCT00142584|f||OTHER|Investigator Study Agreement: Publication Clause - Details of the Study and its results shall not be publicized or published in any form without prior consent of Covance and the Sponsor, Mylan.|t
17180004|NCT01573572|f||OTHER|Contact sponsor directly for details.|t
17180005|NCT03070782|f||LTE60||t
17180006|NCT01083576|f||||f
17180007|NCT01948050|t||||
17180008|NCT01314443|f||||f
17135605|NCT01041573|f||OTHER||t
17135606|NCT01052012|f||||t
17135607|NCT00878228|t||||
17135608|NCT00492401|f||GT60||t
17135609|NCT00929578|f||||f
17135610|NCT00734409|t||||f
17139881|NCT00683774|f||||f
17139882|NCT03595176|f||GT60||t
17139883|NCT03374891|t||||
17139884|NCT00356434|f||||f
17139885|NCT01201967|f||||f
17139886|NCT06853210|t||||
17139887|NCT03285061|f||||f
17139888|NCT03128307|t||||f
17139889|NCT04685408|f||||f
17139890|NCT02632344|f||||f
17180009|NCT00010374|f||||f
17180010|NCT00449046|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180011|NCT02875860|f||||f
17180012|NCT01881776|f||||f
17180013|NCT04044716|t||||
17180014|NCT01891695|t||||
17180015|NCT00276744|t||||f
17180016|NCT03060629|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17180017|NCT00060008|t||||f
17180018|NCT04973826|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180019|NCT00824512|f||GT60||t
17135611|NCT03393013|f||OTHER|"PI shall have the right to publish or present their own data resulting from the Study (Publication) upon the earlier of: (a) the date following a multicenter publication coordinated by Sponsor regarding the Protocol; (b) 12 months after completion of the Protocol by all sites; or (c) the date after submission of the Study Data by Sponsor to the FDA.~The PI must furnish Sponsor with a copy of any Publication at least 30 days in advance of the proposed submission or presentation date."|t
17135612|NCT00797459|f||LTE60||t
17135613|NCT00935220|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135614|NCT01000064|f||||f
17139891|NCT01693562|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17180020|NCT01782495|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180021|NCT00071513|t||||
17180022|NCT02260921|f||||f
17180023|NCT01244425|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17180024|NCT00240162|t||||
17180025|NCT02743871|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180026|NCT02848651|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180027|NCT03057431|f||||f
17180028|NCT01217840|t||||
17180029|NCT03649750|f||||f
17180030|NCT00897104|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180031|NCT00118365|f||LTE60||t
17180032|NCT01059799|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17180033|NCT00750204|t||||
17180034|NCT00662363|f||||f
17180035|NCT01428453|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180036|NCT02607033|t||||
17180037|NCT02421315|f||||f
17180038|NCT02299297|t||||
17180039|NCT03789318|f||||f
17180040|NCT02480114|t||||
17180041|NCT01535053|f||LTE60||t
17180042|NCT00512707|f||||f
17180043|NCT00477971|t||||
17180044|NCT03700671|f||||f
17180045|NCT01317160|f||||f
17180046|NCT01774968|f||GT60||t
17180047|NCT02044393|t||||
17180048|NCT01083368|t||||
17180049|NCT04405037|t||||
17180050|NCT02759471|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17180051|NCT02879305|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180052|NCT00998660|f||OTHER|Sponsor will review results communications prior to public release to determine whether Confidential Information is disclosed and will not censor or in any way interfere with presentation or conclusions beyond the extent necessary to protect Confidential Information. PIs are required to provide results communications for review at least 60 days prior to submission or presentation. When requested by Sponsor, PI will delay publication up to an additional 90 days.|t
17135615|NCT01518192|t||||f
17139892|NCT02903966|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180053|NCT00973739|f||||f
17180054|NCT01955733|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180055|NCT02762266|f||||f
17135616|NCT00798967|f||OTHER|The terms and conditions of NPS Pharmaceuticals agreements with its investigators may vary. However, NPS does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17135617|NCT01415440|f||||f
17135618|NCT03141307|f||||f
17135619|NCT03090737|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135620|NCT03458000|f||||f
17135621|NCT02160977|t||||
17135622|NCT01614769|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17135623|NCT03960138|t||||
17135624|NCT01134887|t||||
17135625|NCT02795988|f||||t
17135626|NCT02341014|t||||
17135627|NCT00390780|f||LTE60||t
17135628|NCT02045277|f||OTHER|Contact sponsor directly for details.|t
17135629|NCT01585961|f||OTHER|There is an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present, or publish trial results after the trial is completed. Please contact Biosense Webster for additional information.|t
17135630|NCT00109733|f||GT60||t
17135631|NCT03904446|t||||
17135632|NCT00669539|f||||f
17135633|NCT02238028|t||||
17135634|NCT02834052|f||||t
17135635|NCT02855411|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135636|NCT01505491|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135637|NCT02759146|f||||f
17135638|NCT01397071|f||||f
17180056|NCT01438424|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135639|NCT01063751|f||OTHER|There is an agreement between Principal Investigators and the Sponsor (or its agents) that requires Investigators to allow Sponsor at least 30 days to review material intended for publications in order to redact any Confidential Information or Inventions therefrom.|t
17135640|NCT00614666|t||||
17135641|NCT03408873|f||||f
17180057|NCT04812964|t||||f
17180058|NCT02329730|f||OTHER||t
17135642|NCT01600131|t||||
17135643|NCT02519244|t||||
17135644|NCT01312428|f||OTHER|To publish, exhibit or lecture, the manuscript, exhibit or speech must be provided to Stryker at least 60 days prior to submission for publication or presentation. The Investigator must receive consent from Stryker prior to publication, exhibition, or disclosure of scientific and clinical data. This review by Stryker is not intended to curtail distribution of scientific and clinical data, but to identify and edit any company confidential material and/or violations of FDA and FTC regulations.|t
17135645|NCT03799718|f||GT60||t
17135646|NCT00748826|f||OTHER|Trial results belong to the SPONSOR only, all investigators are not allowed to publish trial results without permission of the SPONSOR.|t
17135647|NCT02214186|f||||f
17135648|NCT01651052|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17135649|NCT02560701|f||||f
17135650|NCT05748925|t||||
17135651|NCT03964415|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor and its partners for review at least 21 days before submission for publication or presentation. At the request of the sponsor and/or partners, such submission may be delayed up to 60 days. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17135652|NCT01734993|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139893|NCT02987205|f||OTHER|There are restrictions within the site contracts that the sites cannot publish any results and also have confidentiality agreements in place separately that restrict any publications by sites regarding results, findings, etc.|t
17139894|NCT03057106|f||||f
17180059|NCT02758899|t||||f
17180060|NCT03010254|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180061|NCT01404325|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185064|NCT00626431|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication, whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17185065|NCT00802854|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185066|NCT01683864|t||||
17185067|NCT02199028|f||||f
17135653|NCT01024465|f||OTHER|Upon study conclusion, the PI has the right to use the study data for educational purposes, scientific conferences and publications. The sponsor will have a period of 15 days (for abstracts) and 30 days (for scientific publications) to review the proposal for disclosure / publication for the sole purpose of protecting any confidential information. If such disclosure contains Confidential Information, the PI agrees to remove such Confidential Information.|t
17135654|NCT02062151|t||||
17135655|NCT04004507|f||||f
17180062|NCT02144233|t||||f
17180063|NCT02389088|t||||
17180064|NCT03134989|f||||f
17180065|NCT00945139|f||||f
17180066|NCT02141282|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180067|NCT03312933|t||||
17180068|NCT01743131|f||||f
17180069|NCT00224055|f||LTE60||t
17180070|NCT02068443|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17180071|NCT01986855|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17180072|NCT00664742|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180073|NCT04317066|f||OTHER|The sponsor must have the opportunity to review all manuscripts or abstracts before submission. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17180074|NCT02771990|t||||
17180075|NCT00848081|f||GT60||t
17180076|NCT02064868|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17180077|NCT00711711|t||||
17180078|NCT01938378|f||||f
17185068|NCT01881126|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185069|NCT00867217|t||||
17185070|NCT02464449|t||||
17135656|NCT02086565|f||||f
17135657|NCT02116972|f||||t
17135658|NCT00325442|f||OTHER|Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17135659|NCT00789477|f||OTHER|Not less than 45 days prior to submission of a publication (S)ponsor shall be provided with a copy of the publication. The parties shall discuss any comments submitted by S regarding content, \& Institution \& PI shall delete any confidential information that S requests to be deleted. In addition, since the study is being conducted at multiple sites, parties agreed that publication of results shall be made only as part of a publication of the results obtained by all sites performing the study.|t
17135660|NCT00138125|f||LTE60||t
17135661|NCT02092389|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17135662|NCT01242020|f||||f
17135663|NCT01161524|f||OTHER||t
17135664|NCT00339079|f||||f
17135665|NCT04946344|t||||
17135666|NCT01556633|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135667|NCT00564629|f||OTHER|Neither the Institution nor the Investigator shall have the right to publish the Institution findings without prior written consent of Cadence.|t
17135668|NCT03634072|f||||f
17135669|NCT02307526|f||||f
17135670|NCT03419533|f||||f
17135671|NCT01952015|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single-site are postponed until the publication of the pooled data (o.e., data from all sites) in the clinical trial.|t
17135672|NCT02239094|f||||f
17135673|NCT00053846|f||||f
17135674|NCT00592501|t||||
17135675|NCT00279500|f||OTHER|Separate IP agreement.|t
17135676|NCT02186795|f||||f
17135677|NCT03880227|t||||
17135678|NCT02986958|f||||f
17135679|NCT04436510|t||||
17135680|NCT02399475|f||||f
17135681|NCT02807454|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135682|NCT01165203|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135683|NCT01963117|t||||
17135684|NCT01070784|f||OTHER||t
17135685|NCT02582749|f||||f
17135686|NCT02815397|t||||
17135687|NCT02518620|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.|t
17139895|NCT03381274|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17139896|NCT05298774|t||||
17139897|NCT04428580|f||||f
17139898|NCT06048367|f||||t
17135688|NCT00085540|f||LTE60||t
17139899|NCT02136134|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17139900|NCT03070119|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17139901|NCT00732472|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139902|NCT02159768|t||||f
17139903|NCT01266876|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17139904|NCT05180721|t||||f
17139905|NCT04870099|f||||f
17139906|NCT01996865|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180079|NCT00754624|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17180080|NCT00418314|f||OTHER|Publications and presentations proposed by participating centers should be furnished to sponsor for review and comment 30 days (manuscripts) or 7 days (abstracts) prior to submission for publication. Sponsor reserves the right to deny submission of study results if based on data owned by sponsor.|t
17180081|NCT00710710|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180082|NCT00715078|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17180083|NCT04867850|t||||
17135689|NCT01605396|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17135690|NCT00978445|f||||f
17135691|NCT04963179|f||||f
17135692|NCT04267562|f||||f
17135693|NCT03009539|t||||f
17135694|NCT03151148|f||||f
17135695|NCT00494871|f||LTE60||t
17135696|NCT04543955|t||||
17135697|NCT00962065|f||OTHER|The sponsor requires that written permission be given before the PI can release any data publicly.|t
17135698|NCT02433210|f||||f
17135699|NCT02090114|t||||f
17135700|NCT03046472|f||||f
17135701|NCT03823937|f||||f
17135702|NCT01989546|f||||f
17135703|NCT01958671|f||OTHER|The Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17135704|NCT01993329|f||OTHER|No data collected as part of this study will be utilized in any written work, including publications, without the written consent of Sponsor.|t
17135705|NCT02948777|f||||f
17135706|NCT02311478|f||||f
17135707|NCT03242928|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17135708|NCT02834403|t||||
17135709|NCT03691623|f||OTHER|First publication of Sponsor Data shall be made by Sponsor with input from principal investigator (PIs). If no publication within 24 months after study completion, PI may publish Sponsor Data with sponsor's prior written consent. Prior to submitting or presenting data, Sponsor has at least 60 days to to review and comment.|t
17135710|NCT02816710|f||||f
17135711|NCT00273858|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135712|NCT02232516|t||||
17135713|NCT01070550|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135714|NCT01258348|f||GT60||t
17135715|NCT01848821|f||||f
17135716|NCT02433288|f||||f
17135717|NCT00367640|f||||f
17135718|NCT02409784|t||||
17135719|NCT00406315|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135720|NCT04860713|f||||f
17135721|NCT02786355|f||||f
17135722|NCT02142894|f||||f
17135723|NCT04392011|f||||f
17135724|NCT01765647|f||||f
17135725|NCT00733356|f||||f
17135726|NCT02836990|f||||f
17135727|NCT01455428|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135728|NCT03303339|f||||t
17135729|NCT00940927|t||||f
17135730|NCT01747330|f||GT60||t
17135731|NCT00257192|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17135732|NCT00570739|f||OTHER|"The following language is employed: If identified by DSI, any of DSI's confidential information as defined herein shall be deleted...Nothing in this publication section shall be taken as giving DSI and right of editorial control over any publication prepared by the Study Site."|t
17135733|NCT02289755|f||GT60||t
17135734|NCT01206595|f||||f
17135735|NCT01400971|f||GT60||t
17135736|NCT02535949|f||||f
17135737|NCT01921270|t||||
17135738|NCT00455858|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, should be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17135739|NCT02375698|f||||f
17135740|NCT02273310|f||||f
17135741|NCT01595646|f||||f
17135742|NCT02946229|f||||f
17135743|NCT00231062|f||OTHER|If requested by Sponsor, Investigator(s) shall delay the submission of any publication or presentation for up to sixty (60) days from the date of Sponsor's request to permit the preparation and filing of related patent applications by Sponsor or for Sponsor to take other steps to protect its intellectual property interests.|t
17135744|NCT00803244|f||||f
17135745|NCT00616239|t||||
17135746|NCT02873715|f||||f
17135747|NCT02021812|f||||f
17135748|NCT03241173|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17135749|NCT02698423|t||||
17135750|NCT01651260|f||LTE60||t
17135751|NCT00317941|f||OTHER|According the contract he signed, If results should have been edited, the Principal Investigators (PI) should have been obtained the agreement from the sponsor 90 days before the publication. The PI was not allowed to communicate within a public way the information on the study without having obtained the sponsor's agreement.|t
17135752|NCT01259297|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17135753|NCT02991820|t||||
17180084|NCT01411696|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17180085|NCT03263442|f||||f
17180086|NCT01463878|f||||f
17180087|NCT03804879|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180088|NCT01585428|f||||f
17180089|NCT01084174|f||||f
17180090|NCT02536196|f||||f
17180091|NCT00673465|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17180092|NCT01829191|t||||
17180093|NCT00726661|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180094|NCT02237950|f||OTHER|For multicenter studies, PIs can publish data only after study data are published collectively.|t
17180095|NCT01996982|f||||f
17180096|NCT01574326|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17180097|NCT02278250|f||OTHER||t
17180098|NCT01370174|f||||f
17180099|NCT04997161|f||OTHER|"The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years of completion of the Study shall require the Sponsor's prior written consent.~The Investigator will provide the Sponsor with copies of any materials relating to the study or developed technologies that they intend to publish or present at least 30 days in advance of publication, submission, or presentation."|t
17180100|NCT02151253|t||||
17180101|NCT00005937|t||||
17180102|NCT01288469|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17180103|NCT00255047|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180104|NCT01574612|t||||f
17180105|NCT02452398|f||||f
17180106|NCT04216017|f||||f
17180107|NCT01957644|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180108|NCT00927784|f||OTHER|The site investigators have the right to independently publish results of their portion of the study conducted at their site 1 year following study conclusion; the site investigator must submit to the DCC for review and comment,a copy of any proposed manuscript resulting from research at least thirty (30) days prior to estimated publication date. If no response is received within thirty (30) days of the date the manuscript was submitted to the DCC, publication may proceed without delay.|t
17180109|NCT02170051|f||||f
17180110|NCT01867021|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial|t
17180111|NCT00881712|t||||
17180112|NCT01307397|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180113|NCT03748758|f||OTHER|No information, data or results shall be used by the Institution, Investigator or any other individual or entity other than the Sponsor. The use of Study Results by any party other than Sponsor requires prior written approval by the Sponsor.|t
17135754|NCT00064662|f||||f
17135755|NCT03008590|t||||f
17135756|NCT00872833|f||||f
17135757|NCT01713400|t||||
17135758|NCT01417780|f||||f
17135759|NCT01345786|f||OTHER|PI must provide sponsor w/ review copies of abstracts or manuscripts for publication that report any results of the study, 45 days before submission for publication or presentation. The sponsor shall have the right to review/comment on the material. If the parties disagree about the appropriateness of the material, PI must meet with sponsor's representatives before submission for publication, for the purpose of making good faith efforts to discuss and resolve any issues of disagreement.|t
17135760|NCT01929044|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135761|NCT01663740|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17135762|NCT03607682|t||||
17135763|NCT01770353|f||||t
17135764|NCT00376688|f||LTE60||t
17135765|NCT02574312|f||OTHER|DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but PI will retain final editorial control. In case of disagreement, DePuy and PI will make every effort to meet in order to discuss and resolve any issues.|t
17135766|NCT00696657|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17135767|NCT03074162|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135768|NCT03333057|f||GT60||t
17135769|NCT04964063|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180114|NCT01932112|f||||f
17135770|NCT01035606|f||||f
17135771|NCT03350750|f||||f
17135772|NCT02615535|f||||f
17135773|NCT01834144|f||||f
17135774|NCT01120093|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17135775|NCT01849250|f||LTE60||t
17135776|NCT02389816|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17135777|NCT02688842|f||||f
17135778|NCT04412954|t||||
17135779|NCT01525849|f||LTE60||t
17135780|NCT00339183|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135781|NCT00793819|f||LTE60||t
17135782|NCT00446446|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17135783|NCT01488318|t||||
17135784|NCT00477451|f||LTE60||t
17135785|NCT01757704|t||||
17135786|NCT02691247|f||||f
17135787|NCT01844700|f||||f
17135788|NCT02680847|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17135789|NCT02144220|t||||
17135790|NCT03648996|f||||f
17135791|NCT00590681|f||||f
17135792|NCT00504166|f||||f
17180115|NCT00560859|f||||f
17180116|NCT01405742|f||||f
17180117|NCT02503735|t||||
17180118|NCT03672747|f||||f
17180119|NCT03428360|f||GT60||t
17180120|NCT04570150|f||||f
17180121|NCT04061915|f||||f
17180122|NCT01529346|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180123|NCT00386776|t||||
17180124|NCT03454581|f||||f
17180125|NCT02902965|f||||f
17135793|NCT02229864|f||OTHER|"Principal Investigators shall not present or publish, nor submit for publication, any work resulting from the Services without Sponsor's prior written approval.~Except as specifically set forth herein, neither party shall use the other party's name or trademark, or the name nor trademark of such other party's affiliate, in any publicity, advertising or announcement, or disclose the existence or terms of this Agreement, without the consenting party's prior written approval."|t
17135794|NCT02650284|f||OTHER|Since the study has been discontinued due to the sample size not being reached, the data cannot be analysed and there are no trial results to discuss/ publish.|t
17135795|NCT00509873|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135796|NCT00554294|f||||f
17135797|NCT05022004|f||OTHER|"The Sponsor has exclusive rights, including the right of authorship, to all publications concerning Study data and findings. The Institution, the Investigator, and the Co-Investigators are contractually bound not to make any publications, public statements, oral presentations concerning the Study data and findings.~The Sponsor shall have the sole right to review, use, publish, and disclose any data, information, or results developed without limitation."|t
17135798|NCT01461863|t||||
17135799|NCT02084134|t||||
17135800|NCT03395340|f||||f
17135801|NCT01293396|t||||
17135802|NCT04072237|f||||f
17135803|NCT01780389|t||||f
17135804|NCT04985773|f||||t
17135805|NCT01095250|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17135806|NCT01519570|t||||
17135807|NCT04598165|t||||
17135808|NCT03677089|f||||f
17135809|NCT01323673|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135810|NCT00426751|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135811|NCT00540722|f||LTE60||t
17135812|NCT01593748|t||||
17135813|NCT02504892|f||||f
17135814|NCT04229446|f||||f
17135815|NCT02566525|f||||f
17135816|NCT00337467|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135817|NCT01745627|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17135818|NCT02488759|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135819|NCT04083222|f||OTHER||t
17135820|NCT03103750|t||||
17135821|NCT01128972|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135822|NCT04624932|f||||f
17135823|NCT02429427|t||||
17135824|NCT02078713|f||||f
17135825|NCT02096861|f||||f
17135826|NCT04688346|t||||
17135827|NCT00059215|f||GT60||t
17135828|NCT01419275|t||||
17135829|NCT04439838|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17135830|NCT04985799|t||||
17135831|NCT04494633|t||||
17135832|NCT00414310|t||||
17135833|NCT01254604|f||OTHER|Investigator may publish results for his/her study site after publication of results of entire multicenter trial, or after public disclosure of the results online if a multicenter manuscript is not planned. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17135834|NCT03041116|f||OTHER|The Institution and Investigator agree that because the study is part of a multi-center study, any publication by the Institution/Investigator of the study results shall not be made before the first multi-center publication.|t
17135835|NCT03097328|f||||f
17180126|NCT00232817|f||||f
17180127|NCT04481750|f||OTHER||t
17180128|NCT01594125|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180129|NCT01484873|t||||
17135836|NCT02436577|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17135837|NCT01675011|f||||f
17135838|NCT01815333|t||||
17135839|NCT05730829|f||||f
17135840|NCT00931892|f||||f
17135841|NCT01876732|t||||
17135842|NCT00964548|f||||f
17135843|NCT02531373|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17135844|NCT00536731|f||||f
17135845|NCT01675531|f||||f
17135846|NCT00623467|f||OTHER|The sponsor is interested in the publication of the results of every study it performs. All relevant aspects regarding publication will be part of the contract between the sponsor and the investigator/institution. The sponsor has committed to the global industry position on disclosure of information about clinical trials. The information regarding the study protocol is made publicly available on the internet at www.clinicaltrials.gov.|t
17135847|NCT02597673|f||||f
17135848|NCT04705597|f||||t
17135849|NCT02284399|t||||
17135850|NCT06094296|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17135851|NCT03332667|f||||f
17135852|NCT01809262|f||||f
17135853|NCT02404155|f||||f
17135854|NCT02064439|f||OTHER|The steering committee will be responsible for the publication and presentation strategy. All publications will be based on data released or agreed by Bayer, verified by the steering committee.|t
17135855|NCT02631135|f||||f
17135856|NCT00385268|f||||f
17135857|NCT02417233|f||||f
17135858|NCT03649321|t||||
17135859|NCT01702363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139907|NCT03575351|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180130|NCT02564042|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180131|NCT01549392|f||||f
17180132|NCT01356966|t||||
17180133|NCT02743806|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17180134|NCT00660530|f||||f
17185071|NCT02341417|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17185072|NCT00694603|f||||f
17185073|NCT04403698|t||||
17185074|NCT03152552|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185075|NCT01047839|f||OTHER||t
17185076|NCT00567242|f||||f
17135860|NCT01293032|t||||
17135861|NCT02243527|f||||f
17135862|NCT02262039|f||LTE60||t
17135863|NCT04174638|f||||f
17135864|NCT02184143|f||||f
17135865|NCT00321984|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17135866|NCT04929262|f||||f
17135867|NCT01387295|t||||
17135868|NCT02641236|t||||
17135869|NCT02985450|f||||f
17135870|NCT00816907|f||||f
17135871|NCT00431847|f||||f
17135872|NCT01469013|f||GT60||t
17139908|NCT04288089|f||||f
17135873|NCT00002663|f||||t
17135874|NCT01351766|f||||f
17135875|NCT00148733|f||||f
17135876|NCT01603641|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17135877|NCT03161678|t||||
17185077|NCT04899349|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185078|NCT01857531|t||||
17185079|NCT02726451|t||||
17185080|NCT01289067|t||||
17185081|NCT04656847|f||||t
17185082|NCT03301051|f||OTHER|The Investigator understands that the information in the protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical review of the study, without prior written authorization from the Sponsor. It is, however, permissible to discuss information contained in the protocol with a participant in order to obtain consent once Institutional Review Board (IRB) approval is obtained.|t
17185083|NCT00047879|f||||f
17185084|NCT00435370|f||||f
17185085|NCT01965834|t||||
17185086|NCT03943095|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185087|NCT00074035|f||LTE60||t
17185088|NCT03373604|t||||
17185089|NCT01496352|f||LTE60||t
17185090|NCT00710424|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17185091|NCT01962493|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185092|NCT06273774|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17185093|NCT02258477|f||||f
17185094|NCT04414696|t||||
17185095|NCT06660823|t||||
17135878|NCT00739297|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135879|NCT02005601|t||||
17135880|NCT02401555|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a five year period from the time of the non-disclosure agreement execution.|t
17135881|NCT02749721|t||||f
17135882|NCT02137772|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17135883|NCT01253460|t||||
17135884|NCT00443430|f||||f
17135885|NCT00418262|f||||f
17135886|NCT03519308|t||||
17135887|NCT00933335|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17135888|NCT05468086|t||||
17135889|NCT00374907|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180135|NCT00849381|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180136|NCT00303498|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180137|NCT02461355|t||||
17180138|NCT02310464|f||||f
17180139|NCT01988103|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 12 months since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17180140|NCT03590041|f||||f
17180141|NCT01967121|t||||f
17180142|NCT02289898|f||||f
17180143|NCT01493570|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180144|NCT00103142|t||||f
17180145|NCT03267186|t||||
17180146|NCT02598076|f||||f
17180147|NCT01946425|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17180148|NCT03527966|f||||f
17135890|NCT00783705|f||LTE60||t
17135891|NCT01043523|f||||f
17135892|NCT02379923|f||OTHER|PI may publish the results of its data 1 year after completion of the Study. Sponsor can review results prior to public release and embargo communications regarding results for a period ≤60 days from the time submitted to the sponsor for review. Sponsor may request in writing (a) deletion of any Confidential Information, (b) reasonable changes requested by Sponsor, or (c) delay of proposed submission for another period ≤90 days in order to protect the potential patentability of any technology.|t
17135893|NCT01200511|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17135894|NCT01617434|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17135895|NCT00705224|f||OTHER|PI agrees for a period of five years following the Effective Date to retain the Disclosure made to the SPONSOR or on behalf of SPONSOR, in confidence and not disclose it to any third party.|t
17135896|NCT04238663|f||||t
17135897|NCT00968253|t||||
17135898|NCT03596177|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17135899|NCT03569111|f||OTHER|Institution/Investigator shall not publish the Study results until after Sponsor's multi-site publication and final study results are complete or until the elapse of twelve (12) months from the close of the Study at all Study sites, whichever occurs first; unless approved by Sponsor.|t
17135900|NCT01301742|t||||
17135901|NCT00390364|t||||
17139909|NCT03715205|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17139910|NCT03288311|t||||
17139911|NCT02286089|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17139912|NCT03733249|f||||f
17139913|NCT04247828|t||||
17139914|NCT03299166|f||LTE60||t
17139915|NCT00572728|f||LTE60||t
17139916|NCT00002981|t||||
17139917|NCT01529450|f||||f
17139918|NCT03457636|f||||f
17139919|NCT03580525|f||||f
17139920|NCT00113555|f||||f
17139921|NCT01060124|f||||f
17139922|NCT03398824|f||||f
17139923|NCT01251315|f||||f
17139924|NCT03858686|f||||f
17139925|NCT03954704|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17139926|NCT00102804|f||GT60||t
17139927|NCT02094664|f||||f
17139928|NCT01432938|f||GT60||t
17139929|NCT00374127|t||||f
17139930|NCT04330989|t||||
17139931|NCT04035473|f||||f
17139932|NCT00112840|f||LTE60||t
17139933|NCT02299206|t||||
17139934|NCT00691054|t||||f
17139935|NCT04673630|f||||t
17139936|NCT02735044|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17139937|NCT02308709|t||||
17139938|NCT01682759|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17139939|NCT01868594|f||||t
17139940|NCT01394211|t||||
17139941|NCT06535932|f||OTHER|If PI wishes to publish study results, the Proposed Publication will be given to Philips for approval at least sixty (60) days prior to any disclosure or submission for presentation or publication. At the request of Philips, the PI agrees to (i) revise or delete any Philips' Confidential Information as requested by Philips and/or (ii) delay submission of the Proposed Publication for presentation or publication for an additional ninety (90) days to allow for filing of patient protection.|t
17139942|NCT00615420|f||||f
17139943|NCT03738878|f||||f
17139944|NCT00638651|f||||f
17139945|NCT04076579|t||||
17139946|NCT03770689|f||||f
17139947|NCT05815758|f||||f
17139948|NCT02362594|f||OTHER|All draft publications, including abstracts or detailed summaries of any proposed presentations, must be submitted to the Sponsor at the earliest practicable time for review, not less than 30 days before submission or presentation unless otherwise set forth in the clinical trial agreement. Sponsor shall have the right to delete any confidential information contained in any proposed presentation or abstract and may delay publication for up to 60 days for purposes of filing a patent application.|t
17139949|NCT04167514|f||||t
17139950|NCT03991936|t||||
17139951|NCT00939055|f||||f
17139952|NCT03139435|t||||
17139953|NCT00584987|t||||
17139954|NCT03225833|f||||f
17139955|NCT02881151|f||||f
17139956|NCT03258593|f||||f
17139957|NCT05318183|f||||f
17139958|NCT04437511|f||GT60||t
17139959|NCT00911183|t||||
17139960|NCT04228276|t||||
17139961|NCT03825536|t||||
17139962|NCT02498600|f||LTE60||t
17139963|NCT05085275|f||OTHER|No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement between Investigator-Sponsor and the Investigator and/or the Investigator's institution. The Investigator-Sponsor will have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.|t
17139964|NCT01081262|f||LTE60||t
17139965|NCT02912572|t||||
17139966|NCT05306964|t||||f
17139967|NCT00777036|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17139968|NCT01267955|f||LTE60||t
17139969|NCT05379686|t||||
17139970|NCT03811535|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17139971|NCT02421939|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17139972|NCT04453722|f||||f
17139973|NCT01263470|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17139974|NCT00610714|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.|t
17139975|NCT01327573|f||LTE60||t
17139976|NCT00712712|t||||
17139977|NCT05674838|t||||
17139978|NCT02432690|f||LTE60||t
17139979|NCT01058395|t||||
17139980|NCT04083781|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17139981|NCT03501979|f||||f
17139982|NCT04571684|t||||
17139983|NCT03733132|t||||
17139984|NCT02968277|f||||f
17139985|NCT04556175|f||||f
17139986|NCT04430894|t||||
17139987|NCT05549505|f||||t
17180149|NCT00558025|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17180150|NCT03315208|f||||f
17180151|NCT01930747|f||||f
17180152|NCT00982592|f||LTE60||t
17180153|NCT00276159|t||||f
17180154|NCT04356690|t||||
17180155|NCT00333866|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17180156|NCT01454947|t||||
17180157|NCT04247581|f||OTHER||t
17180158|NCT00456547|t||||
17180159|NCT01359449|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180160|NCT00330564|t||||f
17139988|NCT01602822|f||||f
17139989|NCT00854061|f||OTHER|Contact sponsor directly for details.|t
17139990|NCT05492877|f||OTHER|AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17139991|NCT02871791|t||||
17139992|NCT03369340|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17139993|NCT00809055|f||||f
17139994|NCT05333289|f||||t
17139995|NCT04476108|f||||t
17139996|NCT02253992|f||LTE60||t
17139997|NCT00772889|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17139998|NCT03323086|f||||f
17139999|NCT00355615|f||LTE60||t
17140000|NCT03676465|f||||f
17140001|NCT01004874|t||||
17140002|NCT03685643|f||||f
17180161|NCT02393547|t||||
17180162|NCT02927431|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180163|NCT00429104|t||||f
17180164|NCT02648178|t||||
17185096|NCT01625897|f||OTHER||t
17185097|NCT02358603|f||||t
17185098|NCT02985866|t||||
17140003|NCT02159365|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140004|NCT03523715|f||||f
17140005|NCT04430036|t||||
17180165|NCT01285310|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17180166|NCT00143403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180167|NCT00514540|f||||f
17180168|NCT00587639|f||||f
17180169|NCT03402386|f||OTHER||t
17180170|NCT01896531|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180171|NCT00632411|f||||f
17180172|NCT01195415|f||LTE60||t
17180173|NCT00533845|f||||f
17180174|NCT02956486|f||||t
17180175|NCT03241342|f||||f
17180176|NCT01267812|t||||
17180177|NCT00849810|f||||f
17180178|NCT01846611|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17180179|NCT04049123|f||GT60||t
17180180|NCT02671422|t||||
17180181|NCT04772755|f||||f
17180182|NCT01905657|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17180183|NCT02123745|t||||
17180184|NCT02744391|t||||
17180185|NCT01996709|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180186|NCT04702997|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17180187|NCT01754623|f||||f
17180188|NCT03915496|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180189|NCT01880840|f||||f
17180190|NCT02811445|f||||f
17180191|NCT02893878|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180192|NCT05286281|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180193|NCT03032705|t||||
17180194|NCT02825992|f||OTHER|None of the results, in whole or part, of the study carried out under the study protocol, nor any of the information provided by the sponsor for the purposes of performing the study, were allowed to be published or passed on to any third party without the consent of the sponsor. Any Investigator involved with this study was obligated to provide the sponsor with complete test results and all data derived from the study.|t
17180195|NCT02279173|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140006|NCT01842334|f||||f
17140007|NCT02268942|f||OTHER|In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor's ability to obtain patent protection.|t
17140008|NCT03531918|f||||f
17140009|NCT01885104|f||OTHER|Investigators have agreed to provide the Sponsor with the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication or presentation.|t
17140010|NCT04337203|t||||
17140011|NCT04191096|f||OTHER|The sponsor will comply with the requirements for publication of study results. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17140012|NCT05954065|f||||f
17140013|NCT02683668|t||||
17140014|NCT04418427|f||OTHER|Investigators agreed to postponement of single-site study publications until after publication of all multi-center study results, until notification by the Sponsor that a multi-center publication is not planned, or until eighteen (18) months after final database lock.|t
17140015|NCT04495673|t||||
17140016|NCT06115681|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140017|NCT02554721|f||||f
17140018|NCT03276494|f||||f
17140019|NCT01888965|t||||
17140020|NCT00908895|f||||f
17140021|NCT01030757|t||||
17140022|NCT04124952|t||||
17185099|NCT02008890|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185100|NCT02207816|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140023|NCT01654224|f||||f
17140024|NCT02094612|f||||f
17140025|NCT03345849|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140026|NCT03261037|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140027|NCT02943577|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17180196|NCT00157950|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180197|NCT02892760|t||||
17180198|NCT01499667|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17180199|NCT02673489|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180200|NCT00293254|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial, but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180201|NCT02335489|f||GT60||t
17180202|NCT02259582|f||||f
17180203|NCT00759863|t||||
17180204|NCT02653391|f||GT60||t
17180205|NCT00503308|f||||f
17180206|NCT00475176|t||||
17180207|NCT02436889|f||||f
17180208|NCT01034462|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17180209|NCT04273217|f||||t
17180210|NCT02618434|f||||t
17185101|NCT00686166|f||||f
17185102|NCT00360308|f||||f
17140028|NCT01355224|f||||f
17140029|NCT02481986|f||||f
17140030|NCT04654468|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140031|NCT05088460|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17140032|NCT03093350|t||||
17140033|NCT01319045|f||||f
17180211|NCT02106728|f||||f
17180212|NCT01214356|f||||f
17185103|NCT01217073|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17185104|NCT02564523|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17185105|NCT03403725|f||LTE60||t
17185106|NCT00373334|f||OTHER|The only disclosure restriction on the principal investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.|t
17185107|NCT04862143|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185108|NCT03031938|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185109|NCT00454051|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140034|NCT04564027|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17140035|NCT04632589|f||||f
17140036|NCT05564039|f||GT60||t
17140037|NCT04651777|t||||
17140038|NCT04566445|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140039|NCT04785144|f||LTE60||t
17140040|NCT03598140|t||||
17140041|NCT02559115|t||||
17140042|NCT02591511|f||LTE60||t
17140043|NCT05245071|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17180213|NCT00877877|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180214|NCT02935088|f||||t
17180215|NCT02135146|t||||
17180216|NCT00022633|f||||f
17180217|NCT01276353|f||OTHER||t
17180218|NCT03327649|f||||f
17140044|NCT05304611|f||||f
17140045|NCT03993119|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140046|NCT00963820|f||OTHER|Investigator may publish clinical data after the earlier of publication by Sponsor or 12 months after early termination or database lock. Proposed publication copy should be provided to Sponsor at least 30 days prior to submission/disclosure. If requested, Sponsor's confidential information must be removed and publication delayed if Sponsor intends to file a related patent application.|t
17140047|NCT02354690|t||||
17140048|NCT00557362|f||||f
17140049|NCT05064007|f||||f
17140050|NCT06408818|t||||
17140051|NCT04005755|f||||f
17140052|NCT02723019|f||||f
17140053|NCT00513370|f||OTHER|The first publication and presentation of this Study shall reside with Abbott. No independent manuscript may be submitted for publication until the first manuscript has been accepted for publication or twelve (12) months after completion of Study at all sites, which ever occurs first.|t
17140054|NCT00515099|f||||f
17140055|NCT00592072|t||||
17140056|NCT04732780|t||||
17140057|NCT03148899|f||||f
17140058|NCT01228149|t||||
17140059|NCT02750501|f||OTHER|Publication by the PI of any data from this study is strictly prohibited without consent from the sponsor.|t
17140060|NCT01738594|t||||
17140061|NCT00403390|t||||
17140062|NCT01563406|t||||f
17180219|NCT02493621|f||||f
17180220|NCT01905384|t||||
17185110|NCT01571362|f||LTE60||t
17185111|NCT04022668|f||||f
17185112|NCT00209417|f||||f
17185113|NCT02071173|f||||f
17185114|NCT04118348|t||||
17140063|NCT05259800|t||||
17140064|NCT02237898|t||||
17140065|NCT05307523|f||||f
17140066|NCT01359111|f||||f
17140067|NCT01708915|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17180221|NCT03325075|f||||t
17180222|NCT00422591|t||||
17180223|NCT00345254|t||||
17180224|NCT02659631|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140068|NCT03231228|f||OTHER|Following the first publication, the PI may publish data or results from the Study; provided that the PI submits the proposed publication to Sponsor for review at least sixty (60) days prior to the date of submission to the proposed publication. Sponsor may request that any Confidential Information be removed from the proposed publication other than Study data and results. The Investigator certifies that it shall not publish any Study related material other than per this agreement.|t
17140069|NCT03661983|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17140070|NCT00416572|f||||f
17140071|NCT00166504|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140072|NCT01222767|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17140073|NCT00723489|f||||f
17140074|NCT00081263|f||||f
17140075|NCT04517253|f||GT60||t
17140076|NCT02060903|f||||f
17140077|NCT02329860|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17140078|NCT00608491|f||||f
17140079|NCT00958191|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts and abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17140080|NCT00611767|t||||
17140081|NCT02010567|t||||
17140082|NCT00118040|f||LTE60||t
17140083|NCT01930487|f||||f
17140084|NCT05559203|t||||
17140085|NCT03117309|f||||f
17140086|NCT04048876|f||LTE60||t
17140087|NCT03887286|t||||
17140088|NCT01099761|f||||f
17140089|NCT02031627|f||||f
17140090|NCT01347840|f||||f
17140091|NCT00928304|f||LTE60||t
17140092|NCT01010776|f||OTHER|The only disclosure restriction on the PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The Sponsor can require changes to the communication and can extend the embargo.|t
17140093|NCT01637090|t||||
17140094|NCT02583711|f||||f
17140095|NCT01012037|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17140096|NCT02282930|t||||
17140097|NCT01700140|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results without prior approval from the sponsor.|t
17140098|NCT00415623|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17140099|NCT01855867|f||||f
17140100|NCT00678249|f||||f
17140101|NCT01045551|t||||
17140102|NCT00542425|f||OTHER|"The PI/Institution may publish/present results of the Study provided that the Publication is reviewed by the Sponsor for Confidential Information at least 60 days prior to submission. If the Publication contains patent-related information, the submission shall be delayed for 90 days.~The Institution/PI will not publish until after the data from the multi-center study is published in a combined paper as long as it is completed within 18 months from the date of study completion."|t
17140103|NCT02096471|f||GT60||t
17140104|NCT01610414|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140105|NCT02736474|f||||f
17140106|NCT02483611|f||||f
17140107|NCT02382276|f||||f
17140108|NCT05439876|t||||
17140109|NCT04223778|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17140110|NCT05325333|f||||f
17180225|NCT02377466|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140111|NCT03893630|t||||
17140112|NCT01569568|f||||f
17140113|NCT01370499|f||GT60||t
17140114|NCT00887822|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180226|NCT03078647|f||||f
17180227|NCT01485770|f||||f
17180228|NCT01860651|t||||f
17140115|NCT02045979|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140116|NCT02425891|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140117|NCT02306928|t||||
17185115|NCT01491854|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185116|NCT01636882|f||||t
17185117|NCT00121238|f||LTE60||t
17185118|NCT00789438|t||||
17185119|NCT02703350|f||GT60||t
17185120|NCT01026974|f||GT60||t
17185121|NCT00303966|f||LTE60||t
17185122|NCT00325468|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17185123|NCT03280121|f||||f
17185124|NCT02701985|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185125|NCT01640808|f||||f
17185126|NCT04391023|f||||f
17185127|NCT04009291|f||||f
17185128|NCT02189798|f||LTE60||t
17185129|NCT02834780|f||||t
17185130|NCT03449030|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17185131|NCT02415400|f||LTE60||t
17185132|NCT02270450|f||LTE60||t
17185133|NCT02363738|f||||f
17185134|NCT04458948|t||||f
17185135|NCT02087163|f||||f
17185136|NCT03282227|f||LTE60||t
17185137|NCT04330638|f||||f
17140118|NCT01944462|f||LTE60||t
17140119|NCT01599585|f||||f
17140120|NCT05827978|f||||t
17140121|NCT00729560|f||||f
17140122|NCT00103207|f||||f
17140123|NCT03662789|t||||
17140124|NCT01029691|t||||
17140125|NCT01023516|f||||f
17140126|NCT00369564|f||||f
17140127|NCT00137267|t||||
17140128|NCT01104922|t||||
17140129|NCT00638989|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17140130|NCT00853112|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140131|NCT01553591|f||OTHER|The sponsor will work with the Investigators to determine how any manuscript or publication in a scientific journal is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. The sponsor has final approval authority over all such issues. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17140132|NCT01818765|t||||
17185138|NCT00856050|t||||
17185139|NCT02666950|t||||
17185140|NCT00989287|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185141|NCT03743038|f||LTE60||t
17185142|NCT01300546|f||LTE60||t
17185143|NCT02820623|f||||f
17185144|NCT02599194|f||||f
17185145|NCT00617344|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17185146|NCT00596440|t||||
17185147|NCT03166761|t||||
17185148|NCT01864564|f||||f
17185149|NCT02269670|t||||
17185150|NCT00941330|t||||
17185151|NCT02693665|f||||f
17185152|NCT03656133|t||||
17185153|NCT00655980|t||||
17185154|NCT04439110|f||LTE60||t
17185155|NCT04951336|t||||
17185156|NCT00127608|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185157|NCT05245864|t||||
17185158|NCT05501860|f||OTHER|Investigative site, the Principal Investigator, and any other investigators understand and agree that the Study is a multi-center clinical study and that a multicenter publication may be prepared and published by the Sponsor. The investigative site and its investigators will not, individually or together, present or publish any findings, data or results of the Study.|t
17140133|NCT00170846|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140134|NCT02005211|f||GT60||t
17140135|NCT01917136|t||||
17140136|NCT00397631|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140137|NCT02202161|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140138|NCT00832091|f||OTHER|RegeneRx/Sigma-Tau agreements may vary with individual investigators, but will not prohibit any investigator from publishing. RegeneRx/Sigma-Tau support the publication of results from all centers of a multi-center trial but requests that reports based on a single-site data not precede the primary publication of the entire clinical trial.|t
17140139|NCT03667573|t||||
17140140|NCT04180475|f||||f
17140141|NCT00942422|t||||f
17180229|NCT02663232|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180230|NCT02485574|f||||f
17180231|NCT00862745|f||||f
17180232|NCT02403154|f||||f
17180233|NCT01250834|f||GT60||t
17180234|NCT00110149|f||||f
17180235|NCT00563381|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17180236|NCT00667368|f||||f
17180237|NCT03336853|f||||f
17180238|NCT01911689|t||||
17180239|NCT00732615|f||OTHER||t
17185159|NCT04133831|f||||f
17185160|NCT02811861|f||||f
17185161|NCT02925455|f||||f
17185162|NCT05645354|t||||
17185163|NCT03912259|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17185164|NCT01549613|f||||f
17185165|NCT02216123|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185166|NCT04977050|t||||
17185167|NCT03162224|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17185168|NCT04066114|f||||f
17185169|NCT00254982|f||OTHER|The investigator agrees not to pubish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any elecontronic media) that report any results of study.|t
17185170|NCT00728819|t||||
17185171|NCT03117738|f||||t
17185172|NCT04004611|f||GT60||t
17185173|NCT04420689|f||||f
17185174|NCT00515502|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185175|NCT03317002|f||OTHER||t
17185176|NCT02732938|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185177|NCT03927950|t||||f
17185178|NCT03647501|t||||
17185179|NCT04530448|t||||
17140142|NCT02711553|f||OTHER|Other disclosure agreement is maximum of 10 years restriction on the PI that the sponsor can review results communications prior to public release and can embargo communications regarding trial results. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17140143|NCT02187224|t||||
17140144|NCT01229410|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17180240|NCT03566823|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17140145|NCT00998985|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17140146|NCT02152540|f||||f
17140147|NCT02573012|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140148|NCT01635244|f||||f
17140149|NCT01402375|t||||
17140150|NCT01222416|t||||
17140151|NCT02178592|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140152|NCT00928499|f||||f
17140153|NCT00518336|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140154|NCT00125268|t||||f
17140155|NCT04227119|t||||
17140156|NCT00286156|t||||
17140157|NCT00671515|t||||
17140158|NCT02449915|t||||
17140159|NCT04960397|f||||t
17140160|NCT00758576|f||LTE60||t
17140161|NCT01747447|f||||f
17140162|NCT01183728|t||||
17140163|NCT01842282|t||||
17140164|NCT01562379|f||||f
17140165|NCT04806165|f||||f
17180241|NCT01348347|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180242|NCT00191789|f||GT60||t
17180243|NCT00759811|t||||
17180244|NCT00923598|f||||t
17180245|NCT03383198|t||||f
17180246|NCT01516346|f||||f
17180247|NCT00828347|t||||
17180248|NCT01129960|f||OTHER||t
17180249|NCT00165776|f||||f
17180250|NCT00492583|f||||f
17180251|NCT02622321|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180252|NCT00886899|f||||f
17180253|NCT00965718|f||||f
17180254|NCT00138203|f||LTE60||t
17180255|NCT00241280|f||GT60||t
17180256|NCT03498300|f||||f
17180257|NCT01414855|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180258|NCT00368355|t||||
17180259|NCT04899921|t||||
17180260|NCT02999854|f||||f
17140166|NCT02059174|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17140167|NCT02306148|f||||f
17140168|NCT01901809|f||||f
17140169|NCT00087594|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180261|NCT01013701|t||||
17180262|NCT01386554|f||OTHER|Institution/Investigator shall not, without Sponsor's prior written consent, independently publish or otherwise disclose any results of the study until a Multi-Center Publication is published. If a Multi-Center Publication is not submitted for publication within the specified timeframe, Institution and Principal Investigator shall have the right to publish and present the results of Institution's and Principal Investigator's activities solely in accordance with the Sponsor's written provisions.|t
17180263|NCT00001596|t||||f
17180264|NCT03867981|f||||f
17180265|NCT01694641|t||||
17180266|NCT00180414|f||||t
17180267|NCT02927080|f||||t
17180268|NCT01199289|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17180269|NCT03879655|f||||t
17180270|NCT02290509|f||LTE60||t
17180271|NCT00127712|f||||f
17180272|NCT02642614|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180273|NCT04067544|f||||f
17140170|NCT02776904|t||||
17185180|NCT01613248|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185181|NCT02212574|f||||f
17185182|NCT01433354|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single- site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.|t
17185183|NCT02898974|t||||
17185184|NCT05098054|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17185185|NCT02015676|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185186|NCT01016769|t||||
17185187|NCT01426191|f||GT60||t
17185188|NCT02013622|f||||f
17185189|NCT01763931|t||||f
17185190|NCT04650555|f||||f
17185191|NCT04307004|f||||f
17185192|NCT02081846|f||||f
17140171|NCT01952041|f||||f
17140172|NCT01736176|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140173|NCT00186121|f||||f
17140174|NCT03650387|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17140175|NCT00934791|t||||f
17140176|NCT02353806|f||||f
17140177|NCT03763942|t||||
17180274|NCT01320085|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180275|NCT03316131|f||||t
17180276|NCT00478569|f||OTHER|Any study related publication will be multi-center or single-center publications. All proposed site publications and presentations will be submitted to (sponsor) NPS Pharmaceuticals for review in advance of publication.|t
17180277|NCT02070692|f||||f
17180278|NCT04615923|t||||
17180279|NCT02282020|f||||f
17180280|NCT00100815|t||||
17180281|NCT01647282|t||||
17180282|NCT00311623|t||||
17180283|NCT03998189|t||||
17180284|NCT03227029|f||||f
17140178|NCT03558503|f||||f
17140179|NCT02145429|f||||f
17140180|NCT02646891|f||||f
17140181|NCT02274311|f||||f
17180285|NCT03414424|t||||
17180286|NCT01113801|f||GT60||t
17180287|NCT04468204|f||||f
17180288|NCT00770289|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180289|NCT00495170|t||||
17180290|NCT01408914|f||||f
17180291|NCT00330616|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180292|NCT00697203|f||||f
17180293|NCT00811473|f||GT60||t
17180294|NCT04127331|t||||
17180295|NCT01585194|t||||
17140182|NCT02477800|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17140183|NCT02782364|t||||
17140184|NCT01076270|f||LTE60||t
17140185|NCT01948518|f||||f
17140186|NCT02607865|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17140187|NCT02447952|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140188|NCT04589832|f||||f
17180296|NCT01957553|f||LTE60||t
17180297|NCT03254927|f||||f
17180298|NCT00993291|f||||f
17180299|NCT00446290|f||||f
17180300|NCT01333059|t||||
17180301|NCT02733367|f||||f
17140189|NCT01714336|t||||f
17140190|NCT01756833|f||||f
17140191|NCT01766401|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the PI will be subject to mutual agreement between the PI and Forest Research Institute, Inc.|t
17140192|NCT04623255|t||||
17140193|NCT00384449|t||||
17140194|NCT01100762|f||||f
17140195|NCT01040728|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17140196|NCT03116841|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17140197|NCT01875874|f||||t
17140198|NCT00590031|t||||
17140199|NCT01601873|t||||
17140200|NCT02176005|f||LTE60||t
17140201|NCT00826540|t||||
17140202|NCT02871570|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140203|NCT02520141|t||||f
17140204|NCT00703781|f||OTHER|The disclosure restriction on the PI is that the PI will provide to the sponsor a copy of proposed publication information for review, comment and approval following completion of the study and at least sixty (60) days prior to submission of the publication. If sponsor requests in writing, the PI will withhold publication until written permission is given by sponsor.|t
17140205|NCT03452397|f||||t
17140206|NCT02691468|f||||f
17140207|NCT06334055|t||||
17140208|NCT02545049|f||OTHER||t
17140209|NCT01801189|f||||f
17140210|NCT03300557|f||LTE60||t
17140211|NCT01855919|f||GT60||t
17140212|NCT04459416|t||||
17140213|NCT03455530|t||||f
17140214|NCT01592773|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the PI will be subject to mutual agreement between the PI and Forest Research Institute, Inc."|t
17140215|NCT01054339|f||LTE60||t
17140216|NCT00740116|f||||f
17140217|NCT03037489|f||||t
17140218|NCT00461851|f||||f
17140219|NCT00621764|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17140220|NCT01293123|t||||
17140221|NCT00121485|f||||f
17140222|NCT01111331|t||||
17140223|NCT00724243|f||OTHER|Contractor agrees to acknowledge his contractual relationship with Sponsor in his lecturing or publication activities in relation to subject matter and/or in relation to any other matter concerning Sponsor. However, unless Sponsor's prior consent was given, Contractor shall not specify in more detail the content or subject matter of his contract. Contractor shall not publish or provide to 3rd parties for publication purposes any results of his activities without Sponsor's prior written consent.|t
17140224|NCT02386605|t||||
17140225|NCT03031327|f||||f
17140226|NCT00211536|f||GT60||t
17140227|NCT01004861|f||||f
17140228|NCT00003389|f||||f
17140229|NCT00686699|f||OTHER|The principal investigator agrees to provide to the sponsor 30 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17180302|NCT04152603|f||||f
17180303|NCT00748033|f||||f
17180304|NCT01958320|f||||f
17180305|NCT02049957|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17180306|NCT03557151|f||||f
17140230|NCT04610827|t||||
17140231|NCT01662752|f||||f
17140232|NCT00908050|f||||f
17140233|NCT01997892|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140234|NCT02710422|t||||
17140235|NCT01935622|t||||f
17140236|NCT02608099|f||||f
17140237|NCT03040479|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17140238|NCT04657003|f||GT60||t
17140239|NCT00935766|f||OTHER|The PI shall furnish copies of any proposed publication or presentation to the Sponsor for review at least thirty (30) days in advance of the submission of such proposed publication or presentation to a journal, editor or other third party. The sponsor shall have thirty (30) days after receipt of said copies, to object to such proposed presentation or proposed publication.|t
17180307|NCT01414075|f||||t
17180308|NCT03847233|f||OTHER|The restriction depends on the conditions on the Clinical Study Agreement at each site. The PI must notify the sponsor about the publication and receive the approval from the sponsor prior to any results/data relavant to the J-SUPREME II trial to be in public.|t
17180309|NCT02532933|f||||f
17140240|NCT00768040|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140241|NCT04334876|t||||
17140242|NCT00417248|f||||f
17140243|NCT02185040|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17140244|NCT03347279|f||||t
17140245|NCT01646151|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17140246|NCT02385292|f||OTHER|The investigator or other study-related personnel may not disclose to anyone or use any data, information, or materials related to this clinical trial without the express written consent of Oculeve.|t
17140247|NCT01792024|f||||f
17140248|NCT03818399|t||||
17140249|NCT02530281|f||||t
17140250|NCT03557801|t||||
17140251|NCT00535236|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17140252|NCT02390323|t||||
17140253|NCT00141297|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140254|NCT02200510|f||||f
17140255|NCT00290355|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140256|NCT01542632|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17140257|NCT00033514|f||||f
17140258|NCT03502941|t||||f
17140259|NCT04465240|f||||f
17140260|NCT01108263|f||OTHER||t
17140261|NCT01685372|t||||
17140262|NCT01072500|f||||f
17140263|NCT00829010|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140264|NCT02061540|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17140265|NCT02599441|f||||f
17140266|NCT02289833|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140267|NCT04509024|f||||f
17140268|NCT03442595|t||||
17140269|NCT01642004|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140270|NCT00598806|f||OTHER|First publication is the multi-center publication of Study results from all study sites. Other than the multi-center publication, site may publish an independent publication of data generated by site subject to Sponsor review rights (e.g., review for intellectual property, confidentiality).|t
17140271|NCT00811395|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not exceeding 90 days.~To protect by property right the sponsor can postpone the publication of any information, for a period not exceeding 18 months."|t
17140272|NCT02417129|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140273|NCT00706264|f||||f
17140274|NCT00528840|f||OTHER|Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not preceed the primary publication of the entire clinical trial.|t
17140275|NCT00952133|f||||f
17140276|NCT01523613|t||||
17140277|NCT00398086|f||OTHER|Institution may publish the results of its findings if a multicenter publication is not forthcoming within 18 months after study completion. Institution shall provide Celgene with a copy of the papers prior to their submission; Celgene shall complete its review within 30 days after receipt. Upon Celgene's request, proposed publication or presentation can be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of patentable material.|t
17140278|NCT01950364|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17140279|NCT01736930|f||||f
17140280|NCT01166386|t||||
17140281|NCT03714256|f||LTE60||t
17140282|NCT02972658|f||OTHER|The sponsor shall review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. Investigator shall delay publication of their results of the study until the results of the multi-center study are published or presented, provided the multi-center results are published within 24 months of the termination.|t
17180310|NCT01922089|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17180311|NCT01590238|f||||f
17180312|NCT03735433|t||||
17180313|NCT04903626|f||||f
17180314|NCT00573534|f||||f
17180315|NCT02642952|t||||
17180316|NCT00310791|t||||
17180317|NCT01092559|f||LTE60||t
17180318|NCT00467259|f||LTE60||t
17180319|NCT01150981|f||||f
17180320|NCT04285879|t||||f
17180321|NCT05740644|f||||f
17180322|NCT01958008|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180323|NCT01634360|f||||f
17180324|NCT02028065|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17180325|NCT04851314|f||||f
17180326|NCT00877383|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17180327|NCT02402127|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180328|NCT02107482|f||||f
17140283|NCT03958149|t||||
17140284|NCT02785588|f||||f
17140285|NCT02499172|f||||f
17140286|NCT03577028|f||||f
17140287|NCT02055872|t||||
17140288|NCT01488994|f||OTHER|Baxalta's agreements with PIs may vary per individual PI, but contain common elements. For this study, PIs may be restricted from independently publishing results without prior approval.|t
17140289|NCT03798366|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17140290|NCT02089191|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17140291|NCT00474539|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17140292|NCT01227252|f||GT60||t
17140293|NCT02561273|t||||
17140294|NCT01550315|t||||
17180329|NCT04868890|f||||t
17140296|NCT00676806|t||||
17140297|NCT02192190|f||GT60||t
17140298|NCT03227692|f||||f
17140299|NCT01657253|f||OTHER|"All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.~All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor."|t
17180330|NCT00867009|f||GT60||t
17180331|NCT02418026|t||||
17180332|NCT00147199|f||OTHER|Any publication of the result of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results are described in the investigator contract.|t
17180333|NCT01850524|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17180334|NCT02727751|f||GT60||t
17180335|NCT03358290|f||OTHER|The sponsor can review results communications at least 60 days prior to public release. The sponsor will have a review period of 60 days and can embargo communications regarding trial results for an additional period of 60 days from the end of sponsor review period. The sponsor may require removal of any and all confidential information (other than study results) in the communication.|t
17180336|NCT01706081|t||||
17140300|NCT02079311|f||OTHER|The Investigator shall provide the Sponsor with a draft of the manuscript intended for publication or presentation at least \[14\] days before the date of intended submission for publication. However the Sponsor should be notified about the intention to publish the results at least \[14\] days before the manuscript is sent for review. All comments and suggested changes made by the Sponsor shall be considered in good faith in determining the final form of such publication.|t
17140301|NCT01970540|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17140302|NCT01603628|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17140303|NCT04995666|t||||
17140304|NCT00952588|f||LTE60||t
17140305|NCT01796106|f||LTE60||t
17140306|NCT02795182|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17140307|NCT04107935|t||||
17140308|NCT01021553|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140309|NCT00890201|t||||
17140310|NCT00033293|f||OTHER|Must obtain prior Sponsor approval|t
17140311|NCT00935701|f||||f
17140312|NCT02087241|f||||f
17140313|NCT02181504|f||OTHER|If the site intends to publish the Clinical Trial results and other information with an academic intention, or Allergan intends to utilize the related information for distribution activities of its own, the said party must obtain the consent from the other party in advance. However, except for the case based on the due reason including that the consent of trial subjects cannot be obtained though it is mandatory, the other party cannot refuse the consent.|t
17140314|NCT00545584|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140315|NCT03525613|f||||t
17140316|NCT02584660|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17140317|NCT03341728|t||||
17140318|NCT00461552|f||GT60||t
17140319|NCT00389805|t||||
17140320|NCT01315873|f||||f
17140321|NCT01289028|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17140322|NCT02120469|t||||
17140323|NCT02076243|t||||
17140324|NCT06022224|f||||t
17140325|NCT01183481|t||||f
17140326|NCT03267576|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17140327|NCT01369069|f||||f
17140328|NCT00882362|f||||f
17140329|NCT01268514|f||LTE60||t
17140330|NCT01846208|f||||f
17140331|NCT01424306|f||||f
17140332|NCT00369928|f||OTHER|It will be the Sponsor's responsibility to convene and charter a Publications Committee consisting of representation from the Sponsor and key academic and investigational centers. The Publications Committee will be primarily responsible for the creation, review, and submission of publications and presentations relating to the major aspects of the study (design, baseline data, mortality and safety data) and ancillary analyses after the completion of the study.|t
17140333|NCT00193128|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17140334|NCT03344562|t||||
17140335|NCT01555541|t||||
17140336|NCT03726749|f||||f
17140337|NCT04957745|f||||f
17140338|NCT01646346|t||||
17140339|NCT02463331|f||||f
17140340|NCT02274766|f||||f
17180337|NCT01973166|f||||f
17180338|NCT04140292|t||||
17180339|NCT00459667|f||OTHER|The sponsor is interested in the publication of the results of every study it performs. As some of the information concerning the study drug and the sponsor's development activities may be strictly confidential, any publication manuscript (including conference contributions, etc.) must first be reviewed by the sponsor before its submission or presentation. Publication of subgroup data and single center data shall not be performed until the complete study has been published.|t
17180340|NCT00556712|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180341|NCT04080297|f||||f
17180342|NCT02626520|f||||f
17140341|NCT02130635|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140342|NCT02608892|t||||
17140343|NCT02590406|f||||f
17140344|NCT00984009|f||GT60||t
17140345|NCT01628718|f||||f
17140346|NCT02036476|f||||f
17140347|NCT02168816|t||||
17140348|NCT02985684|f||||t
17140349|NCT01436357|f||LTE60||t
17140350|NCT05281094|f||||t
17140351|NCT05315297|t||||
17140352|NCT02583399|f||||f
17140353|NCT01432236|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140354|NCT04607291|t||||
17140355|NCT03350724|t||||
17140356|NCT02134912|f||LTE60||t
17140357|NCT02759939|t||||
17140358|NCT03474380|f||||f
17140359|NCT03288987|f||||t
17140360|NCT01143116|f||||f
17140361|NCT02807376|f||LTE60||t
17140362|NCT00846027|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140363|NCT02009501|t||||
17140364|NCT04905563|f||||f
17140365|NCT01797302|t||||f
17140366|NCT01228084|t||||
17140367|NCT03228836|f||||f
17140368|NCT01173874|t||||
17180343|NCT00353262|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180344|NCT00289315|f||||f
17180345|NCT01909154|t||||
17180346|NCT00463346|t||||f
17180347|NCT01572909|f||||t
17180348|NCT03641651|f||||f
17140369|NCT03894501|f||||f
17140370|NCT02908841|t||||f
17140371|NCT01611558|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140372|NCT01520727|f||OTHER||t
17140373|NCT00366106|f||OTHER|A copy of the disclosure must be given to Millennium for review at least 30 days before it is submitted for publication or disclosure. If a Development is contained in the disclosure, Research Organization and/or Principal Investigator defer publication or disclosure for 90 days from the time Millennium notifies that it wants to file a patent application on the Development provided such notice was provided by Millennium within 30 days of the copy first provided to Millennium.|t
17140374|NCT04005885|f||||f
17140375|NCT03597789|t||||
17180349|NCT04779489|t||||
17180350|NCT00951665|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140376|NCT04652102|f||||t
17140377|NCT03442933|f||||f
17140378|NCT03986671|f||||f
17140379|NCT00696774|f||GT60||t
17140380|NCT02139176|f||||f
17140381|NCT01056601|t||||
17140382|NCT02169466|f||OTHER||t
17140383|NCT01671605|f||||f
17140384|NCT02442765|f||||t
17140385|NCT00887913|f||OTHER|PI is under a general confidentiality agreement and must have prior written approval by the Sponsor prior to publishing the study results.|t
17140386|NCT01371721|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.|t
17140387|NCT01200758|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140388|NCT01795716|f||||f
17140389|NCT00407420|t||||
17140390|NCT03196973|f||OTHER|"Any publication by PI of the Study Results shall not be made before the first multi-center publication.~PI shall allow Sponsor not less than 60 days to review any manuscript and not less than 30 days to review any other documentation which describes or discloses the Study Results. Sponsor can request an additional 60 days.~Sponsor reserves the right to remove all Confidential Information from any publications or presentations."|t
17180351|NCT02723084|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180352|NCT02659709|f||||f
17180353|NCT00714389|t||||f
17140391|NCT01809327|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17140392|NCT01564485|f||||f
17140393|NCT02390362|t||||
17140394|NCT04009824|f||||f
17140395|NCT03701061|t||||
17140396|NCT01142791|f||||f
17140397|NCT04840849|f||||t
17140398|NCT03032523|f||||f
17140399|NCT00957723|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study. These manuscripts and abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17140400|NCT00281528|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation|t
17140401|NCT04396106|f||OTHER|Principal Investigator may publish or present results pertaining to the PI's activities after the first publication of the multicentre clinical trial results, or 18 months after the clinical study database lock. Any such publications must be submitted for review by Sponsor before submission. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140402|NCT03516227|f||||f
17140403|NCT05592145|t||||
17140404|NCT01984294|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17140405|NCT01987609|f||||f
17180354|NCT02450903|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17180355|NCT01164956|f||||f
17180356|NCT00967798|t||||
17180357|NCT01409564|f||||f
17180358|NCT00258882|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180359|NCT02328755|t||||
17180360|NCT00788151|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17180361|NCT00503009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180362|NCT01349803|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17180363|NCT02169739|f||||f
17180364|NCT01710033|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180365|NCT02880189|t||||
17180366|NCT04396990|t||||
17180367|NCT00826020|f||||f
17180368|NCT01244906|t||||
17180369|NCT03040466|t||||f
17180370|NCT04309656|f||||t
17180371|NCT03720470|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180372|NCT00453921|t||||f
17180373|NCT00460031|t||||
17180374|NCT04532099|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17180375|NCT01194479|t||||
17180376|NCT00644995|t||||
17180377|NCT02066233|t||||
17180378|NCT02772081|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17180379|NCT01141907|f||||f
17180380|NCT00176826|t||||
17180381|NCT02451839|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17180382|NCT03103919|f||GT60||t
17140406|NCT00806494|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140407|NCT02610231|f||OTHER||t
17140408|NCT01279954|f||||f
17140409|NCT02709889|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140410|NCT00537810|t||||
17140411|NCT01066546|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140412|NCT03258762|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140413|NCT01711359|f||GT60||t
17140414|NCT02698176|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17140415|NCT03474172|f||||f
17140416|NCT02253173|f||OTHER||t
17140417|NCT02561572|t||||
17140418|NCT00795717|f||LTE60||t
17140419|NCT00211692|f||||f
17140420|NCT01800162|f||||f
17140421|NCT01586962|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17140422|NCT00424463|f||OTHER||t
17140423|NCT02020304|t||||
17140424|NCT00498706|f||||f
17140425|NCT01497665|f||||f
17180383|NCT01291173|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17140426|NCT02469597|t||||
17180384|NCT00390858|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180385|NCT02728895|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17180386|NCT05081011|t||||
17140427|NCT04728815|t||||
17140428|NCT00631969|f||OTHER|In the protocol it is specified that all results are the property of the sponsor. The investigator must discuss any publication with the sponsor prior to release and obtain written consent of the sponsor. The investigator must send a draft publication to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication.|t
17140429|NCT00957034|f||LTE60||t
17140430|NCT00703729|f||||f
17180387|NCT02734238|t||||
17180388|NCT01949051|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180389|NCT01506479|f||||f
17180390|NCT01782859|t||||
17180391|NCT04994522|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors (ICMJE) authorship requirements.|t
17180392|NCT02611778|f||||t
17180393|NCT02426892|t||||
17180394|NCT00530764|f||OTHER|"Publication Policy:~GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release."|t
17180395|NCT03198234|f||||f
17180396|NCT01340898|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180397|NCT02056340|f||||f
17180398|NCT02417701|f||LTE60||t
17180399|NCT02947997|f||||f
17180400|NCT00830596|t||||
17180401|NCT04474704|f||||f
17180402|NCT02669433|f||OTHER|All proposed manuscripts, publications or abstracts must be reviewed and approved by the Sponsor 60 days prior to submission for publication. All confidential information identified by the Sponsor must be deleted prior to submission.|t
17180403|NCT03128892|t||||
17180404|NCT00459108|f||LTE60||t
17180405|NCT01563003|t||||
17180406|NCT01322360|f||GT60||t
17180407|NCT01457521|f||||f
17180408|NCT03473808|t||||f
17180409|NCT02157298|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17180410|NCT01339429|f||||f
17180411|NCT01085591|f||OTHER||t
17180412|NCT00396591|f||OTHER|The investigator has the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 for abstracts) in advance of any submission for publication. The Sponsor may request for the publication to be delayed for a limited time, not to exceed 90 days to preserve its proprietary rights.|t
17180413|NCT00848367|f||||f
17180414|NCT01537029|f||||f
17180415|NCT00818662|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication (by USCD) or 12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of ≤45 days(e.g., for intellectual property protection)|t
17180416|NCT01472081|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180417|NCT03605303|f||GT60||t
17180418|NCT03388294|t||||
17180419|NCT02200445|f||||f
17180420|NCT03334903|f||||f
17180421|NCT01346839|f||||f
17180422|NCT00623727|f||OTHER|"Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~No publication of single center data should be done prior of publication if multi -center data."|t
17180423|NCT00501293|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17180424|NCT01188694|f||||f
17180425|NCT01104636|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180426|NCT01706003|t||||
17180427|NCT04538066|f||OTHER|The Sponsor has the right to the primary publication. Following primary publication, the PI may publish results from the Study but must submit the publication to Sponsor for approval at least 60 days prior to journal submission. If there is patentable subject matter in the proposed publication, publication shall be delayed to allow for the preparation of a patent application. If primary manuscript is not submitted within 12 months after end of the Study, PI may publish own Study results.|t
17180428|NCT00696696|f||||f
17180429|NCT00536601|t||||
17180430|NCT01313767|f||OTHER|"All the results which arise directly or indirectly from the clinical trial in any form shall be the exclusive property of the sponsor.~PIs and the sponsor will discuss, prior to public release of the results, any draft publication or communication made by the investigator. PIs shall not mention any information for a patent or for any intellectual property rights. The sponsor may use or explit all the results at its own discretion, without any limitation to its property right."|t
17180431|NCT02366845|f||||f
17180432|NCT01531374|f||LTE60||t
17180433|NCT01287897|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigators will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180434|NCT00249444|t||||
17180435|NCT00082355|t||||
17180436|NCT01969240|f||||f
17180437|NCT01207765|t||||
17180438|NCT00936910|f||||f
17180439|NCT00412854|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180440|NCT02986789|f||GT60||t
17180441|NCT02452346|t||||
17180442|NCT04483011|f||||f
17180443|NCT03518073|f||GT60||t
17180444|NCT03045081|f||||f
17180445|NCT01485640|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17180446|NCT01853046|f||LTE60||t
17180447|NCT05359666|f||||f
17180448|NCT01711177|t||||
17180449|NCT05022784|t||||
17140431|NCT03053180|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140432|NCT00387829|f||GT60||t
17140433|NCT01465958|f||LTE60||t
17180450|NCT03020407|t||||
17185193|NCT02576678|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17185194|NCT00682734|t||||
17185195|NCT02251990|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17185196|NCT03265600|t||||f
17185197|NCT02293538|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185198|NCT00430768|f||LTE60||t
17185199|NCT00322348|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents). The only disclosure restriction on the PI is that they cannot disclose or publish any information to do with the trial without consent from AstraZeneca.|t
17185200|NCT01298128|f||||f
17185201|NCT01090453|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185202|NCT00729833|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185203|NCT00695669|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185204|NCT05045625|t||||
17185205|NCT00417079|f||OTHER|Publication of the study will be made jointly in the name of all wholehearted collaborators. Other papers will be authored based on the contributions of the individuals to the overall study. Substudies with scientific merit which have received prior approval from the Steering Committee (SC) may be published in the names of the contributing investigators. A copy of all manuscripts will be provided to the sponsors for their review. The final decision to publish articles will be made by the SC.|t
17185206|NCT02512575|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17185207|NCT03570619|f||OTHER|Other sites/PI's are not to publish|t
17185208|NCT01750073|t||||
17185209|NCT01022762|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, e.g. when the clinical trial report is available. This includes the right to not release interim results of clinical trials. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17185210|NCT01302119|f||OTHER|Institution or Principal Investigator may only publish Study results after: (i) the results of the multicenter Study in its entirety have been publicly disclosed by the Sponsor in an abstract, manuscript or presentation form, or (ii) two (2) years after conclusion of the Study at all sites, whichever is first to occur.|t
17185211|NCT02235493|f||OTHER|Participation in this single-center study involves a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis. Therefore, the PI is subject to certain disclosure and publication limitations.|t
17185212|NCT03336619|f||||f
17185213|NCT03341910|f||||f
17185214|NCT00744653|t||||
17185215|NCT01316926|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185216|NCT03826667|f||LTE60||t
17185217|NCT02649868|t||||
17185218|NCT00679939|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185219|NCT01680328|f||OTHER|Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17185220|NCT05608629|t||||
17185221|NCT00983073|f||OTHER|Grünenthal reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17185222|NCT01453595|t||||
17185223|NCT02959996|f||||f
17185224|NCT02962908|f||||f
17185225|NCT00936390|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17140434|NCT03109418|t||||
17140435|NCT02043704|t||||
17140436|NCT00669240|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140437|NCT02132169|f||||t
17140438|NCT00532441|f||||f
17140439|NCT03702439|t||||
17140440|NCT04397757|t||||
17140441|NCT00626327|f||||f
17140442|NCT03502265|t||||
17185226|NCT04348604|f||||f
17140443|NCT00808028|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140444|NCT01866839|f||||f
17140445|NCT02773849|f||||f
17140446|NCT02418000|f||||f
17140447|NCT00508001|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17140448|NCT00848172|t||||f
17140449|NCT00147082|t||||
17140450|NCT02381795|f||||f
17140451|NCT00932399|t||||f
17140452|NCT02176226|t||||
17140453|NCT02465957|f||||t
17140454|NCT01245972|f||||f
17140455|NCT01412333|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140456|NCT02718625|f||||f
17140457|NCT00779116|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17140458|NCT04050540|f||||f
17140459|NCT01060150|f||LTE60||t
17140460|NCT01947127|t||||
17180451|NCT00708162|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17180452|NCT02699554|f||||f
17180453|NCT00708643|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17180454|NCT00065507|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180455|NCT03635957|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights.|t
17180456|NCT00350636|f||LTE60||t
17180457|NCT01525550|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180458|NCT03889158|f||||f
17180459|NCT01843751|t||||
17180460|NCT04577118|f||||f
17180461|NCT03742154|f||||f
17180462|NCT00614315|f||||f
17180463|NCT03108027|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17180464|NCT00268996|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180465|NCT00913003|t||||f
17180466|NCT02763189|t||||
17180467|NCT05392998|f||||f
17180468|NCT04900220|f||||f
17180469|NCT01214629|f||GT60||t
17180470|NCT00576927|f||||f
17185227|NCT02097108|f||OTHER||t
17185228|NCT05520138|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180471|NCT03266094|f||GT60||t
17180472|NCT03171415|f||||f
17180473|NCT03715764|t||||
17185229|NCT00506493|f||LTE60||t
17185230|NCT00955357|f||GT60||t
17185231|NCT01760239|f||||f
17185232|NCT00692094|f||||f
17185233|NCT01698684|f||GT60||t
17185234|NCT03663231|t||||f
17140461|NCT01836549|f||||f
17140462|NCT02516306|f||LTE60||t
17140463|NCT00266799|f||OTHER|If investigator wishes to publish study information, a copy of the manuscript must be provided to sponsor for review at least 60 days before submission of publication/presentation. In the event issues arise regarding scientific integrity/regulatory compliance, sponsor will review these issues with investigator. Investigator will not publish data derived from the individual site until 12 months after conclusion/abandonment/termination of study at all sites.|t
17140464|NCT02736149|f||||t
17185235|NCT00852631|f||||f
17185236|NCT01515410|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary other than study data.|t
17185237|NCT00868439|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17185238|NCT01189279|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185239|NCT00971048|f||LTE60||t
17140465|NCT00242710|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185240|NCT01250977|t||||
17185241|NCT04109703|t||||
17185242|NCT03321396|t||||
17185243|NCT02167074|f||||f
17185244|NCT02578238|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17185245|NCT01540851|t||||
17185246|NCT01507220|f||||f
17185247|NCT00937924|f||||f
17140466|NCT00579527|t||||
17140467|NCT03961529|f||||f
17185248|NCT00224874|f||||f
17140468|NCT03644173|t||||
17140469|NCT00362440|f||||f
17140470|NCT00381706|f||LTE60||t
17180474|NCT00667004|f||OTHER|Contact sponsor directly for details.|t
17180475|NCT01338493|f||OTHER|Confidential Information shall not be disclosed and shall be property of sponsor during the term of the agreement and for 3 years after agreement termination. Results might be published or presented, however sponsor should receive publication for review at least 90 days prior to submittal. Sponsor shall limit its review to a determination of whether Confidential Information is disclosed, to allow sponsor to protect its rights in copyrightable material, and to check for technical correctness.|t
17180476|NCT01705652|f||||f
17180477|NCT00541034|t||||
17180478|NCT00656474|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days. The sponsor can require changes to the communication to remove any confidential information.|t
17180479|NCT01962207|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185249|NCT01043432|t||||
17185250|NCT03644186|f||||f
17185251|NCT04235036|t||||
17185252|NCT02192502|f||||f
17185253|NCT01381692|f||LTE60||t
17140471|NCT04554394|f||GT60||t
17140472|NCT01396486|t||||
17140473|NCT00886587|f||OTHER|Investigators agreed not to publish the study results without prior sponsor approval.|t
17140474|NCT03490734|t||||
17140475|NCT03514394|f||||f
17140476|NCT00374452|t||||
17185254|NCT01869491|f||||f
17185255|NCT01270347|f||OTHER||t
17140477|NCT00523744|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140478|NCT01003067|t||||
17140479|NCT03099304|f||OTHER|Clinical Study Agreement|t
17140480|NCT01401101|t||||
17140481|NCT00715949|f||||f
17140482|NCT01024946|t||||
17140483|NCT05375838|f||||t
17185256|NCT03842995|f||||f
17185257|NCT01972516|f||LTE60||t
17185258|NCT02195986|f||||t
17185259|NCT02571218|f||||f
17185260|NCT03335033|t||||
17185261|NCT00601926|t||||
17185262|NCT03369444|f||||f
17185263|NCT02937168|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17185264|NCT02491671|f||||f
17140484|NCT00869375|f||||f
17140485|NCT02313506|f||||f
17140486|NCT00945594|t||||
17140487|NCT03194256|t||||
17140488|NCT02993783|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17140489|NCT01309581|t||||f
17185265|NCT00535730|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180480|NCT02484729|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17180481|NCT03194698|t||||
17180482|NCT01980875|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17180483|NCT02625259|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17180484|NCT00665847|f||LTE60||t
17180485|NCT02530554|f||OTHER|Confidential information as part of the contract.|t
17180486|NCT01364207|t||||
17180487|NCT00492115|f||||f
17180488|NCT03564145|f||OTHER|Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.|t
17180489|NCT03143569|f||||f
17180490|NCT02663674|f||LTE60||t
17180491|NCT01031069|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180492|NCT05286307|t||||
17180493|NCT01103284|f||OTHER|Investigator shall submit any paper or presentation to the Sponsor for review and comments at least 60 days prior to submitting the same to a third party. Upon receiving any request from the Sponsor to delete any Confidential Information or request to delay in publication up to 90 days to allow the filing of any Sponsor application, the Investigator shall take the request action. Investigator shall not be restricted after 18 months from completion of their site's performance in the study.|t
17180494|NCT02801942|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180495|NCT00911495|f||LTE60||t
17180496|NCT05584176|f||||f
17180497|NCT02057198|t||||
17180498|NCT01985581|t||||f
17180499|NCT03878745|f||||f
17180500|NCT03540147|t||||f
17180501|NCT01214161|t||||
17180502|NCT01042236|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180503|NCT02338960|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17180504|NCT00227903|f||||f
17180505|NCT01475331|f||||f
17180506|NCT02261714|f||||t
17180507|NCT02345811|f||||f
17180508|NCT02877082|t||||
17180509|NCT03633487|f||||f
17180510|NCT02489344|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17180511|NCT03480750|f||||f
17180512|NCT01132482|f||||f
17180513|NCT03683758|f||||f
17180514|NCT05584644|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180515|NCT00723892|f||OTHER|Data publishing of the observational study is forbidden. Data and results of the observational study are the exclusive property of the Sponsor.|t
17180516|NCT01622699|t||||
17180517|NCT01172847|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180518|NCT01163279|f||||f
17180519|NCT00119392|t||||
17180520|NCT02411292|t||||
17180521|NCT02493608|t||||
17185266|NCT05525494|f||||f
17140490|NCT03198884|f||||f
17140491|NCT01202643|t||||f
17140492|NCT03049852|f||||f
17140493|NCT02067104|t||||
17140494|NCT01431794|t||||
17140495|NCT03860181|t||||
17140496|NCT01512849|f||OTHER||t
17140497|NCT01385098|f||||f
17140498|NCT00554840|t||||
17180522|NCT02232425|f||OTHER|Sponsor may choose to collaborate on authorship, and sponsor's agent has 60-day review|t
17180523|NCT00665353|f||||f
17185267|NCT00762320|f||||f
17185268|NCT04072159|t||||
17185269|NCT01177904|t||||
17185270|NCT04084314|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185271|NCT01055769|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185272|NCT00802074|f||||f
17185273|NCT00670774|t||||
17185274|NCT02474927|t||||f
17185275|NCT02298192|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator (s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for upto 60 days to protect intellectual property.|t
17185276|NCT01371851|f||||f
17140499|NCT00925522|f||OTHER|Approval from St. Jude Medical prior to any publication.|t
17140500|NCT00410514|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17185277|NCT00833638|f||GT60||t
17140501|NCT07072962|f||OTHER|This is an NIH SBIR grant with BioSensics LLC as the prime awardee. A subaward contract agreement between BioSensics LLC and Baylor College of Medicine is in place, which may restrict the sharing of certain results deemed confidential.|t
17140502|NCT00656799|f||OTHER|In case a proposed publication contains reference to an invention owned by the sponsor or to which the sponsor otherwise has rights, the sponsor may request a reasonable suspension of the publication.|t
17140503|NCT00508469|f||OTHER||t
17140504|NCT00511706|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185278|NCT01669122|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185279|NCT03543254|t||||
17185280|NCT01261338|f||||f
17185281|NCT00234065|f||||f
17140505|NCT04144140|f||||t
17140506|NCT01493024|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17140507|NCT00959192|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140508|NCT01967134|f||||f
17140509|NCT00443534|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140510|NCT00364611|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 60 days in advance of any submission for publication. The Sponsor may request for the publication to be delayed for a limited time, not to exceed 90 days to preserve its proprietary rights.|t
17180524|NCT01601626|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17180525|NCT00498602|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180526|NCT04585022|f||||f
17180527|NCT02632552|t||||
17180528|NCT00546637|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180529|NCT01074450|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17180530|NCT01846507|f||||f
17180531|NCT00450450|f||OTHER|Must obtain prior Sponsor approval.|t
17180532|NCT04984993|f||OTHER|"After completion, the results of the clinical investigation (CI) may be published (first publication shall be referred to as the Primary Paper). Results of the CI shall not be published before the primary paper after which PIs may propose publications, including or based on results of the CI, to the Sponsor for review at least 2 months before the planned submission for publication or public disclosure. The Sponsor will provide written approval or reasoned refusal for submission or disclosure."|t
17180533|NCT02402309|f||||t
17180534|NCT02865187|f||||f
17185282|NCT05374421|f||||f
17140511|NCT05466240|f||OTHER|Principal Investigator may publish or present results pertaining to the PI's activities after the first publication of the multicentre clinical trial results. Publications must be submitted for review by Sponsor before submission. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140512|NCT00305773|f||LTE60||t
17140513|NCT04097925|f||||f
17140514|NCT02679222|t||||
17140515|NCT02636049|f||GT60||t
17140516|NCT01749930|f||||f
17140517|NCT04735432|t||||
17140518|NCT00413231|f||OTHER|The Principal Investigator (PI) and institution agree not to publish the results of the study until after the earliest of the following: a)conclusion of the study, b)the early termination of the study, c)at discretion and approval of the sponsor, or d)after sponsor confirms there will be no multicenter study publication, whichever occurs first. PI and institution further agree to submit to sponsor copies of any proposed publication or public presentation at least sixty days before dissemination.|t
17140519|NCT00945945|f||GT60||t
17140520|NCT01823991|t||||
17140521|NCT05158244|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140522|NCT01066819|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140523|NCT00551200|f||GT60||t
17140524|NCT00805194|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140525|NCT03891199|f||||f
17140526|NCT02184520|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17140527|NCT01671176|f||||f
17140528|NCT02275052|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140529|NCT03595982|t||||
17140530|NCT00948389|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140531|NCT01619176|f||OTHER|If discussion include scientific publication there is no restriction|t
17140532|NCT02911324|f||||f
17140533|NCT03128372|f||||f
17140534|NCT00721136|f||||f
17140535|NCT00732199|t||||
17140536|NCT01747928|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140537|NCT02404792|f||||f
17140538|NCT03574987|t||||
17140539|NCT04586127|f||||f
17140540|NCT01051856|f||||f
17140541|NCT00750867|t||||f
17140542|NCT01969565|t||||
17140543|NCT01683058|f||||f
17140544|NCT04062240|t||||
17140545|NCT01957111|f||||f
17140546|NCT01057394|f||||f
17140547|NCT03500419|t||||
17140548|NCT01783223|f||||f
17140549|NCT02541994|t||||f
17140550|NCT03062605|t||||
17140551|NCT01948791|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data in the clinical trial.|t
17140552|NCT03481634|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140553|NCT00994890|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140554|NCT01469637|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17140555|NCT04491591|t||||
17140556|NCT00472043|f||||t
17140557|NCT02802735|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140558|NCT04733664|f||LTE60||t
17140559|NCT02975206|f||||t
17180535|NCT03318315|f||LTE60||t
17140560|NCT00866606|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140561|NCT01205646|t||||f
17140562|NCT02109939|f||||t
17140563|NCT01058356|f||||f
17140564|NCT02582151|f||||f
17140565|NCT00606021|f||GT60||t
17140566|NCT01901679|f||||f
17140567|NCT01134328|f||||t
17140568|NCT01230827|f||LTE60||t
17140569|NCT00805142|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17140570|NCT00060333|t||||
17140571|NCT01021423|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication.~* Multicenter publication has priority over subset (single center) publication, for duration of 1 year after study completion.~* Individual investigators have publication right after multicenter publication is complete or 1 year after study completion, whichever is first. Celgene has the right to comment and right to ask delay of publication for up to 90 days."|t
17140572|NCT00394654|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17140573|NCT00122317|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17140574|NCT02886338|t||||
17140575|NCT00807456|f||LTE60||t
17140576|NCT03756285|f||GT60||t
17140577|NCT01021293|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140578|NCT02390167|f||GT60||t
17140579|NCT01084096|f||||f
17140580|NCT01928186|f||||f
17140581|NCT01354964|t||||
17140582|NCT04540627|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is \>60 days but \< or= 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication if it does not include any reference to the Sponsor, any Study Identifier, or any Property or other Confidential Information of the Sponsor, other than the anonymized Non-drug data.|t
17140583|NCT02308839|f||||f
17140584|NCT01265719|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140585|NCT04335929|f||||f
17140586|NCT03999203|t||||
17140587|NCT05604781|f||||f
17140588|NCT00570089|f||||f
17140589|NCT00303329|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140590|NCT02408016|t||||
17140591|NCT01722552|t||||
17140592|NCT02967562|t||||
17140593|NCT00106626|t||||
17140594|NCT04335552|t||||
17140595|NCT02870348|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17140596|NCT00672139|f||LTE60||t
17140597|NCT02996981|t||||
17140598|NCT00107536|f||LTE60||t
17140599|NCT01038635|t||||
17140600|NCT01034709|f||||f
17140601|NCT02065479|t||||f
17140602|NCT01562327|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140603|NCT03018340|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17140604|NCT03243981|t||||
17140605|NCT01878786|f||||f
17140606|NCT01195636|f||GT60||t
17140607|NCT00203294|t||||
17140608|NCT00256204|f||OTHER|Should the Oversight Committee wish to publish the results of this study, the Oversight Committee agrees to provide Teva with a manuscript for review 60 days prior to submission for publication. Teva retains the right to delete from the manuscript confidential information and to object to suggested publication and/or its timing (at the sole discretion of Teva).|t
17140609|NCT03427528|t||||
17140610|NCT00808132|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140611|NCT00550615|t||||
17185283|NCT05132699|t||||
17185284|NCT02899728|f||LTE60||t
17180536|NCT02436356|f||OTHER|Sponsor has 30 days prior to proposed submission date/release of publication to review results, provide comments. Within 30 days of receipt of proposed publication, Sponsor shall advise PI in writing if information contains Sponsor's confidential information (CI) or patentable matter. In addition, upon written request by Sponsor, PI shall delay submission of such publication for an additional 60 days in order to allow Active Life to apply for patent or other protection for Sponsor inventions.|t
17180537|NCT00810407|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180538|NCT00674661|f||OTHER|Site has the right to publish or communicate study results upon the earlier of: (a) publication of a multi-center publication of the Study results coordinated by Sponsor; or (b) submission of the Study data by Sponsor to the FDA; provided that the Sponsor reviews the proposed communication of results within ninety (90) days in advance of its release. Sponsor can request delay of publication or data release to allow for filing of patent application prior to the publication or release.|t
17180539|NCT02574247|f||||f
17180540|NCT01382446|f||||f
17180541|NCT02707991|f||||f
17180542|NCT04210310|t||||
17180543|NCT00641862|f||||f
17180544|NCT00676455|t||||f
17180545|NCT01528254|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17180546|NCT01166763|t||||
17180547|NCT04339296|f||||f
17180548|NCT01909479|f||LTE60||t
17180549|NCT04446377|f||OTHER|The investigator agreed that the primary publication, will be coordinated by the sponsor, will be the first publication to present the pooled study results. After the primary publication, or if the primary publication is not published within 2 years of termination of the study, the investigator may freely publish or present the results of his or her work conducted under the clinical trial agreement, subject to providing the sponsor with the opportunity to review the contents.|t
17180550|NCT01733407|t||||
17180551|NCT00737282|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17180552|NCT00278655|t||||f
17180553|NCT02810392|t||||
17180554|NCT00840294|t||||
17180555|NCT01187043|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17180556|NCT02196558|f||||f
17180557|NCT00379574|f||||f
17180558|NCT03626623|f||||f
17180559|NCT04059094|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17180560|NCT02994979|f||||f
17180561|NCT03305822|t||||
17180562|NCT03445650|f||||t
17180563|NCT01705288|t||||
17180564|NCT02835274|f||||t
17180565|NCT01182493|f||GT60||t
17180566|NCT01853826|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180567|NCT00360828|t||||f
17180568|NCT02081690|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17180569|NCT00959842|f||||f
17180570|NCT00982488|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180571|NCT03204981|t||||
17180572|NCT01662908|f||OTHER||t
17180573|NCT01148745|f||||f
17180574|NCT00397982|f||LTE60||t
17180575|NCT04244786|t||||
17180576|NCT00264641|t||||
17180577|NCT02703909|f||||f
17180578|NCT00613938|f||GT60||t
17180579|NCT02636868|f||OTHER|The Steering Committee is responsible for publications, including who will be authoring publications. The sponsor has the right to review publications before they are published and can provide suggested edits, but cannot require changes or prevent publication.|t
17180580|NCT03220217|f||||t
17180581|NCT03025542|f||GT60||t
17180582|NCT03745937|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17180583|NCT02635828|f||||f
17185285|NCT05557942|f||||t
17185286|NCT02477618|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17185287|NCT02680054|t||||
17185288|NCT01839734|t||||
17185289|NCT05540522|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185290|NCT03754803|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17185291|NCT05239039|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140612|NCT02405091|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17185292|NCT04560166|f||||f
17185293|NCT02119260|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185294|NCT01738984|f||||f
17185295|NCT00857207|t||||
17140613|NCT01009333|f||||f
17140614|NCT02074436|t||||
17140615|NCT01309646|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140616|NCT01694966|f||OTHER|Publications to be reviewed by sponsor prior to submission.|t
17140617|NCT04084210|t||||
17140618|NCT00247962|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17140619|NCT01955005|t||||
17140620|NCT02815982|t||||
17140621|NCT02555722|f||OTHER||t
17140622|NCT00352027|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17140623|NCT00702949|t||||
17140624|NCT00598585|f||||f
17140625|NCT00824746|f||LTE60||t
17140626|NCT00135694|f||||f
17140627|NCT02505269|t||||
17140628|NCT00852761|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140629|NCT03922711|f||OTHER|Data and results are owned by the sponsor. Results can be used by the institution for (a) internal noncommercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of the sponsor.|t
17140630|NCT03147495|f||||f
17140631|NCT02607735|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17140632|NCT04111185|t||||
17140633|NCT01072656|t||||
17180584|NCT05024058|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17180585|NCT00139399|t||||
17180586|NCT00429507|t||||
17140634|NCT00877890|f||LTE60||t
17180587|NCT02734810|f||OTHER||t
17180588|NCT00528398|t||||
17180589|NCT00488345|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180590|NCT03626714|f||||f
17180591|NCT02127567|t||||
17180592|NCT00903617|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185296|NCT01009931|t||||
17185297|NCT03272633|t||||
17185298|NCT03035292|f||||f
17185299|NCT00447057|f||GT60||t
17185300|NCT00440531|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185301|NCT02172755|f||OTHER||t
17185302|NCT02181803|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17185303|NCT03151005|t||||
17185304|NCT05090709|t||||
17185305|NCT04786444|f||||t
17185306|NCT02131272|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17185307|NCT02462876|f||||f
17185308|NCT01922115|f||||f
17185309|NCT01786512|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17185310|NCT03166618|f||OTHER|The TI is responsible for compliance with the protocol at the investigational site. A representative of Allergan will make frequent contact with the TI and his/her research staff and will conduct regular monitoring visits at the site to review subject and device accountability records for compliance with the protocol|t
17185311|NCT01925950|f||GT60||t
17185312|NCT01795833|t||||
17185313|NCT00605293|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185314|NCT00381940|f||LTE60||t
17140635|NCT00742391|f||OTHER|After the Study is completed, Institution shall have the right to publish their own data resulting from the Study upon the earlier of (a) publication of a multi-center publication coordinated by Sponsor or (b) the date of submission of the data resulting from the Study by Sponsor to the FDA. Institution shall furnish Sponsor with a copy of any proposed publication or release at least 90 days in advance of the proposed submission or presentation date.|t
17140636|NCT02599324|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140637|NCT02355665|f||OTHER|Prior to submission for publication, PI was to provide sponsor with ≥ 60 days for publication review. No publication that included sponsor confidential information was to be submitted without sponsor's consent. If requested, the PI was to withhold publication for up to 60 additional days to allow for patent application filing. First publication of study results was to be a joint, multicenter publication; if not submitted within 6 months after end of study, the PI may publish the site results.|t
17140638|NCT01914510|t||||
17140639|NCT00095836|t||||
17140640|NCT00989664|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140641|NCT02363322|f||||f
17140642|NCT02705755|f||||f
17140643|NCT05453006|f||||f
17180593|NCT00407563|f||OTHER|Proposed publication must be submitted to Funder at least 60 days prior to the submission for publication. If Funder requests in writing, the proposed publication may be held for an additional 90 days.|t
17180594|NCT03055260|f||||f
17180595|NCT02507505|t||||
17180596|NCT03182829|f||LTE60||t
17180597|NCT00254540|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17180598|NCT00225251|f||||f
17180599|NCT03045328|t||||
17180600|NCT00592839|f||OTHER|The sponsor can (i) review results communications prior to public release and can embargo communications regarding trial results for a period of at least 60 days but no more than 180 days from the time submitted to the sponsor for review; and (ii) require in instances of a multi-center study, that a single PI not disclose study data until after the multi-center results are published, provided such results are published within eighteen (18) months of the conclusion of the study.|t
17185315|NCT00798720|t||||
17185316|NCT03137303|f||||f
17185317|NCT02858050|f||||f
17140644|NCT00027846|f||OTHER|Must obtain sponsor approval.|t
17140645|NCT02033369|f||||f
17140646|NCT02885506|f||OTHER|Richmond shall not issue or submit any press release for publication without MMV's prior written approval. In recognition that Richmond and the Site Principal Investigator have a responsibility to ensure that results of scientific interest arising from a Clinical Trial are appropriately published and disseminated, Richmond may, upon MMV's written consent which will not be unreasonably withheld, publish Results of a clinical trial carried out under a Project Agreement.|t
17180601|NCT00786487|f||||f
17180602|NCT02355691|t||||f
17180603|NCT00462761|f||||f
17140647|NCT02889861|f||OTHER|Publication/presentation (manuscript, abstract or poster) to a journal/scientific meeting is sent to sponsor for review at least 1 month before submission who may delay submission by up to 90 days if it reasonably believes that publication of results may compromise its intellectual property rights or else insist that such data are removed. No single center/groups of centers may publish individually. Publication will not include confidential information without the permission of the sponsor.|t
17140648|NCT01864746|f||OTHER|Only after the sponsor's publication of the overall study results of the primary endpoint do participating sites have the right to publish publications related to study data collected by participating sites, and any results of add-on research conducted by participating sites, subject to compliance with the study publications and presentations policy.|t
17140649|NCT01005966|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140650|NCT01451203|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for to seek patent protection.|t
17140651|NCT03890731|f||LTE60||t
17140652|NCT03308799|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less or equal to 60 days from the time submitted to the sponsor for review. At the end of the Review Period, the sponsor may reasonably require that publication be delayed to permit the filing of patent application. Publication shall not be delayed more than 90 days after receipt of the proposed publication.|t
17140653|NCT00027027|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140654|NCT03521089|t||||
17140655|NCT00290329|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180604|NCT03060447|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17180605|NCT01290640|t||||f
17180606|NCT01623323|f||GT60||t
17180607|NCT03274440|t||||
17180608|NCT01110707|f||OTHER||t
17180609|NCT02369341|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180610|NCT04249310|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180611|NCT02710045|t||||
17180612|NCT03178773|f||||f
17180613|NCT00765375|t||||
17180614|NCT02545101|f||OTHER|"As a multicentre study, the first publication shall be based on consolidated analysed data from all centres, i.e. the publication of results from individual institution/Investigator is not allowed before the publication of the full study results.~The PI agrees to give the sponsor 60 days to review the communications. If case of propietary information inadvertenly divulged, intellectual property rights at risk or inaccurate information presented, changes can be required by the sponsor."|t
17180615|NCT03035708|t||||
17180616|NCT01928329|t||||
17180617|NCT03187262|t||||
17180618|NCT05167734|t||||
17180619|NCT02604212|f||||f
17180620|NCT00451321|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180621|NCT00598663|f||||f
17180622|NCT01119131|t||||
17180623|NCT01341964|f||||f
17180624|NCT00909389|f||OTHER|Other disclosures agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.|t
17180625|NCT00003492|f||||f
17180626|NCT01516424|t||||f
17180627|NCT00597766|f||||f
17180628|NCT01608659|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17180629|NCT01183897|t||||
17180630|NCT00847704|t||||
17180631|NCT00775645|f||||f
17180632|NCT03036072|t||||
17180633|NCT02111850|f||||f
17180634|NCT00513474|t||||
17180635|NCT01710254|f||||f
17180636|NCT00555750|t||||
17180637|NCT00605813|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180638|NCT00573755|t||||
17180639|NCT00705081|f||LTE60||t
17140656|NCT02039687|f||LTE60||t
17180640|NCT02132767|f||||f
17180641|NCT02074631|t||||
17180642|NCT00778700|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17180643|NCT01230801|f||GT60||t
17180644|NCT01270711|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17180645|NCT01166724|t||||
17180646|NCT00383149|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180647|NCT00453544|f||||f
17180648|NCT02457910|t||||
17185318|NCT03561090|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17185319|NCT00373399|f||||f
17185320|NCT04162769|f||||f
17185321|NCT02163733|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17185322|NCT02633800|f||GT60||t
17185323|NCT02526654|f||||f
17185324|NCT00000392|f||||f
17185325|NCT02836418|f||||t
17185326|NCT05457608|f||||f
17185327|NCT01358968|f||GT60||t
17185328|NCT01992380|f||LTE60||t
17185329|NCT00386880|t||||
17185330|NCT03430674|t||||
17185331|NCT00476476|f||||f
17185332|NCT04149405|t||||
17185333|NCT00423176|f||LTE60||t
17185334|NCT01654549|t||||
17185335|NCT05072080|f||OTHER|This is a multi-center study and agreements with investigators depends on the individual site contract.|t
17185336|NCT02633137|t||||
17185337|NCT05554237|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185338|NCT04224155|f||OTHER|Contact Sponsor directly for details|t
17185339|NCT02395042|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17140657|NCT00053482|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17140658|NCT01349491|f||||f
17180649|NCT02315170|t||||
17180650|NCT03721276|t||||
17180651|NCT00450333|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17180652|NCT01689701|f||||f
17180653|NCT02375113|f||||f
17180654|NCT03107754|t||||
17180655|NCT00734903|f||||f
17180656|NCT01953120|f||||t
17180657|NCT01347008|f||||f
17180658|NCT01857232|f||GT60||t
17185340|NCT01324271|f||GT60||t
17185341|NCT05130970|t||||
17185342|NCT02308748|f||||f
17185343|NCT02979262|f||||f
17185344|NCT05207813|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17185345|NCT03736434|f||||f
17185346|NCT04988308|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17185347|NCT00866840|t||||
17185348|NCT02625623|f||||f
17185349|NCT00808808|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.The principal investigators (PIs) also agree for data to be presented first as a joint, multi-center publication.|t
17185350|NCT03591068|f||OTHER|Disclosure agreement is described in CTA between sponsor and PI|t
17185351|NCT02352948|f||||t
17140659|NCT05064449|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17140660|NCT03812224|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140661|NCT01641952|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140662|NCT02500901|f||||f
17140663|NCT02990325|f||GT60||t
17140664|NCT01822886|f||||f
17140665|NCT00561912|t||||f
17140666|NCT04495166|f||||f
17140667|NCT02643420|f||||t
17140668|NCT01710709|f||OTHER||t
17140669|NCT04446039|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140670|NCT01398176|f||||f
17140671|NCT00348686|f||LTE60||t
17140672|NCT01258738|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140673|NCT00689611|f||LTE60||t
17140674|NCT00568399|t||||
17140675|NCT01904760|t||||
17140676|NCT00783263|f||LTE60||t
17140677|NCT00405756|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 90 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation.|t
17140678|NCT03018028|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17140679|NCT02543801|t||||f
17140680|NCT03727802|f||LTE60||t
17180659|NCT00416078|t||||
17180660|NCT01190878|f||OTHER||t
17180661|NCT01829230|t||||
17180662|NCT02733588|f||||f
17180663|NCT00233103|t||||
17180664|NCT04387435|t||||
17180665|NCT03855280|f||||f
17180666|NCT00989014|f||GT60||t
17180667|NCT00969150|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17180668|NCT01879332|f||OTHER||t
17180669|NCT00461682|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180670|NCT03457129|t||||
17180671|NCT00883116|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17180672|NCT01361464|f||LTE60||t
17180673|NCT03087760|f||||f
17180674|NCT02573857|f||LTE60||t
17180675|NCT05020990|f||||t
17180676|NCT00671502|f||||f
17180677|NCT04128267|t||||
17180678|NCT04501666|f||||t
17180679|NCT03021265|t||||
17180680|NCT01722071|t||||
17180681|NCT00642941|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17180682|NCT01614067|f||||f
17180683|NCT01505868|t||||
17180684|NCT02289079|t||||
17180685|NCT00680043|f||OTHER|The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.|t
17180686|NCT00553150|t||||
17185352|NCT00490646|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185353|NCT01178086|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185354|NCT02313428|f||||f
17185355|NCT02057874|t||||
17185356|NCT03910413|f||||f
17185357|NCT00240487|t||||f
17185358|NCT03100617|f||||f
17185359|NCT01258608|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185360|NCT04098939|f||||f
17185361|NCT02943408|f||||f
17185362|NCT01106833|f||||f
17185363|NCT01621126|t||||
17140681|NCT02364999|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185364|NCT00886340|f||||f
17185365|NCT02062359|f||||f
17185366|NCT01949311|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17185367|NCT02338154|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 30 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 60 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17185368|NCT02120027|f||OTHER|Prior to submitting the results of this study for publication or presentation, the Investigator will allow the sponsor at least 30 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17185369|NCT01002872|f||||f
17185370|NCT00414817|f||||f
17185371|NCT03078270|f||||f
17185372|NCT00385580|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185373|NCT00746122|t||||
17185374|NCT03393000|f||LTE60||t
17185375|NCT01773070|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17185376|NCT01471054|f||||f
17185377|NCT01843192|f||LTE60||t
17185378|NCT01559844|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17185379|NCT00951041|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140682|NCT01566981|f||||f
17140683|NCT02246309|f||||f
17140684|NCT00792922|f||||f
17140685|NCT03323385|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17140686|NCT04422951|t||||
17140687|NCT01849289|f||OTHER|Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17140688|NCT01365195|f||||f
17140689|NCT02365961|f||||f
17140690|NCT00660816|t||||
17140691|NCT02692560|f||||f
17140692|NCT00641745|f||||f
17140693|NCT00420212|f||OTHER|The provisions of the agreements are subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17185380|NCT01514448|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17185381|NCT02314624|t||||
17185382|NCT00324870|f||LTE60||t
17185383|NCT00725452|f||||f
17140694|NCT01326910|f||OTHER|The trial was conducted as work made for hire, and disclosure of results by the investigator is prohibited without the prior written consent of Sponsor.|t
17140695|NCT01681836|f||||f
17140696|NCT02394028|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140697|NCT00205374|t||||f
17140698|NCT02142712|f||||f
17140699|NCT02239562|f||LTE60||t
17140700|NCT01981096|f||||f
17140701|NCT01225211|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17140702|NCT00807989|f||GT60||t
17185384|NCT00620750|f||||f
17185385|NCT04477187|f||||f
17140703|NCT01241318|f||LTE60||t
17140704|NCT01893879|f||||f
17140705|NCT01579162|f||||t
17140706|NCT04129242|f||||f
17140707|NCT03675685|f||||f
17140708|NCT02746991|f||GT60||t
17140709|NCT00392210|t||||f
17140710|NCT02140762|f||||f
17185386|NCT03148470|t||||f
17185387|NCT01402141|t||||f
17185388|NCT00713648|f||OTHER|Novo Nordisk (NN) reserves the right not to release data until after specified milestones, e.g., finalisation of clinical trial report. This includes the right not to release interim results of clinical trials, as release of such information can invalidate the trial results. At end of trial, one or more manuscripts will be prepared collaboratively between Investigator(s) and NN. NN reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17185389|NCT00082173|f||||f
17185390|NCT01733732|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185391|NCT00746590|f||||f
17185392|NCT01291498|t||||
17185393|NCT01738750|t||||
17185394|NCT00464815|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185395|NCT04139564|t||||
17185396|NCT02007291|f||||f
17185397|NCT04386096|t||||
17185398|NCT01260350|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17185399|NCT04402866|f||||f
17185400|NCT01814371|f||||f
17185401|NCT02794285|f||||t
17140711|NCT04815291|f||||f
17140712|NCT02994043|t||||f
17140713|NCT02067806|f||||f
17140714|NCT00962780|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140715|NCT01775995|t||||
17185402|NCT04460742|f||||f
17185403|NCT03996473|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. If a multicenter publication is not published within 18 months after completion of the study and database lock at all research sites or any earlier termination or abandonment of the study, PI shall have the right to publish and present the results.|t
17185404|NCT06116591|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185405|NCT01972841|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication temporarily to seek patent protection or permanently withhold the publication.|t
17185406|NCT03712891|t||||
17185407|NCT04969198|t||||
17185408|NCT03256162|t||||
17185409|NCT01904448|t||||
17185410|NCT05553808|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17185411|NCT03819491|f||||f
17185412|NCT02672111|f||||t
17185413|NCT01839110|f||OTHER||t
17185414|NCT02046980|f||||f
17185415|NCT01328574|f||||f
17185416|NCT01483924|f||GT60||t
17185417|NCT03160027|t||||
17140716|NCT02055976|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140717|NCT00751335|f||||f
17140718|NCT02275559|f||||f
17140719|NCT00198042|f||||f
17140720|NCT02514889|f||||f
17140721|NCT03458234|t||||
17140722|NCT00750360|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140723|NCT02049385|t||||
17140724|NCT01640353|f||OTHER|The only disclosure restriction on the site is that the sponsor can review results communications prior to public release and must have at least 30 days to do so.|t
17140725|NCT03758612|f||||t
17140726|NCT03479203|f||||f
17140727|NCT01603615|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17140728|NCT03419741|t||||
17140729|NCT04354870|t||||
17140730|NCT03384316|f||||f
17140731|NCT03428230|f||||f
17140732|NCT01091116|f||||f
17140733|NCT01160458|f||||f
17140734|NCT04450394|f||GT60||t
17140735|NCT02194699|f||LTE60||t
17140736|NCT00836342|f||||f
17140737|NCT00001151|t||||
17140738|NCT02155660|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17140739|NCT01192139|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140740|NCT00303719|t||||
17140741|NCT01273207|t||||
17140742|NCT04853368|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140743|NCT05386368|f||||f
17140744|NCT00821886|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17140745|NCT01880320|f||||f
17140746|NCT02176031|f||||f
17140747|NCT02127970|f||OTHER|PI agrees that the first results publication shall be made in conjunction with a joint multi-center publication. If the multi-center publication is not submitted within 18 months after conclusion of the study at all sites, or if the sponsor confirms not to publish the results, the PI may publish the results from the institution subject to terms of the clinical trial agreement. The publication must be sent to Sponsor at least 60 days before the intended submission date for reference and comment.|t
17140748|NCT00542321|t||||f
17140749|NCT01639599|t||||f
17140750|NCT04138758|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17185418|NCT01386528|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property"|t
17185419|NCT01994954|f||||f
17185420|NCT00850473|t||||
17185421|NCT00449176|f||LTE60||t
17185422|NCT02154763|f||||f
17185423|NCT00526123|f||OTHER|SPONSOR shall have the right to review and comment on such publication with respect to disclosure of SPONSOR Confidential Information prior to submission and review, and no such SPONSOR Confidential Information shall be disclosed therein without SPONSOR's express written consent. Such review and comment will be provided within 30 calendar days from the date of receipt by the SPONSOR. Investigator shall delete any SPONSOR confidential information contained in such publication.|t
17185424|NCT02045238|t||||
17185425|NCT02958969|f||||f
17185426|NCT02363946|f||||f
17185427|NCT00262821|f||LTE60||t
17185428|NCT01988779|t||||
17185429|NCT01041638|f||LTE60||t
17185430|NCT01284426|f||||f
17185431|NCT02080468|f||OTHER|Described in site contract|t
17185432|NCT01922076|f||LTE60||t
17185433|NCT00676182|f||||f
17185434|NCT04493216|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17185435|NCT03595579|f||||t
17140751|NCT03306589|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140752|NCT00816062|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require deletion of confidential information.The sponsor cannot require changes beyond those necessary to protect confidential information. The sponsor cannot extend the embargo.|t
17185436|NCT02606903|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17185437|NCT01030861|f||||f
17185438|NCT03643952|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17185439|NCT01597050|f||LTE60||t
17185440|NCT00483184|f||LTE60||t
17185441|NCT00558428|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17185442|NCT05224050|t||||
17185443|NCT01292876|f||||f
17185444|NCT01627327|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185445|NCT01175850|f||GT60||t
17185446|NCT04294966|t||||
17185447|NCT04528069|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185448|NCT02436265|t||||
17185449|NCT03901326|f||||f
17185450|NCT02525874|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17185451|NCT01692782|f||OTHER|"There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.~In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish."|t
17185452|NCT03252587|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185453|NCT04052204|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185454|NCT02161133|f||||f
17185455|NCT01016938|t||||
17185456|NCT04158050|f||||f
17185457|NCT03945188|f||||f
17185458|NCT01982240|f||||t
17185459|NCT04341116|f||||t
17185460|NCT00363675|t||||
17185461|NCT01803074|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185462|NCT02081573|f||||f
17185463|NCT02807558|f||OTHER|Note that the agreements are between the clinical sites and the Sponsor (or its agents), which restrict the clinical trial sites' rights to discuss or publish trial results after the trial is completed.|t
17185464|NCT04575467|f||||t
17185465|NCT00003298|f||LTE60||t
17185466|NCT00930293|t||||
17185467|NCT01798550|t||||
17185468|NCT03565887|f||GT60||t
17185469|NCT01454583|t||||f
17185470|NCT04434560|t||||
17185471|NCT02677116|f||GT60||t
17185472|NCT03182868|t||||f
17185473|NCT01967732|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17185474|NCT03342638|t||||
17185475|NCT00554970|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185476|NCT03028974|f||||f
17185477|NCT02654808|t||||f
17140753|NCT00718887|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140754|NCT05102734|f||||f
17140755|NCT03055806|f||OTHER|Sponsor may chose to collaborate on authorship, and sponsor's agent has 60-day review.|t
17140756|NCT04601194|f||||f
17140757|NCT00125138|f||OTHER|The PI could publish the results of the Study after the earlier of (a) the cooperative publication of the data, or (b) 18 months after Sponsor's final evaluation of all data; the PI will submit for review and approval any proposed abstracts and manuscripts at least 45 days prior to submission. The Institution and PI agree to delete any information the Sponsor deems confidential or proprietary; if the parties disagree, then they agree to meet prior to submission to discuss and resolve the issues.|t
17140758|NCT00041119|f||LTE60||t
17140759|NCT04383665|f||||f
17140760|NCT01973205|f||OTHER|Sponsor shall review results communications prior to public release to evaluate the manuscript for accuracy, ascertain whether information (other than the results of the Clinical Trial) is being improperly disclosed, provided information which may have not have yet been made available by the Sponsor, provide input for consideration regarding the content and/or conclusion(s) of the manuscript and determine whether the manuscript discloses any potentially patentable invention(s).|t
17140761|NCT04056325|t||||
17140762|NCT04249076|f||OTHER|Any publication shall be expressly authorized in written by the Sponsor|t
17140763|NCT00089505|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17140764|NCT01117428|f||||f
17140765|NCT00611351|t||||
17140766|NCT02532998|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17140767|NCT02519777|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17140768|NCT02195531|f||||f
17140769|NCT00602043|f||LTE60||t
17140770|NCT04912297|t||||
17140771|NCT04542525|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185478|NCT01292239|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17185479|NCT00113568|f||OTHER||t
17185480|NCT01410773|t||||
17185481|NCT00584727|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17185482|NCT02293044|t||||
17185483|NCT00377403|f||||f
17185484|NCT01687257|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17185485|NCT00969501|f||||f
17185486|NCT00736645|t||||
17185487|NCT00295022|f||GT60||t
17185488|NCT00734630|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17185489|NCT01181050|f||OTHER|Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.|t
17185490|NCT01018394|t||||
17185491|NCT03240692|f||||f
17185492|NCT00683644|f||||f
17185493|NCT01027000|f||LTE60||t
17185494|NCT04123067|t||||
17185495|NCT00127101|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185496|NCT00843167|f||||f
17185497|NCT01565707|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 90 days prior to publication for review and comment. Sponsor may delay the publication temporarily to seek patent protection or permanently withhold the publication.|t
17185498|NCT04302350|t||||
17185499|NCT02012491|f||||f
17185500|NCT03762473|f||||f
17185501|NCT00126438|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17140772|NCT00545740|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17140773|NCT02625610|f||||f
17140774|NCT00082628|f||OTHER||t
17140775|NCT03459794|t||||
17140776|NCT01612494|f||||f
17140777|NCT02177942|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140778|NCT01351415|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140779|NCT01234337|f||OTHER|"Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~No publication of single center data should be done prior to publication of multi-center data."|t
17185502|NCT01420848|t||OTHER|The copyright of the search results are the exclusive property of the Journal of School Nursing, University of Saint Paul, barring any reproduction, in whole or in part in any form or means of printed or electronic, without the prior and necessary authorization is requested.|t
17185503|NCT01389973|f||LTE60||t
17185504|NCT02626780|f||||f
17185505|NCT03456700|t||||
17185506|NCT04154787|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17185507|NCT01116934|t||||
17185508|NCT01437449|t||||
17185509|NCT01367262|f||GT60||t
17185510|NCT02858895|f||||t
17185511|NCT03163758|f||||f
17185512|NCT04907942|f||||f
17185513|NCT03962894|f||||f
17185514|NCT02277444|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17185515|NCT04171102|f||||f
17185516|NCT04918784|f||LTE60||t
17185517|NCT02160314|f||OTHER|"The STUDY SITE and PRINCIPAL INVESTIGATOR agree that all data, calculations, interpretations, opinions and recommendations regarding the STUDY (hereinafter referred to as RESULTS) shall be the property of P\&G. The STUDY SITE and PRINCIPAL INVESTIGATOR agree to consider the RESULTS as INFORMATION subject to confidentiality restrictions"|t
17185518|NCT01751126|f||||t
17185519|NCT02993445|t||||
17185520|NCT00799292|f||||f
17185521|NCT00265980|t||||
17185522|NCT02586025|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185523|NCT04205630|f||OTHER|The PI agrees to provide to the Sponsor 60 days prior to intended submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The Sponsor has the right to review and comment with respect to publications, abstracts, slides, and manuscripts including the data analysis and presentation. In case of disagreement, efforts will be undertaken to resolve any such issues, but the ultimate decision remains with the Sponsor.|t
17185524|NCT01618162|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone pubication and/or communication for up to 60 days to protect intellectual property.|t
17185525|NCT04124926|f||||t
17185526|NCT02964416|f||||f
17140780|NCT04118127|f||||f
17140781|NCT03480360|t||||f
17140782|NCT00412425|t||||f
17140783|NCT01646255|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17140784|NCT02380703|f||||f
17140785|NCT03480841|t||||f
17140786|NCT01362049|f||||f
17140787|NCT00852124|f||||f
17140788|NCT01228435|f||||f
17140789|NCT02183792|f||||f
17140790|NCT00498927|t||||
17140791|NCT02269709|t||||
17140792|NCT00426842|f||||f
17140793|NCT01032265|f||||f
17185527|NCT03871595|t||||
17185528|NCT00911534|f||||f
17185529|NCT03152526|f||OTHER|Institution conducted study as an independent contractor, supervised by the PI. PI may publish results provided that 12 months have elapsed since the completion of the study and sponsor has not initiated publication of a study report and at least 30 days prior to submission sponsor receives a draft to review. This study did not result in any publications.|t
17185530|NCT04867369|t||||
17185531|NCT04435366|f||OTHER|No individual site or investigator may publish or present any results from the trial until a joint, multi-center publication of the trial results is made by Sponsor in conjunction with various participating investigators and appropriate sites contributing data and comments. Subsequently, individual investigators may request to publish or present results from the trial; however approval will be at the sole discretion of the Sponsor.|t
17185532|NCT05711641|f||||f
17185533|NCT02477111|f||||t
17185534|NCT00989768|f||||f
17185535|NCT00162370|f||LTE60||t
17185536|NCT02921997|f||LTE60||t
17185537|NCT03896035|t||||
17185538|NCT03492281|f||OTHER|The Sponsor does not object to publication by Institution or Principal Investigator (PI) of results of the Trial based on information collected or generated by the Institution or PI. However, the Institution and PI are required to provide the Sponsor with an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed to ensure against any inadvertent disclosure of Sponsor Confidential Information or unprotected Sponsor Inventions.|t
17185539|NCT01506193|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185540|NCT00743366|f||||f
17185541|NCT03206203|t||||
17185542|NCT00335322|t||||
17185543|NCT01152580|f||||f
17140794|NCT01156012|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17140795|NCT02475564|f||||f
17140796|NCT01665040|f||||t
17140797|NCT00939094|f||OTHER|"No publication or presentation with respect to the study until the earlier of 1) publication of the first Multi-Center Publication and 2) the second anniversary of the completion, or termination of the study.~Sponsor to review at least 60 days prior submission. Sponsor can withhold material for submission for additional 90 days"|t
17140798|NCT01906489|f||OTHER||t
17185544|NCT01570829|f||||t
17185545|NCT03364751|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17185546|NCT00675766|f||||f
17185547|NCT01625221|f||GT60||t
17185548|NCT02275065|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17185549|NCT03213158|t||||
17185550|NCT01777854|f||||f
17185551|NCT02652481|f||||f
17185552|NCT04126408|f||||f
17185553|NCT01551199|t||||
17185554|NCT01239030|f||OTHER|PI is restricted from using, disclosing, presenting, or publishing trial information without the prior written consent from the Sponsor|t
17185555|NCT03084666|f||||f
17185556|NCT01201057|f||OTHER|For a multicenter study, the PIs can only publish after the results of the trial have been published collectively.|t
17185557|NCT04259086|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17185558|NCT03085485|f||||f
17185559|NCT01662882|f||LTE60||t
17185560|NCT01775904|f||GT60||t
17185561|NCT00518115|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185562|NCT04891419|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17185563|NCT00827918|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17185564|NCT03030222|f||OTHER|Subsites will not publish until after all multicenter articles have been submitted for publication. Sponsor will have 18 months after the close of the Study at all sites to arrange for the submission of multicenter publications. If such multicenter publications are not submitted within 24 months after conclusion of the Study at all sites, Site Investigator and Subsite may publish the results from the Subsite's data, individually, pursuant to approval by Sponsor and Steering Committee.|t
17185565|NCT03088826|f||||f
17185566|NCT04365660|t||||
17185567|NCT01311674|f||||f
17140799|NCT01319539|f||LTE60||t
17140800|NCT04492514|t||||
17140801|NCT01522963|f||||f
17140802|NCT01524900|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17140803|NCT03824704|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17140804|NCT00298766|f||||f
17140805|NCT00923481|f||||f
17140806|NCT02988115|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that publication be withheld.|t
17140807|NCT01731951|f||OTHER|Consistent with Good Publication Practices and ICMJE guidelines, the sponsor shall have right to publish such primary (multicenter) data and information without approval from investigator. Investigator has right to publish study site-specific data after primary data published. If an investigator wishes to publish information from study, a copy of manuscript must be provided to sponsor for review at least 60 days before submission for publication or presentation|t
17140808|NCT03287089|f||||f
17140809|NCT00661362|f||OTHER|The Principal Investigator will provide AstraZeneca as soon as possible with preliminary data and drafts of proposed publications and disclosures, whether oral or in writing, with the proposed final manuscript. AZ shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed.|t
17140810|NCT00775138|f||||t
17185568|NCT00450411|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17185569|NCT02430194|f||||f
17140811|NCT04880642|f||||f
17140812|NCT02906644|t||||
17140813|NCT02452034|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17140814|NCT00561795|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140815|NCT01672827|f||||f
17140816|NCT04235959|f||LTE60||t
17185570|NCT02137369|t||||
17185571|NCT04184791|f||||f
17185572|NCT01297959|f||||f
17185573|NCT02243943|t||||
17185574|NCT01667432|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185575|NCT02339831|f||||f
17185576|NCT02077166|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination."|t
17185577|NCT03519854|f||OTHER|The Sponsor recognizes the right of the investigators to publish, but all publications must be based on data validated by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17140817|NCT01694667|f||||f
17140818|NCT02135848|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140819|NCT01521260|t||||
17140820|NCT02358876|f||LTE60||t
17140821|NCT04212221|f||||t
17140822|NCT03123549|f||||t
17140823|NCT05223478|f||GT60||t
17140824|NCT00636506|f||||f
17140825|NCT03742271|f||GT60||t
17140826|NCT03810053|t||||
17140827|NCT01624974|f||OTHER|This study is intended for publication, even if terminated prematurely. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17140828|NCT01376908|f||OTHER||t
17140829|NCT02430389|t||||
17140830|NCT01468844|t||||
17185578|NCT02813070|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17185579|NCT00818753|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17185580|NCT03195010|t||||
17140831|NCT04745065|f||||f
17140832|NCT00266695|f||GT60||t
17140833|NCT03607994|f||||f
17140834|NCT02417935|f||LTE60||t
17140835|NCT02850276|f||||t
17140836|NCT01899729|f||||t
17140837|NCT01454531|f||OTHER|All presentations/publications must be approved by ALK prior to public presentation/submission. Investigators agree not to present data gathered from one trial centre or a small group of trial centres before the full publication unless formally agreed by all other investigators and ALK. ALK has the right to review and comment any manuscript within 30 days of receipt, but cannot prevent publications of findings.|t
17140838|NCT02910492|f||||f
17140839|NCT01158885|f||GT60||t
17140840|NCT01408862|f||LTE60||t
17140841|NCT01813149|t||||f
17140842|NCT02646332|t||||
17140843|NCT00780676|t||||
17140844|NCT00252499|t||||
17140845|NCT04490499|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17140846|NCT01882439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140847|NCT00527722|t||||f
17140848|NCT00245635|t||||
17140849|NCT03125902|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185581|NCT01712009|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140850|NCT00890396|f||||f
17140851|NCT02504424|f||||f
17140852|NCT00440232|t||||
17140853|NCT00362297|f||||f
17140854|NCT01070381|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17140855|NCT01869686|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140856|NCT01066637|t||||
17140857|NCT01259388|t||||
17140858|NCT03512028|f||||f
17140859|NCT02743494|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140860|NCT03529162|f||||f
17140861|NCT00983827|t||||
17140862|NCT01521494|f||||f
17140863|NCT00758420|f||GT60||t
17140864|NCT05414422|f||OTHER|The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17140865|NCT02728804|f||LTE60||t
17140866|NCT01854918|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140867|NCT00673075|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17140868|NCT00574340|t||||f
17140869|NCT02146352|f||OTHER|PI must wait 9 months after close of study for Sponsor to present collaborative publication. If Sponsor does not publish within 9 months after close of study, PI may publish institution's results at that time. Sponsor can review results prior to public release and embargo communications on trial results for a period that is more than 60 days but less than or equal to 6 months from the date the PI gets the objection. The Sponsor cannot require changes to the communication nor extend the embargo.|t
17185582|NCT00593567|f||||f
17185583|NCT01946542|f||||f
17185584|NCT00590902|t||||
17140870|NCT02918006|f||||t
17140871|NCT02510885|f||||f
17140872|NCT03091920|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17140873|NCT03373006|f||||f
17140874|NCT00453349|f||LTE60||t
17140875|NCT04369742|t||||
17140876|NCT01861587|f||||f
17140877|NCT00381810|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140878|NCT02185729|f||||f
17140879|NCT02098733|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17140880|NCT00695318|f||GT60||t
17140881|NCT00434876|t||||f
17140882|NCT01922336|f||||t
17140883|NCT01503229|f||||f
17140884|NCT00240331|f||||f
17140885|NCT02551874|f||||f
17140886|NCT02491463|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140887|NCT01491802|f||||f
17140888|NCT03927703|f||OTHER|The PI must wait 18 months after the closeout of the trial at all Study sites or until the publication of the multi-site Sponsor results. The only restriction on PI publication after that time is that the sponsor can review results communications prior to public release and can request confidential or proprietary information be removed or can embargo communications regarding trial results for a period that is more than 90 days but less than 120 days.|t
17140889|NCT02600715|f||||f
17140890|NCT00386152|f||GT60||t
17140891|NCT02615158|f||||f
17140892|NCT00508872|t||||f
17140893|NCT03007472|f||||t
17140894|NCT00519090|f||OTHER|The terms and conditions of Novartis' agreements may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data in the clinical trial.|t
17140895|NCT01977651|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17140896|NCT00253747|f||||f
17140897|NCT00104299|f||||f
17140898|NCT00431132|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17140899|NCT03672006|t||||
17140900|NCT00608426|f||||f
17140901|NCT00275834|t||||f
17140902|NCT02630459|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17140903|NCT01453439|f||||f
17140904|NCT01014442|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17140905|NCT03010358|t||||
17140906|NCT03520842|t||||
17140907|NCT02512094|f||||f
17140908|NCT00724594|f||||f
17140909|NCT00859495|t||||
17140910|NCT01220024|f||OTHER||t
17140911|NCT02467504|t||||
17140912|NCT00174460|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140913|NCT00490815|f||GT60||t
17140914|NCT01508221|f||||t
17140915|NCT00579059|f||OTHER|Biomet owns copyright to database.|t
17140916|NCT04047472|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17140917|NCT02030067|f||||f
17140918|NCT01756846|f||||f
17140919|NCT01284127|t||||f
17140920|NCT02350660|t||||
17140921|NCT00699582|f||||f
17140922|NCT01756391|f||||f
17140923|NCT03845504|t||||
17140924|NCT03681808|f||OTHER|Contact sponsor directly for details.|t
17140925|NCT01529827|t||||
17140926|NCT02853318|t||||
17140927|NCT01997333|f||||f
17140928|NCT01843933|f||||f
17140929|NCT02909504|t||||
17140930|NCT04411472|f||||f
17140931|NCT04098172|f||||t
17140932|NCT01747655|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17140933|NCT00982111|f||GT60||t
17140934|NCT03769753|t||||
17140935|NCT01482598|f||||f
17140936|NCT01373294|t||||
17140937|NCT02699632|f||||f
17140938|NCT01657903|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185585|NCT01253525|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17185586|NCT00785291|f||LTE60||t
17185587|NCT00844857|f||GT60||t
17185588|NCT00570674|f||||f
17185589|NCT05183022|f||||f
17185590|NCT02979639|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140939|NCT00807768|f||LTE60||t
17140940|NCT00620815|f||GT60||t
17140941|NCT03088345|t||||
17140942|NCT01920061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17140943|NCT02155725|f||OTHER||t
17140944|NCT00842829|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17140945|NCT00517634|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140946|NCT02936206|f||||f
17140947|NCT03143855|t||||
17140948|NCT01078389|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17140949|NCT01002573|f||||f
17140950|NCT02028182|f||||f
17140951|NCT01519648|f||||f
17140952|NCT02198040|f||||f
17140953|NCT04524663|t||||
17140954|NCT00337935|t||||
17140955|NCT01884675|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140956|NCT02361307|t||||
17140957|NCT00711009|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17185591|NCT01760889|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17185592|NCT04050865|f||||f
17185593|NCT01466985|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17185594|NCT05616962|f||||f
17185595|NCT04924283|f||||f
17185596|NCT00175825|f||GT60||t
17185597|NCT00608582|f||||f
17140958|NCT03359811|t||||
17140959|NCT01682876|f||LTE60||t
17140960|NCT03852901|f||||f
17140961|NCT02534324|t||||
17185598|NCT01393782|t||||
17185599|NCT00160680|f||GT60||t
17140962|NCT01138995|f||LTE60||t
17140963|NCT01459016|f||GT60||t
17140964|NCT04259749|f||||f
17140965|NCT00303602|f||GT60||t
17140966|NCT03374982|t||||
17140967|NCT03993314|f||||f
17185600|NCT01808950|f||OTHER|Investigator is granted a right to publish and present Trial Results together with other investigators of Trial and to be referred to in publications containing such results. However, investigator shall not publish or present Trial Results unless Investigator has submitted to Spirig a draft of the intended publication or presentation for review and approval.|t
17185601|NCT00985725|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17185602|NCT05276830|f||||t
17185603|NCT02450331|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185604|NCT01410474|f||||f
17185605|NCT03232983|t||||f
17185606|NCT03046212|t||||
17140968|NCT00663208|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17140969|NCT03500302|f||LTE60||t
17140970|NCT02873598|t||||
17140971|NCT04067310|t||||f
17140972|NCT01249404|f||||f
17140973|NCT04563845|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17140974|NCT02146274|f||||f
17140975|NCT03414372|t||||
17140976|NCT01494753|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17140977|NCT00182793|t||||
17140978|NCT02719028|f||||f
17140979|NCT01539720|f||||f
17140980|NCT03287960|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17140981|NCT03730987|t||||
17140982|NCT01753765|f||LTE60||t
17140983|NCT02083406|f||||f
17140984|NCT03938857|t||||
17185607|NCT02261493|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185608|NCT00530855|f||GT60||t
17185609|NCT00815295|f||||f
17185610|NCT01137474|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185611|NCT02219048|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185612|NCT04794803|f||||f
17185613|NCT04475549|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17185614|NCT04040751|t||||
17185615|NCT03624504|f||||t
17185616|NCT02862457|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17185617|NCT01388816|f||LTE60||t
17185618|NCT00951483|t||||f
17185619|NCT03015402|f||||f
17185620|NCT01813474|f||||f
17185621|NCT02186210|f||||t
17185622|NCT01995461|t||||
17185623|NCT01684748|f||||f
17185624|NCT01826812|f||||f
17185625|NCT01955954|f||||f
17140985|NCT02516605|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17140986|NCT02577107|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17140987|NCT00577382|f||||f
17140988|NCT02839330|f||LTE60||t
17140989|NCT04805892|f||||f
17140990|NCT03802331|t||||
17185626|NCT02671032|f||||t
17185627|NCT00540124|f||GT60||t
17185628|NCT01921296|t||||
17185629|NCT00796302|f||||f
17185630|NCT01207102|t||||
17185631|NCT03792126|f||||f
17185632|NCT02300220|t||||
17185633|NCT04322682|f||||t
17185634|NCT02238379|t||||
17185635|NCT00441090|f||OTHER||t
17140991|NCT02074059|f||GT60||t
17140992|NCT00804596|f||LTE60||t
17140993|NCT00779506|f||LTE60||t
17140994|NCT04051320|t||||
17140995|NCT01632345|f||LTE60||t
17140996|NCT01077310|f||||f
17140997|NCT04269629|f||||f
17140998|NCT01535638|t||||
17140999|NCT05060003|t||||
17185636|NCT01441102|t||||
17185637|NCT00605280|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141000|NCT00819052|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17141001|NCT00090844|f||||f
17141002|NCT01558791|f||||f
17141003|NCT01277666|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141004|NCT03702166|t||||
17141005|NCT01888367|f||LTE60||t
17141006|NCT01835964|t||||
17141007|NCT03969589|t||||
17141008|NCT03417999|t||||f
17141009|NCT00149227|f||||f
17141010|NCT00490477|f||||f
17141011|NCT00039377|f||LTE60||t
17185638|NCT02291614|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17185639|NCT01662310|f||OTHER|If an Investigator wishes to publish information from study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. If requested by the Sponsor, investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application. Investigators will not publish data derived from individual site until Sponsor confirms there will be no multi-center study publication.|t
17185640|NCT00683826|t||||f
17185641|NCT01302847|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17185642|NCT00205348|t||||f
17185643|NCT00374322|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185644|NCT03969719|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclosure previously undisclosed confidential information other than study results.|t
17185645|NCT01417026|t||||
17185646|NCT02130193|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185647|NCT01212770|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17185648|NCT00829387|f||||f
17185649|NCT03036163|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed|t
17185650|NCT00707031|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17185651|NCT00182754|t||||
17185652|NCT01054768|t||||
17185653|NCT02471651|t||||
17185654|NCT02747238|t||||
17141012|NCT01020812|t||||
17141013|NCT02927990|f||||f
17141014|NCT00960323|f||GT60||t
17141015|NCT01667731|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17141016|NCT00612573|f||LTE60||t
17141017|NCT01425268|f||||f
17141018|NCT03633461|f||||t
17141019|NCT02257970|f||||f
17141020|NCT01345162|f||||f
17141021|NCT01871870|t||||
17141022|NCT02049476|f||||f
17141023|NCT01256424|f||LTE60||t
17141024|NCT00991458|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141025|NCT02547064|f||||f
17141026|NCT02515890|t||||
17141027|NCT01716585|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141028|NCT00504595|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17141029|NCT02764229|f||OTHER|Center results cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then Investigator can publish if manuscript is submitted to Lycera ≥ 60 days prior to submission (or per Investigator contract). If Lycera decides publication would hinder development, Investigator must delay submission. Investigator must delete confidential information before submission and defer publication to allow patent applications.|t
17141030|NCT00672490|f||OTHER||t
17141031|NCT00967473|f||OTHER|Per clinical protocol confidentiality/study publication specifications all data discoveries arising out of the study, patentable of nonpatentable, shall be the sole property of Alcon Inc. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17141032|NCT00851721|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study: PIs may require prior written approval, or be restricted from independently publishing results until the earlier of the primary multicenter publication or ≤36 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) prior to submission for publication, and shall review and if necessary amend the manuscript in ≤60 days|t
17185655|NCT02085252|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17185656|NCT00951275|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185657|NCT01460940|f||||f
17185658|NCT01112579|f||||f
17185659|NCT04304833|t||||
17185660|NCT01951625|f||||f
17185661|NCT04866017|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17185662|NCT01475136|f||GT60||t
17185663|NCT04506970|t||||
17185664|NCT03355326|t||||
17185665|NCT00003508|f||||f
17185666|NCT01377480|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts with regard to proprietary information, accuracy, and fair-balance and compliance.|t
17185667|NCT00871689|t||||
17185668|NCT03576768|t||||
17185669|NCT00915031|f||||t
17185670|NCT01986881|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for an additional 60 days. Investigator will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.|t
17185671|NCT04333420|f||||t
17185672|NCT04179175|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17185673|NCT00610116|f||||f
17185674|NCT04177680|f||||f
17185675|NCT04149925|f||||f
17185676|NCT02030015|t||||
17185677|NCT00365391|f||LTE60||t
17185678|NCT03014674|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185679|NCT01096992|f||||f
17185680|NCT04250727|t||||
17185681|NCT05745142|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185682|NCT01911403|f||OTHER||t
17185683|NCT03722927|f||||f
17185684|NCT03224182|f||||f
17185685|NCT02822222|f||||t
17185686|NCT04279314|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17185687|NCT02481310|t||||
17185688|NCT00833560|f||GT60||t
17141033|NCT02816255|t||||
17141034|NCT00026559|t||||
17141035|NCT03485976|f||||f
17141036|NCT03451630|t||||
17185689|NCT00643916|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17185690|NCT01791725|f||GT60||t
17185691|NCT00512148|f||OTHER|The investigator is free to individually communicate, orally present, or publish in scientific journals or other scholarly media the study information at the conclusion of the study without the prior approval of the sponsor provided that 1) the results of the study in its entirety have been publically disclosed by or with the consent of the sponsor 2)18 months after the conclusion of the study at all sites, whichever is first to occur.|t
17185692|NCT00677833|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185693|NCT05072457|f||||f
17185694|NCT02001194|f||||f
17185695|NCT00184548|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial in accordance with the latest Vancouver guidelines. Any such scientific paper, resentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication / presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17185696|NCT02606279|f||||f
17185697|NCT02690974|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185698|NCT01091155|f||OTHER|14.1 Review. Institution may publish the results of the Study, based on information collected or generated by Institution and Principal Investigator within the framework thereof, subject to the provisions of this section. In any event, however, no publication, presentation in any forum or any other form of disclosure with respect to the Study or the results thereof will be made prior to the publication of the Joint Publication without Sponsor's prior written consent.|t
17185699|NCT01355588|f||||f
17141037|NCT02041533|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17141038|NCT02813681|f||||f
17141039|NCT02026193|f||||f
17141040|NCT01680835|f||||f
17141041|NCT02347124|f||||f
17141042|NCT01455064|f||GT60||t
17141043|NCT02172820|f||||f
17141044|NCT01874288|f||LTE60||t
17141045|NCT03370133|f||GT60||t
17141046|NCT01365468|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141047|NCT03524664|f||||f
17141048|NCT02694562|f||||f
17141049|NCT00423267|f||OTHER|"The investigator agrees not to publish or present any interim results~of the study without the Sponsor's prior written consent. The investigator further agrees to provide review copies to the Sponsor 45 days prior to submission for publication or presentation. The sponsor has the right to review and comment. If the parties disagree concerning the appropriateness of the data analysis and presentation, and/or confidentiality, investigator agrees to meet with the sponsor to discuss and resolve."|t
17141050|NCT01333865|t||||
17141051|NCT00684073|f||OTHER|The sponsor agreement is always necessary before PI publishing or communications. The sponsor can review the communication project during 28 days. The sponsor can require changes to the communication and can extend the embargo.|t
17141052|NCT00515021|f||||f
17185700|NCT02184611|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141053|NCT00591786|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17141054|NCT00554229|f||OTHER|AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed to allow for the filing of a patent application.|t
17141055|NCT01140646|t||||
17141056|NCT04126187|t||||
17141057|NCT00689728|f||GT60||t
17141058|NCT03245372|f||||f
17185701|NCT00522301|t||||
17185702|NCT01666951|f||OTHER||t
17185703|NCT02366910|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17185704|NCT01907191|f||||f
17141059|NCT04047342|t||||
17141060|NCT00784836|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17141061|NCT02720627|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17141062|NCT00660829|f||OTHER|For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.|t
17141063|NCT03590613|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141064|NCT00280059|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141065|NCT02984228|t||||
17141066|NCT01130831|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17141067|NCT00951912|t||||
17141068|NCT01513460|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141069|NCT00367380|f||LTE60||t
17141070|NCT00489216|t||||
17141071|NCT00396266|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17141072|NCT03815006|t||||
17141073|NCT02612194|t||||
17141074|NCT02539160|t||||
17141075|NCT01681004|f||||f
17141076|NCT00372905|t||||
17141077|NCT02312934|t||||
17141078|NCT02978339|t||||
17141079|NCT00701064|t||||
17141080|NCT00689299|f||||f
17141081|NCT02218424|t||||f
17141082|NCT02613910|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141083|NCT03395704|f||OTHER|Disclosure was restricted for all data, unless published by the company.|t
17141084|NCT00758394|f||GT60||t
17185705|NCT02623322|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185706|NCT03563716|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17185707|NCT03775200|f||LTE60||t
17185708|NCT04605978|f||||t
17141085|NCT01197495|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141086|NCT03721549|t||||
17141087|NCT03539900|t||||
17141088|NCT04823494|f||||t
17141089|NCT03726320|t||||
17141090|NCT02679560|t||||
17141091|NCT01684930|t||||
17141092|NCT01062230|t||||f
17141093|NCT00578331|f||OTHER||t
17141094|NCT00620126|t||||
17141095|NCT00784225|f||LTE60||t
17185709|NCT03813238|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17185710|NCT02583425|f||||f
17141096|NCT00313716|f||||f
17141097|NCT02399345|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141098|NCT01041027|t||||
17141099|NCT01347931|f||||f
17141100|NCT02493712|f||||t
17141101|NCT02528643|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17141102|NCT04120116|f||OTHER|PIs must obtain sponsor's written consent before publishing or presenting the trial results|t
17141103|NCT02087085|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141104|NCT01191190|t||||
17185711|NCT03318523|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17185712|NCT03581981|t||||
17185713|NCT02080871|f||||f
17185714|NCT00234052|f||||f
17185715|NCT02428296|t||||
17185716|NCT02723864|f||||f
17185717|NCT00828984|f||LTE60||t
17185718|NCT04465357|f||OTHER|Per contractual agreement PIs agree to submit drafts of all publications to sponsor and funding sponsor between a period of 5 and 45 days depending on publication type (e.g. manuscript, poster, etc.).|t
17185719|NCT01040858|f||||f
17185720|NCT02548455|f||LTE60||t
17185721|NCT01335204|t||||
17185722|NCT00831779|f||||f
17185723|NCT02436330|t||||f
17185724|NCT02230956|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185725|NCT00338884|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185726|NCT02396745|t||||
17185727|NCT01970982|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17185728|NCT01146496|f||||f
17185729|NCT04496219|f||||f
17185730|NCT00765674|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185731|NCT02432105|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185732|NCT03053050|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17185733|NCT02459574|t||||
17185734|NCT00251745|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17185735|NCT00636649|t||||f
17185736|NCT04508699|t||||
17185737|NCT01610427|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185738|NCT00499031|f||||f
17185739|NCT00477230|f||||f
17185740|NCT01143688|f||||f
17185741|NCT01785680|f||||f
17185742|NCT03409666|f||GT60||t
17185743|NCT00361140|t||||f
17185744|NCT03432364|f||||f
17185745|NCT03043079|t||||
17185746|NCT03320018|t||||
17185747|NCT00993655|t||||f
17185748|NCT03284788|f||||f
17185749|NCT03026790|t||||
17185750|NCT01718028|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185751|NCT03104699|f||||t
17185752|NCT01690130|t||||
17185753|NCT00152464|f||GT60||t
17185754|NCT01644734|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17185755|NCT05159622|f||||f
17185756|NCT00361374|f||||f
17185757|NCT03384173|t||||
17185758|NCT03509974|f||OTHER|Principal Investigators and Team at Sick Kids preparing a publication for peer review with sponsor coordination.|t
17185759|NCT00464646|f||LTE60||t
17185760|NCT01615328|f||LTE60||t
17185761|NCT03338894|f||||f
17185762|NCT00626028|f||OTHER||t
17185763|NCT04321239|t||||
17185764|NCT01984684|f||OTHER|Melinta has the right to first publication of results, which would be made in conjunction with the PIs from all appropriate sites. Thereafter, PIs may publish results provided the PI submits the proposed publication to Melinta for review at least 60 days prior to the date of the proposed publication. Melinta may remove any information that is considered confidential and/or proprietary. If a publication is not submitted within 12 months of study conclusion, the PI may publish results.|t
17185765|NCT04575051|t||||
17185766|NCT05198466|f||||f
17185767|NCT03583554|t||||
17185768|NCT03178266|f||||f
17185769|NCT02472964|f||||t
17185770|NCT01215292|t||||f
17185771|NCT04672941|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17185772|NCT01680848|f||||f
17185773|NCT00765388|f||OTHER|Investigator may publish the Inventions subject to the prior written consent of Sponsor. The Investigator shall submit the manuscript to Sponsor for approval, provided however that the Investigator will submit the manuscript at least thirty (30) days before disclosure for such proposed publication. If Sponsor wishes to file patent applications on Inventions Sponsor is allowed to delay the publication upon to a maximum period of 6 months since he above-mentioned submission.|t
17185774|NCT01846182|t||||
17185775|NCT02342886|f||OTHER|The Investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting for review and removal of confidential information.|t
17185776|NCT01328080|f||||f
17185777|NCT00862134|f||OTHER|Single site data may be published/presented prior to the publication of multi-center data from overall study if agreed to by the sponsor in writing, or 12 months have elapsed following termination or completion of the study, whichever comes first.|t
17185778|NCT02191267|f||||f
17185779|NCT00316082|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185780|NCT00528775|t||||
17185781|NCT01011829|t||||
17185782|NCT00587964|t||||
17185783|NCT01163097|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 90 days). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17141105|NCT02680158|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141106|NCT03734601|t||||
17141107|NCT00883896|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141108|NCT01856920|f||||t
17141109|NCT02545270|f||||f
17141110|NCT00731094|t||||f
17141111|NCT03380091|t||||
17141112|NCT00761891|f||||f
17141113|NCT01707667|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17141114|NCT00777790|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17141115|NCT01196793|t||||
17141116|NCT01905241|f||||f
17141117|NCT02675933|f||||f
17141118|NCT04382066|f||LTE60||t
17141119|NCT00958282|t||||
17141120|NCT03326323|f||||f
17141121|NCT02109731|f||||f
17185784|NCT01569438|f||OTHER|60 days prior to the submission of any results, the PI shall submit to SPONSOR any proposed PUBLICATION, which period may be extended for an additional 30 days if requested by SPONSOR. If any Confidential Information should be redacted or patent applications relating to an Invention should be filed prior to PUBLICATION, then PUBLICATION will be delayed until patent application has been filed. Delay of a PUBLICATION shall not exceed 24 months from the date of such notice to the PI.|t
17141122|NCT04225026|f||OTHER|The Institution shall provide Sponsor with an advance copy of any proposed publication at least 45 days prior to the planned date of submission or presentation and Sponsor shall have 45 days to review. Institution may be asked by Sponsor to delete confidential information, consider reasonable changes requested by Sponsor or delay proposed submission for additional period, not to exceed 90 days, to protect the potential patentability of any technology.|t
17141123|NCT04462731|t||||
17141124|NCT00779142|t||||
17141125|NCT03698370|t||||
17141126|NCT04533204|f||||f
17141127|NCT03982069|t||||f
17141128|NCT01218477|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17141129|NCT03137433|f||||f
17141130|NCT00083616|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17185785|NCT00452387|f||OTHER|Prior to publication or presentation of Sponsored Research results, Researcher agrees to provide Bayer with such presentation or manuscript at least 30 days prior to its submission for the sole purpose of allowing Bayer to redact confidential information and protect any existing or future patents. The Principal Investigator shall acknowledge Bayer contributions where appropriate.|t
17185786|NCT03649230|f||LTE60||t
17185787|NCT01693068|f||OTHER||t
17141131|NCT00265382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141132|NCT01474993|f||||f
17141133|NCT00760994|f||||f
17141134|NCT01853397|f||OTHER|Authorship and manuscript composition will reflect joint cooperation between the PI and Solta Medical personnel. Authorship will be established prior to the writing of the manuscript. No individual publications will be allowed prior to completion of the final report of the study except as agreed with Solta Medical. All publications must be reviewed and approved by Solta Medical prior to submission for publication.|t
17141135|NCT02132312|f||||t
17141136|NCT03547960|t||||
17141137|NCT01724021|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141138|NCT03503617|f||||f
17141139|NCT02452892|f||||f
17141140|NCT00486720|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141141|NCT03570476|t||||f
17141142|NCT00955682|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141143|NCT02117024|f||||f
17141144|NCT03138798|t||||
17141145|NCT00565721|f||||f
17141146|NCT01483378|f||LTE60||t
17141147|NCT02500706|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17141148|NCT00529152|f||OTHER|Sponsor has the right to review manuscript at least 60 days prior to submission and posters/abstracts at least 30 days. If review indicates potentially patentable or confidential information would be disclosed, submission may be delayed an extra 30 days to allow filing the necessary patent applications and to co-operate with the sponsor to protect confidential information. Investigator will delay single center publications until after disclosure of pooled data (all sites) by Sponsor.|t
17141149|NCT03523390|f||||f
17141150|NCT01497899|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17141151|NCT05047601|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141152|NCT00286234|f||||f
17141153|NCT02499380|f||||f
17141154|NCT04241627|t||||
17141155|NCT00283062|f||OTHER|The investigator shall provide the Steering Committee a copy of any manuscript, abstract or oral communication derived from the study for review and comment at least 30 days in advance of any submission. The Sponsor's representatives shall have the right to review and/or delay any publication or presentation to prevent disclosure of Sponsor's confidential information and preserve intellectual property rights.|t
17141156|NCT02205177|f||||f
17185788|NCT00579280|t||||
17185789|NCT02510144|t||||
17185790|NCT00977665|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17185791|NCT00668902|f||||f
17185792|NCT02115633|f||||f
17185793|NCT01159054|t||||
17185794|NCT01400503|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17185795|NCT00058123|f||||f
17185796|NCT02925676|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor extend the embargo with up to 90 days if filling a patent is wanted by the Sponsor.|t
17185797|NCT02151266|t||||
17185798|NCT01169675|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17185799|NCT03987841|f||||f
17185800|NCT02354664|t||||
17185801|NCT02365519|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17141157|NCT00827112|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141158|NCT01475214|f||||f
17141159|NCT01522391|f||||t
17141160|NCT00877929|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17141161|NCT03006276|f||||f
17141162|NCT02127931|t||||
17141163|NCT00422942|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141164|NCT02828982|f||||f
17141165|NCT00617994|f||OTHER|Clinical Study Agreement|t
17141166|NCT03691831|f||||f
17141167|NCT03922945|f||GT60||t
17141168|NCT00911508|f||OTHER|The Study has been designed as a multicenter study and the data generated from Institution/PI's evaluation may not be sufficient to draw meaningful conclusions. Thus, Institution/PI shall not individually publish the results of the Study.|t
17141169|NCT04156802|f||||f
17141170|NCT04250558|f||||f
17141171|NCT02079077|f||||f
17141172|NCT00772031|f||LTE60||t
17141173|NCT00656136|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17141174|NCT00635804|f||LTE60||t
17141175|NCT01097057|f||||f
17141176|NCT01101321|f||GT60||t
17141177|NCT02681094|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17141178|NCT02210559|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17141179|NCT00310440|f||LTE60||t
17141180|NCT01098266|f||||t
17141181|NCT00525499|f||OTHER|The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor.|t
17141182|NCT03339999|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141183|NCT01111058|t||||
17141184|NCT01733758|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141185|NCT05602818|f||||t
17141186|NCT00538434|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17141187|NCT04594213|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17141188|NCT01182480|t||||
17141189|NCT03814499|f||LTE60||t
17141190|NCT01589185|f||GT60||t
17185802|NCT02291679|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17185803|NCT02048072|f||||f
17185804|NCT04450108|f||||f
17185805|NCT00725296|f||||f
17185806|NCT03657277|t||||f
17185807|NCT01031810|t||||
17141191|NCT02046993|f||||f
17185808|NCT03360942|f||||f
17185809|NCT04648150|f||||f
17141192|NCT00886626|t||||f
17141193|NCT00598442|f||OTHER|The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.|t
17141194|NCT04620356|f||||f
17141195|NCT00457951|f||OTHER|Confidentiality and Non-Disclosure Agreement|t
17141196|NCT01729559|f||||f
17141197|NCT01028131|t||||f
17141198|NCT03764813|t||||
17141199|NCT00667381|f||||f
17141200|NCT04646668|t||||
17141201|NCT01654666|t||||f
17141202|NCT03947333|t||||f
17141203|NCT00535262|t||||
17141204|NCT02898662|f||||t
17185810|NCT01774149|f||||f
17185811|NCT00657618|f||||f
17185812|NCT01880723|f||||f
17185813|NCT03703466|f||GT60||t
17185814|NCT05338333|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185815|NCT00254202|f||GT60||t
17185816|NCT05073133|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17185817|NCT05878197|f||||f
17185818|NCT04427202|f||||f
17185819|NCT01602536|t||||
17185820|NCT04295005|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17185821|NCT03751631|f||||f
17185822|NCT00428090|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185823|NCT03255824|t||||
17185824|NCT01866943|f||||f
17185825|NCT00863655|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data in the clinical trial.|t
17185826|NCT02157779|t||||
17141205|NCT00917553|t||||f
17141206|NCT01616173|t||||
17185827|NCT01826227|t||||
17185828|NCT03294330|f||||f
17185829|NCT00430248|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17185830|NCT02249819|f||||f
17185831|NCT00002558|t||||
17185832|NCT01754467|t||||
17141207|NCT00014560|t||||
17185833|NCT02065336|f||||f
17185834|NCT01970462|t||||
17185835|NCT00617981|f||LTE60||t
17185836|NCT02316769|f||||f
17185837|NCT00677235|f||LTE60||t
17185838|NCT01040260|t||||
17185839|NCT04570436|f||||t
17185840|NCT04111757|f||OTHER|Contact Sponsor directly for details|t
17185841|NCT00929162|f||OTHER|AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed to allow for the filing of a patent application.|t
17185842|NCT02133534|t||||f
17185843|NCT01274182|f||OTHER|The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.|t
17185844|NCT02355002|f||||f
17185845|NCT04322604|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17185846|NCT03205371|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17185847|NCT01851174|t||||
17141208|NCT02195895|f||||f
17185848|NCT02835339|f||||f
17185849|NCT01077544|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17185850|NCT03923959|f||||f
17185851|NCT04918147|f||||f
17141209|NCT03432819|f||||f
17185852|NCT04273139|f||||f
17185853|NCT01375114|t||||
17185854|NCT03338829|t||||
17185855|NCT05163418|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is 1 year from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185856|NCT03575325|t||||
17185857|NCT02612311|f||||f
17185858|NCT00715429|f||||f
17141210|NCT04738123|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17141211|NCT00665002|t||||
17141212|NCT03604159|t||||
17141213|NCT03223649|f||||f
17141214|NCT03970330|f||||f
17141215|NCT00787527|t||||f
17185859|NCT04085328|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185860|NCT00514735|f||||f
17185861|NCT04393441|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17185862|NCT00689221|f||OTHER|All manuscripts and materials relating to Study shall be submitted to Sponsor at least 60 days prior to submitting/presenting and allow Sponsor 60 days for review. If Sponsor requests, any confidential information shall be removed. In multi-center study, any publication shall not be made before the first multi-center publication; provided, however, that if no multi-center publication is made within 1 year from database lock, then Site may publish individually in accordance with this provision.|t
17185863|NCT01749982|f||||f
17185864|NCT00036569|f||||f
17185865|NCT01596582|t||||f
17185866|NCT04435665|f||||t
17185867|NCT03923933|t||||f
17185868|NCT02454101|f||||f
17185869|NCT00419263|f||||f
17185870|NCT03311373|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17185871|NCT01786967|t||||f
17185872|NCT04557930|f||||f
17185873|NCT01563536|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17185874|NCT03156660|f||||f
17185875|NCT01270126|f||||f
17185876|NCT00538590|f||||f
17185877|NCT01256567|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17185878|NCT06030414|f||||f
17185879|NCT01352598|f||||f
17185880|NCT02732366|t||||f
17185881|NCT05238233|t||||
17185882|NCT01345721|f||GT60||t
17185883|NCT00506064|t||||f
17185884|NCT00686881|f||||f
17185885|NCT00671931|t||||f
17185886|NCT02460692|t||||
17185887|NCT03260868|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17185888|NCT01298999|f||||f
17185889|NCT00541450|f||OTHER|The disclosure restriction on the PI is that an investigator and/or his/her colleagues may publish the results for their study site independently subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first. The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.|t
17185890|NCT00803452|t||||
17185891|NCT04839965|f||||t
17185892|NCT02816138|f||||f
17185893|NCT00981084|f||LTE60||t
17185894|NCT00876915|f||||f
17185895|NCT00289887|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185896|NCT01266850|f||LTE60||t
17185897|NCT01437124|f||||f
17185898|NCT01139190|f||LTE60||t
17185899|NCT04128293|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185900|NCT00437645|f||OTHER|Disclosure Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17185901|NCT03597568|f||||f
17185902|NCT03382782|f||||f
17185903|NCT01316510|t||||
17185904|NCT01490502|t||||
17185905|NCT00337272|f||OTHER|PI must provide Sponsor an advance copy of any proposed publication whether in journals or in conferences or other public forum at least 60 days prior to any submission for publication or public presentation so that Sponsor may determine whether it contains any Confidential Information of Sponsor, and/or any discovery or invention is made.|t
17185906|NCT04186780|f||||f
17185907|NCT01699022|f||||f
17185908|NCT00772590|t||||f
17185909|NCT02565914|f||||t
17185910|NCT00378352|f||LTE60||t
17185911|NCT03610464|f||||f
17185912|NCT05095272|t||||
17185913|NCT01197508|f||GT60||t
17185914|NCT01301391|f||LTE60||t
17185915|NCT02629991|f||||f
17185916|NCT02799784|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185917|NCT01624948|f||||f
17185918|NCT01949870|f||LTE60||t
17185919|NCT02570126|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185920|NCT00917579|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185921|NCT00754338|f||GT60||t
17185922|NCT04683926|f||OTHER|Sponsor shall retain title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the performance of the Services. Such publications shall not be made by Celerion without the prior written consent of Sponsor.|t
17185923|NCT00941993|f||GT60||t
17185924|NCT04385368|f||OTHER||t
17185925|NCT02740049|t||||
17185926|NCT01256411|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17185927|NCT02123108|t||||
17185928|NCT04721925|f||||f
17185929|NCT01132326|f||LTE60||t
17185930|NCT00952367|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17185931|NCT04504331|f||||f
17185932|NCT05120115|f||||f
17185933|NCT00708916|f||||f
17185934|NCT00850889|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185935|NCT03882879|f||||f
17185936|NCT02954354|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17185937|NCT04495179|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17141216|NCT02243306|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141217|NCT00733096|f||||f
17141218|NCT01199952|f||||f
17185938|NCT02968420|f||||f
17185939|NCT00673309|f||||f
17185940|NCT02355743|f||||f
17185941|NCT04212091|f||||f
17185942|NCT01812655|t||||f
17185943|NCT04540874|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17185944|NCT04653766|f||OTHER||t
17185945|NCT02563496|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17185946|NCT01522417|f||||f
17185947|NCT05725317|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185948|NCT00344461|f||||f
17185949|NCT03063294|t||||
17185950|NCT00636610|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141219|NCT03258710|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141220|NCT03137173|f||GT60||t
17141221|NCT02980211|f||||f
17141222|NCT01148836|t||||
17185951|NCT02355028|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185952|NCT01971723|f||||f
17185953|NCT05899686|t||||f
17185954|NCT04549363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17141223|NCT03461705|t||||
17141224|NCT00195702|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection|t
17141225|NCT03044730|t||||
17141226|NCT00690612|f||GT60||t
17141227|NCT01409382|f||||f
17141228|NCT01233076|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17141229|NCT01115166|t||||f
17141230|NCT01786707|t||||
17141231|NCT02641691|t||||
17141232|NCT02058940|t||||
17185955|NCT02669784|t||||
17141233|NCT01519700|f||OTHER|PI shall provide Sponsor with any presentation at least 15 working days prior to disclosure and any other publication at least 45 working days prior to disclosure. Sponsor may require amendments on reasonable grounds: (a) accuracy of publication; (b) confidentiality of proprietary information; (c) intellectual property protection; (d) to enable further information to be provided. Sponsor may require publications or presentations to be delayed up to four (4) months to enable patent application.|t
17185956|NCT02821403|t||||
17185957|NCT03289234|f||OTHER||t
17141234|NCT01881867|f||GT60||t
17185958|NCT01592370|f||LTE60||t
17185959|NCT05460325|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141235|NCT03044691|t||||
17141236|NCT02377674|f||OTHER|Researchers engaged in Project can present research results provided the Sponsor has been furnished copies at least one month in advance of the submission. Sponsor shall have thirty (30) days, after receipt of said copies, to object because there is confidential subject matter or proprietary information of Sponsor which needs protection. In the event that Sponsor makes such objection, said Researcher(s) shall refrain from making such publication or presentation for a maximum of six months|t
17141237|NCT01789476|f||GT60||t
17141238|NCT00965458|f||||f
17141239|NCT00994123|f||LTE60||t
17141240|NCT02223637|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trials.|t
17141241|NCT00692198|f||||f
17141242|NCT04177862|f||||f
17141243|NCT05111548|t||||
17141244|NCT00379639|f||OTHER|Upon investigator submission of a publication or presentation to Celgene, Celgene shall complete its review within 60 days after receipt of the proposed publication or presentation. Upon Celgene's request, proposed publication or presentation will be delayed up to 60 additional days to enable Celgene to secure adequate intellectual property protection of property of Celgene that would be affected by such proposed publication or presentation|t
17141245|NCT00594958|f||OTHER||t
17141246|NCT05637515|f||OTHER|Institution and Investigator shall have the right to publish or present the results of Institution. Institution and Investigator are required to submit any proposed publication or presentation to Sponsor for review at least 30 days prior to submitting any such proposed publication. Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Data).|t
17141247|NCT03233009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141248|NCT00564876|f||||f
17141249|NCT00278473|t||||
17141250|NCT04516291|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141251|NCT03039686|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141252|NCT02158949|f||||f
17141253|NCT00721513|t||||
17141254|NCT02322866|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141255|NCT02145949|f||||f
17141256|NCT00103376|t||||
17141257|NCT00224952|t||||
17141258|NCT02505945|f||OTHER|PI must provide sponsor copy of any proposed publication at least (45)days prior to the submission. PI shall defer any publication until release of the publication of the results of the Study by the sponsors joint publication committee. In the event that a multiple center publication is not submitted within 12 mo. after the completion at all centers, PI may publish Study results from their individual experience, after submitting to Sponsor for review (90)days prior to submission.|t
17185960|NCT01323530|f||||t
17185961|NCT01111123|f||||f
17185962|NCT00119405|t||||
17185963|NCT01865708|f||||f
17185964|NCT01735201|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17185965|NCT01553318|f||||f
17185966|NCT02238925|f||||f
17185967|NCT03896009|f||||t
17185968|NCT02127372|t||||f
17185969|NCT03073148|f||||f
17185970|NCT01357616|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17185971|NCT03247790|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information..|t
17185972|NCT02281448|t||||
17185973|NCT02052310|f||OTHER|"The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.~The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).~FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total)."|t
17185974|NCT02650219|f||||f
17185975|NCT01505387|f||OTHER||t
17185976|NCT02258139|f||OTHER|Contact sponsor directly for details.|t
17185977|NCT00420199|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17185978|NCT03387579|f||||f
17185979|NCT03466086|f||GT60||t
17185980|NCT04208516|t||||
17185981|NCT04020341|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17185982|NCT00677352|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141259|NCT01270139|t||OTHER|This project and manuscript were not prepared or funded in any part by a commercial organization. Nanoparticles and biomedical facilities were supplied free for the study by the non-profit Agiko Foundation (Yekaterinburg, Russia). All rights of authors are reserved by the Russian Law. The access of the non-russian international and alien academic and governmental organizations to the essential and primary documents of the trial is restricted by the Russian government.|t
17185983|NCT05763628|f||||t
17185984|NCT00716092|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17185985|NCT01144026|f||||f
17185986|NCT00781391|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site's proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.|t
17185987|NCT04535947|f||OTHER|All information concerning SDP-4 and the operations of Silk Technologies, such as patent applications, formulas, manufacturing processes, basic scientific data or formulation information not previously published, are considered CONFIDENTIAL and shall remain the sole property of Silk Technologies. The Investigator agrees to use this information only in accomplishing this study and will not use it for other purposes without the written consent of Silk Technologies|t
17185988|NCT03616184|f||||f
17141260|NCT00134563|f||OTHER|"The investigator can publish only the results of the work performed pursuant to this protocol. Prior to publication, the investigator provides the sponsor with the manuscript for review and comment at least 45 days in advance of its submission for publication.~The sponsor can require the investigator to withhold publication an additional 90 days to allow for filing a patent application or taking such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17141261|NCT02452320|f||||f
17185989|NCT03802123|f||||f
17141262|NCT03382639|f||||t
17185990|NCT01822587|f||||f
17185991|NCT04225533|f||OTHER|PI shall be free to publish and/or present about the Study. All publications must be submitted to the sponsor at least 30 days prior to submission for review/comment. PI will consider any such comments in good faith but is under no obligation to incorporate. If Sponsor notifies PI that it desires patent applications, PI will defer Publication for a period not to exceed 60 days; \& if Publication contains Company's Confidential, the PI agrees to delete such Company's Confidential Information.|t
17185992|NCT04270292|f||||f
17141263|NCT02406586|t||||
17141264|NCT03198559|f||||f
17141265|NCT01072175|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141266|NCT00218439|f||||f
17141267|NCT02477215|t||||
17141268|NCT01474291|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141269|NCT04871451|f||||f
17141270|NCT00438815|f||OTHER|Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to sponsor for pre-review. If sponsor requests, PI must delete sponsor confidential information before publication and/or delay publication for 90 days so sponsor can file for patents or take other action to protect its patent rights.|t
17141271|NCT03028324|t||||
17141272|NCT02790476|f||||f
17141273|NCT03740152|f||||f
17141274|NCT00679354|f||LTE60||t
17141275|NCT02206776|f||||f
17141276|NCT01636102|f||GT60||t
17141277|NCT00697255|f||OTHER|All publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to the Sponsor, at least 6 weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17185993|NCT00658567|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17185994|NCT02681614|t||||f
17185995|NCT00420992|f||OTHER|Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the Sponsor for review. Sponsor may request a delay in publication to allow the filing of patent applications before publication or release. The sponsor can require deletion of Confidential Information or request correction of inaccuracies.|t
17185996|NCT02003352|t||||
17141278|NCT01005355|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17141279|NCT03570658|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141280|NCT01303159|f||||f
17141281|NCT00496782|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141282|NCT02735382|f||||f
17141283|NCT02242305|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141284|NCT05489146|t||||f
17141285|NCT03820388|t||||
17141286|NCT00469391|f||||f
17141287|NCT01005875|t||||
17141288|NCT00078715|f||||f
17141289|NCT00242658|f||||f
17141290|NCT01815099|t||||
17141291|NCT00643851|f||||f
17141292|NCT01353976|f||||f
17141293|NCT04557189|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141294|NCT01728454|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141295|NCT01190839|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17141296|NCT01832753|f||||f
17141297|NCT03077646|f||||f
17141298|NCT02058966|f||||f
17141299|NCT04927858|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141300|NCT02545504|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17141301|NCT00329433|f||LTE60||t
17141302|NCT01080794|f||||f
17141303|NCT01336647|f||LTE60||t
17141304|NCT03808298|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141305|NCT01858701|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17141306|NCT01559649|t||||
17141307|NCT05056311|t||||
17141308|NCT02713490|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17141309|NCT03799198|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17185997|NCT04886479|f||||t
17141310|NCT01054209|t||||
17141311|NCT03330275|f||GT60||t
17185998|NCT00053989|t||||
17185999|NCT00382824|f||||f
17186000|NCT01058304|t||||
17141312|NCT00151775|f||OTHER|If identified by Daiichi Sankyo Inc.(DSI), any of DSI's confidential information, as defined to the author, shall be deleted. Nothing in our site agreement shall be taken as giving DSI any right of editorial control over any publication prepared by the study site.|t
17186001|NCT01820559|f||OTHER||t
17186002|NCT02618967|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141313|NCT01008059|t||||
17186003|NCT01368965|f||||f
17141314|NCT00474994|t||||
17141315|NCT01700907|f||||f
17186004|NCT00762450|f||LTE60||t
17186005|NCT03905330|f||LTE60||t
17186006|NCT01029054|t||||
17141316|NCT02181634|f||||f
17186007|NCT01936857|t||||
17186008|NCT01939548|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186009|NCT00490282|t||||
17186010|NCT04198805|t||||f
17186011|NCT03599349|f||||f
17186012|NCT04209075|t||||
17186013|NCT03818672|f||OTHER|Contact sponsor for details.|t
17186014|NCT03221387|f||||f
17186015|NCT00553696|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186016|NCT01723722|t||||
17186017|NCT02276222|f||OTHER|In the event the Study is part of a multi-center study , the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17186018|NCT03645759|f||||f
17186019|NCT01648270|t||||
17186020|NCT02170025|f||OTHER|PI(s) shall provide to Bayer any proposed publication or oral presentation relating to the Study or the Study Drug or the Results at least sixty (60) days prior to the intended submission or presentation of the Publication in order to allow Bayer to review it.|t
17186021|NCT00572195|f||OTHER|Each Investigator and Institution agree that the 1st publication of study results shall be a joint, multi-center publication. Each Investigator, Coordinator, and Institution agree to submit publications to the RNS® System Study Publication Committee for review prior to submission for publication (at least 30 days for manuscripts and at least 7 days for abstracts) to assure that publication does not compromise the scientific integrity of the study or contain confidential NeuroPace information.|t
17186022|NCT00902694|f||||f
17186023|NCT04969263|f||||f
17186024|NCT02693743|t||||
17186025|NCT01024608|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17186026|NCT02412137|t||||
17186027|NCT04913363|t||||
17186028|NCT04981678|t||||
17186029|NCT04922554|f||OTHER||t
17186030|NCT04676425|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments|t
17186031|NCT00791843|t||||
17141317|NCT01778296|t||||
17141318|NCT02843282|f||||f
17141319|NCT04550234|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17141320|NCT01928758|t||||
17141321|NCT02718131|f||||f
17141322|NCT00719706|t||||
17141323|NCT01512758|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17141324|NCT01827462|f||||f
17141325|NCT00987558|f||OTHER||t
17186032|NCT03717402|t||||
17186033|NCT02565901|f||||f
17186034|NCT00990964|f||||f
17186035|NCT01332227|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186036|NCT00514943|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17186037|NCT03764449|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141326|NCT00682539|t||||
17141327|NCT03558230|t||||
17141328|NCT01911546|f||||f
17141329|NCT02546193|t||||f
17141330|NCT01287403|t||||f
17141331|NCT00148109|t||||f
17141332|NCT00649220|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 weeks before submission. Sponsor to give written opinion within 30 days. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17141333|NCT01399619|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141334|NCT02557308|f||||t
17141335|NCT02357394|f||||f
17141336|NCT00351611|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141337|NCT00267202|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17141338|NCT00368069|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17141339|NCT04680273|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141340|NCT03907072|f||||f
17141341|NCT00591305|f||||f
17141342|NCT01430559|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141343|NCT04168775|t||||
17141344|NCT01177943|f||GT60||t
17141345|NCT00808665|t||||
17141346|NCT03319160|f||||f
17141347|NCT02431559|f||LTE60||t
17141348|NCT02543918|f||LTE60||t
17141349|NCT01135368|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141350|NCT01411917|t||||
17141351|NCT02791906|t||||
17141352|NCT01756209|t||||f
17141353|NCT04806334|t||||
17141354|NCT00954356|f||GT60||t
17186038|NCT01100255|f||||f
17186039|NCT02173548|t||||
17186040|NCT04635579|f||||f
17141355|NCT01731600|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17141356|NCT00465894|t||||f
17141357|NCT01636076|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17141358|NCT00540228|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141359|NCT01212627|f||||f
17141360|NCT02173158|f||OTHER|Described in site contract|t
17186041|NCT02066402|f||LTE60||t
17186042|NCT04493931|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186043|NCT00266825|t||||
17141361|NCT02195349|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186044|NCT04452292|t||||
17186045|NCT01782443|t||||
17186046|NCT00595504|t||||
17186047|NCT03039595|t||||
17186048|NCT01291784|t||||
17186049|NCT02872701|f||LTE60||t
17186050|NCT00187226|t||||
17186051|NCT02182973|f||||f
17186052|NCT01235546|f||||f
17141362|NCT00765726|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186053|NCT01123382|f||||f
17141363|NCT01265511|f||||f
17141364|NCT00323479|f||LTE60||t
17141365|NCT01272245|t||||
17141366|NCT01362062|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141367|NCT00967343|f||||f
17141368|NCT00950755|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141369|NCT02549040|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17141370|NCT00508820|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141371|NCT02926833|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17141372|NCT01189201|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141373|NCT01277757|f||LTE60||t
17141374|NCT04308668|t||||
17141375|NCT01266967|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141376|NCT01945866|f||OTHER|Trial results can not be discussed until they have been made available to the public|t
17141377|NCT01004822|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141378|NCT01674010|f||GT60||t
17141379|NCT01206296|t||||
17141380|NCT01520038|t||||
17141381|NCT03159455|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141382|NCT00187655|t||||
17141383|NCT05040295|t||||
17141384|NCT00953849|t||||
17186054|NCT02054806|f||OTHER|"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."|t
17186055|NCT00885092|t||||
17186056|NCT03059901|f||||f
17186057|NCT00645164|f||||f
17141385|NCT01801475|f||||f
17141386|NCT00421928|f||LTE60||t
17141387|NCT00444028|f||LTE60||t
17141388|NCT02022566|t||||
17186058|NCT01362439|f||GT60||t
17186059|NCT01133158|f||||f
17186060|NCT01281644|t||||
17186061|NCT01755702|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186062|NCT00691938|t||||
17186063|NCT04860518|f||GT60||t
17186064|NCT01965782|f||GT60||t
17186065|NCT02755597|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186066|NCT01069354|f||||f
17186067|NCT00594854|f||LTE60||t
17186068|NCT02684006|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141389|NCT00346775|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141390|NCT00960869|f||OTHER|PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.|t
17141391|NCT01714726|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo. (Note that this agreement language may appear in the study protocol)|t
17141392|NCT00548340|f||||f
17141393|NCT01096017|f||LTE60||t
17141394|NCT01358266|f||||f
17141395|NCT02600559|f||OTHER|Publication subject to Sponsor consent.|t
17141396|NCT00501969|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17141397|NCT00665366|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17141398|NCT01545375|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141399|NCT01846039|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141400|NCT03814824|f||||f
17141401|NCT04854421|f||||f
17141402|NCT01980056|f||||f
17141403|NCT00408408|f||LTE60||t
17141404|NCT03724552|f||||f
17141405|NCT01533974|f||||f
17141406|NCT00399542|f||||f
17141407|NCT03172026|t||||
17141408|NCT00265109|f||||f
17141409|NCT02463097|f||GT60||t
17141410|NCT01757821|f||||f
17141411|NCT00334893|f||LTE60||t
17141412|NCT02078557|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17141413|NCT01830621|t||||f
17141414|NCT01552408|f||||f
17186069|NCT02413580|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17186070|NCT03804710|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186071|NCT02660827|f||GT60||t
17186072|NCT01428076|f||||f
17186073|NCT00387673|f||||f
17186074|NCT00045305|f||LTE60||t
17186075|NCT03138096|t||||
17186076|NCT02216773|f||||f
17186077|NCT04274894|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186078|NCT02279043|f||||f
17186079|NCT03848403|f||GT60||t
17186080|NCT02124265|f||||f
17186081|NCT02386995|t||||
17186082|NCT04510675|f||||f
17186083|NCT00774579|t||||
17186084|NCT00976352|t||||
17141415|NCT04930562|f||||f
17141416|NCT03301272|t||||
17141417|NCT02347345|f||||f
17141418|NCT03457701|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17141419|NCT01288911|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17141420|NCT03279731|f||||f
17141421|NCT00545974|t||||f
17141422|NCT01811693|f||||f
17141423|NCT00387621|t||||f
17186085|NCT01330433|f||||f
17186086|NCT02114151|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17141424|NCT02451137|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17141425|NCT03747497|f||||t
17141426|NCT01977573|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141427|NCT02993731|f||OTHER|The primary author agrees to, prior to submitting a manuscript, abstract, or any other written/oral presentation describing the Results for publication/presentation, forward a copy to the Sponsor at least 45 days prior to their submission. The Sponsor may request an additional 30-day embargo. The Sponsor may require the primary author to delete any Confidential Information (other than the Clinical Results) and to require that any publication/presentation acknowledge the Sponsor's support.|t
17141428|NCT03014700|f||OTHER||t
17141429|NCT04398030|f||||f
17141430|NCT02946515|f||||f
17141431|NCT02501642|t||||
17141432|NCT01171794|t||||
17186087|NCT01494584|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186088|NCT01666808|t||||
17186089|NCT01499082|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17186090|NCT02638948|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \<=60 days from submitting for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186091|NCT02411565|t||||
17186092|NCT02963974|t||||
17186093|NCT00810264|f||OTHER||t
17186094|NCT01830127|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17186095|NCT06213701|t||||
17186096|NCT00567190|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186097|NCT02495025|f||||f
17186098|NCT00313820|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186099|NCT00860379|f||||f
17186100|NCT01515748|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17186101|NCT03407794|f||||f
17186102|NCT04102579|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17186103|NCT03419364|t||||
17186104|NCT02543658|t||||
17186105|NCT00662857|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17186106|NCT00989092|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186107|NCT03040713|f||LTE60||t
17186108|NCT04539821|t||||
17186109|NCT02691182|f||||t
17186110|NCT02563002|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17141433|NCT02748096|t||||
17141434|NCT01756586|f||||f
17141435|NCT02477319|f||||f
17141436|NCT01153971|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141437|NCT03410693|f||OTHER||t
17141438|NCT00953576|f||||f
17141439|NCT02965027|f||||f
17141440|NCT02818582|f||||f
17141441|NCT02196025|f||||f
17141442|NCT02582216|f||||f
17141443|NCT03628781|f||||f
17141444|NCT00656669|t||||
17141445|NCT03377803|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17141446|NCT03778021|f||||f
17141447|NCT00679042|f||||f
17141448|NCT02687815|f||||f
17141449|NCT02558634|f||||f
17141450|NCT04812678|t||||
17141451|NCT03757585|t||||
17186111|NCT01844284|f||||t
17186112|NCT00611858|t||||f
17141452|NCT03472586|f||||f
17141453|NCT02528331|t||||
17141454|NCT01793610|f||||f
17141455|NCT05981443|t||||f
17141456|NCT06045026|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141457|NCT00612456|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141458|NCT01258803|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17141459|NCT00920582|f||LTE60||t
17141460|NCT03360695|f||||f
17141461|NCT04419558|f||OTHER|The multisite consortium can publish any time after the data is collected and analyzed by FibroGen. The investigator can only publish after the multisite consortium publishes (or tries to publish and fails). FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).|t
17141462|NCT00903357|f||LTE60||t
17141463|NCT00556140|t||||
17141464|NCT05146999|f||||f
17141465|NCT04668157|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17141466|NCT00383292|f||GT60||t
17141467|NCT03329404|f||LTE60||t
17141468|NCT01016912|f||OTHER|Bristol Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single center publications until after disclosure of the clinical trial's primary publication.|t
17141469|NCT02221882|f||GT60||t
17141470|NCT00796367|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17141471|NCT05664672|f||||f
17141472|NCT02394457|f||||f
17141473|NCT01598831|f||LTE60||t
17141474|NCT02384096|f||GT60||t
17141475|NCT02903121|f||||f
17186113|NCT03172702|f||||t
17186114|NCT06134180|f||||f
17186115|NCT02152982|f||LTE60||t
17186116|NCT03641313|f||LTE60||t
17141476|NCT04236986|t||||f
17141477|NCT04034225|f||OTHER|Submission of data for publication/presentation will be reviewed, coordinated and approved by Sensei in collaboration with the Investigator.|t
17141478|NCT01591044|f||LTE60||t
17141479|NCT02249377|f||||f
17141480|NCT01326481|f||||f
17141481|NCT00307736|t||||f
17141482|NCT01475513|t||||
17141483|NCT02260791|f||OTHER|Investigator and Sponsor will discuss the preparation of a manuscript for publication in a peer reviewed journal or an abstract for presentation. Either party may undertake the task but both must agree to the strategy before work is started. Each party will allow the other 30 days to comment before any results are submitted for publication or presentation. Authorship should reflect work done by the Investigators and Sponsor, in accordance with recognised principles of scientific collaboration.|t
17141484|NCT00606931|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results pending FDA approval or clearance.|t
17141485|NCT04834375|t||||
17186117|NCT04642898|t||||
17186118|NCT03574597|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17186119|NCT03434678|t||||
17186120|NCT05735587|f||||f
17186121|NCT06060457|f||||t
17186122|NCT02061202|t||||
17186123|NCT02676375|f||||f
17186124|NCT00569582|f||GT60||t
17186125|NCT01533493|f||||f
17186126|NCT03628287|f||||f
17141486|NCT03026556|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141487|NCT01294319|f||||f
17141488|NCT02924129|f||OTHER|PI may not publish their site results until study completion and multicenter results are published, unless multicenter results are not submitted for publication within 12 months of study completion or they receive Sponsor authorization. PI must notify sponsor within 30 days of submitting their site results. Sponsor may require a delay of up to 90 days if determined patent applications need to be filed or confidential information removed.|t
17141489|NCT01205399|f||GT60||t
17141490|NCT01348828|f||||f
17141491|NCT00302731|t||||
17141492|NCT01000311|f||GT60||t
17141493|NCT02780869|f||GT60||t
17141494|NCT01610752|f||||f
17141495|NCT02815670|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141496|NCT02208466|f||||f
17141497|NCT02354599|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17141498|NCT02229513|f||||f
17141499|NCT01633398|f||OTHER|Acknowledgement of funding: National Medical Research Council of Singapore (R-172-003-219-511), A\*STAR Biomedical Research Council Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) program (SPF2014/003, SPF2014/004, SPF2014/005), Boston Scientific Investigator Sponsored Research Program and Bayer.|t
17141500|NCT02939326|f||||f
17141501|NCT01087944|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141502|NCT01159665|f||LTE60||t
17141503|NCT00544674|f||OTHER|Single site data may be published/presented prior to the publication of multi-center data from overall study if agreed to by the sponsor in writing, or 12 months have elapsed following termination or completion of the study, whichever comes first.|t
17141504|NCT01377194|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the PI will be patient to mutual agreement between the PI and Forest Research Institute, Inc."|t
17141505|NCT01230489|f||||f
17186127|NCT05163522|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17186128|NCT03412396|t||||
17186129|NCT00406133|f||LTE60||t
17141506|NCT01791543|f||||f
17186130|NCT04880395|f||OTHER|Any documents, reports or data received or generated by PIs under the Agreement, including in particular those containing or reflecting specific information or the Study's results or data, may not be used, disclosed, communicated or published by PIs, whether for its own benefit or that of third parties, free of charge or against payment, in any country, without first obtaining the prior written permission of Fundación Huésped (Sponsor) in each instance.|t
17186131|NCT01895972|f||||f
17186132|NCT02753595|f||||t
17186133|NCT01570868|t||||
17186134|NCT02453581|f||OTHER|Publication and reporting of results and outcomes of this trial will be accurate and honest, undertaken with integrity and transparency and in accordance with QIMR's Policy on Criteria for Authorship. Publication of results will be subjected to fair peer-review. Data will not be released publicly until the manuscript is accepted for publication.|t
17186135|NCT05417620|f||||f
17186136|NCT02782169|f||||f
17186137|NCT02975973|f||||f
17186138|NCT00771810|f||GT60||t
17186139|NCT00765232|t||||
17186140|NCT04542018|t||||
17186141|NCT02953938|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186142|NCT02038894|t||||f
17186143|NCT00101933|f||OTHER|The disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 60 days.|t
17186144|NCT02657031|t||||f
17186145|NCT03078816|t||||f
17141507|NCT00963040|f||||f
17141508|NCT02138227|t||||
17141509|NCT00346476|t||||
17141510|NCT02985541|f||LTE60||t
17186146|NCT05390970|f||||f
17186147|NCT01218126|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186148|NCT00818116|f||||f
17186149|NCT01860703|f||OTHER|"All unpublished information given to the CRO by ApoPharma shall not be published or disclosed to a third party without the prior written consent of ApoPharma.~The data generated by this study are considered confidential information and the property of ApoPharma. This confidential information may be published only in collaboration with participating personnel from ApoPharma or upon ApoPharma written consent to publish the article."|t
17186150|NCT01188109|t||||
17186151|NCT00995072|f||||f
17186152|NCT02306759|t||||
17186153|NCT02721082|f||||f
17186154|NCT00251862|t||||
17186155|NCT02134587|t||||
17186156|NCT00265889|t||||f
17186157|NCT00416182|f||LTE60||t
17186158|NCT01525602|f||||f
17186159|NCT02073461|f||||f
17186160|NCT04349280|t||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17141511|NCT01846442|f||OTHER|Investigators shall provide to the SPONSOR 30 days prior to submission all documents for publication, presentation, etc that report any trial results. The SPONSOR shall have editorial rights on documents and the right to review/comment with regard to (1) proprietary information, (2) accuracy of the information, (3) correctness of the scientific evaluation/conclusions and (4) to ensure that the information is fairly balanced and in compliance with regulations.|t
17141512|NCT01710007|f||LTE60||t
17141513|NCT00887562|f||LTE60||t
17141514|NCT01553708|t||||f
17141515|NCT00761761|f||||f
17141516|NCT01982942|f||GT60||t
17141517|NCT01224171|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141518|NCT03737812|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141519|NCT02624713|f||||f
17141520|NCT02702115|f||||f
17141521|NCT00285857|t||||f
17141522|NCT06304064|f||||f
17141523|NCT04140942|f||||f
17186161|NCT02532179|f||||f
17141524|NCT03927209|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141525|NCT01161173|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17141526|NCT01407068|f||OTHER||t
17186162|NCT00806234|f||||f
17186163|NCT03076970|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17186164|NCT00789815|t||||
17186165|NCT02673398|t||||
17186166|NCT01321554|f||OTHER||t
17186167|NCT02063230|f||||f
17186168|NCT01410058|f||||f
17186169|NCT01203930|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17186170|NCT03966053|t||||
17186171|NCT02124889|t||||f
17186172|NCT04098406|f||LTE60||t
17186173|NCT01580072|t||||
17186174|NCT01783418|t||||
17186175|NCT04791761|t||||
17186176|NCT03548207|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17186177|NCT01756352|t||||f
17186178|NCT00415610|t||||f
17186179|NCT00455975|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17186180|NCT00999466|f||OTHER|There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed. The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ|t
17186181|NCT00319748|t||||
17186182|NCT01113502|t||||
17186183|NCT00995501|t||||
17186184|NCT03002610|f||OTHER|Sponsor had no role in planning of research, its execution or publication.|t
17186185|NCT01701414|t||||
17186186|NCT02227875|f||GT60||t
17186187|NCT04209725|f||GT60||t
17186188|NCT02657317|t||||
17186189|NCT03786952|f||||f
17141527|NCT03693846|f||OTHER|Institution/Investigator shall provide sponsor with a copy of each publication at the earliest practicable time, but in any event not less than thirty (30) days prior to its submission to a journal, publisher, or meeting or fifteen (15) days prior to any public disclosure of any manuscript or other public disclosure (e.g., presentation).|t
17141528|NCT00792467|f||||f
17141529|NCT03911401|f||||f
17141530|NCT00462501|t||||
17141531|NCT05600101|f||||f
17141532|NCT00933543|f||GT60||t
17141533|NCT04837807|f||||f
17141534|NCT01766466|f||OTHER||t
17141535|NCT05227404|t||||
17141536|NCT04652245|f||OTHER|The PI is an employee of the CRO (Contract Research Organization) and disclosure restrictions are specified by the agreement with the CRO. CRO shall not publish any study results without the prior written express consent of the Sponsoring company. In the event that such consent is given the Sponsoring company shall have 90 days from receipt of the proposed publication to review and comment. The Sponsor can require changes to the publication and delay of 90 days to the publication.|t
17141537|NCT00895817|f||||f
17141538|NCT00617942|f||||f
17141539|NCT00596622|f||||f
17141540|NCT01230021|f||OTHER|Novo Nordisk (NN) reserves the right not to release data until after specified milestones, e.g., finalisation of clinical trial report. This includes the right not to release interim results of clinical trials, as release of such information can invalidate the trial results. At end of trial, one or more manuscripts will be prepared collaboratively between Investigator(s) and NN. NN reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17141541|NCT04246996|f||||f
17141542|NCT02442284|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141543|NCT01365182|f||||f
17141544|NCT02023515|f||||f
17141545|NCT02309372|t||||
17141546|NCT02054572|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141547|NCT01590810|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17141548|NCT02129192|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17141549|NCT01466972|f||||f
17141550|NCT01231620|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141551|NCT02400281|f||||f
17141552|NCT00412360|f||||f
17141553|NCT01594424|f||||f
17141554|NCT02576652|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141555|NCT03216499|f||||f
17141556|NCT01668017|f||||f
17141557|NCT02486263|f||||f
17141558|NCT00553319|t||||
17141559|NCT01078974|t||||
17141560|NCT00508118|f||||f
17141561|NCT00976521|f||OTHER|Any proposed manuscript or publication will be submitted to Sponsor and Lead PI for comment at least 60 days prior to release of that manuscript or publication. There will be no publicizing of any data or results without the Sponsor's prior written permission. The publishing party will make every reasonable attempt to incorporate comments received from the Sponsor during such 60-day period.|t
17141562|NCT00495794|t||||
17141563|NCT03039699|f||||t
17141564|NCT03342911|f||||f
17141565|NCT04511533|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186190|NCT03468933|t||||
17186191|NCT03033225|t||||
17186192|NCT02515279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186193|NCT00226239|f||||f
17186194|NCT01800968|f||||f
17186195|NCT02865720|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17141566|NCT04969653|f||||f
17186196|NCT03266770|t||||
17141567|NCT02918968|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17141568|NCT01388946|f||||f
17141569|NCT03661346|f||||f
17141570|NCT00727246|t||||
17141571|NCT02696382|t||||
17141572|NCT05375942|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141573|NCT00483574|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17141574|NCT00998166|f||||f
17141575|NCT04548349|f||||f
17186197|NCT02220894|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17141576|NCT03554798|f||||f
17141577|NCT04988035|f||||t
17141578|NCT03602976|f||||f
17141579|NCT04626947|t||||f
17141580|NCT01428882|f||||f
17141581|NCT02967393|f||||f
17141582|NCT00429026|t||||f
17141583|NCT03831282|f||GT60||t
17141584|NCT04278846|f||||f
17141585|NCT00635362|t||||
17141586|NCT04338685|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141587|NCT03556202|f||GT60||t
17141588|NCT01539512|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17186198|NCT05007392|f||||t
17186199|NCT02453685|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17186200|NCT02925611|t||||
17186201|NCT00453986|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186202|NCT00303862|f||LTE60||t
17186203|NCT02778100|f||GT60||t
17186204|NCT01001052|f||GT60||t
17186205|NCT00825266|f||||f
17186206|NCT00522626|f||||f
17186207|NCT03479697|f||||f
17186208|NCT00552084|t||||
17186209|NCT01338025|f||||f
17186210|NCT03017079|f||||f
17186211|NCT03538951|f||||f
17186212|NCT01387139|t||||
17141589|NCT03449342|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17141590|NCT03158532|f||||f
17141591|NCT04479358|t||||
17141592|NCT00764465|f||GT60||t
17141593|NCT01333501|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141594|NCT00674440|t||||
17141595|NCT00914940|t||||
17141596|NCT00938457|t||||
17141597|NCT04095039|f||||f
17141598|NCT02370173|t||||
17141599|NCT03205605|f||||t
17141600|NCT03164629|t||||
17141601|NCT00945815|f||||f
17141602|NCT04553497|f||||f
17186213|NCT04839354|t||||
17186214|NCT04120233|t||||
17186215|NCT01165775|f||||f
17186216|NCT03779906|f||||f
17186217|NCT03520322|t||||
17186218|NCT02553460|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17186219|NCT04814368|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186220|NCT01077830|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17186221|NCT01194570|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141603|NCT01990339|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141604|NCT01038609|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141605|NCT01728194|t||||f
17141606|NCT00928642|f||||f
17141607|NCT04604015|f||||f
17141608|NCT01314261|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141609|NCT04524507|t||||
17141610|NCT01143818|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17141611|NCT02711306|f||||f
17141612|NCT03655951|t||||
17141613|NCT02811640|t||||
17141614|NCT01979003|t||||
17141615|NCT03575975|t||||
17141616|NCT02441517|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement|t
17141617|NCT01393444|t||||f
17141618|NCT01526343|f||||f
17141619|NCT00129220|f||GT60||t
17141620|NCT01883362|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17141621|NCT01383317|t||||
17141622|NCT01766024|f||OTHER||t
17141623|NCT02569996|f||||f
17141624|NCT01349816|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17141625|NCT03740724|f||LTE60||t
17141626|NCT02730234|f||||f
17141627|NCT01397409|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141628|NCT02911285|f||||f
17141629|NCT01207427|f||OTHER||t
17141630|NCT01790633|f||||f
17141631|NCT01716221|t||||
17141632|NCT00957827|f||||f
17141633|NCT02930889|t||||
17141634|NCT03503565|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17141635|NCT03427931|t||||
17186222|NCT01337674|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission|t
17186223|NCT02355067|f||||f
17141636|NCT00198107|f||||f
17141637|NCT02279082|f||LTE60||t
17141638|NCT00990782|t||||
17141639|NCT02848781|t||||
17141640|NCT02883400|f||||f
17141641|NCT00333437|t||||
17141642|NCT03996694|f||||f
17141643|NCT03022526|t||||f
17141644|NCT01685320|t||||
17141645|NCT00451191|f||||f
17141646|NCT01972282|f||||f
17141647|NCT01269346|f||||f
17141648|NCT00247416|f||||f
17141649|NCT00798161|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17141650|NCT02706327|f||||f
17141652|NCT02928900|f||||f
17141653|NCT02213666|f||||f
17141654|NCT01319422|t||||
17141655|NCT04337827|t||||
17141656|NCT03417245|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17141657|NCT04491955|f||||f
17186224|NCT00800839|t||||
17186225|NCT00939484|f||LTE60||t
17141658|NCT00892710|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17141659|NCT02708524|f||GT60||t
17141660|NCT00822185|f||OTHER|Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.|t
17141661|NCT03781167|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141662|NCT00638820|t||||
17141663|NCT02951143|t||||
17141664|NCT01590628|f||||f
17141665|NCT00475657|f||GT60||t
17141666|NCT02992743|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17141667|NCT00761735|f||OTHER|The sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to (1) proprietary information that is protected, (2) the accuracy of the information contained in the publication, and (3) to ensure that the presentation is fairly balanced and in compliance with FDA regulations.|t
17141668|NCT00381680|f||OTHER|Must obtain prior Sponsor approval.|t
17141669|NCT00398476|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141670|NCT03290131|f||OTHER||t
17141671|NCT04804579|t||||
17141672|NCT03099096|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141673|NCT00731640|f||OTHER|Specify: No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17141674|NCT04899362|t||||
17141675|NCT04389294|f||||f
17141676|NCT00401414|f||||f
17141677|NCT00450814|t||||
17141678|NCT04629534|t||||
17141679|NCT03732534|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17186226|NCT01224925|t||||
17186227|NCT02178059|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17186228|NCT05178121|t||||f
17186229|NCT00245102|f||LTE60||t
17186230|NCT01953003|f||||f
17186231|NCT01835262|t||||
17186232|NCT03092375|t||||
17186233|NCT01857882|t||||f
17186234|NCT02512679|f||||f
17186235|NCT00553501|f||LTE60||t
17186236|NCT02293395|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17186237|NCT01023568|f||||f
17186238|NCT00224770|f||OTHER|The only disclosure restriction on the PI is that the funding agency (NIH/NINDS) can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the funding agency for review. The funding agency cannot require changes to the communication and cannot extend the embargo.|t
17186239|NCT00861614|f||LTE60||t
17186240|NCT03391765|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186241|NCT01255592|f||GT60||t
17186242|NCT02035332|f||||f
17186243|NCT00551070|f||LTE60||t
17186244|NCT00838682|f||||f
17141680|NCT02190604|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141681|NCT02797951|f||GT60||t
17141682|NCT03709342|f||||f
17186245|NCT03202472|t||||
17186246|NCT03675451|t||||f
17186247|NCT04372628|f||||f
17141683|NCT02694393|t||||f
17141684|NCT03735849|f||||f
17141685|NCT05113277|t||||
17141686|NCT03455556|t||||
17141687|NCT02369874|f||||f
17141688|NCT01012765|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17141689|NCT01326312|f||||f
17141690|NCT02219477|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141691|NCT02071823|f||OTHER||t
17141692|NCT02185131|f||||f
17141693|NCT00499694|t||||
17141694|NCT00234533|f||||t
17141695|NCT00889928|f||OTHER||t
17141696|NCT01484691|t||||f
17186248|NCT03315143|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17186249|NCT00549757|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17186250|NCT02641392|f||OTHER|.Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17186251|NCT04067401|f||||f
17186252|NCT01477853|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17186253|NCT01050816|f||LTE60||t
17186254|NCT00248781|t||||
17186255|NCT01532128|f||OTHER||t
17186256|NCT00948974|f||||f
17186257|NCT01446666|f||||f
17186258|NCT00238433|t||||
17186259|NCT00580814|f||||f
17186260|NCT01814748|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17186261|NCT04044456|t||||
17186262|NCT01972529|f||OTHER||t
17186263|NCT02274857|f||OTHER|All manuscripts should be submitted to the sponsor for review and comment prior to submission to the publisher.|t
17186264|NCT00948298|f||||f
17186265|NCT00939874|f||OTHER|The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor. This includes periodic information releases and announcements to the news media or a third party regarding the progress of this Study.|t
17186266|NCT00330174|f||||f
17186267|NCT02403180|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17186268|NCT05711537|t||||
17141697|NCT05705544|f||||f
17141698|NCT03958045|t||||
17141699|NCT04081727|f||LTE60||t
17141700|NCT00422227|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17141701|NCT00847002|f||LTE60||t
17141702|NCT03575806|f||||f
17141703|NCT01458535|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141704|NCT01238861|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17141705|NCT01855607|t||||
17141706|NCT00460421|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (approximately up to 90 days). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17141707|NCT04602078|f||||f
17141708|NCT04001790|t||||
17141709|NCT04542304|f||OTHER||t
17141710|NCT01513538|f||||f
17141711|NCT05888740|f||OTHER|Institution and Investigator shall have the right to publish data obtained from the Study provided that the Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for written approval, for which approval shall not be unreasonably denied. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.|t
17141712|NCT04963231|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17141713|NCT04576702|f||||f
17141714|NCT01100931|f||||f
17141715|NCT03413618|t||||
17141716|NCT00229931|f||||f
17141717|NCT00465101|f||||f
17141718|NCT00361504|f||LTE60||t
17141719|NCT03045926|f||OTHER|The sponsor shall have the right and title to all documentation, reports, records, data, specimens or other work product generated in connection with the performance of the study. All materials, documents, and information of every kind and description supplied by the sponsor (with the exception of that which is in the public domain), and any sponsor intellectual property shall be the sole and exclusive property of the the sponsor.|t
17141720|NCT01374516|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17141721|NCT03219372|t||||
17141722|NCT00401726|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17141723|NCT02067728|f||||f
17141724|NCT01015170|f||||f
17141725|NCT03866811|t||||f
17141726|NCT00814502|t||GT60||t
17141727|NCT01225029|t||||
17141728|NCT00830310|f||GT60||t
17141729|NCT01050998|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17141730|NCT00629343|t||||
17141731|NCT02787655|t||||
17141732|NCT00620191|t||||f
17141733|NCT02304484|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141734|NCT00145795|t||||
17141735|NCT02967055|t||||
17141736|NCT00976989|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141737|NCT00570492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141738|NCT02283411|f||||f
17141739|NCT05510297|f||||f
17141740|NCT02500732|f||||f
17141741|NCT04409262|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186269|NCT00330915|f||GT60||t
17186270|NCT00118716|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186271|NCT00801801|t||||f
17186272|NCT01445652|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17186273|NCT00454571|f||LTE60||t
17141742|NCT03328325|f||||f
17186274|NCT02436811|t||||
17141743|NCT01738672|t||||
17141744|NCT03759340|f||||f
17141745|NCT00736840|f||OTHER|Any manuscript, abstract or other publication or presentation of results or information arising from the study (including ancillary studies involving trial patients) must be prepared in conjunction with Exalenz. Such materials must be submitted to Exalenz for review and comment at least 30 days prior to submission for publication or presentation.|t
17141746|NCT00735839|f||||f
17141747|NCT03289676|f||||f
17141748|NCT01396434|f||LTE60||t
17141749|NCT00157157|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) 30 days prior to submission or communication. Baxter may request an additional delay of up to 90 days (e.g., to allow for intellectual property protection).|t
17141750|NCT01678794|t||||
17141751|NCT01600677|f||||f
17141752|NCT00121251|f||LTE60||t
17186275|NCT03595332|t||||f
17186276|NCT01804101|f||||f
17186277|NCT01201811|f||OTHER|Multicenter publication must include input from all Investigators involved in the study and Sponsor before its publication; it has priority over subset (single center) publication during 1 year after study completion; Each Investigator has publication rights after multicenter publication is submitted or 1 year after study completion. Sponsor has the right to comment on the publication and ask for a 90-day delay to protect its intellectual property and/or deletion of any confidential information.|t
17186278|NCT00117676|f||OTHER|Institution and investigator may publish or present the results of the trial generated there with prior written consent of Gilead; or 2 years after the trial has ended at all institutions. Proposed publications/target venue must go to Gilead 30 days (manuscripts) or 15 days (abstracts/presentations) prior. Any Gilead confidential information in the document(s) must be deleted, or if requested publication delayed for up to 45 days to permit Gilead to obtain intellectual property protection.|t
17186279|NCT00952822|f||OTHER|Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).|t
17186280|NCT02643862|t||||
17186281|NCT01319799|t||||
17186282|NCT04555096|f||||t
17186283|NCT01250990|t||||
17186284|NCT03673306|f||||f
17186285|NCT02202746|f||OTHER|All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.|t
17186286|NCT04723823|t||||
17186287|NCT00791323|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17186288|NCT02235545|f||||f
17141753|NCT02899884|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141754|NCT02260804|f||OTHER|A confidentiality and non-disclosure agreement (CDA) was executed between Celltrion, Inc. and some PIs who have participated in publications funded by the sponsor for academic purposes for a period that is more than 180 days from the time submitted to the sponsor for review.|t
17141755|NCT02207413|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141756|NCT06212310|t||||f
17141757|NCT01018680|f||GT60||t
17141758|NCT02047929|t||||t
17186289|NCT03701295|f||LTE60||t
17141759|NCT02383966|f||OTHER||t
17141760|NCT02163759|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141761|NCT02032433|f||||f
17141762|NCT02696980|f||||f
17141763|NCT00846573|f||LTE60||t
17141764|NCT05732610|f||||f
17141765|NCT04717323|t||||
17141766|NCT00219349|f||||f
17141767|NCT05461742|t||||
17141768|NCT02777554|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141769|NCT00270205|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17141770|NCT00066573|t||||
17141771|NCT00869362|f||||f
17186290|NCT01464021|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186291|NCT04639193|t||||f
17186292|NCT01106430|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17186293|NCT01341977|f||OTHER|All data and discoveries arising out of the Study shall be the sole property of Alcon or its designated affiliate. Alcon reserves the right of prior review of any publication or presentation of the information related to the Study.|t
17186294|NCT02094443|f||OTHER||t
17186295|NCT01424930|f||GT60||t
17186296|NCT01078155|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186297|NCT03286751|f||GT60||t
17186298|NCT01621880|t||GT60||t
17186299|NCT01127646|f||GT60||t
17186300|NCT01662063|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186301|NCT01537302|f||OTHER|Following the earliest of (a)publication of results, (b)receipt of notice stating that Study has been terminated or (c)18 months after completion or termination, Institution/Investigator (IN) shall have right to publish information \& data collected or produced, provided that drafts are provided to Sponsor (SP) at least 60 days prior to the first submission. SP shall comment within 45 days. IN shall delay publication/presentation to enable SP to secure patent or other proprietary protection.|t
17186302|NCT02313909|f||OTHER|Global PI to provide to Bayer for review any proposed Publication/oral presentation relating to Study/Study Drug/Results at least 20 days prior to submission or presentation of the Publication. Abstracts/posters/oral presentations to be provided to Bayer 5 working days before Publication/presentation. Bayer may provide comments within the applicable period. Under certain circumstances Bayer may request a further delay of publications to avoid adverse effects on a Bayer patent application.|t
17186303|NCT01583686|f||||f
17186304|NCT00293267|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186305|NCT03086330|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17186306|NCT02360319|f||||f
17186307|NCT03581084|t||||
17141772|NCT01241591|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141773|NCT01945034|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141774|NCT03053102|f||||t
17141775|NCT01798056|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141776|NCT04070157|f||||t
17186308|NCT00834106|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17186309|NCT03477279|t||||
17186310|NCT01456299|t||||
17186311|NCT00525525|t||||
17186312|NCT02499679|f||LTE60||t
17186313|NCT05288660|f||||t
17186314|NCT04899245|t||||
17186315|NCT03088267|f||||f
17186316|NCT03899753|f||||f
17186317|NCT02257099|f||||f
17186318|NCT02620917|f||||f
17186319|NCT01398280|f||||f
17186320|NCT00057551|f||||f
17186321|NCT03371940|f||||f
17186322|NCT03531320|f||OTHER|There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17186323|NCT05099926|t||||
17186324|NCT02362048|f||||f
17186325|NCT00724152|f||||f
17186326|NCT00227617|t||||
17186327|NCT01160848|f||||f
17186328|NCT00031486|f||||f
17186329|NCT03685591|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186330|NCT01714804|f||OTHER|The Investigator may not submit the results of the study for publication, without the sponsor's prior permission.|t
17186331|NCT01685138|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17186332|NCT01542957|t||||
17186333|NCT02068495|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17186334|NCT00689026|t||||f
17186335|NCT04639128|t||||
17186336|NCT02703922|f||||f
17141777|NCT02842736|f||OTHER|Investigators have the right to publish their data, with the following provisions: (1) investigators at academic centers have a time frame for submission of their manuscript, or other, to Sponsor prior to publication and (2) investigators at private clinics can request prior written consent.|t
17141778|NCT00453336|t||||
17141779|NCT03323034|f||OTHER|Must obtain prior sponsor approval|t
17141780|NCT02646566|f||||f
17141781|NCT02815540|f||||f
17141782|NCT02660489|t||||
17141783|NCT04887922|t||||
17141784|NCT00718809|f||LTE60||t
17141785|NCT00463385|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17141786|NCT03078504|t||||
17141787|NCT01141569|f||LTE60||t
17141788|NCT00536991|t||||
17141789|NCT01600755|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication unless confidential information is disclosed and cannot extend the embargo.|t
17141790|NCT03464110|t||||
17141791|NCT00447265|f||||f
17141792|NCT02204449|t||||
17141793|NCT00503035|t||||
17141794|NCT03868410|t||||
17141795|NCT01059175|f||||f
17141796|NCT01363999|f||||f
17141797|NCT00643006|t||||f
17141798|NCT03471507|t||||
17141799|NCT01151085|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141800|NCT02103608|f||||f
17141801|NCT01308476|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17141802|NCT01811004|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17141803|NCT06104423|f||||t
17141804|NCT00750061|f||||f
17141805|NCT00812968|f||OTHER|Disclosure agreements vary; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17186337|NCT03934736|f||OTHER|If no multicenter publication has occurred within 18 months of the completion of this Study, Investigator shall have the right to publish or present independently the results of this Study. Investigator shall provide Dynavax with a copy of any such presentation/publication derived from the Study for review at least 30 days in advance of submission. Except for the Study Data, Dynavax reserves the right to delete any Intellectual Property or other confidential information of Dynavax.|t
17186338|NCT00394355|f||OTHER|Principal investigator (PI) agrees not to publish or publicly present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide to the sponsor, 30 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, PI agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues or disagreement.|t
17141806|NCT03986216|t||||
17141807|NCT03246152|t||||
17141808|NCT04435431|f||OTHER|Protection of potential intellectual property of the Sponsor.|t
17141809|NCT01243762|f||OTHER|The sponsor must review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation and can delete information identified as confidential prior to submission.|t
17141810|NCT02059265|f||LTE60||t
17141811|NCT01499498|t||||f
17141812|NCT03303144|f||GT60||t
17141813|NCT04753606|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide sponsor with an advance copy of any proposed communications at least 60 days prior and Sponsor shall have 60 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional period, not to exceed 90 days.|t
17141814|NCT01982539|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.|t
17141815|NCT03648073|f||||f
17141816|NCT03841331|f||GT60||t
17141817|NCT00683852|f||LTE60||t
17141818|NCT04145531|f||||f
17141819|NCT02985996|t||||
17141820|NCT01207219|t||||f
17141821|NCT00442572|f||OTHER|The study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17141822|NCT06016556|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141823|NCT00370994|t||||
17141824|NCT04246593|t||||
17141825|NCT01678586|f||||f
17141826|NCT03260699|f||||f
17186339|NCT00500903|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17186340|NCT05096156|f||||f
17186341|NCT00072761|f||||f
17186342|NCT01648348|f||LTE60||t
17186343|NCT02532556|t||||
17186344|NCT00696410|t||||f
17186345|NCT05340855|t||||
17186346|NCT01951638|f||||f
17186347|NCT01811212|f||LTE60||t
17186348|NCT02080780|f||LTE60||t
17186349|NCT00459342|f||LTE60||t
17186350|NCT02686034|f||LTE60||t
17186351|NCT00566579|t||||f
17186352|NCT03810534|t||||
17186353|NCT03586583|f||||f
17186354|NCT02243280|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186355|NCT02713711|f||||f
17186356|NCT00998400|f||||f
17186357|NCT01083641|f||||f
17186358|NCT03439189|f||||t
17186359|NCT01777321|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186360|NCT01807156|t||||
17186361|NCT03276637|t||||
17186362|NCT03122119|t||||
17186363|NCT00970216|f||||f
17186364|NCT01493687|f||OTHER|At least sixty (60) days prior to submission for publication, presentation or use, the Institution and the Investigator shall submit in writing to the Contract Research Organization and Sponsor for review and comment any proposed oral or written publication, which period may be extended for an additional thirty (30) days if requested in writing by Contract Research Organization and Sponsor.|t
17186365|NCT00705133|f||||f
17186366|NCT03135535|f||LTE60||t
17186367|NCT02364180|t||||
17186368|NCT00089141|f||||f
17186369|NCT00508261|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186370|NCT00180479|f||||f
17186371|NCT01478009|t||||f
17186372|NCT01798394|t||||
17186373|NCT01746095|f||||f
17186374|NCT00526630|f||||f
17186375|NCT01007656|f||||f
17186376|NCT03518125|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Data and results are owned by Sponsor. Results can be used by Institution for (a) internal non-commercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of Sponsor.|t
17186377|NCT02579876|f||||f
17186378|NCT00106184|f||||f
17186379|NCT01032733|f||||f
17186380|NCT02231177|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17186381|NCT00409682|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17186382|NCT01896869|f||OTHER|The Principal Investigators (PIs) from participating sites must provide the Johns Hopkins PI with a copy of any proposed publication for review and comment at least 30 days prior to submission.|t
17186383|NCT01691833|f||||f
17186384|NCT03319537|t||||
17186385|NCT00252538|t||||
17186386|NCT01089374|t||||
17186387|NCT02856113|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17186388|NCT03494166|f||||f
17186389|NCT02857426|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186390|NCT01155154|f||||f
17186391|NCT02110901|f||||f
17186392|NCT00758459|f||LTE60||t
17186393|NCT01238640|t||||
17186394|NCT01780935|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17141827|NCT00634933|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141828|NCT01049360|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the investigator and sponsor.|t
17141829|NCT02058849|f||||f
17141830|NCT00686894|f||OTHER|The PI agrees not to publish or publicly present any interim results of the study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication which report any results of the study. The sponsor shall have the right to review and comment on any presentation.|t
17141831|NCT02147132|t||||
17141833|NCT02191033|t||||f
17141834|NCT02222246|t||||
17141835|NCT02064231|t||||
17141836|NCT04621227|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141837|NCT01548573|t||||
17141838|NCT01249625|f||||f
17141839|NCT01366846|f||||f
17141840|NCT00558831|f||||f
17141841|NCT01342445|f||||f
17141842|NCT05299359|f||||t
17141843|NCT02392078|f||||f
17141844|NCT04961645|t||||
17141845|NCT02652793|f||||f
17141846|NCT02957149|t||||
17141847|NCT04579666|f||||t
17141848|NCT05450198|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17186395|NCT00855595|f||OTHER|A) Investigator shall provide Sponsor with intended publication 60 days upfront publication date, Sponsor has 30 d to comment, recommended changes shall not be unreasonably refused B) Sponsor has the right to ask Investigator to delay publication for a maximum of 90 days C) Investigative data will be pooled and published by Sponsor - no other publication without the consent of all parties prior to publication of the pooled data, or within 12 months after LPLV, whatever comes first|t
17186396|NCT00166296|f||||f
17141849|NCT04384120|f||||f
17186397|NCT04035200|f||||t
17186398|NCT00946296|f||||f
17186399|NCT04283448|f||||f
17186400|NCT02303184|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of Clearside.|t
17186401|NCT01422408|t||||
17186402|NCT03185481|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186403|NCT00701038|f||||f
17141850|NCT00005803|t||||
17141851|NCT04359758|f||||f
17141852|NCT01748162|t||||
17141853|NCT00505765|f||||f
17141854|NCT02743117|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17141855|NCT00766727|f||||t
17186404|NCT03365154|f||LTE60||t
17186405|NCT00386022|f||||f
17141856|NCT03532048|f||||f
17141857|NCT03948646|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied.|t
17141858|NCT01901393|f||||f
17186406|NCT03124979|t||||
17186407|NCT03371082|f||GT60||t
17186408|NCT01064297|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186409|NCT04475432|f||OTHER|It is specified in the protocol that the data generated in this clinical trial, all related information and any materials containing such data and information are the exclusive property of Tarsus Pharmaceuticals, Inc. and are confidential to Tarsus Pharmaceuticals. Also, the investigator or other study-related personnel may not disclose to anyone or use any data, information or materials related to this clinical trial without the express written consent of Tarsus Pharmaceuticals.|t
17141859|NCT04585906|t||||
17141860|NCT01694849|f||OTHER|All materials, information (oral or written) and unpublished documentation provided to the Investigators (or any company/institution acting on their behalf) are the exclusive property of the Sponsor and may not be given or disclosed, either in part or in whole, by the Investigator or by any person under his/her authority to any third party without the prior express consent of the Sponsor.|t
17141861|NCT02223520|t||||
17141862|NCT00596466|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141863|NCT00908375|t||||
17141864|NCT00752206|f||||f
17141865|NCT00678652|f||||f
17141866|NCT04717466|t||||
17141867|NCT05770401|t||||
17141868|NCT00402298|f||||f
17141869|NCT00480077|f||||f
17141870|NCT04784455|f||||f
17141871|NCT03550989|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17141872|NCT04298229|f||||f
17141873|NCT04881149|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17141874|NCT00262119|f||||f
17141875|NCT01683565|f||||f
17141876|NCT00071006|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141877|NCT00859313|f||OTHER|no publication without prior written consent|t
17141878|NCT05261126|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17141879|NCT03901274|f||||f
17141880|NCT05570604|f||||t
17141881|NCT04708223|f||LTE60||t
17141882|NCT00145119|f||||f
17141883|NCT04527380|f||GT60||t
17141884|NCT06241768|t||||
17141885|NCT03671746|f||||f
17141886|NCT05437211|f||||t
17141887|NCT02566304|f||||f
17141888|NCT02265874|f||||f
17141889|NCT00953173|f||||f
17141890|NCT03679117|f||||f
17141891|NCT02478281|f||||f
17141892|NCT00056472|f||||f
17141893|NCT00931515|f||OTHER|Research parties agree not to make any publications of results until notified in writing by Sponsor that study is complete and results published in peer-reviewed journal; however if not published within 18 months, Research parties may pursue publication of individual results. Research parties must submit communication to Sponsor for review/approval at least 30 days prior to submission. Sponsor can require the modification of the manuscript or delay of publication.|t
17141894|NCT02950831|f||||f
17141895|NCT03241485|t||||
17141896|NCT01066624|f||||f
17141897|NCT01875731|t||||
17141898|NCT00113321|t||||f
17186410|NCT04029129|f||||f
17186411|NCT00168038|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.|t
17186412|NCT01345630|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17141899|NCT01941472|t||||
17141900|NCT01375491|f||||f
17141901|NCT00478218|t||||
17141902|NCT01013207|t||||
17141903|NCT00808769|f||OTHER||t
17141904|NCT04158466|f||OTHER|Contact sponsor directly for details.|t
17141905|NCT03724422|t||||
17141906|NCT04196023|f||||f
17141907|NCT03358407|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141908|NCT03605758|t||||
17141909|NCT00489411|t||||
17141910|NCT01283009|t||||
17186413|NCT04233372|t||||
17141911|NCT04436497|t||||
17141912|NCT00694070|f||||f
17141913|NCT04640168|f||LTE60||t
17141914|NCT02866721|f||||f
17141915|NCT04366258|t||||
17141916|NCT00308555|f||||f
17141917|NCT00276458|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17141918|NCT00750373|f||||f
17141919|NCT02940392|f||||f
17141920|NCT02556112|f||||f
17141921|NCT00910000|f||LTE60||t
17141922|NCT03125382|f||||f
17141923|NCT02686749|f||||f
17141924|NCT02276274|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17141925|NCT05147311|t||||f
17141926|NCT02504099|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141927|NCT04505592|f||||f
17141928|NCT05240313|f||||f
17141929|NCT02648646|t||||f
17141930|NCT01015118|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17141931|NCT03522506|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17141932|NCT03480243|f||GT60||t
17141933|NCT01522755|f||||f
17141934|NCT02388906|f||LTE60||t
17141935|NCT04365387|f||||t
17141936|NCT05934591|f||||f
17186414|NCT01090310|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17186415|NCT00695786|t||||
17186416|NCT01364922|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186417|NCT02542839|f||||f
17186418|NCT02018445|f||GT60||t
17186419|NCT01787097|f||||f
17186420|NCT00949884|f||OTHER|"Sponsor reflects the following restrictive language in the Clinical Study Agreements: If identified by DSI, any of DSI's confidential information as defined herein shall be deleted…Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site."|t
17186421|NCT00944658|t||||
17186422|NCT01272960|f||||f
17186423|NCT00963911|t||||
17186424|NCT00297115|f||OTHER|The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.|t
17186425|NCT02832622|f||LTE60||t
17186426|NCT02472652|f||||t
17186427|NCT03704584|f||||f
17186428|NCT03185832|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17186429|NCT05067439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186430|NCT02323646|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review.The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17186431|NCT00521144|f||LTE60||t
17141937|NCT04410991|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17141938|NCT03282123|f||LTE60||t
17141939|NCT00938366|f||OTHER||t
17186432|NCT01370525|f||GT60||t
17186433|NCT01207570|f||||f
17186434|NCT01705496|f||GT60||t
17186435|NCT04280653|f||OTHER|After final publication or not published within 12 months following the conclusion of the last of the multi-center sites, and only with written consent of, and review and comment by, the Sponsor, any publication/lecture manuscripts proposed by the Study Center or the Investigator which are to make public any findings, data or results of the Study or any ancillary study must be submitted to the Sponsor for its review, and comment at least ninety days prior to submission for publication.|t
17186436|NCT01559948|f||||f
17186437|NCT05131165|f||||f
17186438|NCT01267292|t||||
17186439|NCT02298361|f||||f
17186440|NCT02459262|f||||f
17186441|NCT05168579|t||||
17186442|NCT01242748|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17186443|NCT00840801|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186444|NCT03724487|f||||f
17186445|NCT00715650|f||||f
17186446|NCT02416492|f||||f
17186447|NCT00508404|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186448|NCT01591382|t||||
17186449|NCT03170375|t||||
17141940|NCT01211405|f||LTE60||t
17141941|NCT01085331|f||OTHER||t
17186450|NCT00855062|f||||f
17141942|NCT04155567|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17141943|NCT01463631|f||GT60||t
17141944|NCT00740129|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186451|NCT00530062|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17186452|NCT01376323|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186453|NCT01960725|f||||f
17186454|NCT02634788|f||||f
17186455|NCT02831257|f||||f
17186456|NCT01281202|f||GT60||t
17186457|NCT03138733|f||GT60||t
17186458|NCT05107960|f||||t
17186459|NCT06289192|f||||f
17186460|NCT02440633|f||||f
17186461|NCT02003508|f||||f
17186462|NCT00490256|t||||f
17186463|NCT00438880|t||||
17186464|NCT00944047|f||||f
17186465|NCT02612064|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186466|NCT01669798|t||||f
17186467|NCT03125005|f||LTE60||t
17186468|NCT00717860|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17186469|NCT03538015|f||||f
17186470|NCT00698646|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186471|NCT00279201|f||GT60||t
17186472|NCT00316173|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186473|NCT02390531|f||||f
17186474|NCT00511875|t||||
17186475|NCT02618616|f||OTHER|The terms and conditions of the agreements with investigators may vary. However, the investigator is not prohibited from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186476|NCT04225988|f||||f
17186477|NCT00766675|f||LTE60||t
17141945|NCT06288607|t||||
17186478|NCT02240108|f||OTHER|Please contact Sponsor directly for additional information.|t
17186479|NCT03938454|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186480|NCT01142388|f||LTE60||t
17186481|NCT03027414|t||||
17186482|NCT01936896|f||||f
17186483|NCT04244396|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The data and results from the clinical investigation are the sole property of the Sponsor. The Investigators will not use this clinical investigation-related data without the written consent of the Sponsor for any purpose other than for clinical investigation completion."|t
17186484|NCT02597907|t||||
17186485|NCT00335452|f||OTHER|Publication of the study is made jointly in the name of all wholehearted collaborators. Other papers are authored based on the contributions of the individuals to the overall study. Sub-studies with scientific merit which have received prior approvals of the Steering Committee may be published separately in the names of contributing Investigators. A copy of all manuscripts are provided to the Sponsors for their review and the final decision to publish is made by the Steering Committee.|t
17186486|NCT01904864|f||||f
17141946|NCT05966129|t||||
17186487|NCT01163643|f||OTHER|Contact sponsor directly for details.|t
17186488|NCT00691808|f||OTHER|The sponsor requires that written permission be given before the investigator can release any data publicly.|t
17141947|NCT01298323|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17141948|NCT01795534|t||||
17141949|NCT04089566|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17186489|NCT03687190|f||||f
17186490|NCT01750879|f||||f
17141950|NCT01083121|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17141951|NCT02665273|t||||
17141952|NCT03378921|f||||f
17141953|NCT01958619|f||OTHER|After completion of the study, the Investigator may prepare a joint publication with MMV. The Investigator must undertake not to submit any part of the individual data from this protocol for publication without prior consent of MMV at a mutually agreed time. The confidentiality obligation applies to all personnel involved at the investigational site.|t
17141954|NCT00594009|t||||
17141955|NCT02396849|f||||f
17141956|NCT01315158|t||||
17141957|NCT03572153|f||||f
17141958|NCT03677440|f||||f
17141959|NCT01710839|t||||f
17141960|NCT04794491|f||||f
17141961|NCT00985114|f||||f
17141962|NCT01652040|f||||f
17141963|NCT01965600|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186491|NCT02421666|t||||f
17186492|NCT04647032|t||||
17186493|NCT03708588|t||||
17186494|NCT02093663|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17186495|NCT03662074|t||||
17186496|NCT01566331|f||||f
17186497|NCT03685396|t||||f
17186498|NCT01422135|f||OTHER|Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL15 study is required prior to publication submission.|t
17186499|NCT02162680|t||||
17186500|NCT00053495|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17186501|NCT02660801|f||||f
17186502|NCT02252432|f||||f
17186503|NCT02277990|f||OTHER|"In most cases, the contract allows the principal investigator to publish their data after release of a multi-center publication per the publication strategy following Medtronic's review for disclosure of confidential information (CI), technical correctness, disclosure of patentable or copyrightable material, and selection and order of publications by the publications committee. Any such CI and/or item identified as not technically correct is deleted prior to publication/presentation."|t
17186504|NCT04711603|f||||f
17186505|NCT04026529|t||||
17186506|NCT02969837|f||||f
17186507|NCT02098538|t||||
17186508|NCT04252742|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186509|NCT06199934|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186510|NCT04270747|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186511|NCT03459287|f||||f
17141964|NCT01255449|f||||f
17141965|NCT03418727|f||||f
17141966|NCT03145207|f||||t
17141967|NCT01979029|t||||
17141968|NCT04678557|f||||t
17141969|NCT00223990|f||||f
17141970|NCT01441882|t||||f
17141971|NCT01302366|t||||
17141972|NCT02010359|f||||f
17141973|NCT00509223|f||LTE60||t
17141974|NCT02513732|f||LTE60||t
17141975|NCT00467051|f||OTHER|Must obtain prior Sponsor approval.|t
17141976|NCT00934661|t||||
17141977|NCT01740297|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17141978|NCT03724305|f||||f
17141979|NCT05959564|t||||
17141980|NCT00761462|f||LTE60||t
17141981|NCT01479777|t||||
17141982|NCT00835861|f||||f
17141983|NCT02335229|f||GT60||t
17141984|NCT01541644|t||||
17141985|NCT01966458|f||OTHER|In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor's ability to obtain patent protection.|t
17186512|NCT01784068|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17186513|NCT05614089|t||||f
17186514|NCT05656040|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17186515|NCT01712477|t||||
17186516|NCT04176848|f||||f
17186517|NCT01849263|f||LTE60||t
17186518|NCT05701995|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186519|NCT04130802|f||OTHER|Investigator agrees not to publish/present the results until such time as the aggregate study results are published. After such time, Investigator may publish the results in accordance with the following: Investigator shall submit to Sponsor any such proposed publication/presentation resulting from or relating to the Study at least 60 days prior to the submission for publication. Sponsor may require the delay of publication/presentation for an additional period of time not to exceed 120 days.|t
17186520|NCT04987762|f||OTHER||t
17186521|NCT02044991|t||||
17186522|NCT02954523|t||||
17141986|NCT02389621|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17141987|NCT00940446|f||||f
17141988|NCT00437294|f||GT60||t
17141989|NCT00470301|f||LTE60||t
17141990|NCT01002118|f||||f
17141991|NCT02806700|f||||f
17141992|NCT00661037|f||||f
17141993|NCT02464176|t||||
17141994|NCT02277665|f||||f
17141995|NCT05292248|f||||f
17141996|NCT01255865|f||||f
17141997|NCT00953017|t||||
17141998|NCT01711424|t||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17186523|NCT00504426|f||||f
17186524|NCT03988166|f||LTE60||t
17186525|NCT03248375|t||||
17186526|NCT04992546|f||OTHER||t
17186527|NCT04506775|t||||f
17186528|NCT00633464|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186529|NCT04058353|f||OTHER||t
17186530|NCT01349920|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, and on the presentation with regard to the following: proprietary information; the accuracy of the information; and that the presentation is fairly balanced and in compliance with FDA regulations.|t
17186531|NCT00542880|f||OTHER|Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.|t
17186532|NCT00696384|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17186533|NCT04552743|f||||f
17141999|NCT01473602|f||GT60||t
17142000|NCT01055184|f||||f
17142001|NCT00449761|f||||t
17142002|NCT01969201|f||||f
17142003|NCT00344968|f||GT60||t
17142004|NCT03735680|f||||f
17142005|NCT01198327|f||||f
17142006|NCT01422876|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142007|NCT01905631|t||||
17142008|NCT03930524|f||||f
17142009|NCT00054639|f||LTE60||t
17142010|NCT00238108|t||||
17142011|NCT02192307|f||OTHER||t
17142012|NCT03541356|f||||f
17142013|NCT04645342|t||||f
17142014|NCT05028816|f||||f
17142015|NCT05064436|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17142016|NCT04552769|t||||
17186534|NCT02027402|t||||
17186535|NCT03513757|f||||f
17186536|NCT01949779|f||LTE60||t
17186537|NCT04251884|t||||
17186538|NCT04179721|t||||f
17142017|NCT01711736|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186539|NCT02624739|f||||f
17186540|NCT05361655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186541|NCT01984697|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17186542|NCT03308825|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17186543|NCT04737109|f||||f
17186544|NCT02259517|f||||f
17142018|NCT03113760|f||||t
17142019|NCT02506101|f||||f
17142020|NCT00003526|f||||f
17142021|NCT00779857|f||OTHER|The Sponsor can review communications prior to public release and can embargo communication regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the tim submitted to the sponsor for review. The sponsor can redact or modify the proposed publication to remove any language the sponsor believes would be detrimental to intellectual property or inaccurately reflect the results of the study.|t
17142022|NCT05059366|t||||
17142023|NCT00620776|f||||f
17142024|NCT01725217|f||LTE60||t
17142025|NCT03992456|t||||
17142026|NCT01977625|t||||
17186545|NCT01289418|f||||f
17186546|NCT03496974|f||OTHER|The Institution shall provide the Sponsor a copy of each proposed publication, abstract or presentation at least ninety days in advance for a proposed publication to a journal, editor or other third party. The Sponsor shall, within sixty days, advise Institution if there is any of the Sponsor's Confidential Information in proposed publication. Institution shall delete any of the Sponsor's Confidential Information prior to submitting and/or presenting.|t
17186547|NCT04682119|f||GT60||t
17186548|NCT03928028|f||||f
17186549|NCT02802501|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186550|NCT04669600|f||||t
17186551|NCT01544998|t||||
17142027|NCT04113746|f||||f
17142028|NCT02594384|f||||t
17142029|NCT02427568|f||||f
17142030|NCT04964960|t||||
17142031|NCT00483119|f||||f
17142032|NCT04668066|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186552|NCT00710606|f||||f
17186553|NCT02128646|f||||f
17186554|NCT00514683|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17186555|NCT02736825|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17142033|NCT00761085|t||||
17142034|NCT01195662|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17142035|NCT01215968|f||GT60||t
17142036|NCT02339246|f||GT60||t
17142037|NCT05643573|f||OTHER||t
17142038|NCT04768881|f||OTHER||t
17142039|NCT04049474|t||||
17142040|NCT01119118|t||||
17142041|NCT01593761|f||OTHER|"the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than or equal to 60 days but less than or equal to 120 days from the time submitted to the sponsor for review.~The sponsor can request to remove any confidential information (other than study results)."|t
17142042|NCT05689554|f||||f
17142043|NCT03446846|f||OTHER|PI agrees not to independently publish the results before the publication of the multi-center results. PI agrees to submit their proposed publication or presentation to Sponsor at least 2 months prior to disclosure. Sponsor may comment and may require deletion of trade secrets and proprietary or confidential information, other than study data.|t
17142044|NCT01012609|t||||
17142045|NCT01453296|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142046|NCT00615927|t||||f
17142047|NCT03557775|t||||
17142048|NCT02626910|f||||f
17142049|NCT03546270|t||||
17186556|NCT02943941|f||||t
17186557|NCT00790452|t||||f
17186558|NCT01564368|f||||f
17186559|NCT00832767|f||||f
17186560|NCT01373931|f||GT60||t
17142050|NCT01042288|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17142051|NCT03205046|f||||f
17186561|NCT04857034|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186562|NCT02940574|t||||f
17186563|NCT00387894|t||||f
17186564|NCT00659490|f||OTHER|AstraZeneca has exclusive rights to publish the results of the tudy|t
17186565|NCT01887470|f||||f
17186566|NCT00827541|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186567|NCT00520975|f||LTE60||t
17186568|NCT04810221|f||||f
17186569|NCT03642938|t||||
17142052|NCT01023815|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17142053|NCT01383759|t||||
17142054|NCT03253809|f||||t
17142055|NCT03919669|f||||f
17142056|NCT02319642|f||GT60||t
17142057|NCT03414658|f||||f
17142058|NCT00147290|f||||f
17142059|NCT05048875|f||||f
17142060|NCT04957979|f||||f
17142061|NCT02255422|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17186570|NCT00105235|f||||f
17186571|NCT01964326|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142062|NCT04411641|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142063|NCT03810417|f||||f
17142064|NCT03222570|t||||
17142065|NCT04828993|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142066|NCT01250418|f||||f
17186572|NCT01995539|f||GT60||t
17186573|NCT00261495|f||GT60||t
17142067|NCT01761565|f||OTHER|Sponsor must be able to review any publications prior to publication|t
17142068|NCT00104858|t||||
17142069|NCT05182840|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142070|NCT02161380|t||||f
17186574|NCT05383417|t||||
17186575|NCT03953898|f||LTE60||t
17186576|NCT01932697|t||||
17186577|NCT01119768|f||OTHER||t
17186578|NCT01059643|f||GT60||t
17186579|NCT03525548|f||||t
17186580|NCT02032212|f||||f
17186581|NCT00643123|t||||
17186582|NCT02923739|t||||
17142071|NCT00863265|f||||f
17186583|NCT02573402|t||||
17186584|NCT02623855|f||||f
17186585|NCT01059630|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186586|NCT03357614|f||OTHER|The PIs will provide Iterum opportunity to review proposed publication/other type of disclosure before it's submitted/otherwise disclosed. PI will provide manuscripts, abstracts, or full text of intended disclosure (poster, invited speaker presentation, etc) to Iterum at least 30 days before submitted for publication/otherwise disclosed. If any patent action is required to protect intellectual property rights, PI agrees to delay disclosure for a period not to exceed an additional 60 days.|t
17186587|NCT00763958|f||||f
17186588|NCT04681729|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142072|NCT02268214|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17142073|NCT04342390|f||||f
17142074|NCT03741335|f||||f
17142075|NCT04563039|f||GT60||t
17142076|NCT03447015|f||||f
17186589|NCT02470494|f||LTE60||t
17142078|NCT04103645|t||||
17142079|NCT04410978|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142080|NCT00318357|f||GT60||t
17142081|NCT04813484|t||||
17142082|NCT00948896|t||||
17142083|NCT03795233|t||||
17142084|NCT05403502|f||||t
17142085|NCT01054443|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17142086|NCT00409565|f||LTE60||t
17142087|NCT02159872|f||||f
17142088|NCT00516217|f||OTHER|Must obtain prior Sponsor approval.|t
17142089|NCT01003691|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142090|NCT00167414|t||||
17142091|NCT01869959|f||GT60||t
17142092|NCT07002632|t||||
17142093|NCT04479241|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo. The sponsor may request removal of confidential information that does not affect the complete and accurate presentation or interpretation of results.|t
17142094|NCT02576951|f||OTHER||t
17186590|NCT02535364|f||OTHER|Investigators have the right to publish and/or present study data after publication of the sponsor's multicenter study publication provided that the investigator shall (i) provide the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission; (ii) delete any confidential information of the sponsor; and (iii) delay submission for generally up to ninety (90) days to permit the sponsor to prepare and file intellectual property applications.|t
17186591|NCT02489110|t||||
17186592|NCT04766086|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186593|NCT03467932|f||GT60||t
17186594|NCT00723099|t||||
17186595|NCT02496767|f||||f
17186596|NCT02889133|t||||f
17186597|NCT05687032|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186598|NCT03821337|t||||
17186599|NCT05479604|f||||f
17186600|NCT05887947|f||||f
17142095|NCT00822237|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17142096|NCT01605539|f||LTE60||t
17142097|NCT00887965|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142098|NCT00968539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186601|NCT01678131|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17186602|NCT00112580|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186603|NCT03466918|f||OTHER|Without the Sponsor's prior written consent, the Principal Investigator shall not publish the clinical study results or any documents containing any Study information at any academic conferences or in any publications of any nature.|t
17186604|NCT05619003|f||||t
17186605|NCT03444376|f||||f
17186606|NCT04081220|t||||
17186607|NCT00685945|f||||f
17186608|NCT03183388|t||||
17142099|NCT00457249|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17142100|NCT00326118|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142101|NCT02916056|f||OTHER|Where PI requires the use of the Study Results for publication, the PI shall seek the Sponsor's written approval which shall not be unreasonably withheld; provided, however, that (i) Sponsor may require removal of any Confidential Information of Sponsor or may delay publication for a reasonable period of time in order to secure protection any IP Rights; and, (ii) as the Study is designed as a multi-center Study, no publication shall be made until after the first multi-center publication.|t
17142102|NCT00290511|t||||
17142103|NCT00122954|f||||f
17142104|NCT01683331|f||||f
17142105|NCT02406937|f||||f
17142106|NCT00526162|f||OTHER|In most cases, contracts allow investigators to publish study results per the publication plan/protocol following Medtronic's review to determine whether Confidential Information (CI) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred.|t
17142107|NCT05279807|f||LTE60||t
17142108|NCT05993299|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17142109|NCT03110107|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17142110|NCT03985982|f||||t
17142111|NCT03093480|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data|t
17142112|NCT03526549|f||||t
17142113|NCT00070070|f||||f
17142114|NCT03988049|f||||f
17142115|NCT05981365|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142116|NCT04780776|t||||
17142117|NCT03927989|f||||f
17142118|NCT03772574|f||||f
17142119|NCT02203305|t||||f
17142120|NCT03193996|f||||f
17142121|NCT04446182|t||||
17142122|NCT01005810|t||||
17142123|NCT00593385|f||OTHER|No publication or publicizing of data or results without the Sponsor's prior written permission. Party wishing to publish or publicize will submit proposed manuscript or publication to Sponsor for comment at least 60 days prior to release. Publishing party will make every reasonable attempt to incorporate comments received from Sponsor during 60 day period.The publishing party won't use Sponsor's confidential information in manuscript or publication without the prior written consent of sponsor.|t
17142124|NCT00348348|f||OTHER|Sponsor has 45 days to review materials and provide comments back to the investigator.|t
17142125|NCT01471197|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186609|NCT00847405|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17186610|NCT01728792|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17142126|NCT00924313|f||||f
17142127|NCT00659945|f||||f
17142128|NCT00326625|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17142129|NCT00491322|t||||
17142130|NCT01717521|t||||
17186611|NCT00071721|f||||f
17186612|NCT04277455|t||||
17142131|NCT05275673|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17186613|NCT00949715|f||LTE60||t
17186614|NCT04672096|f||||f
17186615|NCT02287350|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.|t
17186616|NCT03091673|f||||f
17186617|NCT01352585|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17186618|NCT00605202|f||||f
17186619|NCT02276066|f||||t
17186620|NCT05050578|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study,|t
17186621|NCT03386032|f||OTHER|The PI is employed by a contract research organization that is solely responsible for execution of the protocol. The contract research organization (and the PI) have signed a non-disclosure agreement, agreeing to keep all study-related information confidential. The Sponsor is responsible for data analysis.|t
17186622|NCT03364348|f||||f
17186623|NCT01042509|f||||f
17186624|NCT02710292|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17186625|NCT04525547|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17186626|NCT00800202|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186627|NCT04425902|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186628|NCT01920282|f||||f
17186629|NCT02803125|t||||
17186630|NCT01768832|f||||f
17142132|NCT02331680|f||||f
17142133|NCT03426995|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142134|NCT05939388|f||||f
17142135|NCT00602667|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17142136|NCT05153629|t||||
17142137|NCT04560088|f||||f
17142138|NCT00885677|f||||f
17142139|NCT00972309|f||||f
17142140|NCT02008396|f||GT60||t
17142141|NCT01233284|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17142142|NCT05405218|f||||f
17142143|NCT02218619|t||||
17186631|NCT02901626|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17186632|NCT00331344|f||LTE60||t
17186633|NCT05674890|f||||f
17186634|NCT02228967|f||||f
17186635|NCT00642902|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17186636|NCT01538472|t||||f
17186637|NCT02309112|f||||f
17186638|NCT03815019|f||||f
17186639|NCT03759834|t||||
17186640|NCT03937219|f||||t
17186641|NCT04803214|f||||f
17186642|NCT00985010|f||||f
17186643|NCT03764072|f||OTHER||t
17186644|NCT02498834|t||||f
17186645|NCT00558064|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17142144|NCT02996266|f||GT60||t
17142145|NCT05436067|t||||
17142146|NCT06212544|f||||f
17142147|NCT00157820|f||LTE60||t
17142148|NCT01721369|f||||f
17142149|NCT06768658|f||||t
17142150|NCT02263118|f||||f
17142151|NCT00563706|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142152|NCT03315780|f||GT60||t
17142153|NCT03839693|f||OTHER|Study Results are considered Confidential Information that may not be published or disclosed without Sponsor's written consent for a period of five (5) years after completion of the Study.|t
17142154|NCT02503215|f||||f
17186646|NCT04204200|f||||f
17186647|NCT03152084|f||OTHER|Study results are Sponsor's intellectual property and PIs cannot present or publish results without prior Sponsor approval.|t
17186648|NCT00982930|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186649|NCT00941798|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186650|NCT01489189|f||OTHER|Trial results can not be discussed until they have been made available to the public.|t
17186651|NCT05597722|t||||f
17186652|NCT04108000|t||||
17186653|NCT04411849|t||||
17186654|NCT03750006|t||||
17186655|NCT02417532|f||||f
17186656|NCT00811382|f||LTE60||t
17186657|NCT00140205|f||||f
17186658|NCT04226365|t||||f
17186659|NCT06412146|f||||f
17186660|NCT03881696|f||||f
17186661|NCT05690776|f||||f
17186662|NCT04082884|t||||
17186663|NCT01649232|t||||f
17186664|NCT02347657|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17186665|NCT00621543|f||||f
17186666|NCT02206217|f||||t
17186667|NCT02709005|f||LTE60||t
17186668|NCT03532308|t||||
17186669|NCT03720938|t||||
17186670|NCT00499863|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17186671|NCT00571701|f||||f
17186672|NCT01247428|f||LTE60||t
17186673|NCT01112228|t||||
17186674|NCT00829686|f||||f
17186675|NCT03351738|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17186676|NCT03997513|f||||f
17186677|NCT01375205|f||||f
17186678|NCT02192775|t||||
17186679|NCT03056534|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 90 days but less than or equal to 180 days from the time submitted to the sponsor for review. Sponsor may delay publication up to 180 days to permit the filing of appropriate patent applications if the sponsor believes any publication contains any information relating to patentable items and cannot extend the embargo.|t
17186680|NCT02063828|f||||f
17186681|NCT00532155|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 30 days in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed 90 days).|t
17186682|NCT03483038|t||||
17186683|NCT02134925|f||LTE60||t
17186684|NCT02492854|t||||
17186685|NCT01091948|t||||
17186686|NCT02158884|f||||f
17186687|NCT00462280|f||LTE60||t
17186688|NCT03210155|f||||f
17186689|NCT01313286|t||||
17186690|NCT02034708|f||OTHER|Each investigator agrees not to publish/present the results of the study main criterion involving only the patients included in his/her center. Publications on specific topics can be performed only after main publication.The sponsor can review the publication at least 30 days before the submission to the scientific review and any abstract project at least 10 working days before submission to the congress scientific committee. The sponsor can require changes to the publication or the abstract.|t
17186691|NCT00654901|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17186692|NCT00724464|f||OTHER|"The principal investigator agrees not to publish or publicly present any interim results of the Study without prior written consent of the SPONSOR. The principal investigator further agrees to provide forty-five (45) days written notice to the SPONSOR prior to submission for publication or presentation~to permit the SPONSOR to review copies of abstracts or manuscripts for publication which report any results of the Study. The SPONSOR shall have the right to review \& comment on any presentation."|t
17142155|NCT00299546|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142156|NCT03099265|t||||
17186693|NCT05741385|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17186694|NCT01089231|f||||f
17186695|NCT04278625|t||||
17186696|NCT04241094|t||||f
17186697|NCT00079001|f||OTHER|Must obtain prior Sponsor approval.|t
17186698|NCT02332590|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142157|NCT02526017|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial prior to submission for publication/presentation.|t
17142158|NCT00921934|f||||f
17142159|NCT03309072|f||||f
17186699|NCT00916032|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication of the main/primary endpoint or ≤24 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) prior to submission for publication, and shall review and if necessary amend the manuscript in ≤30 days|t
17186700|NCT01995487|f||||f
17186701|NCT04739761|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB.|t
17142160|NCT02674568|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142161|NCT00396318|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142162|NCT00938392|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142163|NCT00124709|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17142164|NCT01728376|f||||f
17142165|NCT00626574|f||||f
17142166|NCT03891602|t||||
17142167|NCT03491800|f||||f
17142168|NCT02303977|f||||f
17142169|NCT01256086|f||OTHER|INSTITUTION shall have the right to publish the results of its part of the study either independently or in collaboration with SPONSOR.In either case, INSTITUTION agrees to submit a copy of any manuscript and/or abstract to SPONSOR for review and comment sixty (60) days prior to its submission for publication. SPONSOR shall have said sixty (60) day period to respond to INSTITUTION with any requested revisions. INSTITUTION agrees to delete information identified by SPONSOR as confidential.|t
17142170|NCT04341727|t||||
17186702|NCT02584725|t||||
17186703|NCT01582789|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor. Assuming that the product is marketed, it is the intention of the sponsor to publish the results of the study.|t
17186704|NCT05377359|f||||f
17186705|NCT02012192|f||||f
17186706|NCT01746043|t||||f
17186707|NCT01191840|t||||
17142171|NCT05604521|f||OTHER|"(1) The principal investigator and associated institution are restricted from using the results of the study for commercial purposes; (2) the principal investigator is obligated to provide the Sponsor an opportunity to review planned disseminations of the data for confidential information that if present must be removed on Sponsor's request; (3) it is stipulated that communications such as publications and presentations should be joint."|t
17142172|NCT01491737|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142173|NCT04311411|f||LTE60||t
17142174|NCT01976663|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142175|NCT01817764|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142176|NCT04888377|f||||f
17142177|NCT05644756|f||||f
17142178|NCT02989623|f||||f
17142179|NCT04199312|f||||f
17142180|NCT00478933|f||GT60||t
17142181|NCT00617175|f||LTE60||t
17142182|NCT03586427|f||GT60||t
17142183|NCT00494234|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17186708|NCT01392300|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17186709|NCT02938169|f||||f
17186710|NCT01802437|t||||f
17186711|NCT03168295|t||||
17186712|NCT01342458|f||||f
17186713|NCT01682213|t||||
17186714|NCT00742079|t||||f
17186715|NCT01181726|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17142184|NCT00423137|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142185|NCT03478982|f||GT60||t
17142186|NCT01797458|t||||f
17142187|NCT02352831|t||||
17142188|NCT01298362|f||||f
17142189|NCT02980666|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142190|NCT00762073|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142191|NCT01293682|f||||f
17142192|NCT01265875|f||||f
17142193|NCT04456998|f||OTHER||t
17142194|NCT00400985|f||||f
17142195|NCT03142919|t||||
17142196|NCT03792633|f||LTE60||t
17142197|NCT05382637|t||||
17142198|NCT01714921|f||OTHER|The sponsor reviews publication within 3 weeks after submission of a manuscript. The sponsor can deny publication if the publication is not in accordance with the protocol, the publication would compromise business secrets or the issuing of patents or if the content of the publication is technically incorrect or may compromise other interests of the sponsor.|t
17142199|NCT03179462|t||||f
17142200|NCT00673712|f||||f
17142201|NCT03743571|f||||f
17142202|NCT04115488|t||||
17142203|NCT03884556|f||||f
17142204|NCT00352794|f||||f
17142205|NCT02630992|t||||
17142206|NCT01058707|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17142207|NCT04487886|t||||
17142208|NCT01821391|f||||f
17142209|NCT03832907|t||||
17142210|NCT00828009|f||LTE60||t
17142211|NCT04880850|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17142212|NCT03417102|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142213|NCT03285581|f||||f
17142214|NCT00526227|f||OTHER|In most cases, contracts allow investigators to publish study results per the publication plan/protocol following Medtronic's review to determine whether Confidential Information (CI) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred.|t
17142215|NCT03222856|f||||f
17142216|NCT03280628|f||||f
17142217|NCT01361308|f||OTHER||t
17142218|NCT01001195|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142219|NCT04524351|f||||t
17142220|NCT00700115|t||||f
17142221|NCT03965754|t||||
17142222|NCT02983305|t||||
17142223|NCT00706901|f||||f
17142224|NCT03433482|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17142225|NCT01646268|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17142226|NCT00906776|f||||f
17142227|NCT00461591|f||OTHER|First publication is the multi-center publication of Study results from all study sites. Other than the multi-center publication, site may publish an independent publication of data generated by site subject to Sponsor review rights (e.g., review for intellectual property, confidentiality).|t
17142228|NCT01519635|f||||f
17142229|NCT01300741|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17142230|NCT02325414|f||||f
17142231|NCT02544607|f||||f
17142232|NCT00560573|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142233|NCT01339273|t||||
17142234|NCT00726882|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186716|NCT01264380|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142235|NCT00347776|f||||f
17142236|NCT00594568|f||GT60||t
17142237|NCT04478994|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17142238|NCT01100073|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17142239|NCT00518531|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142240|NCT01656850|f||||f
17142241|NCT01939834|t||||
17142242|NCT01118949|f||GT60||t
17142243|NCT00795210|f||||f
17142244|NCT02850159|f||||f
17142245|NCT00602927|f||||f
17142246|NCT00296192|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17142247|NCT01741259|t||||f
17142248|NCT00057330|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142249|NCT03681769|f||||f
17142250|NCT02305329|f||OTHER||t
17142251|NCT03533829|f||||f
17142252|NCT03722849|t||||
17142253|NCT02354352|f||||f
17142254|NCT04633434|t||||
17142255|NCT03354143|t||||f
17142256|NCT00302068|t||||
17142257|NCT01993238|f||OTHER|Investigator shall notify Sponsor of the intent to publish or present independent Study Data, and agrees not to publish or publicly present and/or discuss such data, Investigator's current findings and/or the results of the Study independently without the express written consent of Sponsor, which consent may be withheld. Prior to submission for publication or presentation, all draft manuscripts must be submitted, reviewed and approved by Sponsor for confidential material.|t
17186717|NCT01147822|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186718|NCT01860586|t||||
17186719|NCT04382924|f||LTE60||t
17186720|NCT00530803|t||||
17186721|NCT02013388|t||LTE60||t
17186722|NCT00429663|f||||f
17186723|NCT04207840|f||||t
17186724|NCT03243422|t||||
17186725|NCT02466646|f||||f
17186726|NCT03261271|t||||
17186727|NCT02173054|f||||f
17186728|NCT01083654|t||||
17186729|NCT01559454|f||||f
17186730|NCT01114204|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17186731|NCT05582304|f||GT60||t
17142258|NCT02203604|t||||f
17142259|NCT04259905|f||||f
17142260|NCT01279265|f||||f
17142261|NCT02511587|t||||
17142262|NCT01958593|t||||
17142263|NCT01465048|t||||f
17186732|NCT01916655|t||||
17186733|NCT03420781|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17186734|NCT03036384|t||||
17186735|NCT00215540|t||||
17186736|NCT00817999|t||||
17186737|NCT00229957|f||||f
17186738|NCT00338598|t||||
17186739|NCT02799472|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186740|NCT01226511|f||GT60||t
17186741|NCT01222195|t||||
17186742|NCT00674570|t||||f
17186743|NCT01337986|f||GT60||t
17186744|NCT00141739|f||||f
17142264|NCT04882085|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142265|NCT05014672|f||||t
17142266|NCT00965562|f||||f
17142267|NCT00816166|f||LTE60||t
17142268|NCT02756182|f||||f
17142269|NCT03225313|t||||
17142270|NCT00308230|f||||f
17142271|NCT03722459|t||||
17142272|NCT05267652|t||||
17142273|NCT01608321|t||||f
17142274|NCT02062385|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17142275|NCT04502862|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142276|NCT04074109|f||||f
17142277|NCT04020822|f||GT60||t
17142278|NCT01319994|t||||
17142279|NCT01340794|f||LTE60||t
17142280|NCT03504839|f||||f
17142281|NCT00685763|t||||
17142282|NCT00698009|t||||f
17142283|NCT02060526|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142284|NCT03572049|f||||f
17142285|NCT00471237|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142286|NCT01510704|f||||f
17142287|NCT01605370|t||||f
17142288|NCT00627094|f||LTE60||t
17142289|NCT01040624|f||||f
17142290|NCT00585468|t||||
17142291|NCT01353586|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17142292|NCT00595946|f||GT60||t
17142293|NCT03056456|f||GT60||t
17142294|NCT04369885|t||||
17142295|NCT00380861|f||LTE60||t
17142296|NCT00943826|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142297|NCT00517868|f||||f
17142298|NCT02277548|t||||
17142299|NCT00625846|f||LTE60||t
17142300|NCT00807040|t||||
17142301|NCT00544713|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142302|NCT02234427|f||||f
17142303|NCT01870921|f||OTHER|At least sixty (60) days prior to submission of any material for publication or presentation, Institution shall provide AstraZeneca with such material for review. If requested in writing by AstraZeneca, Institution shall withhold material from submission for publication or presentation for an additional ninety (90) days to allow for the filing of a patent application or the taking of such measures as AstraZeneca deems appropriate to establish and preserve its proprietary rights.|t
17142304|NCT04409509|f||||t
17142305|NCT02279888|f||||f
17142306|NCT00227591|f||LTE60||t
17142307|NCT02335411|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17142308|NCT00389168|f||LTE60||t
17142309|NCT01891669|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142310|NCT02181075|t||||
17142311|NCT04150107|f||LTE60||t
17142312|NCT03091478|f||||f
17142313|NCT03075826|t||||
17142314|NCT00650806|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17142315|NCT03707145|t||||
17142316|NCT01883141|f||LTE60||t
17142317|NCT04636437|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17186745|NCT04461795|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to sponsor before submission. Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.|t
17186746|NCT00058422|t||||
17186747|NCT00185640|f||||f
17186748|NCT00548132|f||||f
17186749|NCT01520402|t||||
17186750|NCT04711356|f||||f
17186751|NCT01722162|t||||
17186752|NCT03124199|f||||f
17142318|NCT02851069|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142319|NCT05487625|f||||f
17142320|NCT00457795|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17142321|NCT00352664|t||||f
17142322|NCT02970877|f||||f
17186753|NCT04074590|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186754|NCT01355458|f||GT60||t
17186755|NCT00828308|f||||f
17186756|NCT00691132|f||||f
17186757|NCT01856530|t||||
17186758|NCT00361439|t||||
17186759|NCT00755040|f||||f
17186760|NCT02719990|f||OTHER|"US Sites:~Institution shall cause Principal Investigator to submit a complete copy of the proposed publication to Sponsor at least 60 days prior to presentation or submission to any third party.~Non-US sites:~The Investigator and the Institution agree that any proposed publication relating to the research and/or Study conducted under this Agreement will be submitted to Sponsor for review at least 90 days prior to submission for publication.~Additional agreement conditions apply."|t
17142323|NCT03075215|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Sponsor may extend the review period for another 90 days to take steps to protect its intellectual property interests, or to remove any language detrimental to Sponsor's intellectual property interests.|t
17142324|NCT02146365|f||||f
17142325|NCT01843660|f||OTHER|Disclosure restriction on the PI is that the PI should submit manuscript to the Sponsor for review no less than 60 days prior to public release. Only with written approval of the Sponsor, the results communications could be public released.|t
17142326|NCT01977482|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142327|NCT00209560|f||||f
17142328|NCT00795886|f||||f
17142329|NCT03826771|f||||f
17142330|NCT02500147|t||||
17142331|NCT05460832|f||OTHER|Clinical Trial Agreement|t
17142332|NCT05554471|f||LTE60||t
17142333|NCT03188991|f||||f
17142334|NCT00710840|t||||
17142335|NCT00544778|t||||
17186761|NCT02010632|f||||f
17186762|NCT00070135|f||LTE60||t
17186763|NCT00818961|f||||f
17186764|NCT03619590|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186765|NCT06387472|t||||
17186766|NCT02239380|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186767|NCT01061333|f||OTHER|For multicenter studies, subsequent to the multicenter publication, an investigator and colleagues may publish their data independently. Limitations of single site observations should always be described in such a manuscript. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17186768|NCT05650164|f||||t
17186769|NCT02044848|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17186770|NCT00045708|f||LTE60||t
17186771|NCT01679236|f||||f
17186772|NCT01266447|f||LTE60||t
17186773|NCT02597790|f||LTE60||t
17186774|NCT03237858|f||||f
17186775|NCT01160484|f||||f
17186776|NCT00803101|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186777|NCT01782742|t||||
17186778|NCT02623816|f||||f
17186779|NCT01679301|f||||f
17186780|NCT04858802|f||||f
17186781|NCT02026232|t||||
17186782|NCT01529008|f||||t
17186783|NCT02305381|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17186784|NCT04389333|t||||
17186785|NCT05056870|f||GT60||t
17186786|NCT05044325|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17186787|NCT02243202|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17186788|NCT02337517|f||LTE60||t
17186789|NCT00991341|f||||f
17186790|NCT00246337|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186791|NCT01966003|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186792|NCT00571961|f||||f
17186793|NCT03633929|f||||f
17186794|NCT03645967|f||LTE60||t
17142336|NCT00848965|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142337|NCT01976104|f||OTHER||t
17142338|NCT01317199|t||||
17142339|NCT01353209|f||||f
17142340|NCT01335620|t||||
17142341|NCT02951182|f||OTHER||t
17142342|NCT03112720|t||||
17142343|NCT02920866|t||||
17142344|NCT01312948|f||||f
17142345|NCT01301625|f||LTE60||t
17142346|NCT02686437|t||||
17142347|NCT03237325|f||||f
17142348|NCT02684370|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142349|NCT04221373|t||||
17142350|NCT00212446|f||||f
17142351|NCT01509638|f||||f
17142352|NCT00552422|t||||f
17142353|NCT01828164|f||LTE60||t
17142354|NCT03862469|f||||f
17142355|NCT00561600|f||LTE60||t
17142356|NCT00183170|f||||f
17142357|NCT00924820|t||||
17142358|NCT04983589|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142359|NCT00761969|f||||f
17186795|NCT01187914|f||||f
17186796|NCT01134601|f||||f
17142360|NCT00978120|f||||f
17142361|NCT03176953|t||||
17142362|NCT03668379|t||||f
17142363|NCT01068418|f||||f
17142364|NCT02181673|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17142365|NCT03155269|f||||f
17142366|NCT00138658|f||OTHER|"The sponsor can review proposed written or oral material which describes the results of the Study prior to public release and can embargo communications for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.~The results from one institution shall not be presented before the multi-center publication. If there is no multi-center publication within 12 months after the Study completion the Investigator shall have the right to publish the results."|t
17142367|NCT01354015|f||||f
17142368|NCT03733301|f||GT60||t
17142369|NCT04637815|f||||f
17142370|NCT00337727|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142371|NCT00320801|f||GT60||t
17142372|NCT00577031|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142373|NCT00323362|f||OTHER|The CINJ PI, and all co-authors, prior to submission or use, must review any abstract or manuscript.|t
17186797|NCT02287584|f||||t
17186798|NCT02269371|t||||
17186799|NCT01817374|f||||f
17186800|NCT03154281|t||||
17186801|NCT02884414|t||||f
17186802|NCT02798211|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17186803|NCT01982435|f||||f
17186804|NCT05292534|f||GT60||t
17186805|NCT04887948|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186806|NCT02167217|f||||f
17142374|NCT06067191|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142375|NCT04764669|f||||f
17142376|NCT04776135|f||OTHER||t
17142377|NCT01067339|t||||
17142378|NCT00890409|f||||f
17142379|NCT01783860|t||||
17142380|NCT00455923|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142381|NCT03992261|f||||f
17142382|NCT03099655|f||OTHER||t
17142383|NCT00769132|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142384|NCT02230332|f||||f
17142385|NCT02586909|f||||t
17142386|NCT00877799|f||LTE60||t
17142387|NCT04054011|f||||f
17142388|NCT00661960|f||||f
17186807|NCT03086018|t||||
17186808|NCT01782872|t||||
17186809|NCT01892345|f||OTHER|Publication rights are tied to the completion of the multi-center publication.|t
17186810|NCT00638235|f||LTE60||t
17186811|NCT02748694|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17186812|NCT01473381|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17186813|NCT04343586|f||||f
17186814|NCT01005303|t||||
17186815|NCT02487810|f||||f
17186816|NCT01889186|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186817|NCT01257880|f||||f
17186818|NCT03802864|t||||
17186819|NCT02569437|t||||
17186820|NCT00441701|f||OTHER|The investigator agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc.) that report any results of the study.|t
17186821|NCT00077064|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17186822|NCT05028426|t||||
17186823|NCT04710927|t||||
17186824|NCT03155932|f||||f
17142389|NCT00557830|f||OTHER|Prior to publication or presentation of Sponsored Research results, Researcher agrees to provide Bayer with such presentation, abstract, or manuscript at least 30 days prior to its presentation or submission for the sole purpose of allowing Bayer to redact confidential information and protect any existing or future patients. The Principal Investigator shall acknowledge Bayer contributions where appropriate.|t
17142390|NCT00552812|t||||f
17142391|NCT01833897|f||||f
17142392|NCT00669110|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142393|NCT00127192|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142394|NCT04762771|t||||
17186825|NCT03607825|f||OTHER|PI agrees that first publication of the results of the Study shall be made in conjunction with the presentation of a joint multi-center publication. PI may publish individually if multi-center publication is published, or no multi-center publication is published within 12 months of conclusion, or Sponsor confirms in writing there will be no multi-center publication. If no multi-center publication within 12 months, Sponsor will provide PI access to aggregate data.|t
17186826|NCT02007434|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17186827|NCT01287611|f||||f
17186828|NCT01856712|t||||
17186829|NCT02192970|t||||
17186830|NCT01321541|f||||f
17186831|NCT06097676|f||||f
17186832|NCT03299686|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17186833|NCT03745222|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17186834|NCT01959347|f||||f
17142395|NCT00077766|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142396|NCT01886105|f||||f
17142397|NCT03843775|t||||
17142398|NCT04455620|f||OTHER|Principal Investigators respectively study sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17142399|NCT04678440|f||||f
17142400|NCT03539952|f||||f
17142401|NCT00540982|t||||
17142402|NCT02087865|f||||f
17142403|NCT01392469|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17142404|NCT01568255|t||||f
17142405|NCT03255226|f||||f
17142406|NCT01035229|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17142407|NCT00511329|t||||
17142408|NCT01628159|f||||t
17142409|NCT00564486|f||OTHER|Institution or Investigator may publish the results of the study (without raw data, detailed patient Case Report Forms, or patient identification) only after such cooperative publication, or 18 months after Cadence's final evaluation of all study data from all sites, whichever occurs first. At least 60 days prior to submission, or prior to any public presentation, a copy of the abstract, manuscript or presentation will be provided to Cadence who will have 60 days to respond with comments.|t
17142410|NCT02195921|f||||f
17142411|NCT03862807|f||OTHER|It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A separate publication by Institution or PI may not be submitted for publication until after this primary manuscript is published or following 12 months after completion of the study. A copy of any proposed publication based on this study, must be provided and confirmed received at the Sponsor at least 30 days before its submission.|t
17142412|NCT04362761|f||||t
17142413|NCT00684645|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142414|NCT01771627|t||||
17142415|NCT03486327|f||||t
17142416|NCT03126682|t||||
17142417|NCT02682069|f||||f
17142418|NCT02856282|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142419|NCT02074982|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17142420|NCT03065517|f||||f
17142421|NCT02513095|f||OTHER|The PI has no right to discuss/publish/disclose the trial data.|t
17142422|NCT02786810|f||||f
17142423|NCT03305159|t||||
17142424|NCT00798707|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142425|NCT04476654|f||||f
17142426|NCT02525627|f||LTE60||t
17142427|NCT03746080|t||||
17142428|NCT02094573|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17142429|NCT01473589|f||GT60||t
17186835|NCT03954743|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17186836|NCT01923805|t||||f
17186837|NCT00860067|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17186838|NCT01282801|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17186839|NCT00560612|t||||
17186840|NCT02387996|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17186841|NCT01060553|t||||
17186842|NCT03160287|f||||f
17186843|NCT00632281|t||||
17186844|NCT04707196|f||GT60||t
17186845|NCT01862796|t||||
17186846|NCT02481375|f||||f
17186847|NCT04037436|f||||f
17186848|NCT03338621|f||OTHER|"Institution and Principal Investigator shall not publish, present or use the Study Data for its own instruction, research or publication without the prior express written consent of Sponsor. Because the Study is funded, in whole or in part, by the Bill and Melinda Gates Foundation (the Foundation), all peer-reviewed published research relating to the Study must comply with the Foundation's Open Access Policy."|t
17186849|NCT00989586|t||||
17186850|NCT02037438|f||||f
17186851|NCT02255032|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of Clearside.|t
17186852|NCT05375955|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186853|NCT01320943|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17186854|NCT00733980|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186855|NCT00779779|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186856|NCT00404495|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186857|NCT00278538|t||||f
17186858|NCT01493960|f||||f
17186859|NCT00249249|f||GT60||t
17186860|NCT00975221|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186861|NCT05418777|t||||
17186862|NCT03935217|f||||f
17186863|NCT03559218|f||||f
17186864|NCT02882711|t||||
17186865|NCT02790073|f||LTE60||t
17142430|NCT03256526|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclosure previously undisclosed confidential information other than study results.|t
17142431|NCT01160770|f||OTHER|The sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17142432|NCT00566969|f||||f
17142433|NCT01513759|f||GT60||t
17142434|NCT03606109|t||||
17142435|NCT03669640|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142436|NCT05553600|f||OTHER||t
17142437|NCT00665704|t||||f
17142438|NCT04242264|f||||t
17142439|NCT02384200|f||||f
17186866|NCT02357290|t||||
17186867|NCT03921346|f||||f
17186868|NCT02487498|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17186869|NCT03171480|t||||
17186870|NCT00676130|t||||
17186871|NCT00755222|f||OTHER|"Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not preceed the primary publication of the entire clinical trial."|t
17186872|NCT01861574|f||||f
17142440|NCT00556972|f||LTE60||t
17142441|NCT02116309|f||||f
17142442|NCT03710824|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142443|NCT02329834|f||||f
17142444|NCT00578448|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17142445|NCT03864406|t||||
17142446|NCT05102162|f||||f
17142447|NCT01165424|f||OTHER|The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, reveiw copies of abstracts or manuscripts for publication that report any results of the trial. The Sponsor shall have the right to reveiw and comment with respect to publications, abstracts, slides, and manuscripts and the right to reveiw and comment on the data analysis and presentation.|t
17142448|NCT00538473|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142449|NCT00440193|f||LTE60||t
17142450|NCT03107442|f||||f
17142451|NCT04616768|f||||f
17142452|NCT02061293|t||||
17142453|NCT02184988|f||||f
17142454|NCT02262507|f||||f
17142455|NCT01852669|f||||f
17142456|NCT05376293|f||||f
17142457|NCT00379821|f||LTE60||t
17142458|NCT00690573|f||OTHER|Disclosure agreements vary; the Medical Institution shall not disclose any material/information disclosed by Abbott Japan in connection with the Clinical Research or information obtained by conducting the Clinical Research to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting Clinical Research, Institution shall obtain Abbott Japan's prior written approval.|t
17142459|NCT01283282|t||||
17142460|NCT00777920|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17142461|NCT00483717|f||||f
17142462|NCT03878108|t||||
17142463|NCT01682681|f||OTHER|PI cannot provide any trial related information to external parties' without mutual agreement with the Sponsor. This is valid even after the contract is canceled.|t
17142464|NCT00975000|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142465|NCT01525407|t||||
17142466|NCT01819467|t||||
17142467|NCT01441401|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142468|NCT02875340|f||||t
17142469|NCT00896038|t||||
17142470|NCT01607398|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142471|NCT03457727|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142472|NCT00929201|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142473|NCT02384239|t||||
17142474|NCT01299272|f||GT60||t
17142475|NCT00464308|f||GT60||t
17142476|NCT00630994|t||||
17142477|NCT03533608|t||||
17142478|NCT03286426|f||||f
17142479|NCT03514121|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186873|NCT05599269|t||||
17186874|NCT01751230|f||||f
17186875|NCT02659787|t||||
17186876|NCT00582946|t||||
17186877|NCT02401464|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17142480|NCT01900392|f||||f
17142481|NCT03286400|f||||t
17142482|NCT00514709|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17142483|NCT00826176|f||OTHER|Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.|t
17142484|NCT01687400|t||||
17142485|NCT03731325|f||||f
17142486|NCT02530320|f||||f
17142487|NCT00297882|f||||f
17142488|NCT04484805|t||||
17142489|NCT02525575|t||||
17142490|NCT04139642|f||||f
17142491|NCT03910439|f||||f
17142492|NCT00433771|f||||f
17142493|NCT03952377|f||||f
17142494|NCT00539006|f||||f
17142495|NCT02353572|t||||
17142496|NCT00258310|t||||f
17142497|NCT00256217|t||||
17142498|NCT03733418|f||||f
17142499|NCT01139801|f||||f
17142500|NCT00722007|f||OTHER|The sponsor will review publications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. If the sponsor determines the publication contains patentable subject matter the embargo can be extended up to 120 days from the time submitted to the sponsor for review. The PI shall agree to accept the sponsor's reasonable comments and suggestions with respect to publications.|t
17142501|NCT01036594|t||||
17142502|NCT02989922|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17142503|NCT01244516|f||OTHER|Publication required agreement and written authorization from the Sponsor.|t
17142504|NCT01700335|f||||f
17142505|NCT03387267|f||||t
17186878|NCT00864708|f||OTHER|"Principal Investigators are employed by the Department of Veterans Affairs (DVA) which funded the study; the Alfred P. Mann Foundation (AMF) provided the technology that was tested.~There was an agreement between the Principal Investigators of the DVA and the AMF that the AMF would be provided a period of time to review any manuscript for publication and provide input. There was no restriction regarding PI's rights to discuss or publish the results."|t
17186879|NCT01330316|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17186880|NCT03010462|f||||f
17186881|NCT02207725|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization.|t
17186882|NCT03145766|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17186883|NCT00431184|f||||f
17186884|NCT01391325|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17186885|NCT01492686|f||OTHER||t
17186886|NCT03215901|t||||f
17186887|NCT03863522|t||||
17186888|NCT00304512|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17186889|NCT04026165|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17186890|NCT02255357|t||||
17186891|NCT05061537|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186892|NCT03315936|t||||
17142506|NCT00941681|f||OTHER|Sponsor intends to publish the results of the trial in collaboration with the Investigators.|t
17142507|NCT00244881|f||LTE60||t
17142508|NCT03664024|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17142509|NCT03159611|f||||t
17142510|NCT00357734|f||LTE60||t
17142511|NCT02057549|t||||f
17142512|NCT01418365|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142513|NCT03226366|t||||f
17142514|NCT03319368|f||||f
17142515|NCT03000075|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142516|NCT00003726|t||||f
17142517|NCT02212834|f||||f
17142518|NCT02222168|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142519|NCT00530621|f||GT60||t
17142520|NCT03409328|t||||
17186893|NCT01674621|f||OTHER|Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/\> 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/\> 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.|t
17186894|NCT01859793|f||||f
17186895|NCT01735396|t||||
17186896|NCT01148862|f||||f
17186897|NCT02939300|t||||
17186898|NCT03724396|t||||f
17186899|NCT05158296|f||OTHER|Institution shall be free to publish, present, or use any Data and results arising out of its performance of the protocol. At least 30 days prior to submission for publication, institution shall submit to Sponsor for review and comment any proposed oral or written publication. Institution will consider any such comments in good faith but is under no obligation to incorporate Sponsor's suggestions. The review period for abstracts or poster presentations shall be 30 days.|t
17186900|NCT02404389|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17186901|NCT00335257|t||||
17186902|NCT03020225|f||||f
17186903|NCT00652938|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186904|NCT01412801|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186905|NCT02978443|t||||
17186906|NCT01547299|f||OTHER|PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.|t
17186907|NCT01987817|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17186908|NCT01576718|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17186909|NCT01336621|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186910|NCT01742364|f||LTE60||t
17186911|NCT00682643|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186912|NCT03482505|f||GT60||t
17186913|NCT01870388|f||GT60||t
17186914|NCT00263328|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186915|NCT00622180|t||||
17186916|NCT02280239|f||||f
17186917|NCT04512066|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186918|NCT01833143|t||||
17186919|NCT03995784|f||||f
17186920|NCT02907814|t||||
17186921|NCT00834808|f||OTHER|The publication of the results obtained will be authorized, after prior agreement between the various recipients \[investigator and sponsor\].|t
17186922|NCT00583622|t||||f
17186923|NCT00284141|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17186924|NCT00332332|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17186925|NCT01108458|f||||f
17186926|NCT01382602|f||||t
17186927|NCT04170686|f||||f
17186928|NCT03328143|f||||f
17186929|NCT02801669|f||||f
17186930|NCT02696564|f||||f
17186931|NCT01105702|t||||
17186932|NCT00615264|f||OTHER|Investigator shall submit any paper or presentation to the Sponsor for review and comments at least 60 days prior to submitting the same to a third party. Upon receiving any request from the Sponsor to delete any Confidential Information or request to delay in publication up to 90 days to allow the filing of any Sponsor application, the Investigator shall take the request action. Investigator shall not be restricted after 18 months from completion of their site's performance in the study.|t
17142521|NCT02596009|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17186933|NCT03430063|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17186934|NCT01488708|f||GT60||t
17186935|NCT04219618|t||||
17186936|NCT02228395|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186937|NCT00985985|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186938|NCT00509236|f||OTHER|Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or colleagues may publish the results for their study site independently. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17186939|NCT00792103|f||OTHER|Per the study agreement, Investigators have the right to publish or present information and/or data arising from the study, provided the text of any such publication or presentation is submitted for review at least thirty days prior to submission for publication or other disclosure and NuPathe shall have the right to request the removal of any confidential information.|t
17186940|NCT03587142|f||||f
17186941|NCT02768662|f||LTE60||t
17186942|NCT03673462|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17186943|NCT03502616|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17186944|NCT02924324|t||||
17186945|NCT00628901|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to remove any confidential information or other proprietary information of Sponsor.|t
17186946|NCT00770432|f||OTHER||t
17186947|NCT01364597|f||GT60||t
17186948|NCT01498822|f||GT60||t
17186949|NCT04203537|f||GT60||t
17186950|NCT03579290|t||||
17186951|NCT01566630|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17186952|NCT03131960|f||||f
17186953|NCT01625923|f||||f
17186954|NCT04404478|f||||f
17186955|NCT02904902|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17186956|NCT02413463|f||||f
17186957|NCT02002182|t||||
17186958|NCT00125593|t||||
17186959|NCT01597505|f||||f
17186960|NCT05261191|f||GT60||t
17186961|NCT00895622|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17186962|NCT01490125|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17186963|NCT04616014|f||GT60||t
17186964|NCT02237508|f||||f
17186965|NCT04954586|f||||f
17186966|NCT04000594|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17186967|NCT04522180|f||OTHER|Principal investigators are not employees of Ionis Pharmaceuticals. Work with CDT to establish the Principal Investigator agreement.|t
17186968|NCT01905046|f||||f
17186969|NCT06334042|t||||
17186970|NCT04571099|f||||f
17142522|NCT00518011|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142523|NCT03930615|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17142524|NCT04828551|f||||f
17142525|NCT01153685|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142526|NCT04190056|t||||
17186971|NCT03489057|f||||f
17186972|NCT03267680|t||||
17186973|NCT01368900|f||||f
17186974|NCT01786902|f||||f
17186975|NCT04027348|t||||
17186976|NCT02487472|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17186977|NCT02277743|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17142527|NCT01281475|f||||f
17142528|NCT02080273|f||||f
17142529|NCT04797637|f||||f
17142530|NCT01419028|f||OTHER|Participation in a multicenter study involves a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis. Therefore, PIs are subject to certain disclosure and publication limitations.|t
17142531|NCT00741026|f||||f
17186978|NCT01224158|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17186979|NCT01622010|t||||f
17186980|NCT02055157|t||||
17186981|NCT03976466|f||||f
17186982|NCT00733499|f||OTHER|DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but the PI will retain final editorial control.In case of disagreement,DePuy and the PI will make every effort to meet in order to discuss and resolve any issues.|t
17186983|NCT01552954|f||||f
17186984|NCT03929562|t||||
17186985|NCT04843930|t||||f
17186986|NCT01931735|t||||
17186987|NCT00947661|f||OTHER||t
17186988|NCT00586170|f||||f
17186989|NCT03034018|t||||
17186990|NCT02552238|f||||f
17186991|NCT02036645|f||||f
17186992|NCT01778556|t||||
17186993|NCT03188120|t||||f
17186994|NCT00782496|f||LTE60||t
17186995|NCT01481545|t||||
17142532|NCT03781817|f||||f
17142533|NCT01736527|t||||
17142534|NCT00648739|f||||t
17186996|NCT00584402|f||LTE60||t
17186997|NCT03571737|t||||
17186998|NCT01874145|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17186999|NCT02178566|t||||
17187000|NCT02934620|f||||f
17187001|NCT02070484|f||||f
17187002|NCT01474213|t||||
17187003|NCT02658630|t||||
17187004|NCT03238300|t||||
17187005|NCT04064242|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187006|NCT03520400|t||||
17187007|NCT01654601|f||||f
17187008|NCT04398537|f||||f
17187009|NCT00201864|t||||
17187010|NCT00299000|f||OTHER|The first publication of the results shall be made by the Sponsor in a joint publication. If such a multicenter publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from site individually, subject however to comply with the other terms of the agreement.|t
17187011|NCT02412501|f||OTHER||t
17187012|NCT02760056|t||||
17187013|NCT01909570|t||||f
17187014|NCT01862991|f||||f
17187015|NCT02348684|t||||
17187016|NCT01572389|f||||f
17187017|NCT01287520|f||GT60||t
17187018|NCT00708435|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187019|NCT02352363|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17187020|NCT01737684|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication or presentation.|t
17142535|NCT02712359|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17142536|NCT00242567|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17142537|NCT01721200|f||||f
17142538|NCT01107834|f||||f
17142539|NCT02729545|t||||
17142540|NCT01064830|f||||f
17142541|NCT04930536|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17142542|NCT01432600|t||||
17142543|NCT01387672|f||||f
17142544|NCT01150409|t||||
17142545|NCT03079869|t||||
17142546|NCT02411110|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142547|NCT03292731|f||||f
17142548|NCT00944528|t||||
17142549|NCT03901352|f||||f
17142550|NCT00186875|t||||
17142551|NCT00029107|t||||
17142552|NCT02871921|f||||f
17142553|NCT00535873|t||||
17142554|NCT01267227|f||OTHER|Disclosure of the submitted materials approved per contractual agreement.|t
17142555|NCT00824993|t||||
17142556|NCT02998645|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17142557|NCT03506724|t||||
17142558|NCT04611152|f||||t
17142559|NCT03644927|t||||
17142560|NCT00956813|f||LTE60||t
17142561|NCT05444114|f||||f
17142562|NCT04736316|f||||f
17142563|NCT01275170|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17142564|NCT02864953|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17142565|NCT03752866|f||LTE60||t
17142566|NCT01023022|f||LTE60||t
17187021|NCT01691521|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187022|NCT04503096|t||||
17187023|NCT01480596|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142567|NCT03917654|t||||
17142568|NCT04686500|t||||
17187024|NCT01581840|f||||f
17187025|NCT02343003|f||||f
17187026|NCT01299090|f||||f
17142569|NCT00905437|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142570|NCT05794126|f||||t
17142571|NCT03128931|f||GT60||t
17142572|NCT03252015|t||||
17142573|NCT01329562|f||||f
17142574|NCT03628872|t||||f
17142575|NCT00061568|t||||
17142576|NCT00790270|t||||
17142577|NCT01071278|f||OTHER|MSD SHARP \& DOHME GmbH and its comarketing companies have exclusive rights to the use and evaluation of the data collected in this study.|t
17142578|NCT00903409|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142579|NCT00797316|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17142580|NCT01516684|t||||
17142581|NCT03239340|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17142582|NCT04933708|t||||
17142583|NCT01497860|f||||f
17142584|NCT04066894|t||||
17142585|NCT03494816|f||||f
17142586|NCT00314262|t||||
17142587|NCT01126359|t||||
17142588|NCT00902486|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study; provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17142589|NCT02332655|f||||f
17142590|NCT03505606|t||||
17142591|NCT01140815|f||GT60||t
17142592|NCT02284880|f||OTHER||t
17142593|NCT00584831|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17142594|NCT01808508|t||||
17142595|NCT01017731|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17142596|NCT05378269|f||OTHER|PI is not able to publish study data without prior approval from Sponsor.|t
17142597|NCT00359073|t||||f
17142598|NCT02238639|f||LTE60||t
17142599|NCT03387423|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142600|NCT01371006|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142601|NCT03926728|f||||f
17142602|NCT02056431|f||||f
17142603|NCT01956123|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17142604|NCT00398632|f||||f
17142605|NCT02118896|f||OTHER|All information obtained during the conduct of the study is regarded as confidential. Agreement from the sponsor is required prior to disclosing any information relevant to the study.|t
17142606|NCT02912507|f||||f
17142607|NCT02050373|f||||f
17142608|NCT03046966|t||||f
17142609|NCT00572910|f||||f
17142610|NCT00194116|f||||f
17142611|NCT02148835|f||||f
17142612|NCT00592007|t||LTE60||
17142613|NCT01341067|f||||f
17142614|NCT00759668|f||OTHER|Any formal presentation of data publication from this study has to be a joint presentation from both the Investigators and the Sponsor. Being the study multicentric, it is mandatory that the first publication is based on data from all the centres, analysed according to the protocol. Data from a single Centre can not be presented, unless there is a formal agreement from the other Investigators and Alcon.|t
17142615|NCT01569074|f||GT60||t
17142616|NCT01803464|f||||f
17142617|NCT02424851|t||||
17142618|NCT01410565|f||||f
17142619|NCT02860039|f||||f
17142620|NCT01360021|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than less than or equal to 180 days from the date of AZ's request to allow for the filing of a patent app or the taking of such measures as AZ deems appropriate to establish and preserve its proprietary rights in teh material being submitted.|t
17142621|NCT02446496|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142622|NCT01257737|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights.|t
17187027|NCT01153269|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17187028|NCT00818363|f||||t
17187029|NCT00988221|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187030|NCT00633919|f||OTHER|ALK must receive copies of any intended communication in advance of publication (at least 15 working days for an abstract or oral presentation and 45 working days for a journal submission). ALK will review the communications for accuracy (thus avoiding potential discrepancies with submissions to health authorities), verify that confidential information is not being inadvertently divulged and provide any relevant supplementary information.|t
17142623|NCT01143610|t||||f
17142624|NCT00124579|f||||f
17142625|NCT03170271|f||||t
17142626|NCT02466776|t||||
17142627|NCT04935931|t||||
17142628|NCT05168657|f||||f
17142629|NCT01638416|f||||f
17142630|NCT00424632|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187031|NCT02756832|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187032|NCT01781390|f||OTHER|Publications (abstracts, posters or presentations) must be presented to Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection.|t
17187033|NCT04750655|t||||
17187034|NCT01216163|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187035|NCT03879408|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17187036|NCT00728962|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17187037|NCT05807919|t||||
17142631|NCT01984229|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142632|NCT00937859|f||||t
17142633|NCT02325739|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17142634|NCT03186794|t||||
17142635|NCT02139969|f||||f
17142636|NCT02380248|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17142637|NCT03728257|t||||
17142638|NCT04176354|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142639|NCT00621309|f||||f
17142640|NCT01187511|t||||f
17142641|NCT01306968|f||||f
17142642|NCT04993339|t||||
17142643|NCT02925650|f||||f
17142644|NCT01526629|f||||f
17142645|NCT03868059|f||||t
17142646|NCT02949219|f||||t
17142647|NCT01121224|t||||
17142648|NCT02689973|t||||
17142649|NCT03712462|f||||f
17142650|NCT01205568|f||||f
17142651|NCT04800510|t||||
17142652|NCT02044094|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17142653|NCT03515681|t||||
17142654|NCT03353415|f||||f
17142655|NCT02392377|t||||
17142656|NCT00939367|f||OTHER||t
17142657|NCT01298661|f||||f
17142658|NCT03515837|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17142659|NCT01964898|f||||f
17142660|NCT02325401|f||||f
17142661|NCT03526679|f||||f
17142662|NCT02545868|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142663|NCT01932801|f||||f
17142664|NCT04465916|f||OTHER|The data may be considered for publication in a scientific journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data pertaining to the study confidential. The Investigator must consult with the Sponsor before any study data are submitted for publication. The Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.|t
17142665|NCT00448630|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187038|NCT01557322|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187039|NCT02247336|t||||
17187040|NCT02739347|f||LTE60||t
17187041|NCT01986101|f||||t
17187042|NCT03324880|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187043|NCT03300570|f||LTE60||t
17187044|NCT00116272|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17187045|NCT00920023|f||||f
17187046|NCT01235403|f||GT60||t
17187047|NCT04859660|t||||
17187048|NCT02296190|f||||t
17142666|NCT00468312|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's represnetatives will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17142667|NCT01052038|t||||
17142668|NCT03976076|f||OTHER||t
17142669|NCT01325701|f||||f
17142670|NCT00869141|f||||f
17142671|NCT00254488|t||||
17142672|NCT01053078|f||||f
17142673|NCT01643928|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo. Investigator will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.|t
17142674|NCT03692078|f||||f
17142675|NCT01005680|f||GT60||t
17142676|NCT03576131|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock).The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142677|NCT01339858|t||||f
17142678|NCT01456000|f||||f
17142679|NCT04305184|f||||f
17142680|NCT04928794|t||||
17142681|NCT03506646|f||||f
17142682|NCT03069365|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142683|NCT01965431|t||||
17142684|NCT04635631|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187049|NCT00990340|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17187050|NCT04615182|f||OTHER|Site shall have right to publish results. To balance this right with TransMedics' (TM) proprietary interests, site will submit manuscripts intended for publication for TM's review at least 30 days prior to submission date. TM will complete its review within 30 days of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request.|t
17187051|NCT04485130|t||||
17142685|NCT03901339|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17142686|NCT04342130|t||||
17142687|NCT02886494|f||||f
17142688|NCT00457418|f||OTHER|The principal investigator (PI) agrees not to publish/present any interim results of the study without Sponsor's prior written consent. The PI further agrees to provide to the sponsor 30 days prior to submission, review copies. The sponsor shall have editorial rights and the right to review and comment. If the parties disagree, PI agrees to meet with the sponsor's representatives for the purpose of making good faith efforts to discuss and resolve any such issues or disagreement.|t
17187052|NCT00402337|f||OTHER|The disclosure restriction on the PI is that publication cannot be made for 24 months from the date of final data lock of the study, the sponsor can review the publication prior to public release, sponsor requires a minimum 60 day review period for each publication, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request an additional delay period of 60 days in order to protect potentially patentable information.|t
17187053|NCT02821819|f||||f
17187054|NCT01985828|t||||
17187055|NCT02081950|f||||f
17187056|NCT00110890|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17187057|NCT01975220|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17187058|NCT02839343|t||||f
17187059|NCT01852058|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187060|NCT01199926|t||||
17187061|NCT01960530|f||OTHER|The investigator must obtain written consent from the Sponsor prior to any publication of results.|t
17187062|NCT01301274|t||||
17187063|NCT00661661|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187064|NCT01893827|t||||
17187065|NCT04182880|f||||f
17187066|NCT03389477|t||||
17187067|NCT03536546|t||||
17187068|NCT02439749|f||||f
17187069|NCT03403426|f||||f
17187070|NCT00859651|t||||
17187071|NCT00445679|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17187072|NCT04366726|f||OTHER|Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/\> 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/\> 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.|t
17187073|NCT02636270|t||||
17187074|NCT01119898|f||||t
17187075|NCT01806584|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17187076|NCT03021668|f||||f
17187077|NCT00909428|t||||f
17187078|NCT01122381|f||||f
17187079|NCT03474549|f||||f
17187080|NCT04236258|f||||f
17187081|NCT01620567|f||||f
17187082|NCT03445065|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187083|NCT03315130|f||GT60||t
17187084|NCT02707692|t||||
17187085|NCT03535337|f||||f
17187086|NCT02089230|t||||
17187087|NCT02272725|f||||f
17187088|NCT03469284|t||||
17187089|NCT01486615|f||||f
17187090|NCT03610737|f||||f
17187091|NCT02991482|f||||f
17187092|NCT02396537|f||||f
17187093|NCT00871403|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187094|NCT00787319|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187095|NCT02312856|f||GT60||t
17187096|NCT01932294|f||||f
17187097|NCT04415151|t||||
17187098|NCT01778946|t||||
17187099|NCT02150837|t||||
17187100|NCT02608905|t||||
17187101|NCT03075904|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is less than or equal to 60 days from the date that the communication is submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17187102|NCT00659984|f||LTE60||t
17187103|NCT02648971|t||||
17187104|NCT00927355|f||||f
17187105|NCT01800201|f||||f
17187106|NCT03541044|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187107|NCT02635724|f||||f
17187108|NCT04048863|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications and redact proprietary information prior to public release and can embargo communications regarding trial results for a period of at least 45 days from the time submitted to the sponsor for review. The sponsor cannot require changes (other than as described) to the communication however the embargo may be extended an additional 60 days if patent issues are involved.|t
17187109|NCT01159743|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17187110|NCT01446796|t||||
17187111|NCT02424591|t||||
17187112|NCT00312702|f||||f
17187113|NCT01453348|f||||f
17187114|NCT01673893|f||LTE60||t
17187115|NCT04359771|t||||
17142689|NCT01785472|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17142690|NCT00595127|t||||
17142691|NCT01327989|f||OTHER|Physician shall not make any publication without providing Sponsor 60 days notice.If Sponsor determines that the proposed publication contains confidential information, Sponsor may require the delay of publication for a period of time not to exceed 90 days and may require that any confidential information be removed from the publication. Sponsor may also require Physician to delay publication until any factual errors or inaccuracies in the publication are corrected.|t
17142692|NCT02086968|f||OTHER|Sponsor reserves the right to publish the results collected from all sites. PI may publish results from a specific site if there is no multi-site publication within 12 months of the conclusion, abandonment or termination of the study. PI must provide sponsor with copy of draft publication at least 60 days before the scheduled submission to allow sponsor to protect confidential information. PI must withhold submission of publication for 90 days to allow sponsor to seek patent protection.|t
17142693|NCT03099161|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17142694|NCT02723786|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142695|NCT03123120|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17142696|NCT00203892|t||||
17142697|NCT00806416|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142698|NCT02701049|f||||f
17142699|NCT02709759|t||||f
17142700|NCT03359473|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142701|NCT05302414|f||||f
17142702|NCT01610284|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17142703|NCT04035694|t||||
17142704|NCT01102972|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142705|NCT02024386|t||||
17142706|NCT01856257|f||||f
17142707|NCT01125358|f||GT60||t
17142708|NCT01157065|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17142709|NCT01060007|t||||
17142710|NCT00318409|t||||
17142711|NCT06251154|f||||t
17142712|NCT00742859|f||OTHER|Due to multiple studies, centers and countries this may vary.|t
17142713|NCT00956709|t||||
17142714|NCT04527549|f||LTE60||t
17142715|NCT00962013|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts and abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the Sponsor for review at least 60 days prior to submission of publication.The Sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17142716|NCT00486642|f||LTE60||t
17187116|NCT01991821|f||GT60||t
17187117|NCT04581200|f||||f
17187118|NCT04559282|t||||
17142717|NCT03491228|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142718|NCT03003793|t||||
17142719|NCT03706209|f||||f
17142720|NCT00686231|t||||
17142721|NCT00445458|f||LTE60||t
17142722|NCT01527942|t||||
17142723|NCT00116207|f||||f
17142724|NCT00728988|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142725|NCT01771172|f||||f
17142726|NCT01166126|f||LTE60||t
17142727|NCT00111007|f||LTE60||t
17142728|NCT00605839|f||||f
17142729|NCT01381068|t||||
17142730|NCT02843529|t||||
17142731|NCT00752895|t||||
17142732|NCT00083226|f||LTE60||t
17142733|NCT03993288|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17142734|NCT00915473|t||||f
17142735|NCT03443973|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142736|NCT00704717|f||||f
17142737|NCT01476345|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17187119|NCT00622713|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187120|NCT01462162|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187121|NCT03485911|f||||f
17187122|NCT00909480|f||OTHER|Novo Nordisk reserves the right not to release data before passing specified milestones. This includes the right not to release interim results that may later be found to be incorrect. At the end of the trial, one or more manuscripts will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications but will reserve the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17187123|NCT01215357|f||LTE60||t
17187124|NCT00861601|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187125|NCT01616576|f||OTHER|PI agrees to submit any publication to Sponsor (S) at least 30 days prior to submission. Within 30 days of its receipt, S advises PI in writing of any information contained therein which is Confidential Information (CI) (other than Study Data) or which may impair the availability of patent protection for Inventions. S has the right to require PI to remove specifically identified CI and/or to delay the publication for an additional 60 days to enable S to seek patent protection for Inventions.|t
17187126|NCT05266963|t||||
17187127|NCT02786264|t||||
17187128|NCT05414318|f||OTHER|The PI is required to obtain written permission from the Sponsor prior to publishing trial results.|t
17142738|NCT02209454|f||||f
17142739|NCT03151967|f||||f
17187129|NCT03434457|f||||f
17187130|NCT04296890|f||||t
17187131|NCT05400746|t||||
17142740|NCT00197184|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142741|NCT00366678|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17142742|NCT04292171|f||||f
17142743|NCT01777191|f||GT60||t
17142744|NCT00315328|f||||f
17142745|NCT00997672|t||||f
17142746|NCT04253756|f||LTE60||t
17142747|NCT00388674|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17142748|NCT00759174|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142749|NCT01890109|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142750|NCT00540007|t||||
17142751|NCT00568776|f||OTHER|Investigator may publish after release of multi-center study publication, or 18 months after database lock of overall study. Sponsor has 60 days to review any proposed publication and request removal of Sponsor's confidential information. Sponsor may request an additional 90 days if filing a patent.|t
17142752|NCT00996632|t||LTE60||t
17142753|NCT01598740|f||OTHER||t
17142754|NCT02861534|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17142755|NCT02780115|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17142756|NCT01179191|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142757|NCT03029104|f||||f
17142758|NCT00916617|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142759|NCT01177735|t||||
17142760|NCT00623441|f||OTHER|The only disclosure restriction on the PI is that results communications are provided to the sponsor at least 90 days prior to submittal for publication or presentation. The sponsor shall not require changes beyond the extent necessary to allow the sponsor to protect its rights in copyrightable material, and to check for technical correctness.|t
17142761|NCT01988337|f||||f
17142762|NCT01211873|f||OTHER|"No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. The data are the exclusive property of Guerbet.~The investigator undertakes to submit to Guerbet any draft articles or papers related to this study within 30 days of their submission to the scientific review or the congress scientific committee.~All written or oral papers and publications must have the joint agreement of the investigator and the sponsor."|t
17142763|NCT01294709|f||OTHER|Publications derived from this study should include input from the investigator(s), and SPONSOR personnel. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17142764|NCT01793285|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142765|NCT01596088|f||||f
17142766|NCT03466060|f||GT60||t
17142767|NCT01612780|f||LTE60||t
17142768|NCT00556166|t||||
17142769|NCT05005130|t||||
17142770|NCT03345485|f||||f
17142771|NCT02985515|t||||
17142772|NCT00442338|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142773|NCT02964910|f||||t
17142774|NCT03972709|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142775|NCT02360059|t||||
17142776|NCT01339000|f||||f
17142777|NCT01895088|f||||f
17142778|NCT00938015|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142779|NCT02341482|t||||f
17142780|NCT00118209|f||||t
17187132|NCT05454410|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187133|NCT01220869|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17187134|NCT05004688|f||||f
17187135|NCT02227316|t||||
17187136|NCT01081041|f||GT60||t
17187137|NCT00674466|f||||t
17187138|NCT01970787|f||LTE60||t
17187139|NCT01395823|f||OTHER|PI agrees that the first publication and presentation shall be made by sponsor. If publication is not made within 24 months PI may publish their site data provided that sponsor receives 30 days to review.|t
17187140|NCT05076149|f||||t
17187141|NCT00717314|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187142|NCT02087501|f||||f
17187143|NCT00584935|f||OTHER|The investigator is required to submit the final manuscript to the sponsor prior to publication. The sponsor may suggest changes but investigator retains editorial rights.|t
17187144|NCT00094328|f||OTHER|The PI agrees to collaborate with AstraZeneca on the contents and formation of any publication or disclosure and to pay due consideration to comments and opinions offered. AstraZeneca have 60 days for final manuscript review and may require that submission for publication be delayed for a further 90 days in order to file patent applications.|t
17187145|NCT03682705|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17187146|NCT00117156|f||||f
17187147|NCT01919970|f||||f
17142781|NCT00834366|f||OTHER|If a publication based on the results of this study is envisaged, approval from the sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment.|t
17142782|NCT00090259|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142783|NCT00345969|f||LTE60||t
17142784|NCT00960687|f||GT60||t
17142785|NCT00285012|f||OTHER||t
17142786|NCT02873195|f||||t
17142787|NCT05004181|f||OTHER|Principal Investigators respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17142788|NCT00633217|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142789|NCT00096031|f||||f
17142790|NCT00909857|f||GT60||t
17142791|NCT00604175|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17142792|NCT03205163|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17142793|NCT05257109|f||||f
17142794|NCT01389024|f||||f
17142795|NCT00819091|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17142796|NCT01245595|f||||f
17142797|NCT01461369|f||||f
17142798|NCT01247974|f||OTHER|If a multi-site publication is not submitted within twenty-four (24) months after conclusion of the Study at all sites, Institution and/or the Principal Investigator may publish the results from Institution's site individually, subject to Sponsor's rights|t
17142799|NCT04604496|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142800|NCT00734617|t||||
17142801|NCT02367729|f||||f
17142802|NCT00438932|f||||f
17142803|NCT01372254|f||||f
17142804|NCT02742818|f||||f
17187148|NCT04043962|f||||f
17142805|NCT02249065|f||GT60||t
17142806|NCT01260194|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17142807|NCT04854707|f||||f
17142808|NCT00537056|t||||f
17142809|NCT01940276|t||||
17142810|NCT02822612|f||||f
17142811|NCT04007406|f||||f
17142812|NCT02379442|t||||
17142813|NCT05674721|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142814|NCT03891875|f||GT60||t
17187149|NCT00280826|t||||f
17187150|NCT04557826|f||OTHER|All study data and reports of study data are the property of the study sponsor. The sponsor my grant the PI the right to publish the results of this research in a scientific journal, conditional upon the review and concurrence of the sponsor.|t
17187151|NCT04631705|f||OTHER|Publications by PIs are to be submitted to the sponsor for review at least 30 days prior to planned disclosure. Modifications suggested by the sponsor should be considered unless they affect the scientific character or neutrality of the publication. A maximum embargo period of 90 days is applicable only if disclosure would affect (potential) intellectual property rights.|t
17187152|NCT02130284|f||GT60||t
17187153|NCT01875185|t||||
17187154|NCT01521884|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187155|NCT03565068|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17187156|NCT00085202|t||||
17187157|NCT00658138|f||||f
17187158|NCT01286441|f||LTE60||t
17187159|NCT01435655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187160|NCT01436201|f||GT60||t
17187161|NCT00524225|t||||
17187162|NCT01353222|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentation relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17187163|NCT00116844|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187164|NCT00674622|t||||
17187165|NCT00738101|f||||f
17187166|NCT03621202|f||||f
17142815|NCT02067585|f||||f
17142816|NCT04466956|t||||
17142817|NCT00091507|f||||f
17142818|NCT00633009|t||||
17142819|NCT05013749|f||||f
17142820|NCT00246441|f||||f
17187167|NCT04834817|f||||f
17187168|NCT02202434|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17187169|NCT03075501|f||||f
17187170|NCT01886963|f||LTE60||t
17187171|NCT01686165|t||||
17187172|NCT01062763|t||||f
17187173|NCT02494921|t||||
17187174|NCT02714868|f||||f
17187175|NCT03941015|t||||f
17187176|NCT02080195|f||||f
17187177|NCT02211534|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated is not permitted without the prior written consent of the sponsor. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17187178|NCT03505476|t||||
17187179|NCT00539643|t||||
17187180|NCT00500240|t||||
17187181|NCT02508532|f||||t
17142821|NCT02017535|t||||
17187182|NCT03097861|f||||t
17187183|NCT02281760|t||||
17187184|NCT01576367|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17187185|NCT00595270|f||OTHER||t
17187186|NCT00954733|f||||f
17142822|NCT01393626|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.|t
17142823|NCT03506425|t||||
17142824|NCT01141049|t||||
17142825|NCT02643394|t||||
17142826|NCT04088734|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17142827|NCT04193033|t||||
17142828|NCT00609115|f||||f
17187187|NCT03592277|t||||
17187188|NCT03528174|t||||f
17187189|NCT03002038|t||||
17187190|NCT05436912|f||GT60||t
17187191|NCT03885011|f||GT60||t
17187192|NCT01719237|t||||
17187193|NCT02712398|f||||t
17187194|NCT00699140|f||||f
17187195|NCT01725386|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187196|NCT00094211|f||||f
17187197|NCT03812536|f||||f
17187198|NCT02914314|f||||t
17187199|NCT03564782|f||GT60||t
17187200|NCT03597035|f||||f
17187201|NCT01306201|f||||f
17187202|NCT04702568|f||||t
17187203|NCT01973036|f||||f
17187204|NCT01821417|t||||
17187205|NCT04599101|t||||
17187206|NCT05288023|t||||
17187207|NCT00098254|f||||f
17187208|NCT04146896|f||||t
17187209|NCT02118337|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17187210|NCT02914379|f||GT60||t
17187211|NCT01515189|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187212|NCT01126060|t||||
17187213|NCT02139358|t||||
17187214|NCT04838613|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17142829|NCT03083639|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17142830|NCT02125734|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17142831|NCT01591499|f||OTHER|"All the information collected during this study will be considered to be confidential until the analysis has been finalised by the study Sponsor.~All the data collected during this study will remain the property of the study Sponsor and may not be communicated to third parties under any circumstances without the Sponsor's express, written consent.~The results may not be published or passed on (orally or in writing) without the prior consent of the study sponsor."|t
17142832|NCT02704130|t||||
17142833|NCT02666768|f||||f
17142834|NCT03690375|t||||
17142835|NCT03940742|f||GT60||t
17142836|NCT02032823|f||OTHER|Restrictions are imposed by the trial's Steering Committee (SC) and intend to ensure that all publications/presentations are peer reviewed by the SC. Sponsor has the right to review/comment on the content of the material to be published/presented, may request removal of confidential information (e.g. patentable information/trade secrets) within max 90 days. Individual Institutions may publish/present data from their site(s) in compliance with conditions defined in Study Publication Policy.|t
17142837|NCT03428217|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17142838|NCT03889197|f||||f
17142839|NCT05246111|f||||t
17142840|NCT05473247|f||||f
17142841|NCT01445873|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142842|NCT03078192|t||||
17142843|NCT02424357|t||||
17142844|NCT02508649|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17142845|NCT02360124|f||||f
17142846|NCT00417859|f||||f
17142847|NCT03739684|f||OTHER|Study results cannot be published before the earlier of a multi-site publication; or 18 months after the end of the Study at all sites; or confirmation by Sponsor that there will be no multi-site publication. The proposed publication must be submitted to Sponsor at least 60 days prior to publication so that Sponsor can delete Sponsor Confidential Information (other than Study results) and obtain a further 60 days to file on any invention disclosed in the proposed publication.|t
17142848|NCT01115699|t||||f
17142849|NCT03594175|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17187215|NCT01686581|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187216|NCT03857230|f||||f
17187217|NCT02217280|f||||f
17187218|NCT01015976|f||||f
17187219|NCT00736489|f||OTHER|Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.|t
17187220|NCT01933880|f||OTHER|The only disclosure restriction on the PI is a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days .In the event that issues arise regarding scientific integrity, the sponsor will review these issues with the investigator.|t
17142850|NCT01915498|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17142851|NCT01907516|f||||f
17142852|NCT04824560|f||||f
17142853|NCT02181127|f||||f
17142854|NCT04278872|f||||f
17142855|NCT00891527|f||||f
17142856|NCT03291847|f||||f
17142857|NCT00367679|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142858|NCT02953262|t||||
17142859|NCT00740480|f||||f
17142860|NCT01838863|f||||f
17142861|NCT01426828|f||||f
17142862|NCT03349437|f||||f
17142863|NCT02406742|f||LTE60||t
17142864|NCT02039817|f||LTE60||t
17142865|NCT01563029|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142866|NCT01569594|f||||f
17142867|NCT00131573|f||||f
17142868|NCT05150340|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17142869|NCT01826201|f||OTHER|Sponsor approves content of communication.|t
17142870|NCT01615822|f||||f
17142871|NCT01092676|t||||
17142872|NCT00703261|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17142873|NCT02628418|f||||f
17142874|NCT01071083|f||OTHER|The provisions of our agreement are subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17142875|NCT04732728|f||GT60||t
17142876|NCT00203931|t||||
17142877|NCT02426125|f||GT60||t
17142878|NCT02858076|f||||f
17142879|NCT00096200|f||LTE60||t
17142880|NCT03509766|f||||f
17142881|NCT00664066|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142882|NCT03597620|f||||f
17142883|NCT01495793|f||GT60||t
17142884|NCT02587117|t||||
17142885|NCT03014570|f||||f
17142886|NCT01955473|f||||f
17142887|NCT03701516|f||GT60||t
17142888|NCT00478673|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to remove any confidential information or other proprietary information of Sponsor.|t
17187221|NCT02395133|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17187222|NCT00962247|f||||f
17187223|NCT02234063|t||||t
17142889|NCT00981019|t||||
17142890|NCT00358670|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's representative will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17142891|NCT05083559|t||||
17142892|NCT03907540|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17142893|NCT05899218|f||||f
17142894|NCT03151226|t||||
17142895|NCT00919932|f||||f
17142896|NCT02304302|f||||f
17142897|NCT00391118|f||GT60||t
17142898|NCT01345058|t||||
17142899|NCT02820324|f||OTHER||t
17142900|NCT01892020|f||OTHER|Authorship of publications should be in accordance with the Uniform Requirements of the International Committee of Medical Journal Editors. The Investigators offered authorship will be asked to comment and approve the publication. No permission to publish will be granted to any clinical research organization involved in the trial described in trial protocol.|t
17142901|NCT00402779|t||||
17142902|NCT03107715|f||||f
17142903|NCT00094900|t||||
17142904|NCT02149199|f||||f
17142905|NCT03252756|t||||
17187224|NCT02946918|t||||
17187225|NCT01125722|f||||f
17187226|NCT00069784|f||OTHER|"The Steering Committee will be responsible for preparing summaries of the study results for publication in the medical literature, and will have the right to submit such summaries for publication after a review by the sponsor. In such cases comments from the sponsor to the Steering Committee are to be provided within 15 working days. All comments will be carefully considered by the Steering Committee who nevertheless have the final decision on the content of the manuscript."|t
17187227|NCT02654990|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17187228|NCT00045435|t||||
17187229|NCT00402194|f||||f
17187230|NCT00051168|f||LTE60||t
17187231|NCT00709059|f||OTHER|"The participating physician (PP) agrees not to publish/present any~interim results of the Survey without prior written consent of Schering-~Plough (SP). The PP further agrees to provide 30 days written notice to SP prior to submission for publication or presentation to permit SP to review and comment on any presentation, which right shall include editorial rights. If the parties disagree, the PP agrees to meet with SP to discuss and resolve any such issues or disagreement."|t
17187232|NCT01786330|f||||f
17187233|NCT02172625|f||||f
17187234|NCT02053077|t||||
17187235|NCT00186498|f||||f
17187236|NCT04716413|t||||
17187237|NCT00976703|f||||f
17187238|NCT03260127|t||||
17187239|NCT00369681|f||||f
17187240|NCT01610154|t||||
17187241|NCT02949921|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17187242|NCT03585296|f||||f
17187243|NCT03270514|f||||f
17187244|NCT03395808|f||||f
17187245|NCT00462670|f||||f
17187246|NCT00633932|f||OTHER|All PIs were prohibited to disclose all information related to this study withiout AZ approval before this study was completed.|t
17187247|NCT01662531|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187248|NCT00482274|f||||f
17187249|NCT02948959|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17187250|NCT02596022|f||||f
17187251|NCT03921190|f||||f
17142906|NCT01806259|t||||
17142907|NCT01500434|f||OTHER|The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.|t
17142908|NCT01407107|t||||f
17142909|NCT04881448|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17187252|NCT00154310|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187253|NCT01108757|f||||f
17187254|NCT02918500|t||||
17187255|NCT01346514|t||||f
17187256|NCT02299258|t||||
17187257|NCT02881008|f||OTHER||t
17187258|NCT03982043|t||||
17187259|NCT01054573|f||OTHER|It is the policy of the sponsor not to allow the investigators to publish their results or findings prior to the sponsor's publication of the overall trial results. The investigator agrees that before he/she publishes any results of this trial, he/she shall allow at least 45 days for the sponsor to review the prepublication manuscript prior to submission of the manuscript to the publisher as specified in the Clinical Trial Agreement between institution/investigator and sponsor.|t
17187260|NCT00979602|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187261|NCT00152009|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187262|NCT00393523|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142910|NCT02662556|f||OTHER||t
17142911|NCT00788008|f||||f
17142912|NCT02175472|f||OTHER||t
17142913|NCT00005879|t||||
17142914|NCT02953873|f||||f
17142915|NCT03980561|f||||f
17142916|NCT05022121|f||||f
17142917|NCT05406596|f||||f
17142918|NCT02049931|f||||f
17142919|NCT02395536|f||||t
17142920|NCT00131937|f||LTE60||t
17142921|NCT04499391|f||||f
17142922|NCT01640964|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17142923|NCT02787746|f||||f
17142924|NCT04876482|f||||f
17142925|NCT03877484|f||LTE60||t
17142926|NCT01186744|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142927|NCT02547779|f||||f
17142928|NCT01020773|f||||f
17142929|NCT02675426|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17142930|NCT00953927|f||OTHER|The disclosure restrictions on the PI include submission of study data as an Investigator's Brochure prior to publication, sponsor's review (for a period of 60-180 days from the time submission to the sponsor for review), correction of factual errors, accommodation of reasonable comments of sponsor relating to regulatory submissions/interpretation of the Study Data (including assertion of safety and efficacy).|t
17142931|NCT01652573|t||||f
17142932|NCT00934622|f||LTE60||t
17142933|NCT01453101|t||||
17142934|NCT04662086|t||||
17142935|NCT01856686|t||||
17142936|NCT03284424|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17142937|NCT02706041|t||||
17142938|NCT00602979|f||||f
17142939|NCT02962739|f||||f
17142940|NCT03336645|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17142941|NCT00774202|t||||
17142942|NCT01268683|f||||f
17142943|NCT02216214|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17142944|NCT00713830|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17142945|NCT03981614|f||||f
17142946|NCT00499252|f||||f
17142947|NCT00566631|f||GT60||t
17142948|NCT03387735|t||||
17142949|NCT02953418|f||OTHER|Institution and Investigator shall not publish the Study results until after Medtronic's multi-site publication or until the elapse of 12 months from the close of the study at all Study sites, whichever occurs earlier.|t
17142950|NCT03020966|t||||
17142951|NCT00792142|t||||
17142952|NCT02115373|f||OTHER||t
17142953|NCT03747939|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142954|NCT01215955|f||GT60||t
17187263|NCT00993824|t||||
17187264|NCT03148236|f||||f
17187265|NCT00423852|t||||
17187266|NCT04772053|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17142955|NCT01447628|f||OTHER|Any publications should be agreed in advance by the sponsor via the Chief Investigator. Publications will be written by Chief investigator with contributions from collaborating investigators acknowledged appropriately (e.g. via authorship). Trial agreements between sponsor and participating site provide full details of publication restrictions and review timelines.|t
17142956|NCT03087773|t||||
17142957|NCT00185731|f||||f
17142958|NCT00396981|f||LTE60||t
17142959|NCT02494583|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17142960|NCT02072174|f||||t
17142961|NCT01787188|f||||f
17142962|NCT02192541|t||||
17142963|NCT02756078|f||GT60||t
17187267|NCT01916941|f||||f
17187268|NCT02835846|t||||f
17187269|NCT04249219|f||||f
17187270|NCT03787680|t||||
17187271|NCT02541383|f||GT60||t
17142964|NCT05349188|t||||
17142965|NCT00943384|f||LTE60||t
17187272|NCT01737281|t||||
17187273|NCT05458024|t||||
17187274|NCT04986085|f||||f
17187275|NCT05229653|t||||
17187276|NCT01845974|f||OTHER||t
17187277|NCT02667886|f||GT60||t
17187278|NCT00594217|f||||f
17187279|NCT03635489|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187280|NCT00943306|f||OTHER|The CTAs generally envision a multisite publication, with the PI's right to publish individually if the pooled publication does not occur within 12 months of study completion. Sponsor has a 45 to 60 day review/approval period to request deletion of confidential information or to request limited deferral to protect its proprietary technology. In one case, the publication provision is more general, specifying that the Sponsor and clinical site will agree on the manner/terms of publication.|t
17187281|NCT01036022|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187282|NCT00576732|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17142966|NCT00835068|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142967|NCT02575807|f||OTHER|The only disclosure restriction is that study results will first be published in a joint multi-center paper unless (a) written confirmation is provided to the site or PI indicating that there will be no multi-center publication, or (b) at least 12 months have passed after the completion of data analysis at all study sites. Publications will be submitted for sponsor review ≥ 45 days prior to the publication date. Sponsor cannot require changes to the communication or extend the embargo.|t
17142968|NCT02180659|f||||f
17142969|NCT01158976|f||||f
17142970|NCT00481871|f||OTHER|Allos agreements with investigators (PIs) may vary. The PI may publish/make public data from the trial after the earlier of publication by Allos or 18 months after study completion. Allos can review results communications prior to public release and can embargo communications regarding trial results for a period less than or equal to 90 days from submission for review. Allos can request changes to the communication related to confidential or patent information, or to ensure accuracy.|t
17142971|NCT03332212|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17142972|NCT01923961|f||||f
17142973|NCT00397904|t||||
17142974|NCT02058368|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17142975|NCT04141670|f||||f
17142976|NCT02184169|t||||f
17142977|NCT01652872|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142978|NCT01216319|f||GT60||t
17142979|NCT04529096|f||||t
17142980|NCT02357173|f||||f
17142981|NCT00390572|f||||f
17142982|NCT02392559|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17142983|NCT01966107|f||OTHER|This submission /document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17142984|NCT00532779|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 18 months after conclusion of the study at all study centers, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 60 days to review and comment on the proposed publication. The review period may be extended by an additional 30 days upon request. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17142985|NCT00689273|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17142986|NCT01556165|f||||f
17142987|NCT01238172|t||||
17142988|NCT02531698|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187283|NCT01769170|f||OTHER|Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17142989|NCT00701558|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17142990|NCT04633187|f||OTHER|There is an agreement between the Principal Investigators and the Sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17142991|NCT04822701|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17142992|NCT02771340|f||||f
17142993|NCT04148508|t||||f
17142994|NCT00572468|f||||f
17142995|NCT01393717|t||||
17142996|NCT02038959|t||||
17142997|NCT00534209|t||||
17187284|NCT05096208|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187285|NCT01905254|t||||
17187286|NCT02213328|f||||f
17187287|NCT02402296|t||||f
17187288|NCT01508013|f||||f
17187289|NCT02487095|f||||f
17187290|NCT01807650|f||OTHER|Publication requires approval of the sponsor without specification of an embargo time period.|t
17187291|NCT02260401|f||||f
17187292|NCT00855010|f||||f
17187293|NCT02969525|f||GT60||t
17187294|NCT00524030|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187295|NCT01816763|t||||
17187296|NCT04934137|f||||f
17187297|NCT00311155|f||||f
17187298|NCT02241720|f||||f
17187299|NCT00429494|t||||f
17187300|NCT04684641|f||||f
17187301|NCT03289481|f||||f
17187302|NCT02392611|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or The study has been completed at all study sites for at least 2 years"|t
17187303|NCT01129531|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187304|NCT00981474|f||||f
17187305|NCT00939731|t||||
17142998|NCT03233737|f||||f
17142999|NCT01320826|f||||f
17143000|NCT01788163|f||GT60||t
17187306|NCT03800979|f||||f
17187307|NCT01213043|f||OTHER||t
17187308|NCT01678443|t||||
17187309|NCT01175148|f||||f
17187310|NCT01010477|f||||f
17187311|NCT02110732|f||||f
17187312|NCT04836858|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187313|NCT01749501|f||||f
17187314|NCT00597714|t||||
17187315|NCT01350141|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187316|NCT00519896|t||||
17187317|NCT00810082|f||||f
17187318|NCT01588990|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187319|NCT02367716|f||||f
17187320|NCT00750282|f||LTE60||t
17187321|NCT04048759|f||||f
17143001|NCT00545441|f||GT60||t
17143002|NCT00265239|t||||
17143003|NCT03610646|f||||f
17143004|NCT00467038|t||||
17143005|NCT02803138|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143006|NCT00424515|f||||f
17143007|NCT00267020|f||GT60||t
17187322|NCT01641926|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts.|t
17187323|NCT01111838|t||||
17187324|NCT03303469|f||||f
17187325|NCT02294630|f||||f
17187326|NCT00749125|f||||f
17187327|NCT02567825|f||||f
17187328|NCT02444663|t||||
17187329|NCT04741802|t||||
17187330|NCT03195465|t||||f
17187331|NCT00553098|f||||f
17187332|NCT01785563|f||||f
17143008|NCT04071366|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17143009|NCT00021229|f||LTE60||t
17143010|NCT02237118|f||||f
17143011|NCT00399490|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143012|NCT02499406|t||||
17143013|NCT00902265|f||OTHER|PI gives Ferring a draft manuscript 30 days before submission for the final form for to any journal for review and comments. Ferring can ask that confidential information be removed.|t
17143014|NCT04701658|f||GT60||t
17143015|NCT00663039|f||||f
17143016|NCT02866695|f||||f
17143017|NCT03224234|t||||
17187333|NCT01540565|f||LTE60||t
17187334|NCT04399356|f||||f
17143018|NCT05016765|f||||f
17143019|NCT00157573|t||||f
17143020|NCT01346501|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143021|NCT02564952|f||GT60||t
17143022|NCT00756652|f||||f
17187335|NCT05737433|f||||f
17187336|NCT00868699|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17187337|NCT01834222|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143023|NCT01850108|t||||
17143024|NCT00038467|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143025|NCT01988493|f||OTHER||t
17143026|NCT01523301|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17143027|NCT03127943|t||||
17143028|NCT00639158|f||OTHER|Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in Draft of the same) for Sponsor review and comment.|t
17143029|NCT03403712|f||||f
17187338|NCT04251065|f||||f
17187339|NCT04091360|f||||t
17187340|NCT00779558|t||||
17187341|NCT00980005|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187342|NCT00572624|t||||
17187343|NCT00744263|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187344|NCT00910520|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187345|NCT00130793|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187346|NCT00211237|f||LTE60||t
17187347|NCT01121172|f||||f
17187348|NCT03758118|t||||
17187349|NCT01013792|f||OTHER||t
17187350|NCT03154944|t||||
17143030|NCT03265483|f||||f
17143031|NCT03151707|t||||
17143032|NCT00514501|f||LTE60||t
17143033|NCT01308762|f||LTE60||t
17187351|NCT02100722|f||||f
17187352|NCT01782963|t||||f
17187353|NCT03961009|f||OTHER|The results of the Investigators can be divulged to third parties from the trial team only after Kedrion's approval.|t
17187354|NCT05652036|t||||
17187355|NCT03500640|f||||f
17187356|NCT01650519|f||||f
17187357|NCT03557086|f||||f
17187358|NCT01279343|f||||f
17187359|NCT03245255|f||||f
17187360|NCT04765735|f||OTHER|Per the Clinical Investigation Plan: All proposed publications must be reviewed and approved by Medtronic prior to publication. If required by a publisher, the principal investigator agrees to obtain all necessary authorizations from study subjects prior to submitting study-related information for publication.|t
17187361|NCT01495221|t||||
17187362|NCT01250119|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187363|NCT01155830|t||||
17187364|NCT02887989|f||||f
17187365|NCT05648357|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17187366|NCT00255346|t||||
17187367|NCT00708526|t||||
17187368|NCT00409786|f||||f
17187369|NCT01231841|f||||f
17187370|NCT02674490|f||||f
17187371|NCT02440594|f||||f
17187372|NCT00584805|f||||f
17143034|NCT02617446|f||OTHER|All data and results of the clinical study are possessed by sponsor and investigator. Investigator agrees not to submit the results of this study for publication or presentation before the sponsor review the accuracy and no leakage of confidential information in the manuscript.|t
17143035|NCT00530088|t||||
17143036|NCT00902278|f||||f
17143037|NCT02362646|f||||f
17143038|NCT00865306|f||||f
17143039|NCT02656875|f||OTHER||t
17143040|NCT02181842|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17143041|NCT00929864|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143042|NCT03974516|f||LTE60||t
17143043|NCT03474640|f||||t
17143044|NCT03454672|f||OTHER||t
17187373|NCT01993823|f||OTHER|Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.|t
17187374|NCT02341456|f||||f
17187375|NCT00509002|t||||
17187376|NCT00301080|t||||
17187377|NCT01532817|f||LTE60||t
17187378|NCT03066622|t||||
17187379|NCT00641719|f||GT60||t
17187380|NCT03469349|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187381|NCT02306265|f||||f
17187382|NCT04488003|f||||f
17187383|NCT03447730|f||LTE60||t
17187384|NCT03349268|t||||
17143045|NCT00367601|f||||f
17143046|NCT03985293|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143047|NCT04236635|f||||f
17143048|NCT02719639|t||||f
17143049|NCT02251431|f||LTE60||t
17187385|NCT01187329|f||||f
17187386|NCT00692406|t||||
17187387|NCT04145037|f||||f
17187388|NCT01756560|f||||f
17187389|NCT02307513|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17187390|NCT01560260|f||LTE60||t
17187391|NCT05952297|f||||f
17187392|NCT02235701|f||||t
17187393|NCT00525265|f||||f
17187394|NCT03107377|f||||f
17187395|NCT00453102|t||||
17187396|NCT02583763|t||||
17187397|NCT05796518|t||||
17187398|NCT05777174|f||OTHER|MediBeacon requests that no presentation/publication occur until after the first publication of study results or until 1 yr after a study is completed/terminated early, whichever occurs first. Proposed results publication/disclosure must be given to Sponsor for review at least 45 days prior to the date of submission. If a patent application is to be filed, both the Institution and the Sponsor will defer publication or other disclosure for a period of time, not to exceed an additional 60 days.|t
17187399|NCT02690077|f||||f
17187400|NCT05672680|t||||f
17187401|NCT05408468|t||||
17187402|NCT00747123|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187403|NCT04186403|f||||f
17187404|NCT01447849|f||||f
17187405|NCT02201056|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17187406|NCT00405639|t||||f
17187407|NCT01483937|t||||f
17187408|NCT00265330|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187409|NCT02117934|f||OTHER|Principal Investigator may communicate study results with prior written consent from Dynavax.|t
17187410|NCT03108157|t||||
17187411|NCT04534114|f||OTHER|The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17143050|NCT02493088|t||||
17143051|NCT03302299|f||||f
17143052|NCT00858234|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17143053|NCT04318535|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143054|NCT01629134|f||||f
17143055|NCT01678924|f||OTHER||t
17143056|NCT01733186|f||||f
17143057|NCT00640614|f||||f
17143058|NCT00529802|f||LTE60||t
17143059|NCT02007369|t||||
17143060|NCT03569020|f||||f
17143061|NCT02428231|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17143062|NCT02277639|f||||f
17143063|NCT02156466|f||||f
17143064|NCT01784419|t||||
17143065|NCT02253654|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143066|NCT00069160|f||||f
17143067|NCT03044431|t||||
17143068|NCT03456726|f||||t
17143069|NCT04470622|f||||f
17143070|NCT02576054|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17143071|NCT00044005|f||||f
17143072|NCT01190098|t||||f
17143073|NCT02957682|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17143074|NCT02284373|f||||f
17143075|NCT04651218|f||||f
17143076|NCT00765999|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor may request the PI delay submission for any publication while the sponsor files applications for patents or other registrations of intellectual property rights.|t
17143077|NCT00414011|f||OTHER|"All materials that reflects the WRAMC affiliation must be approved and properly cleared before the material is submitted for public dissemination and publication. All publications whereby WRAMC is cited in the bylines will state on the cover page the following sample disclaimer: The views expressed in this \[article, book chapter, speech, presentation, etc.\] are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or U.S. Government."|t
17143078|NCT02476851|f||||f
17187412|NCT03287414|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17187413|NCT02759185|f||||f
17187414|NCT01226914|f||||f
17187415|NCT02613221|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187416|NCT01087996|f||||f
17187417|NCT02668016|t||||
17187418|NCT01298921|f||||f
17187419|NCT01022073|t||||
17187420|NCT00399763|f||||f
17187421|NCT03879603|f||||f
17187422|NCT00513786|t||||
17187423|NCT05067933|f||||t
17187424|NCT03522077|f||||f
17187425|NCT01044576|t||||
17187426|NCT01065350|t||||f
17187427|NCT00626366|t||||
17187428|NCT00971750|t||||
17187429|NCT01657266|f||OTHER|"All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.~All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor."|t
17187430|NCT05093049|f||GT60||t
17187431|NCT01316770|t||||
17187432|NCT04999644|f||||f
17187433|NCT01583101|f||||f
17187434|NCT01974700|t||||
17187435|NCT03443713|f||OTHER|OHSU shall submit for Dexcom's review and comment all publications which result from this Trial. Written copies of results shall be submitted to the Dexcom no later than 45 days before publication and Dexcom shall provide its comments within 30 days, which OHSU will incorporate and honor.|t
17187436|NCT04686279|t||||f
17187437|NCT04255342|f||||f
17187438|NCT01672853|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17143079|NCT01399125|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17143080|NCT03638102|f||||f
17143081|NCT00647426|f||||f
17143082|NCT00804349|t||||f
17187439|NCT02914132|f||||f
17187440|NCT02944656|t||||
17187441|NCT05473000|f||||f
17187442|NCT01265030|f||||f
17187443|NCT02243631|t||||
17187444|NCT03117517|t||||
17187445|NCT01992549|f||OTHER|Octapharma agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Octapharma supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. Octapharma also reserves the right to review data prior to publishing and provide comments/changes within a certain time period.|t
17143083|NCT00822679|f||||f
17187446|NCT01590771|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding the study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17187447|NCT01785628|t||||
17187448|NCT00840996|f||||f
17187449|NCT01900054|f||OTHER||t
17187450|NCT01108835|f||||f
17187451|NCT03285295|f||OTHER|The PI must provide a copy of any proposed publication/presentation at least 60 days prior to submission for sponsor's review/approval. The PI must incorporate changes as the sponsor requires in order to protect the sponsor's proprietary rights and interests. The sponsor may require the PI to include acknowledgement of the sponsor's role in the study. The PI may be requested to delay publication/presentation an extra 60 days to enable sponsor to secure patent or other proprietary protection.|t
17187452|NCT02746575|t||||
17187453|NCT02796274|f||LTE60||t
17187454|NCT00957931|t||||
17187455|NCT00857805|t||||
17187456|NCT04867785|f||GT60||t
17187457|NCT01289041|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17187458|NCT01403441|t||||f
17187459|NCT03926065|f||||f
17187460|NCT03239873|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17187461|NCT02169895|f||OTHER||t
17187462|NCT02670538|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187463|NCT00674323|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187464|NCT00805493|t||||
17187465|NCT01676532|f||||f
17187466|NCT02045433|t||||
17187467|NCT01112514|f||||f
17187468|NCT02176421|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187469|NCT02406885|f||||f
17187470|NCT02145078|t||||
17187471|NCT01077362|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17187472|NCT01872910|f||GT60||t
17187473|NCT00815035|t||||f
17187474|NCT01767935|t||||
17187475|NCT03101241|f||||f
17187476|NCT01422369|f||OTHER|May not publish.|t
17143084|NCT03343054|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143085|NCT03578276|t||||
17143086|NCT02626182|f||||f
17143087|NCT00883740|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143088|NCT00981409|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143089|NCT00390949|t||||
17143090|NCT02556931|f||||f
17143091|NCT00323635|t||||f
17143092|NCT03361917|f||||f
17143093|NCT03869684|f||||t
17143094|NCT00078312|f||GT60||t
17143095|NCT04840901|f||GT60||t
17143096|NCT05354206|f||||f
17143097|NCT04285983|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17143098|NCT04936334|f||||f
17143099|NCT00422058|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk's Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17143100|NCT02209272|t||||
17143101|NCT05144477|f||||f
17143102|NCT03273712|t||||
17143103|NCT00627458|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143104|NCT03778190|t||||
17143105|NCT05149989|t||||
17143106|NCT02587325|f||||f
17143107|NCT01831596|f||||f
17143108|NCT02737072|f||GT60||t
17187477|NCT01678820|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17187478|NCT02300285|t||||
17187479|NCT00578721|t||||
17143109|NCT01197456|f||||f
17143110|NCT00883129|f||||f
17187480|NCT01472874|f||||f
17187481|NCT05778526|f||||f
17187482|NCT02066896|f||||f
17187483|NCT02205801|t||||
17187484|NCT01373450|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17187485|NCT01536184|f||||f
17187486|NCT00510458|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study.These manuscripts and abstracts will be delayed until after the multi-center publication is submitted. All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication. Stryker's review ensures no disclosure of confidential info, no promotion of off-label use, and data is accurate.|t
17187487|NCT01861522|f||OTHER||t
17187488|NCT02716038|f||||f
17143111|NCT01898884|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution may publish results generated from the site individually.|t
17143112|NCT02424799|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187489|NCT04006925|t||||
17187490|NCT01755143|f||||f
17187491|NCT03757234|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17187492|NCT01292070|f||||f
17143113|NCT00834288|f||OTHER|If a publication based on the results of this study is envisaged, approval from the sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment.|t
17187493|NCT01555164|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17187494|NCT01396317|t||||f
17187495|NCT01709305|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17187496|NCT03909178|f||||f
17187497|NCT02294474|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17143114|NCT01336608|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143115|NCT00080288|f||GT60||t
17143116|NCT02328547|f||||f
17143117|NCT00344305|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restricion is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17143118|NCT00176501|t||||
17143119|NCT03612713|t||||f
17143120|NCT00830388|t||||
17143121|NCT01143272|f||||f
17143122|NCT01726335|f||OTHER|The only disclosure restriction on the Principal Investigator is that the Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the Sponsor for review. The Sponsor can require changes to the communication and can extend the embargo.|t
17143123|NCT00545181|f||||f
17143124|NCT01543607|t||||
17143125|NCT01528878|f||GT60||t
17143126|NCT00634582|t||||
17143127|NCT01796860|f||||f
17143128|NCT00149669|f||||f
17143129|NCT02458365|t||||
17143130|NCT03565666|f||||f
17143131|NCT02703454|f||OTHER|The data and results from this study are the sole property of Sponsor. Investigators will not use data from this clinical investigation without the written consent of the Sponsor or generate publication materials as referenced in the Clinical Trial Agreement Single-center results are not allowed to be published or presented before the multi-center results.|t
17143132|NCT00791154|f||||t
17143133|NCT02413879|f||GT60||t
17143134|NCT01396161|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143135|NCT00552617|f||OTHER|Any scientific paper, presentation, or other communication concerning this clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17143136|NCT02533505|f||||f
17143137|NCT02307188|f||||f
17143138|NCT01207401|t||||
17143139|NCT01508325|f||OTHER||t
17143140|NCT03543046|f||||f
17143141|NCT01227954|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17143142|NCT01296152|f||||f
17143143|NCT02353299|f||||f
17143144|NCT01682512|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17143145|NCT01414062|t||||
17143146|NCT04822467|t||||
17143147|NCT04057118|f||OTHER||t
17143148|NCT03583931|f||||f
17143149|NCT02787785|f||||f
17143150|NCT03250507|t||||
17143151|NCT00110084|t||||
17143152|NCT00103259|f||LTE60||t
17143153|NCT01572428|f||||f
17143154|NCT04101721|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17143155|NCT02610842|t||LTE60||t
17143156|NCT04736576|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143157|NCT00535301|f||||f
17143158|NCT01087801|f||||f
17143159|NCT04330482|f||||f
17143160|NCT04671329|f||||t
17143161|NCT03111407|f||||f
17143162|NCT02268045|f||||f
17187498|NCT00171873|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17187499|NCT05200936|f||OTHER|"1. Sponsor has at least 30-60 days to review a proposed publication before submission for purposes of requesting the removal of Sponsor's confidential information.~2. PI's will not publish or disclosure their single-site data prior to a multi-center publication of the aggregate study data, unless Sponsor does not publish a multi-center publication within 12 months following conclusion of the overall study."|t
17187500|NCT03104647|f||||f
17187501|NCT00118898|f||LTE60||t
17143163|NCT01154673|f||||f
17143164|NCT00646282|t||||
17143165|NCT01289990|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17187502|NCT01338012|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating center. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17187503|NCT05879198|f||||f
17187504|NCT02073097|t||||
17187505|NCT01693692|f||||f
17187506|NCT00663117|t||||f
17187507|NCT01959945|f||LTE60||t
17187508|NCT02019563|t||||f
17187509|NCT02209636|t||||
17187510|NCT04022889|f||OTHER|Sites cannot independently publish data from their site until the combined data from all sites has been published. Cerus must review the proposed publication prior to submission to determine if it contains confidential information.|t
17187511|NCT02970032|t||||f
17187512|NCT00605319|f||||f
17187513|NCT01478113|t||||
17187514|NCT01703702|f||LTE60||t
17187515|NCT03093428|t||||
17187516|NCT03980184|t||||
17187517|NCT01616771|f||||f
17187518|NCT04041440|f||||f
17187519|NCT01381874|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17187520|NCT02247804|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187521|NCT00517075|t||||
17187522|NCT02979626|f||||f
17187523|NCT02917265|t||||
17187524|NCT03771157|t||||
17187525|NCT01737996|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17187526|NCT00452413|f||GT60||t
17187527|NCT00985543|f||OTHER|The PI shall not publish or otherwise disseminate the conclusions of the Study, including all or any part of the Results without the prior written consent of the Sponsor, such consent not to be unreasonably withheld or delayed. Any publication or other dissemination of the conclusions of the Study by the PI shall not occur until the Sponsor has published the conclusions of the Study.|t
17187528|NCT03119610|t||||
17187529|NCT00114634|t||||f
17143166|NCT00683904|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143167|NCT01488071|f||OTHER|The results of this study will be published. Authors of the primary publication based on this study must fulfil the criteria defined by the International Committee of Medical Journal Editors (ICMJE). The primary publication must be published before any secondary publications are submitted for publication.|t
17143168|NCT04449354|f||||f
17187530|NCT03283696|f||GT60||t
17187531|NCT02765490|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17187532|NCT01350505|f||||f
17187533|NCT00007475|t||||
17187534|NCT01512745|f||OTHER||t
17187535|NCT02357810|t||||
17187536|NCT00258180|f||||f
17187537|NCT01617005|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187538|NCT01805882|t||||f
17187539|NCT01225822|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17187540|NCT05644353|f||GT60||t
17187541|NCT01407354|f||||f
17187542|NCT00930943|t||||
17187543|NCT02204579|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187544|NCT02778399|f||OTHER|The PI cannot disclose study information which is not publicly available without prior written consent of Sponsor.|t
17187545|NCT02081456|t||||
17187546|NCT00612534|f||OTHER|prior written consent of sponsor|t
17187547|NCT03916744|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187548|NCT02223754|f||GT60||t
17187549|NCT01008475|f||OTHER||t
17187550|NCT04472377|f||||f
17187551|NCT03556358|f||OTHER||t
17143169|NCT05789420|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17143170|NCT02720094|f||||f
17143171|NCT01220128|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143172|NCT02913261|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety|t
17143173|NCT02340078|f||OTHER||t
17143174|NCT00567996|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. any publications from a single-site are postponed until the publication of the pooled date (i.e., data from all sites) in the clinical trial.|t
17143175|NCT02762877|f||LTE60||t
17143176|NCT02524665|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143177|NCT02602080|t||||
17187552|NCT04195880|t||||
17143178|NCT03022799|f||||f
17143179|NCT02642991|f||||f
17143180|NCT00683046|t||||f
17143181|NCT03273257|f||OTHER|Both the International CTEPH Association and the financial sponsor can review results communications prior to public release and can embargo communications regarding trial results for up to 180 days from submission for review|t
17143182|NCT00407966|f||LTE60||t
17143183|NCT04355767|f||||f
17143184|NCT01999322|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property"|t
17143185|NCT02200614|f||OTHER||t
17150710|NCT01383421|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150711|NCT00062010|f||||f
17150712|NCT02856880|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150713|NCT00573157|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17150714|NCT02944383|f||||t
17150715|NCT00364949|t||||f
17187553|NCT02917941|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187554|NCT01351025|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17187555|NCT00515437|f||OTHER|Individual investigators may publish results 1 year after the completion of the trial if a multi-center publication has not occurred.|t
17187556|NCT03573908|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17187557|NCT04466215|f||||f
17187558|NCT02669095|f||GT60||t
17187559|NCT00926003|f||||f
17150716|NCT01183221|t||||
17150717|NCT05367336|t||||
17150718|NCT00807248|f||OTHER|The main publication has to be published before any sub-publications.|t
17150719|NCT01685411|t||||
17143186|NCT00350337|t||||
17143187|NCT00391092|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143188|NCT01901146|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143189|NCT00297492|f||||f
17143190|NCT02414854|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17143191|NCT00606801|f||||f
17143192|NCT01284244|f||||f
17143193|NCT00303316|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17143194|NCT01614613|f||GT60||t
17143195|NCT01557452|f||||f
17143196|NCT02016755|f||||f
17143197|NCT03067506|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17143198|NCT01485588|f||||f
17143199|NCT00337129|f||LTE60||t
17143200|NCT03141931|t||||
17143201|NCT03608696|f||||f
17143202|NCT00306852|f||||f
17143203|NCT01467570|t||||
17143204|NCT04221087|t||||
17143205|NCT01222715|f||LTE60||t
17143206|NCT03372369|t||||f
17143207|NCT02239601|t||||
17143208|NCT04682639|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187560|NCT01986361|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187561|NCT02281526|f||OTHER||t
17187562|NCT00267696|t||||f
17187563|NCT03697980|f||||f
17187564|NCT00539279|f||||f
17187565|NCT03221660|t||||
17187566|NCT02708433|t||||
17187567|NCT02805595|f||||f
17187568|NCT02769065|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187569|NCT00552786|f||||f
17143209|NCT01392170|t||||
17143210|NCT03870737|t||||
17143211|NCT02535247|t||||
17143212|NCT02320838|t||||
17143213|NCT03895307|f||||f
17143214|NCT03964220|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17187570|NCT02764775|f||||f
17187571|NCT03549234|f||||f
17143215|NCT00720473|f||||f
17143216|NCT00690924|t||||
17143217|NCT02748616|t||||
17143218|NCT00589693|f||GT60||t
17143219|NCT00054275|t||||
17187572|NCT00767104|f||||f
17187573|NCT02783820|f||GT60||t
17187574|NCT00856934|t||||
17187575|NCT01186328|f||GT60||t
17187576|NCT03047174|t||||
17187577|NCT03015116|t||||
17187578|NCT01015807|t||||
17187579|NCT02075021|f||||f
17187580|NCT02200939|f||OTHER|For multicenter studies the study data and results will be pooled and analyzed. If a multicenter publication is not submitted within 24 months after conclusion of study, site/investigator may publish individual results. Proposed publication must be submitted to sponsor no later than 90 prior to submission. Sponsor has right within 60 days to modify proposed publication if it will disclose patentable items.|t
17187581|NCT02762981|f||OTHER|Corcept Therapeutics as the Sponsor, has a proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between multiple Investigators and sites and Corcept personnel. Authorship will be established before the writing of the manuscript. As this study involves multiple centers, no individual publications will be allowed before completion of the final report of the multicenter study except as agreed with Corcept.|t
17143220|NCT01080209|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143221|NCT02030834|t||||
17143222|NCT00857493|f||||t
17143223|NCT02572427|t||||
17143224|NCT04333199|t||||
17143225|NCT01468974|f||||f
17143226|NCT00998582|t||||f
17143227|NCT04000373|t||||
17143228|NCT01032330|f||||f
17143229|NCT01155284|t||||
17143230|NCT01766310|f||||f
17143231|NCT03030638|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17143232|NCT01556490|f||||f
17143233|NCT02618772|t||||
17143234|NCT02328404|f||||f
17143235|NCT04348292|f||||f
17143236|NCT04529499|f||OTHER|Publication will be a joint effort between Sponsors and Principal Investigator|t
17143237|NCT00758706|f||LTE60||t
17143238|NCT01039584|f||OTHER||t
17143239|NCT01494649|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143240|NCT03467971|f||||f
17143241|NCT03791619|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at any time.|t
17143242|NCT01174368|t||||
17143243|NCT01236053|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143244|NCT00000135|f||OTHER||t
17143245|NCT01311505|t||||
17143246|NCT00759759|f||||f
17143247|NCT00301873|f||||f
17187582|NCT01382940|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187583|NCT02134210|f||||f
17187584|NCT00244374|f||||f
17187585|NCT00976482|f||GT60||t
17187586|NCT01596283|t||||
17187587|NCT00720902|t||||
17187588|NCT01486758|t||||
17187589|NCT03366220|t||||
17187590|NCT00871819|f||LTE60||t
17187591|NCT02608489|f||||f
17187592|NCT01334944|f||||f
17187593|NCT02254408|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17143248|NCT02432456|t||||
17143249|NCT01456494|t||||
17143250|NCT00500656|f||LTE60||t
17143251|NCT04639310|f||GT60||t
17143252|NCT01211613|t||||
17143253|NCT03853213|t||||
17143254|NCT01458132|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143255|NCT00833976|f||||f
17143256|NCT03911960|f||||f
17143257|NCT02239692|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17143258|NCT03232749|t||||
17143259|NCT01614925|f||||f
17143260|NCT04313023|f||OTHER||t
17143261|NCT00786019|f||||f
17143262|NCT02437890|f||OTHER|Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.|t
17187594|NCT01671839|f||OTHER|Investigator agrees that the first publication of the results shall be made in conjunction with the results from all study centers. If Investigator desires independently to publish information about data obtained at Investigator's facility, then Investigator may do so, provided a copy of any proposed oral presentation or written publication is received by Company at least 45 days in advance of submission for publication.|t
17143263|NCT04723173|t||||
17143264|NCT02996448|f||||f
17143265|NCT01422720|f||OTHER||t
17143266|NCT02082262|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143267|NCT01586624|f||||f
17143268|NCT01375569|f||||f
17187595|NCT02914184|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187596|NCT00798174|f||||t
17187597|NCT00674115|f||OTHER||t
17187598|NCT00525135|t||||
17187599|NCT01642602|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187600|NCT01460160|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187601|NCT00100932|f||||f
17187602|NCT00744328|f||||f
17187603|NCT04229030|f||||f
17187604|NCT02387216|f||||t
17187605|NCT01336959|f||OTHER|All PIs must seek written permission from the sponsor prior to publication on any trial results.|t
17187606|NCT00557622|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187607|NCT01539863|f||||f
17187608|NCT01962025|f||||f
17187609|NCT01468922|f||||f
17187610|NCT02991144|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17187611|NCT01472562|t||||f
17187612|NCT02563522|f||||t
17187613|NCT00675506|f||||f
17187614|NCT00936221|f||||f
17187615|NCT03820323|f||||f
17187616|NCT03151395|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17187617|NCT00879996|f||||f
17187618|NCT02597933|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17187619|NCT04205929|t||||
17187620|NCT01097915|f||||f
17187621|NCT01107743|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187622|NCT00308737|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17187623|NCT02224482|f||||f
17187624|NCT04078035|t||||f
17187625|NCT01644396|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17187626|NCT04394845|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143269|NCT01074307|f||OTHER|The investigator commits him/her to forward to sponsor all papers, manuscripts or conference abstracts intended for publication or presentation that contain data or results generated in connection with the study. Papers and abstracts must be available at sponsor's site in time before the planned submission date to allow for review and comments. Submission for publication need expressed written permission from the sponsor. Any publication should follow publication policy as described in protocol.|t
17143270|NCT02625207|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143271|NCT02162511|f||||f
17187627|NCT02954458|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187628|NCT02130453|t||||
17187629|NCT01960075|f||||f
17187630|NCT03501043|f||||f
17187631|NCT01396395|f||OTHER||t
17187632|NCT03428126|t||||
17187633|NCT02460263|f||||f
17187634|NCT00884754|f||||f
17187635|NCT03176238|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17187636|NCT04524598|t||||
17187637|NCT04395183|f||||f
17187638|NCT00315588|t||||
17187639|NCT02569710|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17187640|NCT04152343|f||||f
17187641|NCT00550550|f||OTHER|"The investigator agrees not to publish or publicly present any interim results~of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of publications that report any results of the study. The sponsor shall have the right to review and comment with respect to proprietary information, data accuracy, and fair balance in compliance with FDA regulations."|t
17187642|NCT03519243|f||||f
17187643|NCT01965938|f||||f
17143272|NCT01160198|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143273|NCT00448682|t||||
17143274|NCT02766088|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143275|NCT01331083|f||||f
17143276|NCT01498419|f||OTHER|The investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting, for review and removal of confidential information.|t
17143277|NCT03555890|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187644|NCT02090634|f||||f
17187645|NCT01164228|f||LTE60||t
17187646|NCT00697190|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17187647|NCT00977769|t||||
17187648|NCT01586312|f||OTHER|The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release.|t
17187649|NCT00799643|f||||f
17187650|NCT02936037|f||||f
17187651|NCT04567693|t||||
17187652|NCT03462706|f||||f
17187653|NCT01411501|f||||f
17187654|NCT04105972|f||OTHER||t
17143278|NCT01818414|t||||
17187655|NCT01161472|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187656|NCT01449240|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187657|NCT00612222|f||||f
17187658|NCT01567943|f||||f
17187659|NCT03355755|t||||
17187660|NCT04042285|t||||
17187661|NCT00010439|f||OTHER|Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation.|t
17187662|NCT00067990|f||||f
17187663|NCT01118455|f||GT60||t
17187664|NCT00543400|t||||
17143279|NCT01286207|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143280|NCT01383954|t||||
17187665|NCT03327402|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187666|NCT03810313|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17187667|NCT00136812|f||||f
17187668|NCT00422799|f||LTE60||t
17143281|NCT00450177|t||||f
17143282|NCT02613416|f||||f
17143283|NCT00763269|f||LTE60||t
17143284|NCT03174925|t||||
17143285|NCT01398982|f||||f
17143286|NCT04247594|f||||f
17143287|NCT02846740|f||||f
17187669|NCT04542226|f||||t
17187670|NCT03029780|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17187671|NCT03560258|f||||f
17187672|NCT03354325|t||||
17187673|NCT04498247|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17187674|NCT02086162|t||||
17187675|NCT01248962|t||||
17187676|NCT01027364|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17187677|NCT02104830|t||||
17187678|NCT00332605|f||||f
17187679|NCT00245856|f||||f
17187680|NCT01003184|f||||f
17187681|NCT02551744|t||||
17187682|NCT03662997|f||||f
17187683|NCT01719224|f||||f
17187684|NCT03767634|f||||f
17187685|NCT02641249|t||||f
17187686|NCT03853317|f||||t
17187687|NCT02289989|f||||f
17187688|NCT00406419|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187689|NCT01535274|t||||
17187690|NCT03679767|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17187691|NCT02400437|f||||f
17187692|NCT02088632|f||||f
17187693|NCT02101918|f||LTE60||t
17187694|NCT00882921|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17187695|NCT02009696|f||OTHER|Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.|t
17187696|NCT05490329|f||||f
17187697|NCT00447954|f||||t
17187698|NCT00856661|f||||f
17187699|NCT02120664|f||GT60||t
17187700|NCT00105586|f||LTE60||t
17187701|NCT02306122|t||||f
17187702|NCT00886639|t||||
17187703|NCT03203694|f||||f
17187704|NCT02578914|f||||t
17187705|NCT00735644|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17187706|NCT02961374|f||LTE60||t
17187707|NCT02780622|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187708|NCT02956434|f||||f
17187709|NCT01518946|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17187710|NCT00384059|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187711|NCT02714205|t||||
17187712|NCT01774071|t||||
17187713|NCT00381641|f||LTE60||t
17187714|NCT01598298|f||GT60||t
17187715|NCT04287868|f||||f
17187716|NCT03813147|f||LTE60||t
17187717|NCT00708721|f||||f
17187718|NCT03463915|f||||f
17187719|NCT02341287|t||||f
17187720|NCT02687412|t||||
17187721|NCT00553202|f||OTHER|Must obtain prior Sponsor approval.|t
17143288|NCT02609178|t||||
17187722|NCT04651114|f||||f
17187723|NCT01966796|f||||f
17187724|NCT01923896|t||||f
17187725|NCT01097395|f||||f
17187726|NCT00592319|t||||f
17187727|NCT02410967|f||||f
17187728|NCT00235443|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17187729|NCT02010697|f||||f
17187730|NCT00474929|t||||
17187731|NCT00819403|f||||f
17187732|NCT03029247|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187733|NCT01045122|t||||
17187734|NCT02593305|f||||f
17187735|NCT01190215|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187736|NCT00584701|f||||f
17187737|NCT00003511|f||||f
17187738|NCT01395043|t||||
17187739|NCT02342314|f||GT60||t
17187740|NCT00041756|f||OTHER||t
17187741|NCT00603265|f||OTHER||t
17187742|NCT02002884|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17187743|NCT02966002|t||||
17187744|NCT02122341|f||||f
17187745|NCT01432535|f||OTHER|The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the Sponsor. The Investigator further agrees to provide review copies of abstracts or manuscripts for publication that report any results of the trial to the Sponsor 45 days prior to submission for publication or presentation. The Sponsor shall have the right to review and comment.|t
17187746|NCT02291432|f||GT60||t
17187747|NCT03377790|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17187748|NCT01200030|f||||f
17187749|NCT02632786|f||OTHER|The PI, institution and the sponsor have agreed that the PI and institution may publish or disclose study results from their site after the earlier of (a) publication of the complete multicenter study results or (b) 18 months after database lock for the multicenter study. The sponsor has at least 45 days to review a proposed publication and may request deletion of confidential information and up to 60 days additional delay to obtain patent protection.|t
17187750|NCT02265224|f||||f
17187751|NCT02134119|f||||f
17187752|NCT01454830|f||||f
17187753|NCT00152763|t||||f
17187754|NCT00569803|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187755|NCT01235975|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187756|NCT02006420|t||||
17187757|NCT00791921|f||||f
17143289|NCT01128153|f||OTHER|At least 60 days prior to submission of any material for publication or presentation, PI shall provide Sponsor with such material for review. If requested in writing by Sponsor, PI shall withhold material from submission for publication or presentation for an additional 90 days from the date of Sponsor's request.|t
17143290|NCT03451331|f||||f
17187758|NCT00389974|f||LTE60||t
17187759|NCT01965158|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17187760|NCT00474175|f||OTHER|Wyeth has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187761|NCT01047475|f||OTHER||t
17187762|NCT01619787|f||||f
17187763|NCT01130883|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17187764|NCT01622543|t||||f
17187765|NCT01798186|f||||f
17187766|NCT02357043|f||GT60||t
17187767|NCT02091739|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17187768|NCT00101660|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187769|NCT00192023|f||GT60||t
17187770|NCT02207439|f||||f
17187771|NCT02912468|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17187772|NCT01320735|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17187773|NCT01290822|t||||
17187774|NCT03501693|f||||f
17143291|NCT02419469|t||||
17143292|NCT00755937|f||||f
17143293|NCT00572156|f||LTE60||t
17143294|NCT02261974|f||||f
17143295|NCT01347879|f||LTE60||t
17143296|NCT00323271|f||||f
17143297|NCT00068770|t||||
17143298|NCT01238822|f||||f
17187775|NCT00089895|f||LTE60||t
17187776|NCT02301156|f||OTHER|TG Therapeutics has the right to review all proposed abstracts, manuscripts or presentations prior to submission for publication; however, the terms and conditions, including timing for review, of TG Therapeutics' agreements with its investigators may vary. Any single-site publications will be postponed until publication of data from the entire clinical trial (pooled from all sites). An investigator may not disclose TG Therapeutics confidential information other than study results.|t
17187777|NCT00675415|t||||
17187778|NCT00525603|f||||f
17187779|NCT03734991|f||||f
17187780|NCT02638623|f||||f
17187781|NCT00735449|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17187782|NCT01741454|t||||f
17187783|NCT03331185|t||||
17187784|NCT01103960|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17187785|NCT00147225|t||||f
17187786|NCT03396432|f||||f
17187787|NCT01032044|f||||f
17187788|NCT02875834|f||||f
17187789|NCT03311230|f||||f
17187790|NCT02998021|t||||
17187791|NCT01302938|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187792|NCT03342053|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187793|NCT01233609|f||||f
17187794|NCT01167179|t||||
17143299|NCT00996918|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143300|NCT01754480|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17143301|NCT02703779|t||||
17143302|NCT04440007|f||||f
17143303|NCT00854607|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17143304|NCT03959137|f||GT60||t
17143305|NCT00190684|f||GT60||t
17143306|NCT03304210|t||||
17143307|NCT00829439|f||||f
17143308|NCT00123487|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143309|NCT00995488|t||||
17143310|NCT02740660|f||||f
17143311|NCT03672396|t||||
17143312|NCT01408576|f||GT60||t
17143313|NCT01289431|f||OTHER|Contact sponsor directly for details.|t
17143314|NCT00563524|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143315|NCT01230502|f||OTHER|The PI, or his designee, must notify the sponsor at least (10) days, if possible, or as soon as possible, prior to submitting this information.|t
17143316|NCT00817778|f||OTHER|CONTRACT RESEARCH ORGANIZATION AGREEMENT by and between ASTRAZENECA AB and the CRO. CRO agrees that AstraZeneca shall have the exclusive right to publish the results of the Study, including all Work Product, and that such results may not be published or otherwise disseminated by CRO without the prior written approval of AstraZeneca.|t
17143317|NCT00823459|f||||f
17143318|NCT02360397|f||||f
17143319|NCT01537549|f||||f
17187795|NCT03017235|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17187796|NCT04602494|f||||f
17187797|NCT02248961|f||OTHER|Any study related information could be made public availiable only after Sponsors written permission.|t
17187798|NCT01288781|t||||
17187799|NCT00453310|t||||
17187800|NCT02444988|f||||f
17187801|NCT03321513|f||||f
17143320|NCT01208922|f||||f
17143321|NCT00716586|f||||f
17143322|NCT00566618|t||||
17143323|NCT01542684|t||||f
17143324|NCT02923115|f||||f
17143325|NCT03061279|t||||
17187802|NCT01976364|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143326|NCT04056299|f||OTHER|"There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17143327|NCT01791127|f||||t
17143328|NCT01117090|f||GT60||t
17143329|NCT00068406|f||LTE60||t
17143330|NCT03231709|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17143331|NCT01875991|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143332|NCT02454972|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.|t
17143333|NCT01377233|f||||f
17143334|NCT01785875|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143335|NCT03112993|f||||f
17143336|NCT00707174|t||||
17143337|NCT04991311|f||||t
17143338|NCT01676311|t||||
17143339|NCT01453374|f||OTHER|A copy of such disclosure must be given to Alkermes for review at least 60 days prior to submission for publication. Revision to such disclosure will be negotiated in good faith by the Institution, Principal Investigator, and Alkermes. The disclosure may be submitted for publication or presented by the Institution and Principal Investigator only following receipt of written notice from an authorized representative of Alkermes stating that the disclosure has been reviewed and approved.|t
17187803|NCT02757521|t||||
17187804|NCT00768430|f||||f
17187805|NCT02318719|f||||f
17187806|NCT02430818|t||||
17187807|NCT05340751|t||||
17187808|NCT04502056|f||||f
17187809|NCT02961881|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17187810|NCT01973491|f||||f
17187811|NCT01928225|f||||f
17187812|NCT04250337|f||GT60||t
17187813|NCT00247624|t||||
17187814|NCT03321006|f||||f
17187815|NCT00365378|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187816|NCT03278886|f||||f
17187817|NCT01316341|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17187818|NCT04161807|f||||f
17187819|NCT02006121|f||||f
17187820|NCT04789577|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17143340|NCT01440595|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17143341|NCT01223196|f||||f
17143342|NCT00123110|t||||f
17187821|NCT05150587|f||||t
17187822|NCT01614847|f||||f
17187823|NCT01165840|f||||f
17143343|NCT05180630|t||||
17143344|NCT02011516|t||||
17187824|NCT00249496|t||||
17187825|NCT02693834|f||||f
17187826|NCT00000143|f||||f
17187827|NCT04848662|f||OTHER|data or results obtained from this study must not be published without prior approval from the Sponsor.|t
17187828|NCT03000673|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187829|NCT01121484|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187830|NCT00562978|t||||
17187831|NCT02378402|t||||
17187832|NCT00299195|t||||
17187833|NCT01348776|f||GT60||t
17187834|NCT04785326|f||||f
17187835|NCT01463293|f||LTE60||t
17187836|NCT02707523|f||||f
17187837|NCT03452176|f||||f
17143345|NCT00709735|f||||f
17143346|NCT01466673|f||OTHER|If Institution \& Principal Investigator wish to publish information from Clinical Trial, a copy of manuscript must be provided to Sponsor at least 60 days prior to submission for publication/presentation and will arrange expedited reviews for the same. No paper with confidential information will be submitted without Sponsor's prior consent. If requested, Institution and Principal Investigator will hold such publication for up to additional 60 days to allow filing of patent application.|t
17143347|NCT02009982|t||||
17143348|NCT00597727|t||||f
17143349|NCT02725671|f||||f
17143350|NCT00965263|t||||
17143351|NCT00963599|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143352|NCT02135094|f||||f
17143353|NCT03496207|f||OTHER|The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication.|t
17143354|NCT01255722|f||OTHER|"No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. The data are the exclusive property of Guerbet.~The investigator undertakes to submit to Guerbet any draft articles or papers related to this study within 30 days of their submission to the scientific review or the congress scientific committee.~All written or oral papers and publications must have the joint agreement of the investigator and the sponsor."|t
17187838|NCT00706784|f||||f
17187839|NCT01361620|t||||f
17187840|NCT00779584|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17187841|NCT00817804|f||LTE60||t
17187842|NCT01458990|f||||f
17187843|NCT02878213|f||||t
17187844|NCT01913639|t||||
17187845|NCT00886262|t||||
17187846|NCT03959592|t||||
17187847|NCT04986982|f||OTHER||t
17187848|NCT01155661|f||GT60||t
17187849|NCT01370005|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17187850|NCT02302066|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17187851|NCT02049710|f||||f
17187852|NCT01283321|f||||f
17187853|NCT02415998|f||||f
17187854|NCT00874432|t||||
17187855|NCT03713021|t||||
17187856|NCT01076283|t||||
17187857|NCT04235582|t||||
17187858|NCT03391960|f||LTE60||t
17187859|NCT01919996|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187860|NCT04591977|f||||f
17187861|NCT00405353|f||||f
17187862|NCT01158378|f||||f
17187863|NCT02593539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187864|NCT01282476|t||||f
17187865|NCT00437125|f||GT60||t
17187866|NCT01542541|f||LTE60||t
17187867|NCT00649389|f||OTHER|Study site may not publish results of study until after coordinated multicenter publication has been submitted for publication or one year after study has ended, whichever occurs first. Therefore, study site will have the opportunity to publish results of study, provided that Daiichi Sankyo has had the opportunity to review and comment on study site's proposed publication prior to being submitted for publication with advice of company patent council and in accord with subject protection needs.|t
17187868|NCT04662671|f||OTHER|Principal Investigators are bound by signed Non-confidentiality Agreements and Clinical Trial Agreements with EmitBio, Inc. as the sponsor of this trial.|t
17187869|NCT01267825|t||||
17187870|NCT01806740|f||OTHER||t
17187871|NCT04666922|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17187872|NCT04551196|t||||
17187873|NCT00983489|f||||f
17187874|NCT03722264|t||||
17187875|NCT00871351|f||OTHER|The investigator agrees not to publish/present any interim results of the study without Sponsor's prior written consent. The investigator further agrees to provide to the sponsor 45 days prior to submission, review copies of abstracts/manuscripts that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor for the purpose of making good faith efforts to discuss and resolve any such issues or disagreement.|t
17187876|NCT00291655|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17187877|NCT02959671|t||||
17187878|NCT02791490|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Sponsor review can be expedited to meet publication timelines.|t
17187879|NCT01984424|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17187880|NCT00077636|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187881|NCT02032173|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17187882|NCT05082142|f||||f
17187883|NCT03661996|f||||t
17187884|NCT01993017|f||||f
17187885|NCT00068380|f||LTE60||t
17187886|NCT00462722|f||||f
17187887|NCT02419547|t||||f
17187888|NCT02949674|t||||
17187889|NCT00917267|f||GT60||t
17187890|NCT02960763|t||||
17187891|NCT00335725|f||||f
17187892|NCT02250521|t||||
17187893|NCT00312858|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187894|NCT01868035|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187895|NCT00432835|t||||
17187896|NCT00423293|f||||f
17187897|NCT01912222|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17187898|NCT04399551|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17187899|NCT01014975|f||OTHER|Site may publish results from the study, after providing sponsor 30 days' notice prior to submitting a manuscript or other materials related to the study to any outside party. At sponsor's request, site will remove any confidential information (other than study results), and site will upon sponsor's request delay publication or presentation for a period of up to 120 days to allow sponsor to protect its interests in any sponsor inventions.|t
17187900|NCT00936481|t||||f
17187901|NCT01336634|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17187902|NCT01863043|f||||f
17187903|NCT01971580|f||||f
17143355|NCT02164539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143356|NCT02245360|f||||f
17187904|NCT00854295|f||||f
17187905|NCT03154359|t||||
17187906|NCT05033743|f||||f
17187907|NCT00345384|f||||f
17187908|NCT00885352|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17187909|NCT01170884|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17187910|NCT00773955|f||LTE60||t
17187911|NCT02223065|f||||f
17187912|NCT00152971|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17187913|NCT03292146|f||||t
17187914|NCT01232465|t||||
17187915|NCT00366301|f||||f
17187916|NCT02354963|t||||
17187917|NCT01896115|f||||f
17187918|NCT04071470|f||||f
17187919|NCT01076088|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17187920|NCT00771875|t||||
17187921|NCT03306043|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187922|NCT04475848|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187923|NCT00785538|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17187924|NCT02494206|t||||
17187925|NCT04276090|t||||
17187926|NCT01799720|t||||f
17187927|NCT01234649|t||||
17187928|NCT00318149|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187929|NCT01238549|t||||
17187930|NCT00785707|f||||f
17187931|NCT02322814|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187932|NCT00118092|f||LTE60||t
17187933|NCT02459093|f||||f
17187934|NCT00591864|t||||
17187935|NCT01871558|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17187936|NCT04394247|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187937|NCT01744860|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187938|NCT02401308|t||||
17187939|NCT02736968|f||LTE60||t
17187940|NCT01861457|f||||f
17143357|NCT03835975|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187941|NCT02041923|f||||f
17187942|NCT01734434|f||GT60||t
17187943|NCT04921969|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17187944|NCT01340482|f||GT60||t
17187945|NCT03518658|f||||f
17187946|NCT00670462|f||||f
17187947|NCT01517243|f||||f
17187948|NCT02105636|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187949|NCT00744237|f||OTHER|"All data generated in this study will be the property of Forest Research Institute. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute."|t
17187950|NCT05197257|t||||
17187951|NCT00802659|t||||
17143358|NCT00061945|f||LTE60||t
17187952|NCT02721641|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187953|NCT01912781|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17187954|NCT01582880|t||||
17187955|NCT00872430|t||||f
17187956|NCT02951351|t||||
17143359|NCT04628221|f||||t
17143360|NCT00975884|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143361|NCT01656967|f||||f
17187957|NCT04537897|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17187958|NCT01580098|t||||
17187959|NCT00197028|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187960|NCT03308058|f||OTHER|"PI, who is no longer with UNMC must approve all publications and make the sponsor AHRQ aware of them.~This is restrictive since he is now in New York and the study and data were and are in Nebraska."|t
17187961|NCT00282815|t||||f
17187962|NCT00669903|f||OTHER|No publication or presentation of results until the earlier of the publication of the first multi-center publication and the second anniversary of the completion of the multi-center study at all sites. Sponsor must receive a copy of proposed manuscript for review and comment at least 60 days prior to its submission for publication or presentation.|t
17187963|NCT00058019|f||LTE60||t
17187964|NCT01827254|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187965|NCT01923389|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187966|NCT01989598|f||LTE60||t
17143362|NCT05166512|f||||f
17143363|NCT04166851|f||||f
17143364|NCT02139306|f||||f
17143365|NCT02956005|f||||f
17143366|NCT03909971|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclosure previously undisclosed confidential information other than study results.|t
17143367|NCT01185639|t||||
17143368|NCT00864084|f||||f
17143369|NCT04583592|f||||f
17143370|NCT00281827|t||||
17143371|NCT01861717|t||||
17187967|NCT04112940|t||||
17187968|NCT04957732|f||||f
17187969|NCT01035333|f||||f
17187970|NCT01613027|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187971|NCT00545363|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187972|NCT00951509|f||||f
17187973|NCT01290536|t||||f
17187974|NCT03125941|t||||
17187975|NCT00582491|t||||
17187976|NCT04192630|f||||f
17187977|NCT01193582|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187978|NCT01425632|f||OTHER||t
17187979|NCT00240526|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187980|NCT01716208|t||||
17187981|NCT03632434|t||||
17143372|NCT03033069|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17143373|NCT00430638|f||OTHER|If identified by Daiichi Sankyo Inc.(DSI), any of DSI's confidential information, as defined to the author, shall be deleted. Nothing in our site agreement shall be taken as giving DSI any right of editorial control over any publication prepared by the study site.|t
17143374|NCT02926053|t||||
17143375|NCT05458895|f||||f
17143376|NCT00176852|f||||f
17143377|NCT00802529|t||||
17143378|NCT03591107|f||||f
17143379|NCT03940326|t||||
17143380|NCT01407575|f||||f
17143381|NCT01222871|f||||f
17143382|NCT02869295|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17143383|NCT01084603|t||||
17143384|NCT02483481|t||||
17143385|NCT03862625|f||||f
17143386|NCT00520494|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143387|NCT01307631|f||LTE60||t
17143388|NCT01093482|f||||f
17143389|NCT03471182|f||||f
17143390|NCT04440163|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143391|NCT02229487|f||||f
17143392|NCT02018042|t||||f
17143393|NCT01954082|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17143394|NCT02873481|f||||f
17143395|NCT01029769|t||||
17143396|NCT00666718|f||GT60||t
17143397|NCT00657917|f||||f
17143398|NCT02492295|t||||
17143399|NCT00810615|t||||
17143400|NCT02525562|f||OTHER|There is an agreement between Principal Investigators and the Sponsor (or its agents) that requires Investigators to allow Sponsor at least 30 days to review material intended for publications in order to redact any Confidential Information or Inventions therefrom.|t
17143401|NCT02567266|t||||f
17143402|NCT02643966|f||||f
17143403|NCT01190202|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143404|NCT03611751|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17187982|NCT01751113|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17187983|NCT01551303|f||||f
17187984|NCT03487718|f||||f
17187985|NCT01208415|f||GT60||t
17187986|NCT01115491|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17187987|NCT04297241|f||||f
17187988|NCT03856996|f||||f
17143405|NCT02441179|t||||f
17187989|NCT01003639|f||||f
17187990|NCT01840319|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17187991|NCT04362137|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17187992|NCT00566943|f||||f
17143406|NCT02702271|f||||f
17143407|NCT03091400|f||||f
17143408|NCT00051636|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17143409|NCT00479765|f||||f
17143410|NCT03056001|t||||
17143411|NCT02580201|f||||f
17143412|NCT01364298|f||||f
17143413|NCT00294632|t||||
17143414|NCT03707522|f||||f
17143415|NCT00420849|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.~* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 180 days."|t
17143416|NCT00659581|t||||
17143417|NCT01337609|f||||f
17143418|NCT03162354|f||||f
17143419|NCT00944125|t||||
17143420|NCT00446134|f||OTHER|Agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Valeant supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143421|NCT00743119|f||||f
17143422|NCT04816877|f||||f
17143423|NCT00727298|f||||f
17143424|NCT01309828|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17150720|NCT02504671|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150721|NCT00210249|f||||f
17187993|NCT01304082|t||||f
17187994|NCT02262260|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17187995|NCT01642082|f||||f
17187996|NCT01794117|f||||f
17187997|NCT03729024|f||||t
17143425|NCT00295620|f||OTHER|PI/Sponsor collaborate in good faith regarding contents/formation of any PI publication/disclosure; PI pays due consideration to comments/opinions of Sponsor. Prior to any publication PI undertakes to provide Sponsor with preliminary data and drafts of publication/disclosures (oral or written) and with proposed final manuscript. Sponsor can review within 30 days and can require that submission for publication/disclosure of manuscript be delayed in order for Sponsor to file patent applications.|t
17143426|NCT04179474|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143427|NCT02556632|t||||
17143428|NCT03934437|f||||f
17143429|NCT01397656|f||||f
17143430|NCT00057785|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17143431|NCT02574260|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143432|NCT02936479|t||||
17143433|NCT03574818|f||||f
17143434|NCT01164137|f||||f
17143435|NCT04523831|f||||t
17143436|NCT02322242|f||||f
17143437|NCT01189071|t||||
17143438|NCT02367781|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143439|NCT02623426|t||||
17143440|NCT01031134|f||||f
17187998|NCT00610701|t||||f
17187999|NCT01152294|f||||f
17188000|NCT00514046|f||||f
17188001|NCT00655551|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17188002|NCT00876460|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17188003|NCT04536571|f||||f
17188004|NCT02061696|t||||f
17188005|NCT01567865|f||||f
17188006|NCT00309608|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17188007|NCT04613882|f||||f
17188008|NCT00621296|f||OTHER||t
17143441|NCT03185949|f||||f
17143442|NCT03724968|t||||
17143443|NCT01142466|f||OTHER||t
17143444|NCT00681824|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of ≤60 days e.g., for intellectual property protection)|t
17143445|NCT03724916|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17143446|NCT00683332|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188009|NCT01051063|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188010|NCT02274649|f||||f
17188011|NCT01928680|t||||
17188012|NCT03857841|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17188013|NCT00386308|f||OTHER||t
17188014|NCT02906683|f||||t
17188015|NCT02781506|t||||
17188016|NCT01242176|t||||
17188017|NCT02240589|f||||f
17188018|NCT02802319|t||||f
17188019|NCT03545113|f||||f
17188020|NCT03472287|f||||f
17188021|NCT01683994|f||||f
17188022|NCT00999661|f||OTHER|The PIs agreed that the first publication of results should be made in conjunction with the presentation of a joint, multicenter publication of the results with the PIs from all sites contributing data, analyses, and comments. If this publication was not submitted within 12 months after conclusion of the Study at all sites, or after Sponsor confirmed there would be no multicenter Study publication, whichever is first, the PIs could have published the results from their individual sites.|t
17143447|NCT03712137|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143448|NCT03836729|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143449|NCT01270841|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights.|t
17143450|NCT04388527|t||||
17143451|NCT00782275|f||||f
17143452|NCT02577900|t||||
17143453|NCT00406107|f||||f
17143454|NCT03851107|f||||f
17143455|NCT00787566|f||OTHER|SNBL and investigators agreed that SNBL would retain the exclusive right to disseminate data arising from the study through either publication or presentation, including study results, and that SNBL would retain exclusive editorial rights over manuscripts or presentations.|t
17143456|NCT00417027|t||||
17143457|NCT00544557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143458|NCT00272337|t||||f
17143459|NCT01169987|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143460|NCT00386100|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143461|NCT02020785|f||||f
17143462|NCT02328807|t||||
17143463|NCT00886782|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143464|NCT01612702|t||||
17143465|NCT03636542|t||||
17143466|NCT00701935|f||||f
17143467|NCT01542736|t||||
17143468|NCT03674827|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143469|NCT01783483|f||||f
17143470|NCT03398928|f||||f
17143471|NCT04130919|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17143472|NCT02624518|f||||f
17143473|NCT00370396|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143474|NCT01462695|f||LTE60||t
17143475|NCT02400905|f||GT60||t
17143476|NCT00524394|f||||f
17143477|NCT01749033|f||||f
17143478|NCT00068237|f||||f
17143479|NCT05552430|f||||f
17150722|NCT00599521|f||OTHER|disclosure restriction varies per institutional request/agreement|t
17188023|NCT00548041|t||||f
17150723|NCT01293539|t||||
17150724|NCT00418301|f||||t
17188024|NCT03638635|f||||f
17188025|NCT01603420|f||||f
17188026|NCT00313911|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17188027|NCT03384953|f||||f
17188028|NCT01987596|t||||
17188029|NCT03223272|t||||
17143480|NCT01358708|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17143481|NCT01890694|f||||f
17143482|NCT04363736|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143483|NCT03567239|t||||
17143484|NCT03125629|t||||
17143485|NCT04542330|t||||
17143486|NCT02176642|t||||
17143487|NCT00217971|f||||f
17143488|NCT02989610|f||||f
17143489|NCT01532349|f||||f
17143490|NCT04508621|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17143491|NCT00808015|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143492|NCT01066039|f||||f
17143493|NCT01083901|t||||f
17143494|NCT06610279|f||||t
17143495|NCT00084617|f||LTE60||t
17143496|NCT01625286|f||||f
17143497|NCT00928135|f||||f
17143498|NCT02033382|f||||f
17143499|NCT03338673|t||||
17143500|NCT01005407|f||LTE60||t
17143501|NCT00434148|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17143502|NCT00828516|t||||f
17143503|NCT00990093|f||LTE60||t
17143504|NCT00393978|f||||f
17143505|NCT04556838|f||||f
17143506|NCT00995930|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17143507|NCT01880541|f||||f
17143508|NCT05003167|f||||f
17143509|NCT02842086|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17143510|NCT03751124|f||||t
17143511|NCT04777591|t||||
17143512|NCT01998035|t||||
17143513|NCT00555399|t||||
17143514|NCT05166421|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17143515|NCT03958071|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17143516|NCT01858558|f||||f
17143517|NCT00343642|f||||f
17143518|NCT02316678|f||||f
17143519|NCT04084028|f||||f
17143520|NCT00569231|t||||
17143521|NCT00821041|t||||
17143522|NCT00700310|f||||f
17143523|NCT00918229|f||||f
17143524|NCT01999231|f||OTHER||t
17143525|NCT03053622|f||GT60||t
17143526|NCT02598622|t||||
17143527|NCT00581386|t||||f
17143528|NCT04575038|f||||f
17143529|NCT01318733|f||GT60||t
17143530|NCT01902134|f||OTHER|Prior to submitting the results of this study for publication or presentation, the PI will allow the Sponsor at least 60 days to review and comment upon the publication manuscript. The Sponsor will provide any manuscript of the results of this study at least 60 days before publishing to the authors for a complete review.|t
17143531|NCT00305110|t||||
17143532|NCT00678379|f||||f
17143533|NCT01835470|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143534|NCT04036227|f||OTHER|Any confidential information relating to the IMP or the study, including any data and results from the study, will be the exclusive property of the Sponsor. The Investigator and any other persons involved in the study are responsible for protecting the confidentiality of this proprietary information belonging to the Sponsor. The results from this study may be submitted for publication at the discretion of the Sponsor.|t
17143535|NCT01363401|f||||f
17143536|NCT02267850|f||||f
17143537|NCT03005379|t||||f
17143538|NCT04335110|f||||f
17143539|NCT00350519|f||GT60||t
17150725|NCT02910674|t||||
17188030|NCT01533714|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. The Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188031|NCT03664739|f||OTHER|Contact sponsor for details.|t
17188032|NCT01421589|f||LTE60||t
17188033|NCT01311362|t||||f
17143540|NCT02595528|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143541|NCT00948025|f||||f
17143542|NCT01637961|f||LTE60||t
17143543|NCT02292433|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143544|NCT03101293|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17188034|NCT00251927|f||||f
17143545|NCT02833857|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143546|NCT03182920|f||GT60||t
17143547|NCT05319977|f||||f
17143548|NCT03333382|t||||
17143549|NCT00550420|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143550|NCT01305265|t||||
17143551|NCT00670267|f||||f
17188035|NCT04204772|t||||f
17143552|NCT03512067|f||||f
17143553|NCT02773446|f||||f
17143554|NCT03237611|t||||f
17188036|NCT02406261|f||GT60||t
17188037|NCT00227760|f||LTE60||t
17188038|NCT03410914|f||||f
17188039|NCT02222896|f||OTHER|Confidential information based on contract.|t
17143555|NCT01613131|f||||f
17143556|NCT01430182|f||||f
17143557|NCT01814761|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143558|NCT03137082|f||||f
17143559|NCT00939705|f||OTHER||t
17143560|NCT01020305|f||||f
17143561|NCT02184494|t||||
17143562|NCT01017029|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17143563|NCT00618774|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17143564|NCT00446264|t||||f
17143565|NCT02753400|f||||f
17143566|NCT01415921|t||||
17143567|NCT04980521|f||||f
17143568|NCT02660385|t||||f
17143569|NCT01830920|f||||f
17143570|NCT01990898|f||||f
17143571|NCT01878500|t||||
17143572|NCT03402126|f||OTHER|Participating Institution and PI agree that it will not independently publish, publicly disclose, present or discuss any results of or information pertaining to the Study until a multi-center publication is released; provided however, that if a multicenter publication is not released within one year after completion of the Study at all Study sites, Participating Institution and PI will have the right to publish the results of and information pertaining to their activities.|t
17143573|NCT02348619|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17143574|NCT00720304|t||||
17143575|NCT01333475|f||||f
17143576|NCT02981602|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17143577|NCT01632683|f||||f
17150726|NCT01687478|f||GT60||t
17188040|NCT02441946|f||LTE60||t
17188041|NCT02111213|f||||f
17188042|NCT00759772|f||||f
17188043|NCT04241575|f||||f
17188044|NCT01568827|f||||f
17188045|NCT02226172|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. Investigators will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.|t
17188046|NCT01865617|t||||
17188047|NCT04548531|f||||f
17188048|NCT01466764|f||||f
17188049|NCT00258440|f||||f
17143578|NCT01706770|f||OTHER|Release of this data (through presentation, publication or other written or oral communication) to other than listed personnel (see protocol) requires the prior written permission from the study Sponsor. Study investigators and all office personnelare prohibited from acknowledging participation in the study to individuals and organizations except those listed.|t
17143579|NCT02282111|f||||f
17143580|NCT00423488|f||OTHER|Investigator agrees not to publish or publicaly present results without prior written authorization from the sponsor, except than for the dispositions provided for in Ministerial Circular n.6 of 02 SEP 2002 and, particularly, disposition n.1a) The investigator further agrees to provide 30 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of material(including text for oral presentation) that report study results.|t
17143581|NCT00527397|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17143582|NCT00383019|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188050|NCT00737061|f||OTHER|"All publications must be submitted for review and approval at least (30) days before the date on which it is to be submitted.~No publication of data wil be permitted prior to the submission and publication of the entire clinical trial."|t
17188051|NCT00439179|f||||f
17188052|NCT01844115|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the investigator will be subject to mutual agreement between the investigator and Forest Research Institute, Inc.|t
17143583|NCT03797222|f||||f
17143584|NCT01777425|t||||
17143585|NCT00725725|f||||f
17143586|NCT00378482|f||OTHER|Sponsor can review results communications prior to public release and can embargo regarding trial results for up to six (6) months from the time submitted to the sponsor for review. All reasonable comments made by the sponsor in relation to the publication will be incorporated into the publication. PI shall not unreasonable withhold or delay its consent to a request from the sponsor for an exceptional additional delay if in the reasonable opinion of the sponsor.|t
17143587|NCT02450760|f||||f
17143588|NCT01355523|f||||f
17143589|NCT01011907|f||||f
17143590|NCT01272193|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17143591|NCT02685956|f||OTHER|Sponsor has 45 days to review and comment. Sponsor may extend the embargo period for no more than an additional 60 days in order to file a patent application due to patentable subject matter contained in the proposed presentation or publication. If the Sponsor objects to the publication or presentation due to the existence of confidential information, the institution shall remove the confidential information before disclosure.|t
17143592|NCT01440647|t||||
17143593|NCT01406873|t||||
17143594|NCT03254719|f||||f
17143595|NCT00736099|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17143596|NCT02290028|f||||t
17143597|NCT03202511|t||||
17143598|NCT05105477|f||||f
17143599|NCT00096382|f||||f
17143600|NCT02177773|t||||
17143601|NCT00289731|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143602|NCT04378010|f||OTHER||t
17143603|NCT02019979|t||||
17188053|NCT00758160|f||LTE60||t
17188054|NCT00993317|f||||f
17188055|NCT02153359|t||||
17188056|NCT04422639|t||||
17188057|NCT01964521|f||LTE60||t
17188058|NCT01372605|f||||f
17188059|NCT01108510|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188060|NCT02796963|t||||
17188061|NCT01258660|f||OTHER|PI (principal investigator) of CRO (contract research organization) will refrain from publishing any data or information generated or derived as a result of the performance of the Services.|t
17188062|NCT00350701|t||||
17188063|NCT02459080|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17188064|NCT01448421|f||OTHER|Upon completion of the Clinical Trial the Principal Investigator and Sponsor shall co-operate in producing a report of the Clinical Trial. The Sponsor will provide the Institution and/or Principal Investigator with the necessary results, and the Institution and/or Principal Investigator will be authorized to publish the results.|t
17188065|NCT01775930|t||||
17188066|NCT01182727|f||||f
17143604|NCT02513459|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143605|NCT00747747|f||||f
17143606|NCT04023994|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143607|NCT00923195|f||||f
17143608|NCT02314520|t||||f
17143609|NCT00467818|f||||f
17143610|NCT04214951|f||||f
17143611|NCT03903640|t||||
17143612|NCT02143947|f||||f
17188067|NCT00363896|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17143613|NCT01244815|f||OTHER|It is planned to first publish/present trial results together with the other sites, unless permission is obtained from Sponsor to publish separate results. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. If there is disagreement concerning appropriateness of the materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve disagreement prior to submission for publication.|t
17143614|NCT01173159|t||||
17143615|NCT01313728|f||GT60||t
17143616|NCT05795062|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143617|NCT03007537|t||||
17143618|NCT03876873|t||||
17143619|NCT03547531|f||||t
17143620|NCT02649608|f||||t
17143621|NCT02117479|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17188068|NCT03657264|f||OTHER||t
17188069|NCT01598428|t||||
17188070|NCT00924469|f||OTHER|Sponsor will retain the right to review all material prior to presentation or submission for publication and neither institution(s) nor Study Co-Chairs/Principal Investigator(s) is/are permitted to publish/present the results of the study, in part or in their entirety, without the written authorization of the Sponsor. The review is aimed at complying with 21CFR312.7 (non promotion of investigational drugs) as well as the intellectual property rights and commercial interests of the Sponsor.|t
17188071|NCT03044353|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188072|NCT01079143|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17188073|NCT02162992|f||||f
17188074|NCT02821832|t||||
17188075|NCT03745794|t||||
17188076|NCT01464255|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor. This restriction will apply for a period of five years from completion of the study.|t
17188077|NCT03051659|t||||
17188078|NCT00786474|f||||f
17188079|NCT02733042|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188080|NCT00960752|t||||
17188081|NCT05259774|t||||
17188082|NCT00461292|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17188083|NCT02180438|f||||f
17143622|NCT02444182|t||||f
17143623|NCT01412710|t||||
17143624|NCT01959230|f||OTHER|Please contact Sponsor directly for additional information.|t
17143625|NCT00459381|f||LTE60||t
17143626|NCT03216954|f||||f
17143627|NCT02487979|f||LTE60||t
17143628|NCT00447694|f||||t
17143629|NCT00837031|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17143630|NCT00717873|f||||f
17188084|NCT01811940|t||||
17188085|NCT00180713|f||OTHER|Standard terms of model non-commercial agreement for UK clinical research apply.|t
17188086|NCT03599986|f||||f
17143631|NCT01507831|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17143632|NCT00879970|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188087|NCT00591123|f||||f
17188088|NCT02326844|f||||f
17188089|NCT01091428|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17188090|NCT02531295|f||||f
17188091|NCT01060020|t||||
17188092|NCT04424290|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17188093|NCT02354924|f||||f
17188094|NCT01432015|f||||f
17188095|NCT00398398|f||||f
17188096|NCT02338713|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17188097|NCT00806624|f||OTHER|Korea study sites agree that any results of the study are not to be published individually or collectively in whole or part by study site, its employees or agents until after the coordinated multicenter publication or one year after the termination of the study, whichever occurs fist.|t
17188098|NCT02550132|f||||f
17188099|NCT01617083|f||||f
17188100|NCT00467142|t||||
17188101|NCT02771210|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17143633|NCT01431755|f||OTHER|Any publication or presentation by PI shall be submitted to Q-Med for review no less than 60 days before submission for publication or presentation. Q-Med will provide any comments to Principal Investigator within thirty (30) days following receipt of the proposed publication/presentation. PI agrees to consider, discuss and give reasonable considerations to comments by Q-Med. Q-Med may also request that the Company name or Q-Med employee name appear or not appear in such publication.|t
17143634|NCT04380701|f||OTHER|PIs respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17143635|NCT00363129|t||||
17143636|NCT03296553|f||||f
17143637|NCT02713243|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17143638|NCT01619085|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17143639|NCT03125915|f||||f
17143640|NCT01458119|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17143641|NCT00435825|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143642|NCT02517099|t||||
17143643|NCT01123980|f||OTHER|Novo Nordisk reserves the right not to release data until specified milestones. This includes the right not to release interim results from clinical trials. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17143644|NCT01225991|f||||f
17188102|NCT01576055|f||LTE60||t
17188103|NCT02694640|f||||f
17188104|NCT04496414|f||GT60||t
17188105|NCT00684762|f||GT60||t
17188106|NCT02572817|f||||f
17188107|NCT05462652|t||||
17188108|NCT00119262|f||LTE60||t
17188109|NCT00734214|f||||f
17188110|NCT02029040|t||||
17188111|NCT01017653|t||||
17188112|NCT02590068|t||||
17188113|NCT00630058|f||OTHER||t
17188114|NCT01651936|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17188115|NCT02512510|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143645|NCT00789828|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17143646|NCT02094937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143647|NCT01133392|t||||
17143648|NCT05788237|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143649|NCT01447329|t||||
17143650|NCT00304954|t||||f
17143651|NCT02661282|t||||
17143652|NCT00524576|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143653|NCT00894465|t||||
17143654|NCT03990389|t||||
17143655|NCT00207714|f||OTHER|Generally, the only disclosure restriction on the Principal Investigator is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143656|NCT03627195|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17143657|NCT02580318|t||||
17143658|NCT01883999|f||OTHER||t
17143659|NCT00328042|t||||
17143660|NCT00833547|f||||f
17143661|NCT01735877|t||||
17143662|NCT00686790|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review.|t
17143663|NCT03379246|t||||
17143664|NCT02542150|t||||
17143665|NCT02082912|t||||
17143666|NCT01110499|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143667|NCT02412956|f||||f
17143668|NCT01577966|t||||f
17143669|NCT00353938|f||||f
17143670|NCT00697112|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143671|NCT00736333|f||||f
17188116|NCT02141659|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17188117|NCT02340520|f||||f
17188118|NCT01231503|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143672|NCT04126733|f||OTHER|Investigators may publish or present individual study data (including case reports) obtained in the course of this study but only after the primary report and/or publication of the study results in their entirety. If publishing individual site data is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17188119|NCT01586338|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17143673|NCT02629133|t||||
17188120|NCT00284089|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17188121|NCT02201446|f||||f
17143674|NCT02598193|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143675|NCT01382901|f||LTE60||t
17143676|NCT02523274|f||||f
17143677|NCT02354976|f||||f
17143678|NCT03726437|f||||f
17143679|NCT01896700|t||||
17143680|NCT00117585|t||||
17188122|NCT01146574|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188123|NCT03053492|f||||f
17188124|NCT01868074|f||||f
17188125|NCT01544491|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17188126|NCT00967018|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17188127|NCT03897205|f||OTHER|"At the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Hansa Biopharma.~Any confidential information relating to imlifidase or the study, including any data and results from the study will be the exclusive property of Hansa Biopharma AB. The investigators and any other persons involved in the trial will protect the confidentiality of the proprietary information belonging to Hansa Biopharma AB."|t
17188128|NCT01272882|t||||
17188129|NCT00580229|f||LTE60||t
17188130|NCT04131959|f||||f
17188131|NCT04642469|f||||t
17188132|NCT02228525|t||||
17188133|NCT00680056|f||||f
17188134|NCT01088529|f||GT60||t
17188135|NCT01821898|f||||f
17188136|NCT02917577|f||||f
17188137|NCT00337662|f||GT60||t
17188138|NCT01381952|f||LTE60||t
17188139|NCT03691948|f||||f
17188140|NCT02344537|t||||
17188141|NCT00798486|f||LTE60||t
17188142|NCT02611830|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17188143|NCT00547105|t||||
17188144|NCT00220961|f||||f
17188145|NCT02058290|f||||f
17188146|NCT00405704|f||||f
17188147|NCT03012061|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188148|NCT02696902|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17188149|NCT00601003|f||||f
17188150|NCT01291225|t||||
17188151|NCT01267253|f||||f
17188152|NCT02768558|f||OTHER|Must obtain prior Sponsor approval.|t
17188153|NCT02855164|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17188154|NCT00383240|f||LTE60||t
17188155|NCT02601937|f||GT60||t
17188156|NCT02924389|t||||
17143681|NCT03118765|f||||t
17143682|NCT00849524|t||||
17143683|NCT00802633|t||||f
17143684|NCT00947518|f||||f
17143685|NCT01610167|f||LTE60||t
17143686|NCT01721967|t||||
17143687|NCT01021137|t||||
17143688|NCT03439293|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17143689|NCT00493181|t||||
17143690|NCT00660049|f||LTE60||t
17143691|NCT00614458|f||||f
17143692|NCT00751972|f||LTE60||t
17143693|NCT02766400|t||||
17143694|NCT00204932|f||LTE60||t
17143695|NCT03593772|f||||f
17143696|NCT03499249|f||||f
17143697|NCT01989195|f||||f
17188157|NCT03918239|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17188158|NCT04448236|f||||f
17188159|NCT04249336|f||||f
17188160|NCT02930122|f||||f
17188161|NCT03390036|f||||f
17188162|NCT00358215|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188163|NCT04329104|f||||f
17188164|NCT03884231|f||||t
17188165|NCT01853254|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143698|NCT04499235|f||OTHER|The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI.|t
17188166|NCT04176133|t||||
17188167|NCT01169259|f||||f
17188168|NCT03728153|f||||f
17188169|NCT01017120|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188170|NCT04764929|t||||
17188171|NCT01087723|f||GT60||t
17188172|NCT00252590|f||||f
17188173|NCT00289770|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188174|NCT01702428|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188175|NCT04995497|t||||
17188176|NCT00154063|f||||f
17188177|NCT02091869|t||||f
17188178|NCT01804673|f||||f
17143699|NCT01565382|f||GT60||t
17143700|NCT02731833|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143701|NCT01559818|f||||f
17143702|NCT04071626|t||||
17143703|NCT01374906|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17188179|NCT03483077|t||||
17188180|NCT05258747|f||OTHER|The terms and conditions of Sandoz's agreements with its investigators may vary. However, Sandoz does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17188181|NCT00451217|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17188182|NCT00358150|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17188183|NCT04668989|f||||f
17188184|NCT00574990|t||||
17188185|NCT01355419|t||||
17188186|NCT01622348|f||||t
17188187|NCT00179010|f||||f
17188188|NCT03765762|f||OTHER|The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI.|t
17143704|NCT02795780|f||LTE60||t
17143705|NCT02475980|f||||f
17143706|NCT04582409|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17143707|NCT01203319|f||||f
17143708|NCT00665626|f||LTE60||t
17143709|NCT04147611|t||||
17143710|NCT00530439|f||||f
17188189|NCT00956540|f||||f
17188190|NCT02392767|f||||f
17188191|NCT01592695|f||||f
17188192|NCT02766673|t||||
17188193|NCT01034579|f||OTHER|PIs have to submit any publication for internal review and approval by EMD Serono before it can be publicly disclosed.|t
17188194|NCT00453479|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188195|NCT01763788|f||GT60||t
17143711|NCT01010230|t||||
17143712|NCT01799213|t||||
17143713|NCT01629693|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17143714|NCT01529749|t||||
17143715|NCT04385199|t||||
17143716|NCT04071392|t||||
17143717|NCT00860574|f||||f
17143718|NCT01246986|f||GT60||t
17143719|NCT02006407|t||||
17143720|NCT00201734|t||||
17188196|NCT03893825|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17188197|NCT02354859|t||||
17188198|NCT02086552|t||||
17188199|NCT00708305|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188200|NCT04711460|t||||
17188201|NCT02823964|f||OTHER||t
17188202|NCT01930435|f||||f
17188203|NCT01560377|f||LTE60||t
17188204|NCT04012814|f||||f
17188205|NCT00390455|f||LTE60||t
17188206|NCT04397523|t||||
17188207|NCT01275196|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17188208|NCT00535743|f||OTHER|The Sponsor recognizes the right of the investigators to publish, but all publications must be based on data validated and released by the Sponsor. Any such scientific paper, presentation, or other communication concerning the clinical trial described in this protocol will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17188209|NCT00832338|t||||
17188210|NCT00981825|f||GT60||t
17188211|NCT03119571|t||||
17188212|NCT03056859|t||||
17188213|NCT02838628|f||||t
17188214|NCT02341144|t||||
17188215|NCT05033080|f||||t
17188216|NCT03560245|f||GT60||t
17188217|NCT01265823|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188218|NCT01850082|f||||f
17143721|NCT01416142|f||OTHER||t
17143722|NCT01335399|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143723|NCT02464059|f||||f
17143724|NCT01326702|f||LTE60||t
17143725|NCT03615079|f||||f
17143726|NCT01835132|t||||f
17143727|NCT00856778|f||||f
17143728|NCT03208933|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17188219|NCT00715741|f||||f
17188220|NCT01356667|t||||
17188221|NCT03228017|t||||
17188222|NCT01018563|f||OTHER||t
17143729|NCT00331773|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17143730|NCT00379587|t||||
17188223|NCT01378520|f||||f
17188224|NCT00903786|f||OTHER||t
17188225|NCT03295266|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17188226|NCT00479089|t||||
17143731|NCT00534092|f||OTHER||t
17143732|NCT00628394|f||||f
17143733|NCT00525031|t||||
17143734|NCT02323295|f||||f
17143735|NCT00830063|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143736|NCT02140164|t||||
17143737|NCT00780715|t||||
17143738|NCT00661674|t||||f
17143739|NCT01872689|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188227|NCT03421496|f||||f
17188228|NCT05822921|f||||f
17188229|NCT03406702|f||||f
17188230|NCT01857622|f||OTHER|PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.|t
17188231|NCT01234766|t||||
17188232|NCT04213989|t||||
17188233|NCT02835443|f||||f
17188234|NCT01086605|t||||
17188235|NCT01024959|f||LTE60||t
17188236|NCT00636792|f||||f
17188237|NCT01414413|t||||
17188238|NCT00709592|t||||
17188239|NCT01950273|t||||
17188240|NCT00472186|f||||f
17188241|NCT01254565|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188242|NCT00178256|t||||
17188243|NCT04800757|t||||
17188244|NCT04076020|t||||
17188245|NCT05022602|f||OTHER|INSTITUTION/INVESTIGATOR will provide such proposed publications/presentations, to SPONSOR for review, at least thirty (30) days prior to submission for publication or of public disclosure. SPONSOR will complete its review within thirty (30) days of receipt of the submitted publications/presentations. The INSTITUTION shall consider SPONSOR's suggestions and comments to the manuscript to be published.|t
17188246|NCT02310126|f||GT60||t
17188247|NCT00855868|f||||f
17188248|NCT00654329|t||||
17188249|NCT02761629|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188250|NCT02132533|t||||
17188251|NCT02001974|f||||f
17188252|NCT00672958|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17188253|NCT01380990|f||||f
17143740|NCT06118359|f||||f
17143741|NCT00881959|f||LTE60||t
17143742|NCT03202628|t||||
17143743|NCT00686374|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188254|NCT03121534|t||||
17188255|NCT02374593|t||||
17188256|NCT04267614|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188257|NCT00210119|t||||
17188258|NCT04827134|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188259|NCT01830881|f||||f
17188260|NCT00988351|f||||f
17188261|NCT02038764|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188262|NCT01306175|t||||
17188263|NCT02136498|f||||f
17188264|NCT04844918|f||GT60||t
17188265|NCT01990820|f||||f
17188266|NCT00183456|f||||f
17188267|NCT02731313|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188268|NCT02649322|t||||
17188269|NCT02708238|f||||f
17188270|NCT04110366|t||||
17188271|NCT01927731|t||||
17188272|NCT01388530|f||||f
17188273|NCT01812005|t||||
17188274|NCT02743793|f||||f
17188275|NCT02065570|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188276|NCT02697006|f||||f
17188277|NCT02293837|f||||f
17188278|NCT04779242|f||||t
17188279|NCT01757067|f||||f
17188280|NCT03285113|f||||f
17188281|NCT02643979|t||||
17188282|NCT00849680|f||OTHER|"As this study is part of a multicenter trial, publications derived from this study should include input from the principal investigator, his/her colleagues, the other investigators in this trial, and SPONSOR personnel.~The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines."|t
17188283|NCT04267575|f||GT60||t
17143744|NCT01070966|f||||f
17143745|NCT01725113|t||||
17143746|NCT01808209|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor. Assuming that the product is marketed, and only with the sponsor's permission, will they allow publication of the results of the study.|t
17143747|NCT03066440|f||||f
17188284|NCT01461993|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188285|NCT00787722|t||||f
17188286|NCT00219141|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17188287|NCT03912220|f||||f
17188288|NCT02066532|f||||f
17188289|NCT03216902|f||OTHER|If Institution/Principal Investigator wishes to publish findings, they must submit draft to Santen at least 30 days prior, deleting Confidential Information if requested. Santen must be allowed up to ninety (90) days to determine if patent application is to be filed. Santen has right to first publication of Multi-Center Research results, but if publication doesn't occur within 12 months after completion, Institution/Principal Investigator may individually publish site's results.|t
17188290|NCT01263106|f||GT60||t
17188291|NCT02913521|f||||f
17188292|NCT03662360|f||||f
17188293|NCT01680458|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188294|NCT01468532|t||||
17188295|NCT00589550|t||||
17188296|NCT03777865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188297|NCT04694482|f||||f
17188298|NCT00401102|f||||f
17188299|NCT00544544|t||||f
17188300|NCT00762021|f||OTHER|Publications relating to the study should not be made without the Sponsor's prior written consent and not prior to the completion of the study. The sponsor shall be notified in writing at least 60 days prior to submission of any intention on the part of the Investigator to publish and shall provide the sponsor an opportunity to comment on any proposed publications.|t
17188301|NCT01414426|f||||f
17188302|NCT04318093|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188303|NCT02397265|t||||
17188304|NCT00127413|t||||
17188305|NCT01515345|t||||f
17188306|NCT00547911|t||||
17188307|NCT02413190|f||||f
17188308|NCT01644474|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17188309|NCT02023879|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17188310|NCT01404611|f||OTHER|Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.|t
17188311|NCT02044458|f||||f
17188312|NCT03363659|t||||
17188313|NCT03872388|t||||
17188314|NCT01040780|t||GT60||t
17188315|NCT00802737|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188316|NCT03677128|f||||f
17188317|NCT04435795|f||||f
17188318|NCT03864926|t||||
17188319|NCT00445601|f||||f
17188320|NCT00214903|t||||
17188321|NCT02543723|f||||f
17188322|NCT01625910|t||||
17188323|NCT02959138|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188324|NCT02391038|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17188325|NCT02873286|f||||t
17188326|NCT01946243|t||||
17188327|NCT00963989|f||||f
17188328|NCT01439087|f||||f
17143748|NCT02145403|t||||
17143749|NCT03947788|f||||f
17143750|NCT03723590|f||||f
17188329|NCT01681368|f||||f
17188330|NCT01189890|f||OTHER|Investigator may publish results for his/her study site after publication of results of entire multicenter trial, or after public disclosure of the results online if a multicenter manuscript is not planned. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17188331|NCT00593554|t||||
17188332|NCT01649596|f||||f
17188333|NCT02254421|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188334|NCT03092960|f||||f
17188335|NCT00839917|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17188336|NCT01129336|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17188337|NCT00867490|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17188338|NCT02367014|f||GT60||t
17188339|NCT03354637|f||||f
17188340|NCT02726399|t||||
17188341|NCT02564055|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188342|NCT04747275|t||||
17188343|NCT00447330|f||||f
17188344|NCT00531011|f||OTHER|The publication of the aggregate data is subject to the prior agreement of all the various sites participating in the study. Publication of the clinical data collected during the Study, can be only after notifying the SPONSOR in advance in order to allow the SPONSOR to verify compliance with confidentiality obligations and intellectual property rights of the SPONSOR.|t
17188345|NCT03268590|f||OTHER|Funding source is the United States Air Force Research Laboratories. The AFRL must approve any presentation or publication of the study results before they can be disseminated.|t
17188346|NCT05719285|f||||f
17188347|NCT02971891|f||||f
17188348|NCT02774343|t||||
17188349|NCT00919893|f||||f
17188350|NCT01375959|f||||f
17188351|NCT04254679|t||||f
17188352|NCT00794820|t||||
17188353|NCT02524054|f||||f
17188354|NCT03537261|f||||f
17143751|NCT01106352|f||LTE60||t
17143752|NCT03944707|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17143753|NCT00183469|t||||
17143754|NCT02951884|t||||
17188355|NCT03237013|t||||
17188356|NCT01861756|f||||f
17188357|NCT00502996|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188358|NCT01729728|f||OTHER|The sponsor reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither party has the right to prohibit publication unless publication can be shown to affect possible patent rights.|t
17188359|NCT02500979|f||||f
17188360|NCT00610675|f||LTE60||t
17188361|NCT00267111|f||||f
17188362|NCT01316692|t||||
17143755|NCT02577042|t||||
17143756|NCT00751998|f||||f
17143757|NCT01965535|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188363|NCT02368002|f||||f
17188364|NCT01536145|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188365|NCT00579982|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188366|NCT05199233|t||||
17188367|NCT00736073|f||||f
17188368|NCT02443103|t||||
17188369|NCT01630590|t||||
17188370|NCT02366936|t||||
17188371|NCT00656916|t||||
17188372|NCT03358329|f||||f
17188373|NCT01313923|f||||f
17188374|NCT02471404|f||||f
17188375|NCT02982720|f||||f
17188376|NCT02144519|f||||f
17188377|NCT00305864|f||LTE60||t
17188378|NCT01450787|f||||f
17188379|NCT02836613|f||GT60||t
17188380|NCT03881059|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188381|NCT05284019|f||||f
17188382|NCT00287469|f||||f
17188383|NCT01844193|f||||f
17188384|NCT01266993|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188385|NCT02942004|f||OTHER|The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution).|t
17188386|NCT03382600|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17188387|NCT01448044|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143758|NCT02983227|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143759|NCT00986154|f||OTHER|A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site's proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.|t
17143760|NCT01032759|t||||
17143761|NCT00068445|t||||
17143762|NCT01493531|f||OTHER|PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.|t
17143763|NCT01946282|f||||f
17143764|NCT01362959|f||||f
17143765|NCT03031431|t||||
17143766|NCT01205529|t||||
17188388|NCT00780442|t||||
17188389|NCT01000376|f||||f
17188390|NCT00507026|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188391|NCT00896454|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188392|NCT00658736|t||||
17188393|NCT03688711|f||||f
17188394|NCT04193293|f||||f
17188395|NCT04675242|f||||f
17188396|NCT02874066|f||||f
17188397|NCT03141528|t||||
17188398|NCT02667444|f||||t
17188399|NCT04719013|f||||t
17188400|NCT02500316|f||||t
17188401|NCT01406717|f||OTHER||t
17188402|NCT03257995|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17188403|NCT01112696|f||LTE60||t
17188404|NCT01872949|f||||f
17188405|NCT02969031|f||||f
17188406|NCT01556763|f||OTHER||t
17143767|NCT02128867|f||||f
17143768|NCT01027884|f||||f
17143769|NCT01147016|t||||
17143770|NCT03670537|t||||
17188407|NCT04170296|f||||f
17188408|NCT00195715|f||OTHER|Any investigator or institution that plans on presenting/publishing results disclosure, should provide written notification to Abbott within 60 days of their presentation/publication. Abbott requests that no presentation/publication will be allowed until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay of any proposed presentation/publication maybe requested if Abbott needs to secure patent or other proprietary protection.|t
17188409|NCT00845871|f||||f
17188410|NCT02076074|t||||
17143771|NCT02059187|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17143772|NCT03070431|f||||f
17143773|NCT01889862|f||GT60||t
17143774|NCT00845026|f||GT60||t
17143775|NCT01325532|f||||f
17143776|NCT03012815|t||||
17143777|NCT01252238|f||||f
17143778|NCT01203774|f||||f
17143779|NCT02565485|t||||
17143780|NCT06371079|f||||f
17188411|NCT01370603|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.|t
17188412|NCT01097460|f||OTHER||t
17188413|NCT04039503|f||GT60||t
17188414|NCT01163747|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143781|NCT03029000|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17143782|NCT00411762|t||||
17143783|NCT03276962|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17143784|NCT00827073|f||||f
17143785|NCT00904189|t||||
17143786|NCT02995694|f||GT60||t
17143787|NCT04974645|f||||f
17143788|NCT02295280|f||||f
17143789|NCT00558519|f||||t
17143790|NCT03056352|t||||
17143791|NCT02278952|t||||f
17143792|NCT03275168|f||||f
17143793|NCT00869089|f||||f
17143794|NCT04643782|f||||f
17143795|NCT01963676|f||||f
17143796|NCT01246973|t||||
17143797|NCT00766506|f||LTE60||t
17143798|NCT02496221|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143799|NCT03262233|t||||
17143800|NCT01893983|t||||
17143801|NCT01120600|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17143802|NCT01165242|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143803|NCT03770000|f||||f
17143804|NCT03877237|t||||
17143805|NCT00142454|f||LTE60||t
17143806|NCT00566098|t||||
17143807|NCT02236754|t||||f
17143808|NCT00382291|f||||f
17143809|NCT01725815|t||||
17143810|NCT02580188|f||||f
17143811|NCT01681771|f||||f
17143812|NCT00265083|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143813|NCT03154333|f||||f
17143814|NCT02096029|f||||f
17143815|NCT04242186|f||||f
17143816|NCT01155063|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143817|NCT01314703|f||||f
17188415|NCT03681639|f||||f
17188416|NCT00654940|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188417|NCT00581113|t||||
17188418|NCT01818141|f||||f
17143818|NCT00597584|f||OTHER|The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.|t
17143819|NCT01551550|f||||f
17143820|NCT03094806|f||||f
17188419|NCT00619476|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143821|NCT01402115|t||||f
17143822|NCT02853929|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143823|NCT02770716|f||||t
17143824|NCT03989115|f||||t
17188420|NCT01554982|f||||f
17188421|NCT00678444|t||||f
17188422|NCT03204695|f||OTHER|Results of this clinical study may be submitted for publication without regard for whether the trial results are positive or negative. Sponsor will be responsible for oversight of the publication process and will have oversight of publications of results of the trial, the Physician Advisory Committee may advise.|t
17143825|NCT02499354|f||||f
17143826|NCT02135874|t||||
17143827|NCT02655354|f||||f
17143828|NCT01759381|t||||
17143829|NCT01460927|f||OTHER|Investigator shall have the right to publish the results of the Trial provided Sponsor has given it prior written approval. Sponsor reserves the right to remove all Confidential Information from any communications, or if Sponsor deems that such removal does not sufficiently protect its intellectual property rights, to require that Investigator refrain from making such communications.|t
17143830|NCT00447603|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17143831|NCT02786498|f||||f
17143832|NCT02410837|f||OTHER|Institution and Investigator shall not publish the Study results until after Sponsor's multi-site publication of complete and final study results or until the elapse of twelve (12) months from the close of the Study at all Study sites, whichever occurs earlier; unless approved by Sponsor.|t
17143833|NCT00919802|f||||f
17143834|NCT03411642|t||||
17188423|NCT04834362|f||||f
17188424|NCT01868789|t||||
17188425|NCT01349829|f||||f
17188426|NCT03095599|f||||f
17188427|NCT00299689|t||||
17188428|NCT00742885|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188429|NCT04781647|f||LTE60||t
17188430|NCT01811563|f||||f
17188431|NCT00329719|f||LTE60||t
17188432|NCT00440180|f||||f
17188433|NCT01995357|t||||
17188434|NCT01026909|t||||
17188435|NCT01807221|f||OTHER||t
17188436|NCT02609659|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17143835|NCT01428024|f||LTE60||t
17143836|NCT01455545|t||||
17143837|NCT00106028|f||OTHER|The findings of the study may be published in a scientific journal or presented at a scientific meeting. Before submitting the results of the study for publication or presentation, the Investigator will allow the Sponsor 30 days in which to review and comment on the manuscript.|t
17143838|NCT01280981|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17143839|NCT04726514|f||||f
17143840|NCT01256398|f||LTE60||t
17143841|NCT01238211|f||LTE60||t
17143842|NCT04428502|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143843|NCT01166997|f||GT60||t
17143844|NCT03550794|f||||f
17143845|NCT00449930|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143846|NCT01864525|f||||f
17143847|NCT03712228|f||||t
17143848|NCT03001011|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17143849|NCT02875067|t||||
17143850|NCT00065065|f||||f
17143851|NCT01241565|f||||f
17188437|NCT01155388|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data has been received by Sponsor, the Site and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 120 days to allow Sponsor to protect its interests.|t
17143852|NCT05288673|f||||t
17143853|NCT01050673|f||||f
17143854|NCT04322968|t||||
17143855|NCT01254045|t||||
17143856|NCT02971605|t||||f
17143857|NCT00597207|f||LTE60||t
17143858|NCT00520351|f||GT60||t
17143859|NCT02122471|f||||t
17143860|NCT04553484|f||OTHER||t
17143861|NCT01298596|f||||f
17143862|NCT04128696|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17143863|NCT00585039|f||||f
17143864|NCT00951899|t||||f
17143865|NCT04929522|t||||
17143866|NCT01901211|f||||f
17143867|NCT02133352|f||||f
17143868|NCT00579254|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17143869|NCT02557672|t||||
17143870|NCT03705169|f||||f
17143871|NCT02464878|f||||f
17143872|NCT02460874|t||||
17143873|NCT01690520|f||||t
17143874|NCT04006847|t||||
17143875|NCT01375010|t||||f
17143876|NCT02614703|f||||f
17188438|NCT01004250|f||GT60||t
17188439|NCT03943589|f||OTHER|"At the end of the study, one or more manuscripts for joint publication may be prepared in collaboration between the investigator(s) offered authorship and Hansa Biopharma.~Any confidential information relating to imlifidase or the study, including any data and results from the study will be the exclusive property of Hansa Biopharma AB. The investigators and any other persons involved in the trial will protect the confidentiality of the proprietary information belonging to Hansa Biopharma AB"|t
17188440|NCT00900627|f||GT60||t
17188441|NCT00373295|f||||f
17188442|NCT00830947|f||LTE60||t
17188443|NCT02291289|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188444|NCT02802020|f||||f
17188445|NCT02137538|t||||
17188446|NCT03294213|f||LTE60||t
17188447|NCT00962585|f||LTE60||t
17188448|NCT00883103|t||||
17188449|NCT00415493|f||||f
17188450|NCT00594906|t||||
17188451|NCT02165904|t||||
17188452|NCT01033773|t||||
17188453|NCT04430335|t||||
17188454|NCT02360774|f||||f
17188455|NCT02139982|t||||
17188456|NCT02173535|f||GT60||t
17143877|NCT02402933|f||LTE60||t
17143878|NCT00361257|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17143879|NCT02919475|f||OTHER|The sponsor can review results communications at least 60 days prior to public release. The sponsor will have a review period of 60 days and can embargo communications regarding trial results for an additional period of 60 days from the end of sponsor review period. The sponsor may require removal of any and all confidential information (other than study results) in the communication.|t
17143880|NCT06156969|t||||
17143881|NCT02370784|t||||f
17143882|NCT00775983|f||||f
17143883|NCT02962882|f||||t
17143884|NCT01312779|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 30 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 60 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17143885|NCT01663714|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143886|NCT00674219|t||||
17143887|NCT00660790|t||||
17143888|NCT02791659|t||||
17143889|NCT03840811|f||LTE60||t
17143890|NCT01904383|t||||
17143891|NCT01625845|t||||f
17143892|NCT01294592|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143893|NCT02762565|t||||
17188457|NCT02682498|f||||f
17188458|NCT01754779|t||||
17143894|NCT03549130|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143895|NCT01113710|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17143896|NCT01078623|f||OTHER|Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and sponsor|t
17143897|NCT00623623|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17143898|NCT02186808|f||||f
17143899|NCT04356573|t||||f
17143900|NCT02424565|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143901|NCT03568500|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17143902|NCT03650400|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17143903|NCT01577537|f||OTHER|For multicenter studies, PIs can publish only after data from all sites are published collectively.|t
17143904|NCT01768000|f||||f
17143905|NCT01809054|t||||
17143906|NCT00950833|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143907|NCT04132232|f||||f
17143908|NCT00368537|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17143909|NCT04248855|f||||t
17143910|NCT00374543|f||||f
17143911|NCT01368276|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17143912|NCT05483920|t||||
17143913|NCT01427920|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17143914|NCT04228302|f||OTHER|PPD may not publish any articles or make any presentations relating to the Services provided to EicOsis hereunder with respect to a Project or referring to data, information or materials generated as part of the Services without the prior written consent of EicOsis.|t
17143915|NCT01674478|t||||
17143916|NCT02281409|t||||
17143917|NCT05784571|t||||
17143918|NCT02732561|f||||f
17143919|NCT01202994|f||||f
17143920|NCT02528318|f||OTHER|The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement among Windtree Therapeutics, Inc. and participating institutions. The publication or presentation of any study results shall comply with all applicable privacy laws, including, but not limited to, HIPAA.|t
17188459|NCT03954158|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188460|NCT02206152|f||||f
17188461|NCT00478608|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17188462|NCT00658697|t||||
17188463|NCT02080520|t||||f
17188464|NCT03875495|f||||f
17188465|NCT05641077|t||||
17188466|NCT03039543|f||||f
17188467|NCT01394250|t||||
17188468|NCT00634322|f||LTE60||t
17188469|NCT03230864|f||||f
17188470|NCT03679013|t||||
17188471|NCT01930643|t||||t
17188472|NCT00432679|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188473|NCT00601718|t||||
17188474|NCT00600743|t||OTHER|The provider of the drug (not sponsor - since this was an investigator initiated protocol) needs to review the results before release. In this case there was a public presentation at a scientific meeting, and the abstract was published. However, before a full report can be released, the provider of the drug needs to review the report.|t
17188475|NCT01177813|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17188476|NCT00581256|t||||
17188477|NCT00109928|f||||f
17188478|NCT01196104|f||OTHER|MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.|t
17188479|NCT00983619|f||OTHER|Medimmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17188480|NCT03772314|t||||
17188481|NCT02444234|f||||f
17188482|NCT01183650|f||GT60||t
17188483|NCT01284140|f||||f
17188484|NCT00088205|f||GT60||t
17188485|NCT03192215|f||||f
17188486|NCT02593032|f||||f
17188487|NCT00110513|f||||f
17188488|NCT02061761|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188489|NCT02337478|t||||
17188490|NCT02258464|f||GT60||t
17188491|NCT00459303|f||||f
17188492|NCT04714216|t||||
17188493|NCT01222832|f||||f
17188494|NCT00968838|t||||f
17188495|NCT01755689|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188496|NCT01327547|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188497|NCT02462083|f||OTHER|Please contact Sponsor directly for additional information.|t
17188498|NCT03076359|f||||f
17188499|NCT01642186|t||||
17188500|NCT01668147|t||||
17188501|NCT02040792|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17188502|NCT00590980|f||||f
17188503|NCT03699124|f||OTHER|The agreement entitles Bavarian Nordic to request the Institution(s) to delay their publication for a period of up to six (6) months from the date of the first submission to Bavarian Nordic.|t
17188504|NCT00506285|f||||f
17188505|NCT01089556|f||GT60||t
17188506|NCT01238575|f||||f
17188507|NCT03405662|t||||f
17188508|NCT02379117|f||||f
17188509|NCT01555021|t||||f
17188510|NCT01448525|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17188511|NCT03875911|f||||f
17188512|NCT02343575|t||||
17188513|NCT00750893|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188514|NCT03824938|t||||
17188515|NCT05126459|t||||
17188516|NCT02420327|f||||f
17188517|NCT00614198|t||||
17188518|NCT00065468|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188519|NCT01225835|f||OTHER|"The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor.~Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention."|t
17188520|NCT02589392|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Disclosure agreement covered by contract.|t
17143921|NCT00837577|f||OTHER|The only disclosure restriction on the PI is that the sponsor must have the opportunity to review all communications regarding trial results for 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17143922|NCT02400073|f||||f
17143923|NCT01602198|f||||f
17188521|NCT02965144|f||||f
17188522|NCT03299062|t||||
17143924|NCT00475852|f||OTHER|The Executive and Steering Committees is responsible for the creation, review, and submission of publications and presentations after study completion. The Investigator agrees that all data are the property of the Sponsors and subject to confidentiality and use restrictions until results are presented in the public domain. Publications or presentations must be submitted to the Sponsors and necessary committees for review before publication, public dissemination, or review by a third-parties.|t
17188523|NCT05515679|t||||
17188524|NCT02207374|f||OTHER|"At the end of the trial, one or more scientific publications may be prepared collaboratively by the Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property."|t
17188525|NCT02087150|f||GT60||t
17188526|NCT02501135|t||||
17188527|NCT02372058|f||||f
17188528|NCT01952301|f||||f
17188529|NCT00972179|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188530|NCT04374565|f||||f
17143925|NCT00272961|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143926|NCT02065791|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17143927|NCT00973856|f||||f
17143928|NCT01890785|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17143929|NCT01964105|f||||f
17143930|NCT00575328|f||||f
17143931|NCT02124746|f||OTHER|Most restrictive: Site may not present or publish results of Trial without advance written notice of Sponsor or two years after completion of Trial at all participating sites. Site must submit all proposed publications or presentations to Sponsor for review. Sponsor can review communications prior to public release and embargo trial results communications for a period between 75 and 180 days from submission to Sponsor for review. Sponsor has right to request Site remove Confidential Information.|t
17143932|NCT00397839|f||||f
17188531|NCT01168674|f||||f
17143933|NCT00124449|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17143934|NCT00571922|t||||
17143935|NCT04080882|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17143936|NCT02522949|f||||f
17143937|NCT06079853|t||||
17143938|NCT02191579|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17143939|NCT01392859|t||||
17143940|NCT00389649|f||||f
17143941|NCT03940586|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17143942|NCT00964223|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17143943|NCT00811070|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143944|NCT01364259|t||||
17143945|NCT05113901|f||||f
17188532|NCT02584855|f||GT60||t
17188533|NCT02138747|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after primary publication of the multi-site data. Sponsor must receive a site's manuscript at least 45 days prior to planned submission to ensure that no confidential information of Sponsor is included in the document. In addition if requested by sponsor any publication or presentation shall be delayed for a period not to exceed 60 days.|t
17188534|NCT00932646|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17188535|NCT00653263|t||||
17188536|NCT00183443|f||||f
17188537|NCT02285595|f||||f
17188538|NCT03844321|f||||f
17188539|NCT02452866|f||||f
17188540|NCT01374802|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17188541|NCT01719900|f||||f
17188542|NCT02559609|f||||f
17143946|NCT01585831|t||||
17143947|NCT02046369|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17143948|NCT03120520|f||OTHER|Contact Sponsor for details.|t
17143949|NCT03927781|f||||f
17143950|NCT01759537|f||LTE60||t
17143951|NCT00420290|t||||
17143952|NCT02092961|f||OTHER|The disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to publication. Sponsor will be allowed a review period of at least 60 days from submission but can request that publication be delayed for a period up to 6 months. Any reasonable comments made by the sponsor will be incorporated by the PI into the publication.|t
17143953|NCT00854620|t||||f
17143954|NCT01623830|t||||
17143955|NCT01792284|f||GT60||t
17143956|NCT02609737|t||||
17143957|NCT04636398|f||||f
17143958|NCT01169649|t||||
17143959|NCT01928446|t||||
17143960|NCT00740727|f||||f
17143961|NCT04364165|f||||f
17143962|NCT01847313|f||||f
17188543|NCT00064025|f||||f
17188544|NCT03277378|f||||f
17188545|NCT02468934|f||LTE60||t
17188546|NCT00518713|f||OTHER|The sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17143963|NCT00478361|t||||
17143964|NCT04126057|f||OTHER||t
17143965|NCT00515073|t||||f
17143966|NCT01456052|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least sixty (60) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any information to which Sponsor objects, any Confidential Information, proprietary information or patentable subject matter.|t
17143967|NCT00463866|f||OTHER||t
17143968|NCT02265952|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17143969|NCT02062606|f||OTHER|The Institution/PI shall not disclose/use any confidential/proprietary information (CI) disclosed to/developed by the Institution during the study. Institution/PI agree to hold the results of the Study in confidence, and shall not disclose them except with prior written consent of K2M. Institution agrees to submit any Articles to K2M for review prior to publication and agrees to edit out any confidential information identified by K2M.|t
17143970|NCT01042977|f||OTHER|If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.|t
17143971|NCT04303845|t||||
17143972|NCT02883673|f||||f
17143973|NCT02784925|t||||
17143974|NCT01886300|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the sponsor's intellectual property rights.|t
17143975|NCT02008721|t||LTE60||t
17143976|NCT01156571|f||OTHER|"In general, PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.~PI must submit results communications to sponsor for review at least 45 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 135 days solely to seek appropriate patent protection."|t
17143977|NCT00267007|f||LTE60||t
17143978|NCT01825876|f||GT60||t
17143979|NCT05149287|t||||
17143980|NCT03751020|t||||
17143981|NCT00711867|f||LTE60||t
17143982|NCT04133519|f||||f
17143983|NCT00297479|t||||
17143984|NCT01664494|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17143985|NCT03196791|f||||f
17143986|NCT02273206|f||||f
17143987|NCT02238977|t||||
17188547|NCT00641186|f||||f
17188548|NCT02922985|f||||f
17188549|NCT02218489|f||OTHER|"The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:~(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial."|t
17188550|NCT02404493|f||OTHER|Principal investigators agreed not to publish the study results without prior sponsor approval.|t
17188551|NCT02388074|t||||f
17188552|NCT00003458|f||||f
17188553|NCT02133924|f||LTE60||t
17188554|NCT01254890|t||||
17188555|NCT04157686|f||OTHER|General research agreement between the sponsor and PI's that includes a confidentiality section that includes a statement that the sponsor is and shall remain the exclusive owner of 'Information'. 'Information' shall include, but shall not be limited to, protocols, trade secrets, know-how, formulations, inventions, techniques, equipment, data and results.|t
17188556|NCT01216293|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17188557|NCT00225420|f||GT60||t
17188558|NCT00360555|f||||f
17188559|NCT01023308|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17188560|NCT00551213|f||OTHER|The Investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17143988|NCT00373685|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17143989|NCT01789281|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17143990|NCT02746705|t||||
17143991|NCT00362401|f||||f
17143992|NCT02163811|t||||f
17143993|NCT00769015|f||||f
17143994|NCT02862535|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17143995|NCT03929224|f||||f
17143996|NCT04304950|f||||f
17143997|NCT03077828|t||||
17143998|NCT03536819|f||||f
17143999|NCT02769000|t||||
17144000|NCT02418910|f||||f
17144001|NCT00140556|f||LTE60||t
17144002|NCT02472977|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144003|NCT00345683|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144004|NCT04288115|t||||f
17144005|NCT03634488|f||||f
17144006|NCT02720224|f||||t
17144007|NCT00729365|f||||f
17144008|NCT01154127|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17144009|NCT01697449|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144010|NCT00676026|f||||f
17144011|NCT01169844|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144012|NCT05037409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144013|NCT00529568|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188561|NCT01383993|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188562|NCT03796689|t||||
17188563|NCT02561455|f||OTHER|"Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement."|t
17188564|NCT00262743|t||||
17188565|NCT05454449|f||||f
17188567|NCT02701582|f||||f
17188568|NCT01406860|t||||
17188569|NCT02774265|f||||f
17188570|NCT01300559|f||LTE60||t
17188571|NCT03748979|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17188572|NCT01335308|f||||f
17188573|NCT03249376|f||||t
17188574|NCT01154036|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17188575|NCT01349907|f||OTHER|No publication or manuscript shall contain any trade secret information of the sponsor or any proprietary or confidential information of the sponsor, and shall be confined to new discoveries and interpretations of scientific fact.|t
17188576|NCT03226457|t||||
17188577|NCT01591460|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188578|NCT00859508|f||LTE60||t
17188579|NCT04102540|f||||f
17188580|NCT01744496|f||GT60||t
17188581|NCT01567163|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17188582|NCT02339389|f||||f
17188583|NCT01048606|f||||f
17188584|NCT02563834|f||||f
17188585|NCT01364727|f||||f
17188586|NCT01927718|t||||
17188587|NCT01009047|f||OTHER|If an Investigator wishes to publish information from the study, a copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication. If requested by the Sponsor, the Investigator will withhold it up to an additional 60 days to allow for filing of a patent application. The Sponsor will not change or suppress the scientific content. For multi-center study, results may not be published before the primary endpoints of a study have been published.|t
17188588|NCT04716881|f||LTE60||t
17188589|NCT01752413|t||||
17188590|NCT01558674|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17188591|NCT04147260|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17188592|NCT00445263|f||||f
17188593|NCT01734850|f||||f
17188594|NCT02204293|f||||f
17188595|NCT01990300|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17188596|NCT01405794|f||||f
17188597|NCT02019602|f||GT60||t
17144014|NCT01201356|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144015|NCT00931385|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17144016|NCT03360656|f||||f
17144017|NCT00738920|f||||f
17144018|NCT03821324|f||||f
17144019|NCT04079842|t||||
17144020|NCT02904200|f||||t
17144021|NCT04444752|f||||t
17144022|NCT02270983|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the Investigator, Forest Research Institute, Inc., an affiliate of Allergan, and Ironwood Pharmaceuticals Inc.|t
17144023|NCT00124176|f||||f
17144024|NCT01265966|f||||f
17144025|NCT00928252|t||||
17188598|NCT00322374|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144026|NCT01605461|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144027|NCT02024698|f||OTHER|The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor.|t
17144028|NCT00331630|f||||f
17144029|NCT02764489|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144030|NCT02038634|t||||
17144031|NCT00693784|f||GT60||t
17180687|NCT03061331|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17188599|NCT00925782|f||OTHER|Institution/PI shall submit to the Sponsor for comment, any manuscript or public release of information at least 90 days prior to its submission or release. If the Sponsor requires additional time in order to protect the results of the Study by patenting or otherwise, Institution agrees to delay submitting the Publication to any third party for up to an additional 90 days after the request by Sponsor. Such request, however, must be received by Institution during the 90-day review period.|t
17188600|NCT02397460|f||OTHER|No data collected as part of this study will be utilized in any written work, including publications, without the written consent of Sponsor. These obligations of confidentiality and non-use shall in no way diminish such obligations as set forth in the Confidentiality Agreement between the Sponsor and the Investigator(s).|t
17188601|NCT02213055|t||||f
17188602|NCT01024751|f||OTHER|All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor.|t
17188603|NCT01141660|f||||f
17188604|NCT01848834|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17188605|NCT01342029|f||||f
17188606|NCT02040090|f||OTHER|agreement disclosure that restricts the right of the PI to discuss or publish trial results after the trial is completed|t
17188607|NCT04894903|t||||
17188608|NCT02875561|t||||f
17188609|NCT01722318|f||||t
17188610|NCT00776100|f||LTE60||t
17188611|NCT03687450|f||||f
17188612|NCT03567993|t||||
17188613|NCT04793464|t||||f
17188614|NCT03698864|f||||f
17188615|NCT03380780|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188616|NCT05221749|f||||f
17188617|NCT00519636|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188618|NCT00915902|f||||f
17188619|NCT00050089|t||||f
17188620|NCT01671748|t||||
17188621|NCT02169830|f||||f
17188622|NCT02555371|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188623|NCT00513019|f||||f
17188624|NCT03615482|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17188625|NCT01500226|f||||f
17188626|NCT02955277|t||||
17188627|NCT01603940|f||||f
17188628|NCT02748564|t||||
17188629|NCT01809210|f||||f
17188630|NCT00504348|f||||f
17188631|NCT01118962|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17188632|NCT01305356|f||||t
17188633|NCT01330043|f||||f
17188634|NCT03685708|t||||
17188635|NCT03988374|f||OTHER|Master service agreement and confidentiality agreement in place|t
17188636|NCT00627042|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17188637|NCT04963764|f||||f
17188638|NCT00344370|f||GT60||t
17188639|NCT03583541|f||||f
17188640|NCT00176865|f||||f
17188641|NCT01686932|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17188642|NCT02571439|f||||f
17188643|NCT00393094|f||||f
17188644|NCT01058863|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17188645|NCT00681187|f||GT60||t
17188646|NCT03653416|f||OTHER||t
17188647|NCT04230980|t||||
17188648|NCT00549822|t||||f
17188649|NCT02788006|f||||f
17188650|NCT00570258|f||||f
17188651|NCT03050398|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17188652|NCT00598481|f||LTE60||t
17188653|NCT03523871|t||||
17188654|NCT01994720|f||||f
17188655|NCT01991197|f||||f
17188656|NCT00792428|f||||f
17188657|NCT02216422|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188658|NCT04285229|f||GT60||t
17188659|NCT00231894|f||||f
17188660|NCT02025205|f||||f
17188661|NCT01767129|f||OTHER||t
17188662|NCT03389893|f||||f
17188663|NCT01146808|t||||f
17188664|NCT01833117|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17188665|NCT01232556|f||||f
17188666|NCT02225275|t||||
17188667|NCT01473420|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188668|NCT00955903|f||||f
17188669|NCT02308501|f||||t
17188670|NCT03020095|f||OTHER|"After conclusion of the study and without prior written approval from Ascletis, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~The study has been completed at all study sites for at least 3 years."|t
17188671|NCT03862482|t||||f
17188672|NCT00388362|f||||f
17188673|NCT04648891|t||||
17188674|NCT03259373|f||||f
17188675|NCT02329600|f||||f
17188676|NCT00850720|t||||
17188677|NCT04374500|t||||
17188678|NCT04963062|f||||f
17188679|NCT01857323|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17188680|NCT03873246|f||||t
17144032|NCT01664052|f||OTHER|A PI may be requested to delay results communications up to 18 months following study conclusion or until a summary of all study results initiated by Sponsor (first publication) has been published. Following first publication embargo, sponsor may review results communications for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor may request a postponement of results communications not to exceed 180 days.|t
17144033|NCT01072032|t||||
17144034|NCT00326885|f||OTHER|The Site may publish the results of the Study after such cooperative publication, or 1 year after Sponsor's final evaluation of all the Study data from all sites, whichever occurs first. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Fresenius Biotech at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17188681|NCT03262701|f||||f
17188682|NCT01368211|f||LTE60||t
17188683|NCT03749460|t||||
17188684|NCT01987830|t||||
17188685|NCT02406209|f||||t
17188686|NCT01349660|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17188687|NCT05764239|f||LTE60||t
17188688|NCT00057811|f||OTHER|Must obtain prior Sponsor approval.|t
17188689|NCT00950937|f||||f
17188690|NCT01475786|f||||t
17188691|NCT00528190|f||||f
17188692|NCT04129580|f||||f
17188693|NCT03248570|t||||
17188694|NCT02018861|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17188695|NCT00827944|f||LTE60||t
17188696|NCT00709891|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188697|NCT02968940|t||||
17188698|NCT01474512|f||GT60||t
17188699|NCT03888885|t||||
17188700|NCT01890967|f||GT60||t
17188701|NCT01861301|f||LTE60||t
17188702|NCT05584657|f||LTE60||t
17188703|NCT04006366|f||||f
17188704|NCT03123263|t||||
17188705|NCT01080196|f||||f
17188706|NCT01440049|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188707|NCT00997243|f||||f
17188708|NCT02900781|f||||f
17144035|NCT01706198|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144036|NCT00950183|f||||f
17188709|NCT02949518|f||||f
17188710|NCT00906503|t||||f
17188711|NCT00479037|f||OTHER|After publication of the results or 24 months after Clinical Trial Report has been finalised, whichever comes first, Nycomed acknowledge the Investigator's rights to publish results from this trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted to Nycomed prior to submission for publication/presentation for review. Review comments will be given within a month from receipt of the manuscript.|t
17188712|NCT00280293|f||LTE60||t
17188713|NCT01041508|f||GT60||t
17188714|NCT01458249|f||OTHER||t
17188715|NCT01824082|f||||f
17188716|NCT02056119|t||||
17188717|NCT01348854|f||OTHER|All proposed submissions for publication or presentation of Trial data must be approved by the Sponsor prior to submission. Under no circumstances shall the Investigator(s) publish or disclose data without the Sponsor's written approval.|t
17188718|NCT03220737|f||GT60||t
17188719|NCT01720797|f||||f
17188720|NCT00178620|t||||f
17188721|NCT00684983|f||LTE60||t
17188722|NCT04011384|t||||
17188723|NCT01094171|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188724|NCT00594932|t||||f
17188725|NCT01083160|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection|t
17188726|NCT00918749|f||LTE60||t
17188727|NCT01951092|f||||f
17188728|NCT01712789|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17188729|NCT01708187|f||||f
17188730|NCT00788255|f||||f
17188731|NCT03055832|f||||f
17188732|NCT01152554|f||GT60||t
17188733|NCT02117544|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17188734|NCT01439711|t||||
17188735|NCT01012973|f||OTHER|Publishing of result communication only after Bayer´s written approval. Manuscript to Bayer sixty days before public release. If no written Bayer comment within 60 days consider approval given. If multi-site study, principal investigator (PI) not do independently publish results before publication of the multi-site paper, but PI not restricted from 24 months from study to completion onwards.|t
17188736|NCT02501759|t||||
17188737|NCT02448719|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17188738|NCT00209027|f||LTE60||t
17188739|NCT01932996|t||||
17188740|NCT02806336|t||||
17188741|NCT00895843|t||||
17188742|NCT03658811|t||||
17188743|NCT00946647|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17188744|NCT03990363|f||||f
17188745|NCT02334527|f||GT60||t
17188746|NCT00556374|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188747|NCT00663962|t||||f
17188748|NCT04436796|f||||f
17144037|NCT04313283|t||||
17144038|NCT02415166|t||||
17144039|NCT01473758|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17188749|NCT00462644|f||||f
17188750|NCT02846558|t||||
17188751|NCT01728805|f||||f
17188752|NCT00810641|f||||f
17188753|NCT01823614|t||||
17188754|NCT03703206|t||||
17188755|NCT02684903|f||||f
17188756|NCT00904150|f||||f
17188757|NCT02841267|f||||f
17188758|NCT02435511|f||||f
17188759|NCT04404257|t||||
17188760|NCT04212169|f||OTHER||t
17188761|NCT02176928|t||||f
17188762|NCT00224133|f||LTE60||t
17188763|NCT02718417|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188764|NCT02451930|f||GT60||t
17188765|NCT02268552|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial|t
17188766|NCT02472314|f||||f
17188767|NCT03415022|f||||f
17188768|NCT04466618|f||||f
17188769|NCT03781960|f||LTE60||t
17188770|NCT01676220|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17188771|NCT04496167|f||||t
17188772|NCT02269943|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year from study completion. Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17188773|NCT03541642|f||||f
17144040|NCT01677910|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17144041|NCT04229303|f||||f
17144042|NCT00606684|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144043|NCT02763579|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144044|NCT02144259|f||||f
17144045|NCT00943800|f||||f
17144046|NCT04895618|f||||f
17188774|NCT02682563|f||||f
17188775|NCT03088137|f||||f
17188776|NCT04612049|f||||f
17188777|NCT00873093|f||LTE60||t
17188778|NCT00136916|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188779|NCT03553940|f||LTE60||t
17188780|NCT04242875|t||||
17188781|NCT04172987|f||GT60||t
17188782|NCT04179461|t||||f
17188783|NCT03285711|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188784|NCT01607411|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188785|NCT02431533|f||||f
17144047|NCT03522584|t||||
17144048|NCT00910858|f||OTHER|"* Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.~* Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 60 days."|t
17144049|NCT04169282|t||||
17144050|NCT00698022|f||GT60||t
17188786|NCT02107443|t||||f
17188787|NCT01638468|f||||f
17144051|NCT00621686|t||||
17144052|NCT01703741|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17144053|NCT01170364|t||||f
17144054|NCT01381900|f||GT60||t
17144055|NCT00892697|f||||f
17144056|NCT02041494|t||||f
17144057|NCT03341273|f||||t
17144058|NCT00685919|t||||
17144059|NCT01717456|f||||f
17188788|NCT01513967|f||LTE60||t
17188789|NCT02906202|f||||t
17188790|NCT01133860|t||||
17188791|NCT01706965|f||||f
17144060|NCT03818919|f||||f
17188792|NCT01563978|f||OTHER|The disclosure restriction on the PI is that the sponsor can review and comment on results communications prior to publication or presentation. Sponsor will be allowed a review period of at least 60 days from submission but can request that the submission be delayed for an additional 90 days from the date of Sponsor's request.|t
17188793|NCT00729690|f||||f
17188794|NCT01591161|f||OTHER|Contact sponsor directly for details.|t
17188795|NCT04562779|t||||
17144061|NCT00033631|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17144062|NCT00528879|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144063|NCT00078819|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144064|NCT00323609|f||LTE60||t
17144065|NCT00267293|t||||f
17144066|NCT02217345|f||||f
17144067|NCT03596918|f||||f
17144068|NCT00950599|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144069|NCT00971204|f||||f
17144070|NCT02436135|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17144071|NCT02729194|t||||
17144072|NCT02372682|f||OTHER|"GE - Contract states: The Institution \[SLU/PI\] is free to publish or present the results of the Study. The Institution agrees to provide Company with a copy of the published manuscript. Company's support will be acknowledged in all such publications or presentations. Thrasher - No restrictions on publication Society of Pediatric Radiology - Manuscripts must be first submitted to SPR annual Meeting and/or to Pediatric Radiology journal, to be considered for publication."|t
17144073|NCT03803085|t||||
17144074|NCT03216200|f||||f
17144075|NCT01401478|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144076|NCT01809314|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144077|NCT01684722|f||||f
17144078|NCT02964897|t||||
17144079|NCT00863057|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17144080|NCT02345486|t||||
17144081|NCT03979677|f||||f
17144082|NCT03082391|t||||t
17144083|NCT03063632|f||LTE60||t
17144084|NCT00927888|f||||f
17144085|NCT00676585|t||||
17144086|NCT02741271|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17188796|NCT00333138|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17188797|NCT05593211|f||||t
17188798|NCT04343222|t||||
17144087|NCT01612156|t||||
17144088|NCT02570165|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144089|NCT01430104|f||GT60||t
17188799|NCT03077620|f||||f
17188800|NCT03225846|f||||f
17188801|NCT00238420|f||LTE60||t
17188802|NCT01053637|t||||
17188803|NCT02102464|f||OTHER|Within 18 months of Sponsor's receipt of data from all sites, Investigators may publish or present the Investigator's individual results. Investigator must submit materials to Sponsor for review and comment at least 30 days prior to presentation or submission for publication. Investigator will consider all reasonable comments from Sponsor. Upon Sponsor's written request, Investigator agrees to delete any Proprietary Information other than Investigator's individual Study results.|t
17188804|NCT04140890|t||||
17188805|NCT03958630|t||||
17188806|NCT03796013|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144090|NCT05478603|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144091|NCT03182686|f||||t
17144092|NCT00757666|f||OTHER|The first publication of the results shall be made a joint, multi-center publication.|t
17144093|NCT01025193|f||||f
17144094|NCT02378506|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144095|NCT00185211|f||OTHER|Submit for review any manuscript / abstract related to the Study at least 90 days prior to publication.The proposed publication / presentation shall only be made after BSP has obtained adequate patent protection for the Results, or after the patentable information has been taken out of the publication/presentation.|t
17144096|NCT01606137|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17144097|NCT02266706|f||OTHER|The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. The Sponsor will make all reasonable efforts to publish the results of the study in an appropriate peer-reviewed journal. Authorship on the primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results.|t
17144098|NCT02544633|f||OTHER|PI can not disclose, discuss, or publish study results until final manuscript has been published.|t
17144099|NCT01977352|t||||
17144100|NCT00677924|f||OTHER|"The site and the PI may be required to withhold the publication for up to 90 days. Subject to a reasoned request from the sponsor, the publication may be further delayed for a period up to 6 months from the date of first submission to the sponsor.~The sponsor has the right to require deletion of any trade secret, proprietary, or confidential information supplied by the sponsor to the site or the PI. The sponsor shall not otherwise have the right to censor publications."|t
17144101|NCT02732587|f||||t
17144102|NCT02257632|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144103|NCT01059071|f||LTE60||t
17144104|NCT03763331|t||||
17144105|NCT00936884|f||LTE60||t
17144106|NCT04741503|t||||
17144107|NCT02280421|f||||f
17144108|NCT02797964|f||OTHER|All proposed publications and presentations by the investigators, personnel, or associates resulting from or relating to this study must be submitted to Sierra Oncology for review before submission for publication or presentation. If the proposed publication or presentation contains patentable subject matter, which, at Sierra Oncology's sole discretion, warrants intellectual property protection, Sierra Oncology may delay publication or presentation for the purpose of pursuing such protection.|t
17144109|NCT01859390|f||||f
17144110|NCT02057952|f||||f
17144111|NCT01567371|t||||
17144112|NCT01275313|f||||f
17144113|NCT04634110|t||||
17144114|NCT02965820|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17144115|NCT01967888|f||||f
17144116|NCT02199652|f||||f
17144117|NCT00553540|f||||f
17144118|NCT02622074|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17144119|NCT02114931|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144120|NCT02578732|f||||f
17144121|NCT03870997|t||||f
17144122|NCT01859325|t||||f
17144123|NCT03565211|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17144124|NCT01894984|f||GT60||t
17144125|NCT00580333|t||||f
17144126|NCT01917188|t||||
17144127|NCT00827359|f||||t
17144128|NCT00667719|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144129|NCT03840135|f||||t
17144130|NCT01159769|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17144131|NCT02555618|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144132|NCT01827371|f||LTE60||t
17144133|NCT03124797|t||||
17144134|NCT02662608|t||||
17144135|NCT01361607|f||GT60||t
17188807|NCT00245011|t||||
17188808|NCT03040687|f||||f
17144136|NCT01814137|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17144137|NCT00219557|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144138|NCT00833781|t||||
17144139|NCT01042496|t||||
17144140|NCT01427803|f||GT60||t
17144141|NCT03412019|t||||
17144142|NCT01023269|f||||f
17188809|NCT02018315|t||||
17188810|NCT00107744|t||||
17188811|NCT01875861|t||||
17188812|NCT02325713|f||||f
17188813|NCT02353832|f||||f
17188814|NCT03824535|t||||
17188815|NCT00322868|f||||f
17188816|NCT04223154|t||||
17188817|NCT00739583|t||||f
17188818|NCT01938664|f||||f
17188819|NCT03985098|f||||f
17188820|NCT03685747|t||||
17188821|NCT00795132|t||||
17188822|NCT01536262|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17188823|NCT00412516|f||OTHER|All results communication must be reviewed and approved by the sponsor. The sponsor has 60 days to review results communications and provide comments.|t
17188824|NCT01781611|f||||f
17188825|NCT03639675|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period described in the contract with the head of the medical institution based on J-GCP (Good clinical practice). The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17188826|NCT02459587|t||||
17188827|NCT02264574|f||OTHER|"1. Institution/Investigator will not publish without Sponsor prior review and approval~2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination."|t
17188828|NCT00412867|f||OTHER|The Sponsor's consent must be obtained in advance if the investigator or other study-related personnel in the study center intend to publish information obtained via this study at a scientific conference or similar venue.|t
17188829|NCT01477749|f||OTHER|The results of the study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the study will be coordinated by Dendreon in communication with institutions contributing patients to the study.|t
17188830|NCT02096081|f||||f
17188831|NCT02886728|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188832|NCT00884286|f||GT60||t
17188833|NCT02029703|f||||f
17188834|NCT00939796|f||GT60||t
17188835|NCT02118714|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188836|NCT01310868|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17188837|NCT02411591|f||GT60||t
17188838|NCT04227340|t||||
17188839|NCT01628874|f||||f
17188840|NCT03018106|t||||
17188841|NCT03619174|f||||f
17188842|NCT03486899|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188843|NCT01010217|t||||
17188844|NCT03190083|t||||
17188845|NCT01782326|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17188846|NCT04183192|f||||f
17188847|NCT04033991|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188848|NCT02410161|t||||
17188849|NCT00738530|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188850|NCT01628510|f||||f
17188851|NCT01653847|f||||f
17188852|NCT04707391|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17188853|NCT03246672|t||||
17188854|NCT01347645|f||||t
17188855|NCT01438229|f||LTE60||t
17188856|NCT01163149|f||LTE60||t
17188857|NCT03983993|t||||
17188858|NCT01107730|f||||f
17188859|NCT02774213|f||LTE60||t
17188860|NCT02554435|f||||f
17188861|NCT01614574|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication|t
17188862|NCT01923428|f||GT60||t
17188863|NCT02550873|f||OTHER|A Publications Committee comprised of Investigators participating in the study and representatives from Promedior was formed to oversee the publication of the study results, which reflected the experience of all participating study centers. Subsequently, individual Investigators may publish results from the study in compliance with their agreement with the Sponsor.|t
17188864|NCT01822353|t||||
17188865|NCT04320615|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188866|NCT01449721|f||||f
17188867|NCT00885495|f||||f
17188868|NCT01400893|f||||t
17188869|NCT04387162|t||||
17188870|NCT03171168|f||||f
17188871|NCT03786094|f||||f
17188872|NCT00670982|f||||f
17188873|NCT02320721|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17188874|NCT04630756|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17188875|NCT00847301|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17188876|NCT00996580|f||OTHER|Details of the study and its results shall not be publicized or published in any form to cooperative publication without prior, written consent of sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17188877|NCT02036515|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17188878|NCT03621982|f||OTHER||t
17188879|NCT00859131|f||||f
17188880|NCT01544582|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17188881|NCT04069221|f||OTHER|PRA shall have the right to publish the results of the research, subject to the sponsor's prior written consent, which shall not be unreasonably withheld or delayed. Following the receipt of such consent, PRA shall submit a copy of the proposed publication to the sponsor who shall have 30 days in which to request amendments thereto which, to the extent that such proposed amendments are reasonable, PRA shall be obliged to incorporate prior to such publication.|t
17144143|NCT01215123|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144144|NCT00947011|t||||
17188882|NCT03317379|t||||
17188883|NCT04445155|f||||f
17188884|NCT00550173|f||GT60||t
17188885|NCT01556243|t||||
17188886|NCT01388543|f||||f
17188887|NCT02359019|t||||
17188888|NCT01213173|f||LTE60||t
17188889|NCT00852137|f||OTHER|Evaluator and Principal Investigator agree not to individually publish the result of the study, but rather, to participate in a joint publication of the Study results coordinated by sponsor, who shall have the first righ to publish. If such joint publication is not submitted for publication within 1 year of study completion at all sites Evaluator and Principal Investigator have the right to individually produce and submit a proposed publication, subject to the prior review of sponsor.|t
17188890|NCT04880161|f||||t
17188891|NCT01354106|f||OTHER|The proposed disclosure must be reviewed by the sponsor. The sponsor shall complete the review within 30 working days after receipt. The PI will discuss and consider in good faith the sponsor recommendations resulting from the review.|t
17188892|NCT02385721|f||||t
17188893|NCT00731042|f||OTHER|PI was a test lab, and they do not publish study result. Sponsor can choose to publish.|t
17188894|NCT02692235|f||||f
17188895|NCT00802841|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17188896|NCT02174198|t||||
17188897|NCT02711995|t||||
17188898|NCT00377741|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188899|NCT04006795|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188900|NCT00107380|f||||f
17188901|NCT03673098|f||||f
17144145|NCT00814658|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo.|t
17188902|NCT03114995|f||||f
17144146|NCT05266456|f||OTHER|Sponsor shall review within the ninety (90) day period. Upon receiving any notification from Sponsor requesting deletion of Confidential Information, correction of inaccuracies, or a delay in publication to allow the filing of patent application, Institution or Investigator shall take the requested action of Sponsor.|t
17188903|NCT02662244|f||||f
17188904|NCT03531905|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that that publication be withheld.|t
17188905|NCT01155726|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17188906|NCT01969162|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is no more than 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17188907|NCT00409240|f||||f
17144147|NCT01141283|f||GT60||t
17144148|NCT00198081|t||||
17144149|NCT01068873|t||||
17188908|NCT04655313|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17188909|NCT02724020|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17188910|NCT00425503|t||||
17188911|NCT00688259|t||||
17188912|NCT02954575|f||||f
17188913|NCT00229619|t||||
17188914|NCT02491892|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188915|NCT01066156|t||||
17188916|NCT01700673|t||||f
17188917|NCT01734382|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188918|NCT00305682|t||||
17188919|NCT00674492|t||||
17188920|NCT00661258|f||||f
17188921|NCT03890120|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188922|NCT00683449|f||LTE60||t
17188923|NCT01600950|f||GT60||t
17188924|NCT04081298|t||||
17188925|NCT02724787|f||||f
17144150|NCT00479401|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17144151|NCT02777931|f||OTHER|The information generated by this study is the property of Medgenics. Publication or other public presentation of NFC-1 data resulting from this study requires prior review and written approval of Medgenics. Abstracts, manuscripts, and presentation materials should be provided to Medgenics for review at least 30 days prior to the relevant submission deadline.|t
17144152|NCT01571635|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17188926|NCT00479674|f||||f
17188927|NCT01008722|f||||f
17188928|NCT00146640|f||||f
17188929|NCT02071095|t||||
17188930|NCT02059161|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17188931|NCT00905060|t||||
17188932|NCT02511561|f||OTHER|Publication subject to Sponsor consent.|t
17188933|NCT03023332|f||||f
17188934|NCT01818700|f||||f
17188935|NCT01852955|f||||f
17188936|NCT02408549|f||GT60||t
17188937|NCT01656759|t||||
17188938|NCT02687919|f||||f
17188939|NCT01192295|f||GT60||t
17188940|NCT02859597|t||||
17188941|NCT02923895|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17188942|NCT00813111|f||||f
17188943|NCT03552978|t||||f
17188944|NCT05087095|f||||f
17188945|NCT01670500|f||||f
17188946|NCT03473756|f||GT60||t
17188947|NCT02148718|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144153|NCT02868281|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144154|NCT01722266|f||||f
17144155|NCT01785186|f||OTHER||t
17144156|NCT03124381|f||OTHER|PI must provide Sponsor 60 days to review any publication (unless expedited review requested); if includes Sponsor's confidential info, written Sponsor approval is required. Sponsor may require another 60 days' delay to file patent app. If multicenter, PI agrees 1st publication is joint publication. If joint publication not submitted within 24 months of study end or Sponsor confirms there will be no joint publication, PI may publish the results individually following previous guidelines.|t
17144157|NCT02533999|f||||f
17188948|NCT00003509|f||||f
17188949|NCT02711826|f||||f
17188950|NCT01960790|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17188951|NCT01500746|f||||f
17188952|NCT02169219|f||||f
17188953|NCT04019561|f||GT60||t
17188954|NCT02044419|f||OTHER|Described in contract.|t
17188955|NCT02886936|f||||f
17188956|NCT03713645|f||||f
17188957|NCT04131907|f||||t
17188958|NCT04248465|f||||t
17188959|NCT05708846|f||||f
17188960|NCT00442286|f||OTHER|The site must notify CVRx and a designated Publication Committee 30 days before submission. The complete text of the publication is required for review. If CVRx does not respond within 30 days of the date received by CVRx, the site may proceed with publication. If CVRx determines that there are changes to be made, the publication maybe delayed for up to 90 days. The site must not submit a publication without the satisfaction of the Publication Committee.|t
17188961|NCT03428815|t||||f
17188962|NCT01700348|f||LTE60||t
17188963|NCT01778062|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17188964|NCT01824472|f||||f
17188965|NCT01736358|f||||f
17188966|NCT01815736|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188967|NCT02413684|t||||
17188968|NCT03387514|t||||
17188969|NCT01159535|t||||
17188970|NCT00118144|f||LTE60||t
17188971|NCT04701593|t||||
17188972|NCT00075803|f||||f
17188973|NCT00394095|t||||
17188974|NCT02516579|f||||t
17188975|NCT03905811|f||||f
17188976|NCT04975789|t||||
17188977|NCT01646320|f||||f
17188978|NCT01489020|f||||f
17188979|NCT02424344|f||OTHER|Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor.|t
17188980|NCT01174550|f||||f
17188981|NCT05257837|f||||f
17188982|NCT01625338|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17188983|NCT02485353|t||||
17188984|NCT03930186|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17188985|NCT02037061|t||||
17144158|NCT00291330|f||OTHER|Any publication of the results of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17144159|NCT01829295|f||||f
17144160|NCT00863369|t||||
17144161|NCT02390219|f||OTHER|Restriction Description: PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or (3)18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days(which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17144162|NCT02033876|t||||
17144163|NCT01360632|f||||f
17144164|NCT01491490|f||OTHER|"All publications must be submitted to GW for corporate review before release. The principal investigators must then incorporate all reasonable comments made by GW into the publication.~GW also reserve the right to delay the submission of such information by up to six months from the date of first submission to them in order to allow them to take steps to protect proprietary information where applicable."|t
17144165|NCT02462382|f||||f
17144166|NCT01084005|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17188986|NCT00557505|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17188987|NCT02033993|t||||f
17188988|NCT01207934|t||||
17188989|NCT01521949|f||||f
17188990|NCT00180687|t||||
17188991|NCT04990440|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17188992|NCT03712098|t||||
17188993|NCT04524104|f||||f
17188994|NCT00724061|t||||
17188995|NCT02783482|f||||f
17188996|NCT02537444|f||||f
17188997|NCT01237678|f||GT60||t
17188998|NCT01723826|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17188999|NCT01272011|t||||
17189000|NCT01627340|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189001|NCT02013687|f||OTHER|In no event shall the PI publish or present, at any time, the data generated in the course of the performance of the study.|t
17189002|NCT01657032|t||||
17189003|NCT03633903|t||||
17189004|NCT05968482|f||OTHER|Master Service agreement: Work Product shall be and remain the sole and exclusive property of Sponsor.|t
17189005|NCT02559817|f||OTHER|All data generated in this study are the property of the Sponsor. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and the Sponsor and will follow the Sponsor's standard operating procedures on publications.|t
17189006|NCT04305236|t||||
17189007|NCT00597870|f||||f
17189008|NCT02186938|t||||
17189009|NCT00761774|f||GT60||t
17189010|NCT01925170|t||||f
17189011|NCT01077024|f||||f
17189012|NCT01603121|f||||f
17189013|NCT00577720|f||LTE60||t
17189014|NCT00628628|t||||f
17189015|NCT02839681|f||||f
17189016|NCT00419003|f||||f
17189017|NCT02531438|f||OTHER|The only disclosure restriction on the Principal Investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication and require the removal of confidential information.|t
17144167|NCT02480010|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144168|NCT03015142|f||||f
17144169|NCT02967133|f||||f
17144170|NCT01034137|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189018|NCT00772928|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17189019|NCT02165124|f||||f
17189020|NCT03100838|f||LTE60||t
17189021|NCT00801242|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17189022|NCT01845636|t||||
17189023|NCT02554513|t||||
17144171|NCT01764854|f||GT60||t
17144172|NCT00936377|t||||f
17144173|NCT03263195|f||||f
17144174|NCT03377556|f||||f
17189024|NCT00832260|f||LTE60||t
17189025|NCT04992442|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17144175|NCT01630200|t||||
17144176|NCT00208949|t||||
17144177|NCT01684566|f||GT60||t
17144178|NCT01924871|f||||f
17144179|NCT02736227|t||||
17144180|NCT04120194|f||||t
17144181|NCT00619619|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144182|NCT02063698|t||||
17144183|NCT00410410|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144184|NCT01953783|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17144185|NCT00686920|f||OTHER|Please contact Sponsor directly for additional information.|t
17144186|NCT02539563|t||||
17144187|NCT02296606|f||||f
17144188|NCT02752256|f||||f
17144189|NCT02159859|t||||
17144190|NCT01271933|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144191|NCT01138150|f||||f
17144192|NCT05085964|f||OTHER|Institution shall be free to publish, present, or use any Data and results arising out of its performance of the protocol. At least 30 days prior to submission for publication, institution shall submit to Sponsor for review and comment any proposed oral or written publication. Institution will consider any such comments in good faith but is under no obligation to incorporate Sponsor's suggestions. The review period for abstracts or poster presentations shall be 30 days.|t
17144193|NCT02077192|f||||t
17144194|NCT03559010|f||||f
17144195|NCT03156270|f||OTHER|PI/Institution will provide Sponsor with a copy of any proposed manuscripts or other material for publication thirty (30) days prior to publication for review and comment. Sponsor's comments shall be given due consideration by PI/Institution. Publication may be delayed at Sponsor's written request for a period not to exceed sixty (60) days if it contains a disclosure of an invention(s) on which either party desires to file a patent.|t
17144196|NCT02005354|t||||
17144197|NCT00591253|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17144198|NCT04525157|f||||f
17144199|NCT01741480|f||||f
17144200|NCT01841359|t||||
17144201|NCT02168270|f||||f
17144202|NCT01190306|f||OTHER|All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.|t
17144203|NCT01102777|f||||f
17189026|NCT00184028|t||||
17144204|NCT01875445|f||||f
17144205|NCT00771901|t||||
17144206|NCT00947765|t||||
17144207|NCT01965652|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17144208|NCT01121900|f||OTHER|If a publication based on the results of this study is envisaged, approval from the Sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment. The choice of scientific journal will be mutually agreed on by the principal investigator and the sponsor.|t
17144209|NCT01328054|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144210|NCT03493698|t||||
17144211|NCT03760510|f||||f
17189027|NCT02760862|f||||f
17189028|NCT00162942|f||LTE60||t
17189029|NCT01354938|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17144212|NCT00235833|f||OTHER|Disclosure agreements vary; most restrictive agreement states Medical Institution shall not disclose materials/information disclosed by Abbott Japan in connection with the Clinical Research, or information obtained by conducting the Clinical Research, to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting the Clinical Research, Medical Institution shall obtain Abbott Japan's prior written approval.|t
17144213|NCT01288833|f||||f
17144214|NCT00492089|f||LTE60||t
17144215|NCT00566709|f||||f
17144216|NCT03443869|f||OTHER|If publication activity was not directed by the sponsor, the investigator agreed to submit all manuscripts or abstracts to the sponsor before submission. This allowed the sponsor to protect proprietary information and to provide comments.|t
17144217|NCT02330081|f||LTE60||t
17144218|NCT00299728|f||||f
17144219|NCT02826603|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144220|NCT03654209|f||||f
17144221|NCT01337050|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144222|NCT00003102|f||||f
17144223|NCT00583596|f||||f
17144224|NCT00656019|t||||
17144225|NCT00096486|t||||
17144226|NCT03558997|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17144227|NCT02230085|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for an undescribed period .|t
17144228|NCT01986790|f||||f
17144229|NCT02173301|f||OTHER|Any publication would have to be collaborative effort between Sponsor and Investigators|t
17144230|NCT02340156|f||||t
17144231|NCT03016078|f||||t
17144232|NCT01710306|t||||
17144233|NCT02123459|f||GT60||t
17144234|NCT00254397|t||||f
17144235|NCT00528437|t||||
17144236|NCT03501550|f||LTE60||t
17144237|NCT01386879|f||||f
17144238|NCT01743677|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144239|NCT03092089|f||||f
17144240|NCT00972153|f||||f
17144241|NCT04136626|t||||
17144242|NCT00409188|f||OTHER|After conclusion of the study, an integrated clinical and statistical study report shall be written by the Sponsor in consultation with the Coordinating Investigator based on the protocol. The first publication will be a full publication of all data from all sites. The Sponsor is entitled to delay publication in order to obtain patent protection. The ICMJE criteria for authorship will be followed. A separate publication plan will be set up to describe further publications.|t
17144243|NCT02879747|f||||f
17144244|NCT01393990|f||GT60||t
17144245|NCT00275028|f||LTE60||t
17144246|NCT02720952|f||||f
17144247|NCT00720798|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144248|NCT00433381|f||LTE60||t
17144249|NCT01014390|f||||f
17144250|NCT01725984|f||||f
17144251|NCT03103581|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17144252|NCT00549198|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144253|NCT00472446|t||||
17144254|NCT01165684|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Novo Nordisk reserves the right to prior review of such publications and to ask for delay of publication of individual site results until after the primary manuscript is accepted for publication.|t
17144255|NCT03135379|t||||
17144256|NCT00671879|f||||f
17144257|NCT04633837|f||||f
17144258|NCT00901628|t||||
17144259|NCT02203747|f||OTHER|Clinical Trial Agreement|t
17144260|NCT00608205|t||||
17144261|NCT01797120|f||LTE60||t
17144262|NCT02462421|t||||
17144263|NCT02117193|t||||
17144264|NCT01909466|f||||f
17144265|NCT01339910|f||||f
17144266|NCT01095757|t||||
17144267|NCT01567306|f||||f
17189030|NCT01253200|f||||f
17189031|NCT02335268|f||||f
17189032|NCT02706626|f||||f
17189033|NCT03785340|f||||f
17189034|NCT01253980|t||||f
17189035|NCT01700530|f||||f
17189036|NCT01023178|t||||
17189037|NCT01577732|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189038|NCT03289455|f||GT60||t
17189039|NCT00333788|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17189040|NCT04951479|t||||
17189041|NCT01682538|f||GT60||t
17189042|NCT02466126|t||||f
17189043|NCT00315627|t||||
17189044|NCT01268059|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17189045|NCT02819479|f||||f
17189046|NCT05310084|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189047|NCT02941146|f||||f
17189048|NCT01021332|f||OTHER|Institute and/or Principle Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 90 days prior to publication for review and comment. Sponsor may delay the publication to seek patent approval.|t
17189049|NCT04731714|f||||f
17189050|NCT03487666|f||||f
17189051|NCT04758403|f||||f
17189052|NCT05343455|f||||f
17189053|NCT04411940|f||||f
17189054|NCT02722941|t||||
17189055|NCT02748512|f||OTHER|The PI is restricted from publicly releasing results.|t
17189056|NCT00787943|f||||f
17189057|NCT00765362|f||LTE60||t
17144268|NCT00738673|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17144269|NCT03038113|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144270|NCT05117099|t||||
17144271|NCT01418352|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17144272|NCT01092702|t||||
17144273|NCT03263819|f||||f
17144274|NCT03151499|t||||f
17144275|NCT00125931|f||||f
17144276|NCT03652961|t||||
17144277|NCT01783496|f||OTHER|Investigator shall notify Sponsor of the intent to publish or present independent Study Data, and agrees not to publish or publicly present and/or discuss such data, Investigator's current findings and/or the results of the Study independently without the express written consent of Sponsor, which consent may be withheld. Prior to submission for publication or presentation, all draft manuscripts must be submitted, reviewed and approved by Sponsor for confidential material.|t
17189058|NCT03019458|f||||f
17189059|NCT00031447|f||||f
17189060|NCT01636362|f||OTHER||t
17189061|NCT01244763|f||OTHER||t
17189062|NCT04990687|t||||
17189063|NCT02521259|f||||f
17189064|NCT01561079|f||||f
17189065|NCT00765661|f||OTHER|The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PIs.|t
17144278|NCT03119064|f||||f
17189066|NCT03748264|f||||f
17189067|NCT00664521|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17189068|NCT02459964|t||||
17189069|NCT00367237|f||OTHER|Investigator must provide 30 days written notice to sponsor prior to submission for publication/presentation, so that sponsor can review the material(s). If the parties disagree concerning the appropriateness of the material for publication, the investigator must meet with sponsor prior to publication/presentation, in order to make good faith efforts to discuss and resolve any disagreements.|t
17189070|NCT00707863|f||||f
17189071|NCT02800928|t||||
17189072|NCT01853163|f||||t
17189073|NCT03560141|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17189074|NCT05677867|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189075|NCT00839982|t||||
17189076|NCT00953160|f||OTHER|"The Doctor will not publish or present the results of the Study, or speak publicly about it, unless Cutera has first had a reasonable opportunity to review and comment on the contents of the proposed presentation or publication."|t
17189077|NCT01341080|t||||
17189078|NCT04830514|t||||f
17189079|NCT01275053|f||||f
17144279|NCT03654898|f||||f
17144280|NCT01620983|f||||f
17144281|NCT03944486|t||||
17144282|NCT00545233|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144283|NCT00446654|f||||f
17144284|NCT01712230|f||||f
17144285|NCT01504867|f||||f
17144286|NCT01783730|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144287|NCT02151461|f||||t
17144288|NCT00707915|f||||f
17144289|NCT00871169|f||||f
17189080|NCT00570661|f||||f
17189081|NCT03248440|f||OTHER|The Principal Investigator will not disclose information regarding this clinical investigation, or publish results of the investigation without authorization from Senju USA, Inc.|t
17189082|NCT01052662|f||||f
17189083|NCT00401817|t||||
17189084|NCT02015663|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17189085|NCT01113463|t||||f
17189086|NCT01054911|f||||f
17189087|NCT03293485|f||OTHER|"Subsequent to the multicenter publication (or after public disclosure of the results at www.clinicaltrials.gov if multicenter manuscript is not planned), an investigator and colleagues may publish their data independently.~Sponsor must have opportunity to review proposed abstracts, manuscripts or presentations 45 days prior to submission for publication/presentation. Confidential information must be deleted prior to submission; this confidentiality does not include efficacy and safety results."|t
17189088|NCT00087490|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189089|NCT02034435|f||||f
17144290|NCT01365845|t||||f
17144291|NCT03210259|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17144292|NCT02110706|t||||
17144293|NCT02087059|f||OTHER|"The terms and conditions of Novartis' agreements with its investigators may vary.~However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."|t
17144294|NCT00252187|t||||f
17144295|NCT03764059|f||OTHER||t
17144296|NCT05017493|f||OTHER|All PIs discuss or publish the results only according to a prior agreement with the sponsor.|t
17144297|NCT01665053|f||OTHER|The sponsor can review results communications to public release and can embargo communications regarding trial results for a period less or equal to 45 days from the time submitted to the sponsor. If the sponsor determines the communication would be detrimental to the intellectual property, the PI will redact or modify or will refrain the publication to a publisher or other party for an additional 120 days to permit the sponsor to file patent applications or take other steps to protect interests|t
17144298|NCT01033383|t||||
17144299|NCT01261325|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17189090|NCT03379233|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17189091|NCT02300311|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17189092|NCT02874846|f||||f
17189093|NCT00768599|f||OTHER||t
17189094|NCT02015195|f||||f
17189095|NCT01318811|f||||f
17189096|NCT00811187|t||||f
17189097|NCT00131911|f||LTE60||t
17189098|NCT00329303|f||GT60||t
17189099|NCT01359410|t||||
17189100|NCT05590910|t||||f
17189101|NCT00994279|t||||
17189102|NCT04833855|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189103|NCT03008122|f||LTE60||t
17189104|NCT04883346|t||||
17189105|NCT04529538|f||OTHER|The only disclosure restriction on the PI is that there should be a joint publication first; after the joint publication or after 24 months without a joint publication from the time of last participant last visit, the PI has a right to present the trial results at meetings or do their own publication in a journal, but they must provide PATH the chance to review the manuscript 60 days in advance of publication.|t
17189106|NCT02322775|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17189107|NCT01641861|f||||f
17189108|NCT05567952|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189109|NCT00777803|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 wks before submission. Sponsor to give written opinion within 30 d. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17189110|NCT04213846|f||||f
17189111|NCT04423393|f||OTHER|"Investigators may discuss or publish results after:~* the study results in their entirety have been publicly disclosed by or with the consent of the Sponsor OR study has been completed at all investigative sites for at least 18 months.~* provision of publication up to 60 days before planned submission to allow Sponsor to remove confidential information or identify Sponsor intellectual property~Publication may be delayed as applicable, up to 120 days for Sponsor to file patent application(s)"|t
17189112|NCT03374072|f||||f
17189113|NCT00432159|f||||f
17189114|NCT05516342|t||||
17189115|NCT01115998|t||||
17189116|NCT03850444|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17189117|NCT04096365|f||OTHER|Investigator must obtain prior written consent of Sponsor before publishing.|t
17189118|NCT05373901|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17189119|NCT01598987|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17189120|NCT02107274|t||||
17189121|NCT01036087|t||||
17189122|NCT03961256|t||||
17189123|NCT02708641|t||||
17189124|NCT01021878|t||||f
17189125|NCT03251144|f||||f
17189126|NCT02651103|t||||
17189127|NCT05305040|f||||f
17189128|NCT05406791|f||||f
17189129|NCT03861728|t||||
17144300|NCT02611206|t||||
17189130|NCT02297503|f||||t
17189131|NCT02021461|f||OTHER||t
17189132|NCT04365413|t||||
17189133|NCT00519779|f||||f
17189134|NCT03330119|t||||f
17189135|NCT01819415|f||||f
17189136|NCT05205941|f||GT60||t
17144301|NCT01878656|f||||f
17144302|NCT03469271|t||||
17144303|NCT00990561|f||||f
17144304|NCT03404206|f||||f
17189137|NCT00550732|f||OTHER|The Principal Investigators agree to provide review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the protocol study to the sponsor, 30 days prior to submission for publication or presentation. The sponsor shall have the right to review and comment on the data analysis and presentation with regard to proprietary information and the accuracy of the information contained in the publication.|t
17189138|NCT00112723|f||LTE60||t
17189139|NCT04170764|t||||
17189140|NCT00305760|t||||
17189141|NCT03302910|f||||f
17189142|NCT04004208|f||OTHER|The disclosure restriction is that the PI has to ensure that the sponsor can review results communications at least 60 days prior to the planned public release.|t
17189143|NCT04463615|t||||
17144305|NCT03187080|t||||
17144306|NCT03872700|t||||
17144307|NCT00722111|t||||
17144308|NCT02707432|t||||f
17144309|NCT01957657|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144310|NCT03331965|f||||f
17189144|NCT02400307|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17189145|NCT03688542|t||||
17189146|NCT00083174|t||||f
17189147|NCT03582137|f||||f
17189148|NCT02303574|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17144311|NCT00616928|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189149|NCT01606189|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17189150|NCT02162732|f||LTE60||t
17189151|NCT01167023|f||GT60||t
17189152|NCT00410384|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189153|NCT00429702|t||||
17189154|NCT02049437|t||||
17189155|NCT00630539|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17189156|NCT00696293|f||||f
17189157|NCT02953548|f||GT60||t
17189158|NCT00310362|t||||
17189159|NCT03453385|f||||f
17189160|NCT04654351|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189161|NCT03682536|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17189162|NCT03888365|f||GT60||t
17189163|NCT03298815|t||||
17189164|NCT02538679|f||||f
17189165|NCT02451423|t||||
17189166|NCT02507219|t||||
17189167|NCT03050294|t||||
17189168|NCT00593320|t||||
17189169|NCT01342887|t||||
17189170|NCT00209274|f||GT60||t
17189171|NCT02753530|f||GT60||t
17189172|NCT01672983|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189173|NCT05160025|t||||
17189174|NCT00465361|t||||
17189175|NCT04351750|f||||f
17189176|NCT01333943|t||||
17189177|NCT01421771|t||||
17189178|NCT02091063|t||||
17189179|NCT02652130|f||OTHER|Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection.|t
17189180|NCT02028884|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189181|NCT00354029|t||||
17189182|NCT00723294|t||||
17189183|NCT02403674|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17189184|NCT02068729|f||OTHER|The Institution/PI shall not disclose/use any confidential/proprietary information (CI) disclosed to/developed by the Institution during the study. Institution/PI agree to hold the results of the Study in confidence, and shall not disclose them except with prior written consent of K2M. Institution agrees to submit any Articles to K2M for review prior to publication and agrees to edit out any confidential information identified by K2M.|t
17189185|NCT00826280|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17189186|NCT03201757|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17189187|NCT01254305|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17189188|NCT01511536|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17189189|NCT02357758|f||||f
17189190|NCT02703532|t||||
17189191|NCT03239210|t||||
17189192|NCT02664220|t||||f
17189193|NCT01403987|t||||
17189194|NCT00751790|f||OTHER|Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.|t
17189195|NCT01276535|f||||f
17189196|NCT02988375|f||||f
17189197|NCT02179918|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189198|NCT00276250|t||||
17189199|NCT03189134|t||||
17189200|NCT04337489|t||||
17189201|NCT00972543|f||OTHER||t
17189202|NCT03413605|t||||
17189203|NCT04537949|f||OTHER|PIs respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17189204|NCT01882062|t||||f
17189205|NCT04296942|f||||f
17189206|NCT04038099|f||||f
17189207|NCT02478359|f||||f
17189208|NCT00562965|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189209|NCT00525057|t||||
17189210|NCT01911221|f||GT60||t
17189211|NCT00965484|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189212|NCT00848211|f||||f
17189213|NCT01124617|f||OTHER||t
17189214|NCT00945477|t||||
17189215|NCT00619151|f||LTE60||t
17189216|NCT02825043|t||||
17144312|NCT03372083|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144313|NCT00598559|f||OTHER|Before any submission is made, Cadence shall be notified of the intention to publish and shall submit the manuscript to Cadence for review and comment.At least 60 days prior to submission for publication, investigator must submit manuscript to sponsor who has 60 days for review and comment. Publication may delayed at Cadence's written request for a period not to exceed 90 days if it contains a disclosure of an invention.|t
17189217|NCT02444143|f||||f
17189218|NCT02402764|t||||
17189219|NCT01982760|t||||
17189220|NCT00859014|t||||
17189221|NCT04796935|f||||f
17189222|NCT00783718|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189223|NCT04536025|f||||f
17189224|NCT04159896|t||||
17189225|NCT02338609|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189226|NCT02655653|t||||
17189227|NCT02223182|f||||t
17189228|NCT03714022|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17189229|NCT05121675|f||||f
17189230|NCT03864133|f||||f
17189231|NCT02668432|t||||
17189232|NCT04447820|f||||t
17189233|NCT02303743|t||||
17189234|NCT02234310|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17189235|NCT00235495|f||||f
17189236|NCT02192359|t||||
17144314|NCT03381248|f||||f
17189237|NCT00114959|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17144315|NCT03974152|f||||f
17144316|NCT01466686|t||||
17144317|NCT00827827|t||||
17144318|NCT04549259|f||||f
17144319|NCT02884206|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144320|NCT00112489|f||||f
17144321|NCT05751629|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144322|NCT01136226|t||||
17144323|NCT02231710|f||||f
17144324|NCT00287287|t||||
17144325|NCT00295854|t||LTE60||t
17144326|NCT00672620|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189238|NCT03251378|f||OTHER||t
17189239|NCT05051540|t||||
17189240|NCT04996069|f||||f
17189241|NCT04060680|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and participating institutions will provide any publication of study data generated by the Investigator and/or participating institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17189242|NCT00935792|t||||
17189243|NCT04739423|f||||t
17189244|NCT01007552|t||||
17189245|NCT05781490|f||||f
17189246|NCT01521143|f||OTHER|For study centers in Australia, no publication of the study results may be made until publication of the results of the study from all centers or until 2 years after study completion, whichever is sooner. For study centers in the USA, no submission for publication or public disclosure of the results by will be made until the results from all centers have been received and analyzed by the sponsor, or the multi-center study has been terminated or abandoned at all centers.|t
17189247|NCT00901485|f||||f
17189248|NCT01929993|t||||f
17189249|NCT01852162|t||||
17189250|NCT01256476|f||OTHER|May not publish.|t
17189251|NCT01866475|f||||f
17189252|NCT00163215|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189253|NCT00231179|f||||f
17189254|NCT02892409|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17189255|NCT02331940|f||||f
17189256|NCT02123966|f||||f
17189257|NCT01460381|f||GT60||t
17189258|NCT01824446|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17189259|NCT04822298|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189260|NCT00951561|f||OTHER|The PI agrees not to originate or use the name of Another Way Products, LLC and/or VIPON, or any of its employees, in any publicity, news release or other public announcement, written or oral, whether to the public, press or otherwise, relating to this protocol, to any amendment herto, or to the performance here under, without the prior written consent of Another Way Products, LLC|t
17189261|NCT02092987|t||||f
17189262|NCT00852475|t||||
17189263|NCT00515086|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17144327|NCT00772577|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144328|NCT03211156|f||LTE60||t
17144329|NCT03255031|t||||
17144330|NCT03563027|t||||
17189264|NCT02373813|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189265|NCT03738241|f||LTE60||t
17189266|NCT02788656|f||||f
17189267|NCT03169361|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189268|NCT02263885|f||||f
17189269|NCT00088465|f||GT60||t
17189270|NCT02688621|f||||f
17189271|NCT03311854|f||||f
17189272|NCT02307123|f||||f
17189273|NCT00180674|t||||
17189274|NCT01106976|f||||f
17189275|NCT02223689|f||||f
17189276|NCT00278564|t||||
17189277|NCT01094743|f||OTHER|Publication requires agreement and written consent from the Sponsor.|t
17189278|NCT02851511|t||||
17189279|NCT03836664|t||||
17189280|NCT01427907|f||||f
17189281|NCT04003974|f||OTHER||t
17189282|NCT00335153|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189283|NCT00372528|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189284|NCT02412761|t||||
17189285|NCT02240680|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17189286|NCT01657682|f||||f
17189287|NCT01719861|f||||f
17189288|NCT03704298|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17189289|NCT00483262|t||||
17189290|NCT04482855|f||||f
17144331|NCT00415532|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144332|NCT01698320|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17144333|NCT01189240|f||LTE60||t
17144334|NCT00386724|f||||t
17189291|NCT03212365|f||||f
17189292|NCT00819234|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17189293|NCT05174065|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144335|NCT01208402|f||||f
17144336|NCT01335464|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17144337|NCT03811249|f||OTHER|The Sponsor encourages publication and presentation of the safety and effectiveness results upon completion of the study. Per the established investigator agreement, the Principal Investigators will work with the Sponsor, in good faith, to ensure all confidential and proprietary informaton is redacted.|t
17189294|NCT00216320|f||||f
17189295|NCT00924560|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17189296|NCT01114620|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144338|NCT00706706|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144339|NCT01943461|f||||f
17144340|NCT02175966|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \<=60 days from submitting for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144341|NCT01154153|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication for review and comment at least 45 days (for abstracts -20 days) in advance of any submission for publication. The Sponsor may request for the publication to be delayed for a limited time, not to exceed 90 days to preserve its proprietary rights.|t
17144342|NCT00696709|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17144343|NCT01227668|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144344|NCT00210626|f||OTHER|All information which is supplied by COBS to the investigator \& not previously published \& any data generated as a result of the study are confidential \& remain the sole property of COBS. Investigator will not use the information for other purposes without COBS prior written consent.|t
17144345|NCT02473510|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17144346|NCT01306253|f||OTHER|The investigator to submit all manuscripts/abstracts to the sponsor for review at least 6 weeks before submission.|t
17144347|NCT02280356|t||||
17144348|NCT01086215|f||LTE60||t
17144349|NCT02524106|f||||f
17144350|NCT02006147|f||||f
17144351|NCT03361956|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17144352|NCT00408876|f||GT60||t
17144353|NCT03198988|f||||t
17144354|NCT01488019|f||||t
17189297|NCT02696226|t||||
17144355|NCT02400710|t||||
17144356|NCT00871728|f||OTHER|PI cannot provide any trial related information to external parties' without mutual agreement with the sponsor. This is valid even after the contract is canceled.|t
17189298|NCT03658629|f||||t
17189299|NCT02909101|t||||
17189300|NCT01125774|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17189301|NCT01221181|t||||
17189302|NCT03323151|f||||f
17189303|NCT00429793|f||LTE60||t
17189304|NCT00097370|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189305|NCT01031043|f||||f
17189306|NCT02337361|f||||f
17189307|NCT02419755|t||||
17189308|NCT02427646|f||||f
17189309|NCT01101542|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189310|NCT04207255|t||||
17189311|NCT00929305|f||||f
17189312|NCT01796665|f||OTHER||t
17189313|NCT02268396|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17189314|NCT03660943|f||||t
17189315|NCT00920374|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189316|NCT02491411|t||||
17189317|NCT04034238|f||||f
17189318|NCT01939158|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189319|NCT02065245|t||||
17189320|NCT01304706|f||GT60||t
17189321|NCT04940390|f||OTHER||t
17189322|NCT01345292|f||OTHER|Principal investigator agreed not to publish the study results without prior sponsor approval.|t
17189323|NCT02023944|t||||
17189324|NCT01033643|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17189325|NCT01893320|t||||
17189326|NCT01161160|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189327|NCT04446975|f||||f
17189328|NCT02271594|f||||f
17189329|NCT00495469|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189330|NCT02062905|f||OTHER||t
17189331|NCT00448864|f||OTHER||t
17189332|NCT01323660|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189333|NCT00350532|f||||f
17189334|NCT04531540|f||OTHER|No information based on the conduct of the study (incl. protocol, data resulting from the study, or the fact that the study was being conducted) will be released without prior written consent of the sponsor unless the requirement is superseded by State or Federal law.|t
17189335|NCT00108524|t||||
17189336|NCT01575860|t||||
17189337|NCT03606460|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189338|NCT04170023|f||||t
17189339|NCT02584790|f||||f
17189340|NCT05142228|t||||f
17189341|NCT04878172|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17189342|NCT01902901|f||||f
17189343|NCT00372567|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189344|NCT01079598|f||LTE60||t
17144357|NCT04147715|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17144358|NCT01626859|f||OTHER||t
17189345|NCT00303303|f||||f
17189346|NCT01330355|f||OTHER|For a period of ten years, the PI agrees to keep confidential and not disclose, without the prior written consent of Sponsor, to any third party or use any technology, data, reports, results of clinical studies conducted under this Study or other information received by Sponsor, or any technology, data, reports, study materials, or other information developed by Sponsor unless disclosure by PI is required by law.|t
17189347|NCT00582790|f||||f
17189348|NCT00480441|t||||
17189349|NCT02865434|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and make modifications to the publication.|t
17189350|NCT01004263|f||OTHER|Investigator agrees to delay publication of study results until Food and Drug Administration (FDA) grants pediatric exclusivity on the study drug. Investigator may publish results for his/her study site after primary publication of results of entire multicenter trial. Sponsor must be able to review all proposed results communications regarding study 60 days prior to submission for publication/presentation. Information identified by the Sponsor as confidential must be deleted prior to submission.|t
17189351|NCT00958009|f||OTHER|Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.|t
17189352|NCT00755755|f||||f
17144359|NCT02629965|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17189353|NCT00558753|t||||
17189354|NCT04668144|t||||
17189355|NCT02929108|t||||
17189356|NCT01027871|f||GT60||t
17189357|NCT01414166|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17144360|NCT00905489|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144361|NCT02407756|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17144362|NCT00895583|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144363|NCT04535583|f||||f
17144364|NCT00924066|f||||f
17144365|NCT00526890|t||||
17144366|NCT04049552|t||||
17144367|NCT01191255|f||||f
17144369|NCT02196506|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144370|NCT01859702|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17144371|NCT01715415|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144372|NCT01015612|f||||t
17144373|NCT00066807|f||||f
17144374|NCT05028751|f||||t
17144375|NCT03586830|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17144376|NCT04578548|f||OTHER||t
17144377|NCT02248285|f||||f
17144378|NCT00395083|t||||
17144379|NCT00628745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144380|NCT03322462|f||LTE60||t
17144381|NCT01976390|f||||f
17144382|NCT02265848|f||||f
17144383|NCT01133821|f||||f
17144384|NCT00325403|f||OTHER|Any publication of the results of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17144385|NCT03220230|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144386|NCT03572933|f||OTHER|If the study is part of a multicenter study, the first publication of the study results shall be made by the sponsor in conjunction with the sponsor's presentation of a joint, multicenter publication of the compiled and analyzed study results.|t
17144387|NCT02625766|f||||f
17144388|NCT01467063|f||||f
17144389|NCT00633152|f||||f
17144390|NCT01907087|f||GT60||t
17189358|NCT03782727|t||||
17189359|NCT02405390|t||||
17189360|NCT02084082|t||||
17189361|NCT05705167|f||||t
17189362|NCT04736056|t||||
17189363|NCT04348370|f||||f
17189364|NCT03163511|f||||f
17189365|NCT03437668|f||||f
17189366|NCT02099539|f||||t
17189367|NCT05812794|t||||
17189368|NCT02956967|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189369|NCT00615433|f||OTHER|For multi-center studies, it is mandatory that the first publication is based on all data obtained from all analyses as stipulated in the protocol. Investigators participating in multicenter studies must agree not to present data gathered individually or by subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and also by Sunovion.|t
17189370|NCT03194776|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17189371|NCT02963597|t||||f
17189372|NCT01823341|f||||f
17189373|NCT02027935|t||||
17189374|NCT03590743|t||||
17189375|NCT00604786|t||||f
17189376|NCT02698436|f||||f
17189377|NCT01394991|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17189378|NCT03073005|f||||f
17189379|NCT02230579|f||||f
17144391|NCT02049359|t||||
17189380|NCT01324882|f||||f
17189381|NCT00725010|f||||f
17189382|NCT01290094|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189383|NCT02414828|f||||f
17189384|NCT04949399|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189385|NCT05737550|f||LTE60||t
17189386|NCT04091672|f||OTHER||t
17189387|NCT05296629|f||||f
17189388|NCT02600429|f||||f
17189389|NCT02401529|t||||
17189390|NCT01414036|f||||f
17189391|NCT00961805|f||||f
17189392|NCT02949271|t||||
17189393|NCT01684046|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17189394|NCT01097655|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189395|NCT05458102|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17189396|NCT03303105|f||||f
17189397|NCT05336123|f||||f
17189398|NCT03371108|f||GT60||t
17189399|NCT05805059|f||||t
17189400|NCT04188288|t||||
17189401|NCT02790606|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17189402|NCT02735915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189403|NCT01789203|t||||
17144392|NCT03273387|f||||f
17144393|NCT05216978|t||||f
17144394|NCT02180061|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17144395|NCT01405950|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17144396|NCT02410252|f||||f
17144397|NCT03818737|t||||
17144398|NCT01772368|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17144399|NCT01452529|f||GT60||t
17144400|NCT03551730|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization|t
17189404|NCT05967442|f||||f
17189405|NCT02213900|f||||f
17189406|NCT03929302|f||||f
17144401|NCT02363010|f||||f
17144402|NCT03347695|t||||f
17144403|NCT00996866|t||||
17189407|NCT03815916|f||LTE60||t
17189408|NCT01600703|t||||
17189409|NCT01123161|f||||f
17144404|NCT00330421|f||LTE60||t
17189410|NCT02633891|t||||
17189411|NCT00051311|f||||f
17189412|NCT03825393|t||||
17189413|NCT02150044|f||GT60||t
17189414|NCT00821236|f||||f
17189415|NCT01055782|t||||
17189416|NCT00578227|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189417|NCT00577629|t||||
17189418|NCT01051778|t||||
17189419|NCT01605136|f||||f
17189420|NCT01072929|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17189421|NCT01366196|t||||
17189422|NCT00052962|f||||f
17189423|NCT04794062|t||||
17144405|NCT01003886|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144406|NCT03907280|t||||
17144407|NCT02491788|f||||f
17144408|NCT00815490|f||||f
17144409|NCT00673361|t||||f
17144410|NCT00829413|f||OTHER|Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement|t
17144411|NCT01464827|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189424|NCT06268301|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189425|NCT01688102|t||||
17189426|NCT00610883|t||||
17189427|NCT02783950|t||||
17144412|NCT02203565|f||||f
17144413|NCT03487796|f||||f
17144414|NCT04272775|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17144415|NCT00124020|f||LTE60||t
17144416|NCT02043366|t||||
17144417|NCT01127581|f||OTHER|Any abstract,presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days prior to submission for any meeting or journal.If deemed necessary by the Sponsor for protection of proprietary information prior to patent filing,the Investigator agrees to a further delay of 60 days before any presentation or publication is submitted.Publications must be in a form that does not reveal technical information that is considered confidential or proprietary.|t
17144418|NCT01489956|f||||f
17144419|NCT00891774|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written consent. The Institution will provide Sponsor with at least sixty (60) days for review of a manuscript, and if requested in writing, the Institution and Principal Investigators will withhold such publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17144420|NCT00004143|f||||f
17144421|NCT01977092|t||||
17144422|NCT02927847|t||||
17144423|NCT00723554|f||||f
17144424|NCT01405820|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17144425|NCT03421652|t||||
17189428|NCT01723774|t||||
17189429|NCT03663712|f||||f
17189430|NCT02487446|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17144426|NCT02619799|t||||
17144427|NCT01142297|f||||f
17144428|NCT01614509|f||||f
17144429|NCT01689974|t||||
17144430|NCT01952574|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144431|NCT05267574|f||OTHER|An Investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with the Sponsor in advance.|t
17189431|NCT04438785|t||||f
17144433|NCT02974114|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144434|NCT01580020|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17144435|NCT01724359|f||LTE60||t
17144436|NCT01534975|t||||f
17189432|NCT04011033|t||||
17189433|NCT00689104|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Primary publication of the multi-center data. Sponsor must receive a site's manuscript at least 45 days prior to planned submission to ensure that no confidential information of Sponsor is included in the document. Sponsor will respond within 30 days and may request changes or delay the publication to seek patent protection.|t
17189434|NCT01925781|t||||
17144437|NCT03503474|t||||
17144438|NCT00168337|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144439|NCT00593333|t||||
17144440|NCT01752920|f||GT60||t
17144441|NCT01738581|t||||
17144442|NCT01186978|t||||
17144443|NCT03979209|f||||f
17144444|NCT01033864|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144445|NCT01709383|f||||f
17144446|NCT03264066|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144447|NCT00926289|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17144448|NCT00686803|f||OTHER|PI was an employed by Palatin, as he was/is an employee of the CRO hired by Palatin to conduct the study. All confidentiality agreed upon between Palatin and the CRO applies.|t
17144449|NCT02115256|t||||
17144450|NCT01297257|f||OTHER|For any publication or presentation of the Protected Materials or any portion thereof, a manuscript of the paper, abstract or other materials will be provided by Consultant to Sponsor for its approval at least sixty (60) days for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.|t
17144451|NCT02668302|f||||f
17144452|NCT01078090|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144453|NCT03529955|t||||
17144454|NCT00580983|t||||
17144455|NCT03740100|f||||f
17144456|NCT02457728|f||||f
17144457|NCT03387059|f||OTHER||t
17144458|NCT03369756|f||OTHER|Institution acknowledges and shall cause Investigator to acknowledge that Sponsor has the right to use the Study Results in any manner deemed appropriate to Sponsor's business interests, both during, and following termination of, this Agreement. Where Institution and/or Investigator require the use of the Study Results for publication, the Institution and/or Investigator shall seek the Sponsor's written approval which shall not be unreasonably withheld.|t
17144459|NCT02468557|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17144460|NCT00982410|t||||
17144461|NCT04967313|t||||
17144462|NCT03167099|t||||
17144463|NCT04014959|f||||f
17144464|NCT01016652|f||OTHER|Written authorization by the Sponsor is required for publication.|t
17144465|NCT02060461|f||||f
17144466|NCT02034799|f||LTE60||t
17144467|NCT05321810|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144468|NCT03827213|t||||
17144469|NCT01956279|t||||
17144470|NCT02806232|f||||f
17144471|NCT00434161|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17144472|NCT01387282|f||OTHER|The Sponsor intends to publish the complete study results in a timely manner that is appropriate to the project. Separate publication of a portion of the study results by any PI is discouraged.|t
17144473|NCT01267266|f||LTE60||t
17144474|NCT02497391|f||GT60||t
17144475|NCT00401882|f||||f
17144476|NCT01828255|f||||f
17144477|NCT00439608|f||||f
17144478|NCT01464359|f||||f
17144479|NCT02557945|t||||
17144480|NCT02429869|t||||
17144481|NCT00658320|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144482|NCT00789802|f||||f
17144483|NCT01975090|f||||f
17144484|NCT00746668|t||||
17144485|NCT00557882|f||||f
17144486|NCT03877055|t||||
17144487|NCT00387712|t||||
17144488|NCT00631670|t||||
17144489|NCT00322309|t||||
17144490|NCT01907737|f||||f
17144491|NCT02030574|f||||f
17144492|NCT02449291|f||||f
17144493|NCT02668783|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17144494|NCT01492582|t||||f
17144495|NCT04467697|f||||t
17144496|NCT01172600|t||||
17144497|NCT00909727|f||GT60||t
17144498|NCT01399723|f||||f
17144499|NCT04081337|f||GT60||t
17144500|NCT00671671|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144501|NCT01578707|f||||f
17144502|NCT01799590|f||OTHER|The disclosure restriction on PI is that the Sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the Sponsor requires.|t
17144503|NCT00730522|f||||f
17144504|NCT03175120|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17144505|NCT00678392|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144506|NCT03341507|f||||f
17144507|NCT00514137|f||LTE60||t
17144508|NCT03882047|f||OTHER|Sponsor has 30 days prior to submission for publication or presentation to review copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the Protocol study. Sponsor shall have editorial rights with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information and the accuracy of the information contained in the publication.|t
17144509|NCT01665170|f||||f
17144510|NCT00441584|f||LTE60||t
17144511|NCT01584609|f||||f
17144512|NCT01172353|f||||f
17144513|NCT00770991|f||||f
17144514|NCT03465891|t||||
17144515|NCT01001169|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144516|NCT01945138|t||||
17189435|NCT01974687|f||OTHER|Institution and Investigator will submit any proposed publication to Sponsor for review and comment at least sixty (60) days prior to submission to a third party. If Sponsor believes in good faith that any proposed publication contains any proprietary or confidential information, Sponsor shall have the right to remove such references to such confidential information.|t
17189436|NCT00814489|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189437|NCT01712685|f||||f
17189438|NCT02613897|t||||
17189439|NCT03253653|f||||f
17189440|NCT05968079|f||||f
17189441|NCT00662909|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17189442|NCT01518257|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144517|NCT02040766|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17144518|NCT01608295|f||||f
17144519|NCT00455663|f||||f
17144520|NCT02950753|f||||f
17144521|NCT02755545|f||||f
17144522|NCT00481247|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144523|NCT02535000|f||||f
17144524|NCT04317781|t||||
17144525|NCT01620489|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17144526|NCT00947856|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144527|NCT04749524|t||||f
17144528|NCT01193517|t||||
17189443|NCT00924664|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144529|NCT01360450|t||||f
17144530|NCT02387814|f||GT60||t
17144531|NCT03621085|f||||f
17144532|NCT01512979|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17144533|NCT00961051|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to publication release and can embargo communications regarding trials results for a period that is more than 90 days but less than or equal to 18 months from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144534|NCT04192799|f||||f
17144535|NCT00874757|t||||
17144536|NCT00759148|f||OTHER|Sponsor reserves the right to review study related information prior to presentation or publication.|t
17144537|NCT00803959|f||||f
17144538|NCT02802514|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144539|NCT03467412|f||||f
17144540|NCT03433001|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144541|NCT00820235|f||LTE60||t
17144542|NCT02040428|f||GT60||t
17144543|NCT01038557|f||||f
17144544|NCT01411267|f||GT60||t
17144545|NCT01165996|t||||f
17144546|NCT03051256|f||OTHER|Sponsor requests an opportunity to review any proposed publication prior to public release to ensure against inadvertent release of confidential information or unprotected inventions. Sponsor has 12 months from the completion or termination of the trial to publish a joint manuscript with all participating sites.|t
17144547|NCT00268346|t||||
17144548|NCT05487456|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17144549|NCT00981253|f||||f
17144550|NCT00294723|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones. This includes the right to not release interim results, because the release of such information can invalidate the results of the entire trial. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17144551|NCT00752791|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144552|NCT01958281|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17144553|NCT02784106|f||||f
17144554|NCT03222141|f||||f
17144555|NCT02536378|f||||f
17189444|NCT02395185|f||||f
17189445|NCT03158948|f||||f
17144556|NCT00798889|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144557|NCT00617461|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144558|NCT00358826|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented as a joint, multi-center publication.|t
17144559|NCT00903383|f||OTHER|The sponsor requires that written permission be given before the PI can release any data publicly.|t
17144560|NCT01195922|t||||
17144561|NCT01110681|f||LTE60||t
17189446|NCT02153788|t||||
17144562|NCT01821625|f||||f
17144563|NCT04571242|f||||f
17144564|NCT00320593|f||||f
17144565|NCT00457665|t||||
17144566|NCT01716754|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17144567|NCT00565370|f||||f
17144568|NCT01847196|f||||f
17144569|NCT04371419|f||||f
17144570|NCT02931565|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17144571|NCT00638157|f||OTHER|The first publication is initiated by Cubist. If First Publication not published within 1 year of Study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17144572|NCT04177810|t||||f
17144573|NCT04756141|t||||
17144574|NCT03267030|f||||f
17144575|NCT01851590|f||||f
17144576|NCT01714505|t||||
17144577|NCT02611752|f||||f
17144578|NCT00310856|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single site are postponed until the publication of the pool data (i.e., data from all sites) in the clinical trial.|t
17144579|NCT02462070|f||OTHER|Contract sponsor directly for details.|t
17144580|NCT00443352|t||||
17144581|NCT00321711|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17144582|NCT02843074|f||GT60||t
17144583|NCT01832090|f||||f
17144584|NCT01211769|f||||f
17189447|NCT04672460|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144585|NCT01214330|f||||f
17144586|NCT01348542|t||||
17144587|NCT03402893|f||||f
17144588|NCT01484028|f||||f
17144589|NCT02922959|t||||f
17144590|NCT00492206|f||LTE60||t
17189448|NCT03575962|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189449|NCT01876043|f||LTE60||t
17189450|NCT01032850|t||||
17189451|NCT00079937|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144591|NCT01199601|f||||f
17144592|NCT00146770|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17144593|NCT03867383|f||||f
17144594|NCT01505465|t||||
17144595|NCT03775681|t||||
17144596|NCT01855126|f||||f
17144597|NCT01149616|f||||f
17144598|NCT01357356|f||||t
17144599|NCT03944785|f||||t
17144600|NCT01748890|t||||
17144601|NCT02669264|f||OTHER|PI can publish after first multi-site publication, or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on the PI is the sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period that is more than 60 but less than or equal to 180 days from the time submitted to sponsor for review. The sponsor can't require changes to the communication and can't extend the embargo.|t
17144602|NCT01688037|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17144603|NCT01879800|f||||f
17144604|NCT03280537|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144605|NCT03083132|t||||
17144606|NCT01588106|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Publications or lectures on the findings of the present clinical trial either as a whole or at individual investigation sites must be approved by the sponsor in advance, and the sponsor reserves the right to review and comment on such documentation before publication.|t
17144607|NCT02995837|f||||f
17144608|NCT02004847|f||||f
17189452|NCT01616563|f||||f
17189453|NCT02206685|t||||
17144609|NCT03342898|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144610|NCT03997448|f||||f
17144611|NCT02661126|f||||f
17144612|NCT01151813|t||||f
17144613|NCT00521456|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144614|NCT02482805|f||||f
17144615|NCT02917447|t||||
17144616|NCT01144663|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144617|NCT03081767|t||||
17144618|NCT01335477|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144619|NCT01007916|f||OTHER|For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.|t
17144620|NCT00958581|f||||f
17189454|NCT02054247|f||||f
17144621|NCT00992264|f||||f
17144622|NCT01927757|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189455|NCT00093795|f||GT60||t
17144623|NCT03295643|t||||
17189456|NCT01195675|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17189457|NCT01106287|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17189458|NCT00072475|f||LTE60||t
17189459|NCT04730947|t||||
17189460|NCT00940017|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189461|NCT01450943|t||||f
17189462|NCT05153174|t||||f
17189463|NCT01385280|t||||
17189464|NCT03614130|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17189465|NCT05328973|t||||
17189466|NCT00946114|f||OTHER||t
17189467|NCT05176353|t||||
17189468|NCT01447914|f||LTE60||t
17189469|NCT01764386|f||OTHER|If not already published by Sponsor as part of a multi-center publication, 24 months after conclusion, abandonment or termination of the study or notification that there will be no such multi-center publication, PI may publish the results for PI's study center individually. Prior to such publication, PI must provide Sponsor with at least 90 days to review and comment on the proposed publication. Sponsor may delay publication for up to an additional 6 month period to file for patent protection.|t
17189470|NCT04454567|f||OTHER|Assembly Biosciences agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Assembly Biosciences supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189471|NCT02757885|t||||
17189472|NCT01175707|f||OTHER|The first publication is initiated by Cubist. If First Publication not published within 1 year of Study conclusion or termination, Investigator has right to publish and disclose the Data. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17189473|NCT01598025|t||||
17189474|NCT00003377|f||||f
17189475|NCT01328587|t||||
17189476|NCT00463151|f||||f
17189477|NCT05349084|t||||
17189478|NCT00688688|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17189479|NCT01950260|t||||
17189480|NCT03283553|f||||f
17189481|NCT03686683|f||OTHER|The results of the Study may be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17189482|NCT03255941|f||||f
17144624|NCT00449072|f||OTHER|The investigator can independently publish study results from his site after the primary publication by the steering committee, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission, and delay publication till the approval of the publication is given in writing by the Sponsor (not to exceed ninety days).|t
17144625|NCT00417274|f||LTE60||t
17144626|NCT02971956|t||||
17144627|NCT01992107|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144628|NCT02022007|t||||
17144629|NCT02087046|f||||f
17144630|NCT01107535|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17144631|NCT01507896|f||OTHER|Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, results may not be published without prior written approval of the Sponsor.|t
17144632|NCT00621179|f||||f
17144633|NCT02422290|f||||f
17144634|NCT01413399|f||||f
17144635|NCT00886483|f||||f
17144636|NCT00192296|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17144637|NCT00818623|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17144638|NCT01684410|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17144639|NCT02649231|t||||
17144640|NCT05425966|t||||
17144641|NCT00543439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144642|NCT05105711|f||||f
17144643|NCT00686036|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17144644|NCT00891878|t||||
17144645|NCT01185288|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144646|NCT01200394|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144647|NCT02666430|f||||f
17144648|NCT03828461|t||||
17144649|NCT00576199|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144650|NCT03035227|f||||f
17144651|NCT02100956|f||||f
17144652|NCT02473991|t||||
17144653|NCT00859469|t||||
17144654|NCT02220907|f||OTHER||t
17144655|NCT03111147|t||||
17144656|NCT03065283|f||||f
17144657|NCT00095199|f||GT60||t
17144658|NCT01896297|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144659|NCT01098240|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144660|NCT01070394|f||||f
17144661|NCT00634283|f||||f
17144662|NCT03118739|f||GT60||t
17144663|NCT00669955|f||OTHER|Restrictions vary in accordance with the agreement with investigators. Axcan will allow publication after a multi-centre publication or after an agreed period, subject to review by Axcan for confidentiality and intellectual protection.|t
17144664|NCT02743442|f||||f
17144665|NCT01170260|t||||
17144666|NCT04317053|t||||
17144667|NCT01077713|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144668|NCT03507439|f||LTE60||t
17189483|NCT00372060|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189484|NCT01034111|f||OTHER|The sponsor shall have the opportunity to review all abstracts, drafts or proposed presentations regarding this study 60 days prior to submission for publication/presentation. Any information that the sponsor identifies as confidential should be deleted prior to submission.|t
17189485|NCT05124899|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189486|NCT00438971|f||||f
17189487|NCT00647348|f||||f
17189488|NCT02987829|f||GT60||t
17189489|NCT01417000|f||LTE60||t
17189490|NCT00797225|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189491|NCT02954055|f||||f
17189492|NCT01363479|f||OTHER|Sponsor and investigator(s) agree that no publications discussing trials' results will occur until release of final report. Sponsor has no objections if the investigators publish study results, however the investigator is requested to contact the sponsor before publishing, to prevent premature disclosure of data and is not intended as a restrictive measure concerning results or opinions of investigators.|t
17189493|NCT05489224|f||OTHER||t
17189494|NCT04640571|t||||
17189495|NCT04515797|t||||
17189496|NCT00832780|t||||
17189497|NCT03569813|t||||f
17189498|NCT01767909|f||OTHER|PIs agree to provide a copy of the manuscript to Dr. Suzanne Craft, Project Director, Wake Forest School of Medicine, and the National Institutes of Health (NIH) must be cited as a funding agency.|t
17189499|NCT03669042|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17189500|NCT04319094|f||||f
17189501|NCT04956692|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17189502|NCT03057132|f||||f
17189503|NCT01016353|f||GT60||t
17189504|NCT05780047|t||||
17189505|NCT04873817|f||OTHER|"* The PI may publish provided that he/she provides the Sponsor with a draft of any Study-related publication, presentation or other disclosure (Publication) at least sixty (60) calendar days prior to any submission for Sponsor's review~* The PI may not publish the data and results separately from its site until publication of the results of the multi-center study or 18 months after study closure, whichever is sooner."|t
17189506|NCT00665561|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144669|NCT00289458|t||||
17189507|NCT02081365|t||||f
17189508|NCT01734811|f||||f
17144670|NCT04274192|t||||f
17144671|NCT01557595|t||||
17189509|NCT00062868|t||||
17189510|NCT01786343|t||||
17189511|NCT03230006|t||||
17189512|NCT00670540|f||OTHER|"The protocol OPTIMEV will follow the international recommendations: Uniforms Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org)"|t
17189513|NCT01866917|t||||
17189514|NCT03896230|t||||
17189515|NCT01515319|t||||
17189516|NCT03719677|t||||
17189517|NCT01449929|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144672|NCT01717898|f||||f
17144673|NCT01621490|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤ 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17144674|NCT00461500|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144675|NCT01806597|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144676|NCT02149303|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17144677|NCT02247479|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144678|NCT01073020|t||||f
17144679|NCT03287050|t||||
17144680|NCT04642950|f||||t
17144681|NCT02275923|f||||f
17144682|NCT02452060|t||||f
17144683|NCT03031899|f||||f
17144684|NCT04160078|t||||
17144685|NCT03740698|t||||
17144686|NCT01045499|t||||
17144687|NCT01469364|f||||f
17144688|NCT03043274|f||||f
17144689|NCT01162499|t||||
17144690|NCT01590433|f||||f
17144691|NCT00555009|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144692|NCT00989261|f||||f
17144693|NCT00718159|f||GT60||t
17144694|NCT02498522|f||LTE60||t
17144695|NCT03532009|f||||t
17144696|NCT03463525|f||||t
17189518|NCT01871285|f||OTHER|PI and Institution reserve the right to publish and present the results of the work performed provided that Institution and/or PI submits a copy of any proposed publication to Sponsor's agent for review and comment at least 90 days in advance of its presentation or submission for publication. In addition, if Sponsor's agent requests, Institution and/or PI will withhold publication or presentation for an additional 60 days to allow for establishing and preserving its proprietary rights.|t
17189519|NCT01959880|f||OTHER|Investigator and his/her collaborators are free to publish the background, methods, and results of their own research without restraint. Prior review of any proposed manuscript or abstract will be provided to the sponsor to prevent premature disclosure of trade secrets or proprietary information. The review will occur 30 days prior to submission of manuscript or abstract for consideration of publication or to a conference. Sponsor reserves right to publish or present the overall study results.|t
17189520|NCT01919619|t||||
17189521|NCT01955382|t||||
17189522|NCT04610684|f||||f
17189523|NCT02655692|f||||f
17189524|NCT00716079|t||||
17189525|NCT04978363|f||||f
17189526|NCT01251614|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189527|NCT00049517|f||||f
17189528|NCT00256308|t||||
17189529|NCT02435901|f||||f
17189530|NCT02933320|f||||f
17189531|NCT00886613|f||OTHER|For multicenter studies, an investigator and his/her colleagues may publish their data independently subsequent to the multicenter publication. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication timelines.|t
17189532|NCT01996644|f||||f
17189533|NCT01515956|t||||
17189534|NCT00427973|f||LTE60||t
17144697|NCT01224210|f||||f
17144698|NCT00681863|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17144699|NCT01333033|f||LTE60||t
17144700|NCT03687125|f||||t
17144701|NCT00804609|f||||f
17144702|NCT02035137|f||||f
17144703|NCT01288859|t||||
17144704|NCT01214603|f||GT60||t
17144705|NCT03588390|t||||
17144706|NCT02444533|t||||
17144707|NCT01388647|f||LTE60||t
17144708|NCT01544166|f||OTHER|The sponsor is interested in the publication of the results of every study it performs. All relevant aspects regarding publication will be part of the contract between the sponsor and the investigator/institution.|t
17144709|NCT03567057|f||||f
17144710|NCT01006707|f||||f
17144711|NCT00490061|f||||f
17144712|NCT01155583|t||||
17144713|NCT00952484|f||LTE60||t
17144714|NCT05085613|t||||
17144715|NCT01982383|t||||
17144716|NCT00585351|f||||f
17144717|NCT02659202|t||||
17144718|NCT01842958|f||GT60||t
17189535|NCT02256969|t||||
17189536|NCT02347943|f||||f
17189537|NCT01873287|f||||f
17189538|NCT00402883|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17189539|NCT03566680|f||||f
17189540|NCT00451698|t||||
17189541|NCT03783533|f||||f
17189542|NCT01492309|t||||
17189543|NCT01169519|f||||f
17144719|NCT01829477|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144720|NCT02511236|t||||
17144721|NCT03361423|f||||f
17144722|NCT01336894|f||LTE60||t
17144723|NCT05034731|f||OTHER|"PI agrees to submit any publication to Sponsor at least 30 days before submission. Within 30 days, Sponsor advises PI in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair availability of patent protection for Inventions.~Sponsor has the right to require PI to remove specifically identified CI and/or to delay the publication for an additional 60 days to enable Sponsor to seek patent protection for Inventions."|t
17144724|NCT02746263|f||||t
17144725|NCT01325207|t||||
17144726|NCT00602030|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17144727|NCT00283686|f||||f
17144728|NCT01076166|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17144729|NCT02970669|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17144730|NCT02531022|f||||f
17144731|NCT00876733|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144732|NCT05476679|f||||f
17144733|NCT01569828|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17144734|NCT04738279|f||||f
17144735|NCT00467584|t||||f
17144736|NCT00319956|t||||
17144737|NCT04616417|f||||f
17144738|NCT02607800|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17144739|NCT00753714|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17144740|NCT02486796|t||||
17144741|NCT00310427|t||||
17144742|NCT02789111|t||||
17144743|NCT01166971|f||OTHER|"The existence of this clinical study is confidential and should not be discussed with persons outside of the study. You shall hold confidential, and not disclose directly or indirectly to any third party other than those persons involved in the study who have a need to know, the protocol, the data arising out of the study, and any other information related to the study or to Alcon's products or research programs that is provided by Alcon to you (the Confidential Information)."|t
17144744|NCT01626885|f||OTHER||t
17144745|NCT00673790|f||OTHER|All data generated in this study will be the property of Forest Research Institute. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute.|t
17144746|NCT04326842|t||||
17144747|NCT01533428|f||OTHER|Institute and/or Principal Investigator may publish or present trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17144748|NCT01483872|t||||
17144749|NCT01364870|f||||f
17144750|NCT01890707|f||||f
17144751|NCT05286528|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144752|NCT00506753|t||||
17144753|NCT00125359|t||||
17144754|NCT02451670|f||||f
17189544|NCT02374957|t||||f
17189545|NCT00748969|t||||
17189546|NCT02334306|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17144755|NCT01513551|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17144756|NCT05569148|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144757|NCT00094302|t||||f
17144758|NCT03705351|f||||f
17144759|NCT02780661|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144760|NCT01806688|f||||f
17144761|NCT01717014|f||||f
17144762|NCT00006170|f||||f
17144763|NCT00322556|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144764|NCT02058628|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189547|NCT01687270|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17189548|NCT00465985|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189549|NCT03302156|t||||
17189550|NCT03532178|t||||f
17189551|NCT02390557|f||||f
17189552|NCT01711918|t||||
17189553|NCT01608971|t||||
17189554|NCT03278028|f||||t
17189555|NCT01360840|f||OTHER||t
17189556|NCT00293462|t||||f
17189557|NCT01579578|f||GT60||t
17189558|NCT01528709|f||||f
17189559|NCT02726178|t||||
17189560|NCT00714233|f||||f
17189561|NCT02284464|f||||f
17189562|NCT04653051|f||GT60||t
17189563|NCT01813422|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189564|NCT01653743|f||OTHER||t
17144765|NCT01767597|f||||f
17144766|NCT02961920|t||||
17144767|NCT00955032|f||||f
17144768|NCT04527471|f||||f
17144769|NCT03020472|f||||f
17144770|NCT00096265|f||LTE60||t
17144771|NCT01506323|t||||
17144772|NCT02192905|f||||f
17144773|NCT00580853|f||||f
17189565|NCT03748771|f||||f
17189566|NCT04889118|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17189567|NCT02397889|t||||
17189568|NCT04500821|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17144774|NCT01626820|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144775|NCT04579926|t||||
17144776|NCT03534986|f||||f
17144777|NCT02588573|f||OTHER||t
17144778|NCT04604184|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144779|NCT03513497|t||||
17144780|NCT03294538|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17144781|NCT00422656|f||||f
17144782|NCT01769378|f||GT60||t
17144783|NCT01787825|f||||f
17144784|NCT04394754|t||||
17144785|NCT06076681|f||||f
17144786|NCT01338636|t||||
17144787|NCT02385526|f||GT60||t
17144788|NCT01602614|f||||f
17189569|NCT01928940|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189570|NCT02408965|f||||f
17189571|NCT01352507|f||GT60||t
17144789|NCT01798485|f||OTHER|Sponsor has the right, 60 days before submission for publication, to review disclosures and require deletion of its confidential information, excluding the study results. Public disclosure shall be delayed for up to 60 additional days in order for the Sponsor to file a patent application, if needed. Single center publications will be postponed until after disclosure of pooled data (all sites), or, for a period of 18 months from study completion/termination at all participating sites.|t
17144790|NCT01254409|f||OTHER|Investigators agree that the first public presentation of data will be a joint, multicentre publication of results. If this does not occur within 12 months after conclusion of the study, investigator may publish the results, provided that the complete manuscript or other publication is submitted to the sponsor for review 30 days prior to submission.|t
17144791|NCT01934296|t||||f
17144792|NCT04992052|t||||
17144793|NCT03521999|t||||
17144794|NCT01564758|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144795|NCT00249821|f||OTHER||t
17144796|NCT02354378|f||||f
17144797|NCT01862328|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17144798|NCT02482571|f||||f
17189572|NCT01511250|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189573|NCT00980278|f||||f
17189574|NCT02148809|t||||
17189575|NCT05487703|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189576|NCT04824131|f||||f
17189577|NCT04887285|f||||f
17189578|NCT04939428|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17144799|NCT01636297|f||||f
17144800|NCT01498484|f||||t
17189579|NCT02696785|f||LTE60||t
17189580|NCT04863898|t||||
17144801|NCT00278512|t||||
17144802|NCT01202747|f||||f
17144803|NCT01620177|f||GT60||t
17144804|NCT04041609|f||||f
17144805|NCT02292238|f||||f
17144806|NCT01789320|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical (or designee).|t
17144807|NCT01103505|f||LTE60||t
17144808|NCT03387033|t||||
17144809|NCT00601484|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144810|NCT04523142|f||GT60||t
17144811|NCT03123822|t||||
17144812|NCT01463683|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17144813|NCT01618305|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17144814|NCT00918671|f||||f
17144815|NCT02708277|f||||f
17189581|NCT00770211|f||OTHER|No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 wks before submission. Sponsor to give written opinion within 30 d. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17189582|NCT02982928|t||||
17189583|NCT01822821|t||||
17189584|NCT01939938|t||||
17189585|NCT00764868|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17189586|NCT00308061|f||||f
17144816|NCT01960816|f||LTE60||t
17144817|NCT02099266|t||||
17144818|NCT01841606|f||||f
17144819|NCT01118728|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17144820|NCT04345471|f||OTHER|PI shall not publish the Study results at any time without the prior written approval of the Sponsor.|t
17144821|NCT02525029|t||||
17144822|NCT03896490|f||||t
17189587|NCT03005288|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17189588|NCT03824236|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17189589|NCT00701311|t||||
17189590|NCT04549051|t||||
17189591|NCT00359619|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189592|NCT01419717|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189593|NCT02857283|t||||
17189594|NCT01207908|t||||
17189595|NCT05080192|t||||
17189596|NCT05074498|f||OTHER||t
17189597|NCT01240356|t||||
17189598|NCT02967016|t||||f
17189599|NCT01211665|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17189600|NCT02685293|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17189601|NCT00498186|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17189602|NCT01390857|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189603|NCT00715390|t||||
17189604|NCT04541186|f||||t
17144823|NCT00003782|f||GT60||t
17144824|NCT00385541|f||||f
17189605|NCT00691028|f||OTHER||t
17189606|NCT03085017|f||||f
17189607|NCT00058058|f||||f
17189608|NCT01528124|t||||
17189609|NCT00360126|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189610|NCT02596906|t||||
17189611|NCT03255018|f||||f
17189612|NCT00790062|t||GT60||
17189613|NCT03681691|f||||f
17189614|NCT03432533|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189615|NCT00372970|f||||f
17189616|NCT04582045|t||||
17189617|NCT00487721|t||||
17144825|NCT01326026|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17144826|NCT05188521|t||||
17144827|NCT04582266|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17144828|NCT01341639|f||OTHER|The SPONSOR and SPONSOR representative must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR or SPONSOR representative as confidential must be deleted prior to submission.|t
17144829|NCT01132118|f||||f
17144830|NCT04942379|f||||f
17144831|NCT00494975|t||||
17144832|NCT02742090|f||OTHER|PI is restricted from publication until after the multi-center paper is published.|t
17144833|NCT01299038|f||||f
17144834|NCT00832078|f||LTE60||t
17144835|NCT03355742|f||||t
17144836|NCT03229252|f||||f
17144837|NCT05432271|t||||
17144838|NCT03158298|t||||
17144839|NCT02891200|f||||f
17144840|NCT02958956|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17144841|NCT04480463|f||||f
17144842|NCT00017563|f||||f
17144843|NCT00444795|f||GT60||t
17144844|NCT00988169|t||||
17144845|NCT04690413|f||||f
17144846|NCT00704418|f||OTHER|The disclosure restriction on the PI is that the PI will provide to the sponsor a copy of proposed publication information for review, comment and approval following completion of the study and at least sixty (60) days prior to submission of the publication. If sponsor requests in writing, the PI will withhold publication until written permission is given by sponsor.|t
17144847|NCT02322879|f||||f
17144848|NCT02637076|t||||
17144849|NCT02642627|f||||f
17144850|NCT02710071|t||||
17144851|NCT01633827|f||||f
17144852|NCT03581474|f||||f
17144853|NCT02637557|f||OTHER|All data generated in this study will be the property of Ironwood. Publication of the results by the Principal Investigator will be subject to mutual agreement between the Investigator and Ironwood.|t
17144854|NCT00613574|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17144855|NCT00176904|t||||f
17144856|NCT01751412|t||||
17144857|NCT01711021|f||||t
17144858|NCT02711956|f||||t
17144859|NCT03734237|f||||f
17144860|NCT01844583|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17144861|NCT01625377|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17144862|NCT01412541|f||GT60||t
17144863|NCT01236170|t||||
17144864|NCT02442856|f||||f
17144865|NCT02207621|f||||f
17144866|NCT02833415|f||||f
17144867|NCT02324972|f||OTHER|Investigators shall not publish any articles or make any presentations or communications (including any written, oral, or electronic manuscript, abstract, presentation, or other publication) relating to the Services, Sponsor Information, Study Drug or other Material, Deliverables or other Developments, in whole or in part, without the prior written consent of Sponsor.|t
17144868|NCT03352427|t||||
17144869|NCT01462565|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144870|NCT01238848|t||||f
17144871|NCT00576901|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144872|NCT02004704|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17189618|NCT01582243|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17189619|NCT01125202|f||||f
17189620|NCT02775617|t||||
17189621|NCT03404609|f||||f
17189622|NCT01674569|f||||f
17144873|NCT01755858|f||LTE60||t
17189623|NCT01454362|t||||
17189624|NCT02419521|f||OTHER||t
17189625|NCT01119703|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17189626|NCT02096003|t||||
17189627|NCT03610633|f||||f
17189628|NCT01763047|f||GT60||t
17189629|NCT01112735|f||||t
17189630|NCT00916006|f||OTHER|"For US sites: The institution and investigator agree not to publish the results of this study without prior written consent of the Sponsor. As used herein, the term publish shall include oral presentations,written abstracts, written manuscripts, etc."|t
17144874|NCT01259869|f||||f
17144875|NCT00175019|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17144876|NCT03209570|t||||
17144877|NCT00928083|f||LTE60||t
17144878|NCT00118053|t||||
17189631|NCT03999944|f||||f
17189632|NCT00884611|f||||f
17144879|NCT00220701|f||||f
17144880|NCT00755326|f||||f
17189633|NCT00883350|f||||f
17189634|NCT01222247|f||LTE60||t
17189635|NCT04639947|t||||
17189636|NCT03486197|t||||f
17189637|NCT00877851|t||||
17189638|NCT03424239|t||||
17189639|NCT01258387|f||OTHER|Sponsor (Acorda) has the right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17189640|NCT02042443|f||LTE60||t
17144881|NCT02140957|t||||
17144882|NCT04041570|f||||f
17144883|NCT03758365|f||OTHER|The final report, the protocol and the raw date are the exclusive property of the sponsor.|t
17144884|NCT01111110|t||||f
17144885|NCT00384033|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144886|NCT03349333|t||||
17144887|NCT00290745|t||||f
17144888|NCT02750306|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17144889|NCT02737306|f||||f
17144890|NCT03267264|f||||f
17144891|NCT04471935|f||||f
17144892|NCT05343156|f||OTHER|Investigator agrees not to publish/present the results until such time as the aggregate study results are published. After such time, Investigator may publish the results in accordance with the following: Investigator shall submit to Sponsor any such proposed publication/presentation resulting from or relating to the Study at least 60 days prior to the submission for publication. Sponsor may require the delay of publication/presentation for an additional period of time not to exceed 120 days.|t
17144893|NCT01915732|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144894|NCT01575522|f||LTE60||t
17144895|NCT02015793|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17144896|NCT00601354|f||||f
17144897|NCT01446913|f||||f
17144898|NCT02521948|f||||f
17144899|NCT02427607|f||OTHER||t
17144900|NCT04000009|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17144901|NCT00679783|f||LTE60||t
17144902|NCT00494806|t||||f
17189641|NCT02320253|f||||f
17189642|NCT04794179|f||||f
17144903|NCT00756964|f||||f
17144904|NCT01754259|f||||f
17144905|NCT00814320|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤60 days eg, for intellectual property protection|t
17189643|NCT00741273|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17189644|NCT05550337|f||OTHER|PIs may not publish results from this generic (ANDA) study unless reviewed and approved by the Sponsor.|t
17189645|NCT04783415|t||||
17189646|NCT03115346|t||||
17189647|NCT04816526|f||||f
17189648|NCT01140347|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17189649|NCT00828919|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189650|NCT00147043|t||||
17189651|NCT02501811|t||||
17189652|NCT04094064|f||||f
17189653|NCT03647475|f||||f
17189654|NCT01260662|f||||f
17189655|NCT03049111|t||||
17189656|NCT00248612|t||||
17189657|NCT03106025|f||||t
17189658|NCT03570255|f||GT60||t
17189659|NCT01124162|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17189660|NCT02680756|f||||t
17189661|NCT03613129|f||LTE60||t
17189662|NCT00938340|f||||f
17189663|NCT04353037|f||||f
17189664|NCT00507208|t||||
17189665|NCT02243007|t||||f
17189666|NCT02950545|f||||f
17189667|NCT03398356|f||||f
17189668|NCT04034121|f||||f
17189669|NCT01648283|f||||f
17144906|NCT00491504|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 45 days from the time submitted to the sponsor for review. If the parties disagree on the communication, the investigator and sponsor's represnetatives will meet for the purpose of making a good faith effort to discuss and resolve any such issues or disagreement.|t
17144907|NCT00306384|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144908|NCT00745251|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17144909|NCT00717977|f||LTE60||t
17144910|NCT00929708|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites. AZ has the right to request delays: up to 60 days for confidential information, and an additional 90 days to protect intellectual property.|t
17144911|NCT01893138|f||LTE60||t
17144912|NCT02154529|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.|t
17144913|NCT00824460|f||OTHER|Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.|t
17144914|NCT00458302|f||OTHER|Sponsor (SP) shall have the 1st right to present the Data without approval from the Principal Investigator (PI). If no publication is submitted by SP within 12 months after closure, or after SP confirms there will be no publication, the PI shall have the right to publish. Prior to submission, the PI will provide the SP with at least 45 days for review of a manuscript. If requested, the PI will withhold such publication for up to an additional 60 days to allow for filing of a patent application|t
17144915|NCT01259427|t||||
17144916|NCT01628120|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single centre publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144917|NCT02232074|f||||f
17144918|NCT03843957|t||||
17144919|NCT01296932|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144920|NCT00974493|f||||f
17189670|NCT04880070|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17189671|NCT02060279|f||||f
17189672|NCT03587194|t||||
17189673|NCT00073957|f||||f
17189674|NCT00530777|f||||f
17189675|NCT02359058|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17189676|NCT03163992|f||||t
17189677|NCT01104103|t||||
17189678|NCT03382821|t||||
17189679|NCT01805323|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17189680|NCT00282438|t||||f
17189681|NCT00875641|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189682|NCT00587132|t||||f
17189683|NCT03178201|t||||
17189684|NCT02095158|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17189685|NCT01008748|t||||
17189686|NCT02775435|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17189687|NCT02282527|f||OTHER|The site may publish results from the study, after providing Sponsor at least 30 days notice prior to submitting a manuscript or other materials related to the study to any outside party. At Sponsor's request, Site will remove any any confidential information (other than study results), and incorporate all reasonable comments by Sponsor, or delay publication or presentation for a period of up to 120 days to allow Sponsor to protect its interests in any Sponsor's Inventions.|t
17189688|NCT00941031|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17189689|NCT00097253|f||||f
17189690|NCT03124108|f||OTHER|The Sponsor retains exclusive ownership of all data, results, reports, findings, discoveries, and any other information collected during this study; these may not be published, given, or disclosed, either in part or in whole, by the Investigator or by any person under his/her authority to any third party without the prior express consent of the Sponsor.|t
17189691|NCT00631917|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189692|NCT01219855|f||LTE60||t
17189693|NCT05650333|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189694|NCT03058783|f||OTHER|Contact sponsor for details.|t
17189695|NCT02403323|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189696|NCT03885596|f||||f
17144921|NCT01579474|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17144922|NCT00130520|f||||f
17144923|NCT01568008|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17144924|NCT02688400|f||OTHER|"All documents, data, know-how, formulae, and unused drugs provided to the Study Site or Investigator for purposes of the Study are and will remain the sponsor's (or its agent) property.~The sponsor (or its agent) will have the right to use the results of the Study in any manner deemed appropriate to the sponsor's business interests.~The sponsor will store information regarding the Study Site and Investigator in a database system, to be used for internal sponsor assessment purposes only."|t
17144925|NCT03467477|f||LTE60||t
17144926|NCT02295774|f||OTHER|PI must send a manuscript to Sponsor prior to its submission for publication. Sponsor will have 60 days after receipt of the manuscript in which to suggest changes. PI will accept to incorporate the publication comments that do not conflict with the reliability of data, with the rights, the safety and welfare of patients. PI retains the right to publish the result of trial in accordance with current legislation with the consent of the Sponsor subject to the rights of intellectual property.|t
17144927|NCT01075763|f||OTHER||t
17144928|NCT00586521|f||LTE60||t
17144929|NCT00747552|f||||f
17144930|NCT00810732|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144931|NCT02261428|t||||
17144932|NCT03083483|t||||
17144933|NCT03493126|t||||
17144934|NCT03731182|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17144935|NCT02006706|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144936|NCT00582036|f||||f
17144937|NCT01673009|t||||
17144938|NCT03617692|f||||f
17144939|NCT04161144|t||||
17144940|NCT00958256|t||||
17144941|NCT04535609|f||OTHER|Material for public dissemination will be submitted to the Sponsor for review at least 60 days prior to submission for publication, public dissemination, or review by a publication committee. During this period, the Sponsor shall be entitled to make a reasoned request that publication be delayed for a period of up to 6 months from the date of first submission to the Sponsor in order to enable the protection of proprietary information and/or Intellectual Property Rights.|t
17144942|NCT01176448|f||||f
17144943|NCT02456532|f||||f
17144944|NCT01000337|t||||f
17144945|NCT01612000|f||LTE60||t
17144946|NCT03256968|f||||f
17189697|NCT03852433|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17189698|NCT01076335|t||||
17189699|NCT02616263|f||||f
17189700|NCT03686384|f||OTHER|Any publication shall be expressly authorized in written by the Sponsor|t
17189701|NCT03643965|f||||t
17189702|NCT02820051|f||||f
17189703|NCT05302791|f||||f
17189704|NCT03541603|t||||f
17189705|NCT04001114|f||||f
17189706|NCT00614744|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17189707|NCT00768066|f||||f
17189708|NCT04831775|f||||f
17189709|NCT00597883|f||||f
17189710|NCT01737268|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment.|t
17189711|NCT01458275|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17189712|NCT03697460|t||||
17189713|NCT02266329|t||||f
17189714|NCT02178436|t||||
17189715|NCT00365417|f||GT60||t
17189716|NCT03499600|f||||f
17189717|NCT00445692|t||||f
17189718|NCT03425539|f||OTHER|Any study-related publication written independently by investigators must be submitted to the sponsor for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, the sponsor may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17189719|NCT01137292|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189720|NCT02014558|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17189721|NCT04580407|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189722|NCT01245413|f||GT60||t
17189723|NCT02530151|t||||
17189724|NCT05567159|f||GT60||t
17189725|NCT01374490|f||OTHER|Contact sponsor directly for details|t
17189726|NCT00672256|t||||f
17189727|NCT02072226|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189728|NCT00810303|t||||f
17189729|NCT02702921|f||LTE60||t
17189730|NCT03635112|f||||t
17189731|NCT02446223|f||||f
17189732|NCT03006341|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17189733|NCT03101592|f||||f
17189734|NCT01770860|f||GT60||t
17189735|NCT02341534|f||||f
17144947|NCT02173704|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144948|NCT00419926|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17144949|NCT03106870|f||||f
17189736|NCT01522339|t||||f
17189737|NCT00601640|t||||
17189738|NCT02347917|f||||t
17189739|NCT03419780|t||||
17189740|NCT01872611|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17189741|NCT03537651|f||OTHER||t
17189742|NCT03298113|f||||f
17189743|NCT02939183|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189744|NCT05096117|f||||f
17189745|NCT04081545|t||||
17189746|NCT00654238|f||||f
17189747|NCT01446003|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17189748|NCT00318656|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189749|NCT03905135|f||||f
17144950|NCT03291509|f||||f
17144951|NCT01617577|f||||f
17144952|NCT02374918|f||||f
17144953|NCT01180244|t||||
17144954|NCT00729859|t||||
17144955|NCT02623829|t||||
17144956|NCT00760383|t||||f
17144957|NCT00710203|t||||f
17144958|NCT03937466|t||||
17144959|NCT00622908|f||OTHER|Sponsor has 45 days to review materials and provide comments back to the investigator.|t
17144960|NCT00113490|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17144961|NCT02162758|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17144962|NCT01659567|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144963|NCT03019965|f||||f
17144964|NCT03213210|f||LTE60||t
17144965|NCT04582396|f||||f
17144966|NCT01650324|f||GT60||t
17144967|NCT00708422|f||OTHER|Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17144968|NCT01654107|f||||f
17144969|NCT00299156|t||||
17144970|NCT00638365|f||OTHER|The sponsor has right of first publication of trial results, which will be a joint, multi-center publication of the study results from all appropriate sites contributing data, analysis and comments.|t
17144971|NCT01491620|f||||f
17144972|NCT01523964|f||LTE60||t
17144973|NCT00963157|f||LTE60||t
17144974|NCT01166568|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~The Sponsor encourages publication and presentation of the safety and efficacy results upon completion of the study. Per the established agreement, the Principal Investigators will work with the Sponsor, in good faith, to ensure all confidential and proprietary information is redacted."|t
17144975|NCT01654380|f||GT60||t
17144976|NCT03335371|f||LTE60||t
17189750|NCT01740557|t||||
17189751|NCT01481935|f||||f
17189752|NCT01248221|t||||f
17189753|NCT00490555|f||||f
17189754|NCT01268566|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17144977|NCT00684671|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144978|NCT02582970|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17144979|NCT01725451|f||GT60||t
17144980|NCT00437281|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17144981|NCT01592799|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17144982|NCT01656889|f||LTE60||t
17144983|NCT00423800|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 45 days from the time submitted to the sponsor for review.|t
17144984|NCT01576588|f||||f
17144985|NCT03520283|t||||
17144986|NCT02114307|t||||
17144987|NCT03482713|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17144988|NCT02178709|t||||
17144989|NCT01241461|f||GT60||t
17144990|NCT00202449|f||||f
17144991|NCT01379781|f||||f
17144992|NCT01526538|f||||f
17144993|NCT03329027|f||OTHER|Permission to use study data is required|t
17144994|NCT04089982|t||||
17144995|NCT03889756|f||||f
17144996|NCT04849988|f||OTHER|Data are the property of the sponsor and cannot be published without prior authorization from the sponsor.|t
17144997|NCT03185065|f||||f
17144998|NCT01535326|t||||
17144999|NCT01052116|f||||f
17145000|NCT00929500|f||||f
17145001|NCT01104207|t||||
17145002|NCT02243020|f||||f
17145003|NCT00836927|f||OTHER|All unpublished information that the Sponsor gives to the Investigator shall be kept confidential and shall not be published or disclosed to a third party without the prior written consent of the Sponsor.|t
17145004|NCT04064229|t||||
17145005|NCT02518230|t||||
17145006|NCT00614055|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17145007|NCT02708290|t||||
17145008|NCT00132002|f||LTE60||t
17145009|NCT01095003|f||||f
17145010|NCT01769209|f||||f
17145011|NCT00049036|f||LTE60||t
17145012|NCT03036579|f||||f
17145013|NCT02848599|f||||f
17145014|NCT02352337|f||||f
17145015|NCT02337933|t||||
17145016|NCT00992407|f||LTE60||t
17145017|NCT00782509|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17145018|NCT02398188|f||OTHER||t
17145019|NCT04875065|f||||f
17145020|NCT02918162|f||||f
17145021|NCT00395226|t||||
17145022|NCT00282256|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or until 18 months have elapsed following study completion. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document.|t
17145023|NCT00868309|f||LTE60||t
17145024|NCT03309449|t||||
17145025|NCT01569451|t||||
17145026|NCT01513148|t||||
17145027|NCT04652453|t||||
17145028|NCT02901899|t||||
17145029|NCT00482547|f||GT60||t
17145030|NCT00936975|f||LTE60||t
17145031|NCT00619385|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights|t
17145032|NCT02255513|f||||t
17145033|NCT02041702|f||LTE60||t
17145034|NCT00203307|t||||
17145035|NCT03730103|t||||
17145036|NCT01488578|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145037|NCT02308111|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45-day review period with the option to extend it to an additional 90 days.|t
17189755|NCT02806895|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17145038|NCT01965561|t||||
17145039|NCT03277183|f||||f
17145040|NCT03271528|f||||f
17145041|NCT00717756|f||||f
17145042|NCT00929357|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145043|NCT01873859|t||||
17145044|NCT03977584|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145045|NCT01042366|t||||
17145046|NCT01066052|f||||f
17145047|NCT03850509|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17145048|NCT00969332|f||||f
17145049|NCT00630565|t||||
17145050|NCT02729896|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145051|NCT01835145|f||LTE60||t
17145052|NCT00582309|f||OTHER|Sponsor may evaluate results and choose not to be a coauthor on the publication.|t
17189756|NCT00928200|f||GT60||t
17189757|NCT00601965|t||||f
17189758|NCT02735187|f||||f
17189759|NCT01348087|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17189760|NCT01007149|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189761|NCT01913340|t||||f
17189762|NCT02784704|f||OTHER|Publications should include input from the PI, his/her colleagues, other PIs in the trial and the Sponsor's personnel; such input should be reflected in the authorship. Agreement of order of authors should be established before writing a manuscript. The PI interested in participating in writing the manuscript should contact the Sponsor. The PI shall not make any publication without the Sponsor's prior written approval, which may be withheld or granted by the Sponsor, in it's sole discretion.|t
17189763|NCT00603538|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189764|NCT05010304|f||||f
17189765|NCT05750745|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189766|NCT05064761|f||||f
17189767|NCT02809911|f||OTHER|Publication Rights. Independent analysis and/or publication of data is not permitted without the prior written consent of the sponsor. Such consent may be contingent on sponsor review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17189768|NCT03109015|t||||
17145053|NCT02286518|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17145054|NCT01983020|t||||f
17145055|NCT01309919|t||||
17145056|NCT00319449|f||OTHER|"The principal investigator (PI) agrees not to publish or publicly present~any interim results of the Study without prior written consent of the SPONSOR.~The PI further agrees to provide thirty (30) days written notice to the SPONSOR prior to submission for publication or presentation to allow SPONSOR to review abstracts or manuscripts for publication."|t
17145057|NCT02102490|f||GT60||t
17145058|NCT01346410|t||||
17145059|NCT00979628|f||||f
17145060|NCT02146430|f||||f
17145061|NCT01893905|f||||f
17145062|NCT01768858|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17145063|NCT03312530|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145064|NCT01797471|t||||
17145065|NCT01693484|t||||
17145066|NCT01691859|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145067|NCT04820842|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145068|NCT00093964|f||OTHER||t
17145069|NCT01090765|f||||f
17145070|NCT02401542|f||||f
17145071|NCT02623959|t||||
17145072|NCT00761592|f||LTE60||t
17145073|NCT02336737|f||||f
17145074|NCT02396381|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17145075|NCT03197064|t||||
17145076|NCT00635778|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17145077|NCT01884025|t||||
17145078|NCT02324465|t||||
17145079|NCT02059993|f||||f
17145080|NCT02655237|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145081|NCT00928954|t||||
17145082|NCT01860976|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145083|NCT02227862|f||GT60||t
17145084|NCT02892500|t||||
17189769|NCT00783692|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189770|NCT03750656|t||||f
17189771|NCT01096056|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189772|NCT02237079|t||||
17189773|NCT02708862|f||||f
17189774|NCT03568162|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is mutually agreed upon between the PI and the Sponsor. The sponsor cannot unilaterally extend the embargo.|t
17189775|NCT01110174|t||||
17189776|NCT03717194|f||||f
17189777|NCT03788291|t||||
17189778|NCT01155999|f||OTHER|All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.|t
17189779|NCT01190176|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189780|NCT01836458|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17189781|NCT02081391|f||OTHER|The sponsor reserves the right to review any proposed presentation of the results of this trial before they are submitted for publication or public disclosure. Neither party (e.g., the sponsor, the coordinating investigator) has the right to prohibit publication or public disclosure unless it can be shown to affect possible patent rights.|t
17189782|NCT02189863|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17189783|NCT01559090|f||||f
17189784|NCT03677375|t||||
17189785|NCT02141581|f||||f
17189786|NCT00126113|t||||f
17189787|NCT03971357|t||||f
17189788|NCT02376933|t||||
17189789|NCT03860077|t||||
17189790|NCT00430677|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17189791|NCT01555762|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189792|NCT01333514|t||||
17189793|NCT00836810|f||||f
17189794|NCT00112112|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.The principal investigators (PIs) also agree for data to be presented first as a joint, multi-center publication.|t
17145085|NCT03445195|f||LTE60||t
17145086|NCT01134081|t||||
17145087|NCT02419313|f||||f
17145088|NCT00620763|t||||
17145089|NCT01141725|f||||f
17145090|NCT02907203|f||||f
17145091|NCT04956666|f||LTE60||t
17145092|NCT03172780|f||||f
17145093|NCT00783796|f||GT60||t
17145094|NCT01816477|t||||
17145095|NCT00819247|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17145096|NCT01766921|f||||f
17189795|NCT00389519|f||OTHER|Investigator agreed not to individually publish results of the study. Investigators may participate in a joint multicenter publication of the study results. Written notice must be provided to King. King has the right to review the publication and can require deletion of Confidential Information and delay of publication to allow for filing of patent applications.|t
17145097|NCT01807871|f||||f
17145098|NCT00698685|t||||
17145099|NCT02540356|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until completion of the multi-center publication or twelve months following the conclusion of the study at all sites, whichever is first. Baxalta requires a review of results communication at least 90 days prior to submission. Baxalta may request an additional delay up to 60 days (e.g. for intellectual property protection).|t
17145100|NCT00855842|f||||f
17145101|NCT02978326|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17145102|NCT04894994|f||LTE60||t
17145103|NCT02566135|f||||f
17145104|NCT02597543|f||||f
17145105|NCT01411995|f||||f
17145106|NCT01937364|t||||
17145107|NCT04104646|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17145108|NCT02974153|f||||f
17145109|NCT02277769|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17145110|NCT03580343|f||LTE60||t
17145111|NCT02099461|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145112|NCT03504852|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145113|NCT02928848|t||||f
17145114|NCT00663871|t||||f
17145115|NCT01565083|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145116|NCT01058421|f||||f
17145117|NCT02742181|t||||
17145118|NCT01050231|t||||f
17145119|NCT00455533|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145120|NCT02785172|f||OTHER|Contact sponsor directly for details.h|t
17145121|NCT02576990|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17145122|NCT02938494|f||OTHER|Contact sponsor directly for details.|t
17145123|NCT01736553|f||||f
17145124|NCT02415959|f||||f
17145125|NCT00911859|f||GT60||t
17145126|NCT01396044|t||||f
17145127|NCT01048333|f||LTE60||t
17145128|NCT01880099|f||||f
17145129|NCT00955747|f||||f
17145130|NCT00634179|t||||
17145131|NCT00539539|t||||f
17145132|NCT00767325|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145133|NCT03538756|f||OTHER|The publication of the principal results from any single center experience within the study can occur following the preparation and publication of the multicenter results. (This restriction no longer applies since the multicenter results have been published.)|t
17145134|NCT00752856|f||||f
17145135|NCT03131999|f||||f
17145136|NCT02260492|f||||f
17189796|NCT02040844|f||OTHER|To avoid disclosures that may affect the proprietary rights of the Sponsor, the Investigator agrees to allow Circassia the opportunity to review all manuscripts and abstracts 60 days prior to submission for publication. Circassia reserves the right to include the report of this study in any regulatory documentation or submission or in any informational materials.|t
17189797|NCT03663101|f||||t
17189798|NCT05579886|f||||t
17189799|NCT01560949|t||||
17189800|NCT03181724|t||||
17189801|NCT03032159|f||||t
17189802|NCT02068885|t||||
17189803|NCT00681811|f||GT60||t
17145137|NCT01323998|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145138|NCT00996736|f||||f
17145139|NCT02688608|f||||f
17189804|NCT03921528|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 45 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17145140|NCT02456909|f||||f
17145141|NCT01497938|f||||f
17145142|NCT00365352|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145143|NCT02322528|t||||
17145144|NCT04849845|f||OTHER|The PI cannot disclose any of the results arising out of or in connection with the clinical trial without the prior express written consent of the Sponsor.|t
17145145|NCT02224456|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145146|NCT01644890|f||OTHER|There is no day limit but it needs sponsor's consent in a document.|t
17145147|NCT05780541|f||||f
17145148|NCT02761980|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145149|NCT00101582|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits sponsor a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Sponsor may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, investigator agrees not to publish any results before the first multi-center publication.|t
17145150|NCT00056160|f||OTHER|The investigator shall have the right to publish and/or present the clinical data generated from the study provided that such Investigator shall furnish sponsor with a copy of the proposed publication or presentation at least 60 days in advance of submission, delete any confidential information, and delay submission for up to 90 days to permit the preparation and filing of appropriate intellectual property applications.|t
17145151|NCT01551095|t||||f
17145152|NCT03093324|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17145153|NCT04583579|f||||f
17145154|NCT00278200|t||||
17145155|NCT00976664|f||||f
17145156|NCT00135707|f||LTE60||t
17145157|NCT00100165|t||||
17145158|NCT00421174|f||||f
17145159|NCT02524379|t||||
17145160|NCT01829464|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145161|NCT02743702|t||||
17145162|NCT02207309|t||||
17145163|NCT02228382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145164|NCT02337465|t||||
17145165|NCT00356200|f||||f
17145166|NCT00812253|f||||f
17145167|NCT03679741|f||GT60||t
17145168|NCT05380635|f||||f
17145169|NCT00795665|t||||
17145170|NCT00231868|t||||
17145171|NCT02627742|f||||f
17145172|NCT02363907|f||||f
17145173|NCT01645306|f||||f
17189805|NCT01562743|f||||f
17145174|NCT02584140|t||||f
17145175|NCT02204371|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145176|NCT00906425|f||LTE60||t
17145177|NCT00368966|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17145178|NCT02866175|f||||f
17145179|NCT01694485|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189806|NCT04159506|f||||f
17189807|NCT02449044|f||||f
17145180|NCT01595009|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17145181|NCT00506909|t||||
17145182|NCT00662025|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145183|NCT03179345|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.|t
17145184|NCT02300025|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145185|NCT00626925|t||||
17145186|NCT00780026|t||||
17145187|NCT00897897|f||LTE60||t
17145188|NCT02959775|f||||f
17145189|NCT01215942|f||GT60||t
17145190|NCT01966042|f||LTE60||t
17145191|NCT03522948|f||||f
17145192|NCT03305055|t||||
17145193|NCT01802879|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145194|NCT01105650|f||||f
17145195|NCT01948505|t||||f
17145196|NCT01047345|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17145197|NCT02116803|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17145198|NCT01060592|f||||f
17189808|NCT02624778|f||OTHER|The sponsor cannot use results communications, embargo communications regarding trial results for at least 5 years from the date of disclosure.|t
17189809|NCT01565538|t||||
17189810|NCT01537133|f||||f
17189811|NCT04760444|f||||f
17189812|NCT00623506|t||||
17189813|NCT01244984|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189814|NCT01168401|f||OTHER|No publication related to study results will be made without Sponsor's prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.|t
17189815|NCT01721564|t||||
17189816|NCT01335789|t||||
17189817|NCT01702896|t||||
17189818|NCT01149681|f||GT60||t
17189819|NCT03710564|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189820|NCT02993471|f||GT60||t
17189821|NCT00930813|f||GT60||t
17189822|NCT00315120|f||||f
17189823|NCT02002819|f||||f
17189824|NCT03999554|f||OTHER|SPONSOR has exclusive right to publish and authorize study publications or communications. INVESTIGATOR makes no presentations/publications of the Study or its results without prior SPONSOR review and approval. SPONSOR will have 90 days to request amendments including but not limited to details that may be detrimental to its intellectual property interests or to the conduct, completion, or analysis of the results of the Study by SPONSOR or its affiliates.|t
17189825|NCT04582877|f||||f
17189826|NCT00003656|t||||f
17189827|NCT03055767|t||||
17189828|NCT02661997|t||||f
17189829|NCT00763282|t||||
17189830|NCT00742274|f||||f
17189831|NCT02427737|f||||f
17189832|NCT00478556|f||||f
17189833|NCT02974010|f||||f
17189834|NCT01941316|f||||f
17189835|NCT00320489|f||GT60||t
17189836|NCT03441984|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189837|NCT05457842|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17189838|NCT00100659|f||LTE60||t
17189839|NCT01675830|t||||f
17189840|NCT04088188|f||||f
17189841|NCT02606734|f||||f
17189842|NCT01670019|f||||f
17145199|NCT01974895|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145200|NCT01984242|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145201|NCT01346852|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145202|NCT04543136|f||LTE60||t
17145203|NCT00585780|f||||f
17145204|NCT00947427|f||||f
17145205|NCT00865709|f||LTE60||t
17145206|NCT00429923|f||GT60||t
17189843|NCT00580801|f||OTHER|The Investigator agrees that before he/she publishes any results of this trial he/she shall allow at least 45 days for the Sponsor to review the pre-publication manuscript prior to submission of the manuscript to the Publisher. In accordance with generally recognized principles of scientific collaboration, co-authorship with any company personnel will be discussed and mutually agreed upon before submission of the manuscript to the Publisher.|t
17189844|NCT03601507|t||||
17189845|NCT03061513|f||||f
17189846|NCT02107014|t||||
17189847|NCT03237936|f||||t
17189848|NCT00295867|f||||f
17189849|NCT01981850|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189850|NCT03168438|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189851|NCT01859195|f||||f
17189852|NCT05015478|f||||f
17189853|NCT04436029|f||GT60||t
17189854|NCT01639443|t||||
17189855|NCT01649427|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17189856|NCT02138916|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17189857|NCT00555581|f||||f
17189858|NCT05822440|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189859|NCT05365386|f||OTHER||t
17189860|NCT00117988|f||LTE60||t
17189861|NCT02387749|t||||
17189862|NCT05196737|t||||
17189863|NCT05096884|t||||
17189864|NCT04927975|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189865|NCT03781804|f||GT60||t
17189866|NCT00337818|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189867|NCT04678830|f||||f
17189868|NCT00336232|f||||f
17189869|NCT03507309|t||||
17189870|NCT06044948|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study|t
17145207|NCT00365261|f||||f
17145208|NCT01041781|t||||
17145209|NCT00662129|t||||
17145210|NCT02153736|f||||f
17189871|NCT03563053|f||||f
17189872|NCT03184428|f||||f
17189873|NCT03369951|f||LTE60||t
17145211|NCT00767507|f||OTHER|"In general, PI communications regarding trial results are prohibited until after the communication and publication of the multi-center results by Sponsor, but no more than 12 months after conclusion of the trial at all sites.~PI must submit results communications to sponsor for review at least 60 days prior to submission for publication and Sponsor may embargo such communications for a period that is less than or equal to 150 days solely to seek appropriate patent protection."|t
17145212|NCT03641742|f||||f
17145213|NCT00809809|f||||f
17145214|NCT00720122|f||||f
17145215|NCT02275364|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145216|NCT02579096|t||||
17145217|NCT03177603|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145218|NCT01361126|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145219|NCT02969499|f||||f
17145220|NCT00974142|f||||f
17145221|NCT02946385|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145222|NCT00313703|t||||f
17145223|NCT01060670|f||OTHER|Investigator shall not publicly disclose any results/information pertaining to the trial until a multi-center publication is released under sponsor's direction; however, if a multi-center publication is not released within 18 months after completion of analysis of all study data from all studies conducted within the multi center trial, Investigator may publish results at their institution as long as they have given sponsor 30 days to review.|t
17145224|NCT01581970|f||||f
17145225|NCT02767388|f||||f
17145226|NCT03519256|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145227|NCT04828161|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145228|NCT05431153|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145229|NCT04488575|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17145230|NCT02458638|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145231|NCT01908127|f||||f
17145232|NCT03495648|t||||
17145233|NCT02236338|t||||
17145234|NCT01082952|t||||
17145235|NCT03093454|f||LTE60||t
17145236|NCT04540497|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145237|NCT02850068|t||||
17145238|NCT01681030|f||GT60||t
17145239|NCT03996603|t||||
17145240|NCT03738332|t||||
17145241|NCT04700449|f||LTE60||t
17145242|NCT01521559|f||OTHER|Without the prior written agreement of the Sponsor, the Institution (I) shall not publish, submit or present for publication, directly or indirectly, any Manuscript (M) prior to publication of an article in a peer-reviewed scientific journal summarizing data generated by all Study centers, unless no such article is so published before the first anniversary of the finalization of the clinical study report, in which case the (I) may publish or submit for publication a (M) without further delay.|t
17145243|NCT00275002|f||LTE60||t
17145244|NCT02909140|f||||f
17145245|NCT02624843|f||||f
17145246|NCT00576381|t||||
17145247|NCT01747850|t||||
17145248|NCT01031537|t||||
17145249|NCT02132247|f||OTHER||t
17145250|NCT00520741|f||GT60||t
17145251|NCT02750761|f||OTHER|Sponsor intends to pursue publication of the results of the study in cooperation with a lead Investigator. Sponsor written approval is required for publication of any data subsets. Final authorship will be determined in accordance with the International Committee of Medical Journal Editors definition of authorship. Participant names and other personal data may not be disclosed in any publication without prior written authorization from Sponsor and the participant.|t
17145252|NCT03256799|t||||
17145253|NCT02354586|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145254|NCT00634907|t||||f
17145255|NCT00688064|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor for review and approval at least 2 months prior to the date of the intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17145257|NCT02224391|t||||
17145258|NCT03718455|t||||
17145259|NCT00084084|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤ 180 days from the time submitted to Shire for review. Shire does not prohibit publication but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17145260|NCT01933295|f||||f
17145261|NCT00108732|f||LTE60||t
17145262|NCT03644095|f||||f
17145263|NCT03922477|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145264|NCT00440596|f||||f
17145265|NCT01004770|f||||f
17145266|NCT03845933|t||||f
17145267|NCT01485536|t||||
17145268|NCT02626949|t||||
17145269|NCT03072459|f||||f
17145270|NCT04094870|t||||
17145271|NCT00669578|t||||
17145272|NCT03384745|f||LTE60||t
17145273|NCT01924390|f||||f
17145274|NCT02984683|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17145275|NCT02739984|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17189874|NCT02926937|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17145276|NCT03008460|f||OTHER|The sponsor requires that reasonable opportunity be given to review the content and conclusions of any abstract, presentation, or paper before the material is submitted for publication or communicated. The sponsor will comment on the draft documents within the time period agreed in the contractual arrangements. Requested amendments will be incorporated by the author, provided they do not alter the scientific value of the material.|t
17145277|NCT04555525|f||||f
17145278|NCT04947579|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145279|NCT01575054|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145280|NCT01566409|f||LTE60||t
17189875|NCT00561574|f||LTE60||t
17189876|NCT01796977|f||LTE60||t
17189877|NCT02147990|f||OTHER|All parties agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission. This will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties. The sponsor may request a delay in publication if there are important intellectual property concerns relating to publication, but does not have the right to suppress publication of the study results indefinitely.|t
17189878|NCT00630864|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189879|NCT00124982|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17189880|NCT04155424|f||||t
17189881|NCT03015740|t||||
17189882|NCT05927480|t||||
17189883|NCT01489176|f||||f
17189884|NCT05541497|t||||
17145281|NCT00764309|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17145282|NCT01179490|f||||f
17189885|NCT03618095|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17189886|NCT01171924|f||||f
17145283|NCT00097695|f||LTE60||t
17145284|NCT05200858|f||||f
17145285|NCT03363581|t||||
17145286|NCT02929979|t||||
17145287|NCT01691508|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145288|NCT02322047|f||||f
17145289|NCT02207231|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17189887|NCT00587288|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17189888|NCT00797862|f||OTHER|The terms and conditions of Novartis' agreements with it's investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of pooled data (i.e., data from all sites) in the clinical trial.|t
17145290|NCT02258256|f||||f
17145291|NCT04637997|t||||
17189889|NCT00531479|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145292|NCT01290263|f||||f
17145293|NCT01315145|f||||f
17145294|NCT03392974|f||||t
17145295|NCT02675543|f||||f
17145296|NCT02016300|t||||
17145297|NCT02309099|t||||
17145298|NCT06165744|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17145299|NCT05456529|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17145300|NCT01631864|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17145301|NCT00583700|t||||
17145302|NCT03238677|f||||f
17145303|NCT00724568|t||||
17145304|NCT02841774|t||||
17145305|NCT02433665|f||||f
17145306|NCT00757601|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17145307|NCT00527423|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. There IS agreement between the Principal Investigator and the Sponsor that restricts the PI's rights to discuss or publish study results until Sponsor can review and comment. Sponsor can also remove confidential or proprietary information.|t
17145308|NCT03104322|f||||f
17145309|NCT01957488|t||||
17145310|NCT01439165|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17145311|NCT00623103|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145312|NCT00376948|t||||f
17145313|NCT00001849|f||||f
17145314|NCT00442936|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17145315|NCT01449266|f||OTHER|"No unpublished data given to the investigator may be transmitted to a third party without approval by the sponsor. The data are the exclusive property of Guerbet.~The investigator undertakes to submit to Guerbet any articles or papers related to this study within 30 days of their submission to journals or congresses.~All publications must have the joint agreement of the investigator and the sponsor.~The investigator remains independent with no relationship of subordination with Guerbet."|t
17189890|NCT01743729|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17189891|NCT05642000|f||||f
17189892|NCT00887640|t||||
17189893|NCT02909439|f||||f
17189894|NCT03127358|f||||f
17145316|NCT02433678|t||||
17145317|NCT01024738|f||GT60||t
17145318|NCT01506947|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17145319|NCT01700621|f||||f
17145320|NCT02166697|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17145321|NCT00939653|f||GT60||t
17145322|NCT03622658|f||||t
17145323|NCT02720510|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145324|NCT02869646|t||||
17145325|NCT02585700|f||||f
17145326|NCT03104205|t||||
17145327|NCT01618266|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145328|NCT02985151|f||||f
17145329|NCT02226796|f||||f
17145330|NCT00625807|t||||
17145331|NCT02187042|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145332|NCT00670956|t||||
17189895|NCT00409708|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145333|NCT00536575|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17145334|NCT02532010|f||||f
17145335|NCT00788957|f||||t
17145336|NCT03387098|f||||t
17145337|NCT03276975|t||||f
17145338|NCT00918567|f||||f
17145339|NCT03587207|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17145340|NCT02568384|f||GT60||t
17145341|NCT01055223|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145342|NCT00966953|f||GT60||t
17145343|NCT03283709|t||||
17145344|NCT00796510|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145345|NCT02799602|f||OTHER|Bayer may recommend any changes to the Publication as deemed necessary for scientific purposes. If the Publication could hinder the ability to obtain patent protection for any Invention, Bayer may request a delay of the Publication for a reasonable period to be able to file the patent application, but not to exceed 6 months from the date publication is received for review. Bayer may request further delay in case the patent application has been filed and the priority application is incomplete.|t
17145346|NCT01734772|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17145347|NCT00329602|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145348|NCT01600495|t||||f
17145349|NCT02097121|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17189896|NCT00785772|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189897|NCT04622527|t||||
17189898|NCT02485964|t||||
17189899|NCT01474538|f||GT60||t
17189900|NCT01456780|t||||
17189901|NCT03835546|t||||
17145350|NCT03066999|f||||f
17145351|NCT00661999|t||||
17145352|NCT00510510|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145353|NCT03595657|f||OTHER|If the sponsor has not published trial results within 18 months since trial completion, the PI is allowed to publish data collected at the corresponding site. The PI should provide draft publication to the sponsor to review prior to distribution to any external parties; the sponsor should provide review comments to the PI within 60 calendar days since receipt of draft publication; the sponsor also has rights to postpone publication for up to 6 months based on reasonable grounds.|t
17145354|NCT04107493|f||||f
17145355|NCT02739542|f||||f
17145356|NCT02042911|f||||f
17189902|NCT02501629|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17189903|NCT01501929|f||||f
17189904|NCT02004613|t||||
17145357|NCT03481309|t||||f
17145358|NCT03495869|t||||
17145359|NCT02346201|f||||f
17145360|NCT03708211|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17145361|NCT01508936|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17145362|NCT00462982|t||||
17145363|NCT00679367|t||||
17145364|NCT02109133|t||||f
17145365|NCT00409578|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145366|NCT00922779|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145367|NCT02448771|t||||
17145368|NCT00770315|f||OTHER|The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17145369|NCT02683187|f||||f
17145370|NCT02585258|f||||f
17145371|NCT04908748|f||||f
17145372|NCT03702621|t||||
17145373|NCT00650936|f||||f
17145374|NCT03194464|t||||
17145375|NCT03103100|f||||f
17145376|NCT02606500|f||||f
17145377|NCT00436007|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145378|NCT00810368|f||||f
17189905|NCT00868231|f||OTHER|All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.|t
17189906|NCT02359838|f||||f
17145379|NCT03331042|f||||f
17145380|NCT00825227|f||GT60||t
17189907|NCT00349908|f||LTE60||t
17189908|NCT04565249|f||OTHER|Per protocol, the data generated in this clinical study are the exclusive property of the Sponsor and are confidential. Any publication of the results of this study must be authorized by the Sponsor.|t
17189909|NCT03120676|t||||
17189910|NCT00926393|f||OTHER|The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca|t
17189911|NCT02333630|t||||
17189912|NCT05349864|t||||
17189913|NCT00984282|f||OTHER|The investigator must discuss any publication with the sponsor prior to release and obtain written consent of the sponsor on the intended publication. He/she must send a draft manuscript of the publication 30 days in advance of submission in order to obtain approval prior to submission of the final version for publication. In case of a difference of opinion, the contents will be discussed in order to find a solution which satisfies both parties.|t
17189914|NCT02223793|f||||f
17189915|NCT00106431|f||OTHER|Sponsor can review results at least 60 days prior to the date of submission for publication or public disclosure; sponsor will complete review within review period and will have authority to require institution/PI to delete confidential information other than the results.|t
17145381|NCT03272139|t||||
17145382|NCT00720096|t||||f
17145383|NCT00524459|t||||
17145384|NCT02428699|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145385|NCT03209882|t||||
17145386|NCT01574248|f||||f
17145387|NCT02922868|t||||
17145388|NCT01781286|f||||f
17189916|NCT02359435|t||||
17189917|NCT00315055|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17189918|NCT01549314|t||||
17189919|NCT00496379|f||||f
17189920|NCT01289119|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17189921|NCT01704846|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17189922|NCT00530335|f||GT60||t
17145389|NCT00995410|f||OTHER|Restriction Description: PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.|t
17145390|NCT03594123|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17145391|NCT02483975|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145392|NCT03365375|f||||f
17145393|NCT03992196|f||GT60||t
17145394|NCT02684578|f||||f
17145395|NCT01505530|f||GT60||t
17189923|NCT02321540|t||||
17189924|NCT01649791|t||||
17189925|NCT04577183|f||||f
17189926|NCT03079375|t||||
17189927|NCT02321748|f||||f
17189928|NCT01268891|f||OTHER|"The results of this study will be published at the discretion of H. Lundbeck A/S. H. Lundbeck A/S will ensure that the authorship of all publications based on this study is in accordance with the criteria defined by the International Committee of Medical Journal Editors (ICMJE).~The primary publication must be published before any secondary publications."|t
17189929|NCT00991276|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17189930|NCT03615001|f||LTE60||t
17189931|NCT01720043|f||||f
17189932|NCT01688973|f||LTE60||t
17145396|NCT03879239|f||OTHER|Permission to use study data is required|t
17145397|NCT02492958|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145398|NCT01193608|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145399|NCT00266409|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17145400|NCT00712010|t||||f
17145401|NCT00635154|t||||
17145402|NCT01399736|f||||f
17145403|NCT03500484|f||||f
17145404|NCT02795104|f||||f
17145405|NCT02026453|t||||f
17145406|NCT01089647|f||||f
17145407|NCT00995553|f||||f
17145408|NCT00927810|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145409|NCT02334059|f||||f
17145410|NCT00006156|t||||f
17145411|NCT00198029|f||||f
17145412|NCT00546390|f||||f
17189933|NCT02022462|f||||f
17189934|NCT03557385|f||||f
17189935|NCT01516892|f||OTHER|A disclosure restriction on the PI is that results publication or presentations be submitted for sponsor review no less than 90 days in advance, during which the sponsor can embargo such communications prior to public release. The embargo may be extended for up to 90 days for the sponsor to preserve its proprietary rights. PI will not publish study results prior to release of a multicenter manuscript including data from all study centers. The sponsor cannot require changes to the communication.|t
17145413|NCT01626079|f||||f
17145414|NCT01709032|t||||
17145415|NCT01457053|t||||
17145416|NCT00814463|t||||
17145417|NCT03982433|f||||f
17145418|NCT00368277|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145419|NCT00984295|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145420|NCT04799158|f||||t
17145421|NCT03978403|f||LTE60||t
17145422|NCT00143819|f||||f
17145423|NCT01790568|t||||
17145424|NCT02994056|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17145425|NCT02199509|t||||
17145426|NCT03309956|t||||
17145427|NCT02768298|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145428|NCT01693783|f||LTE60||t
17145429|NCT00905125|f||LTE60||t
17145430|NCT04603937|f||||t
17145431|NCT02518685|f||||f
17145432|NCT01922349|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17189936|NCT02786771|f||||f
17189937|NCT02796092|t||||f
17145433|NCT01611090|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17145434|NCT01919190|f||||f
17145435|NCT00655642|t||||
17145436|NCT01545076|f||OTHER|CSL agreements may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145437|NCT02518113|f||GT60||t
17145438|NCT00797108|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145439|NCT02270736|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17145440|NCT02134756|f||||f
17145441|NCT04471207|f||||f
17145442|NCT00561730|f||||f
17145443|NCT00376220|f||||f
17145444|NCT04347291|f||||f
17145445|NCT00067236|f||OTHER|Data, calculations, interpretations, opinions, and recommendations will be the property of P\&GP. Manuscripts for publication will be drafted by the Expert Panel which will select appropriate journals in which to publish. P\&GP, through its Expert Panel representation, will provide technical/editorial/review assistance. Other manuscript(s) will supported as appropriate. These materials must be submitted to P\&GP and the Expert Panel for review prior to publication|t
17189938|NCT02534896|f||OTHER||t
17189939|NCT01107626|f||LTE60||t
17189940|NCT00711646|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17189941|NCT04381494|f||||t
17189942|NCT04310579|f||||f
17189943|NCT02365298|f||GT60||t
17189944|NCT01078233|f||||f
17189945|NCT02718118|f||||f
17189946|NCT04555044|f||OTHER|The Sponsor reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17189947|NCT03722446|t||||f
17189948|NCT01779375|f||||f
17189949|NCT00819910|f||LTE60||t
17189950|NCT03102242|f||||f
17189951|NCT02639429|t||||
17189952|NCT00946192|f||||f
17145446|NCT00531206|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17189953|NCT01080131|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17189954|NCT03646669|f||||f
17189955|NCT04371536|f||||f
17189956|NCT03441360|f||||f
17189957|NCT00269399|f||OTHER|Please contact sponsor for details.|t
17189958|NCT01760291|f||||f
17189959|NCT03467724|f||||f
17189960|NCT01325870|f||LTE60||t
17189961|NCT02049866|f||||f
17189962|NCT04208243|t||||
17189963|NCT02955069|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17189964|NCT03700658|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17189965|NCT04148937|f||GT60||t
17189966|NCT02488317|f||||f
17189967|NCT02467491|f||||f
17189968|NCT00913913|t||||
17189969|NCT03107611|f||OTHER|The publication rights for the data generated rests with the sponsor. The site retains the right to use such data or results for its own publication only upon getting the written approval from the sponsor, only after the first publication of such data by the sponsor.|t
17189970|NCT02145182|f||||f
17189971|NCT00016913|t||||f
17189972|NCT00588666|t||||
17189973|NCT02274493|t||||
17189974|NCT03102710|f||||f
17189975|NCT02759731|f||||f
17189976|NCT01101165|f||GT60||t
17189977|NCT00335556|f||OTHER|Must obtain prior Sponsor approval.|t
17189978|NCT01878890|t||||
17189979|NCT04054661|f||||f
17189980|NCT03404843|t||||
17189981|NCT00567164|f||OTHER|Publication of subgroup data and single center data shall not be performed until the complete study has been published. All relevant aspects regarding publication will be part of the contract between the sponsor and the investigator/institution.|t
17189982|NCT04469218|f||||f
17145447|NCT00920140|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145448|NCT01124149|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17145449|NCT01644500|f||GT60||t
17145450|NCT02773836|t||||f
17145451|NCT02153398|f||OTHER|All PIs were prohibited to disclose all information related to this study without AstraZeneca approval before this study was completed.|t
17145452|NCT00721409|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145453|NCT02402166|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17145454|NCT02774798|t||||
17145455|NCT00322491|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17189983|NCT02266810|f||LTE60||t
17189984|NCT00502593|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189985|NCT01664104|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17189986|NCT03761784|f||OTHER|Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.|t
17189987|NCT00586339|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189988|NCT03582956|f||||f
17189989|NCT00197236|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17189990|NCT00746330|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17189991|NCT02524288|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17189992|NCT00517933|f||||f
17189993|NCT03360422|f||||f
17189994|NCT01835899|f||OTHER||t
17189995|NCT04807517|f||||f
17189996|NCT04210024|t||||
17189997|NCT00121199|f||LTE60||t
17189998|NCT05191797|t||||
17189999|NCT01018511|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 3 months prior to publication for review and comment. Sponsor may delay the publication to seek patent protection.|t
17190000|NCT00658411|t||||
17190001|NCT04305912|f||||f
17190002|NCT04550039|t||||
17190003|NCT04888585|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17190004|NCT01912495|t||||
17190005|NCT02908464|f||||f
17190006|NCT01772719|t||||
17190007|NCT01311713|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17190008|NCT01391013|f||GT60||t
17190009|NCT00731211|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17190010|NCT00299702|f||LTE60||t
17190011|NCT00751036|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17190012|NCT05460663|f||||f
17190013|NCT05273801|t||||f
17190014|NCT03820986|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17190015|NCT01729819|f||OTHER|The only disclosure restriction on the PI is that the Sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the Sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow the Sponsor to seek patent protection of the invention.|t
17190016|NCT02912195|f||||f
17190017|NCT02753413|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190018|NCT04464421|f||||f
17190019|NCT02749045|f||||f
17190020|NCT01020838|f||LTE60||t
17190021|NCT01167426|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data|t
17190022|NCT01524536|t||||
17190023|NCT01908634|f||||f
17190024|NCT04176458|f||||f
17190025|NCT01570751|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17190026|NCT05790408|f||||f
17190027|NCT03768856|t||||
17190028|NCT03533036|f||||f
17190029|NCT00558363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190030|NCT04012853|t||||
17190031|NCT04969822|f||||f
17190032|NCT00015457|t||||
17190033|NCT02317705|f||||f
17190034|NCT02219490|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17190035|NCT01599325|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally sixty (60) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17190036|NCT03879642|f||||f
17190037|NCT02430532|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17190038|NCT04490148|t||||
17190039|NCT01879371|t||||
17190040|NCT02121418|f||||f
17190041|NCT00683410|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190042|NCT03068611|t||||
17190043|NCT01103973|f||||f
17190044|NCT04109118|t||||
17190045|NCT01830842|f||||f
17190046|NCT03235349|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17190047|NCT04432974|t||||f
17190048|NCT02443792|f||||f
17190049|NCT01560143|f||||f
17190050|NCT04523181|f||||f
17190051|NCT04391309|f||||f
17190052|NCT01155869|t||||f
17190053|NCT01843465|t||||
17190054|NCT03396913|f||||f
17190055|NCT05824351|t||||
17190056|NCT00828945|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190057|NCT01113515|f||OTHER|The sponsor has prepared an integrated clinical/statistical report. As this was a multicenter study, any publication/presentation of data was to include the entire study population. Publication/presentation of data from individual study centers is not allowed without explicit permission from the sponsor.|t
17190058|NCT02482233|t||||
17190059|NCT03822351|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17190060|NCT00462943|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17190061|NCT02929069|t||||
17190062|NCT04164563|f||||f
17190063|NCT00813488|f||OTHER|All unpublished information given to an investigator by Cephalon shall not be published or disclosed to a third party without the prior written consent of Cephalon.|t
17190064|NCT04985383|f||OTHER|The Clinical Trial Agreement contains language that restricts the PI from discussing or publishing Sponsor confidential and/or proprietary information. The embargo period may be extended by mutual agreement of the Sponsor and PI.|t
17190065|NCT01729871|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17190066|NCT01143077|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17190067|NCT00635817|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17190068|NCT00871429|f||||f
17190069|NCT05526911|f||||t
17190070|NCT05025449|t||||
17190071|NCT00613301|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190072|NCT00569946|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190073|NCT04669249|f||||f
17190074|NCT01144949|f||LTE60||t
17190075|NCT00470626|f||GT60||t
17190076|NCT02891629|f||||f
17190077|NCT04866407|f||||f
17190078|NCT01801930|f||||f
17190079|NCT03669354|f||||f
17190080|NCT00908947|f||OTHER|Prior to PI publication of site results, sponsor requires publication of multi-centers results.|t
17190081|NCT03396835|t||||
17145456|NCT03239522|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145457|NCT01400425|f||LTE60||t
17145458|NCT01424722|f||GT60||t
17190082|NCT02052648|f||GT60||t
17190083|NCT03721016|f||OTHER|General research agreement between the sponsor and PI's that includes a confidentiality section that includes a statement that the sponsor is and shall remain the exclusive owner of 'Information'. ) 'Information' shall include, but shall not be limited to, protocols, trade secrets, know-how, formulations, inventions, techniques, equipment, data and results.|t
17190084|NCT02232178|f||OTHER|results of the multicenter study had to be published prior to the publication of any site specific data.|t
17190085|NCT00817635|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17190086|NCT01720446|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17190087|NCT02175212|f||||f
17190088|NCT01072357|t||||
17190089|NCT01876511|t||||
17190090|NCT00618540|t||||
17145459|NCT00818883|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145460|NCT00048048|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190091|NCT00606580|f||||f
17145461|NCT01556009|t||||
17190092|NCT04974489|f||||f
17190093|NCT01250002|f||||f
17190094|NCT02430181|f||||f
17190095|NCT02280655|t||||
17190096|NCT03256344|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190097|NCT01859312|t||||
17190098|NCT01506362|f||||f
17190099|NCT00843193|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190100|NCT00544440|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190101|NCT03586167|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190102|NCT00591838|t||||
17190103|NCT02512042|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17190104|NCT04163458|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17190105|NCT01559506|f||||f
17190106|NCT01129778|t||||
17190107|NCT01467700|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17190108|NCT01253226|f||GT60||t
17190109|NCT00988637|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17190110|NCT03098966|f||||f
17190111|NCT03593070|f||||f
17190112|NCT01582945|f||||f
17190113|NCT03310983|f||||f
17190114|NCT05887323|f||OTHER|Investigators are permitted to publish study-related results according to the local study contract and protocol. Draft publications or presentations must be provided to the Sponsor prior to any submission to determine if any confidential information is disclosed. Upon Sponsor request, the public disclosure may be delayed to enable the Sponsor to secure proprietary protection. The Sponsor shall not exercise editorial control over the proposed publication other than to correct technical accuracy.|t
17190115|NCT01656304|t||||f
17190116|NCT02908620|f||||f
17190117|NCT04548622|t||||
17190118|NCT00967369|t||||
17145462|NCT00973700|f||||f
17145463|NCT01901055|f||||f
17145464|NCT02983448|f||||f
17145465|NCT01586741|t||||
17145466|NCT00525590|f||||t
17145467|NCT00948675|f||GT60||t
17145468|NCT02296775|f||||t
17145469|NCT00600925|f||||f
17190119|NCT00881335|f||LTE60||t
17190120|NCT00477412|t||||
17190121|NCT01838200|f||LTE60||t
17190122|NCT02165605|t||||
17190123|NCT00762463|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190124|NCT01306331|f||||t
17145470|NCT00770510|f||||f
17145471|NCT00571428|f||OTHER|In addition to the 60 to 180 day restriction above, since this is a multicenter study, first publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish|t
17145472|NCT04087395|f||GT60||t
17190125|NCT03766438|f||||f
17190126|NCT00172185|f||LTE60||t
17190127|NCT04048135|f||||t
17190128|NCT01677936|f||||f
17190129|NCT04358549|f||OTHER|No publication until earlier of: Sponsor publishes multisite results, Sponsor notice that multisite publication no longer planned, and 18 months after Study close. Submission to Sponsor of proposed publication for 30-45 days prior to submission for publication. Good faith consideration by Site of Sponsor's comments; deletion of any of Sponsor's confidential information. Sponsor may require up to additional 60-day delay to file patent applications for patentable subject matter in the publication.|t
17190130|NCT03895034|f||||t
17190131|NCT01118377|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190132|NCT02085356|f||||f
17190133|NCT01510912|f||||f
17190134|NCT00157014|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.|t
17190135|NCT03181958|t||||
17190136|NCT01257503|f||GT60||t
17190137|NCT04867902|f||||f
17190138|NCT05355116|t||||f
17190139|NCT02380742|t||||
17190140|NCT00151996|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190141|NCT03439124|f||GT60||t
17190142|NCT02236559|f||||f
17190143|NCT01117480|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17190144|NCT00943605|f||LTE60||t
17190145|NCT03686813|t||||
17190146|NCT02131324|f||LTE60||t
17190147|NCT00891618|t||||f
17190148|NCT01693614|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190149|NCT01048788|f||||f
17190150|NCT02156687|t||||
17190151|NCT00420316|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190152|NCT01196988|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190153|NCT05419557|f||||f
17190154|NCT00601848|t||||
17190155|NCT00868192|t||||
17190156|NCT04304534|f||OTHER|Contracts Partners shall ensure that all patentable Results made by employees of Center or other parties involved by Contract Partners in connection with the performance of the Study, will be notified to Bayer without delay.|t
17190157|NCT00464672|f||LTE60||t
17190158|NCT00957229|t||||
17190159|NCT00578214|t||||f
17145473|NCT02192099|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145474|NCT02348385|f||||f
17145475|NCT02796664|t||||
17145476|NCT02246478|f||OTHER||t
17190160|NCT00667693|t||||
17190161|NCT02020018|t||||
17190162|NCT04044664|f||||t
17190163|NCT00001575|f||||f
17190164|NCT03736785|f||GT60||t
17190165|NCT01982643|f||||f
17190166|NCT00728845|t||||
17190167|NCT00300456|f||OTHER|Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.|t
17190168|NCT01744691|f||||f
17190169|NCT02086708|t||||
17190170|NCT01190150|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17190171|NCT00578617|t||||f
17190172|NCT04511650|f||OTHER|Product acquired from Aerpio with limited transfer of documents. Site Clinical Trial Agreements (CTAs) not provided.|t
17190173|NCT00964119|t||||
17190174|NCT03727854|f||||f
17190175|NCT01078246|f||||f
17190176|NCT01081145|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17145477|NCT00998023|t||||
17145478|NCT00711464|t||||
17145479|NCT02115646|t||||
17145480|NCT01531205|t||||
17190177|NCT02197234|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17145481|NCT02001558|f||||f
17190178|NCT01615809|f||GT60||t
17145482|NCT04128007|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. Any form of publication that is derived from this study must be submitted to Arcutis, Inc. for review and approval. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17145483|NCT04117607|f||LTE60||t
17145484|NCT01085344|f||||f
17145485|NCT02024087|f||||f
17145486|NCT00950807|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190179|NCT05826431|f||||f
17190180|NCT04771273|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17190181|NCT01543685|f||||f
17190182|NCT02163915|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17190183|NCT02013037|f||||f
17190184|NCT02465359|f||||f
17190185|NCT01304147|t||||
17190186|NCT00708097|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190187|NCT01244828|f||OTHER|Initial public presentation of the Investigator's results will occur only together with the other sites unless permission is obtained from Sponsor. Sponsor must be able to review all proposed results communications regarding study 45 days prior to submission for publication/presentation. In case of disagreement concerning appropriateness of materials, Investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues, prior to submission for publication/presentation.|t
17190188|NCT01278862|f||||f
17190189|NCT04520165|f||||f
17190190|NCT02952261|t||||f
17190191|NCT00603447|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190192|NCT05233085|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17190193|NCT00798265|f||||f
17190194|NCT02162446|f||||t
17190195|NCT00739102|f||GT60||t
17190196|NCT03784963|t||||
17190197|NCT03179787|t||||
17190198|NCT01090024|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17190199|NCT02008292|f||||f
17190200|NCT00777556|f||OTHER|Sponsor has the right before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17190201|NCT03284411|f||||f
17190202|NCT00796068|f||||f
17190203|NCT00920686|f||OTHER|Sponsor may request the Investigator or Institution not to publish or disclose information related to the clinical study.|t
17145487|NCT00337077|f||LTE60||t
17145488|NCT02129348|t||||
17145489|NCT02327195|t||||
17145490|NCT02019940|f||||f
17145491|NCT01434121|t||||
17145492|NCT01598701|t||||f
17145493|NCT02349893|f||||t
17145494|NCT02665143|t||||
17145495|NCT02430870|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17145496|NCT01265784|f||OTHER|At least 60 days prior to submitting or presenting a manuscript, poster, presentation, abstract or other materials relating to the Trial, the PI shall provide to Sponsor all such manuscripts and materials, and Sponsor shall have 60 days to review and comment. If requested, the PI shall remove Confidential lnformation prior to submitting or presenting the materials, and shall delay publication or presentation for up to 90 days to allow Sponsor to protect its interests in any such materials.|t
17145497|NCT00796822|t||||f
17190204|NCT01313182|t||||
17190205|NCT01695317|t||||
17190206|NCT04580303|f||||t
17190207|NCT01444287|f||GT60||t
17190208|NCT00434278|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190209|NCT02299635|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190210|NCT00927823|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190211|NCT00828672|f||OTHER|The Sponsor is an academic institution and not the drug market authorization holder. Participating PIs were selected from other academic institutions. Participating PIs cannot publish full or partial study results before final publication by Sponsor, but they will be nominated as co-authors based on patient accrual at each participating site. Own results can be published afterwards by participant PIs, with the agreement of the Sponsor.|t
17190212|NCT00831792|t||||
17190213|NCT05097573|f||||f
17190214|NCT00742573|t||||
17190215|NCT02701361|f||||f
17190216|NCT04588480|f||OTHER|PIs and respective trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17190217|NCT00246012|f||LTE60||t
17190218|NCT01242085|f||||f
17190219|NCT01178762|f||||f
17190220|NCT00996372|f||GT60||t
17190221|NCT02410291|t||||
17190222|NCT04181632|t||||
17190223|NCT01651949|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17190224|NCT01806714|f||||f
17190225|NCT02469064|f||||f
17190226|NCT00678795|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17190227|NCT02750709|f||||f
17190228|NCT00588965|f||||f
17190229|NCT00404079|t||||
17145498|NCT02603952|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17190230|NCT01120275|f||LTE60||t
17190231|NCT02595398|f||OTHER|The institution and investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of the Sponsor.|t
17190232|NCT00614406|f||||f
17190233|NCT00197015|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190234|NCT00880906|f||||f
17190235|NCT01320072|t||||
17190236|NCT01534910|f||||f
17190237|NCT05334758|f||||f
17190238|NCT02982213|f||||f
17190239|NCT01549652|t||||
17190240|NCT01972152|f||||f
17190241|NCT00559949|f||LTE60||t
17190242|NCT02001714|f||||f
17145499|NCT02698800|f||||f
17145500|NCT04646109|f||||f
17145501|NCT01607645|f||||f
17145502|NCT01867242|f||||f
17145503|NCT03339349|t||||
17145504|NCT02494713|t||||
17145505|NCT00615784|t||||
17145506|NCT04068142|t||||
17190243|NCT00414648|f||||f
17190244|NCT01194258|f||OTHER||t
17190245|NCT03523962|f||||f
17190246|NCT03098030|f||OTHER|Prior to submission for any public disclosure of the data or results, the Institution and Principal Investigator shall provide Sponsor with at least 60 days for review of the Publication. In addition, the Institution and Principal Investigator agree that the first Publication of the results shall be made as a joint, multicenter publication coordinated by Sponsor, with investigators and institutions from all participating sites contributing data.|t
17190247|NCT01726023|f||OTHER|The investigator agrees not to use such Confidential study information and not to disclose them to any other third parties, except that the undersigned shall not be prevented from using or disclosing information: (a) which by written records was previously known; (b) which is now public knowledge, (c) which is lawfully obtained by the undersigned from sources who have a lawful right to disclose such information.|t
17190248|NCT00816829|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.|t
17190249|NCT03394027|f||||f
17190251|NCT03643211|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190252|NCT04858425|f||||t
17190253|NCT04798521|f||||f
17190254|NCT03368001|f||||f
17145507|NCT01661270|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17145508|NCT03184441|f||||f
17145509|NCT00264810|f||OTHER|"Each Investigator and Institution agree that the 1st publication of study results shall be a joint, multi-center publication.~Each Investigator, Coordinator, and Institution agree to submit publications to the RNS® System Study Publication Committee for review prior to submission for publication (at least 30 days for manuscripts and at least 7 days for abstracts) to assure that publication does not compromise the scientific integrity of the study or contain confidential NeuroPace information."|t
17145510|NCT00182091|t||||
17145511|NCT00981305|f||||f
17145512|NCT01264952|t||||f
17145513|NCT02093689|f||OTHER|The data resulting from the Study was to be made public by the sponsor at the end of the study after all results were available and analyzed, with a report on the study to have been prepared in consultation with the PI, rather than being published by the PI.|t
17145514|NCT04634409|f||GT60||t
17145515|NCT01402908|f||||f
17145516|NCT01739790|f||||f
17145517|NCT02581345|f||||f
17145518|NCT02122796|t||||
17145519|NCT02445456|t||||
17145520|NCT00590395|f||||f
17145521|NCT01244126|f||||f
17145522|NCT01451762|f||||f
17145523|NCT02696070|f||OTHER|Publication Rights. Independent analysis and/or publication of data generated or arising from the performance of this Agreement is not permitted without the prior written consent of Regenesis. Such consent may be contingent on Regenesis' review and approval of any proposed analysis and manuscript. Institution will retain the right to review and analyze the database created from this study for its own scientific purposes so long as such scientific purposes are non-commercial in nature.|t
17145524|NCT01771965|f||||f
17145525|NCT00863746|f||OTHER|The investigator must discuss and obtain written consent of the sponsor on the intended publication. The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of the submission in order to obtain approval.|t
17145526|NCT01544361|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17145527|NCT00862979|f||||f
17145528|NCT00248638|t||||f
17145529|NCT01367275|t||||
17145530|NCT01059500|f||||f
17145531|NCT00502775|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145532|NCT03012477|t||||
17145533|NCT00287118|f||OTHER||t
17145534|NCT00262600|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17145535|NCT01385033|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17145536|NCT02906709|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17145537|NCT05227820|f||||f
17145538|NCT05518487|f||||f
17145539|NCT03831451|f||||f
17145540|NCT01931033|f||||f
17145541|NCT02752776|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17145542|NCT01946165|t||||
17145543|NCT01179919|f||||f
17145544|NCT00806156|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17145545|NCT02106065|t||||f
17145546|NCT00337571|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145547|NCT01767064|t||||
17145548|NCT02674334|f||||f
17145549|NCT03552757|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17145550|NCT00449150|f||LTE60||t
17145551|NCT03312257|f||||f
17145552|NCT04558554|f||||f
17145553|NCT02660242|f||||f
17145554|NCT03977051|t||||
17190255|NCT00782639|f||OTHER|The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.|t
17190256|NCT01624168|f||||f
17145555|NCT01345019|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145556|NCT00235456|f||||f
17145557|NCT03830164|t||||
17145558|NCT00386009|f||GT60||t
17145559|NCT04026126|f||||f
17145560|NCT01492400|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145561|NCT00604500|f||OTHER|The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement.|t
17145562|NCT02597998|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145563|NCT00320112|t||||f
17145564|NCT02899338|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145565|NCT02353169|f||||f
17145566|NCT00906347|t||||f
17145567|NCT02933866|f||||t
17145568|NCT00577460|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17145569|NCT04591626|f||GT60||t
17145570|NCT02672553|f||OTHER|PI can't publish/present on overall study results not yet published but may publish his own data subject to EW review prior to submission/presentation, but data analyses of site-specific results can occur only in intervals as specified in the CTA. Publication/presentation of the PI's site-specific results of devices which haven't been market released and which still may be undergoing development, shall not include claims of device safety/effectiveness and will require the review/approval of EW.|t
17145571|NCT00159965|t||||f
17145572|NCT02405195|f||||f
17145573|NCT02507375|f||OTHER|"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study.~The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."|t
17145574|NCT00522457|f||OTHER|The Site may publish the results of the Study after such cooperative publication, or 1 year after Sponsor's final evaluation of all the Study data from all sites, whichever occurs first. Prior to any submission for publication, presentation, or communication of results or information arising from the Study, Investigator shall provide Fresenius Biotech at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17145575|NCT01691248|f||OTHER|Any publication or other public presentation of results from this study requires prior review and written approval of the Sponsor. Draft abstracts, manuscripts, and materials for presentation at scientific meetings should be provided to the Sponsor at least 90 working days prior to abstract or other relevant submission deadlines.|t
17145576|NCT02863575|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17145577|NCT00993616|f||LTE60||t
17145578|NCT03457909|t||||
17145579|NCT03533946|t||||
17145580|NCT03815942|t||||
17145581|NCT02785913|f||||f
17145582|NCT03717064|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145583|NCT01298570|t||||
17145584|NCT02841709|f||||f
17145585|NCT01929109|f||LTE60||t
17145586|NCT00076102|f||||f
17145587|NCT01210001|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17145588|NCT00788125|f||LTE60||t
17145589|NCT01669538|t||||f
17145590|NCT03581448|f||||f
17145591|NCT01076972|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17145592|NCT03900624|f||||f
17145593|NCT03252964|t||||
17145594|NCT00872079|t||||f
17145595|NCT00890981|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145596|NCT05346055|t||||f
17145597|NCT00977106|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145598|NCT03204526|t||||
17145599|NCT01626664|f||LTE60||t
17145600|NCT02747615|f||||f
17190257|NCT03328949|f||OTHER|After publication of the multi-center Study, or earlier with Sponsor's prior written consent, the Institution may publish the results of its subjects enrolled in the Study after first complying with this Section 9 of the contract. The Institution agrees to submit any proposed publications to Sponsor for review and comment at least forty-five (45) days in advance of submitting such proposed publications to a publisher or other third party.|t
17145601|NCT02319148|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145602|NCT00733330|f||OTHER|DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but the PI will retain final editorial control.In case of disagreement,DePuy and the PI will make every effort to meet in order to discuss and resolve any issues.|t
17145603|NCT02388763|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17145604|NCT01153984|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145605|NCT02460159|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17145606|NCT04084483|f||||t
17145607|NCT02003053|t||||
17190258|NCT00604721|f||LTE60||t
17145608|NCT01458405|f||||f
17145609|NCT02194998|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17145610|NCT01362998|t||||
17145611|NCT02497781|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145612|NCT02236130|f||||f
17145613|NCT00454636|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145614|NCT01400113|t||||
17145615|NCT01095510|f||OTHER|Clinical Trial Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.|t
17145616|NCT01025037|f||LTE60||t
17145617|NCT02356471|t||||
17145618|NCT01890915|t||||
17145619|NCT02114697|t||||
17145620|NCT00424489|t||||
17145621|NCT01632709|f||||f
17145622|NCT00982553|t||||f
17145623|NCT01189123|f||||f
17145624|NCT01076452|f||GT60||t
17145625|NCT00860405|f||OTHER|Publications are subject to a prior review of Fresenius Kabi and may only be made in a neutral and anonymous form within the respective circles of experts. Fresenius Kabi shall give its comments, if applicable, within 30 days after having received the respective manuscript. Manuscripts should be submitted for publication within 2 years following the final report.|t
17190259|NCT04776213|f||||f
17190260|NCT02317016|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17190261|NCT00536380|f||OTHER|PI agrees not to publish or publicly present any interim results of Study without prior written consent of sponsor. PI further agrees to provide 45 days written notice to sponsor prior to submission for publication or presentation to permit sponsor to review copies of abstracts or manuscripts for publication (including, without limitation, slides and text of oral or other public presentations and text of any transmission through any electronic media) which report any results of Study.|t
17190262|NCT04066738|t||||
17190263|NCT03693742|t||||
17190264|NCT02931396|t||||f
17190265|NCT02132702|f||||f
17190266|NCT03981549|f||||f
17190267|NCT03059992|f||||f
17190268|NCT04341298|f||OTHER|Institution can independently publish 12 months from completion of the Study. Investigator shall submit the manuscript of any proposed publication to Sponsor at least 30 days before publication, and Sponsor shall have the right to review and comment upon the manuscript in order to protect Sponsor's Confidential Information. Upon Sponsor's request, publication shall be delayed up to 90 additional days.|t
17190269|NCT02738840|f||OTHER||t
17190270|NCT04476472|f||||f
17190271|NCT01801449|t||||t
17190272|NCT01311648|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results within 60 days. The sponsor can require changes to the communication for any patentable subject matter or termed confidential information. The PI cannot publish the results prior the first multicenter publication. If there is no multicenter publication within 18 months after the trial completion the PI has the right to publish the results from the PI site|t
17190273|NCT01645111|t||||
17190274|NCT04057196|t||||
17190275|NCT01062126|f||GT60||t
17190276|NCT03196167|f||||f
17190277|NCT03837028|t||||
17190278|NCT01091454|t||||
17190279|NCT00646451|f||||f
17190280|NCT01362491|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190281|NCT02030028|t||LTE60||t
17190282|NCT00567879|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17190283|NCT01249092|f||||f
17145626|NCT02465567|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17145627|NCT03629925|f||||f
17145628|NCT01074554|t||||f
17145629|NCT00497796|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17145630|NCT01807637|t||||
17145631|NCT04276883|f||||t
17145632|NCT01876706|f||||f
17145633|NCT02339233|f||||f
17190284|NCT00802919|f||||f
17190285|NCT00580073|t||||
17190286|NCT02930343|t||||
17190287|NCT00954707|f||GT60||t
17190288|NCT00516503|t||||f
17190289|NCT02987543|f||||f
17190290|NCT00309452|f||||f
17145634|NCT00765648|f||LTE60||t
17190291|NCT01977612|t||||
17145635|NCT05233163|t||||
17145636|NCT01370408|t||||f
17145637|NCT02120443|t||||
17145638|NCT02073643|f||||f
17190292|NCT01451814|f||||f
17190293|NCT02504619|f||||f
17190294|NCT01280591|f||||f
17190295|NCT01883492|f||||f
17190296|NCT03357341|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190297|NCT01259102|f||GT60||t
17190298|NCT02162667|f||||t
17190299|NCT01541358|t||||
17190300|NCT01956669|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190301|NCT01233050|f||||f
17190302|NCT01771666|t||||
17190303|NCT01368406|f||||f
17190304|NCT01466881|f||LTE60||t
17190305|NCT00130780|t||||
17190306|NCT01134575|t||||
17190307|NCT02047461|f||OTHER|Institution/Investigator shall have the right to publish or present the results of Institution's and Investigator's activities including that Study Data which was obtained or derived at Institution. Institution/ Investigator agree to submit any proposed publication/presentation to Sponsor for review at least 60 days prior to submitting any such proposed publication. Within 30 days of its receipt, Sponsor shall advise if any changes are needed to protect confidentiality.|t
17190308|NCT01970943|f||||f
17190309|NCT05674370|t||||
17190310|NCT01710514|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17190311|NCT02005666|f||||t
17190312|NCT02155829|f||||f
17190313|NCT01919697|f||||t
17190314|NCT01234532|f||||f
17190315|NCT00290732|t||||f
17145639|NCT02780687|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145640|NCT00979732|f||||f
17145641|NCT01062256|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145642|NCT03049488|f||||f
17145643|NCT05723822|f||||f
17145644|NCT00208026|f||||f
17145645|NCT00891293|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145646|NCT01448057|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17145647|NCT03124966|f||LTE60||t
17145648|NCT02777528|f||||f
17145649|NCT00453362|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145650|NCT04885296|f||GT60||t
17145651|NCT03718234|t||||
17145652|NCT01027143|t||||
17145653|NCT02564263|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17145654|NCT02252562|t||||
17145655|NCT02735174|t||||
17145656|NCT01087970|f||GT60||t
17145657|NCT00264797|f||||f
17145658|NCT03027661|t||||
17145659|NCT01307098|f||||t
17145660|NCT02636907|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145661|NCT00762086|f||||f
17145662|NCT00708019|f||||f
17145663|NCT01652001|f||||f
17145664|NCT02921737|f||||f
17145665|NCT03472365|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17190316|NCT02087306|f||OTHER|Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.|t
17190317|NCT00542386|f||OTHER||t
17190318|NCT04897737|f||||f
17145666|NCT03883906|t||||
17145667|NCT00486837|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the Investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17145668|NCT02724800|t||||
17145669|NCT00874237|f||LTE60||t
17145670|NCT02468778|f||OTHER|Institution may publish or present results of its performance of the Study consistent with the terms of this section. If the Study is part of a multi-center clinical study, Institution agrees that the first publication of results will be made as a joint multi-center publication with investigators from all sites contributing data.|t
17145671|NCT00147030|f||||f
17145672|NCT00262964|f||||f
17145673|NCT04559854|t||||
17190319|NCT00434018|t||||
17190320|NCT01191788|t||||
17190321|NCT02596035|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190322|NCT01235949|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190323|NCT04173572|t||||f
17145674|NCT03130699|f||||f
17145675|NCT01199861|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145676|NCT02370407|f||||f
17145677|NCT00669864|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17145678|NCT04552704|f||||t
17145679|NCT02385097|f||||f
17145680|NCT03441581|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145681|NCT00680121|t||||
17145682|NCT01822548|t||||
17145683|NCT02809183|f||||t
17145684|NCT02545998|f||||f
17145685|NCT02942966|f||OTHER|PI acknowledges that Clinical Trial is part of multi-center clinical study. Publication of multi-center data requires prior review and consent of both Sponsor and all participating sites. PI agrees that the first publication of the results of the Clinical Trial shall be made in conjunction with results from other participating sites. Provided, however, that if no multi-center publication is made within one year from database lock, then PI may publish individually.|t
17145686|NCT03118466|f||||f
17190324|NCT01839877|f||||f
17145687|NCT00696449|f||||f
17145688|NCT01430741|t||||
17145689|NCT04826809|t||||
17145690|NCT02789033|f||||f
17145691|NCT04567342|t||||
17145692|NCT00301756|f||LTE60||t
17145693|NCT02070237|f||||f
17145694|NCT00117949|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17145695|NCT01226797|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190325|NCT01224678|f||LTE60||t
17145696|NCT04538040|f||||f
17145697|NCT01606306|f||||f
17145698|NCT03676803|t||||
17145699|NCT00841100|t||||
17145700|NCT01355081|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145701|NCT00205049|t||||f
17145702|NCT02467621|f||||f
17145703|NCT04803357|f||||f
17145704|NCT01046253|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17145705|NCT02914795|t||||
17190326|NCT05457491|t||||
17190327|NCT04536077|t||||
17190328|NCT05484726|f||||f
17190329|NCT02824432|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17190330|NCT00554801|t||||
17190331|NCT04436120|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190332|NCT01199237|t||||
17190333|NCT03392532|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190334|NCT00556543|f||||f
17190335|NCT01838551|f||OTHER|All data generated from this study are the property of Cortendo Inc. (a subsidiary of Strongbridge Biopharma). Independent analyses and/or publication of data by Investigators is not permitted without prior written consent of Cortendo. Publication of results is to be conducted in accordance with Good Publication Practice as per Strongbridge publication policy.|t
17190336|NCT01981356|t||||
17190337|NCT02486588|f||||f
17190338|NCT03354390|t||||
17145706|NCT02339909|f||||f
17145707|NCT03086356|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145708|NCT04183231|t||||
17145709|NCT00860028|f||||f
17145710|NCT00483496|f||OTHER|Publications relating to the TRIAL and results therefrom are subject to prior mutual agreement of the SPONSOR and the INVESTIGATOR.|t
17145711|NCT01658943|f||LTE60||t
17145712|NCT02625545|f||||f
17145713|NCT03144687|f||OTHER|Clinical Study Agreement|t
17145714|NCT01054599|f||||f
17190339|NCT03227757|f||GT60||t
17190340|NCT02703714|t||||
17190341|NCT01875250|f||||f
17145715|NCT00475020|t||||
17145716|NCT03218592|t||||f
17145717|NCT02514174|f||OTHER|The rights of the investigator and of the sponsor with regard to publication of the results of this trial were described in a separate agreement between the investigator or the trial site and the sponsor. As a general rule, no trial results were to be published prior to finalization of the clinical trial report.|t
17145718|NCT02170688|t||||
17145719|NCT01894178|f||||f
17145720|NCT00543309|f||||f
17145721|NCT02148302|f||LTE60||t
17145722|NCT02143102|f||||f
17145723|NCT00369590|f||LTE60||t
17145724|NCT00023309|t||||f
17145725|NCT03247556|f||OTHER||t
17190342|NCT02749968|f||||f
17145726|NCT01203878|f||OTHER|Up to 30 days to review presentations and/or manuscripts. Up to an additional 60 days, if applicable, to file patent applications.|t
17190343|NCT03068468|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17190344|NCT02555449|f||GT60||t
17190345|NCT02466516|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190346|NCT03712930|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17190347|NCT02695290|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17190348|NCT04460898|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190349|NCT03720990|f||||f
17190350|NCT00486759|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190351|NCT02657629|f||||f
17190352|NCT02001623|f||OTHER|All proposed publications and presentations shall be submitted to the sponsor for its review at least 30 days before such presentation or publication is submitted to any third party.|t
17190353|NCT00686517|f||OTHER|The investigator agrees not to publish or publish or present any results of the study without the prior written permission of Schering-Plough The principal investigator further agrees to allow the Sponsor to review, 30 days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication (including texts of oral presentations) which report any results of the study.|t
17145727|NCT03952143|f||GT60||t
17145728|NCT01866319|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17145729|NCT01661114|t||||
17145730|NCT04421508|f||||f
17145731|NCT03980483|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17145732|NCT00784849|t||||
17145733|NCT04622709|t||||
17145734|NCT00760266|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145735|NCT01225146|f||||f
17145736|NCT03249584|f||OTHER|Participating Institutions may publish the results provided that any such Publication shall be after the multi-center publication is released or presented and shall be provided to Medtronic for review at least 30 days prior to submission or presentation.|t
17145737|NCT00659607|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17145738|NCT02191891|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145739|NCT01973348|t||||
17145740|NCT03356821|f||||f
17145741|NCT03912337|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145742|NCT03752528|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17145743|NCT00414765|f||OTHER|Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145744|NCT02458469|f||||f
17145745|NCT00661505|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190354|NCT02281318|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190355|NCT00812877|f||||f
17190356|NCT01064817|f||LTE60||t
17190357|NCT01213706|f||||f
17190358|NCT00610688|t||||
17190359|NCT02228408|f||||f
17190360|NCT03336450|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190361|NCT01772420|t||||
17190362|NCT03670602|f||||f
17190363|NCT01456936|f||OTHER|Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study participating sites. Investigator may not disclose previously undisclosed confidential other than study results.|t
17190364|NCT00543725|f||GT60||t
17190365|NCT00906698|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190366|NCT03557333|f||||f
17190367|NCT02846415|t||||f
17190368|NCT03383887|f||||f
17190369|NCT00657280|f||||f
17190370|NCT02322216|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190371|NCT01585038|f||||f
17190372|NCT01335932|f||||f
17190373|NCT00952718|t||||
17190374|NCT00754936|t||||
17190375|NCT01992354|f||||f
17190376|NCT02476890|f||OTHER|The contents of this protocol and any amendments and results obtained during the course of this study will be kept confidential by the Investigator(s), the Investigator's staff, and IRB. No data collected as part of this study will be utilized in any written work, including publications, without the written consent of Sponsor. These obligations shall in no way diminish such obligations as set forth in the Confidentiality Agreement between the Sponsor and the Investigator(s).|t
17190377|NCT00835380|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190378|NCT03247543|f||OTHER||t
17190379|NCT01097343|f||||f
17190380|NCT02059980|f||||f
17190381|NCT01104415|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17190382|NCT04286529|t||||
17190383|NCT02341625|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190384|NCT00917865|f||||f
17190385|NCT05325853|f||OTHER|"Language in clinical trial agreement states:~INVESTIGATIVE SITE, the Principal Investigator, and any other investigators understand and agree that the Study is a multi-center clinical study and that a multi- center publication may be prepared and published by the Sponsor. The INVESTIGATIVE SITE and its investigators will not, individually or together, present or publish any findings, data or results of the Study."|t
17190386|NCT04979988|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190387|NCT00414206|f||LTE60||t
17190388|NCT01227707|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190389|NCT03468920|t||||
17190390|NCT03028363|f||||t
17190391|NCT02357784|t||||
17190392|NCT01421654|f||LTE60||t
17190393|NCT02698241|f||||f
17190394|NCT01837641|f||LTE60||t
17190395|NCT04318444|t||||
17190396|NCT00906282|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17145746|NCT04534283|t||||
17145747|NCT03561883|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17145748|NCT01318499|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17145749|NCT01988922|t||||
17145750|NCT01641445|f||||f
17145751|NCT01974141|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145752|NCT04977336|f||OTHER||t
17145753|NCT01347710|f||LTE60||t
17145754|NCT01968382|t||||
17145755|NCT01004172|f||||f
17145756|NCT00950872|f||||f
17145757|NCT01434342|t||||
17145758|NCT00970281|f||GT60||t
17145759|NCT00408902|f||LTE60||t
17145760|NCT00113425|t||||
17145761|NCT01139164|t||||
17145762|NCT02003183|f||||f
17145763|NCT00878995|f||||f
17145764|NCT03104738|t||||
17145765|NCT01759290|f||GT60||t
17190397|NCT02540213|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190398|NCT02289560|f||||f
17190399|NCT01286402|t||||f
17190400|NCT00290706|t||||
17190401|NCT04884737|t||||
17190402|NCT00605033|f||OTHER|Investigator will publish/present results together with other study sites, unless written permission is obtained from Sponsor. Investigator provides 45 days' written notice to Sponsor prior to submission for publication/presentation so that Sponsor can review copies of abstracts/manuscripts reporting results. Sponsor has the right to review/comment on any presentation regarding proprietary information, accuracy and fair balance of the information, and compliance with FDA regulations.|t
17190403|NCT03395353|f||||t
17190404|NCT01196429|f||LTE60||t
17190405|NCT03297112|t||||
17190406|NCT01144468|f||||f
17190407|NCT02960659|t||||
17190408|NCT00821184|f||||f
17190409|NCT00538213|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190410|NCT03140176|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190411|NCT01331824|t||||
17190412|NCT00149630|t||||
17190413|NCT00427557|t||||
17190414|NCT03667547|f||OTHER|If publication activity is not directed by the Sponsor, investigators agree to provide all manuscripts or abstracts to the Sponsor before submission.|t
17190415|NCT03223883|f||||f
17145766|NCT01353495|f||||f
17145767|NCT03338972|t||||
17145768|NCT02480764|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145769|NCT03629249|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145770|NCT01853553|t||||
17145771|NCT01475474|f||OTHER||t
17145772|NCT01030965|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145773|NCT01333527|f||||f
17145774|NCT02097290|f||GT60||t
17145775|NCT05277389|f||||f
17145776|NCT06096168|f||||f
17145777|NCT01868009|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145778|NCT00743197|t||||
17145779|NCT01478620|f||OTHER|Each Party acknowledges that it shall not publish any results of the trial,without the prior written authorization of the other Party. If SPONSOR (S.) requests INVESTIGATOR (I.)to publish any results obtained from the study, I. shall prepare and accomplish such publication at the expense of S. after review by S. and subject to written approval of the S. prior to publication. I. must be mentioned as co-author in any kind of publication resulting from such a request by S. to I. to publish.|t
17145780|NCT00672854|f||||f
17190416|NCT05298111|t||||
17190417|NCT02689349|f||||f
17190418|NCT03518112|f||||f
17190419|NCT01185522|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145781|NCT02380183|f||||f
17145782|NCT02130466|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17145783|NCT04529109|f||GT60||t
17145784|NCT01411332|t||||
17145785|NCT02218164|t||||
17145786|NCT01471522|f||||f
17145787|NCT03724149|f||||f
17145788|NCT03165058|t||||
17145789|NCT00444145|t||||
17145790|NCT01374919|f||||f
17145791|NCT00090857|f||||f
17145792|NCT05097326|t||||
17145793|NCT02684344|t||||
17145794|NCT03480425|f||||f
17145795|NCT02424188|f||||f
17145796|NCT00630305|f||OTHER||t
17145797|NCT02753842|f||||f
17145798|NCT01494506|f||OTHER|Authorship/contents of any publication is determined by site and provides sponsor a publication prior to submission. Sponsor has 60 days to review and avoid editorial changes but may request site delete confidential data. If publication contains patentable matter, site agrees to delay publication for 60 days. If study is part of multicenter protocol, site agrees not to independently publish. If multicenter publication is not forthcoming in 18 months after study end, site may proceed accordingly.|t
17145799|NCT02303548|t||||
17145800|NCT05216081|f||||f
17145801|NCT02472522|t||||f
17145802|NCT03100903|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145803|NCT00433147|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17145804|NCT01882647|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review thirty days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17145805|NCT02405325|f||||f
17145806|NCT03311646|t||||
17145807|NCT01492361|f||||t
17145808|NCT03444038|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17145809|NCT01347788|f||||f
17145810|NCT03765502|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding study results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The agreement also provides that if CRU is unwilling to delay the publication or presentation, CRU will remove the information which sponsor has specified it reasonably believes would jeopardize its intellectual property interests.|t
17145811|NCT00683020|t||||
17145812|NCT00728949|f||GT60||t
17145813|NCT01346085|t||||
17145814|NCT03127137|f||||f
17145815|NCT01996033|f||LTE60||t
17145816|NCT01249664|f||OTHER||t
17145817|NCT01682083|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17145818|NCT03433430|f||||f
17145819|NCT01239121|t||||
17145820|NCT01014728|f||||f
17145821|NCT01856309|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17145822|NCT00220337|f||GT60||t
17145823|NCT01050647|f||||f
17145824|NCT00944697|f||||f
17145825|NCT01273181|f||||f
17145826|NCT03657160|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17145827|NCT00488865|f||||f
17145828|NCT02732210|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145829|NCT04638153|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145830|NCT04006171|f||||f
17145831|NCT01440283|t||||
17145832|NCT00537030|f||||f
17145833|NCT06354270|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145834|NCT01939197|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17145835|NCT00745095|t||||
17145836|NCT00958243|f||LTE60||t
17145837|NCT03571048|f||||f
17145838|NCT00162123|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145839|NCT00534703|t||||
17145840|NCT00582400|t||||f
17145841|NCT01936948|f||||f
17145842|NCT02781727|f||||f
17145843|NCT02327130|f||||f
17145844|NCT00406848|f||GT60||t
17145845|NCT00352690|t||||
17145846|NCT02589171|t||||
17190420|NCT00918957|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17190421|NCT01803646|f||OTHER|"The Investigator agrees to submit a copy of any intended communication, presentation or publication (abstract, poster, article, etc.) (all together Communication) at least 2 month in advance of the submission of proposed Communication. The Sponsor shall have 60 days, after receipt of said copies, to object to such proposed Communication. In case of such objection, the Investigator shall refrain from making such Communication for 6 months from date of receipt of such objection."|t
17190422|NCT01131494|f||||f
17190423|NCT02614560|f||GT60||t
17190424|NCT03923491|f||||f
17190425|NCT02174562|f||||f
17190426|NCT05193318|t||||
17190427|NCT00798096|f||OTHER|An Investigator agrees to provide a copy of the publication to AstraZeneca for review at least 30 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AstraZeneca authorized MC publication or a period up to 18 months from study completi|t
17190428|NCT01833065|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17190429|NCT00241644|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190430|NCT03095508|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However Novartis does not prohibit any inversdtigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190431|NCT01027286|t||||
17190432|NCT03201809|t||||
17190433|NCT00545844|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190434|NCT00975806|f||OTHER|Multicenter publications must include input from investigators and Celgene, and agreement be established before publication. Results from a center cannot be submitted for publication prior to a multicenter publication unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene ≤ 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ≤ 90 days.|t
17190435|NCT02377362|f||||t
17190436|NCT00094809|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190437|NCT04889664|t||||
17190438|NCT03608670|f||||f
17190439|NCT02699970|f||LTE60||t
17190440|NCT03636451|f||||f
17190441|NCT04107805|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17190442|NCT00422201|f||LTE60||t
17190443|NCT03408860|f||||f
17190444|NCT01596751|f||||f
17190445|NCT01191086|f||||f
17145847|NCT00448175|f||||f
17145848|NCT02719522|f||||f
17145849|NCT02134522|f||||f
17145850|NCT03883607|f||OTHER|The Sponsor retains exclusive ownership of all data, results, reports, findings, discoveries, and any other information collected during this study; these may not be published, given, or disclosed, either in part or in whole, by the Investigator or by any person under his/her authority to any third party without the prior express consent of the Sponsor.|t
17145851|NCT04025879|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145852|NCT02888171|f||||f
17145853|NCT02419690|f||||f
17145854|NCT02051309|f||||f
17145855|NCT03805438|t||||
17145856|NCT00366899|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17145857|NCT01619800|t||||
17145858|NCT02352298|f||LTE60||t
17145859|NCT00419770|t||||f
17145860|NCT02848326|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17145861|NCT00927992|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145862|NCT02446626|f||||f
17145863|NCT04526210|f||||t
17145864|NCT01781637|f||||f
17145865|NCT02999178|f||OTHER|There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17145866|NCT00458848|f||||f
17190446|NCT00771849|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17190447|NCT01636206|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190448|NCT03748433|t||||
17190449|NCT02046616|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/ or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190450|NCT02736799|f||OTHER|Permission to use study data is required|t
17190451|NCT01183533|f||OTHER|The study PI will submit the manuscript of any proposed publication to the sponsor at least 45 days before publication, and the sponsor shall have the right to review and comment upon the publication. The sponsor shall provide any comments to investigator within 30 days of receipt of the proposed publication or presentation. At the end of the 30 day period, the PI shall be free to proceed with the publication or presentation provided he or she has complied with the sponsor's feedback.|t
17190452|NCT03036735|f||||f
17190453|NCT01156116|t||||
17190454|NCT00344019|f||||f
17190455|NCT02057718|f||OTHER||t
17190456|NCT02503202|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17190457|NCT05252871|t||||
17145867|NCT01483352|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145868|NCT03469297|f||LTE60||t
17145869|NCT01701024|f||||f
17145870|NCT02086188|f||||f
17145871|NCT03471078|f||OTHER|The disclosure restriction on the PI is that the sponsor will review results communications prior to public release and can embargo communications regarding trial results.|t
17145872|NCT02473640|f||OTHER|Investigators do not see trial results ahead of public disclosure unless it is under CDA. Investigators will not be allowed to publish or disclose any study results prior to sponsor communicating it to the public.|t
17145873|NCT02127281|f||||f
17145874|NCT00153803|f||||f
17145875|NCT00038675|t||||
17145876|NCT03292653|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17145877|NCT04720664|t||||
17145878|NCT05628675|t||||
17145879|NCT04486066|t||||f
17145880|NCT05818137|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17145881|NCT01699607|f||||f
17145882|NCT01648166|f||||f
17145883|NCT00883090|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned, before seeking publication review.|t
17190458|NCT01245439|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190459|NCT01050569|f||||f
17190460|NCT03673943|f||||f
17190461|NCT03525119|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17190462|NCT01959412|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17190463|NCT00509769|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190464|NCT04364269|f||OTHER||t
17190465|NCT00383188|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190466|NCT01093534|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 60 days prior to publication for review and comment. Sponsor may delay the publication for up to 6 months to seek patent protection.|t
17190467|NCT00281918|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190468|NCT04026620|t||||
17190469|NCT04173962|t||||
17190470|NCT02987335|f||||f
17190471|NCT01670110|t||||
17190472|NCT02555631|t||||
17190473|NCT03418324|t||||f
17190474|NCT01768676|f||OTHER|After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution \& PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.|t
17190475|NCT04248829|f||||t
17190476|NCT02685033|f||OTHER|PI agrees that the first results publication shall be made in conjunction with a joint multi-center publication. If the multi-center publication is not submitted within 12 months after conclusion of the study at all sites, or if the sponsor confirms not to publish the results, the PI may publish the results from the institution subject to terms of the clinical trial agreement. The publication must be sent to Sponsor at least 60 days before the intended submission date for reference and comment.|t
17190477|NCT01066923|f||||f
17190478|NCT01546155|f||||f
17190479|NCT02899000|f||||f
17190480|NCT00771667|f||GT60||t
17190481|NCT00109967|f||LTE60||t
17190482|NCT02712099|f||||f
17190483|NCT02076919|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190484|NCT00628862|f||LTE60||t
17190485|NCT01063036|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190486|NCT00565110|f||||f
17190487|NCT00703911|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to Novo Nordisk for review at least 60 days before submission for publication or presentation. The investigator will recognize the integrity of a multi-centre study by not publishing data derived from the individual site until the combined results from the completed registry have been published in full, or the sponsor confirms there will be no multi-centre registry publication.|t
17190488|NCT01551056|f||||t
17190489|NCT00853827|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17190490|NCT04059237|t||||
17190491|NCT00906035|f||||f
17190492|NCT02050308|f||||f
17190493|NCT03058991|f||||f
17145884|NCT03344510|f||||f
17190494|NCT00130637|t||||f
17190495|NCT00942149|f||||f
17190496|NCT01460342|f||GT60||t
17145885|NCT01475838|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17145886|NCT00048568|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17145887|NCT03831048|f||OTHER||t
17145888|NCT04083859|f||||f
17145889|NCT00560235|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145890|NCT01365650|f||||f
17145891|NCT01595503|t||||
17145892|NCT01315249|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17145893|NCT04818242|t||||
17145894|NCT00290147|f||||f
17145895|NCT03227445|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145896|NCT01880073|t||||f
17145897|NCT00755196|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17145898|NCT01703832|f||OTHER|Investigator agreements in place restricting the PI from independently publishing the study results. Currently working with both PIs on several publications of the NEUPRO studies.|t
17145899|NCT01991470|f||||f
17145900|NCT00771537|f||||f
17145901|NCT01351506|t||||
17145902|NCT00623779|f||LTE60||t
17145903|NCT02829268|t||||
17145904|NCT01434693|f||LTE60||t
17145905|NCT03138330|t||||
17145906|NCT00440557|f||OTHER|Disclosure restrictions on the PI are pre- review of publications prior to public release. Sponsor can embargo trial result publication for up to 120 days. The PI may not publish the sponsor's confidential information without consent. In multi-center trials, individual PI's may publish results only if the study group has not published results 12 months after study completion, abandonment, or termination. The sponsor cannot require changes to the scientific content and cannot extend the embargo.|t
17145907|NCT01918800|t||||
17145908|NCT01378975|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145909|NCT03054103|t||||
17145910|NCT02343120|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17145911|NCT01765530|t||||
17190497|NCT01689519|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190498|NCT01713530|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17190499|NCT03939819|t||||
17190500|NCT02613364|f||||f
17145912|NCT01874951|f||||f
17145913|NCT03544138|f||||f
17145914|NCT01766778|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17145915|NCT01104662|f||OTHER|The first publication is initiated by Cubist. If first publication not published within 1 year of study conclusion or termination, Investigator has right to publish and disclose the data. Prior to any submission for publication, presentation, or communication of results or information arising from the study, Investigator shall provide Cubist at least 90 days for review and comment upon the manuscript or other material for such publication or presentation.|t
17190501|NCT00436644|t||||
17190502|NCT00619645|t||||
17190503|NCT02526680|f||||f
17190504|NCT00972504|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190505|NCT00597519|t||||
17190506|NCT04246762|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17190507|NCT00410124|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial."|t
17190508|NCT02979899|f||||f
17190509|NCT04495634|t||||
17190510|NCT00741988|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17190511|NCT00811057|t||||f
17190512|NCT02885311|f||||f
17190513|NCT00768651|t||||
17190514|NCT02104765|f||GT60||t
17190515|NCT02124460|f||||f
17190516|NCT00331162|t||||
17190517|NCT00995709|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17190518|NCT01697319|f||GT60||t
17190519|NCT04222959|f||||f
17190520|NCT00392678|f||||f
17190521|NCT03008915|f||||f
17190522|NCT01944319|t||||
17190523|NCT00712166|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17190524|NCT01773122|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190525|NCT01264718|f||||f
17145916|NCT02158936|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novaratis does not prohibit any investigation from publishing. Any publications from a single-site are postposed until the publication of the pooled data (ie. data from all sites) in the clinical trial.|t
17145917|NCT01706926|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17145918|NCT00414466|f||LTE60||t
17145919|NCT02637232|f||OTHER|This is an agreement between the PI and sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Disclosure agreement is covered by a contract.|t
17145920|NCT02248597|t||||
17145921|NCT01269801|f||||f
17145922|NCT02395822|f||||f
17145923|NCT02937701|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145924|NCT02683083|f||||f
17145925|NCT03290326|t||||
17145926|NCT05086835|t||||
17145927|NCT03422653|f||||t
17190526|NCT01673113|t||||
17190527|NCT01769391|f||GT60||t
17190528|NCT03386929|f||LTE60||t
17190529|NCT02837237|f||||f
17190530|NCT01975467|f||||f
17190531|NCT01144182|t||||
17190532|NCT03772964|f||||f
17145928|NCT01101022|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17145929|NCT01519661|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17145930|NCT01139047|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17145931|NCT01941095|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145932|NCT00726739|t||||
17190533|NCT03264456|f||LTE60||t
17190534|NCT03538054|f||||f
17190535|NCT03254394|t||||f
17190536|NCT03360396|f||||f
17190537|NCT02351180|f||||f
17190538|NCT01751724|f||||f
17190539|NCT03906968|t||||
17190540|NCT03121950|t||||
17190541|NCT01867580|f||LTE60||t
17190542|NCT01303835|t||||f
17190543|NCT03425643|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17145933|NCT02918877|f||||f
17145934|NCT03527745|t||||
17145935|NCT01604850|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17145936|NCT00243932|f||||f
17145937|NCT03002597|f||||f
17145938|NCT00880568|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17145939|NCT00849901|f||GT60||t
17145940|NCT00437658|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17145941|NCT01469767|t||||
17145942|NCT04407806|t||||f
17145943|NCT02731157|t||||
17145944|NCT00832377|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17145945|NCT01449630|f||GT60||t
17145946|NCT02016612|f||||f
17145947|NCT01735630|f||GT60||t
17145948|NCT03099538|t||||
17145949|NCT02096718|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145950|NCT04448886|f||||t
17145951|NCT03205553|t||||
17145952|NCT02461771|f||||t
17145953|NCT02980978|f||||f
17145954|NCT01941030|f||LTE60||t
17145955|NCT02930005|t||||
17145956|NCT01313416|f||OTHER||t
17145957|NCT00487669|t||||f
17145958|NCT00822926|t||||
17145959|NCT02304432|f||||f
17145960|NCT00098371|f||LTE60||t
17145961|NCT01314742|f||||f
17145962|NCT02268500|t||||
17190544|NCT03141788|f||||f
17145963|NCT02534493|f||||f
17145964|NCT01993875|f||||f
17145965|NCT03125200|f||OTHER|PI can publish after first multi-site publication, or if no multi-site publication is made within 18 months of study completion/termination. The only disclosure restriction on the PI is the sponsor can review results comms. prior to public release and can embargo comms. regarding trial results for a period that is more than 60 but less than or equal to 180 days from the time submitted to sponsor for review. The sponsor can't require changes to the communication and can't extend the embargo.|t
17145966|NCT01023074|f||||f
17145967|NCT00119379|f||||f
17145968|NCT02227121|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17145969|NCT03929367|t||||
17145970|NCT01569152|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17145971|NCT01706536|f||OTHER|In the event the study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following the completion of the study at all sites, Institution and Investigator shall be free to publish.|t
17145972|NCT02519322|t||||
17145973|NCT04190693|f||||t
17145974|NCT00860314|t||||
17145975|NCT00993187|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17145976|NCT00683293|t||||
17145977|NCT03262012|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17145978|NCT01469546|t||||
17145979|NCT03154658|t||||
17190545|NCT03523702|t||||
17190546|NCT03379740|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17190547|NCT05365633|t||||
17190548|NCT02126878|t||||
17190549|NCT02734056|f||||f
17190550|NCT02220478|f||||f
17190551|NCT01025843|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17190552|NCT03224299|f||||f
17190553|NCT00377455|t||||f
17190554|NCT01070888|f||||f
17190555|NCT00959920|t||||
17190556|NCT02628093|t||||
17190557|NCT01897233|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17190558|NCT02715258|f||OTHER|The Investigator does not have the right to publish the results.|t
17190559|NCT02814643|f||OTHER|At least 30 days prior to submission for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Institution and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication/presentation.|t
17190560|NCT02263508|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190561|NCT00531518|f||||f
17190562|NCT03265210|t||||f
17190563|NCT04020718|f||||f
17190564|NCT01281813|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17190565|NCT03546907|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17190566|NCT00816751|t||||
17190567|NCT02620761|t||||
17190568|NCT04033432|t||||
17145980|NCT02079532|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17145981|NCT01085045|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17145982|NCT00234078|f||||f
17145983|NCT00633399|f||||f
17145984|NCT01137539|t||||
17145985|NCT04455633|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable participant matter.|t
17145986|NCT02532764|f||OTHER|Investigators are restricted from disclosure or results until after multicenter publication or 12 months after the completion of the Study at all participating research centers. Sponsor can review results communication prior to public release and can embargo communications regarding trial results for a period that is more than 45 days (varying per site). Sponsor may request redaction of confidential information.|t
17145987|NCT01717976|t||||
17145988|NCT01027780|f||||f
17145989|NCT03538587|f||||f
17145990|NCT00727571|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17145991|NCT03164772|f||||f
17145992|NCT02831569|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17145993|NCT01453075|f||||f
17145994|NCT04099888|f||||f
17145995|NCT04538170|t||||f
17145996|NCT00637299|f||||f
17145997|NCT02031978|f||||f
17145998|NCT00051025|f||||f
17145999|NCT00274937|f||OTHER|Must obtain prior Sponsor approval.|t
17190569|NCT02192606|f||||f
17190570|NCT03110458|f||||f
17146000|NCT02189941|t||||
17146001|NCT00445003|f||LTE60||t
17146002|NCT01471093|f||||f
17146003|NCT02475954|t||||
17146004|NCT02932878|f||||t
17190571|NCT01458210|f||GT60||t
17190572|NCT04008836|f||||f
17190573|NCT00286741|t||||
17146005|NCT03656783|f||||f
17146006|NCT03503578|t||||
17146007|NCT01918397|t||||
17190574|NCT02633358|f||||f
17190575|NCT00957658|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study. These manuscripts and abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17190576|NCT01833832|f||||f
17146008|NCT00864097|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146009|NCT05194839|f||||t
17146010|NCT00620022|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146011|NCT00262223|f||||f
17146012|NCT03828734|t||||f
17146013|NCT01804270|t||||
17146014|NCT00978822|f||||f
17146015|NCT02006160|f||||f
17146016|NCT01328093|f||GT60||t
17146017|NCT02576249|t||||
17146018|NCT05150964|f||||f
17146019|NCT03661528|f||||t
17146020|NCT02178722|f||OTHER|Clinical Study Agreement|t
17146021|NCT03340727|f||||f
17146022|NCT03553823|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146023|NCT03682900|f||||f
17146024|NCT04448678|f||||f
17146025|NCT03005522|t||||
17146026|NCT03991494|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17146027|NCT01312922|f||||f
17146028|NCT00515203|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146029|NCT01937390|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146030|NCT02126306|f||||f
17146031|NCT02098993|t||||
17146032|NCT02920996|f||||f
17146033|NCT01096290|t||||
17146034|NCT00154102|f||OTHER||t
17146035|NCT00591630|t||||
17146036|NCT00463606|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17146037|NCT02228174|f||LTE60||t
17146038|NCT02682602|t||||f
17146039|NCT06090461|t||||
17146040|NCT01432171|f||GT60||t
17146041|NCT00416520|f||OTHER||t
17146042|NCT03348423|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17146043|NCT00373217|t||||
17146044|NCT01759277|f||||f
17146045|NCT01532141|f||OTHER||t
17146046|NCT04015232|f||||t
17146047|NCT02152566|t||||
17146048|NCT01297348|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146049|NCT01541891|f||OTHER|"All the information is confidential and exclusive property of the sponsor. Information can be revealed only to my staff and regulatory agencies or ethics committee.~All the information from this protocol is confidential and exclusive property of the sponsor, it can not be revealed without written consent from the sponsor."|t
17146050|NCT02334722|t||||
17146051|NCT00856388|t||||
17146052|NCT00643578|f||||f
17146053|NCT01617668|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17146054|NCT00925769|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146055|NCT02017964|f||OTHER|Must obtain prior Sponsor approval|t
17146056|NCT02005536|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17190577|NCT01193153|f||OTHER|At least 60 days prior to submitting a manuscript the Site shall provide to Sponsor a copy of all such manuscripts and materials,and allow Sponsor 60 days to review and comment on them. If Sponsor requests, the Site shall remove any Confidential Information prior to submitting the materials.The Site agrees that if Study is part of a multi-center study,any publication by the Institution of results of the Study conducted at the Site shall not be made before the first multi-center publication.|t
17190578|NCT01988233|f||||f
17190579|NCT03621761|f||||f
17190580|NCT05046132|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17190581|NCT01852019|f||OTHER|Prior to submission for publication or presentation, the Institution will provide the Sponsor thirty (30) days for review and comment, If necessary, Sponsor will be given an additional sixty (60) days to allow Sponsor to file a patent application or taking such other measures as Sponsor deems appropriate to establish and preserve its proprietary rights upon the manuscript or other material for such publication. Sponsor may remove confidential or proprietary information.|t
17190582|NCT01186848|t||||
17190583|NCT00208507|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190584|NCT02903836|f||OTHER||t
17190585|NCT00982033|f||GT60||t
17190586|NCT01669148|t||||
17190587|NCT01183780|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17190588|NCT04379713|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190589|NCT01872819|f||||f
17190590|NCT04089488|f||||f
17190591|NCT00001304|t||||
17190592|NCT02148133|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190593|NCT03808883|f||||f
17190594|NCT04567888|t||||
17190595|NCT04615299|t||||
17190596|NCT00371566|f||OTHER|: GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146057|NCT00686959|f||GT60||t
17146058|NCT00150462|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146059|NCT01212874|f||||f
17190597|NCT00878722|f||LTE60||t
17190598|NCT00319436|t||||f
17190599|NCT01161498|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190600|NCT01544062|f||||f
17190601|NCT02807493|t||||
17190602|NCT02781584|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met.~* The results of the study in their entirely have been publicly disclosed by our with the consent of Gilead in an abstract, manuscript, presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190603|NCT02930590|t||||f
17190604|NCT01123083|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190605|NCT02729701|t||||
17190606|NCT02385669|f||||f
17190607|NCT02810080|f||LTE60||t
17190608|NCT03597100|f||||f
17190609|NCT05257798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190610|NCT02550197|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17146060|NCT01196052|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146061|NCT01572948|f||||f
17146062|NCT03603314|f||||f
17146063|NCT03450070|f||OTHER|The Principal Investigator (PI) will provide Sponsor with at least sixty (60) days to review any Publication. No Publication that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written consent. If requested in writing, the PI withholds such Publication for up to an additional sixty (60) days to allow for filing of a patent application.|t
17146064|NCT01346397|t||||
17146065|NCT01720264|t||||
17146066|NCT00877032|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146067|NCT00924326|f||||f
17146068|NCT00615069|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator willpostpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating study sites.|t
17146069|NCT01929642|f||||f
17146070|NCT00669942|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17146071|NCT04056182|t||||
17146072|NCT00259012|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17146073|NCT02828917|f||||f
17146074|NCT00581971|f||||f
17146075|NCT01954264|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146076|NCT01390233|t||||
17146077|NCT01496183|t||||
17146078|NCT03002077|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17146079|NCT03325426|t||||f
17146080|NCT04625114|f||||f
17146081|NCT03221374|f||||f
17146082|NCT02567968|t||||
17146083|NCT00336479|f||GT60||t
17146084|NCT01479439|t||||f
17146085|NCT02365207|t||||
17146086|NCT01722877|f||||f
17146087|NCT01395030|t||||f
17146088|NCT02079766|f||LTE60||t
17146089|NCT02265783|f||||f
17190611|NCT00419094|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17190612|NCT00989937|t||||
17146090|NCT01658228|t||||
17146091|NCT05067647|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17146092|NCT01884740|t||||
17146093|NCT00857623|f||OTHER||t
17146094|NCT00493831|t||||f
17146095|NCT01106326|f||||f
17146096|NCT00870870|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17146097|NCT03117569|f||||t
17146098|NCT00694551|t||||
17146099|NCT03187002|t||||
17146100|NCT00385684|t||||
17146101|NCT02801877|f||||f
17146102|NCT02924038|t||||
17146103|NCT03601637|f||||f
17146104|NCT00479258|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17146105|NCT00420303|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17146106|NCT02215161|t||||f
17146107|NCT01029353|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication policies.|t
17146108|NCT01900730|t||||
17146109|NCT01520909|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146110|NCT02942264|f||||f
17146111|NCT02535611|t||||
17146112|NCT00569374|t||||
17146113|NCT00064753|f||||f
17146114|NCT00784823|t||||
17146115|NCT03834870|f||||f
17146116|NCT01544127|f||||f
17146117|NCT02870920|f||||f
17146118|NCT00533273|f||OTHER|Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17146119|NCT02914600|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17146120|NCT00454909|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146121|NCT02457520|f||OTHER||t
17146122|NCT02107092|f||OTHER|ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17146123|NCT02703948|f||OTHER|Any and all data resulting from the Study will not be presented or published in any form or media by the PI without the prior written consent of the Sponsor.|t
17146124|NCT03522675|f||||f
17146125|NCT00707161|t||||
17146126|NCT02763865|t||||
17146127|NCT02076022|f||||f
17146128|NCT00312663|f||||f
17146129|NCT04005859|t||||
17146130|NCT00819507|f||||f
17146131|NCT01789905|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146132|NCT02661295|f||||f
17146133|NCT01376167|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146134|NCT03541941|t||||
17146135|NCT00802100|f||||f
17146136|NCT02688556|f||||t
17146137|NCT02849652|f||||f
17146138|NCT00565448|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17146139|NCT00472290|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial resul|t
17146140|NCT00777829|f||||f
17146141|NCT02359305|t||||
17146142|NCT01157091|t||||
17146143|NCT02016170|t||||
17146144|NCT00302952|f||||f
17146145|NCT02597101|f||||f
17146146|NCT00985257|f||LTE60||t
17146147|NCT02373098|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146148|NCT04166032|f||OTHER|Company will review any publication submission within 30 days of estimated due date. If CCF does not hear from company we are to assume we are free to publish. If company identities patentable information they can request for CCF to withhold submission for 90 days.|t
17146149|NCT02008565|f||||f
17146150|NCT02193178|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17146151|NCT03435081|f||GT60||t
17146152|NCT00420238|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17146153|NCT05214560|f||OTHER|PI submits to Sponsor for review a draft 90 days prior to submission of thedraft for publication.Draft shall not divulge any confidential info.Sponsor hasthe right to:review and make comments on any proposed publication; withholdthe use of its name in connection with publication;make any results from thestudy known to its customers and governmental agencies prior topublication.The first publication of the study results shall be made inconjunction with the results from the other PIs.|t
17146154|NCT03639311|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146155|NCT03151057|f||||f
17146156|NCT03018249|f||LTE60||t
17146157|NCT04320849|t||||f
17146158|NCT00699491|f||LTE60||t
17146159|NCT04881968|f||||f
17146160|NCT00304083|f||||f
17146161|NCT02287675|t||||
17146162|NCT03966365|f||OTHER|only the sponsor has the decision to disseminate or publish the information obtained from the investigation and the PIs involved must submit a formal request to the sponsor if they are willing to disseminate or publish such information, they may only publish them if they have the written authorization of the sponsor (Laboratoios Sophia S.A. de C.V.).|t
17146163|NCT01044732|f||||f
17146164|NCT01523899|f||||f
17146165|NCT00824265|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17146166|NCT01402947|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17146167|NCT01248247|t||||
17146168|NCT01108094|f||||f
17146169|NCT04349917|t||||
17146170|NCT00705536|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17146171|NCT04188106|f||||f
17146172|NCT00441467|f||||f
17146173|NCT02289963|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17146174|NCT03514420|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17146175|NCT01042522|f||LTE60||t
17146176|NCT00549718|f||OTHER|For multi-center studies, it is mandatory that the first publication is based on all data obtained from all analyses as stipulated in the protocol. Investigators participating in multicenter studies must agree not to present data gathered individually or by subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and also by DSP-Sepracor.|t
17146177|NCT04742283|f||||t
17190613|NCT02034916|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190614|NCT03131206|f||||f
17190615|NCT01616654|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide his draft of such publication to sponsor to review and approve at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17190616|NCT02057692|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190617|NCT00864682|t||||f
17190618|NCT05372094|f||||f
17190619|NCT02393716|f||||t
17190620|NCT04420195|t||||
17190621|NCT04842604|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190622|NCT01648140|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190623|NCT00478335|t||||
17190624|NCT00608907|f||||f
17190625|NCT01986686|f||||f
17190626|NCT03264248|t||||t
17190627|NCT00470106|f||||f
17190628|NCT02178540|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17190629|NCT00758602|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190630|NCT04628572|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190631|NCT00158054|f||||f
17190632|NCT02470949|f||||f
17190633|NCT03038399|f||||t
17190634|NCT03861169|f||LTE60||t
17190635|NCT01595854|t||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190636|NCT04365400|f||||t
17190637|NCT00079183|t||||
17190638|NCT02371746|f||||f
17146178|NCT01507051|f||OTHER|Any disclosure of study results by the Principal Investigator or investigators has to be in agreement with the sponsor.|t
17146179|NCT01675622|f||||f
17146180|NCT04032977|f||||f
17146181|NCT02880761|f||LTE60||t
17146182|NCT03597256|f||OTHER|Initial publication of data from Study must be a multi-centre publication. Any subsequent publication/presentation must be sent to Sponsor for review 60 days before submission for publication/presentation to allow Sponsor to protect patentable inventions/confidential information. Site and Investigator agree to amend proposed publication/presentation, remove such confidential information from it, or postpone submission for a further 60 days/until intellectual property filings take place.|t
17146183|NCT02106156|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146184|NCT02943447|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146185|NCT01907334|f||||f
17146186|NCT00581139|f||||f
17146187|NCT05017480|f||LTE60||t
17146188|NCT01136382|f||GT60||t
17146189|NCT01794039|t||||
17190639|NCT03320096|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17190640|NCT03743246|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190641|NCT01490580|f||||f
17190642|NCT00949975|f||||f
17190643|NCT02873754|t||||
17190644|NCT00128193|f||LTE60||t
17190645|NCT00082810|f||LTE60||t
17190646|NCT02950558|t||||
17190647|NCT01147380|t||||
17190648|NCT01321606|f||||f
17190649|NCT02914522|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190650|NCT00756730|t||||
17190651|NCT04349150|f||||f
17190652|NCT05382104|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190653|NCT00639002|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17190654|NCT03506880|f||||f
17190655|NCT02509585|f||OTHER|The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.|t
17190656|NCT00739765|t||||
17190657|NCT05686421|f||||f
17190658|NCT00940992|f||OTHER||t
17190659|NCT00839540|f||||f
17190660|NCT00299741|f||||f
17190661|NCT00361283|t||||f
17190662|NCT00208767|f||||f
17190663|NCT00907218|f||||f
17190664|NCT05052983|f||||t
17190665|NCT04133363|f||||f
17190666|NCT04415333|f||||f
17190667|NCT00849147|f||||f
17190668|NCT01210820|f||OTHER|At least 1 month prior to any proposed submission for publication or presentation of Trial data or other findings related to the Trial, the Institution will provide the Sponsor with a manuscript for review, comment, and approval. Under no circumstances shall the Institution or PI publish or disclose the Sponsor's confidential Information without the Sponsor's prior written approval.The manner in which the publication will be generated will be negotiated between the Sponsor and PI.|t
17190669|NCT00482729|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146190|NCT00963482|f||||f
17146191|NCT00485472|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17146192|NCT00594685|f||||f
17146193|NCT00088829|t||||
17190670|NCT01606124|t||||
17190671|NCT00669461|t||||
17190672|NCT02631148|f||||f
17190673|NCT02787694|f||||f
17190674|NCT04860258|f||||t
17190675|NCT00028769|f||||f
17146194|NCT00633594|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17146195|NCT02091882|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17146196|NCT01191320|f||OTHER|Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor's Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor's Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights.|t
17146197|NCT00365300|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17146198|NCT02896361|f||||f
17146199|NCT00556049|f||||f
17146200|NCT00954915|f||GT60||t
17146201|NCT01287013|t||||
17146202|NCT01045096|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of it's obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17146203|NCT01179048|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17146204|NCT02109042|f||GT60||t
17146205|NCT01511939|t||||
17146206|NCT03203447|f||OTHER|The institutions and Investigators participating in this study shall have no right to publish or present the results of this study without the prior written consent of Clearside Biomedical, Inc.|t
17146207|NCT00324168|f||||f
17146208|NCT03649841|t||||
17146209|NCT03497897|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17146210|NCT03618147|f||||f
17146211|NCT01529060|f||||f
17146212|NCT02627924|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17146213|NCT02962934|f||||f
17146214|NCT00528606|f||OTHER|Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not preceed the primary publication of the entire clinical trial.|t
17146215|NCT00874887|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17146216|NCT00959660|t||||f
17146217|NCT03478397|f||||f
17146218|NCT02188303|f||GT60||t
17190676|NCT01134562|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17190677|NCT00357396|t||||
17190678|NCT04002973|t||||
17190679|NCT02496702|t||||
17190680|NCT00487578|f||OTHER|Publication of study data collected by Investigator is authorized subject to the following:Investigator is free to publish results of its part of study in collaboration with other investigators subsequent to the multicenter publication issued by Clinvest. If no multicenter publication is submitted within 12 months of end of study, investigator may publish results of its data. Investigator shall submit a copy of manuscript or abstract to Clinvest for review 30 days prior to journal submission.|t
17190681|NCT02378714|f||||f
17190682|NCT02525796|f||||f
17190683|NCT01199783|f||||f
17190684|NCT00726999|t||||
17190685|NCT00955825|f||||f
17190686|NCT01499134|t||||f
17190687|NCT02488980|f||||f
17190688|NCT01198275|f||||f
17190689|NCT00391846|f||OTHER||t
17190690|NCT00150176|f||OTHER|"Sponsor will be provided an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.~Materials for intended disclosure must be provided to sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, then the disclosure must be delayed for a period not to exceed an additional 60 days."|t
17190691|NCT03624413|t||||
17190692|NCT00970307|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190693|NCT00332644|t||||f
17190694|NCT00393848|f||||f
17190695|NCT03239899|t||||
17190696|NCT02107339|f||||f
17190697|NCT02082158|t||||
17190698|NCT00738699|f||OTHER||t
17190699|NCT00203216|t||||
17190700|NCT01924975|f||||f
17190701|NCT01192542|f||||f
17190702|NCT00355914|t||||
17190703|NCT01169311|f||||f
17190704|NCT00590707|f||||f
17190705|NCT00943735|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190706|NCT03804918|t||||
17190707|NCT01329328|t||||
17190708|NCT00964366|f||GT60||t
17190709|NCT01370694|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17190710|NCT02957539|t||||
17190711|NCT00596167|t||||
17190712|NCT02242773|t||||
17190713|NCT01563354|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17190714|NCT01565928|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190715|NCT01119950|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17190716|NCT01161563|f||LTE60||t
17190717|NCT01591616|f||OTHER|The subject study was a post-approval requirement related to the approval of NDA 21-451 to evaluate the pharmacokinetics and safety of the Oraqix gel in pediatric patients. As the purpose of the study was solely to fulfill a post approval regulatory requirement, the information is considered proprietary to the sponsor (Dentsply International, Inc.) and disclosure by the Investigators to any third party (unless such disclosure was required by government regulations or laws) was prohibited.|t
17190718|NCT00855465|f||OTHER|The embargo can be up to 6 months (equal to the 180 days), moreover if it is necessary the embargo period can be prolonged to expiry of priority year.|t
17190719|NCT01114945|f||||f
17146219|NCT04206332|f||||f
17146220|NCT00193037|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17146221|NCT00912288|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146222|NCT02506309|t||||
17146223|NCT03021538|t||||
17146224|NCT00893464|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17146225|NCT00050778|f||OTHER|In multi-site studies, PI can publish after sponsor publishes or 18 months after study completion. PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17146226|NCT00999037|f||||f
17190720|NCT01157182|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17190721|NCT00716144|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190722|NCT00909363|t||||f
17146227|NCT01275586|t||||
17146228|NCT01270919|f||OTHER||t
17146229|NCT01126736|f||||t
17190723|NCT05641311|f||||t
17190724|NCT02533167|t||||
17190725|NCT00367055|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190726|NCT02459899|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17190727|NCT01118338|f||OTHER|Contact sponsor directly for details.|t
17190728|NCT04470193|f||||f
17190729|NCT04663802|f||||f
17146230|NCT04869787|f||||f
17146231|NCT00813293|f||||f
17190730|NCT03612804|t||||
17190731|NCT03105128|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17190732|NCT05019729|t||||
17146232|NCT05194722|f||||f
17146233|NCT00282048|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146234|NCT00524264|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190733|NCT02885350|t||||
17190734|NCT00038103|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17190735|NCT01597128|f||||f
17190736|NCT03545984|t||||
17190737|NCT00387465|f||LTE60||t
17190738|NCT05012644|t||||
17190739|NCT01910636|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190740|NCT02251613|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190741|NCT01212757|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17190742|NCT02694835|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190743|NCT02983617|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190744|NCT00831272|f||||f
17190745|NCT02698891|t||||
17190746|NCT00516386|f||||f
17190747|NCT00818454|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190748|NCT03848910|f||OTHER|"The Institution must give a copy of any proposed Publication to the Sponsor at least 40 days before forwarding it to any person that is not bound by the confidentiality obligations~The Sponsor may, within that 40-day period:~1. provide comments;~2. request delay of Publication for no more than 120 days, or~3. request that the Discloser remove specified Confidential Information from the Publication."|t
17190749|NCT04763044|f||OTHER|PI should disclose plans to sponsor prior to public release.|t
17190750|NCT01171625|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 60 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 90 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17190751|NCT01376089|f||||f
17190752|NCT00549848|t||||
17190753|NCT03854253|f||||f
17190754|NCT03262935|f||OTHER|The PI agrees to provide to the Sponsor 60 days prior to intended submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The Sponsor has the right to review and comment with respect to publications, abstracts, slides, and manuscripts including the data analysis and presentation. In case of disagreement, efforts will be undertaken to resolve any such issues, but the ultimate decision remains with the Sponsor.|t
17190755|NCT01811706|t||||
17190756|NCT00354640|t||||f
17190757|NCT00753012|t||||f
17190758|NCT02507336|t||||
17190759|NCT02925195|f||||f
17190760|NCT00217672|f||||f
17190761|NCT01787240|f||||f
17190762|NCT03951649|f||||f
17190763|NCT01596504|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish results. The investigator provides the sponsor with a copy of the presentation or publication for review and comment at least 30 days in advance of its submission.~The sponsor can delay the submission for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights."|t
17190764|NCT01901276|t||||f
17190765|NCT04347954|t||||
17190766|NCT00761930|f||LTE60||t
17190767|NCT03257813|f||OTHER||t
17146235|NCT01536405|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17146236|NCT00301366|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor, thirty days in advance of submission, in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution that satisfies both parties.|t
17146237|NCT04213326|f||||f
17146238|NCT01371786|f||OTHER||t
17146239|NCT02549092|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17146240|NCT02511782|t||||
17146241|NCT03627091|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17146242|NCT00450190|f||OTHER||t
17146243|NCT03611608|f||LTE60||t
17146244|NCT02158494|f||||f
17146245|NCT03865654|t||||f
17146246|NCT03660839|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17146247|NCT02744352|t||||
17146248|NCT04149964|t||||
17146249|NCT04753437|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17146250|NCT03325114|t||||
17146251|NCT00633256|t||||
17146252|NCT00318812|t||||f
17146253|NCT02424097|f||||f
17146254|NCT02311361|f||||f
17146255|NCT01978743|f||||f
17146256|NCT00745420|f||||f
17146257|NCT02653664|f||||f
17146258|NCT04657770|f||||f
17146259|NCT00746798|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17146260|NCT03655106|t||||
17190768|NCT02878330|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17190769|NCT01989910|f||||t
17190770|NCT02954848|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17190771|NCT01069341|f||||f
17190772|NCT00922207|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146261|NCT00156247|f||||f
17146262|NCT01163760|f||OTHER|The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.|t
17146263|NCT03334825|f||OTHER|All PIs have been employed by the New York City Department of Health and Mental Hygiene. Dr. Towe is no longer at the New York City Department of Health and Mental Hygiene and is currently at RAND Corporation. Any results communications must be cleared by the New York City Department of Health and Mental Hygiene prior to public release.|t
17146264|NCT01423760|f||OTHER|The Investigator will inform the Sponsor in advance about any plans to publish or present data from the trial. Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their representatives will require pre-submission review by the Sponsor.The Sponsor will not suppress or veto publications, but maintains the right to delay publication in order to protect intellectual property rights.|t
17146265|NCT01367457|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146266|NCT04257474|f||||f
17146267|NCT01882257|t||||
17146268|NCT02058498|t||||
17146269|NCT00487565|f||LTE60||t
17146270|NCT01038856|f||||f
17146271|NCT01643707|f||LTE60||t
17146272|NCT01391793|f||||f
17146273|NCT01666730|t||||
17146274|NCT02087904|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17146275|NCT01327963|f||||f
17146276|NCT01389102|f||OTHER|Investigator shall not publish, or seek to publish, either in whole or in part, any results of the Clinical Investigation without the written consent of the Sponsor.|t
17146277|NCT02910037|t||||f
17146278|NCT00436553|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or until the publication of the trial results in their entirety.|t
17146279|NCT02379247|f||||f
17146280|NCT02770625|f||||t
17146281|NCT01361048|f||||f
17146282|NCT01661686|t||||
17146283|NCT01873586|f||||f
17146284|NCT00624065|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146285|NCT00696020|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146286|NCT01387022|f||||f
17146287|NCT01972204|f||||f
17146288|NCT03959683|t||||
17146289|NCT00904345|t||||
17146290|NCT02495467|f||OTHER||t
17146291|NCT01536574|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146292|NCT00656305|f||||f
17146293|NCT02193165|f||||f
17146294|NCT01498120|f||GT60||t
17146295|NCT01173692|t||||
17190773|NCT01802632|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review, should the submission for publication be delayed in order to file patent application. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190774|NCT02326649|f||||f
17190775|NCT00373269|t||||
17190776|NCT03698708|f||||f
17190777|NCT02806869|f||||f
17190778|NCT03495713|f||||f
17190779|NCT04001517|f||||f
17190780|NCT02880241|f||||f
17190781|NCT03253913|f||||f
17190782|NCT02705586|t||||
17190783|NCT00117663|t||||
17190784|NCT02194933|f||LTE60||t
17190785|NCT03608839|t||||
17190786|NCT02045836|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190787|NCT02053363|f||||f
17190788|NCT01794936|f||||f
17190789|NCT03920215|f||||t
17190790|NCT02000817|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190791|NCT00166166|t||||
17190792|NCT00177216|f||||f
17190793|NCT03320434|f||OTHER||t
17190794|NCT03383146|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17146296|NCT00678639|t||||
17146297|NCT00986245|f||||f
17146298|NCT01629381|f||||f
17146299|NCT01214850|f||GT60||t
17190795|NCT03399370|f||||f
17190796|NCT02498769|t||||
17190797|NCT02739035|f||||f
17190798|NCT03210402|f||OTHER|Participating Institution and Principal Investigator may publish the results of work performed under this Agreement, in accordance with the publication strategy described in the Protocol; provided, however, that any such Publication will be provided to Medtronic for review at least forty five (45) days prior to submission or presentation; provided, however, that such publication strategy in no way shall prevent Institution from freely utilizing data for Publication|t
17190799|NCT05819190|f||LTE60||t
17190800|NCT02517307|f||||f
17190801|NCT00823979|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190802|NCT03586544|f||||f
17190803|NCT03523091|t||||f
17190804|NCT01832506|f||||f
17190805|NCT01001078|t||||
17190806|NCT03863834|f||||f
17190807|NCT02685488|t||||
17190808|NCT00324038|f||||f
17190809|NCT02770248|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17190810|NCT00667745|f||||f
17190811|NCT03768206|f||||f
17146300|NCT01863745|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17146301|NCT00193609|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17146302|NCT00854308|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146303|NCT00076050|f||||f
17146304|NCT00610363|f||OTHER|PI/Institution will provide a copy of any publication to Sponsor prior to submission for review. Sponsor may request to remove confidential information from submission, provided that removal does not preclude the complete and accurate presentation and interpretation of the study results.|t
17146305|NCT03048500|t||||
17146306|NCT01171963|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146307|NCT03252353|f||OTHER||t
17146308|NCT00626548|f||OTHER|"3\. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.~AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed to allow for"|t
17150727|NCT04322149|f||OTHER|PI will not submit any results of the Study until after the first to occur: publication of the trial results, notification by Sponsor the trial submission is no longer planned, or the 18 month anniversary of the completion or early termination of the trial. A copy of any proposed publication or disclosure of the results of the Study will be given to Sponsor for review at least 30 days prior to the date of submission for publication (including abstracts) or of public disclosure|t
17190812|NCT04493242|f||OTHER|Non-disclosure agreements with PIs in place. PIs cannot disclose data for approximately 10 years.|t
17190813|NCT01942707|f||||f
17190814|NCT02812966|t||||
17190815|NCT04257058|t||||
17190816|NCT04969991|f||GT60||t
17190817|NCT05208359|f||||f
17190818|NCT05147233|f||GT60||t
17190819|NCT03645031|t||||
17190820|NCT04670822|f||||f
17190821|NCT04517864|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190822|NCT04199728|t||||
17190823|NCT04722003|f||LTE60||t
17190824|NCT01049503|t||||f
17190825|NCT00726596|t||||
17190826|NCT02234128|f||GT60||t
17190827|NCT02974634|f||||f
17190828|NCT02743078|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17190829|NCT00661778|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190830|NCT02425449|t||||
17190831|NCT02962674|f||OTHER||t
17190832|NCT00364286|t||||
17190833|NCT02195713|f||||f
17190834|NCT02577523|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17190835|NCT01124188|f||||f
17190836|NCT01266265|f||OTHER|Any publication of the result of this trial must be consistent with the United Therapeutics publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190837|NCT01580293|f||LTE60||t
17190838|NCT01645098|t||||
17190839|NCT00768664|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190840|NCT01324453|f||||f
17190841|NCT00708032|f||OTHER|Publication requires agreement and written consent from the Sponsor.|t
17190842|NCT01400776|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190843|NCT01227278|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17190844|NCT00423098|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17190845|NCT01012388|f||OTHER|Sponsor reserves right to review/comment on manuscript intended for publication/presentation which presents trial data. No manuscripts may be submitted for publication without prior review/comment by Sponsor. Title, right to determine disposition of any copyrights, or copyrightable material, first produced/composed in the performance of this research shall remain with PI, provided that PI grants Sponsor irrevocable right to reproduce/translate/use all such copyrighted material for own purposes.|t
17190846|NCT04035668|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190847|NCT02284555|f||OTHER||t
17190848|NCT02320123|f||||f
17190849|NCT04480827|f||||f
17190850|NCT00465816|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190851|NCT02711839|f||||f
17190852|NCT00941655|f||||f
17190853|NCT02477670|f||||t
17190854|NCT03290248|f||OTHER|PI may not publish or otherwise publicly disclose the analyzed study data and conclusions drawn from the study.|t
17190855|NCT01815008|f||||f
17190856|NCT00446550|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17190857|NCT02937831|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17190858|NCT02630719|f||||t
17190859|NCT03426228|f||||f
17190860|NCT03720210|t||||
17190861|NCT00114244|f||LTE60||t
17190862|NCT00711958|f||OTHER|Results stemming from the present trial can only be published if both the Coordinating investigator and the sponsor give their consent. Publications of subcollectives or center specific data are only possible if the whole study results have already been published.|t
17190863|NCT02200523|t||||
17190864|NCT02694978|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data have been received by Sponsor, the Site, and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 180 days to allow Sponsor to protect its interests.|t
17190865|NCT01613716|t||||f
17190866|NCT02224924|t||||
17190867|NCT03020745|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190868|NCT02680457|t||||
17146309|NCT00048581|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146310|NCT01059903|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17146311|NCT00385593|f||||f
17146312|NCT00214422|f||||f
17146313|NCT00319735|f||||f
17146314|NCT03929393|f||||f
17146315|NCT03420300|t||||
17146316|NCT02421952|t||||f
17146317|NCT02140060|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17146318|NCT02158572|f||OTHER|Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL23 study is required prior to publication submission.|t
17146319|NCT04503603|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17146320|NCT02589808|t||||
17146321|NCT00705003|f||||f
17146322|NCT01171690|t||||
17146323|NCT05439252|t||||
17146324|NCT04466111|f||||f
17146325|NCT00105196|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146326|NCT03025880|f||LTE60||t
17146327|NCT01035060|f||||f
17146328|NCT01382719|f||LTE60||t
17146329|NCT02015390|f||||f
17146330|NCT02193880|f||||f
17190869|NCT03184558|f||||t
17190870|NCT02506257|f||||f
17190871|NCT03760419|t||||
17190872|NCT01924767|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190873|NCT01678196|f||||f
17190874|NCT01377623|t||||
17190875|NCT01740817|f||||f
17190876|NCT05340244|f||||f
17190877|NCT00139737|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190878|NCT01256034|t||||
17190879|NCT03781336|t||||
17190880|NCT03460756|f||||f
17190881|NCT03987451|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17190882|NCT03888755|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17190883|NCT02441036|f||||f
17190884|NCT00932022|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17190885|NCT02064959|f||||f
17190886|NCT00004124|f||||f
17190887|NCT02296424|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17190888|NCT04956575|f||||t
17190889|NCT03593876|t||||
17190890|NCT03287622|f||||f
17190891|NCT00432458|t||||
17190892|NCT03823300|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190893|NCT00326924|t||||
17190894|NCT00507689|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190895|NCT01786564|f||||f
17190896|NCT00486330|f||||f
17190897|NCT01290224|t||||f
17190898|NCT00346333|f||||f
17190899|NCT00723450|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190900|NCT03193619|f||||t
17190901|NCT00612586|f||GT60||t
17190902|NCT03192046|f||||f
17190903|NCT00762606|f||||f
17190904|NCT01194154|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17190905|NCT01909336|f||||f
17146331|NCT03136380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146332|NCT04753710|f||||f
17190906|NCT01505881|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17190907|NCT00842257|t||||f
17190908|NCT00395018|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190909|NCT02314117|f||GT60||t
17190910|NCT02026258|t||||
17190911|NCT04439799|t||||f
17190912|NCT05565391|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190913|NCT02716324|f||||f
17146333|NCT00672178|f||||f
17150728|NCT01700049|t||||
17190914|NCT00530842|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17146334|NCT00553280|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146335|NCT02794974|t||||
17190915|NCT02534350|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146336|NCT02202850|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146337|NCT02996682|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190916|NCT04673851|t||||
17190917|NCT01568918|t||||
17190918|NCT04301986|t||||
17190919|NCT00880048|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190920|NCT03368937|t||||
17190921|NCT00346151|f||||f
17190922|NCT01269736|t||||
17190923|NCT02861937|f||||f
17190924|NCT03684265|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17190925|NCT00790790|f||GT60||t
17190926|NCT02570295|t||||
17190927|NCT02570711|f||||f
17190928|NCT02798835|f||||f
17190929|NCT00145041|f||LTE60||t
17190930|NCT03070483|t||||
17190931|NCT01215695|t||||
17190932|NCT01585558|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17190933|NCT01378065|f||LTE60||t
17190934|NCT00891176|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190935|NCT00094575|f||||f
17190936|NCT01390402|t||||
17190937|NCT00430300|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190938|NCT02754479|f||||f
17190939|NCT04181307|t||||
17190940|NCT00617201|f||||f
17190941|NCT00546871|f||OTHER|Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)|t
17190942|NCT03183518|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190943|NCT02299336|f||||f
17190944|NCT01359371|t||||
17190945|NCT02106442|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17190946|NCT04513522|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17190947|NCT04541303|t||||
17190948|NCT00589667|t||||
17190949|NCT03538041|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17190950|NCT00550394|t||||
17146338|NCT02587962|f||OTHER|The Investigator must submit any proposed publication or presentation to the Sponsor, along with information about the scientific journal or presentation forum, at least 30 days before submission of the publication or presentation (2 weeks for abstracts). The Investigator will comply with Sponsor requests to delete confidential information (other than the study results) and to withhold publication or presentation for an additional 60 days in order to obtain patent protection if necessary.|t
17146339|NCT00425672|f||||t
17146340|NCT00086996|f||||f
17146341|NCT02605395|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146342|NCT00184600|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones are reached. This includes the right to not release interim results of clinical trials, because that can invalidate results of the entire trial. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17146343|NCT03257722|f||||f
17146344|NCT04274686|f||||f
17146345|NCT00376623|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146346|NCT00286754|t||||
17146347|NCT00910663|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17146348|NCT02865850|f||||t
17190951|NCT00743444|f||OTHER|There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed. The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ.|t
17190952|NCT02452918|f||OTHER||t
17190953|NCT00807144|t||||
17190954|NCT01307267|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190955|NCT02568644|t||||
17190956|NCT05174013|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17190957|NCT05882812|f||||f
17190958|NCT00854906|t||||f
17190959|NCT00814346|f||||f
17190960|NCT02513238|f||||f
17190961|NCT05136443|f||||f
17190962|NCT02613871|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17190963|NCT00494442|f||OTHER|The sponsor can review and comment prior to publication. In order to ensure that the Sponsor will be able to make comments and suggestions where pertinent, material for public dissemination will be submittted to the Sponsor for review at least sixty (60) days prior to submission for publication, public dissemination, or review by a publication committee|t
17190964|NCT00604019|t||||
17190965|NCT00831415|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190966|NCT01241292|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17190967|NCT03145480|t||||
17190968|NCT03034915|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190969|NCT03861767|t||||
17190970|NCT01087762|f||GT60||t
17190971|NCT00813904|f||OTHER|ZymoGenetics (ZG) agreements vary by trial, but each states that presentation/publication (p/p) cannot disclose Confidential Information (CI), excluding trial results; p/p may not begin until the earlier of 18 months after study end, ZG/lead investigator publishes, or ZG notification that multicenter publication is not planned; ZG has specified time for draft review before submission/presentation and may delay or modify content, require CI removal, and delay p/p for patent application filing.|t
17190972|NCT01188499|f||||f
17146349|NCT02726581|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146350|NCT00552669|f||||f
17146351|NCT02024646|f||||f
17146352|NCT01844375|f||||f
17146353|NCT00176306|f||||f
17146354|NCT01772537|t||||
17146355|NCT01263704|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146356|NCT03020615|t||||
17146357|NCT00724477|f||OTHER|The results of this non-interventional study can be published or presented by members of the scientific committee after revision and agreement by Schering-Plough, and in such a way that the confidential information and industrial property are not revealed. Before publication or presentation, a copy of the final text must be sent by the member(s) of the scientific committee to Schering-Plough for comment.|t
17146358|NCT00252720|f||||f
17146359|NCT02325531|f||||f
17146360|NCT02514122|f||||f
17146361|NCT00112463|f||LTE60||t
17146362|NCT03287310|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146363|NCT01118312|f||||f
17146364|NCT03506386|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17146365|NCT02512393|t||||
17146366|NCT01546545|t||||
17146367|NCT00735904|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146368|NCT01390844|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17146369|NCT02543554|t||||
17146370|NCT03204539|t||||f
17146371|NCT05093205|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146372|NCT00818337|t||||
17146373|NCT03361228|f||OTHER|Clinical Study Agreement|t
17146374|NCT00360360|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17146375|NCT00401778|t||||
17146376|NCT00720330|t||||
17146377|NCT03693430|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17146378|NCT04185909|f||||t
17146379|NCT01417078|f||OTHER|Sponsor has right to review at least forty-five (45) days prior to the date of submission for publication or of public disclosure. Multi-center trials; publication shall be delayed until a publication of the multi-center results or until twelve (12) months have elapsed since the completion of the study, whichever occurs first.|t
17146380|NCT00580138|f||||f
17146381|NCT01709474|f||||f
17146382|NCT01874756|t||||
17146383|NCT03458871|t||||
17146384|NCT01223365|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17146385|NCT03567174|t||||
17146386|NCT03243630|f||||f
17190973|NCT00424762|f||||f
17190974|NCT02311972|t||||f
17190975|NCT01405924|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17190976|NCT03387319|t||||
17146387|NCT01387737|f||OTHER||t
17146388|NCT00911898|f||||f
17146389|NCT02817841|f||||t
17146390|NCT00934934|f||||f
17146391|NCT02087514|f||||f
17146392|NCT01746017|t||||
17146393|NCT00397488|t||||
17190977|NCT04333758|t||||f
17190978|NCT00770965|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17190979|NCT04296227|f||||f
17190980|NCT00888979|f||||f
17190981|NCT01391130|f||GT60||t
17190982|NCT03478696|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190983|NCT03615924|f||||t
17190984|NCT01891968|f||||f
17190985|NCT04141917|f||||f
17190986|NCT00367991|f||||f
17190987|NCT01184508|f||GT60||t
17190988|NCT01576523|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190989|NCT04707313|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17190990|NCT03165175|f||||f
17146394|NCT01458561|f||OTHER|Authorship of 1st publication (Primary Paper) determined by Sponsor. If Primary Paper not sub. for publication within 18 months of study completion, Investigator may publish individual publication/presentation - proposal must be provided to Sponsor for review and comment at least 30 days prior to submission date/public disclosure. Sponsor to review within 30 days of receipt and can remove proprietary/confidential info and/or require delay in publication or public disclosure for up to 30 days.|t
17190991|NCT00834834|f||||f
17190992|NCT00539292|f||||f
17190993|NCT02020616|f||GT60||t
17190994|NCT00748410|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17190995|NCT01071993|f||||f
17190996|NCT00305695|f||LTE60||t
17190997|NCT00147277|f||||f
17190998|NCT02031471|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146395|NCT01215981|t||||
17146396|NCT03075761|t||||
17146397|NCT00722124|t||||f
17146398|NCT00840632|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146399|NCT01294787|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17146400|NCT01725529|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17146401|NCT04927013|t||||
17146402|NCT01948258|t||||
17146403|NCT02262377|f||||f
17146404|NCT00878878|f||||f
17146405|NCT01721681|f||GT60||t
17146406|NCT00723528|f||OTHER|The disclosure restriction on Principle investigator is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.|t
17146407|NCT01993030|f||GT60||t
17146408|NCT03785548|t||||
17146409|NCT01710657|f||GT60||t
17146410|NCT03921294|f||OTHER|Sponsor wishes to review final study report prior to submission for publication.|t
17146411|NCT01033565|f||||f
17146412|NCT01591785|t||||
17146413|NCT00358449|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146414|NCT00546897|t||||
17146415|NCT00987948|t||||f
17146416|NCT02440308|t||||
17146417|NCT00374335|f||||f
17146418|NCT01375660|t||||
17146419|NCT00496964|f||||f
17146420|NCT00469417|f||||t
17146421|NCT00909610|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146422|NCT03585790|f||LTE60||t
17146423|NCT02337218|f||||f
17146424|NCT05327491|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146425|NCT05038293|f||||f
17146426|NCT02163837|f||||f
17146427|NCT02339558|f||LTE60||t
17146428|NCT00645762|f||GT60||t
17146429|NCT01247701|t||||
17146430|NCT04166630|f||||f
17146431|NCT00096447|f||LTE60||t
17146432|NCT00834743|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146433|NCT04088760|t||||
17146434|NCT04091971|f||||f
17146435|NCT05600322|f||||t
17146436|NCT01878825|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146437|NCT02472366|f||LTE60||t
17146438|NCT02728102|f||||f
17146439|NCT00830232|t||||f
17146440|NCT02419937|t||||
17190999|NCT00997386|t||||
17191000|NCT04970342|f||OTHER|The PIs must coordinate with the government (sponsor).|t
17191001|NCT01625013|t||||f
17191002|NCT00762619|f||LTE60||t
17191003|NCT00961636|f||OTHER|Publications derived from this study should include input from the investigator(s) and Sponsor personnel. Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results for their study site independently. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.|t
17146441|NCT02924883|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17146442|NCT01182415|t||||
17146443|NCT01981720|f||OTHER|The clinical trial agreement provided to the sites and Investigators contains a Publication paragraph that indicates the following: shall not, without the Sponsor's prior written consent, independently publish, present or otherwise disclose any results of or information pertaining to the trial until a multicenter publication is published, subject to certain limitations regarding timing and the confidentiality of unpublished data.|t
17146444|NCT00004562|f||OTHER|The NIH Public Access Policy ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication. To help advance science and improve human health, the Policy requires that these papers are accessible to the public on PubMed Central no later than 12 months after publication.|t
17146445|NCT02770820|t||||
17146446|NCT02336165|f||LTE60||t
17146447|NCT01054586|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146448|NCT02841033|f||||f
17146449|NCT03195491|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146450|NCT01314417|t||||f
17146451|NCT04239872|t||||
17146452|NCT02819323|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17146453|NCT03115177|t||||
17146454|NCT02642835|f||||f
17146455|NCT01185821|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146456|NCT02420210|t||||
17146457|NCT00296647|f||||f
17146458|NCT02519491|t||||
17146459|NCT01234103|f||||f
17146460|NCT00854100|f||OTHER|All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc|t
17146461|NCT04298918|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146462|NCT02606708|t||||f
17146463|NCT02110277|f||||f
17146464|NCT05087524|t||||
17146465|NCT03979079|f||||f
17146466|NCT02883452|f||||t
17146467|NCT03447262|f||OTHER||t
17146468|NCT00830206|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17191004|NCT00329732|t||||
17146469|NCT00328926|f||OTHER||t
17191005|NCT02551055|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17146470|NCT04123548|f||||t
17146471|NCT01171989|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146472|NCT00418184|f||OTHER||t
17146473|NCT02300103|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146474|NCT01015625|f||||f
17146475|NCT01256684|f||OTHER|Investigators shall provide to the SPONSOR 30 days prior to submission all documents for publication, presentation, etc that report any trial results. The SPONSOR shall have editorial rights on documents and the right to review/comment with regard to (1) proprietary information, (2) accuracy of the information, (3) correctness of the scientific evaluation/conclusions and (4) to ensure that the information is fairly balanced and in compliance with regulations.|t
17146476|NCT02377947|f||||f
17146477|NCT02674477|t||||f
17146478|NCT00267644|f||||f
17146479|NCT04459585|f||||f
17146480|NCT02098876|f||||f
17146481|NCT01061866|t||||f
17146482|NCT00772941|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146483|NCT04786184|t||||
17146484|NCT00834756|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146485|NCT01472341|f||OTHER|Each site can publish its own results without the results of other sites after the publication of the study or after 24 months from completion of publication. The author list will be established with the participating sites before the layout of the text to be published. The company will need to evaluate all the proposed summaries, manuscripts or presentations 60 days prior to publication. The revision made by Company could be accelerated in order to satisfy the guidelines concerning publication.|t
17146486|NCT03861845|t||||f
17146487|NCT02251886|f||||f
17146488|NCT04060147|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146489|NCT00578552|t||||
17146490|NCT02057458|f||||f
17146491|NCT01534520|t||||
17146492|NCT01783561|f||||f
17146493|NCT02979353|f||||f
17146494|NCT01079988|f||OTHER||t
17146495|NCT00585689|t||||
17146496|NCT00550537|t||||
17146497|NCT00268905|f||||f
17146498|NCT00617305|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146499|NCT01624363|t||||
17146500|NCT03459807|t||||
17146501|NCT04510285|t||||
17146502|NCT01406795|f||||f
17146503|NCT02563808|t||||
17146504|NCT03897088|f||||f
17146505|NCT00855738|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146506|NCT03097783|f||||t
17146507|NCT02392000|t||||
17146508|NCT04384978|f||||f
17146509|NCT03725605|f||OTHER|The PI has the right to publish the study results in scientific or other journals, or to present the study results at professional conferences or other meetings. The PI may use the study results solely for internal research and/or educational purposes and shall not externally publish or present any such results until the earlier of (i) the date of the first study results publication, agreed by the parties and (ii) the end of the 18 month period following the completion of the study.|t
17146510|NCT03555305|f||GT60||t
17146511|NCT00925054|f||GT60||t
17146512|NCT03286465|t||||
17146513|NCT03586726|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146514|NCT00965185|t||||f
17146515|NCT00323193|t||||
17146516|NCT02100228|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146517|NCT01320696|f||||f
17146518|NCT00322465|f||||f
17146519|NCT01073657|t||||
17146520|NCT01790581|f||||f
17146521|NCT00584922|t||||
17146522|NCT00183794|t||||
17146523|NCT03486990|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17146524|NCT02216071|f||||t
17146525|NCT00389064|f||OTHER|The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca|t
17146526|NCT00762307|f||||f
17146527|NCT02779543|t||||f
17146528|NCT02629094|t||||
17146529|NCT02648880|t||||
17146530|NCT03707912|f||||t
17146531|NCT02562378|f||||f
17146532|NCT01104025|t||||
17146533|NCT01811953|t||||f
17146534|NCT00371839|t||||
17146535|NCT01049334|f||LTE60||t
17146536|NCT00396279|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146537|NCT00517530|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146538|NCT00667095|t||||f
17146539|NCT01199848|f||||f
17146540|NCT01832259|t||||
17146541|NCT00905346|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17146542|NCT03351335|f||OTHER|Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.|t
17146543|NCT02071108|f||||f
17146544|NCT00773422|f||||f
17146545|NCT05612724|t||||
17146546|NCT03112863|f||||f
17146547|NCT04000815|f||||f
17146548|NCT00239577|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146549|NCT02631772|f||||f
17146550|NCT02736721|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146551|NCT03988803|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146552|NCT00840099|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17146553|NCT03021018|f||GT60||t
17146554|NCT01032083|f||||f
17146555|NCT01173211|f||LTE60||t
17146556|NCT02196766|f||OTHER|"Principal Investigators are NOT employed by the organization sponsoring the study.~There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The investigators will not be permitted to publish or present at scientific meetings results obtained from the clinical study without prior written consent from the sponsor."|t
17146557|NCT03342157|f||||f
17146558|NCT02269657|t||||
17146559|NCT00620074|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146560|NCT03450057|f||||f
17146561|NCT01838941|f||||f
17146562|NCT02822235|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17146563|NCT03214952|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17146564|NCT02968992|f||||f
17146565|NCT02246166|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146566|NCT03769896|t||||
17146567|NCT00377260|t||||
17146568|NCT00829530|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146569|NCT00840866|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17191006|NCT02023125|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191007|NCT02666742|f||||f
17191008|NCT02205307|f||||f
17146570|NCT04112823|t||||
17191009|NCT02041104|t||||
17191010|NCT01063517|f||LTE60||t
17191011|NCT01350804|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191012|NCT01713946|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191013|NCT04411082|f||||t
17146571|NCT00625443|f||OTHER||t
17191014|NCT02804594|t||||f
17191015|NCT03941912|f||||f
17191016|NCT04483856|f||||t
17146572|NCT01437501|t||||f
17191017|NCT03622580|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191018|NCT02221219|t||||
17191019|NCT01930045|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17191020|NCT02138006|t||||
17191021|NCT01122901|f||LTE60||t
17191022|NCT03557658|f||OTHER|The Investigator does not have the right to publish trial results.|t
17191023|NCT01147341|f||LTE60||t
17191024|NCT03280836|f||||f
17191025|NCT02808338|f||||f
17191026|NCT00057837|f||||f
17191027|NCT00588809|f||LTE60||t
17191028|NCT00463788|f||||f
17146573|NCT04121364|f||LTE60||t
17146574|NCT05452798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146575|NCT02678286|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17146576|NCT00280904|f||LTE60||t
17146577|NCT00234286|t||||
17146578|NCT01422538|f||||f
17146579|NCT01270503|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17146580|NCT02062580|f||||f
17146581|NCT05704426|t||||
17146582|NCT02481830|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146583|NCT04627038|f||||t
17146584|NCT00783367|t||||f
17146585|NCT04920929|f||GT60||t
17146586|NCT03956862|f||||t
17146587|NCT04365153|f||||f
17146588|NCT01363765|f||||f
17146589|NCT01938066|f||||f
17146590|NCT02601560|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17146591|NCT03500692|f||||f
17146592|NCT01880593|t||||
17146593|NCT02272777|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146594|NCT02066922|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17146595|NCT05275205|f||||f
17146596|NCT00440297|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146597|NCT02934347|t||||
17146598|NCT02039908|f||||f
17146599|NCT01802320|f||LTE60||t
17146600|NCT01066143|t||||
17146601|NCT05376319|t||||
17146602|NCT00942968|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146603|NCT01686451|f||LTE60||t
17146604|NCT01466166|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17146605|NCT00834535|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146606|NCT01340495|t||||
17146607|NCT02055963|t||||
17146608|NCT00667862|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17146609|NCT01819597|f||||f
17146610|NCT02495857|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17146611|NCT00654030|f||OTHER|Study chair (Dr. Edward Hirschowitz) is only party available to disclose, discuss, or publish trial results or information concerning the trial after completion.|t
17146612|NCT01435265|f||||f
17146613|NCT04605094|f||||t
17146614|NCT01900691|f||GT60||t
17146615|NCT02724462|t||||f
17146616|NCT00979303|t||||
17146617|NCT01026623|f||LTE60||t
17146618|NCT01644058|t||||
17146619|NCT00561834|t||||
17146620|NCT02128997|f||||f
17146621|NCT01969747|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146622|NCT02393417|f||||t
17146623|NCT02422264|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146624|NCT00603187|f||||f
17146625|NCT03874715|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17146626|NCT00875550|f||||f
17146627|NCT00851877|t||||
17146628|NCT00829673|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146629|NCT00573066|f||||f
17146630|NCT01034358|t||||f
17146631|NCT02473718|f||||f
17146632|NCT00829790|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146633|NCT01534663|t||||
17146634|NCT00627016|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17191029|NCT00360698|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17191030|NCT00831675|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17191031|NCT01059877|f||||f
17191032|NCT03024606|f||||f
17191033|NCT01692938|f||LTE60||t
17191034|NCT04598321|f||||f
17191035|NCT01667796|f||||f
17191036|NCT02547922|f||OTHER|The submission/document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17191037|NCT01867632|f||||f
17191038|NCT00739141|t||||
17191039|NCT02336438|t||||
17191040|NCT01317420|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191041|NCT03194958|f||||f
17191042|NCT00317226|f||LTE60||t
17191043|NCT01968226|t||||
17191044|NCT00886145|t||||
17191045|NCT02971488|f||||f
17191046|NCT00237770|f||||f
17191047|NCT04975308|f||GT60||t
17191048|NCT02709655|f||||f
17191049|NCT00102063|f||||f
17191050|NCT05082025|t||||
17191051|NCT04210180|f||||f
17191052|NCT01179334|f||OTHER|The embargo can be up to 6 months (equal to the 180 days), moreover if it is necessary the embargo period can be prolonged to expiry of priority year.|t
17191053|NCT05190419|f||||f
17146635|NCT03107091|f||GT60||t
17146636|NCT04567186|f||GT60||t
17146637|NCT01707420|f||||f
17146638|NCT01185548|f||GT60||t
17146639|NCT02331394|f||||f
17146640|NCT01313273|f||||f
17146641|NCT03687736|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17146642|NCT02459951|f||||f
17191054|NCT00919763|f||||t
17191055|NCT05216510|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17191056|NCT00256243|t||||f
17191057|NCT05061693|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17191058|NCT01152190|f||GT60||t
17191059|NCT03823911|f||||f
17191060|NCT00547118|t||||
17191061|NCT01335542|t||||
17191062|NCT00442117|f||||f
17191063|NCT01568073|f||OTHER||t
17191064|NCT04009577|f||OTHER||t
17191065|NCT02165761|f||LTE60||t
17191066|NCT00176839|t||||
17191068|NCT00841035|f||||f
17191069|NCT03072953|f||OTHER||t
17191070|NCT02994654|f||||f
17191071|NCT00385801|f||||f
17191072|NCT01190566|f||||f
17146643|NCT00102440|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17146644|NCT02255097|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17146645|NCT02294253|f||||f
17146646|NCT01808794|f||||f
17146647|NCT01010542|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146648|NCT01745120|f||LTE60||t
17146649|NCT02129426|t||||
17146650|NCT00579670|f||OTHER||t
17146651|NCT00850174|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146652|NCT01900626|t||||
17146653|NCT00635492|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146654|NCT01702987|f||||f
17146655|NCT02017223|f||||f
17146656|NCT04263649|f||OTHER|PI submits to Sponsor for review a draft 90 days prior to submission of the draft for publication.Draft shall not divulge any confidential info.Sponsor has the right to:review and make comments on any proposed publication; withhold the use of its name in connection with publication;make any results from the study known to its customers and governmental agencies prior to publication.The first publication of the study results shall be made in conjunction with the results from the other PIs.|t
17146657|NCT04503174|t||||
17146658|NCT05169710|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17146659|NCT00221299|f||||f
17146660|NCT02729714|t||||
17146661|NCT00693628|t||||
17146662|NCT00846495|f||||f
17146663|NCT01686438|t||||
17146664|NCT02431494|t||||
17146665|NCT06358820|f||||f
17146666|NCT01124175|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17191073|NCT05328297|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17146667|NCT00486863|f||LTE60||t
17146668|NCT00355797|f||LTE60||t
17146669|NCT00218257|t||||
17146670|NCT04408586|t||||
17146671|NCT00462345|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146672|NCT00428298|t||||f
17146673|NCT00070291|f||||f
17146674|NCT00520130|f||||f
17146675|NCT03547622|t||||f
17146676|NCT02028715|f||||f
17146677|NCT04915755|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17146678|NCT02533258|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146679|NCT01149473|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146680|NCT02059070|t||||f
17146681|NCT01954394|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17146682|NCT04089735|f||OTHER|The Institutions and Investigators participating in this trial shall have no right to publish or present the results of this study without the prior written consent of the Sponsor.|t
17146683|NCT01439880|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146684|NCT02956460|f||OTHER|Disclosure restriction on the PI is that the sponsor should be notified of any use of study data for results communication.|t
17146685|NCT02598089|f||||f
17146686|NCT00834067|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17146687|NCT04129346|f||||f
17146688|NCT01083693|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17146689|NCT02332863|f||||f
17191074|NCT01613118|f||||t
17146690|NCT00717405|f||OTHER|Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191075|NCT01072006|t||||f
17146691|NCT04107675|f||||f
17146692|NCT03999684|f||||f
17146693|NCT00836056|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146694|NCT00501345|t||||f
17146695|NCT01029340|f||GT60||t
17146696|NCT02648347|f||||t
17146697|NCT01639222|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17146698|NCT03546842|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17146699|NCT01884519|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146700|NCT00214097|f||||t
17146701|NCT01870856|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17146702|NCT02352259|f||||f
17146703|NCT01265056|t||||f
17146704|NCT01416584|f||||f
17146705|NCT01650350|f||||f
17146706|NCT03117296|t||||
17146707|NCT02082392|f||||f
17191076|NCT03544515|t||||
17146708|NCT00833937|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146709|NCT04419311|f||||f
17146710|NCT00465270|f||||f
17146711|NCT03233724|f||||f
17191077|NCT03175172|f||OTHER|The only disclosure restriction is that study results will first be published in a joint multi-center paper unless (a) written confirmation is provided to the site or PI indicating that there will be no multi-center publication, or (b) at least 15 months have passed after the completion of data analysis at all study sites. Publications will be submitted for sponsor review ≥ 30 days prior to the publication date. Sponsor cannot require changes to the communication or extend the embargo.|t
17191078|NCT03169244|t||||
17146712|NCT03135834|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146713|NCT01045161|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17146714|NCT01964092|f||||f
17146715|NCT02605928|f||||f
17146716|NCT00998374|f||||f
17146717|NCT02612337|f||LTE60||t
17146718|NCT02124122|f||||f
17146719|NCT02242201|t||||
17146720|NCT00017953|f||||f
17146721|NCT00408070|t||LTE60||t
17146722|NCT02374853|t||||
17146723|NCT05844553|t||||
17146724|NCT02281084|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17191079|NCT01662336|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191080|NCT02986178|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo. The sponsor can require changes to the communication with respect to confidential information that is not necessary for the complete and accurate presentation and interpretation of the study results.|t
17191081|NCT03622593|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146725|NCT01697696|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17146726|NCT01424644|f||GT60||t
17146727|NCT05593965|t||||f
17146728|NCT01077596|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191082|NCT03762668|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191083|NCT00178399|t||||
17191084|NCT01393119|f||||f
17191085|NCT02544152|f||||t
17191086|NCT00534937|f||LTE60||t
17191087|NCT01759264|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191088|NCT00516321|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191089|NCT05674136|t||||
17191090|NCT02027558|t||||
17191091|NCT02139046|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17191092|NCT02383472|f||||f
17191093|NCT01111526|t||||
17191094|NCT02013830|f||OTHER|The Study being conducted under this agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request the Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191095|NCT02015546|f||||f
17191096|NCT04424641|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191097|NCT00597038|f||||f
17191098|NCT04238429|f||||f
17191099|NCT03245580|f||||f
17191100|NCT02207972|f||||f
17191101|NCT01426269|f||LTE60||t
17191102|NCT04580160|f||||f
17191103|NCT00186186|f||||f
17191104|NCT01337635|f||||f
17191105|NCT03176654|t||||
17146729|NCT03110003|t||||
17146730|NCT04732195|t||||
17146731|NCT02372630|f||||t
17191106|NCT01402531|t||||
17191107|NCT03959241|f||||f
17191108|NCT01145885|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191109|NCT03691428|f||||f
17191110|NCT02527148|f||OTHER|Discloser must give at least 40 days notice to Sponsor including a copy of the proposed publication. The Sponsor can then provide comments (which Discloser is not bound to follow), request delay of publication by no more than 120 days to allow for Sponsor to protect its intellectual property, or request that the Discloser remove certain proprietary or confidential information from the study (other than the results of the study).|t
17191111|NCT01140048|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17191112|NCT01831791|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191113|NCT00494780|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191114|NCT02203630|t||||
17191115|NCT00908830|t||||
17191116|NCT03897348|t||||f
17191117|NCT04054635|t||||
17191118|NCT00891930|f||||t
17191119|NCT03040661|t||||
17146732|NCT02024932|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191120|NCT00846066|t||||
17146733|NCT02445339|t||||
17146734|NCT03020641|f||||f
17146735|NCT03041025|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146736|NCT03962348|t||||f
17191121|NCT01574807|f||||f
17191122|NCT02537522|f||GT60||t
17191123|NCT01323777|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191124|NCT00392054|f||||f
17191125|NCT01493778|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17191126|NCT00857649|f||OTHER|Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and H. Lundbeck A/S. Manuscripts and abstracts must be sent to H. Lundbeck A/S at least one month prior to submission for publication or presentation.|t
17191127|NCT00833365|t||||f
17191128|NCT04177394|f||||f
17191129|NCT00258895|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17191130|NCT00630786|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191131|NCT01649180|f||||f
17191132|NCT00233519|f||OTHER|National Institutes of Health (NIH) can review the content of planned submissions prior to public release (3 weeks notice requested) to insure integrity of the NIH and the Data Safety Monitoring Board (DMSB)staff.|t
17146737|NCT02963259|f||||t
17191133|NCT03603717|f||||f
17191134|NCT00939991|t||||
17191135|NCT02355158|f||GT60||t
17191136|NCT04668339|f||||f
17191137|NCT01731041|t||||
17191138|NCT01904071|t||||
17191139|NCT02860286|f||||t
17191140|NCT00002842|t||||
17191141|NCT03675581|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191142|NCT03557008|t||||
17191143|NCT00701896|f||||f
17191144|NCT01113931|f||LTE60||t
17191145|NCT02567656|f||||t
17191146|NCT01424397|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191147|NCT01241435|f||GT60||t
17191148|NCT00980330|f||GT60||t
17191149|NCT00666276|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191150|NCT03299816|f||||f
17191151|NCT03520413|t||||
17191152|NCT02311907|t||||
17191153|NCT04584099|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17191154|NCT04303156|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17191155|NCT05001945|f||GT60||t
17191156|NCT02448446|t||||
17191157|NCT02425111|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17191158|NCT04283552|t||||
17191159|NCT00545077|f||LTE60||t
17191160|NCT02202499|t||||
17191161|NCT00535145|f||GT60||t
17191162|NCT02200770|f||OTHER|Viela Bio has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multicentre publication.|t
17191163|NCT01647438|f||||f
17191164|NCT01224015|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191165|NCT00712335|f||||f
17191166|NCT01996917|t||||
17191167|NCT03401112|f||||t
17191168|NCT03475316|t||||
17191169|NCT00424645|t||||f
17146738|NCT00939003|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17146739|NCT02131129|f||||f
17146740|NCT00727961|f||||f
17146741|NCT02865122|t||||
17146742|NCT00831428|t||||
17191170|NCT02555215|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17191171|NCT00529789|f||GT60||t
17191172|NCT01430611|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17191173|NCT00959946|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191174|NCT02348658|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17191175|NCT01202955|t||||f
17191176|NCT02115139|f||LTE60||t
17191177|NCT01909778|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191178|NCT03687892|t||||
17191179|NCT02471755|f||||f
17191180|NCT01591733|t||||
17191181|NCT05019144|f||||f
17191182|NCT04740164|t||||
17191183|NCT05323734|f||LTE60||t
17191184|NCT02486718|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâ€™s intellectual property rights.|t
17191185|NCT02248480|f||GT60||t
17191186|NCT01595321|t||||
17191187|NCT04504916|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17191188|NCT02950896|t||||
17191189|NCT00373529|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17191190|NCT01600729|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191191|NCT01579916|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17191192|NCT02763124|t||||
17191193|NCT02247063|t||||
17191194|NCT01123928|t||||
17191195|NCT00732381|f||LTE60||t
17191196|NCT04090190|f||||f
17191197|NCT00457691|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191198|NCT00042224|t||||
17146743|NCT01421277|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17146744|NCT01530880|t||||
17146745|NCT02713425|f||||f
17146746|NCT01015703|f||||f
17146747|NCT00834418|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146748|NCT01705574|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146749|NCT03049215|t||||f
17146750|NCT00200785|f||||f
17191199|NCT00028093|t||||
17191200|NCT01121549|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191201|NCT00493649|f||||f
17191202|NCT05219253|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17146751|NCT00089661|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17146752|NCT01273805|f||||f
17146753|NCT02647944|t||||
17146754|NCT01246076|t||||
17146755|NCT02760368|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17146756|NCT03375463|f||GT60||t
17146757|NCT01602419|f||||f
17146758|NCT01792635|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146759|NCT01860521|f||||f
17146760|NCT00904423|f||||f
17146761|NCT02902211|t||||f
17146762|NCT03025945|f||||f
17146763|NCT01513174|f||||f
17146764|NCT02413320|f||||f
17146765|NCT03617523|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17146766|NCT02682784|t||||
17146767|NCT00467363|t||||
17146768|NCT04533594|t||||
17146769|NCT02757105|f||OTHER|The PI agree that the Sponsor shall have the right to the first publication of the results of the Study. Following the first publication, the PI may publish data or results from the Study; subject to Sponsor for review and approval in writing at least sixty (60) days prior to the date of the publication. Sponsor may require changes and may extend the embargo to protect its intellectual property or other proprietary interests and to allow for the taking actions for this purpose.|t
17146770|NCT01401647|f||GT60||t
17146771|NCT00752973|f||||f
17146772|NCT05428020|f||||f
17146773|NCT00473330|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146774|NCT03502148|f||||f
17191203|NCT03086369|f||GT60||t
17191204|NCT02639286|t||||
17191205|NCT04603924|f||||f
17146775|NCT01975948|f||||f
17146776|NCT01675765|f||OTHER|"Disclosure restriction - study results first published in a joint multi-center paper unless (a) no multi-center publication, or (b) ≥18 months has passed since completion of the study. Thereafter, Investigator may publish provided that Investigator: (i) provides a copy of the publication to Aduro ≥ 30 days in advance of submission for publication; (ii) deletes Aduro Confidential Information (other than the Study results) and (iii) submission may be delayed up to 90 days to permit IP filings."|t
17146777|NCT02834663|f||||f
17146778|NCT03335761|f||||f
17146779|NCT01723397|t||||
17146780|NCT02196675|f||OTHER|Prior to submission for publication or presentation, the Institution will provide Sponsor with at least sixty (60) days for review of a manuscript. Notwithstanding the foregoing, no paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written consent.|t
17146781|NCT02711852|f||||f
17146782|NCT00537979|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17146783|NCT02009163|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17146784|NCT02453386|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17146785|NCT00833586|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146786|NCT01304641|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146787|NCT04544787|t||||
17191206|NCT03594500|t||||
17191207|NCT01765543|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191208|NCT05876949|f||||t
17191209|NCT03644849|f||||f
17191210|NCT00071799|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i) furnish the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17191211|NCT00979992|f||LTE60||t
17191212|NCT03593213|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191213|NCT01269749|t||||
17191214|NCT01254019|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191215|NCT00568854|f||||f
17191216|NCT04153435|t||||
17191217|NCT00665444|f||||f
17191218|NCT00717626|f||||f
17191219|NCT00638963|f||OTHER|The principal investigator (PI) agrees not to publish or publicly present any interim results of the Study without prior written consent of the sponsor. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication or presentation to permit the sponsor to review copies of abstracts or manuscripts for publication in accordance with provisions of laws related to protection of sensitive personal data and patentability of inventions.|t
17191220|NCT01240330|f||||f
17191221|NCT03260140|t||||
17191222|NCT01444417|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191223|NCT02423291|f||||f
17191224|NCT04018924|f||||f
17191225|NCT04925765|f||||f
17191226|NCT01214824|f||GT60||t
17191227|NCT05283395|f||OTHER||t
17191228|NCT03302741|t||||
17191229|NCT03144674|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17191230|NCT00206375|t||||f
17191231|NCT03368664|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17191232|NCT00837616|f||||f
17191233|NCT00605904|t||||
17191234|NCT03505099|f||OTHER|Depending on local requirements, Sponsor's consent necessary before publication of study, or Sponsor can review results communications before public release with a right to request changes to communications regarding trial results between 40 to 60 and up to 90 or 120 days, as applicable, from the time submitted to Sponsor for review to remove references to Sponsor's Confidential Information or delay results communications to permit Sponsor to obtain appropriate Intellectual Property protection.|t
17191235|NCT04178941|t||||
17146788|NCT02155465|t||||
17146789|NCT04395222|t||||
17146790|NCT02388191|f||||f
17146791|NCT03197883|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146792|NCT03686033|f||||t
17146793|NCT03031847|f||||f
17146794|NCT00858845|t||||
17146795|NCT04841317|t||||
17146796|NCT04916548|t||||
17146797|NCT01353664|f||OTHER|There is an agreement between the Principal Investigator and the Sponsor that restricts the PIs rights to publish trial results after the trial is completed. Upon investigator submission of a publication to Celgene, Celgene will complete its review within 60 days after receipt of the publication. Upon Celgene's request, the publication shall be delayed up to 90 additional days to enable Celgene to secure intellectual property protection that would be affected by such proposed publication.|t
17146798|NCT01114893|f||||f
17146799|NCT01085825|t||||
17146800|NCT02089997|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17146801|NCT02441309|t||||
17191236|NCT01810263|f||||f
17191237|NCT00696618|f||||f
17191238|NCT00688519|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191239|NCT00940537|f||||f
17191240|NCT01685606|f||||f
17146802|NCT00415363|f||GT60||t
17146803|NCT01944930|f||||f
17146804|NCT02444715|f||||f
17146805|NCT00095212|t||||f
17146806|NCT02335658|f||||f
17146807|NCT05341622|t||||f
17146808|NCT02658084|t||||
17146809|NCT02305758|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17146810|NCT01379664|t||||
17146811|NCT02032888|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146812|NCT04494867|f||||f
17146813|NCT03616106|t||||f
17146814|NCT02298322|f||||f
17146815|NCT03206177|t||||
17146816|NCT00091260|t||||
17146817|NCT04611789|f||GT60||t
17146818|NCT03880266|f||||f
17146819|NCT03161405|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17146820|NCT00837486|f||OTHER|The disclosure restrictions on the PI allow for the sponsor to review results communications prior to public release and to embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to sponsor for review. The sponsor is also allowed to require changes for technical correctness and to protect confidential information, copyrightable or patentable material; and when reasonably requested, extend the embargo up to an additional 90 days.|t
17146821|NCT02655679|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191241|NCT01353963|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191242|NCT04789408|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17191243|NCT04036058|t||||
17191244|NCT02999477|t||||
17191245|NCT00573833|t||||
17191246|NCT03995069|t||||
17191247|NCT03619226|t||||
17191248|NCT03351075|f||||f
17191249|NCT00925899|f||||f
17191250|NCT02396316|f||||f
17191251|NCT00566735|t||||f
17191252|NCT00402896|t||||
17191253|NCT00925587|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191254|NCT00490802|f||||f
17191255|NCT03454529|t||||
17191256|NCT01582100|f||||f
17191257|NCT01078116|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17191258|NCT02334436|f||||f
17191259|NCT01177670|f||LTE60||t
17191260|NCT02663297|f||OTHER|Subcontractor agrees that the first publication of the Study results will be made by Institution as a multi-site publication. Subcontractor can publish its site-specific results after Institution's publication, 12 months post-study completion, or upon Institution's notice of completion. Subcontractor must provide Institution 30 days for manuscript review and may delay publication for 45 days for institution's patent filing. Institution will register the Study and post results as required by law.|t
17191261|NCT04532528|t||||
17191262|NCT04589689|t||||
17146822|NCT01577381|f||OTHER|Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191263|NCT03061474|t||||
17191264|NCT02888080|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17191265|NCT00845832|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191266|NCT01665092|f||||t
17191267|NCT00189202|t||||
17191268|NCT01039688|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191269|NCT00668863|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191270|NCT01883908|t||||
17146823|NCT02186821|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146824|NCT04189848|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17146825|NCT00819741|f||OTHER|Novo Nordisk reserves the right to not release data until specified milestones, e.g. when the clinical trial report is available. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17146826|NCT00119015|f||||f
17146827|NCT01313780|f||||f
17191271|NCT01296191|t||||
17191272|NCT03844269|f||GT60||t
17191273|NCT01733238|f||||t
17191274|NCT00101010|f||||f
17191275|NCT01271452|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo|t
17191276|NCT00869323|f||||f
17191277|NCT01135511|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191278|NCT00971789|f||||f
17191279|NCT02384070|f||||f
17191280|NCT00376363|f||||f
17191281|NCT01691690|f||||f
17191282|NCT01755949|t||||
17191283|NCT00640250|f||||f
17191284|NCT05082935|t||||
17191285|NCT02122445|f||||f
17191286|NCT02957136|t||||
17191287|NCT01595061|f||LTE60||t
17191288|NCT00960141|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191289|NCT00857545|f||||f
17191290|NCT00566527|f||OTHER|Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).|t
17191291|NCT00457743|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17191292|NCT00356265|f||||f
17191293|NCT01837966|f||||f
17191294|NCT03293498|f||||t
17191295|NCT01278394|f||OTHER|Institution or Principal Investigator may only publish Study results after: (i) the results of the multicenter Study in its entirety have been publicly disclosed by the Sponsor in an abstract, manuscript or presentation form, or (ii) two (2) years after conclusion of the Study at all sites, whichever is first to occur.|t
17191296|NCT00818805|f||||f
17191297|NCT01236560|f||LTE60||t
17191298|NCT00664430|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17146828|NCT03235739|f||||t
17146829|NCT03797872|f||||f
17146830|NCT00834522|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146831|NCT00834249|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146832|NCT01163461|t||||
17146833|NCT02146105|f||||f
17191299|NCT05444244|f||||f
17191300|NCT01792830|t||||
17191301|NCT01198028|t||||
17191302|NCT01576952|f||OTHER||t
17146834|NCT05755282|f||LTE60||t
17146835|NCT04089917|f||||f
17146836|NCT02476994|f||||f
17146837|NCT05025345|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17146838|NCT01558635|f||LTE60||t
17146839|NCT03699020|f||||f
17146840|NCT02246920|f||OTHER|PI may not publish the results of this generic (ANDA) trial without sponsor review and approval.|t
17191303|NCT00658996|f||OTHER||t
17191304|NCT02079844|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17191305|NCT01420549|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and the period of this evaluation is at least 45 days in advance. The sponsor can require changes to the communication or cannot approve it.|t
17191306|NCT00981630|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17146841|NCT04860804|f||||f
17146842|NCT00448019|f||LTE60||t
17146843|NCT02543203|f||LTE60||t
17146844|NCT02077465|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146845|NCT01827163|t||||
17146846|NCT03075553|t||||
17191307|NCT06630390|t||||
17191308|NCT04120454|t||||
17191309|NCT04926181|t||||
17146847|NCT03620747|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17146848|NCT02714062|f||OTHER|The PI may publish the result of the study 12 months or longer after termination of the study. The PI will provide the sponsor a copy of any proposed publication at least 30 days prior to submission for publication.|t
17191310|NCT00683696|f||||f
17191311|NCT05636332|f||||f
17191312|NCT03648762|f||||f
17146849|NCT02294604|f||||f
17191313|NCT01175317|t||||
17191314|NCT04676334|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17191315|NCT03795194|t||||
17191316|NCT03567252|t||||
17146850|NCT01780870|f||||f
17146851|NCT02355886|f||||f
17146852|NCT01200810|f||LTE60||t
17146853|NCT00365846|f||||f
17146854|NCT02477202|t||||
17191317|NCT01040689|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17191318|NCT01185561|t||||
17191319|NCT02616900|f||LTE60||t
17191320|NCT02499159|f||||f
17191321|NCT02601820|t||||
17191322|NCT02242487|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.|t
17191323|NCT01599793|t||||
17191324|NCT01296815|f||||f
17191325|NCT02115828|t||||
17191326|NCT02564744|f||OTHER|Any publication or scientific communication related to this study can only take place once an agreement between the Sponsor and the Investigator has been reached.|t
17191327|NCT03122236|f||||f
17191328|NCT00508924|f||OTHER||t
17191329|NCT02755805|t||||
17191330|NCT02369484|f||||f
17191331|NCT02178241|f||LTE60||t
17191332|NCT02252042|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17146855|NCT00904215|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17146856|NCT00960297|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17146857|NCT05763147|f||||t
17146858|NCT01299454|f||||f
17146859|NCT01891994|t||||
17146860|NCT03965091|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17146861|NCT00982397|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PIs may not publish single-site data until the main multi-site publication has occurred."|t
17191333|NCT02658240|t||||
17191334|NCT01460290|f||||f
17191335|NCT01035658|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17191336|NCT01190007|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191337|NCT00475319|f||||f
17191338|NCT01394510|f||||f
17146862|NCT02363803|t||||
17146863|NCT03140631|t||||
17191339|NCT00439569|f||OTHER|The Publication Policy for the National Institute of Neurological Disorders and Stroke (NINDS) Pilot Therapeutic Trials Network (NPTUNE) outlines procedures for the development and review of concept sheets, abstracts, publications,presentations. Investigators must submit an application to the NPTUNE Publications Committee for the use of data. A Writing Committee, appointed by the Publications Committee,is responsible for initiating, coordinating, and approving publications and presentations.|t
17191340|NCT02755116|f||||f
17191341|NCT01124734|f||||f
17191342|NCT02214160|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17146864|NCT02169115|f||||f
17191343|NCT02423798|f||GT60||t
17146865|NCT02159950|t||||
17191344|NCT01063972|f||||f
17146866|NCT00003659|t||||
17146867|NCT01312844|t||||
17191345|NCT00634621|f||||f
17191346|NCT01510717|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191347|NCT01264679|f||OTHER|If there is no multi-site publication within 18 months after the Study has been completed or terminated at all Study sites, and all data has been received by Sponsor, the Site and SMO shall have the right to publish its results from the Study for non-commercial purposes, if submitted to Sponsor for review 60 days prior to submission of publication. Publication must remove all confidential information and may be delayed by up to 120 days to allow Sponsor to protect its interests.|t
17191348|NCT02476409|t||||
17146868|NCT02648438|f||OTHER|If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.|t
17191349|NCT00275392|t||||
17191350|NCT00468052|t||||
17191351|NCT03189589|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17146869|NCT03138967|t||||
17191352|NCT02204982|f||||t
17191353|NCT00159783|f||OTHER|"If study is part of a multicenter trial, Investigator agrees that the first publication is to be a joint publication covering all centers. However, if a joint manuscript has not been submitted for publication within 12 mos of completion or termination of study at all participating sites, Investigator is free to publish separately.~The sponsor should review any publication prior to submission for publication to ensure no confidential information is released inadvertently."|t
17191354|NCT02928224|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191355|NCT00468910|f||LTE60||t
17191356|NCT01576484|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17146870|NCT04400890|t||||
17146871|NCT03925532|t||||
17146872|NCT02258074|f||||f
17146873|NCT00723710|f||||f
17146874|NCT04405570|f||OTHER|PI is requested to obtain written consent from the Sponsor before anything relating to the study can be published.|t
17191357|NCT00581854|t||||
17191358|NCT01390818|f||OTHER||t
17146875|NCT04499963|t||||
17146876|NCT03444090|f||||f
17146877|NCT01208337|t||||
17146878|NCT02399917|t||||
17146879|NCT02107300|t||||
17146880|NCT03663179|t||||
17146881|NCT03226522|f||||t
17146882|NCT00984126|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17146883|NCT01001208|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial resul|t
17146884|NCT01864174|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146885|NCT02739997|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17146886|NCT00468286|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17146887|NCT02158663|t||||t
17146888|NCT00741858|f||||f
17146889|NCT02738086|t||||
17146890|NCT03552393|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17146891|NCT02308475|t||||f
17191359|NCT01943799|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146892|NCT02414152|f||||f
17146893|NCT02601625|f||OTHER|All of the study information and data collected during the study are confidential and the property of AstraZeneca. After completion of the study, the investigator may prepare a joint publication with AstraZeneca. The investigator must undertake not to submit any part of the individual data from this study for publication without prior consent of AstraZeneca at a mutually agreed time.|t
17146894|NCT00359281|f||OTHER||t
17146895|NCT04887415|t||||
17146896|NCT01415986|f||||f
17146897|NCT03792477|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146898|NCT01681745|f||||f
17146899|NCT00840411|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146900|NCT01424293|f||||f
17146901|NCT01985308|f||||f
17146902|NCT03373162|f||LTE60||t
17146903|NCT00576056|f||||f
17191360|NCT04594759|t||||
17191361|NCT03811574|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17191362|NCT01832480|f||||f
17191363|NCT04923724|f||||f
17191364|NCT00958633|f||||f
17191365|NCT03994705|f||||f
17191366|NCT02601170|f||||f
17191367|NCT02674750|f||OTHER||t
17191368|NCT01597258|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191369|NCT01415349|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17191370|NCT01616459|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191371|NCT04980755|f||||f
17191372|NCT03215095|t||||
17191373|NCT00304031|f||||f
17191374|NCT01188655|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146904|NCT01854047|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17191375|NCT02135679|t||||
17191376|NCT04112069|f||||f
17191377|NCT01875848|t||||
17191378|NCT02189252|f||||f
17191379|NCT00840177|f||LTE60||t
17191380|NCT01391832|f||||f
17191381|NCT01154985|f||||f
17146905|NCT01051570|t||||f
17146906|NCT04322500|f||||f
17146907|NCT02847650|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146908|NCT03818581|f||||f
17146909|NCT02517294|f||||f
17146910|NCT02096211|f||GT60||t
17146911|NCT01281501|t||||
17146912|NCT00519194|f||||f
17146913|NCT03165994|f||||t
17146914|NCT02996591|t||||
17146915|NCT00665470|f||||f
17146916|NCT00738049|f||||f
17191382|NCT03345901|f||||f
17146917|NCT00934050|f||GT60||t
17146918|NCT00461786|f||GT60||t
17146919|NCT00835991|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146920|NCT02149420|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146921|NCT03612960|f||||f
17146922|NCT02378935|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17146923|NCT00272779|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17146924|NCT00561015|f||OTHER|As per revised Protocol dated 14 Feb 2008, Investigator may not submit for publication or presentation, the results of trial without prior written consent of Sponsor. The Investigator agrees to allow at least 45 days for Sponsor to review pre-publication manuscript prior to submission to Publisher. In accordance with generally recognized principles of scientific collaboration, co-authorship with any company personnel will be discussed and mutually agreed upon before submission to Publisher.|t
17146925|NCT03616535|f||||f
17191383|NCT00722046|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191384|NCT02164240|f||||f
17191385|NCT00686855|t||||
17191386|NCT00085436|f||||f
17191387|NCT01668940|f||||f
17191388|NCT02731755|t||||
17191389|NCT01292252|t||||
17191390|NCT00414544|f||OTHER|Study results were presented and published at national meetings. Standard confidentiality agreements were signed by PIs for company confidential information.|t
17191391|NCT00373386|f||||f
17191392|NCT00799396|t||||
17191393|NCT01556724|f||||f
17191394|NCT01318382|f||OTHER|The investigator agrees to provide copies of abstracts or manuscripts for publication that report any results of the trial to the Sponsor 45 days prior to submission for publication or presentation.|t
17191395|NCT01867216|f||GT60||t
17191396|NCT01599104|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191397|NCT00019747|f||||f
17191398|NCT00714714|f||LTE60||t
17191399|NCT01925469|t||||f
17191400|NCT00773370|f||||f
17191401|NCT03573518|f||OTHER|As Study is a Multi-centre Study, no Publication of the Study results may be made until Publication of the results of the Multi-centre study or 2 years after Study Completion, whichever is sooner.|t
17191402|NCT01308567|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17191403|NCT01714492|t||||
17191404|NCT01437605|t||||
17191405|NCT01112670|f||||f
17146926|NCT02440711|f||||f
17146927|NCT01980771|f||||f
17146928|NCT01631331|f||||f
17146929|NCT03199872|f||||f
17146930|NCT00163657|f||LTE60||t
17146931|NCT03935880|t||||
17191406|NCT00779870|t||||
17191407|NCT01149369|f||||f
17191408|NCT02593149|f||||f
17191409|NCT01571557|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191410|NCT01636687|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17146932|NCT02563561|f||||f
17146933|NCT04347018|f||||f
17191411|NCT02771899|t||||f
17191412|NCT03835819|t||||
17191413|NCT01254188|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17191414|NCT03482011|f||GT60||t
17191415|NCT04221828|f||||f
17191416|NCT00995904|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191417|NCT01691326|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17191418|NCT05609032|t||||
17146934|NCT02718326|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17146935|NCT03122535|t||||
17191419|NCT02261467|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191420|NCT01243619|f||||f
17191421|NCT06243796|t||||
17191422|NCT00433199|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment.|t
17146936|NCT02646124|t||||
17146937|NCT03040362|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17191424|NCT00262730|f||||f
17191425|NCT01170962|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17191426|NCT05714696|f||||f
17191427|NCT02407249|f||OTHER|Manuscripts prepared for publication will be submitted to sponsor for review and comments prior to submission to the publisher. This condition should not be construed as a means of restricting publication but is intended solely to assure mutual concurrence regarding data, evaluations, and conclusion, to provide an opportunity to share with the investigator any new and/or unpublished information of which he/she may be unaware, and to assure regulatory compliance of the results presented.|t
17191428|NCT00589277|t||||f
17191429|NCT01460446|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191430|NCT00542789|f||OTHER||t
17191431|NCT00808405|f||||f
17191432|NCT00636207|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17191433|NCT03109795|f||||f
17191434|NCT01641198|t||||f
17191435|NCT01396837|f||||f
17191436|NCT02594735|f||||f
17146938|NCT00857454|f||GT60||t
17191437|NCT02529995|f||GT60||t
17191438|NCT04567407|t||||
17191439|NCT01316263|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17191440|NCT01075217|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. For one site, there is a Clinical Trial Cooperative Research and Development Agreement (CRADA) with a restriction of 180 days after pooled data set is published by the sponsor or 180 after data lock of the complete data.|t
17191441|NCT02969863|t||||
17191442|NCT03737240|f||||f
17191443|NCT01068743|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period of \<= 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trail's primary publication.|t
17146939|NCT03154047|f||OTHER|The PI, institution and the sponsor have agreed that the PI and institution may publish or disclose study results from their site after the earlier of (a) publication of the complete multicenter study results or (b) 18 months after database lock for the multicenter study. The sponsor has at least 45 days to review a proposed publication and may request deletion of confidential information and up to 60 days additional delay to obtain patent protection.|t
17146940|NCT02436005|f||||f
17146941|NCT00573443|f||LTE60||t
17146942|NCT00804856|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146943|NCT01796171|f||LTE60||t
17146944|NCT00418561|f||OTHER|If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17146945|NCT00829309|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146946|NCT01036009|t||||
17146947|NCT02322593|f||||t
17146948|NCT00455312|f||||f
17146949|NCT01693523|t||||
17146950|NCT03343535|f||OTHER|Site shall have right to publish results. To balance this right with TransMedics' (TM proprietary interests, site will submit manuscripts intended for publication for TM's review at least 30d prior to submission date. TM will complete its review within 30d of receipt. TM may request that site delete from its manuscripts any reference to TM confidential information and site shall promptly comply with such request. After 60d period, site will have right to publish manuscript, as amended by TM.|t
17146951|NCT00085293|f||LTE60||t
17146952|NCT02659150|f||||f
17146953|NCT01215279|f||OTHER|The Institutions or Investigators were permitted to publish or present the study results from their site (or the overall results), providing the article or presentation was submitted to and approved by AstraZeneca beforehand.|t
17146954|NCT00274781|f||||f
17146955|NCT05342597|f||OTHER||t
17191444|NCT00364013|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191445|NCT01149512|f||||f
17191446|NCT00585533|t||||
17191447|NCT00523237|t||||
17191448|NCT01369498|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17191449|NCT02539108|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17146956|NCT04314362|f||||f
17146957|NCT00202722|t||||f
17146958|NCT03500341|t||||
17146959|NCT02576938|f||GT60||t
17191450|NCT01236001|f||OTHER|UCB has \> 60 but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.|t
17191451|NCT02933944|f||||t
17191452|NCT02538107|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191453|NCT01943916|f||OTHER|The results of the study are the property of Seno Medical Instruments, Inc. All publications (manuscripts, abstracts or other modes of presentation) must be submitted and reviewed and approved in writing by Seno Medical Instruments, Inc., in advance of submission. The over all study results will first be submitted as a primary paper.|t
17191454|NCT05782231|f||||f
17191455|NCT05274217|f||||f
17191456|NCT00995150|f||LTE60||t
17191457|NCT01499654|f||||f
17191458|NCT01373346|t||||f
17191459|NCT01395758|f||||f
17191460|NCT00357097|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191461|NCT00794118|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17146960|NCT01010932|f||LTE60||t
17146961|NCT00838630|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146962|NCT00448591|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191462|NCT04305405|f||||t
17191463|NCT02528188|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191464|NCT00529659|f||GT60||t
17191465|NCT03887650|f||||f
17191466|NCT01503749|t||||f
17146963|NCT03017885|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review Prior to any Submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI´s intellectual property rights.|t
17191467|NCT01514734|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191468|NCT03512756|f||||t
17191469|NCT00736853|f||OTHER|The only disclosure restriction on the PIs is that the Sponsor can review results communications prior to public release.|t
17191470|NCT01199705|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191471|NCT03226899|f||OTHER|PI may publish or disclose the results of the study 24 months after final data lock provided that sponsor can review the publication prior to public release, sponsor can request removal of confidential information of sponsor (not including results of trial), and sponsor can request a publication delay in order to protect potentially patentable information. Furthermore, if a publication committee is developing an initial publication, PI is to delay disclosure until that publication is published.|t
17191472|NCT02047981|t||||f
17191473|NCT01764464|t||||
17191474|NCT01401023|f||||f
17191475|NCT02515305|f||OTHER||t
17191476|NCT03602911|t||||
17191477|NCT03215927|f||LTE60||t
17191478|NCT02582593|f||||f
17191479|NCT03889925|f||||f
17191480|NCT03073941|f||LTE60||t
17191481|NCT04250883|f||||f
17191482|NCT04951310|t||||
17191483|NCT00227994|f||LTE60||t
17191484|NCT03803605|t||||
17191485|NCT01823536|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17191486|NCT04425629|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17191487|NCT04218110|f||||t
17191488|NCT02271854|f||OTHER|Preliminary agreement between Novartis Consumer Health and the investigator|t
17191489|NCT03538717|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191490|NCT00446459|f||GT60||t
17191491|NCT02918279|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17146964|NCT01289262|f||||f
17146965|NCT00838279|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146966|NCT00838136|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146967|NCT03380845|t||||
17146968|NCT01250912|f||||f
17146969|NCT03359356|t||||
17146970|NCT01218867|f||||f
17146971|NCT01474551|t||||
17146972|NCT01921062|t||||
17146973|NCT05323396|t||||
17146974|NCT01110005|f||||f
17146975|NCT04646213|t||||
17191492|NCT00309907|f||||f
17191493|NCT00244855|t||||
17191494|NCT00869258|t||||
17146976|NCT00803686|f||OTHER|Except as provided herein or as required by applicable law, you agree that you shall keep such Unigene Information confidential and that you shall not, without our prior written consent, transmit, publish, or otherwise disclose to any person or entity either (i) the Unigene Information, (ii) the fact of our disclosure of the Unigene Information to you, or (iii) the existence or terms of any negotiations or discussions between us regarding your potential engagement.|t
17146977|NCT02350647|t||||
17146978|NCT00731783|f||||f
17150729|NCT01206101|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17150730|NCT01248013|t||||f
17150731|NCT03426137|f||||f
17150732|NCT00667810|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150733|NCT03514641|f||OTHER|Investigator has no right to publish the study results.|t
17150734|NCT04234984|t||||
17191495|NCT02706717|f||LTE60||t
17191496|NCT01911169|f||||f
17191497|NCT02512965|f||||f
17191498|NCT03401190|f||||f
17191499|NCT00835770|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17191500|NCT01185782|f||OTHER||t
17191501|NCT02507752|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191502|NCT00149838|f||||f
17191503|NCT01061151|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17191504|NCT03740009|t||||
17146979|NCT00467896|f||||f
17146980|NCT03772522|f||||f
17146981|NCT00834795|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17146982|NCT00579345|f||GT60||t
17146983|NCT02175095|f||||f
17146984|NCT03697109|f||OTHER|No individual publications will be allowed before publication of the multicenter results, except as agreed with the Sponsor. The Investigator agrees to submit all manuscripts or abstracts to the Sponsor for review before submission to the publisher.|t
17146985|NCT01111461|f||OTHER||t
17146986|NCT00440518|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17146987|NCT01415232|t||||f
17146988|NCT00365365|f||OTHER|The investigator shall have the right to independently publish study results from his site after a multicenter publication, or 12 months after the completion of the study by all sites. He must provide the sponsor a copy of any such publication derived from the study for review and comment at least 45 days (20 days for abstracts) in advance of any submission for publication. The Sponsor may request for the publication to be delayed for upto 90 days to preserve its proprietary rights.|t
17146989|NCT00984022|t||||
17146990|NCT01153503|t||||
17146991|NCT00905606|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17146992|NCT04523168|t||||
17146993|NCT02651272|f||||f
17146994|NCT03591458|f||||f
17146995|NCT02557035|f||LTE60||t
17146996|NCT03868891|t||||
17146997|NCT00777023|f||OTHER|The PI agrees that the sponsor shall have the right to the first publication of the results of the study which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish data or results from the study, provide however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and/or proprietary other than study data.|t
17146998|NCT03123094|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17146999|NCT04247282|f||||f
17147000|NCT04111965|f||||t
17147001|NCT02566239|f||||f
17147002|NCT03496623|f||OTHER|Institution clinical trial centers and PIs agreed not to publish or publicly present any results of clinical trial without prior written consent of sponsor, not to be withheld or delayed except as necessary to require removal of any sponsor confidential information (other than as necessary to fully disclose the trial design and results in accordance with applicable publication standards) or as necessary to provide reasonable time for sponsor to perfect any arising intellectual property rights.|t
17147003|NCT01037114|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147004|NCT01565902|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17147005|NCT03645785|f||||f
17147006|NCT02214615|f||||f
17147007|NCT03181594|f||GT60||t
17147008|NCT01727180|f||||f
17147009|NCT03247972|f||LTE60||t
17147010|NCT00968812|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17191505|NCT03926039|f||||f
17191506|NCT01406223|t||||f
17191507|NCT03833661|f||||f
17191508|NCT02869334|f||||f
17191509|NCT01836133|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191510|NCT02808585|f||OTHER|PIs are not permitted to publish or discuss trial results until 5 years after study completion.|t
17191511|NCT01692730|t||||
17191512|NCT00933400|f||||f
17147011|NCT01010555|f||OTHER|No distribution of trial-specific information without express written permission of Director of Centre for Contact Lens Research.|t
17147012|NCT01593852|f||||f
17147013|NCT00123734|f||GT60||t
17147014|NCT00113386|f||||f
17147015|NCT00640562|f||LTE60||t
17147016|NCT02937870|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147017|NCT03749252|f||||t
17147018|NCT03098394|f||||f
17191513|NCT01819883|t||||
17191514|NCT01041417|t||||
17191515|NCT02299375|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191516|NCT00704184|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17191517|NCT00700336|f||||f
17191518|NCT02701257|f||||f
17191519|NCT04578496|f||||f
17191520|NCT03473340|f||||f
17191521|NCT03394885|f||||f
17191522|NCT01212991|f||OTHER|PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than study data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any invention described.|t
17191523|NCT03949335|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.|t
17147019|NCT00609674|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147020|NCT00204373|f||||f
17147021|NCT00571064|f||OTHER||t
17147022|NCT00244764|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147023|NCT02701556|f||LTE60||t
17147024|NCT01837654|t||||
17147025|NCT03410862|f||||f
17147026|NCT02600403|f||||f
17147027|NCT02926677|f||||f
17147028|NCT00840073|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147029|NCT03285594|f||OTHER|Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.|t
17147030|NCT00958334|f||OTHER||t
17147031|NCT04267276|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147032|NCT03702608|f||||f
17147033|NCT01615198|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17147034|NCT01910688|f||LTE60||t
17147035|NCT04608188|f||||f
17147036|NCT03122457|f||LTE60||t
17191524|NCT01351272|t||||
17191525|NCT01926977|t||||
17147037|NCT01141374|t||OTHER|The copyright of the search results are the exclusive property of the Journal of School Nursing, University of Saint Paul, barring any reproduction, in whole or in part in any form or means of printed or electronic, without the prior and necessary authorization is requested.|t
17191526|NCT00801983|f||||f
17191527|NCT01251354|f||||f
17191528|NCT02270645|t||||
17147038|NCT03273153|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147039|NCT01908205|f||||f
17147040|NCT05528588|t||||f
17147041|NCT03134222|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17147042|NCT00906165|f||GT60||t
17147043|NCT03681470|f||GT60||t
17147044|NCT01686477|t||||
17147045|NCT01863030|f||||f
17191529|NCT03149991|t||||
17191530|NCT03546608|f||OTHER||t
17191531|NCT03807778|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17191532|NCT05135000|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17191533|NCT02788773|f||||f
17191534|NCT00130117|f||||f
17191535|NCT04474314|f||||t
17191536|NCT05094141|t||||
17191537|NCT01170026|f||||f
17191538|NCT04411056|t||||
17191539|NCT02098343|f||||f
17191540|NCT05515562|f||||f
17191541|NCT05314634|f||||f
17147046|NCT03290781|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17147047|NCT01136174|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147048|NCT02851992|f||||f
17147049|NCT02233985|f||||f
17147050|NCT01581658|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17147051|NCT02538523|f||||f
17147052|NCT02820350|t||||
17147053|NCT01597245|f||GT60||t
17191542|NCT03785782|t||||
17191543|NCT05777785|f||||f
17191544|NCT05470868|f||||t
17191545|NCT02763319|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17191546|NCT00089544|f||LTE60||t
17147054|NCT03190005|f||||f
17147055|NCT03429712|t||||
17147056|NCT03161158|f||LTE60||t
17147057|NCT00101647|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147058|NCT00583453|f||||f
17147059|NCT00794963|f||||f
17147060|NCT01450189|f||||f
17147061|NCT00567320|f||||f
17147062|NCT01527006|f||OTHER||t
17147063|NCT02115347|f||OTHER|Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.|t
17147064|NCT01776190|f||||f
17147065|NCT00834340|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147066|NCT05956925|f||||f
17147067|NCT02849457|t||||
17147068|NCT02599558|t||||
17147069|NCT02197481|t||||
17147070|NCT03673670|f||OTHER|The PI shall not be permitted to present at symposia, national or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial subject to the publication policy described in the Protocol without prior written approval of the Sponsor.|t
17147071|NCT04408794|f||LTE60||t
17147072|NCT00187720|f||||f
17147073|NCT04238754|f||||f
17147074|NCT02362997|f||||f
17147075|NCT01518972|f||||f
17147076|NCT01175018|t||||
17147077|NCT00575159|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147078|NCT04022954|f||OTHER|First publication of study results will be made as a joint multi-center publication with investigators from all sites contributing data. Institutions may publish data and results individually from its site after any of the following (1) a multi-center publication is published, (2) no multicenter publication is submitted within eighteen months after closures of the Study at all sites or (3) sponsor confirms in writing there will be no multi-center publication.|t
17147079|NCT01499147|t||||
17147080|NCT03872128|t||||
17147081|NCT03733444|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17191547|NCT00233090|t||||
17191548|NCT01622868|f||OTHER|Must obtain prior approval from the sponsor. In addition, PI's are required to abide by the collaborator's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17147082|NCT00556322|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147083|NCT01788423|f||||f
17147084|NCT03637764|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17147085|NCT02760927|f||OTHER|Results of the trial are the exclusive and sole property of the Sponsor, and the Sponsor has the right to publish the results of the trial. Publication of results or release by the PI of information obtained for the Sponsor requires previous written approval and authorization by the Sponsor.|t
17147086|NCT00424619|f||||f
17191549|NCT03113617|t||||f
17191550|NCT00610649|f||LTE60||t
17191551|NCT04252586|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17191552|NCT00232180|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191553|NCT03452189|t||||
17191554|NCT03390296|t||||
17191555|NCT03344536|t||||
17191556|NCT01571596|f||GT60||t
17191557|NCT01950780|f||||f
17191558|NCT00687713|f||||f
17147087|NCT01940341|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17147088|NCT01218672|f||||f
17191559|NCT02767765|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191560|NCT01951170|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191561|NCT01318967|f||||f
17191562|NCT01305252|f||||f
17191563|NCT01647581|f||||f
17191564|NCT04512482|t||||
17191565|NCT01105117|f||||f
17191566|NCT00774397|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191567|NCT00077675|f||LTE60||t
17191568|NCT00687856|t||||
17191569|NCT04530149|f||||f
17191570|NCT00829036|t||||f
17191571|NCT01514149|f||||t
17191572|NCT04977700|t||||
17191573|NCT01956032|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191574|NCT00391898|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17191575|NCT00749749|f||||f
17191576|NCT00293293|t||||f
17191577|NCT03873337|t||||
17191578|NCT02988817|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17191579|NCT01937507|t||||
17191580|NCT04530747|f||||f
17191581|NCT03292913|t||||
17191582|NCT03950622|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17191583|NCT03752151|f||OTHER|"In most cases, the contract allows the principal investigator to publish their data after release of a multi-center publication per the publication strategy following Medtronic's review for disclosure of confidential information (CI), technical correctness, disclosure of patentable or copyrightable material, and selection and order of publications by the publications committee. Any such CI and/or item identified as not technically correct is deleted prior to publication/presentation."|t
17191584|NCT00529516|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191585|NCT00548418|t||||
17191586|NCT02639910|f||||t
17191587|NCT01319617|f||||f
17147089|NCT03703791|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17147090|NCT00841698|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147091|NCT00185458|f||OTHER|The investigators agree to allow the sponsor to review any manuscripts and to negotiate the times and forums of their publication.|t
17147092|NCT00251979|f||OTHER|AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript for any publication or other disclosure to review it and may within such time require that submission for publication or disclosure of the manuscript be delayed.|t
17191588|NCT00939510|t||||
17191589|NCT04086966|f||||f
17191590|NCT04247074|f||GT60||t
17191591|NCT02943590|f||||f
17191592|NCT03049969|t||||
17191593|NCT03639558|t||||
17147093|NCT01576042|f||||f
17147094|NCT02252133|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17147095|NCT00925119|f||||f
17147096|NCT05178927|t||||
17147097|NCT03670017|f||||f
17147098|NCT00835536|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147099|NCT00657553|f||||f
17147100|NCT03173547|f||||t
17147101|NCT00446563|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17147102|NCT03769025|f||||f
17147103|NCT01169558|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147104|NCT03077451|f||||f
17147105|NCT00852696|t||||
17147106|NCT02512900|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17147107|NCT02409355|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147108|NCT00838539|f||LTE60||t
17147109|NCT03482882|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17147110|NCT00913627|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147111|NCT01641380|t||||
17147112|NCT03123471|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17147113|NCT02957942|t||||
17147114|NCT03238781|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17147115|NCT01471041|f||||f
17147116|NCT01249651|f||OTHER|All PIs were prohibited to disclose all information related to this study without AZ approval before this study was completed.|t
17147117|NCT01462279|f||||f
17147118|NCT04044521|f||||f
17147119|NCT00813592|t||||
17147120|NCT00811655|t||||
17147121|NCT03682653|t||||
17147122|NCT01391273|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147123|NCT03801707|t||||
17147124|NCT03873272|t||||
17147125|NCT00787254|f||OTHER|The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.|t
17191594|NCT02414204|t||||
17147126|NCT02608177|f||||f
17147127|NCT00316186|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147128|NCT03071575|f||||f
17147129|NCT01921894|t||||
17191595|NCT03942042|f||GT60||t
17191596|NCT01787760|t||||
17147130|NCT03255733|f||||f
17147131|NCT04299087|t||||
17147132|NCT00594035|f||OTHER|"* The sponsor can review results at least 30 days prior to public release, and at the request of Sponsor, the PI will withhold submission for an additional period, not to exceed 90 days.~* The first publication of the study results shall be made in conjunction with a joint, multi-center publication of the results. If a multi-center publication is not submitted within 12 months after the conclusion of the Study, the PIs may publish the results from their individual site."|t
17147133|NCT00795821|f||GT60||t
17147134|NCT01285713|f||||f
17147135|NCT04310345|t||||
17147136|NCT05700383|f||||f
17147137|NCT02925884|f||||f
17191597|NCT01849055|f||GT60||t
17191598|NCT01239316|f||LTE60||t
17191599|NCT04786457|t||||
17191600|NCT04623008|t||||
17191601|NCT03122886|t||||
17191602|NCT03779048|f||||f
17191603|NCT03422276|f||||f
17191604|NCT05985044|f||||f
17147138|NCT02301975|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147139|NCT01440803|f||||f
17147140|NCT02826694|t||||f
17147141|NCT01609257|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17147142|NCT02125461|f||||f
17147143|NCT03049748|f||||f
17147144|NCT00835484|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147145|NCT04383587|t||||
17147146|NCT01158118|t||||
17147147|NCT04994535|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191605|NCT04588259|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17147148|NCT00604162|f||||f
17147149|NCT02741687|t||||
17147150|NCT01015287|f||GT60||t
17147151|NCT00905840|f||||f
17147152|NCT01370317|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17147153|NCT01688609|f||LTE60||t
17147154|NCT01885117|f||GT60||t
17147155|NCT04813354|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147156|NCT02105272|f||||f
17191606|NCT01164098|t||||f
17191607|NCT03631433|t||||f
17191608|NCT05343715|t||||
17191609|NCT03029598|t||||
17147157|NCT03450850|t||||
17147158|NCT03190915|f||LTE60||t
17147159|NCT02964039|t||||
17147160|NCT01103713|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147161|NCT01172145|t||||f
17191610|NCT03051165|t||||
17191611|NCT02092116|f||OTHER|The Sponsor (or designee) will prepare a final report on the study. The Investigator may not publish or present any information on this study without the express written approval of the Sponsor. Additionally, the Sponsor, may, for any reason, withhold approval for publication or presentation.|t
17191612|NCT03074331|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17191613|NCT01546753|t||||
17147162|NCT02354339|t||||
17147163|NCT00505622|f||||f
17147164|NCT03084471|f||OTHER|Disclosure of study information is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17147165|NCT04405765|f||||f
17147166|NCT00868374|t||||
17147167|NCT01341730|f||||f
17147168|NCT01848938|f||||f
17147169|NCT01757392|f||||t
17147170|NCT01552317|t||||f
17147171|NCT00545506|t||||
17147172|NCT00702377|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17147173|NCT00099047|f||LTE60||t
17191614|NCT01796236|f||GT60||t
17191615|NCT00546754|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147174|NCT00651820|f||||f
17147175|NCT01878292|f||OTHER|All data generated in this study are the property of the sponsor. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and the sponsor and will follow sponsor's standard operating procedures on publications.|t
17147176|NCT01302548|t||||f
17147177|NCT00950989|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17147178|NCT03527485|t||||
17191616|NCT04762875|f||||f
17191617|NCT00311363|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147179|NCT00730691|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17147180|NCT02178787|f||||f
17147181|NCT02554890|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17147182|NCT01521780|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17147183|NCT03043872|f||||t
17147184|NCT03649477|f||OTHER|This study is a multi-center study. Sponsor retains first publication rights for a period of time after conclusion of study. Study has not yet completed.|t
17147185|NCT02430480|f||||f
17147186|NCT01154231|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147187|NCT02740413|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147188|NCT04037969|f||||f
17147189|NCT04870606|f||||f
17147190|NCT04852978|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17147191|NCT00859430|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147192|NCT00001703|f||||f
17147193|NCT03119025|t||||
17147194|NCT01379222|f||||t
17147195|NCT03733730|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17147196|NCT01531894|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17147197|NCT06195579|f||||f
17147198|NCT02545283|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147199|NCT02776774|f||||f
17147200|NCT03635320|f||OTHER|Principal investigator and institution will not be able to publish single-center study data until combined results of the multicenter study are published. If multicenter publication is not performed within 12 months after the end or if sponsor notifies principal investigator and institution in writing that the multicenter study results will not be published, the principal investigator and institution may publish the results of their studies separately in accordance with contract.|t
17147201|NCT04512781|f||||f
17147202|NCT00835575|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147203|NCT00443651|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147204|NCT03606174|f||||f
17147205|NCT00761813|f||||f
17147206|NCT02241551|t||||
17147207|NCT00469898|t||||
17147208|NCT01205035|f||||f
17147209|NCT04665375|t||||
17147210|NCT01667679|f||OTHER||t
17147211|NCT02159183|f||GT60||t
17147212|NCT02777580|f||LTE60||t
17147213|NCT02154672|f||||f
17147214|NCT01294917|f||||f
17147215|NCT02519348|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17147216|NCT01444378|f||GT60||t
17147217|NCT02911792|t||||f
17147218|NCT01244620|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147219|NCT00620711|t||||
17147220|NCT02321098|f||||t
17147221|NCT01663233|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191618|NCT03830866|f||||f
17191619|NCT01759771|t||||
17191620|NCT02101190|f||OTHER||t
17147222|NCT05630885|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17147223|NCT01370733|f||||f
17147224|NCT06539676|f||LTE60||t
17147225|NCT02645409|f||||f
17147226|NCT03419403|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17147227|NCT03466866|f||||f
17147228|NCT02068820|t||||
17147229|NCT02089685|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17147230|NCT00318461|f||OTHER|Novo Nordisk acknowledges the Investigator's right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript.|t
17147231|NCT04134091|f||||t
17147232|NCT00796653|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17147233|NCT03393208|f||||f
17147234|NCT00539110|t||||
17147235|NCT00207090|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147236|NCT00304187|f||||f
17147237|NCT01911676|t||||
17147238|NCT00773253|f||||f
17147239|NCT01566721|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147240|NCT03374176|f||||t
17147241|NCT00398983|f||||f
17147242|NCT02911701|t||||
17147243|NCT01237054|f||||f
17147244|NCT01983969|t||||
17147245|NCT02619682|f||||f
17147246|NCT00520234|f||LTE60||t
17147247|NCT00268203|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147248|NCT00322439|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17147249|NCT01841554|f||||t
17147250|NCT01767103|f||OTHER|Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.|t
17147251|NCT03804983|f||||f
17147252|NCT03600376|f||OTHER|The PIs are not permitted to discuss or publish study results.|t
17147253|NCT02152163|f||||f
17147254|NCT02067611|f||||t
17147255|NCT00796562|t||||
17147256|NCT00424047|f||OTHER|Investigator has the right to publish and/or present study data after multicentric publication or one year has elapsed until completion of this multicentric study provided that he/she (i) furnishes the sponsor a copy of any proposed publication or presentation before its submission, (ii) deletes any sponsor's confidential data as pointed out by sponsor, and (iii) delays any submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications.|t
17147257|NCT02664961|f||LTE60||t
17147258|NCT00312897|t||||
17147259|NCT04633564|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17147260|NCT01010503|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17147261|NCT01097577|t||||
17147262|NCT00748072|t||||
17147263|NCT04493684|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17147264|NCT01963728|f||||f
17147265|NCT05152576|f||||f
17191621|NCT02139943|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17191622|NCT01429350|f||GT60||t
17191623|NCT00716859|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191624|NCT03161327|f||||f
17191625|NCT03750968|f||||f
17191626|NCT03294499|f||||f
17191627|NCT00088413|f||||f
17191628|NCT03762213|f||||f
17191629|NCT01551355|t||||
17191630|NCT00411216|f||||f
17191631|NCT02918071|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17191632|NCT01550549|f||GT60||t
17191633|NCT01029587|f||||f
17191634|NCT00203411|f||||f
17191635|NCT00590369|f||||f
17191636|NCT00632424|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17191637|NCT02531113|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17191638|NCT03350542|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17191639|NCT00774852|f||||f
17191640|NCT03997916|f||||f
17191641|NCT05158153|t||||
17191642|NCT01827787|t||||
17191643|NCT03482635|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation of review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17191644|NCT04242940|f||||f
17191645|NCT01304277|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17191646|NCT02279095|f||||t
17191647|NCT05644444|f||OTHER|Publication of the results of the Study, whether in whole or in part, shall be within the sole and absolute discretion of Reckitt, and PI shall not be entitled to publish any of the data or information arising during the Study without the prior written consent of Reckitt.|t
17191648|NCT03936660|t||||
17191649|NCT02541565|t||||
17191650|NCT04987021|t||||
17191651|NCT02724592|t||||
17191652|NCT02584829|t||||
17191653|NCT04723394|f||OTHER|Publication of any part or entirely of study results requires prior written approval from sponsor, with no timeframe for sponsor to review.|t
17191654|NCT01965665|t||||
17191655|NCT00253890|f||||f
17191656|NCT00083551|t||||
17191657|NCT02765100|t||||
17191658|NCT02675244|f||||f
17191659|NCT01900249|f||LTE60||t
17191660|NCT02652442|t||||
17191661|NCT01065506|f||||f
17191662|NCT01047241|t||||
17191663|NCT00741455|t||||
17147266|NCT04115293|f||GT60||t
17147267|NCT01414153|f||GT60||t
17191664|NCT03689920|f||||t
17191665|NCT00914589|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17191666|NCT01290341|f||OTHER|Institution and Principal Investigator agreed not to individually publish or assist other person or entity with any articles, papers, and/or make presentations, speeches referring to the protocol, clinical trial data, the study, or the study drug or any data, results, materials, or information generated or obtained by the Institution or the Principal Investigator without the prior written consent of Merz, which consent may be withheld in the sole discretion of Merz.|t
17191667|NCT01919450|t||||f
17147268|NCT04974684|f||||f
17147269|NCT00712959|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17191668|NCT03036813|f||||t
17191669|NCT01102231|f||||t
17191670|NCT03903822|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147270|NCT03155425|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17147271|NCT00828295|f||||f
17147272|NCT02028221|f||||f
17147273|NCT01402050|f||||f
17147274|NCT03581097|f||||f
17147275|NCT01376037|f||||f
17147276|NCT02328040|f||||f
17147277|NCT04726345|t||||
17147278|NCT04516434|t||||
17147279|NCT04278560|f||||f
17147280|NCT02832063|f||OTHER|PI may not publish or otherwise publicly disclose the analyzed study data and conclusions drawn from the study without the written consent of Sponsor.|t
17191671|NCT00785512|f||OTHER|Sponsor can review results communications prior to public release \& can embargo communications re: results for 60 days from time submitted to sponsor for review. PI shall not disclose sponsor's confidential information. Upon sponsor's request, PI shall delete any proprietary info \& shall not include raw data in the publication. On sponsor's request, PI shall delay submission for any pub while sponsor files patent applications. Any publication will give recognition to Sponsor's support.|t
17191672|NCT00194714|t||||
17191673|NCT00895531|t||||
17191674|NCT00529100|f||LTE60||t
17191675|NCT03733119|t||||
17191676|NCT02253537|f||||f
17191677|NCT03231358|f||||f
17191678|NCT04470375|f||||f
17191679|NCT00807937|f||OTHER||t
17191680|NCT03337399|f||||f
17191681|NCT02708108|t||||
17191682|NCT00510887|t||||
17191683|NCT01542229|t||||
17191684|NCT02214550|f||||f
17191685|NCT03485950|t||||
17191686|NCT05360901|t||||f
17147281|NCT02303405|f||||f
17147282|NCT01867164|f||||f
17147283|NCT03086460|f||OTHER|Chiesi can publish and/or present any results of this study at scientific meetings, and to submit the clinical trial data to national and international Regulatory Authorities. Chiesi reserves the right to use such data for industrial purposes. Investigators will inform Chiesi before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation. Data from individual study sites must not be published separately.|t
17147284|NCT03600805|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17147285|NCT02718963|f||||f
17191687|NCT00988858|f||GT60||t
17191688|NCT03764475|f||OTHER|The Sponsor is supportive of publishing clinical trial findings. The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17191689|NCT05113771|f||||f
17191690|NCT05510245|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191691|NCT00390299|t||||
17191692|NCT04661410|f||||f
17191693|NCT01186198|f||GT60||t
17191694|NCT00970359|t||||
17191695|NCT00068601|f||LTE60||t
17191696|NCT01061671|f||||f
17191697|NCT05368831|f||||t
17191698|NCT00856739|t||||
17191699|NCT01136486|t||||
17191700|NCT00223795|t||||
17191701|NCT00513526|f||||f
17191702|NCT00475501|t||LTE60||t
17191703|NCT04732338|t||||
17147286|NCT03415308|f||||f
17147287|NCT02342535|f||||f
17147288|NCT01471353|t||||
17147289|NCT00836472|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147290|NCT01695239|f||GT60||t
17147291|NCT02007863|t||||
17147292|NCT03502811|f||||f
17147293|NCT01735994|f||||f
17147294|NCT05239195|t||||
17147295|NCT03170219|f||||f
17191704|NCT04426500|t||||
17191705|NCT01803555|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17191706|NCT02460900|f||||f
17191707|NCT05165485|f||OTHER||t
17191708|NCT04888637|t||||
17191709|NCT04163328|t||||
17191710|NCT05938413|t||||
17191711|NCT02188420|t||||
17191712|NCT04817670|f||||t
17191713|NCT03312907|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17191714|NCT02576574|f||OTHER||t
17191715|NCT02980276|t||||
17191716|NCT04879524|t||||
17191717|NCT01780298|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17191718|NCT04139668|t||||
17191719|NCT03718065|f||||f
17191720|NCT03025789|f||OTHER|The sponsor authorizes publications by a single site provided that multicentric results are published beforehand and that any communication is submitted to sponsor for review at least 28 days ahead of the expected date of publication. The sponsor can submit comments for a period of 28 days. Upon sponsor request, any confidential information will have to be removed from the communication before publishing.|t
17191721|NCT05286385|t||||
17191722|NCT04907474|f||||f
17147296|NCT03552484|f||||f
17147297|NCT04808362|f||||f
17147298|NCT03264092|f||||f
17147299|NCT04162899|f||||f
17147300|NCT04145635|f||||f
17147301|NCT02663349|f||||f
17147302|NCT01204294|t||||
17147303|NCT03382925|t||||
17147304|NCT03128723|f||OTHER|Prior to submission for any public disclosure of the data or results, the PI will provide the Sponsor with at least 60 days for review of the publication. Sponsor's written consent is required for any publication containing the Sponsor's confidential information. The Sponsor may request that the PI withholds such publication for up to an additional 60 days to allow for filing of a patent application.|t
17147305|NCT00673660|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147306|NCT01383486|f||GT60||t
17147307|NCT01124305|f||||f
17147308|NCT02448862|f||||f
17147309|NCT00064038|f||||f
17147310|NCT03359863|t||||f
17147311|NCT02825680|t||||
17147312|NCT03435835|f||||f
17147313|NCT02314403|t||||
17147314|NCT01929863|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147315|NCT00323882|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147316|NCT02687126|t||||
17147317|NCT00830024|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147318|NCT01456221|f||||f
17147319|NCT00436163|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191723|NCT03827304|f||||f
17191724|NCT02411084|f||OTHER|Institution and Investigators agree that any publication by Institution or Investigators of the Study Results shall not be made before the first multi-centre publication. In the event there is no multi-centre publication within twenty-four (24) months after a Study has been completed, Institution shall have the right to publish its results from the Study.|t
17191725|NCT04259450|f||OTHER|The sponsor has the right to review communications for 90 days prior to public release (whereby the sponsor may ask to consider modifications to ensure necessary protection of sponsor's IP). Any publication shall be not made before the first multi-centre publication if the study is a part of a multi-centred clinical trial. Also, if a publication concerns the analyses of data from a multi-centred clinical trial, the communication shall make reference to the relevant multi-centre publication|t
17191726|NCT01534494|f||||f
17191727|NCT02880137|t||||
17191728|NCT00434304|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191729|NCT00804648|f||OTHER|Prior to submission for publication or presentation, the PI will provide the Sponsor with at least 60 days for review of a manuscript. If requested in writing, the PI will withhold publication for up to an additional 60 days.|t
17191730|NCT01643616|f||||f
17147320|NCT02709018|f||||f
17147321|NCT06647173|f||||f
17147322|NCT02530905|f||OTHER|The most restrictive relevant agreement provides that the PI can only publish the study results with the approval of Sponsor.|t
17147323|NCT01278953|f||LTE60||t
17147324|NCT01473953|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17147325|NCT03100344|f||OTHER|All the information provided to the investigator and his/her staff and all data obtained through this clinical trial are confidential. The Sponsor reserves all proprietary rights. No information may be disclosed to any third party without prior written consent from the Sponsor.|t
17147326|NCT02358538|f||||f
17147327|NCT01935674|f||||f
17147328|NCT01494532|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147329|NCT02433977|f||||f
17147330|NCT02057835|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147331|NCT02392286|t||||
17147332|NCT00834717|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147333|NCT02222818|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17147334|NCT01660243|f||OTHER|The disclosure restriction on the PIs is that sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to sponsor for review. Sponsor can require changes to the communication which is considered confidential and/or proprietary. If necessary, sponsor shall have the right to request to delay the proposed disclosure for an additional 60 days.|t
17147335|NCT03025087|t||||
17147336|NCT03821675|f||LTE60||t
17147337|NCT00508651|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17147338|NCT03098485|f||||f
17147339|NCT04200833|t||||
17147340|NCT05710718|f||||f
17147341|NCT06381102|t||||
17147342|NCT01319383|f||||f
17147343|NCT01987765|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147344|NCT00772603|f||OTHER||t
17147345|NCT04757298|f||||f
17147346|NCT00836004|f||OTHER|Prinicipal Investigator is not permitted to discuss or publish trial results.|t
17147347|NCT01528696|t||||
17147348|NCT01056484|t||||
17147349|NCT00033917|t||||
17147350|NCT00446966|f||||f
17147351|NCT01988376|t||||
17147352|NCT01564394|f||||f
17147353|NCT00859521|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147354|NCT00834132|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147355|NCT02305732|f||||f
17147356|NCT02888756|f||LTE60||t
17147357|NCT01515891|f||OTHER||t
17147358|NCT05058430|f||||f
17147359|NCT02768701|f||GT60||t
17147360|NCT01547286|f||||f
17147361|NCT00540995|t||||
17147362|NCT00488774|f||OTHER|Twelve months after study ends, Sponsor will be provided with a copy of materials at least 45 days prior to submission, with details of proposed date, journal or conference name of publication \& it will have 30 days post receipt to send written request that publication be delayed on the basis it exposes intellectual property that requires propriety protection but it will be only for 60 days after which Investigator will be free to publish. The participation of Sponsor will be acknowledged.|t
17147363|NCT02682238|f||OTHER|Agreement terms prioritized a multi-center publication at the study end. Should such a publication not be completed, an investigator right to individually publish results of his/her study (limited to his/her site data) was included, if for purely scientific or educational purposes; not for any commercial purposes. PI(s) were to submit draft materials to the Sponsor 60 days prior to Investigator release of individual abstract or manuscript. Additional disclosure restrictions and terms applied .|t
17147364|NCT00075478|t||||
17147365|NCT03270462|t||||
17147366|NCT02075463|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147367|NCT00462228|f||OTHER|Publications and Copyrights: INSTITUTE will be free to publish papers dealing with final results of research under this Agreement, 90 days after submitting such papers to FOREST for review providing that INSTITUTE gives due regard to FOREST's comments on the proposed publication.|t
17147368|NCT00245063|f||LTE60||t
17147369|NCT01370369|f||OTHER|There is a restriction on joint publications prepared in collaboration between investigator and sponsor as Ferring reserves the right to be involved in this decision. In the event of any disagreement in the content of any publication both investigator's and Ferring´s opinion will be fairly and sufficiently represented in the publication.|t
17147370|NCT05099380|f||GT60||t
17147371|NCT00252967|f||||f
17147372|NCT02294786|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17147373|NCT01778010|t||||
17147374|NCT02157623|t||||
17147375|NCT00927069|t||LTE60||t
17147376|NCT02558491|t||||
17147377|NCT00834431|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147378|NCT00746395|t||||
17147379|NCT00835263|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147380|NCT03249454|t||||
17147381|NCT01913405|f||OTHER|Agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication. The sponsor requires a review of results communication (e .g. for confidential information) \>= 30 days prior to submission and may request an additional delay of \<=180 days (e .g. for intellectual property protection).|t
17147382|NCT03856320|t||||f
17147383|NCT03987191|t||||
17147384|NCT01020474|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147385|NCT03261167|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147386|NCT00835146|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147387|NCT03199963|f||||f
17147388|NCT00466167|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17147389|NCT01144494|t||||
17147390|NCT02927639|t||||
17147391|NCT04342663|f||||f
17147392|NCT03366792|t||||
17147393|NCT02450539|f||GT60||t
17147394|NCT01640197|f||||f
17147395|NCT00402103|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17147396|NCT04078022|t||||
17147397|NCT01370811|f||LTE60||t
17147398|NCT01895335|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17147399|NCT00418938|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17147400|NCT00463684|f||||f
17147401|NCT00115063|f||||f
17147402|NCT00191815|f||GT60||t
17147403|NCT01075282|f||GT60||t
17147404|NCT01794845|t||||
17147405|NCT02139826|f||OTHER|Sponsor may choose to collaborate on authorship, and sponsor's agent has 60-day review|t
17147406|NCT00429416|t||||
17147407|NCT06999265|t||||
17147408|NCT02316548|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17147409|NCT02571907|f||||f
17147410|NCT02324660|t||||
17191731|NCT01939899|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17147411|NCT03666026|f||||f
17147412|NCT02286739|f||LTE60||t
17147413|NCT02566850|t||||
17147414|NCT01343004|f||OTHER|Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/\> 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/\> 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.|t
17147415|NCT03447353|f||||f
17147416|NCT00089011|t||||
17147417|NCT00526188|f||LTE60||t
17147418|NCT04196907|f||GT60||t
17147419|NCT02642653|f||||f
17147420|NCT00830258|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147421|NCT03909607|f||||f
17147422|NCT00682461|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147423|NCT02267187|f||||f
17147424|NCT02798458|f||||f
17147425|NCT04035187|f||||f
17147426|NCT04210557|t||||
17147427|NCT03423654|t||||
17147428|NCT03220958|t||||
17147429|NCT01116739|t||||
17147430|NCT02255149|f||||f
17147431|NCT01361633|t||||
17147432|NCT00238615|f||||f
17147433|NCT03121586|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17147434|NCT02909907|f||||f
17147435|NCT00002601|t||||
17147436|NCT01839279|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17147437|NCT00392665|t||||f
17147438|NCT03276754|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147439|NCT03437265|f||OTHER|The agreement between Norgine and Quotient Sciences states that Quotient have no publication rights.|t
17147440|NCT00316277|t||||f
17191732|NCT00585052|t||||
17191733|NCT00858117|t||||
17191734|NCT00371787|f||||f
17191735|NCT04425863|f||||f
17191736|NCT02355275|f||||f
17191737|NCT03285542|f||||f
17191738|NCT01854385|f||||f
17147441|NCT03517085|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147442|NCT00840476|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147443|NCT01798264|f||GT60||t
17191739|NCT02966275|t||||
17191740|NCT00277355|f||||f
17191741|NCT00538759|f||||f
17191742|NCT02597920|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17191743|NCT00642850|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191744|NCT04040296|f||||f
17191745|NCT05489484|f||||f
17191746|NCT01537419|f||||f
17191747|NCT00444600|f||||f
17147444|NCT01572662|t||||
17147445|NCT03364192|f||||f
17147446|NCT00918645|f||||f
17147447|NCT03446768|f||||f
17147448|NCT05133180|f||||f
17147449|NCT00107991|f||||f
17147450|NCT01535222|f||OTHER|Sponsor can review results communications prior to public release. Sponsor will complete review within 60 days. If Sponsor believes proposed publication contains patentable information, disclosure shall be delayed to 90 days to permit patent filing. If additional time is required an extension shall be granted not to exceed an additional 90 days. If Sponsor believes proposed publication contains confidential information, site shall delete such information.|t
17147451|NCT00935012|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147452|NCT01442155|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147453|NCT03669861|f||||f
17147454|NCT03169062|t||||
17147455|NCT00705666|f||OTHER|Any published results concerning the data of the non-interventional study is forbidden. Study data and results are exclusive property of the sponsor.|t
17191748|NCT05132478|t||||
17191749|NCT01852071|f||||f
17191750|NCT01414738|t||||
17191751|NCT01839331|f||LTE60||t
17191752|NCT04056624|f||||f
17191753|NCT03224390|t||||
17147456|NCT00374231|t||||
17191754|NCT00703820|t||||
17147457|NCT03259139|t||||
17147458|NCT02284867|f||||f
17147459|NCT01590563|f||||f
17147460|NCT03256695|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17147461|NCT01604941|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17147462|NCT03930732|f||||t
17147463|NCT03406156|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17147464|NCT04708028|t||||
17147465|NCT02699463|f||||f
17147466|NCT01108445|f||LTE60||t
17147467|NCT04188392|t||||
17147468|NCT00585286|f||||f
17147469|NCT01447511|t||||
17147470|NCT01316055|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17147471|NCT00003470|f||||f
17147472|NCT01825798|f||||f
17147473|NCT01125163|t||||f
17147474|NCT05350137|f||||f
17191755|NCT03977935|t||||
17191756|NCT03531840|f||||f
17191757|NCT00770757|t||||
17191758|NCT00761605|f||LTE60||t
17191759|NCT02267824|f||||f
17191760|NCT03451721|f||||t
17191761|NCT00350792|f||GT60||t
17191762|NCT01985334|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191763|NCT01195883|f||||f
17191764|NCT00396084|f||||f
17191765|NCT04110743|t||||
17191766|NCT02665988|f||||f
17191767|NCT01565148|f||||f
17191768|NCT01763970|t||||
17191769|NCT03359889|t||||
17191770|NCT01199575|t||||
17191771|NCT00212134|f||||f
17191772|NCT02409667|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17191773|NCT01925339|t||||
17191774|NCT03960463|f||||f
17191775|NCT03133182|f||||f
17191776|NCT04498052|f||||f
17191777|NCT04999085|t||||
17191778|NCT02581215|f||||f
17191779|NCT03613740|t||||
17191780|NCT04188379|f||OTHER||t
17191781|NCT05406258|f||||f
17191782|NCT02566902|f||||f
17191783|NCT01108003|t||||
17191784|NCT03112174|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191785|NCT02036424|t||||
17191786|NCT02748317|f||||f
17191787|NCT00687167|f||GT60||t
17191788|NCT00332241|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147475|NCT03500094|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17147476|NCT01030133|t||||
17147477|NCT04025229|t||||
17147478|NCT01718301|t||||
17147479|NCT04517604|f||||f
17147480|NCT01958294|f||LTE60||t
17147481|NCT05511935|f||||f
17147482|NCT05090839|t||||
17147483|NCT03913377|f||GT60||t
17147484|NCT03499353|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147485|NCT01117623|f||||f
17191789|NCT00924807|t||||
17191790|NCT00802464|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191791|NCT00402246|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication."|t
17191792|NCT00825630|f||||f
17147486|NCT00862563|f||||f
17147487|NCT00736190|f||OTHER|Investigators may discuss or publish results (without Gilead's confidential information) after all results have been publicly disclosed by/with consent of Gilead or study has been completed \>=2 years. Proposed publication/presentation and destination details must be submitted \>=30 days before submission. The investigator agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary.|t
17147488|NCT01556906|f||OTHER|Information is unavailable.|t
17191793|NCT05262738|t||||
17191794|NCT03504423|f||||f
17191795|NCT01471691|t||||
17191796|NCT01808339|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191797|NCT02622568|f||||f
17191798|NCT05848817|t||||
17191799|NCT00106080|t||||
17191800|NCT02549170|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17191801|NCT02379819|f||OTHER|The aggregate data resulting from this study will be the proprietary information of the Sponsor and may be made public after all data have been analyzed and the study results are available. None of the data resulting from this study will be allowed to be presented or published in any form, by the Investigator or any other person, without the prior written approval of the Sponsor.|t
17191802|NCT01625104|f||||f
17191803|NCT00595790|f||OTHER||t
17191804|NCT03988023|f||||t
17147489|NCT01896934|f||||f
17147490|NCT04590027|f||||f
17147491|NCT00933686|f||OTHER||t
17147492|NCT01384591|f||||f
17147493|NCT00840216|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147494|NCT05041361|t||||f
17147495|NCT01642277|f||||f
17147496|NCT03302780|t||||f
17147497|NCT03605342|t||||
17147498|NCT00848536|f||LTE60||t
17147499|NCT00796328|f||||f
17147500|NCT03682601|f||||f
17147501|NCT03317444|f||||t
17147502|NCT02944617|t||||
17147503|NCT00506831|f||||f
17147504|NCT02488239|f||OTHER|The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.|t
17147505|NCT03283982|t||||
17147506|NCT03279250|t||||
17147507|NCT02913924|t||||
17147508|NCT00263588|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e.; data from all sites) in the clinical trial.|t
17147509|NCT00918684|t||||f
17147510|NCT00909038|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17147511|NCT00484679|t||||f
17147512|NCT00835692|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147513|NCT01149733|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147514|NCT04345653|t||||
17147515|NCT03808376|f||LTE60||t
17147516|NCT03644550|f||||f
17147517|NCT00700739|f||OTHER|Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after DePuy has been given the opportunity of reviewing the proposed presentation or publication at least 30 days prior to the intended submission, presentation, or publication date.|t
17147518|NCT03734861|f||||f
17147519|NCT04667338|f||||t
17147520|NCT00284518|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147521|NCT03488108|t||||
17147522|NCT03810703|t||||
17147523|NCT03602339|f||LTE60||t
17147524|NCT01297504|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17147525|NCT01348789|f||GT60||t
17147526|NCT05168735|t||||
17147527|NCT03503318|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17147528|NCT01668602|t||||
17147529|NCT02319824|t||||
17147530|NCT01636661|f||||f
17147531|NCT03867838|t||||f
17147532|NCT00834873|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147533|NCT01885949|f||||f
17147534|NCT04827394|t||||
17147535|NCT04594252|f||||t
17147536|NCT03331289|f||||f
17147537|NCT00477594|f||OTHER|After the multicenter publication or 12 months after completion of the study the PI may publish the results of his/her data from the study. The PI shall provide the sponsor with an advance copy at least 60 days prior to planned submission and the Sponsor shall have 60 days to review (contracts have variable timeframes; maximum times are stated here). The sponsor may request the deletion of any confidential information, or a delay in submission for an additional period not to exceed 90 days.|t
17147538|NCT03114891|f||||f
17147539|NCT02068794|t||||
17147540|NCT02635750|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147541|NCT04377087|t||||
17147542|NCT02875392|t||||
17147543|NCT03599193|f||||f
17147544|NCT00835705|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147545|NCT01592240|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results|t
17147546|NCT01909713|f||LTE60||t
17147547|NCT01011413|f||||f
17147548|NCT03246503|f||||t
17147549|NCT02751424|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147550|NCT03206749|f||OTHER||t
17147551|NCT01492439|t||||f
17147552|NCT00716625|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147553|NCT05523895|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17191805|NCT03703336|f||||f
17191806|NCT00533910|f||||f
17191807|NCT02088853|t||||
17191808|NCT02568683|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17191809|NCT01736215|f||||f
17191810|NCT02346526|t||||
17191811|NCT00194896|t||||
17191812|NCT01248936|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191813|NCT03930420|f||||f
17191814|NCT04556981|f||OTHER||t
17191815|NCT00609336|t||||
17191816|NCT02238483|f||||f
17191817|NCT01388361|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17191818|NCT00539734|t||||
17191819|NCT01061034|f||||f
17191820|NCT01070069|f||OTHER||t
17191821|NCT03635151|t||||
17191822|NCT03631550|f||||f
17191823|NCT05330234|t||||
17191824|NCT01877343|t||||
17147554|NCT03674892|f||||f
17147555|NCT00824291|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17147556|NCT01907607|t||||
17147557|NCT01505933|t||||
17147558|NCT00395694|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147559|NCT01648582|f||GT60||t
17147560|NCT02699866|f||GT60||t
17147561|NCT01959672|t||||
17147562|NCT01058668|f||OTHER|"All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17147563|NCT01068821|f||||f
17191825|NCT00440011|f||LTE60||t
17147564|NCT04859517|f||||t
17147565|NCT00908128|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147566|NCT02842853|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17191826|NCT00419341|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191827|NCT04200365|f||||t
17191828|NCT03799783|t||||
17191829|NCT02020252|f||||f
17191830|NCT02793154|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191831|NCT01538719|t||||
17191832|NCT03664960|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17191833|NCT04708509|f||||f
17191834|NCT04870645|t||||
17191835|NCT03783026|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191836|NCT03568422|f||||f
17191837|NCT04156581|t||||
17191838|NCT03602612|f||||f
17191839|NCT05568615|f||OTHER||t
17191840|NCT03529110|f||||f
17191841|NCT03237481|f||||f
17191842|NCT03439891|t||||
17191843|NCT02476695|f||||f
17191844|NCT03873779|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17191845|NCT04270526|t||||
17191846|NCT04279574|f||GT60||t
17191847|NCT03043599|t||||
17191848|NCT05773313|t||||
17191849|NCT00639860|f||||f
17191850|NCT02374463|f||||f
17191851|NCT04204993|t||||
17191852|NCT01266122|f||||f
17191853|NCT00421889|f||LTE60||t
17191854|NCT03756571|f||||f
17147567|NCT04089553|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17147568|NCT01403194|t||||f
17147569|NCT02479763|f||||f
17147570|NCT04626414|f||||t
17147571|NCT02464657|t||||
17147572|NCT01808651|f||GT60||t
17147573|NCT01165047|f||||f
17147574|NCT01161420|f||||f
17147575|NCT00608322|t||||
17147576|NCT05479058|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17147577|NCT00834444|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147578|NCT04313751|t||||
17147579|NCT03325881|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17147580|NCT03060486|t||||
17147581|NCT02121067|t||||
17147582|NCT00835614|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147583|NCT02294981|t||||f
17147584|NCT00829712|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147585|NCT00606281|f||||f
17147586|NCT00617396|f||||f
17147587|NCT03556618|t||||
17147588|NCT05752721|t||||
17147589|NCT01188681|f||||f
17147590|NCT02280863|f||OTHER||t
17147591|NCT03236311|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17147592|NCT00909753|f||OTHER|Principal Investigator is not allowed to discuss or publish trial results.|t
17147593|NCT02351700|f||||f
17147594|NCT02336074|f||OTHER|The NHS Organisations shall not publish or otherwise disseminate conclusions of the Study, including all or any part of the Results of the Study without prior written consent of the Sponsor, such consent not to be unreasonably withheld or delayed.|t
17147595|NCT02679729|f||OTHER|All clinical study findings and documents will be regarded as confidential and property of the sponsor. No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB.|t
17147596|NCT00836758|f||||f
17147597|NCT00906399|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17147598|NCT01124786|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147599|NCT04739735|t||||
17147600|NCT06185088|t||||
17147601|NCT00574847|t||||
17147602|NCT02811003|f||LTE60||t
17147603|NCT02055547|f||OTHER|"The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.~Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."|t
17147604|NCT01279486|t||||
17147605|NCT03067987|t||||f
17147606|NCT00834275|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147607|NCT00829764|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147608|NCT01750294|f||||f
17147609|NCT00665925|f||LTE60||t
17147611|NCT00334815|f||LTE60||t
17147612|NCT02197416|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147613|NCT02451696|t||||
17147614|NCT05014828|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17147615|NCT00721162|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17147616|NCT00041392|f||||f
17147617|NCT02392195|f||||f
17147618|NCT00907907|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147619|NCT00545792|t||||
17147620|NCT02891863|f||OTHER|This an early-stage feasibility study with significant intellectual property value to the sponsor. The sponsor controls access to the data and no publications can be submitted without the sponsors approval. Since the study was stopped early due to futility it may not be publishable, but preliminary data was submitted via abstract for presentation at Heart Rhythm 2017.|t
17147621|NCT03679598|f||||f
17147622|NCT05373173|f||||f
17147623|NCT03779334|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147624|NCT00529464|t||||f
17147625|NCT03957551|t||||
17147626|NCT05283148|f||||f
17147627|NCT00095784|f||LTE60||t
17147628|NCT03676634|f||||f
17147629|NCT02052895|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 50 days from the time submitted to the sponsor for review. Only if the disclosure becomes an obstacle to the sponsor's business or registration or maintenance of the sponsor's invention, the sponsor may require changes to the communication and may extend the embargo.|t
17147630|NCT05780463|f||||f
17147631|NCT03131895|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17147632|NCT00540423|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147633|NCT04077645|f||||f
17147634|NCT02213263|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147635|NCT02277093|t||||
17147636|NCT02903407|t||||
17147637|NCT05143047|f||||f
17147638|NCT00216736|f||||f
17147639|NCT00418145|t||||
17147640|NCT03214588|f||OTHER|Generally, the PI may publish results of the study following the publication of results by the Sponsor.|t
17147641|NCT01631552|f||OTHER|"After conclusion of the study and without prior written approval from Immunomedics, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Immunomedics in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17147642|NCT03480763|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17147643|NCT01718873|f||||f
17147644|NCT05143801|f||||f
17147645|NCT03629054|t||||
17147646|NCT00205777|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147647|NCT05485662|t||||
17191855|NCT00978042|f||OTHER|As this study involves multiple centers, no individual publications will be allowed prior to completion of the final report of the multicenter study except as agreed with Allergan.|t
17147648|NCT00367133|f||||f
17147649|NCT01439620|f||||f
17147650|NCT01252953|t||||
17147651|NCT01665508|f||||f
17147652|NCT03272685|f||||f
17147653|NCT02463981|f||||f
17147654|NCT00883233|f||OTHER|Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor for review and approval at least 2 months prior to the date of the intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.|t
17147655|NCT00858780|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147656|NCT00863330|t||||
17147657|NCT02615249|f||||f
17147658|NCT05098743|f||||f
17147659|NCT00351039|f||||f
17147660|NCT03703258|f||||f
17147661|NCT03349632|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17147662|NCT00842309|t||||
17147663|NCT02911025|f||||f
17147664|NCT03218787|f||OTHER||t
17147665|NCT03719040|f||LTE60||t
17147666|NCT02264977|f||||f
17147667|NCT02923349|f||OTHER|Clinical Study Agreement|t
17191856|NCT00520546|t||||f
17191857|NCT02101281|f||||f
17191858|NCT04452318|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17147668|NCT01189747|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147669|NCT04063878|f||LTE60||t
17147670|NCT02751827|f||||f
17147671|NCT01248728|f||||f
17191859|NCT01828554|t||||
17147672|NCT00147498|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147673|NCT01838681|f||||f
17147674|NCT00815087|t||||
17147675|NCT01229150|f||||f
17147676|NCT02011945|f||LTE60||t
17147677|NCT03531827|f||||f
17147678|NCT00849797|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147679|NCT00679081|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for at least 30 days in advance of public release. The sponsor can request removal of any confidential or proprietary information provided by sponsor and extend such review period for another 90 days to file patent applications or take other steps to protect the sponsor's intellectual property interests.|t
17191860|NCT03951805|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17147680|NCT02584608|t||||
17147681|NCT04198363|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17147682|NCT05344118|t||||
17147683|NCT03442322|t||||f
17147684|NCT01404988|t||||
17147685|NCT02588339|t||||
17147686|NCT03922490|f||||f
17147687|NCT03578809|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17147688|NCT01002287|f||||f
17147689|NCT02997176|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147690|NCT01881763|t||||
17147691|NCT01624233|f||GT60||t
17147692|NCT00373256|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147693|NCT04372238|t||||
17147694|NCT04241458|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147695|NCT06144424|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17147696|NCT01246258|t||||
17147697|NCT02645253|f||OTHER|All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.|t
17147698|NCT02331108|f||||f
17147699|NCT02752074|f||OTHER|Clinical Study Agreement.|t
17147700|NCT01447017|f||OTHER|"The following disclosure restriction on the PI was included in clinical study protocol:~If an Investigator wishes to publish results from this clinical study, written permission to publish must be obtained from the Sponsor in advance. As some of the information regarding the IP and development activities at the Sponsor may be of a strictly confidential nature, the Sponsor must first review any publication manuscript prior to their submission to journals, meetings or conferences."|t
17191861|NCT00604669|t||||f
17191862|NCT01695954|t||||f
17191863|NCT03921866|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191864|NCT04328727|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17191865|NCT03684044|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191866|NCT00595413|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17191867|NCT04149002|t||||
17191868|NCT04629950|t||||
17191869|NCT03233633|t||||
17191870|NCT02131597|t||||
17191871|NCT01198145|f||LTE60||t
17191872|NCT00891436|f||OTHER|The sponsor has the right to review the results prior to publication of the results. But no embargo or time limit was given.|t
17191873|NCT01697969|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191874|NCT01561989|t||||
17191875|NCT01381406|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191876|NCT01066026|f||||f
17191877|NCT03447249|f||||t
17191878|NCT02189915|f||||f
17191879|NCT02574455|f||OTHER|"After study conclusion and without prior written approval from Immunomedics and Gilead sciences, investigators in this study may communicate, orally present/publish in scientific journals/other media only after following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Immunomedics and Gilead sciences in an abstract, manuscript/presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17191880|NCT02677896|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17191881|NCT03148496|t||||
17191882|NCT00593866|t||||
17191883|NCT03565315|t||||
17191884|NCT01499199|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191885|NCT02692417|f||||f
17191886|NCT00282971|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17191887|NCT00536341|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17191888|NCT00533546|f||||f
17191889|NCT01637246|f||||f
17191890|NCT03276871|t||||f
17191891|NCT02372253|t||||f
17191892|NCT00629850|t||||
17191893|NCT00393484|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17191894|NCT03201562|f||OTHER|The PI must not present the study results until the aggregate multi-site study results are published. The PI must submit to sponsor any proposed publication or presentation at least 60 days prior to the submission. Sponsor may require the delay of publication or presentation for an additional period of time not to exceed 120 days for the purposes of filing patent applications to patentable subject matter or the resolution of any inaccuracies or misleading statements.|t
17191895|NCT00001277|t||||
17191896|NCT00879060|t||||
17191897|NCT04767698|f||||f
17191898|NCT01381471|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17191899|NCT00957242|f||||f
17191900|NCT02539225|f||GT60||t
17191901|NCT03101371|f||||f
17191902|NCT02318134|t||||
17191903|NCT04766034|t||||
17191904|NCT01976312|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety|t
17191905|NCT03010631|f||OTHER||t
17191906|NCT04048382|f||||f
17191907|NCT02556138|t||||
17191908|NCT00490100|t||||
17191909|NCT01985542|f||||f
17191910|NCT03498196|f||||f
17191911|NCT01205048|f||OTHER||t
17191912|NCT01255670|t||||
17191913|NCT02269475|f||LTE60||t
17191914|NCT01037985|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191915|NCT02730871|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191916|NCT00823472|t||||
17191917|NCT04019444|f||LTE60||t
17191918|NCT01609218|f||GT60||t
17191919|NCT01996605|f||||f
17191920|NCT04220229|f||||f
17191921|NCT04428112|t||||f
17191922|NCT01207492|f||||f
17147701|NCT01175135|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147702|NCT01701063|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17147703|NCT04692155|f||||f
17147704|NCT02554877|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147705|NCT00274651|f||LTE60||t
17147706|NCT04474405|f||LTE60||t
17147707|NCT04547192|t||||f
17147708|NCT04723693|f||||f
17147709|NCT00538031|t||||
17147710|NCT01410227|f||OTHER|Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or ≥12 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥40 days prior to submission or communication. Baxter may request an additional delay of ≤45 days eg, for intellectual property protection.|t
17147711|NCT03497130|t||||
17147712|NCT04002648|t||||
17147713|NCT01484912|f||||f
17147714|NCT02622386|t||||
17147715|NCT02890992|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17147716|NCT03158727|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17147717|NCT00669162|t||||
17147718|NCT00911274|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17147719|NCT01528150|f||LTE60||t
17147720|NCT00807495|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17147721|NCT02412852|f||||f
17147722|NCT00841542|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147723|NCT01169753|t||||
17147724|NCT04029545|f||||f
17147725|NCT00924638|f||GT60||t
17147726|NCT02992067|f||||f
17147727|NCT01007994|f||||f
17147728|NCT04411680|f||LTE60||t
17147729|NCT00748566|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147730|NCT00624286|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17147731|NCT00841659|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147732|NCT00495222|f||||f
17147733|NCT00073307|f||OTHER|"The agreed point of publication is 12-18 months after database lock at the earliest.~* Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).~* No publication of single center data should be done prior of publication if multi -center data."|t
17147734|NCT00794547|t||||f
17147735|NCT00685477|f||||f
17147736|NCT04306952|f||||f
17147737|NCT01001403|t||||f
17147738|NCT01190865|f||LTE60||t
17147739|NCT00326872|f||LTE60||t
17147740|NCT02436200|t||||
17147741|NCT00746421|f||LTE60||t
17147742|NCT00957021|f||OTHER|Each investigator shall have privileges for their own center's results at the completion of the study. These manuscripts and abstracts will be delayed until after the multi-center publication is submitted.All publications shall be submitted to the sponsor for review at least 60 days prior to submission for publication.The sponsor shall not edit or otherwise influence the publications other than to ensure that confidential information is not disclosed and that the data is accurately represented.|t
17147743|NCT01822119|f||GT60||t
17147744|NCT01483820|f||LTE60||t
17147745|NCT00867360|f||||f
17147746|NCT05604209|t||||
17147747|NCT00112437|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147748|NCT01960296|t||||
17147749|NCT02003391|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17191923|NCT02769858|t||||f
17191924|NCT02807779|f||||f
17191925|NCT03638427|t||||
17191926|NCT03757949|f||||t
17191927|NCT04585191|f||||f
17147750|NCT02272803|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147751|NCT03573544|f||||f
17147752|NCT01345539|t||||
17147753|NCT00227370|f||||f
17147754|NCT03846193|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17147755|NCT04693429|f||||t
17147756|NCT00902538|f||OTHER|A site may not publish results until after a multi-center publication has been submitted for publication or until one year after the study has ended, whichever occurs first. Then, the site will have the opportunity to publish the results, provided that Daiichi Sankyo Europe has had the opportunity to review and comment on the site's proposed publication prior to its being submitted for publication with the advice of company patent council and in accord with needs for subject protection.|t
17147757|NCT00725322|t||||
17147758|NCT00926887|f||||f
17147759|NCT00365053|f||LTE60||t
17147760|NCT00660660|f||OTHER|If Sponsor does not publish within 2 years after study completion, PI is permitted to publish, with confidential information removed from manuscript. Sponsor will have opportunity to review and approve publication at least 60 days prior to being submitted/disclosed. Sponsor can request, in writing, an additional 90 day embargo.|t
17147761|NCT02132910|f||||f
17147762|NCT03256227|t||||
17147763|NCT02244554|f||||f
17147764|NCT00834964|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147765|NCT02722239|f||OTHER|PI signed the Protocol and agreed to conform fully to the Protocol requirements. According to the Protocol the PI should inform the Sponsor in writing beforehand and provide the sponsor with all manuscripts or abstracts before submitting them to the editorial office or scientific expert board, and obtain a written permission from the Sponsor. The period is not mentioned.|t
17147766|NCT00081653|f||||f
17147767|NCT01876992|t||||
17147768|NCT00491738|f||OTHER||t
17147769|NCT05293106|t||||
17147770|NCT02694536|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17191928|NCT01701986|t||||
17191929|NCT03702842|f||||f
17191930|NCT04814186|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191931|NCT04917588|f||||t
17191932|NCT04919590|t||||
17191933|NCT01853748|f||||f
17191934|NCT02631603|f||||f
17191935|NCT03632941|t||||
17191936|NCT03342027|f||||f
17191937|NCT02237417|f||GT60||t
17191938|NCT06336629|f||||t
17191939|NCT04043455|f||||f
17191940|NCT05194917|f||||f
17191941|NCT04520061|f||||f
17147771|NCT00385736|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17147772|NCT01426360|f||||f
17147773|NCT01662960|f||||f
17147774|NCT00433745|t||||f
17147775|NCT02727192|f||||f
17147776|NCT00928057|f||LTE60||t
17147777|NCT00845130|f||||f
17147778|NCT05497557|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17191942|NCT04192747|f||||t
17191943|NCT04922021|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17191944|NCT05786391|t||||
17147779|NCT00629122|t||||f
17147780|NCT06078501|t||||
17191945|NCT03817684|t||||
17191946|NCT03314753|f||OTHER|"Publications from this retrospective data collection are regulated separately in the publication plan, which was reviewed and approved by the Publication Committee.~Medical Centers / Investigators may publish the results of work performed under the applicable site agreement. Any such publication shall be at a time determined by Medtronic and shall be provided to Medtronic for review at least 60 days prior to submission or presentation."|t
17191947|NCT01285999|t||||f
17191948|NCT02544074|t||||
17191949|NCT03189524|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17147781|NCT01380782|f||GT60||t
17147782|NCT05387408|t||||
17147783|NCT03428750|f||||f
17147784|NCT01919112|f||||f
17147785|NCT00635648|f||OTHER|Twenty-four months after completion of this study or after publication of the multicenter results, an investigator may publish the results for their study site independently. The sponsor must have the opportunity to review all proposed publications or presentations regarding the study 60 days before submission.|t
17147786|NCT04194801|f||GT60||t
17147787|NCT00294047|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147788|NCT02157974|f||||f
17147789|NCT01339247|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147790|NCT00985439|f||||f
17191950|NCT02723955|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17147791|NCT05274763|f||||f
17147792|NCT01174186|f||||f
17147793|NCT02960295|t||||
17147794|NCT01051349|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17147795|NCT01647828|f||||f
17147796|NCT01906372|f||||f
17147797|NCT04428307|t||||
17147798|NCT00847535|f||GT60||t
17147799|NCT05604014|f||||f
17147800|NCT02484807|f||LTE60||t
17147801|NCT03393754|f||||f
17147802|NCT00075608|t||||
17147803|NCT02177617|f||||f
17147804|NCT02054715|f||OTHER|"Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive~https://nctn-data-archive.nci.nih.gov/"|t
17147805|NCT01438060|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17147806|NCT02725580|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17147807|NCT01442376|f||OTHER|If Sponsor does not submit a publication regarding the study to a journal within 12 months from study data analysis completion, the Investigator may publish an analysis of the study data collected as a result of the conduct of the study by the Investigator. The Investigator shall ensure that at least 60 days prior to submitting/presenting a manuscript/material relating to study to publishers a copy of all manuscripts/materials is provided to the Sponsor to allow the Sponsor sixty days to review.|t
17191951|NCT04300647|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147808|NCT03499873|f||OTHER|The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17147809|NCT01964950|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17147810|NCT04404725|f||||f
17147811|NCT01075516|f||||f
17147812|NCT00834405|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147813|NCT02252016|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17147814|NCT00840281|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147815|NCT04631562|f||||t
17147816|NCT04171115|f||||t
17147817|NCT02471807|f||||t
17147818|NCT05327777|f||||f
17191952|NCT03657212|f||||f
17191953|NCT02824029|t||||
17191954|NCT03845829|f||||f
17191955|NCT04751526|t||||
17191956|NCT04928001|f||||f
17191957|NCT01693120|f||OTHER||t
17147819|NCT03031795|f||||f
17147820|NCT00932477|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17191958|NCT04153565|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17191959|NCT01741363|f||||f
17191960|NCT06146374|f||LTE60||t
17191961|NCT01285635|t||||
17191962|NCT03990649|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17191963|NCT00505934|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17191964|NCT01296646|f||||f
17191965|NCT03050814|f||||f
17191966|NCT01443845|f||OTHER||t
17191967|NCT02014129|f||GT60||t
17191968|NCT05137236|f||||t
17147821|NCT02227238|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147822|NCT04025021|t||||
17147823|NCT03966911|f||GT60||t
17147824|NCT01986647|f||||f
17147825|NCT00868998|t||||
17147826|NCT00595153|f||||f
17147827|NCT03498560|t||||
17147828|NCT04541173|f||||f
17147829|NCT03985657|f||||f
17147830|NCT01004510|t||||
17147831|NCT01790685|f||OTHER|There is a restriction on the PI regarding disclosure of study results, which will be updated once the manuscript is published.|t
17147832|NCT00474188|f||OTHER|The investigator shall have the right to publish and/or present the data generated from the study provided that the investigator shall (i) furnish the sponsor with a copy of any proposed publication or presentation at least thirty (30) days in advance of the submission of such material, (ii) delete from such material any confidential information of the sponsor, and (iii) delay submission of same for up to sixty (60) days to permit the preparation and filing of intellectual property applications.|t
17147833|NCT01952691|t||||
17147834|NCT00199901|f||||f
17147835|NCT01279109|t||||
17147836|NCT05776901|f||||f
17191969|NCT02724956|t||||
17191970|NCT02134951|f||||f
17191971|NCT00431834|f||LTE60||t
17191972|NCT04071756|f||||f
17191973|NCT03628885|f||||f
17147837|NCT00917735|f||||f
17147838|NCT02302716|f||GT60||t
17147839|NCT04523480|f||||f
17147840|NCT00529191|t||||f
17147841|NCT01911429|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17191974|NCT02461628|t||||f
17191975|NCT00324350|f||||f
17191976|NCT02647905|f||LTE60||t
17191977|NCT02015520|f||||f
17191978|NCT05119855|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17147842|NCT01557751|f||||f
17147843|NCT02043132|f||||f
17147844|NCT01923740|f||LTE60||t
17147845|NCT00158925|f||OTHER||t
17147846|NCT00472212|f||||f
17147847|NCT02462837|f||||f
17147848|NCT00114504|t||||
17147849|NCT00958724|f||LTE60||t
17147850|NCT01026402|f||LTE60||t
17147851|NCT02121184|f||||f
17147852|NCT00840203|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147853|NCT03616379|f||||f
17147854|NCT05562011|f||||f
17147855|NCT03349567|f||||f
17147856|NCT00178178|f||||f
17147857|NCT05032807|t||||
17191979|NCT02932579|f||||f
17147858|NCT00487435|f||LTE60||t
17147859|NCT02705716|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147860|NCT00562718|t||||
17147861|NCT01868243|f||||f
17147862|NCT01608906|f||||f
17147863|NCT02905435|f||LTE60||t
17147864|NCT01507662|f||||f
17147865|NCT01395017|f||||f
17147866|NCT03541252|t||||
17147867|NCT04364191|f||||f
17147868|NCT03961204|f||||f
17147869|NCT01165450|t||||
17147870|NCT01566435|t||||
17147871|NCT00860938|t||||
17147872|NCT01222234|t||||
17147873|NCT03733145|t||||
17147874|NCT04236596|t||||
17147875|NCT06923033|t||||f
17147876|NCT05984290|f||||t
17147877|NCT02324335|f||GT60||t
17147878|NCT04336332|t||||
17147879|NCT00851409|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to its submission or disclosure. The sponsor may request to delete information identified by sponsor as confidential information prior to submitting such manuscript and/or abstract for publication. For a multi-center study, the investigator must wait (i) at least 24 months after the study is completed at all sites or (ii) until after the multi-center publication.|t
17147880|NCT02225106|f||||f
17147881|NCT00798603|f||LTE60||t
17147882|NCT01127087|t||||f
17147883|NCT02316223|t||||
17147884|NCT01275664|f||LTE60||t
17147885|NCT00521586|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147886|NCT00529763|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17147887|NCT03669250|f||||f
17147888|NCT00828321|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147889|NCT03234907|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17147890|NCT02664415|f||||f
17147891|NCT04039022|f||||t
17147892|NCT02155257|t||||
17147893|NCT02107196|f||OTHER|Prior to submitting the results of this study for publication or presentation, the Investigator will allow the sponsor at least 30 days time to review and comment upon the publication manuscript. It is agreed, that the results of the study will not be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17147894|NCT00516295|f||LTE60||t
17147895|NCT01243151|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147896|NCT03119662|f||OTHER|The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.|t
17147897|NCT04956289|f||OTHER|The most restrictive relevant agreement on the PI provides that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is not less than 30 days from the time submitted to the sponsor for review.|t
17147898|NCT03123874|t||||
17147899|NCT01630616|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17147900|NCT02218541|t||||
17147901|NCT03390257|f||||f
17147902|NCT01993186|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147903|NCT01853176|t||||
17147904|NCT00198133|t||||
17147905|NCT03827395|f||LTE60||t
17147906|NCT00731939|f||||f
17147907|NCT00493805|f||||f
17147908|NCT02287480|t||||
17147909|NCT02072096|f||||f
17147910|NCT01634139|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17147911|NCT01694563|f||||t
17147912|NCT01168856|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147913|NCT01266902|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17147914|NCT00979147|f||||f
17147915|NCT02674711|f||||f
17147916|NCT00387153|f||OTHER|Sponsor has the right to the 1st publication within 12 months of study conclusion. After, the institution/PI may publish data after submission to the sponsor for review.|t
17191980|NCT01972724|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17191981|NCT02168400|t||||
17147917|NCT04567329|f||||f
17147918|NCT01087502|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17147919|NCT01457196|f||GT60||t
17191982|NCT05608564|f||||f
17191983|NCT00111813|f||OTHER|"The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as~confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines."|t
17147920|NCT00985751|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17147921|NCT00380588|f||GT60||t
17147922|NCT02047305|f||||f
17147923|NCT01451541|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17147924|NCT01780350|f||||f
17147925|NCT03366428|f||||f
17147926|NCT00804973|f||GT60||t
17147927|NCT02096692|f||OTHER|Principal Investigators agree to submit copies of any manuscript proposed for publication to Sponsor for review at least 30 days in advance of submission for publication or presentation. Sponsor may extend such review period for another 90 days to file patent applications or take other steps to protect its intellectual property interests, or to remove from the paper or presentation any language that is detrimental to Sponsor's intellectual property interests.|t
17147928|NCT03275623|t||||
17147929|NCT00999687|t||||
17147930|NCT00659828|t||||
17147931|NCT01120028|t||||f
17147932|NCT04116957|t||||
17147933|NCT03684928|f||||f
17147934|NCT03018925|f||||f
17147935|NCT01253564|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17147936|NCT00527098|t||||f
17147937|NCT00557245|t||||
17147938|NCT00642993|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17147939|NCT02986139|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17147940|NCT00414726|f||||f
17147941|NCT02034513|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17147942|NCT02985749|f||||f
17147943|NCT02308241|t||||
17147944|NCT04408924|f||GT60||t
17147945|NCT00691704|t||||
17191984|NCT01929759|f||||f
17191985|NCT03693937|f||||f
17191986|NCT01000480|f||GT60||t
17191987|NCT00570700|t||||
17147946|NCT04661202|f||||f
17147947|NCT04158687|f||OTHER|If an Investigator wants to publish study data or results, the publication or presentation must be provided to Concert for review at least 60 days in advance. If Concert needs to file a patent application prior to publication, the publication can be delayed up to 90 days from Sponsor providing notice to the investigator of such need.|t
17147948|NCT02889393|t||||
17147949|NCT04102345|t||||
17191988|NCT00174382|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17191989|NCT00296036|f||LTE60||t
17147950|NCT00496860|f||LTE60||t
17147951|NCT02518945|t||||
17147952|NCT00835666|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17147953|NCT03599362|t||||
17147954|NCT02511535|t||||
17147955|NCT03707587|f||||f
17147956|NCT01537887|f||GT60||t
17147957|NCT02312154|f||||f
17147958|NCT01370083|f||||f
17147959|NCT01167829|t||||
17147960|NCT03358147|f||OTHER|Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.|t
17191990|NCT05686408|f||OTHER|An industry standard NDA is in place with all investigators.|t
17191991|NCT02576509|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17191992|NCT04688450|t||||
17191993|NCT03089125|f||||f
17191994|NCT01353313|f||OTHER|Investigators must adhere to the Neonatal Research Network Publication Policies|t
17191995|NCT04755660|f||||f
17191996|NCT02879162|t||||
17191997|NCT02217904|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17191998|NCT00670046|t||||
17191999|NCT00335036|f||||f
17192000|NCT02121002|f||||f
17192001|NCT03403413|t||||
17192002|NCT03655262|f||||f
17192003|NCT03501264|t||||
17192004|NCT04583423|f||OTHER|If publication activity was not directed by the Sponsor, the investigator agreed to submit all manuscripts or abstracts to the Sponsor before submission. This allowed the Sponsor to protect proprietary information and to provide comments.|t
17192005|NCT03351699|f||OTHER|Subsequent to the multicenter publication (or after public disclosure of the results at www.clinicaltrials.gov if multicenter manuscript is not planned), an investigator and colleagues may publish their data independently. Sponsor must have opportunity to review proposed abstracts, manuscripts or presentations 45 days prior to submission for publication/presentation. Confidential information must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17192006|NCT04704284|t||||
17192007|NCT05644730|f||||f
17192008|NCT05946551|t||||
17192009|NCT00603954|f||||f
17192010|NCT02633267|f||||f
17192011|NCT00580866|f||||f
17192012|NCT02477605|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17192013|NCT00567489|f||||t
17192014|NCT02570022|f||||f
17192015|NCT00041938|f||||f
17192016|NCT03101930|f||||f
17192017|NCT01083316|t||||
17192018|NCT00331136|f||||f
17192019|NCT04515641|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17192020|NCT01215344|t||||
17192021|NCT00065260|t||||
17192022|NCT00780234|t||||
17192023|NCT02178098|f||OTHER|If the Principal Investigator plans to publish information from the study, a copy of the manuscript should be provided to the Sponsor for review before submission for publication or presentation. The Sponsor may request that the publication be withheld.|t
17147961|NCT01044537|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192024|NCT04011631|f||||f
17192025|NCT03432858|f||||f
17192026|NCT02382744|f||||f
17192027|NCT01411592|t||||
17192028|NCT01044303|f||||f
17192029|NCT01109524|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192030|NCT01553058|t||||
17192031|NCT01923480|f||OTHER||t
17192032|NCT00194610|t||||
17192033|NCT00031694|f||LTE60||t
17192034|NCT05123742|f||||f
17192035|NCT05239182|t||||
17192036|NCT00903162|f||||f
17192037|NCT02960204|f||OTHER|Any publication or discussion must be approved by the Sponsor prior to release.|t
17192038|NCT00475241|t||||
17192039|NCT03087708|t||||
17192040|NCT01303445|f||OTHER|Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17192041|NCT04939246|t||||
17192042|NCT04994509|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192043|NCT06546657|f||||f
17192044|NCT04278586|f||||f
17192045|NCT05540535|f||||f
17192046|NCT05386238|f||||f
17192047|NCT04714320|f||||t
17192048|NCT05057897|f||||t
17192049|NCT03346538|f||OTHER||t
17192050|NCT05672667|t||||
17192051|NCT04524390|f||LTE60||t
17192052|NCT05930782|f||||f
17192053|NCT04540913|f||GT60||t
17192054|NCT03438188|f||||f
17192055|NCT02991807|f||||f
17192056|NCT02300298|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192057|NCT00792636|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192058|NCT01610297|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17192059|NCT00574834|f||OTHER|Results of this trial were too preliminary to report. Trial was ended due to lack of funding to complete. No conclusions could be drawn from existing data.|t
17192060|NCT01007396|t||||
17147962|NCT00425308|f||OTHER|Disclosure Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17147963|NCT04442503|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17147964|NCT01250730|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17147965|NCT02933060|f||||f
17147966|NCT01945580|f||OTHER|Before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.|t
17147967|NCT03068780|f||||t
17147968|NCT04540094|f||||f
17147969|NCT05034874|f||OTHER|Sponsor requires an opportunity to review any proposed disclosure at least 60 days prior to disclosure. Potential modifications may be suggested. PI will delete any information identified as confidential by sponsor or defer to permit filing of any patent applications. First publication will be a joint publication by Sponsor involving all trial sites. PI may publish if joint manuscript not submitted within 12 months of completion of clinical study report or termination of the trial at all sites.|t
17147970|NCT00989950|f||||f
17147971|NCT00101439|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17147972|NCT01851772|f||LTE60||t
17147973|NCT00840658|f||||f
17147974|NCT01867658|f||GT60||t
17147975|NCT00474058|f||OTHER|"UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."|t
17147976|NCT03101358|f||||f
17147977|NCT03334734|f||OTHER|The agreements between the Principal Investigators and the CRO restricts the PIs' rights to discuss or publish trial results after the trial is completed.|t
17147978|NCT02426918|f||OTHER|Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.|t
17147979|NCT02845336|t||||
17147980|NCT02045108|f||||f
17147981|NCT02974907|f||||f
17147982|NCT00654186|t||||
17147983|NCT05616728|f||||t
17147984|NCT00690495|f||LTE60||t
17147985|NCT01024855|t||||f
17147986|NCT01632423|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17147987|NCT01003938|t||||
17147988|NCT00076622|t||||f
17147989|NCT00674128|t||||
17147990|NCT03306277|f||OTHER|Sponsor can review results communications prior to public release and has right to request changes to communications regarding trial results for a period that is more or equal to 30 days but less than or equal to 150 days from the time submitted to the Sponsor for review in order to either delete references to Sponsor's Confidential Information or delay such results communications to permit Sponsor to obtain appropriate Intellectual Property protection as set forth in the agreement.|t
17147991|NCT04224753|t||||
17147992|NCT03209505|t||||f
17147993|NCT00829452|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17147994|NCT03082586|f||||f
17147995|NCT01296841|t||||
17147996|NCT04431518|f||||f
17147997|NCT00881751|f||||t
17147998|NCT00301964|f||LTE60||t
17147999|NCT02385708|f||||f
17148000|NCT01852799|f||||f
17148001|NCT05533411|f||GT60||t
17148002|NCT00834561|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17148003|NCT01559363|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17148004|NCT00672984|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually|t
17148005|NCT00645853|f||LTE60||t
17148006|NCT04060251|f||||f
17148007|NCT01151618|f||LTE60||t
17148008|NCT01632306|f||GT60||t
17148009|NCT01156987|f||||f
17192061|NCT02590432|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148010|NCT00838162|f||GT60||t
17148011|NCT03867760|f||||f
17148012|NCT02286466|f||||f
17192062|NCT03405714|f||GT60||t
17192063|NCT02740231|f||||t
17148013|NCT02153645|f||OTHER|"Investigator shall allow SPONSOR 60 days to review any manuscript and 30 days to review any poster presentation, abstract or any other written or oral material which discloses the Study Results. SPONSOR may request in writing an additional 60 days for review.~SPONSOR may remove all Confidential Information from any publications or presentations, or if deemed not sufficient to protect its Intellectual Property Rights, then SPONSOR may embargo the publication or presentation."|t
17148014|NCT00874276|f||||f
17148015|NCT01723202|t||||
17148016|NCT03694197|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17148017|NCT02957331|f||||f
17148018|NCT03247686|f||||t
17148019|NCT00605150|t||||
17148020|NCT01487499|f||||f
17148021|NCT03102879|f||||f
17148022|NCT01472432|f||||f
17148023|NCT01390415|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148024|NCT00128219|f||LTE60||t
17148025|NCT02583048|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17148026|NCT01851876|t||||
17148027|NCT01151280|f||||f
17148028|NCT00757705|f||LTE60||t
17148029|NCT03544242|t||||
17148030|NCT02578641|f||||f
17148031|NCT02313558|f||||f
17148032|NCT02015832|f||||t
17148033|NCT01710358|f||GT60||t
17148034|NCT04707846|t||||
17148035|NCT02297230|f||||f
17148036|NCT00735696|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17148037|NCT00084864|t||||
17148038|NCT04406194|f||OTHER||t
17148039|NCT01741545|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submitting for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148040|NCT01456962|f||||f
17148041|NCT02109458|t||||
17148042|NCT03820258|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17148043|NCT02704091|f||OTHER|The sponsor requires that reasonable opportunity be given to review the content and conclusions of any abstract, presentation, or paper before the material is submitted for publication or communicated. The sponsor will comment on the draft documents within the time period agreed in the contractual arrangements. Requested amendments will be incorporated by the author, provided they do not alter the scientific value of the material.|t
17148044|NCT03073798|t||||
17148045|NCT01186458|f||||f
17148046|NCT01496118|f||||f
17148047|NCT02420353|f||||f
17148048|NCT04608448|t||||
17148049|NCT01149057|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148050|NCT00577655|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If review shows that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for up to 90 additional days to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure of multicenter data, but not longer than 12 months from study completion/termination at all participating sites.|t
17148051|NCT00875524|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17148052|NCT01370863|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17148053|NCT02761915|f||||f
17148054|NCT01143337|f||OTHER||t
17148055|NCT03276559|f||||f
17148056|NCT00270634|f||GT60||t
17148057|NCT00819169|f||||t
17148058|NCT00406393|f||||f
17148059|NCT04090658|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17148060|NCT03277248|f||||f
17192064|NCT01881412|f||||f
17192065|NCT00243503|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192066|NCT02410018|f||||f
17192067|NCT03076515|f||||f
17192068|NCT02374307|t||||
17192069|NCT00999167|f||OTHER||t
17192070|NCT02554786|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17148061|NCT01663896|f||OTHER|Proposals for all publications, abstracts, presentations, or journal manuscripts arising from, or related to the Study will be submitted for approval to the Publications Committee. Accordingly, decisions on timing and content of publications and presentations from the Study will be coordinated with the Study Publication Committee and Sponsor.|t
17192071|NCT05052996|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17192072|NCT00522951|f||GT60||t
17192073|NCT02794480|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192074|NCT01017146|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192075|NCT01771731|t||||f
17192076|NCT01747486|t||||
17192077|NCT00087139|f||LTE60||t
17192078|NCT00976495|f||||f
17192079|NCT02321514|f||GT60||t
17192080|NCT04128319|f||OTHER|Investigators agree to the disclosure requirements in a Protocol Rider. This states that the BMT CTN DCC will lead on the initial study Publication, and for any subsequent study Publication, with either a) the advance review of Sponsor or b) two years after the completion of the Study at all Study Sites, the DCC, Participating Sites, and Principal Investigators may publicly disclose or submit for Publication an article, poster or other material that includes analysis of the study results.|t
17192081|NCT04484935|f||||t
17148062|NCT02701101|f||OTHER|The Principal Investigator and Institution shall be free to publish and present the results and data from the Study per the following conditions.The manuscript or abstract proposed to be published or presented shall be submitted to Sponsor for review and comment at least forty-five (45) days prior to submission for publication or presentation to allow Sponsor to protect its rights to any patentable inventions disclosed in such publication or presentation.|t
17148063|NCT02083809|f||||f
17148064|NCT03614728|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17148065|NCT00379353|t||||f
17148066|NCT01824576|f||||f
17148067|NCT02818894|f||||f
17192082|NCT00132964|t||||
17192083|NCT01094184|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192084|NCT02150967|f||||f
17148068|NCT01152112|f||||f
17148069|NCT01691612|t||||
17148070|NCT00858403|t||||
17148071|NCT00363077|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192085|NCT03892564|f||||t
17192086|NCT04992390|t||||
17192087|NCT05873062|f||||f
17192088|NCT01216176|t||||
17192089|NCT04847479|f||||f
17192090|NCT03725722|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. After such a publication is made public, or if no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17192091|NCT05505045|f||||f
17192092|NCT01643070|f||||f
17192093|NCT01600014|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192094|NCT02975505|t||||
17192095|NCT01259401|t||||
17192096|NCT05769595|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17192097|NCT06241794|f||||f
17192098|NCT03481777|t||||t
17192099|NCT05696080|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17192100|NCT00696124|f||||f
17192101|NCT05768373|f||||f
17192102|NCT03954184|t||||
17148072|NCT05315713|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148073|NCT02243579|f||LTE60||t
17148074|NCT00556673|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148075|NCT01131260|f||||t
17148076|NCT00835081|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17148077|NCT00421304|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction in not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17148078|NCT03196284|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17148079|NCT00412464|f||||f
17148080|NCT01730846|f||||f
17148081|NCT02535923|f||||f
17148082|NCT01018862|f||||f
17148083|NCT05471349|t||||
17148084|NCT02233751|f||OTHER||t
17148085|NCT00840879|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17148086|NCT00840840|f||OTHER|PI is not permitted to discuss or publish trial results.|t
17148087|NCT00159419|t||||f
17148088|NCT01109849|f||||f
17148089|NCT01006967|f||||f
17148090|NCT01023776|t||||f
17148091|NCT02906813|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148092|NCT00754052|f||OTHER||t
17148093|NCT00697801|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148094|NCT04364854|f||||f
17148095|NCT02435433|f||GT60||t
17148096|NCT00659815|f||OTHER|The results of the study may be published or presented by the investigator(s) after the review by, and in consultation and agreement with the Sponser, and such that confidential or proprietary information is not disclosed.|t
17148097|NCT02651987|f||||f
17148098|NCT00522041|f||OTHER|Publication statement in clinical trial agreement.|t
17148099|NCT03540160|f||GT60||t
17148100|NCT01664039|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17148101|NCT01310855|f||OTHER|"The excerpts below are present on all site agreements between site staff (including PI) and the sponsor:~* The Site shall ensure that only those of its employees or officers directly concerned with the conduct of the Trial at the Site shall have access to the Confidential Information relating to the Trial.~* The Site agrees it will not publish any information, data or results without the express written permission of the TMG, such permission not to be unreasonably withheld."|t
17148102|NCT01085539|f||LTE60||t
17148103|NCT00726830|f||||f
17148104|NCT02640235|f||||f
17148105|NCT01322633|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192103|NCT03398200|t||||
17148106|NCT05109104|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148107|NCT02372006|f||LTE60||t
17148108|NCT01807026|f||GT60||t
17148109|NCT00458822|t||||
17192104|NCT01649271|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192105|NCT06180967|f||GT60||t
17192106|NCT05756075|t||||f
17192107|NCT03433469|t||||
17192108|NCT04605198|f||||f
17192109|NCT04038957|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17192110|NCT03821844|f||||f
17192111|NCT03591770|t||||
17192112|NCT01998984|f||OTHER|Prior to submitting or presenting a manuscript relating to the clinical trial to a publisher, reviewer or other outside person, the investigator shall provide to LEO Pharma A/S a copy of all such manuscripts, and LEO Pharma A/S shall have rights to review and comment. Upon the request of LEO Pharma A/S the investigator shall remove any confidential information (other than results generated by the investigator) prior to submitting or presenting the manuscripts.|t
17192113|NCT04354337|f||||f
17148110|NCT00467597|t||||
17148111|NCT02235870|f||||t
17148112|NCT01046084|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17148113|NCT02166606|f||OTHER|Consultant (PI) acknowledges and agrees that (i) Consultant shall not publish any data, report, white papers or other materials arising out of the Services performed pursuant to this Agreement without the prior written consent of Boston Scientific, and (ii) any such publication shall not include Boston Scientific Confidential Information except prior written consent of Boston Scientific.|t
17148114|NCT01958476|f||||f
17148115|NCT02248714|f||||f
17148116|NCT04476277|t||||
17148117|NCT01971645|t||||
17148118|NCT01962298|t||||
17148119|NCT00537095|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17148120|NCT00533507|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148121|NCT01576705|t||||
17148122|NCT03727139|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17148123|NCT00566722|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17148124|NCT02896296|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17148125|NCT01874535|f||||f
17148126|NCT02597049|f||GT60||t
17148127|NCT02463487|f||||f
17148128|NCT00243347|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17148129|NCT03124758|t||||
17148130|NCT01044433|f||||f
17148131|NCT03329209|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148132|NCT05065619|f||OTHER||t
17148133|NCT01390948|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148134|NCT05203146|t||||
17148135|NCT02452463|t||||
17148136|NCT05740098|f||||f
17148137|NCT01528735|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148138|NCT01401062|f||||f
17148139|NCT00755235|f||||f
17148140|NCT00757172|t||||
17148141|NCT03555695|f||||f
17148142|NCT03544216|f||||f
17148143|NCT04194151|f||||f
17148144|NCT01499043|f||||f
17148145|NCT00538863|f||||f
17148146|NCT04203823|f||LTE60||t
17148147|NCT00438633|t||||
17148148|NCT01912807|t||||f
17148149|NCT01968031|f||GT60||t
17148150|NCT00919113|f||LTE60||t
17148151|NCT03506633|f||||f
17148152|NCT01894230|t||||
17148153|NCT01759251|f||OTHER|Investigator shall not publish /present the results without Abbott's prior written consent. In the event that applicable law permits Investigator to publish or present results without Abbott's prior written consent, Investigator shall provide Abbott with a complete copy of such publication or presentation at least 60 days prior to submission for publication or presentation and Investigator shall reasonably consider all comments which Abbott may provide regarding such publication or presentation.|t
17148154|NCT00640393|f||LTE60||t
17148155|NCT01134549|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148156|NCT00396162|f||||f
17148157|NCT02856594|f||||f
17148158|NCT03387462|f||||f
17148159|NCT01884844|f||||f
17148160|NCT01460628|t||||f
17148161|NCT02920476|t||||
17148162|NCT01944722|f||||t
17148163|NCT00210639|f||GT60||t
17148164|NCT01202253|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148165|NCT02854800|t||||f
17148166|NCT05014438|f||LTE60||t
17148167|NCT02627963|f||||f
17148168|NCT01545193|t||||
17148169|NCT00152451|f||GT60||t
17148170|NCT05053360|t||||f
17148171|NCT00503867|f||||f
17148172|NCT00897676|t||||
17148173|NCT04697173|t||||f
17148174|NCT03807440|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148175|NCT00323258|t||||f
17148176|NCT01586039|f||||f
17148177|NCT02518139|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148178|NCT04436198|t||||
17148179|NCT02442687|f||||f
17148180|NCT01859598|f||||f
17148181|NCT00354835|f||OTHER|Must obtain prior Sponsor approval.|t
17148182|NCT01968551|f||OTHER||t
17148183|NCT00573313|t||||f
17148184|NCT00431041|f||OTHER|"PIs may not present or publish data prior to publication of the multicenter data or 12 months have elapsed following database lock.~Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of up to 90 days from the time submitted to the sponsor for review.~PIs may not engage in contacts with the media related to the study, study interventions or data without prior written consent."|t
17148185|NCT03255980|f||||t
17148186|NCT01597791|f||||f
17148187|NCT03405363|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148188|NCT02533466|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148189|NCT02096705|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148190|NCT01949532|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148191|NCT00884390|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148192|NCT05412121|t||||
17148193|NCT01533038|f||||f
17148194|NCT04736537|f||||f
17148195|NCT02670551|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148196|NCT02611323|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148197|NCT01215721|f||||f
17148198|NCT00045162|f||||f
17148199|NCT01899053|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148200|NCT03105297|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192114|NCT01843374|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the communication of results, it being understood that results shall be published regardless of outcome|t
17192115|NCT03397108|t||||
17148201|NCT03786770|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (60) days prior to the submission thereof for publication or disclosure to a third party: (i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17148202|NCT00714051|t||||f
17148203|NCT03231345|t||||
17148204|NCT01910831|f||||f
17148205|NCT01929681|f||||f
17148206|NCT03250117|f||OTHER|The Sponsor has rights to first publication of results unless waived by Sponsor. PIs may publish following Sponsor first publication or 18 months after conclusion, abandonment or termination of study. Sponsor to review proposed publications prior to public release and can embargo results for up to 60 days from the time submitted to the Sponsor for review and may remove any information that is considered confidential and/or proprietary other than Study data and results.|t
17148207|NCT00787124|t||||f
17148208|NCT01073631|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148209|NCT01971554|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17148210|NCT02161705|f||||f
17148211|NCT01426854|f||OTHER|Results, materials of research, relevant intellectual property, and trial materials may not be used, disclosed, revealed, or published in any form without Sponsor's prior written consent.|t
17148212|NCT00438750|f||||f
17148213|NCT03505151|t||||
17148214|NCT01942135|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148215|NCT00950300|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148216|NCT01717040|t||||
17148217|NCT00494013|f||GT60||t
17148218|NCT04750239|f||||f
17148219|NCT00919711|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148220|NCT00903877|t||||f
17192116|NCT03554265|t||||
17192117|NCT02605837|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17192118|NCT02652260|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17192119|NCT05056246|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17192120|NCT04046848|f||||t
17192121|NCT05055778|f||||f
17192122|NCT03190174|f||||f
17192123|NCT03899961|t||||
17192124|NCT05656911|f||OTHER|The results of this study may be published or presented at scientific meetings by the sponsor. If this is foreseen by the investigator, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.|t
17192125|NCT02837510|f||||f
17192126|NCT03088813|f||||t
17192127|NCT02780388|f||OTHER|Viela Bio has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it is understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multicentre publication.|t
17192128|NCT04527146|f||||f
17192129|NCT05107401|f||||f
17192130|NCT03363854|f||OTHER|LEO Pharma A/S seeks publication of all phase 3 clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17192131|NCT00977691|t||||
17192132|NCT01903811|f||LTE60||t
17192133|NCT05166135|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192134|NCT04468776|f||||f
17192135|NCT03569176|t||||
17192136|NCT04440176|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192137|NCT03079024|t||||
17192138|NCT01704079|f||LTE60||t
17192139|NCT00003042|t||||
17192140|NCT03285763|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192141|NCT03624972|t||||
17192142|NCT03456076|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192143|NCT00439413|f||GT60||t
17192144|NCT00265200|t||||
17192145|NCT04579250|t||||
17192146|NCT04059042|f||||f
17192147|NCT03733028|t||||
17192148|NCT04711135|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17192149|NCT00998881|f||OTHER||t
17192150|NCT02283749|f||||f
17192151|NCT00818246|t||||
17192152|NCT03128359|t||||
17192153|NCT02006758|f||||t
17192154|NCT03399604|f||||f
17192155|NCT04788641|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17192156|NCT03283371|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17192157|NCT02462759|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17192158|NCT00093015|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148221|NCT00087529|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148222|NCT00685334|f||||f
17192159|NCT02561702|t||||
17192160|NCT04600752|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192161|NCT01256840|f||||f
17148223|NCT01891357|f||GT60||t
17148224|NCT03944057|f||||f
17148225|NCT04573309|f||||t
17148226|NCT02300987|f||OTHER|The terms and conditions of Novartis'agreements with its investigators may vary. However Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148227|NCT02488109|t||||f
17148228|NCT03969641|f||||f
17148229|NCT01541215|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17148230|NCT02633241|t||||
17148231|NCT03232736|f||||f
17148232|NCT02466087|t||||
17148233|NCT01086228|f||GT60||t
17192162|NCT03398148|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192163|NCT02791230|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192164|NCT05233098|f||||f
17192165|NCT04076293|f||||f
17192166|NCT04201834|t||||f
17192167|NCT00212355|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17192168|NCT03661359|f||||f
17192169|NCT04310735|f||||f
17192170|NCT04104321|f||||f
17192171|NCT04608045|f||OTHER|The PI and Sponsor plan to publish the data.|t
17192172|NCT03517553|t||||
17192173|NCT03271151|t||||f
17192174|NCT03575052|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17192175|NCT03103321|f||||f
17192176|NCT04247542|f||OTHER|The sponsor is responsible for the conduct of the study, data analyses, and all results. All data are proprietary and belong to the sponsor, not to the investigator.|t
17148234|NCT02658019|t||||
17148235|NCT00820599|f||||t
17148236|NCT01098851|f||LTE60||t
17148237|NCT05353036|t||||
17148238|NCT00452348|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148239|NCT00960154|f||LTE60||t
17148240|NCT00486434|f||GT60||t
17148241|NCT00544167|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17148242|NCT02725515|f||||f
17148243|NCT00874549|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17148244|NCT02898740|t||||
17148245|NCT01981044|f||||f
17148246|NCT02383706|f||||f
17148247|NCT00859040|f||GT60||t
17192177|NCT04118452|f||||f
17192178|NCT05086744|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148248|NCT00831987|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17148249|NCT03538795|f||||f
17148250|NCT02998541|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17148251|NCT01513239|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.|t
17148252|NCT01327976|f||GT60||t
17148253|NCT03167606|f||||f
17148254|NCT00059332|f||||f
17148255|NCT00413049|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148256|NCT02587143|f||||f
17148257|NCT04179396|f||OTHER|Sponsor's agreements with investigators require proposed public disclosures of trial results to be submitted to Sponsor for review prior to publication. Sponsor may request deletion of confidential information or a delay in publication to address intellectual property concerns, but Sponsor may not suppress publication of the trial results indefinitely. Sponsor may request delay of a single-center publication until after the release of a multi-site publication or an agreed upon period of time.|t
17148258|NCT02837913|f||||f
17192179|NCT04300231|f||||f
17192180|NCT05273723|t||||
17192181|NCT05986565|f||||f
17192182|NCT04500301|t||||
17192183|NCT04431050|t||||
17192184|NCT03755141|t||||
17192185|NCT02058108|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17192186|NCT01154192|t||||
17192187|NCT00411151|t||||
17192188|NCT02191085|f||||f
17192189|NCT01121991|f||OTHER||t
17148259|NCT03314857|f||OTHER|Without the Sponsor's prior written consent, the Principal Investigator shall not publish the clinical study results or any documents containing any Study information at any academic conferences or in any publications of any nature.|t
17148260|NCT02906917|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17148261|NCT01286805|t||||
17192190|NCT00409838|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148262|NCT00874822|t||||
17148263|NCT03056144|f||||f
17148264|NCT04281472|f||||t
17148265|NCT05278858|t||||
17148266|NCT04848688|t||||
17148267|NCT03504085|f||||f
17148268|NCT04133311|f||||f
17148269|NCT02911909|t||||
17148270|NCT00728754|f||OTHER|PI shall furnish SPONSOR with a copy of any proposed publication thirty (30) days prior to submission for publication for review and comment. SPONSOR may request PI to delay publishing such proposed publication for a maximum of an additional sixty (60) days in order to protect the potential patentability of any invention described therein.|t
17148271|NCT01926119|t||||
17148272|NCT03053245|f||||f
17148273|NCT00009945|f||GT60||t
17148274|NCT01728636|f||||f
17148275|NCT00295490|t||||
17148276|NCT03868631|f||||f
17148277|NCT02282722|f||GT60||t
17148278|NCT05194202|f||||f
17148279|NCT01691430|f||||f
17148280|NCT03930849|f||||f
17148281|NCT01251393|t||||t
17148282|NCT00660387|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148283|NCT04729101|f||||t
17148284|NCT03086135|f||GT60||t
17148285|NCT01639664|f||||f
17148286|NCT01023061|f||||f
17148287|NCT00762411|f||GT60||t
17148288|NCT02959840|t||||
17148289|NCT02259348|t||||
17148290|NCT04812548|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17148291|NCT04211766|f||||f
17148292|NCT03686215|f||LTE60||t
17148293|NCT02485158|f||||f
17148294|NCT01134198|t||||
17148295|NCT01813435|f||||t
17148296|NCT03035890|t||||
17148297|NCT01490190|f||OTHER|The principal investigator agrees not to publish or publicly present interim results of the Study without prior written consent of sponsor, agrees to provide 45 days written notice to sponsor prior to submission for publication or presentation, and permits sponsor to review copies of abstracts and manuscripts for publication, and slides and text of oral presentations and text of any electronically transmitted media such as the Internet, World Wide Web, etc.|t
17148298|NCT02560051|t||||
17192191|NCT01619410|f||||f
17148299|NCT04632641|t||||
17148300|NCT02817828|f||||t
17148301|NCT00072514|t||||
17148302|NCT01528293|f||OTHER|Sponsor can review results communications prior to public release but cannot embargo communications regarding trial results unless those communications are found inaccurate, contain Confidential Information, or would hinder seeking patent protection.|t
17148303|NCT00856349|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Investigators and Participating Institutions will provide any publication of Study Data generated by PI and/or Participating Institution to Medtronic for review prior to submission to determine if confidential information (CI) is included and to check for technical correctness. Medtronic may not censor/interfere with the publication beyond the extent necessary to protect CI."|t
17148304|NCT05061992|t||||
17148305|NCT01157234|t||OTHER||
17148306|NCT04808908|t||||
17148307|NCT01095887|t||||
17148308|NCT00287053|f||||f
17148309|NCT02542462|f||||f
17148310|NCT00397254|f||OTHER|Investigator is free to publish results of it's part of the study in collaboration with the other investigators subsequent to the multicenter publication issued by Clinvest. Principal Investigator (PI) may publish results of it's data with copy of any manuscript for review to Clinvest 60 days prior to submission for publication.|t
17148311|NCT02340780|t||||f
17148312|NCT02181140|f||||f
17148313|NCT04462198|f||||f
17148314|NCT00582205|t||||
17148315|NCT01055834|f||||f
17148316|NCT01717313|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17148317|NCT01800838|t||||
17148318|NCT00835588|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17148319|NCT01412281|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 90 days from the time submitted to the sponsor for review. The sponsor can make a reasoned request that publication be delayed for up to 3 months from the date of first submission to the sponsor in order to enable the sponsor to protect proprietary information, Intellectual Property, etc.|t
17148320|NCT01617096|f||OTHER||t
17148321|NCT01753362|t||||
17148322|NCT04473326|f||||f
17148323|NCT02611362|f||||f
17192192|NCT01250769|f||OTHER|Philips shall have the final authority to determine whether or not to publish study results.|t
17192193|NCT02538900|f||||f
17192194|NCT04110054|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17192195|NCT02874534|f||||f
17192196|NCT01261052|t||||
17192197|NCT02923180|t||||
17192198|NCT01188369|t||||
17192199|NCT03928522|f||||f
17192200|NCT02885636|t||||
17192201|NCT04287985|f||OTHER|Agreements are in place that restrict investigators from publishing the results of the trial.|t
17192202|NCT05751785|f||||f
17192203|NCT01340066|f||GT60||t
17192204|NCT02789020|t||||
17192205|NCT02395978|f||||t
17192206|NCT00011986|f||||f
17192207|NCT03771352|f||||t
17192208|NCT03380390|f||||t
17192209|NCT01172418|f||||f
17192210|NCT05171777|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192211|NCT02538341|f||||f
17192212|NCT00632749|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192213|NCT00839241|f||GT60||t
17192214|NCT03988842|t||||
17192215|NCT00352976|t||||
17192216|NCT01227265|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17192217|NCT03448458|t||||
17192218|NCT03690206|f||||f
17192219|NCT05028582|f||OTHER|The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17192220|NCT01959698|t||||
17192221|NCT04402294|f||||f
17192222|NCT00186992|t||||
17148324|NCT01155531|t||||
17148325|NCT00354159|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Medtronic reviews publications to determine if confidential information (CI) is included. Any such CI is deleted before publication. Medtronic may not censor/interfere with the publication. Investigators may publish single-site publications after a decision by Medtronic that no multi-site study publication will be done or 12 months after the study is closed, whichever is earlier."|t
17148326|NCT02046122|t||||
17148327|NCT01653704|f||||f
17192223|NCT03769168|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17192224|NCT05478525|f||||t
17192225|NCT01489813|f||||f
17192226|NCT05644002|f||||f
17192227|NCT04842500|t||||
17192228|NCT04799197|t||||
17148328|NCT01728116|f||OTHER|PI to provide to Sponsor for review at least sixty (60) days in advance of submission for publication. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.|t
17148329|NCT05128058|t||||
17148330|NCT01532908|f||LTE60||t
17192229|NCT05104697|f||||f
17148331|NCT01196390|f||LTE60||t
17148332|NCT03141151|t||||
17148333|NCT01885897|t||||
17148334|NCT04610580|f||||t
17148335|NCT01097694|f||||f
17192230|NCT03845465|t||||f
17192231|NCT03547908|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192232|NCT04541043|f||||t
17192233|NCT03416023|f||OTHER|Data need to be submitted by the PIs to the sponsor for review and comment at least 60 days prior to submission for publication, public dissemination, or review by a publication committee. All reasonable comments made by the sponsor shall be incorporated into the publication. The sponsor shall be entitled to make a reasoned request that publication be delayed for a period of up to 6 months from the date of first submission to the sponsor.|t
17192234|NCT05419505|f||||t
17192235|NCT03358875|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192236|NCT03599648|f||||f
17192237|NCT02380612|f||||f
17192238|NCT01064440|f||||f
17192239|NCT04656925|f||||f
17192240|NCT06194214|f||GT60||t
17192241|NCT03890913|f||||f
17192242|NCT03494504|f||||t
17192243|NCT04881162|f||||t
17192244|NCT04832360|f||||f
17148336|NCT04320745|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148337|NCT02004691|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17148338|NCT01320722|t||||
17148339|NCT00021541|f||||f
17148340|NCT03407729|t||||f
17148341|NCT02943096|t||||
17148342|NCT04142658|f||GT60||t
17148343|NCT04387617|t||||
17148344|NCT02413008|f||OTHER||t
17148345|NCT00939523|t||||
17148346|NCT00024258|t||||
17148347|NCT01050764|f||||f
17148348|NCT03790137|t||||
17148349|NCT00758758|f||LTE60||t
17148350|NCT02119936|t||||
17148351|NCT00570128|f||OTHER||t
17148352|NCT03711396|t||||
17148353|NCT04194008|f||||f
17148354|NCT02218216|f||||f
17148355|NCT03111381|f||||f
17148356|NCT00640341|f||OTHER|The results of the study may be published or presented by the investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17148357|NCT02973269|f||OTHER|The Study Center and/or Investigator shall submit to Revance a copy of the proposed publication at least sixty (45) days prior to the submission thereof for publication or disclosure to a third party:(i)to provide Revance with the opportunity to review and comment on the contents thereof, (ii)to identify any Confidential Information to be deleted from the proposed publication or disclosure, and (iii)or delay the publication or disclosure 90 days to allow Revance to pursue patent protections.|t
17148358|NCT01520987|f||OTHER||t
17148359|NCT02005562|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148360|NCT05259852|f||||f
17148361|NCT02966340|t||||
17192245|NCT01631214|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17192246|NCT05833789|t||||
17192247|NCT03805594|t||||
17192248|NCT03229811|f||||f
17192249|NCT04093362|f||||t
17192250|NCT03717415|f||||t
17148362|NCT01622660|t||||
17148363|NCT04590781|f||||t
17148364|NCT01680016|f||OTHER|The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial|t
17148365|NCT01120899|t||||f
17148366|NCT01273857|f||||f
17148367|NCT00202839|f||OTHER|Principal Investigator and Institution further agree to provide forty-five (45) days written notice to Sponsor prior to submission for publication or presentation to permit Sponsor to review drafts of abstracts and manuscripts for publication.|t
17148368|NCT00442351|f||OTHER|The PI is not allowed to release any interim results of the Study without prior consent of the sponsor, and must provide 45 days written notice to the sponsor prior to public release to permit the sponsor's review. The PI can use the study results for his/her own teaching, research, and publication purposes only, not for commercial purposes, except as authorized by the sponsor. No publication shall contain any trade secret or proprietary/confidential information of the sponsor.|t
17148369|NCT01863186|f||||t
17148370|NCT00377156|t||||
17148371|NCT00288704|f||OTHER|The only disclosure restriction on the PI,after completion of a trial,is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review;provided that the sponsor can remove confidential or proprietary information from such communications. The sponsor cannot require other changes to the communication and cannot extend the embargo.|t
17192251|NCT03401853|t||||f
17192252|NCT05288283|f||||f
17192253|NCT02488863|f||||f
17192254|NCT01046136|f||LTE60||t
17192255|NCT04759833|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17192256|NCT03446157|t||||
17192257|NCT02664558|f||||t
17192258|NCT01989455|f||LTE60||t
17192259|NCT00632203|f||OTHER|"The principal investigator (PI) agrees not to publish/publicly present any interim results of the study without prior written consent from the Sponsor. The PI further agrees to provide 45 days written notice to the Sponsor prior to~submission, to permit the Sponsor to review copies of abstracts/manuscripts for publication, which report any results of the study. The Sponsor shall have the right to review and comment on any presentation."|t
17192260|NCT02641912|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192261|NCT04238247|f||||f
17148372|NCT01579006|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148373|NCT02413034|f||||f
17148374|NCT02473393|f||||f
17148375|NCT02697617|f||||f
17148376|NCT02460835|t||||
17148377|NCT02212106|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148378|NCT01151449|f||LTE60||t
17148379|NCT00517192|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17148380|NCT02318550|t||||
17148381|NCT02733627|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148382|NCT00183196|f||||f
17148383|NCT01119625|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148384|NCT03237156|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148385|NCT01721772|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148386|NCT01897077|t||||
17148387|NCT02016235|t||||
17148388|NCT05004649|f||||f
17148389|NCT01698554|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148390|NCT02654145|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148391|NCT02637141|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148392|NCT01991548|f||||f
17148393|NCT01943435|t||||
17148394|NCT03885934|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17148395|NCT01936662|t||||
17148396|NCT00106106|t||||f
17148397|NCT04535986|f||||t
17148398|NCT01328782|t||||f
17148399|NCT00400634|f||GT60||t
17148400|NCT01559116|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148401|NCT02377349|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148402|NCT03259165|f||||f
17148403|NCT05248399|t||||
17148404|NCT00550147|f||||f
17148405|NCT01824498|f||||f
17148406|NCT01567527|f||OTHER|Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.|t
17148407|NCT02623218|t||||
17148408|NCT01726803|f||||f
17148409|NCT00759707|f||||f
17148410|NCT04207333|t||||
17148411|NCT00936351|t||||f
17148412|NCT01547728|t||GT60||t
17148413|NCT03828539|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148414|NCT01341405|f||OTHER|Publication requires prior expressed written consent of Sponsor.|t
17148415|NCT02616380|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148416|NCT00826241|f||||f
17148417|NCT00924053|t||||
17148418|NCT03950674|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17148419|NCT00193492|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the propsed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17148420|NCT00830167|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148421|NCT02224053|f||OTHER|The Principal Investigator (PI) agrees to collaborate on the contents and formation of any publication and to pay due consideration to comments and opinions offered. AstraZeneca have 30 days for final manuscript review and may require that submission for publication be delayed in order to file patent application.|t
17148422|NCT00609154|f||||f
17148423|NCT04720547|f||||f
17148424|NCT02589067|f||||f
17148425|NCT00124618|t||||
17148426|NCT03193021|f||GT60||t
17148427|NCT01139762|f||GT60||t
17148428|NCT01675596|f||||f
17148429|NCT02614196|f||||f
17148430|NCT01539239|f||OTHER|Sites participating in the trial may not publish their single center results until the aggregate study results have been published unless first obtaining written consent from the sponsor.|t
17148431|NCT02179788|f||||f
17148432|NCT00789776|t||||
17148433|NCT02627001|f||||f
17148434|NCT02219009|f||OTHER|Center may publish study results but ≥ 60 days prior to any public presentation, a copy is sent to Sponsor for review and Center can delay publication for 60 days to permit Sponsor to protect its intellectual property rights or confidential information contained within the publication. The first publication is a joint publication, if Center is part of a multi-center study. Center is free to publish, if there is no multi-center publication within 18 months of completion/ termination of study.|t
17148435|NCT00274625|f||GT60||t
17148436|NCT04313296|t||||
17148437|NCT03087786|f||OTHER|"The sponsor and the PI have a Confidentiality Agreement stating:~* Each Party shall not disclose Confidential Information publicly or to any third party in an unauthorized manner.~* Each Party's obligations of confidentiality, non-disclosure and limited use imposed by this Agreement shall not apply to information or items that are required to be disclosed by governmental authority or by judicial process."|t
17148438|NCT00880334|t||||
17148439|NCT01149434|t||||f
17148440|NCT02509260|t||||
17148441|NCT01775722|t||||
17148442|NCT01876953|t||||
17148443|NCT02419573|t||||f
17192262|NCT05064735|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17192263|NCT02886286|t||||
17148444|NCT02229084|t||||
17148445|NCT00630253|t||||
17148446|NCT02179190|f||||f
17148447|NCT03504020|f||OTHER|Site will not independently publish, publicly disclose, present or discuss any results of or information pertaining to the study until a multi-center publication is released; provide however that if a multi-center publication is not released within 1 year after completion of the study at all sites involved in the study, Study Site will have the right to publish the results of, and information pertaining to , their activities conducted under their CTA, in accordance with provision of CTA.|t
17148448|NCT00881569|f||||f
17148449|NCT02948426|f||||f
17148450|NCT03515044|f||OTHER|Contact sponsor for details.|t
17148451|NCT01993940|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17148452|NCT04164758|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17192264|NCT02376790|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17192265|NCT03014453|f||||f
17148453|NCT03660787|f||||f
17148454|NCT02858037|f||OTHER||t
17148455|NCT04404907|f||||f
17148456|NCT01670097|t||||
17192266|NCT00901901|f||OTHER|The PI must send a draft manuscript of the publication or abstract to the sponsor 30 days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17192267|NCT02272816|f||OTHER|No PI may present data from his/her centre separately from the rest of the study results unless approved by the Trial Steering Committee and the Sponsor.|t
17192268|NCT01136876|f||GT60||t
17192269|NCT01241916|f||||f
17192270|NCT00976937|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17192271|NCT01011946|t||||
17192272|NCT04820686|f||LTE60||t
17192273|NCT01424670|f||LTE60||t
17192274|NCT03169894|f||||f
17192275|NCT02891915|f||LTE60||t
17192276|NCT00709098|f||||f
17192277|NCT01967836|t||||
17192278|NCT03481816|f||||f
17192279|NCT01704196|f||||f
17192280|NCT01091168|f||||f
17192281|NCT03640949|t||||
17192282|NCT03582722|t||||
17192283|NCT06024174|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17192284|NCT04567615|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192285|NCT03481660|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148457|NCT00697827|f||OTHER|All unpublished information given to the investigator by Synthes Spine shall not be published or disclosed to a third party without the prior written consent of Synthes Spine. All information concerning In-Space, Synthes Spine operations, patent application drawings, manufacturing processes, basic scientific data and design information, supplied by the sponsor to the investigator and not previously published, is considered confidential and remains the sole property of Synthes Spine.|t
17148458|NCT03732833|f||OTHER|General research agreement between the sponsor and PI's that includes a confidentiality section that includes a statement that the sponsor is and shall remain the exclusive owner of 'Information'. ) 'Information' shall include, but shall not be limited to, protocols, trade secrets, know-how, formulations, inventions, techniques, equipment, data and results.|t
17148459|NCT00325780|f||GT60||t
17148460|NCT02311894|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148461|NCT01282086|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17148462|NCT03617419|t||||
17148463|NCT00702507|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192286|NCT03012841|f||OTHER|Principle Investigator (PI) agrees they will not independently discuss or publish trial results until a multi-center publication is released. If a multi-center publication is not released within one year after completion of the Study at all Study sites, PIs will have the right to publish the results of and information pertaining to their activities. Any such Publication must be submitted to Medtronic for review and comment at least sixty (60) days prior to submission or presentation.|t
17192287|NCT03683069|t||||
17192288|NCT04941287|f||LTE60||t
17192289|NCT04065048|f||||f
17192290|NCT00880425|t||||f
17192291|NCT04491968|t||||
17192292|NCT05857644|f||GT60||t
17192293|NCT05369208|f||OTHER|PIs are not allowed to publish clinical trial data on their own after trial completion.|t
17192294|NCT05096819|t||||
17192295|NCT05307978|f||OTHER||t
17192296|NCT03324984|t||||
17192297|NCT01536886|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192298|NCT04607044|f||||f
17192299|NCT05075408|f||||f
17192300|NCT01727518|t||||
17192301|NCT05683392|f||||f
17192302|NCT04878354|f||OTHER|No publication can be made before the first multi-center publication. PI shall allow Sponsor (S) not less than 60 days to review publications and 30 days to review presentations. S can comment and require removal of confidential information. Upon S request, PI must delay the publication or presentation for 6 months to permit S to file a patent application or take other steps to protect S' information. Any other public statements regarding the trial requires prior written consent from S.|t
17192303|NCT04847999|f||||f
17192304|NCT02879448|f||OTHER||t
17192305|NCT03433339|f||||f
17192306|NCT05952076|f||OTHER||t
17192307|NCT05332340|f||||t
17192308|NCT04143061|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17192309|NCT01718743|t||||
17192310|NCT05485922|f||LTE60||t
17192311|NCT03739996|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17192312|NCT01673984|f||||f
17192313|NCT02553642|t||||
17192314|NCT04437433|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192315|NCT02155010|f||||f
17192316|NCT00894543|f||||f
17192317|NCT04048681|t||||
17192318|NCT01532388|f||||f
17192319|NCT02919449|f||||f
17192320|NCT00727909|f||||f
17192321|NCT05767437|f||||f
17192322|NCT03578536|t||||
17192323|NCT05198310|f||OTHER|Investigator shall not publish before a first multi-center publication by Sponsor. Before submission, Sponsor has 60 days to review any manuscript and 30 days to review any poster, abstract or any other materials. If Sponsor requests in writing, Investigator shall withhold disclosure for an additional 90 days.|t
17192324|NCT04436107|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period,Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192325|NCT03144518|t||||
17192326|NCT00448669|t||||f
17192327|NCT02638337|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17192328|NCT01691079|t||||
17192329|NCT03794024|t||||
17192330|NCT00445315|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192331|NCT02376530|f||||f
17192332|NCT03338816|f||LTE60||t
17192333|NCT03092726|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17192334|NCT04950127|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192335|NCT03032406|t||||
17192336|NCT03833167|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors (ICMJE) authorship requirements.|t
17148464|NCT01277510|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17192337|NCT05187442|f||||f
17192338|NCT01948661|f||||f
17192339|NCT03271489|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192340|NCT02860130|f||OTHER|The sponsor reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17192341|NCT03330795|f||||f
17192342|NCT05018910|f||||f
17192343|NCT05575076|f||OTHER|The Institution and PI must request review and comment of any proposed publication by the sponsor at least 90 days prior to submission of the publication. The sponsor will advise of any information which is confidential information or which may impair the sponsor's ability to obtain patent protection, and has the right to require confidential information or factual errors to be removed, or to delay the proposed publication by an additional 90 days to allow the sponsor to seek patent protection.|t
17192344|NCT01127373|t||||
17192345|NCT02290613|f||||f
17192346|NCT02713126|t||||
17192347|NCT00100698|f||||f
17192348|NCT01426412|f||GT60||t
17192349|NCT05450458|f||||f
17192350|NCT02371395|f||||f
17192351|NCT04157348|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17192352|NCT02965846|f||OTHER|As this study was terminated, no data will be published.|t
17192353|NCT00262301|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to its submission or disclosure. The sponsor may request to delete information identified by sponsor as confidential information prior to submitting such manuscript and/or abstract for publication. For a multi-center study, the investigator must wait (i) at least 24 months after the study is completed at all sites or (ii) until after the multi-center publication.|t
17192354|NCT01084707|t||||
17192355|NCT00715884|f||GT60||t
17192356|NCT00215787|t||||
17192357|NCT02412748|f||||f
17192358|NCT03069313|f||||f
17192359|NCT00620698|f||||f
17192360|NCT01872078|f||OTHER|AstraZeneca will manage the publication of the results of the Clinical Trial in partnership with the authors. AstraZeneca recognises that Institutions/Investigators may wish to make publications regarding Clinical Trial results. The Institution/Investigator agrees to collaborate in good faith with AstraZeneca. Prior to any such publication, the Institution/Investigator shall provide AstraZeneca with preliminary data and drafts of proposed publications.|t
17192361|NCT01494922|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192362|NCT00972439|f||||f
17192363|NCT06377358|f||||f
17148465|NCT01685008|f||GT60||t
17148466|NCT01377441|f||||f
17148467|NCT01816230|f||||f
17148468|NCT00784095|t||||f
17148469|NCT01689155|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17148470|NCT01540045|t||||
17192364|NCT05928624|t||||f
17192365|NCT03236441|f||||f
17192366|NCT02152137|f||||t
17192367|NCT05510232|t||||
17192368|NCT02721381|f||||f
17192369|NCT04337372|f||||f
17148471|NCT02667951|f||||f
17148472|NCT00057941|f||LTE60||t
17148473|NCT02585245|t||||
17148474|NCT01898598|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148475|NCT03833427|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17148476|NCT00176891|f||||f
17148477|NCT01499160|t||||
17148478|NCT02361736|t||||
17148479|NCT00860262|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17192370|NCT05307783|f||||f
17192371|NCT04883645|f||||f
17192372|NCT00979576|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192373|NCT05687903|f||||t
17192374|NCT04855760|f||||t
17192375|NCT05613205|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192376|NCT05794763|t||||
17192377|NCT04869982|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192378|NCT05931861|f||OTHER|The data resulting from this clinical investigation will be the proprietary information of Sponsor. An investigator shall not publish any data (poster, abstract, paper, etc.) without having consulted with Laboratoires THÉA in advance.|t
17192379|NCT04112316|f||||f
17192380|NCT03857620|f||||f
17192381|NCT02473250|t||||
17192382|NCT00567398|f||||t
17192383|NCT05265312|f||||f
17192384|NCT03830177|f||||f
17192385|NCT03137771|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17148480|NCT02387762|f||OTHER|Site and PI can publish/publicly present the results of the study only with prior written consent of Sponsor or otherwise after expiry of 12 months following completion of the study. Site and PI agree to provide 45 days written notice to Sponsor prior to submission for publication or presentation.|t
17148481|NCT00593827|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148482|NCT01596127|t||||f
17148483|NCT00987480|t||||
17148484|NCT00688844|t||||
17148485|NCT01374451|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17148486|NCT01223027|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148487|NCT02946255|f||||f
17148488|NCT03201003|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17148489|NCT00834613|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17148490|NCT00663234|f||OTHER|In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights|t
17148491|NCT01994980|f||||f
17148492|NCT01709903|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial|t
17148493|NCT02061280|f||||f
17148494|NCT00096460|f||||f
17148495|NCT01751087|f||||f
17148496|NCT01756885|f||||f
17148497|NCT02061358|f||OTHER|The Sponsor will make the results of the study publicly available, including for purposes of national and international registration, publication, and information for medical and pharmaceutical professionals.|t
17148498|NCT00724958|f||||f
17148499|NCT00697619|f||||f
17148500|NCT03093025|f||||t
17148501|NCT00258856|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17148502|NCT05157048|t||||f
17148503|NCT01754376|t||||
17148504|NCT04556734|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148505|NCT04264819|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148506|NCT02400463|t||||
17148507|NCT00377572|f||||f
17148508|NCT02937506|f||||f
17148509|NCT01705717|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148510|NCT00769314|f||LTE60||t
17148511|NCT03480685|f||||f
17192386|NCT03602014|f||||f
17192387|NCT01898494|f||LTE60||t
17148512|NCT01662024|f||||f
17148513|NCT02846883|f||||f
17148514|NCT04768296|f||||t
17148515|NCT04492397|f||||f
17148516|NCT00122447|t||||
17148517|NCT01453153|f||OTHER|All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless written permission from the sponsor (Halozyme) is obtained.|t
17148518|NCT04578132|t||||
17148519|NCT05113563|f||||f
17192388|NCT03289039|t||||
17192389|NCT05540002|f||||f
17192390|NCT04732494|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17192391|NCT03897686|f||OTHER||t
17192392|NCT04905407|f||OTHER|Note that the agreements are between the clinical sites and the Sponsor (or its agents), which restrict the clinical trial sites' rights to discuss or publish trial results after the trial is completed.|t
17192393|NCT05178810|f||LTE60||t
17192394|NCT03263026|f||||f
17148520|NCT00799708|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148521|NCT03343639|f||||t
17148522|NCT00076245|f||||f
17148523|NCT02153723|t||||f
17148524|NCT02274558|f||OTHER|Generally, the PI has the right to publish results provided such publication does not violate confidentiality or IP provisions within the contract with the Sponsor. Prior to submission for publication or presentation of results, the PI must provide the Sponsor time for review. The Sponsor can request the PI to withhold or remove information from all publications. For a multi-center study, any publication of results by the PI shall not be made before the first multi-center publication.|t
17148525|NCT02655224|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17148526|NCT03033134|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17148527|NCT04592419|f||OTHER|Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148528|NCT05838456|t||||
17148529|NCT05393271|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17148530|NCT02943993|f||||f
17148531|NCT02483416|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148532|NCT04968925|f||GT60||t
17148533|NCT03408730|f||||f
17148534|NCT00876265|f||OTHER|Any proposed press release, announcement, disclosure for publication, whether or not in writing, prepared by or on behalf of Consultant as part of services under this Agreement or that relates to the work performed hereunder must be reviewed and approved in writing by Merz prior to dissemination.|t
17148535|NCT02754492|f||OTHER|Sponsor retains the right to review and comment on any public disclosure of study results. If no response is received within 30 days, the Principal Investigator may presume that the submission for publication may proceed without delay. If the Sponsor asks to defer publication, Study Site shall not publish, or otherwise disclose to any third party, any of the information contained in the publication or presentation until such time as permission is granted from the Sponsor.|t
17148536|NCT01408888|f||GT60||t
17148537|NCT00487695|f||||f
17148538|NCT00264381|f||||f
17148539|NCT00695110|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. If the communication contains subject matter for which patent protection should be sought, the Sponsor will notify the PI whereupon the PI agrees to grant the Sponsor an additional 60 days to file documents necessary to protect such invention.|t
17148540|NCT04542694|f||||f
17148541|NCT02167594|f||LTE60||t
17148542|NCT01957150|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148543|NCT00000136|f||||f
17148544|NCT01207752|f||OTHER||t
17148545|NCT02786953|t||||
17148546|NCT01632215|f||||f
17148547|NCT01745094|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi center data. Sponsor must receive a site's manuscript prior to publication for review and comment.|t
17148548|NCT03414034|f||||t
17148549|NCT02725645|t||||
17148550|NCT04010227|t||||
17148551|NCT00640926|f||OTHER|The sponsor retains publication rights.|t
17148552|NCT03922750|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17148553|NCT02985398|f||||f
17148554|NCT01841073|t||||
17148555|NCT00668395|t||||f
17148556|NCT03174158|f||||f
17148557|NCT05665387|f||||f
17148558|NCT01176981|f||||f
17148559|NCT02805517|t||||
17148560|NCT01211262|f||OTHER|Publication/presentation (manuscript, abstract or poster) to a journal/scientific meeting is sent to sponsor for review at least 1 month before submission who may delay submission by up to 90 days if it reasonably believes that publication of results may compromise its intellectual property rights or else insist that such data are removed. No single center/groups of centers may publish individually. Publication will not include confidential information without the permission of the sponsor.|t
17148561|NCT04049097|f||GT60||t
17148562|NCT01321177|f||||f
17148563|NCT01970592|t||||
17148564|NCT00499473|f||LTE60||t
17148565|NCT00160524|f||GT60||t
17148566|NCT02661022|f||OTHER|Institution's individual results may be submitted for publication only after the results of the multicenter study are published, 18 months after study completion at all sites, or notification from Stemline Therapeutics, Inc. that submission of a multicenter publication is no longer planned, whichever shall occur first.|t
17192395|NCT06064916|t||||
17192396|NCT02697136|f||OTHER|PI can publish results only 12 months from study completion and database lock or after the multicenter publication, whichever is sooner. All proposed publications/disclosures must be made available for sponsor review 90 days prior to public release and sponsor must respond within 45 days. The sponsor cannot require changes to the communication.|t
17192397|NCT01095796|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192398|NCT02926911|t||||
17192399|NCT04116736|f||||t
17192400|NCT04349072|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192401|NCT01363492|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication|t
17192402|NCT05512962|f||||f
17192403|NCT00879333|f||OTHER|Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.|t
17192404|NCT02672033|t||||
17192405|NCT02671435|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17192406|NCT03547999|f||||f
17192407|NCT00738023|f||||f
17192408|NCT00761189|t||LTE60||t
17148567|NCT03448692|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148568|NCT03702816|t||||
17148569|NCT00608634|t||||f
17148570|NCT03490227|f||||f
17148571|NCT01598896|f||||f
17148572|NCT03346902|f||||f
17148573|NCT04553406|f||OTHER|The PI may not publish the results prior to the first multi-site publication. If there is no multi-site publication within 18 months after Trial completion the PI may publish results from the trial, subject to the following. PI will submit proposed Publication to Sponsor 60 days prior to submission of the Publication. PI will, at Sponsor's request, delay such Publication for up to 90 days for Sponsor to obtain appropriate intellectual property protection.|t
17148574|NCT00749658|f||||f
17148575|NCT00633022|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148576|NCT03573336|f||OTHER||t
17148577|NCT04388787|t||||
17148578|NCT03298880|t||||
17148579|NCT02299869|f||OTHER||t
17148580|NCT02756949|f||LTE60||t
17148581|NCT02940522|f||||f
17148582|NCT02710214|t||||f
17148583|NCT00929981|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148584|NCT02497235|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148585|NCT01188226|t||||f
17148586|NCT04832971|f||OTHER|The only disclosure restriction on the PI is that the sponsor retains first right to publish results for this multi-center study, and thereafter can review results communications prior to release and can embargo communications regarding trial results for a period that is 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication of results but can require removal of its confidential information (excluding results).|t
17148587|NCT04980456|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17192409|NCT02759016|f||||f
17192410|NCT03939312|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148588|NCT00927251|f||OTHER|"Generally, contracts allow investigators to publish study results per the protocol and publication plan. Medtronic reviews publications to determine if confidential information (CI) is included. Any such CI is deleted before publication. Medtronic may not censor/interfere with the publication. Investigators may publish single-site publications after a decision by Medtronic that no multi-site study publication will be done or 12 months after the study is closed, whichever is earlier."|t
17148589|NCT01427881|t||||
17148590|NCT03687242|f||||t
17148591|NCT00324896|f||||f
17148592|NCT01802216|t||||
17148593|NCT02877017|t||||
17148594|NCT03211039|f||||f
17148595|NCT00217724|f||||f
17148596|NCT03490916|t||||
17148597|NCT00969124|f||||f
17148598|NCT02575339|f||||f
17148599|NCT04675775|t||||
17148600|NCT04633642|f||||f
17148601|NCT05431777|f||||t
17148602|NCT03433703|f||||t
17148603|NCT05932810|t||||
17148604|NCT01405469|t||||
17148605|NCT02451358|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17148606|NCT01859637|f||GT60||t
17148607|NCT01214980|f||||f
17148608|NCT00974350|f||||t
17148609|NCT01344018|f||||f
17148610|NCT05070754|f||||f
17148611|NCT00252564|t||||
17148612|NCT00994604|f||||f
17148613|NCT04561115|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17148614|NCT00743145|f||||f
17148615|NCT01583530|f||OTHER|For multi-center trials, no investigator will be authorized to publish study results from an individual center until the earlier of the multi-center trial results are published or 12 months after the end or termination of the multi-center trial at all sites. All manuscripts and abstracts must be submitted to the sponsor for review at least 30 days prior to submission for publication or for presentation at a scientific meeting. The sponsor may delay publication for up to 3 months.|t
17192411|NCT02119650|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17192412|NCT01721291|t||||
17192413|NCT04430634|f||||f
17192414|NCT03744312|t||||
17192415|NCT05134337|f||GT60||t
17192416|NCT04592198|f||||f
17148616|NCT02416180|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148617|NCT01170715|t||||
17192417|NCT03152786|t||||
17192418|NCT04924062|f||OTHER|The investigator agreed to submit all manuscripts or abstracts to the Sponsor before submission. This allowed the Sponsor to protect proprietary information and to provide comments.|t
17192419|NCT04499950|t||||
17192420|NCT02428192|f||LTE60||t
17148618|NCT03486938|f||GT60||t
17148619|NCT02571634|f||||f
17148620|NCT03480022|t||||
17148621|NCT00283842|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication|t
17148622|NCT05068661|t||||
17148623|NCT02472639|f||||f
17148624|NCT01181596|f||GT60||t
17192421|NCT04955717|f||||f
17192422|NCT04059354|t||||
17192423|NCT05403801|f||||f
17148625|NCT00751023|f||||f
17148626|NCT02339038|t||||
17148627|NCT02308696|f||||f
17148628|NCT04768114|t||||
17148629|NCT01194908|t||||
17148630|NCT02013050|f||OTHER|There were limitations put on the sites from publishing data until the sponsor had published data. That data is now published.|t
17148631|NCT01285076|f||OTHER|The investigator can publish the study results only following the sponsor's review and approval.|t
17148632|NCT03980522|f||OTHER|Sponsor has the first right to publish information obtained from the trial. After Sponsor publishes, PI may publish its own trial results, provided that Sponsor may embargo such publication for up to 60 days for purposes of identifying confidential information (other than trial data) that must be removed and up to an additional 90 days to prepare a patent application if there is patentable subject matter in the PI's proposed publication.|t
17148633|NCT04892147|t||||
17148634|NCT05263505|f||||f
17148635|NCT04721145|f||||f
17148636|NCT02707276|t||||
17148637|NCT04155840|t||||
17148638|NCT01785615|f||||f
17148639|NCT04841967|f||||f
17148640|NCT00360490|f||OTHER|Institution and Principal Investigator shall provide Sponsor an advanced copy of any proposed publication at least 60 days prior to the planned date of publication. Sponsor shall have 30 days to recommend changes. Institution and Principal Investigator agree that adoption of recommended changes shall not be unreasonably refused.|t
17192424|NCT03888989|f||||f
17192425|NCT03651895|t||||
17192426|NCT02525692|f||OTHER|Within 12 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given the opportunity to review and comment. Institution publications may be delayed up to an additional 90 days to allow the Sponsor to seek patent protection.|t
17148641|NCT03294317|f||OTHER|Investigator and Participating Institution shall submit any contemplated publication or presentation of this study to Medtronic for review at least 60 days prior to submission, If notified by Medtronic within such 60- day period that such publication or presentation contains Confidential Information, Investigator and Participating Institution each agree to delete Confidential Information, other than Study results, prior to any publication or presentation.|t
17148642|NCT01160640|f||||f
17148643|NCT03061903|f||||f
17148644|NCT04315272|f||||f
17148645|NCT00642811|f||OTHER|An Investigator agrees to provide a copy of the publication to AZ for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.|t
17148646|NCT00268762|t||||f
17148647|NCT00772148|f||OTHER||t
17148648|NCT01562613|f||GT60||t
17148649|NCT00239005|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148650|NCT02614898|f||||f
17148651|NCT03108820|f||||f
17148652|NCT00787605|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety.|t
17148653|NCT03382041|f||||f
17148654|NCT00178711|f||||f
17148655|NCT00948792|f||||f
17148656|NCT03297541|f||||f
17148657|NCT03493919|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17148658|NCT04640194|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148659|NCT04428645|t||||
17148660|NCT05590039|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17148661|NCT04773600|f||OTHER|The process of coordinating publication efforts is detailed in the Clinical Trial Agreement.|t
17148662|NCT00704496|t||||
17148663|NCT00500318|f||OTHER|"All data generated in this study will be the property of the Sponsor. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and the Sponsor."|t
17148664|NCT00706719|f||OTHER||t
17148665|NCT03243396|t||||
17148666|NCT01257581|t||||
17148667|NCT02824640|f||||f
17148668|NCT01504711|t||||
17148669|NCT01853371|f||||f
17192427|NCT02396199|f||GT60||t
17192428|NCT04898023|t||||
17148670|NCT00964353|f||||f
17148671|NCT02951195|f||OTHER||t
17148672|NCT02246764|f||||f
17148673|NCT04982445|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17148674|NCT04178096|t||||
17148675|NCT00555893|f||||f
17192429|NCT01563341|t||||
17192430|NCT02349412|t||||
17192431|NCT03460236|f||||f
17192432|NCT03611153|t||||
17192433|NCT04840199|f||||f
17192434|NCT00753090|f||||f
17192435|NCT02201108|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17192436|NCT03535727|f||||f
17192437|NCT03055377|f||||f
17192438|NCT04934722|f||OTHER|The sponsor will comply with the requirements for publication of study results. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17192439|NCT05215847|f||||t
17192440|NCT03157167|f||||f
17192441|NCT01939275|t||||
17192442|NCT05145257|f||||f
17192443|NCT06023082|f||||f
17192444|NCT04823611|f||||t
17192445|NCT05444192|f||||f
17192446|NCT04522713|f||||f
17148676|NCT02161549|f||||f
17148677|NCT03223909|f||OTHER|IPs may not share, disclose or partially or completely publish the information of this research in order to request and receive written approval from the sponsor.|t
17148678|NCT02046317|t||||
17148679|NCT01628549|f||OTHER|The data obtained in this study are the property of the Sponsor, any manuscript or other presentation of data must first be reviewed by the Sponsor before its submission.|t
17148680|NCT00177164|f||||f
17148681|NCT00965757|f||OTHER||t
17148682|NCT02429583|t||||
17148683|NCT00960414|t||||f
17148684|NCT01398787|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17192447|NCT05623345|f||||f
17192448|NCT01385176|f||||f
17192449|NCT05384730|t||||
17148685|NCT01332968|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148686|NCT02351167|t||||
17148687|NCT02564016|t||||f
17148688|NCT01653405|t||||
17148689|NCT02099318|f||||f
17148690|NCT00113919|t||||
17148691|NCT01742208|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17148692|NCT00715676|f||GT60||t
17148693|NCT00372996|f||||f
17148694|NCT01091363|f||||f
17148695|NCT00890916|t||||
17148696|NCT01837537|f||||f
17148697|NCT02760433|f||OTHER|Any study related information could be made public available only after Sponsors written permission.|t
17148698|NCT02151149|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days. Investigator must delete confidential information before submission or defer publication to permit patent applications|t
17148699|NCT02092857|t||||
17148700|NCT00216060|f||||f
17148701|NCT05889039|f||||f
17148702|NCT03428945|f||||f
17148703|NCT00982228|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17148704|NCT01438476|t||||
17148705|NCT02058160|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17148706|NCT01115933|f||GT60||t
17148707|NCT00926367|f||||f
17148708|NCT01266603|t||||
17148709|NCT02725411|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148710|NCT02054754|f||OTHER||t
17148711|NCT00645827|t||||
17148712|NCT02911935|f||||f
17148713|NCT00603512|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148714|NCT00685750|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148715|NCT04979858|f||||f
17192450|NCT01772472|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192451|NCT03295734|f||||f
17192452|NCT03926819|f||OTHER||t
17148716|NCT02654015|f||||f
17148717|NCT02846233|t||||f
17148718|NCT01896505|f||OTHER||t
17148719|NCT00462839|t||||
17148720|NCT00260689|t||||
17148721|NCT05317195|f||OTHER|"We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belong to the Sponsor."|t
17148722|NCT03919695|t||||
17148723|NCT01706263|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148724|NCT02063217|f||||f
17192453|NCT04431726|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192454|NCT00731341|f||||f
17192455|NCT04093752|f||LTE60||t
17192456|NCT01101451|f||LTE60||t
17192457|NCT04854096|f||OTHER|"UK: The Sponsor recognizes that the PI may have a responsibility to ensure that results of scientific interest arising from the Clinical Trial are appropriately published.~Germany: Details of study and its results shall not be publicized or published in any form without prior written consent of the sponsor.~Malaysia: Institution and Investigator may publish or otherwise publicly disclose, for non-commercial purposes."|t
17192458|NCT04757610|f||OTHER|The principles for publication of results of this study will be addressed in clinical trial agreements between Opthea (Sponsor) and the study site, and Opthea and the subcontractors performing the study. Results means any and all information and know-how (whether patentable or not) which is discovered, invented or developed or which arises in the course of or as a result of the conduct of the Study, including any and all improvements to the products being studied.|t
17192459|NCT00073749|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192460|NCT04154384|t||||f
17192461|NCT05048186|f||||f
17192462|NCT00951379|f||LTE60||t
17192463|NCT02467166|f||||f
17192464|NCT04218266|f||OTHER||t
17192465|NCT02742519|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17192466|NCT04377308|t||||
17192467|NCT03580369|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17192468|NCT04881175|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17192469|NCT03242148|f||OTHER||t
17192470|NCT04774380|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17192471|NCT04774237|f||||f
17192472|NCT04923347|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192473|NCT04970407|f||||t
17192474|NCT02960230|t||||
17192475|NCT06066541|t||||
17192476|NCT02819843|t||||
17192477|NCT04022343|t||||
17192478|NCT03055858|f||LTE60||t
17192479|NCT04586920|f||GT60||t
17192480|NCT04761302|f||||f
17192481|NCT04052516|f||OTHER|Each Investigator is obligated to keep data pertaining to the study confidential. The Investigator must consult with the Sponsor before any study data are submitted for publication. The Sponsor reserves the right to deny publication rights until mutual agreement on the content, format, interpretation of data in the manuscript, and journal selected for publication are achieved.|t
17192482|NCT03625323|f||OTHER|Approval from the Sponsor is required for the PI to publish or disseminate results from the medical investigation.|t
17192483|NCT03948763|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17192484|NCT05415436|t||||f
17192485|NCT03264131|f||OTHER|Study publication should be a joint publication of all sites. A separate site publication is restricted until 24 months after the study completion or study publication.|t
17192486|NCT00753987|f||||f
17192487|NCT04505774|f||||f
17148725|NCT01020526|f||OTHER|Sponsor has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study participating sites. Investigator may not disclose previously undisclosed confidential other than study results.|t
17192488|NCT02815813|t||||f
17192489|NCT04563793|f||||f
17192490|NCT02597946|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17148726|NCT02095340|f||||f
17148727|NCT02132650|t||||
17148728|NCT02212457|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148729|NCT01120691|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17148730|NCT00938782|f||||f
17148731|NCT03370510|f||||f
17148732|NCT00804999|f||||f
17192491|NCT04995484|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. A coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17192492|NCT06072404|f||||f
17192493|NCT02485834|f||||t
17192494|NCT05058391|f||||t
17192495|NCT05136404|f||GT60||t
17192496|NCT03584516|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17192497|NCT00448240|f||||f
17192498|NCT04868110|f||||f
17192499|NCT03379168|f||||f
17192500|NCT05343390|t||||
17192501|NCT04286282|t||||
17192502|NCT05806788|t||||
17192503|NCT04511702|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17192504|NCT01894061|t||||
17192505|NCT05996744|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192506|NCT02840474|f||||f
17148733|NCT01525628|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192507|NCT03192891|f||||f
17192508|NCT05141903|f||||f
17148734|NCT00089973|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148735|NCT01992094|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial|t
17148736|NCT01214239|t||||
17148737|NCT01049581|t||LTE60||t
17148738|NCT03646162|f||||t
17148739|NCT02367872|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148740|NCT02625298|f||||f
17148741|NCT05068284|f||||f
17148742|NCT00965731|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148743|NCT05135273|f||GT60||t
17148744|NCT04225260|f||GT60||t
17148745|NCT04129944|f||OTHER|Publication of Study results will not be made before the first multi-site publication by Sponsor. If no manuscript is submitted within 12 months after the Study's database lock, Investigator may publish Study results if he/she submits all proposed Publications to Sponsor 60 days prior to submission. Investigator shall delete Sponsor's Confidential Information and delay Publication up to 60 days to allow Sponsor to file a patent on Confidential Information in the Publication.|t
17148746|NCT00493792|t||||
17148747|NCT04241133|f||||f
17148748|NCT00348816|t||||
17148749|NCT01190930|f||OTHER|Must obtain prior Sponsor approval|t
17148750|NCT02988882|f||||f
17148751|NCT00046839|f||||f
17148752|NCT02050321|t||||
17148753|NCT00766493|f||OTHER|Gore has the right to review disclosures, requesting a delay of less than 90 days. Each investigator will postpone single center publications until after disclosure of multi-center data, less than 12 months from study completion/termination at all participating sites.|t
17148754|NCT05653362|f||||f
17148755|NCT00721955|f||LTE60||t
17148756|NCT01292837|f||GT60||t
17148757|NCT01889797|f||||f
17148758|NCT04531527|f||OTHER|No information based on the conduct of the study (incl. protocol, data resulting from the study, or the fact that the study was being conducted) will be released without prior written consent of the sponsor unless the requirement is superseded by State or Federal law.|t
17148759|NCT01272076|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results until the device is released on the market.|t
17148760|NCT00569660|t||||f
17148761|NCT02180230|f||||f
17148762|NCT03937791|f||||f
17148763|NCT01362192|f||||f
17148764|NCT01589601|f||||f
17148765|NCT01819064|f||||f
17148766|NCT01077258|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148767|NCT00434837|t||||
17148768|NCT00142116|f||||f
17148769|NCT00726895|f||GT60||t
17148770|NCT02287636|t||||
17192509|NCT06391177|f||OTHER|Principal investigators (PIs) are not permitted to publish the data. Data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the PIs to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority over all such issues.|t
17192510|NCT03089398|f||||f
17192511|NCT05062265|f||||f
17192512|NCT05439603|f||||f
17192513|NCT03737058|f||||f
17192514|NCT02682316|t||||
17192515|NCT05693610|f||||f
17192516|NCT05927753|f||OTHER|Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee, for comment. Such comments shall aim to ensure the scientific integrity of the proposed publications and/or presentations and ensure that the data and material referring to Sponsor products and activities receive fair, accurate, and reasonable presentation.|t
17192517|NCT00150813|f||GT60||t
17192518|NCT04640961|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17192519|NCT03052608|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192520|NCT03113500|t||||
17192521|NCT05535257|t||||
17192522|NCT04204278|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17192523|NCT05653856|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period no less than 90 days but less than or equal to 120 days from the time submitted to the sponsor for review. Also, the PI can utilize results of clinical tests and site and patient outcome information only for its own internal non-commercial teaching, research, patient care, and treatment and publication purposes.|t
17192524|NCT04820855|t||||
17192525|NCT04179149|f||||f
17192526|NCT04058626|t||||
17192527|NCT01198366|f||||f
17192528|NCT00650104|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192529|NCT00931710|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17192530|NCT01376700|f||OTHER|Agreements may vary with individual PIs, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or up to 2 years after study completion. Baxter requires a review of results communications (eg for confidential information) ≥30 days prior to submission/communication. Baxter may request additional delay of ≤6 months (e.g., for intellectual property protection). Prior authorization may be required|t
17192531|NCT04752163|t||||
17192532|NCT01549899|f||||f
17192533|NCT00601900|f||LTE60||t
17148771|NCT04079452|f||||f
17148772|NCT00345033|t||||
17148773|NCT01881737|f||||f
17192534|NCT05873751|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192535|NCT02345720|f||GT60||t
17192536|NCT02317783|t||||
17192537|NCT01762059|t||||
17192538|NCT02140645|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192539|NCT02318901|f||||f
17192540|NCT00593489|f||||f
17148774|NCT02102932|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights|t
17148775|NCT01562132|f||LTE60||t
17148776|NCT02250651|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148777|NCT03496298|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17148778|NCT01658995|t||||
17192541|NCT00611559|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192542|NCT04442126|f||||t
17192543|NCT06450405|f||||f
17192544|NCT03424811|t||||
17192545|NCT04455035|t||||
17192546|NCT03217565|f||LTE60||t
17192547|NCT02728557|f||||f
17192548|NCT03416010|f||||f
17192549|NCT05574426|f||||f
17192550|NCT04030130|t||||
17192551|NCT03819686|t||||
17192552|NCT04788537|f||||f
17192553|NCT00837369|t||||f
17192554|NCT04899115|t||||
17192555|NCT03697070|f||||f
17192556|NCT05161715|f||OTHER|After the multicenter publication or 12 months after completion of the study, whichever occurs first, Institution may publish the results of its study data. Institution and PI shall provide Sponsor with an advance copy of any proposed communications at least 30 days prior and Sponsor shall have 30 days to review. Sponsor may request (a) the deletion of any Confidential Information, (b) reasonable changes, or (c) a delay for an additional 60 day period.|t
17192557|NCT03743636|f||||f
17192558|NCT01938547|f||||t
17192559|NCT05038566|t||||
17192560|NCT04842643|f||OTHER||t
17192561|NCT02226341|t||||
17192562|NCT00739648|f||||f
17192563|NCT01757665|f||OTHER|Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 30 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 60 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.|t
17192564|NCT02387853|f||OTHER|LEO acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192565|NCT05387447|t||||f
17148779|NCT01186562|f||||f
17148780|NCT03316976|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17148781|NCT02522780|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17148782|NCT04106817|f||||f
17148783|NCT02260635|f||GT60||t
17148784|NCT03310619|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148785|NCT00152516|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17148786|NCT02427399|t||||f
17148787|NCT03538262|t||||
17192566|NCT03679611|f||||f
17192567|NCT03391466|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192568|NCT03655132|t||||
17192569|NCT05568004|f||||f
17192570|NCT05919082|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17192571|NCT04272619|t||||
17192572|NCT05783219|f||||f
17192573|NCT03818191|t||||f
17192574|NCT04703322|f||||f
17192575|NCT06311084|t||||
17192576|NCT04049747|t||||
17192577|NCT05249439|t||||
17192578|NCT01707030|t||||
17192579|NCT03526861|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17192580|NCT05862870|f||||f
17192581|NCT03727061|t||||
17192582|NCT00274469|f||LTE60||t
17192583|NCT03526354|f||||f
17192584|NCT06647238|f||||f
17192585|NCT06155721|t||||
17192586|NCT04095104|t||||f
17192587|NCT04277936|f||||f
17192588|NCT02057939|t||||
17192589|NCT03912831|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17148788|NCT02289820|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17148789|NCT01812473|f||||f
17148790|NCT01517867|t||||
17148791|NCT02033317|f||OTHER|Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor's confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.|t
17148792|NCT03847974|f||LTE60||t
17148793|NCT01924364|f||||f
17148794|NCT01685216|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17148795|NCT00756717|t||||
17148796|NCT02418754|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17148797|NCT04974580|f||||f
17148798|NCT00250705|f||||f
17148799|NCT01493596|f||GT60||t
17148800|NCT02466386|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17148801|NCT04784637|t||||
17148802|NCT01688882|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17148803|NCT03259789|f||OTHER|The investigator does not have the right to publish trial results.|t
17148804|NCT00889252|f||OTHER|Investigator agrees not to publish or publicly present the results of the study without the prior written approval of the sponsor.|t
17148805|NCT02416934|f||||f
17148806|NCT00398073|t||||
17148807|NCT04235660|t||||
17148808|NCT00591760|f||||f
17148809|NCT01833169|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148810|NCT03718039|f||||f
17148811|NCT00879684|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148812|NCT00105157|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148813|NCT00127166|f||OTHER|Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17148814|NCT01237080|f||||f
17148815|NCT02169336|f||OTHER|Discussion and/or publication of data generated is not permitted without the prior written consent of the sponsor.|t
17148816|NCT01148225|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148817|NCT00393705|f||GT60||t
17148818|NCT02490800|f||GT60||t
17148819|NCT03365791|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148820|NCT03693950|f||||f
17148821|NCT01475487|t||||
17192590|NCT03527160|f||||f
17192591|NCT01522924|t||||
17192592|NCT02910713|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17192593|NCT00766649|t||||f
17192594|NCT03767517|t||||
17192595|NCT05792423|f||||f
17192596|NCT06149104|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17192597|NCT05338086|f||||t
17192598|NCT04533022|f||||f
17192599|NCT02163447|f||||f
17192600|NCT06240091|t||||
17148822|NCT03203642|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17148823|NCT03169816|t||||
17148824|NCT03388008|f||||f
17148825|NCT02710240|f||||f
17148826|NCT00559637|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17148827|NCT02832167|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148828|NCT00968019|f||||f
17148829|NCT01109576|t||||
17148830|NCT01958060|t||||
17148831|NCT01550367|t||||
17148832|NCT02293460|f||||t
17148833|NCT02304406|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148834|NCT03023709|f||||f
17148835|NCT04284553|t||||
17148836|NCT01074008|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17148837|NCT00224484|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148838|NCT00673764|f||OTHER|The PI should hold confidential, and not disclose directly or indirectly to any third party other than Contractors, the data arising out of the study. Alcon reserves the right of prior review of any publication or presentation of information related to the study.|t
17148839|NCT02805309|f||||f
17148840|NCT00603564|f||||f
17148841|NCT04489303|t||||
17148842|NCT01196117|t||||f
17148843|NCT01350934|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.|t
17148844|NCT03547635|f||OTHER|Investigators are barred from publishing or disclosing results until a multicenter publication is published or until a period of 24 months after study completion passes, whichever comes first.|t
17148845|NCT03028896|f||||f
17148846|NCT03239496|f||||f
17148847|NCT00275275|t||||
17148848|NCT02415387|f||||f
17148849|NCT02339415|f||||f
17148850|NCT00003404|f||||f
17148851|NCT00676650|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148852|NCT00683592|f||OTHER|The investigators have the right to publish or permit the publication of any information or material relating to or arising out of this protocol after prior submission to PGxHealth provided that, if PGxHealth requests, the investigator will delay publication for a maximum of six months to enable PGxHealth to protect their rights in such information or material.|t
17148853|NCT00685035|f||||f
17148854|NCT03653026|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection|t
17148855|NCT02104817|f||OTHER|The Principal Investigator shall provide AstraZeneca with copies of any materials relating to the Study, the Study Documentation, or the Developed Technologies that either Party intends to publish (or submit for publication) or make any presentations relating to, at least 60 days in advance of publication, submission or presentation.|t
17148856|NCT01225055|f||||f
17148857|NCT03307564|t||||
17148858|NCT00611884|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17148859|NCT00981799|f||GT60||t
17148860|NCT01201759|t||||f
17148861|NCT00687739|f||||f
17148862|NCT04269993|f||||f
17148863|NCT03287687|f||||f
17148864|NCT00115869|f||||f
17148865|NCT02005276|f||||f
17148866|NCT01963260|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17148867|NCT04994431|t||||
17148868|NCT00722436|t||||
17148869|NCT01067521|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17148870|NCT03419962|f||||f
17148871|NCT00452543|f||||f
17148872|NCT02914457|f||LTE60||t
17148873|NCT01769222|f||||f
17148874|NCT01098539|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148875|NCT01849458|f||||f
17148876|NCT01781234|t||||
17148877|NCT03439085|t||||
17148878|NCT01863433|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148879|NCT02174276|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17148880|NCT01206439|f||||f
17148881|NCT00781079|t||||
17148882|NCT00515216|f||||f
17148883|NCT02786927|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17148884|NCT01801917|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17148885|NCT04307849|t||||
17148886|NCT05467982|t||||f
17148887|NCT02997722|f||||f
17148888|NCT04381481|t||||
17148889|NCT00708682|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148890|NCT02922582|f||OTHER|Institution and investigator shall reasonably cooperate with Pacira to prepare abstract and manuscript reporting primary results within 90 and 120 days, respectively, of single and/or pooled analysis final CSR and shall publish no other trial results within 12 months after completion of final CSR. Institution shall submit all proposed written materials related to the trial ≥60 days before submission for presentation/publication. Pacira may embargo publication for an additional 90 days.|t
17148891|NCT03185741|f||||f
17148892|NCT01634854|t||||
17148893|NCT01337596|f||GT60||t
17148894|NCT02569541|f||OTHER|The Sponsor has the right to first publication of results, which would be made in conjunction with the PIs from all appropriate sites. Thereafter, PIs may publish results provided the PI submits the proposed publication to the Sponsor for review at least 60 days prior to the date of the proposed publication. The Sponsor may remove information that is considered confidential and/or proprietary and delay the proposed publication for an additional 60 days to enable filing of patent applications.|t
17148895|NCT00578968|t||||f
17148896|NCT00945334|f||||f
17148897|NCT00108628|t||||
17148898|NCT01636934|t||||
17148899|NCT00292591|f||||f
17148900|NCT02297841|f||OTHER|Master service agreement and confidentiality agreement in place|t
17148901|NCT03429049|f||||t
17148902|NCT04814459|f||||f
17148903|NCT01891812|t||||
17148904|NCT01841060|t||||
17148905|NCT01833754|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17148906|NCT01872715|f||GT60||t
17148907|NCT02814708|f||||f
17148908|NCT01578317|t||||
17148909|NCT01765270|f||||f
17148910|NCT02252445|t||||
17148911|NCT03431337|f||||f
17148912|NCT00329160|f||OTHER||t
17148913|NCT04501094|f||||f
17148914|NCT00963430|f||LTE60||t
17148915|NCT02315261|f||||f
17148916|NCT00063258|t||||f
17148917|NCT00623636|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17148918|NCT00784979|t||||
17148919|NCT00894933|f||||f
17148920|NCT02812771|f||OTHER|Please contact sponsor directly for details.|t
17148921|NCT01503333|f||||f
17148922|NCT00468208|f||||f
17148923|NCT01235715|t||||f
17148924|NCT03619876|t||||
17148925|NCT00646763|f||||f
17148926|NCT00396630|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192601|NCT05113966|f||OTHER|Investigator agrees to submit any disclosure to Sponsor for review at least thirty (30) days prior to submission. Within sixty (60) days of its receipt, Sponsor can provide feedback on any disclosure Sponsor may require Investigator to remove, Confidential Information (other than study data), and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for inventions.|t
17192602|NCT05386355|f||||f
17192603|NCT06143670|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17192604|NCT03747484|t||||
17148927|NCT00357955|f||||f
17148928|NCT04443569|t||||
17148929|NCT00996437|f||||f
17148930|NCT02576717|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17148931|NCT01755975|t||||
17148932|NCT00399893|f||LTE60||t
17148933|NCT01625507|f||||f
17148934|NCT01729026|f||||f
17148935|NCT00906373|f||OTHER|Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.|t
17148936|NCT01597479|f||||f
17148937|NCT00848042|f||OTHER||t
17148938|NCT03346850|t||||
17148939|NCT00979212|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17148940|NCT03971578|t||||f
17148941|NCT04886063|f||OTHER||t
17148942|NCT00309985|f||LTE60||t
17148943|NCT02448563|f||||f
17148944|NCT03720704|f||||f
17148945|NCT02340962|f||LTE60||t
17148946|NCT01450800|t||||
17148947|NCT00265785|f||||f
17148948|NCT03401918|t||||
17148949|NCT01294449|f||OTHER|The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.|t
17148950|NCT03222037|f||GT60||t
17148951|NCT00496262|f||OTHER|The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.|t
17148952|NCT02221817|t||||
17148953|NCT01334957|f||||f
17148954|NCT02203578|t||||
17148955|NCT00420095|f||GT60||t
17148956|NCT00654641|f||||f
17148957|NCT02625974|f||LTE60||t
17148958|NCT01977456|f||||f
17148959|NCT01142661|f||||f
17148960|NCT00434590|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17148961|NCT00851006|f||||f
17148962|NCT02129062|f||LTE60||t
17148963|NCT02722616|f||||f
17148964|NCT03460990|f||OTHER||t
17148965|NCT01923311|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17148966|NCT02031237|t||||
17148967|NCT01435824|t||||
17148968|NCT01011335|f||||f
17148969|NCT00117806|t||||f
17148970|NCT04231409|f||||t
17148971|NCT01474915|f||||f
17148972|NCT01765751|t||||
17148973|NCT05258630|f||||f
17148974|NCT03303417|t||||
17148975|NCT01848210|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 30 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results.|t
17148976|NCT02076776|t||||
17148977|NCT02426541|f||OTHER|"All drafts of proposed publications, written reports, training materials, advertisements and similar documents related to the Services and intended to be communicated or published to any third party (Communications) must be submitted to Antaros for AstraZeneca's review and approval prior to dissemination."|t
17148978|NCT00745134|t||||
17148979|NCT00631007|f||OTHER|Investigator and Institution shall only be permitted to publish or present the results of that portion of the Study conducted at Institution with Sponsor's prior written consent, which consent may be withheld at Sponsor's sole discretion.|t
17148980|NCT02674633|f||||f
17148981|NCT00683787|t||||
17148982|NCT00460109|t||||
17148983|NCT02994394|f||||f
17148984|NCT02327325|t||||
17148985|NCT01507233|f||||f
17192605|NCT03833245|f||||f
17192606|NCT03775109|f||||f
17192607|NCT03347383|f||||f
17192608|NCT04030169|f||||f
17192609|NCT05691452|f||||f
17192610|NCT03564600|f||||f
17192611|NCT05110495|t||||
17148986|NCT05560555|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148987|NCT02457819|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17148988|NCT06217796|f||||f
17148989|NCT03330236|t||||
17148990|NCT01191476|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17148991|NCT01901848|t||||
17148992|NCT00763555|f||OTHER||t
17148993|NCT00852917|f||OTHER|Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm's ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm's confidential information|t
17148994|NCT02488824|f||||f
17148995|NCT00493064|f||||f
17148996|NCT04317599|f||||t
17148997|NCT00809965|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17148998|NCT02315066|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17148999|NCT00112294|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149000|NCT01142908|t||||
17149001|NCT03636386|f||||t
17149002|NCT01186016|f||||f
17149003|NCT03417739|t||||
17149004|NCT01055886|f||||f
17149005|NCT02255487|f||||f
17149006|NCT02972515|f||||f
17149007|NCT01086969|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17149008|NCT01041209|t||||
17149009|NCT00176930|t||||
17149010|NCT00585312|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149011|NCT01679054|f||||f
17149012|NCT04291508|f||||f
17149013|NCT04203667|f||||f
17149014|NCT02329431|f||||f
17149015|NCT01362296|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149016|NCT00571194|t||||
17149017|NCT02459418|f||OTHER|Contract agreement. Results may not be published or referred to, in whole or in part, without the prior express written consent of the Sponsor.|t
17149018|NCT00653159|t||||
17149019|NCT00109837|f||||f
17149020|NCT00381849|t||||f
17149021|NCT04167618|f||||f
17149022|NCT05996198|t||||
17149023|NCT02046863|f||LTE60||t
17149024|NCT00835796|f||OTHER|Principal Investigator is not permitted to discuss or publish trial results.|t
17149025|NCT01402128|t||||f
17149026|NCT00651183|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17149027|NCT00951093|t||||
17149028|NCT01363011|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149029|NCT04412057|f||||f
17149030|NCT02156154|t||||
17149031|NCT02051595|t||||
17149032|NCT01961882|f||||f
17149033|NCT03710590|t||||f
17149034|NCT00407745|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192612|NCT04847544|f||||t
17149035|NCT00108082|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149036|NCT01563237|f||||t
17149037|NCT02419924|t||||
17149038|NCT00955552|f||||f
17149039|NCT00784030|f||||f
17149040|NCT02940730|f||||f
17149041|NCT01922219|t||||
17149042|NCT03036839|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149043|NCT00412737|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192613|NCT04716634|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192614|NCT02793687|f||GT60||t
17192615|NCT03467542|f||OTHER|"The Principal Investigator may publish the results if Sponsor has not published within eighteen (18) months after FDA approval of the Trial Devices.~The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."|t
17192616|NCT04593472|f||||f
17192617|NCT04236856|f||||t
17192618|NCT04538417|t||||
17192619|NCT03394846|f||||f
17192620|NCT04549168|f||||t
17192621|NCT03262779|t||||
17192622|NCT04868227|t||||
17192623|NCT03988634|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17192624|NCT04725240|f||OTHER|All information regarding setmelanotide supplied by Rhythm to the investigator is privileged and confidential information. The investigator agrees to use this information to accomplish the study and will not use it for other purposes without consent from Rhythm. The information obtained from the clinical study will be used towards the development of setmelanotide and may be disclosed to regulatory authority(ies), other investigators, corporate partners, or consultants as required.|t
17192625|NCT02249949|f||||t
17192626|NCT04414644|f||||f
17192627|NCT02867384|f||||f
17192628|NCT05061095|f||||f
17192629|NCT03414814|f||||f
17192630|NCT01351805|f||||f
17192631|NCT03822845|t||||
17192632|NCT05633407|f||OTHER||t
17192633|NCT02500758|f||||f
17192634|NCT05386069|t||||
17192635|NCT04999592|f||||f
17192636|NCT05179395|t||||
17192637|NCT01388777|t||||
17192638|NCT00084552|t||||
17192639|NCT02471638|f||LTE60||t
17192640|NCT05529966|t||||
17192641|NCT04222660|t||||
17149044|NCT01701037|t||||
17149045|NCT02740920|t||||f
17149046|NCT01064531|f||LTE60||t
17149047|NCT00513617|f||||f
17192642|NCT02520063|f||||f
17192643|NCT05005221|t||||
17192644|NCT03940703|f||||t
17192645|NCT04521478|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192646|NCT04578912|t||||
17192647|NCT04712994|f||||f
17192648|NCT06190678|f||GT60||t
17192649|NCT05320432|t||||
17192650|NCT05535062|f||||f
17192651|NCT03285321|f||||f
17149048|NCT03449199|f||||f
17149049|NCT01091103|f||OTHER|PI agrees not to independently publish the results before the publication of the multi-center PI paper. Sponsor shall review and comment 30 days prior to submission or disclosure. If publication or disclosure contains Sponsor Confidential Information, other than Study Data, PI agrees to remove Confidential Information from publication or disclosure. Sponsor may request that PI delay such publication for an additional 60 days to protect the patentability of any Invention described.|t
17149050|NCT01270620|f||||f
17149051|NCT00684567|f||||f
17149052|NCT03136406|f||||t
17149053|NCT03404401|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable.|t
17192652|NCT05194969|t||||
17192653|NCT04173663|f||||f
17192654|NCT03931291|f||LTE60||t
17192655|NCT04850807|f||||f
17192656|NCT02278562|f||||f
17192657|NCT02187003|f||||t
17192658|NCT05816551|f||||f
17192659|NCT04311996|t||||
17192660|NCT02379156|f||||f
17192661|NCT02630823|t||||
17192662|NCT04178733|t||GT60||t
17192663|NCT05159583|f||||f
17192664|NCT05126862|t||||f
17192665|NCT04119284|t||||
17192666|NCT03744936|t||||f
17192667|NCT03328702|t||||
17192668|NCT04833777|t||||
17149054|NCT00988208|f||OTHER|Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 24 months after study completion. Individual investigators have publication rights after multicenter publication is complete (or 24 months after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 60 days.|t
17149055|NCT00271739|t||||
17149056|NCT03008837|f||||f
17149057|NCT01573533|t||||
17149058|NCT01045707|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17192669|NCT03636503|f||||f
17192671|NCT05461131|f||||f
17192672|NCT03896516|t||||
17192673|NCT04172441|f||||t
17192674|NCT04674358|f||||t
17192675|NCT03648840|f||||f
17192676|NCT03739450|t||||
17192677|NCT05382936|f||OTHER|"* Stemline shall have the right to publish the results of the study~* This is a multi-site study; therefore, publication of results from all sites is expected~* Institution's (PI's) results may be submitted for publication only after multicenter results have been published, 18 months after study completion.~* PI to submit copy of publication/presentation to Stemline for review/comment at least 60 days prior to submission for publication"|t
17192678|NCT03703700|f||||f
17192679|NCT05968495|f||OTHER|The data produced by this sponsored study is the sole property of Sponsor. Sponsor must be provided with the opportunity to review all Investigator-prepared abstracts, publications, or presentations for a period of thirty (30) days for presentational materials and abstracts and forty-five (45) days for manuscripts.|t
17192680|NCT03101904|t||||f
17192681|NCT05054374|t||||
17192682|NCT03453619|f||||t
17192683|NCT03625882|f||||t
17192684|NCT02643667|t||||
17192685|NCT02790931|f||||f
17192686|NCT04690673|f||||f
17192687|NCT05549726|f||||f
17192688|NCT03484702|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192689|NCT01226979|t||||
17192690|NCT03604263|f||||f
17192691|NCT02651324|f||||f
17192692|NCT01974245|f||||f
17192693|NCT01195831|f||OTHER|The company acknowledges the investigators' right to publish the results of the trial. The company retains the right to have any publication submitted to the company for review at least 30 days prior to the proposed submission or presentation date. Investigators must undertake not to submit any part of their individual data for publication without prior consent of LEO.|t
17192694|NCT01857934|t||||
17192695|NCT05595629|f||||f
17192696|NCT03713086|f||||f
17192697|NCT01582711|f||||f
17192698|NCT02784509|f||||f
17192699|NCT02662062|f||||f
17192700|NCT04600323|f||||f
17192701|NCT03841669|t||||
17192702|NCT05406921|f||||f
17192703|NCT03222128|f||||t
17192704|NCT04299009|f||||f
17192705|NCT00676715|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâ€™s intellectual property rights.|t
17192706|NCT01820260|f||||f
17192707|NCT04356027|f||GT60||t
17192708|NCT04831281|f||||t
17192709|NCT02097420|f||OTHER||t
17192710|NCT04092387|f||||f
17192711|NCT02193958|f||||f
17192712|NCT03161379|t||||
17192713|NCT02728076|t||||
17192714|NCT04456920|t||||
17192715|NCT02384317|f||||t
17192716|NCT04140708|f||||f
17192717|NCT04089371|f||||f
17192718|NCT05166811|f||||f
17192719|NCT04936035|f||OTHER||t
17192720|NCT02808676|f||||f
17192721|NCT05849051|t||||f
17192722|NCT03978871|f||||f
17192723|NCT04450342|f||OTHER|"Upon completion of the Trial the PI may prepare the data derived from the Trial for publication, and will submit to Sponsor for review and comment prior to publication. To ensure that Sponsor will be able to make comment and suggestions where pertinent, the material for public dissemination will be submitted for review at least 40 to 90 days\* prior to submission for publication, public dissemination or review by a publication committee.~\*Country dependent, no timeframe is mandated for France."|t
17192724|NCT00220740|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution that satisfies both parties.|t
17192725|NCT06041139|t||||
17192726|NCT04314895|f||||f
17192727|NCT03941860|f||LTE60||t
17192728|NCT05328648|t||||
17192729|NCT03396588|t||||f
17192730|NCT00812461|f||OTHER|The main publication has to be published before any sub publication. The investigators shall obtain Lundbeck's written approval before publishing any publication relating to nalmefene, the Study, the Protocol and/or the results recorded during the Study.|t
17192731|NCT05297864|t||||
17192732|NCT03964350|t||||
17192733|NCT01328262|t||||
17192734|NCT04402489|f||OTHER||t
17192735|NCT05902793|f||||t
17192736|NCT05121740|f||LTE60||t
17192737|NCT03676582|t||||
17192738|NCT02287311|t||||
17192739|NCT03158805|f||||f
17192740|NCT05418296|t||||
17192741|NCT05543746|t||||
17192742|NCT02829814|f||OTHER|An industry standard NDA is in place with all investigators.|t
17192743|NCT00616967|t||||f
17192744|NCT05059262|f||||t
17192745|NCT04864912|f||OTHER|The first publication would be a joint publication covering data from all centers, and subsequent publications will refer to that first publication. Investigators can publish or present after agreement between the Coordinating and Principal Investigators, and the Sponsor after the main publication is submitted and approved. Conference presentations or publications must be sent for review at least to the Sponsor 30 - 60 days (site-specific) prior to submission or presentation.|t
17192746|NCT05449795|f||||f
17192747|NCT06320964|f||||f
17192748|NCT04501861|t||||
17192749|NCT04234698|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192750|NCT02312960|f||GT60||t
17192751|NCT04301778|t||||
17192752|NCT05695989|f||||f
17192753|NCT03281291|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192754|NCT04382898|f||OTHER|The results of this trial may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17192755|NCT05229120|f||||f
17192756|NCT02900924|f||GT60||t
17192757|NCT04950192|f||OTHER|No publication or presentation concerning a single site experience may be permitted until the multi-center study has been published. Notwithstanding the foregoing or in the event such multicenter publication is not submitted within twelve (12) months of completion of the Study at all sites or if Sponsor confirms there will be no multicenter publication, Principal Investigator shall furnish Sponsor with a copy of any proposed publication or presentation at least forty-five (45) days|t
17192758|NCT03972813|f||||f
17192759|NCT02365766|f||||f
17192760|NCT01566695|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is \> 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.|t
17192761|NCT03763708|f||||f
17192762|NCT02897531|f||||f
17192763|NCT05470400|f||||f
17192764|NCT05272852|f||||f
17192765|NCT05956002|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192766|NCT05974046|f||||t
17192767|NCT02991534|t||||
17192768|NCT02307565|t||||f
17192769|NCT02589275|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17192770|NCT04401800|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192771|NCT03385629|f||||f
17192772|NCT05868772|t||||
17192773|NCT05102591|f||||f
17192774|NCT04768569|t||||
17192775|NCT02281955|t||||
17192776|NCT02913872|t||||
17192777|NCT04072822|t||||f
17192778|NCT03095274|f||||f
17192779|NCT04391894|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17192780|NCT01889199|t||||
17192781|NCT02323321|f||OTHER||t
17192782|NCT00446225|f||||f
17192783|NCT01057433|f||OTHER|May not publish.|t
17192784|NCT02811679|t||||
17192785|NCT06365086|f||||f
17192787|NCT05611073|t||||
17192788|NCT03361748|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192789|NCT04986501|f||||f
17192790|NCT03113422|f||||f
17192791|NCT06207058|f||||f
17192792|NCT02814838|f||||f
17192793|NCT03811366|f||||f
17192794|NCT01361711|t||||
17192795|NCT02596126|f||||f
17192796|NCT03717506|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17192797|NCT04280445|f||||f
17192798|NCT05993078|f||||f
17192799|NCT01525966|t||||f
17192800|NCT05098795|f||||f
17149059|NCT03764735|f||OTHER|Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor will have the final decision regarding the manuscript and publication.|t
17149060|NCT00450983|t||||
17149061|NCT04735068|f||||f
17149062|NCT01601691|f||||f
17149063|NCT00035555|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149064|NCT02618382|f||||f
17149065|NCT03843125|f||GT60||t
17149066|NCT03173560|f||||f
17149067|NCT04254809|f||||f
17149068|NCT03023137|f||||f
17149069|NCT02608476|f||OTHER|The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.|t
17149070|NCT02795676|f||||f
17149071|NCT00605176|f||||f
17149072|NCT01992874|f||OTHER||t
17149073|NCT00838981|f||||f
17149074|NCT04253236|f||||f
17149075|NCT00587431|t||||
17149076|NCT03566238|f||OTHER|Albireo will retain the ownership of all data. All proposed publications based on this study must be subject to the sponsor's approval requirements.|t
17149077|NCT02710591|f||||t
17149078|NCT00597428|f||GT60||t
17149079|NCT00373425|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript at least 60 days prior to publication for review and comment. Sponsor may delay the publication for up to 6 months to seek patent protection.|t
17149080|NCT03073811|t||||
17149081|NCT03942211|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17149082|NCT01183884|t||||
17149083|NCT04511208|f||||f
17149084|NCT04547036|t||||f
17192801|NCT05063994|f||||t
17192802|NCT04630262|f||OTHER|Data collection in this study was conducted according to the Clinical Investigation Plan and all applicable regulations unless otherwise stated. Data is not anticipated to be used for publication or as the basis for future regulatory submissions except as part of routine post-market surveillance on the associated products. The database was closed without source data verification or final data cleanup. No statistical analysis of this data will occur.|t
17192803|NCT05114460|t||||
17192804|NCT04975880|f||OTHER|Before publishing or presenting trial results, the Principal Investigator is to submit copies of any Proposed Manuscripts to Sponsor at least 60 days in advance of submission. If Sponsor determines that the publication or presentation would be detrimental to its or its affiliates' intellectual property interests, an additional 90 days can be instituted to allow Sponsor to take appropriate steps to protect its or its affiliates' intellectual property interests.|t
17192805|NCT03984695|f||||f
17192806|NCT04638998|f||||f
17192807|NCT03692676|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149085|NCT01835548|f||LTE60||t
17149086|NCT01169038|t||||f
17149087|NCT01488448|t||||
17149088|NCT00537017|f||OTHER|The investigator agrees not to publish or publicly present any interim results of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.|t
17149089|NCT01834027|t||||f
17192808|NCT05519228|f||LTE60||t
17192809|NCT01180634|f||OTHER||t
17192810|NCT03692611|t||||
17192811|NCT04419168|t||||f
17192812|NCT04490915|f||||t
17149090|NCT03168906|f||||f
17149091|NCT02219308|f||||f
17149092|NCT01621906|t||||
17149093|NCT02447887|t||||
17149094|NCT02839798|f||||f
17149095|NCT00401245|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149096|NCT02344745|f||||f
17149097|NCT02788513|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149098|NCT02919111|t||||f
17150735|NCT02038907|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149099|NCT02014441|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149100|NCT01933919|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149101|NCT00991510|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17149102|NCT00928226|t||||
17149103|NCT02356211|t||||f
17149104|NCT03765996|f||||f
17149105|NCT02970552|t||||
17149106|NCT02510261|f||||f
17149107|NCT01312181|f||||f
17149108|NCT02443324|f||GT60||t
17149109|NCT04057248|f||||f
17149110|NCT02451150|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149111|NCT03244475|f||||f
17149112|NCT02780167|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149113|NCT00367016|t||||f
17149114|NCT01148524|f||GT60||t
17149115|NCT03110380|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149116|NCT01734694|f||||f
17149117|NCT01355302|f||OTHER||t
17149118|NCT02531594|f||||f
17149119|NCT03750695|f||||f
17149120|NCT02525263|f||||f
17149121|NCT03460899|t||||
17149122|NCT04480307|f||||f
17149123|NCT05862844|f||||f
17149124|NCT01264835|f||LTE60||t
17192813|NCT05009251|f||||f
17149125|NCT01203917|f||LTE60||t
17192814|NCT05374837|f||||f
17192815|NCT03149315|f||||f
17192816|NCT06470087|t||||
17149126|NCT00108550|t||||f
17149127|NCT04660032|t||||f
17149128|NCT03224520|f||||f
17149129|NCT02684396|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17149130|NCT01903564|f||||f
17149131|NCT01514513|f||||f
17149132|NCT01609582|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17192817|NCT03786783|f||LTE60||t
17192818|NCT02910583|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192819|NCT04453592|t||||
17149133|NCT00819767|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149134|NCT02690935|f||GT60||t
17149135|NCT02994290|t||||
17149136|NCT00808509|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192820|NCT01331005|f||OTHER|Members of the Network can not discuss the trial results until the primary outcome has been made publicly available.|t
17192821|NCT03205800|t||||
17192822|NCT02029443|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17192823|NCT04469036|t||||
17149137|NCT02169791|f||||f
17149138|NCT02010996|t||||f
17149139|NCT01139294|t||||
17149140|NCT02762994|f||||f
17149141|NCT05103657|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149142|NCT01216410|t||||f
17149143|NCT04234464|f||OTHER|Data or results obtained from this study must not be published without prior approval from the Sponsor.|t
17149144|NCT03635983|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149145|NCT04763278|t||||
17149146|NCT01235442|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149147|NCT03604432|t||||
17149148|NCT01701973|f||||f
17149149|NCT01104090|t||||
17149150|NCT02412722|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17149151|NCT02941523|f||LTE60||t
17149152|NCT04449341|f||||f
17149153|NCT04330157|t||||f
17149154|NCT04499482|t||||f
17149155|NCT00337987|t||||
17149156|NCT01899326|t||||
17149157|NCT01263561|f||||f
17149158|NCT01396421|f||||f
17149159|NCT04728620|t||||
17149160|NCT02376257|f||||f
17149161|NCT03689894|t||||
17149162|NCT00681473|t||||
17149163|NCT04084990|t||||
17149164|NCT02528409|f||||f
17149165|NCT01321697|t||||
17149166|NCT00243152|f||||f
17149167|NCT05427045|t||||
17149168|NCT00548431|f||||f
17149169|NCT04149535|f||||f
17149170|NCT02875028|t||||
17149171|NCT03180528|t||||
17149172|NCT04703855|f||LTE60||t
17149173|NCT04628936|f||OTHER|"PI shall have the right to publish or present their own data resulting from the Study (Publication) upon the earlier of: (a) the date following a multicenter publication coordinated by Sponsor regarding the Protocol; (b) 12 months after completion of the Protocol by all sites; or (c) the date after submission of the Study Data by Sponsor to the FDA.~The PI must furnish Sponsor with a copy of any Publication at least 30 days in advance of the proposed submission or presentation date."|t
17149174|NCT02786719|t||||
17149175|NCT01989676|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149176|NCT01114997|f||||f
17149177|NCT00114231|t||||
17149178|NCT00368316|f||||f
17192824|NCT03393975|f||||t
17192825|NCT04083235|f||OTHER||t
17149179|NCT01976728|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17149180|NCT01185028|t||||
17149181|NCT00966381|t||||
17149182|NCT01119807|f||||f
17149183|NCT01124695|f||LTE60||t
17149184|NCT02668822|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17149185|NCT01522950|f||||f
17149186|NCT01795079|f||||f
17149187|NCT03519282|f||||t
17149188|NCT00298740|t||||
17149189|NCT04894084|t||LTE60||t
17149190|NCT02956616|t||||
17149191|NCT01345318|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149192|NCT00317642|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17149193|NCT01602471|f||||f
17149194|NCT03180801|f||OTHER|The PI requires the Sponsor's consent to publish any material that contains Sponsor Property; including Study Data.|t
17149195|NCT01049412|f||GT60||t
17149196|NCT03756883|f||OTHER|Sponsor reserves the right to review and approve all publications based off data from the study.|t
17149197|NCT02445287|f||||f
17149198|NCT03235479|f||LTE60||t
17192826|NCT01007591|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192827|NCT02549339|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192828|NCT03016169|f||OTHER|The PI may not publish study results until publication of results of multi center study or 2 years after study completion, whichever is sooner. PI allows Sponsor to review any proposed publication at least 40 days before forwarding it to any person that is not bound by confidentiality agreement between Sponsor and PI. Sponsor can request delay publication for no more than 120 days to allow Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property.|t
17192829|NCT02207062|t||||
17192830|NCT05458011|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17192831|NCT05106257|t||||
17192832|NCT02724878|t||||t
17192833|NCT04838262|f||||f
17192834|NCT05150860|t||||f
17192835|NCT05082909|t||||
17192836|NCT04539574|t||||
17192837|NCT03175029|f||||t
17192838|NCT03164980|f||||f
17192839|NCT03381261|f||||f
17149199|NCT04205162|f||||f
17149200|NCT01011556|f||GT60||t
17149201|NCT00263887|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed within thirty days and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution, which satisfies both parties.|t
17149202|NCT00779402|f||OTHER|The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentations relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.|t
17149203|NCT00693225|t||||f
17149204|NCT01315028|t||||
17149205|NCT02359864|f||||f
17149206|NCT00725764|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149207|NCT01928615|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149208|NCT00090753|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17149209|NCT02767947|f||OTHER|Please contact Sponsor directly for additional information.|t
17149210|NCT01256060|f||||f
17149211|NCT01466036|t||||
17149212|NCT01808248|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149213|NCT00761176|f||||f
17149214|NCT00109850|f||||f
17149215|NCT00476593|t||||
17149216|NCT03430011|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149217|NCT04126343|f||GT60||t
17149218|NCT00084799|f||||f
17149219|NCT03712124|f||OTHER|The Sponsor can review results and/or communications prior to public release and can embargo communications regarding trial results for a period that is up to 180 days from the time submitted to the sponsor for review. The sponsor may consult with the PI to require changes to the communication or extend the embargo.|t
17149220|NCT01332721|f||LTE60||t
17149221|NCT04314843|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149222|NCT00551616|f||||f
17149223|NCT00569777|f||OTHER|The PI may not publish or publicly present the data and or results of the study without prior approval from Vistakon.|t
17149224|NCT00709306|f||||f
17192840|NCT05227209|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17192841|NCT04950660|t||||
17192842|NCT03761537|t||||
17192843|NCT05524233|f||||f
17192844|NCT05134350|f||GT60||t
17192845|NCT02530671|f||||f
17192846|NCT02736409|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17149225|NCT04718129|f||||f
17149226|NCT01378962|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192847|NCT04390048|t||||
17192848|NCT02038569|f||OTHER|LEO acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192849|NCT03126019|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17192850|NCT03094663|t||||
17192851|NCT05200247|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192852|NCT03940963|f||OTHER|The Sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of at least sixty days prior to submission for publication for sponsor to review and comment. The Sponsor may extend the embargo for an additional 60 days to allow for the filing of a patent application or taking such measures Sponsor deems appropriate to establish and preserve its proprietary rights.|t
17192853|NCT01809691|f||LTE60||t
17192854|NCT03843151|t||||
17192855|NCT01787383|f||LTE60||t
17192856|NCT04533347|f||||t
17192857|NCT05147155|t||||
17149227|NCT02030535|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149228|NCT01588548|f||OTHER|AstraZeneca will manage the publication of the results of the Clinical Trial in partnership with the authors. AstraZeneca recognises that Institutions/Investigators may wish to make publications regarding Clinical Trial results. The Institution/Investigator agrees to collaborate in good faith with AstraZeneca. Prior to any such publication, the Institution/Investigator shall provide AstraZeneca with preliminary data and drafts of proposed publications.|t
17149229|NCT00292227|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17149230|NCT03257254|f||||f
17149231|NCT00857818|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149232|NCT03840382|f||||f
17149233|NCT02175368|t||||
17149234|NCT03941834|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192858|NCT04831216|t||||f
17192859|NCT03526874|f||||f
17192860|NCT05741489|t||||
17192861|NCT05268302|t||||
17149235|NCT02121041|f||||f
17149236|NCT01560819|t||||f
17149237|NCT00802178|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17150736|NCT02878486|t||||
17150737|NCT04536935|f||||f
17150738|NCT01732484|t||||
17192862|NCT04285567|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192863|NCT05319860|t||||
17192864|NCT00579124|f||||f
17192865|NCT03854578|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192866|NCT05264376|f||||f
17192867|NCT04263311|t||||
17192868|NCT02954341|f||||f
17192869|NCT05634226|t||||f
17192870|NCT05493423|f||||f
17192871|NCT05086016|f||||f
17192872|NCT06074523|t||||
17192873|NCT01426425|f||OTHER|"In most cases, the contract allows the principal investigator to publish their data per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (CI), (b) technical correctness and (c) selection and order of publications by the publications committee. Any such CI and/or item identified as not technically correct is deleted prior to publication/presentation. Medtronic may not otherwise interfere with the publication."|t
17192874|NCT06093659|f||||f
17192875|NCT01253824|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17192876|NCT00512070|f||||f
17192877|NCT02506959|t||||
17192878|NCT03610490|t||||
17192879|NCT03932682|f||OTHER|Any publication by Institution or Investigator shall not be made before the first multicenter publication of the entire study results. Seqirus must be notified of any intent to publish data collected from the study and prior approval from Seqirus must be obtained prior to submission for publication.|t
17192880|NCT04080531|t||||
17192881|NCT04806594|f||||f
17192882|NCT02543281|f||||f
17192883|NCT03143153|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192884|NCT02312557|t||||
17192885|NCT04237298|f||||f
17192886|NCT05448651|f||||t
17192887|NCT01415154|t||||
17192888|NCT02891096|f||||f
17192889|NCT05551195|f||LTE60||t
17192890|NCT05285618|t||||
17192891|NCT00170573|f||||f
17192892|NCT04251299|t||||
17149238|NCT00097786|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17149239|NCT02000531|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149240|NCT00556491|t||||
17149241|NCT01239472|f||||f
17149242|NCT01280617|f||||f
17192893|NCT04556656|f||OTHER|"PIs are not employed by the organization sponsoring the study.~There is an agreement between PIs and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~Data and results are owned by the sponsor. Results can be used by the institution for (a) internal noncommercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of the sponsor."|t
17192894|NCT05722704|t||||
17192895|NCT06069713|t||||f
17192896|NCT03498651|t||||
17192897|NCT05323084|t||||f
17192898|NCT04382404|f||||f
17192899|NCT05102409|f||||t
17192900|NCT02960893|f||LTE60||t
17192901|NCT04951492|t||||
17192902|NCT05687916|f||||t
17192903|NCT05134636|f||||f
17192904|NCT02682342|t||||
17149243|NCT05966090|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17149244|NCT05045469|f||||f
17149245|NCT02001051|f||||f
17149246|NCT04090879|f||||f
17192905|NCT02651428|f||GT60||t
17192906|NCT02380885|f||||f
17192907|NCT06064955|t||||
17192908|NCT03792555|f||OTHER|The only disclosure restriction on the PI is that PIs cannot publish until the multi-center publication is first published. If no multi-center publication is published within 18 months of the completion date, the PI may publish their results, provided that the Sponsor is given the opportunity to review the proposed publication in advance.|t
17192909|NCT04485039|f||OTHER|The agreement restricts the right of the PI to discuss or publish trial results.|t
17192910|NCT04005716|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192911|NCT02085421|t||||
17192912|NCT04021602|f||||f
17192913|NCT02783300|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17192914|NCT03535272|f||||f
17192915|NCT04302493|f||||f
17192916|NCT03892616|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17192917|NCT00378105|f||GT60||t
17192918|NCT05192200|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192919|NCT03907397|f||||f
17192920|NCT03562377|f||OTHER|LEO Pharma A/S seeks publication of all phase 3 clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17192921|NCT03001414|f||OTHER|The first publication or presentation or results is to be made by the study sponsor within 18 months of trial completion. For publications or results communications after that time, Principal Investigators must provide a copy of the proposed manuscript or presentation to the study sponsor for review at least 45 days prior to submission for consideration of publication, and the sponsor may request removal of confidential information which is protected as intellectual property.|t
17192922|NCT03272373|f||OTHER|Any proposed publication or presentation will be submitted to sponsor for review (not for approval or disapproval) at least thirty (30) days prior to submission for publication or presentation. If proposed publication or presentation contains patentable subject matter that needs protection, sponsor may request PI to delay the publication or presentation for an additional ninety (90) days to allow Sponsor to file a patent application.|t
17192923|NCT04663087|t||||
17192924|NCT03818711|t||||f
17192925|NCT03930342|f||||f
17192926|NCT03859869|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17192927|NCT03748342|t||||
17192928|NCT04572750|t||||
17192929|NCT03606642|t||||
17192930|NCT05021640|f||OTHER|SPONSOR agrees that the Principal Investigator shall have the right to publish or permit the publication of any information or material relating to or arising out of the work after prior submittal to SPONSOR provided that if SPONSOR shall so request, the investigator will delay publication for a maximum of ninety (90) days after submittal to SPONSOR to enable SPONSOR to protect its rights. SPONSOR will comment on such documents within thirty (30) days.|t
17192931|NCT04737772|f||||f
17192932|NCT05691309|t||||
17192933|NCT03973320|t||||
17192934|NCT03376321|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17192935|NCT02496780|t||||
17192936|NCT02992925|f||OTHER||t
17192937|NCT01804816|f||||f
17192938|NCT05680675|t||||
17192939|NCT03400059|f||||f
17149247|NCT00232479|f||LTE60||t
17149248|NCT03460158|t||||
17149249|NCT02136238|f||||f
17149250|NCT00529217|t||||
17149251|NCT01845116|t||||f
17149252|NCT01098110|f||OTHER|The investigator agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts, and to review and comment on the data analysis and presentation.|t
17149253|NCT02147587|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149254|NCT02958319|f||||f
17192940|NCT04421378|f||OTHER||t
17192941|NCT04150718|t||||
17192942|NCT02592330|f||||f
17192943|NCT03090152|t||||
17192944|NCT03958955|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17192945|NCT04673929|f||||f
17192946|NCT04638829|f||OTHER|PIs are not allowed to publish clinical trial data on their own after trial completion.|t
17192947|NCT02927769|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149255|NCT01546519|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17149256|NCT03068949|f||||f
17192948|NCT02807636|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192949|NCT04088630|t||||
17192950|NCT03315754|f||||f
17192951|NCT04024813|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17192952|NCT05034952|f||||t
17192953|NCT02111798|t||||
17192954|NCT05493787|f||||f
17149257|NCT01519947|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17192955|NCT04783935|f||||t
17192956|NCT01600222|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192957|NCT02437318|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17192958|NCT05275842|f||||f
17192959|NCT00920621|f||||f
17192960|NCT04245501|f||||f
17149258|NCT01028911|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149259|NCT01303068|f||||f
17149260|NCT01992016|f||||f
17149261|NCT02274948|f||||f
17149262|NCT00707434|t||||
17149263|NCT01077817|f||||f
17149264|NCT00530348|f||OTHER|PI can publish after sponsor published, after a defined period of time after study completion, and/or with written sponsor approval. Generally PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information be removed, and can further defer publication upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17149265|NCT04364763|f||GT60||t
17149266|NCT01386125|f||OTHER|The Investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.|t
17149267|NCT00448227|f||OTHER|There is typically a disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.|t
17149268|NCT02907073|t||||
17149269|NCT00676494|f||OTHER|Investigators will have the right to publish results of the Study, provided that Investigators submit copies of any proposed publication to Sponsor for review at least 30 days and up to 60 days in advance of publication. Sponsor may extend such review period for another 90 days to file patent applications or protect its Related Rights.|t
17149270|NCT00732160|f||||f
17149271|NCT01201486|t||||
17149272|NCT00218335|f||||f
17149273|NCT00680524|t||||
17149274|NCT03604549|f||||f
17149275|NCT01160445|f||||f
17192961|NCT00961571|f||LTE60||t
17149276|NCT03904550|f||||f
17149277|NCT01839838|t||||
17192962|NCT03070184|f||||f
17192963|NCT05327101|f||||f
17192964|NCT04638309|f||LTE60||t
17192965|NCT05337748|f||||f
17192966|NCT05097430|f||||f
17192967|NCT04321031|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149278|NCT00981227|f||OTHER||t
17149279|NCT00985231|f||OTHER|Study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.|t
17149280|NCT01463982|f||OTHER|The investigator will complete the report on this study through discussion with Hanmi Pharmaceutical Co., Ltd. after the study is completed. If the report is to be published, prior agreement in writing should be made between the two parties.|t
17149281|NCT04220775|f||||f
17149282|NCT00436917|t||||f
17149283|NCT00931463|f||OTHER|"There is a Clinical Trial Agreement signed with each PI detailing the publication policy and disclosure of study's information, in summary:~* The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor, except for the purposes of internal training~* Publications or presentations of results from the Study will follow the agreement's publication/presentation guidelines"|t
17149284|NCT02438540|f||||f
17149285|NCT02913131|t||||
17150739|NCT05472662|f||OTHER|Investigators should inform Chiesi Farmaceutici S.p.A. before using the results of the study for publication or presentation, and agree to provide the Sponsor with a copy of the proposed presentation.|t
17149286|NCT01083680|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149287|NCT05766787|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149288|NCT01435928|f||OTHER|In addition to the \<60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.|t
17149289|NCT03922139|t||||
17149290|NCT00442546|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149291|NCT03182751|t||||
17149292|NCT01619579|f||GT60||t
17149293|NCT02124902|t||||
17149294|NCT02938442|t||||
17149295|NCT02928536|t||||
17149296|NCT04815850|t||||
17149297|NCT04100096|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17149298|NCT01118026|f||GT60||t
17149299|NCT02137382|f||||f
17149300|NCT00831233|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17149301|NCT02211014|f||OTHER|"Site and PI can publish/publicly present the results of the study only with prior written consent of Sponsor or otherwise after expiry of 12 months following completion of the study.~Site and PI agree to provide 30 days written notice to Sponsor prior to submission for publication or presentation."|t
17149302|NCT01915940|f||OTHER|"No presentation or publication of Institution's data relating to the Trial may occur until after the Trial has been completed at all sites. If Investigator desires to present or publish, investigator must submit any and all manuscripts, posters, abstracts, or other intended publications (hereinafter collectively referred to as manuscripts) to Sponsor at least sixty (60) days prior to the actual submission of such manuscript(s) for publication."|t
17149303|NCT02960438|f||||f
17149304|NCT02265341|t||||
17149305|NCT01647711|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149306|NCT02322788|f||GT60||t
17149307|NCT01344616|f||||f
17149308|NCT02760264|f||||t
17149309|NCT05918822|f||||t
17149310|NCT01796964|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149311|NCT04025684|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149312|NCT01844531|t||||f
17149313|NCT02744755|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149314|NCT01163084|f||LTE60||t
17149315|NCT01470196|f||||f
17149316|NCT02916693|f||||f
17149317|NCT02667821|f||||f
17149318|NCT00337428|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149319|NCT01999894|f||OTHER|"All data generated in this study are the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc."|t
17149320|NCT05181800|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17149321|NCT01740791|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149322|NCT03170869|f||||f
17149323|NCT04936594|t||||
17149324|NCT01966809|f||||f
17149325|NCT00220727|f||OTHER|The investigator will be free to disclose at scientific meetings and to publish in the scientific literature data resulting from these trials. A copy of any manuscript must be sent to sponsor for review at least 1 month prior to submission for publication.|t
17149326|NCT02020967|f||||t
17149327|NCT03507686|f||OTHER|Our agreement is subject to confidentiality but generally, the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor's Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of the Sponsor's intellectual property contained in the proposed publication.|t
17149328|NCT02508116|t||||
17149329|NCT02630316|f||OTHER|Institution and/or Principal Investigator agree not to publish or publicly present any results of the Study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation.|t
17149330|NCT00983528|t||||
17149331|NCT00575380|f||OTHER|PI cannot publish or discuss trial results until written communication is received from Inspire|t
17149332|NCT00559364|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication but will prohibit disclosure of Sponsor's confidential information within any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17149333|NCT00136760|t||||
17149334|NCT02663882|t||||f
17149335|NCT05070390|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding thist rial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17149336|NCT00703976|t||||
17149337|NCT00760526|f||||f
17149338|NCT00869440|f||OTHER|At least 60 days prior to submission for publication, presentation or use, sponsor shall review and comment any proposed oral or written publication, which period may be extended for an additional 30 days. To seek patent protection, sponsor shall have the right to delay the proposed publication for an additional 60 days.|t
17149339|NCT00843830|t||||
17149340|NCT03558139|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149341|NCT02808819|f||OTHER|≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.|t
17149342|NCT03573817|f||OTHER|The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149343|NCT02013531|f||||f
17149344|NCT03546647|f||||f
17149345|NCT02400476|f||||f
17149346|NCT03396874|t||||
17149347|NCT00588731|f||||f
17149348|NCT00613730|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial resul|t
17149349|NCT00133679|t||||
17149350|NCT02056652|f||||f
17149351|NCT02452528|f||||f
17149352|NCT02093923|f||OTHER|Dyax agreements vary, but Dyax will not prohibit any investigator from publishing. Dyax reviews publications prior to public release and can request deferral by up to 60 days beyond the proposed publication date if necessary to preserve its intellectual property. Dyax can request changes to publications to remove non-study-related confidential information. Dyax can also request deferral of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149353|NCT03253094|f||||f
17149354|NCT00248170|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17149355|NCT01557582|f||LTE60||t
17150740|NCT04620135|f||||f
17150741|NCT04988152|f||||t
17192968|NCT05536440|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17192969|NCT06283173|f||||f
17192970|NCT04882449|f||OTHER||t
17192971|NCT04784559|f||||f
17192972|NCT03138512|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17192973|NCT03332017|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17192974|NCT01261312|f||||f
17192975|NCT04682106|t||||f
17192976|NCT05165108|t||||
17192977|NCT03436745|f||||f
17192978|NCT03661840|t||||
17192979|NCT01969539|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17192980|NCT03406871|f||||f
17192981|NCT04588298|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17192982|NCT05473234|t||||
17192983|NCT05593510|t||||
17192984|NCT01747863|f||||f
17192985|NCT02120456|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17192986|NCT05520190|t||||
17192987|NCT02226276|t||||
17192988|NCT03476187|f||||f
17192989|NCT02754882|f||||t
17192990|NCT04060355|t||||
17192991|NCT04648033|t||||
17192992|NCT03270956|f||OTHER|"60-day review period can be extended an additional 30 days if Sponsor determines publication describes potentially patentable inventions. Publication not to be delayed more than 90 days after receipt of the proposed publication.~Sponsor may not require changes to the communication except to request removal of Sponsor Confidential Information.~No publication or disclosure shall be made by PI until the earlier of publication coordinated by Sponsor or 18 months after Study completion"|t
17192993|NCT04956861|f||||f
17192994|NCT05215314|t||||
17192995|NCT04294225|t||||
17192996|NCT02790502|f||||f
17192997|NCT01580488|f||OTHER|The sponsor is entitled to review and comment on publications prior to submission or presentation. Upon request of the sponsor, the investigator shall delay publication or presentation to allow for protection of the sponsors inventions and other intellectual property.|t
17192998|NCT03738228|f||LTE60||t
17192999|NCT05751382|f||||f
17193000|NCT05470517|f||||f
17193001|NCT05671029|f||||t
17193002|NCT03338790|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193003|NCT04106583|f||OTHER||t
17193004|NCT03366649|t||||
17193005|NCT03673111|t||||
17193006|NCT03846505|f||||f
17193007|NCT05481216|f||||t
17193008|NCT01744782|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17193009|NCT04649359|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193010|NCT02243709|f||||f
17149356|NCT02843659|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149357|NCT02521181|f||||f
17149358|NCT02413294|t||||
17193011|NCT05845398|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17193012|NCT03443323|f||||f
17193013|NCT04610892|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the sponsor for review before submission.|t
17193014|NCT03683719|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. After such publication is made public, or if no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17193015|NCT00277394|f||LTE60||t
17193016|NCT04059770|f||||f
17193017|NCT04896476|f||LTE60||t
17193018|NCT03135548|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149359|NCT02408445|t||||
17149360|NCT01631682|t||||
17149361|NCT01253317|t||||
17149362|NCT00503113|f||||f
17149363|NCT01598545|t||||
17149364|NCT01195116|f||||f
17149365|NCT06442410|f||GT60||t
17149366|NCT03907241|f||||f
17193019|NCT03924986|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17193020|NCT04922502|f||||f
17193021|NCT03445988|f||||f
17149367|NCT02717078|t||||
17193022|NCT03988608|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17193023|NCT05424549|f||||t
17193024|NCT05441579|t||||
17193025|NCT02689284|f||LTE60||t
17193026|NCT05592418|f||LTE60||t
17193027|NCT03662698|t||||
17193028|NCT05569252|f||||f
17193029|NCT03665597|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193030|NCT05260684|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193031|NCT04739956|f||||f
17193032|NCT02386722|t||||
17193033|NCT03519581|f||||f
17193034|NCT03396926|t||||
17193035|NCT03110315|f||||f
17193036|NCT01781468|f||||t
17193037|NCT00450658|f||OTHER|PI reserves the right to publish or otherwise make public the Study results provided that such communication occurs only after (i) the results of the multicenter Study in its entirety have been publicly disclosed by, or with consent of the sponsor or (ii) 18 months after conclusion of the Study at all sites, whichever comes first. Following this, PI can publish, present or use any non-confidential study results following Sponsor review. PI will not make public raw data or Case Reports.|t
17193038|NCT01083758|f||OTHER|LEO acknowledges the investigators' right to publish the results of the trial, irrespective of outcome. Pubs/presentations by investigator(s) shall not be made before the results of a joint publication is public. LEO retains the right to have any publication submitted to LEO for review at least 30 days prior to this paper being submitted for publication/presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193039|NCT02386371|f||||t
17193040|NCT04727554|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17193041|NCT05763823|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17193042|NCT05392192|f||||t
17193043|NCT05229146|f||||f
17193044|NCT05371652|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193045|NCT03778112|f||||f
17193046|NCT03555448|f||||f
17149368|NCT02012452|t||||
17149369|NCT02688387|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17193047|NCT05134233|t||||
17193048|NCT01573442|t||||
17193049|NCT03649659|f||||f
17193050|NCT02724631|t||||
17193051|NCT04763265|f||||t
17193052|NCT04510974|f||||f
17193053|NCT04418466|f||||t
17193054|NCT01963793|f||OTHER|Prior to submitting or presenting a manuscript relating to the clinical trial to a publisher, reviewer or other outside person, the Investigator shall submit to LEO, in writing, a copy of the intended publication, describing the detail of any Research Results that the Investigator intends to Publish, at least 60 days before the date of the proposed submission for publication.|t
17193055|NCT01552473|t||||
17149370|NCT03388502|t||||
17193056|NCT04836195|f||||f
17193057|NCT05609760|t||||
17193058|NCT04049643|f||||f
17193059|NCT05089734|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149371|NCT04403399|t||||
17149372|NCT01606228|f||||f
17149373|NCT00546910|f||GT60||t
17149374|NCT01115855|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149375|NCT03815240|t||||
17149376|NCT03122587|t||||
17149377|NCT03170388|f||OTHER|Please contact sponsor for details.|t
17193060|NCT05302596|t||||
17193061|NCT04353661|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17193062|NCT00667251|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17193063|NCT04927637|f||||f
17193064|NCT01140880|f||||f
17193065|NCT01212029|t||||
17193066|NCT03131648|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17193067|NCT02671903|t||||
17193068|NCT04258709|f||||f
17193069|NCT05633953|f||||t
17193070|NCT03047928|t||||
17193071|NCT02729311|t||||f
17193072|NCT05324124|t||||
17193073|NCT04034251|f||||f
17193074|NCT02287610|f||OTHER|Physician agrees to obtain written consent of Horizon prior to publishing or presenting any results of the SUNRAY Observational Study.|t
17193075|NCT04419389|f||LTE60||t
17193076|NCT05273749|f||OTHER|An industry standard NDA is in place with all study investigators.|t
17193077|NCT04969419|f||||f
17193078|NCT05247489|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17193079|NCT03771898|f||||t
17193080|NCT04541706|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193081|NCT05563246|f||GT60||t
17193082|NCT02167867|f||||f
17193083|NCT01416831|t||||
17193084|NCT04179500|f||OTHER|"Institution and Principal Investigator shall not publish, present or use the Study Data for its own instruction, research or publication without the prior express written consent of Sponsor. Because the Study is funded, in whole or in part, by the Bill and Melinda Gates Foundation (the Foundation), all peer-reviewed published research relating to the Study must comply with the Foundation's Open Access Policy."|t
17193085|NCT03420833|t||||
17193086|NCT03662607|f||||f
17193087|NCT04812535|f||||f
17193088|NCT03336333|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17193089|NCT03992274|t||||
17193090|NCT04621266|f||||f
17193091|NCT03623321|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17193092|NCT04511286|t||||
17193093|NCT01785719|t||||
17193094|NCT03151616|f||||f
17193095|NCT05391893|t||||
17193096|NCT04750473|t||||
17193097|NCT04294290|f||||f
17193098|NCT05337943|f||||f
17193099|NCT04406857|f||LTE60||t
17193100|NCT03699709|f||||f
17193101|NCT04562649|f||||f
17193103|NCT05368103|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149378|NCT02285634|t||||
17149379|NCT03173170|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17149380|NCT01009515|t||||
17149381|NCT01321437|t||||
17149382|NCT01118845|f||||f
17193104|NCT04864691|t||||
17193105|NCT06020534|t||||
17193106|NCT04650087|f||||f
17193108|NCT03039023|t||||
17193109|NCT04130438|t||||
17193110|NCT05268393|f||||f
17193111|NCT05009004|t||||
17193112|NCT05256706|t||||
17193113|NCT04410042|t||||
17193114|NCT03898986|f||||f
17193115|NCT03850678|f||||f
17193116|NCT03720795|f||||f
17193117|NCT03891667|f||||f
17193118|NCT03302494|f||OTHER|Results of this clinical study may be submitted for publication without regard for whether the trial results are positive or negative. Sponsor will be responsible for oversight of the publication process and will have oversight of publications of results of the trial, the Physician Advisory Committee may advise.|t
17193119|NCT00534469|t||||
17193120|NCT04622943|f||||f
17193121|NCT05717907|t||||
17193122|NCT05076708|f||||f
17193123|NCT04115540|t||||
17193124|NCT05590312|t||||
17193125|NCT03269136|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193126|NCT04456517|t||||
17193127|NCT04055090|f||OTHER|Investigator Agreement|t
17193128|NCT04721912|f||||f
17193129|NCT05282173|f||||f
17193130|NCT05093829|f||||f
17193131|NCT05194514|t||||
17193132|NCT02727699|f||OTHER||t
17193133|NCT03509116|t||||
17193134|NCT02995434|f||||f
17193135|NCT03779204|t||||
17193136|NCT05228730|t||||
17193137|NCT03818659|t||||
17193138|NCT04363515|f||||f
17193139|NCT04318548|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193140|NCT04927065|f||||t
17193141|NCT03378570|t||||
17193142|NCT04241068|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17193143|NCT04492007|f||OTHER|Investigators' joint publication is required.|t
17193144|NCT04347161|f||||f
17193145|NCT04169373|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17193146|NCT01333969|t||||
17149383|NCT02578745|t||||
17149384|NCT00330460|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149385|NCT01857973|f||GT60||t
17149386|NCT00908882|t||||
17149387|NCT04458467|f||||f
17149388|NCT00574067|f||||f
17149389|NCT01731886|f||||f
17149390|NCT00129116|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149391|NCT00271024|f||||f
17149392|NCT00388037|f||LTE60||t
17193147|NCT01999075|f||||f
17193148|NCT05081583|t||||
17193149|NCT01413100|t||||
17149393|NCT01290237|f||||f
17193150|NCT05369403|f||GT60||t
17193151|NCT04750525|t||||
17193152|NCT05948670|t||||
17193153|NCT02907099|t||||
17193154|NCT00390793|f||||f
17193155|NCT03675282|t||||
17149394|NCT00602537|f||||f
17149395|NCT02539368|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149396|NCT00931996|f||||f
17149397|NCT02752802|f||||f
17193156|NCT05817708|f||LTE60||t
17193157|NCT03056040|f||||t
17193158|NCT04977947|f||||f
17193159|NCT04029688|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17193160|NCT05875142|t||||
17193161|NCT05784662|f||||f
17193162|NCT04274764|t||||
17193163|NCT02677298|f||||t
17193164|NCT03611621|f||||t
17193165|NCT03210272|t||||
17193166|NCT03499821|f||OTHER|All data generated from the study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee are completed. The results of the study may be published or presented by the Investigator(s) after review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded to the Sponsor or designee for comment.|t
17193167|NCT03920111|t||||
17193168|NCT04764448|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17193169|NCT01997840|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193170|NCT04487145|f||||f
17193171|NCT01494662|f||||f
17193172|NCT05311384|t||||
17193173|NCT04322643|t||||
17193174|NCT05329493|t||||
17193175|NCT05386758|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193176|NCT04145466|f||||f
17149398|NCT00444821|f||||f
17149399|NCT00612677|t||||f
17149400|NCT05197829|t||||
17149401|NCT00268892|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.|t
17149402|NCT05022563|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193177|NCT05896267|f||GT60||t
17193178|NCT05710107|t||||
17193179|NCT04717492|f||||f
17193180|NCT05071807|f||||f
17193181|NCT04918823|f||||f
17193182|NCT04072380|f||GT60||t
17193183|NCT05551637|t||||
17193184|NCT05582746|f||||f
17193185|NCT05351554|f||||t
17193186|NCT03774082|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17193187|NCT04889755|t||||f
17193188|NCT05521308|t||||
17193189|NCT03792256|f||OTHER|Must obtain prior sponsor approval|t
17193190|NCT04760678|f||||t
17193191|NCT01458782|t||||
17193192|NCT01748448|f||||f
17193193|NCT05065658|t||||
17193194|NCT00583349|t||||f
17193195|NCT01926496|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17193196|NCT03427580|t||||f
17193197|NCT00845481|f||OTHER|LEO retains the right to publish the results of this clinical trial|t
17193198|NCT03232138|t||||f
17193199|NCT04142788|f||||f
17193200|NCT05516147|t||||
17193201|NCT03992339|f||||f
17193202|NCT03338933|t||||f
17149403|NCT01640184|f||||f
17149404|NCT02927834|f||||f
17149405|NCT00479388|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149406|NCT00777855|t||||
17150765|NCT06077487|t||||
17150766|NCT00759902|f||||f
17150767|NCT02579161|t||||
17150768|NCT00134043|f||LTE60||t
17150769|NCT02327117|f||||f
17193203|NCT05694286|t||||
17193204|NCT01728857|f||OTHER|Zeltiq requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Zeltiq requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Zeltiq needs to secure patent or proprietary protection.|t
17193205|NCT03853746|t||||
17193206|NCT00999804|f||||f
17193207|NCT04640298|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17193208|NCT05523154|t||||
17193209|NCT05079789|t||||
17193210|NCT04166773|f||GT60||t
17193211|NCT05908344|f||||f
17193212|NCT04259632|t||||
17193213|NCT05305235|t||||
17193214|NCT05546749|f||||f
17193215|NCT05326776|f||||f
17193216|NCT04952909|f||GT60||t
17193217|NCT03575897|f||||f
17193218|NCT04267172|t||||
17193219|NCT03150810|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17193220|NCT05116787|f||||t
17193221|NCT03983018|t||||
17193222|NCT03557697|t||||
17193223|NCT03611491|f||||t
17193224|NCT05796583|f||||f
17193225|NCT05026320|f||OTHER|"Principal Investigator (PI) agrees to submit any proposed publication, abstract or presentation related to the Study (Publication) to Sponsor at least 30 days prior to submission. Sponsor shall advise PI or Designee in writing of any information that is Confidential Information (CI) or Sponsor's Intellectual Property (SIP). Sponsor shall have the right to require PI or Designee, to remove CI and/or delay the Publication for an additional 60 days to enable Sponsor to seek protection of SIP."|t
17193226|NCT05478499|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193227|NCT02962895|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17193228|NCT05894577|t||||
17193229|NCT05481320|f||||f
17193230|NCT05093478|t||||
17193231|NCT04509674|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193232|NCT04461405|f||||f
17193233|NCT05184894|f||||f
17193234|NCT03476460|f||||f
17193235|NCT02222155|f||||t
17193236|NCT06190340|f||||f
17193237|NCT01606215|t||||
17193238|NCT04592549|f||||t
17193239|NCT05184192|t||||
17193240|NCT05565092|f||||t
17193241|NCT05349500|t||||f
17193242|NCT03703492|t||||
17193243|NCT04550468|f||||f
17193244|NCT03640312|f||||f
17193245|NCT04948697|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17149407|NCT01876368|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17193246|NCT05123118|f||||f
17193247|NCT06132867|f||OTHER||t
17193248|NCT04323137|t||||f
17193249|NCT03463824|t||||
17193250|NCT04177823|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193251|NCT04229992|f||||f
17193252|NCT05178316|f||||f
17193253|NCT04873401|f||||f
17193254|NCT03457142|t||||
17193255|NCT03770273|t||||
17193256|NCT00418886|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17149408|NCT01955044|f||||f
17149409|NCT02260258|f||||f
17149410|NCT01644149|f||LTE60||t
17149411|NCT01411488|f||||f
17149412|NCT01610063|t||||
17149413|NCT04405739|f||OTHER|PI is requested to obtain written consent from the Sponsor before anything relating to the study can be published.|t
17149414|NCT01436643|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149415|NCT03718117|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149416|NCT03069417|f||||f
17149417|NCT01867606|t||||
17149418|NCT01246713|f||||f
17149419|NCT02568007|t||||
17193257|NCT04060654|f||OTHER|The PI will not disseminate, present or publish any of the study data without the prior written approval from Indivior to do so.|t
17193258|NCT03707951|t||||
17193259|NCT04887129|t||||
17193260|NCT02203552|t||||
17193261|NCT04606069|t||||
17193262|NCT05570175|f||||f
17193263|NCT02921230|f||OTHER||t
17193264|NCT03436290|f||||f
17193265|NCT03064217|t||||
17193266|NCT01084876|f||||t
17193267|NCT04971395|f||||f
17193268|NCT02924272|f||||t
17193269|NCT06213194|f||||f
17193270|NCT02100813|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193271|NCT03729999|t||||
17193272|NCT04359108|f||||f
17193273|NCT06393088|f||||f
17193274|NCT02515773|f||||f
17193275|NCT04176965|f||||f
17193276|NCT03903146|t||||
17193277|NCT02919683|f||||f
17193278|NCT03652688|t||||f
17193279|NCT03468218|t||||
17193280|NCT01814501|t||||
17193281|NCT03829410|f||||t
17193282|NCT03033576|f||LTE60||t
17193283|NCT05179837|t||||
17193284|NCT03719443|f||||f
17193285|NCT05051124|t||||f
17193286|NCT04782973|f||||f
17193287|NCT04924660|f||||f
17193288|NCT06205407|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193289|NCT06491433|f||||f
17193290|NCT04572399|f||||f
17193291|NCT04749615|t||||
17193292|NCT04516967|f||OTHER|PIs are not allowed to publish clinical trial data on their own after trial completion.|t
17193293|NCT04676022|f||OTHER|A contractual agreement is in place between the PI and the Sponsor that restricts the rights to discuss or publish trial results without prior review by the sponsor.|t
17193294|NCT03736720|t||||
17193295|NCT02235909|f||GT60||t
17193296|NCT03547869|f||||f
17193297|NCT03194217|f||LTE60||t
17193298|NCT03197662|t||||
17193299|NCT06398886|t||||
17193300|NCT05891353|f||||f
17193301|NCT01463423|t||||
17193302|NCT04541147|t||||
17193303|NCT04495894|t||||
17193304|NCT05682937|f||||f
17193305|NCT05579899|f||OTHER|Upon written approval by Evommune, the PI may publicly disclose site results for only (1) non-commercial and (2) internal scientific research and educational purposes|t
17193306|NCT03364647|t||||
17193307|NCT04660201|f||||t
17193308|NCT04064164|t||||
17149420|NCT00402025|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149421|NCT03623035|t||||
17149422|NCT02248662|f||||f
17149423|NCT01114581|f||LTE60||t
17149424|NCT02105701|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.|t
17193309|NCT05373862|f||OTHER|Publications and/or presentation of clinical investigation results will be coordinated and governed between Biosense Webster, Inc., the clinical investigation author(s) and if applicable local law. Authorship will be determined prior to development of any manuscript.|t
17193310|NCT01000961|f||OTHER|Investigators may publish or disclose study data, with the restriction that sponsor may embargo such communications for a period up to 60 days from the time submitted to sponsor. As a multi-center study, first publication of results will take place in conjunction with all investigators. If such a multi-center publication is not forthcoming within 18 months of study completion, individual investigators may publish as restricted according to limitations expressed above (60 day embargo).|t
17149425|NCT03234608|f||||f
17149426|NCT02148445|f||||f
17149427|NCT03450629|f||OTHER||t
17149428|NCT04230876|t||||
17149429|NCT02774850|f||||f
17149430|NCT00739973|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17149431|NCT01662362|f||GT60||t
17193311|NCT05538754|f||OTHER|All data generated from the study will be regarded as confidential, until appropriate analysis and review by the Sponsor or designee is completed. The results of the study may be published or presented by the Investigator(s) after review by, and in consultation and agreements with the Sponsor, and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded to the Sponsor or designee for comment.|t
17193312|NCT05480124|t||||
17193313|NCT03885518|f||||f
17193314|NCT04709783|t||||
17193315|NCT05030233|t||LTE60||t
17193316|NCT03365882|f||LTE60||t
17193317|NCT05044793|f||OTHER|The institution or PI will submit a copy of any proposed publication/disclosure to Sponsor, at least sixty (60) days prior to submission. Sponsor may request changes or other measures to ensure the information is fairly stated. At Sponsor's request the Institution and/or the PI shall not publish/disclose information related to the Study. If Sponsor indicates that such publication or disclosure contains Confidential Information, the Institution and PI agree to remove such Confidential Information|t
17193318|NCT05177848|f||||f
17193319|NCT03771417|f||||t
17193320|NCT05087693|f||||f
17193321|NCT04342494|t||||
17193322|NCT05746494|t||||f
17193323|NCT01214616|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17193324|NCT03721952|f||||f
17193325|NCT05292365|f||||f
17193326|NCT04633122|f||||t
17193327|NCT04185298|t||||
17193328|NCT01798498|f||||t
17193329|NCT03896789|f||||f
17193330|NCT04471038|f||||t
17193331|NCT00227344|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17193332|NCT01987895|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17193333|NCT05364671|f||||t
17149432|NCT01181531|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17149433|NCT00987831|f||LTE60||t
17149434|NCT00576303|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149435|NCT02792218|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149436|NCT00810602|t||||
17149437|NCT01745952|f||||f
17149438|NCT00824369|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149439|NCT00392782|t||||
17149440|NCT00858013|f||||f
17149441|NCT03512002|f||||f
17149442|NCT02280226|f||||f
17149443|NCT00749411|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149444|NCT00096122|f||LTE60||t
17149445|NCT03183141|f||||t
17149446|NCT04052698|t||||
17149447|NCT02756637|t||||
17149448|NCT01507090|t||||
17149449|NCT04947150|f||||f
17149450|NCT02449473|f||LTE60||t
17149451|NCT04034355|f||||t
17149452|NCT02190279|f||||f
17149453|NCT01467479|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17149454|NCT03326986|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17149455|NCT00455962|f||||f
17149456|NCT01197417|f||||f
17149457|NCT01652729|f||LTE60||t
17149458|NCT01311557|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17149459|NCT02418455|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17193334|NCT02359890|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17193335|NCT05256017|f||||t
17193336|NCT05368402|f||||f
17193337|NCT05780437|f||||f
17193338|NCT04015167|f||||f
17193339|NCT03536754|f||OTHER||t
17193340|NCT03452579|t||||
17193341|NCT04891224|f||||f
17193342|NCT05490459|f||OTHER|The results of the clinical trial or their parts shall not be published by Provider, Investigator, or other persons participating in the clinical trial shall not be disclosed to the general public without prior written consent of Sponsor. The Sponsor shall not refuses to grant consent without a reasonable cause.|t
17193343|NCT03382652|f||||f
17193344|NCT04858321|f||||f
17193345|NCT04810650|f||||f
17193346|NCT05794243|t||||
17193347|NCT05733975|t||||
17193348|NCT05057247|f||||f
17193349|NCT01597388|f||||f
17193350|NCT05328362|f||||f
17193351|NCT05455086|f||||f
17193352|NCT02761057|f||LTE60||t
17193353|NCT04788511|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17193354|NCT03637660|f||LTE60||t
17193355|NCT04652700|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17193356|NCT01898754|f||||f
17193357|NCT06037369|t||||
17193358|NCT04209465|f||||f
17193359|NCT05492318|f||||f
17193360|NCT05008835|f||OTHER|Investigator may publish the study results, relative to their own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the Sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17193361|NCT04171999|t||||
17193362|NCT03993509|t||||
17193363|NCT04505904|t||||
17193364|NCT03629990|f||||f
17193365|NCT04277442|f||LTE60||t
17193366|NCT03544281|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193367|NCT05235750|t||||
17193368|NCT04876118|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17193369|NCT03092518|f||||f
17193370|NCT02301910|f||OTHER||t
17193371|NCT02547987|t||||f
17193372|NCT04282148|f||LTE60||t
17193373|NCT04925986|t||||
17193374|NCT06181760|f||||f
17193375|NCT04770532|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17193376|NCT04938492|t||||
17193377|NCT04025554|t||||
17193378|NCT03854214|t||||
17193379|NCT04338061|f||||t
17193380|NCT03752203|t||||
17193381|NCT03631784|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193382|NCT02876588|t||||f
17193383|NCT02251548|t||||
17193384|NCT04437615|f||||f
17193385|NCT02035787|f||||t
17193386|NCT06414213|f||||f
17193387|NCT01396278|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17193388|NCT02143726|t||||
17193389|NCT04515576|f||GT60||t
17193390|NCT05028634|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193391|NCT04728347|f||||f
17193392|NCT03953508|f||||f
17193393|NCT01106209|t||||
17193394|NCT02487056|t||||
17193395|NCT05308004|t||||
17193396|NCT03762915|t||||
17193397|NCT01160211|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149460|NCT02973321|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17149461|NCT02407171|t||||
17193398|NCT02577835|f||||f
17193399|NCT05409183|f||||f
17193400|NCT02274662|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17193401|NCT04806451|f||||t
17193402|NCT05835336|f||||f
17193403|NCT02936752|f||LTE60||t
17193404|NCT03659734|f||||f
17193405|NCT04489771|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193406|NCT03241459|f||LTE60||t
17193407|NCT03793972|t||||
17193408|NCT02979522|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17193409|NCT05916664|t||||
17193410|NCT03059030|t||||
17193411|NCT04059484|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17149462|NCT00865514|f||||f
17193412|NCT02949362|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17193413|NCT06165146|f||GT60||t
17149463|NCT03920280|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149464|NCT01557920|t||||
17149465|NCT02423317|f||LTE60||t
17149466|NCT00089076|f||LTE60||t
17149467|NCT03420768|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149468|NCT00983476|t||||f
17149469|NCT02969876|f||||f
17149470|NCT01175473|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17149471|NCT01265667|f||||f
17149472|NCT01997723|f||||f
17149473|NCT01857206|f||GT60||t
17149474|NCT00807209|f||||f
17149475|NCT00003531|f||||f
17149476|NCT02487082|f||||f
17149477|NCT00251316|t||||
17149478|NCT00346164|f||OTHER|Must obtain prior Sponsor approval.|t
17149479|NCT02039063|f||||f
17149480|NCT02621463|f||||f
17149481|NCT00467831|t||||
17149482|NCT01198873|f||OTHER|"If no publication has occurred within 12 months after trial completion, the Investigator can present or publish trial results. A copy is submitted to the Sponsor for review and comment at least 30 days in advance of any presentation or submission for publication.~The Sponsor can require to delay the communication for a period not exceeding 90 days to allow for filing a patent application or such other measures as Sponsor deems appropriate to establish and preserve its proprietary rights."|t
17149483|NCT03139240|t||||
17149484|NCT03417830|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149485|NCT00823199|t||||f
17149486|NCT00171340|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17149487|NCT01998243|f||||f
17149488|NCT01056640|t||||
17149489|NCT04569786|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17149490|NCT00810888|f||||f
17149491|NCT01684878|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149492|NCT02692482|f||||f
17149493|NCT01435031|f||GT60||t
17149494|NCT02492841|f||||f
17149495|NCT03746002|t||||
17149496|NCT04925713|f||||t
17149497|NCT01841216|f||||f
17149498|NCT03851588|f||||f
17149499|NCT02563769|f||OTHER|The results in this trial are considered proprietary and still under evaluation.|t
17149500|NCT00611325|t||||f
17149501|NCT00690482|f||LTE60||t
17149502|NCT02820740|f||||f
17149503|NCT02919826|t||||
17149504|NCT03770078|t||||
17149505|NCT00925301|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17149506|NCT01117987|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17149507|NCT04117945|f||||f
17149508|NCT02767934|t||||f
17149509|NCT01917968|f||OTHER|Before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.|t
17149510|NCT00834236|t||||
17149511|NCT03391115|f||||f
17149512|NCT00862537|t||||
17149513|NCT04232540|t||||f
17149514|NCT03438006|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17149515|NCT03200535|t||||f
17149516|NCT01447225|f||LTE60||t
17149517|NCT01451996|t||||
17149518|NCT03078478|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17149519|NCT04350008|f||GT60||t
17193414|NCT03199469|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17193415|NCT05332366|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17193416|NCT05453773|f||||f
17193417|NCT02023866|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17193418|NCT02485938|f||||f
17193419|NCT03307343|f||||f
17193420|NCT04683744|f||||f
17193421|NCT02432404|f||||f
17193422|NCT05136417|f||||f
17193423|NCT03447470|f||||f
17193424|NCT05851573|f||||f
17193425|NCT04624633|t||||
17193426|NCT04316871|f||||f
17193427|NCT05087992|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193428|NCT04091750|f||||f
17193429|NCT01842542|f||||f
17193430|NCT04473222|f||||f
17193431|NCT04636528|f||||f
17193432|NCT06321809|t||||
17193433|NCT03123848|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17193434|NCT01369355|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17193435|NCT02436096|f||OTHER|An industry standard NDA is in place with all investigators.|t
17193436|NCT03131154|f||||t
17193437|NCT06424236|f||OTHER|PI's may publish data and study results individually after the earlier of: 1) multi-center Publication is published; 2) no multi-center publication is submitted within 18 months after conclusion, abandonment, or termination of the Protocol at all sites; or 3) sponsor confirms in writing there will be no multi-center Publication. PI must submit results communications to the sponsor at least 75 days prior to submission or presentation. Sponsor can require changes to the communication.|t
17193438|NCT02817776|f||||f
17193439|NCT01824394|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for 60 to 180 days from the time submitted to the sponsor for review. For multicenter studies, the first results communications should be a joint multicenter publication. PIs may communicate results from their institution as indicated above if a multicenter publication is not submitted by the Sponsor or representatives within 12 months of the study's conclusion.|t
17193440|NCT05603143|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17193441|NCT05783102|f||||f
17149520|NCT02339090|f||OTHER|"US Sites:~Institution shall cause Principal Investigator to submit a complete copy of the proposed publication to Sponsor at least 60 days prior to presentation or submission to any third party.~Non-US sites:~The Investigator and the Institution agree that any proposed publication relating to the research and/or Study conducted under this Agreement will be submitted to Sponsor for review at least 90 days prior to submission for publication.~Additional agreement conditions apply."|t
17149521|NCT01168687|t||||
17149522|NCT04243096|f||||t
17193442|NCT05647304|f||OTHER|If the investigators wish to publish data from this investigation (poster, abstract, article, etc.), they must first seek approval from REGEnLIFE.|t
17193443|NCT06238609|f||||f
17193444|NCT01363388|f||OTHER||t
17149523|NCT02737592|f||OTHER|Master service agreement and confidentiality agreement in place|t
17149524|NCT00101413|f||LTE60||t
17149525|NCT00955721|t||||
17193445|NCT02683447|t||||
17193446|NCT03448107|t||||
17193447|NCT03115476|f||OTHER|LEO Pharma acknowledges the investigator right to publish the entire results of the study, irrespective of outcome. LEO Pharma retains the right to have any publication submitted to LEO Pharma for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO Pharma.|t
17193448|NCT02489903|f||||f
17193449|NCT04980248|f||||t
17193450|NCT05257486|f||||f
17193451|NCT04542317|f||||f
17193452|NCT04700163|f||||f
17193453|NCT05590962|f||||f
17193454|NCT03976362|f||OTHER|If publication activity was not directed by the Sponsor, the investigator agreed to submit all manuscripts or abstracts to the Sponsor before submission. This allowed the Sponsor to protect proprietary information and to provide comments.|t
17193455|NCT00613106|f||OTHER|PI reserves the right to publish or otherwise make public the Study results provided that such communication occurs only after (i) the results of the multicenter Study in its entirety have been publicly disclosed by, or with consent of the sponsor or (ii) 18 months after conclusion of the Study at all sites, whichever comes first. Following this, PI can publish, present or use any non-confidential study results following Sponsor review. PI will not make public raw data or Case Reports.|t
17149526|NCT04974736|f||||f
17149527|NCT03581188|f||||f
17149528|NCT03064438|f||||f
17193456|NCT02396134|t||||
17193457|NCT01424150|t||||
17193458|NCT05126433|f||||f
17193459|NCT01986712|f||||f
17193460|NCT04158804|f||||f
17193461|NCT04710498|t||||
17193462|NCT05084508|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193463|NCT05296525|f||||f
17193464|NCT06264986|f||||f
17193465|NCT02918890|f||||f
17149529|NCT01937351|f||OTHER|Following the earliest of (a)publication of results, (b)receipt of notice stating that Study has been terminated or (c)18 months after completion or termination, Institution/Investigator (IN) shall have right to publish information \& data collected or produced, provided that drafts are provided to Sponsor (SP) at least 60 days prior to the first submission. SP shall comment within 45 days. IN shall delay publication/presentation to enable SP to secure patent or other proprietary protection.|t
17149530|NCT01961687|f||||t
17149531|NCT02284347|f||GT60||t
17149532|NCT03185182|f||||f
17149533|NCT01301482|t||||
17149534|NCT00480324|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149535|NCT02999984|f||||f
17149536|NCT01316419|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149537|NCT04039919|f||GT60||t
17149538|NCT00754013|f||||f
17149539|NCT02310789|f||||t
17149540|NCT00983918|t||||
17149541|NCT02948257|f||GT60||t
17149542|NCT00977548|t||||
17149543|NCT02070757|f||OTHER|Sponsor will review proposed publication within forty five (45) calendar days and reserves the right to defer such publication an additional forty five (45) calendar days to protect Sponsor's intellectual property as applicable. If a joint manuscript has not been submitted for publication within twelve (12) months of completion or termination of Trial at all participating sites, Principal Investigator is free to publish separately, subject to the other requirements of this Agreement.|t
17149544|NCT01546922|t||||
17149545|NCT03325972|t||||
17149546|NCT04086641|f||||f
17149547|NCT02551679|f||LTE60||t
17149548|NCT01613378|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17193466|NCT04065841|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17193467|NCT01420237|f||OTHER|Each study investigator has independent publication privileges for their own center's results after multi-center publications are submitted. Sponsor requires review of publications. Sponsor shall not edit or influence the publications except to ensure that confidential information is not disclosed, no off-label device use is promoted, and that data is accurately represented. Any publications must be submitted to Stryker for review at least 60 days prior to submission of publication.|t
17193468|NCT05417009|t||||
17149549|NCT00794417|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17149550|NCT00792623|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149551|NCT00521989|f||GT60||t
17149552|NCT02065713|f||||f
17149553|NCT03614494|t||||
17149554|NCT02694549|f||||t
17149555|NCT01534078|t||||
17193469|NCT01461655|f||OTHER|Prior to submitting or presenting a manuscript, the investigator shall provide to LEO Pharma a copy of all such manuscripts, and LEO Pharma shall have rights to review and comment. Upon the request of LEO Pharma the investigator shall remove any confidential information prior to submitting or presenting the manuscripts. The investigator shall, upon the request of LEO Pharma, delay publication or presentation to allow LEO Pharma to protect its inventions and other intellectual property rights.|t
17193470|NCT05653427|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17193471|NCT01264406|f||||f
17193472|NCT04671446|t||||f
17193473|NCT04256941|t||||
17193474|NCT02933970|f||||f
17193475|NCT03300648|f||||f
17193476|NCT02908477|t||||
17149556|NCT02459665|f||||f
17149557|NCT01220609|f||LTE60||t
17193477|NCT02140554|f||||t
17193478|NCT05590403|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193479|NCT05659537|f||GT60||t
17193480|NCT02289209|t||||
17193481|NCT04856163|t||||
17149558|NCT02225665|f||OTHER|All proposed written materials related to the study or an outline of any proposed oral presentations, shall be submitted to Sangamo for approval at least 45 days prior to submission of materials for publication or any oral disclosure to a third party. If Sangamo determines that a description of patentable subject matter is contained in such written material or outline, it shall notify the clinical site within 1 month after receipt and Sangamo will have an additional 90 days for review.|t
17149559|NCT03852524|t||||
17149560|NCT03478865|t||||
17149561|NCT01470417|t||||
17149562|NCT03488030|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149563|NCT01790113|f||||f
17149564|NCT00194792|t||||
17149565|NCT01714739|f||LTE60||t
17149566|NCT03585959|f||OTHER|Institution/Investigator may publish the results of work performed under this Agreement, in accordance with the Publication Policy described in the Clinical Investigation Plan and publication guidelines from the Declaration of Helsinki. Institution and Investigator shall not publish the Study results until after Medtronic's Multi-site publication or until the elapse of twelve (12) months from the close of the Study at all Study sites, whichever occurs first.|t
17149567|NCT03093272|f||||t
17149568|NCT00614822|f||||f
17149569|NCT05633082|f||||t
17149570|NCT02674386|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149571|NCT00277524|f||||f
17149572|NCT01439724|t||||
17149573|NCT02681406|f||||f
17149574|NCT01040793|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication|t
17149575|NCT01913795|f||||f
17149576|NCT00939627|f||LTE60||t
17149577|NCT03297294|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149578|NCT02127073|t||||
17149579|NCT01491633|f||||f
17149580|NCT00467987|t||||
17149581|NCT02776553|t||||
17149582|NCT01748955|f||||f
17149583|NCT01566526|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149584|NCT01043926|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17149585|NCT00738361|t||||
17149586|NCT00104247|f||OTHER|The first publication of the results shall be made by Sponsor in a joint publication. If such a multi-center publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from their site individually, subject however to comply with the other terms of the agreement.|t
17149587|NCT02598895|f||||f
17149588|NCT01886937|t||||f
17149589|NCT00063882|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17149590|NCT01930175|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149591|NCT00834899|f||||f
17149592|NCT03060759|f||||f
17149593|NCT03314662|f||LTE60||t
17149594|NCT01393457|t||||
17149595|NCT01117766|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149596|NCT00438659|t||||
17149597|NCT02244424|f||||f
17149598|NCT04290494|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17149599|NCT03366194|f||||f
17149600|NCT02369354|f||||f
17149601|NCT02664987|f||OTHER|The Investigator may not publish the results of the study without prior approval from Mundipharma.|t
17149602|NCT03407612|t||||
17149603|NCT01684215|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149604|NCT01682642|f||||f
17149605|NCT01552369|f||||f
17149606|NCT02234752|f||||f
17149607|NCT01679197|f||||f
17149608|NCT03919448|f||||f
17149609|NCT03438539|f||||f
17149610|NCT02429375|t||||
17193482|NCT05369533|f||||f
17193483|NCT04799704|t||||
17193484|NCT02884011|t||||
17193485|NCT04526704|f||||f
17193486|NCT00881621|f||LTE60||t
17149611|NCT04213209|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149612|NCT00385788|t||||
17149613|NCT00880087|f||||f
17149614|NCT01002794|f||||f
17193487|NCT03158714|f||||f
17149615|NCT01005329|f||LTE60||t
17149616|NCT00483548|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149617|NCT02997657|t||||f
17193488|NCT04574024|t||||
17149618|NCT04523324|f||||f
17149619|NCT01272921|t||||
17149620|NCT01132664|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17193489|NCT03936322|t||||
17149621|NCT00126126|f||||f
17193490|NCT05275231|t||||
17149622|NCT01005706|f||||f
17193491|NCT05434078|f||||f
17149623|NCT02062801|f||||f
17193492|NCT04406441|f||||f
17149624|NCT01223235|t||||
17149625|NCT04975321|f||||f
17149626|NCT00156715|t||||f
17149627|NCT01680783|f||||f
17149628|NCT00868296|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17149629|NCT01057381|t||||
17149630|NCT00804141|f||OTHER|Please contact Sponsor directly for additional information.|t
17149631|NCT00572039|f||||f
17149632|NCT02462486|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17193493|NCT02734290|t||||
17193494|NCT03158129|t||||
17193495|NCT06181006|f||GT60||t
17149633|NCT03767062|f||||f
17149634|NCT02240186|t||||f
17149635|NCT00941720|t||||f
17149636|NCT01682148|f||OTHER|The Sponsor required reasonable opportunity to review any abstract, presentation or paper before the material was submitted for publication or communicated. This also applied to any amendments that were requested by referees or journal editors. The Sponsor committed to comment on the draft documents within the time period agreed in the contractual arrangements between the Sponsor and authors or their institution. Delays were also possible if publication would adversely affect patentability.|t
17149637|NCT00775528|f||OTHER|At 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy and allow Sponsor 60 days to review and comment.|t
17149638|NCT02087176|f||||f
17149639|NCT03648879|f||||f
17149640|NCT04776954|t||||
17149641|NCT03812991|f||||f
17149642|NCT04740931|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149643|NCT00895037|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149644|NCT02063087|f||||f
17149645|NCT03496987|t||||
17149646|NCT00925756|f||||f
17149647|NCT01029392|t||||
17149648|NCT01103479|f||||f
17149649|NCT01534637|t||||
17193496|NCT03867500|t||||
17193497|NCT00554788|f||OTHER|Must obtain prior Sponsor approval.|t
17193498|NCT02702102|t||||
17193499|NCT03897465|f||||f
17193500|NCT05119023|t||||
17193501|NCT03153410|t||||
17193502|NCT03408340|t||||
17193503|NCT05805865|t||||
17193504|NCT03274310|f||||f
17193505|NCT00817219|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193506|NCT03676764|t||||
17193507|NCT05456360|t||||
17193508|NCT00875277|f||OTHER|LEO retains the right to publish the results of this clinical trial.|t
17193509|NCT04719390|t||||
17193510|NCT04292223|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17193511|NCT00391365|f||||f
17193512|NCT05467345|f||||f
17149650|NCT00605917|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149651|NCT00890552|t||||
17149652|NCT00724373|f||OTHER|All data will be the property of the Sponsor. Although under no obligation, it is asked that the investigator discuss any publication with the sponsor prior to release and obtain written consent. The sponsor recognises the right of the investigator to publish the results upon study completion. However, it is asked that the investigator send a draft to the sponsor 30 days in advance of submission in order to obtain approval.|t
17193513|NCT04963270|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149653|NCT02549573|f||OTHER|Sponsor has the first right, within 9 months following the later to occur 1) close out meeting or 2) Sponsor possessing all data, to publish the lead paper. Following the foregoing, Institution has the right to publish the results provided the Institution provides a Publications Committee, which includes the Sponsor, with a draft at least 30 days before submission. At Sponsor's request, Institution shall withhold publication for 45 days to allow filing of a patent application.|t
17149654|NCT00161382|f||||f
17149655|NCT03043560|f||||f
17149656|NCT00440115|f||||f
17193514|NCT04026555|t||||
17149657|NCT01839695|f||||f
17149658|NCT00206102|f||OTHER|The PI agrees to collaborate in good faith with AstraZeneca with regards to the contents and formation of any publication or disclosure to be made by the PI and to pay due consideration to the comments, views and opinions offered by AstraZeneca|t
17149659|NCT03123783|f||||t
17149660|NCT02642237|f||||f
17193515|NCT04150900|t||||
17193516|NCT04927364|t||||
17193517|NCT03483610|t||||
17193518|NCT02919306|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17193519|NCT03560609|f||||f
17149661|NCT02953678|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17193520|NCT04293055|f||||f
17193521|NCT02839161|f||||f
17149662|NCT03535857|f||||f
17149663|NCT00380757|t||||
17149664|NCT05529511|t||||
17149665|NCT01730040|f||OTHER|Not less than 45 days prior to submission for publication or presentation, the Institution shall, or cause the Principal Investigator to, provide the Sponsor with a copy of the Manuscript. The Institution shall consider in good faith any comments from the Sponsor regarding the content, and shall delete Confidential Information upon written request of the Sponsor. At the Sponsor's request, the Institution shall delay publication for an additional 60 days to allow patent applications to be filed.|t
17149666|NCT01042535|t||||
17149667|NCT01546142|f||OTHER|The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.|t
17149668|NCT00682617|t||||
17149669|NCT01213836|f||LTE60||t
17149670|NCT00255151|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17149671|NCT00107042|f||OTHER|The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.|t
17149672|NCT00423683|t||LTE60||t
17149673|NCT01286558|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17149674|NCT00362817|t||||
17149675|NCT03662308|t||||
17149676|NCT01191242|t||||
17149677|NCT04109313|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17149678|NCT01322971|f||||f
17149679|NCT00655850|t||||f
17149680|NCT01567826|t||||
17149681|NCT04364737|f||||f
17193522|NCT04195698|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149682|NCT03702049|f||||f
17149683|NCT00573170|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149684|NCT00986570|f||||f
17149685|NCT00276549|t||||
17149686|NCT00608517|t||||
17149687|NCT04862156|f||||f
17149688|NCT01833533|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149689|NCT01122316|t||||
17149690|NCT02457611|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17193523|NCT05459688|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and can extend the embargo for up to 90 days.|t
17149691|NCT00384293|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149692|NCT00493454|t||||f
17149693|NCT00103038|t||||
17149694|NCT01218984|f||OTHER|Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.|t
17149695|NCT03476317|t||||
17149696|NCT02865395|t||||
17149697|NCT01501110|f||||f
17149698|NCT02075606|f||||f
17149699|NCT01483625|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17149700|NCT04625673|t||||
17149701|NCT02310763|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149702|NCT04019054|t||||
17193524|NCT01959425|f||OTHER|Any results communications proposed to be published or presented shall be submitted to Sponsor at least 60 days prior to public release to permit Sponsor to direct removal of any confidential information contained therein. The first results communications should be a multicenter, joint publication. If a multicenter publication is not submitted by the Sponsor or designee within 12 months of the Study conclusion, PIs may publish results from their institution in accordance with the above.|t
17149703|NCT05444543|t||||
17149704|NCT01261624|f||LTE60||t
17149705|NCT04744155|f||||f
17149706|NCT02094261|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review, should the submission for publication be delayed in order to file patent application. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17193525|NCT04625283|t||||
17193526|NCT04500613|t||||
17149707|NCT03877926|f||||t
17149708|NCT04155073|f||||f
17193527|NCT03032107|t||||
17193528|NCT04632992|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17193529|NCT04187833|t||||
17193530|NCT03097549|f||||f
17193531|NCT02547233|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193532|NCT02146378|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193533|NCT03603600|f||OTHER|Contact Sponsor directly for details|t
17193534|NCT05170009|t||||f
17149709|NCT03554317|f||OTHER|PI may not publish results before Sponsor/Sponsor PI. If no multicenter publication within 12 months from study completion or termination at all sites, PI may publish results as long as Sponsor PI has copy of communication for review and comment at least 30 days before submission. Sponsor may request PI hold communication for additional 65 days to allow for filing of patent application or other methods to preserve proprietary and/or patent rights.|t
17149710|NCT01352182|f||||f
17149711|NCT00124462|t||||
17149712|NCT00537199|t||||f
17149713|NCT00860743|t||||
17149714|NCT01396382|t||||
17149715|NCT03827018|f||OTHER|Sponsor has the sole and exclusive right to publish information obtained from the trial. PI has no right to publish. PI may be invited to publish.|t
17149716|NCT02898103|f||||f
17149717|NCT02080507|t||||
17149718|NCT00350402|t||||f
17193535|NCT03524612|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17193536|NCT05457647|f||||f
17193537|NCT02535338|f||LTE60||t
17193538|NCT04137289|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193539|NCT04492722|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca. Access to this document must be restricted to relevant parties.|t
17193540|NCT05329220|f||OTHER|Institution/Investigator agree to submit any proposed publication or presentation to Sponsor for review at least 60 days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Sponsor shall have the right to require Institution/Investigator to remove specifically identified Confidential Information and/or to delay the proposed publication or presentation for an additional 60 days to enable Sponsor to seek patent protection for Inventions.|t
17193541|NCT02601313|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17193542|NCT03766009|t||||
17193543|NCT04552223|t||||
17193544|NCT03869866|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17193545|NCT04682587|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193546|NCT00506519|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals regardless of whether the findings are positive or negative, and acknowledges the investigators' right to publish results irrespective of outcome. Investigators are permitted to publish their individual data with the prior review and consent of LEO Pharma A/S|t
17193547|NCT01186367|t||||
17193548|NCT02975882|f||OTHER|Must obtain prior Sponsor approval|t
17193549|NCT02737436|f||||f
17193550|NCT02105766|t||||
17193551|NCT03701399|f||OTHER||t
17193552|NCT05191472|t||||
17193553|NCT02132936|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193554|NCT02561585|f||||f
17193555|NCT03134196|f||OTHER|No Participating Clinical Center (PCC) investigator is permitted to present or publish data obtained during the conduct of this trial without prior approval from the publications committee. PCC investigators must submit a proposal requesting access to trial data.|t
17193556|NCT03800108|f||||f
17193557|NCT03443388|f||||f
17193558|NCT06516705|f||||f
17193559|NCT00753545|f||LTE60||t
17193560|NCT06190691|f||GT60||t
17193561|NCT05746455|f||||f
17193562|NCT05130762|f||||t
17193563|NCT03477968|f||OTHER|All the informations regarding the PIs restrictions are specified in the study agreement for each study site.|t
17193564|NCT03016754|f||||f
17193565|NCT03839940|t||||
17193566|NCT03241745|t||||
17193567|NCT03023410|f||||f
17193568|NCT06469138|f||||t
17193569|NCT04799899|f||||f
17193570|NCT00470704|t||||
17193571|NCT04019873|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17149719|NCT00304707|f||||f
17149720|NCT01884688|t||||
17149721|NCT02938013|t||||
17193572|NCT02305277|f||OTHER||t
17193573|NCT05210608|f||||f
17193574|NCT01120223|f||OTHER|LEO acknowledges the investigators' right to publish the results of the trial, irrespective of outcome. Pubs/presentations by investigator(s) shall not be made before the results of a joint publication is public. LEO retains the right to have any publication submitted to LEO for review at least 30 days prior to this paper being submitted for publication/presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17149722|NCT04099641|f||||f
17149723|NCT00712244|f||OTHER|No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.|t
17149724|NCT01931527|f||||f
17149725|NCT02210052|t||||
17149726|NCT04798482|t||||
17149727|NCT01192399|f||||t
17149728|NCT00789113|f||||f
17149729|NCT01382251|f||||f
17149730|NCT00562120|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193575|NCT04908722|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193576|NCT02319759|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193577|NCT04213872|t||||
17193578|NCT03339713|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17193579|NCT01902173|f||LTE60||t
17193580|NCT02649842|f||OTHER|The sponsor must review results communication prior to public release and can embargo communications regarding trial results at any time.|t
17193581|NCT02262728|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193582|NCT05540665|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17193583|NCT02619838|t||||
17193584|NCT05505292|t||||
17193585|NCT04066244|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17193586|NCT01073566|f||||f
17193587|NCT02100891|f||||f
17193588|NCT01389856|f||OTHER||t
17193589|NCT03309306|f||||f
17193590|NCT03916042|f||||t
17193591|NCT05604508|f||||f
17193592|NCT05533359|f||||f
17193593|NCT01422434|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17149731|NCT00545688|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149732|NCT00932282|t||||f
17149733|NCT04678817|f||||f
17149734|NCT02966184|t||||
17149735|NCT03860207|f||||f
17149736|NCT01010126|f||LTE60||t
17149737|NCT00635830|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149738|NCT05218109|t||||
17149739|NCT01959490|t||||
17149740|NCT00784134|t||||
17193594|NCT05006872|f||||f
17193595|NCT01972919|t||||
17193596|NCT04149704|f||||f
17193597|NCT00528268|t||||
17193598|NCT02268253|f||OTHER|"1. Individual site results may be submitted for publication only after the results of the multicenter study are published, 12 months after study completion at all sites, or notification from Stemline that submission of a multicenter publication is no longer planned.~2. Thereafter, the PI is free to publish the results.~3. The PI is required to furnish Stemline with a copy of any proposed publication or presentation for review and comment at least thirty (30) days prior to submission."|t
17193599|NCT03001713|f||||f
17193600|NCT05362487|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193601|NCT01743807|f||GT60||t
17149741|NCT03785145|f||OTHER|General research agreement between the sponsor and PI's that includes a confidentiality section with a statement that the sponsor is and shall remain the exclusive owner of 'Information'. 'Information' shall include, but shall not be limited to, protocols, trade secrets, know-how, formulations, inventions, techniques, equipment, data and results.|t
17149742|NCT03694808|t||||
17193602|NCT06215521|f||GT60||t
17193603|NCT04096040|f||||f
17149743|NCT02631837|f||||f
17149744|NCT03250299|f||GT60||t
17149745|NCT01202071|f||||f
17149746|NCT03346070|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17193604|NCT03333590|f||||f
17193605|NCT04973254|t||||
17193606|NCT01814813|t||||
17193607|NCT03344094|f||||f
17193608|NCT03808818|f||LTE60||t
17193609|NCT05838313|f||||f
17193610|NCT05415722|f||||f
17193611|NCT04629716|f||||f
17193612|NCT04537715|f||OTHER||t
17193613|NCT03031470|f||||f
17149747|NCT03660241|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149748|NCT00934596|f||||f
17149749|NCT03341546|t||||
17149750|NCT01221090|f||||f
17149751|NCT00708708|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149752|NCT02597582|f||||f
17149753|NCT04776746|f||OTHER|Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment.|t
17149754|NCT00418522|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149755|NCT02504723|f||||f
17149756|NCT00882206|t||||
17149757|NCT00892281|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17149758|NCT01612884|t||||
17149759|NCT00865098|f||OTHER||t
17149760|NCT02790034|f||OTHER||t
17149761|NCT03440424|f||||t
17149762|NCT01138826|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149763|NCT05206448|f||||f
17149764|NCT03360916|f||||f
17149765|NCT01333072|f||||f
17149766|NCT02502734|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149767|NCT01430819|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17149768|NCT03649412|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial|t
17149769|NCT02280187|f||LTE60||t
17149770|NCT04668274|f||||t
17149771|NCT02363439|f||||t
17149772|NCT01143649|f||||f
17149773|NCT00707447|t||||
17149774|NCT01719562|f||||f
17149775|NCT00508027|t||||f
17149776|NCT04061577|f||||f
17149777|NCT03208673|f||OTHER|"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.~(Note that this agreement language may appear in the study protocol)"|t
17149778|NCT00768118|t||||
17149779|NCT03891329|f||||f
17149780|NCT02740179|f||||f
17149781|NCT02326363|t||||
17149782|NCT01832402|t||||
17149783|NCT04625062|f||||f
17149784|NCT01202877|t||||
17193614|NCT03461276|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17193615|NCT01414400|f||||f
17149785|NCT00396331|f||OTHER|PI agrees to submit the draft of any proposed public release or proposed publication to Genzyme and Genzyme may review the proposed public release or draft of the publication for up to 30 days prior to submission for public release, presentation or use. PI agrees (1) to withhold submission for an additional period not to exceed 60 days to allow Genzyme to take action to protect patent rights or trade secret rights (2) to give due consideration to any editorial comments of Genzyme.|t
17149786|NCT00606138|f||||f
17149787|NCT01351350|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17149788|NCT02339740|f||OTHER|Must obtain prior approval.|t
17149789|NCT04072315|f||||t
17149790|NCT02096588|t||||f
17149791|NCT00303667|t||||
17149792|NCT02377921|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17193616|NCT02310646|f||OTHER|LEO acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193617|NCT03865498|t||||f
17193618|NCT02619994|f||||f
17193619|NCT05869383|f||||f
17193620|NCT04473430|f||||f
17193621|NCT03270501|t||||
17193622|NCT04531280|f||||f
17193623|NCT06180954|f||GT60||t
17193624|NCT03812679|f||OTHER|The Sponsor reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17193625|NCT05486078|f||||f
17193626|NCT02985957|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193627|NCT04711447|f||||f
17149793|NCT01615887|f||||f
17149794|NCT03903159|f||||f
17149795|NCT00737737|t||||
17149796|NCT02540447|t||||
17149797|NCT02443545|f||LTE60||t
17149798|NCT00604201|t||||
17149799|NCT00536484|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149800|NCT00706355|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149801|NCT01506908|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149802|NCT01020799|f||OTHER|No publication or presentation of results until the earlier of the publication of the first multi-center publication and the second anniversary of the completion of the multi-center study at all sites. Sponsor must receive a copy of proposed manuscript for review and comment at least 60 days prior to its submission for publication or presentation.|t
17149803|NCT02732691|f||||f
17149804|NCT01425528|t||||
17149805|NCT04184999|f||||f
17149806|NCT02985879|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149807|NCT00595335|t||||f
17149808|NCT04718545|t||||
17149809|NCT03632135|f||||f
17149810|NCT01647958|f||||f
17149811|NCT00544817|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 days but ≤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.|t
17149812|NCT01131299|t||||
17149813|NCT01398059|f||||f
17149814|NCT01885182|f||||f
17149815|NCT03686150|f||||f
17149816|NCT01207440|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149817|NCT03341000|f||||t
17149818|NCT01252719|f||OTHER|The Institution and PI agree that the Sponsor shall have the right to the first publication of the Study results. The Pl may publish data or results from the Study; provided, however, that the Institution and/or PI submits the proposed publication to Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary.|t
17149819|NCT02813421|f||||f
17193628|NCT05263037|t||||
17193629|NCT04802967|f||||f
17193630|NCT04114877|t||||
17193631|NCT03945292|f||OTHER|The only disclosure restriction on the PI is that the sponsor retains first right to publish results for this multi-center study, and thereafter can review results communications prior to release and can embargo communications regarding trial results for a period that is 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication of results but can require removal of its confidential information (excluding results).|t
17193632|NCT06429319|f||||f
17193633|NCT04295798|f||||f
17193634|NCT01857245|f||||f
17193635|NCT04321395|t||||
17193636|NCT03524118|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193637|NCT03122847|t||||
17193638|NCT03916510|f||||f
17193639|NCT04650269|t||||
17193640|NCT04987320|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17193641|NCT01437709|t||||
17193642|NCT00085735|f||||f
17193643|NCT01824875|f||LTE60||t
17193644|NCT02014649|f||||t
17193645|NCT00433329|f||||f
17193646|NCT01098812|f||OTHER|Study results may be published by PI upon written approval by sponsor (AMO). Any proposed submission for publication or presentation of study data must be provided to AMO 90 days prior to submission for review, comment and approval. Sponsor may delay or withhold submission as necessary (ongoing study activities, patents pending, etc.).|t
17193647|NCT01129102|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17193648|NCT01715285|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193649|NCT02598388|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193650|NCT05020249|f||GT60||t
17193651|NCT04002830|f||||f
17193652|NCT03628924|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17193653|NCT03959696|f||||f
17193654|NCT03474679|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193655|NCT05337306|f||||f
17193656|NCT01753414|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17193657|NCT03913702|t||||
17193658|NCT04341896|t||||f
17193659|NCT04971681|f||||f
17193660|NCT00686335|f||OTHER|Anything concerning publication, information and communication is described under law number R5121-13 of the French Code de la Santé Publique. Any information about results cannot be given without the accordance of Horizon Pharma (formerly Nitec Pharma).|t
17193661|NCT04332926|t||||
17193662|NCT05832996|f||||f
17193663|NCT02291302|f||||f
17193664|NCT04350463|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17193665|NCT04111536|f||||f
17193666|NCT04547920|f||||f
17193667|NCT05672069|f||||f
17193668|NCT06019559|f||LTE60||t
17193669|NCT05949788|t||||
17193670|NCT05213390|f||||f
17193671|NCT01824537|t||||
17193672|NCT03858634|f||OTHER|Sponsor has the first right to publish study results. PI may publish study results after Sponsor publishes the study results or 18 months after study completion at all participating sites, whichever comes first, provided that Sponsor may embargo such publication for up to 60 days for purposes of identifying confidential information that must be removed and up to an additional 60 days to prepare a patent application if there is patentable subject matter in the PI's proposed publication.|t
17193673|NCT04676763|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17193674|NCT04997148|f||||t
17193675|NCT02724449|f||||f
17193676|NCT04543357|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193677|NCT04623671|f||||f
17193678|NCT04663737|f||||f
17193679|NCT04215146|f||||f
17193680|NCT01943409|f||||f
17193681|NCT03848065|f||OTHER|The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17193682|NCT00670358|t||||
17193683|NCT03496168|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193684|NCT04137367|t||||f
17193685|NCT03907878|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17193686|NCT05144009|f||||t
17193687|NCT04499924|f||||t
17193688|NCT01648023|f||||f
17193689|NCT05403827|f||OTHER|INSTITUTION/INVESTIGATOR may publish/present results after SPONSOR publication. Prior SPONSOR review protects confidential info \& patentable material. Confidential info will be removed. Patentable findings may delay publication for patent filing. Acknowledgement of SPONSOR's support is at SPONSOR's option, with prior consent required for any SPONSOR reference.|t
17193690|NCT04475679|t||||
17193691|NCT05597085|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193692|NCT03379675|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17193693|NCT04502888|f||OTHER|Site agrees not to publish any Study Results or data before the publication of results from the Overall Study. After Sponsor haspublished the results of the Overall Study, Site may publish or present results generated at Site. If Sponsor has not publishedresults of the Overall Study within 18 months of data base lock, Site may publish the results of the Study that were generated atSite. Site agrees to first submit to Sponsor the proposed publication at least 30 days prior to the submission.|t
17193694|NCT03462030|t||||
17193695|NCT03381196|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193696|NCT02675751|f||OTHER|The sponsor must review results communications prior to public release and can embargo communications regarding trial results at any time.|t
17193697|NCT03371381|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193698|NCT02979327|t||||
17193699|NCT03069924|f||||f
17193700|NCT04098263|f||||f
17193701|NCT01539083|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17193702|NCT05499377|f||||f
17193703|NCT02573493|t||||
17193704|NCT03629678|f||||f
17193705|NCT02433613|f||OTHER|Details are described in the project specific Publication Plan.|t
17193706|NCT01496313|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17193707|NCT02677805|f||OTHER||t
17193708|NCT05714761|t||||
17193709|NCT03150173|t||||
17193710|NCT05477095|f||||f
17193711|NCT04518917|f||||f
17193712|NCT02191618|f||||f
17193713|NCT02316002|f||||f
17193714|NCT02852330|f||||t
17193715|NCT01802788|f||LTE60||t
17193716|NCT04573517|t||||
17193717|NCT04625686|f||||f
17193718|NCT03011333|f||||f
17193719|NCT05827094|f||||f
17193720|NCT05074303|f||||f
17193721|NCT05269667|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigators are free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17193722|NCT04349371|t||||
17193723|NCT05022329|f||||f
17193724|NCT05246280|f||OTHER|Clinical Trial Agreement states that no publications will be made unless approval by the sponsor is granted.|t
17193725|NCT04599062|t||||
17193726|NCT03374787|f||||f
17193727|NCT04074759|f||||t
17193728|NCT04204265|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17193729|NCT05038878|t||||
17193730|NCT05459857|f||||f
17193731|NCT03468868|f||||f
17193732|NCT05399459|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193733|NCT02231164|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193734|NCT01210807|f||OTHER||t
17193735|NCT04436276|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17193736|NCT00324805|f||LTE60||t
17193737|NCT03931174|t||||f
17193738|NCT03322267|t||||
17193739|NCT03046251|f||||f
17193740|NCT05757453|f||||f
17193741|NCT05746299|t||||
17193742|NCT03852472|f||||t
17193743|NCT01919554|f||||f
17193744|NCT05977530|f||||f
17193745|NCT06457802|f||||f
17193746|NCT01467427|f||OTHER|At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.|t
17193747|NCT03161028|f||||f
17193748|NCT00736723|f||||f
17193749|NCT03492216|f||||f
17193750|NCT05966870|f||||f
17193751|NCT04016662|f||||f
17193752|NCT03021096|t||||
17193753|NCT05082116|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17193754|NCT01037881|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193755|NCT00764751|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submit-ted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193756|NCT04563546|t||||
17193757|NCT03298477|f||||f
17193758|NCT02809443|f||||f
17193759|NCT02998268|t||||
17193760|NCT01175356|f||OTHER|Must obtain prior approval.|t
17193761|NCT02268461|t||||
17193762|NCT06074172|f||||f
17193763|NCT03020199|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17193764|NCT05583578|f||||f
17193765|NCT05216315|f||||f
17193766|NCT04005794|f||||f
17193767|NCT04313972|f||||f
17193768|NCT02547363|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193769|NCT04447469|f||OTHER|Any publication or presentation of data related to the Clinical Trial, including but not limited to, publications in specialized journals or disclosures in Medical Congresses, must be previously authorized in writing.|t
17193770|NCT05201079|f||OTHER|If the results are not submitted by the sponsor, the PI may publish them in scientific journals, provided that they mention the sponsor, at least, within the first year after the authorization and marketing in any country (for non-commercialized products). The sponsor must receive for review a copy of the text, except otherwise agreed, at least 45 days before the submission (20 days before for Abstracts). The PI may only use these data with prior express written authorization from the sponsor.|t
17193771|NCT03569631|f||OTHER|The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.|t
17193772|NCT05808257|t||||f
17193773|NCT04568486|t||||
17193774|NCT04042233|t||||
17193775|NCT03986931|f||||f
17193776|NCT04907851|f||||t
17193777|NCT04752709|t||||
17193778|NCT04111874|f||||f
17193779|NCT05562401|f||||f
17193780|NCT00704262|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193781|NCT05281562|f||||f
17193782|NCT03029884|t||||
17193783|NCT05322044|t||||
17193784|NCT05477186|f||OTHER|GSK agreements may vary with individual investigators but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17193785|NCT04364048|f||||f
17193787|NCT05792085|t||||
17193788|NCT01767636|t||||
17193789|NCT01652196|t||||
17193790|NCT05692960|t||||
17193791|NCT04719832|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17193792|NCT04382664|f||||f
17193793|NCT04880863|f||OTHER|Study Sites or Principal Investigators shall not publish the Results or the outcomes of their individual participation in the Study, until after the completion of the Study at all participating sites and the review, analysis, and write-up of the Study by the Sponsor.|t
17193794|NCT04528173|f||||f
17193795|NCT04898673|t||||f
17193796|NCT03899259|f||GT60||t
17193797|NCT04797897|f||OTHER|The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 40 days but less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor may request removal of specified Confidential Information (other than results of the study) to the communication as is reasonably required to protect the Intellectual Property of the sponsor and cannot extend the embargo.|t
17193798|NCT05670587|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17193799|NCT01197378|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17193800|NCT05778695|f||||f
17193801|NCT01544114|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17149820|NCT03135899|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149821|NCT02548312|t||||f
17149822|NCT04146363|f||GT60||t
17149823|NCT02914236|f||OTHER|First publication of study results shall be made in conjunction with the results from all clinical study centers participating in the multicenter study. If results of the multi-center study have not been published in full within 18 months after completion of the study, investigator shall be free to publish results. Investigator agrees to submit all proposed publications to the sponsor at least 60 days prior submission; the company has the right to comment.|t
17149824|NCT00441350|f||||t
17149825|NCT00706095|f||||f
17149826|NCT02676284|f||||f
17149827|NCT01685073|f||||f
17149828|NCT01332578|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149829|NCT03050697|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149830|NCT00440466|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149831|NCT00743509|t||||f
17149832|NCT01891305|f||OTHER|Neither institution nor principal investigator shall publish the results of the trial without prior written consent of the sponsor, which it may withhold in its sole discretion.|t
17149833|NCT03768726|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149834|NCT01787279|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights|t
17149835|NCT02695719|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17149836|NCT00140413|f||OTHER|With respect to any proposed publication, the PI must submit to the sponsor a copy of the proposed publication at least 2 months prior to submission for the purposes of: providing the sponsor the oppotunity to review and comment on the contents of proposed publication; and to identify any trade secret, proprietary or confidential information to be removed from the proposed publication. The sponsor will provide comments within 30 days of receipt of proposed publication.|t
17149837|NCT03623620|f||||f
17149838|NCT00811434|t||||
17149839|NCT01360866|f||OTHER|Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.|t
17149840|NCT01304693|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149841|NCT02129647|t||||
17149842|NCT03647046|f||||f
17149843|NCT00918463|t||||f
17149844|NCT01784666|f||||f
17149845|NCT01014624|f||||f
17149846|NCT00836017|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149847|NCT01715896|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.|t
17149848|NCT02164734|f||||f
17149849|NCT03923699|t||||
17149850|NCT01746264|t||||
17193802|NCT04649476|f||||f
17193803|NCT04223505|f||||f
17193804|NCT05482698|f||LTE60||t
17193805|NCT03879863|f||||t
17193806|NCT05533918|f||||f
17193807|NCT03024437|f||||f
17193808|NCT04625465|f||||f
17193809|NCT04501614|f||||t
17193810|NCT05566639|f||||t
17193811|NCT03498612|t||||
17193812|NCT05239455|f||OTHER|Available upon request.|t
17193813|NCT02589522|f||LTE60||t
17193814|NCT03800654|t||||
17193815|NCT04159415|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17193816|NCT01799265|f||LTE60||t
17193817|NCT03459729|t||||
17193818|NCT06182033|f||||f
17193819|NCT02364557|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17193820|NCT03134092|f||||f
17149851|NCT03028740|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149852|NCT04060719|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149853|NCT04578886|t||||
17149854|NCT00894517|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17149855|NCT01048502|t||||
17149856|NCT03336242|f||LTE60||t
17149857|NCT02224573|f||OTHER||t
17149858|NCT01557842|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17149859|NCT03053583|f||||f
17149860|NCT03005067|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149861|NCT02560779|f||||f
17149862|NCT02296853|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17149863|NCT00619359|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149864|NCT03233958|f||||f
17149865|NCT01661881|f||||f
17149866|NCT01359748|f||||f
17149867|NCT01803269|t||||f
17149868|NCT04647383|f||||f
17149869|NCT00873119|f||LTE60||t
17149870|NCT04844021|t||||f
17149871|NCT01258101|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149872|NCT02243293|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17193821|NCT05844137|t||||
17193822|NCT04200456|f||GT60||t
17193823|NCT04828005|f||||f
17193824|NCT03450980|f||||f
17193825|NCT03509402|f||||f
17193826|NCT05530603|t||||
17193827|NCT02043678|f||GT60||t
17193828|NCT05543629|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193829|NCT04568603|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17193830|NCT04131686|f||||t
17193831|NCT03313076|t||||f
17193832|NCT04119843|f||||t
17193833|NCT03904147|f||GT60||t
17193834|NCT04406623|f||OTHER|Site agrees not to publish any Study Results or data before the publication of results from the Overall Study. After Sponsor has published the results of the Overall Study, Site may publish or present results generated at Site. If Sponsor has not published results of the Overall Study within 18 months of data base lock, Site may publish the results of the Study that were generated at Site. Site agrees to first submit to Sponsor the proposed publication at least 30 days prior to the submission.|t
17193835|NCT01623167|t||||
17193836|NCT04233216|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17193837|NCT04307355|f||||f
17193838|NCT02690558|t||||
17193839|NCT04225273|f||OTHER|per site CTA|t
17193840|NCT03652389|t||||
17193841|NCT05448105|t||||
17193842|NCT04413708|f||||f
17193843|NCT03768505|f||OTHER|This study was terminated early however, each PI has a CDA in place that restricts them from discussing any results of the clinical study at a scientific meeting or any other public or private forum or to publish in a scientific or academic journal the results of the clinical study without the approval of the Sponsor Company (MEI Pharma Inc.).|t
17193844|NCT04032704|f||||t
17193845|NCT02861300|t||||
17193846|NCT03133546|f||||f
17193847|NCT05135650|f||||f
17149873|NCT02181296|t||||f
17149874|NCT00656968|t||||f
17149875|NCT00952276|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17149876|NCT02658487|t||||
17149877|NCT01300624|t||||
17149878|NCT03707041|f||LTE60||t
17149879|NCT00614926|t||||
17149880|NCT00118378|t||||
17149881|NCT00856830|f||||f
17149882|NCT02954159|f||||f
17149883|NCT03465748|t||||
17149884|NCT02596321|f||||f
17149885|NCT01231750|t||||
17149886|NCT01117337|f||||f
17193848|NCT06103188|t||||
17193849|NCT00986856|f||||f
17193850|NCT01541553|f||OTHER|"The sponsor is entitled to review and comment on publications prior to submission or presentation.~Upon request of the sponsor, the investigator shall delay publication or presentation to allow for protection of the sponsors inventions and other intellectual property."|t
17193851|NCT05386030|f||||t
17193852|NCT04324359|f||||t
17149887|NCT03575871|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149888|NCT00474851|f||||f
17149889|NCT02791893|f||||f
17149890|NCT03394755|f||||f
17149891|NCT01744093|t||||f
17149892|NCT01570283|f||||f
17149893|NCT04051463|t||||
17149894|NCT01173471|f||OTHER|The Sponsor recognises that the Trust and Investigator have a responsibility under the Research Governance Framework for Health and Social Care to ensure that results of scientific interest arising from the Clinical Trial are appropriately published and disseminated. Such data will be submitted to the Sponsor for review and comment prior to publication. The Trust agrees, and shall ensure that the Investigator agrees, that all reasonable comments made by the Sponsor will be incorporated.|t
17149895|NCT00256776|f||||f
17149896|NCT00685802|f||GT60||t
17149897|NCT03998436|f||OTHER|"There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.~The sponsor has prepared an integrated clinical/statistical report. As this was a multicenter study, any publication/presentation of data was to include the entire study population. Publication/presentation of data from individual study centers is not allowed without explicit permission from the sponsor."|t
17149898|NCT00251225|t||||
17149899|NCT02546362|f||OTHER|"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 45 days from the time submitted to the sponsor for review. Sponsor may request:~* deletion of any trade secret, proprietary, or confidential information of Sponsor~* an additional 60 days to take measures to preserve its Intellectual Property rights~Sponsor's written consent is required for results communication before trial completion."|t
17149900|NCT02593396|t||LTE60||t
17149901|NCT01980342|t||||
17149902|NCT04317313|t||||
17149903|NCT01453413|f||GT60||t
17149904|NCT00845975|f||||f
17149905|NCT00355472|f||OTHER||t
17149906|NCT03095118|t||||
17149907|NCT02408120|t||||
17193853|NCT02862210|t||||
17193854|NCT01733316|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17193855|NCT03058289|f||GT60||t
17193856|NCT01674140|f||||f
17193857|NCT05546411|t||||
17193858|NCT02606422|t||||
17193859|NCT04947397|t||||f
17149908|NCT01144403|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17149909|NCT01825837|f||OTHER||t
17149910|NCT02269631|t||||
17193860|NCT04731818|f||||f
17149911|NCT00904748|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149912|NCT01067716|f||OTHER|At least ninety (90) days prior to any proposed submission for publication or presentation of Study Data or other findings related to the Study, Institution will provide Sponsor with a manuscript of such submission(s) for review, comment, and approval. For greater certainty, neither Institution nor Principal Investigator shall have any right to publish any information or results concerning the Study without the express written consent of Sponsor.|t
17149913|NCT00680186|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17193861|NCT02151981|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review, should the submission for publication be delayed in order to file patent application. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17193862|NCT00597909|f||OTHER||t
17149914|NCT01099631|t||||
17149915|NCT05472116|t||||
17149916|NCT00285584|f||LTE60||t
17193863|NCT01946789|f||||t
17193864|NCT05374798|f||||f
17193865|NCT05576155|t||||
17193866|NCT04078191|f||OTHER|Clinical Trail Agreement prevents any PIs to publish data that has not been approved by the sponsor.|t
17193867|NCT04032041|f||||f
17193868|NCT01275677|f||LTE60||t
17193869|NCT05012683|f||||f
17193870|NCT00207636|f||||f
17193871|NCT05002608|f||||f
17193872|NCT04409353|f||||f
17193873|NCT04081103|f||||t
17193874|NCT05309291|f||OTHER|Baxter Healthcare Corporation reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17193875|NCT04581564|f||||f
17193876|NCT05209152|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17193877|NCT04168580|t||||
17193878|NCT03491969|t||||
17193879|NCT03287817|f||GT60||t
17193880|NCT06181227|f||GT60||t
17193881|NCT05292872|f||||f
17193882|NCT05260112|t||||
17193883|NCT03854227|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17193884|NCT03668236|f||||f
17193885|NCT04863378|t||||
17193886|NCT03798093|f||||f
17193887|NCT06132282|t||||
17193888|NCT03936959|f||GT60||t
17193889|NCT06215430|f||GT60||t
17193890|NCT04376502|t||||
17149917|NCT00645944|t||||f
17149918|NCT02389101|f||||f
17149919|NCT01807117|t||||
17193891|NCT03748953|f||||t
17193892|NCT05986682|f||||f
17193893|NCT04044768|f||LTE60||t
17193894|NCT01574274|t||||
17193895|NCT05089019|f||GT60||t
17193896|NCT03626766|t||||
17193897|NCT01593917|f||||f
17193898|NCT03216057|t||||
17193899|NCT04564742|f||||f
17193900|NCT05194540|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17193901|NCT02841579|f||||f
17193902|NCT05270408|f||||f
17193903|NCT05331053|f||||f
17193904|NCT06044090|t||||
17193905|NCT04910152|t||||
17193906|NCT02465268|f||||f
17193907|NCT03532282|t||||
17193908|NCT01501955|f||||f
17193909|NCT02993159|f||||f
17193910|NCT02895464|f||||f
17193911|NCT03482557|f||||f
17193912|NCT04992520|f||||f
17193913|NCT05651308|f||||f
17193914|NCT03625167|t||||
17193915|NCT05245682|t||||
17193916|NCT03316573|t||||
17193917|NCT00248287|f||||f
17193918|NCT05825755|f||||f
17193919|NCT02749006|f||||f
17193920|NCT04893239|f||||f
17193921|NCT03728790|t||||f
17193922|NCT03896867|t||||
17193923|NCT04524442|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17193924|NCT02675777|f||||f
17193925|NCT05228457|f||||f
17193926|NCT00167674|f||||f
17193927|NCT04084288|f||||f
17193928|NCT00691002|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submit-ted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17193929|NCT03213691|f||LTE60||t
17193930|NCT02587403|f||||f
17193931|NCT01152450|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17193932|NCT05139810|f||OTHER|There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17193933|NCT02966873|f||||f
17193934|NCT04082143|t||||
17193935|NCT04753697|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17193936|NCT02626533|t||||
17193937|NCT04947527|f||||f
17193938|NCT02723591|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17193939|NCT03691935|t||||
17193940|NCT05124704|t||||
17193941|NCT05493072|f||||f
17193942|NCT04089137|f||||f
17193943|NCT04383496|f||||f
17193944|NCT04164888|f||||f
17193945|NCT03034356|t||||
17193946|NCT02823145|f||GT60||t
17193947|NCT05292391|f||LTE60||t
17193948|NCT02568566|f||LTE60||t
17193949|NCT06212804|f||||f
17193950|NCT03856515|t||||
17193951|NCT05809453|t||||
17193952|NCT02696707|f||||f
17193953|NCT00636077|f||||f
17193954|NCT05251909|t||||
17149920|NCT01523587|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17149921|NCT01298778|t||||
17149922|NCT04965389|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149923|NCT00572117|f||||f
17149924|NCT02709486|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149925|NCT00589849|t||||
17149926|NCT01818518|t||||
17149927|NCT02463799|f||||f
17149928|NCT02919813|t||||
17149929|NCT01855048|f||||t
17149930|NCT02139124|f||||f
17149931|NCT02691741|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17149932|NCT03465436|f||GT60||t
17193955|NCT05543915|t||||
17193956|NCT04881903|t||||
17193957|NCT04418232|f||||f
17193958|NCT04478643|f||||f
17193959|NCT02815566|f||||f
17193960|NCT03994653|t||||
17193961|NCT03252847|f||||t
17193962|NCT05034328|f||LTE60||t
17193963|NCT05445427|t||||
17193964|NCT02969707|f||||f
17193965|NCT03287336|f||||f
17193966|NCT02427464|f||OTHER|Investigator Agreement .....|t
17193967|NCT02714257|f||||f
17193968|NCT04103580|f||||f
17193969|NCT04145440|f||||t
17193970|NCT00104676|f||||f
17193971|NCT04700176|t||||
17193972|NCT00576979|f||||f
17193973|NCT03697096|f||||f
17193974|NCT03766685|f||GT60||t
17193975|NCT04676165|t||||
17193976|NCT05297565|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17193977|NCT03128021|f||||f
17193978|NCT05166577|f||GT60||t
17193979|NCT04054193|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17193980|NCT03084536|t||||
17193981|NCT05704543|f||||t
17193982|NCT05073458|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17193983|NCT02272998|t||||
17193984|NCT02938377|f||||f
17193985|NCT04053075|f||||f
17193986|NCT04830800|f||||t
17193987|NCT04285515|f||||f
17193988|NCT03816332|f||LTE60||t
17193989|NCT03710603|f||||t
17193990|NCT01456949|f||OTHER||t
17193991|NCT03785964|f||LTE60||t
17193992|NCT03744182|f||||f
17193993|NCT03709121|f||||t
17193994|NCT04176601|f||||f
17193995|NCT04201262|f||||t
17193996|NCT02618577|f||||f
17193997|NCT05446168|f||||f
17193998|NCT03512327|t||||
17193999|NCT03847311|f||||f
17194000|NCT03511664|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17194001|NCT05050149|f||||f
17194002|NCT04162665|t||||
17194003|NCT04777721|t||||
17194004|NCT04577963|f||||t
17194005|NCT00636389|f||GT60||t
17194006|NCT04857723|f||||t
17194007|NCT03221426|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194008|NCT06130410|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194009|NCT03257410|f||OTHER|The sponsor reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17194010|NCT02561247|f||OTHER|Baxter Healthcare Corporation reserves the right of prior review and approval of data from this study relative to the potential release of proprietary information to any publication or for any presentation.|t
17194011|NCT02276885|t||||
17194012|NCT03435614|t||||
17194013|NCT04171141|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194014|NCT03526887|f||||f
17194015|NCT04858451|f||OTHER||t
17194016|NCT03314454|f||||f
17194017|NCT00967447|f||OTHER|Any publication of the results of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract|t
17194018|NCT04314713|f||OTHER|PI cannot publish without written authorization from the DOD.|t
17194019|NCT05495555|t||||
17194020|NCT02927236|t||||
17194021|NCT05534789|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194022|NCT03656510|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.|t
17194023|NCT01710488|f||||f
17194024|NCT05698875|f||||f
17194025|NCT05496231|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194026|NCT01205828|f||GT60||t
17194027|NCT03828799|f||||f
17194028|NCT05196919|f||OTHER|PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.|t
17194029|NCT06232590|f||||t
17194030|NCT05940194|f||||f
17194031|NCT03085810|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194032|NCT03621371|f||||f
17194033|NCT01959607|f||OTHER|"We confirm we have the contractual provisions in place which specifies that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.~The Intellectual Property rights and research results from the present study belongs to the Sponsor."|t
17194034|NCT03584633|f||||f
17194035|NCT03576885|t||||
17194036|NCT03235544|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17194037|NCT00950742|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194038|NCT04447755|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194039|NCT05476328|t||||
17194040|NCT01658930|f||||f
17194041|NCT03701763|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17194042|NCT03603002|f||||f
17194043|NCT00592852|t||||
17194044|NCT05495971|f||||f
17194045|NCT05658224|t||||
17194046|NCT02589795|t||||
17194047|NCT02322203|t||||
17194048|NCT03599661|t||||
17194049|NCT04909801|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194050|NCT03725384|f||||f
17194051|NCT04117347|f||||f
17194052|NCT03687086|t||||f
17194053|NCT02505984|f||||f
17194054|NCT05194956|t||||
17194055|NCT01922050|f||OTHER|LEO acknowledges the investigator's right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194056|NCT04421989|f||||f
17194057|NCT05299242|f||||f
17194058|NCT05192109|f||||f
17194059|NCT04498390|f||GT60||t
17194060|NCT02975375|f||||f
17194061|NCT04971109|f||OTHER|The agreement restricts the right of the PI to discuss or publish trial results.|t
17194062|NCT05987813|t||||
17194063|NCT02709161|t||||
17194064|NCT03100760|f||||f
17194065|NCT04231149|t||||
17194066|NCT04520191|f||||f
17194067|NCT04979442|f||||f
17194068|NCT05283304|t||||t
17194069|NCT04298983|t||||
17194070|NCT04506307|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17194071|NCT02116530|f||LTE60||t
17194072|NCT03711734|f||||f
17194073|NCT05029622|f||OTHER||t
17194074|NCT05671653|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194075|NCT03974178|f||OTHER|The sponsor authorizes publications by a single site provided that multicentric results are published beforehand and that any communication is submitted to sponsor for review at least 28 days ahead of the expected date of publication. Upon sponsor request, any confidential information will have to be removed from the communication before publishing.|t
17194076|NCT05526430|t||||
17194077|NCT04508309|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review.|t
17194078|NCT02305888|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194079|NCT04914676|t||||
17194080|NCT05200403|t||||
17194081|NCT03913442|t||||
17194082|NCT02460458|f||OTHER||t
17194083|NCT05436262|f||||f
17194084|NCT05299073|f||||t
17194085|NCT03952338|f||||f
17194086|NCT04850898|f||||t
17194087|NCT05002088|f||OTHER|The sponsor will have the right to publish overall study results. Investigators may publish results from their respective participating site per their discretion but only after the multi-center publication is published or 12 months have passed from the study conclusion without a multi-center publication.|t
17194088|NCT04068181|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17194089|NCT05070728|f||||t
17194090|NCT03374241|f||||t
17194091|NCT04770402|t||||
17194092|NCT04197310|t||||
17194093|NCT04550221|f||||f
17194094|NCT04811040|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17194095|NCT05274074|f||||f
17194096|NCT01828099|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17194097|NCT05875467|f||||f
17194098|NCT03859635|f||||f
17194099|NCT04568434|f||OTHER||t
17194100|NCT03905798|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194101|NCT05446870|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194102|NCT05485779|f||OTHER|"The results of this study may be published or presented at scientific meetings. If foreseen, the PI agrees to submit all manuscripts or abstracts to the sponsor before submission.~The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data."|t
17194103|NCT03138603|t||||
17194104|NCT04515849|f||LTE60||t
17194105|NCT05370040|f||||t
17194106|NCT03272217|f||||f
17194107|NCT05095779|t||||f
17194108|NCT05205460|t||||
17194109|NCT05093842|f||||f
17194110|NCT03953417|t||||
17194111|NCT03987022|t||||
17194112|NCT06201559|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194113|NCT02887521|f||GT60||t
17194114|NCT02112526|f||||t
17194115|NCT03571581|t||||f
17194116|NCT03663569|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17194117|NCT05877976|t||||
17194118|NCT04248725|f||||f
17194119|NCT05622812|f||||t
17194120|NCT02844465|f||OTHER|PIs are required to submit proposals through the publication committee and receive approval from the publication committee before publishing results.|t
17194121|NCT04228042|t||||
17194122|NCT03819153|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17194123|NCT03397654|t||||
17194124|NCT03240016|t||||
17194125|NCT06176963|f||||t
17194126|NCT02317887|f||||t
17194127|NCT05452460|f||||f
17194128|NCT03680092|t||||
17149933|NCT02697773|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149934|NCT01118117|f||LTE60||t
17149935|NCT01448356|t||||
17194129|NCT04971031|f||||t
17194130|NCT04362254|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194131|NCT04642820|t||||
17194132|NCT05469464|f||||f
17194133|NCT01208662|f||||f
17194134|NCT00321048|t||||f
17194135|NCT04707625|f||||f
17194136|NCT06473662|f||||t
17194137|NCT03463044|f||||f
17194138|NCT05764525|f||||f
17194139|NCT03334630|f||OTHER|While the language in each agreement may vary slightly, in general it states that the Principal Investigator (PI) agrees to not independently discuss/publish trial results until a multi-center publication is released. If the multi-center publication is not submitted within one year after study completion across all centers, PIs may publish the results pertaining to their activities. PI must submit this request to the Sponsor for review/comment at least forty-five (45) days prior to submission.|t
17194140|NCT04252573|f||||f
17194141|NCT03404115|f||||t
17194142|NCT03030261|t||||
17194143|NCT04019977|f||||f
17194144|NCT03617679|t||||
17194145|NCT03910478|f||LTE60||t
17194146|NCT05293171|f||||f
17194147|NCT05133739|f||GT60||t
17194148|NCT04066205|f||||f
17194149|NCT02641639|f||||f
17194150|NCT06415292|f||||f
17194151|NCT04766892|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194152|NCT01712490|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17194153|NCT03478956|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194154|NCT04800211|f||||f
17194156|NCT04730739|f||||f
17194157|NCT05170841|f||LTE60||t
17194158|NCT03806790|f||OTHER|LEO Pharma A/S seeks publication of all phase 3 clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17194159|NCT05123586|f||GT60||t
17194160|NCT04865289|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194161|NCT04677738|f||||f
17194162|NCT04707469|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17194163|NCT02733159|f||||f
17194164|NCT05546385|f||||f
17194165|NCT06122194|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194166|NCT00291525|f||||f
17194167|NCT02724969|t||||f
17194168|NCT05121441|f||||f
17194169|NCT01309672|f||||f
17194170|NCT02397954|f||OTHER|Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.|t
17194171|NCT03626220|t||||
17194172|NCT03916185|f||||f
17194173|NCT05593900|f||||f
17194174|NCT05312008|f||||f
17194175|NCT04283149|f||OTHER|All data generated from the study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee are completed. The results of the study may be published or presented by the Investigator(s) after review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed. Prior to publication or presentation, a copy of the final text should be forwarded to Sponsor or designee for comment.|t
17194176|NCT03982459|t||||f
17194177|NCT03738852|f||||f
17194178|NCT04942613|t||||
17194179|NCT02593773|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17194180|NCT05446129|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194181|NCT05049850|f||||t
17194182|NCT06258174|f||GT60||t
17194183|NCT05934942|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194184|NCT02010242|f||LTE60||t
17194185|NCT04471246|f||||f
17194186|NCT04731129|t||||
17194187|NCT03386578|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17194188|NCT05907174|f||||f
17194189|NCT03916276|f||||f
17194190|NCT02668692|f||GT60||t
17194191|NCT04432506|t||||
17194192|NCT04567238|t||||
17194193|NCT01627574|f||||f
17194194|NCT03528928|f||||f
17194195|NCT05233800|f||||f
17194196|NCT05590728|f||LTE60||t
17194197|NCT03734679|f||OTHER|The PI agrees that no publication may be made until Publication of the results of the multi-center Study or 2 years after Study Completion, whichever is the sooner. The PI must give a copy of any proposed publication to the Sponsor at least 40 days prior to public release. The sponsor may provide comments on the proposed publication, which the PI will not be bound to follow them.|t
17194198|NCT04339101|t||||
17194199|NCT03249090|f||||f
17194200|NCT02432261|f||||f
17194201|NCT00915759|f||OTHER||t
17194202|NCT04200911|t||||
17194203|NCT04134208|t||||
17194204|NCT04726371|f||||f
17194205|NCT03362476|f||||f
17194206|NCT05974501|t||||f
17194207|NCT04270942|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17194208|NCT06081309|f||||f
17194209|NCT04386057|f||||f
17194210|NCT05679908|f||OTHER|An industry standard NDA is in place with all investigators.|t
17194211|NCT04295512|t||||
17194212|NCT04707326|f||||f
17194213|NCT02800356|f||||f
17194214|NCT03283722|f||||t
17194215|NCT05623228|f||||f
17194216|NCT04737330|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17194217|NCT04625725|t||GT60||t
17194218|NCT04884308|f||||f
17194219|NCT03298451|f||OTHER|Investigator agrees not to independently publish the results of the Study until first occurrence of one of the following: (i) multi-centre primary Publication is published; (ii) no multi-centre primary publication is submitted within two years after conclusion, abandonment, or termination of the Study at all sites; or (iii) Sponsor confirms in writing there will be no multi-centre primary Publication.|t
17194220|NCT03746106|t||||
17194221|NCT01651403|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17194222|NCT05873556|f||||f
17194223|NCT03381586|f||||t
17194224|NCT06214559|f||||f
17194225|NCT03812549|f||||f
17194226|NCT05299723|f||||f
17194227|NCT03220035|f||LTE60||t
17194228|NCT00696111|f||||f
17194229|NCT03162783|f||||t
17194230|NCT00248807|f||||f
17194231|NCT04447040|f||OTHER|Publication of study results by the Investigator is discussed in the Clinical Study Agreement, as appropriate. Results from this study may be published in the form of oral or written presentations at scientific meetings or as one or more peer-reviewed journal articles. In these cases, no information on individual subjects will be revealed.|t
17194232|NCT04076618|t||||
17194233|NCT01928394|f||GT60||t
17194234|NCT04433208|f||||f
17194235|NCT03208049|t||||
17194236|NCT02398656|t||||
17194237|NCT04299464|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194238|NCT03676192|f||OTHER||t
17194239|NCT04079218|t||||
17194240|NCT02694822|f||||t
17194241|NCT02424617|f||||t
17194242|NCT03841773|f||OTHER|An industry standard NDA is in place with all investigators.|t
17194243|NCT01868997|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights.|t
17194244|NCT02052882|t||||
17194245|NCT04778397|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17194246|NCT04870307|t||||
17194247|NCT05906784|t||||f
17194248|NCT03664700|f||||f
17194249|NCT04491617|t||||
17194250|NCT04036253|t||||
17194251|NCT01346540|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194252|NCT05061069|t||||f
17194253|NCT05147116|f||||f
17194254|NCT03672916|f||||f
17194255|NCT04197336|f||||f
17194256|NCT04585815|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194257|NCT00866684|f||||t
17194258|NCT03808961|t||||t
17149936|NCT02149121|f||OTHER|Investigators could publish any information whatsoever and/or any discussion relating to Sponsor, Confidential Information, Inventions or work performed by investigator for Sponsor with the prior written consent of Sponsor.|t
17149937|NCT03291041|f||||f
17194259|NCT04587453|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17194260|NCT03125070|f||||f
17194261|NCT04141891|f||||f
17194262|NCT05086796|f||||f
17194263|NCT02795858|t||||
17194264|NCT02573779|t||||
17194265|NCT04231331|f||||f
17194266|NCT05090683|f||||f
17194267|NCT03085719|t||||
17194268|NCT04032847|f||OTHER|Range of other disclosure agreements across study sites. Following multi-center publication of the Study results made by Sponsor, the Institution and/or Principal Investigator may publish data or results from the Study provided the Sponsor is given 45 to 90 days to review and/or make comments and suggestions where pertinent.|t
17194269|NCT03213665|f||LTE60||t
17194270|NCT03056573|f||LTE60||t
17194271|NCT04689256|t||||f
17194272|NCT04867278|t||||
17194273|NCT05104463|f||OTHER||t
17194274|NCT01885689|t||||
17194275|NCT04484428|f||||t
17194276|NCT05267470|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17194277|NCT03825588|t||||f
17194278|NCT04230681|t||||
17194279|NCT06149338|f||||f
17194280|NCT02433379|f||GT60||t
17194281|NCT02038777|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194282|NCT03743532|f||||f
17194283|NCT04533737|f||OTHER|LEO Pharma A/S seeks publication of all phase 3 clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17194284|NCT05705518|f||||f
17194285|NCT04294641|f||||f
17194286|NCT03643744|t||||
17194287|NCT04487860|f||||t
17194288|NCT06085547|f||||f
17194289|NCT05163496|f||||f
17194290|NCT04314778|f||||f
17194291|NCT05841004|f||LTE60||t
17194292|NCT04024020|t||||
17194293|NCT05646355|t||||
17194294|NCT04738591|f||||f
17194295|NCT03523572|f||||f
17194296|NCT05269966|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17194297|NCT05575219|t||||
17194298|NCT04685135|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication|t
17194299|NCT03519178|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194300|NCT05427253|f||||t
17194301|NCT02315703|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17194302|NCT02240238|f||||t
17194303|NCT04901078|f||||t
17194304|NCT03476343|t||||
17194305|NCT03088878|f||||f
17194306|NCT02657005|f||||f
17194307|NCT04506866|f||||f
17194308|NCT04911296|t||||
17194309|NCT06357169|t||||
17194310|NCT04083170|f||||t
17194311|NCT01221948|f||||f
17194312|NCT00746096|f||OTHER|There is an agreement between the sponsor and PI that no restricts the PI's right but need to discuss the timing of publish date of trial results after the trial is completed.|t
17194313|NCT04059185|f||||f
17194314|NCT03756662|f||||f
17194315|NCT04618315|f||||f
17194316|NCT03911141|t||||f
17194317|NCT03295721|f||||f
17194318|NCT04752657|t||||
17194319|NCT03325985|t||||
17194320|NCT04047602|t||||
17194321|NCT02684227|t||||
17194322|NCT03606408|f||||t
17194323|NCT03556293|f||||f
17194324|NCT00661141|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17194325|NCT05828017|t||||
17194326|NCT05012163|f||||f
17149938|NCT03166124|f||GT60||t
17194327|NCT05062330|f||||t
17194328|NCT05716763|f||OTHER|The results of this study are Unither-Pharmaceuticals proprietary and cannot be published or presented in any scientific meeting without any agreement from the sponsor.|t
17194329|NCT02567409|f||LTE60||t
17194330|NCT04132518|f||OTHER|The initial publication of data from the Study must be a multi-center publication. Any subsequent publication/presentation must be sent to Sponsor for review 60 days before submission for publication/presentation to allow Sponsor to protect patentable inventions/confidential information. Site and Investigator agree to amend proposed publication/presentation, remove such confidential information from it, or postpone submission for a further 60 days/until intellectual property filings take place.|t
17194331|NCT03092453|t||||
17194332|NCT05524402|f||||f
17194333|NCT04428203|t||||
17194334|NCT03703908|f||OTHER||t
17194335|NCT04180462|t||||
17194336|NCT03308877|t||||
17194337|NCT03397706|f||GT60||t
17194338|NCT05089877|f||||f
17194339|NCT04359654|t||||
17194340|NCT04267120|t||||
17194341|NCT05863156|t||||
17194342|NCT05216406|f||||f
17194343|NCT03617445|f||||f
17194344|NCT04690582|f||||f
17194345|NCT03711474|f||||f
17194346|NCT05487404|f||||t
17194347|NCT03625115|f||||f
17194348|NCT03221309|f||||f
17194349|NCT04101357|f||OTHER|Principal Investigators respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor.|t
17194350|NCT05868382|f||||t
17194351|NCT02497950|f||LTE60||t
17194352|NCT01236781|f||||f
17194353|NCT04028284|t||||
17194354|NCT05229822|t||||
17194355|NCT03314688|t||||
17194356|NCT00179400|f||||f
17194357|NCT04243070|f||||f
17194358|NCT01009788|t||||
17194359|NCT04308681|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194360|NCT05565820|f||LTE60||t
17194361|NCT02393885|f||OTHER||t
17194362|NCT00429364|f||OTHER|All publications and presentations resulting from studies from the PHN Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P\&P Committee along with Network Investigators. Members of the P\&P Committee can recommend changes to publications.|t
17194363|NCT04871529|f||LTE60||t
17194364|NCT04070573|t||||
17194365|NCT04003246|f||||t
17194366|NCT03914742|f||LTE60||t
17194367|NCT05237284|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data|t
17194368|NCT02950259|t||||
17194369|NCT05987072|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194370|NCT03733925|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194371|NCT03213873|t||||f
17194372|NCT00957047|f||OTHER||t
17194373|NCT02852655|f||||f
17194374|NCT03149822|t||||
17194375|NCT02834390|f||||f
17194376|NCT04544007|f||||t
17194377|NCT02998528|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194378|NCT06029452|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194379|NCT02413489|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194380|NCT04247802|t||||
17194381|NCT02575950|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194382|NCT03209973|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17194383|NCT05218096|f||||t
17194384|NCT05193409|f||||t
17194385|NCT00957684|f||OTHER||t
17194386|NCT04797195|f||||f
17194387|NCT04362085|f||||f
17194388|NCT04660539|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194389|NCT05256654|f||LTE60||t
17194390|NCT05167864|t||||
17194391|NCT06007781|f||OTHER||t
17194392|NCT03852550|f||||f
17194393|NCT05204654|f||||f
17194394|NCT02807545|f||||f
17194395|NCT05207982|f||||f
17194396|NCT04089059|f||||f
17194397|NCT04185246|f||LTE60||t
17194398|NCT03728608|t||||
17194399|NCT02329262|t||||
17194400|NCT05207956|f||||f
17194401|NCT02296684|t||||
17194402|NCT01254864|t||||
17194403|NCT03895996|f||LTE60||t
17194404|NCT06180980|f||GT60||t
17194405|NCT01828112|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17194406|NCT01188928|f||OTHER|Prior to submitting or presenting a manuscript relating to the clinical trial to a publisher, reviewer, or other outside person, the Investigator shall provide to LEO a copy of all such manuscripts, and LEO shall have rights to review and comment. Upon the request of LEO the Investigator shall remove any confidential information (other than results generated by the Investigator) prior to submitting or presenting the manuscripts.|t
17194407|NCT02945176|f||||f
17194408|NCT05244187|f||||f
17194409|NCT04410328|f||||f
17194410|NCT02446236|t||||
17194411|NCT05184452|f||||f
17194412|NCT05586490|f||||f
17194413|NCT04786119|f||LTE60||t
17194414|NCT05076266|f||LTE60||t
17194415|NCT05425420|t||||
17194416|NCT05280574|t||||
17194417|NCT04197869|t||||
17194418|NCT01385189|f||||f
17194419|NCT02361216|f||||t
17194420|NCT03505008|t||||f
17194421|NCT01730937|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17194422|NCT03980925|f||||f
17194423|NCT03367754|t||||
17194424|NCT01866163|f||OTHER|LEO acknowledges the investigators' right to publish the results of the trial, irrespective of outcome. Pubs/presentations by investigator(s) shall not be made before the results of a joint publication is public. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194425|NCT05130814|f||||f
17194426|NCT05848947|f||OTHER|Upon completion of the Study, Institution and Investigator may publish or present the Study Data subject to the following terms: a copy of any proposed publication or disclosure of the results of the Study will be given to the Sponsor for review at least thirty (30) days prior to the date of submission for publication (including abstracts) or of public disclosure.|t
17194427|NCT02988661|t||||
17194428|NCT04204083|f||OTHER|"INVESTIGATOR may publish the Data/Results with the consent of the SPONSOR if:~1. Publication is done after primary publication covering data from all participating sites, and provided the Data/Results do not contain any Confidential Information.~2. Eighteen (18) months has elapsed after entire completion of the Clinical Trial at all participating sites."|t
17194429|NCT06324344|f||||f
17194430|NCT04750538|t||||
17194431|NCT00780494|t||||
17194432|NCT03624465|f||||f
17194433|NCT03213678|f||LTE60||t
17194434|NCT04218851|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17194435|NCT03298945|t||||
17194436|NCT03702270|t||||
17194437|NCT05645757|f||LTE60||t
17194438|NCT03924635|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17194439|NCT00539591|t||||
17194440|NCT01960452|f||||f
17194441|NCT04414722|f||||f
17194442|NCT04249362|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17194443|NCT03655028|t||||
17194444|NCT03513302|f||||f
17194445|NCT05618587|f||||f
17194446|NCT03268382|f||||f
17194447|NCT03442309|t||||
17194448|NCT04862416|t||||
17194449|NCT04862234|t||||
17194450|NCT02584647|t||||
17194451|NCT03292484|f||OTHER|"* Institutions cannot publish until the multi-center sponsor publication is published~* Or, institutions cannot publish until 18 months after study completion~* And Sponsor review of any publications is required prior to any institution publications according to contractual agreements"|t
17194452|NCT05290493|f||||f
17194453|NCT05419830|f||||f
17194454|NCT03677141|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194455|NCT03018366|f||||f
17194456|NCT06038708|f||||f
17194457|NCT05838027|f||||f
17194458|NCT03550170|f||||f
17194459|NCT04056611|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194460|NCT02946736|f||||f
17194461|NCT02631746|f||LTE60||t
17194462|NCT04571619|f||||f
17194463|NCT05776875|t||||
17194464|NCT04709419|f||OTHER|All study records and results will be owned by the institution. Any medical records from the study will remain the property of the institution. The Institution is The University of Texas Southwestern Medical Center.|t
17194465|NCT05683340|f||||f
17194466|NCT02224144|t||||
17194467|NCT05046639|f||||f
17194468|NCT02962076|f||LTE60||t
17194469|NCT04741776|t||||f
17194470|NCT04089865|f||||f
17194471|NCT05482360|t||||
17194472|NCT04417998|t||||
17194473|NCT02780700|t||||f
17194474|NCT04622774|f||||t
17194475|NCT06397443|t||||
17194476|NCT03687762|f||||f
17194477|NCT03824366|t||||
17194478|NCT01449513|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194479|NCT04587024|f||||f
17194480|NCT04466098|t||||
17194481|NCT05069896|f||GT60||t
17194482|NCT04068831|t||||
17194483|NCT04820322|f||||f
17194484|NCT05395871|t||||
17194485|NCT00323856|f||OTHER|Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.|t
17194486|NCT04209595|f||||f
17194487|NCT03156465|t||||
17194488|NCT04200313|f||||f
17194489|NCT04380337|t||||
17194490|NCT04538378|f||||f
17194491|NCT05715528|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17194492|NCT05205486|f||OTHER|"Study data may be considered for reporting or publication. Sponsor will be responsible for these activities and may work with the investigators to determine how the manuscript is written, the number and order of authors, the journal, and other related issues. The sponsor has final approval authority over all such issues.~Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, which shall be in the sponsor's sole discretion."|t
17194493|NCT04214860|f||GT60||t
17194494|NCT03485729|f||OTHER|Within 12 months of the completion of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given the opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow the Sponsor to seek patent protection.|t
17194495|NCT00544414|t||||
17194496|NCT05035654|f||OTHER|Except as approved by Sponsor, single center data will not be published before multicenter data, unless \>1 year has elapsed since completion of the Study. PI may publish single center data provided that PI shall: i) provide a copy of the publication to Sponsor at least 60 days in advance of submission for publication; ii) delete Sponsor Confidential Information and make other reasonable changes; and iii) delay submission by up to 90 additional days to permit intellectual property filings.|t
17194497|NCT04880733|f||||f
17194498|NCT03812289|t||||
17194499|NCT04934072|f||||t
17194500|NCT02484430|f||LTE60||t
17194501|NCT03174275|f||OTHER|Results should be deferred until published.|t
17194502|NCT04456296|f||||t
17194503|NCT02997202|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.|t
17194504|NCT04874948|f||GT60||t
17194505|NCT04271046|f||||f
17194506|NCT00303459|f||LTE60||t
17194507|NCT01570361|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17194508|NCT04129554|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194509|NCT01146704|f||||f
17194510|NCT03309644|f||||f
17194511|NCT05571267|f||OTHER|No individual site or investigator may publish or present any results from the trial until a joint, multi-center publication of the trial results is made by Sponsor in conjunction with various participating investigators and appropriate sites contributing data and comments. Subsequently, individual investigators may request to publish or present results from the trial; however approval will be at the sole discretion of the Sponsor.|t
17194512|NCT03993392|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multicenter publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17194513|NCT01116895|f||OTHER|Individual publications or presentations of data by one or more Investigator(s) shall not be made before the results of the joint publication have been made public. The company retains the right to have any publication submitted to the company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194514|NCT05962814|t||||
17194515|NCT04826471|f||||f
17194516|NCT05270876|f||||t
17194517|NCT04304144|f||||t
17194518|NCT03804788|t||||
17194519|NCT04615273|f||||f
17194520|NCT05465239|f||||f
17194521|NCT03673501|f||||f
17194522|NCT04599634|f||||f
17194523|NCT03714815|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 30 days before submission for publication or presentation.|t
17194524|NCT04999111|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17194525|NCT03931408|t||||
17194526|NCT01314105|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194527|NCT02056834|f||LTE60||t
17194528|NCT06106022|f||OTHER|Principal investigators (PIs) are not permitted to publish the data. Data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the PIs to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority over all such issues.|t
17194529|NCT06193070|t||||
17194530|NCT03276676|t||||
17194531|NCT04753788|f||||f
17194532|NCT05015751|f||||f
17194533|NCT03926130|f||GT60||t
17194534|NCT03583333|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194535|NCT04469270|f||OTHER|The Study is part of a multi-center research study, and publication of the results of the Study conducted at the Site shall not be made before the first multi-center publication by Sponsor. If there is not a multi-center publication within eighteen (18) months after the Study has been completed or terminated at all Study sites, and all data has been received, Site shall have the right to publish its results from the Study, subject to the following notice requirements.|t
17194536|NCT05723575|t||||
17194537|NCT01569659|t||||
17194538|NCT04723147|t||||
17194539|NCT04086121|f||OTHER|"Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.~Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.~BI may request a delay of the publication in order to protect BI's intellectual property rights."|t
17194540|NCT04444518|f||||f
17194541|NCT04580914|f||||f
17194542|NCT03580356|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17194543|NCT01540994|t||||
17194544|NCT03118518|f||||t
17194545|NCT04393207|t||||
17194546|NCT03536884|f||GT60||t
17194547|NCT06197360|t||||f
17194548|NCT03489434|f||||f
17194549|NCT03331835|f||OTHER|The investigators have agreed to refrain from publishing based on data from this trial until the multi-center publication containing data from all sites has been published (usually after approx. 18 months). After this, any publication by individual investigators must be reviewed by the sponsor prior to submission. Sponsor has the right to remove any commercially confidential information and/or delay the publication up to 4 months to allow time for activities protecting intellectual rights.|t
17194550|NCT04667468|f||||f
17194551|NCT05791435|t||||
17194552|NCT05210569|t||||
17194553|NCT01726257|f||||f
17194554|NCT04750941|t||||
17194555|NCT04560595|f||||f
17194556|NCT03314740|f||||f
17194557|NCT02367040|f||LTE60||t
17194558|NCT05814211|f||LTE60||t
17194559|NCT04075318|f||||f
17194560|NCT05856435|f||||f
17194561|NCT02323880|f||OTHER|Must obtain prior sponsor approval|t
17194562|NCT03421340|f||||f
17194563|NCT05660434|t||||
17194564|NCT05424380|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194565|NCT02909686|f||||f
17194566|NCT03858517|f||||f
17194567|NCT05664958|f||||f
17194568|NCT04951076|f||||t
17194569|NCT01820611|f||||f
17194570|NCT05736458|f||||f
17194571|NCT02990338|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17194572|NCT00971087|f||LTE60||t
17194573|NCT04479761|f||||f
17194574|NCT04186819|f||||f
17194575|NCT04011644|t||||f
17194576|NCT05265065|t||||
17194577|NCT03252288|f||||f
17194578|NCT04574583|f||||f
17194579|NCT05900154|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194580|NCT04181736|t||||
17194581|NCT05080283|t||||
17194582|NCT04046094|f||||f
17194583|NCT02865538|f||OTHER|"The PI is required to postpone communication of results until a joint, multicenter publication of the multicenter study has occurred, or the sponsor confirms that no joint publication will be prepared, or 18 months since completion of the data analysis have passed.~The sponsor can review planned publications for up to 60 days and request reasonable amendments. The review period can be extended by up to 6 months in case a patent application is planned."|t
17194584|NCT03106740|f||||f
17194585|NCT04565990|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194586|NCT04797858|f||||f
17194587|NCT03229057|f||||f
17194588|NCT05423730|t||||
17194589|NCT01130519|f||||f
17194590|NCT05363163|f||||f
17194591|NCT00670241|f||||f
17194592|NCT04659603|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17194593|NCT02839265|t||||
17194594|NCT05552508|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB.|t
17194595|NCT06037668|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17194596|NCT04012931|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17194597|NCT05285137|f||OTHER||t
17194598|NCT03717935|f||||f
17194599|NCT04601480|t||||
17194600|NCT03484819|f||LTE60||t
17194601|NCT06435624|f||||f
17194602|NCT05493852|f||||f
17194603|NCT01199133|f||||f
17194604|NCT03988621|f||||f
17194605|NCT05013385|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194606|NCT03165786|t||||
17194607|NCT04629339|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17194608|NCT04938726|f||||f
17194609|NCT01447719|f||GT60||t
17194610|NCT03717753|t||||f
17194611|NCT03914469|t||||f
17194612|NCT05308979|f||||f
17194613|NCT04588415|f||||f
17194614|NCT03235440|t||||f
17194615|NCT03318159|f||||f
17194616|NCT01121588|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194617|NCT05408663|f||OTHER|Confidentiality Disclosure Agreement|t
17194618|NCT02938923|f||||f
17194619|NCT04332211|t||||
17194620|NCT04984590|f||||f
17194621|NCT04583280|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194622|NCT04068792|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194623|NCT03606512|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194624|NCT05513937|f||LTE60||t
17194625|NCT02846545|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194626|NCT06468982|f||||f
17194627|NCT03691298|f||LTE60||t
17194628|NCT04072861|f||||f
17194629|NCT02492711|f||LTE60||t
17194630|NCT05932407|f||||t
17194631|NCT05215613|f||LTE60||t
17194632|NCT03245840|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17194633|NCT03995979|f||||f
17194634|NCT04505410|t||||f
17194635|NCT01586910|f||||t
17194636|NCT03154190|f||||f
17194637|NCT03169972|f||||t
17194638|NCT02437136|f||OTHER|Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication.|t
17194639|NCT04117178|t||||
17194640|NCT04312841|t||||
17194641|NCT02827838|t||||
17194642|NCT05850052|t||||
17194643|NCT03640286|f||||t
17194644|NCT05524116|t||||f
17194645|NCT03181516|f||||f
17194646|NCT05405985|f||||t
17194647|NCT03635424|f||OTHER|Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) \& won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) \& its rights in patentable or copyrightable materials, \& check technical accuracy of MDT data. If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested.|t
17194648|NCT05533190|f||||f
17194649|NCT01917084|f||||f
17194650|NCT04227288|f||||f
17194651|NCT03938246|f||||f
17194652|NCT04451772|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17194653|NCT04167553|f||||f
17194654|NCT02787031|f||||f
17194655|NCT03254420|t||||
17194656|NCT05717400|t||||
17194657|NCT03631290|t||||
17194658|NCT02828358|f||LTE60||t
17194659|NCT05268276|t||||
17194660|NCT05224544|f||GT60||t
17194661|NCT04804540|f||||t
17194662|NCT05172232|t||||
17194663|NCT01828021|f||||f
17194664|NCT00844415|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17194665|NCT02473445|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17194666|NCT04881461|f||OTHER|No publication can be made before the first multi-center publication. PI shall allow Sponsor (S) no less than 60 days to review publications and presentations. S can comment and require removal of confidential information. Upon S request, PI must delay the publication or presentation for 6 months to permit S to file a patent application or take other steps to protect S' information. Any other public statements regarding the trial requires prior written consent from S.|t
17194667|NCT03015532|f||||f
17194668|NCT05970861|t||||
17194669|NCT05100628|f||LTE60||t
17194670|NCT03866837|t||||
17194671|NCT00677365|f||||f
17194672|NCT05422885|f||||f
17194673|NCT00758862|f||OTHER|The Company acknowledges the investigator's right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194674|NCT03655080|t||||
17194675|NCT02542631|f||LTE60||t
17194676|NCT02641730|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17194677|NCT00319046|f||LTE60||t
17194678|NCT00721149|f||OTHER|The PI is allowed to publish but must submit draft publication(s) to Biosense Webster, Inc. at least 30 days prior to submission for publication or presentation.|t
17194679|NCT01240122|t||||
17194680|NCT00631475|f||OTHER|Actelion, with steering committee, shall complete the review and provide any modifications required to protect Actelion's patent rights and confidential information within sixty (60) days of receipt of the proposed publication. During this period, Investigator shall not permit publication. If Actelion reasonably anticipates filing a patent application claiming an invention arising out of the Study, such publication shall be delayed until after the application is filed.|t
17194681|NCT05158504|f||||f
17194682|NCT05652010|f||OTHER||t
17194683|NCT04923776|t||||
17194684|NCT04817176|f||||f
17194685|NCT04707768|f||OTHER||t
17194686|NCT02518048|f||OTHER|Before submitting or presenting a manuscript about the clinical trial to a third party, the investigator shall give LEO a copy of any such manuscript, and LEO has the right to review and comment. Upon the request of LEO, the investigator shall remove any confidential information before submitting or presenting a manuscript. To allow LEO to protect its inventions and other intellectual property rights, the publication or presentation can be delayed.|t
17194687|NCT04678856|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17194688|NCT04282980|f||||t
17194689|NCT05860114|f||||f
17194690|NCT03571386|f||||f
17194691|NCT04311632|f||OTHER|The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor can require changes; and in those instances, the publication shall be resubmitted to the sponsor and will have an additional 30 days for review.|t
17194692|NCT04605159|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194693|NCT02278211|f||OTHER|It is agreed that the Co-Sponsors shall publish the results of the full Study and that the Site and the Site Principal Investigator shall not publish the results of the Study carried out at the Site without the prior permission in writing from Edinburgh (which shall not be unreasonably withheld) and in any case not prior to the publication of the results of the full Study.|t
17194694|NCT04158739|f||OTHER|Must obtain prior sponsor approval|t
17194695|NCT04778410|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17194696|NCT02944968|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17194697|NCT02905331|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194698|NCT01385202|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17194699|NCT03681262|t||||
17194700|NCT04370834|f||LTE60||t
17194701|NCT04102111|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194702|NCT02782676|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17194703|NCT04614948|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17194704|NCT04055012|t||||
17194705|NCT05633147|f||||t
17194706|NCT03663205|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17194707|NCT02326974|f||||f
17194708|NCT02577354|f||||f
17194709|NCT05043064|f||||f
17194710|NCT04924400|t||||
17194711|NCT04424316|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194712|NCT04265807|f||||f
17194713|NCT00412607|f||OTHER|Please contact Biosense Webster for additional information.|t
17194714|NCT06609486|t||||
17194715|NCT04109066|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194716|NCT05864040|f||||f
17194717|NCT05741294|f||||t
17194718|NCT04325815|f||||f
17194719|NCT04675034|f||OTHER|AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17194720|NCT04163991|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17194721|NCT04078152|f||OTHER||t
17194722|NCT02510235|f||||f
17194723|NCT05890105|t||||
17194724|NCT03367156|t||||
17194725|NCT05507437|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17194726|NCT04276935|t||||
17194727|NCT04084574|t||||
17194728|NCT00942877|f||||f
17194729|NCT04502186|f||||f
17194730|NCT00887198|f||OTHER|A copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17194731|NCT03334695|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17194732|NCT05007080|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17194733|NCT02874742|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194734|NCT04442165|f||||t
17194735|NCT01950234|t||||
17194736|NCT02561611|f||||f
17194737|NCT04801368|t||||
17194738|NCT06603766|f||||f
17194739|NCT05070741|f||||f
17194740|NCT03582033|f||||t
17194741|NCT03812614|t||||f
17194742|NCT05205161|f||OTHER|No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca AB. Access to this document must be restricted to relevant parties.|t
17194743|NCT04763772|t||||
17194744|NCT04214418|f||OTHER|Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.|t
17194745|NCT02637609|f||||f
17194746|NCT02293954|t||||
17194747|NCT00450216|f||OTHER|PI reserves the right to publish or otherwise make public the Study results provided that such communication occurs only after (i) the results of the multicenter Study in its entirety have been publicly disclosed by, or with consent of the sponsor or (ii) 18 months after conclusion of the Study at all sites, whichever comes first. Following this, PI can publish, present or use any non-confidential study results following Sponsor review. PI will not make public raw data or Case Reports.|t
17194748|NCT04206787|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194749|NCT05008055|t||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17194750|NCT05117008|t||||
17194751|NCT04635059|t||||
17194752|NCT03011034|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17194753|NCT03419052|t||||
17194754|NCT04099732|t||||
17194755|NCT05123027|f||||f
17194756|NCT03735979|f||||f
17194757|NCT05958927|f||||f
17194758|NCT00319111|f||OTHER|Results from multi-center studies must be published or presented at congresses only in their entirety and not as individual center data, except for ancillary studies. Any study-related article or abstract written independently by investigators should be submitted to Actelion for review at least 60 days prior to submission for publication or presentation.|t
17194759|NCT04807777|f||OTHER|"Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor-investigator.~Any investigator involved with this study is obligated to provide the sponsor-investigator with complete test results and all data derived from the study."|t
17194760|NCT04743973|t||||
17194761|NCT05654662|f||OTHER|HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17194762|NCT03165955|f||||f
17194763|NCT06412965|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194764|NCT04499521|f||||f
17194765|NCT03990883|f||||t
17194766|NCT05505578|f||||f
17194767|NCT04427007|t||||
17194768|NCT04633278|f||OTHER|The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the Sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.|t
17194769|NCT05247034|t||||
17194770|NCT03505710|f||||f
17194771|NCT05735652|t||||
17194772|NCT04536012|t||||
17194773|NCT04389957|t||||
17194774|NCT03778801|f||||f
17194775|NCT06356285|t||||
17194776|NCT06655818|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194777|NCT05147584|f||||f
17194778|NCT05460871|t||||
17194779|NCT03967379|f||||f
17194780|NCT03329937|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17194781|NCT04664959|f||||t
17194782|NCT01223352|f||OTHER|The only agreement between the sponsor and the investigators is that any study-related article or abstract written independently by investigators must be submitted to the sponsor for review at least 60 days prior to submission for publication or presentation.|t
17194783|NCT04623775|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194784|NCT00964392|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17149939|NCT01398839|t||OTHER|All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.|t
17149940|NCT01699763|t||||
17194785|NCT05960032|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194786|NCT03969563|t||||f
17194787|NCT01474122|f||OTHER||t
17194788|NCT03652272|f||||f
17194789|NCT04173247|t||||
17194790|NCT05985382|f||||f
17194791|NCT04214834|f||||f
17194792|NCT04947137|f||||t
17194793|NCT03901534|f||||f
17194794|NCT03884101|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194795|NCT03370913|f||LTE60||t
17194796|NCT05883345|t||||
17194797|NCT06097494|f||||f
17194798|NCT05683158|f||||f
17194799|NCT00640822|f||OTHER|The Company acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194800|NCT03248479|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years."|t
17194801|NCT04679389|t||||
17194802|NCT05112900|f||||f
17194803|NCT05541484|f||||f
17194804|NCT05386589|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17194805|NCT03279978|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194806|NCT05525104|t||||
17194807|NCT04479514|t||||
17194808|NCT03636490|f||||f
17194809|NCT03489122|t||||
17194810|NCT04464564|f||||f
17194811|NCT05891275|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194812|NCT05374538|f||||f
17194813|NCT02095691|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17194814|NCT03498521|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17194815|NCT03188692|f||OTHER||t
17194816|NCT02163694|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17194817|NCT04633538|t||||
17194818|NCT05061017|t||||
17194819|NCT02938520|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17194820|NCT05275556|f||OTHER|PIs may publish, but there are limitations to protect confidential information and/or allow the sponsor to publish first.|t
17194821|NCT03372057|f||||f
17194822|NCT05953740|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments|t
17194823|NCT03880955|f||||f
17194824|NCT04567316|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194825|NCT03003533|f||||t
17194826|NCT04564209|t||||
17194827|NCT05257603|f||||f
17194828|NCT02361658|t||||
17194829|NCT03771612|f||||f
17194830|NCT05334355|t||||f
17194831|NCT04024059|f||||f
17194832|NCT05496140|t||||
17194833|NCT05698368|t||||
17194834|NCT02911805|t||||
17194835|NCT05954546|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194836|NCT01438853|f||||t
17194837|NCT02624050|t||||
17194838|NCT05215054|f||||f
17194839|NCT01536938|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194840|NCT04330040|f||OTHER|The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.|t
17194841|NCT03745716|f||LTE60||t
17194842|NCT00626795|f||OTHER|The Company acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submit-ted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194843|NCT04159519|f||OTHER|This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.|t
17194844|NCT05305560|f||OTHER|The PI can present and discuss the results but publication is subject to the sponsor's prior approval|t
17194845|NCT03998488|t||||
17194846|NCT02246127|f||||f
17194847|NCT04998305|f||||f
17194848|NCT05311176|f||||t
17194849|NCT01880515|f||||f
17194850|NCT04734197|f||||t
17194851|NCT01144455|f||||f
17194852|NCT06262347|f||||f
17194853|NCT01746979|f||||f
17194854|NCT05512650|f||||f
17194855|NCT03364127|t||||
17194856|NCT05830799|f||||t
17194857|NCT05757193|t||||
17194858|NCT04819191|f||||f
17194859|NCT04560179|f||||f
17194860|NCT04602611|t||||
17194861|NCT04631016|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17194862|NCT06010836|t||||
17194863|NCT04496752|t||||
17194864|NCT02506673|t||||
17194865|NCT04524689|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17194866|NCT04967599|t||||
17194867|NCT04369911|t||||
17194868|NCT05451693|t||||
17194869|NCT03662022|f||||t
17194870|NCT03681912|f||||f
17194871|NCT04490109|f||OTHER|Sponsor shall have 60 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional 90 days to enable Sponsor to seek patent protections.|t
17194872|NCT04323397|f||||f
17194873|NCT03884439|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194874|NCT03904576|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194875|NCT04780581|f||||f
17194876|NCT01756300|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17194877|NCT00503971|f||||f
17194878|NCT05592223|f||||f
17194879|NCT04704869|t||||
17194880|NCT05836012|f||||t
17194881|NCT03817983|t||||
17149941|NCT05368012|t||||
17149942|NCT03943537|t||||
17149943|NCT04974619|f||||f
17194882|NCT03744676|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17194883|NCT03333915|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights|t
17194884|NCT01768013|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17194885|NCT05990335|f||||f
17194886|NCT05454514|f||||f
17194887|NCT05785130|t||||
17194888|NCT03351998|f||||f
17194889|NCT02785991|f||||f
17194890|NCT02461134|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17194891|NCT04761198|f||OTHER|All PIs must seek written permission from the sponsor before publication of any trial results.|t
17194892|NCT03533257|f||||f
17194893|NCT05886452|t||||
17194894|NCT03250676|f||||f
17194895|NCT03587805|f||OTHER|The sponsor seeks publication of all clinical trials in peer-reviewed journals within 12 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by the sponsor within these 12 months, the investigator has the right to publish the results from clinical trial generated by him/herself.|t
17194896|NCT04626427|f||||f
17194897|NCT01651000|f||LTE60||t
17194898|NCT03982186|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17194899|NCT02765412|t||||
17194900|NCT03697408|t||||
17194901|NCT04244175|f||||t
17194902|NCT04595331|f||OTHER||t
17194903|NCT03781089|t||||
17194904|NCT05020353|f||||f
17194905|NCT06024642|f||LTE60||t
17194906|NCT05448014|t||||
17194907|NCT06237686|f||||t
17194908|NCT04310423|f||||f
17194909|NCT05265871|t||||
17194910|NCT05985395|t||||f
17194911|NCT03601897|f||||t
17194912|NCT02777593|f||||f
17194913|NCT04107116|f||||f
17194914|NCT03547271|f||OTHER|The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17194915|NCT04835363|f||||f
17194916|NCT06065735|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17194917|NCT02532621|f||OTHER|"The results proposed to be published or presented shall be submitted to Sponsor for review and comment at least 45 days prior to submission to allow Sponsor to protect its rights to any patentable inventions disclosed and to permit Sponsor to request removal of any Confidential Information provided by Sponsor.~Any such publication or presentation shall acknowledge, as appropriate, the contribution of Sponsor, its employees, agents and representatives."|t
17194918|NCT03522298|f||LTE60||t
17194919|NCT02360371|f||||f
17194920|NCT04795245|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17194921|NCT02919917|f||||f
17194922|NCT03418740|f||||f
17194923|NCT05933772|f||OTHER||t
17194924|NCT04881110|f||||f
17149944|NCT00493779|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149945|NCT01475253|f||OTHER||t
17149946|NCT00836719|t||||f
17149947|NCT02148913|t||||
17149948|NCT02678442|t||||
17149949|NCT02834806|f||||f
17149950|NCT01045993|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after the disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149951|NCT05506358|f||||f
17149952|NCT01659736|t||||f
17149953|NCT00391079|f||OTHER|GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications for example, manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.|t
17149954|NCT01004042|t||||
17149955|NCT03301532|t||||f
17149956|NCT00262041|f||GT60||t
17149957|NCT03633448|f||||f
17149958|NCT02384941|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17149959|NCT00971737|t||||
17149960|NCT00252174|t||||
17149961|NCT02025010|f||||t
17149962|NCT00949988|t||||
17149963|NCT03714555|t||||
17149964|NCT00484419|f||OTHER|"Sponsor reflects the following restrictive language in the Clinical Study Agreements: If identified by DSI, any of DSI's confidential information as defined herein shall be deleted…Nothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site."|t
17194925|NCT04157517|f||||t
17194926|NCT02933489|f||||f
17194927|NCT02994927|f||OTHER|The PI shall provide Sponsor with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor shall have 60 days to review the proposed publication. Sponsor may request in writing, and the PI shall agree to, (a) the deletion of any Confidential Information, (b) any reasonable changes requested by Sponsor, or (c) a delay of such proposed submission for an additional period, not to exceed 90 days.|t
17194928|NCT04281498|t||||
17194929|NCT03417284|t||||
17194930|NCT05132400|f||||f
17194931|NCT00640978|t||||f
17194932|NCT02076009|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17194933|NCT04243759|f||||f
17194934|NCT00449748|t||||
17194935|NCT03076021|f||||f
17194936|NCT01897441|t||||
17194937|NCT06229119|t||||
17194938|NCT00329836|t||||
17194939|NCT03875339|f||||f
17194940|NCT04093869|t||||
17194941|NCT04177771|f||||t
17194942|NCT02806726|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.|t
17194943|NCT05129501|f||||f
17194944|NCT04166513|t||||
17194945|NCT05866926|f||LTE60||t
17194946|NCT05267639|t||||
17194947|NCT02047500|f||||f
17194948|NCT05419856|f||OTHER|The INSTITUTION and the INVESTIGATOR may not use any information other than publicly available information regarding the Study in any publicity and advertising without SPONSOR's prior written consent and ethics committee approval.|t
17194949|NCT03816397|f||||f
17194950|NCT04198701|f||GT60||t
17194951|NCT05718687|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17194952|NCT03493542|f||OTHER|If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17194953|NCT05485935|f||GT60||t
17194954|NCT04731233|f||||f
17194955|NCT03839446|t||||
17194956|NCT04342260|t||||
17194957|NCT01527188|f||||f
17194958|NCT04549792|f||||f
17194959|NCT01265537|f||||f
17194960|NCT03782116|t||||
17194961|NCT03512301|t||||f
17194962|NCT00447980|f||||t
17194963|NCT03952520|t||||
17194964|NCT03635567|f||OTHER|The Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement. If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17194965|NCT05157841|f||OTHER|"Disclosure restrictions include:~* PIs or any other party are not allowed to publish any publication for a period of twelve months following completion of the clinical study report for the trial.~* PIs or any other party shall submit a proposal to the Sponsor for approval to obtain trial results that have not been previously made public and any publication, abstract or paper or other written materials to the trial shall be submitted to the Sponsor at least 60 days prior to submission."|t
17194966|NCT03237377|f||||f
17194967|NCT04933474|f||||f
17194968|NCT04174170|f||||f
17194969|NCT00324415|f||||f
17149965|NCT05212883|t||||
17194970|NCT03944915|f||||f
17194971|NCT05441683|f||||f
17194972|NCT00942734|t||||
17194973|NCT02765854|t||||
17194974|NCT06664684|f||||f
17194975|NCT05292222|t||||
17194976|NCT05966766|t||||
17194977|NCT04908930|f||||f
17194978|NCT04586244|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17194979|NCT04494958|f||||f
17194980|NCT05771467|f||||f
17194981|NCT03520114|f||||f
17194982|NCT01220531|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.|t
17194983|NCT04873232|f||OTHER|There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|t
17194984|NCT05047952|t||||
17194985|NCT02325154|t||||
17194986|NCT00709956|f||||f
17194987|NCT03008382|t||||
17194988|NCT03698669|t||||f
17194989|NCT05372042|f||||f
17194990|NCT00983307|t||||
17194991|NCT01612351|t||||
17194992|NCT03801616|t||||
17194993|NCT02611687|f||OTHER||t
17194994|NCT03873805|t||||
17194995|NCT03983382|t||||
17194996|NCT04165213|f||||f
17194997|NCT04726410|f||||f
17194998|NCT05377411|t||||
17194999|NCT05643196|t||||
17195000|NCT04772534|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17195001|NCT04194450|t||||
17195002|NCT05858905|f||||t
17195003|NCT03718130|f||||f
17195004|NCT04282109|f||||f
17195005|NCT03340428|f||||f
17195006|NCT04098276|f||||f
17195007|NCT02954809|t||||
17195008|NCT02295891|f||||f
17195009|NCT03242915|f||OTHER|"* Participating Sites agree not to publish or publicly present the Study Data or Study Results until Michigan or Michigan's Principal Investigator have first Published the Study Data or Study Results~* All Study Data and Results generated by the Participating Site will be owned by Participating Site~* Sponsors have the right to review and comment on any Public Presentation as defined by the contract~* Other limitations outline within the contract"|t
17195010|NCT05988398|f||||f
17195011|NCT05109871|t||||
17195012|NCT04276779|f||||f
17195013|NCT01992913|t||||
17195014|NCT02831283|t||||
17195015|NCT03872466|t||||
17195016|NCT01778686|f||||f
17195017|NCT01499368|f||||f
17195018|NCT06059443|f||||f
17195019|NCT03092674|f||LTE60||t
17195020|NCT01105091|f||||f
17195021|NCT03934931|f||||f
17195022|NCT05002738|t||||
17195023|NCT04227899|f||GT60||t
17195024|NCT06102421|t||||
17195025|NCT02989662|f||||f
17195026|NCT00328783|t||||
17195027|NCT00357682|f||||f
17195028|NCT03228719|t||||
17195029|NCT05769634|t||||
17195030|NCT04408755|f||||f
17195031|NCT02726386|f||OTHER|The sponsor must review and approve any results of the study or abstracts for professional meetings prepared by the investigator(s). Published data must not compromise the objectives of the study. Data from individual study centers in multicenter studies must not be published separately.|t
17195032|NCT00308997|t||||
17195033|NCT04955431|f||||f
17195034|NCT04490356|t||||
17195035|NCT03733626|t||||
17195036|NCT03907982|t||||
17195037|NCT05424718|f||OTHER|Any presentation, abstract, or manuscript will be made available for review by the study sponsor(s) prior to submission|t
17195038|NCT03142009|t||||
17195039|NCT03696433|t||||
17195040|NCT01553149|f||LTE60||t
17195041|NCT01607853|f||OTHER|The sponsor is entitled to review and comment on publications prior to submission or presentation. Upon request of the sponsor, the investigator shall delay publication or presentation to allow for protection of the sponsors inventions and other intellectual property.|t
17195042|NCT03875001|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195043|NCT03215706|f||LTE60||t
17195044|NCT00945724|f||||f
17195045|NCT00994643|t||||
17195046|NCT04300127|f||||f
17195047|NCT05412004|f||GT60||t
17195048|NCT00968149|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195049|NCT02719574|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.|t
17195050|NCT06336967|f||||f
17195051|NCT02720068|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.|t
17195052|NCT00495677|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195053|NCT05441449|t||||
17195054|NCT03786926|f||||t
17195055|NCT01167010|f||OTHER||t
17195056|NCT05875701|f||OTHER||t
17195057|NCT00704769|f||OTHER||t
17195058|NCT04174560|f||LTE60||t
17195059|NCT02823327|f||||f
17195060|NCT04712903|f||||t
17195061|NCT04889989|f||OTHER|Sponsor shall have the first right to publish the study data. If publication of the study data by the Sponsor has not occurred within eighteen (18) months of study completion/termination, the PI may publish the results from the PI his/her site individually. The PI should provide the Sponsor with at least thirty (30) days for review of the publication.|t
17195062|NCT04046549|f||OTHER|Horizon requests that any investigator/institution that plans on presenting/publishing results provide written notification of their request 60 days prior to their presentation/publication. Horizon requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Horizon needs to secure patent or proprietary protection.|t
17195063|NCT04012567|f||LTE60||t
17195064|NCT04319887|f||OTHER|"PI may publish their site's results if:~* Multi-center results are published, unless authorized by Sponsor. If multi-center results are not submitted within 12 months of clinical trial conclusion, PI may publish their results; AND~* Provide Sponsor 60 days to review. If Sponsor response not received within 60 days, PI may publish. If Sponsor determines the proposed publication contains confidential or patentable information, Sponsor may delay publication for up to 90 days from discovery."|t
17195065|NCT04386746|t||||
17195066|NCT05495945|t||||
17195067|NCT04529616|f||||t
17195068|NCT05073510|f||OTHER|The results and data obtained in the Clinical Trial shall be the exclusive property of the Sponsor, who reserves the right to use the results of this Trial to submit them to the authorities of any country.|t
17195069|NCT03109873|t||||
17195070|NCT06202560|t||||f
17195071|NCT03705793|t||||f
17195072|NCT03027128|f||||t
17195073|NCT03094052|t||||
17195074|NCT00113360|t||||f
17195075|NCT02454283|f||||f
17195076|NCT02467270|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17195077|NCT01969916|f||||f
17195078|NCT04632394|t||||
17195079|NCT02988193|f||||f
17195080|NCT02299349|t||||
17195081|NCT04129164|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17195082|NCT03868930|t||||
17195083|NCT06065501|f||||f
17195084|NCT03286114|t||||
17195085|NCT03694262|f||||f
17195086|NCT01773993|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195087|NCT04664881|t||||
17195088|NCT02231749|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195089|NCT03820544|t||||
17195090|NCT01380743|f||OTHER|The investigator can only publish the results from this trial provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review. If requested, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication for an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17195091|NCT04868656|t||||
17195092|NCT02656706|f||||f
17195093|NCT03725332|t||||
17195094|NCT06017115|f||||f
17195095|NCT05707351|f||||t
17195096|NCT01996436|t||||
17195097|NCT02951052|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195098|NCT04227600|f||||t
17195099|NCT05545280|t||||
17195100|NCT03891758|f||OTHER||t
17195101|NCT00650078|f||OTHER|The first publication shall be the presentation of a joint, multicenter publication of the Study results. If such a multicenter publication is not submitted within 24 months after conclusion of the Study at all sites, INSTITUTION/INVESTIGATOR may publish the results from the INSTITUTION'S site individually, provided that it is submitted to SPONSOR for review and comment 60 days prior to submission for publication.|t
17195102|NCT05672017|f||||f
17195103|NCT05517902|f||||t
17195104|NCT01513122|f||OTHER|"There is a Clinical Trial Agreement signed with each PI detailing the publication policy and disclosure of study's information, in summary:~The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor, except for the purposes of internal training Publications or presentations of results from the Study will follow the agreement's publication/presentation guidelines"|t
17195105|NCT05795153|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195106|NCT05207033|f||||f
17195107|NCT04644029|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.|t
17195108|NCT00739908|f||OTHER|The investigators were informed that the first publication or disclosure of study results shall be a complete, joint multicenter publication or disclosure coordinated by CeNeRx. Thereafter, any secondary publications will reference the original publication(s).|t
17195109|NCT03875313|f||OTHER|No publication by the PI before either a multi-site publication or 18 months after final multi-site study report. PI can only publish their own results and provide 45 days in advance notice. PI must delete any Calithera confidential information from the publication other than study results and give good faith consideration to other comments made by Calithera. The PI must delay the publication for up to 45 days if requested by Calithera and publicly acknowledge Calithera and Pfizer support.|t
17195110|NCT04121546|f||||f
17195111|NCT01864538|f||||f
17195112|NCT06203990|f||||f
17195113|NCT01046825|f||OTHER|MSA states Site is unable to publish until all completed case report forms have been delivered to Sponsor, (Study Completion). Site shall have the right to publish after publication of a multi-center publication coordinated by the Sponsor or (12) mths. after Study Completion; provided, that prior to any such publication or public release of such data, Site shall furnish Sponsor with a copy of any proposed publication at least (45)days in advance of the proposed publication or presentation date.|t
17195114|NCT03304418|t||||
17195115|NCT02075554|f||OTHER|PI may release for publication with Sponsor's prior approval.|t
17195116|NCT00624442|f||OTHER|Sponsor intends to publish the results of the trial in collaboration with the Investigators.|t
17195117|NCT02757898|t||||
17195118|NCT04993677|f||||t
17195119|NCT04899778|f||||f
17195120|NCT01318694|f||OTHER||t
17195121|NCT00003222|t||||
17195122|NCT03248492|f||||f
17195123|NCT02224729|t||||
17195124|NCT03767335|f||OTHER|The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17195125|NCT03705390|f||OTHER|"The Clinical Centre shall not publish or otherwise disseminate the conclusions of the Study, including all or any part of the Results of the Study without the prior written consent of the Sponsor, such consent not to be unreasonably withheld or delayed. Any publication or other dissemination of the conclusions of the Study by the National Health Organisation (NHS) Organisation shall not' occur until the Sponsor has published the conclusions of the Study.~Results published- PubMed ID: 38990927"|t
17195126|NCT05988957|f||||f
17195127|NCT04495621|f||OTHER|The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.|t
17195128|NCT06199986|t||||
17195129|NCT04757753|f||||f
17195130|NCT01313559|t||||
17195131|NCT02514915|t||||
17195132|NCT03910218|t||||
17195133|NCT02752685|t||||
17195134|NCT03201939|f||||f
17195135|NCT00391443|f||OTHER|Actelion, with steering committee, shall complete the review and provide any modifications required to protect Actelion's patent rights and confidential information within sixty (60) days of receipt of the proposed publication. During this period, Investigator shall not permit publication. If Actelion reasonably anticipates filing a patent application claiming an invention arising out of the Study, such publication shall be delayed until after the application is filed.|t
17195136|NCT04079517|t||||
17195137|NCT04908514|f||||t
17195138|NCT05501548|t||||
17195139|NCT05362474|t||||
17195140|NCT05180539|f||||f
17195141|NCT03779984|t||||
17195142|NCT02566889|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17195143|NCT04518943|t||||
17195144|NCT03699163|f||||f
17195145|NCT00124735|f||OTHER|Any scientific paper, presentation, or other communication concerning the clinical trial described in the protocol will first be submitted to Organon, at least 6 weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.|t
17195146|NCT00630487|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17195147|NCT04599296|f||||f
17195148|NCT06995755|f||||f
17195149|NCT03598998|t||||
17195150|NCT02701283|f||OTHER|Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) \& won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) \& its rights in patentable or copyrightable materials, \& check technical accuracy of MDT data. If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested.|t
17195151|NCT04591080|t||||
17195152|NCT05856266|f||||f
17195153|NCT01830595|t||||
17195154|NCT04940624|f||||t
17195155|NCT02382003|t||||
17195156|NCT04479787|f||LTE60||t
17195157|NCT06637774|t||||
17195158|NCT04959812|f||||f
17195159|NCT02379351|f||||f
17195160|NCT05039021|f||OTHER|Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.|t
17195161|NCT03373916|f||||f
17195162|NCT03653364|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17195163|NCT00686595|f||OTHER|"Investigator agrees not to publish or publicly present any of the~study results without prior written authorization from sponsor, except than for the dispositions provided in the Minister's Decree and Ministerial Circular. Investigator agrees to provide 45 days written notice to sponsor prior to submission for publication or presentation to permit sponsor to review copies of abstracts/manuscripts for publication (including text for oral presentations) which report any study results."|t
17195164|NCT05288348|f||||f
17195165|NCT03213457|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195166|NCT04261790|t||||
17195167|NCT05934292|f||OTHER|The sponsor must have the opportunity to review all manuscripts or abstracts before submission. Any information identified by the sponsor as confidential must be deleted prior to submission.|t
17195168|NCT02586974|t||||
17195169|NCT05714059|f||OTHER|PI agrees not to publish until 12 months from trial completion or until sponsor publishes multi-center results, whichever occurs first. In either case, sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period more than 60 days but less than or equal to 180 days from the date that the communication is submitted to sponsor for review. Sponsor cannot require changes to the communication and cannot extend the embargo.|t
17195170|NCT04899674|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195171|NCT03774472|t||||
17195172|NCT05155306|t||||
17195173|NCT05648890|f||||f
17195174|NCT05116774|f||||t
17195175|NCT03150862|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17195176|NCT03857646|t||||
17195177|NCT04158141|f||OTHER|PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.|t
17195178|NCT03850899|t||||
17195179|NCT04056910|t||||
17195180|NCT04505722|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.|t
17195181|NCT04755595|f||||f
17195182|NCT00319696|f||OTHER|Any study-related article or abstract written independently by investigators should be submitted to Actelion for review at least 60 days prior to submission for publication or presentation.|t
17195183|NCT02206828|f||||t
17195184|NCT04977583|t||||
17195185|NCT02422615|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17195186|NCT01639131|f||||f
17195187|NCT02524769|t||||
17195188|NCT04098575|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195189|NCT05274321|t||||f
17195190|NCT01105975|f||GT60||t
17195191|NCT00195403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195192|NCT06003075|t||||
17195193|NCT02956642|t||||f
17195194|NCT00410423|t||||
17195195|NCT00087685|t||||
17195196|NCT05018143|f||||f
17195197|NCT04018495|f||||f
17195198|NCT04059406|f||||t
17195199|NCT05601882|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195200|NCT04121741|f||||f
17195201|NCT03473223|f||||t
17195202|NCT03524092|f||GT60||t
17195203|NCT03834740|f||||f
17195204|NCT00115934|f||||f
17195205|NCT03997474|f||OTHER|Range of other disclosure agreements across study sites. Following multi-center publication of the Study results made by Sponsor, the Institution and/or Principal Investigator may publish data or results from the Study provided the Sponsor is given 45 to 90 days to review and/or make comments and suggestions where pertinent.|t
17195206|NCT05617300|f||||f
17195207|NCT03183050|f||||f
17149966|NCT00102687|f||OTHER|The investigator shall have the right to publish and/or present study data provided that the investigator shall (i)furnish the sponsor a copy of any proposed publication or presentation generally thirty (30) days in advance of the submission, (ii) delete any confidential information of the sponsor, and (iii) delay submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications or until sponsor gives its consent in a timely manner.|t
17195208|NCT00754065|f||OTHER|The Institution and/or Principal Investigator shall furnish the Sponsor with a copy of any proposed publication material at least sixty (60) days in advance of the date of submission for publication or presentation so that the proposed publication may be edited appropriately to remove any confidential information before publication or the Sponsor shall have sufficient additional time (not to exceed sixty (60) days) to file a patent application for such Confidential Information.|t
17195209|NCT03776812|f||OTHER|No individual publications will be allowed before publication of the multicenter results except as agreed with Corcept. The Investigator agrees to submit all manuscripts or abstracts to Corcept for review before submission to the publisher.|t
17195210|NCT03053960|t||||
17195211|NCT02348632|f||OTHER|The sponsor can review trial results communications prior to public release and can embargo such communications for a period of at least 60 days from the time submitted to sponsor for review. If requested by sponsor, the PI will withhold publication for up to an additional 30 days. Furthermore, the first publication of study results must be a joint publication of all study sites unless a joint manuscript has not been submitted for publication within 12 months of completion of the study.|t
17195212|NCT01171976|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17195213|NCT06688357|f||||f
17149967|NCT03847194|f||||f
17149968|NCT03176784|f||||f
17195214|NCT02879318|f||||f
17195215|NCT03222609|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195216|NCT01084863|f||||t
17195217|NCT04305327|f||OTHER|LEO Pharma A/S seeks publication of all clinical trials in peer-reviewed journals within 18 months after completion or termination of the clinical trial, regardless of whether the findings are positive or negative. If no publication is submitted by LEO Pharma A/S within these 18 months, the investigator has the right to publish the results from the clinical trial generated by him/herself.|t
17195218|NCT00743951|f||||f
17195219|NCT03275285|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17195220|NCT06191679|f||||f
17195221|NCT03656718|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195222|NCT03211247|f||OTHER||t
17195223|NCT02039401|f||||f
17195224|NCT06284941|t||||
17195225|NCT05747599|f||||f
17195226|NCT05827068|f||||t
17195227|NCT00353496|f||||f
17195228|NCT04980300|f||||f
17195229|NCT01347255|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17195230|NCT05709860|t||||
17195231|NCT02278185|f||||f
17195232|NCT01470144|f||GT60||t
17149969|NCT01652976|t||||
17195233|NCT01663363|f||OTHER|The agreement between the Principal Investigator and the Sponsor (or its agents) restricts the PI's rights to discuss or publish trial results until after the trial is completed and requires prior approval from the sponsor.|t
17195234|NCT03459196|f||OTHER|There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.|t
17195235|NCT02325466|f||OTHER||t
17195236|NCT01074294|f||OTHER|Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.|t
17195237|NCT01925144|f||GT60||t
17195238|NCT02284113|f||LTE60||t
17195239|NCT03885232|f||||f
17195240|NCT01315132|t||||
17195241|NCT03260569|f||||f
17195242|NCT03840902|f||||t
17195243|NCT03660930|t||||
17195244|NCT03509909|f||||f
17195245|NCT03433794|f||||f
17195246|NCT03593356|f||||f
17195247|NCT05139992|f||OTHER|ASH Research Collaborative Clinical Trial Network Participation Agreement executed between ASH Research Collaborative (Sponsor) and participating PIs \& Institutions contains disclosure language.|t
17195248|NCT01208974|t||||
17195249|NCT05521516|f||||f
17195250|NCT03777657|f||OTHER|BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \& may request a further delay to protect its IP rights.|t
17149970|NCT03739138|f||OTHER|If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17195251|NCT02500576|t||||
17195252|NCT06229106|f||||f
17195253|NCT03399500|f||||f
17195254|NCT03691493|f||||f
17149971|NCT02646917|f||||f
17195255|NCT03867201|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195256|NCT01983683|f||OTHER|Any study-related publication written independently by investigators must be submitted to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights.|t
17195257|NCT05365997|f||||f
17195258|NCT05464732|t||||
17195259|NCT03400150|f||OTHER||t
17195260|NCT05501600|f||||f
17195261|NCT05357989|f||OTHER|The terms and conditions of Annovis Bio's agreements with its investigators may vary. However, Annovis Bio does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data for a clinical trial or for 12 months.|t
17195262|NCT04039113|f||OTHER|The Investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.|t
17195263|NCT05786612|f||||f
17195264|NCT04926740|f||||f
17195265|NCT04538352|t||||
17195266|NCT04528459|t||||
17195267|NCT05787054|f||||f
17195268|NCT02377700|f||||f
17195269|NCT00655499|f||||f
17195270|NCT01078909|t||||
17195271|NCT03140670|t||||
17195272|NCT00220805|f||OTHER|The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.|t
17195273|NCT00146172|f||LTE60||t
17195274|NCT03684590|f||||f
17195275|NCT01288443|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17195276|NCT01596972|f||||f
17195277|NCT04327843|f||||f
17195278|NCT00176800|t||||
17195279|NCT01964300|f||||f
17195280|NCT00557492|t||||
17195281|NCT02438137|t||||
17195282|NCT02285270|t||||
17195283|NCT04868617|f||OTHER|The results of the investigation, may be communicated by abstracts, posters, or oral presentations provided that opportunity is given for sponsor to discuss the contents and any conclusions drawn, before the abstract, paper, or visual presentations are finalized. Sponsor will undertake to comment on the draft documents within 30 working days of receipt, but the final decision on the contents and format of the publication from the conclusions drawn, will remain with the authors.|t
17195284|NCT00623194|f||OTHER|Novo Nordisk reserves the right not to release data until specified milestones, e.g., a Clinical Trial Report is available. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between authors and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.|t
17195285|NCT01260896|f||OTHER|The Principal Investigator is not permitted to discuss or publish trial results.|t
17195286|NCT00312208|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17195287|NCT03744559|f||||f
17195288|NCT00982644|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17195289|NCT00909649|t||||f
17195290|NCT00943917|f||OTHER|Sponsor has the right to submit multicenter results within 12 months after completion of the study. Thereafter, PI may publish the results of its data after submitting advance copy of the planned publication to sponsor. PI to agree to sponsor changes regarding deletion of confidential information, reasonable changes, or a delay of up to 90 days for patent purposes.|t
17195291|NCT02844439|f||||f
17195292|NCT04614454|f||||f
17195293|NCT04612244|f||||f
17195294|NCT03170648|f||||f
17195295|NCT03500549|f||||t
17195296|NCT02754596|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of data from this study.|t
17195297|NCT02107261|f||||t
17195298|NCT04337931|f||LTE60||t
17195299|NCT02431273|f||||f
17195300|NCT04436289|f||||f
17195301|NCT06456723|t||||
17195302|NCT03357952|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17195303|NCT01371994|f||OTHER|Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data, or 18 months after data lock, whichever occurs first. Sponsor must receive a site's manuscript at least 30 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.|t
17195304|NCT03280030|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.|t
17195305|NCT00747565|f||OTHER|PIs may not publish or disclose study data without Sponsor's prior written approval.|t
17195306|NCT05120856|f||||f
17195307|NCT00319020|f||OTHER|Any study-related article or abstract written independently by investigators should be submitted to Actelion for review at least 60 days prior to submission for publication or presentation.|t
17195308|NCT00227266|f||||f
17195309|NCT04153890|f||||f
17195310|NCT00593840|t||||
17195311|NCT05246709|t||||
17195312|NCT02414633|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17195313|NCT01637402|t||||f
17195314|NCT02111096|f||GT60||t
17195315|NCT03709706|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17195316|NCT00609869|t||||
17195317|NCT01627561|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195318|NCT00698867|f||OTHER|A publication which uses data in addition to the authors will be reviewed by all who have contributed data, and all of the contributors will be recognized. All publications will be reviewed by BIOMET at least 30 days prior to publication.|t
17195319|NCT00890591|f||||f
17195320|NCT03455985|f||||f
17195321|NCT01579318|f||LTE60||t
17195322|NCT02797132|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17195323|NCT02347332|f||||f
17195324|NCT01970007|f||GT60||t
17195325|NCT03878979|f||||f
17195326|NCT01816971|t||||
17195327|NCT00112359|f||OTHER|Institution and investigator may publish or present the results of the trial generated there with prior written consent of Gilead; or 2 years after the trial has ended at all institutions. Proposed publications/target venue must go to Gilead 30 days (manuscripts) or 15 days (abstracts/presentations) prior. Any Gilead confidential information in the document(s) must be deleted, or if requested publication delayed for up to 45 days to permit Gilead to obtain intellectual property protection.|t
17195328|NCT01961609|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17195329|NCT01988402|t||||
17195330|NCT01262339|f||||f
17195331|NCT00582972|f||||f
17195332|NCT00588406|t||||
17195333|NCT01566890|f||||f
17195334|NCT03983434|f||||f
17195335|NCT00588471|t||||f
17195336|NCT04004325|f||OTHER|At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property|t
17195337|NCT01357512|f||||f
17195338|NCT01211184|t||||f
17195339|NCT00822120|f||||f
17195340|NCT01324310|f||OTHER|There IS an agreement between the Principal Investigator and the Sponsor that restricts the PIs rights to publish trial results after the trial is completed. Upon investigator submission of a publication to Celgene, Celgene will complete its review within 60 days after receipt of the publication. Upon Celgene's request, the publication shall be delayed up to 90 additional days to enable Celgene to secure intellectual property protection that would be affected by such proposed publication.|t
17195341|NCT02999763|f||||f
17195342|NCT04060212|t||||
17195343|NCT04027439|f||||f
17195344|NCT03664011|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17195345|NCT01693822|f||OTHER|There is an agreement between principal investigators and the Sponsor (or its agents) that restricts the PIs rights to discuss or publish trial results after the trial is completed.|t
17195346|NCT00317720|t||||f
17195347|NCT02787005|f||OTHER|The Sponsor must have had the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must have been deleted prior to submission; this confidentiality did not include efficacy and safety results. Sponsor review could be expedited to meet publication timelines.|t
17195348|NCT03736564|t||||f
17195349|NCT00979121|f||OTHER|sponsor can review results communications prior to public release and can embargo communications regarding trial results until presented at the American Thoracic Society international meeting.|t
17195350|NCT02016872|t||||
17195351|NCT03029286|f||||f
17195352|NCT03477175|f||||t
17195353|NCT03593226|f||OTHER|The restrictions are as per the signed agreement with each PI and institution.|t
17195354|NCT00545545|f||LTE60||t
17195355|NCT05507970|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication and remove information and/or data that may impair the Sponsor's ability to obtain patent protection.|t
17195356|NCT05019742|f||||f
17195357|NCT03978637|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17195358|NCT03959423|f||GT60||t
17195359|NCT02549352|f||OTHER|LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.|t
17195360|NCT05048394|f||||f
17195361|NCT04530487|t||||
17195362|NCT03876457|t||||
17195363|NCT01184326|f||||t
17195364|NCT01036724|f||||f
17195365|NCT01617369|f||LTE60||t
17195366|NCT00557284|f||||f
17195367|NCT02432300|t||||
17195368|NCT01211106|f||||f
17195369|NCT04213807|f||OTHER|Investigator agrees that no submission for publication or public disclosure by the Investigator will be made until after publication of the results of the Multicenter Trial, except as set forth in the clinical trial agreement. If, however, there is no multicenter publication within eighteen (18) months after completion or termination of the Study, Investigator may publish or publicly present the Study Data in accordance with the clinical trial agreement.|t
17195370|NCT01574716|f||OTHER||t
17195371|NCT01411137|f||||f
17195372|NCT00692913|f||OTHER|The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts,or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.|t
17195373|NCT03801148|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17195374|NCT04334317|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17195375|NCT03621735|t||||
17195376|NCT03614663|f||GT60||t
17195377|NCT01128595|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195378|NCT00605306|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195379|NCT00372775|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195380|NCT00575016|f||LTE60||t
17195381|NCT01149759|f||||f
17195382|NCT00336505|f||OTHER||t
17195383|NCT01561300|f||||f
17195384|NCT03234374|f||||f
17195385|NCT00724126|f||GT60||t
17195386|NCT01929291|t||||
17195387|NCT02502526|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17195388|NCT01952366|f||||f
17195389|NCT00571649|f||GT60||t
17195390|NCT01421667|f||LTE60||t
17195391|NCT00503906|t||||
17195392|NCT01387516|t||||
17195393|NCT01913314|f||GT60||t
17195394|NCT00859781|t||||
17195395|NCT04057820|f||||f
17195396|NCT04517435|t||||
17195397|NCT02415127|f||OTHER|Horizon requests that any Investigator/institution that plans on presenting or publishing results provide written notification of their request a minimum of 60 days prior to presentation or publication. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsors' Intellectual Property rights .|t
17195398|NCT04032106|f||||f
17195399|NCT04882917|f||||t
17195400|NCT02678689|f||OTHER|The only disclosure restrictions on the PI are that (i) they cannot publish results communications until after the multicenter dataset is published, (ii) the sponsor has an opportunity to review results communications prior to public release, and (iii) the sponsor can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days.|t
17195401|NCT03160885|f||OTHER|LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.|t
17195402|NCT02761187|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17195403|NCT02307682|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17195404|NCT05630833|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17195405|NCT03905694|f||OTHER|It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A separate publication by Institution or PI may not be submitted for publication until after this primary manuscript is published or following 12 months after completion of the study. A copy of any proposed publication based on this study, must be provided and confirmed received at the Sponsor at least 30 days before its submission.|t
17195406|NCT03170349|f||||t
17195407|NCT04551066|f||OTHER|Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.|t
17195408|NCT05529992|f||||t
17195409|NCT04207736|f||||t
17195410|NCT05747014|f||OTHER|PIs may publish as long as publications are provided to Medtronic for review at least 60 days prior to submission or presentation. Additionally, PIs will not independently publish, publicly disclose, present or discuss any Study results until a multi-center publication is released. If a multi-center publication is not released within one year after completion PIs will have the right to publish the results of and information pertaining to their activities on the Study.|t
17195411|NCT02896907|t||||
17195412|NCT00536120|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17195413|NCT02760654|f||||f
17195414|NCT02967458|t||||
17195415|NCT01084694|t||||
17195416|NCT00290537|t||||f
17195417|NCT00945321|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195418|NCT02633215|f||||f
17195419|NCT04017611|t||||
17195420|NCT03406325|f||||f
17195421|NCT02291913|f||GT60||t
17195422|NCT00351299|t||||
17195423|NCT04876417|f||||f
17195424|NCT02866942|t||||
17195425|NCT00439270|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195426|NCT01268306|f||||f
17195427|NCT01970410|f||||f
17195428|NCT02568215|f||||f
17195429|NCT00246805|f||OTHER|should INVESTIGATOR contemplate publishing/presenting, he shall provide copies of any abstracts, papers, or manuscripts to sponsor for review at least 30 days prior to submittal for publication or presentation. Sponsor shall limit its review to a determination of whether Confidential Information is disclosed and to check for technical correctness and shall not attempt to censor or in any way interfere with PARTICIPATING INSTITUTION's or INVESTIGATOR's presentation or conclusions|t
17195430|NCT00293397|t||||
17195431|NCT01218009|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data|t
17195432|NCT00174252|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of \< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195433|NCT03170882|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.|t
17195434|NCT03802994|t||||f
17195435|NCT04023175|f||||f
17195436|NCT01753999|t||||
17195437|NCT02392234|f||OTHER|PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.|t
17195438|NCT02029235|t||||
17195439|NCT01738438|t||||
17195440|NCT02928172|f||||f
17195441|NCT04066075|f||||f
17195442|NCT00309166|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195443|NCT00701701|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17195444|NCT03224481|t||||
17195445|NCT03789110|t||||
17195446|NCT01855750|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17195447|NCT04300023|t||||
17195448|NCT05525572|t||||
17195449|NCT04057131|f||||t
17195450|NCT03425682|f||||f
17195451|NCT05140902|t||||
17195452|NCT05890794|f||OTHER|The PI may publish the study results but must submit the publication to the sponsor for review at least 60 days prior to publication. The sponsor may request changes/removals of sponsor information. The PI should remove such information if the correct presentation of the results is still ensured. The PI must consider the sponsor's other comments but must not adopt them. If publication could affect the patentability of the invention, the sponsor may request an additional period of up to 120 days.|t
17195453|NCT03277989|f||||f
17195454|NCT03436992|f||||f
17195455|NCT05704725|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17195456|NCT03227861|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17195457|NCT03516942|f||LTE60||t
17195458|NCT00085982|t||||
17195459|NCT00490139|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195460|NCT03301467|f||OTHER|The PI shall provide Sponsor with an advance copy of any proposed publication or oral presentation at least 60 days prior to the planned date of submission or presentation and Sponsor shall have 60 days to review the proposed publication. Sponsor may request in writing, and the PI shall agree to, (a) the deletion of any Confidential Information, (b) any reasonable changes requested by Sponsor, or (c) a delay of such proposed submission for an additional period, not to exceed 90 days.|t
17195461|NCT02798471|f||||f
17195462|NCT05293717|t||||
17195463|NCT04989816|f||||f
17195464|NCT01982682|t||||
17195465|NCT00712179|f||||f
17195466|NCT00065182|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195467|NCT00754325|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17195468|NCT01143142|t||||
17195469|NCT00145587|t||||
17195470|NCT01750684|f||OTHER|Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.|t
17195471|NCT00702884|t||LTE60||t
17195472|NCT02185794|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17195473|NCT01092416|f||OTHER|Any previously unpublished information provided to the Investigators by the Sponsor is confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study not use it for other purposes without the Sponsor's written consent. An Investigator can generate additional publication ideas based on the trial data. The Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data.|t
17195474|NCT00366249|f||OTHER|The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.|t
17195475|NCT00777049|f||||f
17195476|NCT03478969|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17195477|NCT01185600|f||||f
17195478|NCT02941549|f||||t
17195479|NCT01214759|t||||
17195480|NCT01436175|f||OTHER|If a multi-centre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multi-centre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17195481|NCT01410409|f||||f
17195482|NCT03577106|t||||f
17195483|NCT00635700|f||||f
17149972|NCT04403763|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17149973|NCT01376310|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17149974|NCT00176631|t||||
17149975|NCT01553201|t||||f
17149976|NCT02743728|t||||
17149977|NCT04070287|f||||f
17149978|NCT00594620|t||||
17195484|NCT03601715|t||||
17195485|NCT00123409|t||||f
17195486|NCT00918333|t||||
17195487|NCT01119755|t||||
17195488|NCT01313884|t||||
17195489|NCT00263757|t||||f
17195490|NCT01342367|t||||f
17195491|NCT02964741|f||||f
17195492|NCT00640159|f||||f
17195493|NCT01500200|f||OTHER|Should an Investigator desire to disclose study results, Sponsor will review the results disclosure prior to public release and can embargo the disclosure for a period of at least 60 days. Revisions to the disclosure will be negotiated in good faith. For a multicenter study the Investigators agree to publish/publicly present the results together with the other sites for the 12 month period after study results are available unless Sponsor grants written permission in advance.|t
17195494|NCT00455650|f||||f
17195495|NCT04860505|t||||
17195496|NCT01209195|f||LTE60||t
17195497|NCT00647400|f||OTHER|Disclosure agreements vary; the Medical Institution shall not disclose any material/information disclosed by Abbott Japan in connection with the Clinical Research or information obtained by conducting the Clinical Research to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting Clinical Research, Institution shall obtain Abbott Japan's prior written approval.|t
17195498|NCT01212744|f||GT60||t
17195499|NCT02167451|t||||
17195500|NCT01218659|f||OTHER|The investigator can publish only the results from this trial, provided they supply the sponsor (or authorized entity) a copy of any proposed publication for review prior to submission for publication. If requested and prior to publication, the investigator will remove information deemed confidential or proprietary by the sponsor and will withhold publication an additional period of time to allow the sponsor to take appropriate measures to establish and preserve its proprietary rights.|t
17195501|NCT02555306|f||||f
17195502|NCT03066609|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17195503|NCT00135200|t||||
17195504|NCT00909324|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195505|NCT04124432|f||||f
17195506|NCT00523419|f||GT60||t
17195507|NCT03496545|t||||
17195508|NCT01437319|f||GT60||t
17195509|NCT01499849|f||||f
17195510|NCT00811941|f||OTHER|The main publication has to be published before any sub publication. The investigators shall obtain Lundbeck's written approval before publishing any publication relating to nalmefene, the Study, the Protocol and/or the results recorded during the Study.|t
17195511|NCT03938337|t||||
17195512|NCT00622700|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17195513|NCT03611556|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17195514|NCT00482911|f||||f
17195515|NCT02313675|f||||f
17195516|NCT00645359|t||||
17195517|NCT00972621|f||OTHER|At least ninety (90) days prior to any proposed submission for publication or presentation of Study Data or other findings related to the Study, Institution will provide Sponsor with a manuscript of such submission(s) for review, comment, and approval.|t
17195518|NCT02078648|f||||f
17195519|NCT04088227|f||||f
17195520|NCT01675492|f||OTHER|The sponsor must review results communications prior to public release and can embargo communications regarding trial results at any time.|t
17195521|NCT01162096|t||||
17195522|NCT03485287|f||||f
17195523|NCT03762850|f||OTHER||t
17195524|NCT03083366|f||||f
17195525|NCT03668899|f||||f
17195526|NCT04406272|t||||
17195527|NCT02036970|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17195528|NCT00979459|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.|t
17195529|NCT02298842|f||OTHER|Sponsor retains the right to review and comment on any public disclosure of study results. If no response is received within 30 days,the Principal Investigator may presume that the submission for publication may proceed without delay. If the Sponsor asks to defer publication, Study Site shall not publish, or otherwise disclose to any third party, any of the information contained in the publication or presentation until such time as permission is granted from the Sponsor.|t
17195530|NCT02386098|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17195531|NCT04503681|f||||f
17195532|NCT03352713|f||||f
17195533|NCT01812759|t||||
17195534|NCT00360269|f||||f
17195535|NCT02351791|t||||
17195536|NCT00753337|f||OTHER|Medtronic has a legitimate interest in ensuring that a multi-center publication is the first publication to be released regarding the completed Study. The Institution agrees that it will not publish or disclose any results of or information pertaining to the study until a multi-center publication is released. If a publication is not released within one year after completion of the study, the Institution will have the right to publish information pertaining to their activities conducted.|t
17195537|NCT03849937|f||||f
17195538|NCT03437733|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17195539|NCT00210106|t||||
17195540|NCT00825344|f||||f
17195541|NCT01675063|f||OTHER|The PI is not involved with the ultimate analysis of the data which is to be used for proprietary algorithm development. The PI was engaged with his opinion on algorithm development and review of waveform data.|t
17195542|NCT02186509|t||||
17195543|NCT02261805|t||||
17195544|NCT05405244|t||||
17195545|NCT00739934|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195546|NCT03418922|f||||t
17195547|NCT03451422|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17195548|NCT03355573|f||GT60||t
17195549|NCT01567605|f||||f
17195550|NCT02534285|t||||
17195551|NCT04191824|t||||
17195552|NCT03631407|f||OTHER|The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission.|t
17195553|NCT01378416|f||||f
17195554|NCT01201772|f||||f
17195555|NCT02646618|f||||f
17195556|NCT00390884|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17195557|NCT03304587|f||||f
17195558|NCT04187573|f||||f
17195559|NCT01458366|t||||f
17195560|NCT02397096|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17195561|NCT05580003|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17195562|NCT04795167|f||GT60||t
17195563|NCT02052440|f||||f
17195564|NCT05051982|t||||
17195565|NCT03333109|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17195566|NCT04474496|t||||
17195567|NCT01447706|f||LTE60||t
17195568|NCT00918203|f||GT60||t
17195569|NCT02788019|t||||
17195570|NCT00589875|f||||f
17195571|NCT00258830|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.|t
17195572|NCT03488719|f||||f
17195573|NCT05025384|f||||f
17195574|NCT03610581|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.|t
17195575|NCT02868970|f||||f
17195576|NCT05637970|f||||f
17195577|NCT01713660|f||OTHER|"Clinical Trial Agreement including Neither Institution nor Principal Investigator shall have any right to publish or present any information or results concerning the Study without express written consent of Sponsor. Under no circumstances shall Institution or Principal Investigator publish or disclose any of Sponsor's proprietary information, as defined by the CDAs, without Sponsor's prior written approval."|t
17195578|NCT05162261|f||OTHER||t
17195579|NCT05885763|f||||t
17195580|NCT05485805|f||OTHER||t
17195581|NCT01586104|t||||
17195582|NCT04218357|f||||f
17195583|NCT05349838|f||||f
17195584|NCT05075395|t||||
17195585|NCT02488408|f||||t
17195586|NCT03110575|f||OTHER|An industry standard NDA is in place with all investigators.|t
17195587|NCT04701203|f||||f
17195588|NCT06140290|t||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17149979|NCT00767520|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17149980|NCT00958126|f||OTHER|CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17149981|NCT00720226|f||||f
17149982|NCT03401073|f||||f
17149983|NCT01481740|f||||f
17149984|NCT00733369|f||OTHER|DePuy reserves the right to review the contents of publications in advance.The PI may freely disclose the trial results only after DePuy has been given the opportunity of reviewing the proposed results communications at least 30 days prior to the intended release.DePuy will advise the PI of any perceived errors,omissions or corrections but the PI will retain final editorial control.In case of disagreement,DePuy and the PI will make every effort to meet in order to discuss and resolve any issues.|t
17149985|NCT00279955|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred."|t
17149986|NCT02510014|f||OTHER|Proposed publications shall be submitted to Sponsor 30 days prior to submission for publication, and may be withheld for an additional period, up to 90 days, to allow Sponsor to file patent applications. If a multi-center publication isn't submitted for publication within 12 months of the conclusion of the Study at all sites, or is published in a shorter period, the results from the institution's site may be published individually.|t
17149987|NCT01343095|t||||
17149988|NCT01875471|f||GT60||t
17149989|NCT00654654|f||OTHER|Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval prior to publication or presentation in any form.|t
17149990|NCT04179019|f||||f
17149991|NCT02083926|f||||f
17149992|NCT02610816|f||||t
17149993|NCT01949116|f||||f
17149994|NCT04079127|f||||f
17149995|NCT03438227|t||||
17149996|NCT00049842|f||OTHER|No public presentation/publication of any interim results will be made by any principal investigator (PI) or any other member of the study staff without the Sponsor's prior written consent. The PI further agrees to provide to the sponsor 30 days prior to submission, review copies that report any results of the study. The sponsor shall have the right to review, comment, and edit. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues/disagreement.|t
17149997|NCT01813071|f||||f
17149998|NCT00613834|f||||f
17149999|NCT00842530|f||OTHER|Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications|t
17150000|NCT01251978|t||||
17150001|NCT02939950|f||OTHER|Please contact Sponsor directly for additional information.|t
17150002|NCT00486018|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150003|NCT01660022|f||GT60||t
17150004|NCT02409329|f||||f
17150005|NCT04400760|f||||f
17150006|NCT00766831|f||||f
17150007|NCT00788593|f||OTHER|Restrictions vary in accordance with each agreement with the individual investigators. Sponsor will allow publication after a multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and can defer publication for a period of time to allow for Sponsor to obtain patent or other intellectual property right protection.|t
17150008|NCT03020719|f||||f
17150009|NCT00754468|f||||f
17150010|NCT00787020|f||||f
17150011|NCT04553913|t||||
17150012|NCT00094094|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150013|NCT00710749|f||GT60||t
17150014|NCT04583163|t||||
17150015|NCT06357286|t||||
17150016|NCT01000610|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150017|NCT03740113|f||||f
17150018|NCT04843566|t||||f
17150019|NCT04963569|t||||
17150020|NCT02631876|f||||t
17150021|NCT01592721|f||||f
17150022|NCT00784524|f||||f
17150023|NCT02277704|f||OTHER|An industry standard NDA is in place with all investigators.|t
17150024|NCT01408563|t||||
17150025|NCT01432574|t||||
17150026|NCT02516410|f||OTHER|Restriction Description: PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or (3)18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications|t
17150027|NCT00996931|t||||f
17150028|NCT04051684|t||||
17150029|NCT06141824|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150030|NCT00666848|t||||f
17150031|NCT00735917|f||LTE60||t
17150032|NCT02698865|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150033|NCT03861481|f||GT60||t
17150034|NCT00773734|f||OTHER|Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 days. Investigator must delete confidential information before submission or defer publication to permit patent applications.|t
17150035|NCT02473783|f||||t
17150036|NCT01220297|f||||f
17150037|NCT01287039|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17150038|NCT00099268|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17150039|NCT05016622|t||||
17150040|NCT01237353|t||||f
17150041|NCT02581163|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150042|NCT03438396|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 12 months but less than 18 months from the end of study (database lock). The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17150043|NCT02006628|f||GT60||t
17150044|NCT01421342|t||||
17150045|NCT03578237|t||||
17150046|NCT02488330|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150047|NCT03738020|f||OTHER||t
17150048|NCT01642914|f||OTHER|"All data generated in this trial will be the property of Forest Research Institute, Inc. and Ironwood Pharmaceuticals, Inc. An integrated clinical and statistical report will be prepared at the completion of the trial.~Publication of the results by the Investigator will be subject to mutual agreement between the Investigator, Ironwood Pharmaceuticals, Inc., and Forest Research Institute, Inc."|t
17150049|NCT01705236|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17150050|NCT00171301|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17150051|NCT04319159|f||OTHER|It is understood that no results or data shall be independently published by the Principal Investigator, the Institution, or its other Representatives prior to Sponsor's approval. The Principal Investigator may publish the results of his or her investigative findings under the Study to the extent they are included in the individual Study publication or as part of a comprehensive publication.|t
17150052|NCT02100319|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17150053|NCT02370914|f||||f
17150054|NCT00296491|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150055|NCT01300052|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150056|NCT03451006|t||||
17150057|NCT01929395|t||||
17150058|NCT03604341|t||||
17150059|NCT02312713|f||||f
17150060|NCT00897949|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150061|NCT01553747|f||OTHER|The sponsor will work with the Investigators to determine how any manuscript or publication in a scientific journal is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. The sponsor has final approval authority over all such issues. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.|t
17150062|NCT01341587|f||||f
17150063|NCT02990806|f||||f
17150064|NCT00466726|f||||f
17150065|NCT02470091|f||OTHER|Must obtain prior sponsor approval|t
17150066|NCT01829919|f||OTHER||t
17150067|NCT02903238|f||||f
17150068|NCT00700817|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17150069|NCT01338987|f||||f
17150070|NCT00489281|t||||
17150071|NCT00606502|f||OTHER|Allos agreements with investigators (PIs) may vary. The PI may publish/make public data from the study after the earlier of publication by Allos or 24 months after database lock. Allos is allowed 60 days to review and comment on the communication prior to public release. Allos can request removal of confidential information (other than study results).|t
17150072|NCT02854059|f||OTHER|All MS must be sent to Sponsor for review at least 60d before submission. Sponsor may request changes. All reasonable comments will be incorporated by Investigator. If MS contains info that could impact proprietary or IP interests, the Sponsor is entitled to request a 6 mth publication delay, allowing actions to protect its interests. The Investigator/Trust shall not unreasonably withhold or delay its consent to such request from the Sponsor or for an exceptional additional delay if requested.|t
17150073|NCT02480582|f||||f
17150074|NCT01470612|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150075|NCT05012865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from the study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150076|NCT01770431|f||GT60||t
17150077|NCT03407118|f||GT60||t
17150078|NCT02556307|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150079|NCT01510652|f||LTE60||t
17150080|NCT00384176|f||OTHER|If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.|t
17150081|NCT00854373|t||||
17150082|NCT00307931|f||OTHER|UCB has \> 60 days but \<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17150083|NCT00515034|f||GT60||t
17150084|NCT01392326|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17150085|NCT02508259|f||||f
17150086|NCT00965055|t||||
17150087|NCT04141696|t||||
17150088|NCT05626803|f||||t
17150089|NCT00493246|f||OTHER|The Investigator may publish 18 months after Cadence's final evaluation of all study data from all sites, whichever occurs first.Manuscripts/abstracts will be provided to Cadence for review and comment at least 30 days prior to submission.Cadence shall have 30 days to respond with comments.|t
17150090|NCT05506930|t||||
17150091|NCT05017974|t||||
17150092|NCT02054130|f||OTHER|MedImmune has 60 days to review results communications prior to public release and may delete information that compromises on-going studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.|t
17150093|NCT00094458|f||GT60||t
17150094|NCT00834652|f||||f
17150095|NCT04943159|f||||f
17150096|NCT01011075|f||GT60||t
17150097|NCT02017860|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17150098|NCT00946348|f||||f
17150099|NCT01206816|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150100|NCT03050203|t||||
17150101|NCT02493777|f||||t
17150102|NCT00754442|f||||f
17150103|NCT01231373|f||GT60||t
17150104|NCT02547766|f||||f
17150105|NCT00351351|f||||f
17150106|NCT01134627|f||OTHER||t
17150107|NCT00754494|f||LTE60||t
17150108|NCT00867048|f||||f
17150109|NCT00977431|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150110|NCT01010750|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17150111|NCT03069677|t||||t
17150112|NCT00518882|f||OTHER|Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17150113|NCT01397617|f||||f
17150114|NCT00567476|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.|t
17150115|NCT02696031|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single-site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety|t
17150116|NCT02777918|t||||
17150117|NCT00058214|f||LTE60||t
17150118|NCT00411398|f||||f
17150119|NCT01606852|f||||f
17150120|NCT03856593|t||||
17150121|NCT01155778|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17150122|NCT03978091|f||LTE60||t
17150123|NCT02324673|f||||f
17150124|NCT01602016|t||||
17150125|NCT02595008|f||||t
17150126|NCT02214420|t||||
17150127|NCT03078582|f||OTHER|Disclosure agreements are negotiated separately with each PI.|t
17150128|NCT02046525|f||||f
17150129|NCT02689063|f||||f
17150130|NCT02994355|f||||f
17150131|NCT03050918|t||||
17150132|NCT02972502|t||||
17150133|NCT01933464|f||||f
17150134|NCT01347866|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150135|NCT00869024|t||||
17150136|NCT00293202|f||||t
17150137|NCT02442271|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150138|NCT00408564|f||||f
17150139|NCT01560507|t||||
17150140|NCT02080832|t||||
17150141|NCT02427984|f||||f
17150142|NCT01594047|f||||f
17150143|NCT01491035|f||||f
17150144|NCT03179163|t||||
17150145|NCT01277718|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150146|NCT00775684|f||||f
17150147|NCT01524913|t||||
17150148|NCT00695435|t||||
17150149|NCT04464993|f||||f
17150150|NCT04527328|f||LTE60||t
17150151|NCT03351231|f||LTE60||t
17150152|NCT02858726|f||||t
17150153|NCT01972035|t||||
17150154|NCT00233987|f||||f
17150155|NCT01862419|f||||f
17150156|NCT00518622|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150157|NCT01688726|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17150158|NCT01036490|f||||f
17150159|NCT00603291|f||||f
17150160|NCT03805100|f||||t
17150161|NCT00289757|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150162|NCT03474432|f||||f
17150163|NCT02177136|f||OTHER|Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45-day review period with the option to extend to an additional 90 days.|t
17150164|NCT01386684|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150165|NCT00131378|f||||f
17150166|NCT03197558|f||OTHER|PI must submit communications to Sponsor for review and comment to verify accurate content at least 30 days prior to submitting to any third party. A delay up to 90 days may be requested by Sponsor in order to file patent applications relating to an Invention if applicable. Sponsor and PI agree that any Institution Publication shall only be made after the Multicenter Publication, provided that the Multicenter Publication is submitted within 18 months after conclusion of the study at all sites.|t
17150167|NCT00353652|t||||
17150168|NCT03533374|f||||f
17150169|NCT02072148|t||||
17150170|NCT02466230|t||||
17150171|NCT00782821|t||||
17150172|NCT02528123|t||||
17150173|NCT01598350|t||||
17150174|NCT02274844|f||||f
17150175|NCT01892657|f||LTE60||t
17150176|NCT01507155|t||||
17150177|NCT03840616|f||OTHER|Neither institution nor investigator can disclose information pertaining to study until sponsor issues multi-center publication. If multi-center publication is not issued within 18 months of study completion and database lock at all sites, sponsor has 30 days from receipt to review institution's and/or investigator's communication and can require removal of confidential information other than study data and/or delay release of institution's and/or investigator's communication for 60 days.|t
17150178|NCT00140621|f||OTHER|Prior to publishing results from this study in academic meetings, medical journals, etc., the investigator and subinvestigator of the post-manufacturing/marketing clinical study must obtain the approval from the sponsor of the post-manufacturing/marketing clinical study in writing.|t
17150179|NCT03463993|f||||f
17150180|NCT01478828|t||||
17150181|NCT01835379|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.|t
17150182|NCT00136318|f||||f
17150183|NCT01884064|t||||f
17150184|NCT01829113|f||GT60||t
17150185|NCT01570348|t||||
17150186|NCT01490931|t||||
17150187|NCT03581214|f||||f
17150188|NCT03808740|f||||f
17150189|NCT02010255|f||OTHER|"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:~* The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or~* The study has been completed at all study sites for at least 2 years"|t
17150190|NCT05528861|f||OTHER|Clinical Trial Agreement contains a limit on publication of results following completion of the trial. PIs are not allowed to publish results until a joint publication for the multicenter study or a set period of time. After that time, PIs may only publish results from their portion of the study.|t
17150191|NCT01602172|t||||
17150192|NCT02654587|f||||f
17150193|NCT01045031|f||||f
17150194|NCT01843348|f||OTHER|Other disclosure agreement that restricts the right of the PI to discuss or publish trail results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigation from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., from all sites) in the clinical trial.|t
17150195|NCT02039414|f||||f
17150196|NCT00430950|f||OTHER|Results of Study shall not be published without prior express written consent and approval of Sponsor. If Contractor wishes to use data generated at Sites by Investigator, such data includes but not limited to data used in collection of metrics, copy of any intended publication, details of use must be sent in writing to Quintiles and Sponsor for review. Sponsor has right to change proposed publication and/or prohibit publication and Contractor must comply with requirements of Sponsor|t
17150197|NCT02537873|t||||
17150198|NCT02429934|f||LTE60||t
17150199|NCT03657108|t||||
17150200|NCT00703508|f||||f
17150201|NCT01064323|t||||
17150202|NCT00831623|f||||f
17150203|NCT05307887|t||||
17150204|NCT01564459|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17150205|NCT00106938|f||GT60||t
17150206|NCT02416011|t||||
17150207|NCT03545191|f||OTHER|Any study-related publication written independently by investigators must be submitted to Idorsia for review at least 30 days prior to submission for publication or presentation at a congress. Upon review, Idorsia may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period.|t
17150208|NCT00195013|t||||
17150209|NCT04722601|t||||
17150210|NCT02746627|f||||f
17150211|NCT03052972|f||LTE60||t
17150212|NCT02340221|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150213|NCT03499119|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150214|NCT00588640|t||||
17150215|NCT01393730|f||||t
17150216|NCT00103402|f||||f
17150217|NCT03182582|t||||
17150218|NCT01481324|f||||f
17150219|NCT03218163|t||||f
17150220|NCT01172821|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17150221|NCT00123955|t||||
17150222|NCT01418482|f||LTE60||t
17150223|NCT01663727|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150224|NCT02218307|t||||
17150225|NCT02332980|t||||
17150226|NCT00003138|f||||f
17150227|NCT00102518|f||||f
17150228|NCT04495283|f||||t
17150229|NCT03028948|f||||f
17150230|NCT05142566|f||||f
17150231|NCT02246439|f||OTHER|Institution will provide to Sponsor, for review and comment, all manuscripts or other material prior to such publication. Sponsor shall have 30 days to review any such publication. The Sponsor can require changes to the communication and such confidential information shall be deleted and/or the submission of the proposed publication shall be delayed for an additional 60 days.|t
17150232|NCT01553279|f||||f
17150233|NCT00380692|f||GT60||t
17150234|NCT01388166|f||OTHER|Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150235|NCT00158756|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150236|NCT01429051|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17150237|NCT04132336|f||||f
17150238|NCT01939496|f||OTHER|A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.|t
17150239|NCT03052322|f||OTHER||t
17150240|NCT00973765|f||||f
17150241|NCT04920916|f||||f
17150242|NCT02011113|f||OTHER|Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.|t
17150243|NCT03949803|t||||
17150244|NCT00468728|f||LTE60||t
17150245|NCT03251963|f||||f
17150246|NCT04505293|t||||
17150247|NCT01517659|f||||f
17150248|NCT02712333|f||||f
17150249|NCT00775606|f||||f
17150250|NCT02278718|f||||f
17150251|NCT01546649|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17150252|NCT04440449|t||||
17150253|NCT03212794|t||||
17150254|NCT01763918|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150255|NCT00767338|f||||f
17150256|NCT02494817|f||||f
17150257|NCT03453840|f||||f
17150258|NCT03395639|f||||f
17150259|NCT00942331|f||LTE60||t
17150260|NCT02994251|t||||
17150261|NCT04475250|t||||
17150262|NCT00597116|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17150263|NCT00253981|t||||f
17150264|NCT04588688|t||||
17150265|NCT00757848|f||||f
17150266|NCT02071953|f||||f
17150267|NCT01901874|f||||t
17150268|NCT04209335|f||||f
17150269|NCT04632706|f||OTHER|The PI does not have the right to publish or otherwise present any results or data related to the study without an expressed written agreement from the Sponsor.|t
17150270|NCT03832738|f||LTE60||t
17150271|NCT03977701|f||||f
17150272|NCT00706992|f||||f
17150273|NCT01769274|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150274|NCT00306163|f||GT60||t
17150275|NCT02377063|t||||
17150276|NCT00702208|f||||f
17150277|NCT02025751|f||||f
17150278|NCT03864042|f||LTE60||t
17150279|NCT02220725|f||OTHER|Conducted in healthy volunteers at Clinical Research Organization.|t
17150280|NCT03487848|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150281|NCT00731549|f||||f
17150282|NCT02333487|f||||f
17150283|NCT01111019|f||OTHER||t
17150284|NCT01524302|f||||f
17150285|NCT00986453|f||LTE60||t
17150286|NCT01583218|f||OTHER|Due to multi centers, studies and countries this varies.|t
17150287|NCT03168321|f||OTHER|Please contact Sponsor directly for additional information.|t
17150288|NCT01299805|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17150289|NCT03083821|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submitter for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150290|NCT02646449|f||||f
17150291|NCT02522403|f||||f
17150292|NCT02287909|f||||f
17150293|NCT04718194|t||||f
17150294|NCT01108666|t||||
17150295|NCT02091141|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150296|NCT00605865|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150297|NCT03955471|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.|t
17150298|NCT03012672|t||||f
17150299|NCT00522171|f||OTHER|Sponsor has at least 60 days for review to ensure non disclosure of Confidential information. If Study is a multicenter study, PI agrees that the first publication shall include results from all PIs contributing data. If multicenter publication is not submitted within 12 months,or after Sponsor confirms there will be no multicenter Study publication, the Institution and/or such PI may publish the results from their respective site individually in accordance with this paragraph.|t
17150300|NCT03715998|f||GT60||t
17150301|NCT01660191|t||||
17150302|NCT01032018|t||||
17150303|NCT02130583|f||||f
17150304|NCT02119286|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150305|NCT00619112|f||||f
17150306|NCT01996332|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150307|NCT02113189|f||||f
17150308|NCT03265288|f||||f
17150309|NCT00652028|f||||f
17150310|NCT03716076|f||||f
17150311|NCT01385306|f||LTE60||t
17150312|NCT00931268|f||LTE60||t
17150313|NCT00430495|f||OTHER|Prior to publishing results, Institution and Principal Investigator (PI) must first provide Sponsor with a copy of proposed publication for review at least 30 days prior to submission. If Institution and PI do not agree to modification, they shall so notify Sponsor and postpone submission for additional 60 days to allow Sponsor to seek legal remedies or file patent applications. There is a need for coordinated approach to any publication of results from sites for any multi-site study.|t
17150314|NCT02751359|t||||
17150315|NCT02400671|f||||f
17150316|NCT02145026|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150317|NCT00857792|f||||f
17150318|NCT01797835|f||||f
17150319|NCT00723645|f||||f
17150320|NCT03728634|f||OTHER||t
17150321|NCT04421586|t||||
17150322|NCT00967044|t||||f
17150323|NCT00076804|f||||f
17150324|NCT01284296|f||||f
17150325|NCT04295135|f||||f
17150326|NCT03484117|f||||f
17150327|NCT00289874|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150328|NCT03835325|f||GT60||t
17150329|NCT03852459|f||GT60||t
17150330|NCT00578071|t||||
17150331|NCT00770692|f||||f
17150332|NCT02447926|t||||
17150333|NCT00560937|t||||
17150334|NCT03676751|t||||
17150335|NCT01138111|f||LTE60||t
17150336|NCT03629028|t||||
17150337|NCT01401257|f||OTHER|"No individual publication (paper, abstract, poster, oral presentation) is allowed until results of the complete study have been published.~The Investigator agrees that any proposed publication, presentation or use of results arising from the Investigation will be submitted to Pharnext for review and written agreement prior to submission."|t
17150338|NCT02687360|t||||
17150339|NCT02989168|f||||t
17150340|NCT01846273|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.|t
17150341|NCT03431974|f||OTHER|Sponsor shall retain title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the performance of the Services. Such publications shall not be made by PI without the prior written consent of Sponsor.|t
17150342|NCT02939014|f||OTHER|In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application|t
17150343|NCT00456495|f||||f
17150344|NCT05069155|f||||f
17150345|NCT01297322|f||||f
17150346|NCT00712985|t||||f
17150347|NCT01856361|t||||
17150348|NCT03334721|f||||f
17150349|NCT01902628|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150350|NCT04969861|f||OTHER|There are restrictions to the PI's rights to discuss or publish trial results.|t
17150351|NCT03755336|f||||f
17150352|NCT03340064|f||GT60||t
17150353|NCT00997139|t||||
17150354|NCT00313443|f||||f
17150355|NCT00856973|f||OTHER||t
17150356|NCT02664363|f||||f
17150357|NCT05713552|f||GT60||t
17150358|NCT04556552|t||||
17150359|NCT03439852|t||||
17150360|NCT01215513|f||OTHER|The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.|t
17150361|NCT01825889|f||GT60||t
17150362|NCT00793780|t||||
17150363|NCT02858492|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150364|NCT00937378|f||||t
17150365|NCT03111914|t||||
17150366|NCT04425538|f||||f
17150367|NCT03247517|f||OTHER||t
17150368|NCT02040779|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17150369|NCT02132637|f||GT60||t
17150370|NCT01936519|f||||f
17150371|NCT03949244|f||||f
17150372|NCT03687658|t||||
17150373|NCT00127036|t||||f
17150374|NCT02070302|t||||f
17150375|NCT03656874|f||||f
17150376|NCT00584844|f||||f
17150377|NCT01195103|t||||f
17150378|NCT03760250|f||||f
17150379|NCT01615263|t||||
17150380|NCT00857259|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or disclosure of the trial results in their entirety.|t
17150381|NCT01370213|f||||f
17150382|NCT02701413|f||||f
17150383|NCT01227655|f||OTHER||t
17150384|NCT00472797|f||OTHER|Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.|t
17150385|NCT01621191|f||GT60||t
17150386|NCT01321008|t||||f
17150387|NCT02477774|t||||f
17150388|NCT03399318|f||||f
17150389|NCT02749292|f||||f
17150390|NCT02458092|f||||f
17150391|NCT01825122|f||LTE60||t
17150392|NCT00251641|f||OTHER|PI must provide sponsor w/ review copies of abstracts or manuscripts for publication that report any results of the study, 45 days before submission for publication or presentation. The sponsor shall have the right to review/comment on the material. If the parties disagree about the appropriateness of the material, PI must meet with sponsor's representatives before submission for publication, for the purpose of making good faith efforts to discuss and resolve any issues of disagreement.|t
17150393|NCT01797484|t||||
17150394|NCT02093221|f||||t
17150395|NCT04017754|t||||
17150396|NCT00257920|f||GT60||t
17150397|NCT03508687|f||||f
17150398|NCT00631852|f||||f
17150399|NCT00534794|f||OTHER|PI cannot publish or discuss trial results until written communication is received from Inspire.|t
17150400|NCT03097588|t||||
17150401|NCT03456960|f||OTHER|Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.|t
17150402|NCT00653991|f||||f
17150403|NCT03828448|f||||f
17150404|NCT02037165|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17150405|NCT00532935|f||OTHER|Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150406|NCT01300923|f||||f
17150407|NCT01568866|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150408|NCT01698775|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17150409|NCT01869478|t||||
17150410|NCT01244061|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150411|NCT02494102|t||||
17150412|NCT02384850|f||||t
17150413|NCT01588236|f||OTHER||t
17150414|NCT02013375|t||||
17150415|NCT02674061|f||OTHER|The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.|t
17150416|NCT01319773|f||OTHER|A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo|t
17150417|NCT05882279|f||OTHER|The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.|t
17150418|NCT01334710|t||||
17150419|NCT01558297|f||||f
17150420|NCT00375492|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150421|NCT01232491|f||OTHER|Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.|t
17150422|NCT00586482|t||||f
17150423|NCT02932228|t||||
17150424|NCT00821873|f||LTE60||t
17150425|NCT03310411|f||OTHER|Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.|t
17150426|NCT03623386|t||||
17150427|NCT05080426|t||||
17150428|NCT04271735|t||||
17150429|NCT00515541|f||||f
17150430|NCT00922272|f||OTHER|If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.|t
17150431|NCT02588950|f||OTHER|The only disclosure restriction on PI is that sponsor can review results communications and comment 30 days prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. If PI is unwilling to delay the results communication then PI can remove the information that sponsor has specified it reasonably believes would jeopardize its intellectual property interests.|t
17150432|NCT03188718|f||||f
17150433|NCT02072824|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150434|NCT03084367|f||||f
17150435|NCT00841906|f||||f
17150436|NCT00903448|f||LTE60||t
17150437|NCT02667288|f||OTHER|The institution and Investigator agree not to publish the results of this study without the prior written consent of the Sponsor|t
17150438|NCT00912093|f||OTHER|Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.|t
17150439|NCT01280409|t||||f
17150440|NCT04397445|f||||f
17150441|NCT03921151|t||||
17150442|NCT01207648|f||OTHER||t
17150443|NCT00270257|f||OTHER|All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts \& five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17150444|NCT03667014|t||||f
17150445|NCT01387581|f||||f
17150446|NCT03001219|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150447|NCT03733210|f||||f
17180688|NCT03195088|f||OTHER|Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.|t
17180689|NCT02998840|f||OTHER|Sponsor shall have 45 days to review the papers. Sponsor shall have the right to require Institution/Principal Investigator, as applicable, to remove specifically identified confidential information and/or delay the proposed publication or presentation for an additional one hundred twenty (120) days to enable Sponsor to seek patent protections.|t
17180690|NCT01686633|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180691|NCT02192814|f||GT60||t
17180692|NCT00195676|f||OTHER|Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.|t
17180693|NCT01189812|f||||f
17180694|NCT00616655|f||OTHER|In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish|t
17180695|NCT03761147|t||||
17180696|NCT02059057|f||||f
17180697|NCT00309842|t||||
17180698|NCT01026792|f||LTE60||t
17180699|NCT00423150|f||OTHER|"The investigator agrees not to publish or publicly present any interim results~of the study without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor, 45 days prior to submission, review copies of abstracts or manuscripts for publication that report any results of the study. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission, for the purpose of making good faith efforts to discuss/resolve any such issues."|t
17180700|NCT03204305|f||||f
17180701|NCT00535223|t||||f
17150448|NCT02621034|f||||f
17150449|NCT02963441|f||OTHER|If a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study, Institution will be free to publish the methods, data and results of the Study|t
17180702|NCT02953314|f||OTHER||t
17180703|NCT02335099|f||||f
17180704|NCT02045797|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17180705|NCT01765153|f||||f
17180706|NCT03578081|t||||
17180707|NCT00319644|f||||f
17150450|NCT01338649|f||||f
17150451|NCT02669940|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150452|NCT00361335|f||OTHER|Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.|t
17150453|NCT05065983|f||OTHER|PI may publish or release study data after the earlier of (a) the date of publication of a multi-center publication coordinated by Sponsor on the study data, or (b) the date of submission of the study data by Sponsor to regulatory authorities for regulatory approval; provided that PI furnishes Sponsor with a copy of any proposed publication or release at least ninety days in advance of the proposed submission or presentation date for review. PI must acknowledge Sponsor on any publication.|t
17150454|NCT00986180|f||GT60||t
17150455|NCT01765582|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150456|NCT01691820|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150457|NCT03261960|f||OTHER|The sole disclosure restriction which sponsor imposes on the PI is a sixty (60) day limited restriction in order to the protect potentially proprietary information which may be patentable|t
17150458|NCT04493320|f||||f
17150459|NCT00616941|f||LTE60||t
17150460|NCT02372071|f||||f
17150461|NCT00714493|f||GT60||t
17150462|NCT00506129|t||||
17150463|NCT05227300|t||||
17150464|NCT03161964|f||||f
17150465|NCT00557076|t||||
17150466|NCT02551432|f||||f
17150467|NCT02408068|f||||f
17150468|NCT03041324|f||||f
17150469|NCT02666352|f||OTHER|The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.|t
17150470|NCT02138136|f||||t
17150471|NCT04982874|f||||f
17150472|NCT00706381|t||||
17150473|NCT01026181|f||||f
17150474|NCT03529461|t||||
17150475|NCT01782482|f||OTHER|Sponsor reserves the right of prior review of any publication or presentation of information related to the study.|t
17150476|NCT02003911|f||||f
17150477|NCT00511992|t||||
17150478|NCT00038649|t||||
17150479|NCT00995085|f||LTE60||t
17150480|NCT03736928|f||OTHER|PIs agree not to present or publish any data or reports collected individually or by subgroup of sites prior to full, initial publication based on all data obtained from all sites.|t
17150481|NCT03096847|f||OTHER|The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.|t
17150482|NCT01640873|f||OTHER|The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.|t
17150483|NCT02728752|f||||f
17150484|NCT00891839|f||OTHER|Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.|t
17150485|NCT02192164|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150486|NCT03329079|f||||f
17150487|NCT00359788|f||OTHER|Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.|t
17150488|NCT02143583|f||OTHER|The PI coordinator of the study owns shares in Anergis SA|t
17150489|NCT00673933|f||GT60||t
17150490|NCT04932941|f||||t
17150491|NCT00321594|f||LTE60||t
17150492|NCT03110601|f||||t
17150493|NCT02287493|t||||
17150494|NCT01195272|f||OTHER|The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the sponsor's intellectual property rights.|t
17150495|NCT02664545|f||||f
17150496|NCT04905290|f||||f
17150497|NCT03295318|f||||f
17150498|NCT04319718|t||||f
17150499|NCT01288053|t||||
17150500|NCT00144781|f||OTHER|In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.|t
17150501|NCT02068092|t||||
17150502|NCT01045421|f||OTHER|The first study related publication will be a multi-center publication submitted after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review in advance of publication.|t
17150503|NCT02221037|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150504|NCT02307266|f||OTHER|Disclosure agreement covered by contract.|t
17150505|NCT01453894|f||||f
17150506|NCT00256984|f||LTE60||t
17150507|NCT02149290|t||||
17150508|NCT02470390|f||OTHER|The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.|t
17150509|NCT02766374|t||||
17150510|NCT01995266|f||OTHER|Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submitting for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.|t
17150511|NCT03758404|f||||t
17150512|NCT03596151|f||LTE60||t
17150513|NCT01700036|t||||
17150514|NCT04029311|f||||f
17150515|NCT03996148|t||||
17150516|NCT00679926|f||||f
17150517|NCT00729248|f||||f
17150518|NCT01996943|t||||
17150519|NCT04280705|f||LTE60||t
17150520|NCT03573505|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17150521|NCT03222583|f||OTHER|AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.|t
17150522|NCT02802449|f||||f
17150523|NCT04268316|t||||
17150524|NCT00746018|t||||
17150525|NCT01030653|f||||f
17150526|NCT00003224|t||||
17150527|NCT05855616|f||||f
17150528|NCT04032158|f||||t
17150529|NCT00059787|f||LTE60||t
17150530|NCT02135653|t||||
17150531|NCT00725530|f||LTE60||t
17150742|NCT00988065|f||OTHER|Investigator may not publish/publicly present interim results without prior consent of Sponsor. Any materials that report results of the study must be sent to Sponsor 45 days prior to submission for publication/presentation. Sponsor has right to review and comment. In case of any disagreements concerning appropriateness of the materials, investigator and Sponsor must meet to make a good faith effort to discuss/resolve the issues or disagreement, prior to submission for publication/presentation.|t
17150743|NCT02685202|t||||
17150744|NCT02130882|t||||f
17150745|NCT02365870|f||||f
17150746|NCT00669071|f||OTHER|The principal investigator has the right to publish or present the data resulting from this study, with agreed upon reviews by all interested parties, and in accordance with any confidentiality agreements that may exist.|t
17150747|NCT01194973|f||OTHER|Participation in this multicenter study involved a commitment to publish the data from the study in a cooperative publication prior to release of study results on an individual basis.|t
17150748|NCT03844789|f||||f
17150749|NCT00359632|f||||f
17150750|NCT02615171|f||||f
17150751|NCT00016718|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17150752|NCT00621049|f||OTHER|The sponsor can review/embargo results communications prior to public release for a period that is \>60 but =180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites|t
17150753|NCT00888459|t||||f
17150754|NCT01000493|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150755|NCT01408628|t||||
17150756|NCT01941940|f||OTHER|The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.|t
17150757|NCT00750308|f||||f
17150758|NCT00513682|f||OTHER|Restrictions may vary in accordance with each agreement that is negotiated with individual investigators. Sponsor will allow publication after multi-center publication has been published or after an agreed period of time if no such multi-center publication is submitted for publication. Sponsor can ask that Sponsor's confidential information be removed from any publication and defer publication for period of time to allow Sponsor to obtain patent or other intellectual property right protection.|t
17150759|NCT02523196|f||||f
17150760|NCT01121666|f||||f
17150761|NCT03176459|f||OTHER|Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication ≤18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for ≤120 days to allow Sponsor to protect its interests in Inventions.|t
17150762|NCT00321737|f||OTHER|No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.|t
17150763|NCT00290251|f||LTE60||t
17150764|NCT01745211|f||OTHER|The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.|t
17180708|NCT02554812|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150770|NCT02128217|f||OTHER|In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.|t
17150771|NCT05071313|f||OTHER|If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.|t
17150772|NCT00541970|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150773|NCT00321828|f||LTE60||t
17150774|NCT01461226|f||||f
17150775|NCT04763564|t||||f
17150776|NCT00858143|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of \<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.|t
17150777|NCT03853148|f||||f
17150778|NCT00852969|f||||f
17150779|NCT02440022|f||||t
17150780|NCT00658658|f||OTHER|The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.|t
17150781|NCT00678041|t||||
17150782|NCT02358343|f||||f
17150783|NCT00281671|f||||f
17150784|NCT00090610|f||||f
17150785|NCT02444793|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150786|NCT03576183|f||OTHER||t
17150787|NCT04498403|f||OTHER|Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.|t
17150788|NCT01951885|t||||
17150789|NCT00866658|f||OTHER|If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.|t
17150790|NCT01276301|t||||
17150791|NCT01859130|f||||f
17150792|NCT00166036|f||||f
17150793|NCT01462318|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17150794|NCT03827564|f||OTHER|Allergan as the sponsor has proprietary interest in this study. Authorship and manuscript composition will reflect joint cooperation between investigators and Allergan personnel. Authorship will be established prior to the writing of the manuscript. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.|t
17150795|NCT00891371|t||||
17150796|NCT02238626|f||||f
17150797|NCT00197392|f||GT60||t
17150798|NCT02622113|f||OTHER||t
17150799|NCT00307034|f||OTHER|GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.|t
17150800|NCT01076686|f||||f
17150801|NCT02244918|f||||f
17150802|NCT04442490|f||OTHER|Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.|t
17150803|NCT01449279|t||||
17150804|NCT00505375|f||||f
17150805|NCT03347422|f||OTHER|The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.|t
17150806|NCT02746471|f||OTHER|"In most cases, contracts allow investigators (PI) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (CI), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PI's may not publish single-site data until the main multi-site publication has occurred."|t
17150807|NCT00910091|f||||f
17150808|NCT04870138|f||LTE60||t
